{"meta":{"query_hash":"38079aa63b5f","filters":{"topic":"HIV/AIDS drug development and treatment"},"cohort_total":1576,"direct_labels_cover":3,"predictions_cover":1576,"exported":1576,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/38079aa63b5f","api":"https://metacan.xera.ac/api/v1/cohort?topic=HIV%2FAIDS+drug+development+and+treatment"},"results":[{"id":"W1083409746","doi":"10.1097/qad.0000000000000752","title":"The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B","year":2015,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Integrase; Elvitegravir; Virology; Raltegravir; Integrase inhibitor; Biology; Viral replication; Virus; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.02563378964854876,"score_gpt":0.2861205282047034,"score_spread":0.2604867385561547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1083409746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479985,0.00051985116,0.00072841876,0.0029864674,0.00009513827,0.0006469779,0.000003526033,0.00002609281,0.00019369704],"genre_scores_gemma":[0.99719596,0.00007099283,0.00079138303,0.00016161983,0.00003769876,0.00017003127,0.000123263,0.000011137172,0.0014379257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992383,0.000030364074,0.00022473912,0.00022030172,0.00012452989,0.00016172706],"domain_scores_gemma":[0.9995062,0.00005888732,0.000056127545,0.00024946276,0.00006435929,0.0000649803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042718573,0.000108476495,0.00015207707,0.00011582348,0.000052059386,0.000020180914,0.000039651073,0.000064187516,0.0000055043765],"category_scores_gemma":[0.00019805323,0.00007320041,0.0000275802,0.00019649307,0.000049259983,0.00009523303,0.00001576892,0.00008290576,0.000027923166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013189723,0.00020360434,0.9632026,0.00007185529,0.000066776745,0.000015183832,0.0032999949,0.000002937386,0.0008280464,0.0034797778,0.0031972588,0.024313008],"study_design_scores_gemma":[0.0150507735,0.0017725143,0.9290235,0.00047452748,0.00035083882,0.00008216508,0.0041243406,0.006963059,0.008456931,0.009177841,0.024006365,0.00051716826],"about_ca_topic_score_codex":0.00008394534,"about_ca_topic_score_gemma":0.00015483265,"teacher_disagreement_score":0.03417911,"about_ca_system_score_codex":0.00018788663,"about_ca_system_score_gemma":0.00010438493,"threshold_uncertainty_score":0.29850262},"labels":[],"label_agreement":null},{"id":"W124813241","doi":"10.2144/02332ht03","title":"Nonradioactive Detection of Retroviral- Associated RNase H Activity in a Microplate-Based, High-Throughput Format","year":2002,"lang":"en","type":"article","venue":"BioTechniques","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"RNase H; Reverse transcriptase; Biotinylation; RNase P; Oligonucleotide; Molecular biology; Biology; RNA-Directed DNA Polymerase; DNA; High-throughput screening; Enzyme; Streptavidin; Biochemistry; RNA; Chemistry; Biotin","score_opus":0.015950727166417104,"score_gpt":0.24043314203366678,"score_spread":0.22448241486724968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W124813241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937493,0.00013085348,0.0033021641,0.0012192605,0.00004458921,0.00066218094,0.00002434581,0.00024105862,0.00062623207],"genre_scores_gemma":[0.99381983,0.00017205575,0.005037618,0.000073302224,0.000017964987,0.000052840314,0.000022138885,0.00002128463,0.00078295363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900174,0.000069539,0.00026319557,0.00022981058,0.0002031024,0.00023261335],"domain_scores_gemma":[0.9994579,0.00004014481,0.00016686587,0.00021129659,0.000063944855,0.000059828177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018370562,0.0001857002,0.00036845016,0.00029641986,0.000044389886,0.00000894311,0.0000519975,0.00026953197,0.000054111075],"category_scores_gemma":[0.00006307355,0.00016205412,0.00009786111,0.00039126785,0.000059458125,0.00014804087,0.000021941301,0.00023717682,0.000017938768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009396975,0.0027147986,0.0151387565,0.00015668466,0.00025582412,0.0002029882,0.00089244416,0.00000193879,0.9263809,0.000030263876,0.0030186623,0.050267078],"study_design_scores_gemma":[0.0016593565,0.0004516794,0.00948136,0.00019558008,0.000054952372,0.000008693474,0.000017803193,0.00066938804,0.9860481,0.00003250182,0.0012265522,0.00015403188],"about_ca_topic_score_codex":0.00036388895,"about_ca_topic_score_gemma":0.00010878711,"teacher_disagreement_score":0.059667237,"about_ca_system_score_codex":0.00061191525,"about_ca_system_score_gemma":0.00003930447,"threshold_uncertainty_score":0.66083753},"labels":[],"label_agreement":null},{"id":"W127451339","doi":"10.1089/aid.2014.0043","title":"Prevalence and Virologic Consequences of Transmitted HIV-1 Drug Resistance in Uganda","year":2014,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Cancer Institute; National Institute of Mental Health; Canadian Institutes of Health Research; U.S. Public Health Service","keywords":"Nevirapine; Medicine; Regimen; Drug resistance; Viral load; Internal medicine; HIV drug resistance; Human immunodeficiency virus (HIV); Cohort; Virology; Antiretroviral therapy; Immunology; Biology","score_opus":0.04255780298273655,"score_gpt":0.33541465189805625,"score_spread":0.2928568489153197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W127451339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295366,0.0022491314,0.0000060150883,0.0012550072,0.0000070850792,0.00031984347,0.000009494554,0.000018910314,0.003180869],"genre_scores_gemma":[0.98282075,0.0011284727,0.0006961121,0.000049628452,0.000019674058,0.000031140054,0.0000064434344,0.000009392449,0.015238368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844235,0.00020710802,0.00026450044,0.00032827625,0.00040144665,0.0003563227],"domain_scores_gemma":[0.9991306,0.00038343202,0.000041630876,0.00019129079,0.00010349222,0.0001495336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010050196,0.00012596216,0.0003138337,0.00033340114,0.00014971546,0.000027656257,0.00009369894,0.000057808076,0.00009400771],"category_scores_gemma":[0.00021098011,0.000094571966,0.00002562297,0.00024142861,0.0011192642,0.00008684838,0.000043235887,0.00024103251,0.000008361278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030636028,0.00013444258,0.98578596,0.00047982676,0.000033348726,0.000036056317,0.0010576369,2.5416e-8,0.0044127423,0.0065450636,0.0008029656,0.0004055543],"study_design_scores_gemma":[0.002798094,0.00084541854,0.96391934,0.0005959406,0.000032557316,0.0000086234395,0.00029180894,0.0000015379344,0.015695449,0.011008214,0.004640892,0.00016210035],"about_ca_topic_score_codex":0.00007146895,"about_ca_topic_score_gemma":0.00036385274,"teacher_disagreement_score":0.021866614,"about_ca_system_score_codex":0.00003445732,"about_ca_system_score_gemma":0.00007757655,"threshold_uncertainty_score":0.41239753},"labels":[],"label_agreement":null},{"id":"W1343435","doi":"10.1177/135965350501000608","title":"A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Toronto General Hospital; St. Thomas Hospital; University Health Network; Ottawa Hospital","funders":"Malmö Högskola; Sahlgrenska Universitetssjukhuset; Temple University; University of Miami","keywords":"Ritonavir; Lopinavir; Discontinuation; Lopinavir/ritonavir; Medicine; Saquinavir; Internal medicine; Adverse effect; Randomized controlled trial; Gastroenterology; Intention-to-treat analysis; Population; Viral load; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.03754823925892261,"score_gpt":0.33972346927245534,"score_spread":0.30217523001353275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1343435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97438765,0.0003478178,0.000016588752,0.009813822,0.0013099686,0.010327349,0.000019946507,0.0001384966,0.0036383744],"genre_scores_gemma":[0.9884389,0.0006076664,0.00073499343,0.001089163,0.0013091989,0.0014697827,0.00025931792,0.00008329651,0.006007673],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99571484,0.0008764951,0.0010499406,0.00069342164,0.00091118895,0.0007540844],"domain_scores_gemma":[0.9980193,0.0007843576,0.00022604862,0.00063067576,0.00016508273,0.00017457666],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015277847,0.00059471634,0.0013580578,0.00032489226,0.00019946016,0.00008540003,0.00031227063,0.00021229262,0.00027537576],"category_scores_gemma":[0.00037899983,0.00037006155,0.00056756975,0.0007820242,0.000197398,0.00026760748,0.00008391598,0.00043672716,0.0009486838],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94093764,0.0021633937,0.0010895934,0.0000059012946,0.00038036314,0.00003218383,0.0012608436,0.0000024113617,0.00020053623,0.00014144985,0.0021420408,0.051643617],"study_design_scores_gemma":[0.94381726,0.0026955483,0.002003658,0.00011582239,0.00017740847,0.0000022707702,0.0000640755,0.000072359246,0.001354329,0.0000663819,0.049214672,0.0004162052],"about_ca_topic_score_codex":0.00007164688,"about_ca_topic_score_gemma":0.0000712217,"teacher_disagreement_score":0.051227413,"about_ca_system_score_codex":0.00035051533,"about_ca_system_score_gemma":0.0002719139,"threshold_uncertainty_score":0.9998751},"labels":[],"label_agreement":null},{"id":"W1412433324","doi":"10.1093/ofid/ofu051.110","title":"1222ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies","year":2014,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Liver Centre; University of Toronto","funders":"","keywords":"Dasabuvir; Ombitasvir; Medicine; Ribavirin; Baseline (sea); Virology; Virus; Chronic hepatitis","score_opus":0.016315627316465794,"score_gpt":0.3135393475786043,"score_spread":0.2972237202621385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1412433324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937293,0.0010354441,0.000025413481,0.0036461845,0.000047602083,0.0010958321,0.00011961066,0.000042146195,0.00025847254],"genre_scores_gemma":[0.9969247,0.00040039656,0.00013126488,0.00029992822,0.000027020196,0.000108816916,0.0000762773,0.00003208018,0.0019995219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793816,0.00049564405,0.00053073064,0.00044647243,0.00027617376,0.0003128148],"domain_scores_gemma":[0.997888,0.0007523029,0.0004107086,0.0004887055,0.00029373815,0.00016652062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006089093,0.0003693648,0.0010281844,0.00018295836,0.0004063245,0.00005591246,0.00018310691,0.000073741736,0.000029863766],"category_scores_gemma":[0.0012532513,0.00020789978,0.00009989884,0.00032695467,0.0006473846,0.00019292641,0.00056229415,0.00011686325,0.0000022454994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008614385,0.0012049292,0.9793894,0.00034391138,0.0019923225,0.00003528183,0.0005902671,0.000008775533,0.0031327005,0.0007405437,0.00082050596,0.0031269237],"study_design_scores_gemma":[0.008212893,0.0024899985,0.9742204,0.0005824449,0.0025284304,0.00005117577,0.0019943984,0.00011430638,0.0076421653,0.0010049463,0.0007920695,0.00036677776],"about_ca_topic_score_codex":0.00011570137,"about_ca_topic_score_gemma":0.00012490025,"teacher_disagreement_score":0.00516906,"about_ca_system_score_codex":0.000061361716,"about_ca_system_score_gemma":0.00017264608,"threshold_uncertainty_score":0.8477907},"labels":[],"label_agreement":null},{"id":"W1467889550","doi":"10.1128/9781555815493.ch4","title":"Nucleoside Analogue Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase","year":2014,"lang":"en","type":"book-chapter","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reverse transcriptase; Retrovirus; Virology; Biology; Integrase; Nucleoside analogue; Lamivudine; Integrase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Context (archaeology); Virus; Viral replication; RNA; Nucleoside; Human immunodeficiency virus (HIV); Genetics; Hepatitis B virus; Gene; Viral load; Antiretroviral therapy","score_opus":0.07815633392520493,"score_gpt":0.36183706447076064,"score_spread":0.2836807305455557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1467889550","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06708606,0.0018029602,0.000013105252,0.0010624435,0.00018668399,0.0013340625,0.00016494439,0.00007693454,0.9282728],"genre_scores_gemma":[0.46714237,0.0006598747,0.00007650138,0.00003363082,0.00010729831,0.00001222504,0.00028977424,0.0000688895,0.5316094],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964154,0.00010897425,0.0007037261,0.00062258437,0.0015148319,0.0006345069],"domain_scores_gemma":[0.99840665,0.00013072591,0.00015757029,0.0007444395,0.00043178245,0.00012885848],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012622005,0.0004145235,0.0009001633,0.0009948263,0.00025710635,0.000027804093,0.00027993324,0.00040513853,0.0004548467],"category_scores_gemma":[0.0000897695,0.0003504976,0.00041814026,0.00019208937,0.00067631446,0.00006900971,0.00013596592,0.0010898263,0.0010134734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014115709,0.001580569,0.0038563244,0.0023006632,0.0020591612,0.0034823597,0.002965743,1.6953388e-7,0.41737685,0.20944856,0.29818353,0.05733452],"study_design_scores_gemma":[0.0059041437,0.003112143,0.0019193605,0.0053297523,0.0007735731,0.000051400326,0.00027026696,0.000016739856,0.15157159,0.0067396425,0.8229507,0.0013606977],"about_ca_topic_score_codex":0.00034177682,"about_ca_topic_score_gemma":0.000080917365,"teacher_disagreement_score":0.52476716,"about_ca_system_score_codex":0.0002035213,"about_ca_system_score_gemma":0.00037194218,"threshold_uncertainty_score":0.9998947},"labels":[],"label_agreement":null},{"id":"W1483464410","doi":"10.1177/135965350701200405","title":"Plasma Concentrations of the HIV-Protease Inhibitor Lopinavir are Suboptimal in Children Aged 2 Years and Below","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Cmin; Lopinavir; Pharmacokinetics; Cmax; Lopinavir/ritonavir; Medicine; Regimen; Ritonavir; Human immunodeficiency virus (HIV); Area under the curve; Pharmacology; Internal medicine; Viral load; Immunology; Antiretroviral therapy","score_opus":0.011341620185126057,"score_gpt":0.25182638738981433,"score_spread":0.24048476720468828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1483464410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979957,0.00023299138,0.000008540857,0.0008262401,0.000038073922,0.0006330029,0.00001542578,0.000014837464,0.00023519468],"genre_scores_gemma":[0.99821913,0.00018335464,0.00036573317,0.00009774293,0.000049577196,0.000009065999,0.00002399668,0.000011028437,0.0010403927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930876,0.000032121887,0.00018783385,0.00014776141,0.00014871648,0.00017482182],"domain_scores_gemma":[0.9997104,0.000026689884,0.00007175417,0.0001337051,0.000018744688,0.000038709386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014234714,0.00010766851,0.00017813244,0.000060271363,0.000049816892,0.0000080189275,0.00004936675,0.000052866482,0.000017578708],"category_scores_gemma":[0.000011557397,0.000073754585,0.000051004812,0.0001866526,0.00010886589,0.00005823711,0.000017170672,0.00011521565,0.000009703248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020089615,0.00019703775,0.98765564,0.000004167303,0.00005365813,0.000022430893,0.0006890568,3.377698e-7,0.0045227823,0.0000560893,0.00030147156,0.0062964195],"study_design_scores_gemma":[0.0035302087,0.000065941436,0.9517524,0.000085406624,0.000012187114,0.000009036337,0.00010837798,0.000006937593,0.04397892,0.000016169448,0.00035875294,0.000075644035],"about_ca_topic_score_codex":0.00002113522,"about_ca_topic_score_gemma":0.000029138588,"teacher_disagreement_score":0.039456137,"about_ca_system_score_codex":0.000028455586,"about_ca_system_score_gemma":0.000051130726,"threshold_uncertainty_score":0.30076244},"labels":[],"label_agreement":null},{"id":"W1498429378","doi":"10.1111/ajt.12109","title":"Human Immunodeficiency Virus in Solid Organ Transplantation","year":2013,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Society of Transplantation; American Society of Transplantation","keywords":"Medicine; Solid organ; Transplantation; Human immunodeficiency virus (HIV); Virology; Organ transplantation; Immunology; Surgery","score_opus":0.0073647236828566455,"score_gpt":0.26960410560925047,"score_spread":0.26223938192639384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1498429378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964167,0.000075019125,0.0015244603,0.0009925178,0.000059728853,0.00020841153,0.0000051392944,0.000013386999,0.0007046632],"genre_scores_gemma":[0.9965641,0.00084044144,0.0021682587,0.000117948824,0.0000347384,0.000009153213,0.00004870247,0.000016102415,0.00020056208],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998742,0.000060215752,0.00057302485,0.00011626352,0.00029525583,0.00021324182],"domain_scores_gemma":[0.99939924,0.000035337765,0.00027223994,0.00007773098,0.0001257038,0.000089765424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018361524,0.00013553053,0.00033179266,0.00035874435,0.00006005004,0.000019973151,0.00007396299,0.000030287027,0.0001746468],"category_scores_gemma":[0.0000047848885,0.00010935248,0.00008676659,0.0003349241,0.00007676498,0.00027309376,0.0000015697698,0.00017083989,0.000049881848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013613816,0.0016065143,0.18793374,0.0003624848,0.00043608196,0.0016923337,0.039513476,0.00027339318,0.6738623,0.00023768956,0.00029731257,0.09242331],"study_design_scores_gemma":[0.005933087,0.0013089516,0.92603624,0.00059096236,0.00046220323,0.0019587844,0.0022095158,0.00007123191,0.06089559,0.00018310334,0.00007915911,0.0002711705],"about_ca_topic_score_codex":0.00023689843,"about_ca_topic_score_gemma":0.000059174625,"teacher_disagreement_score":0.7381025,"about_ca_system_score_codex":0.00009169933,"about_ca_system_score_gemma":0.00009425238,"threshold_uncertainty_score":0.44592646},"labels":[],"label_agreement":null},{"id":"W1503303110","doi":"","title":"Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.","year":2009,"lang":"en","type":"review","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Abacavir; Biology; Protease; Atazanavir; Drug resistance; Virology; Genotype; Protease inhibitor (pharmacology); Genetics; Lentivirus; Genetic diversity; Human immunodeficiency virus (HIV); Viral load; Viral disease; Medicine; Polymerase chain reaction; Antiretroviral therapy; Gene; Enzyme; Population","score_opus":0.022810080062975083,"score_gpt":0.25383739343834105,"score_spread":0.23102731337536597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1503303110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008931598,0.9931315,4.240591e-7,0.0001704897,0.000014985622,0.0054319645,0.000013631927,0.000011598734,0.00033221618],"genre_scores_gemma":[0.0015794165,0.99432504,0.00018132845,0.000032784374,0.000014824686,0.0010129284,0.000035584868,0.000013935957,0.00280417],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9976884,0.0001909952,0.0010919793,0.00038277078,0.00036957458,0.0002762412],"domain_scores_gemma":[0.9984713,0.0002508147,0.00066702603,0.000407049,0.00007290612,0.00013089803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072955573,0.00032930294,0.00346061,0.0002329895,0.000025553074,0.000004551564,0.00020597661,0.0001660911,0.000008589659],"category_scores_gemma":[0.00048479595,0.00022420324,0.0002985726,0.00043254878,0.00010204327,0.0000336265,0.0001697887,0.00018149627,0.000009458452],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022439635,0.0001248266,0.0015715084,0.97600406,0.00022261888,0.00003986623,0.00008853688,3.183765e-9,2.841467e-7,0.0000026974003,0.0011162561,0.020806892],"study_design_scores_gemma":[0.0004167356,0.00001421579,0.009169527,0.9760505,0.0063838474,0.000021061758,0.000018214787,3.106101e-7,0.000011170559,0.000021871809,0.007657902,0.00023464725],"about_ca_topic_score_codex":0.000008135806,"about_ca_topic_score_gemma":0.000011143408,"teacher_disagreement_score":0.020572245,"about_ca_system_score_codex":0.00018207288,"about_ca_system_score_gemma":0.00011350928,"threshold_uncertainty_score":0.9142743},"labels":[],"label_agreement":null},{"id":"W1507008385","doi":"10.1046/j.1365-2125.2003.01842.x","title":"Clinical trials of antiretroviral drugs: the role of the MRC AIDS Therapeutic Trials Committee (ATTC) and the MRC Clinical Trials Unit (CTU)","year":2003,"lang":"en","type":"review","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Zidovudine; Clinical trial; Intensive care medicine; Adverse effect; Human immunodeficiency virus (HIV); Internal medicine; Immunology; Viral disease","score_opus":0.3428413324597647,"score_gpt":0.5673397148136443,"score_spread":0.2244983823538796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1507008385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054728994,0.974516,0.000023033052,0.0035694968,0.009304116,0.00603079,0.00025930782,0.000016511636,0.0008078859],"genre_scores_gemma":[0.008402768,0.9807917,0.00034340066,0.002670639,0.0061115744,0.000090959955,0.000026902193,0.00011092335,0.0014511364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8051348,0.1576552,0.03466676,0.0006982273,0.0012237291,0.0006213321],"domain_scores_gemma":[0.6929766,0.2666285,0.037331827,0.001086692,0.0012223814,0.0007539716],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.35662895,0.0009322018,0.031101102,0.00027976086,0.00031511494,0.00009582255,0.001721264,0.0018414416,0.0010692813],"category_scores_gemma":[0.10077405,0.00042258212,0.016569337,0.0007309123,0.005096625,0.00012260563,0.00043997366,0.00627109,0.000022405235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005258628,0.0022082215,0.0042305263,0.0008544759,0.01995359,0.00015325157,0.00006969786,3.8280032e-7,0.0000020650969,0.00021651146,0.026655756,0.9403969],"study_design_scores_gemma":[0.049170624,0.0020626253,0.0009344934,0.006469699,0.062078368,0.0013802286,0.00019003476,0.000010233517,0.000014796992,0.0013021576,0.87602335,0.00036336714],"about_ca_topic_score_codex":0.00002696963,"about_ca_topic_score_gemma":0.0000074216678,"teacher_disagreement_score":0.94003356,"about_ca_system_score_codex":0.000070864844,"about_ca_system_score_gemma":0.004186786,"threshold_uncertainty_score":0.9998439},"labels":[],"label_agreement":null},{"id":"W1523887359","doi":"10.4137/cmt.s32","title":"Raltegravir: Its use in the Treatment of HIV Infection","year":2009,"lang":"en","type":"article","venue":"Clinical Medicine Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Raltegravir; Medicine; Integrase inhibitor; Context (archaeology); Pharmacology; Drug; Clinical trial; Human immunodeficiency virus (HIV); Integrase; Antiretroviral therapy; Intensive care medicine; Virology; Viral load; Internal medicine","score_opus":0.18152407667860665,"score_gpt":0.4358891105728506,"score_spread":0.254365033894244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1523887359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96426314,0.0010165456,0.000047834816,0.032029536,0.00022200982,0.0007724684,0.0000022862216,0.00003803991,0.0016081639],"genre_scores_gemma":[0.98383594,0.008276948,0.00028593052,0.0035294227,0.0003574292,0.000015497937,0.000039707364,0.00001204262,0.0036470715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983251,0.00018881445,0.0007671059,0.00021961078,0.00029221285,0.00020712995],"domain_scores_gemma":[0.998565,0.0007511853,0.00013827163,0.00036618664,0.000090797,0.00008851839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000512695,0.00019315953,0.0005737573,0.000117585754,0.000034940334,0.000005696031,0.00007267546,0.00012233865,0.000076358316],"category_scores_gemma":[0.0001341869,0.00009492953,0.00015137908,0.00032721047,0.0001455902,0.0000472691,0.0000038725266,0.00018092852,0.00004899731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009757111,0.0074344226,0.7223809,0.00002590173,0.00039437352,0.00014370382,0.0042130267,0.0000033191639,0.00030172337,0.0014186183,0.002413479,0.26029482],"study_design_scores_gemma":[0.009634586,0.0071598934,0.77715635,0.00020987171,0.0006808971,0.00003075525,0.00016448551,0.00017623442,0.00040474077,0.0004716388,0.20378482,0.00012574003],"about_ca_topic_score_codex":0.000014481874,"about_ca_topic_score_gemma":0.00002096937,"teacher_disagreement_score":0.2601691,"about_ca_system_score_codex":0.000074585405,"about_ca_system_score_gemma":0.00006955491,"threshold_uncertainty_score":0.38711137},"labels":[],"label_agreement":null},{"id":"W1529006453","doi":"10.1111/hiv.12118","title":"A meta‐analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir‐boosted protease inhibitor maintenance therapy in HIV‐infected adults with established virological suppression after induction","year":2013,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of British Columbia; Université de Montréal","funders":"ViiV Healthcare","keywords":"Atazanavir; Medicine; Ritonavir; Confidence interval; Internal medicine; Meta-analysis; Randomized controlled trial; Regimen; Gastroenterology; Protease inhibitor (pharmacology); Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology","score_opus":0.041135178005979225,"score_gpt":0.2899651818157964,"score_spread":0.24883000380981718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529006453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14509645,0.8407068,0.00004240488,0.0017844267,0.000071339164,0.0119122015,0.0002064194,0.000065561886,0.00011436022],"genre_scores_gemma":[0.14958201,0.84271914,0.00095837045,0.00010827414,0.0001212998,0.0023048022,0.0025885974,0.00012050303,0.0014969815],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959943,0.000625371,0.0013892185,0.0007856195,0.00082784216,0.00037759947],"domain_scores_gemma":[0.9971169,0.00041150858,0.0010600768,0.00083406136,0.00035815506,0.00021926663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004357756,0.0007817578,0.0053592036,0.000812474,0.0000597489,0.000009150948,0.000195679,0.00033795167,0.0003956976],"category_scores_gemma":[0.00013602801,0.0003003846,0.0004131401,0.0026448024,0.00060148793,0.0001081398,0.00009162957,0.0006577107,0.0000032375237],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.099056974,0.011257317,0.05675155,0.04203702,0.44790515,0.0013633262,0.013621283,0.00007135996,0.00048793087,0.000045805737,0.0035228443,0.32387945],"study_design_scores_gemma":[0.073827974,0.004998595,0.13035487,0.11608378,0.56199086,0.00036995136,0.0007072372,0.00028481157,0.0002689923,0.000004959972,0.109532245,0.001575733],"about_ca_topic_score_codex":0.00015632383,"about_ca_topic_score_gemma":0.00012219172,"teacher_disagreement_score":0.3223037,"about_ca_system_score_codex":0.00012832704,"about_ca_system_score_gemma":0.0002911595,"threshold_uncertainty_score":0.9999448},"labels":[],"label_agreement":null},{"id":"W1532561425","doi":"10.1111/j.1468-1293.2010.00890.x","title":"Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort","year":2010,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Ontario HIV Treatment Network; University of British Columbia; Public Health Ontario; Maple Leaf Medical Clinic; Health Sciences Centre; Ottawa Hospital; University Health Network; University of Toronto; McGill University Health Centre; McGill University; Simon Fraser University; University of Ottawa; AIDS Vancouver; Sunnybrook Health Science Centre","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Medicine; Interquartile range; Viral load; Cohort; Hazard ratio; Confidence interval; Internal medicine; Multivariate analysis; Cohort study; Antiretroviral therapy; Univariate analysis; Human immunodeficiency virus (HIV); Immunology","score_opus":0.02672448578000688,"score_gpt":0.27027338935132883,"score_spread":0.24354890357132195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1532561425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921494,0.000021268086,0.0000073482497,0.004172188,0.00016327956,0.0011711105,0.00013093723,0.00007478861,0.0021096736],"genre_scores_gemma":[0.9940059,0.00002297501,0.00007758877,0.0006551086,0.00008466342,0.000069538924,0.0019169609,0.000039204344,0.003128025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779993,0.00013192746,0.00034026985,0.00053565594,0.00059354503,0.00059867883],"domain_scores_gemma":[0.99863917,0.00027724,0.00015210088,0.00027190143,0.000099925,0.00055965065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032959713,0.00042037864,0.0007464694,0.00054811843,0.00015111927,0.000012823144,0.00011923876,0.00031975246,0.0004606807],"category_scores_gemma":[0.00029911412,0.00023265566,0.00006132542,0.00042032605,0.0003402646,0.00010741092,0.000022147306,0.00083272904,0.000037677633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030465875,0.00044748661,0.989534,0.0000033375838,0.0002895103,0.0004079708,0.004209608,0.0000010473209,0.0021619243,0.000016511338,0.0019648874,0.00065901515],"study_design_scores_gemma":[0.0098963315,0.0014461188,0.98243743,0.0004430227,0.00012654776,0.0000051497627,0.000382077,0.0000871325,0.0042706328,0.000003929246,0.0006577833,0.00024384784],"about_ca_topic_score_codex":0.006274472,"about_ca_topic_score_gemma":0.030822901,"teacher_disagreement_score":0.024548428,"about_ca_system_score_codex":0.00034804436,"about_ca_system_score_gemma":0.00024769088,"threshold_uncertainty_score":0.98686206},"labels":[],"label_agreement":null},{"id":"W1548492282","doi":"10.18433/j31g7r","title":"Evaluation of the Efficacy and Safety of Changes in Antiretroviral Regimens for HIV-infected Patients","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Antiretroviral therapy; Virology; Pharmacology; Viral load","score_opus":0.07204588450988561,"score_gpt":0.40061751380461025,"score_spread":0.3285716292947246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1548492282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946155,0.00031014107,0.000028417706,0.0039655375,0.00018452623,0.0005501207,0.0000057693323,0.0000025700172,0.00033740394],"genre_scores_gemma":[0.99917626,0.00017186871,0.0004317227,0.000106864274,0.000064973676,0.000003957215,0.0000013614474,0.0000043651708,0.000038640388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980261,0.00023436049,0.0004548698,0.0001239946,0.0009787208,0.00018196716],"domain_scores_gemma":[0.99870455,0.00032637292,0.00034673588,0.00005844495,0.0004580788,0.00010583635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003207615,0.000099618504,0.00028578285,0.00016120746,0.000070929505,0.000007935381,0.00013077636,0.000020958432,0.000054461947],"category_scores_gemma":[0.00069191464,0.000056069606,0.00007414316,0.0003733316,0.0002890936,0.00011024235,0.000039574177,0.00011890132,5.447151e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010765557,0.000740131,0.82926655,0.000085422835,0.00010196138,8.375634e-7,0.00052975246,0.00004798888,0.02188016,0.00007710277,0.00033320478,0.14586036],"study_design_scores_gemma":[0.050575975,0.0013531393,0.59373534,0.0005875667,0.0018786293,0.000027552036,0.00012525046,0.037087753,0.29261276,0.00020413972,0.021609662,0.00020224231],"about_ca_topic_score_codex":0.0000028631514,"about_ca_topic_score_gemma":0.000003896763,"teacher_disagreement_score":0.2707326,"about_ca_system_score_codex":0.0000746015,"about_ca_system_score_gemma":0.00021689465,"threshold_uncertainty_score":0.22864522},"labels":[],"label_agreement":null},{"id":"W1551896540","doi":"10.3390/v7072790","title":"Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence","year":2015,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Integrase; Integrase inhibitor; Drug resistance; Virology; Biology; Drug; Medicine; Pharmacology; Genetics; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.078721512924904,"score_gpt":0.33043320093932566,"score_spread":0.2517116880144217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1551896540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002950517,0.993715,0.000020208941,0.00038752455,0.00013870535,0.0011612497,0.00016265581,0.0000802137,0.0040393844],"genre_scores_gemma":[0.000049568174,0.9801952,0.0010042896,0.00032862203,0.00014048045,0.00013782251,0.00009433032,0.00006605865,0.017983584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811643,0.00007130006,0.0005183248,0.00060593145,0.0003700126,0.0003180183],"domain_scores_gemma":[0.9988898,0.0001551985,0.00006261784,0.0003684325,0.00009567986,0.0004282753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021010259,0.00051822804,0.0014762722,0.00024063882,0.000078618265,0.000041381125,0.00012241345,0.00019952065,0.000027859898],"category_scores_gemma":[0.00015658503,0.00036250302,0.0002179766,0.00037483944,0.00010152866,0.00009453258,0.00003346748,0.0002954443,0.00025865668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015707176,0.0001526397,0.000069630725,0.010435727,0.0004991158,0.0003814879,0.0010143603,8.4521965e-8,0.0000071961713,0.00009171054,0.043022458,0.9441685],"study_design_scores_gemma":[0.00062895997,0.000053855798,0.000002477949,0.023054693,0.0009643487,0.000016838665,0.00012320031,1.3208478e-7,0.000035826164,0.0000054014604,0.97476274,0.00035154482],"about_ca_topic_score_codex":0.000003336127,"about_ca_topic_score_gemma":0.00006258082,"teacher_disagreement_score":0.94381696,"about_ca_system_score_codex":0.00024744286,"about_ca_system_score_gemma":0.0004925332,"threshold_uncertainty_score":0.9998827},"labels":[],"label_agreement":null},{"id":"W1557785974","doi":"10.4137/cmt.s1088","title":"Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults","year":2009,"lang":"en","type":"article","venue":"Clinical Medicine Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Ritonavir; Atazanavir; Tolerability; Medicine; Lopinavir; Protease inhibitor (pharmacology); Pharmacology; Cobicistat; Discontinuation; Darunavir; Adverse effect; Viral load; Pharmacotherapy; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.053827536458433196,"score_gpt":0.38340906998960606,"score_spread":0.32958153353117287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1557785974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91111404,0.0031421536,0.00082004536,0.077276364,0.0005980742,0.0059277336,0.00014867935,0.00023069668,0.0007422408],"genre_scores_gemma":[0.98685443,0.001522171,0.0023438965,0.0064109955,0.00093315257,0.00015655691,0.0002511417,0.00006987472,0.0014577775],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963331,0.00020478146,0.0015731852,0.00073105685,0.00063513534,0.0005227383],"domain_scores_gemma":[0.997132,0.0010126507,0.00047540394,0.00053636276,0.0003512248,0.0004923766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076534954,0.00052021124,0.0012971631,0.0001964345,0.000117343865,0.0000111800955,0.00017639257,0.00027080733,0.00005206184],"category_scores_gemma":[0.00024470082,0.00036615066,0.0002741294,0.00031634344,0.0004707601,0.00006705395,0.000031820397,0.0005207247,0.000024578103],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03145644,0.00919865,0.04721279,0.0005015655,0.0019300876,0.0002618964,0.003648428,0.0000029377427,0.01758155,0.0007057542,0.009969784,0.8775301],"study_design_scores_gemma":[0.3034357,0.07845599,0.18714389,0.015494859,0.00673934,0.00034399453,0.0017975922,0.007604715,0.09293974,0.0040499778,0.29916215,0.0028320444],"about_ca_topic_score_codex":0.000007959976,"about_ca_topic_score_gemma":0.0000026960713,"teacher_disagreement_score":0.87469804,"about_ca_system_score_codex":0.00010835829,"about_ca_system_score_gemma":0.00022792109,"threshold_uncertainty_score":0.99987906},"labels":[],"label_agreement":null},{"id":"W1557841390","doi":"10.1684/vir.2013.0479","title":"Antiretroviral therapy with integrase inhibitors: more options.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Elvitegravir; Dolutegravir; Cobicistat; Integrase; Raltegravir; Integrase inhibitor; Ritonavir; Pharmacology; Medicine; Virology; Tenofovir alafenamide; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.01473888742573415,"score_gpt":0.22096804733516248,"score_spread":0.20622915990942833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1557841390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859955,0.00033485063,0.000019407335,0.0079736365,0.00007799355,0.0015379823,0.000002061313,0.00012130871,0.0039373157],"genre_scores_gemma":[0.96531886,0.00010283412,0.0009917092,0.00040948417,0.0001338412,0.0027519295,0.000044086628,0.000022888535,0.03022439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912286,0.00001527688,0.0001450334,0.00019800692,0.00021368107,0.00030514871],"domain_scores_gemma":[0.99948967,0.000016335256,0.000038261023,0.0001959207,0.000073335425,0.00018646485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000738436,0.00015289395,0.0001835198,0.00011223179,0.00005312724,0.000037138852,0.000048332047,0.000047282596,0.00015707388],"category_scores_gemma":[0.000017060813,0.00009024971,0.000053000178,0.00020016887,0.000070860544,0.00014541553,0.000014320275,0.00010705696,0.00017837301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018785249,0.0006257865,0.49584356,0.000020657704,0.00040399158,0.000095112155,0.0006189869,4.6388422e-7,0.000110804234,0.00014262143,0.038355093,0.46359506],"study_design_scores_gemma":[0.0042518796,0.0001483332,0.962045,0.000041806306,0.00007043827,0.000047877027,0.0004220486,0.000020048066,0.0061442773,0.000055002827,0.026521659,0.00023162267],"about_ca_topic_score_codex":0.000049096823,"about_ca_topic_score_gemma":0.0000040794716,"teacher_disagreement_score":0.46620142,"about_ca_system_score_codex":0.00007972637,"about_ca_system_score_gemma":0.000042563992,"threshold_uncertainty_score":0.36802766},"labels":[],"label_agreement":null},{"id":"W1567454225","doi":"10.1155/2011/169045","title":"Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; McGill University Health Centre; Université de Montréal","funders":"Gilead Sciences; GlaxoSmithKline; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Regimen; Human immunodeficiency virus (HIV); Intensive care medicine; Antiretroviral therapy; Viral load; Health care; Health professionals; Alternative medicine; Internal medicine; Family medicine; Adverse effect; Pathology","score_opus":0.015367756578425552,"score_gpt":0.28635970563588375,"score_spread":0.2709919490574582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1567454225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548097,0.019395353,0.0002875191,0.022863232,0.00037721224,0.0011079944,0.0011196716,0.000015051295,0.000024214938],"genre_scores_gemma":[0.98853457,0.0002696829,0.00069210527,0.008957033,0.00045991415,0.00006446521,0.00081377843,0.0000252263,0.00018325409],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888533,0.00008456135,0.00042743082,0.0001816792,0.000075330725,0.00034568086],"domain_scores_gemma":[0.99775934,0.00020318627,0.00022355099,0.00011830072,0.0008501043,0.00084553036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011135981,0.00019089163,0.00046641094,0.00010941131,0.00029070515,0.000012601992,0.000104496416,0.00013161195,0.00013244835],"category_scores_gemma":[0.00035037292,0.00009901619,0.00014706832,0.00007225373,0.00023528795,0.000035772515,0.000010283278,0.00016483036,0.0000014223762],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013290411,0.00014870353,0.79220027,0.00016265521,0.00060828764,0.000085128384,0.010740993,1.4425204e-7,0.00001746077,0.000062418854,0.15001501,0.044629917],"study_design_scores_gemma":[0.052861582,0.011815759,0.38726366,0.004815263,0.0010512585,0.0012885742,0.031645652,0.0000136822755,0.000354457,0.00013948214,0.5079404,0.0008101932],"about_ca_topic_score_codex":0.011378871,"about_ca_topic_score_gemma":0.11641253,"teacher_disagreement_score":0.40493658,"about_ca_system_score_codex":0.0002027249,"about_ca_system_score_gemma":0.0056288037,"threshold_uncertainty_score":0.9985256},"labels":[],"label_agreement":null},{"id":"W1577647292","doi":"10.1186/1758-2652-11-s1-p22","title":"Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients","year":2008,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Darunavir; Medicine; Lopinavir; Pharmacology; Internal medicine; Virology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.02994891501858672,"score_gpt":0.3097666932872059,"score_spread":0.2798177782686192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1577647292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955486,0.00018141893,0.00014875275,0.0021547738,0.00040000028,0.0002941811,0.00003976149,0.000009818418,0.0012226824],"genre_scores_gemma":[0.9908864,0.0006368317,0.0023562245,0.0002667827,0.00015635965,0.000010856895,0.00006280592,0.000017402654,0.005606352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971868,0.000068090834,0.0011310208,0.00024263996,0.0011186729,0.00025276846],"domain_scores_gemma":[0.9982215,0.00012742865,0.0007821918,0.00026291152,0.00046375048,0.00014222786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029920376,0.00026862006,0.000727378,0.00024761344,0.00014201234,0.00001708299,0.00043931205,0.00010268036,0.0002136711],"category_scores_gemma":[0.000104863604,0.00017008185,0.0012146336,0.000714646,0.00018802761,0.00023585431,0.000092361595,0.00028417888,0.0000094263205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005851958,0.02508269,0.9174675,0.00002866633,0.012577792,0.00018621719,0.017660728,0.00049350143,0.0013761284,0.00022247658,0.008890956,0.010161393],"study_design_scores_gemma":[0.13473046,0.005561574,0.7983135,0.0008906672,0.0037531727,0.00029656777,0.0030175725,0.0018740621,0.018514834,0.00019025522,0.032149345,0.00070798566],"about_ca_topic_score_codex":0.000054211283,"about_ca_topic_score_gemma":0.000015923466,"teacher_disagreement_score":0.12887849,"about_ca_system_score_codex":0.0010138336,"about_ca_system_score_gemma":0.00042160647,"threshold_uncertainty_score":0.69357365},"labels":[],"label_agreement":null},{"id":"W1581132202","doi":"10.18433/j32p5c","title":"Evaluation of Renal Adverse Effects of Combination Anti-retroviral Therapy including Tenofovir in HIV-infected Patients","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Darunavir; Raltegravir; Atazanavir; Medicine; Renal function; Ritonavir; Cart; Pharmacology; Elvitegravir; Reverse-transcriptase inhibitor; Internal medicine; Adverse effect; Integrase inhibitor; Creatinine; Virology; Protease inhibitor (pharmacology); Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.07130599499987371,"score_gpt":0.40025207729732737,"score_spread":0.32894608229745365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1581132202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970605,0.00053227996,0.000032691594,0.0009448984,0.00024080757,0.00075958174,0.000001308964,0.000006526068,0.00042141989],"genre_scores_gemma":[0.9990119,0.0003678298,0.0004278259,0.00010246777,0.0000461781,0.000010701634,0.0000035253913,0.000007056144,0.000022562961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965714,0.0003672655,0.0007757979,0.00016133428,0.0018672019,0.0002570018],"domain_scores_gemma":[0.9979879,0.00025630783,0.0005244183,0.00006149925,0.0009988443,0.00017099093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023118844,0.00015421689,0.00040107232,0.00050391984,0.000068843074,0.00001302564,0.00016708879,0.000034364017,0.00033430386],"category_scores_gemma":[0.0004299854,0.00010406712,0.00012836298,0.0007711794,0.00023840238,0.00059710315,0.000042562482,0.00022176107,0.000010509241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001846063,0.0017600611,0.7767767,0.00006392208,0.00013570514,0.000009408959,0.0005151506,0.0000755654,0.13540144,0.000021462212,0.00023193573,0.084824085],"study_design_scores_gemma":[0.025802094,0.0006906403,0.5415601,0.00034560487,0.00042903455,0.000012304221,0.00007707024,0.021163289,0.40912622,0.00015397154,0.000506626,0.0001330432],"about_ca_topic_score_codex":0.00001838711,"about_ca_topic_score_gemma":7.316065e-7,"teacher_disagreement_score":0.2737248,"about_ca_system_score_codex":0.00022256117,"about_ca_system_score_gemma":0.00040390526,"threshold_uncertainty_score":0.4243734},"labels":[],"label_agreement":null},{"id":"W158673270","doi":"10.1007/978-1-4614-7291-9_9","title":"Targeting RT Translocation","year":2013,"lang":"en","type":"book-chapter","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Chromosomal translocation; Reverse transcriptase; Deoxyribonucleotides; DNA; Nucleotide; Biology; RNA; Virology; Human immunodeficiency virus (HIV); Chemistry; Computational biology; Genetics; Molecular biology; Gene","score_opus":0.01642558363832228,"score_gpt":0.23281733290852516,"score_spread":0.21639174927020288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W158673270","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003945277,0.0008048864,0.00038197005,0.0030692008,0.000098562654,0.00058307144,0.0000024691963,0.00011937755,0.994901],"genre_scores_gemma":[0.0015122086,0.00060407136,0.005184028,0.0002327938,0.00018441389,0.000025534544,0.000475685,0.000049569502,0.9917317],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913913,0.000002680964,0.0002592745,0.00023889776,0.00021911834,0.00014088869],"domain_scores_gemma":[0.9995797,0.000017100621,0.000060046194,0.00016209453,0.0000822405,0.00009880935],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000054851807,0.0002332951,0.00031289828,0.00010428892,0.00003898963,0.000011526805,0.000036548427,0.0001958573,0.01714707],"category_scores_gemma":[0.000004825424,0.00017262879,0.00010112221,0.000012110897,0.000022762248,0.000034864956,0.000009567141,0.00015167908,0.0070017627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000625908,0.00014511218,0.00029608773,0.00032989995,0.0013856374,0.00016274978,0.000998749,0.0000010995813,0.00054160244,0.16096681,0.66596407,0.1691456],"study_design_scores_gemma":[0.00079908565,0.000037340164,0.0000380423,0.0003068688,0.00020633661,0.000016148995,0.000020771486,0.000044932574,0.0003974436,0.0014890261,0.9963876,0.00025640952],"about_ca_topic_score_codex":0.0000068828735,"about_ca_topic_score_gemma":0.0000031169254,"teacher_disagreement_score":0.33042353,"about_ca_system_score_codex":0.00008795827,"about_ca_system_score_gemma":0.00010142454,"threshold_uncertainty_score":0.9937714},"labels":[],"label_agreement":null},{"id":"W1589739884","doi":"10.4212/cjhp.v53i2.716","title":"Change in Formulations for Acetazolamide and Allopurinol Suspensions","year":2000,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Acetazolamide; Allopurinol; Medicine; Pharmacology; Chemistry; Internal medicine","score_opus":0.03629287645162773,"score_gpt":0.30874099063789795,"score_spread":0.27244811418627024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1589739884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95223296,0.00090203586,0.0000018619212,0.045261633,0.000100677215,0.0005381744,0.000008336436,0.0000031872773,0.00095116213],"genre_scores_gemma":[0.9967115,0.00020428369,0.00034084468,0.0005299202,0.00015269175,0.00001783248,0.0000064245723,0.000011713947,0.0020248247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940145,0.0000129091395,0.00020893483,0.00006595037,0.00008807458,0.000222669],"domain_scores_gemma":[0.9994442,0.000042092,0.000050151328,0.00006922277,0.00006981371,0.00032455675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014915617,0.00008777547,0.0001569593,0.00014969437,0.00015998314,0.00002330503,0.000065664986,0.000017822293,0.00033756145],"category_scores_gemma":[0.00002367823,0.000058471436,0.00006209459,0.00010587887,0.000048912552,0.00014744257,0.0000041549765,0.00013157146,0.000012558851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039934856,0.0003069966,0.78450733,0.00004864945,0.00056358404,0.0013044232,0.02338191,0.000027481205,0.00013005178,0.0018383515,0.019208191,0.16828369],"study_design_scores_gemma":[0.01303422,0.00056060246,0.6385757,0.00029453076,0.00047631632,0.0006577041,0.0003483663,0.00067136285,0.0008878895,0.0020304485,0.34211168,0.00035121624],"about_ca_topic_score_codex":0.0019647141,"about_ca_topic_score_gemma":0.027915964,"teacher_disagreement_score":0.32290348,"about_ca_system_score_codex":0.00012787266,"about_ca_system_score_gemma":0.00039290797,"threshold_uncertainty_score":0.98982203},"labels":[],"label_agreement":null},{"id":"W1592526552","doi":"","title":"Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Nephrogenic diabetes insipidus; Abacavir; Cidofovir; Fanconi syndrome; Discontinuation; Adefovir; Pediatrics; Dolutegravir; Ritonavir; Human immunodeficiency virus (HIV); Virology; Internal medicine; Diabetes insipidus; Antiretroviral therapy; Viral load; Kidney; Lamivudine; Virus","score_opus":0.01090064811531882,"score_gpt":0.199139596355942,"score_spread":0.18823894824062318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592526552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150586,0.00058259274,0.000009289607,0.0006512059,0.00009834388,0.0023272878,0.0000051380257,0.00012402088,0.004696272],"genre_scores_gemma":[0.9962026,0.00001967135,0.0006147738,0.00023430555,0.000011688662,0.0011122092,0.000043233278,0.00005696797,0.0017045737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972005,0.000041318846,0.00048452112,0.0005494921,0.0005914909,0.0011327001],"domain_scores_gemma":[0.9989007,0.00007926976,0.00016150251,0.00047397168,0.000086935455,0.00029759764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004483057,0.0003836649,0.000611446,0.0004985874,0.0001170311,0.000032748274,0.00014319996,0.00012995489,0.000027194994],"category_scores_gemma":[0.000034905857,0.0002717404,0.0000815941,0.0012166231,0.000098575314,0.00023286873,0.00006479173,0.00020350389,0.000058319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020263002,0.0033584882,0.82958645,0.0003169238,0.0016622731,0.02687947,0.0041408106,0.0000127400845,0.0015451126,0.000104129496,0.00026075103,0.13010658],"study_design_scores_gemma":[0.0065829842,0.00076431606,0.97890127,0.00028944918,0.00023390273,0.002553408,0.0008090406,0.000007527564,0.008174107,0.000016010981,0.0011436065,0.0005243888],"about_ca_topic_score_codex":0.00005052042,"about_ca_topic_score_gemma":0.0001252497,"teacher_disagreement_score":0.14931484,"about_ca_system_score_codex":0.00053839013,"about_ca_system_score_gemma":0.00018572288,"threshold_uncertainty_score":0.9999735},"labels":[],"label_agreement":null},{"id":"W15969640","doi":"10.1177/135965350000500112","title":"The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan","year":2000,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Regimen; Internal medicine; Medicine; Drug resistance; Genotyping; Confounding; Viral load; HIV drug resistance; Observational study; Odds ratio; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genotype; Biology","score_opus":0.052429182704700567,"score_gpt":0.34540640566846403,"score_spread":0.2929772229637635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W15969640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908755,0.005173685,0.00026268337,0.0024128843,0.000013215625,0.00074969896,0.00036251757,0.00003535549,0.00011444753],"genre_scores_gemma":[0.9846761,0.007385265,0.0023191238,0.000055731154,0.00004276688,0.000014388652,0.00016216097,0.00002231491,0.0053221076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758023,0.0004901853,0.00050616544,0.0006744497,0.00048456743,0.00026437597],"domain_scores_gemma":[0.99815893,0.00063006347,0.00020187527,0.0007334727,0.00020089261,0.000074745396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022096143,0.00028052862,0.0010865681,0.00049058284,0.0003993859,0.00005497195,0.00014181744,0.00005905097,0.00002733526],"category_scores_gemma":[0.00017330828,0.00017819273,0.00016010678,0.002367121,0.00025719704,0.00020822197,0.00006167585,0.00014300026,0.0000014874892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015460408,0.00008058695,0.9444903,0.0000061737314,0.023310075,0.000016453898,0.007753913,0.0000058352443,0.001278422,0.000028537113,0.0004057873,0.0071634836],"study_design_scores_gemma":[0.0038471697,0.0003151297,0.9838695,0.00007246486,0.0052513373,7.273121e-7,0.0012353215,0.0007506815,0.002108373,0.00014924932,0.0021382996,0.0002617413],"about_ca_topic_score_codex":0.000045023226,"about_ca_topic_score_gemma":0.00026594725,"teacher_disagreement_score":0.03937918,"about_ca_system_score_codex":0.00015484526,"about_ca_system_score_gemma":0.00008467973,"threshold_uncertainty_score":0.72664887},"labels":[],"label_agreement":null},{"id":"W1603290129","doi":"10.1186/1758-2652-13-s4-o50","title":"Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)","year":2010,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Rash; Dosing; Efavirenz; Internal medicine; Integrase inhibitor; Antiretroviral therapy; Pharmacology; Viral load; Human immunodeficiency virus (HIV); Virology","score_opus":0.013789104567095903,"score_gpt":0.25967404484040635,"score_spread":0.24588494027331045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1603290129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98677176,0.00021432151,0.000014861554,0.011635934,0.00085984863,0.00021150868,0.000004767263,0.000008344944,0.0002786501],"genre_scores_gemma":[0.9934846,0.00090050034,0.0026930356,0.00051989895,0.00016517211,0.000005083543,0.0000030891133,0.000015433689,0.0022131796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984205,0.00007465844,0.00054010015,0.0001664361,0.00062306115,0.00017524113],"domain_scores_gemma":[0.9991098,0.0001554673,0.00033563445,0.00012764936,0.00021353477,0.000057933074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008858263,0.00016204521,0.00028567715,0.00018945485,0.000061847684,0.00005246485,0.00024648785,0.00010083284,0.000034630233],"category_scores_gemma":[0.00022116,0.0001065019,0.00026020064,0.0002200964,0.00010816743,0.00027282952,0.000080481615,0.00066276843,0.0000036637925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013980339,0.00094663794,0.95825905,0.000014744656,0.00023156805,0.000063050014,0.0026005933,0.0000035504413,0.016718147,0.00022703884,0.0011054525,0.018432125],"study_design_scores_gemma":[0.010296141,0.00068889174,0.9705391,0.0004763294,0.00003092385,0.0001473372,0.00089093135,0.0007000661,0.011764987,0.00040858262,0.003903546,0.00015314105],"about_ca_topic_score_codex":0.000054067288,"about_ca_topic_score_gemma":0.000051819527,"teacher_disagreement_score":0.018278984,"about_ca_system_score_codex":0.00026737025,"about_ca_system_score_gemma":0.0001940639,"threshold_uncertainty_score":0.43430215},"labels":[],"label_agreement":null},{"id":"W1606512644","doi":"10.1097/qad.0b013e328318f130","title":"Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute on Alcohol Abuse and Alcoholism; U.S. Public Health Service; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Nevirapine; Abacavir; Efavirenz; Lopinavir; Medicine; Nelfinavir; Lamivudine; Ritonavir; Internal medicine; Regimen; Hazard ratio; Zidovudine; Odds ratio; Cohort; Confidence interval; Viral load; Immunology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.04690240772965168,"score_gpt":0.3747066830842476,"score_spread":0.3278042753545959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606512644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959472,0.000069815775,0.000022231072,0.0016461839,0.0005442006,0.0011843503,0.000010841233,0.0000716614,0.0005035205],"genre_scores_gemma":[0.9907969,0.0007424807,0.0059279045,0.0016321768,0.00023387177,0.00006266895,0.0001004759,0.00004736412,0.0004561452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955724,0.00060028327,0.0018134658,0.0007942462,0.0005750741,0.00064455805],"domain_scores_gemma":[0.9984015,0.0005985566,0.00019622663,0.00041267983,0.000108872744,0.00028213905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014011835,0.00039051316,0.0009966032,0.00036547918,0.00009774381,0.000013593194,0.00021137553,0.00038091195,0.00006422962],"category_scores_gemma":[0.0008694626,0.00025155328,0.00030508902,0.00062947755,0.00012965867,0.00039278148,0.00007742383,0.00082855456,0.00013535064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013164491,0.0026637323,0.92833126,0.000014119642,0.00013798289,0.0007673648,0.0010749886,9.568608e-7,0.00004364087,0.0000051251,0.00015718183,0.06548722],"study_design_scores_gemma":[0.008432231,0.004919212,0.98450434,0.00015571657,0.000054802495,0.000018540943,0.0001440365,0.000025019874,0.00012819307,0.000026675205,0.0012777117,0.00031351417],"about_ca_topic_score_codex":0.00003961602,"about_ca_topic_score_gemma":0.000042736578,"teacher_disagreement_score":0.06517371,"about_ca_system_score_codex":0.00012563843,"about_ca_system_score_gemma":0.00019407005,"threshold_uncertainty_score":0.9999937},"labels":[],"label_agreement":null},{"id":"W1647538163","doi":"10.1111/j.1747-0285.2010.00995.x","title":"Design, Biologic Evaluation, and SAR of Novel Pseudo‐peptide Incorporating Benzheterocycles as HIV‐1 Protease Inhibitors","year":2010,"lang":"en","type":"article","venue":"Chemical Biology & Drug Design","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Natural Science Foundation of China","keywords":"Substituent; HIV-1 protease; Chemistry; Stereochemistry; Isostere; Protease; Sulfonamide; Protease inhibitor (pharmacology); Potency; Pyrrolidine; Isopropyl; Docking (animal); Hydrogen bond; Enzyme; Biochemistry; Human immunodeficiency virus (HIV); In vitro; Organic chemistry; Biology; Medicine","score_opus":0.03402141036641947,"score_gpt":0.29277029500734336,"score_spread":0.2587488846409239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1647538163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191,0.00018871686,0.004111406,0.0016895962,0.000095517455,0.0017041671,0.000009743944,0.00007965435,0.00021121593],"genre_scores_gemma":[0.86119324,0.000013789349,0.13802648,0.00015724296,0.00011282997,0.00015066203,0.00014019346,0.000021382533,0.00018416428],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981958,0.00017092143,0.0005586625,0.00055436016,0.00019253946,0.00032766446],"domain_scores_gemma":[0.9985268,0.00045552824,0.00026813126,0.00028731057,0.00024217897,0.00022006065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010807858,0.00031774558,0.00051825197,0.00014318526,0.000092674905,0.000011472134,0.00013319806,0.00032193802,0.00008964105],"category_scores_gemma":[0.00091516646,0.00023155741,0.000081968596,0.00018634404,0.00052317855,0.000064236716,0.00009306616,0.0003443091,0.000040854004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023261203,0.00035347065,0.020128604,0.000031587962,0.00011993753,0.000007582819,0.00028341156,0.00000332602,0.9730688,0.00011000836,0.0009963465,0.0046643508],"study_design_scores_gemma":[0.0030185943,0.00016794489,0.0004842112,0.000089865396,0.00020940647,0.00008234409,0.00010474485,0.0014836154,0.99144894,0.002421824,0.00021978859,0.00026873033],"about_ca_topic_score_codex":0.000010508799,"about_ca_topic_score_gemma":7.335051e-7,"teacher_disagreement_score":0.13391508,"about_ca_system_score_codex":0.0000633317,"about_ca_system_score_gemma":0.00029079415,"threshold_uncertainty_score":0.9442637},"labels":[],"label_agreement":null},{"id":"W1665734223","doi":"10.7705/biomedica.v33i4.1462","title":"Resistencia a drogas antirretrovirales en pacientes expuestos a terapia antirretroviral en Cali, Colombia, 2008-2010","year":2013,"lang":"es","type":"article","venue":"Biomédica","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.008722072778387125,"score_gpt":0.24482318313243845,"score_spread":0.23610111035405132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1665734223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97194475,0.0063596303,0.000031625023,0.012025141,0.0013598334,0.002477985,0.0002296458,0.00036874018,0.005202663],"genre_scores_gemma":[0.90167135,0.0014029254,0.002782551,0.00050717854,0.00074938324,0.0002753177,0.00037174282,0.00013151411,0.09210804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942773,0.0004972178,0.0011602086,0.001276942,0.0012275621,0.0015607998],"domain_scores_gemma":[0.9969742,0.00043207017,0.00041558396,0.001052213,0.0002752253,0.00085070945],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005959472,0.0010018421,0.0013043694,0.00083084096,0.00045627035,0.00039116674,0.0006145298,0.0007034726,0.0028852702],"category_scores_gemma":[0.00042952178,0.00084598956,0.00052224495,0.0009794511,0.0006789607,0.00048148175,0.00033896,0.0005955229,0.008890251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023700847,0.0017160662,0.6680033,0.00047351499,0.0011433722,0.00074919994,0.0034155513,8.709259e-8,0.04153171,0.00047073842,0.26433033,0.017929135],"study_design_scores_gemma":[0.006485561,0.0018333477,0.7010394,0.0017157935,0.0009991805,0.00016766271,0.0022265103,0.00019729855,0.01254595,0.00008534198,0.27127582,0.0014281879],"about_ca_topic_score_codex":0.0008132736,"about_ca_topic_score_gemma":0.000034962188,"teacher_disagreement_score":0.086905375,"about_ca_system_score_codex":0.0005423923,"about_ca_system_score_gemma":0.00071687665,"threshold_uncertainty_score":0.99939907},"labels":[],"label_agreement":null},{"id":"W1674196795","doi":"10.1016/s1473-3099(15)00152-8","title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"Janssen Research and Development; ViiV Healthcare","keywords":"Rilpivirine; Efavirenz; Emtricitabine; Regimen; Medicine; Dolutegravir; Nucleoside Reverse Transcriptase Inhibitor; Internal medicine; Raltegravir; Reverse-transcriptase inhibitor; Pharmacology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.017478170525456083,"score_gpt":0.2684220902275357,"score_spread":0.25094391970207963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1674196795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249005,0.0005131249,0.00039026898,0.00087953365,0.00048135978,0.0040052356,0.00013417908,0.00041640538,0.0006898674],"genre_scores_gemma":[0.9960639,0.00021727024,0.0001354601,0.00035563004,0.0010766117,0.0011239704,0.00028381316,0.0000957099,0.00064767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968618,0.000400738,0.0005972965,0.00070732174,0.00069957256,0.00073323684],"domain_scores_gemma":[0.9983343,0.00013781438,0.00029490783,0.0006097165,0.0001914895,0.00043176708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047240168,0.0006570139,0.0011445304,0.00045802532,0.0002449226,0.000117709315,0.0001225031,0.00015817427,0.000041705607],"category_scores_gemma":[0.00015699666,0.00040803637,0.00022807303,0.0010590266,0.0002846913,0.00057018286,0.000037863105,0.0005983711,0.000058291684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68569714,0.002406686,0.29073974,0.00028872036,0.00073253666,0.0015881372,0.0074858847,0.0010827781,0.00015645837,0.000021576467,0.003051442,0.0067489226],"study_design_scores_gemma":[0.9433708,0.004476647,0.039041467,0.002285376,0.0023712232,0.00041877385,0.0017430303,0.00095524796,0.00041583227,0.000071188304,0.0037562505,0.0010941166],"about_ca_topic_score_codex":0.0021654975,"about_ca_topic_score_gemma":0.0012526884,"teacher_disagreement_score":0.25767374,"about_ca_system_score_codex":0.0010296017,"about_ca_system_score_gemma":0.0008326743,"threshold_uncertainty_score":0.99983716},"labels":[],"label_agreement":null},{"id":"W1692190376","doi":"10.2147/dddt.s84850","title":"Dolutegravir &amp;ndash; a review of the pharmacology, efficacy, and safety in the treatment of HIV","year":2015,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Integrase inhibitor; Tolerability; Medicine; Pharmacology; Adverse effect; Integrase; Drug; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load","score_opus":0.09921393294740355,"score_gpt":0.36567768045984955,"score_spread":0.266463747512446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1692190376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043926755,0.99229354,0.0000135319915,0.0010039569,0.00011151117,0.005803778,0.000018628949,0.00001505198,0.00030071678],"genre_scores_gemma":[0.00001806433,0.9929649,0.002043731,0.00021905606,0.000049180086,0.0005221568,0.00015718571,0.000041428008,0.003984283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996781,0.0007940005,0.0011825878,0.0004562302,0.00046515072,0.0003210473],"domain_scores_gemma":[0.9982762,0.00054187473,0.0005348021,0.0004320616,0.00010184456,0.000113272545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015432831,0.0006528621,0.002419371,0.00021407091,0.00010927297,0.000012282897,0.00027687574,0.00016395,0.00005695759],"category_scores_gemma":[0.000019201862,0.00028869702,0.00026164655,0.0005922088,0.00022893724,0.000032979762,0.00005012961,0.00021881108,0.000012023854],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020636788,0.0009324528,0.00015405184,0.0098407585,0.0010223017,0.000018141925,0.005438306,4.5621707e-8,0.0000022017732,0.000023033319,0.0064081727,0.9759542],"study_design_scores_gemma":[0.004006561,0.00012068313,0.000164641,0.025347224,0.00095582794,0.0000675263,0.00005131542,3.1250644e-7,0.00008177508,0.000016108826,0.9689261,0.00026196922],"about_ca_topic_score_codex":0.0000062361687,"about_ca_topic_score_gemma":0.0000052257055,"teacher_disagreement_score":0.9756922,"about_ca_system_score_codex":0.0002263721,"about_ca_system_score_gemma":0.0013135561,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W1703585126","doi":"10.1177/135965350200700407","title":"Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Viral load; Discontinuation; Antiretroviral therapy; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Virology; Intensive care medicine; Immunology","score_opus":0.10938389424447433,"score_gpt":0.35304386302550805,"score_spread":0.24365996878103374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1703585126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632204,0.002027894,0.000021799335,0.00025469004,0.00004436902,0.0008569998,0.00003145501,0.00001221187,0.0004285225],"genre_scores_gemma":[0.9975253,0.0015164141,0.0004446418,0.000046329253,0.000027841623,0.000023378174,0.000036889625,0.00001775768,0.00036145755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666315,0.0004520195,0.001508021,0.00032833245,0.00080422446,0.00024422802],"domain_scores_gemma":[0.99817705,0.00023596121,0.0009801111,0.0003663943,0.00020453751,0.000035925503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016212667,0.000276546,0.0019553436,0.00058531715,0.000021690605,0.0000059515423,0.00014148052,0.00018675874,0.00021330029],"category_scores_gemma":[0.00019952834,0.00018591995,0.00064762693,0.0009768971,0.0001892928,0.00014527599,0.000031007505,0.00014070247,0.0000020707312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005618596,0.003051837,0.6488753,0.00003821447,0.0028827868,0.000009286155,0.0036613885,0.000009202594,0.30526057,0.000024217474,0.0000399442,0.030528696],"study_design_scores_gemma":[0.009976742,0.001423007,0.5454181,0.0002655409,0.000524678,4.8867776e-7,0.00007866185,0.0001863196,0.44189018,0.000020491569,0.00005675202,0.0001590198],"about_ca_topic_score_codex":0.00004843053,"about_ca_topic_score_gemma":0.000014401902,"teacher_disagreement_score":0.13662963,"about_ca_system_score_codex":0.000060964652,"about_ca_system_score_gemma":0.000047447553,"threshold_uncertainty_score":0.7581596},"labels":[],"label_agreement":null},{"id":"W1722705940","doi":"10.1089/aid.2013.0262","title":"Burden of Nonnucleoside Reverse Transcriptase Inhibitor Resistance in HIV-1-Infected Patients: A Systematic Review and Meta-Analysis","year":2014,"lang":"en","type":"review","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug resistance; Internal medicine; Clinical trial; Meta-analysis; Publication bias; Biology; Genetics","score_opus":0.10542069626091369,"score_gpt":0.3927186584773566,"score_spread":0.2872979622164429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1722705940","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025599173,0.9942197,0.0000018538937,0.00014006029,0.000007569466,0.004583975,0.00028511987,0.000023686405,0.00048200012],"genre_scores_gemma":[0.0014764722,0.9797134,0.00029116147,0.00006501242,0.000027007945,0.00074570184,0.00039581428,0.000060500548,0.017224945],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99429667,0.0013852547,0.0018783595,0.00082412746,0.0010355333,0.0005800454],"domain_scores_gemma":[0.9970831,0.000630585,0.0005181536,0.00090689544,0.0005040179,0.00035721282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023586536,0.00060001586,0.00962273,0.002474841,0.0001644131,0.0000657712,0.00023407205,0.00023868943,0.00032315636],"category_scores_gemma":[0.00092514243,0.00038596478,0.0012123351,0.0023320238,0.00036779622,0.00012433651,0.00012622388,0.00066182384,0.000036485988],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003330675,0.0002908258,0.0006138712,0.9404872,0.053868406,0.0000685404,0.00024157684,5.6117453e-9,6.2459156e-7,0.00042921896,0.0037423517,0.00022404523],"study_design_scores_gemma":[0.0013368572,0.00069364667,0.000086474945,0.14770009,0.64758414,0.000006024027,0.00005883251,9.436479e-8,0.000002950245,0.000054010092,0.2019819,0.0004949857],"about_ca_topic_score_codex":0.00013101335,"about_ca_topic_score_gemma":0.00024235934,"teacher_disagreement_score":0.79278713,"about_ca_system_score_codex":0.00021134138,"about_ca_system_score_gemma":0.00020373921,"threshold_uncertainty_score":0.9998592},"labels":[],"label_agreement":null},{"id":"W172708961","doi":"10.1177/135965350601100108","title":"Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; AIDS Vancouver; University of British Columbia; Providence Health Care","funders":"","keywords":"Nephrotoxicity; Antiretroviral therapy; Medicine; Mitochondrial toxicity; Human immunodeficiency virus (HIV); Lentivirus; Mechanism (biology); Kidney; Virology; Immunology; Internal medicine; Pharmacology; Viral load; Viral disease","score_opus":0.020830012184985775,"score_gpt":0.2323322019368617,"score_spread":0.2115021897518759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W172708961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950071,0.0000173722,0.00028094987,0.00031053027,0.00083277526,0.0015693735,0.000041152492,0.00016362226,0.001777106],"genre_scores_gemma":[0.9957047,0.00028616234,0.00025612328,0.00023952578,0.000502188,0.00014566684,0.00041191062,0.00006490847,0.0023887914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977818,0.00013555882,0.00045935428,0.0005207419,0.0006604006,0.00044210962],"domain_scores_gemma":[0.99905765,0.000038879843,0.0002699012,0.00031806968,0.00017723191,0.00013827629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008294287,0.00043662236,0.0005647065,0.00032568883,0.0001776828,0.0000431035,0.000111010246,0.0001582843,0.00008214364],"category_scores_gemma":[0.000035282064,0.00034398216,0.0003062339,0.0003913477,0.00010277726,0.0006277448,0.000026029495,0.0002419087,0.00008183837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021655949,0.007230993,0.27689928,0.000038232036,0.0011817667,0.0001498509,0.0012370368,0.0000054091834,0.635271,0.00247892,0.0037943583,0.050057177],"study_design_scores_gemma":[0.016627237,0.0033286866,0.22387694,0.00013025198,0.0000562674,0.0000024904525,0.0000518591,0.00004297377,0.75395995,0.00034324895,0.001233037,0.00034706015],"about_ca_topic_score_codex":0.00034848787,"about_ca_topic_score_gemma":0.000005470412,"teacher_disagreement_score":0.11868891,"about_ca_system_score_codex":0.00014243339,"about_ca_system_score_gemma":0.00015220749,"threshold_uncertainty_score":0.99990124},"labels":[],"label_agreement":null},{"id":"W1744409238","doi":"10.1016/s1054-3589(00)49024-1","title":"Inhibitors of HIV- I reverse transcriptase","year":2000,"lang":"en","type":"review","venue":"Advances in pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Polymerase; DNA polymerase; Biology; DNA; Virology; Nucleoside analogue; Enzyme; Nucleoside Reverse Transcriptase Inhibitor; Nucleoside; RNase H; RNA; Gene; Biochemistry","score_opus":0.02473578816740324,"score_gpt":0.3811810742160259,"score_spread":0.35644528604862263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1744409238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023651843,0.9915342,0.0000023378536,0.00019478009,0.0008205157,0.0011262873,0.00007077078,0.000030684958,0.0061967955],"genre_scores_gemma":[0.000015939131,0.9910632,0.0005991823,0.00013740122,0.00018131896,0.00024286254,0.00026539175,0.00004177654,0.007452923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980691,0.00015327024,0.00086671684,0.00041005132,0.00016490958,0.0003359524],"domain_scores_gemma":[0.9993149,0.00013665283,0.00022902271,0.00017850474,0.000025665284,0.00011523092],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000136513,0.00039000585,0.0019809506,0.00045570338,0.00002201533,0.0000015760057,0.00014045776,0.00022856012,0.0019174922],"category_scores_gemma":[0.000010107575,0.00030825078,0.00035646214,0.00047282645,0.00015263756,0.0001077769,0.00002195487,0.00041452688,0.00020447555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010529276,0.0004442705,0.00006865178,0.010116753,0.00025372265,0.000658247,0.00013058112,0.0000016884791,0.0000045612364,0.000019229114,0.017151976,0.971045],"study_design_scores_gemma":[0.0019487755,0.00007714325,8.8125125e-7,0.004723725,0.0017922592,0.00009549179,0.0000144743035,0.0000010073276,0.00009275073,0.000020163428,0.99101746,0.0002158381],"about_ca_topic_score_codex":0.0000019388517,"about_ca_topic_score_gemma":0.0000027004642,"teacher_disagreement_score":0.9738655,"about_ca_system_score_codex":0.00019519682,"about_ca_system_score_gemma":0.00035793032,"threshold_uncertainty_score":0.99993694},"labels":[],"label_agreement":null},{"id":"W176098340","doi":"10.2165/00002018-200124030-00005","title":"Saquinavir Soft Gelatin Capsule","year":2001,"lang":"en","type":"review","venue":"Drug Safety","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Saquinavir; Pharmacology; Medicine; Indinavir; Ritonavir; Protease inhibitor (pharmacology); Nelfinavir; Virology; Virus","score_opus":0.03345830669221781,"score_gpt":0.3288295794363439,"score_spread":0.29537127274412606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176098340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003026369,0.94834226,0.000040111587,0.00060394034,0.0003026195,0.0014002289,0.00007610332,0.00018409126,0.049047638],"genre_scores_gemma":[0.0000025305244,0.7625676,0.00081396016,0.00007325679,0.00032030724,0.000115888375,0.0014339421,0.00009355757,0.23457898],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973203,0.00013753917,0.00091526215,0.00064542366,0.0004362852,0.00054519076],"domain_scores_gemma":[0.998499,0.00015441059,0.0002922088,0.0006955842,0.000062356776,0.0002964531],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034751164,0.00070773065,0.0024104393,0.00024404578,0.00015254547,0.000022431994,0.0001984566,0.00033523422,0.0015635077],"category_scores_gemma":[0.000067546185,0.00050968875,0.0007780687,0.0005682037,0.00006690331,0.000057937814,0.00011282518,0.000583537,0.0049254624],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012976349,0.00018299343,0.000040094306,0.0049654013,0.0005221812,0.00046019795,0.00022005034,1.209627e-7,6.242008e-8,0.00009669552,0.024071725,0.9694275],"study_design_scores_gemma":[0.00084403093,0.000020580846,0.00002892404,0.011073816,0.0020034988,0.0003081079,0.000034794044,0.0000026773844,0.0000011129567,0.000017949289,0.98521423,0.00045025253],"about_ca_topic_score_codex":0.000023911745,"about_ca_topic_score_gemma":0.000013107916,"teacher_disagreement_score":0.9689773,"about_ca_system_score_codex":0.0005909647,"about_ca_system_score_gemma":0.0006891664,"threshold_uncertainty_score":0.9997355},"labels":[],"label_agreement":null},{"id":"W176944265","doi":"10.1177/135965350100600206","title":"Avanti 3: A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Lamivudine plus Zidovudine versus Lamivudine plus Zidovudine plus Nelfinavir in HIV-1-Infected Antiretroviral-Naive Patients","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; St. Paul's Hospital","funders":"","keywords":"Lamivudine; Nelfinavir; Zidovudine; Medicine; Tolerability; Placebo; Gastroenterology; Internal medicine; Adverse effect; Pharmacology; Randomized controlled trial; Indinavir; Virology; Sida; Viral load; Human immunodeficiency virus (HIV); Viral disease; Antiretroviral therapy; Virus","score_opus":0.04664450726182794,"score_gpt":0.318903719057104,"score_spread":0.27225921179527607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176944265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98379445,0.0007409641,0.00014134929,0.003511677,0.0006985451,0.008483175,0.000057486523,0.00012657975,0.0024457895],"genre_scores_gemma":[0.99132854,0.0034677335,0.0003293212,0.00025271976,0.0003636444,0.00025655935,0.0005580632,0.00009432205,0.0033491252],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99539024,0.00041261452,0.0014937914,0.00089862227,0.0008547531,0.0009499534],"domain_scores_gemma":[0.9971493,0.0010076724,0.0005072646,0.0007171005,0.00032275036,0.00029593954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001070355,0.000846529,0.0026241976,0.000624424,0.00026809436,0.00006923658,0.00035208088,0.00018748666,0.00016046182],"category_scores_gemma":[0.00037462698,0.00055846246,0.00040495908,0.0015686437,0.00045104392,0.0002689743,0.00020945483,0.00049970334,0.00009731507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.926188,0.0012517396,0.062457908,0.00004008229,0.0009174234,0.00013152312,0.0020890061,0.000063072825,0.000291459,0.00027297324,0.0013621616,0.004934684],"study_design_scores_gemma":[0.9569485,0.0024981112,0.032212425,0.00037016446,0.00033953658,0.000013570074,0.00017076611,0.00064271013,0.0011620257,0.000020974008,0.0050377916,0.0005834281],"about_ca_topic_score_codex":0.0003139797,"about_ca_topic_score_gemma":0.00012232126,"teacher_disagreement_score":0.030760529,"about_ca_system_score_codex":0.0004629776,"about_ca_system_score_gemma":0.0003961962,"threshold_uncertainty_score":0.99968666},"labels":[],"label_agreement":null},{"id":"W1778298262","doi":"10.1186/1471-2334-6-146","title":"Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort","year":2006,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia; HIV Legal Network; St. Paul's Hospital","funders":"Canadian Institutes of Health Research; Canadian HIV Trials Network, Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Logistic regression; Propensity score matching; Odds ratio; Odds; Internal medicine; Cohort; Multivariate analysis; Antiretroviral therapy; Medical microbiology; Emergency medicine; Human immunodeficiency virus (HIV); Viral load; Immunology","score_opus":0.010945383468104983,"score_gpt":0.2682683836451802,"score_spread":0.2573230001770752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1778298262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955782,0.0010167283,0.000034256078,0.0001227432,0.00008753859,0.00057844067,0.00002568555,0.00012279977,0.0024335983],"genre_scores_gemma":[0.99799454,0.00008788379,0.00021059206,0.000021795098,0.00009831535,0.000050544735,0.00012507182,0.000019486848,0.0013917903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990942,0.000033705943,0.000241078,0.00023643159,0.0002224658,0.00017215201],"domain_scores_gemma":[0.9994485,0.00006519483,0.00011733193,0.00015971837,0.00007842126,0.00013086524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030391235,0.00018049768,0.00041537036,0.000100726094,0.000084167834,0.000016283,0.000028831491,0.000058634603,0.00007184977],"category_scores_gemma":[0.000031139152,0.00013778899,0.00010190471,0.00014181137,0.00009377112,0.00007403587,0.000021723217,0.000059369144,0.000012601466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000321149,0.0016956234,0.99172693,0.000059771617,0.00015676065,0.000016594951,0.00020833182,0.0000015673502,0.00026593328,0.00015232456,0.0022388422,0.0031561404],"study_design_scores_gemma":[0.0032181765,0.00069380563,0.98969424,0.000065048145,0.00021283713,0.000009464449,0.00013175095,0.000040707866,0.00495876,0.00017182612,0.000646459,0.00015690076],"about_ca_topic_score_codex":0.00014117407,"about_ca_topic_score_gemma":0.000017352813,"teacher_disagreement_score":0.004692827,"about_ca_system_score_codex":0.00006810537,"about_ca_system_score_gemma":0.00014341928,"threshold_uncertainty_score":0.56188715},"labels":[],"label_agreement":null},{"id":"W178626500","doi":"10.2165/00003088-200746020-00002","title":"Efavirenz and Nevirapine in HIV-1 Infection","year":2007,"lang":"en","type":"review","venue":"Clinical Pharmacokinetics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia; University of British Columbia","funders":"","keywords":"Nevirapine; Efavirenz; Medicine; Virology; Pharmacotherapy; Human immunodeficiency virus (HIV); Reverse-transcriptase inhibitor; Antiretroviral therapy; Pharmacology; Viral load; Internal medicine","score_opus":0.21109861450931747,"score_gpt":0.5207145243752711,"score_spread":0.30961590986595366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W178626500","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021969211,0.995216,0.00003904053,0.00027671695,0.00060374144,0.0011429383,0.000014421787,0.000069229274,0.0024181798],"genre_scores_gemma":[0.000028794364,0.98985153,0.0008346971,0.00030286793,0.00074911787,0.00004619729,0.00028651496,0.00006708029,0.007833171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99702847,0.00017526493,0.001641171,0.00056776445,0.0002349448,0.00035240175],"domain_scores_gemma":[0.9984717,0.00058057345,0.0002876108,0.00027487977,0.000052460637,0.00033278958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008719611,0.00046745376,0.0020649435,0.00038803593,0.000032107924,0.00001756722,0.000080059974,0.0004893997,0.00020284318],"category_scores_gemma":[0.00019615826,0.0003591553,0.0004216733,0.0004993443,0.00015543509,0.000035436202,0.00011352224,0.0010834028,0.00038242026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029441191,0.00050595903,0.0059652086,0.004843266,0.000260704,0.00026857248,0.000013183575,9.81449e-8,1.10622025e-7,0.000013724408,0.0082414895,0.9798582],"study_design_scores_gemma":[0.0026068776,0.00011689137,0.0011871317,0.006242055,0.0021413458,0.0000778764,0.0000010554594,0.000019782818,0.0000014277033,0.000010862531,0.9872961,0.0002985701],"about_ca_topic_score_codex":0.0000029228959,"about_ca_topic_score_gemma":0.0000036606618,"teacher_disagreement_score":0.97955966,"about_ca_system_score_codex":0.0001230555,"about_ca_system_score_gemma":0.000203013,"threshold_uncertainty_score":0.99988604},"labels":[],"label_agreement":null},{"id":"W1788007137","doi":"10.1111/hiv.12089","title":"<scp>HIV</scp>‐1 drug resistance prevalence, drug susceptibility and variant characterization in the <scp>J</scp>acobi <scp>M</scp>edical <scp>C</scp>enter paediatric cohort, <scp>B</scp>ronx, <scp>NY</scp>, <scp>USA</scp>","year":2013,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; Public Health Agency of Canada","keywords":"Medicine; Cart; Viral load; Cohort; Drug resistance; Reverse transcriptase; Virology; Human immunodeficiency virus (HIV); Reverse-transcriptase inhibitor; Drug; Antiretroviral therapy; Internal medicine; Immunology; Pharmacology; RNA; Biology; Microbiology","score_opus":0.00854295945124265,"score_gpt":0.2277559972683018,"score_spread":0.21921303781705917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1788007137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91954905,0.015455484,0.0014198156,0.003911267,0.0036711951,0.012572163,0.0011663157,0.0014457596,0.040808972],"genre_scores_gemma":[0.4902398,0.021155473,0.0027331477,0.0069828858,0.00812783,0.004173882,0.008740431,0.0013124886,0.45653406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96679467,0.0035998637,0.0071845436,0.0070398506,0.008023169,0.0073578833],"domain_scores_gemma":[0.95015585,0.033181597,0.004040748,0.0057625375,0.002211696,0.0046475674],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.010403353,0.0053535644,0.0066777836,0.0035106346,0.0021079977,0.0010293879,0.0038959181,0.0024723324,0.00029826097],"category_scores_gemma":[0.042752795,0.0042393035,0.0014699553,0.0067932196,0.0034771455,0.0027365857,0.0017505506,0.0057642823,0.003804352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002607073,0.0032331438,0.3168629,0.0028002847,0.0014188199,0.0015343772,0.035454582,0.000021346455,0.0038571195,0.0005386075,0.63354367,0.0007090505],"study_design_scores_gemma":[0.017751703,0.0010827344,0.43599492,0.0036331539,0.003845695,0.0007415343,0.02668105,0.0013040697,0.0024212806,0.0009478146,0.5052597,0.00033630987],"about_ca_topic_score_codex":0.00042404278,"about_ca_topic_score_gemma":0.00081555493,"teacher_disagreement_score":0.42930922,"about_ca_system_score_codex":0.0019153194,"about_ca_system_score_gemma":0.0020630367,"threshold_uncertainty_score":0.9992348},"labels":[],"label_agreement":null},{"id":"W1828063937","doi":"10.1007/s40121-015-0071-0","title":"Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada","year":2015,"lang":"en","type":"article","venue":"Infectious Diseases and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Dolutegravir; Medicine; Atazanavir; Ritonavir; Raltegravir; Elvitegravir; Efavirenz; Rilpivirine; Abacavir; Cost effectiveness; Darunavir; Cobicistat; Adverse effect; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Virology; Antiretroviral therapy","score_opus":0.025647103168988244,"score_gpt":0.2825397717375404,"score_spread":0.2568926685685522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1828063937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675864,0.0016112569,0.0000015584158,0.00004432452,0.00006271806,0.0011675508,0.000049064252,0.0000131164525,0.00029178034],"genre_scores_gemma":[0.9971733,0.0022834537,0.000009715349,0.000025556785,0.000011746618,0.0003329246,0.000071450886,0.000013195723,0.00007865477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991559,0.000091298694,0.00018454879,0.00024477238,0.00012716392,0.00019635654],"domain_scores_gemma":[0.9994746,0.00010090352,0.000050792765,0.00011275526,0.000048021964,0.00021296476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000037184647,0.00020687615,0.00040750465,0.00013186828,0.000029401644,0.000009504972,0.000019219911,0.00003472051,0.0000101278265],"category_scores_gemma":[0.000013785611,0.00014459688,0.00003641386,0.00017253938,0.00004414542,0.000066907836,0.0000090781,0.000029247898,0.0000010200555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096094864,0.0012288094,0.9540674,0.000013944634,0.00011186924,0.00006407915,0.0012365815,0.0000078990615,0.000020422305,0.000024259583,0.000008894013,0.04225486],"study_design_scores_gemma":[0.02326648,0.0011841106,0.97331136,0.00008180988,0.000040025287,0.000006443279,0.00060093537,0.000035088153,0.00050892116,0.00012533336,0.00070320256,0.00013630163],"about_ca_topic_score_codex":0.37809852,"about_ca_topic_score_gemma":0.23856099,"teacher_disagreement_score":0.13953753,"about_ca_system_score_codex":0.0010947398,"about_ca_system_score_gemma":0.00075231976,"threshold_uncertainty_score":0.7753333},"labels":[],"label_agreement":null},{"id":"W1845536215","doi":"10.1177/135965350300800406","title":"Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Amprenavir; Regimen; Drug resistance; Protease inhibitor (pharmacology); Internal medicine; Medicine; Viral load; Pharmacology; Virology; Immunology; Biology; Protease; Virus; HIV-1 protease; Antiretroviral therapy; Microbiology","score_opus":0.009401912719932652,"score_gpt":0.25375400540812737,"score_spread":0.24435209268819472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1845536215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932172,0.00032744007,0.000026063564,0.0020880548,0.00015486093,0.0010197621,0.000010815527,0.00012849433,0.0030273506],"genre_scores_gemma":[0.9623465,0.00013342766,0.0015043187,0.0005559731,0.000029734685,0.00013383327,0.00005220255,0.000046224355,0.035197772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977456,0.0003658013,0.0004223197,0.00053690746,0.00039433126,0.0005350629],"domain_scores_gemma":[0.9990316,0.0001678827,0.00010236588,0.00040929965,0.00013637847,0.00015249425],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047955042,0.00032809807,0.00045159692,0.00029404042,0.00013618193,0.000032973567,0.0001264227,0.0000745236,0.000060633527],"category_scores_gemma":[0.00020113161,0.00027127462,0.00009344477,0.0006656883,0.00006647845,0.00016840656,0.00002461267,0.00017837969,0.0001311323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01449845,0.0010955061,0.92768157,0.000017037828,0.00016394306,0.0002239943,0.028044289,0.0000033323358,0.014817442,0.000248868,0.010178045,0.0030275483],"study_design_scores_gemma":[0.01890196,0.00069967145,0.67073655,0.0005538296,0.00003891552,0.0000039849606,0.0012579625,0.000010589847,0.11479717,0.000106988635,0.19206944,0.0008229084],"about_ca_topic_score_codex":0.000019791456,"about_ca_topic_score_gemma":0.00008002074,"teacher_disagreement_score":0.25694495,"about_ca_system_score_codex":0.00021888445,"about_ca_system_score_gemma":0.00018244538,"threshold_uncertainty_score":0.99997395},"labels":[],"label_agreement":null},{"id":"W1879590988","doi":"","title":"Effet d’un court traitement antirétroviral durant la primo-infection au VIH","year":2014,"lang":"fr","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Sida; Medicine; Viral disease","score_opus":0.00679729492821369,"score_gpt":0.24432781452302907,"score_spread":0.2375305195948154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1879590988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80017215,0.0010814343,0.013142077,0.028219914,0.004831372,0.0015331418,0.000020406445,0.00032130178,0.15067823],"genre_scores_gemma":[0.8256534,0.00044522184,0.002672194,0.0004017522,0.0010823617,0.0000573442,0.00011100768,0.000051194416,0.16952555],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972386,0.00030916245,0.00058264914,0.00052047434,0.00052510854,0.00082401047],"domain_scores_gemma":[0.99879694,0.00023327692,0.0001328573,0.0003628402,0.00008627725,0.00038778546],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00096981425,0.00047085393,0.0005927321,0.00018569948,0.00023432996,0.0000629597,0.000091412534,0.00025657733,0.0024649964],"category_scores_gemma":[0.00008123898,0.00037817462,0.00024071458,0.00024130582,0.00016200579,0.00017531868,0.00006109336,0.00027753832,0.0025761758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035697696,0.004139296,0.33171025,0.0009839707,0.0019590051,0.00048271118,0.0049276785,0.000030489235,0.0032596088,0.028781854,0.06373742,0.55963075],"study_design_scores_gemma":[0.009702661,0.00094969507,0.22596714,0.00076044665,0.0011271561,0.00028773982,0.0002061741,0.003134479,0.017747506,0.00023430664,0.73924243,0.000640256],"about_ca_topic_score_codex":0.00058559456,"about_ca_topic_score_gemma":0.00021103316,"teacher_disagreement_score":0.67550504,"about_ca_system_score_codex":0.0006351024,"about_ca_system_score_gemma":0.00026558235,"threshold_uncertainty_score":0.999867},"labels":[],"label_agreement":null},{"id":"W1881862380","doi":"10.1177/135965350501002s02","title":"Possible Ways Nucleoside Analogues Can Affect Mitochondrial Dna Content and Gene Expression during HIV Therapy","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Mitochondrial toxicity; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Mitochondrial DNA; Toxicity; Biology; Nucleoside analogue; Mitochondrion; Reverse-transcriptase inhibitor; Nucleoside; Mitochondrial respiratory chain; Virology; Affect (linguistics); Pharmacology; Gene; Human immunodeficiency virus (HIV); Polymerase chain reaction; Medicine; Genetics; Internal medicine; Psychology","score_opus":0.03792874157312286,"score_gpt":0.2623311100440043,"score_spread":0.2244023684708814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1881862380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336857,0.002287129,0.00004107505,0.0027004122,0.00013673183,0.00069812336,0.000014572389,0.00012756724,0.0006258498],"genre_scores_gemma":[0.9852581,0.005891414,0.0028500971,0.0003475291,0.00055500766,0.0000469915,0.0000759214,0.000046698642,0.0049282513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859744,0.00006191484,0.00026424837,0.00041564825,0.0002697806,0.00039097408],"domain_scores_gemma":[0.99942744,0.00004195486,0.00008526051,0.00026691894,0.00004482658,0.00013358063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008882336,0.00031371604,0.00042098484,0.00014250894,0.00021910488,0.000052886866,0.000084339095,0.000102063794,0.00008326428],"category_scores_gemma":[0.000007700563,0.00021611224,0.0001349857,0.00012717635,0.000079938916,0.00016720526,0.000029983414,0.00013605479,0.000048171038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012266306,0.000336877,0.0810407,0.000009562666,0.0001982275,0.000077255885,0.0015474515,5.1732536e-7,0.8929082,0.000022434844,0.0011887013,0.021443415],"study_design_scores_gemma":[0.009178155,0.0002778288,0.108705945,0.00011369113,0.000021231475,0.000030495823,0.000102806756,0.000018999497,0.8764383,0.000027447646,0.004839365,0.0002457385],"about_ca_topic_score_codex":0.000030428977,"about_ca_topic_score_gemma":0.000031833573,"teacher_disagreement_score":0.027665244,"about_ca_system_score_codex":0.00007084923,"about_ca_system_score_gemma":0.000050526392,"threshold_uncertainty_score":0.8812802},"labels":[],"label_agreement":null},{"id":"W1892162356","doi":"10.4212/cjhp.v61i2.38","title":"Atazanavir in Combination with Acid-Lowering Therapy: Correction","year":2008,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Atazanavir; Chemistry; Medicine; Pharmacology; Family medicine; Antiretroviral therapy","score_opus":0.01960733865392568,"score_gpt":0.25869178293413386,"score_spread":0.2390844442802082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1892162356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901052,0.00075904984,0.00001743763,0.0072068847,0.00051286566,0.00021862367,0.0000010176896,0.0000058074265,0.001173101],"genre_scores_gemma":[0.9980832,0.00018726272,0.000059737416,0.00018832639,0.0000988337,0.000004186452,0.000005299108,0.000013998474,0.0013591861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934274,0.000022530745,0.00019606478,0.00006906055,0.00018658863,0.0001830048],"domain_scores_gemma":[0.99944913,0.000017220014,0.000106407744,0.00007590273,0.00011940248,0.00023192984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015924043,0.00010101627,0.00015583626,0.00020260109,0.00017060661,0.000017076292,0.0000829601,0.000016640526,0.00007996385],"category_scores_gemma":[0.00001781031,0.00006154741,0.000047962065,0.00023009938,0.00007693398,0.00017250322,0.0000033529575,0.00024345105,0.000013749435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042460617,0.00027413736,0.9510095,0.000007194091,0.00026695756,0.0032764755,0.010091587,0.000036927937,0.00023807865,0.00002392403,0.015731692,0.018618932],"study_design_scores_gemma":[0.031096127,0.0030119198,0.82822466,0.0005655211,0.0002146965,0.0048729563,0.0013384852,0.000329804,0.039900433,0.0001254498,0.08972955,0.00059040246],"about_ca_topic_score_codex":0.0023887167,"about_ca_topic_score_gemma":0.005787323,"teacher_disagreement_score":0.12278483,"about_ca_system_score_codex":0.00033843398,"about_ca_system_score_gemma":0.000952067,"threshold_uncertainty_score":0.3611041},"labels":[],"label_agreement":null},{"id":"W1894928795","doi":"10.1155/2009/721956","title":"Severe Skin Rash Associated with Atazanavir","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nine Circles Community Health Centre; Health Sciences Centre","funders":"","keywords":"Atazanavir; Rash; Maculopapular rash; Discontinuation; Medicine; Dermatology; Adverse effect; Surgery; Internal medicine; Immunology; Antiretroviral therapy","score_opus":0.005125764163311467,"score_gpt":0.20459442340453746,"score_spread":0.19946865924122598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1894928795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462396,0.0017367637,0.000019379004,0.0028329033,0.00015897807,0.00010655775,0.00004536974,0.000010602901,0.00046548003],"genre_scores_gemma":[0.9971863,0.00029802028,0.000025092982,0.0011584744,0.00011773592,0.000002427871,0.00006449344,0.000012482232,0.0011349506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917394,0.000056306297,0.0002553443,0.00012692687,0.000088171495,0.00029929043],"domain_scores_gemma":[0.9980455,0.00008287835,0.000116744566,0.00006978141,0.00015694159,0.0015281339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009718403,0.00013792174,0.0003808211,0.00019416127,0.00016132017,0.0000069516977,0.000054847074,0.00014195502,0.00059309247],"category_scores_gemma":[0.00035165474,0.000091519796,0.00008748969,0.0001345013,0.00038271915,0.00003769632,0.000008803344,0.0002294269,0.0000105180325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057751073,0.00013975384,0.965392,0.000015565616,0.0005629517,0.005827492,0.00023443747,6.907734e-7,0.00004488151,0.000029983396,0.024523906,0.0031705773],"study_design_scores_gemma":[0.011774055,0.0013482487,0.8084094,0.00070751243,0.0006979178,0.07216448,0.00017563671,0.0000050904373,0.00007905175,0.000075585194,0.10418767,0.0003753834],"about_ca_topic_score_codex":0.0005474067,"about_ca_topic_score_gemma":0.007005177,"teacher_disagreement_score":0.15698265,"about_ca_system_score_codex":0.00019805554,"about_ca_system_score_gemma":0.003088278,"threshold_uncertainty_score":0.64939463},"labels":[],"label_agreement":null},{"id":"W1898410970","doi":"10.1080/15257770.2015.1075551","title":"Synthesis of Cyclobutane Nucleosides 2-Preparation of Thymine and Uracil Analogues","year":2015,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Thymine; Uracil; Chemistry; Sodium methoxide; Alkylation; Nucleoside; Borohydride; Stereochemistry; Organic chemistry; Catalysis; DNA; Biochemistry","score_opus":0.021300920231802186,"score_gpt":0.2772179691273827,"score_spread":0.25591704889558053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1898410970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853336,0.0010040323,0.000041102772,0.0017119979,0.0001244386,0.0006923034,0.000068301895,0.00020644096,0.010817748],"genre_scores_gemma":[0.9822716,0.00046990733,0.015834283,0.00015183767,0.00010355463,0.000035089906,0.000049833594,0.0001079191,0.0009759563],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965339,0.00013642173,0.0012401966,0.0006809311,0.0008649767,0.0005435847],"domain_scores_gemma":[0.9972001,0.0003452672,0.0005666055,0.00077856734,0.0005761802,0.00053329876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006753984,0.0005610046,0.001362164,0.0004882302,0.00012771241,0.00004834936,0.0002680604,0.00025610675,0.00022259346],"category_scores_gemma":[0.00084642903,0.00048346043,0.00028107146,0.0006066528,0.00068755687,0.00048038567,0.00021433203,0.00021907705,0.00010006638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006528288,0.0040397374,0.6841593,0.0021232187,0.003614264,0.0004795739,0.017558262,0.00015070118,0.1617172,0.010140598,0.02737455,0.08211435],"study_design_scores_gemma":[0.013322622,0.004898375,0.402492,0.0037402774,0.004902385,0.001226614,0.015196114,0.005499761,0.5044203,0.0056086048,0.035916343,0.0027766537],"about_ca_topic_score_codex":0.00014385655,"about_ca_topic_score_gemma":0.000047193626,"teacher_disagreement_score":0.34270304,"about_ca_system_score_codex":0.00016862743,"about_ca_system_score_gemma":0.00022102924,"threshold_uncertainty_score":0.9997617},"labels":[],"label_agreement":null},{"id":"W1908239450","doi":"","title":"Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nevirapine; Efavirenz; Internal medicine; Interquartile range; Lamivudine; Hazard ratio; Stavudine; Medicine; Viral load; Discontinuation; Confidence interval; Zidovudine; Gastroenterology; Pharmacology; Antiretroviral therapy; Virology; Human immunodeficiency virus (HIV); Viral disease; Virus","score_opus":0.033026764697957255,"score_gpt":0.2715409996638946,"score_spread":0.23851423496593735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1908239450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796646,0.00037188368,0.000035725483,0.0143898465,0.000074730866,0.004805118,0.00015868577,0.000052892457,0.0004464991],"genre_scores_gemma":[0.98768544,0.00021569805,0.000733518,0.00064488844,0.00008122686,0.0021931739,0.00008754496,0.00003626479,0.008322244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979626,0.000049891503,0.00072846963,0.00046738624,0.00033388697,0.0004577907],"domain_scores_gemma":[0.99841547,0.00045045803,0.00039617185,0.0004394698,0.00010377029,0.00019463213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037450474,0.00039402692,0.00092657184,0.0001432344,0.00016246451,0.000019645368,0.00017832486,0.00009880191,0.000059742208],"category_scores_gemma":[0.00005218453,0.00022111829,0.00018767662,0.0002460105,0.00026494917,0.000084356354,0.000084528205,0.00011124498,0.000009382708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041914713,0.011175913,0.77438986,0.00053748675,0.0071335114,0.0000652977,0.030086499,0.00019960538,0.00019107688,0.00015008108,0.009933502,0.124222435],"study_design_scores_gemma":[0.046875104,0.0019924142,0.9091644,0.00013635553,0.0017150148,0.000028374856,0.0002562177,0.004091337,0.033052,0.000020689655,0.0023547192,0.00031333131],"about_ca_topic_score_codex":0.000051361123,"about_ca_topic_score_gemma":0.0002943033,"teacher_disagreement_score":0.13477457,"about_ca_system_score_codex":0.00020948736,"about_ca_system_score_gemma":0.000130121,"threshold_uncertainty_score":0.90169424},"labels":[],"label_agreement":null},{"id":"W1912770731","doi":"10.1155/2009/940745","title":"Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV‐Infected Adults – Canadian Consensus Guidelines","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; University of Alberta; St. Paul's Hospital; Jewish General Hospital; University of Ottawa; Ottawa Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Raltegravir; Human immunodeficiency virus (HIV); Medicine; Virology; Antiretroviral therapy; Intensive care medicine; Viral load","score_opus":0.014113254850878894,"score_gpt":0.26037349847340996,"score_spread":0.24626024362253107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1912770731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843667,0.0032735385,0.0000036131487,0.011685622,0.00013583676,0.0002702636,0.00019296251,0.0000030820681,0.00006838689],"genre_scores_gemma":[0.9977573,0.0010140631,0.00011561978,0.0008301425,0.00009309158,0.0000026319422,0.000074141084,0.000006920895,0.00010609646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986996,0.00011234383,0.00063240115,0.00013299794,0.00008890071,0.0003337627],"domain_scores_gemma":[0.9981279,0.000177962,0.00019438656,0.00012496093,0.00030539613,0.0010694127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012064438,0.00017294688,0.0005382198,0.0004750261,0.000058193542,0.000008910709,0.00007295968,0.0001423788,0.00016524603],"category_scores_gemma":[0.0005139633,0.00010372448,0.00015450375,0.00019175398,0.00028875284,0.000022251179,0.0000027148672,0.00012212427,0.0000017584986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044403004,0.0007978397,0.9399053,0.000051085502,0.00044029628,0.0037836854,0.0015363469,0.00003967535,0.00033906003,0.0001563995,0.02094886,0.03155742],"study_design_scores_gemma":[0.020751119,0.006905549,0.7643417,0.0016444813,0.0011842455,0.0098115085,0.0011738129,0.00012210978,0.0005603768,0.00009965365,0.19295736,0.00044806622],"about_ca_topic_score_codex":0.0700352,"about_ca_topic_score_gemma":0.30152178,"teacher_disagreement_score":0.23148659,"about_ca_system_score_codex":0.000235217,"about_ca_system_score_gemma":0.0034738719,"threshold_uncertainty_score":0.9361575},"labels":[],"label_agreement":null},{"id":"W1922584461","doi":"10.1128/jvi.01881-15","title":"The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance","year":2015,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Elvitegravir; Raltegravir; Integrase; Dolutegravir; Biology; Integrase inhibitor; Virology; Genetics; Infectivity; Context (archaeology); Viral replication; Virus; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.02260723615302471,"score_gpt":0.25872928621272184,"score_spread":0.23612205005969714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1922584461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649039,0.00090413145,0.00081134523,0.032764263,0.000068277994,0.0003174513,0.000008734429,0.0000027337635,0.00021918309],"genre_scores_gemma":[0.9886409,0.00015417695,0.008892807,0.000105816354,0.000015043543,0.000017754815,0.00000497978,0.0000072252797,0.0021612658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853444,0.00019140367,0.0006750725,0.00014587257,0.00032331972,0.00012987405],"domain_scores_gemma":[0.9983555,0.00027911158,0.0006780182,0.00029441,0.00033492033,0.000058052778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014097854,0.000121555175,0.00036361482,0.00011664741,0.00015880456,0.000010148964,0.00015272317,0.000052404364,0.0000029689857],"category_scores_gemma":[0.00023835625,0.000054735174,0.00003231262,0.00023118955,0.00058463134,0.00008598688,0.00005088729,0.00022231547,7.134304e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038023215,0.002889288,0.48983857,0.00048754958,0.002302617,0.00008182114,0.08648938,0.00009393066,0.0068517076,0.3289188,0.036328387,0.0076947026],"study_design_scores_gemma":[0.017313065,0.00018540518,0.9423158,0.00054822804,0.0002702959,0.00008267719,0.0019888398,0.000063099564,0.017128745,0.014958078,0.005001031,0.00014469614],"about_ca_topic_score_codex":0.000032307,"about_ca_topic_score_gemma":0.0018591202,"teacher_disagreement_score":0.45247728,"about_ca_system_score_codex":0.00014010107,"about_ca_system_score_gemma":0.00044081802,"threshold_uncertainty_score":0.22320357},"labels":[],"label_agreement":null},{"id":"W1934296086","doi":"10.1111/j.1468-1293.2011.00950.x","title":"Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource‐limited settings","year":2011,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; Simon Fraser University","funders":"Canadian Institutes of Health Research; International AIDS Society","keywords":"Medicine; Confidence interval; Drug resistance; Odds ratio; Internal medicine; Antiretroviral therapy; Ritonavir; HIV drug resistance; Viral load; Reverse-transcriptase inhibitor; Resistance mutation; Virology; Oncology; Human immunodeficiency virus (HIV); Pharmacology; Reverse transcriptase; Genetics; Polymerase chain reaction","score_opus":0.03683765368516333,"score_gpt":0.27691614269244874,"score_spread":0.2400784890072854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934296086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8869791,0.0038306112,0.00081654394,0.08852105,0.00013166766,0.00472332,0.00024384596,0.00023025041,0.0145236235],"genre_scores_gemma":[0.9450538,0.000554541,0.008439496,0.00023308716,0.00010644616,0.0005669518,0.0029878144,0.00004628272,0.042011537],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835914,0.000038593647,0.00068955787,0.00038050686,0.00024583834,0.00028638676],"domain_scores_gemma":[0.99858713,0.00043610303,0.00031567345,0.00035874444,0.00016996561,0.00013240258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002280831,0.00024443626,0.0005115294,0.0003400615,0.00011350097,0.000004085319,0.00008883221,0.00007548068,0.00004093325],"category_scores_gemma":[0.0002781516,0.00018562346,0.0000836446,0.00048923603,0.00016028351,0.00008281871,0.000012287329,0.00007964348,0.00000991052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006039805,0.0069893417,0.47719955,0.0018578311,0.001463867,0.0001446665,0.10645007,0.000007451128,0.027273523,0.0029161377,0.35099804,0.018659709],"study_design_scores_gemma":[0.058272414,0.0042780144,0.12791857,0.0035045778,0.0020262948,0.000041185715,0.008739426,0.0006657533,0.05909889,0.0009029328,0.73364896,0.00090299436],"about_ca_topic_score_codex":0.00007505887,"about_ca_topic_score_gemma":0.0002153971,"teacher_disagreement_score":0.3826509,"about_ca_system_score_codex":0.00022275819,"about_ca_system_score_gemma":0.000078524,"threshold_uncertainty_score":0.7569505},"labels":[],"label_agreement":null},{"id":"W1940459603","doi":"10.1586/14787210.2015.1068117","title":"Tackling virological failure in HIV-infected children living in Africa","year":2015,"lang":"en","type":"review","venue":"Expert Review of Anti-infective Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université du Québec à Montréal","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Developing country; Antiretroviral therapy; Intensive care medicine; Antiretroviral treatment; Drug resistance; Pediatrics; Immunology; Viral load; Economic growth; Biology","score_opus":0.03691895856483726,"score_gpt":0.35308849703344214,"score_spread":0.31616953846860485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1940459603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071980245,0.99329525,0.000016169102,0.00026478939,0.00009054343,0.004345563,0.000015511181,0.00007906495,0.0011733279],"genre_scores_gemma":[0.00028234615,0.997665,0.0006157231,0.00018042224,0.00018660449,0.00052238215,0.00025324704,0.000098782366,0.0001954904],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99545026,0.0009830317,0.0015744334,0.00085664936,0.0005074769,0.00062813633],"domain_scores_gemma":[0.9979299,0.00042698462,0.0006459557,0.0006177907,0.00019224906,0.00018715074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001461793,0.0009583884,0.0059065684,0.0007119205,0.000042021475,0.000016848779,0.00028674383,0.00047726632,0.000418608],"category_scores_gemma":[0.00039748455,0.00061853934,0.00091150176,0.0015052689,0.00012365887,0.00011892989,0.000124228,0.0008247556,0.00014672255],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039714414,0.0025305452,0.022810206,0.020476134,0.0011355949,0.00021687367,0.0016643318,2.4147369e-7,0.000010717581,0.00005064319,0.0058653266,0.94519967],"study_design_scores_gemma":[0.001397308,0.00025816,0.0038034224,0.1954064,0.00023058204,0.00011843608,0.00001796989,0.0000011273703,0.0000070668316,0.000009211204,0.79819334,0.00055695925],"about_ca_topic_score_codex":0.000029478084,"about_ca_topic_score_gemma":0.000011400118,"teacher_disagreement_score":0.9446427,"about_ca_system_score_codex":0.000601674,"about_ca_system_score_gemma":0.00069230644,"threshold_uncertainty_score":0.9996266},"labels":[],"label_agreement":null},{"id":"W1942725639","doi":"10.1128/jvi.01725-15","title":"Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity","year":2015,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Raltegravir; Integrase; Infectivity; Biology; Virology; Drug resistance; Mutation; Viral replication; Integrase inhibitor; Resistance mutation; Molecular biology; Viral load; Genetics; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy; Reverse transcriptase; Gene","score_opus":0.0526299831356294,"score_gpt":0.27979937069945715,"score_spread":0.22716938756382776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1942725639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9485466,0.0014083812,0.0004906757,0.047486596,0.00012361596,0.0004009116,0.0007484754,0.000024141968,0.0007706276],"genre_scores_gemma":[0.9846872,0.00004802358,0.006097597,0.0010945976,0.00012394336,0.00004144529,0.000093022405,0.000013565716,0.0078005893],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99856967,0.0002563271,0.00038133626,0.00024886793,0.00032262245,0.00022116478],"domain_scores_gemma":[0.99804604,0.00067095173,0.0003344742,0.0002011256,0.0005118954,0.00023551876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046018854,0.00018338748,0.00040945734,0.00013848064,0.00029867663,0.000027551494,0.000107051084,0.00009259384,0.00010361742],"category_scores_gemma":[0.0003014128,0.00011283698,0.00004864731,0.000185447,0.00049120816,0.00015262752,0.000036704478,0.00032697336,0.000007514404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021587681,0.0018237286,0.105169065,0.00026178884,0.0063114646,0.0015631593,0.029600868,0.00014662607,0.031184157,0.09355208,0.7082184,0.00058095995],"study_design_scores_gemma":[0.006130515,0.00028096722,0.8667272,0.00030364018,0.0007599676,0.0006121613,0.0024671871,0.000027496115,0.0021786117,0.0038066139,0.11641012,0.00029554614],"about_ca_topic_score_codex":0.000015793732,"about_ca_topic_score_gemma":0.00068426284,"teacher_disagreement_score":0.7615581,"about_ca_system_score_codex":0.00013316053,"about_ca_system_score_gemma":0.00038603082,"threshold_uncertainty_score":0.46013585},"labels":[],"label_agreement":null},{"id":"W1958688023","doi":"10.1111/hiv.12029","title":"Pharmacokinetics of the combination raltegravir/atazanavir in <scp>HIV</scp>‐1‐infected patients","year":2013,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Radboud Universiteit","keywords":"Raltegravir; Atazanavir; Emtricitabine; Lamivudine; Medicine; Regimen; Pharmacology; Pharmacokinetics; Nucleoside Reverse Transcriptase Inhibitor; Viral load; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","score_opus":0.010062509461834289,"score_gpt":0.2496838622939348,"score_spread":0.2396213528321005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958688023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805332,0.00018305784,0.000030107542,0.0076186615,0.00028249642,0.0012035928,0.000008840375,0.0000369547,0.010103115],"genre_scores_gemma":[0.9845973,0.00011142643,0.00016175756,0.00049721054,0.00007267884,0.00006329988,0.00029145184,0.000023642702,0.01418123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983896,0.00008015376,0.0004939082,0.00022228577,0.00054355554,0.00027047447],"domain_scores_gemma":[0.9989374,0.00020236697,0.000180525,0.00030646223,0.00024288583,0.0001303043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016602522,0.00020844913,0.00039921395,0.00021206617,0.000046411496,0.000004606095,0.00013742845,0.000074174255,0.0002725684],"category_scores_gemma":[0.00045729414,0.00012212097,0.00005895112,0.0006010898,0.00015787486,0.000075549106,0.00005491404,0.00022234366,0.00018243954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015923548,0.0008380362,0.8746782,0.00009649612,0.00008031906,0.000009647416,0.0019257893,0.0000026192633,0.0030167075,0.00018820567,0.11506781,0.004080237],"study_design_scores_gemma":[0.013342745,0.00020161418,0.95881206,0.00051500165,0.00018729434,0.00000538616,0.00037208624,0.00048677262,0.005937348,0.0001757696,0.019900005,0.000063904474],"about_ca_topic_score_codex":0.000066838176,"about_ca_topic_score_gemma":0.000011378667,"teacher_disagreement_score":0.09516781,"about_ca_system_score_codex":0.00010021675,"about_ca_system_score_gemma":0.00006528029,"threshold_uncertainty_score":0.49799487},"labels":[],"label_agreement":null},{"id":"W1963635957","doi":"10.1310/hct0902-73","title":"Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients","year":2008,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Tolerability; Enfuvirtide; Dosing; Regimen; Adverse effect; Pharmacokinetics; Internal medicine; Pharmacology; Immunology","score_opus":0.1454580302820737,"score_gpt":0.40894059936397603,"score_spread":0.2634825690819023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963635957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946424,0.00029139064,0.000068185574,0.0007472218,0.0006371714,0.0013873569,0.00006214013,0.000056564433,0.002107613],"genre_scores_gemma":[0.99431044,0.00095019094,0.0031942176,0.00009098261,0.00026623925,0.000018337882,0.00016898976,0.00004313164,0.0009574428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933258,0.0012325968,0.0037700278,0.00061531283,0.000603981,0.00045224465],"domain_scores_gemma":[0.9892284,0.00863451,0.001126771,0.00047196719,0.0002149424,0.0003233996],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035445003,0.000373677,0.0024097327,0.00028825752,0.00011005099,0.000013120017,0.00014022528,0.00033606729,0.00016329183],"category_scores_gemma":[0.01298233,0.00030029807,0.00042081275,0.00049926795,0.00038406576,0.00012366578,0.00012255846,0.00041937947,0.00008420866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052944794,0.0043263333,0.9012566,0.00018283077,0.00097408245,0.00014521886,0.0017315958,0.000010187243,0.0019097545,0.00010190303,0.0045233746,0.03189329],"study_design_scores_gemma":[0.17025967,0.0015882544,0.8142516,0.0014485848,0.00088895345,0.00000803657,0.00012385318,0.00010288656,0.0033370373,0.00003930098,0.0075080483,0.0004437754],"about_ca_topic_score_codex":0.000041567735,"about_ca_topic_score_gemma":0.000014122353,"teacher_disagreement_score":0.11731487,"about_ca_system_score_codex":0.00013665708,"about_ca_system_score_gemma":0.00035414743,"threshold_uncertainty_score":0.9999449},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W1963976670","doi":"10.1016/j.bmcl.2008.09.004","title":"Synthesis and use of sulfonamide-, sulfoxide-, or sulfone-containing aminoglycoside–CoA bisubstrates as mechanistic probes for aminoglycoside N-6′-acetyltransferase","year":2008,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; McMaster University","keywords":"Aminoglycoside; Chemistry; Sulfone; Sulfonamide; Sulfoxide; Aminocyclitol; Stereochemistry; Chemical synthesis; Acetyltransferase; Tetrahedral carbonyl addition compound; Biochemistry; Antibiotics; In vitro; Organic chemistry; Acetylation","score_opus":0.039279468220463805,"score_gpt":0.2537460795991811,"score_spread":0.2144666113787173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963976670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921287,0.00039641667,0.0007980012,0.0053147376,0.000086661945,0.0010015698,0.000079360994,0.000140239,0.000054360116],"genre_scores_gemma":[0.9919871,0.00049307937,0.004534587,0.00078998733,0.00018120318,0.00021365525,0.0001542889,0.00010162544,0.0015444563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969019,0.000041656454,0.0009061861,0.00080344576,0.0006308571,0.00071591407],"domain_scores_gemma":[0.99760884,0.0010209592,0.00025382324,0.0004644672,0.00018777039,0.00046415522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028565363,0.00063927856,0.0010860541,0.00015388205,0.00024765095,0.00003127575,0.00019037016,0.00023582252,0.00028075484],"category_scores_gemma":[0.0011210581,0.0005065986,0.00019889601,0.00035064432,0.00051135255,0.00017852064,0.00005307633,0.0002777754,0.000014497112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020282464,0.000279018,0.009626954,0.0010503375,0.00053312787,0.0013436534,0.00093539414,0.0000010765408,0.98223776,0.00002720613,0.0013359411,0.0006012799],"study_design_scores_gemma":[0.0036638423,0.00031104664,0.003625409,0.0008975131,0.00093864626,0.0027544457,0.00076201593,0.00006903298,0.98557293,0.000016508951,0.0008747925,0.0005137953],"about_ca_topic_score_codex":0.00011798522,"about_ca_topic_score_gemma":0.000014949055,"teacher_disagreement_score":0.006001545,"about_ca_system_score_codex":0.00023161057,"about_ca_system_score_gemma":0.0005299602,"threshold_uncertainty_score":0.9997386},"labels":[],"label_agreement":null},{"id":"W1963997070","doi":"10.1016/s0960-894x(00)00452-2","title":"Synthesis and antiviral activities of N-9-oxypurine 1,3-Dioxolane and 1,3-oxathiolane nucleosides","year":2000,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Dioxolane; Chemistry; Sodium hydride; Purine; Stereochemistry; Hydride; Sugar; Combinatorial chemistry; Organic chemistry; Enzyme","score_opus":0.005507895142253967,"score_gpt":0.20398037243298744,"score_spread":0.19847247729073347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963997070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888263,0.000832686,0.0000025139611,0.0086722765,0.000022215003,0.00014131467,0.000014207232,0.000054930115,0.001433569],"genre_scores_gemma":[0.996373,0.00078624545,0.0004002732,0.00035455826,0.00017004751,0.000009644071,0.000022328748,0.000027780014,0.0018561084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998778,0.000020562604,0.00028977473,0.0003397046,0.00029604664,0.0002759356],"domain_scores_gemma":[0.9993947,0.00012299576,0.00008126993,0.00021225482,0.000018356635,0.00017040639],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013810952,0.00026409715,0.00050387793,0.00005129548,0.00006711051,0.000012618964,0.00006791646,0.00009486906,0.0009789751],"category_scores_gemma":[0.00005910136,0.00021333269,0.000049308397,0.000119081546,0.0003327768,0.00006651067,0.00003343712,0.00016588233,0.000010904255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025412475,0.000116616924,0.028092712,0.0005049806,0.00023824196,0.00025214095,0.00062838726,2.7748635e-8,0.9539643,0.0000028200207,0.0013848767,0.014560787],"study_design_scores_gemma":[0.0016832378,0.0000628311,0.029336156,0.000500519,0.00037754606,0.0007752401,0.00039645392,0.000011618445,0.9638515,0.0000062310824,0.0027448228,0.0002538326],"about_ca_topic_score_codex":0.00002522777,"about_ca_topic_score_gemma":0.0000015046069,"teacher_disagreement_score":0.014306955,"about_ca_system_score_codex":0.00004778358,"about_ca_system_score_gemma":0.000051295465,"threshold_uncertainty_score":0.99993426},"labels":[],"label_agreement":null},{"id":"W1964314707","doi":"10.1089/aid.2006.22.321","title":"Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients","year":2006,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria General Hospital","funders":"","keywords":"Nevirapine; Term (time); Virology; Medicine; Human immunodeficiency virus (HIV); Type (biology); Intensive care medicine; Immunology; Antiretroviral therapy; Biology; Viral load; Physics","score_opus":0.07484616678756568,"score_gpt":0.33874267743960085,"score_spread":0.2638965106520352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964314707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702615,0.0006072623,0.0000066989337,0.00009925532,0.000009935207,0.0005397018,0.000010800537,0.000023258252,0.0016769252],"genre_scores_gemma":[0.9965145,0.00009578658,0.00024386076,0.000013022805,0.00003755338,0.000012494153,0.00023360738,0.000019326118,0.0028298434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984766,0.00010737801,0.0003159201,0.0003061838,0.00041903995,0.00037482995],"domain_scores_gemma":[0.9992621,0.00019608391,0.00004913493,0.00020719021,0.00015577272,0.00012971889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033801902,0.00015374631,0.00033588358,0.00053344143,0.00013440171,0.000031427287,0.0000639548,0.00007888206,0.00007742891],"category_scores_gemma":[0.0001257014,0.00012110821,0.00003367331,0.0004331018,0.00033457903,0.00007372585,0.00006970673,0.0002193268,0.000011967191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008411768,0.0010292839,0.99368846,0.00017515311,0.000046448236,0.000026814305,0.00010016663,5.297837e-7,0.00034607056,0.00080129615,0.00034946747,0.0025951522],"study_design_scores_gemma":[0.006292225,0.001323442,0.98956245,0.00018013091,0.000023320985,0.0000011040565,0.000018260425,0.0000041599747,0.0019976476,0.00006796945,0.00042551573,0.0001037933],"about_ca_topic_score_codex":0.00013338694,"about_ca_topic_score_gemma":0.00016577629,"teacher_disagreement_score":0.0054510483,"about_ca_system_score_codex":0.00008244863,"about_ca_system_score_gemma":0.000105230836,"threshold_uncertainty_score":0.49386498},"labels":[],"label_agreement":null},{"id":"W1964456736","doi":"10.1016/j.bmcl.2013.02.021","title":"Nucleotide competing reverse transcriptase inhibitors: Discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Chemistry; Reverse transcriptase; Potency; Stereochemistry; Chemical synthesis; Reverse-transcriptase inhibitor; Nucleotide; Amine gas treating; Drug discovery; Enzyme inhibitor; Structure–activity relationship; Combinatorial chemistry; Enzyme; Biochemistry; In vitro; RNA; Organic chemistry","score_opus":0.009566750940539827,"score_gpt":0.20632578782272287,"score_spread":0.19675903688218305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964456736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98285526,0.0003335031,0.000085331936,0.015465917,0.00019223159,0.0006251063,0.000030716303,0.00006464459,0.00034726155],"genre_scores_gemma":[0.99674964,0.00008171962,0.0013438392,0.0006028521,0.00039405876,0.000035931487,0.00016007647,0.000065248794,0.00056666293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99714535,0.00004108371,0.001045151,0.00050756027,0.0007520045,0.00050883915],"domain_scores_gemma":[0.9985343,0.00009262753,0.00043377347,0.00047623916,0.00016819224,0.00029483176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023579739,0.0004707193,0.0009573586,0.00012121108,0.00008948308,0.000020257687,0.00021018452,0.00016368456,0.0006104875],"category_scores_gemma":[0.00014729975,0.00040920652,0.00027101053,0.00042909433,0.00055293954,0.00030081358,0.00006478163,0.000337562,0.000033965232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023272156,0.00038591068,0.0111765,0.0014673108,0.0003717314,0.00011016614,0.0019032342,5.465074e-7,0.97662103,0.0000017986583,0.007356635,0.00037240968],"study_design_scores_gemma":[0.0034020848,0.00010630229,0.005540629,0.0019850486,0.00050025305,0.00009550771,0.0033823887,0.000007886783,0.9842365,0.000005594006,0.00040637766,0.00033142004],"about_ca_topic_score_codex":0.00018507114,"about_ca_topic_score_gemma":0.0000030174674,"teacher_disagreement_score":0.0148630645,"about_ca_system_score_codex":0.00019990867,"about_ca_system_score_gemma":0.00024995624,"threshold_uncertainty_score":0.99983597},"labels":[],"label_agreement":null},{"id":"W196587641","doi":"10.69645/xjnt9019","title":"What to do in therapy in the face of HIV drug resistance?","year":2007,"lang":"en","type":"article","venue":"˜The œbiomedical & life sciences collection.","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Face (sociological concept); Human immunodeficiency virus (HIV); Resistance (ecology); Drug; Drug resistance; Antiretroviral therapy; Medicine; Virology; Pharmacology; Sociology; Viral load; Biology; Microbiology; Social science","score_opus":0.01906077432853252,"score_gpt":0.30095202288422945,"score_spread":0.2818912485556969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W196587641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8249371,0.002829525,0.0007325513,0.16121617,0.0009050323,0.0016386402,0.0000025384877,0.000032530552,0.0077059027],"genre_scores_gemma":[0.9674711,0.0004963604,0.0007111933,0.0021062996,0.000104996114,0.00006328142,0.000003467494,0.000006523798,0.029036757],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977419,0.00012326267,0.00044333673,0.00030639238,0.0010167236,0.0003683819],"domain_scores_gemma":[0.99900913,0.0004911649,0.00007255142,0.000218301,0.000048580307,0.00016027526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033420897,0.00013061795,0.0002374346,0.00047990755,0.0002521418,0.000051935087,0.00036446188,0.000058163358,0.00011582309],"category_scores_gemma":[0.00014042298,0.00006519124,0.000058116842,0.0049986006,0.00057636725,0.0001265119,0.000038487808,0.00018873833,0.000035003017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020512412,0.0034729273,0.14872123,0.000075798,0.00015228015,0.00023151893,0.1544573,0.000043835775,0.0009071353,0.0012301472,0.6538582,0.034798402],"study_design_scores_gemma":[0.006455739,0.0005498539,0.19188015,0.0006714426,0.000032449214,0.000044691365,0.081102446,0.00028211737,0.0012741971,0.0015301815,0.71577346,0.0004032764],"about_ca_topic_score_codex":0.000058688816,"about_ca_topic_score_gemma":0.0019891458,"teacher_disagreement_score":0.15910986,"about_ca_system_score_codex":0.00014436824,"about_ca_system_score_gemma":0.00046803302,"threshold_uncertainty_score":0.26584217},"labels":[],"label_agreement":null},{"id":"W1966067024","doi":"10.1089/apc.2007.0136","title":"Potential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection","year":2008,"lang":"en","type":"review","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Gilead Sciences; Merck","keywords":"Raltegravir; Maraviroc; Medicine; Etravirine; Intensive care medicine; Rilpivirine; CCR5 receptor antagonist; Antiretroviral therapy; Enfuvirtide; Integrase inhibitor; Dosing; Human immunodeficiency virus (HIV); Dolutegravir; Cart; Viral load; Pharmacology; Immunology; Immune system","score_opus":0.02715115993716108,"score_gpt":0.31031110540102813,"score_spread":0.283159945463867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966067024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013750677,0.9799041,0.00017237752,0.00002106838,0.00025541146,0.0041270545,0.00010766697,0.00002028313,0.0016413254],"genre_scores_gemma":[0.01269235,0.9832229,0.0013508155,0.00004597055,0.00008891083,0.00032685933,0.0008070935,0.000030403833,0.0014346798],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985538,0.000066116205,0.0005407733,0.00028331252,0.0003204754,0.0002355143],"domain_scores_gemma":[0.9993526,0.000049118185,0.00015917927,0.0002804399,0.000065992645,0.00009267464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007871243,0.00032224506,0.0009912974,0.0005201029,0.00006823229,0.000015879088,0.00008808951,0.00014006275,0.0000118168255],"category_scores_gemma":[0.000008742302,0.0002039572,0.0003362732,0.0005982323,0.000024820609,0.000039701034,0.00006929597,0.000120053366,0.000010614456],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040441093,0.000105103936,0.00064722076,0.0065947245,0.00039398548,0.00004637424,0.0022283085,0.0000010383458,8.624599e-8,0.00011506121,0.003925094,0.98590255],"study_design_scores_gemma":[0.0014644959,0.012171192,0.00012963082,0.008668956,0.0019319432,0.00004384436,0.00092913694,8.471053e-7,0.000007089041,0.000007720359,0.97437,0.00027515908],"about_ca_topic_score_codex":0.000043131004,"about_ca_topic_score_gemma":0.000006195191,"teacher_disagreement_score":0.9856274,"about_ca_system_score_codex":0.000117076,"about_ca_system_score_gemma":0.00011744212,"threshold_uncertainty_score":0.8317133},"labels":[],"label_agreement":null},{"id":"W1966112664","doi":"10.1016/s0009-9120(02)00286-2","title":"Simple rapid method for quantification of antiretrovirals by liquid chromatography—tandem mass-spectrometry","year":2002,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Center for Research Resources; NIH Clinical Center; National Institutes of Health","keywords":"Chromatography; Analyte; Chemistry; Ammonium acetate; Mass spectrometry; Selected reaction monitoring; Tandem mass spectrometry; Stavudine; Bioanalysis; Triple quadrupole mass spectrometer; Sample preparation; Liquid chromatography–mass spectrometry; High-performance liquid chromatography; Analytical Chemistry (journal); Lamivudine","score_opus":0.049147772645053024,"score_gpt":0.3696246830104388,"score_spread":0.3204769103653858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966112664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634961,0.004738339,0.022396939,0.0033078243,0.00020230366,0.00096727745,0.00024628665,0.00019107507,0.0044538868],"genre_scores_gemma":[0.9513076,0.00080661033,0.04223113,0.00018642501,0.000175424,0.000051454714,0.00051192974,0.000031542757,0.0046978584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979477,0.000050403654,0.0009293693,0.0005339171,0.00024794292,0.00029067558],"domain_scores_gemma":[0.99829036,0.0005492777,0.00030989162,0.0005121925,0.00013056966,0.00020773245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006721739,0.00021425035,0.0006390659,0.000073389514,0.000062585474,0.000011738936,0.00014276413,0.00031069876,0.00043370688],"category_scores_gemma":[0.0006139467,0.00018529115,0.00046471602,0.0003544476,0.00015481125,0.00003297517,0.000024752413,0.00017314557,0.00003176329],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002717987,0.001220425,0.040643316,0.0002945184,0.0004896346,0.000006098447,0.000023708279,5.9580916e-8,0.8066422,0.000043455108,0.14411731,0.006247521],"study_design_scores_gemma":[0.0026245601,0.0006567799,0.0011737043,0.0000736157,0.00024639332,0.000007604821,0.000055269447,0.00024049115,0.97856057,0.00007549838,0.016074877,0.00021061272],"about_ca_topic_score_codex":0.0000011225405,"about_ca_topic_score_gemma":8.18141e-8,"teacher_disagreement_score":0.17191844,"about_ca_system_score_codex":0.00004017586,"about_ca_system_score_gemma":0.000048423157,"threshold_uncertainty_score":0.7555954},"labels":[],"label_agreement":null},{"id":"W1966171209","doi":"10.1074/jbc.m114.614305","title":"Derivatives of Mesoxalic Acid Block Translocation of HIV-1 Reverse Transcriptase","year":2014,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Chemistry; Docking (animal); Mutagenesis; Chromosomal translocation; Ternary complex; Stereochemistry; Foscarnet; Binding site; Human immunodeficiency virus (HIV); Biology; Biochemistry; Enzyme; Mutation; Virology; RNA","score_opus":0.022754605350147925,"score_gpt":0.25557572128401673,"score_spread":0.2328211159338688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966171209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652153,0.00057678344,0.00044569955,0.0015250447,0.000023147362,0.00006192248,0.000009387934,0.0000056465096,0.0008308264],"genre_scores_gemma":[0.9962471,0.0002527805,0.0029413472,0.000046182075,0.000068524954,0.0000014545074,0.000017203514,0.000004569376,0.00042084864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990334,0.000035767935,0.0005543868,0.00009545994,0.00017757321,0.00010339797],"domain_scores_gemma":[0.9992513,0.00005666995,0.00032975624,0.0001013263,0.00015781022,0.000103137914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026403554,0.00011196724,0.00044466127,0.00003195017,0.000015275324,0.0000017233708,0.00008582408,0.00011945762,0.00018346093],"category_scores_gemma":[0.0001672498,0.000069076465,0.00019548548,0.000102667575,0.000120324185,0.000028554256,0.0000061221017,0.00014077875,0.0000019036174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034188907,0.000392157,0.010583833,0.00014164601,0.00015231979,0.000013509991,0.00028991204,0.0000017111546,0.9860091,0.00001211711,0.00052979204,0.001532015],"study_design_scores_gemma":[0.0018554335,0.00024376456,0.0048933714,0.00021399892,0.00010063588,0.00010577747,0.00022037496,0.00000925207,0.98915017,0.000073311,0.0030681829,0.00006575648],"about_ca_topic_score_codex":4.7566851e-7,"about_ca_topic_score_gemma":5.438296e-8,"teacher_disagreement_score":0.005690461,"about_ca_system_score_codex":0.000026284113,"about_ca_system_score_gemma":0.000062715604,"threshold_uncertainty_score":0.28168565},"labels":[],"label_agreement":null},{"id":"W1966245088","doi":"10.1097/qad.0b013e32835f1db0","title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy","year":2013,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"International AIDS Society","keywords":"Nevirapine; Efavirenz; Medicine; Antiretroviral therapy; Virology; Adverse effect; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Sida; Viral disease; Viral load; Internal medicine","score_opus":0.04381395519450773,"score_gpt":0.30655411684669637,"score_spread":0.2627401616521886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966245088","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006126093,0.99096143,0.000017378801,0.00017686462,0.00010879796,0.0020826387,0.000048699578,0.00013138818,0.0003467064],"genre_scores_gemma":[0.0015949294,0.98058575,0.0007856833,0.00014754216,0.00010037717,0.00028436873,0.0014736518,0.000110376415,0.014917326],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997979,0.00012295353,0.0005304356,0.00054545223,0.0004044233,0.00041777123],"domain_scores_gemma":[0.99875927,0.00016675016,0.00033913195,0.0004206179,0.00009634476,0.00021791102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020551917,0.0006911164,0.0020216904,0.0002961243,0.000116871524,0.00001324672,0.00012344633,0.0003375381,0.00026831494],"category_scores_gemma":[0.00006429206,0.00041193631,0.00032380494,0.0004981959,0.000093903596,0.00008813646,0.00004012521,0.0003442643,0.00020006808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007070465,0.0005492084,0.020466767,0.0022414331,0.0019764716,0.00015152815,0.00004370023,1.8373838e-7,4.2286416e-7,0.000009324856,0.0009701217,0.97352016],"study_design_scores_gemma":[0.0069399034,0.0023456968,0.0017460966,0.018153427,0.0024491022,0.00003256667,0.0000069781236,0.000017713468,0.0000058127366,0.000006024931,0.9676874,0.0006092219],"about_ca_topic_score_codex":0.000025823747,"about_ca_topic_score_gemma":0.0000058984697,"teacher_disagreement_score":0.97291094,"about_ca_system_score_codex":0.00021094111,"about_ca_system_score_gemma":0.0003865667,"threshold_uncertainty_score":0.9998332},"labels":[],"label_agreement":null},{"id":"W1966567607","doi":"10.3390/v6093377","title":"Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?","year":2014,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Gilead Sciences; Bristol-Myers Squibb","keywords":"Dolutegravir; Integrase; Integrase inhibitor; Drug resistance; Drug; Virology; Food and drug administration; Human immunodeficiency virus (HIV); Pharmacology; Medicine; Antiretroviral therapy; Pharmacotherapy; Resistance mutation; Viral load; Biology; Internal medicine; Genetics; Gene; Reverse transcriptase","score_opus":0.08767629477125227,"score_gpt":0.3627778801964917,"score_spread":0.27510158542523944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966567607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017085442,0.99025774,0.000011939076,0.0035596734,0.00019633921,0.001918805,0.00015829323,0.00011246561,0.0036138892],"genre_scores_gemma":[0.000017181435,0.8621412,0.0014652831,0.0032112405,0.00022082079,0.00037011926,0.00009516183,0.00011411262,0.1323649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971074,0.00012851293,0.00090387557,0.0008165775,0.0005235335,0.00052012503],"domain_scores_gemma":[0.9981829,0.0002894793,0.0002649481,0.00093474897,0.00007320097,0.0002547168],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003743567,0.00075931585,0.0025102403,0.0006128737,0.000109057895,0.000063408945,0.00034962784,0.00029384127,0.0018295713],"category_scores_gemma":[0.00006681664,0.0005046973,0.00047385256,0.00068500463,0.000049123155,0.00008828775,0.00008691212,0.0003799547,0.003010846],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018282556,0.00051577226,0.0032484739,0.008483425,0.00083282037,0.00016415649,0.005011396,4.772799e-8,0.0000019478855,0.00007266446,0.5580053,0.42348123],"study_design_scores_gemma":[0.0012437253,0.00006211404,0.000059542013,0.019227918,0.00036268943,0.0000056672106,0.000012918911,3.143294e-7,0.00015995576,0.00010108421,0.97828233,0.00048175975],"about_ca_topic_score_codex":0.00020763319,"about_ca_topic_score_gemma":0.00088397384,"teacher_disagreement_score":0.42299947,"about_ca_system_score_codex":0.00036284895,"about_ca_system_score_gemma":0.00045633738,"threshold_uncertainty_score":0.9997405},"labels":[],"label_agreement":null},{"id":"W1967273981","doi":"10.1016/j.bmcl.2013.02.042","title":"Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Potency; Reverse transcriptase; Chemistry; Human immunodeficiency virus (HIV); Nucleotidyltransferase; Nucleotide; In vitro; Enzyme; Stereochemistry; Virology; Biochemistry; RNA; Biology","score_opus":0.008815738321974504,"score_gpt":0.20745604351950322,"score_spread":0.19864030519752873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967273981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695788,0.00036465994,0.00010769338,0.028972726,0.00016559639,0.00043654148,0.000019003697,0.00006464024,0.0002903441],"genre_scores_gemma":[0.99540216,0.00006136314,0.00091775245,0.00032093638,0.00027655062,0.000016246973,0.00015736914,0.000041722684,0.0028058772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977205,0.000028472105,0.00096470735,0.00038487485,0.00057593896,0.00032551918],"domain_scores_gemma":[0.9987034,0.000046357043,0.00041045208,0.00041181777,0.00014162995,0.00028629816],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022416784,0.0003096799,0.000576072,0.000095975774,0.00006199426,0.000012679926,0.0001783585,0.00011966494,0.0013108302],"category_scores_gemma":[0.000147039,0.00027209078,0.00017042448,0.00036570174,0.00024620732,0.00017106613,0.000031105574,0.00020726939,0.0000809837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009210843,0.0001511722,0.0066418517,0.0007179026,0.0001811948,0.00003423748,0.0016096883,4.799773e-7,0.9597406,0.00000619155,0.030325942,0.00049865094],"study_design_scores_gemma":[0.002118729,0.000035412082,0.0065940586,0.0006068731,0.00038866338,0.000119345146,0.0024016255,0.000007472025,0.9857904,0.000010058006,0.0017133789,0.00021401815],"about_ca_topic_score_codex":0.0000934095,"about_ca_topic_score_gemma":0.0000010909318,"teacher_disagreement_score":0.02865179,"about_ca_system_score_codex":0.00014247444,"about_ca_system_score_gemma":0.000215552,"threshold_uncertainty_score":0.9999731},"labels":[],"label_agreement":null},{"id":"W1967347018","doi":"10.2174/157016212799937218","title":"Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN","year":2012,"lang":"en","type":"article","venue":"Current HIV Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Lopinavir; Darunavir; Ritonavir; Lopinavir/ritonavir; Medicine; Internal medicine; Viral load; Regimen; Adverse effect; Confidence interval; Gastroenterology; Human immunodeficiency virus (HIV); Clinical endpoint; Antiretroviral therapy; Virology; Randomized controlled trial","score_opus":0.12884667541667524,"score_gpt":0.4274122400514905,"score_spread":0.2985655646348152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967347018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945311,0.0015293903,0.0000021772007,0.00036388545,0.00022122164,0.00092854927,0.000016190254,0.000011751734,0.0023957689],"genre_scores_gemma":[0.99773043,0.0012541988,0.0000946928,0.0000029701212,0.000048337504,0.00011818561,0.0001748234,0.000016711376,0.0005596346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787074,0.000224031,0.00039128837,0.00033148724,0.00047219795,0.0007102271],"domain_scores_gemma":[0.9990311,0.00032389315,0.00004751803,0.0002715985,0.00008410647,0.0002417314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047429654,0.00018675716,0.000403999,0.000540593,0.00006607733,0.000007954076,0.0001025176,0.00009169583,0.00013407816],"category_scores_gemma":[0.00019038036,0.00014845342,0.00004632204,0.00056297006,0.00026476872,0.00012811355,0.00012601871,0.00029726862,0.00012125054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026577273,0.0042254175,0.9294708,0.000057635883,0.000037503625,0.000016271657,0.0046518347,4.1310787e-7,0.00010357648,0.00026358152,0.00021859804,0.05829664],"study_design_scores_gemma":[0.024263391,0.0011396272,0.9529304,0.00020720446,0.000022995626,0.0000017429193,0.0007766608,0.0000359035,0.0010046966,0.000017730576,0.019447243,0.00015240062],"about_ca_topic_score_codex":0.00006324162,"about_ca_topic_score_gemma":0.00009116388,"teacher_disagreement_score":0.05814424,"about_ca_system_score_codex":0.0005663678,"about_ca_system_score_gemma":0.00017043434,"threshold_uncertainty_score":0.60537547},"labels":[],"label_agreement":null},{"id":"W1967916181","doi":"10.2215/cjn.03880609","title":"Predictors of Complication after Percutaneous Ultrasound-Guided Kidney Biopsy in HIV-Infected Individuals","year":2009,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority","funders":"National Institute on Drug Abuse","keywords":"Medicine; Complication; Odds ratio; Surgery; Internal medicine; Population; Gastroenterology","score_opus":0.022984046253883176,"score_gpt":0.3310944356325313,"score_spread":0.30811038937864815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967916181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97110575,0.00010857071,0.00007803174,0.028306812,0.00008517259,0.00021981122,0.00001677988,0.0000086006485,0.000070441085],"genre_scores_gemma":[0.9767301,0.0004740194,0.008006385,0.014531256,0.00011755512,0.0000019440286,0.000009130172,0.000010739726,0.00011888546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975151,0.00029619044,0.0014638392,0.00017516006,0.00032617676,0.00022356118],"domain_scores_gemma":[0.99709755,0.0006660501,0.0015193864,0.0003032786,0.00025193312,0.00016181836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071001577,0.00016046046,0.0010032586,0.00008124822,0.000027763072,0.0000035762112,0.00025745988,0.00012800244,0.000047731268],"category_scores_gemma":[0.0003792424,0.000104542516,0.0006997404,0.00043745886,0.0010166834,0.00003956785,0.000042715703,0.00044459198,0.000004482621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056446204,0.0010220755,0.9252318,0.000015907273,0.00063192897,0.000025022897,0.000978279,0.0000062634613,0.016285054,0.00000786949,0.053883255,0.0013480722],"study_design_scores_gemma":[0.0020027326,0.001112533,0.9877392,0.00011653973,0.00034942015,0.0018323461,0.00024073353,0.000021869686,0.00029062218,0.00018318163,0.006027047,0.00008374505],"about_ca_topic_score_codex":0.000009879488,"about_ca_topic_score_gemma":7.3735526e-7,"teacher_disagreement_score":0.06250742,"about_ca_system_score_codex":0.00008366652,"about_ca_system_score_gemma":0.0003430205,"threshold_uncertainty_score":0.426312},"labels":[],"label_agreement":null},{"id":"W1968114154","doi":"10.1007/s40262-013-0110-5","title":"Clinical Pharmacokinetic Drug Interactions Associated with Artemisinin Derivatives and HIV-Antivirals","year":2013,"lang":"en","type":"review","venue":"Clinical Pharmacokinetics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia; University of British Columbia","funders":"","keywords":"Nevirapine; Dihydroartemisinin; Artemether; Lumefantrine; Artesunate; Artemether/lumefantrine; Pharmacology; Artemisinin; Pharmacokinetics; Medicine; Drug; Ritonavir; Malaria; Plasmodium falciparum; Virology; Human immunodeficiency virus (HIV); Immunology; Viral load; Antiretroviral therapy","score_opus":0.15551299804731164,"score_gpt":0.47791693531647056,"score_spread":0.32240393726915895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968114154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005182815,0.98080575,0.000055890225,0.0010850246,0.0013422949,0.005357811,0.0001337267,0.00030215658,0.005734543],"genre_scores_gemma":[0.00045828457,0.9298705,0.0017516294,0.0005857026,0.0009857545,0.00043453308,0.0007272311,0.00020357818,0.06498278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99251217,0.0012385948,0.0035866685,0.0013733411,0.0005782323,0.0007109953],"domain_scores_gemma":[0.9926155,0.003975292,0.0015137248,0.0006377562,0.00033906606,0.0009186303],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012780395,0.0011502852,0.004614129,0.00029790762,0.00015722946,0.00009847611,0.00033610145,0.00039939815,0.0010094643],"category_scores_gemma":[0.0009086423,0.00078063674,0.0010313276,0.0005947187,0.00086688483,0.00015608832,0.00029642816,0.002516978,0.00085042464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007486885,0.0031573772,0.0039268616,0.002326121,0.004252729,0.00028121515,0.0000776057,1.8636582e-7,7.9839145e-7,0.000009310287,0.080605134,0.904614],"study_design_scores_gemma":[0.025602583,0.00040406233,0.0004673693,0.011365227,0.011921978,0.000081958126,0.000031054515,0.000089752575,0.0000045703628,0.000011096967,0.94923663,0.00078370527],"about_ca_topic_score_codex":0.0000010932067,"about_ca_topic_score_gemma":0.0000017553239,"teacher_disagreement_score":0.9038303,"about_ca_system_score_codex":0.00013734102,"about_ca_system_score_gemma":0.0006022887,"threshold_uncertainty_score":0.9999275},"labels":[],"label_agreement":null},{"id":"W1968328048","doi":"10.1016/j.tips.2009.10.001","title":"The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters","year":2009,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Drug; Pharmacology; Antiretroviral drug; ATP-binding cassette transporter; Drug interaction; Efflux; Pharmacokinetics; Transporter; Human immunodeficiency virus (HIV); Drug metabolism; Antiretroviral therapy; Medicine; Virology; Biology; Viral load; Biochemistry","score_opus":0.08393546633828616,"score_gpt":0.41716502166454655,"score_spread":0.3332295553262604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968328048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008949215,0.97965914,2.8361072e-7,0.0006159544,0.00013055369,0.00030662905,0.000024890847,0.00001904126,0.0102942735],"genre_scores_gemma":[0.065721504,0.9309793,0.00026645366,0.000027073118,0.0000392574,0.000035397556,0.000023017255,0.0000047912963,0.0029031923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982887,0.00014404439,0.0006904667,0.00030831347,0.00030046754,0.0002680243],"domain_scores_gemma":[0.9990897,0.00042464968,0.00030213138,0.00008125725,0.00002411549,0.00007814444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053642644,0.00024651914,0.001070071,0.00032713238,0.00014473582,0.000015540567,0.000261641,0.00004201004,0.00027261712],"category_scores_gemma":[0.000013228634,0.00011928537,0.00024017932,0.0007801198,0.001159094,0.00007646362,0.000035751284,0.00025206176,0.000002315675],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033690398,0.00022859588,0.0013532387,0.00031424084,0.000103520986,0.000013907988,0.0003457862,4.2707768e-7,0.000009432334,0.00038330056,0.00067298964,0.99654084],"study_design_scores_gemma":[0.0011681691,0.00044386167,0.004145849,0.0038930331,0.0015087501,0.000052980675,0.0010232064,0.00007133907,0.0001472483,0.00060198794,0.98660296,0.00034059113],"about_ca_topic_score_codex":0.00003192534,"about_ca_topic_score_gemma":0.000039624447,"teacher_disagreement_score":0.99620026,"about_ca_system_score_codex":0.000059004182,"about_ca_system_score_gemma":0.00010682689,"threshold_uncertainty_score":0.48643163},"labels":[],"label_agreement":null},{"id":"W1968491140","doi":"10.1111/j.1468-1293.2006.00418.x","title":"Evaluation of nevirapine‐switch strategies for HIV treatment","year":2006,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Nevirapine; Human immunodeficiency virus (HIV); Virology; Intensive care medicine; Antiretroviral therapy; Viral load","score_opus":0.15600724176685657,"score_gpt":0.4199217767101455,"score_spread":0.263914534943289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968491140","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013040451,0.9802258,0.00032349947,0.0012243107,0.0002510838,0.005108321,0.00010687217,0.00006520961,0.012681849],"genre_scores_gemma":[0.000043688637,0.9577424,0.0009625684,0.00002480997,0.0008733356,0.0015350955,0.005708236,0.00008923385,0.033020616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637073,0.00017507449,0.0012785562,0.0005741932,0.0012262797,0.0003751884],"domain_scores_gemma":[0.9977675,0.00027541752,0.0006156301,0.00059432676,0.00059023063,0.00015687276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011232421,0.000723107,0.0032818234,0.0005130622,0.00006862295,0.000009573656,0.00012366734,0.00028855575,0.00047509948],"category_scores_gemma":[0.00014135681,0.000424043,0.0005567788,0.00039779145,0.00014156502,0.000060550512,0.000019270094,0.0001383424,0.000091035305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039673767,0.00043124316,0.000020819545,0.010283503,0.0014953776,0.000021146394,0.00030970323,0.0000019771396,0.000002002217,0.00033130424,0.0811457,0.9059175],"study_design_scores_gemma":[0.007505656,0.0006588765,0.000014787594,0.017587192,0.029530518,0.000054755405,0.00020731406,0.00010302849,0.0000065400127,0.00020036908,0.9438578,0.00027316777],"about_ca_topic_score_codex":0.000037055255,"about_ca_topic_score_gemma":0.000026354388,"teacher_disagreement_score":0.90564436,"about_ca_system_score_codex":0.0008632115,"about_ca_system_score_gemma":0.0029876174,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W1968691774","doi":"10.1046/j.1365-3148.2002.00387.x","title":"US NAT yield: where are we after 2 years?","year":2002,"lang":"en","type":"review","venue":"Transfusion Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nat; Residual risk; Virology; Human immunodeficiency virus (HIV); Hepatitis B virus; Hepatitis B; Hepatitis C virus; Medicine; Biology; Virus; Computer science; Internal medicine","score_opus":0.0552448887094162,"score_gpt":0.31794013262509013,"score_spread":0.26269524391567395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968691774","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050047413,0.9823007,0.000023205026,0.01002729,0.00062056165,0.001763036,0.000031791227,0.00016591775,0.005017464],"genre_scores_gemma":[0.000013365796,0.9176167,0.00018039216,0.00038125284,0.0008769131,0.00026967627,0.00015508175,0.00012739489,0.08037918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966496,0.00010343448,0.0010431339,0.0007640098,0.0009294842,0.00051032583],"domain_scores_gemma":[0.9983572,0.00019868191,0.00022904122,0.0006863476,0.00008138573,0.00044739494],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025470497,0.0008059738,0.0031982928,0.00055683375,0.00007434136,0.000011725184,0.00019467634,0.00060255016,0.020245215],"category_scores_gemma":[0.0000430411,0.00051140063,0.00059111166,0.00064333034,0.00015323836,0.000064316264,0.00003409602,0.000835761,0.0014329667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063725616,0.00024361379,0.0002122566,0.018467655,0.00046928454,0.003109849,0.00077682536,1.9733593e-8,8.816841e-7,0.000009648999,0.10258033,0.87406594],"study_design_scores_gemma":[0.0016987468,0.00018004209,0.00009752255,0.11223644,0.0036471686,0.00038393444,0.000075812764,9.0807924e-7,7.4011507e-7,0.000005498511,0.8812959,0.00037726434],"about_ca_topic_score_codex":0.000039180723,"about_ca_topic_score_gemma":0.00013181212,"teacher_disagreement_score":0.87368864,"about_ca_system_score_codex":0.00022406763,"about_ca_system_score_gemma":0.00015916316,"threshold_uncertainty_score":0.99973375},"labels":[],"label_agreement":null},{"id":"W1968781739","doi":"10.1371/journal.pone.0121099","title":"Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Simon Fraser University; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Grand Challenges Canada; National Institutes of Health; Michael Smith Health Research BC; International Development Research Centre","keywords":"Natural product; Viral replication; Virology; Integrase; Biology; Protease; Reverse transcriptase; Drug discovery; Cytotoxicity; Virtual screening; In vitro; Virus; Enzyme; Human immunodeficiency virus (HIV); Biochemistry; RNA; Gene","score_opus":0.0420008687609489,"score_gpt":0.2329681664199694,"score_spread":0.19096729765902049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968781739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98378,0.0015399527,0.0000018501869,0.012015231,0.000063722466,0.00048816862,0.000017117647,0.000064169784,0.0020297668],"genre_scores_gemma":[0.94824,0.000029679344,0.0042688227,0.00010104967,0.00017932574,0.00001975861,0.00005644186,0.000024502802,0.047080442],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998849,0.000025131107,0.00024324842,0.00023992072,0.00046473014,0.00017799229],"domain_scores_gemma":[0.99940103,0.00003445932,0.00010418655,0.00026794407,0.000077006305,0.00011537897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012110965,0.0001518499,0.00030251074,0.00009628978,0.00005985022,0.000028566299,0.00009433765,0.000035011555,0.00002349851],"category_scores_gemma":[0.00019420733,0.0000968026,0.00004282979,0.000311645,0.0001208668,0.00023238113,0.00016497623,0.00015449886,0.000019083669],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008434611,0.0042898175,0.72472113,0.00054020534,0.0020887477,0.00007855018,0.008464549,0.0000012434293,0.2018062,0.00036391983,0.053934213,0.0028679378],"study_design_scores_gemma":[0.0034630962,0.00016477484,0.071291775,0.0012611361,0.00061727647,0.000034266515,0.001485352,0.000103494225,0.91915643,0.0001295915,0.002023697,0.00026908217],"about_ca_topic_score_codex":0.000015732365,"about_ca_topic_score_gemma":0.0000034484153,"teacher_disagreement_score":0.71735024,"about_ca_system_score_codex":0.00002257,"about_ca_system_score_gemma":0.0001302472,"threshold_uncertainty_score":0.39474955},"labels":[],"label_agreement":null},{"id":"W1969073576","doi":"10.1371/journal.pone.0004096","title":"Nevirapine Resistance and Breast-Milk HIV Transmission: Effects of Single and Extended-Dose Nevirapine Prophylaxis in Subtype C HIV-Infected Infants","year":2008,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Fogarty International Center; National Institute of Allergy and Infectious Diseases; Johns Hopkins University; Elizabeth Glaser Pediatric AIDS Foundation","keywords":"Nevirapine; Medicine; Population; Breast milk; Breast feeding; Transmission (telecommunications); Virology; Viral load; Breastfeeding; Internal medicine; Immunology; Biology; Human immunodeficiency virus (HIV); Pediatrics; Antiretroviral therapy","score_opus":0.016254418674636114,"score_gpt":0.20905301408198887,"score_spread":0.19279859540735275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969073576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883681,0.008518818,0.000020257212,0.0014633248,0.000012029092,0.00094904884,0.000011872727,0.00006267148,0.00059386273],"genre_scores_gemma":[0.98570126,0.0027299025,0.00445944,0.00005330204,0.000038837592,0.000046646648,0.00004750909,0.00003455277,0.0068885544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984569,0.000072914605,0.0003954797,0.0003972175,0.00038299023,0.00029450937],"domain_scores_gemma":[0.99920774,0.00011810918,0.000103066806,0.00025833125,0.00010250987,0.00021025055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102431964,0.00026822186,0.0006757938,0.00024990446,0.00007514596,0.000007794424,0.00005253805,0.00011483373,0.00005507312],"category_scores_gemma":[0.00009851975,0.00021972791,0.0000419733,0.00046540287,0.00016844855,0.00012542628,0.00003433089,0.00017673278,0.00001187484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041999533,0.0149188265,0.49316028,0.0066415984,0.0008974399,0.0016576023,0.004455069,3.2372807e-7,0.44923413,0.00004813657,0.00075324683,0.02403339],"study_design_scores_gemma":[0.013888142,0.0011511565,0.8369135,0.004870576,0.00035220291,0.0001462978,0.000027681926,0.00008421144,0.14143401,0.000060926257,0.0006677683,0.00040349213],"about_ca_topic_score_codex":0.000008598954,"about_ca_topic_score_gemma":0.000017482856,"teacher_disagreement_score":0.34375325,"about_ca_system_score_codex":0.000055321932,"about_ca_system_score_gemma":0.0000995566,"threshold_uncertainty_score":0.8960244},"labels":[],"label_agreement":null},{"id":"W1969081293","doi":"10.1517/13543776.2014.898753","title":"LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Integrase; Allosteric regulation; Integrase inhibitor; Human immunodeficiency virus (HIV); Biology; Computational biology; Pharmacology; Virology; Enzyme; Antiretroviral therapy; Biochemistry; Viral load","score_opus":0.07985944761990504,"score_gpt":0.35796034411425753,"score_spread":0.2781008964943525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969081293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027005035,0.99329984,0.00007291196,0.00079822645,0.0014674751,0.0032529654,0.000115072784,0.00008105658,0.00090972916],"genre_scores_gemma":[0.000045438635,0.98798364,0.00013931372,0.0010709554,0.00039213433,0.00067181187,0.0052933786,0.00017580477,0.0042274892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952361,0.0003151047,0.0018660612,0.0010041107,0.00093136233,0.00064729166],"domain_scores_gemma":[0.99695694,0.00016408772,0.0010231138,0.0013018476,0.00018472513,0.00036926905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005529197,0.0011986787,0.004222106,0.0005401428,0.000094864234,0.000022942922,0.00038908306,0.0004543511,0.0004943234],"category_scores_gemma":[0.00005355698,0.0007783201,0.0013371041,0.00050502113,0.00012158777,0.000069340065,0.000121474266,0.0005633868,0.0034239052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057310404,0.00088627,0.00011701457,0.027199103,0.0014611942,0.000030453639,0.00018264638,6.980732e-8,0.000003534401,0.000019552539,0.10727623,0.8627666],"study_design_scores_gemma":[0.0013437838,0.00028206845,0.000019915702,0.17553495,0.0006157666,0.00005520739,0.0000125862025,0.000007646641,0.000040294042,0.000004595188,0.8215383,0.000544847],"about_ca_topic_score_codex":0.000024552817,"about_ca_topic_score_gemma":7.5642697e-7,"teacher_disagreement_score":0.8622218,"about_ca_system_score_codex":0.0005001365,"about_ca_system_score_gemma":0.00049074506,"threshold_uncertainty_score":0.9994668},"labels":[],"label_agreement":null},{"id":"W1969090927","doi":"10.1016/j.jmb.2009.03.025","title":"HIV-1 Reverse Transcriptase Can Simultaneously Engage Its DNA/RNA Substrate at Both DNA Polymerase and RNase H Active Sites: Implications for RNase H Inhibition","year":2009,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"RNase H; Reverse transcriptase; RNase P; DNA polymerase; DNA; RNase MRP; RNA; Polymerase; Chemistry; Molecular biology; RNA-Directed DNA Polymerase; Substrate (aquarium); Biology; Biochemistry; Gene","score_opus":0.01769969661077224,"score_gpt":0.2876260941323345,"score_spread":0.2699263975215622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969090927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97507477,0.0011052986,0.0012250084,0.02159781,0.00004979277,0.00052393513,0.00030358104,0.000016130152,0.000103650724],"genre_scores_gemma":[0.9952659,0.0002804771,0.0016540445,0.0017435466,0.00008591205,0.0000135988985,0.00033427362,0.000019982683,0.000602272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987431,0.00012373242,0.0004809448,0.00025194875,0.00010069942,0.0002995693],"domain_scores_gemma":[0.99890643,0.0001000572,0.00030336625,0.00015697938,0.00020250335,0.00033063965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002075379,0.00023353011,0.00041865354,0.00022600756,0.0001629103,0.000013113709,0.000060203773,0.00014779781,0.000036429745],"category_scores_gemma":[0.00016422721,0.0001895534,0.00019848067,0.00013402366,0.00006840903,0.0000673598,0.000011105572,0.00022356902,0.0000050995427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011260766,0.00034350978,0.00041771863,0.000023321303,0.00023615807,0.0010336492,0.0006593016,0.000005450338,0.99126506,0.00026062658,0.0011179907,0.00351111],"study_design_scores_gemma":[0.009133818,0.0018995916,0.002367246,0.00013260712,0.00072890427,0.0023390795,0.00030063558,0.000046319117,0.9777035,0.0007024747,0.00433136,0.0003144252],"about_ca_topic_score_codex":0.0000031540653,"about_ca_topic_score_gemma":0.000014631692,"teacher_disagreement_score":0.0201911,"about_ca_system_score_codex":0.00018167376,"about_ca_system_score_gemma":0.00018773545,"threshold_uncertainty_score":0.77297634},"labels":[],"label_agreement":null},{"id":"W1969187255","doi":"10.7448/ias.17.4.19757","title":"Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Women's College Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Regimen; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Drug resistance; Immunology","score_opus":0.0081908315418498,"score_gpt":0.22737919955488717,"score_spread":0.21918836801303737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969187255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9216354,0.000083688115,0.00025140005,0.07666564,0.00022645608,0.00048711817,0.000016015369,0.000007882628,0.00062639074],"genre_scores_gemma":[0.9764696,0.000025754034,0.007709341,0.0014639356,0.0002901938,0.000019984771,0.0000061411497,0.000011406072,0.0140036605],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990677,0.000040958825,0.00028704677,0.00010997304,0.00037190068,0.00012237043],"domain_scores_gemma":[0.9989446,0.00024888624,0.00038244468,0.0001120635,0.00026222816,0.000049784045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006449274,0.0001123745,0.00021552017,0.000026399804,0.000174302,0.00003998468,0.00026044116,0.000042622698,0.000036449866],"category_scores_gemma":[0.00034941407,0.000049570797,0.00030125273,0.00006757718,0.000109147564,0.00007501068,0.00008860254,0.0001373038,0.0000061870714],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057290713,0.0009521899,0.4027597,0.00018461137,0.0045230114,0.000006860143,0.01484422,0.00008659068,0.0025040254,0.007459896,0.55313903,0.007810788],"study_design_scores_gemma":[0.03177615,0.0021391553,0.1648949,0.0015994243,0.0007958049,0.00013202932,0.0016086135,0.0038745997,0.005691459,0.008140085,0.7787782,0.0005696005],"about_ca_topic_score_codex":0.0000012382794,"about_ca_topic_score_gemma":0.0000029942876,"teacher_disagreement_score":0.2378648,"about_ca_system_score_codex":0.00017583526,"about_ca_system_score_gemma":0.000043526186,"threshold_uncertainty_score":0.20214385},"labels":[],"label_agreement":null},{"id":"W1969286169","doi":"10.1097/00007691-200410000-00009","title":"Simplification of Therapeutic Drug Monitoring for Twice-Daily Regimens of Lopinavir/Ritonavir for HIV infection","year":2004,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"Canadian Institutes of Health Research; GlaxoSmithKline","keywords":"Lopinavir; Ritonavir; Lopinavir/ritonavir; Therapeutic drug monitoring; Medicine; Pharmacology; Drug; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy","score_opus":0.04081947053148,"score_gpt":0.32680750250110724,"score_spread":0.28598803196962724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969286169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836132,0.0020510566,0.008423135,0.0019248698,0.0011756711,0.0023790258,0.000021355965,0.00016573025,0.00024594815],"genre_scores_gemma":[0.98925745,0.0003936183,0.00639819,0.000019170062,0.00068437046,0.0004912799,0.00003701071,0.00009116592,0.0026277394],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791956,0.000043571305,0.0007283136,0.000437853,0.00040737158,0.00046330414],"domain_scores_gemma":[0.9983183,0.00029290345,0.00040864147,0.0004886199,0.00037520356,0.000116337425],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047865382,0.00036191067,0.0006212856,0.00026771062,0.00018903585,0.000022352002,0.00015502621,0.0001246359,0.000005694677],"category_scores_gemma":[0.000028928467,0.0003327745,0.00029530784,0.00033488488,0.000088709974,0.00019767563,0.000029182593,0.00016532719,0.000011066309],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029647097,0.0024893994,0.4520743,0.0026731107,0.0028937794,0.0000064024334,0.020449411,0.0009454194,0.35855728,0.0032606171,0.00011280232,0.15357278],"study_design_scores_gemma":[0.008283727,0.00038165852,0.08771716,0.0012602025,0.0009952682,0.000011616109,0.0015652352,0.00012351155,0.89155465,0.0027277928,0.0049229255,0.00045625764],"about_ca_topic_score_codex":0.00007204499,"about_ca_topic_score_gemma":0.0000026013456,"teacher_disagreement_score":0.53299737,"about_ca_system_score_codex":0.00042853545,"about_ca_system_score_gemma":0.0002095042,"threshold_uncertainty_score":0.99991244},"labels":[],"label_agreement":null},{"id":"W1969477241","doi":"10.1097/00002030-200501030-00013","title":"Impact of African herbal medicines on antiretroviral metabolism","year":2004,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; McMaster University; AIDS Vancouver; Canadian College of Naturopathic Medicine","funders":"","keywords":"CYP3A4; Traditional medicine; Pharmacology; Medicine; Drug metabolism; Drug; Human immunodeficiency virus (HIV); Verapamil; Cytochrome P450; Metabolism; Internal medicine; Immunology","score_opus":0.012248729531571486,"score_gpt":0.28976274267713215,"score_spread":0.2775140131455607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969477241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698765,0.00027517029,0.000026835785,0.0010357822,0.000107495325,0.00017912504,0.000008178251,0.000044720266,0.011335014],"genre_scores_gemma":[0.9956001,0.000037075974,0.0013249862,0.00011418837,0.0001431553,0.0000075534226,0.00002546412,0.000017492817,0.0027299635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905676,0.00001546776,0.00022196826,0.00017351145,0.0003112259,0.00022105813],"domain_scores_gemma":[0.9995021,0.000025928613,0.000062524574,0.00022021879,0.000053760432,0.00013546649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000967829,0.00016522018,0.00039526413,0.00016818663,0.000030596297,0.00000420913,0.00006059317,0.000051515974,0.00016548569],"category_scores_gemma":[0.000054378947,0.000103033046,0.00018422375,0.00030214645,0.000076933116,0.000045358785,0.000017111475,0.00009105925,0.00008616783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087959116,0.0017578198,0.93922395,0.000068957874,0.0015673683,0.00035021605,0.0034128376,0.000029477573,0.009961846,0.005335121,0.003960792,0.03345201],"study_design_scores_gemma":[0.009822195,0.0047734664,0.9585786,0.00024882916,0.0005210629,0.000050324645,0.000314473,0.0000062832596,0.021577943,0.0006746157,0.003170389,0.00026184274],"about_ca_topic_score_codex":0.00017078353,"about_ca_topic_score_gemma":0.0000022323288,"teacher_disagreement_score":0.03319017,"about_ca_system_score_codex":0.00012017673,"about_ca_system_score_gemma":0.00019050938,"threshold_uncertainty_score":0.42015657},"labels":[],"label_agreement":null},{"id":"W1969553435","doi":"10.1097/00002030-200109070-00010","title":"World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Biology; Drug resistance; Virology; Phenotype; Reverse-transcriptase inhibitor; Geometric mean; Virus; Viral disease; Immunology; Sida; Genetics; Gene","score_opus":0.03402508561659482,"score_gpt":0.2856144878839818,"score_spread":0.25158940226738696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969553435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270177,0.00021509653,0.00045534183,0.0018350234,0.000045987712,0.0008883307,0.00001197564,0.000091659684,0.003754824],"genre_scores_gemma":[0.9386753,0.00002867708,0.048209596,0.00015860287,0.000045455123,0.000121868994,0.00013206531,0.000015478005,0.012612954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847925,0.000111848036,0.00048622978,0.00041692506,0.00015731592,0.00034843993],"domain_scores_gemma":[0.9986361,0.0008817415,0.00009736856,0.00022510889,0.000093300485,0.00006636385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008195997,0.00017926891,0.00035715566,0.00030054798,0.00005758646,0.000015978329,0.00007757343,0.00009058302,0.00007183341],"category_scores_gemma":[0.0017844614,0.00014035385,0.000046439578,0.0010075269,0.000042509157,0.00008146175,0.000029267716,0.00013297511,0.000036932513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003053585,0.00034866593,0.9939404,0.000041585172,0.000035161404,0.000043853917,0.0006716531,0.000011330405,0.00074266165,0.00038776261,0.00029292068,0.0031786615],"study_design_scores_gemma":[0.0032654905,0.00016678375,0.9876328,0.00031267005,0.00004657778,0.000002324481,0.00010362065,0.00017863368,0.0002843785,0.0056117997,0.0022359996,0.00015889238],"about_ca_topic_score_codex":0.000052647956,"about_ca_topic_score_gemma":0.000902512,"teacher_disagreement_score":0.05402646,"about_ca_system_score_codex":0.00033447504,"about_ca_system_score_gemma":0.00010697273,"threshold_uncertainty_score":0.5723464},"labels":[],"label_agreement":null},{"id":"W1969554945","doi":"10.1089/aid.2011.0097","title":"The Prevalence of Drug Resistance Mutations Among Treatment-Naive HIV-Infected Individuals in Beijing, China","year":2011,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Reverse transcriptase; Virology; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Genotype; Drug-naïve; Human immunodeficiency virus (HIV); Protease; Medicine; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Biology; Drug; Immunology; Sida; Viral disease; Viral load; Polymerase chain reaction; Antiretroviral therapy; Gene; Pharmacology; Enzyme; Microbiology; Genetics","score_opus":0.05901514221648519,"score_gpt":0.34535997776393373,"score_spread":0.28634483554744855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969554945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876034,0.00096324744,0.0000018307476,0.0001830884,0.000013540591,0.0007299072,0.00003512154,0.000029684063,0.010440177],"genre_scores_gemma":[0.92183006,0.00088252133,0.00035898358,0.0000047857857,0.000021806689,0.00014793342,0.000022726754,0.00001773943,0.07671343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981035,0.00022786375,0.0003543202,0.00032575327,0.00049710256,0.00049144134],"domain_scores_gemma":[0.99884987,0.00035986194,0.00009386254,0.0003588815,0.00017054277,0.00016696607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070127274,0.00017137354,0.0002785263,0.00042147824,0.0005049631,0.000047925176,0.00016151463,0.00005625089,0.00021144876],"category_scores_gemma":[0.00025765173,0.00011071687,0.000057618247,0.00046414614,0.00084659975,0.00016782634,0.00007986765,0.00024182156,0.000021290167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012963454,0.0004158748,0.9865991,0.00013179483,0.00014183333,0.000042633725,0.006711476,2.9940093e-8,0.00013190937,0.0043071993,0.00095551024,0.00043302766],"study_design_scores_gemma":[0.0015564057,0.00059944415,0.98974824,0.00025733665,0.000060773942,0.0000019072211,0.0006202569,5.3928625e-7,0.0040212222,0.0018102449,0.0012263745,0.00009727422],"about_ca_topic_score_codex":0.000344445,"about_ca_topic_score_gemma":0.0016793994,"teacher_disagreement_score":0.06627326,"about_ca_system_score_codex":0.00015637347,"about_ca_system_score_gemma":0.00017449305,"threshold_uncertainty_score":0.4514903},"labels":[],"label_agreement":null},{"id":"W1969870292","doi":"10.1345/aph.10064","title":"Déjàvu all over Again: Adverse Reactions to Nonnucleoside Reverse Transcriptase Inhibitors","year":2000,"lang":"en","type":"letter","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Reverse transcriptase; Déjà vu; Adverse effect; Virology; Reverse-transcriptase inhibitor; Pharmacology; Human immunodeficiency virus (HIV); Viral disease; Sida; Psychiatry; Polymerase chain reaction; Biochemistry","score_opus":0.06015397830116239,"score_gpt":0.3605866559118444,"score_spread":0.30043267761068204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969870292","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023878079,0.001006079,0.00000772181,0.965831,0.0007333304,0.0017061101,0.00050047215,0.00017369335,0.0061635114],"genre_scores_gemma":[0.0013331894,0.008329306,0.0006192687,0.8794387,0.0025070969,0.00014339625,0.00078154105,0.00019516792,0.106652364],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679935,0.00012814658,0.00087169564,0.0007017198,0.0007793403,0.00071977347],"domain_scores_gemma":[0.9985153,0.00008116303,0.0002604914,0.00058131746,0.00017911757,0.0003825979],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024180378,0.00068583444,0.00094092044,0.0007055884,0.00008505043,0.000016679665,0.00022668269,0.00048616674,0.009041749],"category_scores_gemma":[0.000011667692,0.0006233805,0.00075320975,0.0004175635,0.00009113561,0.0001738394,0.000015494874,0.0010378478,0.00062569557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073212734,0.0004448698,0.00009741928,0.0002129846,0.0016417793,0.0013525833,0.0013926801,0.0000061695227,0.043929067,0.0000016027817,0.9452065,0.004982173],"study_design_scores_gemma":[0.002940965,0.00019757306,0.000052513755,0.00050758256,0.00039134608,0.000031293723,0.000026124491,0.0000045061547,0.095294796,0.000017373013,0.9000441,0.00049181347],"about_ca_topic_score_codex":0.00016880159,"about_ca_topic_score_gemma":0.0000047513768,"teacher_disagreement_score":0.10048885,"about_ca_system_score_codex":0.000100386635,"about_ca_system_score_gemma":0.00024579815,"threshold_uncertainty_score":0.99962175},"labels":[],"label_agreement":null},{"id":"W1970503235","doi":"10.1016/s0924-8579(00)00270-3","title":"Resistance to antiretroviral drugs in patients with primary HIV-1 infection","year":2000,"lang":"en","type":"article","venue":"International Journal of Antimicrobial Agents","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Montreal Clinical Research Institute; Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Virology; Genotype; Reverse transcriptase; Drug resistance; Transmission (telecommunications); Biology; Lentivirus; Nucleoside Reverse Transcriptase Inhibitor; Multiple drug resistance; Viral load; Viral disease; Virus; Medicine; Microbiology; Genetics; RNA; Antiretroviral therapy; Gene","score_opus":0.004898061892324394,"score_gpt":0.2311947620192762,"score_spread":0.2262967001269518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970503235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950357,0.0000052089845,0.000030321495,0.0021073117,0.00028023063,0.00017761835,0.0000146997,0.000008356321,0.0023405536],"genre_scores_gemma":[0.9872616,0.000042109958,0.0019529773,0.0008692653,0.0001400112,0.000001267301,0.00006265928,0.000014759796,0.009655378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998768,0.0000233917,0.0004034213,0.00013679756,0.00051691587,0.00015153106],"domain_scores_gemma":[0.99938893,0.000010561663,0.00014228081,0.00007080155,0.00029297013,0.00009446141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010453322,0.00012658346,0.00022571231,0.00034248113,0.000026309785,0.000032341788,0.00011999889,0.00003841833,0.0003097893],"category_scores_gemma":[0.000013341457,0.000098749086,0.00007730722,0.00017695152,0.000022558692,0.0002180242,0.00002062024,0.00013913537,0.00013034082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037958378,0.00084611354,0.96642345,0.000013413394,0.000217723,0.0001801135,0.00048548813,0.000044367353,0.00022767001,0.0000038081143,0.019104093,0.008657941],"study_design_scores_gemma":[0.006294589,0.00024530312,0.9740539,0.00060068106,0.000038669157,0.000032446645,0.0000051824345,0.0000019860195,0.0010142666,0.0000041003404,0.017596936,0.000111921],"about_ca_topic_score_codex":0.000010947748,"about_ca_topic_score_gemma":0.000010561546,"teacher_disagreement_score":0.008546019,"about_ca_system_score_codex":0.00036992517,"about_ca_system_score_gemma":0.000109992834,"threshold_uncertainty_score":0.4026871},"labels":[],"label_agreement":null},{"id":"W1970570408","doi":"10.1186/1471-2334-12-s1-p94","title":"Biochemical mechanism of clinical resistance to rilpivirine","year":2012,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Rilpivirine; Emtricitabine; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Medicine; Virology; Etravirine; Drug resistance; Human immunodeficiency virus (HIV); Tenofovir; Antiretroviral drug; Reverse-transcriptase inhibitor; Drug; Pharmacology; Antiretroviral therapy; Biology; Viral load; RNA; Genetics","score_opus":0.028613518326776874,"score_gpt":0.33743851299936967,"score_spread":0.3088249946725928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970570408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98846954,0.00059195707,0.00088994607,0.00024799796,0.00031668678,0.00042813303,0.000026654872,0.00012752689,0.008901542],"genre_scores_gemma":[0.99162525,0.000033728233,0.0022243029,0.00020330615,0.000368052,0.000058309754,0.00003328601,0.000019866058,0.0054338807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988506,0.000050750186,0.00040268383,0.00020271359,0.00022653164,0.00026672625],"domain_scores_gemma":[0.998923,0.00015550408,0.00008473872,0.00027068725,0.000082326034,0.00048372228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017156788,0.00014430599,0.0003847742,0.00009296364,0.000040772557,0.0000049788755,0.000046801113,0.000067325855,0.00021629971],"category_scores_gemma":[0.00054836937,0.000116907904,0.00019337243,0.00019673511,0.000048549256,0.000051545027,0.000052480696,0.00006810532,0.00025666686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032609407,0.0016885722,0.9778841,0.00013145186,0.00012435224,0.0000074112704,0.00007639804,2.4751412e-7,0.00033477327,0.003909846,0.015050246,0.00046648883],"study_design_scores_gemma":[0.0048468746,0.00026222292,0.9418605,0.00024805366,0.0007200786,0.0000231438,0.000056895722,0.000008002097,0.019510763,0.00079836213,0.03130915,0.00035597006],"about_ca_topic_score_codex":0.000003835311,"about_ca_topic_score_gemma":0.000012146686,"teacher_disagreement_score":0.036023635,"about_ca_system_score_codex":0.00005240384,"about_ca_system_score_gemma":0.00013845993,"threshold_uncertainty_score":0.4767366},"labels":[],"label_agreement":null},{"id":"W1970953407","doi":"10.1345/aph.10249","title":"Role of Therapeutic Drug Monitoring for Protease Inhibitors","year":2001,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia; Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Therapeutic drug monitoring; Protease; Pharmacology; Intensive care medicine; Clinical trial; Drug; Protease inhibitor (pharmacology); MEDLINE; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Viral load; Antiretroviral therapy; Enzyme; Biology","score_opus":0.12957484759024512,"score_gpt":0.4481745995100262,"score_spread":0.31859975191978107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970953407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004183705,0.99508876,0.000007398061,0.0003792732,0.00016963338,0.0035383494,0.00006183274,0.000039790513,0.0002966032],"genre_scores_gemma":[0.0003170637,0.992702,0.0004548076,0.00007129217,0.00054190104,0.0007193796,0.00006410189,0.00011238052,0.00501704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798816,0.00008744916,0.0008878036,0.00034129818,0.00034277182,0.0003524987],"domain_scores_gemma":[0.99854654,0.00014648844,0.00062725303,0.00029069665,0.00023107252,0.00015792492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035170617,0.00047074468,0.0018683742,0.00034874573,0.000043781336,0.000007854147,0.00017752714,0.00014170355,0.0001442965],"category_scores_gemma":[0.000010588847,0.00034713463,0.0009882457,0.000369411,0.00005753559,0.000061954925,0.000016693559,0.0001867336,0.000013198237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018171324,0.0006145695,0.00022435583,0.009665037,0.0020637144,0.0000069384755,0.0003632581,1.8218222e-7,0.001476686,0.000015688945,0.002427239,0.98296064],"study_design_scores_gemma":[0.0013447658,0.00012345641,0.0000045708207,0.00884137,0.00091714994,0.000008605592,0.00003948569,0.0000023543673,0.08880476,0.00007766909,0.8995984,0.00023736997],"about_ca_topic_score_codex":0.000010448846,"about_ca_topic_score_gemma":2.2586134e-7,"teacher_disagreement_score":0.98272324,"about_ca_system_score_codex":0.00003947037,"about_ca_system_score_gemma":0.00036413773,"threshold_uncertainty_score":0.9998981},"labels":[],"label_agreement":null},{"id":"W1970961290","doi":"10.3851/imp2750","title":"Pharmacokinetics of Raltegravir in the Semen of HIV-Infectedmen","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Women's College Hospital; University of Toronto; Maple Leaf Medical Clinic; St. Michael's Hospital","funders":"Johnson and Johnson; Merck Canada; Abbott Canada; Gilead Sciences; Ontario HIV Treatment Network; Pfizer; ViiV Healthcare; Eli Lilly and Company","keywords":"Raltegravir; Pharmacokinetics; Semen; Medicine; Blood sampling; Blood plasma; Internal medicine; Venous blood; Pharmacology; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Andrology; Immunology; Antiretroviral therapy","score_opus":0.01959320124081224,"score_gpt":0.29079744455224044,"score_spread":0.2712042433114282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970961290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98808205,0.00026403856,0.000010037221,0.002132683,0.00002290212,0.0005911946,0.0000032244654,0.0000105265435,0.008883356],"genre_scores_gemma":[0.99628794,0.0008376126,0.00034608573,0.00019716487,0.000027789541,0.000031012776,0.000020683896,0.000010065434,0.0022416292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927896,0.00006125258,0.00023431628,0.000098968325,0.00018339437,0.00014311979],"domain_scores_gemma":[0.99963397,0.000056440564,0.00007411169,0.00016697777,0.000050436305,0.000018073355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014103214,0.00010657539,0.00023130087,0.00008272893,0.000013639661,0.000004576149,0.00009149728,0.00003180495,0.00018971882],"category_scores_gemma":[0.0000053489,0.00005975061,0.00006572749,0.00022818994,0.00005854354,0.000051075695,0.000010937368,0.00007859398,0.000049738574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018308514,0.0012270785,0.75792027,0.000047344052,0.00024707217,0.000019355997,0.0049214596,0.0000010720305,0.14328116,0.00039974932,0.010375415,0.08137693],"study_design_scores_gemma":[0.0072565214,0.00046668196,0.66372263,0.00011350992,0.000054951037,0.0000062633176,0.0005088546,0.0001235282,0.3105216,0.0005118804,0.016545007,0.00016856733],"about_ca_topic_score_codex":0.000051059844,"about_ca_topic_score_gemma":0.000003101433,"teacher_disagreement_score":0.16724044,"about_ca_system_score_codex":0.000010915757,"about_ca_system_score_gemma":0.000032095446,"threshold_uncertainty_score":0.24365592},"labels":[],"label_agreement":null},{"id":"W1971270591","doi":"10.1046/j.1468-1293.2002.00110.x","title":"Naively changing HAART","year":2002,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Interquartile range; Antiretroviral therapy; Human immunodeficiency virus (HIV); Prospective cohort study; Viral load; Pediatrics; Cohort; Internal medicine; Family medicine","score_opus":0.03303624157819233,"score_gpt":0.2554385941759556,"score_spread":0.22240235259776328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971270591","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17205466,0.00664179,0.0010403765,0.29499525,0.0009557931,0.0011519013,0.0000074621007,0.00064714806,0.52250564],"genre_scores_gemma":[0.6162644,0.0003068657,0.001126604,0.0021857733,0.0006867125,0.000031721986,0.00005371558,0.000028925495,0.3793153],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879956,0.00001533234,0.0002319355,0.00023938151,0.00035535402,0.0003584051],"domain_scores_gemma":[0.9994028,0.000044402794,0.000047256653,0.0002314982,0.000052601674,0.0002213936],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015267062,0.00017623766,0.00034059436,0.00029027145,0.00009979862,0.0000041454573,0.000056711142,0.000053265132,0.0060628704],"category_scores_gemma":[0.00008307717,0.00012086815,0.000052943233,0.0003608077,0.000090285765,0.0000446536,0.00002547624,0.00012387049,0.0021466177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007034959,0.00038030423,0.032653205,0.0001262345,0.000285721,0.0012414944,0.012393299,5.643231e-7,0.0015362094,0.0013021863,0.91204107,0.03796936],"study_design_scores_gemma":[0.007836697,0.00029822567,0.007853164,0.00085762294,0.0003285885,0.00039558223,0.0012547375,0.0010848313,0.0013705199,0.000074624884,0.97836816,0.0002772725],"about_ca_topic_score_codex":0.0000032908204,"about_ca_topic_score_gemma":0.0000013155454,"teacher_disagreement_score":0.44420972,"about_ca_system_score_codex":0.0000735327,"about_ca_system_score_gemma":0.000015340587,"threshold_uncertainty_score":0.99863034},"labels":[],"label_agreement":null},{"id":"W1971304024","doi":"10.1310/hct0801-36","title":"Virologic and Immunologic Impact and Durability of Enfuvirtide-Based Antiretroviral Therapy in HIV-Infected Treatment-Experienced Patients in a Clinical Setting","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Maple Leaf Medical Clinic","funders":"Canadian Institutes of Health Research","keywords":"Enfuvirtide; Medicine; Interquartile range; Viral load; Discontinuation; Internal medicine; Regimen; Hazard ratio; Retrospective cohort study; Adverse effect; Salvage therapy; Gastroenterology; Human immunodeficiency virus (HIV); Confidence interval; Immunology; Chemotherapy","score_opus":0.13038906756558047,"score_gpt":0.4729908189783467,"score_spread":0.3426017514127663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971304024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972648,0.0003262053,0.000017220114,0.00038284523,0.00011243133,0.0017459819,0.00002683559,0.0000399244,0.00008373555],"genre_scores_gemma":[0.9976645,0.0009721157,0.000997902,0.00012946113,0.00005967187,0.000039113143,0.00006937042,0.000015723295,0.000052108946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99280286,0.0021826753,0.0036559582,0.0006741025,0.00022594229,0.0004584587],"domain_scores_gemma":[0.9888095,0.009808045,0.0007380227,0.00034884454,0.000076239456,0.00021932177],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012005878,0.00034134375,0.002166146,0.0002607074,0.000046759185,0.00001604749,0.00007815724,0.00041340844,0.00007485234],"category_scores_gemma":[0.012204996,0.00020970563,0.0004273529,0.0003586247,0.00048263164,0.00008270509,0.00004747284,0.00034073275,0.000007847741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008532721,0.003375471,0.9005891,0.000012524937,0.00012986711,0.0000566044,0.00024324302,7.870959e-7,0.00038396553,0.000004465697,0.000012305932,0.086658925],"study_design_scores_gemma":[0.043515135,0.0070009492,0.94800556,0.00009193512,0.00006609109,0.000002199871,0.00009720564,0.000108503555,0.00081758096,0.00006994664,0.00005593037,0.00016895877],"about_ca_topic_score_codex":0.00006895605,"about_ca_topic_score_gemma":0.000036020574,"teacher_disagreement_score":0.08648997,"about_ca_system_score_codex":0.00015557621,"about_ca_system_score_gemma":0.00022513315,"threshold_uncertainty_score":0.9961156},"labels":[],"label_agreement":null},{"id":"W1971306812","doi":"10.1038/clpt.2011.249","title":"Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers","year":2012,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Institute of General Medical Sciences; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Omeprazole; Efavirenz; CYP2C19; CYP3A; Pharmacology; Pharmacokinetics; Chemistry; CYP3A4; CYP2B6; Oral administration; Drug interaction; Metabolism; Medicine; Cytochrome P450; Biochemistry; Immunology","score_opus":0.09949900459842544,"score_gpt":0.4534612111092563,"score_spread":0.3539622065108309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971306812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936126,0.00044523567,0.00002977627,0.004697402,0.0007051332,0.00038094967,0.0000027866938,0.000017846101,0.00010828127],"genre_scores_gemma":[0.99739164,0.00053476857,0.0004348849,0.0013357854,0.00011300996,0.000012867924,0.000013027747,0.000012156302,0.000151842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986551,0.00023706672,0.0005894276,0.00017946845,0.00012522447,0.00021374803],"domain_scores_gemma":[0.9992376,0.00028205392,0.00020155511,0.000109804976,0.00004934277,0.0001196344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007501736,0.00012105746,0.0004519918,0.000100695324,0.000028659351,0.0000014576963,0.000038004655,0.00019593033,0.000028280178],"category_scores_gemma":[0.00002492881,0.00010594467,0.00010219209,0.00017846852,0.00016156585,0.00008941448,0.00002325569,0.0002885029,0.0000037238965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004797972,0.0031020092,0.9268383,0.00008516258,0.0009233756,0.000015291886,0.00093367626,0.0000011544172,0.04515218,0.000009693143,0.00028696455,0.01785425],"study_design_scores_gemma":[0.0103704985,0.0019472346,0.9220134,0.00007476627,0.0015371885,0.000024556022,0.00023285566,0.00028137676,0.06023777,0.000023854716,0.0030813708,0.00017514598],"about_ca_topic_score_codex":0.000007713183,"about_ca_topic_score_gemma":0.0000061068044,"teacher_disagreement_score":0.017679103,"about_ca_system_score_codex":0.00006350486,"about_ca_system_score_gemma":0.00017077365,"threshold_uncertainty_score":0.43202984},"labels":[],"label_agreement":null},{"id":"W1971708343","doi":"10.7448/ias.15.6.18288","title":"Etravirine with 2 NRTIs: an effective switch option for ARV simplification and side effect management","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Efavirenz; Atazanavir; Regimen; Viral load; Etravirine; Internal medicine; Nevirapine; Side effect (computer science); Human immunodeficiency virus (HIV); Pediatrics; Antiretroviral therapy; Immunology","score_opus":0.00791360355421626,"score_gpt":0.27995447281803004,"score_spread":0.27204086926381377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971708343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952156,0.00012234297,0.005742821,0.0031801122,0.00030875104,0.00063076254,0.000004004986,0.000008988583,0.00048066198],"genre_scores_gemma":[0.98252136,0.000062726576,0.014779751,0.00020838954,0.00033164903,0.000044354772,0.0000112076705,0.00001226863,0.0020283186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919623,0.000032191478,0.00020292334,0.00009024574,0.00036156375,0.00011687008],"domain_scores_gemma":[0.99932736,0.00012264079,0.00021218673,0.00008780049,0.0001681482,0.00008187514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063884887,0.00010648245,0.00015668898,0.000042118798,0.00007806057,0.000025436046,0.00009478593,0.000036230853,0.0000073432675],"category_scores_gemma":[0.000033051125,0.00005735127,0.00015547397,0.000071113966,0.000031743453,0.00024053856,0.000030404126,0.00011558885,0.0000022013867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043659466,0.002188895,0.7436771,0.00048501915,0.010196484,0.000017219087,0.0058294344,0.00017702908,0.025959717,0.0060825646,0.011807921,0.18921268],"study_design_scores_gemma":[0.008913822,0.0016452842,0.9458925,0.0004723063,0.0012848977,0.00051852426,0.0008974611,0.000855278,0.024147656,0.0006697303,0.0145034455,0.00019909127],"about_ca_topic_score_codex":0.0000019997153,"about_ca_topic_score_gemma":0.0000012138496,"teacher_disagreement_score":0.20221542,"about_ca_system_score_codex":0.00025958926,"about_ca_system_score_gemma":0.000017960445,"threshold_uncertainty_score":0.23387168},"labels":[],"label_agreement":null},{"id":"W1971784984","doi":"10.1016/j.bmcl.2013.04.043","title":"Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: In vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Chemistry; Reverse transcriptase; Potency; Bioavailability; In vivo; Pharmacology; Pharmacokinetics; Enzyme inhibitor; Enzyme; CYP3A4; Efflux; Reverse-transcriptase inhibitor; Biochemistry; In vitro; Cytochrome P450; Biology; RNA","score_opus":0.007814370448937416,"score_gpt":0.1949019201887962,"score_spread":0.1870875497398588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971784984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993887,0.0004529809,0.00005733395,0.0050614867,0.000035266632,0.00044823997,0.000014902867,0.000012934858,0.00002985305],"genre_scores_gemma":[0.9971737,0.00023140741,0.0023418893,0.000081746046,0.000030791667,0.00001544154,0.000048957834,0.000019622821,0.00005641204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831206,0.00003648992,0.000871072,0.00028713146,0.0002967938,0.00019647139],"domain_scores_gemma":[0.99925995,0.00003842477,0.000333169,0.00016447397,0.00010119305,0.00010278741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002745193,0.00019730725,0.00051191455,0.00015909031,0.000024441608,0.0000078072835,0.00006107561,0.00009421089,0.00008996718],"category_scores_gemma":[0.00010726417,0.0001868179,0.000040367373,0.00033907001,0.00028887097,0.00015702135,0.000030540774,0.00012518972,7.0903036e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029074648,0.00020971583,0.013737522,0.0010972877,0.00005524672,0.000019143567,0.0015566718,0.000014931496,0.98257023,4.8535844e-7,0.00019104728,0.00025698292],"study_design_scores_gemma":[0.0026698462,0.00003858047,0.0047552665,0.00097210245,0.000112893606,0.00002769062,0.0023370017,0.00023625772,0.98870367,0.0000023602333,0.000014345077,0.00012996754],"about_ca_topic_score_codex":0.00019480565,"about_ca_topic_score_gemma":0.0000055612936,"teacher_disagreement_score":0.008982256,"about_ca_system_score_codex":0.00009543661,"about_ca_system_score_gemma":0.00007331282,"threshold_uncertainty_score":0.76182127},"labels":[],"label_agreement":null},{"id":"W1972374930","doi":"10.1097/00126334-200406010-00016","title":"CD4+ T-Cell Gain With Nonnucleoside or Protease Inhibitors: Convenience May Not Always Be The Most Convenient:Reply","year":2004,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Observational study; Protease inhibitor (pharmacology); Cohort; Medicine; Population; Human immunodeficiency virus (HIV); Protease; Antiretroviral therapy; Cd4 t cell; Internal medicine; Reverse-transcriptase inhibitor; Viral load; Immunology; T cell; Chemistry","score_opus":0.018947919487942996,"score_gpt":0.2514488425548982,"score_spread":0.2325009230669552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972374930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97348565,0.0015656861,0.0004998962,0.021790143,0.00048060756,0.0013168037,0.000017911867,0.00009628848,0.00074699917],"genre_scores_gemma":[0.98829174,0.0002711501,0.004517258,0.00091016816,0.00009599093,0.000058032256,0.000013231745,0.00008286911,0.005759578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957559,0.00013938097,0.0014308122,0.00045895882,0.001433304,0.000781621],"domain_scores_gemma":[0.99715495,0.0002726301,0.0010004787,0.00070177246,0.0005359029,0.00033426442],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013928048,0.00053334626,0.0009590517,0.0005224002,0.00045810896,0.000116211755,0.00055841665,0.00012168355,0.00014921013],"category_scores_gemma":[0.00042048463,0.000281524,0.0003365687,0.0014321057,0.00062596425,0.0005171924,0.00012881434,0.00032559084,0.00015202942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04922389,0.03999616,0.12574923,0.0047748494,0.008454778,0.108033516,0.13786487,0.0064736614,0.4347575,0.0069129104,0.046359256,0.03139936],"study_design_scores_gemma":[0.066832885,0.023652174,0.03182711,0.008231375,0.0035231262,0.059050396,0.031398423,0.0003487073,0.7293248,0.00045538056,0.042259723,0.0030958708],"about_ca_topic_score_codex":0.00007043633,"about_ca_topic_score_gemma":0.0000052215505,"teacher_disagreement_score":0.29456732,"about_ca_system_score_codex":0.0003769208,"about_ca_system_score_gemma":0.0015839112,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W1972694260","doi":"10.1016/j.clinbiochem.2008.08.015","title":"The serum free light chain assay: An alternative to Bence Jones protein analysis in screening for monoclonal gammopathies","year":2008,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Bence Jones protein; Monoclonal; Immunoglobulin light chain; Paraproteinemias; Medicine; Monoclonal antibody; Antibody; Immunology","score_opus":0.054317055056317565,"score_gpt":0.35710868650103206,"score_spread":0.3027916314447145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972694260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98334247,0.00022077313,0.0012071328,0.014198808,0.00004580219,0.0006120022,0.00004474975,0.000037288297,0.00029097343],"genre_scores_gemma":[0.9729959,0.00005907014,0.014685146,0.0002452731,0.0003193066,0.00027606823,0.00008704446,0.000017082728,0.011315157],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981462,0.00007356807,0.00063061115,0.00053209375,0.000289995,0.00032754536],"domain_scores_gemma":[0.9984934,0.00042622857,0.00013383254,0.00054138986,0.0001335983,0.0002715801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010332062,0.00019912265,0.00044936902,0.000079612815,0.00019751534,0.000021657808,0.00028707404,0.00014956508,0.000020336558],"category_scores_gemma":[0.0016103807,0.00013695596,0.00025617942,0.00045074456,0.0001462661,0.000042374842,0.00011737112,0.0002409455,0.000009630594],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018204193,0.0014299223,0.9562907,0.00009601332,0.0020255733,0.00042608086,0.0011579363,0.000037079837,0.009007058,0.000117753785,0.0050709886,0.022520447],"study_design_scores_gemma":[0.00870182,0.0009990638,0.28454557,0.0006416228,0.00091907015,0.00004936847,0.0013766901,0.0060279947,0.68311566,0.00092003675,0.011650996,0.0010521039],"about_ca_topic_score_codex":0.000014228693,"about_ca_topic_score_gemma":0.00006358271,"teacher_disagreement_score":0.67410856,"about_ca_system_score_codex":0.00005999107,"about_ca_system_score_gemma":0.00015282356,"threshold_uncertainty_score":0.55849016},"labels":[],"label_agreement":null},{"id":"W1972752819","doi":"10.1177/009127002401102803","title":"Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers","year":2002,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Amprenavir; Pharmacokinetics; Bioequivalence; Pharmacology; Prodrug; Bioavailability; Crossover study; Medicine; Chemistry; Protease; Biochemistry","score_opus":0.08639558196707112,"score_gpt":0.4306749514898969,"score_spread":0.3442793695228258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972752819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98617166,0.001232222,0.000020653484,0.010592427,0.00080346636,0.00036905418,0.0000067730984,0.0000048650463,0.00079884846],"genre_scores_gemma":[0.9915954,0.0040654973,0.0009005509,0.0013436398,0.00041629357,0.0000034060345,0.0000016289703,0.000015495494,0.0016581195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965114,0.00063282927,0.0021516166,0.00012185747,0.00033797548,0.0002442971],"domain_scores_gemma":[0.99761355,0.000829324,0.00090572494,0.00015726643,0.00027140375,0.00022273758],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023751163,0.00014105802,0.000909756,0.00018608215,0.00002154972,0.0000013839465,0.0002618667,0.00009945404,0.0016004647],"category_scores_gemma":[0.00020190381,0.00008726032,0.00020854874,0.00024986392,0.00030541685,0.00007218281,0.00004773561,0.00068446755,0.000020525507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041491125,0.026706062,0.60883445,0.0007185245,0.0031931682,0.00096431497,0.008820977,0.0009777665,0.043480016,0.000056426972,0.20187427,0.06288288],"study_design_scores_gemma":[0.23758891,0.04587962,0.3575317,0.001500879,0.011630068,0.0043322286,0.0023753678,0.03024467,0.11042856,0.00066547166,0.19662032,0.0012022068],"about_ca_topic_score_codex":0.000009356691,"about_ca_topic_score_gemma":0.000005577458,"teacher_disagreement_score":0.25130278,"about_ca_system_score_codex":0.000044671146,"about_ca_system_score_gemma":0.0001910822,"threshold_uncertainty_score":0.9993122},"labels":[],"label_agreement":null},{"id":"W1973042449","doi":"10.1063/1.2770720","title":"Quantum study of HIV-1 protease-bridge water interaction","year":2007,"lang":"en","type":"article","venue":"The Journal of Chemical Physics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Ab initio; Quantum; Conjugate; Molecule; Protease; Computational chemistry; Human immunodeficiency virus (HIV); Basis set; Chemistry; Chemical physics; Materials science; Physics; Density functional theory; Mathematics; Quantum mechanics; Biology; Biochemistry; Enzyme; Organic chemistry","score_opus":0.02727526026957254,"score_gpt":0.29810901076576624,"score_spread":0.2708337504961937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973042449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982846,0.000015876063,0.00035456437,0.00073230633,0.00006761877,0.00022952074,5.0443407e-7,0.000005215251,0.0003098391],"genre_scores_gemma":[0.9993286,0.0000037234624,0.00009317009,0.00003515128,0.00029039432,0.0000010432129,0.0000032999571,0.000010236102,0.0002343497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990851,0.000025881165,0.00038392504,0.000050563336,0.0003241927,0.00013029086],"domain_scores_gemma":[0.99939907,0.00007205801,0.00018309316,0.00012262771,0.00015402102,0.00006911452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003929856,0.000091694266,0.00024305953,0.000031757885,0.000020010126,0.0000034766078,0.000079903635,0.000023721697,0.000021820973],"category_scores_gemma":[0.000020488156,0.000043306838,0.00008286348,0.000073434785,0.000033543878,0.00006958644,0.000027770453,0.00024069012,0.000021373246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003483226,0.005390133,0.011221864,0.00006782718,0.0007286353,0.00010126187,0.013554855,0.000009913168,0.95677805,0.00004186675,0.004057917,0.0045644282],"study_design_scores_gemma":[0.002345855,0.00036844573,0.0020960884,0.000093510156,0.00034120135,0.00011256862,0.00093397376,0.000028654635,0.9927303,0.0004600414,0.00042854232,0.00006077755],"about_ca_topic_score_codex":0.000003227398,"about_ca_topic_score_gemma":1.5402026e-7,"teacher_disagreement_score":0.03595227,"about_ca_system_score_codex":0.000068539135,"about_ca_system_score_gemma":0.000025900734,"threshold_uncertainty_score":0.17660016},"labels":[],"label_agreement":null},{"id":"W1973346526","doi":"10.3851/imp1558","title":"Use of Newer Antiretroviral Agents, Darunavir and Etravirine with or without Raltegravir, in Pregnancy: A Report of two Cases","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; St. Michael's Hospital; Hospital for Sick Children; University of Ottawa; Women's College Hospital; University of Toronto","funders":"","keywords":"Etravirine; Raltegravir; Darunavir; Medicine; Pregnancy; Regimen; Obstetrics; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Biology","score_opus":0.06270585587226628,"score_gpt":0.33928624158068993,"score_spread":0.27658038570842364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973346526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979953,0.00059070444,0.000016936343,0.0002974748,0.000023282197,0.00066176575,0.000009429621,0.00002515465,0.00037996063],"genre_scores_gemma":[0.98773485,0.0013273713,0.0035650276,0.000095511925,0.000018726085,0.000009257644,0.000037929705,0.000022145081,0.007189156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867964,0.0000479036,0.000443634,0.00030921208,0.00028010385,0.00023949989],"domain_scores_gemma":[0.9992994,0.000051669256,0.0002082867,0.0003119175,0.000069401176,0.0000593027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115696435,0.00024201331,0.0006364819,0.00019019167,0.000026974489,0.000012304063,0.000052358668,0.000056401248,0.000028292003],"category_scores_gemma":[0.000027751445,0.00014662175,0.00006187758,0.00035823925,0.00013618584,0.00021486187,0.000013264934,0.00011492527,0.0000013040367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022191696,0.00075707963,0.93222314,0.000032855874,0.00013370233,0.0032935962,0.00066515384,5.517664e-7,0.0067137154,0.00007380098,0.00011956869,0.053767692],"study_design_scores_gemma":[0.013879046,0.0059736543,0.91569674,0.0019200372,0.0001331415,0.0009831405,0.00012447555,0.000067921545,0.05880191,0.00008003149,0.001957802,0.00038211493],"about_ca_topic_score_codex":0.00033297148,"about_ca_topic_score_gemma":0.00010449689,"teacher_disagreement_score":0.053385578,"about_ca_system_score_codex":0.000023184079,"about_ca_system_score_gemma":0.0001381852,"threshold_uncertainty_score":0.5979061},"labels":[],"label_agreement":null},{"id":"W1973466444","doi":"10.7448/ias.17.4.19796","title":"Efficacy and safety of rilpivirine‐based regimens in treatment‐experienced HIV‐1 infected patients: a prospective cohort study","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rilpivirine; Medicine; Efavirenz; Regimen; Internal medicine; Viral load; Dolutegravir; Clinical endpoint; Prospective cohort study; Raltegravir; Adverse effect; Cohort; Human immunodeficiency virus (HIV); Clinical trial; Virology; Antiretroviral therapy","score_opus":0.007254443299365803,"score_gpt":0.2645567200129045,"score_spread":0.25730227671353867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973466444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973248,0.0000145022605,0.000069813956,0.0011591631,0.00015310121,0.0007026495,0.000005573336,0.0000061101,0.00056426594],"genre_scores_gemma":[0.99752533,0.000021736265,0.0011806069,0.000085997155,0.000059078528,0.000018302364,0.000006471263,0.000009628788,0.0010928388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986512,0.000072859504,0.0004925254,0.00014499738,0.00053236267,0.000106049934],"domain_scores_gemma":[0.99890393,0.00016876368,0.0003840207,0.00013397532,0.0003509398,0.00005836338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034696347,0.0001402401,0.00035255178,0.00008102865,0.000051027942,0.000012892887,0.00012914225,0.000039414757,0.00003629469],"category_scores_gemma":[0.00023483114,0.0000809794,0.00019933935,0.00018589283,0.00007968542,0.00008907408,0.000051522722,0.0001379717,0.0000013976925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005922358,0.0025701337,0.9912362,0.0000051427937,0.0007661186,0.0000032036023,0.0037512,0.000032939846,0.00021610955,0.00003979622,0.000308305,0.0004786257],"study_design_scores_gemma":[0.017188212,0.0011132593,0.9784704,0.00013163144,0.00017191588,0.000009820294,0.0005127157,0.00028658524,0.0013554625,0.000031465283,0.00066026626,0.00006825985],"about_ca_topic_score_codex":0.000015980255,"about_ca_topic_score_gemma":0.000010021748,"teacher_disagreement_score":0.016595976,"about_ca_system_score_codex":0.00056815654,"about_ca_system_score_gemma":0.00013206954,"threshold_uncertainty_score":0.3302244},"labels":[],"label_agreement":null},{"id":"W1973544723","doi":"10.1016/s0140-6736(09)60338-x","title":"Organ transplantation between HIV-infected patients","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transplantation; Medicine; Organ transplantation; Human immunodeficiency virus (HIV); Scopus; Internal medicine; Immunology; MEDLINE; Biology","score_opus":0.014973178367195066,"score_gpt":0.2586434253732829,"score_spread":0.24367024700608783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973544723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744106,0.0000049719883,0.000036991187,0.0063232193,0.00010063735,0.0002190216,0.000032641772,0.000077515455,0.005763924],"genre_scores_gemma":[0.9946274,0.000014579947,0.00042557914,0.00018405697,0.0003461684,0.000009286444,0.0005167956,0.000010407553,0.0038657219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995302,0.000015940132,0.00009447518,0.00008912164,0.000110714056,0.00015956094],"domain_scores_gemma":[0.9996671,0.000041541094,0.000027076849,0.00019397691,0.00003365997,0.00003664957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008587451,0.00007532646,0.00017170774,0.00002613829,0.000067307396,0.000009713375,0.00006624556,0.000037275597,0.00022646094],"category_scores_gemma":[0.000017954599,0.000043364118,0.000023842847,0.00009171716,0.00002330837,0.000028184762,0.000007786425,0.00014399854,0.0004502639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000522949,0.000053548218,0.9814145,0.000020735977,0.000056136112,0.0000043558343,0.0007029859,4.771266e-8,0.0011480777,0.00007477402,0.01305033,0.00342222],"study_design_scores_gemma":[0.003209518,0.000024771385,0.9615297,0.000021412894,0.00012599041,0.000003832917,0.000008230923,0.00000242359,0.007857284,0.00006051904,0.027097793,0.000058556652],"about_ca_topic_score_codex":0.0000044485278,"about_ca_topic_score_gemma":0.000014226983,"teacher_disagreement_score":0.019884827,"about_ca_system_score_codex":0.0000119442075,"about_ca_system_score_gemma":0.000023276676,"threshold_uncertainty_score":0.5787382},"labels":[],"label_agreement":null},{"id":"W1973945374","doi":"10.1186/1471-2377-10-44","title":"Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS","year":2010,"lang":"en","type":"article","venue":"BMC Neurology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Alberta Health Services","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"Medicine; Gabapentin; Pregabalin; Lamotrigine; Adverse effect; Epilepsy; Internal medicine; Anesthesia; Psychiatry; Pathology","score_opus":0.02388381172848037,"score_gpt":0.30416419916047427,"score_spread":0.2802803874319939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973945374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958916,0.00019728608,0.0000034063837,0.002877186,0.00033663184,0.00031547254,0.0000032859596,0.000026129803,0.0003490148],"genre_scores_gemma":[0.9958828,0.000322618,0.0017193826,0.000541782,0.00005280824,0.00001708984,0.000011566257,0.000018966495,0.0014329512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873304,0.00010687338,0.0005241161,0.00029973997,0.000111642934,0.00022458461],"domain_scores_gemma":[0.99900556,0.00047433618,0.00010166705,0.00030041786,0.000034262437,0.00008377867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035893157,0.00015706416,0.0006147714,0.0001615397,0.000022557091,0.0000035575529,0.00008498605,0.00014169945,0.000102693266],"category_scores_gemma":[0.0001482404,0.000115514114,0.00010452527,0.00011009262,0.00017181167,0.00003151053,0.000056883448,0.0003573752,0.000033931097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027251116,0.0004101135,0.98998064,0.000014265545,0.000045828274,0.000035055244,0.0001585414,0.0000010809306,0.0007222782,0.00065171387,0.0000936834,0.0076142666],"study_design_scores_gemma":[0.0050114966,0.00038953323,0.9925449,0.000008393201,0.00002960248,0.000046721016,0.000009872615,0.000029093135,0.0006456456,0.00012379786,0.0010794821,0.00008146638],"about_ca_topic_score_codex":0.000012866717,"about_ca_topic_score_gemma":0.00013114917,"teacher_disagreement_score":0.0075328,"about_ca_system_score_codex":0.0000028127042,"about_ca_system_score_gemma":0.00006838151,"threshold_uncertainty_score":0.47105289},"labels":[],"label_agreement":null},{"id":"W1974003181","doi":"10.1371/journal.pone.0022019","title":"Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention","keywords":"Nevirapine; Emtricitabine; Lamivudine; Resistance mutation; Drug resistance; Virology; Efavirenz; Reverse-transcriptase inhibitor; Reverse transcriptase; HIV drug resistance; Drug; Multiplex; Abacavir; Pharmacology; Viral load; Medicine; Biology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Polymerase chain reaction; Virus; Microbiology; Bioinformatics; Genetics","score_opus":0.10262282331959025,"score_gpt":0.23874723604593043,"score_spread":0.13612441272634018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974003181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97976524,0.00019512378,0.00017291696,0.0013405532,0.000019101348,0.0017735879,0.000027288059,0.0001730419,0.016533136],"genre_scores_gemma":[0.8824756,0.000006222013,0.10293089,0.00037041376,0.000081172606,0.00021099883,0.000046323912,0.00004669755,0.01383164],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783206,0.00008359751,0.0004633643,0.00062888506,0.0005221884,0.00046992587],"domain_scores_gemma":[0.9986307,0.00008300651,0.00007191432,0.00047012785,0.00015516303,0.00058908056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049070956,0.00031121276,0.00056144816,0.000194192,0.00015568813,0.000025988584,0.000110169545,0.00005012507,0.0001488395],"category_scores_gemma":[0.00051157083,0.00028330082,0.0000652462,0.00046622808,0.000053759988,0.000120072196,0.00006247954,0.00017681503,0.00039146535],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032938553,0.026065521,0.52029514,0.007200515,0.0025989474,0.0005169617,0.14495529,0.000006494202,0.2284967,0.0003879656,0.061352197,0.004830391],"study_design_scores_gemma":[0.027583346,0.0011877033,0.084297255,0.009783098,0.0058834017,0.000095750984,0.013944837,0.0008751298,0.8396411,0.0012075388,0.011241189,0.0042596576],"about_ca_topic_score_codex":0.00007340264,"about_ca_topic_score_gemma":0.00008178924,"teacher_disagreement_score":0.6111444,"about_ca_system_score_codex":0.0001869876,"about_ca_system_score_gemma":0.00010112181,"threshold_uncertainty_score":0.9999619},"labels":[],"label_agreement":null},{"id":"W1974397412","doi":"10.7448/ias.17.4.19765","title":"Tolerability is more important than simplicity for treatment durability","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Regimen; Darunavir; Discontinuation; Ritonavir; Cobicistat; Atazanavir; Raltegravir; Internal medicine; Dosing; Tolerability; Elvitegravir; Viral load; Hazard ratio; Human immunodeficiency virus (HIV); Adverse effect; Confidence interval; Virology; Antiretroviral therapy","score_opus":0.017974966506802373,"score_gpt":0.29832317166638406,"score_spread":0.2803482051595817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974397412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94369084,0.000043856846,0.0005966812,0.054477107,0.0005106039,0.00035114153,0.000040727227,0.000011212015,0.00027782968],"genre_scores_gemma":[0.9859262,0.000047819118,0.00739623,0.001426236,0.00046045275,0.000018334671,0.00000910677,0.000012864929,0.0047027287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984337,0.000032141448,0.00064159237,0.00017987694,0.0005474224,0.00016523054],"domain_scores_gemma":[0.9984952,0.00020584388,0.00044361656,0.00026007005,0.00047993168,0.00011529444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007462873,0.00016995052,0.00037703666,0.000025454487,0.00012215444,0.000027659233,0.00025108602,0.00007197737,0.000111019246],"category_scores_gemma":[0.00023720064,0.000090411864,0.0011797993,0.000079382284,0.00008399351,0.00009187364,0.000055020122,0.0001158148,0.0000030045665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045867614,0.001353854,0.9587673,0.000046093664,0.0019554077,0.0000036125207,0.0029211133,0.000015617612,0.0023243662,0.0004905606,0.025575098,0.006088301],"study_design_scores_gemma":[0.012515784,0.001716102,0.6632753,0.00025147386,0.0011229396,0.00050117983,0.0012386221,0.005104169,0.05203613,0.015268748,0.24655074,0.00041883072],"about_ca_topic_score_codex":0.000017609424,"about_ca_topic_score_gemma":0.0000077891555,"teacher_disagreement_score":0.29549202,"about_ca_system_score_codex":0.0008815914,"about_ca_system_score_gemma":0.00022408472,"threshold_uncertainty_score":0.36868888},"labels":[],"label_agreement":null},{"id":"W1974539348","doi":"10.2174/157016210794088227","title":"Rates of Initial Virological Suppression and Subsequent Virological Failure After Initiating Highly Active Antiretroviral Therapy: The Impact of Aboriginal Ethnicity and Injection Drug Use","year":2010,"lang":"en","type":"article","venue":"Current HIV Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Laboratory of Public Health; University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"Medicine; Confounding; Viral load; Hazard ratio; Odds ratio; Internal medicine; Logistic regression; Proportional hazards model; Cohort; Demography; Regimen; Retrospective cohort study; Incidence (geometry); Human immunodeficiency virus (HIV); Immunology; Confidence interval","score_opus":0.08197268743314988,"score_gpt":0.4502216911067614,"score_spread":0.3682490036736115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974539348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818015,0.0003810962,0.0000093906465,0.0006032962,0.00007223126,0.00062800676,0.00006119332,0.000015334563,0.000049323728],"genre_scores_gemma":[0.99902344,0.0005684878,0.000115930176,0.0000072423572,0.000113390415,0.000060920986,0.00005232932,0.000011534111,0.000046709578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979483,0.00050799537,0.00030647966,0.00033737684,0.0005333754,0.00036648315],"domain_scores_gemma":[0.99857473,0.00067485636,0.00010827799,0.0002080373,0.0002754425,0.00015863747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008814388,0.00019949151,0.00035746145,0.00020575714,0.00017240044,0.000042105163,0.00009089608,0.00013416067,0.00016178847],"category_scores_gemma":[0.0002841416,0.00010008452,0.000096640215,0.0002751232,0.00088286004,0.00020444737,0.00013013146,0.0012347597,0.0000035434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004183881,0.0007179597,0.92667395,0.000060593666,0.00011740934,0.000037552236,0.0031916853,0.0000012369795,0.050992303,0.000093687675,0.00041173192,0.013518031],"study_design_scores_gemma":[0.0020818468,0.001246131,0.9667648,0.00009777869,0.000029390683,0.000038584272,0.00027354027,0.00029082422,0.028635018,0.00012788476,0.00030735877,0.000106807056],"about_ca_topic_score_codex":0.00013830338,"about_ca_topic_score_gemma":0.000028223834,"teacher_disagreement_score":0.040090907,"about_ca_system_score_codex":0.00005263355,"about_ca_system_score_gemma":0.00019182882,"threshold_uncertainty_score":0.53644854},"labels":[],"label_agreement":null},{"id":"W1974626772","doi":"10.1016/j.bmcl.2004.05.049","title":"Lysine sulfonamides as novel HIV-protease inhibitors: Nε-disubstituted ureas","year":2004,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); TransCanada (Canada)","funders":"","keywords":"Chemistry; Sulfonamide; Lysine; Enzyme inhibitor; Protease; Human immunodeficiency virus (HIV); Protease inhibitor (pharmacology); Chemical synthesis; Enzyme; Biochemistry; Stereochemistry; Combinatorial chemistry; In vitro; Pharmacology; Virology; Amino acid; Antiretroviral therapy; Viral load","score_opus":0.009638792407571444,"score_gpt":0.2314912214735235,"score_spread":0.22185242906595204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974626772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9191688,0.00062213856,0.0005148282,0.07727576,0.00020163522,0.0005027047,0.000022668,0.00027877136,0.0014127445],"genre_scores_gemma":[0.98946345,0.000058359532,0.0017217706,0.0034494277,0.0013250749,0.000056018627,0.000611298,0.0000780148,0.0032366079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971624,0.000012773511,0.0005818308,0.0007108406,0.00089043786,0.00064169103],"domain_scores_gemma":[0.9984704,0.00004139024,0.0001807857,0.00055382645,0.00011530154,0.0006382681],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019997299,0.0005489096,0.00059814897,0.00010754484,0.00016486969,0.0000335935,0.00022532367,0.00021050291,0.0008591295],"category_scores_gemma":[0.00031533864,0.00045589497,0.00019375398,0.0005445865,0.0003316992,0.000119075245,0.000078061166,0.00044248512,0.0005420674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002466288,0.0006077238,0.00301709,0.00024206427,0.00033931126,0.0015269382,0.0004125057,0.000004464464,0.9858534,0.000031550084,0.007409288,0.00030905538],"study_design_scores_gemma":[0.010892579,0.000065709566,0.0028988759,0.0010194591,0.00063763454,0.0018998104,0.00040096193,0.000007773355,0.9636339,0.000042874253,0.017880106,0.00062035024],"about_ca_topic_score_codex":0.000068970134,"about_ca_topic_score_gemma":0.000002278222,"teacher_disagreement_score":0.073826335,"about_ca_system_score_codex":0.00077157706,"about_ca_system_score_gemma":0.00065597193,"threshold_uncertainty_score":0.9997893},"labels":[],"label_agreement":null},{"id":"W1974701222","doi":"10.1086/651168","title":"Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV‐1 Reverse Transcriptase","year":2010,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; China Scholarship Council; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; McGill University; Gilead Sciences; Novartis Foundation; GlaxoSmithKline; Bristol-Myers Squibb; National Science Foundation","keywords":"Resistance mutation; Zidovudine; Lamivudine; Reverse transcriptase; Virology; Reverse-transcriptase inhibitor; Biology; Medicine; Human immunodeficiency virus (HIV); Pharmacology; Sida; Genetics; Viral disease; Virus; Polymerase chain reaction","score_opus":0.031239709410062693,"score_gpt":0.32449804964568946,"score_spread":0.29325834023562675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974701222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711293,0.0005279368,0.00027502174,0.0013393911,0.00014149786,0.0005404772,0.000010430984,0.000011874821,0.00004044941],"genre_scores_gemma":[0.99920356,0.0003120187,0.00019377263,0.00016437781,0.00007998357,0.00001926256,0.00000624297,0.000005723968,0.000015048875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881285,0.00044238917,0.00039784162,0.00009958185,0.00012823896,0.00011911665],"domain_scores_gemma":[0.99630487,0.0031614834,0.00024956343,0.00008771055,0.000083858875,0.00011253871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014873173,0.00012762005,0.0004328802,0.0001328772,0.000065477485,0.0000046939417,0.000043913486,0.00007552356,0.00003010063],"category_scores_gemma":[0.002170247,0.000062897576,0.00014669009,0.00009748633,0.00015403735,0.00006941136,0.000007458992,0.0002292309,0.00000226936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011817958,0.00079807127,0.9609322,0.00018192857,0.00020429154,0.000120896555,0.00061570975,0.000048412145,0.016910592,0.00040103344,0.001190181,0.006778719],"study_design_scores_gemma":[0.018484559,0.014128543,0.9495861,0.0012974148,0.0011668425,0.0014818022,0.00051994866,0.00022379993,0.008175258,0.0035073708,0.001176132,0.00025220733],"about_ca_topic_score_codex":0.00000870895,"about_ca_topic_score_gemma":0.000010605953,"teacher_disagreement_score":0.013330473,"about_ca_system_score_codex":0.00006920693,"about_ca_system_score_gemma":0.000069969064,"threshold_uncertainty_score":0.25981453},"labels":[],"label_agreement":null},{"id":"W1974974898","doi":"10.1046/j.1468-1293.2003.00131.x","title":"Discrepant results in the interpretation of HIV‐1 drug‐resistance genotypic data among widely used algorithms","year":2003,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Didanosine; Abacavir; Stavudine; Concordance; Zalcitabine; Genotyping; Medicine; Lamivudine; Genotype; Drug resistance; Algorithm; Virology; Genetics; Internal medicine; Biology; Virus; Computer science; Gene","score_opus":0.031248385946257652,"score_gpt":0.29279405302832245,"score_spread":0.2615456670820648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974974898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6376229,0.008838394,0.020159163,0.23302457,0.0011463289,0.0057531204,0.0004059075,0.00024969818,0.09279993],"genre_scores_gemma":[0.970899,0.00018004623,0.004325105,0.00027761972,0.00008524549,0.000033700257,0.001127748,0.000021683196,0.02304988],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997831,0.00018925601,0.0007152194,0.00042370087,0.0005810838,0.0002597583],"domain_scores_gemma":[0.9982952,0.00033890855,0.00021269807,0.0009861981,0.00007327808,0.0000937425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013397797,0.00020793134,0.000467391,0.0001787236,0.000051474977,0.0000066584976,0.000291529,0.00005119921,0.000077366],"category_scores_gemma":[0.0007702409,0.00011911434,0.00003936756,0.00044983806,0.00022600607,0.00012451762,0.00004259693,0.00019251989,0.000029294564],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041906238,0.0022008175,0.18358119,0.00087339163,0.0009793787,0.0017033254,0.16996083,0.00006119386,0.0012719309,0.005130751,0.61364955,0.016397],"study_design_scores_gemma":[0.075742364,0.0006259126,0.40915775,0.012110654,0.0026592351,0.00020233117,0.041029178,0.024766171,0.004521432,0.0024200454,0.42522407,0.0015408675],"about_ca_topic_score_codex":0.00005101243,"about_ca_topic_score_gemma":0.000614596,"teacher_disagreement_score":0.3332761,"about_ca_system_score_codex":0.000075465054,"about_ca_system_score_gemma":0.000122033984,"threshold_uncertainty_score":0.4857342},"labels":[],"label_agreement":null},{"id":"W1976052550","doi":"10.1111/j.1468-1293.2007.00489.x","title":"A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector<sup>®</sup> vs standard needles for enfuvirtide administration<sup>*</sup>","year":2007,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; McMaster University Medical Centre; University of Toronto; University Health Network; AIDS Vancouver; St. Michael's Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Enfuvirtide; Administration (probate law); Preference; Radiochemistry; Nuclear medicine; Statistics","score_opus":0.05454077960715443,"score_gpt":0.3557680433040224,"score_spread":0.301227263696868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976052550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930083,0.00014325682,0.0032892406,0.00057778857,0.00006156746,0.002559021,0.000055622586,0.00004274561,0.00026242848],"genre_scores_gemma":[0.9980207,0.000019722249,0.0011260319,0.00009267999,0.00016480828,0.00007601133,0.00015163151,0.000024931009,0.00032347284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743193,0.00017944604,0.0009812524,0.00042514643,0.00063809846,0.00034411278],"domain_scores_gemma":[0.99832565,0.0004841882,0.00035697906,0.00028971123,0.00038651624,0.00015696978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002082522,0.00027062144,0.00064281357,0.00034004726,0.0002605032,0.000025453763,0.000063595166,0.00009603836,0.000029415565],"category_scores_gemma":[0.0012420664,0.00018114556,0.000053633976,0.0005493997,0.00014639078,0.00022924562,0.000040560084,0.0002435148,0.0000015076475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025517733,0.0010394896,0.96821433,0.00016593433,0.00017073523,0.000006040996,0.026643489,0.000029335346,0.00017535721,0.00008356901,0.00019667392,0.00072325615],"study_design_scores_gemma":[0.0152285965,0.0022951295,0.92002076,0.0005639082,0.0002899966,0.000009322117,0.05891687,0.0014448783,0.00044296673,0.00007137223,0.0005088469,0.00020737057],"about_ca_topic_score_codex":0.00022574766,"about_ca_topic_score_gemma":0.00022396051,"teacher_disagreement_score":0.048193604,"about_ca_system_score_codex":0.00035735464,"about_ca_system_score_gemma":0.00035049923,"threshold_uncertainty_score":0.7386902},"labels":[],"label_agreement":null},{"id":"W1976121966","doi":"10.1016/j.ijid.2008.08.028","title":"Primary drug resistance in antiretroviral-naïve injection drug users","year":2008,"lang":"en","type":"article","venue":"International Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; University of Waterloo; University of British Columbia","funders":"","keywords":"Drug; Antiretroviral drug; Drug resistance; Human immunodeficiency virus (HIV); Medicine; Pharmacology; Antiretroviral therapy; Virology; Viral load; Biology; Microbiology","score_opus":0.006651798878298774,"score_gpt":0.24837570204279116,"score_spread":0.24172390316449238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976121966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223083,0.0010024053,0.000055173132,0.0017531869,0.00079959043,0.00012987995,0.000008421209,0.000035748835,0.0039847656],"genre_scores_gemma":[0.99013335,0.00069783395,0.0002889924,0.00033423252,0.0003380212,0.000007064273,0.000027465827,0.000017426668,0.008155634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984812,0.000053266107,0.00050373893,0.00014909725,0.0006600345,0.00015265355],"domain_scores_gemma":[0.9989565,0.000089320296,0.00030006992,0.000093614144,0.00042079744,0.00013971784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012055144,0.00015125693,0.00028828013,0.0005980861,0.0000642178,0.000025237629,0.0001230315,0.000032105534,0.00008264794],"category_scores_gemma":[0.00015513884,0.00012872338,0.00019700028,0.00022039183,0.000073958865,0.0003475236,0.000029538294,0.0001958172,0.000026997539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007883699,0.00080966344,0.9758855,0.00002068474,0.0003110168,0.0018935342,0.0007420819,0.000045122342,0.00011202577,0.000048393333,0.018557515,0.0007860843],"study_design_scores_gemma":[0.0053178854,0.00010546728,0.984858,0.0004770994,0.00011694441,0.0013344268,0.00013411039,0.000011669223,0.0006021443,0.000510559,0.0063453345,0.00018637805],"about_ca_topic_score_codex":0.00003254537,"about_ca_topic_score_gemma":0.00010119966,"teacher_disagreement_score":0.0122121805,"about_ca_system_score_codex":0.0007699972,"about_ca_system_score_gemma":0.0004212665,"threshold_uncertainty_score":0.5249187},"labels":[],"label_agreement":null},{"id":"W1976340594","doi":"10.1097/qai.0b013e3182a4b991","title":"Baseline Clinical HIV Genotypes Are a Valid Measure of Transmitted Drug Resistance Within the Treatment-Naive Population","year":2013,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Alberta Health Services; University of Alberta; Western University; Public Health Agency of Canada","funders":"Biotechnology and Biological Sciences Research Council; University of Alberta; Public Health Agency of Canada; Health Research Board","keywords":"Genotyping; Interquartile range; Genotype; Medicine; Drug resistance; Internal medicine; Population; Human immunodeficiency virus (HIV); Immunology; Biology; Genetics; Environmental health","score_opus":0.026113474473818246,"score_gpt":0.28701545449670857,"score_spread":0.26090198002289033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976340594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259157,0.008663951,0.00031014511,0.0070771114,0.00043086542,0.0007180658,0.000014422006,0.000041803058,0.00015204561],"genre_scores_gemma":[0.9848198,0.0008394779,0.005340132,0.000057666606,0.00008400401,0.000023575973,0.000030792897,0.000044789238,0.0087597435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99598014,0.0004571009,0.0020892457,0.00028744395,0.00084574596,0.00034030614],"domain_scores_gemma":[0.99662954,0.00054955005,0.0014581331,0.00049071753,0.000718687,0.00015336093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001934088,0.00034570243,0.0011515263,0.00036287995,0.00019513142,0.00003966379,0.00029899634,0.00012998776,0.00013028433],"category_scores_gemma":[0.00053727825,0.00019402943,0.00064488116,0.0007357386,0.00021550104,0.00028879588,0.000019403025,0.00016794726,0.00007545419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039883386,0.008830447,0.9042671,0.0006466209,0.0055618505,0.0009287303,0.02182967,0.00022605,0.00941482,0.00058122067,0.016367711,0.027357468],"study_design_scores_gemma":[0.0111318845,0.0015398903,0.9661362,0.0020220445,0.0023938578,0.00071565405,0.005417371,0.00048531964,0.0069106254,0.0009789013,0.0017093959,0.00055885257],"about_ca_topic_score_codex":0.000054667133,"about_ca_topic_score_gemma":0.00002018516,"teacher_disagreement_score":0.06186913,"about_ca_system_score_codex":0.00018406527,"about_ca_system_score_gemma":0.00026861142,"threshold_uncertainty_score":0.79122907},"labels":[],"label_agreement":null},{"id":"W1978033187","doi":"10.1097/qai.0b013e318061b611","title":"A Prospective Randomized Controlled Trial of Structured Treatment Interruption in HIV-Infected Patients Failing Highly Active Antiretroviral Therapy (Canadian HIV Trials Network Study 164)","year":2007,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; McGill University; HIV Legal Network; University of Toronto","funders":"","keywords":"Antiretroviral therapy; Medicine; Human immunodeficiency virus (HIV); Randomized controlled trial; Sida; Prospective cohort study; Lentivirus; Viral load; Clinical trial; Internal medicine; Virology; Viral disease","score_opus":0.02263925907264187,"score_gpt":0.3062515439900097,"score_spread":0.28361228491736784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978033187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985349,0.0009823033,0.000107951666,0.00013946426,0.0012448042,0.011912075,0.000016904056,0.000033304004,0.00021420248],"genre_scores_gemma":[0.998253,0.00031553322,0.0005328845,0.000009482243,0.00015275803,0.00015943582,0.000051215153,0.00005172475,0.00047399593],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922892,0.001419136,0.0042159557,0.0004058111,0.00093245436,0.00073744793],"domain_scores_gemma":[0.9943693,0.0016423129,0.0027250375,0.00033614718,0.000686691,0.00024049521],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072601424,0.00058972393,0.0057434016,0.0020481152,0.00016523847,0.00005423725,0.000230777,0.00020918009,0.00006783721],"category_scores_gemma":[0.0022577767,0.00036060836,0.0014036244,0.0012859885,0.00017392376,0.00033030784,0.00003007942,0.0002093096,0.0000081246835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86314255,0.0040687886,0.11342866,0.0000124924145,0.0033932072,0.00024742752,0.007888851,0.000053288866,0.00060508976,0.000028081298,0.000017328206,0.007114222],"study_design_scores_gemma":[0.82546544,0.011514112,0.15777688,0.00028366433,0.0010956172,0.000042214047,0.002119642,0.000056071458,0.0012984282,0.00009441069,0.000008607315,0.00024488854],"about_ca_topic_score_codex":0.0007077024,"about_ca_topic_score_gemma":0.00042865393,"teacher_disagreement_score":0.04434822,"about_ca_system_score_codex":0.0013535254,"about_ca_system_score_gemma":0.0008117674,"threshold_uncertainty_score":0.9998846},"labels":[],"label_agreement":null},{"id":"W1978815542","doi":"10.1016/j.antiviral.2007.06.010","title":"Protease inhibitor resistance in HIV-infected patients: Molecular and clinical perspectives","year":2007,"lang":"en","type":"review","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Ritonavir; Drug resistance; Protease; Protease inhibitor (pharmacology); Virology; Biology; Drug; Human immunodeficiency virus (HIV); Virus; Genetics; Viral load; Pharmacology; Antiretroviral therapy; Enzyme","score_opus":0.10836164955973147,"score_gpt":0.47973365930862316,"score_spread":0.3713720097488917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978815542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010950713,0.9779668,0.00000430089,0.00027153597,0.000044270688,0.0038239742,0.000024002671,0.000036252393,0.0068781613],"genre_scores_gemma":[0.0034117333,0.9824776,0.0007672261,0.000010632756,0.00013527808,0.0001800157,0.00018420683,0.00006696704,0.012766345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569166,0.0009009865,0.0008358773,0.00088920194,0.0009697229,0.00071254733],"domain_scores_gemma":[0.99820465,0.0006356153,0.00012560452,0.00042777543,0.0004198603,0.0001865205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002233201,0.00038467164,0.0014787515,0.00096674054,0.000099154495,0.000050766954,0.0001429876,0.00041372393,0.000017524777],"category_scores_gemma":[0.0019333618,0.00028604455,0.00029698864,0.0012353604,0.00042474855,0.00008801033,0.00022081852,0.0015850597,0.000257485],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053347094,0.0033131866,0.0411296,0.01139503,0.0005536499,0.0032530646,0.0005679943,6.2299144e-10,0.000002227997,0.0007791353,0.006027055,0.9324456],"study_design_scores_gemma":[0.0030881136,0.00038954816,0.0051699067,0.023618352,0.00025316636,0.000005457566,0.0001474784,6.245551e-7,0.000024554065,0.00005797214,0.9668276,0.0004172318],"about_ca_topic_score_codex":0.000014247528,"about_ca_topic_score_gemma":0.000048954036,"teacher_disagreement_score":0.9608005,"about_ca_system_score_codex":0.00048524264,"about_ca_system_score_gemma":0.0009177675,"threshold_uncertainty_score":0.9999592},"labels":[],"label_agreement":null},{"id":"W1979167762","doi":"10.1097/qai.0b013e3181963ae6","title":"Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in Subjects Receiving HAART During Acute or Early HIV Infection","year":2009,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases","keywords":"Tolerability; Medicine; Regimen; Internal medicine; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Seroconversion; Clinical trial; Log-rank test; Sida; Immunology; Viral load; Viral disease; Antiretroviral therapy; Human immunodeficiency virus (HIV); Adverse effect; Survival analysis","score_opus":0.018993488643035395,"score_gpt":0.28041563237977984,"score_spread":0.26142214373674444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979167762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743974,0.0007602962,0.000048593138,0.00097365276,0.00027137922,0.00032776143,0.0000021486062,0.00003915463,0.00013724837],"genre_scores_gemma":[0.99764115,0.00029769368,0.0014275984,0.000011579228,0.000023403016,0.0000038284197,0.0000044294634,0.000020919933,0.0005693915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758303,0.000121695215,0.0011366053,0.00027262548,0.00049409125,0.0003919305],"domain_scores_gemma":[0.9985036,0.0003104664,0.0005538055,0.0003045591,0.00019890704,0.00012862837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085663673,0.0002646735,0.00088033825,0.0008332526,0.000116522155,0.0000335289,0.00012060963,0.000116438285,0.000033364006],"category_scores_gemma":[0.00060620037,0.00020037926,0.00021325034,0.0009701605,0.00011837084,0.00034613765,0.00003217743,0.00017052286,0.000007985355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015466262,0.0036997893,0.8961584,0.0003990172,0.0006985716,0.0019210203,0.005941754,0.00030027845,0.06453186,0.000027640272,0.00010941379,0.010745999],"study_design_scores_gemma":[0.0121972915,0.0026627618,0.9645408,0.0009108004,0.00028453712,0.0005622903,0.00015415219,0.00007443714,0.018391833,0.000020537915,0.000015368898,0.00018518278],"about_ca_topic_score_codex":0.000021680866,"about_ca_topic_score_gemma":0.0000059007493,"teacher_disagreement_score":0.06838241,"about_ca_system_score_codex":0.00028703187,"about_ca_system_score_gemma":0.0002887619,"threshold_uncertainty_score":0.81712294},"labels":[],"label_agreement":null},{"id":"W1979235170","doi":"10.7448/ias.15.6.18112","title":"Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor‐based regimen: week 24 phase 3 results from VIKING‐3","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dolutegravir; Regimen; Medicine; Integrase inhibitor; Resistance mutation; Population; Viral load; Internal medicine; Gastroenterology; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; RNA; Biology","score_opus":0.02256180464424634,"score_gpt":0.29002347722904404,"score_spread":0.2674616725847977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979235170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918644,0.000032252767,0.00012834786,0.0068744314,0.00048244576,0.0001661564,0.000071672235,0.000008249654,0.00037205475],"genre_scores_gemma":[0.99096,0.000011918373,0.00756382,0.0002901263,0.00043885905,0.0000032843698,0.000028693648,0.000017739056,0.0006855424],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982072,0.00010219407,0.0004661798,0.00016107425,0.00086711365,0.00019622895],"domain_scores_gemma":[0.9986042,0.00021623528,0.00061957864,0.00022022509,0.00022366605,0.00011611338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007031635,0.00019478114,0.000351291,0.00012282262,0.000048839054,0.00002226607,0.00024732703,0.00009259332,0.00002409883],"category_scores_gemma":[0.00013931702,0.0001091929,0.00031863817,0.00023230514,0.0000845328,0.0003755257,0.00004140021,0.00053829834,0.0000031453644],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04912713,0.037169598,0.56309265,0.00009436548,0.005418574,0.0003196876,0.02411888,0.00021170756,0.2556933,0.0005605915,0.04834258,0.015850943],"study_design_scores_gemma":[0.05412018,0.004144675,0.09023665,0.003062665,0.0006047872,0.00012986962,0.004064124,0.0013360216,0.8324789,0.00029176904,0.009035761,0.00049461814],"about_ca_topic_score_codex":0.00008219702,"about_ca_topic_score_gemma":0.000057066216,"teacher_disagreement_score":0.5767856,"about_ca_system_score_codex":0.00046555718,"about_ca_system_score_gemma":0.00031653995,"threshold_uncertainty_score":0.44527572},"labels":[],"label_agreement":null},{"id":"W1979277621","doi":"10.3109/07853890.2012.732704","title":"Update on rilpivirine: A new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication","year":2012,"lang":"en","type":"review","venue":"Annals of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Rilpivirine; Reverse transcriptase; Reverse-transcriptase inhibitor; Virology; Medicine; Nucleoside Reverse Transcriptase Inhibitor; Dosing; Viral load; Drug; Pharmacology; Antiretroviral drug; Drug resistance; Lentivirus; Clinical trial; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Viral disease; Internal medicine; RNA","score_opus":0.1385581499132086,"score_gpt":0.3901720947956616,"score_spread":0.25161394488245303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979277621","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009146736,0.96575975,0.000044465924,0.028885905,0.00033309785,0.0018163843,0.000092997354,0.00004419921,0.0029317096],"genre_scores_gemma":[0.00035512738,0.97730976,0.0005451182,0.001096711,0.0009384745,0.00006794185,0.0012650323,0.000088388464,0.018333435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99621683,0.00011191091,0.001749117,0.00063159014,0.00084313645,0.0004474128],"domain_scores_gemma":[0.9966248,0.00012315265,0.0010450538,0.0013958305,0.00025286415,0.0005582651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096050085,0.0006430659,0.0031455555,0.00078813237,0.00003848014,0.0000029905734,0.00023592559,0.0003184827,0.0005082407],"category_scores_gemma":[0.0002603687,0.00042461816,0.00061757513,0.0006915024,0.00020011394,0.00008345322,0.000044551423,0.00040225402,0.00028991286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020209077,0.0004931346,0.000029524495,0.009605599,0.0007056567,0.000051047107,0.00030048,8.90874e-8,0.00004646702,0.00014972291,0.319766,0.6686502],"study_design_scores_gemma":[0.002451262,0.00057269214,0.00007924441,0.039900813,0.003794493,0.00006425257,0.000035951976,0.0000012087714,0.000816888,0.000029611734,0.9519847,0.00026885365],"about_ca_topic_score_codex":0.000053272557,"about_ca_topic_score_gemma":0.000002540451,"teacher_disagreement_score":0.66838133,"about_ca_system_score_codex":0.00007271201,"about_ca_system_score_gemma":0.00046981362,"threshold_uncertainty_score":0.9998206},"labels":[],"label_agreement":null},{"id":"W1979533192","doi":"10.1186/1742-4690-7-80","title":"Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C","year":2010,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Recombinant DNA; RNase H; Biology; Enzyme; Primer (cosmetics); RNA; Molecular biology; Virology; RNase P; Escherichia coli; Biochemistry; Chemistry; Gene","score_opus":0.015350451929905667,"score_gpt":0.272327653181468,"score_spread":0.2569772012515623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979533192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758244,0.00036597898,0.000022378883,0.0011148099,0.00011187465,0.00014939626,0.00002863796,0.000012030092,0.0006124687],"genre_scores_gemma":[0.99667394,0.00009564084,0.0013809144,0.00005568989,0.000012933103,0.000005407172,0.00015698104,0.0000071331065,0.0016113501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910873,0.00004642754,0.0003248999,0.00023511211,0.00011823644,0.00016661343],"domain_scores_gemma":[0.999342,0.00009643042,0.00014067229,0.00023793356,0.000082255574,0.00010068245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014766779,0.0001342169,0.0007825923,0.00032148336,0.000021263239,0.0000015812622,0.000055645087,0.00015574567,0.00031322747],"category_scores_gemma":[0.000058441165,0.00010549321,0.00013464285,0.00041109542,0.00029617673,0.000023925377,0.000019390794,0.00018511682,0.000011068036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009034144,0.00052558974,0.62584573,0.00006444749,0.0022131621,0.000037823353,0.0013016245,6.298184e-7,0.36156172,0.0023036927,0.005030207,0.00021194725],"study_design_scores_gemma":[0.0048283804,0.0010724948,0.6531872,0.000034090222,0.006768945,0.000060143288,0.0003251268,0.0005843575,0.32243827,0.00014812627,0.010269809,0.00028304622],"about_ca_topic_score_codex":0.000042602154,"about_ca_topic_score_gemma":0.00004395778,"teacher_disagreement_score":0.039123442,"about_ca_system_score_codex":0.000014812244,"about_ca_system_score_gemma":0.00007239398,"threshold_uncertainty_score":0.4301888},"labels":[],"label_agreement":null},{"id":"W1979579157","doi":"10.1002/jps.22449","title":"COMMENTARY: Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Lamivudine","year":2011,"lang":"en","type":"review","venue":"Journal of Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"World Health Organization","keywords":"Biopharmaceutics Classification System; Bioequivalence; Lamivudine; Pharmacology; Active ingredient; Bioavailability; Dosage form; Drug; Biopharmaceutics; Dissolution testing; Medicine; Chemistry; Virology","score_opus":0.15748315373085983,"score_gpt":0.4528296627799481,"score_spread":0.2953465090490882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979579157","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001441193,0.9935423,0.00008273039,0.003976552,0.00068347645,0.0010267051,0.000091259935,0.000019090363,0.00043377953],"genre_scores_gemma":[0.00015537375,0.99372077,0.004247329,0.00074353284,0.0005185246,0.00003786553,0.00004881507,0.000028187902,0.00049961294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711984,0.00011530286,0.0011976513,0.00033341415,0.00060504064,0.0006287466],"domain_scores_gemma":[0.9979054,0.00032618514,0.00077880616,0.00013974222,0.00016090635,0.0006889993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015672736,0.00045378398,0.0018459285,0.00058031577,0.00022659679,0.000059422273,0.0004698317,0.00016880386,0.00033158239],"category_scores_gemma":[0.00010240768,0.00024760337,0.0010907135,0.00068284007,0.00052730006,0.00029523572,0.00010124786,0.00054052955,0.00004271753],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022645484,0.0007151777,0.0003013579,0.0031160032,0.001129344,0.00024989576,0.00013806667,1.1825627e-7,0.0000035661656,0.0003012855,0.04789183,0.9459269],"study_design_scores_gemma":[0.0020976646,0.0006642895,0.000007741911,0.0041599926,0.0039734556,0.00034703876,0.00005709499,0.000033865163,0.00008227665,0.00023214174,0.9880718,0.00027263624],"about_ca_topic_score_codex":0.0000029110086,"about_ca_topic_score_gemma":0.0000019970744,"teacher_disagreement_score":0.9456543,"about_ca_system_score_codex":0.00019434426,"about_ca_system_score_gemma":0.00055476424,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W1979634477","doi":"10.1016/j.antiviral.2007.03.001","title":"Insertions in the β3–β4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity","year":2007,"lang":"en","type":"review","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Reverse transcriptase; Viral replication; Protease; Biology; Virology; Drug resistance; Virus; Mechanism of action; Enzyme; Drug; Gene; Genetics; Pharmacology; In vitro; Polymerase chain reaction; Biochemistry","score_opus":0.23435612412653742,"score_gpt":0.45694309828154583,"score_spread":0.22258697415500842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979634477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84470516,0.15351164,0.0000034413754,0.000069421665,0.000015089284,0.001283273,0.000060330694,0.000005785613,0.00034582845],"genre_scores_gemma":[0.579012,0.4206609,0.00002445433,0.0000047571307,0.000005071811,0.000021858523,0.00004281626,0.000009063727,0.00021907873],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760854,0.000556511,0.00068822916,0.00041105074,0.0004961163,0.00023957518],"domain_scores_gemma":[0.99828225,0.0003613793,0.0002124273,0.00071725086,0.0003941975,0.0000324845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003542434,0.00020649601,0.0007988031,0.000507035,0.00011941883,0.000008631863,0.00018111445,0.00015073227,0.000007125837],"category_scores_gemma":[0.00041619985,0.00012695503,0.00010982112,0.0010052976,0.00053067255,0.000093391434,0.000052691288,0.0005814125,0.0000033695012],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010922697,0.0058578607,0.009812148,0.038983516,0.00055406307,0.000040340925,0.016062168,1.3854815e-7,0.17929678,0.017356671,0.00038389186,0.7305602],"study_design_scores_gemma":[0.013620568,0.015876858,0.15498334,0.10317221,0.0032762322,0.00022467555,0.01737405,0.00007835067,0.55448896,0.013919211,0.119895644,0.00308992],"about_ca_topic_score_codex":0.0011336472,"about_ca_topic_score_gemma":0.00026120275,"teacher_disagreement_score":0.7274702,"about_ca_system_score_codex":0.00010278547,"about_ca_system_score_gemma":0.00029361525,"threshold_uncertainty_score":0.5177076},"labels":[],"label_agreement":null},{"id":"W1980015659","doi":"10.1021/tx300172s","title":"Bioactivation of Nevirapine to a Reactive Quinone Methide: Implications for Liver Injury","year":2012,"lang":"en","type":"article","venue":"Chemical Research in Toxicology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Therapure Biopharma (Canada); University of Toronto","funders":"Canadian Institutes of Health Research; University of Toronto","keywords":"Covalent bond; In vivo; Chemistry; Microsome; Western blot; Blot; In vitro; Biochemistry; Biology; Molecular biology; Genetics","score_opus":0.224146309983941,"score_gpt":0.4957676370219786,"score_spread":0.27162132703803765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980015659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733712,0.0002096145,0.00025539595,0.023236815,0.000033303804,0.001433067,0.000020155769,0.000015341198,0.0014251017],"genre_scores_gemma":[0.9890074,0.00003732229,0.008764757,0.00016878214,0.00010804735,0.00090595044,0.000049301627,0.000013993554,0.0009444417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987589,0.00008352836,0.00026141462,0.00021975428,0.00018423653,0.0004921422],"domain_scores_gemma":[0.9982147,0.000995015,0.00004096964,0.0002171998,0.00028085418,0.00025125899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089574436,0.000089973895,0.00027203918,0.0004104996,0.00003419118,0.0000027981848,0.00009269937,0.00016341521,0.00006587839],"category_scores_gemma":[0.0017005415,0.000076872646,0.000050106482,0.0006777336,0.00014823898,0.00005626101,0.00009695712,0.00025586577,0.000039049653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007470879,0.001086163,0.010998229,0.00006893326,0.00006293526,0.0000013177545,0.0006465827,7.382183e-8,0.95845103,0.0038120546,0.0057950336,0.018330544],"study_design_scores_gemma":[0.0010531624,0.00035421248,0.032048997,0.000053011667,0.00002032265,0.000006981671,0.000115503324,0.000011789787,0.94976693,0.0010112224,0.015478263,0.000079599056],"about_ca_topic_score_codex":0.000017452861,"about_ca_topic_score_gemma":0.000004142486,"teacher_disagreement_score":0.023068033,"about_ca_system_score_codex":0.00043857523,"about_ca_system_score_gemma":0.00018986838,"threshold_uncertainty_score":0.31347755},"labels":[],"label_agreement":null},{"id":"W1980505437","doi":"10.7326/0003-4819-135-9-200111060-00017","title":"HIV-1 Protease Inhibitors May Interfere with the Ubiquitous Intracellular Proteases","year":2001,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Proteases; Protease; Medicine; Prohormone; Protease inhibitor (pharmacology); MASP1; Serine protease; Virology; Internal medicine; Enzyme; Human immunodeficiency virus (HIV); Biochemistry; Biology; Antiretroviral therapy; Viral load; Hormone","score_opus":0.03134295991659605,"score_gpt":0.29123507283670125,"score_spread":0.25989211292010517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980505437","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016483855,0.0031232976,0.00015688957,0.9707411,0.00034570988,0.002721343,0.000039145652,0.00009158887,0.0062970878],"genre_scores_gemma":[0.10233536,0.0008561778,0.0003456702,0.61338884,0.015957339,0.00085997384,0.0008027432,0.00029345544,0.26516044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960152,0.0001831165,0.001019224,0.00068210065,0.0013912055,0.00070913805],"domain_scores_gemma":[0.9971732,0.00024194054,0.000784474,0.00086980255,0.0006707913,0.0002597735],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004963872,0.0008426019,0.0014180089,0.0005000057,0.00009067578,0.000026302841,0.0005293581,0.0004689663,0.001274904],"category_scores_gemma":[0.00028304994,0.00040791408,0.00029606582,0.00036298315,0.00078980153,0.000091275,0.00013808986,0.0022391188,0.00015537298],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012039657,0.00023958126,0.0040532956,0.0008257001,0.0014262489,0.009415109,0.0009625593,5.044873e-7,0.0001811659,0.000009408895,0.97686845,0.0048140185],"study_design_scores_gemma":[0.0023388818,0.0024520785,0.0001383121,0.012684967,0.00069143216,0.0012574474,0.00045300685,0.000008332085,0.014983484,0.000045450313,0.9645413,0.0004052759],"about_ca_topic_score_codex":0.00026990924,"about_ca_topic_score_gemma":0.000011964113,"teacher_disagreement_score":0.35735226,"about_ca_system_score_codex":0.00009306168,"about_ca_system_score_gemma":0.00030058832,"threshold_uncertainty_score":0.9998373},"labels":[],"label_agreement":null},{"id":"W1980955186","doi":"10.1097/qad.0b013e3283350f08","title":"Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis","year":2009,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Raltegravir; Efavirenz; Integrase inhibitor; Medicine; Rifabutin; Pharmacology; Tuberculosis; Pharmacokinetics; Integrase; Reverse-transcriptase inhibitor; Drug; Virology; Viral load; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Pathology","score_opus":0.010158052974629881,"score_gpt":0.27183171957741414,"score_spread":0.26167366660278424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980955186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93959486,0.00016457241,0.000007684255,0.056817673,0.00009216866,0.0008971377,0.000021930042,0.000036012574,0.00236793],"genre_scores_gemma":[0.8855283,0.0008715633,0.0032710093,0.08773615,0.00090247625,0.00013806565,0.0036400117,0.00014297034,0.017769415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881774,0.000035114044,0.00029806516,0.00029107882,0.00032964756,0.00022834964],"domain_scores_gemma":[0.99952316,0.000031768584,0.00011323794,0.00018733495,0.00008957964,0.00005493597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006550718,0.00028586292,0.00048513807,0.0003754959,0.000021094793,0.0000101943115,0.000038030685,0.00015995046,0.000060656435],"category_scores_gemma":[0.0000049119103,0.00020785212,0.00005677238,0.00027433533,0.00005008673,0.00005514288,0.000022077202,0.00050794886,0.000015643425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028619336,0.00029790305,0.8609387,0.00019846536,0.00025635565,0.0001274227,0.00018438234,0.0000023937323,0.000015040302,0.0000041347344,0.12707065,0.010618361],"study_design_scores_gemma":[0.043247342,0.0011672166,0.5769205,0.0012858206,0.0017271424,0.00003069745,0.000008829302,0.00002529589,0.001836338,0.000055807828,0.37302983,0.00066515646],"about_ca_topic_score_codex":0.00010647572,"about_ca_topic_score_gemma":0.000011944233,"teacher_disagreement_score":0.28401816,"about_ca_system_score_codex":0.00010634074,"about_ca_system_score_gemma":0.00005853105,"threshold_uncertainty_score":0.84759635},"labels":[],"label_agreement":null},{"id":"W1981592939","doi":"10.2165/00003088-200140090-00005","title":"Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice and Once Daily Administration in Patients with HIV","year":2001,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Cmin; Pharmacokinetics; Cmax; Lamivudine; Medicine; Pharmacology; Trough Concentration; Internal medicine; Gastroenterology; Immunology; Virus","score_opus":0.038506566473534634,"score_gpt":0.3774059128336198,"score_spread":0.3388993463600852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981592939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997565,0.00009100747,0.000016512979,0.0010047489,0.00012626576,0.0005297373,0.000014520836,0.000013534498,0.0006386916],"genre_scores_gemma":[0.9978844,0.0002659088,0.000900801,0.00007700896,0.00006247895,0.000007288389,0.00002764858,0.000019155112,0.00075534545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981564,0.00008384464,0.0009382148,0.00025172177,0.00037615275,0.00019365798],"domain_scores_gemma":[0.99894345,0.00021680062,0.00035101667,0.00020923864,0.00015979951,0.00011969944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001934864,0.00017939034,0.0004949343,0.0000752671,0.000034378514,0.0000055555906,0.000116686875,0.00007303367,0.00005175224],"category_scores_gemma":[0.00010065596,0.00012173926,0.000064279615,0.0003409281,0.00023610679,0.000044575303,0.00008009621,0.0002931581,0.0000031890556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021263752,0.0018480021,0.9914307,0.00012487694,0.00010969178,0.000012436309,0.00020762131,0.00006112464,0.0010254381,0.000007962359,0.0004174923,0.0026282535],"study_design_scores_gemma":[0.014505776,0.00053493574,0.95472986,0.00023718893,0.00034017643,0.000005181294,0.000050208797,0.001724812,0.02570093,0.0000045238503,0.002038782,0.00012761548],"about_ca_topic_score_codex":0.0000013514768,"about_ca_topic_score_gemma":0.0000059433055,"teacher_disagreement_score":0.036700856,"about_ca_system_score_codex":0.00003069234,"about_ca_system_score_gemma":0.0000761991,"threshold_uncertainty_score":0.4964383},"labels":[],"label_agreement":null},{"id":"W1982322658","doi":"10.1074/jbc.m112.433441","title":"Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase with a Nucleotide-competing Inhibitor and Its ATP Enhancer","year":2013,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Nucleotide; Reverse transcriptase; Pyrophosphate; Biochemistry; Binding site; Mutant; Enzyme; Biology; Footprinting; Nucleoside; Nucleic acid; Chemistry; Stereochemistry; DNA; RNA","score_opus":0.025560158722346543,"score_gpt":0.24517774937626174,"score_spread":0.2196175906539152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982322658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981038,0.00024781044,0.000049274102,0.0010802178,0.000010124302,0.000118856384,0.000008195172,0.000004865962,0.0003768708],"genre_scores_gemma":[0.99705046,0.00011213193,0.00252198,0.000039217062,0.000052175335,0.0000029056655,0.00001381713,0.000004406587,0.0002029123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991915,0.00001633632,0.00046154068,0.00007781849,0.00015099409,0.00010176056],"domain_scores_gemma":[0.9992678,0.00003872388,0.0003649311,0.00005220663,0.00017787845,0.00009845639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011625773,0.00010259341,0.00034768562,0.000025823645,0.00001802199,0.000004194852,0.000045491888,0.00006542526,0.00039498176],"category_scores_gemma":[0.000042114778,0.000057394573,0.000073425974,0.000057627418,0.000064990105,0.000086464745,0.000013893729,0.000117763724,0.0000036633546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039915336,0.00019706649,0.011390787,0.00029390227,0.000075671,0.00004495174,0.0005142733,7.230061e-7,0.9861805,0.0000014049066,0.0005456276,0.00035597067],"study_design_scores_gemma":[0.0024114354,0.0003644002,0.0075597772,0.0006227349,0.00007741549,0.0003882342,0.0008904152,0.0001390712,0.98694927,0.000014137408,0.00050056656,0.00008251744],"about_ca_topic_score_codex":0.0000018023129,"about_ca_topic_score_gemma":6.979171e-8,"teacher_disagreement_score":0.0038310094,"about_ca_system_score_codex":0.000028873905,"about_ca_system_score_gemma":0.000030728304,"threshold_uncertainty_score":0.43247733},"labels":[],"label_agreement":null},{"id":"W1982475294","doi":"10.1021/op900004c","title":"Polymorphic Crystallization and Transformation of the Anti-Viral/HIV Drug Stavudine","year":2009,"lang":"en","type":"article","venue":"Organic Process Research & Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Stavudine; Human immunodeficiency virus (HIV); Crystallization; Transformation (genetics); Virology; Drug; Medicine; Pharmacology; Chemistry; Biology; Genetics; Antiretroviral therapy; Viral load; Organic chemistry","score_opus":0.020207108149071958,"score_gpt":0.3078338761570689,"score_spread":0.28762676800799697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982475294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778573,0.00045044906,0.00057803694,0.018009044,0.000026263644,0.0010358053,0.0000036157228,0.000051617517,0.0019878868],"genre_scores_gemma":[0.9924833,0.00039561687,0.00070772576,0.0000946523,0.000022118424,0.0000295125,0.000052293348,0.000018699258,0.006196072],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976895,0.00007657726,0.00045004627,0.00028021363,0.0011008562,0.0004028479],"domain_scores_gemma":[0.99911356,0.000035450437,0.00008598258,0.0002141287,0.00040593502,0.00014492925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007836729,0.00017816645,0.00027246543,0.00026544824,0.00031763056,0.000037556445,0.00017516562,0.00006587402,0.00016678633],"category_scores_gemma":[0.00011607181,0.00011829306,0.00003189675,0.00091096724,0.00010704428,0.0002012471,0.000053954453,0.00023992687,0.000032306198],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011764822,0.004255884,0.13101804,0.0038248273,0.0010128926,0.000102702084,0.15803406,0.000025363515,0.5410811,0.006041785,0.01120499,0.1422219],"study_design_scores_gemma":[0.002884671,0.00009844318,0.16674873,0.0006675634,0.000052867133,0.000052911106,0.0015207537,0.00011670129,0.81882143,0.001196091,0.007556701,0.00028316065],"about_ca_topic_score_codex":0.0000023095188,"about_ca_topic_score_gemma":0.000011096293,"teacher_disagreement_score":0.27774033,"about_ca_system_score_codex":0.00020839024,"about_ca_system_score_gemma":0.0010455414,"threshold_uncertainty_score":0.48238507},"labels":[],"label_agreement":null},{"id":"W1982703698","doi":"10.1002/jlcr.1741","title":"Synthesis of deuterium‐labelled fosamprenavir calcium","year":2010,"lang":"en","type":"article","venue":"Journal of Labelled Compounds and Radiopharmaceuticals","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Chemistry; Deuterium; Yield (engineering); Radiochemistry; Calcium; Combinatorial chemistry; Organic chemistry; Nuclear physics","score_opus":0.024516054685068754,"score_gpt":0.3262247074523881,"score_spread":0.30170865276731934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982703698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903555,0.0021875377,0.000098766424,0.0054295356,0.00056494307,0.00025834097,0.0000094052775,0.000017847382,0.00239805],"genre_scores_gemma":[0.9878103,0.001194237,0.009131555,0.00020267438,0.00027472095,0.000006922353,0.0000021781034,0.000027743794,0.0013496485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805045,0.000085624524,0.0009056444,0.00018900516,0.00045990827,0.0003093708],"domain_scores_gemma":[0.9980693,0.0005246224,0.00039003935,0.00021295265,0.00030950215,0.0004936059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007030422,0.00025409058,0.0009690878,0.0002691998,0.00011156628,0.00002935276,0.00015768573,0.00014653371,0.00020756069],"category_scores_gemma":[0.00015895517,0.00017348879,0.00024764158,0.00022209213,0.00023607604,0.00010871202,0.000064563006,0.0005445989,0.000010446393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023631123,0.004591231,0.02334843,0.0004378342,0.0025654556,0.0007647568,0.00079322787,0.0000013790027,0.9351168,0.00097544247,0.0057865046,0.023255814],"study_design_scores_gemma":[0.03625092,0.0007751008,0.006414481,0.0007471219,0.0032479994,0.004976677,0.00021639706,0.0008729279,0.78511053,0.0005427824,0.16022739,0.0006176469],"about_ca_topic_score_codex":0.0000024701606,"about_ca_topic_score_gemma":8.311033e-7,"teacher_disagreement_score":0.1544409,"about_ca_system_score_codex":0.000039596365,"about_ca_system_score_gemma":0.00019303533,"threshold_uncertainty_score":0.7074668},"labels":[],"label_agreement":null},{"id":"W1983103111","doi":"10.1128/jvi.03485-14","title":"Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions","year":2015,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Integrase; Biology; Integrase inhibitor; Virology; Drug resistance; Mutation; Elvitegravir; Infectivity; Genetics; Cross-resistance; Raltegravir; Resistance mutation; Virus; Human immunodeficiency virus (HIV); Gene; Reverse transcriptase; Viral load; Antiretroviral therapy; RNA","score_opus":0.02162395705225153,"score_gpt":0.28354017231247913,"score_spread":0.2619162152602276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983103111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696284,0.00061338255,0.0014888608,0.024582831,0.00024880603,0.00023496737,0.000005593128,0.00001313669,0.003184034],"genre_scores_gemma":[0.9883244,0.000040053197,0.0056670164,0.00018075046,0.00010907281,0.000013454649,0.00003474524,0.000012243466,0.005618286],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986356,0.00012349579,0.00052274286,0.00015699031,0.00035664323,0.00020454994],"domain_scores_gemma":[0.99891853,0.00008222127,0.0003152627,0.00012798919,0.00036397506,0.00019200385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044186396,0.00014453146,0.00037858606,0.00033162316,0.000052569903,0.000014179132,0.00007409243,0.000112919864,0.000021529044],"category_scores_gemma":[0.00020515859,0.00010359274,0.000053262243,0.00032665973,0.00019010289,0.0001587649,0.000011006888,0.0003841887,0.000014754448],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06358733,0.012947496,0.3160964,0.0004408041,0.0018078382,0.0407888,0.017589437,0.00037790072,0.013540208,0.15056118,0.3789491,0.0033135205],"study_design_scores_gemma":[0.08298277,0.005973309,0.63293004,0.0025335469,0.0012418035,0.0038713238,0.0055077635,0.00043943047,0.008100385,0.01659804,0.23876692,0.0010546938],"about_ca_topic_score_codex":0.00001163521,"about_ca_topic_score_gemma":0.0018159213,"teacher_disagreement_score":0.31683362,"about_ca_system_score_codex":0.00059966854,"about_ca_system_score_gemma":0.00060224725,"threshold_uncertainty_score":0.42243895},"labels":[],"label_agreement":null},{"id":"W1983625611","doi":"10.1086/491738","title":"Treatment Interruption of Highly Active Antiretroviral Therapy in Patients with Nadir CD4 Cell Counts &gt;200 Cells/mm<sup>3</sup>","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"International AIDS Society","keywords":"Viral load; Medicine; Internal medicine; Gastroenterology; Genotyping; Antiretroviral therapy; Multivariate analysis; Human immunodeficiency virus (HIV); Immunology; Genotype; Biology","score_opus":0.006897808642254589,"score_gpt":0.23189984459041782,"score_spread":0.22500203594816323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983625611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769205,0.00030644398,0.000008662236,0.00012082498,0.00005239911,0.00028542947,0.000021243355,0.000011290631,0.0015016403],"genre_scores_gemma":[0.9982881,0.000722823,0.000036366455,0.00004994062,0.0000903942,0.0000046015684,0.000013828619,0.000016561133,0.00077738287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991504,0.00006964987,0.00028374782,0.000080322156,0.00027123804,0.00014461813],"domain_scores_gemma":[0.99934876,0.000054761607,0.0002430397,0.000120221266,0.00014414919,0.00008903976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057509224,0.00015825685,0.0002847305,0.0001841056,0.000042259177,0.000008274737,0.000056739256,0.00003370874,0.000117246294],"category_scores_gemma":[0.0000075802313,0.00008387001,0.00009888753,0.00014163944,0.000054566466,0.00011709835,0.000008160445,0.00009069895,0.00002942309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040092003,0.005045542,0.9470376,0.000026345926,0.00056036166,0.00003308881,0.0029527054,0.00041697174,0.000273903,0.0000062051026,0.0009991014,0.03863897],"study_design_scores_gemma":[0.04121918,0.018870903,0.90753174,0.0005194793,0.0013117767,0.00007773072,0.00080112985,0.00025153824,0.021387927,0.000047843,0.0075415084,0.0004392701],"about_ca_topic_score_codex":0.000022515034,"about_ca_topic_score_gemma":0.00000867164,"teacher_disagreement_score":0.039505888,"about_ca_system_score_codex":0.00039693,"about_ca_system_score_gemma":0.00016294586,"threshold_uncertainty_score":0.342012},"labels":[],"label_agreement":null},{"id":"W1983697728","doi":"10.2165/11596340-000000000-00000","title":"Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients","year":2011,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Darunavir; Raltegravir; Ritonavir; Medicine; Maraviroc; Viral load; Regimen; Adverse effect; Internal medicine; Integrase inhibitor; Clinical endpoint; Gastroenterology; Virology; Pharmacology; Randomized controlled trial; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.042722759738994726,"score_gpt":0.290875164831624,"score_spread":0.24815240509262929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983697728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508016,0.00009568496,0.0000014163627,0.00013572411,0.00022948942,0.00053848204,0.000004283546,0.00004695158,0.04814638],"genre_scores_gemma":[0.9946605,0.00006523075,0.0011058815,0.000049347997,0.00001737751,0.00010906536,0.000118805125,0.000021445958,0.0038523609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988166,0.000034143766,0.00027874348,0.00032408003,0.00020644836,0.00033998728],"domain_scores_gemma":[0.99950314,0.000037943562,0.00004915057,0.00026600307,0.000029034025,0.00011471642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007170171,0.00020471502,0.00030477418,0.00019118801,0.000039304217,0.000006570263,0.00008204192,0.00008704461,0.00054713007],"category_scores_gemma":[0.000028139248,0.00017065326,0.000059725928,0.00029551913,0.000058498346,0.000098167424,0.000030741994,0.00009648638,0.0003898131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016046276,0.002191548,0.8901406,0.0000120525465,0.000076688724,0.00020012494,0.066328935,5.1397234e-7,0.0000351503,0.00008339802,0.00030053937,0.039025836],"study_design_scores_gemma":[0.046201214,0.0011674431,0.93213516,0.00021464184,0.00009190747,0.0000037592151,0.006488275,0.00009906124,0.0038676306,0.0001330713,0.009116902,0.0004809037],"about_ca_topic_score_codex":0.00048259186,"about_ca_topic_score_gemma":0.00039337564,"teacher_disagreement_score":0.05984066,"about_ca_system_score_codex":0.00038462048,"about_ca_system_score_gemma":0.000093405426,"threshold_uncertainty_score":0.69590384},"labels":[],"label_agreement":null},{"id":"W1983876041","doi":"10.1177/1545109709347373","title":"Etravirine for HIV-I: Addressing the Limitations of the Nonnucleoside Reverse Transcriptase Inhibitor Class","year":2009,"lang":"en","type":"review","venue":"Journal of the International Association of Physicians in AIDS Care","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Etravirine; Reverse-transcriptase inhibitor; Reverse transcriptase; Medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Viral load; Gene; Genetics; Polymerase chain reaction","score_opus":0.07058939411086747,"score_gpt":0.3359226662136757,"score_spread":0.26533327210280827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983876041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005372424,0.87674797,0.00022169764,0.09400305,0.0082525425,0.00561196,0.0029552756,0.000025324229,0.006809741],"genre_scores_gemma":[0.040831394,0.92553514,0.0045619677,0.001768205,0.0026375335,0.00011295481,0.00033524362,0.00012909004,0.024088442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972941,0.00020684054,0.0012186983,0.00013340577,0.001000811,0.00014612761],"domain_scores_gemma":[0.9950925,0.00072687,0.002895511,0.00022940128,0.0010326083,0.000023125553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054167496,0.00022801285,0.0009222229,0.0002673352,0.000095076975,0.000023789367,0.0005966477,0.00014970318,0.0000074889717],"category_scores_gemma":[0.0008487728,0.00011780377,0.0014844174,0.0004936454,0.00005500215,0.000114946524,0.00004497176,0.0005305592,0.0000014828809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017133856,0.0009958049,0.0027593672,0.0021886583,0.0034865404,0.000008917296,0.0056879707,0.00015260419,0.00031632438,0.0013041238,0.087072164,0.8958562],"study_design_scores_gemma":[0.001642062,0.00010615803,0.0010507996,0.018725606,0.0022611497,0.000012321095,0.0010874599,0.000016768505,0.0005481638,0.00019477321,0.9742296,0.0001251707],"about_ca_topic_score_codex":0.0000037930806,"about_ca_topic_score_gemma":0.00003382125,"teacher_disagreement_score":0.89573103,"about_ca_system_score_codex":0.0013981035,"about_ca_system_score_gemma":0.0005638865,"threshold_uncertainty_score":0.48038983},"labels":[],"label_agreement":null},{"id":"W1984234311","doi":"10.1016/j.bmcl.2008.12.074","title":"Investigation on the role of the tetrazole in the binding of thiotetrazolylacetanilides with HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases","year":2008,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Tetrazole; Chemistry; Moiety; Mutant; Reverse transcriptase; Stereochemistry; Aryl; Wild type; Ring (chemistry); Biochemistry; Organic chemistry; Polymerase chain reaction; Gene","score_opus":0.022501324469527358,"score_gpt":0.20184612592217296,"score_spread":0.1793448014526456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984234311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97404283,0.00032183126,0.000001112561,0.024873503,0.000029276602,0.00033192366,0.0000069230055,0.000010999426,0.00038162086],"genre_scores_gemma":[0.9986114,0.00008758852,0.000049370807,0.0009953325,0.00004995222,0.000009608219,0.000016868695,0.000014567468,0.00016529269],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988008,0.000036034453,0.00027852238,0.00020246598,0.00049971556,0.00018244612],"domain_scores_gemma":[0.9993292,0.00012866466,0.00013240422,0.00030956662,0.00004338143,0.000056799305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002608991,0.00018424814,0.00025069722,0.000039151066,0.000110629335,0.0000050051844,0.0001768853,0.000061480765,0.000058942267],"category_scores_gemma":[0.000079141966,0.000082452185,0.00004309336,0.0005345974,0.00049963256,0.00003587678,0.00001541409,0.00028019163,0.0000025947804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002541753,0.00006478677,0.058014892,0.00009077357,0.00007676695,0.000058171394,0.0046875747,8.374579e-7,0.93542427,0.00001916673,0.0012560439,0.000052514253],"study_design_scores_gemma":[0.0016672901,0.000068105815,0.012101808,0.00052096095,0.00016080402,0.00034768917,0.004368272,0.00000728511,0.9798581,0.000007208207,0.00079765025,0.00009480239],"about_ca_topic_score_codex":0.000044842316,"about_ca_topic_score_gemma":0.000007481087,"teacher_disagreement_score":0.04591308,"about_ca_system_score_codex":0.00006954278,"about_ca_system_score_gemma":0.00016805435,"threshold_uncertainty_score":0.33623028},"labels":[],"label_agreement":null},{"id":"W1984717160","doi":"10.2165/00019053-200018040-00007","title":"The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; HIV Legal Network; St. Paul's Hospital","funders":"Centers for Disease Control and Prevention","keywords":"Didanosine; Zalcitabine; Stavudine; Lamivudine; Zidovudine; Medicine; Indinavir; Cost effectiveness; Reverse-transcriptase inhibitor; Internal medicine; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus","score_opus":0.02345318179831839,"score_gpt":0.3238373498151319,"score_spread":0.3003841680168135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984717160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932957,0.0011589704,0.000089548295,0.0008953179,0.00018834986,0.0020215942,0.00011793187,0.000017404911,0.002215124],"genre_scores_gemma":[0.98188627,0.004367214,0.00037092462,0.000047517806,0.00010216447,0.0003067193,0.000054714837,0.000025080562,0.012839424],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992147,0.000050312003,0.0002999383,0.0001662482,0.000064648695,0.0002041687],"domain_scores_gemma":[0.9985903,0.0009502757,0.00010491411,0.00025423302,0.000044237684,0.000056023866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029608974,0.00015739059,0.00034094317,0.000033801218,0.0001324256,0.000009454433,0.000105094245,0.000030626394,0.00012779966],"category_scores_gemma":[0.0000076702145,0.000084783154,0.00021226998,0.000059674763,0.00013427771,0.000038817627,0.000008162517,0.000038301117,0.00003247881],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012791453,0.002527243,0.10238016,0.00035200507,0.0052843,0.000012151352,0.0023314627,0.00058967416,0.008137915,0.0035909275,0.007970689,0.85403204],"study_design_scores_gemma":[0.018497445,0.0018221851,0.007973489,0.000077350116,0.0014282777,0.000018166782,0.00027122675,0.0043686535,0.3659869,0.00016936343,0.59915096,0.00023597316],"about_ca_topic_score_codex":0.000015616793,"about_ca_topic_score_gemma":0.0000029341613,"teacher_disagreement_score":0.85379606,"about_ca_system_score_codex":0.0001810925,"about_ca_system_score_gemma":0.00010015732,"threshold_uncertainty_score":0.34573567},"labels":[],"label_agreement":null},{"id":"W1984745693","doi":"10.1111/j.1468-1293.2007.00426.x","title":"Once‐daily nevirapine dosing: a pharmacokinetics, efficacy and safety review","year":2007,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Dosing; Nevirapine; Medicine; Rash; Pharmacokinetics; Context (archaeology); Pharmacology; Toxicity; Intensive care medicine; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Immunology; Biology","score_opus":0.08053371491894012,"score_gpt":0.4031688171063051,"score_spread":0.32263510218736496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984745693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.0880054e-7,0.97445756,0.00006971523,0.010262564,0.00043829877,0.0034012813,0.000025522197,0.00015475834,0.011189585],"genre_scores_gemma":[6.8315563e-7,0.9549765,0.0008515776,0.0026793224,0.0013211147,0.000090644164,0.0014886986,0.00013328412,0.038458146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556977,0.00016494904,0.0018422746,0.00092709425,0.0008289691,0.00066693756],"domain_scores_gemma":[0.9973248,0.00048502887,0.0005642587,0.00074660213,0.00015483359,0.00072443177],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011618055,0.0010626812,0.005003074,0.00052841235,0.00012823948,0.000011367154,0.00022302745,0.00031214757,0.0016775544],"category_scores_gemma":[0.00039541276,0.0006630866,0.00036597843,0.00093550194,0.00037776248,0.00004921875,0.00012891267,0.00085461425,0.0005018489],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006390576,0.00015317432,0.0000101156165,0.06985136,0.0006053401,0.00072173745,0.00009081132,5.345558e-9,6.702247e-7,0.00003651289,0.1611246,0.76734173],"study_design_scores_gemma":[0.0045945668,0.00018512321,0.000018585502,0.26088652,0.009297996,0.00090987585,0.000007894873,0.0000010129775,8.3419116e-7,0.0000017292651,0.7237184,0.00037742808],"about_ca_topic_score_codex":0.000005622363,"about_ca_topic_score_gemma":0.0000011515675,"teacher_disagreement_score":0.7669643,"about_ca_system_score_codex":0.00030822834,"about_ca_system_score_gemma":0.00040723066,"threshold_uncertainty_score":0.99958205},"labels":[],"label_agreement":null},{"id":"W1985120639","doi":"10.1097/00126334-200006010-00006","title":"Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels","year":2000,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Ritonavir; Indinavir; Medicine; Confidence interval; Odds ratio; Protease inhibitor (pharmacology); Regimen; Internal medicine; Viral load; Yesterday; Antiretroviral therapy; Human immunodeficiency virus (HIV); Family medicine","score_opus":0.01927818095663723,"score_gpt":0.2744191760115836,"score_spread":0.25514099505494636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985120639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893512,0.00078390277,0.000040678857,0.0062087053,0.00045966613,0.0012308724,0.000015149092,0.00008629439,0.0018235095],"genre_scores_gemma":[0.9552733,0.0000529009,0.0050285463,0.00046655434,0.000035069897,0.000051621497,0.000008260354,0.00005989602,0.039023887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995824,0.00008763859,0.001852484,0.00044290436,0.0011403873,0.00065258786],"domain_scores_gemma":[0.9977884,0.00007585858,0.00046037903,0.00055580575,0.0005254771,0.000594056],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00067167444,0.0004099573,0.00091029494,0.0008105067,0.00020526552,0.000067814755,0.0002778137,0.00014779883,0.0026346457],"category_scores_gemma":[0.0004076214,0.0003176595,0.0003603888,0.0017751182,0.00007928514,0.00033546227,0.000076797325,0.00018276455,0.0024674644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005751236,0.008516035,0.072026104,0.00046534164,0.0035942413,0.020440778,0.05313294,0.00036195584,0.23185569,0.00010089636,0.10282637,0.5009284],"study_design_scores_gemma":[0.02343036,0.023749426,0.5323131,0.009488035,0.0021945653,0.032529704,0.0053577516,0.00019277156,0.26514223,0.00092874403,0.10108031,0.0035929957],"about_ca_topic_score_codex":0.000018802626,"about_ca_topic_score_gemma":5.2740717e-7,"teacher_disagreement_score":0.4973354,"about_ca_system_score_codex":0.0002684058,"about_ca_system_score_gemma":0.0005300279,"threshold_uncertainty_score":0.9999275},"labels":[],"label_agreement":null},{"id":"W1985133649","doi":"10.1097/00002030-200009080-00032","title":"Acute monoarthritis complicating therapy with indinavir","year":2000,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Indinavir; Rash; Monoarthritis; Lamivudine; Dermatology; Ritonavir; Internal medicine; Immunology; Surgery; Arthritis; Viral load; Hepatitis B virus","score_opus":0.016758847643326014,"score_gpt":0.2563882737381717,"score_spread":0.23962942609484567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985133649","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09832937,0.0025407518,0.000031803622,0.8458086,0.00014362964,0.0017166404,0.00011647219,0.00038384338,0.050928857],"genre_scores_gemma":[0.011300806,0.0033889862,0.012487998,0.762502,0.002649216,0.0005873659,0.0046797427,0.0002777638,0.20212609],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847364,0.000033592587,0.0002482471,0.0004602499,0.00037984058,0.00040442662],"domain_scores_gemma":[0.9992375,0.00005056626,0.00009877518,0.0004899879,0.00004483356,0.000078363075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004410065,0.0003949037,0.00058918784,0.00017020226,0.00010747896,0.00003713834,0.00013564665,0.0003576987,0.0008019558],"category_scores_gemma":[0.000001778529,0.0002785668,0.00012083533,0.00021599878,0.00008138022,0.000049190327,0.000020541023,0.0008847871,0.0005936477],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010918329,0.000087747314,0.009387111,0.000032283995,0.0011264759,0.0031907868,0.00034836278,8.2694484e-8,0.00002673956,0.00000512168,0.8374417,0.14824444],"study_design_scores_gemma":[0.0027314632,0.0006034138,0.0012253763,0.00039120603,0.00024183527,0.00046417367,0.000011814523,0.000001367828,0.0004266628,0.00003351483,0.99354225,0.00032693188],"about_ca_topic_score_codex":0.0000191341,"about_ca_topic_score_gemma":0.0000011062441,"teacher_disagreement_score":0.15610057,"about_ca_system_score_codex":0.000090781905,"about_ca_system_score_gemma":0.00012666277,"threshold_uncertainty_score":0.9999666},"labels":[],"label_agreement":null},{"id":"W1985224328","doi":"10.4212/cjhp.v62i6.849","title":"Antiretroviral Therapeutic Drug Monitoring in Canada: Current Status and Recommendations for Clinical Practice","year":2009,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Université de Montréal; Toronto General Hospital; McGill University Health Centre","funders":"Ministère de la Santé; Ministère de la Santé et des Services sociaux","keywords":"Therapeutic drug monitoring; Efavirenz; Drug; Medicine; Pharmacology; Nevirapine; Therapeutic index; Pharmacokinetics; CYP2B6; Reverse-transcriptase inhibitor; Internal medicine; Antiretroviral therapy; Immunology; Cytochrome P450; Human immunodeficiency virus (HIV); Viral load","score_opus":0.05731177966175689,"score_gpt":0.39475986807757235,"score_spread":0.3374480884158155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985224328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8696112,0.010049012,0.000006410454,0.11840682,0.0014048669,0.00036251257,0.000013452626,0.0000025276843,0.00014318983],"genre_scores_gemma":[0.9961908,0.0021821859,0.0005919661,0.0005853389,0.0003079415,0.0000033559963,0.000004871418,0.000008791517,0.00012474411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989345,0.00006829737,0.00044281193,0.000094777046,0.00015733892,0.00030227052],"domain_scores_gemma":[0.9988571,0.00022791163,0.00019136966,0.00007664927,0.00016492711,0.0004820483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050517125,0.00010693356,0.00021542619,0.00010602393,0.00014396498,0.00003713535,0.00008480503,0.000011751,0.000013335268],"category_scores_gemma":[0.00018376538,0.00007487491,0.00005933881,0.00011530639,0.00003464579,0.00019300319,0.000004865361,0.00036453985,0.0000011053522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011181808,0.000103505474,0.7095533,0.000007658703,0.00012591346,0.00013097566,0.0012699442,0.0000014426859,0.0000021191686,0.00009062972,0.013815653,0.27478707],"study_design_scores_gemma":[0.005983509,0.00057340966,0.5787874,0.00022006038,0.0004100885,0.00009871874,0.0020630213,0.00006967045,0.00013743354,0.00034373032,0.4111056,0.00020737566],"about_ca_topic_score_codex":0.2820349,"about_ca_topic_score_gemma":0.44710764,"teacher_disagreement_score":0.39728996,"about_ca_system_score_codex":0.000825317,"about_ca_system_score_gemma":0.0064268876,"threshold_uncertainty_score":0.99920577},"labels":[],"label_agreement":null},{"id":"W1985234859","doi":"10.1097/01.qai.0000209902.89878.c9","title":"Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression","year":2006,"lang":"en","type":"letter","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lopinavir; Ritonavir; Lopinavir/ritonavir; Medicine; Drug resistance; Protease inhibitor (pharmacology); Pharmacology; Viral load; Viremia; Reverse-transcriptase inhibitor; Virology; Internal medicine; Immunology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Biology","score_opus":0.018863236447655352,"score_gpt":0.2693002337440271,"score_spread":0.25043699729637175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985234859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61321616,0.032513287,0.00075188203,0.34380245,0.004369452,0.0029663753,0.00034851668,0.00016550109,0.0018663595],"genre_scores_gemma":[0.5949794,0.0055720555,0.024349956,0.036675498,0.0038662432,0.0002836399,0.0031874545,0.0011081834,0.32997754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994442,0.00017623638,0.002416221,0.0005644929,0.0014544072,0.00094664114],"domain_scores_gemma":[0.9955695,0.00050256884,0.002228216,0.0007295611,0.0008520973,0.00011800428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086006266,0.0008263267,0.0023329973,0.0011846948,0.00018687783,0.000068814945,0.00074456615,0.0006529229,0.00013352375],"category_scores_gemma":[0.00021373831,0.000588314,0.0014251986,0.00057897536,0.0003652316,0.0003503647,0.00010093188,0.000667842,0.00008008502],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010188286,0.0013486472,0.0013696064,0.0009085374,0.0008217821,0.0026333295,0.0007690405,0.000012448795,0.0145950345,0.000032123346,0.97067636,0.00581428],"study_design_scores_gemma":[0.020788927,0.007393798,0.0073632207,0.011607257,0.0017581541,0.007650653,0.00071036414,0.000049759765,0.06090516,0.0021315163,0.87779915,0.0018420616],"about_ca_topic_score_codex":0.000024870826,"about_ca_topic_score_gemma":5.1353925e-7,"teacher_disagreement_score":0.32811117,"about_ca_system_score_codex":0.00041630378,"about_ca_system_score_gemma":0.0006749285,"threshold_uncertainty_score":0.99965686},"labels":[],"label_agreement":null},{"id":"W1985772041","doi":"10.1007/pl00000626","title":"Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)","year":2000,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Primer (cosmetics); Virology; Drug resistance; Zalcitabine; Nucleoside; Human immunodeficiency virus (HIV); Didanosine; Biology; Reverse-transcriptase inhibitor; DNA; Nucleotidyltransferase; Genotype; Nucleoside analogue; Zidovudine; Chemistry; Genetics; Viral load; Polymerase chain reaction; Antiretroviral therapy; RNA; Viral disease; Gene","score_opus":0.019403020330170207,"score_gpt":0.272155119305221,"score_spread":0.2527520989750508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985772041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007822541,0.99173886,0.001965573,0.00080673245,0.00015677085,0.0014273026,0.00006551606,0.000046671077,0.0030103484],"genre_scores_gemma":[0.0014975197,0.98349136,0.009398983,0.00063875096,0.00004518041,0.00010530114,0.00013371337,0.00007782819,0.0046113534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967136,0.00017099448,0.00083136425,0.0009653543,0.00080985186,0.00050887046],"domain_scores_gemma":[0.9985762,0.000035617733,0.00022279883,0.0004897986,0.00006354289,0.00061201566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005046387,0.0005861008,0.0016501774,0.0005336467,0.00016935723,0.00004284401,0.0003217613,0.00024825495,0.00011555641],"category_scores_gemma":[0.000082496976,0.00046169912,0.00057141855,0.0009021649,0.00033850467,0.00007530477,0.00007344659,0.00022598867,0.00008638447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056101196,0.0032139265,0.000049471582,0.08299371,0.004724621,0.019406717,0.0038263744,0.0000455384,0.055597298,0.047526833,0.05755682,0.7244977],"study_design_scores_gemma":[0.0005422028,0.00016307979,5.0766965e-7,0.009145857,0.0016303867,0.000039581802,0.0000789865,0.0000036991119,0.020929236,0.00036056366,0.96656346,0.00054240937],"about_ca_topic_score_codex":0.000007865444,"about_ca_topic_score_gemma":0.0000018421382,"teacher_disagreement_score":0.90900666,"about_ca_system_score_codex":0.000060811126,"about_ca_system_score_gemma":0.00073352136,"threshold_uncertainty_score":0.99978346},"labels":[],"label_agreement":null},{"id":"W1985928587","doi":"10.1097/00002030-200001280-00003","title":"Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use","year":2000,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre; Natural Sciences and Engineering Research Council of Canada","funders":"U.S. Public Health Service","keywords":"Virology; Zidovudine; Zalcitabine; Reverse transcriptase; Drug resistance; Biology; Genotype; Resistance mutation; Viral quasispecies; Lamivudine; Lentivirus; Sexual transmission; Reverse-transcriptase inhibitor; Virus; Transmission (telecommunications); Stavudine; Viral disease; Sida; Polymerase chain reaction; Human immunodeficiency virus (HIV); Genetics; Gene","score_opus":0.013456445864588943,"score_gpt":0.26676165770263904,"score_spread":0.2533052118380501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985928587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99796015,0.00011683449,0.0000049169,0.0003009495,0.000038107853,0.0006373972,0.00011315869,0.000069213216,0.0007592623],"genre_scores_gemma":[0.9240827,0.000044324424,0.002087276,0.00018046334,0.000030193747,0.000030044372,0.00007273427,0.00002820103,0.07344406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981231,0.000121691664,0.00055435085,0.00038667492,0.0004166639,0.00039752724],"domain_scores_gemma":[0.99908483,0.0002728558,0.0000986731,0.0003092716,0.00005548801,0.00017887536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037487253,0.00024370721,0.00046892173,0.00027383585,0.00005570846,0.000030362771,0.00012235665,0.00008672419,0.00070854224],"category_scores_gemma":[0.00025887773,0.00019194532,0.000051511317,0.0007053618,0.000039358827,0.00022990392,0.00005200818,0.00019499687,0.00010433459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067532057,0.0003578259,0.96397746,0.00013491772,0.00011076332,0.000052725005,0.0072584543,0.0000023829766,0.0046645347,0.000014931852,0.0076278816,0.015122805],"study_design_scores_gemma":[0.007962751,0.0030156937,0.9583841,0.0010327768,0.00026637336,0.000020514348,0.0015463762,0.000032145403,0.020312786,0.000008173688,0.0068869977,0.00053134386],"about_ca_topic_score_codex":0.0006728858,"about_ca_topic_score_gemma":0.00004807397,"teacher_disagreement_score":0.07387746,"about_ca_system_score_codex":0.00016181749,"about_ca_system_score_gemma":0.00020851927,"threshold_uncertainty_score":0.78273034},"labels":[],"label_agreement":null},{"id":"W1986400554","doi":"10.1371/journal.pone.0109420","title":"A Significant Reduction in the Frequency of HIV-1 Drug Resistance in Québec from 2001 to 2011 Is Associated with a Decrease in the Monitored Viral Load","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; McGill University; Clinique Paro Excellence; Université de Montréal; Institut National de Santé Publique du Québec","funders":"ViiV Healthcare; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Drug resistance; Emtricitabine; Efavirenz; Medicine; Internal medicine; Viral load; Logistic regression; Nevirapine; Darunavir; Virology; Resistance mutation; HIV drug resistance; Odds ratio; Gastroenterology; Biology; Reverse transcriptase; Human immunodeficiency virus (HIV); Antiretroviral therapy; Polymerase chain reaction; Genetics","score_opus":0.021077751242016336,"score_gpt":0.22106822533038337,"score_spread":0.19999047408836704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986400554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783312,0.00018097655,0.000003512113,0.019679472,0.000007803417,0.00075804215,0.000019353203,0.00001200038,0.0010076587],"genre_scores_gemma":[0.9950223,0.000021694403,0.0016060256,0.00025734756,0.000035996258,0.00019033153,0.000045095425,0.000012527467,0.002808668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998497,0.00024607856,0.00030776203,0.00022991431,0.00050098606,0.0002182563],"domain_scores_gemma":[0.9992726,0.00018882721,0.00009851257,0.00030673412,0.00007075333,0.00006261408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058602315,0.00013637957,0.00031402174,0.00011993534,0.00002846818,0.000009609225,0.00014160105,0.000046395937,0.00005864284],"category_scores_gemma":[0.00032769007,0.000078834404,0.00002604873,0.0003593451,0.000046463017,0.000050085444,0.000010364361,0.00017862787,0.00003844267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013285625,0.008566147,0.8884665,0.000044858225,0.0003217715,0.0001493944,0.072905995,0.0000015925862,0.016950203,0.0000530093,0.0110533945,0.00015860974],"study_design_scores_gemma":[0.007605214,0.0002337205,0.96611404,0.0025119148,0.00039364328,0.0000018660982,0.004060133,0.000085694475,0.017506273,0.00086466887,0.00030008506,0.0003227324],"about_ca_topic_score_codex":0.03284875,"about_ca_topic_score_gemma":0.07756467,"teacher_disagreement_score":0.0776476,"about_ca_system_score_codex":0.00038438698,"about_ca_system_score_gemma":0.00034566858,"threshold_uncertainty_score":0.97359157},"labels":[],"label_agreement":null},{"id":"W1986732741","doi":"10.1097/coh.0b013e32801682e2","title":"Resistance and viral subtypes: how important are the differences and why do they occur?","year":2007,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Resistance (ecology); Computational biology; Biology","score_opus":0.030879486214885638,"score_gpt":0.29620928923932793,"score_spread":0.2653298030244423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986732741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609933,0.0335573,0.00004729573,0.0042650052,0.0005152054,0.00032483623,0.000020247879,0.000021522059,0.0002553258],"genre_scores_gemma":[0.99016637,0.0089053,0.0001422799,0.000038416656,0.0001446323,0.000016637903,0.000021492548,0.0000075962475,0.00055729906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991159,0.000031400923,0.00020752424,0.00026764593,0.00016791042,0.00020962699],"domain_scores_gemma":[0.9995495,0.00011122578,0.000081372484,0.00012849456,0.000024839115,0.000104579296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030837583,0.00016417805,0.00023180038,0.00009315936,0.000114582916,0.000057213623,0.000044006283,0.000047066096,0.000005973964],"category_scores_gemma":[0.00003860159,0.00009393015,0.00002483526,0.000096487696,0.00012507937,0.000069796035,0.000044611523,0.00014810484,0.0000011221881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010244548,0.000065750246,0.9867888,0.00017215572,0.000022005037,0.000005684877,0.0012418091,6.675752e-9,0.0000112881,0.0020451078,0.0025163637,0.0070285704],"study_design_scores_gemma":[0.0019296424,0.000096276824,0.9266706,0.0009958317,0.000037330658,0.000016946873,0.0022359341,0.000016707954,0.000045157893,0.0014935102,0.06626936,0.0001926929],"about_ca_topic_score_codex":0.0000033953766,"about_ca_topic_score_gemma":0.00002791058,"teacher_disagreement_score":0.063753,"about_ca_system_score_codex":0.000020329488,"about_ca_system_score_gemma":0.000022894528,"threshold_uncertainty_score":0.38303605},"labels":[],"label_agreement":null},{"id":"W1986803970","doi":"10.1097/qad.0000000000000424","title":"Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy","year":2014,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"Gilead Sciences","keywords":"Emtricitabine; Efavirenz; Lamivudine; Tenofovir; Virology; Drug resistance; Medicine; Resistance mutation; Drug; Reverse-transcriptase inhibitor; Pharmacotherapy; Pharmacology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Biology; Virus; Genetics; Reverse transcriptase; RNA","score_opus":0.01668110883885854,"score_gpt":0.25128046438876284,"score_spread":0.2345993555499043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986803970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97930765,0.0006074537,0.0007441389,0.01653688,0.0000951242,0.0016754532,0.0001213179,0.00013896696,0.0007730133],"genre_scores_gemma":[0.94333106,0.00067474827,0.007038902,0.0011301661,0.00013847629,0.00032591203,0.00018695064,0.000065306915,0.047108505],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972742,0.00011371897,0.0006351334,0.0007700969,0.0006762638,0.00053055433],"domain_scores_gemma":[0.9975705,0.00084962,0.0002452429,0.00079373055,0.00024684265,0.0002940677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037130737,0.000521135,0.0007911686,0.0002608528,0.0002813896,0.000024009363,0.00027370907,0.00015565354,0.0005551883],"category_scores_gemma":[0.00031582432,0.00033567732,0.00017659721,0.0007429261,0.00016977095,0.00010155586,0.000072414325,0.00022890697,0.00012334206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053317647,0.00803927,0.88679314,0.0007411779,0.001402747,0.0003642405,0.005470083,0.0009832872,0.0056286305,0.0004400474,0.025424803,0.011394907],"study_design_scores_gemma":[0.050116327,0.023275182,0.35128275,0.0016515931,0.000515863,0.0000731663,0.00012578738,0.0008706064,0.042030238,0.0002387337,0.5281865,0.0016332517],"about_ca_topic_score_codex":0.000015014379,"about_ca_topic_score_gemma":0.00030563533,"teacher_disagreement_score":0.5355104,"about_ca_system_score_codex":0.00020100927,"about_ca_system_score_gemma":0.0001140754,"threshold_uncertainty_score":0.9999095},"labels":[],"label_agreement":null},{"id":"W1986920049","doi":"10.1097/00002030-200009290-00019","title":"Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy","year":2000,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Virology; Reverse transcriptase; Drug resistance; Transmission (telecommunications); Genotype; Seroconversion; Biology; Medicine; GenBank; Lentivirus; Viral disease; Protease; Virus; Immunology; Polymerase chain reaction; Genetics; Gene","score_opus":0.004215356267187049,"score_gpt":0.21256854116946336,"score_spread":0.2083531849022763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986920049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738497,0.00018541564,0.000012539375,0.00016376772,0.00003583872,0.00036970855,0.000007968793,0.000022344435,0.001817426],"genre_scores_gemma":[0.9968801,0.00029399057,0.0006747533,0.000033902554,0.00001887883,0.00001724657,0.000032910746,0.000015603006,0.0020326183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989285,0.00005118986,0.00036195602,0.00026711484,0.00016711616,0.0002241563],"domain_scores_gemma":[0.99961543,0.000054475524,0.00005524234,0.00015380919,0.00004705656,0.00007398243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015043012,0.00015268452,0.00033248356,0.00027729993,0.000025148189,0.000008045512,0.00004140356,0.000087276065,0.00013513704],"category_scores_gemma":[0.000059235088,0.00013198573,0.000036791393,0.0005133926,0.000047610454,0.000095553805,0.000018179184,0.00013086913,0.00005133278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017913313,0.00040220015,0.9365261,0.00007638983,0.00005505042,0.00011446498,0.0015846039,0.0000018478431,0.011356569,0.000013483435,0.000040436335,0.048037525],"study_design_scores_gemma":[0.0044540083,0.00044507545,0.98414093,0.00031857024,0.00004381216,0.0000073509145,0.00011283625,0.0001586352,0.009929288,0.000040755414,0.00022018494,0.00012854105],"about_ca_topic_score_codex":0.00037600487,"about_ca_topic_score_gemma":0.0003071495,"teacher_disagreement_score":0.047908984,"about_ca_system_score_codex":0.00010267756,"about_ca_system_score_gemma":0.0000732779,"threshold_uncertainty_score":0.5382222},"labels":[],"label_agreement":null},{"id":"W1986998055","doi":"10.1097/coh.0b013e3283136c9b","title":"Combining protease inhibitors with new drug classes in treatment-experienced patients","year":2008,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Ontario HIV Treatment Network","keywords":"Regimen; Intensive care medicine; Medicine; Drug; Drug resistance; Protease; Protease inhibitor (pharmacology); Drug class; Population; Bioinformatics; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Surgery; Viral load; Biology","score_opus":0.03616147600852786,"score_gpt":0.29865990766421596,"score_spread":0.2624984316556881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986998055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972213,0.0009013329,0.000011253275,0.00035293467,0.00041814384,0.0008064803,0.0000039320544,0.000033264543,0.0002513806],"genre_scores_gemma":[0.9968969,0.0008815103,0.0005073325,0.000010499448,0.0000974127,0.00017582875,0.00017192641,0.000015692163,0.0012428577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888045,0.00003082432,0.0002937123,0.00032599972,0.00021538352,0.00025363476],"domain_scores_gemma":[0.99956405,0.000031129548,0.00006208298,0.00012450386,0.000028005368,0.00019023432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042451727,0.00022193894,0.0003079323,0.00025043267,0.00007744793,0.000013056192,0.00003641168,0.00003813486,0.000022457074],"category_scores_gemma":[0.00002043924,0.00015525053,0.000034578745,0.00032798527,0.000076866236,0.00014132481,0.000025407287,0.00011701328,0.000013047811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018580563,0.00099321,0.9753834,0.00005571219,0.000015114916,0.000010538619,0.0068651154,0.0000017366369,0.000005468983,0.000058955495,0.0014150209,0.015009915],"study_design_scores_gemma":[0.03966857,0.0017759304,0.90278834,0.003275259,0.000040732353,0.000036548772,0.0020727334,0.000119878605,0.0016763563,0.000073563395,0.047809247,0.000662827],"about_ca_topic_score_codex":0.000045193632,"about_ca_topic_score_gemma":0.000006922962,"teacher_disagreement_score":0.07259505,"about_ca_system_score_codex":0.0001503548,"about_ca_system_score_gemma":0.00022214325,"threshold_uncertainty_score":0.63309324},"labels":[],"label_agreement":null},{"id":"W1987084124","doi":"10.1186/1471-2334-13-509","title":"Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions","year":2013,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Public Health Agency of Canada; University of Ottawa","funders":"","keywords":"Phylogenetic tree; Medicine; Psychological intervention; Context (archaeology); Genotyping; Population; Demographics; Cluster (spacecraft); Public health; Human immunodeficiency virus (HIV); Men who have sex with men; Demography; Medical microbiology; Drug resistance; Genotype; Family medicine; Environmental health; Biology; Virology; Pathology; Genetics","score_opus":0.029264847638790684,"score_gpt":0.3166102292166375,"score_spread":0.28734538157784684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987084124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8564177,0.0033445586,0.113139525,0.023020208,0.00011136218,0.002106401,0.00052294537,0.0003758269,0.0009614377],"genre_scores_gemma":[0.9782133,0.000045877037,0.0004155482,0.00010175332,0.000034380817,0.0020502673,0.0019043752,0.000024921595,0.017209545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834704,0.00011200906,0.0005713439,0.00041182322,0.00014772109,0.00041007347],"domain_scores_gemma":[0.9988658,0.0001505199,0.00014064123,0.00035679637,0.00016296063,0.0003232741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013717612,0.00021546271,0.0004981594,0.0010458953,0.00024281665,0.000087128064,0.000088077424,0.000041402298,0.0004810513],"category_scores_gemma":[0.00007784774,0.00019109799,0.00065510185,0.0016584245,0.0001043391,0.00012147253,0.000020315396,0.000069196445,0.00004430262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028908094,0.0016029757,0.9753627,0.00035804074,0.00075592735,0.000001677872,0.00032034665,0.000024760626,0.0000048891097,0.00033333755,0.014321515,0.0068849158],"study_design_scores_gemma":[0.0021055539,0.000032940487,0.9937259,0.00008756012,0.0009814862,0.0000027259487,0.00019194242,0.00020914806,0.000008838015,0.000967448,0.0015133091,0.00017314362],"about_ca_topic_score_codex":0.00011348772,"about_ca_topic_score_gemma":0.014605508,"teacher_disagreement_score":0.121795595,"about_ca_system_score_codex":0.00034687156,"about_ca_system_score_gemma":0.00024283979,"threshold_uncertainty_score":0.81502163},"labels":[],"label_agreement":null},{"id":"W1987208122","doi":"10.1371/journal.pone.0068213","title":"Evolution of Primary HIV Drug Resistance in a Subtype C Dominated Epidemic in Mozambique","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Public Health Agency of Canada","funders":"U.S. Public Health Service; Centers for Disease Control and Prevention; Universidade Federal do Rio de Janeiro; Ministério da Educação; Public Health Agency; U.S. Department of Health and Human Services; Public Health Agency of Canada; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; U.S. President’s Emergency Plan for AIDS Relief","keywords":"Drug resistance; Subtyping; HIV drug resistance; Virology; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Antiretroviral treatment; Lopinavir; Human immunodeficiency virus (HIV); Biology; Reverse-transcriptase inhibitor; Medicine; Antiretroviral therapy; Viral load; Genetics; Polymerase chain reaction; Gene","score_opus":0.01721150096168966,"score_gpt":0.21440240327715232,"score_spread":0.19719090231546266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987208122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877208,0.0011361033,0.000008526043,0.0049412246,0.000007905219,0.0007580531,0.000002226023,0.00002663723,0.005398558],"genre_scores_gemma":[0.9594499,0.00014822437,0.0063697123,0.000060722534,0.000013375267,0.0001373312,0.000040346982,0.000014134057,0.033766262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989552,0.00006833515,0.0003744248,0.00019088612,0.00021091486,0.00020025468],"domain_scores_gemma":[0.99949634,0.00008934507,0.00008609278,0.00018774343,0.00008516941,0.000055316497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002376188,0.00010868611,0.00040898618,0.0002420862,0.000011249353,0.0000026242706,0.000053497046,0.00006513938,0.00010511682],"category_scores_gemma":[0.00013841609,0.00009770312,0.000027382717,0.00037170036,0.000034624074,0.00008923651,0.000022753386,0.00014704757,0.00015395579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004628017,0.0036997371,0.9237855,0.00078386045,0.0001328163,0.000058517155,0.001600114,0.0000011429188,0.06426805,0.00033025522,0.0047118957,0.00016527229],"study_design_scores_gemma":[0.004906073,0.00002948073,0.9580323,0.002836645,0.00008758572,0.0000013542689,0.00012040627,0.00040333244,0.03177938,0.001520186,0.00010624704,0.00017702735],"about_ca_topic_score_codex":0.00018592516,"about_ca_topic_score_gemma":0.00075931166,"teacher_disagreement_score":0.03424675,"about_ca_system_score_codex":0.0005964116,"about_ca_system_score_gemma":0.00015414662,"threshold_uncertainty_score":0.3984218},"labels":[],"label_agreement":null},{"id":"W1987638744","doi":"10.7448/ias.17.1.18617","title":"Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy‐years","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital; HIV Legal Network; University of British Columbia","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Viremia; Viral load; Efavirenz; Medicine; Lopinavir; Internal medicine; Immunology; Cumulative incidence; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Cohort","score_opus":0.026588594352728628,"score_gpt":0.29065922595437477,"score_spread":0.2640706316016461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987638744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548984,0.00014374519,0.0003314458,0.0031874825,0.00034162178,0.00008691412,0.0000013700114,0.0000038794105,0.0004136963],"genre_scores_gemma":[0.9948614,0.000046951765,0.0037286303,0.00029942952,0.0002105816,5.0957993e-7,0.0000012559933,0.000008365062,0.00084286963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989894,0.000042383126,0.00034527783,0.00007170994,0.00046445755,0.00008677318],"domain_scores_gemma":[0.9991359,0.00019146001,0.00035403797,0.00010850214,0.00016577571,0.000044287634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000498778,0.00008593534,0.000218453,0.00002973434,0.000077125056,0.000022927321,0.00021829443,0.000037578844,0.00001976089],"category_scores_gemma":[0.0001143967,0.000045822293,0.00026033833,0.00009112826,0.00010914003,0.000067498484,0.000104874634,0.00021255591,0.0000016120338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035225923,0.00035595353,0.95837253,0.00004740814,0.0022040028,0.000009087568,0.0041753436,0.00041651717,0.018523775,0.0010581516,0.008089907,0.006395053],"study_design_scores_gemma":[0.008395616,0.00023351694,0.9398037,0.0012144047,0.00073659205,0.00068503985,0.00088963803,0.013202198,0.013604848,0.0005969548,0.02044766,0.000189808],"about_ca_topic_score_codex":0.000012147791,"about_ca_topic_score_gemma":0.000001367132,"teacher_disagreement_score":0.018568818,"about_ca_system_score_codex":0.0001564846,"about_ca_system_score_gemma":0.00008455707,"threshold_uncertainty_score":0.1868579},"labels":[],"label_agreement":null},{"id":"W1987788334","doi":"10.5414/cpp44284","title":"Bioequivalence of abacavir generic and innovator formulations under fasting and fed conditions","year":2006,"lang":"en","type":"article","venue":"International Journal of Clinical Pharmacology and Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Abacavir; Bioequivalence; Cmax; Innovator; Pharmacokinetics; Pharmacology; Bioavailability; Area under the curve; Chemistry; Chromatography; Mathematics; Medicine; Human immunodeficiency virus (HIV); Viral load","score_opus":0.08713436940041538,"score_gpt":0.454361885679592,"score_spread":0.3672275162791766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987788334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052626,0.0007651787,0.0008444978,0.0069790473,0.00049446797,0.00007237179,0.0000112917805,0.0000041616445,0.0003027172],"genre_scores_gemma":[0.995484,0.0010111855,0.0017616319,0.001125725,0.0003767725,0.0000012839906,0.000007663419,0.000005086314,0.00022666444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903595,0.00004252909,0.00063483935,0.00008156682,0.00013633669,0.00006878427],"domain_scores_gemma":[0.99885476,0.00042340037,0.00033503666,0.00002419864,0.00030750947,0.000055116696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027063882,0.00007226219,0.00022711529,0.0001135442,0.00003904127,0.000008551717,0.000043830074,0.000066844565,0.00002748284],"category_scores_gemma":[0.000023120836,0.00005552695,0.000046735127,0.000058286518,0.00023426286,0.0000781506,0.000029360112,0.00016963111,6.351894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009779045,0.0009411426,0.9438548,0.000030708077,0.002387346,0.00007903884,0.00022841555,0.000028650902,0.021298349,0.006893299,0.00063290866,0.022647455],"study_design_scores_gemma":[0.007555859,0.00041620887,0.97139305,0.0000751259,0.0005515893,0.00045501054,0.00009456528,0.00102077,0.0019661195,0.0070440597,0.009322301,0.00010532278],"about_ca_topic_score_codex":0.0000016804638,"about_ca_topic_score_gemma":9.5223146e-7,"teacher_disagreement_score":0.027538287,"about_ca_system_score_codex":0.00001330302,"about_ca_system_score_gemma":0.00010359152,"threshold_uncertainty_score":0.22643232},"labels":[],"label_agreement":null},{"id":"W1987829805","doi":"10.1186/1758-2652-13-s4-p36","title":"Use of once‐daily raltegravir‐based HAART in HIV‐infected injection drug users","year":2010,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; University of Waterloo; University of British Columbia","funders":"","keywords":"Raltegravir; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Drug; Integrase inhibitor; Virology; Pharmacology; Viral load","score_opus":0.01735185027029396,"score_gpt":0.26909317469914473,"score_spread":0.2517413244288508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987829805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942304,0.000011383912,0.00010913607,0.009088019,0.0009771336,0.00012833512,0.000007724773,0.0000081445705,0.00024706504],"genre_scores_gemma":[0.97868353,0.000020316258,0.012671771,0.0004299487,0.00018450382,0.0000029184232,0.000009723323,0.000012437078,0.007984831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986518,0.000038114355,0.00048770395,0.00009751834,0.0006108585,0.00011397513],"domain_scores_gemma":[0.998849,0.00015028898,0.0004115076,0.00013507032,0.00039191724,0.0000622199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043394158,0.000116784504,0.00023393989,0.00012301025,0.000041852312,0.000025474736,0.0001937892,0.0000734433,0.00014672746],"category_scores_gemma":[0.00022668547,0.00007335379,0.0004433193,0.00023609237,0.00007749326,0.0002150272,0.000039707975,0.00052962935,0.000006271826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030761329,0.0006441671,0.91606337,0.000016254658,0.00051644974,0.000014566613,0.0014794491,0.0003847357,0.039737344,0.00021526817,0.039353207,0.0012675582],"study_design_scores_gemma":[0.012976572,0.0003832975,0.78419954,0.0009859022,0.0004537066,0.00039610176,0.0010064902,0.00945401,0.11733488,0.0006148416,0.0718367,0.0003579518],"about_ca_topic_score_codex":0.00006071809,"about_ca_topic_score_gemma":0.00008899976,"teacher_disagreement_score":0.13186385,"about_ca_system_score_codex":0.00026717238,"about_ca_system_score_gemma":0.00033483442,"threshold_uncertainty_score":0.29912806},"labels":[],"label_agreement":null},{"id":"W1988041293","doi":"10.1186/1742-4690-6-14","title":"Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance","year":2009,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Health Research; Gilead Sciences","keywords":"Resistance mutation; Processivity; Reverse transcriptase; Biology; Primer (cosmetics); Molecular biology; Virology; Enzyme; RNA; Chemistry; Biochemistry; Polymerase","score_opus":0.004459001498142942,"score_gpt":0.20960170551478702,"score_spread":0.20514270401664408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988041293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98569065,0.0010210865,0.000024008235,0.012222607,0.000070452494,0.00035815348,0.0000044726507,0.000014175433,0.0005943638],"genre_scores_gemma":[0.9925462,0.0001507221,0.00016381196,0.0007001979,0.000017510896,0.000011212221,0.000013019105,0.0000063929397,0.0063909413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931,0.0001007422,0.0001600899,0.0001936126,0.00009732969,0.00013821363],"domain_scores_gemma":[0.99963254,0.00011844333,0.000052165364,0.00013251076,0.000016337823,0.000048016493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011623438,0.00010487456,0.00021091044,0.0001078177,0.000049539176,0.0000029237874,0.000027408429,0.00007102502,0.000012778287],"category_scores_gemma":[0.00007420611,0.00007401923,0.000030763258,0.00015351197,0.000089394285,0.000029828221,0.0000062728113,0.0001487976,0.000007105823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01055216,0.0025086862,0.7255775,0.0011529722,0.00044035903,0.0006497549,0.00896415,0.000017022789,0.17595835,0.02175048,0.040242918,0.012185651],"study_design_scores_gemma":[0.005357256,0.00043609593,0.97472197,0.00016703217,0.00024227491,0.000018279554,0.000072698494,0.000024853884,0.009150925,0.0013104911,0.008387288,0.00011081723],"about_ca_topic_score_codex":0.00000740238,"about_ca_topic_score_gemma":0.00006402601,"teacher_disagreement_score":0.2491445,"about_ca_system_score_codex":0.000041061132,"about_ca_system_score_gemma":0.000036941252,"threshold_uncertainty_score":0.30184168},"labels":[],"label_agreement":null},{"id":"W1988113084","doi":"10.1310/f45l-fdkk-y48n-n2bt","title":"Comparative CD4 T-Cell Responses of Reverse Transcriptase Inhibitor Therapy With or Without Nelfinavir Matched for Viral Exposure","year":2001,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Nelfinavir; Medicine; Viral load; Quartile; Protease inhibitor (pharmacology); Internal medicine; Amprenavir; Indinavir; Area under the curve; Gastroenterology; Immunology; Pharmacology; Confidence interval; Virus; Protease; Antiretroviral therapy","score_opus":0.336951842305224,"score_gpt":0.4781353444316747,"score_spread":0.1411835021264507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988113084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053293,0.0003900255,0.0006452006,0.0037633504,0.00025798992,0.0035772582,0.00016785414,0.00006864775,0.00059673283],"genre_scores_gemma":[0.91319025,0.00080898876,0.019104786,0.0007779747,0.00051031914,0.00031078307,0.00013887954,0.00004717306,0.06511086],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958585,0.0010868565,0.0018923521,0.0004718328,0.00035444053,0.000336025],"domain_scores_gemma":[0.99466676,0.0038113166,0.00057157676,0.0004014549,0.0002118639,0.00033702963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00427514,0.00032940056,0.0024223782,0.0001383939,0.00007646216,0.000017244905,0.0001122915,0.00021379294,0.00033727693],"category_scores_gemma":[0.001447701,0.00018327015,0.0005186975,0.00026914207,0.00022396931,0.00008678126,0.000012018148,0.00020468095,0.00005056331],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6643287,0.009367252,0.19015254,0.0002239491,0.0021701327,0.0004001283,0.005136255,0.0000028113968,0.022550253,0.00009161055,0.09745477,0.008121604],"study_design_scores_gemma":[0.2842488,0.028662177,0.011725525,0.0012709391,0.0026788912,0.00009354138,0.0041512153,0.00009196639,0.1344985,0.0002626686,0.5311776,0.0011381536],"about_ca_topic_score_codex":0.0000060402267,"about_ca_topic_score_gemma":0.000009081162,"teacher_disagreement_score":0.43372282,"about_ca_system_score_codex":0.000038342056,"about_ca_system_score_gemma":0.0006483224,"threshold_uncertainty_score":0.74735403},"labels":[],"label_agreement":null},{"id":"W1988215656","doi":"10.1177/1087057111402201","title":"A High-Throughput Continuous Assay for Screening and Characterization of Inhibitors of HIV Reverse-Transcriptase DNA Polymerase Activity","year":2011,"lang":"en","type":"article","venue":"SLAS DISCOVERY","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Reverse transcriptase; DNA polymerase; Polymerase; Primer (cosmetics); High-throughput screening; Fluorophore; Förster resonance energy transfer; DNA; Chemistry; Plate reader; Molecular biology; Fluorescence; Combinatorial chemistry; Biochemistry; Polymerase chain reaction; Biology; Gene","score_opus":0.01873007429130568,"score_gpt":0.23399926084509018,"score_spread":0.2152691865537845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988215656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99044347,0.000060053637,0.00796609,0.00033160296,0.00013548808,0.0005592197,0.00030659905,0.00002012747,0.00017733006],"genre_scores_gemma":[0.9938711,0.00004062631,0.0024363128,0.000043685464,0.000052126656,0.000030168954,0.00023747797,0.000022020362,0.0032664961],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991165,0.00003676941,0.0002867042,0.0002276134,0.0001625287,0.00016988955],"domain_scores_gemma":[0.9994616,0.000046454486,0.00019832933,0.00016671783,0.00005841796,0.00006851538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015574906,0.00016101064,0.00041552176,0.00010823672,0.000040334213,0.000008385281,0.000034679644,0.00007220904,0.00003123014],"category_scores_gemma":[0.000038188347,0.00013600948,0.000109590284,0.00010851988,0.00009452428,0.0003673817,0.000022316579,0.00005514013,0.0000014114888],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023765988,0.00095658016,0.10055166,0.00047522204,0.0005514181,0.000030839863,0.0030418665,1.2004296e-7,0.8819348,0.001132344,0.0007020761,0.008246477],"study_design_scores_gemma":[0.0038802142,0.0002783761,0.0731673,0.00035056888,0.00036684985,0.000007359743,0.0002486561,0.000021878865,0.92090064,0.000054021544,0.0005616778,0.00016248108],"about_ca_topic_score_codex":0.00010331278,"about_ca_topic_score_gemma":0.000007511517,"teacher_disagreement_score":0.038965818,"about_ca_system_score_codex":0.000023679559,"about_ca_system_score_gemma":0.0000760356,"threshold_uncertainty_score":0.5546305},"labels":[],"label_agreement":null},{"id":"W1988338542","doi":"10.1001/jamainternmed.2014.6786","title":"Changes in Glomerular Kidney Function Among HIV-1<b>–</b>Uninfected Men and Women Receiving Emtricitabine<b>–</b>Tenofovir Disoproxil Fumarate Preexposure Prophylaxis","year":2014,"lang":"en","type":"article","venue":"JAMA Internal Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health","keywords":"Emtricitabine; Medicine; Pre-exposure prophylaxis; Interquartile range; Renal function; Placebo; Internal medicine; Kidney disease; Regimen; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy; Men who have sex with men; Pathology","score_opus":0.005375879425049405,"score_gpt":0.2134918684859669,"score_spread":0.2081159890609175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988338542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791797,0.00031306344,0.00036817687,0.008221188,0.00035139977,0.0009261166,0.000007633872,0.00015720094,0.010475516],"genre_scores_gemma":[0.9719902,0.00019429447,0.0001945041,0.0009293064,0.00070919027,0.00027613295,0.00010865825,0.00006277342,0.025534905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727625,0.00019673565,0.00062387274,0.0006500855,0.000610494,0.00064259354],"domain_scores_gemma":[0.9983643,0.0001955818,0.0002530727,0.00038077816,0.0001798707,0.00062639546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010186798,0.00046815345,0.00085441465,0.0007282529,0.00009692597,0.000044522065,0.00014939065,0.00023249972,0.00052124995],"category_scores_gemma":[0.0015498709,0.00033246385,0.000055092663,0.0006423973,0.00023416932,0.00024596282,0.00012327053,0.00056700676,0.00006134333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010517986,0.0002330544,0.92507446,0.00040827275,0.00028787903,0.00016404466,0.0069115306,0.0000013870148,0.0047197635,0.000036691254,0.006555412,0.0545557],"study_design_scores_gemma":[0.013210651,0.0066195913,0.955871,0.003097355,0.00020934723,0.000117144264,0.0014074564,0.0012843953,0.001462145,0.00020121143,0.016053865,0.00046585215],"about_ca_topic_score_codex":0.00024858015,"about_ca_topic_score_gemma":0.000121775534,"teacher_disagreement_score":0.054089848,"about_ca_system_score_codex":0.00050254125,"about_ca_system_score_gemma":0.00009349043,"threshold_uncertainty_score":0.99991274},"labels":[],"label_agreement":null},{"id":"W1988346372","doi":"10.1097/qai.0b013e3182282cfc","title":"Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy","year":2011,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; University of Ottawa; McGill University Health Centre; McGill University; Ontario HIV Treatment Network; Women's College Hospital; Ottawa Hospital; University Health Network; University of Toronto; University of British Columbia; AIDS Vancouver; St. Michael's Hospital","funders":"National Center for Research Resources; Canadian Institutes of Health Research","keywords":"Emtricitabine; Abacavir; Medicine; Lamivudine; Internal medicine; Efavirenz; Ritonavir; Regimen; Hazard ratio; Atazanavir; Interquartile range; Lopinavir; Viral load; Cart; Oncology; Virology; Human immunodeficiency virus (HIV); Confidence interval; Antiretroviral therapy; Hepatitis B virus; Virus","score_opus":0.045535333409579944,"score_gpt":0.29375450703667333,"score_spread":0.2482191736270934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988346372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349844,0.0040851645,0.00006563639,0.00009608992,0.00023203135,0.0005125543,0.000015350224,0.000047337715,0.0014474044],"genre_scores_gemma":[0.99598986,0.0010064801,0.0021088945,0.000011413032,0.000028506247,0.000012538055,0.00004193896,0.000052478867,0.0007478849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695176,0.00012541906,0.0015957387,0.00028300213,0.00058894453,0.00045514957],"domain_scores_gemma":[0.9974328,0.00022631817,0.0013079,0.0002950566,0.00055717,0.00018074302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041737943,0.00041992968,0.0013779211,0.00089323305,0.00016914788,0.000023965544,0.00018679303,0.00013805678,0.00009780642],"category_scores_gemma":[0.00025150206,0.00028904527,0.00031330303,0.00083755155,0.00026581532,0.00042497448,0.0000637205,0.00012742651,0.000021163256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049783813,0.002912039,0.9664966,0.00005439125,0.0006895162,0.00012306959,0.009013633,0.0000022944719,0.0030448153,0.000023032608,0.00006629383,0.017076487],"study_design_scores_gemma":[0.009214338,0.005207849,0.9660217,0.00038754876,0.0004602297,0.00019900917,0.0016639406,0.00008554586,0.01639027,0.000052827872,0.000053350384,0.0002633847],"about_ca_topic_score_codex":0.000035195353,"about_ca_topic_score_gemma":0.0000012755585,"teacher_disagreement_score":0.016813103,"about_ca_system_score_codex":0.00021877304,"about_ca_system_score_gemma":0.00020759577,"threshold_uncertainty_score":0.9999562},"labels":[],"label_agreement":null},{"id":"W1988746734","doi":"10.1093/nar/gkn678","title":"Examining the ribonuclease H primer grip of HIV-1 reverse transcriptase by charge neutralization of RNA/DNA hybrids","year":2008,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Drug Abuse; Canadian Institutes of Health Research; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"RNase H; Biology; Reverse transcriptase; Primer (cosmetics); RNase P; DNA polymerase; RNase MRP; Molecular biology; RNA; DNA; Polymerase; Ribonuclease; RNase PH; Biochemistry; Gene; Chemistry","score_opus":0.07695440560108803,"score_gpt":0.3175509742471009,"score_spread":0.24059656864601286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988746734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894942,0.00035739254,0.000060000206,0.0025977138,0.000056560057,0.0007524693,0.000101909674,0.000036092326,0.006543672],"genre_scores_gemma":[0.9749054,0.00045870937,0.00044531206,0.000095614865,0.00005814359,0.000035020614,0.00018524504,0.000045380984,0.023771225],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997324,0.0002540336,0.00049228454,0.00033738834,0.0011121663,0.00048013323],"domain_scores_gemma":[0.99864095,0.00013400312,0.00010083404,0.00054310483,0.000371187,0.00020992022],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00094850454,0.0001888378,0.00039386636,0.00027142087,0.00025074344,0.000009236487,0.00025189627,0.00010297248,0.001049643],"category_scores_gemma":[0.00018875684,0.00013358037,0.00011680173,0.00073648157,0.00056550314,0.00013282706,0.00006522375,0.0003659201,0.00014015289],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011442921,0.0018122009,0.15490502,0.0004420497,0.00047866945,0.00029057273,0.01112704,0.0000022723984,0.38461435,0.0006158278,0.43867436,0.005893371],"study_design_scores_gemma":[0.010244318,0.0012737433,0.112371504,0.00062903675,0.00031733816,0.0001738251,0.0025467826,0.0007606266,0.7000539,0.00006380236,0.17104813,0.00051701866],"about_ca_topic_score_codex":0.000081176026,"about_ca_topic_score_gemma":0.0000014702644,"teacher_disagreement_score":0.31543952,"about_ca_system_score_codex":0.000109459455,"about_ca_system_score_gemma":0.00026171003,"threshold_uncertainty_score":0.9998635},"labels":[],"label_agreement":null},{"id":"W1988861859","doi":"10.1177/095632020001100405","title":"Drug Resistance and Drug Combination Features of the Human Immunodeficiency Virus Inhibitor, BCH-10652 [(±)-2′-Deoxy-3′-Oxa-4′-Thiocytidine, dOTC]","year":2000,"lang":"en","type":"article","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Zidovudine; Zalcitabine; Virology; Lamivudine; Didanosine; Biology; Pharmacology; Chemistry; Virus; Viral disease","score_opus":0.00462799010712656,"score_gpt":0.23209112979432714,"score_spread":0.22746313968720058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988861859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96117073,0.0022181745,0.0000010508015,0.0035313736,0.000047045673,0.00036742503,0.000014712037,0.00007270672,0.032576803],"genre_scores_gemma":[0.8486062,0.00081609096,0.00016263603,0.00017727092,0.000063661355,0.000018318227,0.000050197315,0.000037110858,0.1500685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998307,0.00003848135,0.00041321781,0.00045038605,0.0004640859,0.00032685886],"domain_scores_gemma":[0.99910396,0.000045097648,0.00017844449,0.00051547325,0.000091652866,0.00006536015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001764314,0.00035084935,0.0004382875,0.00003786846,0.00028256024,0.000038490838,0.00021814246,0.00012124573,0.00029690046],"category_scores_gemma":[0.000015804007,0.0002580783,0.00017493131,0.00032754245,0.00031183494,0.00011773085,0.000037855287,0.00029546532,0.000011538206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032314024,0.0008905808,0.011967121,0.00033583984,0.00018810508,0.000020940222,0.0024241523,2.8458084e-7,0.95976585,0.00014392896,0.014351478,0.00958856],"study_design_scores_gemma":[0.00360774,0.00001818387,0.019150686,0.0004360354,0.00007034306,0.00001582761,0.00014525573,0.000003866718,0.96402663,0.00027922294,0.011973837,0.0002723929],"about_ca_topic_score_codex":0.000052753574,"about_ca_topic_score_gemma":0.000018272498,"teacher_disagreement_score":0.11749171,"about_ca_system_score_codex":0.00010724764,"about_ca_system_score_gemma":0.000095514035,"threshold_uncertainty_score":0.9999871},"labels":[],"label_agreement":null},{"id":"W1988918312","doi":"10.1139/g03-046","title":"A single point mutation in<i>Drosophila</i><i>dihydrofolate reductase</i>confers methotrexate resistance to a transgenic CHO cell line","year":2003,"lang":"en","type":"article","venue":"Genome","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Yarmouk University; Natural Sciences and Engineering Research Council of Canada; Fondation J. Armand Bombardier","keywords":"Dihydrofolate reductase; Biology; Chinese hamster ovary cell; Molecular biology; Schneider 2 cells; Mutant; Complementary DNA; Drosophila melanogaster; Transfection; Cell culture; Transgene; Point mutation; Wild type; Hamster; Genetics; Gene; RNA interference; RNA","score_opus":0.018324677423733886,"score_gpt":0.25157505076276765,"score_spread":0.23325037333903376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988918312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96708864,0.0017481851,0.0009272598,0.007388228,0.00016195487,0.0016801622,0.000032457297,0.00010321161,0.020869918],"genre_scores_gemma":[0.9578737,0.00012426476,0.01866511,0.00078939105,0.000055816705,0.00014500135,0.00010845245,0.000053191605,0.022185056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981121,0.00010601118,0.000483763,0.0005230244,0.0002673155,0.0005077952],"domain_scores_gemma":[0.99915075,0.000038395985,0.00008544237,0.00035940832,0.00007320802,0.00029279728],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040559925,0.00028467522,0.00042895065,0.00029428306,0.00007385227,0.000025510522,0.000085366635,0.0000908168,0.00020568559],"category_scores_gemma":[0.000054444972,0.00026946407,0.0001203444,0.00067961426,0.000032356405,0.00008862045,0.000013502027,0.00017076913,0.00033122176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000714199,0.0011101643,0.00041511125,0.00023488523,0.00018541218,0.0009015623,0.009719229,0.0003481866,0.9845086,0.0003162968,0.0006240081,0.00092237786],"study_design_scores_gemma":[0.013366986,0.00073945476,0.004523126,0.00036113532,0.00046584642,0.00014207755,0.0008011771,0.000040477247,0.711685,0.002231114,0.26445127,0.0011923072],"about_ca_topic_score_codex":0.000008757974,"about_ca_topic_score_gemma":0.000066885674,"teacher_disagreement_score":0.27282354,"about_ca_system_score_codex":0.00034839215,"about_ca_system_score_gemma":0.00018757419,"threshold_uncertainty_score":0.99997574},"labels":[],"label_agreement":null},{"id":"W1989112527","doi":"10.1097/coh.0b013e328331b5e2","title":"First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach","year":2009,"lang":"en","type":"review","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Ontario HIV Treatment Network","keywords":"Darunavir; Etravirine; Regimen; Protease inhibitor (pharmacology); Ritonavir; Medicine; Enfuvirtide; Integrase inhibitor; Drug resistance; Reverse-transcriptase inhibitor; Clinical trial; Intensive care medicine; Virology; Nucleoside Reverse Transcriptase Inhibitor; Viral load; Pharmacology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Internal medicine; Immunology; Biology; Gp41; Genetics","score_opus":0.20362157308530723,"score_gpt":0.42359523791846476,"score_spread":0.21997366483315753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989112527","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018492804,0.99755704,0.00012063889,0.00038286214,0.00040230664,0.0012586939,0.000022371773,0.00002632372,0.000044828437],"genre_scores_gemma":[0.0004736305,0.99644226,0.0019290396,0.000012788355,0.0003927935,0.00009219043,0.00037549576,0.00002784275,0.0002539356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748427,0.00021954048,0.0010974614,0.00064466946,0.00029360972,0.00026043114],"domain_scores_gemma":[0.99877036,0.00029861485,0.00035919578,0.00034299376,0.00005237747,0.00017643314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006223374,0.00047229097,0.002131981,0.00038777283,0.000050062266,0.000024832609,0.000118579366,0.0003045217,0.0000151656905],"category_scores_gemma":[0.00010582554,0.00031689458,0.00034780882,0.00040362874,0.0002064854,0.000087678025,0.00005689833,0.0005126164,0.000005584637],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009075287,0.00064387236,0.02882155,0.023792546,0.00011307348,0.0000029013142,0.0000689924,2.1763316e-7,2.3502611e-8,0.00015976664,0.0021127742,0.94419354],"study_design_scores_gemma":[0.0031312834,0.00089922,0.0009039401,0.08890846,0.00031507894,0.00001955019,0.0000150223295,0.00008262485,3.833628e-7,0.000027275146,0.9053847,0.00031245794],"about_ca_topic_score_codex":0.0000021550043,"about_ca_topic_score_gemma":2.0165362e-7,"teacher_disagreement_score":0.9438811,"about_ca_system_score_codex":0.00004580274,"about_ca_system_score_gemma":0.00040977067,"threshold_uncertainty_score":0.9999283},"labels":[],"label_agreement":null},{"id":"W1989295953","doi":"10.1002/bdd.375","title":"Dose‐dependent pharmacokinetics of 1‐(2‐Deoxy‐<i>β</i>‐<scp>D</scp>‐ ribofuranosyl)‐2,4‐difluoro‐5‐iodobenzene: A potential mimic of 5‐iodo‐2′‐deoxyuridine","year":2003,"lang":"en","type":"article","venue":"Biopharmaceutics & Drug Disposition","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pharmacokinetics; Chemistry; Oral administration; Half-life; Pharmacology; Medicine","score_opus":0.013658812850854747,"score_gpt":0.27964024280547356,"score_spread":0.2659814299546188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989295953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894264,0.0039453125,0.00063481834,0.0007130814,0.000895181,0.00146316,0.0003053539,0.00012903099,0.002487658],"genre_scores_gemma":[0.98842734,0.0022130318,0.002912525,0.0002506121,0.00018866903,0.00006556259,0.00051310094,0.000102340964,0.0053268145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959736,0.00023862704,0.001260997,0.00067656895,0.001109593,0.0007406359],"domain_scores_gemma":[0.9976793,0.00016768157,0.00062332046,0.0005558154,0.0005010025,0.00047288724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050382817,0.00064399897,0.0009355364,0.0005195887,0.00016091942,0.000042261825,0.0002643332,0.0002383561,0.00018961275],"category_scores_gemma":[0.000107140106,0.0006032058,0.0004684847,0.0007265713,0.00023022474,0.00021550094,0.000095569994,0.0004187518,0.000088329725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005305305,0.0030879362,0.0051760715,0.00090442627,0.0010712193,0.00026161608,0.0013120562,0.00015238937,0.98010176,0.00075053785,0.004155341,0.0024961068],"study_design_scores_gemma":[0.009601052,0.00021594699,0.0035223407,0.00029782028,0.0022944848,0.00019894248,0.00048916694,0.00075317855,0.965416,0.0001401674,0.016785,0.00028588562],"about_ca_topic_score_codex":0.00001675834,"about_ca_topic_score_gemma":0.000003559297,"teacher_disagreement_score":0.014685754,"about_ca_system_score_codex":0.0002253916,"about_ca_system_score_gemma":0.00028737486,"threshold_uncertainty_score":0.99964195},"labels":[],"label_agreement":null},{"id":"W1989653575","doi":"10.7448/ias.16.1.18580","title":"Capacity building and predictors of success for HIV‐1 drug resistance testing in the Asia‐Pacific region and Africa","year":2013,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; Yonsei University College of Medicine; Faculty of Medicine, Chulalongkorn University; Medical Research Council; Center for AIDS Research, University of Washington; Ministerie van Buitenlandse Zaken; Universiti Malaya; Mahidol University; Chulalongkorn University; Chiang Mai University; Capital Medical University; NIH Clinical Center; National Yang-Ming University; University of New South Wales; Australian Government; Yonsei University; Universiti Sains Malaysia; Aids Fonds; Johnson Cancer Research Center, Kansas State University; Queen Mary University of London; Faculty of Medicine Siriraj Hospital, Mahidol University; amfAR, The Foundation for AIDS Research","keywords":"Genotyping; Medicine; External quality assessment; HIV drug resistance; Electropherogram; Human immunodeficiency virus (HIV); Drug resistance; Virology; Viral load; Genotype; Antiretroviral therapy; Genetics; Biology; Gene; Pathology","score_opus":0.024312989939456235,"score_gpt":0.24702534183783276,"score_spread":0.22271235189837651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989653575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657471,0.00022497457,0.00020182034,0.03285709,0.00012459507,0.00022483207,0.0000040633,0.0000027114572,0.0006127682],"genre_scores_gemma":[0.98324186,0.000056366254,0.013319754,0.00006179367,0.000112350484,0.000009731072,6.533115e-7,0.0000055500504,0.0031919214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917144,0.000032183863,0.0003016607,0.00008090364,0.0003251761,0.00008862164],"domain_scores_gemma":[0.99895114,0.00039733754,0.00029731574,0.00006908037,0.00025262107,0.00003253522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005444711,0.000076572476,0.00015476135,0.00003992873,0.00007324532,0.00003207851,0.00015995449,0.00002938612,0.0000030270683],"category_scores_gemma":[0.0002641471,0.000039966417,0.000107927335,0.00011449353,0.00009034725,0.0001449239,0.0000377812,0.0001537785,1.1854277e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008983071,0.00015405341,0.91995853,0.00010359916,0.00037358128,0.000004344408,0.010968834,0.0000074019763,0.0030018117,0.00080099545,0.06387475,0.0006622948],"study_design_scores_gemma":[0.0074371323,0.00020668283,0.919928,0.0026613735,0.00046231356,0.0005961617,0.012594262,0.002362875,0.0075531555,0.013507757,0.03239104,0.00029925138],"about_ca_topic_score_codex":0.000008172498,"about_ca_topic_score_gemma":0.0000043378695,"teacher_disagreement_score":0.0327953,"about_ca_system_score_codex":0.000100975965,"about_ca_system_score_gemma":0.000049072863,"threshold_uncertainty_score":0.16297832},"labels":[],"label_agreement":null},{"id":"W1989905402","doi":"10.1016/j.jviromet.2012.05.003","title":"A high-throughput assay for HIV-1 integrase 3′-processing activity using time-resolved fluorescence","year":2012,"lang":"en","type":"article","venue":"Journal of Virological Methods","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration","keywords":"Integrase; Biology; High-throughput screening; Oligonucleotide; DNA; Enzyme; Molecular biology; Virology; Integrase inhibitor; Human immunodeficiency virus (HIV); Biochemistry; Viral load; Antiretroviral therapy","score_opus":0.08237197151410343,"score_gpt":0.413395563366417,"score_spread":0.33102359185231356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989905402","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39459196,0.0005884478,0.6021294,0.0020733224,0.00024214633,0.0002446672,0.0000036465867,0.00002447844,0.00010193363],"genre_scores_gemma":[0.31074616,0.000021397294,0.6881964,0.00017166769,0.0004485972,0.000006672009,0.000002344937,0.000016741602,0.00038999363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978499,0.0005933724,0.0005518989,0.00019815197,0.0003233768,0.00048329882],"domain_scores_gemma":[0.9978384,0.0009248626,0.00049647875,0.00015512848,0.00021165247,0.00037347252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038419322,0.00025226906,0.0008089558,0.00015582539,0.00014371179,0.000029564726,0.00013631191,0.00021398229,0.00018126],"category_scores_gemma":[0.0016928724,0.00015149213,0.00030750883,0.00021737654,0.000119547236,0.00032740363,0.00006259731,0.000469618,0.000015703443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031729548,0.0019837637,0.013313096,0.00010292869,0.00051935244,0.00012662119,0.0005034281,0.000024808376,0.49812362,0.00013683025,0.0015712467,0.48042133],"study_design_scores_gemma":[0.025603555,0.005520838,0.12118591,0.0017505793,0.0069110077,0.0041253394,0.00056794664,0.04673559,0.7211794,0.0058893445,0.058567204,0.0019632357],"about_ca_topic_score_codex":0.0000020043544,"about_ca_topic_score_gemma":1.1591271e-7,"teacher_disagreement_score":0.4784581,"about_ca_system_score_codex":0.00023253121,"about_ca_system_score_gemma":0.00014827296,"threshold_uncertainty_score":0.617767},"labels":[],"label_agreement":null},{"id":"W1989931393","doi":"10.1177/2325957413495565","title":"Impact of the Data Collection on Adverse Events of Anti-HIV Drugs Cohort Study on Abacavir Prescription among Treatment-Naive, HIV-Infected Patients in Canada","year":2013,"lang":"en","type":"article","venue":"Journal of the International Association of Providers of AIDS Care (JIAPAC)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario HIV Treatment Network; University of British Columbia; University of Ottawa; McGill University; McGill University Health Centre; Simon Fraser University; University Health Network; Ottawa Hospital; University of Toronto; Women's College Hospital; Maple Leaf Medical Clinic; AIDS Vancouver; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; International AIDS Society","keywords":"Abacavir; Medicine; Medical prescription; Adverse effect; Human immunodeficiency virus (HIV); Cohort; Pharmacy; Internal medicine; Family medicine; Pharmacology; Antiretroviral therapy; Viral load","score_opus":0.008737751827300808,"score_gpt":0.25088257238516026,"score_spread":0.24214482055785946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989931393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693674,0.0000066934626,0.0000015982023,0.00062870816,0.00046528172,0.0013820603,0.00020706278,0.0000025579789,0.00036927388],"genre_scores_gemma":[0.9986178,0.00001781293,0.000053376483,0.000017100094,0.000030513987,0.000013016098,0.00009405666,0.000013554088,0.0011427555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968495,0.00022197413,0.0009990118,0.00017332968,0.0016211137,0.00013509166],"domain_scores_gemma":[0.9952845,0.00020761084,0.0026897418,0.00031553127,0.00145035,0.00005224279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034366935,0.00018368386,0.0005032891,0.00031467224,0.00004464566,0.00000650238,0.00039297508,0.00006788448,0.00003472156],"category_scores_gemma":[0.0007768227,0.000109006585,0.00027735732,0.00031315404,0.000029955356,0.00032202798,0.00008367012,0.00018145678,0.0000011666152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003715589,0.0015411517,0.9896965,0.000020589267,0.0018484754,0.0000011129299,0.0018356316,0.0005786877,0.00033353065,0.0000014678513,0.003464787,0.00030649934],"study_design_scores_gemma":[0.005637454,0.000957596,0.9878128,0.0003839869,0.0003141961,9.227418e-7,0.002044436,0.00017149386,0.0025781111,0.000009240873,0.00001892028,0.00007079983],"about_ca_topic_score_codex":0.09697907,"about_ca_topic_score_gemma":0.024703227,"teacher_disagreement_score":0.07227584,"about_ca_system_score_codex":0.0056735124,"about_ca_system_score_gemma":0.0013117249,"threshold_uncertainty_score":0.99814355},"labels":[],"label_agreement":null},{"id":"W1989966812","doi":"10.5414/cn107214","title":"A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function","year":2011,"lang":"en","type":"article","venue":"Clinical Nephrology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Renal function; Urology; Cystatin C; Kidney disease; Population; Internal medicine","score_opus":0.09052359295997067,"score_gpt":0.3455747278962916,"score_spread":0.2550511349363209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989966812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985099,0.00007013823,0.00014501445,0.00033565125,0.000040840805,0.00053798885,0.0000050097938,0.0000359217,0.00031957886],"genre_scores_gemma":[0.99798506,0.000014602683,0.0013343565,0.00012363943,0.000016323547,0.000030448435,0.0002580993,0.0000126857385,0.00022478998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841136,0.00025183338,0.0007029407,0.00030939368,0.0001336575,0.00019081759],"domain_scores_gemma":[0.9991622,0.00015662171,0.00021576294,0.00018407905,0.000171644,0.0001096678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031923773,0.0001515576,0.0005970039,0.00012294251,0.000029939754,0.0000038693233,0.00004770294,0.00019380938,0.00013849772],"category_scores_gemma":[0.00017842368,0.00010921416,0.000043278556,0.00021275344,0.0002004804,0.00008027839,0.00002323074,0.00017573638,0.000015361748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008114201,0.001556224,0.98794854,0.000025165295,0.00022690874,0.000017217633,0.00021932735,0.0000046817836,0.00023061315,0.000022545586,0.00047948078,0.0011550948],"study_design_scores_gemma":[0.009531076,0.0020597593,0.98587257,0.00006398296,0.0002849531,0.0000016619952,0.000019220595,0.0010586631,0.00065738556,0.000063171785,0.00029538904,0.0000921654],"about_ca_topic_score_codex":0.000041159943,"about_ca_topic_score_gemma":0.00019539768,"teacher_disagreement_score":0.0020759685,"about_ca_system_score_codex":0.000022170605,"about_ca_system_score_gemma":0.00007164438,"threshold_uncertainty_score":0.44536242},"labels":[],"label_agreement":null},{"id":"W1989997223","doi":"10.1186/1742-4690-6-s2-i18","title":"Biochemical and virological analysis of the preference for the K65R multi-resistance nucleoside mutation in subtype C viruses","year":2009,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Virology; Nucleoside; Mutation; Drug resistance; Resistance mutation; Biology; Medicine; Genetics; Reverse transcriptase; RNA; Gene","score_opus":0.03971031434941532,"score_gpt":0.29691634859522714,"score_spread":0.25720603424581184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989997223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394953,0.0006928056,0.0004471237,0.0044690156,0.000018184579,0.0003393437,0.000007801738,0.000009949796,0.00006625225],"genre_scores_gemma":[0.9975521,0.00009454459,0.001313918,0.00066297065,0.0000106387015,0.000023710541,0.000010143522,0.000003603908,0.00032838425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930596,0.00005313105,0.0002078287,0.00019555994,0.00009042686,0.00014709345],"domain_scores_gemma":[0.99938613,0.0002922545,0.00008178802,0.00018142171,0.000030593026,0.000027829354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015077145,0.000091206515,0.0002724623,0.00009250186,0.000046302233,0.0000037285472,0.00008119422,0.00010319232,0.000016294258],"category_scores_gemma":[0.0002328677,0.00004692877,0.000081384605,0.00033604214,0.00014483358,0.000016689411,0.000016157595,0.00009873124,0.0000013786328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015010608,0.00049089803,0.9191168,0.000031178533,0.0007047593,0.000015086597,0.00077548914,0.000049310896,0.071874596,0.001865172,0.0003797539,0.0031958967],"study_design_scores_gemma":[0.0011044109,0.00013809897,0.98974943,0.000010040354,0.00062588026,0.0000031305392,0.00003071208,0.0015027215,0.0061770924,0.00015821974,0.00045271832,0.000047538346],"about_ca_topic_score_codex":0.000009601377,"about_ca_topic_score_gemma":0.00020099536,"teacher_disagreement_score":0.070632644,"about_ca_system_score_codex":0.00003130679,"about_ca_system_score_gemma":0.00002733073,"threshold_uncertainty_score":0.19136997},"labels":[],"label_agreement":null},{"id":"W1990102942","doi":"10.1503/cmaj.131626","title":"Managing drug interactions in HIV-infected adults with comorbid illness","year":2014,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Northern Alberta Institute of Technology; University of Alberta Hospital; Toronto General Hospital; University of Alberta","funders":"","keywords":"Antiretroviral therapy; Medicine; Antiretroviral drug; ANTIRETROVIRAL AGENTS; Human immunodeficiency virus (HIV); Intensive care medicine; Drug; Pharmacotherapy; Disease; Viral load; Immunology; Psychiatry; Internal medicine","score_opus":0.00920327477175424,"score_gpt":0.2766537668431133,"score_spread":0.26745049207135907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990102942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004325922,0.9241421,0.00013438253,0.052445907,0.0022074794,0.0016927307,0.000082293926,0.000099174315,0.018763347],"genre_scores_gemma":[0.00041612086,0.9835286,0.00016114603,0.001059262,0.0011384916,0.00007371966,0.00042736193,0.0000673896,0.013127898],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675804,0.00034094552,0.00087545306,0.00028908387,0.0011290652,0.00060743483],"domain_scores_gemma":[0.9969893,0.00032813888,0.0005417595,0.0001620741,0.00026927068,0.001709432],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010400541,0.00036050798,0.0014078153,0.0009689445,0.000221144,0.00008107565,0.00018266453,0.00025881839,0.0022905986],"category_scores_gemma":[0.0006082065,0.00026168086,0.00025843858,0.00062795106,0.000031557556,0.00009515582,0.000018205428,0.0021792965,0.0005636129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000012390636,0.000075751894,0.006155271,0.001218878,0.00061841065,0.0027582573,0.00056872895,3.3352623e-7,1.7132552e-9,0.000033063927,0.08052322,0.9080357],"study_design_scores_gemma":[0.001680088,0.000015104264,0.0003592418,0.028044567,0.00046717562,0.0016966785,0.00021277544,0.000042339227,4.5749935e-8,0.000007172533,0.9671989,0.00027592425],"about_ca_topic_score_codex":0.0012796341,"about_ca_topic_score_gemma":0.10540031,"teacher_disagreement_score":0.9077598,"about_ca_system_score_codex":0.0045950157,"about_ca_system_score_gemma":0.0064198105,"threshold_uncertainty_score":0.99998355},"labels":[],"label_agreement":null},{"id":"W1990570958","doi":"10.3851/imp2076","title":"Pill Burden in HIV Infection: 20 Years of Experience","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Medicine; Pill; Medical prescription; Cohort; Pharmacy; Dosing; Human immunodeficiency virus (HIV); Cohort study; Internal medicine; Pediatrics; Immunology; Pharmacology; Family medicine","score_opus":0.026215799350104187,"score_gpt":0.3016907207139864,"score_spread":0.2754749213638822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990570958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948672,0.00046670483,0.000012411642,0.00039056616,0.000095687516,0.00016042877,9.539756e-7,0.000019739184,0.0039862865],"genre_scores_gemma":[0.99381095,0.00064768636,0.00029507375,0.000058480775,0.00011052854,0.000017511613,0.000008330164,0.000008957872,0.0050424724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947006,0.000020927033,0.00013291472,0.00008929566,0.00011936155,0.00016743415],"domain_scores_gemma":[0.9997868,0.000017493288,0.00003202163,0.00011334563,0.000015214803,0.000035110574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008176767,0.000075442375,0.0001584963,0.00008057666,0.000013852563,0.0000029869966,0.000028993947,0.000036469388,0.00014249184],"category_scores_gemma":[0.000006589234,0.00006249964,0.00004350293,0.00017707127,0.000040093233,0.00012018373,0.000010264629,0.000053541466,0.00009839808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008485493,0.00022193046,0.956216,0.0000042157767,0.000034246263,0.000010517018,0.006570261,1.7114164e-7,0.007458044,0.00009811484,0.0004947647,0.028806886],"study_design_scores_gemma":[0.0021102305,0.00010086569,0.869156,0.000051738993,0.000007701771,0.000007645014,0.00019465813,0.0000065221147,0.06048375,0.000026012325,0.06774579,0.000109100416],"about_ca_topic_score_codex":0.00004389035,"about_ca_topic_score_gemma":0.0000043394966,"teacher_disagreement_score":0.08706001,"about_ca_system_score_codex":0.000024883138,"about_ca_system_score_gemma":0.000020870057,"threshold_uncertainty_score":0.25486612},"labels":[],"label_agreement":null},{"id":"W1990828872","doi":"10.1186/1742-4690-9-110","title":"Multiple choices for HIV therapy with integrase strand transfer inhibitors","year":2012,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Raltegravir; Elvitegravir; Dolutegravir; Medicine; Integrase; Human immunodeficiency virus (HIV); Antiretroviral therapy; Integrases; Integrase inhibitor; Clinical trial; Virology; Drug; Pharmacology; Intensive care medicine; Internal medicine; Viral load","score_opus":0.01778805454923803,"score_gpt":0.25776848513275175,"score_spread":0.2399804305835137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990828872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435836,0.00068968534,0.0014066099,0.002022252,0.000121037665,0.0007173483,0.00001657719,0.000059247213,0.0006089113],"genre_scores_gemma":[0.9938835,0.000109787434,0.001457166,0.0003586408,0.00027397272,0.00014061168,0.0001074313,0.000029981946,0.0036389409],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990974,0.000028849174,0.00016805848,0.00019652967,0.00011478776,0.0003943516],"domain_scores_gemma":[0.9994932,0.00013506178,0.000023310427,0.00014926911,0.000034966208,0.00016422762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012849928,0.00018173306,0.0003019963,0.00010746823,0.000063634165,0.000005997762,0.0000436274,0.00012202366,0.00013504771],"category_scores_gemma":[0.000019465197,0.00011168964,0.000083725565,0.000091264046,0.00008477297,0.000084389976,0.000004557959,0.00012238501,0.000039919396],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025452944,0.0006006355,0.979684,0.000035205147,0.00041768985,0.000012916142,0.0011364407,8.140949e-7,0.006257484,0.00018861819,0.0016284238,0.007492506],"study_design_scores_gemma":[0.04255435,0.0038133732,0.28407618,0.000082237675,0.00056490954,0.00015860217,0.000528387,0.00010843278,0.10536265,0.00004350557,0.562104,0.0006033751],"about_ca_topic_score_codex":0.000009670186,"about_ca_topic_score_gemma":0.000035637793,"teacher_disagreement_score":0.6956078,"about_ca_system_score_codex":0.00004285072,"about_ca_system_score_gemma":0.00005103059,"threshold_uncertainty_score":0.45545712},"labels":[],"label_agreement":null},{"id":"W1990925084","doi":"10.1016/s1473-3099(13)70257-3","title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Raltegravir; Dolutegravir; Medicine; Emtricitabine; Tolerability; Abacavir; Lamivudine; Population; Internal medicine; Clinical trial; Integrase inhibitor; Human immunodeficiency virus (HIV); Viral load; Adverse effect; Antiretroviral therapy; Virology; Virus; Chronic hepatitis","score_opus":0.030394587461602993,"score_gpt":0.2889750520106316,"score_spread":0.2585804645490286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990925084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98565674,0.0001526952,0.000031437932,0.00093248254,0.0007174282,0.008971809,0.00014686564,0.00046396969,0.0029265482],"genre_scores_gemma":[0.99474823,0.0002867967,0.000078601755,0.00015170814,0.0013764434,0.0021556208,0.00039522088,0.00007575227,0.00073164975],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996249,0.00037142087,0.0008902238,0.00093613536,0.0007393389,0.0008138836],"domain_scores_gemma":[0.9971546,0.0007322547,0.00044708984,0.0010582173,0.00024776242,0.00036009517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004595702,0.00070330926,0.0013985266,0.00034364103,0.0003656985,0.0002390876,0.00026804407,0.00017811797,0.00011464467],"category_scores_gemma":[0.00030318496,0.00044755664,0.00030280228,0.0008682173,0.00021341987,0.00048117514,0.00012482285,0.0006749435,0.00054579705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.537554,0.0026406976,0.45485517,0.00003697441,0.00062211714,0.00010161843,0.0015839014,0.000039468803,0.000015453628,0.00000715132,0.0011435316,0.0013998974],"study_design_scores_gemma":[0.6238386,0.0033750471,0.37005427,0.0002903759,0.0008147429,0.0000058091155,0.00050609536,0.00010678347,0.000058104568,0.000046283953,0.0004905346,0.00041332887],"about_ca_topic_score_codex":0.020330127,"about_ca_topic_score_gemma":0.004597378,"teacher_disagreement_score":0.08628462,"about_ca_system_score_codex":0.0005095578,"about_ca_system_score_gemma":0.00043404044,"threshold_uncertainty_score":0.99979764},"labels":[],"label_agreement":null},{"id":"W1991331972","doi":"10.1186/1742-4690-5-43","title":"Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report","year":2008,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Viral quasispecies; Virology; Peripheral blood mononuclear cell; Drug resistance; Frameshift mutation; Genotyping; Medicine; Biology; Mutation; Nonsense mutation; Genetics; Virus; Gene; Genotype; In vitro; Hepatitis C virus","score_opus":0.02070934300538851,"score_gpt":0.24756705980488503,"score_spread":0.2268577167994965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991331972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927754,0.00030368505,0.000024358686,0.005335248,0.00015809239,0.00036990878,0.000013247152,0.000098047356,0.0044198893],"genre_scores_gemma":[0.95475,0.000112379814,0.0015797872,0.0002595904,0.000088911314,0.000039268387,0.00008939584,0.000023224246,0.043057457],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99822605,0.00008847938,0.0004944962,0.00048693645,0.0002500126,0.00045404249],"domain_scores_gemma":[0.99906796,0.00014391502,0.0001303754,0.00042647318,0.00006041245,0.00017088572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002063476,0.00023955779,0.00055159174,0.000349224,0.00015093375,0.0000055149344,0.00007828643,0.0001543535,0.00019565913],"category_scores_gemma":[0.00017375281,0.0002033141,0.00012821588,0.00027366658,0.0002126294,0.00006522228,0.00007746566,0.00024623002,0.00032899203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006453168,0.00038778564,0.44388452,0.000025189553,0.00012561677,0.5417246,0.0021017047,0.000003398175,0.00090016995,0.0001223694,0.0098978095,0.00018150023],"study_design_scores_gemma":[0.017005943,0.0007037918,0.6177397,0.00009504967,0.00035571732,0.23121028,0.0022320203,0.00022146148,0.0028050093,0.00006194135,0.12677136,0.0007977348],"about_ca_topic_score_codex":0.0003372033,"about_ca_topic_score_gemma":0.00049550657,"teacher_disagreement_score":0.31051433,"about_ca_system_score_codex":0.00029082477,"about_ca_system_score_gemma":0.00018443986,"threshold_uncertainty_score":0.8290909},"labels":[],"label_agreement":null},{"id":"W1992008940","doi":"10.1097/qad.0b013e32832d3b54","title":"Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy","year":2009,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; Medical Research Council; Abbott Laboratories; European Commission; Pfizer; National Institutes of Health; National Science Foundation","keywords":"Nevirapine; Antiretroviral therapy; Medicine; Limiting; Oncology; Virology; Internal medicine; Intensive care medicine; Human immunodeficiency virus (HIV); Pharmacology; Viral load","score_opus":0.024268833290610897,"score_gpt":0.27532071640018946,"score_spread":0.25105188310957854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992008940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979686,0.00018715985,0.000050881008,0.000164068,0.00007207805,0.00073009625,0.000017928278,0.000080385704,0.0007288077],"genre_scores_gemma":[0.99597955,0.00010941857,0.0023312855,0.00019767245,0.00007814011,0.000035198704,0.00015367244,0.00002433537,0.0010907233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987238,0.000040088176,0.00036287683,0.0002780223,0.00017280158,0.00042241736],"domain_scores_gemma":[0.9994407,0.00014726294,0.00012763232,0.00015297746,0.00004858274,0.0000828071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014118975,0.00025391762,0.000417992,0.0002034383,0.00014648671,0.000028877423,0.000048870435,0.00006857089,0.000023306031],"category_scores_gemma":[0.000115768155,0.00018770479,0.000147095,0.0001748796,0.00002089466,0.00015732645,0.0000083505165,0.00006922438,0.000006095986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032318122,0.0003274202,0.853516,0.0000049822484,0.000095721865,0.0000060974985,0.00331075,0.000003642212,0.00016375477,0.000053690103,0.00003593901,0.1421588],"study_design_scores_gemma":[0.016195197,0.012486945,0.95331544,0.00014060592,0.00011336929,6.4123196e-7,0.0025393,0.00025447848,0.013494895,0.00025954115,0.00085317343,0.00034639094],"about_ca_topic_score_codex":0.00006941113,"about_ca_topic_score_gemma":0.0000057295465,"teacher_disagreement_score":0.14181241,"about_ca_system_score_codex":0.00024015889,"about_ca_system_score_gemma":0.00005613866,"threshold_uncertainty_score":0.7654379},"labels":[],"label_agreement":null},{"id":"W1992247166","doi":"10.1371/journal.pone.0092717","title":"Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Hôpital Notre-Dame","funders":"National Institute of Mental Health; Gilead Sciences; Bristol-Myers Squibb","keywords":"Renal function; Medicine; Discontinuation; Fanconi syndrome; Internal medicine; Creatinine; Urology; Gastroenterology; Ritonavir; Prospective cohort study; Aminoaciduria; Tenofovir; Emtricitabine; Kidney; Urine; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy","score_opus":0.008442121094587376,"score_gpt":0.19406751946850867,"score_spread":0.18562539837392128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992247166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701244,0.000045385517,0.00012698007,0.000101015954,0.000012830644,0.0024747644,0.00003598241,0.00006361739,0.00012696898],"genre_scores_gemma":[0.9987932,0.0000063048465,0.00027942355,0.000017326967,0.000017972132,0.00023625909,0.00010342059,0.000025573936,0.0005205235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848837,0.00010778396,0.00038633973,0.00036708787,0.00042387415,0.00022657664],"domain_scores_gemma":[0.9992896,0.000070072456,0.0001621866,0.0002015824,0.00016885174,0.00010770956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000187335,0.00021260303,0.00054269936,0.00019111016,0.00007259663,0.0000127761095,0.00003353823,0.00006987434,0.000024797497],"category_scores_gemma":[0.000070826645,0.0001561604,0.000020023344,0.00031009785,0.000049158287,0.0001246327,0.000025685036,0.00015484661,0.0000065961312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024485083,0.012394083,0.98205686,0.000085412925,0.00082493806,0.000073306044,0.0008785454,0.0000042984634,0.00090960826,0.0000033350864,0.00005985643,0.00026127498],"study_design_scores_gemma":[0.025468562,0.0051904586,0.9661443,0.00028812725,0.000873503,0.00003833915,0.00015317978,0.0012409549,0.00043546918,0.000010677076,0.00000657452,0.00014981099],"about_ca_topic_score_codex":0.00007322462,"about_ca_topic_score_gemma":0.0004279764,"teacher_disagreement_score":0.023020053,"about_ca_system_score_codex":0.00013700359,"about_ca_system_score_gemma":0.000035825204,"threshold_uncertainty_score":0.6368036},"labels":[],"label_agreement":null},{"id":"W1992471537","doi":"10.1089/apc.2006.0174","title":"TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals","year":2007,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; University of British Columbia","funders":"Centers for Disease Control and Prevention; Bristol-Myers Squibb; Abbott Fund","keywords":"Enfuvirtide; Medicine; Regimen; Viral load; Randomization; Liter; Human immunodeficiency virus (HIV); Internal medicine; Gastroenterology; Randomized controlled trial; Immunology; Gp41","score_opus":0.025378342350285635,"score_gpt":0.2913723892716112,"score_spread":0.26599404692132556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992471537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950744,0.0035678877,0.000044847377,0.000014624175,0.000028006647,0.00059589895,0.000018601188,0.000016358374,0.00063940295],"genre_scores_gemma":[0.9926689,0.00040111656,0.006697725,0.000029769202,0.000008068174,0.000012944936,0.00006937055,0.00001152472,0.00010053365],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985438,0.00020930188,0.0003972878,0.0002878771,0.00037239873,0.00018935886],"domain_scores_gemma":[0.9990429,0.00019352409,0.00017539135,0.00020539225,0.00028827655,0.000094461895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096362166,0.00018864208,0.0004394664,0.00016412357,0.00007562749,0.000009380475,0.000032668424,0.000098753284,0.000039463586],"category_scores_gemma":[0.000070964634,0.00012881313,0.000033713648,0.0001540576,0.0002020093,0.000119360084,0.000044119457,0.00007846424,5.723459e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0368619,0.00064958504,0.33109286,0.0001839325,0.0004966477,0.000057497888,0.009402661,0.000024040331,0.012343553,0.00018274997,0.000022271002,0.6086823],"study_design_scores_gemma":[0.024867397,0.27261484,0.6508028,0.00040486848,0.0014934108,0.00008321322,0.026760647,0.00030222264,0.02181179,0.00007889604,0.00027191904,0.00050799974],"about_ca_topic_score_codex":0.000047900034,"about_ca_topic_score_gemma":0.000021314552,"teacher_disagreement_score":0.60817426,"about_ca_system_score_codex":0.00007012384,"about_ca_system_score_gemma":0.00009019686,"threshold_uncertainty_score":0.5252847},"labels":[],"label_agreement":null},{"id":"W1992716585","doi":"10.1016/s0753-3322(02)00271-8","title":"Lopinavir/ritonavir versus nelfinavir therapy for HIV","year":2002,"lang":"en","type":"article","venue":"Biomedicine & Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Lopinavir; Nelfinavir; Lopinavir/ritonavir; Ritonavir; Medicine; Virology; Human immunodeficiency virus (HIV); Pharmacology; Antiretroviral therapy; Viral load","score_opus":0.07490508948681959,"score_gpt":0.354966134109685,"score_spread":0.2800610446228654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992716585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55170244,0.05561257,0.0031076707,0.34945098,0.0069753616,0.011107066,0.00026721766,0.0017783759,0.019998323],"genre_scores_gemma":[0.675903,0.05743477,0.015592999,0.02622742,0.0082866,0.00230485,0.0012161554,0.00059596513,0.21243823],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763113,0.00004206196,0.0004954392,0.0005876673,0.00052048475,0.00072320685],"domain_scores_gemma":[0.99860454,0.00017441144,0.00013166056,0.00040593935,0.00014023468,0.00054324424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024294709,0.00048031003,0.0006172224,0.0003352644,0.00019019317,0.000024381474,0.00020483563,0.00013417851,0.0034650317],"category_scores_gemma":[0.000027232876,0.0003607531,0.0002686216,0.00054425147,0.00018178755,0.000122682,0.00001708062,0.00019024752,0.00046062967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005501262,0.001963176,0.0040607285,0.00008972753,0.0011190207,0.00015302598,0.0016090046,5.562214e-7,0.07113695,0.00014087059,0.55300385,0.36122182],"study_design_scores_gemma":[0.052321583,0.001381878,0.0008398381,0.00009883545,0.00016335348,0.00004270757,0.00008178667,0.00049937045,0.023875173,0.000029642393,0.9202954,0.00037039534],"about_ca_topic_score_codex":0.000008480372,"about_ca_topic_score_gemma":8.160119e-7,"teacher_disagreement_score":0.36729157,"about_ca_system_score_codex":0.00021258682,"about_ca_system_score_gemma":0.00010779236,"threshold_uncertainty_score":0.9998844},"labels":[],"label_agreement":null},{"id":"W1992735344","doi":"10.1074/jbc.m009097200","title":"Analysis of Efficiency and Fidelity of HIV-1 (+)-Strand DNA Synthesis Reveals a Novel Rate-limiting Step during Retroviral Reverse Transcription","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Limiting; Reverse transcriptase; DNA; Human immunodeficiency virus (HIV); Computational biology; Transcription (linguistics); Fidelity; Biology; Genetics; Chemistry; Virology; Computer science; Gene; Polymerase chain reaction; Engineering","score_opus":0.025136261453561754,"score_gpt":0.2544392641344741,"score_spread":0.22930300268091233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992735344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986425,0.00024379305,0.00035037912,0.0003084125,0.000011237015,0.000066575594,0.000029613542,0.0000059931367,0.00034146296],"genre_scores_gemma":[0.99804354,0.0003929195,0.0011965293,0.0000135844975,0.000043751497,0.0000014194943,0.000010726196,0.0000042594397,0.0002933028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858654,0.000041335166,0.0008275223,0.00017091597,0.00020927165,0.00016443193],"domain_scores_gemma":[0.9988943,0.00017510976,0.0005283497,0.000113288355,0.00016654651,0.0001224035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006436134,0.00014133807,0.00074859214,0.00010488146,0.00003895068,0.0000056968825,0.000073510266,0.00014324495,0.00015897675],"category_scores_gemma":[0.0005186648,0.00009383502,0.00031887108,0.00036864943,0.00011672417,0.000048118083,0.000015870131,0.00016971662,3.227863e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066722295,0.00029244754,0.21573041,0.00014947492,0.0005706491,0.000056320554,0.00008229987,0.000013362182,0.7820889,8.151941e-7,0.000012263134,0.00033585532],"study_design_scores_gemma":[0.0025090298,0.000172267,0.43166855,0.000468606,0.0021569491,0.00022222086,0.0006199728,0.00020766829,0.5617646,0.0000075421303,0.000053071635,0.00014954487],"about_ca_topic_score_codex":0.0000025223726,"about_ca_topic_score_gemma":4.2834571e-7,"teacher_disagreement_score":0.2203243,"about_ca_system_score_codex":0.00006720334,"about_ca_system_score_gemma":0.000040116796,"threshold_uncertainty_score":0.3826481},"labels":[],"label_agreement":null},{"id":"W1992881313","doi":"10.1111/j.1365-2141.2008.07467.x","title":"CP‐4055 and CP‐4126 are active in ara‐C and gemcitabine‐resistant lymphoma cell lines","year":2008,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gemcitabine; Chemistry; Nucleoside; Cell culture; Nucleoside analogue; Pharmacology; Biochemistry; Cancer research; Cancer; Biology; Medicine; Internal medicine","score_opus":0.01039855139209381,"score_gpt":0.22326354454984726,"score_spread":0.21286499315775345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992881313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8194102,0.029038524,0.0000048442453,0.15014839,0.0002982673,0.0003547472,0.000056566532,0.000015979373,0.00067250436],"genre_scores_gemma":[0.62304395,0.124943994,0.00834923,0.20299545,0.0052709933,0.0001292861,0.00057270646,0.0005317067,0.034162648],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99753195,0.00017360308,0.0009822238,0.00042068565,0.00038760144,0.0005039328],"domain_scores_gemma":[0.9983553,0.0002552472,0.0007849408,0.00015883484,0.00025984447,0.00018579997],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016647704,0.00041635285,0.001952767,0.0005742263,0.0001057952,0.0000466933,0.00013457114,0.0007411099,0.000058559537],"category_scores_gemma":[0.00014189036,0.0004044116,0.00017438142,0.0001592143,0.0002896243,0.0001266454,0.0000823237,0.0010844489,0.000010733581],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002917789,0.00021642182,0.006643669,0.0005507532,0.0003156487,0.5322686,0.00032506863,1.1591437e-7,0.000033638644,0.000001867471,0.45439827,0.004954177],"study_design_scores_gemma":[0.009503037,0.00029788283,0.038106054,0.0035096172,0.0004696451,0.6770475,0.00035661465,0.0000031933532,0.000583922,0.00015006203,0.2694789,0.0004935993],"about_ca_topic_score_codex":0.0000688142,"about_ca_topic_score_gemma":0.00016562219,"teacher_disagreement_score":0.19636619,"about_ca_system_score_codex":0.00015758119,"about_ca_system_score_gemma":0.00035872182,"threshold_uncertainty_score":0.9998408},"labels":[],"label_agreement":null},{"id":"W1993572662","doi":"10.1054/drup.2002.0235","title":"HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries","year":2001,"lang":"en","type":"article","venue":"Drug Resistance Updates","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Intensive care medicine; Drug resistance; Antiretroviral therapy; Developing country; Human immunodeficiency virus (HIV); Drug; Transmission (telecommunications); Resource (disambiguation); Immunology; Viral load; Pharmacology; Biology; Computer science","score_opus":0.00856328859968757,"score_gpt":0.2516728424776016,"score_spread":0.243109553877914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993572662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61812985,0.016817506,0.00017697022,0.36216086,0.0000716589,0.0014158908,0.00008168203,0.00006798698,0.0010775932],"genre_scores_gemma":[0.84781677,0.008057942,0.0029198602,0.0005455331,0.00026846296,0.00031676365,0.00025747207,0.000040198625,0.13977702],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987935,0.00004213633,0.00037798073,0.00034755885,0.00017377551,0.0002650598],"domain_scores_gemma":[0.9989943,0.00028529807,0.00014902509,0.00038768986,0.00013416052,0.000049561713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039193273,0.00018155474,0.00031512536,0.00012898823,0.00021022637,0.000032107288,0.00012355813,0.00004146872,0.00002965208],"category_scores_gemma":[0.00008382401,0.00012598261,0.00006162973,0.00035854717,0.00023544695,0.00011286561,0.000020508709,0.00009921685,0.0000047706285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037043914,0.0002998833,0.25376874,0.00021462323,0.00021472744,0.00000796237,0.0030671947,0.0000038739113,0.0013654522,0.014678768,0.7185008,0.0041735726],"study_design_scores_gemma":[0.0020597929,0.0000166171,0.061483175,0.000096312775,0.0000556786,0.0000041227695,0.00078198564,0.000013819945,0.004956183,0.0010187316,0.9293721,0.000141511],"about_ca_topic_score_codex":0.00000702148,"about_ca_topic_score_gemma":0.00053527526,"teacher_disagreement_score":0.36161533,"about_ca_system_score_codex":0.00008828307,"about_ca_system_score_gemma":0.00007172097,"threshold_uncertainty_score":0.51374215},"labels":[],"label_agreement":null},{"id":"W1994094375","doi":"10.1097/qco.0b013e3283298f1f","title":"Management of paediatric HIV-1 resistance","year":2009,"lang":"en","type":"review","venue":"Current Opinion in Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor","funders":"Wellcome Trust; Gilead Sciences; Bristol-Myers Squibb","keywords":"Medicine; Darunavir; Drug resistance; Transmission (telecommunications); Clinical trial; Pre-exposure prophylaxis; Intensive care medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Virology; Internal medicine; Men who have sex with men","score_opus":0.04017794438014056,"score_gpt":0.36111234582419827,"score_spread":0.3209344014440577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994094375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005342096,0.99381536,0.000019646115,0.00003968079,0.0017792231,0.0016734985,0.0001441432,0.00010517081,0.0024179032],"genre_scores_gemma":[0.00004047918,0.9959574,0.00006498143,0.0000027892756,0.0003492546,0.00043022583,0.0013662815,0.00004125538,0.0017473821],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768007,0.0001102207,0.0009382396,0.0005349366,0.0004052964,0.00033123422],"domain_scores_gemma":[0.9987633,0.000098017714,0.00042153272,0.00046166196,0.00006403403,0.00019140239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009849352,0.0005027535,0.0016114324,0.0007707402,0.000048725316,0.000017067714,0.00013894904,0.00012953111,0.000108054315],"category_scores_gemma":[0.00003112597,0.00041340984,0.00061676727,0.0010429948,0.00005200753,0.00005520936,0.00007489064,0.00025141865,0.00020285741],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029341158,0.0015898512,0.00431372,0.10414284,0.00029408914,0.000028961445,0.000022349652,5.517294e-7,6.665316e-10,0.0006755373,0.025734859,0.8631679],"study_design_scores_gemma":[0.0011904689,0.000039636034,0.0018531925,0.067244984,0.0014609939,0.000008868567,0.000007851812,4.7198614e-7,3.1839935e-8,0.00014885391,0.92773724,0.00030739067],"about_ca_topic_score_codex":5.1931204e-7,"about_ca_topic_score_gemma":5.678997e-7,"teacher_disagreement_score":0.9020024,"about_ca_system_score_codex":0.00045762747,"about_ca_system_score_gemma":0.00031894387,"threshold_uncertainty_score":0.9998318},"labels":[],"label_agreement":null},{"id":"W1994215747","doi":"10.1139/cjc-2014-0356","title":"Carbocyclodipeptides as modified nucleosides: synthesis and anti-HIV activities","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University Grants Commission","keywords":"Chemistry; Nucleoside; Isopropyl; Tetrahydrofuran; Hydroxymethyl; Azide; Thymine; Stereochemistry; Uracil; Nucleobase; Nucleic acid; Combinatorial chemistry; Organic chemistry; DNA; Biochemistry","score_opus":0.007681054454081251,"score_gpt":0.20659833897752475,"score_spread":0.19891728452344348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994215747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708161,0.00034699083,0.000008443123,0.0022643404,0.00004702026,0.000039222607,0.0000048873985,0.0000067722763,0.026466245],"genre_scores_gemma":[0.99290824,0.00005280478,0.00028625462,0.00012569528,0.00017236033,0.000002365972,0.0000022415247,0.000017342922,0.0064326967],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928623,0.000017853874,0.00022066935,0.00011109009,0.00013937414,0.00022475843],"domain_scores_gemma":[0.9988612,0.00011519194,0.00011370181,0.00012586801,0.00006337333,0.00072067307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016181394,0.00013882463,0.00032453256,0.00008585027,0.00010125345,0.000040590145,0.00007280474,0.00008259107,0.0002445155],"category_scores_gemma":[0.00030031573,0.00011803582,0.00007819024,0.000054666023,0.00011337165,0.00007028418,0.000006413728,0.0001885156,0.000009284436],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004157317,0.0002929842,0.59608793,0.0021070135,0.0030219338,0.0054500448,0.012219405,0.00005741859,0.28942087,0.00034424372,0.047543045,0.043039396],"study_design_scores_gemma":[0.002556626,0.00006956064,0.02497414,0.0017034445,0.0005441669,0.0037280591,0.0034966024,0.000069658934,0.91568226,0.00032530614,0.046325244,0.00052494206],"about_ca_topic_score_codex":0.00022529403,"about_ca_topic_score_gemma":0.00020243942,"teacher_disagreement_score":0.6262614,"about_ca_system_score_codex":0.0001027876,"about_ca_system_score_gemma":0.0007732371,"threshold_uncertainty_score":0.48133612},"labels":[],"label_agreement":null},{"id":"W1994430329","doi":"10.1016/j.jviromet.2005.01.011","title":"Sequence analysis of murine leukemia virus envelope gene from inoculated mice","year":2005,"lang":"en","type":"article","venue":"Journal of Virological Methods","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Biology; Virology; Murine leukemia virus; Virus; Nucleic acid; Reverse transcriptase; Gene; Viral envelope; Viral replication; Gammaretrovirus; RNA; Viral pathogenesis; DNA; Molecular biology; Genetics","score_opus":0.0652079779731913,"score_gpt":0.3966392704477646,"score_spread":0.33143129247457326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994430329","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97365016,0.0012128381,0.023013413,0.0015888623,0.000069688314,0.000100860976,0.000013338121,0.000015880512,0.00033495954],"genre_scores_gemma":[0.47123748,0.00044167164,0.5274498,0.00038782883,0.000113470946,0.0000018222048,0.000014869658,0.000007651994,0.00034542195],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976391,0.0004645718,0.001036482,0.00022721318,0.000399842,0.00023274907],"domain_scores_gemma":[0.9981257,0.00056036824,0.00062451814,0.00021660751,0.00022779894,0.00024504797],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001305781,0.00021050658,0.0011590548,0.00044649438,0.00004032762,0.000009787755,0.0001906149,0.00019927988,0.001189122],"category_scores_gemma":[0.00052510935,0.00013171541,0.00046343927,0.0008679316,0.00010668832,0.000095692805,0.000064594424,0.00038458177,0.000016718372],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011972212,0.00062934065,0.043518785,0.000010864768,0.007226001,0.0005818207,0.00041512615,0.0010776642,0.832523,0.00003986648,0.00019789948,0.11258243],"study_design_scores_gemma":[0.0034290643,0.000734106,0.48752582,0.00006688876,0.007996488,0.00020413613,0.000042615953,0.0048244814,0.47514227,0.00040697778,0.019352593,0.0002745623],"about_ca_topic_score_codex":0.000027432143,"about_ca_topic_score_gemma":0.0000069236808,"teacher_disagreement_score":0.5044364,"about_ca_system_score_codex":0.00030268208,"about_ca_system_score_gemma":0.00016336121,"threshold_uncertainty_score":0.9997239},"labels":[],"label_agreement":null},{"id":"W1994805141","doi":"10.7448/ias.17.4.19507","title":"Large disparities in HIV treatment cascades between eight European and high‐income countries – analysis of break points","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Demography; Human immunodeficiency virus (HIV); Incidence (geometry); Transmission (telecommunications); High income countries; Antiretroviral therapy; Viral load; HIV diagnosis; Environmental health; Pediatrics; Family medicine; Developing country; Economic growth","score_opus":0.008008849010912597,"score_gpt":0.2512538054581412,"score_spread":0.2432449564472286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994805141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881077,0.00016849532,0.0002039878,0.010755803,0.00010953605,0.000067815476,0.00008906568,0.00000380607,0.0004937977],"genre_scores_gemma":[0.99440765,0.00031480452,0.0013917012,0.00019118836,0.00015752236,0.000001314476,0.000022932618,0.000009418191,0.003503447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874866,0.00008542667,0.00048497217,0.0001033762,0.0004550437,0.00012254372],"domain_scores_gemma":[0.99912125,0.00020486387,0.0003344886,0.00011048303,0.00016612773,0.000062765444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006421645,0.00012606005,0.0004447953,0.00018156586,0.00005498329,0.000027202854,0.00016034802,0.000037795144,0.00006614509],"category_scores_gemma":[0.000057677287,0.000071819035,0.00039591815,0.00021972164,0.000080713624,0.000102942206,0.000076618635,0.00011850786,0.00000290799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047512847,0.00013913501,0.9919719,0.00001637932,0.0043565403,0.000008322524,0.0013466192,0.000015091449,0.00004319659,0.0009939686,0.00078981253,0.00027149898],"study_design_scores_gemma":[0.0024774857,0.00011622368,0.98656315,0.0001771578,0.0014590659,0.000024572451,0.00023328731,0.00028699584,0.0010714714,0.00027933766,0.0072405487,0.000070691334],"about_ca_topic_score_codex":0.00004151778,"about_ca_topic_score_gemma":0.00003869052,"teacher_disagreement_score":0.010564615,"about_ca_system_score_codex":0.00028500796,"about_ca_system_score_gemma":0.000053680877,"threshold_uncertainty_score":0.2928695},"labels":[],"label_agreement":null},{"id":"W1994966130","doi":"10.1097/00126334-200204010-00007","title":"Higher Rate of Toxicity With No Increased Efficacy When Hydroxyurea Is Added to a Regimen of Stavudine Plus Didanosine and Nevirapine in Primary HIV Infection","year":2002,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Didanosine; Nevirapine; Stavudine; Regimen; Hydroxycarbamide; Medicine; Adverse effect; Internal medicine; Gastroenterology; Chemotherapy; Viral load; Human immunodeficiency virus (HIV); Immunology; Viral disease; Sida; Zidovudine; Antiretroviral therapy","score_opus":0.015442281310396825,"score_gpt":0.23358178395079893,"score_spread":0.2181395026404021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994966130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389964,0.0025608495,0.0000720122,0.0020822245,0.00009311865,0.0005574713,0.000012524665,0.000023367806,0.0006988078],"genre_scores_gemma":[0.99281174,0.0007203084,0.0026531057,0.00011597926,0.000027128157,0.000009971703,0.00001399454,0.000038706807,0.0036090517],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974381,0.00014019487,0.0012550142,0.00028135438,0.0005373594,0.0003479869],"domain_scores_gemma":[0.99814993,0.00018369044,0.00076987816,0.00034944975,0.0003725004,0.0001745611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077726506,0.00032956808,0.0012802279,0.0010294905,0.000056548502,0.000017672512,0.00015302155,0.00010656339,0.00029134506],"category_scores_gemma":[0.00019894911,0.00023584164,0.0001625394,0.0010959781,0.0001659428,0.00030869566,0.00008198661,0.00013652944,0.000020500596],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015071739,0.01215708,0.45684415,0.0026113125,0.0034092048,0.0017261219,0.019868048,0.00033001366,0.45774928,0.00013354419,0.017141145,0.01295836],"study_design_scores_gemma":[0.023876885,0.0068053533,0.92166907,0.0032091206,0.000712493,0.000700416,0.00016596916,0.00024879654,0.04077276,0.00004496684,0.0012944214,0.0004997342],"about_ca_topic_score_codex":0.0000903474,"about_ca_topic_score_gemma":0.0000031538361,"teacher_disagreement_score":0.46482494,"about_ca_system_score_codex":0.00024604934,"about_ca_system_score_gemma":0.00015470728,"threshold_uncertainty_score":0.9617343},"labels":[],"label_agreement":null},{"id":"W1995273109","doi":"10.2165/00044011-200020050-00001","title":"Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary General Hospital; Foothills Medical Centre","funders":"","keywords":"Zalcitabine; Zidovudine; Medicine; Saquinavir; Context (archaeology); Didanosine; Regimen; Internal medicine; Clinical endpoint; Clinical trial; Phases of clinical research; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology; Viral disease","score_opus":0.03442539373868219,"score_gpt":0.3394667003142452,"score_spread":0.305041306575563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995273109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914482,0.00006738643,0.0000028049228,0.0005185601,0.00011424274,0.007082294,0.000029977811,0.0001626409,0.0005738708],"genre_scores_gemma":[0.98466307,0.00014253923,0.0005480005,0.00015072965,0.00007700863,0.0002600307,0.0014964773,0.000055407378,0.012606756],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948793,0.0006892274,0.0025538604,0.0007980071,0.0005841185,0.00049549906],"domain_scores_gemma":[0.99717426,0.0008725488,0.0005460329,0.00052944064,0.00036715917,0.0005105804],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007779538,0.0004927342,0.0015067637,0.0002954177,0.00009446681,0.000022984736,0.00017000413,0.00023493131,0.00079166173],"category_scores_gemma":[0.0015770658,0.0003644598,0.0002006327,0.0010820878,0.00025157447,0.00021255016,0.000055612036,0.000387797,0.00016445901],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06942828,0.014796377,0.8829904,0.00018381789,0.0006884988,0.0002506054,0.011665385,0.00017168708,0.00010908951,0.0000023919547,0.0022814265,0.017432002],"study_design_scores_gemma":[0.6133344,0.003568116,0.369968,0.0009602517,0.0012236531,0.000005829231,0.0006518327,0.008688154,0.0008207885,0.00001636244,0.00029595615,0.00046660408],"about_ca_topic_score_codex":0.0002123187,"about_ca_topic_score_gemma":0.000456785,"teacher_disagreement_score":0.54390615,"about_ca_system_score_codex":0.0004285802,"about_ca_system_score_gemma":0.0005799569,"threshold_uncertainty_score":0.99988073},"labels":[],"label_agreement":null},{"id":"W1995556150","doi":"10.1081/ncn-100105246","title":"SYNTHESIS OF UNNATURAL 7-SUBSTITUTED-1-(2-DEOXY-β-D-RIBOFURANOSYL)ISOCARBOSTYRILS<sup>†</sup>: “THYMINE REPLACEMENT” ANALOGS OF DEOXYTHYMIDINE FOR EVALUATION AS ANTIVIRAL AND ANTICANCER AGENTS","year":2001,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cytotoxicity; Thymidine kinase; Herpes simplex virus; Cytotoxic T cell; Transfection; Chemistry; Thymine; Stereochemistry; Nucleoside; Nucleoside analogue; Cell culture; Thymidine; In vitro; Gene; Biology; Virus; Virology; Biochemistry; DNA; Genetics","score_opus":0.0188142465237849,"score_gpt":0.29341583869261806,"score_spread":0.2746015921688332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995556150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028766,0.0010010474,0.000068604706,0.002091013,0.00018630974,0.002250221,0.000105051964,0.00014089161,0.0038692115],"genre_scores_gemma":[0.99116606,0.0013094032,0.005877455,0.00027971907,0.00016167545,0.00014794241,0.00017503864,0.00013594431,0.0007467753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955424,0.00016448434,0.0013714009,0.0009630167,0.0011635796,0.00079508184],"domain_scores_gemma":[0.9970688,0.00046025863,0.0006149388,0.00080137944,0.0007423812,0.00031222557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010723239,0.0006956417,0.0014304529,0.0005841373,0.0002521765,0.000052561783,0.0002982376,0.00031160394,0.0006740828],"category_scores_gemma":[0.0010295898,0.0006186472,0.00042691187,0.00080578396,0.0006093873,0.00049803674,0.00015859962,0.0002547191,0.000042040232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012424617,0.0034202107,0.74869883,0.002115208,0.005494007,0.00021153406,0.005496613,0.000244882,0.08690149,0.0048102867,0.00965921,0.12052308],"study_design_scores_gemma":[0.04200734,0.004383368,0.55396795,0.0052457373,0.011666391,0.0006487602,0.0056880293,0.06988225,0.27114487,0.0027709776,0.029424632,0.0031697059],"about_ca_topic_score_codex":0.00013261862,"about_ca_topic_score_gemma":0.000027128894,"teacher_disagreement_score":0.19473092,"about_ca_system_score_codex":0.00028856305,"about_ca_system_score_gemma":0.00030411908,"threshold_uncertainty_score":0.99962646},"labels":[],"label_agreement":null},{"id":"W1995559092","doi":"10.1097/01.aids.0000232228.88511.0b","title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Didanosine; Lamivudine; Resistance mutation; Virology; Zidovudine; Abacavir; Biology; Reverse transcriptase; Drug resistance; Genotype; Stavudine; Genotyping; Reverse-transcriptase inhibitor; Virus; Sida; Genetics; Viral disease; Polymerase chain reaction; Gene; Hepatitis B virus","score_opus":0.010216665694789984,"score_gpt":0.2445065241397908,"score_spread":0.2342898584450008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995559092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9037222,0.0014835318,0.00019090317,0.0033965446,0.0001377338,0.00061881915,0.000018622999,0.00013944482,0.09029216],"genre_scores_gemma":[0.7349338,0.000040595172,0.023189275,0.0011345219,0.000114890645,0.000051647796,0.00007676263,0.000029282257,0.24042925],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998736,0.000030591793,0.00029941605,0.00033223227,0.00025556496,0.00034616023],"domain_scores_gemma":[0.9994622,0.00003527705,0.000045427758,0.00024743707,0.000094503426,0.000115174356],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013710147,0.00021024437,0.0002974448,0.00018771124,0.000061849714,0.0000194193,0.0000988823,0.000097740216,0.00014286274],"category_scores_gemma":[0.000046943038,0.00016465347,0.000048906397,0.0007684422,0.00002733593,0.00007006997,0.00003905938,0.00013037852,0.0012045626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002920802,0.0004502706,0.69020396,0.000077497556,0.000042418957,0.00037339755,0.0014347703,0.0000054573147,0.009523537,0.00074643036,0.29586405,0.000986158],"study_design_scores_gemma":[0.0024568173,0.00010996542,0.1780155,0.0001673075,0.00005591323,0.000007799673,0.000237883,0.0000015816869,0.05456821,0.00021231345,0.7638455,0.00032120277],"about_ca_topic_score_codex":0.000050160364,"about_ca_topic_score_gemma":0.00024714763,"teacher_disagreement_score":0.51218843,"about_ca_system_score_codex":0.00018325401,"about_ca_system_score_gemma":0.00017342514,"threshold_uncertainty_score":0.9995731},"labels":[],"label_agreement":null},{"id":"W1995626592","doi":"10.1097/00002030-200411190-00011","title":"Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal","year":2004,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Centre Hospitalier de l’Université de Montréal; McGill University; McGill University Health Centre","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Viral load; Genotyping; Medicine; Drug resistance; Internal medicine; Transmission (telecommunications); Human immunodeficiency virus (HIV); Young adult; HIV drug resistance; Retrospective cohort study; Antiretroviral therapy; Immunology; Genotype; Biology; Genetics","score_opus":0.014772385299684089,"score_gpt":0.2445255957273308,"score_spread":0.2297532104276467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995626592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700767,0.00020661803,0.0000034658603,0.0008047014,0.000008052786,0.00054014375,0.000021536742,0.000016965285,0.0013908762],"genre_scores_gemma":[0.9974306,0.0000301511,0.0002817074,0.00006918486,0.000004313868,0.00005198308,0.0000616982,0.000011218666,0.0020591323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987358,0.00013419738,0.00033373304,0.00021192894,0.0003327929,0.00025155864],"domain_scores_gemma":[0.9993438,0.00024374387,0.00010370887,0.00020457458,0.000036639387,0.000067507135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039078447,0.00016643782,0.00032243645,0.0002787508,0.000018563436,0.000007849929,0.000115084746,0.000062178624,0.000034317884],"category_scores_gemma":[0.00042627074,0.000101214224,0.00003478653,0.0009798919,0.000058533406,0.000086950604,0.000019307043,0.0001823046,0.000004306581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090702684,0.0007556674,0.9851267,0.000052647178,0.000044620865,0.000109288136,0.013493335,0.00001679942,0.00002101738,0.00010192683,0.00010136307,0.00008593905],"study_design_scores_gemma":[0.0064188493,0.00007812312,0.99110115,0.0009200552,0.00006127934,8.714482e-7,0.0004526638,0.0000020478737,0.00047179003,0.00036135156,0.000030758983,0.000101076286],"about_ca_topic_score_codex":0.00070591836,"about_ca_topic_score_gemma":0.017288279,"teacher_disagreement_score":0.01658236,"about_ca_system_score_codex":0.00024831737,"about_ca_system_score_gemma":0.00026698617,"threshold_uncertainty_score":0.9647265},"labels":[],"label_agreement":null},{"id":"W1996065655","doi":"10.1097/qad.0b013e32835e0752","title":"Adverse events associated with nevirapine use in pregnancy","year":2013,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Nevirapine; Pregnancy; Adverse effect; Medicine; Obstetrics; Virology; Human immunodeficiency virus (HIV); Internal medicine; Biology; Antiretroviral therapy; Viral load; Genetics","score_opus":0.05958510759104319,"score_gpt":0.3121598086075477,"score_spread":0.25257470101650453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996065655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00065406377,0.9958177,0.0000029119958,0.000033770444,0.00008813966,0.0022774586,0.00002105201,0.00007111735,0.0010337501],"genre_scores_gemma":[0.00006501481,0.90990734,0.0008626376,0.000026457745,0.000028814839,0.00048534386,0.0008551161,0.000074983334,0.08769432],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822754,0.0001237428,0.00053145544,0.0004197657,0.00032578968,0.00037170466],"domain_scores_gemma":[0.9990168,0.00012252448,0.0002501402,0.00039852795,0.00006699754,0.00014499182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010854775,0.00048386963,0.0017229246,0.00034449287,0.000030476622,0.000007879046,0.00010958723,0.00027829094,0.0002660159],"category_scores_gemma":[0.00013087336,0.0003011788,0.00025326986,0.00064676546,0.000028621269,0.00015442068,0.000052686766,0.00033979336,0.00069544447],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013334217,0.00067857606,0.037431527,0.0039774673,0.0016099729,0.00060969254,0.00010497281,7.6856864e-8,7.443863e-8,0.000028801276,0.0013842739,0.9541612],"study_design_scores_gemma":[0.0026028256,0.0002593393,0.0032398698,0.13964377,0.0021226795,0.00003287968,0.0000102624235,0.0000011411236,5.2831666e-7,0.0000057546363,0.8516695,0.00041148762],"about_ca_topic_score_codex":0.00003320778,"about_ca_topic_score_gemma":0.000026522092,"teacher_disagreement_score":0.9537497,"about_ca_system_score_codex":0.0004094741,"about_ca_system_score_gemma":0.0003908487,"threshold_uncertainty_score":0.99994403},"labels":[],"label_agreement":null},{"id":"W1996104688","doi":"10.1310/hct0805-259","title":"Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients on Their First PI-Containing HAART Regimen","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; GDI Integrated Facility Services (Canada); St. Michael's Hospital; Western University; McMaster University Medical Centre; University of British Columbia; Abbott (Canada); University of Toronto","funders":"Abbott Canada; Gilead Sciences","keywords":"Medicine; Regimen; Lopinavir; Lamivudine; Ritonavir; Adverse effect; Discontinuation; Randomized controlled trial; Internal medicine; Lopinavir/ritonavir; Clinical endpoint; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Immunology; Virus; Antiretroviral therapy; Hepatitis B virus","score_opus":0.11908434106831939,"score_gpt":0.38938264742990997,"score_spread":0.2702983063615906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996104688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97013974,0.00009575516,0.000037044356,0.009058801,0.00082682614,0.011107956,0.000028091747,0.00009283501,0.008612956],"genre_scores_gemma":[0.9951258,0.00050087116,0.00046563678,0.00069984724,0.0005976619,0.00052633864,0.00012956765,0.0000510509,0.0019032258],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98818046,0.0048244847,0.0046930667,0.0008565412,0.00078401004,0.0006614622],"domain_scores_gemma":[0.89157104,0.10526552,0.0019362173,0.00071908615,0.00021015514,0.00029800317],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03296312,0.00060974807,0.0059944717,0.00030368337,0.00019564797,0.000048523845,0.00026588503,0.0005245082,0.00013484748],"category_scores_gemma":[0.06607142,0.00031464285,0.0011171038,0.00033428325,0.0005098413,0.0000809005,0.000117101496,0.00078677695,0.000051957864],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98279303,0.0022420208,0.008449757,0.00001652922,0.0012819332,0.0000714828,0.0005753332,0.000005379403,0.000048820555,0.001096385,0.0013186805,0.0021006442],"study_design_scores_gemma":[0.9794906,0.005935324,0.009272313,0.0007025262,0.0007242008,0.0000013964907,0.00022196464,0.00014859086,0.0002467416,0.00026935563,0.002678955,0.00030804635],"about_ca_topic_score_codex":0.000017095848,"about_ca_topic_score_gemma":0.0000317694,"teacher_disagreement_score":0.10044104,"about_ca_system_score_codex":0.00015319746,"about_ca_system_score_gemma":0.00021346725,"threshold_uncertainty_score":0.99993056},"labels":[],"label_agreement":null},{"id":"W1996161025","doi":"10.1007/s10059-000-0525-3","title":"Characterization of Mutant HIV-1 Integrase Carrying Amino Acid Changes in the Catalytic Domain","year":2000,"lang":"en","type":"article","venue":"Molecules and Cells","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Armand Frappier Museum","funders":"Medical Research Council","keywords":"Mutant; Mutagenesis; Integrase; Enzyme; Amino acid; Isoleucine; Chemistry; Biochemistry; Biology; Leucine; Gene","score_opus":0.006894816889893893,"score_gpt":0.21013597642047038,"score_spread":0.20324115953057648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996161025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963725,0.00012393047,0.000037815567,0.0017679556,0.000013579525,0.00023413086,0.000015644093,0.0000068762133,0.0014275728],"genre_scores_gemma":[0.99719,0.00034314647,0.0001454014,0.00022066015,0.000017739978,0.000018307523,0.00012663643,0.000007668155,0.001930423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950165,0.000025522993,0.0001257832,0.00012152755,0.00010739249,0.00011815375],"domain_scores_gemma":[0.9998053,0.000011553646,0.000030307336,0.00010913595,0.000010912982,0.000032812182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000821779,0.00009268916,0.00014669322,0.000056657307,0.00002787196,0.0000101526475,0.00003811201,0.00003109511,0.0001175168],"category_scores_gemma":[0.0000019026228,0.000057691264,0.00002312277,0.00009721819,0.000033668515,0.000018901428,0.000008608354,0.000052679094,0.00002215108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008015053,0.00018821501,0.0027252373,0.000086030595,0.000045060722,0.00021794128,0.0103205135,5.2995927e-7,0.9523221,0.00008356836,0.000059777325,0.033870872],"study_design_scores_gemma":[0.001459121,0.000114700735,0.015245726,0.00019905175,0.00010153246,0.00004882811,0.001676971,0.0001127973,0.97186667,0.000043191318,0.008991805,0.00013962795],"about_ca_topic_score_codex":0.000016990627,"about_ca_topic_score_gemma":0.000028809438,"teacher_disagreement_score":0.033731245,"about_ca_system_score_codex":0.000017855367,"about_ca_system_score_gemma":0.000017242792,"threshold_uncertainty_score":0.23525815},"labels":[],"label_agreement":null},{"id":"W1996852853","doi":"10.1016/s1473-3099(11)70068-8","title":"Transmitted antiretroviral-resistant HIV: a coming anarchy?","year":2011,"lang":"en","type":"letter","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institute of Population and Public Health; St. Paul's Hospital","funders":"National Institute on Drug Abuse","keywords":"Zidovudine; Human immunodeficiency virus (HIV); Drug resistance; Antiretroviral therapy; Medicine; Antiretroviral treatment; Virology; Scopus; Antiretroviral drug; HIV drug resistance; Immunology; Viral load; Internal medicine; MEDLINE; Biology; Viral disease; Microbiology","score_opus":0.024399968129990946,"score_gpt":0.25719969426302003,"score_spread":0.23279972613302907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996852853","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07654811,0.0045612487,0.00012055461,0.86678535,0.000883309,0.0028381078,0.0011659608,0.001932976,0.045164358],"genre_scores_gemma":[0.31091505,0.0012316279,0.00015868146,0.6218521,0.009996867,0.00054356677,0.0032434876,0.0003083057,0.05175032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759454,0.00019952224,0.000410602,0.0005199465,0.0005078985,0.0007675162],"domain_scores_gemma":[0.9984143,0.00022556754,0.00020536775,0.0009104467,0.00009258368,0.00015177138],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013109189,0.0005794913,0.0011507937,0.00023948714,0.00029955365,0.0000696752,0.00029257996,0.000314711,0.00056901627],"category_scores_gemma":[0.00006777808,0.00036458738,0.000438248,0.00030810127,0.00024675348,0.00006609148,0.00006241125,0.0011327777,0.00043792746],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028918433,0.00022860337,0.08546271,0.0005354376,0.0010299195,0.001915269,0.00039223616,2.17613e-7,0.000015643498,0.00005740824,0.90871805,0.0013553499],"study_design_scores_gemma":[0.003618064,0.00031066313,0.02462379,0.0006584586,0.0025344521,0.00014718897,0.000029365563,0.000013175312,0.000058957125,0.0008536088,0.9665702,0.0005820618],"about_ca_topic_score_codex":0.00011685387,"about_ca_topic_score_gemma":0.000019944951,"teacher_disagreement_score":0.24493329,"about_ca_system_score_codex":0.0002131305,"about_ca_system_score_gemma":0.0002817378,"threshold_uncertainty_score":0.9998806},"labels":[],"label_agreement":null},{"id":"W1997121017","doi":"10.1006/viro.2001.1032","title":"Mutations at Amino Acid Positions 63, 189, and 396 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Partially Restore the DNA Polymerase Activity of a TRP229TYR Mutant RT","year":2001,"lang":"en","type":"article","venue":"Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds Wetenschappelijk Onderzoek; European Commission","keywords":"Reverse transcriptase; Biology; Mutant; Primer (cosmetics); Polymerase; DNA polymerase; Molecular biology; Mutation; Recombinant DNA; Resistance mutation; Virus; Point mutation; Enzyme; Virology; DNA; RNA; Biochemistry; Gene; Chemistry","score_opus":0.021743286613164117,"score_gpt":0.2783521067979468,"score_spread":0.2566088201847827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997121017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950224,0.000720383,0.000043873617,0.0029861107,0.000074265175,0.00037049878,0.00008738756,0.000023765111,0.00067129877],"genre_scores_gemma":[0.9980391,0.00019002178,0.00009694577,0.00017557599,0.000019223211,0.000031435393,0.00008792058,0.000015045162,0.0013446984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890745,0.00012890433,0.0003217001,0.00023822993,0.00016326057,0.00024048604],"domain_scores_gemma":[0.99931455,0.00007215179,0.00013597903,0.0003312348,0.000065825545,0.000080235295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014645491,0.00016390345,0.00035415147,0.00013801423,0.0002476541,0.000003962138,0.00008122938,0.000102591206,0.00031384875],"category_scores_gemma":[0.00003759179,0.00011995347,0.00009042302,0.0002637946,0.00042309682,0.00005764879,0.000034431483,0.00012768467,0.000019662724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075819495,0.00076192577,0.006174238,0.000021050344,0.00016677809,0.00017587685,0.0024206075,0.0000018777932,0.9880253,0.00038704986,0.00022423257,0.00088286534],"study_design_scores_gemma":[0.0059669614,0.00225593,0.35518318,0.00007700455,0.0013159984,0.0007612759,0.00049567176,0.00009709393,0.6296808,0.00027461638,0.0035851737,0.0003062765],"about_ca_topic_score_codex":0.00024951476,"about_ca_topic_score_gemma":0.00042399514,"teacher_disagreement_score":0.3583445,"about_ca_system_score_codex":0.00006205244,"about_ca_system_score_gemma":0.000118212,"threshold_uncertainty_score":0.48915604},"labels":[],"label_agreement":null},{"id":"W1997469203","doi":"10.1097/qad.0000000000000168","title":"Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1","year":2013,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health","keywords":"Resistance mutation; Reverse transcriptase; Biology; Resveratrol; Mutant; Molecular biology; Virology; Biochemistry; Gene; RNA","score_opus":0.0066362545044426685,"score_gpt":0.20718026145276508,"score_spread":0.20054400694832242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997469203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983452,0.00027873693,0.00011145042,0.005879976,0.000050975017,0.00069262896,0.000011166407,0.00016754899,0.009355499],"genre_scores_gemma":[0.9610518,0.000028473805,0.013192251,0.00036803653,0.0001209407,0.00009438414,0.000047635003,0.000053196993,0.025043264],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984497,0.000041948624,0.000322392,0.00036735882,0.0003757091,0.00044290393],"domain_scores_gemma":[0.9991319,0.000107339554,0.000087189605,0.00029637775,0.00015216609,0.00022500237],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014978755,0.00027127427,0.0003746267,0.00020497556,0.00015165511,0.000056855184,0.00008660904,0.00007299199,0.00096906984],"category_scores_gemma":[0.00011338985,0.0001817302,0.000081132646,0.0004193039,0.00006381401,0.00017627314,0.000045339537,0.00014306017,0.001915313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008034552,0.0009889536,0.62937635,0.00022694608,0.0012570824,0.0005942389,0.002305178,0.000010764478,0.24544676,0.0006648556,0.110059954,0.008265438],"study_design_scores_gemma":[0.020726077,0.0033547739,0.31862864,0.0021590397,0.002025463,0.00018755907,0.0049274745,0.0009481435,0.523234,0.00025455214,0.12066308,0.0028912087],"about_ca_topic_score_codex":0.00006442041,"about_ca_topic_score_gemma":0.0000039997517,"teacher_disagreement_score":0.31074774,"about_ca_system_score_codex":0.00015255902,"about_ca_system_score_gemma":0.00014735812,"threshold_uncertainty_score":0.99994415},"labels":[],"label_agreement":null},{"id":"W1997984013","doi":"10.1371/journal.pone.0113813","title":"Expanding Access to HIV Viral Load Testing: A Systematic Review of RNA Stability in EDTA Tubes and PPT beyond Current Time and Temperature Thresholds","year":2014,"lang":"en","type":"review","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Viral load; Confidence interval; Viremia; Whole blood; Human immunodeficiency virus (HIV); Medicine; RNA; Internal medicine; Immunology; Chemistry; Biochemistry","score_opus":0.08021154708852188,"score_gpt":0.3331097553027567,"score_spread":0.2528982082142348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997984013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009917959,0.98335046,3.3168513e-7,0.00022491957,0.000021560414,0.006086609,0.000058818456,0.00003198468,0.00030733406],"genre_scores_gemma":[0.0002877387,0.9979772,0.0004105391,0.000060735834,0.00006379768,0.0005632075,0.00013514025,0.00004399834,0.0004576725],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99695385,0.00024619157,0.001289545,0.0006016388,0.0006139573,0.00029482247],"domain_scores_gemma":[0.99828804,0.00044021368,0.0003062103,0.00053550047,0.0001989145,0.00023112928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010227625,0.0005344146,0.0049670045,0.00024868923,0.00004892325,0.000057319667,0.00018903243,0.00016414384,0.00004017441],"category_scores_gemma":[0.0014120704,0.00035663694,0.00013895653,0.00049353094,0.000058286252,0.000107268774,0.00025298807,0.0003795179,0.000029475283],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000905304,0.00066839164,0.0017230178,0.99036175,0.00044459393,0.000013224651,0.00016799272,3.1431524e-9,0.0000340898,0.0000028448214,0.00023665046,0.006338409],"study_design_scores_gemma":[0.00049052667,0.00010151812,0.000054583084,0.99197483,0.005942069,0.000022537484,0.000006792044,0.000005040209,0.00007359407,0.000006690115,0.0010048138,0.00031702418],"about_ca_topic_score_codex":0.000003999524,"about_ca_topic_score_gemma":0.0000043925565,"teacher_disagreement_score":0.014626686,"about_ca_system_score_codex":0.00027712478,"about_ca_system_score_gemma":0.0003287045,"threshold_uncertainty_score":0.99988854},"labels":[],"label_agreement":null},{"id":"W1998200336","doi":"10.1155/2012/595762","title":"Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future","year":2012,"lang":"en","type":"article","venue":"AIDS Research and Treatment","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia; Providence Health Care","funders":"","keywords":"Enfuvirtide; Etravirine; Darunavir; Medicine; Raltegravir; Tolerability; Maraviroc; Intensive care medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Pharmacology; Virology; Immunology; Adverse effect","score_opus":0.09518902415624984,"score_gpt":0.3972955165309512,"score_spread":0.30210649237470133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998200336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866031,0.0078278,0.000037548005,0.0012143963,0.000054601795,0.0036120755,0.00010212271,0.000023046967,0.0005253432],"genre_scores_gemma":[0.98889655,0.0036163987,0.0018998866,0.00000678421,0.00052586454,0.000969375,0.00015933142,0.000028151324,0.0038976646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835926,0.00018826059,0.00019085198,0.00031320885,0.00035477645,0.00059365085],"domain_scores_gemma":[0.9986683,0.0005276509,0.000039210536,0.00023971472,0.00017106191,0.00035403113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006060545,0.00022697153,0.00043052877,0.00021861664,0.00019256423,0.000023840732,0.000044073087,0.00008321889,0.000022057975],"category_scores_gemma":[0.000013097664,0.0001419091,0.000087073524,0.0001954115,0.00020602043,0.000118458505,0.000045410074,0.00008958487,0.0000065522004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066518122,0.003121249,0.67457426,0.00026669708,0.0010918126,0.000031094354,0.0013951126,8.934731e-8,0.0034011577,0.0009887862,0.001051865,0.30742604],"study_design_scores_gemma":[0.027087774,0.01394017,0.6304554,0.0001949012,0.0001799854,0.000033778164,0.0013863473,0.000029900442,0.064976886,0.0001742114,0.26125482,0.00028583757],"about_ca_topic_score_codex":0.00007865284,"about_ca_topic_score_gemma":0.000003587262,"teacher_disagreement_score":0.3071402,"about_ca_system_score_codex":0.00016692567,"about_ca_system_score_gemma":0.00008999848,"threshold_uncertainty_score":0.5786885},"labels":[],"label_agreement":null},{"id":"W1998388433","doi":"10.1046/j.1365-2125.2000.00238.x","title":"Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver disease","year":2000,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Nelfinavir; Pharmacokinetics; Medicine; Pharmacology; CYP2C19; Liver disease; Gastroenterology; Internal medicine; Dosing; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Metabolism","score_opus":0.024466734971866064,"score_gpt":0.3377171044572584,"score_spread":0.3132503694853923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998388433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662215,0.002515418,0.000004388361,0.00023834046,0.00012247378,0.0003823434,0.000022844846,0.000007778987,0.000084269195],"genre_scores_gemma":[0.9941297,0.0052205487,0.0001538954,0.00017207052,0.000116074516,0.0000034449638,0.0000094616735,0.00001688202,0.0001778918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982285,0.00023419718,0.00082898216,0.00022238983,0.00023108302,0.00025483896],"domain_scores_gemma":[0.99872607,0.00031749226,0.00035680842,0.00006613142,0.00016525693,0.00036826913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040256738,0.00015147206,0.00063617923,0.00010515827,0.000063061685,0.000013171047,0.0000728504,0.000083152576,0.00045747892],"category_scores_gemma":[0.00014091068,0.00013773193,0.000090786925,0.0001446999,0.0003429927,0.00015077912,0.00004158513,0.0004687965,0.0000021347525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049807825,0.008296077,0.73270094,0.0001082554,0.0002746302,0.001668122,0.000088040724,0.0000325974,0.007643785,5.054191e-7,0.00070762145,0.24349867],"study_design_scores_gemma":[0.029157003,0.0016606407,0.96461344,0.0002688746,0.00044758763,0.00015565316,0.000002828375,0.00028662765,0.0012758622,0.0000073049705,0.0019931167,0.00013106715],"about_ca_topic_score_codex":0.00005522225,"about_ca_topic_score_gemma":0.000044129018,"teacher_disagreement_score":0.2433676,"about_ca_system_score_codex":0.00007259303,"about_ca_system_score_gemma":0.00024079095,"threshold_uncertainty_score":0.56165445},"labels":[],"label_agreement":null},{"id":"W1998720149","doi":"10.2460/ajvr.2004.65.835","title":"Pharmacokinetics of zidovudine in cats","year":2004,"lang":"en","type":"article","venue":"American Journal of Veterinary Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Peter's Hospital","funders":"","keywords":"Pharmacokinetics; Zidovudine; Bioavailability; Volume of distribution; CATS; Crossover study; Chemistry; Plasma concentration; Area under the curve; High-performance liquid chromatography; Oral administration; Pharmacology; Medicine; Human immunodeficiency virus (HIV); Internal medicine; Chromatography; Immunology","score_opus":0.11770166330510942,"score_gpt":0.45951069421993745,"score_spread":0.34180903091482806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998720149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429256,0.00033946012,0.000026923331,0.0041282848,0.000044326196,0.00013545972,0.0000017556156,0.0000032373412,0.0010279668],"genre_scores_gemma":[0.993784,0.000713376,0.0048559355,0.00003578659,0.000078320765,0.000003912008,0.0000017756354,0.000014816579,0.00051206216],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99834365,0.00012347654,0.00045116435,0.0001100724,0.000672596,0.00029901988],"domain_scores_gemma":[0.9990641,0.000107918364,0.00015832987,0.00014111433,0.00034327173,0.00018527554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082603283,0.000095004274,0.00040403253,0.0006678925,0.00002626306,0.0000055969413,0.00014669895,0.00001952369,0.000080735386],"category_scores_gemma":[0.00008342434,0.00007361854,0.00008143666,0.0008330872,0.00034626262,0.000061319515,0.00006304889,0.00040013803,0.000015856762],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010412173,0.0066232462,0.25227255,0.00040793465,0.0010360341,0.029635135,0.0094468165,0.00026797387,0.45475486,0.00017189565,0.0028754822,0.2320959],"study_design_scores_gemma":[0.046952534,0.106985226,0.57094467,0.0046167355,0.00031218966,0.022961183,0.0115717305,0.00010499275,0.17066163,0.0010070635,0.06299448,0.00088755874],"about_ca_topic_score_codex":0.00004409908,"about_ca_topic_score_gemma":0.0000018708344,"teacher_disagreement_score":0.31867212,"about_ca_system_score_codex":0.00023061875,"about_ca_system_score_gemma":0.00042105053,"threshold_uncertainty_score":0.30020767},"labels":[],"label_agreement":null},{"id":"W1999076794","doi":"10.1046/j.1468-1293.2001.00048.x","title":"Assessing the cost‐effectiveness of HAART for adults with HIV in England","year":2001,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Life expectancy; Biostatistics; Public health; Population; Epidemiology; Antiretroviral therapy; Psychological intervention; Viral load; Gerontology; Family medicine; Human immunodeficiency virus (HIV); Internal medicine; Demography; Environmental health","score_opus":0.023146417108468504,"score_gpt":0.31423412432459935,"score_spread":0.29108770721613086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999076794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813838,0.00042128869,0.0029343183,0.009397938,0.000082453,0.001679403,0.0000038809185,0.000027116306,0.0040697814],"genre_scores_gemma":[0.99642015,0.00007889615,0.0006610406,0.00011958756,0.00014334513,0.00020786283,0.0001240454,0.000019719828,0.0022253282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897265,0.00007890004,0.00025400458,0.00020922242,0.00026145205,0.0002237721],"domain_scores_gemma":[0.9988467,0.0006697542,0.00008219779,0.00020992,0.00011377201,0.00007767417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073557865,0.00015570904,0.00042618657,0.00012713147,0.000052904677,0.0000051433294,0.00006128136,0.00004534327,0.000059250822],"category_scores_gemma":[0.00017330563,0.00007611094,0.000032872038,0.00029261055,0.00013397378,0.00006651348,0.000012144047,0.00010838476,0.0000066918824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00388063,0.0004441002,0.9653787,0.00062661624,0.00020181268,0.00027830395,0.006582653,0.00001515219,0.0008960271,0.00018942764,0.0021014423,0.019405138],"study_design_scores_gemma":[0.062139157,0.0010120039,0.8330995,0.009907784,0.00044486174,0.0002912679,0.0037054543,0.0009485038,0.0034439152,0.00011825097,0.0846377,0.00025163384],"about_ca_topic_score_codex":0.000026424297,"about_ca_topic_score_gemma":0.00006318378,"teacher_disagreement_score":0.13227923,"about_ca_system_score_codex":0.000078242294,"about_ca_system_score_gemma":0.000101986705,"threshold_uncertainty_score":0.31037143},"labels":[],"label_agreement":null},{"id":"W1999156037","doi":"10.1371/journal.pone.0059014","title":"Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Università degli Studi di Siena; ACT Government; Sidaction; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Didanosine; Genotyping; Linear discriminant analysis; Statistics; Logistic regression; Human immunodeficiency virus (HIV); Medicine; Genotype; Biology; Mathematics; Genetics; Virology; Viral load; Antiretroviral therapy","score_opus":0.052222742752997826,"score_gpt":0.34057114660174626,"score_spread":0.28834840384874844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999156037","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8553701,0.00021433659,0.13980305,0.0022424096,0.000010790195,0.0021633864,0.000004678046,0.0000635426,0.00012768919],"genre_scores_gemma":[0.4748152,0.000014675639,0.5225356,0.0001574112,0.000054584878,0.0012771337,0.000082916515,0.000019345203,0.0010431232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903494,0.000035325826,0.00024297678,0.00029092238,0.00014815167,0.00024770026],"domain_scores_gemma":[0.9993953,0.000078096135,0.000055904988,0.00024383693,0.0001174788,0.00010935783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030308703,0.000116249365,0.0002394137,0.00017752744,0.00007019857,0.000022802787,0.00006349642,0.000048181,0.000025378868],"category_scores_gemma":[0.00017043052,0.000109595014,0.000022341315,0.0003093343,0.000007498661,0.00015034391,0.000025013345,0.000061166575,0.000038719143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031952528,0.002380229,0.12834322,0.0006397248,0.00022468422,0.0000026154078,0.0031866867,0.000005878373,0.8401667,0.0025008305,0.0003262454,0.021903675],"study_design_scores_gemma":[0.005234476,0.0003006983,0.3027719,0.0018343016,0.00033262922,0.0000012870056,0.00024338448,0.009507418,0.67054385,0.00479438,0.003887471,0.00054823427],"about_ca_topic_score_codex":0.000019722902,"about_ca_topic_score_gemma":0.00011669688,"teacher_disagreement_score":0.38273257,"about_ca_system_score_codex":0.00016200866,"about_ca_system_score_gemma":0.000037530488,"threshold_uncertainty_score":0.44691548},"labels":[],"label_agreement":null},{"id":"W1999579927","doi":"10.1097/01.aids.0000242816.80462.81","title":"Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases","keywords":"Virology; Biology; Reverse transcriptase; Virus; Mutant; Mutation; Protease; Reverse-transcriptase inhibitor; Transmission (telecommunications); Resistance mutation; Drug resistance; Population; Lentivirus; Concordance; Genetics; Viral disease; Sida; Gene; Polymerase chain reaction; Medicine; Enzyme","score_opus":0.005106432506727994,"score_gpt":0.21299697354105893,"score_spread":0.20789054103433094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999579927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99147993,0.001452843,0.0000976116,0.00061421003,0.00003334135,0.00015102523,0.000017655473,0.00004604181,0.006107325],"genre_scores_gemma":[0.98786885,0.000043380733,0.0046470077,0.000113552305,0.000066866785,0.0000080397485,0.000050954022,0.00001909144,0.007182264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922174,0.0000246088,0.00021519506,0.00023362962,0.00008353984,0.00022126964],"domain_scores_gemma":[0.9997097,0.000067067056,0.000036369198,0.0001304422,0.000012526075,0.000043879663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087931,0.00015246653,0.00024616095,0.00009708187,0.000045455316,0.000018747765,0.000041738254,0.00006131909,0.000040938223],"category_scores_gemma":[0.000012073998,0.0001153876,0.000040520386,0.00013690279,0.000052024156,0.00009059703,0.0000149876805,0.000101639525,0.000023086273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012430892,0.00007117258,0.98945016,0.000015835833,0.000044828103,0.000039616076,0.0016073632,5.729881e-7,0.0038185096,0.00019235737,0.00047739132,0.004157884],"study_design_scores_gemma":[0.0060151303,0.00017197474,0.964617,0.00045298363,0.000067372064,0.000005739658,0.00072950806,0.00030650722,0.01562383,0.0033672524,0.008282368,0.00036032806],"about_ca_topic_score_codex":0.00029178167,"about_ca_topic_score_gemma":0.00012670383,"teacher_disagreement_score":0.024833154,"about_ca_system_score_codex":0.000048449354,"about_ca_system_score_gemma":0.000030155501,"threshold_uncertainty_score":0.47053698},"labels":[],"label_agreement":null},{"id":"W1999659324","doi":"10.2174/1874357900701010008","title":"Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy","year":2007,"lang":"en","type":"article","venue":"The Open Virology Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; University of Waterloo; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Etravirine; Reverse transcriptase; Mutation; Virology; Medicine; Reverse-transcriptase inhibitor; Lentivirus; Human immunodeficiency virus (HIV); Antiretroviral therapy; Stop codon; Biology; RNA; Genetics; Gene; Viral load; Viral disease","score_opus":0.0877051675841134,"score_gpt":0.42435104185257894,"score_spread":0.33664587426846554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999659324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88570714,0.000048736456,0.00070998445,0.11054031,0.00012366699,0.00074399746,0.000018089131,0.000009360529,0.0020987072],"genre_scores_gemma":[0.98253757,0.00007010165,0.002802761,0.009221625,0.00007011789,0.000027351076,0.000019246601,0.000017828761,0.0052334066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832994,0.0004692363,0.00060824864,0.00017822029,0.0001698692,0.0002444755],"domain_scores_gemma":[0.9982483,0.00082474813,0.00018981795,0.00037439805,0.000116270145,0.00024651393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035559635,0.00012693927,0.00031621213,0.00016027926,0.0003427767,0.000014616466,0.00030926336,0.00009242339,0.0006295647],"category_scores_gemma":[0.00018477172,0.0000775809,0.00014876573,0.00020546293,0.00017621,0.00004069181,0.000034568428,0.0003161817,0.00020937377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24981138,0.0070311227,0.31966487,0.000012828235,0.0019430417,0.00092556747,0.0077840355,0.00025102607,0.1914877,0.0020009622,0.14631265,0.07277482],"study_design_scores_gemma":[0.010729456,0.0022745095,0.83173066,0.00005120157,0.00021828654,0.00043958027,0.000192836,0.000010922003,0.008375523,0.00043759838,0.14540732,0.00013211787],"about_ca_topic_score_codex":0.0000075689577,"about_ca_topic_score_gemma":0.000038705777,"teacher_disagreement_score":0.51206577,"about_ca_system_score_codex":0.00011585931,"about_ca_system_score_gemma":0.00029147541,"threshold_uncertainty_score":0.68932915},"labels":[],"label_agreement":null},{"id":"W1999838828","doi":"10.1074/jbc.c300523200","title":"Defining a Molecular Mechanism of Synergy between Nucleoside and Nonnucleoside AIDS Drugs","year":2004,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Mechanism (biology); Nucleoside; Pharmacology; Virology; Computational biology; Chemistry; Medicine; Stereochemistry; Biology; Philosophy; Epistemology","score_opus":0.010714689384111391,"score_gpt":0.2427940563641315,"score_spread":0.23207936698002013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999838828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962582,0.0006986728,0.00049469026,0.00087739783,0.000017237358,0.00004818132,0.0000050432654,0.000012155363,0.0015884192],"genre_scores_gemma":[0.9870595,0.00016065662,0.012498283,0.00009684052,0.00006604407,0.0000014197047,0.00000818086,0.000010176139,0.00009890895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989367,0.000015963587,0.0004927997,0.0001496304,0.00022308718,0.0001817801],"domain_scores_gemma":[0.99922824,0.00007582583,0.0002855303,0.00010239031,0.00010112155,0.0002069008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022734712,0.00015720424,0.0005125942,0.000043904944,0.00003271104,0.000008249438,0.00008860227,0.00017573725,0.000055964614],"category_scores_gemma":[0.0001527756,0.00010326781,0.00016317489,0.00010121084,0.0000930924,0.000032907006,0.000059247057,0.00022903229,0.0000035005673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025202113,0.0003476705,0.028914602,0.00015371258,0.0006732121,0.000896002,0.00036756034,0.0000064502415,0.9613216,0.0022974622,0.000045294015,0.0047243913],"study_design_scores_gemma":[0.0026388352,0.00042413746,0.0038710034,0.00037160423,0.00020040393,0.0004552378,0.00033539275,0.0000013080681,0.9863486,0.004906891,0.00030993606,0.00013663205],"about_ca_topic_score_codex":0.0000027808694,"about_ca_topic_score_gemma":5.8168396e-8,"teacher_disagreement_score":0.025043597,"about_ca_system_score_codex":0.00007175859,"about_ca_system_score_gemma":0.00010243434,"threshold_uncertainty_score":0.4211139},"labels":[],"label_agreement":null},{"id":"W2000002965","doi":"10.1016/j.antiviral.2008.09.003","title":"Perspectives on antiviral drug development","year":2008,"lang":"en","type":"review","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Antiviral drug; Drug; Drug resistance; Human immunodeficiency virus (HIV); Drug development; Virology; Transmission (telecommunications); Drug discovery; Medicine; Hepatitis B; Hepatitis C virus; Hepatitis C; Immunology; Biology; Virus; Bioinformatics; Pharmacology; Computer science","score_opus":0.1582562275679278,"score_gpt":0.4559104479425719,"score_spread":0.2976542203746441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000002965","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068916177,0.93000096,0.0000018531744,0.00040465806,0.00011767642,0.0020837737,0.000017761186,0.00012061965,0.06656354],"genre_scores_gemma":[0.0012936163,0.8385057,0.0006492654,0.00001595484,0.00031487393,0.0002901271,0.00025080054,0.00012920049,0.15855049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99384254,0.0006459609,0.00077398814,0.0012912572,0.002149725,0.0012965085],"domain_scores_gemma":[0.9978619,0.0006412752,0.00015267068,0.0007812039,0.00037032246,0.00019257766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010315025,0.0008066288,0.0022765347,0.0016183094,0.000613985,0.00008506882,0.00044211413,0.00036032157,0.00008374966],"category_scores_gemma":[0.0003261353,0.0005668631,0.0006834201,0.001430838,0.00045877736,0.00011616278,0.00034908715,0.0019217543,0.00905573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007744348,0.00096750184,0.00013101863,0.0030115147,0.0007653412,0.0018223047,0.0031253227,1.8664654e-9,0.0000012890265,0.0003807271,0.048286933,0.9414306],"study_design_scores_gemma":[0.00069949194,0.00017189095,0.00006313043,0.012609378,0.00012980672,0.00009330369,0.000700423,8.35524e-7,0.00015414853,0.000010890718,0.9848576,0.0005090544],"about_ca_topic_score_codex":0.000012254859,"about_ca_topic_score_gemma":0.000007854852,"teacher_disagreement_score":0.94092155,"about_ca_system_score_codex":0.0012016558,"about_ca_system_score_gemma":0.0034801601,"threshold_uncertainty_score":0.99967825},"labels":[],"label_agreement":null},{"id":"W2000253496","doi":"10.1111/j.1468-1293.2006.00351.x","title":"Analysis of genotypic and phenotypic clinical cut‐off levels for ritonavir‐boosted saquinavir","year":2006,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Saquinavir; Medicine; Ritonavir; Genotype; Internal medicine; Cohort; Clinical trial; Drug resistance; Protease inhibitor (pharmacology); Oncology; Prospective cohort study; Pharmacology; Viral load; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Biology; Genetics","score_opus":0.12317869402488892,"score_gpt":0.4259068830817296,"score_spread":0.3027281890568407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000253496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027307039,0.99391156,0.00030512502,0.0009357493,0.00029890917,0.0024798831,0.0003393991,0.00006697235,0.0013893461],"genre_scores_gemma":[0.00016907325,0.9655881,0.0016341892,0.00013718086,0.00081967213,0.00023482568,0.0051670377,0.00009977243,0.026150139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99526966,0.0002104622,0.0025148566,0.00094039575,0.00056910893,0.0004955412],"domain_scores_gemma":[0.9963049,0.0013726456,0.00092593324,0.00079252804,0.00024499386,0.0003589476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010859049,0.0007760169,0.007038117,0.0012094564,0.00009505711,0.000008430003,0.00021077698,0.00058754836,0.0003104279],"category_scores_gemma":[0.00040575594,0.0005108347,0.0011509326,0.0014294492,0.00046300574,0.000040812658,0.00008792861,0.00045212114,0.00004174742],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012226762,0.00038182043,0.0032323068,0.01077967,0.009983798,0.000076847464,0.0001488282,2.4347742e-7,8.716232e-7,0.00012528776,0.019367995,0.9557801],"study_design_scores_gemma":[0.003853572,0.00039208969,0.004170444,0.009899845,0.07982757,0.000037210084,0.000028171868,0.000053635624,0.0000010078007,0.000024559726,0.9013506,0.00036128788],"about_ca_topic_score_codex":0.000024878642,"about_ca_topic_score_gemma":0.00004697973,"teacher_disagreement_score":0.95541877,"about_ca_system_score_codex":0.00016644728,"about_ca_system_score_gemma":0.00046619715,"threshold_uncertainty_score":0.99973434},"labels":[],"label_agreement":null},{"id":"W2000279978","doi":"10.1021/jm100432w","title":"Improved Syntheses of 5′-<i>S</i>-(2-Aminoethyl)-6-<i>N</i>-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine","year":2010,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Nucleoside; Fluorescence; Conjugate; Nucleoside transporter; Stereochemistry; Fluorescein isothiocyanate; Transporter; Fluorescein; Isothiocyanate; Biochemistry","score_opus":0.01696478617686045,"score_gpt":0.25913738734892044,"score_spread":0.24217260117206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000279978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721014,0.00070342066,0.00034365655,0.0005617169,0.00009979407,0.0005591275,0.00040407805,0.000006974258,0.000111058835],"genre_scores_gemma":[0.9961605,0.00011471003,0.0033370117,0.000021748414,0.000107750195,0.0000051698657,0.00006962574,0.000026113239,0.00015738676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99695015,0.000045152512,0.001748632,0.00026021627,0.0007489849,0.00024686137],"domain_scores_gemma":[0.9963328,0.0003512148,0.0019975957,0.00035605344,0.00076754706,0.00019476618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071066,0.0003056371,0.0014243843,0.00019342965,0.00005982318,0.0000058580135,0.00025783616,0.00017337671,0.00012515706],"category_scores_gemma":[0.00029111785,0.00019773083,0.00052422576,0.00048197753,0.00060125627,0.00011127845,0.00004390832,0.00042964812,5.645911e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010047022,0.0011604036,0.06928393,0.0016181658,0.0022795086,0.000011939772,0.0014130356,0.000013167943,0.9229539,0.000011193114,0.00012824574,0.0001217965],"study_design_scores_gemma":[0.004849771,0.0006219425,0.100670844,0.0011615368,0.0063619916,0.00004559868,0.0007324793,0.00023747985,0.885147,0.000020278932,0.00003996895,0.000111133566],"about_ca_topic_score_codex":0.000025316493,"about_ca_topic_score_gemma":0.00001217631,"teacher_disagreement_score":0.037806932,"about_ca_system_score_codex":0.000052563555,"about_ca_system_score_gemma":0.00031494568,"threshold_uncertainty_score":0.80632293},"labels":[],"label_agreement":null},{"id":"W2000546717","doi":"10.1021/ml500002n","title":"Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1","year":2014,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Potency; Integrase; Substituent; Human immunodeficiency virus (HIV); Quinoline; Integrase inhibitor; Pharmacology; Chemistry; Virology; Medicine; Stereochemistry; Computational biology; Biology; Biochemistry; In vitro; Antiretroviral therapy; Viral load","score_opus":0.006403068426088089,"score_gpt":0.2256575334010468,"score_spread":0.2192544649749587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000546717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896314,0.00010815675,0.000296352,0.008022898,0.00008733315,0.0001658692,0.000024337029,0.000028976172,0.0016346367],"genre_scores_gemma":[0.99532217,0.00001900793,0.00044456098,0.00064986764,0.0003370174,0.000013782045,0.0002843447,0.000026545387,0.0029026954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829453,0.000019798845,0.0005307984,0.0003170628,0.00055781787,0.0002799663],"domain_scores_gemma":[0.9989149,0.00015931048,0.00024337167,0.00044174647,0.00008261327,0.00015807732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002439443,0.00026207557,0.00059582194,0.00008549532,0.00002817042,0.0000063731964,0.0001395027,0.00009175188,0.00006898116],"category_scores_gemma":[0.00022402462,0.00020038395,0.00014729952,0.00022628979,0.00030200844,0.00009096612,0.000059486396,0.00023739645,0.000030048333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026661583,0.00023484047,0.03573726,0.0009210251,0.0002340378,0.000116026764,0.0010785965,0.0000011436964,0.9478372,0.000008546309,0.013005435,0.0005592905],"study_design_scores_gemma":[0.0033291797,0.0000900982,0.0025813447,0.0011437391,0.00051923376,0.00011621153,0.00053619593,0.000052941457,0.98936653,0.000007892748,0.0020478615,0.00020878487],"about_ca_topic_score_codex":0.000026424159,"about_ca_topic_score_gemma":0.0000015268726,"teacher_disagreement_score":0.041529335,"about_ca_system_score_codex":0.00010601308,"about_ca_system_score_gemma":0.0001278475,"threshold_uncertainty_score":0.817142},"labels":[],"label_agreement":null},{"id":"W2001060128","doi":"10.1097/coh.0b013e3280287a4d","title":"Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies","year":2007,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; McGill University Health Centre; Hôpital Saint-Luc; Royal Victoria Regional Health Centre; Université de Montréal","funders":"","keywords":"Immune system; Cytotoxic T cell; Biology; Epitope; Virology; Viral replication; Virus; Immunology; Viral evolution; Drug resistance; Gene; Antibody; Genome; Genetics","score_opus":0.034165043694071855,"score_gpt":0.31628829638441,"score_spread":0.2821232526903381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001060128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.796428,0.15050901,0.037176605,0.011835091,0.001292615,0.0024479742,0.000029331966,0.000039151662,0.00024218688],"genre_scores_gemma":[0.97856575,0.0018195723,0.012760779,0.0000148796025,0.000075486314,0.00028918803,0.00008757383,0.000020456731,0.0063663027],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881846,0.000059271817,0.0005261798,0.00019130814,0.00019844103,0.00020636484],"domain_scores_gemma":[0.9985197,0.001037483,0.00012602353,0.00019373614,0.00008179131,0.0000412769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020250771,0.00015336761,0.00028066384,0.00012872429,0.00027904767,0.000019400431,0.00008451506,0.000033105134,0.000009157793],"category_scores_gemma":[0.00011417028,0.00008416335,0.000063095,0.00023083512,0.00023866819,0.000045689045,0.0000488213,0.000107305445,0.0000010017367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05636117,0.0057705655,0.05060507,0.0053554676,0.0033656824,0.000007746583,0.36011174,0.00007676343,0.05088216,0.17943189,0.007887041,0.2801447],"study_design_scores_gemma":[0.04720781,0.00016894269,0.21830684,0.0037728816,0.00032652318,0.000014745735,0.018909968,0.0011984876,0.024430344,0.0017582641,0.6831895,0.00071566587],"about_ca_topic_score_codex":0.0000041520866,"about_ca_topic_score_gemma":0.0000063128196,"teacher_disagreement_score":0.6753025,"about_ca_system_score_codex":0.000043605356,"about_ca_system_score_gemma":0.00013917152,"threshold_uncertainty_score":0.3432082},"labels":[],"label_agreement":null},{"id":"W2001120648","doi":"10.1074/jbc.m804882200","title":"Mutations M184V and Y115F in HIV-1 Reverse Transcriptase Discriminate against “Nucleotide-competing Reverse Transcriptase Inhibitors”","year":2008,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Drug Abuse; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Reverse transcriptase; Resistance mutation; Human immunodeficiency virus (HIV); Nucleotide; Virology; Reverse-transcriptase inhibitor; Nucleotidyltransferase; RNA-Directed DNA Polymerase; Biology; Genetics; Polymerase chain reaction; RNA; Gene","score_opus":0.028037055515467715,"score_gpt":0.24757989649102696,"score_spread":0.21954284097555926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001120648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936409,0.0006708914,0.000023340177,0.004005513,0.000079566205,0.00015011012,0.000033513494,0.000021644366,0.0013745044],"genre_scores_gemma":[0.99399406,0.0010188963,0.0031633503,0.00033612992,0.0001547759,0.000005961689,0.0000820974,0.000014363685,0.001230386],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983645,0.000060403585,0.00077943894,0.00025721366,0.00023923151,0.0002991946],"domain_scores_gemma":[0.99914414,0.000084167164,0.00022655958,0.00012477823,0.00009641297,0.00032391615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033096192,0.00025056288,0.0005446719,0.000094095856,0.00011663651,0.00001249861,0.000093585426,0.00017737148,0.00016787866],"category_scores_gemma":[0.00023330514,0.00017591531,0.00022786464,0.00020216226,0.00024714798,0.000119324926,0.00001951403,0.0005264465,0.000009765724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011277308,0.0016885807,0.20418853,0.00035629518,0.00025696398,0.014163766,0.004448645,0.00001533931,0.76191914,0.0000124399385,0.009259773,0.0025628002],"study_design_scores_gemma":[0.0408123,0.0012105961,0.124147944,0.0042796344,0.0011450415,0.013090602,0.020404752,0.00025856937,0.70868665,0.00039326138,0.08345843,0.0021122124],"about_ca_topic_score_codex":0.000004502796,"about_ca_topic_score_gemma":8.1502526e-7,"teacher_disagreement_score":0.08004059,"about_ca_system_score_codex":0.00012795089,"about_ca_system_score_gemma":0.00011865516,"threshold_uncertainty_score":0.7173618},"labels":[],"label_agreement":null},{"id":"W2001182572","doi":"10.1086/605688","title":"Poor Agreement between 2 Assays for Measuring Low Levels of HIV‐1 Viral Load","year":2009,"lang":"en","type":"letter","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Centers for Disease Control and Prevention; Bristol-Myers Squibb","keywords":"Viral load; Medicine; Virology; Human immunodeficiency virus (HIV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Internal medicine","score_opus":0.07607636490388592,"score_gpt":0.35276341850084153,"score_spread":0.2766870535969556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001182572","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13838927,0.0036092307,0.0034542093,0.814578,0.0036908444,0.012324847,0.0076729045,0.0012681284,0.015012575],"genre_scores_gemma":[0.55789876,0.00047024796,0.0010133095,0.34468716,0.027266506,0.000797399,0.0063430644,0.00038070793,0.061142825],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956863,0.00020572841,0.0016717324,0.000867195,0.0009102101,0.00065881805],"domain_scores_gemma":[0.99639404,0.0014284803,0.00065267127,0.0006406747,0.0004970367,0.00038712224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053859357,0.000639596,0.0019754784,0.00023185767,0.00013159527,0.000040068022,0.00021823347,0.0008603582,0.00029017497],"category_scores_gemma":[0.001299664,0.0005348747,0.001459124,0.0001626934,0.00022413212,0.0000792075,0.000092437076,0.0009506676,0.00021256483],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090392,0.0011231616,0.26687604,0.00086153887,0.0018179916,0.00022072977,0.000021887177,0.0000014992772,0.000003873677,0.000007225399,0.70854187,0.020433774],"study_design_scores_gemma":[0.012464182,0.0020889675,0.3604806,0.0022444595,0.007942681,0.000010829068,0.0000101278165,0.000020090503,0.00032467302,0.0016470492,0.61163026,0.0011360617],"about_ca_topic_score_codex":0.000007993904,"about_ca_topic_score_gemma":0.0000053741455,"teacher_disagreement_score":0.46989083,"about_ca_system_score_codex":0.000490901,"about_ca_system_score_gemma":0.001026437,"threshold_uncertainty_score":0.99971026},"labels":[],"label_agreement":null},{"id":"W2001457922","doi":"10.1097/qad.0b013e3283097d0f","title":"Therapeutic monitoring is necessary for the association itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis","year":2008,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Merck Canada","keywords":"Efavirenz; Itraconazole; Pharmacokinetics; Medicine; Dosing; Histoplasmosis; Therapeutic index; Pharmacology; Gastroenterology; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Drug; Antifungal; Viral load; Dermatology","score_opus":0.012382841252274488,"score_gpt":0.24068390180010657,"score_spread":0.22830106054783209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001457922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7766452,0.008978705,0.00002324708,0.21216893,0.00024450853,0.0015070847,0.00004914845,0.000050145372,0.0003330284],"genre_scores_gemma":[0.9182691,0.0032716945,0.001389409,0.045045357,0.0005301351,0.000865476,0.0003220444,0.000114359085,0.030192424],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988082,0.000036177793,0.00023615359,0.00032626776,0.00031165476,0.00028156422],"domain_scores_gemma":[0.99908495,0.00049713417,0.00014450302,0.00016650991,0.00006630396,0.000040611805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110616675,0.00027610126,0.00040032808,0.00014194357,0.00013827045,0.000029010604,0.00005000672,0.00030388508,0.000009204379],"category_scores_gemma":[0.0000217399,0.00017125261,0.000053956348,0.00016454715,0.000045508797,0.000064685046,0.00002471895,0.0004669862,0.0000023105501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016519723,0.000107093554,0.7941851,0.00020171625,0.000919949,0.00029220703,0.004970097,3.4587202e-7,0.000064330845,0.0000034716988,0.14798643,0.05110404],"study_design_scores_gemma":[0.006465979,0.0014333943,0.1652314,0.0013547963,0.0021188054,0.00021782379,0.000952754,0.000093090064,0.0031847707,0.00005605373,0.81809795,0.00079319824],"about_ca_topic_score_codex":0.000046565274,"about_ca_topic_score_gemma":0.0000034883853,"teacher_disagreement_score":0.67011154,"about_ca_system_score_codex":0.00033587788,"about_ca_system_score_gemma":0.00006925205,"threshold_uncertainty_score":0.69834787},"labels":[],"label_agreement":null},{"id":"W2001551451","doi":"10.1097/qai.0b013e31819c2937","title":"A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks","year":2009,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"","keywords":"Lopinavir; Medicine; Ritonavir; Lopinavir/ritonavir; Tolerability; Discontinuation; Regimen; Dosing; Confidence interval; Viral load; Adverse effect; Liter; Internal medicine; Emtricitabine; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.017972374903930798,"score_gpt":0.2866532367496648,"score_spread":0.26868086184573403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001551451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812084,0.0044796728,0.00010582753,0.012721536,0.0001845318,0.00072986196,0.00002206609,0.00003822243,0.0005099228],"genre_scores_gemma":[0.991859,0.0008403741,0.006129296,0.0005622845,0.000031989348,0.0000071368527,0.000013830022,0.00003557591,0.0005204944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955282,0.0002275667,0.0021303198,0.00065093214,0.0007292331,0.0007337438],"domain_scores_gemma":[0.9981321,0.00031659473,0.000615378,0.00048134328,0.00021562379,0.00023895882],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018625214,0.00050250697,0.0015098035,0.0008957902,0.00016684896,0.00010320919,0.00024833358,0.00022119528,0.000014453474],"category_scores_gemma":[0.000639548,0.0004209319,0.00019402835,0.0015249535,0.00022810402,0.0005733175,0.000089033834,0.00034195356,0.000012509898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033620935,0.0049310136,0.7738789,0.00074768136,0.0004162774,0.0076064058,0.054897834,0.00028824265,0.04724447,0.00013557401,0.0011346344,0.07509803],"study_design_scores_gemma":[0.016493775,0.0052168304,0.963374,0.0031146288,0.00017982368,0.00088854466,0.00194676,0.00029726845,0.0066226493,0.0002835237,0.00095791573,0.00062423263],"about_ca_topic_score_codex":0.00015019343,"about_ca_topic_score_gemma":0.000016119631,"teacher_disagreement_score":0.18949515,"about_ca_system_score_codex":0.0005956008,"about_ca_system_score_gemma":0.00051781087,"threshold_uncertainty_score":0.9998242},"labels":[],"label_agreement":null},{"id":"W2001744429","doi":"10.1177/095632020401500402","title":"Mutations and Polymorphisms Associated with Antiretroviral Drugs in HIV-1C-Infected African Patients","year":2004,"lang":"en","type":"article","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fogarty International Center; National Institutes of Health","keywords":"Stavudine; Didanosine; Resistance mutation; Nevirapine; Efavirenz; Zidovudine; Lamivudine; Virology; Reverse transcriptase; Reverse-transcriptase inhibitor; Biology; Viral load; Regimen; Medicine; Internal medicine; Virus; Viral disease; Antiretroviral therapy; Polymerase chain reaction; Genetics; Gene","score_opus":0.0045901976957082825,"score_gpt":0.2143922775556601,"score_spread":0.2098020798599518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001744429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390155,0.000041209838,0.000013439867,0.0015071473,0.000013288513,0.00030429664,0.000023961153,0.00010076445,0.004094367],"genre_scores_gemma":[0.9952667,0.000036217676,0.00039060073,0.00016973812,0.00003238012,0.000023980621,0.00052544405,0.00004381821,0.0035111678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871,0.000014197722,0.0002532837,0.00037778745,0.0002818163,0.00036292875],"domain_scores_gemma":[0.99950564,0.000028715624,0.00011261715,0.00017546555,0.00007171685,0.00010584624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006295173,0.00028950794,0.00037227504,0.00007637123,0.00008185196,0.000028043074,0.00006168802,0.00012115546,0.000056601748],"category_scores_gemma":[0.00003026552,0.00024117836,0.000060908304,0.0004639428,0.00015468657,0.00011689454,0.000016812588,0.000186739,0.000013116674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026917222,0.0011846464,0.9720015,0.000031467727,0.00021680933,0.000052254247,0.002047866,0.0000011206913,0.021832919,0.00001045364,0.00011097103,0.0022408233],"study_design_scores_gemma":[0.024623018,0.00033728863,0.67713034,0.0004070816,0.00011181885,0.000015560212,0.0003426616,0.000031138185,0.29609838,0.00010495318,0.00025683845,0.00054091087],"about_ca_topic_score_codex":0.00004676449,"about_ca_topic_score_gemma":0.000009873602,"teacher_disagreement_score":0.29487115,"about_ca_system_score_codex":0.0002532946,"about_ca_system_score_gemma":0.00015174341,"threshold_uncertainty_score":0.98349684},"labels":[],"label_agreement":null},{"id":"W2002800705","doi":"10.1128/aac.02729-14","title":"Effects of the W153L Substitution in HIV Reverse Transcriptase on Viral Replication and Drug Resistance to Multiple Categories of Reverse Transcriptase Inhibitors","year":2014,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Institute for Health and Care Research","keywords":"Reverse transcriptase; Virology; Biology; RNase H; Nevirapine; Viral replication; Nucleotidyltransferase; Lentivirus; Reverse-transcriptase inhibitor; Enzyme; Nucleoside Reverse Transcriptase Inhibitor; Virus; Genetics; RNA; Biochemistry; Gene; Viral load; Viral disease; Antiretroviral therapy","score_opus":0.005481747144956179,"score_gpt":0.21544446437647868,"score_spread":0.20996271723152252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002800705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900667,0.000044489112,0.00006823312,0.008890798,0.00008684373,0.0007551706,0.000018107476,0.000010470166,0.000059206584],"genre_scores_gemma":[0.99539685,0.00033491227,0.00050113414,0.0018152578,0.00002267504,0.000014279366,0.00002484447,0.000013903539,0.0018761115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991199,0.000055526576,0.00027720124,0.00028549653,0.00012470674,0.00013719944],"domain_scores_gemma":[0.99954736,0.00003167772,0.00008813875,0.0002377166,0.0000345416,0.000060591818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016443328,0.00015581957,0.0002770587,0.00008506418,0.000063583764,0.000006942268,0.000053694665,0.000056161844,0.0000058659093],"category_scores_gemma":[0.00003434093,0.000112675756,0.000064315725,0.00016653289,0.00011340796,0.00005622075,0.0000075675634,0.000074796466,0.0000013508032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032994696,0.0012467676,0.14161623,0.0011739192,0.00014093753,0.000014438312,0.012566985,0.0000050503,0.766473,0.00069132773,0.06809129,0.0046805833],"study_design_scores_gemma":[0.0067466814,0.00008117053,0.086276814,0.0007160723,0.00007969694,0.000002886521,0.00007360503,0.000019099783,0.8533367,0.000040149633,0.052473802,0.00015333708],"about_ca_topic_score_codex":0.00008478461,"about_ca_topic_score_gemma":0.000059324273,"teacher_disagreement_score":0.08686367,"about_ca_system_score_codex":0.000034833443,"about_ca_system_score_gemma":0.00002606291,"threshold_uncertainty_score":0.4594784},"labels":[],"label_agreement":null},{"id":"W2002856951","doi":"10.1021/ja905452f","title":"A Stereoselective Approach to Nucleosides and 4′-Thioanalogues from Acyclic Precursors","year":2009,"lang":"en","type":"article","venue":"Journal of the American Chemical Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Chemistry; Nucleobase; Stereoselectivity; Combinatorial chemistry; Stereochemistry; Organic chemistry; DNA; Catalysis; Biochemistry","score_opus":0.01081318839942581,"score_gpt":0.25482633693350176,"score_spread":0.24401314853407596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002856951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854218,0.00018794865,0.00007758234,0.013123542,0.000019833686,0.00013701375,0.0000032860041,0.000009218954,0.001019804],"genre_scores_gemma":[0.97057164,0.00008233247,0.025687074,0.0031535605,0.00015309942,0.0000020981254,0.000002009631,0.000009295764,0.00033886792],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99912465,0.000031279247,0.0002431082,0.00015127962,0.00027394367,0.00017577081],"domain_scores_gemma":[0.9992829,0.00007757044,0.0002527612,0.00012765665,0.00007175166,0.0001873596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010247527,0.00013502296,0.00040851108,0.00002035541,0.000055291886,0.000019963918,0.00013788046,0.000035011988,0.000007015246],"category_scores_gemma":[0.00006605931,0.00007696168,0.00028255102,0.00027688476,0.00014339334,0.000048486494,0.000044902936,0.00027019175,0.0000044460567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012268488,0.0020766982,0.1709168,0.000029479415,0.0027838598,0.000016279335,0.029159939,0.000005623898,0.59370565,0.000039451053,0.160226,0.039813392],"study_design_scores_gemma":[0.0038702558,0.00085858913,0.7488715,0.00036664144,0.0012814216,0.00038021806,0.0067230104,0.00014635087,0.22637494,0.001911335,0.00867661,0.0005391204],"about_ca_topic_score_codex":0.000017854449,"about_ca_topic_score_gemma":2.952448e-7,"teacher_disagreement_score":0.5779547,"about_ca_system_score_codex":0.00015683133,"about_ca_system_score_gemma":0.000058880494,"threshold_uncertainty_score":0.31384063},"labels":[],"label_agreement":null},{"id":"W2003655730","doi":"10.1310/b6t0-n98j-1j3m-eqpk","title":"Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens","year":2002,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Abacavir; Mycophenolate; Internal medicine; Salvage therapy; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Immunology; Antiretroviral therapy; Chemotherapy; Transplantation","score_opus":0.2900278795689513,"score_gpt":0.4613258626269102,"score_spread":0.1712979830579589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003655730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514665,0.0014100936,0.00003684948,0.010528163,0.00058510527,0.0018575605,0.000098094766,0.00006531607,0.010272192],"genre_scores_gemma":[0.94610083,0.0049482114,0.004584917,0.00014368277,0.00049683877,0.00006431253,0.000040904157,0.000037965547,0.043582328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497813,0.001453886,0.002612948,0.00037001356,0.00032116598,0.00026385227],"domain_scores_gemma":[0.9932697,0.0050099976,0.00071357924,0.00069011445,0.00013230479,0.00018433394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043551037,0.00026052727,0.001673177,0.00006714511,0.00014132613,0.000017591938,0.00009066304,0.00016996455,0.00088072807],"category_scores_gemma":[0.0034844403,0.00013950779,0.00064462825,0.00019708693,0.0002831238,0.00009555439,0.000049847018,0.00016946926,0.00016156754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018611,0.024349289,0.19903322,0.0006953318,0.01868129,0.024101483,0.02125119,0.00011780964,0.004339277,0.0045762933,0.12179425,0.5624496],"study_design_scores_gemma":[0.10157844,0.006198164,0.008705049,0.002596708,0.008143618,0.0064240275,0.0050461,0.0010711682,0.048025522,0.0009927561,0.80989796,0.0013205049],"about_ca_topic_score_codex":0.000030702282,"about_ca_topic_score_gemma":0.000009701094,"teacher_disagreement_score":0.6881037,"about_ca_system_score_codex":0.00007460237,"about_ca_system_score_gemma":0.0001273807,"threshold_uncertainty_score":0.9643355},"labels":[],"label_agreement":null},{"id":"W2003964436","doi":"10.1186/1741-7015-10-34","title":"Novel therapeutic strategies targeting HIV integrase","year":2012,"lang":"en","type":"review","venue":"BMC Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Integrase; Raltegravir; Elvitegravir; Integrase inhibitor; Dolutegravir; Chromatin; Medicine; Virology; Viral replication; Computational biology; Biology; Human immunodeficiency virus (HIV); Genetics; Virus; DNA; Antiretroviral therapy; Viral load","score_opus":0.13857473309661678,"score_gpt":0.3780654544569821,"score_spread":0.2394907213603653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003964436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000019299664,0.98416555,0.0025216648,0.0005773096,0.0006004495,0.0013206304,0.000015301319,0.00016989617,0.010627251],"genre_scores_gemma":[0.000040530704,0.9649766,0.004126225,0.000142026,0.0019180129,0.00021048375,0.0014088228,0.00012814491,0.027049122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969935,0.00011408342,0.0010891977,0.0005672058,0.00059226423,0.00064373796],"domain_scores_gemma":[0.9980124,0.0004467522,0.00042253302,0.00060072355,0.00010601373,0.00041156376],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007498096,0.00085336657,0.002911686,0.00042125795,0.0000998871,0.000021399419,0.00022564756,0.0003550429,0.0015466877],"category_scores_gemma":[0.00015915767,0.00046814993,0.0004288359,0.00046928567,0.00019821484,0.00010199262,0.00007022146,0.00064718496,0.0008521279],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041505646,0.00049303635,0.0002527775,0.03478037,0.0016369907,0.000103908904,0.0009118942,8.781241e-8,0.0000117496165,0.0022041341,0.014833859,0.9447297],"study_design_scores_gemma":[0.0015434381,0.00008809002,0.00002020003,0.024511144,0.007829753,0.00028844347,0.00077995716,0.000004557641,0.0000016222101,0.00002657661,0.96452165,0.00038457802],"about_ca_topic_score_codex":0.00001899949,"about_ca_topic_score_gemma":0.000011584653,"teacher_disagreement_score":0.9496878,"about_ca_system_score_codex":0.00028058156,"about_ca_system_score_gemma":0.0012105141,"threshold_uncertainty_score":0.99992585},"labels":[],"label_agreement":null},{"id":"W2004270155","doi":"10.1135/cccc20061063","title":"Synthesis and Biological Evaluation of Some 4'-C-(Hydroxymethyl)-α- and -β-D-Arabinofuranosyl Pyrimidine and Adenine Nucleosides","year":2006,"lang":"en","type":"article","venue":"Collection of Czechoslovak Chemical Communications","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Deoxycytidine kinase; Pyrimidine; Nucleoside; Thymidine kinase; Purine; Thymidine; Hydroxymethyl; Biochemistry; Chemistry; Kinase; Nucleoside analogue; Adenosine kinase; Cytotoxicity; Purine metabolism; Enzyme; Stereochemistry; Adenosine deaminase; Deoxycytidine; Biology; DNA; In vitro","score_opus":0.04698025935926908,"score_gpt":0.3000911184388823,"score_spread":0.2531108590796132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004270155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876159,0.0059535634,0.000022124512,0.004342662,0.000011712928,0.00045732784,0.000011487919,0.000035237525,0.0015500193],"genre_scores_gemma":[0.99109125,0.002564722,0.005886212,0.000019609486,0.00001799971,0.00010441852,0.000044695156,0.000011322003,0.00025978262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998909,0.00012246598,0.00041783333,0.0002096697,0.00022779594,0.00011322918],"domain_scores_gemma":[0.9986176,0.0005020419,0.00015690734,0.0003911134,0.00025842965,0.00007392604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004159063,0.00014091378,0.0003678183,0.00018152314,0.00013238203,0.0000101955775,0.00008872186,0.00013437791,0.000037765643],"category_scores_gemma":[0.00045141907,0.00012034337,0.00004807764,0.00032223758,0.0004903878,0.0000801217,0.0001383096,0.00012729035,9.3092467e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033656514,0.0011932668,0.07333553,0.00018935688,0.00032855326,8.956143e-7,0.00047935292,0.0000030168228,0.90107536,0.0044912626,0.0016165838,0.016950242],"study_design_scores_gemma":[0.0036060223,0.0001889111,0.10909867,0.00027921892,0.0009287229,0.00008367877,0.00022505589,0.004634501,0.87232965,0.0065671913,0.0017895488,0.00026884844],"about_ca_topic_score_codex":0.000054124997,"about_ca_topic_score_gemma":0.000010421639,"teacher_disagreement_score":0.035763144,"about_ca_system_score_codex":0.0000666873,"about_ca_system_score_gemma":0.00006586918,"threshold_uncertainty_score":0.49074602},"labels":[],"label_agreement":null},{"id":"W2004519011","doi":"10.1016/j.sjbs.2014.12.011","title":"Theoretical investigation of the interactions in binding pocket of Reverse Transcriptase","year":2014,"lang":"en","type":"article","venue":"Saudi Journal of Biological Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Reverse transcriptase; Nevirapine; Molecular dynamics; Molecule; Amino acid; Ligand (biochemistry); Quantum chemical; Combinatorial chemistry; Computational biology; Quantum; Binding pocket; Human immunodeficiency virus (HIV); Chemistry; Computer science; Computational chemistry; Binding site; Physics; Biology; Receptor; Biochemistry; Virology; RNA; Quantum mechanics; Gene","score_opus":0.05055604345489879,"score_gpt":0.30624320917434233,"score_spread":0.25568716571944355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004519011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923886,0.000063169835,0.00004468696,0.006499288,0.000114790506,0.00006408524,0.0000015842103,0.0000014302883,0.00082237914],"genre_scores_gemma":[0.9981293,0.000045733446,0.0016551049,0.00011533933,0.000017913882,6.1128384e-7,5.1477866e-7,8.340588e-7,0.00003466156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991568,0.00014281165,0.0003474938,0.00006873889,0.000195679,0.00008852484],"domain_scores_gemma":[0.9994685,0.00016990992,0.00021064057,0.000044997443,0.00005470091,0.000051225867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00105704,0.000050055565,0.00018591133,0.000099621226,0.000043380493,0.0000036095325,0.00011505061,0.000026271797,0.00019246496],"category_scores_gemma":[0.0004597122,0.000021080506,0.00008723803,0.00035025124,0.00083599496,0.00005458094,0.000015376405,0.000111500034,0.0000012186564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015301125,0.00016949108,0.8585312,0.000018034376,0.000030169682,0.000005546709,0.0008561428,0.0000069402226,0.1182123,0.018202579,0.00031047454,0.0035041582],"study_design_scores_gemma":[0.0020545886,0.0015954905,0.7919013,0.0012497555,0.0001110323,0.00018387251,0.0020581794,0.0002631016,0.16193467,0.036998674,0.0015133056,0.00013601966],"about_ca_topic_score_codex":0.000003397296,"about_ca_topic_score_gemma":0.0000028638292,"teacher_disagreement_score":0.066629834,"about_ca_system_score_codex":0.000022911192,"about_ca_system_score_gemma":0.00006710309,"threshold_uncertainty_score":0.30802584},"labels":[],"label_agreement":null},{"id":"W2004873336","doi":"10.1097/qai.0000000000000002","title":"Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease","year":2013,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of British Columbia; HIV Legal Network; St. Paul's Hospital; St. Michael's Hospital; University of Toronto","funders":"National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Medicine; Cost effectiveness; Quality-adjusted life year; Intensive care medicine; Viral load; Antiretroviral therapy; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Risk analysis (engineering)","score_opus":0.014925295377628293,"score_gpt":0.26571551085700246,"score_spread":0.2507902154793742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004873336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971028,0.00086587155,0.000047641042,0.00014934916,0.00018964273,0.0014581697,0.000018940415,0.00002612889,0.00014143527],"genre_scores_gemma":[0.9977921,0.000110038454,0.0009466195,0.000007988845,0.000012584238,0.00010942175,0.000047766982,0.000047469322,0.00092599296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970565,0.00020883349,0.0010651782,0.00032840695,0.00081763306,0.0005234436],"domain_scores_gemma":[0.9979753,0.00026232665,0.000591473,0.00039715908,0.0004970813,0.00027664183],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041344608,0.0004054575,0.001097677,0.00079820916,0.000095333715,0.000038339625,0.00023167592,0.000077833836,0.00010788775],"category_scores_gemma":[0.00018853265,0.000256004,0.00030141955,0.00090133946,0.00025856987,0.00059957127,0.00004974288,0.000089945446,0.00004690561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035386449,0.0039737048,0.97626364,0.00021193248,0.00033997916,0.0002927288,0.0036693092,0.000052728905,0.0059029483,0.000037501646,0.00004213557,0.0056747734],"study_design_scores_gemma":[0.0142592965,0.0029285655,0.9740061,0.0011321978,0.00025748473,0.000037443893,0.0018274138,0.00010861987,0.0050923782,0.000031656193,0.000040400824,0.0002784238],"about_ca_topic_score_codex":0.000090541274,"about_ca_topic_score_gemma":0.0000012796622,"teacher_disagreement_score":0.010720652,"about_ca_system_score_codex":0.000498244,"about_ca_system_score_gemma":0.00042073824,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W2005214630","doi":"10.7326/0003-4819-153-6-201009210-00002","title":"Sex-Based Outcomes of Darunavir–Ritonavir Therapy","year":2010,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Darunavir; Ritonavir; Internal medicine; Regimen; Adverse effect; Viral load; Confidence interval; Logistic regression; Clinical trial; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.04821574226875196,"score_gpt":0.3682586919071952,"score_spread":0.3200429496384432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005214630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626055,0.00039415414,0.00005666057,0.026665391,0.00037283413,0.0002668631,0.000010824567,0.00002879429,0.009599021],"genre_scores_gemma":[0.9892911,0.00013128179,0.00070122036,0.0027460004,0.0001632839,0.000013027975,0.00002367492,0.00002158535,0.006908845],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845654,0.000025288637,0.00058968936,0.00019756416,0.0005213013,0.00020960743],"domain_scores_gemma":[0.9987306,0.0002049991,0.00023526186,0.00036352902,0.0002960009,0.00016962226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003849687,0.00020902463,0.0007291648,0.00023480841,0.000020337824,0.0000022206575,0.00017510196,0.000084569394,0.0009833754],"category_scores_gemma":[0.00023090279,0.00012618527,0.00016653986,0.00014115579,0.00028766206,0.000042544187,0.000022956629,0.00024796903,0.000019928399],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091957056,0.0010150453,0.8620664,0.00010799971,0.0008537983,0.00011960638,0.00091984257,5.2492084e-7,0.06647001,0.0004197247,0.013992016,0.053115483],"study_design_scores_gemma":[0.008650996,0.0018746884,0.24420065,0.0007874457,0.00010863555,0.000029546933,0.00023582709,0.00005081168,0.68441236,0.0003589643,0.05909374,0.00019634052],"about_ca_topic_score_codex":0.00021286521,"about_ca_topic_score_gemma":0.000025189654,"teacher_disagreement_score":0.61794233,"about_ca_system_score_codex":0.0000072571866,"about_ca_system_score_gemma":0.00009811947,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W2005274373","doi":"10.1097/00126334-200309011-00002","title":"HIV Resistance to Nevirapine and Other Non-Nucleoside Reverse Transcriptase Inhibitors","year":2003,"lang":"en","type":"review","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Nevirapine; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Virology; Drug resistance; Reverse-transcriptase inhibitor; HIV drug resistance; Human immunodeficiency virus (HIV); Lentivirus; Medicine; Nucleoside analogue; Biology; Nucleoside; Gene; Antiretroviral therapy; Viral disease; Sida; Genetics; Viral load; RNA","score_opus":0.0300000668209544,"score_gpt":0.3000444041612817,"score_spread":0.2700443373403273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005274373","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013371501,0.9948252,0.0000698075,0.00077845994,0.0007977496,0.0011395692,0.00006090321,0.000041559728,0.0009496034],"genre_scores_gemma":[0.00027060037,0.96547884,0.0049966,0.0001999419,0.00010583473,0.000041033672,0.00002274607,0.00018427568,0.028700158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99518585,0.00022732932,0.0024779262,0.0005765677,0.0008525125,0.0006797938],"domain_scores_gemma":[0.9973655,0.00016639943,0.0011279234,0.0006469847,0.00023097919,0.0004622526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013409876,0.0008670611,0.0037227855,0.0015707911,0.00019359321,0.000083836036,0.00037809834,0.00034286742,0.00014878133],"category_scores_gemma":[0.0002591513,0.0006225159,0.001130961,0.0016213495,0.00018598227,0.00024704591,0.00006586199,0.00035241235,0.00025099659],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001012147,0.0030079675,0.0009703622,0.053938385,0.0071494514,0.011538974,0.006011658,0.0000037205848,0.00067429326,0.00033920002,0.2063746,0.70897925],"study_design_scores_gemma":[0.0018032225,0.00046348895,0.00008997476,0.03130577,0.0032048996,0.0033435412,0.0002369307,4.399873e-7,0.000054945333,0.000017573306,0.9589117,0.0005675092],"about_ca_topic_score_codex":0.0000047361236,"about_ca_topic_score_gemma":0.0000012560255,"teacher_disagreement_score":0.7525371,"about_ca_system_score_codex":0.0003507312,"about_ca_system_score_gemma":0.0007022388,"threshold_uncertainty_score":0.99962264},"labels":[],"label_agreement":null},{"id":"W2005333158","doi":"10.1007/s40273-013-0048-3","title":"Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Darunavir; Lopinavir; Emtricitabine; Medicine; Ritonavir; Regimen; Lopinavir/ritonavir; Cost effectiveness; Clinical trial; Viral load; Cost-effectiveness analysis; Intensive care medicine; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Risk analysis (engineering)","score_opus":0.06119449999214679,"score_gpt":0.3712327756547588,"score_spread":0.31003827566261205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005333158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94620156,0.00042557082,0.028417926,0.012175271,0.001414122,0.01020662,0.00054091326,0.0002228172,0.0003951828],"genre_scores_gemma":[0.9674586,0.0015993955,0.0026527697,0.0015104383,0.00080207374,0.014690384,0.006225166,0.00013782337,0.004923339],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840283,0.000065961256,0.0004393614,0.00049445,0.00011400631,0.0004834167],"domain_scores_gemma":[0.99722236,0.0017610858,0.00017424344,0.00035027124,0.00027680027,0.00021525075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041442065,0.00036123357,0.00060014875,0.0003396933,0.0003782293,0.000112867376,0.00016523252,0.00009729399,0.00027762118],"category_scores_gemma":[0.000050850074,0.0002800364,0.00046805284,0.00049599155,0.0001036667,0.00024540446,0.00006248547,0.00017975674,0.00018667348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03720695,0.0041095996,0.3379635,0.0024514976,0.105117716,0.00005108831,0.005484933,0.15476625,0.0022673642,0.005021802,0.13973829,0.20582104],"study_design_scores_gemma":[0.028043903,0.00030472598,0.01956046,0.000045784152,0.007099338,0.00001043025,0.00030831966,0.24063854,0.006703539,0.00037148327,0.69629854,0.00061494624],"about_ca_topic_score_codex":0.0005352341,"about_ca_topic_score_gemma":0.00007019162,"teacher_disagreement_score":0.5565603,"about_ca_system_score_codex":0.0007824395,"about_ca_system_score_gemma":0.00020104168,"threshold_uncertainty_score":0.9999652},"labels":[],"label_agreement":null},{"id":"W2005767120","doi":"10.1093/jac/dkf227","title":"Cyclin-dependent kinases as cellular targets for antiviral drugs","year":2002,"lang":"en","type":"review","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale; University of Alberta","keywords":"Cyclin-dependent kinase; Biology; Virology; Herpes simplex virus; Antiviral drug; Kinase; Virus; Viral replication; CDK inhibitor; Cancer; Cell cycle; Cell biology; Genetics","score_opus":0.025576515660532262,"score_gpt":0.3154024202218885,"score_spread":0.28982590456135626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005767120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055681606,0.9940408,0.00013923415,0.0016462881,0.00087358925,0.0015701222,0.0000624047,0.0000345188,0.0010762119],"genre_scores_gemma":[0.00012471397,0.9730994,0.004001915,0.0005535734,0.001368167,0.000013371443,0.00011707058,0.00018240315,0.020539392],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968603,0.000086235494,0.0016099457,0.00041744954,0.0004953916,0.00053063314],"domain_scores_gemma":[0.9974393,0.0001587653,0.001547691,0.00032997385,0.00029666602,0.00022757493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043763593,0.0007702521,0.003397422,0.0005632976,0.00012165765,0.000077713754,0.00033245856,0.00045821012,0.00037182609],"category_scores_gemma":[0.000046384615,0.00054637634,0.002248743,0.00024940542,0.000083479244,0.00013077207,0.000032639084,0.0005939088,0.00016360838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046821026,0.0015842341,0.00001776178,0.007869827,0.0033211366,0.0008594229,0.00046565762,2.1605962e-7,0.00077176426,0.000012462903,0.112153046,0.8724763],"study_design_scores_gemma":[0.004777448,0.00040198627,5.5070143e-7,0.010755699,0.0020897293,0.0007732226,0.000020086725,0.0000011989154,0.008773144,0.000016308995,0.97191757,0.0004730745],"about_ca_topic_score_codex":0.0000025826118,"about_ca_topic_score_gemma":4.551843e-7,"teacher_disagreement_score":0.8720032,"about_ca_system_score_codex":0.0003509832,"about_ca_system_score_gemma":0.0006876063,"threshold_uncertainty_score":0.99969876},"labels":[],"label_agreement":null},{"id":"W2005994369","doi":"10.3851/imp1416","title":"Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"International Development Research Centre; Wellcome Trust","keywords":"Drug resistance; Medicine; Population; Cohort; Internal medicine; Cohort study; Epidemiology; Virology; Immunology; Biology; Genetics; Environmental health","score_opus":0.01668746901360428,"score_gpt":0.26401004703574676,"score_spread":0.24732257802214247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005994369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656653,0.000437218,0.0000024905553,0.0009227248,0.000030329516,0.0007828761,0.000030590138,0.000023302544,0.0012039228],"genre_scores_gemma":[0.99489033,0.0009928236,0.00011929635,0.00018210961,0.000009627235,0.000021779282,0.000053344742,0.000011268375,0.003719424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988187,0.00014630737,0.00030727696,0.00019201708,0.00029727447,0.00023842562],"domain_scores_gemma":[0.9994581,0.000078995305,0.00011122879,0.0002512813,0.00007720774,0.00002323267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024759627,0.00015404142,0.00023685962,0.00015155677,0.00003699879,0.000010311978,0.0001698023,0.000045694123,0.00002880711],"category_scores_gemma":[0.000043695305,0.00009950741,0.000058218935,0.00058435125,0.000044936543,0.000092507245,0.000008555795,0.00012838599,0.000015198088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000411534,0.0019388373,0.9429409,0.0000084377125,0.00005015875,0.000014441501,0.044252563,0.0000029631085,0.0003357386,0.000022201422,0.0010397332,0.008982482],"study_design_scores_gemma":[0.005893519,0.0004138497,0.9903179,0.000099833116,0.00000963173,2.493784e-7,0.00021756992,0.000022290698,0.0019350789,0.00063459546,0.00034884387,0.000106672254],"about_ca_topic_score_codex":0.000024014766,"about_ca_topic_score_gemma":0.000027484017,"teacher_disagreement_score":0.047376957,"about_ca_system_score_codex":0.000051512816,"about_ca_system_score_gemma":0.000074368276,"threshold_uncertainty_score":0.40577942},"labels":[],"label_agreement":null},{"id":"W2006142506","doi":"10.1097/qad.0000000000000606","title":"Dolutegravir inhibits HIV-1 Env evolution in primary human cells","year":2015,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Integrase; Integrase inhibitor; Virology; Drug resistance; Human immunodeficiency virus (HIV); Drug; Biology; Genetics; Pharmacology; Antiretroviral therapy; Viral load","score_opus":0.01974283562679008,"score_gpt":0.25851122048084174,"score_spread":0.23876838485405166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006142506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592131,0.00030684416,0.00009409,0.00066537847,0.00012549995,0.00031878025,0.000004530325,0.000070366455,0.039201442],"genre_scores_gemma":[0.9509208,0.000009231298,0.0026790563,0.0001562131,0.00009882223,0.000027704798,0.00014341214,0.000017787683,0.04594698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989997,0.00003793672,0.00023084448,0.00022157628,0.0002703142,0.00023962234],"domain_scores_gemma":[0.99953187,0.000016568298,0.000038950166,0.00020105537,0.000048470156,0.0001631164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002402061,0.00014178816,0.00023863051,0.00020091423,0.000035256373,0.000009580438,0.00005302189,0.00008325092,0.000054060438],"category_scores_gemma":[0.000017076543,0.00011835404,0.000048752707,0.00025666424,0.0000369229,0.00009286207,0.000043142605,0.00013343846,0.00080405985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017965744,0.0011039644,0.89102805,0.00009143241,0.0001157777,0.00031262691,0.0031310406,0.000008058146,0.03776555,0.002277837,0.057676334,0.006309653],"study_design_scores_gemma":[0.024603698,0.0013140299,0.7711947,0.00072453916,0.0003343534,0.00010595456,0.0013117691,0.00006847864,0.085143484,0.0036855692,0.11048951,0.0010239412],"about_ca_topic_score_codex":0.00005209793,"about_ca_topic_score_gemma":0.00001530561,"teacher_disagreement_score":0.1198334,"about_ca_system_score_codex":0.0005629155,"about_ca_system_score_gemma":0.00019158253,"threshold_uncertainty_score":0.99997395},"labels":[],"label_agreement":null},{"id":"W2006154282","doi":"10.1016/j.inoche.2006.02.024","title":"Molecular interactions of zinc(II) cyclams toward maleate and fumarate anions","year":2006,"lang":"en","type":"article","venue":"Inorganic Chemistry Communications","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Pukyong National University; National Research Foundation","keywords":"Zinc; Chemistry; Organic chemistry","score_opus":0.014174014491283258,"score_gpt":0.26572184316544295,"score_spread":0.2515478286741597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006154282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9425528,0.0010453098,0.00010884074,0.01281696,0.000019400673,0.00020611312,0.000037359092,0.00008117644,0.04313201],"genre_scores_gemma":[0.9876388,0.00031205488,0.0029199345,0.000042692216,0.000019893823,0.000036005134,0.00040013462,0.000019355753,0.008611176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992233,0.000022091439,0.00032459386,0.00017030176,0.00011464158,0.00014506512],"domain_scores_gemma":[0.99864286,0.000060893613,0.00011055089,0.0009871109,0.000119338256,0.0000792444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056607834,0.00014439004,0.00021757987,0.000041837346,0.00019024566,0.000013220642,0.00022197326,0.000062386796,0.0002349964],"category_scores_gemma":[0.00003076194,0.00014353525,0.00006721648,0.00023688658,0.0001693084,0.000055918554,0.00030518282,0.00019973516,0.000020734587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018298531,0.00082400895,0.010646159,0.00009353119,0.0002140782,0.000011486287,0.0006041606,0.000003097348,0.9837351,0.0014381479,0.0018378175,0.00057410926],"study_design_scores_gemma":[0.0020862967,0.000040475923,0.015744552,0.0002550115,0.0005039073,0.00035484083,0.0007410795,0.0003690222,0.9152542,0.00076793,0.06350367,0.00037903374],"about_ca_topic_score_codex":0.000060780116,"about_ca_topic_score_gemma":0.000026946087,"teacher_disagreement_score":0.068480924,"about_ca_system_score_codex":0.00008880332,"about_ca_system_score_gemma":0.00011176975,"threshold_uncertainty_score":0.58531976},"labels":[],"label_agreement":null},{"id":"W2006389041","doi":"10.1097/00126334-200412150-00017","title":"Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 Infection","year":2004,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University","funders":"","keywords":"Resistance mutation; Viremia; Virology; Population; Biology; Mutation; Reverse transcriptase; Virus; Medicine; Genetics; RNA; Gene","score_opus":0.017078848399730284,"score_gpt":0.27033170960417996,"score_spread":0.2532528612044497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006389041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358517,0.0009050007,0.001483911,0.0013244173,0.00028376584,0.0003720453,0.0000053763724,0.000041758984,0.0019985305],"genre_scores_gemma":[0.99174815,0.00026425053,0.0056866957,0.000019145886,0.00002896807,0.000015853955,0.000058974845,0.00003421501,0.0021437441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971659,0.00012665204,0.0014895569,0.00025937217,0.00060797815,0.00035053998],"domain_scores_gemma":[0.9982197,0.00022319108,0.0008472269,0.00025728886,0.00036080673,0.00009174264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009077116,0.00023648221,0.0008353991,0.0011525668,0.00013089283,0.000035733443,0.00014191333,0.000088876994,0.000035951834],"category_scores_gemma":[0.0005100975,0.00021028434,0.00024668194,0.0014156357,0.00011166947,0.0005737816,0.00004100188,0.00016649162,0.000024287025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032272278,0.003925955,0.85108703,0.0010076179,0.0013839286,0.002654642,0.040866762,0.005222598,0.08323756,0.0014069454,0.0008199988,0.005159754],"study_design_scores_gemma":[0.010127342,0.0004410249,0.9645409,0.0020762975,0.00039477542,0.0010464787,0.0022770516,0.00007181194,0.017811643,0.0008391485,0.00008258339,0.0002909296],"about_ca_topic_score_codex":0.000045896926,"about_ca_topic_score_gemma":0.000017508397,"teacher_disagreement_score":0.1134539,"about_ca_system_score_codex":0.00056180154,"about_ca_system_score_gemma":0.00066383113,"threshold_uncertainty_score":0.8575147},"labels":[],"label_agreement":null},{"id":"W2006674154","doi":"10.1310/hct1302-111","title":"Impact of Baseline Virologic, Immunologic, and Demographic Characteristics on Virologic Responses in the Gemini Study","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Division of Chemistry","keywords":"Medicine; Baseline (sea); Immunology; Internal medicine","score_opus":0.2652432090282322,"score_gpt":0.4965311565393695,"score_spread":0.23128794751113735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006674154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958458,0.0005766154,0.0000066182283,0.0015957266,0.00016952236,0.0015631466,0.00004805967,0.000029266419,0.00016524793],"genre_scores_gemma":[0.9972917,0.0013155461,0.00020395088,0.00043740662,0.00026403513,0.00008513729,0.000031842028,0.000012268038,0.00035812554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913455,0.0057931393,0.0018866397,0.00032594756,0.00028363933,0.0003651234],"domain_scores_gemma":[0.9798569,0.018902153,0.0005618391,0.0004899639,0.000054312557,0.0001348464],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028034134,0.00026886418,0.0015577096,0.00021874388,0.000064133834,0.000013520975,0.00015546863,0.00025119516,0.0001952599],"category_scores_gemma":[0.024602104,0.00012516839,0.00040859787,0.00027805206,0.00023572535,0.00004550075,0.00007138513,0.00045224032,0.00005885043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008962499,0.0061510107,0.97526276,0.000007590614,0.0004093967,0.00006465708,0.00041031334,1.6515821e-7,0.00018081076,0.000029393672,0.00068097573,0.007840453],"study_design_scores_gemma":[0.0072306492,0.0049698884,0.98616666,0.000036155943,0.00039930354,0.000016091433,0.00027772173,0.000007716562,0.000021395219,0.00005630957,0.0007006392,0.00011746847],"about_ca_topic_score_codex":0.0000060405464,"about_ca_topic_score_gemma":0.0000017984477,"teacher_disagreement_score":0.013109013,"about_ca_system_score_codex":0.000027683724,"about_ca_system_score_gemma":0.00007275699,"threshold_uncertainty_score":0.9836141},"labels":[],"label_agreement":null},{"id":"W2007284161","doi":"10.1042/bj3480077","title":"Mutational analysis of Lys65 of HIV-1 reverse transcriptase","year":2000,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Enzyme kinetics; Mutant; Enzyme; Mutagenesis; Amino acid; Polymerase; Biology; DNA; Biochemistry; Protein subunit; Lysine; Stereochemistry; DNA polymerase; Active site; Chemistry; RNA; Gene","score_opus":0.010695461238550131,"score_gpt":0.2593516628405988,"score_spread":0.24865620160204865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007284161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996939,0.0003024455,0.000107705135,0.0012576971,0.000019029882,0.000054496413,0.000050361705,0.000005459648,0.0012638208],"genre_scores_gemma":[0.99067104,0.00010598205,0.004610402,0.00008496819,0.000050065246,0.0000014443015,0.00013985464,0.000005975141,0.0043302933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903595,0.000019292533,0.00040206485,0.00010047752,0.0003261875,0.000116002324],"domain_scores_gemma":[0.9995347,0.000027080849,0.0000902289,0.000093899995,0.00010522605,0.00014884997],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000113487826,0.00008694034,0.00032999503,0.00021405517,0.00002264608,0.0000034991492,0.000054651257,0.000055227134,0.0055521056],"category_scores_gemma":[0.00002491224,0.00006646816,0.00031907338,0.00044619376,0.00006923643,0.000030037558,0.0000035641197,0.000104778715,0.000022147651],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002492758,0.0031835856,0.1318196,0.00015425654,0.015427343,0.00063554745,0.0029306512,0.000107811444,0.7255288,0.00015125783,0.097674765,0.019893615],"study_design_scores_gemma":[0.011805521,0.0003238879,0.12599368,0.00043884633,0.017590208,0.0009834039,0.00056015956,0.0011164931,0.81617224,0.00026781662,0.024256526,0.00049118936],"about_ca_topic_score_codex":0.0000026263617,"about_ca_topic_score_gemma":1.767397e-7,"teacher_disagreement_score":0.090643466,"about_ca_system_score_codex":0.00004207328,"about_ca_system_score_gemma":0.00010577151,"threshold_uncertainty_score":0.995357},"labels":[],"label_agreement":null},{"id":"W2007366697","doi":"10.1128/jvi.03353-14","title":"Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase","year":2015,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Raltegravir; Integrase; Elvitegravir; Biology; Virology; Integrases; Integrase inhibitor; Drug resistance; Viral replication; Genetics; Virus; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.009773955372611819,"score_gpt":0.24426872612377967,"score_spread":0.23449477075116784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007366697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551475,0.0009038187,0.00012536581,0.0029062915,0.00023460454,0.0001393512,0.0000025343452,0.0000019466722,0.00017136303],"genre_scores_gemma":[0.99884164,0.00014785623,0.0001810297,0.00002836173,0.00004874693,0.0000026931161,0.0000014550075,0.0000052874116,0.00074290193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910516,0.00011050548,0.00040295586,0.00007828262,0.00018660017,0.00011647473],"domain_scores_gemma":[0.99926287,0.00015360942,0.00027547975,0.00012249086,0.00009752319,0.00008800296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111784044,0.00010338643,0.0004467189,0.00015629757,0.000017753178,0.0000022306303,0.000081662925,0.000068779766,0.000015494046],"category_scores_gemma":[0.00022664893,0.000053900374,0.00008560001,0.00009963124,0.00019255129,0.00003076706,0.000038656246,0.00019305883,0.0000010407383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022590472,0.0015845242,0.93412834,0.00026356708,0.00051593303,0.0002581668,0.0025158995,0.0000061469786,0.052121647,0.0023545471,0.0034009572,0.0005912126],"study_design_scores_gemma":[0.008019156,0.0005401098,0.92699903,0.00050486275,0.00044696624,0.00014172078,0.00015797302,0.000031691754,0.060901064,0.0012725834,0.00090404355,0.000080811486],"about_ca_topic_score_codex":0.00000625999,"about_ca_topic_score_gemma":0.0001223984,"teacher_disagreement_score":0.008779419,"about_ca_system_score_codex":0.00006141046,"about_ca_system_score_gemma":0.00012194281,"threshold_uncertainty_score":0.21979935},"labels":[],"label_agreement":null},{"id":"W2007555548","doi":"10.1097/qad.0b013e3281c61997","title":"Stopping antiretroviral therapy: easier said than done","year":2007,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Medicine; Regimen; Antiretroviral therapy; Viral load; Intensive care medicine; Human immunodeficiency virus (HIV); Pharmacotherapy; Immunology; Bioinformatics; Internal medicine; Biology","score_opus":0.02806436458154884,"score_gpt":0.27795199067191967,"score_spread":0.24988762609037082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007555548","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12972198,0.0049386765,0.00027237672,0.79400504,0.0019436044,0.001818561,0.000053509713,0.000591679,0.06665458],"genre_scores_gemma":[0.02490877,0.00060298614,0.0034476817,0.57721305,0.0063967584,0.000054005293,0.0015237312,0.00019916208,0.38565385],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753153,0.00005979704,0.00040240932,0.0005682528,0.0007209425,0.0007170489],"domain_scores_gemma":[0.99897474,0.00008718134,0.00013848011,0.0005877689,0.0000869996,0.00012482725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022542069,0.0005333296,0.00076867983,0.00047568558,0.00011150569,0.000042558157,0.0001771951,0.0007519986,0.00063894637],"category_scores_gemma":[0.000023366074,0.00040973988,0.00033061634,0.0003327901,0.00009901553,0.00007829883,0.000057585417,0.0012870705,0.00077284337],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008874758,0.00009930733,0.07349698,0.000098054785,0.00076108007,0.0030897197,0.00032702717,2.5689872e-8,0.00015862,0.000015845186,0.8930509,0.028813705],"study_design_scores_gemma":[0.0021831717,0.00047950714,0.0052920156,0.00029768355,0.00022382865,0.000104909544,0.000035366316,0.0000011937802,0.0011712207,0.000026552683,0.9897456,0.00043890422],"about_ca_topic_score_codex":0.00005971524,"about_ca_topic_score_gemma":0.0000020485056,"teacher_disagreement_score":0.3189993,"about_ca_system_score_codex":0.00025666997,"about_ca_system_score_gemma":0.0002057307,"threshold_uncertainty_score":0.99983543},"labels":[],"label_agreement":null},{"id":"W2007864962","doi":"10.1021/jm050255t","title":"Novel 8-Substituted Dipyridodiazepinone Inhibitors with a Broad-Spectrum of Activity against HIV-1 Strains Resistant to Non-nucleoside Reverse Transcriptase Inhibitors","year":2005,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Reverse transcriptase; Chemistry; Nucleotidyltransferase; Virology; Nucleoside Reverse Transcriptase Inhibitor; Virus; Reverse-transcriptase inhibitor; Nucleoside; Lentivirus; Mutant; Broad spectrum; Human immunodeficiency virus (HIV); Stereochemistry; Biology; Viral disease; RNA; Combinatorial chemistry; Biochemistry","score_opus":0.010151953813229447,"score_gpt":0.23769272638091352,"score_spread":0.22754077256768407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007864962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796948,0.00025188798,0.00064738106,0.017107176,0.00014484332,0.00033257244,0.000054881035,0.00002401803,0.0017424427],"genre_scores_gemma":[0.9912355,0.000100836114,0.005867021,0.0002966853,0.0010971788,0.000007729229,0.00002505483,0.000044520573,0.0013254953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99689245,0.000022054188,0.0010208333,0.00033887685,0.0012589673,0.0004668408],"domain_scores_gemma":[0.9978127,0.000058086407,0.00065690913,0.00033760822,0.00029381557,0.00084087276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005350685,0.00041978576,0.00097516645,0.00024675802,0.000088392655,0.000015201232,0.00019728081,0.0001779993,0.00012121636],"category_scores_gemma":[0.00016006248,0.00030826917,0.00028103587,0.0005199066,0.00021951481,0.00020949914,0.000030402973,0.0007236559,0.000009214664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004000308,0.0014765853,0.0018798603,0.00042161852,0.0005672224,0.0012361109,0.0016174893,0.00008335449,0.9742751,0.0000021213737,0.01130127,0.0031389692],"study_design_scores_gemma":[0.012508571,0.00071294844,0.007993823,0.00387038,0.0007878715,0.0011099799,0.0013264017,0.00005207437,0.9588509,0.0000024291148,0.012387351,0.00039723067],"about_ca_topic_score_codex":0.000024970654,"about_ca_topic_score_gemma":0.000029550212,"teacher_disagreement_score":0.01681049,"about_ca_system_score_codex":0.00059982867,"about_ca_system_score_gemma":0.0009653083,"threshold_uncertainty_score":0.99993694},"labels":[],"label_agreement":null},{"id":"W2008170509","doi":"10.1021/jm010226s","title":"Synthesis and Antiviral Activity of Novel 5-(1-Cyanamido-2-haloethyl) and 5-(1-Hydroxy(or methoxy)-2-azidoethyl) Analogues of Uracil Nucleosides","year":2001,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Uracil; Stereochemistry; Thymidine kinase; Medicinal chemistry; Virus; Herpes simplex virus; Virology; Biochemistry; DNA","score_opus":0.027004920555822244,"score_gpt":0.29296066237023616,"score_spread":0.2659557418144139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008170509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939452,0.001716388,0.00019218135,0.0024457483,0.000039423732,0.00010623645,0.000015917016,0.0000091965285,0.0015297334],"genre_scores_gemma":[0.9924954,0.0024163676,0.0038425897,0.00004537613,0.00018222537,0.0000025225606,0.000002894644,0.000021333319,0.0009912482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800646,0.00004924006,0.0007662059,0.00023021067,0.000696488,0.0002513973],"domain_scores_gemma":[0.9978122,0.00062947185,0.0007889811,0.0002008024,0.00028766747,0.00028086212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009190476,0.00027494945,0.0011125195,0.00016933393,0.000054074022,0.000009394741,0.00011925036,0.00017490082,0.00010307187],"category_scores_gemma":[0.00094304176,0.00018651105,0.00015982676,0.00025691587,0.00044744488,0.00015982118,0.000059075945,0.00036576553,4.576173e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028480273,0.001054183,0.06570222,0.0013675091,0.0011044528,0.0007571223,0.0010802725,0.0000017370294,0.8861744,0.000007189536,0.00047531066,0.0394276],"study_design_scores_gemma":[0.0051817857,0.0005589922,0.04208086,0.0022076985,0.0014606917,0.0039670826,0.0016056092,0.00023760225,0.941316,0.000055150947,0.0010802017,0.00024832002],"about_ca_topic_score_codex":0.000035096964,"about_ca_topic_score_gemma":0.000007492824,"teacher_disagreement_score":0.05514163,"about_ca_system_score_codex":0.00007798631,"about_ca_system_score_gemma":0.00027409237,"threshold_uncertainty_score":0.76057},"labels":[],"label_agreement":null},{"id":"W2008177815","doi":"10.1128/aac.00534-08","title":"Interaction Studies of Tipranavir-Ritonavir with Clarithromycin, Fluconazole, and Rifabutin in Healthy Volunteers","year":2008,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Ottawa Hospital; University of Ottawa","funders":"","keywords":"Rifabutin; Ritonavir; Pharmacokinetics; Metabolite; Clarithromycin; Pharmacology; Area under the curve; Fluconazole; Medicine; Internal medicine; Active metabolite; Gastroenterology; Drug interaction; Human immunodeficiency virus (HIV); Antifungal; Immunology; Antiretroviral therapy; Viral load; Dermatology","score_opus":0.031161810015192665,"score_gpt":0.30757071300591854,"score_spread":0.27640890299072585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008177815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163765,0.00032570693,0.000008605745,0.00755286,0.00004432581,0.00029147632,0.000005201646,0.000014519665,0.00011962863],"genre_scores_gemma":[0.9854113,0.010356632,0.0007699104,0.0026823867,0.000027277809,0.000005873406,0.000021347472,0.000017029317,0.000708238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992368,0.000017974144,0.00024016597,0.00023102519,0.00010016796,0.00017382871],"domain_scores_gemma":[0.999712,0.000019955982,0.00006735616,0.000088549474,0.000052154046,0.000059972077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006428559,0.00016191315,0.00037391653,0.00010057096,0.00008046698,0.000005172066,0.000024737115,0.000057853224,0.000025608955],"category_scores_gemma":[0.0000030892154,0.00011961845,0.000028638562,0.00012293062,0.00017649577,0.00007954252,0.000015558559,0.00011143702,0.0000026892071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027335973,0.0007543794,0.9673906,0.00022254315,0.0005430576,0.00011118943,0.007133536,0.0000034905604,0.004130217,0.000020621965,0.009954777,0.007001994],"study_design_scores_gemma":[0.018995048,0.0010207508,0.934143,0.00086469355,0.00010728341,0.0005945321,0.0019101192,0.000112829206,0.021141326,0.000015501915,0.020720115,0.00037479468],"about_ca_topic_score_codex":0.0001686794,"about_ca_topic_score_gemma":0.000077305034,"teacher_disagreement_score":0.03324759,"about_ca_system_score_codex":0.000043984663,"about_ca_system_score_gemma":0.000046660687,"threshold_uncertainty_score":0.4877899},"labels":[],"label_agreement":null},{"id":"W2008295611","doi":"10.1021/cb8001039","title":"Vinylogous Ureas as a Novel Class of Inhibitors of Reverse Transcriptase-Associated Ribonuclease H Activity","year":2008,"lang":"en","type":"article","venue":"ACS Chemical Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health","keywords":"Reverse transcriptase; Ribonuclease; RNase H; Chemistry; Enzyme; Nucleotidyltransferase; Biology; Stereochemistry; Biochemistry; Virology; RNA; Gene","score_opus":0.019856285392927643,"score_gpt":0.25665557782262993,"score_spread":0.2367992924297023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008295611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684525,0.00007216029,0.000008703586,0.001459576,0.00006966799,0.000234055,0.00008929814,0.00003817598,0.0011831004],"genre_scores_gemma":[0.99843293,0.000059740643,0.00038448678,0.00019488456,0.000031583062,0.0000120494215,0.00018079193,0.000015530442,0.0006879825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893045,0.00003959116,0.0003504418,0.00027423256,0.00014227703,0.00026302846],"domain_scores_gemma":[0.99924433,0.00011958562,0.00016635425,0.00020930188,0.000113248454,0.00014716129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009933753,0.00018366936,0.00059353927,0.00008343876,0.000028833267,6.859139e-7,0.000085072585,0.00031485394,0.00008693738],"category_scores_gemma":[0.00037064689,0.00014829337,0.00016885974,0.00022814744,0.00037740968,0.000028387933,0.00003750764,0.00019072308,0.000023397255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065530994,0.0016065427,0.02840234,0.000034538534,0.000261332,0.000048767357,0.000340248,7.811649e-8,0.9648654,0.00011726674,0.0029062321,0.0007619669],"study_design_scores_gemma":[0.0044886684,0.0002993263,0.005625896,0.000060934937,0.00019272204,0.00009161761,0.000034968478,0.000008252729,0.98518425,0.00008476356,0.0037770553,0.00015155267],"about_ca_topic_score_codex":0.00014843685,"about_ca_topic_score_gemma":0.000004388519,"teacher_disagreement_score":0.022776444,"about_ca_system_score_codex":0.00010228668,"about_ca_system_score_gemma":0.00016955519,"threshold_uncertainty_score":0.6047228},"labels":[],"label_agreement":null},{"id":"W2009045054","doi":"10.1097/qad.0b013e328318f148","title":"Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Simon Fraser University","funders":"","keywords":"Interquartile range; Medicine; Cart; Hazard ratio; Regimen; Cohort; Internal medicine; Proportional hazards model; Tuberculosis; Viral load; Pediatrics; Immunology; Human immunodeficiency virus (HIV); Confidence interval; Pathology","score_opus":0.03348925582005062,"score_gpt":0.31678363845375895,"score_spread":0.2832943826337083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009045054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794376,0.00044864448,0.000008122373,0.00043728558,0.00006739533,0.00021268826,0.000001759206,0.000018490613,0.0008618654],"genre_scores_gemma":[0.99571806,0.002115048,0.0010946443,0.00009072019,0.000022002894,0.000012504035,0.00002418652,0.000005736253,0.0009171016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990836,0.00006369194,0.00034446886,0.00015536936,0.00024875914,0.00010414828],"domain_scores_gemma":[0.99955046,0.00021152753,0.00006259537,0.000068611516,0.000073553725,0.000033278597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042168322,0.000086247725,0.00032110084,0.00015561243,0.000036499412,0.0000029149476,0.000032826618,0.00008401995,0.00003497572],"category_scores_gemma":[0.00022758458,0.00006141144,0.0000621972,0.00020910885,0.000119208285,0.00005577669,0.000021854421,0.00011582629,0.000007030872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007354683,0.00043415392,0.9841464,0.0000040078803,0.000095258125,0.000021191143,0.00019407761,9.2128694e-8,0.00004666201,0.00020369374,0.000100651385,0.01468022],"study_design_scores_gemma":[0.0038697016,0.00058183476,0.9949954,0.000012114362,0.000012978092,0.000017073839,0.00002721909,0.000022801358,0.000115788825,0.00015395091,0.0001326236,0.00005850257],"about_ca_topic_score_codex":0.000012713725,"about_ca_topic_score_gemma":8.194818e-7,"teacher_disagreement_score":0.014621717,"about_ca_system_score_codex":0.000035776167,"about_ca_system_score_gemma":0.00009009723,"threshold_uncertainty_score":0.2504286},"labels":[],"label_agreement":null},{"id":"W2009282612","doi":"10.3851/imp1418","title":"Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Simon Fraser University; St. Paul's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Discontinuation; Hazard ratio; Dosing; Nevirapine; Cohort; Logistic regression; Proportional hazards model; Odds ratio; Cohort study; Viral load; Confidence interval; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.022198433971798034,"score_gpt":0.30640844060340283,"score_spread":0.2842100066316048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009282612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952467,0.0006979484,0.000020030224,0.0014205008,0.00003537471,0.0008774142,0.0000018459637,0.000049059174,0.0016511056],"genre_scores_gemma":[0.9945893,0.001004615,0.0006843271,0.00018370993,0.000048282393,0.000004473322,0.000011801815,0.0000134269285,0.0034600303],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989989,0.000048651877,0.00029471877,0.00025120442,0.00021661041,0.00018990785],"domain_scores_gemma":[0.9995527,0.000049528182,0.00007267751,0.00022143491,0.00004272623,0.000060891132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017290938,0.00018354508,0.00042452017,0.00009436966,0.0000673409,0.000011144063,0.00005359778,0.000043922493,0.00002916204],"category_scores_gemma":[0.00001553824,0.00013042045,0.00007300959,0.00019420302,0.000057468253,0.000072789306,0.000012543078,0.0000891743,0.000013587028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029709467,0.0041741035,0.4778872,0.000008431583,0.00042850678,0.00012573438,0.0037872652,3.6288714e-7,0.01711107,0.00009376376,0.0001936658,0.49321893],"study_design_scores_gemma":[0.016190529,0.00209784,0.967194,0.000071414404,0.000084166204,0.0000105610425,0.00023552934,0.000045228473,0.009394214,0.00001766657,0.0045008324,0.0001579934],"about_ca_topic_score_codex":0.000013983147,"about_ca_topic_score_gemma":0.0000024537983,"teacher_disagreement_score":0.49306095,"about_ca_system_score_codex":0.000021420969,"about_ca_system_score_gemma":0.000038832546,"threshold_uncertainty_score":0.5318392},"labels":[],"label_agreement":null},{"id":"W2009325269","doi":"10.1089/aid.2006.0178","title":"Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients","year":2007,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Heart Institute","funders":"Boehringer Ingelheim","keywords":"Ritonavir; Medicine; Nausea; Adverse effect; Internal medicine; Vomiting; Gastroenterology; Pharmacokinetics; Viral load; Diarrhea; Protease inhibitor (pharmacology); Randomized controlled trial; Tolerability; Nelfinavir; Pharmacology; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.056309134312184504,"score_gpt":0.36558009969294003,"score_spread":0.30927096538075555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009325269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972018,0.00032401198,0.0000035621229,0.000032089913,0.00000917486,0.0007635706,0.000015244891,0.000017641274,0.0016329284],"genre_scores_gemma":[0.99838036,0.00022139015,0.00035574025,0.0000062493623,0.000016261314,0.000014295354,0.000068726134,0.000018610384,0.00091836357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836445,0.000059497914,0.00036974114,0.0003025658,0.0004918626,0.00041189237],"domain_scores_gemma":[0.99888295,0.00032293025,0.00007615601,0.00023261344,0.00029479832,0.00019057498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034644853,0.00017874237,0.00044005664,0.0005303074,0.00013004082,0.000013908794,0.00006535246,0.00007755903,0.00006318345],"category_scores_gemma":[0.00012889908,0.00012071705,0.000026348243,0.00059686595,0.0005627148,0.00009953751,0.00005876195,0.00015299772,0.000004000392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005064218,0.0011541903,0.9807653,0.000069996844,0.00014764519,0.000046077792,0.0014045176,8.599582e-8,0.003736464,0.00035861987,0.000033422955,0.0072194533],"study_design_scores_gemma":[0.010807609,0.008660785,0.96119386,0.00025579752,0.0000377262,0.0000034789593,0.00038054452,5.803746e-7,0.017963165,0.000044207478,0.0005459443,0.0001063289],"about_ca_topic_score_codex":0.00041007897,"about_ca_topic_score_gemma":0.0010047142,"teacher_disagreement_score":0.019571476,"about_ca_system_score_codex":0.00011647866,"about_ca_system_score_gemma":0.00012696996,"threshold_uncertainty_score":0.49226984},"labels":[],"label_agreement":null},{"id":"W2009419809","doi":"10.1128/aac.00348-13","title":"Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; National Institute for Health and Care Research","keywords":"Rilpivirine; Etravirine; Reverse transcriptase; Reverse-transcriptase inhibitor; Virology; Human immunodeficiency virus (HIV); Resistance mutation; Nucleoside Reverse Transcriptase Inhibitor; Mutation; Drug resistance; Biology; Genetics; Sida; Viral disease; Antiretroviral therapy; RNA; Gene; Viral load","score_opus":0.004679426358660938,"score_gpt":0.2260923867380987,"score_spread":0.22141296037943775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009419809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804605,0.00002975818,0.0000737414,0.010876614,0.000025474057,0.0007793056,0.00009441617,0.000009343901,0.00006532069],"genre_scores_gemma":[0.99714977,0.00022988241,0.00032946776,0.001268851,0.000011184493,0.00003112912,0.0001156888,0.000019898469,0.00084410666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992471,0.000060049988,0.00024448335,0.00022671833,0.0000893694,0.00013231291],"domain_scores_gemma":[0.99961567,0.000074689786,0.00008761508,0.00011283365,0.000040363597,0.00006882957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001137321,0.00018508565,0.00027716567,0.00013893301,0.000089424095,0.000015257071,0.000027532356,0.000037747017,0.000059717117],"category_scores_gemma":[0.000005953531,0.00011650446,0.00004227496,0.00014369577,0.000078593155,0.000108022985,0.0000079626125,0.000090386704,0.0000029256184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077683856,0.0011697179,0.25878203,0.0011379233,0.0006899998,0.0001053156,0.05683342,0.00004116047,0.61887604,0.000058861122,0.026953876,0.027583249],"study_design_scores_gemma":[0.0178227,0.0017832782,0.3540723,0.0027544782,0.00035359428,0.00012126317,0.0021408307,0.00009832951,0.6129869,0.000013047147,0.0074163196,0.00043694212],"about_ca_topic_score_codex":0.00018984235,"about_ca_topic_score_gemma":0.00027769772,"teacher_disagreement_score":0.09529026,"about_ca_system_score_codex":0.000037299927,"about_ca_system_score_gemma":0.000012047808,"threshold_uncertainty_score":0.4750914},"labels":[],"label_agreement":null},{"id":"W2009692041","doi":"10.1097/qad.0b013e3283229f81","title":"Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men","year":2009,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Ritonavir; Internal medicine; Medicine; Randomized controlled trial; Human immunodeficiency virus (HIV); Virology; Gastroenterology; Viral load; Pharmacology; Immunology; Antiretroviral therapy","score_opus":0.014128864552742761,"score_gpt":0.27113573933764085,"score_spread":0.2570068747848981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009692041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929021,0.000121694735,0.000141702,0.0036385707,0.000015013958,0.00067172426,0.0000116838355,0.00024581893,0.0022516723],"genre_scores_gemma":[0.9875062,0.000041917036,0.007846362,0.00075827545,0.000025101608,0.00011314865,0.00006146975,0.000014888014,0.0036326095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822015,0.0001395612,0.00031001962,0.00050621654,0.00028914976,0.0005349172],"domain_scores_gemma":[0.9990581,0.0001572093,0.00005288784,0.00028075796,0.00008102592,0.0003699883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019741528,0.00032439723,0.00057068287,0.00016342248,0.0001749479,0.000038023696,0.0001098563,0.0001507076,0.00020352818],"category_scores_gemma":[0.00012922876,0.00020943017,0.000045244855,0.00046333362,0.00021106086,0.00009779455,0.000050786835,0.00021907779,0.000093558396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029125249,0.0036519764,0.7125718,0.000027961258,0.00094290357,0.003031842,0.01773981,0.000033052558,0.18626387,0.0005045744,0.0025009494,0.043606002],"study_design_scores_gemma":[0.007831703,0.00562613,0.96693224,0.000093429255,0.00011118567,0.00025654427,0.0029573513,0.00036696089,0.009420489,0.000072350005,0.0058295988,0.0005019961],"about_ca_topic_score_codex":0.000008072764,"about_ca_topic_score_gemma":0.0000014360457,"teacher_disagreement_score":0.25436047,"about_ca_system_score_codex":0.0001455176,"about_ca_system_score_gemma":0.000096097276,"threshold_uncertainty_score":0.85403144},"labels":[],"label_agreement":null},{"id":"W2009957327","doi":"10.1128/jvi.00335-13","title":"Replication Fitness of Multiple Nonnucleoside Reverse Transcriptase-Resistant HIV-1 Variants in the Presence of Etravirine Measured by 454 Deep Sequencing","year":2013,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"National Institute of General Medical Sciences; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Etravirine; Reverse transcriptase; Biology; Virology; Viral replication; Reverse-transcriptase inhibitor; Replication (statistics); Reverse genetics; Virus; Genetics; Gene; RNA; Genome","score_opus":0.022275882550339767,"score_gpt":0.2566462376537658,"score_spread":0.23437035510342605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009957327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919622,0.00042104343,0.0006547927,0.006352557,0.00006153143,0.00036371566,0.0000119928445,0.000003293906,0.00016888595],"genre_scores_gemma":[0.9970177,0.00011201752,0.002403352,0.00017863896,0.000026372225,0.000013237982,0.000010089489,0.000009717853,0.00022890573],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99837744,0.00020456252,0.00077806524,0.00014790616,0.00032254538,0.00016944975],"domain_scores_gemma":[0.99866754,0.00020631746,0.0004975551,0.00033344983,0.00023059014,0.00006452015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009001715,0.00011390768,0.0004314746,0.00015499299,0.000025895613,0.0000040220084,0.0001899797,0.000089622525,0.00011180679],"category_scores_gemma":[0.00044402602,0.000073336254,0.00009565132,0.00019161851,0.0001000204,0.00012507472,0.000011890345,0.00021677211,0.0000056811446],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006912672,0.00044055877,0.03736577,0.000074167816,0.000151409,0.000085265114,0.0029184239,0.000052050877,0.95256525,0.000036501035,0.004596953,0.0010224083],"study_design_scores_gemma":[0.0152387675,0.0019301975,0.7591007,0.00066982885,0.0007198855,0.0009205882,0.0033191945,0.0026716078,0.20950645,0.00060371886,0.0050088214,0.00031024287],"about_ca_topic_score_codex":0.00016217612,"about_ca_topic_score_gemma":0.00006112922,"teacher_disagreement_score":0.7430588,"about_ca_system_score_codex":0.00007973611,"about_ca_system_score_gemma":0.00011614531,"threshold_uncertainty_score":0.29905656},"labels":[],"label_agreement":null},{"id":"W2010101309","doi":"10.7448/ias.15.6.18283","title":"Novel Kivexa‐based regimens in early courses of treatment for HIV infection","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Infectious Diseases Centre","funders":"","keywords":"Medicine; Maraviroc; Regimen; Abacavir; Raltegravir; Atazanavir; Viral load; Internal medicine; Ritonavir; Lamivudine; Pharmacology; Surgery; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Hepatitis B virus; Virus","score_opus":0.03276478979184281,"score_gpt":0.309353608662204,"score_spread":0.2765888188703612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010101309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911312,0.0000799822,0.0018828186,0.0058574476,0.0005705901,0.00022001292,0.000018306942,0.000004118803,0.00023555408],"genre_scores_gemma":[0.9827282,0.000043856053,0.012330859,0.0001584064,0.00027347569,0.000011730524,0.0000064524415,0.00000948951,0.004437522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991801,0.000013745019,0.00033301825,0.000058977676,0.00029427206,0.00011990601],"domain_scores_gemma":[0.99917203,0.000120669785,0.00033336144,0.00007796739,0.00024227188,0.00005370073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003107491,0.00009475665,0.0002034217,0.00007059289,0.00003216168,0.000007533106,0.000083934545,0.00004666098,0.000027257769],"category_scores_gemma":[0.00006422441,0.000056084573,0.0004500118,0.000092225426,0.00003648976,0.00012413623,0.000016790318,0.00008750231,0.000002128772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002458144,0.0013920846,0.9815372,0.000019057461,0.0008172733,9.199353e-7,0.0018460035,0.00013318371,0.007728177,0.000325919,0.005363082,0.00059128535],"study_design_scores_gemma":[0.017382286,0.0011418513,0.8593627,0.0006215668,0.00065537164,0.00015139829,0.0005120921,0.0011259374,0.07158503,0.00017197223,0.047106657,0.00018308751],"about_ca_topic_score_codex":0.000031221534,"about_ca_topic_score_gemma":0.0000062094114,"teacher_disagreement_score":0.12217446,"about_ca_system_score_codex":0.0007753023,"about_ca_system_score_gemma":0.00021239837,"threshold_uncertainty_score":0.22870626},"labels":[],"label_agreement":null},{"id":"W2010128338","doi":"10.1097/qad.0b013e3280187505","title":"Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations","year":2007,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"GlaxoSmithKline","keywords":"Reverse transcriptase; Resistance mutation; Virology; Biology; Nucleoside Reverse Transcriptase Inhibitor; Virus; RNA; Reverse-transcriptase inhibitor; Viral replication; Molecular biology; Genetics; Gene","score_opus":0.010974031749870878,"score_gpt":0.2567079742645271,"score_spread":0.2457339425146562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010128338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814219,0.0007672683,0.0010967432,0.0044252835,0.000077395416,0.00035547974,0.000013362461,0.000032610667,0.011809971],"genre_scores_gemma":[0.9719085,0.000032877924,0.004410608,0.00021663812,0.000021785001,0.00001012817,0.000028280418,0.000009926114,0.023361262],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991895,0.000028456017,0.00025830176,0.00015679785,0.00018908651,0.00017788657],"domain_scores_gemma":[0.999421,0.00020410212,0.000058687518,0.0001791819,0.000058445017,0.00007856842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004938374,0.000102356564,0.00018791495,0.00007778004,0.000120087745,0.000007458837,0.0000519441,0.000028781826,0.000053273907],"category_scores_gemma":[0.00008690804,0.0000682933,0.00005197388,0.00022790968,0.00014433876,0.000045641304,0.000010494091,0.00008573822,0.00001226088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030408367,0.0018440384,0.72160476,0.0006086814,0.0011027327,0.0011527196,0.14130084,0.000006711376,0.01632181,0.03405409,0.05056434,0.028398426],"study_design_scores_gemma":[0.031707034,0.0011915014,0.33988273,0.001735662,0.0031581,0.00020194877,0.070317134,0.0002167988,0.11533987,0.0019384656,0.4329558,0.001354957],"about_ca_topic_score_codex":0.000012066753,"about_ca_topic_score_gemma":0.000025421683,"teacher_disagreement_score":0.38239145,"about_ca_system_score_codex":0.000029604103,"about_ca_system_score_gemma":0.000060301492,"threshold_uncertainty_score":0.278492},"labels":[],"label_agreement":null},{"id":"W2010135166","doi":"10.1155/2012/760706","title":"HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury","year":2012,"lang":"en","type":"article","venue":"International Journal of Hepatology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MaRS; University of Toronto","funders":"","keywords":"Medicine; Intensive care medicine; Population; Drug; Pneumonia; Adverse effect; Immunology; Internal medicine; Pharmacology","score_opus":0.027021354622270323,"score_gpt":0.3027042173718396,"score_spread":0.27568286274956927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010135166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942855,0.0012741055,0.00015416667,0.003180902,0.00042760538,0.00007360386,0.0000032083976,0.000009934531,0.00059097516],"genre_scores_gemma":[0.99383384,0.00066338776,0.0040471056,0.00041399014,0.0003530912,0.0000025836302,0.000005933452,0.000011260406,0.00066883094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990462,0.000052876097,0.0003505993,0.00008190125,0.000277874,0.00019055158],"domain_scores_gemma":[0.99924093,0.000089357025,0.00022606734,0.00006408075,0.00023059548,0.00014894239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019363004,0.000120616096,0.0002884399,0.00024860678,0.00002621253,0.000013100988,0.000101480815,0.000042794356,0.00026058336],"category_scores_gemma":[0.00010099273,0.000088218054,0.00008361092,0.000044726774,0.00005646977,0.00016903886,0.000035480523,0.00018680084,0.000053160064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063636,0.00029228968,0.980296,0.0000051421357,0.00030994375,0.00047958095,0.00027717027,3.168866e-8,0.0030901744,0.00052529736,0.0026606903,0.011427277],"study_design_scores_gemma":[0.009861131,0.0030453973,0.84937793,0.00048967043,0.00033093977,0.076114446,0.00038787967,0.00019029224,0.01576009,0.0003015423,0.043764435,0.00037626256],"about_ca_topic_score_codex":0.000010007119,"about_ca_topic_score_gemma":8.4905054e-7,"teacher_disagreement_score":0.13091813,"about_ca_system_score_codex":0.00009550372,"about_ca_system_score_gemma":0.00012217139,"threshold_uncertainty_score":0.3597428},"labels":[],"label_agreement":null},{"id":"W2010586460","doi":"10.1128/aac.44.4.1117-1118.2000","title":"Antiretroviral-Drug Concentrations in Semen","year":2000,"lang":"en","type":"letter","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Semen; Pharmacokinetics; Drug; Antiretroviral drug; Human immunodeficiency virus (HIV); Pharmacology; Medicine; Antiretroviral therapy; Virology; Viral load; Andrology","score_opus":0.01111691687139277,"score_gpt":0.2465847437772471,"score_spread":0.23546782690585433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010586460","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25109363,0.00008711491,0.0000017416291,0.7440631,0.00013442269,0.0007095773,0.000061165876,0.0000543749,0.0037948827],"genre_scores_gemma":[0.025337355,0.006567043,0.00031334063,0.8503795,0.00085079897,0.000020171326,0.0014777326,0.00008171699,0.114972316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848837,0.0000338725,0.00036728388,0.00048208953,0.00019415401,0.00043423133],"domain_scores_gemma":[0.99956965,0.000018141527,0.0000885917,0.00023087347,0.000026103708,0.00006663239],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000052493597,0.00038715938,0.0005669676,0.00017268202,0.00008788367,0.00006151501,0.0000921001,0.00034464625,0.0011932024],"category_scores_gemma":[0.0000017475439,0.00032927105,0.00012388128,0.0001627361,0.00009235428,0.0000674802,0.000017061991,0.0005714119,0.00009749223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005840063,0.00015823463,0.04154945,0.00009716734,0.0001877159,0.00054741814,0.00064371206,1.7382622e-7,0.00013628289,0.0000017107103,0.95135707,0.005262661],"study_design_scores_gemma":[0.0034702725,0.000044502736,0.0069215805,0.0003203877,0.00008387795,0.00004839414,0.000013277154,0.000012845553,0.0007733319,0.000010797654,0.9879732,0.0003275061],"about_ca_topic_score_codex":0.00007934016,"about_ca_topic_score_gemma":0.000012984826,"teacher_disagreement_score":0.22575627,"about_ca_system_score_codex":0.00008984915,"about_ca_system_score_gemma":0.00011856289,"threshold_uncertainty_score":0.99991596},"labels":[],"label_agreement":null},{"id":"W2010706007","doi":"10.1074/jbc.m109.024026","title":"Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase","year":2009,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Reverse transcriptase; Virology; Human immunodeficiency virus (HIV); Mutation; Resistance mutation; Biology; Genetics; RNA; Gene","score_opus":0.013271226257027651,"score_gpt":0.2400374878360745,"score_spread":0.22676626157904686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010706007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978967,0.00020375225,0.00033630268,0.019075926,0.000014614452,0.00013130106,0.000013177575,0.0000108866025,0.0012470424],"genre_scores_gemma":[0.992792,0.000035086847,0.0013359186,0.0008871603,0.000024498568,0.000003461365,0.000036386915,0.0000039191,0.0048815385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918467,0.000033253462,0.00029938327,0.000118197415,0.0002081963,0.00015631311],"domain_scores_gemma":[0.9995266,0.000055548317,0.00014749788,0.00007945695,0.00007452297,0.00011637512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029418233,0.000114797076,0.00024724338,0.000020907395,0.000034936653,0.00000952871,0.000088808956,0.000099215686,0.00007896534],"category_scores_gemma":[0.00019711992,0.000056351862,0.00006672631,0.00019023118,0.000027459257,0.00003155259,0.000004364045,0.0002341517,0.000004292824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028846965,0.0011951369,0.005871617,0.000022806125,0.00019289595,0.0019001352,0.0006643993,0.0000107287715,0.9412404,0.00003269468,0.044211816,0.0017726829],"study_design_scores_gemma":[0.012932326,0.0016919369,0.09475801,0.0012992774,0.0003083164,0.00065501535,0.0016518099,0.000016210337,0.8626172,0.0020303465,0.021493504,0.00054606993],"about_ca_topic_score_codex":4.1400884e-7,"about_ca_topic_score_gemma":0.0000013564437,"teacher_disagreement_score":0.088886395,"about_ca_system_score_codex":0.00016050291,"about_ca_system_score_gemma":0.000055597447,"threshold_uncertainty_score":0.22979622},"labels":[],"label_agreement":null},{"id":"W2011309585","doi":"10.1002/jcc.10176","title":"A density functional study of the hydrogen‐bond network within the HIV‐1 protease catalytic site cleft","year":2003,"lang":"en","type":"article","venue":"Journal of Computational Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Université de Montréal; Compute Canada","funders":"","keywords":"Protonation; Chemistry; Active site; Catalytic triad; Catalysis; Protease; Hydrogen bond; HIV-1 protease; Monomer; Acetic acid; Amine gas treating; Interaction energy; Stereochemistry; Crystallography; Computational chemistry; Enzyme; Molecule; Organic chemistry","score_opus":0.01141239819425463,"score_gpt":0.2297339720388085,"score_spread":0.21832157384455386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011309585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979976,0.00010110283,0.00011130613,0.0009053342,0.00008487138,0.00027172908,0.000003165189,0.0000046565574,0.0005202712],"genre_scores_gemma":[0.997567,0.00000100003,0.00069658796,0.0001023477,0.0001821979,0.0000050593567,0.00001260074,0.000009427397,0.0014237864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985489,0.000053211726,0.00048361142,0.00010687759,0.0006976562,0.00010973217],"domain_scores_gemma":[0.99880457,0.00013072349,0.00048231267,0.0001432482,0.0003484262,0.000090714566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043259832,0.0001245609,0.00022859538,0.000019779256,0.00015090195,0.000011482689,0.00009079526,0.000038441383,0.000056593657],"category_scores_gemma":[0.00012343656,0.0000683491,0.00014189114,0.00019976978,0.000067717316,0.00004029833,0.00002831214,0.00027799731,0.000007953174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007913576,0.0031591689,0.7316615,0.00016292353,0.0019048669,0.00023864902,0.0033157412,0.24246146,0.0023170405,0.00010870204,0.013743543,0.00013505778],"study_design_scores_gemma":[0.027581584,0.0006821046,0.8533248,0.0010794675,0.0033520644,0.011689643,0.0063180113,0.0042870045,0.070315875,0.014692962,0.005845117,0.0008313642],"about_ca_topic_score_codex":0.000001235957,"about_ca_topic_score_gemma":0.0000013482646,"teacher_disagreement_score":0.23817445,"about_ca_system_score_codex":0.00009924812,"about_ca_system_score_gemma":0.00061144005,"threshold_uncertainty_score":0.27871957},"labels":[],"label_agreement":null},{"id":"W2012176284","doi":"10.1097/00002030-200312050-00010","title":"Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies","year":2003,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Nucleoside Reverse Transcriptase Inhibitor; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Observational study; Reverse transcriptase; Antiretroviral therapy; Virology; Medicine; Human immunodeficiency virus (HIV); Protease; Lentivirus; Viral disease; Viral load; Internal medicine; Biology; Enzyme; RNA; Genetics","score_opus":0.08234275748098312,"score_gpt":0.3157285010397512,"score_spread":0.23338574355876807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012176284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957549,0.00030570742,0.000004531756,0.002301958,0.00003984575,0.0015120483,0.000016079526,0.000012089564,0.000052850173],"genre_scores_gemma":[0.9966232,0.00015089454,0.0019465516,0.0002975962,0.000019992021,0.00028922543,0.000023803559,0.0000135765085,0.00063517067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988676,0.00016142978,0.0003172975,0.00025845045,0.0002225577,0.00017268801],"domain_scores_gemma":[0.9995297,0.00017534559,0.00007976734,0.00010656552,0.000063140105,0.000045432407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002723206,0.00021651482,0.00040210862,0.0002477387,0.00006240024,0.000012010504,0.00002332099,0.000059346792,0.0000069944626],"category_scores_gemma":[0.00011069801,0.00012838098,0.000057319125,0.00037105352,0.00009866556,0.00014681715,0.0000048863826,0.00009913082,0.0000010788617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052788306,0.00094205467,0.9851447,0.000062667714,0.00017257831,0.000038700207,0.0045493054,0.0000020353716,0.0045698155,0.000114930655,0.00015777907,0.0037175654],"study_design_scores_gemma":[0.01655362,0.0026618289,0.89496624,0.00023992252,0.00014022659,0.000010749063,0.003425534,0.0000747111,0.080231346,0.00008237747,0.0013978002,0.00021562791],"about_ca_topic_score_codex":0.000089406705,"about_ca_topic_score_gemma":0.000052713232,"teacher_disagreement_score":0.09017843,"about_ca_system_score_codex":0.00016908749,"about_ca_system_score_gemma":0.00018651284,"threshold_uncertainty_score":0.5235225},"labels":[],"label_agreement":null},{"id":"W2012639630","doi":"10.1097/qad.0b013e32835d9f6d","title":"Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline","year":2012,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Rilpivirine; Etravirine; Virology; Reverse transcriptase; Biology; Resistance mutation; Reverse-transcriptase inhibitor; Drug resistance; Genotype; Efavirenz; Virus; Viral load; Gene; Polymerase chain reaction; Genetics","score_opus":0.02318042712319964,"score_gpt":0.2842067913414958,"score_spread":0.26102636421829617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012639630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954724,0.00035843684,0.0003302614,0.0021911212,0.000113510134,0.00042584928,0.00010214305,0.000050274713,0.00095605163],"genre_scores_gemma":[0.98546743,0.000026576192,0.0040112883,0.00095382606,0.00014157555,0.00007276586,0.00012908934,0.000029850495,0.009167623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877864,0.000059649465,0.00034372276,0.0002617884,0.00019894014,0.0003572464],"domain_scores_gemma":[0.9992686,0.00013271668,0.000043915836,0.00019843166,0.000040028113,0.00031630337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034823484,0.00020084217,0.00030788526,0.00024148404,0.00009070909,0.000011937253,0.000039752435,0.000049605056,0.00029577228],"category_scores_gemma":[0.00016714558,0.00017656606,0.000047332687,0.00031541038,0.00004195659,0.00015470212,0.00004147119,0.000116611525,0.00009472117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000473314,0.00029507466,0.9865328,0.00007559309,0.000054463828,0.00020705975,0.0025459072,5.74134e-7,0.004856765,0.00012861544,0.0026374215,0.0021923895],"study_design_scores_gemma":[0.0060778987,0.000304405,0.8426116,0.000610392,0.00025141702,0.00006020813,0.0009435083,0.00001650264,0.016088478,0.000019107736,0.13259462,0.0004218265],"about_ca_topic_score_codex":0.00009821494,"about_ca_topic_score_gemma":0.0008932743,"teacher_disagreement_score":0.14392118,"about_ca_system_score_codex":0.00016663148,"about_ca_system_score_gemma":0.000031662643,"threshold_uncertainty_score":0.7200155},"labels":[],"label_agreement":null},{"id":"W2012666111","doi":"10.1186/1758-2652-13-s4-o51","title":"Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)","year":2010,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Raltegravir; Integrase inhibitor; Medicine; Integrase; Pharmacology; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load","score_opus":0.013499303548303945,"score_gpt":0.2601361236000707,"score_spread":0.24663682005176676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012666111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886924,0.000025365807,0.00001497783,0.009228502,0.0008063092,0.00040338762,0.000018742985,0.00000452251,0.000805809],"genre_scores_gemma":[0.99298316,0.000008747079,0.0013891078,0.000116427625,0.0002285829,0.000006109557,8.8124256e-7,0.000016156368,0.0052508237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764854,0.00013888243,0.00069274,0.00016357064,0.0011952277,0.00016106274],"domain_scores_gemma":[0.99769104,0.0003130407,0.0011696776,0.00032923836,0.0004495818,0.00004740611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013784047,0.00017541964,0.00034760617,0.00006794423,0.00012887277,0.000025109173,0.0005778815,0.000070846734,0.000013845692],"category_scores_gemma":[0.0006330764,0.00007445946,0.00046375536,0.00041117313,0.0001884878,0.0001464251,0.00020322156,0.0010194696,5.531795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002510746,0.0026735822,0.8700437,0.00007544369,0.0013460676,0.000028346623,0.016696803,0.00006143106,0.09780466,0.00018042927,0.0075659,0.0010129155],"study_design_scores_gemma":[0.014969514,0.00045027724,0.6332996,0.0035272632,0.00049538095,0.00014736698,0.011662651,0.00019591706,0.33205807,0.00046569214,0.0024891924,0.0002390437],"about_ca_topic_score_codex":0.00006304219,"about_ca_topic_score_gemma":0.0006836867,"teacher_disagreement_score":0.23674406,"about_ca_system_score_codex":0.00029980254,"about_ca_system_score_gemma":0.00046517508,"threshold_uncertainty_score":0.44291446},"labels":[],"label_agreement":null},{"id":"W2012849897","doi":"10.1016/j.antiviral.2005.12.006","title":"Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor","year":2006,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institut National de la Recherche Scientifique; Armand Frappier Museum","funders":"","keywords":"Protease; Protease inhibitor (pharmacology); Virology; Virus; Drug resistance; In vitro; Biology; Enzyme inhibitor; Microbiology; Enzyme; Viral load; Antiretroviral therapy; Biochemistry","score_opus":0.04953128474737692,"score_gpt":0.3854512389809993,"score_spread":0.3359199542336224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012849897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799623,0.00039650218,0.000016617463,0.00031145124,0.000038414764,0.001111234,0.000049155093,0.00004117814,0.018073171],"genre_scores_gemma":[0.94566745,0.000032512275,0.00058204564,0.0000057460575,0.000080462225,0.00006342034,0.00004013713,0.000029038103,0.053499196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760056,0.00010593153,0.00032370424,0.00048392068,0.00088059524,0.0006052796],"domain_scores_gemma":[0.9989536,0.000099085715,0.00009398318,0.0003646564,0.00043215725,0.000056527533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008521036,0.00021230658,0.00038445144,0.0002977408,0.00036257776,0.00007152296,0.00012934367,0.000117107455,0.00003213354],"category_scores_gemma":[0.00017574479,0.00017409428,0.00007797918,0.0007554545,0.0006545627,0.00025162066,0.00017828487,0.00040289058,0.00007916112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082417676,0.0014659719,0.08713567,0.00024140753,0.000040477345,0.000079031684,0.00016583734,4.018573e-8,0.9062014,0.0010540299,0.0012892482,0.0015026613],"study_design_scores_gemma":[0.0022180227,0.000370329,0.29276747,0.00022141005,0.000020341542,0.0000045080346,0.000040495393,0.00003605295,0.70259947,0.00017473337,0.0013679643,0.0001792303],"about_ca_topic_score_codex":0.0006746979,"about_ca_topic_score_gemma":0.00014849067,"teacher_disagreement_score":0.20563178,"about_ca_system_score_codex":0.00011338275,"about_ca_system_score_gemma":0.000349892,"threshold_uncertainty_score":0.7099359},"labels":[],"label_agreement":null},{"id":"W2013435387","doi":"10.1089/aid.2012.0141","title":"Positional Adaptability in the Design of Mutation-Resistant Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors: A Supramolecular Perspective","year":2012,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burman University","funders":"McGill University","keywords":"Supramolecular chemistry; RNase H; Reverse transcriptase; Stereochemistry; Chemistry; Computational biology; Combinatorial chemistry; Biology; Biochemistry; Crystallography; RNA","score_opus":0.09242584869322905,"score_gpt":0.3738508998285368,"score_spread":0.28142505113530775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013435387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530447,0.001170473,0.00019799249,0.0015612566,0.000014800497,0.00088499207,0.000046835918,0.000013690538,0.00080546906],"genre_scores_gemma":[0.9974933,0.000046866306,0.0018565924,0.00009192059,0.00007315514,0.00008902394,0.000037933885,0.000014091056,0.00029709388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776703,0.00050949736,0.00028650506,0.00024355261,0.000754158,0.000439249],"domain_scores_gemma":[0.99889827,0.00036443406,0.000039923565,0.00024077366,0.00028658906,0.00016998619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018303223,0.00014046628,0.00023972848,0.00033834163,0.00023058485,0.00003315809,0.000098466524,0.00006249244,0.00018921735],"category_scores_gemma":[0.00029698398,0.000097337346,0.00007166847,0.0003905514,0.00046022274,0.00019922266,0.000029830364,0.00031127923,0.000025205412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042864266,0.006407602,0.7521157,0.00033178102,0.0005582385,0.00063819886,0.04311472,0.0000034605273,0.07575095,0.10270697,0.013536613,0.00054932164],"study_design_scores_gemma":[0.005707588,0.0038294971,0.9210789,0.00038232215,0.00019144792,0.00007973295,0.033475358,0.00000899942,0.025223197,0.0068287477,0.0028388798,0.000355293],"about_ca_topic_score_codex":0.0004230336,"about_ca_topic_score_gemma":0.00005033115,"teacher_disagreement_score":0.16896322,"about_ca_system_score_codex":0.00022509701,"about_ca_system_score_gemma":0.00018766643,"threshold_uncertainty_score":0.3969302},"labels":[],"label_agreement":null},{"id":"W2013564109","doi":"10.1097/coh.0b013e3282f0dd0b","title":"HIV antiretroviral medications and hepatotoxicity","year":2007,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Intensive care medicine; ANTIRETROVIRAL AGENTS; MEDLINE; Antiretroviral treatment; Antiretroviral drug; Virology; Viral load; Chemistry","score_opus":0.031363237918237974,"score_gpt":0.3347280069580108,"score_spread":0.30336476903977283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013564109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98776186,0.0056257383,0.0014470085,0.0020209977,0.00089852075,0.00040788818,0.000020657879,0.000059787923,0.0017575428],"genre_scores_gemma":[0.99451876,0.002631745,0.0011717586,0.00003092225,0.00022660852,0.000017509774,0.00013679429,0.000009728331,0.0012561587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999116,0.000017760573,0.000252531,0.00023312536,0.0001703212,0.00021027109],"domain_scores_gemma":[0.9995918,0.00005589782,0.000040712366,0.000112804446,0.000023977045,0.00017479615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026960595,0.00012684042,0.00019687397,0.0002017895,0.00007463186,0.000013028349,0.00003250346,0.00005355813,0.000057428933],"category_scores_gemma":[0.000033288194,0.000103274855,0.000028472357,0.00019969537,0.00009910695,0.00006967189,0.000041647432,0.0001467332,0.000028888722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029039235,0.00018872585,0.95605385,0.00012144822,0.000018315714,0.0000031915151,0.00049038895,3.8810654e-8,0.000049151804,0.002159086,0.0037134332,0.037173316],"study_design_scores_gemma":[0.003991494,0.00018852121,0.8591053,0.0007317508,0.000050063918,0.000045526645,0.00038057484,0.00029541415,0.00045997387,0.00024975842,0.13423917,0.00026245447],"about_ca_topic_score_codex":0.0000029501743,"about_ca_topic_score_gemma":9.178142e-7,"teacher_disagreement_score":0.13052574,"about_ca_system_score_codex":0.000040781128,"about_ca_system_score_gemma":0.000045862947,"threshold_uncertainty_score":0.42114264},"labels":[],"label_agreement":null},{"id":"W2013730769","doi":"10.1080/15257770.2011.652330","title":"Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine","year":2012,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Azacitidine; Decitabine; Nucleoside; Cytidine; Cytarabine; Biology; Pharmacology; Myeloid leukemia; Cancer research; Biochemistry; DNA methylation","score_opus":0.01297906387430655,"score_gpt":0.2503358334172825,"score_spread":0.23735676954297594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013730769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993714,0.0012862067,0.0000058262026,0.0008062546,0.00003888709,0.0007844458,0.00003233868,0.000055343447,0.0032766939],"genre_scores_gemma":[0.9964237,0.00031232307,0.0026740998,0.0002733784,0.00008448695,0.000028054461,0.000025696625,0.00007380053,0.000104458355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731374,0.00009579265,0.0010156372,0.00041586158,0.0005252015,0.0006337477],"domain_scores_gemma":[0.998663,0.00017010311,0.00027885768,0.00051319686,0.000089665926,0.00028516966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008354672,0.00044297925,0.00092058803,0.00034837867,0.00015718138,0.000026301897,0.00022441297,0.00017629155,0.00016886204],"category_scores_gemma":[0.000060429174,0.00033189193,0.00017749156,0.00045785322,0.00063390395,0.00038779835,0.00008703615,0.00030140294,0.0000084102285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030929985,0.0011124017,0.68661654,0.00032077442,0.00025031707,0.000030166084,0.01633027,0.0000010067043,0.28035793,0.0048842616,0.00027755604,0.009509493],"study_design_scores_gemma":[0.0031679685,0.0004307569,0.94436383,0.0003900079,0.00040463163,0.00014225928,0.008675784,0.000081371516,0.039973166,0.00062226446,0.0013932632,0.00035470285],"about_ca_topic_score_codex":0.00012509536,"about_ca_topic_score_gemma":0.000073950316,"teacher_disagreement_score":0.2577473,"about_ca_system_score_codex":0.00006208687,"about_ca_system_score_gemma":0.000039573628,"threshold_uncertainty_score":0.99991333},"labels":[],"label_agreement":null},{"id":"W2013976388","doi":"10.1310/p52n-kxjh-1945-ux7x","title":"The Cost-Effectiveness of Triple Nucleoside Analogue Therapy Antiretroviral Regimens in the Treatment of HIV in the United Kingdom","year":2000,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Life expectancy; Nucleoside analogue; Quality-adjusted life year; Cost effectiveness; Clinical trial; Quality of life (healthcare); Observational study; Population; Antiretroviral therapy; Human immunodeficiency virus (HIV); Intensive care medicine; Viral load; Internal medicine; Nucleoside; Family medicine; Environmental health; Risk analysis (engineering)","score_opus":0.2806454061765764,"score_gpt":0.465997805989622,"score_spread":0.18535239981304558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013976388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072987,0.00044210756,0.000006662573,0.003976643,0.00013363533,0.0038923891,0.00004424439,0.000013304623,0.0007611214],"genre_scores_gemma":[0.99360454,0.0046186205,0.00006796367,0.00024709862,0.0001422571,0.0002813815,0.00013431536,0.0000180786,0.0008857493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892146,0.007896333,0.0018406393,0.00031486677,0.00042331123,0.00031026237],"domain_scores_gemma":[0.9788746,0.019892478,0.00041626234,0.0006974389,0.00006244408,0.000056753106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014534367,0.00025174892,0.0013561683,0.0001577928,0.00009759766,0.000022495298,0.00030976528,0.00015665924,0.00009215896],"category_scores_gemma":[0.0014507008,0.000099178986,0.00054209225,0.0008639056,0.00031918523,0.00003559084,0.000010645527,0.00022875919,0.000028990771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026208427,0.012420989,0.82525706,0.000052612082,0.00130147,0.00024952128,0.0052293255,0.00004462542,0.00035238947,0.0023360117,0.0038462155,0.12270133],"study_design_scores_gemma":[0.053265736,0.0043811523,0.7888859,0.00037979652,0.00042177062,0.000012886197,0.0008935692,0.00012826994,0.0019644937,0.0005186717,0.14893328,0.00021448598],"about_ca_topic_score_codex":0.0002491285,"about_ca_topic_score_gemma":0.00006992878,"teacher_disagreement_score":0.14508706,"about_ca_system_score_codex":0.00008777246,"about_ca_system_score_gemma":0.00016005454,"threshold_uncertainty_score":0.50373507},"labels":[],"label_agreement":null},{"id":"W2014005798","doi":"10.1097/01.aids.0000199825.34241.49","title":"Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":316,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; U.S. Public Health Service","keywords":"Drug resistance; Nelfinavir; HIV drug resistance; Reverse-transcriptase inhibitor; Reverse transcriptase; Virology; Drug; Biology; Protease inhibitor (pharmacology); Population; Nevirapine; Medicine; Internal medicine; Virus; Viral disease; Pharmacology; Sida; Viral load; Polymerase chain reaction; Antiretroviral therapy; Genetics","score_opus":0.01743706402851803,"score_gpt":0.2396594699764665,"score_spread":0.22222240594794848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014005798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926611,0.00042033728,0.0011928004,0.0029533114,0.000070097936,0.0014249438,0.00007439128,0.000073003335,0.0011300222],"genre_scores_gemma":[0.96321726,0.000014975502,0.010225366,0.00014593072,0.00007658548,0.00046868398,0.0002494775,0.000018616676,0.025583103],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897957,0.000041489464,0.00027867072,0.00030797246,0.00015860576,0.00023368382],"domain_scores_gemma":[0.9995099,0.000102689664,0.00005550178,0.00015327799,0.00004714253,0.00013150413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021142613,0.00017708809,0.00025069003,0.00006293058,0.000194334,0.000018011178,0.000040564406,0.00011486457,0.000056598088],"category_scores_gemma":[0.00008877033,0.00014052066,0.00007513715,0.0001275239,0.00008777152,0.00010333491,0.000009933588,0.00013138153,0.000019978397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023710285,0.0014184287,0.48835775,0.00042848304,0.00019219855,0.00024566668,0.0011711015,0.0000029861937,0.03974527,0.0027913195,0.46051028,0.0027654672],"study_design_scores_gemma":[0.054777585,0.0035590061,0.27889153,0.0013987721,0.0018639632,0.00009111289,0.0021073525,0.0005414716,0.12902173,0.012921766,0.5124478,0.002377926],"about_ca_topic_score_codex":0.000025575206,"about_ca_topic_score_gemma":0.000017552216,"teacher_disagreement_score":0.20946623,"about_ca_system_score_codex":0.00004961599,"about_ca_system_score_gemma":0.000048502134,"threshold_uncertainty_score":0.5730266},"labels":[],"label_agreement":null},{"id":"W2014255419","doi":"10.1097/qad.0b013e328336e962","title":"Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine","year":2010,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Emtricitabine; Lamivudine; Internal medicine; Medicine; Drug resistance; Resistance mutation; Odds ratio; Virology; Reverse-transcriptase inhibitor; Viral load; Oncology; Gastroenterology; Pharmacology; Reverse transcriptase; Human immunodeficiency virus (HIV); Biology; Antiretroviral therapy; Virus; Genetics; Polymerase chain reaction","score_opus":0.01224960433921843,"score_gpt":0.27505257416531437,"score_spread":0.2628029698260959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014255419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903571,0.000048286514,0.00011197488,0.006422879,0.00006155895,0.00023527163,0.000008675845,0.000050576717,0.0027036588],"genre_scores_gemma":[0.97919756,0.0000127388475,0.007276008,0.00012734083,0.000029978923,0.00003280275,0.0000944819,0.000011601947,0.013217506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992614,0.00001792925,0.00023028922,0.00017163446,0.00015641209,0.00016234879],"domain_scores_gemma":[0.99945456,0.00017600365,0.000063488136,0.00013340799,0.00007722474,0.000095319556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001379532,0.00011635915,0.00025330824,0.00014918277,0.00014551918,0.000007758267,0.000038934668,0.00007719977,0.000518918],"category_scores_gemma":[0.00019385217,0.00007946282,0.000041767467,0.00024517725,0.0001123699,0.000061333354,0.00005708121,0.00014891593,0.000026124879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017229591,0.00050391175,0.95627517,0.00003859455,0.00022725001,0.00010020668,0.0017088932,0.0000018964598,0.02408452,0.010572238,0.0012203511,0.005094652],"study_design_scores_gemma":[0.017342746,0.0025160199,0.9102463,0.00014026053,0.00088840764,0.0004943236,0.0019425036,0.0009738553,0.01609524,0.0015338418,0.047294438,0.0005320426],"about_ca_topic_score_codex":0.000007579364,"about_ca_topic_score_gemma":0.00004502714,"teacher_disagreement_score":0.046074085,"about_ca_system_score_codex":0.000032545482,"about_ca_system_score_gemma":0.00006638462,"threshold_uncertainty_score":0.56817883},"labels":[],"label_agreement":null},{"id":"W2014399345","doi":"10.1177/095632020701800201","title":"Apricitabine: A Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection","year":2007,"lang":"en","type":"review","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Reverse-transcriptase inhibitor; Pharmacology; Nucleoside Reverse Transcriptase Inhibitor; Emtricitabine; Nucleoside analogue; Nucleoside; Reverse transcriptase; Lamivudine; Deoxycytidine kinase; Didanosine; Resistance mutation; Zalcitabine; Biology; Virology; Deoxycytidine; Chemotherapy; Virus; Biochemistry; RNA","score_opus":0.04955322289353962,"score_gpt":0.3322231562892709,"score_spread":0.28266993339573127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014399345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041443217,0.9879849,0.0005534178,0.0009131012,0.00024333716,0.0042974534,0.0008066849,0.00016118842,0.0008955874],"genre_scores_gemma":[0.0014364371,0.98282164,0.0015649454,0.00011928337,0.00075185165,0.00040280446,0.0013714156,0.0002021236,0.011329508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680513,0.000027690448,0.0012862963,0.0008178394,0.00043524732,0.0006278209],"domain_scores_gemma":[0.99788094,0.0003198567,0.00064501987,0.00080521853,0.00017625085,0.00017271361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002902156,0.001062011,0.0024723217,0.0002079581,0.00019221501,0.000035011795,0.00020203221,0.00055155123,0.00013249557],"category_scores_gemma":[0.000038700226,0.0006793664,0.001882994,0.00078568823,0.00021581462,0.00007994841,0.000016242533,0.00028786293,0.000021809832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018234885,0.006209542,0.00026092335,0.023796115,0.006628526,0.000120322555,0.0007117476,4.922713e-7,0.03810285,0.000039998187,0.011992722,0.91031325],"study_design_scores_gemma":[0.0056171897,0.00036796732,0.000039980696,0.0040624742,0.0034536754,0.00006218082,0.000041517327,0.000014793856,0.05904878,0.0000035865883,0.92674565,0.0005421761],"about_ca_topic_score_codex":0.00006857642,"about_ca_topic_score_gemma":0.000013031715,"teacher_disagreement_score":0.91475296,"about_ca_system_score_codex":0.0007045132,"about_ca_system_score_gemma":0.00045791038,"threshold_uncertainty_score":0.9995658},"labels":[],"label_agreement":null},{"id":"W2015037490","doi":"10.1016/j.bmcl.2012.10.034","title":"Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold","year":2012,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Boehringer Ingelheim (Canada)","funders":"World Health Organization","keywords":"Capsid; Chemistry; Benzimidazole; Potency; Stereochemistry; Structure–activity relationship; Furan; Human immunodeficiency virus (HIV); Pharmacology; Virology; Biochemistry; In vitro; Organic chemistry; Biology","score_opus":0.007416334076399914,"score_gpt":0.21298971604479036,"score_spread":0.20557338196839045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015037490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922325,0.00053979753,0.00048313366,0.0054937834,0.000053523683,0.0003730777,0.00009363197,0.000024293258,0.00070623826],"genre_scores_gemma":[0.9982152,0.00010025805,0.00048401885,0.00016580832,0.000094661074,0.000016484248,0.00029192702,0.00002804418,0.00060362084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998382,0.00003978172,0.0005200839,0.00027218467,0.00049186335,0.00029414383],"domain_scores_gemma":[0.9989175,0.000062109524,0.00042454439,0.00031236192,0.0001496917,0.00013380148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020721309,0.00024685165,0.00043310536,0.00006785815,0.000095125026,0.000004057504,0.000093294206,0.00013501283,0.00008708128],"category_scores_gemma":[0.00008715161,0.00018671135,0.0000992662,0.00035972704,0.0003013582,0.00011458256,0.00006761066,0.00014789363,0.0000043876066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009161082,0.0002935895,0.029508542,0.00028718126,0.00015129455,0.000002532286,0.0016769628,0.000011669798,0.9626145,0.0000042804763,0.0052421857,0.00011565503],"study_design_scores_gemma":[0.0017973811,0.000031395277,0.010848015,0.0003251728,0.00043277195,0.000055515146,0.00045430416,0.00019769525,0.98561585,0.0000018814878,0.00008648165,0.00015352867],"about_ca_topic_score_codex":0.000036756574,"about_ca_topic_score_gemma":0.0000021289075,"teacher_disagreement_score":0.023001362,"about_ca_system_score_codex":0.00021352281,"about_ca_system_score_gemma":0.00011228227,"threshold_uncertainty_score":0.7613868},"labels":[],"label_agreement":null},{"id":"W2015832753","doi":"10.1097/coh.0b013e328331d353","title":"Epidemiology of treatment failure: a focus on recent trends","year":2009,"lang":"en","type":"review","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; AIDS Vancouver","funders":"International AIDS Society; Canadian Institutes of Health Research; University of Alabama at Birmingham","keywords":"Medicine; Intensive care medicine; Antiretroviral therapy; Tolerability; Drug resistance; Viral load; ANTIRETROVIRAL AGENTS; Human immunodeficiency virus (HIV); Immunology; Internal medicine; Adverse effect; Biology","score_opus":0.164420895679534,"score_gpt":0.4292909128002124,"score_spread":0.2648700171206784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015832753","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009347948,0.99658185,0.000009416642,0.0010518975,0.00085116486,0.0007119808,0.000079868594,0.000029620427,0.000674833],"genre_scores_gemma":[0.000020837058,0.9960059,0.00051446795,0.000009060373,0.00032063527,0.00022432623,0.0012895232,0.000029691255,0.0015855635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973493,0.0002932392,0.0011607864,0.0006477198,0.00015408896,0.00039485452],"domain_scores_gemma":[0.9986348,0.0003486798,0.00038965978,0.00038743133,0.000034623834,0.00020478155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029918985,0.0006198245,0.003005713,0.0008756426,0.000038151167,0.0000032150276,0.00009065829,0.0002873677,0.000118481854],"category_scores_gemma":[0.000082955165,0.0003967036,0.00045908825,0.0005511166,0.00007523829,0.000026608528,0.00003620475,0.00031954868,0.000048766782],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004153894,0.0007370797,0.003177165,0.0034580717,0.0001830308,0.000004063223,0.000091413276,1.8167229e-7,1.0525848e-8,0.0015303001,0.0050188326,0.9857583],"study_design_scores_gemma":[0.0018850805,0.0012494228,0.00044538133,0.023773996,0.00044847355,0.00003619266,0.0000098212795,0.0000030074357,6.0241206e-7,0.0001590352,0.9717133,0.0002756789],"about_ca_topic_score_codex":0.000004858324,"about_ca_topic_score_gemma":0.0000021991862,"teacher_disagreement_score":0.98548263,"about_ca_system_score_codex":0.00058615895,"about_ca_system_score_gemma":0.00029347255,"threshold_uncertainty_score":0.9998485},"labels":[],"label_agreement":null},{"id":"W2015965641","doi":"10.1097/00002030-200401020-00016","title":"Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients","year":2004,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Amprenavir; Ritonavir; Lopinavir; Protease inhibitor (pharmacology); Virology; Lopinavir/ritonavir; Medicine; Saquinavir; Protease; Lentivirus; Enzyme inhibitor; Pharmacology; Human immunodeficiency virus (HIV); Viral disease; Enzyme; Chemistry; HIV-1 protease; Viral load; Antiretroviral therapy; Biochemistry","score_opus":0.005137784996321593,"score_gpt":0.23127325999393186,"score_spread":0.22613547499761028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015965641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605215,0.0001278451,0.000025026684,0.0017012275,0.000038896873,0.0015409223,0.00001922515,0.00004823359,0.0004464633],"genre_scores_gemma":[0.98288083,0.000011902793,0.0072365412,0.00021744236,0.00004630048,0.0011824692,0.00006393495,0.000029738065,0.008330832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986057,0.00002033538,0.0002578167,0.00047093624,0.0003005194,0.00034468475],"domain_scores_gemma":[0.999343,0.000009727126,0.00004166317,0.00028065694,0.00005859029,0.00026639938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004268035,0.00028689808,0.00032823725,0.00016229006,0.00006162982,0.000023915,0.000044828692,0.00006825676,0.000016690763],"category_scores_gemma":[0.000012249804,0.00019463677,0.000038483675,0.00033619686,0.00007578502,0.00014356776,0.00003733801,0.0000816608,0.000058102636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016107323,0.0010175802,0.9819435,0.00004704656,0.000055963854,0.0004290368,0.00759841,0.0000018806672,0.00014415212,0.000076597134,0.00006491574,0.007010186],"study_design_scores_gemma":[0.019704057,0.0054862304,0.9379232,0.0015348543,0.00010841327,0.000014833359,0.00053477165,0.0000010856785,0.0173627,0.00017926862,0.016640618,0.0005099463],"about_ca_topic_score_codex":0.00006008048,"about_ca_topic_score_gemma":0.0004015121,"teacher_disagreement_score":0.044020277,"about_ca_system_score_codex":0.0005705936,"about_ca_system_score_gemma":0.00014958986,"threshold_uncertainty_score":0.7937057},"labels":[],"label_agreement":null},{"id":"W2016523223","doi":"10.1067/mcp.2000.112363","title":"Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus","year":2000,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Saquinavir; Ketoconazole; Ritonavir; Pharmacokinetics; Medicine; Confidence interval; Pharmacology; Cerebrospinal fluid; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Viral load; Antiretroviral therapy","score_opus":0.021377398073675405,"score_gpt":0.3672882227734733,"score_spread":0.3459108246997979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016523223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978607,0.00026032593,0.0000010065432,0.0004658746,0.00009205596,0.0009226594,0.000031673924,0.000025614796,0.00034007893],"genre_scores_gemma":[0.99757075,0.0006084452,0.000068110916,0.0014045684,0.000039133025,0.000051998715,0.00008697599,0.000017192173,0.00015282903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852955,0.00028160767,0.0004998368,0.00032256093,0.00014188033,0.000224546],"domain_scores_gemma":[0.99897194,0.0006580549,0.0000978489,0.00012721053,0.000044316206,0.000100648576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019481879,0.00021190876,0.0005104795,0.00005824841,0.0000948972,0.000007987789,0.000060544542,0.00014891279,0.0002541291],"category_scores_gemma":[0.000006740499,0.0001537803,0.000048394628,0.00012231304,0.00046893663,0.000045393543,0.000022850789,0.00032538004,0.00001752655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045107384,0.00207834,0.9510956,0.000025061074,0.0004526806,0.000026577243,0.00033266994,0.0000050480357,0.015553478,0.0000073266715,0.0000994699,0.025813058],"study_design_scores_gemma":[0.030651147,0.009442145,0.9267877,0.00012599441,0.0010268854,0.0000063204366,0.000013850321,0.00036112862,0.028669847,0.000020530053,0.0026839408,0.00021052972],"about_ca_topic_score_codex":0.000019742703,"about_ca_topic_score_gemma":0.000011681549,"teacher_disagreement_score":0.026140409,"about_ca_system_score_codex":0.0000449783,"about_ca_system_score_gemma":0.000061530234,"threshold_uncertainty_score":0.62709785},"labels":[],"label_agreement":null},{"id":"W2016558849","doi":"10.1124/dmd.109.027706","title":"Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine","year":2009,"lang":"en","type":"article","venue":"Drug Metabolism and Disposition","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institute of Allergy and Infectious Diseases; Center for AIDS Research, University of Washington; Case Western Reserve University; National Institutes of Health; School of Medicine, Case Western Reserve University; Université Laval","keywords":"Glucuronidation; UGT2B7; Efavirenz; Zidovudine; Microsome; Glucuronide; Chemistry; Metabolite; Reverse-transcriptase inhibitor; Pharmacology; Enzyme; Biochemistry; Biology; Reverse transcriptase; Virology; Human immunodeficiency virus (HIV)","score_opus":0.0049128738720268265,"score_gpt":0.2321590014846999,"score_spread":0.22724612761267307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016558849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631155,0.0008449748,0.000030546435,0.0020820666,0.0000710266,0.00044873558,0.00003170829,0.0000195969,0.00015980087],"genre_scores_gemma":[0.9981461,0.00018560918,0.000531224,0.0001355075,0.00004922716,0.000013804301,0.00050363975,0.000011779085,0.00042310037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998826,0.00013150093,0.0003569958,0.00026712424,0.00027155058,0.00014681194],"domain_scores_gemma":[0.9993961,0.000030432315,0.000233086,0.00017727049,0.00007515629,0.00008795821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002459567,0.0001875083,0.00034010486,0.00017780163,0.00007906178,0.000022159717,0.00004816291,0.00003795254,0.000005291834],"category_scores_gemma":[0.000013089023,0.00012776726,0.000039368566,0.00030742615,0.000111882786,0.00053001667,0.000018602916,0.00012240301,7.5948907e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002176553,0.00094848906,0.18136813,0.00026707345,0.000112269816,0.0000074982313,0.019003803,0.000013687475,0.74613935,0.0015047513,0.0013847481,0.047073632],"study_design_scores_gemma":[0.0031956518,0.00007517525,0.47558007,0.00024802767,0.00029108775,0.0000125261495,0.000935692,0.00037400937,0.5186058,0.00034085335,0.00017860864,0.00016247561],"about_ca_topic_score_codex":0.0002311471,"about_ca_topic_score_gemma":0.000053273874,"teacher_disagreement_score":0.29421195,"about_ca_system_score_codex":0.000037040125,"about_ca_system_score_gemma":0.00004333055,"threshold_uncertainty_score":0.52101976},"labels":[],"label_agreement":null},{"id":"W2016674979","doi":"10.1016/j.jviromet.2012.10.018","title":"Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing","year":2012,"lang":"en","type":"article","venue":"Journal of Virological Methods","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Public Health Agency","keywords":"Pyrosequencing; Sanger sequencing; Drug resistance; Biology; HIV drug resistance; Genetics; Drug; Virology; Human immunodeficiency virus (HIV); Mutation; Gene; Pharmacology; Viral load; Antiretroviral therapy","score_opus":0.03687657338918217,"score_gpt":0.34958609188306533,"score_spread":0.3127095184938832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016674979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9395192,0.005465583,0.04675022,0.006240732,0.0006344131,0.00043504193,0.0000071049444,0.00004365889,0.0009039936],"genre_scores_gemma":[0.646141,0.00026059244,0.34506375,0.00029739088,0.0002782917,0.0000072193807,0.0000037102504,0.00003322899,0.007914815],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9946145,0.0018016627,0.0015811778,0.000424353,0.00071932795,0.00085901114],"domain_scores_gemma":[0.9969974,0.0010774652,0.00086885365,0.00037958167,0.00023553232,0.00044113514],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0070616794,0.0004229701,0.0013675891,0.0003541789,0.00016704174,0.000049556333,0.0003076863,0.0001973563,0.0002059456],"category_scores_gemma":[0.0010936856,0.0003137842,0.0003248681,0.0008081569,0.00018647908,0.0004032808,0.000049843817,0.00090610725,0.000016599846],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013145427,0.0045414357,0.18993723,0.0007390337,0.001496693,0.0049791704,0.009527114,0.00020948151,0.7616236,0.0010990136,0.00790824,0.0047935243],"study_design_scores_gemma":[0.015767269,0.000116563715,0.8124594,0.0025859145,0.0006813372,0.00057203666,0.00069759774,0.00041918457,0.14519204,0.004411708,0.015797388,0.001299582],"about_ca_topic_score_codex":0.000003946444,"about_ca_topic_score_gemma":0.00006418242,"teacher_disagreement_score":0.6225221,"about_ca_system_score_codex":0.0006232732,"about_ca_system_score_gemma":0.00020750081,"threshold_uncertainty_score":0.9999314},"labels":[],"label_agreement":null},{"id":"W2016782622","doi":"10.5151/chempro-15bmos-bmos2013_2013101710110","title":"Studies of continuous-flow synthesis of nonpeptidal bistetrahydrofuran moiety of Darunavir","year":2013,"lang":"en","type":"article","venue":"Proceedings of the 15th Brazilian Meeting on Organic Synthesis Proceedings","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Microsemi (Canada)","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Darunavir; Protease; Moiety; Context (archaeology); Human immunodeficiency virus (HIV); Chemistry; Reverse transcriptase; HIV-1 protease; Combinatorial chemistry; Pharmacology; Medicine; Virology; Stereochemistry; Antiretroviral therapy; Biochemistry; Biology; Viral load; Enzyme","score_opus":0.012594133627646326,"score_gpt":0.24334868748978034,"score_spread":0.230754553862134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016782622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826973,0.00032273805,2.8148253e-7,0.0038869819,0.00010651795,0.0012969376,0.00002568374,0.000091122034,0.011572429],"genre_scores_gemma":[0.99334794,0.00024444592,0.0046383315,0.00006429342,0.00007526213,0.00014620279,0.0000011080291,0.00010291747,0.0013794663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956259,0.000018412935,0.0018145846,0.00069830654,0.0012424191,0.00060036144],"domain_scores_gemma":[0.99412173,0.0008514988,0.0022052408,0.0003849494,0.0022364112,0.00020017893],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012122481,0.00063575275,0.002061411,0.00045439537,0.00017150349,0.000027531158,0.0009906769,0.0002649037,0.00022816306],"category_scores_gemma":[0.009582985,0.00044184606,0.000574074,0.0011812994,0.0008054045,0.00030305423,0.00039980438,0.00031339074,0.000028006034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004591993,0.0011097298,0.1851491,0.006148568,0.001928184,9.377236e-7,0.0069378796,7.9441463e-7,0.7811599,0.0002845132,0.009966632,0.0068545616],"study_design_scores_gemma":[0.0009936211,0.00030531414,0.014166883,0.006898119,0.0009930158,0.000019543564,0.0107383495,0.000057788257,0.9651024,0.00021047065,0.00016975761,0.00034475417],"about_ca_topic_score_codex":0.000039654322,"about_ca_topic_score_gemma":0.000002483547,"teacher_disagreement_score":0.18394248,"about_ca_system_score_codex":0.00017723559,"about_ca_system_score_gemma":0.00014909796,"threshold_uncertainty_score":0.9998033},"labels":[],"label_agreement":null},{"id":"W2016842950","doi":"10.1097/01.aids.0000210609.52836.d1","title":"Impact of pregnancy on abacavir pharmacokinetics","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIH Clinical Center; National Institute of Allergy and Infectious Diseases","keywords":"Abacavir; Medicine; Cmax; Pregnancy; Pharmacokinetics; Confidence interval; Obstetrics; Gestation; Prospective cohort study; Area under the curve; Gynecology; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology","score_opus":0.01375273910729229,"score_gpt":0.3091882229130941,"score_spread":0.2954354838058018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016842950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.941627,0.00036793159,0.000022892596,0.00016874219,0.000048574177,0.00019718491,0.000009879127,0.000033543325,0.057524256],"genre_scores_gemma":[0.97840315,0.000054298504,0.0009425925,0.000022799397,0.000063776526,0.000009558247,0.000043639408,0.0000136829985,0.02044652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940455,0.000010230295,0.00015970446,0.000116306175,0.00016344173,0.000145774],"domain_scores_gemma":[0.99970055,0.000024317284,0.000041607498,0.00014537227,0.00003722512,0.000050935614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028045735,0.00010910469,0.0001757922,0.00008394022,0.000016871028,0.0000030083331,0.000034911056,0.00003339133,0.00021451678],"category_scores_gemma":[0.0000071623485,0.00007537491,0.000114964336,0.00013820014,0.000024000412,0.00002173299,0.000010880032,0.000058114867,0.00012058957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016327931,0.0014231977,0.91652614,0.00005423188,0.00035065378,0.00012814815,0.00016892192,0.000030585514,0.011263225,0.00072487746,0.013174451,0.055992283],"study_design_scores_gemma":[0.005154009,0.0014859212,0.922122,0.00047373713,0.0002755185,0.000022367325,0.000012913806,0.00005500743,0.06500036,0.00024083199,0.0049660616,0.00019126169],"about_ca_topic_score_codex":0.000035493063,"about_ca_topic_score_gemma":5.597339e-7,"teacher_disagreement_score":0.055801023,"about_ca_system_score_codex":0.000061968494,"about_ca_system_score_gemma":0.00005421567,"threshold_uncertainty_score":0.30736998},"labels":[],"label_agreement":null},{"id":"W2017028114","doi":"10.1097/coh.0b013e3280287a60","title":"Mechanisms of resistance associated with excision of incorporated nucleotide analogue inhibitors of HIV-1 reverse transcriptase","year":2007,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reverse transcriptase; Zidovudine; Thymidine; Resistance mutation; Stavudine; Nucleoside analogue; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Nucleotidyltransferase; Biology; Nucleoside; Nucleotide; Virology; Human immunodeficiency virus (HIV); DNA; Genetics; RNA; Viral disease; Gene","score_opus":0.027093218319751294,"score_gpt":0.28135812732138393,"score_spread":0.2542649090016326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017028114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936833,0.0011843928,0.0035806193,0.00021744896,0.0004283157,0.00049321435,0.00017254348,0.00002094194,0.00021925115],"genre_scores_gemma":[0.9966753,0.00031038962,0.0022889022,0.000004200649,0.000017613145,0.0000049782025,0.00042135877,0.000013208247,0.00026403047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986032,0.00005091553,0.0006451126,0.00021486839,0.0003185156,0.00016733554],"domain_scores_gemma":[0.9992001,0.00007456864,0.0003229253,0.00014952091,0.00016014272,0.000092761074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005019658,0.00016036646,0.000470744,0.00035203877,0.000023660252,0.0000022303363,0.000050256054,0.00007427651,0.000020624255],"category_scores_gemma":[0.00006800722,0.00012483998,0.00006181589,0.0006673837,0.00011759266,0.00006910764,0.000016820439,0.000120472374,0.0000010987108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043123295,0.0038676956,0.9271879,0.0027654653,0.00039757296,0.000044334607,0.0038415021,0.000020245208,0.028819188,0.008709999,0.012208313,0.00782542],"study_design_scores_gemma":[0.04168899,0.0030517238,0.69502944,0.038987335,0.0006481074,0.000014991679,0.0051596854,0.00030250466,0.19955699,0.0037668576,0.0106171835,0.0011762091],"about_ca_topic_score_codex":0.000008196082,"about_ca_topic_score_gemma":0.000012507161,"teacher_disagreement_score":0.23215851,"about_ca_system_score_codex":0.00005560483,"about_ca_system_score_gemma":0.00008473711,"threshold_uncertainty_score":0.5090827},"labels":[],"label_agreement":null},{"id":"W2017080577","doi":"10.1016/s0022-5347(05)66911-x","title":"INCREASED PREVALENCE AND ANALYSIS OF RISK FACTORS FOR INDINAVIR NEPHROLITHIASIS","year":2000,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Indinavir; Medicine; Incidence (geometry); Cohort; Internal medicine; Creatinine; Urinary system; Cumulative incidence; Human immunodeficiency virus (HIV); Gastroenterology; Urology; Virology; Sida; Viral disease","score_opus":0.012170885057417561,"score_gpt":0.2631552582845544,"score_spread":0.25098437322713685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017080577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978944,0.0007801011,0.00007582801,0.0009999505,0.000015736618,0.000115361814,0.000025669247,0.0000027947133,0.000090172645],"genre_scores_gemma":[0.9973505,0.0017081732,0.000325615,0.00010186276,0.000024305087,0.0000013386552,0.000004933802,0.000005131965,0.00047811065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926794,0.00012837864,0.00030856766,0.00006112961,0.00012008868,0.00011391043],"domain_scores_gemma":[0.9988195,0.00066191255,0.0002619868,0.00011263404,0.00007472366,0.00006927713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050780136,0.00008111221,0.00038342786,0.00022489656,0.000048433423,0.000002177535,0.000074920936,0.000050727394,0.0003060982],"category_scores_gemma":[0.0001303902,0.000043459797,0.00013076041,0.0002241409,0.000094057985,0.000031850508,0.000009119294,0.00011283236,0.0000014040982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019161523,0.0001545608,0.9855113,0.000020717202,0.0035506708,0.000008785652,0.0032803784,0.00005995304,0.00017035045,0.000014223354,0.00028286045,0.005030046],"study_design_scores_gemma":[0.001470095,0.0005436652,0.9830433,0.0000089242385,0.012380121,0.00007128098,0.00010213518,0.0002523746,0.00037422817,0.00015078524,0.0015623185,0.00004073558],"about_ca_topic_score_codex":0.00002824743,"about_ca_topic_score_gemma":0.000008128316,"teacher_disagreement_score":0.00882945,"about_ca_system_score_codex":0.00001634795,"about_ca_system_score_gemma":0.000046793644,"threshold_uncertainty_score":0.33515605},"labels":[],"label_agreement":null},{"id":"W2017422147","doi":"10.1089/088922203769232548","title":"Drug Resistance Profiles of Recombinant Reverse Transcriptases from Human Immunodeficiency Virus Type 1 Subtypes A/E, B, and C","year":2003,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Virology; Recombinant DNA; Lentivirus; Drug resistance; Reverse transcriptase; Human immunodeficiency virus (HIV); Virus; Viral disease; Biology; Polymerase chain reaction; Microbiology; Genetics; Gene","score_opus":0.057918116640412354,"score_gpt":0.3412137338795128,"score_spread":0.28329561723910046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017422147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98554474,0.008932379,0.0000015561245,0.00016532197,0.000059899616,0.00044855874,0.000035865447,0.000033393284,0.0047782934],"genre_scores_gemma":[0.9554102,0.0017934156,0.0009592789,0.000026589232,0.000020699417,0.00002715515,0.00005942828,0.000027509244,0.041675735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979326,0.0002095403,0.00038997305,0.0004616742,0.0005337175,0.00047249132],"domain_scores_gemma":[0.9989174,0.00017409127,0.000075195785,0.0003776957,0.00026588686,0.00018971195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000730283,0.0002108063,0.00044736656,0.00033978673,0.0005110546,0.00005628858,0.00011367866,0.00007929344,0.00040626948],"category_scores_gemma":[0.00022354502,0.00016761226,0.00005573511,0.0003710075,0.0006215705,0.00014251676,0.000047091777,0.00029755748,0.000019788633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010501865,0.0015272308,0.72993857,0.0005691268,0.00041558774,0.00020130308,0.003603748,3.081957e-8,0.17540556,0.052764393,0.03365655,0.0008677173],"study_design_scores_gemma":[0.009504495,0.004646098,0.41410565,0.0018529884,0.00038467124,0.000027071144,0.0048765377,5.944515e-7,0.31768206,0.0278358,0.21807322,0.0010107983],"about_ca_topic_score_codex":0.00079027814,"about_ca_topic_score_gemma":0.00058060826,"teacher_disagreement_score":0.3158329,"about_ca_system_score_codex":0.00006743121,"about_ca_system_score_gemma":0.00015609944,"threshold_uncertainty_score":0.683503},"labels":[],"label_agreement":null},{"id":"W2017953463","doi":"10.1371/journal.pmed.0040036","title":"A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism","year":2007,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Protease; Biology; Drug resistance; Virology; Protease inhibitor (pharmacology); Virus; Cleavage (geology); Mutation; HIV-1 protease; Genetics; Viral load; Enzyme; Gene; Biochemistry; Antiretroviral therapy","score_opus":0.021332520214009807,"score_gpt":0.25396994857206745,"score_spread":0.23263742835805765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017953463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8072646,0.0012954103,0.018227192,0.13674596,0.00066245854,0.0048518134,0.00003855912,0.0008005356,0.03011348],"genre_scores_gemma":[0.9059951,0.00001668642,0.018262345,0.0016007625,0.00076241134,0.00013961911,0.00021190321,0.00006962419,0.07294157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744767,0.00002433603,0.0005918566,0.00048179764,0.0009007704,0.000553593],"domain_scores_gemma":[0.99850684,0.00016008313,0.0001571964,0.00044236073,0.00021166037,0.0005218465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006933532,0.00034943066,0.0005592173,0.000309061,0.00012503592,0.000009067823,0.000116390525,0.00010571159,0.00049033295],"category_scores_gemma":[0.00028082292,0.00025145637,0.000082422855,0.00046815875,0.00015088187,0.00006431081,0.000022268197,0.00028962304,0.0002508112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008613914,0.009742,0.032898925,0.0028654705,0.001438054,0.007429105,0.009467667,0.0000021722065,0.73183477,0.011369681,0.18201864,0.0023195827],"study_design_scores_gemma":[0.036619328,0.00051089143,0.008043334,0.0057695773,0.0012211644,0.00009682885,0.0014354909,0.0002885794,0.88046706,0.0008482346,0.06372964,0.00096989097],"about_ca_topic_score_codex":0.000015428146,"about_ca_topic_score_gemma":0.000078381716,"teacher_disagreement_score":0.14863226,"about_ca_system_score_codex":0.0002419796,"about_ca_system_score_gemma":0.00027947506,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W2019398901","doi":"10.1517/14728214.11.2.217","title":"Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Reverse transcriptase; Pharmacology; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Dosing; Drug; Regimen; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Internal medicine; Biology; RNA","score_opus":0.03402692502663547,"score_gpt":0.3494930753719826,"score_spread":0.31546615034534714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019398901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008444631,0.99231386,0.00007591548,0.0014852314,0.0018895427,0.0036247906,0.00006974859,0.00008190764,0.00037455047],"genre_scores_gemma":[0.000063686195,0.9927502,0.00029265936,0.00004677149,0.00077051093,0.0016795319,0.0012998801,0.00010635602,0.002990399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972387,0.00011868957,0.0011589075,0.000640226,0.00040725915,0.00043623394],"domain_scores_gemma":[0.9986366,0.0002741959,0.0004027556,0.000513765,0.000069974165,0.00010270995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023712424,0.0007027134,0.0016323206,0.0006881059,0.0001633441,0.000013643326,0.00010791939,0.0002599727,0.000055627122],"category_scores_gemma":[0.000029735347,0.00044355687,0.0010602965,0.0005735517,0.000059264294,0.00008568658,0.000013439804,0.0001991975,0.000029285931],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002118944,0.0013687784,0.00011347385,0.0032403737,0.0004124516,0.000011132275,0.0053608846,0.000011405138,7.348012e-7,0.000075833894,0.026077705,0.96311533],"study_design_scores_gemma":[0.003607144,0.0003707622,0.000016644182,0.02046376,0.00021186935,0.000007869842,0.00029303005,0.00008663865,0.000049686587,0.0000036748133,0.9745359,0.0003530291],"about_ca_topic_score_codex":0.00043248452,"about_ca_topic_score_gemma":0.000026259177,"teacher_disagreement_score":0.9627623,"about_ca_system_score_codex":0.0007773846,"about_ca_system_score_gemma":0.00023909318,"threshold_uncertainty_score":0.99980164},"labels":[],"label_agreement":null},{"id":"W2019792136","doi":"10.1097/qai.0b013e31802f1296","title":"Time Trends for HIV-1 Antiretroviral Resistance Among Antiretroviral-Experienced and Naive Pregnant Women in New York City During 1991 to Early 2001","year":2006,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; U.S. Public Health Service","keywords":"Medicine; Confidence interval; Drug resistance; HIV drug resistance; Antiretroviral therapy; Internal medicine; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Drug-naïve; Young adult; Human immunodeficiency virus (HIV); Pregnancy; Nucleoside Reverse Transcriptase Inhibitor; Viral load; Virology; Drug; Biology; Pharmacology","score_opus":0.012153520834878351,"score_gpt":0.2427109359483958,"score_spread":0.23055741511351743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019792136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539864,0.002734685,0.000047931437,0.00050853146,0.00018574024,0.00047347485,0.00001950429,0.00005323849,0.00057826075],"genre_scores_gemma":[0.8926492,0.00007601226,0.0028291796,0.000012992083,0.00007554675,0.000031251177,0.000015414784,0.000048566824,0.10426185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646586,0.00006968772,0.0012628128,0.0004719315,0.00063505507,0.001094623],"domain_scores_gemma":[0.9985452,0.00011249901,0.00051901524,0.0003286287,0.00013455063,0.00036009567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007914361,0.00041395347,0.0011362528,0.0013259117,0.00022216635,0.00009719145,0.00029491851,0.0001390998,0.00009044763],"category_scores_gemma":[0.00020415637,0.00033999447,0.0002538352,0.0014822219,0.00021897476,0.00051157543,0.00008490456,0.00014339053,0.000025348012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033146124,0.0011669581,0.90968955,0.00027613193,0.00030782248,0.0013327551,0.019210892,0.000048946033,0.05264919,0.00006566943,0.006468149,0.005469335],"study_design_scores_gemma":[0.0068964656,0.0026592417,0.9812561,0.0013463772,0.000113180045,0.00028461916,0.0015111573,0.000055437213,0.004802952,0.00007500508,0.0005262162,0.0004732106],"about_ca_topic_score_codex":0.00012279682,"about_ca_topic_score_gemma":0.000014054528,"teacher_disagreement_score":0.10368359,"about_ca_system_score_codex":0.000565612,"about_ca_system_score_gemma":0.00025637943,"threshold_uncertainty_score":0.9999052},"labels":[],"label_agreement":null},{"id":"W2020104576","doi":"10.1086/381760","title":"Severe Anemia Secondary to a Probable Drug Interaction between Zidovudine and Valproic Acid","year":2004,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Zidovudine; Valproic Acid; Medicine; Lamivudine; Abacavir; Anemia; Drug interaction; Regimen; Pharmacology; Drug; Glucuronidation; Sida; Human immunodeficiency virus (HIV); Viral disease; Virology; Internal medicine; Virus; Epilepsy; Psychiatry; Chemistry","score_opus":0.025078777510750078,"score_gpt":0.33873378461167725,"score_spread":0.3136550071009272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020104576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911823,0.00031785344,0.00008279655,0.0041268338,0.00025622998,0.00079817703,0.00003153603,0.00025320647,0.002951068],"genre_scores_gemma":[0.99443716,0.000116063326,0.00028633839,0.0010284256,0.00045262784,0.0000945871,0.00013544945,0.000029220659,0.003420131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984606,0.000060997656,0.0005481308,0.00047586844,0.0001817495,0.0002726486],"domain_scores_gemma":[0.9987073,0.00021464235,0.00010673674,0.00024509957,0.00009663615,0.000629563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018091072,0.0002265973,0.00052205817,0.00012690276,0.00013613571,0.000045762798,0.000050243158,0.000095023104,0.00019064292],"category_scores_gemma":[0.00043982966,0.00018690164,0.00016714315,0.00022614696,0.000084729254,0.00016122455,0.00009084722,0.0002827116,0.0003782387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103939026,0.0008145745,0.97049814,0.0001499141,0.000239981,0.000069791626,0.00012589364,0.000010849784,0.000030947496,0.000041727326,0.00661287,0.021301378],"study_design_scores_gemma":[0.0065705874,0.00066151685,0.9771997,0.00034721373,0.00059349457,0.000053270498,0.000084942556,0.000001883745,0.0004575447,0.0018073589,0.011883867,0.00033862],"about_ca_topic_score_codex":0.000021558813,"about_ca_topic_score_gemma":0.000056854355,"teacher_disagreement_score":0.020962756,"about_ca_system_score_codex":0.00019554018,"about_ca_system_score_gemma":0.00030062825,"threshold_uncertainty_score":0.76216274},"labels":[],"label_agreement":null},{"id":"W2020201613","doi":"10.1503/cmaj.061284","title":"Interaction between lopinavir/ritonavir and warfarin","year":2007,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ritonavir; Lopinavir; Warfarin; Protease; Pharmacology; Medicine; Drug interaction; Chemistry; Enzyme; Drug; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Internal medicine; Biochemistry; Viral load; Atrial fibrillation","score_opus":0.012567878773146041,"score_gpt":0.28276189417629405,"score_spread":0.270194015403148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020201613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91195947,0.00019354686,0.0002895461,0.07448205,0.0005988279,0.00014716393,0.0000066251228,0.000025597205,0.012297143],"genre_scores_gemma":[0.99069613,0.00011832329,0.00043595204,0.0027353624,0.0015887432,0.0000018054551,0.000029419323,0.000013035903,0.0043812483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837327,0.000039779607,0.0003420955,0.00011916016,0.00075606717,0.0003695987],"domain_scores_gemma":[0.99783784,0.00014827149,0.000111168214,0.00005077246,0.00015928161,0.0016926689],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013766881,0.00009917681,0.00019537717,0.00022414836,0.00018610468,0.00004357473,0.000048373575,0.00024995347,0.0013779801],"category_scores_gemma":[0.00050546764,0.000085627864,0.000052349726,0.00014739878,0.000023132794,0.000102866026,0.000009864505,0.00066706684,0.00015639534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012331208,0.000022412247,0.81817263,0.000006327355,0.00016941308,0.00075605774,0.00028959205,3.6211745e-8,0.000008154465,0.000071541916,0.033339053,0.14715242],"study_design_scores_gemma":[0.0011412062,0.000042990927,0.5243311,0.00009926819,0.000058297635,0.00062663615,0.0005351238,0.00001051063,0.000068548325,0.000079033176,0.47291642,0.00009089233],"about_ca_topic_score_codex":0.00065939385,"about_ca_topic_score_gemma":0.006776254,"teacher_disagreement_score":0.43957737,"about_ca_system_score_codex":0.0013919799,"about_ca_system_score_gemma":0.0010347995,"threshold_uncertainty_score":0.9995349},"labels":[],"label_agreement":null},{"id":"W2020208771","doi":"10.7448/ias.15.6.18398","title":"Observational study on HIV‐1‐infected patients treated with an ARV combination therapy including raltegravir: the RACING cohort results at month 12","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Raltegravir; Adverse effect; Regimen; Concomitant; Internal medicine; Viral load; Observational study; myalgia; Cohort; Cohort study; Prospective cohort study; Nausea; Pediatrics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.06850768114030224,"score_gpt":0.31754591224889156,"score_spread":0.2490382311085893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020208771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388695,0.000016434755,0.00001784537,0.0044521634,0.00033139007,0.00063255377,0.000021649053,0.000016321794,0.000624718],"genre_scores_gemma":[0.99440205,0.000027322025,0.00044680876,0.0005584739,0.00026401965,0.000017814926,0.00013694458,0.000020977297,0.0041255993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976884,0.00014206435,0.0005140863,0.00014615798,0.0013265174,0.00018273387],"domain_scores_gemma":[0.9982704,0.00022088323,0.00061460113,0.00019887717,0.0005990387,0.000096179916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000974588,0.00019460662,0.00024127537,0.00006437825,0.00034663343,0.000046142304,0.00025952188,0.000053628755,0.000038068236],"category_scores_gemma":[0.00012677479,0.00008946305,0.00022979782,0.00019548311,0.000052427607,0.00036764325,0.000071166396,0.00030532427,0.0000062196814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014640711,0.0026327672,0.98533106,0.0000016923234,0.0013326965,0.000002654047,0.0041771065,0.000048732047,0.00024492628,0.00007102223,0.0042059706,0.00048732507],"study_design_scores_gemma":[0.009264661,0.0010531355,0.9849375,0.0000994732,0.00017972889,0.000027842854,0.0006519564,0.00026391706,0.0014860975,0.000028169901,0.001906161,0.00010138176],"about_ca_topic_score_codex":0.000016626964,"about_ca_topic_score_gemma":0.000008432449,"teacher_disagreement_score":0.00780059,"about_ca_system_score_codex":0.00092098804,"about_ca_system_score_gemma":0.00009386932,"threshold_uncertainty_score":0.36481974},"labels":[],"label_agreement":null},{"id":"W2020574257","doi":"10.1021/jm060732n","title":"Synthesis and Structure−Activity Relationships of Truncated Bisubstrate Inhibitors of Aminoglycoside 6‘-<i>N</i>-Acetyltransferases","year":2006,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University","funders":"","keywords":"Chemistry; Aminoglycoside; Acetyltransferases; Enzyme; Acetyltransferase; Stereochemistry; Structure–activity relationship; Biochemistry; Amine gas treating; Combinatorial chemistry; Acetylation; Antibiotics; Organic chemistry; In vitro","score_opus":0.011695706228451843,"score_gpt":0.2274533924639309,"score_spread":0.21575768623547906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020574257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742407,0.0009242311,0.000049324906,0.0008545224,0.0000413847,0.0000821543,0.000018318196,0.000006856036,0.0005991366],"genre_scores_gemma":[0.9987132,0.00013308984,0.00072764687,0.000005842674,0.00015727084,0.0000013580295,0.000007954786,0.0000126329605,0.000241014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851096,0.000038546208,0.0006942246,0.00012038284,0.0004983364,0.00013754927],"domain_scores_gemma":[0.9987242,0.00029525434,0.0005033915,0.00011827294,0.00022507046,0.00013376729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003082667,0.00016921251,0.0005831816,0.00010911247,0.00004023147,0.0000040578266,0.000058804908,0.0001262049,0.00008818493],"category_scores_gemma":[0.00024817567,0.00012380828,0.000113876784,0.0001957258,0.00019449813,0.00007521559,0.000008661735,0.00033113718,2.479781e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055003696,0.0002378891,0.13977721,0.00049848785,0.00020638741,0.00011150054,0.00015493821,0.000006389475,0.85691833,0.0000051033608,0.0003869752,0.0011467342],"study_design_scores_gemma":[0.0015880308,0.00009938615,0.09342024,0.00076115015,0.00053495413,0.0006403663,0.00025605096,0.000008925565,0.9024337,0.00008874009,0.000087907734,0.0000805694],"about_ca_topic_score_codex":0.00002648845,"about_ca_topic_score_gemma":0.0000059711306,"teacher_disagreement_score":0.046356976,"about_ca_system_score_codex":0.000066884895,"about_ca_system_score_gemma":0.00024226835,"threshold_uncertainty_score":0.50487554},"labels":[],"label_agreement":null},{"id":"W2021038940","doi":"10.1097/qai.0b013e3180600709","title":"Protease Inhibitor-Based Regimens for HIV Therapy","year":2007,"lang":"en","type":"review","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Tolerability; Medicine; Protease inhibitor (pharmacology); Dosing; Pill; Human immunodeficiency virus (HIV); Internal medicine; Drug resistance; Randomized controlled trial; Pharmacology; Intensive care medicine; Virology; Antiretroviral therapy; Viral load; Adverse effect; Biology","score_opus":0.07211581144489648,"score_gpt":0.35484451115391263,"score_spread":0.28272869970901615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021038940","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006145547,0.99352723,0.00060401065,0.0005933113,0.00089796237,0.0033729733,0.00005767534,0.00009151203,0.00024077667],"genre_scores_gemma":[0.00021136827,0.9799615,0.008527189,0.0000565702,0.00031873485,0.0002176821,0.0002183799,0.00022759903,0.010260954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99444044,0.00018803452,0.0028663229,0.00053638243,0.0010965541,0.0008722849],"domain_scores_gemma":[0.99530756,0.00068575586,0.002279578,0.0007435358,0.00064634724,0.00033724177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024028828,0.0009480886,0.004128404,0.0021051231,0.00024051171,0.000080762344,0.00054543593,0.0005261067,0.00009510713],"category_scores_gemma":[0.00046255073,0.00062339636,0.0026608033,0.0013571001,0.00020474593,0.00019636143,0.000054462053,0.0003637391,0.00015422594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007240607,0.0020283333,0.000078747966,0.013051753,0.0019207825,0.0016601842,0.00031010614,0.0000026174052,0.000051975134,0.000060501276,0.011496652,0.9686143],"study_design_scores_gemma":[0.0055626556,0.0019074447,0.000035798646,0.023990396,0.0022458588,0.0027781222,0.00011038239,0.000006951406,0.00028034518,0.00003313967,0.96241766,0.00063126633],"about_ca_topic_score_codex":0.0000019189438,"about_ca_topic_score_gemma":1.4616681e-7,"teacher_disagreement_score":0.967983,"about_ca_system_score_codex":0.00059987203,"about_ca_system_score_gemma":0.0025316188,"threshold_uncertainty_score":0.99962175},"labels":[],"label_agreement":null},{"id":"W2021855902","doi":"10.1177/095632020501600502","title":"<i>In Vitro</i> Activity of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor (NRTI), against 215 HIV-1 Isolates Resistant to Other NRTIs","year":2005,"lang":"en","type":"article","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Didanosine; Abacavir; Zidovudine; Nucleoside Reverse Transcriptase Inhibitor; Lamivudine; Reverse transcriptase; Virology; Reverse-transcriptase inhibitor; Stavudine; Deoxycytidine; Zalcitabine; Deoxycytidine kinase; Resistance mutation; Biology; Human immunodeficiency virus (HIV); Virus; Viral load; Sida; Chemotherapy; Polymerase chain reaction; Viral disease; Biochemistry; Gemcitabine; Antiretroviral therapy","score_opus":0.008584953640573333,"score_gpt":0.24390346410491645,"score_spread":0.23531851046434313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021855902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730224,0.00027822214,0.00006552013,0.021509046,0.00004349582,0.0005294655,0.00008725835,0.00008591517,0.0043786597],"genre_scores_gemma":[0.9532642,0.00021421327,0.005318855,0.002792809,0.00040679643,0.00002517063,0.00004606514,0.0000938872,0.037838038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978549,0.00002900223,0.00057311653,0.0006287644,0.00035057683,0.0005636668],"domain_scores_gemma":[0.99892646,0.000041646796,0.00016459495,0.00051157706,0.0000626148,0.00029308282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018036034,0.00048315,0.00077404955,0.00013320454,0.00005559494,0.00002268862,0.00017495145,0.00020298194,0.00041964915],"category_scores_gemma":[0.00003301006,0.0004460261,0.00028386715,0.0005634489,0.00008704336,0.00022596776,0.000028868846,0.00027476458,0.00010389554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004124481,0.00088390446,0.0015307841,0.00014083584,0.00017232851,0.000075566786,0.0010044478,0.0000019046771,0.94885534,0.000001681879,0.031037133,0.012171576],"study_design_scores_gemma":[0.005503068,0.00007117017,0.00041621926,0.0002841289,0.000058301903,0.000010594402,0.00007228057,0.000049140304,0.8538786,0.000009128259,0.1392908,0.00035653997],"about_ca_topic_score_codex":0.00009020259,"about_ca_topic_score_gemma":0.000025074221,"teacher_disagreement_score":0.10825366,"about_ca_system_score_codex":0.00027898216,"about_ca_system_score_gemma":0.00026338152,"threshold_uncertainty_score":0.99979913},"labels":[],"label_agreement":null},{"id":"W2021877795","doi":"10.1086/375597","title":"Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel","year":2003,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":516,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Food and Drug Administration; International AIDS Society","keywords":"Medicine; Drug resistance; HIV drug resistance; Antiretroviral drug; Human immunodeficiency virus (HIV); Intensive care medicine; Immunology; Antiretroviral therapy; Virology; Family medicine; Viral load; Biology","score_opus":0.044524686221327915,"score_gpt":0.35195115730712484,"score_spread":0.3074264710857969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021877795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252677,0.0001414699,0.000023686209,0.000097062206,0.00025430194,0.00037610915,0.000033906337,0.00009155528,0.0064551216],"genre_scores_gemma":[0.99550503,0.00014922711,0.0016049616,0.00012537668,0.00005012589,0.000035138906,0.00023146452,0.00002530526,0.0022733656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981997,0.00018255663,0.0007314503,0.00039746327,0.00024220064,0.00024661922],"domain_scores_gemma":[0.9984554,0.00029705925,0.0002573869,0.00030705522,0.0005289244,0.00015419736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030711642,0.00020160133,0.00040784027,0.00013135315,0.00014294327,0.000025794821,0.00009952343,0.000081530416,0.00015120354],"category_scores_gemma":[0.0016281437,0.00016900546,0.00011169791,0.0009821821,0.00020670278,0.0002145053,0.000029696463,0.00024849706,0.000023837558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014979864,0.0034147908,0.99265397,0.000051745905,0.00014644023,0.000025614045,0.00020011503,0.0000059983777,0.000088204804,0.0004646438,0.0006940472,0.002104643],"study_design_scores_gemma":[0.0060437038,0.0010995344,0.9892676,0.0006330522,0.00019465362,0.000007699388,0.00019781348,0.000097681565,0.00018312648,0.0001944209,0.0018095928,0.0002711101],"about_ca_topic_score_codex":0.00008541222,"about_ca_topic_score_gemma":0.000295922,"teacher_disagreement_score":0.005893905,"about_ca_system_score_codex":0.00013259066,"about_ca_system_score_gemma":0.00040925056,"threshold_uncertainty_score":0.68918425},"labels":[],"label_agreement":null},{"id":"W2021978223","doi":"10.1371/journal.pone.0072784","title":"The Prevalence of Transmitted Resistance to First-Generation Non-Nucleoside Reverse Transcriptase Inhibitors and Its Potential Economic Impact in HIV-Infected Patients","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Efavirenz; Drug resistance; Reverse-transcriptase inhibitor; HIV drug resistance; Medicine; Reverse transcriptase; Virology; Viral load; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Internal medicine; Biology; Polymerase chain reaction; Genetics","score_opus":0.012280100056317066,"score_gpt":0.20758352358601345,"score_spread":0.19530342352969637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021978223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604666,0.00016187939,0.000005793243,0.0021703856,0.000030083427,0.0014352412,0.00006141419,0.000015012233,0.00007350389],"genre_scores_gemma":[0.9963986,0.0003012493,0.000416516,0.0000405273,0.000035836143,0.00010465035,0.000045647266,0.00001599633,0.00264096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902135,0.00003520122,0.00034246367,0.00022106449,0.00018329223,0.00019659822],"domain_scores_gemma":[0.9995321,0.00003203246,0.000067674104,0.00015402988,0.000088711044,0.00012546513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000924102,0.00014388363,0.00023450529,0.000102600214,0.00007663762,0.00001775046,0.00005247978,0.00005100563,0.00011459631],"category_scores_gemma":[0.000041905754,0.00010548827,0.000047602607,0.00011540822,0.000025885809,0.00014907538,0.000009702718,0.00007608134,0.00006033511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013582776,0.0034636685,0.71999145,0.0015352651,0.00082442205,0.000021764836,0.0060015214,0.000060959333,0.2513641,0.000020365658,0.014296857,0.0010613379],"study_design_scores_gemma":[0.0048285397,0.00031582764,0.85638505,0.00083159027,0.00034527158,7.703061e-7,0.000035155943,0.0029224104,0.13400115,0.000013028855,0.00010662926,0.00021457336],"about_ca_topic_score_codex":0.000063202315,"about_ca_topic_score_gemma":0.0002330638,"teacher_disagreement_score":0.1363936,"about_ca_system_score_codex":0.00017494439,"about_ca_system_score_gemma":0.000069320784,"threshold_uncertainty_score":0.43016866},"labels":[],"label_agreement":null},{"id":"W2022061101","doi":"10.1021/bi101480z","title":"Efavirenz Binding Site in HIV-1 Reverse Transcriptase Monomers","year":2010,"lang":"en","type":"article","venue":"Biochemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences","keywords":"Efavirenz; Reverse transcriptase; Human immunodeficiency virus (HIV); Virology; Chemistry; Binding site; Reverse-transcriptase inhibitor; Biology; RNA; Biochemistry; Viral load; Antiretroviral therapy","score_opus":0.007364695116959684,"score_gpt":0.2362246815979191,"score_spread":0.2288599864809594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022061101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554586,0.00006768225,0.0000020909613,0.0013578543,0.000100150006,0.00013202796,0.00048444484,0.000039203536,0.0022706622],"genre_scores_gemma":[0.97790474,0.000024017052,0.0015251103,0.000109210705,0.000084523155,0.000027086118,0.0028358267,0.000015213449,0.017474264],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992194,0.0000049645514,0.00018074903,0.00024921083,0.00012367051,0.00022200824],"domain_scores_gemma":[0.99954337,0.000011922686,0.000032468157,0.00023972681,0.00001605382,0.00015648012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089359346,0.00014694726,0.00017253219,0.00007434609,0.000033956087,0.000009963275,0.000058095287,0.00012668436,0.00047052364],"category_scores_gemma":[0.000030993135,0.00013550896,0.00007223705,0.00016121865,0.000046242694,0.000034141936,0.000013740415,0.00023916176,0.00031127996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006696087,0.00018378696,0.0730899,0.000073247975,0.00003281583,0.00023400185,0.00020604733,1.1820061e-7,0.8692336,0.0000025287613,0.056212325,0.00066466583],"study_design_scores_gemma":[0.00335097,0.000016503516,0.006387963,0.00012992903,0.00008803555,0.000073319905,0.00020977252,0.000028764218,0.86280406,0.0000039310808,0.12661411,0.0002926774],"about_ca_topic_score_codex":0.000016787644,"about_ca_topic_score_gemma":0.000007852219,"teacher_disagreement_score":0.07040179,"about_ca_system_score_codex":0.00007235885,"about_ca_system_score_gemma":0.000097342374,"threshold_uncertainty_score":0.55258954},"labels":[],"label_agreement":null},{"id":"W2022259265","doi":"10.1097/qad.0b013e328318f16c","title":"Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute on Governance; AIDS Vancouver","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases","keywords":"Reverse transcriptase; RNA; Biology; Molecular biology; RNA-Directed DNA Polymerase; Primer (cosmetics); Gene; Thymidine; Reverse transcription polymerase chain reaction; Mutation; Genetics; Virology; DNA; Messenger RNA; Chemistry","score_opus":0.016022735839279264,"score_gpt":0.2454308411127033,"score_spread":0.22940810527342403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022259265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997193,0.0004983391,0.00013537114,0.0010007027,0.00003628248,0.00040459147,0.000008077575,0.000053159718,0.00067049154],"genre_scores_gemma":[0.9917431,0.00010742754,0.0020332641,0.00011541117,0.000014385409,0.00004832934,0.0000712204,0.00001173526,0.0058551366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992437,0.00004484122,0.00018192662,0.00018812878,0.0001547034,0.00018672581],"domain_scores_gemma":[0.9996552,0.00006065419,0.00003062272,0.000117360425,0.000037482278,0.00009868958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008252939,0.00012382283,0.00022349793,0.00018567845,0.000080114565,0.0000048070297,0.00002775554,0.000043167263,0.00010168986],"category_scores_gemma":[0.00008352911,0.00010218709,0.000036400907,0.0004929106,0.000055084663,0.00005179161,0.000006882413,0.000096890166,0.00008987575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009911326,0.0010471926,0.96429694,0.00016882269,0.00012108075,0.0013886628,0.019527687,0.000014487147,0.0032703949,0.00010981407,0.008253375,0.0017024383],"study_design_scores_gemma":[0.010125196,0.0005576186,0.9717653,0.00053145416,0.00033545698,0.00044986195,0.0019550882,0.0008956909,0.009022579,0.000048505146,0.0039043368,0.0004089087],"about_ca_topic_score_codex":0.000022196555,"about_ca_topic_score_gemma":0.000012640799,"teacher_disagreement_score":0.017572599,"about_ca_system_score_codex":0.00007342718,"about_ca_system_score_gemma":0.000091512215,"threshold_uncertainty_score":0.4167069},"labels":[],"label_agreement":null},{"id":"W2022547531","doi":"10.1016/j.bmc.2013.01.007","title":"Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a carbamoyl linker","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Partenariat Canadien Contre Le Cancer","keywords":"Chemistry; HeLa; Linker; Stereochemistry; Nucleotide; DNA; Chemical synthesis; In vitro; Combinatorial chemistry; Biochemistry","score_opus":0.0320144626913331,"score_gpt":0.25949674234028447,"score_spread":0.22748227964895137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022547531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548465,0.0007334247,0.0005402918,0.0015928233,0.000022279264,0.00063348125,0.0000070989045,0.000041739437,0.00094419124],"genre_scores_gemma":[0.994555,0.00008473064,0.004391101,0.00006730241,0.000096234624,0.00007200091,0.000050008148,0.000032319036,0.00065132754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982923,0.000035074092,0.00034812023,0.00034003975,0.0007249275,0.00025951056],"domain_scores_gemma":[0.9989079,0.00014425415,0.00016367348,0.00025965204,0.00034804246,0.0001764679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046530497,0.0002574841,0.0004608335,0.000064129854,0.000052326217,0.000012937737,0.000075091186,0.00010513884,0.0005323337],"category_scores_gemma":[0.00029513024,0.00017809954,0.000036867732,0.00023616699,0.00019405906,0.00007685173,0.000030954146,0.00014333942,0.00002015035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001639657,0.00042277784,0.017417707,0.00040418774,0.00044947644,0.000029620902,0.0008562503,0.0000010930551,0.9745063,0.0000031028778,0.0010083964,0.004737129],"study_design_scores_gemma":[0.0050678654,0.00020513903,0.037642214,0.0009838575,0.0018040336,0.00022605398,0.0013748801,0.0023917109,0.94991297,0.00002584831,0.000074513875,0.00029092014],"about_ca_topic_score_codex":0.00005199655,"about_ca_topic_score_gemma":0.0000032258024,"teacher_disagreement_score":0.024593333,"about_ca_system_score_codex":0.00012746452,"about_ca_system_score_gemma":0.0004205041,"threshold_uncertainty_score":0.7262688},"labels":[],"label_agreement":null},{"id":"W2022650067","doi":"10.1097/qai.0b013e318263277e","title":"Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection","year":2012,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"","keywords":"Raltegravir; Efavirenz; Lamivudine; Tolerability; Integrase inhibitor; Medicine; Adverse effect; Pharmacology; Virology; Viral load; Reverse-transcriptase inhibitor; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Chronic hepatitis; Virus","score_opus":0.015334923150471632,"score_gpt":0.287476288008139,"score_spread":0.2721413648576674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022650067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941702,0.004863969,0.000043782733,0.00012595009,0.00022675522,0.0003707186,0.000009404967,0.000010574128,0.00017865704],"genre_scores_gemma":[0.99656147,0.002544914,0.00038958932,0.000004406504,0.000028957516,0.0000053376484,0.000019322068,0.000021812039,0.00042418306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811405,0.00011104052,0.0009809727,0.000112950576,0.00043496006,0.00024603578],"domain_scores_gemma":[0.9985759,0.00015795397,0.0007247158,0.00018333054,0.00027255804,0.000085529464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050083286,0.00019249391,0.00078115566,0.00063270674,0.000039337054,0.000007112084,0.00006382966,0.00009288244,0.000058829864],"category_scores_gemma":[0.00011818225,0.00014440886,0.0002473586,0.00045681547,0.0001979367,0.00028300838,0.000028021139,0.000049547412,0.0000052219852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008130342,0.008122232,0.8085494,0.00029449203,0.0012746133,0.00012882875,0.013152541,0.0000072495045,0.029525038,0.0004967589,0.000041982574,0.13027652],"study_design_scores_gemma":[0.011896143,0.0077323653,0.9442483,0.00028273085,0.0003332198,0.000371839,0.0006481549,0.0000087115795,0.034151036,0.00007030854,0.00013038883,0.00012680511],"about_ca_topic_score_codex":0.00003799091,"about_ca_topic_score_gemma":2.5421744e-7,"teacher_disagreement_score":0.1356989,"about_ca_system_score_codex":0.0001372897,"about_ca_system_score_gemma":0.00016760261,"threshold_uncertainty_score":0.5888822},"labels":[],"label_agreement":null},{"id":"W2022687162","doi":"10.1097/qad.0b013e328359a95c","title":"Tenofovir use and pregnancy among women initiating HAART","year":2012,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; U.S. Public Health Service","keywords":"Tenofovir; Pregnancy; Obstetrics; Medicine; Sida; Human immunodeficiency virus (HIV); Gynecology; Viral disease; Virology; Biology","score_opus":0.026572780852402972,"score_gpt":0.2546534505674634,"score_spread":0.22808066971506044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022687162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942467,0.00050618855,0.000023663488,0.00015747886,0.00006699758,0.00019214222,0.0000019644092,0.000059999405,0.004744837],"genre_scores_gemma":[0.97886026,0.00005742172,0.0024100472,0.00013564047,0.00006696069,0.000060531213,0.000014002602,0.000017507735,0.018377606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999266,0.000020356885,0.00013509482,0.00012373742,0.0001242481,0.00033055388],"domain_scores_gemma":[0.99953806,0.00006129857,0.000033947967,0.00013482796,0.000025394713,0.00020645568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011260098,0.000111795714,0.00016833284,0.00006941976,0.00007087379,0.00002212138,0.000022050242,0.000046402532,0.00012765091],"category_scores_gemma":[0.00008271039,0.00008580489,0.000023507248,0.00009879075,0.00004107397,0.00035553673,0.000041616004,0.00007467045,0.00008319347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000070517335,0.00009988767,0.98504984,0.00002893141,0.000084546366,0.000019855885,0.004179291,2.289431e-8,0.00019857749,0.00014499864,0.00041563745,0.009771369],"study_design_scores_gemma":[0.0012677381,0.00011882352,0.9887977,0.00033387978,0.00007436804,0.00001954836,0.0006193242,0.000006665332,0.001649557,0.000037425587,0.0069317985,0.000143121],"about_ca_topic_score_codex":0.000010140257,"about_ca_topic_score_gemma":9.869073e-7,"teacher_disagreement_score":0.015386445,"about_ca_system_score_codex":0.00006209368,"about_ca_system_score_gemma":0.000023893492,"threshold_uncertainty_score":0.34990218},"labels":[],"label_agreement":null},{"id":"W2022787293","doi":"10.1186/1741-7015-11-249","title":"What if HIV were unable to develop resistance against a new therapeutic agent?","year":2013,"lang":"en","type":"article","venue":"BMC Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Dolutegravir; Drug resistance; Drug; Integrase inhibitor; Resistance mutation; Human immunodeficiency virus (HIV); Food and drug administration; Viral replication; Pharmacology; Virology; ANTIRETROVIRAL AGENTS; Antiretroviral therapy; Intensive care medicine; Virus; Viral load; Genetics; Gene; Reverse transcriptase","score_opus":0.03277880346640674,"score_gpt":0.2805638879207553,"score_spread":0.24778508445434858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022787293","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26999813,0.029055046,0.011682138,0.55147684,0.0034941726,0.0083788,0.0000069267944,0.0009440387,0.12496394],"genre_scores_gemma":[0.10826012,0.0012765997,0.016472997,0.011622415,0.00073291286,0.00022283792,0.00015314133,0.000077276556,0.8611817],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770087,0.000054246375,0.0005312977,0.00053660525,0.0006109425,0.0005660398],"domain_scores_gemma":[0.9981463,0.00014673702,0.00009972592,0.00061213144,0.00026729822,0.0007278415],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029196969,0.00035909415,0.0006111859,0.00023280083,0.0001174716,0.000052127456,0.00018962013,0.00010237232,0.0024277912],"category_scores_gemma":[0.00026888272,0.00024329757,0.000060042643,0.0007968864,0.00007533125,0.0002553045,0.00006496242,0.00016589738,0.003714009],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023705798,0.0001669153,0.018993257,0.0002205942,0.00026579015,0.00012822566,0.005488675,0.000004189312,0.0016222853,0.00048470302,0.93416154,0.038226746],"study_design_scores_gemma":[0.0060937293,0.00017727024,0.037164636,0.0026170677,0.00021673011,0.000020558527,0.0039176405,0.000042957356,0.0012356861,0.00055565324,0.9475482,0.00040986954],"about_ca_topic_score_codex":0.00004442815,"about_ca_topic_score_gemma":0.00016120025,"teacher_disagreement_score":0.73621774,"about_ca_system_score_codex":0.0002569173,"about_ca_system_score_gemma":0.00067090243,"threshold_uncertainty_score":0.99848413},"labels":[],"label_agreement":null},{"id":"W2022895457","doi":"10.3851/imp1953","title":"A Case of a Potential Drug Interaction between Clobazam and Etravirine-Based Antiretroviral Therapy","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Maple Leaf Medical Clinic; St. Michael's Hospital","funders":"","keywords":"Etravirine; Clobazam; Pharmacology; CYP3A4; CYP2C19; Metabolite; Reverse-transcriptase inhibitor; Drug; Active metabolite; Drug interaction; Pharmacokinetics; Cytochrome P450; Medicine; Internal medicine; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Metabolism; Virology; Epilepsy","score_opus":0.043888118196605555,"score_gpt":0.2934531332387544,"score_spread":0.24956501504214884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022895457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747205,0.00037574445,0.00012768427,0.00026469486,0.00010739589,0.00046625477,0.000014371384,0.00006269669,0.0011090982],"genre_scores_gemma":[0.9972072,0.0004954256,0.0012005161,0.00012582367,0.000103739534,0.000015049602,0.000037043792,0.000030483721,0.00078468927],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989042,0.000080957434,0.00031457574,0.00028931716,0.00017230397,0.0002385939],"domain_scores_gemma":[0.9994602,0.000036645917,0.00013467557,0.000219738,0.000067944435,0.0000807572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017472185,0.00024024976,0.00040698663,0.00019562859,0.000079881465,0.000015212941,0.000058731544,0.00008033028,0.000108555585],"category_scores_gemma":[0.000005340902,0.00018029923,0.00014735844,0.00019146096,0.00012744083,0.0001578854,0.000016185972,0.00015370015,0.000016324193],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002402545,0.0008966563,0.73197824,0.00003528755,0.00053827476,0.0018348772,0.0028880537,1.0423269e-7,0.013855738,0.0000805427,0.0003327578,0.24515694],"study_design_scores_gemma":[0.022806605,0.0040361895,0.39543906,0.00023344511,0.0002501171,0.00086432416,0.0009491984,0.00020700449,0.5708918,0.00029702854,0.003296294,0.00072895247],"about_ca_topic_score_codex":0.0002841426,"about_ca_topic_score_gemma":0.000009852297,"teacher_disagreement_score":0.55703604,"about_ca_system_score_codex":0.000024639676,"about_ca_system_score_gemma":0.00006461488,"threshold_uncertainty_score":0.73523897},"labels":[],"label_agreement":null},{"id":"W2022970838","doi":"10.7448/ias.17.4.19518","title":"The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Integrase; Raltegravir; Integrase inhibitor; Virology; Mutation; Mutagenesis; Resistance mutation; Drug resistance; Viral replication; Biology; Medicine; Genetics; Virus; Viral load; Human immunodeficiency virus (HIV); Reverse transcriptase; Gene; Antiretroviral therapy; Polymerase chain reaction","score_opus":0.012504043813566717,"score_gpt":0.28962404396114966,"score_spread":0.2771200001475829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022970838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7839246,0.00031602298,0.0021434985,0.20953175,0.0009956853,0.0005756603,0.0000406516,0.000022467042,0.0024496792],"genre_scores_gemma":[0.93080837,0.0003398181,0.011573835,0.0037373388,0.00021992216,0.000014590643,0.000026086087,0.00002202897,0.05325802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767715,0.00015461484,0.00079657196,0.000184717,0.00098283,0.00020412871],"domain_scores_gemma":[0.99791944,0.0007089432,0.00054598984,0.0002119907,0.0004962162,0.000117434385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016074328,0.00017600373,0.0002896369,0.00005296076,0.00015260643,0.000083272476,0.0005212575,0.000086635904,0.000100985424],"category_scores_gemma":[0.0006999108,0.00009148702,0.00035416413,0.00025652943,0.0000791462,0.00011719224,0.00008991475,0.00053265376,0.000026001388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009450665,0.00063522643,0.029490948,0.000018729803,0.0012948544,0.000020314066,0.0057377154,0.000017223529,0.0029522097,0.0004956039,0.9541666,0.004225491],"study_design_scores_gemma":[0.009086128,0.0008633146,0.048432272,0.0019006128,0.0006088445,0.00033069993,0.0038014103,0.0014743773,0.020771703,0.005543882,0.90665525,0.00053148664],"about_ca_topic_score_codex":0.000008738274,"about_ca_topic_score_gemma":0.000044619774,"teacher_disagreement_score":0.20579442,"about_ca_system_score_codex":0.0006939528,"about_ca_system_score_gemma":0.00028374596,"threshold_uncertainty_score":0.37307325},"labels":[],"label_agreement":null},{"id":"W2023156689","doi":"10.1097/00007890-201007272-00006","title":"BK VIRUS HIGH LEVEL REPLICATION IN VITRO REDUCED BY CYCLOSPORINE A, PROXIMAL TUBULE CELL TYPE AND CULTURE ENVIRONMENT (POLARITY) BUT NOT BY TACROLIMUS","year":2010,"lang":"en","type":"article","venue":"Transplantation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"In vitro; Tacrolimus; Polarity (international relations); Cell culture; Virology; Replication (statistics); Chemistry; Cell biology; Cell; Biology; Molecular biology; Medicine; Transplantation; Internal medicine; Genetics; Biochemistry","score_opus":0.009785769830601487,"score_gpt":0.22909526782280062,"score_spread":0.21930949799219915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023156689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712306,0.00010979176,0.00019657098,0.0013185288,0.00006326306,0.0005941667,0.00029288817,0.000038473,0.00026325326],"genre_scores_gemma":[0.98290676,0.0008476833,0.0042869234,0.000095809904,0.00003837206,0.000060946353,0.0037983237,0.000021017338,0.00794419],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989541,0.000021374983,0.000246685,0.000386073,0.0002029574,0.00018878392],"domain_scores_gemma":[0.99958104,0.000016574415,0.00006740584,0.00021028242,0.00002612877,0.00009857644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001136067,0.00017577689,0.00019259137,0.00006506484,0.000059937414,0.000014889406,0.00004570382,0.0001425392,0.00005383648],"category_scores_gemma":[0.000006638401,0.00015460419,0.000021080354,0.000112174785,0.000035857876,0.000104157996,0.0000055992577,0.0002343037,0.000040093226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009512001,0.00034653285,0.0030905586,0.00008303616,0.00002182688,0.000024887899,0.0010542924,5.891357e-7,0.99222225,0.000017661801,0.0005157952,0.0016713891],"study_design_scores_gemma":[0.0032568248,0.00010090787,0.025653379,0.000018712095,0.00011768625,0.00003325306,0.000023708772,0.00004432547,0.9668685,0.000023523546,0.0036990207,0.00016015607],"about_ca_topic_score_codex":0.00022821761,"about_ca_topic_score_gemma":0.000040958217,"teacher_disagreement_score":0.025353728,"about_ca_system_score_codex":0.00006103781,"about_ca_system_score_gemma":0.00003562734,"threshold_uncertainty_score":0.63045764},"labels":[],"label_agreement":null},{"id":"W2023487690","doi":"10.1016/j.ab.2003.06.001","title":"A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity","year":2003,"lang":"en","type":"article","venue":"Analytical Biochemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of General Medical Sciences; amfAR, The Foundation for AIDS Research","keywords":"RNase H; Reverse transcriptase; Fluorescence; DNA; High-throughput screening; Molecular biology; RNA; Ribonuclease; Nucleotide; Chemistry; Duplex (building); Fluorescein; Förster resonance energy transfer; RNase P; Ribonucleotide; Biochemistry; Biology; Gene","score_opus":0.02129078227101781,"score_gpt":0.27731534587161,"score_spread":0.25602456360059217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023487690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608755,0.00009379292,0.0010379332,0.0009209502,0.00004725117,0.0004023108,0.00015930386,0.00006999934,0.0011808823],"genre_scores_gemma":[0.99415857,0.0000061400096,0.0030328354,0.000100229874,0.000027381378,0.000027334263,0.00029189565,0.000030037945,0.002325569],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815184,0.000060030514,0.00045343253,0.00047659193,0.00041828747,0.00043983673],"domain_scores_gemma":[0.9989183,0.0001344898,0.00015965596,0.0003766949,0.00018686872,0.00022400184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046608844,0.00029186998,0.0005445686,0.00008646168,0.00016932288,0.000017345896,0.00010495743,0.00023654866,0.00021817142],"category_scores_gemma":[0.00064596196,0.0002638858,0.00037645074,0.00040769178,0.00022864767,0.00005580714,0.000015839838,0.00022151202,0.0000088600145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004272632,0.0024993524,0.0095581785,0.00027915096,0.00046785525,0.00005947686,0.0000821692,0.0000035988658,0.97908396,0.00031245095,0.006312411,0.0009141506],"study_design_scores_gemma":[0.0043340144,0.00020198694,0.0013379205,0.00030486393,0.0006633396,0.0000036056865,0.00009481765,0.00073874614,0.99119765,0.000057379086,0.00076979096,0.00029587618],"about_ca_topic_score_codex":0.00008678881,"about_ca_topic_score_gemma":0.0000032376397,"teacher_disagreement_score":0.012113716,"about_ca_system_score_codex":0.00021092907,"about_ca_system_score_gemma":0.00028965238,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W2024664208","doi":"10.1007/bf02256074","title":"Stimulation of human flap endonuclease 1 by human immunodeficiency virus type 1 integrase: Possible role for flap endonuclease 1 in 5′-end processing of human immunodeficiency virus type 1 integration intermediates","year":2002,"lang":"en","type":"article","venue":"Journal of Biomedical Science","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Integrase; DNA ligase; Nucleotide excision repair; Biology; DNA repair; Base excision repair; DNA; Endonuclease; DNA glycosylase; Molecular biology; Biochemistry","score_opus":0.02229933051235939,"score_gpt":0.31383239660453377,"score_spread":0.2915330660921744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024664208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632823,0.0018887549,0.00028108864,0.0002546074,0.00022451914,0.0004142582,0.000023120074,0.000020021853,0.000565366],"genre_scores_gemma":[0.998325,0.00011176127,0.0010049833,0.000038086022,0.00006354379,0.000006874734,0.00005546448,0.000023473753,0.00037080087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99617606,0.00006875074,0.0015590407,0.00037706833,0.001289553,0.00052953564],"domain_scores_gemma":[0.99752086,0.00010479697,0.0009975261,0.00026954335,0.000809566,0.00029772302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00153456,0.00028428333,0.000667472,0.0010894118,0.00036506326,0.00007006804,0.00054916204,0.00014288478,0.00056142657],"category_scores_gemma":[0.0007360581,0.00020921437,0.00016406988,0.0018679696,0.0012038859,0.0006152208,0.000099126555,0.00039352872,0.0000121674575],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021441864,0.0020731175,0.0030247374,0.00009804785,0.000031252242,0.000023885708,0.00275586,0.0000051559805,0.96697026,0.00012765206,0.00041997046,0.024255624],"study_design_scores_gemma":[0.0127912555,0.012860494,0.034306392,0.0039805477,0.000589678,0.00019538587,0.004492546,0.019235054,0.90752274,0.0015082953,0.0015743806,0.0009432335],"about_ca_topic_score_codex":0.00017027785,"about_ca_topic_score_gemma":0.000034322005,"teacher_disagreement_score":0.059447538,"about_ca_system_score_codex":0.00044090874,"about_ca_system_score_gemma":0.00042561628,"threshold_uncertainty_score":0.85315144},"labels":[],"label_agreement":null},{"id":"W2025259834","doi":"10.3390/v2040900","title":"HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors","year":2010,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"RNase H; Reverse transcriptase; Ribonuclease; Human immunodeficiency virus (HIV); Virology; Mechanism (biology); RNase P; Drug; Enzyme; Biology; Medicine; Chemistry; Pharmacology; RNA; Biochemistry; Gene","score_opus":0.010869021662373702,"score_gpt":0.2475730728648344,"score_spread":0.2367040512024607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025259834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997567,0.0000780464,0.000006781902,0.00083891617,0.0002467653,0.00019570794,0.00003752425,0.000081354854,0.00094788935],"genre_scores_gemma":[0.9948364,0.000018040053,0.0016818597,0.0005490834,0.00015246787,0.0000066981306,0.000035796846,0.000022500144,0.002697171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993497,0.0000066556468,0.00013064439,0.00020261551,0.00014519025,0.00016519483],"domain_scores_gemma":[0.99955297,0.000026159556,0.000033058743,0.00018935083,0.000024969839,0.00017348077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041694697,0.00014003635,0.00016639655,0.00009693442,0.00007433027,0.00002283518,0.00003645645,0.000073693,0.0002963138],"category_scores_gemma":[0.000049548424,0.00010460029,0.000028944429,0.00008299921,0.00005805025,0.000080061705,0.00004066741,0.0001493717,0.00021353141],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003291573,0.00062155584,0.29305476,0.00023732742,0.00058588595,0.0008137948,0.0027920105,3.2464192e-7,0.60056937,0.03343209,0.046772297,0.02079142],"study_design_scores_gemma":[0.0045641833,0.00015279671,0.036170382,0.0001150273,0.0004652485,0.00027148778,0.00025170768,0.00006436336,0.78682315,0.006563941,0.16398722,0.0005705125],"about_ca_topic_score_codex":0.000027456272,"about_ca_topic_score_gemma":0.00004758814,"teacher_disagreement_score":0.2568844,"about_ca_system_score_codex":0.000016787633,"about_ca_system_score_gemma":0.000056742832,"threshold_uncertainty_score":0.4265476},"labels":[],"label_agreement":null},{"id":"W2025483541","doi":"10.1074/jbc.m607710200","title":"The Pyrophosphate Analogue Foscarnet Traps the Pre-translocational State of HIV-1 Reverse Transcriptase in a Brownian Ratchet Model of Polymerase Translocation","year":2006,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Foscarnet; Reverse transcriptase; Virology; Chromosomal translocation; Pyrophosphate; Human immunodeficiency virus (HIV); Chemistry; Tenofovir; Medicine; Enzyme; Polymerase chain reaction; Biochemistry; Viral disease; Gene","score_opus":0.014960379383709681,"score_gpt":0.23619434088919986,"score_spread":0.22123396150549018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025483541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906383,0.0023253057,0.00085505575,0.005737551,0.00001992342,0.0001837751,0.000091731585,0.000004619325,0.00014370754],"genre_scores_gemma":[0.9977863,0.0008367339,0.0005222944,0.00006050858,0.00003648194,0.000009179505,0.000075623044,0.0000068913046,0.000665987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984703,0.000057483256,0.0008750714,0.00013196339,0.00028441998,0.00018074409],"domain_scores_gemma":[0.99918437,0.00009978527,0.00034644746,0.00014957397,0.00014554331,0.00007427179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004954669,0.00015413646,0.00036449445,0.0000352285,0.000048049056,0.000006585269,0.00017037759,0.00009493356,0.000029589737],"category_scores_gemma":[0.00003470558,0.00007584488,0.00022343501,0.00020664166,0.0002502487,0.00004385236,0.0000054855736,0.00025251077,4.9052056e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002216468,0.001115268,0.009621879,0.00011491331,0.00022156318,0.000047189103,0.0012005823,0.0022689106,0.9761531,0.00004740675,0.0011248249,0.0058679217],"study_design_scores_gemma":[0.005425791,0.00023593451,0.02694718,0.0002849887,0.00018718555,0.00010463543,0.00046955748,0.0026881797,0.9612984,0.0012335917,0.00093975844,0.00018481755],"about_ca_topic_score_codex":0.000027683162,"about_ca_topic_score_gemma":0.000015654545,"teacher_disagreement_score":0.0173253,"about_ca_system_score_codex":0.000058575668,"about_ca_system_score_gemma":0.0002701558,"threshold_uncertainty_score":0.30928645},"labels":[],"label_agreement":null},{"id":"W2025485735","doi":"10.1002/qsar.200810166","title":"QSAR Studies of HEPT Derivatives Using Support Vector Machines","year":2009,"lang":"en","type":"article","venue":"QSAR & Combinatorial Science","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Support vector machine; Thymine; Quantitative structure–activity relationship; Kernel (algebra); Steric effects; Artificial neural network; Chemistry; Molecular descriptor; Human immunodeficiency virus (HIV); Artificial intelligence; Biological system; Computer science; Combinatorial chemistry; Stereochemistry; Mathematics; Biology; Biochemistry; Virology","score_opus":0.045015148517982995,"score_gpt":0.36315382141133834,"score_spread":0.31813867289335535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025485735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945678,0.00030813625,0.00002279108,0.0012389896,0.0013177585,0.0002948462,0.0000024190329,0.00004874222,0.0021984961],"genre_scores_gemma":[0.9969355,0.000042097323,0.002125736,0.00008267898,0.00015221514,0.0000034383852,0.000003053527,0.000007215651,0.0006480743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982935,0.000031112748,0.00030478637,0.00033413142,0.00066407863,0.0003723711],"domain_scores_gemma":[0.99911594,0.000064936794,0.00012496849,0.00023879658,0.00029896369,0.00015638336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000552886,0.00017846553,0.00040813175,0.00017330244,0.0002541667,0.000022164582,0.00019777766,0.000038551352,0.00004606937],"category_scores_gemma":[0.00044003286,0.00013264875,0.00006942509,0.0008541289,0.00052313274,0.00023108748,0.00007605007,0.00008420287,0.000015862342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060875603,0.003006525,0.18805242,0.0002180529,0.0004726186,0.00030105855,0.019791761,0.0000147735645,0.6651471,0.09870772,0.0037089107,0.019970289],"study_design_scores_gemma":[0.012179448,0.0038293484,0.28573257,0.0008717163,0.0005487072,0.00011804765,0.002425019,0.00077300175,0.64719284,0.036191564,0.008820718,0.0013170529],"about_ca_topic_score_codex":0.000017000762,"about_ca_topic_score_gemma":0.0000014534785,"teacher_disagreement_score":0.09768015,"about_ca_system_score_codex":0.00021834856,"about_ca_system_score_gemma":0.0004969197,"threshold_uncertainty_score":0.540926},"labels":[],"label_agreement":null},{"id":"W2025612185","doi":"10.1016/j.antiviral.2013.04.001","title":"Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors","year":2013,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Integrase; DNA; High-throughput screening; HIV Long Terminal Repeat; Ligand binding assay; Biology; Binding site; Small molecule; Virology; Biochemistry; Long terminal repeat; Chemistry; Molecular biology; Gene; Genome","score_opus":0.07631490118335602,"score_gpt":0.36356287961036593,"score_spread":0.2872479784270099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025612185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871071,0.000030234629,0.008322019,0.001790273,0.000086885935,0.0020241805,0.00006728696,0.00003466399,0.0005373467],"genre_scores_gemma":[0.95219654,0.000012089674,0.03996525,0.000010079072,0.000046094272,0.00041425863,0.0004547387,0.000035900805,0.0068650446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969107,0.00011072906,0.0009193542,0.000445886,0.0010475033,0.0005658254],"domain_scores_gemma":[0.9976801,0.00051335426,0.00022303581,0.0003806787,0.0010701923,0.00013260753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024066279,0.00023313912,0.00045438792,0.000980808,0.00017557593,0.000044088007,0.00023656314,0.00013386151,0.000057721612],"category_scores_gemma":[0.0011449135,0.00018028298,0.00016496367,0.0008828664,0.00029282673,0.00020480614,0.00010099175,0.00030594305,0.0002787518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000315766,0.001516574,0.01978412,0.00045616017,0.00021960518,0.000007575858,0.0014818881,3.6867553e-7,0.93048126,0.00038507336,0.009507031,0.035844598],"study_design_scores_gemma":[0.0028114521,0.00014043451,0.0049546165,0.00081034546,0.000051119456,0.0000014380987,0.0016985436,0.002560717,0.98561144,0.00004010369,0.0011472458,0.00017257214],"about_ca_topic_score_codex":0.000051758063,"about_ca_topic_score_gemma":0.00002255771,"teacher_disagreement_score":0.055130173,"about_ca_system_score_codex":0.00029706937,"about_ca_system_score_gemma":0.001006262,"threshold_uncertainty_score":0.7351727},"labels":[],"label_agreement":null},{"id":"W2025935798","doi":"10.1371/journal.pmed.1001810","title":"Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Simon Fraser University; Public Health Agency of Canada","funders":"U.S. Public Health Service; National Institutes of Health; Biotechnology and Biological Sciences Research Council; World Health Organization; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation","keywords":"Drug resistance; Odds ratio; Molecular epidemiology; GenBank; Epidemiology; Virology; Medicine; Genotype; Demography; Biology; Genetics; Internal medicine","score_opus":0.22184059188928293,"score_gpt":0.37218686217976144,"score_spread":0.1503462702904785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025935798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049661035,0.9888862,0.00010392902,0.004658076,0.000017280296,0.0010538524,0.00020273995,0.000018538713,0.00009332319],"genre_scores_gemma":[0.013196015,0.975864,0.007286698,0.00040286992,0.00003167902,0.0003569906,0.0020467013,0.000055071847,0.00076000555],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99523675,0.0013745733,0.0014865203,0.0008277241,0.0006822814,0.00039214283],"domain_scores_gemma":[0.9977912,0.0005318527,0.0006159781,0.000611103,0.00011146753,0.00033841757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019833639,0.000663638,0.00614684,0.001803813,0.0000607008,0.0000082627685,0.00019889444,0.00028079445,0.000085790736],"category_scores_gemma":[0.00017182044,0.00034303823,0.00045509613,0.0016162492,0.00053870725,0.00004795191,0.00005366126,0.00042560673,7.541737e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027266596,0.0016778334,0.01670423,0.024569208,0.43711725,0.003251492,0.029201359,0.0000013781124,0.000017446058,0.002389636,0.002793042,0.48200446],"study_design_scores_gemma":[0.0033490479,0.00062595843,0.002835342,0.002525454,0.9232446,0.00029650098,0.0009688593,0.0000397193,0.0000052752243,0.0031363438,0.062264096,0.0007087908],"about_ca_topic_score_codex":0.00008051349,"about_ca_topic_score_gemma":0.00027926188,"teacher_disagreement_score":0.48612738,"about_ca_system_score_codex":0.0000365876,"about_ca_system_score_gemma":0.00012622474,"threshold_uncertainty_score":0.9999022},"labels":[],"label_agreement":null},{"id":"W2025994307","doi":"10.1111/j.1468-1293.2006.00402.x","title":"Long‐term assessment of nevirapine‐containing highly active antiretroviral therapy in antiretroviral‐naive HIV‐infected patients: 3‐year follow‐up of the VIRGO study","year":2006,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Styrelsen för Internationellt Utvecklingssamarbete; Bristol-Myers Squibb","keywords":"Nevirapine; Medicine; Didanosine; Stavudine; Viral load; Regimen; Internal medicine; Reverse-transcriptase inhibitor; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.013225529710386758,"score_gpt":0.2826019917329998,"score_spread":0.26937646202261306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025994307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993541,0.00021065796,0.000045504225,0.0006984796,0.00037537224,0.00219251,0.00003180947,0.000047593996,0.002857056],"genre_scores_gemma":[0.9962791,0.00008237433,0.00014804461,0.000103528946,0.00015728861,0.000052447413,0.0002667757,0.00005037319,0.0028600693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965905,0.00026387617,0.0011049577,0.00050649734,0.0010785874,0.00045561182],"domain_scores_gemma":[0.99817896,0.00017087438,0.0006083501,0.0006180685,0.00032090387,0.00010283466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040396705,0.00045418262,0.0012130871,0.0004916142,0.00008750507,0.000007840478,0.00025596787,0.00012317036,0.00016963852],"category_scores_gemma":[0.000121893754,0.0002781862,0.00019969189,0.0009886068,0.00029000404,0.00016142034,0.00010005461,0.000374845,0.000008399174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012912864,0.0025390615,0.9859011,0.000065858134,0.000385856,0.000058783713,0.0026829566,0.000003034713,0.0028414093,0.000085837804,0.0010727228,0.0030720583],"study_design_scores_gemma":[0.036498554,0.0058523184,0.9523878,0.0007455025,0.00029909346,0.0000029447829,0.0012186405,0.00003842674,0.002607429,0.000014430805,0.00012041923,0.00021440935],"about_ca_topic_score_codex":0.00037843795,"about_ca_topic_score_gemma":0.000100506935,"teacher_disagreement_score":0.035207268,"about_ca_system_score_codex":0.00030941417,"about_ca_system_score_gemma":0.00026566134,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W2026296457","doi":"10.1517/14656566.2014.868884","title":"Raltegravir as antiretroviral therapy in HIV/AIDS","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Raltegravir; Medicine; Tolerability; Integrase inhibitor; Antiretroviral therapy; Dosing; Pharmacology; Drug; Drug resistance; Dolutegravir; Nucleoside Reverse Transcriptase Inhibitor; Lamivudine; Human immunodeficiency virus (HIV); Adverse effect; Intensive care medicine; Virology; Viral load; Virus; Chronic hepatitis","score_opus":0.08558497252242242,"score_gpt":0.42983217118888994,"score_spread":0.3442471986664675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026296457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000072511655,0.9898049,0.0000065444533,0.0009837018,0.0013036054,0.0035442354,0.00002402972,0.00020196218,0.0040584896],"genre_scores_gemma":[0.000009751661,0.96189314,0.0009546348,0.0021202576,0.0010825102,0.0014437346,0.0006588503,0.00025969572,0.031577412],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620837,0.0003543839,0.0010450961,0.0009968193,0.00067326304,0.0007220928],"domain_scores_gemma":[0.9984651,0.00015631027,0.00032850314,0.0006462688,0.000059196256,0.00034462815],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025364748,0.0011702997,0.0025809668,0.0009354016,0.000101374266,0.00007332713,0.0003737146,0.00045347356,0.0066882195],"category_scores_gemma":[0.000012026596,0.0007878026,0.0008706251,0.00068693486,0.00008584898,0.00015348068,0.000033444205,0.00079579366,0.005309134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021662291,0.0009051563,0.000059802678,0.00046622413,0.00053923635,0.000081291284,0.00055252534,5.9544487e-8,0.000049894683,0.0002572231,0.07423877,0.9226332],"study_design_scores_gemma":[0.0063719475,0.0009604173,0.0000038476196,0.006965632,0.000024893852,0.00006825146,0.00004354417,0.0000056000504,0.0004343563,0.000020052148,0.984374,0.00072744506],"about_ca_topic_score_codex":0.000036442838,"about_ca_topic_score_gemma":2.3780012e-7,"teacher_disagreement_score":0.92190576,"about_ca_system_score_codex":0.0005193509,"about_ca_system_score_gemma":0.0005844567,"threshold_uncertainty_score":0.9994573},"labels":[],"label_agreement":null},{"id":"W2026564608","doi":"10.1016/j.bmcl.2011.05.005","title":"Inhibition of multi-drug resistant HIV-1 reverse transcriptase by nucleoside β-triphosphates","year":2011,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute on Minority Health and Health Disparities; National Center for Research Resources; National Institute of General Medical Sciences; National Institute on Drug Abuse","keywords":"Chemistry; Reverse transcriptase; Nucleoside; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Drug; Human immunodeficiency virus (HIV); Virology; Nucleotidyltransferase; Lentivirus; Stereochemistry; Pharmacology; Viral disease; Biochemistry; RNA; Gene","score_opus":0.01667636170259626,"score_gpt":0.2131609807127487,"score_spread":0.19648461901015243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026564608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862223,0.0012989518,0.00015402485,0.010949908,0.000094652,0.00035416335,0.000084774816,0.00011011919,0.0007310617],"genre_scores_gemma":[0.99123514,0.00015058536,0.0024165357,0.0017439659,0.00009854558,0.00002167107,0.00038316316,0.00005182636,0.0038985438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980942,0.00002705923,0.00058167404,0.00044219,0.00046934787,0.00038555355],"domain_scores_gemma":[0.9990146,0.000028156779,0.00019822092,0.00036426194,0.00007934731,0.00031537513],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022006374,0.00033645326,0.0004844551,0.000061306484,0.00007303379,0.0000059087674,0.00012583152,0.00011684945,0.0016598002],"category_scores_gemma":[0.00006567589,0.00028651228,0.00015057206,0.00026100967,0.00026188567,0.000080690756,0.000024339559,0.00024547215,0.00007239814],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045280956,0.00044504055,0.0033366363,0.00034283957,0.00016607966,0.0004231943,0.0022503305,1.6375862e-8,0.8871242,0.0000021217202,0.105314024,0.00014273371],"study_design_scores_gemma":[0.004441382,0.00004040772,0.0014897344,0.00051416445,0.00042388737,0.00007928487,0.0012288798,0.000005312232,0.9835484,0.0000035335067,0.007965647,0.0002593481],"about_ca_topic_score_codex":0.00010249667,"about_ca_topic_score_gemma":0.0000024706364,"teacher_disagreement_score":0.09734838,"about_ca_system_score_codex":0.00019736419,"about_ca_system_score_gemma":0.00011621264,"threshold_uncertainty_score":0.9999587},"labels":[],"label_agreement":null},{"id":"W2026869349","doi":"10.1016/j.bmcl.2007.07.095","title":"Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality","year":2007,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ryerson University; University of Minnesota","keywords":"Protease; Chemistry; Moiety; Potency; HIV-1 protease; Stereochemistry; Structure–activity relationship; Enzyme inhibitor; Protease inhibitor (pharmacology); Enzyme; Human immunodeficiency virus (HIV); Biochemistry; In vitro; Virology; Antiretroviral therapy; Viral load; Biology","score_opus":0.011571441025566566,"score_gpt":0.2325556936341822,"score_spread":0.22098425260861562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026869349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98075926,0.00016823642,0.0015923003,0.015640417,0.00016167841,0.0003940971,0.000018002325,0.00007020514,0.0011958028],"genre_scores_gemma":[0.9940439,0.0000056702966,0.0011307461,0.00070930645,0.00076908094,0.000014504808,0.00029383018,0.000031613265,0.0030013444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773204,0.000018316625,0.0007009693,0.0004137647,0.00076335313,0.0003715634],"domain_scores_gemma":[0.9989254,0.00007461443,0.00030711963,0.00033541588,0.00010767822,0.00024976174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060957944,0.00030183158,0.00043734157,0.00007846292,0.000081728365,0.000011142299,0.0001086365,0.000119584525,0.00012537374],"category_scores_gemma":[0.00020723358,0.00024301528,0.00014263843,0.00035903146,0.000253775,0.00010396444,0.00006471395,0.00028957622,0.000026564292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035831454,0.00032825235,0.065118656,0.00040499136,0.00017249864,0.00042105105,0.00017468483,4.1675048e-7,0.92708546,0.000009447005,0.004852722,0.0010735239],"study_design_scores_gemma":[0.002517854,0.000050144205,0.023358244,0.00041466719,0.00024068973,0.0002676821,0.0005674318,0.000006140198,0.97115344,0.0000121305275,0.0011664261,0.0002451383],"about_ca_topic_score_codex":0.000029800154,"about_ca_topic_score_gemma":0.0000016302558,"teacher_disagreement_score":0.044068012,"about_ca_system_score_codex":0.0003566753,"about_ca_system_score_gemma":0.00025894775,"threshold_uncertainty_score":0.99098754},"labels":[],"label_agreement":null},{"id":"W2026883608","doi":"10.1016/j.bmcl.2014.09.030","title":"Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents","year":2014,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Chemistry; Stereochemistry; Amine gas treating; Nucleoside; Cytotoxicity; Potency; Chemical synthesis; Tertiary amine; In vitro; Combinatorial chemistry; Aromatic amine; Structure–activity relationship; Biochemistry; Organic chemistry","score_opus":0.008775690583677987,"score_gpt":0.23579168762609543,"score_spread":0.22701599704241743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026883608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644253,0.0003714938,0.0002988041,0.033653144,0.00011294594,0.00023946675,0.0000042001675,0.0000728632,0.00082175486],"genre_scores_gemma":[0.99511945,0.00014248012,0.0010170003,0.0013461211,0.0005845762,0.000004651468,0.00007366027,0.000041917512,0.0016701304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981462,0.00003393665,0.00048781963,0.0004528714,0.00051242975,0.00036675707],"domain_scores_gemma":[0.99892783,0.00006465139,0.00021534842,0.00032134342,0.00006661683,0.000404181],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022826604,0.00034151034,0.00064373866,0.00008453221,0.00007931599,0.000015481148,0.00014442373,0.000130734,0.0007927135],"category_scores_gemma":[0.00031473508,0.00027722033,0.000102430575,0.00025001756,0.0002671497,0.00006567397,0.00008704024,0.00020887941,0.000046349538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022756893,0.00012589747,0.014859031,0.00023796981,0.00030850316,0.0001343534,0.00040222556,5.914809e-7,0.9710201,0.000010424767,0.010230679,0.002442635],"study_design_scores_gemma":[0.010002854,0.0001717425,0.061146807,0.0005007613,0.0007447355,0.0005460068,0.0003244407,0.00006534254,0.915782,0.000055518307,0.010234715,0.00042509567],"about_ca_topic_score_codex":0.000031263127,"about_ca_topic_score_gemma":5.512165e-7,"teacher_disagreement_score":0.055238143,"about_ca_system_score_codex":0.00007019049,"about_ca_system_score_gemma":0.00015410631,"threshold_uncertainty_score":0.999968},"labels":[],"label_agreement":null},{"id":"W2027121987","doi":"10.1186/1758-2652-12-25","title":"Five‐year follow up of genotypic resistance patterns in HIV‐1 subtype C infected patients in Botswana after failure of thymidine analogue‐based regimens","year":2009,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Stavudine; Didanosine; Lamivudine; Medicine; Zidovudine; Genotype; Internal medicine; Reverse-transcriptase inhibitor; Resistance mutation; Regimen; Nevirapine; Reverse transcriptase; Virology; Gastroenterology; Human immunodeficiency virus (HIV); Viral load; Biology; Virus; Genetics; Antiretroviral therapy; Viral disease; Polymerase chain reaction","score_opus":0.007193319229568291,"score_gpt":0.23408761075330023,"score_spread":0.22689429152373194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027121987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378407,0.00008181836,0.00006501184,0.005559554,0.0001648733,0.0001604932,0.00003712669,0.0000030728415,0.00014395811],"genre_scores_gemma":[0.9947447,0.000050907944,0.0029151607,0.00027844033,0.000046660647,0.000002499334,0.000025144267,0.000008896181,0.0019275476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839604,0.00005363761,0.0006638186,0.0001186991,0.0006291464,0.0001386705],"domain_scores_gemma":[0.998783,0.000068408954,0.00052460673,0.00015155716,0.00042569428,0.000046725745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029864858,0.00013273937,0.00035118096,0.0001700111,0.00001577992,0.0000068820045,0.000220614,0.00007808177,0.00008468155],"category_scores_gemma":[0.00012794655,0.000089978625,0.0003518912,0.0003219125,0.000037895214,0.00010013092,0.00003429603,0.0002550749,0.0000017022331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009136693,0.0005742904,0.99138457,0.000032743774,0.00024041018,0.000016969374,0.0011470201,0.00005720875,0.0009176063,0.000058780653,0.00453216,0.00012456207],"study_design_scores_gemma":[0.0067838696,0.0001995404,0.98719615,0.0008005031,0.00007342961,0.0000031753837,0.00018907295,0.000090707545,0.0037844132,0.00024425588,0.00055507605,0.00007978818],"about_ca_topic_score_codex":0.000022067008,"about_ca_topic_score_gemma":0.00023951703,"teacher_disagreement_score":0.0058702,"about_ca_system_score_codex":0.00037090766,"about_ca_system_score_gemma":0.00019318274,"threshold_uncertainty_score":0.36692217},"labels":[],"label_agreement":null},{"id":"W2027224364","doi":"10.1074/jbc.m111.268235","title":"Impact of Primer-induced Conformational Dynamics of HIV-1 Reverse Transcriptase on Polymerase Translocation and Inhibition","year":2011,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Merck Canada Inc. (Canada)","funders":"Canadian Institutes of Health Research","keywords":"Primer (cosmetics); Reverse transcriptase; Allosteric regulation; DNA; RNA; Biology; Molecular biology; Polymerase; DNA polymerase; RNase H; Enzyme; Biochemistry; Chemistry; Gene","score_opus":0.0369482396157401,"score_gpt":0.27073471358775375,"score_spread":0.23378647397201366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027224364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987576,0.000078180674,0.00009821291,0.00023657778,0.000012201392,0.000072243936,0.000046701964,0.000003321336,0.0006949854],"genre_scores_gemma":[0.99911886,0.00009410208,0.00059206376,0.000018746998,0.0000215387,0.0000010063302,0.00009705356,0.0000030285444,0.000053621658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992648,0.000014503665,0.0004445067,0.000064226035,0.00013692363,0.000075081734],"domain_scores_gemma":[0.99940413,0.000025234378,0.0002942562,0.000056175795,0.0001220906,0.00009813609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001332209,0.00009549577,0.00026530307,0.000043515905,0.000014284011,0.0000015016135,0.000028123859,0.0001072615,0.00024104059],"category_scores_gemma":[0.000039454313,0.000058934802,0.00014370935,0.000060930503,0.00006686094,0.000051179246,0.000003442284,0.00012346142,8.96154e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022424057,0.00096107187,0.028644696,0.000110835914,0.00026606498,0.000037552796,0.0008382087,9.307221e-7,0.9627117,0.00005608639,0.00012617558,0.0040042833],"study_design_scores_gemma":[0.0030573108,0.0009083651,0.05312805,0.00023955794,0.0000972069,0.00019891742,0.0002838906,0.00006024369,0.9418594,0.00007742625,0.000009990662,0.000079619094],"about_ca_topic_score_codex":0.0000046372256,"about_ca_topic_score_gemma":1.3420146e-7,"teacher_disagreement_score":0.024483351,"about_ca_system_score_codex":0.00007454296,"about_ca_system_score_gemma":0.00011741094,"threshold_uncertainty_score":0.26392254},"labels":[],"label_agreement":null},{"id":"W2027642737","doi":"10.1517/14656560903176446","title":"New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Windsor Regional Hospital; Toronto General Hospital; University of Alberta","funders":"","keywords":"Darunavir; Etravirine; Raltegravir; Maraviroc; Rilpivirine; Medicine; Pharmacology; Drug; Intensive care medicine; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.02840759937183873,"score_gpt":0.37771341237789124,"score_spread":0.3493058130060525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027642737","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015532838,0.99008936,0.000013568382,0.0028349326,0.00045717586,0.0038321046,0.0001651204,0.000052988475,0.002539246],"genre_scores_gemma":[0.000011807566,0.98668057,0.0019830172,0.0013792731,0.0003846585,0.00008652916,0.00023422214,0.0001271,0.009112812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958486,0.00041606254,0.0015904519,0.0008608351,0.00084288156,0.00044119748],"domain_scores_gemma":[0.9975369,0.0002661528,0.0010053768,0.0007659658,0.00010908502,0.00031653073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046593617,0.00097116036,0.002975404,0.00029322665,0.00012142484,0.000020716856,0.0004170735,0.0002334351,0.00043305315],"category_scores_gemma":[0.000041490202,0.00061573327,0.0006453343,0.0007013167,0.00025782202,0.00008830523,0.00009718242,0.00062867336,0.000013609007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000517593,0.0004167959,0.00002338848,0.02086496,0.0005510554,0.000009207946,0.00024108753,2.109728e-8,0.0001352331,0.00016346255,0.061205443,0.91587174],"study_design_scores_gemma":[0.005049688,0.00031046636,0.000093912655,0.101661265,0.00037439712,0.000036668258,0.000008220863,0.0000016857646,0.0007601971,0.000014409154,0.8912275,0.00046162677],"about_ca_topic_score_codex":0.000024138453,"about_ca_topic_score_gemma":7.6412954e-7,"teacher_disagreement_score":0.9154101,"about_ca_system_score_codex":0.00013419556,"about_ca_system_score_gemma":0.00055902306,"threshold_uncertainty_score":0.9996294},"labels":[],"label_agreement":null},{"id":"W2027898836","doi":"10.1097/qai.0b013e31816d9bf4","title":"Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data","year":2008,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Amprenavir; Abacavir; Ritonavir; Nelfinavir; Stavudine; Saquinavir; Indinavir; Didanosine; Lamivudine; Medicine; Lopinavir; Darunavir; Zidovudine; Population; Drug resistance; Internal medicine; Pharmacology; Virology; Viral load; Biology; HIV-1 protease; Viral disease; Genetics; Human immunodeficiency virus (HIV); Protease; Virus; Antiretroviral therapy","score_opus":0.09043002959631191,"score_gpt":0.3847453856332044,"score_spread":0.29431535603689246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027898836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046546,0.0025862153,0.0050751762,0.0005869248,0.00033622197,0.00074025,0.00008790104,0.000018133964,0.000103716084],"genre_scores_gemma":[0.89003444,0.0026600217,0.10615009,0.00001594147,0.000039300223,0.000011486271,0.00017788689,0.00002566948,0.0008851422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99429774,0.0001555953,0.004194868,0.00039304205,0.0006916375,0.00026713457],"domain_scores_gemma":[0.993642,0.002208895,0.0026301767,0.00074787386,0.0006689883,0.00010208348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036095814,0.00023907165,0.0022948175,0.0005479587,0.000119324424,0.00001271684,0.0004301723,0.00015901514,0.000021339043],"category_scores_gemma":[0.0051646032,0.00017858099,0.0005940118,0.0009935807,0.0004931924,0.00033779448,0.00012546552,0.00011622676,0.0000022568931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.101655364,0.006990076,0.8590906,0.0007968412,0.011723517,0.0004546558,0.003232848,0.00003004323,0.0018269266,0.00037925295,0.0027274329,0.011092395],"study_design_scores_gemma":[0.11221327,0.010441215,0.83949685,0.0012134933,0.022969896,0.00055027194,0.00078720687,0.008736997,0.0012536775,0.000928974,0.0008265827,0.0005815796],"about_ca_topic_score_codex":0.000006227246,"about_ca_topic_score_gemma":0.000002753666,"teacher_disagreement_score":0.10107492,"about_ca_system_score_codex":0.000043588698,"about_ca_system_score_gemma":0.00046933885,"threshold_uncertainty_score":0.72823215},"labels":[],"label_agreement":null},{"id":"W2028160062","doi":"10.1081/cnv-120027590","title":"The Role of Surrogate Markers in the Clinical Development of Antiretroviral Therapy: A Model for Early Evaluation of Targeted Cancer Drugs","year":2004,"lang":"en","type":"review","venue":"Cancer Investigation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; St. Paul's Hospital; University of British Columbia; McGill University; McGill University Health Centre","funders":"","keywords":"Surrogate endpoint; Medicine; Clinical trial; Drug resistance; Efficacy; Drug development; Drug; Targeted therapy; Oncology; Cancer; Immunology; Internal medicine; Pharmacology; Biology","score_opus":0.15887438748470356,"score_gpt":0.4261522573596967,"score_spread":0.26727786987499313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028160062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08872802,0.90695566,0.000023401844,0.0001643963,0.00013425051,0.0038619551,0.00006758505,0.0000073245733,0.000057440957],"genre_scores_gemma":[0.05458811,0.94043124,0.0017671825,0.000028734274,0.00006078717,0.0025864353,0.00030361087,0.000040569787,0.00019333095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689585,0.00035537555,0.0014886907,0.0002891799,0.0007681529,0.00020273597],"domain_scores_gemma":[0.9976921,0.0002908063,0.0011669844,0.00029248864,0.0005041756,0.00005345582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031621896,0.00026968514,0.0010252417,0.00014963106,0.00007087213,0.0000082723855,0.00020762236,0.00019793889,0.000009244575],"category_scores_gemma":[0.00015185765,0.00015018541,0.0003043343,0.0004416302,0.00025024512,0.000059445912,0.000020138948,0.00019441341,7.0763997e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014766841,0.00008753719,0.004494452,0.002593574,0.00055927987,1.2580365e-7,0.005545872,0.00011404057,0.000012508491,0.0000884008,0.00007006577,0.98628646],"study_design_scores_gemma":[0.0626881,0.0025579836,0.0619411,0.26042297,0.029978782,0.0000082180995,0.005550791,0.08773528,0.013431335,0.018462865,0.4534349,0.0037876477],"about_ca_topic_score_codex":0.00015630694,"about_ca_topic_score_gemma":0.00014222671,"teacher_disagreement_score":0.9824988,"about_ca_system_score_codex":0.0005795651,"about_ca_system_score_gemma":0.008850048,"threshold_uncertainty_score":0.99676883},"labels":[],"label_agreement":null},{"id":"W2028199175","doi":"10.1371/journal.pone.0046181","title":"Prolonged and Substantial Discordance in Prevalence of Raltegravir-Resistant HIV-1 in Plasma versus PBMC Samples Revealed by 454 “Deep” Sequencing","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; University of California, San Francisco; Center for AIDS Research, University of Washington","keywords":"Raltegravir; Peripheral blood mononuclear cell; Virology; Viral load; Integrase inhibitor; Population; Drug resistance; Immunology; Medicine; Integrase; Biology; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genetics; In vitro","score_opus":0.055573376885497724,"score_gpt":0.2572940121989963,"score_spread":0.20172063531349854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028199175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626166,0.0021862725,0.0000063343045,0.0003992552,0.00002614975,0.00071091106,0.00005259362,0.00002110145,0.00033573038],"genre_scores_gemma":[0.99247134,0.0005543657,0.0051844446,0.0000107046,0.000035336285,0.00008159523,0.00005213115,0.000020106045,0.0015899818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853194,0.00007546156,0.00040069685,0.0002629696,0.00034320314,0.00038571842],"domain_scores_gemma":[0.99936956,0.0001620206,0.00011520007,0.00019900418,0.000033689554,0.000120532764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029248188,0.00018378178,0.00045802927,0.00013602186,0.000030110106,0.000006795454,0.000071434675,0.000065659566,0.000041464573],"category_scores_gemma":[0.00018005286,0.00015748767,0.000028427656,0.00024121455,0.00009014941,0.00015436405,0.000036516092,0.00016665427,0.000010480063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002435325,0.001376798,0.8726531,0.0010000143,0.00014181696,0.000033332934,0.0031491318,4.623947e-7,0.118736595,0.00008148787,0.0000620444,0.00032987905],"study_design_scores_gemma":[0.018492676,0.0005495636,0.7790683,0.004276759,0.0006395718,0.000009114818,0.0010257824,0.00036287165,0.19488391,0.000050929342,0.00009736741,0.00054316974],"about_ca_topic_score_codex":0.000067281784,"about_ca_topic_score_gemma":0.0003542031,"teacher_disagreement_score":0.09358483,"about_ca_system_score_codex":0.00022946572,"about_ca_system_score_gemma":0.00008863066,"threshold_uncertainty_score":0.6422161},"labels":[],"label_agreement":null},{"id":"W2028457843","doi":"10.1097/qad.0b013e32833e6d14","title":"Virologic and immunologic response to HAART, by age and regimen class","year":2010,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Center for Research Resources; National Institute of Mental Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Canadian Institutes of Health Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; U.S. Public Health Service; National Cancer Institute; National Institutes of Health","keywords":"Regimen; Discontinuation; Medicine; Internal medicine; Hazard ratio; Protease inhibitor (pharmacology); Cohort; Viral load; Reverse-transcriptase inhibitor; Confidence interval; Prospective cohort study; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.007805669881322653,"score_gpt":0.24676328553141963,"score_spread":0.238957615650097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028457843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875215,0.00037015692,0.0000071998998,0.00908563,0.00006162781,0.00025578978,0.000004325358,0.00005767796,0.0026360634],"genre_scores_gemma":[0.9511695,0.00007397164,0.002863523,0.00087829883,0.000020228199,0.00003174414,0.00001049788,0.000010400351,0.04494182],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993094,0.000047073772,0.00011534803,0.00024203613,0.00009138313,0.00019475639],"domain_scores_gemma":[0.99950755,0.00011074176,0.000022500935,0.00020769743,0.00001460905,0.00013692741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028662282,0.00012687797,0.0002000686,0.00008457479,0.00007388993,0.000020407128,0.000043322674,0.00010361429,0.00008426942],"category_scores_gemma":[0.00012448896,0.00009048964,0.000019914745,0.00009185973,0.00010103055,0.000037428224,0.00007319649,0.00016032548,0.00008178923],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026861676,0.00025733322,0.1205854,0.000019667576,0.0002155818,0.0007879178,0.001703838,4.7632618e-8,0.79953164,0.0005373649,0.04029071,0.033384364],"study_design_scores_gemma":[0.0039792308,0.0020436104,0.31298324,0.000036248413,0.0001322511,0.00022891574,0.00028798683,0.000009069548,0.017058596,0.0004065767,0.66252446,0.0003097864],"about_ca_topic_score_codex":0.000009713607,"about_ca_topic_score_gemma":0.0000045750867,"teacher_disagreement_score":0.782473,"about_ca_system_score_codex":0.000017412129,"about_ca_system_score_gemma":0.000022902803,"threshold_uncertainty_score":0.369006},"labels":[],"label_agreement":null},{"id":"W2028578469","doi":"10.1002/ijc.11339","title":"Sensitization of ara‐C‐resistant lymphoma cells by a pronucleotide analogue","year":2003,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Fondation de France; National Cancer Institute; Ligue Contre le Cancer","keywords":"Deoxycytidine kinase; Intracellular; Cytotoxicity; Cell culture; Cytarabine; Deoxycytidine; Nucleoside; Gemcitabine; Biochemistry; Molecular biology; Biology; Chemistry; Leukemia; In vitro; Chemotherapy; Immunology","score_opus":0.006706168817428823,"score_gpt":0.273879019683536,"score_spread":0.2671728508661072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028578469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844687,0.002173716,0.0010458436,0.006521594,0.00092137716,0.00017738283,0.000056762452,0.0000074172526,0.0046272],"genre_scores_gemma":[0.9944703,0.00047011732,0.0012744307,0.00020209327,0.00010976988,0.000002728404,0.000012648365,0.000011005951,0.0034468872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989132,0.000027975999,0.00039700017,0.00007798364,0.0004951587,0.00008864023],"domain_scores_gemma":[0.9988817,0.00003461093,0.00033840374,0.000054340977,0.0006184332,0.00007248576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012981035,0.000086036605,0.00019901505,0.00014922529,0.000014504822,0.000011348931,0.00006818074,0.000031894324,0.00031532202],"category_scores_gemma":[0.000046328874,0.000066879635,0.000095238545,0.00008701204,0.000030513509,0.00008035449,0.000007405663,0.0000470184,0.0000075141957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004527671,0.0029085348,0.1782974,0.00018711464,0.009031439,0.0016307178,0.002588023,0.0006998901,0.6094098,0.005999631,0.117848665,0.06687109],"study_design_scores_gemma":[0.010897578,0.0002936882,0.022604553,0.0009671299,0.00048845727,0.00039918942,0.0002145448,0.00017583059,0.75806344,0.00073032704,0.20491567,0.00024960542],"about_ca_topic_score_codex":0.000022427823,"about_ca_topic_score_gemma":0.000020770916,"teacher_disagreement_score":0.15569285,"about_ca_system_score_codex":0.00027426734,"about_ca_system_score_gemma":0.00032639405,"threshold_uncertainty_score":0.3452555},"labels":[],"label_agreement":null},{"id":"W2028600960","doi":"10.1074/jbc.m114.569707","title":"Inhibition of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase by GSK5750 Correlates with Slow Enzyme-Inhibitor Dissociation","year":2014,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research; GlaxoSmithKline","keywords":"RNase H; Reverse transcriptase; RNase P; Enzyme; Active site; Ribonuclease; Biochemistry; Binding site; Dissociation constant; Chemistry; Biology; Molecular biology; RNA","score_opus":0.008903864329265498,"score_gpt":0.21326210583551963,"score_spread":0.20435824150625415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028600960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974527,0.00008329677,0.0001241105,0.0017276682,0.000037814687,0.00009279193,0.000042172604,0.00000595864,0.0004335137],"genre_scores_gemma":[0.9987754,0.000036838537,0.00022205514,0.000045934154,0.000075789816,0.0000016627545,0.000027072194,0.0000058575397,0.00080935884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912685,0.000055653127,0.00035112875,0.00010502168,0.00025068625,0.0001106414],"domain_scores_gemma":[0.999013,0.00008591195,0.0005552992,0.0001070079,0.00014371223,0.000095036994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024675927,0.0001215878,0.0003490079,0.000015648662,0.000036870097,0.000003662961,0.000058402635,0.00014281609,0.00010059751],"category_scores_gemma":[0.00021915295,0.000060685063,0.00017857841,0.00010498677,0.00012899426,0.00004852793,0.000013251773,0.00023066775,0.0000013995675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008765351,0.0006757091,0.050675247,0.000089342175,0.00011316584,0.000010925565,0.0001298934,0.0000025013735,0.9413321,0.0000040952036,0.0054907342,0.00059977756],"study_design_scores_gemma":[0.0022916908,0.0002818793,0.009720217,0.00032490856,0.00017449926,0.00004925872,0.00010857442,0.000026431588,0.98581624,0.000039904222,0.00109109,0.000075276024],"about_ca_topic_score_codex":0.0000015883668,"about_ca_topic_score_gemma":1.9999334e-7,"teacher_disagreement_score":0.044484194,"about_ca_system_score_codex":0.00007648271,"about_ca_system_score_gemma":0.000058771016,"threshold_uncertainty_score":0.2474665},"labels":[],"label_agreement":null},{"id":"W2028605760","doi":"10.1074/jbc.m803521200","title":"Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms","year":2008,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"RNase H; Reverse transcriptase; Zidovudine; Mutant; RNase P; Biology; Cleavage (geology); Molecular biology; Mutation; Enzyme; Polymerase; Thymidine; DNA; Biochemistry; Human immunodeficiency virus (HIV); Virology; RNA; Gene","score_opus":0.020560639648095597,"score_gpt":0.2608850153677251,"score_spread":0.24032437571962953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028605760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99090415,0.0010446667,0.002666204,0.004525978,0.000054285592,0.00021937554,0.000022526221,0.000015778169,0.00054704124],"genre_scores_gemma":[0.98114735,0.0011708131,0.014536869,0.0002910522,0.000077528166,0.000015203632,0.000019316514,0.00000994841,0.0027319014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986263,0.000046682984,0.00053538405,0.00029240802,0.00027078835,0.00022846732],"domain_scores_gemma":[0.99928766,0.0000759314,0.00018513517,0.00011350844,0.00008338458,0.00025436096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030653836,0.00020134637,0.00043344652,0.000059117854,0.000105976724,0.000013038743,0.00006628061,0.00016153016,0.00012382722],"category_scores_gemma":[0.00014366364,0.0001462285,0.00007791152,0.00016671298,0.000092976275,0.000095384836,0.00002760794,0.00030894158,0.0000051823163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020352833,0.0007918719,0.010636243,0.00014530915,0.00015890098,0.004290479,0.0018493712,0.000008015972,0.97726226,0.00017830156,0.002298782,0.00034516866],"study_design_scores_gemma":[0.009674461,0.00072369794,0.025392529,0.0007259975,0.00017139288,0.005704164,0.0032403204,0.000010052387,0.94012433,0.0046609375,0.0089867255,0.0005853794],"about_ca_topic_score_codex":0.0000043999685,"about_ca_topic_score_gemma":0.00000843281,"teacher_disagreement_score":0.03713793,"about_ca_system_score_codex":0.00017752351,"about_ca_system_score_gemma":0.00008472914,"threshold_uncertainty_score":0.5963025},"labels":[],"label_agreement":null},{"id":"W2028674397","doi":"10.1186/1758-2652-7-1-69","title":"Substitutions in the Reverse Transcriptase and Protease Genes of HIV‐1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs","year":2005,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Resistance mutation; Reverse transcriptase; Protease; Drug resistance; Medicine; Virology; Protease inhibitor (pharmacology); Genotype; Somatic hypermutation; Virus; Biology; Gene; Genetics; Viral load; Enzyme; Immunology; Antiretroviral therapy; Polymerase chain reaction; Antibody","score_opus":0.009167697189781127,"score_gpt":0.23359302458358147,"score_spread":0.22442532739380033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028674397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941174,0.00020665054,0.000003847415,0.005246544,0.000025300997,0.0002686082,0.000029781222,0.0000021347626,0.00009976275],"genre_scores_gemma":[0.99772227,0.00020279414,0.0012235718,0.00021130897,0.0000307813,0.0000054653806,0.000014265871,0.00000513383,0.0005843934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990717,0.00005354603,0.00032103318,0.000084775085,0.00037979663,0.000089116314],"domain_scores_gemma":[0.9995357,0.000041352094,0.00018636287,0.00006773987,0.0001315285,0.000037354752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003167555,0.000098630415,0.00018099327,0.00008804138,0.000042313124,0.000015460357,0.000109308414,0.00003878001,0.000014945239],"category_scores_gemma":[0.000034564328,0.000048598253,0.00008521182,0.00020572527,0.00011514833,0.00014836599,0.000017982182,0.00016639635,4.818196e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020353083,0.00043689692,0.9912885,0.000012143148,0.00020269408,0.000008962098,0.005581604,0.000013173359,0.00033145968,0.00006342713,0.00061273406,0.0012449184],"study_design_scores_gemma":[0.008934133,0.00033188311,0.98311806,0.00036970119,0.00022812406,0.00008574404,0.0016585037,0.00017105436,0.00283071,0.00003759905,0.0021462352,0.00008824846],"about_ca_topic_score_codex":0.00006123012,"about_ca_topic_score_gemma":0.00002353031,"teacher_disagreement_score":0.0087306015,"about_ca_system_score_codex":0.00012192263,"about_ca_system_score_gemma":0.000103101724,"threshold_uncertainty_score":0.19817792},"labels":[],"label_agreement":null},{"id":"W2028958622","doi":"10.1128/aac.05821-11","title":"<i>In Vitro</i> Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine","year":2011,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Microbicide; Nevirapine; HIV drug resistance; Microbicides for sexually transmitted diseases; Drug resistance; Efavirenz; Context (archaeology); Vaginal microbicide; Reverse transcriptase; Virology; Reverse-transcriptase inhibitor; Lamivudine; Biology; Sexual transmission; Pharmacology; Medicine; Population; Viral load; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy; Microbiology; Genetics; Polymerase chain reaction","score_opus":0.009384632928134108,"score_gpt":0.22083097559352025,"score_spread":0.21144634266538614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028958622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857622,0.000072933086,0.0000053572053,0.009534988,0.0000867336,0.0004564695,0.00003657873,0.0000138017485,0.004030948],"genre_scores_gemma":[0.9279251,0.00055599015,0.0021202427,0.0054375594,0.00003374018,0.000010381207,0.000023757415,0.000027388343,0.0638658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991447,0.000023741197,0.00027084159,0.00023474918,0.000102855505,0.00022311808],"domain_scores_gemma":[0.9995717,0.000007919164,0.00010333565,0.00023656513,0.000030557043,0.000049932634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009347274,0.0001694901,0.00029486412,0.000057005625,0.0000597088,0.000007907025,0.00011519538,0.000044816734,0.00029415652],"category_scores_gemma":[0.0000028141858,0.00011103905,0.00008005097,0.00016382492,0.00011009593,0.000055255514,0.000041448602,0.000091772454,0.000017968694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002045757,0.0011739323,0.14359477,0.00025808864,0.000289502,0.00008082393,0.0077127204,1.03943236e-7,0.45143226,0.00006355504,0.3915929,0.0017556053],"study_design_scores_gemma":[0.0036905087,0.000012528301,0.049322516,0.0002257276,0.000040865154,0.000016839089,0.000050239312,0.0000028629097,0.8748372,0.000027253358,0.07163136,0.00014210757],"about_ca_topic_score_codex":0.00010098285,"about_ca_topic_score_gemma":0.00007177144,"teacher_disagreement_score":0.42340493,"about_ca_system_score_codex":0.000030725256,"about_ca_system_score_gemma":0.00005369097,"threshold_uncertainty_score":0.45280412},"labels":[],"label_agreement":null},{"id":"W2029349004","doi":"10.1097/qad.0b013e3282ef6db7","title":"Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores","year":2007,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Lopinavir; Ritonavir; Lopinavir/ritonavir; Medicine; Virology; Protease inhibitor (pharmacology); Pharmacology; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.016740317370636172,"score_gpt":0.2905655454898116,"score_spread":0.2738252281191754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029349004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920874,0.0002332749,0.00015505133,0.0027901141,0.00043698726,0.0021105416,0.00006449688,0.00019880965,0.0019233095],"genre_scores_gemma":[0.9776814,0.000021318941,0.0062713143,0.00026120243,0.00012388651,0.00015932691,0.0011085111,0.00010473446,0.014268332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996555,0.00017044546,0.00068419985,0.0008680991,0.0008431613,0.0008791276],"domain_scores_gemma":[0.99804705,0.00040672935,0.00016003678,0.00065572787,0.0002367132,0.00049376715],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039800713,0.0006357724,0.0007230908,0.00064499286,0.00018689384,0.00004844886,0.00017467036,0.00024093989,0.00023167943],"category_scores_gemma":[0.000092199545,0.00051149406,0.00014077895,0.001103627,0.00012906692,0.00025496978,0.00007037599,0.00025236374,0.0011271128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08015321,0.0033743843,0.83061653,0.00006722045,0.0006599724,0.0027530147,0.0037118115,0.000031398693,0.0012336643,0.00017083318,0.0012351366,0.07599279],"study_design_scores_gemma":[0.03722578,0.0071652564,0.92141557,0.0004960746,0.00031281624,0.000027878814,0.0003337277,0.000012406418,0.0036483114,0.000027178523,0.028665645,0.0006693424],"about_ca_topic_score_codex":0.0003680425,"about_ca_topic_score_gemma":0.00034533793,"teacher_disagreement_score":0.090799026,"about_ca_system_score_codex":0.0014893156,"about_ca_system_score_gemma":0.00029298337,"threshold_uncertainty_score":0.9997337},"labels":[],"label_agreement":null},{"id":"W2029533867","doi":"10.1097/01.aids.0000162334.12815.5b","title":"The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART","year":2005,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Nevirapine; Efavirenz; Viral load; Medicine; Human immunodeficiency virus (HIV); Virology; Reverse-transcriptase inhibitor; Sida; Lentivirus; Immunology; Viral disease; Antiretroviral therapy","score_opus":0.008330654188125512,"score_gpt":0.24319865303070448,"score_spread":0.23486799884257897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029533867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98721075,0.0017590355,0.0001006756,0.00931767,0.000043655302,0.0008546113,0.000034378136,0.000022155617,0.0006570768],"genre_scores_gemma":[0.99389946,0.0005158823,0.00045361987,0.0003056093,0.000083136285,0.00002745531,0.00003608616,0.00001828763,0.0046604406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879044,0.00012231017,0.00036675285,0.00021148284,0.00031386092,0.00019515032],"domain_scores_gemma":[0.9974358,0.0019677368,0.000116311516,0.00034064957,0.000060898165,0.000078590405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086313946,0.00021601254,0.00039854588,0.000051507453,0.00014135714,0.000009590705,0.00008049281,0.000059650476,0.0001108647],"category_scores_gemma":[0.00026174457,0.00009337172,0.000067783294,0.00014647037,0.00021425495,0.000028633696,0.000037764414,0.00012938143,0.000022752007],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084589034,0.0044313087,0.32477808,0.0021938535,0.002142391,0.0001800894,0.0033113672,0.0006952469,0.015934823,0.0009883704,0.054393344,0.5063621],"study_design_scores_gemma":[0.069164805,0.018799797,0.05353386,0.0015668429,0.00183023,0.000037862977,0.00014999631,0.0087211095,0.41667035,0.00002123824,0.4288382,0.0006657002],"about_ca_topic_score_codex":0.000013133784,"about_ca_topic_score_gemma":0.000023316172,"teacher_disagreement_score":0.5056964,"about_ca_system_score_codex":0.000054576616,"about_ca_system_score_gemma":0.00008514171,"threshold_uncertainty_score":0.3807588},"labels":[],"label_agreement":null},{"id":"W2029589529","doi":"10.1097/qco.0000000000000017","title":"Pharmacological considerations on the use of antiretrovirals in pregnancy","year":2013,"lang":"en","type":"review","venue":"Current Opinion in Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Pregnancy; Transplacental; Efavirenz; Viral load; Pharmacokinetics; Protease inhibitor (pharmacology); Obstetrics; Human immunodeficiency virus (HIV); Intensive care medicine; Pharmacology; Fetus; Antiretroviral therapy; Immunology; Placenta","score_opus":0.26586980372013785,"score_gpt":0.4272894152647048,"score_spread":0.16141961154456697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029589529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004388887,0.9941565,0.0000022092677,0.0001450314,0.001471355,0.0034538321,0.00013419897,0.000050093837,0.00014793956],"genre_scores_gemma":[0.0016087559,0.9960148,0.000011018694,0.000020323609,0.00012044456,0.0017178351,0.0003330356,0.000024940378,0.00014887578],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979755,0.00036607997,0.0007989059,0.00036757023,0.00024439013,0.00024753],"domain_scores_gemma":[0.9980518,0.0012091605,0.00029560216,0.00026903086,0.00006710496,0.00010727034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000066534434,0.00037628386,0.0011626788,0.00046722058,0.000061869614,0.00003952449,0.00006952084,0.00012696981,0.000709202],"category_scores_gemma":[0.0005498768,0.00021793495,0.00034629708,0.00044124617,0.000117036965,0.00009384382,0.00005924614,0.00039285538,0.00014880234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021182295,0.006562413,0.07056921,0.021293517,0.00047317744,0.000029793231,0.00012646677,0.000010932309,2.2365722e-7,0.0037439337,0.069245346,0.8279238],"study_design_scores_gemma":[0.0015108298,0.000199025,0.0024019287,0.08318515,0.0007055863,0.00001963394,0.000007332337,0.000017324057,0.0000013869819,0.0002065492,0.91140556,0.0003396975],"about_ca_topic_score_codex":0.000009005675,"about_ca_topic_score_gemma":0.0000018666095,"teacher_disagreement_score":0.8421602,"about_ca_system_score_codex":0.00024290582,"about_ca_system_score_gemma":0.00046434384,"threshold_uncertainty_score":0.88871294},"labels":[],"label_agreement":null},{"id":"W2029638039","doi":"10.1016/j.coviro.2012.08.004","title":"The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance","year":2012,"lang":"en","type":"review","venue":"Current Opinion in Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Selection (genetic algorithm); Drug resistance; Computational biology; Analogy; Antiviral drug; Drug; Resistance (ecology); Drug discovery; Genetics; Bioinformatics; Computer science; Pharmacology; Ecology","score_opus":0.05282398209107061,"score_gpt":0.37393635699668243,"score_spread":0.32111237490561184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029638039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008837604,0.99547017,0.00014897958,0.0006523989,0.0013818552,0.0013010416,0.00008994153,0.0000065596973,0.00006527538],"genre_scores_gemma":[0.0037379938,0.9945295,0.0003161754,0.0000039803876,0.00014834499,0.00044662802,0.00018986996,0.000019481702,0.0006080696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797314,0.00028222022,0.00094939274,0.0002706354,0.00019985493,0.00032475108],"domain_scores_gemma":[0.9986806,0.00044820932,0.0003482718,0.00035295056,0.00008196696,0.00008803267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005196746,0.00027438995,0.0010387937,0.00014174511,0.00014416996,0.0000058942505,0.000199511,0.000111583824,0.000013969169],"category_scores_gemma":[0.00013457227,0.0001432601,0.00012353463,0.00027166688,0.00024837736,0.000016066964,0.00016896517,0.00026065027,0.000018314866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083685976,0.00025019379,0.004794865,0.008221145,0.00026811464,0.0000011342053,0.0013873638,1.0123975e-7,0.0000012272595,0.00090612186,0.0026966394,0.9813894],"study_design_scores_gemma":[0.0004598289,0.000015835914,0.00919766,0.004083095,0.00023618416,0.0000068506024,0.000023647854,9.128321e-7,0.000007235536,0.000024162302,0.9858208,0.00012378844],"about_ca_topic_score_codex":0.0000010612252,"about_ca_topic_score_gemma":0.0000483751,"teacher_disagreement_score":0.98312414,"about_ca_system_score_codex":0.00010671732,"about_ca_system_score_gemma":0.00045895594,"threshold_uncertainty_score":0.5841977},"labels":[],"label_agreement":null},{"id":"W2029815847","doi":"10.1097/01.aids.0000131377.28694.04","title":"Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection","year":2004,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Superinfection; Biology; Virology; Multiple drug resistance; Genotype; Drug resistance; Reverse transcriptase; Medical microbiology; Phylogenetic tree; Microbiology; Genetics; Virus; Polymerase chain reaction; Gene","score_opus":0.017069810276791452,"score_gpt":0.25435212065579144,"score_spread":0.237282310379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029815847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939429,0.000034606837,0.0004793413,0.00049863756,0.00007725134,0.00028205913,0.000001815998,0.000038084996,0.0046453048],"genre_scores_gemma":[0.9938138,0.000026050027,0.003961753,0.00007093027,0.000025080115,0.000027934027,0.000020672758,0.000010992232,0.0020427501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993041,0.000014098167,0.00020193274,0.00017482442,0.00015246808,0.00015255935],"domain_scores_gemma":[0.9997224,0.000018462119,0.000028342603,0.000120998644,0.000040678467,0.00006908464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011864541,0.00009986922,0.00020906188,0.0002616525,0.000032187774,0.000005005946,0.000022975697,0.00004453257,0.000024083169],"category_scores_gemma":[0.00004564743,0.000089894915,0.00006216451,0.00037006286,0.000022628707,0.00008618971,0.000020847841,0.00007230982,0.000112970585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017302552,0.00040793887,0.8951753,0.00013053966,0.00005456079,0.000040211846,0.00261323,0.00028428092,0.09516468,0.0001546636,0.00007059783,0.005730981],"study_design_scores_gemma":[0.0032719339,0.0005592307,0.90720654,0.00051006925,0.00007455955,0.000030513538,0.00021913505,0.000019973093,0.08555841,0.00003757117,0.00233578,0.0001763186],"about_ca_topic_score_codex":0.00021671521,"about_ca_topic_score_gemma":0.000069167756,"teacher_disagreement_score":0.012031211,"about_ca_system_score_codex":0.0005036254,"about_ca_system_score_gemma":0.00008640287,"threshold_uncertainty_score":0.3665808},"labels":[],"label_agreement":null},{"id":"W2029985310","doi":"10.1345/aph.1g418","title":"Possible Interaction Between Lopinavir/Ritonavir And Valproic Acid Exacerbates Bipolar Disorder","year":2005,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Lopinavir/ritonavir; Lopinavir; Ritonavir; Valproic Acid; Bipolar disorder; Pharmacology; Internal medicine; Virology; Psychiatry; Human immunodeficiency virus (HIV); Epilepsy; Viral load; Antiretroviral therapy","score_opus":0.054750993949960323,"score_gpt":0.38700439249586355,"score_spread":0.33225339854590324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029985310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590702,0.017678875,0.00006949256,0.022290533,0.000062653926,0.00036177793,0.000016457094,0.000060777755,0.00038922866],"genre_scores_gemma":[0.981584,0.010667834,0.0010988765,0.0009959028,0.0003221807,0.000027495738,0.000050721934,0.00003665576,0.0052162902],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896777,0.0000408134,0.00029967458,0.00024056362,0.00020552421,0.00024562827],"domain_scores_gemma":[0.999479,0.000045988214,0.00010798713,0.00013733984,0.00008866769,0.0001410357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015998255,0.00019881976,0.00032121205,0.00016991286,0.00006877614,0.000017332059,0.00006439004,0.00005929666,0.0004936861],"category_scores_gemma":[0.0000063007187,0.00016311697,0.00009432627,0.00017318498,0.000058914262,0.00026079957,0.000018525943,0.00013551787,0.00006496862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036390434,0.00057908095,0.2638693,0.00010097812,0.0007514258,0.000009139673,0.0012439202,0.0000032191303,0.18979967,0.000036977817,0.0084100645,0.53483236],"study_design_scores_gemma":[0.0020329163,0.0001741439,0.020910736,0.00009379659,0.0000722326,0.000010270954,0.000065212625,0.000065852924,0.6112796,0.000064071646,0.36508426,0.00014691491],"about_ca_topic_score_codex":0.000027355922,"about_ca_topic_score_gemma":0.0000047223434,"teacher_disagreement_score":0.53468543,"about_ca_system_score_codex":0.000022157888,"about_ca_system_score_gemma":0.00004358501,"threshold_uncertainty_score":0.6651717},"labels":[],"label_agreement":null},{"id":"W2030376296","doi":"10.1021/ac801174r","title":"Impedance Method for Detecting HIV-1 Protease and Screening For Its Inhibitors Using Ferrocene−Peptide Conjugate/Au Nanoparticle/Single-Walled Carbon Nanotube Modified Electrode","year":2008,"lang":"en","type":"article","venue":"Analytical Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute","funders":"National Research Council Canada; McGill University","keywords":"Chemistry; Conjugate; Pepstatin; Saquinavir; Dielectric spectroscopy; Protease; Combinatorial chemistry; Electrode; Electrochemistry; Enzyme; Organic chemistry; Human immunodeficiency virus (HIV)","score_opus":0.05528004090536499,"score_gpt":0.30936907986917245,"score_spread":0.25408903896380747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030376296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852358,0.00019149318,0.012463094,0.00070224964,0.0000186944,0.00096959656,0.00001143641,0.00008620246,0.00032140207],"genre_scores_gemma":[0.9585212,0.000006765403,0.03815669,0.000082587285,0.00024996445,0.00016554454,0.00003501335,0.00005511331,0.0027271514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979391,0.000024220943,0.0004911141,0.00059690187,0.0002547173,0.00069392775],"domain_scores_gemma":[0.9987754,0.0003111683,0.00013556206,0.00020873501,0.00020491437,0.0003642061],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031937516,0.00033140846,0.000564075,0.000052420164,0.00031588972,0.000026282796,0.00006989977,0.00017330944,0.0000063373045],"category_scores_gemma":[0.00094386033,0.00030343057,0.00017996541,0.00020630533,0.0000862086,0.000074268035,0.000048225298,0.00018390169,9.221433e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010334756,0.00019890424,0.0063806553,0.0005066165,0.0003227491,0.00006141004,0.00041577144,0.00011300284,0.990082,0.00001389961,0.000063165666,0.0008083272],"study_design_scores_gemma":[0.0032547326,0.00008639713,0.000052489013,0.00016787459,0.0003834076,0.0001568613,0.00010609958,0.25101382,0.74437517,0.000027483125,0.000118531556,0.0002571567],"about_ca_topic_score_codex":0.000021113865,"about_ca_topic_score_gemma":0.0000030419453,"teacher_disagreement_score":0.2509008,"about_ca_system_score_codex":0.00028757492,"about_ca_system_score_gemma":0.00029553953,"threshold_uncertainty_score":0.99994177},"labels":[],"label_agreement":null},{"id":"W2030675531","doi":"10.1371/journal.pone.0027456","title":"8-Modified-2′-Deoxyadenosine Analogues Induce Delayed Polymerization Arrest during HIV-1 Reverse Transcription","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Sidaction; Université de Strasbourg; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Deoxyadenosine; Reverse transcriptase; Chemistry; Polymerization; Transcription (linguistics); Cell biology; Biophysics; Adenosine; Biology; Biochemistry; RNA; Gene; Organic chemistry","score_opus":0.06633171106258719,"score_gpt":0.2268525203735639,"score_spread":0.16052080931097673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030675531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933186,0.00021215543,0.00019717794,0.0012688641,0.000056694564,0.00045382234,0.000019123436,0.00017636128,0.0042971773],"genre_scores_gemma":[0.9854329,0.0002116424,0.0032241265,0.000114412,0.00014291216,0.00005206603,0.0004241279,0.00003537125,0.010362402],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879396,0.00003365847,0.00029290572,0.00028985337,0.00032794225,0.00026165377],"domain_scores_gemma":[0.99943435,0.000010043846,0.00008080536,0.0002406978,0.00007796626,0.00015615787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006400909,0.00019286788,0.00030146,0.00019921888,0.00010930129,0.000011922254,0.00006556797,0.000106230706,0.00030837077],"category_scores_gemma":[0.000027889195,0.00017852282,0.000061812374,0.0002676688,0.00004150261,0.00017937052,0.000015328038,0.0001439644,0.0002887947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012058661,0.0065692696,0.07828073,0.0003585693,0.0017199902,0.00024328503,0.008212337,0.0000012787904,0.9019404,0.0003186731,0.00061803433,0.00053158513],"study_design_scores_gemma":[0.00442258,0.00025178082,0.17497657,0.00072757964,0.0014396278,0.000020060344,0.00034953732,0.00017869695,0.81705385,0.00006757123,0.00010373041,0.0004084048],"about_ca_topic_score_codex":0.000050788673,"about_ca_topic_score_gemma":0.000019682278,"teacher_disagreement_score":0.09669584,"about_ca_system_score_codex":0.00009883366,"about_ca_system_score_gemma":0.00005112902,"threshold_uncertainty_score":0.727995},"labels":[],"label_agreement":null},{"id":"W2031047671","doi":"10.1053/ajkd.2000.9791","title":"Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir","year":2000,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital","funders":"","keywords":"Indinavir; Crystalluria; Urinalysis; Medicine; Urinary system; Microhematuria; Internal medicine; Urine; Asymptomatic; Gastroenterology; Creatinine; Urology; Immunology; Kidney; Human immunodeficiency virus (HIV); Proteinuria; Sida; Viral disease","score_opus":0.004528328088156029,"score_gpt":0.2428244022498495,"score_spread":0.23829607416169346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031047671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777466,0.00013112479,0.0000015786918,0.000589152,0.000005660708,0.00040974916,0.00009587208,0.000010895205,0.0009813142],"genre_scores_gemma":[0.9977949,0.00008048744,0.0002877028,0.00013828524,0.00003247314,0.000027208309,0.0000314518,0.000018513418,0.0015889573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835646,0.00015850716,0.00055047876,0.00018343807,0.00053066656,0.00022045562],"domain_scores_gemma":[0.9985672,0.00008608598,0.00044674106,0.0001551989,0.00019856104,0.000546199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010956386,0.00021665888,0.0008432046,0.00048985897,0.000046436813,0.000015296435,0.00010183091,0.00001671539,0.00032253738],"category_scores_gemma":[0.00009502742,0.00014376965,0.00012626428,0.00086781237,0.00024028022,0.00017872252,0.000014356632,0.00013875798,0.0000072441303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024451907,0.0048412047,0.9768828,0.00001603334,0.0018614362,0.00079540606,0.008314774,0.000021539523,0.000005811657,0.0000032649295,0.00035345767,0.004459084],"study_design_scores_gemma":[0.0062237126,0.005347082,0.9666932,0.00044192132,0.0017207181,0.0001294416,0.018859217,0.0000020747932,0.00032947873,0.000011518268,0.00009296255,0.00014862484],"about_ca_topic_score_codex":0.00016512205,"about_ca_topic_score_gemma":0.000008100896,"teacher_disagreement_score":0.010544443,"about_ca_system_score_codex":0.00016252,"about_ca_system_score_gemma":0.00055962225,"threshold_uncertainty_score":0.58627564},"labels":[],"label_agreement":null},{"id":"W2031074234","doi":"10.2174/138161206776873626","title":"Effects of Nucleotides and Nucleotide Analogue Inhibitors of HIV-1 Reverse Transcriptase in a Ratchet Model of Polymerase Translocation","year":2006,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Polymerase; Nucleotide; Förster resonance energy transfer; Reverse transcriptase; Primer (cosmetics); Biology; Chemistry; Biophysics; Chromosomal translocation; Biochemistry; Enzyme; Stereochemistry; Molecular biology; RNA; Gene; Fluorescence","score_opus":0.08674554430126692,"score_gpt":0.36468660747547876,"score_spread":0.27794106317421186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031074234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020602925,0.99093807,0.003840123,0.00007236595,0.00011714751,0.00273656,0.0001888012,0.000021200294,0.000025461024],"genre_scores_gemma":[0.017802173,0.97999173,0.0016433595,0.000010579892,0.00003336473,0.00011138687,0.00028369948,0.00005666977,0.00006700735],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969626,0.0003829035,0.0014853469,0.00046485613,0.00038324506,0.0003210231],"domain_scores_gemma":[0.9987406,0.00033667174,0.00038238315,0.00022287582,0.00008125196,0.00023621824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043992366,0.00052378554,0.0023304566,0.00059779553,0.000020646663,0.0000049007353,0.00012094485,0.00020205209,0.000016968877],"category_scores_gemma":[0.000067318804,0.00042961686,0.00045027558,0.00056812214,0.00027626584,0.000087510925,0.000021086098,0.0004147827,0.000004249077],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038111547,0.0035506026,0.0001572967,0.12485719,0.0005143879,0.00007050631,0.00071820564,0.000050913615,0.0030350897,0.0001800878,0.0018732781,0.8646113],"study_design_scores_gemma":[0.056260843,0.0016216586,0.00025188888,0.3749011,0.057189513,0.00012158869,0.0001837904,0.040474266,0.24363478,0.00042148953,0.220661,0.0042780987],"about_ca_topic_score_codex":0.000010120326,"about_ca_topic_score_gemma":9.921605e-7,"teacher_disagreement_score":0.8603332,"about_ca_system_score_codex":0.000116698495,"about_ca_system_score_gemma":0.0005009339,"threshold_uncertainty_score":0.9998156},"labels":[],"label_agreement":null},{"id":"W2031391945","doi":"10.1016/j.bcp.2013.04.002","title":"Agonism of human pregnane X receptor by rilpivirine and etravirine: Comparison with first generation non-nucleoside reverse transcriptase inhibitors","year":2013,"lang":"en","type":"article","venue":"Biochemical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Etravirine; Rilpivirine; Efavirenz; Nevirapine; Pregnane X receptor; Pharmacology; Raltegravir; Reverse-transcriptase inhibitor; Biology; Chemistry; Reverse transcriptase; Nuclear receptor; Virology; Biochemistry; Transcription factor; Human immunodeficiency virus (HIV); Viral load; Gene","score_opus":0.013124397897219397,"score_gpt":0.27296170018792865,"score_spread":0.2598373022907092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031391945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377346,0.0007927516,0.000026404,0.00425501,0.000118904405,0.00079817214,0.00002048932,0.000034984605,0.00017982999],"genre_scores_gemma":[0.99541086,0.00018879963,0.0014447535,0.00030588033,0.00016203264,0.0001269847,0.00040929456,0.00002463051,0.0019267856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886835,0.000028685383,0.00037447512,0.00032742508,0.00015874013,0.00024232954],"domain_scores_gemma":[0.9994387,0.000039532006,0.000106514315,0.00011441832,0.00007965409,0.00022117105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060354992,0.000216418,0.00039564032,0.00007343752,0.0000757946,0.000008593305,0.000057236346,0.00013231873,0.0007518324],"category_scores_gemma":[0.000010220412,0.00017092975,0.000046517616,0.00011632594,0.00022660453,0.00006862289,0.000027652548,0.00016855753,0.00003817551],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007560572,0.00040106807,0.0025346128,0.000074930875,0.00009824739,0.0000049087225,0.00016741596,2.389963e-7,0.55048424,0.0000018564739,0.44600752,0.00014934341],"study_design_scores_gemma":[0.0048406417,0.0004908227,0.00118719,0.0000803152,0.00026075108,0.000013659294,0.000042960357,0.00011893979,0.9728251,0.0000023486334,0.019959541,0.00017769533],"about_ca_topic_score_codex":0.000078384895,"about_ca_topic_score_gemma":0.000003820622,"teacher_disagreement_score":0.42604795,"about_ca_system_score_codex":0.0000656196,"about_ca_system_score_gemma":0.000042048894,"threshold_uncertainty_score":0.82320374},"labels":[],"label_agreement":null},{"id":"W2031428123","doi":"10.7448/ias.17.4.19780","title":"Efficacy and tolerability of Etravirine in HIV‐1 adult patients: Results of a large French prospective cohort","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Enfuvirtide; Etravirine; Tolerability; Raltegravir; Regimen; Internal medicine; Cohort; Ritonavir; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Adverse effect; Virology; Immunology","score_opus":0.004761610780821688,"score_gpt":0.25015049019827146,"score_spread":0.24538887941744977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031428123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599165,0.000023094317,0.00006292843,0.0026065141,0.00013782133,0.00021956784,0.000034497,0.0000020512161,0.0009218869],"genre_scores_gemma":[0.99628353,0.00003594327,0.0026134728,0.000100198566,0.000058723555,0.0000026036523,0.000008569406,0.000004952276,0.00089198456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859667,0.00004162158,0.0006433993,0.00010677489,0.00052737753,0.000084180305],"domain_scores_gemma":[0.9985068,0.00014902273,0.00047766734,0.00011113283,0.0007139493,0.000041469986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006971736,0.00008646504,0.0003045851,0.000048043683,0.000020192865,0.0000047710864,0.00013623569,0.000045477293,0.000019724237],"category_scores_gemma":[0.0007230715,0.00005212872,0.00018431043,0.00012131398,0.000073751355,0.00006883123,0.00007090928,0.00019215926,6.404137e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038431823,0.0011416633,0.992926,0.000026028376,0.00038140704,7.6194374e-7,0.0018566293,0.000007291537,0.00027355622,0.0002263253,0.0022480192,0.0005279815],"study_design_scores_gemma":[0.010137046,0.0002779246,0.9847422,0.0002865925,0.00007354065,0.000007949234,0.0001205444,0.0002028926,0.0030936324,0.0003460812,0.0006684612,0.00004311195],"about_ca_topic_score_codex":0.000023032291,"about_ca_topic_score_gemma":0.000013845776,"teacher_disagreement_score":0.009752727,"about_ca_system_score_codex":0.0001868224,"about_ca_system_score_gemma":0.00007594242,"threshold_uncertainty_score":0.21257475},"labels":[],"label_agreement":null},{"id":"W2032305014","doi":"10.1021/jo060430t","title":"Solventless Protocol for Efficient Bis-<i>N</i>-Boc Protection of Adenosine, Cytidine, and Guanosine Derivatives","year":2006,"lang":"en","type":"article","venue":"The Journal of Organic Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Cytidine; Guanosine; Chemistry; Deoxyguanosine; Moiety; Silylation; Adenosine; Guanine; Stereochemistry; Deoxyadenosine; Nucleotide; Nucleic acid; Organic chemistry; Biochemistry; Adduct; Catalysis","score_opus":0.014855156978690299,"score_gpt":0.26649153180986485,"score_spread":0.25163637483117457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032305014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96614057,0.00019242696,0.0040242006,0.0035127925,0.000033024433,0.025638264,0.0000058722962,0.000017111706,0.000435724],"genre_scores_gemma":[0.9935811,0.000009646215,0.0015092755,0.000016261405,0.00025946353,0.0024612234,0.00000443783,0.000027455051,0.0021311198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990851,0.00001584994,0.0004453671,0.00008817613,0.00023330755,0.00013214735],"domain_scores_gemma":[0.9990955,0.00005420564,0.0004377698,0.00012233539,0.00023915565,0.000051026338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002399374,0.0001367047,0.00027675665,0.000035783454,0.00006939943,0.000008677724,0.00007849098,0.00005646225,0.000102888065],"category_scores_gemma":[0.00006946001,0.00008137584,0.000071150076,0.00015620406,0.000079432015,0.000028323884,0.000026927002,0.0001304596,6.2421503e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008280743,0.0004940326,0.0015553937,0.0005745845,0.00011707733,0.000006673901,0.00018705172,0.000015076719,0.99447304,0.000005536543,0.0014439438,0.00029948872],"study_design_scores_gemma":[0.0045086276,0.00017322226,0.0024866995,0.0003945545,0.00017043584,0.00045395544,0.00023162107,0.000062481806,0.9888918,0.000046122892,0.0024997457,0.000080759295],"about_ca_topic_score_codex":0.000002868139,"about_ca_topic_score_gemma":8.9875056e-7,"teacher_disagreement_score":0.027440533,"about_ca_system_score_codex":0.00008355501,"about_ca_system_score_gemma":0.0001978893,"threshold_uncertainty_score":0.33184105},"labels":[],"label_agreement":null},{"id":"W2032458137","doi":"10.1097/qai.0b013e3181a4f9c4","title":"Expanding Antiretroviral Options in Resource-Limited Settings-A Cost-Effectiveness Analysis","year":2009,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"National Institute on Drug Abuse; Agency for Healthcare Research and Quality","keywords":"Antiretroviral therapy; Resource (disambiguation); Human immunodeficiency virus (HIV); Medicine; Cost–benefit analysis; Intensive care medicine; Risk analysis (engineering); Computer science; Virology; Viral load; Biology","score_opus":0.022118988146960044,"score_gpt":0.30619225535893496,"score_spread":0.2840732672119749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032458137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945144,0.0023642145,0.00056215853,0.0013109443,0.00014923645,0.00044764442,0.00000582811,0.0000613206,0.00058425416],"genre_scores_gemma":[0.99693316,0.00024997137,0.0016246076,0.000066518434,0.000034565117,0.000011474206,0.00004191398,0.000025681002,0.0010120845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969485,0.00026776476,0.0011996868,0.00032790078,0.0006915847,0.00056456815],"domain_scores_gemma":[0.99839675,0.0003131685,0.0005446815,0.0003616204,0.00021820581,0.00016556622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019749443,0.00031945982,0.001220218,0.0031356832,0.00018966763,0.00007134486,0.00025199904,0.00013709663,0.00005528678],"category_scores_gemma":[0.0004466895,0.0002561116,0.00064935634,0.0044604014,0.00009767924,0.0003685614,0.0000434628,0.00021345398,0.000028925684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023235078,0.0046931133,0.83688295,0.00026094494,0.004288748,0.0062286267,0.006133964,0.0032921545,0.07242453,0.00052822,0.000970097,0.061973143],"study_design_scores_gemma":[0.0045253593,0.0015415384,0.9832312,0.0007594338,0.0016624774,0.0010837689,0.0017634751,0.0004276753,0.0040860185,0.00011810905,0.00045820954,0.0003427457],"about_ca_topic_score_codex":0.000008298453,"about_ca_topic_score_gemma":9.1257186e-7,"teacher_disagreement_score":0.14634824,"about_ca_system_score_codex":0.0004515474,"about_ca_system_score_gemma":0.00016965017,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W2032745022","doi":"10.4021/jem.v1i3.34","title":"Influence of Efavirenz and Nevirapine on the Pharmacodynamics and Pharmacokinetics of Gliclazide in Rabbits","year":2011,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gliclazide; Medicine; Pharmacokinetics; Efavirenz; Pharmacology; Pharmacodynamics; Nevirapine; Reverse-transcriptase inhibitor; Diabetes mellitus; Endocrinology; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy","score_opus":0.02321115172852707,"score_gpt":0.2811576343942844,"score_spread":0.2579464826657573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032745022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98928297,0.0091160145,0.0000043463397,0.0010618645,0.00005933671,0.00012496651,0.0000033858228,0.0000019903634,0.00034513278],"genre_scores_gemma":[0.98058075,0.01849708,0.0005409654,0.00021677918,0.000027811395,0.0000022100394,3.9988868e-7,0.0000058765213,0.00012813698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918205,0.00006687901,0.00041165968,0.00008976914,0.00010632691,0.00014334498],"domain_scores_gemma":[0.99939317,0.000114627976,0.00025695362,0.000072360985,0.00009356014,0.00006932843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018987822,0.00011409101,0.00041445694,0.00021032362,0.000022049973,0.0000017122237,0.000055919838,0.00003699105,0.000016001339],"category_scores_gemma":[0.000070034344,0.000068527246,0.000034112523,0.000098658704,0.00023322996,0.00006246958,0.00004037822,0.00023264848,3.3542435e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042988444,0.0017667613,0.59826136,0.00044817373,0.0022650813,0.00109208,0.012077526,0.00005131133,0.24382219,0.028875383,0.00050919765,0.10653208],"study_design_scores_gemma":[0.008122751,0.00034017576,0.8463578,0.00019063549,0.000659939,0.0009022016,0.00020583476,0.000053797805,0.13552819,0.0007742055,0.006756132,0.000108317094],"about_ca_topic_score_codex":0.000010442416,"about_ca_topic_score_gemma":0.000002915103,"teacher_disagreement_score":0.24809644,"about_ca_system_score_codex":0.000005471523,"about_ca_system_score_gemma":0.000038906557,"threshold_uncertainty_score":0.279446},"labels":[],"label_agreement":null},{"id":"W2032847961","doi":"10.1371/journal.pmed.0050158","title":"Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy","year":2008,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada","funders":"Centers for Disease Control and Prevention","keywords":"Drug resistance; Resistance mutation; HIV drug resistance; Genotyping; Drug; Virology; Reverse transcriptase; Genotype; Medicine; Viral load; Biology; Genetics; Virus; Pharmacology; Polymerase chain reaction; Antiretroviral therapy; Gene","score_opus":0.05074698755939865,"score_gpt":0.2885208412925289,"score_spread":0.23777385373313026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032847961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710128,0.0014626789,0.0000046068885,0.022906613,0.000054592554,0.0012792592,0.000036679765,0.00010196226,0.003140817],"genre_scores_gemma":[0.9028018,0.0006022126,0.001303369,0.000049627106,0.0001924303,0.00018615561,0.00046349282,0.000029788649,0.09437109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980971,0.000089870315,0.000454725,0.00050727295,0.0004527861,0.00039822515],"domain_scores_gemma":[0.998921,0.00017692406,0.00019269933,0.0003371617,0.00009941815,0.00027282766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007422328,0.00037850966,0.0007726194,0.0003024403,0.00026259793,0.000008904957,0.00005122869,0.00007318957,0.0000683161],"category_scores_gemma":[0.00010838237,0.00024515876,0.000064247884,0.0003883177,0.00024166104,0.00010056029,0.000015277234,0.0001214782,0.000026149926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073537417,0.003039154,0.97699493,0.00006256649,0.00062239124,0.0018205617,0.0114155775,0.0000079547835,0.00032059854,0.000037258797,0.0037862249,0.0011573852],"study_design_scores_gemma":[0.022379218,0.0008149604,0.9672076,0.00076212594,0.0011253675,0.00009098621,0.0010154002,0.00015568172,0.0019999656,0.000044498327,0.0040634843,0.00034071045],"about_ca_topic_score_codex":0.0003003084,"about_ca_topic_score_gemma":0.0018111131,"teacher_disagreement_score":0.09123027,"about_ca_system_score_codex":0.00083290413,"about_ca_system_score_gemma":0.00018921116,"threshold_uncertainty_score":0.9997284},"labels":[],"label_agreement":null},{"id":"W2033179506","doi":"10.2217/17469600.1.3.291","title":"Strategies for the Optimal Sequencing of Antiretroviral Drugs Toward Overcoming and Preventing Drug Resistance","year":2007,"lang":"en","type":"article","venue":"Future HIV Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Abacavir; Stavudine; Drug resistance; Drug; Ritonavir; Emtricitabine; Nucleoside; Virology; Lamivudine; Pharmacology; Zidovudine; Tenofovir; Biology; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genetics; Virus; Viral load; Viral disease","score_opus":0.016532946684643918,"score_gpt":0.27504856154417584,"score_spread":0.2585156148595319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033179506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824007,0.007538904,0.0040773116,0.003525474,0.0002028963,0.0007416989,0.000008769929,0.000045581957,0.0014586472],"genre_scores_gemma":[0.9689184,0.00074566744,0.021558752,0.0001495645,0.0004961077,0.000020943855,0.000015990854,0.000025088822,0.008069481],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990467,0.000019906869,0.0002667979,0.00020314011,0.0002006817,0.00026278105],"domain_scores_gemma":[0.999408,0.00018672418,0.00012312706,0.00016974795,0.000063933876,0.000048437883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056212157,0.00016661854,0.0002574538,0.000062248946,0.00016096662,0.00003076811,0.000080565704,0.000054596254,0.000014421003],"category_scores_gemma":[0.000008566389,0.00010422918,0.00009947429,0.000120808916,0.00006857512,0.000116017814,0.000016964894,0.00011607555,8.8124784e-7],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013275291,0.00068156363,0.10392567,0.0018826432,0.003608697,0.0001890408,0.35502675,0.000056107514,0.1050871,0.041881736,0.04187391,0.33251148],"study_design_scores_gemma":[0.024559397,0.00072064827,0.05376769,0.0015281189,0.00065517833,0.0000818674,0.23748639,0.0008199422,0.16061018,0.00196844,0.51646036,0.0013417851],"about_ca_topic_score_codex":0.000007384248,"about_ca_topic_score_gemma":0.000015200527,"teacher_disagreement_score":0.47458646,"about_ca_system_score_codex":0.0000634487,"about_ca_system_score_gemma":0.00013080213,"threshold_uncertainty_score":0.42503422},"labels":[],"label_agreement":null},{"id":"W2033276174","doi":"10.1002/jmv.20582","title":"Effects of drug resistance on viral load in patients failing antiretroviral therapy","year":2006,"lang":"en","type":"article","venue":"Journal of Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Virology; Viral load; Drug resistance; Antiretroviral therapy; Antiretroviral drug; Drug; Medicine; Human immunodeficiency virus (HIV); Lentivirus; Viral disease; Biology; Pharmacology; Microbiology","score_opus":0.003917074410522451,"score_gpt":0.24228170467179397,"score_spread":0.23836463026127153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033276174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992935,0.0009930498,0.000026060425,0.00519918,0.00026234178,0.00015590036,5.246159e-7,0.0000051312973,0.0004227862],"genre_scores_gemma":[0.9976992,0.0002665903,0.00030542724,0.00049045944,0.00017427973,0.0000023107123,0.0000030999204,0.000011262741,0.0010473526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770963,0.00014372478,0.0006649404,0.00012983002,0.0011202294,0.00023166738],"domain_scores_gemma":[0.9991169,0.00027975073,0.00029880786,0.00009121523,0.00008995848,0.000123365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063040043,0.00013427426,0.0005486249,0.00021331258,0.000020524541,0.0000030833958,0.00013377925,0.00015915997,0.0000625436],"category_scores_gemma":[0.00031290328,0.00008993368,0.00012102831,0.00012705558,0.00011681261,0.00004401271,0.000019131245,0.0004308827,0.000009267824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008094523,0.0047849948,0.9490765,0.00017628618,0.00023390127,0.0022818183,0.0006579003,0.000004925756,0.0024504329,0.0005374882,0.0126042,0.019097054],"study_design_scores_gemma":[0.032357257,0.0026691665,0.94255185,0.0007583372,0.00007431759,0.00002698574,0.000024459936,0.000026848158,0.011856948,0.00050724606,0.009002585,0.00014399929],"about_ca_topic_score_codex":0.000015698479,"about_ca_topic_score_gemma":0.000022774722,"teacher_disagreement_score":0.024262734,"about_ca_system_score_codex":0.00014175226,"about_ca_system_score_gemma":0.00024522794,"threshold_uncertainty_score":0.36673892},"labels":[],"label_agreement":null},{"id":"W2033289767","doi":"10.1097/qad.0b013e32832b4461","title":"Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals","year":2009,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Agence Nationale de la Recherche; King Chulalongkorn Memorial Hospital","keywords":"Saquinavir; Ritonavir; Pharmacokinetics; Boosting (machine learning); Pharmacology; Medicine; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy; Computer science; Machine learning","score_opus":0.016639732617929132,"score_gpt":0.284577906861826,"score_spread":0.2679381742438969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033289767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921351,0.00009176507,0.000016277865,0.0038688087,0.0000847184,0.0005728942,0.000019095982,0.000055589815,0.0031557167],"genre_scores_gemma":[0.99558437,0.00003069483,0.0020625268,0.00019002813,0.000076221135,0.000026756501,0.0000777248,0.000011555635,0.0019401194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876285,0.00009731091,0.00037777933,0.00022405523,0.0002609286,0.00027705572],"domain_scores_gemma":[0.9991591,0.00036261504,0.00011368499,0.0002470388,0.00004793513,0.00006965673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003547589,0.00016893855,0.00031602872,0.00013177529,0.00010507412,0.000020136267,0.000091263355,0.00007366722,0.000060304366],"category_scores_gemma":[0.00025261316,0.0000997921,0.00007895153,0.00039860923,0.00007152795,0.00010088109,0.000026933445,0.00019193334,0.000030398518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117210155,0.0005759548,0.9057804,0.000042760716,0.00016924345,0.00007985516,0.006414743,0.000041128496,0.05215005,0.0015271682,0.00088050077,0.032221008],"study_design_scores_gemma":[0.0040760464,0.0004119597,0.795172,0.00061969494,0.00021310727,0.000034424436,0.0005967897,0.00023556016,0.19704905,0.00016628452,0.0012123403,0.00021274661],"about_ca_topic_score_codex":0.000036522695,"about_ca_topic_score_gemma":0.000012931882,"teacher_disagreement_score":0.144899,"about_ca_system_score_codex":0.0000905953,"about_ca_system_score_gemma":0.00013047887,"threshold_uncertainty_score":0.40694037},"labels":[],"label_agreement":null},{"id":"W2033405042","doi":"10.7448/ias.15.6.18242","title":"Retention on third agents in HAART regimens at the Maple Leaf Clinic in Toronto, Ontario, Canada","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Efavirenz; Lopinavir; Regimen; Integrase inhibitor; Internal medicine; Viral load; Protease inhibitor (pharmacology); Atazanavir; Nevirapine; Retrospective cohort study; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.03164007297062948,"score_gpt":0.29549252061469394,"score_spread":0.26385244764406446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033405042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708868,0.00019882405,0.000001810728,0.017601594,0.001501968,0.00014765888,0.000003853983,0.0000020977584,0.009655347],"genre_scores_gemma":[0.8831942,0.00009127279,0.00027262158,0.0018503558,0.00021953216,0.000004777289,0.000007439315,0.00000778007,0.11435203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998499,0.000054720385,0.0004473196,0.0000866878,0.00073198305,0.00018034062],"domain_scores_gemma":[0.9993352,0.00009964358,0.00027793998,0.00013869579,0.00008348768,0.00006501907],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084579986,0.00010460862,0.00017781566,0.00002182285,0.000059432576,0.000011798688,0.00021606412,0.00005241262,0.0013741952],"category_scores_gemma":[0.00006856846,0.0000562746,0.00025916172,0.00006599768,0.00002682082,0.00013723841,0.000082848856,0.00033577433,0.000015718586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016279836,0.00023648591,0.6913727,0.000004100781,0.00027695956,0.000013634547,0.0023126216,0.000011994082,0.000112320704,0.000064873726,0.30512232,0.00030917933],"study_design_scores_gemma":[0.0023079847,0.000081116006,0.82848376,0.00025837534,0.00006672755,0.000090325055,0.0014496199,0.000041373794,0.0007455001,0.000076804965,0.16631627,0.000082126164],"about_ca_topic_score_codex":0.2253995,"about_ca_topic_score_gemma":0.8658301,"teacher_disagreement_score":0.6404306,"about_ca_system_score_codex":0.009007923,"about_ca_system_score_gemma":0.00052216067,"threshold_uncertainty_score":0.99953866},"labels":[],"label_agreement":null},{"id":"W2033626418","doi":"10.1371/journal.pone.0036549","title":"K65R in Subtype C HIV-1 Isolates from Patients Failing on a First-Line Regimen Including d4T or AZT: Comparison of Sanger and UDP Sequencing Data","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; McGill University; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Biology; Virology; Efavirenz; Sanger sequencing; Stavudine; Zidovudine; Reverse transcriptase; Reverse-transcriptase inhibitor; Nevirapine; Lamivudine; Genetics; Human immunodeficiency virus (HIV); Polymerase chain reaction; Viral load; Virus; Mutation; Gene; Viral disease; Hepatitis B virus; Antiretroviral therapy","score_opus":0.2046382280713387,"score_gpt":0.32371993961197204,"score_spread":0.11908171154063335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033626418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977603,0.0008034673,0.000007944312,0.00057099096,0.000024147235,0.00042932061,0.00007791287,0.000029533787,0.0002963926],"genre_scores_gemma":[0.9929853,0.00014732785,0.0052930852,0.00004663079,0.00008854934,0.000014192309,0.00094115466,0.000018862751,0.000464874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873483,0.000033661312,0.0003875435,0.00028498736,0.00028433415,0.00027462232],"domain_scores_gemma":[0.9990525,0.00028407862,0.0001481611,0.00034466627,0.000050332517,0.000120227814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019071528,0.0001754544,0.00051406404,0.0001202847,0.00006923985,0.000010279422,0.00010459691,0.0000776868,0.00010717138],"category_scores_gemma":[0.00023969136,0.00012555842,0.000017107308,0.00017185755,0.000025117663,0.00020130613,0.00020292017,0.00016350366,0.0000429984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047775824,0.002480406,0.985456,0.0001838667,0.0003343894,0.000007157375,0.005203744,0.0000015019151,0.0041400855,0.000002650893,0.00026323993,0.0014491986],"study_design_scores_gemma":[0.022191446,0.0018532888,0.66389155,0.018055988,0.002702583,0.000004630975,0.0036052493,0.027430778,0.25638974,0.0000668772,0.0023890203,0.0014188355],"about_ca_topic_score_codex":0.00012814162,"about_ca_topic_score_gemma":0.00029769563,"teacher_disagreement_score":0.32156444,"about_ca_system_score_codex":0.00017284445,"about_ca_system_score_gemma":0.00003341286,"threshold_uncertainty_score":0.51201236},"labels":[],"label_agreement":null},{"id":"W2033969240","doi":"10.1089/apc.2013.0009","title":"Atazanavir and Other Determinants of Hyperbilirubinemia in a Cohort of 1150 HIV-Positive Patients: Results from 9 Years of Follow-Up","year":2013,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Atazanavir; Proportional hazards model; Ritonavir; Internal medicine; Cumulative incidence; Hazard ratio; Incidence (geometry); Prospective cohort study; Cohort; Cohort study; Adverse effect; Confidence interval; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Immunology","score_opus":0.00711774510344957,"score_gpt":0.22732325700138084,"score_spread":0.22020551189793128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033969240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978428,0.00034475562,6.267723e-7,0.0000037315663,0.000045243378,0.0005928979,0.00046583015,0.0000044701196,0.0006996545],"genre_scores_gemma":[0.9989336,0.00006865563,0.0006093639,0.000021390038,0.0000061784995,0.000024653018,0.00017381475,0.000012550012,0.00014976281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988805,0.000035969406,0.00049498543,0.00023457798,0.00022403648,0.00012995284],"domain_scores_gemma":[0.9992828,0.000107777705,0.00017482253,0.00018806258,0.00017871674,0.00006786309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049649294,0.00013298937,0.00045374167,0.00012757788,0.000012920692,0.0000030898234,0.000037064325,0.000074462194,0.000019482199],"category_scores_gemma":[0.00006978165,0.00010896913,0.000052455536,0.0001264001,0.0000922491,0.00006420394,0.000053519776,0.000053292206,0.000002801577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030187605,0.00015817584,0.8470421,0.000053770153,0.000082207895,0.000005989256,0.009868055,1.2945985e-7,0.00031871762,0.0000032599814,0.00012522461,0.1420405],"study_design_scores_gemma":[0.0073515107,0.009091379,0.96308917,0.0007592543,0.00018769142,9.512885e-7,0.0028703364,0.000019759269,0.016348485,0.000019653065,0.000109317756,0.00015251923],"about_ca_topic_score_codex":0.0016201236,"about_ca_topic_score_gemma":0.00011793951,"teacher_disagreement_score":0.14188798,"about_ca_system_score_codex":0.000033259545,"about_ca_system_score_gemma":0.000039994276,"threshold_uncertainty_score":0.4443632},"labels":[],"label_agreement":null},{"id":"W2034681616","doi":"10.1177/1545109708328538","title":"Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity","year":2008,"lang":"en","type":"article","venue":"Journal of the International Association of Physicians in AIDS Care","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Bill and Melinda Gates Foundation","keywords":"Lopinavir; Medicine; Regimen; Ritonavir; Stavudine; Lamivudine; Didanosine; Interquartile range; Internal medicine; Zidovudine; Viral load; Lopinavir/ritonavir; Reverse-transcriptase inhibitor; Adverse effect; Gastroenterology; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease; Virus","score_opus":0.025898980964233258,"score_gpt":0.29095702863574946,"score_spread":0.2650580476715162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034681616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962603,0.00007207852,0.000025186946,0.0027891845,0.000266622,0.00016033622,0.00032131307,0.0000028660534,0.000102137536],"genre_scores_gemma":[0.998024,0.00008044265,0.0009449004,0.00017629123,0.00011154131,0.0000016675389,0.00004312367,0.00000931997,0.0006087148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795765,0.00017779744,0.0009398076,0.0001328297,0.0006761129,0.00011578777],"domain_scores_gemma":[0.9975106,0.00033332806,0.0013579115,0.00021869564,0.0005592001,0.000020243453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089409953,0.00012174775,0.0005384036,0.00023688374,0.000021564145,0.0000039684155,0.00047268326,0.000088703804,0.000041508232],"category_scores_gemma":[0.00066718186,0.000083577404,0.00019740872,0.00025808543,0.00005769979,0.00016689632,0.000101568236,0.00027337886,0.0000010198571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035019054,0.0006929348,0.9748714,0.000021613745,0.0003291445,0.000022156331,0.0011653055,0.00006227955,0.017640214,0.00010296932,0.0004114312,0.0011786503],"study_design_scores_gemma":[0.005993029,0.000894678,0.949379,0.0003024354,0.000038758924,0.0000061690916,0.0006048902,0.00011022488,0.04225917,0.0001803372,0.0001600682,0.00007121274],"about_ca_topic_score_codex":0.000055629644,"about_ca_topic_score_gemma":0.00016348978,"teacher_disagreement_score":0.02549237,"about_ca_system_score_codex":0.000505493,"about_ca_system_score_gemma":0.00017946305,"threshold_uncertainty_score":0.34081876},"labels":[],"label_agreement":null},{"id":"W2035341996","doi":"10.1310/hct1002-76","title":"Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Clair College","funders":"GlaxoSmithKline","keywords":"Medicine; Abacavir; Lopinavir/ritonavir; Lopinavir; Ritonavir; Interquartile range; Lamivudine; Adverse effect; Viral load; Internal medicine; Gastroenterology; Pharmacology; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Virus; Chronic hepatitis","score_opus":0.12890663139448505,"score_gpt":0.4384300801451987,"score_spread":0.30952344875071364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035341996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899601,0.00063804036,0.0002365081,0.0040611913,0.00041666892,0.00225859,0.000055230386,0.00007499415,0.0022986976],"genre_scores_gemma":[0.9936683,0.001291945,0.0015201144,0.00018226352,0.00033034984,0.000039134782,0.00045218473,0.000036220707,0.0024794769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505395,0.0007247885,0.002460884,0.0007188764,0.00061266084,0.00042886304],"domain_scores_gemma":[0.99435216,0.0040450916,0.0006566879,0.0005065827,0.00012804256,0.00031141157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034535662,0.0004287641,0.0021396622,0.0002334677,0.00007793717,0.00002809003,0.00015755133,0.00037539928,0.00014053404],"category_scores_gemma":[0.0019943547,0.00031767343,0.0002942908,0.00042375005,0.0002677383,0.0001872839,0.00007051291,0.0005131379,0.0000568214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12466704,0.011064266,0.4697827,0.00033639953,0.0015639559,0.0008976953,0.0006825441,0.000024980096,0.00081749726,0.0026481724,0.0017761685,0.38573855],"study_design_scores_gemma":[0.11543112,0.003339131,0.87700534,0.0011346382,0.0005795429,0.000018753566,0.000029796505,0.00009591082,0.00040624535,0.00016448252,0.0014368494,0.00035817546],"about_ca_topic_score_codex":0.000017299799,"about_ca_topic_score_gemma":0.000033461132,"teacher_disagreement_score":0.40722263,"about_ca_system_score_codex":0.00019593106,"about_ca_system_score_gemma":0.00029545423,"threshold_uncertainty_score":0.9999275},"labels":[],"label_agreement":null},{"id":"W2035644343","doi":"10.1007/s11095-014-1336-0","title":"In Vitro and In Situ Evaluation of pH-Dependence of Atazanavir Intestinal Permeability and Interactions with Acid-Reducing Agents","year":2014,"lang":"en","type":"article","venue":"Pharmaceutical Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Atazanavir; Chemistry; Ileum; Intestinal permeability; Jejunum; Pharmacology; Biochemistry; Efflux; Permeability (electromagnetism); Bioavailability; Chromatography; Internal medicine; Membrane; Biology; Immunology; Medicine","score_opus":0.22594472538073795,"score_gpt":0.5127677129813628,"score_spread":0.28682298760062486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035644343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99646366,0.00013644942,0.000031024865,0.0015512081,0.00001084452,0.00047850865,0.0000016524939,0.0000031472607,0.0013235313],"genre_scores_gemma":[0.9990223,0.00003918935,0.00075675885,0.000013985903,0.000010663821,0.00004478876,0.0000052095247,0.0000055912437,0.00010151831],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820286,0.0003888016,0.00023511366,0.00023947061,0.0007217418,0.00021202335],"domain_scores_gemma":[0.9988994,0.00052727154,0.000028080245,0.000117928095,0.00029659658,0.00013073249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003318802,0.000074782896,0.00019584637,0.00026153948,0.00002817189,0.0000070759534,0.000044700544,0.000025029978,0.00009038277],"category_scores_gemma":[0.0014455072,0.000057618734,0.000012212762,0.0003225905,0.00025257244,0.00011161397,0.00008241525,0.00035670935,0.000003139815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026553643,0.0009585753,0.32907456,0.00041037743,0.000049016904,0.00002323369,0.002050654,0.000011221378,0.5818977,0.0000570541,0.000029090426,0.08278321],"study_design_scores_gemma":[0.0053786337,0.00020199832,0.37749967,0.000528235,0.00008727242,0.00004690464,0.0005696788,0.055244748,0.55991435,0.00030363156,0.00013512933,0.00008972751],"about_ca_topic_score_codex":0.00010094763,"about_ca_topic_score_gemma":0.00011941297,"teacher_disagreement_score":0.08269348,"about_ca_system_score_codex":0.00016235327,"about_ca_system_score_gemma":0.00016975713,"threshold_uncertainty_score":0.23496237},"labels":[],"label_agreement":null},{"id":"W2037266897","doi":"10.1097/00126334-200309011-00008","title":"Efficacy and Durability of Nevirapine in Antiretroviral-Experienced Patients","year":2003,"lang":"en","type":"review","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; Providence Health Care; AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Nevirapine; Medicine; Durability; Human immunodeficiency virus (HIV); Antiretroviral drug; Antiretroviral treatment; Virology; Antiretroviral therapy; Viral load; Computer science","score_opus":0.030066715746091172,"score_gpt":0.31876117174935126,"score_spread":0.2886944560032601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037266897","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2512768,0.74743783,0.0000034623033,0.0000244871,0.0003279262,0.00078598026,0.000009624799,0.000012595621,0.00012131309],"genre_scores_gemma":[0.06508132,0.9333652,0.00067230867,0.0000063324605,0.000016349037,0.00001873435,0.000035757206,0.000061946754,0.0007420437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948123,0.00032614425,0.003105421,0.00044604836,0.0008104472,0.00049960025],"domain_scores_gemma":[0.9968091,0.00032817834,0.0018568777,0.0005257346,0.0003053604,0.0001747319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011353437,0.00062276726,0.004181636,0.0014652285,0.00007560906,0.000028455557,0.00034063222,0.00030689657,0.000060595266],"category_scores_gemma":[0.00085048313,0.00042995161,0.0007347502,0.0016951594,0.00035151868,0.00026619443,0.000106694,0.00028844748,0.000017037451],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047635954,0.004764133,0.03302524,0.019371904,0.0009684021,0.0006176162,0.0018075741,0.0000012779274,0.00006778217,0.000043416443,0.00022168661,0.93863463],"study_design_scores_gemma":[0.061009713,0.024021916,0.29395637,0.20508352,0.013797239,0.00995997,0.0021129001,0.000017393537,0.0005031021,0.00019908011,0.3844052,0.0049335985],"about_ca_topic_score_codex":0.0000058482365,"about_ca_topic_score_gemma":2.918775e-7,"teacher_disagreement_score":0.93370104,"about_ca_system_score_codex":0.0003040247,"about_ca_system_score_gemma":0.00062500243,"threshold_uncertainty_score":0.9998152},"labels":[],"label_agreement":null},{"id":"W2037384950","doi":"10.1097/00002030-200207260-00009","title":"The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to &lt; 400 copies/ml","year":2002,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Interquartile range; Viral load; Medicine; Gastroenterology; Internal medicine; Confidence interval; Retrospective cohort study; Hazard ratio; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.015056974039275806,"score_gpt":0.2682065288761816,"score_spread":0.2531495548369058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037384950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744475,0.00037647825,0.0000048678558,0.0004930476,0.00029463638,0.00041796427,0.0000030241724,0.000012249531,0.0009529565],"genre_scores_gemma":[0.99539393,0.0000411836,0.0004766053,0.00022693745,0.000042173357,0.000022625529,0.000011326256,0.00001123549,0.003774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899364,0.000062895095,0.00033140896,0.00020631708,0.00023697004,0.00016874999],"domain_scores_gemma":[0.9994694,0.00012919655,0.00007107442,0.00018390524,0.00005673916,0.00008970375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013603501,0.000121071294,0.000250039,0.000065951834,0.000035808855,0.0000052597707,0.00007170515,0.00005338363,0.00005942314],"category_scores_gemma":[0.00007631316,0.000069301495,0.00003925173,0.000075859694,0.00015023592,0.000054754386,0.000055502038,0.00017735442,0.000016485035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009842354,0.00041395525,0.9230924,0.00001907582,0.00007551294,0.000027187472,0.00094361964,2.1238468e-7,0.00008562062,0.000046044075,0.012142557,0.06216958],"study_design_scores_gemma":[0.005614548,0.0015847431,0.9694029,0.00025964752,0.00006580419,0.0000025309098,0.000085914835,0.00006975002,0.00053219276,0.0000080346235,0.022233553,0.00014034653],"about_ca_topic_score_codex":0.000012161434,"about_ca_topic_score_gemma":0.000018147173,"teacher_disagreement_score":0.062029235,"about_ca_system_score_codex":0.00017082458,"about_ca_system_score_gemma":0.00004160192,"threshold_uncertainty_score":0.2826033},"labels":[],"label_agreement":null},{"id":"W2037387936","doi":"10.1097/qai.0b013e3181cbd235","title":"Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial","year":2010,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Canadian Institutes of Health Research","funders":"Canadian Institutes of Health Research","keywords":"Abacavir; Reverse transcriptase; Zidovudine; Stavudine; Population; Medicine; Lamivudine; Internal medicine; Virology; Reverse-transcriptase inhibitor; Univariate analysis; Viral load; Regimen; Genotype; Multivariate analysis; Immunology; Biology; Human immunodeficiency virus (HIV); Viral disease; Virus; Antiretroviral therapy; Genetics; Polymerase chain reaction","score_opus":0.016186290333706315,"score_gpt":0.28693630733139713,"score_spread":0.2707500169976908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037387936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963117,0.00018059167,0.000025712641,0.0011377399,0.0008777715,0.00079790206,0.000002909193,0.000016070235,0.00064955035],"genre_scores_gemma":[0.99755484,0.00008612228,0.0017340169,0.000024548139,0.000047845002,0.000074816446,0.00002524039,0.000018351484,0.00043423532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781513,0.00014932564,0.0009933364,0.00019505387,0.0005114615,0.0003356959],"domain_scores_gemma":[0.99890316,0.00027158504,0.00035816588,0.00026274688,0.00013522945,0.00006912382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000878225,0.0002177191,0.00052333804,0.00080238644,0.00013381336,0.00004882514,0.00021444084,0.00010593876,0.00008120634],"category_scores_gemma":[0.00038348467,0.000131902,0.00021884732,0.0010345698,0.00013404601,0.00030453026,0.000018959683,0.00017210975,0.000031503012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03506028,0.035521008,0.6700492,0.0001115719,0.0007935703,0.004003969,0.16373937,0.00024316528,0.032464247,0.0028672093,0.00070403784,0.05444237],"study_design_scores_gemma":[0.18852472,0.009842249,0.7674917,0.00030513314,0.00029834078,0.0017715892,0.024826078,0.00014957716,0.0035657296,0.0013805027,0.0013148539,0.0005295131],"about_ca_topic_score_codex":0.00004948619,"about_ca_topic_score_gemma":0.00004673296,"teacher_disagreement_score":0.15346444,"about_ca_system_score_codex":0.00021993382,"about_ca_system_score_gemma":0.0002536502,"threshold_uncertainty_score":0.5378807},"labels":[],"label_agreement":null},{"id":"W2037740736","doi":"10.1310/hct1304-179","title":"A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia; Ottawa Hospital; Abbott (Canada); University of Ottawa","funders":"Ontario HIV Treatment Network; Abbott Laboratories","keywords":"Medicine; Ritonavir; Lopinavir; Adverse effect; Pharmacokinetics; Prospective cohort study; Lopinavir/ritonavir; Internal medicine; Viral load; Pharmacology; Gastroenterology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.28697042477038737,"score_gpt":0.5185631127525557,"score_spread":0.23159268798216837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037740736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971732,0.00019145204,0.000054889744,0.0032679548,0.0003183443,0.023965476,0.00004483271,0.000034722052,0.00039031735],"genre_scores_gemma":[0.99682885,0.00024682452,0.00038844367,0.00040922282,0.00025540896,0.0010303047,0.000039708233,0.000043496573,0.0007577568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99188465,0.0040684417,0.0024848715,0.00056997535,0.00061018975,0.00038189397],"domain_scores_gemma":[0.9924791,0.0057126437,0.0005431353,0.0007359217,0.0002962397,0.00023300035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013682237,0.0003538952,0.0014135474,0.00011163182,0.00017831288,0.00006125656,0.0004174004,0.00006139306,0.000061721534],"category_scores_gemma":[0.0041062413,0.00018604232,0.0000931865,0.000606697,0.00014950543,0.00011222322,0.0002566243,0.00037963848,0.00008262584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012500225,0.04787905,0.9018008,0.000012272481,0.0007750353,0.0000030707931,0.0062842327,0.0000049298956,0.00013366413,0.000045042278,0.0016566834,0.028904976],"study_design_scores_gemma":[0.09507014,0.0060251486,0.8935567,0.00009046992,0.0008022522,8.198971e-7,0.0011397197,0.00007779877,0.00011834372,0.000037181282,0.002882065,0.00019932026],"about_ca_topic_score_codex":0.000069046306,"about_ca_topic_score_gemma":0.000053136693,"teacher_disagreement_score":0.08256991,"about_ca_system_score_codex":0.00013146613,"about_ca_system_score_gemma":0.00016125668,"threshold_uncertainty_score":0.7586586},"labels":[],"label_agreement":null},{"id":"W2038025308","doi":"10.1097/00002030-200102160-00017","title":"An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Ottawa Hospital","funders":"","keywords":"Indinavir; Nelfinavir; Zidovudine; Medicine; Lamivudine; Pregnancy; Protease inhibitor (pharmacology); Pharmacokinetics; Internal medicine; Regimen; Gastroenterology; Pharmacology; Viral load; Immunology; Viral disease; Virus; Biology; Antiretroviral therapy","score_opus":0.017358071589255494,"score_gpt":0.2805689781276017,"score_spread":0.26321090653834617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038025308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968704,0.00061220187,0.00016917639,0.00057752413,0.0001342531,0.0012462299,0.0000051053503,0.00007385132,0.00031123328],"genre_scores_gemma":[0.98362666,0.000078476056,0.0048162495,0.000009825324,0.00021357818,0.0003124855,0.000028369663,0.000032146167,0.010882207],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989288,0.000023308477,0.00030093666,0.0002470535,0.00022348516,0.0002764205],"domain_scores_gemma":[0.9994069,0.000024380715,0.00008612445,0.0002765702,0.000073079405,0.00013295302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096089316,0.0001742493,0.00026470673,0.00011685192,0.000083373016,0.000010803698,0.0000687294,0.00004312083,0.000042341457],"category_scores_gemma":[0.000015046048,0.00013929988,0.000098008815,0.00016133535,0.000025233883,0.00011017915,0.000019693969,0.00007055826,0.000015468891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021982535,0.00062684127,0.96911246,0.00018766602,0.00017115969,0.00004693679,0.0015225168,0.0000050386393,0.011616884,0.00005691678,0.000034641227,0.016399145],"study_design_scores_gemma":[0.009349717,0.0008995037,0.25673223,0.0020884979,0.00043134662,0.000050525738,0.0012386128,0.00010650447,0.7271351,0.0001878511,0.0013896157,0.00039044258],"about_ca_topic_score_codex":0.000008398109,"about_ca_topic_score_gemma":4.8985964e-7,"teacher_disagreement_score":0.71551824,"about_ca_system_score_codex":0.00010618208,"about_ca_system_score_gemma":0.000056779125,"threshold_uncertainty_score":0.5680484},"labels":[],"label_agreement":null},{"id":"W2038176250","doi":"10.1038/tpj.2013.13","title":"Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent","year":2013,"lang":"en","type":"article","venue":"The Pharmacogenomics Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Université de Montréal; Child and Family Research Institute; University of British Columbia","funders":"National Center for Chronic Disease Prevention and Health Promotion; National Institute of General Medical Sciences; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research","keywords":"Drug; Genetic variation; Single-nucleotide polymorphism; Biology; Population; Genetic genealogy; Pharmacogenetics; Medicine; Genetics; Gene; Genotype; Oncology; Pharmacology; Environmental health","score_opus":0.026841845351331925,"score_gpt":0.2912807117363871,"score_spread":0.26443886638505515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038176250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602807,0.001340708,0.00030477488,0.0008748963,0.0000825353,0.0011259496,0.00014606805,0.0000057164143,0.00009130967],"genre_scores_gemma":[0.9892466,0.0008350935,0.00948278,0.00005459119,0.0001002287,0.00014628051,0.0000073343745,0.00003124333,0.00009582069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882364,0.00009142804,0.00051765743,0.00014539952,0.00014071914,0.00028116556],"domain_scores_gemma":[0.99893636,0.00029398513,0.00035757959,0.00010925969,0.0001444963,0.0001583401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004487658,0.00017311506,0.0004160118,0.00015575928,0.0001463629,0.000019335792,0.00011559149,0.00003844658,0.00012549935],"category_scores_gemma":[0.000030430416,0.00012193698,0.00013052889,0.00010636629,0.00007447031,0.00005847283,0.000026493239,0.00016072764,6.062111e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006537421,0.00048825386,0.78764343,0.00023317228,0.0018628518,0.000008086906,0.01235509,0.00011014356,0.15894389,0.00007021464,0.00033645643,0.037294682],"study_design_scores_gemma":[0.07204541,0.0012401751,0.7523181,0.001399041,0.008803262,0.00029394662,0.008218455,0.035469063,0.11548737,0.002783755,0.000896218,0.0010452347],"about_ca_topic_score_codex":0.0011960331,"about_ca_topic_score_gemma":0.00006169218,"teacher_disagreement_score":0.07139167,"about_ca_system_score_codex":0.00022833797,"about_ca_system_score_gemma":0.00022233833,"threshold_uncertainty_score":0.49724457},"labels":[],"label_agreement":null},{"id":"W2038196376","doi":"10.1517/14728222.5.4.443","title":"Targeting HIV-1 integrase","year":2001,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Targets","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Hyacinthe; Université de Montréal","funders":"","keywords":"Integrase; Integrase inhibitor; Reverse transcriptase; Virology; Biology; Human immunodeficiency virus (HIV); Virus; Protease; Computational biology; Enzyme; Genetics; Antiretroviral therapy; RNA; Viral load; Gene; Biochemistry","score_opus":0.031080944117598503,"score_gpt":0.3157572426580873,"score_spread":0.2846762985404888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038196376","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04943241,0.40155703,0.030617578,0.31961328,0.015173097,0.00826702,0.000070899936,0.00454859,0.1707201],"genre_scores_gemma":[0.91784734,0.018205313,0.0075732013,0.013471331,0.0016435619,0.00029799656,0.00081803,0.00017341113,0.039969802],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984302,0.00005978091,0.00031611972,0.00040381006,0.00036110316,0.00042897186],"domain_scores_gemma":[0.9992629,0.000073901814,0.00007288855,0.00031568462,0.00006550047,0.00020912477],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015197115,0.00030483073,0.00032603097,0.00016519445,0.00016094849,0.000024548941,0.00010880807,0.00010704276,0.0018403486],"category_scores_gemma":[0.000033927656,0.00022441524,0.00013580789,0.00020298653,0.00004979048,0.00007743461,0.000027616577,0.00020242087,0.0012766506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003410535,0.0049397056,0.041041873,0.000055883804,0.0019769,0.00079311326,0.018921804,0.00003313109,0.018431244,0.0070628617,0.40076074,0.5025722],"study_design_scores_gemma":[0.0022909148,0.00021263104,0.001078395,0.000108611996,0.000009972754,0.00005954487,0.0007241931,0.00037150132,0.0047602965,0.000178949,0.9899277,0.00027725808],"about_ca_topic_score_codex":0.0000065316362,"about_ca_topic_score_gemma":5.5050424e-7,"teacher_disagreement_score":0.86841494,"about_ca_system_score_codex":0.00016179534,"about_ca_system_score_gemma":0.0000767363,"threshold_uncertainty_score":0.999501},"labels":[],"label_agreement":null},{"id":"W2038900287","doi":"10.1097/qai.0b013e3181cae4a1","title":"Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+&lt;200 cell/mm3 in Mexico","year":2010,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Drug Abuse","keywords":"Lopinavir/ritonavir; Efavirenz; Lopinavir; Medicine; Ritonavir; Lamivudine; Internal medicine; Confidence interval; Viral load; Gastroenterology; Randomized controlled trial; Clinical endpoint; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.017871010261181385,"score_gpt":0.2887138184398692,"score_spread":0.27084280817868783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038900287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902723,0.0015657874,0.000023873134,0.0010411213,0.0005831572,0.0035014004,0.00001613614,0.000026703012,0.0029695523],"genre_scores_gemma":[0.98959273,0.0007880378,0.0047336505,0.000021938551,0.00005591058,0.00020685779,0.000026987962,0.000075108015,0.004498763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995342,0.00036268416,0.0021619482,0.0005282012,0.00090451457,0.0007006646],"domain_scores_gemma":[0.9970212,0.00061668444,0.0012269525,0.0005909808,0.00034407424,0.00020011658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022646266,0.00060377904,0.0030064152,0.0014015996,0.000116054754,0.0000882963,0.00065615703,0.00024704737,0.00010899186],"category_scores_gemma":[0.00042823015,0.00039633064,0.0003794097,0.0016241833,0.00046189848,0.0006791697,0.00014455315,0.000391015,0.00004173436],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7748329,0.015811158,0.17915292,0.00020976734,0.00095416524,0.0032532203,0.006877502,0.000034430024,0.015068518,0.00062626443,0.00018566992,0.0029934493],"study_design_scores_gemma":[0.92055815,0.007974438,0.043046247,0.0011532194,0.00062595075,0.0011174369,0.0010114956,0.00007036821,0.02331885,0.00039968552,0.00020886493,0.00051526166],"about_ca_topic_score_codex":0.00021563479,"about_ca_topic_score_gemma":0.00011873383,"teacher_disagreement_score":0.14572525,"about_ca_system_score_codex":0.0004684942,"about_ca_system_score_gemma":0.0012305868,"threshold_uncertainty_score":0.99984884},"labels":[],"label_agreement":null},{"id":"W2039034130","doi":"10.1089/aid.2006.0198","title":"A 21-Base Pair Insertion/Duplication at Codon 69 of the HIV Type 1 Reverse Transcriptase in a Patient Undergoing Multiple Nucleoside Therapy","year":2007,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Didanosine; Stavudine; Reverse transcriptase; Virology; Nucleoside Reverse Transcriptase Inhibitor; Genetics; Biology; Abacavir; Insertion; Gene duplication; Point mutation; Context (archaeology); Stop codon; Virus; Mutation; Gene; Polymerase chain reaction; Viral load; Antiretroviral therapy","score_opus":0.08135282156246067,"score_gpt":0.3423018956125299,"score_spread":0.26094907405006923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039034130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974196,0.00053405785,0.0000077749855,0.000787028,0.000022933835,0.00074334873,0.000011883075,0.000022303482,0.0004510528],"genre_scores_gemma":[0.9962016,0.00037678253,0.00027824286,0.00017803493,0.000023490435,0.000029905785,0.000038258713,0.000019946632,0.002853741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983979,0.00012968497,0.00032954852,0.0002719906,0.0005031052,0.00036776534],"domain_scores_gemma":[0.99900347,0.00028058485,0.00006355465,0.00032989334,0.00017804156,0.00014446657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074236083,0.00012989216,0.00020372498,0.0003201451,0.00027808262,0.000016928518,0.000090831265,0.00007057652,0.000114752474],"category_scores_gemma":[0.00022409551,0.00008806393,0.000060550097,0.0005013416,0.00022978285,0.00008178328,0.000055688237,0.00023100963,0.000027487333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014577862,0.0006070797,0.92130035,0.000080198675,0.000055588975,0.00004061025,0.0020340753,6.5532e-7,0.06808564,0.00035029423,0.003063263,0.0029244274],"study_design_scores_gemma":[0.004845823,0.0018996953,0.83666116,0.00035731794,0.000019925206,0.000008627451,0.0012588797,0.000008763219,0.13761649,0.00023486934,0.016943181,0.00014529932],"about_ca_topic_score_codex":0.00041471244,"about_ca_topic_score_gemma":0.0018709172,"teacher_disagreement_score":0.08463924,"about_ca_system_score_codex":0.0002745126,"about_ca_system_score_gemma":0.000142251,"threshold_uncertainty_score":0.3591143},"labels":[],"label_agreement":null},{"id":"W2039093847","doi":"10.1111/j.1365-2125.2005.02337.x","title":"Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV‐1‐infected patients","year":2005,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Lopinavir/ritonavir; Pharmacokinetics; Ritonavir; Lopinavir; Interquartile range; Dosing; Medicine; Cmin; Pharmacology; Geometric mean; Morning; Confidence interval; Regimen; Internal medicine; Cmax; Human immunodeficiency virus (HIV); Coronavirus disease 2019 (COVID-19); Viral load; Antiretroviral therapy","score_opus":0.029674263777898467,"score_gpt":0.3787857349324178,"score_spread":0.34911147115451935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039093847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938007,0.0005555653,0.000031915602,0.004116472,0.00038116786,0.00040164092,0.000009557629,0.000003883938,0.00069912407],"genre_scores_gemma":[0.99574524,0.0015180297,0.0013579662,0.00088065834,0.00034682264,0.00000599933,0.0000116747,0.0000124809585,0.000121153535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673206,0.00055372086,0.001906415,0.00017960844,0.00039344165,0.00023475917],"domain_scores_gemma":[0.9977569,0.00076522754,0.0009637027,0.00008477429,0.00030532872,0.00012407044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014864301,0.00012480844,0.0006819897,0.00019888299,0.000026244612,0.000008448858,0.00022100184,0.00013379798,0.00016944729],"category_scores_gemma":[0.00050543004,0.00011465607,0.00016084309,0.00035751925,0.00015952282,0.0001637387,0.000037879014,0.00068501045,0.000009015779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027731666,0.009488492,0.73968035,0.00016399304,0.0005197157,0.0021710508,0.0033052207,0.00039396147,0.0071137813,0.00003141616,0.012713012,0.22164582],"study_design_scores_gemma":[0.019529019,0.00066399545,0.9695527,0.0007206509,0.00022020981,0.00039667808,0.00007250901,0.0004480326,0.0013134246,0.00007640829,0.0068891235,0.00011724964],"about_ca_topic_score_codex":0.00006642968,"about_ca_topic_score_gemma":0.0000352392,"teacher_disagreement_score":0.22987233,"about_ca_system_score_codex":0.00011100441,"about_ca_system_score_gemma":0.000358461,"threshold_uncertainty_score":0.46755388},"labels":[],"label_agreement":null},{"id":"W2039285600","doi":"10.1002/cmdc.201200580","title":"Monitoring Binding of HIV‐1 Capsid Assembly Inhibitors Using <sup>19</sup>F Ligand‐and <sup>15</sup>N Protein‐Based NMR and X‐ray Crystallography: Early Hit Validation of a Benzodiazepine Series","year":2013,"lang":"en","type":"article","venue":"ChemMedChem","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Boehringer Ingelheim (Canada)","funders":"University of Utah","keywords":"Capsid; Ligand (biochemistry); Human immunodeficiency virus (HIV); Crystallography; Chemistry; Stereochemistry; Virology; Biology; Biochemistry; Receptor","score_opus":0.01990205283640837,"score_gpt":0.24412789759394835,"score_spread":0.22422584475753998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039285600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972997,0.00046789084,0.000075751996,0.0006301837,0.000027162943,0.00124266,0.000018867668,0.00007538908,0.0001623931],"genre_scores_gemma":[0.987577,0.00005255548,0.011307908,0.000014226542,0.00015059314,0.0001368729,0.00008078011,0.000060068967,0.00061996374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978415,0.00004617048,0.00068609224,0.0004884036,0.00048706736,0.0004507847],"domain_scores_gemma":[0.99871886,0.00009381127,0.00032831504,0.0003156276,0.0002640391,0.00027933484],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002878268,0.00041781002,0.00072489196,0.00046226883,0.0001480995,0.00006019362,0.000092768365,0.00022555068,0.00003892818],"category_scores_gemma":[0.00015378148,0.0003745087,0.00014127453,0.0005130401,0.00023131288,0.00044411558,0.00009248317,0.00021235387,0.0000055896694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118947704,0.00022503007,0.26570886,0.0009567987,0.00032876868,0.000023081206,0.0040145298,0.00010404362,0.7273855,0.000009581973,0.00014681526,0.0009780029],"study_design_scores_gemma":[0.0026941388,0.00019374206,0.008003674,0.0012419508,0.00026378306,0.000021815513,0.0013580512,0.0008167433,0.984933,0.00004332839,0.0001100784,0.0003196828],"about_ca_topic_score_codex":0.00011576668,"about_ca_topic_score_gemma":0.0000010943774,"teacher_disagreement_score":0.2577052,"about_ca_system_score_codex":0.0001243756,"about_ca_system_score_gemma":0.00018033198,"threshold_uncertainty_score":0.99987066},"labels":[],"label_agreement":null},{"id":"W2039311442","doi":"10.1002/jmv.21034","title":"Overcoming resistance to existing therapies in HIV‐infected patients: The role of new antiretroviral drugs","year":2008,"lang":"en","type":"review","venue":"Journal of Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital","funders":"","keywords":"Drug resistance; Medicine; Intensive care medicine; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Virology; Drug; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Viral load; Pharmacology","score_opus":0.025411566120388793,"score_gpt":0.3236200702295361,"score_spread":0.2982085041091473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039311442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011557047,0.9835418,0.000026683507,0.0033972522,0.00024290249,0.00042243057,0.0000046330374,0.00000780062,0.0007994845],"genre_scores_gemma":[0.0015610653,0.9956134,0.0008870138,0.00035447718,0.00041084542,0.0000075687035,0.000014726379,0.000034163524,0.0011167532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632484,0.00036502062,0.0016140874,0.00021153265,0.0011432739,0.0003412639],"domain_scores_gemma":[0.9975878,0.0007544162,0.0010028428,0.00022499621,0.00011821702,0.00031172635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007570104,0.00031850726,0.0022224889,0.0004502469,0.00005236668,0.0000067004535,0.0004038375,0.00042405553,0.00016214715],"category_scores_gemma":[0.00142839,0.00017340468,0.00043142098,0.00044047105,0.00015314943,0.00004570286,0.00010445587,0.0011012143,0.000018637294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029110938,0.0004187481,0.0132163735,0.00079955044,0.0006053873,0.0004258457,0.0026102844,1.6039279e-7,0.0000016051472,0.0001635967,0.00825557,0.97321177],"study_design_scores_gemma":[0.002212762,0.00038006593,0.0017749252,0.010319074,0.00033472877,0.00021807197,0.000103936305,0.0000017282828,0.0000025636614,0.00006938662,0.98445463,0.00012810512],"about_ca_topic_score_codex":0.000016140506,"about_ca_topic_score_gemma":0.000021577724,"teacher_disagreement_score":0.9761991,"about_ca_system_score_codex":0.00022978973,"about_ca_system_score_gemma":0.0013314713,"threshold_uncertainty_score":0.70712376},"labels":[],"label_agreement":null},{"id":"W2039379609","doi":"10.2174/1381612043382422","title":"Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance","year":2004,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph-Humber; Heritage Medical Research Clinic","funders":"","keywords":"Medicine; Drug; Drug resistance; Clinical trial; Antiretroviral drug; Pharmacology; Human immunodeficiency virus (HIV); Immunology; Virology; Antiretroviral therapy; Biology; Viral load; Internal medicine","score_opus":0.11287333945636722,"score_gpt":0.3904895653915296,"score_spread":0.2776162259351624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039379609","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012342218,0.9878667,0.0037684285,0.0004671239,0.0004286069,0.005771371,0.000086612876,0.00016897997,0.0014298372],"genre_scores_gemma":[0.00068361295,0.98142064,0.009059173,0.00003943697,0.00027864156,0.0010192681,0.0008058538,0.00016826349,0.0065251086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99493295,0.00071279146,0.0012201264,0.0011224074,0.0009095711,0.0011021738],"domain_scores_gemma":[0.99820447,0.00038884208,0.00038247425,0.000493787,0.00006541139,0.00046502904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009657235,0.0011153319,0.0026007472,0.00049845915,0.00016025915,0.000083903185,0.0003953551,0.00037466164,0.0002459973],"category_scores_gemma":[0.000097099626,0.0008617938,0.00060986436,0.00070831453,0.0002195257,0.00015733605,0.0001539253,0.0016106719,0.0007193229],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036593442,0.0027755653,0.00046831922,0.07027697,0.00084181747,0.001570583,0.0008474107,0.0000033222161,0.00002242234,0.0011098728,0.006706959,0.9150108],"study_design_scores_gemma":[0.0035638763,0.000048212976,0.000005414624,0.0590022,0.0015227514,0.000014691782,0.00002395318,0.000073301075,0.0011852146,0.00015249097,0.93356997,0.00083790085],"about_ca_topic_score_codex":7.4859736e-7,"about_ca_topic_score_gemma":8.7982505e-7,"teacher_disagreement_score":0.926863,"about_ca_system_score_codex":0.0010182776,"about_ca_system_score_gemma":0.0011930303,"threshold_uncertainty_score":0.9993833},"labels":[],"label_agreement":null},{"id":"W2039396792","doi":"10.1007/s11538-007-9234-9","title":"Drug-Sparing Regimens for HIV Combination Therapy: Benefits Predicted for “Drug Coasting”","year":2007,"lang":"en","type":"article","venue":"Bulletin of Mathematical Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Drug; Medicine; Clinical trial; Drug resistance; Pharmacotherapy; Efficacy; Drug holiday; Human immunodeficiency virus (HIV); Pharmacokinetics; Combination therapy; Intensive care medicine; Pharmacology; Internal medicine; Immunology; Biology","score_opus":0.025447399550292158,"score_gpt":0.28169459119106693,"score_spread":0.25624719164077475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039396792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8780639,0.00065396243,0.050044097,0.05096714,0.00027063332,0.0059241294,0.00017136325,0.00028660794,0.013618144],"genre_scores_gemma":[0.8288849,0.00007422835,0.13812205,0.0004764408,0.00019180136,0.0004613185,0.0006747937,0.000066907945,0.031047577],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987456,0.00002456236,0.0005179697,0.00025626912,0.00011418682,0.00034138424],"domain_scores_gemma":[0.99785393,0.0014863645,0.00017437941,0.00017596023,0.0002111327,0.00009824568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085038197,0.00017431041,0.00047540333,0.000101568774,0.00007397181,0.0000046085897,0.00008681708,0.00011661751,0.00019213282],"category_scores_gemma":[0.0005730321,0.00012994862,0.00012857377,0.000064790824,0.00010313054,0.0000065832373,0.00003374053,0.00006988429,0.000036338683],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059292233,0.00701982,0.0209764,0.0027192663,0.0016376454,0.000014936124,0.0043484117,0.0000058410546,0.0070807785,0.5972475,0.29532728,0.057692923],"study_design_scores_gemma":[0.043672193,0.0023413233,0.0061712526,0.0016198442,0.0006933226,0.00010461935,0.0009771329,0.0017151181,0.14130808,0.05584082,0.74458957,0.0009667234],"about_ca_topic_score_codex":0.0000027634455,"about_ca_topic_score_gemma":0.0000021617668,"teacher_disagreement_score":0.54140663,"about_ca_system_score_codex":0.000040656072,"about_ca_system_score_gemma":0.000035134264,"threshold_uncertainty_score":0.5299151},"labels":[],"label_agreement":null},{"id":"W2040027667","doi":"10.1097/qai.0b013e31819675e9","title":"The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time","year":2009,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; St. Paul's Hospital","funders":"National Institute of Mental Health; University of British Columbia","keywords":"Efavirenz; Lopinavir; Atazanavir; Hazard ratio; Medicine; Internal medicine; Nevirapine; Ritonavir; Reverse-transcriptase inhibitor; Confidence interval; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.012685214411452117,"score_gpt":0.27763539314147856,"score_spread":0.26495017873002646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040027667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943542,0.003752499,0.000008793986,0.00067803526,0.00016632678,0.00041175692,0.00000554072,0.000026356993,0.00059650186],"genre_scores_gemma":[0.99681705,0.0010737398,0.00008020331,0.000036484547,0.000020139689,0.000004207408,0.0000050636627,0.00001940256,0.0019437198],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978298,0.00019466897,0.0007226147,0.00021781038,0.0006977883,0.0003373372],"domain_scores_gemma":[0.9982907,0.0004669549,0.00060967397,0.00037240563,0.0001589803,0.000101268924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009618501,0.0002937147,0.00083992304,0.00023995768,0.00019272415,0.000037458154,0.00022736443,0.00009156599,0.000020390846],"category_scores_gemma":[0.00018186728,0.00016032973,0.00027722336,0.000387119,0.00023173384,0.00020543694,0.000029677309,0.00014705246,0.000014805577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026028877,0.0039639696,0.188353,0.00021556375,0.004037072,0.0013176482,0.006394386,0.00003968827,0.33587536,0.0010232414,0.0028731225,0.4298781],"study_design_scores_gemma":[0.010658937,0.033004552,0.86265117,0.00057756924,0.0004003854,0.0004222624,0.000100879755,0.0003123256,0.09055938,0.00092834124,0.00008747213,0.00029674856],"about_ca_topic_score_codex":0.000007265715,"about_ca_topic_score_gemma":1.6430768e-7,"teacher_disagreement_score":0.67429817,"about_ca_system_score_codex":0.0000927205,"about_ca_system_score_gemma":0.00012363751,"threshold_uncertainty_score":0.6538057},"labels":[],"label_agreement":null},{"id":"W2040151922","doi":"10.1097/ftd.0b013e318274197e","title":"Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor","year":2012,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Institute for Health and Care Research","keywords":"Efavirenz; Internal medicine; Constitutive androstane receptor; Pharmacokinetics; Bayesian multivariate linear regression; Interquartile range; Biology; Pharmacology; Medicine; Oncology; Viral load; Genetics; Human immunodeficiency virus (HIV); Linear regression; Virology; Antiretroviral therapy; Gene","score_opus":0.013269721440270815,"score_gpt":0.24857312603911438,"score_spread":0.23530340459884358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040151922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971775,0.0009510585,0.0000089766845,0.00011047498,0.00014580884,0.00087958766,0.000011687598,0.000027307282,0.00068763783],"genre_scores_gemma":[0.99908805,0.000039454506,0.00021592565,0.000019299783,0.00004953629,0.0000812025,0.000030510922,0.000023228955,0.0004528221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845594,0.00012298074,0.00034262068,0.00019174012,0.00048711308,0.000399588],"domain_scores_gemma":[0.99924463,0.00015318916,0.00025513078,0.00021117217,0.00008712019,0.000048751266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005631477,0.00022957593,0.00037897364,0.00018078402,0.00010415089,0.000015502115,0.000099831,0.00007614963,0.000013998599],"category_scores_gemma":[0.000022871374,0.00013871114,0.000036548718,0.00052327727,0.00007715781,0.00016203309,0.000017924061,0.0002699876,0.000007932132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002908253,0.0013913526,0.9639029,0.000023472212,0.00016018067,0.0000049561495,0.019880893,0.0000037957846,0.013200029,0.000079667996,0.000003715533,0.0010582429],"study_design_scores_gemma":[0.005675377,0.000305096,0.98087674,0.0007726062,0.00014472826,0.000008091274,0.0019770863,0.0000025167465,0.010029917,0.0000069399953,0.00002799625,0.00017291498],"about_ca_topic_score_codex":0.0001478229,"about_ca_topic_score_gemma":0.000026141044,"teacher_disagreement_score":0.017903807,"about_ca_system_score_codex":0.00039906995,"about_ca_system_score_gemma":0.00006975829,"threshold_uncertainty_score":0.5656476},"labels":[],"label_agreement":null},{"id":"W2040200721","doi":"10.3851/imp1959","title":"Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Janssen Canada","keywords":"Rilpivirine; Efavirenz; Pharmacokinetics; Medicine; Pharmacology; Ex vivo; Internal medicine; In vivo; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Biology","score_opus":0.057001649691341326,"score_gpt":0.32261737048495226,"score_spread":0.26561572079361095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040200721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615514,0.00035921708,0.000018118095,0.00025247282,0.000104487335,0.00043300737,0.0000027185965,0.000019307989,0.0026555397],"genre_scores_gemma":[0.99672014,0.0005881375,0.0021509733,0.000090746005,0.000014971123,0.000018985298,0.000017973925,0.000016505022,0.00038159222],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989504,0.00006340445,0.00039930816,0.00018702219,0.00020072286,0.00019914772],"domain_scores_gemma":[0.99958354,0.000045391254,0.0001398355,0.00015622436,0.000028169088,0.0000468452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001885935,0.00014877267,0.00038461105,0.00016526842,0.000017662085,0.0000023906211,0.00006404276,0.000049085567,0.00004266402],"category_scores_gemma":[0.000011078155,0.00012190649,0.00012494858,0.00028000728,0.000053526892,0.00008780703,0.000009271748,0.00008464765,0.000009546223],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009206576,0.0024080803,0.80102354,0.0001219736,0.00043683036,0.0002577838,0.0054952777,5.8969005e-7,0.0667819,0.00010986956,0.00013126212,0.11402634],"study_design_scores_gemma":[0.009986343,0.0025102862,0.29801878,0.00021425288,0.00006540417,0.0000073349065,0.0001794083,0.000055648587,0.68837154,0.0001031119,0.00030990594,0.00017801128],"about_ca_topic_score_codex":0.00009786394,"about_ca_topic_score_gemma":0.000029462339,"teacher_disagreement_score":0.6215896,"about_ca_system_score_codex":0.00002884005,"about_ca_system_score_gemma":0.00012145559,"threshold_uncertainty_score":0.4971202},"labels":[],"label_agreement":null},{"id":"W2040472577","doi":"10.1177/1091581814529309","title":"Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy","year":2014,"lang":"en","type":"article","venue":"International Journal of Toxicology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories","funders":"","keywords":"Mitochondrial toxicity; Toxicity; Pharmacology; Medicine; Reverse transcriptase; Lactic acidosis; Nucleoside analogue; Lipodystrophy; Nucleoside Reverse Transcriptase Inhibitor; Zidovudine; Nucleoside; Internal medicine; Immunology; Biology; Viral load; Virus; Antiretroviral therapy; Biochemistry; Viral disease","score_opus":0.02234577583511188,"score_gpt":0.3265876299972269,"score_spread":0.304241854162115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040472577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706231,0.00010244195,0.0035857335,0.022048932,0.0016561418,0.00044540004,0.00003858991,0.000011796925,0.001487864],"genre_scores_gemma":[0.98759377,0.00006991606,0.009470376,0.0007283956,0.00050148607,0.000014076783,0.00004145332,0.000015136819,0.0015653851],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984717,0.00007628456,0.0008265404,0.00012310679,0.00036866465,0.00013374338],"domain_scores_gemma":[0.99841905,0.0002765099,0.00046199263,0.000082407205,0.0006680836,0.00009198263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006313581,0.000112478374,0.00039431296,0.00028158678,0.000028463595,0.0000086106775,0.00016851377,0.00011785866,0.00023109851],"category_scores_gemma":[0.00037448428,0.00008666585,0.00025891827,0.00006795642,0.00008025182,0.00007333726,0.000015871357,0.00016336214,0.0000081460175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05768352,0.0145350285,0.11594137,0.00017086173,0.0057756198,0.00035504633,0.0032543403,0.00005103619,0.30501857,0.034871437,0.07380232,0.38854083],"study_design_scores_gemma":[0.09419759,0.019918963,0.11735336,0.00060491345,0.0005365393,0.0011152847,0.00030408934,0.002977601,0.26185775,0.006206483,0.49439573,0.0005316945],"about_ca_topic_score_codex":0.0000015424289,"about_ca_topic_score_gemma":0.0000034779287,"teacher_disagreement_score":0.4205934,"about_ca_system_score_codex":0.00014078392,"about_ca_system_score_gemma":0.00019205015,"threshold_uncertainty_score":0.35341308},"labels":[],"label_agreement":null},{"id":"W2040508296","doi":"10.1038/tpj.2013.17","title":"Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent","year":2013,"lang":"en","type":"article","venue":"The Pharmacogenomics Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Institute of General Medical Sciences; Canadian Institutes of Health Research","keywords":"Omeprazole; CYP2C19; CYP2B6; Efavirenz; Pharmacology; CYP3A; Genotype; CYP3A4; Chemistry; Pharmacokinetics; Drug metabolism; Metabolism; Cytochrome P450; Biology; Biochemistry; Genetics; Drug; Gene","score_opus":0.02058355303763288,"score_gpt":0.27388738843625793,"score_spread":0.25330383539862505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040508296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874148,0.002126549,0.00012610362,0.00819345,0.000573618,0.00045709105,0.000015759795,0.000023486755,0.0010691568],"genre_scores_gemma":[0.9914209,0.0025089444,0.0007053858,0.00080597337,0.0005150247,0.000019710711,0.000018561655,0.000034546283,0.00397091],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985924,0.000076590986,0.00049308257,0.00015703512,0.00037137038,0.00030954258],"domain_scores_gemma":[0.99897754,0.000048694063,0.00029184655,0.00020244218,0.00024111592,0.00023832974],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00043616846,0.00019661755,0.0003205231,0.00017707405,0.00018968739,0.000040513438,0.00019751924,0.00006211726,0.002251258],"category_scores_gemma":[0.00002166089,0.00012413652,0.00015341617,0.00019389286,0.00006817845,0.00015659377,0.00006505147,0.00043887927,0.00080690073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049378374,0.0006860246,0.0070599252,0.000039617025,0.0027824426,0.00008238462,0.006040182,0.00006089456,0.8911272,0.00009429694,0.02975954,0.061773673],"study_design_scores_gemma":[0.017290242,0.00020362537,0.04176479,0.000104041574,0.0033564344,0.0043541305,0.001391201,0.0019048046,0.7731279,0.0019898391,0.15373585,0.0007771543],"about_ca_topic_score_codex":0.000032325042,"about_ca_topic_score_gemma":0.0000013677773,"teacher_disagreement_score":0.1239763,"about_ca_system_score_codex":0.00015582728,"about_ca_system_score_gemma":0.0002074035,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W2040718125","doi":"10.1097/01.fpc.0000230413.97596.fa","title":"Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study","year":2006,"lang":"en","type":"article","venue":"Pharmacogenetics and Genomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Center for Research Resources; ACT Government; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases","keywords":"Efavirenz; CYP2B6; Pharmacogenetics; Pharmacology; Nelfinavir; Single-nucleotide polymorphism; Biology; Medicine; Internal medicine; Genotype; Oncology; CYP3A4; Viral load; Virology; Genetics; Gene; Cytochrome P450; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.08553449737478164,"score_gpt":0.4370506260796645,"score_spread":0.35151612870488286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040718125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996221,0.00086700433,0.00031552272,0.00071662676,0.00025630748,0.0014760148,0.000030093803,0.00004243376,0.000074980715],"genre_scores_gemma":[0.9802214,0.0005814529,0.01698971,0.0004673288,0.00041629176,0.00009647755,0.000028838129,0.000045313987,0.0011531909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973215,0.00066787726,0.000978723,0.00056277285,0.00017187619,0.00029728483],"domain_scores_gemma":[0.9984953,0.0005301098,0.00016726973,0.00026582132,0.000115669995,0.00042586515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019547855,0.00027905128,0.0006314672,0.00020008006,0.00018301187,0.00007848843,0.00007492686,0.000066169596,0.000026264428],"category_scores_gemma":[0.00020445336,0.0002445492,0.00009353646,0.00012451319,0.000061511724,0.00004552977,0.00010397642,0.00018189658,0.000018303339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015703237,0.0038102616,0.5988414,0.000037294343,0.001145557,0.00042280066,0.005875022,0.00010327288,0.08097015,0.000045937868,0.0010057199,0.2920393],"study_design_scores_gemma":[0.045936875,0.009899446,0.8227714,0.00013612867,0.0043456284,0.00032885236,0.0057148887,0.007275593,0.0092576705,0.00024215311,0.09269305,0.0013983411],"about_ca_topic_score_codex":0.00007268143,"about_ca_topic_score_gemma":0.00013034888,"teacher_disagreement_score":0.29064098,"about_ca_system_score_codex":0.00008166609,"about_ca_system_score_gemma":0.00009146377,"threshold_uncertainty_score":0.9972427},"labels":[],"label_agreement":null},{"id":"W2041282028","doi":"10.1074/jbc.275.13.9251","title":"Mechanism by Which Phosphonoformic Acid Resistance Mutations Restore 3′-Azido-3′-deoxythymidine (AZT) Sensitivity to AZT-resistant HIV-1 Reverse Transcriptase","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Virology; Zidovudine; Mechanism (biology); Human immunodeficiency virus (HIV); Chemistry; Biology; RNA; Genetics; Viral disease; Gene","score_opus":0.013289807224331755,"score_gpt":0.23995850541799768,"score_spread":0.22666869819366592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041282028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98468375,0.0007688078,0.0002118078,0.011240225,0.00007274093,0.00024307046,0.0002202439,0.000048764265,0.002510558],"genre_scores_gemma":[0.97086346,0.00039993148,0.005206381,0.00054521847,0.0001735257,0.000013565698,0.00018458927,0.000021996599,0.02259135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979852,0.00006947183,0.0007373848,0.00036664467,0.0004206476,0.00042067398],"domain_scores_gemma":[0.9985862,0.000087282584,0.00022652592,0.00027162157,0.00027863824,0.00054977485],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050973985,0.00032751003,0.0006480943,0.000050270017,0.00015717874,0.000025776522,0.00014079385,0.0002724938,0.0015850144],"category_scores_gemma":[0.00026474678,0.00023265848,0.0002512554,0.000376636,0.00008317159,0.00009447517,0.000021021866,0.00048037266,0.000100235135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002604945,0.00052900234,0.00046176722,0.00007325747,0.00018190434,0.0010952235,0.00024381201,0.000003980693,0.9476674,0.000017899032,0.0464627,0.0006580976],"study_design_scores_gemma":[0.003117537,0.00031899588,0.0020080355,0.0004023011,0.00023932334,0.00063255336,0.00035506993,0.000011610901,0.8859765,0.00027572789,0.106269434,0.00039293015],"about_ca_topic_score_codex":0.0000044377152,"about_ca_topic_score_gemma":0.000008183107,"teacher_disagreement_score":0.06169093,"about_ca_system_score_codex":0.0003633575,"about_ca_system_score_gemma":0.00021575321,"threshold_uncertainty_score":0.99932766},"labels":[],"label_agreement":null},{"id":"W2041424522","doi":"10.1097/qad.0b013e3283121c90","title":"Transmission networks of drug resistance acquired in primary/early stage HIV infection","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Institut National de Santé Publique du Québec; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Transmission (telecommunications); Reverse transcriptase; Drug resistance; Biology; Virology; Population; Cluster (spacecraft); Genetics; Polymerase chain reaction; Medicine; Gene","score_opus":0.0100116389240154,"score_gpt":0.22859913899589251,"score_spread":0.2185875000718771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041424522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900253,0.00046402653,0.0017686123,0.00043356977,0.000049534778,0.0002751645,0.0000014606426,0.000042768308,0.0069396095],"genre_scores_gemma":[0.91443735,0.0005702506,0.002870463,0.00004810258,0.000028918525,0.000016597973,0.000041201565,0.0000143175075,0.08197277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991414,0.000039724786,0.00026903106,0.00017494541,0.00020150367,0.00017339052],"domain_scores_gemma":[0.99964035,0.000035618647,0.00005811089,0.00015888787,0.000036536905,0.0000704804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013622412,0.00011483913,0.00026064212,0.00013202033,0.0000462968,0.0000027967696,0.000034435434,0.00006377015,0.0000842556],"category_scores_gemma":[0.000008864906,0.00009588134,0.00006397654,0.00032999256,0.00004813043,0.00008980949,0.0000106482485,0.00007723816,0.000014493201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050779287,0.00035515186,0.9859207,0.00011033061,0.00005759986,0.00014392988,0.0026432585,0.000038493974,0.001452288,0.000088324574,0.0032480466,0.0054340563],"study_design_scores_gemma":[0.003452868,0.000088065455,0.96611124,0.0003160699,0.00004350105,0.000007264157,0.00002408848,0.00011557703,0.0056405426,0.000024388932,0.024040423,0.00013593926],"about_ca_topic_score_codex":0.0000471786,"about_ca_topic_score_gemma":0.000017448707,"teacher_disagreement_score":0.075587876,"about_ca_system_score_codex":0.00011750298,"about_ca_system_score_gemma":0.000086060456,"threshold_uncertainty_score":0.39099276},"labels":[],"label_agreement":null},{"id":"W2041466580","doi":"10.1097/qad.0b013e3282f21b9d","title":"Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"DuPont","keywords":"Lamivudine; Indinavir; Efavirenz; Zidovudine; Reverse-transcriptase inhibitor; Tolerability; Regimen; Nelfinavir; Virology; Medicine; Pharmacology; Viral load; Gastroenterology; Internal medicine; Adverse effect; Human immunodeficiency virus (HIV); Virus; Viral disease; Antiretroviral therapy; Hepatitis B virus","score_opus":0.026593851846294283,"score_gpt":0.27569717295007656,"score_spread":0.24910332110378228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041466580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786544,0.00015200383,0.00032360567,0.0004934649,0.00012699312,0.000752023,0.00001771325,0.000048362,0.00022041582],"genre_scores_gemma":[0.99611735,0.00011689377,0.001483934,0.00006659341,0.00006820949,0.00004236378,0.000085335894,0.000016654374,0.0020026749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913985,0.000024836727,0.00029915976,0.00023489495,0.00013910363,0.00016218722],"domain_scores_gemma":[0.99951357,0.00006629964,0.000059138383,0.00018398334,0.00006146167,0.0001155795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012605113,0.00014482533,0.0003360491,0.000095098956,0.00009027956,0.000004172563,0.000024099629,0.000075392076,0.000050757542],"category_scores_gemma":[0.000063958236,0.00012233452,0.00010616985,0.00012992053,0.000116157615,0.000087864144,0.000012503362,0.00007436779,0.000012542402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073258445,0.00055391004,0.97665524,0.00026483764,0.00015164915,0.00005286911,0.0017957273,0.0000020958566,0.0034642313,0.00003319794,0.0032874502,0.01300619],"study_design_scores_gemma":[0.011184082,0.0007119963,0.948942,0.0001959289,0.00035313764,0.00010033641,0.00003152489,0.000028502414,0.03453237,0.000020505056,0.0037136383,0.00018597033],"about_ca_topic_score_codex":0.000041732874,"about_ca_topic_score_gemma":0.000007471645,"teacher_disagreement_score":0.031068135,"about_ca_system_score_codex":0.000087745066,"about_ca_system_score_gemma":0.00008427093,"threshold_uncertainty_score":0.4988657},"labels":[],"label_agreement":null},{"id":"W2041782265","doi":"10.1097/01.aids.0000232242.51286.7b","title":"Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"International AIDS Society","keywords":"Reverse transcriptase; Virology; Nucleoside Reverse Transcriptase Inhibitor; Biology; Human immunodeficiency virus (HIV); Stop codon; Protease; Mutation; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Medicine; Viral disease; Polymerase chain reaction; Gene; Genetics; Sida; Antiretroviral therapy; Enzyme; Viral load","score_opus":0.008045789189237394,"score_gpt":0.22171945370255183,"score_spread":0.21367366451331443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041782265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966911,0.00004076769,0.000104467625,0.0019763655,0.0000386262,0.00067802734,0.00013682518,0.00003060192,0.00030322035],"genre_scores_gemma":[0.988352,0.000002263466,0.007079465,0.0001851288,0.00001757986,0.00006119727,0.00014518607,0.000011772546,0.0041454285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986999,0.0001328495,0.00028874786,0.00030514336,0.00033370414,0.00023963397],"domain_scores_gemma":[0.99946517,0.00011317902,0.000052282478,0.00022139619,0.00004555775,0.00010243724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001701438,0.00016294688,0.0003162534,0.00013384043,0.000033139964,0.000007408551,0.00009091641,0.000069024885,0.000111165944],"category_scores_gemma":[0.000074600226,0.000111838286,0.000044650606,0.000288233,0.000105869396,0.000091468864,0.000020379985,0.00010497982,0.000055188077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006801221,0.0009369391,0.97856724,0.000012721618,0.000046327972,0.0002693892,0.0012562514,0.000018944025,0.008782809,0.00005867983,0.0024773774,0.00077212206],"study_design_scores_gemma":[0.0060530393,0.002091553,0.9732333,0.0002034954,0.0001102901,0.000004454237,0.00025220675,0.000017100056,0.011153046,0.00009682194,0.006573199,0.00021150614],"about_ca_topic_score_codex":0.00053050683,"about_ca_topic_score_gemma":0.00008238014,"teacher_disagreement_score":0.00833912,"about_ca_system_score_codex":0.00008005573,"about_ca_system_score_gemma":0.00011760808,"threshold_uncertainty_score":0.4560633},"labels":[],"label_agreement":null},{"id":"W2041886349","doi":"10.1016/j.ejps.2012.02.018","title":"Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells","year":2012,"lang":"en","type":"article","venue":"European Journal of Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Adefovir; Efflux; Verapamil; Metabolite; Chemistry; Metabolism; Pharmacology; Caco-2; Internal medicine; Endocrinology; Biochemistry; Biology; Cell; Calcium; Medicine; Immunology","score_opus":0.026295981371813368,"score_gpt":0.30577211179159774,"score_spread":0.27947613041978436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041886349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830196,0.01385591,0.000009281234,0.00049134856,0.00013237842,0.0001720798,0.0000032449861,0.0000033243164,0.002312822],"genre_scores_gemma":[0.99727046,0.0016668468,0.00069492764,0.0001440199,0.00009243403,7.554253e-7,4.2618663e-7,0.000008383227,0.00012174704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981828,0.0003529726,0.0005030429,0.00014335754,0.0005402452,0.0002776165],"domain_scores_gemma":[0.9991184,0.0002786173,0.00019269856,0.000047728903,0.00004945383,0.00031313542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022889099,0.0001540649,0.0004577348,0.00027944695,0.000039021063,0.000008459149,0.00013181743,0.000019884597,0.0000320491],"category_scores_gemma":[0.00009196045,0.000096054755,0.000076550314,0.00032377287,0.00026235302,0.00023192869,0.00002228547,0.0001928111,0.0000048106153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043494607,0.0026665702,0.11340711,0.00079399557,0.00030530585,0.00081141025,0.0106187565,0.000007990792,0.84323543,0.0025308174,0.00015436167,0.025033314],"study_design_scores_gemma":[0.0037538917,0.00044166655,0.42306367,0.00032255772,0.00049592124,0.00012040916,0.00022707372,0.000040231873,0.56252193,0.00001480568,0.008867589,0.00013023046],"about_ca_topic_score_codex":0.0000011976391,"about_ca_topic_score_gemma":2.3477239e-7,"teacher_disagreement_score":0.30965656,"about_ca_system_score_codex":0.000009784264,"about_ca_system_score_gemma":0.000043427306,"threshold_uncertainty_score":0.39169994},"labels":[],"label_agreement":null},{"id":"W2042014721","doi":"10.1097/qad.0b013e328351f5b2","title":"Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings","year":2012,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Drug resistance; Antiretroviral therapy; Intensive care medicine; MEDLINE; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Family medicine","score_opus":0.048561361805135796,"score_gpt":0.3244813757358465,"score_spread":0.2759200139307107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042014721","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.068283215,0.92628604,2.2589705e-7,0.00012228245,0.0001730538,0.002217742,0.00017181854,0.00005632949,0.0026892659],"genre_scores_gemma":[0.007682235,0.9678789,0.00027500966,0.00017006356,0.00009760404,0.00018760924,0.0021569638,0.00010255895,0.021449061],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977297,0.0001503278,0.0009005675,0.00042012698,0.00037352688,0.00042572338],"domain_scores_gemma":[0.9986742,0.00022505452,0.00039908884,0.0005166815,0.000045955545,0.0001390209],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016824235,0.0006459854,0.0026181203,0.0006186314,0.000033593027,0.0000083527075,0.00012362182,0.00029402247,0.00031003755],"category_scores_gemma":[0.000034948327,0.00038397202,0.0006085285,0.0004176182,0.000046406945,0.00004503741,0.000038163093,0.00023755844,0.00015062359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007084455,0.0015804006,0.204325,0.0011510438,0.0007707088,0.000023911742,0.0002602766,1.6487148e-8,1.3405923e-7,0.000014661952,0.0002873453,0.79151565],"study_design_scores_gemma":[0.004069385,0.002934107,0.014228909,0.0024795658,0.00086345436,0.00000391265,0.000018265173,2.4323003e-7,0.000027536276,0.0000017194068,0.9750831,0.00028979115],"about_ca_topic_score_codex":0.000012996539,"about_ca_topic_score_gemma":0.0000024624533,"teacher_disagreement_score":0.97479576,"about_ca_system_score_codex":0.0004716237,"about_ca_system_score_gemma":0.00015401076,"threshold_uncertainty_score":0.99986124},"labels":[],"label_agreement":null},{"id":"W2042060010","doi":"10.1089/apc.2012.0135","title":"A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy","year":2012,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; Pfizer; National Institute of Mental Health; EMD Serono; National Institutes of Health; International AIDS Society; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Ontario HIV Treatment Network; National Institute on Aging; Bristol-Myers Squibb","keywords":"Raltegravir; Medicine; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Virology; Integrase inhibitor; Reverse transcriptase; Human immunodeficiency virus (HIV); Randomized controlled trial; Pharmacology; Internal medicine; Antiretroviral therapy; Viral load; Polymerase chain reaction; Genetics; Biology","score_opus":0.011137920869515313,"score_gpt":0.24631066969188978,"score_spread":0.23517274882237446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042060010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908016,0.00026408024,0.000081272956,0.00005624073,0.00021685222,0.008247762,0.00008765355,0.000030319015,0.00021422724],"genre_scores_gemma":[0.99050796,0.000059291877,0.004939923,0.000104666164,0.00015258892,0.0030955537,0.00018297294,0.00003855089,0.0009184917],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980114,0.00013638874,0.0006836585,0.00033507586,0.00036457507,0.00046891192],"domain_scores_gemma":[0.99892914,0.00015502429,0.00018661977,0.00026276827,0.00016649361,0.00029996998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003912879,0.00032765552,0.0010293843,0.00034226358,0.00007167267,0.000013453088,0.00003936283,0.000109468565,0.000052952775],"category_scores_gemma":[0.00016268759,0.00019883689,0.000153876,0.0003421095,0.00010294334,0.00015213041,0.000024215344,0.000128578,0.0000036428437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93792075,0.0013652196,0.0059417374,0.00045327484,0.00031049797,0.000029192763,0.021114813,6.1334384e-7,0.0009079455,0.000024601028,0.00069860334,0.031232763],"study_design_scores_gemma":[0.907651,0.072257996,0.00006827969,0.00056731683,0.00048089123,0.000009700156,0.0043617017,0.000017417822,0.010456875,0.000007131252,0.0038147839,0.00030687847],"about_ca_topic_score_codex":0.000050239283,"about_ca_topic_score_gemma":0.000011454167,"teacher_disagreement_score":0.07089277,"about_ca_system_score_codex":0.00022038817,"about_ca_system_score_gemma":0.0002658641,"threshold_uncertainty_score":0.8108333},"labels":[],"label_agreement":null},{"id":"W2042985334","doi":"10.1111/j.1471-0528.2008.01820.x","title":"Serious toxicity associated with continuous nevirapine‐based HAART in pregnancy","year":2008,"lang":"en","type":"article","venue":"BJOG An International Journal of Obstetrics & Gynaecology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's Health Research Institute; University of British Columbia; Children's & Women's Health Centre of British Columbia","funders":"","keywords":"Nevirapine; Medicine; Discontinuation; Pregnancy; Toxicity; Cohort; Prospective cohort study; Population; Obstetrics; Internal medicine; Cohort study; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Immunology; Biology; Environmental health","score_opus":0.023635002831237976,"score_gpt":0.27751499066600566,"score_spread":0.2538799878347677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042985334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943946,0.0005801404,0.00028359814,0.0009643217,0.0013593372,0.00025660516,0.000010701129,0.000023468834,0.0021272479],"genre_scores_gemma":[0.99597055,0.00013612458,0.0019400663,0.00036879367,0.000057265046,0.000011124775,0.000053397034,0.00002258685,0.0014400647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981014,0.00011798474,0.0006655351,0.00020036213,0.00064180663,0.00027291896],"domain_scores_gemma":[0.99767536,0.0005547507,0.00051929115,0.00013320171,0.0009426349,0.0001747772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022123613,0.00019121268,0.0005158803,0.0008663937,0.000054421158,0.000018787225,0.00026456203,0.00016048347,0.00039896643],"category_scores_gemma":[0.0016780047,0.00015161505,0.00011570319,0.00045328084,0.00009587105,0.0002272245,0.000027168127,0.0003738606,0.000013797483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019279962,0.0020863938,0.96882457,0.000006068719,0.00045104028,0.016294438,0.00043365714,0.00013635634,0.000058122307,0.00006625685,0.00032643278,0.011123894],"study_design_scores_gemma":[0.011941504,0.0015298558,0.98291516,0.000116766394,0.000082970684,0.00081335596,0.000078597135,0.00027612463,0.00056765974,0.00003354409,0.0014782918,0.00016614322],"about_ca_topic_score_codex":0.0000060978364,"about_ca_topic_score_gemma":0.000033953962,"teacher_disagreement_score":0.015481083,"about_ca_system_score_codex":0.0009300976,"about_ca_system_score_gemma":0.00074194156,"threshold_uncertainty_score":0.61826825},"labels":[],"label_agreement":null},{"id":"W2043015418","doi":"10.1097/01.qai.0000196666.16616.fe","title":"A Population-Based Approach to Determine the Prevalence of Transmitted Drug-Resistant HIV Among Recent Versus Established HIV Infections","year":2006,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Manitoba Health; Saskatchewan Health; Alberta Health; BC Centre for Disease Control; Public Health Agency of Canada","funders":"International AIDS Society","keywords":"Drug resistance; HIV drug resistance; Medicine; Reverse transcriptase; Population; Virology; Genotype; Drug; Cohort; Cohort study; Exact test; Immunology; Human immunodeficiency virus (HIV); Internal medicine; Biology; Viral load; Polymerase chain reaction; Pharmacology; Genetics; Gene; Antiretroviral therapy; Environmental health","score_opus":0.014994345537100145,"score_gpt":0.24397117076660854,"score_spread":0.2289768252295084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043015418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931265,0.0013812893,0.0016346329,0.0017713758,0.00034599958,0.000711458,0.0000283375,0.000053050462,0.00094732875],"genre_scores_gemma":[0.9922479,0.00011170099,0.004051541,0.000019136063,0.000044380948,0.000040415085,0.000049197788,0.000040023064,0.0033957309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683297,0.00016999031,0.0014002277,0.00029128214,0.00088322884,0.00042232347],"domain_scores_gemma":[0.9978156,0.00043249238,0.0006521933,0.00048372702,0.00047923744,0.00013673802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092324277,0.00031654473,0.00072537863,0.0007844073,0.0002417478,0.000052088177,0.00034945173,0.000084939085,0.00008966123],"category_scores_gemma":[0.00037482317,0.00020918467,0.00037326157,0.0017154374,0.00015509623,0.00026107408,0.0000346025,0.00014709243,0.000013552093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005774644,0.010721858,0.9345477,0.0022273213,0.0012492185,0.00035193452,0.004911537,0.010981409,0.015043599,0.0005728996,0.007188512,0.0064293416],"study_design_scores_gemma":[0.0070624654,0.0008612503,0.9826313,0.0007321693,0.0011484612,0.0002106259,0.00058953254,0.0013250355,0.004143153,0.000063340485,0.00087817974,0.00035448442],"about_ca_topic_score_codex":0.000112511654,"about_ca_topic_score_gemma":0.000014898236,"teacher_disagreement_score":0.048083577,"about_ca_system_score_codex":0.00027442013,"about_ca_system_score_gemma":0.00032759647,"threshold_uncertainty_score":0.8530303},"labels":[],"label_agreement":null},{"id":"W2043256741","doi":"10.1097/qad.0000000000000203","title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","year":2014,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Hazard ratio; Proportional hazards model; Drug resistance; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Survival analysis; Medicine; Immunology; Virology; Oncology; Biology; Confidence interval; Genetics","score_opus":0.008666400610767164,"score_gpt":0.20749765614477872,"score_spread":0.19883125553401154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043256741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331725,0.00007546416,0.0001543688,0.0039026334,0.000040719206,0.00033894286,0.000015963406,0.0002221147,0.0019325323],"genre_scores_gemma":[0.91165346,0.000012141502,0.0030058648,0.00034254763,0.00005331219,0.000055038832,0.000085579966,0.0000391124,0.08475294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983445,0.00008771051,0.0002828061,0.0004320961,0.0004080863,0.000444846],"domain_scores_gemma":[0.99910927,0.000092088936,0.00012787002,0.0003817181,0.000118198055,0.00017084685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002219026,0.0002898657,0.00042171607,0.00012762372,0.00017072645,0.000025552281,0.00011824924,0.00012952185,0.00022130784],"category_scores_gemma":[0.00013727164,0.00020975916,0.00008716903,0.00037183551,0.000077971345,0.00008140819,0.00004200703,0.00023834038,0.00023003021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017697376,0.0010536414,0.89695317,0.0003592525,0.0022155559,0.0011714384,0.0045328513,0.000009754849,0.053415455,0.000528793,0.03640279,0.001587576],"study_design_scores_gemma":[0.016853217,0.000356759,0.7390992,0.0013976457,0.0007928534,0.00006861686,0.0003167078,0.00014808532,0.22289427,0.000447256,0.01648635,0.0011390597],"about_ca_topic_score_codex":0.0000061925957,"about_ca_topic_score_gemma":0.000145529,"teacher_disagreement_score":0.1694788,"about_ca_system_score_codex":0.0003074481,"about_ca_system_score_gemma":0.00008694806,"threshold_uncertainty_score":0.855373},"labels":[],"label_agreement":null},{"id":"W2043590076","doi":"10.1086/428852","title":"HIV‐1 Drug Resistance: Degree of Underestimation by a Cross‐Sectional versus a Longitudinal Testing Approach","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Drug resistance; Resistance mutation; Genotype; HIV drug resistance; Genotyping; Medicine; Population; Virology; Epidemiology; Human immunodeficiency virus (HIV); Viral load; Biology; Internal medicine; Antiretroviral therapy; Genetics; Reverse transcriptase; Environmental health; Polymerase chain reaction","score_opus":0.04266134497433801,"score_gpt":0.30028809943581897,"score_spread":0.257626754461481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043590076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99026555,0.0017956574,0.0024129248,0.0007806616,0.000118999305,0.00019791076,0.000018250686,0.00003388439,0.0043761656],"genre_scores_gemma":[0.99533147,0.000051867704,0.0019638785,0.000024569694,0.0002372535,0.0000058523574,0.000016662223,0.000014616868,0.0023538575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987297,0.000073330964,0.00047085134,0.00010073249,0.00046510174,0.00016026119],"domain_scores_gemma":[0.99849087,0.00041833235,0.0004460633,0.00013451574,0.0003816821,0.00012855524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031753434,0.0001435587,0.0002476137,0.00013235025,0.00018745354,0.0000284978,0.00009012206,0.00003351884,0.000057212033],"category_scores_gemma":[0.0004323713,0.00009271795,0.00013158526,0.00025014475,0.0001275264,0.00017620692,0.000022284186,0.00016547418,0.000010637161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031035203,0.0011758041,0.9750079,0.000120797326,0.00056844595,0.000014487838,0.00036816805,0.0010652089,0.00018879343,0.00010763263,0.017217722,0.0010615162],"study_design_scores_gemma":[0.011290949,0.00028287253,0.9829522,0.00030720347,0.0012305942,0.0005653189,0.00023237675,0.00082178676,0.00076412014,0.00043490093,0.00089929684,0.00021840876],"about_ca_topic_score_codex":0.0000066721095,"about_ca_topic_score_gemma":0.000017240916,"teacher_disagreement_score":0.016318426,"about_ca_system_score_codex":0.0002791302,"about_ca_system_score_gemma":0.00028335207,"threshold_uncertainty_score":0.37809286},"labels":[],"label_agreement":null},{"id":"W2043903698","doi":"10.1107/s0108767302085604","title":"HIV integrase: from structure to drug design","year":2002,"lang":"en","type":"article","venue":"Acta Crystallographica Section A Foundations of Crystallography","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Western University","funders":"","keywords":"Integrase; Drug; Integrase inhibitor; Virology; Human immunodeficiency virus (HIV); Antiretroviral drug; Medicine; Computational biology; Pharmacology; Antiretroviral therapy; Biology; Viral load","score_opus":0.017950195198095067,"score_gpt":0.24501523923146482,"score_spread":0.22706504403336975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043903698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9368043,0.00049170613,0.038133107,0.015889466,0.0006782333,0.0028442694,0.0003872886,0.0006930563,0.0040785754],"genre_scores_gemma":[0.95918566,0.00023466126,0.037423503,0.00039251387,0.00015084875,0.00014395555,0.0005612926,0.00006844688,0.001839141],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706066,0.00016640408,0.0008169878,0.0007674713,0.0006854602,0.00050300744],"domain_scores_gemma":[0.9977092,0.0002656482,0.00029263817,0.00082529784,0.00045433902,0.00045286928],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020433239,0.0005112628,0.0006677378,0.002402387,0.0003526447,0.000101038,0.0002943653,0.00024101217,0.0032677166],"category_scores_gemma":[0.00014111043,0.00046544574,0.0005420396,0.003492316,0.00030477223,0.0003641975,0.000081797,0.00040964707,0.000008808053],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011014823,0.0036894071,0.11875945,0.00018317836,0.005686878,0.000095810254,0.006408747,0.00025495715,0.6569971,0.00073378824,0.20089294,0.0051962454],"study_design_scores_gemma":[0.0069084945,0.00089796,0.05580525,0.0004952099,0.0018796243,0.00015702723,0.001950608,0.00095222285,0.0025564483,0.005701228,0.9211126,0.0015833568],"about_ca_topic_score_codex":0.000090893445,"about_ca_topic_score_gemma":0.00018831273,"teacher_disagreement_score":0.7202196,"about_ca_system_score_codex":0.0000960453,"about_ca_system_score_gemma":0.00007743972,"threshold_uncertainty_score":0.9997797},"labels":[],"label_agreement":null},{"id":"W2044183074","doi":"10.1681/asn.2015010059","title":"Kidney Transplantation in HIV-Infected Recipients","year":2015,"lang":"en","type":"letter","venue":"Journal of the American Society of Nephrology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Centre for Advancing Health Outcomes; University of British Columbia; Providence Health Care","funders":"","keywords":"Medicine; Contraindication; Immunosuppression; Dialysis; Transplantation; Population; Internal medicine; Kidney transplantation; Regimen; Kidney disease; Life expectancy; Immunology; Pathology","score_opus":0.01791308809813791,"score_gpt":0.27469720371698225,"score_spread":0.25678411561884434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044183074","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21462327,0.00009173225,0.000045023477,0.7845461,0.00023042667,0.00021507051,0.000030520383,0.000006814568,0.00021106255],"genre_scores_gemma":[0.010088396,0.0014091216,0.007904642,0.97327965,0.0016209473,0.0000078795865,0.00015690489,0.000055352015,0.0054770824],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981048,0.00023337631,0.00068973034,0.00015690236,0.0005396808,0.0002754818],"domain_scores_gemma":[0.99775875,0.00012767472,0.0015099115,0.00022716654,0.0002740452,0.000102427846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035572288,0.0002267569,0.001015868,0.00015384059,0.000028098948,0.0000043315936,0.00024427436,0.0002651739,0.000041074185],"category_scores_gemma":[0.000051007235,0.0001455145,0.00059969106,0.00040612632,0.0004009154,0.000044269556,0.000031303272,0.0013473135,0.000009833378],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036625162,0.000116990836,0.019986559,0.00008035477,0.00070543285,0.0001838046,0.0014391522,0.0000035674873,0.0010519907,2.7887148e-7,0.9755993,0.0004663458],"study_design_scores_gemma":[0.0037850242,0.00051394064,0.06724262,0.00037311678,0.0007898627,0.00096109556,0.00013839563,0.000018950039,0.00013827093,0.00006371564,0.92582923,0.00014579529],"about_ca_topic_score_codex":0.000036752834,"about_ca_topic_score_gemma":0.0000034977545,"teacher_disagreement_score":0.20453489,"about_ca_system_score_codex":0.00033636583,"about_ca_system_score_gemma":0.0008126541,"threshold_uncertainty_score":0.5933909},"labels":[],"label_agreement":null},{"id":"W2044478694","doi":"10.1385/cbb:42:1:087","title":"AZT Binding to Na,K-ATPase","year":2005,"lang":"en","type":"article","venue":"Cell Biochemistry and Biophysics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Université du Québec","funders":"Natural Sciences and Engineering Research Council of Canada; New York Institute of Technology","keywords":"Antiparallel (mathematics); Protein secondary structure; Chemistry; Binding constant; Drug; Crystallography; ATPase; Binding site; Biochemistry; Enzyme; Biology; Pharmacology","score_opus":0.00709955484640593,"score_gpt":0.22770510703214358,"score_spread":0.22060555218573766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044478694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033576,0.00015180213,0.000021934247,0.0019841345,0.000029380652,0.00011936338,0.0000123050795,0.000045085264,0.0073002055],"genre_scores_gemma":[0.95449185,0.000043161763,0.0025472697,0.00030621656,0.0002678718,0.00001013388,0.000085603126,0.000011940071,0.04223593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99932337,0.0000031796037,0.00011759188,0.00024909584,0.000113482856,0.0001933027],"domain_scores_gemma":[0.9995443,0.000012025243,0.000027419768,0.00016660744,0.000028368464,0.00022125074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003409904,0.00015115982,0.00015067779,0.00002557423,0.00007753265,0.000019522073,0.00004269558,0.000068012385,0.00005105258],"category_scores_gemma":[0.00000644666,0.0001260116,0.000048425696,0.0001458972,0.00003369224,0.00002884678,0.00004398783,0.0000781761,0.0002696944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043603737,0.00023698373,0.0013521075,0.0001098333,0.0000317138,0.00003075641,0.00021638011,4.584326e-7,0.9807417,0.000012879067,0.003962603,0.013260974],"study_design_scores_gemma":[0.00062016706,0.000032492615,0.00013444746,0.000051655366,0.000052921103,0.000011184848,0.00010085763,0.000020680258,0.9796539,0.00000637781,0.019163584,0.00015175954],"about_ca_topic_score_codex":9.161496e-7,"about_ca_topic_score_gemma":1.2581589e-7,"teacher_disagreement_score":0.035843916,"about_ca_system_score_codex":0.000050657232,"about_ca_system_score_gemma":0.000046923004,"threshold_uncertainty_score":0.51386034},"labels":[],"label_agreement":null},{"id":"W2044991833","doi":"10.1177/0091270007307572","title":"Pharmacokinetics of Lamivudine, Zidovudine, and Nevirapine Administered as a Fixed‐Dose Combination Formulation Versus Coadministration of the Individual Products","year":2007,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nuvo Pharmaceuticals (Canada); Patheon (Canada); BioPhage Pharma (Canada); Quebec Rehabilitation Research Network","funders":"","keywords":"Nevirapine; Fixed-dose combination; Lamivudine; Zidovudine; Pharmacokinetics; Bioequivalence; Pharmacology; Medicine; Crossover study; Viral load; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral disease","score_opus":0.11958774544962152,"score_gpt":0.4448748509857567,"score_spread":0.32528710553613516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044991833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870693,0.00029001388,0.00006101698,0.0102029815,0.0013159063,0.00053688086,0.0000049841888,0.0000049080018,0.0005139963],"genre_scores_gemma":[0.9977846,0.00053216855,0.0004903661,0.0003659115,0.00041121102,0.0000016647571,0.000010088776,0.000010479485,0.00039351542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975698,0.0002325274,0.0015055002,0.00010749937,0.00043024067,0.00015446015],"domain_scores_gemma":[0.9964486,0.0013073136,0.0014866823,0.000128204,0.00052530546,0.00010392009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030916736,0.00013300325,0.00048386925,0.00011172569,0.000060637136,0.000004459596,0.00016575737,0.00010073959,0.00006964818],"category_scores_gemma":[0.0007344729,0.00007545854,0.00012256784,0.000266619,0.00025599392,0.00010108753,0.00006626223,0.0003631822,0.0000019446134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13887155,0.017369175,0.3050473,0.0012987935,0.010845598,0.00026721315,0.008166286,0.00016205345,0.30205598,0.003332427,0.067672476,0.14491114],"study_design_scores_gemma":[0.051748455,0.008568069,0.6201425,0.00017639353,0.0049434975,0.00031849078,0.0004037982,0.0003710804,0.30086175,0.00044110027,0.011831191,0.00019363762],"about_ca_topic_score_codex":0.0000018068732,"about_ca_topic_score_gemma":0.0000035576293,"teacher_disagreement_score":0.31509525,"about_ca_system_score_codex":0.000027839476,"about_ca_system_score_gemma":0.00034791487,"threshold_uncertainty_score":0.30771098},"labels":[],"label_agreement":null},{"id":"W2045020204","doi":"10.1177/2325957414557269","title":"The Use of Therapeutic Drug Monitoring in Complex Antituberculous and Antiretroviral Drug Dosing in HIV/Tuberculosis-Coinfected Patients","year":2014,"lang":"en","type":"article","venue":"Journal of the International Association of Providers of AIDS Care (JIAPAC)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"ViiV Healthcare","keywords":"Drug; Dosing; Tuberculosis; Medicine; Human immunodeficiency virus (HIV); Antiretroviral drug; Therapeutic drug monitoring; Pharmacology; Virology; Intensive care medicine; Antiretroviral therapy; Pathology; Viral load","score_opus":0.014019809085059126,"score_gpt":0.24947922160197256,"score_spread":0.23545941251691344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045020204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953214,0.00016123224,0.00001240135,0.003766901,0.00034798987,0.00025378066,0.000012418284,0.0000035510775,0.00012034369],"genre_scores_gemma":[0.998406,0.00011133806,0.0010307988,0.000049859995,0.000056648034,0.0000023367554,0.000009062314,0.0000127007015,0.00032123487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977526,0.00019670001,0.0008891193,0.00011232703,0.0008998084,0.00014940907],"domain_scores_gemma":[0.9969992,0.00059223006,0.0013536079,0.000121323596,0.0008978072,0.000035851543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006652921,0.00013763255,0.00041033785,0.00031417087,0.000053946573,0.000037172093,0.00019848761,0.000057414432,0.000003678552],"category_scores_gemma":[0.0009769514,0.00008882665,0.00018559836,0.00023277158,0.000070328504,0.0003008618,0.0000688556,0.00022822326,3.3291943e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019744204,0.00018092516,0.9876426,0.000058595957,0.00035029414,0.0000013890683,0.0035918308,0.0001547113,0.0021523773,0.00008784096,0.00040987958,0.0051721423],"study_design_scores_gemma":[0.0037002119,0.00016872035,0.9840436,0.00067023135,0.0001387941,0.000003481351,0.0012001203,0.0004549925,0.008749271,0.00014724713,0.0006360618,0.00008727839],"about_ca_topic_score_codex":0.00020217094,"about_ca_topic_score_gemma":0.00013432649,"teacher_disagreement_score":0.0065968935,"about_ca_system_score_codex":0.0006855127,"about_ca_system_score_gemma":0.00012536992,"threshold_uncertainty_score":0.36222458},"labels":[],"label_agreement":null},{"id":"W2045508941","doi":"10.1016/j.coviro.2012.08.007","title":"The development of novel HIV integrase inhibitors and the problem of drug resistance","year":2012,"lang":"en","type":"review","venue":"Current Opinion in Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research; amfAR, The Foundation for AIDS Research","keywords":"Elvitegravir; Integrase; Raltegravir; Biology; Integrase inhibitor; Drug resistance; Genetics; Computational biology; Mutation; Gene; Virus; Antiretroviral therapy","score_opus":0.07104980686834479,"score_gpt":0.36003892553523487,"score_spread":0.2889891186668901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045508941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009749271,0.9962542,0.000059599373,0.0007625181,0.0009384883,0.0016172259,0.000015217207,0.00000920482,0.00024603878],"genre_scores_gemma":[0.00009328162,0.99639547,0.0018019796,0.0000034629943,0.00012832611,0.00048260824,0.00015119025,0.000025950618,0.0009177593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997443,0.00025303522,0.0014269571,0.00030674832,0.0002550517,0.00031517213],"domain_scores_gemma":[0.99810046,0.00067645137,0.00074259966,0.0003354616,0.000069638874,0.000075378885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001264474,0.00036016305,0.0014669469,0.00021408097,0.00009372741,0.000005973462,0.00021523352,0.00016026876,0.000009580809],"category_scores_gemma":[0.000056792764,0.00016913943,0.00019255703,0.0002883261,0.00058191654,0.000028161905,0.00018612186,0.00047730352,0.000009551078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027746998,0.0006630129,0.0006656,0.024385849,0.00044503988,4.2073884e-7,0.0038418549,6.759867e-8,5.899515e-7,0.0075318078,0.0036252905,0.95856297],"study_design_scores_gemma":[0.0022453077,0.000010592295,0.00010261377,0.012643301,0.00031073083,0.000008952973,0.00009015633,0.0000014190397,0.0000047086955,0.00006028074,0.9843873,0.00013468767],"about_ca_topic_score_codex":0.0000016179331,"about_ca_topic_score_gemma":0.0000253798,"teacher_disagreement_score":0.98076195,"about_ca_system_score_codex":0.00012129968,"about_ca_system_score_gemma":0.00054014864,"threshold_uncertainty_score":0.6897306},"labels":[],"label_agreement":null},{"id":"W2045871034","doi":"10.1016/s1473-3099(09)70136-7","title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","year":2009,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Seventh Framework Programme","keywords":"Lamivudine; Reverse transcriptase; Medicine; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Drug resistance; Nucleoside analogue; Didanosine; Virology; Nucleoside; Viral load; Zidovudine; Resistance mutation; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease; Biology; Virus; RNA","score_opus":0.07017780613493417,"score_gpt":0.3493240932979655,"score_spread":0.2791462871630313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045871034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027272888,0.9899651,0.000012378471,0.0018364898,0.000009192332,0.005017053,0.00018221348,0.0001603688,0.000089948575],"genre_scores_gemma":[0.006739587,0.98981136,0.000067007044,0.000695703,0.000091728834,0.001556431,0.00017882414,0.00004387347,0.0008155071],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99704325,0.0005333416,0.00097476266,0.0007052373,0.00034740032,0.00039601387],"domain_scores_gemma":[0.99791634,0.0004732753,0.00049833866,0.00069820904,0.00020234007,0.00021151995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003025838,0.000784765,0.008376109,0.00039998398,0.0001454641,0.000065977685,0.00015097175,0.00014778801,0.000023677963],"category_scores_gemma":[0.00029965054,0.00035135567,0.0006757918,0.0016876614,0.00008547214,0.00008013905,0.000053951775,0.00028678955,0.000010188567],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013019134,0.0012372668,0.027249474,0.68183154,0.27468187,0.00047777386,0.0004025002,0.000023106488,1.0440415e-7,0.00007673976,0.0009936828,0.011724061],"study_design_scores_gemma":[0.0026877364,0.0008778569,0.007857891,0.12420035,0.8584968,0.000071638286,0.00002074321,0.000003851383,5.861936e-7,0.00003929647,0.0050187567,0.00072451856],"about_ca_topic_score_codex":0.000045669516,"about_ca_topic_score_gemma":0.00017691497,"teacher_disagreement_score":0.5838149,"about_ca_system_score_codex":0.00021283758,"about_ca_system_score_gemma":0.00010234149,"threshold_uncertainty_score":0.99989384},"labels":[],"label_agreement":null},{"id":"W2046047836","doi":"10.1186/1758-2652-13-s4-o4","title":"Long‐term probability of detecting drug‐resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection","year":2010,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic; Heritage Medical Research Clinic","funders":"","keywords":"Medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Term (time); Virology; Drug; Pharmacotherapy; Antiretroviral drug; Intensive care medicine; Immunology; Viral load; Internal medicine; Pharmacology","score_opus":0.01016888244976383,"score_gpt":0.24572078631600947,"score_spread":0.23555190386624564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046047836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756575,0.000014432163,0.000027014814,0.0016364418,0.0004461842,0.00021663209,0.000006277003,0.0000039444344,0.00008330665],"genre_scores_gemma":[0.99783546,0.000012500611,0.0017087329,0.000059654598,0.000104603845,0.0000026312894,0.0000022628808,0.000009080084,0.00026507862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851245,0.00004319899,0.0006538283,0.00009251662,0.0005994005,0.000098588585],"domain_scores_gemma":[0.99848706,0.000109764114,0.00084217766,0.00014236051,0.00039075874,0.00002785933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010317982,0.00010133567,0.00021507358,0.000052462896,0.00007235288,0.000014851836,0.00020749548,0.000048663176,0.00003277044],"category_scores_gemma":[0.0002540756,0.000053632415,0.00032742156,0.00016269877,0.00010261143,0.000121123834,0.00006696611,0.00041420825,8.8367074e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031368903,0.00040237274,0.9914104,0.000030743813,0.00024778224,9.008375e-7,0.0028392095,0.000032368756,0.003719586,0.000039646275,0.00023926968,0.0007240669],"study_design_scores_gemma":[0.0025133025,0.00018003504,0.9714635,0.00023348548,0.00004208823,0.0000054996444,0.00020973492,0.00014752631,0.024793966,0.00028460642,0.00007421523,0.000052032963],"about_ca_topic_score_codex":0.000029864554,"about_ca_topic_score_gemma":0.00008606357,"teacher_disagreement_score":0.021074379,"about_ca_system_score_codex":0.00019236922,"about_ca_system_score_gemma":0.00013165441,"threshold_uncertainty_score":0.21870664},"labels":[],"label_agreement":null},{"id":"W2046122324","doi":"10.1128/jvi.00947-14","title":"Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors","year":2014,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Integrase; Biology; Integrase inhibitor; Virology; Genetics; Human immunodeficiency virus (HIV); Mutation; Lentivirus; Antiretroviral therapy; Viral load; Gene; Viral disease","score_opus":0.005212556212584096,"score_gpt":0.2690626435649293,"score_spread":0.2638500873523452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046122324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98374903,0.00006471868,0.0026683055,0.012469576,0.00025773092,0.00038559668,0.0000075012613,0.0000122800675,0.00038524784],"genre_scores_gemma":[0.99690354,0.00001349303,0.0018668867,0.00027509645,0.0002255302,0.0000107931055,0.000015622698,0.000019676518,0.00066937815],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797475,0.00044001124,0.0007909545,0.00024945423,0.000316653,0.0002281898],"domain_scores_gemma":[0.99839956,0.0006675529,0.0001628997,0.0002733459,0.00022957176,0.00026707473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012949947,0.00023330527,0.00077093585,0.00042571203,0.000053305863,0.000008174034,0.00012746491,0.00012947043,0.00017226214],"category_scores_gemma":[0.0009731932,0.00015383503,0.00023655793,0.00018709248,0.00014360434,0.0000679137,0.000014366805,0.0004292565,0.000040210623],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07367614,0.0044634887,0.11282853,0.0012142436,0.0031602683,0.0007363678,0.025619684,0.00035394036,0.6405076,0.00166026,0.04187044,0.09390904],"study_design_scores_gemma":[0.028127382,0.029658627,0.027856538,0.0012120357,0.0023433396,0.0002216505,0.0007065801,0.000096952834,0.88756615,0.0026220188,0.018996362,0.000592338],"about_ca_topic_score_codex":0.000010663609,"about_ca_topic_score_gemma":0.00025869807,"teacher_disagreement_score":0.24705859,"about_ca_system_score_codex":0.00017384427,"about_ca_system_score_gemma":0.000120437806,"threshold_uncertainty_score":0.62732106},"labels":[],"label_agreement":null},{"id":"W2046186304","doi":"10.1016/j.nephro.2007.07.004","title":"Néphropathie tubulo-interstitielle associée à l'indinavir","year":2007,"lang":"fr","type":"article","venue":"Néphrologie & Thérapeutique","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Indinavir; Medicine; Virology; Human immunodeficiency virus (HIV); Sida; Viral disease","score_opus":0.024495424989614552,"score_gpt":0.3150843463456272,"score_spread":0.29058892135601266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046186304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41102284,0.08620147,0.016926445,0.114008166,0.022435809,0.005014604,0.00025655472,0.0018433923,0.34229073],"genre_scores_gemma":[0.7233902,0.0057577183,0.00422688,0.0044461493,0.0022789729,0.00009203972,0.0002003322,0.00015929963,0.25944838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99361086,0.0003411642,0.0012381623,0.0012125626,0.00083565305,0.0027615877],"domain_scores_gemma":[0.9965826,0.00092815666,0.00039067218,0.000980192,0.00028660792,0.0008317232],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0026888521,0.0010448929,0.001202543,0.0004925023,0.00045117707,0.000091402006,0.0005618883,0.001462665,0.0039811255],"category_scores_gemma":[0.00031464157,0.0009756042,0.0006051676,0.00080569845,0.0008223928,0.00032906106,0.0003727476,0.0016101015,0.006386339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031275542,0.008686657,0.19633856,0.0010287536,0.005732073,0.023364654,0.011694912,0.00004087204,0.009362431,0.03502458,0.25410333,0.45149562],"study_design_scores_gemma":[0.005143057,0.0017105307,0.044279177,0.00089256593,0.0014128836,0.00068373844,0.0020099678,0.00020015429,0.026490478,0.0018831592,0.914037,0.0012573245],"about_ca_topic_score_codex":0.00015631413,"about_ca_topic_score_gemma":0.0002962087,"teacher_disagreement_score":0.6599336,"about_ca_system_score_codex":0.0019387121,"about_ca_system_score_gemma":0.0008665717,"threshold_uncertainty_score":0.99983364},"labels":[],"label_agreement":null},{"id":"W2046580262","doi":"10.1186/1742-4690-6-s2-p6","title":"Comparative biochemical analysis of wildtype and drug resistant HIV-1 integrase subtypes B and C","year":2009,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Integrase; Human immunodeficiency virus (HIV); Drug; Virology; Medicine; Integrase inhibitor; Computational biology; Bioinformatics; Genetics; Biology; Pharmacology; Antiretroviral therapy; Viral load","score_opus":0.01043413830095975,"score_gpt":0.2714211825964466,"score_spread":0.26098704429548686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046580262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424416,0.001415033,0.000019076344,0.003152953,0.000009380179,0.00012721993,0.000009296528,0.000014915052,0.0010079392],"genre_scores_gemma":[0.9972357,0.00018398318,0.00095291773,0.00016328598,0.000011831782,0.0000028920874,0.000071750495,0.000003323396,0.00137429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929917,0.000044687564,0.00021055261,0.00022285954,0.00008878203,0.00013394319],"domain_scores_gemma":[0.9995674,0.00010176507,0.00006929636,0.0001321737,0.00003901699,0.000090344874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106014835,0.000117058764,0.0006554434,0.000272647,0.000026934129,0.000003845702,0.000027575697,0.00006932072,0.000044563996],"category_scores_gemma":[0.000039676113,0.00008391227,0.00006245621,0.000287226,0.00016494337,0.000018971414,0.000018399915,0.000094649324,0.0000047594935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006964621,0.0007948187,0.8638761,0.000059181686,0.0063511473,0.0001881497,0.0050965976,0.0000023615585,0.10140239,0.0035089643,0.010002108,0.0017535653],"study_design_scores_gemma":[0.0049826833,0.00087570224,0.9637282,0.00004259758,0.0056610266,0.000034979672,0.00046902726,0.00066612917,0.02089309,0.0003272254,0.002095544,0.00022380157],"about_ca_topic_score_codex":0.000012569805,"about_ca_topic_score_gemma":0.000022029499,"teacher_disagreement_score":0.09985209,"about_ca_system_score_codex":0.000024962075,"about_ca_system_score_gemma":0.000029855693,"threshold_uncertainty_score":0.3421843},"labels":[],"label_agreement":null},{"id":"W2046864912","doi":"10.1046/j.1468-1293.2001.00046.x","title":"MIKADO: a multicentre, open‐label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine","year":2001,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Bristol-Myers Squibb","keywords":"Stavudine; Saquinavir; Medicine; Tolerability; Zalcitabine; Interquartile range; Indinavir; Internal medicine; Lamivudine; Viral load; Gastroenterology; Protease inhibitor (pharmacology); Virology; Pharmacology; Drug holiday; Adverse effect; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy","score_opus":0.051161541669558164,"score_gpt":0.3377636946142292,"score_spread":0.28660215294467106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046864912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737158,0.0004152733,0.00010665326,0.021213587,0.000050273964,0.0031820908,0.00001049723,0.000028720044,0.0012771245],"genre_scores_gemma":[0.99057144,0.000308221,0.0007417339,0.00033895098,0.00007744637,0.000056244073,0.000019280627,0.000028700024,0.0078579765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998137,0.00013398826,0.00036509905,0.0004591571,0.0005718539,0.0003329049],"domain_scores_gemma":[0.9988362,0.00018584412,0.00010673694,0.00043159476,0.0001530346,0.0002865743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008200052,0.0003128856,0.00075605884,0.00014235,0.00016786288,0.000016656055,0.0001450461,0.000022876446,0.000117410775],"category_scores_gemma":[0.00017209341,0.00015781463,0.000012682902,0.00047901235,0.00022913952,0.000118192314,0.00022729216,0.00017230283,0.000011350988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027366046,0.00599048,0.90358275,0.00014393097,0.00088823313,0.0004627883,0.009940484,0.0000013310906,0.010528053,0.00006780085,0.002806044,0.038222034],"study_design_scores_gemma":[0.05822185,0.027764404,0.90403074,0.0007464008,0.001267237,0.00018512276,0.0045111426,0.0003015424,0.0004934324,0.000011625098,0.0021956959,0.00027081658],"about_ca_topic_score_codex":0.00044010975,"about_ca_topic_score_gemma":0.0004373383,"teacher_disagreement_score":0.037951216,"about_ca_system_score_codex":0.000071628354,"about_ca_system_score_gemma":0.00008348075,"threshold_uncertainty_score":0.6435494},"labels":[],"label_agreement":null},{"id":"W2047128784","doi":"10.1111/j.1468-1293.2005.00308.x","title":"Incidence of and risk factors for tenofovir‐induced nephrotoxicity: a retrospective cohort study","year":2005,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Maple Leaf Medical Clinic; Health Sciences Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Creatinine; Nephrotoxicity; Urinalysis; Renal function; Retrospective cohort study; Tenofovir; Proteinuria; Incidence (geometry); Internal medicine; Odds ratio; Cohort; Urology; Gastroenterology; Surgery; Toxicity; Urinary system; Human immunodeficiency virus (HIV); Kidney; Immunology","score_opus":0.01933717789578743,"score_gpt":0.294551134789501,"score_spread":0.2752139568937136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047128784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938239,0.00014884435,0.00018057194,0.0018546259,0.000052969463,0.0030373603,0.000017179664,0.000048948656,0.0008355993],"genre_scores_gemma":[0.99535245,0.00013478847,0.00095168257,0.00008828317,0.00021547238,0.0001285459,0.00003248593,0.000023632241,0.0030726355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984327,0.000042972384,0.00042509596,0.0003847181,0.0004747663,0.00023974567],"domain_scores_gemma":[0.99893504,0.00021512495,0.00019745852,0.0002890827,0.00017864245,0.0001846241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005471218,0.00023221075,0.0007508249,0.00019319491,0.00009479856,0.0000039000633,0.00006618549,0.000068184585,0.00013819188],"category_scores_gemma":[0.00064576865,0.00015236906,0.000053541455,0.00022908689,0.00013039903,0.00007299401,0.000038459028,0.00015584752,0.000010220084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019775926,0.00042974963,0.9877741,0.000031124673,0.00045260924,0.000014315536,0.006044211,4.3030104e-7,0.0013379147,0.00004070012,0.0021291643,0.0015479395],"study_design_scores_gemma":[0.0064202966,0.0016095109,0.9837923,0.00014930996,0.0009073162,0.000013699786,0.0025599624,0.00020044575,0.002863283,0.000041923722,0.0013061375,0.00013582355],"about_ca_topic_score_codex":0.00017749448,"about_ca_topic_score_gemma":0.00013292905,"teacher_disagreement_score":0.0062225377,"about_ca_system_score_codex":0.00017291731,"about_ca_system_score_gemma":0.00007621731,"threshold_uncertainty_score":0.621343},"labels":[],"label_agreement":null},{"id":"W2047404338","doi":"10.1074/jbc.m102976200","title":"Structures of Complexes Formed by HIV-1 Reverse Transcriptase at a Termination Site of DNA Synthesis","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University; Harvard University; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Reverse transcriptase; Duplex (building); RNase H; DNA; Footprinting; Chemistry; Stereochemistry; RNase P; Nuclease; RNA; Biology; Molecular biology; Biochemistry; Base sequence; Gene","score_opus":0.020875147622402716,"score_gpt":0.25659351860548296,"score_spread":0.23571837098308024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047404338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800485,0.00032993007,0.00002945603,0.0007723805,0.00001628793,0.00006632579,0.00008073518,0.000005113881,0.0006949158],"genre_scores_gemma":[0.99716115,0.00026117003,0.0009918335,0.000035586687,0.00004237616,0.000001943926,0.000059819387,0.0000046442424,0.0014414593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905455,0.000020951911,0.0005022314,0.00009732012,0.00020305072,0.00012189202],"domain_scores_gemma":[0.9992124,0.00010500928,0.00037943452,0.00008753726,0.000112298774,0.00010335404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013282309,0.000120772514,0.0004406663,0.000033552235,0.000024732863,0.0000023900802,0.00007068978,0.00012277349,0.00079295377],"category_scores_gemma":[0.00018040361,0.0000727427,0.00019059323,0.00008032772,0.00011358432,0.000032968386,0.000015207487,0.00010074834,0.0000017368801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072719663,0.00025559726,0.04116749,0.000121092424,0.00012674756,0.00008703,0.00011245025,3.6706183e-7,0.9505403,0.0000018400063,0.005503423,0.0013564387],"study_design_scores_gemma":[0.0012841241,0.00013039162,0.01588759,0.00015292583,0.00014881241,0.00039576498,0.00013187833,0.0000051024704,0.97617704,0.00007159277,0.00553942,0.00007537095],"about_ca_topic_score_codex":0.0000012885185,"about_ca_topic_score_gemma":2.6736146e-7,"teacher_disagreement_score":0.0256367,"about_ca_system_score_codex":0.00008025893,"about_ca_system_score_gemma":0.000035699304,"threshold_uncertainty_score":0.86822873},"labels":[],"label_agreement":null},{"id":"W2047404999","doi":"10.1371/journal.pone.0023726","title":"Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); McGill University; University of British Columbia","funders":"Abbott Canada","keywords":"Medicine; Lopinavir; Ritonavir; Regimen; Tolerability; Lopinavir/ritonavir; Adverse effect; Internal medicine; Viral load; Randomized controlled trial; Gastroenterology; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.07806324269220996,"score_gpt":0.26879201006257813,"score_spread":0.19072876737036817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047404999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919392,0.000035168174,0.000014988675,0.0012228758,0.000014888919,0.0036167086,0.000004283502,0.000028074764,0.0031238182],"genre_scores_gemma":[0.99839276,0.000039126695,0.00069852103,0.00017873496,0.000011828135,0.00016324168,0.000016320599,0.000019811403,0.00047966233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981883,0.00039276638,0.0005195992,0.00030802458,0.00038065098,0.0002106256],"domain_scores_gemma":[0.99826795,0.0009605003,0.0001827241,0.00040722417,0.00011418009,0.0000674464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009690364,0.00019794088,0.0008022738,0.000093531,0.000071646624,0.000011742919,0.00009202122,0.00003087202,0.000089910274],"category_scores_gemma":[0.00051427924,0.00011213187,0.00006309692,0.00016364014,0.00013760797,0.000047578756,0.000030527477,0.00015685281,0.000009265769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13191223,0.050961994,0.8085946,0.00006535046,0.0007914251,0.000014588248,0.005369799,7.961239e-7,0.00050894415,0.00009595148,0.000068352936,0.0016159635],"study_design_scores_gemma":[0.30049014,0.0012528682,0.69054973,0.00060990686,0.00021139064,1.6611463e-7,0.00031956774,0.00012844088,0.0061736656,0.0001163051,0.0000061329392,0.00014167043],"about_ca_topic_score_codex":0.000058882455,"about_ca_topic_score_gemma":0.00001626731,"teacher_disagreement_score":0.16857792,"about_ca_system_score_codex":0.00009058076,"about_ca_system_score_gemma":0.000076062286,"threshold_uncertainty_score":0.45726052},"labels":[],"label_agreement":null},{"id":"W2047666331","doi":"10.1016/s0197-2456(03)00029-1","title":"An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial","year":2003,"lang":"en","type":"article","venue":"Controlled Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Ottawa Hospital; HIV Legal Network","funders":"Medical Research Council; U.S. Department of Veterans Affairs","keywords":"Medicine; Clinical trial; Antiretroviral therapy; Randomization; Randomized controlled trial; Human immunodeficiency virus (HIV); Viral load; Family medicine; Internal medicine","score_opus":0.35517968728271626,"score_gpt":0.47920898201340134,"score_spread":0.12402929473068508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047666331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9278386,0.00031892033,0.015066688,0.0008425301,0.0013397598,0.054364458,0.00007025679,0.000021585667,0.00013717264],"genre_scores_gemma":[0.98723614,0.00044371092,0.009438534,0.00021182816,0.00031881247,0.001768204,0.00006606705,0.000037127975,0.00047956934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9803535,0.012246211,0.006076964,0.00056801265,0.00045762424,0.0002977193],"domain_scores_gemma":[0.9458841,0.050370377,0.002515033,0.00057842705,0.00048045826,0.00017162132],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04303233,0.00036330096,0.0061690696,0.00013454996,0.00013894298,0.00015641745,0.00032193272,0.00040773963,0.00005833604],"category_scores_gemma":[0.04196118,0.00019311665,0.0008885684,0.00023931517,0.00073745026,0.00020945484,0.000040055915,0.00028378615,0.0000012739176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9679818,0.016714875,0.0062863077,0.000013430362,0.0017605473,7.7028835e-7,0.0001373408,0.00001584296,0.00024158528,0.0020851647,0.0001262338,0.0046360902],"study_design_scores_gemma":[0.9793573,0.013251373,0.0012283116,0.00008389338,0.0010251147,2.9361297e-7,0.00007188152,0.0027941882,0.000118843396,0.0016802913,0.00020496736,0.00018356009],"about_ca_topic_score_codex":0.000009561657,"about_ca_topic_score_gemma":0.000006413953,"teacher_disagreement_score":0.05939752,"about_ca_system_score_codex":0.000031373937,"about_ca_system_score_gemma":0.0021598693,"threshold_uncertainty_score":0.9853996},"labels":[],"label_agreement":null},{"id":"W2047734031","doi":"10.1086/427192","title":"Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Drug resistance; Internal medicine; Medicine; Hazard ratio; Viral load; Proportional hazards model; Cohort; Resistance mutation; Cohort study; Immunology; Virology; Human immunodeficiency virus (HIV); Reverse transcriptase; Confidence interval; Biology; Polymerase chain reaction; Genetics","score_opus":0.007131593421158709,"score_gpt":0.2540523036130282,"score_spread":0.2469207101918695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047734031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948846,0.0024247975,0.00008816087,0.0007383315,0.0001254008,0.00039406525,0.000047246373,0.000027998469,0.0012693616],"genre_scores_gemma":[0.9971397,0.0009618649,0.00012035198,0.00013081789,0.00020856885,0.0000100122625,0.000021608004,0.000021707054,0.0013854001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834096,0.0001783861,0.0006919684,0.000108999186,0.0004293066,0.00025040336],"domain_scores_gemma":[0.9987245,0.00023702132,0.0005344668,0.00016617605,0.0002169795,0.00012083607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045017837,0.00018005645,0.00045968662,0.0003317033,0.00012986656,0.000015844766,0.00011267153,0.00003879306,0.000088367735],"category_scores_gemma":[0.0002432976,0.0001170599,0.00019968992,0.00044326333,0.00010322202,0.00024240922,0.00002079868,0.00021864202,0.000008624836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004783292,0.0010398657,0.9923461,0.000033817734,0.00040905044,0.000048169633,0.0022999372,0.0000506186,0.00021963604,0.000037894133,0.002369882,0.0006666681],"study_design_scores_gemma":[0.00981667,0.00047820483,0.9836779,0.00044347582,0.0006441647,0.00008505754,0.00094979734,0.00012813412,0.0023646096,0.00012149385,0.0011098484,0.00018060823],"about_ca_topic_score_codex":0.000011293301,"about_ca_topic_score_gemma":0.000042556065,"teacher_disagreement_score":0.009338341,"about_ca_system_score_codex":0.00019491119,"about_ca_system_score_gemma":0.00032432968,"threshold_uncertainty_score":0.47735643},"labels":[],"label_agreement":null},{"id":"W2047767458","doi":"10.1016/j.antiviral.2010.06.001","title":"Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes","year":2010,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"National Institutes of Health; National Institute for Health and Care Research","keywords":"Drug resistance; Virology; Biology; Mutation; Virus; Protease; Protease inhibitor (pharmacology); Recombinant DNA; Resistance mutation; Human immunodeficiency virus (HIV); Lentivirus; Genetics; Viral disease; Enzyme; Viral load; Gene; Reverse transcriptase; Polymerase chain reaction; Antiretroviral therapy","score_opus":0.025592750565193487,"score_gpt":0.35780198163759624,"score_spread":0.33220923107240274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047767458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98689973,0.00008914124,0.00003817463,0.004118184,0.000044323337,0.0011192842,0.000072608476,0.000024841569,0.007593697],"genre_scores_gemma":[0.8479516,0.000036174577,0.0021011466,0.000020454567,0.00008783236,0.00012512061,0.00018398059,0.00002197224,0.14947172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99735385,0.00010411487,0.0004276824,0.0005189373,0.0010025554,0.00059286266],"domain_scores_gemma":[0.9987206,0.00016080204,0.00008544118,0.0005305662,0.00036444503,0.00013813056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011065904,0.00021552497,0.00059960625,0.0011678666,0.000111893525,0.0000372359,0.00022893024,0.00015434485,0.00009645897],"category_scores_gemma":[0.00045615705,0.00016375381,0.00014165798,0.0027459501,0.00029538822,0.00014594742,0.00012608686,0.0008171135,0.00017633157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001277901,0.0024713657,0.37676072,0.00035066914,0.00079965673,0.00053743226,0.0063510383,6.74006e-7,0.57386756,0.00037728783,0.034794874,0.002410801],"study_design_scores_gemma":[0.006887408,0.00018323571,0.30520064,0.0007024949,0.00050621544,0.000004967856,0.0010315172,0.0006945027,0.65556246,0.0000639427,0.028659895,0.0005027088],"about_ca_topic_score_codex":0.00015152029,"about_ca_topic_score_gemma":0.0018257098,"teacher_disagreement_score":0.14187801,"about_ca_system_score_codex":0.00010419346,"about_ca_system_score_gemma":0.00034550828,"threshold_uncertainty_score":0.66776866},"labels":[],"label_agreement":null},{"id":"W2047933255","doi":"10.1097/00126334-200311010-00016","title":"CD4 Cell Count Response to Nonnucleoside Reverse Transcriptase Inhibitor- or Protease Inhibitor-Based Highly Active Antiretroviral Therapy in an Observational Cohort Study","year":2003,"lang":"en","type":"letter","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Observational study; Antiretroviral therapy; Virology; Human immunodeficiency virus (HIV); Medicine; Cohort study; Cohort; Reverse transcriptase; Internal medicine; Viral load; Biology; Polymerase chain reaction","score_opus":0.04243573842494728,"score_gpt":0.2936363295040862,"score_spread":0.2512005910791389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047933255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93668914,0.00052183797,0.000020862355,0.056380063,0.0011747242,0.004930201,0.00016728077,0.00007288205,0.000043023967],"genre_scores_gemma":[0.94677126,0.00012304529,0.0029303252,0.038338006,0.0005452336,0.00044754826,0.00042317592,0.00033465293,0.010086735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99065214,0.0015808071,0.002796283,0.001052307,0.0028328008,0.0010856768],"domain_scores_gemma":[0.9957074,0.0005126828,0.0013274563,0.0010250803,0.0010387119,0.00038867097],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034530992,0.0011709951,0.0024658472,0.003476705,0.00028810475,0.00017443184,0.00068246917,0.0007109899,0.00025800915],"category_scores_gemma":[0.0005994197,0.00088584755,0.0006702616,0.0026065377,0.00021210288,0.00080996845,0.000053605334,0.0013249643,0.00008215071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07489647,0.020224957,0.38139284,0.00072588515,0.0016303185,0.0816819,0.009858617,0.00013166993,0.07329516,0.0000021323956,0.35442376,0.001736282],"study_design_scores_gemma":[0.06502026,0.087085284,0.6646603,0.0046056537,0.0025031732,0.002373507,0.0077882884,0.00006364556,0.03860316,0.000026032649,0.12319079,0.004079928],"about_ca_topic_score_codex":0.000087738954,"about_ca_topic_score_gemma":0.000007359679,"teacher_disagreement_score":0.28326744,"about_ca_system_score_codex":0.0016287911,"about_ca_system_score_gemma":0.0036863147,"threshold_uncertainty_score":0.99935925},"labels":[],"label_agreement":null},{"id":"W2048253923","doi":"10.1128/jcm.06689-11","title":"Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; School of Medicine, Stanford University; International AIDS Society","keywords":"Concordance; Genotyping; Drug resistance; Sequence analysis; Sequence (biology); Computational biology; Computer science; Bioinformatics; Medicine; Biology; Genetics; Genotype; Gene","score_opus":0.059500399311311854,"score_gpt":0.38382416077184683,"score_spread":0.324323761460535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048253923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851923,0.0009906784,0.0015148453,0.0111920545,0.00030247058,0.00014511864,0.0000070962396,0.000025728004,0.0006297234],"genre_scores_gemma":[0.8844004,0.00013136836,0.09699805,0.0007663271,0.00060715823,0.000004097556,0.00003209935,0.000019576928,0.01704087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733603,0.00028238917,0.0016068656,0.00021655622,0.00014317242,0.00041497222],"domain_scores_gemma":[0.9972129,0.0007150498,0.0011713034,0.00024709216,0.00041316866,0.00024048456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025301,0.00019046187,0.0011354624,0.00024803102,0.00008826225,0.000020810252,0.00020035682,0.00017066715,0.00017352728],"category_scores_gemma":[0.00080985675,0.00011757903,0.00039687788,0.0005230457,0.00015934622,0.00022569143,0.000057405185,0.00055472564,0.000052456962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010324976,0.00047679635,0.9688359,0.000051150255,0.0034082509,0.00014115745,0.00043653793,0.0000067369742,0.007232643,0.000054742988,0.014679975,0.0036436294],"study_design_scores_gemma":[0.013313291,0.0005829291,0.6418865,0.001576614,0.010125356,0.001944364,0.00037037782,0.00011737712,0.0081096785,0.00014481845,0.32089597,0.00093271467],"about_ca_topic_score_codex":0.0000018426305,"about_ca_topic_score_gemma":0.000028577006,"teacher_disagreement_score":0.3269494,"about_ca_system_score_codex":0.000105986524,"about_ca_system_score_gemma":0.00036782632,"threshold_uncertainty_score":0.47947338},"labels":[],"label_agreement":null},{"id":"W2048393533","doi":"10.1002/jmv.21329","title":"PL‐100, a novel HIV‐1 protease inhibitor displaying a high genetic barrier to resistance: An in vitro selection study","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; PerkinElmer Biosignal","funders":"","keywords":"Nelfinavir; Protease; Virology; Biology; Mutation; Indinavir; Saquinavir; Mutagenesis; Protease inhibitor (pharmacology); Amprenavir; Virus; Mutant; Drug resistance; Viral replication; Molecular biology; HIV-1 protease; Genetics; Enzyme; Gene; Viral disease; Viral load; Biochemistry","score_opus":0.017234924742516814,"score_gpt":0.29100661993095067,"score_spread":0.27377169518843386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048393533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838332,0.000114518654,0.0009252057,0.014254395,0.0002056115,0.0006225937,0.0000025247596,0.000013188945,0.000028750652],"genre_scores_gemma":[0.99085516,0.000030598236,0.0065773916,0.00091445335,0.00057951984,0.000055312383,0.0000038135074,0.0000216574,0.0009621238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973522,0.00018821246,0.00077525165,0.00025894528,0.0010825454,0.00034284906],"domain_scores_gemma":[0.99872494,0.00008618216,0.00018464403,0.0001376125,0.00011407517,0.0007525693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079744036,0.0001811148,0.00057512516,0.00043734675,0.00009525009,0.0000073125593,0.00014974955,0.000193751,0.00020930766],"category_scores_gemma":[0.0006195747,0.00013275306,0.0000742679,0.0003401845,0.0000691673,0.00008067568,0.000046395322,0.00063264475,0.00002176822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027785122,0.019799903,0.713079,0.00013778811,0.0009124954,0.033380527,0.016454838,0.0000669874,0.16791345,0.000055291443,0.012442226,0.007972408],"study_design_scores_gemma":[0.039185036,0.0064794333,0.9201752,0.00041528424,0.0004077508,0.0063268538,0.0011482614,0.00047452716,0.008306754,0.00006890721,0.016542496,0.00046952028],"about_ca_topic_score_codex":0.000028684442,"about_ca_topic_score_gemma":0.00013579003,"teacher_disagreement_score":0.20709622,"about_ca_system_score_codex":0.00029748,"about_ca_system_score_gemma":0.0006946291,"threshold_uncertainty_score":0.54135126},"labels":[],"label_agreement":null},{"id":"W2048514971","doi":"10.1097/qad.0b013e3283612419","title":"Dolutegravir in antiretroviral-naive adults with HIV-1","year":2013,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Tolerability; Dolutegravir; Emtricitabine; Efavirenz; Medicine; Abacavir; Regimen; Adverse effect; Lamivudine; Internal medicine; Clinical endpoint; Viral load; Integrase inhibitor; Gastroenterology; Human immunodeficiency virus (HIV); Pharmacology; Randomized controlled trial; Virology; Antiretroviral therapy; Virus; Hepatitis B virus","score_opus":0.0061395433520202445,"score_gpt":0.2205028907488554,"score_spread":0.21436334739683516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048514971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98604935,0.00009784796,0.000030218167,0.0013508779,0.000037383375,0.00047134256,0.0000021615954,0.000052388874,0.011908411],"genre_scores_gemma":[0.96748537,0.000027949245,0.0051900255,0.00020664994,0.000042772477,0.00008491493,0.00004694285,0.000018436825,0.026896918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991629,0.000017011074,0.00015753532,0.0002218946,0.00018655171,0.0002541181],"domain_scores_gemma":[0.9995937,0.000023781004,0.00003112101,0.00019848232,0.000048860624,0.00010406133],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000048533253,0.00014747398,0.0002312625,0.00014368033,0.000027518176,0.000014837226,0.00005233267,0.000052753465,0.00040016902],"category_scores_gemma":[0.000013902405,0.00009607209,0.000036729074,0.00027136196,0.000033986093,0.00012181632,0.000020475094,0.00011603387,0.001519049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014032287,0.00017050574,0.9819693,0.000026434183,0.00005635606,0.00013748642,0.0008341946,4.031723e-7,0.00022729751,0.000107098975,0.005033618,0.011297007],"study_design_scores_gemma":[0.0076321117,0.0009776577,0.9805702,0.0004984346,0.00007597561,0.00005308696,0.0010161264,0.00009568251,0.0030890666,0.00011752359,0.0055844933,0.00028965753],"about_ca_topic_score_codex":0.00018250449,"about_ca_topic_score_gemma":0.00001309405,"teacher_disagreement_score":0.018563978,"about_ca_system_score_codex":0.000075350916,"about_ca_system_score_gemma":0.000064439504,"threshold_uncertainty_score":0.9992584},"labels":[],"label_agreement":null},{"id":"W2048723540","doi":"10.1371/journal.pone.0074414","title":"Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Apoptosis; Programmed cell death; Biology; Cytotoxicity; Peripheral blood mononuclear cell; Biochemistry; In vitro","score_opus":0.03322445030006834,"score_gpt":0.23331602614765534,"score_spread":0.200091575847587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048723540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039704,0.0000112762045,0.0000075059193,0.0028956046,0.000018532664,0.0005052456,0.0000012220468,0.00006928647,0.0060942974],"genre_scores_gemma":[0.98730534,0.000043567223,0.0019152795,0.000040920124,0.000055442226,0.00011324679,0.00007358707,0.00001395031,0.010438646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99930626,0.000016908132,0.00018906665,0.0001330813,0.0002359616,0.000118732445],"domain_scores_gemma":[0.9995055,0.000041194406,0.000084014726,0.00014712136,0.00016043376,0.0000616952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053539967,0.000094520256,0.0002151082,0.0001244008,0.000033291624,0.000007638551,0.000021310292,0.000047321493,0.0003478312],"category_scores_gemma":[0.00006705518,0.000079084035,0.00003942713,0.00016782232,0.000013913298,0.00013617009,0.000013781143,0.00007051289,0.00056169997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031367763,0.00278842,0.30129403,0.00017612148,0.00058679574,6.357669e-7,0.00077765743,1.7075008e-7,0.68895537,0.000056701843,0.0023129894,0.0030197403],"study_design_scores_gemma":[0.00082637614,0.00006154048,0.11049586,0.0002588142,0.0001999709,6.025497e-7,0.000055940032,0.00006729347,0.8877858,0.00007418814,0.00010155652,0.00007205332],"about_ca_topic_score_codex":0.00015425806,"about_ca_topic_score_gemma":0.0000057737984,"teacher_disagreement_score":0.19883044,"about_ca_system_score_codex":0.00007899595,"about_ca_system_score_gemma":0.00003199524,"threshold_uncertainty_score":0.72197044},"labels":[],"label_agreement":null},{"id":"W2048991605","doi":"10.4021//jmc.v4i4.1058","title":"Drug Interactions With Cyclosporine-Rifampicin-Clarithromycin in a Kidney Transplant Recipient With Mycobacterium Malmoense","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Clarithromycin; Rifampicin; Ethambutol; Renal function; Internal medicine; Kidney; Creatinine; Pharmacology; Drug; Gastroenterology; Urology; Tuberculosis; Pathology","score_opus":0.01264723505736069,"score_gpt":0.26288079633085126,"score_spread":0.25023356127349056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048991605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94704324,0.00013164035,0.00011041717,0.051703162,0.0002085506,0.0002957085,0.0000065198797,0.00001541427,0.0004853672],"genre_scores_gemma":[0.9933074,0.00031105822,0.0024371473,0.0011443311,0.00026788484,0.000024179231,0.000021116373,0.0000243624,0.0024625177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976493,0.0000705333,0.00063368044,0.00018357206,0.0011600291,0.0003028955],"domain_scores_gemma":[0.9982899,0.00020649093,0.00022765949,0.0001596944,0.00021137271,0.0009048825],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003611239,0.00022629023,0.0005530731,0.00030222593,0.000045444733,0.000027928789,0.00011294106,0.000066427136,0.0022613367],"category_scores_gemma":[0.00015689673,0.00012130077,0.00009201396,0.00026596783,0.000106865875,0.00022422892,0.000016674063,0.00069955713,0.000042024552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063078357,0.0042036828,0.8391057,0.00038405857,0.001160856,0.08475083,0.005382056,0.00001236934,0.00071698177,0.00009328131,0.051448695,0.00643361],"study_design_scores_gemma":[0.033411358,0.004324921,0.6961509,0.022142773,0.0013551,0.17018165,0.0059429184,0.00017502227,0.00436204,0.000065451386,0.061062675,0.0008251867],"about_ca_topic_score_codex":0.0003402778,"about_ca_topic_score_gemma":0.0005110516,"teacher_disagreement_score":0.14295483,"about_ca_system_score_codex":0.00018877034,"about_ca_system_score_gemma":0.000799233,"threshold_uncertainty_score":0.9986507},"labels":[],"label_agreement":null},{"id":"W2049361389","doi":"10.1592/phco.23.1.29.31915","title":"Tenofovir: A Nucleotide Analog for The Management of Human Immunodeficiency Virus Infection","year":2003,"lang":"en","type":"review","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; St. Michael's Hospital; Toronto Public Health","funders":"","keywords":"Efavirenz; Stavudine; Zidovudine; Lamivudine; Pharmacology; Virology; Adverse effect; Medicine; Reverse-transcriptase inhibitor; Hypophosphatemia; Internal medicine; Gastroenterology; Viral load; Virus; Viral disease; Antiretroviral therapy; Hepatitis B virus","score_opus":0.05300262064673796,"score_gpt":0.4021831293945341,"score_spread":0.34918050874779616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049361389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009920124,0.9852881,0.000090027905,0.00060437736,0.00073081534,0.0029790525,0.000020495354,0.00002323868,0.0003437623],"genre_scores_gemma":[0.0014567472,0.9926802,0.000079089004,0.0007071594,0.00034732636,0.00018118147,0.00001482869,0.00010061918,0.0044328533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966283,0.00074834825,0.0014874059,0.00029835344,0.00038915983,0.00044845618],"domain_scores_gemma":[0.9970893,0.0005284455,0.0017174915,0.00031242793,0.00022816144,0.00012417423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002562302,0.000652081,0.0017751347,0.00044761988,0.00084636634,0.00003055282,0.0005056298,0.00014589386,0.00070619513],"category_scores_gemma":[0.000002186997,0.00032640484,0.00094693614,0.00038533178,0.00041572662,0.000115735726,0.000046281828,0.00080066413,0.000005787046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023123494,0.0032017047,0.0001541627,0.0063238596,0.032698672,0.000116461204,0.0039993967,0.000012357467,0.014975731,0.00052752387,0.040121377,0.8955564],"study_design_scores_gemma":[0.008932816,0.0007397343,0.00003853459,0.0012899201,0.00993613,0.00032807357,0.0001342426,0.0000050589433,0.0022668184,0.00023287734,0.97577333,0.00032247973],"about_ca_topic_score_codex":0.000015367576,"about_ca_topic_score_gemma":0.0000027962938,"teacher_disagreement_score":0.93565196,"about_ca_system_score_codex":0.00016269981,"about_ca_system_score_gemma":0.00018127888,"threshold_uncertainty_score":0.9999188},"labels":[],"label_agreement":null},{"id":"W2049519861","doi":"10.1371/journal.pone.0079981","title":"Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials","year":2013,"lang":"en","type":"review","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Bill and Melinda Gates Foundation","keywords":"Emtricitabine; Lamivudine; Medicine; Abacavir; Randomized controlled trial; Internal medicine; Relative risk; Meta-analysis; Regimen; Virology; Confidence interval; Virus","score_opus":0.35481244178494165,"score_gpt":0.4065608417892648,"score_spread":0.05174840000432318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049519861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029988003,0.9800431,0.000005818966,0.000222154,0.0000031958557,0.019331452,0.00012099771,0.000013849071,0.00022945458],"genre_scores_gemma":[0.000039201186,0.9879404,0.0015492326,0.000026076772,0.0000091175625,0.0023933006,0.00027084758,0.00002383558,0.0077480013],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99224615,0.0025092268,0.0041193445,0.00039631792,0.00057235087,0.00015662529],"domain_scores_gemma":[0.98776764,0.0077434964,0.0034333603,0.00053164497,0.00039417789,0.0001296598],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004251899,0.00056505774,0.078023255,0.00076761225,0.000022431846,0.00001209457,0.00009784181,0.0001371475,0.00049799826],"category_scores_gemma":[0.0043963436,0.0002722353,0.003939368,0.0010832525,0.00014232329,0.000035710702,0.00006321336,0.00014719125,0.000018504981],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001633188,0.0005439353,4.0850023e-7,0.50540906,0.49360564,0.0000017883458,0.000094637406,5.7456937e-9,4.870702e-7,0.00002028873,0.00006389499,0.0000965202],"study_design_scores_gemma":[0.016687207,0.000043300945,4.560705e-7,0.12774716,0.8552036,0.0000035111577,0.000007509604,0.0000074119057,0.000010628069,0.0000034975703,0.00012801401,0.00015765277],"about_ca_topic_score_codex":0.000007778836,"about_ca_topic_score_gemma":0.0000012774282,"teacher_disagreement_score":0.3776619,"about_ca_system_score_codex":0.00004577962,"about_ca_system_score_gemma":0.00014445063,"threshold_uncertainty_score":0.999973},"labels":[],"label_agreement":null},{"id":"W2049792332","doi":"10.1371/journal.pone.0017402","title":"“Dynamic Range” of Inferred Phenotypic HIV Drug Resistance Values in Clinical Practice","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; St. Paul's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Lamivudine; Medicine; Emtricitabine; Drug resistance; Context (archaeology); Internal medicine; Abacavir; HIV drug resistance; Viral load; Cohort; Zidovudine; Efavirenz; Drug; Virology; Human immunodeficiency virus (HIV); Pharmacology; Antiretroviral therapy; Biology; Virus; Viral disease; Genetics","score_opus":0.06719432952204937,"score_gpt":0.3099559382134025,"score_spread":0.24276160869135313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049792332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576482,0.00097125553,0.000029097419,0.0038795231,0.000040155326,0.0005393346,0.0000050548383,0.0000558388,0.036831524],"genre_scores_gemma":[0.8599454,0.00048520672,0.08155757,0.00017911794,0.00003374208,0.000040881598,0.000022197022,0.000025461695,0.057710428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846184,0.00013023001,0.0005988419,0.00025026005,0.00036266717,0.00019613035],"domain_scores_gemma":[0.9989348,0.00030691922,0.00018483102,0.00032935585,0.00015087995,0.000093209215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058553397,0.00013268458,0.00048570865,0.00011704274,0.000022643237,0.0000036144468,0.00008751411,0.00007293047,0.00016084775],"category_scores_gemma":[0.0009115574,0.00011480706,0.00006642175,0.00020419531,0.00008387089,0.00011911198,0.000036761576,0.00020700293,0.00019196337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005093047,0.029800603,0.9390751,0.00072636537,0.0020809248,0.0004148494,0.014151501,1.8833327e-7,0.0006977187,0.0008735786,0.0054231654,0.0016629227],"study_design_scores_gemma":[0.014939128,0.00024812753,0.96455485,0.0030660476,0.0023557509,0.0000072955277,0.0012863738,0.00037202347,0.007339854,0.0022694515,0.0030155256,0.0005455914],"about_ca_topic_score_codex":0.00001348799,"about_ca_topic_score_gemma":0.00011873399,"teacher_disagreement_score":0.09770282,"about_ca_system_score_codex":0.00007430834,"about_ca_system_score_gemma":0.00013289695,"threshold_uncertainty_score":0.4681696},"labels":[],"label_agreement":null},{"id":"W2049958520","doi":"10.1097/qai.0b013e3181e674f4","title":"The Impact of Kidney Function at Highly Active Antiretroviral Therapy Initiation on Mortality in HIV-Infected Women","year":2010,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Research Resources; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases","keywords":"Hazard ratio; Medicine; Renal function; Serostatus; Kidney disease; Confidence interval; Internal medicine; Population; Proportional hazards model; Immunology; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.015398446976110832,"score_gpt":0.2868699104036792,"score_spread":0.2714714634275684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049958520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977801,0.00022697881,0.000009494175,0.00046869807,0.0005638671,0.00034243293,0.000016989512,0.000025621615,0.00056584436],"genre_scores_gemma":[0.99874365,0.00038123166,0.000048216378,0.00003368916,0.000044839853,0.000014776686,0.000031847154,0.000027442531,0.00067428115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976844,0.00015223831,0.00093238294,0.00019249925,0.00062334904,0.0004151392],"domain_scores_gemma":[0.99810517,0.00025908634,0.0007955112,0.00035247623,0.00030318132,0.00018456855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011384409,0.00026391784,0.0006285436,0.0005973396,0.0001822788,0.0000316787,0.00018898047,0.00013317827,0.00013568178],"category_scores_gemma":[0.00067163265,0.00015138669,0.00034541916,0.0008444068,0.00017005639,0.0003254516,0.000037237816,0.00025699942,0.000032977532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049596317,0.0016860202,0.7718307,0.00003403237,0.0009630989,0.00013199588,0.0037316284,0.000033344313,0.20503552,0.00014736892,0.0008905241,0.01055615],"study_design_scores_gemma":[0.0044120466,0.00388102,0.97345114,0.00012444927,0.00006909659,0.00017928687,0.00037846086,0.00005945531,0.016964316,0.00018987183,0.00014682295,0.00014404018],"about_ca_topic_score_codex":0.000041888947,"about_ca_topic_score_gemma":0.0000037616956,"teacher_disagreement_score":0.20162046,"about_ca_system_score_codex":0.00058177975,"about_ca_system_score_gemma":0.00063057477,"threshold_uncertainty_score":0.617337},"labels":[],"label_agreement":null},{"id":"W2050347354","doi":"10.1185/030079904125004006","title":"Triple nucleoside treatment with abacavir plus the lamivudine/ zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)","year":2004,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Abacavir; Lamivudine; Indinavir; Zidovudine; Regimen; Tolerability; Population; Internal medicine; Viral load; Intention-to-treat analysis; Gastroenterology; Randomized controlled trial; Immunology; Adverse effect; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus","score_opus":0.18496230111015938,"score_gpt":0.4390745304334409,"score_spread":0.25411222932328154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050347354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729119,0.0023398125,0.00012725039,0.018508587,0.00038222907,0.0052855667,0.00008655847,0.000030706586,0.00032740412],"genre_scores_gemma":[0.98957664,0.008430676,0.00018840676,0.000057990477,0.00015765107,0.00051285303,0.0005379099,0.000027136392,0.00051076553],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956035,0.00033176062,0.0007715808,0.00065793685,0.0019058043,0.0007294164],"domain_scores_gemma":[0.9980227,0.00048037665,0.00016242791,0.00043751768,0.00029497905,0.00060199917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00195171,0.00032298156,0.0007575366,0.00042179227,0.0002542614,0.00009506188,0.00046771506,0.00013337035,0.00003946366],"category_scores_gemma":[0.0007463697,0.00018524096,0.00004956789,0.0011764473,0.00046098419,0.00021769234,0.00030068718,0.00060043397,0.000029107252],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41341522,0.03195945,0.013083032,0.0005091488,0.00045280805,0.0002892919,0.009002827,0.0000075819294,0.0003825647,0.0016343064,0.010183743,0.51908],"study_design_scores_gemma":[0.87590456,0.055523008,0.020075964,0.008994119,0.00005775275,0.00004106234,0.0019073023,0.0014734897,0.0026432334,0.00070834294,0.03207128,0.0005998771],"about_ca_topic_score_codex":0.0009989588,"about_ca_topic_score_gemma":0.00021440908,"teacher_disagreement_score":0.5184801,"about_ca_system_score_codex":0.0006751559,"about_ca_system_score_gemma":0.0012563296,"threshold_uncertainty_score":0.7553907},"labels":[],"label_agreement":null},{"id":"W2050508755","doi":"10.1097/00002030-200101050-00010","title":"Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Regimen; Tolerability; Viral load; Internal medicine; Adverse effect; Population; Protease inhibitor (pharmacology); Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.014718806605097966,"score_gpt":0.25667599569750266,"score_spread":0.24195718909240468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050508755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849124,0.00013375001,0.00087055314,0.010692732,0.00005566503,0.0026556605,0.00004015048,0.00023964778,0.0003994731],"genre_scores_gemma":[0.92207086,0.000058232232,0.05250721,0.0011362846,0.00012964263,0.00062971027,0.00027275956,0.00005871108,0.02313656],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834263,0.000054179553,0.00028020877,0.0005010417,0.0003041099,0.00051782397],"domain_scores_gemma":[0.99881506,0.00028637174,0.0000686467,0.0004416188,0.00013562365,0.00025268728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002473007,0.00032190906,0.00045668776,0.00022102363,0.00018709477,0.0000319369,0.00013194403,0.00011557293,0.00014383682],"category_scores_gemma":[0.00017789553,0.00021198005,0.00011188162,0.00044368618,0.000049840342,0.00009202619,0.00004326249,0.00014358861,0.0002076933],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013663281,0.0006188921,0.95861936,0.000018600374,0.00044377436,0.00007932108,0.0021512813,0.00001954257,0.0030206107,0.000045568137,0.026011141,0.0076055555],"study_design_scores_gemma":[0.028732596,0.0023166994,0.26724932,0.00016088455,0.00023545646,0.00009281223,0.00066032977,0.00017013316,0.02257357,0.000062941,0.67713547,0.0006098014],"about_ca_topic_score_codex":0.000036276877,"about_ca_topic_score_gemma":0.0001622298,"teacher_disagreement_score":0.69137007,"about_ca_system_score_codex":0.000099135716,"about_ca_system_score_gemma":0.0001158222,"threshold_uncertainty_score":0.86442953},"labels":[],"label_agreement":null},{"id":"W2050647037","doi":"10.1074/jbc.m304262200","title":"Site-specific Footprinting Reveals Differences in the Translocation Status of HIV-1 Reverse Transcriptase","year":2003,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Terminator (solar); Reverse transcriptase; Footprinting; Polymerase; Nucleotide; Chemistry; Enzyme; Nucleoside analogue; Nucleic acid; Nucleoside; DNA; T7 RNA polymerase; Molecular biology; Gene; Biology; Biochemistry; Polymerase chain reaction; Bacteriophage","score_opus":0.050335167740367615,"score_gpt":0.2645464337869361,"score_spread":0.21421126604656848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050647037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574155,0.0015246811,0.000081737104,0.000824571,0.000024504478,0.00009348955,0.000004293865,0.0000033706733,0.0017018145],"genre_scores_gemma":[0.99685895,0.0014497569,0.0012995789,0.00004676443,0.0000392778,0.0000028881987,0.00000814303,0.000003104697,0.0002915176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989137,0.00008059704,0.00052590476,0.000104895844,0.0001928699,0.00018205025],"domain_scores_gemma":[0.9994131,0.00012622171,0.00020889353,0.000097076365,0.00007256083,0.0000821875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005009289,0.00010581506,0.00032594736,0.000030109757,0.000024766527,0.0000066741322,0.000080869155,0.00009293448,0.00018114845],"category_scores_gemma":[0.00018342397,0.000054222717,0.0001326368,0.00014116995,0.00006987832,0.000020299603,0.000003091765,0.00024004032,0.0000019638437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000252769,0.0005879354,0.48008856,0.00008882325,0.00005395349,0.0001356541,0.0013704514,0.0000011259925,0.51469535,0.000059142054,0.00064309884,0.0020231425],"study_design_scores_gemma":[0.006704796,0.00044413444,0.36075434,0.00085599435,0.00015292838,0.0005853231,0.0067617353,0.000004554392,0.59144837,0.00063414866,0.031343933,0.00030974433],"about_ca_topic_score_codex":0.0000010285719,"about_ca_topic_score_gemma":2.292021e-7,"teacher_disagreement_score":0.11933423,"about_ca_system_score_codex":0.00005045971,"about_ca_system_score_gemma":0.00006189772,"threshold_uncertainty_score":0.22111382},"labels":[],"label_agreement":null},{"id":"W2050892293","doi":"10.1310/hct1203-151","title":"Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based HAART Regimen in Treatment-Naïve HIV-lnfected Patients","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute; Sunnybrook Health Science Centre; McGill University; Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada); Maple Leaf Medical Clinic; Université de Montréal","funders":"","keywords":"Medicine; Ritonavir; Discontinuation; Atazanavir; Viral load; Regimen; Internal medicine; Human immunodeficiency virus (HIV); Gastroenterology; Antiretroviral therapy; Immunology","score_opus":0.1576212044445199,"score_gpt":0.40258714999977185,"score_spread":0.24496594555525195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050892293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912225,0.00015246961,0.00004720556,0.0010262231,0.00018142335,0.004921986,0.00018466287,0.00013194937,0.002131606],"genre_scores_gemma":[0.9938053,0.00038807333,0.00240624,0.0000868304,0.00013451664,0.0006119819,0.00069869176,0.000064186774,0.0018041917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99357575,0.0025588032,0.0018844331,0.0010796905,0.00037374045,0.0005275997],"domain_scores_gemma":[0.99344754,0.004753808,0.00045767846,0.0007164181,0.00014163725,0.00048293304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002563819,0.0006268145,0.0025186583,0.00019848466,0.00012483144,0.000026515387,0.000096799515,0.00031983972,0.00025500535],"category_scores_gemma":[0.0014524745,0.0003769034,0.0004465329,0.00032848166,0.0003098659,0.00012717153,0.000045479454,0.00020032344,0.0001853838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019890664,0.008762817,0.94173783,0.000060681858,0.00089253223,0.000298561,0.0002835587,8.188962e-7,0.000021387477,0.00006363658,0.00017493697,0.027812552],"study_design_scores_gemma":[0.08619694,0.0069812597,0.8978273,0.0004190723,0.0011866135,0.0000121065295,0.000043349013,0.000035421377,0.0014870287,0.00013201145,0.0052799517,0.00039890406],"about_ca_topic_score_codex":0.00020601007,"about_ca_topic_score_gemma":0.00015734685,"teacher_disagreement_score":0.06630627,"about_ca_system_score_codex":0.0006662475,"about_ca_system_score_gemma":0.00048491705,"threshold_uncertainty_score":0.9998683},"labels":[],"label_agreement":null},{"id":"W2051030056","doi":"10.1097/00126334-200305010-00007","title":"Randomized, Controlled Study of the Effects of a Short Course of Prednisone on the Incidence of Rash Associated With Nevirapine in Patients Infected With HIV-1","year":2003,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Nevirapine; Prednisone; Medicine; Rash; Internal medicine; Incidence (geometry); Gastroenterology; Surgery; Immunology; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.0065686500006616215,"score_gpt":0.2294005958633899,"score_spread":0.22283194586272828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051030056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951074,0.0010109177,0.000015408052,0.00008389731,0.000098971024,0.0035753371,0.000005296446,0.0000064971186,0.00009623357],"genre_scores_gemma":[0.99957967,0.00009923101,0.00006181386,0.000008122205,0.0000023635998,0.000054980028,0.0000030606795,0.000026346208,0.00016444322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511904,0.0011969878,0.0019606012,0.00017844196,0.001278362,0.00026656457],"domain_scores_gemma":[0.9937121,0.0024385508,0.002398565,0.00045563473,0.00094459846,0.000050507777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027966178,0.00032135614,0.0029590805,0.00046483023,0.000059844977,0.0000066941934,0.00030836294,0.00007890185,0.000012822896],"category_scores_gemma":[0.0040296135,0.000133142,0.00037350322,0.0015033447,0.00044859716,0.00011445867,0.000042621617,0.00017196921,4.3488373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07721719,0.013073583,0.89639485,0.00020643564,0.003929276,0.00005407046,0.00561151,0.00017501393,0.003111958,0.00004849312,0.000025125377,0.00015246437],"study_design_scores_gemma":[0.34309542,0.0073326877,0.6330184,0.0033942217,0.0017339871,0.00003596943,0.0013464286,0.00003801823,0.009873715,0.000013433941,3.7181394e-7,0.00011737004],"about_ca_topic_score_codex":0.000019018813,"about_ca_topic_score_gemma":0.0000100485795,"teacher_disagreement_score":0.26587823,"about_ca_system_score_codex":0.00009500485,"about_ca_system_score_gemma":0.00042654903,"threshold_uncertainty_score":0.54293734},"labels":[],"label_agreement":null},{"id":"W2051548413","doi":"10.3851/imp1839","title":"Next-Generation Sequencing of Dried Blood Spot Specimens: A Novel Approach to HIV Drug-Resistance Surveillance","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Sanger sequencing; Dried blood spot; Pyrosequencing; Genotyping; Multiplex; DNA sequencing; Dried blood; Human immunodeficiency virus (HIV); Drug resistance; Medicine; HIV drug resistance; Genotype; Virology; Biology; Genetics; Viral load; DNA; Gene; Antiretroviral therapy; Chemistry","score_opus":0.10091096437737697,"score_gpt":0.2592985268608887,"score_spread":0.15838756248351177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051548413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97458845,0.00041688836,0.0013914587,0.0004635701,0.000080278434,0.0006387351,0.000012053426,0.00005925753,0.022349276],"genre_scores_gemma":[0.9492801,0.00020606031,0.03161063,0.00018047502,0.00012884669,0.000038814767,0.000064332206,0.00003079357,0.018459935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987266,0.000042723925,0.00032915839,0.00036150022,0.00026902035,0.0002709988],"domain_scores_gemma":[0.99936664,0.000022419697,0.00011356496,0.00031974842,0.00010233095,0.000075282056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024787872,0.00021875899,0.0003929557,0.000118458585,0.00006735184,0.000015118656,0.00010599292,0.000054594162,0.000044351593],"category_scores_gemma":[0.000014284279,0.00017906068,0.00009606733,0.00031942612,0.000051709994,0.00011938048,0.000018480927,0.00008307152,0.00003961313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006897809,0.0014628222,0.036133863,0.00004899175,0.0004519441,0.000031403324,0.00945102,0.0000016998474,0.94464904,0.002449856,0.0026611206,0.0019684383],"study_design_scores_gemma":[0.005470967,0.00013236063,0.025724022,0.000118112024,0.00005789055,0.000012245639,0.0004257895,0.00015210698,0.9618413,0.00007255159,0.0055788066,0.0004138369],"about_ca_topic_score_codex":0.000027275644,"about_ca_topic_score_gemma":0.000047861904,"teacher_disagreement_score":0.030219173,"about_ca_system_score_codex":0.000057346315,"about_ca_system_score_gemma":0.000104356295,"threshold_uncertainty_score":0.7301882},"labels":[],"label_agreement":null},{"id":"W2052119440","doi":"10.1097/00002030-200001280-00021","title":"HIV drug-resistance testing on archived samples to help current clinical decisions","year":2000,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regimen; Medicine; Drug resistance; Zidovudine; Ritonavir; Abacavir; HIV drug resistance; Viral load; Intensive care medicine; Internal medicine; Immunology; Human immunodeficiency virus (HIV); Viral disease; Biology; Antiretroviral therapy; Genetics","score_opus":0.10852042892389716,"score_gpt":0.3609991252660553,"score_spread":0.25247869634215814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052119440","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017002294,0.0012224186,0.00043357137,0.9479536,0.0014286331,0.0019168804,0.0003210545,0.0003690491,0.029352525],"genre_scores_gemma":[0.0019708974,0.0007077511,0.097028725,0.42618608,0.009451137,0.0003887372,0.0029687418,0.00025894583,0.46103898],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964953,0.00018822623,0.0009124301,0.0009633917,0.0007839559,0.0006566725],"domain_scores_gemma":[0.9955746,0.00298397,0.00015658358,0.0008509082,0.00010000403,0.00033393883],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031363766,0.00055603567,0.0009954557,0.0004062737,0.00017098497,0.000045951674,0.00030373037,0.00027409385,0.00029604748],"category_scores_gemma":[0.0010944095,0.00043357522,0.00036479862,0.0003029475,0.0000941175,0.00002814151,0.00010158574,0.0017290011,0.0031721015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012675332,0.00023222553,0.014222807,0.00004876793,0.0001576952,0.00055280305,0.00015126815,7.2355334e-7,0.0000023720136,0.000013126048,0.8551858,0.12930563],"study_design_scores_gemma":[0.0012065765,0.0001268892,0.008183318,0.0026239243,0.00025247424,0.0000113812985,0.000011083401,0.0000026450987,0.000021877519,0.00026554518,0.9868815,0.00041277907],"about_ca_topic_score_codex":0.0000042094653,"about_ca_topic_score_gemma":0.000015318137,"teacher_disagreement_score":0.5217675,"about_ca_system_score_codex":0.00016641962,"about_ca_system_score_gemma":0.00033398505,"threshold_uncertainty_score":0.9998116},"labels":[],"label_agreement":null},{"id":"W2052146571","doi":"10.1016/j.bmcl.2013.03.074","title":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: Structure–activity relationships (SAR) of the C3-phenyl moiety","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Chemistry; Moiety; Diazepine; Stereochemistry; Capsid; Structure–activity relationship; Human immunodeficiency virus (HIV); Series (stratigraphy); Enzyme inhibitor; Enzyme; In vitro; Ring (chemistry); Biochemistry; Organic chemistry; Virology","score_opus":0.00965030125485551,"score_gpt":0.20088903390944504,"score_spread":0.19123873265458954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052146571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847886,0.00013735889,0.00046369963,0.01364808,0.00012313764,0.00050233776,0.000036856116,0.00003316562,0.00026676932],"genre_scores_gemma":[0.99632025,0.000028581831,0.002587341,0.00010233291,0.00016317102,0.000010969598,0.000095076946,0.000033421682,0.00065885193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799025,0.00007596084,0.0006852983,0.00031581701,0.0006710885,0.00026157702],"domain_scores_gemma":[0.9984094,0.00010168343,0.00059411465,0.0005224772,0.00023140703,0.00014090353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020864441,0.00029866787,0.00058561575,0.000070568734,0.000092897586,0.000006488476,0.00019447495,0.00019362409,0.000607961],"category_scores_gemma":[0.00028981417,0.00021161391,0.00016736423,0.0005373202,0.0003622006,0.00015588937,0.00007957375,0.00035070692,0.000003874238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007844165,0.00015117123,0.030946301,0.00047807803,0.00023505323,0.0000046026853,0.000824085,0.00015453306,0.9634112,0.0000054304696,0.003562534,0.00014857824],"study_design_scores_gemma":[0.0014955008,0.000037604666,0.030757137,0.000464593,0.00032578217,0.000069317684,0.00045407863,0.0002991195,0.96580577,0.000015072731,0.00010560061,0.00017044219],"about_ca_topic_score_codex":0.00008337128,"about_ca_topic_score_gemma":0.000004435251,"teacher_disagreement_score":0.013545747,"about_ca_system_score_codex":0.00018228707,"about_ca_system_score_gemma":0.0002473923,"threshold_uncertainty_score":0.86293644},"labels":[],"label_agreement":null},{"id":"W2052640466","doi":"10.1002/chin.200014083","title":"ChemInform Abstract: Azodicarboxamides: A New Class of Cysteine Proteinase Inhibitor for Hepatitis A Virus and Human Rhinovirus 3C Enzymes.","year":2000,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Rhinovirus; Enzyme; Class (philosophy); Cysteine; Virology; Cysteine Proteinase Inhibitors; Hepatitis C virus; Virus; Biochemistry; Artificial intelligence; Computer science","score_opus":0.013686859410980547,"score_gpt":0.2544720161408908,"score_spread":0.24078515672991027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052640466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5435149,0.0005942957,4.3305448e-7,0.0007852398,0.000045033263,0.0023040897,0.00008943325,0.00013396097,0.4525326],"genre_scores_gemma":[0.74409467,0.00019216898,0.0004931366,0.00018407534,0.00023033605,0.00029167192,0.00032420922,0.00004380525,0.25414592],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820644,9.6417956e-8,0.0007307569,0.00029828152,0.00034955295,0.00041489265],"domain_scores_gemma":[0.998911,0.000053744814,0.0002095241,0.000350176,0.00010242783,0.00037310284],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000151651,0.0003484896,0.0005892338,0.00013070782,0.00010392233,0.000032081032,0.00010900619,0.00020318989,0.0015365084],"category_scores_gemma":[0.000066982735,0.0002968126,0.00016119034,0.00017622144,0.0001378404,0.00022433957,0.000041006275,0.00015796673,0.000045436733],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000851228,0.0005018461,0.001230376,0.0013306197,0.0004147174,0.00007125076,0.003909637,6.478343e-8,0.025504347,0.00077098433,0.08004121,0.8853737],"study_design_scores_gemma":[0.00555128,0.00037651305,0.001613677,0.00036712774,0.00016184863,0.00005321588,0.000092987866,0.0000066591288,0.7343918,0.000074866475,0.25700474,0.00030530637],"about_ca_topic_score_codex":0.00041234406,"about_ca_topic_score_gemma":0.0001474704,"teacher_disagreement_score":0.8850684,"about_ca_system_score_codex":0.00017928141,"about_ca_system_score_gemma":0.00031851843,"threshold_uncertainty_score":0.9999484},"labels":[],"label_agreement":null},{"id":"W2052962870","doi":"10.1016/j.tet.2010.08.037","title":"Rapid, mild method for phosphonate diester hydrolysis: development of a one-pot synthesis of tenofovir disoproxil fumarate from tenofovir diethyl ester","year":2010,"lang":"en","type":"article","venue":"Tetrahedron","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Chemistry; Phosphonate; Tenofovir; Hydrolysis; Alkylation; Prodrug; Organic chemistry; Combinatorial chemistry; Human immunodeficiency virus (HIV); Biochemistry; Catalysis; Virology","score_opus":0.023643339579581864,"score_gpt":0.28089309603030477,"score_spread":0.2572497564507229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052962870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99044955,0.0007605058,0.0031033189,0.0015385044,0.0003317022,0.0016201806,0.000153998,0.000111236724,0.0019309983],"genre_scores_gemma":[0.7499621,0.0000805493,0.2448931,0.000107340136,0.00007984753,0.0004852043,0.00013587705,0.00008360943,0.0041723857],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99693847,0.00007192801,0.0011298773,0.00069131365,0.0006012473,0.0005671462],"domain_scores_gemma":[0.9978085,0.0005859481,0.0004315687,0.000723489,0.00021332038,0.000237135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007306256,0.0005078842,0.0012454126,0.00030326733,0.00013315339,0.000020015907,0.00027783948,0.00027818937,0.00043738922],"category_scores_gemma":[0.00020145011,0.00039703227,0.0003588218,0.00030006078,0.00015713158,0.00014820894,0.00011629536,0.0002934472,0.00006324686],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002730028,0.0034589563,0.028952131,0.0011043284,0.0047675595,0.00003126294,0.010548378,0.0000046757064,0.41861293,0.0001160839,0.0011529743,0.5285207],"study_design_scores_gemma":[0.004312011,0.00028777693,0.06996474,0.0005440135,0.001293311,0.000006533644,0.00038050144,0.00042114028,0.9067659,0.0003870372,0.01505087,0.0005862174],"about_ca_topic_score_codex":0.000108482905,"about_ca_topic_score_gemma":0.00023537726,"teacher_disagreement_score":0.5279345,"about_ca_system_score_codex":0.000105934254,"about_ca_system_score_gemma":0.0003059855,"threshold_uncertainty_score":0.9998481},"labels":[],"label_agreement":null},{"id":"W2052991207","doi":"10.1056/nejmoa012354","title":"Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of Toronto; University Health Network","funders":"","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Nelfinavir; Medicine; Virology; Protease inhibitor (pharmacology); Human immunodeficiency virus (HIV); Pharmacology; Viral load; Antiretroviral therapy","score_opus":0.08347689925760145,"score_gpt":0.34030159437203783,"score_spread":0.2568246951144364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052991207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8009954,0.0146566415,0.004024142,0.16646373,0.0050993534,0.0016655719,0.000018241304,0.000046127494,0.0070307897],"genre_scores_gemma":[0.97933847,0.0056181164,0.00096173363,0.00016152288,0.006236184,0.000013697369,0.000020729143,0.000024879815,0.007624684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986967,0.000042709606,0.00055761926,0.00011133062,0.00039090068,0.00020073612],"domain_scores_gemma":[0.9984675,0.0006082374,0.0003128919,0.00016375602,0.00020049965,0.00024709024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003102544,0.00018374207,0.0005298631,0.00016976144,0.00008028023,0.0000052703313,0.00006534622,0.00006309317,0.00036651798],"category_scores_gemma":[0.0003053399,0.000091318085,0.00017041854,0.00017099213,0.000104390616,0.000067555375,0.00000745333,0.00012531062,0.00001044972],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007567605,0.0009514604,0.017018035,0.00007403263,0.0014381977,0.00027952678,0.005946808,0.00003501836,0.0005159377,0.00024265474,0.057531286,0.90839946],"study_design_scores_gemma":[0.19977917,0.01230287,0.0076271305,0.00045135623,0.0018450862,0.00091925403,0.00025766456,0.00025127505,0.0020654358,0.00014279335,0.7742292,0.00012872445],"about_ca_topic_score_codex":0.000056895085,"about_ca_topic_score_gemma":0.000025949228,"teacher_disagreement_score":0.9082707,"about_ca_system_score_codex":0.00016760343,"about_ca_system_score_gemma":0.00014447152,"threshold_uncertainty_score":0.4013115},"labels":[],"label_agreement":null},{"id":"W2053270776","doi":"10.1097/qad.0b013e32834e87e6","title":"Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection","year":2011,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Etravirine; Medicine; Cost effectiveness; Regimen; Viral load; Quality-adjusted life year; Incremental cost-effectiveness ratio; Darunavir; Cohort; Demography; Internal medicine; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.03787113214884931,"score_gpt":0.2878189129143684,"score_spread":0.2499477807655191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053270776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958754,0.0000335575,0.00029070117,0.000024771638,0.000022430144,0.0012143082,0.0000018551691,0.000033837663,0.0025031476],"genre_scores_gemma":[0.99786544,0.00010316371,0.0009129697,0.00000857441,0.00000600154,0.00043375648,0.000068914145,0.000015910295,0.00058525254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993259,0.00006093393,0.00013621665,0.00019433562,0.00014654678,0.00013606851],"domain_scores_gemma":[0.9996185,0.00003924628,0.000059345202,0.00014845844,0.000085728396,0.000048759906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095777934,0.00015132541,0.000260194,0.00017453794,0.00002521799,0.000003206446,0.00002399894,0.00004391925,0.00006840063],"category_scores_gemma":[0.000005618686,0.00009050868,0.000027508288,0.0003543297,0.00006403153,0.00010797456,0.0000047051444,0.00004685201,0.000010118752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048543857,0.0019158749,0.96736616,0.000036652957,0.00014055356,0.000038735474,0.005964262,0.0000016967325,0.0005886373,0.00023758937,0.0000018450577,0.018853635],"study_design_scores_gemma":[0.017071672,0.006613946,0.8538848,0.00029941162,0.000041290303,0.000019315192,0.00028996903,0.000016779677,0.12152407,0.000017708035,0.000118946584,0.00010204548],"about_ca_topic_score_codex":0.00039819302,"about_ca_topic_score_gemma":0.000085122854,"teacher_disagreement_score":0.12093543,"about_ca_system_score_codex":0.00015564174,"about_ca_system_score_gemma":0.0000734566,"threshold_uncertainty_score":0.36908367},"labels":[],"label_agreement":null},{"id":"W2053792903","doi":"10.1038/nsmb.1540","title":"Nucleic acid polymerases use a general acid for nucleotidyl transfer","year":2009,"lang":"en","type":"article","venue":"Nature Structural & Molecular Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Institutes of Health","keywords":"Chemistry; Polymerase; Pyrophosphate; Deprotonation; Nucleic acid; Active site; DNA polymerase; Protonation; Stereochemistry; Biochemistry; DNA polymerase beta; Leaving group; Enzyme; DNA; Catalysis; Base excision repair; DNA repair; Organic chemistry","score_opus":0.007258418535612243,"score_gpt":0.30032796231614606,"score_spread":0.2930695437805338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053792903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848839,0.0028140212,0.0009722714,0.009779221,0.00032897678,0.0008185961,0.00010199473,0.00012447014,0.00017654442],"genre_scores_gemma":[0.9797192,0.000030285208,0.012010524,0.0062515284,0.00021254075,0.000024382129,0.000768592,0.00003520711,0.0009476986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99842495,0.000055984172,0.00028732204,0.0005388365,0.00015083047,0.00054210087],"domain_scores_gemma":[0.99933195,0.000021053975,0.0000401869,0.0003069239,0.00011037827,0.00018953545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000045855668,0.0003814608,0.0004954824,0.00016150337,0.00012621483,0.0000286914,0.00014404712,0.00057412154,0.00013399287],"category_scores_gemma":[0.000073364834,0.00027434205,0.00031382887,0.00019352834,0.00009026194,0.000075252356,0.000018882163,0.00041588343,0.000011830766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054231024,0.000046252913,0.0014427173,0.000015903594,0.00029497527,0.0001467577,0.00012556418,7.7796636e-7,0.9649449,0.015700748,0.0010960446,0.015643029],"study_design_scores_gemma":[0.005320414,0.0009891815,0.021916943,0.0000392091,0.00038500107,0.00037450116,0.000021266389,0.00010453978,0.94993407,0.0030275139,0.017330738,0.00055664964],"about_ca_topic_score_codex":0.00000581429,"about_ca_topic_score_gemma":0.0000055860705,"teacher_disagreement_score":0.020474225,"about_ca_system_score_codex":0.000073123425,"about_ca_system_score_gemma":0.00008443575,"threshold_uncertainty_score":0.99997085},"labels":[],"label_agreement":null},{"id":"W2053970957","doi":"10.1186/1742-4690-11-s1-p133","title":"Naturally occurring protease inhibitor resistance mutations and their frequencies in HIV proviral sequences of drug-naïve sex workers in Nairobi, Kenya","year":2014,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Nelfinavir; Drug resistance; Indinavir; Medicine; Lopinavir; Virology; Protease inhibitor (pharmacology); Kenya; Resistance mutation; Protease; Human immunodeficiency virus (HIV); Viral load; Biology; Genetics; Antiretroviral therapy; Polymerase chain reaction; Gene; Reverse transcriptase","score_opus":0.006907654294545668,"score_gpt":0.22828556483082982,"score_spread":0.22137791053628414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053970957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953947,0.000640429,0.000027410124,0.002104764,0.00004751013,0.0006062231,0.000009303479,0.000030670824,0.0011389942],"genre_scores_gemma":[0.99466425,0.000016494425,0.002384156,0.00011205061,0.000036214373,0.00009826649,0.000025562877,0.000013822151,0.002649195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868107,0.00015251683,0.0003964928,0.0003356406,0.0001289905,0.0003052656],"domain_scores_gemma":[0.99941415,0.000168618,0.0001287726,0.00017540532,0.000038590424,0.00007447881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033619333,0.00019191748,0.0004255609,0.0003086586,0.000045212364,0.000008789191,0.00008053922,0.00012164693,0.000009312659],"category_scores_gemma":[0.00018749997,0.00014753573,0.00004367118,0.00026759788,0.00028060577,0.00010302206,0.00003979149,0.0002762313,0.0000037861191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022260266,0.000112195004,0.98335665,0.00016133995,0.00003282941,0.00006695037,0.0050887596,0.000023571612,0.009417876,0.0004354705,0.00012816113,0.0009535853],"study_design_scores_gemma":[0.01379412,0.00087249535,0.91201264,0.0019933074,0.00013281549,0.000118986056,0.014011758,0.0012244233,0.047823224,0.003800281,0.0031921787,0.0010237816],"about_ca_topic_score_codex":0.00013594644,"about_ca_topic_score_gemma":0.001188765,"teacher_disagreement_score":0.07134403,"about_ca_system_score_codex":0.00017372427,"about_ca_system_score_gemma":0.00018522951,"threshold_uncertainty_score":0.60163325},"labels":[],"label_agreement":null},{"id":"W2054015555","doi":"10.1097/qai.0b013e318189a753","title":"The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes","year":2008,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"National Institute of Mental Health","keywords":"Drug; Drug resistance; Drug-naïve; Medicine; Pharmacology; Immunology; Biology; Genetics","score_opus":0.06327083541841826,"score_gpt":0.3008636213031623,"score_spread":0.23759278588474403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054015555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797747,0.013434119,0.00002772877,0.0055456134,0.00020000238,0.00040817057,0.000021054613,0.00002796189,0.0005606131],"genre_scores_gemma":[0.99084353,0.0012410154,0.0035520853,0.00008899844,0.00006627313,0.000019781637,0.000011851351,0.00003351016,0.0041429684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965472,0.00022676343,0.001402824,0.00031831747,0.0009855719,0.00051928463],"domain_scores_gemma":[0.99641377,0.0022110587,0.00062007183,0.00033174944,0.00022990066,0.00019345469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001961755,0.00029971753,0.0007091994,0.00075792335,0.0006566483,0.000105496474,0.00038312195,0.000089788904,0.000022641212],"category_scores_gemma":[0.0011182732,0.0002141351,0.0001527789,0.0013928703,0.00028982427,0.0004263692,0.00013789335,0.00030659267,0.00007260609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074556374,0.00010748245,0.9763923,0.000037377926,0.00011355226,0.00026828327,0.014202124,0.0000016534719,0.000053124506,0.00020033347,0.0071331672,0.0014160404],"study_design_scores_gemma":[0.0017256425,0.00018642489,0.9882191,0.00084952055,0.00010256242,0.00048582786,0.004133119,0.0000010559964,0.0005799533,0.00062148547,0.002868489,0.00022686402],"about_ca_topic_score_codex":0.000010236069,"about_ca_topic_score_gemma":0.00000987922,"teacher_disagreement_score":0.012193103,"about_ca_system_score_codex":0.00016956992,"about_ca_system_score_gemma":0.00036720675,"threshold_uncertainty_score":0.8732176},"labels":[],"label_agreement":null},{"id":"W2054311444","doi":"10.1097/qai.0b013e318061b5fd","title":"Methadone Dosing Strategies in HIV-Infected Injection Drug Users Enrolled in a Directly Observed Therapy Program","year":2007,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; University of British Columbia","funders":"","keywords":"Methadone; Efavirenz; Lopinavir; Medicine; Ritonavir; Atazanavir; Nevirapine; Dosing; Lopinavir/ritonavir; Pharmacology; Pharmacokinetics; Drug; Reverse-transcriptase inhibitor; Directly Observed Therapy; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology","score_opus":0.02708812786653825,"score_gpt":0.2983546219393285,"score_spread":0.27126649407279024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054311444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910042,0.0062287785,0.0001461959,0.0005560308,0.0004153564,0.000918917,0.0000010119351,0.00012824667,0.0006012123],"genre_scores_gemma":[0.9924868,0.0009946884,0.0055881143,0.00002213951,0.000037624355,0.000029541625,0.000016027208,0.00005435734,0.0007707095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962277,0.00024348997,0.0017360885,0.00033136172,0.0007273255,0.00073407],"domain_scores_gemma":[0.9983232,0.00035358584,0.00063414953,0.00028463348,0.00026090632,0.00014354088],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031258096,0.00040403308,0.0011314208,0.0022076599,0.00011201313,0.00010563115,0.00023328855,0.00016655924,0.00004267688],"category_scores_gemma":[0.00026976806,0.00031092294,0.0003413815,0.002972451,0.00012793585,0.00070646225,0.00004117874,0.000317528,0.000017540435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056544673,0.007527208,0.7820681,0.00021049005,0.0008364615,0.0043504992,0.019255316,0.00047098892,0.09548657,0.00013423731,0.00021721673,0.08378845],"study_design_scores_gemma":[0.015779454,0.0016914651,0.95188844,0.0011182674,0.0001275152,0.0012959188,0.009159372,0.00020164312,0.017821297,0.00020197924,0.00025994994,0.0004546661],"about_ca_topic_score_codex":0.00015391599,"about_ca_topic_score_gemma":0.00010533442,"teacher_disagreement_score":0.16982037,"about_ca_system_score_codex":0.00053156196,"about_ca_system_score_gemma":0.00048449117,"threshold_uncertainty_score":0.9999343},"labels":[],"label_agreement":null},{"id":"W2054614641","doi":"10.1111/j.1468-1293.2008.00660.x","title":"Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)<sup>*</sup>","year":2009,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"GlaxoSmithKline","keywords":"Medicine; Lopinavir/ritonavir; Ritonavir; Lopinavir; Adverse effect; Pharmacokinetics; Population; Lamivudine; Dosing; Zidovudine; CCR5 receptor antagonist; Internal medicine; Gastroenterology; Nausea; Pharmacology; Viral load; Virology; Virus; Viral disease; Antiretroviral therapy; Hepatitis B virus; Receptor; Chemokine receptor","score_opus":0.010325760430882605,"score_gpt":0.2569921573094452,"score_spread":0.2466663968785626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054614641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914405,0.00014143417,0.000015711043,0.00494552,0.000029626199,0.0019703363,0.000026174017,0.000019286414,0.0014114189],"genre_scores_gemma":[0.99878514,0.00023157737,0.00007455652,0.00009561441,0.000027765347,0.000023766805,0.000113712704,0.000016838829,0.0006310576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779683,0.00023919059,0.00068828126,0.00039700698,0.0006093524,0.00026933424],"domain_scores_gemma":[0.99893296,0.00017487844,0.00030044833,0.00039319106,0.00012829661,0.0000702313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005145408,0.00029629545,0.0007874947,0.00031615733,0.000059497794,0.0000042030474,0.00011297971,0.000091670874,0.000011759021],"category_scores_gemma":[0.00013723849,0.0001726394,0.000043024596,0.0007845705,0.0002469401,0.00013699131,0.00003755444,0.0002980316,0.0000018391089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006318154,0.0060948175,0.95387566,0.00006114833,0.00009184212,0.000057034413,0.009794345,0.000009339872,0.0005583975,0.00007116659,0.00021827868,0.022849843],"study_design_scores_gemma":[0.05296109,0.003409932,0.939273,0.001008054,0.000085442436,0.000008234846,0.0010580858,0.00018283511,0.0015159404,0.00004675994,0.0003045459,0.00014609464],"about_ca_topic_score_codex":0.00024529494,"about_ca_topic_score_gemma":0.00016468397,"teacher_disagreement_score":0.046642937,"about_ca_system_score_codex":0.0001630375,"about_ca_system_score_gemma":0.0001138597,"threshold_uncertainty_score":0.70400304},"labels":[],"label_agreement":null},{"id":"W2055698455","doi":"10.1016/j.antiviral.2006.02.008","title":"Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment","year":2006,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Quest Diagnostics; University of Washington","keywords":"Protease inhibitor (pharmacology); Protease; Virology; HIV-1 protease; Human immunodeficiency virus (HIV); Term (time); Medicine; Biology; Enzyme; Viral load; Antiretroviral therapy; Biochemistry","score_opus":0.025661647620190287,"score_gpt":0.32368918038969136,"score_spread":0.29802753276950106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055698455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928543,0.00024682627,0.000027804945,0.00064053177,0.000029339935,0.0041309963,0.00010511425,0.00006684118,0.0018982195],"genre_scores_gemma":[0.97310394,0.00006040677,0.00061656506,0.0000053842764,0.00012553533,0.0007080472,0.00040387112,0.000050420815,0.02492581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674934,0.00037071353,0.0004802108,0.0005627393,0.0011260872,0.0007109175],"domain_scores_gemma":[0.998198,0.00036878246,0.00019503769,0.00038250117,0.0006967283,0.00015900683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006027121,0.00033183637,0.0004767,0.0004405467,0.00033644104,0.00006151772,0.0001273315,0.00014823722,0.000051535342],"category_scores_gemma":[0.0003453037,0.00023572033,0.00012343153,0.0007797765,0.0004625952,0.00026696955,0.00009339566,0.0003707047,0.00014842875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013951435,0.00321451,0.95352376,0.00042668727,0.00026772518,0.0009765174,0.0008219309,0.0000028926586,0.036931258,0.000026128244,0.00065641996,0.0017570081],"study_design_scores_gemma":[0.0074198702,0.002033079,0.56748056,0.0031552776,0.0003089752,0.000052942396,0.00021066146,0.00021661958,0.41870797,0.000058378508,0.000035446035,0.00032019717],"about_ca_topic_score_codex":0.00046173885,"about_ca_topic_score_gemma":0.0000694648,"teacher_disagreement_score":0.3860432,"about_ca_system_score_codex":0.00053888,"about_ca_system_score_gemma":0.00092643965,"threshold_uncertainty_score":0.9612396},"labels":[],"label_agreement":null},{"id":"W2055807403","doi":"10.1007/s11908-011-0229-1","title":"Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs","year":2011,"lang":"en","type":"article","venue":"Current Infectious Disease Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Raltegravir; Drug; Medicine; Abacavir; Pharmacology; Reverse transcriptase; Drug interaction; Integrase inhibitor; Protease inhibitor (pharmacology); Dolutegravir; Antiretroviral drug; Reverse-transcriptase inhibitor; Integrase; Efavirenz; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load; Biology","score_opus":0.02712275422645458,"score_gpt":0.30514812432570915,"score_spread":0.27802537009925454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055807403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923691,0.00027431233,0.00003835044,0.0009884816,0.0011696145,0.0011404303,0.0000855742,0.00032267303,0.0036114356],"genre_scores_gemma":[0.99254483,0.00043953126,0.00005622898,0.00012893016,0.00038990736,0.00015954804,0.00093610754,0.00007763206,0.0052672722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970052,0.00012389288,0.00091003935,0.000932962,0.0004535887,0.0005742896],"domain_scores_gemma":[0.99750715,0.000110760644,0.00050706166,0.00071914546,0.000109646295,0.0010462264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025874755,0.0005810575,0.0006311361,0.0008376742,0.00026530802,0.00008321273,0.00007444085,0.000049102036,0.0005096208],"category_scores_gemma":[0.000107838765,0.0004982074,0.00027595475,0.00047319342,0.00007041813,0.00044125403,0.00006348762,0.00070172787,0.0001897908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003239514,0.0029481673,0.96524066,0.00005171743,0.00028986682,0.00088635593,0.0035503083,0.0000026131283,0.000023838309,0.000034112996,0.017408377,0.009240026],"study_design_scores_gemma":[0.0041046506,0.00028246955,0.9458239,0.0010691748,0.0007136253,0.00021375848,0.0004403729,0.00015614105,0.0007316953,0.0003012914,0.045311376,0.00085152395],"about_ca_topic_score_codex":0.0002656865,"about_ca_topic_score_gemma":0.00017745531,"teacher_disagreement_score":0.027902998,"about_ca_system_score_codex":0.0006046865,"about_ca_system_score_gemma":0.0005373148,"threshold_uncertainty_score":0.999747},"labels":[],"label_agreement":null},{"id":"W2056290188","doi":"10.1185/030079904125004051","title":"Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine","year":2004,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Abacavir; Regimen; Lamivudine; Internal medicine; Zidovudine; Indinavir; Randomized controlled trial; Population; Viral load; Dosing; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus","score_opus":0.08232951022776082,"score_gpt":0.39161202277814156,"score_spread":0.30928251255038075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056290188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971337,0.00043363162,0.00009584814,0.0011020057,0.000084161125,0.0010081709,0.000020946445,0.00003273372,0.000088828456],"genre_scores_gemma":[0.9982585,0.0007905158,0.00008888892,0.000018998015,0.000030010382,0.000101695165,0.0006090854,0.0000131672805,0.00008918971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745464,0.00015060291,0.000472768,0.00037565138,0.0011252344,0.0004210731],"domain_scores_gemma":[0.9987523,0.00034486727,0.00009997711,0.00013458211,0.00023896116,0.00042930426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080227474,0.00019668201,0.0004683369,0.0004473997,0.000097522265,0.000016930024,0.00008242379,0.00014667449,0.00006357454],"category_scores_gemma":[0.0013524978,0.000121278295,0.000026517859,0.0006415091,0.00039682077,0.000097419834,0.00007163616,0.0004958618,0.000006390405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016624597,0.0016749926,0.9829713,0.00022611715,0.000037123726,0.0000392718,0.0002273269,4.375122e-7,0.000024302193,0.000121041136,0.00012781737,0.0128878],"study_design_scores_gemma":[0.030194513,0.0069826017,0.95909053,0.0019083839,0.00002384143,0.0000072617154,0.00011962838,0.00035449042,0.0004187964,0.00006423064,0.00068995595,0.00014576348],"about_ca_topic_score_codex":0.00007031244,"about_ca_topic_score_gemma":0.000035199275,"teacher_disagreement_score":0.028532052,"about_ca_system_score_codex":0.00017668183,"about_ca_system_score_gemma":0.0004176081,"threshold_uncertainty_score":0.4945585},"labels":[],"label_agreement":null},{"id":"W2056461111","doi":"10.1097/01.aids.0000216372.53819.db","title":"Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector)","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Enfuvirtide; Medicine; Internal medicine; Nuclear medicine; Surgery; Immunology","score_opus":0.01972393306703938,"score_gpt":0.2475350858153075,"score_spread":0.22781115274826813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056461111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914521,0.0001309007,0.0009901301,0.00018114438,0.00039443877,0.00043337842,0.000025073316,0.00026231943,0.006130543],"genre_scores_gemma":[0.987365,0.000007792393,0.004396542,0.000023832803,0.00028873485,0.00003112339,0.00006891403,0.000036359594,0.0077817193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866885,0.000058608297,0.00038173958,0.00034529448,0.00026064948,0.00028485272],"domain_scores_gemma":[0.9992987,0.000060433562,0.00012709745,0.00031387637,0.00009461922,0.000105287734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018591466,0.0002333126,0.00030680763,0.0003884031,0.00026253692,0.0000513711,0.000042334857,0.00013462856,0.000036367965],"category_scores_gemma":[0.0000527582,0.00021193772,0.000083484825,0.0004783498,0.000048140904,0.00021714334,0.00004680869,0.00015981964,0.00006269935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076183584,0.000786795,0.811215,0.00069665024,0.00085788046,0.00029449852,0.0025962703,0.0004943824,0.16315,0.0032996538,0.0067746155,0.009072416],"study_design_scores_gemma":[0.041982774,0.004796887,0.6591566,0.0044529005,0.004922743,0.019768817,0.012956103,0.03504179,0.15958299,0.0015220487,0.052243967,0.0035723753],"about_ca_topic_score_codex":0.001953656,"about_ca_topic_score_gemma":0.0001629848,"teacher_disagreement_score":0.1520584,"about_ca_system_score_codex":0.0005494243,"about_ca_system_score_gemma":0.00010430336,"threshold_uncertainty_score":0.8642569},"labels":[],"label_agreement":null},{"id":"W2056867349","doi":"10.1517/14712598.2.7.751","title":"HIV-1 drug resistance: can we overcome?","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Drug resistance; Drug; Nucleoside Reverse Transcriptase Inhibitor; Virology; Protease; Protease inhibitor (pharmacology); Biology; HIV drug resistance; Medicine; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Viral load; Pharmacology; Genetics; Enzyme; RNA; Gene","score_opus":0.15405837618061594,"score_gpt":0.3821740819905895,"score_spread":0.22811570580997356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056867349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033041254,0.9824016,0.0000032548583,0.010058779,0.0006826554,0.0014035526,0.000052822626,0.0002142055,0.0051797894],"genre_scores_gemma":[0.0000030346282,0.9573358,0.0005592253,0.0010380716,0.0008363316,0.00050413935,0.0010076578,0.00006680726,0.038648926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715924,0.00033027894,0.0007129713,0.00089683983,0.00038678496,0.00051389966],"domain_scores_gemma":[0.9984788,0.00031301234,0.00024582903,0.00063867756,0.000043092492,0.00028062332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00017994281,0.0008304553,0.002254195,0.00021435824,0.00015399078,0.000032151183,0.00029412785,0.0005847736,0.0024215349],"category_scores_gemma":[0.00003857373,0.00043806675,0.0008343321,0.00035927826,0.00012754988,0.000021756689,0.00004986967,0.00052490656,0.0010357121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012264188,0.0005526861,0.000012931252,0.00015074578,0.00032111612,0.000054892233,0.00024058246,6.4983476e-9,8.377569e-7,0.00038679002,0.17103323,0.8271235],"study_design_scores_gemma":[0.0012996865,0.0001561474,0.000006255992,0.00700847,0.000004438394,0.000023038992,0.000026386018,2.1671013e-7,0.000007997826,0.000066844535,0.99089795,0.0005025862],"about_ca_topic_score_codex":0.0000015968379,"about_ca_topic_score_gemma":6.8372464e-7,"teacher_disagreement_score":0.82662094,"about_ca_system_score_codex":0.00038438253,"about_ca_system_score_gemma":0.00012991915,"threshold_uncertainty_score":0.9998071},"labels":[],"label_agreement":null},{"id":"W2056893015","doi":"10.7448/ias.17.4.19738","title":"HIV‐1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV‐1 group M","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Integrase; Raltegravir; Virology; Integrases; Integrase inhibitor; Biology; Virus; Genetics; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.014171828281632244,"score_gpt":0.2542602712392589,"score_spread":0.24008844295762663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056893015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94295895,0.00008089762,0.02351919,0.031746123,0.00080153195,0.0004634492,0.00009869648,0.00001437435,0.00031679415],"genre_scores_gemma":[0.9680332,0.000019729072,0.017218048,0.0009990217,0.00050876127,0.0000315683,0.00004958017,0.000021730666,0.013118346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821925,0.00006136098,0.00054273155,0.00025171132,0.0007206249,0.00020431528],"domain_scores_gemma":[0.9985904,0.0003592492,0.0003137333,0.00018796504,0.00035045546,0.00019820342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007313953,0.00022148114,0.00034881334,0.00006442229,0.00018840391,0.00008511717,0.000290698,0.000073647505,0.000062197134],"category_scores_gemma":[0.0003276239,0.000127281,0.0005900891,0.00010058341,0.00012534953,0.00014000773,0.00010546732,0.00027061906,0.000005743849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006371599,0.0042975717,0.6720537,0.00036325867,0.004546419,0.000051572762,0.00829432,0.000059695438,0.028217774,0.03507786,0.23271708,0.007949163],"study_design_scores_gemma":[0.018446568,0.0017649145,0.6553304,0.0018865773,0.0008717647,0.0003454414,0.0021502934,0.002817135,0.0067479243,0.023545485,0.2852626,0.0008308776],"about_ca_topic_score_codex":0.000004288229,"about_ca_topic_score_gemma":0.000068299196,"teacher_disagreement_score":0.05254553,"about_ca_system_score_codex":0.00045982376,"about_ca_system_score_gemma":0.00009903619,"threshold_uncertainty_score":0.5190368},"labels":[],"label_agreement":null},{"id":"W2057925552","doi":"10.1128/jvi.06591-11","title":"Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir","year":2011,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Merck; Jewish General Hospital; Canadian Foundation for AIDS Research; Gilead Sciences","keywords":"Integrase; Dolutegravir; Biology; Integrase inhibitor; Mutagenesis; Mutation; DNA; Raltegravir; Virology; Viral replication; Reverse transcriptase; Genetics; Molecular biology; Virus; Gene; Viral load; Polymerase chain reaction","score_opus":0.03907600993030807,"score_gpt":0.24492764659075109,"score_spread":0.205851636660443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057925552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894151,0.000044280783,0.0036017217,0.0059700753,0.00033720452,0.00040139194,0.00003837719,0.0000035221758,0.00018832287],"genre_scores_gemma":[0.997609,0.00003922843,0.00045427305,0.0005445627,0.00011082324,0.000013617615,0.000037341928,0.000012525514,0.0011786344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987743,0.0001808277,0.0005538286,0.00012670488,0.00021793015,0.0001464388],"domain_scores_gemma":[0.99937135,0.00004333726,0.00020446199,0.00015299475,0.00015646635,0.000071363575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044528325,0.00014114045,0.0003070479,0.00020307177,0.000048152957,0.000008952673,0.00012044957,0.00010343328,0.0002237673],"category_scores_gemma":[0.000053784715,0.00007483653,0.000111804926,0.00019029308,0.00008077644,0.00012988453,0.000010339332,0.00028204915,0.0000066513967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033420636,0.0006679144,0.020304931,0.00007287245,0.00033186664,0.00014649205,0.020166807,0.000010211076,0.94936866,0.00070975575,0.0014040496,0.0034743608],"study_design_scores_gemma":[0.005332456,0.00059949356,0.32827112,0.0003588601,0.00027499834,0.00017052247,0.0014041746,0.00006657435,0.6607102,0.00022138446,0.002428749,0.00016146482],"about_ca_topic_score_codex":0.0000067823994,"about_ca_topic_score_gemma":0.0011424617,"teacher_disagreement_score":0.30796617,"about_ca_system_score_codex":0.00009452479,"about_ca_system_score_gemma":0.00017541711,"threshold_uncertainty_score":0.30517453},"labels":[],"label_agreement":null},{"id":"W2057957357","doi":"10.1128/aac.48.8.2993-2998.2004","title":"Nucleotide and Amino Acid Polymorphisms at Drug Resistance Sites in Non-B-Subtype Variants of Human Immunodeficiency Virus Type 1","year":2004,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research; American Physicians Fellowship for Medicine in Israel; amfAR, The Foundation for AIDS Research","keywords":"Biology; Virology; Reverse transcriptase; Genetics; Genotype; Virus; Mutation; Drug resistance; Amino acid substitution; Amino acid; Nucleotide; Silent mutation; Gene; Polymerase chain reaction; Missense mutation","score_opus":0.010443262658583427,"score_gpt":0.2461105614376177,"score_spread":0.23566729877903428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057957357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644697,0.00032139412,0.000004311411,0.0020781453,0.000043809705,0.0002592634,0.000009523916,0.000015781781,0.00082081807],"genre_scores_gemma":[0.98985463,0.0015089958,0.00068620645,0.0009707114,0.000018052058,0.0000022458507,0.00003779486,0.000025763633,0.0068955915],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990752,0.000011583467,0.00027501438,0.0002889227,0.00011614188,0.00023314581],"domain_scores_gemma":[0.99962693,0.000008173471,0.00009596538,0.00017277568,0.000034801727,0.000061328814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082809296,0.00019172742,0.00033426838,0.00010539117,0.00011503247,0.000016278304,0.00006522363,0.000063656924,0.00013853938],"category_scores_gemma":[0.000004226507,0.0001626835,0.00004089495,0.00018734709,0.000118140444,0.00006294028,0.000040654297,0.000074571915,0.000016481485],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004981752,0.0006132405,0.121624045,0.000085884625,0.00010669679,0.00007727978,0.003708889,4.3566035e-7,0.8690213,0.000079761936,0.0035624276,0.0006218949],"study_design_scores_gemma":[0.007424003,0.00011909848,0.61162823,0.0003729597,0.00005423678,0.00002482616,0.0000637591,0.0000038432713,0.3777462,0.00012741715,0.0021592248,0.0002761673],"about_ca_topic_score_codex":0.000145369,"about_ca_topic_score_gemma":0.00019629746,"teacher_disagreement_score":0.49127507,"about_ca_system_score_codex":0.00007078576,"about_ca_system_score_gemma":0.000040039064,"threshold_uncertainty_score":0.66340405},"labels":[],"label_agreement":null},{"id":"W2058163419","doi":"10.1074/jbc.m110.105775","title":"N348I in HIV-1 Reverse Transcriptase Can Counteract the Nevirapine-mediated Bias toward RNase H Cleavage during Plus-strand Initiation","year":2010,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"RNase H; Nevirapine; Reverse transcriptase; Efavirenz; Polymerase; Biology; Primer (cosmetics); DNA polymerase; Mutant; Molecular biology; DNA; Virology; Chemistry; Biochemistry; RNA; Human immunodeficiency virus (HIV); Gene","score_opus":0.03905481006227305,"score_gpt":0.26609950271982685,"score_spread":0.2270446926575538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058163419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922747,0.00015470787,0.0000066120915,0.0066452543,0.00011673511,0.00013973482,0.0000416688,0.0000141780765,0.0006063946],"genre_scores_gemma":[0.9983654,0.00033638458,0.00020761529,0.00032200402,0.00027113198,0.000005575827,0.00008980866,0.000009063888,0.00039302072],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987559,0.000043501033,0.00057894416,0.00015601641,0.0002388311,0.00022683037],"domain_scores_gemma":[0.99921083,0.0001272268,0.00025483893,0.00013407264,0.00008621764,0.000186834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004090345,0.0001821357,0.00036603527,0.000051273437,0.000056235338,0.000022350356,0.00013538178,0.0001937074,0.00040659466],"category_scores_gemma":[0.00041029748,0.00009902147,0.00016523995,0.00015761073,0.00009963498,0.0000737656,0.00001599766,0.0008396589,0.000011444438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014700711,0.00040009458,0.07334201,0.00011296833,0.00012551551,0.0019103704,0.00096132595,0.000004048437,0.91968197,0.000002204577,0.001677368,0.00031204868],"study_design_scores_gemma":[0.016916603,0.00027782487,0.19210565,0.00053914543,0.00022750898,0.002248542,0.0017634969,0.00008461453,0.76962084,0.000049801707,0.015718324,0.0004476672],"about_ca_topic_score_codex":0.000005917239,"about_ca_topic_score_gemma":0.000006730518,"teacher_disagreement_score":0.15006116,"about_ca_system_score_codex":0.00012742185,"about_ca_system_score_gemma":0.00017405969,"threshold_uncertainty_score":0.44519264},"labels":[],"label_agreement":null},{"id":"W2058454024","doi":"10.1128/aac.00118-06","title":"Absorption, Metabolism, and Excretion of [ <sup>14</sup> C]Viramidine in Humans","year":2006,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International","keywords":"Excretion; Metabolism; Absorption (acoustics); Radiochemistry; Chemistry; Biochemistry; Physics","score_opus":0.008440938334208023,"score_gpt":0.23563206051002714,"score_spread":0.2271911221758191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058454024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959082,0.00015204113,0.000036514833,0.0029481126,0.000021237676,0.00026701743,0.00000874085,0.000018593912,0.0006395229],"genre_scores_gemma":[0.9924068,0.0017292901,0.00064359023,0.0008277979,0.00007491574,0.000005111522,0.00008968862,0.000019245103,0.0042035864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992329,0.000015843465,0.00026776982,0.0002195178,0.000100437515,0.00016352512],"domain_scores_gemma":[0.99975115,0.000008506861,0.00006370829,0.0000993962,0.000037497044,0.00003973525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009025117,0.00015291716,0.00030085442,0.00012299247,0.000044708486,0.000015229096,0.000028995835,0.00007381517,0.0001369694],"category_scores_gemma":[0.0000023834855,0.00012618421,0.000043882177,0.00012406457,0.00007809531,0.0000644557,0.000013773069,0.00006125825,0.0000053093854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007232203,0.0018906756,0.8535502,0.00032914284,0.000330768,0.00005706743,0.004009454,0.000028112698,0.07122094,0.0010923467,0.049700737,0.017067313],"study_design_scores_gemma":[0.009273202,0.00008223538,0.896855,0.00019315405,0.00010428419,0.000025476324,0.00009814856,0.00019376804,0.029107083,0.00024122541,0.06356157,0.00026488036],"about_ca_topic_score_codex":0.00012411567,"about_ca_topic_score_gemma":0.000022973478,"teacher_disagreement_score":0.043304745,"about_ca_system_score_codex":0.00001884311,"about_ca_system_score_gemma":0.000015573596,"threshold_uncertainty_score":0.5145643},"labels":[],"label_agreement":null},{"id":"W2058752290","doi":"10.1158/1538-7445.am10-3165","title":"Abstract 3165: Anti-tumor activity of the eIF4E-targeted drug ribavirin in breast cancer cells","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Jewish General Hospital","funders":"","keywords":"Cancer research; EIF4E; Oncogene; Breast cancer; Cancer; Medicine; Ribavirin; Internal medicine; Biology; Immunology; Cell cycle; Translation (biology); Messenger RNA; Biochemistry","score_opus":0.030994318691018253,"score_gpt":0.3675388529047714,"score_spread":0.33654453421375313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058752290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734814,0.00021698515,2.0609927e-7,0.00967889,0.0003372726,0.0007291303,0.00011608574,0.000017257382,0.0015560561],"genre_scores_gemma":[0.99132484,0.00025618848,0.000030174839,0.00005071958,0.00015502253,0.00021774339,0.000004228891,0.000028041126,0.007933064],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99798167,0.00009720172,0.00023674977,0.00034756132,0.0007883584,0.000548491],"domain_scores_gemma":[0.9988956,0.00012659252,0.00007579761,0.00047900726,0.00025671866,0.0001662808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007583501,0.00016280073,0.00032612684,0.0002170268,0.000121164005,0.000019409867,0.00027192675,0.00007674205,0.001872918],"category_scores_gemma":[0.00003996108,0.000105014784,0.000091651505,0.0007315911,0.00029583296,0.00009281955,0.00013386674,0.0010854434,0.00006031524],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002242961,0.0003987877,0.25552806,0.00014009172,0.000067036366,0.00005279801,0.00053392694,0.0000065373024,0.72831523,0.000015639785,0.009562774,0.0051548346],"study_design_scores_gemma":[0.00093956495,0.0000065020354,0.56176186,0.00016809348,0.000011356382,0.0000042656898,0.000057598703,0.000016131356,0.43378904,0.000013575281,0.0031590136,0.000073003604],"about_ca_topic_score_codex":0.005821275,"about_ca_topic_score_gemma":0.004804508,"teacher_disagreement_score":0.3062338,"about_ca_system_score_codex":0.0003382652,"about_ca_system_score_gemma":0.0013604357,"threshold_uncertainty_score":0.99903953},"labels":[],"label_agreement":null},{"id":"W2059157689","doi":"10.1371/journal.pone.0086919","title":"Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; University of British Columbia; HIV Legal Network","funders":"Canadian Institutes of Health Research; Karolinska Institutet; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Efavirenz; CYP2B6; Pharmacokinetics; NONMEM; Genotype; Pharmacology; Population; Pharmacogenetics; Medicine; Biology; Internal medicine; Virology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genetics; CYP3A4; Cytochrome P450","score_opus":0.06498660881589974,"score_gpt":0.2847850319854382,"score_spread":0.21979842316953846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059157689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911834,0.00020341945,0.00075458566,0.00838891,0.000017110298,0.0011715929,0.00001294735,0.00005998618,0.0002730962],"genre_scores_gemma":[0.99423003,0.000059344187,0.0036212986,0.00019396572,0.00012450079,0.00042887568,0.00033936472,0.000017502236,0.000985088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992551,0.00006632747,0.00016164665,0.00019269063,0.00019270308,0.00013148214],"domain_scores_gemma":[0.9994126,0.00014441997,0.000057053454,0.00020693998,0.00007492189,0.00010406918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014065685,0.00011825139,0.000208584,0.000058672627,0.00016628086,0.000022494272,0.00004699469,0.000032891225,0.000027741346],"category_scores_gemma":[0.00006054112,0.00007400907,0.000036746245,0.000068871515,0.000055192224,0.00002943279,0.000009764621,0.000049083723,0.000009376768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010941497,0.030016057,0.6106759,0.0010857374,0.0038204314,0.0000055409755,0.006784971,0.00022822342,0.121291004,0.0161533,0.0018970631,0.19710033],"study_design_scores_gemma":[0.03067803,0.00084001437,0.7403684,0.00022209693,0.0029853117,0.0000036019476,0.00009683227,0.14008306,0.0800268,0.0019529853,0.0022440383,0.000498823],"about_ca_topic_score_codex":0.000015264446,"about_ca_topic_score_gemma":0.000019229166,"teacher_disagreement_score":0.1966015,"about_ca_system_score_codex":0.000035033143,"about_ca_system_score_gemma":0.000020742202,"threshold_uncertainty_score":0.30180022},"labels":[],"label_agreement":null},{"id":"W2059227925","doi":"10.1071/ch08177","title":"Antiviral Agents. I. Synthesis and Antiviral Evaluation of Trimeric Naphthoquinone Analogues of Conocurvone","year":2008,"lang":"en","type":"article","venue":"Australian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lethbridge College; University of Lethbridge","funders":"","keywords":"Chemistry; Naphthoquinone; Green chemistry; Natural product; Proteaceae; Biocatalysis; Combinatorial chemistry; Stereochemistry; Organic chemistry; Supramolecular chemistry; Reaction mechanism; Catalysis; Molecule; Biology","score_opus":0.06315395085546,"score_gpt":0.3139363872120888,"score_spread":0.2507824363566288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059227925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749076,0.0003892924,0.000007685348,0.0003891805,0.000033108507,0.000098860786,0.000012071486,0.0000037957143,0.0015752587],"genre_scores_gemma":[0.9966866,0.0003081052,0.0010373229,0.0000054010343,0.00006339323,0.0000019689376,0.000012694936,0.000010835638,0.0018737133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984681,0.000057193913,0.00064327347,0.00012511069,0.0005534282,0.00015291969],"domain_scores_gemma":[0.9987103,0.00006216119,0.0006099655,0.00013334831,0.00038495692,0.00009931225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054494315,0.0001529437,0.0005765716,0.00009905192,0.000030253657,0.0000037584227,0.000073471696,0.00008495897,0.00015654534],"category_scores_gemma":[0.00018133038,0.00012626631,0.00015558694,0.00018053103,0.0002417309,0.00011368809,0.000014979511,0.00013127056,0.000002145485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005381728,0.00074319774,0.28276822,0.00041609208,0.0013098546,0.00034547658,0.0008327599,0.0000039314405,0.6954618,0.0000017910359,0.0042310543,0.013347656],"study_design_scores_gemma":[0.002378762,0.00011554583,0.08797982,0.00035685865,0.00074266206,0.00054473523,0.00027234852,0.0000101756705,0.9073671,0.00001960987,0.00011501864,0.000097331074],"about_ca_topic_score_codex":0.0000046280197,"about_ca_topic_score_gemma":1.9523112e-7,"teacher_disagreement_score":0.21190533,"about_ca_system_score_codex":0.00005098297,"about_ca_system_score_gemma":0.0002902292,"threshold_uncertainty_score":0.5148991},"labels":[],"label_agreement":null},{"id":"W2059600432","doi":"10.1093/nar/gkr694","title":"Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase","year":2011,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; University of Missouri; National Institute of General Medical Sciences; amfAR, The Foundation for AIDS Research","keywords":"Biology; Virology; Reverse transcriptase; Murine leukemia virus; Virus; RNA; Genetics; Gene","score_opus":0.07953630040213854,"score_gpt":0.33505766907566253,"score_spread":0.255521368673524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059600432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016553,0.0040951255,0.0000042555716,0.0010480001,0.00006078608,0.0006143494,0.00003567679,0.00006130643,0.003914956],"genre_scores_gemma":[0.9831979,0.0036294437,0.0025813724,0.000050218467,0.000053166023,0.00006153468,0.000040488914,0.000039082886,0.010346785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773735,0.0001455813,0.00050420937,0.0004604407,0.00069308525,0.00045936447],"domain_scores_gemma":[0.9988151,0.0000875993,0.0000750377,0.00037655473,0.00041603306,0.00022967096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006015198,0.00022157165,0.00046659578,0.0003615157,0.00018896008,0.000011569401,0.00009253591,0.00017294477,0.0002635719],"category_scores_gemma":[0.00026898194,0.0001812101,0.000087010296,0.0006331645,0.0008361158,0.00013257083,0.000114512644,0.00046180125,0.00008656137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021295794,0.0007502635,0.0042133797,0.0008754592,0.00060012564,0.00050276285,0.011679916,6.1904274e-8,0.9141795,0.0009792726,0.062381282,0.0017083853],"study_design_scores_gemma":[0.0056503536,0.0005868737,0.0075165783,0.0012267948,0.00017079318,0.000027811706,0.002438972,0.00001217917,0.9666652,0.0013763653,0.01404612,0.0002819621],"about_ca_topic_score_codex":0.000100083664,"about_ca_topic_score_gemma":0.000052145246,"teacher_disagreement_score":0.052485686,"about_ca_system_score_codex":0.00038065872,"about_ca_system_score_gemma":0.00020113196,"threshold_uncertainty_score":0.7389533},"labels":[],"label_agreement":null},{"id":"W2059692709","doi":"10.1128/aac.01192-10","title":"Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes","year":2010,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Etravirine; Virology; Biology; Reverse transcriptase; Efavirenz; Mutagenesis; Virus; Phenotype; Genotype; Mutation; Viral replication; Gene; Genetics; Viral load; Polymerase chain reaction; Antiretroviral therapy","score_opus":0.007032365309337579,"score_gpt":0.2343713665226056,"score_spread":0.22733900121326803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059692709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906004,0.000002831801,0.00003341663,0.00870384,0.00005755919,0.0004891126,0.000026475169,0.000005676995,0.000080702586],"genre_scores_gemma":[0.99667495,0.00010432932,0.00040309707,0.0011206054,0.000017690889,0.0000058449787,0.000053807114,0.000010822987,0.0016088736],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99936074,0.000017687224,0.00022334988,0.00020460534,0.000072625575,0.0001210203],"domain_scores_gemma":[0.9997448,0.000008173395,0.000050689297,0.00012555302,0.000028013,0.000042772004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012774265,0.00010930828,0.0001941962,0.00007744812,0.0000327166,0.000011262875,0.0000391257,0.000057150428,0.00005167161],"category_scores_gemma":[0.000008770128,0.00008318603,0.000025606969,0.00015748094,0.00005580972,0.00005983943,0.0000103964785,0.000103172555,0.0000021208236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024542373,0.0001497718,0.46971172,0.00006781615,0.000011259101,0.000007249718,0.0027375207,2.495798e-7,0.525916,0.000009006504,0.00031835423,0.00082568504],"study_design_scores_gemma":[0.0025701248,0.000017642653,0.8754694,0.0001606623,0.000010136399,0.000003847259,0.000061461746,0.000024923445,0.11837266,0.0000070907904,0.0032225486,0.000079524085],"about_ca_topic_score_codex":0.000052365343,"about_ca_topic_score_gemma":0.0008056613,"teacher_disagreement_score":0.4075433,"about_ca_system_score_codex":0.000020467354,"about_ca_system_score_gemma":0.000031190782,"threshold_uncertainty_score":0.3392228},"labels":[],"label_agreement":null},{"id":"W2059780880","doi":"10.1097/01.qai.0000243105.80393.42","title":"Performance of Immunologic Responses in Predicting Viral Load Suppression","year":2006,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Viral load; Logistic regression; Medicine; Predictive value; Internal medicine; Predictive value of tests; Immunology; Antiretroviral therapy; Sida; Positive predicative value; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.01249596940770653,"score_gpt":0.25336742172947585,"score_spread":0.24087145232176932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059780880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917157,0.006558831,0.0000083957975,0.00034630002,0.0003295332,0.00020845044,0.0000039721463,0.000032675667,0.00079608866],"genre_scores_gemma":[0.9945766,0.0005541064,0.0013351517,0.0000064102014,0.000031525018,0.000006016765,0.000006199335,0.000023662338,0.0034603272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971429,0.00012512816,0.0014158228,0.00019202344,0.0007191157,0.0004049801],"domain_scores_gemma":[0.99847865,0.0002181626,0.0007006922,0.00027478562,0.00027912314,0.00004857754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012970996,0.00023514131,0.0007601326,0.0008071622,0.00009813565,0.000016793992,0.00024623214,0.0001256,0.000055658453],"category_scores_gemma":[0.0003667169,0.00016845965,0.0002309679,0.0007162652,0.00016921783,0.0003544614,0.000081157144,0.00016287388,0.000021057034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002198016,0.0010552527,0.8409849,0.00019203726,0.00011655684,0.0005741036,0.0011759403,0.0001864124,0.14949648,0.00002802235,0.0002423342,0.003749964],"study_design_scores_gemma":[0.0039600194,0.0017968267,0.9412446,0.0014552628,0.00013231437,0.0016645121,0.0007841395,0.0004437516,0.04811304,0.00006282126,0.00015534823,0.00018735917],"about_ca_topic_score_codex":0.00003756017,"about_ca_topic_score_gemma":0.0000015337943,"teacher_disagreement_score":0.10138344,"about_ca_system_score_codex":0.00026535508,"about_ca_system_score_gemma":0.00040267673,"threshold_uncertainty_score":0.6869585},"labels":[],"label_agreement":null},{"id":"W2060087439","doi":"10.1089/dna.2004.23.783","title":"AZT Binds RNA at Multiple Sites","year":2004,"lang":"en","type":"article","venue":"DNA and Cell Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Biology; RNA; Genetics; Computational biology; Virology; Gene","score_opus":0.01179613686846839,"score_gpt":0.23389105509169097,"score_spread":0.22209491822322258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060087439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865405,0.00085813703,0.000011138364,0.0015034876,0.000069538815,0.00011558045,0.0000059960767,0.000033009386,0.010862622],"genre_scores_gemma":[0.98457706,0.0002534759,0.00050657074,0.0002668271,0.00005481759,0.00001032303,0.00017627006,0.000007062452,0.014147601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994979,0.000010620919,0.000100132274,0.00018275411,0.000032267944,0.00017634437],"domain_scores_gemma":[0.99975425,0.00003007544,0.000023075174,0.00009236121,0.000013344651,0.00008689795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003544088,0.00009969142,0.00016181864,0.000048900063,0.00006663443,0.0000030652884,0.000023818367,0.00008691123,0.00013882702],"category_scores_gemma":[0.000009098828,0.0000691649,0.000034432942,0.00005035403,0.00006234061,0.000011437427,0.000035755602,0.000046356647,0.0002757223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012527475,0.00024692516,0.399766,0.00003291489,0.00008121086,0.00008962512,0.000787226,5.8676494e-7,0.591408,0.0002815252,0.0015007613,0.005679962],"study_design_scores_gemma":[0.007516045,0.00045833338,0.03104148,0.000024062407,0.00009982244,0.000049542155,0.0001492491,0.000014413751,0.75278455,0.00046925413,0.20715295,0.00024027585],"about_ca_topic_score_codex":0.000015221492,"about_ca_topic_score_gemma":0.000042096126,"teacher_disagreement_score":0.36872452,"about_ca_system_score_codex":0.00004073569,"about_ca_system_score_gemma":0.000026214266,"threshold_uncertainty_score":0.35439444},"labels":[],"label_agreement":null},{"id":"W2060458916","doi":"10.3851/imp2742","title":"A Systematic Review of the Use of Atazanavir in Women Infected with HIV-1","year":2013,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Gilead Sciences","keywords":"Atazanavir; Medicine; Ritonavir; Discontinuation; Tolerability; Regimen; Systematic review; Human immunodeficiency virus (HIV); MEDLINE; Clinical trial; Adverse effect; Family medicine; Antiretroviral therapy; Intensive care medicine; Viral load; Internal medicine","score_opus":0.053926122615212825,"score_gpt":0.3084194161421629,"score_spread":0.25449329352695005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060458916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013718844,0.99233055,0.0000011605117,0.00008752034,0.000023248338,0.006031757,0.000022100192,0.00001348806,0.00011826607],"genre_scores_gemma":[0.00007597536,0.9950813,0.00011765412,0.00011912756,0.000009742036,0.0007212031,0.000053732037,0.000043023687,0.0037782618],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99775696,0.00041066765,0.0010491429,0.00022712725,0.00033194487,0.0002241659],"domain_scores_gemma":[0.9981279,0.00019191948,0.00084860594,0.00069568655,0.00009898436,0.000036953483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002830403,0.0003830378,0.0036548807,0.00016567479,0.00001618634,0.000008136554,0.000184519,0.00011199636,0.00006106776],"category_scores_gemma":[0.00007543166,0.00016022037,0.00036538942,0.0008104467,0.00008493723,0.00008091364,0.000036956382,0.0002019332,0.000044510427],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002151335,0.00026233797,0.00052482006,0.9364487,0.0011484517,0.000013969771,0.00021373936,8.32103e-9,0.0000012528745,0.000014917196,0.0004982128,0.06085211],"study_design_scores_gemma":[0.0006951253,0.00011829488,0.000100420584,0.8531123,0.00076074334,0.000017173716,0.00000852255,3.5305513e-7,0.00000965391,0.0000013655269,0.14502792,0.00014814801],"about_ca_topic_score_codex":0.000018989762,"about_ca_topic_score_gemma":0.0000027672636,"teacher_disagreement_score":0.14452972,"about_ca_system_score_codex":0.00011681666,"about_ca_system_score_gemma":0.00032743756,"threshold_uncertainty_score":0.6533597},"labels":[],"label_agreement":null},{"id":"W2061769309","doi":"10.1097/qad.0b013e32833cf265","title":"HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays","year":2010,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Integrase; Elvitegravir; Raltegravir; Integrase inhibitor; Dolutegravir; Virology; Biology; Drug resistance; Genetics; Enzyme; Mutation; Gene; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Biochemistry","score_opus":0.00650397997286881,"score_gpt":0.2414046497349354,"score_spread":0.23490066976206658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061769309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973797,0.000113090675,0.00012253181,0.001303431,0.00013664784,0.00026654798,0.000030516818,0.000027337519,0.00062014686],"genre_scores_gemma":[0.9943472,0.000022131711,0.0015549408,0.00007182286,0.0000767171,0.000030391178,0.00007502931,0.000020072941,0.0038016657],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989005,0.000025635929,0.0003263225,0.0003074036,0.00021160246,0.00022854176],"domain_scores_gemma":[0.99935424,0.00008204102,0.00005537979,0.00025017138,0.0000569103,0.00020123283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013166126,0.00019512161,0.0003450094,0.00024497008,0.000022095204,0.000012649226,0.00007502069,0.00012253638,0.00017710615],"category_scores_gemma":[0.00020377674,0.00014880426,0.00006211304,0.00021144177,0.00006699078,0.000045075612,0.00007281995,0.0002967166,0.000027997798],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003469407,0.00041250838,0.86490154,0.00009076477,0.00007981161,0.00008963932,0.00093974924,2.5902764e-8,0.124213904,0.0010629813,0.00513912,0.0027230303],"study_design_scores_gemma":[0.0029861648,0.00019927087,0.13540488,0.00059481885,0.0001323107,0.000015194179,0.0005395323,0.000008302074,0.85546774,0.00012283058,0.0042410404,0.0002879122],"about_ca_topic_score_codex":0.00006755931,"about_ca_topic_score_gemma":0.000309854,"teacher_disagreement_score":0.73125386,"about_ca_system_score_codex":0.000044922144,"about_ca_system_score_gemma":0.000065190834,"threshold_uncertainty_score":0.60680616},"labels":[],"label_agreement":null},{"id":"W2062233777","doi":"10.2147/hiv.s32377","title":"Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir","year":2013,"lang":"en","type":"article","venue":"HIV/AIDS - Research and Palliative Care","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Rilpivirine; Emtricitabine; Tenofovir; Medicine; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load","score_opus":0.05175853997717449,"score_gpt":0.3487375114825807,"score_spread":0.2969789715054062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062233777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963989,0.0012317228,0.000047686757,0.00010463333,0.000013874921,0.0013782998,0.000044488137,0.000009138329,0.00077123387],"genre_scores_gemma":[0.99806285,0.0005962429,0.00070829503,0.000006357188,0.000010209636,0.00010564313,0.000100953934,0.000011737686,0.00039772037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982403,0.00039386377,0.0003357173,0.0003523789,0.00043173472,0.00024600446],"domain_scores_gemma":[0.99772936,0.00072049716,0.000106349056,0.00015987725,0.0011410136,0.00014292964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049465493,0.00016459935,0.00047538223,0.00025172264,0.000081648905,0.000022209992,0.00004076214,0.00009646599,0.00004099151],"category_scores_gemma":[0.00032977562,0.00011543561,0.000027679424,0.0005112784,0.0005297255,0.00016398083,0.0000815137,0.0002498827,0.0000028835664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007699935,0.0008416438,0.9819704,0.00069717556,0.00011743056,0.0000032794342,0.0014770704,5.1965113e-8,0.00010221813,0.0001345042,0.00014729345,0.013738933],"study_design_scores_gemma":[0.0076156133,0.0039246194,0.98599267,0.00055427046,0.000027055003,4.629735e-7,0.0006960525,0.000033050397,0.00063050975,0.00030470963,0.00012041576,0.00010059763],"about_ca_topic_score_codex":0.00019131872,"about_ca_topic_score_gemma":0.00007001324,"teacher_disagreement_score":0.013638335,"about_ca_system_score_codex":0.00006983174,"about_ca_system_score_gemma":0.00014872452,"threshold_uncertainty_score":0.47073275},"labels":[],"label_agreement":null},{"id":"W2062514953","doi":"10.1128/aac.01835-13","title":"Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Elvitegravir; Integrase; Dolutegravir; Raltegravir; Integrase inhibitor; Biology; DNA; Virology; Genetics; Chemistry; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.00547975468341358,"score_gpt":0.2256827680605884,"score_spread":0.22020301337717482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062514953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935819,0.00011280517,0.000014539552,0.005288615,0.000020706157,0.00031429218,0.000026119786,0.000008032533,0.0006329726],"genre_scores_gemma":[0.99388725,0.00040609066,0.00090679683,0.00050526496,0.000010820649,0.000009990771,0.00005712377,0.000009114082,0.004207579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992032,0.000022346465,0.00031576952,0.00019062082,0.000117877426,0.00015019519],"domain_scores_gemma":[0.9995349,0.000020832784,0.00010511653,0.00022433886,0.00006511197,0.00004968527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000063879816,0.00013400437,0.0003685503,0.00016363601,0.000040122926,0.000008504108,0.0000970903,0.00006020948,0.00019875393],"category_scores_gemma":[0.000008713159,0.00008532195,0.00016515277,0.00064886204,0.00017484235,0.000037846352,0.000023618859,0.00008922869,0.0000053208882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017936561,0.0011486624,0.7785718,0.00006708303,0.0017308715,0.0000042840775,0.0028731532,0.0000031245822,0.18121314,0.00048425532,0.031988032,0.0017362573],"study_design_scores_gemma":[0.0033056445,0.000013432597,0.69903994,0.00032294763,0.00079263083,0.0000029393273,0.00037514832,0.00022849427,0.27835816,0.00020850862,0.01714006,0.00021211397],"about_ca_topic_score_codex":0.0002135236,"about_ca_topic_score_gemma":0.00012730727,"teacher_disagreement_score":0.09714502,"about_ca_system_score_codex":0.00003413393,"about_ca_system_score_gemma":0.00004890077,"threshold_uncertainty_score":0.34793282},"labels":[],"label_agreement":null},{"id":"W2062515126","doi":"10.1097/00002030-200005050-00006","title":"Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy","year":2000,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Nevirapine; Regimen; Medicine; Viral load; Internal medicine; Protease; Protease inhibitor (pharmacology); Randomization; Gastroenterology; Triglyceride; Human immunodeficiency virus (HIV); Immunology; Randomized controlled trial; Virology; Cholesterol; Antiretroviral therapy; Biology; Enzyme","score_opus":0.020952653011840836,"score_gpt":0.2711883243056001,"score_spread":0.25023567129375923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062515126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966395,0.0013058358,0.000012726824,0.0005677145,0.000033517877,0.00089486694,0.000007648107,0.00004397054,0.0004942273],"genre_scores_gemma":[0.9953834,0.00079609995,0.00012209742,0.00007517129,0.000022362128,0.00005627392,0.00018068336,0.000020940619,0.0033429826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894345,0.00006340508,0.00032659815,0.0002600696,0.00021270389,0.00019376981],"domain_scores_gemma":[0.9995573,0.00004569922,0.000082872684,0.00017535419,0.00005234528,0.00008639936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018905771,0.00017212777,0.00031120863,0.00019793696,0.000047184454,0.000014874585,0.000037594913,0.00008842408,0.00024314219],"category_scores_gemma":[0.000025921769,0.00014243378,0.000041197327,0.00040196604,0.000046349305,0.00014058879,0.000012702519,0.00011404595,0.000012098291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037637723,0.00062688574,0.94221985,0.000053100583,0.000073483105,0.000015044741,0.00048795264,0.000005445544,0.0016198645,0.00004402982,0.00026487838,0.054213077],"study_design_scores_gemma":[0.0124102915,0.0005745187,0.9029663,0.0003405127,0.000051640953,0.000014053388,0.00003765966,0.00004117303,0.083144456,0.000055392687,0.00018562426,0.00017837869],"about_ca_topic_score_codex":0.0001353004,"about_ca_topic_score_gemma":0.000022732915,"teacher_disagreement_score":0.08152459,"about_ca_system_score_codex":0.000071986,"about_ca_system_score_gemma":0.00005569568,"threshold_uncertainty_score":0.58082813},"labels":[],"label_agreement":null},{"id":"W2062589870","doi":"10.1517/17425250902942302","title":"Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Drug Metabolism & Toxicology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Adverse effect; Medicine; Intensive care medicine; Concomitant; Regimen; Drug resistance; Drug; Disease; Antiretroviral therapy; Population; Pharmacology; Human immunodeficiency virus (HIV); Immunology; Internal medicine; Viral load; Biology; Environmental health","score_opus":0.023407324063850637,"score_gpt":0.3440731979562234,"score_spread":0.3206658738923727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062589870","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064956513,0.98956317,0.000010657827,0.0065926127,0.00095787796,0.0020141446,0.000046348312,0.000054591208,0.00011102286],"genre_scores_gemma":[0.00183374,0.9922441,0.0017563124,0.00058531354,0.0005303168,0.00016123809,0.00048522165,0.00005032679,0.002353411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663603,0.000926048,0.0009025838,0.00082677184,0.00031850662,0.0003900463],"domain_scores_gemma":[0.9984014,0.00019643958,0.0007590015,0.00040989625,0.00009427891,0.00013896909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005680903,0.000590092,0.0023921938,0.00041477807,0.00020043903,0.000029045907,0.000099855155,0.00017244961,0.000009725514],"category_scores_gemma":[0.000074301526,0.000423718,0.00018951602,0.00031592124,0.00016677135,0.00010202516,0.000046238718,0.00048808166,0.00000790351],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023482283,0.00045975533,0.000020757168,0.0022802223,0.00042915036,0.000009803598,0.002221159,5.475149e-8,0.000023002445,0.002323686,0.004844093,0.9871535],"study_design_scores_gemma":[0.0014516924,0.00013522693,0.001071183,0.004004009,0.00023603148,0.000051381223,0.000060402228,0.000006698213,0.00013034575,0.00013695135,0.9923731,0.00034299772],"about_ca_topic_score_codex":0.000017004651,"about_ca_topic_score_gemma":0.000019062743,"teacher_disagreement_score":0.987529,"about_ca_system_score_codex":0.00015301385,"about_ca_system_score_gemma":0.00041647782,"threshold_uncertainty_score":0.9998215},"labels":[],"label_agreement":null},{"id":"W2062808593","doi":"10.1097/qai.0b013e318160a529","title":"Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51)","year":2008,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); University of Toronto","funders":"","keywords":"Ritonavir; Amprenavir; Medicine; Lopinavir; Saquinavir; Regimen; Viral load; Pharmacokinetics; Pharmacology; Concomitant; Internal medicine; Randomization; Combination therapy; Gastroenterology; Clinical trial; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Protease; Chemistry; HIV-1 protease","score_opus":0.018704203568662134,"score_gpt":0.2755719956910863,"score_spread":0.25686779212242417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062808593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625385,0.00062488014,0.000011334532,0.00019283472,0.00009291907,0.0027379873,0.000009658565,0.000020867263,0.000055645465],"genre_scores_gemma":[0.9981027,0.00068220304,0.0006690431,0.0000116294095,0.000007655545,0.000054390617,0.00003909654,0.00004826188,0.00038500948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650466,0.00030668193,0.0015972186,0.0003294287,0.00092906784,0.00033295737],"domain_scores_gemma":[0.99789435,0.00019273064,0.0011011622,0.00025330565,0.00044938215,0.000109052635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050024764,0.00039806974,0.0012775,0.0010649073,0.00010040436,0.000015526883,0.00015350331,0.00008822711,0.000028139155],"category_scores_gemma":[0.00012907627,0.0002469468,0.00010155704,0.0013758391,0.0003403146,0.00039931692,0.00003145677,0.00012158791,0.000001559017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039810758,0.028459797,0.89800316,0.00007874298,0.0006230246,0.00075478596,0.017565306,0.000121042576,0.0053148577,0.0000077998175,0.0000108244885,0.009249883],"study_design_scores_gemma":[0.1574723,0.05735595,0.75024796,0.0010687134,0.00027093853,0.00034780422,0.0030628154,0.0001269593,0.029662197,0.0000047034846,0.000032323886,0.00034734624],"about_ca_topic_score_codex":0.00024441365,"about_ca_topic_score_gemma":0.000010977735,"teacher_disagreement_score":0.14775524,"about_ca_system_score_codex":0.0002544002,"about_ca_system_score_gemma":0.00036712704,"threshold_uncertainty_score":0.9999983},"labels":[],"label_agreement":null},{"id":"W2062889937","doi":"10.2165/00003088-200544020-00001","title":"Interactions Between Antiretrovirals and Antineoplastic Drug Therapy","year":2005,"lang":"en","type":"review","venue":"Clinical Pharmacokinetics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; St. Michael's Hospital","funders":"","keywords":"Pharmacology; Drug interaction; Medicine; CYP2B6; Taxane; Docetaxel; Efavirenz; Drug; Ifosfamide; Pharmacokinetics; Reverse-transcriptase inhibitor; Abacavir; CYP3A4; Oncology; Cancer; Chemotherapy; Internal medicine; Cytochrome P450; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV); Viral load; Breast cancer","score_opus":0.19453442601007181,"score_gpt":0.5078662005472501,"score_spread":0.31333177453717825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062889937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008366479,0.99461496,0.000016742595,0.000872164,0.00074125105,0.0011849711,0.00008281133,0.00012210819,0.0015283258],"genre_scores_gemma":[0.00048447176,0.9745906,0.00096979184,0.00027553434,0.0027124423,0.000047089896,0.00039662348,0.00010408958,0.020419382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967001,0.00025140654,0.0016974421,0.0006777577,0.00028488092,0.0003883945],"domain_scores_gemma":[0.99675167,0.0018643343,0.00047021284,0.00037101534,0.00008736177,0.00045542122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043829085,0.0006200488,0.0027166642,0.00025167808,0.00009058394,0.000046271947,0.00017621205,0.00025258012,0.0005141514],"category_scores_gemma":[0.00018604886,0.00044201312,0.0007085437,0.00030819597,0.00021173616,0.00006107961,0.00013268844,0.001149409,0.00053338526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022428325,0.00035740001,0.0036433432,0.0013714731,0.0010644279,0.00006561529,0.000024080164,2.9384848e-8,2.2627378e-7,0.000003851531,0.026936349,0.9665108],"study_design_scores_gemma":[0.0021544367,0.00011444957,0.00071023713,0.003845155,0.004371929,0.00006246118,0.0000034391244,0.000009315803,0.0000028253173,0.000004886502,0.9883417,0.00037919835],"about_ca_topic_score_codex":9.762679e-7,"about_ca_topic_score_gemma":5.632354e-7,"teacher_disagreement_score":0.96613157,"about_ca_system_score_codex":0.00006646384,"about_ca_system_score_gemma":0.00028158783,"threshold_uncertainty_score":0.9998032},"labels":[],"label_agreement":null},{"id":"W2063250935","doi":"10.1097/qad.0000000000000404","title":"Selective acquisition of G190S in HIV-1 subtype A from Russia leading to efavirenz and nevirapine treatment failure","year":2014,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Nevirapine; Efavirenz; Human immunodeficiency virus (HIV); Virology; Medicine; Reverse-transcriptase inhibitor; Sida; Viral disease; Antiretroviral therapy; Viral load","score_opus":0.01336163153373931,"score_gpt":0.2547310700070815,"score_spread":0.2413694384733422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063250935","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45789042,0.0009957362,0.00021068552,0.53585595,0.0001878672,0.002032742,0.00018864204,0.00010551263,0.0025324093],"genre_scores_gemma":[0.8442456,0.00025644444,0.011858453,0.108834796,0.0020244918,0.0003578308,0.0048511694,0.0001687647,0.027402453],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836075,0.00009064206,0.0003914042,0.0005530763,0.00027251424,0.00033160168],"domain_scores_gemma":[0.9992574,0.0001332748,0.00014017672,0.00031248733,0.000057895788,0.00009876682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000090841655,0.00042213371,0.00095872156,0.00046582063,0.00003880303,0.00001885167,0.00007002902,0.00043113937,0.00015769509],"category_scores_gemma":[0.000021483074,0.0003324752,0.00011307032,0.00032363913,0.00004223706,0.000056173718,0.000037491533,0.00036098,0.00019846579],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040113938,0.00035950204,0.19314142,0.00029966136,0.0015404712,0.0008515858,0.0046757516,0.000001789704,0.0035349936,0.00006659591,0.78196406,0.013163008],"study_design_scores_gemma":[0.0088140685,0.0030619008,0.044014454,0.002503192,0.0014183528,0.000056866756,0.00015264384,0.0000307582,0.012967256,0.00027827863,0.9257997,0.00090247573],"about_ca_topic_score_codex":0.0002732402,"about_ca_topic_score_gemma":0.00007991492,"teacher_disagreement_score":0.42702118,"about_ca_system_score_codex":0.00045884238,"about_ca_system_score_gemma":0.00012204496,"threshold_uncertainty_score":0.99991274},"labels":[],"label_agreement":null},{"id":"W2063369576","doi":"10.2174/1573406411208061133","title":"Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors","year":2012,"lang":"en","type":"article","venue":"Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"5'-nucleotidase; Chemistry; Identification (biology); Small molecule; Molecule; Combinatorial chemistry; Computational biology; Biochemistry; Enzyme; Biology; Organic chemistry","score_opus":0.010210763719401475,"score_gpt":0.25289948300524534,"score_spread":0.24268871928584387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063369576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98812884,0.00082397985,0.000047934704,0.0010269344,0.00012592618,0.00018020486,0.0000040961245,0.000052519383,0.009609588],"genre_scores_gemma":[0.9841562,0.000038226855,0.00015474956,0.000079895435,0.00038441067,0.000025456817,0.00010106219,0.00002285205,0.015037128],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864817,0.000015089261,0.00042432756,0.00021175995,0.0003850163,0.00031566405],"domain_scores_gemma":[0.9991087,0.00003438873,0.00015658115,0.00030939936,0.00009992805,0.00029105417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030247748,0.00018362585,0.00028839518,0.000052075662,0.00004645093,0.00000558433,0.00008673278,0.000110351255,0.0005280432],"category_scores_gemma":[0.0001812547,0.00015337161,0.00009719868,0.0002043712,0.000112999405,0.000056078912,0.000037710466,0.00017355371,0.00015761495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014771995,0.0006537408,0.08295744,0.00052833935,0.00017779547,0.00006864073,0.0013844414,3.928126e-7,0.9098359,0.00003287491,0.0024549724,0.0017577509],"study_design_scores_gemma":[0.0013289283,0.00004482682,0.00813666,0.00019128608,0.00023782752,0.000118750555,0.0005270985,0.000019820962,0.9871947,0.000016708347,0.0020495038,0.00013389908],"about_ca_topic_score_codex":0.000011479875,"about_ca_topic_score_gemma":5.548529e-7,"teacher_disagreement_score":0.0773588,"about_ca_system_score_codex":0.00013792486,"about_ca_system_score_gemma":0.00015382083,"threshold_uncertainty_score":0.6254313},"labels":[],"label_agreement":null},{"id":"W2063397858","doi":"10.1097/00126334-200309010-00016","title":"Polymorphism in Protease and Reverse Transcriptase and Phenotypic Drug Resistance of HIV-1 Recombinant CRF02_AG Isolates From Patients With No Prior Use of Antiretroviral Drugs in Abidjan, Côte d'Ivoire","year":2003,"lang":"en","type":"letter","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Genotyping; Drug resistance; Virology; Reverse transcriptase; Genotype; Biology; Human immunodeficiency virus (HIV); HIV drug resistance; Cote d ivoire; Lentivirus; Genetics; Viral load; Polymerase chain reaction; Viral disease; Gene; Antiretroviral therapy","score_opus":0.009047602859325782,"score_gpt":0.2036764612547791,"score_spread":0.1946288583954533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063397858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97765464,0.008126027,0.000004925356,0.01263604,0.00029220738,0.001108083,0.00014479326,0.000011281598,0.000021984162],"genre_scores_gemma":[0.97851306,0.0023297179,0.007665173,0.0017601524,0.000048957227,0.000034085628,0.00025202887,0.00016461889,0.009232176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955834,0.0003372731,0.0021352726,0.00056551787,0.0008079587,0.0005705358],"domain_scores_gemma":[0.99713206,0.000276544,0.0015993653,0.00049282674,0.00037280426,0.00012638963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063295267,0.00065307296,0.0021596937,0.0014268046,0.00007646642,0.000040782827,0.00024850105,0.00036561998,0.00004108962],"category_scores_gemma":[0.00026964847,0.0004903611,0.00023663994,0.00079354644,0.00044574394,0.0005660217,0.00005584857,0.0006814586,0.0000039676274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075491727,0.003217417,0.9149376,0.0034516524,0.0010698024,0.003901049,0.018170344,0.0000029755413,0.004070597,0.000010007441,0.040390287,0.0032290746],"study_design_scores_gemma":[0.05250033,0.00506905,0.87612224,0.03476507,0.0026919206,0.00043269366,0.0019172436,0.000049125283,0.003776639,0.00027521892,0.020050623,0.002349878],"about_ca_topic_score_codex":0.00031143546,"about_ca_topic_score_gemma":0.000011829512,"teacher_disagreement_score":0.044951156,"about_ca_system_score_codex":0.00023573037,"about_ca_system_score_gemma":0.0004269849,"threshold_uncertainty_score":0.9997548},"labels":[],"label_agreement":null},{"id":"W2063702342","doi":"10.1016/j.bmcl.2010.10.131","title":"Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly","year":2010,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Diazepine; Chemistry; Stereochemistry; Capsid; Bicyclic molecule; Imidazole; Ring (chemistry); Pyrazole; Substituent; Biochemistry; Organic chemistry","score_opus":0.006118364677811453,"score_gpt":0.21560819250069554,"score_spread":0.20948982782288408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063702342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895387,0.0002039737,0.00004481009,0.008830635,0.00022554291,0.00023672995,0.000050826293,0.000035009973,0.0008337313],"genre_scores_gemma":[0.9963002,0.000049297018,0.0009136896,0.00013696087,0.00037206427,0.00001083712,0.00014950256,0.00003976706,0.0020276608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777496,0.000019028721,0.0008447151,0.00035419138,0.00068406924,0.00032305124],"domain_scores_gemma":[0.99862725,0.000075381475,0.0004617616,0.000525287,0.0001423124,0.0001679901],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025082036,0.00032566654,0.0008245722,0.000111907015,0.000034646422,0.0000054885572,0.00020258068,0.00018346218,0.00032100113],"category_scores_gemma":[0.00022367532,0.00026540656,0.00020416865,0.0003782349,0.0005039699,0.00013751241,0.0000785948,0.00034596268,0.000008766087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022170949,0.0003105023,0.014334959,0.0009061156,0.00028997686,0.00008062245,0.0006288383,2.9537082e-7,0.9776903,0.0000152276825,0.0053427666,0.00017873192],"study_design_scores_gemma":[0.0020441345,0.00008133913,0.004989645,0.0005320087,0.00033792053,0.00020590794,0.00044529603,0.000003618445,0.9900375,0.0000066359416,0.0011188575,0.00019715998],"about_ca_topic_score_codex":0.000047208436,"about_ca_topic_score_gemma":0.000007621283,"teacher_disagreement_score":0.012347222,"about_ca_system_score_codex":0.00007303971,"about_ca_system_score_gemma":0.00031722666,"threshold_uncertainty_score":0.9999798},"labels":[],"label_agreement":null},{"id":"W2064751972","doi":"10.1097/01.coh.0000221600.64659.d3","title":"The pharmacogenetics of antiretroviral therapy","year":2006,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Pharmacogenetics; Antiretroviral therapy; Medicine; MEDLINE; Human immunodeficiency virus (HIV); Intensive care medicine; Pharmacology; Virology; Viral load; Genotype; Biology; Genetics","score_opus":0.03318939502688227,"score_gpt":0.3310700012604018,"score_spread":0.29788060623351953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064751972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96617645,0.030923935,0.000056618337,0.0007354415,0.0010414552,0.00028798459,0.000009896142,0.000015727857,0.0007524728],"genre_scores_gemma":[0.9829882,0.015494278,0.00020989412,0.0000068571735,0.00021179164,0.000015774693,0.000052208212,0.000007511443,0.0010135331],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994031,0.000022441587,0.00020608531,0.00011042252,0.00012968502,0.0001282525],"domain_scores_gemma":[0.9997783,0.000038504004,0.000042634514,0.000085728585,0.000024629411,0.000030255673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009679867,0.00008857488,0.00013113017,0.000060804752,0.000050277467,0.000009200983,0.000038119066,0.000021191183,0.000014117543],"category_scores_gemma":[0.0000046720315,0.00005364974,0.00003852712,0.00012625751,0.00007223281,0.000020476109,0.000017105136,0.00006843071,0.000005029203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007111957,0.00021587586,0.86920834,0.00005427639,0.000018329263,6.135282e-7,0.00011119018,0.0000011050797,0.00034288928,0.0014562922,0.006178225,0.122341774],"study_design_scores_gemma":[0.0067616785,0.00034518968,0.3726084,0.0003403651,0.00002662002,0.000008985469,0.000115023286,0.00031176378,0.0064221174,0.0005595987,0.61231124,0.00018903168],"about_ca_topic_score_codex":0.0000038423923,"about_ca_topic_score_gemma":2.499229e-7,"teacher_disagreement_score":0.606133,"about_ca_system_score_codex":0.000013487735,"about_ca_system_score_gemma":0.000033143973,"threshold_uncertainty_score":0.21877728},"labels":[],"label_agreement":null},{"id":"W2065173886","doi":"10.2165/00003495-200868010-00004","title":"Antiretroviral Therapy","year":2008,"lang":"en","type":"review","venue":"Drugs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Ritonavir; Medicine; Stavudine; Context (archaeology); Abacavir; Emtricitabine; Drug resistance; Antiretroviral therapy; Drug; Protease inhibitor (pharmacology); Lamivudine; Pharmacology; Intensive care medicine; Human immunodeficiency virus (HIV); Virology; Computational biology; Biology; Viral load; Virus; Genetics","score_opus":0.04814279697015873,"score_gpt":0.3389261771370195,"score_spread":0.2907833801668608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065173886","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023195447,0.97890353,0.0000010103751,0.000110590874,0.0001908825,0.0007785047,0.0000127754,0.00010945987,0.019870073],"genre_scores_gemma":[0.0000045215975,0.91428113,0.0002861208,0.000091796705,0.00027605824,0.00008630554,0.00045917925,0.000067346555,0.08444757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986326,0.00004745138,0.0003793556,0.00035412982,0.00029883147,0.00028760586],"domain_scores_gemma":[0.99927723,0.00005166245,0.00013088752,0.00037961398,0.000030472858,0.00013012091],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005318391,0.00042208607,0.0015846211,0.00020961143,0.00007345889,0.0000127432695,0.00011177396,0.00022032493,0.00026142973],"category_scores_gemma":[0.000009576049,0.0002709382,0.0006331851,0.00027766215,0.00005276008,0.000030223813,0.000030481558,0.0002688328,0.0020097757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065798667,0.00011493294,0.000057166693,0.0012416785,0.00037512594,0.00022966058,0.00022816748,8.9512847e-10,2.9476388e-8,0.00002854467,0.027620088,0.970098],"study_design_scores_gemma":[0.00069826574,0.00007085028,0.000007228422,0.003628133,0.00026748897,0.00024286479,0.000009640868,1.9851662e-7,0.000002051112,0.0000030683934,0.99483067,0.00023951607],"about_ca_topic_score_codex":0.000004788907,"about_ca_topic_score_gemma":1.5151807e-7,"teacher_disagreement_score":0.9698585,"about_ca_system_score_codex":0.00015274805,"about_ca_system_score_gemma":0.0005103561,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W2065598411","doi":"10.7448/ias.17.4.19815","title":"Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Regimen; Internal medicine; Nephrotoxicity; Viral load; Toxicity; Gastroenterology; Surgery; Human immunodeficiency virus (HIV); Immunology","score_opus":0.011106532568088067,"score_gpt":0.27819078688605603,"score_spread":0.26708425431796795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065598411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756785,0.00010739635,0.000023640107,0.02237297,0.00023756747,0.0002955935,0.000009736012,0.0000067366977,0.0012678321],"genre_scores_gemma":[0.9942195,0.00018740208,0.0021095772,0.0007313414,0.00018377876,0.000009163954,0.0000046658597,0.000011483909,0.002543077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856573,0.0001347322,0.00042017805,0.00019337128,0.0005281292,0.00015783754],"domain_scores_gemma":[0.9991034,0.00021005783,0.00029588648,0.0001301061,0.00016891208,0.000091602895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057076913,0.0001701507,0.00033358496,0.00007921241,0.00010857821,0.00004129553,0.00017626662,0.000076498414,0.00009018172],"category_scores_gemma":[0.00018410952,0.000094334675,0.0002410364,0.00010713657,0.000072709896,0.00015124226,0.00013824861,0.0002770137,0.0000041345347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031663699,0.0062987423,0.8651983,0.00002378691,0.0042909766,0.0003637326,0.03621277,0.000022203516,0.032500647,0.0005293115,0.020128101,0.03126504],"study_design_scores_gemma":[0.01705369,0.0056729023,0.9057515,0.00083467085,0.00062436867,0.0008139387,0.02982831,0.0008258102,0.019102171,0.0008455737,0.018300917,0.00034609644],"about_ca_topic_score_codex":0.00006631769,"about_ca_topic_score_gemma":0.000019953106,"teacher_disagreement_score":0.04055323,"about_ca_system_score_codex":0.0013603966,"about_ca_system_score_gemma":0.00010572035,"threshold_uncertainty_score":0.38468564},"labels":[],"label_agreement":null},{"id":"W2065669491","doi":"10.3402/gha.v8.26065","title":"Prevention of mother-to-child HIV-1 transmission in Burkina Faso: evaluation of vertical transmission by PCR, molecular characterization of subtypes and determination of antiretroviral drugs resistance","year":2015,"lang":"en","type":"article","venue":"Global Health Action","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Quebec Population Health Research Network","funders":"","keywords":"Transmission (telecommunications); Medicine; Resistance mutation; Drug resistance; Virology; Nevirapine; HIV drug resistance; Viral load; Polymerase chain reaction; Human immunodeficiency virus (HIV); Pediatrics; Immunology; Antiretroviral therapy; Reverse transcriptase; Biology; Genetics","score_opus":0.019859474267982086,"score_gpt":0.3372198428099018,"score_spread":0.31736036854191974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065669491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97280455,0.0004819306,0.024677666,0.0009002442,0.00004262774,0.0008701399,0.000027090366,0.000008716167,0.00018704774],"genre_scores_gemma":[0.9974984,0.00018014258,0.0019923255,0.000016727721,0.0000072390717,0.0000130875815,0.00022757135,0.000007997612,0.00005653441],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982247,0.0002068954,0.00061089755,0.00019647733,0.0006301483,0.00013087876],"domain_scores_gemma":[0.9992382,0.000012001537,0.00025509062,0.00010709635,0.0002602038,0.00012742679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007171913,0.0001117387,0.00034096287,0.00014669227,0.000020238676,0.0000019888048,0.00003148101,0.000095218646,0.000006868734],"category_scores_gemma":[0.00004177287,0.00010476201,0.00004461682,0.00035937165,0.00003443056,0.0001266483,0.0000057031307,0.000051780986,4.8871453e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040955874,0.0012403064,0.025204206,0.0020464568,0.000039118746,0.0000010842018,0.002766057,0.000019780913,0.26915562,0.00016486734,0.00007661302,0.6951903],"study_design_scores_gemma":[0.0115133375,0.002582024,0.33003318,0.00414613,0.0003667436,0.000008970965,0.00043093128,0.011165228,0.6379491,0.0009228403,0.0006397229,0.00024179606],"about_ca_topic_score_codex":0.000066364664,"about_ca_topic_score_gemma":0.000011810857,"teacher_disagreement_score":0.6949485,"about_ca_system_score_codex":0.00033755042,"about_ca_system_score_gemma":0.00030363048,"threshold_uncertainty_score":0.42720708},"labels":[],"label_agreement":null},{"id":"W2065920350","doi":"10.1128/jvi.02706-06","title":"Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations","year":2007,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"National Institute of General Medical Sciences; National Institutes of Health; Boehringer Ingelheim","keywords":"Biology; Protease; HIV-1 protease; Mutant; Virology; Isothermal titration calorimetry; Protease inhibitor (pharmacology); Biochemistry; Virus; Enzyme; Viral load; Antiretroviral therapy","score_opus":0.012051435211906679,"score_gpt":0.3110769952820948,"score_spread":0.29902556007018816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065920350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937193,0.0003826658,0.000843765,0.0035758954,0.000085776606,0.00028846433,0.00000326768,0.000009084894,0.0010918174],"genre_scores_gemma":[0.9893003,0.000020489208,0.0033966633,0.00020035372,0.00002807808,0.0000036582958,0.0000037018815,0.000014912318,0.007031845],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987263,0.00015170447,0.0005916066,0.000110588124,0.00021916925,0.0002005957],"domain_scores_gemma":[0.9989257,0.00017163386,0.0003238994,0.00018941224,0.0002719661,0.00011738814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00130321,0.000112066795,0.00032565193,0.00039812902,0.000074620664,0.0000036742372,0.00011668355,0.00006772256,0.00009442263],"category_scores_gemma":[0.00023150387,0.000086580396,0.000087679946,0.0003084372,0.0000887645,0.00004824211,0.000020459885,0.0002114243,0.000024118202],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015076375,0.0007069596,0.0037083114,0.000026858892,0.00017972708,0.00076829485,0.0031190217,0.000021322114,0.97439754,0.000600987,0.0007893323,0.0006052578],"study_design_scores_gemma":[0.010826051,0.004646089,0.74207336,0.00060723326,0.0007124454,0.0010930594,0.0012911734,0.000048317048,0.20527422,0.0029012512,0.029993486,0.00053332257],"about_ca_topic_score_codex":0.000012071986,"about_ca_topic_score_gemma":0.00007666528,"teacher_disagreement_score":0.7691233,"about_ca_system_score_codex":0.00014861955,"about_ca_system_score_gemma":0.00027984643,"threshold_uncertainty_score":0.3530646},"labels":[],"label_agreement":null},{"id":"W2065946034","doi":"10.1002/anie.200501399","title":"Regio‐ and Chemoselective 6′‐N‐Derivatization of Aminoglycosides: Bisubstrate Inhibitors as Probes To Study Aminoglycoside 6′‐<i>N</i>‐Acetyltransferases","year":2005,"lang":"en","type":"article","venue":"Angewandte Chemie International Edition","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; McMaster University","keywords":"Acetyltransferases; Aminoglycoside; Acetyltransferase; Chemistry; Regioselectivity; Derivatization; Enzyme; Combinatorial chemistry; Acetylation; Antibiotics; Biochemistry; Stereochemistry; Chromatography; Mass spectrometry","score_opus":0.012528768824695632,"score_gpt":0.2764657625477379,"score_spread":0.2639369937230423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065946034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910385,0.00007600243,0.00072091765,0.0049568177,0.00016110319,0.0008676814,0.000023625402,0.00006968231,0.0020856925],"genre_scores_gemma":[0.995617,0.000117116426,0.0014968701,0.00034556718,0.000555499,0.00018068426,0.0003182434,0.00002497174,0.0013440996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855876,0.00001746703,0.0004092916,0.00036514507,0.00047835923,0.00017095364],"domain_scores_gemma":[0.9991946,0.00006468336,0.00011692464,0.00013115535,0.00036394186,0.0001286469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001236476,0.00021894128,0.00026637333,0.0002447302,0.00006911991,0.000031738313,0.000076511446,0.00007327365,0.0001422314],"category_scores_gemma":[0.00012801649,0.00020101927,0.000062187486,0.00027100422,0.000056439047,0.00028276644,0.00003125448,0.000103782986,0.000026258362],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012282344,0.0038481567,0.12264569,0.00013030774,0.0011935431,0.0000793801,0.013646869,0.00002327432,0.8317612,0.00027515288,0.010950305,0.014217912],"study_design_scores_gemma":[0.0022271404,0.00032541275,0.02126128,0.00019623453,0.00012468784,0.000052600135,0.0009781143,0.000018382005,0.97279775,0.00014097527,0.0017026743,0.00017471686],"about_ca_topic_score_codex":0.00004347902,"about_ca_topic_score_gemma":0.0000486854,"teacher_disagreement_score":0.1410366,"about_ca_system_score_codex":0.0001883092,"about_ca_system_score_gemma":0.000079630954,"threshold_uncertainty_score":0.8197328},"labels":[],"label_agreement":null},{"id":"W2066141181","doi":"10.3390/v6072858","title":"Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients","year":2014,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"U.S. Department of Health and Human Services","keywords":"Raltegravir; Dolutegravir; Elvitegravir; Integrase inhibitor; Regimen; Medicine; Clinical trial; Darunavir; Integrase; Pharmacology; Clinical endpoint; Population; Drug resistance; Virology; Internal medicine; Oncology; Viral load; Biology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genetics","score_opus":0.371913622032879,"score_gpt":0.5418493594956924,"score_spread":0.16993573746281337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066141181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013278632,0.9813163,0.000038423426,0.000018988454,0.00048444304,0.0028282637,0.001714871,0.000063664615,0.00025635827],"genre_scores_gemma":[0.0015245469,0.9952053,0.00033131766,0.0000173878,0.00018452256,0.0001285709,0.0007922123,0.00008168874,0.0017344862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930189,0.0012336865,0.0045384034,0.000548799,0.0004171063,0.0002430866],"domain_scores_gemma":[0.9953777,0.0023605612,0.0013068562,0.0005287812,0.00020091799,0.00022519227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017191845,0.0006462892,0.0072113313,0.0005504917,0.00003832158,0.000010556552,0.00014015487,0.00039465193,0.0001102574],"category_scores_gemma":[0.0015971232,0.00036647505,0.0020487518,0.0005055535,0.00024050898,0.000060617094,0.000016129849,0.00021749135,0.00005460719],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022464816,0.0063874577,0.0022088196,0.018187024,0.014558852,0.00006515958,0.00060086884,3.1126672e-7,0.00003250736,0.00006616897,0.00533498,0.95031136],"study_design_scores_gemma":[0.016958827,0.0024327107,0.000026762738,0.03435095,0.028164556,0.0000017177454,0.00006847542,8.517966e-7,0.0036541473,0.000016846478,0.913864,0.00046014664],"about_ca_topic_score_codex":0.000054956112,"about_ca_topic_score_gemma":0.00007367132,"teacher_disagreement_score":0.9498512,"about_ca_system_score_codex":0.00015996861,"about_ca_system_score_gemma":0.0008167602,"threshold_uncertainty_score":0.9998787},"labels":[],"label_agreement":null},{"id":"W2066288117","doi":"10.1016/j.bmcl.2013.03.073","title":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: Addressing configurational instability through scaffold modification","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Chemistry; Diazepine; Capsid; Scaffold; Stereochemistry; Series (stratigraphy); Human immunodeficiency virus (HIV); Combinatorial chemistry; Virology; Organic chemistry; Biochemistry; Ring (chemistry)","score_opus":0.02493696215396006,"score_gpt":0.25137057921075967,"score_spread":0.2264336170567996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066288117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97117823,0.00023256366,0.0021477868,0.024696874,0.00009112805,0.00057017436,0.00002593837,0.000067259105,0.0009900696],"genre_scores_gemma":[0.99250853,0.000048053993,0.0058280244,0.00031002404,0.00022721705,0.000051753927,0.0006569942,0.000031393316,0.00033800153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977723,0.000042373664,0.0008435507,0.00040166904,0.00066822325,0.00027188475],"domain_scores_gemma":[0.99860245,0.00006614616,0.00045326367,0.00038320705,0.00034964658,0.00014526879],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019943592,0.00029232635,0.00053693407,0.000069503774,0.000084371786,0.000015687614,0.00012921839,0.00016280392,0.0009797141],"category_scores_gemma":[0.00019999931,0.0002547238,0.00011307818,0.0003727889,0.00033375085,0.0003118297,0.000037338847,0.00016291445,0.000013269162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009685831,0.00026536803,0.003445724,0.000545712,0.00015241839,0.0000080354985,0.0009447077,0.00013680256,0.9900541,0.000016976092,0.004146965,0.00018636104],"study_design_scores_gemma":[0.0018437683,0.000042930806,0.0038970527,0.00054081617,0.00019726506,0.0000733767,0.00072347594,0.000790709,0.99140906,0.000020396516,0.00024240508,0.00021871443],"about_ca_topic_score_codex":0.0000736444,"about_ca_topic_score_gemma":0.0000014571135,"teacher_disagreement_score":0.024386851,"about_ca_system_score_codex":0.000245023,"about_ca_system_score_gemma":0.00025074155,"threshold_uncertainty_score":0.9999905},"labels":[],"label_agreement":null},{"id":"W2066315689","doi":"10.1097/qad.0000000000000199","title":"Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors","year":2014,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration","keywords":"Dolutegravir; Virology; Integrase; Reverse transcriptase; Nevirapine; Integrase inhibitor; Lamivudine; Resistance mutation; Drug resistance; Regimen; Medicine; Biology; Virus; Human immunodeficiency virus (HIV); Genetics; Viral load; Internal medicine; Antiretroviral therapy; Polymerase chain reaction; Gene","score_opus":0.009225039585877502,"score_gpt":0.24220230199277862,"score_spread":0.23297726240690111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066315689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95887494,0.0012053652,0.00067028066,0.009127255,0.0003180372,0.00090255914,0.00007852661,0.00009194415,0.028731115],"genre_scores_gemma":[0.9732222,0.0002428242,0.004649988,0.00048043366,0.00006172666,0.00009123635,0.00012549311,0.000027993332,0.021098098],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815315,0.00016709027,0.0006251259,0.00035414204,0.00037154864,0.00032895635],"domain_scores_gemma":[0.9989012,0.00015054623,0.00014643127,0.00054448674,0.00012233516,0.0001349908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059790607,0.00025050002,0.00038891734,0.00021473024,0.00012558751,0.000011089061,0.00018474794,0.000085490996,0.000051220522],"category_scores_gemma":[0.0002783114,0.0001741072,0.00017171216,0.00085189054,0.00018012777,0.000121740384,0.00002183447,0.00026533907,0.000045914123],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028537256,0.0032835393,0.31857613,0.0014293867,0.0010666138,0.00081695965,0.04379122,0.00019211361,0.055263445,0.025645463,0.50887185,0.038209565],"study_design_scores_gemma":[0.022821162,0.0006396996,0.08991431,0.007614572,0.0011927293,0.000014168028,0.03453818,0.0007736853,0.08025917,0.00519216,0.75475276,0.0022873865],"about_ca_topic_score_codex":0.000034195218,"about_ca_topic_score_gemma":0.00059976627,"teacher_disagreement_score":0.24588096,"about_ca_system_score_codex":0.00010344,"about_ca_system_score_gemma":0.00016119916,"threshold_uncertainty_score":0.7099886},"labels":[],"label_agreement":null},{"id":"W2066396351","doi":"10.1021/ci200626m","title":"Efficient a Priori Identification of Drug Resistant Mutations Using Dead-End Elimination and MM-PBSA.","year":2012,"lang":"en","type":"article","venue":"Journal of Chemical Information and Modeling","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Dihydrofolate reductase; Drug resistance; Drug; Computational biology; Drug discovery; Biology; Pharmacology; Methotrexate; Bioinformatics; Genetics; Immunology","score_opus":0.025028492071667935,"score_gpt":0.29386622087925546,"score_spread":0.2688377288075875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066396351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776118,0.00030473366,0.02137532,0.00046781357,0.00004390898,0.00010234067,0.0000021926944,0.00000467033,0.00008722273],"genre_scores_gemma":[0.9920028,0.000049335595,0.007849997,0.00002438161,0.000034758596,0.0000012172745,0.000015848915,0.0000033113356,0.00001837437],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99895483,0.000009947966,0.0006680237,0.00003395701,0.0002443757,0.00008888563],"domain_scores_gemma":[0.99916315,0.000028276183,0.00036258376,0.00004277136,0.00030042676,0.00010276835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004391251,0.00006583309,0.00014918357,0.00018257755,0.000043831664,0.000021309028,0.000018507537,0.000037688536,0.0000039869024],"category_scores_gemma":[0.00010173229,0.000052343603,0.00003610762,0.00008656457,0.000024958343,0.000387951,0.000012986095,0.00008011199,8.906702e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013146017,0.0009189053,0.0076081445,0.0013947815,0.00046482647,0.0000043436885,0.08332236,0.02415833,0.83099586,0.003853842,0.00018850439,0.045775518],"study_design_scores_gemma":[0.0020174105,0.000027693657,0.0012951589,0.0003182469,0.00032075137,0.00015573174,0.0029338372,0.8968835,0.09564011,0.00011881599,0.00017124036,0.00011753264],"about_ca_topic_score_codex":0.0000022991467,"about_ca_topic_score_gemma":9.908713e-8,"teacher_disagreement_score":0.8727251,"about_ca_system_score_codex":0.00007537061,"about_ca_system_score_gemma":0.000061515406,"threshold_uncertainty_score":0.21345103},"labels":[],"label_agreement":null},{"id":"W2066583628","doi":"10.1097/qco.0b013e32835ba81c","title":"Evolution of HIV integrase resistance mutations","year":2012,"lang":"en","type":"review","venue":"Current Opinion in Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"U.S. Food and Drug Administration; Canadian Institutes of Health Research; Canadian Foundation for AIDS Research; amfAR, The Foundation for AIDS Research","keywords":"Integrase; Medicine; Human immunodeficiency virus (HIV); Virology; Integrase inhibitor; Mutation; Genetics; Computational biology; Antiretroviral therapy; Gene; Viral load; Biology","score_opus":0.05826734291732691,"score_gpt":0.3755644519799044,"score_spread":0.31729710906257746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066583628","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019721454,0.9948884,0.00013836418,0.000024171457,0.0025586628,0.0012271979,0.00033505794,0.00009389798,0.00071451435],"genre_scores_gemma":[0.00085859856,0.99463314,0.00003766244,9.944807e-7,0.00042431676,0.00062911137,0.0026396355,0.000042432333,0.0007340933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808395,0.00015482314,0.0008168164,0.00035626345,0.0002942259,0.00029394362],"domain_scores_gemma":[0.99870294,0.0001900201,0.00041475773,0.00035190352,0.00012386809,0.00021651098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010346833,0.00040341148,0.0012125002,0.00075994927,0.00006472871,0.000012553304,0.00008744591,0.00014116886,0.00017230642],"category_scores_gemma":[0.00017820315,0.00032643462,0.00048681398,0.0007761643,0.00010672983,0.00010795728,0.000046829664,0.00029014092,0.00022140623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050343053,0.004918316,0.07690454,0.12523034,0.000582683,0.000005883513,0.00024784787,0.0000018800727,4.3241933e-8,0.004941984,0.019965895,0.7671502],"study_design_scores_gemma":[0.0008231422,0.000023727509,0.001653087,0.042045813,0.0016804173,0.000013870643,0.000025995156,0.0000019239346,1.5176609e-7,0.0002255984,0.953237,0.00026928147],"about_ca_topic_score_codex":0.0000054202665,"about_ca_topic_score_gemma":0.000008214457,"teacher_disagreement_score":0.9332711,"about_ca_system_score_codex":0.0010009687,"about_ca_system_score_gemma":0.00087550515,"threshold_uncertainty_score":0.99991876},"labels":[],"label_agreement":null},{"id":"W2067293915","doi":"10.1097/qai.0b013e31825a289b","title":"Transmitted Drug Resistance and Phylogenetic Relationships Among Acute and Early HIV-1–Infected Individuals in New York City","year":2012,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; International AIDS Society","keywords":"Cohort; Transmission (telecommunications); Phylogenetic tree; Drug resistance; Genotype; HIV drug resistance; Virology; Medicine; Cohort study; Human immunodeficiency virus (HIV); Demography; Biology; Internal medicine; Viral load; Genetics; Antiretroviral therapy; Gene","score_opus":0.02445949772954113,"score_gpt":0.24580867069724202,"score_spread":0.2213491729677009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067293915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757257,0.022056863,0.00015251883,0.001327768,0.00012833727,0.00034602414,0.000005565485,0.000031598094,0.00022563839],"genre_scores_gemma":[0.9871416,0.0006771355,0.0057964474,0.000014209956,0.000034479453,0.0000060369716,0.000008207974,0.000031616655,0.0062902365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976985,0.00019701637,0.000943041,0.00022101386,0.0004580434,0.00048238723],"domain_scores_gemma":[0.99868923,0.0002960863,0.00040393177,0.00021339468,0.000088519715,0.000308811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012237388,0.0002782717,0.00071355945,0.0007656671,0.00017382456,0.000054463093,0.00012980263,0.00013188006,0.000031788768],"category_scores_gemma":[0.00021567507,0.00022473994,0.00011969634,0.0009564609,0.00019151533,0.00043461498,0.000039365845,0.00024649533,0.000011079353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108279695,0.00021626787,0.9886324,0.00004587531,0.00023619182,0.00008519402,0.00822583,0.0000011332462,0.0010967196,0.00007345199,0.00055249286,0.0007261684],"study_design_scores_gemma":[0.0035129138,0.0001245723,0.9927598,0.0005031495,0.00045904773,0.0005179332,0.00053570926,0.000006839411,0.0008088784,0.0002638153,0.000291785,0.00021551854],"about_ca_topic_score_codex":0.000018498022,"about_ca_topic_score_gemma":0.000013816659,"teacher_disagreement_score":0.021379726,"about_ca_system_score_codex":0.00009268819,"about_ca_system_score_gemma":0.00018574702,"threshold_uncertainty_score":0.9164629},"labels":[],"label_agreement":null},{"id":"W2067632599","doi":"10.1097/01.aids.0000176219.48484.f1","title":"Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use","year":2005,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Medicine; Drug resistance; Confidence interval; Population; Reverse-transcriptase inhibitor; Hazard ratio; Internal medicine; Proportional hazards model; HIV drug resistance; Viral load; Immunology; Sida; Virology; Human immunodeficiency virus (HIV); Viral disease; Antiretroviral therapy; Biology; Environmental health","score_opus":0.0078037088255468985,"score_gpt":0.21724104498821153,"score_spread":0.20943733616266463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067632599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99857056,0.00018477192,0.000020584997,0.000033613214,0.000031341064,0.00021701877,0.000005361973,0.000022199745,0.0009145677],"genre_scores_gemma":[0.9571193,0.000013947648,0.0029495065,0.000015086388,0.000013168102,0.000006381628,0.000034592504,0.000012544221,0.03983548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993723,0.000025858326,0.00018795398,0.00014084805,0.00017337101,0.00009968615],"domain_scores_gemma":[0.9995671,0.000024982743,0.0001226424,0.0001272528,0.000109210945,0.000048823385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058339203,0.000103495724,0.00023551601,0.000122065205,0.000016862703,0.0000028004808,0.00001980741,0.000032387565,0.000020857466],"category_scores_gemma":[0.00003321737,0.000076772485,0.00002480468,0.00011783566,0.000124208,0.00016643222,0.000011781394,0.000056606612,0.0000021778599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038784998,0.00021176419,0.99459827,0.0000553201,0.0000904091,0.0000013131983,0.001334589,7.222845e-7,0.00022083445,0.000023039203,0.0022706094,0.0008052873],"study_design_scores_gemma":[0.0030163347,0.00033094006,0.9909848,0.00019824647,0.00012364978,8.8310685e-7,0.000042638403,0.000020081328,0.0030135552,0.0000022180952,0.0021847673,0.000081895545],"about_ca_topic_score_codex":0.00007688497,"about_ca_topic_score_gemma":0.0000935743,"teacher_disagreement_score":0.041451246,"about_ca_system_score_codex":0.00016139062,"about_ca_system_score_gemma":0.00007729746,"threshold_uncertainty_score":0.3130691},"labels":[],"label_agreement":null},{"id":"W2068276081","doi":"10.1097/00002030-200305230-00020","title":"Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection","year":2003,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; Providence Health Care","funders":"","keywords":"Reverse transcriptase; Drug resistance; Discontinuation; Virology; Lentivirus; Protease; Sida; Viral disease; Medicine; Drug; Human immunodeficiency virus (HIV); Mutation; Protease inhibitor (pharmacology); HIV drug resistance; Immunology; Antiretroviral therapy; Biology; Viral load; Internal medicine; Enzyme; Pharmacology; Genetics; Polymerase chain reaction; Gene","score_opus":0.011134528679663799,"score_gpt":0.2527924710056558,"score_spread":0.24165794232599203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068276081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8177257,0.0055972063,0.000034338278,0.17322758,0.00010663164,0.0023583786,0.000030775493,0.000023709068,0.0008956466],"genre_scores_gemma":[0.92056215,0.0036616176,0.0035621386,0.044447858,0.00027947448,0.0016442443,0.0017659423,0.00007245883,0.024004124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987548,0.00020749273,0.00032013594,0.00023608065,0.00035158056,0.0001299186],"domain_scores_gemma":[0.9993545,0.00007875354,0.00019851861,0.00026022314,0.000081749924,0.000026281135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027901467,0.00016622993,0.0002782555,0.00018783612,0.000034521956,0.000008221345,0.00004364684,0.000121382276,0.000029199036],"category_scores_gemma":[0.000034265002,0.000104221115,0.00007952415,0.0002450475,0.00012172638,0.000068794216,0.000010580307,0.00030135253,0.0000021105132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013647629,0.00062949146,0.7362704,0.0021337685,0.00022777576,0.00038126393,0.0034088138,2.635051e-7,0.0002748677,0.000024541801,0.24144015,0.013843876],"study_design_scores_gemma":[0.0030459506,0.00017848039,0.86469615,0.0021765288,0.00026086153,0.000010013196,0.00005357727,0.000004132901,0.0006212621,0.0003665062,0.12835038,0.00023615186],"about_ca_topic_score_codex":0.00000402492,"about_ca_topic_score_gemma":0.0000042643637,"teacher_disagreement_score":0.12877972,"about_ca_system_score_codex":0.000050509734,"about_ca_system_score_gemma":0.00011912458,"threshold_uncertainty_score":0.42500138},"labels":[],"label_agreement":null},{"id":"W2068516450","doi":"10.1002/chin.200051209","title":"ChemInform Abstract: Syntheses of 4‐[1‐(2‐Deoxy‐β‐D‐ribofuranosyl)] Derivatives of 2‐Substituted‐5‐fluoroaniline: “Cytosine Replacement” Analogues of Deoxycytidine for Evaluation as Anticancer and antihuman Immunodeficiency Virus (anti‐HIV) Agents.","year":2000,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Human immunodeficiency virus (HIV); Deoxycytidine; Cytosine; Chemistry; Virology; Combinatorial chemistry; Stereochemistry; Medicine; DNA; Biochemistry; Chemotherapy; Internal medicine","score_opus":0.029224170809762057,"score_gpt":0.30752029731571395,"score_spread":0.2782961265059519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068516450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.892121,0.0011738231,0.0000017840078,0.00013924416,0.000036259804,0.0011489632,0.00014238434,0.000028824052,0.10520768],"genre_scores_gemma":[0.9921038,0.0015363962,0.0004368123,0.000026769789,0.000031849122,0.00008318639,0.0005264648,0.000025975163,0.005228727],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975472,6.430457e-7,0.0011584607,0.0003226387,0.000637746,0.00033327626],"domain_scores_gemma":[0.9981592,0.0002184198,0.000568516,0.00042601122,0.00052802445,0.00009978237],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052128587,0.0003390769,0.00083416887,0.00022179451,0.00008718151,0.000012172142,0.00013768977,0.00014272217,0.0031293212],"category_scores_gemma":[0.00050560525,0.00028035056,0.00017919228,0.00031630287,0.0003757605,0.00031917036,0.000045269702,0.000097320335,0.000009369276],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042195925,0.0024126724,0.012498997,0.0048880875,0.002089242,0.000012508893,0.010706212,0.000013314309,0.40055168,0.0008561346,0.0051239207,0.55662763],"study_design_scores_gemma":[0.0038335857,0.00025531487,0.02841934,0.0008246093,0.000527363,0.000025668453,0.0005690262,0.00014790602,0.9624551,0.00007471691,0.0026166881,0.00025071137],"about_ca_topic_score_codex":0.00005533056,"about_ca_topic_score_gemma":0.000005905881,"teacher_disagreement_score":0.5619034,"about_ca_system_score_codex":0.00012307179,"about_ca_system_score_gemma":0.00032282883,"threshold_uncertainty_score":0.9999649},"labels":[],"label_agreement":null},{"id":"W2068537002","doi":"10.1097/00002030-200100005-00005","title":"Mechanisms of HIV-1 drug resistance","year":2001,"lang":"fr","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug resistance; Human immunodeficiency virus (HIV); Drug; Virology; HIV drug resistance; Medicine; Biology; Pharmacology; Viral load; Antiretroviral therapy; Genetics","score_opus":0.02269537892393157,"score_gpt":0.2883001814446287,"score_spread":0.2656048025206971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068537002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001918544,0.9448933,0.0014376533,0.001576197,0.001160537,0.0010830024,0.00009722584,0.000051989704,0.049680915],"genre_scores_gemma":[0.000067381094,0.52461344,0.009956585,0.000045626326,0.00017424388,0.000070408714,0.00028920476,0.00005724731,0.46472585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656314,0.00023466683,0.001206338,0.00064920884,0.0006550057,0.00069165503],"domain_scores_gemma":[0.99787784,0.00031616478,0.00051960925,0.0008243264,0.00015811459,0.00030397743],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000615518,0.00072417856,0.0025692112,0.0003109186,0.00009768324,0.000015730502,0.00033505665,0.0003471735,0.004583848],"category_scores_gemma":[0.000120109165,0.0005855158,0.0007031777,0.000939087,0.00015270854,0.000072221126,0.00011365862,0.00041231807,0.005635082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008479496,0.0010632918,0.00061719836,0.042977188,0.0030762907,0.001343222,0.000858799,3.4313507e-7,0.000021920332,0.090335846,0.13352597,0.72609514],"study_design_scores_gemma":[0.0010551873,0.00005620565,0.000024356612,0.038691558,0.003251472,0.000052423704,0.00011722174,0.0000013903069,0.00022556499,0.0014716054,0.9546197,0.00043332655],"about_ca_topic_score_codex":0.000012185839,"about_ca_topic_score_gemma":0.000019089239,"teacher_disagreement_score":0.82109374,"about_ca_system_score_codex":0.0005058489,"about_ca_system_score_gemma":0.0007118891,"threshold_uncertainty_score":0.9996596},"labels":[],"label_agreement":null},{"id":"W2069431872","doi":"10.1128/jvi.00889-06","title":"Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action","year":2006,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Reverse transcriptase; Virology; Human immunodeficiency virus (HIV); Mechanism of action; Mechanism (biology); Virus; RNA-Directed DNA Polymerase; RNA; Genetics; In vitro; Gene","score_opus":0.021481273448330885,"score_gpt":0.26887440540480034,"score_spread":0.24739313195646945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069431872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951988,0.00023997364,0.0024645878,0.0013359833,0.0001236368,0.00013744614,0.000007343325,0.000008807214,0.0004834387],"genre_scores_gemma":[0.99661857,0.00005381971,0.0022462162,0.00011884486,0.00007799264,0.000003127393,0.000008654499,0.000013962769,0.0008588113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890023,0.00003451085,0.0005300866,0.000111638765,0.00025000627,0.00017353067],"domain_scores_gemma":[0.9992459,0.000021777765,0.00042525324,0.00011396291,0.00014186486,0.000051273284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024294325,0.00013641121,0.00042912035,0.0003048349,0.000060092287,0.000004124408,0.00006321448,0.00010090383,0.00010420236],"category_scores_gemma":[0.000010250431,0.00009355062,0.00011736699,0.00015206763,0.000087146414,0.00010167293,0.000009244725,0.00022252933,0.000004393343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012390531,0.0012146977,0.0032035473,0.000033848537,0.00017829212,0.00025003456,0.00036330248,0.000014184148,0.9911387,0.001574319,0.0005024521,0.00028759008],"study_design_scores_gemma":[0.02707323,0.0076997005,0.048302006,0.00036434396,0.0015293626,0.00656976,0.0007830712,0.00006935154,0.8959239,0.002091488,0.009214276,0.0003794797],"about_ca_topic_score_codex":0.000072939656,"about_ca_topic_score_gemma":0.000041700714,"teacher_disagreement_score":0.09521475,"about_ca_system_score_codex":0.000072298855,"about_ca_system_score_gemma":0.00012008505,"threshold_uncertainty_score":0.38148835},"labels":[],"label_agreement":null},{"id":"W2069793776","doi":"10.1007/s00044-010-9307-4","title":"Modification and biological evaluation of novel 4-hydroxy-pyrone derivatives as non-peptidic HIV-1 protease inhibitors","year":2010,"lang":"en","type":"article","venue":"Medicinal Chemistry Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Natural Science Foundation of China","keywords":"Chemistry; IC50; Protease; Stereochemistry; HIV-1 protease; Pyrone; EC50; Enzyme; Western blot; Human immunodeficiency virus (HIV); Binding affinities; Biochemistry; In vitro; Virology; Biology; Receptor; Gene","score_opus":0.13078086184705237,"score_gpt":0.41781420849913786,"score_spread":0.28703334665208546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069793776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927546,0.0001586343,0.000045963443,0.0040183086,0.00002554322,0.00095653854,0.0000063472353,0.000020088175,0.005493138],"genre_scores_gemma":[0.9959271,0.00004309767,0.00079487107,0.000014139551,0.00022522798,0.00026643148,0.00015839374,0.00001334027,0.002557396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99743634,0.00006887772,0.00031944795,0.00039475632,0.0014729877,0.0003075751],"domain_scores_gemma":[0.9984416,0.00015287622,0.00008468493,0.00029956273,0.0007365617,0.0002847211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002745959,0.00015764566,0.00027021297,0.00011745349,0.00012408741,0.000011693119,0.00010541203,0.00017714068,0.0004990303],"category_scores_gemma":[0.0018534278,0.000114361326,0.00003850682,0.00034174355,0.0006391005,0.00005263166,0.000077830584,0.00061983126,0.000028367711],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022504764,0.00056662405,0.025174016,0.0001961602,0.000051876417,0.000012437366,0.00072073727,6.1300295e-7,0.968049,0.000021433214,0.0006478681,0.004334211],"study_design_scores_gemma":[0.004740673,0.00024231487,0.027753178,0.0002997924,0.000081997925,0.000100590274,0.0011587557,0.0027289616,0.9616986,0.00018642249,0.0008682397,0.00014047138],"about_ca_topic_score_codex":0.000028800012,"about_ca_topic_score_gemma":0.000001224818,"teacher_disagreement_score":0.0066516637,"about_ca_system_score_codex":0.00011030239,"about_ca_system_score_gemma":0.00058337784,"threshold_uncertainty_score":0.54640317},"labels":[],"label_agreement":null},{"id":"W2069838995","doi":"10.1038/nrneph.2009.142","title":"The nephrotoxic effects of HAART","year":2009,"lang":"en","type":"review","venue":"Nature Reviews Nephrology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Medicine; Atazanavir; Nephrotoxicity; Acute kidney injury; Kidney disease; Renal function; Indinavir; Kidney; Internal medicine; Lactic acidosis; Intensive care medicine; Immunology; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.01618819751141285,"score_gpt":0.3473566833462624,"score_spread":0.33116848583484954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069838995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.8112307e-7,0.98948,0.0000040212503,0.001029481,0.000387513,0.0068117203,0.0000040452605,0.00004746132,0.0022348713],"genre_scores_gemma":[5.8493794e-7,0.9876705,0.00066825433,0.0015231551,0.00044366927,0.00074786186,0.00014187733,0.00005841788,0.008745688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963947,0.00074523996,0.0013845596,0.00058637623,0.00032390584,0.00056521024],"domain_scores_gemma":[0.9966852,0.0010096816,0.0009218131,0.0011203901,0.0000938797,0.00016903973],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007315494,0.00078739924,0.0051847636,0.00024142858,0.00013803643,0.000013988397,0.00043122118,0.0016479321,0.00005326928],"category_scores_gemma":[0.00052254245,0.00037858888,0.0015512129,0.00066068623,0.00018421597,0.000029834631,0.000089324574,0.0019300181,0.00052581384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018536837,0.00011380291,0.0000024963038,0.022855211,0.00054603064,0.00011280361,0.000015698153,1.7628523e-9,0.0000014950267,0.00063770823,0.07431588,0.90138036],"study_design_scores_gemma":[0.000539927,0.00023587025,0.000014421212,0.019388795,0.0043461123,0.00042603124,5.6095075e-7,1.5367293e-7,0.0000057710927,0.00009102743,0.9747035,0.0002478106],"about_ca_topic_score_codex":4.788888e-7,"about_ca_topic_score_gemma":0.000004365971,"teacher_disagreement_score":0.9011325,"about_ca_system_score_codex":0.00016520331,"about_ca_system_score_gemma":0.000504578,"threshold_uncertainty_score":0.9998666},"labels":[],"label_agreement":null},{"id":"W2070038463","doi":"10.1002/jmv.20788","title":"Relationship between mutations in HIV‐1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre‐treated HIV infected patients","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"RNase H; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Virology; Mutation; Nucleoside; RNase P; Nucleoside analogue; Biology; Ribonuclease; Molecular biology; Genetics; RNA; Gene","score_opus":0.012781623025993161,"score_gpt":0.2793358664702331,"score_spread":0.26655424344423995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070038463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98422164,0.00023450903,0.00028627765,0.014742279,0.00006019164,0.00029941322,0.000017504799,0.000010497476,0.00012771622],"genre_scores_gemma":[0.99744725,0.000057171477,0.0018607414,0.00021924336,0.000063486645,0.0000065840686,0.000093657276,0.000014056141,0.00023782921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787045,0.00021939035,0.0009784893,0.00018651044,0.00048078212,0.0002643707],"domain_scores_gemma":[0.9982638,0.0009130363,0.0002398437,0.00008493366,0.00008782261,0.0004105925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011348014,0.0001549917,0.00042799,0.00070253573,0.000073351825,0.000008573274,0.000057800527,0.00027605993,0.00005135434],"category_scores_gemma":[0.0014764727,0.0001293453,0.000049162423,0.00044213238,0.00024461077,0.00014193289,0.000018585015,0.00064695865,0.0000048308466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005137141,0.00038618103,0.9932781,0.000034392335,0.00005067918,0.0011251896,0.0027835013,0.0000014870321,0.000067429704,0.00015334807,0.00092767476,0.00067830854],"study_design_scores_gemma":[0.011098732,0.00020345561,0.98537934,0.0002870434,0.00014268009,0.00008679988,0.0003540398,0.0000120277455,0.00007632781,0.0008859818,0.0013767277,0.00009685954],"about_ca_topic_score_codex":0.000024026704,"about_ca_topic_score_gemma":0.00059254956,"teacher_disagreement_score":0.014523036,"about_ca_system_score_codex":0.00016097286,"about_ca_system_score_gemma":0.00018006974,"threshold_uncertainty_score":0.5274548},"labels":[],"label_agreement":null},{"id":"W2070505454","doi":"10.7448/ias.17.1.18944","title":"Do HIV‐1 non‐B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review","year":2014,"lang":"en","type":"review","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Queen's University; McGill University Health Centre","funders":"","keywords":"Medicine; Drug resistance; Disease; Antiretroviral therapy; Genotype; Human immunodeficiency virus (HIV); Viral load; Immunology; Internal medicine; Genetics; Biology; Gene","score_opus":0.06788173221596815,"score_gpt":0.43689774766208406,"score_spread":0.3690160154461159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070505454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024663038,0.9936373,0.0000753324,0.0020184733,0.00029447902,0.0014224021,0.00006201288,0.0000076909555,0.00001596909],"genre_scores_gemma":[0.0033006065,0.9921254,0.0019968725,0.00009391894,0.0002280379,0.0000614938,0.00011698513,0.000026635927,0.0020500384],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962847,0.0004589075,0.0020338625,0.00026684764,0.00081923336,0.00013644292],"domain_scores_gemma":[0.99625707,0.000820014,0.002065596,0.00032413247,0.000343077,0.0001900967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011962854,0.0003216719,0.0020494875,0.000106387,0.00007701033,0.00007845198,0.0003974371,0.00013497665,0.000057671838],"category_scores_gemma":[0.0016962119,0.00015581968,0.0019331222,0.0002600138,0.00007614592,0.00015459719,0.00010720249,0.00051485334,0.000011022068],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004150672,0.0016986942,0.2926761,0.63402665,0.011876139,0.00015735577,0.0006507481,0.000003712107,0.000002075386,0.000063402935,0.026120804,0.032309264],"study_design_scores_gemma":[0.0007941915,0.000053785636,0.018616116,0.9662325,0.009849205,0.000053455857,0.000015084758,0.00007528212,2.4961398e-7,0.00012361146,0.0040213997,0.0001651278],"about_ca_topic_score_codex":0.0000060271745,"about_ca_topic_score_gemma":0.000012860248,"teacher_disagreement_score":0.33220583,"about_ca_system_score_codex":0.000641912,"about_ca_system_score_gemma":0.0006223088,"threshold_uncertainty_score":0.63541424},"labels":[],"label_agreement":null},{"id":"W2070552896","doi":"10.7448/ias.15.6.18114","title":"Computational models that predict response to HIV therapy can reduce virological failure and therapy costs in resource‐limited settings","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Medicine; Regimen; Viral load; Antiretroviral therapy; Receiver operating characteristic; Pharmacotherapy; Human immunodeficiency virus (HIV); Area under the curve; Internal medicine; Intensive care medicine; Immunology","score_opus":0.024735800235683388,"score_gpt":0.2778742070883375,"score_spread":0.2531384068526541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070552896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8848701,0.00037346213,0.00016414649,0.11407913,0.00012604408,0.00023860086,0.000017307153,0.000010166326,0.000121004254],"genre_scores_gemma":[0.9842028,0.0001838432,0.007905554,0.005969463,0.00023403659,0.000010215366,0.000011913274,0.000015334199,0.001466842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983857,0.00015611225,0.0003614751,0.0001383097,0.00075027294,0.00020808728],"domain_scores_gemma":[0.9990053,0.00033436273,0.00021914346,0.000100733494,0.00017266732,0.00016777619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001222174,0.000158529,0.0002448642,0.000107220934,0.00008574396,0.000036702175,0.00022740058,0.00009397708,0.000047756348],"category_scores_gemma":[0.000100912635,0.000092753515,0.00022425075,0.0001703461,0.00007232086,0.00016904194,0.00008075153,0.00034917696,0.0000020298041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012040043,0.0017149311,0.74945575,0.000011797701,0.002065817,0.000056603803,0.024438,0.0039727064,0.011264078,0.00038935238,0.18304867,0.0115422765],"study_design_scores_gemma":[0.01725345,0.00089124736,0.8105657,0.00057275017,0.000095056486,0.001425443,0.0044770874,0.005918012,0.0052963877,0.0016257229,0.15145035,0.00042876272],"about_ca_topic_score_codex":0.0000036109332,"about_ca_topic_score_gemma":9.435305e-7,"teacher_disagreement_score":0.10810967,"about_ca_system_score_codex":0.00042348893,"about_ca_system_score_gemma":0.00014048826,"threshold_uncertainty_score":0.37823784},"labels":[],"label_agreement":null},{"id":"W2070663444","doi":"10.1074/jbc.m303528200","title":"Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC","year":2003,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Resistance mutation; Primer (cosmetics); Zidovudine; Biology; Mutation; Mutant; Virology; Nucleotidyltransferase; Enzyme; Virus; Genetics; Molecular biology; RNA; Chemistry; Gene; Viral disease; Biochemistry","score_opus":0.018828040327559588,"score_gpt":0.2556548884342267,"score_spread":0.2368268481066671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070663444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997033,0.00051997975,0.00005756446,0.0015727823,0.000009429933,0.00009152537,0.000018456129,0.0000017255601,0.00069556065],"genre_scores_gemma":[0.9978892,0.00008565836,0.0015777274,0.00006307184,0.000014711893,0.00000454318,0.0000075644966,0.0000025043341,0.00035497377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993093,0.00004739458,0.0003210817,0.0001034289,0.00011348882,0.000105329396],"domain_scores_gemma":[0.99960226,0.0001414417,0.000086210275,0.00005779772,0.00003229107,0.00008000276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003602089,0.00008743716,0.00023694712,0.000033786295,0.000023556007,0.00000596148,0.000033895165,0.00006180441,0.000041024163],"category_scores_gemma":[0.00041105328,0.00004859803,0.00003376765,0.00012119215,0.00006800128,0.00001845028,0.0000067391616,0.00015482822,5.4355945e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027071808,0.0021294886,0.50562733,0.0005195133,0.000209243,0.00525364,0.0076231994,0.0000132560845,0.47105968,0.001210767,0.0025662794,0.0010804362],"study_design_scores_gemma":[0.018915119,0.0011935222,0.66356754,0.0022339148,0.0004973329,0.0037721172,0.01647046,0.000028948889,0.26476017,0.0072073755,0.02057021,0.0007833007],"about_ca_topic_score_codex":8.3949396e-7,"about_ca_topic_score_gemma":0.000008759882,"teacher_disagreement_score":0.20629951,"about_ca_system_score_codex":0.00003557017,"about_ca_system_score_gemma":0.00004294616,"threshold_uncertainty_score":0.19817702},"labels":[],"label_agreement":null},{"id":"W2071096069","doi":"10.7448/ias.15.6.18204","title":"The prevalence and economic burden of 1<sup>st</sup>‐generation NNRTI resistance","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Drug resistance; Cohort study; Observational study; Disease burden; Disease","score_opus":0.015023867735824686,"score_gpt":0.2616105731557526,"score_spread":0.24658670541992792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071096069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808912,0.0018461145,0.00004502571,0.015937543,0.00040634582,0.00009806817,0.000011517985,0.0000027219614,0.000761434],"genre_scores_gemma":[0.9696413,0.0011554956,0.002050012,0.00011705009,0.0007905875,0.0000028720422,0.0000016830114,0.0000064898923,0.02623446],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991489,0.00003117181,0.00034054214,0.00006098559,0.00031876154,0.00009965562],"domain_scores_gemma":[0.9992704,0.00010846441,0.00032040785,0.00010514922,0.00014361534,0.000051974224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006192087,0.00007470666,0.00012634978,0.00001774335,0.000104808394,0.000023508448,0.00018403857,0.00003389078,0.000063440886],"category_scores_gemma":[0.000075215066,0.00003914955,0.00019118417,0.000034635686,0.00008165046,0.00016742465,0.00005675932,0.00012415102,0.0000040645427],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004856336,0.00037064945,0.6511824,0.00020452567,0.0037045768,0.0000045325537,0.016188106,0.00073708897,0.008114663,0.008610386,0.30510092,0.0052965265],"study_design_scores_gemma":[0.008354092,0.00037346812,0.24030986,0.0014206949,0.0015564661,0.0007591713,0.0044869245,0.016006976,0.04191087,0.002727712,0.6815566,0.00053718383],"about_ca_topic_score_codex":0.000003837038,"about_ca_topic_score_gemma":0.00000314415,"teacher_disagreement_score":0.41087255,"about_ca_system_score_codex":0.00023329757,"about_ca_system_score_gemma":0.00010915754,"threshold_uncertainty_score":0.15964723},"labels":[],"label_agreement":null},{"id":"W2071185947","doi":"10.1097/01.aids.0000433240.78739.30","title":"Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care","year":2013,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"National Institute of Allergy and Infectious Diseases; National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality","keywords":"Medicine; Confidence interval; HIV drug resistance; Drug resistance; Cohort study; Men who have sex with men; Cohort; Sexual transmission; Internal medicine; Sida; Retrospective cohort study; Viral load; Transmission (telecommunications); Demography; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Viral disease; Biology; Syphilis","score_opus":0.01585610398698743,"score_gpt":0.2391124118349218,"score_spread":0.22325630784793438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071185947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967445,0.000118841825,0.000055414355,0.00028392728,0.00004004477,0.00071481935,0.00002074641,0.0000283495,0.001993365],"genre_scores_gemma":[0.96567017,0.00001977431,0.0021976575,0.000025984122,0.000014335488,0.00008073006,0.0003631948,0.0000168939,0.03161127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918866,0.000025840573,0.0002639941,0.00016042568,0.00017673195,0.00018431952],"domain_scores_gemma":[0.9995346,0.0000430524,0.000059343176,0.00012703518,0.00015494743,0.000081026534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051575164,0.00012475248,0.0002563389,0.00014174453,0.000034871904,0.000006800197,0.000045346867,0.000051626783,0.000071499584],"category_scores_gemma":[0.000022174972,0.00009911329,0.000049299888,0.00011845864,0.000049652124,0.000119057586,0.000011023025,0.000056916328,0.000006483688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010065116,0.00017486495,0.9680629,0.00028053691,0.000034619694,0.0000076006495,0.003480512,2.1597396e-7,0.00024116627,0.00003770271,0.0063838246,0.021195402],"study_design_scores_gemma":[0.0067755184,0.0005292139,0.9705425,0.00048225248,0.00010315691,3.7210626e-7,0.0052584554,0.00004998293,0.009350245,0.000047982576,0.006630775,0.00022955214],"about_ca_topic_score_codex":0.00009382773,"about_ca_topic_score_gemma":0.00003663782,"teacher_disagreement_score":0.031074334,"about_ca_system_score_codex":0.000065945336,"about_ca_system_score_gemma":0.000075247444,"threshold_uncertainty_score":0.40417227},"labels":[],"label_agreement":null},{"id":"W2071219960","doi":"10.1111/j.1365-2125.2005.02369.x","title":"Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz","year":2005,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lopinavir; Efavirenz; Ritonavir; Reverse-transcriptase inhibitor; Lopinavir/ritonavir; Pharmacokinetics; Confidence interval; Pharmacology; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy","score_opus":0.12691293369133516,"score_gpt":0.47964600431801924,"score_spread":0.3527330706266841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071219960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9041469,0.04874358,0.0010558948,0.041384216,0.0035929095,0.00088345894,0.000023557708,0.00001584362,0.000153649],"genre_scores_gemma":[0.9586799,0.029167356,0.0028489854,0.0027529697,0.0037751207,0.000032458604,0.0000055436835,0.000022184224,0.002715447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975109,0.00023813658,0.0015389188,0.00017704783,0.00030373098,0.00023123663],"domain_scores_gemma":[0.9967164,0.0017776709,0.0007866889,0.00008130784,0.00044077748,0.00019715096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018129727,0.00012804361,0.00071068737,0.00006649756,0.00007968154,0.0000120334025,0.00021357564,0.000117526775,0.0005360911],"category_scores_gemma":[0.0007123565,0.00009832115,0.0004125529,0.00014218838,0.00023769241,0.00018605568,0.000035309757,0.00055254996,0.0000131949555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018318354,0.0010619959,0.0017873588,0.00005166585,0.0010467203,0.00009523564,0.000058770718,0.00003126621,0.008955084,0.000007951998,0.405664,0.5794081],"study_design_scores_gemma":[0.02060097,0.0007722546,0.05051179,0.00044799282,0.0038487774,0.0024887605,0.000047962207,0.0003778877,0.026026279,0.00007958809,0.8946107,0.00018705065],"about_ca_topic_score_codex":0.000007205392,"about_ca_topic_score_gemma":0.0000025917964,"teacher_disagreement_score":0.57922107,"about_ca_system_score_codex":0.000043147687,"about_ca_system_score_gemma":0.00027962864,"threshold_uncertainty_score":0.58698213},"labels":[],"label_agreement":null},{"id":"W2071348779","doi":"10.1007/s40121-013-0020-8","title":"Integrase Strand Transfer Inhibitors in HIV Therapy","year":2013,"lang":"en","type":"article","venue":"Infectious Diseases and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"McGill University; Gilead Sciences","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Medicine; Integrase; Integrase inhibitor; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Drug resistance; ANTIRETROVIRAL AGENTS; Pharmacology; Viral load; Genetics; Biology","score_opus":0.007987669879841293,"score_gpt":0.23480978133292513,"score_spread":0.22682211145308384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071348779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98448545,0.011818715,0.000029624971,0.0016364,0.00007889313,0.00085793785,0.000009515292,0.000093501265,0.0009899846],"genre_scores_gemma":[0.9840778,0.013663499,0.000012428824,0.00090149674,0.00008689818,0.00019853209,0.000029768471,0.000025182791,0.0010043551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991557,0.000035971785,0.00020155842,0.00024280042,0.00013528607,0.00022866222],"domain_scores_gemma":[0.9995647,0.000042753174,0.000015999081,0.00013355474,0.00004066598,0.00020229738],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000038818056,0.00021310932,0.0002669755,0.00015622619,0.00006656066,0.00005073043,0.000029287372,0.00006444176,0.0009910375],"category_scores_gemma":[0.0000046848027,0.00014423915,0.00010334026,0.00016760852,0.000065637345,0.00012544265,0.0000047822814,0.000107539185,0.00005637925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000272018,0.0012192295,0.8216151,0.000018024843,0.00023453464,0.00004860124,0.0008073011,0.0000012390823,0.00066651235,0.00010489125,0.0026620491,0.17235051],"study_design_scores_gemma":[0.029772786,0.0009436374,0.89863575,0.00020417303,0.00008317498,0.00006116912,0.00039006938,0.00008249507,0.003159855,0.0023659763,0.063708,0.0005928905],"about_ca_topic_score_codex":0.00014885777,"about_ca_topic_score_gemma":0.000020748821,"teacher_disagreement_score":0.17175761,"about_ca_system_score_codex":0.000039145165,"about_ca_system_score_gemma":0.000060292325,"threshold_uncertainty_score":0.9999222},"labels":[],"label_agreement":null},{"id":"W2071538535","doi":"10.1016/j.drup.2009.02.001","title":"Mutational ‘hot-spots’ in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: Sequence and structural comparison","year":2009,"lang":"en","type":"review","venue":"Drug Resistance Updates","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Antifolate; Biology; Dihydrofolate reductase; Plasmodium falciparum; Genetics; Antimetabolite; Malaria; Gene; Immunology","score_opus":0.027419261102729693,"score_gpt":0.3193452072151339,"score_spread":0.2919259461124042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071538535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10083828,0.89428943,8.689531e-7,0.00063288625,0.00009893669,0.003204757,0.0004914432,0.000105061714,0.00033835144],"genre_scores_gemma":[0.026545068,0.93899006,0.0032284565,0.000047450434,0.00017257605,0.00048607908,0.007697449,0.000145675,0.02268721],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964055,0.00026962947,0.0010936972,0.0010478053,0.0005518763,0.00063152873],"domain_scores_gemma":[0.99830824,0.0002315009,0.0007050202,0.00035196551,0.00016765673,0.0002356372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003723382,0.00086316356,0.0024371503,0.00036377576,0.00023482097,0.00018174872,0.00016975564,0.00028733336,0.00005706422],"category_scores_gemma":[0.00014803832,0.0006396216,0.000116486124,0.0007158576,0.00032845762,0.00026660756,0.00005870358,0.00054707564,0.000008702164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025418444,0.0031743278,0.08365779,0.12901276,0.011354293,0.022728737,0.014805173,0.0000097740785,0.0003200686,0.004531953,0.054713648,0.650273],"study_design_scores_gemma":[0.007688511,0.00015288264,0.028972244,0.08200377,0.0028327897,0.00030230306,0.00022443861,0.0000362361,0.00019556227,0.0006616826,0.87450254,0.0024270432],"about_ca_topic_score_codex":0.000011930711,"about_ca_topic_score_gemma":0.00077661005,"teacher_disagreement_score":0.8197889,"about_ca_system_score_codex":0.00042273448,"about_ca_system_score_gemma":0.0006638627,"threshold_uncertainty_score":0.99960554},"labels":[],"label_agreement":null},{"id":"W2071621051","doi":"10.1310/hag3-8ya5-udqc-36nx","title":"Virologic and Immunologic Response to a Boosted Double-Protease Inhibitor-Based Therapy in Highly Pretreated HIV-1-Infected Patients","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Abbott Canada; Abbott Laboratories","keywords":"Saquinavir; Medicine; Lopinavir; Regimen; Protease inhibitor (pharmacology); Internal medicine; Ritonavir; Viral load; Lamivudine; Gastroenterology; Immunology; Odds ratio; Reverse-transcriptase inhibitor; Nelfinavir; Drug resistance; Pharmacology; Virology; Virus; Antiretroviral therapy; Biology","score_opus":0.12595465333192757,"score_gpt":0.40690000416868316,"score_spread":0.2809453508367556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071621051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980963,0.00025556303,0.000013420575,0.013900663,0.0001590207,0.004264613,0.000050426683,0.00020428676,0.00018899002],"genre_scores_gemma":[0.99320513,0.00016233082,0.0016700026,0.0016035978,0.00018376682,0.00038815802,0.00018372334,0.00003632733,0.0025669904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933051,0.002956181,0.0021518988,0.0007571513,0.00034683704,0.00048284733],"domain_scores_gemma":[0.99449867,0.0040417933,0.0003968761,0.0005015405,0.00016240755,0.00039870007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0061432393,0.00041208527,0.0015760625,0.0004274724,0.000086381835,0.000041733456,0.00012483394,0.0004485641,0.00031287858],"category_scores_gemma":[0.008033012,0.00027744533,0.00028807868,0.00057511864,0.00013280699,0.000084058374,0.00007197527,0.0003916694,0.0005326293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22681078,0.0057218475,0.721313,0.000020912408,0.00036128378,0.000188711,0.00027878126,0.000016459744,0.0050944244,0.000008796261,0.0055964477,0.034588564],"study_design_scores_gemma":[0.1412928,0.0055867825,0.8178546,0.0003092711,0.0001860229,0.000004084556,0.000024093157,0.0001324938,0.009393724,0.000023155344,0.024717316,0.00047565086],"about_ca_topic_score_codex":0.000010069106,"about_ca_topic_score_gemma":0.0000073384717,"teacher_disagreement_score":0.09654162,"about_ca_system_score_codex":0.00019067,"about_ca_system_score_gemma":0.00027649372,"threshold_uncertainty_score":0.99996775},"labels":[],"label_agreement":null},{"id":"W2071680567","doi":"10.1097/00002030-200409240-00005","title":"The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection","year":2004,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre","funders":"","keywords":"Regimen; Enfuvirtide; Medicine; Internal medicine; Reverse-transcriptase inhibitor; Salvage therapy; Sida; Prospective cohort study; Antiretroviral therapy; Cohort; Viral load; Protease inhibitor (pharmacology); Cohort study; Human immunodeficiency virus (HIV); Viral disease; Chemotherapy; Immunology","score_opus":0.01740227073411185,"score_gpt":0.3345181246373217,"score_spread":0.3171158539032099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071680567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965479,0.0001425121,0.00000356956,0.0009792743,0.00014519705,0.00035642873,0.000009558318,0.000023422836,0.0017921448],"genre_scores_gemma":[0.99806947,0.00092506903,0.00009061006,0.000026360238,0.00016971631,0.00003671481,0.00003546644,0.00001033352,0.00063627167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930716,0.000041734096,0.00016521887,0.00014816089,0.0001604456,0.00017726744],"domain_scores_gemma":[0.99966806,0.00004734978,0.000062957464,0.00014439093,0.00003187357,0.000045389083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006812513,0.00015971741,0.00021827313,0.00012232625,0.00007356244,0.0000106466805,0.000034819444,0.00006472221,0.000023392318],"category_scores_gemma":[0.0000095413325,0.000078022626,0.0001386201,0.00024289242,0.0000608792,0.00007382406,0.0000058816436,0.00008948687,0.000024809933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026245974,0.0016566366,0.7603588,0.0000070800547,0.0008312507,0.00012958302,0.0058166995,0.0001234839,0.0026218225,0.0014950355,0.00018819066,0.22414681],"study_design_scores_gemma":[0.010757841,0.013369075,0.871911,0.0001077726,0.000056464236,0.000023225286,0.0003771405,0.000007804394,0.10119584,0.00067143684,0.0013561351,0.00016629767],"about_ca_topic_score_codex":0.00093832554,"about_ca_topic_score_gemma":0.00006650517,"teacher_disagreement_score":0.22398052,"about_ca_system_score_codex":0.00062986097,"about_ca_system_score_gemma":0.00026612353,"threshold_uncertainty_score":0.31816703},"labels":[],"label_agreement":null},{"id":"W2071683275","doi":"10.1097/01.qai.0000137005.63376.6e","title":"Resistance Issues With New Nucleoside/Nucleotide Backbone Options","year":2004,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Resistance mutation; Abacavir; Zidovudine; Stavudine; Medicine; Emtricitabine; Lamivudine; Drug resistance; Clinical trial; Nucleoside Reverse Transcriptase Inhibitor; Virology; Nucleoside; Reverse transcriptase; Internal medicine; Pharmacology; Biology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genetics; Viral load; Virus; Viral disease; Polymerase chain reaction","score_opus":0.01552054243376064,"score_gpt":0.2637781314582683,"score_spread":0.24825758902450765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071683275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576134,0.01646961,0.0007837168,0.022372978,0.00033456596,0.00036048016,0.0000051552324,0.00011972863,0.0019403577],"genre_scores_gemma":[0.90438014,0.0019360229,0.05170843,0.00012812625,0.00011832319,0.000006412378,0.000011489807,0.00008259858,0.041628473],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972813,0.00004101317,0.0010055162,0.00029538255,0.0008599729,0.00051683054],"domain_scores_gemma":[0.99820817,0.00007919856,0.0005242003,0.00046182252,0.00034380908,0.0003827913],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005081693,0.00035068495,0.0008555395,0.00061114406,0.00023230186,0.000078208235,0.00029779976,0.000096770214,0.0001886958],"category_scores_gemma":[0.00024785547,0.0002471094,0.0002990833,0.0010816256,0.00020373544,0.00049252843,0.000050365878,0.00016459619,0.00029909232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0212576,0.026987752,0.19127439,0.003381065,0.018362513,0.056351516,0.07870444,0.006112704,0.24345802,0.07329368,0.24221459,0.03860174],"study_design_scores_gemma":[0.063691,0.011584547,0.6777911,0.0163285,0.004898352,0.031085413,0.015024177,0.00002944654,0.07446828,0.017158698,0.08440484,0.003535647],"about_ca_topic_score_codex":0.00004137269,"about_ca_topic_score_gemma":0.000019566503,"teacher_disagreement_score":0.4865167,"about_ca_system_score_codex":0.0003022954,"about_ca_system_score_gemma":0.00094794965,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W2071800230","doi":"10.3851/imp2709","title":"The Cost of Antiretroviral Drug Resistance in HIV-Positive Patients","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"Alberta Health Services","keywords":"Medicine; HIV drug resistance; Drug resistance; Dosing; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Biology","score_opus":0.007901470614739147,"score_gpt":0.2416222029467469,"score_spread":0.23372073233200777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071800230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877337,0.0004974033,0.000006392148,0.002375196,0.00006852277,0.0008901473,0.0000075159646,0.000015891908,0.008405182],"genre_scores_gemma":[0.97409374,0.00064409216,0.0002935141,0.0001324298,0.000021334245,0.00005477602,0.000036583715,0.000014819518,0.024708698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903923,0.00006649041,0.00025526385,0.00016936283,0.00022717367,0.00024248578],"domain_scores_gemma":[0.99949205,0.00009512036,0.000088853245,0.000192164,0.00009810101,0.000033702538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116898416,0.00013847061,0.00023129204,0.00006347973,0.00007932379,0.00001823726,0.00009216315,0.000034659293,0.000031350995],"category_scores_gemma":[0.000016015081,0.00008270728,0.00007010043,0.00021144199,0.00011482372,0.00012180329,0.000017904013,0.0001002489,0.000118224074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003912913,0.0004061432,0.9535871,0.000007831969,0.00007629144,0.0000093766885,0.001355512,3.4140523e-8,0.0008212476,0.0005241049,0.009693367,0.033127688],"study_design_scores_gemma":[0.0041550454,0.0001367384,0.9643893,0.00013361186,0.000009261115,3.0967635e-7,0.0001642131,0.000010399513,0.02063623,0.00030559467,0.009930321,0.00012897205],"about_ca_topic_score_codex":0.0000491631,"about_ca_topic_score_gemma":0.000048817725,"teacher_disagreement_score":0.032998715,"about_ca_system_score_codex":0.000051519597,"about_ca_system_score_gemma":0.00004253438,"threshold_uncertainty_score":0.3372705},"labels":[],"label_agreement":null},{"id":"W2071822666","doi":"10.1054/drup.2000.0126","title":"Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase","year":2000,"lang":"en","type":"article","venue":"Drug Resistance Updates","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Health Canada","keywords":"Reverse transcriptase; Context (archaeology); Nucleoside; Drug resistance; Biology; Nucleoside Reverse Transcriptase Inhibitor; Enzyme; Drug; Human immunodeficiency virus (HIV); Virology; Amino acid; Genetics; Pharmacology; RNA; Biochemistry; Gene","score_opus":0.006801987319243661,"score_gpt":0.22515922886026052,"score_spread":0.21835724154101685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071822666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98108315,0.0011383888,0.00004629677,0.012072607,0.00007320155,0.0007251552,0.000080955164,0.00008917,0.0046910774],"genre_scores_gemma":[0.92276514,0.00021457454,0.026534116,0.00066949177,0.000042456337,0.00007282256,0.00014326742,0.00005131244,0.04950684],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977983,0.000058584686,0.00068622903,0.00055293954,0.00044198788,0.00046195483],"domain_scores_gemma":[0.9990538,0.00007225132,0.00009015392,0.0004655504,0.000070340386,0.00024792674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029202312,0.00031565162,0.00059397507,0.00025513276,0.000068121546,0.000017832557,0.00017707855,0.000106973166,0.0005655698],"category_scores_gemma":[0.00007018176,0.0002972959,0.00014486891,0.00068657147,0.000087591,0.00013745409,0.000025201982,0.00019343878,0.0001384436],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007893604,0.001678354,0.025472354,0.0010519075,0.00029086418,0.00092062756,0.009563596,0.000013960515,0.31949744,0.0052626356,0.627015,0.0013396819],"study_design_scores_gemma":[0.004598878,0.000026076912,0.0039305827,0.002504603,0.00013567845,0.000003235554,0.0012042557,0.000015196205,0.7554456,0.0016952044,0.22986288,0.0005778003],"about_ca_topic_score_codex":0.000024720295,"about_ca_topic_score_gemma":0.0005581941,"teacher_disagreement_score":0.4359482,"about_ca_system_score_codex":0.00024339638,"about_ca_system_score_gemma":0.000109830886,"threshold_uncertainty_score":0.9999479},"labels":[],"label_agreement":null},{"id":"W2072728217","doi":"10.1182/blood.v98.4.1078","title":"Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Ontario HIV Treatment Network","keywords":"Nelfinavir; Apoptosis; Caspase; Saquinavir; Protease; Ritonavir; Cell biology; Caspase-9; Mitochondrion; Biology; Caspase 3; Chemistry; Pharmacology; Biochemistry; Programmed cell death; Enzyme; Human immunodeficiency virus (HIV); Virology","score_opus":0.007867603037829704,"score_gpt":0.2255433754639587,"score_spread":0.21767577242612898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072728217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502814,0.0001475002,0.001218988,0.0010237853,0.0002341063,0.0011779804,0.000010946344,0.00008886951,0.0010696915],"genre_scores_gemma":[0.98635805,0.000050280123,0.0062956437,0.000023363054,0.0004918867,0.00005424181,0.00006526797,0.000035388897,0.0066258716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984244,0.000046527424,0.0004552246,0.00032154165,0.00041418467,0.0003381361],"domain_scores_gemma":[0.9993689,0.000017563234,0.00012571915,0.00024753032,0.00007851998,0.00016173325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011499414,0.00022182445,0.00039682028,0.00014793637,0.00007511313,0.000014363736,0.000085433385,0.000112362584,0.00027762973],"category_scores_gemma":[0.00003432217,0.00018952844,0.00021155541,0.00022834713,0.00004635818,0.000090743735,0.000028361344,0.00013780012,0.00006721064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018361739,0.017464656,0.039566725,0.0015384235,0.0026624664,0.0054991837,0.003152738,0.00001644074,0.920934,0.0011803844,0.00108849,0.0050602956],"study_design_scores_gemma":[0.02554646,0.00040395372,0.0014863934,0.0008148974,0.0019067845,0.0008337861,0.00015967363,0.00012800233,0.96666116,0.00045368474,0.0012047195,0.0004004861],"about_ca_topic_score_codex":0.0000095861,"about_ca_topic_score_gemma":0.0000022339086,"teacher_disagreement_score":0.045727134,"about_ca_system_score_codex":0.000019956255,"about_ca_system_score_gemma":0.00013600421,"threshold_uncertainty_score":0.77287453},"labels":[],"label_agreement":null},{"id":"W2073523050","doi":"10.1089/08892220050140964","title":"Mutations in the HIV Type 1 Integrase of Patients Receiving Long-Term Dideoxynucleoside Therapy Do Not Confer Resistance to Zidovudine","year":2000,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Institutes of Health","keywords":"Integrase; Zidovudine; Integrases; Virology; Biology; Integrase inhibitor; Mutation; Genetics; Lentivirus; Mutant; Recombinant DNA; Resistance mutation; Virus; Reverse transcriptase; Gene; Human immunodeficiency virus (HIV); RNA; Antiretroviral therapy; Viral disease; Viral load","score_opus":0.07307505761967352,"score_gpt":0.3759893807946429,"score_spread":0.30291432317496936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073523050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387884,0.00026258774,0.0000011237744,0.0009944368,0.000012419881,0.0006666851,0.000023194616,0.000014332913,0.0041463478],"genre_scores_gemma":[0.9857889,0.00052363315,0.00020853365,0.00022319879,0.000037065143,0.00005893303,0.0000756537,0.000018973464,0.013065142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982859,0.00017182808,0.00030590635,0.00028295643,0.0005893587,0.0003640456],"domain_scores_gemma":[0.9989101,0.00030880573,0.00003403349,0.00032590702,0.0002835353,0.00013756662],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059701275,0.00014109924,0.00025622142,0.00036150828,0.000218711,0.000067899484,0.00016478938,0.000049598337,0.00091657066],"category_scores_gemma":[0.00022396552,0.000090996975,0.00003960853,0.00056827255,0.00022524991,0.00009746498,0.000035974525,0.00027491036,0.000103748134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078250776,0.00051877287,0.98308563,0.0000388075,0.00007261461,0.00004457496,0.0029028961,1.5260179e-7,0.00069464056,0.00056759553,0.0038070013,0.007484787],"study_design_scores_gemma":[0.0017684759,0.00094537245,0.9898396,0.00023810171,0.000014257659,0.0000011263645,0.00027088504,1.7370088e-7,0.00192583,0.00020096773,0.0047023627,0.00009281399],"about_ca_topic_score_codex":0.00008092404,"about_ca_topic_score_gemma":0.0006876863,"teacher_disagreement_score":0.008918794,"about_ca_system_score_codex":0.0000796932,"about_ca_system_score_gemma":0.000094017094,"threshold_uncertainty_score":0.9999967},"labels":[],"label_agreement":null},{"id":"W2074171743","doi":"10.7448/ias.15.6.18113","title":"Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness","year":2012,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Integrase; Virology; Integrase inhibitor; Recombinant DNA; Viral replication; Virus; Resistance mutation; Mutation; Recombinant virus; Viral evolution; Drug resistance; Biology; Mutagenesis; Molecular biology; Viral load; Genetics; Human immunodeficiency virus (HIV); Gene; Reverse transcriptase; Antiretroviral therapy; Polymerase chain reaction; Genome","score_opus":0.01183608156442615,"score_gpt":0.28264853268101764,"score_spread":0.27081245111659147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074171743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857025,0.00025389303,0.00066801574,0.012345976,0.00017060048,0.00018893156,0.000055113258,0.0000061867863,0.0006087752],"genre_scores_gemma":[0.97692406,0.00009697045,0.009312426,0.00033668848,0.000103676895,0.000014139567,0.000039986375,0.000008360327,0.013163668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990384,0.000035282275,0.00033027123,0.000107537824,0.00037869922,0.000109798246],"domain_scores_gemma":[0.9992579,0.000054111333,0.00027488108,0.000092953735,0.00023623007,0.00008389486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003328724,0.00009889634,0.00016628207,0.00006408324,0.00009035798,0.000015847503,0.00011929069,0.00006001776,0.00003962227],"category_scores_gemma":[0.0001068058,0.00006356852,0.00016849066,0.00019923385,0.000050005863,0.00021543486,0.000048552105,0.00018523919,0.000002642085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031607502,0.00075945974,0.7253503,0.000034901328,0.00058429374,0.0000020553164,0.012743003,0.0000179116,0.05737588,0.0009908677,0.20128016,0.00054504536],"study_design_scores_gemma":[0.005258574,0.00029032043,0.72483057,0.001155665,0.0006506477,0.000555093,0.00797088,0.0002721183,0.1981915,0.0014631313,0.058996223,0.00036527865],"about_ca_topic_score_codex":0.000008018729,"about_ca_topic_score_gemma":0.000022723289,"teacher_disagreement_score":0.14228395,"about_ca_system_score_codex":0.00054747117,"about_ca_system_score_gemma":0.00005724651,"threshold_uncertainty_score":0.25922492},"labels":[],"label_agreement":null},{"id":"W2074423441","doi":"10.1016/j.molbiopara.2011.06.007","title":"Molecular characterization of Plasmodium falciparum putative polynucleotide kinase/phosphatase","year":2011,"lang":"en","type":"article","venue":"Molecular and Biochemical Parasitology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Thailand Research Fund; Mahidol University","keywords":"Biology; DNA; DNA repair; Gene; Biochemistry; Molecular biology; Phosphatase; Enzyme; Genetics","score_opus":0.011796324733639072,"score_gpt":0.262785838608485,"score_spread":0.2509895138748459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074423441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963848,0.00041362346,0.0013546577,0.0006561306,0.00005346056,0.0002724294,0.000035165533,0.000029211547,0.00080054614],"genre_scores_gemma":[0.99723685,0.000026553806,0.001811502,0.00031517886,0.000009009071,0.000023234907,0.00047027747,0.000017978007,0.00008940554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989779,0.000041739295,0.00027153184,0.00032355057,0.00013467306,0.00025061256],"domain_scores_gemma":[0.99948543,0.000016409189,0.0000926452,0.00017764642,0.0000635057,0.0001643596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004860247,0.00019378845,0.00036845615,0.00009505921,0.000028521012,0.00000410403,0.00006383128,0.00015185197,0.000049627557],"category_scores_gemma":[0.000038548904,0.00016642561,0.0000864368,0.00014084807,0.00020480623,0.000029329367,0.000054232027,0.000100510835,0.000021486912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003762731,0.0003271017,0.020581212,0.00004891666,0.00020876522,0.00058444723,0.00029151223,6.579168e-8,0.97551197,0.0013946599,0.00008945764,0.00058563775],"study_design_scores_gemma":[0.0011324589,0.00017510544,0.021505319,0.000030444011,0.00018548073,0.00008935231,0.000029357227,0.000027763697,0.9762982,0.00019409342,0.0001838185,0.00014860321],"about_ca_topic_score_codex":0.000015775402,"about_ca_topic_score_gemma":3.1435042e-7,"teacher_disagreement_score":0.0012005664,"about_ca_system_score_codex":0.000019527064,"about_ca_system_score_gemma":0.000043304964,"threshold_uncertainty_score":0.67866397},"labels":[],"label_agreement":null},{"id":"W2074595878","doi":"10.1007/s40271-015-0123-2","title":"Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial","year":2015,"lang":"en","type":"article","venue":"Patient","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cilag; AbbVie Canada; Janssen Canada; Merck Canada; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Rilpivirine; Emtricitabine; Medicine; Regimen; Tolerability; Internal medicine; Randomized controlled trial; Ritonavir; Lamivudine; Human immunodeficiency virus (HIV); Protease inhibitor (pharmacology); Pharmacology; Adverse effect; Viral load; Virology; Virus; Antiretroviral therapy","score_opus":0.035566704048321386,"score_gpt":0.2744014148754535,"score_spread":0.23883471082713212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074595878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895155,0.00014254022,0.00006289004,0.0021266884,0.00015401919,0.004998277,0.0014200344,0.000037222646,0.0015428376],"genre_scores_gemma":[0.9818113,0.000007983374,0.011796849,0.0008580112,0.000034218137,0.0022456874,0.0018945896,0.000037200214,0.0013142],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964334,0.0003073547,0.0013062044,0.000681911,0.0008214073,0.00044976117],"domain_scores_gemma":[0.99763423,0.000946182,0.0004137253,0.00033451995,0.00026568805,0.00040562285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050329376,0.00042606788,0.0015480064,0.00044051043,0.000054486347,0.00007039001,0.00015737565,0.00016134644,0.0006817798],"category_scores_gemma":[0.0017108236,0.00030505538,0.00010752693,0.00044302738,0.00012529237,0.00022470266,0.0004177734,0.00019504863,0.00006266693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72199273,0.01431707,0.19656353,0.000040042432,0.0016434113,0.00073452457,0.014222735,0.000007729484,0.0005152738,0.00003780434,0.04675298,0.0031721843],"study_design_scores_gemma":[0.91564345,0.004197875,0.07070109,0.0005357168,0.0006499486,0.000025857202,0.00052191986,0.000091318274,0.0012597551,0.0005125496,0.0052408585,0.0006196797],"about_ca_topic_score_codex":0.0001563013,"about_ca_topic_score_gemma":0.000027644823,"teacher_disagreement_score":0.19365071,"about_ca_system_score_codex":0.00025238987,"about_ca_system_score_gemma":0.00033680524,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W2074712302","doi":"10.1007/s00280-003-0699-4","title":"Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"Cytarabine; In vivo; Pharmacology; Nucleoside; In vitro; Chemistry; Leukemia; Biology; Biochemistry; Immunology","score_opus":0.014840424263793414,"score_gpt":0.297704482429017,"score_spread":0.2828640581652236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074712302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542207,0.000896514,0.000018566232,0.0026977733,0.00014180041,0.00045402668,0.00002448472,0.000012082095,0.00033267905],"genre_scores_gemma":[0.99627936,0.0016518811,0.0001670561,0.0010113149,0.00005483111,0.000035812798,0.000009187687,0.000017229713,0.00077331724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991076,0.00008666633,0.00022866091,0.00025064865,0.00009289096,0.00023352561],"domain_scores_gemma":[0.99962187,0.00007392594,0.0001009965,0.000098558885,0.000027907661,0.00007673509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001227123,0.00018610789,0.0003995515,0.000087123844,0.000085796215,0.000004346415,0.000051701634,0.00005753129,0.0007098356],"category_scores_gemma":[0.0000032127236,0.00013378727,0.000043958957,0.00018458882,0.0002077581,0.00004354962,0.000021999236,0.0001616919,6.2723444e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004051762,0.00022671025,0.18583304,0.0001288223,0.00023269698,0.000013143792,0.00059449335,0.000011009762,0.80869603,0.00006223858,0.0016920366,0.0021046163],"study_design_scores_gemma":[0.010849968,0.00016434265,0.109547555,0.00006540017,0.0001580997,0.000019572943,0.000051687108,0.00016523014,0.8691927,0.000068741334,0.009573232,0.00014342411],"about_ca_topic_score_codex":0.00011142059,"about_ca_topic_score_gemma":0.00012662863,"teacher_disagreement_score":0.07628548,"about_ca_system_score_codex":0.00013171246,"about_ca_system_score_gemma":0.00011608203,"threshold_uncertainty_score":0.7772202},"labels":[],"label_agreement":null},{"id":"W2075038980","doi":"10.1111/j.1468-1293.2007.00466.x","title":"Prediction of clinical benefits of ritonavir‐boosted TMC114 from treatment effects on CD4 counts and HIV RNA","year":2007,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Medicine; Hazard ratio; Ritonavir; Confidence interval; Internal medicine; Randomized controlled trial; Viral load; Proportional hazards model; Clinical trial; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.04934452228439241,"score_gpt":0.3266710907693723,"score_spread":0.2773265684849799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075038980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98409367,0.0012587345,0.00005449196,0.0013495202,0.00040866275,0.00047103257,0.000072025105,0.000036262478,0.012255631],"genre_scores_gemma":[0.991506,0.00071965525,0.00055556296,0.00014968928,0.00059677125,0.000009727809,0.00040698252,0.000019314264,0.0060363207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985844,0.000036190282,0.0006025973,0.00024896435,0.0003725061,0.00015534741],"domain_scores_gemma":[0.9987912,0.00055801217,0.00017195458,0.00022869393,0.000073455274,0.0001766633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034244498,0.00017417113,0.0006344465,0.00013621095,0.000024400739,0.0000010542011,0.000034907505,0.00012053403,0.00016454833],"category_scores_gemma":[0.00014657772,0.00011410507,0.00006362769,0.00011969668,0.00012425908,0.000019990695,0.000013164579,0.00009774299,0.000053779135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002570877,0.0016084723,0.6202258,0.0002601006,0.001112615,0.00021802462,0.0020557651,0.0000011504334,0.0037298426,0.00037955312,0.028485253,0.33935252],"study_design_scores_gemma":[0.020159762,0.003237194,0.919291,0.0021000747,0.0009591539,0.000016882233,0.00017335126,0.0000851476,0.027922185,0.00005562344,0.02587075,0.00012885104],"about_ca_topic_score_codex":0.000030789226,"about_ca_topic_score_gemma":0.000008129605,"teacher_disagreement_score":0.33922368,"about_ca_system_score_codex":0.00006361583,"about_ca_system_score_gemma":0.00005312061,"threshold_uncertainty_score":0.46530697},"labels":[],"label_agreement":null},{"id":"W2075712918","doi":"10.1016/j.jmb.2007.05.012","title":"The Nucleoside Triphosphate Diphosphohydrolase-1/CD39 Is Incorporated into Human Immunodeficiency Type 1 Particles, Where It Remains Biologically Active","year":2007,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Nucleoside triphosphate; Viral envelope; Nucleoside; Virus; Extracellular; Biology; ATP hydrolysis; Apyrase; Biochemistry; Enzyme; Cell biology; Adenosine triphosphate; Nucleotide; Virology; ATPase","score_opus":0.013103458141766505,"score_gpt":0.31142161478876806,"score_spread":0.29831815664700156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075712918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984309,0.0050643054,0.0008653163,0.00812884,0.00021817659,0.00025534144,0.000002569003,0.000020991636,0.0011354258],"genre_scores_gemma":[0.9945501,0.00088285306,0.002778574,0.0009998576,0.00005435548,0.0000030091408,0.000014342494,0.000021714484,0.00069519615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980959,0.00014628141,0.00084459136,0.00023705904,0.00023003458,0.00044609688],"domain_scores_gemma":[0.99827695,0.0001460555,0.000621749,0.00028857213,0.0004752446,0.00019142324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011365197,0.00023580481,0.00046803863,0.00013123521,0.00027544255,0.000024711933,0.0002658914,0.00021626407,0.00008985111],"category_scores_gemma":[0.00026136343,0.00013289117,0.00021553891,0.00045681652,0.00027358066,0.000049904404,0.00008465101,0.0003878819,0.00006249557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002481752,0.0005705392,0.023739336,0.000012728825,0.0009391873,0.0014785148,0.0008317931,0.000004325637,0.9456834,0.0025351292,0.0034129901,0.018310258],"study_design_scores_gemma":[0.0076820645,0.0059744855,0.03363026,0.0002665391,0.0006057154,0.000900106,0.0012368258,0.00004591805,0.82266396,0.01675189,0.109652914,0.0005893031],"about_ca_topic_score_codex":0.000025879686,"about_ca_topic_score_gemma":0.000044552944,"teacher_disagreement_score":0.123019464,"about_ca_system_score_codex":0.00020299245,"about_ca_system_score_gemma":0.00024452852,"threshold_uncertainty_score":0.54191446},"labels":[],"label_agreement":null},{"id":"W2076696614","doi":"10.1002/jmv.22047","title":"Subtype diversity associated with the development of HIV‐1 resistance to integrase inhibitors","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de Santé Publique du Québec; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Integrase; Raltegravir; Virology; Integrase inhibitor; Biology; Phylogenetic tree; Genetics; Genotype; Reverse transcriptase; Genetic diversity; Lentivirus; Virus; Gene; Human immunodeficiency virus (HIV); Polymerase chain reaction; Viral disease; Viral load; Antiretroviral therapy; Medicine; Population","score_opus":0.025945497997766836,"score_gpt":0.25028813728882715,"score_spread":0.22434263929106033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076696614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97763795,0.0000965393,0.000675433,0.020352654,0.00011194648,0.000115370836,0.00000112359,0.0000065979566,0.001002408],"genre_scores_gemma":[0.9947287,0.00001836565,0.00296993,0.0006575632,0.00005267954,0.000002080346,0.000002537978,0.000007528313,0.0015606197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982626,0.00009971745,0.0004519813,0.00010365251,0.0008909143,0.0001911235],"domain_scores_gemma":[0.9989042,0.00015966009,0.00031689563,0.00010582356,0.0002050084,0.00030838212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012396437,0.000112426096,0.00038249185,0.00013237745,0.0000974923,0.0000018531068,0.00023343651,0.00013222534,0.00041217107],"category_scores_gemma":[0.0005856199,0.00005626368,0.00006725227,0.00020246692,0.0001719229,0.000030192197,0.0001402687,0.00036003152,0.000018799317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008168394,0.0026802989,0.81751794,0.00006497726,0.003411177,0.0028666148,0.052686147,7.070776e-7,0.00058094104,0.0005061763,0.10321033,0.008306298],"study_design_scores_gemma":[0.008843032,0.0016362022,0.93529326,0.0009850259,0.0007618651,0.00020865953,0.0027354679,0.000005650995,0.0103149945,0.00015467452,0.038805872,0.000255273],"about_ca_topic_score_codex":0.0000039489405,"about_ca_topic_score_gemma":0.00034897128,"teacher_disagreement_score":0.11777534,"about_ca_system_score_codex":0.00012029027,"about_ca_system_score_gemma":0.0005775702,"threshold_uncertainty_score":0.45129842},"labels":[],"label_agreement":null},{"id":"W2077031675","doi":"10.1177/0091270006296763","title":"Pharmacokinetics of Saquinavir With Atazanavir or Low‐Dose Ritonavir Administered Once Daily (ASPIRE I) or Twice Daily (ASPIRE II) in Seronegative Volunteers","year":2007,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity Western University","funders":"","keywords":"Saquinavir; Cmin; Pharmacokinetics; Ritonavir; Atazanavir; Cmax; Dosing; Pharmacology; Medicine; Crossover study; Adverse effect; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology","score_opus":0.07292333696626545,"score_gpt":0.4390793595960441,"score_spread":0.36615602262977864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077031675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98827094,0.00048824472,0.000097205004,0.0084507875,0.0009878254,0.0009059075,0.000020061863,0.000022498149,0.0007565278],"genre_scores_gemma":[0.9857744,0.0011662735,0.0023001703,0.0033388413,0.00083964516,0.000010764438,0.0000101364385,0.00005846803,0.0065012868],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99444354,0.00069671386,0.0030502437,0.00036168113,0.00077362556,0.00067419355],"domain_scores_gemma":[0.9938257,0.0030944252,0.0016600142,0.00032299184,0.00055085524,0.0005460651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004211073,0.00045572827,0.0016410435,0.0002946746,0.00014021758,0.000009055523,0.0006141607,0.00025798075,0.0007417569],"category_scores_gemma":[0.0004888442,0.00024102848,0.000282914,0.0007593862,0.00086152105,0.00023485287,0.00020833666,0.0016104331,0.000029850167],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5868197,0.017651709,0.14668001,0.0008252373,0.0076039247,0.018098012,0.014740113,0.0004843376,0.050873946,0.000029337787,0.045673903,0.11051974],"study_design_scores_gemma":[0.21683279,0.06727467,0.45071352,0.0043071094,0.012077791,0.0057756053,0.009535761,0.0018243225,0.10823473,0.00009300538,0.12141362,0.0019170853],"about_ca_topic_score_codex":0.000030512248,"about_ca_topic_score_gemma":0.00021261627,"teacher_disagreement_score":0.36998692,"about_ca_system_score_codex":0.00021763235,"about_ca_system_score_gemma":0.0013496651,"threshold_uncertainty_score":0.9828856},"labels":[],"label_agreement":null},{"id":"W2077817920","doi":"10.1177/0091270008319792","title":"Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple‐Dose Administration in Healthy Subjects","year":2008,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Carbamazepine; Efavirenz; Pharmacokinetics; Crossover study; Pharmacology; Confidence interval; Dosing; Pharmacokinetic interaction; Drug interaction; Active metabolite; Metabolite; Medicine; Chemistry; Internal medicine; Antiretroviral therapy; Epilepsy; Viral load; Human immunodeficiency virus (HIV); Immunology","score_opus":0.0899044327554101,"score_gpt":0.4442458723768858,"score_spread":0.3543414396214757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077817920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98253965,0.0007110841,0.000023094086,0.01550256,0.00077935477,0.00033051657,0.0000023271084,0.000008302201,0.00010310926],"genre_scores_gemma":[0.99343514,0.0030418716,0.00024642644,0.0018254158,0.0011722976,0.000008932756,0.000004940808,0.000012769143,0.00025221068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768186,0.0005494589,0.0012271703,0.00013373063,0.00020190807,0.00020588192],"domain_scores_gemma":[0.997684,0.0014373378,0.00045381798,0.000076131844,0.000108607186,0.0002401004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012300913,0.00014196569,0.00057611364,0.00015379876,0.0000525658,0.00000353616,0.00007779898,0.00009839354,0.00014201937],"category_scores_gemma":[0.0001989484,0.00009108133,0.00010692566,0.00013896069,0.00016969745,0.00010565665,0.00003305037,0.00074766314,0.000018282512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0314624,0.0011161285,0.93716717,0.00005331863,0.00044955182,0.00128174,0.0009770597,0.000009510787,0.0016971604,6.457751e-7,0.0051756245,0.020609664],"study_design_scores_gemma":[0.018523807,0.0025350703,0.9646935,0.00006928067,0.00062327966,0.0011821948,0.000057030877,0.00031159937,0.0022056594,0.000019787967,0.009670054,0.00010872302],"about_ca_topic_score_codex":0.000007557799,"about_ca_topic_score_gemma":0.000017261831,"teacher_disagreement_score":0.027526317,"about_ca_system_score_codex":0.00006880665,"about_ca_system_score_gemma":0.00030345595,"threshold_uncertainty_score":0.3714189},"labels":[],"label_agreement":null},{"id":"W2077861249","doi":"10.1128/aac.03819-14","title":"HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase","year":2014,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Integrase; Raltegravir; Integrases; Biology; Integrase inhibitor; Enzyme; Virology; Virus; Biochemistry; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.009234846378758937,"score_gpt":0.24540941700445892,"score_spread":0.2361745706257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077861249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879265,0.00004326231,0.0015850434,0.008370492,0.0002630947,0.0008105638,0.000035922178,0.00009127091,0.00087384833],"genre_scores_gemma":[0.9823761,0.00027232085,0.002013338,0.005923111,0.00016762,0.000021997068,0.00021289813,0.0000626653,0.008949967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801284,0.00007563882,0.0004322869,0.00073198334,0.00023118599,0.00051609345],"domain_scores_gemma":[0.99894226,0.00006673241,0.00010365902,0.0004297548,0.00005962793,0.00039794578],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031521486,0.0004872334,0.00061085884,0.00016012172,0.00019878076,0.000097202144,0.00014636462,0.0001530501,0.0005511894],"category_scores_gemma":[0.000027316944,0.00034646533,0.00014340047,0.00025962837,0.00018977273,0.000113824266,0.000078734716,0.00022529624,0.00018386541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004133185,0.0058329743,0.6789773,0.00070498826,0.00096435746,0.00017688416,0.0060209744,0.0000014727577,0.04271367,0.0016188214,0.21509668,0.04375867],"study_design_scores_gemma":[0.019652665,0.0019719289,0.70500314,0.0012922226,0.0006678518,0.00013786643,0.00042692525,0.0005679693,0.010039198,0.00034435323,0.25802022,0.0018756782],"about_ca_topic_score_codex":0.00008090262,"about_ca_topic_score_gemma":0.00007139456,"teacher_disagreement_score":0.04292354,"about_ca_system_score_codex":0.00008583643,"about_ca_system_score_gemma":0.00002952327,"threshold_uncertainty_score":0.99989873},"labels":[],"label_agreement":null},{"id":"W2077881754","doi":"10.1111/j.1468-1293.2009.00725.x","title":"Discordance in HIV‐1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma","year":2009,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; Children's Hospital of Eastern Ontario; Ottawa Hospital; Health Canada; University of Ottawa","funders":"Public Health Agency of Canada","keywords":"Viral load; Efavirenz; Semen; Medicine; Virology; Drug; Nevirapine; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV); Internal medicine; Pharmacology; Andrology","score_opus":0.010580824557167433,"score_gpt":0.2510419605975394,"score_spread":0.24046113604037198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077881754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766206,0.0011415249,0.000046653826,0.016544359,0.000059467995,0.00034955333,0.000004037101,0.000046646608,0.005187165],"genre_scores_gemma":[0.9929239,0.00038127124,0.0007061698,0.0003873083,0.00013854196,0.000010050423,0.00009663448,0.000010370733,0.0053457166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881256,0.000027977087,0.0003329028,0.000306545,0.00022867555,0.00029137215],"domain_scores_gemma":[0.9995286,0.000051287145,0.000061785104,0.00014892007,0.000022099686,0.00018734334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014466596,0.00020260968,0.00046043436,0.00013845573,0.0000855491,0.000014077669,0.000044925226,0.000037673242,0.00003244275],"category_scores_gemma":[0.000040105566,0.0001529794,0.00001924282,0.00016583382,0.00018024331,0.000113863614,0.000024917785,0.00017161423,0.000009782008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015426285,0.00024238662,0.981652,0.00005384237,0.000062897096,0.00031744924,0.0039269174,0.0000019607114,0.0031902026,0.0022704147,0.00451249,0.0036151272],"study_design_scores_gemma":[0.029523175,0.00091003976,0.9522395,0.001543754,0.00050428195,0.0003046315,0.0017450341,0.0045757913,0.002774314,0.0004051447,0.0050378563,0.00043646139],"about_ca_topic_score_codex":0.00002818683,"about_ca_topic_score_gemma":0.000053590127,"teacher_disagreement_score":0.029412534,"about_ca_system_score_codex":0.00004321848,"about_ca_system_score_gemma":0.00004636681,"threshold_uncertainty_score":0.62383187},"labels":[],"label_agreement":null},{"id":"W2078270157","doi":"10.1097/qad.0b013e328302f3b5","title":"Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"Canadian Institutes of Health Research; Health Canada; Merck Canada; University of British Columbia","keywords":"Raltegravir; Enfuvirtide; Tolerability; Regimen; Medicine; Adverse effect; Viral load; Maraviroc; Ritonavir; Pharmacology; Salvage therapy; Internal medicine; Human immunodeficiency virus (HIV); Oncology; Virology; Immunology; Antiretroviral therapy; Chemotherapy; Gp41","score_opus":0.016853798705849167,"score_gpt":0.25737073576390157,"score_spread":0.2405169370580524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078270157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968883,0.00004528697,0.00005253876,0.0008607044,0.00009066702,0.0006527538,0.00006209776,0.000060345887,0.0012873012],"genre_scores_gemma":[0.9720222,0.000014223866,0.019105898,0.00057346484,0.000025418161,0.00007105788,0.00015372987,0.000025008801,0.008009012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983081,0.000061224244,0.0005071878,0.0003817973,0.00045959494,0.0002821027],"domain_scores_gemma":[0.9988931,0.00016342697,0.0001644832,0.00040919555,0.00012993973,0.00023986274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009282165,0.00025880805,0.0006400529,0.00013111685,0.00007799233,0.0000055019395,0.00014437753,0.00010019854,0.0001575942],"category_scores_gemma":[0.0002761978,0.00017190987,0.0001451321,0.00019294297,0.000081688144,0.0000614637,0.00009092275,0.00012883781,0.00018297584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008666123,0.0007207272,0.9775225,0.000008217517,0.0004224913,0.00017066395,0.0037516628,0.0000037106017,0.01397302,0.00005867628,0.001796321,0.0007054171],"study_design_scores_gemma":[0.0050882464,0.0006907563,0.945047,0.00006614104,0.000160907,0.000002818512,0.00018233544,0.000013904504,0.047333345,0.00012997081,0.0010792624,0.00020531834],"about_ca_topic_score_codex":0.00027788812,"about_ca_topic_score_gemma":0.000017169097,"teacher_disagreement_score":0.033360325,"about_ca_system_score_codex":0.00008738641,"about_ca_system_score_gemma":0.00009317057,"threshold_uncertainty_score":0.7010281},"labels":[],"label_agreement":null},{"id":"W2078303991","doi":"10.3109/07853890.2011.572905","title":"Ritonavir-boosted protease inhibitors in HIV therapy","year":2011,"lang":"en","type":"review","venue":"Annals of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Ritonavir; Protease inhibitor (pharmacology); Pharmacology; Dyslipidemia; Medicine; Lopinavir; Dosing; Protease; Pharmacokinetics; Cobicistat; Drug; CYP3A4; Virology; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Biology; Cytochrome P450; Enzyme; Disease; Biochemistry","score_opus":0.20984372767959977,"score_gpt":0.4139710501749096,"score_spread":0.20412732249530982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078303991","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008430047,0.9854787,9.79196e-7,0.005320336,0.00018099014,0.00277799,0.000019714404,0.000046186346,0.0060907993],"genre_scores_gemma":[0.000050808525,0.9859111,0.00012804796,0.0003936895,0.00044995113,0.0003249881,0.00048317132,0.00007832442,0.012179974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698913,0.00018404915,0.0013917105,0.0005001,0.00050470233,0.0004303193],"domain_scores_gemma":[0.99825335,0.0001389499,0.0005497104,0.000581365,0.00018193087,0.0002946798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007735293,0.0006224403,0.0032475216,0.0008511098,0.000027723921,0.0000028147865,0.00020719075,0.00037072657,0.0006931347],"category_scores_gemma":[0.00021458464,0.00037417508,0.00039260267,0.00070882094,0.00026503834,0.000053280964,0.000051274463,0.00050305255,0.00017009261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013345706,0.00056957157,0.00028461445,0.0068367654,0.00047205063,0.0003263189,0.00062204036,4.94074e-9,0.000001653363,0.00010128359,0.05155778,0.9390945],"study_design_scores_gemma":[0.0028751804,0.00045995897,0.00007921784,0.06336416,0.0003861569,0.00006433431,0.000045758276,2.4148687e-7,0.000082394676,0.00006423297,0.9323206,0.0002577541],"about_ca_topic_score_codex":0.00007816615,"about_ca_topic_score_gemma":0.0000060306525,"teacher_disagreement_score":0.9388367,"about_ca_system_score_codex":0.0000544784,"about_ca_system_score_gemma":0.00052412186,"threshold_uncertainty_score":0.999871},"labels":[],"label_agreement":null},{"id":"W2078593189","doi":"10.1310/2xvk-pbgl-735n-wh72","title":"Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations","year":2006,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Enfuvirtide; Ritonavir; Concomitant; Medicine; Protease inhibitor (pharmacology); Lopinavir; Regimen; Viral load; Pharmacology; Internal medicine; Protease; Virology; Human immunodeficiency virus (HIV); Immunology; Gp41; Antiretroviral therapy; Biology; Enzyme","score_opus":0.47053954744420085,"score_gpt":0.5174414029777028,"score_spread":0.04690185553350196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078593189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057480697,0.85687804,0.000038052814,0.004828272,0.00082000473,0.046828702,0.03226652,0.00034120833,0.0005185052],"genre_scores_gemma":[0.00013402652,0.9674606,0.008697753,0.000050433253,0.00028893218,0.0009819973,0.021045294,0.00009313971,0.00124787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879429,0.0050645634,0.004814952,0.0013370857,0.00040571066,0.00043483067],"domain_scores_gemma":[0.9836466,0.011746919,0.0025078866,0.0013904993,0.00022738361,0.00048071216],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036636824,0.00080332125,0.0065315263,0.00044823939,0.00009052298,0.000068748814,0.00022689716,0.0005778226,0.00016699274],"category_scores_gemma":[0.011419769,0.0004957747,0.00032777505,0.0006985502,0.000403882,0.00021111681,0.00019175178,0.0005436824,0.000029493915],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018325273,0.004362983,0.005377381,0.00085070956,0.0019779776,0.00033399728,0.00027443146,1.7595914e-7,0.0000019391996,0.000011586813,0.0068333303,0.978143],"study_design_scores_gemma":[0.017168665,0.0013507655,0.00038270326,0.009739674,0.004981916,0.00007881435,0.00017338539,0.000016819598,0.000053775846,0.0000067231035,0.9655459,0.0005008613],"about_ca_topic_score_codex":0.000060742477,"about_ca_topic_score_gemma":0.00017823605,"teacher_disagreement_score":0.9776421,"about_ca_system_score_codex":0.00034088272,"about_ca_system_score_gemma":0.0024894092,"threshold_uncertainty_score":0.99974936},"labels":[],"label_agreement":null},{"id":"W2078861644","doi":"10.1074/jbc.m110254200","title":"Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase","year":2002,"lang":"fr","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"RNase H; Reverse transcriptase; Mutant; RNase P; Active site; DNA polymerase; Biology; Enzyme; Molecular biology; Mutagenesis; Wild type; Biochemistry; Stereochemistry; Chemistry; RNA; Gene","score_opus":0.037671654620196525,"score_gpt":0.26602191103740996,"score_spread":0.22835025641721343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078861644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661042,0.026309472,0.00012722387,0.004557109,0.0001980522,0.00007311238,0.00029686125,0.0000045858665,0.0023293952],"genre_scores_gemma":[0.9780365,0.0043038893,0.002262664,0.000063018706,0.00026514742,0.0000013307745,0.000097642085,0.0000068307545,0.014962979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979726,0.000066151144,0.0011534976,0.00016890625,0.00039762602,0.00024121166],"domain_scores_gemma":[0.9983063,0.00021287166,0.00075462327,0.0001458813,0.0003318778,0.00024849817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003748615,0.0002026562,0.0009702135,0.00013554699,0.000026480291,0.0000044700428,0.00015330268,0.00028187706,0.015291141],"category_scores_gemma":[0.00030314884,0.00014229739,0.0008027632,0.0006259497,0.00031602464,0.00005354385,0.00001798656,0.00030496792,0.000023106177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017764855,0.011726897,0.30635175,0.0017326369,0.033337522,0.0041370895,0.0030968508,0.00076437177,0.5449615,0.00015531317,0.05549085,0.036468726],"study_design_scores_gemma":[0.014278341,0.0015678974,0.07987558,0.0024048584,0.030412404,0.0014038021,0.0034669887,0.0036055325,0.7879984,0.00030933233,0.073737346,0.0009395596],"about_ca_topic_score_codex":0.000002716399,"about_ca_topic_score_gemma":2.418868e-7,"teacher_disagreement_score":0.24303685,"about_ca_system_score_codex":0.00013141622,"about_ca_system_score_gemma":0.00009240662,"threshold_uncertainty_score":0.985609},"labels":[],"label_agreement":null},{"id":"W2079158442","doi":"10.1016/j.dld.2006.01.020","title":"Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review","year":2006,"lang":"en","type":"review","venue":"Digestive and Liver Disease","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Antiretroviral therapy; Protease; Pharmacology; Protease inhibitor (pharmacology); Virology; Human immunodeficiency virus (HIV); Intensive care medicine; Viral load; Enzyme; Biochemistry","score_opus":0.02701074401696683,"score_gpt":0.29300330503964883,"score_spread":0.265992561022682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079158442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013991926,0.99358696,0.0000017531969,0.00015883878,0.00001527929,0.004353657,0.00015182508,0.00005412913,0.00027836158],"genre_scores_gemma":[0.00035858765,0.99505687,0.00008764716,0.00023261437,0.00012641442,0.00060172984,0.00058922614,0.00005283049,0.0028940835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835503,0.00012457791,0.0003412021,0.0006216854,0.00028154184,0.00027594346],"domain_scores_gemma":[0.9988915,0.000058377325,0.00019386689,0.0002607222,0.000074016214,0.00052151526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010412206,0.00059429207,0.001471775,0.00012960081,0.00011425865,0.000038854378,0.00005027532,0.000098494405,0.00003234708],"category_scores_gemma":[0.00003058161,0.00034886607,0.00022056425,0.0002261959,0.0001957306,0.00010217165,0.000051968324,0.00023030174,0.000023409984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002099548,0.00062762894,0.042227965,0.06598074,0.0005009264,0.0020426721,0.000052596162,2.7682971e-9,6.2939264e-8,0.000028134798,0.003410296,0.88491905],"study_design_scores_gemma":[0.0011473483,0.0003482473,0.007830083,0.10427926,0.0034309204,0.000075938224,0.0000033661527,0.0000010329247,8.589604e-7,0.0000040998357,0.88241047,0.00046835403],"about_ca_topic_score_codex":0.000040085542,"about_ca_topic_score_gemma":0.000001902493,"teacher_disagreement_score":0.8844507,"about_ca_system_score_codex":0.00007439726,"about_ca_system_score_gemma":0.0005188154,"threshold_uncertainty_score":0.99989635},"labels":[],"label_agreement":null},{"id":"W2079256899","doi":"10.1097/01.aids.0000163930.68907.37","title":"Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors","year":2005,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Reverse transcriptase; Virology; Genotype; Biology; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Resistance mutation; Lentivirus; Drug resistance; Mutation; Nucleotidyltransferase; Mutant; Genetics; Human immunodeficiency virus (HIV); Polymerase chain reaction; Gene; Viral disease; RNA","score_opus":0.012115789054203638,"score_gpt":0.24329987101558365,"score_spread":0.23118408196138002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079256899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96153575,0.00032062607,0.00022824726,0.02725212,0.00028298295,0.001386749,0.0008740642,0.00011293276,0.008006511],"genre_scores_gemma":[0.8905344,0.00005725751,0.011193885,0.0017386982,0.00011117183,0.00008428933,0.0005123024,0.000052673116,0.09571532],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798346,0.00006244606,0.0006259475,0.000462411,0.00044807396,0.00041764777],"domain_scores_gemma":[0.9987477,0.000050652157,0.00010102068,0.00048011832,0.00017680107,0.00044372494],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020040896,0.00032813783,0.0005457794,0.0002860316,0.00015852683,0.000013057132,0.00011938062,0.00012511828,0.0009454936],"category_scores_gemma":[0.00006521236,0.00030580236,0.00023864133,0.0004879908,0.00012501706,0.00014637913,0.000020977704,0.00016994686,0.00035792176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018496665,0.0010998357,0.047358755,0.0004468606,0.0005387105,0.0007158014,0.020748034,0.000047398633,0.13120049,0.0005902896,0.79188144,0.0035227283],"study_design_scores_gemma":[0.008237926,0.00034642324,0.007863161,0.00077264797,0.00087201333,0.00003909137,0.001725332,0.000023781951,0.21087267,0.00003019478,0.7686606,0.00055613415],"about_ca_topic_score_codex":0.00011838625,"about_ca_topic_score_gemma":0.00074494345,"teacher_disagreement_score":0.08770881,"about_ca_system_score_codex":0.0003780039,"about_ca_system_score_gemma":0.0002522231,"threshold_uncertainty_score":0.99996775},"labels":[],"label_agreement":null},{"id":"W2079321673","doi":"10.1007/s00228-005-0900-2","title":"A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients","year":2005,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Nevirapine; Lopinavir; Lopinavir/ritonavir; Pharmacokinetics; Ritonavir; Regimen; Pharmacology; Reverse-transcriptase inhibitor; Medicine; Population; Human immunodeficiency virus (HIV); Internal medicine; Gastroenterology; Viral load; Antiretroviral therapy; Virology","score_opus":0.05791000055017056,"score_gpt":0.40825114173839,"score_spread":0.35034114118821946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079321673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954545,0.000021924774,0.000045587603,0.0027207239,0.0002325083,0.0007201115,0.0000023642137,0.000007550753,0.0007947491],"genre_scores_gemma":[0.99685305,0.000049297352,0.0009558766,0.0015142845,0.00045306992,0.0000044100016,0.000011829971,0.000016958877,0.00014123585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964292,0.0012506023,0.0016781437,0.00017205371,0.00031782966,0.0001521724],"domain_scores_gemma":[0.9985691,0.00025560887,0.0006533471,0.000117594755,0.00024339862,0.00016098526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017260513,0.00014374327,0.000462865,0.00018643447,0.00003206355,0.0000060624643,0.00017149071,0.000028310544,0.00004393586],"category_scores_gemma":[0.00037751455,0.000093027935,0.000105141335,0.0002900709,0.00004838816,0.00007498247,0.000046327164,0.00047296102,0.00003964425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049015908,0.01488879,0.92929524,0.00001880999,0.0003752995,0.00015300175,0.000995057,0.004893638,0.00031433447,0.000008299131,0.0039289235,0.040227026],"study_design_scores_gemma":[0.012570314,0.0038108334,0.9773053,0.00004462049,0.00023690144,0.000014785507,0.000031906253,0.00014036302,0.00029386545,0.0000016531942,0.005474309,0.00007514032],"about_ca_topic_score_codex":6.1930655e-7,"about_ca_topic_score_gemma":8.102293e-7,"teacher_disagreement_score":0.04801008,"about_ca_system_score_codex":0.000050553877,"about_ca_system_score_gemma":0.000074909854,"threshold_uncertainty_score":0.37935692},"labels":[],"label_agreement":null},{"id":"W2079791067","doi":"10.1093/infdis/jit114","title":"Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine","year":2013,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Institute of Allergy and Infectious Diseases; U.S. Public Health Service","keywords":"Stavudine; Zidovudine; Nevirapine; Efavirenz; Lamivudine; Virology; Didanosine; Reverse-transcriptase inhibitor; Abacavir; Biology; Drug resistance; Medicine; Viral load; Virus; Antiretroviral therapy; Genetics; Viral disease; Hepatitis B virus","score_opus":0.019193992470901027,"score_gpt":0.2719988606338227,"score_spread":0.2528048681629217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079791067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843244,0.001290803,0.0025189377,0.009824879,0.00009508152,0.0016340032,0.0001277771,0.00008872652,0.000095381816],"genre_scores_gemma":[0.997379,0.0004395563,0.0005402492,0.00026707395,0.00014185556,0.00013776863,0.000079017125,0.00004105635,0.00097441225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986624,0.00008234337,0.0005613292,0.00012954311,0.00027196982,0.00029238252],"domain_scores_gemma":[0.99770314,0.0005688549,0.0005445208,0.0001853579,0.0008168696,0.00018123379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028102013,0.00022773935,0.00041750766,0.00019610168,0.00052816584,0.000094237985,0.000091231144,0.000041820043,0.000052597326],"category_scores_gemma":[0.00043464743,0.00013529541,0.00017009824,0.0003078146,0.00015920858,0.0003531257,0.000007888767,0.00014378519,0.0000060484012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058397483,0.004428913,0.9346966,0.0005278947,0.0051425206,0.00006968996,0.0121857375,0.00027505678,0.0025093742,0.00045329574,0.026481856,0.007389308],"study_design_scores_gemma":[0.118421964,0.02509075,0.75658286,0.0106770955,0.019401168,0.000819948,0.011275498,0.0007534386,0.006183964,0.012989779,0.03518455,0.0026189834],"about_ca_topic_score_codex":0.00001842948,"about_ca_topic_score_gemma":0.00021120372,"teacher_disagreement_score":0.17811374,"about_ca_system_score_codex":0.00027598775,"about_ca_system_score_gemma":0.00039191943,"threshold_uncertainty_score":0.55171865},"labels":[],"label_agreement":null},{"id":"W2079791093","doi":"10.1128/aac.48.11.4189-4194.2004","title":"Differential Maintenance of the M184V Substitution in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Various Nucleoside Antiretroviral Agents in Tissue Culture","year":2004,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Resistance mutation; Didanosine; Zalcitabine; Virology; Reverse transcriptase; Abacavir; Lamivudine; Biology; Reverse-transcriptase inhibitor; Nucleoside analogue; Nucleoside; Virus; Viral load; Antiretroviral therapy; Biochemistry; RNA","score_opus":0.012752092724179055,"score_gpt":0.2628045841648711,"score_spread":0.2500524914406921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079791093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979011,0.000085883665,0.000017929768,0.0012573183,0.0000906475,0.00046144464,0.000031856765,0.00000574468,0.00014808547],"genre_scores_gemma":[0.9972746,0.00088019244,0.00005079429,0.0008423539,0.00001161631,0.0000031173356,0.000048779395,0.000011719105,0.0008768501],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99910104,0.00003607165,0.00031325378,0.00018966071,0.0001658767,0.00019406468],"domain_scores_gemma":[0.99965656,0.0000037594266,0.000103891136,0.00018553002,0.000029075758,0.000021208087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007965357,0.00016142118,0.00027066394,0.000053397605,0.000078483776,0.000011364958,0.00014629899,0.000081712664,0.00007024728],"category_scores_gemma":[0.000004581071,0.00009298566,0.00007102298,0.00026463473,0.00015743573,0.000052146293,0.000014831395,0.00013838414,0.0000024843293],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003700049,0.0022414927,0.1382138,0.000115064766,0.0000868498,0.000042145537,0.010602388,0.000004935424,0.8365255,0.00026111532,0.010373284,0.0011634345],"study_design_scores_gemma":[0.016018732,0.0005857986,0.55489314,0.00081853446,0.00014234887,0.00004717,0.00041851957,0.000014021213,0.4110127,0.00012944001,0.01558918,0.00033041686],"about_ca_topic_score_codex":0.00078257214,"about_ca_topic_score_gemma":0.000086602515,"teacher_disagreement_score":0.42551276,"about_ca_system_score_codex":0.000056032393,"about_ca_system_score_gemma":0.00004156804,"threshold_uncertainty_score":0.3791845},"labels":[],"label_agreement":null},{"id":"W2080148423","doi":"10.1111/j.1468-1293.2007.00482.x","title":"Interactions between protease inhibitors and acid‐reducing agents: a systematic review","year":2007,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Public Health; Ottawa Hospital","funders":"Bristol-Myers Squibb","keywords":"Medicine; Pharmacokinetics; Pharmacology; Pharmacokinetic interaction; MEDLINE; Drug; Protease; Drug interaction; Bioinformatics; Biochemistry; Enzyme; Chemistry","score_opus":0.08758024552919101,"score_gpt":0.3963001512662285,"score_spread":0.30871990573703745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080148423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000020149641,0.98611164,0.000076340395,0.0025577152,0.0002734975,0.0087771,0.000022468592,0.00011443323,0.0020647764],"genre_scores_gemma":[0.0000055380397,0.97575885,0.0004183993,0.0004050303,0.00092610955,0.0009905011,0.0009402113,0.000091995316,0.02046337],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959627,0.00023522561,0.0020664092,0.00064960413,0.0006551271,0.00043097438],"domain_scores_gemma":[0.9974119,0.0003877848,0.00082062144,0.0006853439,0.00012822851,0.0005661318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011943154,0.0007704311,0.0056461045,0.0006938087,0.00012829382,0.000014750878,0.00014159665,0.00020380993,0.0004323415],"category_scores_gemma":[0.0010952906,0.00045550376,0.00038757228,0.00073329115,0.00013861018,0.00008399275,0.00009145028,0.0006950206,0.00043615],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032253124,0.000063103915,0.000021170394,0.8176884,0.00091935095,0.00027307353,0.00022864551,8.467652e-10,1.4625786e-7,0.0000054056277,0.028574059,0.15222342],"study_design_scores_gemma":[0.0004219841,0.00004934783,0.0000016741927,0.5156223,0.014635372,0.00040947253,0.000047100562,2.6694184e-7,7.2985523e-7,0.0000010988803,0.46863434,0.00017628525],"about_ca_topic_score_codex":0.000011195858,"about_ca_topic_score_gemma":0.0000015618508,"teacher_disagreement_score":0.4400603,"about_ca_system_score_codex":0.00044549035,"about_ca_system_score_gemma":0.00030727033,"threshold_uncertainty_score":0.99978966},"labels":[],"label_agreement":null},{"id":"W2080674340","doi":"10.1111/j.1468-1293.2007.00430.x","title":"Superior virological response to boosted protease inhibitor‐based highly active antiretroviral therapy in an observational treatment programme","year":2007,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Michael Smith Health Research BC; Abbott Laboratories","keywords":"Medicine; Internal medicine; Hazard ratio; Confidence interval; Proportional hazards model; Viral load; Regimen; Antiretroviral therapy; Protease inhibitor (pharmacology); Gastroenterology; Human immunodeficiency virus (HIV); Immunology","score_opus":0.09340718761937664,"score_gpt":0.3456087570938736,"score_spread":0.252201569474497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080674340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96655965,0.000094408744,0.00009452326,0.02989392,0.00010736726,0.0029203917,0.000016742479,0.00014611837,0.0001668758],"genre_scores_gemma":[0.9904703,0.000011484153,0.0033313208,0.0021871286,0.00036310786,0.0004471933,0.00053308863,0.000037829468,0.0026185422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734855,0.000209203,0.00058074907,0.00058110856,0.0006321355,0.0006482321],"domain_scores_gemma":[0.9984891,0.00029624894,0.0000847979,0.00035565105,0.00014860046,0.00062560843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093241385,0.0003933361,0.00063469907,0.000508326,0.000098970515,0.000012903158,0.00009702692,0.00016410634,0.00024689749],"category_scores_gemma":[0.0003301038,0.00025046038,0.00008401887,0.00068521,0.00016782685,0.000115220755,0.00001905992,0.00019366613,0.000063771426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08477747,0.004728876,0.67596334,0.000026353986,0.00013900589,0.002943707,0.0064586345,0.000004506421,0.12545808,0.00006286424,0.00079944736,0.098637745],"study_design_scores_gemma":[0.02692523,0.021947943,0.8948388,0.0002458458,0.00006978897,0.00003255648,0.00091945793,0.00013472361,0.028845638,0.000011981594,0.02572069,0.00030736288],"about_ca_topic_score_codex":0.00008876648,"about_ca_topic_score_gemma":0.000092588496,"teacher_disagreement_score":0.21887547,"about_ca_system_score_codex":0.0007649851,"about_ca_system_score_gemma":0.0004303633,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W2081507925","doi":"10.1186/1758-2652-11-s1-p81","title":"Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments","year":2008,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Abbott (Canada); Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Lopinavir; Ritonavir; Lopinavir/ritonavir; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load","score_opus":0.011050357178492213,"score_gpt":0.27159215695556355,"score_spread":0.2605417997770713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081507925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829686,0.0001216966,0.00005965495,0.0007567578,0.0002705803,0.00029413367,0.000015004242,0.0000068966647,0.00017840268],"genre_scores_gemma":[0.99708474,0.0010914668,0.0007176957,0.000054969212,0.00008817731,0.000009907648,0.000008106243,0.000012550364,0.0009324165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844337,0.00008554879,0.0005524307,0.00015870944,0.00061152753,0.00014844359],"domain_scores_gemma":[0.99903744,0.00015494874,0.00037022377,0.00012082932,0.00021776067,0.00009879155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020317551,0.00018030248,0.00046777498,0.0000811624,0.000086275075,0.000009130634,0.0001775321,0.0000761262,0.000027933947],"category_scores_gemma":[0.00011015427,0.00010665063,0.00035022548,0.0001631982,0.00014458939,0.00014967142,0.00009558261,0.00020671848,0.0000012133789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014596411,0.0006664389,0.9863938,0.00004630255,0.00066778716,0.000043290427,0.0044323965,0.0000072493276,0.0046483977,0.00006933039,0.0002207081,0.0013446443],"study_design_scores_gemma":[0.008560641,0.00044286854,0.97663456,0.00088316185,0.00008378617,0.00018111193,0.00047710864,0.00017390992,0.012356668,0.000028316357,0.000086970416,0.00009088791],"about_ca_topic_score_codex":0.000035113346,"about_ca_topic_score_gemma":0.0000033683361,"teacher_disagreement_score":0.0097592445,"about_ca_system_score_codex":0.0005349274,"about_ca_system_score_gemma":0.00020151248,"threshold_uncertainty_score":0.43490866},"labels":[],"label_agreement":null},{"id":"W2081798390","doi":"10.1586/14787210.5.1.13","title":"Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections","year":2007,"lang":"en","type":"review","venue":"Expert Review of Anti-infective Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Lopinavir; Ritonavir; Protease inhibitor (pharmacology); Medicine; Lopinavir/ritonavir; Pharmacology; Human immunodeficiency virus (HIV); Boosting (machine learning); Virology; Antiretroviral therapy; Viral load; Computer science","score_opus":0.0643904626506469,"score_gpt":0.4123920813847466,"score_spread":0.3480016187340997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081798390","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020396294,0.97874767,0.0031487606,0.0005073071,0.0004750622,0.016162008,0.00012195933,0.0001320106,0.00068484544],"genre_scores_gemma":[0.00001077174,0.9903155,0.002028024,0.00041236385,0.0005495553,0.0040959413,0.001253308,0.0001518044,0.0011827413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965526,0.00019420896,0.0014870373,0.00076627487,0.00051785365,0.00048203068],"domain_scores_gemma":[0.9970552,0.00041055333,0.0009653758,0.0006545473,0.00070492626,0.0002094531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008818934,0.0009391557,0.0041333237,0.0005532969,0.00018819288,0.000022915605,0.00018483015,0.00038923472,0.00013585296],"category_scores_gemma":[0.0002450891,0.00066618435,0.0018154652,0.00091878185,0.00016758191,0.00015728346,0.000054795048,0.00043127537,0.0000907104],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006941612,0.0034609474,0.000075023505,0.08602942,0.0016047686,0.000015590264,0.00024099901,2.9400972e-8,0.000028694123,0.00051209365,0.00793229,0.90003073],"study_design_scores_gemma":[0.0036851396,0.0006511678,0.000030915264,0.13768645,0.0007112417,0.00010947983,0.000009490658,0.0000016699996,0.00023566664,0.000016073185,0.8563521,0.00051059364],"about_ca_topic_score_codex":0.000019880392,"about_ca_topic_score_gemma":0.00000170924,"teacher_disagreement_score":0.89952016,"about_ca_system_score_codex":0.0008704057,"about_ca_system_score_gemma":0.0012414291,"threshold_uncertainty_score":0.99957895},"labels":[],"label_agreement":null},{"id":"W2082219663","doi":"10.1159/000046198","title":"The Natural History of Leukocyturia Associated with Indinavir Treatment in HIV+ Individuals","year":2000,"lang":"en","type":"article","venue":"American Journal of Nephrology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital","funders":"","keywords":"Indinavir; Crystalluria; Medicine; Urinalysis; Asymptomatic; Internal medicine; Kidney disease; Urinary system; Microhematuria; Gastroenterology; Prospective cohort study; Urology; Human immunodeficiency virus (HIV); Sida; Kidney; Immunology; Viral disease; Proteinuria","score_opus":0.00884438542701423,"score_gpt":0.23820646760255326,"score_spread":0.22936208217553902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082219663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931938,0.0013935984,8.0412775e-7,0.004170644,0.00006648351,0.00015584844,0.0000024770377,0.0000062559325,0.0010100756],"genre_scores_gemma":[0.98913264,0.00047357366,0.00039538497,0.00053291454,0.000046756075,0.000008665238,0.000009380724,0.000014371286,0.009386289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869746,0.00019550876,0.00047762648,0.000116386786,0.00024369176,0.00026934978],"domain_scores_gemma":[0.99887764,0.0002933687,0.0005234553,0.0001369013,0.000080637765,0.00008797353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025728537,0.00016233807,0.00061936287,0.00018858376,0.000033116386,0.0000033931244,0.000113251044,0.00004406536,0.00014059132],"category_scores_gemma":[0.000031320393,0.000086288645,0.00010361746,0.00023353573,0.0005103224,0.00005080099,0.000008711637,0.00023488437,0.000009674951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006618244,0.0019141302,0.6418698,0.0000068476993,0.0041880547,0.001664583,0.015070319,0.00004155013,0.00065700384,0.00009015382,0.016954325,0.31092504],"study_design_scores_gemma":[0.008949095,0.0067375284,0.7266466,0.000109541856,0.00045501295,0.0008999173,0.000781993,0.000020104859,0.00017670692,0.000049267794,0.2550087,0.00016551507],"about_ca_topic_score_codex":0.000060177175,"about_ca_topic_score_gemma":0.00012375278,"teacher_disagreement_score":0.3107595,"about_ca_system_score_codex":0.0011223365,"about_ca_system_score_gemma":0.0007210142,"threshold_uncertainty_score":0.35187486},"labels":[],"label_agreement":null},{"id":"W2082329556","doi":"10.3390/v2112493","title":"Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs","year":2010,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Drug resistance; Biology; Resistance (ecology); Medicine; Genetics","score_opus":0.02075292661349134,"score_gpt":0.2665421247028003,"score_spread":0.24578919808930896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082329556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031913,0.00004568625,0.0000046376504,0.00042488874,0.000030826846,0.00020130578,0.0000071044806,0.000008755362,0.008957645],"genre_scores_gemma":[0.99401844,0.0000045530096,0.004560598,0.00011429074,0.000012551421,0.0000064687947,0.000004848637,0.0000046774544,0.0012735884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932605,0.000018700073,0.0001899401,0.00011339027,0.00023603693,0.00011587858],"domain_scores_gemma":[0.9996461,0.00005407079,0.00005439327,0.00017317267,0.000041875126,0.000030355897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022315969,0.000077641,0.00016874548,0.00009805068,0.000055683413,0.0000027354727,0.0001203794,0.000031755644,0.000040399347],"category_scores_gemma":[0.000040419138,0.00005184646,0.000027261085,0.00021370573,0.000040661474,0.000038132737,0.000092591574,0.00007751233,0.000047818412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029415372,0.0003621798,0.90793157,0.000040763673,0.000052446583,0.000007261134,0.031251445,1.4011634e-7,0.05387773,0.00038573108,0.002367702,0.003428907],"study_design_scores_gemma":[0.00079145125,0.000025050313,0.62250525,0.00008245023,0.000029298932,4.395012e-7,0.0021080635,8.2612274e-7,0.33143863,0.00007258896,0.042858064,0.00008786172],"about_ca_topic_score_codex":0.000024084067,"about_ca_topic_score_gemma":0.0006893691,"teacher_disagreement_score":0.28542626,"about_ca_system_score_codex":0.00001994038,"about_ca_system_score_gemma":0.000107695494,"threshold_uncertainty_score":0.21142372},"labels":[],"label_agreement":null},{"id":"W2083163706","doi":"10.1007/s11908-002-0089-9","title":"Management of HIV-infected patients with multidrug-resistant virus","year":2002,"lang":"en","type":"article","venue":"Current Infectious Disease Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Virology; Multiple drug resistance; Human immunodeficiency virus (HIV); Medicine; Virus; Drug resistance; Biology; Microbiology","score_opus":0.010725557594015564,"score_gpt":0.23918887149885762,"score_spread":0.22846331390484206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083163706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074167,0.001017412,0.00006136841,0.00009376444,0.00041028816,0.0013394788,0.00003905064,0.00021861462,0.0060783653],"genre_scores_gemma":[0.99526924,0.00039747878,0.00011283845,0.000012929724,0.000038935086,0.00014445145,0.00027943368,0.00003990918,0.0037048033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783665,0.000032633016,0.00057352544,0.00047595706,0.00071775255,0.00036347177],"domain_scores_gemma":[0.9983167,0.000024136487,0.00039494276,0.0005557811,0.00025994828,0.0004484582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008166782,0.0003185947,0.0003998067,0.00020899632,0.00009974212,0.000018236375,0.000037974278,0.000041849493,0.0005507837],"category_scores_gemma":[0.000038484704,0.00024128899,0.00017299963,0.00037561485,0.00005263393,0.000090884634,0.000055828506,0.0001258257,0.00011386732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018737953,0.0057558524,0.97626257,0.0006196571,0.00067037804,0.0019371926,0.000091551155,0.000011597735,0.000010162324,0.00003172914,0.0043693045,0.010052634],"study_design_scores_gemma":[0.004704487,0.00016333007,0.9460299,0.0010479072,0.0015758976,0.000035044162,0.000011792161,0.00008191115,0.00024709915,0.000034081477,0.045660768,0.00040779758],"about_ca_topic_score_codex":0.0000059665954,"about_ca_topic_score_gemma":0.0000034479751,"teacher_disagreement_score":0.041291464,"about_ca_system_score_codex":0.0003396928,"about_ca_system_score_gemma":0.00005675267,"threshold_uncertainty_score":0.98394793},"labels":[],"label_agreement":null},{"id":"W2083455376","doi":"10.1371/journal.pmed.0040346","title":"Should We Include Connection Domain Mutations of HIV-1 Reverse Transcriptase in HIV Resistance Testing?","year":2007,"lang":"en","type":"letter","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Human immunodeficiency virus (HIV); Virology; Drug resistance; Mutation; Resistance mutation; HIV drug resistance; Lentivirus; Connection (principal bundle); Biology; Genetics; Medicine; Antiretroviral therapy; Polymerase chain reaction; Viral disease; Gene; Viral load","score_opus":0.06969914612705483,"score_gpt":0.2975422701946685,"score_spread":0.22784312406761367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083455376","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059808497,0.001934592,0.00032999867,0.97531617,0.00034160103,0.001531944,0.00016254213,0.0001395336,0.0142627675],"genre_scores_gemma":[0.018122053,0.0014926929,0.047391057,0.6020464,0.008868231,0.00069776765,0.0159556,0.00055146764,0.30487475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640644,0.00013736554,0.0011912247,0.0006200327,0.0011117222,0.000533239],"domain_scores_gemma":[0.9979168,0.000719549,0.00039068362,0.0005257865,0.00027946619,0.00016768825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005688439,0.00053157425,0.0012805715,0.0011583708,0.00008584957,0.000004937017,0.0001628786,0.00062151754,0.00055840396],"category_scores_gemma":[0.00075694063,0.00042795466,0.00012477672,0.0010823628,0.0003532017,0.00007082263,0.000024309456,0.0015417644,0.00007861947],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002888982,0.00036553753,0.0053870394,0.0020492831,0.00032206016,0.0044382955,0.0036456557,9.450104e-7,0.0019480065,0.000033710556,0.98133135,0.000189244],"study_design_scores_gemma":[0.009400597,0.00028004445,0.0010350863,0.0135429,0.0013485231,0.00011070016,0.0010969924,0.000028763785,0.001407427,0.00056063756,0.97070456,0.00048378945],"about_ca_topic_score_codex":0.00006280816,"about_ca_topic_score_gemma":0.00013237835,"teacher_disagreement_score":0.3732698,"about_ca_system_score_codex":0.000506087,"about_ca_system_score_gemma":0.00030446268,"threshold_uncertainty_score":0.99981725},"labels":[],"label_agreement":null},{"id":"W2083477796","doi":"10.1086/422143","title":"Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial","year":2004,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Lamivudine; Efavirenz; Zidovudine; Medicine; Regimen; Internal medicine; Gastroenterology; Confidence interval; Viral load; Randomized controlled trial; Adverse effect; Reverse-transcriptase inhibitor; Immunology; Sida; Human immunodeficiency virus (HIV); Viral disease; Virus; Antiretroviral therapy; Hepatitis B virus","score_opus":0.03136428149386789,"score_gpt":0.33765793544682704,"score_spread":0.30629365395295916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083477796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215394,0.00064153376,0.0005801627,0.0011430854,0.00030572093,0.00483958,0.00003367156,0.000092450646,0.00020984234],"genre_scores_gemma":[0.99493456,0.0029850476,0.0001711385,0.000059026625,0.0002123889,0.0011561395,0.00010020209,0.000030039842,0.0003514568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805075,0.00015992447,0.0007442766,0.00047971145,0.00029024837,0.00027510678],"domain_scores_gemma":[0.9962129,0.0027394914,0.00035815555,0.0002879658,0.00022086794,0.00018064208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028940354,0.00033242043,0.0011192815,0.00015352028,0.0001461721,0.000031946438,0.000053070442,0.00010880737,0.00001803888],"category_scores_gemma":[0.00065463193,0.00017890472,0.00029851164,0.00038247884,0.00065168546,0.00014070112,0.00001932117,0.00012192357,0.0000055805167],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55368143,0.0063406765,0.43153486,0.000106577165,0.00096695026,0.000038533995,0.00038660405,0.000054465978,0.0000011754103,0.0003587451,0.00006382256,0.0064661773],"study_design_scores_gemma":[0.8510725,0.029984906,0.11534825,0.00046467717,0.0020886594,0.0000078538005,0.00009713094,0.00019073935,0.000050269482,0.00018087591,0.00030329067,0.00021084982],"about_ca_topic_score_codex":0.0001887055,"about_ca_topic_score_gemma":0.00031088205,"teacher_disagreement_score":0.3161866,"about_ca_system_score_codex":0.00023730691,"about_ca_system_score_gemma":0.00035405878,"threshold_uncertainty_score":0.72955227},"labels":[],"label_agreement":null},{"id":"W2083942034","doi":"10.1371/journal.pone.0054435","title":"The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Australian Government; Gilead Sciences; Australian Research Council; University of New South Wales; Bristol-Myers Squibb","keywords":"Raltegravir; Medicine; Discontinuation; Lopinavir; Life expectancy; Quality-adjusted life year; Dolutegravir; Cost-effectiveness analysis; Cost effectiveness; Regimen; Ritonavir; Cost–benefit analysis; Orphan drug; Demography; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Environmental health; Internal medicine; Population; Family medicine","score_opus":0.02194987038773688,"score_gpt":0.20954783618811723,"score_spread":0.18759796580038035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083942034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979931,0.00028558724,6.807828e-7,0.00032027153,0.000008922091,0.0011313692,0.000017391712,0.000012456967,0.00023022834],"genre_scores_gemma":[0.9982569,0.0003293877,0.00011711884,0.000025613874,0.0000143840025,0.00009409629,0.000058148,0.000014076015,0.0010902253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913245,0.00004050325,0.00027735348,0.00017096763,0.00017456253,0.00020416001],"domain_scores_gemma":[0.99956685,0.00006860618,0.00007922798,0.00012857429,0.0000777668,0.00007895505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092125934,0.00013148104,0.00029017674,0.00011436698,0.00004190089,0.000019426618,0.000037919934,0.000061426355,0.000070438036],"category_scores_gemma":[0.000045551762,0.00008529557,0.00001716778,0.000155636,0.00006985067,0.00006519383,0.00003386527,0.00011073839,0.00000895426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017971874,0.0010405893,0.99102587,0.000028876932,0.00012675306,0.0000027027997,0.003047349,9.013743e-7,0.0014171166,0.0000055439878,0.000057083922,0.0030675181],"study_design_scores_gemma":[0.0055653923,0.00014339267,0.99012125,0.00014274819,0.000025993573,2.719845e-7,0.0002019777,0.00016680537,0.0034601828,0.00006390624,0.000021296972,0.00008677495],"about_ca_topic_score_codex":0.000029899571,"about_ca_topic_score_gemma":0.00021416032,"teacher_disagreement_score":0.0053856736,"about_ca_system_score_codex":0.000026201807,"about_ca_system_score_gemma":0.000024212817,"threshold_uncertainty_score":0.34782523},"labels":[],"label_agreement":null},{"id":"W2084010722","doi":"10.1097/01.ftd.0000177665.34845.fa","title":"Steady-State Pharmacokinetics and Tolerability of Indinavir-Lopinavir/R Combination Therapy in Antiretroviral-Experienced Patients","year":2005,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; University Health Network; University of Toronto; AIDS Vancouver; St. Michael's Hospital","funders":"","keywords":"Indinavir; Lopinavir; Pharmacokinetics; Tolerability; Antiretroviral therapy; Medicine; Pharmacology; Metabolic clearance rate; Human immunodeficiency virus (HIV); Ritonavir; Viral load; Virology; Adverse effect","score_opus":0.022692047626458253,"score_gpt":0.30525620345049254,"score_spread":0.28256415582403427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084010722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978563,0.0006541133,0.000009915973,0.00033599016,0.00018596461,0.0005989319,0.0000026497332,0.000038729708,0.0003173725],"genre_scores_gemma":[0.9976356,0.00080807187,0.00043318485,0.00003719497,0.000049919774,0.0000409703,0.000009188176,0.000022389659,0.0009634684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998638,0.00007169548,0.00042868016,0.00026853324,0.00032935085,0.00026374793],"domain_scores_gemma":[0.9994599,0.000055331704,0.00012618894,0.00018828722,0.0000911036,0.00007917395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022059085,0.00020482714,0.00035280234,0.00016471703,0.00005730086,0.000016144153,0.00008046677,0.000045495548,0.000022024546],"category_scores_gemma":[0.000008727401,0.00017704752,0.000043460594,0.00025577328,0.00008791224,0.00017510657,0.000033782024,0.00015472091,0.00000654142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024023223,0.0007055809,0.7714282,0.00003098582,0.000046804988,0.0000025780137,0.0077503724,0.000007051439,0.005053863,0.000010733457,0.0000027181015,0.21472086],"study_design_scores_gemma":[0.0064025,0.0002716606,0.86177015,0.0001393629,0.000028817176,0.0000014896927,0.000431351,0.00019351105,0.13010967,0.000060540613,0.00041380568,0.00017711119],"about_ca_topic_score_codex":0.000022011798,"about_ca_topic_score_gemma":0.0000014939575,"teacher_disagreement_score":0.21454376,"about_ca_system_score_codex":0.00017573017,"about_ca_system_score_gemma":0.000040825646,"threshold_uncertainty_score":0.72197884},"labels":[],"label_agreement":null},{"id":"W2084110639","doi":"10.1007/s11373-005-9011-4","title":"Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy","year":2005,"lang":"en","type":"article","venue":"Journal of Biomedical Science","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint Paul University","funders":"","keywords":"Reverse transcriptase; Mutant; Mutation; Biology; Nucleoside Reverse Transcriptase Inhibitor; Genetics; Didanosine; Molecular biology; Virology; Virus; Polymerase chain reaction; Antiretroviral therapy; Gene; Viral load","score_opus":0.01605865730836419,"score_gpt":0.29136534813738296,"score_spread":0.27530669082901876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084110639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954502,0.00022957045,0.00034736513,0.0036388964,0.000090781505,0.00015486825,0.00003316722,0.000003414876,0.00005171669],"genre_scores_gemma":[0.99713016,0.00015362175,0.0021597259,0.00012586075,0.00004038875,0.0000016457666,0.000012796314,0.000004568485,0.0003712298],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976259,0.00007572164,0.0007354023,0.00017466005,0.0011101615,0.0002781944],"domain_scores_gemma":[0.99886096,0.0001157574,0.0004195756,0.00016630534,0.00024384669,0.00019358537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091171224,0.00012186808,0.00046349672,0.0007088608,0.000101321704,0.0000104843475,0.00026552525,0.00005822615,0.0003151363],"category_scores_gemma":[0.00018710119,0.00006762732,0.00016386833,0.004075678,0.00094294216,0.00024600694,0.000023624512,0.00017297032,0.0000017041446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019223612,0.0017358441,0.43078947,0.00004666603,0.0016142043,0.00021560107,0.013945085,0.0005588978,0.52514446,0.0003165856,0.0030062562,0.02070455],"study_design_scores_gemma":[0.0042970106,0.0004619031,0.9730324,0.00012220931,0.00047633253,0.00007324886,0.00041360743,0.007658171,0.01266024,0.000027434986,0.00067885756,0.00009855759],"about_ca_topic_score_codex":0.000036695856,"about_ca_topic_score_gemma":0.0000574486,"teacher_disagreement_score":0.54224294,"about_ca_system_score_codex":0.00028715873,"about_ca_system_score_gemma":0.00065673754,"threshold_uncertainty_score":0.34743097},"labels":[],"label_agreement":null},{"id":"W2084506449","doi":"10.1186/1471-2334-14-s3-o2","title":"The frequencies of naturally occurring protease inhibitor resistance mutations in HIV proviral sequences of drug naïve sex workers in Nairobi, Kenya and their correlation with host immune response driven positively selected mutations in HIV-1","year":2014,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Medical microbiology; Parasitology; Immune system; Drug resistance; Virology; Immunology; Human immunodeficiency virus (HIV); Biology; Host (biology); Pre-exposure prophylaxis; Protease; Medicine; Microbiology; Genetics; Men who have sex with men; Zoology","score_opus":0.004268794862562915,"score_gpt":0.21481578427650705,"score_spread":0.21054698941394415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084506449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745274,0.0005102954,0.000115978364,0.0002583416,0.000022053297,0.001409474,0.00006508251,0.0000413705,0.00012466175],"genre_scores_gemma":[0.9984852,0.000009718394,0.0005846673,0.000008582032,0.000010567033,0.00031038673,0.00009563936,0.000016529606,0.0004786898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845064,0.00041862344,0.00047031546,0.00025374102,0.00019213137,0.00021455958],"domain_scores_gemma":[0.99845517,0.0008854181,0.00025385513,0.00014783263,0.00019483382,0.000062886196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002869272,0.00019993693,0.00031366074,0.00038049402,0.000138859,0.000025843914,0.000060117138,0.000052473915,0.0000022789782],"category_scores_gemma":[0.00073752104,0.00013801338,0.00004495442,0.0008235539,0.00030584043,0.00020252807,0.000022092046,0.00017396746,0.0000012481898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018755707,0.00030246438,0.9858721,0.00012997545,0.000044693712,0.000016660424,0.0073834006,0.0011076092,0.0030906703,0.00007766811,0.000012097053,0.00008709373],"study_design_scores_gemma":[0.0033227792,0.00015293418,0.98617244,0.0012692735,0.000060023507,0.0000094883035,0.0049146772,0.0009664141,0.002866537,0.000102584156,0.0000067881797,0.00015607936],"about_ca_topic_score_codex":0.0003012919,"about_ca_topic_score_gemma":0.0055543585,"teacher_disagreement_score":0.0052530663,"about_ca_system_score_codex":0.00030289247,"about_ca_system_score_gemma":0.00082279247,"threshold_uncertainty_score":0.5628022},"labels":[],"label_agreement":null},{"id":"W2084545711","doi":"10.1007/s11908-012-0305-1","title":"HIV Drug Resistance and the Advent of Integrase Inhibitors","year":2012,"lang":"en","type":"article","venue":"Current Infectious Disease Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research; amfAR, The Foundation for AIDS Research","keywords":"Integrase; Virology; Integrase inhibitor; Drug resistance; Human immunodeficiency virus (HIV); Drug; Dolutegravir; Medicine; Computational biology; Biology; Pharmacology; Antiretroviral therapy; Microbiology; Viral load","score_opus":0.007649057878486275,"score_gpt":0.25746358890353016,"score_spread":0.2498145310250439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084545711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97678393,0.016318716,0.000027769267,0.0024375883,0.0014464955,0.00089200534,0.000008573355,0.00014478937,0.0019401291],"genre_scores_gemma":[0.9894169,0.0009102674,0.000015919482,0.000024794155,0.00019119785,0.000136575,0.000044446715,0.000021225882,0.009238681],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864614,0.00006511443,0.00045213389,0.0002103399,0.00035465154,0.00027163126],"domain_scores_gemma":[0.9987582,0.00012284305,0.00029130842,0.00034327057,0.00010051583,0.0003838849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000544913,0.00017932768,0.00030009056,0.000110081724,0.000094046656,0.000011551195,0.000022661856,0.000026157457,0.000032877026],"category_scores_gemma":[0.00041468593,0.000108846514,0.00016442464,0.0002099092,0.00013370394,0.000082047554,0.00005493126,0.00013660091,0.000030290754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017620606,0.00078627066,0.94910765,0.00034064337,0.0001886239,0.00012888428,0.0007513032,5.680191e-7,0.000005036061,0.00047571515,0.046061132,0.0019779499],"study_design_scores_gemma":[0.00856202,0.000030536256,0.36341977,0.0028242706,0.0035521889,0.00037924666,0.00040390936,0.00002938204,0.0017210341,0.002913523,0.61540496,0.00075912045],"about_ca_topic_score_codex":0.000006102981,"about_ca_topic_score_gemma":0.000008190013,"teacher_disagreement_score":0.5856879,"about_ca_system_score_codex":0.00014084851,"about_ca_system_score_gemma":0.0001383341,"threshold_uncertainty_score":0.4438632},"labels":[],"label_agreement":null},{"id":"W2084758156","doi":"10.1007/s00705-009-0583-6","title":"Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study","year":2010,"lang":"en","type":"article","venue":"Archives of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Drug resistance; Biology; Virology; Dried blood spot; Reverse transcriptase; Protease; Transmission (telecommunications); Medical microbiology; Human immunodeficiency virus (HIV); HIV-1 protease; Polymerase chain reaction; Genetics; Gene; Enzyme","score_opus":0.01418407495050524,"score_gpt":0.2687920450011634,"score_spread":0.25460797005065816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084758156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521416,0.00017944037,0.00015843577,0.0020468067,0.000047083973,0.00038710266,0.000009938889,0.000014808681,0.0019422128],"genre_scores_gemma":[0.991261,0.000040177314,0.00622418,0.000031062787,0.0000198492,0.000033760167,0.000020936066,0.000010898122,0.0023581479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988975,0.000118500706,0.00038078343,0.00028134004,0.00014039938,0.00018149914],"domain_scores_gemma":[0.9991159,0.00039778612,0.00010235157,0.00030508774,0.00001040626,0.00006846085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011517265,0.00012950593,0.00044096945,0.00014296634,0.00002347486,0.0000012835865,0.0001420389,0.000024657036,0.00009478132],"category_scores_gemma":[0.000048735303,0.0001040772,0.000041131458,0.00010983234,0.00023624231,0.000022749391,0.000031522315,0.00016369658,0.0000043441783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003792474,0.0021774804,0.62472653,0.000030957017,0.00006671957,0.00006174738,0.030406851,0.0000012872779,0.33703446,0.00008512394,0.000109783745,0.0015065689],"study_design_scores_gemma":[0.0055443095,0.00049703143,0.974025,0.00006352017,0.000022714725,0.000002282446,0.0007582806,0.00008073492,0.016807942,0.00057989557,0.0015129732,0.00010528856],"about_ca_topic_score_codex":0.000107277105,"about_ca_topic_score_gemma":0.0017005159,"teacher_disagreement_score":0.34929848,"about_ca_system_score_codex":0.000004885105,"about_ca_system_score_gemma":0.000041541913,"threshold_uncertainty_score":0.4244145},"labels":[],"label_agreement":null},{"id":"W2084945406","doi":"10.1097/ftd.0b013e318030839e","title":"Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected Adults","year":2007,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Indinavir; Cmax; Hazard ratio; Medicine; Confidence interval; Adverse effect; Population; Internal medicine; Proportional hazards model; Pharmacokinetics; Trough Concentration; Area under the curve; Gastroenterology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Immunology","score_opus":0.015176204427940756,"score_gpt":0.2929622919429483,"score_spread":0.27778608751500755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084945406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725974,0.0004148189,0.00005895426,0.0002007945,0.00023658287,0.0005256827,0.0000016487936,0.000064006184,0.0012377473],"genre_scores_gemma":[0.9973633,0.0000957979,0.0007664298,0.000027485254,0.00015997866,0.000025818066,0.000008723178,0.000027746039,0.0015246872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998478,0.00004475062,0.00048186773,0.00025002708,0.00033289846,0.000412441],"domain_scores_gemma":[0.99933213,0.000112872156,0.0001422188,0.00022141998,0.00007981433,0.00011155937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032388564,0.00020898852,0.00035407188,0.00017590867,0.00005018958,0.00001341321,0.000079691534,0.00009044684,0.000029004255],"category_scores_gemma":[0.000017174942,0.00018110011,0.000079433004,0.0003888672,0.000049576363,0.00012857791,0.000021198728,0.00018128782,0.000058812802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009478136,0.0003060889,0.9044104,0.000056593955,0.00011364627,0.00013753035,0.016128372,0.0000011581059,0.009051885,0.00006065304,0.000003925308,0.068781935],"study_design_scores_gemma":[0.0038250408,0.00015275562,0.81687397,0.00059822423,0.00009968415,0.000023837492,0.0012193351,0.000031554868,0.17667796,0.000044313292,0.00028945398,0.00016388117],"about_ca_topic_score_codex":0.0001823893,"about_ca_topic_score_gemma":0.000016568341,"teacher_disagreement_score":0.16762607,"about_ca_system_score_codex":0.00024404167,"about_ca_system_score_gemma":0.00011052479,"threshold_uncertainty_score":0.7385048},"labels":[],"label_agreement":null},{"id":"W2084993052","doi":"10.1074/jbc.m110836200","title":"Primer Unblocking and Rescue of DNA Synthesis by Azidothymidine (AZT)-resistant HIV-1 Reverse Transcriptase","year":2002,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Primer (cosmetics); Virology; Zidovudine; Human immunodeficiency virus (HIV); Reverse-transcriptase inhibitor; Biology; Chemistry; Polymerase chain reaction; Gene; Genetics; Antiretroviral therapy; Viral disease; Viral load","score_opus":0.02490187939202513,"score_gpt":0.2329912058211522,"score_spread":0.20808932642912709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084993052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187386,0.003822696,0.00002023214,0.002953496,0.00002391205,0.00007390409,0.000038278336,0.000010486347,0.0011831286],"genre_scores_gemma":[0.99400616,0.001362922,0.0012988499,0.00007655151,0.000085045656,0.0000027982146,0.000008567376,0.00000925622,0.0031498445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998837,0.00003823271,0.00054995384,0.00016665329,0.00022094362,0.00018720544],"domain_scores_gemma":[0.9992825,0.00010728193,0.0001907697,0.0001234305,0.0000887944,0.00020722236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027699684,0.00017166501,0.00051410915,0.00003512689,0.000040955885,0.0000073862543,0.00008687425,0.00015815401,0.0009112541],"category_scores_gemma":[0.000281105,0.00010622441,0.00016703956,0.000099905905,0.00013700369,0.000036381545,0.000019717738,0.00021264992,0.000004481436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035821533,0.00049734215,0.008077697,0.00013752494,0.0002458753,0.00027421472,0.00010532706,3.6127398e-7,0.9770387,0.0000024460628,0.011357667,0.0019046504],"study_design_scores_gemma":[0.0016758259,0.0001800142,0.0016608918,0.0004162271,0.00026271565,0.0003586001,0.00019215718,0.000017584269,0.9729276,0.0000127867725,0.02214493,0.00015072327],"about_ca_topic_score_codex":0.0000018042015,"about_ca_topic_score_gemma":9.787959e-8,"teacher_disagreement_score":0.010787263,"about_ca_system_score_codex":0.000060859435,"about_ca_system_score_gemma":0.000025603016,"threshold_uncertainty_score":0.99775934},"labels":[],"label_agreement":null},{"id":"W2085102628","doi":"10.1021/jo000510b","title":"Chiral Synthesis of 4-[1-(2-Deoxy-β-<scp>l</scp>-ribofuranosyl)] Derivatives of 2-Substituted 5-Fluoroaniline:  “Cytosine Replacement” Analogues of Deoxy-β-<scp>l</scp>-cytidine","year":2000,"lang":"en","type":"article","venue":"The Journal of Organic Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Citation; Cytosine; Social media; Library science; Computer science; Information retrieval; World Wide Web; Chemistry; Biochemistry","score_opus":0.009444838758984046,"score_gpt":0.2301143132166423,"score_spread":0.22066947445765825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085102628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918557,0.002684079,0.00007666645,0.00052646105,0.00007229129,0.00030377094,0.000064913984,0.000032873522,0.0043832343],"genre_scores_gemma":[0.9886462,0.0026325753,0.002063006,0.000039620307,0.00026040847,0.0000054863726,0.000050761464,0.00007066957,0.006231281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960625,0.00013075038,0.0019906843,0.00031858144,0.001004242,0.0004932065],"domain_scores_gemma":[0.99495536,0.0016272288,0.0017350266,0.0007452957,0.00066182733,0.0002752489],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095385144,0.0005340046,0.0015383448,0.00017425891,0.000111535424,0.000013273044,0.00053946476,0.000246442,0.0014977342],"category_scores_gemma":[0.0025936256,0.0003712724,0.00042129154,0.0007993318,0.00047339764,0.0001821834,0.0001086507,0.00051300426,0.000016045184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044321283,0.0012431778,0.0100761065,0.00072915567,0.00215773,0.00008737866,0.002860627,0.000030514359,0.9770491,0.000010008242,0.0044787754,0.00083422835],"study_design_scores_gemma":[0.003438159,0.00028831084,0.007437716,0.00098876,0.0015043358,0.00076894695,0.0023648913,0.00002565214,0.98183465,0.00011086586,0.0011391228,0.00009859956],"about_ca_topic_score_codex":0.000011024981,"about_ca_topic_score_gemma":0.0000033593572,"teacher_disagreement_score":0.004785555,"about_ca_system_score_codex":0.00020315823,"about_ca_system_score_gemma":0.00062086654,"threshold_uncertainty_score":0.99987394},"labels":[],"label_agreement":null},{"id":"W2085310757","doi":"10.1128/aac.00314-07","title":"Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir","year":2007,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; McGill University; Gilead Sciences","keywords":"Reverse transcriptase; Zidovudine; Nucleotide; Thymidine; Reverse-transcriptase inhibitor; Nucleotide excision repair; Biology; Tenofovir; Molecular biology; Virology; Nucleoside; DNA; Chemistry; Virus; RNA; Human immunodeficiency virus (HIV); Biochemistry; DNA damage; Viral disease; Gene","score_opus":0.01224921166701914,"score_gpt":0.2630841846614157,"score_spread":0.25083497299439655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085310757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984582,0.00019327192,0.000079008074,0.00040080876,0.00006575914,0.0005327597,0.000011423605,0.0000041237863,0.00025462432],"genre_scores_gemma":[0.998034,0.001295861,0.00008032562,0.00028965855,0.0000070417323,0.0000011000567,0.000007350688,0.000011274355,0.00027336556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99910766,0.000031667154,0.00037096802,0.0001277674,0.00020291297,0.00015901926],"domain_scores_gemma":[0.99943936,0.00005654875,0.00019092366,0.00020173292,0.00008410047,0.00002732168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021870715,0.00011975299,0.0002692447,0.00007170813,0.00006462999,0.0000019439406,0.0000942483,0.00005341085,0.000044840646],"category_scores_gemma":[0.00001312897,0.00006448149,0.000108463515,0.00026407922,0.00018741048,0.000020016172,0.000007652503,0.00006380065,7.064777e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005323183,0.0011312257,0.005675849,0.00021141251,0.000085465,0.000001453119,0.004042099,9.637974e-7,0.98176813,0.00010467578,0.00056034554,0.0058860816],"study_design_scores_gemma":[0.0022832172,0.00036492528,0.07454251,0.00035953155,0.00007494963,0.0000014978566,0.00011718864,0.0000051919046,0.9214513,0.00001301586,0.0007319506,0.000054760476],"about_ca_topic_score_codex":0.00012948479,"about_ca_topic_score_gemma":0.000005230104,"teacher_disagreement_score":0.06886666,"about_ca_system_score_codex":0.000017454959,"about_ca_system_score_gemma":0.000050116112,"threshold_uncertainty_score":0.2629479},"labels":[],"label_agreement":null},{"id":"W2085312586","doi":"10.2165/00003088-200544060-00003","title":"Application and Impact of Population Pharmacokinetics in the Assessment of Antiretroviral Pharmacotherapy","year":2005,"lang":"en","type":"review","venue":"Clinical Pharmacokinetics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Dosing; Population; Pharmacokinetics; Pharmacotherapy; Drug; Pharmacodynamics; Intensive care medicine; Pharmacology; Clinical trial; Therapeutic drug monitoring; Internal medicine; Environmental health","score_opus":0.09711398041052753,"score_gpt":0.533612792953196,"score_spread":0.4364988125426684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085312586","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012403656,0.98310536,0.00014097305,0.00021119816,0.00019611281,0.0033339246,0.00012867186,0.00002769318,0.00045241337],"genre_scores_gemma":[0.06567445,0.93155605,0.0014642896,0.0000960574,0.00041970538,0.000089741465,0.0004913879,0.000058099125,0.0001502404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958965,0.00048842543,0.0023411245,0.0004752477,0.0005098618,0.00028883966],"domain_scores_gemma":[0.9974242,0.00076363113,0.0011278897,0.00041955922,0.00011711188,0.000147623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011987246,0.0004981937,0.00222604,0.00032351218,0.000029178927,0.000012574049,0.0002827332,0.0002707762,0.000105590756],"category_scores_gemma":[0.000048850186,0.0003093018,0.0008117983,0.00062092737,0.00019614401,0.00005133007,0.000067287154,0.000766791,0.000004917979],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060348884,0.0013261891,0.04478496,0.0029778525,0.0006521295,0.000010979637,0.000052724146,0.000014755,0.00003392828,0.00002877845,0.0011349609,0.9489224],"study_design_scores_gemma":[0.009090177,0.0011458729,0.05260727,0.0036994258,0.008374135,0.000069120826,0.0000152286575,0.0052836197,0.000025094254,0.00003413932,0.9190292,0.0006267158],"about_ca_topic_score_codex":0.000018272247,"about_ca_topic_score_gemma":9.850829e-7,"teacher_disagreement_score":0.94829565,"about_ca_system_score_codex":0.00015938487,"about_ca_system_score_gemma":0.00029278456,"threshold_uncertainty_score":0.9999359},"labels":[],"label_agreement":null},{"id":"W2085468466","doi":"10.1097/qai.0b013e318050d88c","title":"Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137","year":2007,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Committee of Toronto","funders":"","keywords":"Emtricitabine; Tenofovir; Ritonavir; Pharmacokinetics; Pharmacology; Medicine; Chemistry; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load","score_opus":0.01476316533453271,"score_gpt":0.2877523368080423,"score_spread":0.2729891714735096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085468466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836504,0.013510327,0.00044639996,0.0006066188,0.0004712234,0.00057815004,0.000025670313,0.000037738624,0.00067349],"genre_scores_gemma":[0.99193996,0.0014116983,0.0043852297,0.00003078031,0.00005810864,0.0000063183056,0.00003372456,0.00006194386,0.0020722067],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9954054,0.00011592384,0.0023642073,0.0003967153,0.0010960264,0.0006217648],"domain_scores_gemma":[0.9969816,0.00047877763,0.0013653234,0.0003449503,0.0005427564,0.00028657692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019941065,0.0005004167,0.0014703169,0.0012504567,0.0001938795,0.000049290968,0.00025792653,0.000204027,0.000032224478],"category_scores_gemma":[0.00042318527,0.000397781,0.00038210908,0.0014381465,0.00035801122,0.00047166354,0.00012539187,0.00022947675,0.0000058772157],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026860416,0.0030287837,0.31463584,0.0013166675,0.0021571396,0.002197457,0.0064023724,0.000024545467,0.6266118,0.00027246136,0.00046971257,0.040197138],"study_design_scores_gemma":[0.018637722,0.0059169442,0.8088812,0.0017241715,0.0030977684,0.004451691,0.004555748,0.0003290153,0.1505382,0.00030831053,0.00059783587,0.00096137956],"about_ca_topic_score_codex":0.000025510086,"about_ca_topic_score_gemma":0.0000026496343,"teacher_disagreement_score":0.49424538,"about_ca_system_score_codex":0.00017165567,"about_ca_system_score_gemma":0.00047775215,"threshold_uncertainty_score":0.9998474},"labels":[],"label_agreement":null},{"id":"W2085481779","doi":"10.1310/hct1105-260","title":"A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Saskatchewan","keywords":"Raltegravir; Abacavir; Medicine; Lamivudine; Adverse effect; Viral load; Internal medicine; Discontinuation; Gastroenterology; Human immunodeficiency virus (HIV); Virology; Chronic hepatitis; Antiretroviral therapy","score_opus":0.15240359952108895,"score_gpt":0.4151683571378847,"score_spread":0.26276475761679574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085481779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281836,0.000022646453,0.0000017128648,0.00094966847,0.0010431497,0.004095298,0.00012355045,0.000025249674,0.00092036335],"genre_scores_gemma":[0.9968096,0.000064798245,0.00024164838,0.000059071805,0.0003263652,0.000058849597,0.000069791786,0.00002402137,0.00234583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934268,0.0015279431,0.0037220982,0.0005125159,0.0005380371,0.00027257664],"domain_scores_gemma":[0.992402,0.005358677,0.0012320839,0.00067628064,0.00016898983,0.00016195934],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0068745483,0.00028214636,0.0019759445,0.00019201773,0.000052705123,0.000014439263,0.0001980076,0.0001668719,0.000058215777],"category_scores_gemma":[0.028260175,0.00016314747,0.00029984835,0.00048594215,0.0002534496,0.00007379158,0.00014895327,0.00066906615,0.000022946424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14478958,0.024604918,0.8188484,0.00004475143,0.00040310263,0.000017908536,0.0006508117,3.8456974e-7,0.00091186224,0.00004860762,0.0032670903,0.00641259],"study_design_scores_gemma":[0.3551731,0.015292361,0.6270727,0.00021707106,0.00055679376,0.0000012046759,0.00019293503,0.000015445225,0.0005848349,0.000086499866,0.00062609825,0.00018097063],"about_ca_topic_score_codex":0.000103450846,"about_ca_topic_score_gemma":0.000254049,"teacher_disagreement_score":0.21038352,"about_ca_system_score_codex":0.000023421964,"about_ca_system_score_gemma":0.00019847337,"threshold_uncertainty_score":0.9799252},"labels":[],"label_agreement":null},{"id":"W2086266172","doi":"10.1158/1538-7445.am2013-857","title":"Abstract 857: Anti-tumor and anti-metastatic activity of the eIF4E-targeted drug ribavirin in human and murine models of breast cancer.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cancer research; Clonogenic assay; Ribavirin; EIF4E; Cancer; Metastasis; Metastatic breast cancer; Breast cancer; Oncogene; In vivo; Medicine; Cancer cell; Biology; Immunology; Internal medicine; Cell cycle; Translation (biology); Messenger RNA; Virus; Biochemistry","score_opus":0.05163084837579567,"score_gpt":0.3702067618812005,"score_spread":0.3185759135054048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086266172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951358,0.0010867349,9.5202194e-7,0.0024312316,0.0000249659,0.0009505565,0.000078856065,0.0000074238533,0.00028347076],"genre_scores_gemma":[0.99781436,0.0007238861,0.000045583984,0.000015137686,0.000022451626,0.00017174774,0.000004530976,0.000019561676,0.0011827248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984593,0.00011036886,0.00028196664,0.00029182818,0.00050040876,0.00035616267],"domain_scores_gemma":[0.9991664,0.000105609826,0.00009815871,0.00027195064,0.00022889124,0.00012896859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049985806,0.00014745526,0.00043618973,0.0002240905,0.00009585543,0.000017398053,0.00011903302,0.000031630756,0.00033252794],"category_scores_gemma":[0.000024913057,0.00009746791,0.000040018986,0.00041728542,0.00038913076,0.00017042819,0.00014610756,0.0003293312,0.0000021488897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001617277,0.000642284,0.55753046,0.0012148798,0.00023574117,0.00003772865,0.0017344924,0.00007634355,0.4278537,0.00008267651,0.0015758483,0.008854119],"study_design_scores_gemma":[0.0019459139,0.00002664931,0.91210264,0.0005541319,0.00002770752,0.0000087101425,0.00020976391,0.00037049083,0.08445242,0.00017961107,0.000034069737,0.00008788837],"about_ca_topic_score_codex":0.012079336,"about_ca_topic_score_gemma":0.0011209075,"teacher_disagreement_score":0.35457218,"about_ca_system_score_codex":0.00014357528,"about_ca_system_score_gemma":0.00035477013,"threshold_uncertainty_score":0.9944993},"labels":[],"label_agreement":null},{"id":"W2086729134","doi":"10.1371/journal.pone.0009263","title":"HIV Drug Resistance Surveillance Using Pooled Pyrosequencing","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Government of Canada","keywords":"Pyrosequencing; Sanger sequencing; Biology; Genetics; Population; Genotype; Amplicon; Drug resistance; Sequence analysis; Single-nucleotide polymorphism; Virology; Mutation; Gene; Polymerase chain reaction; Medicine","score_opus":0.03155281199217719,"score_gpt":0.24198108035932014,"score_spread":0.21042826836714296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086729134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871698,0.0001813551,0.000035561185,0.005270104,0.00007109442,0.00030913373,0.0000072473363,0.00012883954,0.00682689],"genre_scores_gemma":[0.878022,0.000025229656,0.03323639,0.00013896465,0.00018405668,0.00001605915,0.000032694534,0.000031430223,0.08831318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988134,0.000023821809,0.00022533367,0.0002739635,0.00037689204,0.00028659715],"domain_scores_gemma":[0.99926734,0.000060084352,0.00007400484,0.00033801308,0.00012032463,0.00014026248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021048097,0.00015719657,0.00033067656,0.00007929193,0.00011468773,0.00002196733,0.00007576861,0.000058594607,0.00021820926],"category_scores_gemma":[0.00013484157,0.00013902146,0.000049028633,0.0001878335,0.000052981235,0.000069342226,0.000030004649,0.000241522,0.00019666507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015339437,0.0012692228,0.22145608,0.00024753014,0.000605507,0.00020786055,0.0009070255,6.810529e-7,0.77191645,0.00025862662,0.0028048279,0.0001728187],"study_design_scores_gemma":[0.0059361276,0.000030243458,0.0439613,0.0015725988,0.00083108747,0.000026676284,0.00019849915,0.0012353538,0.93709683,0.0005024228,0.007703847,0.0009049839],"about_ca_topic_score_codex":0.000010516251,"about_ca_topic_score_gemma":0.0002448431,"teacher_disagreement_score":0.17749478,"about_ca_system_score_codex":0.00010502174,"about_ca_system_score_gemma":0.00014528711,"threshold_uncertainty_score":0.56691307},"labels":[],"label_agreement":null},{"id":"W2086824413","doi":"10.1385/cbb:46:1:27","title":"Aspirin Interaction With Ribonuclease A","year":2006,"lang":"en","type":"article","venue":"Cell Biochemistry and Biophysics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Innovation and Economic Development Trois Rivières","funders":"","keywords":"Aspirin; Ribonuclease; Chemistry; Computational biology; Medicine; Biochemistry; Biology; RNA","score_opus":0.0038466052212521172,"score_gpt":0.1958236260543111,"score_spread":0.19197702083305898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086824413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97900665,0.00006261778,0.00002445246,0.00037928767,0.000015616673,0.00007664884,0.0000047175217,0.00003498882,0.020395046],"genre_scores_gemma":[0.98008555,0.00001252051,0.0006577702,0.00005284874,0.00013270944,0.00000636256,0.0001643696,0.000008990136,0.018878907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99955255,0.0000026424093,0.000080159654,0.00017633988,0.00008054712,0.00010774109],"domain_scores_gemma":[0.9997569,0.000007093067,0.000035686768,0.00010883181,0.00002873032,0.000062788495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00001369525,0.00011466897,0.000104407234,0.000013218105,0.000047380163,0.000016457983,0.00001810916,0.000043199427,0.000020601643],"category_scores_gemma":[9.507527e-7,0.00008308605,0.000028193017,0.00007959228,0.00004938947,0.000029895707,0.000013827136,0.00006847242,0.000029486677],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031711816,0.000807699,0.010426014,0.00034204475,0.00005858716,0.00015735805,0.00007150696,0.0000012803378,0.9798093,0.00006046751,0.0031664437,0.0047822054],"study_design_scores_gemma":[0.0009488884,0.00005926661,0.000986633,0.00006913221,0.00008130396,0.000034062425,0.0000702972,0.00003515469,0.99147844,0.000046890287,0.0060707657,0.00011918141],"about_ca_topic_score_codex":0.000008739589,"about_ca_topic_score_gemma":6.335936e-7,"teacher_disagreement_score":0.01166915,"about_ca_system_score_codex":0.000027897428,"about_ca_system_score_gemma":0.00003313888,"threshold_uncertainty_score":0.33881506},"labels":[],"label_agreement":null},{"id":"W2086911097","doi":"10.1046/j.1365-2125.2001.01393.x","title":"Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers","year":2001,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Ritonavir; Mefloquine; Pharmacokinetics; Pharmacology; Cmax; Metabolite; Drug interaction; Medicine; Internal medicine; Viral load; Chloroquine; Immunology; Malaria; Human immunodeficiency virus (HIV)","score_opus":0.06650468204039094,"score_gpt":0.45370960383849784,"score_spread":0.3872049217981069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086911097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98146117,0.002077385,0.00004860211,0.014099368,0.0014413467,0.00024937888,0.0000039295155,0.000012852672,0.0006059735],"genre_scores_gemma":[0.9808186,0.013326156,0.0007773655,0.0023899851,0.0018265757,0.0000060609354,0.00000945103,0.0000182649,0.0008275171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974035,0.00031188547,0.0015552272,0.00021734802,0.00022446012,0.00028759585],"domain_scores_gemma":[0.9984517,0.00056602963,0.00036421904,0.000046604655,0.00015732812,0.0004140902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012426514,0.00013405106,0.0008146693,0.00021081403,0.00004394835,0.000015066398,0.00008784763,0.00012916634,0.000589734],"category_scores_gemma":[0.0002149125,0.00013710666,0.00015933615,0.00019506302,0.00013298893,0.00016167309,0.00004131446,0.0009701426,0.00002466164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003638933,0.0011029608,0.5596595,0.000043899054,0.00044872612,0.0071865474,0.000078613615,0.000008367748,0.00031759014,0.0000010788498,0.030212922,0.39730087],"study_design_scores_gemma":[0.03373786,0.0020374397,0.7379757,0.0004160386,0.000702462,0.012301851,0.000090124275,0.00037167376,0.00019229781,0.00007391061,0.21189259,0.00020804176],"about_ca_topic_score_codex":0.00003944442,"about_ca_topic_score_gemma":0.00003296587,"teacher_disagreement_score":0.39709282,"about_ca_system_score_codex":0.00009477556,"about_ca_system_score_gemma":0.00018681437,"threshold_uncertainty_score":0.6457174},"labels":[],"label_agreement":null},{"id":"W2087314182","doi":"10.1007/s00044-013-0879-7","title":"Synthesis, molecular docking and antiviral screening of novel N′-substitutedbenzylidene-2-(4-methyl-5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-1(4H)-yl)acetohydrazides","year":2013,"lang":"en","type":"article","venue":"Medicinal Chemistry Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Karachi","keywords":"Human immunodeficiency virus (HIV); Chemistry; EC50; Cytotoxic T cell; Reverse transcriptase; Docking (animal); Stereochemistry; In vitro; Molecular biology; Biochemistry; Virology; Biology; Gene; RNA; Medicine","score_opus":0.05432034330679223,"score_gpt":0.3502299735932986,"score_spread":0.29590963028650635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087314182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823738,0.002548151,0.00039266326,0.003181255,0.000043057815,0.00073541445,0.000011582132,0.000080551734,0.010633535],"genre_scores_gemma":[0.9911552,0.00027360473,0.005221364,0.000058849982,0.0002225767,0.0001862431,0.00004633439,0.00006467421,0.0027711175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99538505,0.00011398167,0.00073275814,0.00080721546,0.0019096888,0.0010512806],"domain_scores_gemma":[0.9971039,0.0007948884,0.00016745113,0.00065871386,0.0007021998,0.00057282054],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017510515,0.0004471699,0.00089404726,0.0003418478,0.00028102007,0.00007759252,0.00035117846,0.00030092552,0.0006087395],"category_scores_gemma":[0.0017654536,0.00037482666,0.00016275446,0.00081869337,0.0008898532,0.00021950006,0.00032556482,0.0009656737,0.00005056724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020214356,0.0004053652,0.025125531,0.0010495575,0.00037366766,0.00039058368,0.00060712744,0.000012639484,0.9585003,0.00007650375,0.0011841307,0.012072446],"study_design_scores_gemma":[0.0027649587,0.00012575208,0.008425859,0.0018696198,0.00019738024,0.00026275235,0.0018206711,0.0016551046,0.9811004,0.000105230385,0.0012957259,0.0003765396],"about_ca_topic_score_codex":0.00029313305,"about_ca_topic_score_gemma":0.00000596056,"teacher_disagreement_score":0.022600103,"about_ca_system_score_codex":0.00017396138,"about_ca_system_score_gemma":0.00040165268,"threshold_uncertainty_score":0.99987036},"labels":[],"label_agreement":null},{"id":"W2087762541","doi":"10.1081/ncn-100002520","title":"EFFECT OF SUBSTITUTING ARABINONUCLEOSIDES FOR DEOXYNUCLEOTIDES IN THE DNA PRIMING STRAND ON THE POLYMERASE ACTION OF HIV-1 RT","year":2001,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Primer (cosmetics); DnaG; DNA; DNA polymerase; DNA clamp; DNA polymerase II; Primase; Molecular biology; Polymerase; Biology; DNA replication; DNA synthesis; Chemistry; Polymerase chain reaction; Genetics; Circular bacterial chromosome; Reverse transcriptase; Gene","score_opus":0.025845655126063745,"score_gpt":0.2933488589747745,"score_spread":0.26750320384871074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087762541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832595,0.00024911566,0.00006669435,0.00434476,0.00019189242,0.002793794,0.0000367184,0.00012312831,0.0038679596],"genre_scores_gemma":[0.9973376,0.00021078021,0.0010660803,0.00054132316,0.00017923414,0.00016497828,0.000040729145,0.00012731091,0.00033199546],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957684,0.00044785906,0.00132605,0.0007126742,0.0008853131,0.0008596887],"domain_scores_gemma":[0.9950576,0.0029659434,0.0006092041,0.0010158665,0.00018159476,0.0001697902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023666972,0.00070890813,0.001193587,0.00048711803,0.00047132585,0.000088610206,0.0006314438,0.0002372959,0.0002218409],"category_scores_gemma":[0.0008629346,0.0004259026,0.0006337991,0.0009074872,0.0006268873,0.0003334411,0.00009110186,0.00051347195,0.000054699525],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017268483,0.0039851107,0.5142415,0.0030809937,0.0017849292,0.0004248508,0.017068705,0.00037729807,0.30805397,0.01727715,0.0067520803,0.10968493],"study_design_scores_gemma":[0.017532242,0.005760268,0.20833856,0.0044298368,0.0024302267,0.0004930764,0.009308929,0.0025988272,0.7348515,0.0009582857,0.011810518,0.0014877601],"about_ca_topic_score_codex":0.00008763572,"about_ca_topic_score_gemma":0.000072026975,"teacher_disagreement_score":0.4267975,"about_ca_system_score_codex":0.00019485477,"about_ca_system_score_gemma":0.00012860127,"threshold_uncertainty_score":0.9998193},"labels":[],"label_agreement":null},{"id":"W2088089484","doi":"10.1002/jmv.21567","title":"Prevalence of the K65R resistance reverse transcriptase mutation in different HIV‐1 subtypes in Israel","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Virology; Reverse transcriptase; Biology; Abacavir; Mutation; Didanosine; Virus; Resistance mutation; Drug resistance; Lentivirus; Viral disease; Sida; Polymerase chain reaction; Viral load; Genetics; Antiretroviral therapy; Gene","score_opus":0.010163990816899629,"score_gpt":0.26817890872747424,"score_spread":0.2580149179105746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088089484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9052532,0.00095763267,0.00006920138,0.09331874,0.00012527868,0.00012816023,0.0000019234951,0.000002091122,0.00014377781],"genre_scores_gemma":[0.996858,0.00066268985,0.00021619273,0.0010312097,0.00005712043,0.0000019790068,0.0000012132784,0.000003837414,0.0011677804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983035,0.00019182719,0.0006333436,0.00010281582,0.000611524,0.00015703021],"domain_scores_gemma":[0.99940974,0.00011203723,0.00021027836,0.000112658534,0.00004570089,0.00010956463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006783188,0.0000958221,0.00035975085,0.00015939338,0.000013404757,0.0000016132996,0.00016290344,0.0001349715,0.00015592182],"category_scores_gemma":[0.0004690757,0.00005312601,0.00009330442,0.00015782073,0.00010301368,0.000042573705,0.000009977798,0.00041321467,0.000002794018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004109578,0.0030947225,0.9564955,0.0004345978,0.0001274277,0.0038612306,0.003818366,0.000014740079,0.005909046,0.0015725143,0.010413087,0.010149169],"study_design_scores_gemma":[0.005200437,0.00030494452,0.98981607,0.0007428273,0.00008840494,0.00018230779,0.00016872611,0.00006720922,0.0012447282,0.00072022463,0.0014114103,0.000052739237],"about_ca_topic_score_codex":0.000006018497,"about_ca_topic_score_gemma":0.00008687707,"teacher_disagreement_score":0.09228753,"about_ca_system_score_codex":0.000101725826,"about_ca_system_score_gemma":0.00019514922,"threshold_uncertainty_score":0.21664158},"labels":[],"label_agreement":null},{"id":"W2088250967","doi":"10.1111/j.1468-1293.2007.00463.x","title":"Performance of a World Health Organization first‐line regimen (stavudine/lamivudine/nevirapine) in antiretroviral‐naïve individuals in a Western setting","year":2007,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver","funders":"Michael Smith Health Research BC","keywords":"Nevirapine; Lamivudine; Medicine; Stavudine; Interquartile range; Regimen; Viral load; Context (archaeology); Internal medicine; Hazard ratio; Population; Proportional hazards model; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV); Confidence interval; Virus; Environmental health; Hepatitis B virus; Biology","score_opus":0.016441138176845334,"score_gpt":0.2853515226771034,"score_spread":0.26891038450025806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088250967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704846,0.0007455866,0.00016212378,0.02632599,0.00010336191,0.00086126744,0.000005649023,0.00006502835,0.0012463691],"genre_scores_gemma":[0.98962575,0.0005958441,0.0014632501,0.000852709,0.00020348822,0.000012580048,0.00034337337,0.0000495243,0.006853463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997061,0.000055837412,0.0012924144,0.00041535645,0.0005909081,0.00058449584],"domain_scores_gemma":[0.9987327,0.00018789626,0.0004238584,0.0003331653,0.00012907447,0.00019334364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017589141,0.00031492137,0.0009238062,0.0014419174,0.0000652122,0.000005107267,0.0001306747,0.00009097377,0.00017640543],"category_scores_gemma":[0.00032354554,0.00025327402,0.000036639234,0.0026963619,0.00011121303,0.00014569989,0.000067764544,0.00031133226,0.000034152297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015263048,0.00029172428,0.9855686,0.00052327523,0.00004803645,0.000085138745,0.0050276075,0.000016093072,0.0002618387,0.000026691447,0.002673147,0.0053252117],"study_design_scores_gemma":[0.010031013,0.0007599908,0.9777966,0.0048549674,0.000059967293,0.00003784016,0.0005279349,0.00033251656,0.0013884188,0.0000099177405,0.0039704894,0.00023030101],"about_ca_topic_score_codex":0.00010046307,"about_ca_topic_score_gemma":0.0009482354,"teacher_disagreement_score":0.02547328,"about_ca_system_score_codex":0.00041369954,"about_ca_system_score_gemma":0.00022031952,"threshold_uncertainty_score":0.99999195},"labels":[],"label_agreement":null},{"id":"W2088300675","doi":"10.3390/v5071787","title":"Posttranslational Modifications of HIV-1 Integrase by Various Cellular Proteins during Viral Replication","year":2013,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada; Manitoba Health Research Council; Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"SUMO protein; Integrase; Acetylation; Biology; Viral replication; Ubiquitin; Cell biology; Ku70; Phosphorylation; Replication (statistics); Integrase inhibitor; Computational biology; Human immunodeficiency virus (HIV); Genetics; DNA; Virology; Virus; Gene; DNA repair; Antiretroviral therapy; Viral load","score_opus":0.05975787163440771,"score_gpt":0.3272956705729445,"score_spread":0.2675377989385368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088300675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00065551006,0.9942403,0.0005377468,0.00028831698,0.000040854262,0.002976325,0.00049640227,0.0000940013,0.00067058724],"genre_scores_gemma":[0.00032267,0.9791636,0.0026285825,0.000022997667,0.000084566775,0.0012539984,0.0032957203,0.00007134067,0.013156534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822134,0.00006635939,0.0007457104,0.00047525938,0.00029977266,0.00019156431],"domain_scores_gemma":[0.9986259,0.000063247884,0.0003739487,0.0007093083,0.00011727892,0.000110338086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010071314,0.00034568718,0.00091104547,0.00026551067,0.0000888759,0.000019462734,0.00014740389,0.00021143047,0.00028352515],"category_scores_gemma":[0.00005740972,0.0002616468,0.0002701986,0.00025409955,0.00006846355,0.00010371528,0.00002706647,0.00022511973,0.00054718653],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000810844,0.0036785414,0.0005420968,0.035899818,0.003989636,0.00004689384,0.0009213039,0.0000021948715,0.018463546,0.003180877,0.031076265,0.9021177],"study_design_scores_gemma":[0.00048672204,0.000037528298,0.000029773571,0.0037788695,0.001260126,0.000023527007,0.00000894558,0.000008312186,0.005230257,0.000037220696,0.9888391,0.00025963504],"about_ca_topic_score_codex":0.000052551724,"about_ca_topic_score_gemma":0.0000016766751,"teacher_disagreement_score":0.95776284,"about_ca_system_score_codex":0.00016265157,"about_ca_system_score_gemma":0.0003647371,"threshold_uncertainty_score":0.99998355},"labels":[],"label_agreement":null},{"id":"W2089338386","doi":"10.1016/j.jconrel.2009.05.007","title":"Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead","year":2009,"lang":"en","type":"review","venue":"Journal of Controlled Release","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Pharmacotherapy; Medicine; Drug; Biopharmaceutical; Pharmacology; Dosing; Intensive care medicine; Drug delivery; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Viral load; Biology; Internal medicine; Biotechnology; Chemistry","score_opus":0.042577430321764226,"score_gpt":0.3117240022951725,"score_spread":0.2691465719734083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089338386","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024902084,0.9867113,0.000008546933,0.009897216,0.00040253394,0.0024249135,0.0000045129937,0.000012798989,0.00028914234],"genre_scores_gemma":[0.0012156599,0.994932,0.00005152007,0.00013302655,0.00066765165,0.00007404719,0.0000059368904,0.00004990665,0.0028702766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960625,0.0008729786,0.0017880556,0.00026062896,0.000642006,0.0003738376],"domain_scores_gemma":[0.99666834,0.0011237047,0.001486778,0.00022725998,0.00019036057,0.00030356206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024061375,0.00054359157,0.0051578926,0.0006803339,0.00011933809,0.00022185201,0.00019177007,0.00019376822,0.000024069945],"category_scores_gemma":[0.000101674355,0.00026198663,0.0009179114,0.00019445061,0.00011235679,0.00027124558,0.000023431223,0.0009044037,0.000012636945],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074110385,0.00036446366,0.0000074699537,0.0039582467,0.0038711594,0.0020439525,0.0011789625,0.0000033579156,0.0000013527315,0.00015164638,0.0025692051,0.97843915],"study_design_scores_gemma":[0.0878073,0.00014040075,0.0000033034744,0.057228126,0.0058312444,0.0010857868,0.00075105217,0.00008796402,7.937848e-7,0.00004515713,0.8467512,0.00026768693],"about_ca_topic_score_codex":0.00000777129,"about_ca_topic_score_gemma":0.000009084528,"teacher_disagreement_score":0.97817147,"about_ca_system_score_codex":0.00042827384,"about_ca_system_score_gemma":0.0008392868,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W2089392459","doi":"10.1016/j.antinf.2014.01.008","title":"Est-il possible qu’il n’y aura jamais de résistance contre le dolutégravir si ce médicament est utilisé en première ligne ?","year":2014,"lang":"fr","type":"article","venue":"Journal des Anti-infectieux","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Human immunodeficiency virus (HIV); Drug resistance; Medicine; Virology; Antiretroviral therapy; Viral load; Genetics; Biology","score_opus":0.008311368478585312,"score_gpt":0.2520636880494709,"score_spread":0.24375231957088556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089392459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8962905,0.033434898,0.0056914724,0.021523328,0.0044493377,0.0011445745,0.00009333343,0.00023026064,0.037142314],"genre_scores_gemma":[0.9025076,0.019796418,0.004869679,0.0005076661,0.0032463481,0.000046416502,0.000035792888,0.0001631143,0.068826966],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99397,0.0006953902,0.0013982943,0.000803548,0.0010505875,0.0020822],"domain_scores_gemma":[0.9957725,0.0006996778,0.0007707953,0.0007162809,0.00058774615,0.0014530208],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022624047,0.000983809,0.0014698278,0.0004103353,0.0012018891,0.00056341634,0.0004746725,0.0005786457,0.0008152807],"category_scores_gemma":[0.00063102006,0.000862066,0.0006890439,0.00074818346,0.00048005336,0.00069471315,0.00018874159,0.0015027302,0.00078402413],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006595305,0.0051942705,0.68123233,0.001481562,0.003131087,0.0031668367,0.007689606,0.0003751998,0.00797433,0.011626133,0.07790184,0.19956724],"study_design_scores_gemma":[0.016600745,0.0022174122,0.21847723,0.008233825,0.0024676668,0.006175446,0.003588526,0.0023887397,0.017455366,0.0045041614,0.7160206,0.0018702581],"about_ca_topic_score_codex":0.001053593,"about_ca_topic_score_gemma":0.00077292015,"teacher_disagreement_score":0.63811874,"about_ca_system_score_codex":0.0019477262,"about_ca_system_score_gemma":0.0021030123,"threshold_uncertainty_score":0.999994},"labels":[],"label_agreement":null},{"id":"W2089422405","doi":"10.1310/0xh7-f2v2-1k0r-nu2w","title":"Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; St. Paul's Hospital","funders":"","keywords":"Medicine; Enfuvirtide; Regimen; Internal medicine; Confidence interval; Odds ratio; Viral load; Randomization; Logistic regression; Clinical trial; Human immunodeficiency virus (HIV); Immunology","score_opus":0.08973515316492171,"score_gpt":0.4063030425292003,"score_spread":0.3165678893642786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089422405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937641,0.00018783836,0.00016988296,0.002790678,0.000104185536,0.0021540807,0.00013002811,0.000088868896,0.00061034726],"genre_scores_gemma":[0.98521256,0.0001047867,0.008016078,0.00026186815,0.00019519209,0.00007832785,0.00035401853,0.000035222336,0.00574197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968694,0.00041313787,0.0015505815,0.00043869735,0.00044408382,0.00028413642],"domain_scores_gemma":[0.9961369,0.002147895,0.0005457499,0.0003577649,0.00036759643,0.0004440777],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012240176,0.00023883986,0.0012023839,0.000098612785,0.000046896217,0.0000108748445,0.00007692142,0.0000786335,0.00025841524],"category_scores_gemma":[0.008850142,0.00014995794,0.00026523022,0.00020022754,0.000120235665,0.000098696815,0.000036761296,0.00015224399,0.00020244354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005553167,0.0019840945,0.9554344,0.00006121382,0.0003973451,0.000046805948,0.00008622569,0.000014545117,0.000013275596,0.000023400411,0.0027638788,0.033621658],"study_design_scores_gemma":[0.025953643,0.0005976517,0.9629265,0.0007716229,0.0012248548,7.6888983e-7,0.000032483462,0.00011466347,0.00025394355,0.000028539955,0.007872788,0.00022251118],"about_ca_topic_score_codex":5.275696e-7,"about_ca_topic_score_gemma":6.5472375e-7,"teacher_disagreement_score":0.033399146,"about_ca_system_score_codex":0.000051284223,"about_ca_system_score_gemma":0.000259406,"threshold_uncertainty_score":0.9994987},"labels":[],"label_agreement":null},{"id":"W2089585442","doi":"10.1089/apc.2011.0113","title":"Effects of the H <sub>2</sub> -Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients","year":2011,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Stephen's University","funders":"Bristol-Myers Squibb","keywords":"Atazanavir; Medicine; Tenofovir; Famotidine; Ritonavir; Pharmacokinetics; Pharmacology; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy","score_opus":0.009069225275147821,"score_gpt":0.2148514074036833,"score_spread":0.2057821821285355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089585442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764967,0.00013161215,0.000004438473,0.000023284767,0.00011844515,0.0013808057,0.00006488146,0.000016540504,0.00061030523],"genre_scores_gemma":[0.99928796,0.00012259386,0.00020990607,0.00009960963,0.000015535132,0.00007288456,0.000078484496,0.00002832359,0.00008470894],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986218,0.00011221422,0.000356236,0.0002587656,0.00041732035,0.00023361851],"domain_scores_gemma":[0.99910456,0.0001438117,0.00019203038,0.00028494574,0.0001926208,0.000082023944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006303057,0.0002664714,0.00041428514,0.0001128566,0.000083771025,0.000005781432,0.00011072957,0.000066620785,0.000019740908],"category_scores_gemma":[0.000051461826,0.000120712015,0.000076933575,0.0003949146,0.00018891777,0.0000451442,0.000079698766,0.00017113151,0.0000054202856],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014660814,0.0010977902,0.91199756,0.00030005293,0.00020387511,0.000015044176,0.0076563926,8.003047e-7,0.007927395,0.000041456853,0.00030124807,0.06899233],"study_design_scores_gemma":[0.0071552163,0.029133337,0.15749787,0.0010007215,0.00041542324,0.00000358145,0.0009679313,0.000014365252,0.8032926,0.000004345485,0.0002852678,0.00022934194],"about_ca_topic_score_codex":0.000047365804,"about_ca_topic_score_gemma":0.000037929574,"teacher_disagreement_score":0.7953652,"about_ca_system_score_codex":0.00006253942,"about_ca_system_score_gemma":0.00009026552,"threshold_uncertainty_score":0.4922493},"labels":[],"label_agreement":null},{"id":"W2089639895","doi":"10.1097/qai.0b013e31823c8b69","title":"Polymorphic Mutations Associated With the Emergence of the Multinucleoside/Tide Resistance Mutations 69 Insertion and Q151M","year":2011,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; Genetics; Mutation; Logistic regression; Virology; Medicine; Internal medicine; Gene","score_opus":0.023153332703132537,"score_gpt":0.23571685586470428,"score_spread":0.21256352316157173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089639895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421453,0.0021181705,0.000120475524,0.0024944579,0.00014316475,0.00029715727,0.000009633432,0.000020086942,0.00058232225],"genre_scores_gemma":[0.9955109,0.00013754473,0.0011039342,0.000033113054,0.0000083463565,0.000012186825,0.000006189708,0.000021824764,0.0031660076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982735,0.00014198622,0.0006945492,0.00014709943,0.0005143037,0.00022854072],"domain_scores_gemma":[0.9982274,0.00021682339,0.00079569116,0.00027599416,0.00042073146,0.00006336939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006221779,0.00017451853,0.00036474445,0.00024057856,0.00035081813,0.00001688061,0.0002271987,0.000056618454,0.00006764328],"category_scores_gemma":[0.00051677745,0.00008982868,0.00015229262,0.0010518419,0.0004097136,0.00022205192,0.000041753283,0.0001180619,0.0000065705835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019511151,0.0046864604,0.7413004,0.00039716787,0.0045781517,0.0007254019,0.12367007,0.00024199412,0.10886206,0.0031792014,0.004319409,0.0060885376],"study_design_scores_gemma":[0.0015459044,0.0003352987,0.9836536,0.0006063672,0.00060153904,0.0003227017,0.005046667,0.0000601421,0.0073256004,0.00032361882,0.000047301757,0.00013125752],"about_ca_topic_score_codex":0.00003676382,"about_ca_topic_score_gemma":0.000052940202,"teacher_disagreement_score":0.24235317,"about_ca_system_score_codex":0.000053921194,"about_ca_system_score_gemma":0.0002333038,"threshold_uncertainty_score":0.36631075},"labels":[],"label_agreement":null},{"id":"W2090849279","doi":"10.1002/jhet.5570380609","title":"Nucleic acid related compounds. 114. Synthesis of 2,6‐(disubstituted)purine 2′,3′‐dideoxynucleosides and selected cytotoxic, anti‐hepatitis b, and adenosine deaminase substrate activities","year":2001,"lang":"en","type":"article","venue":"Journal of Heterocyclic Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Heritage; University of Alberta","funders":"","keywords":"Chemistry; Adenosine deaminase; Purine; Ribonucleoside; Stereochemistry; Nucleic acid; Adenosine; Biochemistry; Enzyme","score_opus":0.006659596151916561,"score_gpt":0.2217332219981624,"score_spread":0.21507362584624584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090849279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966296,0.0020025081,0.000005692658,0.0006880999,0.000040441755,0.0001393137,0.000014409748,0.000031788433,0.00044816325],"genre_scores_gemma":[0.9938142,0.004802491,0.000698887,0.000020089492,0.00007452723,0.0000055217974,0.000016241527,0.000034816476,0.00053325435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823266,0.00003618285,0.0008293176,0.00025342143,0.00035282993,0.0002955624],"domain_scores_gemma":[0.9986138,0.00015953922,0.00058105413,0.00019443604,0.00016910843,0.0002820733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013089557,0.00031994676,0.0008595807,0.00015311298,0.00010782212,0.000042132266,0.00009747096,0.00017221388,0.00012410386],"category_scores_gemma":[0.0001461958,0.0002683961,0.00012937655,0.0002509236,0.00021820569,0.00024511517,0.00004997581,0.0003323303,0.0000022753266],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035764952,0.00037285412,0.22855416,0.0003373511,0.0006010212,0.00095837715,0.00025572543,0.000001085796,0.76716864,0.0000013820819,0.0002488181,0.0011429468],"study_design_scores_gemma":[0.0024419338,0.000111009234,0.16733977,0.00079167046,0.00045962035,0.0071399636,0.00018470419,0.00004311511,0.8209946,0.000021440199,0.0002615532,0.00021060352],"about_ca_topic_score_codex":0.00001622138,"about_ca_topic_score_gemma":0.000009567189,"teacher_disagreement_score":0.061214387,"about_ca_system_score_codex":0.00011729089,"about_ca_system_score_gemma":0.00007351757,"threshold_uncertainty_score":0.9999768},"labels":[],"label_agreement":null},{"id":"W2092362194","doi":"10.2460/ajvr.2004.65.841","title":"Pharmacokinetics of lamivudine in cats","year":2004,"lang":"en","type":"article","venue":"American Journal of Veterinary Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Peter's Hospital","funders":"","keywords":"Cmax; Bioavailability; Pharmacokinetics; Lamivudine; Volume of distribution; Chemistry; Oral administration; Pharmacology; Animal science; CATS; Crossover study; Area under the curve; Plasma concentration; Medicine; Internal medicine; Biology; Immunology; Virus","score_opus":0.11335854976301678,"score_gpt":0.456324914332494,"score_spread":0.3429663645694772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092362194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423933,0.00032535664,0.000024535926,0.0041479333,0.000040929135,0.00013006838,0.0000017817628,0.000003221315,0.001086865],"genre_scores_gemma":[0.9940895,0.0007335427,0.004483469,0.00003329705,0.0000726562,0.000003721744,0.0000018369346,0.000014361736,0.0005676422],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840033,0.00012258448,0.00043276095,0.000106078296,0.0006493129,0.00028892554],"domain_scores_gemma":[0.9991052,0.000106581625,0.00015174088,0.00013598234,0.00033259258,0.00016791033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008107353,0.000091676804,0.00039170985,0.0006360504,0.000024998275,0.000005457786,0.000141463,0.000019041216,0.00007184983],"category_scores_gemma":[0.0000807216,0.00007097345,0.000077381854,0.00080376933,0.00033380202,0.00005979962,0.00006135635,0.00038786538,0.000014692744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013531305,0.0067514246,0.2441197,0.00042880172,0.0010471578,0.03110931,0.010121243,0.00026027884,0.43392754,0.00024564166,0.0027669552,0.25569066],"study_design_scores_gemma":[0.048383124,0.10794776,0.5658548,0.004881194,0.00031339086,0.02178404,0.012711686,0.00011302632,0.16911471,0.001097886,0.066893324,0.0009050651],"about_ca_topic_score_codex":0.000047680576,"about_ca_topic_score_gemma":0.0000025247532,"teacher_disagreement_score":0.3217351,"about_ca_system_score_codex":0.00022011736,"about_ca_system_score_gemma":0.00041138398,"threshold_uncertainty_score":0.28942135},"labels":[],"label_agreement":null},{"id":"W2092746828","doi":"10.1186/1742-4690-6-103","title":"Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes","year":2009,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Integrase; Raltegravir; Elvitegravir; Integrase inhibitor; Enzyme; Virology; Human immunodeficiency virus (HIV); Dolutegravir; Chemistry; Integrases; Biology; Biochemistry; Antiretroviral therapy; Viral load","score_opus":0.015448185915729492,"score_gpt":0.2900465907530761,"score_spread":0.2745984048373466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092746828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947007,0.00079230004,0.000087143475,0.0025199486,0.000011892471,0.00008678554,0.000008760217,0.000017770659,0.001774701],"genre_scores_gemma":[0.997185,0.000065447166,0.0010088431,0.00022467166,0.000015241888,0.0000023485743,0.0001240507,0.0000028080528,0.0013716096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938726,0.000030017902,0.00018121109,0.00018413138,0.00008335079,0.00013400501],"domain_scores_gemma":[0.9996188,0.00006616784,0.000061219755,0.00013547008,0.000038956674,0.00007936345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006016997,0.00010305946,0.0005348151,0.00027777487,0.000017472039,0.0000022228999,0.00003215728,0.00008520901,0.00011520191],"category_scores_gemma":[0.00003354231,0.00007655845,0.00008110318,0.00035913556,0.00011363024,0.000015767886,0.000013172748,0.00009015201,0.000017784412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010969694,0.00077091664,0.91273576,0.00002199107,0.0050256583,0.00011859612,0.002162969,0.0000042108218,0.059474397,0.0053528906,0.011084531,0.002151116],"study_design_scores_gemma":[0.002141619,0.00090079627,0.9188414,0.000017918637,0.004205063,0.000037015656,0.00022662604,0.0010120436,0.06966565,0.00016270508,0.0026181075,0.00017101163],"about_ca_topic_score_codex":0.000005605395,"about_ca_topic_score_gemma":0.0000059937456,"teacher_disagreement_score":0.010191254,"about_ca_system_score_codex":0.000027106405,"about_ca_system_score_gemma":0.000032719865,"threshold_uncertainty_score":0.31219628},"labels":[],"label_agreement":null},{"id":"W2092806574","doi":"10.2174/1381612043384501","title":"Effects of HIV-1 Entry Inhibitors in Combination","year":2004,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal","funders":"","keywords":"Antagonism; Drug; Pharmacology; Enfuvirtide; CCR5 receptor antagonist; Computational biology; Pharmacokinetics; Human immunodeficiency virus (HIV); Biology; Chemokine receptor; Receptor; Virology; Immunology; Biochemistry; Chemokine","score_opus":0.08612413756744675,"score_gpt":0.4030711237683696,"score_spread":0.3169469862009229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092806574","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000919317,0.99426705,0.0010782725,0.00009267521,0.000707929,0.0035979724,0.0000080217815,0.000052498788,0.00018636335],"genre_scores_gemma":[0.00018946784,0.9981213,0.0004770455,0.000010472227,0.00010257371,0.0003274278,0.00023799558,0.000052663625,0.00048100998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745363,0.00033416375,0.0008953099,0.00045573924,0.00045774033,0.00040342016],"domain_scores_gemma":[0.998685,0.0005723934,0.00022595945,0.00018827521,0.000056612527,0.0002717783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003223185,0.0005092653,0.0017177414,0.00050677726,0.000026833919,0.000012129117,0.00013615382,0.00024828874,0.000068689755],"category_scores_gemma":[0.00014801069,0.00039491302,0.00040540702,0.0006069881,0.0000960283,0.000059927384,0.00006371285,0.0006965622,0.0003234641],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049104485,0.0023525862,0.00005364568,0.08269825,0.00019405414,0.00014975696,0.00007720654,5.778205e-7,0.000004039331,0.00030569956,0.0017578413,0.9123572],"study_design_scores_gemma":[0.0055419924,0.000121226825,0.000022243294,0.08916105,0.0027831048,0.000028473254,0.0000023807477,0.00003700101,0.0010535005,0.000099084245,0.9007791,0.0003708291],"about_ca_topic_score_codex":3.303204e-7,"about_ca_topic_score_gemma":3.0479686e-8,"teacher_disagreement_score":0.9119864,"about_ca_system_score_codex":0.0006926472,"about_ca_system_score_gemma":0.0007526031,"threshold_uncertainty_score":0.9998503},"labels":[],"label_agreement":null},{"id":"W2093002176","doi":"10.2165/00019053-200119010-00007","title":"Economic Analysis of Initial HIV Treatment","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Efavirenz; Indinavir; Lamivudine; Zidovudine; Regimen; Medicine; Internal medicine; Reverse-transcriptase inhibitor; Clinical trial; Viral load; Pediatrics; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Viral disease","score_opus":0.028594484494454984,"score_gpt":0.36910868197365654,"score_spread":0.34051419747920153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093002176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786141,0.000112830494,0.000049644867,0.0016157205,0.00013878022,0.00023286098,0.00008069724,0.000037161437,0.019118186],"genre_scores_gemma":[0.98891634,0.0010289943,0.0005388671,0.0002260444,0.00014576472,0.000033827273,0.0002949134,0.00001934582,0.008795923],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990965,0.000015424686,0.00039414046,0.00024750552,0.000043371056,0.000203034],"domain_scores_gemma":[0.9994514,0.000051075425,0.000121996825,0.00020538879,0.00001894274,0.00015117587],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073651936,0.00017657099,0.00055192766,0.00039390873,0.000035810197,0.000010120464,0.00006152107,0.00003985539,0.0030219716],"category_scores_gemma":[0.0000023120956,0.00015960228,0.00030769123,0.00014016447,0.00003824642,0.00007688167,0.000020345868,0.000042097443,0.0004820737],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001009718,0.0011120058,0.9300222,0.000021524882,0.021266667,0.00015370002,0.0011839118,0.003054369,0.0010007975,0.0005638844,0.0051225196,0.03548873],"study_design_scores_gemma":[0.026040485,0.00050399743,0.07693861,0.000032439923,0.03290964,0.0001366233,0.00046523532,0.093721025,0.10312232,0.00013131017,0.6649164,0.0010819416],"about_ca_topic_score_codex":0.000051911305,"about_ca_topic_score_gemma":0.000051270585,"teacher_disagreement_score":0.85308355,"about_ca_system_score_codex":0.0005175736,"about_ca_system_score_gemma":0.00015978086,"threshold_uncertainty_score":0.9978894},"labels":[],"label_agreement":null},{"id":"W2093786954","doi":"10.1097/qad.0000000000000519","title":"Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials","year":2014,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Cilag; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb","keywords":"Dolutegravir; Abacavir; Medicine; Emtricitabine; Darunavir; Raltegravir; Internal medicine; Efavirenz; Ritonavir; Lamivudine; Confidence interval; Integrase inhibitor; Clinical endpoint; Randomized controlled trial; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Hepatitis B virus","score_opus":0.031210985391889632,"score_gpt":0.30007949094222713,"score_spread":0.2688685055503375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093786954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918729,0.00030244907,0.000096336844,0.0007542676,0.00013814446,0.00255282,0.000031590036,0.00005784652,0.0041936166],"genre_scores_gemma":[0.9912253,0.00017164742,0.0020102686,0.000057136836,0.00008281371,0.0002998019,0.00038849868,0.00003766029,0.005726888],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99639326,0.0010363616,0.0013600329,0.0004351324,0.0003358595,0.00043937357],"domain_scores_gemma":[0.9958891,0.0031004306,0.00036568218,0.00042817625,0.00006319349,0.0001533978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029683812,0.00039992953,0.002870119,0.00067646755,0.00004268418,0.0000143921325,0.00011835677,0.00021107163,0.0006176829],"category_scores_gemma":[0.0020527316,0.00026656632,0.0004700962,0.0005942412,0.00013836267,0.00007639217,0.00006319952,0.0001517377,0.00026356435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026255243,0.0016473727,0.9457659,0.00005107613,0.0010643947,0.00006562019,0.003156273,0.000009431694,0.0011902252,0.0014508844,0.00083163974,0.018511934],"study_design_scores_gemma":[0.69813406,0.00085138035,0.28506288,0.000449121,0.0011956773,0.000018400828,0.00008418379,0.00015885438,0.008576733,0.0014550178,0.003599449,0.0004142339],"about_ca_topic_score_codex":0.00038471457,"about_ca_topic_score_gemma":0.00040670426,"teacher_disagreement_score":0.6718788,"about_ca_system_score_codex":0.0005186863,"about_ca_system_score_gemma":0.0001701145,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W2094241860","doi":"10.1056/nejmoa1215541","title":"Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":878,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Dolutegravir; Abacavir; Medicine; Lamivudine; Virology; Integrase inhibitor; Regimen; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Internal medicine; Viral load; Hepatitis B virus","score_opus":0.02589605435681262,"score_gpt":0.28813615888254507,"score_spread":0.26224010452573243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094241860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8732094,0.0076260953,0.0072804424,0.10606717,0.0014569925,0.0019150712,0.000007587825,0.000027527645,0.0024096677],"genre_scores_gemma":[0.9668818,0.0060257493,0.0022020475,0.00019893129,0.0044505824,0.000034475775,0.000029674478,0.000026336307,0.020150386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987256,0.000034190678,0.0005956219,0.000106237676,0.00035303106,0.00018535132],"domain_scores_gemma":[0.9985293,0.00044084835,0.00034927757,0.00016989559,0.00030352516,0.00020711074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003370672,0.00018562393,0.0006005288,0.00018722485,0.000065205975,0.000006628833,0.00006477439,0.000056675184,0.0003072844],"category_scores_gemma":[0.00012963027,0.00008122395,0.00016836474,0.00015934107,0.000089493995,0.000076207405,0.0000058539645,0.000112403955,0.000017539965],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019871457,0.00069800374,0.038035322,0.000094805415,0.0016887987,0.00007346356,0.0061797593,0.000064338776,0.002933756,0.00025824082,0.07238622,0.87560016],"study_design_scores_gemma":[0.16985574,0.009801763,0.08845765,0.0006456648,0.0022032796,0.0011448459,0.00054087123,0.00045552728,0.0029049853,0.0007818942,0.7230367,0.00017106906],"about_ca_topic_score_codex":0.00023991139,"about_ca_topic_score_gemma":0.00004002747,"teacher_disagreement_score":0.8754291,"about_ca_system_score_codex":0.00018360687,"about_ca_system_score_gemma":0.00020936893,"threshold_uncertainty_score":0.33645487},"labels":[],"label_agreement":null},{"id":"W2094303174","doi":"10.3389/fphar.2015.00090","title":"Will drug resistance against dolutegravir in initial therapy ever occur?","year":2015,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Integrase; Integrase inhibitor; Drug resistance; Pharmacology; Medicine; Virology; Human immunodeficiency virus (HIV); Biology; Antiretroviral therapy; Genetics; Viral load","score_opus":0.04704367438094377,"score_gpt":0.38704123804987317,"score_spread":0.3399975636689294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094303174","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000101704776,0.9821525,0.000021231099,0.000679131,0.0042342627,0.0024411525,0.000042044154,0.00006197697,0.010266],"genre_scores_gemma":[0.00002063563,0.9664632,0.0028689813,0.0006705765,0.00045793853,0.00074026786,0.00044399922,0.00009251501,0.028241862],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649215,0.0006391861,0.0010155481,0.00077016285,0.0003530151,0.00072992116],"domain_scores_gemma":[0.99893105,0.00010950446,0.00031023764,0.0003210655,0.00008002508,0.00024809962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070396543,0.00070504314,0.0029607483,0.001073024,0.000044150005,0.000012954006,0.00035429368,0.0004956747,0.00016379097],"category_scores_gemma":[0.000027419048,0.0005677462,0.00032103652,0.0008485668,0.00014971486,0.0001533878,0.00006604026,0.0010798314,0.00010940812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035764405,0.00036166972,0.00037554238,0.0013373913,0.00047595744,0.0015699298,0.0005574588,3.300885e-7,4.2130748e-7,0.000006977933,0.50799394,0.48696277],"study_design_scores_gemma":[0.0065030847,0.0000321214,0.000011429274,0.0026546363,0.00045475658,0.000014511769,0.00007566424,0.000005333537,0.0000054332686,0.00010006979,0.98967755,0.00046542552],"about_ca_topic_score_codex":0.000007856047,"about_ca_topic_score_gemma":0.000031599437,"teacher_disagreement_score":0.48649734,"about_ca_system_score_codex":0.0016702972,"about_ca_system_score_gemma":0.0016571627,"threshold_uncertainty_score":0.9996774},"labels":[],"label_agreement":null},{"id":"W2094521579","doi":"10.1310/hct1206-313","title":"Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"ACT Government","keywords":"Medicine; Darunavir; Ritonavir; Coinfection; Internal medicine; Incidence (geometry); Adverse effect; Lopinavir; Hepatitis C; Gastroenterology; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy","score_opus":0.13167708687691224,"score_gpt":0.3890928780651015,"score_spread":0.25741579118818925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094521579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518764,0.00006389252,0.000007158169,0.00053889723,0.00024145996,0.0022884363,0.00036316866,0.000025743122,0.001283632],"genre_scores_gemma":[0.99608856,0.00079733797,0.0002635543,0.000079538906,0.00017087928,0.00007622677,0.00040764915,0.00003351665,0.0020827437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99371123,0.0025735176,0.0025902202,0.00047551497,0.00035978778,0.00028975485],"domain_scores_gemma":[0.97945184,0.01878337,0.0009005039,0.00054132455,0.00010908465,0.00021389805],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058112415,0.000376435,0.0021959676,0.00011870081,0.00006303688,0.0000064067,0.000116139985,0.00023236277,0.0004208507],"category_scores_gemma":[0.010716122,0.00020441301,0.00039770367,0.00019800042,0.0002599625,0.000039940147,0.00007767932,0.00022755822,0.00015134622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0281526,0.0057039256,0.8866084,0.00010644697,0.000641729,0.000051288203,0.00061730866,2.323515e-7,0.00023562658,0.00004951438,0.0011939455,0.07663896],"study_design_scores_gemma":[0.06925373,0.01127573,0.8948661,0.0011050005,0.0015150949,0.000004659779,0.000027797423,0.000066834364,0.014770226,0.000021477492,0.0067908405,0.000302506],"about_ca_topic_score_codex":0.00002071581,"about_ca_topic_score_gemma":0.0000070259084,"teacher_disagreement_score":0.07633645,"about_ca_system_score_codex":0.00013051456,"about_ca_system_score_gemma":0.00010580474,"threshold_uncertainty_score":0.99761707},"labels":[],"label_agreement":null},{"id":"W2094661145","doi":"10.1128/jvi.02904-13","title":"The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity","year":2013,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health; National Institute for Health and Care Research","keywords":"Rilpivirine; Resistance mutation; Etravirine; Virology; Reverse transcriptase; Biology; Mutation; Lamivudine; Nucleoside Reverse Transcriptase Inhibitor; Nevirapine; Reverse-transcriptase inhibitor; Context (archaeology); Virus; Genetics; Viral load; Gene; RNA; Hepatitis B virus; Antiretroviral therapy","score_opus":0.01014737479234531,"score_gpt":0.24562973988799783,"score_spread":0.2354823650956525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094661145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9464792,0.0007367027,0.0008427081,0.051031973,0.00016698673,0.0005303215,0.000008495145,0.0000047903495,0.00019881934],"genre_scores_gemma":[0.9960805,0.00048678392,0.0012323491,0.0003188456,0.0000533933,0.00004331156,0.0000057793304,0.000008668385,0.0017703705],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983341,0.00032213502,0.0006771968,0.00019520955,0.0002959974,0.00017535365],"domain_scores_gemma":[0.99862087,0.00029602897,0.0005564441,0.0002785253,0.00018599755,0.000062145366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010337954,0.0001246802,0.00024021254,0.00008908436,0.00020300623,0.000020240264,0.00015049157,0.000069749636,0.000018073799],"category_scores_gemma":[0.0005802634,0.000067526424,0.00005939611,0.00031311813,0.00018169865,0.00020856211,0.000016867563,0.0002695026,0.00000395705],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00422161,0.0004965274,0.025368039,0.00015983146,0.00028088182,0.000074692056,0.011830706,0.00012354684,0.8747309,0.002337395,0.07431358,0.006062305],"study_design_scores_gemma":[0.00611974,0.0009337399,0.7735658,0.00053799426,0.0003389748,0.00033267718,0.005900892,0.0002204793,0.16520856,0.010488166,0.03601731,0.00033564042],"about_ca_topic_score_codex":0.00007000539,"about_ca_topic_score_gemma":0.0007386357,"teacher_disagreement_score":0.7481978,"about_ca_system_score_codex":0.00008519402,"about_ca_system_score_gemma":0.000062097584,"threshold_uncertainty_score":0.27536476},"labels":[],"label_agreement":null},{"id":"W2095352546","doi":"10.1139/v00-012","title":"Solid phase assisted synthesis of HIV-1 protease inhibitors. Expedient entry to unsymmetrical substitution of a <i>C</i><sub>2</sub> symmetric template","year":2000,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry; Protease; Linker; Amide; Amine gas treating; Hydrolysis; HIV-1 protease; Cleavage (geology); Solid-phase synthesis; Stereochemistry; Combinatorial chemistry; Enzyme; Organic chemistry; Peptide; Biochemistry","score_opus":0.01138570330185761,"score_gpt":0.2586105432846548,"score_spread":0.2472248399827972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095352546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968976,0.00040311046,0.000039421673,0.00064366026,0.00007722693,0.0002784279,0.00009586595,0.0000072723838,0.0015574287],"genre_scores_gemma":[0.99838173,0.00006744517,0.0004812345,0.00004854167,0.00016431183,0.000016260206,0.000025408042,0.00002187291,0.0007932023],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997967,0.000033209133,0.00094420754,0.0002074029,0.00046840557,0.00037977248],"domain_scores_gemma":[0.99742824,0.00011547904,0.00038733927,0.00023645583,0.00037699158,0.0014555025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025729774,0.00023105791,0.0006374979,0.0006366039,0.000067115936,0.000020388823,0.0001403974,0.00015736114,0.00030233545],"category_scores_gemma":[0.0008260836,0.00020663874,0.00025271444,0.0011374453,0.000116260235,0.00011107694,0.000009473198,0.0002406183,0.000018586885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016840077,0.0020189309,0.024275215,0.00088840735,0.0010415412,0.0036196609,0.0009115821,0.00006100928,0.84489906,0.000008699409,0.02773252,0.092859365],"study_design_scores_gemma":[0.0025341448,0.00014036069,0.0017015422,0.00097141863,0.0002825669,0.00058094243,0.000101681624,0.000013396373,0.98815715,0.0000037137813,0.0053381515,0.00017491092],"about_ca_topic_score_codex":0.00014193653,"about_ca_topic_score_gemma":0.00003137488,"teacher_disagreement_score":0.14325811,"about_ca_system_score_codex":0.00055883237,"about_ca_system_score_gemma":0.0021513286,"threshold_uncertainty_score":0.8426483},"labels":[],"label_agreement":null},{"id":"W2095477466","doi":"10.1097/qai.0b013e318230372e","title":"Comparative Effectiveness of Initial Antiretroviral Therapy Regimens","year":2011,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary","funders":"H2020 European Research Council; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Bristol-Myers Squibb; University of Washington; GlaxoSmithKline; National Institute of Mental Health; Medical Research Council; ACT Government","keywords":"Abacavir; Internal medicine; Efavirenz; Lopinavir; Confidence interval; Odds ratio; Medicine; Hazard ratio; Cohort; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.05499173454209696,"score_gpt":0.3264207127536775,"score_spread":0.2714289782115806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095477466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920252,0.0036858784,0.00016724339,0.00004997627,0.00046369986,0.0003619142,0.0000056865606,0.00003048506,0.003209892],"genre_scores_gemma":[0.9971659,0.00035761393,0.0018316448,0.000010158399,0.000028962384,0.0000075388925,0.000008053011,0.000028694827,0.00056143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976659,0.0002781523,0.0009443282,0.00020234578,0.00056920014,0.00034006787],"domain_scores_gemma":[0.99820787,0.00026056936,0.00067959575,0.000294829,0.00044583986,0.00011131848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011642681,0.00027970044,0.0012434608,0.0006233247,0.00009380323,0.000012830756,0.00025094402,0.00010104739,0.00012506223],"category_scores_gemma":[0.000097043376,0.00019651197,0.00041098797,0.0006826998,0.0003052785,0.0002933715,0.000047197496,0.00012402002,0.000044424436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026761485,0.0140513135,0.44707778,0.0012783763,0.008194835,0.005212387,0.059358906,0.000022558974,0.41236305,0.0034247607,0.0012753864,0.020979162],"study_design_scores_gemma":[0.009170636,0.009073933,0.5820738,0.0011611655,0.00038306337,0.002133083,0.0022047511,0.00001834201,0.39279684,0.00049952394,0.00013983317,0.00034503985],"about_ca_topic_score_codex":0.000018979297,"about_ca_topic_score_gemma":2.2882077e-7,"teacher_disagreement_score":0.134996,"about_ca_system_score_codex":0.00009990994,"about_ca_system_score_gemma":0.00031428307,"threshold_uncertainty_score":0.80135256},"labels":[],"label_agreement":null},{"id":"W2095909696","doi":"10.1016/s0140-6736(00)04577-3","title":"Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios","year":2001,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; St. Paul's Hospital","funders":"","keywords":"Saquinavir; Confusion; Interpretation (philosophy); Consistency (knowledge bases); Protease inhibitor (pharmacology); Pharmacology; Selection (genetic algorithm); Plasma concentration; Human immunodeficiency virus (HIV); Medicine; Computer science; Antiretroviral therapy; Psychology; Viral load; Artificial intelligence; Family medicine","score_opus":0.04611651094092576,"score_gpt":0.33996805428893423,"score_spread":0.29385154334800845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095909696","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39543697,0.00036813694,0.08165278,0.50786287,0.00046021797,0.004056459,0.000074929456,0.000113481234,0.009974174],"genre_scores_gemma":[0.9947862,0.0001546802,0.001990777,0.000717642,0.00043168117,0.00020851046,0.00011242031,0.000008186357,0.0015899126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993438,0.00004472736,0.0002370295,0.00011355182,0.000116252006,0.00014465167],"domain_scores_gemma":[0.99883544,0.00061088847,0.0001244952,0.0002633783,0.00013376122,0.000032032014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002197628,0.000080958795,0.00018048134,0.000010225538,0.00013594137,0.000020923064,0.00007167786,0.00003597826,0.00004210301],"category_scores_gemma":[0.00019327278,0.00004449266,0.000052852727,0.000097003394,0.00009343687,0.00008563368,0.000009617262,0.000072873576,0.00001733139],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005630676,0.0009825111,0.1876947,0.00018888462,0.0012672672,0.000008147141,0.01571271,0.00029636247,0.043441977,0.110539496,0.59591275,0.038324513],"study_design_scores_gemma":[0.028750468,0.00096643606,0.24645151,0.00043919575,0.0022339774,0.0003897706,0.004024996,0.19344363,0.0677387,0.006853032,0.44796965,0.0007386461],"about_ca_topic_score_codex":0.0000021658352,"about_ca_topic_score_gemma":0.000012835799,"teacher_disagreement_score":0.5993492,"about_ca_system_score_codex":0.000049921946,"about_ca_system_score_gemma":0.00014883216,"threshold_uncertainty_score":0.1814358},"labels":[],"label_agreement":null},{"id":"W2096147608","doi":"10.1021/mp049959+","title":"Structure and Specificity of a Human Valacyclovir Activating Enzyme:  A Homology Model of BPHL","year":2004,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of General Medical Sciences","keywords":"Active site; Hydrolase; Prodrug; Chemistry; Stereochemistry; Docking (animal); Catalytic triad; Homology modeling; Nucleoside; Serine; Serine hydrolase; Histidine; Molecular model; Enzyme; Amino acid; Binding site; Biochemistry","score_opus":0.03329270910812323,"score_gpt":0.3262130551928278,"score_spread":0.2929203460847046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096147608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954089,0.00043792446,0.0027394698,0.00043234698,0.000021932901,0.00028438953,0.000018106539,0.000019250434,0.0006377165],"genre_scores_gemma":[0.9879204,0.000060316932,0.011650147,0.00012552313,0.000015161287,0.000003892154,0.000022648303,0.000022218239,0.0001796717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908817,0.000027586906,0.00028375597,0.00019958572,0.00021430083,0.00018658678],"domain_scores_gemma":[0.9995162,0.000014982068,0.00010967887,0.00018031229,0.000080467806,0.000098353674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074137344,0.00016219441,0.0003344374,0.00011344786,0.00004293798,0.0000036959304,0.000060747254,0.00008566567,0.000026590526],"category_scores_gemma":[0.000020830577,0.00014663613,0.000066914734,0.00013884633,0.00012434165,0.000028405004,0.00006293555,0.00017945349,7.9837247e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007301453,0.00024262509,0.0040623373,0.0001832928,0.0002463749,0.0000869697,0.0012940518,0.0020339887,0.98894227,0.0012521197,0.000013231525,0.001569715],"study_design_scores_gemma":[0.0031424616,0.00008178014,0.00047996384,0.00006423227,0.00019478443,0.000046718756,0.00006352033,0.002455236,0.9920354,0.0012328756,0.00008953757,0.00011352845],"about_ca_topic_score_codex":0.000009765326,"about_ca_topic_score_gemma":0.0000024009564,"teacher_disagreement_score":0.008910677,"about_ca_system_score_codex":0.00006294242,"about_ca_system_score_gemma":0.000108220374,"threshold_uncertainty_score":0.59796476},"labels":[],"label_agreement":null},{"id":"W2097059709","doi":"10.1128/aac.47.2.747-754.2003","title":"Lamivudine Can Exert a Modest Antiviral Effect against Human Immunodeficiency Virus Type 1 Containing the M184V Mutation","year":2003,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Resistance mutation; Virology; Biology; Lamivudine; Reverse-transcriptase inhibitor; Zalcitabine; Nucleotidyltransferase; Zidovudine; Nevirapine; Abacavir; Molecular biology; Primer (cosmetics); Didanosine; Nucleoside Reverse Transcriptase Inhibitor; Virus; Polymerase chain reaction; Chemistry; Genetics; RNA; Viral load; Viral disease; Sida; Hepatitis B virus","score_opus":0.012560656404586933,"score_gpt":0.2673867431771094,"score_spread":0.2548260867725225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097059709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438524,0.00009419847,0.000029391169,0.0015728676,0.00010348591,0.0004929821,0.0000055337337,0.00004481701,0.0032715055],"genre_scores_gemma":[0.99357814,0.00063683564,0.00015253115,0.00301327,0.000037928352,0.000010372856,0.00009299162,0.00003313291,0.0024448226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903274,0.000061123865,0.00021639015,0.000268638,0.00013793557,0.00028318705],"domain_scores_gemma":[0.9996186,0.000026975213,0.00007865168,0.00017891626,0.000048852842,0.00004803018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020094038,0.00023373798,0.00029737415,0.00006274121,0.0003497557,0.00005686109,0.000065203756,0.00006888288,0.00006355212],"category_scores_gemma":[0.000012499388,0.00015108658,0.000075830125,0.00018183488,0.00009054081,0.000054259755,0.000014497578,0.00012119988,0.000014921891],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013001412,0.0015772212,0.3256198,0.00018636853,0.0012801961,0.00036416354,0.0117292525,0.00001882904,0.5870236,0.00094471546,0.020878367,0.049077347],"study_design_scores_gemma":[0.035056144,0.0025639767,0.12243369,0.000872793,0.00056619424,0.00037602568,0.0008584007,0.0010388237,0.7268998,0.0001458812,0.10747511,0.0017131747],"about_ca_topic_score_codex":0.00006524532,"about_ca_topic_score_gemma":0.000023820301,"teacher_disagreement_score":0.2031861,"about_ca_system_score_codex":0.000054328677,"about_ca_system_score_gemma":0.00005525163,"threshold_uncertainty_score":0.6161132},"labels":[],"label_agreement":null},{"id":"W2097847166","doi":"10.1371/journal.pmed.0020112","title":"Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration","year":2005,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; Doris Duke Charitable Foundation","keywords":"Reverse transcriptase; Virology; Drug resistance; Genotype; Biology; Lentivirus; Protease; Human immunodeficiency virus (HIV); Medicine; Genetics; Polymerase chain reaction; Viral disease; Gene; Enzyme","score_opus":0.01993683919710418,"score_gpt":0.294829505157253,"score_spread":0.2748926659601488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097847166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98966104,0.0012491266,0.0000048760735,0.0074738353,0.000021627942,0.0007713933,0.00015241402,0.000017648927,0.00064803456],"genre_scores_gemma":[0.9978467,0.00062712183,0.00057796005,0.00011369894,0.00009256612,0.000009842853,0.000105568964,0.000009857639,0.0006166732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898106,0.000040319654,0.00034561974,0.0002045183,0.00029308198,0.00013541774],"domain_scores_gemma":[0.9993719,0.000032855485,0.00013924592,0.00017204408,0.00013675158,0.00014719478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001635892,0.00016026085,0.00040416454,0.00008100883,0.000026965638,0.0000026012865,0.000028006447,0.00006001115,0.000047873746],"category_scores_gemma":[0.0001625429,0.00010131983,0.00003410433,0.00027181048,0.0001521905,0.00006158327,0.0000058142596,0.00006669318,0.000003945974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028587362,0.0024906446,0.7696109,0.00038451373,0.0010880771,0.00012460294,0.008315666,0.0000034924806,0.1345331,0.00035056187,0.021719625,0.032791477],"study_design_scores_gemma":[0.07601239,0.021722993,0.8521276,0.0018401502,0.00096068135,0.000078924204,0.0006317188,0.00066009484,0.03998375,0.000080666854,0.0054798163,0.00042119285],"about_ca_topic_score_codex":0.00008221478,"about_ca_topic_score_gemma":0.000011766657,"teacher_disagreement_score":0.09454935,"about_ca_system_score_codex":0.00009343565,"about_ca_system_score_gemma":0.00017221451,"threshold_uncertainty_score":0.41317025},"labels":[],"label_agreement":null},{"id":"W2098883581","doi":"10.1086/648729","title":"Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection","year":2009,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; University of British Columbia; St. Paul's Hospital","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research; International AIDS Society; Pfizer","keywords":"Medicine; Incidence (geometry); Population; Drug resistance; Viral load; Internal medicine; Virology; Zidovudine; HIV drug resistance; Immunology; Antiretroviral therapy; Viral disease; Human immunodeficiency virus (HIV); Biology; Microbiology","score_opus":0.013685760928222868,"score_gpt":0.29964283342023545,"score_spread":0.2859570724920126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098883581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813163,0.00032896263,0.000074166426,0.00043437627,0.00009051456,0.00048614683,0.000009585653,0.00011348294,0.00033112755],"genre_scores_gemma":[0.99643546,0.00017437109,0.00027934476,0.00038892543,0.00004035452,0.000021308084,0.000016881539,0.000012666237,0.002630683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840504,0.000137233,0.0006504486,0.0003772658,0.00019449304,0.00023553403],"domain_scores_gemma":[0.9986769,0.0005260642,0.00019391043,0.00022163126,0.00015179852,0.00022971751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023436807,0.0001350197,0.00065396074,0.000049352093,0.00008183813,0.000050933028,0.000063394386,0.000104681625,0.00006425749],"category_scores_gemma":[0.0013953656,0.00013977723,0.00014060612,0.00029861543,0.00020721111,0.00009002828,0.000022848433,0.00021212065,0.000008585511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037116138,0.0015760043,0.9912975,0.000024697605,0.000077530785,0.00022427416,0.000019466692,0.0000010762325,0.00007816723,0.0000045060456,0.00034102073,0.0059846104],"study_design_scores_gemma":[0.0037247797,0.0006382744,0.99428415,0.00027143545,0.0001909336,0.000020390127,0.000034816418,0.00006330581,0.00006172308,0.00038309762,0.0001708465,0.00015622171],"about_ca_topic_score_codex":0.00035770593,"about_ca_topic_score_gemma":0.035570502,"teacher_disagreement_score":0.035212796,"about_ca_system_score_codex":0.00012528656,"about_ca_system_score_gemma":0.00020517404,"threshold_uncertainty_score":0.9820278},"labels":[],"label_agreement":null},{"id":"W2099024584","doi":"10.1128/aac.00905-08","title":"Effect of a Single Dose of Ritonavir on the Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered in Healthy Volunteers","year":2008,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Ritonavir; Bioavailability; Pharmacokinetics; Pharmacology; Reverse-transcriptase inhibitor; Crossover study; Drug interaction; Chemistry; In vivo; Population; Medicine; Human immunodeficiency virus (HIV); Viral load; Virology; Biology; Antiretroviral therapy","score_opus":0.022279851919752264,"score_gpt":0.2834980746598564,"score_spread":0.2612182227401041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099024584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964825,0.000057244324,8.48161e-7,0.0023323414,0.00006720198,0.0008789706,0.0000418508,0.000008050294,0.000130997],"genre_scores_gemma":[0.99755776,0.0005975508,0.00012510212,0.0012140478,0.000020388534,0.000017726974,0.000020066474,0.000023272049,0.0004240914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989486,0.000071769726,0.0004290118,0.00020125978,0.00017067217,0.00017871597],"domain_scores_gemma":[0.9995431,0.00005444491,0.00013223778,0.00016881317,0.000036371253,0.00006508844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001453964,0.00019109128,0.00048183723,0.00014778863,0.000037621867,0.000002355525,0.000067497174,0.00006184735,0.000100969664],"category_scores_gemma":[0.00000867317,0.00012808989,0.00013278662,0.00023038061,0.00018110129,0.00003004386,0.000010102662,0.0000950776,0.0000020139496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0118096685,0.004632308,0.1382036,0.00064123253,0.0002343347,0.00014183235,0.004986639,0.0000010205262,0.8191311,0.000006447553,0.011497336,0.008714514],"study_design_scores_gemma":[0.019047556,0.0036152285,0.052271992,0.00064515707,0.00019006684,0.000054033975,0.00007021089,0.000016407519,0.91982925,8.3412164e-7,0.0040969113,0.00016233545],"about_ca_topic_score_codex":0.00010431773,"about_ca_topic_score_gemma":0.000007517239,"teacher_disagreement_score":0.100698195,"about_ca_system_score_codex":0.00003106798,"about_ca_system_score_gemma":0.0000515383,"threshold_uncertainty_score":0.5223354},"labels":[],"label_agreement":null},{"id":"W2099286443","doi":"10.1186/1752-1947-3-9307","title":"Correlations between atazanavir Ctrough and hyperbilirubinemia: a case report","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Case Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Atazanavir; Ritonavir; Medicine; Tolerability; Cobicistat; Unconjugated hyperbilirubinemia; Discontinuation; Therapeutic drug monitoring; Pharmacology; Internal medicine; Drug; Antiretroviral therapy; Bilirubin; Human immunodeficiency virus (HIV); Viral load; Virology; Adverse effect","score_opus":0.021480250064225166,"score_gpt":0.3238701515499059,"score_spread":0.30238990148568073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099286443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97276264,0.0011327609,0.00037627784,0.024039716,0.00022389513,0.00019133299,0.0000017388761,0.000023076722,0.001248553],"genre_scores_gemma":[0.99480355,0.00013350492,0.0023873835,0.00026936014,0.0006204665,0.0000021134201,0.000016458443,0.00001264645,0.0017545276],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99689704,0.00004661553,0.001412731,0.0002279117,0.0011861235,0.00022956736],"domain_scores_gemma":[0.9976739,0.00018730397,0.0007052502,0.00027319565,0.00023903044,0.0009212615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016926383,0.00017919057,0.00060074695,0.00017817071,0.00012829478,0.000021643233,0.000027116434,0.00022842507,0.00019176776],"category_scores_gemma":[0.001752976,0.00012395697,0.00016818657,0.00020402462,0.00008383937,0.00013612804,0.000029644054,0.00063124904,0.000003436939],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027746222,0.0001975754,0.04336996,0.000018418537,0.00015797149,0.9327943,0.00021105644,4.2588852e-7,0.000008590841,0.000015510666,0.0060939603,0.017104518],"study_design_scores_gemma":[0.0012962137,0.00028500482,0.0072352663,0.00023851026,0.00065604836,0.97630364,0.00021623957,0.000021449297,0.000063191714,0.00019235467,0.013383743,0.000108348075],"about_ca_topic_score_codex":0.000035055138,"about_ca_topic_score_gemma":0.000013779452,"teacher_disagreement_score":0.04350936,"about_ca_system_score_codex":0.00011961783,"about_ca_system_score_gemma":0.0007152291,"threshold_uncertainty_score":0.50548184},"labels":[],"label_agreement":null},{"id":"W2099504516","doi":"10.6064/2012/238278","title":"The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance","year":2012,"lang":"en","type":"review","venue":"Scientifica","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Integrase; Nucleoside Reverse Transcriptase Inhibitor; Virology; Drug resistance; Reverse-transcriptase inhibitor; Integrase inhibitor; Drug; Human immunodeficiency virus (HIV); Biology; Antiretroviral therapy; Medicine; Pharmacology; Viral load; RNA; Genetics","score_opus":0.055071564777323556,"score_gpt":0.3180143730300801,"score_spread":0.26294280825275657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099504516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001412157,0.9941426,0.00003295077,0.00095393433,0.00045606762,0.002479659,0.00010193199,0.000010881831,0.00040981988],"genre_scores_gemma":[0.002066103,0.8899849,0.009639221,0.000040814444,0.00012102445,0.00041924903,0.0004903831,0.00006118503,0.09717713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781054,0.00012560404,0.0009519579,0.0003455502,0.0004258757,0.00034048106],"domain_scores_gemma":[0.9987771,0.00023079316,0.00035962445,0.0004578453,0.00007249019,0.00010217747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018628879,0.0003092255,0.00091607537,0.00025761573,0.00017268007,0.000036041492,0.00027727167,0.00009011509,0.000007852356],"category_scores_gemma":[0.000078608966,0.0001508341,0.00027106862,0.000612738,0.00029119416,0.00007027799,0.000040150182,0.0001926912,0.000010244345],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016282832,0.00034499838,0.00009415845,0.010725241,0.00025506603,0.000013137119,0.021893186,5.3698597e-9,0.000043692147,0.00032339816,0.07807101,0.88807327],"study_design_scores_gemma":[0.00071544555,0.000008508704,0.00003949414,0.00678801,0.00065778097,0.000003996641,0.00081015064,4.838002e-7,0.00029379362,0.000017286928,0.9905228,0.00014225453],"about_ca_topic_score_codex":0.000004944245,"about_ca_topic_score_gemma":0.000118452735,"teacher_disagreement_score":0.9124518,"about_ca_system_score_codex":0.00008776615,"about_ca_system_score_gemma":0.00081834855,"threshold_uncertainty_score":0.6150836},"labels":[],"label_agreement":null},{"id":"W2099539543","doi":"10.1128/jvi.76.13.6836-6840.2002","title":"A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance","year":2002,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Efavirenz; Nevirapine; Reverse transcriptase; Virology; Biology; Reverse-transcriptase inhibitor; Nucleotidyltransferase; Resistance mutation; Virus; Genetics; Viral load; Sida; Polymerase chain reaction; Viral disease; Antiretroviral therapy; Gene","score_opus":0.025680468163097003,"score_gpt":0.2425080825409542,"score_spread":0.21682761437785722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099539543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883225,0.0009862828,0.00002225353,0.009373189,0.0001607745,0.00032011213,0.0000076781025,0.0000062463564,0.0008009916],"genre_scores_gemma":[0.9963986,0.0001797872,0.00014877052,0.0007948862,0.000036368165,0.0000051129664,0.0000057169987,0.00001528661,0.0024154168],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99827576,0.0003452274,0.0006352161,0.00014100292,0.00038885468,0.00021396745],"domain_scores_gemma":[0.9989509,0.00008296284,0.00050431583,0.00024286915,0.00017300923,0.000045924797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048809344,0.00015844182,0.0003899434,0.00021909288,0.00011744208,0.000007811598,0.00018187915,0.00011264965,0.000085089174],"category_scores_gemma":[0.00014681714,0.00008552369,0.0001526947,0.0006121505,0.00018608615,0.000118812735,0.0000064399105,0.00042440853,0.0000049877453],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011043323,0.0111642,0.06183141,0.00030823113,0.0016222161,0.014750224,0.08603853,0.00016913215,0.6697485,0.0013779779,0.1402143,0.0017319795],"study_design_scores_gemma":[0.09405213,0.015969388,0.6620778,0.006446902,0.007412531,0.00956412,0.014590777,0.0003851019,0.05021622,0.0018926432,0.13569275,0.001699639],"about_ca_topic_score_codex":0.000025103727,"about_ca_topic_score_gemma":0.00019212122,"teacher_disagreement_score":0.6195323,"about_ca_system_score_codex":0.0001388763,"about_ca_system_score_gemma":0.00008184694,"threshold_uncertainty_score":0.34875548},"labels":[],"label_agreement":null},{"id":"W2099697190","doi":"10.1001/jama.283.18.2417","title":"Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":783,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Drug resistance; Intensive care medicine; Human immunodeficiency virus (HIV); HIV drug resistance; Antiretroviral therapy; MEDLINE; Viral load; Immunology","score_opus":0.02896580900075403,"score_gpt":0.2595900500640946,"score_spread":0.23062424106334056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099697190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96473724,0.000016454782,0.0000107978285,0.005653333,0.00013369063,0.0004146977,0.000017343236,0.00005161139,0.028964818],"genre_scores_gemma":[0.91104794,0.00009506236,0.008408638,0.0001590672,0.00011473939,0.00037849677,0.00015442279,0.000013461206,0.07962818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989859,0.00003684358,0.00032755264,0.00022107911,0.00020714349,0.00022147365],"domain_scores_gemma":[0.9995098,0.000063375,0.00007594717,0.0001572351,0.00010965745,0.000084000916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023053847,0.000113410846,0.00018204785,0.00010594981,0.000057244382,0.000017181499,0.00007080127,0.00004414024,0.00021408823],"category_scores_gemma":[0.00011053118,0.00010746296,0.0000663804,0.0003811881,0.00004222685,0.00024246544,0.0000161107,0.00012812717,0.0000322778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008505762,0.00041225177,0.74223226,0.00003243114,0.00008533265,0.000013484994,0.0008277699,0.000005382732,0.00001536656,0.00012619839,0.0047590854,0.2514054],"study_design_scores_gemma":[0.0023990222,0.000023613591,0.96958774,0.00009969655,0.000043712338,0.000011988728,0.00011805835,0.0001781423,0.00059440086,0.000072142044,0.026733119,0.00013835706],"about_ca_topic_score_codex":0.00007063152,"about_ca_topic_score_gemma":0.00017000455,"teacher_disagreement_score":0.25126702,"about_ca_system_score_codex":0.0001793267,"about_ca_system_score_gemma":0.000049867715,"threshold_uncertainty_score":0.43822122},"labels":[],"label_agreement":null},{"id":"W2099736382","doi":"10.1093/jac/dkp422","title":"Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine","year":2009,"lang":"en","type":"review","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Resistance mutation; Lamivudine; Emtricitabine; Nucleoside Reverse Transcriptase Inhibitor; Virology; Reverse transcriptase; Deoxycytidine; Reverse-transcriptase inhibitor; Nucleoside analogue; Drug resistance; Biology; Nucleoside; Medicine; Human immunodeficiency virus (HIV); Virus; Viral load; Chemotherapy; Microbiology; Genetics; Antiretroviral therapy; RNA; Gemcitabine","score_opus":0.017737067703600017,"score_gpt":0.28173539970752876,"score_spread":0.26399833200392875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099736382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029617938,0.9869956,0.000032241118,0.009982921,0.0005431291,0.0011999133,0.000048879865,0.000016226344,0.0008849087],"genre_scores_gemma":[0.000021086404,0.9515278,0.0073361853,0.00079855527,0.00064695545,0.0000016817075,0.000017526598,0.00007549364,0.03957475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739164,0.00009867178,0.0015218569,0.00024433548,0.0004546003,0.00028891765],"domain_scores_gemma":[0.9975524,0.000045219105,0.0015938375,0.00041442303,0.00021183491,0.00018229746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030478527,0.00049033324,0.0024048123,0.00034145586,0.00006506599,0.000022329228,0.00036159478,0.00028307084,0.00021447954],"category_scores_gemma":[0.00004156199,0.00028040152,0.00160678,0.00071028766,0.00009117071,0.00009398681,0.000016224429,0.00062526844,0.000015933221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005869126,0.0006642729,0.000011449823,0.0051571894,0.0009877047,0.00014045235,0.00040207687,1.3070122e-7,0.0032293196,0.000015295289,0.7161204,0.27268478],"study_design_scores_gemma":[0.0031716311,0.0001225787,0.000010632587,0.029091531,0.0013828633,0.00041156227,0.000009455457,7.674204e-8,0.008156031,0.000010025335,0.9574112,0.00022237428],"about_ca_topic_score_codex":0.0000027161095,"about_ca_topic_score_gemma":0.000002701511,"teacher_disagreement_score":0.2724624,"about_ca_system_score_codex":0.0002522044,"about_ca_system_score_gemma":0.0016661574,"threshold_uncertainty_score":0.99996483},"labels":[],"label_agreement":null},{"id":"W2099826019","doi":"10.1016/s0140-6736(11)60936-7","title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"International AIDS Society","keywords":"Rilpivirine; Emtricitabine; Efavirenz; Medicine; Viral load; Internal medicine; Regimen; Reverse-transcriptase inhibitor; Virology; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.04770636682178646,"score_gpt":0.2973200934542903,"score_spread":0.2496137266325038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099826019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816163,0.00012452001,0.000018307668,0.0011036023,0.000068538284,0.0070161032,0.000025243708,0.00009475607,0.009932601],"genre_scores_gemma":[0.9941392,0.00014956004,0.00059070665,0.000056478795,0.00031659813,0.0015382906,0.00012665728,0.000039254,0.0030432674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841565,0.00012732095,0.00035206336,0.00040275478,0.0002562103,0.00044600057],"domain_scores_gemma":[0.9988072,0.00032913042,0.00019274757,0.00044048514,0.00007993884,0.00015047788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023191076,0.00040748707,0.0013757106,0.00021437021,0.0001008483,0.000024333234,0.000107476204,0.00008157972,0.00013951292],"category_scores_gemma":[0.000050745046,0.00018727314,0.000082646664,0.00042656937,0.00014237693,0.000121172976,0.00002581807,0.00020107027,0.000032145872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9814925,0.0022168343,0.0053144386,0.000019371319,0.0014960278,0.00029616852,0.004827822,9.2875916e-7,0.000064423075,0.00002128442,0.00012870123,0.004121461],"study_design_scores_gemma":[0.9850644,0.00726831,0.004011121,0.00015173551,0.0010745717,0.00003448331,0.0002541348,0.000071015704,0.0014536476,0.000010275631,0.00036831436,0.00023797418],"about_ca_topic_score_codex":0.0001470627,"about_ca_topic_score_gemma":0.00039157778,"teacher_disagreement_score":0.0125228595,"about_ca_system_score_codex":0.00017895369,"about_ca_system_score_gemma":0.00024598147,"threshold_uncertainty_score":0.76367766},"labels":[],"label_agreement":null},{"id":"W2099953361","doi":"10.1128/aac.44.12.3451-3455.2000","title":"Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients","year":2000,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Wellcome Trust","keywords":"Virology; Protease; Cytolysis; Immunology; Hepatitis C virus; Protease inhibitor (pharmacology); Virus; Antibody; Hepatitis; Hepatitis B virus; Viral disease; Biology; Medicine; Internal medicine; Gastroenterology; Viral load; Enzyme; Antiretroviral therapy","score_opus":0.009235378437476079,"score_gpt":0.2506006972361954,"score_spread":0.2413653187987193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099953361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975127,0.000017812017,0.00004076705,0.0001280867,0.0000464093,0.0016438231,0.00050026027,0.000041058633,0.00006907056],"genre_scores_gemma":[0.9949898,0.002993605,0.00034060105,0.0006466674,0.000042032127,0.00012954467,0.00019570511,0.000046025758,0.000616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984161,0.00006678315,0.00058713026,0.0004071148,0.00020277812,0.0003200654],"domain_scores_gemma":[0.999338,0.000028095757,0.00025667122,0.00018809705,0.00011677054,0.000072381175],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009426711,0.00030996485,0.00052092475,0.0002445852,0.00018112505,0.000043047046,0.00004854564,0.00014883712,0.0012104055],"category_scores_gemma":[0.00002101407,0.00026061415,0.00015382738,0.00032586165,0.000061765175,0.00024412601,0.000022510665,0.00012715528,0.000008670899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017827358,0.0009807826,0.9409576,0.00014486832,0.00018825576,0.000013123237,0.004281434,9.4002075e-7,0.00398716,5.859091e-7,0.00028393036,0.047378603],"study_design_scores_gemma":[0.009177343,0.0013416068,0.9552114,0.00042431813,0.00014345716,0.0000062402833,0.000011804825,0.00018990933,0.032587517,0.000015942142,0.00056891056,0.00032155841],"about_ca_topic_score_codex":0.0048986324,"about_ca_topic_score_gemma":0.0012287701,"teacher_disagreement_score":0.047057047,"about_ca_system_score_codex":0.00016198744,"about_ca_system_score_gemma":0.000077916564,"threshold_uncertainty_score":0.9999846},"labels":[],"label_agreement":null},{"id":"W2101549718","doi":"10.1086/339706","title":"Broad Nucleoside‐Analogue Resistance Implications for Human Immunodeficiency Virus Type 1 Reverse‐Transcriptase Mutations at Codons 44 and 118","year":2002,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Didanosine; Zalcitabine; Stavudine; Abacavir; Lamivudine; Virology; Reverse transcriptase; Zidovudine; Biology; Nucleoside analogue; Nucleoside; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Reverse-transcriptase inhibitor; Virus; Genetics; Gene; Viral disease; RNA; Sida","score_opus":0.025188744561769633,"score_gpt":0.28135943872562114,"score_spread":0.2561706941638515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101549718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823145,0.009601249,0.00025339142,0.0052410355,0.00012168228,0.0005032193,0.00021101897,0.000042354088,0.0017115178],"genre_scores_gemma":[0.99374527,0.0015526202,0.00013312149,0.00025321133,0.00005737846,0.000016853159,0.000034034925,0.000018187708,0.004189317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991887,0.000053610347,0.00034841683,0.000103710896,0.00013640146,0.00016912524],"domain_scores_gemma":[0.9990232,0.00017975536,0.00021218276,0.00020119964,0.00024323317,0.00014045379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013179687,0.00013148118,0.00022800016,0.00012721588,0.0006540605,0.000023452896,0.000078630466,0.00003148161,0.00015800043],"category_scores_gemma":[0.00013193127,0.00008995893,0.00012874603,0.00021795345,0.00014195108,0.000099299294,0.000015678579,0.000096716045,0.000018142064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019996394,0.0067990227,0.49720502,0.000554967,0.0035415334,0.00014891953,0.0101153385,0.00015150617,0.09315617,0.0079798205,0.37305114,0.0052969432],"study_design_scores_gemma":[0.015153755,0.002009535,0.85322005,0.0007342411,0.01051589,0.0019719298,0.0012011703,0.00008897276,0.0023912515,0.011235617,0.10065177,0.0008258232],"about_ca_topic_score_codex":0.000024497347,"about_ca_topic_score_gemma":0.00015623453,"teacher_disagreement_score":0.35601503,"about_ca_system_score_codex":0.00015157669,"about_ca_system_score_gemma":0.000060863065,"threshold_uncertainty_score":0.50305706},"labels":[],"label_agreement":null},{"id":"W2101770554","doi":"10.1128/aac.46.6.1851-1856.2002","title":"A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors","year":2002,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Medical Research Council; Medical Research Council Canada; amfAR, The Foundation for AIDS Research; Howard Hughes Medical Institute","keywords":"Reverse-transcriptase inhibitor; Efavirenz; Virology; Reverse transcriptase; Nevirapine; Virus; Extracellular; Biology; Infectivity; Cell culture; Lentivirus; Molecular biology; Viral load; Viral disease; RNA; Biochemistry; Antiretroviral therapy","score_opus":0.019284218559198475,"score_gpt":0.2750010061534755,"score_spread":0.255716787594277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101770554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977092,0.000037823072,0.0001042613,0.0012064603,0.00010495317,0.0005065693,0.00012653733,0.000019262101,0.00018490257],"genre_scores_gemma":[0.99698436,0.00070339115,0.00062347576,0.00043988356,0.000046896912,0.0000051253082,0.00005400638,0.00003030361,0.0011125515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989871,0.000016402451,0.00034227077,0.0002767579,0.0001575544,0.00021993589],"domain_scores_gemma":[0.99951583,0.000010758566,0.00017429322,0.00015733109,0.000083576095,0.000058201247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000682383,0.00020339916,0.00041906652,0.00013836163,0.00013109623,0.000013313944,0.00004687269,0.00010731941,0.00037480812],"category_scores_gemma":[0.000003747185,0.00017975301,0.00016833097,0.0001766643,0.000111638896,0.00012170331,0.000013845563,0.0000774828,0.0000057229377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033035138,0.001088651,0.0031183655,0.00019302066,0.00017624724,0.000007652093,0.0024341461,7.530917e-7,0.9714211,0.000015841124,0.019356873,0.0018569677],"study_design_scores_gemma":[0.004760776,0.00022937244,0.0016199279,0.00022510155,0.00012446813,0.000011909145,0.00004242062,0.00016449722,0.9876592,0.0000113261785,0.004974823,0.00017614833],"about_ca_topic_score_codex":0.00012513813,"about_ca_topic_score_gemma":0.0000055951114,"teacher_disagreement_score":0.016238099,"about_ca_system_score_codex":0.00003209047,"about_ca_system_score_gemma":0.000023844133,"threshold_uncertainty_score":0.7330115},"labels":[],"label_agreement":null},{"id":"W2102119991","doi":"10.1093/infdis/jir562","title":"Pharmacokinetics and Placental Transfer of Single-Dose Tenofovir 1% Vaginal Gel in Term Pregnancy","year":2011,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Pregnancy; Pharmacokinetics; Amniotic fluid; Cord blood; Obstetrics; Dosing; Gestation; Adverse effect; Fetus; Andrology; Gynecology; Physiology; Internal medicine; Biology","score_opus":0.019389680534781538,"score_gpt":0.25042290171725734,"score_spread":0.2310332211824758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102119991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954613,0.0028973785,0.000046430534,0.000102123806,0.00007892737,0.00020008568,0.000008369727,0.000009221536,0.0011962028],"genre_scores_gemma":[0.99856734,0.0011168842,0.00005310707,0.000038083872,0.000041892297,0.0000026295975,0.0000016397222,0.000012507887,0.00016590992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992312,0.00006123684,0.00032527975,0.00006380453,0.00018352055,0.00013491017],"domain_scores_gemma":[0.9995691,0.00006180846,0.000096213545,0.00007909256,0.00007230979,0.00012143606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009277128,0.00012215291,0.00024889945,0.00015607542,0.00003316144,0.0000050577737,0.000056634155,0.000024469922,0.00010539699],"category_scores_gemma":[0.000023239958,0.00007313465,0.00007409723,0.00010930235,0.00010648202,0.00008704096,0.000015601629,0.00011693601,0.000002120249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011322865,0.0023945784,0.97636926,0.00013108595,0.00028685687,0.00023893014,0.0039146584,0.0000031283555,0.0066814804,0.00001956101,0.000111184294,0.008716999],"study_design_scores_gemma":[0.012441524,0.0018694176,0.9598972,0.00127532,0.0016207962,0.0013400534,0.00047841464,0.000017214948,0.020544505,0.00024039873,0.00010683066,0.00016832665],"about_ca_topic_score_codex":0.000011755317,"about_ca_topic_score_gemma":0.000009929848,"teacher_disagreement_score":0.016472053,"about_ca_system_score_codex":0.00005633789,"about_ca_system_score_gemma":0.000088033514,"threshold_uncertainty_score":0.29823446},"labels":[],"label_agreement":null},{"id":"W2102128538","doi":"10.1177/0091270008329550","title":"Lopinavir/Ritonavir Pharmacokinetics in a Substitution of High‐Dose Soft‐Gelatin Capsule to Tablet Formulation","year":2009,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; HIV Legal Network; AIDS Vancouver","funders":"","keywords":"Pharmacokinetics; Lopinavir; Ritonavir; Capsule; Lopinavir/ritonavir; Pharmacology; Gelatin; Medicine; Bioequivalence; Chemistry; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.05661761758653071,"score_gpt":0.43117385757911747,"score_spread":0.37455623999258675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102128538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98000056,0.00027245324,0.0007764153,0.017458806,0.00078358897,0.00043984086,0.000003504817,0.000008366905,0.00025649456],"genre_scores_gemma":[0.9944529,0.0005340923,0.0017221358,0.0022130483,0.00059904536,0.0000028549841,0.000006755898,0.000008901448,0.00046024824],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974622,0.0003075876,0.00156181,0.0001200862,0.00031053624,0.00023775316],"domain_scores_gemma":[0.99840933,0.00045069627,0.0005938005,0.00011164006,0.00024233217,0.0001921782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00188785,0.00014496087,0.000665353,0.00019786443,0.000039692102,0.0000035168068,0.00016462913,0.000114425726,0.00021690172],"category_scores_gemma":[0.0002470518,0.000094854884,0.0001447797,0.00032953662,0.00007580002,0.00010668734,0.000030219358,0.0005246421,0.000029088744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049066693,0.015714506,0.11374613,0.0002617262,0.0020721944,0.0015073116,0.0043034307,0.019455723,0.44164136,0.0018331138,0.093609266,0.25678855],"study_design_scores_gemma":[0.05361166,0.0066451817,0.769799,0.0005317789,0.0025778024,0.00068499806,0.00013877262,0.0039452408,0.1198817,0.0035382758,0.038185213,0.00046036072],"about_ca_topic_score_codex":0.000010274919,"about_ca_topic_score_gemma":0.000003972413,"teacher_disagreement_score":0.6560529,"about_ca_system_score_codex":0.00010020763,"about_ca_system_score_gemma":0.00027520605,"threshold_uncertainty_score":0.386807},"labels":[],"label_agreement":null},{"id":"W2102218736","doi":"10.1016/j.meegid.2006.09.004","title":"Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors","year":2006,"lang":"en","type":"article","venue":"Infection Genetics and Evolution","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Vlaamse regering; KU Leuven; Fonds Wetenschappelijk Onderzoek","keywords":"Saquinavir; Nelfinavir; Indinavir; Protease; Protease inhibitor (pharmacology); Biology; Mutation; Drug resistance; Virology; Genetics; Computational biology; Human immunodeficiency virus (HIV); Gene; Sida; Viral load; Viral disease; Enzyme; Antiretroviral therapy","score_opus":0.006164417086795389,"score_gpt":0.21002717858868497,"score_spread":0.2038627615018896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102218736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829134,0.001080285,0.012936223,0.0001990237,0.00008857068,0.00031636065,0.0000114491895,0.00004097251,0.002413735],"genre_scores_gemma":[0.9965569,0.00016048529,0.0014412871,0.000014326482,0.00016084976,0.0000256901,0.00015092174,0.000008951537,0.0014806285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991996,0.000029257051,0.00027830526,0.00018540326,0.00015766335,0.00014972116],"domain_scores_gemma":[0.9995819,0.000011963663,0.000114681774,0.00013075807,0.00009858675,0.000062107465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120769335,0.00010931768,0.00021037573,0.00023741508,0.000104578336,0.000010465931,0.000012380747,0.0000734883,0.000012152703],"category_scores_gemma":[0.000009754256,0.00010037115,0.00009384855,0.0007228195,0.00004254583,0.000028689987,0.000012983594,0.000052953827,0.000004424033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040136954,0.00013902743,0.98949623,0.00004052939,0.00026061723,0.0000039719944,0.00006161014,0.0049389824,0.0011468572,0.0003150312,0.0026470188,0.0009100076],"study_design_scores_gemma":[0.00066438655,0.000050822,0.9834066,0.00007049781,0.0008247729,0.0000017820637,0.000015094747,0.008264776,0.0013262915,0.0004451856,0.0048093293,0.000120480465],"about_ca_topic_score_codex":0.00005454598,"about_ca_topic_score_gemma":0.00028597855,"teacher_disagreement_score":0.01364348,"about_ca_system_score_codex":0.00011337165,"about_ca_system_score_gemma":0.000051288276,"threshold_uncertainty_score":0.40930167},"labels":[],"label_agreement":null},{"id":"W2102530919","doi":"10.1086/375233","title":"A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy","year":2003,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada); Ottawa Hospital","funders":"","keywords":"Ritonavir; Indinavir; Saquinavir; Lopinavir; Medicine; Pharmacology; Protease inhibitor (pharmacology); Bioavailability; Protease; Pharmacokinetics; Virology; Viral load; Enzyme; Human immunodeficiency virus (HIV); Antiretroviral therapy; Chemistry; Biochemistry","score_opus":0.07586664810447359,"score_gpt":0.434544337341717,"score_spread":0.3586776892372434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102530919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030291732,0.99274755,0.0000011289764,0.00012542495,0.00036303172,0.005635012,0.0000616288,0.000076637065,0.0006866861],"genre_scores_gemma":[0.0000666919,0.9960615,0.000015599473,0.00067801203,0.00016551063,0.001270939,0.0006173443,0.00006482367,0.0010596004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958309,0.000807614,0.0021725257,0.00058995915,0.00032483012,0.0002741556],"domain_scores_gemma":[0.9974906,0.0006386463,0.0007785132,0.0005499025,0.00020292823,0.00033945165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064951985,0.00051266793,0.003404862,0.00027678628,0.00004039659,0.000012940559,0.000110884284,0.000337117,0.0002489891],"category_scores_gemma":[0.0014038079,0.00036748548,0.0013757696,0.00072075694,0.00017336375,0.00006613712,0.00004552101,0.0005052332,0.00016780454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031687076,0.00898356,0.01220657,0.15753874,0.00042024555,0.00010884731,0.00000654212,1.2704923e-8,2.123958e-8,0.000047851376,0.0063947923,0.81426114],"study_design_scores_gemma":[0.0031304134,0.00039388504,0.00096329907,0.24963723,0.0012571097,0.00001408235,0.0000012364433,3.7744937e-7,4.718266e-7,0.00008082096,0.74424213,0.0002789418],"about_ca_topic_score_codex":0.0000043402106,"about_ca_topic_score_gemma":0.0000021882186,"teacher_disagreement_score":0.8139822,"about_ca_system_score_codex":0.00023746442,"about_ca_system_score_gemma":0.001466727,"threshold_uncertainty_score":0.9998777},"labels":[],"label_agreement":null},{"id":"W2102951977","doi":"10.1093/cid/ciu919","title":"End-Stage Renal Disease Among HIV-Infected Adults in North America","year":2014,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Minority Health and Health Disparities; National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Eye Institute; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Canadian Institutes of Health Research; National Institute on Drug Abuse; U.S. Public Health Service; National Institutes of Health","keywords":"Medicine; End stage renal disease; Diabetes mellitus; Incidence (geometry); Dialysis; Poisson regression; Internal medicine; Cohort; Hemodialysis; Coinfection; Disease; Confidence interval; Cohort study; Hepatitis C; Immunology; Human immunodeficiency virus (HIV); Population; Environmental health; Endocrinology","score_opus":0.014218387330384432,"score_gpt":0.30073716577062737,"score_spread":0.2865187784402429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102951977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952478,0.00012559754,0.00017125158,0.00059670315,0.00023230207,0.000686659,0.00011317744,0.00038180812,0.0024447222],"genre_scores_gemma":[0.9942906,0.0001846548,0.000039666676,0.00077324716,0.000372711,0.0001612834,0.0009199017,0.00004456796,0.003213387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740785,0.00028236257,0.00082710077,0.0006698721,0.0003331595,0.00047965389],"domain_scores_gemma":[0.99729866,0.0007042075,0.00020467294,0.00053272786,0.00011245634,0.0011472859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015761223,0.00034021045,0.00070428225,0.00021781772,0.00011109093,0.00003637907,0.00010712367,0.00010287674,0.00077768345],"category_scores_gemma":[0.0019292713,0.00028081794,0.00039633387,0.0005430917,0.0003600252,0.00013074854,0.00009095938,0.00033746162,0.0006359347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004156046,0.0030913434,0.9806732,0.00008353554,0.00013536784,0.00030842572,0.000068379064,0.00004237843,6.274213e-7,0.00004772794,0.0031971955,0.011936217],"study_design_scores_gemma":[0.005501152,0.00033845915,0.9728695,0.00018964578,0.00031181972,0.0000014359173,0.000020165064,0.0011406693,0.0000033038086,0.00006557032,0.019256882,0.0003013543],"about_ca_topic_score_codex":0.000054267082,"about_ca_topic_score_gemma":0.0005013635,"teacher_disagreement_score":0.016059687,"about_ca_system_score_codex":0.00012475127,"about_ca_system_score_gemma":0.0002724564,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W2103216867","doi":"10.1093/jac/dkh009","title":"Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1","year":2003,"lang":"en","type":"review","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Resistance mutation; Lamivudine; Nucleoside Reverse Transcriptase Inhibitor; Virology; Drug resistance; Biology; Zidovudine; Mutation; Lentivirus; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Virus; Viral disease; Antiretroviral therapy; Sida; Genetics; Viral load; RNA; Gene","score_opus":0.04750766420487013,"score_gpt":0.2980717287385201,"score_spread":0.25056406453365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103216867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060299654,0.9850519,0.00026384872,0.0032945208,0.00036086928,0.0018484498,0.00007616277,0.000017145065,0.0030571679],"genre_scores_gemma":[0.001216373,0.98914343,0.005383003,0.00022142331,0.00010263534,0.0000077746745,0.000060840786,0.00006546023,0.0037990592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739045,0.00035302507,0.0015098335,0.0001934947,0.00032228895,0.00023091394],"domain_scores_gemma":[0.99816114,0.00020794477,0.0010997949,0.0002867862,0.0001585863,0.000085753374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009739196,0.00034943223,0.0015878051,0.0005379773,0.00009750712,0.000030615425,0.00023094461,0.00025966438,0.000094695926],"category_scores_gemma":[0.00007082927,0.00022928514,0.0007801963,0.0005892711,0.00012110619,0.0001246873,0.0000051074794,0.000936191,0.000010496439],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003069606,0.012855058,0.02486867,0.065170124,0.015686303,0.009235454,0.07456927,0.000067495894,0.0013348862,0.0017514125,0.5574171,0.23397462],"study_design_scores_gemma":[0.0029956275,0.00005150361,0.0004478059,0.01702222,0.0015752759,0.00065957964,0.0002318415,6.5664693e-7,0.000103610815,0.00003738329,0.97663987,0.00023465669],"about_ca_topic_score_codex":0.000006757779,"about_ca_topic_score_gemma":0.00003351117,"teacher_disagreement_score":0.41922274,"about_ca_system_score_codex":0.00022313235,"about_ca_system_score_gemma":0.00071782916,"threshold_uncertainty_score":0.9349977},"labels":[],"label_agreement":null},{"id":"W2103271027","doi":"10.1111/j.1747-0285.2009.00870.x","title":"Dimethylthiazolidine Carboxylic Acid as a Rigid P3 Unit in Inhibitors of Serine Proteases: Application to Two Targets<sup>†</sup>","year":2009,"lang":"en","type":"article","venue":"Chemical Biology & Drug Design","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Proteases; Peptidomimetic; Serine; Serine protease; Protease; Peptide; NS3; Residue (chemistry); Chemistry; Enzyme; Biochemistry; Amino acid; Amino acid residue; Active site; Carboxylic acid; Stereochemistry; Peptide sequence","score_opus":0.012393212426533271,"score_gpt":0.285200667038772,"score_spread":0.2728074546122387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103271027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881273,0.0005677679,0.0012791735,0.0067181806,0.00002732227,0.0023838691,0.000010445921,0.00011692743,0.0007690302],"genre_scores_gemma":[0.9868838,0.0000408934,0.01105086,0.00063046697,0.00012787044,0.00038383022,0.00023972336,0.000024548417,0.00061800657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980146,0.00012463654,0.0006133106,0.00059109245,0.00017690808,0.0004793954],"domain_scores_gemma":[0.9989224,0.00012936063,0.00012480645,0.00040285444,0.0001189407,0.0003016186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038784242,0.00034539442,0.00071096915,0.00028650733,0.000036855454,0.0000056168697,0.00019202486,0.00020936097,0.000076667464],"category_scores_gemma":[0.00023864803,0.00028128704,0.00010710951,0.000724648,0.00011801998,0.000047462436,0.00006214083,0.00028533564,0.00016119872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000960757,0.0008604611,0.007286456,0.00004564342,0.000103158534,0.00003470418,0.0011779467,0.00004641616,0.97369874,0.00026819026,0.0008562751,0.014661269],"study_design_scores_gemma":[0.0027979782,0.00037675715,0.00043585701,0.00011241315,0.000081218044,0.000024577384,0.000108371925,0.0003367129,0.98993367,0.00143029,0.004083424,0.00027874784],"about_ca_topic_score_codex":0.000059908918,"about_ca_topic_score_gemma":0.0000029628488,"teacher_disagreement_score":0.01623493,"about_ca_system_score_codex":0.00014742407,"about_ca_system_score_gemma":0.00019735772,"threshold_uncertainty_score":0.99996394},"labels":[],"label_agreement":null},{"id":"W2103866977","doi":"10.1371/journal.pmed.0030356","title":"Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART","year":2006,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"National Institute of Mental Health; Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Drug resistance; Proportional hazards model; Confounding; Internal medicine; Marginal structural model; Hazard ratio; HIV drug resistance; Prospective cohort study; Mortality rate; Survival analysis; Cohort study; Viral load; Immunology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Confidence interval; Biology; Genetics","score_opus":0.0101225546133104,"score_gpt":0.2193876191845347,"score_spread":0.2092650645712243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103866977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524087,0.00020429699,0.000020152176,0.00060219126,0.00002966922,0.00047976375,0.000044458007,0.000045807803,0.0033327998],"genre_scores_gemma":[0.9949097,0.000050606348,0.0010295688,0.00005437033,0.00004983044,0.00002211526,0.0002874423,0.000028395249,0.0035679652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979189,0.00007566349,0.00065151026,0.000290681,0.00079825363,0.00026496316],"domain_scores_gemma":[0.99833274,0.00016482171,0.0005982588,0.00031710463,0.0004367997,0.0001502499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032877814,0.00021681568,0.00062403304,0.00014856864,0.00009387132,0.0000020031946,0.00009147825,0.00005443692,0.0003231234],"category_scores_gemma":[0.00046577034,0.00014675815,0.000046394343,0.00040337213,0.00017596525,0.00009001019,0.00001928811,0.0001256382,0.000003387439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035887078,0.0011045818,0.98689824,0.00013099436,0.00033862822,0.000025476604,0.0019581695,0.0000018383103,0.00024106793,0.000015518604,0.008877141,0.000049460807],"study_design_scores_gemma":[0.0064163585,0.00047378472,0.9762518,0.002531983,0.00095464446,3.3628567e-7,0.00043500063,0.00028670652,0.012226168,0.00011726336,0.00014002307,0.00016593863],"about_ca_topic_score_codex":0.0013284655,"about_ca_topic_score_gemma":0.0021401641,"teacher_disagreement_score":0.0119851,"about_ca_system_score_codex":0.000059675815,"about_ca_system_score_gemma":0.00007444852,"threshold_uncertainty_score":0.59846234},"labels":[],"label_agreement":null},{"id":"W2104591118","doi":"10.1186/1471-2334-13-517","title":"HIV-1 drug resistance-associated mutations among HIV-1 infected drug-naïve antenatal clinic attendees in rural Kenya","year":2013,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Public Health Agency; Public Health Agency of Canada","keywords":"Drug resistance; Medical microbiology; Transmission (telecommunications); Kenya; Virology; Medicine; Reverse transcriptase; HIV drug resistance; Nevirapine; Parasitology; Human immunodeficiency virus (HIV); Biology; Viral load; Gene; Antiretroviral therapy; Polymerase chain reaction; Microbiology; Genetics; Pathology","score_opus":0.00735063885817815,"score_gpt":0.2432576820940884,"score_spread":0.23590704323591025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104591118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099165,0.000376673,0.000025666031,0.0008815376,0.00023840141,0.0015030886,0.00015522196,0.00058306684,0.0052446877],"genre_scores_gemma":[0.9435689,0.00007069504,0.00011890032,0.00012251943,0.00010587822,0.0006067509,0.00176571,0.00006552168,0.05357517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742115,0.00022954181,0.0007442136,0.00049948413,0.00043911202,0.0006665098],"domain_scores_gemma":[0.9981302,0.00050510606,0.0002654688,0.0003889984,0.00030641095,0.0004038376],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014467759,0.00044635628,0.0006489398,0.0005170377,0.00026385312,0.000107624306,0.0001212329,0.00012325255,0.0012826878],"category_scores_gemma":[0.00070848817,0.00039351624,0.00031364636,0.00084918184,0.00023339142,0.00044345533,0.00007674036,0.00029165635,0.0020695801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008705219,0.0014570886,0.9562534,0.0000953531,0.00024330063,0.00012807445,0.00071312074,0.000010851734,0.00001596526,0.000029703504,0.04083899,0.00012711089],"study_design_scores_gemma":[0.00662205,0.00003206851,0.9901335,0.0004855755,0.0003686603,0.000013209544,0.0009264888,0.00019650253,0.000052369465,0.00040387863,0.00032961578,0.00043606164],"about_ca_topic_score_codex":0.00033736575,"about_ca_topic_score_gemma":0.0049213064,"teacher_disagreement_score":0.048330482,"about_ca_system_score_codex":0.00055896665,"about_ca_system_score_gemma":0.00041937592,"threshold_uncertainty_score":0.99985164},"labels":[],"label_agreement":null},{"id":"W2105097884","doi":"10.1128/jvi.05584-11","title":"Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations","year":2011,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health; International AIDS Society; National Institute for Health and Care Research","keywords":"Biology; Processivity; Reverse transcriptase; Virology; Mutation; Viral replication; Replication (statistics); Genetics; Enzyme; Virus; DNA; Gene; Polymerase; Polymerase chain reaction","score_opus":0.03248330267094528,"score_gpt":0.2574115625760269,"score_spread":0.22492825990508158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105097884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874799,0.00009183483,0.0017237858,0.010124888,0.00001949865,0.00048201773,0.000012232427,0.000004006273,0.00006180788],"genre_scores_gemma":[0.9988233,0.000013151386,0.0006132261,0.00032155795,0.000011712997,0.000046383557,0.0000418528,0.0000063363373,0.00012248455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992434,0.0001390597,0.00029142716,0.00010761557,0.00010881348,0.00010969969],"domain_scores_gemma":[0.99931055,0.00016593096,0.00029387258,0.000081972175,0.000118422,0.000029234836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071077363,0.00007826013,0.00018220393,0.00009632625,0.000069391805,0.000005913087,0.000044944318,0.00006227037,0.000006860087],"category_scores_gemma":[0.00020086738,0.000042563275,0.000027357179,0.00013922907,0.00009030978,0.000115038216,0.0000032533994,0.00017813071,7.7557524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010666942,0.0050895135,0.7486657,0.00019184477,0.0009837606,0.00026956704,0.13844003,0.00031293053,0.065877356,0.002684772,0.011458676,0.0153589565],"study_design_scores_gemma":[0.010469085,0.0011530533,0.97393745,0.00011858781,0.0004197752,0.0003749716,0.0019217446,0.0021556541,0.006950394,0.0016547745,0.00071126875,0.00013324023],"about_ca_topic_score_codex":0.00003211199,"about_ca_topic_score_gemma":0.0004475961,"teacher_disagreement_score":0.22527179,"about_ca_system_score_codex":0.0000944439,"about_ca_system_score_gemma":0.000076836404,"threshold_uncertainty_score":0.173568},"labels":[],"label_agreement":null},{"id":"W2105543437","doi":"10.1179/1528433614z.0000000015","title":"Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)","year":2015,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Regimen; Lamivudine; Adverse effect; Emtricitabine; Internal medicine; Viral load; Surgery; Gastroenterology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Chronic hepatitis","score_opus":0.3198417514449129,"score_gpt":0.47750882426556046,"score_spread":0.15766707282064757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105543437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96913016,0.0005576324,0.0000066427747,0.023255287,0.00029178918,0.0028881652,0.00023637948,0.000058335158,0.0035756384],"genre_scores_gemma":[0.99331653,0.0008954185,0.001276269,0.0006333952,0.0005302722,0.0001579061,0.00018280081,0.000026706062,0.002980675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99222916,0.0038394474,0.002098625,0.00094377773,0.0005005719,0.00038841678],"domain_scores_gemma":[0.98680955,0.011495101,0.0005291464,0.0006526523,0.000083437866,0.00043011399],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008785741,0.00037572556,0.001679557,0.00009303346,0.00013378361,0.000066214016,0.00015874334,0.000280292,0.0000996471],"category_scores_gemma":[0.015227756,0.00019778124,0.00023846028,0.00023019813,0.0002106395,0.00011123361,0.00020191923,0.0003976243,0.00011829516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.102435865,0.017466467,0.55669034,0.000012526077,0.00367514,0.0037950214,0.037099876,0.0000037889106,0.0006918264,0.0001780741,0.15503958,0.12291151],"study_design_scores_gemma":[0.15962659,0.010760904,0.6970369,0.00091481383,0.0022470227,0.000041750343,0.03765026,0.00020605193,0.0024484266,0.0015429991,0.08668858,0.0008356581],"about_ca_topic_score_codex":0.00046235425,"about_ca_topic_score_gemma":0.00014896989,"teacher_disagreement_score":0.14034662,"about_ca_system_score_codex":0.00057258696,"about_ca_system_score_gemma":0.0002873235,"threshold_uncertainty_score":0.9930674},"labels":[],"label_agreement":null},{"id":"W2105595131","doi":"10.1093/jac/dkn067","title":"Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells","year":2008,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Stavudine; Zidovudine; Mitochondrial DNA; Biology; Thymidine; Reverse-transcriptase inhibitor; Toxicity; Reverse transcriptase; Pharmacology; Molecular biology; Mitochondrion; Immunology; Gene; DNA; Medicine; Genetics; Internal medicine; RNA; Human immunodeficiency virus (HIV)","score_opus":0.010716442285914493,"score_gpt":0.23815576108695702,"score_spread":0.2274393188010425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105595131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967558,0.00044071215,0.00004695935,0.0021976088,0.00017663579,0.00022789586,0.0000025017455,0.000007512838,0.00014441086],"genre_scores_gemma":[0.98541385,0.005142648,0.007163834,0.00022329978,0.00016330525,0.0000010365028,0.0000054457237,0.000020506837,0.0018661026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891704,0.000041920997,0.00047421266,0.00016476259,0.00023137718,0.00017069829],"domain_scores_gemma":[0.99927294,0.000057181493,0.00035067427,0.000107837266,0.000127513,0.00008385424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015975286,0.00018908155,0.0005442006,0.00027924104,0.00005266646,0.000007563406,0.00006265076,0.00009783811,0.000012137398],"category_scores_gemma":[0.000026766225,0.00013811412,0.00012475012,0.00023228931,0.0001016956,0.00013055999,0.000008046701,0.0002363547,0.0000026488167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027147462,0.0011469364,0.029495547,0.00021145829,0.00029819144,0.0005896441,0.003005769,0.000008935412,0.950921,0.00000879455,0.010706102,0.00089288113],"study_design_scores_gemma":[0.007472035,0.00033607674,0.06415186,0.0008404738,0.000052478772,0.00028872842,0.000041389576,0.0000039240867,0.9244625,0.000008261324,0.0022166842,0.00012561193],"about_ca_topic_score_codex":0.000009670169,"about_ca_topic_score_gemma":0.000016771819,"teacher_disagreement_score":0.034656316,"about_ca_system_score_codex":0.00010167134,"about_ca_system_score_gemma":0.00008271556,"threshold_uncertainty_score":0.56321305},"labels":[],"label_agreement":null},{"id":"W2105946373","doi":"10.1016/j.bmcl.2006.04.011","title":"Lysine sulfonamides as novel HIV-protease inhibitors: Nε-Acyl aromatic α-amino acids","year":2006,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Chemistry; Sulfonamide; Protease; Lysine; Protease inhibitor (pharmacology); Enzyme inhibitor; Potency; Human immunodeficiency virus (HIV); Amino acid; Stereochemistry; Biochemistry; In vitro; Enzyme; Virology","score_opus":0.007701417357923256,"score_gpt":0.21794682161367196,"score_spread":0.2102454042557487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105946373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95553905,0.00056916487,0.00024914063,0.040026132,0.00016902154,0.00049405696,0.000019261168,0.00025789635,0.00267628],"genre_scores_gemma":[0.98225456,0.000025261888,0.0016378105,0.0020074537,0.0017394058,0.00006905689,0.00067518454,0.00008777922,0.011503466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99685794,0.000021787422,0.00075424195,0.0007006209,0.00096601143,0.0006993896],"domain_scores_gemma":[0.99859583,0.000081217666,0.00023886014,0.0005969548,0.000072039606,0.00041507077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024280304,0.00059582945,0.00069311686,0.00011797489,0.00015895438,0.00004298085,0.00023510675,0.00020538091,0.0009602397],"category_scores_gemma":[0.00020474097,0.0004961814,0.00020411411,0.0004923951,0.00031023845,0.00011403082,0.00008548391,0.00038748322,0.0005000622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012829891,0.0005261556,0.012065425,0.0003555773,0.00020286039,0.0008943903,0.00019303581,9.561005e-7,0.95670986,0.000007135931,0.028544758,0.00037156465],"study_design_scores_gemma":[0.006784483,0.000078579535,0.011390042,0.00092689897,0.00070792454,0.001515498,0.0004428788,0.00004548398,0.95584416,0.000049178812,0.021499345,0.0007155226],"about_ca_topic_score_codex":0.00007499873,"about_ca_topic_score_gemma":0.000001867147,"teacher_disagreement_score":0.038018677,"about_ca_system_score_codex":0.0005313237,"about_ca_system_score_gemma":0.00032945315,"threshold_uncertainty_score":0.99995303},"labels":[],"label_agreement":null},{"id":"W2105950729","doi":"10.2217/17584310.3.2.109","title":"Stavudine in First-Line Antiretroviral Regimens in Resource-Limited Settings: Time for a Better Solution","year":2009,"lang":"en","type":"article","venue":"HIV Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Abbott Laboratories","keywords":"Stavudine; Antiretroviral therapy; Resource (disambiguation); Human immunodeficiency virus (HIV); First line; Medicine; Intensive care medicine; Computer science; Virology; Viral load; Internal medicine","score_opus":0.015903672131937892,"score_gpt":0.260794820296549,"score_spread":0.2448911481646111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105950729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93469983,0.00038385767,0.00013348766,0.06292267,0.00002284321,0.0010119249,0.000013316068,0.00008093055,0.0007311281],"genre_scores_gemma":[0.96755093,0.00023450327,0.005096133,0.0055429926,0.00021433343,0.0000922721,0.00059386966,0.00004285864,0.020632107],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987757,0.000036286725,0.00033166626,0.00030291313,0.00017165851,0.00038173885],"domain_scores_gemma":[0.9995563,0.000065893364,0.00007220142,0.00021081092,0.000031660533,0.00006312234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027694923,0.00019813114,0.0003473312,0.0003071645,0.000054850007,0.000013017793,0.000062036794,0.00009957619,0.000091355614],"category_scores_gemma":[0.000028653922,0.00016365666,0.00008202153,0.0003277625,0.000024625542,0.000066453606,0.000008919366,0.00013232692,0.000063053136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115543185,0.00493597,0.40647402,0.00012705756,0.00037169154,0.0005629563,0.012318121,0.00007151867,0.03770962,0.00015934232,0.32301188,0.2027035],"study_design_scores_gemma":[0.06064593,0.004444165,0.27760175,0.0010881107,0.000087973225,0.00004826001,0.00020675312,0.007937866,0.013291125,0.0008234635,0.6328471,0.0009775115],"about_ca_topic_score_codex":0.000005905318,"about_ca_topic_score_gemma":0.000012468966,"teacher_disagreement_score":0.3098352,"about_ca_system_score_codex":0.00018727983,"about_ca_system_score_gemma":0.000038645932,"threshold_uncertainty_score":0.6673725},"labels":[],"label_agreement":null},{"id":"W2106467173","doi":"10.1093/jac/dku187","title":"Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects","year":2014,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Rilpivirine; Nevirapine; Emtricitabine; Medicine; Efavirenz; Reverse-transcriptase inhibitor; Pharmacology; Internal medicine; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.007943296467291827,"score_gpt":0.22490109192197558,"score_spread":0.21695779545468374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106467173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97171247,0.0003750831,0.002317816,0.024077361,0.00017515692,0.00062636257,0.000014744136,0.00006289846,0.0006380831],"genre_scores_gemma":[0.97446096,0.0005474975,0.017200636,0.005350588,0.00059460825,0.0000066996836,0.00004261118,0.00009543734,0.0017009357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99693114,0.00016906275,0.0012002547,0.0005434635,0.00046748528,0.00068859593],"domain_scores_gemma":[0.9980595,0.00032450265,0.0005616043,0.00036732334,0.0002647004,0.00042235115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007342198,0.0005573654,0.0014058261,0.00089098385,0.00011022597,0.000116227464,0.0002781537,0.00025208268,0.00016424403],"category_scores_gemma":[0.00031722852,0.00042073554,0.00022630832,0.0008553009,0.00007320202,0.0003183589,0.0000984252,0.00058399583,0.00003891804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033599704,0.0015392374,0.06266738,0.000054668835,0.0004084049,0.00037346888,0.0014113464,0.000043939952,0.90864044,0.000011774311,0.009741729,0.011747629],"study_design_scores_gemma":[0.077135436,0.005995722,0.28647345,0.0023546515,0.0008268139,0.001846416,0.00019051369,0.00070802495,0.48755592,0.00048033017,0.13432775,0.0021049415],"about_ca_topic_score_codex":0.00004710828,"about_ca_topic_score_gemma":0.000020500329,"teacher_disagreement_score":0.42108452,"about_ca_system_score_codex":0.00035439237,"about_ca_system_score_gemma":0.00027677655,"threshold_uncertainty_score":0.99982446},"labels":[],"label_agreement":null},{"id":"W2106686118","doi":"10.1086/342681","title":"Durability of Response to Treatment among Antiretroviral‐Experienced Subjects: 48‐Week Results from AIDS Clinical Trials Group Protocol 359","year":2002,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of North Carolina at Chapel Hill; York University; National Institute of Allergy and Infectious Diseases; Johns Hopkins University; University of Washington; Gilead Sciences; University of Miami; Abbott Laboratories","keywords":"Medicine; Protocol (science); Clinical trial; Human immunodeficiency virus (HIV); Internal medicine; Immunology; Alternative medicine; Pathology","score_opus":0.06948832704406786,"score_gpt":0.3813955334754987,"score_spread":0.31190720643143083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106686118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810672,0.00010273506,0.000041954074,0.0007402708,0.0002200538,0.017450053,0.0001080663,0.00004225791,0.000227448],"genre_scores_gemma":[0.99641955,0.00009704957,0.00019774627,0.000090805974,0.0003108506,0.0021181735,0.0000080198815,0.000023437566,0.00073434284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934297,0.0029939406,0.0024293864,0.00027014164,0.00059672736,0.00028010202],"domain_scores_gemma":[0.9931926,0.004136033,0.0013198515,0.0005539596,0.00029994483,0.00049761956],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004162284,0.00030626805,0.0013107057,0.00024520443,0.0001489737,0.000032087493,0.000182662,0.00010016853,0.00031746016],"category_scores_gemma":[0.010692659,0.00016165017,0.00070084335,0.00040994462,0.00027342397,0.00017400949,0.000047396894,0.00020057157,0.000039045422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07958682,0.009075685,0.877695,0.00003611138,0.0012203236,0.0002244711,0.005126225,0.000018741275,0.0020426575,0.000003503787,0.0031370597,0.021833407],"study_design_scores_gemma":[0.041368805,0.024720296,0.92027026,0.0005744874,0.0019307155,0.00008675471,0.0012920729,0.000050903243,0.0062440527,0.00014064345,0.0030107026,0.0003103214],"about_ca_topic_score_codex":0.00014291053,"about_ca_topic_score_gemma":0.000029812734,"teacher_disagreement_score":0.042575248,"about_ca_system_score_codex":0.00038284622,"about_ca_system_score_gemma":0.00024378221,"threshold_uncertainty_score":0.99764067},"labels":[],"label_agreement":null},{"id":"W2106720283","doi":"10.1097/qad.0b013e328011e691","title":"HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance","year":2006,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":331,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Reverse transcriptase; Drug resistance; HIV drug resistance; Virology; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Reverse-transcriptase inhibitor; Mutation; Protease inhibitor (pharmacology); Protease; Biology; Human immunodeficiency virus (HIV); Medicine; Genetics; Viral load; Polymerase chain reaction; Antiretroviral therapy; Gene; Enzyme","score_opus":0.028099359696446714,"score_gpt":0.3117433572995661,"score_spread":0.28364399760311937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106720283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017993334,0.9932454,0.00022987455,0.0007865232,0.00009390477,0.0035120626,0.00073034345,0.000070196096,0.0013136959],"genre_scores_gemma":[0.000015694248,0.77199936,0.0103590395,0.000043705866,0.00010614548,0.0012456415,0.0027742067,0.000057173656,0.21339901],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985224,0.00008034849,0.00048906,0.00046035924,0.00017905087,0.00026876922],"domain_scores_gemma":[0.99913937,0.00016484433,0.00015470061,0.00031634874,0.00007959484,0.00014517097],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025175934,0.00037437113,0.0011993728,0.00016684266,0.00012316281,0.000023559673,0.000070110276,0.00012739291,0.00003321162],"category_scores_gemma":[0.00007822355,0.00029108548,0.0003230436,0.00025792708,0.000074272284,0.00004994667,0.000011529031,0.00015908803,0.00005253369],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012733288,0.00044769436,0.0014309193,0.064848244,0.0008750217,0.00032778113,0.00035655702,9.687753e-8,0.0000012662596,0.0008319628,0.4151891,0.515564],"study_design_scores_gemma":[0.0012392532,0.000026176042,0.000026387965,0.005029594,0.001186054,0.000024754281,0.0000150463575,8.6570464e-7,0.0000026173373,0.00006774004,0.9921105,0.00027099464],"about_ca_topic_score_codex":0.000009468168,"about_ca_topic_score_gemma":0.000011277773,"teacher_disagreement_score":0.5769214,"about_ca_system_score_codex":0.00012624434,"about_ca_system_score_gemma":0.00035334378,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W2106943062","doi":"10.1093/cid/cit261","title":"Reply to Gonzalez-Serna et al","year":2013,"lang":"fr","type":"letter","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Wellcome Trust","keywords":"Columbia university; Medicine; Demography; Human immunodeficiency virus (HIV); Resistance (ecology); Demographics; Drug resistance; Test (biology); Epidemiology; CONTEST; Gerontology; History; Family medicine; Political science; Media studies; Sociology; Internal medicine; Law","score_opus":0.03755335508100887,"score_gpt":0.3706619075548166,"score_spread":0.3331085524738077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106943062","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044595815,0.003851684,0.00017253662,0.9194758,0.011457436,0.002961591,0.000434566,0.0006361241,0.016414449],"genre_scores_gemma":[0.007319553,0.0026099207,0.00016596747,0.8021072,0.0076662395,0.000644659,0.0013112513,0.0002082685,0.17796694],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925543,0.00091658754,0.0022645823,0.0019400844,0.0008850001,0.0014394232],"domain_scores_gemma":[0.99194485,0.003377894,0.0005554228,0.0015485021,0.00046426815,0.0021090673],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006962175,0.0011879718,0.0022153337,0.00037003946,0.00027529776,0.00024410467,0.00041697628,0.0008601193,0.008462817],"category_scores_gemma":[0.004097562,0.0010178344,0.0015107427,0.00051152176,0.0005417061,0.0002279277,0.0004385939,0.0023194079,0.052500967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067721245,0.0019443865,0.33825466,0.00019439009,0.0013361445,0.0012862171,0.00007471106,0.0000044328303,0.0000012669711,0.000104434424,0.6442559,0.012475771],"study_design_scores_gemma":[0.0031066102,0.0010695386,0.15240967,0.0014090335,0.001826589,0.00004282779,0.000023129836,0.000026259955,0.000005582233,0.00031093176,0.8388794,0.0008904292],"about_ca_topic_score_codex":0.00028337335,"about_ca_topic_score_gemma":0.000042123014,"teacher_disagreement_score":0.19462352,"about_ca_system_score_codex":0.00064784905,"about_ca_system_score_gemma":0.0012147641,"threshold_uncertainty_score":0.9999823},"labels":[],"label_agreement":null},{"id":"W2107003598","doi":"10.1001/archinte.166.5.521","title":"Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Archives of Internal Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cart; Medicine; Confidence interval; Antiretroviral therapy; Viral load; Cohort; Internal medicine; Cohort study; Human immunodeficiency virus (HIV); Immunology","score_opus":0.009059645356893496,"score_gpt":0.27640418830599744,"score_spread":0.2673445429491039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107003598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930476,0.0002671815,0.00009047676,0.0015717052,0.000040653253,0.00021071879,0.000013320958,0.000008412918,0.0047499468],"genre_scores_gemma":[0.9981341,0.00019539068,0.0006075075,0.0000549726,0.00008575472,0.0000053485232,0.000044607605,0.000008476041,0.0008638576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896497,0.00007521545,0.00042882963,0.00013641806,0.0002688647,0.00012571292],"domain_scores_gemma":[0.9992923,0.0002571952,0.00026533692,0.00011675418,0.00003289039,0.000035481662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014199334,0.00012549436,0.0004906495,0.00033164636,0.000008919048,7.462585e-7,0.00008897213,0.000043686152,0.0002270877],"category_scores_gemma":[0.00008537292,0.00008009307,0.00006940546,0.000112739304,0.00035080872,0.000025691454,0.000030364747,0.00013156264,0.0000023235357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017195322,0.00074860366,0.87262136,0.000063632346,0.00015761546,0.000046499637,0.0013288967,0.0000012900024,0.10473636,0.00048770302,0.00045059604,0.017637929],"study_design_scores_gemma":[0.008692651,0.0037952084,0.91163665,0.0007718903,0.00006441177,0.000013635412,0.00009094209,0.00034050955,0.0727411,0.0014971843,0.00028560826,0.00007021001],"about_ca_topic_score_codex":0.00045548246,"about_ca_topic_score_gemma":0.0000737321,"teacher_disagreement_score":0.03901531,"about_ca_system_score_codex":0.000011990404,"about_ca_system_score_gemma":0.00002127871,"threshold_uncertainty_score":0.32661006},"labels":[],"label_agreement":null},{"id":"W2107462692","doi":"10.4212/cjhp.v53i2.708","title":"The Role of the Pharmacist Caring for People Living with HIV/AIDS: A Canadian Position Paper","year":2000,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; Children's & Women's Health Centre of British Columbia; Dalhousie University; Queen Elizabeth II Health Sciences Centre; Children's Hospital of Eastern Ontario; University of Saskatchewan; University of Ottawa; University of Manitoba; Capital District Health Authority; Health Sciences Centre; Ottawa Hospital; Alberta Hip and Knee Clinic; St. Paul's Hospital; Toronto General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Merck Canada; University Health Network","keywords":"Medicine; Pharmacy; Pharmacist; Family medicine; Position paper; Human immunodeficiency virus (HIV); Pharmacy practice; Affect (linguistics); Nursing; Psychology","score_opus":0.006720376695656128,"score_gpt":0.23266395206707915,"score_spread":0.22594357537142304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107462692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96588117,0.001560686,0.0000029065084,0.026383778,0.00024806664,0.000680497,0.000048124995,0.000005094695,0.0051897],"genre_scores_gemma":[0.99531853,0.00009366971,0.000105232524,0.0005258846,0.00022569491,0.00002054732,0.0000045872666,0.000028628996,0.0036772368],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881035,0.000057453773,0.00031967257,0.0001068887,0.00026290287,0.0004427084],"domain_scores_gemma":[0.99871045,0.00012551398,0.00016408628,0.00019720531,0.00022424255,0.00057851075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036794014,0.00016783814,0.00022526515,0.00010057464,0.0008787581,0.00008017858,0.0003275662,0.000023832852,0.00034465527],"category_scores_gemma":[0.000044362703,0.000079868725,0.00017780914,0.00023433626,0.00013456239,0.00016655026,0.000008655963,0.00027106632,0.000013381208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071718544,0.00023191865,0.84229475,0.00009175593,0.0027893588,0.000293531,0.039670624,0.00030676418,0.00094903616,0.001180669,0.029052727,0.082421675],"study_design_scores_gemma":[0.012847539,0.0013171207,0.16254437,0.0017544181,0.0032610272,0.002296641,0.009448741,0.0010704088,0.012879834,0.0010988022,0.79053843,0.0009426366],"about_ca_topic_score_codex":0.066324405,"about_ca_topic_score_gemma":0.4565171,"teacher_disagreement_score":0.76148576,"about_ca_system_score_codex":0.00048566586,"about_ca_system_score_gemma":0.002897066,"threshold_uncertainty_score":0.939893},"labels":[],"label_agreement":null},{"id":"W2107720872","doi":"10.1097/qad.0b013e32833a2a14","title":"Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts","year":2010,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Simon Fraser University","funders":"","keywords":"Efavirenz; Medicine; Pregnancy; Obstetrics; Observational study; Confidence interval; Population; Live birth; Meta-analysis; Cohort study; Prospective cohort study; Relative risk; Gynecology; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Biology; Environmental health; Immunology","score_opus":0.11284798414811895,"score_gpt":0.3539304180450634,"score_spread":0.24108243389694448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107720872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005764584,0.996373,0.000005125247,0.00014517126,0.000018671959,0.0028473092,0.00042865152,0.000005306879,0.000119105585],"genre_scores_gemma":[0.00018148647,0.99390423,0.0016984422,0.000045391425,0.0000030312438,0.00037410422,0.00079668243,0.000022517275,0.002974139],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99634963,0.0002205674,0.0025195975,0.00033822915,0.00044750606,0.00012446758],"domain_scores_gemma":[0.99661416,0.0009738107,0.0014674201,0.0007252388,0.00015818265,0.000061163366],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0005972705,0.00039508913,0.014632958,0.00048229212,0.000011975383,0.0000030467081,0.0001453505,0.00021030377,0.00041030897],"category_scores_gemma":[0.00034475618,0.00022315257,0.0021183519,0.0009144578,0.000064340056,0.000047981142,0.00006795296,0.00017115723,0.0000041219005],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000039294214,0.00020022661,0.018385526,0.7544719,0.22467707,0.000009253384,0.000112074726,8.069706e-8,7.569863e-8,0.00007209876,0.000032004868,0.002035736],"study_design_scores_gemma":[0.0003051767,0.000028625838,0.0032286537,0.15463474,0.8367175,0.0000024430838,0.0000033317078,7.214897e-7,0.0000015593108,0.0000085553365,0.0049330057,0.0001357121],"about_ca_topic_score_codex":0.000073418516,"about_ca_topic_score_gemma":0.00005280861,"teacher_disagreement_score":0.6120404,"about_ca_system_score_codex":0.000047176694,"about_ca_system_score_gemma":0.00023617847,"threshold_uncertainty_score":0.9999958},"labels":[],"label_agreement":null},{"id":"W2108156511","doi":"10.1186/1742-4690-10-21","title":"DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition","year":2013,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Duke Cancer Institute; McMaster University","keywords":"Transduction (biophysics); SAMHD1; Integrase; Biology; Virology; DNA; Viral replication; Integrase inhibitor; Virus; DNA damage; Signal transduction; Cell biology; Molecular biology; Chemistry; Gene; Human immunodeficiency virus (HIV); Viral load; Biochemistry; Reverse transcriptase; Antiretroviral therapy","score_opus":0.006500095709878905,"score_gpt":0.24577622692719375,"score_spread":0.23927613121731484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108156511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932667,0.00020137508,0.0014511427,0.003093937,0.00008206831,0.00033560515,0.000008378924,0.000045274228,0.0015155395],"genre_scores_gemma":[0.9907539,0.000093513816,0.0028904525,0.00024205995,0.000049388997,0.00005794681,0.00031097804,0.000016396045,0.0055853957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899924,0.00006933016,0.00033167208,0.00024407607,0.00015196807,0.00020369988],"domain_scores_gemma":[0.99943507,0.00007960835,0.00013190143,0.00018769446,0.00008301405,0.000082711325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114326605,0.00016763767,0.00033670093,0.0001654284,0.000050343493,0.0000114571285,0.00005093766,0.0001406732,0.00078202656],"category_scores_gemma":[0.00009956308,0.00012884184,0.000070944916,0.00014509863,0.00013747529,0.0001589305,0.000036574253,0.00016622736,0.00031740527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008762682,0.00019000366,0.0134619465,0.00004836303,0.000083117375,0.00001993765,0.0007531391,2.2411622e-7,0.96073246,0.00024778536,0.016015194,0.008360173],"study_design_scores_gemma":[0.0018653346,0.0005201614,0.01883587,0.00011423762,0.000117773976,0.000023858915,0.0005844446,0.00024853868,0.97433907,0.00064467127,0.0025395963,0.0001664483],"about_ca_topic_score_codex":0.00012971007,"about_ca_topic_score_gemma":0.000030715037,"teacher_disagreement_score":0.013606573,"about_ca_system_score_codex":0.000107748856,"about_ca_system_score_gemma":0.000041637057,"threshold_uncertainty_score":0.8562643},"labels":[],"label_agreement":null},{"id":"W2108624165","doi":"10.1124/jpet.109.153130","title":"The Role of Nucleoside Transporters in the Erythrocyte Disposition and Oral Absorption of Ribavirin in the Wild-Type and Equilibrative Nucleoside Transporter 1(−/−) Mice","year":2009,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institutes of Health; Valeant Pharmaceuticals International; National Institute on Alcohol Abuse and Alcoholism; Eli Lilly and Company","keywords":"Ribavirin; Nucleoside; Pharmacokinetics; Chemistry; Pharmacology; Absorption (acoustics); Liver injury; Transporter; Toxicokinetics; Biochemistry; Biology; Genotype; Gene","score_opus":0.013903858167755679,"score_gpt":0.31107957321571383,"score_spread":0.29717571504795814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108624165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882955,0.0064071985,0.0000065421764,0.0049134223,0.000042906795,0.00025353816,0.000002164724,0.0000014224738,0.00007732247],"genre_scores_gemma":[0.99627966,0.0023766684,0.0001160002,0.0011809767,0.000027541488,0.000003103649,0.0000028948198,0.0000049268647,0.000008256632],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991532,0.0001375971,0.00037191345,0.00008040344,0.00013988049,0.000117003845],"domain_scores_gemma":[0.9996336,0.000107500724,0.00016230565,0.000042848802,0.00002852803,0.000025199082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036757736,0.000111563044,0.00022873306,0.00006615613,0.000060972496,0.000008666302,0.00007085073,0.000052144762,0.000007996747],"category_scores_gemma":[9.3930925e-7,0.00005684835,0.00004013084,0.000114301445,0.00021283879,0.00012349541,0.000004235398,0.00018966703,9.8746014e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004277872,0.00080108485,0.017062355,0.0000135082,0.00023032851,0.000057076628,0.04332803,0.000005582863,0.9259029,0.00027110317,0.00004794433,0.008002208],"study_design_scores_gemma":[0.010526213,0.0032466166,0.20953785,0.00014392423,0.0007555293,0.00047716146,0.038443834,0.0004952302,0.73347753,0.0011459452,0.0015711657,0.0001789827],"about_ca_topic_score_codex":0.000005697227,"about_ca_topic_score_gemma":0.000011211984,"teacher_disagreement_score":0.1924755,"about_ca_system_score_codex":0.000023811592,"about_ca_system_score_gemma":0.000031879856,"threshold_uncertainty_score":0.23182082},"labels":[],"label_agreement":null},{"id":"W2109046728","doi":"10.1371/journal.pone.0004724","title":"Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update","year":2009,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":960,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Drug resistance; HIV drug resistance; Resistance mutation; Drug; Mutation; Virology; Medicine; Resistance (ecology); Human immunodeficiency virus (HIV); Biology; Genetics; Pharmacology; Antiretroviral therapy; Gene; Viral load; Reverse transcriptase; Polymerase chain reaction","score_opus":0.0173285574361156,"score_gpt":0.23991080857804828,"score_spread":0.22258225114193267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109046728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85353345,0.0047125625,0.00135,0.124070324,0.000057874444,0.002858935,0.0005857877,0.0002985146,0.01253254],"genre_scores_gemma":[0.7136631,0.0002961522,0.04148069,0.0003373914,0.000070758004,0.00011330611,0.0006040093,0.00003067576,0.2434039],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843955,0.000039477225,0.00045580053,0.00032514505,0.0004180624,0.00032198086],"domain_scores_gemma":[0.9989746,0.00013879787,0.00014210236,0.0003333905,0.00028275623,0.00012835122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020525824,0.00020738713,0.00054249045,0.00012975755,0.000106562744,0.000011727744,0.000108360975,0.000050988438,0.00009658455],"category_scores_gemma":[0.00007873615,0.00019097679,0.00011752867,0.00034913854,0.000061780396,0.00007494196,0.000005283958,0.000100453646,0.00005860302],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009266855,0.030185616,0.050813366,0.005098167,0.005895502,0.00026227234,0.014566514,0.000014955524,0.052116003,0.010354839,0.81778187,0.003644035],"study_design_scores_gemma":[0.04489246,0.00029652138,0.15336251,0.00674,0.0038590776,0.000007684345,0.0009061124,0.00054485427,0.580257,0.016172945,0.19038098,0.0025798269],"about_ca_topic_score_codex":0.0000014368128,"about_ca_topic_score_gemma":0.00020218364,"teacher_disagreement_score":0.6274009,"about_ca_system_score_codex":0.000078877034,"about_ca_system_score_gemma":0.00012707167,"threshold_uncertainty_score":0.77878076},"labels":[],"label_agreement":null},{"id":"W2110215558","doi":"10.1097/qad.0b013e3282f5ff71","title":"Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute of Allergy and Infectious Diseases; National Center for Research Resources; National Institute of Mental Health; University of California, San Diego; Center for AIDS Research, University of Washington; U.S. Public Health Service; National Institutes of Health; International AIDS Society; U.S. Department of Veterans Affairs","keywords":"Drug resistance; Medicine; Population; HIV drug resistance; Cohort; Genotype; Virology; Cohort study; Resistance mutation; Human immunodeficiency virus (HIV); Internal medicine; Reverse transcriptase; Biology; Genetics; Viral load; Antiretroviral therapy; Polymerase chain reaction; Gene; Environmental health","score_opus":0.02660204158813506,"score_gpt":0.28693799180121515,"score_spread":0.2603359502130801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110215558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856868,0.0040781177,0.0020361794,0.0046785655,0.00011282172,0.0008062225,0.00005320669,0.000051782878,0.0024963506],"genre_scores_gemma":[0.84973115,0.00021501166,0.016830133,0.00011918587,0.000027094678,0.000047642647,0.000014328484,0.000023059407,0.13299237],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981854,0.000098173594,0.00056850933,0.00034524294,0.0005227677,0.00027989855],"domain_scores_gemma":[0.99874175,0.00023859587,0.00014918657,0.0006103522,0.00014078066,0.000119341494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026322596,0.00023499994,0.0005900671,0.0001281118,0.00010419863,0.0000050504564,0.00031372125,0.000048460963,0.00012313863],"category_scores_gemma":[0.00005914789,0.00016284364,0.00014360288,0.0004080156,0.00022525014,0.00007069868,0.000047471753,0.00015913005,0.000032182026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023716893,0.0011222168,0.81228167,0.0023494044,0.0005723396,0.00013581454,0.07273829,0.000006401827,0.006087112,0.00033974805,0.09693297,0.0050623673],"study_design_scores_gemma":[0.0055349725,0.00027959398,0.32791817,0.0037081975,0.0009785529,0.00003890719,0.0016190794,0.00027998094,0.5800953,0.0002467834,0.07850824,0.00079221],"about_ca_topic_score_codex":0.000010321612,"about_ca_topic_score_gemma":0.00008622186,"teacher_disagreement_score":0.57400817,"about_ca_system_score_codex":0.00007788138,"about_ca_system_score_gemma":0.00011229073,"threshold_uncertainty_score":0.66405714},"labels":[],"label_agreement":null},{"id":"W2110280683","doi":"10.1086/313861","title":"Clinical Utility of Testing Human Immunodeficiency Virus for Drug Resistance","year":2000,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Medicine; Drug resistance; HIV drug resistance; Intensive care medicine; Clinical trial; Drug; Human immunodeficiency virus (HIV); Clinical study design; Antiretroviral therapy; Immunology; Internal medicine; Viral load; Pharmacology","score_opus":0.15843402043783736,"score_gpt":0.47341921341310933,"score_spread":0.31498519297527194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110280683","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016087634,0.98641914,0.000020255764,0.000036776626,0.00052661134,0.002677914,0.00042779848,0.00022743593,0.008055282],"genre_scores_gemma":[0.0014655426,0.9851291,0.00030192942,0.00007513239,0.00053469156,0.00040190734,0.0006219968,0.00009630319,0.011373395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99327475,0.00060289237,0.004158439,0.00110068,0.00036327718,0.0004999732],"domain_scores_gemma":[0.9906745,0.0062213847,0.0012849761,0.0010577111,0.00031976882,0.0004416393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014418255,0.0006448853,0.0045874813,0.00018266543,0.00027965356,0.00003118511,0.00028978623,0.0004946182,0.00035911083],"category_scores_gemma":[0.0044167964,0.00049326057,0.0030663025,0.0005224918,0.00068553386,0.00006036443,0.000109429515,0.00068271114,0.00013066303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009855818,0.0058255647,0.05500871,0.014549867,0.0009460072,0.000041742787,0.000012112325,4.373137e-8,3.498773e-8,0.000058104535,0.01364613,0.9098131],"study_design_scores_gemma":[0.0021832827,0.00037435172,0.008534544,0.013658843,0.0073217615,0.000006316053,0.000004371405,0.0000041588437,2.703699e-7,0.00048627748,0.9669628,0.00046302393],"about_ca_topic_score_codex":0.000011273491,"about_ca_topic_score_gemma":0.000028021015,"teacher_disagreement_score":0.9533167,"about_ca_system_score_codex":0.00010933716,"about_ca_system_score_gemma":0.0014575971,"threshold_uncertainty_score":0.9997519},"labels":[],"label_agreement":null},{"id":"W2110471430","doi":"10.1186/1742-4690-10-22","title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","year":2013,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Dolutegravir; Integrase; Integrase inhibitor; Drug resistance; Virology; Medicine; Drug; Antiretroviral therapy; HIV drug resistance; Mutation; Viral evolution; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Genetics; Biology; Gene; Genome","score_opus":0.00948701864596269,"score_gpt":0.24761254318751116,"score_spread":0.23812552454154848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110471430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988921,0.0006935148,0.00015542029,0.004987262,0.00034432314,0.001044143,0.0000499415,0.00012599846,0.0036783929],"genre_scores_gemma":[0.91148937,0.00005081872,0.0015206051,0.00050472794,0.00024904805,0.00020955251,0.0003763474,0.000036877787,0.085562676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983378,0.00011680197,0.00032444202,0.00047150892,0.00025497694,0.0004944542],"domain_scores_gemma":[0.9990846,0.00011956134,0.0001070869,0.00041295125,0.000054586668,0.00022122575],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000112583104,0.00026984338,0.00050190085,0.00012633932,0.00010275906,0.00002554026,0.00016406542,0.000202549,0.0027632918],"category_scores_gemma":[0.00005340426,0.00021624743,0.0001185631,0.00011408018,0.00009771176,0.0001456614,0.000097566786,0.0002983218,0.002491192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028682422,0.0005484227,0.8690114,0.00007453554,0.0010212064,0.00017885558,0.0013533013,0.000011476635,0.009131456,0.00029687493,0.1036877,0.0143979145],"study_design_scores_gemma":[0.00961812,0.000321453,0.7168429,0.00018175821,0.0010794107,0.00009353709,0.00023559852,0.0015768947,0.0067993575,0.001848326,0.26069495,0.0007076683],"about_ca_topic_score_codex":0.00023961099,"about_ca_topic_score_gemma":0.000018170183,"teacher_disagreement_score":0.15700726,"about_ca_system_score_codex":0.00009928858,"about_ca_system_score_gemma":0.000080662554,"threshold_uncertainty_score":0.9982855},"labels":[],"label_agreement":null},{"id":"W2110687378","doi":"10.1128/aac.01447-05","title":"Impact of Human Immunodeficiency Virus Type 1 Subtype C on Drug Resistance Mutations in Patients from Botswana Failing a Nelfinavir-Containing Regimen","year":2006,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Nelfinavir; Regimen; Virology; Drug resistance; Medicine; Drug; Human immunodeficiency virus (HIV); Lentivirus; Sida; Biology; Pharmacology; Viral disease; Internal medicine; Microbiology; Viral load; Antiretroviral therapy","score_opus":0.010297826575517905,"score_gpt":0.2697256651415454,"score_spread":0.25942783856602747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110687378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981641,0.000057018202,0.0000035682197,0.00043309867,0.000035540488,0.00027521473,0.000024220712,0.000018162127,0.0009890299],"genre_scores_gemma":[0.99658704,0.00008532178,0.00035607044,0.00025657748,0.00002228848,0.0000029798894,0.00030567584,0.000024282717,0.0023597858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903834,0.000022059028,0.00031543453,0.0002596263,0.0001363348,0.00022823138],"domain_scores_gemma":[0.9995706,0.00002132403,0.00013324954,0.00016650574,0.0000625725,0.000045713416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006885256,0.00017999299,0.00030207008,0.00012303212,0.0001026971,0.000020735204,0.00006008543,0.000054463108,0.00008883763],"category_scores_gemma":[0.00000796116,0.00014946453,0.00007755403,0.00021113953,0.000049534097,0.00006119765,0.000012889035,0.000091314934,0.000008740383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010818603,0.0012775245,0.9630309,0.000017351364,0.00014035476,0.000017388225,0.0020297202,0.000009770123,0.02397495,0.000038707352,0.0073218993,0.001059627],"study_design_scores_gemma":[0.00571659,0.00022611796,0.9845054,0.0002545772,0.00003951526,5.9059096e-7,0.00005786756,0.000014221773,0.008161709,0.00010083709,0.0007456321,0.0001769276],"about_ca_topic_score_codex":0.0016212427,"about_ca_topic_score_gemma":0.00017660279,"teacher_disagreement_score":0.021474566,"about_ca_system_score_codex":0.00012347099,"about_ca_system_score_gemma":0.00007793763,"threshold_uncertainty_score":0.6094986},"labels":[],"label_agreement":null},{"id":"W2111172881","doi":"10.1186/1758-2652-8-2-36","title":"Efficacy, Safety and Pharmacokinetics of Once‐Daily Saquinavir Soft‐Gelatin Capsule/Ritonavir in Antiretroviral‐Naive, HIV‐Infected Patients","year":2006,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Saquinavir; Efavirenz; Medicine; Ritonavir; Pharmacokinetics; Internal medicine; Population; Pharmacology; Adverse effect; Gastroenterology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.006755406053565435,"score_gpt":0.2511666038837161,"score_spread":0.24441119783015064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111172881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962602,0.0001523569,0.000084684434,0.002015076,0.00036825347,0.00020268274,0.000038500537,0.000007559345,0.00087064115],"genre_scores_gemma":[0.99278396,0.00017276051,0.0030351034,0.0001528289,0.00019041821,0.0000014737558,0.000033415694,0.000016132028,0.0036138853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812275,0.000052486383,0.00078051735,0.00014060854,0.00073915685,0.00016450846],"domain_scores_gemma":[0.9987865,0.0001220936,0.0005550084,0.00010498886,0.0003689749,0.00006243791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030252745,0.00017284809,0.00035735453,0.0000947265,0.000056687193,0.000018030012,0.00021642233,0.00008183665,0.00005884975],"category_scores_gemma":[0.000100594945,0.000116326366,0.00032763922,0.00023213058,0.00012215208,0.00013517437,0.00010877671,0.00034993017,0.0000034964405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045921223,0.0009998108,0.9773161,0.000027597034,0.00038556763,0.000014708184,0.00053575466,0.00020830071,0.008172204,0.00006514439,0.008210659,0.0036049858],"study_design_scores_gemma":[0.0109645175,0.00024316256,0.972127,0.00037308433,0.00018664416,0.000046092562,0.000092313276,0.0008908668,0.008452992,0.00010332861,0.0063914848,0.00012846889],"about_ca_topic_score_codex":0.000035094865,"about_ca_topic_score_gemma":0.0000039622173,"teacher_disagreement_score":0.010505306,"about_ca_system_score_codex":0.0003505407,"about_ca_system_score_gemma":0.00013892242,"threshold_uncertainty_score":0.47436514},"labels":[],"label_agreement":null},{"id":"W2111257615","doi":"10.1086/644768","title":"Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy–Experienced Patients with HIV Infection in North America","year":2009,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University; University of Calgary; Simon Fraser University","funders":"National Institute of Allergy and Infectious Diseases; National Center for Research Resources; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; U.S. Public Health Service; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Regimen; Internal medicine; Proportional hazards model; Viral load; Mortality rate; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.02073094666257519,"score_gpt":0.3231218992976396,"score_spread":0.30239095263506444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111257615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871886,0.0000814925,0.000005263801,0.0001765223,0.00005993501,0.0006486804,0.000022252574,0.00010855179,0.00017846866],"genre_scores_gemma":[0.9985265,0.0005083058,0.000025098323,0.00016582185,0.000051769926,0.00011916587,0.00040967387,0.000017335922,0.00017631317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981615,0.00014291506,0.00057646516,0.0005549725,0.00023237005,0.00033177235],"domain_scores_gemma":[0.9991407,0.00008656035,0.00015347649,0.00026389718,0.00005540471,0.0002999744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006333984,0.00032370145,0.00062780536,0.0003144387,0.00007655222,0.000032915304,0.000036342622,0.00009648397,0.00005206369],"category_scores_gemma":[0.00006853854,0.0002228072,0.00015530847,0.0006711914,0.00023828358,0.000208762,0.000015901393,0.00017640438,0.000007619288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002531292,0.006043483,0.93221545,0.000006298563,0.000100424535,0.000117174925,0.00045399024,0.00002244286,9.342993e-7,0.000002502769,0.00004168002,0.06074248],"study_design_scores_gemma":[0.010757066,0.0029568868,0.98551947,0.000052941,0.00010219444,0.0000013479699,0.00004617446,0.000119397104,0.000009708079,0.000011301516,0.00018908888,0.00023441459],"about_ca_topic_score_codex":0.0004053091,"about_ca_topic_score_gemma":0.004540105,"teacher_disagreement_score":0.060508065,"about_ca_system_score_codex":0.00028374788,"about_ca_system_score_gemma":0.000085347376,"threshold_uncertainty_score":0.90858144},"labels":[],"label_agreement":null},{"id":"W2111884657","doi":"10.1310/hct1306-335","title":"Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Abacavir; Darunavir; Emtricitabine; Lamivudine; Regimen; Ritonavir; Internal medicine; Gastroenterology; Viral load; Creatinine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Hepatitis B virus; Virus","score_opus":0.17419158608269425,"score_gpt":0.4424751159049179,"score_spread":0.26828352982222364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111884657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95611507,0.002858878,0.00093399547,0.026552523,0.0007419895,0.0077295243,0.00016440869,0.0002746171,0.0046289735],"genre_scores_gemma":[0.96252054,0.0014219383,0.0099937515,0.0008413733,0.0011657448,0.00049689226,0.00079195783,0.00008994035,0.022677844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996468,0.0006923368,0.0014680673,0.0005023481,0.00038347326,0.00048576482],"domain_scores_gemma":[0.9936095,0.0048454227,0.0005065991,0.000418772,0.00015602972,0.0004636967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060703023,0.00035688197,0.0015078897,0.00011796348,0.0001587894,0.000037619793,0.000097251934,0.00028680565,0.00013037212],"category_scores_gemma":[0.0022355975,0.00023034531,0.0002998275,0.00018732496,0.0001770894,0.00015961987,0.000041816565,0.00026687697,0.00015201721],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04579486,0.012956826,0.3058602,0.00024387224,0.00435702,0.000098330805,0.0019785175,0.0000014223632,0.0014860604,0.004061403,0.07940871,0.5437528],"study_design_scores_gemma":[0.20441689,0.005160019,0.252421,0.00056836003,0.0021392587,0.0001226286,0.0003375295,0.0002187961,0.0034350306,0.00066411623,0.529419,0.001097385],"about_ca_topic_score_codex":0.0000028680183,"about_ca_topic_score_gemma":0.0000019795264,"teacher_disagreement_score":0.5426554,"about_ca_system_score_codex":0.00006916757,"about_ca_system_score_gemma":0.00014102847,"threshold_uncertainty_score":0.9393209},"labels":[],"label_agreement":null},{"id":"W2112289092","doi":"10.1089/apc.2015.0199","title":"The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients","year":2015,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Hip and Knee Clinic","funders":"University of Calgary; Alberta Health Services","keywords":"Polypharmacy; Medicine; Pill; Antiretroviral therapy; Dosing; Adverse effect; Human immunodeficiency virus (HIV); Pediatrics; Internal medicine; Pharmacology; Viral load; Family medicine","score_opus":0.014704366892456246,"score_gpt":0.28435650810092067,"score_spread":0.2696521412084644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112289092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415,0.00047871197,0.0000025748047,0.00002169046,0.0001326047,0.0007157389,0.000067136425,0.000013741172,0.004417808],"genre_scores_gemma":[0.9989726,0.00015176088,0.000034765853,0.000038617756,0.0000326122,0.000021839616,0.00008788481,0.000018906763,0.00064101623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985192,0.00010153784,0.00039068342,0.00020651154,0.0005091825,0.00027287548],"domain_scores_gemma":[0.9988133,0.00013777925,0.0002319717,0.00033327905,0.00034078577,0.00014291618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018093818,0.00023887177,0.00038826308,0.00008861923,0.0001253761,0.000021091533,0.000121963145,0.00005853889,0.000019093424],"category_scores_gemma":[0.000072763854,0.00011012883,0.00023008492,0.00020811702,0.00024331058,0.000084140884,0.000060695642,0.00014716164,0.000010094191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006350238,0.00023165897,0.8040838,0.000010864962,0.00022670018,0.000003855085,0.0048108934,7.89345e-7,0.00009085162,0.000041122712,0.0037678666,0.18609655],"study_design_scores_gemma":[0.013506267,0.18188982,0.7739779,0.00027853064,0.0002425782,0.0000031144161,0.005252157,0.0001459388,0.022860905,0.00004587969,0.0013927312,0.00040420808],"about_ca_topic_score_codex":0.00018629932,"about_ca_topic_score_gemma":0.0000052758282,"teacher_disagreement_score":0.18569234,"about_ca_system_score_codex":0.00009554921,"about_ca_system_score_gemma":0.00014831331,"threshold_uncertainty_score":0.44909233},"labels":[],"label_agreement":null},{"id":"W2112519486","doi":"10.1182/blood-2009-02-205153","title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University; Hamilton Health Sciences; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"EIF4E; Ribavirin; Myeloid leukemia; Cancer research; Leukemia; Medicine; Myeloid; Clinical trial; Acute leukemia; Initiation factor; Translation (biology); Biology; Oncology; Immunology; Internal medicine; Messenger RNA; Gene; Genetics; Virus","score_opus":0.018673705328499574,"score_gpt":0.3086300032636587,"score_spread":0.2899562979351591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112519486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996565,0.00022813158,0.00003484509,0.0006711077,0.00005378675,0.0010284716,0.000004145172,0.00001570581,0.0013987981],"genre_scores_gemma":[0.9940372,0.00002398615,0.0050458875,0.00009341443,0.000069643575,0.000027613749,0.000015534264,0.0000150112155,0.0006717169],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841577,0.00009798075,0.0006603044,0.00025552043,0.00034764194,0.00022280573],"domain_scores_gemma":[0.9992497,0.000052720436,0.00022422348,0.00033268728,0.00006266788,0.00007797615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045735142,0.00016055822,0.0004924133,0.00006996502,0.000027520307,0.0000042958823,0.0001395335,0.00010009887,0.000012824806],"category_scores_gemma":[0.0001312638,0.00009609116,0.0001591786,0.00031678044,0.00007048727,0.000029570794,0.00004882726,0.00020357248,0.000003427191],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06082346,0.025993897,0.7317359,0.00029417462,0.0045181187,0.0026143517,0.0031665845,0.00018425997,0.1212211,0.000987631,0.0007387442,0.04772179],"study_design_scores_gemma":[0.1521902,0.0029388473,0.045908097,0.00043776198,0.0011243267,0.000048651582,0.00006052506,0.00005666213,0.79512435,0.00010137225,0.001764612,0.00024461],"about_ca_topic_score_codex":0.000008750643,"about_ca_topic_score_gemma":0.0000102673,"teacher_disagreement_score":0.6858278,"about_ca_system_score_codex":0.000056921966,"about_ca_system_score_gemma":0.0005869697,"threshold_uncertainty_score":0.39184836},"labels":[],"label_agreement":null},{"id":"W2112697477","doi":"10.1007/s10495-007-0755-3","title":"HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo","year":2007,"lang":"en","type":"review","venue":"APOPTOSIS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institutes of Health; National Institute of Allergy and Infectious Diseases; Mayo Foundation for Medical Education and Research","keywords":"Protease; Apoptosis; Biology; In vivo; Enzyme; Biochemistry","score_opus":0.03324303604070666,"score_gpt":0.3068117189763224,"score_spread":0.27356868293561576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112697477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029554326,0.96526855,0.000008846289,0.00032564267,0.00014478677,0.0036821791,0.00004054689,0.00008829813,0.000886838],"genre_scores_gemma":[0.0043343045,0.98861545,0.0024970726,0.00007192938,0.00016661218,0.00074263656,0.0002026653,0.00012597442,0.0032433395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967481,0.00013219289,0.0011880645,0.000833427,0.00041855875,0.0006796711],"domain_scores_gemma":[0.9988173,0.00019197738,0.00027051984,0.0003859451,0.000041899217,0.00029233904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005991675,0.00074217806,0.0023395794,0.0013965074,0.00006201172,0.00003945236,0.00012723298,0.0005049528,0.000086213586],"category_scores_gemma":[0.00008798102,0.00060527516,0.0003490294,0.0011007689,0.00006849885,0.00010551559,0.00011969436,0.00062579487,0.00008126954],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019067494,0.0006819978,0.0019323669,0.015691116,0.00047099564,0.00015627897,0.00059127936,0.0000014093632,0.00061966747,0.0000091380125,0.0008795486,0.9787755],"study_design_scores_gemma":[0.0035810985,0.00007595802,0.000026999585,0.04594509,0.0017150433,0.00004794723,0.00015287883,0.00002493423,0.040365033,0.000028628068,0.90670145,0.0013349669],"about_ca_topic_score_codex":0.00007902421,"about_ca_topic_score_gemma":0.0000069283597,"teacher_disagreement_score":0.97744054,"about_ca_system_score_codex":0.0005978323,"about_ca_system_score_gemma":0.00028285474,"threshold_uncertainty_score":0.99963987},"labels":[],"label_agreement":null},{"id":"W2113596204","doi":"10.1093/jac/dku387","title":"Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance","year":2014,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Dolutegravir; Raltegravir; Elvitegravir; Integrase; Integrase inhibitor; Virology; Drug resistance; Medicine; Pharmacology; Biology; Genetics; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.007377258439793518,"score_gpt":0.2325686694543317,"score_spread":0.22519141101453818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113596204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991556,0.00030875605,0.0019292042,0.0054924837,0.00009693036,0.00025525113,0.0000041123244,0.000008124503,0.00034916805],"genre_scores_gemma":[0.94600815,0.000091695176,0.051943347,0.00030839277,0.000074309915,0.0000020153802,9.299386e-7,0.00002405383,0.0015471171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986587,0.00003907571,0.00063380797,0.00018791869,0.00024896988,0.00023151745],"domain_scores_gemma":[0.9991345,0.0000650133,0.0003696553,0.00014136973,0.00016752064,0.00012193841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042514974,0.00017830447,0.00052448973,0.00032043483,0.000045615125,0.000017980235,0.00008139711,0.000058976788,0.0000055382447],"category_scores_gemma":[0.00007539413,0.0001444008,0.00010316493,0.00026792273,0.000049723556,0.00010525266,0.000017448392,0.00017928774,0.0000016850079],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030407726,0.000906961,0.01998759,0.00026019846,0.00013360396,0.00005863645,0.007558124,0.000031382388,0.96134335,0.00028610975,0.0043963655,0.0019969146],"study_design_scores_gemma":[0.023962842,0.00039045615,0.03665285,0.007665129,0.000098821896,0.0001532736,0.0004672742,0.0001766386,0.87150323,0.00015465125,0.058184847,0.0005899693],"about_ca_topic_score_codex":0.0000122084475,"about_ca_topic_score_gemma":0.00021906426,"teacher_disagreement_score":0.08984009,"about_ca_system_score_codex":0.00030297108,"about_ca_system_score_gemma":0.00012796413,"threshold_uncertainty_score":0.5888493},"labels":[],"label_agreement":null},{"id":"W2113780394","doi":"10.1371/journal.pmed.1001196","title":"No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial","year":2012,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Stichting Sanquin Bloedvoorziening; Universiteit Maastricht; Universitair Medisch Centrum Utrecht; Erasmus Medisch Centrum; Leids Universitair Medisch Centrum; Maastricht Universitair Medisch Centrum","keywords":"Cart; Medicine; Randomized controlled trial; Randomization; Clinical endpoint; Viral load; Intention-to-treat analysis; Internal medicine; Antiretroviral therapy; Surgery; Human immunodeficiency virus (HIV); Immunology","score_opus":0.04625949345079913,"score_gpt":0.29148481466275783,"score_spread":0.2452253212119587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113780394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96900475,0.0018545563,0.000010925656,0.004049207,0.0021182252,0.004512212,0.000011544484,0.0001510238,0.018287538],"genre_scores_gemma":[0.90140224,0.003952375,0.0004958541,0.00011213993,0.0038685657,0.00094932126,0.00025714966,0.0000720238,0.08889034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99721617,0.0002592661,0.00088941376,0.0003594225,0.0007064528,0.00056926534],"domain_scores_gemma":[0.9977638,0.0008824286,0.00033912386,0.00057859125,0.00012154231,0.00031452836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004796985,0.00052178605,0.0017896653,0.00023554408,0.00019354495,0.000009183804,0.00009071242,0.00013397087,0.0009806176],"category_scores_gemma":[0.00045410014,0.0002299299,0.0003788382,0.00027180914,0.00036692337,0.00013332693,0.000044773176,0.0001535212,0.00020669996],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.958437,0.0051913206,0.01651451,0.00024059622,0.005388449,0.00018548491,0.0051744943,7.8086356e-7,0.0017332354,0.00006377803,0.0016365629,0.005433766],"study_design_scores_gemma":[0.9521869,0.008563418,0.0038647417,0.00038957683,0.0051029013,0.00005307991,0.00018437825,0.000032507578,0.009691924,0.0000038108585,0.019677844,0.0002489356],"about_ca_topic_score_codex":0.00015376357,"about_ca_topic_score_gemma":0.000019735064,"teacher_disagreement_score":0.0706028,"about_ca_system_score_codex":0.0009685862,"about_ca_system_score_gemma":0.0003063009,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W2113908393","doi":"10.18433/j3ns3x","title":"Interactions between Phytochemical Components of Sutherlandia Frutescens and the Antiretroviral, Atazanavir In Vitro: Implications for Absorption and Metabolism","year":2012,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medical Research Council; Rhodes University; National Research Foundation; Atlantic Philanthropies","keywords":"Atazanavir; Phytochemical; Glycoside; Chemistry; Microsome; Biochemistry; Traditional medicine; Chromatography; Biology; In vitro; Organic chemistry; Medicine","score_opus":0.09578712185318233,"score_gpt":0.41743719254662265,"score_spread":0.3216500706934403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113908393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864626,0.002766004,0.00013228488,0.01007915,0.00010892236,0.0003342131,0.000022740109,0.000004054012,0.000090066285],"genre_scores_gemma":[0.9973339,0.0007824265,0.0014690225,0.00014755313,0.0002158931,0.000011693848,0.0000061200526,0.0000050562003,0.000028363393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989587,0.000072352515,0.00042897766,0.000107727115,0.0002032535,0.00022898255],"domain_scores_gemma":[0.999001,0.0004731929,0.00019341361,0.000047987425,0.000074817704,0.00020957881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093175756,0.000104099185,0.0003251536,0.00014139587,0.00011115372,0.000021267468,0.000097231874,0.000018862,0.000017711434],"category_scores_gemma":[0.00007951307,0.000059783237,0.000088078006,0.000223682,0.00048572422,0.000310486,0.00003964156,0.00019588882,0.0000010409163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008353232,0.00036496375,0.65741813,0.000046561236,0.000161092,0.0000010430384,0.000690437,4.5951916e-7,0.305584,0.00040111048,0.0002154512,0.0342814],"study_design_scores_gemma":[0.024499808,0.000116132636,0.6776011,0.00016015403,0.0016809086,0.00029737453,0.0003920446,0.0020641899,0.2254538,0.0005944477,0.066886954,0.00025308842],"about_ca_topic_score_codex":0.000012491594,"about_ca_topic_score_gemma":4.6228433e-7,"teacher_disagreement_score":0.080130234,"about_ca_system_score_codex":0.000031903197,"about_ca_system_score_gemma":0.000043742017,"threshold_uncertainty_score":0.24378897},"labels":[],"label_agreement":null},{"id":"W2113999479","doi":"10.1093/jac/dkt204","title":"The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites","year":2013,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Mutation; Genetics; Biology; Virology; Single-nucleotide polymorphism; Thymidine; Nucleotide; Human immunodeficiency virus (HIV); Selection (genetic algorithm); Molecular biology; Genotype; DNA; Gene","score_opus":0.008312833761768263,"score_gpt":0.23210005325623848,"score_spread":0.22378721949447022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113999479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843064,0.00014626535,0.00005798374,0.015007293,0.0000886631,0.00028458558,0.000009239372,0.000009546396,0.00009005097],"genre_scores_gemma":[0.9940596,0.0006607833,0.0007432044,0.00049169705,0.00009681622,0.0000021629708,0.000058969763,0.000026485299,0.0038602569],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987694,0.000049462284,0.00060559943,0.00013084253,0.00023370101,0.00021096416],"domain_scores_gemma":[0.999023,0.000051710023,0.0004822564,0.00009852238,0.0002740364,0.00007046601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001872545,0.00016653936,0.00035723063,0.00017531923,0.00008433029,0.000028687156,0.00009616328,0.00008843507,0.0005909898],"category_scores_gemma":[0.000019873143,0.0001089691,0.00014179334,0.000299943,0.00006461501,0.00014700425,0.000012969073,0.00017019449,0.000044723365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078658876,0.0003073,0.07819772,0.000015435808,0.00026552874,0.000007166865,0.00063090207,0.00000473491,0.783957,0.0000023486252,0.13462298,0.0012023115],"study_design_scores_gemma":[0.0049823145,0.00027650315,0.04945119,0.00013554706,0.0000803261,0.00016505453,0.00005877064,0.00022584308,0.94066167,0.000023140401,0.0038120085,0.0001276505],"about_ca_topic_score_codex":0.00006441924,"about_ca_topic_score_gemma":0.000047695274,"teacher_disagreement_score":0.15670466,"about_ca_system_score_codex":0.0001750116,"about_ca_system_score_gemma":0.000098558645,"threshold_uncertainty_score":0.64709234},"labels":[],"label_agreement":null},{"id":"W2114211214","doi":"10.1128/aac.00093-06","title":"Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects","year":2006,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Nevirapine; Ritonavir; Amprenavir; Regimen; Pharmacology; Medicine; Virology; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Antiretroviral therapy; Biology; Protease; HIV-1 protease","score_opus":0.011871262026462853,"score_gpt":0.2685214373089335,"score_spread":0.2566501752824707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114211214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977949,0.00013867494,0.00003063688,0.0011056899,0.000021133132,0.00039117958,0.000007954432,0.000038155675,0.0004716265],"genre_scores_gemma":[0.9972453,0.0007071922,0.00040167107,0.00042504325,0.00005791996,0.000008027621,0.00011852526,0.000028758708,0.0010075584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990722,0.00002227617,0.00023866385,0.00033526646,0.00010098379,0.00023060129],"domain_scores_gemma":[0.9997152,0.000013468431,0.00007692367,0.000110965135,0.000026658883,0.00005678588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071451424,0.00023387173,0.00034449593,0.0001420044,0.00013239578,0.00005813076,0.000030433173,0.00007885906,0.000030754305],"category_scores_gemma":[0.0000015313863,0.00017786962,0.000025433445,0.00015212635,0.000112402704,0.00013482521,0.000024349034,0.00013116626,0.0000020971897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019062779,0.00031364118,0.9408855,0.000052188192,0.00008903782,0.000016427395,0.00048037927,3.3315828e-7,0.049413458,0.000016852282,0.0005242705,0.008017282],"study_design_scores_gemma":[0.007851072,0.00026396787,0.95196396,0.00031196367,0.00008454312,0.00007107267,0.00004233279,0.000020996655,0.03188053,0.000034472334,0.0072108614,0.00026421674],"about_ca_topic_score_codex":0.0007047646,"about_ca_topic_score_gemma":0.00018497558,"teacher_disagreement_score":0.017532924,"about_ca_system_score_codex":0.00003490519,"about_ca_system_score_gemma":0.000020727639,"threshold_uncertainty_score":0.72533125},"labels":[],"label_agreement":null},{"id":"W2115212891","doi":"10.1371/journal.pmed.0040335","title":"N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance","year":2007,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Health and Medical Research Council; National Institute of General Medical Sciences; Medical Research Council; National Institutes of Health; National Science Council; Monash University","keywords":"Nevirapine; Zidovudine; Reverse transcriptase; Virology; Human immunodeficiency virus (HIV); Drug resistance; Reverse-transcriptase inhibitor; Medicine; Nucleoside Reverse Transcriptase Inhibitor; Biology; Antiretroviral therapy; Genetics; Viral disease; Viral load; Polymerase chain reaction","score_opus":0.023467970569917947,"score_gpt":0.26466254150507035,"score_spread":0.2411945709351524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115212891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90638,0.0031658448,0.00051014434,0.07481173,0.00013049925,0.0010865773,0.000012663998,0.000040671654,0.013861852],"genre_scores_gemma":[0.9927092,0.0005762389,0.0011129444,0.0012095877,0.00014299901,0.000019588719,0.00008147541,0.000015793314,0.004132178],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985993,0.00006219828,0.00047405664,0.00022815462,0.00040052296,0.00023580596],"domain_scores_gemma":[0.9992735,0.00020881994,0.00009981221,0.00023573264,0.000072311865,0.00010983839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010327424,0.0001714743,0.00043526827,0.00023460099,0.000049534643,0.0000025425788,0.00006413379,0.00006448222,0.00017829423],"category_scores_gemma":[0.00018260918,0.00010376189,0.00003713393,0.00040988342,0.00025934097,0.000049987266,0.0000077233135,0.00017727028,0.0000078260155],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008841691,0.0045591467,0.34770638,0.0035585046,0.0016995054,0.004973142,0.095169686,0.0000017484289,0.27537727,0.021952571,0.22488633,0.011274022],"study_design_scores_gemma":[0.07389334,0.002525286,0.27941877,0.007718523,0.002205087,0.0004486747,0.0487757,0.000098324286,0.038513236,0.002358908,0.5431061,0.00093807385],"about_ca_topic_score_codex":0.000031718697,"about_ca_topic_score_gemma":0.00014593922,"teacher_disagreement_score":0.31821975,"about_ca_system_score_codex":0.000062951105,"about_ca_system_score_gemma":0.00004027292,"threshold_uncertainty_score":0.4231287},"labels":[],"label_agreement":null},{"id":"W2115230664","doi":"10.1016/j.jval.2014.03.1639","title":"Real World Drug Utilization Of Hiv Therapies In Canada","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Cohort; Medicine; Darunavir; Pharmacy; Internal medicine; Pediatrics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Family medicine","score_opus":0.03396572503607699,"score_gpt":0.28732043045250916,"score_spread":0.2533547054164322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115230664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860735,0.00032305575,0.000016866605,0.010575466,0.00008964045,0.0003148289,0.0000032405346,0.00001052422,0.0025928624],"genre_scores_gemma":[0.9955028,0.00037123534,0.0010107758,0.00023021811,0.00002164093,0.000010220759,0.000027017311,0.000008790488,0.0028172857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908006,0.00011628695,0.0003327751,0.00011831703,0.00017648746,0.00017607717],"domain_scores_gemma":[0.99962497,0.00009552196,0.00007546773,0.00011971639,0.00001835666,0.00006596847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036209135,0.00007193666,0.00023799327,0.00017146494,0.000016579786,0.000001495862,0.000032547494,0.000012788841,0.000033739892],"category_scores_gemma":[0.000024085339,0.000059996448,0.000012853247,0.0003016709,0.000011291989,0.000019158577,0.000007711224,0.00006866506,0.0000034939753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003772588,0.00007994472,0.98417425,0.00017684829,0.000009503198,0.0000063716966,0.0026670606,0.00024361812,0.00000586818,0.001387829,0.0018809161,0.009330055],"study_design_scores_gemma":[0.0025269422,0.000050391285,0.9680562,0.0007715748,0.000006659623,0.0000018439135,0.00081540237,0.0075843697,0.00043892275,0.0005765706,0.019058237,0.000112859234],"about_ca_topic_score_codex":0.9010486,"about_ca_topic_score_gemma":0.9362356,"teacher_disagreement_score":0.035187032,"about_ca_system_score_codex":0.000734555,"about_ca_system_score_gemma":0.0016642039,"threshold_uncertainty_score":0.29522264},"labels":[],"label_agreement":null},{"id":"W2115454452","doi":"10.2174/157016211795945232","title":"Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PITreated Patients After 2 mos. of BID Induction","year":2011,"lang":"en","type":"article","venue":"Current HIV Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Tolerability; Nevirapine; Regimen; Medicine; Adverse effect; Internal medicine; Toxicity; Clinical endpoint; Gastroenterology; Cohort; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Randomized controlled trial; Immunology","score_opus":0.12207361070884193,"score_gpt":0.3763719483886481,"score_spread":0.2542983376798062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115454452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956039,0.00059725705,0.000018359458,0.00055139104,0.00019002336,0.0011126668,0.00001593877,0.00008286528,0.0018275871],"genre_scores_gemma":[0.9969014,0.0005448662,0.0001444379,0.00001290931,0.00007829585,0.00026918453,0.00034875105,0.000051513794,0.0016486208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974088,0.00025958137,0.0005126406,0.00045787275,0.000873039,0.0004880387],"domain_scores_gemma":[0.998621,0.00007048331,0.000102097576,0.00044701825,0.00055390707,0.0002054905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072097103,0.00020346751,0.000331489,0.00084139366,0.00004952051,0.0000149692905,0.00015546713,0.00011917304,0.0004283071],"category_scores_gemma":[0.0002537849,0.00016719304,0.000074842355,0.0010946983,0.00016570663,0.00018066919,0.00010248809,0.00047284583,0.0005619041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016704196,0.0030652694,0.8995858,0.00021558987,0.00008787379,0.000026539645,0.005478366,3.2697247e-7,0.0007279452,0.0001111398,0.006012668,0.08301809],"study_design_scores_gemma":[0.0040109684,0.0005888052,0.96063435,0.0005096329,0.00004972184,0.000001884615,0.00026645666,0.000057276364,0.01219814,0.00018923152,0.021299135,0.0001944249],"about_ca_topic_score_codex":0.000107887565,"about_ca_topic_score_gemma":0.000021977286,"teacher_disagreement_score":0.08282366,"about_ca_system_score_codex":0.00030701802,"about_ca_system_score_gemma":0.00023989947,"threshold_uncertainty_score":0.72223276},"labels":[],"label_agreement":null},{"id":"W2115713173","doi":"10.1586/14789072.2.5.671","title":"Efavirenz for HIV-1 infection in adults: an overview","year":2004,"lang":"en","type":"review","venue":"Expert Review of Anti-infective Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Efavirenz; Human immunodeficiency virus (HIV); Virology; Medicine; Antiretroviral therapy; Viral load","score_opus":0.05617184678986189,"score_gpt":0.4116185440108182,"score_spread":0.35544669722095634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115713173","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006467915,0.9905058,0.00007349094,0.00020074913,0.00026406586,0.008483585,0.000060041562,0.000083474915,0.0002640927],"genre_scores_gemma":[0.0000059756603,0.9946555,0.00095026044,0.00038701054,0.00027772633,0.0021673297,0.0012332016,0.00014048797,0.00018249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965122,0.00037371405,0.0014844728,0.00082815223,0.00035829062,0.00044320352],"domain_scores_gemma":[0.997874,0.00018167181,0.0007709958,0.0007282201,0.0002801676,0.00016493005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063457206,0.00091935054,0.0049571414,0.0004824923,0.00006937576,0.00001467619,0.00018064673,0.00034779514,0.00027807817],"category_scores_gemma":[0.000113384835,0.00062987796,0.001533906,0.00086568366,0.00009394532,0.00020744448,0.000035912966,0.0003447003,0.00008067324],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054176613,0.0012824484,0.0002991762,0.17930977,0.0005573055,0.000016818374,0.0002915037,4.7565393e-8,0.0000010634635,0.0001926276,0.00085784536,0.81713724],"study_design_scores_gemma":[0.0022238814,0.00048604404,0.00021588801,0.3580234,0.00031131945,0.000047147078,0.00000435349,3.9817297e-7,0.000025071091,0.000028184237,0.63826543,0.0003688771],"about_ca_topic_score_codex":0.00011542806,"about_ca_topic_score_gemma":0.00001987977,"teacher_disagreement_score":0.81676835,"about_ca_system_score_codex":0.00075344194,"about_ca_system_score_gemma":0.0009052259,"threshold_uncertainty_score":0.99961525},"labels":[],"label_agreement":null},{"id":"W2116146956","doi":"10.1016/s1473-3099(13)70093-8","title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","year":2013,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; Merck","keywords":"Raltegravir; Placebo; Medicine; Human immunodeficiency virus (HIV); Alternative medicine; Physical therapy; Pharmacology; Family medicine; Antiretroviral therapy; Viral load","score_opus":0.06449202045576986,"score_gpt":0.36258853998545576,"score_spread":0.2980965195296859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116146956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840771,0.002823121,0.000032121767,0.0016768264,0.000052827567,0.010635078,0.0003647484,0.000015361928,0.00032282827],"genre_scores_gemma":[0.9954226,0.0015021553,0.00017059113,0.000046273515,0.00014433808,0.0021587238,0.00007505874,0.000009995908,0.0004702735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99848664,0.00028113337,0.00076724676,0.00014998746,0.00014119071,0.00017381152],"domain_scores_gemma":[0.99088526,0.008289012,0.00042107966,0.0002530072,0.00011484015,0.00003679545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010836786,0.00016187492,0.0017893588,0.00008163247,0.00005244211,0.0000066714742,0.00006716837,0.000026971647,0.00001203004],"category_scores_gemma":[0.0018734264,0.00007116483,0.00032612815,0.00010058517,0.00012627312,0.000026360585,0.000011387933,0.000023406059,0.0000010734329],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8478121,0.006145409,0.05614169,0.0010088566,0.010043353,0.000006882436,0.016703596,0.00031263102,0.0006159214,0.001516676,0.016863989,0.042828888],"study_design_scores_gemma":[0.9499142,0.0019572645,0.038559943,0.00034306344,0.003386348,0.0000036930742,0.00086308457,0.00012844276,0.00079852034,0.0025736603,0.0013458934,0.00012584934],"about_ca_topic_score_codex":0.00005676712,"about_ca_topic_score_gemma":0.000032962904,"teacher_disagreement_score":0.10210213,"about_ca_system_score_codex":0.000049724626,"about_ca_system_score_gemma":0.00008968666,"threshold_uncertainty_score":0.29020175},"labels":[],"label_agreement":null},{"id":"W2116147829","doi":"10.1186/1742-4690-2-62","title":"Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import","year":2005,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute; University of Manitoba","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Integrase; Biology; Viral replication; Nuclear localization sequence; Viral life cycle; Nuclear transport; Reverse transcriptase; Mutant; Viral protein; Virology; DNA; Virus; Transcription (linguistics); Molecular biology; Cell biology; Cell nucleus; Gene; Genetics; RNA","score_opus":0.012669924666617541,"score_gpt":0.2654239674979861,"score_spread":0.25275404283136854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116147829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969941,0.00027276657,0.00010176682,0.0019180977,0.000078964535,0.00049335114,0.000020292617,0.000014161809,0.00010651213],"genre_scores_gemma":[0.9988542,0.000060010614,0.0002338756,0.00009619789,0.000031209256,0.000009696573,0.00005211091,0.000010828129,0.000651837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991239,0.000046417532,0.00035941546,0.00017360978,0.00012215304,0.00017452035],"domain_scores_gemma":[0.9994437,0.00003019605,0.00017046776,0.00020271775,0.00011469106,0.000038226528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022001499,0.00011495873,0.00033282998,0.00010507011,0.00009905205,0.000002414887,0.00006202508,0.00010662114,0.00004170087],"category_scores_gemma":[0.00007251038,0.0000785468,0.00012388607,0.00013261993,0.00021970135,0.000027693019,0.000019469351,0.000104528895,0.0000035469877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014322919,0.00070266315,0.004632479,0.000053280026,0.0001323104,0.000008617161,0.0009866272,0.0000070087913,0.98461396,0.005210353,0.0006899228,0.001530503],"study_design_scores_gemma":[0.043594386,0.016155817,0.23818734,0.00065857643,0.006098923,0.0011809997,0.0015162899,0.009198518,0.60826916,0.0010631762,0.07299959,0.0010771941],"about_ca_topic_score_codex":0.000026579357,"about_ca_topic_score_gemma":0.000018467568,"teacher_disagreement_score":0.37634477,"about_ca_system_score_codex":0.000087117616,"about_ca_system_score_gemma":0.00005643393,"threshold_uncertainty_score":0.32030457},"labels":[],"label_agreement":null},{"id":"W2116612156","doi":"10.1128/aac.47.7.2376-2379.2003","title":"The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates","year":2003,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Amprenavir; Efavirenz; Virology; Reverse transcriptase; Resistance mutation; Reverse-transcriptase inhibitor; Biology; Human immunodeficiency virus (HIV); Drug resistance; Medicine; Viral disease; Sida; Microbiology; Polymerase chain reaction; Viral load; Genetics; Enzyme; Protease; Antiretroviral therapy","score_opus":0.023331590810789338,"score_gpt":0.30292495942300585,"score_spread":0.2795933686122165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116612156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735796,0.00066977466,0.00001720278,0.00132452,0.00005461486,0.00039341795,0.0000028889715,0.000005507281,0.00017413446],"genre_scores_gemma":[0.99405766,0.0039086603,0.0006623886,0.00060773536,0.000006329535,0.0000059327267,0.000007711381,0.000010275995,0.0007333269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990318,0.000059499886,0.00041859533,0.00022790859,0.000076827986,0.00018541107],"domain_scores_gemma":[0.9996832,0.000040459432,0.00006489076,0.00013406148,0.0000297172,0.000047652808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046870706,0.00013888035,0.00022674724,0.000054393317,0.00019091087,0.000022714725,0.00005539384,0.00006335,0.00001114775],"category_scores_gemma":[0.000019593885,0.00008486625,0.000026339234,0.00019555794,0.00015420228,0.000040385796,0.0000137002025,0.00011309709,0.0000017788882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001941741,0.0011103645,0.89309293,0.00012544998,0.00022098141,0.000028817987,0.014002375,0.0000014705416,0.069019206,0.0008465948,0.0023202326,0.017289862],"study_design_scores_gemma":[0.0069107004,0.00018895927,0.85424805,0.0004847947,0.000065860295,0.000016663322,0.0005181665,0.000015658265,0.03352759,0.00009077825,0.10361808,0.00031472638],"about_ca_topic_score_codex":0.00004069982,"about_ca_topic_score_gemma":0.0007161093,"teacher_disagreement_score":0.10129784,"about_ca_system_score_codex":0.000031794585,"about_ca_system_score_gemma":0.00007589481,"threshold_uncertainty_score":0.34607455},"labels":[],"label_agreement":null},{"id":"W2116758166","doi":"10.1177/135965350801302s07","title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Antiretroviral therapy; Population; Public health; Human immunodeficiency virus (HIV); Environmental health; Viral load; Family medicine; Internal medicine; Pathology","score_opus":0.028690203976617243,"score_gpt":0.29083398245131176,"score_spread":0.2621437784746945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116758166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953158,0.00047597862,0.000032443168,0.0031953785,0.000050438306,0.0006643461,0.000012153015,0.00008464031,0.00016885852],"genre_scores_gemma":[0.9244279,0.00191344,0.00030950818,0.00008627431,0.00003463744,0.000011421276,0.00036038223,0.00003266231,0.07282372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998631,0.00023033236,0.00031026517,0.00032727048,0.00021126315,0.00028986958],"domain_scores_gemma":[0.99952215,0.000059147187,0.00011552972,0.00014123187,0.00006408341,0.00009784386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025609852,0.0002368175,0.00041185104,0.00026452585,0.0001745467,0.000020702875,0.000038466922,0.000043278204,0.000025991632],"category_scores_gemma":[0.00003251983,0.00018877967,0.000052851006,0.0006105425,0.00003288029,0.0001271844,0.000013501344,0.00007043961,0.00002455652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007658993,0.00055104186,0.99135673,0.000007738001,0.00008935252,0.000035103847,0.0028153763,2.453491e-7,0.0016132147,0.000011885567,0.0008923723,0.0025503254],"study_design_scores_gemma":[0.002959675,0.00016058114,0.98045087,0.00010186232,0.000011045602,0.0000013444829,0.00010834236,0.0000070195542,0.015198061,0.000014900198,0.0008185226,0.00016776151],"about_ca_topic_score_codex":0.00010555171,"about_ca_topic_score_gemma":0.001006495,"teacher_disagreement_score":0.072654866,"about_ca_system_score_codex":0.00027984413,"about_ca_system_score_gemma":0.00008543134,"threshold_uncertainty_score":0.7698211},"labels":[],"label_agreement":null},{"id":"W2116874132","doi":"10.1128/aac.05161-11","title":"Inhibition of HIV-1 by Octadecyloxyethyl Esters of (<i>S</i>)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl] Nucleosides and Evaluation of Their Mechanism of Action","year":2011,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Cytosine; Cidofovir; Guanine; Nucleic acid; Biology; Reverse transcriptase; Uracil; DNA; Stereochemistry; Mechanism of action; Thymine; Virology; Chemistry; Virus; Biochemistry; Nucleotide; In vitro; RNA; Gene","score_opus":0.03869346990183048,"score_gpt":0.27120420035624576,"score_spread":0.23251073045441528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116874132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99860924,0.00008495235,0.00021597283,0.00028310853,0.000037338712,0.00044010414,0.000049497277,0.000007044369,0.00027273505],"genre_scores_gemma":[0.9965961,0.001252552,0.001789905,0.00014415885,0.000006486958,0.000005077903,0.0000493845,0.000017898607,0.00013844715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907637,0.000041832165,0.00040114383,0.00018774836,0.0001877603,0.00010516488],"domain_scores_gemma":[0.9993044,0.000016840035,0.000352131,0.00012720069,0.00015671291,0.000042701213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003018784,0.00014920293,0.00039270913,0.000107834836,0.000024530704,0.000002840537,0.00003245277,0.00009105191,0.000137822],"category_scores_gemma":[0.0000061817377,0.00011941985,0.00007261366,0.00011446637,0.00012873445,0.00008621353,0.000017904858,0.0000455059,5.305326e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045443478,0.0006501039,0.01751261,0.00027395593,0.00030481553,5.122641e-7,0.006454215,3.414294e-7,0.95926875,0.00006788789,0.0010061112,0.014006246],"study_design_scores_gemma":[0.003523519,0.00021926522,0.01835278,0.00023644435,0.00018839295,0.000005327762,0.00041930928,0.00009900774,0.9764426,0.0002988615,0.00012273584,0.00009179767],"about_ca_topic_score_codex":0.00007465332,"about_ca_topic_score_gemma":0.0000032778287,"teacher_disagreement_score":0.017173791,"about_ca_system_score_codex":0.000021061802,"about_ca_system_score_gemma":0.000040899966,"threshold_uncertainty_score":0.48698},"labels":[],"label_agreement":null},{"id":"W2117284107","doi":"10.6000/1927-5129.2015.11.71","title":"Synthesis of Mannich Bases of 8-Hydroxyquinoline","year":2015,"lang":"en","type":"article","venue":"Journal of Basic & Applied Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"8-Hydroxyquinoline; Mannich reaction; Aldehyde; Chemistry; Antifungal; Mannich base; Organic chemistry; Combinatorial chemistry; Catalysis; Biology; Microbiology","score_opus":0.04145943361845493,"score_gpt":0.29241085253976734,"score_spread":0.2509514189213124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117284107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745737,0.00045187128,0.00010517091,0.0019690106,0.00011474623,0.000118709024,0.000002741246,0.0000055631585,0.022658492],"genre_scores_gemma":[0.99086255,0.00005666963,0.008377556,0.000054268243,0.00008534179,0.0000027143394,4.707193e-7,0.0000052405103,0.00055520254],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827987,0.000022604194,0.0005970061,0.00011710623,0.0008227463,0.00016067391],"domain_scores_gemma":[0.99877954,0.00017619348,0.000538809,0.00011844974,0.00022386471,0.00016315399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012133879,0.00010589905,0.00048970594,0.00030309227,0.00003702461,0.000007644563,0.00019331384,0.00003649628,0.000076104734],"category_scores_gemma":[0.00018208711,0.000066481,0.00010409702,0.00043618307,0.00031567717,0.000088406894,0.000031659056,0.00008051213,0.000010183377],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004927733,0.009712515,0.38497204,0.0012608045,0.0028349916,0.0007306823,0.017283648,0.0012764804,0.24432108,0.016417498,0.09367905,0.22258349],"study_design_scores_gemma":[0.0036202916,0.0012473281,0.012691675,0.0007552307,0.0006244576,0.00031436223,0.005212811,0.00023440986,0.96595794,0.0015591902,0.007537519,0.00024478644],"about_ca_topic_score_codex":0.0000049472083,"about_ca_topic_score_gemma":0.0000023690789,"teacher_disagreement_score":0.72163683,"about_ca_system_score_codex":0.000044696662,"about_ca_system_score_gemma":0.00059263763,"threshold_uncertainty_score":0.27110165},"labels":[],"label_agreement":null},{"id":"W2118020641","doi":"10.1093/cid/cis937","title":"Association Between Tenofovir Exposure and Reduced Kidney Function in a Cohort of HIV-Positive Patients: Results From 10 Years of Follow-up","year":2012,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Tenofovir; Human immunodeficiency virus (HIV); Cohort; Renal function; Cohort study; Internal medicine; Association (psychology); Virology","score_opus":0.016970792603279626,"score_gpt":0.29265366774290535,"score_spread":0.27568287513962575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118020641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977555,0.00012072779,0.0000049785394,0.00017699905,0.00026810254,0.00045083626,0.00069491036,0.000029777231,0.00049814006],"genre_scores_gemma":[0.99703616,0.00009818592,0.000022174538,0.00008485706,0.00017898243,0.000021988057,0.0016277025,0.000013221504,0.00091674476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841744,0.00017585469,0.0007515462,0.00023235581,0.00024990967,0.00017291614],"domain_scores_gemma":[0.9980176,0.0009854615,0.00038814225,0.00015644278,0.0001759248,0.0002764339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003592904,0.00012014128,0.00050984015,0.00010255621,0.000024367595,0.0000053573926,0.000026160988,0.0001611758,0.00004963928],"category_scores_gemma":[0.0037587257,0.00010995552,0.0001359633,0.00017323434,0.000060999522,0.00011800249,0.000035204444,0.00011711387,0.000023355014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006301111,0.001465422,0.98549885,0.000020270183,0.000765768,0.0000013541407,0.00026547984,1.7295557e-7,0.000018928162,0.000002707298,0.0049001933,0.0064307526],"study_design_scores_gemma":[0.009042731,0.00050246314,0.9881649,0.00018009667,0.0012390781,7.6173016e-8,0.0000364504,0.0000019896872,0.000105627005,0.000057020115,0.00057578925,0.00009379829],"about_ca_topic_score_codex":0.00007270436,"about_ca_topic_score_gemma":0.000010788474,"teacher_disagreement_score":0.008412619,"about_ca_system_score_codex":0.000139112,"about_ca_system_score_gemma":0.00011084961,"threshold_uncertainty_score":0.44998172},"labels":[],"label_agreement":null},{"id":"W2118399321","doi":"10.1128/aac.46.7.2254-2256.2002","title":"Pressure of Zidovudine Accelerates the Reversion of Lamivudine Resistance-Conferring M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1","year":2002,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reversion; Resistance mutation; Zidovudine; Reverse transcriptase; Virology; Lamivudine; Mutation; Reverse-transcriptase inhibitor; Virus; Biology; Sida; Genetics; Viral disease; RNA; Gene","score_opus":0.03060800966477378,"score_gpt":0.2672358188059311,"score_spread":0.23662780914115733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118399321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586076,0.0005353905,0.0000037774794,0.0025949858,0.000030268193,0.00034897256,0.000016202177,0.0000046539485,0.0006049655],"genre_scores_gemma":[0.9948728,0.0022522986,0.000117939744,0.00035122343,0.000011771749,0.0000025416487,0.000023694318,0.000009624869,0.002358111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925315,0.00003965898,0.00031862158,0.00013271703,0.00014432185,0.00011149873],"domain_scores_gemma":[0.99956954,0.000022246693,0.00014803419,0.00017456633,0.00007247929,0.000013132266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017165161,0.00011421594,0.00025452394,0.00006559811,0.00006879117,0.000006362105,0.00009922352,0.000046426718,0.00025796366],"category_scores_gemma":[0.000007342672,0.00006699293,0.00006034629,0.00023261493,0.000104281266,0.000051906965,0.00000958858,0.00007473058,0.0000010758507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081548176,0.0018911294,0.06897562,0.00072846515,0.00043147185,0.00002992391,0.027277451,0.000010487688,0.8601125,0.00022627963,0.03657171,0.002929466],"study_design_scores_gemma":[0.012708247,0.0006246098,0.21511808,0.00137744,0.00054594164,0.000028771527,0.0018796433,0.00023671318,0.7306946,0.000095871976,0.03633767,0.00035243496],"about_ca_topic_score_codex":0.00009776746,"about_ca_topic_score_gemma":0.000020987187,"teacher_disagreement_score":0.14614245,"about_ca_system_score_codex":0.000009477741,"about_ca_system_score_gemma":0.000012364032,"threshold_uncertainty_score":0.2824521},"labels":[],"label_agreement":null},{"id":"W2118756687","doi":"10.1155/2013/579741","title":"Potential Impact of a Free Online HIV Treatment Response Prediction System for Reducing Virological Failures and Drug Costs after Antiretroviral Therapy Failure in a Resource-Limited Setting","year":2013,"lang":"en","type":"article","venue":"BioMed Research International","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Core Research for Evolutional Science and Technology; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; Università degli Studi di Brescia; U.S. Department of Defense","keywords":"Medicine; Intensive care medicine; Antiretroviral therapy; Drug; Human immunodeficiency virus (HIV); Viral load; Cost–benefit analysis; Risk analysis (engineering); Pharmacology; Family medicine","score_opus":0.02342793094472823,"score_gpt":0.3341222579479091,"score_spread":0.3106943270031809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118756687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262286,0.00015497084,0.000039731905,0.0148529615,0.000076487806,0.0016183573,0.00055625214,0.000041691237,0.000036672773],"genre_scores_gemma":[0.99474376,0.000044474913,0.002145045,0.000013496539,0.00024981576,0.0005299207,0.00059803476,0.00002293239,0.0016525227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976822,0.00038187875,0.00044558663,0.00040689076,0.0006724074,0.00041101823],"domain_scores_gemma":[0.99875146,0.00041019486,0.00009426962,0.00023011595,0.00034110495,0.0001728467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009858374,0.000199832,0.00030436608,0.0010459059,0.00008796549,0.0000671614,0.00014857239,0.0001288281,0.000102160026],"category_scores_gemma":[0.00036679083,0.00013165674,0.00015227703,0.00030182028,0.00017284608,0.00013513639,0.000101799116,0.00019100029,0.000006878403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06268928,0.003903695,0.5164348,0.000195002,0.002210735,0.00054914673,0.004498079,0.000038870618,0.32507652,0.000059238955,0.032904018,0.051440623],"study_design_scores_gemma":[0.019313414,0.003770268,0.95177585,0.0007420564,0.000040983734,0.00015780731,0.0021512264,0.011085296,0.006044698,0.000042879437,0.004662267,0.00021326767],"about_ca_topic_score_codex":0.0005090386,"about_ca_topic_score_gemma":0.00003910437,"teacher_disagreement_score":0.43534106,"about_ca_system_score_codex":0.0012396858,"about_ca_system_score_gemma":0.0002176419,"threshold_uncertainty_score":0.5368806},"labels":[],"label_agreement":null},{"id":"W2118820814","doi":"10.1517/14656566.7.2.229","title":"6th International Workshop on Clinical Pharmacology of HIV Therapy","year":2006,"lang":"en","type":"article","venue":"Expert Opinion on Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical pharmacology; Antiretroviral therapy; Pharmacology; Pharmacokinetics; Pharmacodynamics; Human immunodeficiency virus (HIV); Antiretroviral drug; ANTIRETROVIRAL AGENTS; Drug; Family medicine; Viral load","score_opus":0.06906413491715782,"score_gpt":0.43962418552232163,"score_spread":0.37056005060516384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118820814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58868456,0.016239218,0.0014917648,0.26783448,0.03615347,0.0045548375,0.0001112783,0.0008639166,0.084066465],"genre_scores_gemma":[0.7748905,0.11978852,0.003765497,0.044712275,0.014665014,0.0004312789,0.00069865276,0.00021803263,0.040830217],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981671,0.00012766247,0.00059691386,0.00041362428,0.0004368036,0.00025788532],"domain_scores_gemma":[0.9991709,0.00023282038,0.00017903476,0.0002028722,0.00009089004,0.00012348218],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023243124,0.00027293753,0.00041043657,0.00023294525,0.000057242924,0.000011187795,0.00018046773,0.00011743136,0.0038621433],"category_scores_gemma":[0.000007320124,0.00020656762,0.00024517038,0.00015859396,0.00009921932,0.00005677493,0.000014957087,0.00024278107,0.00020027159],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072408305,0.0060318927,0.013009802,0.000005030113,0.0008458785,0.000039632574,0.0004776959,0.00004003586,0.042532142,0.00061072054,0.82273054,0.10643582],"study_design_scores_gemma":[0.014551117,0.0003951628,0.002443067,0.00007218267,0.000004838583,0.000007486745,0.000034312492,0.00021386053,0.12329147,0.000031521693,0.85877854,0.00017644785],"about_ca_topic_score_codex":0.0000058153487,"about_ca_topic_score_gemma":2.2698934e-7,"teacher_disagreement_score":0.22312221,"about_ca_system_score_codex":0.00009900308,"about_ca_system_score_gemma":0.00009270149,"threshold_uncertainty_score":0.99704844},"labels":[],"label_agreement":null},{"id":"W2118856136","doi":"10.1155/2012/256982","title":"The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs","year":2012,"lang":"en","type":"article","venue":"Molecular Biology International","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Drug resistance; Medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Affect (linguistics); Drug; Antiretroviral drug; Resistance (ecology); Phenotype; Resistance mutation; Genetics; Virology; Immunology; Viral load; Biology; Pharmacology; Gene; Reverse transcriptase","score_opus":0.011497843477380528,"score_gpt":0.29298086380851013,"score_spread":0.2814830203311296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118856136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955383,0.000475153,0.00020828225,0.0026096054,0.00009306376,0.00012474279,0.000049484494,0.0000033846773,0.0008979728],"genre_scores_gemma":[0.9989145,0.00004068258,0.00020275803,0.00007524284,0.000021516918,0.000010176726,0.000026487902,0.0000028918894,0.000705744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994822,0.00004505049,0.00014080056,0.00009408909,0.00011541038,0.00012244952],"domain_scores_gemma":[0.9996026,0.000106644155,0.00007319862,0.00012246528,0.000054273463,0.00004082284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009457076,0.000079972204,0.000112343565,0.000050001625,0.000034630233,0.0000040055634,0.000117875425,0.000029430736,0.000052456846],"category_scores_gemma":[0.000087621214,0.00003781239,0.000053780182,0.000061020546,0.00015363672,0.00000921337,0.000039033708,0.000049508933,0.000013578106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021021317,0.00009023004,0.96516854,0.0000026610371,0.00025621484,0.0000024078895,0.00045974183,5.144615e-7,0.024052339,0.006823797,0.0011372748,0.0017960741],"study_design_scores_gemma":[0.00054325804,0.00043369547,0.95461994,0.000060557955,0.000038612794,0.0000097081165,0.00008686502,0.00003608107,0.042887017,0.00054608873,0.0006492791,0.00008889549],"about_ca_topic_score_codex":0.000017277911,"about_ca_topic_score_gemma":0.000001896707,"teacher_disagreement_score":0.018834678,"about_ca_system_score_codex":0.000025884468,"about_ca_system_score_gemma":0.00003792578,"threshold_uncertainty_score":0.15419444},"labels":[],"label_agreement":null},{"id":"W2119121320","doi":"10.1093/cid/ciu834","title":"Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access","year":2014,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Logistic regression; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Reverse-transcriptase inhibitor; Integrase; Viral load; Pediatrics; Immunology","score_opus":0.018913651475809475,"score_gpt":0.32554477313486724,"score_spread":0.30663112165905776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119121320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906729,0.00008451083,0.00001950319,0.007990116,0.00009597887,0.0006727681,0.000012107194,0.00015966814,0.00029248715],"genre_scores_gemma":[0.9988875,0.000054818996,0.00013846687,0.00023908779,0.0001928664,0.0001861873,0.00005188548,0.000027810935,0.00022141867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979881,0.00027562736,0.0006070872,0.0005435614,0.0002158212,0.00036978192],"domain_scores_gemma":[0.99892855,0.00020060805,0.00015202444,0.00037489392,0.000063446816,0.00028048686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031260954,0.00022668527,0.0005625776,0.00023084239,0.00010180072,0.000047512804,0.00011522601,0.00014406675,0.00006657447],"category_scores_gemma":[0.0007068515,0.00016756912,0.00012195234,0.0003845874,0.00013146763,0.00014849156,0.00009521111,0.0003941711,0.000039611652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031057367,0.0011126483,0.9964059,0.00014414702,0.00005790828,0.00016169503,0.00018875534,0.000044945908,0.00001788332,0.000050160113,0.00029586355,0.0012095413],"study_design_scores_gemma":[0.006706479,0.00043223883,0.99121517,0.00035390002,0.000084840154,0.000022929053,0.00034786688,0.00007874676,0.000029364779,0.0003746786,0.00016028353,0.00019349769],"about_ca_topic_score_codex":0.000053080457,"about_ca_topic_score_gemma":0.00061868026,"teacher_disagreement_score":0.008214597,"about_ca_system_score_codex":0.00018934015,"about_ca_system_score_gemma":0.00021141137,"threshold_uncertainty_score":0.683327},"labels":[],"label_agreement":null},{"id":"W2119514403","doi":"10.1002/rcm.231","title":"Self‐association of an amphipathic helix peptide inhibitor of HIV‐1 integrase assessed by electro spray ionization mass spectrometry in trifluoroethanol/water mixtures","year":2001,"lang":"en","type":"article","venue":"Rapid Communications in Mass Spectrometry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Moncton","funders":"Sidaction","keywords":"Chemistry; Integrase; Electrospray ionization; Monomer; Mass spectrometry; Crystallography; DNA; Chromatography; Organic chemistry; Biochemistry; Polymer","score_opus":0.010798631750142215,"score_gpt":0.27115848137638854,"score_spread":0.2603598496262463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119514403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850115,0.0023615917,0.0021490287,0.0055181016,0.000083537,0.0010585135,0.000043543252,0.00013919202,0.0036349867],"genre_scores_gemma":[0.9136318,0.0045324387,0.0791911,0.00005781956,0.000056588477,0.00011093402,0.0011208104,0.000058112422,0.0012403973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961763,0.0007530022,0.0012790443,0.0004717881,0.0007000441,0.00061982416],"domain_scores_gemma":[0.99700177,0.0004599735,0.00051678624,0.0015814919,0.0003000268,0.00013995526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016347532,0.00038654907,0.000878502,0.0022449892,0.00010672333,0.000037930866,0.00067744707,0.00035164642,0.00027930597],"category_scores_gemma":[0.00041370126,0.0003507307,0.00017210972,0.0032799728,0.00010752971,0.00035282274,0.000111865156,0.00084388774,0.000027886308],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028749544,0.0040456345,0.2685469,0.00014374733,0.00036892036,0.000020973064,0.0012531122,0.000008953396,0.7234499,0.0006623964,0.0006143411,0.00059764285],"study_design_scores_gemma":[0.0075887917,0.0008031553,0.03972621,0.00043322428,0.00032478193,0.000034004723,0.0012872033,0.0014932578,0.9432146,0.00191821,0.002560164,0.0006163965],"about_ca_topic_score_codex":0.00006222264,"about_ca_topic_score_gemma":0.00013447185,"teacher_disagreement_score":0.2288207,"about_ca_system_score_codex":0.0017636168,"about_ca_system_score_gemma":0.00025334084,"threshold_uncertainty_score":0.99989444},"labels":[],"label_agreement":null},{"id":"W2119874144","doi":"10.1111/j.1468-1293.2006.00381.x","title":"Regimen‐dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor‐based highly active antiretroviral therapy","year":2006,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"British HIV Association; Michael Smith Health Research BC","keywords":"Nelfinavir; Medicine; Saquinavir; Indinavir; Internal medicine; Odds ratio; Ritonavir; Regimen; Confidence interval; Lopinavir; Protease inhibitor (pharmacology); Combination therapy; Viral load; Logistic regression; Pharmacotherapy; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology","score_opus":0.024920091355485532,"score_gpt":0.27811588258275877,"score_spread":0.25319579122727326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119874144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234253,0.00013957924,0.00008428459,0.004843129,0.00008494832,0.0017391472,0.0000103467255,0.000041193878,0.0007148262],"genre_scores_gemma":[0.9973039,0.000043935488,0.0009395903,0.00070396275,0.00012875312,0.00025428532,0.00020487314,0.000018476045,0.00040222154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823165,0.00014206451,0.00045679588,0.00041807062,0.0004410653,0.00031035498],"domain_scores_gemma":[0.99936146,0.00012983264,0.00011604079,0.0001859627,0.00006911046,0.00013759245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025991155,0.0002424349,0.0004179862,0.0003593945,0.0000702479,0.000009870099,0.00006339269,0.00011205415,0.00011018198],"category_scores_gemma":[0.00012951998,0.00016194375,0.000026740503,0.0003899247,0.0000696661,0.00010079844,0.000029727284,0.0002382309,0.000012784919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023152349,0.0014064218,0.9736138,0.000017958335,0.00001889169,0.00013457047,0.0015852385,0.00000877119,0.005445028,0.00007171753,0.000825146,0.014557194],"study_design_scores_gemma":[0.023220211,0.0030030434,0.9652886,0.0005381201,0.000014209701,0.0000024897931,0.00014364302,0.00027114045,0.0067438264,0.00010840291,0.00048337565,0.0001829324],"about_ca_topic_score_codex":0.00024944876,"about_ca_topic_score_gemma":0.000036510017,"teacher_disagreement_score":0.020904977,"about_ca_system_score_codex":0.00013680106,"about_ca_system_score_gemma":0.00009316216,"threshold_uncertainty_score":0.66038746},"labels":[],"label_agreement":null},{"id":"W2120293408","doi":"10.1016/s1473-3099(09)70328-7","title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","year":2010,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Resistance mutation; Lamivudine; Drug resistance; Regimen; Medicine; Reverse-transcriptase inhibitor; Reverse transcriptase; Virology; Genotyping; Internal medicine; Antiretroviral therapy; Etravirine; Protease inhibitor (pharmacology); Viral load; Human immunodeficiency virus (HIV); Biology; Genotype; Virus; Polymerase chain reaction; Genetics","score_opus":0.028817505781338303,"score_gpt":0.30387874313044216,"score_spread":0.27506123734910387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120293408","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009684603,0.9806441,2.0351008e-7,0.00008016542,0.00014558579,0.008901684,0.0001607939,0.00009713606,0.00028569702],"genre_scores_gemma":[0.0058363066,0.9892776,0.00000837508,0.00007994232,0.00008236204,0.0038890068,0.00051641103,0.00004516239,0.00026481427],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99685293,0.0005463966,0.0012554624,0.00045065477,0.0003793202,0.00051521254],"domain_scores_gemma":[0.99809116,0.0003366334,0.0006150018,0.0007295568,0.000094704345,0.0001329565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024946197,0.00063395273,0.005423617,0.00027477252,0.00004984606,0.000021644788,0.00023201887,0.00022583449,0.000019731071],"category_scores_gemma":[0.0006776295,0.00030971543,0.0008064009,0.0005950704,0.000115518116,0.000048040412,0.00006517593,0.0003754083,0.00008037333],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013333488,0.003840816,0.07225567,0.75006366,0.0007767695,0.00017467691,0.00012628063,5.4079795e-8,1.017628e-7,0.000017859307,0.00062607473,0.17198469],"study_design_scores_gemma":[0.009577946,0.0015509821,0.0051600523,0.8667639,0.016900156,0.000055150424,0.000011208468,0.0000027237159,0.0000015407238,0.000056337143,0.09920962,0.0007104101],"about_ca_topic_score_codex":0.000055184068,"about_ca_topic_score_gemma":0.00026206044,"teacher_disagreement_score":0.17127427,"about_ca_system_score_codex":0.00040330252,"about_ca_system_score_gemma":0.00027996575,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W2120838488","doi":"10.1086/320998","title":"The Steady‐State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1–Infected Persons","year":2001,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"Universiteit van Amsterdam","keywords":"Nevirapine; Efavirenz; Pharmacokinetics; Pharmacology; Reverse-transcriptase inhibitor; Regimen; Medicine; Virology; Human immunodeficiency virus (HIV); Sida; Viral load; Internal medicine; Antiretroviral therapy; Viral disease","score_opus":0.013920075710654421,"score_gpt":0.2830916950576756,"score_spread":0.2691716193470212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120838488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510586,0.0036544404,0.000015423306,0.00059189106,0.00007524052,0.000254759,0.0000034244435,0.000009892134,0.00028908986],"genre_scores_gemma":[0.99600595,0.0035807749,0.000006119613,0.000035238074,0.000018236718,0.0000031152847,0.0000041804196,0.000011134659,0.0003352647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989674,0.00016802934,0.00041822216,0.00006464906,0.00022738571,0.0001543289],"domain_scores_gemma":[0.9992321,0.0002043025,0.0002566362,0.000111963294,0.00013812295,0.000056839617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037032412,0.00011811521,0.00024583956,0.00022849087,0.00011477554,0.000017696037,0.00007826438,0.00002255184,0.000032611002],"category_scores_gemma":[0.00010257895,0.0000667069,0.00005348006,0.00035344827,0.00011494162,0.00008566214,0.00002530899,0.00017618263,0.0000017926217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064249977,0.0016390551,0.9706544,0.000039225815,0.0001926753,0.00008204352,0.004437558,0.00013022986,0.015074362,0.000053538817,0.0002915837,0.006762799],"study_design_scores_gemma":[0.012077178,0.0012476504,0.9797851,0.00034823126,0.00052646524,0.00023463377,0.0008045415,0.00035691864,0.0024322385,0.0010773764,0.0009492717,0.0001604322],"about_ca_topic_score_codex":0.00011325461,"about_ca_topic_score_gemma":0.00016131245,"teacher_disagreement_score":0.012642123,"about_ca_system_score_codex":0.000104728904,"about_ca_system_score_gemma":0.00010056154,"threshold_uncertainty_score":0.27202287},"labels":[],"label_agreement":null},{"id":"W2121720236","doi":"10.1056/nejmra1004180","title":"Development of Antiretroviral Drug Resistance","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug resistance; Antiretroviral drug; ANTIRETROVIRAL AGENTS; Drug; HIV drug resistance; Resistance (ecology); Virology; Antiretroviral therapy; Medicine; Computational biology; Biology; Pharmacology; Genetics; Viral load","score_opus":0.03104493270825844,"score_gpt":0.26200902139422877,"score_spread":0.23096408868597032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121720236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714759,0.0022349434,0.00072417205,0.0046821623,0.0004862812,0.00015616152,6.5886553e-7,0.000014530358,0.020225182],"genre_scores_gemma":[0.91152096,0.00018379619,0.06357523,0.000114239694,0.00070653914,8.1661784e-7,0.000004628983,0.000015815076,0.023878003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982767,0.000035435565,0.00082934456,0.00010941445,0.0005660597,0.00018301484],"domain_scores_gemma":[0.99886465,0.000056358695,0.00043322958,0.00014350895,0.00021664049,0.00028559705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007621833,0.0001559925,0.0005844517,0.00025591967,0.00003870692,0.0000017836655,0.00011332708,0.000038842954,0.0004465282],"category_scores_gemma":[0.00013700873,0.000094246534,0.00007017795,0.00018915639,0.00009088376,0.000067682115,0.000017686802,0.00019140985,0.000009958627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00941324,0.0011157827,0.2286362,0.00051955006,0.0018282535,0.0026910463,0.13008805,3.8802293e-7,0.015507127,0.0015778316,0.1371754,0.47144714],"study_design_scores_gemma":[0.13269399,0.0014573785,0.08941635,0.0042660204,0.000940272,0.0011390154,0.0023671312,0.0000036910344,0.06746602,0.0009666248,0.6989004,0.00038309442],"about_ca_topic_score_codex":0.000010340291,"about_ca_topic_score_gemma":0.000039310442,"teacher_disagreement_score":0.561725,"about_ca_system_score_codex":0.000066749424,"about_ca_system_score_gemma":0.0004934824,"threshold_uncertainty_score":0.48891708},"labels":[],"label_agreement":null},{"id":"W2121769821","doi":"10.1517/14656566.3.2.81","title":"Salvage antiretroviral therapy in HIV infection","year":2002,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Salvage therapy; Discontinuation; Regimen; Intensive care medicine; Drug resistance; Antiretroviral therapy; Combination therapy; Drug; Protease inhibitor (pharmacology); Internal medicine; Viral load; Human immunodeficiency virus (HIV); Pharmacology; Immunology; Chemotherapy","score_opus":0.10216402638026828,"score_gpt":0.42054423431703697,"score_spread":0.3183802079367687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121769821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043142754,0.9932041,0.000012793912,0.0007032352,0.0013485603,0.002082329,0.000016862268,0.00021483986,0.0023741229],"genre_scores_gemma":[0.000019136973,0.98862034,0.00019845598,0.0011092228,0.0010966646,0.0006155773,0.0004107265,0.00018546858,0.0077444045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721277,0.00027066874,0.0007954056,0.00074951904,0.00047556357,0.0004961037],"domain_scores_gemma":[0.998984,0.000098219585,0.0002642644,0.00042990257,0.000034201825,0.00018941936],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00019170337,0.00083366205,0.0018019583,0.00089124026,0.000090507776,0.000041954256,0.00015672889,0.00036520456,0.0022972743],"category_scores_gemma":[0.000007695614,0.0006070935,0.0006720641,0.0006626894,0.000049488073,0.00011411403,0.000018191067,0.0006325921,0.00095104426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013251102,0.0010764003,0.00026913674,0.00050151715,0.00037358855,0.00006723329,0.00044407844,1.5340844e-7,0.0000162949,0.00003352609,0.051603716,0.94548184],"study_design_scores_gemma":[0.0050717317,0.00047227723,0.000026547745,0.0061878995,0.0000205996,0.000049072958,0.0000050402346,0.000018186625,0.00015572304,0.0000028886288,0.9874591,0.0005309314],"about_ca_topic_score_codex":0.000020375985,"about_ca_topic_score_gemma":5.641001e-7,"teacher_disagreement_score":0.94495094,"about_ca_system_score_codex":0.00056167814,"about_ca_system_score_gemma":0.0001761679,"threshold_uncertainty_score":0.99982685},"labels":[],"label_agreement":null},{"id":"W2121875360","doi":"10.1128/aac.06378-11","title":"Small-Angle X-Ray Scattering Analysis of the Bifunctional Antibiotic Resistance Enzyme Aminoglycoside (6′) Acetyltransferase-Ie/Aminoglycoside (2″) Phosphotransferase-Ia Reveals a Rigid Solution Structure","year":2012,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; McMaster University","keywords":"Aminoglycoside; Phosphotransferase; Phosphotransferases; Enzyme; Acetyltransferase; Phosphofructokinase 2; Chemistry; Small-angle X-ray scattering; Stereochemistry; Biochemistry; Antibiotics; Scattering; Physics; Acetylation","score_opus":0.015627904915890382,"score_gpt":0.24187922004661072,"score_spread":0.22625131513072033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121875360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365187,0.00029269725,0.0007673255,0.0041216137,0.00022946279,0.0005658813,0.00017320692,0.000033486296,0.00016447558],"genre_scores_gemma":[0.99087125,0.0005722841,0.0018233819,0.0028347676,0.00012426557,0.00000594661,0.00016786219,0.000042773278,0.0035574895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981634,0.000065244,0.0005118761,0.0004260543,0.00030969025,0.00052375713],"domain_scores_gemma":[0.99916244,0.00004428644,0.00014449742,0.0003912886,0.00009012657,0.00016736862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001775937,0.00038147884,0.00066671206,0.00022743651,0.00027763782,0.000032896034,0.00013856901,0.00016529614,0.0004774862],"category_scores_gemma":[0.000008934882,0.00027206092,0.00036383886,0.0007699948,0.00018973897,0.0001357198,0.000028578987,0.00018796086,0.00000795486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054446823,0.0005861419,0.50882596,0.00021421228,0.0031476943,0.000008353095,0.0018512908,0.000021118247,0.47537804,0.00006904402,0.008344659,0.0010090113],"study_design_scores_gemma":[0.0025246323,0.000040320698,0.65133786,0.0002759932,0.001792285,0.00002244969,0.000048201062,0.0000563615,0.3374678,0.00000921509,0.0061174813,0.0003074315],"about_ca_topic_score_codex":0.00008415841,"about_ca_topic_score_gemma":0.00016662433,"teacher_disagreement_score":0.14251187,"about_ca_system_score_codex":0.000112016416,"about_ca_system_score_gemma":0.00006538023,"threshold_uncertainty_score":0.9999732},"labels":[],"label_agreement":null},{"id":"W2121894182","doi":"10.1016/s0168-8278(09)60941-7","title":"939 PRECLINICAL PHARMACOKINETIC AND ADME CHARACTERIZATION OF VCH-222, A NOVEL NON-NUCLEOSIDE HCV NS5B POLYMERASE INHIBITOR","year":2009,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"ADME; Pharmacokinetics; Pharmacology; Polymerase; Nucleoside; Virology; Chemistry; Medicine; Enzyme; Biochemistry","score_opus":0.01650155133904074,"score_gpt":0.3074844762368338,"score_spread":0.29098292489779304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121894182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98737776,0.0002990547,0.00023188545,0.011418966,0.0002512854,0.00017710733,0.000006038892,0.000008190139,0.00022971848],"genre_scores_gemma":[0.9962272,0.00035007953,0.0019394982,0.00086774956,0.00024229026,0.0000018897233,0.000012946052,0.000012040634,0.0003463137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986075,0.000045492216,0.0008023369,0.00014591953,0.00020374265,0.00019499804],"domain_scores_gemma":[0.9989771,0.00008432531,0.0004845699,0.00010267257,0.0001503281,0.00020097788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021163243,0.0001461449,0.00061434944,0.00023629215,0.000030656793,0.000006493563,0.000061377716,0.000116690615,0.00008342934],"category_scores_gemma":[0.000089176276,0.00011564962,0.00011324115,0.00012691741,0.00007038049,0.00010008633,0.000021100099,0.00021433047,0.0000073830934],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017792024,0.0016781226,0.31271997,0.000069499605,0.00031965258,0.00043527925,0.0005705427,4.350538e-7,0.63891405,0.000039179762,0.00079863373,0.042675424],"study_design_scores_gemma":[0.020681966,0.0028586532,0.7023191,0.00053894165,0.001117022,0.0046244175,0.000050960425,0.0007075875,0.2591621,0.00010426708,0.0075056236,0.00032936005],"about_ca_topic_score_codex":0.000002666828,"about_ca_topic_score_gemma":0.0000013462391,"teacher_disagreement_score":0.38959914,"about_ca_system_score_codex":0.00003745904,"about_ca_system_score_gemma":0.00019308533,"threshold_uncertainty_score":0.47160548},"labels":[],"label_agreement":null},{"id":"W2121938481","doi":"10.2196/med20.2712","title":"The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials","year":2013,"lang":"en","type":"article","venue":"Medicine 2 0","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Clinical trial; Medicine; Disease; Intensive care medicine; Immunology; Internal medicine","score_opus":0.041725369627797604,"score_gpt":0.36915505490031536,"score_spread":0.32742968527251776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121938481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853871,0.0026519839,0.000018509483,0.0018420842,0.0005005105,0.0038988418,0.000010686387,0.0000771413,0.005613184],"genre_scores_gemma":[0.99428207,0.0007126206,0.00056847546,0.0015792121,0.00045500588,0.00030232454,0.00019137669,0.00006324452,0.001845687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938761,0.00080921577,0.0028359343,0.0008363971,0.0007953981,0.0008469464],"domain_scores_gemma":[0.99715066,0.0009632857,0.0004896587,0.00081260613,0.0002591067,0.00032471193],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004837929,0.0005016878,0.001627875,0.00022366707,0.0005600715,0.00007785357,0.00036816357,0.00021394201,0.00018573536],"category_scores_gemma":[0.00078098645,0.00026821595,0.00021385765,0.00045508382,0.000548794,0.00014048605,0.00027320953,0.00068973075,0.00016807445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010623184,0.001555486,0.85295784,0.00010865178,0.00030458183,0.00008149542,0.0030435803,0.0000020891357,0.00055759744,0.00010612507,0.0067834537,0.13343677],"study_design_scores_gemma":[0.021583758,0.002816316,0.9483312,0.0010313652,0.0003975191,0.000004949827,0.00081391935,0.000042758107,0.000018853512,0.000047770267,0.024527926,0.0003836786],"about_ca_topic_score_codex":0.00036415423,"about_ca_topic_score_gemma":0.00030172057,"teacher_disagreement_score":0.1330531,"about_ca_system_score_codex":0.00022312085,"about_ca_system_score_gemma":0.00012629436,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W2122026430","doi":"10.1093/infdis/jis750","title":"Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study","year":2012,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Dolutegravir; Raltegravir; Regimen; Cohort; Medicine; Viral load; Integrase inhibitor; Elvitegravir; Dosing; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.01656090380541293,"score_gpt":0.27322790795775004,"score_spread":0.2566670041523371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122026430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780583,0.0009133892,0.0000061809997,0.00017947113,0.00013644928,0.00057138863,0.000008806245,0.000009546426,0.00036891756],"genre_scores_gemma":[0.99922514,0.00038780997,0.000021490921,0.000013077992,0.00007515361,0.000005289412,0.0000024003918,0.000013602606,0.00025604106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998581,0.0002551683,0.0005458521,0.000094765666,0.00033128512,0.00019192828],"domain_scores_gemma":[0.99864775,0.00033114728,0.0005011992,0.00024036209,0.00015736173,0.00012215362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036856753,0.00018306305,0.000447441,0.0001635039,0.00012150676,0.000008659238,0.00007043425,0.000030234489,0.000012301227],"category_scores_gemma":[0.00020149024,0.000079881414,0.0000978079,0.00050267304,0.00013117185,0.000118837335,0.000030430258,0.00012783508,0.0000010493169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010602977,0.004349699,0.9724762,0.00002683454,0.00045798253,0.000018670835,0.010196682,0.000060537834,0.0006181862,0.000016153119,0.000042471842,0.0011336012],"study_design_scores_gemma":[0.013060344,0.003165537,0.9779921,0.00031032803,0.00092261704,0.00013712134,0.0021218874,0.0000032478463,0.0019410122,0.000011954697,0.0002472982,0.00008652069],"about_ca_topic_score_codex":0.00025409044,"about_ca_topic_score_gemma":0.00026866648,"teacher_disagreement_score":0.008074795,"about_ca_system_score_codex":0.00018613043,"about_ca_system_score_gemma":0.00024880323,"threshold_uncertainty_score":0.32574695},"labels":[],"label_agreement":null},{"id":"W2122161550","doi":"10.1139/v06-052","title":"Enantiomeric synthesis of carbocyclic analogs of <scp>D</scp>- and <scp>L</scp>-6-azapyrimidine ribonucleosides","year":2006,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry; Stereochemistry; Enantiomer; Cyclopentenone; Metathesis; Moiety; Ring-closing metathesis; Desymmetrization; Combinatorial chemistry; Enantioselective synthesis; Organic chemistry; Catalysis","score_opus":0.006745236256283296,"score_gpt":0.20175988704077027,"score_spread":0.195014650784487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122161550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821586,0.0034173338,0.000006199499,0.00034203823,0.000057925765,0.00008711677,0.000043255037,0.0000067264928,0.013880788],"genre_scores_gemma":[0.993818,0.0002188027,0.0005489265,0.000030508718,0.00016421385,0.0000031678371,0.00001723518,0.0000305642,0.005168605],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833655,0.00002267245,0.00074922404,0.00018743514,0.00030729937,0.0003967892],"domain_scores_gemma":[0.99785346,0.00039953625,0.00057925103,0.0002212858,0.0002767713,0.00066970335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023559351,0.00024184561,0.0007420281,0.0003079857,0.00007130312,0.000019036845,0.00015740284,0.00015496995,0.000050765047],"category_scores_gemma":[0.00086437905,0.00021098032,0.000203434,0.00036714642,0.00028773487,0.00007771611,0.000015284691,0.0002117204,0.0000026162413],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026048314,0.00036055653,0.53097457,0.0015489473,0.0014834881,0.0019266995,0.001751575,0.000029179924,0.40031222,0.000047409943,0.057427164,0.00411215],"study_design_scores_gemma":[0.0014953293,0.000084545296,0.07677116,0.0007931763,0.0005995939,0.0008773534,0.001501295,0.000017512251,0.8988182,0.00015066855,0.018816706,0.00007444101],"about_ca_topic_score_codex":0.001592263,"about_ca_topic_score_gemma":0.0006410998,"teacher_disagreement_score":0.498506,"about_ca_system_score_codex":0.0001780771,"about_ca_system_score_gemma":0.0011560199,"threshold_uncertainty_score":0.86035275},"labels":[],"label_agreement":null},{"id":"W2122280827","doi":"10.1001/jama.296.7.827","title":"Treatment for Adult HIV Infection","year":2006,"lang":"en","type":"article","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1037,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Antiretroviral therapy; Ritonavir; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Intensive care medicine; MEDLINE; Human immunodeficiency virus (HIV); Family medicine; Immunology; Viral load","score_opus":0.011525131692059118,"score_gpt":0.2615392131010178,"score_spread":0.2500140814089587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122280827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93095964,0.00009850605,0.0011352382,0.028195966,0.00018945034,0.0011028327,0.00002218217,0.00018696513,0.038109187],"genre_scores_gemma":[0.8262647,0.000042030766,0.0040782723,0.00023840863,0.0005628162,0.00029505068,0.00037896313,0.000018960027,0.1681208],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99951977,0.0000059059857,0.00011893743,0.00013665158,0.00007918897,0.0001395625],"domain_scores_gemma":[0.9996998,0.00002633755,0.000027831373,0.00010130698,0.00010276384,0.00004200669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000021807733,0.000098922974,0.00013347017,0.00005743391,0.000054727643,0.000014138627,0.000010862418,0.000051639745,0.000058996717],"category_scores_gemma":[0.000022317296,0.00007021243,0.00008551644,0.00006365258,0.00000980556,0.00004137543,0.000003980073,0.000022599319,0.0002029664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071105344,0.0021245216,0.5339785,0.0001016319,0.00038563323,0.0000967572,0.0005086253,0.000010660118,0.0011608837,0.007707241,0.2697666,0.18344788],"study_design_scores_gemma":[0.018875591,0.00058483717,0.19080651,0.000064321466,0.00031692305,0.000063808,0.000040648127,0.0004961799,0.027283482,0.0007519675,0.760512,0.0002037457],"about_ca_topic_score_codex":0.000106019244,"about_ca_topic_score_gemma":0.000069157955,"teacher_disagreement_score":0.4907454,"about_ca_system_score_codex":0.00019616817,"about_ca_system_score_gemma":0.000042553937,"threshold_uncertainty_score":0.28631797},"labels":[],"label_agreement":null},{"id":"W2122354449","doi":"10.1093/ije/dyu046","title":"Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort","year":2014,"lang":"en","type":"article","venue":"International Journal of Epidemiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; Simon Fraser University; University of British Columbia","funders":"Canadian Institutes of Health Research; National Institute on Drug Abuse; U.S. President’s Emergency Plan for AIDS Relief","keywords":"Cohort; Medicine; Cohort study; Family medicine; Observational study; Viral load; Human immunodeficiency virus (HIV); Demography; Internal medicine","score_opus":0.1855614565163045,"score_gpt":0.4927781277835306,"score_spread":0.30721667126722607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122354449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8895524,0.00067430444,0.0018860147,0.09976699,0.0010104883,0.00042503196,0.000004751193,0.00001195361,0.006668078],"genre_scores_gemma":[0.98265254,0.0007462518,0.009888036,0.0024433052,0.0014520156,0.00005297275,0.00019204534,0.000016219787,0.0025566057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955211,0.0011310938,0.0010033806,0.00024103424,0.0018474328,0.00025591522],"domain_scores_gemma":[0.9932734,0.003257966,0.00035591502,0.00012914542,0.002687954,0.0002956605],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024328507,0.000119984805,0.00049964816,0.00039977243,0.00006658756,0.000011144991,0.00021661066,0.00017096294,0.001466253],"category_scores_gemma":[0.028219158,0.000087512926,0.00009729496,0.0001202159,0.00026532495,0.00012220355,0.00008400073,0.00049620104,0.000066699045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020662931,0.000132882,0.93504614,0.0000073395377,0.000636511,0.000048114514,0.00005976294,0.0000070027063,0.000054269374,0.0076708994,0.028260503,0.027869971],"study_design_scores_gemma":[0.0019597518,0.00017252895,0.9262181,0.0001638565,0.000105916486,0.0010499909,0.000023491515,0.005768314,0.000064980166,0.007151322,0.057250034,0.0000717266],"about_ca_topic_score_codex":0.000019096453,"about_ca_topic_score_gemma":0.0000071674885,"teacher_disagreement_score":0.097323686,"about_ca_system_score_codex":0.00029173377,"about_ca_system_score_gemma":0.000689887,"threshold_uncertainty_score":0.9994466},"labels":[],"label_agreement":null},{"id":"W2122621859","doi":"10.1128/jvi.00271-12","title":"Subunit-Selective Mutational Analysis and Tissue Culture Evaluations of the Interactions of the E138K and M184I Mutations in HIV-1 Reverse Transcriptase","year":2012,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Institute for Health and Care Research","keywords":"Reverse transcriptase; Virology; Etravirine; Biology; Mutation; Resistance mutation; Rilpivirine; Lamivudine; Emtricitabine; Reverse-transcriptase inhibitor; Genetics; Virus; RNA; Gene; Viral load; Hepatitis B virus","score_opus":0.01459243348311442,"score_gpt":0.3211820228400785,"score_spread":0.3065895893569641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122621859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923162,0.00039762317,0.000318642,0.0065390225,0.000078719866,0.0001522453,0.000025550255,8.854649e-7,0.00017112095],"genre_scores_gemma":[0.99805486,0.000049627983,0.0010198631,0.000094816634,0.000025389701,0.000005033374,0.000008734024,0.000003137338,0.00073851796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921906,0.00017394914,0.00032552215,0.000052567128,0.00015091595,0.00007800936],"domain_scores_gemma":[0.9993095,0.00013109812,0.00026012797,0.00007139433,0.00018336745,0.000044537017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026047448,0.0000631444,0.00022634098,0.00023556734,0.000060956478,0.0000022065558,0.000040260984,0.000041252628,0.000082477476],"category_scores_gemma":[0.00015487717,0.000034597542,0.00008769261,0.00047490094,0.00013588823,0.00009829595,0.000011538166,0.00018433055,6.537757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020365146,0.0006407985,0.9360323,0.000022614584,0.0016906548,0.0000065636655,0.027133983,0.00024127259,0.03145025,0.00045034775,0.0011047577,0.001022828],"study_design_scores_gemma":[0.001328369,0.00009061188,0.9879561,0.000033319808,0.0023960837,0.0002512263,0.0014174898,0.00014438812,0.0049709408,0.00030864534,0.0010697077,0.000033137436],"about_ca_topic_score_codex":0.000017866982,"about_ca_topic_score_gemma":0.00017064289,"teacher_disagreement_score":0.0519238,"about_ca_system_score_codex":0.000044318447,"about_ca_system_score_gemma":0.000103330196,"threshold_uncertainty_score":0.14108469},"labels":[],"label_agreement":null},{"id":"W2122778067","doi":"10.1128/aac.44.10.2816-2823.2000","title":"Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of BCH-10652 in Healthy Adult Males","year":2000,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Pharmacokinetics; Chemistry; Tolerability; Pharmacology; Liter; Volume of distribution; Placebo; Oral administration; Internal medicine; Adverse effect; Medicine","score_opus":0.016493122919182614,"score_gpt":0.2818806240974776,"score_spread":0.265387501178295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122778067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930673,0.00010832391,0.000003398416,0.005839526,0.00002473339,0.00028964246,0.000022857237,0.000009499286,0.0006346922],"genre_scores_gemma":[0.989221,0.0066964533,0.0012049078,0.0019053924,0.00002116674,0.0000018942133,0.000024784047,0.000014649828,0.00090980047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991431,0.000022927155,0.00036775414,0.00019981497,0.00009858626,0.0001677752],"domain_scores_gemma":[0.9997012,0.000020642654,0.000068494905,0.000099074394,0.00004387151,0.00006670533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007175295,0.00014358618,0.0003956284,0.00006773807,0.000028330713,0.0000064309897,0.000038731836,0.000056320732,0.00046349657],"category_scores_gemma":[0.0000035215073,0.00011782368,0.00004163419,0.00011725696,0.00013527635,0.000036995458,0.000015192417,0.000055530378,0.000002099251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037189815,0.002554202,0.79584736,0.0005028039,0.00019023161,0.00002184377,0.0024201511,0.000003894362,0.034385037,0.00002511518,0.0038729387,0.15645747],"study_design_scores_gemma":[0.028485594,0.0013717222,0.72751015,0.0007952704,0.00016355026,0.00008259137,0.00017565707,0.00015371003,0.19719878,0.000098046396,0.043500144,0.00046478488],"about_ca_topic_score_codex":0.00009572443,"about_ca_topic_score_gemma":0.000035656933,"teacher_disagreement_score":0.16281375,"about_ca_system_score_codex":0.000021033757,"about_ca_system_score_gemma":0.000032828393,"threshold_uncertainty_score":0.50749624},"labels":[],"label_agreement":null},{"id":"W2123797407","doi":"10.1586/14787210.1.3.389","title":"The role of lopinavir/ritonavir (Kaletra®) in the management of HIV infected adults","year":2003,"lang":"en","type":"review","venue":"Expert Review of Anti-infective Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Etobicoke General Hospital; University of Toronto","funders":"","keywords":"Lopinavir; Ritonavir; Lopinavir/ritonavir; Medicine; Protease inhibitor (pharmacology); Pandemic; Human immunodeficiency virus (HIV); Expert opinion; Coronavirus disease 2019 (COVID-19); Pharmacology; Virology; Intensive care medicine; Internal medicine; Antiretroviral therapy; Viral load","score_opus":0.018739451335537546,"score_gpt":0.3470957610545236,"score_spread":0.32835630971898605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123797407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030778092,0.9887708,0.0000072997664,0.00016222008,0.00011798112,0.005615535,0.000023034183,0.000016890175,0.0049784654],"genre_scores_gemma":[0.00022495748,0.99827963,0.00025164115,0.00013474429,0.000052427087,0.0006460671,0.00013117182,0.000060916936,0.00021845225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958929,0.0009016086,0.0016935384,0.00047047448,0.0006702316,0.00037125262],"domain_scores_gemma":[0.99703187,0.00044400603,0.0011360527,0.0010610257,0.00026883584,0.000058240184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011782643,0.00068906666,0.0033381074,0.00022137557,0.00007445822,0.000009042645,0.00048799242,0.00018207685,0.00009763061],"category_scores_gemma":[0.00003934738,0.00032813183,0.0011445249,0.0012260521,0.00026962106,0.00005855655,0.00006268957,0.0003794611,0.000025162864],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005116688,0.0011286908,0.00060066546,0.0445482,0.0018833408,0.00002644244,0.0006785407,1.8616035e-8,0.0000045626466,0.00092873414,0.0006842466,0.9494654],"study_design_scores_gemma":[0.0011884228,0.00025340225,0.0007291715,0.16549173,0.0005044646,0.000033803437,0.00016923899,2.0657806e-7,0.00015224496,0.000042515025,0.8311947,0.00024011682],"about_ca_topic_score_codex":0.00002990031,"about_ca_topic_score_gemma":0.000003400871,"teacher_disagreement_score":0.94922525,"about_ca_system_score_codex":0.00015761571,"about_ca_system_score_gemma":0.00026750896,"threshold_uncertainty_score":0.9999171},"labels":[],"label_agreement":null},{"id":"W2123853362","doi":"10.1128/jvi.02005-12","title":"Molecular Mechanism of Antagonism between the Y181C and E138K Mutations in HIV-1 Reverse Transcriptase","year":2012,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Institute for Health and Care Research","keywords":"Processivity; Reverse transcriptase; Biology; Virology; Mutation; Enzyme; Etravirine; Recombinant DNA; DNA; Genetics; DNA replication; Biochemistry; Gene; Polymerase chain reaction","score_opus":0.015392340702498359,"score_gpt":0.27043660169522715,"score_spread":0.2550442609927288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123853362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98709506,0.00073350884,0.0010372994,0.010728532,0.00009391158,0.000121009885,0.0000084342655,0.000002098891,0.00018013534],"genre_scores_gemma":[0.9980325,0.0001231144,0.0013442797,0.00029194838,0.00006539008,0.00000239847,0.000006623246,0.000007306347,0.00012642943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992287,0.00009058032,0.0003484613,0.000053673673,0.00012579832,0.00015276918],"domain_scores_gemma":[0.9995636,0.000071835944,0.00015465186,0.000079118545,0.000038037637,0.000092776936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040299713,0.00007867292,0.00028770184,0.00015872823,0.000025486299,0.0000020640948,0.000047874917,0.00006652153,0.00003779079],"category_scores_gemma":[0.000035518835,0.000049637805,0.000067752335,0.000083656065,0.00007136574,0.00006658041,0.000010847152,0.00018301822,0.00000542144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008632659,0.0015575439,0.51806897,0.00014168593,0.0017488122,0.0014922834,0.020005597,0.000023482273,0.4303939,0.015869763,0.00270237,0.007132327],"study_design_scores_gemma":[0.021442289,0.0020553276,0.66572577,0.0002472682,0.003476076,0.0036712063,0.0031307274,0.00010734167,0.2662124,0.009424563,0.024096288,0.0004107627],"about_ca_topic_score_codex":0.0000046809128,"about_ca_topic_score_gemma":9.1620853e-7,"teacher_disagreement_score":0.1641815,"about_ca_system_score_codex":0.000026776122,"about_ca_system_score_gemma":0.00005407527,"threshold_uncertainty_score":0.20241709},"labels":[],"label_agreement":null},{"id":"W2123872558","doi":"10.1016/j.ijid.2008.05.111","title":"Retroviral Biodiversity: Practical Consequences for HIV Treatment and Prevention","year":2008,"lang":"en","type":"article","venue":"International Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Reverse transcriptase; Biology; Genome; Drug resistance; Genetics; Virology; Resistance mutation; Mutation; Viral replication; Mutation rate; Human immunodeficiency virus (HIV); Gene; Computational biology; RNA; Virus","score_opus":0.03062378567246601,"score_gpt":0.3229620637489587,"score_spread":0.2923382780764927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123872558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903538,0.00029681978,0.000701895,0.007830628,0.0002827769,0.00019050599,0.000047523794,0.000017737862,0.00027827633],"genre_scores_gemma":[0.9963164,0.0007773986,0.0012384169,0.00013017384,0.0002020209,0.0000081569015,0.000038282156,0.000004003122,0.0012851928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993805,0.000022835864,0.000208585,0.0000925678,0.00021535909,0.0000801191],"domain_scores_gemma":[0.9992136,0.000108670516,0.0001771119,0.000036774632,0.0003425045,0.0001213651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046936042,0.0000895069,0.00017237273,0.00016870064,0.00007874965,0.00002145895,0.000030940108,0.000028206612,0.00005926969],"category_scores_gemma":[0.00017697258,0.00006577235,0.0001487868,0.000035291563,0.00011080682,0.00018128737,0.000012431004,0.000040661806,0.000010364021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094762765,0.0009287759,0.9823457,0.000010621946,0.0012215436,0.00081238284,0.00026155042,0.0000035150847,0.00014302628,0.00022852894,0.009587678,0.0035090242],"study_design_scores_gemma":[0.061351813,0.012956234,0.74435484,0.00069424376,0.004739937,0.046920925,0.0011651426,0.00017635482,0.0095845135,0.008230819,0.10899302,0.00083214924],"about_ca_topic_score_codex":0.000006325766,"about_ca_topic_score_gemma":0.0000034476477,"teacher_disagreement_score":0.23799089,"about_ca_system_score_codex":0.00023831455,"about_ca_system_score_gemma":0.00036331665,"threshold_uncertainty_score":0.26821187},"labels":[],"label_agreement":null},{"id":"W2124388656","doi":"10.2217/fvl.11.35","title":"HIV-1 Reverse Transcriptase Inhibitors: Beyond Classic Nucleosides and Non-Nucleosides","year":2011,"lang":"en","type":"article","venue":"Future Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reverse transcriptase; Nucleoside; Nucleoside analogue; RNase H; Allosteric regulation; Enzyme; Nucleotide; Human immunodeficiency virus (HIV); Chemistry; Nucleoside Reverse Transcriptase Inhibitor; RNase P; Drug; Pharmacology; Virology; Biochemistry; Biology; RNA","score_opus":0.011068267264342398,"score_gpt":0.2120074923303937,"score_spread":0.2009392250660513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124388656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97210926,0.0012358557,0.000042797077,0.012992065,0.00079921656,0.0005073754,0.000031738342,0.00013021573,0.012151503],"genre_scores_gemma":[0.98066163,0.00046931513,0.0072344956,0.0031786135,0.0009421099,0.00005598202,0.00008955221,0.000057992143,0.0073102997],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986418,0.000054246346,0.00031500123,0.0004456492,0.00014612936,0.00039717412],"domain_scores_gemma":[0.99929684,0.000029516514,0.00007647559,0.00029840556,0.000042066127,0.00025669008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012586749,0.00029820573,0.0004572929,0.00020455466,0.00012773865,0.000011233109,0.000080666,0.0002889714,0.000751207],"category_scores_gemma":[0.000015660442,0.00023292286,0.00011061075,0.00015306722,0.00023027715,0.00012322252,0.000041280844,0.0002728022,0.00034864282],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031643622,0.002035006,0.3659673,0.00042310034,0.0014045674,0.0035603452,0.043037754,2.603936e-7,0.07396372,0.0037280808,0.47647706,0.026238466],"study_design_scores_gemma":[0.008061067,0.0011356979,0.26012883,0.00012449347,0.00091282214,0.00059843407,0.003034964,0.00003076238,0.01639509,0.0011989658,0.7077147,0.0006642306],"about_ca_topic_score_codex":0.000018844463,"about_ca_topic_score_gemma":0.000048756956,"teacher_disagreement_score":0.2312376,"about_ca_system_score_codex":0.000040665895,"about_ca_system_score_gemma":0.00006474271,"threshold_uncertainty_score":0.94983184},"labels":[],"label_agreement":null},{"id":"W2124631799","doi":"10.1128/jvi.01164-10","title":"Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor","year":2010,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Elvitegravir; Biology; Integrase; Raltegravir; Viral replication; Mutagenesis; In silico; Mutation; Point mutation; Virus; Virology; Genetics; Molecular biology; Gene; Viral load","score_opus":0.02040213939468007,"score_gpt":0.30687173805300166,"score_spread":0.2864695986583216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124631799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97215474,0.00004546512,0.013093959,0.013765188,0.00048196915,0.0003141467,0.000040144427,0.0000054707543,0.00009894946],"genre_scores_gemma":[0.9484607,0.000005503797,0.037695326,0.00024310793,0.00032211395,0.000029098142,0.00003467369,0.000012172908,0.013197334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989641,0.000028355382,0.0006329059,0.00011653474,0.00014375632,0.00011435171],"domain_scores_gemma":[0.99877524,0.00012008332,0.00039787404,0.0001422434,0.00046618975,0.000098347016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056275434,0.00008418459,0.0002521436,0.00035866507,0.00005338088,0.000009464625,0.00006356332,0.00009058543,0.0000675433],"category_scores_gemma":[0.00059702806,0.000068524656,0.000092145216,0.00015465636,0.000043137756,0.00009160723,0.000009733967,0.00016352172,0.000012330373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093479943,0.0003306466,0.0007170338,0.000022261444,0.00009664393,0.000008954528,0.00062674744,0.000013888876,0.9833555,0.0014893468,0.012065417,0.00033874967],"study_design_scores_gemma":[0.0057500657,0.0007002457,0.012824821,0.00006729204,0.00032059723,0.000203697,0.0002079635,0.00041410222,0.91274846,0.00057903444,0.06605306,0.00013064864],"about_ca_topic_score_codex":4.9127317e-7,"about_ca_topic_score_gemma":0.0002923263,"teacher_disagreement_score":0.070607044,"about_ca_system_score_codex":0.000052848714,"about_ca_system_score_gemma":0.00030669125,"threshold_uncertainty_score":0.27943546},"labels":[],"label_agreement":null},{"id":"W2124777219","doi":"10.1007/s40273-014-0173-7","title":"Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Darunavir; Ritonavir; Quality of Life Research; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Health economics; Public health; Health administration; Cost effectiveness; Pharmacoeconomics; Intensive care medicine; Virology; Viral load; Nursing","score_opus":0.017243557705987324,"score_gpt":0.2933875668528628,"score_spread":0.2761440091468755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124777219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723285,0.00004161777,0.00021724383,0.00015961104,0.00016191977,0.001743555,0.000059082227,0.000015752254,0.00036838607],"genre_scores_gemma":[0.99853164,0.0002645057,0.00018362424,0.00006582791,0.000040189432,0.00034450344,0.00041877484,0.000025477535,0.00012544474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992043,0.000065278924,0.00023620132,0.00023667369,0.00006852923,0.00018906017],"domain_scores_gemma":[0.99941194,0.00021827774,0.00012332799,0.000109287364,0.0000647492,0.00007239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016061433,0.00018317917,0.00038631467,0.00010638937,0.000040785686,0.00000713372,0.000036757556,0.000032663593,0.00001562965],"category_scores_gemma":[0.000008003391,0.00015106046,0.000051329193,0.00008038481,0.000026048392,0.00010991945,0.0000066041202,0.00004570837,0.00000441208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043738266,0.00049170543,0.94476265,0.00014390127,0.00022314631,0.000004511149,0.00021411607,0.0002073126,0.0005533395,0.000098916054,0.000091161724,0.048835397],"study_design_scores_gemma":[0.0922183,0.0026272028,0.6606702,0.00033953955,0.00022175636,0.000012464799,0.00012765305,0.014224467,0.22046722,0.00006663914,0.008590134,0.00043437455],"about_ca_topic_score_codex":0.1402458,"about_ca_topic_score_gemma":0.114663765,"teacher_disagreement_score":0.28409243,"about_ca_system_score_codex":0.0014694049,"about_ca_system_score_gemma":0.0005912403,"threshold_uncertainty_score":0.9014913},"labels":[],"label_agreement":null},{"id":"W2124976010","doi":"10.1128/aac.05181-14","title":"Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity","year":2015,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Lamivudine; Virology; Human immunodeficiency virus (HIV); Drug resistance; Genetics; Biology; Virus; Antiretroviral therapy; Viral load","score_opus":0.026361048266867058,"score_gpt":0.25225345684198497,"score_spread":0.22589240857511791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124976010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869062,0.00014783464,0.000035059766,0.0112320315,0.000029301496,0.00032915597,0.000026922167,0.000015222553,0.001278317],"genre_scores_gemma":[0.99336785,0.0013103647,0.000874799,0.0010430298,0.000018351015,0.0000067875294,0.00003311299,0.000009582351,0.0033361015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993976,0.000026093714,0.00015832159,0.00020466246,0.000103580394,0.00010973799],"domain_scores_gemma":[0.9995561,0.000019645238,0.000088217945,0.00015713042,0.00008918891,0.000089715504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099655445,0.00012476528,0.00020140984,0.000036076155,0.00012346085,0.0000166964,0.0000385554,0.000048708196,0.0000071857207],"category_scores_gemma":[0.00002496323,0.00008255918,0.000030152669,0.00011379343,0.00027200658,0.000056646124,0.000025583968,0.00005920624,0.0000010874381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007635994,0.001625056,0.81519145,0.00026731426,0.0006625919,0.000018463772,0.00933272,7.318125e-7,0.026425885,0.0061104186,0.13261427,0.006987502],"study_design_scores_gemma":[0.013976051,0.00014723159,0.8246505,0.0006657166,0.00024068022,0.00006710748,0.00068245287,0.000071843264,0.08145721,0.0011081902,0.07653401,0.00039896867],"about_ca_topic_score_codex":0.00003268428,"about_ca_topic_score_gemma":0.000039747418,"teacher_disagreement_score":0.056080252,"about_ca_system_score_codex":0.000032157175,"about_ca_system_score_gemma":0.00004966815,"threshold_uncertainty_score":0.33666655},"labels":[],"label_agreement":null},{"id":"W2125970410","doi":"10.4212/cjhp.v67i1.1321","title":"Orogastric Administration of Crushed Darunavir Tablets for a Critically Ill Patient","year":2014,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Darunavir; Ritonavir; Lopinavir; Lamivudine; Gastroenterology; Abacavir; Lopinavir/ritonavir; Viral load; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Hepatitis B virus","score_opus":0.013605820230552837,"score_gpt":0.2774963976862782,"score_spread":0.26389057745572536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125970410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635571,0.0002876486,0.0003138879,0.03324399,0.00043272815,0.00050926843,0.00003369575,0.0000048517522,0.0016168155],"genre_scores_gemma":[0.996946,0.000011502644,0.0016525874,0.0008287547,0.0001638041,0.000009555926,0.000012899418,0.000015011213,0.00035988443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989836,0.00003577352,0.00042199696,0.00008529764,0.00022200652,0.00025130654],"domain_scores_gemma":[0.9982059,0.00009383386,0.00019367013,0.000114115865,0.00090894394,0.00048352362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002739658,0.000117843825,0.00024614471,0.00013648716,0.0001243936,0.000026694779,0.0001191458,0.000023684408,0.00012803516],"category_scores_gemma":[0.00047936302,0.00007818683,0.00012960147,0.00012389563,0.00008994109,0.00010025553,0.000006199957,0.00013427419,0.000008088576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005707373,0.004199153,0.14298382,0.0009847465,0.004629135,0.0029953977,0.023602339,0.00013054798,0.008881956,0.014529419,0.30200982,0.4893463],"study_design_scores_gemma":[0.031857166,0.020596618,0.050811015,0.0011472809,0.0033279583,0.0017671955,0.0022596733,0.001492729,0.09756079,0.0047449665,0.78335553,0.0010790959],"about_ca_topic_score_codex":0.00033381148,"about_ca_topic_score_gemma":0.0008548775,"teacher_disagreement_score":0.48826718,"about_ca_system_score_codex":0.00015154459,"about_ca_system_score_gemma":0.0014910671,"threshold_uncertainty_score":0.31883663},"labels":[],"label_agreement":null},{"id":"W2126414664","doi":"10.1128/aac.44.4.821-826.2000","title":"Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function","year":2000,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Amprenavir; Protease inhibitor (pharmacology); Pharmacokinetics; Enzyme inhibitor; Pharmacology; Ritonavir; Protease; Medicine; Virology; Human immunodeficiency virus (HIV); Biology; Enzyme; Viral load; Antiretroviral therapy; Biochemistry; HIV-1 protease","score_opus":0.016688583347732117,"score_gpt":0.2574691009100379,"score_spread":0.24078051756230576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126414664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99852777,0.00004925834,0.0000050139406,0.0003005857,0.000037803402,0.0006892276,0.00000642962,0.000029409328,0.00035452953],"genre_scores_gemma":[0.9947958,0.00045092593,0.0002847589,0.00069272,0.000036334615,0.000012299748,0.00005434018,0.000030143492,0.003642681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990496,0.00002538464,0.00029403748,0.00024018736,0.00015018469,0.00024060073],"domain_scores_gemma":[0.9996591,0.000007850425,0.00008007258,0.00013881724,0.00004808459,0.000066066605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065913875,0.00020838808,0.00029666492,0.00010640087,0.00007359546,0.000019046009,0.000047461992,0.000062077066,0.0007972592],"category_scores_gemma":[0.000002211495,0.00014489761,0.00004155372,0.000302916,0.00008133901,0.000080378464,0.0000108863505,0.00009444343,0.000011285979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016114848,0.0061660893,0.18527481,0.0003570701,0.00035986817,0.0002091581,0.0035848415,0.0000125879005,0.7149332,0.0000028487755,0.0028858497,0.0700988],"study_design_scores_gemma":[0.040336598,0.0054154755,0.24720483,0.0012452997,0.00039540933,0.00017353246,0.000122006946,0.0002680445,0.6848949,0.0000125988345,0.019139783,0.00079150783],"about_ca_topic_score_codex":0.00015828705,"about_ca_topic_score_gemma":0.000049946728,"teacher_disagreement_score":0.0693073,"about_ca_system_score_codex":0.00004557567,"about_ca_system_score_gemma":0.000087403845,"threshold_uncertainty_score":0.8729429},"labels":[],"label_agreement":null},{"id":"W2127706932","doi":"10.1016/j.artmed.2009.05.002","title":"A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy","year":2009,"lang":"en","type":"article","venue":"Artificial Intelligence in Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Cancer Institute","keywords":"Viral load; Random forest; Support vector machine; Test set; Regimen; Artificial neural network; Artificial intelligence; Machine learning; Feature selection; Data set; Human immunodeficiency virus (HIV); Set (abstract data type); Computer science; Statistics; Medicine; Mathematics; Immunology; Internal medicine","score_opus":0.22381905826522347,"score_gpt":0.46589087016693426,"score_spread":0.2420718119017108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127706932","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25771546,0.0002463479,0.72132474,0.01974255,0.00007632531,0.00083842216,0.0000032059675,0.000013743577,0.000039210856],"genre_scores_gemma":[0.9251967,0.00003712395,0.07438525,0.00021134192,0.00004994892,0.000046444446,0.00002807469,0.0000060527896,0.00003904106],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99841946,0.00013120375,0.0008053164,0.0001971178,0.00029553374,0.00015138659],"domain_scores_gemma":[0.99761856,0.001772275,0.00015163372,0.00015611,0.00024541526,0.000056006847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017750337,0.00012159687,0.0004296223,0.0002388414,0.000060248953,0.0000032945147,0.00010549001,0.000071083174,0.000044382276],"category_scores_gemma":[0.0004998066,0.00007521312,0.00006040312,0.00044603538,0.00014623613,0.000033778073,0.000010075162,0.000119702134,0.0000031097125],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016410263,0.002223214,0.015303877,0.000032686796,0.00013253043,0.0000036844554,0.014860479,0.18529677,0.03198763,0.021380777,0.00044056107,0.71192753],"study_design_scores_gemma":[0.0005805886,0.0026061577,0.019669313,0.00016456564,0.000059331363,0.0000027596584,0.0011637094,0.89763194,0.029266423,0.048404604,0.00038563373,0.00006497612],"about_ca_topic_score_codex":0.000015439446,"about_ca_topic_score_gemma":0.0000064530145,"teacher_disagreement_score":0.71233517,"about_ca_system_score_codex":0.000055266024,"about_ca_system_score_gemma":0.000059328275,"threshold_uncertainty_score":0.3067102},"labels":[],"label_agreement":null},{"id":"W2128157000","doi":"10.1139/v99-222","title":"Structure of 8-[4'-(3''-nitrobenzamido) benzamido]naphthalene-1,3,6-trisulfonate (NF-033), and molecular basis of its cellular toxicity","year":2000,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Chemistry; Toxicity; Molecule; Monoclinic crystal system; Crystal structure; Suramin; Stereochemistry; Naphthalene; Crystallography; Biochemistry; Receptor; Organic chemistry","score_opus":0.005118681945891192,"score_gpt":0.19882517705452768,"score_spread":0.1937064951086365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128157000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911977,0.004958906,0.0000070589167,0.00064513704,0.000037861097,0.00011081076,0.0001237666,0.0000036049807,0.0029151344],"genre_scores_gemma":[0.9969886,0.00021567062,0.000573479,0.00007782769,0.00007461756,7.1716494e-7,0.000023163595,0.00002443551,0.0020215192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998559,0.000023868175,0.0006203021,0.00017845158,0.00031750844,0.00030085415],"domain_scores_gemma":[0.99840945,0.000028905702,0.00031449375,0.00022138875,0.0002755511,0.0007501946],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011599413,0.00022730163,0.00057941914,0.00014526705,0.000047818245,0.000011530812,0.00016080389,0.00018325537,0.0023590354],"category_scores_gemma":[0.00007627853,0.00020312217,0.00017646962,0.00021866799,0.00013373046,0.00007302645,0.000010167905,0.00027347048,0.0000017875601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014099403,0.00006804729,0.014968831,0.00058548234,0.00048592818,0.0010834784,0.0005133476,0.000031303673,0.9777999,0.0000114080285,0.0008370651,0.0034742479],"study_design_scores_gemma":[0.001602317,0.00007579367,0.0022521093,0.00040327656,0.00021369256,0.0005343272,0.00013145592,0.000014683331,0.9919683,0.00009942484,0.00254705,0.00015757205],"about_ca_topic_score_codex":0.00009610719,"about_ca_topic_score_gemma":0.00009312222,"teacher_disagreement_score":0.014168431,"about_ca_system_score_codex":0.00013444599,"about_ca_system_score_gemma":0.0011853132,"threshold_uncertainty_score":0.9985529},"labels":[],"label_agreement":null},{"id":"W2128258602","doi":"10.1128/aac.01168-08","title":"Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations","year":2009,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Resistance mutation; Reverse transcriptase; Virology; Mutation; Biology; Drug resistance; Virus; HIV drug resistance; Reverse-transcriptase inhibitor; Sida; Genetics; Polymerase chain reaction; Viral disease; Viral load; Antiretroviral therapy; Gene","score_opus":0.014177847558831561,"score_gpt":0.2851666750639915,"score_spread":0.27098882750515996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128258602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989968,0.00011495411,0.000044458513,0.0075220284,0.00007037139,0.0006225104,0.00029130047,0.00005169452,0.0013147024],"genre_scores_gemma":[0.97026527,0.0005776428,0.0017655999,0.0028809465,0.000060794624,0.000022745427,0.0022009918,0.000024015213,0.022201998],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99859834,0.00004286258,0.00044227016,0.00039299048,0.00018325761,0.00034026033],"domain_scores_gemma":[0.9995222,0.00004658585,0.00011546596,0.00014616475,0.00009890345,0.00007069918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012349548,0.0002635871,0.0004053824,0.00024014137,0.00023972306,0.00005120387,0.00009317877,0.00009846618,0.001311231],"category_scores_gemma":[0.000030785286,0.00019017077,0.00004694564,0.0006333443,0.00006968025,0.00014504022,0.000013152811,0.0001963343,0.000019925983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009478639,0.010132608,0.052179236,0.00038692355,0.0010973939,0.0028112475,0.06833079,0.00024795168,0.52292705,0.0025063697,0.31258765,0.01731413],"study_design_scores_gemma":[0.04572561,0.0012210035,0.6712357,0.0025344768,0.00035126857,0.00024542614,0.0023069878,0.0006291953,0.10742621,0.0014978825,0.1645709,0.0022553378],"about_ca_topic_score_codex":0.00010661432,"about_ca_topic_score_gemma":0.0009700642,"teacher_disagreement_score":0.61905646,"about_ca_system_score_codex":0.00017220702,"about_ca_system_score_gemma":0.00016864827,"threshold_uncertainty_score":0.9996017},"labels":[],"label_agreement":null},{"id":"W2128877207","doi":"10.1111/hiv.12141","title":"Etravirine in treatment‐experienced, <scp>HIV</scp>‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase <scp>II PIANO</scp> study","year":2014,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Janssen Pharmaceuticals; Janssen Research and Development; ViiV Healthcare","keywords":"Etravirine; Medicine; Tolerability; Efavirenz; Regimen; Viral load; Nevirapine; Internal medicine; Adverse effect; Rash; Gastroenterology; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.009750343844143116,"score_gpt":0.2721351079692547,"score_spread":0.2623847641251116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128877207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935929,0.0010479633,0.00007117087,0.0013412664,0.00007764101,0.0016924746,0.000042527936,0.000057929617,0.0020760973],"genre_scores_gemma":[0.98807406,0.00067533314,0.00015825006,0.00017362581,0.000109357956,0.00005548937,0.00023402709,0.00003759115,0.010482273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969525,0.00025766421,0.0008508166,0.0007658126,0.0006741472,0.000499072],"domain_scores_gemma":[0.99796635,0.0005072338,0.0003137229,0.0007558148,0.00011532283,0.0003415437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005196296,0.0005165599,0.0013605015,0.0006920777,0.00022468367,0.000015179271,0.00019002323,0.00011331645,0.00002510629],"category_scores_gemma":[0.0010356484,0.0003164067,0.00011607669,0.0019472927,0.0004677109,0.00008973011,0.00013273046,0.00024229412,0.000009855498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024436144,0.0060383766,0.96305746,0.000062968604,0.0016995722,0.000061089944,0.021607885,0.0000047517724,0.0010360278,0.00006001052,0.002658374,0.003469115],"study_design_scores_gemma":[0.04338547,0.0015678926,0.94230473,0.00060936646,0.0033567331,0.000018662318,0.0023782672,0.0001441893,0.00061668275,0.000011256021,0.005525814,0.00008096413],"about_ca_topic_score_codex":0.00011104507,"about_ca_topic_score_gemma":0.000575821,"teacher_disagreement_score":0.043141108,"about_ca_system_score_codex":0.0001561314,"about_ca_system_score_gemma":0.00008309494,"threshold_uncertainty_score":0.9999288},"labels":[],"label_agreement":null},{"id":"W2129105382","doi":"10.1111/j.1574-6968.2005.00095.x","title":"<i>Plasmodium vivax</i>dihydrofolate reductase as a target of sulpha drugs","year":2006,"lang":"en","type":"article","venue":"FEMS Microbiology Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agence Universitaire de la Francophonie","keywords":"Dihydrofolate reductase; Dihydropteroate synthase; Pyrimethamine; Biology; Aminopterin; Mutant; Biochemistry; Enzyme; Plasmodium falciparum; Methotrexate; Gene","score_opus":0.0037829164808267732,"score_gpt":0.21009622957170515,"score_spread":0.2063133130908784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129105382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97295487,0.0003204699,0.000044583838,0.023464829,0.0003389851,0.00039504995,0.00007274504,0.000082415885,0.0023260335],"genre_scores_gemma":[0.9805882,0.000018105758,0.0032421795,0.0032083269,0.00016468688,0.000027367696,0.0011562777,0.00003846168,0.011556377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985059,0.00006521196,0.00045059875,0.0004174915,0.000079982296,0.00048084825],"domain_scores_gemma":[0.9993222,0.000053916116,0.00016503528,0.00032339658,0.000049904113,0.00008554359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015102346,0.00028724514,0.0005165917,0.00020726751,0.00007467104,0.0000072725265,0.00012677748,0.0001571525,0.00029793786],"category_scores_gemma":[0.000013742827,0.00024112375,0.00017181905,0.00020066935,0.00026489998,0.000048522696,0.000055519362,0.00018873812,0.000540584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018957842,0.0002240814,0.0059855212,0.00002888574,0.0002047172,0.00020633837,0.0003432948,0.000011442701,0.85345054,0.000065196444,0.13922434,0.00006605469],"study_design_scores_gemma":[0.003785825,0.0001355525,0.0010265999,0.00008685396,0.00017530046,0.00057173497,0.000067533525,0.00000711508,0.8378772,0.000099659104,0.1558354,0.0003311843],"about_ca_topic_score_codex":0.0001188005,"about_ca_topic_score_gemma":0.000004770468,"teacher_disagreement_score":0.020256503,"about_ca_system_score_codex":0.00010290301,"about_ca_system_score_gemma":0.00009918778,"threshold_uncertainty_score":0.9832741},"labels":[],"label_agreement":null},{"id":"W2129106897","doi":"10.1097/01.qai.0000185313.48933.2c","title":"Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks","year":2005,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Enfuvirtide; Human immunodeficiency virus (HIV); Medicine; Antiretroviral therapy; Virology; Viral load; Immunology","score_opus":0.013102904530421991,"score_gpt":0.27470602469526734,"score_spread":0.2616031201648453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129106897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977813,0.0008571613,0.00010927735,0.00025270332,0.00008946374,0.0005518589,0.00001080153,0.000019916995,0.00032753567],"genre_scores_gemma":[0.992753,0.0005217309,0.0060561704,0.000008821084,0.000012789972,0.000014703664,0.000045346987,0.00003480834,0.0005525982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966414,0.00019137375,0.0018232128,0.0002854015,0.00065428275,0.0004043467],"domain_scores_gemma":[0.99807656,0.00017129726,0.0010034604,0.00035160562,0.00028496736,0.00011208355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007016074,0.00033971178,0.0013507913,0.0013361467,0.000050593957,0.00001763385,0.00021194211,0.00012686253,0.00014308505],"category_scores_gemma":[0.00010572187,0.00024281221,0.00021586212,0.001354707,0.00020837586,0.0007594175,0.000030869574,0.00011083842,0.000008845439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02875468,0.02428868,0.8201048,0.00038460325,0.0010086463,0.0011679446,0.029154023,0.0021172592,0.06355781,0.0005861306,0.00006307746,0.028812354],"study_design_scores_gemma":[0.05923726,0.010389088,0.8814791,0.0019779468,0.00029156407,0.0006088581,0.0067209606,0.002136397,0.0366373,0.00003305467,0.000061937535,0.0004265665],"about_ca_topic_score_codex":0.000099151825,"about_ca_topic_score_gemma":0.00003509471,"teacher_disagreement_score":0.061374273,"about_ca_system_score_codex":0.0005293717,"about_ca_system_score_gemma":0.00036766124,"threshold_uncertainty_score":0.99015945},"labels":[],"label_agreement":null},{"id":"W2129710521","doi":"10.1001/jama.285.9.1155","title":"Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults&lt;SUBTITLE&gt;A Randomized Equivalence Trial&lt;/SUBTITLE&gt;","year":2001,"lang":"id","type":"article","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":279,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lamivudine; Indinavir; Abacavir; Zidovudine; Medicine; Regimen; Virology; Placebo; Efavirenz; Internal medicine; Stavudine; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Viral disease; Virus; Antiretroviral therapy","score_opus":0.014644764124624416,"score_gpt":0.2650518327198785,"score_spread":0.2504070685952541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129710521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91579145,0.0069508255,0.00026481482,0.011318894,0.0039047569,0.010863145,0.00038759867,0.0008039657,0.049714558],"genre_scores_gemma":[0.82403785,0.01637584,0.00080048904,0.0006889595,0.003030106,0.0010883332,0.002079389,0.0004569763,0.15144205],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9834817,0.0017042679,0.004837287,0.0033427987,0.0029091462,0.003724791],"domain_scores_gemma":[0.9906755,0.0023874475,0.0021386135,0.0023906361,0.0010493792,0.0013584262],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0040267487,0.003025422,0.006683233,0.0025905936,0.00065114157,0.00048471763,0.0014213931,0.0018299691,0.0067495015],"category_scores_gemma":[0.005079828,0.002660439,0.0018041236,0.0048016757,0.0012041444,0.0013680224,0.0008884683,0.002472426,0.01178778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7336872,0.0090476,0.11952917,0.0015192304,0.004477779,0.010825473,0.0048147244,0.000028920802,0.008859037,0.0011839641,0.08526917,0.020757696],"study_design_scores_gemma":[0.8909482,0.0028333892,0.033903006,0.005616727,0.0029403935,0.00038738316,0.0004010393,0.0026670115,0.0037547424,0.00020734663,0.053129856,0.0032109546],"about_ca_topic_score_codex":0.00034511063,"about_ca_topic_score_gemma":0.00041046596,"teacher_disagreement_score":0.15726092,"about_ca_system_score_codex":0.002169098,"about_ca_system_score_gemma":0.0011674557,"threshold_uncertainty_score":0.99982893},"labels":[],"label_agreement":null},{"id":"W2129929638","doi":"10.1128/aac.00149-07","title":"In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1","year":2007,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Micropharma (Canada); PerkinElmer Biosignal","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Nelfinavir; Amprenavir; Saquinavir; Indinavir; Lopinavir; Protease; Virology; Biology; Ritonavir; Protease inhibitor (pharmacology); Atazanavir; Virus; Drug resistance; Viral load; Microbiology; HIV-1 protease; Enzyme; Biochemistry; Antiretroviral therapy","score_opus":0.014766946953984311,"score_gpt":0.2981155288827982,"score_spread":0.28334858192881385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129929638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998571,0.0000662756,0.00002369086,0.00030297844,0.000040283845,0.0005441407,0.00003404921,0.000009503316,0.00040808268],"genre_scores_gemma":[0.99616593,0.00010027693,0.0009362905,0.00019703289,0.000024595936,0.0000037628945,0.000015123222,0.000017596609,0.0025393944],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991088,0.000010052354,0.00029463283,0.0002400237,0.00012958949,0.0002168815],"domain_scores_gemma":[0.99960583,0.000013149728,0.00014292999,0.00013162437,0.00006343599,0.00004303301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001801907,0.00016267717,0.000349392,0.00011417381,0.00006113538,0.000011926129,0.000045880588,0.000079220365,0.00003455895],"category_scores_gemma":[0.0000073723054,0.00013603961,0.00004625319,0.00019941418,0.00018283783,0.00009849795,0.000028006625,0.00008904317,0.000001335456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019004196,0.0012288082,0.04906658,0.00018337481,0.000052998144,0.000015515829,0.00082134304,2.6399531e-8,0.944652,0.0000141628,0.0003422956,0.0017224414],"study_design_scores_gemma":[0.0038329887,0.00010532833,0.1765392,0.00012762018,0.000015639267,0.0000044194044,0.000020412446,0.0000047852172,0.8185129,0.0000058684686,0.0007238482,0.000106986874],"about_ca_topic_score_codex":0.00012719545,"about_ca_topic_score_gemma":0.000023649107,"teacher_disagreement_score":0.12747261,"about_ca_system_score_codex":0.000030470826,"about_ca_system_score_gemma":0.000052594693,"threshold_uncertainty_score":0.5547534},"labels":[],"label_agreement":null},{"id":"W2130044431","doi":"10.1093/jac/dku058","title":"Has the time come to abandon efavirenz for first-line antiretroviral therapy?","year":2014,"lang":"en","type":"review","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Efavirenz; Antiretroviral therapy; Medicine; Human immunodeficiency virus (HIV); Virology; First line therapy; Intensive care medicine; Internal medicine; Viral load","score_opus":0.040970593595679616,"score_gpt":0.32333441560276993,"score_spread":0.2823638220070903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130044431","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018742549,0.9682748,0.00061125157,0.024156284,0.00087555265,0.0038965524,0.00008559445,0.000051605162,0.00017410885],"genre_scores_gemma":[0.000120672026,0.9843991,0.0021373404,0.0027965182,0.0018643249,0.000027516198,0.00009514649,0.00018002074,0.008379408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718255,0.00010614903,0.0014595547,0.00035564235,0.0004041924,0.00049193687],"domain_scores_gemma":[0.99746627,0.0003545567,0.0011793055,0.00046294628,0.00030472764,0.00023221767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078722136,0.000723689,0.0033473184,0.00041674744,0.00025961365,0.0001473847,0.0005293433,0.00033964516,0.0001885169],"category_scores_gemma":[0.000059924503,0.00038563978,0.0019245757,0.00038648958,0.000120776764,0.0000802927,0.000036605714,0.00053209596,0.00014715455],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012045158,0.0005960139,0.0000404087,0.002553889,0.0023265746,0.000047973266,0.00035966025,0.0000014133641,0.0002434837,0.0000069568005,0.22924508,0.76337403],"study_design_scores_gemma":[0.0058942856,0.0013498563,0.000007543853,0.007999775,0.00090231333,0.00064499397,0.000002404946,0.000004480694,0.0006639416,0.000008086814,0.982144,0.00037830469],"about_ca_topic_score_codex":0.0000032965131,"about_ca_topic_score_gemma":0.000002096359,"teacher_disagreement_score":0.7629957,"about_ca_system_score_codex":0.00023781332,"about_ca_system_score_gemma":0.0006898097,"threshold_uncertainty_score":0.9998596},"labels":[],"label_agreement":null},{"id":"W2130075256","doi":"10.1086/429672","title":"No Inherent Association between Minor Mutations in HIV Protease at Baseline and Selection of the L90M Mutation at the Time of the First Virological Failure","year":2005,"lang":"en","type":"letter","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Biology; Mutation; Protease; Virology; Human immunodeficiency virus (HIV); Genetics; Gene","score_opus":0.006377853510451093,"score_gpt":0.22270085026586217,"score_spread":0.21632299675541108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130075256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7769123,0.00025403465,0.000008437243,0.22143315,0.00007087715,0.00110529,0.000112325884,0.0000092870205,0.0000943118],"genre_scores_gemma":[0.9800221,0.00011919627,0.000021317726,0.009750519,0.001204147,0.00006451407,0.000120966775,0.00003147929,0.008665801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976972,0.0006511963,0.0006835348,0.00012894499,0.0006593011,0.00017981854],"domain_scores_gemma":[0.9970205,0.000954227,0.001429345,0.00017845519,0.0003711039,0.000046372214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056172657,0.00022915074,0.00043635152,0.00012609478,0.00030347667,0.000015747624,0.0001513758,0.00021810998,0.0002937214],"category_scores_gemma":[0.0007532483,0.00009373884,0.00026828764,0.0003023736,0.00015531907,0.00007167625,0.00009164417,0.0006799251,0.000017766733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022429654,0.0003013409,0.75392526,0.00013340003,0.0006829963,0.00001300833,0.0006275,0.0002866507,0.00016451401,5.7263685e-7,0.24335349,0.00028695702],"study_design_scores_gemma":[0.003534176,0.000386491,0.95006615,0.0006979022,0.004695006,0.0003027216,0.00006764787,0.000211179,0.0009502599,0.000111008085,0.03878126,0.0001961781],"about_ca_topic_score_codex":0.00003239146,"about_ca_topic_score_gemma":0.00024013316,"teacher_disagreement_score":0.21168263,"about_ca_system_score_codex":0.0009041851,"about_ca_system_score_gemma":0.0002240804,"threshold_uncertainty_score":0.38225588},"labels":[],"label_agreement":null},{"id":"W2130271048","doi":"10.1128/aac.48.1.124-129.2004","title":"Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children","year":2003,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Pharmacokinetics; Geometric mean; Reverse-transcriptase inhibitor; Medicine; Dosing; Regimen; Pharmacology; Tenofovir; Area under the curve; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Internal medicine; Virology; Mathematics","score_opus":0.012024366752006783,"score_gpt":0.25703466750485643,"score_spread":0.24501030075284966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130271048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807775,0.00017692406,0.000011265678,0.0003930887,0.000034823606,0.00048003782,0.000018719675,0.000023027966,0.0007843664],"genre_scores_gemma":[0.99536777,0.0020748428,0.00030090773,0.0006595027,0.000011325697,0.0000048252564,0.00004852867,0.000031362004,0.0015009474],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989383,0.000038089653,0.00034328713,0.0002933912,0.00011425838,0.00027267207],"domain_scores_gemma":[0.999632,0.000010615973,0.00010641867,0.00014164267,0.000037841477,0.000071481234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010748842,0.0002335983,0.00036150622,0.00013806392,0.00008398068,0.000025352154,0.000049088198,0.000059522554,0.00011280834],"category_scores_gemma":[0.000004634087,0.00019191836,0.000050086666,0.00020285608,0.00012864674,0.000062079525,0.000022642798,0.00010479402,0.000003624953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019528258,0.0017284879,0.46440864,0.00007342301,0.00022075782,0.000025756799,0.0019543332,0.0000018143404,0.5191942,0.000033112734,0.0009895819,0.011174585],"study_design_scores_gemma":[0.014389668,0.00034191995,0.63757753,0.00020036858,0.0001094274,0.000074162934,0.000052159707,0.000030356163,0.34111977,0.000061862826,0.0056439103,0.00039889142],"about_ca_topic_score_codex":0.00006212556,"about_ca_topic_score_gemma":0.000012482257,"teacher_disagreement_score":0.17807445,"about_ca_system_score_codex":0.000030627092,"about_ca_system_score_gemma":0.000032536467,"threshold_uncertainty_score":0.7826203},"labels":[],"label_agreement":null},{"id":"W2130447065","doi":"10.1086/376835","title":"Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease","year":2003,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Medicine; Internal medicine; Antiretroviral therapy; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Viral load; Population; Medical prescription; Sida; Salvage therapy; Retrospective cohort study; Drug; Human immunodeficiency virus (HIV); Immunology; Oncology; Viral disease; Gastroenterology; Pharmacology; Chemotherapy","score_opus":0.012976170005315093,"score_gpt":0.2671359092746456,"score_spread":0.2541597392693305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130447065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981051,0.0007253377,0.000058602167,0.00042127934,0.000071309776,0.00043917366,0.000011534715,0.000018983565,0.0001486582],"genre_scores_gemma":[0.9991735,0.00042845725,0.000098608456,0.000090403824,0.000031904252,0.000014456185,0.000019902409,0.000014767704,0.00012800733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885243,0.00016327998,0.00043020913,0.000093146904,0.00027592992,0.00018500291],"domain_scores_gemma":[0.99927765,0.0001512566,0.00021305683,0.00012718368,0.00007483223,0.00015601334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017598558,0.00014810973,0.00029211678,0.00021626285,0.0000716303,0.000017614777,0.000049703256,0.000023711698,0.000053387233],"category_scores_gemma":[0.00023100266,0.000083801904,0.00007683863,0.00032850687,0.000054015574,0.00019372953,0.0000050017784,0.00014171818,0.0000027937826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013453087,0.0007100697,0.9953029,0.000016568998,0.000087490866,0.00010177582,0.0002790209,0.0009431051,0.000046881276,0.00013703389,0.00003954835,0.0009902567],"study_design_scores_gemma":[0.007940501,0.00040781344,0.9904528,0.0001773144,0.00016146387,0.00006658232,0.00015889946,0.000086092376,0.000096756405,0.00022922453,0.00012895907,0.00009358573],"about_ca_topic_score_codex":0.000036267233,"about_ca_topic_score_gemma":0.00010794745,"teacher_disagreement_score":0.0065951925,"about_ca_system_score_codex":0.00020012347,"about_ca_system_score_gemma":0.0002607186,"threshold_uncertainty_score":0.34173426},"labels":[],"label_agreement":null},{"id":"W2130749192","doi":"10.1677/joe.0.1780449","title":"The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells","year":2003,"lang":"en","type":"article","venue":"Journal of Endocrinology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Concordia University; Jewish General Hospital","funders":"Canadian Foundation for AIDS Research","keywords":"Glucose transporter; Indinavir; Saquinavir; Amprenavir; Chemistry; Glucose uptake; Protease; Insulin; Pi; Chromosomal translocation; Ritonavir; Membrane transport; Internal medicine; Biochemistry; Endocrinology; Biology; Membrane; HIV-1 protease; Enzyme; Virus; Medicine; Immunology","score_opus":0.008196364987149114,"score_gpt":0.25244917792925364,"score_spread":0.24425281294210452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130749192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705637,0.0005996586,0.000011883256,0.00084771006,0.00047872268,0.00039004866,7.551631e-7,0.0000050114513,0.0006098298],"genre_scores_gemma":[0.9981851,0.0004172535,0.00015927377,0.00005549437,0.00006615602,0.00001186974,0.0000011117378,0.000012966111,0.0010907956],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867415,0.000115528615,0.0005429439,0.000114869385,0.00023520125,0.00031727648],"domain_scores_gemma":[0.9992529,0.00017366688,0.00025983318,0.0001479282,0.000073510215,0.00009212611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016543335,0.00014733095,0.00043903562,0.0002483732,0.000038070626,0.0000033804265,0.00008712821,0.00005781136,0.000026419475],"category_scores_gemma":[0.00010687905,0.00008758228,0.00015360276,0.00014106177,0.00009779721,0.000040932995,0.000007050521,0.000337126,0.000012064834],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005881868,0.00093215064,0.97049606,0.00014938519,0.00026386708,0.0071088234,0.00035697542,0.0000074044297,0.015989013,0.00049271743,0.000479732,0.0031356746],"study_design_scores_gemma":[0.0069475174,0.0016157626,0.4375642,0.00035014813,0.00015449148,0.0006609373,0.000057899706,6.021118e-7,0.55021876,0.00005766161,0.002267561,0.00010450565],"about_ca_topic_score_codex":0.0000038646353,"about_ca_topic_score_gemma":0.00001027247,"teacher_disagreement_score":0.5342297,"about_ca_system_score_codex":0.00008933692,"about_ca_system_score_gemma":0.00018271801,"threshold_uncertainty_score":0.35715017},"labels":[],"label_agreement":null},{"id":"W2130770322","doi":"10.1016/j.clpt.2003.11.133","title":"Absence of circadian variation in the pharmacokinetics (PK) of lopinavir/ritonavir (LPV/R) in a once-daily (QD) dosing regimen in hiv-1-infected subjects","year":2004,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Dosing; Cmax; Ritonavir; Lopinavir/ritonavir; Pharmacokinetics; Lopinavir; Medicine; Pharmacology; Regimen; Human immunodeficiency virus (HIV); Geometric mean; Internal medicine; Chemistry; Gastroenterology; Viral load; Mathematics; Antiretroviral therapy; Immunology","score_opus":0.05824986706197384,"score_gpt":0.39219260239882797,"score_spread":0.33394273533685415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130770322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98515123,0.000642248,0.00008453046,0.012334851,0.00037434633,0.0010170252,0.0000073309016,0.000020957339,0.00036747585],"genre_scores_gemma":[0.9916898,0.0016439436,0.0009701036,0.0053898017,0.00012401251,0.00004804939,0.00002535427,0.00002554504,0.00008337516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705464,0.00054437714,0.0013165431,0.00038443567,0.00028720696,0.00041280873],"domain_scores_gemma":[0.9982566,0.00093454117,0.00035768966,0.00025883023,0.00010426754,0.00008807315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011893647,0.00024756737,0.0006938446,0.0003274345,0.000030768926,0.00000610706,0.0002709778,0.00027287254,0.000042294385],"category_scores_gemma":[0.00005215995,0.00020155935,0.0001300987,0.0009601396,0.00035096216,0.000078272926,0.000050304254,0.0007796727,0.000017895332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027866573,0.00997328,0.87909466,0.00025335167,0.00073909253,0.0007314701,0.01839737,0.0013115063,0.07861964,0.00026357683,0.0004439931,0.007385394],"study_design_scores_gemma":[0.027031472,0.00067621656,0.9515805,0.00044445827,0.00056878163,0.00002931523,0.0003038416,0.0010409139,0.015009699,0.0006754477,0.0023473292,0.0002920136],"about_ca_topic_score_codex":0.00007770223,"about_ca_topic_score_gemma":0.00010086279,"teacher_disagreement_score":0.072485834,"about_ca_system_score_codex":0.0002618501,"about_ca_system_score_gemma":0.00053419865,"threshold_uncertainty_score":0.8219352},"labels":[],"label_agreement":null},{"id":"W2130909538","doi":"10.1086/521252","title":"Outcomes of Dosage Adjustments Used to Manage Antiretroviral Drug Interactions","year":2007,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; St. Joseph’s Healthcare Hamilton; McMaster University; University of Toronto","funders":"Ontario HIV Treatment Network","keywords":"Medicine; Confidence interval; Viral load; Nevirapine; Efavirenz; Rifabutin; Drug; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Pharmacology; Virology","score_opus":0.03805019685639329,"score_gpt":0.3994785303139267,"score_spread":0.36142833345753345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130909538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239635,0.00006766804,0.00027690304,0.00077273854,0.00070852536,0.00058531505,0.000036350226,0.00017200809,0.004984159],"genre_scores_gemma":[0.9862396,0.000027766586,0.00016881649,0.0007309547,0.0001388527,0.000025156512,0.00006236919,0.00002522075,0.012581226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982614,0.00005855115,0.00077478687,0.00033540968,0.00027267257,0.00029721006],"domain_scores_gemma":[0.99827766,0.0006335985,0.00015484892,0.00035437124,0.00009152537,0.00048800022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000270002,0.00020557705,0.0006046185,0.0002559657,0.00007815233,0.000014323751,0.00008200388,0.00004727165,0.00029621643],"category_scores_gemma":[0.0005552171,0.00016196567,0.00040682088,0.00031908584,0.00010250192,0.000098853976,0.00008666301,0.00017781524,0.0003558184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012501692,0.002688382,0.9808322,0.00004128213,0.0005207764,0.00013084116,0.00017196375,0.0000011681966,0.000024006236,0.00010173795,0.004135133,0.011227444],"study_design_scores_gemma":[0.0026404585,0.0002987987,0.99000984,0.00008492813,0.0005114123,0.0000031852544,0.00011287788,0.00000602724,0.00023731284,0.00009077777,0.0058547533,0.00014962113],"about_ca_topic_score_codex":0.00004085896,"about_ca_topic_score_gemma":0.00016095456,"teacher_disagreement_score":0.011077823,"about_ca_system_score_codex":0.00010728297,"about_ca_system_score_gemma":0.00006355363,"threshold_uncertainty_score":0.6604768},"labels":[],"label_agreement":null},{"id":"W2130934452","doi":"10.1111/hiv.12156","title":"A comparison of computational models with and without genotyping for prediction of response to second‐line <scp>HIV</scp> therapy","year":2014,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Institute of Infection and Immunity; National Institute of Allergy and Infectious Diseases; U.S. Public Health Service; Università degli Studi di Brescia; Core Research for Evolutional Science and Technology; University of Cape Town; University of New South Wales; U.S. Department of Defense; Gilead Sciences; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Genotyping; Genotype; Medicine; Regimen; Viral load; Internal medicine; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Oncology; Antiretroviral therapy; Virology; Genetics; Biology","score_opus":0.042530756923936826,"score_gpt":0.3136006925623039,"score_spread":0.27106993563836707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130934452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83787376,0.0003370947,0.15770653,0.0026504837,0.00003568324,0.00084084936,0.00005023812,0.00003073978,0.00047461185],"genre_scores_gemma":[0.96891934,0.000016215621,0.027873784,0.00024188965,0.00009923676,0.000055845197,0.00022104174,0.000023737486,0.0025489312],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99877506,0.000059804403,0.0004403333,0.00023325821,0.00033046174,0.00016105188],"domain_scores_gemma":[0.9987939,0.0004626,0.00017583648,0.00015851032,0.0002604812,0.00014866427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005837822,0.00016451014,0.0006004769,0.0002332978,0.000051679013,0.0000026030286,0.000044336404,0.000052710177,0.000017928944],"category_scores_gemma":[0.000153095,0.00010990562,0.000030584135,0.0001653859,0.00012136788,0.000045898796,0.000013683408,0.0000701996,0.0000019228048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027302034,0.0018644508,0.75668687,0.0014770622,0.0019226489,0.00000795044,0.06733546,0.014363765,0.062766135,0.0025680568,0.04471849,0.018987061],"study_design_scores_gemma":[0.0759992,0.016528778,0.39406988,0.0034513557,0.00089197204,0.00011283582,0.0040223426,0.42304724,0.032072663,0.0022179754,0.04731144,0.00027430386],"about_ca_topic_score_codex":0.0000032461144,"about_ca_topic_score_gemma":0.000006025496,"teacher_disagreement_score":0.40868348,"about_ca_system_score_codex":0.000031339856,"about_ca_system_score_gemma":0.00009389617,"threshold_uncertainty_score":0.4481821},"labels":[],"label_agreement":null},{"id":"W2131078522","doi":"10.1128/aac.02719-13","title":"Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor","year":2014,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Integrase; ADME; Integrase inhibitor; Potency; Chemistry; Pharmacology; Allosteric regulation; Biology; Pharmacokinetics; Biochemistry; Enzyme; In vitro; Virus; Virology; DNA; Viral load","score_opus":0.014916488444149362,"score_gpt":0.2730193150283184,"score_spread":0.25810282658416905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131078522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911454,0.000011105678,0.0005932888,0.005994063,0.00011583743,0.00049740006,0.00004763249,0.000034215274,0.0015611108],"genre_scores_gemma":[0.97920936,0.00019693641,0.0052269013,0.002960503,0.00020624339,0.000011929258,0.00019988608,0.000039394028,0.011948838],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988431,0.00001394309,0.0003926403,0.00034831234,0.00015542797,0.00024658983],"domain_scores_gemma":[0.9993735,0.000039924296,0.00012723659,0.00024409415,0.00007355838,0.00014170636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001590041,0.00023160501,0.0004518481,0.000094286865,0.00006104158,0.00002097615,0.00007545147,0.00012012516,0.00022349965],"category_scores_gemma":[0.000022674327,0.00017182637,0.00013441709,0.00012908815,0.00012636797,0.000062648964,0.000042989446,0.00012813714,0.000104443796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018226178,0.0052666087,0.47740072,0.00064076256,0.0011320655,0.000029533874,0.004606518,8.8385724e-7,0.15190524,0.00011104421,0.31658393,0.04050008],"study_design_scores_gemma":[0.034295693,0.00094133493,0.2195542,0.0014636806,0.0005713136,0.00012333375,0.00018748104,0.0017553169,0.46039426,0.00002756834,0.2797219,0.00096393464],"about_ca_topic_score_codex":0.00002219547,"about_ca_topic_score_gemma":0.0000048529637,"teacher_disagreement_score":0.30848902,"about_ca_system_score_codex":0.000023740258,"about_ca_system_score_gemma":0.000063483196,"threshold_uncertainty_score":0.7006876},"labels":[],"label_agreement":null},{"id":"W2131218326","doi":"10.1111/j.1468-1293.2010.00871.x","title":"Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study)","year":2010,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"Pfizer","keywords":"Medicine; Task (project management); Regimen; Set (abstract data type); Standard deviation; Human immunodeficiency virus (HIV); Data set; Statistics; Machine learning; Artificial intelligence; Data mining; Computer science; Internal medicine; Family medicine; Mathematics","score_opus":0.03828018161141736,"score_gpt":0.3072018566378002,"score_spread":0.26892167502638287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131218326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766413,0.0011204337,0.000028231809,0.02005106,0.00021544169,0.0013683243,0.000059933456,0.00006349203,0.0004517656],"genre_scores_gemma":[0.9910299,0.00006929022,0.000047437356,0.00051564904,0.00028505124,0.00009423481,0.0002373807,0.000027885859,0.0076931715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981707,0.00022254129,0.0004161299,0.00039568907,0.0005833438,0.00021163195],"domain_scores_gemma":[0.9984171,0.0002251968,0.00011566066,0.0010083481,0.000077601275,0.00015611827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010044881,0.00022424044,0.00041069466,0.00009278531,0.00024498106,0.000013372788,0.00030350836,0.00006261427,0.00007871058],"category_scores_gemma":[0.00014458944,0.00010362392,0.000028132374,0.00020570756,0.00025868716,0.00006280551,0.00010175178,0.0001814089,0.00000967402],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001288517,0.00039821537,0.05632483,0.00002156241,0.00025878404,0.000032032818,0.014983814,4.506392e-8,0.23374622,0.000018019524,0.69063455,0.0022933967],"study_design_scores_gemma":[0.026998203,0.007871469,0.18506873,0.0008509289,0.0006569102,0.00023624253,0.047268175,0.00038943626,0.011831426,0.000004257877,0.7183381,0.00048616514],"about_ca_topic_score_codex":0.00014629528,"about_ca_topic_score_gemma":0.000023655171,"teacher_disagreement_score":0.2219148,"about_ca_system_score_codex":0.000043354885,"about_ca_system_score_gemma":0.000046422243,"threshold_uncertainty_score":0.4225661},"labels":[],"label_agreement":null},{"id":"W2131221639","doi":"10.1128/jvi.78.5.2242-2246.2004","title":"Genetic Basis of Hypersusceptibility to Protease Inhibitors and Low Replicative Capacity of Human Immunodeficiency Virus Type 1 Strains in Primary Infection","year":2004,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"National Center for Research Resources; Fogarty International Center; Center for AIDS Research, University of Washington; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Biology; Ritonavir; Virology; Amprenavir; Virus; Reverse transcriptase; Protease; Genotype; Mutation; Lentivirus; Integrase; Genetics; Human immunodeficiency virus (HIV); HIV-1 protease; Viral load; Enzyme; Viral disease; Polymerase chain reaction; Gene","score_opus":0.01819946504420863,"score_gpt":0.27624083708946157,"score_spread":0.25804137204525296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131221639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99889106,0.000114850525,0.000046119585,0.00043175826,0.00004212294,0.0003318795,0.0000032122339,0.0000028552558,0.00013615222],"genre_scores_gemma":[0.998177,0.000057794237,0.0016752119,0.0000429988,0.000021004336,0.0000042934553,0.0000012529952,0.0000058923556,0.000014547806],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990093,0.00006595571,0.00053754856,0.0001324831,0.00014174098,0.000112936475],"domain_scores_gemma":[0.99930197,0.00002134366,0.00030802502,0.00014219947,0.0001565721,0.000069879774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034024968,0.000091501715,0.00037611308,0.00025542543,0.000023621722,0.0000015491793,0.000038466595,0.000075673044,0.000018897701],"category_scores_gemma":[0.00013528526,0.000072811126,0.000058114405,0.00020974468,0.00013935607,0.000042899068,0.000024364072,0.00016565606,0.0000014683279],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044865615,0.0010539247,0.3014565,0.00008518306,0.00006626708,0.000023452016,0.0018821254,0.00006243153,0.6929118,0.00002072547,0.000008241409,0.0019806838],"study_design_scores_gemma":[0.002025314,0.0028809016,0.9056821,0.00009697516,0.000062379826,0.00008058128,0.00006516259,0.000001860671,0.08884119,0.00020235887,0.000011723021,0.00004945752],"about_ca_topic_score_codex":0.00016629627,"about_ca_topic_score_gemma":0.00008967446,"teacher_disagreement_score":0.6042256,"about_ca_system_score_codex":0.00020719296,"about_ca_system_score_gemma":0.00019132605,"threshold_uncertainty_score":0.29691517},"labels":[],"label_agreement":null},{"id":"W2131499894","doi":"10.1177/00912700122012706","title":"Pharmacokinetics and Tolerability of GW420867X, a Nonnucleoside Reverse Transcriptase Inhibitor, following Single Escalating Doses in Healthy Male Volunteers","year":2001,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Pharmacology; Dosing; Tolerability; Medicine; Reverse-transcriptase inhibitor; Adverse effect; Placebo; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy","score_opus":0.06472534940166322,"score_gpt":0.4050944900719915,"score_spread":0.3403691406703283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131499894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98380375,0.0009331137,0.000050096918,0.013328671,0.001093755,0.00035355872,0.000002901622,0.000007707764,0.00042646652],"genre_scores_gemma":[0.9946693,0.0013951935,0.0013115697,0.0018059947,0.00042268483,0.0000025578024,0.0000013239459,0.000016023674,0.00037533973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967157,0.0006168584,0.0019289711,0.00016606193,0.0002811798,0.00029122946],"domain_scores_gemma":[0.9976257,0.0013514985,0.0005204074,0.000112775495,0.00012921783,0.00026038056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030301635,0.00016909985,0.0009171354,0.00017709752,0.000059221235,0.000004720226,0.0001252099,0.000109043096,0.0002822779],"category_scores_gemma":[0.0004228231,0.00011502824,0.00026985456,0.00029487157,0.00023993988,0.00010912345,0.00004274785,0.0006908534,0.000003599376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022221694,0.004741897,0.83205944,0.00021492851,0.0009178925,0.0014168146,0.0033578204,0.00015722054,0.10246548,0.000004710892,0.013539514,0.01890261],"study_design_scores_gemma":[0.25218725,0.026643684,0.43011862,0.0029282267,0.014340848,0.0070011015,0.0082585355,0.008018612,0.07383946,0.00064038584,0.17434339,0.0016798835],"about_ca_topic_score_codex":0.000023484672,"about_ca_topic_score_gemma":0.000016617507,"teacher_disagreement_score":0.4019408,"about_ca_system_score_codex":0.00008600711,"about_ca_system_score_gemma":0.00021667489,"threshold_uncertainty_score":0.46907154},"labels":[],"label_agreement":null},{"id":"W2131642166","doi":"10.1128/aac.44.4.1041-1046.2000","title":"Single-Dose Pharmacokinetics and Safety of the Oral Antiviral Compound Adefovir Dipivoxil in Children Infected with Human Immunodeficiency Virus Type 1","year":2000,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"U.S. Food and Drug Administration","keywords":"Adefovir; Pharmacokinetics; Prodrug; Gastroenterology; Pharmacology; Adverse effect; Dose; Medicine; Internal medicine; Area under the curve; Oral administration; Virology; Virus; Hepatitis B virus; Lamivudine","score_opus":0.010274585500286176,"score_gpt":0.24765252906312343,"score_spread":0.23737794356283726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131642166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808604,0.0000705811,9.697742e-7,0.0006319802,0.000020992933,0.00044112248,0.000014737966,0.000016549146,0.0007170283],"genre_scores_gemma":[0.9966675,0.0010772309,0.00012886249,0.0008263472,0.000017041171,0.0000015596311,0.000041712552,0.000022301127,0.001217468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920595,0.00003204073,0.00023147254,0.00021460593,0.00011788272,0.00019805632],"domain_scores_gemma":[0.9997209,0.000007887885,0.00006617048,0.00014120195,0.000028628303,0.000035266425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000563674,0.00018970246,0.00028272087,0.000055921973,0.00011248395,0.000021100346,0.00006787767,0.000053936466,0.0001786671],"category_scores_gemma":[0.0000012880083,0.000119343116,0.000036305293,0.0002472147,0.00020230329,0.000052361316,0.00002481944,0.00011296961,0.0000030087638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008699841,0.0011170041,0.8798142,0.000025333646,0.00021789107,0.000010238933,0.00089879363,0.0000023283067,0.09898858,0.0000067693086,0.0007234971,0.017325379],"study_design_scores_gemma":[0.008903823,0.0002378103,0.9465921,0.00015064559,0.00008563759,0.000065596214,0.000012200555,0.000021856002,0.03850799,0.000004920437,0.005240537,0.00017686436],"about_ca_topic_score_codex":0.00012017691,"about_ca_topic_score_gemma":0.000027199094,"teacher_disagreement_score":0.06677792,"about_ca_system_score_codex":0.000025936384,"about_ca_system_score_gemma":0.000032572287,"threshold_uncertainty_score":0.4866671},"labels":[],"label_agreement":null},{"id":"W2131915809","doi":"10.1586/eri.09.93","title":"<i>Plasmodium falciparum</i>: new molecular targets with potential for antimalarial drug development","year":2009,"lang":"en","type":"review","venue":"Expert Review of Anti-infective Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Plasmodium falciparum; Malaria; Phosphoribosyltransferase; Biology; Histone deacetylase; Antimalarial Agent; Drug resistance; Plasmodium (life cycle); Drug discovery; Hypoxanthine; Computational biology; Virology; Histone; Genetics; Bioinformatics; Hypoxanthine-guanine phosphoribosyltransferase; Parasite hosting; Biochemistry; Enzyme; DNA; Immunology; Gene","score_opus":0.020438787839726802,"score_gpt":0.33559028089464316,"score_spread":0.31515149305491635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131915809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030833693,0.984821,0.0045799557,0.00068743055,0.00034634132,0.0088708075,0.000028670876,0.00010917103,0.0005257453],"genre_scores_gemma":[0.000013031134,0.9728193,0.022776429,0.0008513564,0.00044893718,0.0006657476,0.0009958012,0.00019029014,0.0012390569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954984,0.00027173705,0.0015763891,0.001103504,0.00079549284,0.0007544541],"domain_scores_gemma":[0.99727935,0.0001266378,0.0010303728,0.00075028057,0.00045004959,0.00036332506],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006086519,0.001409814,0.0059267953,0.0003746048,0.00016264067,0.000036240148,0.0003630024,0.0003158766,0.00020230252],"category_scores_gemma":[0.00005622707,0.00089437957,0.001632917,0.0005978866,0.00011855566,0.00012893727,0.000062406994,0.00038779277,0.00006775277],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025873407,0.0010267058,0.00001108983,0.028563542,0.0038125338,0.00015448581,0.00034421578,3.5686966e-7,0.000048621536,0.000086843385,0.02140482,0.9442881],"study_design_scores_gemma":[0.003749848,0.0005546706,0.000017709262,0.09527548,0.0012188469,0.00016479565,0.0000063250172,8.181883e-7,0.0020720738,0.000012455514,0.8960793,0.00084767945],"about_ca_topic_score_codex":0.000014930513,"about_ca_topic_score_gemma":0.0000016801168,"teacher_disagreement_score":0.9434404,"about_ca_system_score_codex":0.0003171726,"about_ca_system_score_gemma":0.003084793,"threshold_uncertainty_score":0.99986523},"labels":[],"label_agreement":null},{"id":"W2132329088","doi":"10.1128/aac.44.4.929-937.2000","title":"Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity against Human Cytomegalovirus","year":2000,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Ganciclovir; Human cytomegalovirus; Foscarnet; Cidofovir; In vitro; Mechanism of action; Pharmacology; Cytotoxicity; Biology; Virology; Stereochemistry; Chemistry; Virus; Biochemistry","score_opus":0.018516643825895723,"score_gpt":0.2459094401740208,"score_spread":0.2273927963481251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132329088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671245,0.0001092145,0.0000033169276,0.0021435283,0.000012227441,0.000327437,0.000016306994,0.00002480932,0.0006506987],"genre_scores_gemma":[0.99400514,0.0031361687,0.00035854854,0.00039753804,0.000037329326,0.0000043924306,0.00001700056,0.000024771305,0.0020191367],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990914,0.000025261792,0.000298837,0.00025366768,0.0001257034,0.00020512546],"domain_scores_gemma":[0.9996348,0.0000064425526,0.00012742514,0.00012640432,0.000048489943,0.000056438705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007418098,0.00022082933,0.00048526353,0.000091035065,0.00011167397,0.00001636868,0.000043891545,0.00006496974,0.00005579564],"category_scores_gemma":[0.000003872631,0.00016704465,0.000074429285,0.00011712459,0.00028159973,0.0001518227,0.000028621078,0.000073723284,0.0000014411946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008238029,0.00060429674,0.041285615,0.00026908208,0.00031263402,0.000022670238,0.002258269,8.236428e-7,0.92056805,0.000011977546,0.0003748386,0.03346797],"study_design_scores_gemma":[0.003265767,0.00024193282,0.06105487,0.00047204783,0.000041732088,0.000039151284,0.00010431654,0.00003353237,0.9327304,0.000007950242,0.0018244267,0.00018388951],"about_ca_topic_score_codex":0.00004583932,"about_ca_topic_score_gemma":0.0000067601245,"teacher_disagreement_score":0.03328408,"about_ca_system_score_codex":0.000015822056,"about_ca_system_score_gemma":0.00003012709,"threshold_uncertainty_score":0.68118834},"labels":[],"label_agreement":null},{"id":"W2132471816","doi":"10.1093/jac/dkt041","title":"Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings","year":2013,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; U.S. Public Health Service; National Institutes of Health","keywords":"Human immunodeficiency virus (HIV); Genotype; Medicine; Antiretroviral therapy; Intensive care medicine; Resource (disambiguation); Computational biology; Computer science; Viral load; Immunology; Biology; Genetics","score_opus":0.012074905353674325,"score_gpt":0.2484359532488226,"score_spread":0.23636104789514825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132471816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8965538,0.00007715444,0.00016019604,0.102313325,0.00003318484,0.00078594516,0.000012867094,0.000020168365,0.00004336816],"genre_scores_gemma":[0.9831824,0.00025755877,0.010958584,0.002763281,0.00015200095,0.000015543568,0.000026813124,0.00005243632,0.0025913976],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984062,0.00012596935,0.00058967434,0.00026990002,0.0002956868,0.00031257662],"domain_scores_gemma":[0.99903905,0.000103796745,0.00023787287,0.00015857034,0.0001872784,0.00027344908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002423741,0.00033118768,0.00064357393,0.00044198992,0.00007305269,0.00006721613,0.000099778226,0.00011028424,0.00007828738],"category_scores_gemma":[0.000017242102,0.00021984268,0.0001377962,0.00022035849,0.00006181106,0.000112506976,0.000017804867,0.00019307766,0.0000069925773],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056798555,0.005261842,0.14949656,0.00010749524,0.0027879544,0.0004701211,0.050653726,0.003829551,0.5057279,0.000018333243,0.18003792,0.044810075],"study_design_scores_gemma":[0.15052938,0.010317634,0.40402362,0.0035431958,0.00050376717,0.0043390915,0.0027274003,0.008192086,0.24875571,0.0006097636,0.1641041,0.0023542366],"about_ca_topic_score_codex":0.000025377767,"about_ca_topic_score_gemma":0.000009777735,"teacher_disagreement_score":0.25697216,"about_ca_system_score_codex":0.00036687747,"about_ca_system_score_gemma":0.00028697474,"threshold_uncertainty_score":0.8964924},"labels":[],"label_agreement":null},{"id":"W2132506678","doi":"10.1128/aac.01536-13","title":"Role of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and Other Nonnucleoside Reverse Transcriptase Inhibitors","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Institute for Health and Care Research","keywords":"Rilpivirine; Reverse transcriptase; Etravirine; Nevirapine; Virology; Efavirenz; Reverse-transcriptase inhibitor; Biology; Emtricitabine; Viral replication; Chemistry; Viral load; Human immunodeficiency virus (HIV); Genetics; Virus; RNA; Gene","score_opus":0.007245197270705556,"score_gpt":0.21634139466117797,"score_spread":0.20909619739047242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132506678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985404,0.00009898496,0.0000062806275,0.013087345,0.000055449276,0.00089632,0.000037521782,0.000011271018,0.00040279632],"genre_scores_gemma":[0.98932475,0.00038849624,0.00073438085,0.0059260502,0.000027841332,0.000022618553,0.000011023992,0.000024036288,0.0035407846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989667,0.000038748054,0.00034273526,0.00029157804,0.00012609696,0.00023417572],"domain_scores_gemma":[0.9996242,0.000009087681,0.00005842224,0.000186463,0.00002705365,0.00009475184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117860494,0.00019743279,0.00030908233,0.00013376892,0.000052144092,0.00001675016,0.00006712094,0.00008031776,0.00018555514],"category_scores_gemma":[0.000007158102,0.0001450089,0.00006591937,0.00027923207,0.00010943866,0.00010815355,0.000013222706,0.000113488844,0.000013456121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008094977,0.0008452697,0.5072969,0.00019273053,0.00009201019,0.00003201133,0.008502445,0.00000357129,0.40355763,0.00012623557,0.075527206,0.0030144793],"study_design_scores_gemma":[0.0121512655,0.00008340037,0.47807732,0.001300696,0.00007812758,0.000021112091,0.00063985965,0.00003429704,0.16157272,0.00010233269,0.34552395,0.00041491914],"about_ca_topic_score_codex":0.00048953755,"about_ca_topic_score_gemma":0.00044815044,"teacher_disagreement_score":0.26999673,"about_ca_system_score_codex":0.000052845353,"about_ca_system_score_gemma":0.00003712579,"threshold_uncertainty_score":0.5913291},"labels":[],"label_agreement":null},{"id":"W2132557478","doi":"10.1128/aac.46.8.2687-2691.2002","title":"Induction of Apoptosis by a Nonnucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor","year":2002,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Public Health","funders":"","keywords":"Reverse-transcriptase inhibitor; Reverse transcriptase; Efavirenz; Jurkat cells; Virology; Nucleoside Reverse Transcriptase Inhibitor; Peripheral blood mononuclear cell; Biology; Virus; Apoptosis; Nucleoside; Nucleotidyltransferase; Viral disease; Immunology; RNA; In vitro; Viral load; Sida; T cell; Biochemistry","score_opus":0.019566528077685618,"score_gpt":0.247279936168372,"score_spread":0.22771340809068638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132557478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958403,0.00015142471,0.000008849114,0.0028550408,0.000115342285,0.00024679175,0.00002454928,0.000028543936,0.00072917604],"genre_scores_gemma":[0.98936176,0.0021939245,0.00031072274,0.0017295795,0.00004224449,0.0000033764993,0.000056495872,0.000025248044,0.0062766336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999203,0.00001469401,0.0002543028,0.00022498934,0.00012334074,0.00017962694],"domain_scores_gemma":[0.99966466,0.0000038075293,0.00007672819,0.00014460349,0.000047223766,0.00006299524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004915856,0.00016676757,0.00025979884,0.000095235446,0.00011456614,0.000014782487,0.00004689097,0.000085932494,0.00080469967],"category_scores_gemma":[0.0000025816041,0.0001411232,0.00007740909,0.00021437394,0.00008076687,0.0000770351,0.0000091126485,0.00008367105,0.000027624466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010709975,0.00094845874,0.0056412783,0.000041727697,0.00018330527,0.0000041843705,0.0015989825,6.8078506e-8,0.780756,0.000011154755,0.20546219,0.0052455342],"study_design_scores_gemma":[0.006018417,0.00037498702,0.004327997,0.00018725658,0.000212219,0.000028473245,0.00014161211,0.000021364833,0.8287153,0.000008094986,0.15965818,0.00030609494],"about_ca_topic_score_codex":0.00007704354,"about_ca_topic_score_gemma":0.0000015670181,"teacher_disagreement_score":0.04795929,"about_ca_system_score_codex":0.000027065036,"about_ca_system_score_gemma":0.000010823534,"threshold_uncertainty_score":0.8810897},"labels":[],"label_agreement":null},{"id":"W2132585743","doi":"10.1186/1742-4690-11-7","title":"The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness","year":2014,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health; Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Integrase; Virology; Human immunodeficiency virus (HIV); Integrase inhibitor; Genetics; Mutation; Drug resistance; Substitution (logic); Medicine; Amino acid substitution; Drug; Biology; Antiretroviral therapy; Viral load; Gene; Pharmacology","score_opus":0.005441236661451402,"score_gpt":0.2259729518336836,"score_spread":0.2205317151722322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132585743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96210355,0.00017427577,0.000102674036,0.036624078,0.0000632281,0.00045646538,0.000009349971,0.00003525641,0.00043112185],"genre_scores_gemma":[0.99044645,0.00007514402,0.00013359071,0.00032103827,0.00007419059,0.00016566073,0.00010486908,0.000015112947,0.0086639365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982772,0.0004995719,0.00030500584,0.00033950122,0.00027450043,0.0003042307],"domain_scores_gemma":[0.998366,0.00086980656,0.00026486092,0.00035823332,0.00009415211,0.000046976435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010556171,0.00017254573,0.0002779397,0.00013963364,0.00018085152,0.000020060315,0.00012482255,0.00012662621,0.0000116307965],"category_scores_gemma":[0.0009449021,0.000084612264,0.000038889637,0.00030572346,0.00020798929,0.000089451896,0.000026873287,0.00034603372,0.000032250697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027124896,0.00017687399,0.98425394,0.00002158293,0.00008574189,0.00008421966,0.0013720631,0.00001228286,0.001481661,0.00809825,0.00094237796,0.000758505],"study_design_scores_gemma":[0.0034749291,0.00020948068,0.98236865,0.000112632675,0.00012207807,0.000021768301,0.0008239471,0.00028097988,0.0074870633,0.00077532686,0.0041297115,0.00019342829],"about_ca_topic_score_codex":0.00047623744,"about_ca_topic_score_gemma":0.01140212,"teacher_disagreement_score":0.03630304,"about_ca_system_score_codex":0.0006666779,"about_ca_system_score_gemma":0.00015437952,"threshold_uncertainty_score":0.63626504},"labels":[],"label_agreement":null},{"id":"W2132769220","doi":"10.1097/qad.0b013e32830fe940","title":"Bayesian network analyses of resistance pathways against efavirenz and nevirapine","year":2008,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Efavirenz; Nevirapine; Lamivudine; Emtricitabine; Reverse-transcriptase inhibitor; Virology; Resistance mutation; Biology; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Genetics; Gene; Virus; Viral load; Antiretroviral therapy; Polymerase chain reaction","score_opus":0.04094619701623359,"score_gpt":0.2826154154522667,"score_spread":0.24166921843603312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132769220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754725,0.006840435,0.0004765472,0.00057230034,0.000056578006,0.00021400455,0.000006971743,0.000056177912,0.016304472],"genre_scores_gemma":[0.9792782,0.0013765318,0.009981673,0.00019080225,0.000092465576,0.0000095539135,0.000039306356,0.000014408296,0.009017027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999165,0.00002757587,0.00024589323,0.00019141228,0.00018009829,0.00019000948],"domain_scores_gemma":[0.9995182,0.000045068857,0.00006851925,0.00021737322,0.00004594649,0.00010489776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009362521,0.00013348437,0.00033889533,0.00007646572,0.000090977024,0.000003567633,0.000040805695,0.000048121146,0.00003970335],"category_scores_gemma":[0.000026610394,0.00010353073,0.000067695546,0.0003122694,0.00010201625,0.000046874182,0.00002530214,0.00006507722,0.000011304371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000328834,0.00042163953,0.92612654,0.00020872543,0.00094636786,0.00081465335,0.0017742739,0.000029843735,0.009117468,0.0010480767,0.035623178,0.023560379],"study_design_scores_gemma":[0.013428537,0.0012319442,0.7725087,0.0017589646,0.0013260545,0.00016325117,0.0005913465,0.0005180491,0.073878504,0.0012856671,0.132096,0.0012130267],"about_ca_topic_score_codex":0.0000069489142,"about_ca_topic_score_gemma":0.000007914515,"teacher_disagreement_score":0.1536179,"about_ca_system_score_codex":0.000024134431,"about_ca_system_score_gemma":0.00006628974,"threshold_uncertainty_score":0.42218608},"labels":[],"label_agreement":null},{"id":"W2132906384","doi":"10.1128/aac.01109-08","title":"Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2","year":2008,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"University of Cambridge; Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Abacavir; Stavudine; Zidovudine; Virology; Didanosine; Lamivudine; Drug resistance; Biology; Nucleoside analogue; Emtricitabine; Resistance mutation; Population; Virus; Nucleoside; Genetics; Medicine; Reverse transcriptase; Viral disease; Hepatitis B virus; Polymerase chain reaction; Gene","score_opus":0.010433883468270483,"score_gpt":0.24830595708782358,"score_spread":0.2378720736195531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132906384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812955,0.0003663439,0.0000059704766,0.0010033982,0.000012993016,0.00035396547,0.000018838437,0.000008336689,0.00010060607],"genre_scores_gemma":[0.9920104,0.005195719,0.00034381915,0.00050850736,0.000010743057,0.0000071252343,0.000030802068,0.00001615848,0.001876686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992906,0.000014072462,0.00022561767,0.00023194792,0.00006427434,0.0001734921],"domain_scores_gemma":[0.99979293,0.000013449926,0.0000585615,0.000079623234,0.000018667437,0.000036749643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046877965,0.00015218776,0.00032053934,0.00009031698,0.00007727993,0.000009828808,0.00003464947,0.00004881843,0.00001509875],"category_scores_gemma":[0.0000029885666,0.0001163606,0.0000318409,0.00007734064,0.00006497895,0.00003956127,0.000016073214,0.000067500434,2.3969582e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003113032,0.000509906,0.9309011,0.00019737703,0.00007439114,0.000029546156,0.008625875,1.3829752e-7,0.05391745,0.00006339557,0.0044897585,0.0008797344],"study_design_scores_gemma":[0.005422868,0.000074556316,0.95254123,0.00030080837,0.000025998244,0.000013653407,0.00010373033,0.000009745962,0.03784041,0.000063520005,0.003440111,0.0001633429],"about_ca_topic_score_codex":0.000111988964,"about_ca_topic_score_gemma":0.0005486186,"teacher_disagreement_score":0.02164013,"about_ca_system_score_codex":0.000024026484,"about_ca_system_score_gemma":0.000012485392,"threshold_uncertainty_score":0.47450474},"labels":[],"label_agreement":null},{"id":"W2133117185","doi":"10.1093/infdis/jiu051","title":"Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study","year":2014,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; Gilead Sciences; ViiV Healthcare; GlaxoSmithKline; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Medicine; Discontinuation; Regimen; Tolerability; Integrase inhibitor; Adverse effect; Viral load; Internal medicine; Population; Phases of clinical research; Pharmacology; Clinical trial; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.008909296242199214,"score_gpt":0.2590626394812267,"score_spread":0.2501533432390275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133117185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984007,0.00015691122,0.000027482569,0.00026748393,0.00012593647,0.00078291167,0.000029689878,0.000015001553,0.00019391568],"genre_scores_gemma":[0.9992589,0.0000584591,0.000035961923,0.0000830374,0.00005648756,0.000012666189,0.000007773615,0.000021610756,0.00046512656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978314,0.00034733416,0.0007510048,0.0001774292,0.0006435242,0.00024932058],"domain_scores_gemma":[0.99828106,0.0002882453,0.000669868,0.00036447137,0.00023155868,0.00016481327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004928862,0.00025955134,0.0005807072,0.00022344972,0.00018676464,0.000027949562,0.00019579596,0.000038407972,0.000013537188],"category_scores_gemma":[0.00035899703,0.00010581524,0.000119175995,0.0005005312,0.00019482434,0.00014023758,0.000059401526,0.00025302035,0.0000016360023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026214669,0.008799764,0.95384055,0.00004006295,0.00032491528,0.000056979145,0.0056445706,0.00002315366,0.00048672274,0.00001681549,0.00044571978,0.004106083],"study_design_scores_gemma":[0.062123857,0.010976045,0.92116046,0.000596695,0.0010035496,0.000055275064,0.002704159,0.000040433675,0.00062609906,0.000086910004,0.00041224863,0.00021425817],"about_ca_topic_score_codex":0.00010780717,"about_ca_topic_score_gemma":0.00014615952,"teacher_disagreement_score":0.03590919,"about_ca_system_score_codex":0.000117347416,"about_ca_system_score_gemma":0.00020942239,"threshold_uncertainty_score":0.43150204},"labels":[],"label_agreement":null},{"id":"W2133168934","doi":"10.1128/aac.00434-10","title":"Structure-Activity Analysis of Vinylogous Urea Inhibitors of Human Immunodeficiency Virus-Encoded Ribonuclease H","year":2010,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of General Medical Sciences; U.S. Department of Health and Human Services; National Cancer Institute; National Institutes of Health; Canadian Foundation for AIDS Research; Howard Hughes Medical Institute","keywords":"Stereochemistry; Pharmacophore; Chemistry; Ring (chemistry); Thiophene; Cycloheptane; Structure–activity relationship; RNase H; RNase P; Biochemistry; RNA; Organic chemistry","score_opus":0.00806824028643254,"score_gpt":0.2648902585892312,"score_spread":0.25682201830279866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133168934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998793,0.000012194979,0.000015169483,0.000459902,0.000081287515,0.00021753165,0.00008081342,0.000018646022,0.00032142032],"genre_scores_gemma":[0.9986067,0.000104927356,0.0004103236,0.00029546494,0.00002692454,0.000001451725,0.000073754934,0.00001951009,0.00046093325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902964,0.000017167042,0.0003268111,0.00026336862,0.00017406506,0.00018897503],"domain_scores_gemma":[0.9993359,0.000013602326,0.0002138012,0.00027963953,0.00008119127,0.00007590523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000829604,0.00020085837,0.00057575817,0.00026967755,0.00009403417,0.000012652381,0.00008401876,0.000118586766,0.00054635835],"category_scores_gemma":[0.0000068887753,0.00015809386,0.00020667801,0.00043879222,0.00018734125,0.00005709538,0.000030121037,0.0001432402,0.0000015580101],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017298287,0.0006626209,0.10083862,0.000041047704,0.0010975585,0.000006748013,0.0009584231,0.000001553532,0.8913181,0.000031337186,0.00082777056,0.0040432676],"study_design_scores_gemma":[0.0020316152,0.000116161995,0.27921146,0.000029234578,0.0007784538,0.00000670226,0.00002855825,0.00009990343,0.7165471,0.00001796686,0.00096881104,0.00016403302],"about_ca_topic_score_codex":0.0003110821,"about_ca_topic_score_gemma":0.00013426616,"teacher_disagreement_score":0.17837286,"about_ca_system_score_codex":0.000016554128,"about_ca_system_score_gemma":0.00004397224,"threshold_uncertainty_score":0.64468807},"labels":[],"label_agreement":null},{"id":"W2133315239","doi":"10.1001/jama.283.3.381","title":"Antiretroviral Therapy in Adults","year":2000,"lang":"en","type":"review","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1036,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Interim; Antiretroviral therapy; Intensive care medicine; Clinical trial; Clinical research; Human immunodeficiency virus (HIV); MEDLINE; ANTIRETROVIRAL AGENTS; Alternative medicine; Family medicine; Viral load; Pathology","score_opus":0.028414026171137394,"score_gpt":0.3167798492283666,"score_spread":0.2883658230572292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133315239","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033844827,0.9822692,1.0879908e-7,0.00022617093,0.00008484677,0.000913026,0.000012738691,0.00004640553,0.016109038],"genre_scores_gemma":[0.000032778484,0.96793914,0.00015251528,0.00010149661,0.0002586024,0.000110718946,0.00036968995,0.00004574458,0.030989304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872595,0.00005867195,0.00041853896,0.0003286215,0.00020547531,0.0002627468],"domain_scores_gemma":[0.999484,0.000044294353,0.00008677061,0.0002842387,0.000017349359,0.000083371946],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009462135,0.00033061838,0.0013177451,0.000280501,0.00002052667,0.000018620583,0.00009652416,0.0002891577,0.00068309106],"category_scores_gemma":[0.000015344212,0.00021591855,0.00031121893,0.00033370787,0.000022411818,0.000043085805,0.000015438867,0.00033445327,0.0010985911],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067201945,0.00016773661,0.000488313,0.0025601638,0.00011816834,0.00040431268,0.00013646409,3.1776834e-9,6.8416774e-9,0.000009904543,0.00434443,0.9917033],"study_design_scores_gemma":[0.0026160798,0.00015409979,0.0002080431,0.022411536,0.00011762799,0.00005480408,0.000005709642,6.1393894e-7,5.575654e-7,0.000004213962,0.9742394,0.00018730512],"about_ca_topic_score_codex":0.000019513045,"about_ca_topic_score_gemma":0.0000053724402,"teacher_disagreement_score":0.991516,"about_ca_system_score_codex":0.00016580753,"about_ca_system_score_gemma":0.0003005332,"threshold_uncertainty_score":0.99967915},"labels":[],"label_agreement":null},{"id":"W2133338060","doi":"10.1086/508353","title":"Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial","year":2006,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université du Québec à Montréal","funders":"","keywords":"Enfuvirtide; Ritonavir; Medicine; Protease inhibitor (pharmacology); Internal medicine; Regimen; Viral load; Randomized controlled trial; Protease; Salvage therapy; Population; Gastroenterology; Pharmacology; Virology; Immunology; Human immunodeficiency virus (HIV); Chemotherapy; Biology; Antiretroviral therapy","score_opus":0.02845844023461723,"score_gpt":0.32918766735983374,"score_spread":0.3007292271252165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133338060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995228,0.0002842755,0.0000039367096,0.00082485966,0.00044929446,0.0025774152,0.00012569067,0.000064580665,0.00044194947],"genre_scores_gemma":[0.99766594,0.000049108196,0.000014325357,0.00016017242,0.0004535975,0.00043503084,0.00034921823,0.000020965144,0.00085165584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711245,0.0004945175,0.0011601673,0.00051305135,0.00043905008,0.00028074085],"domain_scores_gemma":[0.9971574,0.0015092108,0.0003655309,0.0006860844,0.00010689551,0.00017490739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018762052,0.00029157937,0.00081599335,0.00012814856,0.00018934101,0.000032240234,0.00016780745,0.00013496955,0.000117049945],"category_scores_gemma":[0.0012251555,0.00015101148,0.0010168185,0.001099426,0.00042194448,0.0000733335,0.00007544487,0.00019363876,0.000026185538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006804511,0.0118484,0.97625285,0.000006621985,0.0008138846,0.000018978057,0.00023184087,0.0000486833,0.0000035424928,0.000016320273,0.0010778889,0.0028764757],"study_design_scores_gemma":[0.07069273,0.0008156933,0.9237427,0.00007850579,0.0027167117,1.7013869e-7,0.00008712929,0.000043178366,0.00011043607,0.00014677366,0.0014110127,0.00015495835],"about_ca_topic_score_codex":0.0020632232,"about_ca_topic_score_gemma":0.0012269523,"teacher_disagreement_score":0.06388822,"about_ca_system_score_codex":0.0003113132,"about_ca_system_score_gemma":0.00041433892,"threshold_uncertainty_score":0.61580694},"labels":[],"label_agreement":null},{"id":"W2133649749","doi":"10.1056/nejmoa035026","title":"Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":915,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Paul's Hospital; University of British Columbia","funders":"Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Enfuvirtide; Regimen; Medicine; Viral load; Internal medicine; Liter; Virology; Randomization; Drug resistance; Dolutegravir; Human immunodeficiency virus (HIV); Randomized controlled trial; Immunology; Gastroenterology; Antiretroviral therapy; Biology; Gp41; Microbiology","score_opus":0.012743613756548259,"score_gpt":0.25473743879861455,"score_spread":0.2419938250420663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133649749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99189883,0.00076278334,0.0009580255,0.005325241,0.00025706264,0.00030022298,0.0000034611112,0.000011756049,0.00048259925],"genre_scores_gemma":[0.9931716,0.00063599186,0.0027985827,0.00023957243,0.0010597602,0.000005101692,0.00003226006,0.000020249066,0.0020369205],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986228,0.000092129754,0.00058768375,0.00016896888,0.00031505106,0.00021338271],"domain_scores_gemma":[0.9989992,0.000127742,0.00026682878,0.00011163325,0.00013243534,0.00036215736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005117994,0.00018057378,0.0005134963,0.00037375453,0.00006335629,0.000008945173,0.00003447577,0.000045890498,0.000069547925],"category_scores_gemma":[0.00036121774,0.000115573785,0.000052131443,0.0002595441,0.000063066866,0.00011120918,0.00000820479,0.00022316283,0.0000035080488],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030222752,0.0003756815,0.90119374,0.00011319666,0.00014192268,0.00035732827,0.012400414,0.000026124066,0.002409268,0.000092366696,0.013293005,0.06657468],"study_design_scores_gemma":[0.18731111,0.0044864,0.38286844,0.0013691317,0.00073961215,0.0010331065,0.002045126,0.000162393,0.0018034605,0.00042403236,0.41735145,0.00040573304],"about_ca_topic_score_codex":0.00004242666,"about_ca_topic_score_gemma":0.0003523676,"teacher_disagreement_score":0.5183253,"about_ca_system_score_codex":0.00009387914,"about_ca_system_score_gemma":0.00019994276,"threshold_uncertainty_score":0.4712962},"labels":[],"label_agreement":null},{"id":"W2134646116","doi":"10.1139/v10-054","title":"Synthesis and biological evaluation of acyclic nucleotide analogues with a furo[2,3- <i>d</i> ]pyrimidin-2(3 <i>H</i> )-one base","year":2010,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry; Thymidine kinase; Sonogashira coupling; Stereochemistry; Nucleotide; Uracil; Nucleoside; Thymidine; Isopropyl; Bicyclic molecule; Intramolecular force; Virus; Medicinal chemistry; Virology; Biochemistry; DNA","score_opus":0.02608479963675838,"score_gpt":0.23783890158463128,"score_spread":0.2117541019478729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134646116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945457,0.00034627732,0.0000039642628,0.0020219486,0.000032878477,0.00009695739,0.000016710264,0.0000040485684,0.0029315061],"genre_scores_gemma":[0.998294,0.000044486835,0.0013111781,0.0000769728,0.000098245386,0.0000051131938,0.000011536408,0.000011397478,0.00014710295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990767,0.000026068832,0.00029557443,0.0001316257,0.0002821996,0.00018782854],"domain_scores_gemma":[0.99858177,0.00008377335,0.00020574513,0.000148426,0.00035993414,0.0006203287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053979584,0.0001293688,0.00032434924,0.00008400345,0.000053359086,0.000015036099,0.00008001365,0.00009688848,0.00051509193],"category_scores_gemma":[0.00047310235,0.00009233556,0.000062836974,0.000121173114,0.00019298948,0.000054931505,0.000006551104,0.00023649531,0.0000023287216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028719648,0.0002426627,0.32361317,0.00020412284,0.0007528584,0.0007338532,0.000771522,0.0000047471904,0.6516603,0.000019238014,0.002516731,0.019193588],"study_design_scores_gemma":[0.0029866574,0.0001433057,0.06355346,0.000545866,0.0010102874,0.0019563485,0.0005648959,0.00004392248,0.9249929,0.00013264688,0.003812791,0.00025690338],"about_ca_topic_score_codex":0.00011841719,"about_ca_topic_score_gemma":0.00092598493,"teacher_disagreement_score":0.2733326,"about_ca_system_score_codex":0.00008109663,"about_ca_system_score_gemma":0.0014254822,"threshold_uncertainty_score":0.5639895},"labels":[],"label_agreement":null},{"id":"W2134749295","doi":"10.1590/s1020-49892011001200026","title":"Progress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the Caribbean","year":2011,"lang":"en","type":"article","venue":"Revista Panamericana de Salud Pública","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pan American Health Organization; Public Health Agency; Public Health Agency of Canada; Bill and Melinda Gates Foundation","keywords":"HIV drug resistance; Latin Americans; Human immunodeficiency virus (HIV); Sustainability; Medicine; Antiretroviral therapy; Drug resistance; Economic growth; Geography; Political science; Viral load; Virology; Biology","score_opus":0.016684595938613128,"score_gpt":0.2935234951744125,"score_spread":0.2768388992357994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134749295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70504534,0.011218169,0.007030619,0.2542811,0.000099822886,0.019096829,0.00063040695,0.00013788705,0.0024598236],"genre_scores_gemma":[0.9952669,0.00013218803,0.003126407,0.00037143222,0.000013283587,0.000101911835,0.00004716602,0.000020054731,0.0009206156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987213,0.0002040055,0.00050535006,0.00018120701,0.00017553635,0.00021258568],"domain_scores_gemma":[0.9988752,0.0001468196,0.00052137504,0.00025641837,0.00013499033,0.000065192115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033069443,0.00012618453,0.000463568,0.00010375412,0.00007312683,0.000010173492,0.000104462015,0.000015291764,0.00004176135],"category_scores_gemma":[0.00006838232,0.000075744625,0.000056514877,0.0009039701,0.00030516382,0.000030376577,0.00002084142,0.00007296764,4.4394238e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006766914,0.00023299169,0.9333919,0.00062649464,0.0003513764,0.0000023640562,0.010930635,0.000002514548,0.00011028987,0.019517446,0.010862785,0.023294492],"study_design_scores_gemma":[0.011649697,0.00016593431,0.94803447,0.00047328186,0.0004918193,0.0000042781426,0.007068511,0.00032266317,0.0010311517,0.0002541887,0.030252533,0.00025149807],"about_ca_topic_score_codex":0.0007238725,"about_ca_topic_score_gemma":0.0016403175,"teacher_disagreement_score":0.2902216,"about_ca_system_score_codex":0.00012479839,"about_ca_system_score_gemma":0.00042468938,"threshold_uncertainty_score":0.30887762},"labels":[],"label_agreement":null},{"id":"W2135417699","doi":"10.1086/650002","title":"Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials","year":2010,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Raltegravir; Medicine; Antiretroviral therapy; Internal medicine; Integrase inhibitor; Pharmacotherapy; Drug; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Virology","score_opus":0.03522055684703406,"score_gpt":0.35366694229318596,"score_spread":0.3184463854461519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135417699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996853,0.00013734668,0.000008464282,0.00024380613,0.00013174699,0.002313975,0.000110584515,0.00003383027,0.00016726235],"genre_scores_gemma":[0.99854916,0.0006739372,0.000083783074,0.000038949594,0.000043583892,0.00011273714,0.00015470348,0.000021306385,0.0003218411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975666,0.00035118998,0.0011683768,0.00043899738,0.00026498805,0.00020985954],"domain_scores_gemma":[0.99707335,0.0014874223,0.0005983307,0.0004188026,0.00017020454,0.00025191015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043041233,0.0003123681,0.0012192271,0.00011397597,0.00013025256,0.00002580251,0.00006063719,0.000099301295,0.000052203115],"category_scores_gemma":[0.0004217776,0.00015360954,0.00016800218,0.00031585307,0.00075365085,0.00010240672,0.000036582875,0.00017904575,7.476923e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063633576,0.012152756,0.91471153,0.00003445629,0.00057482143,0.000013858328,0.00054144405,0.000003690919,0.000048923182,0.000023415541,0.000057170615,0.008204361],"study_design_scores_gemma":[0.1895304,0.0066228784,0.80245537,0.0002260657,0.0004795749,0.0000025066079,0.000046235273,0.000008492983,0.00035770205,0.000017270486,0.000105424064,0.00014805235],"about_ca_topic_score_codex":0.00007724687,"about_ca_topic_score_gemma":0.00025589048,"teacher_disagreement_score":0.12589683,"about_ca_system_score_codex":0.000049602284,"about_ca_system_score_gemma":0.0002664256,"threshold_uncertainty_score":0.62640154},"labels":[],"label_agreement":null},{"id":"W2135776147","doi":"10.1086/605894","title":"Signature Nucleotide Polymorphisms at Positions 64 and 65 in Reverse Transcriptase Favor the Selection of the K65R Resistance Mutation in HIV‐1 Subtype C","year":2009,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Gilead Sciences; GlaxoSmithKline","keywords":"Reverse transcriptase; Virology; Biology; Human immunodeficiency virus (HIV); Mutation; Genetics; Single-nucleotide polymorphism; Resistance mutation; Selection (genetic algorithm); Lentivirus; Genotype; Polymerase chain reaction; Gene; Viral disease","score_opus":0.00456886788809532,"score_gpt":0.21998612203161164,"score_spread":0.2154172541435163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135776147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873442,0.0016284946,0.000020072854,0.010328161,0.00006180436,0.00030325257,0.000014126313,0.0000078631165,0.0002920393],"genre_scores_gemma":[0.99836725,0.00033208675,0.000029735342,0.00040907844,0.000039846163,0.0000030123315,0.0000044625667,0.0000071932495,0.00080731075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908894,0.00020142602,0.00030642125,0.00007160671,0.00021524861,0.00011637534],"domain_scores_gemma":[0.9994231,0.00011563216,0.0002125201,0.00010831796,0.00008678367,0.00005364151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023792128,0.000105846564,0.0001815234,0.0001346839,0.00014954849,0.000009544319,0.00006476834,0.000037226248,0.000029787174],"category_scores_gemma":[0.000094893265,0.000052267496,0.000088409775,0.00041072528,0.00007545862,0.000099166464,0.0000075528164,0.00021442283,0.0000015414338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047549717,0.0022003315,0.927475,0.0001075384,0.00034711912,0.0002468722,0.009091254,0.00084376626,0.037757307,0.000725639,0.014242474,0.0022077523],"study_design_scores_gemma":[0.0025616656,0.00021622983,0.99141914,0.0003923047,0.0004393468,0.00028408368,0.00036575293,0.000044210123,0.0029253485,0.0009896919,0.00028833825,0.0000738925],"about_ca_topic_score_codex":0.000031125044,"about_ca_topic_score_gemma":0.0004997286,"teacher_disagreement_score":0.06394416,"about_ca_system_score_codex":0.00019914877,"about_ca_system_score_gemma":0.00011877323,"threshold_uncertainty_score":0.21314067},"labels":[],"label_agreement":null},{"id":"W2135800359","doi":"10.1186/s12977-015-0145-9","title":"Intasome architecture and chromatin density modulate retroviral integration into nucleosome","year":2015,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Université de Bordeaux; Comisión Nacional de Investigación Científica y Tecnológica; Centre National de la Recherche Scientifique; Institute of Genetics; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche; Universidad de Chile; Cancer Research UK","keywords":"Chromatin; Nucleosome; Integrase; Histone; DNA; Biology; ChIA-PET; Integrases; Computational biology; Chromatin remodeling; Genetics; Cell biology","score_opus":0.013481950799216704,"score_gpt":0.2525289460895097,"score_spread":0.239046995290293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135800359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135226,0.00020941255,0.00085239665,0.006153733,0.00014302469,0.0002808328,0.000002409585,0.00011066666,0.00089527585],"genre_scores_gemma":[0.98806095,0.0000261304,0.008656532,0.00057774346,0.00013942795,0.0000139984295,0.000089106616,0.000023346742,0.0024127625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883455,0.00009198758,0.00024836257,0.00034889494,0.0002068514,0.0002693672],"domain_scores_gemma":[0.99930125,0.00003656236,0.000079068996,0.00026051802,0.000067769244,0.00025483192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021337892,0.00021135047,0.00040131068,0.00019582153,0.00006820258,0.000017122202,0.000060668423,0.00019871652,0.000038544953],"category_scores_gemma":[0.00017388015,0.00016265214,0.000053465137,0.00015388947,0.00015705428,0.00007911671,0.00008893284,0.00029021414,0.0001342362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027863374,0.0006712884,0.70695853,0.00021787106,0.0007412189,0.0010906544,0.020421028,0.00002881333,0.12026485,0.004820335,0.010175739,0.13182333],"study_design_scores_gemma":[0.020757362,0.007213024,0.8614125,0.00025849848,0.0008746166,0.003104922,0.001332408,0.005930805,0.031782027,0.040783223,0.025051503,0.0014990913],"about_ca_topic_score_codex":0.0000738136,"about_ca_topic_score_gemma":0.00008233058,"teacher_disagreement_score":0.154454,"about_ca_system_score_codex":0.00018583148,"about_ca_system_score_gemma":0.000091199865,"threshold_uncertainty_score":0.66327614},"labels":[],"label_agreement":null},{"id":"W2135826395","doi":"10.1124/pr.111.005553","title":"The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition","year":2012,"lang":"en","type":"review","venue":"Pharmacological Reviews","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Efavirenz; Atazanavir; Nevirapine; Indinavir; Drug resistance; Drug; Pharmacology; Pharmacogenetics; Medicine; Pharmacogenomics; HIV drug resistance; Abacavir; Biology; Virology; Genotype; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Genetics","score_opus":0.06003369805638381,"score_gpt":0.3679547553847849,"score_spread":0.3079210573284011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135826395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019948606,0.9947779,0.000002457184,0.000287992,0.00006072442,0.0024321915,0.000039050236,0.00001717202,0.00038761066],"genre_scores_gemma":[0.0023030913,0.99152607,0.00076199503,0.000027553973,0.00012070409,0.00052052294,0.0001647677,0.000025957052,0.0045493706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975909,0.0004983821,0.0010088695,0.00037063437,0.0001821519,0.0003490838],"domain_scores_gemma":[0.9986696,0.00045883254,0.0005025025,0.00015284459,0.000027657865,0.00018852763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054699683,0.00043697417,0.0016319855,0.00010719979,0.00017105293,0.000022535844,0.00007374387,0.00010957159,0.0000645604],"category_scores_gemma":[0.0000550205,0.00022836638,0.00024836365,0.00030257058,0.00020720977,0.00006146489,0.00007226072,0.00023095476,0.000017924858],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047129353,0.00029265508,0.00071861345,0.0021857808,0.00020302166,0.000022763239,0.00025025022,3.780438e-8,0.00007791664,0.00010188713,0.00024209352,0.99585783],"study_design_scores_gemma":[0.0011241118,0.00006175905,0.00020154435,0.0033506774,0.0040144837,0.00004671358,0.000020329539,0.000016113143,0.00009250212,0.00003488222,0.99082416,0.00021272775],"about_ca_topic_score_codex":0.000002660552,"about_ca_topic_score_gemma":0.000006367072,"teacher_disagreement_score":0.9956451,"about_ca_system_score_codex":0.00017841376,"about_ca_system_score_gemma":0.000083594125,"threshold_uncertainty_score":0.93125105},"labels":[],"label_agreement":null},{"id":"W2135842910","doi":"10.1093/jac/dkq338","title":"Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function","year":2010,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Etravirine; Virology; Efavirenz; Nevirapine; Reverse transcriptase; Biology; Resistance mutation; Polymerase; Virus; Viral replication; Enzyme; RNA; Genetics; Viral load; Gene; Biochemistry","score_opus":0.0059232847178020175,"score_gpt":0.24859864555904418,"score_spread":0.24267536084124217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135842910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939016,0.000014247571,0.00017424265,0.0053371848,0.0002337483,0.0002540146,0.000024242152,0.000006010658,0.00005469347],"genre_scores_gemma":[0.99805343,0.00009999207,0.00068950723,0.00032844808,0.00021393773,0.0000012065804,0.000014377473,0.000018086354,0.00058100984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992055,0.00002272774,0.00036154006,0.00014381968,0.00015549475,0.00011087116],"domain_scores_gemma":[0.9993055,0.000025106889,0.00028413688,0.0001880913,0.000108914675,0.00008824217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001281046,0.00014387889,0.00026684775,0.00015022192,0.00008680792,0.00002333047,0.00005020978,0.00008723104,0.00008386747],"category_scores_gemma":[0.000022627446,0.0000876138,0.00018825395,0.000112650836,0.00010507398,0.000108548375,0.000007292966,0.0002678264,0.000002329421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013016992,0.00032746105,0.014717235,0.000022437216,0.00020473092,0.0000045029433,0.00070709875,0.0000017342529,0.9695373,0.000011001982,0.010502073,0.002662688],"study_design_scores_gemma":[0.008974395,0.00073376665,0.24547486,0.00022396988,0.00032538795,0.00036227453,0.00005074177,0.000079655714,0.7408437,0.000041406514,0.0027437531,0.00014609216],"about_ca_topic_score_codex":0.000012456269,"about_ca_topic_score_gemma":0.0000043144055,"teacher_disagreement_score":0.23075762,"about_ca_system_score_codex":0.000040912997,"about_ca_system_score_gemma":0.00010482046,"threshold_uncertainty_score":0.3572787},"labels":[],"label_agreement":null},{"id":"W2135892517","doi":"10.1097/00002030-200106150-00003","title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; St. Paul's Hospital","funders":"Institut National Du Cancer","keywords":"Nevirapine; Zidovudine; Medicine; Didanosine; Regimen; Internal medicine; Viral load; Reverse-transcriptase inhibitor; Immunology; Logistic regression; Sida; Lentivirus; Human immunodeficiency virus (HIV); Gastroenterology; Pharmacology; Virology; Antiretroviral therapy; Viral disease","score_opus":0.013836081185837455,"score_gpt":0.2546148819587632,"score_spread":0.24077880077292574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135892517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436086,0.000024209377,0.0000159409,0.004617977,0.000029028117,0.000667267,0.000021239712,0.00009902692,0.0001644629],"genre_scores_gemma":[0.99159575,0.0000139741505,0.002755611,0.0010993078,0.000027377919,0.0001164979,0.00018049192,0.000027765675,0.00418325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982114,0.00026641655,0.00037568787,0.00042368,0.00027421478,0.00044859786],"domain_scores_gemma":[0.9991854,0.00019944856,0.00006747103,0.00027842936,0.000055086628,0.00021420734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006391269,0.00025484353,0.0005119484,0.00046297422,0.00003944761,0.00002062729,0.00009998661,0.00020550717,0.00034225962],"category_scores_gemma":[0.0003841145,0.00018531844,0.000039700877,0.0011233301,0.00003789755,0.000113185626,0.000046869965,0.00025445165,0.00009822346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064397096,0.0011420519,0.98309624,0.0000038232815,0.00012669365,0.00094526797,0.0017691982,0.000014269011,0.003668797,0.000018088584,0.00039066712,0.002385163],"study_design_scores_gemma":[0.010876399,0.0060003726,0.97952116,0.00012253402,0.00005693285,0.00003361709,0.0001397524,0.00009054182,0.0016801135,0.000028048538,0.0012132628,0.00023728861],"about_ca_topic_score_codex":0.000056698296,"about_ca_topic_score_gemma":0.00017855085,"teacher_disagreement_score":0.004858321,"about_ca_system_score_codex":0.00023873389,"about_ca_system_score_gemma":0.00012815544,"threshold_uncertainty_score":0.7557066},"labels":[],"label_agreement":null},{"id":"W2136170186","doi":"10.1128/aac.00907-08","title":"Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered over 21 Days with Lopinavir-Ritonavir in Human Immunodeficiency Virus Type 1-Infected Subjects","year":2008,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Lopinavir; Bioavailability; Ritonavir; Pharmacokinetics; Lopinavir/ritonavir; Pharmacology; Reverse-transcriptase inhibitor; Dosing; Population; Medicine; Chemistry; Sida; Virology; Viral load; Virus; Viral disease; Antiretroviral therapy","score_opus":0.021347406731805556,"score_gpt":0.27728343088170393,"score_spread":0.25593602414989836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136170186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99827015,0.00011419223,0.0000033235076,0.0003474572,0.000095209405,0.00090739725,0.000048219048,0.000044098084,0.0001699619],"genre_scores_gemma":[0.99592185,0.0011569726,0.00036180296,0.00089586206,0.000034826728,0.000016273798,0.00016608484,0.00005841146,0.0013879365],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99849874,0.000038354956,0.00045873405,0.0004218075,0.00022489984,0.0003574725],"domain_scores_gemma":[0.9994048,0.00001613189,0.0001324118,0.00024807345,0.00008083963,0.00011772554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000064737105,0.0003490434,0.00052393536,0.0002374527,0.00013104963,0.0000143774105,0.00009131193,0.000109595465,0.0002386488],"category_scores_gemma":[0.0000052806936,0.0002865772,0.00009805846,0.0004713465,0.00019675169,0.00011409116,0.000021296213,0.00017829164,0.0000077701525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016314487,0.0025768862,0.37393555,0.00009936644,0.00011538241,0.00055606867,0.0017998944,8.367546e-7,0.6161481,0.0000023743596,0.002300256,0.00083383574],"study_design_scores_gemma":[0.026389344,0.00084201037,0.6435233,0.0004613895,0.00021788348,0.00025078809,0.00006566291,0.000028556206,0.32009837,0.0000011312306,0.007661004,0.00046057583],"about_ca_topic_score_codex":0.0002892685,"about_ca_topic_score_gemma":0.00006110676,"teacher_disagreement_score":0.2960497,"about_ca_system_score_codex":0.00006466486,"about_ca_system_score_gemma":0.00011486473,"threshold_uncertainty_score":0.99995863},"labels":[],"label_agreement":null},{"id":"W2136228389","doi":"10.1371/journal.pone.0014764","title":"Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; Ottawa Hospital; University of Ottawa; St. Paul's Hospital","funders":"Medical Research Council; Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Viral load; Adverse effect; Randomized controlled trial; Internal medicine; Mortality rate; Clinical trial; Human immunodeficiency virus (HIV); Pediatrics; Confidence interval; Immunology","score_opus":0.12891818126181634,"score_gpt":0.28618936238470843,"score_spread":0.1572711811228921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136228389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977848,0.0001434705,0.00003799594,0.0006121582,0.000038173283,0.0009758656,0.000028354123,0.000030036994,0.000349149],"genre_scores_gemma":[0.9882901,0.0005105873,0.009086255,0.000014800832,0.0000398228,0.0000841635,0.00018440871,0.000011498869,0.001778409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990459,0.000068598776,0.00038228135,0.00023678796,0.0001542654,0.0001121298],"domain_scores_gemma":[0.9994356,0.00007269433,0.00014829333,0.00022689841,0.00007622108,0.000040288865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015263403,0.0001271748,0.00028552156,0.0000969921,0.00003434613,0.000006284237,0.00003053089,0.00004671676,0.000012570263],"category_scores_gemma":[0.00015890827,0.000083059516,0.0000413887,0.00009934268,0.00005288388,0.00008380779,0.00001947601,0.00007629196,0.000012198855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26874036,0.026052939,0.48726586,0.0001249006,0.0016807297,0.00006626881,0.05865681,0.0000019520983,0.11795501,0.00009155055,0.00019128779,0.03917236],"study_design_scores_gemma":[0.12662819,0.0027973363,0.6927849,0.001038643,0.00072233466,0.0000014850219,0.0012977492,0.0013841253,0.17295209,0.00005812811,0.00012292233,0.00021211473],"about_ca_topic_score_codex":0.00096343353,"about_ca_topic_score_gemma":0.00063395407,"teacher_disagreement_score":0.20551905,"about_ca_system_score_codex":0.00016407318,"about_ca_system_score_gemma":0.00003502825,"threshold_uncertainty_score":0.33870688},"labels":[],"label_agreement":null},{"id":"W2136451994","doi":"10.1310/7lyw-gqff-wprq-k3qw","title":"Clinical Impact of Double Protease Inhibitor Boosting with Lopinavir/Ritonavir and Amprenavir as Part of Salvage Antiretroviral Therapy","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; Health Sciences Centre; Canadians Living with HIV; Sunnybrook Health Science Centre; University of Waterloo; University Health Network; University of Toronto; Montreal General Hospital; McGill University","funders":"Abbott Laboratories","keywords":"Lopinavir; Medicine; Amprenavir; Ritonavir; Regimen; Salvage therapy; Internal medicine; Hazard ratio; Atazanavir; Lopinavir/ritonavir; Protease inhibitor (pharmacology); Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Confidence interval; Immunology; Protease; Chemotherapy; HIV-1 protease","score_opus":0.20446275338973807,"score_gpt":0.483843551421669,"score_spread":0.27938079803193094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136451994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463326,0.00069192535,0.000031690925,0.00030998883,0.0002354994,0.0023120437,0.000045042416,0.000045992452,0.0016945818],"genre_scores_gemma":[0.992366,0.0010003131,0.003631146,0.00009859479,0.00047991774,0.00006334602,0.00004965389,0.000046658573,0.0022643642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936108,0.001531523,0.0033611734,0.00061585085,0.0004955853,0.00038507706],"domain_scores_gemma":[0.9942107,0.003316389,0.0012764317,0.00053598534,0.00020391293,0.0004565679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008796408,0.00037358183,0.0025497484,0.000109130015,0.00006773002,0.000022689841,0.000105162544,0.00032508827,0.00022898774],"category_scores_gemma":[0.005136954,0.0002236263,0.0008328555,0.0002769751,0.0005172547,0.00012369792,0.000044616478,0.00044610244,0.000034434706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012170236,0.0021938635,0.957266,0.00008997108,0.0010578965,0.00009241288,0.00010769394,7.9403736e-7,0.0006860379,0.00018645907,0.0014503609,0.024698315],"study_design_scores_gemma":[0.24944901,0.05073906,0.59939,0.0051628766,0.0025644465,0.00020470747,0.00039895758,0.00004361686,0.052188985,0.00086392346,0.037306614,0.0016878123],"about_ca_topic_score_codex":0.00004134416,"about_ca_topic_score_gemma":0.000001756884,"teacher_disagreement_score":0.35787597,"about_ca_system_score_codex":0.00003950076,"about_ca_system_score_gemma":0.00085663784,"threshold_uncertainty_score":0.91192156},"labels":[],"label_agreement":null},{"id":"W2137554174","doi":"10.1177/135965350801302s05","title":"World Health Organization/HIVResNet Drug Resistance Laboratory Strategy","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Accreditation; Quality assurance; Medicine; Human immunodeficiency virus (HIV); Developing country; Population; External quality assessment; Operations research; Environmental health; Antiretroviral therapy; Viral load; Virology; Engineering; Economic growth; Medical education; Pathology","score_opus":0.021361288121692214,"score_gpt":0.2737638945577415,"score_spread":0.25240260643604934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137554174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96544695,0.0043111583,0.000061422725,0.018109342,0.0001483947,0.00056427816,0.000016301301,0.00025144318,0.011090706],"genre_scores_gemma":[0.83519584,0.0037651202,0.0011244218,0.0015810902,0.000121202385,0.000009315126,0.00010787829,0.00003825609,0.1580569],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891436,0.000072035036,0.00024099146,0.00025672445,0.00024304923,0.00027282818],"domain_scores_gemma":[0.99945194,0.000030275862,0.00008708786,0.00024014471,0.00009158734,0.000098985554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121280005,0.00017708793,0.0002886194,0.00012402091,0.00023871557,0.000015035688,0.000072428236,0.000030249326,0.00020138931],"category_scores_gemma":[0.000009810067,0.0001425963,0.000038893373,0.0008635736,0.000073567986,0.000112826645,0.00000975564,0.0001158625,0.0002419913],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033401023,0.0009144234,0.46516198,0.000041146435,0.00027894677,0.0003671166,0.004460489,6.9819123e-7,0.0018969872,0.0018941842,0.5184875,0.006162532],"study_design_scores_gemma":[0.0057507735,0.00015444317,0.21487358,0.00016008253,0.00001745939,0.000018182143,0.00024470524,0.000005678783,0.03515647,0.00021080533,0.7429396,0.0004682459],"about_ca_topic_score_codex":0.000016037056,"about_ca_topic_score_gemma":0.00015152058,"teacher_disagreement_score":0.2502884,"about_ca_system_score_codex":0.00008454024,"about_ca_system_score_gemma":0.0004923051,"threshold_uncertainty_score":0.5814908},"labels":[],"label_agreement":null},{"id":"W2137684917","doi":"10.1093/aje/kwq101","title":"Epidemiology of Antiretroviral Multiclass Resistance","year":2010,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Interquartile range; Medicine; Epidemiology; Antiretroviral therapy; Drug resistance; Incidence (geometry); Viral load; Internal medicine; Antiretroviral treatment; Logistic regression; Human immunodeficiency virus (HIV); Immunology; Biology; Mathematics","score_opus":0.02980662070135818,"score_gpt":0.3460565670153246,"score_spread":0.3162499463139664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137684917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789537,0.0009783633,0.0018921895,0.016543085,0.0005134537,0.00011685427,0.0000057196225,0.000013068393,0.0009835573],"genre_scores_gemma":[0.85071105,0.00023085356,0.14606176,0.0012227552,0.00024025657,0.00000283152,0.0000057002644,0.000016694494,0.0015081039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655944,0.0008618922,0.0017340146,0.00023949437,0.000118024735,0.00048714117],"domain_scores_gemma":[0.9911455,0.0058415253,0.0020561614,0.00034773105,0.00029312342,0.0003159409],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00441782,0.00020160177,0.002039088,0.00026725087,0.000040382507,4.2688214e-7,0.00019838974,0.00012030766,0.00011613707],"category_scores_gemma":[0.014641131,0.00013926541,0.00035656174,0.00025684864,0.0013046722,0.000058112488,0.00003651204,0.00067441945,0.000021700835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005745604,0.00019598972,0.9782099,0.000021618802,0.0003051109,0.00008372586,0.00014508989,0.0000045723436,0.001804991,0.004298832,0.0035752105,0.010780415],"study_design_scores_gemma":[0.0028076542,0.00291631,0.94782484,0.00016989082,0.00034416752,0.0011225854,0.00037212454,0.00013436854,0.0011037466,0.0040014717,0.03894651,0.00025633717],"about_ca_topic_score_codex":0.00005025055,"about_ca_topic_score_gemma":0.00003892035,"teacher_disagreement_score":0.14416957,"about_ca_system_score_codex":0.00005770383,"about_ca_system_score_gemma":0.00023610906,"threshold_uncertainty_score":0.99365896},"labels":[],"label_agreement":null},{"id":"W2137732012","doi":"10.1016/j.jcv.2005.01.011","title":"Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Centre for Disease Control","funders":"","keywords":"Reverse transcriptase; Genotyping; Virology; Biology; Genotype; Protease; Molecular biology; Human immunodeficiency virus (HIV); Polymerase chain reaction; Genetics; Gene; Enzyme","score_opus":0.13525983677665204,"score_gpt":0.436060702803202,"score_spread":0.30080086602655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137732012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97407144,0.0004283009,0.000027230572,0.023766449,0.000280074,0.00044693492,0.0000061332057,0.000003547161,0.0009698581],"genre_scores_gemma":[0.99416775,0.00043667833,0.0019657903,0.0011175625,0.00036817743,0.0000070448687,0.000002495465,0.0000070746105,0.0019274307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626833,0.0012109148,0.0017555022,0.00018322434,0.00043682026,0.00014520054],"domain_scores_gemma":[0.9974125,0.000913791,0.0009314026,0.00021133725,0.000365644,0.0001653468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069188913,0.00013145393,0.00082409615,0.000064914915,0.000059201575,0.0000043040814,0.00011022966,0.00017541768,0.00011892462],"category_scores_gemma":[0.0014487479,0.00007424263,0.00028246574,0.00009113714,0.0003524382,0.00009100195,0.000018866209,0.0006907104,0.000029563931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01677662,0.0037338368,0.89750683,0.00006126082,0.0009779395,0.000032584212,0.0011238268,0.00012226251,0.00045346929,0.00010668271,0.036109187,0.042995524],"study_design_scores_gemma":[0.015246785,0.002805911,0.8921647,0.00037410727,0.0012255582,0.000069408765,0.000098638164,0.002964075,0.00080377125,0.00013154303,0.083993435,0.000122054196],"about_ca_topic_score_codex":3.4180064e-7,"about_ca_topic_score_gemma":0.0000070380484,"teacher_disagreement_score":0.04788425,"about_ca_system_score_codex":0.00004268538,"about_ca_system_score_gemma":0.00039183686,"threshold_uncertainty_score":0.30275264},"labels":[],"label_agreement":null},{"id":"W2137873375","doi":"10.1086/422037","title":"Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive Patients","year":2004,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Nelfinavir; Lopinavir; Ritonavir; Lopinavir/ritonavir; Lamivudine; Medicine; Stavudine; Hazard ratio; Internal medicine; Zidovudine; Virology; Confidence interval; Viral load; Immunology; Viral disease; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","score_opus":0.010228936119542382,"score_gpt":0.24224758716788422,"score_spread":0.23201865104834185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137873375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593455,0.00047624542,0.00013554066,0.002416539,0.00008413178,0.0006580322,0.00019544021,0.000019286548,0.00008023438],"genre_scores_gemma":[0.9974492,0.0004513904,0.00016395113,0.0010432643,0.000080810154,0.000011545944,0.000015279895,0.000026793163,0.0007577255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980331,0.00027998182,0.00064370286,0.00018999455,0.0005380633,0.00031515196],"domain_scores_gemma":[0.99843746,0.0003316353,0.0003017656,0.00023131179,0.0002912632,0.0004065548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007310936,0.0002712025,0.0005465196,0.00038994662,0.00009352945,0.00001824523,0.00015437475,0.00006936741,0.000063220454],"category_scores_gemma":[0.000480744,0.00017223465,0.00012996249,0.0003525088,0.00011238908,0.00013128467,0.0000750955,0.00021333419,0.00007993716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04091418,0.004591736,0.92535424,0.00006853017,0.00027066233,0.00042479782,0.001915068,0.0010274478,0.019077376,0.00000357265,0.0018174768,0.004534903],"study_design_scores_gemma":[0.013922069,0.007268949,0.9644564,0.0004647636,0.00030111766,0.00012742878,0.00011997539,0.000018749535,0.012208539,0.00007588746,0.0007915111,0.00024463414],"about_ca_topic_score_codex":0.000056249806,"about_ca_topic_score_gemma":0.000005864378,"teacher_disagreement_score":0.03910213,"about_ca_system_score_codex":0.0003513857,"about_ca_system_score_gemma":0.00046240864,"threshold_uncertainty_score":0.7023525},"labels":[],"label_agreement":null},{"id":"W2137947649","doi":"10.1097/qai.0b013e318222f461","title":"Chronic Kidney Disease and Estimates of Kidney Function in HIV Infection: A Cross-Sectional Study in the Multicenter AIDS Cohort Study","year":2011,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; University Health Network; Hospital for Sick Children","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases","keywords":"Renal function; Medicine; Kidney disease; Creatinine; Internal medicine; Multicenter AIDS Cohort Study; Serostatus; Cystatin C; Cohort; Endocrinology; Immunology; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.023271682142598088,"score_gpt":0.28956347279876454,"score_spread":0.2662917906561665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137947649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713916,0.0007897496,0.000044066037,0.0001551537,0.00040403585,0.0013251258,0.000006321049,0.000018115852,0.00011830275],"genre_scores_gemma":[0.9992993,0.00008967032,0.00017819492,0.000037727914,0.000039225728,0.00007622785,0.000012818035,0.000022498542,0.00024437148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723965,0.00019717675,0.0012630066,0.00029575414,0.0007069904,0.00029744452],"domain_scores_gemma":[0.9987108,0.00011705258,0.0004207001,0.00030821006,0.0002150099,0.00022824519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020609775,0.00026250107,0.0006155147,0.00088056125,0.00012628776,0.000047987098,0.00017575614,0.00006143359,0.00015101416],"category_scores_gemma":[0.00070007885,0.00017249721,0.00015809364,0.0008429064,0.00016543771,0.00040545495,0.0000740571,0.00018715253,0.000014388871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009099583,0.005533059,0.9875098,0.00009972072,0.00039094422,0.00039070807,0.0047221472,0.000015038205,0.00014257737,0.000011716127,0.00007164261,0.00020269872],"study_design_scores_gemma":[0.008343091,0.0033314826,0.9852368,0.00026280317,0.00049005443,0.00026058374,0.0016877388,0.000101596794,0.000059988924,0.00006060894,0.000023018216,0.0001421917],"about_ca_topic_score_codex":0.00013972167,"about_ca_topic_score_gemma":0.000015694626,"teacher_disagreement_score":0.007433133,"about_ca_system_score_codex":0.00024240882,"about_ca_system_score_gemma":0.0005252192,"threshold_uncertainty_score":0.7034232},"labels":[],"label_agreement":null},{"id":"W2138068891","doi":"10.1177/1545109710382041","title":"Virologic and Immunologic Effectiveness of Tipranavir/Ritonavir (TPV/r)- Versus Darunavir/Ritonavir (DRV/r)-Based Regimens in Clinical Practice","year":2010,"lang":"en","type":"article","venue":"Journal of the International Association of Physicians in AIDS Care","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Maple Leaf Medical Clinic; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Darunavir; Ritonavir; Medicine; Virology; Human immunodeficiency virus (HIV); Internal medicine; Antiretroviral therapy; Viral load","score_opus":0.01002039908343711,"score_gpt":0.3308328701613097,"score_spread":0.3208124710778726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138068891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99263185,0.00019592531,0.0000123647005,0.004047752,0.0015567014,0.00026391022,0.000027404772,0.0000046975656,0.0012593813],"genre_scores_gemma":[0.9969489,0.000074475276,0.0024615088,0.0001617528,0.0001514187,0.000008089454,0.00001521727,0.000011759284,0.00016687383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751407,0.00044675937,0.0009396394,0.00017635657,0.0007737303,0.00014945213],"domain_scores_gemma":[0.9949427,0.0024587754,0.0015537582,0.00018027054,0.0008352142,0.0000292506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020100507,0.00015619435,0.0005648821,0.00024141734,0.00003328983,0.00001294181,0.0002998889,0.00019571415,0.00001091211],"category_scores_gemma":[0.002776951,0.00011624411,0.00028440685,0.0002941742,0.00011182232,0.00022217164,0.00007714239,0.0008120113,0.0000019876907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003831945,0.0016126184,0.958659,0.00008281892,0.00079400436,0.000055889337,0.00067179673,0.0001803468,0.022350308,0.00077189493,0.00018004347,0.010809366],"study_design_scores_gemma":[0.011426854,0.0009108914,0.9677016,0.000809983,0.000289834,0.000016156713,0.0011343586,0.00010598779,0.014809619,0.00037743518,0.002280742,0.00013649577],"about_ca_topic_score_codex":0.000043827175,"about_ca_topic_score_gemma":0.00007587322,"teacher_disagreement_score":0.01067287,"about_ca_system_score_codex":0.0006153024,"about_ca_system_score_gemma":0.00027576945,"threshold_uncertainty_score":0.47402972},"labels":[],"label_agreement":null},{"id":"W2138125850","doi":"10.1097/00002030-200312050-00007","title":"Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects","year":2003,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wildlife Habitat Canada (Canada)","funders":"","keywords":"Atazanavir; Nelfinavir; Lamivudine; Stavudine; Medicine; Indinavir; Adverse effect; Efavirenz; Internal medicine; Ritonavir; Gastroenterology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Hepatitis B virus; Virus","score_opus":0.023661503473487118,"score_gpt":0.3160456122305906,"score_spread":0.29238410875710347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138125850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932802,0.00045391527,0.00009059222,0.00025375222,0.00012110802,0.001199903,0.000003910662,0.00002462306,0.004572016],"genre_scores_gemma":[0.99152833,0.0004917476,0.0033496167,0.00006614,0.00005735777,0.000040159757,0.000026404485,0.000021812939,0.0044183987],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982713,0.00025653408,0.0006388896,0.0003105051,0.000268291,0.0002545054],"domain_scores_gemma":[0.9989438,0.0004965425,0.00015377982,0.00023157851,0.000059730904,0.00011459028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016693199,0.00020225148,0.0011070033,0.00021446781,0.0000292754,0.000008685858,0.000043789532,0.00009658977,0.00006502888],"category_scores_gemma":[0.0006312581,0.00013210867,0.00013142971,0.00035868047,0.00023948212,0.000073715295,0.000022147524,0.00017413445,0.000010718642],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39064115,0.00073874363,0.60219103,0.000060328177,0.00043900547,0.0002066259,0.00033972063,7.743183e-7,0.00007417711,0.0011832126,0.00025050173,0.003874741],"study_design_scores_gemma":[0.98116153,0.0025773223,0.012415076,0.00021785528,0.0004162339,0.000029026873,0.00015196331,0.000029952464,0.0014189681,0.00011112516,0.0012840747,0.00018688882],"about_ca_topic_score_codex":0.000039806357,"about_ca_topic_score_gemma":0.000014623823,"teacher_disagreement_score":0.5905204,"about_ca_system_score_codex":0.000035552155,"about_ca_system_score_gemma":0.00015928973,"threshold_uncertainty_score":0.5387236},"labels":[],"label_agreement":null},{"id":"W2138216643","doi":"10.1128/jvi.77.16.8621-8632.2003","title":"Diminished RNA Primer Usage Associated with the L74V and M184V Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Provides a Possible Mechanism for Diminished Viral Replication Capacity","year":2003,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Bristol-Myers Squibb","keywords":"Biology; Reverse transcriptase; Resistance mutation; Virology; Primer (cosmetics); Viral replication; Mutant; Virus; Mutation; DNA; RNA; Molecular biology; Genetics; Gene; Chemistry","score_opus":0.03286918346993,"score_gpt":0.2878247390146312,"score_spread":0.2549555555447012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138216643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956083,0.00013361948,0.00025794128,0.0030823427,0.000040860497,0.0006142046,0.000009070925,0.000004246302,0.00024937303],"genre_scores_gemma":[0.9983416,0.000029076786,0.0009905063,0.00030956845,0.000010167219,0.00003316907,0.000011600177,0.000010192995,0.00026408967],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988612,0.00022585691,0.00042525266,0.00013971626,0.00018650704,0.00016144557],"domain_scores_gemma":[0.9989551,0.00020124897,0.00040705592,0.00020259382,0.00020041382,0.000033596796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010960337,0.00011548786,0.0003028225,0.0001165467,0.00014572748,0.000012339781,0.00009723019,0.00007717499,0.000015632659],"category_scores_gemma":[0.00038972727,0.000059747592,0.000068536974,0.00019448898,0.00014925348,0.00009077915,0.000005333959,0.00019728494,4.7884487e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002965472,0.0039575337,0.049058333,0.000107816995,0.001217632,0.00013728204,0.03921575,0.000018464907,0.88224995,0.01892922,0.0011040526,0.0010385166],"study_design_scores_gemma":[0.045786355,0.026238676,0.5947567,0.0005696107,0.0063033565,0.001816248,0.012793124,0.0006717005,0.279425,0.027239367,0.003507574,0.00089228887],"about_ca_topic_score_codex":0.000028003946,"about_ca_topic_score_gemma":0.00007309052,"teacher_disagreement_score":0.6028249,"about_ca_system_score_codex":0.000050589515,"about_ca_system_score_gemma":0.00015292212,"threshold_uncertainty_score":0.24364361},"labels":[],"label_agreement":null},{"id":"W2138414945","doi":"10.1128/aac.00591-12","title":"Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors","year":2012,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Virology; Drug resistance; Drug; Biology; Human immunodeficiency virus (HIV); Medicine; Antiretroviral therapy; Pharmacology; Viral load; RNA; Genetics","score_opus":0.015417941873933746,"score_gpt":0.2519633552548478,"score_spread":0.23654541338091406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138414945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97544605,0.0003359493,0.0002699668,0.022714116,0.0001213178,0.0007867669,0.00001428481,0.00001751162,0.0002940368],"genre_scores_gemma":[0.9415318,0.0007670786,0.01588428,0.0034608599,0.00015395893,0.000016472259,0.000057328238,0.000031206393,0.03809704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917763,0.00001781807,0.00028310347,0.00016937219,0.00010570004,0.00024638907],"domain_scores_gemma":[0.9996427,0.000026780779,0.00008628884,0.00011119949,0.000029271469,0.00010373255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022001374,0.0001773678,0.00032066667,0.000048532227,0.00013683154,0.0000149872,0.00004480603,0.000047692854,0.000028900004],"category_scores_gemma":[0.0000060553743,0.00011351278,0.00008090162,0.000083305604,0.00012819425,0.00008364601,0.000013618088,0.00005505021,0.00000335909],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004164633,0.0005988947,0.059969384,0.0003921333,0.0006759077,0.0000039455804,0.042622924,4.3701274e-8,0.013149764,0.00043043686,0.8547488,0.023243126],"study_design_scores_gemma":[0.0206487,0.000018536339,0.012152025,0.00025653865,0.00017494727,0.000008428158,0.00043380112,0.000005275451,0.11747559,0.000037806476,0.8485505,0.000237854],"about_ca_topic_score_codex":0.000009677401,"about_ca_topic_score_gemma":0.000007736896,"teacher_disagreement_score":0.10432582,"about_ca_system_score_codex":0.000020310275,"about_ca_system_score_gemma":0.000072264826,"threshold_uncertainty_score":0.4628917},"labels":[],"label_agreement":null},{"id":"W2138734727","doi":"10.1128/aac.00462-09","title":"Lack of Effect of Efavirenz on the Pharmacokinetics of Tipranavir-Ritonavir in Healthy Volunteers","year":2009,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Ontario HIV Treatment Network","keywords":"Pharmacokinetics; Ritonavir; Efavirenz; Pharmacology; Medicine; Dosing; Adverse effect; Gastroenterology; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.02154348559387436,"score_gpt":0.3220991442173508,"score_spread":0.30055565862347644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138734727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98968786,0.000064393374,0.0000025836277,0.00919808,0.00003625397,0.00043547296,0.000012384302,0.0000054994803,0.0005574978],"genre_scores_gemma":[0.9950925,0.0012594771,0.0000912557,0.0030809832,0.000020502646,0.000002080202,0.0000135935215,0.00001099241,0.00042861223],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992095,0.000043113723,0.00031626577,0.00014434246,0.00014137175,0.00014541076],"domain_scores_gemma":[0.99962366,0.000057701833,0.00011241646,0.00013933577,0.00002859641,0.000038270864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016784402,0.00014494333,0.0004063733,0.00008162868,0.00002020556,0.0000024732299,0.00006722325,0.000052276184,0.000074683485],"category_scores_gemma":[0.000006358614,0.00008972855,0.000082088976,0.00016267382,0.00008588765,0.000017122635,0.000007818732,0.000088025554,0.0000024007988],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015523134,0.004316546,0.4655199,0.0009796716,0.00078842184,0.000043681437,0.0051113283,0.000022506754,0.31432647,0.00023327893,0.06146515,0.1316699],"study_design_scores_gemma":[0.014461898,0.0029058314,0.1822538,0.00066915795,0.00012364387,0.000008869968,0.000041971212,0.000114763265,0.7902261,0.000020468118,0.008999864,0.00017363823],"about_ca_topic_score_codex":0.00004204844,"about_ca_topic_score_gemma":0.0000032751702,"teacher_disagreement_score":0.47589964,"about_ca_system_score_codex":0.000018071618,"about_ca_system_score_gemma":0.000027202826,"threshold_uncertainty_score":0.36590242},"labels":[],"label_agreement":null},{"id":"W2138769482","doi":"10.1093/jac/dkq129","title":"Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates","year":2010,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Virology; Biology; Frameshift mutation; Mutation; Resistance mutation; Drug resistance; Reverse transcriptase; Protease; Group-specific antigen; Virus; Gene; Microbiology; Genetics; Polymerase chain reaction; Enzyme","score_opus":0.006052799596855793,"score_gpt":0.23402885258200246,"score_spread":0.22797605298514667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138769482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922033,0.00051614636,0.000031292726,0.006822566,0.00006922142,0.0002443654,0.000004110671,0.000002330939,0.00010669742],"genre_scores_gemma":[0.9937605,0.0003209264,0.0052559697,0.00010944963,0.00012715619,9.543978e-7,0.0000013562952,0.000010315816,0.00041334433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99924374,0.000030940264,0.00040671282,0.00007687663,0.00013855852,0.00010314691],"domain_scores_gemma":[0.9993242,0.000036658897,0.0003426559,0.00010867619,0.00015145175,0.00003634908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033549557,0.000097700744,0.00028674607,0.00014092446,0.000024786648,0.000007128247,0.00007569662,0.00006516154,0.00002499829],"category_scores_gemma":[0.00003122566,0.000060434806,0.00007781119,0.0001552531,0.00009667016,0.000069324,0.0000066200655,0.00018592151,8.0389475e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012264572,0.00038024885,0.07524257,0.00009317786,0.00006177137,0.000014885806,0.0014768387,3.739956e-7,0.91774637,0.000052095555,0.0032458084,0.00045942646],"study_design_scores_gemma":[0.005631555,0.00022209651,0.06339879,0.00046229697,0.00006721339,0.00018603266,0.00021642965,0.000009941989,0.9236032,0.0001426723,0.0059544793,0.00010533486],"about_ca_topic_score_codex":0.000009411281,"about_ca_topic_score_gemma":0.000035995243,"teacher_disagreement_score":0.011843777,"about_ca_system_score_codex":0.000027468168,"about_ca_system_score_gemma":0.00017341331,"threshold_uncertainty_score":0.24644598},"labels":[],"label_agreement":null},{"id":"W2139034522","doi":"10.1128/aac.00800-09","title":"Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to Etravirine","year":2009,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Etravirine; Efavirenz; Virology; Nevirapine; Reverse transcriptase; Biology; Recombinant DNA; Reverse-transcriptase inhibitor; Nucleotidyltransferase; Mutation; Resistance mutation; Polymerase; Virus; Enzyme; Molecular biology; DNA; Polymerase chain reaction; RNA; Genetics; Gene; Viral load; Biochemistry; Antiretroviral therapy","score_opus":0.015158603396945174,"score_gpt":0.278089468055972,"score_spread":0.2629308646590268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139034522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97003675,0.00020545149,0.0000358994,0.028316025,0.00007326502,0.0005173128,0.00001444785,0.00003326842,0.0007676063],"genre_scores_gemma":[0.9734493,0.0010042283,0.0010044867,0.015374427,0.000031116175,0.0000042104334,0.00004646211,0.00001789026,0.009067902],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99911124,0.00003728385,0.00022821169,0.00028818115,0.000097247044,0.00023786697],"domain_scores_gemma":[0.99960715,0.000018442995,0.000055951357,0.00016666893,0.00006572513,0.00008609148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016224016,0.00019192317,0.00025954845,0.00006994816,0.0003744637,0.000046608573,0.000050497532,0.000052614134,0.000045198554],"category_scores_gemma":[0.000010465717,0.00013536228,0.00004942229,0.00019306284,0.00008284556,0.00005686223,0.000009606778,0.000111747046,0.0000090958865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036248236,0.0020528422,0.011236461,0.00013393987,0.0007806752,0.0006012855,0.048928864,0.0000036261467,0.6086353,0.003052253,0.28445685,0.03649304],"study_design_scores_gemma":[0.017172521,0.0019474635,0.3596169,0.0013691091,0.00051135663,0.00030490625,0.0029627243,0.000041364303,0.13420463,0.00047913028,0.4801833,0.0012065789],"about_ca_topic_score_codex":0.00005472832,"about_ca_topic_score_gemma":0.000048832004,"teacher_disagreement_score":0.4744307,"about_ca_system_score_codex":0.00003940979,"about_ca_system_score_gemma":0.000035822777,"threshold_uncertainty_score":0.55199134},"labels":[],"label_agreement":null},{"id":"W2139205343","doi":"10.1086/430706","title":"Accuracy, Precision, and Consistency of Expert HIV Type 1 Genotype Interpretation: An International Comparison (The GUESS Study)","year":2005,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences","keywords":"Interpretation (philosophy); Medicine; Genotype; Consistency (knowledge bases); Human immunodeficiency virus (HIV); Statistics; Family medicine; Genetics; Artificial intelligence; Mathematics; Computer science; Biology; Gene","score_opus":0.05234632993567892,"score_gpt":0.42117269248817635,"score_spread":0.36882636255249746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139205343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950647,0.0010600655,0.00010161132,0.0015024524,0.00041080476,0.00051752134,0.000008929606,0.00006345432,0.0012704713],"genre_scores_gemma":[0.9981925,0.00038744276,0.00015620593,0.00039094334,0.0002924145,0.000031785603,0.000064193715,0.000011948074,0.00047254926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861777,0.00014758001,0.00064177084,0.00026806013,0.0002231738,0.000101662576],"domain_scores_gemma":[0.99835443,0.00072697323,0.00017799703,0.00029336082,0.0002827894,0.00016442029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021512763,0.00012915565,0.00035020048,0.00006152741,0.00007631107,0.000030138326,0.000105101215,0.000050684954,0.000310776],"category_scores_gemma":[0.0010560604,0.000085048974,0.00009046295,0.000113400565,0.00017920948,0.00014986611,0.000077132354,0.00011497,0.00006491877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030972544,0.0036351024,0.906065,0.000007643953,0.00031178334,0.00000647179,0.0010943722,0.0000081143235,0.00000545653,0.000052282896,0.0031129385,0.08539111],"study_design_scores_gemma":[0.0027787674,0.00091117073,0.9762878,0.00007433,0.00034838743,0.000008337498,0.0007013724,0.0016537327,0.000039657185,0.00009944605,0.016968293,0.00012874836],"about_ca_topic_score_codex":0.00000771118,"about_ca_topic_score_gemma":0.00004434799,"teacher_disagreement_score":0.085262366,"about_ca_system_score_codex":0.000039311275,"about_ca_system_score_gemma":0.00012676595,"threshold_uncertainty_score":0.34681964},"labels":[],"label_agreement":null},{"id":"W2139264675","doi":"10.1016/j.jval.2014.03.1569","title":"Budget Impact Analysis Of Dolutegravir In The Treatment Of Human Immunodeficiency Virus (Hiv) In Ontario, Canada","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dolutegravir; Medicine; Regimen; Formulary; Population; Pharmacy; Internal medicine; Human immunodeficiency virus (HIV); Pediatrics; Demography; Family medicine; Viral load; Environmental health; Antiretroviral therapy","score_opus":0.026532311481493216,"score_gpt":0.30557076732917104,"score_spread":0.27903845584767784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139264675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745524,0.0005571166,0.0000029804971,0.0006935367,0.000028100509,0.0004891857,0.000019062936,0.0000032528387,0.0007515191],"genre_scores_gemma":[0.99920034,0.0001432712,0.0001302402,0.0000718865,0.000005526306,0.000028104341,0.000099144694,0.0000075945395,0.00031387928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981001,0.00025953917,0.00076413614,0.00021090754,0.00033461305,0.00033071626],"domain_scores_gemma":[0.9991654,0.00017210591,0.00019160363,0.0003820863,0.000023300126,0.00006550204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072289613,0.00016676544,0.0007762908,0.0006228258,0.000035355188,0.0000034090563,0.00010681861,0.00004243902,0.000076292374],"category_scores_gemma":[0.000019092915,0.00010325467,0.00012327395,0.0010984002,0.000026850887,0.000021139682,0.00000835286,0.00012238849,0.0000011227564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007356723,0.0013392306,0.98059505,0.00003870431,0.00017877496,0.000023487723,0.013966892,0.002297294,0.00009352804,0.00018672555,0.00007336943,0.0011333508],"study_design_scores_gemma":[0.0019801678,0.0007122767,0.994404,0.000111363755,0.00011884086,0.0000019532229,0.0005674556,0.0011559405,0.00016729394,0.00005344996,0.0006505571,0.00007667557],"about_ca_topic_score_codex":0.9980503,"about_ca_topic_score_gemma":0.9972074,"teacher_disagreement_score":0.01380895,"about_ca_system_score_codex":0.0030387961,"about_ca_system_score_gemma":0.002139841,"threshold_uncertainty_score":0.7946346},"labels":[],"label_agreement":null},{"id":"W2139430929","doi":"10.1016/s0140-6736(12)61853-4","title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":546,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Sunnybrook Health Science Centre; Health Sciences Centre","funders":"ViiV Healthcare","keywords":"Dolutegravir; Raltegravir; Medicine; Emtricitabine; Integrase inhibitor; Abacavir; Lamivudine; Adverse effect; Clinical endpoint; Virology; Internal medicine; Efavirenz; Clinical trial; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","score_opus":0.038874733125972394,"score_gpt":0.28644908395491,"score_spread":0.24757435082893758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139430929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98238724,0.00010187458,0.000016930206,0.008264402,0.00035418934,0.004255499,0.00004467352,0.00010985111,0.0044653146],"genre_scores_gemma":[0.9948275,0.00018077645,0.0003514788,0.00022734627,0.0009514319,0.0005369217,0.00012730049,0.000036289937,0.0027609589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769396,0.00020823446,0.00052150036,0.0005327255,0.0005136925,0.0005298894],"domain_scores_gemma":[0.99804896,0.00040147992,0.00021583687,0.001080062,0.00012797985,0.00012566129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065885554,0.00039872312,0.00085777557,0.000089725494,0.00025537447,0.00012650335,0.0003511779,0.00009902829,0.000093766415],"category_scores_gemma":[0.00008978076,0.0001923611,0.000116411364,0.00052112766,0.00016054418,0.00020612245,0.000108930115,0.00063686154,0.0008263007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31397712,0.00086990534,0.66299367,0.000020590873,0.00048760854,0.00011551423,0.008170934,0.000021073813,0.00003779811,0.000019059064,0.01136417,0.0019225754],"study_design_scores_gemma":[0.39928633,0.0006747048,0.59416306,0.00024730415,0.0002545517,0.000005265117,0.0016297766,0.00010523489,0.00012456169,0.000022517022,0.0032428694,0.00024381987],"about_ca_topic_score_codex":0.013035323,"about_ca_topic_score_gemma":0.004393389,"teacher_disagreement_score":0.085309185,"about_ca_system_score_codex":0.00019178996,"about_ca_system_score_gemma":0.00017333511,"threshold_uncertainty_score":0.99995166},"labels":[],"label_agreement":null},{"id":"W2139646927","doi":"10.1081/ncn-120022960","title":"A New Synthesis of 9-(2-Deoxy-2-fluoro-β-<scp>D</scp>-arabinofuranosyl)guanine (araF-G)","year":2003,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Guanine; Thymine; Stereochemistry; Chemistry; Stereospecificity; Nucleotide; Catalysis; DNA; Biochemistry","score_opus":0.010782134949057682,"score_gpt":0.23296087013762415,"score_spread":0.22217873518856646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139646927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9016495,0.0013245387,0.0003461162,0.0016472153,0.00052411336,0.0013504961,0.00004314748,0.00070037355,0.09241455],"genre_scores_gemma":[0.92085093,0.00046011788,0.05345017,0.0005893353,0.00023113415,0.000073320356,0.00003279052,0.0003240048,0.023988182],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994364,0.00023686487,0.0015579803,0.0012280734,0.0012216093,0.001391445],"domain_scores_gemma":[0.9955961,0.0009527436,0.00056890154,0.0014495698,0.00036488983,0.0010678004],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066875276,0.0010766725,0.0018505484,0.0006701117,0.0003422173,0.00011936341,0.00056839536,0.00047951972,0.0022214488],"category_scores_gemma":[0.0021116692,0.00096854666,0.0008102164,0.0012517205,0.00041635233,0.00051898515,0.00017732014,0.0005651371,0.0016236694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008494213,0.0049640094,0.3470714,0.0016318874,0.005823573,0.0016197611,0.010957468,0.00005057956,0.1806863,0.054147694,0.30259115,0.08960676],"study_design_scores_gemma":[0.00954303,0.0011159364,0.09483392,0.0016872808,0.0028045569,0.00097395596,0.003826122,0.00017953455,0.46650568,0.0033040366,0.41402367,0.0012022838],"about_ca_topic_score_codex":0.000099900055,"about_ca_topic_score_gemma":0.000021677586,"teacher_disagreement_score":0.28581938,"about_ca_system_score_codex":0.00034994265,"about_ca_system_score_gemma":0.0006145683,"threshold_uncertainty_score":0.9992765},"labels":[],"label_agreement":null},{"id":"W2139910608","doi":"10.1128/aac.47.11.3644-3646.2003","title":"Favorable Interactions between Enfuvirtide and 1-β- <scp>d</scp> -2,6-Diaminopurine Dioxolane In Vitro","year":2003,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Enfuvirtide; In vitro; Protease; Reverse transcriptase; Chemistry; Dioxolane; Virology; Human immunodeficiency virus (HIV); Didanosine; Biology; Pharmacology; Enzyme; Biochemistry; Antiretroviral therapy; Immunology; RNA; Viral load; Antigen","score_opus":0.013971665764141624,"score_gpt":0.2573913026190984,"score_spread":0.2434196368549568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139910608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423254,0.000083948704,0.00003586796,0.0020164654,0.0000648897,0.00031562292,0.000014938501,0.000032548607,0.0032032125],"genre_scores_gemma":[0.9739792,0.0011427943,0.0015637699,0.0016408307,0.0000635197,0.00001040883,0.00008051973,0.000030250356,0.02148873],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990046,0.000031315525,0.00025245122,0.00031186055,0.000094897034,0.0003048455],"domain_scores_gemma":[0.9995714,0.00007114389,0.0000593713,0.00013692233,0.000023203002,0.00013800449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010183231,0.00021607816,0.00036117382,0.00014525719,0.00009564472,0.000042294854,0.000038756036,0.00006861245,0.00007508348],"category_scores_gemma":[0.000023984969,0.00018386505,0.00004903008,0.00015892467,0.000058485886,0.00009810594,0.000019065865,0.00015180791,0.000025989537],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094151685,0.0007379295,0.88106656,0.00011068698,0.00039991408,0.00013326554,0.0024548715,4.5023424e-7,0.060184788,0.000062518295,0.036609232,0.018145632],"study_design_scores_gemma":[0.0075111007,0.00009830489,0.2606127,0.00016766206,0.00011080473,0.00013487236,0.00028630186,0.00001674132,0.27230757,0.00008458844,0.4584859,0.00018345092],"about_ca_topic_score_codex":0.000044775657,"about_ca_topic_score_gemma":0.0000135357095,"teacher_disagreement_score":0.6204539,"about_ca_system_score_codex":0.00004614017,"about_ca_system_score_gemma":0.000036816673,"threshold_uncertainty_score":0.7497799},"labels":[],"label_agreement":null},{"id":"W2140979341","doi":"10.1111/bph.12480","title":"Differential interactions of antiretroviral agents with <scp>LXR</scp>, <scp>ER</scp> and <scp>GR</scp> nuclear receptors: potential contributing factors to adverse events","year":2013,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Higher Education Authority","keywords":"Pregnane X receptor; Nuclear receptor; Constitutive androstane receptor; Receptor; Liver X receptor; Efavirenz; Allosteric regulation; Chemistry; In silico; Cell biology; Biology; Pharmacology; Biochemistry; Immunology; Transcription factor","score_opus":0.01003641453594984,"score_gpt":0.26298784188865487,"score_spread":0.25295142735270504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140979341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959182,0.00026924012,0.00022020798,0.00022078572,0.0018894459,0.00089363154,0.00007395966,0.000046641162,0.0004678975],"genre_scores_gemma":[0.9914552,0.00051160314,0.0010266198,0.00028130956,0.0005909443,0.000020924184,0.00006780909,0.000079905025,0.005965712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965576,0.00027843207,0.0011109137,0.00044750163,0.0006640473,0.00094150123],"domain_scores_gemma":[0.9969599,0.00054087245,0.00093811087,0.000120151984,0.0006887912,0.0007521536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029708855,0.00044514702,0.001085715,0.0005171324,0.00035087336,0.000068589354,0.00027959337,0.00020208639,0.0006703292],"category_scores_gemma":[0.00069256173,0.00041873,0.0003045031,0.0003558287,0.00019331751,0.0005869785,0.00021752832,0.00081513444,0.00008545186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020827072,0.003425352,0.4390586,0.00025659706,0.005915849,0.0030534782,0.0052875443,0.00006220391,0.13650955,0.000009129965,0.3961048,0.010108598],"study_design_scores_gemma":[0.03531838,0.0048539345,0.8070216,0.0020954537,0.0041153617,0.0091238795,0.013318918,0.00057562423,0.06550985,0.000047719757,0.057759225,0.0002600519],"about_ca_topic_score_codex":0.00016928674,"about_ca_topic_score_gemma":0.000018267092,"teacher_disagreement_score":0.367963,"about_ca_system_score_codex":0.00026556407,"about_ca_system_score_gemma":0.00020744411,"threshold_uncertainty_score":0.99982643},"labels":[],"label_agreement":null},{"id":"W2141178214","doi":"10.1074/jbc.m112.351551","title":"HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors","year":2012,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Korea Food and Drug Administration","keywords":"Reverse transcriptase; DNA; Nucleoside; Zidovudine; Efavirenz; Biology; Nevirapine; Molecular biology; Nucleoside analogue; Thymidine; Virology; Chemistry; Genetics; Polymerase chain reaction; Virus; Gene","score_opus":0.011096975802230864,"score_gpt":0.2633050822871451,"score_spread":0.25220810648491426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141178214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885167,0.0012579594,0.00002870671,0.009054293,0.000113947266,0.00025461605,0.00003157602,0.000013377437,0.0007288228],"genre_scores_gemma":[0.99415016,0.00029299204,0.002633323,0.0002695301,0.00030059746,0.000010672796,0.000015926527,0.000014781681,0.002312038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981991,0.00010158808,0.00091825536,0.00019009288,0.00029181046,0.00029912978],"domain_scores_gemma":[0.99819326,0.00069888664,0.00040097468,0.00021444487,0.00009177316,0.0004006782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009638781,0.0002289586,0.00059767056,0.000041311094,0.00009684462,0.0000144758205,0.00015457807,0.00014983112,0.00012764591],"category_scores_gemma":[0.00085973646,0.00011888833,0.00025647882,0.00014907628,0.00023659343,0.000080571626,0.00004680029,0.0003841536,0.000010773646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034798386,0.00058781344,0.28414565,0.00033453797,0.00044038385,0.00025909275,0.0014805523,0.000002115455,0.64947295,0.000006344586,0.05888562,0.00090509065],"study_design_scores_gemma":[0.0052421466,0.00071326474,0.066606544,0.00109181,0.0007756174,0.0005048524,0.0007506587,0.000003345848,0.8911713,0.00005720192,0.032731693,0.00035161135],"about_ca_topic_score_codex":0.0000033795877,"about_ca_topic_score_gemma":7.9423404e-7,"teacher_disagreement_score":0.2416983,"about_ca_system_score_codex":0.00006353182,"about_ca_system_score_gemma":0.00007260348,"threshold_uncertainty_score":0.48481256},"labels":[],"label_agreement":null},{"id":"W2141610926","doi":"10.1086/655764","title":"HIV‐1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy","year":2010,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; China Scholarship Council; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Novartis Foundation; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases; Pfizer; National Institutes of Health; National Science Foundation","keywords":"Resistance mutation; Zidovudine; Lamivudine; Reverse transcriptase; Cart; Medicine; Drug resistance; Virology; Mutation; Reverse-transcriptase inhibitor; Genotype; Antiretroviral therapy; Virus; Viral load; Genetics; Biology; Gene; RNA; Viral disease","score_opus":0.026265299126836252,"score_gpt":0.3596697020952359,"score_spread":0.3334044029683997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141610926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360895,0.00012771114,0.0029907816,0.0016987075,0.00025825843,0.0007875453,0.00038430636,0.00004283991,0.00010087931],"genre_scores_gemma":[0.9981953,0.00040875984,0.00040742953,0.000063657404,0.000038828653,0.00011186123,0.0006449712,0.000012198046,0.000116984294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905765,0.00004671029,0.00051307114,0.00020187916,0.00008203715,0.00009865949],"domain_scores_gemma":[0.9988799,0.00035806734,0.00020349088,0.00017557887,0.00026848746,0.00011444779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001835259,0.00010398506,0.0002974665,0.000100499004,0.000091850925,0.0000067682745,0.000039120037,0.00008456288,0.000039972365],"category_scores_gemma":[0.00037637775,0.000091159905,0.00016354215,0.00017894266,0.00026275864,0.000095984346,0.000007677614,0.00008889905,0.0000012732544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013137683,0.0017040608,0.9780953,0.00009086029,0.00012946725,6.0505084e-7,0.00006690353,8.806906e-7,0.00072820595,0.00799964,0.00051783054,0.010534902],"study_design_scores_gemma":[0.0050868555,0.00082317495,0.98204,0.000039881394,0.0002970465,0.0000042352804,0.0001090891,0.00050854,0.0004704317,0.0101557225,0.00035613577,0.00010890159],"about_ca_topic_score_codex":0.000020626905,"about_ca_topic_score_gemma":0.00005412216,"teacher_disagreement_score":0.010426001,"about_ca_system_score_codex":0.000017512251,"about_ca_system_score_gemma":0.000106635154,"threshold_uncertainty_score":0.37173933},"labels":[],"label_agreement":null},{"id":"W2142351731","doi":"10.1097/00002030-200006160-00017","title":"Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies","year":2000,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Zidovudine; Lamivudine; Virology; Protease inhibitor (pharmacology); Medicine; Lentivirus; Sida; Antiretroviral therapy; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Viral disease; Virus","score_opus":0.03081825935387778,"score_gpt":0.30194693310712606,"score_spread":0.2711286737532483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142351731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958543,0.0017343094,0.0000021289552,0.00047911648,0.00011905485,0.001095061,0.0000071785503,0.000015085099,0.0006937282],"genre_scores_gemma":[0.99727714,0.0006210751,0.00047191486,0.000055984754,0.000020568223,0.000054856027,0.000018723487,0.000012680638,0.0014670715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980823,0.00020249166,0.0004988837,0.00029742855,0.00073259167,0.00018634787],"domain_scores_gemma":[0.99915856,0.00011665921,0.00018681379,0.00023798196,0.00026165598,0.000038303784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007707243,0.00019178134,0.00046295498,0.00013280532,0.000082349085,0.0000061798078,0.0000829227,0.00007624692,0.000060130253],"category_scores_gemma":[0.0003844689,0.00012264132,0.00010256134,0.00041865266,0.00017130232,0.00013732328,0.00004431028,0.00011595951,0.000005092141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026378626,0.00056044216,0.9844277,0.000056340563,0.00016702521,0.0000056387485,0.0010267624,0.0000050314775,0.0029210625,0.00007458303,0.00018561944,0.010306038],"study_design_scores_gemma":[0.008444135,0.0005424741,0.97559583,0.0005015497,0.00016014904,8.7100847e-7,0.00015376703,0.0001414577,0.01351515,0.00064710015,0.00016338742,0.00013414155],"about_ca_topic_score_codex":0.000010952359,"about_ca_topic_score_gemma":0.00000609988,"teacher_disagreement_score":0.010594088,"about_ca_system_score_codex":0.0001089328,"about_ca_system_score_gemma":0.00006941614,"threshold_uncertainty_score":0.50011677},"labels":[],"label_agreement":null},{"id":"W2142565170","doi":"10.1128/aac.01703-13","title":"Effects of Substitutions at the 4′ and 2 Positions on the Bioactivity of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Chemistry; National Center for Research Resources; National Institute of General Medical Sciences; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; National Science Foundation","keywords":"Deamination; Chemistry; Stereochemistry; Deoxyadenosine; Steric effects; DNA; Reverse transcriptase; Nuclear magnetic resonance spectroscopy; Active site; Purine; Biochemistry; Enzyme; RNA","score_opus":0.007643076900553359,"score_gpt":0.2258195694560081,"score_spread":0.21817649255545474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142565170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968605,0.00011774899,0.000021821312,0.030196479,0.000032355663,0.00063994847,0.000012641046,0.000008915768,0.0003651347],"genre_scores_gemma":[0.9946167,0.0013043629,0.00010231291,0.0020737248,0.000022608856,0.000018878669,0.000012584138,0.0000099382805,0.0018388861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994795,0.000030578478,0.00013953711,0.0001366379,0.00009458453,0.00011918608],"domain_scores_gemma":[0.99956644,0.00012857611,0.00007158625,0.00014905012,0.00004292918,0.000041450243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055750745,0.00012183183,0.00019138667,0.000036065725,0.00018322722,0.000012377193,0.000045027347,0.00004536767,0.00018335949],"category_scores_gemma":[0.000008482331,0.00006101526,0.000057985377,0.000097711636,0.0002870606,0.000037168757,0.000026936315,0.00006610145,0.000013046884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004040532,0.0025898705,0.068737075,0.00038039763,0.0013935796,0.00001348371,0.0051843952,0.0000011280508,0.7610336,0.0026028245,0.14747259,0.01018699],"study_design_scores_gemma":[0.002056689,0.00013856041,0.36318895,0.0001844938,0.00014464978,0.000023825723,0.000058945785,0.000014381236,0.6292395,0.00010243845,0.004748646,0.00009895278],"about_ca_topic_score_codex":0.00008674419,"about_ca_topic_score_gemma":0.000008514384,"teacher_disagreement_score":0.29445186,"about_ca_system_score_codex":0.000019926925,"about_ca_system_score_gemma":0.000019590176,"threshold_uncertainty_score":0.24881302},"labels":[],"label_agreement":null},{"id":"W2142606513","doi":"10.4212/cjhp.v65i2.1120","title":"Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Royal University Hospital; Université de Montréal; Alberta Health Services; Institute for Clinical Evaluative Sciences; University of Ottawa; McGill University Health Centre; Alberta Hip and Knee Clinic; Windsor Regional Hospital; Health Sciences Centre; Ottawa Hospital; Children's Hospital of Eastern Ontario; St. Paul's Hospital; Nine Circles Community Health Centre; Memorial University of Newfoundland; Regina Qu'Appelle Health Region; University of Alberta; Toronto General Hospital","funders":"amfAR, The Foundation for AIDS Research","keywords":"Human immunodeficiency virus (HIV); Pharmacist; Family medicine; Medicine; Clinical pharmacy; Nursing; Pharmacy","score_opus":0.040831218857969455,"score_gpt":0.36360849439148757,"score_spread":0.3227772755335181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142606513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834836,0.0013200627,0.0000068101294,0.013125056,0.0006221045,0.0006161823,0.000025364952,0.00000251557,0.0007982889],"genre_scores_gemma":[0.995691,0.000045387544,0.002669915,0.00072222954,0.00042134797,0.000008849749,0.0000053984813,0.00002063741,0.00041521672],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985196,0.00007743361,0.00069710467,0.00008298323,0.00030230577,0.00032058216],"domain_scores_gemma":[0.9979682,0.00019389167,0.00044805097,0.00015016494,0.0008398587,0.0003998542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009888437,0.0001351651,0.0002814677,0.00010070477,0.000119195574,0.00001729658,0.00022238566,0.000024868423,0.000030962587],"category_scores_gemma":[0.00090495317,0.00006770134,0.00015174285,0.00018137773,0.00011121009,0.0002959692,0.00001946922,0.000293955,0.0000061703563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033774378,0.0003256729,0.9800413,0.000013565742,0.00031438714,0.000014076699,0.0017629135,0.000007761046,0.000010709792,0.000052959247,0.010298726,0.0068201777],"study_design_scores_gemma":[0.024109874,0.0009635745,0.41434935,0.00056446024,0.0018982756,0.0001772342,0.0026656205,0.00013636785,0.0021665904,0.000114489536,0.5524797,0.0003744456],"about_ca_topic_score_codex":0.00065323507,"about_ca_topic_score_gemma":0.0007233619,"teacher_disagreement_score":0.56569195,"about_ca_system_score_codex":0.00018332482,"about_ca_system_score_gemma":0.0010795483,"threshold_uncertainty_score":0.27607805},"labels":[],"label_agreement":null},{"id":"W2142639094","doi":"10.1093/cid/ciu019","title":"Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive Individuals","year":2014,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"National Institute on Drug Abuse; National Institutes of Health; GlaxoSmithKline; ViiV Healthcare; Canadian Institutes of Health Research; Ministry of Health, British Columbia; Gilead Sciences; Bristol-Myers Squibb","keywords":"Viremia; Drug resistance; Medicine; Genotyping; Viral load; HIV drug resistance; Confidence interval; Reverse transcriptase; Virology; Internal medicine; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genotype; Biology; Polymerase chain reaction; Genetics","score_opus":0.025202661032823422,"score_gpt":0.3058731207928454,"score_spread":0.280670459760022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142639094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974815,0.00049353944,0.000004452484,0.0007941861,0.0001202745,0.00072957005,0.00009867621,0.00007546157,0.00020231157],"genre_scores_gemma":[0.9980184,0.00018301955,0.00016608227,0.00015257219,0.00011688503,0.00008700058,0.00004050105,0.0000143772095,0.0012211852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823827,0.00019085941,0.000630365,0.0004953217,0.00018780175,0.00025740542],"domain_scores_gemma":[0.9982101,0.0010013233,0.00017686954,0.00022801726,0.000085909785,0.00029777997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037089371,0.00025084743,0.00066554925,0.00011539834,0.00012642142,0.0000116056135,0.000049081707,0.00012160332,0.00001466372],"category_scores_gemma":[0.0014259486,0.00018288636,0.00009367282,0.00018760786,0.0001667759,0.00010614943,0.00009840038,0.00012124498,0.000017787057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024150271,0.0007953396,0.9953059,0.00018312073,0.000079470214,0.0000060283837,0.00018622489,0.000008811134,0.000059504757,0.000022803591,0.00019069464,0.0029206148],"study_design_scores_gemma":[0.0037637877,0.00055203453,0.9944222,0.00019269233,0.00023778898,0.0000029299024,0.000030239771,0.0003082814,0.000063713094,0.00011052003,0.00015761022,0.00015818323],"about_ca_topic_score_codex":0.000007930048,"about_ca_topic_score_gemma":0.0000846466,"teacher_disagreement_score":0.003522285,"about_ca_system_score_codex":0.00025483058,"about_ca_system_score_gemma":0.00009861995,"threshold_uncertainty_score":0.74578893},"labels":[],"label_agreement":null},{"id":"W2143415894","doi":"10.1186/1471-2334-13-256","title":"Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study","year":2013,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; McMaster University; Victoria General Hospital; Dalhousie University; Windsor Regional Hospital; University Health Network; Ottawa Hospital; Health Sciences Centre; McGill University Health Centre; University of Ottawa; St. Michael's Hospital; Sunnybrook Health Science Centre; B.C. Women's Hospital & Health Centre; University of Toronto; University of British Columbia; Public Health Ontario; Centre hospitalier universitaire de Québec; Women's College Hospital","funders":"Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Nevirapine; Efavirenz; Cmax; Medicine; Regimen; Lopinavir; Internal medicine; Viral load; Population; Pharmacokinetics; Cross-sectional study; Ritonavir; Reverse-transcriptase inhibitor; Gastroenterology; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Pathology","score_opus":0.02186590198945783,"score_gpt":0.29299148803464437,"score_spread":0.27112558604518655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143415894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651563,0.00003643595,0.000024178467,0.000016269727,0.00022809637,0.0023803143,0.000020452491,0.0003736698,0.00040497325],"genre_scores_gemma":[0.9986396,0.000012832461,0.000018319854,0.000068888294,0.0000936612,0.0003619901,0.00017342165,0.00005362624,0.0005776999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976686,0.0002490833,0.00040465052,0.00057473785,0.00056203606,0.0005408784],"domain_scores_gemma":[0.9989231,0.0002666036,0.00018111484,0.00025279226,0.0001493083,0.00022706343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015098145,0.00044868363,0.00046816442,0.0005006184,0.0002778019,0.00016087771,0.000087463166,0.000110843175,0.0005038372],"category_scores_gemma":[0.00013424791,0.00030316354,0.00010245241,0.00055360165,0.00010205595,0.00030727065,0.000049645594,0.00028786523,0.000089845904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001025552,0.006624298,0.98975194,0.000051483457,0.00017360227,0.00004129785,0.000842451,0.00013322393,0.0006444861,0.0000068083523,0.00009247025,0.00061236374],"study_design_scores_gemma":[0.014669543,0.0070644226,0.9764126,0.0000513394,0.00006039509,0.0000099626495,0.0003978309,0.00029203377,0.0006793585,0.000030267025,0.000011143375,0.00032110047],"about_ca_topic_score_codex":0.00010021604,"about_ca_topic_score_gemma":0.000018565273,"teacher_disagreement_score":0.013643991,"about_ca_system_score_codex":0.00052868575,"about_ca_system_score_gemma":0.00014613377,"threshold_uncertainty_score":0.99994206},"labels":[],"label_agreement":null},{"id":"W2143656408","doi":"10.1128/aac.00646-07","title":"Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine","year":2007,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Emory University","keywords":"Zidovudine; Reverse transcriptase; RNase H; Biology; Virology; Mutation; RNase P; Virus; Nucleotidyltransferase; Genetics; Gene; RNA; Viral disease","score_opus":0.020722738638920914,"score_gpt":0.29806619951117774,"score_spread":0.2773434608722568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143656408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566096,0.00008147434,0.00014633538,0.0034210875,0.000048799862,0.0004473613,0.000024091658,0.000018001487,0.00015185897],"genre_scores_gemma":[0.99412453,0.00043157756,0.0015615335,0.0020087662,0.000016772681,0.0000057797783,0.00008582948,0.000018252247,0.0017469537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895066,0.000036724985,0.0003865108,0.00029116875,0.00009181799,0.00024311157],"domain_scores_gemma":[0.9996182,0.000036737143,0.000083680236,0.00011196502,0.000051975163,0.00009746657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033182875,0.00015895066,0.00029292217,0.0001618311,0.00013021533,0.000019130688,0.000042239546,0.000077883546,0.000074106436],"category_scores_gemma":[0.000022190814,0.00013262655,0.000032192376,0.00042426307,0.00006439043,0.000056686265,0.000011988538,0.00012468385,0.0000041997528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011354764,0.002170265,0.96469367,0.000030139234,0.00019966581,0.00021053372,0.0076739197,0.000003774109,0.01886425,0.000109700755,0.003905396,0.0010032316],"study_design_scores_gemma":[0.007441439,0.0001631884,0.9854313,0.0003222583,0.000057020876,0.0000040746368,0.00029230068,0.000011189874,0.0011800844,0.00006601198,0.0048281047,0.00020303462],"about_ca_topic_score_codex":0.00010269293,"about_ca_topic_score_gemma":0.0017479822,"teacher_disagreement_score":0.020737644,"about_ca_system_score_codex":0.00008287128,"about_ca_system_score_gemma":0.000039467366,"threshold_uncertainty_score":0.5408353},"labels":[],"label_agreement":null},{"id":"W2144136328","doi":"10.1310/hct1105-312","title":"A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; College of Medicine, University of Cincinnati; University at Buffalo; University of California, San Diego; BioCryst; Deutsches Krebsforschungszentrum; International AIDS Society; University of Cincinnati; Johns Hopkins University; ACT Government; Georgia Clinical and Translational Science Alliance; Tulane University; University of Minnesota; University of Rochester; University of Miami; Northwestern University; York University; Bristol-Myers Squibb; University of Pennsylvania; Gilead Sciences; Vanderbilt University; Emory University; University of Nebraska Medical Center; National Institutes of Health; Ohio State University; University of Southern California; GlaxoSmithKline","keywords":"Medicine; Abacavir; Zidovudine; Regimen; Internal medicine; Lamivudine; Clinical endpoint; Placebo; Viral load; Indinavir; Population; Efavirenz; Discontinuation; Adverse effect; Gastroenterology; Randomized controlled trial; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus; Pathology","score_opus":0.06691439298854879,"score_gpt":0.3846769090118663,"score_spread":0.3177625160233175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144136328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97358584,0.000022211427,0.000076900615,0.0038426374,0.0005273025,0.020209849,0.0000115970215,0.00008788593,0.0016357794],"genre_scores_gemma":[0.99295247,0.000054929966,0.0018269756,0.00015016636,0.00061056204,0.0027632099,0.00014342113,0.000033683224,0.0014646089],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912134,0.0037479731,0.003521409,0.00067385245,0.0005082809,0.00033511987],"domain_scores_gemma":[0.98334974,0.013878566,0.0016716096,0.0005840738,0.0002511042,0.00026488275],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017668495,0.000377157,0.0041034836,0.00033063197,0.00005658979,0.00002091651,0.00012391216,0.00047886308,0.00013078096],"category_scores_gemma":[0.05392823,0.0002079982,0.00070972956,0.0002553069,0.00026527894,0.00008248122,0.000042888718,0.000863389,0.00008936341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9889856,0.0027008005,0.0024888534,0.00003432045,0.00041551207,0.000071082555,0.0004188937,0.0000027410763,0.0011744638,0.00014735264,0.00045914808,0.0031012155],"study_design_scores_gemma":[0.9913904,0.0029361385,0.0009821963,0.00091224886,0.0006707912,0.000007899755,0.0001267402,0.00056385604,0.0018267985,0.000106308435,0.00026500062,0.00021159044],"about_ca_topic_score_codex":0.000013602551,"about_ca_topic_score_gemma":0.000016631677,"teacher_disagreement_score":0.036259733,"about_ca_system_score_codex":0.000049625396,"about_ca_system_score_gemma":0.00036853933,"threshold_uncertainty_score":0.95404094},"labels":[],"label_agreement":null},{"id":"W2144190487","doi":"10.1345/aph.1a447","title":"Interactions between Recreational Drugs and Antiretroviral Agents","year":2002,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Nelfinavir; Pharmacology; Methadone; Nevirapine; Ritonavir; Drug interaction; Recreational Drug; Drug; CYP2D6; Mephedrone; Cytochrome P450; Human immunodeficiency virus (HIV); Internal medicine; Virology; Viral load; Antiretroviral therapy","score_opus":0.24170252153728114,"score_gpt":0.48349549282402493,"score_spread":0.2417929712867438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144190487","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004151586,0.9942611,0.000004657807,0.0008978145,0.00011639663,0.0007042607,0.000152152,0.000037114714,0.0034113755],"genre_scores_gemma":[0.00019075343,0.97356945,0.00026412783,0.00024451167,0.00033942828,0.000058153077,0.00041036602,0.00005443988,0.02486876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998471,0.00009434573,0.0005933546,0.00031956422,0.00029005538,0.00023165398],"domain_scores_gemma":[0.99907446,0.00015245005,0.00032766967,0.00017264276,0.00009518883,0.00017758508],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001486023,0.0003614144,0.0013282864,0.00037055722,0.00006476007,0.000016560307,0.00009356417,0.000109747096,0.001903534],"category_scores_gemma":[0.000009182307,0.00028150307,0.00041977275,0.000248822,0.00006854341,0.00009938366,0.000023147646,0.00024812424,0.000110264555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018674591,0.00018771285,0.00060402555,0.0019510009,0.0018518649,0.0000136157505,0.00023552687,1.1069788e-8,0.000007361506,0.000015923657,0.038015306,0.95709896],"study_design_scores_gemma":[0.0008089222,0.00009492406,0.00007105872,0.00478125,0.0009172893,0.000020160738,0.000008303668,0.0000035863459,0.00024171393,0.00001258783,0.9928358,0.00020436409],"about_ca_topic_score_codex":0.000006994603,"about_ca_topic_score_gemma":1.788571e-7,"teacher_disagreement_score":0.95689464,"about_ca_system_score_codex":0.000037504557,"about_ca_system_score_gemma":0.0001133557,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W2144464230","doi":"10.1016/j.bmcl.2004.12.068","title":"Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure–activity relationship studies","year":2005,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SNC-Lavalin (Canada)","funders":"","keywords":"Chemistry; Protease; Proteases; Enzyme; Enzyme inhibitor; Lysine; Biochemistry; Pepsin; Arginine; Cathepsin; Structure–activity relationship; Ornithine; Stereochemistry; Amino acid; In vitro","score_opus":0.01706852400378075,"score_gpt":0.2620541486762605,"score_spread":0.24498562467247972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144464230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8953312,0.0009945681,0.00006373066,0.10295095,0.00004814062,0.00036902813,0.000015420042,0.00007452158,0.00015245329],"genre_scores_gemma":[0.99540734,0.00009942135,0.0008496464,0.0007549382,0.0006476698,0.000048248654,0.000039169834,0.00003409742,0.0021194492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982841,0.000045405894,0.00033446323,0.0005098479,0.0004933754,0.00033280472],"domain_scores_gemma":[0.99901164,0.00022150083,0.00016179003,0.0002954857,0.00006362177,0.00024594401],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016375823,0.00037212783,0.00049251784,0.00007133462,0.00019817817,0.00003145348,0.00008287767,0.00010742236,0.00014725438],"category_scores_gemma":[0.0008600937,0.0002795329,0.00007852876,0.0002266811,0.00034081104,0.00020673727,0.00008011155,0.000301432,0.000025075451],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025666435,0.00020227367,0.053897362,0.00039922816,0.0006038723,0.00021031493,0.0014414163,9.199323e-7,0.93424714,0.000009907641,0.0054122233,0.0033186632],"study_design_scores_gemma":[0.0016464659,0.000031066866,0.037379473,0.00053204276,0.00056478975,0.00036814186,0.0009467204,0.000012424533,0.9563939,0.000029816936,0.0017566028,0.00033853608],"about_ca_topic_score_codex":0.000008763715,"about_ca_topic_score_gemma":0.000001972739,"teacher_disagreement_score":0.102196015,"about_ca_system_score_codex":0.00041252715,"about_ca_system_score_gemma":0.00015112851,"threshold_uncertainty_score":0.99996567},"labels":[],"label_agreement":null},{"id":"W2144957732","doi":"10.1124/mol.60.5.1143","title":"Acquisition of Human Concentrative Nucleoside Transporter 2 (hCNT2) Activity by Gene Transfer Confers Sensitivity to Fluoropyrimidine Nucleosides in Drug-Resistant Leukemia Cells","year":2001,"lang":"en","type":"article","venue":"Molecular Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institutes of Health Research","funders":"","keywords":"Uridine; Nucleoside; Cladribine; Deoxyadenosine; Thymidine; Nucleoside transporter; Chemistry; Deoxyuridine; Biochemistry; Cytarabine; Adenosine; Nucleoside analogue; Stereochemistry; In vitro; Leukemia; Biology; Transporter; DNA; Gene; RNA","score_opus":0.009042938658610876,"score_gpt":0.27335204993894285,"score_spread":0.26430911128033197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144957732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374974,0.000103744394,0.0015188919,0.0022811503,0.00010427417,0.0011995772,0.000087327695,0.000053288797,0.0009019849],"genre_scores_gemma":[0.9975261,0.00008119472,0.00036756168,0.0013582269,0.000033947443,0.00006773577,0.0001269599,0.00004611048,0.000392142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978884,0.00030390194,0.00045872634,0.0005337318,0.00029396525,0.00052131637],"domain_scores_gemma":[0.9992925,0.00006124435,0.0000692601,0.0001855927,0.00011408418,0.00027731844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026742075,0.00035276622,0.0007109151,0.00020762031,0.00007380774,0.000008778198,0.00007926621,0.00014065098,0.000503238],"category_scores_gemma":[0.0000034970008,0.00035022586,0.0001660401,0.00031047265,0.00016799118,0.00008762131,0.000020289415,0.00023901559,0.000025369478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017888158,0.0007744941,0.0017767337,0.000057023473,0.00033346805,0.0028206746,0.0016404014,0.000075538395,0.98788047,0.00007108557,0.0022310496,0.00055026903],"study_design_scores_gemma":[0.005833864,0.00026606003,0.007767867,0.00005669696,0.00037704498,0.000030335115,0.00011478608,0.00013405917,0.98357546,0.000012471424,0.0015401932,0.00029116208],"about_ca_topic_score_codex":0.00035095864,"about_ca_topic_score_gemma":0.00017664742,"teacher_disagreement_score":0.005991133,"about_ca_system_score_codex":0.0004906759,"about_ca_system_score_gemma":0.0001781404,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W2144984387","doi":"10.1016/s0140-6736(06)69154-x","title":"Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials","year":2006,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"International AIDS Society","keywords":"Ritonavir; Regimen; Medicine; Protease inhibitor (pharmacology); Internal medicine; Viral load; Randomized controlled trial; Pharmacology; Gastroenterology; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.17824790617597613,"score_gpt":0.4109949463905229,"score_spread":0.23274704021454679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144984387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897441,0.00017289825,0.000033034958,0.000100560115,0.000022437085,0.009340111,0.00053319515,0.000008136482,0.00004548027],"genre_scores_gemma":[0.98615724,0.00004295679,0.0014444556,0.000005820301,0.000009216236,0.0005256859,0.011723753,0.000021028103,0.000069862734],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938919,0.002800686,0.0018070472,0.0004792112,0.00077978004,0.00024136511],"domain_scores_gemma":[0.99499065,0.0017633799,0.0016882548,0.0009935914,0.0005304697,0.00003367896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063252132,0.00031061395,0.00303394,0.00041533637,0.00006450728,0.000023069535,0.00050961744,0.000060453134,0.000019061777],"category_scores_gemma":[0.00037335776,0.00016376386,0.0001358538,0.0010489245,0.0002464808,0.00035808145,0.00006427295,0.00007503577,2.52859e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7293165,0.01569096,0.24195173,0.00010244406,0.0025452361,0.000002021052,0.00811934,0.00091787084,0.0008190846,0.00005941177,0.000023476465,0.00045196823],"study_design_scores_gemma":[0.73635876,0.001784939,0.22536533,0.00046966044,0.003910892,4.8246083e-8,0.0030540577,0.028015742,0.000827099,0.00007762309,5.503039e-7,0.00013527779],"about_ca_topic_score_codex":0.0056175645,"about_ca_topic_score_gemma":0.010049888,"teacher_disagreement_score":0.027097872,"about_ca_system_score_codex":0.0003562107,"about_ca_system_score_gemma":0.00015147,"threshold_uncertainty_score":0.84921145},"labels":[],"label_agreement":null},{"id":"W2145186026","doi":"10.1086/588675","title":"Increased Resilience to the Development of Drug Resistance with Modern Boosted Protease Inhibitor–Based Highly Active Antiretroviral Therapy","year":2008,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; St. Paul's Hospital; University of British Columbia","funders":"International AIDS Society","keywords":"Internal medicine; Regimen; Ritonavir; Odds ratio; Medicine; Confidence interval; Drug resistance; HIV drug resistance; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Cohort; Lopinavir; Viral load; Immunology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Biology","score_opus":0.009266751754815304,"score_gpt":0.23575608825846128,"score_spread":0.22648933650364597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145186026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958752,0.0006699702,0.00063959137,0.0015191659,0.00004849063,0.00095376436,0.000011875864,0.00003128258,0.0002506627],"genre_scores_gemma":[0.99787694,0.00006983682,0.00086930266,0.00029076484,0.00008554117,0.000042548967,0.0000053528706,0.000025263094,0.0007344232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980566,0.00022797358,0.0005264069,0.00015571638,0.00078700157,0.0002462967],"domain_scores_gemma":[0.9982207,0.00023198515,0.0004881302,0.00031846412,0.00049649726,0.00024426795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003431695,0.00024334455,0.00040216613,0.00019782264,0.0004180481,0.000013768492,0.00020722696,0.000029879393,0.000016660852],"category_scores_gemma":[0.00015857823,0.00011263426,0.00011852013,0.00047771924,0.00020584842,0.00013131925,0.000028967412,0.0002013217,0.00000672336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062591575,0.006006774,0.84996104,0.0002552028,0.0020920439,0.0006470704,0.036529627,0.00095687126,0.018066946,0.000024884916,0.00922354,0.013644401],"study_design_scores_gemma":[0.017017681,0.0023831038,0.73867786,0.0016491297,0.00073461625,0.00034591614,0.001265302,0.00009738758,0.23437472,0.00009842799,0.0028030882,0.00055280316],"about_ca_topic_score_codex":0.00002403422,"about_ca_topic_score_gemma":0.00008297549,"teacher_disagreement_score":0.21630776,"about_ca_system_score_codex":0.0002309844,"about_ca_system_score_gemma":0.0017183636,"threshold_uncertainty_score":0.4593092},"labels":[],"label_agreement":null},{"id":"W2145601478","doi":"10.1345/aph.1a335","title":"Extrapyramidal Symptoms with Ritonavir/Indinavir Plus Risperidone","year":2002,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; St. John’s Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Indinavir; Ritonavir; Risperidone; Medicine; Extrapyramidal symptoms; Pharmacology; Escitalopram; Parkinsonism; Sertraline; Drug interaction; Nelfinavir; Internal medicine; Anesthesia; Pediatrics; Psychiatry; Pharmacokinetics; Viral load; Antipsychotic; Virology; Schizophrenia (object-oriented programming); Sida; Viral disease; Human immunodeficiency virus (HIV); Antidepressant","score_opus":0.07099165670950677,"score_gpt":0.34780385993395185,"score_spread":0.2768122032244451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145601478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97384584,0.004703884,0.000077401746,0.013423293,0.00010455182,0.0006127105,0.00002314667,0.00012194704,0.0070872256],"genre_scores_gemma":[0.9682699,0.004770199,0.0007844672,0.0024468855,0.00019196498,0.000055856308,0.00002263212,0.00005870082,0.023399381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850357,0.000035748526,0.000316875,0.0003092569,0.00043864822,0.00039589766],"domain_scores_gemma":[0.99922824,0.000038714123,0.00012524588,0.000253889,0.00012881734,0.00022507353],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011898244,0.00027975367,0.00045530422,0.00017098046,0.00007578909,0.000014922448,0.00012071732,0.00006790939,0.0034323889],"category_scores_gemma":[0.0000030851354,0.00020508606,0.00014901903,0.0003103327,0.00014732279,0.0001369354,0.000011243342,0.0001599619,0.00017483711],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066314763,0.006833401,0.08032885,0.00036463144,0.006298342,0.0013691378,0.011489858,0.000065236956,0.3834266,0.00063808187,0.22835961,0.27419475],"study_design_scores_gemma":[0.017774018,0.0013177819,0.004631999,0.0002931584,0.00021578508,0.00012778155,0.0001240463,0.0009921507,0.77773035,0.00008269452,0.19613215,0.000578118],"about_ca_topic_score_codex":0.000016957752,"about_ca_topic_score_gemma":0.0000021055873,"teacher_disagreement_score":0.3943037,"about_ca_system_score_codex":0.00003480458,"about_ca_system_score_gemma":0.000051172163,"threshold_uncertainty_score":0.9974786},"labels":[],"label_agreement":null},{"id":"W2145897295","doi":"10.1097/00002030-200305020-00007","title":"A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients","year":2003,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Nevirapine; Indinavir; Lamivudine; Stavudine; Regimen; Medicine; Didanosine; Protease inhibitor (pharmacology); Internal medicine; Gastroenterology; Viral load; Virology; Immunology; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy","score_opus":0.01880254107202309,"score_gpt":0.2842333637586474,"score_spread":0.26543082268662427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145897295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98292875,0.000011050987,0.00013347676,0.00037336687,0.00008677351,0.016092004,0.0000021260632,0.000057985784,0.00031448583],"genre_scores_gemma":[0.99178296,0.0000068188206,0.0016075901,0.00011997293,0.000032888387,0.0027083426,0.000047939327,0.000028828237,0.003664663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99839675,0.00031050388,0.00040588368,0.00029764767,0.00037636235,0.00021286766],"domain_scores_gemma":[0.9993,0.00012783606,0.000090679765,0.00020521696,0.00014398972,0.00013227017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053765264,0.0002257911,0.0006949246,0.00025946493,0.000062807965,0.000019823274,0.000040122904,0.000049862614,0.00014632885],"category_scores_gemma":[0.0004901622,0.00012710599,0.000058925034,0.0005792918,0.000025363599,0.00006775156,0.000012107438,0.00010284465,0.00004702853],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6350239,0.0084816525,0.3519856,0.0000080835125,0.00019700636,0.00003707569,0.002620159,0.0000010019395,0.00000507249,0.000019892605,0.000075305536,0.0015452498],"study_design_scores_gemma":[0.9812806,0.008978415,0.007719069,0.00010218059,0.00012500102,0.000002403325,0.0001267748,0.000024711539,0.0008723234,0.000020641784,0.00057779456,0.00017004406],"about_ca_topic_score_codex":0.000032494503,"about_ca_topic_score_gemma":0.000051665465,"teacher_disagreement_score":0.34625673,"about_ca_system_score_codex":0.0001188742,"about_ca_system_score_gemma":0.0001796859,"threshold_uncertainty_score":0.5183231},"labels":[],"label_agreement":null},{"id":"W2145943124","doi":"10.1128/aac.00113-13","title":"Identification and Characterization of a Novel HIV-1 Nucleotide-Competing Reverse Transcriptase Inhibitor Series","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Reverse transcriptase; Resistance mutation; Nucleotidyltransferase; Biology; Primer (cosmetics); Reverse-transcriptase inhibitor; Virology; Polymerase; Viral replication; Virus; Recombinant DNA; Nucleotide; Enzyme; Molecular biology; Polymerase chain reaction; Chemistry; Biochemistry; RNA; Gene","score_opus":0.009971801753501637,"score_gpt":0.2215484239756706,"score_spread":0.21157662222216897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145943124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872817,0.0000069809726,0.00016078114,0.010519234,0.000056431,0.00041729343,0.000027907228,0.000021802189,0.00006140967],"genre_scores_gemma":[0.9908507,0.0005931938,0.0012683022,0.0013382278,0.00005130589,0.000010289748,0.00016187868,0.000020195233,0.0057059033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99936455,0.000009236814,0.00024874898,0.00018630542,0.00007623883,0.00011493873],"domain_scores_gemma":[0.9996908,0.0000046186997,0.000098194505,0.000088982975,0.000059729784,0.000057732566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054230237,0.00012413047,0.00019785382,0.00007829679,0.00007007836,0.000036314163,0.000024555957,0.000047424313,0.00015069958],"category_scores_gemma":[0.0000032911453,0.00010583233,0.000035463247,0.00009505618,0.0000658284,0.00020203955,0.000009278658,0.00004073579,0.000011240385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007547402,0.0002555649,0.027200295,0.00012005596,0.00007170723,0.000001835517,0.0018838923,3.6671402e-8,0.963879,0.000028230723,0.0029971094,0.0034868293],"study_design_scores_gemma":[0.007087386,0.00009803783,0.36100394,0.0004379243,0.00013151509,0.00006469963,0.0004110472,0.00022079829,0.5961017,0.000010888424,0.034118116,0.00031395178],"about_ca_topic_score_codex":0.000013967981,"about_ca_topic_score_gemma":7.285791e-7,"teacher_disagreement_score":0.36777726,"about_ca_system_score_codex":0.000011462785,"about_ca_system_score_gemma":0.000015036216,"threshold_uncertainty_score":0.43157172},"labels":[],"label_agreement":null},{"id":"W2147458973","doi":"10.1038/nrd4010","title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"Ligue Contre le Cancer; Olav Raagholt og Gerd Meidel Raagholts stiftelse; Association pour la Recherche sur le Cancer","keywords":"Nucleoside; Medicine; Cancer; Drug development; Nucleoside analogue; Cancer treatment; Cancer therapy; Drug; Computational biology; Pharmacology; Biology; Internal medicine; Genetics","score_opus":0.02570177930017246,"score_gpt":0.35785438894856236,"score_spread":0.3321526096483899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147458973","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037369807,0.9941388,0.000005923235,0.0003001735,0.00011841631,0.0047122883,0.0001395744,0.00001130901,0.00019986267],"genre_scores_gemma":[0.00006901905,0.9941119,0.0021689998,0.00015107285,0.00013034482,0.0018554957,0.0003949126,0.000045193286,0.0010730417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761826,0.00015701912,0.0010793372,0.00055448787,0.0002816626,0.00030923286],"domain_scores_gemma":[0.9985734,0.00040637044,0.00054263003,0.0003275873,0.000048279395,0.0001016863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046349235,0.0005876691,0.0026947535,0.000218043,0.000094594005,0.000062098916,0.00019343932,0.00022775277,0.00001106821],"category_scores_gemma":[0.00015939803,0.0002926014,0.00038892348,0.00027586025,0.00012210498,0.00035850613,0.00009123878,0.000463417,0.0000059731465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016076316,0.00011866201,0.0006119627,0.04444409,0.00015317545,0.0000056169188,0.00041853907,2.1533465e-8,2.2869668e-7,0.00019911742,0.0025834497,0.95144904],"study_design_scores_gemma":[0.00045490454,0.000018349632,0.0003721397,0.035087395,0.0015537436,0.000010804579,0.00010263918,6.848489e-7,0.0000022815993,0.00007295578,0.96203333,0.00029078667],"about_ca_topic_score_codex":0.0000061017513,"about_ca_topic_score_gemma":0.00019584647,"teacher_disagreement_score":0.9594499,"about_ca_system_score_codex":0.00012739346,"about_ca_system_score_gemma":0.00041688862,"threshold_uncertainty_score":0.9999526},"labels":[],"label_agreement":null},{"id":"W2147476319","doi":"10.1093/ofid/ofu003","title":"Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial","year":2014,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Center for AIDS Research, University of North Carolina at Chapel Hill; York University; National Center for Research Resources; Georgia Clinical and Translational Science Alliance; National Center for Advancing Translational Sciences; ACT Government; National Institute of Allergy and Infectious Diseases; Georgetown University; Johns Hopkins University; University of Cincinnati; University of Pittsburgh; Deutsches Krebsforschungszentrum; University of Washington; Ohio State University","keywords":"Atazanavir; Renal function; Emtricitabine; Medicine; Efavirenz; Cystatin C; Abacavir; Urology; Ritonavir; Creatinine; Lopinavir; Lamivudine; Kidney disease; Internal medicine; Confidence interval; Gastroenterology; Endocrinology; Human immunodeficiency virus (HIV); Viral load; Virology; Antiretroviral therapy","score_opus":0.010360955655798228,"score_gpt":0.26667081855386865,"score_spread":0.2563098628980704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147476319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836387,0.00016779147,0.0013095632,0.0014263255,0.00035605588,0.0045039626,0.000050941268,0.00010739525,0.008439235],"genre_scores_gemma":[0.9959181,0.000011043469,0.0001375465,0.00059532153,0.00011404319,0.001548689,0.00029096438,0.00002548288,0.0013587896],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99847996,0.00027876892,0.00040863256,0.00027918213,0.00031775856,0.00023567681],"domain_scores_gemma":[0.9989624,0.00026239947,0.00024791187,0.00024163877,0.0001461543,0.0001395026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038369664,0.00021362021,0.00081382715,0.00020656979,0.000117070624,0.00007123365,0.0000764982,0.000058397323,0.000693982],"category_scores_gemma":[0.00038296852,0.00016101766,0.00024263286,0.0002359506,0.00009640215,0.00014555526,0.00005927495,0.00006683473,0.000055433247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75657666,0.0018022015,0.23380986,0.00008216625,0.00055040605,0.000021256647,0.0001702977,0.0000052076625,0.00003698831,0.0004960692,0.0021489705,0.0042999014],"study_design_scores_gemma":[0.9682985,0.003405096,0.023201425,0.00019406716,0.0015948196,0.0000057957614,0.00007083467,0.0003194053,0.00044862638,0.0006653794,0.001554326,0.00024172688],"about_ca_topic_score_codex":0.0000971482,"about_ca_topic_score_gemma":0.00019133158,"teacher_disagreement_score":0.21172182,"about_ca_system_score_codex":0.00006919554,"about_ca_system_score_gemma":0.00019158098,"threshold_uncertainty_score":0.75986165},"labels":[],"label_agreement":null},{"id":"W2147662860","doi":"10.1086/589622","title":"A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination Therapy","year":2008,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Ottawa; Ottawa Hospital","funders":"Gilead Sciences; University of North Carolina at Chapel Hill; Brigham and Women's Hospital; GlaxoSmithKline","keywords":"Lopinavir; Ritonavir; Efavirenz; Lopinavir/ritonavir; Lamivudine; Zidovudine; Medicine; Pharmacology; Lipoatrophy; Internal medicine; Gastroenterology; Virology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease","score_opus":0.034474519854766225,"score_gpt":0.3114694589639115,"score_spread":0.27699493910914524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147662860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984817,0.010893289,0.00024694655,0.0018125926,0.00065852253,0.00089882244,0.000027467726,0.00008134013,0.0005640011],"genre_scores_gemma":[0.98562586,0.012936825,0.000062967905,0.00020439233,0.00014528818,0.00003588916,0.000093978655,0.000063872314,0.00083089503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969565,0.00039956687,0.001051437,0.00023784836,0.0009949625,0.00035963376],"domain_scores_gemma":[0.997201,0.0004973128,0.0010627966,0.00039006578,0.0006137323,0.00023503817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037512425,0.00044618678,0.00094207464,0.0003339354,0.0004129315,0.000033538323,0.0002929523,0.00014596243,0.00011293314],"category_scores_gemma":[0.00008273389,0.0003032783,0.0004524571,0.00055412896,0.00030893314,0.00035123652,0.000023598212,0.00038635093,0.000022935134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026112821,0.030597845,0.8282203,0.0001156085,0.003932348,0.00014925793,0.008666213,0.00012747307,0.015954686,0.0004898023,0.034034602,0.051599044],"study_design_scores_gemma":[0.19601987,0.03689655,0.5944521,0.001229228,0.0019039795,0.0009407958,0.0022624996,0.0005473251,0.12323311,0.0020372963,0.03864522,0.0018320327],"about_ca_topic_score_codex":0.00008951235,"about_ca_topic_score_gemma":0.000008579251,"teacher_disagreement_score":0.23376821,"about_ca_system_score_codex":0.0003666349,"about_ca_system_score_gemma":0.00039318003,"threshold_uncertainty_score":0.99994195},"labels":[],"label_agreement":null},{"id":"W2147841770","doi":"10.1086/499369","title":"Efavirenz and CYP2B6 Polymorphism: Implications for Drug Toxicity and Resistance","year":2006,"lang":"en","type":"letter","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"GlaxoSmithKline","keywords":"Medicine; Efavirenz; CYP2B6; Toxicity; Drug resistance; Pharmacology; Drug; Internal medicine; Genetics; Virology; CYP3A4; Biology; Human immunodeficiency virus (HIV); Cytochrome P450","score_opus":0.028592325931792305,"score_gpt":0.33706710225156405,"score_spread":0.30847477631977177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147841770","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10161968,0.0074062394,0.00016385182,0.88322574,0.00042879555,0.0023123408,0.001473359,0.00038122557,0.0029887361],"genre_scores_gemma":[0.15144049,0.0032438315,0.0011867561,0.625642,0.0094158435,0.0022340966,0.0075889416,0.00032148315,0.19892652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979286,0.00009200389,0.0006867275,0.0007783745,0.0001517465,0.00036254208],"domain_scores_gemma":[0.99749464,0.0014114021,0.00024366599,0.0004431397,0.00013070273,0.0002764331],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014408422,0.00038859848,0.0008549659,0.00012971375,0.00026262805,0.00006864024,0.00007229625,0.00043628854,0.00002743383],"category_scores_gemma":[0.0003345056,0.0003307668,0.0003083323,0.00012083162,0.00040129694,0.00005972887,0.00007029762,0.00051831146,0.0000184064],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028596167,0.00038812426,0.28156278,0.00026327188,0.00021769268,0.000037333335,0.000008173906,1.7717792e-8,0.0000011035105,0.00010322513,0.7160745,0.0013151588],"study_design_scores_gemma":[0.0028256238,0.00011548638,0.38955027,0.00022349854,0.0014662916,0.000012871906,0.0000025894399,0.000001964307,0.0000046895916,0.006191725,0.5992483,0.00035667355],"about_ca_topic_score_codex":0.000014317913,"about_ca_topic_score_gemma":0.0000826271,"teacher_disagreement_score":0.25758374,"about_ca_system_score_codex":0.000093804694,"about_ca_system_score_gemma":0.00022615364,"threshold_uncertainty_score":0.99991447},"labels":[],"label_agreement":null},{"id":"W2148313388","doi":"10.1074/jbc.m112.398180","title":"Biochemical Mechanism of HIV-1 Resistance to Rilpivirine","year":2012,"lang":"fr","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Rilpivirine; Reverse transcriptase; Protein subunit; Chemistry; Dodecameric protein; Etravirine; Mutant; Biophysics; Stereochemistry; Molecular biology; Human immunodeficiency virus (HIV); Biology; Biochemistry; DNA; Virology; Antiretroviral therapy; RNA","score_opus":0.023045718893627387,"score_gpt":0.26892739360864865,"score_spread":0.24588167471502126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148313388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439564,0.033048227,0.0006157709,0.011977548,0.0007891521,0.00015730182,0.000059179205,0.000012914705,0.009383505],"genre_scores_gemma":[0.9457689,0.0010957308,0.011103229,0.0001650262,0.002039724,0.0000037417888,0.00001818172,0.000015547383,0.039789956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997874,0.00005345126,0.000924811,0.00018828285,0.00037261477,0.00058682455],"domain_scores_gemma":[0.99811274,0.0001908558,0.00046944845,0.00021186231,0.0002321859,0.0007829352],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000695899,0.00028012984,0.00076877774,0.00004905011,0.000034464832,0.0000072944495,0.00023045455,0.00040037147,0.0018461127],"category_scores_gemma":[0.00066268403,0.00019365967,0.00031173974,0.00023959774,0.00017538074,0.00006708496,0.00011565357,0.00043631444,0.00014200459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008920227,0.0018445711,0.017272485,0.0004893218,0.00048184377,0.00023186769,0.00031138954,6.415144e-7,0.9258258,0.0008662583,0.05054482,0.0012389828],"study_design_scores_gemma":[0.0012783811,0.00015740842,0.0020295922,0.0009418882,0.00020655293,0.00033647695,0.00022549283,0.0000014595157,0.8934994,0.00027543854,0.10084888,0.00019905502],"about_ca_topic_score_codex":4.955459e-7,"about_ca_topic_score_gemma":8.252871e-8,"teacher_disagreement_score":0.050304063,"about_ca_system_score_codex":0.00027093934,"about_ca_system_score_gemma":0.0001382948,"threshold_uncertainty_score":0.99906635},"labels":[],"label_agreement":null},{"id":"W2148754173","doi":"10.1128/jvi.76.15.7874-7882.2002","title":"Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins","year":2002,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Biology; Cyclin-dependent kinase; Herpes simplex virus; Viral replication; Virology; Lymphocytic choriomeningitis; Vaccinia; Virus; CDK inhibitor; Kinase; Cell biology; Cell cycle; Cell; Biochemistry; In vitro; Recombinant DNA","score_opus":0.022776866792826794,"score_gpt":0.287551291112141,"score_spread":0.2647744243193142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148754173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383205,0.004322368,0.000022184715,0.0012386865,0.00007640118,0.00037029933,0.0000167975,0.000010469821,0.000110723275],"genre_scores_gemma":[0.9975739,0.001243339,0.0006390532,0.00012173482,0.00006602823,0.000004738977,0.000014035428,0.00001792668,0.0003192372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799514,0.00015048774,0.001006555,0.00028231984,0.00032194285,0.00024356165],"domain_scores_gemma":[0.9985572,0.00007476918,0.00082814356,0.0001703243,0.00024026044,0.00012930667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006489605,0.00020398558,0.00059651374,0.00019780062,0.00010967867,0.000010092794,0.00009590978,0.00014335233,0.00018584827],"category_scores_gemma":[0.0001639112,0.00015580254,0.00007685663,0.00018210789,0.00025590148,0.000095960306,0.00007017483,0.0002757023,0.0000031588468],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067197834,0.0011945735,0.002117251,0.000058573958,0.00018060612,0.000107027256,0.0006212036,0.0000046285836,0.98984325,0.000051943436,0.0012409721,0.0039079795],"study_design_scores_gemma":[0.0039779823,0.0026480225,0.005278807,0.00008477185,0.0004065716,0.000079929596,0.00020808651,0.00008213425,0.98227507,0.00010948286,0.0046683494,0.0001808041],"about_ca_topic_score_codex":0.00005665577,"about_ca_topic_score_gemma":0.000011017374,"teacher_disagreement_score":0.007568205,"about_ca_system_score_codex":0.00006736499,"about_ca_system_score_gemma":0.0000563767,"threshold_uncertainty_score":0.6353443},"labels":[],"label_agreement":null},{"id":"W2149148148","doi":"10.1016/j.bmcl.2013.12.070","title":"Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses","year":2013,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Reverse transcriptase; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Nucleoside; Mutant; Chemistry; Virology; Nucleotidyltransferase; Bioavailability; Pharmacokinetics; Human immunodeficiency virus (HIV); Lentivirus; Pharmacology; RNA; Biology; Viral disease; Biochemistry","score_opus":0.01159597471099505,"score_gpt":0.2173978595742735,"score_spread":0.20580188486327844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149148148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810124,0.00037713177,0.00008691679,0.00991987,0.00013111404,0.0006888272,0.000121290956,0.00006311851,0.0005104751],"genre_scores_gemma":[0.9937636,0.00017390693,0.0012269393,0.0025120922,0.00022538297,0.000042851694,0.00017920401,0.00007345348,0.0018025156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99693906,0.000046546345,0.0010150967,0.0006076766,0.0008431469,0.00054845377],"domain_scores_gemma":[0.99826735,0.000070211434,0.00037972504,0.000711233,0.00017735997,0.00039409226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028574758,0.0004931412,0.00091403315,0.00016199498,0.00007998716,0.000025601312,0.0002787091,0.000174815,0.00054740347],"category_scores_gemma":[0.00013907261,0.00038898844,0.00023880204,0.00048216386,0.0004456635,0.00031533325,0.00005682432,0.00028947304,0.00006396637],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007069279,0.0006120241,0.010417692,0.0008443965,0.00032354452,0.00048771754,0.00082170306,4.878082e-7,0.9622982,0.00000149594,0.023271764,0.00021403372],"study_design_scores_gemma":[0.004980095,0.00018502912,0.005104708,0.0013077841,0.00051874877,0.00006137662,0.0015758811,0.00002038768,0.98361486,0.0000039719175,0.0022435489,0.0003835803],"about_ca_topic_score_codex":0.00027296733,"about_ca_topic_score_gemma":0.000009338663,"teacher_disagreement_score":0.021316674,"about_ca_system_score_codex":0.00027656677,"about_ca_system_score_gemma":0.00037205467,"threshold_uncertainty_score":0.9998562},"labels":[],"label_agreement":null},{"id":"W2149573022","doi":"10.1086/590943","title":"Emergence of Drug Resistance in HIV Type 1–Infected Patients after Receipt of First‐Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials","year":2008,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Centers for Disease Control and Prevention; Wellcome Trust","keywords":"Medicine; Lamivudine; Resistance mutation; Abacavir; Internal medicine; Reverse-transcriptase inhibitor; Drug resistance; Confidence interval; Stavudine; Zidovudine; HIV drug resistance; Reverse transcriptase; Viral load; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Biology; Virus; Viral disease; Polymerase chain reaction","score_opus":0.10017312878987983,"score_gpt":0.4421207301729995,"score_spread":0.3419476013831197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149573022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008161226,0.983817,0.0000025700817,0.000049018374,0.00066110695,0.0066007907,0.00045833783,0.000046843674,0.00020309797],"genre_scores_gemma":[0.009515937,0.98838186,0.000046661124,0.00007409769,0.00014514098,0.00048610292,0.0005777034,0.00007316306,0.00069930305],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9818074,0.0048016566,0.011559935,0.0007956456,0.00070564693,0.00032969433],"domain_scores_gemma":[0.98269,0.007938911,0.0069326637,0.0010654224,0.0010473134,0.00032568615],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002882521,0.0007120397,0.015012374,0.00038298464,0.000035752328,0.000004766738,0.0002764104,0.0004731375,0.00028591574],"category_scores_gemma":[0.035614513,0.0004645453,0.0035799814,0.0013821101,0.0004394167,0.000088561595,0.00011034189,0.00058031315,0.00003942046],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009552227,0.0072448635,0.24227105,0.71225685,0.002591728,0.00005114227,0.0000494419,3.29234e-8,1.2504619e-8,0.0000058070154,0.004768035,0.029805813],"study_design_scores_gemma":[0.005591014,0.0013726688,0.019561809,0.9405876,0.01027361,0.0000023309249,0.0000064618584,0.0000011170166,0.0000016513184,0.000026416477,0.022079743,0.0004955836],"about_ca_topic_score_codex":0.000010112573,"about_ca_topic_score_gemma":0.00003221699,"teacher_disagreement_score":0.22833075,"about_ca_system_score_codex":0.00009256729,"about_ca_system_score_gemma":0.0012776682,"threshold_uncertainty_score":0.99978065},"labels":[],"label_agreement":null},{"id":"W2149588086","doi":"10.1128/aac.01738-10","title":"Mechanism of Resistance to GS-9148 Conferred by the Q151L Mutation in HIV-1 Reverse Transcriptase","year":2011,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Gilead Sciences","keywords":"Mutation; Mutant; Nucleoside; Biology; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Stereochemistry; Chemistry; Biochemistry; Molecular biology; RNA; Gene","score_opus":0.019928366865705146,"score_gpt":0.2403241730958878,"score_spread":0.22039580623018265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149588086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622155,0.00003748124,0.0004386466,0.011216073,0.00006186315,0.0005967974,0.00004765159,0.000015338326,0.0013645772],"genre_scores_gemma":[0.98207235,0.00029843842,0.0015372781,0.005244898,0.000012649921,0.0000124315675,0.000052133033,0.000017277493,0.010752563],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931383,0.00002259809,0.0002218212,0.00019063163,0.000096512485,0.0001546032],"domain_scores_gemma":[0.99971265,0.0000076271053,0.000053700853,0.00013409051,0.000032439606,0.000059502818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009835584,0.000130269,0.00021307511,0.00005776401,0.000043472985,0.000007469371,0.000060629925,0.000050705778,0.00023035072],"category_scores_gemma":[0.0000036756437,0.000091997244,0.0000466399,0.00012505386,0.00004318837,0.000041260093,0.0000072047847,0.000056349614,0.000013469892],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038273865,0.0020639822,0.028072264,0.00026121072,0.0005265734,0.0002083573,0.06308899,3.9953866e-7,0.19532615,0.0017744426,0.69554996,0.009300287],"study_design_scores_gemma":[0.015897822,0.00028205832,0.03963269,0.000581424,0.0001786864,0.00004286115,0.0015838359,0.000029978124,0.77802724,0.0004275753,0.16281988,0.0004959503],"about_ca_topic_score_codex":0.00007912679,"about_ca_topic_score_gemma":0.00004584478,"teacher_disagreement_score":0.5827011,"about_ca_system_score_codex":0.000023481345,"about_ca_system_score_gemma":0.000028585371,"threshold_uncertainty_score":0.37515387},"labels":[],"label_agreement":null},{"id":"W2149701672","doi":"10.1093/cid/cit529","title":"Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation","year":2013,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; Université de Montréal","funders":"Canadian Institutes of Health Research; Merck Canada; ViiV Healthcare; Gilead Sciences; GlaxoSmithKline","keywords":"Viremia; Medicine; Viral load; Hazard ratio; Cumulative incidence; Proportional hazards model; Internal medicine; Cohort; Incidence (geometry); Confidence interval; Cohort study; Confounding; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.028921538349166942,"score_gpt":0.28723597228411574,"score_spread":0.2583144339349488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149701672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99803394,0.00006404351,0.000012652506,0.0003226015,0.00014325217,0.00084791455,0.0002474338,0.000035282625,0.00029286108],"genre_scores_gemma":[0.99828446,0.00004738322,0.00019218036,0.0001843971,0.000045066456,0.000062951694,0.0009280757,0.000014349591,0.00024112471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811447,0.00013526136,0.00094370265,0.00035553676,0.00027439123,0.00017664571],"domain_scores_gemma":[0.9983479,0.0007877474,0.0002951304,0.00025200078,0.00015960074,0.00015765303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016734155,0.00015613329,0.0005905823,0.00010109623,0.000026889496,0.000008671222,0.00006557894,0.00014869393,0.000070544884],"category_scores_gemma":[0.0015511033,0.0001351282,0.00043009172,0.00017727024,0.00011004569,0.00012592095,0.000054741307,0.0001435911,0.000058831018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021838448,0.0024328965,0.9922147,0.000022698585,0.00049603736,0.000016410117,0.00022175019,0.000015686157,0.000055718447,0.000004222479,0.0010962557,0.003205243],"study_design_scores_gemma":[0.0063449764,0.00044417314,0.9918326,0.00033116573,0.00046976758,1.8166337e-7,0.00010869469,0.00012316667,0.000064787826,0.00011537264,0.00004760249,0.00011748972],"about_ca_topic_score_codex":0.00032254227,"about_ca_topic_score_gemma":0.00008055635,"teacher_disagreement_score":0.006126592,"about_ca_system_score_codex":0.00012470596,"about_ca_system_score_gemma":0.00011454336,"threshold_uncertainty_score":0.5510368},"labels":[],"label_agreement":null},{"id":"W2150012432","doi":"10.1093/infdis/jir506","title":"Optimizing Initial Therapy for HIV Infection","year":2011,"lang":"en","type":"letter","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Atazanavir; Efavirenz; Abacavir; Emtricitabine; Hazard ratio; Lamivudine; Viral load; Lopinavir; Raltegravir; Medicine; Confidence interval; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","score_opus":0.02517830726059587,"score_gpt":0.2846655624079437,"score_spread":0.25948725514734783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150012432","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18519267,0.015243389,0.008618479,0.7658193,0.007221976,0.006115568,0.00029563988,0.00048554645,0.011007403],"genre_scores_gemma":[0.28553954,0.022099776,0.0015526053,0.6143736,0.051619455,0.00040388596,0.0009081294,0.00065150997,0.022851482],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985372,0.0001458916,0.0005341309,0.00013652079,0.0003565971,0.00028964868],"domain_scores_gemma":[0.99820036,0.0003480337,0.00067885796,0.00023464167,0.0004267768,0.00011132752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025258047,0.00033648312,0.0006053926,0.00035633484,0.00020648277,0.00003812505,0.00012084971,0.00025160334,0.0002517875],"category_scores_gemma":[0.000119099925,0.00019226283,0.0005672126,0.00013100386,0.0000894944,0.00012616173,0.000023275079,0.0007916346,0.00003298585],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009762337,0.0004142083,0.010591363,0.00015301847,0.0018007625,0.00024792214,0.00067792746,0.000011766082,0.00001363764,0.000004610812,0.981464,0.0036445225],"study_design_scores_gemma":[0.009544942,0.001989846,0.0043134275,0.000746553,0.004420056,0.001989305,0.000047003155,0.000012694183,0.0006679744,0.0009980537,0.9748198,0.00045038335],"about_ca_topic_score_codex":0.00001485474,"about_ca_topic_score_gemma":0.00000277576,"teacher_disagreement_score":0.15144572,"about_ca_system_score_codex":0.00020801653,"about_ca_system_score_gemma":0.0004552933,"threshold_uncertainty_score":0.7840251},"labels":[],"label_agreement":null},{"id":"W2150030072","doi":"10.1086/597810","title":"Reconsidering First‐Line Antiretroviral Therapy in Resource‐Limited Settings: The Need for Operational Research","year":2009,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Antiretroviral therapy; Resource (disambiguation); Medicine; Intensive care medicine; Human immunodeficiency virus (HIV); Virology; Computer science; Viral load","score_opus":0.053561539848840566,"score_gpt":0.3255683429664626,"score_spread":0.27200680311762204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150030072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526377,0.0013174482,0.00005041773,0.04503308,0.00005120088,0.00057821494,0.0000046829623,0.000018092695,0.00030919534],"genre_scores_gemma":[0.9965604,0.0006966108,0.00007593784,0.0017611784,0.0003627197,0.000014426816,0.0000093563085,0.000013556383,0.0005058235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864626,0.0002108657,0.00040865096,0.00009402769,0.0003879564,0.00025226036],"domain_scores_gemma":[0.9983321,0.0009479358,0.00014190562,0.00016544624,0.00032050593,0.00009212599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013155066,0.00012442966,0.00024027824,0.0002753381,0.00039325657,0.000052633844,0.00012258811,0.00003816263,0.000046474892],"category_scores_gemma":[0.00065151067,0.000061637686,0.00013281839,0.00037195708,0.000086117056,0.00010317326,0.000015485099,0.00030147273,0.0000044330245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010197406,0.0037203126,0.77876514,0.00009907906,0.0010988577,0.00025272038,0.011603753,0.0025737116,0.0029640554,0.0003272323,0.11101926,0.0773785],"study_design_scores_gemma":[0.046106804,0.018754559,0.78870666,0.0021696056,0.0008641195,0.0024802873,0.007981199,0.002725389,0.0097217765,0.011256976,0.10842329,0.0008093557],"about_ca_topic_score_codex":0.0000058524547,"about_ca_topic_score_gemma":0.000017333521,"teacher_disagreement_score":0.07656914,"about_ca_system_score_codex":0.00015069662,"about_ca_system_score_gemma":0.00024167383,"threshold_uncertainty_score":0.30246514},"labels":[],"label_agreement":null},{"id":"W2150097268","doi":"10.1124/jpet.108.145854","title":"The Role of the Equilibrative Nucleoside Transporter 1 (ENT1) in Transport and Metabolism of Ribavirin by Human and Wild-Type or Ent1(-/-) Mouse Erythrocytes","year":2009,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Valeant Pharmaceuticals International; National Institute on Alcohol Abuse and Alcoholism; Eli Lilly and Company","keywords":"Ribavirin; Nucleoside; In vivo; Nucleoside analogue; Metabolism; Pharmacology; Red blood cell; Biochemistry; Ex vivo; Chemistry; Biology; In vitro; Hepatitis C virus; Virology; Virus","score_opus":0.013497341994624096,"score_gpt":0.31212759911079263,"score_spread":0.29863025711616853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150097268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780885,0.019916313,0.0000017857766,0.001612992,0.00006280386,0.00022119765,0.0000060433495,0.0000025669465,0.00008780649],"genre_scores_gemma":[0.99533474,0.0038032138,0.00014602666,0.0005140269,0.000026958827,0.0000024337114,0.000001924848,0.000008567988,0.00016208673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991101,0.000069775015,0.0004371173,0.00009893221,0.00014371143,0.00014038503],"domain_scores_gemma":[0.9995984,0.000053589923,0.00021091235,0.00005387864,0.000026227119,0.000056979177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013239404,0.00014372887,0.00035820462,0.000054834054,0.00008899475,0.00000513384,0.00007490814,0.00006429461,0.000032160384],"category_scores_gemma":[0.0000010715756,0.0000744599,0.00005876836,0.00008307711,0.00030147485,0.0000970933,0.000011643356,0.00018128943,6.062893e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019174911,0.0005895551,0.018215865,0.0000088315755,0.00042478135,0.000014022027,0.0071234237,7.064066e-7,0.9701225,0.00009354969,0.000059140508,0.0014301088],"study_design_scores_gemma":[0.00476313,0.00065434416,0.01848704,0.000031432817,0.00036662616,0.0000808769,0.0021199763,0.000018125447,0.9704123,0.00011976234,0.0028726968,0.00007364621],"about_ca_topic_score_codex":0.0000033248089,"about_ca_topic_score_gemma":0.0000033196802,"teacher_disagreement_score":0.01724627,"about_ca_system_score_codex":0.000015789017,"about_ca_system_score_gemma":0.000054919845,"threshold_uncertainty_score":0.30363867},"labels":[],"label_agreement":null},{"id":"W2150487989","doi":"10.1128/aac.49.7.2648-2656.2005","title":"The L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Counteracts Enhanced Excision of Zidovudine Monophosphate Associated with Thymidine Analog Resistance Mutations","year":2005,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Center for AIDS Research, University of Washington; U.S. Public Health Service; McGill University","keywords":"Zidovudine; Primer (cosmetics); Didanosine; Biology; Reverse transcriptase; Nucleotidyltransferase; Virology; Lamivudine; Mutation; Molecular biology; Virus; Genetics; Chemistry; RNA; Viral disease; Gene","score_opus":0.010490358677214286,"score_gpt":0.26239000505859605,"score_spread":0.2518996463813818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150487989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952269,0.00022111113,0.000059735306,0.0037266293,0.000037733393,0.00038528777,0.000019094134,0.000017567249,0.00030590937],"genre_scores_gemma":[0.99280924,0.0018263512,0.00030803704,0.0007787546,0.000014092358,0.000008185719,0.00018276364,0.000018647177,0.004053904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990626,0.000030026024,0.00033910177,0.0002122104,0.00016078708,0.00019530587],"domain_scores_gemma":[0.9995021,0.000036969646,0.00015997878,0.00014171717,0.00011495483,0.00004427202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016546027,0.00015906157,0.0002444028,0.00007889377,0.00019824672,0.000022914484,0.000060693328,0.000052294552,0.000072316434],"category_scores_gemma":[0.000018266763,0.000106340485,0.000040748633,0.00033109105,0.00009226653,0.00010527298,0.0000059590116,0.00008684127,0.0000037332593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005326615,0.003865977,0.028137371,0.00014043461,0.00092663,0.00017309464,0.016994353,0.00025061276,0.9106483,0.00016798772,0.01841523,0.014953432],"study_design_scores_gemma":[0.026572684,0.00080805446,0.30790105,0.0014357002,0.0003266713,0.000026146448,0.0006776673,0.0005231429,0.6285204,0.00014179517,0.032373805,0.0006928548],"about_ca_topic_score_codex":0.00005653619,"about_ca_topic_score_gemma":0.00039921238,"teacher_disagreement_score":0.28212786,"about_ca_system_score_codex":0.00009325078,"about_ca_system_score_gemma":0.000060628976,"threshold_uncertainty_score":0.4336439},"labels":[],"label_agreement":null},{"id":"W2150491582","doi":"10.1080/15257770008033850","title":"Syntheses of 1-[(2-Hydroxyethoxy)methyl]- and 1-[(1,3-Dihydroxy-2-Propoxy)methyl]- Derivatives of 5-Substituted-2,4-difluorobenzene: Unnatural Acyclo Thymidine Mimics for Evaluation as Anticancer and Antiviral Agents","year":2000,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Herpes simplex virus; Stereochemistry; Cytotoxicity; Chemistry; Broad spectrum; Thymidine; Human immunodeficiency virus (HIV); Virus; Combinatorial chemistry; In vitro; Virology; Biology; Biochemistry","score_opus":0.020818151716627136,"score_gpt":0.3045720713108172,"score_spread":0.28375391959419005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150491582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99061465,0.0022949753,0.000055559925,0.0013384237,0.00015446253,0.0021714738,0.000103710816,0.000121503486,0.0031452081],"genre_scores_gemma":[0.9738919,0.0023966539,0.022378273,0.0002299961,0.00011305489,0.000092119124,0.0000895436,0.00014046971,0.00066797313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959619,0.00022404599,0.001182918,0.0009715224,0.00094549183,0.00071413146],"domain_scores_gemma":[0.9974316,0.0006264512,0.0004915199,0.0006347465,0.00050556025,0.000310121],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009775205,0.00073181884,0.0014296634,0.00042462267,0.0003025083,0.000073644995,0.00027717918,0.0003346701,0.00087292073],"category_scores_gemma":[0.0008570357,0.0006333551,0.00030910954,0.0005670171,0.0010427525,0.0006396233,0.00015082235,0.00030950707,0.000027563847],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004215928,0.0017764131,0.093988545,0.0020675114,0.002861927,0.00006588452,0.007955464,0.00011682858,0.46234173,0.003942581,0.0012257454,0.41944146],"study_design_scores_gemma":[0.017814098,0.0024316453,0.21805868,0.0038440542,0.004826251,0.00022746096,0.003244625,0.027061457,0.701899,0.005646166,0.012699141,0.002247413],"about_ca_topic_score_codex":0.00013543686,"about_ca_topic_score_gemma":0.000024474537,"teacher_disagreement_score":0.41719404,"about_ca_system_score_codex":0.00015132662,"about_ca_system_score_gemma":0.00023294674,"threshold_uncertainty_score":0.9996118},"labels":[],"label_agreement":null},{"id":"W2151267346","doi":"10.4212/cjhp.v61i1.7","title":"Atazanavir and Acid-Lowering Therapy","year":2008,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Atazanavir; Medicine; Regimen; Pharmacology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Virology","score_opus":0.028981119098552544,"score_gpt":0.2735911373647052,"score_spread":0.24461001826615264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151267346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762102,0.005954914,0.0000033649512,0.016037617,0.00027844257,0.00014550322,0.0000031646657,0.000005441104,0.00136139],"genre_scores_gemma":[0.9962547,0.0012097795,0.00012247499,0.0004992558,0.00024699536,0.0000018780498,0.000001805359,0.000014808009,0.0016483217],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993415,0.000015317346,0.0001938866,0.000072911986,0.0001598359,0.00021658838],"domain_scores_gemma":[0.99920356,0.000017813414,0.000082929204,0.00009326687,0.00008957208,0.00051283836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001408768,0.00011283023,0.00017730574,0.00011010535,0.0002790972,0.000023165121,0.00010324246,0.000016597194,0.00014880471],"category_scores_gemma":[0.00001938138,0.000068408626,0.00007534522,0.00010150286,0.00014200197,0.00012473465,0.000007766674,0.0002055124,0.000020790996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031773892,0.00019965605,0.83187354,0.000022498496,0.0012710346,0.010847735,0.02089392,0.0000033607448,0.0023078755,0.00012030362,0.08799889,0.044143442],"study_design_scores_gemma":[0.014660052,0.0013078323,0.23751765,0.00025383083,0.0003524187,0.007887207,0.00076561054,0.000035537396,0.059742365,0.00028907863,0.6765507,0.00063770736],"about_ca_topic_score_codex":0.0008999129,"about_ca_topic_score_gemma":0.00064623496,"teacher_disagreement_score":0.5943559,"about_ca_system_score_codex":0.00010897498,"about_ca_system_score_gemma":0.0008114154,"threshold_uncertainty_score":0.27896228},"labels":[],"label_agreement":null},{"id":"W2151298956","doi":"10.1177/135965350300800601","title":"Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Medicine; Viral load; Internal medicine; Odds ratio; Population; Logistic regression; Immunology; Lentivirus; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.02188071117907574,"score_gpt":0.26681899492091177,"score_spread":0.24493828374183602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151298956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978572,0.00021974072,0.000007209629,0.00013225393,0.000045271478,0.0013225739,0.0000051010193,0.00008432039,0.00032629672],"genre_scores_gemma":[0.9936268,0.00048803032,0.0004886558,0.00005891451,0.000022349926,0.00026567728,0.00008051683,0.000023004031,0.0049461056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983408,0.00025892808,0.000305987,0.00045790637,0.00021710781,0.00041928238],"domain_scores_gemma":[0.99945456,0.000119963,0.0000926744,0.00016992046,0.000022219272,0.00014068987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002759945,0.0003027197,0.00046246802,0.00018825439,0.000127844,0.00007472835,0.00003476698,0.00010789418,0.00003552037],"category_scores_gemma":[0.000041360112,0.00020336077,0.00005919921,0.00023469131,0.000104577724,0.00024087328,0.000013430336,0.00013726634,0.000002965495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009450599,0.0006973975,0.976878,0.000012359385,0.00007417147,0.000107800355,0.0024101594,0.000002314853,0.00065512274,0.00002141307,0.000052688276,0.018143523],"study_design_scores_gemma":[0.011947133,0.0016922508,0.98206186,0.00008562623,0.000028018234,0.00000882192,0.00037836467,0.0005262631,0.00243989,0.00013270025,0.00047422163,0.00022482895],"about_ca_topic_score_codex":0.00062640646,"about_ca_topic_score_gemma":0.000114137816,"teacher_disagreement_score":0.017918695,"about_ca_system_score_codex":0.00018242362,"about_ca_system_score_gemma":0.00005976792,"threshold_uncertainty_score":0.8292812},"labels":[],"label_agreement":null},{"id":"W2151427720","doi":"10.1093/jac/dks287","title":"Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-09","year":2012,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Toronto Public Health; Public Health Agency of Canada; St. Michael's Hospital; Canadian AIDS Treatment Information Exchange; Ontario HIV Treatment Network; Public Health Ontario; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Medicine; HIV drug resistance; Drug resistance; Resistance mutation; Internal medicine; Genotype; Population; Cohort; Virology; Record linkage; Human immunodeficiency virus (HIV); Reverse transcriptase; Viral load; Antiretroviral therapy; Biology; Polymerase chain reaction; Genetics; Environmental health","score_opus":0.009791156206794814,"score_gpt":0.21132889637497493,"score_spread":0.2015377401681801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151427720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938686,0.000671998,0.000033561704,0.0072323172,0.0001246852,0.00025034582,0.0000043501514,0.000010355873,0.0022855017],"genre_scores_gemma":[0.9511966,0.0000918169,0.0116187,0.00072703685,0.00012390887,0.0000024327449,0.0000063674056,0.000041798994,0.036191344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981225,0.00007771934,0.0007368587,0.00019058032,0.0003276828,0.00054461905],"domain_scores_gemma":[0.99899787,0.00016909126,0.00033929,0.00015612089,0.000104253544,0.00023336711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005155779,0.00026186657,0.00057865534,0.00030031544,0.00008090105,0.000022655133,0.00013513274,0.00008452718,0.00018972372],"category_scores_gemma":[0.0000673848,0.00023558068,0.0001062721,0.00044851904,0.00005422644,0.00024967815,0.000008911762,0.00055546034,0.0000033064293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014656124,0.000540177,0.91116333,0.00011188474,0.00015063368,0.00061785174,0.0066836025,0.000013487771,0.009831658,0.000006732437,0.069258854,0.00015616446],"study_design_scores_gemma":[0.01271042,0.000025934063,0.9349867,0.0029633057,0.00010291389,0.0001563395,0.0005726997,0.000009763865,0.016805425,0.000016285774,0.031178746,0.00047147242],"about_ca_topic_score_codex":0.15021522,"about_ca_topic_score_gemma":0.9789669,"teacher_disagreement_score":0.8287516,"about_ca_system_score_codex":0.001810011,"about_ca_system_score_gemma":0.002448273,"threshold_uncertainty_score":0.9606701},"labels":[],"label_agreement":null},{"id":"W2151647473","doi":"10.1086/499364","title":"Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study","year":2006,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; University of California, San Diego; National Institute of Neurological Disorders and Stroke; University of Pittsburgh; University of Washington; Case Western Reserve University; University of Minnesota; Pfizer; Northwestern University; Biogen; University of Rochester; University of Miami; York University; Bristol-Myers Squibb; Quest Diagnostics; University of Pennsylvania; Gilead Sciences; Vanderbilt University; National Institutes of Health; Ohio State University; ACT Government; University of Southern California; Emory University; Brigham and Women's Hospital; GlaxoSmithKline","keywords":"Efavirenz; Discontinuation; Medicine; CYP2B6; Internal medicine; Interquartile range; Genotype; Gastroenterology; Pharmacogenetics; Pharmacokinetics; Population; Pharmacology; Viral load; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Biology; Genetics; Cytochrome P450; CYP3A4","score_opus":0.08505330597271046,"score_gpt":0.45010521602996983,"score_spread":0.36505191005725934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151647473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555135,0.0005270439,0.000051655996,0.00017497037,0.0007811693,0.0021972496,0.00014762724,0.00017254605,0.00039641027],"genre_scores_gemma":[0.99497694,0.0004082318,0.00018719259,0.00015522275,0.0016267459,0.00051706564,0.0003478867,0.000050424846,0.0017302752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934435,0.001876286,0.0031403054,0.00075472513,0.00044905074,0.00033611406],"domain_scores_gemma":[0.9960441,0.0018839288,0.00063846196,0.00060637057,0.00028504702,0.00054207444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014898167,0.00043688898,0.0018285944,0.00014304733,0.000101420395,0.000045940276,0.00009773749,0.00020856223,0.0003743397],"category_scores_gemma":[0.0011366497,0.00030542343,0.0010494393,0.00024850396,0.00027875477,0.00013079839,0.000056631015,0.00019443217,0.00008202794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014029226,0.046072096,0.87258565,0.000019965255,0.0012113799,0.00017548802,0.00009715332,0.0000059866916,0.000008902236,0.000035798144,0.0006445397,0.077740125],"study_design_scores_gemma":[0.025334772,0.013694584,0.95378417,0.00007676599,0.004742079,0.000005248188,0.00019013906,0.00007988512,0.00010185819,0.000105577295,0.0015857915,0.00029913196],"about_ca_topic_score_codex":0.00004943356,"about_ca_topic_score_gemma":0.00027790232,"teacher_disagreement_score":0.08119852,"about_ca_system_score_codex":0.000099534365,"about_ca_system_score_gemma":0.00024931395,"threshold_uncertainty_score":0.9999398},"labels":[],"label_agreement":null},{"id":"W2151762449","doi":"10.2174/1570162x11311030008","title":"Evaluation of Treatment Tolerability, Satisfaction and Laboratory Parameters in HIV+ Patients Switching from Ritonavir Capsule to Tablet Formulation§","year":2013,"lang":"en","type":"article","venue":"Current HIV Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Ritonavir; Medicine; Tolerability; Atazanavir; Interquartile range; Darunavir; Internal medicine; Saquinavir; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Adverse effect; Antiretroviral therapy; Immunology","score_opus":0.11610089302589621,"score_gpt":0.4061699258264637,"score_spread":0.2900690328005675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151762449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616164,0.00035230533,0.000029120873,0.0007387428,0.0000923544,0.002431876,0.00006357102,0.000013497023,0.00011691818],"genre_scores_gemma":[0.99802613,0.00006755186,0.0009509695,0.000006477071,0.000029549365,0.00053301366,0.00029490324,0.0000133791145,0.000078028424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974834,0.00035080122,0.00037710185,0.00036859204,0.001119219,0.00030093658],"domain_scores_gemma":[0.99846,0.00016453944,0.000057996614,0.00026135938,0.0008692866,0.00018682428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010967364,0.00014844176,0.00027390404,0.00038597186,0.00008967183,0.000036786492,0.000043143777,0.000057059104,0.00016838916],"category_scores_gemma":[0.0003354103,0.00012125491,0.000032023243,0.00041527013,0.000031444142,0.00022744642,0.0000598037,0.00017021058,0.00014951902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046247416,0.00050615735,0.8156307,0.00003689449,0.000049958933,5.065238e-7,0.0021551766,0.00006445904,0.0016844376,0.000009998438,0.00091202545,0.17890349],"study_design_scores_gemma":[0.0040941634,0.00023219071,0.98379964,0.0002327592,0.00006849943,1.7601768e-7,0.00030182695,0.0053607053,0.0046764407,0.00050230813,0.0006183007,0.00011299182],"about_ca_topic_score_codex":0.0011930605,"about_ca_topic_score_gemma":0.00024020759,"teacher_disagreement_score":0.1787905,"about_ca_system_score_codex":0.0014139079,"about_ca_system_score_gemma":0.00036889146,"threshold_uncertainty_score":0.49446318},"labels":[],"label_agreement":null},{"id":"W2151768713","doi":"10.1128/aac.02403-13","title":"<i>In Vitro</i>Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Reverse transcriptase; Efavirenz; Rilpivirine; Virology; Reverse-transcriptase inhibitor; Etravirine; Mutant; In vitro; Potency; IC50; Chemistry; Virus; Biology; Polymerase chain reaction; Viral load; Antiretroviral therapy; Biochemistry; Gene","score_opus":0.008411565222724697,"score_gpt":0.22009188451063894,"score_spread":0.21168031928791423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151768713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838257,0.00000650868,0.000119357566,0.015097336,0.00009280064,0.0005649035,0.000056801204,0.000018000857,0.00021859778],"genre_scores_gemma":[0.9765911,0.00041627645,0.0022621814,0.010309116,0.000086175154,0.000018801722,0.000231276,0.00003468226,0.01005036],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912804,0.000011468754,0.0003116578,0.00023614868,0.000109488275,0.00020320153],"domain_scores_gemma":[0.9996602,0.000006544536,0.000082278755,0.00013021818,0.000049370745,0.000071380404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005013065,0.00017862543,0.00031873988,0.00014099783,0.00003688083,0.00001935614,0.00004448611,0.00008139091,0.0005602225],"category_scores_gemma":[0.0000026100408,0.00015034773,0.00007646844,0.0001778077,0.000054121538,0.0001763745,0.000011044393,0.00007409475,0.00005471795],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025233603,0.0006578334,0.0073988433,0.00007490532,0.00007133847,0.000012841545,0.0010511684,7.416923e-8,0.9642523,0.000008812575,0.024387434,0.0018321245],"study_design_scores_gemma":[0.008620543,0.0000626175,0.035694424,0.00020628532,0.000057142857,0.000030100884,0.000060297938,0.00006989561,0.87674963,0.000008542508,0.07821271,0.00022780422],"about_ca_topic_score_codex":0.000057376612,"about_ca_topic_score_gemma":0.0000014772455,"teacher_disagreement_score":0.08750265,"about_ca_system_score_codex":0.00002866078,"about_ca_system_score_gemma":0.00003371102,"threshold_uncertainty_score":0.61340433},"labels":[],"label_agreement":null},{"id":"W2151831449","doi":"10.4172/2155-6113.s5-008","title":"Modelling Treatment Response Could Reduce Virological Failure in Different Patient Populations","year":2012,"lang":"en","type":"article","venue":"Journal of AIDS & Clinical Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine","score_opus":0.43054065386745244,"score_gpt":0.5296109048910831,"score_spread":0.09907025102363065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151831449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853718,0.00054905144,0.00024045342,0.012949657,0.00022302424,0.00045298078,0.000004380215,0.000009817658,0.00019880297],"genre_scores_gemma":[0.988915,0.0005659514,0.007995848,0.0000712245,0.000508801,0.000024755622,0.000008546108,0.000021536858,0.0018883011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99466586,0.0015580292,0.0015525101,0.00024832296,0.0012678328,0.0007074186],"domain_scores_gemma":[0.99570847,0.0025312426,0.00023940176,0.0003102812,0.0004073303,0.0008032851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056299847,0.00021385461,0.0007814419,0.0005960844,0.00012746721,0.000029740799,0.0001457805,0.0002657095,0.00021557137],"category_scores_gemma":[0.002043706,0.00012256655,0.00039524818,0.0004349325,0.00016733055,0.00015733884,0.000089085464,0.0012792901,0.00007484543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025415452,0.014819955,0.91410154,0.000020235735,0.0005232055,0.0008053018,0.0022292917,0.0006371196,0.0008012247,0.0004474735,0.006291268,0.033907913],"study_design_scores_gemma":[0.022617808,0.03793659,0.8267029,0.00096687995,0.00058010215,0.00055746856,0.003247822,0.0048382827,0.0019146724,0.0020989273,0.097916,0.00062257046],"about_ca_topic_score_codex":0.00001943714,"about_ca_topic_score_gemma":0.0000120132445,"teacher_disagreement_score":0.09162474,"about_ca_system_score_codex":0.00078090513,"about_ca_system_score_gemma":0.0003728795,"threshold_uncertainty_score":0.555795},"labels":[],"label_agreement":null},{"id":"W2151881247","doi":"10.1086/422007","title":"Antiretroviral Resistance among HIV‐Infected Persons Who Have Died in British Columbia, in the Era of Modern Antiretroviral Therapy","year":2004,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Medicine; Drug resistance; Antiretroviral therapy; Internal medicine; Cohort; Sida; Human immunodeficiency virus (HIV); Cohort study; Viral load; Immunology; Viral disease; Biology","score_opus":0.007014959740130178,"score_gpt":0.23087181901886186,"score_spread":0.2238568592787317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151881247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531585,0.002867863,0.000034002896,0.00055525947,0.000057807465,0.00048355423,0.00003039484,0.000018478315,0.00063677464],"genre_scores_gemma":[0.9976526,0.0012826858,0.000026724752,0.00015883749,0.00008738245,0.000011563093,0.0000089384075,0.000025003284,0.00074624945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817014,0.00026228366,0.0006006511,0.00014608864,0.000512196,0.000308654],"domain_scores_gemma":[0.99895275,0.00018122405,0.00038238888,0.00023991264,0.00014615923,0.000097559205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042799232,0.00016960705,0.0005443132,0.00014813307,0.00014857539,0.00008968954,0.00020166225,0.000067722765,0.000035570243],"category_scores_gemma":[0.00016928052,0.00013560432,0.00023443323,0.00045973947,0.00026047765,0.0002147602,0.000023139042,0.00047956628,0.000001746457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036897458,0.0012091893,0.9902159,0.00003777667,0.00016439412,0.00045974206,0.0035728703,0.00010369107,0.00013312069,0.00000601089,0.00091950723,0.0028088447],"study_design_scores_gemma":[0.00819995,0.00075399445,0.9879916,0.0008893245,0.0001725261,0.00018371454,0.0008657138,0.00003806386,0.00009404674,0.00063790265,0.00003601557,0.00013715235],"about_ca_topic_score_codex":0.003854853,"about_ca_topic_score_gemma":0.035190813,"teacher_disagreement_score":0.031335957,"about_ca_system_score_codex":0.0002655854,"about_ca_system_score_gemma":0.0003536348,"threshold_uncertainty_score":0.9824144},"labels":[],"label_agreement":null},{"id":"W2152564006","doi":"10.1093/nar/gkp1022","title":"A single-label phenylpyrrolocytidine provides a molecular beacon-like response reporting HIV-1 RT RNase H activity","year":2009,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"RNase H; Biology; Molecular beacon; RNA; RNase P; Molecular biology; DNA; Ribonuclease; Cytidine; Oligonucleotide; Duplex (building); Cleavage (geology); Nuclease; Fluorescence; Enzyme; Biochemistry; Combinatorial chemistry; Chemistry; Gene","score_opus":0.08185003296055052,"score_gpt":0.37417185856642304,"score_spread":0.2923218256058725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152564006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666495,0.00026659193,0.00017936807,0.024814561,0.00005617132,0.0013357257,0.000009366697,0.00025519743,0.006433555],"genre_scores_gemma":[0.9623353,0.000026589536,0.00701433,0.00040506577,0.00012404053,0.00009881472,0.000037838858,0.00006826884,0.029889772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946368,0.0005855866,0.00087298383,0.00091903965,0.0017450773,0.0012405319],"domain_scores_gemma":[0.99711734,0.0003744148,0.00033517266,0.0009860754,0.0005895322,0.0005974489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046318485,0.00038675597,0.0006832325,0.0006835458,0.000429552,0.00013014262,0.00027390374,0.00024542623,0.00020307765],"category_scores_gemma":[0.0045566745,0.0003293014,0.00019247195,0.0011388712,0.0002675931,0.00025354745,0.00019858398,0.00097487937,0.00038924598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009613792,0.0027309612,0.0052114804,0.000095922565,0.00023690418,0.0076533747,0.0014445194,0.0000018920292,0.8825506,0.000082767394,0.011971136,0.07840667],"study_design_scores_gemma":[0.01938875,0.0074026794,0.0510635,0.0012676271,0.00035128242,0.0015864711,0.001360915,0.0040514623,0.7969451,0.0009687478,0.11414808,0.0014654027],"about_ca_topic_score_codex":0.000024590847,"about_ca_topic_score_gemma":0.0000047945455,"teacher_disagreement_score":0.10217694,"about_ca_system_score_codex":0.0009151981,"about_ca_system_score_gemma":0.0009589134,"threshold_uncertainty_score":0.9999159},"labels":[],"label_agreement":null},{"id":"W2152773167","doi":"10.1345/aph.1g630","title":"Carbamazepine Toxicity Induced by Lopinavir/Ritonavir and Nelfinavir","year":2006,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Medicine; Lopinavir; Ritonavir; Nelfinavir; Carbamazepine; Lopinavir/ritonavir; Toxicity; Pharmacology; Virology; Internal medicine; Epilepsy; Human immunodeficiency virus (HIV); Viral load; Psychiatry; Antiretroviral therapy","score_opus":0.03973679266087376,"score_gpt":0.3550858570373171,"score_spread":0.31534906437644333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152773167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761074,0.0040848507,0.000022914599,0.01697788,0.000066459535,0.00038011503,0.00003910286,0.000059800062,0.0022614724],"genre_scores_gemma":[0.98796046,0.0022593231,0.00033604744,0.0028251463,0.00015787438,0.000029137638,0.000081757295,0.000034583132,0.006315649],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874043,0.00004117434,0.0003387659,0.00028080697,0.00026978579,0.00032904273],"domain_scores_gemma":[0.9993872,0.000037535694,0.00011176347,0.00016579677,0.00010580244,0.0001919193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017537735,0.0002310383,0.0003935089,0.00010638471,0.000059081452,0.000012658938,0.000073343,0.000080730344,0.00023250536],"category_scores_gemma":[0.000008414408,0.00019685423,0.0000975759,0.00020242679,0.00007172773,0.000102691156,0.00001847891,0.00012631652,0.000016631064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002887512,0.00072763,0.012011154,0.000054920543,0.00020533649,0.0000269678,0.00018263422,5.112936e-7,0.88977486,0.00015016936,0.07800774,0.01856929],"study_design_scores_gemma":[0.0031321652,0.00022612281,0.00875219,0.00006520844,0.00004452728,0.000013276276,0.000018712417,0.000029011613,0.87894094,0.00022305542,0.10836417,0.00019061001],"about_ca_topic_score_codex":0.00018835101,"about_ca_topic_score_gemma":0.0000060560124,"teacher_disagreement_score":0.030356426,"about_ca_system_score_codex":0.000021677875,"about_ca_system_score_gemma":0.000080497215,"threshold_uncertainty_score":0.80274826},"labels":[],"label_agreement":null},{"id":"W2152778462","doi":"10.1310/hct1004-207","title":"Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Enfuvirtide; Medicine; Discontinuation; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Tenofovir; Internal medicine; Immunology; Viral load","score_opus":0.16061886623418828,"score_gpt":0.46734059060930044,"score_spread":0.30672172437511214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152778462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987904,0.0001477299,0.00010868983,0.0065231016,0.00013652456,0.0014201071,0.00004609446,0.000077717705,0.003636018],"genre_scores_gemma":[0.9917169,0.00018139965,0.0018880673,0.00025555055,0.00019792444,0.000030746654,0.00034916634,0.000015016756,0.005365192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950451,0.0011648043,0.002766634,0.00038588917,0.00036422338,0.00027330682],"domain_scores_gemma":[0.9961684,0.0025938055,0.00061940827,0.00033752515,0.00009998762,0.00018088271],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0060385084,0.00021714016,0.0016479216,0.0002447138,0.00002615641,0.000016083952,0.00008785574,0.00023144043,0.00031558823],"category_scores_gemma":[0.010768692,0.00015663996,0.00037343198,0.0004507111,0.000066868924,0.00009181553,0.000022697192,0.000234496,0.00019609343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011034822,0.0025817025,0.9505733,0.000017006016,0.0002652823,0.000048132613,0.0003346791,0.0000030286744,0.0010030577,0.0003474825,0.008599215,0.035123628],"study_design_scores_gemma":[0.017773824,0.00071964436,0.9704337,0.00045702604,0.0004021248,0.0000039267793,0.00004387056,0.00005368535,0.0061471784,0.00073117396,0.0030465757,0.00018723834],"about_ca_topic_score_codex":0.0000059111617,"about_ca_topic_score_gemma":0.000007844313,"teacher_disagreement_score":0.03493639,"about_ca_system_score_codex":0.000060032384,"about_ca_system_score_gemma":0.00019841586,"threshold_uncertainty_score":0.997564},"labels":[],"label_agreement":null},{"id":"W2152825728","doi":"10.1007/978-3-0348-7869-2_3","title":"The basic principles for combination therapy","year":2004,"lang":"en","type":"book-chapter","venue":"Birkhäuser Basel eBooks","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Intensive care medicine; Tuberculosis; Combination therapy; Cancer therapy; Endocarditis; Antiretroviral therapy; Cancer; Immunology; Pharmacology; Internal medicine; Viral load; Pathology","score_opus":0.04872231649013223,"score_gpt":0.26546846283237685,"score_spread":0.21674614634224462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152825728","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008815367,0.0014416312,0.00017906072,0.0047927224,0.00052686664,0.004946963,0.00007753353,0.0002958285,0.98685783],"genre_scores_gemma":[0.004384054,0.00050948863,0.0008406844,0.00051805406,0.00025513693,0.00041481157,0.00027448498,0.00016143761,0.99264187],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827284,0.000014673773,0.000475814,0.00045548682,0.0004360225,0.0003451765],"domain_scores_gemma":[0.9985697,0.0002337397,0.0002390522,0.00058928353,0.00022771709,0.00014045463],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032084642,0.0004852955,0.0004672385,0.00015734011,0.0003781293,0.00006200329,0.00017528377,0.0002958965,0.00015755699],"category_scores_gemma":[0.000028638111,0.00030927907,0.00034599513,0.000014019167,0.00014463418,0.00002506699,0.000043139942,0.0002472173,0.00018706657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005973826,0.00013954099,0.00012372954,0.00014413473,0.000972979,0.00005749231,0.0005203218,6.1520245e-7,0.000056076384,0.9150764,0.007957888,0.07435347],"study_design_scores_gemma":[0.0047596777,0.00026028205,0.00019747204,0.00039792282,0.00022427109,0.000014684719,0.000014607616,0.000013938284,0.0014719991,0.030692946,0.96161175,0.00034046153],"about_ca_topic_score_codex":0.0000049643922,"about_ca_topic_score_gemma":0.00003349936,"teacher_disagreement_score":0.9536539,"about_ca_system_score_codex":0.0003243236,"about_ca_system_score_gemma":0.0006802341,"threshold_uncertainty_score":0.9999359},"labels":[],"label_agreement":null},{"id":"W2152830821","doi":"10.2217/hiv.09.40","title":"The K65R Mutation in HIV-1 Reverse Transcriptase: Genetic Barriers, Resistance Profile and Clinical Implications","year":2009,"lang":"en","type":"article","venue":"HIV Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Resistance mutation; Stavudine; Lamivudine; Virology; Nevirapine; Biology; Zidovudine; Emtricitabine; Didanosine; Abacavir; Reverse transcriptase; Drug resistance; Genetics; Viral load; Human immunodeficiency virus (HIV); Virus; RNA; Viral disease; Antiretroviral therapy; Hepatitis B virus","score_opus":0.01831863474859166,"score_gpt":0.3086983567991576,"score_spread":0.29037972205056595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152830821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79381466,0.008562198,0.00046288955,0.19177575,0.00011042551,0.0019881565,0.00005065893,0.00009156783,0.003143656],"genre_scores_gemma":[0.95069814,0.010016517,0.008258742,0.0021297778,0.00010633156,0.00015103306,0.00013042844,0.00002173176,0.02848733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991326,0.0000809401,0.0002965808,0.00021725493,0.00010697688,0.00016565187],"domain_scores_gemma":[0.99949884,0.000076748525,0.00004930929,0.00023507472,0.000034496465,0.00010553274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022948184,0.000105467465,0.00015576993,0.00004212045,0.00014589616,0.0000193609,0.00005617638,0.000054001906,0.000054746084],"category_scores_gemma":[0.000032173648,0.000071093185,0.000050254712,0.00015348273,0.000071789014,0.000040686242,0.0000026539924,0.00010862424,0.000033869354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025381546,0.00080983073,0.43168098,0.000030779967,0.00029418067,0.00018504396,0.005203013,0.0000021050876,0.0030834998,0.004805105,0.2783999,0.27296737],"study_design_scores_gemma":[0.0038595377,0.00012349349,0.76967776,0.00004838248,0.000034699056,0.000014487905,0.00017999005,0.000038698865,0.0002795813,0.0012663626,0.22436626,0.00011071995],"about_ca_topic_score_codex":0.0000016015447,"about_ca_topic_score_gemma":0.0000269347,"teacher_disagreement_score":0.33799678,"about_ca_system_score_codex":0.00004464878,"about_ca_system_score_gemma":0.000100308585,"threshold_uncertainty_score":0.2899096},"labels":[],"label_agreement":null},{"id":"W2152989668","doi":"10.1128/jvi.75.2.589-594.2001","title":"Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir","year":2001,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Indinavir; Saquinavir; Ritonavir; Protease; Biology; Virology; Cleavage (geology); Reverse transcriptase; Lentivirus; Protease inhibitor (pharmacology); Molecular biology; Virus; HIV-1 protease; Sida; Viral disease; Biochemistry; Enzyme; Viral load; Polymerase chain reaction; Gene","score_opus":0.013016573314804838,"score_gpt":0.29387097480388574,"score_spread":0.2808544014890809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152989668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968371,0.00087404216,0.000037232494,0.0010809612,0.00006735826,0.0007525978,0.000032570988,0.000041126284,0.0002770198],"genre_scores_gemma":[0.9867973,0.00008374132,0.00056934427,0.00018272235,0.00007623859,0.00004159683,0.00008645916,0.000038666047,0.012123936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807876,0.00017028066,0.000665232,0.00027435602,0.00039546873,0.00041587104],"domain_scores_gemma":[0.9984195,0.00008322102,0.0006225869,0.0001774526,0.00046644462,0.00023074892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037704184,0.00027576805,0.0005537735,0.0002456104,0.00032955394,0.000049984108,0.00011078568,0.00019578204,0.00013720956],"category_scores_gemma":[0.00035015377,0.00019149248,0.00006789563,0.0006809205,0.0002763974,0.00023596827,0.000033349163,0.00054516864,0.000025610681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013914084,0.005664015,0.52207744,0.00010467572,0.0010616559,0.0066944333,0.0023360986,0.000011540533,0.43857157,0.00003898468,0.008377206,0.0011483143],"study_design_scores_gemma":[0.025868246,0.011299646,0.91011834,0.0008466228,0.0011018105,0.0028633745,0.00022553295,0.00004869694,0.030412808,0.00017598586,0.016248774,0.0007901653],"about_ca_topic_score_codex":0.000022751534,"about_ca_topic_score_gemma":0.00008637075,"teacher_disagreement_score":0.40815875,"about_ca_system_score_codex":0.00023908983,"about_ca_system_score_gemma":0.0003801858,"threshold_uncertainty_score":0.78088367},"labels":[],"label_agreement":null},{"id":"W2153647503","doi":"10.1139/v11-001","title":"The synthesis of the 8-<i>C</i>-substituted 2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine (PMEDAP) derivatives by diverse cross-coupling reactions","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Gilead Sciences","keywords":"Chemistry; Sonogashira coupling; Moiety; Stereochemistry; Stille reaction; Purine; Alkyl; Aryl; Coupling reaction; Negishi coupling; Bicyclic molecule; Chemical synthesis; Organic chemistry; Enzyme; Palladium; Biochemistry; Catalysis; In vitro","score_opus":0.019972882595645045,"score_gpt":0.2370576394685412,"score_spread":0.21708475687289613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153647503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227685,0.0011375055,0.000027524378,0.0011166062,0.00022849567,0.00011113479,0.00003230667,0.000006027793,0.005063523],"genre_scores_gemma":[0.993249,0.0001489134,0.00052688894,0.000032355274,0.00007853979,0.000008247872,0.000004169504,0.000017780598,0.005934105],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884677,0.000015537084,0.0004998099,0.00013021856,0.00021630959,0.0002913764],"domain_scores_gemma":[0.9983242,0.00019412793,0.0004224331,0.00031159012,0.00029086578,0.0004567846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032260432,0.0001691994,0.0002834225,0.000050747276,0.000367667,0.000029059289,0.0003184405,0.00009504241,0.00040042298],"category_scores_gemma":[0.0007069929,0.00010293135,0.00019912374,0.0002473668,0.0004797161,0.00009593691,0.000023590786,0.00031543477,0.0000052782825],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059090985,0.0005113021,0.7224473,0.00047112975,0.0034576722,0.00073427474,0.0099643245,0.000047566537,0.2275079,0.00011884519,0.024208643,0.00994015],"study_design_scores_gemma":[0.0006753581,0.0000141689825,0.031933002,0.0002866901,0.00018739008,0.0001877572,0.0015484268,0.000007943618,0.9435652,0.00005461162,0.021403968,0.00013549661],"about_ca_topic_score_codex":0.00071011315,"about_ca_topic_score_gemma":0.00041779643,"teacher_disagreement_score":0.7160573,"about_ca_system_score_codex":0.0002565449,"about_ca_system_score_gemma":0.0013865572,"threshold_uncertainty_score":0.4384351},"labels":[],"label_agreement":null},{"id":"W2153766845","doi":"10.1086/499044","title":"Response to Antiretroviral Therapy in HIV-Infected Patients Attending a Public, Urban Clinic in Kampala, Uganda","year":2005,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Interquartile range; Odds ratio; Internal medicine; Viral load; Regimen; Confidence interval; Reverse-transcriptase inhibitor; Immunology; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.03325741667840492,"score_gpt":0.35064507117136573,"score_spread":0.3173876544929608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153766845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944268,0.00015646672,0.00001109875,0.003110281,0.00025788895,0.0011239909,0.000034122044,0.00020967044,0.0006696704],"genre_scores_gemma":[0.99500877,0.00019004902,0.00008080489,0.002052238,0.00025213027,0.0001436919,0.0001303185,0.000048662554,0.0020933372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966217,0.00049459207,0.0012388532,0.00067543087,0.00034995397,0.000619413],"domain_scores_gemma":[0.9975316,0.0011599705,0.00016620557,0.00036331467,0.00013573255,0.00064320886],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074652315,0.00033831596,0.00080079614,0.00070775143,0.00008830934,0.00006180674,0.00012874477,0.00019897756,0.0005220971],"category_scores_gemma":[0.0032900746,0.00028721237,0.00031385053,0.0009710583,0.0001154438,0.00022458908,0.000090413574,0.0003964896,0.0009353701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021478257,0.0064900215,0.9570639,0.000011796452,0.00009138752,0.0000891821,0.00021737287,0.000002217262,0.000014545109,0.000009169185,0.00833484,0.02552774],"study_design_scores_gemma":[0.0148912985,0.00221342,0.9643694,0.0001601366,0.000044508997,0.0000018418942,0.00002886143,0.000041707674,0.000018159262,0.000020690264,0.017918041,0.0002918997],"about_ca_topic_score_codex":0.000017014449,"about_ca_topic_score_gemma":0.00015310678,"teacher_disagreement_score":0.02523584,"about_ca_system_score_codex":0.00045471912,"about_ca_system_score_gemma":0.00039864896,"threshold_uncertainty_score":0.999958},"labels":[],"label_agreement":null},{"id":"W2153781964","doi":"10.1093/jac/dkt447","title":"An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes","year":2013,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; U.S. Public Health Service; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Human immunodeficiency virus (HIV); Genotyping; Antiretroviral therapy; Genotype; Selection (genetic algorithm); Medicine; Drug development; Lentivirus; Intensive care medicine; Viral load; Computational biology; Biology; Computer science; Virology; Viral disease; Drug; Machine learning; Pharmacology; Genetics","score_opus":0.026820052067374013,"score_gpt":0.2750047772728234,"score_spread":0.2481847252054494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153781964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90618825,0.00006250929,0.016803382,0.07523208,0.00020397497,0.001313319,0.000027628374,0.000028695658,0.00014017778],"genre_scores_gemma":[0.91900945,0.000050849696,0.07403255,0.0032843018,0.00023606514,0.00001834839,0.000030992353,0.00004797678,0.0032894565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979577,0.0000663165,0.00085523585,0.00024252106,0.000568999,0.00030923664],"domain_scores_gemma":[0.9985295,0.00006600793,0.00041277346,0.00035714955,0.00031929128,0.0003152687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036421715,0.0003259871,0.00065794855,0.00019556875,0.00018514776,0.000092915056,0.0003534985,0.000073330644,0.000149782],"category_scores_gemma":[0.000008094598,0.00015730926,0.00023415958,0.00021994111,0.000039815004,0.00024364663,0.000035910994,0.00012620188,0.00016001512],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007750482,0.0052181073,0.08167578,0.0003715603,0.011571556,0.00016708812,0.16020702,0.04391272,0.062840715,0.0006416911,0.49012133,0.13552195],"study_design_scores_gemma":[0.06151134,0.005011844,0.23488316,0.004201427,0.0022556586,0.0023522666,0.011325578,0.011149386,0.3247119,0.0005091871,0.33922237,0.002865899],"about_ca_topic_score_codex":0.000025439891,"about_ca_topic_score_gemma":0.000016638312,"teacher_disagreement_score":0.26187116,"about_ca_system_score_codex":0.0004039596,"about_ca_system_score_gemma":0.0007670114,"threshold_uncertainty_score":0.64148855},"labels":[],"label_agreement":null},{"id":"W2154094145","doi":"10.2147/tcrm.s1709","title":"Combating HIV resistance &amp;ndash; focus on darunavir","year":2008,"lang":"en","type":"article","venue":"Therapeutics and Clinical Risk Management","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Darunavir; Medicine; Human immunodeficiency virus (HIV); Focus (optics); Virology; Pharmacology; Antiretroviral therapy; Viral load","score_opus":0.06666891908404485,"score_gpt":0.35367158264617315,"score_spread":0.28700266356212834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154094145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86273044,0.0019053475,0.0014940255,0.016833464,0.00025929892,0.0012062005,0.000019835667,0.00020528106,0.11534609],"genre_scores_gemma":[0.8721315,0.029921109,0.014679229,0.0022413228,0.00013357394,0.00003290669,0.000033447748,0.00004096361,0.08078593],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835426,0.000100289464,0.00052310014,0.00040374938,0.00034219486,0.00027638502],"domain_scores_gemma":[0.99897945,0.00026207042,0.00014905108,0.00041729584,0.000037709957,0.00015440249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000519646,0.00021209283,0.00037166738,0.00006538306,0.00026867844,0.000018569064,0.00009197203,0.000078525205,0.00005683292],"category_scores_gemma":[0.00002203183,0.00015941447,0.0001302438,0.00013135192,0.00016442072,0.000024604631,0.00008147716,0.00027600152,0.00023107242],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018870942,0.0036177475,0.54309154,0.00013852357,0.0035055906,0.00042145138,0.001262446,0.0000041517187,0.0000055264777,0.027835717,0.015423556,0.40280667],"study_design_scores_gemma":[0.006502631,0.00045381417,0.24612658,0.00023438032,0.00091951614,0.0000071359004,0.000174226,0.00012996233,0.00003491921,0.0067382045,0.73832256,0.00035608388],"about_ca_topic_score_codex":0.0000034371974,"about_ca_topic_score_gemma":0.000021340526,"teacher_disagreement_score":0.722899,"about_ca_system_score_codex":0.000048115417,"about_ca_system_score_gemma":0.000022174396,"threshold_uncertainty_score":0.65007335},"labels":[],"label_agreement":null},{"id":"W2154257259","doi":"10.1093/aje/kwr141","title":"Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America","year":2011,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Eye Institute; National Center for Research Resources; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; Canadian Institutes of Health Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; U.S. Public Health Service; National Cancer Institute; National Institutes of Health","keywords":"Human immunodeficiency virus (HIV); Virology; Drug resistance; Medicine; Drug; Antiretroviral drug; Estimation; HIV drug resistance; Environmental health; Antiretroviral therapy; Biology; Pharmacology; Viral load; Microbiology","score_opus":0.04499809891308119,"score_gpt":0.31165853864062104,"score_spread":0.26666043972753983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154257259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986909,0.00018125403,0.000039650702,0.00061464973,0.00001929614,0.0002287232,0.000014408082,0.000003005304,0.00020808252],"genre_scores_gemma":[0.99688894,0.000106170526,0.0027693552,0.0001220289,0.0000042239844,0.000002234511,0.000016157956,0.000010172986,0.00008070749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750257,0.0008263504,0.0010431119,0.0001995998,0.00020198134,0.00022637255],"domain_scores_gemma":[0.9968796,0.0006487109,0.0017727169,0.0005445228,0.00011389643,0.00004058025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010932385,0.00014967512,0.0007065693,0.0001919291,0.00004825398,0.000001316773,0.00042897827,0.000024739576,0.000020620084],"category_scores_gemma":[0.0010065874,0.000073553936,0.000060161226,0.0007144148,0.00067850045,0.000105146464,0.00005866019,0.0002702001,9.1684035e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010190686,0.00044539841,0.990262,0.000032570362,0.000067441426,0.0000053583626,0.0027746733,0.000075104625,0.000070574315,0.0000373375,0.000053455286,0.0051570497],"study_design_scores_gemma":[0.001114312,0.0008961803,0.996389,0.00053459656,0.00009265227,0.0000035229525,0.00023389365,0.00030248836,0.00030265408,0.000046785888,0.000016221426,0.000067737645],"about_ca_topic_score_codex":0.0006734778,"about_ca_topic_score_gemma":0.0001118923,"teacher_disagreement_score":0.006126987,"about_ca_system_score_codex":0.00009969593,"about_ca_system_score_gemma":0.000127767,"threshold_uncertainty_score":0.29994425},"labels":[],"label_agreement":null},{"id":"W2154395879","doi":"10.1345/aph.1l689","title":"Adverse Effects of Antiretrovirals in HIV-Infected Pregnant Women","year":2009,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority; Alberta Health Services","funders":"","keywords":"Medicine; Pregnancy; Internal medicine; Anemia; Reverse-transcriptase inhibitor; Combination therapy; Adverse effect; Zidovudine; Vomiting; Nausea; Obstetrics; Viral load; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.020026315709054374,"score_gpt":0.33797136023200813,"score_spread":0.31794504452295375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154395879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505705,0.0014203812,0.000012100966,0.001875019,0.00005036417,0.00061282964,0.000006206258,0.000034676545,0.0009313474],"genre_scores_gemma":[0.99283403,0.0034035668,0.00025124755,0.0010123671,0.00003179304,0.000024029456,0.00001176588,0.00001572345,0.0024154729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988086,0.000062534804,0.0003820927,0.0001878757,0.00023850136,0.0003203534],"domain_scores_gemma":[0.9994124,0.00006649648,0.00015091359,0.00016852606,0.00008506315,0.00011656684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018413646,0.00017784812,0.0004991649,0.00028676755,0.000014288636,0.0000020773261,0.00007818529,0.00005286265,0.00022116904],"category_scores_gemma":[0.000022562492,0.00014237135,0.00011660113,0.00036271912,0.000040528048,0.00008968226,0.0000071878803,0.00008653524,0.000018058452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010835027,0.002309396,0.06640406,0.0002660594,0.00035890524,0.00015576172,0.0034786463,0.0000051975776,0.87213486,0.00008381716,0.0044359504,0.049283855],"study_design_scores_gemma":[0.0067642936,0.0008536966,0.067526005,0.000536167,0.00002816396,0.0000029253788,0.00003389851,0.00003477421,0.9207949,0.00010603092,0.0031920485,0.0001270755],"about_ca_topic_score_codex":0.000006645204,"about_ca_topic_score_gemma":5.042477e-7,"teacher_disagreement_score":0.049156778,"about_ca_system_score_codex":0.00003220968,"about_ca_system_score_gemma":0.00008158179,"threshold_uncertainty_score":0.58057356},"labels":[],"label_agreement":null},{"id":"W2155395980","doi":"10.1128/aac.50.2.694-701.2006","title":"Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent","year":2006,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); AIDS Vancouver","funders":"","keywords":"Nelfinavir; Saquinavir; Indinavir; Virology; Stavudine; Reverse transcriptase; Biology; Amprenavir; Ritonavir; Lamivudine; Genotyping; Concordance; Protease; Drug resistance; Genotype; Virus; Sida; Viral load; Genetics; Viral disease; Polymerase chain reaction; Antiretroviral therapy; HIV-1 protease; Enzyme; Gene","score_opus":0.014886383926483854,"score_gpt":0.2718370485688829,"score_spread":0.2569506646423991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155395980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957976,0.0001679717,0.0008674686,0.0019318957,0.000045421773,0.0010144119,0.0001093581,0.000016263606,0.00004964845],"genre_scores_gemma":[0.9943866,0.00013561294,0.0024461956,0.00039333527,0.000059665614,0.00003142261,0.000098338256,0.000020369602,0.002428431],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914527,0.000014110516,0.00029292988,0.00027032246,0.00010813851,0.00016924093],"domain_scores_gemma":[0.9996582,0.000010060308,0.00011609234,0.00010672714,0.000052456355,0.000056411653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007867256,0.00016244985,0.00028712317,0.000081045706,0.00012305484,0.000022470684,0.000044643835,0.000047295795,0.000013429905],"category_scores_gemma":[0.00000384917,0.00013407995,0.0000585945,0.0000918085,0.00006158238,0.00006654831,0.000010451196,0.00004544561,0.0000012042243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024629338,0.0012273048,0.425088,0.0009808085,0.00037877788,0.00003308848,0.0058563515,0.0000027258473,0.5220473,0.0000877021,0.019156076,0.022678936],"study_design_scores_gemma":[0.008769512,0.0005151997,0.33361053,0.0009875488,0.0003114947,0.000007723355,0.00039418467,0.000024529229,0.6403229,0.00027791556,0.014257611,0.00052081817],"about_ca_topic_score_codex":0.00014748567,"about_ca_topic_score_gemma":0.000064625194,"teacher_disagreement_score":0.118275635,"about_ca_system_score_codex":0.000032258053,"about_ca_system_score_gemma":0.000024003002,"threshold_uncertainty_score":0.54676217},"labels":[],"label_agreement":null},{"id":"W2155477225","doi":"10.1186/1743-422x-7-68","title":"Characterization of the HIV-1 integrase chromatin- and LEDGF/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase","year":2010,"lang":"en","type":"article","venue":"Virology Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Manitoba Medical Service Foundation; Manitoba Health Research Council","keywords":"Integrase; Biology; Chromatin; Virology; Human immunodeficiency virus (HIV); Computational biology; Genetics; Integrase inhibitor; Core (optical fiber); DNA; Antiretroviral therapy; Physics; Viral load","score_opus":0.006877283639979851,"score_gpt":0.2321274587231534,"score_spread":0.22525017508317355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155477225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965285,0.000039038754,0.00017950434,0.0027689766,0.00017670893,0.00019361243,0.000052898493,0.0000097412285,0.000051038118],"genre_scores_gemma":[0.9980789,0.000032170006,0.00022333668,0.000067477595,0.00004126593,0.000008311322,0.00008502836,0.000012496377,0.0014510191],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99892074,0.000102490405,0.0004950153,0.00013725473,0.0001895076,0.00015497216],"domain_scores_gemma":[0.9989599,0.00016401455,0.00046626574,0.00025162747,0.00008178911,0.000076410455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007103688,0.00014387605,0.00037827337,0.00023555296,0.00017072892,0.0000136326,0.00014546429,0.00010231587,0.00012450968],"category_scores_gemma":[0.00020083955,0.00007006344,0.00015417574,0.00040092572,0.0005112412,0.00005967491,0.000051050676,0.0004806072,0.000008428083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012136895,0.0001262485,0.32186127,0.00002883563,0.0016112685,0.000018128454,0.0063859737,0.0000020194286,0.6689504,0.00021188242,0.0002732367,0.0004093562],"study_design_scores_gemma":[0.0058077043,0.00050034997,0.77772856,0.0002569174,0.0076861214,0.0017743795,0.009615796,0.0020415785,0.19211052,0.0014492032,0.0006449834,0.00038390144],"about_ca_topic_score_codex":0.000014103729,"about_ca_topic_score_gemma":0.000117123825,"teacher_disagreement_score":0.47683987,"about_ca_system_score_codex":0.00003477992,"about_ca_system_score_gemma":0.0001165058,"threshold_uncertainty_score":0.28571042},"labels":[],"label_agreement":null},{"id":"W2155545633","doi":"10.1159/000178978","title":"A Comparison of the Predictive Performance of Different Methods of Kidney Function Estimation in a Well-Characterized HIV-Infected Population","year":2008,"lang":"en","type":"article","venue":"Nephron Clinical Practice","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Renal function; Medicine; Creatinine; Urology; Body surface area; Population; Cystatin C; Kidney disease; Urine; Plasma clearance; Internal medicine; Endocrinology; Pharmacokinetics","score_opus":0.06431355793762367,"score_gpt":0.4320089106942,"score_spread":0.36769535275657633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155545633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932182,0.00002629624,0.0033778516,0.0016494195,0.00023129203,0.0007151408,0.0000051003467,0.000019047791,0.00075765594],"genre_scores_gemma":[0.98143977,0.00010328196,0.017873526,0.00016846055,0.000030478783,0.00002241175,0.00009130957,0.000011078099,0.00025969584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723125,0.00071533147,0.001345785,0.00020518295,0.0003861777,0.00011630179],"domain_scores_gemma":[0.9965226,0.0016505709,0.0012224346,0.00028470412,0.00022965753,0.00009003193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009114735,0.00013788912,0.00066372816,0.00010232527,0.000045066463,0.0000020325394,0.00006197143,0.00014791886,0.000060739152],"category_scores_gemma":[0.0051420787,0.00009272477,0.0001401227,0.0003144403,0.00011731035,0.00023856339,0.000044933942,0.00033426777,0.000006302218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005926771,0.002823547,0.9758697,0.00016229576,0.00022474876,0.0000012708877,0.0007341148,0.000076002034,0.0031899065,0.000035204666,0.00052155904,0.010434869],"study_design_scores_gemma":[0.0036717241,0.0008077271,0.9497958,0.00027993054,0.0005008834,0.000008683312,0.00007360729,0.037909996,0.005690681,0.00001652928,0.001177814,0.000066653025],"about_ca_topic_score_codex":0.00003635823,"about_ca_topic_score_gemma":0.0000035750015,"teacher_disagreement_score":0.037833996,"about_ca_system_score_codex":0.000088840745,"about_ca_system_score_gemma":0.0001964064,"threshold_uncertainty_score":0.615592},"labels":[],"label_agreement":null},{"id":"W2155601702","doi":"10.1128/jvi.79.14.9081-9087.2005","title":"Defective Replication in Human Immunodeficiency Virus Type 1 When Non-\\batchmode \\documentclass[fleqn,10pt,legalpaper]{article} \\usepackage{amssymb} \\usepackage{amsfonts} \\usepackage{amsmath} \\pagestyle{empty} \\begin{document} \\(\\mathrm{tRNA}_{3}^{\\mathrm{Lys}}\\) \\end{document}Primers Are Used for Reverse Transcription","year":2005,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Physics; Combinatorics; Human immunodeficiency virus (HIV); Biology; Virology; Mathematics","score_opus":0.016084021030507066,"score_gpt":0.3078480335955643,"score_spread":0.29176401256505724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155601702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97862935,0.0021207333,0.0015407639,0.013352066,0.0007014085,0.0024321948,0.000036905207,0.0001451626,0.0010413965],"genre_scores_gemma":[0.98136586,0.0012011516,0.009257461,0.0016987496,0.0004924619,0.00023159846,0.00013621402,0.00020351172,0.005412969],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.992796,0.0004998332,0.002714256,0.0012940615,0.001188199,0.0015076512],"domain_scores_gemma":[0.99500316,0.00033105374,0.0019708122,0.0014152895,0.00070229813,0.0005773717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025007082,0.0010226747,0.0019681766,0.0012463317,0.00048443416,0.00017375432,0.0006957351,0.00068276655,0.0007348762],"category_scores_gemma":[0.0003802918,0.0009380077,0.00087187835,0.00082498905,0.00034179084,0.0017123583,0.00012744304,0.001229283,0.0002731041],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004829052,0.0044672363,0.023293762,0.00035970763,0.0022119877,0.00054855575,0.017412186,0.00047312255,0.92498016,0.0018775346,0.01304177,0.0065049264],"study_design_scores_gemma":[0.10562731,0.015598894,0.21745144,0.0032967934,0.010019535,0.003388117,0.009029852,0.0025345588,0.38990647,0.015008117,0.22240533,0.005733591],"about_ca_topic_score_codex":0.00022410923,"about_ca_topic_score_gemma":0.0006348905,"teacher_disagreement_score":0.5350737,"about_ca_system_score_codex":0.0020179923,"about_ca_system_score_gemma":0.0005922893,"threshold_uncertainty_score":0.99930704},"labels":[],"label_agreement":null},{"id":"W2155715952","doi":"10.1086/313850","title":"Initial Therapy with Protease Inhibitor-Sparing Regimens: Evaluation of Nevirapine and Delavirdine","year":2000,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Institut National Du Cancer; ACT Government","keywords":"Didanosine; Nevirapine; Medicine; Zidovudine; Viral load; Protease inhibitor (pharmacology); Internal medicine; Lamivudine; Gastroenterology; Indinavir; Chemotherapy; Pharmacology; Virology; Immunology; Antiretroviral therapy; Viral disease; Human immunodeficiency virus (HIV); Virus","score_opus":0.06135841305907544,"score_gpt":0.3833099662384131,"score_spread":0.32195155317933766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155715952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943288,0.0018183676,0.000009461281,0.0003835291,0.00006177497,0.0012032671,0.00000800022,0.00008506342,0.0021017322],"genre_scores_gemma":[0.997613,0.00082195667,0.000059680337,0.0002247092,0.00023217493,0.0001640774,0.000052571053,0.000021487005,0.000810328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998522,0.00017575566,0.00045585277,0.00031528415,0.00037496074,0.00015618409],"domain_scores_gemma":[0.99906343,0.00014419475,0.00011677247,0.0002380353,0.00021137674,0.00022619677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041777577,0.00017064299,0.00039995596,0.00007304146,0.00007482142,0.000015582706,0.000028345701,0.00007346696,0.00055194896],"category_scores_gemma":[0.0002280995,0.00011878514,0.00009802823,0.00017431001,0.00020870387,0.00010405188,0.0000150650985,0.00012035807,0.00002426046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011526456,0.002235658,0.75199366,0.000048910373,0.0004441158,0.000032925753,0.000080651356,0.000021611506,0.000027071224,0.000018621631,0.0007478,0.24319631],"study_design_scores_gemma":[0.031837393,0.0038801944,0.95284784,0.00059772946,0.0019347324,0.000047752874,0.000046629273,0.0008196322,0.001022715,0.00055017625,0.0060401317,0.00037509017],"about_ca_topic_score_codex":0.0000134588745,"about_ca_topic_score_gemma":0.000007994898,"teacher_disagreement_score":0.24282122,"about_ca_system_score_codex":0.000043273172,"about_ca_system_score_gemma":0.0002666716,"threshold_uncertainty_score":0.6043454},"labels":[],"label_agreement":null},{"id":"W2156570438","doi":"10.1177/1545109709333081","title":"Hematologic Changes Associated With Zidovudine Following Single-Drug Substitution From Stavudine in a Home-Based AIDS Care Program in Rural Uganda","year":2009,"lang":"en","type":"article","venue":"Journal of the International Association of Physicians in AIDS Care","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Leukopenia; Zidovudine; Stavudine; Anemia; Medicine; Incidence (geometry); Internal medicine; Pediatrics; Gastroenterology; Immunology; Chemotherapy; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.008398298326282316,"score_gpt":0.25311389089837527,"score_spread":0.24471559257209297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156570438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934292,0.00031083665,0.000015177659,0.005261834,0.0003436374,0.00038650839,0.00004111536,0.000016245316,0.00019546878],"genre_scores_gemma":[0.99786997,0.000014195589,0.0014296175,0.00021958673,0.00010824111,0.000015324254,0.00017040988,0.000012703712,0.00015995947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790806,0.00012043876,0.00061362283,0.00015188474,0.0009880925,0.00021793206],"domain_scores_gemma":[0.99819213,0.00018526556,0.00092777476,0.00010344677,0.00056212046,0.000029264447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027406722,0.00019447206,0.00058167556,0.00046389355,0.00003615614,0.000028814518,0.00022502801,0.00010149008,0.000008284342],"category_scores_gemma":[0.0003642276,0.00013977039,0.00022404395,0.00069612975,0.000023338816,0.00017792448,0.00002285842,0.00033538506,7.5409065e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031285445,0.0011211177,0.9826415,0.00002057341,0.0003164365,0.0000922025,0.004155909,0.00058320584,0.0023787448,0.000046626974,0.000103554376,0.008227255],"study_design_scores_gemma":[0.0161647,0.00104255,0.9458514,0.005616445,0.0002587348,0.0000037696705,0.00781396,0.00034298093,0.022087302,0.00036510394,0.00018859073,0.00026446232],"about_ca_topic_score_codex":0.00005912025,"about_ca_topic_score_gemma":0.001821028,"teacher_disagreement_score":0.036790118,"about_ca_system_score_codex":0.004073397,"about_ca_system_score_gemma":0.00020487035,"threshold_uncertainty_score":0.9997498},"labels":[],"label_agreement":null},{"id":"W2156681099","doi":"10.1128/aac.02114-13","title":"Competitive Fitness Assays Indicate that the E138A Substitution in HIV-1 Reverse Transcriptase Decreases <i>In Vitro</i> Susceptibility to Emtricitabine","year":2014,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"National Institute of General Medical Sciences; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Etravirine; Rilpivirine; Emtricitabine; Reverse transcriptase; Virology; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Tenofovir; Human immunodeficiency virus (HIV); Biology; Nucleoside; In vitro; Lamivudine; Virus; Genetics; RNA; Antiretroviral therapy; Viral load; Gene","score_opus":0.01445984829590002,"score_gpt":0.24737755696231978,"score_spread":0.23291770866641975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156681099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97940105,0.000025331992,0.00026454387,0.01875117,0.00007273497,0.00077128713,0.00003792924,0.000025079375,0.00065089396],"genre_scores_gemma":[0.98893327,0.0003002333,0.0006298618,0.0089340275,0.000044771725,0.000024022616,0.00016887404,0.00001883206,0.0009461299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987816,0.000096884294,0.00026904428,0.00038000764,0.00016144937,0.0003109709],"domain_scores_gemma":[0.99952,0.000052579664,0.00005871199,0.0002128254,0.000031520784,0.00012438258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003430292,0.00022973558,0.00036879227,0.00014678507,0.00009748877,0.000029371637,0.000096756456,0.00008047246,0.00012605234],"category_scores_gemma":[0.00002165778,0.00015955936,0.00007715367,0.00031008536,0.00011886893,0.00007937785,0.000020270892,0.00014401904,0.00003136155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035149897,0.002595945,0.86259127,0.00016933127,0.00018889173,0.00014739935,0.0065498445,0.000013007195,0.09036941,0.0006223469,0.020193422,0.013044162],"study_design_scores_gemma":[0.015989225,0.00015888971,0.6879569,0.0004569069,0.00011886213,0.00004575612,0.00046430842,0.00015098153,0.14075801,0.000090915535,0.15327756,0.00053168106],"about_ca_topic_score_codex":0.00014146096,"about_ca_topic_score_gemma":0.00015966725,"teacher_disagreement_score":0.17463434,"about_ca_system_score_codex":0.00012079852,"about_ca_system_score_gemma":0.00006482632,"threshold_uncertainty_score":0.6506642},"labels":[],"label_agreement":null},{"id":"W2156954694","doi":"10.2147/dddt.s89338","title":"A novel small-molecule inhibitor of HIV-1 entry","year":2015,"lang":"en","type":"article","venue":"Drug Design Development and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of California, San Francisco; McGill University","keywords":"Human immunodeficiency virus (HIV); Small molecule; Drug; Drug resistance; Antiretroviral therapy; ANTIRETROVIRAL AGENTS; Pharmacology; Lentivirus; Medicine; Virology; Chemistry; Viral load; Biology; Viral disease; Biochemistry; Microbiology","score_opus":0.0504161142988806,"score_gpt":0.25327954943224573,"score_spread":0.20286343513336513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156954694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774051,0.003506487,0.0115921665,0.0020186554,0.00018871817,0.0011686075,0.0000045230217,0.00012596503,0.0039897775],"genre_scores_gemma":[0.78146315,0.0007629077,0.1727462,0.00057941227,0.00015349682,0.00017605908,0.00013658546,0.000083073886,0.04389914],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856985,0.00004344717,0.0004093271,0.0003225,0.00035129362,0.000303576],"domain_scores_gemma":[0.9991975,0.00006053719,0.000112125854,0.00018690634,0.00015061125,0.00029231946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044362695,0.0002815836,0.00041099152,0.00019267197,0.00007122854,0.000022640781,0.00008775742,0.00008093406,0.00004342286],"category_scores_gemma":[0.000024161025,0.00021845535,0.00005686505,0.00022817087,0.00007119822,0.00006454335,0.000043445725,0.00010137259,0.000061485924],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115832165,0.010255226,0.19376807,0.0005102241,0.005269732,0.0007124509,0.13893895,0.000018509172,0.18795641,0.0018956464,0.11993583,0.32915574],"study_design_scores_gemma":[0.016172113,0.00021694013,0.0040177274,0.00026448356,0.000069801914,0.000088896115,0.0010820896,0.00008991289,0.8681191,0.00011856285,0.10918743,0.0005729069],"about_ca_topic_score_codex":0.0000049729774,"about_ca_topic_score_gemma":0.0000019897839,"teacher_disagreement_score":0.6801627,"about_ca_system_score_codex":0.0000817,"about_ca_system_score_gemma":0.0006292715,"threshold_uncertainty_score":0.89083505},"labels":[],"label_agreement":null},{"id":"W2157533742","doi":"10.1086/497610","title":"Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; ACT Government; School of Medicine, Vanderbilt University; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases","keywords":"Efavirenz; Nelfinavir; CYP2B6; CYP2C19; Medicine; Population; Pharmacology; Pharmacogenetics; Abacavir; Internal medicine; Virology; Biology; Viral load; Genotype; Virus; CYP3A4; Genetics; Cytochrome P450; Antiretroviral therapy","score_opus":0.07383009193538165,"score_gpt":0.43369223007498864,"score_spread":0.359862138139607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157533742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755365,0.00084059726,0.00009962341,0.00046106346,0.00019413089,0.0007685066,0.00002043184,0.00002862646,0.00003338137],"genre_scores_gemma":[0.99724925,0.0009800269,0.0002703151,0.000477605,0.00061318866,0.000009714094,0.0000039067754,0.000027177895,0.0003688065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959694,0.0016944237,0.001461799,0.0001737707,0.00045159325,0.00024900484],"domain_scores_gemma":[0.9965348,0.0015178174,0.0007598233,0.00026263302,0.0003301565,0.0005947606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035183635,0.00023543424,0.0010063003,0.00026702913,0.00014064224,0.000032853422,0.00014522616,0.000054154352,0.000064776905],"category_scores_gemma":[0.0029601892,0.00013045636,0.00025726677,0.00022444405,0.00012878417,0.00015757875,0.00006604042,0.00022772419,0.000006008341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019322274,0.0035398125,0.90463454,0.000024595058,0.0010000323,0.00024843845,0.0017353671,0.000008964844,0.00042227513,0.000006061303,0.00035886723,0.0686988],"study_design_scores_gemma":[0.016928954,0.034662336,0.9404801,0.0002933572,0.004578058,0.0005577335,0.0015131518,0.000022500608,0.0006103336,0.0000132349705,0.00014775486,0.00019245855],"about_ca_topic_score_codex":0.000013907895,"about_ca_topic_score_gemma":0.000036681475,"teacher_disagreement_score":0.068506345,"about_ca_system_score_codex":0.00008850145,"about_ca_system_score_gemma":0.00035136443,"threshold_uncertainty_score":0.5319856},"labels":[],"label_agreement":null},{"id":"W2157539481","doi":"10.1086/591705","title":"Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Dose‐Ranging Study Involving Treatment‐Experienced Patients with HIV‐1 Infection","year":2008,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; University of British Columbia Hospital","funders":"","keywords":"Tolerability; Medicine; Placebo; Etravirine; Internal medicine; Adverse effect; Regimen; Rash; Gastroenterology; Dose-ranging study; Viral load; Pharmacology; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Pathology","score_opus":0.03664855972347149,"score_gpt":0.3584581727088652,"score_spread":0.32180961298539373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157539481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739265,0.00028939225,0.000013391012,0.00004902887,0.00007398356,0.0019910142,0.000017592098,0.000063885775,0.00010903507],"genre_scores_gemma":[0.9988213,0.0007760854,0.000034326946,0.000023455972,0.00003759325,0.00012143619,0.00007417329,0.000023252574,0.00008832948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997945,0.00020293503,0.0009366078,0.00043566318,0.00026459168,0.00021517139],"domain_scores_gemma":[0.99862856,0.00045855675,0.00026201675,0.00030150608,0.00015033448,0.00019900087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016720228,0.00026591227,0.0008623213,0.00022956879,0.000110449466,0.000006857461,0.000042873122,0.00007823713,0.000049504088],"category_scores_gemma":[0.00029837078,0.00018832437,0.00015798776,0.0004008906,0.00033538934,0.0001312087,0.000047497164,0.00012247724,0.0000025449008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003863216,0.05755665,0.91439897,0.000046333174,0.00033403543,0.000051150942,0.002674012,0.000015373447,0.000019781892,0.0000028768973,0.000012159101,0.02102543],"study_design_scores_gemma":[0.05306878,0.016463773,0.9295351,0.00015902909,0.0002351811,0.0000048586116,0.00017224418,0.00005583627,0.00012136729,0.000011500367,0.000019671506,0.00015267028],"about_ca_topic_score_codex":0.00011768184,"about_ca_topic_score_gemma":0.000052484364,"teacher_disagreement_score":0.049205564,"about_ca_system_score_codex":0.000119413366,"about_ca_system_score_gemma":0.00018004679,"threshold_uncertainty_score":0.7679645},"labels":[],"label_agreement":null},{"id":"W2157776316","doi":"10.1517/17425250903273160","title":"Saquinavir, the pioneer antiretroviral protease inhibitor","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Drug Metabolism & Toxicology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Saquinavir; Tolerability; Protease inhibitor (pharmacology); Medicine; Pill; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Protease; ANTIRETROVIRAL AGENTS; Intensive care medicine; Virology; Viral load; Adverse effect; Biology","score_opus":0.041917384538215266,"score_gpt":0.3556561561045075,"score_spread":0.31373877156629226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157776316","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057552123,0.98182213,0.000006194582,0.00704879,0.0039050062,0.004696799,0.000038756916,0.00022967203,0.0021950803],"genre_scores_gemma":[0.000043546497,0.9696103,0.0005988728,0.002382332,0.0037068357,0.0016950361,0.00048756966,0.00015258855,0.02132295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99487996,0.000912901,0.0012945994,0.0011830158,0.00078578776,0.00094375265],"domain_scores_gemma":[0.9973282,0.00032479514,0.00057285646,0.0012400976,0.00011477004,0.00041928326],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006182923,0.0012406684,0.003583766,0.0006194343,0.00036361557,0.00006833931,0.0005396832,0.00077070243,0.00048635082],"category_scores_gemma":[0.00023341265,0.00071113807,0.0011973977,0.00069381844,0.00025526152,0.0000850361,0.00018259855,0.0012662121,0.0014589339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012022997,0.001008233,0.000003719074,0.0005845975,0.00044487955,0.00012724225,0.0005995502,1.6609083e-7,0.00000773815,0.0014936225,0.10980492,0.88580513],"study_design_scores_gemma":[0.0017995846,0.00036130619,0.000037527036,0.0035646444,0.00035883667,0.00021786796,0.000065740496,0.0000027682759,0.00008508999,0.000035099776,0.9928203,0.00065123016],"about_ca_topic_score_codex":0.000010968302,"about_ca_topic_score_gemma":0.0000014560627,"teacher_disagreement_score":0.8851539,"about_ca_system_score_codex":0.00037279187,"about_ca_system_score_gemma":0.0009665257,"threshold_uncertainty_score":0.99953395},"labels":[],"label_agreement":null},{"id":"W2157921853","doi":"10.1093/infdis/jiu677","title":"Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis","year":2015,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Bill and Melinda Gates Foundation","keywords":"Randomized controlled trial; Medicine; HIV drug resistance; Human immunodeficiency virus (HIV); Drug; Dual (grammatical number); Drug resistance; Clinical trial; Intensive care medicine; Internal medicine; Pharmacology; Virology; Biology; Antiretroviral therapy; Viral load","score_opus":0.029139881067766087,"score_gpt":0.29924042291292197,"score_spread":0.27010054184515586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157921853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963943,0.0012243564,0.00019014817,0.0002485422,0.00042351964,0.0010968206,0.000019044322,0.0000215015,0.00038178876],"genre_scores_gemma":[0.9956159,0.00029007767,0.0003841911,0.00001450384,0.00031746025,0.000016949247,0.0000029543453,0.0000221407,0.003335795],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99604744,0.001441186,0.0015177894,0.00013157514,0.00069062255,0.00017136597],"domain_scores_gemma":[0.9952413,0.0016180498,0.0020298949,0.00028684046,0.00051902555,0.00030491987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038352015,0.00020366529,0.0012087219,0.00017202843,0.00008201954,0.000015026223,0.000121495985,0.00006578295,0.000034527962],"category_scores_gemma":[0.0063389195,0.0001002284,0.0005978133,0.00023930789,0.00047517332,0.0001154077,0.000046374953,0.00026152245,0.0000032095083],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7607113,0.0032140552,0.22166015,0.00014748996,0.0024471097,0.00011212829,0.0069506285,0.00010337112,0.00005590195,0.000009070709,0.004072979,0.00051580137],"study_design_scores_gemma":[0.9685726,0.0067626047,0.010052242,0.001355894,0.008006082,0.00013257905,0.002696637,0.000071711824,0.0015470918,0.00039251623,0.00016794923,0.00024208387],"about_ca_topic_score_codex":0.000020847056,"about_ca_topic_score_gemma":0.0000746996,"teacher_disagreement_score":0.21160792,"about_ca_system_score_codex":0.00012530005,"about_ca_system_score_gemma":0.0007186364,"threshold_uncertainty_score":0.75887364},"labels":[],"label_agreement":null},{"id":"W2158986060","doi":"10.1111/j.1468-1293.2009.00806.x","title":"High level of primary drug resistance in Mali","year":2010,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Primary (astronomy); Drug; Drug resistance; Resistance (ecology); Pharmacology; Genetics","score_opus":0.03052927863204607,"score_gpt":0.2662767119559609,"score_spread":0.23574743332391485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158986060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90029883,0.000688056,0.00007370428,0.056343213,0.00045574753,0.00045438114,0.000015978341,0.000047544254,0.041622534],"genre_scores_gemma":[0.8115999,0.00009325161,0.012665072,0.0005101173,0.00022013806,0.000024777568,0.00013636542,0.000021746044,0.17472863],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99869215,0.000021739297,0.00042967705,0.00023784838,0.00039390952,0.00022464427],"domain_scores_gemma":[0.9992418,0.0001026285,0.000099322846,0.00034940618,0.0000764015,0.00013039666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036555034,0.0001623259,0.00053293654,0.0002221518,0.00002460449,0.0000015258336,0.00009227783,0.00006755608,0.0007633487],"category_scores_gemma":[0.00013413822,0.00011473031,0.000038882154,0.0002932023,0.00018581611,0.000040077917,0.000028171551,0.00026640802,0.00006611354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013212559,0.0011995597,0.33045033,0.0010771761,0.0002375721,0.0011846671,0.008577291,4.7694886e-7,0.076772794,0.014965386,0.55595,0.008263467],"study_design_scores_gemma":[0.015437046,0.00009434359,0.7675186,0.0014975438,0.00019954573,0.000046495876,0.0003327604,0.0000066902453,0.014442166,0.0012324848,0.19890395,0.0002883748],"about_ca_topic_score_codex":0.00007525249,"about_ca_topic_score_gemma":0.00071487407,"teacher_disagreement_score":0.43706825,"about_ca_system_score_codex":0.00006662255,"about_ca_system_score_gemma":0.0001462007,"threshold_uncertainty_score":0.83581334},"labels":[],"label_agreement":null},{"id":"W2159036513","doi":"10.1128/aac.44.6.1609-1615.2000","title":"Absolute Bioavailability and Disposition of (−) and (+) 2′-Deoxy- 3′-Oxa-4′-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans","year":2000,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Pharmacokinetics; Chemistry; Bioavailability; Volume of distribution; Steady state (chemistry); Coefficient of variation; Pharmacology; Chromatography; Medicine","score_opus":0.01239263603357221,"score_gpt":0.255528225462565,"score_spread":0.24313558942899277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159036513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99810255,0.00032743125,0.000005284196,0.0009892801,0.000020342555,0.0004069405,0.00001583699,0.00001190969,0.00012040249],"genre_scores_gemma":[0.99484557,0.0035283999,0.0007127197,0.0002912641,0.000017547161,0.0000035228736,0.00002967906,0.000016739634,0.0005545607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909925,0.000025448408,0.0003186252,0.00028720387,0.00008952047,0.00017994738],"domain_scores_gemma":[0.99970275,0.000026606576,0.000071559974,0.00010933524,0.000020848636,0.00006889615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001324162,0.00018082962,0.00043613496,0.00008901991,0.000062643136,0.000018129915,0.000027674154,0.00008465427,0.000088794826],"category_scores_gemma":[0.000004743652,0.00015115974,0.000043478147,0.00010593311,0.0001783149,0.000087509514,0.000020067568,0.00006987919,7.6768697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014110116,0.0014603776,0.59207034,0.00051037356,0.00038188192,0.000053686632,0.0071206386,8.731847e-7,0.2895679,0.000018053475,0.0007297278,0.10667517],"study_design_scores_gemma":[0.014090673,0.0007620699,0.89661264,0.0008306248,0.00024394746,0.00007372606,0.00023306618,0.000101918085,0.0835327,0.000107789456,0.0030117077,0.00039915854],"about_ca_topic_score_codex":0.00019640458,"about_ca_topic_score_gemma":0.00008177874,"teacher_disagreement_score":0.3045423,"about_ca_system_score_codex":0.000028712457,"about_ca_system_score_gemma":0.000022207318,"threshold_uncertainty_score":0.6164115},"labels":[],"label_agreement":null},{"id":"W2159335869","doi":"10.1186/1742-4690-5-102","title":"Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication","year":2008,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Montreal Clinical Research Institute; Université de Montréal; University of Manitoba","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Manitoba Medical Service Foundation; Manitoba Health Research Council","keywords":"Integrase; Mutant; Saccharomyces cerevisiae; Biology; Chromatin; Complementation; Protein-fragment complementation assay; Viral replication; Chromatin remodeling; Cell biology; Genetics; Yeast; Molecular biology; DNA; Gene; Virus","score_opus":0.021889207087588163,"score_gpt":0.27078176072127835,"score_spread":0.2488925536336902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159335869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938571,0.000042502023,0.00022658549,0.0052264603,0.000045317716,0.00046272084,0.00001202277,0.000010398164,0.00011690183],"genre_scores_gemma":[0.9988022,0.000010754991,0.00026407774,0.0001230827,0.000027778136,0.000020495629,0.000052668118,0.0000068782633,0.000692066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991648,0.00008419421,0.00029425664,0.00019022197,0.00014607144,0.00012044361],"domain_scores_gemma":[0.9992181,0.000064521424,0.00022029088,0.00039024543,0.00006293103,0.000043923294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030767682,0.00009536299,0.00024434825,0.00006991587,0.00009088091,0.0000018801778,0.000085089996,0.000075915894,0.000004217143],"category_scores_gemma":[0.00025033133,0.000053036092,0.000049446655,0.00016072934,0.00029745017,0.000023876857,0.00006251378,0.00011761138,0.000007842795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008403752,0.00023462798,0.85594285,0.000085897926,0.00018453812,0.00013643659,0.00550271,0.0000033824103,0.12726116,0.0067500556,0.0020333277,0.0010246426],"study_design_scores_gemma":[0.003912351,0.0009159402,0.89718735,0.00026689953,0.00034134637,0.004501663,0.0006061383,0.00029098507,0.09018276,0.00080420554,0.0008083062,0.00018206531],"about_ca_topic_score_codex":0.000040828967,"about_ca_topic_score_gemma":0.000023556177,"teacher_disagreement_score":0.04124449,"about_ca_system_score_codex":0.00008651534,"about_ca_system_score_gemma":0.000076619006,"threshold_uncertainty_score":0.2162749},"labels":[],"label_agreement":null},{"id":"W2159463266","doi":"10.1093/jac/dkq260","title":"Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort","year":2010,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Northwest Regional Development Agency; National Institute for Health and Care Research","keywords":"Efavirenz; CYP2B6; Haplotype; Cohort; Human immunodeficiency virus (HIV); Medicine; Virology; Internal medicine; Antiretroviral therapy; Biology; Genetics; Genotype; Viral load; CYP3A4; Gene","score_opus":0.0027276437106622275,"score_gpt":0.21193092918706252,"score_spread":0.2092032854764003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159463266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949743,0.000015186477,0.000018593695,0.0045523145,0.00008840666,0.00018836732,0.000011387198,0.000005173666,0.00014623762],"genre_scores_gemma":[0.99432844,0.00014784434,0.004756297,0.00020282558,0.0000943215,3.2860473e-7,0.000012148214,0.000014962554,0.0004428571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925023,0.000016528307,0.00032682694,0.00009218654,0.0001903319,0.00012390486],"domain_scores_gemma":[0.9993273,0.000033202443,0.00035346785,0.000071230905,0.00015140497,0.00006340493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013615741,0.000112615904,0.00034069305,0.000118580734,0.000029264325,0.000015344565,0.000043984255,0.00010220818,0.000083001825],"category_scores_gemma":[0.000023759558,0.00007967111,0.00004739585,0.00013099775,0.000046181303,0.00008904809,0.000004472891,0.00029319772,0.0000010157306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003865143,0.0001434581,0.6436628,0.000012898665,0.00020499602,0.000015150562,0.00063539564,0.0000031253514,0.35289568,0.000017706772,0.0016491694,0.00037309268],"study_design_scores_gemma":[0.009491175,0.00022559779,0.5145631,0.00019774749,0.00014167355,0.0003629123,0.000054036867,0.0000375373,0.47191617,0.000019227136,0.002862444,0.000128402],"about_ca_topic_score_codex":0.000006078733,"about_ca_topic_score_gemma":0.000090429625,"teacher_disagreement_score":0.12909973,"about_ca_system_score_codex":0.0000668599,"about_ca_system_score_gemma":0.00018438831,"threshold_uncertainty_score":0.32488936},"labels":[],"label_agreement":null},{"id":"W2159511225","doi":"10.1016/j.bbmt.2009.09.003","title":"A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Plerixafor; Pharmacokinetics; Oncology; Pharmacology; Internal medicine; Urology","score_opus":0.011566491938282313,"score_gpt":0.26169094552900124,"score_spread":0.25012445359071894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159511225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990568,0.00024239265,0.000035429577,0.000087074855,0.000008390682,0.0004315463,0.000008792827,0.000005456717,0.00012410663],"genre_scores_gemma":[0.9986309,0.00031260663,0.0009646854,0.0000073471406,0.0000053468207,0.000010596603,0.00004446903,0.0000029924195,0.000021048509],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999464,0.000031868985,0.00023778729,0.00011393968,0.00006679405,0.00008562244],"domain_scores_gemma":[0.99979013,0.000028839886,0.0000850869,0.000044311688,0.000026639489,0.000025000414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007981129,0.00008164865,0.00025040156,0.00013747736,0.000010507014,5.6747217e-7,0.000020523978,0.00003202876,0.0000070379774],"category_scores_gemma":[0.0000015711548,0.000057603494,0.000017414264,0.00009447176,0.000036395464,0.000021217082,0.0000017455064,0.00003314006,7.9268496e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027439713,0.0021534865,0.46889868,0.00027775357,0.00026930083,0.00005778306,0.006008807,0.000028803792,0.51667064,0.000025066978,0.000002001961,0.0028636872],"study_design_scores_gemma":[0.022768285,0.008351034,0.6249436,0.00040248493,0.0011070773,0.00008752312,0.00040611648,0.00005183095,0.34175098,0.000024920419,0.0000026009207,0.00010356261],"about_ca_topic_score_codex":0.000045581586,"about_ca_topic_score_gemma":0.00006856681,"teacher_disagreement_score":0.1749197,"about_ca_system_score_codex":0.000003725182,"about_ca_system_score_gemma":0.000030425763,"threshold_uncertainty_score":0.23490024},"labels":[],"label_agreement":null},{"id":"W2159943759","doi":"10.1001/jama.283.4.492","title":"Nucleoside Analogs Plus Ritonavir in Stable Antiretroviral Therapy–Experienced HIV-Infected Children&lt;SUBTITLE&gt;A Randomized Controlled Trial&lt;/SUBTITLE&gt;","year":2000,"lang":"en","type":"article","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, University of North Carolina at Chapel Hill; National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; Abbott Laboratories; University of California, San Diego; University of North Carolina at Chapel Hill; National Institutes of Health; Bristol-Myers Squibb; York University; University of Pittsburgh; University of Minnesota; Harvard University; Bunning Food Allergy Institute, Ann and Robert H. Lurie Children's Hospital of Chicago; Children's Hospital of Philadelphia","keywords":"Medicine; Ritonavir; Regimen; Stavudine; Lamivudine; Zidovudine; Indinavir; Internal medicine; Didanosine; Randomized controlled trial; Protease inhibitor (pharmacology); Clinical trial; Nelfinavir; Viral load; Gastroenterology; Immunology; Viral disease; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virus","score_opus":0.007770306467116419,"score_gpt":0.2457569508733633,"score_spread":0.2379866444062469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159943759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595136,0.0012275688,0.000015031397,0.0014035063,0.00026834622,0.0063358434,0.000020828678,0.0002364521,0.030978808],"genre_scores_gemma":[0.9480749,0.0011710201,0.00045159555,0.00049493136,0.00038728703,0.0008640781,0.00031382326,0.00007798812,0.048164383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99611354,0.00046697774,0.0012124883,0.0006981011,0.0007293917,0.0007795123],"domain_scores_gemma":[0.998336,0.00042857404,0.00026726173,0.00056649017,0.00012984249,0.0002717852],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010011455,0.00058582745,0.002692514,0.00043254605,0.00017905704,0.00012873813,0.0002367252,0.00031907597,0.0069348295],"category_scores_gemma":[0.00038255926,0.00041529114,0.00065308943,0.00070377055,0.00021823027,0.00028735996,0.00004079038,0.00038396908,0.0009214066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9583383,0.0014147703,0.008413344,0.000015470472,0.0010886588,0.00027014274,0.0027368688,0.000016731477,0.0036335755,0.00021820384,0.0071832417,0.016670657],"study_design_scores_gemma":[0.9769351,0.0004414116,0.009486528,0.00013983707,0.0002524892,0.000028893894,0.00005480717,0.00093009573,0.0022531713,0.000064517466,0.0089498125,0.000463333],"about_ca_topic_score_codex":0.000224958,"about_ca_topic_score_gemma":0.00010075435,"teacher_disagreement_score":0.018596768,"about_ca_system_score_codex":0.0003344456,"about_ca_system_score_gemma":0.0004276168,"threshold_uncertainty_score":0.9998565},"labels":[],"label_agreement":null},{"id":"W2160398795","doi":"10.1093/ndt/gfm251","title":"An unusual case of acute kidney injury due to vancomycin lessons learnt from reliance on eGFR","year":2007,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Medicine; Renal function; Creatinine; Nephrotoxicity; Vancomycin; Acute kidney injury; Intensive care medicine; Context (archaeology); Kidney; Kidney disease; Population; Dosing; Internal medicine; Urology","score_opus":0.011893978548490131,"score_gpt":0.3093319593861022,"score_spread":0.2974379808376121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160398795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869821,0.000012227322,0.007309499,0.0042683897,0.00013785939,0.00035872616,0.00041621417,0.00007076666,0.00044420958],"genre_scores_gemma":[0.9896158,0.00013223139,0.0056374497,0.0024978728,0.00012509474,0.000030406321,0.0016367073,0.000024577113,0.0002998606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985175,0.00010292513,0.00044487126,0.00042780678,0.00021042042,0.0002964386],"domain_scores_gemma":[0.9990377,0.00013882064,0.0001129324,0.0003119823,0.00008423455,0.00031437556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028809588,0.00021595805,0.0004840391,0.00041388362,0.00009478459,0.0000068935356,0.000077639525,0.00019505728,0.000104871615],"category_scores_gemma":[0.00001752491,0.00019393773,0.00011237048,0.00042284306,0.00006112326,0.00009197181,0.0000053116228,0.00017301721,0.00010651097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037150867,0.0041423594,0.10995065,0.00022960271,0.0062871724,0.04900004,0.037719358,0.00024127503,0.62664443,0.0017180985,0.009330192,0.11758598],"study_design_scores_gemma":[0.011493002,0.0030831867,0.41003323,0.00025740988,0.008207614,0.0014521327,0.0004421696,0.00029973657,0.55600923,0.0003467943,0.007630592,0.00074492017],"about_ca_topic_score_codex":0.0003563395,"about_ca_topic_score_gemma":0.0008275055,"teacher_disagreement_score":0.30008256,"about_ca_system_score_codex":0.00008559965,"about_ca_system_score_gemma":0.00010793092,"threshold_uncertainty_score":0.7908551},"labels":[],"label_agreement":null},{"id":"W2160557134","doi":"10.1002/1099-1654(200007/08)10:4<217::aid-rmv279>3.0.co;2-l","title":"Clinical uses of non-nucleoside reverse transcriptase inhibitors","year":2000,"lang":"en","type":"review","venue":"Reviews in Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Virology; Medicine; Biology; Virus; RNA; Genetics; Antiretroviral therapy; Viral load; Gene","score_opus":0.07942076290952066,"score_gpt":0.4329437341303579,"score_spread":0.35352297122083726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160557134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000092087816,0.9940849,0.000009700109,0.0010644896,0.00057709747,0.0024997606,0.000020909936,0.00002726452,0.0016238024],"genre_scores_gemma":[0.0000037856566,0.9945685,0.0012099119,0.001312992,0.00045089828,0.00030479036,0.00024514968,0.000071783405,0.0018321386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914275,0.0016431188,0.004817392,0.0008716884,0.0006529464,0.0005873692],"domain_scores_gemma":[0.9970332,0.0007661803,0.0007125589,0.00081483484,0.00003081475,0.00064244267],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0035539926,0.00072205043,0.0086911125,0.00047373987,0.00003119392,0.000003691043,0.0004255368,0.0016449082,0.004532241],"category_scores_gemma":[0.0014823197,0.00047048175,0.0018850166,0.00066031225,0.00062642456,0.000040507093,0.00008491012,0.0017891147,0.0012505294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048872098,0.0007938773,0.0004711583,0.018675728,0.00025055362,0.001152296,0.00004999429,7.511227e-9,1.2814759e-7,0.000014443999,0.03243504,0.9461079],"study_design_scores_gemma":[0.0015925209,0.0002517496,0.00005698382,0.05718432,0.002150811,0.00030091772,0.000003679765,0.0000020904797,3.5640932e-7,0.000009905254,0.9381588,0.00028784646],"about_ca_topic_score_codex":0.000017270777,"about_ca_topic_score_gemma":0.00002449858,"teacher_disagreement_score":0.94582003,"about_ca_system_score_codex":0.00013365917,"about_ca_system_score_gemma":0.0011792269,"threshold_uncertainty_score":0.9997747},"labels":[],"label_agreement":null},{"id":"W2160889671","doi":"10.1128/aac.04274-14","title":"The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir","year":2014,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Integrase; Dolutegravir; Integrase inhibitor; Mutant; Virology; Recombinant DNA; Biology; Viral replication; Molecular biology; DNA; Enzyme; Mutation; Chemistry; Virus; Biochemistry; Human immunodeficiency virus (HIV); Viral load; Gene; Antiretroviral therapy","score_opus":0.010620104848997357,"score_gpt":0.22807988873755242,"score_spread":0.21745978388855505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160889671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829595,0.000039921913,0.00025513678,0.013773379,0.00008324126,0.00047151087,0.000010933657,0.000036393747,0.002369954],"genre_scores_gemma":[0.98261744,0.0012664482,0.00075238425,0.0034576613,0.000046172067,0.000014883195,0.0001240596,0.000027569033,0.0116933845],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989716,0.0000417268,0.00024041341,0.00029544558,0.00015159856,0.00029923845],"domain_scores_gemma":[0.9994919,0.000042709446,0.00008366566,0.00022515128,0.00006342103,0.000093184506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018463343,0.00023429097,0.00028980707,0.00006952392,0.00020207262,0.000058627476,0.00009065118,0.000078439036,0.000023414732],"category_scores_gemma":[0.000012629056,0.00013901437,0.000050930816,0.00017796013,0.00020438123,0.00006190649,0.000014004977,0.00014959827,0.000026525384],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02178845,0.0031685405,0.6411517,0.0004980801,0.0016046399,0.00040162946,0.005777729,0.0000155981,0.01744659,0.011131342,0.20201266,0.09500301],"study_design_scores_gemma":[0.043007858,0.0005952635,0.32728186,0.0019820542,0.0001958333,0.000037626036,0.00047868607,0.00045666168,0.027976453,0.0003242048,0.59652287,0.0011406454],"about_ca_topic_score_codex":0.000029126124,"about_ca_topic_score_gemma":0.0004132983,"teacher_disagreement_score":0.3945102,"about_ca_system_score_codex":0.00007420363,"about_ca_system_score_gemma":0.000086378204,"threshold_uncertainty_score":0.56688416},"labels":[],"label_agreement":null},{"id":"W2160907968","doi":"10.1093/jac/dks342","title":"In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor","year":2012,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Darunavir; Protease; Hydrogen bond; Chemistry; HIV-1 protease; In vitro; Human immunodeficiency virus (HIV); Biology; Virology; Biochemistry; Enzyme; Antiretroviral therapy; Molecule; Viral load","score_opus":0.016710118326424706,"score_gpt":0.28840270190332856,"score_spread":0.27169258357690385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160907968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995976,0.00031769162,0.000028229872,0.0029345062,0.00025005144,0.0004232716,0.000006157661,0.000003138897,0.000060985127],"genre_scores_gemma":[0.9954032,0.000057706773,0.0030491282,0.00035074318,0.0006696871,0.0000025950405,0.000019349241,0.000015636768,0.00043198466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988735,0.000072441515,0.0004575332,0.00009291202,0.00034045303,0.00016315983],"domain_scores_gemma":[0.9992729,0.000008714617,0.00031162388,0.000071930175,0.00023456209,0.00010031467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005905494,0.0001317302,0.00031328024,0.0002153928,0.000031454292,0.000015229037,0.00003478862,0.00007718132,0.00034272822],"category_scores_gemma":[0.000026000836,0.000102106635,0.000088554254,0.00010655071,0.000037446578,0.0003094292,0.000008548038,0.0001356502,0.0000042370416],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011518154,0.00024545827,0.0041133114,0.000038209306,0.000118037424,0.000011484522,0.0014272548,0.0000077292325,0.98547745,0.0000027088117,0.0034554186,0.0039511207],"study_design_scores_gemma":[0.00911549,0.00012533652,0.007314814,0.000085702544,0.00012980896,0.0005556984,0.000065598986,0.00031602473,0.98148566,0.000020995793,0.00068485556,0.00010000882],"about_ca_topic_score_codex":0.000004745931,"about_ca_topic_score_gemma":0.0000017904722,"teacher_disagreement_score":0.007963675,"about_ca_system_score_codex":0.00013120662,"about_ca_system_score_gemma":0.00023411102,"threshold_uncertainty_score":0.4163788},"labels":[],"label_agreement":null},{"id":"W2160992646","doi":"10.1128/aac.01387-08","title":"Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy","year":2009,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; University of California, Davis; U.S. Public Health Service; Bristol-Myers Squibb; University of Miami; York University; Gilead Sciences; Vanderbilt University; University of Southern California; GlaxoSmithKline; University of Texas Southwestern Medical Center; Pfizer; University of California, San Diego; Deutsches Krebsforschungszentrum; Abbott Laboratories","keywords":"Lopinavir; Ritonavir; Indinavir; Pharmacokinetics; Medicine; Protease inhibitor (pharmacology); Pharmacology; Viral load; Internal medicine; In vivo; Immunology; Gastroenterology; Virus; Biology; Antiretroviral therapy","score_opus":0.013797988769331686,"score_gpt":0.28551539131580644,"score_spread":0.27171740254647475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160992646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950379,0.000047823753,0.00005399422,0.0020686954,0.000079386075,0.002457542,0.0000252111,0.000074753996,0.00015466296],"genre_scores_gemma":[0.9966323,0.00029943208,0.00036970899,0.0020822827,0.000060396054,0.00003008957,0.000043931625,0.00003779881,0.0004440559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979044,0.00016884225,0.0005877698,0.00061322324,0.00029745398,0.00042827058],"domain_scores_gemma":[0.99917823,0.000053462987,0.0001657041,0.0003270066,0.00012572815,0.0001498555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003832991,0.00039205828,0.00056918664,0.00031759407,0.00015153836,0.000028077238,0.00012466499,0.00013677725,0.00010075455],"category_scores_gemma":[0.00003724307,0.00032912788,0.0001248757,0.0005327249,0.00009992921,0.00008872203,0.000025356516,0.00023824429,0.000008170942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016458727,0.0030054438,0.015545742,0.000042302592,0.00010356079,0.000022720069,0.0049506957,0.00003508616,0.94434005,0.0000065779814,0.00043997815,0.015049091],"study_design_scores_gemma":[0.009518661,0.001695704,0.31691945,0.00034301667,0.000030621464,0.000003056136,0.00007277509,0.000055566394,0.6706748,0.000019392723,0.00042629824,0.00024067692],"about_ca_topic_score_codex":0.00008726059,"about_ca_topic_score_gemma":0.000010642634,"teacher_disagreement_score":0.3013737,"about_ca_system_score_codex":0.00017803366,"about_ca_system_score_gemma":0.00013333085,"threshold_uncertainty_score":0.9999161},"labels":[],"label_agreement":null},{"id":"W2162208421","doi":"10.1093/cid/cis1203","title":"SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen","year":2013,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Clair College","funders":"","keywords":"Abacavir; Emtricitabine; Lamivudine; Medicine; Regimen; Internal medicine; Pharmacology; Clinical endpoint; Reverse-transcriptase inhibitor; Gastroenterology; Virology; Viral load; Randomized controlled trial; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy","score_opus":0.020992828216116016,"score_gpt":0.31672749933024247,"score_spread":0.29573467111412644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162208421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880761,0.00003134027,0.000029456378,0.0005088699,0.00015313528,0.0106003,0.000091976835,0.0001936281,0.00031521183],"genre_scores_gemma":[0.9980144,0.000008983433,0.00010093848,0.00055928144,0.00013230572,0.0008093244,0.00014657169,0.000053822794,0.0001743751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578094,0.0006204673,0.0014506623,0.0010520658,0.00056999846,0.0005258502],"domain_scores_gemma":[0.9966651,0.0013435237,0.00034382383,0.00046938052,0.0004112727,0.0007669034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004599315,0.0005071171,0.0013101219,0.0004231521,0.00014943676,0.00006829809,0.00013884241,0.00015576056,0.000086326836],"category_scores_gemma":[0.005755816,0.00038913754,0.0001771868,0.00069827284,0.000097207754,0.00019446938,0.0002974137,0.00045368684,0.00020408085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006098307,0.019541496,0.96528804,0.000029701714,0.00041558387,0.00007879389,0.0018568113,0.000028319439,0.00034284554,0.000009055964,0.00024749164,0.006063522],"study_design_scores_gemma":[0.027184466,0.01804319,0.9529508,0.00042310465,0.0004069378,7.201413e-7,0.00026446857,0.000103803846,0.00012241845,0.00009357918,0.000028397137,0.00037813897],"about_ca_topic_score_codex":0.0003017803,"about_ca_topic_score_gemma":0.000076369804,"teacher_disagreement_score":0.021086158,"about_ca_system_score_codex":0.0003161328,"about_ca_system_score_gemma":0.00024703285,"threshold_uncertainty_score":0.99985605},"labels":[],"label_agreement":null},{"id":"W2162326198","doi":"10.1517/14656566.2.2.303","title":"Pharmacology and clinical experience with saquinavir","year":2001,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria General Hospital; Ottawa Hospital","funders":"","keywords":"Saquinavir; Ritonavir; Medicine; Pharmacology; Nelfinavir; Protease inhibitor (pharmacology); Nucleoside Reverse Transcriptase Inhibitor; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.11299448764175786,"score_gpt":0.5016361084492189,"score_spread":0.38864162080746106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162326198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000074463765,0.993855,0.000027642649,0.001228,0.0014109056,0.0019451648,0.000011018343,0.00015883973,0.0012889755],"genre_scores_gemma":[0.0000059504173,0.9885856,0.0007384743,0.0027830834,0.0015591274,0.0007508888,0.00013788878,0.00014201677,0.0052969707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970128,0.00029620656,0.00084039144,0.0009777764,0.0003903642,0.00048246223],"domain_scores_gemma":[0.99853474,0.00028832388,0.00031100208,0.00035431513,0.000054047443,0.00045754315],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021248563,0.0007883251,0.0020783236,0.00027692306,0.00013654673,0.000031327556,0.0001948369,0.00032166997,0.0016426935],"category_scores_gemma":[0.0000065060235,0.00049612444,0.00037611823,0.00036975756,0.00025593687,0.00008219309,0.000040188246,0.0006090518,0.00020119594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005460718,0.0008798957,0.0001737049,0.00047452946,0.0010644819,0.00025315429,0.00047098522,2.2872657e-8,0.000006169448,0.00001845307,0.03499854,0.961114],"study_design_scores_gemma":[0.005581661,0.0007800022,0.00001096148,0.004303036,0.00016372718,0.00046497775,0.000041939573,0.000006162504,0.00006673447,0.0000011496145,0.9880628,0.00051684707],"about_ca_topic_score_codex":0.000004426093,"about_ca_topic_score_gemma":3.015641e-7,"teacher_disagreement_score":0.96059716,"about_ca_system_score_codex":0.00018231932,"about_ca_system_score_gemma":0.00033822496,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W2162386351","doi":"10.2174/187231210792928297","title":"Comparative Efflux of Saquinavir, Ritonavir and Lopinavir from Primary Human Cells","year":2010,"lang":"en","type":"article","venue":"Drug Metabolism Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; Statistics Canada","funders":"Ontario HIV Treatment Network; Abbott Laboratories","keywords":"Saquinavir; Ritonavir; Lopinavir; Pharmacology; Efflux; Chemistry; Drug; Peripheral blood mononuclear cell; Protease inhibitor (pharmacology); Virology; Biology; Biochemistry; Viral load; In vitro; Virus","score_opus":0.010036944363371037,"score_gpt":0.2564478154845611,"score_spread":0.24641087112119003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162386351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928419,0.00052778673,0.000024604067,0.003644529,0.00047610348,0.00051872,0.000063332795,0.00005802496,0.0018450174],"genre_scores_gemma":[0.9878168,0.00004979663,0.0077642417,0.0016284705,0.00033649904,0.00003927611,0.00026946113,0.000033667704,0.0020617573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984166,0.00007401432,0.00041045668,0.00042856156,0.0003684197,0.00030195067],"domain_scores_gemma":[0.9990591,0.00012465942,0.00016202684,0.00040401582,0.000057583773,0.00019261413],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017114251,0.00031840347,0.0008625766,0.00016235375,0.00011235952,0.000024020463,0.00013804341,0.00008573252,0.00016488832],"category_scores_gemma":[0.000007937896,0.00026459902,0.00012907965,0.00016049527,0.0003137598,0.00013661364,0.00008795609,0.0003981091,0.00008397127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007112052,0.00027600807,0.014718184,0.000060176393,0.00030947663,0.000050350256,0.0041878363,5.948418e-7,0.9668605,0.00027576697,0.011567439,0.001622581],"study_design_scores_gemma":[0.0044326927,0.000025417798,0.4269473,0.00010624467,0.00057787984,0.000014349263,0.00023442629,0.0000071128284,0.49174565,0.00012926519,0.07538477,0.0003949169],"about_ca_topic_score_codex":0.00017472163,"about_ca_topic_score_gemma":0.000029953406,"teacher_disagreement_score":0.47511482,"about_ca_system_score_codex":0.00002875252,"about_ca_system_score_gemma":0.00005223956,"threshold_uncertainty_score":0.9999806},"labels":[],"label_agreement":null},{"id":"W2162457674","doi":"10.1093/jac/dks455","title":"Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial","year":2012,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Vlaamse regering","keywords":"Enfuvirtide; Tropism; Maraviroc; Virology; Tissue tropism; Biology; Regimen; Medicine; Immunology; Internal medicine; Human immunodeficiency virus (HIV); Virus; Gp41","score_opus":0.006042812916100174,"score_gpt":0.23702116692554545,"score_spread":0.23097835400944527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162457674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970641,0.00013962277,0.000026043526,0.0021142708,0.0000998297,0.0004773565,0.0000036093718,0.0000033324009,0.0000718288],"genre_scores_gemma":[0.998415,0.0000897986,0.0010012898,0.0002568249,0.00015318257,0.0000026665982,0.000007869481,0.000015917016,0.000057474736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989266,0.00008313152,0.0004468269,0.00009891109,0.00023398579,0.00021055335],"domain_scores_gemma":[0.9993696,0.00004132936,0.00030286965,0.00010491386,0.00009510765,0.000086177315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030828605,0.00014201172,0.00037269792,0.0002212258,0.00002813592,0.000010433417,0.00007009513,0.00005106618,0.000009955228],"category_scores_gemma":[0.000045770277,0.000086943386,0.00007186289,0.00017289484,0.000065575754,0.00023863399,0.000010157893,0.00019584064,7.009473e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14485583,0.0025031306,0.8308926,0.000044260545,0.0001604745,0.000030377063,0.005609694,0.000007455443,0.010286118,0.000020022686,0.0007426665,0.0048473356],"study_design_scores_gemma":[0.120289184,0.00086615275,0.87269914,0.00053900166,0.000090047935,0.000024818923,0.0005126742,0.000011096506,0.004433199,0.000030289915,0.00035871833,0.00014567698],"about_ca_topic_score_codex":0.0000072390926,"about_ca_topic_score_gemma":0.000004913173,"teacher_disagreement_score":0.0418065,"about_ca_system_score_codex":0.00014868917,"about_ca_system_score_gemma":0.00012967056,"threshold_uncertainty_score":0.35454485},"labels":[],"label_agreement":null},{"id":"W2162598494","doi":"10.1093/cid/cis206","title":"Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011","year":2012,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; McGill University; Jewish General Hospital","funders":"Centers for Disease Control and Prevention; National Institutes of Health; U.S. President’s Emergency Plan for AIDS Relief; Center for AIDS Research, University of Washington; World Health Organization; Strong; Styrelsen för Internationellt Utvecklingssamarbete; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation","keywords":"HIV drug resistance; Medicine; Human immunodeficiency virus (HIV); Accreditation; General partnership; Drug resistance; Transmission (telecommunications); Family medicine; Antiretroviral therapy; Viral load; Medical education; Microbiology; Computer science; Telecommunications; Business","score_opus":0.03218233329459399,"score_gpt":0.38255265372934805,"score_spread":0.3503703204347541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162598494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561716,0.004936202,0.000863494,0.02525758,0.0009174173,0.001829894,0.000062361316,0.00059114635,0.009370336],"genre_scores_gemma":[0.95833045,0.00094955176,0.000322398,0.0011469336,0.00032792243,0.000035730798,0.0004025477,0.000032739088,0.038451727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984052,0.00022178344,0.0005269169,0.00031963893,0.00022287206,0.0003035886],"domain_scores_gemma":[0.998714,0.00020129496,0.00021110421,0.00024220384,0.00009287715,0.00053850544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039830842,0.00019076274,0.00038349853,0.00011510098,0.00018905688,0.000037379057,0.00003575741,0.000051078732,0.00051935314],"category_scores_gemma":[0.00014600619,0.00015753554,0.000088275105,0.00024081126,0.00007685912,0.00016709941,0.000032456264,0.00019661465,0.00029400527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004597976,0.0023918266,0.89697653,0.00008338605,0.00012941063,0.0000054991046,0.00003570689,0.0000014454606,6.2408014e-7,0.0020130277,0.09216744,0.006149112],"study_design_scores_gemma":[0.0021855035,0.0001368194,0.9606439,0.00019998505,0.00022864858,0.0000023970524,0.000031696847,0.000009795172,0.000016480626,0.00076430367,0.035610836,0.00016963993],"about_ca_topic_score_codex":0.0000031747363,"about_ca_topic_score_gemma":0.00011563615,"teacher_disagreement_score":0.06366735,"about_ca_system_score_codex":0.00020788594,"about_ca_system_score_gemma":0.00037486356,"threshold_uncertainty_score":0.6424113},"labels":[],"label_agreement":null},{"id":"W2162727299","doi":"10.1186/1758-2652-12-11","title":"Differences in resistance mutations among HIV‐1 non‐subtype B infections: a systematic review of evidence (1996–2008)","year":2009,"lang":"en","type":"review","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre; McGill University; Queen's University","funders":"National Aeronautics and Space Administration Postdoctoral Program","keywords":"Reverse transcriptase; Nelfinavir; Virology; Medicine; Drug resistance; Genotype; Genotyping; Mutation; Human immunodeficiency virus (HIV); Protease; Resistance mutation; Genetics; Biology; Polymerase chain reaction; Viral load; Antiretroviral therapy; Gene; Enzyme","score_opus":0.06727778033456412,"score_gpt":0.3535231972104745,"score_spread":0.2862454168759104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162727299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014045027,0.9958575,0.00005478914,0.002156742,0.00036039486,0.0011413377,0.00001570874,0.00000611589,0.00026700873],"genre_scores_gemma":[0.0006133659,0.98709154,0.0012784831,0.00017571337,0.00012469778,0.000068208945,0.000012505267,0.000016648524,0.0106188385],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963328,0.00022938114,0.0020647012,0.00018211608,0.0010478044,0.00014317578],"domain_scores_gemma":[0.99551964,0.0007290965,0.0027558473,0.00028735978,0.00063787564,0.000070165894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001307589,0.00029340028,0.0021927184,0.00020741341,0.000062069106,0.000028994242,0.0005885587,0.00013814787,0.000054284752],"category_scores_gemma":[0.0016645051,0.00014555399,0.0017694194,0.0006922426,0.00009860189,0.00020213843,0.00007015712,0.00059598556,0.000011866783],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018680494,0.0006709604,0.0075361896,0.9655685,0.0037652294,0.000048746635,0.0006809066,0.0000013883314,0.0000010405415,0.00008743887,0.017102566,0.0045183594],"study_design_scores_gemma":[0.00031552475,0.00006199245,0.0010562931,0.9784674,0.0035787618,0.00019239441,0.0000699875,0.000008545665,0.0000021530254,0.00008225054,0.016033676,0.00013099014],"about_ca_topic_score_codex":0.0000064143173,"about_ca_topic_score_gemma":0.000018312456,"teacher_disagreement_score":0.012898938,"about_ca_system_score_codex":0.000869855,"about_ca_system_score_gemma":0.00093680585,"threshold_uncertainty_score":0.59355193},"labels":[],"label_agreement":null},{"id":"W2162761942","doi":"10.1086/655681","title":"Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients","year":2010,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":558,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Renal function; Nephrotoxicity; Cochrane Library; Confidence interval; Meta-analysis; Internal medicine; Randomized controlled trial; Hypophosphatemia; Creatinine; Adverse effect; Relative risk; Kidney","score_opus":0.04352254162317223,"score_gpt":0.37872501134624253,"score_spread":0.33520246972307033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162761942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000663557,0.993397,0.000007656731,0.000080095066,0.000075695076,0.0055691996,0.00044233183,0.00008251874,0.00027915256],"genre_scores_gemma":[0.00022920492,0.9956994,0.000023357192,0.0001847174,0.000038874656,0.000997719,0.0014605647,0.00005794395,0.0013082058],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993313,0.001129053,0.0039746203,0.00082895986,0.00040544505,0.00034891002],"domain_scores_gemma":[0.9950623,0.001568914,0.0017038315,0.0009080892,0.00028079844,0.0004761001],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009014785,0.00076625805,0.014410597,0.0005735765,0.00006829412,0.000025319721,0.0001665619,0.0004612479,0.0002998133],"category_scores_gemma":[0.002404223,0.00045644882,0.00415045,0.0013926645,0.00024305831,0.00008127355,0.00014987067,0.000722497,0.00009699354],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019786463,0.0028072211,0.028264822,0.7932116,0.16912615,0.000044246146,0.000009361012,1.2296864e-7,3.2429026e-9,0.000022208573,0.0002511355,0.006243344],"study_design_scores_gemma":[0.0012020179,0.00016866613,0.004139154,0.08121481,0.89839363,0.000006804145,0.0000012016619,0.0000017154834,2.531001e-8,0.00001717662,0.014471718,0.00038310257],"about_ca_topic_score_codex":0.000007783537,"about_ca_topic_score_gemma":0.00005443732,"teacher_disagreement_score":0.7292675,"about_ca_system_score_codex":0.00010843231,"about_ca_system_score_gemma":0.00045970888,"threshold_uncertainty_score":0.9997887},"labels":[],"label_agreement":null},{"id":"W2162816563","doi":"10.1093/cid/cir938","title":"Transmitted HIV Drug Resistance Among Drug-Naive Subjects Recently Infected With HIV in Mexico City: A World Health Organization Survey to Classify Resistance and to Field Test Two Alternative Patient Enrollment Methods","year":2012,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Medicine; Voluntary counseling and testing; Drug resistance; HIV drug resistance; Family medicine; Human immunodeficiency virus (HIV); Informed consent; Internal medicine; Virology; Immunology; Viral load; Environmental health; Health facility; Health services; Alternative medicine; Pathology; Antiretroviral therapy; Population; Biology","score_opus":0.026329774339984926,"score_gpt":0.3606434810252987,"score_spread":0.3343137066853138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162816563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788826,0.00062808156,0.00387743,0.013100881,0.00026232438,0.0024191919,0.00011169658,0.00019632504,0.00052145164],"genre_scores_gemma":[0.9880894,0.00025565914,0.0031288012,0.0040568807,0.00011259253,0.00023926482,0.00023861465,0.00006492155,0.003813903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581736,0.0012989377,0.0010338579,0.0007731259,0.00041913695,0.00065756787],"domain_scores_gemma":[0.9937052,0.0038834682,0.00033071212,0.00041633766,0.0003954748,0.0012688148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011476272,0.000429841,0.00094609224,0.0004232082,0.00019773205,0.000060773178,0.00010234411,0.000075314,0.00007954388],"category_scores_gemma":[0.004125451,0.00035493218,0.000087478584,0.0020686358,0.00012264981,0.00019788172,0.00008826681,0.00037612364,0.000028549095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000820097,0.002383776,0.9742918,0.00009097929,0.00019240534,0.000029874065,0.002308145,0.000012381319,0.000003254509,0.00004347024,0.01804678,0.0017770331],"study_design_scores_gemma":[0.0044325767,0.0002774836,0.9884375,0.00088417483,0.00014778883,0.0000014284461,0.00012347719,0.000014936219,0.0006291249,0.000075961674,0.004580112,0.0003954384],"about_ca_topic_score_codex":0.00019083524,"about_ca_topic_score_gemma":0.028158816,"teacher_disagreement_score":0.02796798,"about_ca_system_score_codex":0.0005816696,"about_ca_system_score_gemma":0.0003966319,"threshold_uncertainty_score":0.99989027},"labels":[],"label_agreement":null},{"id":"W2163613858","doi":"10.1345/aph.1g423","title":"Advances in Human Immunodeficiency Virus Therapeutics","year":2006,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Emtricitabine; Tolerability; Adverse effect; Regimen; Lamivudine; Intensive care medicine; Darunavir; Zidovudine; Raltegravir; Clinical trial; Protease inhibitor (pharmacology); Human immunodeficiency virus (HIV); Pharmacology; Internal medicine; Antiretroviral therapy; Virology; Viral load; Virus; Viral disease","score_opus":0.14511968912446915,"score_gpt":0.4916037776663066,"score_spread":0.34648408854183743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163613858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000115491304,0.9927364,0.000006632086,0.00020682061,0.00010577943,0.00093789736,0.000039506816,0.00004144301,0.005810037],"genre_scores_gemma":[0.00007539065,0.9950995,0.0000996921,0.0003218754,0.00010204084,0.000108717424,0.0001733984,0.00008086274,0.003938544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977972,0.000116326024,0.0009631124,0.00037275132,0.000347896,0.0004027014],"domain_scores_gemma":[0.9990339,0.00007233069,0.00043367955,0.0003136432,0.00008580641,0.00006063857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002774965,0.0004995573,0.0018118726,0.00050012395,0.00005315374,0.000012034867,0.00023009037,0.0001726599,0.00029418134],"category_scores_gemma":[0.0000020834987,0.00036886067,0.000570619,0.00053221354,0.00009089112,0.000104333536,0.000019324581,0.0003089981,0.00004158268],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034583318,0.00093836774,0.00005794123,0.0036987392,0.00031588122,0.000047479887,0.00011495691,6.498511e-7,0.0005565678,0.00008036462,0.0011252605,0.99302924],"study_design_scores_gemma":[0.0011120314,0.00010813375,0.0000083338255,0.004623911,0.00034165755,0.000012010966,0.000005814039,0.000001617294,0.0035518021,0.000081970145,0.9898508,0.0003018831],"about_ca_topic_score_codex":0.000025973599,"about_ca_topic_score_gemma":0.0000081116905,"teacher_disagreement_score":0.99272734,"about_ca_system_score_codex":0.000057229216,"about_ca_system_score_gemma":0.00022890801,"threshold_uncertainty_score":0.9998763},"labels":[],"label_agreement":null},{"id":"W2163970712","doi":"10.1128/aac.00870-06","title":"Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors","year":2006,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Nelfinavir; Amprenavir; Indinavir; Biology; Virology; Protease; Protease inhibitor (pharmacology); Drug resistance; Virus; Genotype; Wild type; Lentivirus; Context (archaeology); Resistance mutation; Genetics; Mutant; Gene; HIV-1 protease; Viral load; Viral disease; Reverse transcriptase; Sida; Polymerase chain reaction; Enzyme","score_opus":0.010547362006515642,"score_gpt":0.24821972120229616,"score_spread":0.2376723591957805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163970712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989038,0.000048083763,0.0000042306665,0.00876906,0.000034393626,0.0015971506,0.000009373457,0.000018936129,0.0004807536],"genre_scores_gemma":[0.98197,0.000008709682,0.001584257,0.0033602386,0.00004577094,0.000055368833,0.000057241527,0.000024144669,0.012894282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877846,0.000029924866,0.00038480625,0.00029735643,0.00021713236,0.00029231582],"domain_scores_gemma":[0.9995822,0.0000068883646,0.000080516555,0.00019609452,0.00006476613,0.0000695809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017005528,0.00021967595,0.00027383168,0.00014808039,0.00016647887,0.000036594192,0.00013279704,0.00004931414,0.00011372545],"category_scores_gemma":[0.000005984766,0.00015109695,0.000043271535,0.00041870167,0.000041592542,0.000038924893,0.00003442169,0.000099013065,0.000046188212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008667889,0.0014518404,0.020589978,0.00008164664,0.00008726701,0.000077769204,0.008466549,0.000002911355,0.9012751,0.000022479771,0.062255833,0.0048218407],"study_design_scores_gemma":[0.003702095,0.00016395288,0.21595375,0.00049360393,0.000033390457,0.000013656324,0.00009723069,0.0000046527143,0.6903737,0.00001940291,0.088674925,0.0004696071],"about_ca_topic_score_codex":0.00016819507,"about_ca_topic_score_gemma":0.00012401488,"teacher_disagreement_score":0.21090136,"about_ca_system_score_codex":0.00008732739,"about_ca_system_score_gemma":0.00013357672,"threshold_uncertainty_score":0.61615545},"labels":[],"label_agreement":null},{"id":"W2164174571","doi":"10.1345/aph.1m489","title":"Atazanavir-Associated Choledocholithiasis Leading to Acute Hepatitis in an HIV-infected Adult","year":2009,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Dalhousie University","funders":"","keywords":"Atazanavir; Medicine; Gallstones; Gastroenterology; Bilirubin; Internal medicine; Surgery; Human immunodeficiency virus (HIV); Immunology; Viral load; Antiretroviral therapy","score_opus":0.04118667118701082,"score_gpt":0.39802869859577417,"score_spread":0.35684202740876336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164174571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830271,0.00016529321,0.000022950007,0.015013817,0.000057271416,0.0005662908,0.00005366988,0.00010163561,0.0009919602],"genre_scores_gemma":[0.9827977,0.0016847367,0.0005812184,0.0114458315,0.000075800366,0.00003245696,0.00016345707,0.000031691052,0.0031871072],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839336,0.00008548141,0.00043377606,0.0003336413,0.0003159681,0.00043779012],"domain_scores_gemma":[0.9990592,0.000029526302,0.000118006996,0.00022166142,0.00028458997,0.00028701947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020742942,0.00024813757,0.0005101328,0.0003827517,0.00004878014,0.000019845476,0.0001304172,0.00008377802,0.00030490645],"category_scores_gemma":[0.000032189928,0.00022786493,0.00012693452,0.0006903828,0.000021960705,0.00022324562,0.000009481175,0.00016258551,0.00009671387],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010963097,0.0027441285,0.5305743,0.000019697218,0.0007870527,0.00025777076,0.0058738957,0.000013766708,0.35662094,0.00010700147,0.042260952,0.059644178],"study_design_scores_gemma":[0.009680462,0.0011971861,0.37235993,0.00038017213,0.00014494403,0.000009942304,0.00005455736,0.0002663933,0.60711133,0.00009509787,0.008236365,0.00046358127],"about_ca_topic_score_codex":0.00008093306,"about_ca_topic_score_gemma":0.00006899731,"teacher_disagreement_score":0.25049043,"about_ca_system_score_codex":0.00007438199,"about_ca_system_score_gemma":0.00006968328,"threshold_uncertainty_score":0.9292062},"labels":[],"label_agreement":null},{"id":"W2164189282","doi":"10.1124/dmd.114.062315","title":"Polyinosinic/Polycytidylic Acid–Mediated Changes in Maternal and Fetal Disposition of Lopinavir in Rats","year":2015,"lang":"en","type":"article","venue":"Drug Metabolism and Disposition","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Lopinavir; Placenta; Pharmacokinetics; Pharmacology; Gestation; Fetus; Transporter; Chemistry; Endocrinology; Fetal membrane; Internal medicine; Andrology; Medicine; Pregnancy; Biology; Immunology; Biochemistry; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.012679871804323381,"score_gpt":0.25294579774341636,"score_spread":0.24026592593909296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164189282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929496,0.0045631225,0.00001784349,0.0016299665,0.00011573521,0.00037516502,0.000040128976,0.000020749818,0.00028770597],"genre_scores_gemma":[0.998033,0.0008549711,0.0002864353,0.00010925524,0.00006540819,0.00004542937,0.00028946658,0.000014198393,0.0003018352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989499,0.00007663908,0.0002845969,0.00025140544,0.00022134143,0.00021613929],"domain_scores_gemma":[0.99957806,0.00002311222,0.00008492456,0.000106274194,0.00003866347,0.00016895878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021892371,0.0001814258,0.00039267138,0.0003434909,0.0000283146,0.000020418927,0.00003236344,0.00007806131,0.000011011549],"category_scores_gemma":[0.000018338023,0.00015225919,0.0000276554,0.00024940353,0.00007682123,0.00019605402,0.000038226077,0.000099263816,0.0000076056062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031943123,0.0011157471,0.8503617,0.0004138131,0.00013160748,0.00036544583,0.01181802,0.0000022455915,0.087928735,0.0017913231,0.00033231042,0.042544745],"study_design_scores_gemma":[0.005544207,0.00007155947,0.9360627,0.00032279675,0.00011603648,0.000056852703,0.00050759764,0.00020292049,0.05640814,0.00023509157,0.00029335258,0.00017874863],"about_ca_topic_score_codex":0.00024910833,"about_ca_topic_score_gemma":0.0003021909,"teacher_disagreement_score":0.085700996,"about_ca_system_score_codex":0.00005543094,"about_ca_system_score_gemma":0.000052925592,"threshold_uncertainty_score":0.62089497},"labels":[],"label_agreement":null},{"id":"W2164233023","doi":"10.1111/j.1468-1293.2008.00552.x","title":"Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts<sup>*</sup>","year":2008,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Nevirapine; Medicine; Confidence interval; Hazard ratio; Odds ratio; Internal medicine; Antiretroviral therapy; Rash; Clinical endpoint; Gastroenterology; Randomized controlled trial; Human immunodeficiency virus (HIV); Immunology; Viral load","score_opus":0.04850864254294756,"score_gpt":0.3059052452783625,"score_spread":0.2573966027354149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164233023","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060077514,0.98238206,0.000028285423,0.00023545542,0.00010311572,0.0018909691,0.000050778992,0.000039565257,0.009262042],"genre_scores_gemma":[0.0036065215,0.9920555,0.00047613,0.0003459783,0.00012572932,0.00008718129,0.0004921766,0.000047563888,0.0027632318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774605,0.00009718278,0.0008587182,0.0004901864,0.000474385,0.00033349937],"domain_scores_gemma":[0.9989385,0.00016833303,0.0002188704,0.00033687023,0.000084591346,0.00025284544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018674851,0.00046147493,0.002206683,0.00045801318,0.000037488782,0.0000034296058,0.00013920465,0.00026608363,0.00044455525],"category_scores_gemma":[0.00016722488,0.00029721454,0.0001376951,0.0004346364,0.000117841104,0.00003213149,0.00010181173,0.0003301649,0.0001495942],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040951354,0.002568702,0.09351142,0.030654984,0.0009370746,0.0012955099,0.0039951038,0.000003086424,0.000026174004,0.00007338215,0.17632112,0.69020396],"study_design_scores_gemma":[0.0029788264,0.0003208609,0.0016090755,0.006711822,0.00047948954,0.00004419083,0.000065568536,0.000020340614,0.0000071942595,0.000005341045,0.9874869,0.0002703693],"about_ca_topic_score_codex":0.000008509005,"about_ca_topic_score_gemma":5.296249e-7,"teacher_disagreement_score":0.8111658,"about_ca_system_score_codex":0.00013116763,"about_ca_system_score_gemma":0.00015667593,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W2164320488","doi":"10.2174/138161207780162845","title":"Nucleoside Transport as a Potential Target for Chemotherapy in Malaria","year":2007,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Canadian Institutes of Health Research; Canada Research Chairs; Wellcome Trust","keywords":"Malaria; Plasmodium falciparum; Nucleoside transporter; Inosine; Hypoxanthine; Biology; Purine; Nucleoside; Nucleotide salvage; Transporter; Plasmodium vivax; Adenosine; Virology; Biochemistry; Gene; Nucleotide; Immunology; Enzyme","score_opus":0.18769124856270938,"score_gpt":0.4677304823084273,"score_spread":0.28003923374571793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164320488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006475529,0.9658532,0.025587898,0.00049976696,0.0008124162,0.006682526,0.00005767306,0.000114873146,0.00038513],"genre_scores_gemma":[0.000049188282,0.98673755,0.009234878,0.00017259864,0.0004893421,0.0007643766,0.0007400626,0.00013620633,0.0016758089],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964177,0.00014894432,0.0011677161,0.0008438805,0.00050441275,0.0009173284],"domain_scores_gemma":[0.9986006,0.00027663485,0.00017842036,0.00030950236,0.000081001,0.00055383466],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008958371,0.00082297385,0.0022370445,0.000507055,0.00007182636,0.000024998975,0.00024363557,0.00044227994,0.00092678657],"category_scores_gemma":[0.000046090296,0.000650199,0.00095249084,0.0004977645,0.00009941632,0.000070522896,0.000023026905,0.000869124,0.00036724913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068696676,0.0015198635,0.000026952304,0.011461123,0.0005136635,0.00038671945,0.00006236802,7.986317e-7,0.0000036396684,0.00031696615,0.0032990207,0.98172194],"study_design_scores_gemma":[0.0053663617,0.00018205485,0.00001665666,0.007117072,0.0024117432,0.0001300637,0.0000037446998,0.00019063218,0.000099930985,0.0001408004,0.9837601,0.00058084016],"about_ca_topic_score_codex":8.209443e-7,"about_ca_topic_score_gemma":2.035877e-7,"teacher_disagreement_score":0.9811411,"about_ca_system_score_codex":0.00041704107,"about_ca_system_score_gemma":0.00090422196,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W2164396803","doi":"10.1002/chem.200802172","title":"Synthesis of a Phosphonate‐Linked Aminoglycoside–Coenzyme A Bisubstrate and Use in Mechanistic Studies of an Enzyme Involved in Aminoglycoside Resistance","year":2009,"lang":"en","type":"article","venue":"Chemistry - A European Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Aminoglycoside; Phosphonate; Chemistry; Enzyme; Biochemistry; Antibiotics","score_opus":0.033545259539921796,"score_gpt":0.2681652152969553,"score_spread":0.2346199557570335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164396803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698925,0.0021363855,0.000018283179,0.00027137215,0.000022940183,0.00017006141,0.000011097453,0.000017806851,0.0003628131],"genre_scores_gemma":[0.99386394,0.0009877431,0.003995946,0.00004366885,0.000038038284,0.0000053970916,0.000008621002,0.000029866053,0.0010267693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978544,0.00015507684,0.0010004719,0.00034334388,0.00031405172,0.00033267235],"domain_scores_gemma":[0.99872845,0.00017640145,0.0004233301,0.0002822926,0.00017300878,0.00021654017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081232464,0.00029826452,0.00072574755,0.00018303018,0.00005424402,0.00002968926,0.00015622877,0.000054635475,0.00003112012],"category_scores_gemma":[0.0006126138,0.00025746014,0.000085610736,0.0003270404,0.00014835745,0.00016043834,0.000040750845,0.00035824286,0.0000026346722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026595208,0.0016744817,0.021326121,0.00089058134,0.0004203545,0.01212738,0.0049367766,0.000017674538,0.9509766,0.000044329874,0.00067707355,0.004249087],"study_design_scores_gemma":[0.006355743,0.00028458264,0.122680105,0.0045398427,0.00026896357,0.0004831303,0.0028060286,0.00027529473,0.8613101,0.00038715347,0.0001730822,0.00043596327],"about_ca_topic_score_codex":0.0000060402454,"about_ca_topic_score_gemma":0.000051035637,"teacher_disagreement_score":0.10135399,"about_ca_system_score_codex":0.00016616545,"about_ca_system_score_gemma":0.00013568877,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W2164903312","doi":"10.1128/aac.45.10.2733-2739.2001","title":"Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults","year":2001,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"National Institutes of Health; National Center for Research Resources; National Institute of Mental Health; Johns Hopkins University; University of Washington; Gilead Sciences","keywords":"Pharmacokinetics; Medicine; Placebo; Adverse effect; Dosing; Reverse-transcriptase inhibitor; Pharmacology; Discontinuation; Internal medicine; Virus; Gastroenterology; Sida; Virology; Viral disease; Pathology","score_opus":0.011411558386447253,"score_gpt":0.2844821790997805,"score_spread":0.27307062071333327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164903312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759305,0.000047723486,0.000007988462,0.0010795699,0.00008414844,0.0008046601,0.00003235987,0.00001238928,0.00033812743],"genre_scores_gemma":[0.99561834,0.0030058033,0.000035083285,0.00023477952,0.000033391665,0.000004099933,0.000020981526,0.000018777848,0.0010287121],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989389,0.000046131478,0.0003847798,0.00025523375,0.00015483427,0.00022011889],"domain_scores_gemma":[0.99951637,0.000014146819,0.00019474067,0.00018592669,0.000043909007,0.000044906337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001302167,0.00020504289,0.00043748892,0.00009878861,0.00013327524,0.000009893709,0.00008447617,0.000073710464,0.00008045945],"category_scores_gemma":[0.000007099103,0.00013957774,0.000092508955,0.0002532369,0.00020531724,0.000069107424,0.00006760947,0.00012024616,5.777375e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047419228,0.011054323,0.090423524,0.00014141807,0.00024408412,0.00001983368,0.0023023612,7.821333e-7,0.7698993,0.000018346947,0.00059716124,0.07787965],"study_design_scores_gemma":[0.335844,0.0043055955,0.19010004,0.00046265614,0.00018811328,0.000030149846,0.000057620447,0.00022923715,0.463224,0.000018735416,0.005163785,0.0003760552],"about_ca_topic_score_codex":0.00023073316,"about_ca_topic_score_gemma":0.000025025425,"teacher_disagreement_score":0.3066753,"about_ca_system_score_codex":0.000027524591,"about_ca_system_score_gemma":0.000043295593,"threshold_uncertainty_score":0.5691815},"labels":[],"label_agreement":null},{"id":"W2165286507","doi":"10.1002/poc.1269","title":"Acid catalyzed intramolecular attack of <i>β</i>‐phenylthioureido group on amide function. Parallel formation of thiodihydrouracil and 4‐iminothiodihydrouracil. Different pathways in the Edman degradation reaction in the formation of six‐ <i>versus</i> five‐membered cyclic intermediates","year":2007,"lang":"en","type":"article","venue":"Journal of Physical Organic Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University; National Science Foundation","keywords":"Chemistry; Amide; Protonation; Reaction rate constant; Imine; Intramolecular force; Medicinal chemistry; Hydrolysis; Cyclopentane; Stereochemistry; Ring strain; Tetrahedral carbonyl addition compound; Catalysis; Ring (chemistry); Nucleophile; Organic chemistry; Kinetics","score_opus":0.015230917244048507,"score_gpt":0.2421350048073254,"score_spread":0.22690408756327687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165286507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998189,0.000077172765,0.0005793296,0.0006282326,0.000044467455,0.00027103157,0.000006243827,0.0000049087243,0.00019962098],"genre_scores_gemma":[0.9995394,0.00009989012,0.00007284535,0.00004735224,0.0000972701,0.0000061815517,0.0001159474,0.000010558488,0.000010594356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802774,0.00008743361,0.00093075266,0.00012822099,0.00065132824,0.0001745193],"domain_scores_gemma":[0.9980449,0.0004022998,0.001151433,0.00021044396,0.00013464614,0.00005627327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065421645,0.00020271268,0.00046550247,0.00011191726,0.000039144794,0.000012830163,0.00015680706,0.00010704461,0.000007362883],"category_scores_gemma":[0.00022862449,0.00012118574,0.00015573166,0.00030232736,0.00008230244,0.00029951095,0.000025476398,0.00043675303,0.0000011446962],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017998846,0.0012392219,0.00082369323,0.00038116067,0.00008431412,0.000018344,0.008985357,0.000018435438,0.98374957,0.0000489408,0.00008647005,0.002764626],"study_design_scores_gemma":[0.0059469016,0.000572194,0.01629736,0.00046927546,0.00030123937,0.0000967907,0.00693564,0.0006618876,0.96832526,0.00022408439,0.000036252182,0.00013310395],"about_ca_topic_score_codex":0.0000079153515,"about_ca_topic_score_gemma":0.00003730587,"teacher_disagreement_score":0.0154736675,"about_ca_system_score_codex":0.00019801657,"about_ca_system_score_gemma":0.000048057947,"threshold_uncertainty_score":0.4941811},"labels":[],"label_agreement":null},{"id":"W2165344326","doi":"10.1258/095646204322916614","title":"High resistance to antiretroviral drugs: the Indian experience","year":2004,"lang":"en","type":"article","venue":"International Journal of STD & AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug resistance; HIV drug resistance; Acquired resistance; Human immunodeficiency virus (HIV); Internal medicine; Antiretroviral therapy; Virology; Viral load; Biology; Microbiology; Cancer","score_opus":0.008349331459919038,"score_gpt":0.2822342153960939,"score_spread":0.2738848839361748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165344326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786504,0.00014642229,0.00040519543,0.018840475,0.0007696182,0.00010184818,0.0000059308677,0.000009631466,0.0010705079],"genre_scores_gemma":[0.9852081,0.00005414633,0.0077304514,0.0011358463,0.0004691296,0.0000058588353,0.0000038861126,0.000010332169,0.0053822338],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985426,0.000017109607,0.0003713246,0.00011145749,0.00081156084,0.00014596272],"domain_scores_gemma":[0.9991961,0.00003837953,0.0001648773,0.0001194556,0.0003504689,0.00013067997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019801647,0.00010977428,0.00017774348,0.000207044,0.00005899549,0.00005090181,0.00033438846,0.000029962473,0.000109952576],"category_scores_gemma":[0.00010323179,0.00006789291,0.00010845918,0.00017167813,0.000059242484,0.00016797808,0.00004544859,0.00016755033,0.0000693109],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008085225,0.0031234513,0.45359308,0.0000754409,0.0052872277,0.0150106205,0.23586838,0.0005897548,0.017108534,0.06338391,0.034908436,0.16296595],"study_design_scores_gemma":[0.035062764,0.006070201,0.3463161,0.005088986,0.00054811116,0.0038937181,0.034025654,0.000006142189,0.18175869,0.0149298925,0.3708857,0.0014140407],"about_ca_topic_score_codex":0.000023801733,"about_ca_topic_score_gemma":0.000011300931,"teacher_disagreement_score":0.33597726,"about_ca_system_score_codex":0.000332429,"about_ca_system_score_gemma":0.0002075117,"threshold_uncertainty_score":0.27685922},"labels":[],"label_agreement":null},{"id":"W2165346130","doi":"10.1371/journal.pone.0021189","title":"Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; Center for AIDS Research, University of Washington; University of California, San Diego; National Institutes of Health; Canadian Institutes of Health Research; National Center for Research Resources; ACT Government","keywords":"Viral load; Drug resistance; Medicine; Cohort; Pharmacotherapy; HIV drug resistance; Cohort study; Drug; Antiretroviral therapy; Internal medicine; Virology; Human immunodeficiency virus (HIV); Biology; Pharmacology; Genetics","score_opus":0.03359453330329354,"score_gpt":0.2570381605532174,"score_spread":0.22344362724992384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165346130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905932,0.0065627582,0.000006666475,0.00037393006,0.000028720193,0.0015892385,0.0000043506125,0.00002473709,0.0008164216],"genre_scores_gemma":[0.9925704,0.0034326215,0.00090487255,0.00013680963,0.000048733407,0.00011822174,0.00000817698,0.0000135049795,0.0027666867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985766,0.00029633415,0.0003725483,0.00026465516,0.00031420423,0.00017569195],"domain_scores_gemma":[0.9991855,0.0003646025,0.00009174989,0.00022894505,0.00006343006,0.00006577746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007764228,0.0001534865,0.00045721608,0.000031580734,0.000035113582,0.000008490411,0.00007400235,0.000073953415,0.000008611453],"category_scores_gemma":[0.00006758713,0.00009230935,0.00003189263,0.00015420887,0.000110332636,0.000034868823,0.000008439321,0.0001956577,0.0000034505415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002144587,0.0019085002,0.9882418,0.00085119717,0.00054397184,0.000056316036,0.004231509,7.900449e-8,0.00020346232,0.0001614773,0.00057538156,0.0010817129],"study_design_scores_gemma":[0.0043897675,0.000623793,0.9864118,0.0043273736,0.00037169136,0.0000028853378,0.00005555202,0.00010249658,0.0031545667,0.00014041095,0.00027584116,0.00014382911],"about_ca_topic_score_codex":0.000036529644,"about_ca_topic_score_gemma":0.000053401825,"teacher_disagreement_score":0.004175957,"about_ca_system_score_codex":0.000035111017,"about_ca_system_score_gemma":0.00006275928,"threshold_uncertainty_score":0.37642658},"labels":[],"label_agreement":null},{"id":"W2165657451","doi":"10.1086/315243","title":"Human Immunodeficiency Virus–Infected Persons with Mutations Conferring Resistance to Zidovudine Show Reduced Virologic Responses to Hydroxyurea and Stavudine‐Lamivudine","year":2000,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; AIDS Vancouver","funders":"","keywords":"Stavudine; Lamivudine; Zidovudine; Didanosine; Virology; Internal medicine; Odds ratio; Medicine; Confidence interval; Viral disease; Immunology; Gastroenterology; Virus; Hepatitis B virus","score_opus":0.01151590962245981,"score_gpt":0.26625590049409253,"score_spread":0.25473999087163274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165657451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992617,0.00070231286,0.00006916007,0.0042851116,0.000035425855,0.0005445467,0.00003741198,0.000076467186,0.0016325683],"genre_scores_gemma":[0.9928851,0.00013969961,0.00019395139,0.00041454338,0.000078582416,0.000026269205,0.000009183907,0.000030233497,0.006222441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985064,0.00016205586,0.00043257303,0.00020456636,0.00037555667,0.0003188386],"domain_scores_gemma":[0.99876,0.00021268845,0.00017951493,0.00026886704,0.00023987159,0.00033908372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003016147,0.00027065756,0.0004467272,0.00037437544,0.0005287095,0.000058020498,0.00012247564,0.000041210835,0.0003560837],"category_scores_gemma":[0.00023881819,0.00016290505,0.00009355285,0.0005809505,0.00014385411,0.00013422049,0.00003284321,0.00020308288,0.00002794251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02000707,0.006165237,0.666837,0.00029676902,0.0039292607,0.0014887955,0.022793353,0.004532147,0.24987812,0.0004594079,0.017516846,0.0060959896],"study_design_scores_gemma":[0.0060592773,0.0038605498,0.97742426,0.0007373675,0.0018917063,0.0009800725,0.0009343896,0.000027813316,0.003976546,0.00022347826,0.0033790146,0.00050549535],"about_ca_topic_score_codex":0.000029123805,"about_ca_topic_score_gemma":0.00012442579,"teacher_disagreement_score":0.3105873,"about_ca_system_score_codex":0.00018443231,"about_ca_system_score_gemma":0.0002077133,"threshold_uncertainty_score":0.66430753},"labels":[],"label_agreement":null},{"id":"W2165910865","doi":"10.1128/aac.00096-10","title":"Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors","year":2010,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; McGill University Health Centre; Institut National de Santé Publique du Québec; Centre Hospitalier de l’Université de Montréal","funders":"U.S. Food and Drug Administration","keywords":"Darunavir; Phenotype; Genotype; Biology; Drug resistance; Virology; Microbiology; Genetics; Viral load; Gene; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.020689091335193595,"score_gpt":0.30849141711826616,"score_spread":0.2878023257830726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165910865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684256,0.00011826176,0.00014671567,0.0014620727,0.0001280844,0.0010364775,0.0001269926,0.000047314596,0.00009149012],"genre_scores_gemma":[0.9890539,0.00040784752,0.0068638893,0.002118621,0.00017443454,0.000017702656,0.000065336266,0.000065408385,0.0012328603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973301,0.00010526765,0.00094720157,0.0009004143,0.00031115126,0.00040583956],"domain_scores_gemma":[0.99857754,0.00007131959,0.00036122216,0.0004568198,0.00013600707,0.000397086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006733234,0.0004076763,0.0009653481,0.00028377495,0.00021744928,0.000086660526,0.00012801167,0.00024928435,0.000077329576],"category_scores_gemma":[0.00004372482,0.0003456949,0.00013570637,0.00034962507,0.00021160491,0.00018318964,0.00008271026,0.00033226554,0.0000015611569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028904288,0.00052187766,0.9174313,0.00012656403,0.0020881076,0.000027069273,0.002061528,0.0000020049297,0.0718108,0.00007259704,0.00041324168,0.0025544744],"study_design_scores_gemma":[0.004462111,0.00025260673,0.9754003,0.00037470515,0.0017018582,0.0000074194277,0.00021097815,0.0002748715,0.009044086,0.00003576445,0.007712792,0.00052247185],"about_ca_topic_score_codex":0.00028431552,"about_ca_topic_score_gemma":0.0021475428,"teacher_disagreement_score":0.062766716,"about_ca_system_score_codex":0.000040674782,"about_ca_system_score_gemma":0.00009635586,"threshold_uncertainty_score":0.9998995},"labels":[],"label_agreement":null},{"id":"W2166026801","doi":"10.1007/s11538-013-9903-9","title":"Resistance to Protease Inhibitors in a Model of HIV-1 Infection with Impulsive Drug Effects","year":2013,"lang":"en","type":"article","venue":"Bulletin of Mathematical Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Drug; Drug resistance; Protease; Dosing; HIV-1 protease; Protease inhibitor (pharmacology); Virus; Pharmacology; Biology; Virology; Enzyme; Viral load; Antiretroviral therapy; Microbiology; Biochemistry","score_opus":0.0061771458076735645,"score_gpt":0.23048798861032885,"score_spread":0.22431084280265529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166026801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850702,0.00003130111,0.0015661496,0.008111706,0.000010021922,0.0017993387,0.0000029294636,0.000018556075,0.0033897446],"genre_scores_gemma":[0.9542821,0.0000044951616,0.039489187,0.000100038,0.000011378965,0.00042530696,0.000007773859,0.000012115101,0.005667609],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914575,0.000059615904,0.00033566082,0.00018375157,0.00010105965,0.00017415627],"domain_scores_gemma":[0.9993731,0.00018991923,0.00009632398,0.00015791954,0.00009128167,0.00009145777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016581904,0.00012826553,0.00042873714,0.0001202259,0.000011572529,0.0000018832843,0.00003956818,0.00006949718,0.000163549],"category_scores_gemma":[0.00028809387,0.00008224794,0.000044076765,0.00011052532,0.000094033414,0.000007919503,0.000034778273,0.00007946754,0.0002101838],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008502923,0.01941435,0.36569452,0.026818454,0.0016050906,0.00021520692,0.021446712,0.00043110547,0.2148376,0.122619234,0.20499253,0.013422288],"study_design_scores_gemma":[0.032056548,0.0054773064,0.04173943,0.017476305,0.0007491308,0.00010517281,0.00081440207,0.00345085,0.7794455,0.10048969,0.016196437,0.0019992106],"about_ca_topic_score_codex":0.000025318708,"about_ca_topic_score_gemma":0.000008466462,"teacher_disagreement_score":0.5646079,"about_ca_system_score_codex":0.00004164754,"about_ca_system_score_gemma":0.000044910754,"threshold_uncertainty_score":0.3353974},"labels":[],"label_agreement":null},{"id":"W2166415870","doi":"10.1177/135965350100600103","title":"Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"HIV drug resistance; Drug resistance; Medicine; Drug; Intensive care medicine; Human immunodeficiency virus (HIV); Quality assurance; Antiretroviral therapy; Viral load; Pharmacology; External quality assessment; Immunology; Pathology; Biology; Genetics","score_opus":0.08782025257169648,"score_gpt":0.3617538820014005,"score_spread":0.273933629429704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166415870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570472,0.0012877872,0.00012292023,0.040298864,0.00013853092,0.000859715,0.000017390741,0.000025764808,0.00020181868],"genre_scores_gemma":[0.9517164,0.0032773563,0.012073696,0.0015744084,0.00009989137,0.00013046886,0.000024546076,0.000032953136,0.031070258],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989866,0.00005393363,0.00035185117,0.00018761336,0.0002192677,0.00020072774],"domain_scores_gemma":[0.9988499,0.0004530224,0.000105607076,0.00024995793,0.0003091064,0.00003239082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024474115,0.00014119862,0.0002479231,0.000064094915,0.00005451659,0.000013894253,0.00005298617,0.000042410804,0.000019419387],"category_scores_gemma":[0.0003374921,0.00008331902,0.000082979604,0.0002754109,0.00005858255,0.00013769111,0.000012691621,0.00008044196,0.000011537284],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067777825,0.0014923621,0.45208672,0.000048145812,0.0004495222,0.00028659412,0.0035115904,0.0000035329856,0.0065516364,0.0010206206,0.49104354,0.036727957],"study_design_scores_gemma":[0.005498766,0.00012460997,0.02766389,0.00019334986,0.00004715774,0.0000049813875,0.0003556657,0.00012107153,0.016153073,0.00013108806,0.94953096,0.00017538974],"about_ca_topic_score_codex":0.000012986968,"about_ca_topic_score_gemma":0.0001889691,"teacher_disagreement_score":0.45848742,"about_ca_system_score_codex":0.000035437934,"about_ca_system_score_gemma":0.00014283079,"threshold_uncertainty_score":0.3397651},"labels":[],"label_agreement":null},{"id":"W2166464802","doi":"10.1093/jac/dkr582","title":"The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors","year":2012,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Queen's University","funders":"Canadian Institutes of Health Research; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Protease; Biology; Gene; HIV-1 protease; Virology; Drug resistance; Human immunodeficiency virus (HIV); Protease inhibitor (pharmacology); Lentivirus; Virus; Genetics; Viral disease; Enzyme; Viral load; Antiretroviral therapy; Biochemistry","score_opus":0.0070135737138884045,"score_gpt":0.23595238205461413,"score_spread":0.22893880834072572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166464802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679584,0.00056586077,0.000039471604,0.0298463,0.000065699845,0.001304727,0.000008633251,0.0000035144058,0.00020739717],"genre_scores_gemma":[0.99149674,0.000077963385,0.006499241,0.0007682421,0.00017209406,0.000034653436,0.000011568742,0.000022877406,0.000916644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788326,0.00019641782,0.0009419651,0.00012799338,0.00052131293,0.00032904968],"domain_scores_gemma":[0.998896,0.000086680695,0.00054414617,0.00025707798,0.00012594457,0.00009013545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017474353,0.00020777986,0.0003765762,0.00020064313,0.0001339675,0.000019603069,0.00030273962,0.000061876744,0.000021272539],"category_scores_gemma":[0.000039364964,0.00010367678,0.00014799436,0.0004100897,0.000084943895,0.000114363895,0.000029318735,0.00024624405,0.000012022849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005745172,0.0025949415,0.10087726,0.00010039447,0.00022167899,0.000051985582,0.08594546,0.000008028866,0.7801957,0.000044855744,0.020279448,0.0039350446],"study_design_scores_gemma":[0.003403051,0.00007399559,0.030153038,0.0005774341,0.000044719272,0.00012399416,0.001492136,0.000001947535,0.9385474,0.00002676495,0.02541177,0.00014376616],"about_ca_topic_score_codex":0.000007358909,"about_ca_topic_score_gemma":0.000036766905,"teacher_disagreement_score":0.15835166,"about_ca_system_score_codex":0.00026297307,"about_ca_system_score_gemma":0.0003030876,"threshold_uncertainty_score":0.42278162},"labels":[],"label_agreement":null},{"id":"W2166733691","doi":"10.1093/jac/dku199","title":"Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity","year":2014,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"ViiV Healthcare; Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Integrase; Integrase inhibitor; Virology; Biology; Viral replication; Virus; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.010789528856622379,"score_gpt":0.24913330815830895,"score_spread":0.23834377930168657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166733691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98107815,0.000017889635,0.0015244477,0.01649116,0.00005806356,0.0006386134,0.00008547329,0.000007839267,0.0000983377],"genre_scores_gemma":[0.9872608,0.000050579518,0.010797502,0.0010971735,0.00010476201,0.000009807024,0.000010289887,0.000021876438,0.0006471904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849993,0.00014162043,0.0006068975,0.00026622394,0.000290107,0.0001952403],"domain_scores_gemma":[0.99854404,0.000115764706,0.00043477642,0.00042236366,0.00028595843,0.0001970913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006698115,0.00021663071,0.0005933651,0.00033758,0.00004946021,0.000019964973,0.0001846038,0.00009337054,0.00003340492],"category_scores_gemma":[0.0004777315,0.00014560742,0.00014920894,0.00041102257,0.00008482857,0.00015546531,0.00003623687,0.00024626096,0.000004523218],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046519455,0.00072410447,0.017526848,0.000086216736,0.000119862714,0.000008007317,0.0017213983,0.0000074365253,0.9257553,0.000095878146,0.044886626,0.0044163275],"study_design_scores_gemma":[0.0027312024,0.00032743844,0.06826711,0.0013060448,0.000069028705,0.00004754935,0.00016146146,0.000010104444,0.9199178,0.00006229756,0.0069454517,0.00015449975],"about_ca_topic_score_codex":0.0001664045,"about_ca_topic_score_gemma":0.00038568894,"teacher_disagreement_score":0.050740257,"about_ca_system_score_codex":0.00024528784,"about_ca_system_score_gemma":0.00014782332,"threshold_uncertainty_score":0.59376985},"labels":[],"label_agreement":null},{"id":"W2167186042","doi":"10.1002/prot.20455","title":"Quantum study of mutational effect in binding of efavirenz to HIV‐1 RT","year":2005,"lang":"en","type":"article","venue":"Proteins Structure Function and Bioinformatics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Efavirenz; Chemistry; Mutant; Binding energy; Ab initio; Interaction energy; Conformational change; Reverse transcriptase; Residue (chemistry); Human immunodeficiency virus (HIV); Stereochemistry; Biology; Biochemistry; Physics; Virology; Molecule; Atomic physics; RNA","score_opus":0.007703824435045705,"score_gpt":0.24579462329601603,"score_spread":0.23809079886097034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167186042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749434,0.000017285043,0.0005837746,0.00027449586,0.00005067615,0.001317046,0.00001570862,0.00001500583,0.00023168075],"genre_scores_gemma":[0.99109936,0.0000020392793,0.008524608,0.00004326531,0.00002606854,0.000025671001,0.00004986534,0.000005858005,0.0002232383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991062,0.000018032077,0.00042101083,0.00008559254,0.00025935672,0.00010979378],"domain_scores_gemma":[0.9996353,0.000027512486,0.00012429118,0.00009554733,0.00005454503,0.00006280474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001299452,0.00012375448,0.00026396243,0.00031669266,0.00003544033,0.0000073518668,0.000027466791,0.000052505213,0.00005996176],"category_scores_gemma":[0.000043008207,0.00008549279,0.00002685932,0.00028055842,0.000019085031,0.000098827906,0.000023715234,0.00008508433,0.000008417653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026758208,0.0012695885,0.7898711,0.0019040729,0.00054942176,0.000009895952,0.029128844,0.00042547792,0.010880928,0.0007336874,0.00075102696,0.16180016],"study_design_scores_gemma":[0.030844044,0.010199749,0.8586385,0.0009840522,0.0006418916,0.00009209756,0.011305752,0.019293029,0.06447613,0.0003147465,0.002477087,0.0007328826],"about_ca_topic_score_codex":0.000007551384,"about_ca_topic_score_gemma":0.000038694452,"teacher_disagreement_score":0.16106728,"about_ca_system_score_codex":0.000046451943,"about_ca_system_score_gemma":0.000040673043,"threshold_uncertainty_score":0.3486295},"labels":[],"label_agreement":null},{"id":"W2167458439","doi":"10.1124/mol.104.004408","title":"Role of Human Nucleoside Transporters in the Cellular Uptake of Two Inhibitors of IMP Dehydrogenase, Tiazofurin and Benzamide Riboside","year":2004,"lang":"en","type":"article","venue":"Molecular Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Nucleoside; Nucleoside transporter; Uridine; Cytotoxicity; Biochemistry; Biology; Thymidine; Transporter; In vitro; RNA","score_opus":0.0073497419433682775,"score_gpt":0.2739029985109642,"score_spread":0.26655325656759593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167458439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974578,0.0010592998,0.00003368424,0.0004639351,0.000031295935,0.00054587016,0.000010413125,0.000008950999,0.0003887548],"genre_scores_gemma":[0.999178,0.000045277186,0.0004704121,0.00018731791,0.000018425295,0.000029182944,0.000030979692,0.000020379808,0.000020052574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987255,0.000073863004,0.00055352837,0.0002112313,0.00021213756,0.0002237883],"domain_scores_gemma":[0.9995373,0.000025257714,0.00016199892,0.00016305859,0.00004125815,0.0000711267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023792747,0.0001695115,0.0004256576,0.00020511492,0.000025596997,0.0000015532237,0.0001096028,0.00006854038,0.000041811658],"category_scores_gemma":[0.000004675898,0.00013507898,0.00012135908,0.00022427639,0.0001908237,0.000027052618,0.00002344493,0.00013653767,0.0000013765958],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009844075,0.0005656638,0.015448342,0.00009319107,0.00023780784,0.00036193995,0.002503155,0.00015292542,0.9797019,0.00042464997,0.000030668205,0.00038136737],"study_design_scores_gemma":[0.005997404,0.0002329242,0.008132786,0.00006197851,0.00040158766,0.000021218724,0.0004081872,0.000021680722,0.98402685,0.00046244555,0.00014032904,0.000092595066],"about_ca_topic_score_codex":0.0001548934,"about_ca_topic_score_gemma":0.00006818213,"teacher_disagreement_score":0.0073155565,"about_ca_system_score_codex":0.00004020713,"about_ca_system_score_gemma":0.00009469354,"threshold_uncertainty_score":0.5508361},"labels":[],"label_agreement":null},{"id":"W2167698825","doi":"10.1128/aac.46.7.2087-2094.2002","title":"Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT","year":2002,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Biology; Virology; Clade; Reverse transcriptase; Efavirenz; Genotype; Virus; Genetics; Gene; Polymerase chain reaction; Phylogenetic tree; Viral load","score_opus":0.0204471731276801,"score_gpt":0.24326440253582143,"score_spread":0.22281722940814133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167698825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979144,0.0007472358,0.000013541109,0.00046074463,0.00006512568,0.0002994546,0.0000207847,0.000010739273,0.0004679749],"genre_scores_gemma":[0.98755985,0.006766898,0.0037448953,0.00044021316,0.000012575189,0.0000024808223,0.000016620572,0.000021514446,0.0014349561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875647,0.000024587422,0.0005635526,0.00026566684,0.00019230753,0.00019739107],"domain_scores_gemma":[0.9994359,0.000010303415,0.0002039102,0.0001883525,0.000089095236,0.00007244938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008280272,0.00020232756,0.00042349065,0.0001112226,0.00011130816,0.0000059395225,0.00008364594,0.00009181685,0.000207791],"category_scores_gemma":[0.0000055051264,0.00017587701,0.00007129853,0.00019644106,0.00021015583,0.00004593887,0.000025146555,0.000083518964,0.0000029722703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026028586,0.0008088351,0.036878638,0.00047869724,0.0002655153,0.000018910316,0.013112044,5.964457e-7,0.92813313,0.00001257613,0.007146222,0.012884532],"study_design_scores_gemma":[0.005751331,0.0002807256,0.20071328,0.0010448211,0.0001534428,0.000008259015,0.00035401285,0.000017782168,0.7616295,0.000009576003,0.029644115,0.00039312374],"about_ca_topic_score_codex":0.000028946683,"about_ca_topic_score_gemma":0.000019804422,"teacher_disagreement_score":0.16650361,"about_ca_system_score_codex":0.00002608106,"about_ca_system_score_gemma":0.000045251876,"threshold_uncertainty_score":0.71720564},"labels":[],"label_agreement":null},{"id":"W2167891197","doi":"10.1097/00002030-200107060-00008","title":"Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nevirapine; Didanosine; Zidovudine; Medicine; Drug resistance; Virology; Internal medicine; Pharmacology; Viral load; Biology; Human immunodeficiency virus (HIV); Viral disease; Microbiology; Antiretroviral therapy","score_opus":0.009891963436428253,"score_gpt":0.24173374472820455,"score_spread":0.2318417812917763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167891197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947675,0.00040824525,0.00004485062,0.0005519152,0.000031319723,0.00023296537,0.0000017447481,0.000010686014,0.0039507938],"genre_scores_gemma":[0.96807945,0.000143749,0.025193699,0.000022643138,0.000004416403,0.000014364632,0.000039764236,0.000009426974,0.006492485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991121,0.000018279889,0.00039832384,0.00014295234,0.00020221912,0.00012607103],"domain_scores_gemma":[0.9995805,0.00004221117,0.000100067686,0.00012513221,0.00010436714,0.000047735553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015475652,0.000100250756,0.00026826738,0.00020099178,0.000032372613,0.0000025569718,0.000039233815,0.000028027423,0.000026955666],"category_scores_gemma":[0.00006260983,0.00008741464,0.00002216083,0.0003868323,0.00004219896,0.000058532878,0.000034142915,0.00005099844,0.0000031913746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006170645,0.0009271694,0.9833539,0.00008200999,0.000057087873,0.000004750551,0.0022375716,1.4716261e-7,0.00037110347,0.00045851385,0.0004524959,0.011993506],"study_design_scores_gemma":[0.0049674474,0.00005335115,0.98004884,0.00043618082,0.000030909367,6.788537e-7,0.00010286343,0.000004367143,0.005445809,0.000091004316,0.008731377,0.000087166896],"about_ca_topic_score_codex":0.0000061114793,"about_ca_topic_score_gemma":0.0000695624,"teacher_disagreement_score":0.026688028,"about_ca_system_score_codex":0.00006218202,"about_ca_system_score_gemma":0.000064400185,"threshold_uncertainty_score":0.35646656},"labels":[],"label_agreement":null},{"id":"W2168213451","doi":"10.1093/jac/dkv048","title":"Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response","year":2015,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"CHIST-ERA; Merck Sharp and Dohme; Agence Nationale de Recherches sur le Sida et les Hépatites Virales","keywords":"Etravirine; Raltegravir; Darunavir; Integrase inhibitor; Medicine; Virology; Internal medicine; Integrase; Drug resistance; Viral load; Human immunodeficiency virus (HIV); Biology; Antiretroviral therapy; Genetics","score_opus":0.027098823670025956,"score_gpt":0.28606424061549424,"score_spread":0.25896541694546826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168213451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726138,0.000099116405,0.000029743585,0.025970558,0.0004128744,0.0005906147,0.000059458547,0.000015431116,0.00020839981],"genre_scores_gemma":[0.992204,0.00015341546,0.0016974702,0.0016437911,0.00045038675,0.0000022244824,0.000014268521,0.000031163647,0.0038032865],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716496,0.0005469433,0.0010340284,0.0002460582,0.0006680782,0.00033990297],"domain_scores_gemma":[0.9977802,0.00031688166,0.00082351785,0.00039823324,0.0003649403,0.00031625092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021185526,0.00033606877,0.0009107537,0.0002536465,0.000093200404,0.000024565783,0.00026477926,0.00021548818,0.00017299807],"category_scores_gemma":[0.0004977581,0.00017515259,0.0006644414,0.00035711884,0.00014810634,0.00007626562,0.00004194503,0.00039747916,0.00002154583],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6062539,0.002414755,0.004593968,0.000014826088,0.00059210643,0.00030170783,0.00063039386,0.000022404041,0.28708765,0.0000059102977,0.09776513,0.00031722398],"study_design_scores_gemma":[0.35945255,0.016024692,0.098495156,0.0007636093,0.00080763426,0.0012508644,0.00010527765,0.00011993413,0.46938193,0.00006549905,0.052883916,0.00064895395],"about_ca_topic_score_codex":0.00001906156,"about_ca_topic_score_gemma":0.000006582703,"teacher_disagreement_score":0.24680139,"about_ca_system_score_codex":0.000734769,"about_ca_system_score_gemma":0.00089660706,"threshold_uncertainty_score":0.7142515},"labels":[],"label_agreement":null},{"id":"W2168296515","doi":"10.1542/peds.2005-0975","title":"Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection","year":2005,"lang":"en","type":"article","venue":"PEDIATRICS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Institutes of Health","keywords":"Medicine; Salvage therapy; Regimen; Internal medicine; Dosing; Tolerability; Viral load; Enfuvirtide; Gastroenterology; Human immunodeficiency virus (HIV); Virology; Adverse effect; Immunology; Chemotherapy; Antibody","score_opus":0.025315627105393555,"score_gpt":0.3100084937258335,"score_spread":0.28469286662043997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168296515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954424,0.0012335439,0.00054813834,0.00071102363,0.00013153991,0.001040897,0.000027929864,0.00008226606,0.0007822958],"genre_scores_gemma":[0.96197164,0.011834546,0.012782807,0.00018119121,0.0014973977,0.000106304054,0.00028987275,0.00006454056,0.011271684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985431,0.000046489855,0.00040759955,0.00037623805,0.00030133207,0.00032523868],"domain_scores_gemma":[0.99911314,0.0000957957,0.00021770246,0.00025089073,0.00012785173,0.00019458731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031388624,0.00025675376,0.00041190925,0.0003252849,0.00012251825,0.000035176694,0.00006796961,0.0001378609,0.000067569315],"category_scores_gemma":[0.000051297473,0.00021188083,0.00011688772,0.0003831891,0.000040404626,0.00028778106,0.00003503772,0.00011702732,0.00003846124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013344543,0.0012892166,0.9663421,0.000259955,0.00013428018,0.000016565426,0.0010263381,0.000032049265,0.0001847168,0.00013062611,0.010966096,0.018283634],"study_design_scores_gemma":[0.08562198,0.0094610695,0.82225055,0.000062974075,0.0039902534,0.00012427058,0.00058815995,0.0074123247,0.0041564326,0.0007222015,0.06329658,0.0023132106],"about_ca_topic_score_codex":0.000027228356,"about_ca_topic_score_gemma":0.0000040554983,"teacher_disagreement_score":0.14409153,"about_ca_system_score_codex":0.00009668815,"about_ca_system_score_gemma":0.00015676083,"threshold_uncertainty_score":0.86402494},"labels":[],"label_agreement":null},{"id":"W2169264636","doi":"10.1093/cid/civ327","title":"Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s","year":2015,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Dental and Craniofacial Research; National Institute of Allergy and Infectious Diseases; University of California, Los Angeles; Rush University; University of Cincinnati; University of Pittsburgh; Johns Hopkins University; National Institute of Mental Health; National Heart, Lung, and Blood Institute; Northwestern University; Gilead Sciences; Vanderbilt University; University of Rochester; National Institutes of Health; Ohio State University; ACT Government; University of Southern California; University of Washington; National Institute on Drug Abuse; York University; Bristol-Myers Squibb","keywords":"Raltegravir; Ritonavir; Darunavir; Atazanavir; Medicine; Internal medicine; Immunology; CD14; Inflammation; Gastroenterology; Pharmacology; Viral load; Immune system; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.055418134036118935,"score_gpt":0.36153349546648966,"score_spread":0.3061153614303707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169264636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525905,0.00021556608,0.00007693219,0.002538592,0.000112973175,0.00077712914,0.000015852998,0.00014604701,0.0008578667],"genre_scores_gemma":[0.99839264,0.00017821879,0.00007363748,0.00032261186,0.00025278438,0.00012073306,0.0004127999,0.000031733594,0.00021486239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984575,0.00019554723,0.00044126608,0.0003709123,0.0002850382,0.00024976322],"domain_scores_gemma":[0.99889106,0.0002899496,0.00018113376,0.00024319402,0.00013218945,0.0002624863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033567633,0.00025061963,0.0004894245,0.00020309981,0.000076062366,0.00004942659,0.00004987219,0.00013544533,0.000028768804],"category_scores_gemma":[0.00034742753,0.00018330042,0.00007727569,0.00031094858,0.00020681618,0.0002330194,0.000030439649,0.00022991367,0.000026032969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013205546,0.0010759248,0.9253426,0.0000381998,0.00012634367,0.00007287359,0.00016532504,0.000007560559,0.00022069144,0.00006354716,0.00017766026,0.071388714],"study_design_scores_gemma":[0.017775964,0.0019830135,0.97207206,0.00031940528,0.0001816466,0.000006571436,0.00015461374,0.00029989515,0.0039095306,0.00034572402,0.0026168083,0.00033473934],"about_ca_topic_score_codex":0.00006341971,"about_ca_topic_score_gemma":0.00020498945,"teacher_disagreement_score":0.071053974,"about_ca_system_score_codex":0.00011637592,"about_ca_system_score_gemma":0.0003913988,"threshold_uncertainty_score":0.7474774},"labels":[],"label_agreement":null},{"id":"W2169689184","doi":"10.1086/597016","title":"HIV Drug Resistance Tests: An Update on Methods for Calculating Phenotypic Fold Change from a Viral Genotype","year":2009,"lang":"en","type":"letter","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"GlaxoSmithKline; Pfizer; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Medicine; Genotype; Phenotype; Human immunodeficiency virus (HIV); Drug resistance; Virology; HIV drug resistance; Drug; Immunology; Viral load; Genetics; Biology; Antiretroviral therapy; Pharmacology; Gene","score_opus":0.07231684703143507,"score_gpt":0.4215815158006387,"score_spread":0.3492646687692036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169689184","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054649916,0.01069651,0.0034067512,0.9100683,0.0042029084,0.009715491,0.0023683088,0.0023607127,0.0025311557],"genre_scores_gemma":[0.010581151,0.00060296105,0.026861368,0.8890814,0.027197903,0.0016488394,0.014893182,0.0004161108,0.028717063],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995537,0.0006870035,0.0012353475,0.0014135457,0.00039434753,0.0007327637],"domain_scores_gemma":[0.99494374,0.0027592182,0.00055931706,0.0010410221,0.0002202556,0.0004764244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048834254,0.00077995245,0.0016435004,0.00022743174,0.0002864336,0.00010246545,0.00024807279,0.00079039385,0.00020655058],"category_scores_gemma":[0.0014035424,0.0006523138,0.0008832986,0.0002217532,0.0001647748,0.0001499687,0.000071083225,0.0012855281,0.0002302642],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006236521,0.0018092635,0.03340835,0.00029421225,0.0010805503,0.00047521203,0.00014561547,0.0000011929164,0.0000030856872,0.00010486848,0.9109337,0.05112035],"study_design_scores_gemma":[0.005154685,0.0005450727,0.04041487,0.000983733,0.0031991706,0.00000259835,0.000010010892,0.00017038414,0.000017883418,0.00824882,0.9402979,0.0009548772],"about_ca_topic_score_codex":0.000026812524,"about_ca_topic_score_gemma":0.00008080156,"teacher_disagreement_score":0.050165474,"about_ca_system_score_codex":0.0003469854,"about_ca_system_score_gemma":0.00030454114,"threshold_uncertainty_score":0.99959284},"labels":[],"label_agreement":null},{"id":"W2170014989","doi":"10.1086/375781","title":"Rates of Disease Progression among Human Immunodeficiency Virus–Infected Persons Initiating Multiple‐Drug Rescue Therapy","year":2003,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Virology; Rescue therapy; Medicine; Drug; Human immunodeficiency virus (HIV); Disease; Immunology; Pharmacotherapy; Internal medicine; Pharmacology","score_opus":0.016852318140514386,"score_gpt":0.30080134415364435,"score_spread":0.28394902601312993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170014989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387443,0.004681908,0.00003055154,0.00015473449,0.000109182,0.00047260505,0.000015068838,0.00004307099,0.0006184661],"genre_scores_gemma":[0.99887043,0.0006996763,0.00005086853,0.000051034276,0.00006497424,0.000016003336,0.000012547397,0.000030547893,0.00020391528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981651,0.0003964588,0.0005976421,0.00012734848,0.0004560533,0.00025739975],"domain_scores_gemma":[0.99831533,0.00031391656,0.0005416009,0.000254626,0.0003349294,0.0002396195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004676643,0.00023593902,0.00040803215,0.00024114727,0.00040426286,0.000029260395,0.00011855517,0.00003642425,0.0001408957],"category_scores_gemma":[0.00065020967,0.00013337111,0.0002864784,0.00034643337,0.00021018821,0.00019155012,0.000025044043,0.00023504658,0.000004923565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006029095,0.0020487201,0.98670316,0.00006728106,0.00036417574,0.00006212142,0.0019356326,0.00007170442,0.0067975554,0.000044048553,0.00037840594,0.0009242598],"study_design_scores_gemma":[0.0072946507,0.0007272895,0.96852314,0.001002648,0.0008569839,0.000095233016,0.001154592,0.0000733613,0.019548958,0.00024852983,0.00022393736,0.00025065013],"about_ca_topic_score_codex":0.000042873744,"about_ca_topic_score_gemma":0.000020277783,"teacher_disagreement_score":0.018180018,"about_ca_system_score_codex":0.00010527221,"about_ca_system_score_gemma":0.0003368633,"threshold_uncertainty_score":0.5438716},"labels":[],"label_agreement":null},{"id":"W2170104292","doi":"10.1177/135965350400900512","title":"Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nevirapine; Efavirenz; Medicine; Internal medicine; Stavudine; Adverse effect; Lamivudine; Quality of life (healthcare); Health related quality of life; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Disease","score_opus":0.03863834630585736,"score_gpt":0.29900894697576225,"score_spread":0.2603706006699049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170104292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973674,0.00072142057,0.000024246814,0.0007158281,0.000024507925,0.00078485475,0.000012286342,0.000054216176,0.00029526357],"genre_scores_gemma":[0.99551684,0.0030748518,0.0004703553,0.00033326037,0.000034051198,0.000027719,0.000087030596,0.000036078538,0.00041983827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984115,0.00007561374,0.0005339384,0.0003476838,0.0003162374,0.00031506224],"domain_scores_gemma":[0.99930423,0.00007875209,0.0001973466,0.00023748203,0.000088706576,0.000093479706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022026671,0.0003104748,0.00076517643,0.00018480678,0.000070706184,0.000014997995,0.0000733203,0.00009457731,0.00003478713],"category_scores_gemma":[0.00003601922,0.00018873592,0.000080615115,0.0004192916,0.00014155029,0.00016823228,0.000017018705,0.00013690075,0.0000061274695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013517107,0.0013861193,0.95286864,0.00003137977,0.00023650186,0.00003049202,0.0009004275,0.0000018959885,0.00056621135,0.00007849358,0.000013458482,0.030369287],"study_design_scores_gemma":[0.046217546,0.0071715224,0.93909895,0.00025992823,0.000014799196,0.0000018772064,0.00008889655,0.000006124084,0.006541605,0.000033316122,0.0003169811,0.00024846583],"about_ca_topic_score_codex":0.0004628617,"about_ca_topic_score_gemma":0.0002014611,"teacher_disagreement_score":0.03270044,"about_ca_system_score_codex":0.00006472887,"about_ca_system_score_gemma":0.00016354556,"threshold_uncertainty_score":0.7696428},"labels":[],"label_agreement":null},{"id":"W2170561155","doi":"10.1586/14787210.1.1.75","title":"Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics","year":2003,"lang":"en","type":"review","venue":"Expert Review of Anti-infective Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Therapeutic drug monitoring; Pharmacogenomics; Therapeutic index; Pharmacology; Protease inhibitor (pharmacology); Medicine; Drug; Therapeutic effect; Protease; Reverse transcriptase; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Biology; Viral load; RNA","score_opus":0.03309191973711181,"score_gpt":0.36409914934510784,"score_spread":0.331007229607996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170561155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007303801,0.99405706,0.000011859864,0.00011167194,0.0002837136,0.0040649283,0.000018361488,0.000037318194,0.00068468123],"genre_scores_gemma":[0.00035956275,0.9977841,0.0006550813,0.00022315423,0.00021369137,0.00032722982,0.00003967595,0.00013114043,0.00026636364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966111,0.00076998933,0.0012123435,0.0005722441,0.00044118948,0.0003931028],"domain_scores_gemma":[0.99758583,0.0003743156,0.0009986082,0.00068927667,0.00023390044,0.00011805135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009091889,0.0008830462,0.004265161,0.0002134754,0.00013182088,0.000020663336,0.00029862742,0.0001701198,0.00015347316],"category_scores_gemma":[0.00002444901,0.0004742119,0.0012365453,0.00053161604,0.00029233648,0.00009106873,0.00005762392,0.00042430623,0.000011977356],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006790224,0.00042736498,0.0007103065,0.0086715035,0.0030219906,0.0000069918474,0.00072289683,4.547672e-8,0.0002861058,0.000046503224,0.00015037163,0.985888],"study_design_scores_gemma":[0.0022540833,0.00027176543,0.000057902864,0.03780455,0.00093813176,0.000077512705,0.000087203014,0.0000011496697,0.0045879306,0.000021517997,0.9534562,0.00044204944],"about_ca_topic_score_codex":0.000022103188,"about_ca_topic_score_gemma":6.205252e-8,"teacher_disagreement_score":0.985446,"about_ca_system_score_codex":0.00014314495,"about_ca_system_score_gemma":0.00045198834,"threshold_uncertainty_score":0.99977094},"labels":[],"label_agreement":null},{"id":"W2171618626","doi":"10.1002/jmv.10203","title":"Antiretroviral drug resistance among HIV‐1 infected children failing treatment","year":2002,"lang":"en","type":"article","venue":"Journal of Medical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Nevirapine; Lamivudine; Zidovudine; Drug resistance; Medicine; Virology; Reverse transcriptase; Genotyping; HIV drug resistance; Viral load; Protease inhibitor (pharmacology); Lentivirus; Genotype; Viral disease; Immunology; Internal medicine; Biology; Virus; Polymerase chain reaction; Gene; Antiretroviral therapy; Genetics; Hepatitis B virus","score_opus":0.010080028136229281,"score_gpt":0.24938011834290114,"score_spread":0.23930009020667187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171618626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96734196,0.0015962742,0.000115179435,0.029290099,0.00023216307,0.00016968956,0.000002300308,0.000030410816,0.0012219491],"genre_scores_gemma":[0.98140144,0.0014775253,0.00086250564,0.00045348273,0.00052091514,0.0000047590875,0.000012536965,0.00002183525,0.015244991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976573,0.0001453717,0.00072841643,0.00020638923,0.000889703,0.00037279856],"domain_scores_gemma":[0.9987213,0.00016472356,0.0003269945,0.00018475846,0.00008488433,0.00051735435],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043690973,0.0002234212,0.00069439714,0.00025803052,0.00008367889,0.000013395041,0.00017219568,0.00022961966,0.0019456387],"category_scores_gemma":[0.00034333768,0.0001471064,0.00023810857,0.0001920196,0.00022446776,0.00009467943,0.00003670157,0.00048636209,0.00012326844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003162088,0.0011861158,0.9443927,0.000018009458,0.0008186141,0.002348999,0.00095461984,0.0000013358983,0.00012402705,0.00008721444,0.037458204,0.012293959],"study_design_scores_gemma":[0.031539883,0.002618892,0.8718239,0.000673707,0.0013086029,0.0033586952,0.00017224792,0.0007913404,0.0015693774,0.00014697546,0.085467964,0.0005283756],"about_ca_topic_score_codex":0.000010007422,"about_ca_topic_score_gemma":0.00003508523,"teacher_disagreement_score":0.07256876,"about_ca_system_score_codex":0.00020915025,"about_ca_system_score_gemma":0.00014621225,"threshold_uncertainty_score":0.9989667},"labels":[],"label_agreement":null},{"id":"W2172274075","doi":"10.1086/431199","title":"Efficacy of Antiretroviral Therapy Programs in Resource‐Poor Settings: A Meta‐analysis of the Published Literature","year":2005,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Viral load; Observational study; Meta-analysis; MEDLINE; Antiretroviral therapy; Internal medicine; Human immunodeficiency virus (HIV); Intensive care medicine; Family medicine","score_opus":0.10373908077582315,"score_gpt":0.40679709903954947,"score_spread":0.3030580182637263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172274075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027038243,0.9938731,5.264966e-7,0.00047189178,0.00010004228,0.0023283842,0.00014646987,0.00007474806,0.00030097316],"genre_scores_gemma":[0.0075692735,0.98942447,0.000028904911,0.00035449475,0.00021713262,0.0002971117,0.0009215496,0.00005962779,0.0011274334],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951222,0.0009371748,0.0023380327,0.0007394374,0.00051513844,0.00034803522],"domain_scores_gemma":[0.99601036,0.0012121501,0.0013397223,0.0010099027,0.00019521441,0.00023262897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007711083,0.0005882244,0.0063773273,0.0007674768,0.000054476,0.00006989555,0.00035509228,0.0005045255,0.00015623713],"category_scores_gemma":[0.0013027927,0.00029881267,0.009045525,0.004136373,0.00035348564,0.000086351356,0.00013779543,0.00073578866,0.000006570717],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009775179,0.0066215666,0.0702929,0.0036292933,0.16833471,0.00003297359,0.000104469735,0.0000016838846,2.0567906e-8,0.0000198275,0.0016447855,0.74922],"study_design_scores_gemma":[0.002120939,0.00037182667,0.010547823,0.0044074883,0.32907566,0.000004093178,0.000009957114,0.0000052104347,2.611531e-7,0.0000088967845,0.6531942,0.0002536872],"about_ca_topic_score_codex":0.0000074549216,"about_ca_topic_score_gemma":0.000018678438,"teacher_disagreement_score":0.74896634,"about_ca_system_score_codex":0.00009647571,"about_ca_system_score_gemma":0.0005947168,"threshold_uncertainty_score":0.9999464},"labels":[],"label_agreement":null},{"id":"W2173616003","doi":"10.1016/j.bmcl.2007.06.012","title":"Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases","year":2007,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Chemistry; Mutant; Bioavailability; Nucleoside; Enzyme; Enzyme inhibitor; Nucleotidyltransferase; Stereochemistry; Biochemistry; Pharmacology; RNA; Biology; Gene","score_opus":0.007492722331657846,"score_gpt":0.21867622616240145,"score_spread":0.2111835038307436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173616003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97800404,0.0013457674,0.000013737144,0.019084498,0.00019029292,0.00037471898,0.000011999928,0.000040645406,0.0009342859],"genre_scores_gemma":[0.99535733,0.00030680344,0.00029818236,0.0016952093,0.00019066922,0.000003890352,0.000030430814,0.000036029796,0.0020814792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981682,0.000013534449,0.00046894627,0.00042552088,0.0005119325,0.000411897],"domain_scores_gemma":[0.99906236,0.000059958,0.00014904914,0.0003469487,0.00008524936,0.00029644617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036836983,0.0003259239,0.0004376164,0.00006250702,0.00013988728,0.000016514216,0.00013063238,0.00014841536,0.0002186853],"category_scores_gemma":[0.00008500066,0.00022305561,0.00008061157,0.00041604214,0.00044779156,0.00006971371,0.00006522964,0.00030070957,0.00002243336],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004333074,0.00011391333,0.015717292,0.00030866658,0.00017604626,0.00023862006,0.0009527068,1.4225041e-7,0.9691282,0.0000026863606,0.012429199,0.0004992124],"study_design_scores_gemma":[0.0034856272,0.0000738927,0.007394999,0.0005614467,0.00043870113,0.00064463756,0.0016577581,0.000004752143,0.9735076,0.000003482456,0.011997203,0.00022992062],"about_ca_topic_score_codex":0.00011899465,"about_ca_topic_score_gemma":0.000010248397,"teacher_disagreement_score":0.017389288,"about_ca_system_score_codex":0.00013838886,"about_ca_system_score_gemma":0.00017642613,"threshold_uncertainty_score":0.90959436},"labels":[],"label_agreement":null},{"id":"W2174122554","doi":"10.1016/j.bmcl.2003.11.049","title":"Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives","year":2003,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Nevirapine; Chemistry; Pharmacokinetics; Microsome; Mutant; Pharmacology; Virology; Virus; Human immunodeficiency virus (HIV); Structure–activity relationship; In vitro; Biochemistry; Viral load; Antiretroviral therapy","score_opus":0.01144913933502341,"score_gpt":0.22079358025555568,"score_spread":0.20934444092053225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174122554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98133254,0.00053264166,0.0016552305,0.014448257,0.00019216837,0.000611414,0.000021499214,0.00019942042,0.0010067995],"genre_scores_gemma":[0.99096155,0.00009063055,0.0041475734,0.0024891575,0.0003378615,0.00007339418,0.00012813396,0.000104858016,0.0016668335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968752,0.000056395933,0.0005469167,0.0009031537,0.0007968196,0.00082146225],"domain_scores_gemma":[0.9982326,0.000103873266,0.00030515232,0.0006528653,0.00012089355,0.00058459904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003239542,0.00070904905,0.00080728304,0.0001528768,0.00021551855,0.000040351584,0.00020516786,0.00020906302,0.0002604663],"category_scores_gemma":[0.00018459876,0.00053916185,0.0001746582,0.0007813721,0.00043970384,0.00016339777,0.000059277983,0.0005792384,0.000043637847],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054291764,0.0005288784,0.0026936233,0.00026464646,0.00055050774,0.00034514794,0.00047608314,8.178893e-7,0.9911743,0.000002319024,0.0024971347,0.0009236491],"study_design_scores_gemma":[0.0071987356,0.00014725309,0.00438078,0.00048000753,0.00035730045,0.0003015705,0.00043244823,0.000022952223,0.975128,0.0000011984603,0.010908592,0.000641178],"about_ca_topic_score_codex":0.000015977996,"about_ca_topic_score_gemma":0.000003631951,"teacher_disagreement_score":0.01604629,"about_ca_system_score_codex":0.0004915689,"about_ca_system_score_gemma":0.00046964004,"threshold_uncertainty_score":0.999706},"labels":[],"label_agreement":null},{"id":"W2175721119","doi":"10.3389/fpubh.2015.00244","title":"Low Virologic Failure and Drug Resistance among HIV-Infected Patients Receiving Hospital-Based ART While Care and Outreach through Community in Guangxi, China","year":2015,"lang":"en","type":"article","venue":"Frontiers in Public Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"State Key Laboratory of Infectious Disease Prevention and Control; Ministry of Science and Technology of the People's Republic of China; National Natural Science Foundation of China; International Development Research Centre; Shandong University","keywords":"Medicine; Regimen; HIV drug resistance; Viral load; Internal medicine; Drug resistance; Logistic regression; Outreach; Transmission (telecommunications); Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.014777980456015145,"score_gpt":0.2430722619965295,"score_spread":0.22829428154051437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2175721119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764594,0.0009678593,0.0002806038,0.018550212,0.00021921068,0.0010691073,0.000026276613,0.0000842152,0.002343117],"genre_scores_gemma":[0.98488957,0.0001636439,0.012740907,0.00046387702,0.000018595312,0.00008112608,0.0007402488,0.000028274344,0.000873773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976683,0.00062551326,0.00044877664,0.00037765826,0.0003006076,0.0005790953],"domain_scores_gemma":[0.99886906,0.00006396536,0.00017352574,0.0003801338,0.00011478512,0.0003985199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090591336,0.00027555865,0.00060794275,0.00031117236,0.00019548344,0.00005466779,0.0001176489,0.00014157478,0.0000057970433],"category_scores_gemma":[0.00036401278,0.0002429023,0.000032559135,0.00051848555,0.00017170803,0.00032443443,0.00008345475,0.000619884,0.0000032281753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005178837,0.00053981587,0.87665325,0.00022444708,0.000022328764,0.000015605277,0.028277311,0.0000016648062,8.57772e-8,0.000007503233,0.09114192,0.0030643025],"study_design_scores_gemma":[0.0064701885,0.000264976,0.9631723,0.000427911,0.000011802239,9.095523e-7,0.0085113365,0.00012136895,0.0000050165386,0.0001177089,0.020662641,0.00023382764],"about_ca_topic_score_codex":0.00043608175,"about_ca_topic_score_gemma":0.0041918517,"teacher_disagreement_score":0.08651908,"about_ca_system_score_codex":0.0010053662,"about_ca_system_score_gemma":0.00055519945,"threshold_uncertainty_score":0.99052685},"labels":[],"label_agreement":null},{"id":"W2175841092","doi":"10.1016/j.bmcl.2003.09.058","title":"Lysine sulfonamides as novel HIV-Protease inhibitors: optimization of the Nε -acyl-phenyl spacer","year":2003,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SNC-Lavalin (Canada)","funders":"","keywords":"Chemistry; Lysine; Protease; Sulfonamide; Enzyme inhibitor; Human immunodeficiency virus (HIV); Stereochemistry; Enzyme; Protease inhibitor (pharmacology); Chemical synthesis; HIV-1 protease; Biochemistry; Combinatorial chemistry; In vitro; Virology; Amino acid","score_opus":0.008609353486990216,"score_gpt":0.21671591386853117,"score_spread":0.20810656038154096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2175841092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95206875,0.00032217754,0.001222262,0.042325262,0.00022787885,0.00057139085,0.0000143258,0.00007477687,0.0031731545],"genre_scores_gemma":[0.9902847,0.00003338822,0.0030545194,0.0015012405,0.0003349017,0.00002620143,0.00008995207,0.000050330207,0.004624775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981004,0.00003186328,0.0004605881,0.0003907668,0.0006746315,0.00034173127],"domain_scores_gemma":[0.9988881,0.000050561044,0.00023989005,0.0004925463,0.000114428985,0.00021448919],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022786052,0.00032502203,0.00040208455,0.00005047554,0.0001055612,0.00001362608,0.00014722155,0.00012944182,0.0011856062],"category_scores_gemma":[0.00046430773,0.00022273128,0.0001512841,0.00047904043,0.00026275736,0.000063276144,0.000051496307,0.00024923167,0.000034127876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010493033,0.00029639294,0.008052444,0.00021469122,0.00019336384,0.000058653324,0.00035681707,0.000053619908,0.9826078,0.000020604999,0.007978636,0.00006206005],"study_design_scores_gemma":[0.003615758,0.000034050525,0.0012668852,0.00051206775,0.00040381696,0.0003367207,0.000580212,0.00007384415,0.98669684,0.0000071522586,0.006204499,0.0002681647],"about_ca_topic_score_codex":0.000018811374,"about_ca_topic_score_gemma":5.5260904e-7,"teacher_disagreement_score":0.040824022,"about_ca_system_score_codex":0.0002644135,"about_ca_system_score_gemma":0.00036082786,"threshold_uncertainty_score":0.9997274},"labels":[],"label_agreement":null},{"id":"W2177185936","doi":"10.1081/ncn-120027814","title":"Synthesis and Antiviral Activity of Novel Fluorinated 2′,3′‐Dideoxynucleosides","year":2004,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Medical Research Council Canada","keywords":"Chemistry; Cytotoxicity; In vitro; Stereochemistry; Rhinovirus; Structure–activity relationship; Biochemistry; Virus; Virology; Biology","score_opus":0.015621196529054348,"score_gpt":0.2507450003406599,"score_spread":0.23512380381160553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2177185936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885048,0.00022730512,0.00018931244,0.0037029898,0.00017343379,0.0008195512,0.000059363454,0.0004278693,0.0058953497],"genre_scores_gemma":[0.97360516,0.0002858906,0.02485058,0.00025011742,0.00010514836,0.00004756455,0.000013610379,0.0001745171,0.0006673868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99651873,0.00006756661,0.00084099785,0.0009689514,0.0007417331,0.0008620229],"domain_scores_gemma":[0.9978332,0.0002722543,0.00037666544,0.0008172694,0.00025934697,0.00044125246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042848918,0.0007525147,0.0013350951,0.00052770274,0.00033092638,0.000095424184,0.00029847812,0.00032967623,0.00022203023],"category_scores_gemma":[0.00041371436,0.00067610154,0.0003842399,0.0007324367,0.0007855597,0.0006396372,0.00029464054,0.00043337324,0.00013466751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019440836,0.005540063,0.11077998,0.0009889242,0.0019453728,0.00046728007,0.0031210075,0.0000446989,0.79079205,0.012783651,0.0011278036,0.070465095],"study_design_scores_gemma":[0.009297848,0.00076403754,0.3185723,0.0015121901,0.0011881487,0.00044859204,0.0007898471,0.00047740282,0.66039324,0.0009254044,0.0043953434,0.0012356173],"about_ca_topic_score_codex":0.00020743663,"about_ca_topic_score_gemma":0.00003631398,"teacher_disagreement_score":0.20779234,"about_ca_system_score_codex":0.00030010904,"about_ca_system_score_gemma":0.00023480118,"threshold_uncertainty_score":0.999569},"labels":[],"label_agreement":null},{"id":"W2180766154","doi":"10.1081/ncn-120023084","title":"Synthesis and Antitumor Activity of<i>N</i>-Sulfonyl Derivatives of Nucleobases and Sulfonamido Nucleoside Derivatives","year":2003,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation, Science and Economic Development Canada","funders":"","keywords":"Nucleobase; Sulfonyl; Pyrimidine; Chemistry; Ring (chemistry); Nucleoside; Stereochemistry; Combinatorial chemistry; DNA; Organic chemistry; Biochemistry","score_opus":0.014315591248056665,"score_gpt":0.24618729758026225,"score_spread":0.23187170633220558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180766154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900345,0.0012247624,0.00010116421,0.000996783,0.00010518298,0.00088621007,0.000079122074,0.00018147806,0.0063907765],"genre_scores_gemma":[0.97604096,0.0014601891,0.021666525,0.00017776061,0.0000407333,0.00004250282,0.000007933559,0.00016280585,0.00040060506],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962115,0.00029401894,0.0010562828,0.00100444,0.0006756803,0.0007580672],"domain_scores_gemma":[0.9968584,0.0009446999,0.00065104244,0.0007683171,0.0003114372,0.0004660627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005826175,0.0008161447,0.0017483353,0.0005330424,0.00033232608,0.000074134994,0.00023709801,0.00025683147,0.00040990993],"category_scores_gemma":[0.001264289,0.0007311381,0.00030042575,0.0007085528,0.0017305717,0.0006748532,0.00023838987,0.0003397657,0.000022169936],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010962285,0.0018731548,0.48344958,0.0015618615,0.0014765557,0.00015592139,0.0040831077,0.0000046568234,0.45950365,0.018647375,0.0009088758,0.027239025],"study_design_scores_gemma":[0.0027521274,0.0005426298,0.44980857,0.0010912619,0.00070794916,0.00025209002,0.0021466862,0.00013524338,0.5361023,0.0010184952,0.0046530855,0.00078959175],"about_ca_topic_score_codex":0.00007857496,"about_ca_topic_score_gemma":0.000020582342,"teacher_disagreement_score":0.076598614,"about_ca_system_score_codex":0.000103175444,"about_ca_system_score_gemma":0.00020755103,"threshold_uncertainty_score":0.999514},"labels":[],"label_agreement":null},{"id":"W2182164191","doi":"10.1016/s1701-2163(15)31051-3","title":"Increase in Transaminase Levels Following the Use of Raltegravir in a Woman With a High HIV Viral Load at 35 Weeks of Pregnancy","year":2013,"lang":"en","type":"article","venue":"Journal of Obstetrics and Gynaecology Canada","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health","keywords":"Medicine; Raltegravir; Viral load; Pregnancy; Human immunodeficiency virus (HIV); Transaminase; Obstetrics; Antiretroviral therapy; Virology; Enzyme","score_opus":0.01524662104256543,"score_gpt":0.21377384635212632,"score_spread":0.19852722530956088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182164191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965308,0.0019103453,0.000004452992,0.00085991796,0.00026770655,0.00033235058,0.000012671357,9.626474e-7,0.00008084619],"genre_scores_gemma":[0.99790925,0.00006825893,0.00076535833,0.0000989305,0.0000034147454,0.000010157548,0.000002861407,0.000009788677,0.0011320038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865615,0.00007983606,0.0005890616,0.00011244623,0.00033901018,0.00022348101],"domain_scores_gemma":[0.99821347,0.0010952586,0.00030316648,0.00012023943,0.00013812141,0.00012972129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016016333,0.00014076599,0.00053899223,0.0002929135,0.000032821266,0.0000066060943,0.000083589584,0.00007318643,0.00008843593],"category_scores_gemma":[0.0005525426,0.00008355669,0.000057053923,0.00040230615,0.00006352464,0.00010980381,0.000021810209,0.00022321062,2.3768374e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006317038,0.00031877466,0.9762783,0.00008172183,0.00024173193,0.0061682723,0.0009270724,0.000052444266,0.00010178621,0.000027741666,0.00041556664,0.015323398],"study_design_scores_gemma":[0.009490824,0.0005011376,0.98808,0.00020090408,0.00015565298,0.00007164695,0.00033822987,0.000072623356,0.0004399242,0.00003193842,0.0005139386,0.00010314512],"about_ca_topic_score_codex":0.032788057,"about_ca_topic_score_gemma":0.1266584,"teacher_disagreement_score":0.093870334,"about_ca_system_score_codex":0.0009137714,"about_ca_system_score_gemma":0.0016011446,"threshold_uncertainty_score":0.9736527},"labels":[],"label_agreement":null},{"id":"W2185595601","doi":"10.7448/ias.18.1.20824","title":"Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first‐line therapy","year":2015,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Medicine; Emtricitabine; Drug resistance; Resistance mutation; Lamivudine; Integrase inhibitor; Virology; Regimen; Drug; Clinical trial; Pharmacology; Protease inhibitor (pharmacology); Reverse transcriptase; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Virus; Biology; Genetics","score_opus":0.029462334386409734,"score_gpt":0.30409863460324243,"score_spread":0.2746363002168327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185595601","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31034157,0.0038164284,0.0006713478,0.6824316,0.0012395757,0.0006880467,0.00010778051,0.000007495257,0.00069616846],"genre_scores_gemma":[0.96232396,0.0021553093,0.004836249,0.0041950564,0.0010656578,0.000049877934,0.000015358015,0.000021742946,0.02533679],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871016,0.00005064146,0.0005417132,0.00010679847,0.0004568613,0.00013382606],"domain_scores_gemma":[0.9982067,0.0003555971,0.0005492691,0.00027139502,0.0005612339,0.000055841116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010270887,0.00012610389,0.0002319743,0.000034101624,0.00013024561,0.000015983484,0.00066350395,0.00005475627,0.000009711358],"category_scores_gemma":[0.00017083378,0.00005354778,0.0005481518,0.00023893907,0.0000947446,0.00007842967,0.000065008535,0.0003148425,0.0000014078357],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005486384,0.00043335796,0.1788685,0.000024552633,0.0012261537,0.0000015294598,0.007585988,0.00066400896,0.0005680661,0.002584909,0.8019714,0.005522899],"study_design_scores_gemma":[0.006036726,0.000053124233,0.12926205,0.0003999825,0.00015332588,0.00003823168,0.0027932583,0.0006596687,0.0010058914,0.0080599,0.8514025,0.0001353422],"about_ca_topic_score_codex":0.000012226011,"about_ca_topic_score_gemma":0.00014280523,"teacher_disagreement_score":0.67823654,"about_ca_system_score_codex":0.00048993126,"about_ca_system_score_gemma":0.0004671192,"threshold_uncertainty_score":0.21836151},"labels":[],"label_agreement":null},{"id":"W2188871070","doi":"","title":"Pooled 48-Week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients","year":2008,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rash; Tolerability; Placebo; Adverse effect; Medicine; Nausea; Etravirine; Diarrhea; Internal medicine; Incidence (geometry); Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.013882078105251768,"score_gpt":0.25142919142862064,"score_spread":0.23754711332336886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2188871070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952747,0.00012083072,0.000014316615,0.00030601653,0.000020795034,0.00064671115,0.00006952888,0.00003235473,0.0035147383],"genre_scores_gemma":[0.98982614,0.0007739808,0.0009511502,0.00002057728,0.0000062223894,0.000020946485,0.00047746603,0.000015144088,0.007908389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803096,0.00006557913,0.00084745715,0.0004487169,0.00031756106,0.0002897012],"domain_scores_gemma":[0.9989383,0.00020451305,0.0002099754,0.0003141594,0.00014805174,0.00018499048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000125815,0.00028648062,0.0010021259,0.0007616547,0.00007340915,0.000005680348,0.00005021257,0.00009973463,0.00015925082],"category_scores_gemma":[0.00016814699,0.00020626125,0.00011200676,0.0013901794,0.00018388417,0.00009936711,0.000044626293,0.000071536844,0.0000067498104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003139488,0.003553288,0.9803743,0.00003579177,0.001880384,0.00008138855,0.0061353203,0.000020249588,0.0015461381,0.000023946453,0.00022502516,0.0029847235],"study_design_scores_gemma":[0.027343122,0.0008189833,0.9589724,0.00006345877,0.0010888667,0.000007803457,0.00032373378,0.00035822365,0.010547253,0.0000019828058,0.00029574646,0.00017842461],"about_ca_topic_score_codex":0.00043115686,"about_ca_topic_score_gemma":0.00032883737,"teacher_disagreement_score":0.024203636,"about_ca_system_score_codex":0.00012443455,"about_ca_system_score_gemma":0.00009465496,"threshold_uncertainty_score":0.841109},"labels":[],"label_agreement":null},{"id":"W2196190612","doi":"10.1016/s1473-3099(15)00348-5","title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":304,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tenofovir alafenamide; Medicine; Emtricitabine; Cobicistat; Regimen; Tolerability; Internal medicine; Rilpivirine; Clinical endpoint; Elvitegravir; Pharmacology; Viral load; Adverse effect; Gastroenterology; Clinical trial; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.034184723645303935,"score_gpt":0.32817029413836707,"score_spread":0.2939855704930631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196190612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023707,0.00012663845,0.00077534164,0.0017128036,0.00020415937,0.015624813,0.0003142978,0.00028920927,0.00071567425],"genre_scores_gemma":[0.99281925,0.000057949543,0.00054663804,0.00074792054,0.00044587796,0.0044812406,0.00029399412,0.00006976868,0.0005373409],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966986,0.0004248232,0.00068183575,0.000893032,0.0004917333,0.0008099689],"domain_scores_gemma":[0.997323,0.00071586965,0.00033805534,0.0007922732,0.00028342693,0.0005473778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063672726,0.0006378489,0.0018624166,0.00021725331,0.00038625038,0.0002450227,0.00037255982,0.00011146464,0.00004196561],"category_scores_gemma":[0.00083273667,0.00037286527,0.00015400091,0.00050110795,0.00009267284,0.00044191195,0.0002614826,0.00036155473,0.00007313955],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34265316,0.013440043,0.63304704,0.00006292104,0.0012335632,0.00027180352,0.0038276054,0.00017022436,0.0005277676,0.000008667177,0.0011970311,0.0035601773],"study_design_scores_gemma":[0.75429434,0.0074735065,0.23002106,0.00037108356,0.0018257697,0.00002259546,0.0011316374,0.003069815,0.00023078447,0.00020513548,0.00066439016,0.00068985886],"about_ca_topic_score_codex":0.0012879611,"about_ca_topic_score_gemma":0.0023501117,"teacher_disagreement_score":0.4116412,"about_ca_system_score_codex":0.00040684434,"about_ca_system_score_gemma":0.00046205684,"threshold_uncertainty_score":0.9998723},"labels":[],"label_agreement":null},{"id":"W2201163923","doi":"10.1371/journal.pone.0145772","title":"HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Centers for Disease Control and Prevention; National Institutes of Health; Wellcome Trust; U.S. President’s Emergency Plan for AIDS Relief; World Health Organization; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation","keywords":"Resistance mutation; Drug resistance; HIV drug resistance; Genotype; Virology; Viral load; Medicine; Reverse-transcriptase inhibitor; Regimen; Lentivirus; Biology; Reverse transcriptase; Human immunodeficiency virus (HIV); Antiretroviral therapy; Internal medicine; Polymerase chain reaction; Genetics; Viral disease","score_opus":0.049362632592289166,"score_gpt":0.2603012519101174,"score_spread":0.2109386193178282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201163923","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7158506,0.03299771,0.05202777,0.06408585,0.00023922286,0.02362447,0.0010770785,0.0014258188,0.10867147],"genre_scores_gemma":[0.42368516,0.000021688662,0.4650308,0.000072312316,0.0001847854,0.001213004,0.00054199196,0.000043746193,0.10920653],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886423,0.000019894598,0.00031853642,0.00026243326,0.00033591795,0.00019895581],"domain_scores_gemma":[0.99855936,0.00012720842,0.00013869579,0.00029780366,0.00074302877,0.00013389082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012613495,0.00013014609,0.00028409148,0.000096111115,0.00011965839,0.000012805084,0.000087910616,0.000042393098,0.000013847723],"category_scores_gemma":[0.00025145322,0.00012575346,0.00005377454,0.0002835409,0.000055489854,0.000068492925,0.000021761649,0.00007126906,0.00007481682],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016722884,0.045599084,0.23367894,0.046371885,0.01422834,0.0004465993,0.10833034,0.0001854358,0.1505838,0.04774675,0.31632233,0.019783609],"study_design_scores_gemma":[0.07466381,0.0010439131,0.035398275,0.019335676,0.019116635,0.000039992865,0.034563646,0.002646716,0.51910895,0.06520444,0.22392385,0.0049541024],"about_ca_topic_score_codex":0.000001661864,"about_ca_topic_score_gemma":0.00004199582,"teacher_disagreement_score":0.41300303,"about_ca_system_score_codex":0.0001532545,"about_ca_system_score_gemma":0.00025542313,"threshold_uncertainty_score":0.5128077},"labels":[],"label_agreement":null},{"id":"W2203567572","doi":"10.1021/acs.jmedchem.5b01037","title":"Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors","year":2015,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Prodrug; Integrase; Chemistry; Pharmacophore; Pharmacokinetics; Integrase inhibitor; Pharmacology; Drug discovery; Human immunodeficiency virus (HIV); Small molecule; Combinatorial chemistry; Computational biology; Stereochemistry; Biochemistry; Virology; Antiretroviral therapy; Viral load; DNA","score_opus":0.029288405158090274,"score_gpt":0.2838816336195302,"score_spread":0.25459322846143995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2203567572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512875,0.0013400718,0.0009565548,0.0012540676,0.0001110534,0.00019834915,0.000026858339,0.000004466475,0.000979831],"genre_scores_gemma":[0.9947997,0.000077016346,0.0009755476,0.00004047622,0.0005040537,0.0000051718503,0.000026941281,0.00001596701,0.0035551256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793124,0.000028540895,0.000930197,0.00016486783,0.00076766184,0.0001774969],"domain_scores_gemma":[0.9986519,0.00004515163,0.00029212836,0.00016242584,0.0005126406,0.0003357506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058899465,0.00020254662,0.00065332657,0.00011488988,0.0000165667,0.000008947257,0.00010662166,0.00008853188,0.00009772777],"category_scores_gemma":[0.00019180465,0.00014087092,0.00014832719,0.00020899165,0.00009755413,0.00020048016,0.000012413253,0.00029207068,0.0000017385017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020414705,0.000744828,0.0032647697,0.0007857608,0.00038817365,0.0003765465,0.0030609667,0.00006113542,0.9770831,0.000009326869,0.008327669,0.0038562464],"study_design_scores_gemma":[0.0050643315,0.0009378924,0.00049865013,0.0012519363,0.00037189905,0.00058504764,0.0037816833,0.000032170377,0.98632467,0.0000272594,0.0009977956,0.00012664522],"about_ca_topic_score_codex":0.00000437898,"about_ca_topic_score_gemma":0.000008858281,"teacher_disagreement_score":0.009241583,"about_ca_system_score_codex":0.00014898356,"about_ca_system_score_gemma":0.00079047505,"threshold_uncertainty_score":0.57445496},"labels":[],"label_agreement":null},{"id":"W2205249602","doi":"10.1093/cid/civ963","title":"Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe","year":2015,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; AIDS Fondet; Ministry of Education and Science; Vetenskapsrådet; Fonds National de la Recherche Luxembourg; Ministry of Health, British Columbia; Istituto Superiore di Sanità; Research Promotion Foundation; Vlaamse regering; European Commission; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Medicine; Drug resistance; Human immunodeficiency virus (HIV); Transmission (telecommunications); Drug; Second line; Current (fluid); Virology; First line; Pharmacology; Internal medicine; Microbiology; Biology; Telecommunications","score_opus":0.026696616841779194,"score_gpt":0.3334869405195758,"score_spread":0.3067903236777966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205249602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840129,0.004498262,0.00006068462,0.00804403,0.00023991909,0.0010686903,0.00002428477,0.00009646788,0.0019547392],"genre_scores_gemma":[0.99524766,0.0017652458,0.000012906694,0.00012268925,0.00010267871,0.000057799258,0.000054860375,0.000017791432,0.0026183508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983513,0.00040684163,0.00053563213,0.0002953045,0.00025212878,0.00015879549],"domain_scores_gemma":[0.9978003,0.0013891999,0.00012493829,0.0002625245,0.00012045108,0.0003025794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006042386,0.00017227007,0.0005285705,0.0000770154,0.000051594452,0.0000095058085,0.000057218294,0.000047867754,0.000015024547],"category_scores_gemma":[0.0017343282,0.000095031486,0.00011971002,0.0003004944,0.00030216528,0.000032982698,0.000032013435,0.0002206757,0.000018009247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004237586,0.0022817773,0.9521113,0.00026134125,0.00010889857,0.000059083064,0.00033179455,0.000015214467,0.000001114064,0.00022673614,0.028289586,0.012075536],"study_design_scores_gemma":[0.06762752,0.0015797997,0.8006789,0.0030571048,0.0011563284,0.00000650324,0.000026891183,0.00055277016,0.00016965707,0.0011318601,0.123667076,0.0003455806],"about_ca_topic_score_codex":0.000003422777,"about_ca_topic_score_gemma":0.000027219447,"teacher_disagreement_score":0.15143242,"about_ca_system_score_codex":0.000043437147,"about_ca_system_score_gemma":0.00014424924,"threshold_uncertainty_score":0.38752714},"labels":[],"label_agreement":null},{"id":"W2211057491","doi":"10.1155/2007/423578","title":"Triple Active Antiretroviral Regimen Including Enfuvirtide Via the Biojector is Effective and Safe","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic; University of Toronto","funders":"","keywords":"Enfuvirtide; Efavirenz; Human immunodeficiency virus (HIV); Medicine; Regimen; Protease inhibitor (pharmacology); Virology; Antiretroviral therapy; Viral load; Internal medicine; Immunology","score_opus":0.005776437609685661,"score_gpt":0.2489230572775883,"score_spread":0.24314661966790263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211057491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912137,0.0032944374,0.00016318644,0.0042925314,0.00036315699,0.00029789374,0.000035837544,0.0000072087764,0.00033209455],"genre_scores_gemma":[0.9973929,0.00026113662,0.000029103034,0.0017632949,0.00025711663,0.0000038560197,0.00001134752,0.000011792582,0.0002694588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989806,0.000085509004,0.0003093004,0.000170361,0.0000847128,0.0003695574],"domain_scores_gemma":[0.99824536,0.00028908678,0.00015247299,0.000083364925,0.000108839544,0.0011209003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037326544,0.00016481112,0.00038038898,0.0002756457,0.00025709727,0.00001698536,0.00006465171,0.0001447122,0.00019247708],"category_scores_gemma":[0.00044861427,0.000100617,0.000104071965,0.00015638418,0.0004834459,0.000052290005,0.000027286189,0.00030965448,0.0000056537283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054309715,0.00012345037,0.81435186,0.00006135574,0.0010451479,0.0016578616,0.0020823616,6.8320375e-8,0.004088011,0.00012688439,0.009797832,0.1661221],"study_design_scores_gemma":[0.014025248,0.0041220244,0.79565454,0.00071919133,0.0014808109,0.020629723,0.0016075398,0.000017386175,0.007008344,0.00062976446,0.1535226,0.0005828346],"about_ca_topic_score_codex":0.0014464854,"about_ca_topic_score_gemma":0.0029000537,"teacher_disagreement_score":0.16553926,"about_ca_system_score_codex":0.0002623624,"about_ca_system_score_gemma":0.00085278496,"threshold_uncertainty_score":0.41030422},"labels":[],"label_agreement":null},{"id":"W2221434518","doi":"10.14205/2309-4435.2015.03.01.3","title":"Comparative Bioavailability Study of Two Antiretroviral FDC Containing Abacavir 600mg and Lamivudine 300mg in Healthy Human Indian Volunteers","year":2015,"lang":"en","type":"article","venue":"Journal of Applied Biopharmaceutics and Pharmacokinetics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Abacavir; Lamivudine; Bioavailability; Pharmacology; Bioequivalence; Human immunodeficiency virus (HIV); Antiretroviral drug; Medicine; Virology; Traditional medicine; Antiretroviral therapy; Viral load; Virus","score_opus":0.08218382833130472,"score_gpt":0.398313480235387,"score_spread":0.31612965190408227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2221434518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971694,0.00091511896,0.0000046631894,0.00034067838,0.00014050148,0.00078364403,0.000015188849,0.000009528908,0.0006212877],"genre_scores_gemma":[0.99831444,0.0005070936,0.00076309126,0.00021268285,0.0001258967,0.0000065265363,0.0000097268285,0.00002000783,0.00004052427],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997876,0.000085282416,0.0010028936,0.00025462967,0.00047563942,0.00030556822],"domain_scores_gemma":[0.99856573,0.00008005222,0.00047824887,0.00011889513,0.00026065088,0.00049644784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009542056,0.0002916229,0.00088925165,0.00040752016,0.00007228178,0.000027527954,0.00010441406,0.000070276175,0.000012869488],"category_scores_gemma":[0.0000125740435,0.00023750814,0.000052101914,0.00034873892,0.00021107528,0.0000752895,0.000094248644,0.00055375317,0.0000015567606],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012068524,0.005284333,0.86602235,0.00042825183,0.0012008266,0.00054299744,0.04870261,0.00017142227,0.056660842,0.00017202551,0.0004147176,0.008331084],"study_design_scores_gemma":[0.36700708,0.04226324,0.31693223,0.0008609241,0.0053900774,0.00092742406,0.11312256,0.009645496,0.12713379,0.0006508126,0.013604075,0.0024622832],"about_ca_topic_score_codex":0.000036165216,"about_ca_topic_score_gemma":0.000026203354,"teacher_disagreement_score":0.54909015,"about_ca_system_score_codex":0.00013687837,"about_ca_system_score_gemma":0.00016981074,"threshold_uncertainty_score":0.9685301},"labels":[],"label_agreement":null},{"id":"W2229778990","doi":"10.1093/jac/dkv429","title":"Backbones versus core agents in initial ART regimens: one game, two players","year":2016,"lang":"en","type":"review","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Core (optical fiber); Medicine; Computer science","score_opus":0.12328855570594749,"score_gpt":0.4042440385662959,"score_spread":0.28095548286034844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229778990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033941225,0.9864225,0.000037858143,0.0029196923,0.0022360964,0.0015283538,0.00006207771,0.000040732495,0.0033586046],"genre_scores_gemma":[0.000082413106,0.9888024,0.001526789,0.00043789227,0.0010433862,0.000006638779,0.000072511495,0.00012785976,0.007900163],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99702364,0.00009475971,0.0015511966,0.00036105435,0.00048270114,0.0004866303],"domain_scores_gemma":[0.99778545,0.00017832499,0.001308354,0.00032040032,0.00017747033,0.00023001971],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000408439,0.00064134755,0.0029470518,0.0007905856,0.00004134921,0.00003928335,0.00028452533,0.00036483377,0.00074295554],"category_scores_gemma":[0.00004862207,0.00043608193,0.00096168584,0.00037810512,0.00011626652,0.0001453989,0.000038469323,0.0006650131,0.00038387734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050082733,0.0017338593,0.000117996635,0.003950166,0.0050009745,0.0025507186,0.00046548338,4.987985e-7,0.00030834382,0.000027677537,0.18409279,0.7967432],"study_design_scores_gemma":[0.018372124,0.000314447,0.0000128455595,0.037330203,0.00076360506,0.0008051651,0.000010267315,4.1777943e-7,0.0003869261,0.0000063508523,0.9416014,0.00039624306],"about_ca_topic_score_codex":0.0000026086382,"about_ca_topic_score_gemma":0.0000061963433,"teacher_disagreement_score":0.79634696,"about_ca_system_score_codex":0.00067143666,"about_ca_system_score_gemma":0.0010742693,"threshold_uncertainty_score":0.9998091},"labels":[],"label_agreement":null},{"id":"W2230176182","doi":"10.1155/2014/373898","title":"HIV and Liver transplantation: The British Columbia Experience, 2004 to 2013","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; Vancouver General Hospital; University of British Columbia; University of Toronto","funders":"Provincial Health Services Authority","keywords":"Human immunodeficiency virus (HIV); Liver transplantation; Transplantation; Medicine; Intensive care medicine; Virology; Political science; Surgery","score_opus":0.003164416894137765,"score_gpt":0.19951899109778112,"score_spread":0.19635457420364336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230176182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876196,0.0034026431,0.00013229286,0.008260654,0.00019923937,0.00012888265,0.000030938092,0.000004660164,0.00022110074],"genre_scores_gemma":[0.9929823,0.0015020885,0.000052621326,0.0037154555,0.00017589986,0.000006892952,0.000013068427,0.0000063572274,0.0015453149],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994117,0.000047871774,0.00019318263,0.00010638899,0.000052912706,0.0001879363],"domain_scores_gemma":[0.9986073,0.00006864846,0.00004380308,0.00004968899,0.00009352735,0.0011370381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112406415,0.00006572581,0.00019583238,0.000048508246,0.00025790944,0.000086914304,0.000047253223,0.00006881264,0.0006635597],"category_scores_gemma":[0.0001715337,0.00005586288,0.000042273507,0.00006423211,0.00025099085,0.00002789759,0.000006207562,0.00010916273,0.00000821772],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030964056,0.000051198538,0.7175331,0.00005861972,0.00013370001,0.0015645878,0.0010418617,6.328355e-7,0.00006476896,0.000028924194,0.2344734,0.04501825],"study_design_scores_gemma":[0.0029507182,0.0004742708,0.3703052,0.0004498461,0.00028439082,0.031549636,0.00025714785,0.000009644281,0.000013351884,0.00008527368,0.5934582,0.00016231091],"about_ca_topic_score_codex":0.014321729,"about_ca_topic_score_gemma":0.19829234,"teacher_disagreement_score":0.3589848,"about_ca_system_score_codex":0.000042531163,"about_ca_system_score_gemma":0.00050135044,"threshold_uncertainty_score":0.992242},"labels":[],"label_agreement":null},{"id":"W2233867682","doi":"10.3109/23744235.2015.1133927","title":"Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients","year":2016,"lang":"en","type":"article","venue":"Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Mylan; ViiV Healthcare; Janssen Pharmaceuticals; Gilead Sciences; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Etravirine; Regimen; Internal medicine; Cohort; Adverse effect; Population; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Immunology","score_opus":0.01022351240661606,"score_gpt":0.27036797857286904,"score_spread":0.260144466166253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2233867682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977493,0.00010531288,0.000022963086,0.00006949797,0.000046506953,0.0009683698,0.00006284981,0.00007367165,0.0009014873],"genre_scores_gemma":[0.99878526,0.00053751894,0.000015916516,0.0000146848615,0.000020484506,0.000096519434,0.00009022788,0.00002230634,0.0004170574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871063,0.000060349434,0.00047218447,0.0003194377,0.00019027042,0.0002471044],"domain_scores_gemma":[0.9989729,0.00023239419,0.00018954994,0.0002559741,0.00011696032,0.000232234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049574315,0.00023431891,0.0005594704,0.00024776807,0.00004505627,0.000005693112,0.000038453218,0.00006574732,0.00009907688],"category_scores_gemma":[0.00023289201,0.00015457944,0.000092327384,0.00023243739,0.00015698773,0.00009631164,0.000034257282,0.000035047633,0.00000840013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009977658,0.0017968264,0.99066794,0.00006001476,0.00033214287,0.000034671888,0.00074606715,0.0000012458447,0.0005144305,0.00004424048,0.000020080832,0.004784548],"study_design_scores_gemma":[0.016168129,0.0011865488,0.980634,0.0004232836,0.00029419616,0.000005934274,0.00003372091,0.0000030059193,0.0010710909,0.0000064421,0.000025123232,0.00014855385],"about_ca_topic_score_codex":0.00012165125,"about_ca_topic_score_gemma":0.00007535498,"teacher_disagreement_score":0.015170363,"about_ca_system_score_codex":0.00031269254,"about_ca_system_score_gemma":0.00023649911,"threshold_uncertainty_score":0.6303566},"labels":[],"label_agreement":null},{"id":"W2234981304","doi":"10.1016/j.jcv.2015.07.175","title":"Evolving patterns of antiretroviral drug resistance from HIV genotyping in Northern Alberta, Canada: 2007–2013, a retrospective 15 year analysis","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Government of Alberta; University of Calgary; University of Alberta; Provincial Laboratory of Public Health","funders":"","keywords":"Virology; Virus; Herpes simplex virus; Varicella zoster virus; Hepatitis C virus; Hepatitis B virus; Vaccination; Medicine; Cytomegalovirus; Poliovirus; Immunology; Viral disease; Herpesviridae","score_opus":0.021456483600313075,"score_gpt":0.30200595909931366,"score_spread":0.28054947549900056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234981304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929931,0.00056912244,0.00016367782,0.0053041326,0.0003327068,0.00009289876,0.000017095846,0.0000029907567,0.0005242568],"genre_scores_gemma":[0.9946504,0.000102061684,0.0013315766,0.00024175404,0.00032123306,0.0000012367639,0.000017243123,0.000015248937,0.003319216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705195,0.00028124318,0.0016747499,0.00025325996,0.00047596384,0.00026280293],"domain_scores_gemma":[0.9974291,0.00065103447,0.0010151551,0.0002455842,0.00038311305,0.0002760417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011041646,0.00016047839,0.0014218902,0.00025248903,0.00002100946,0.0000058078554,0.00016590186,0.00014626679,0.00018728939],"category_scores_gemma":[0.0013355048,0.00012586848,0.0003137738,0.00030179505,0.000072124625,0.000079121826,0.000047939633,0.00054902246,0.000013954195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010713793,0.0002304751,0.9893256,0.000007315681,0.001383121,0.00041044384,0.00054621085,0.000027758311,0.000010923449,0.000008335224,0.0068186754,0.00015975429],"study_design_scores_gemma":[0.003964928,0.0002074145,0.9918437,0.000086209235,0.00083692704,0.0000067955175,0.00029112838,0.00015104798,0.000023618735,0.00012104879,0.0023647298,0.00010247776],"about_ca_topic_score_codex":0.102522664,"about_ca_topic_score_gemma":0.92413664,"teacher_disagreement_score":0.821614,"about_ca_system_score_codex":0.00037587978,"about_ca_system_score_gemma":0.0011985946,"threshold_uncertainty_score":0.9034537},"labels":[],"label_agreement":null},{"id":"W2252811454","doi":"10.1097/qai.0000000000000790","title":"Brief Report","year":2015,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Cilag; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Dolutegravir; Abacavir; Lamivudine; Emtricitabine; Efavirenz; Medicine; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Chronic hepatitis; Virus","score_opus":0.0341467119659951,"score_gpt":0.29198968615366744,"score_spread":0.2578429741876723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252811454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804972,0.0058996826,0.00033349713,0.0037395942,0.0012171265,0.00022694032,0.0000021628946,0.00008325336,0.008000545],"genre_scores_gemma":[0.96412855,0.00018077786,0.004756019,0.00006685054,0.00010734943,0.0000052051755,0.000015517908,0.000043302076,0.030696452],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9970379,0.000062902065,0.0012567071,0.00022644157,0.0010069971,0.00040909273],"domain_scores_gemma":[0.9978256,0.000080422906,0.00066145865,0.00043725307,0.00065282336,0.00034239434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001618221,0.0002482301,0.00078197627,0.0005718302,0.000088776025,0.000045633235,0.00023529155,0.00010369763,0.000089108755],"category_scores_gemma":[0.0008873758,0.00018016725,0.00034439497,0.00075701094,0.00012944796,0.00032787002,0.000073024006,0.00012024695,0.00023096974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030646413,0.007606212,0.48519233,0.00055883033,0.004268163,0.17943041,0.017655345,0.0001640968,0.02464718,0.0020471176,0.21817693,0.057188746],"study_design_scores_gemma":[0.02569609,0.0067116586,0.34059125,0.0019567336,0.0022949332,0.41208693,0.009167519,0.0001861847,0.023938432,0.0026785752,0.17308931,0.0016023945],"about_ca_topic_score_codex":0.000010885681,"about_ca_topic_score_gemma":4.430339e-7,"teacher_disagreement_score":0.23265651,"about_ca_system_score_codex":0.00024060415,"about_ca_system_score_gemma":0.00079904724,"threshold_uncertainty_score":0.7347007},"labels":[],"label_agreement":null},{"id":"W2254287415","doi":"10.1093/jac/dkv176","title":"Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout","year":2015,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Dolutegravir; Raltegravir; Integrase; Integrase inhibitor; Virology; Pharmacology; Reverse transcriptase; Viral replication; Drug; Chemistry; Medicine; Virus; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biochemistry; RNA","score_opus":0.007820138784715847,"score_gpt":0.27129681585754784,"score_spread":0.263476677072832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254287415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98139775,0.00033859102,0.00010600921,0.016292183,0.00015602724,0.000491416,0.000005975011,0.000023234348,0.0011888092],"genre_scores_gemma":[0.9681425,0.0006021979,0.005100794,0.0020376253,0.0003794724,0.000011590396,0.000041305568,0.00005246234,0.023632042],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856156,0.00008725988,0.0005531138,0.00021639084,0.00029832002,0.00028338397],"domain_scores_gemma":[0.99898404,0.000025289362,0.00028082807,0.00029914748,0.00020068877,0.00021003095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007221416,0.00024855143,0.00056592573,0.0003009484,0.00003367177,0.000038108912,0.00013570423,0.00012646198,0.000051877858],"category_scores_gemma":[0.000054676777,0.00017292735,0.00016812266,0.0003462192,0.000042031068,0.000176009,0.000016735392,0.0003317566,0.00008242758],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008662296,0.0015924264,0.14322811,0.00019045438,0.00056815165,0.0012942277,0.017811045,0.000045714263,0.34515357,0.000014376461,0.4656655,0.015774136],"study_design_scores_gemma":[0.024986014,0.0006479652,0.010098627,0.0012623544,0.00016971755,0.0010697228,0.00048544284,0.000039010345,0.54563785,0.00007895183,0.4150338,0.00049054535],"about_ca_topic_score_codex":0.000007840904,"about_ca_topic_score_gemma":0.000013456534,"teacher_disagreement_score":0.20048428,"about_ca_system_score_codex":0.00042998977,"about_ca_system_score_gemma":0.00025684337,"threshold_uncertainty_score":0.70517725},"labels":[],"label_agreement":null},{"id":"W2254808774","doi":"10.1021/acs.orglett.5b02769","title":"Seven-Membered Ring Nucleoside Analogues: Stereoselective Synthesis and Studies on Their Conformational Properties","year":2015,"lang":"en","type":"article","venue":"Organic Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"European Research Council; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Directorate-General for Research and Innovation","keywords":"Chemistry; Stereoselectivity; Ring (chemistry); Stereochemistry; Nucleoside; Epoxide; Combinatorial chemistry; Organic chemistry; Catalysis","score_opus":0.0483592539318408,"score_gpt":0.2496609631248015,"score_spread":0.2013017091929607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254808774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858063,0.00020886409,0.000014636431,0.013023137,0.00007706408,0.0002499654,0.000004599159,0.00006475614,0.0005506852],"genre_scores_gemma":[0.99719745,0.000035626817,0.00023427996,0.0019753329,0.00006541511,0.000022011693,0.000010018059,0.000019635625,0.0004402091],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992177,0.000037429385,0.00019011853,0.00017834763,0.00020053271,0.00017590026],"domain_scores_gemma":[0.9995525,0.000092857335,0.00006308647,0.00011173087,0.000079656485,0.000100152356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015460762,0.00017162508,0.00026624708,0.000099266465,0.00008955242,0.000024257628,0.000041506173,0.00003175327,0.000022610431],"category_scores_gemma":[0.00018228084,0.000110506946,0.000029824625,0.000105275445,0.00007956856,0.000120468765,0.00003832406,0.00008851769,0.00010552399],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002471866,0.0011163747,0.09830437,0.00094815047,0.013389266,0.0005917444,0.40962183,0.00008219541,0.3597153,0.00094122667,0.09857539,0.01424226],"study_design_scores_gemma":[0.007895325,0.00053977326,0.028424934,0.0016657204,0.00074684405,0.00046035173,0.056225546,0.0006718152,0.89693713,0.00017751385,0.005170601,0.0010844166],"about_ca_topic_score_codex":0.000004433936,"about_ca_topic_score_gemma":0.000012175147,"teacher_disagreement_score":0.53722185,"about_ca_system_score_codex":0.00025506434,"about_ca_system_score_gemma":0.00008858436,"threshold_uncertainty_score":0.45063424},"labels":[],"label_agreement":null},{"id":"W2256401900","doi":"10.1155/2006/402409","title":"Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients","year":2006,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; St. Paul's Hospital; University of Ottawa; Ottawa Hospital; Health Sciences Centre; Toronto General Hospital; University of Toronto; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Enfuvirtide; Human immunodeficiency virus (HIV); Medicine; Virology; Intensive care medicine; Immunology","score_opus":0.008692312465374141,"score_gpt":0.23283081835504255,"score_spread":0.2241385058896684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2256401900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833637,0.00073841296,0.000062355095,0.014751941,0.00028108654,0.00029388737,0.00044818202,0.0000024726587,0.00005794751],"genre_scores_gemma":[0.9982386,0.0000767493,0.00032593228,0.00073641207,0.00008007177,0.000009350006,0.00014978323,0.000009230961,0.00037385526],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.999095,0.000052531686,0.0004183942,0.00010002622,0.000046113222,0.00028790117],"domain_scores_gemma":[0.9985093,0.00035152517,0.00012353798,0.00007215487,0.00019386364,0.00074960996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013903121,0.00010458583,0.00027672603,0.0003519148,0.0001106084,0.000011645906,0.000053898777,0.00009885293,0.0001994458],"category_scores_gemma":[0.00055699504,0.00007093507,0.0000933402,0.00011625507,0.0002129461,0.00002561495,0.0000064693572,0.00014058057,0.0000017566528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005749932,0.0001032722,0.9400143,0.000017996857,0.00013853205,0.00010923453,0.00009742822,0.0000130672615,0.000027748787,0.00043088326,0.05387636,0.005113702],"study_design_scores_gemma":[0.0099047255,0.0009117467,0.44203997,0.0004407579,0.0005886997,0.0011557334,0.0003457121,0.00008257792,0.0000958721,0.00027467753,0.54390126,0.00025825348],"about_ca_topic_score_codex":0.088138275,"about_ca_topic_score_gemma":0.53040487,"teacher_disagreement_score":0.49797434,"about_ca_system_score_codex":0.00030833934,"about_ca_system_score_gemma":0.0031074537,"threshold_uncertainty_score":0.9179339},"labels":[],"label_agreement":null},{"id":"W2257021625","doi":"10.1089/aid.2014.5447a.abstract","title":"Glycolysis Inhibitors as Potential Anti-HIV Compounds","year":2014,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McGill University","funders":"","keywords":"Human immunodeficiency virus (HIV); Library science; Virology; Medicine; Computer science","score_opus":0.03616799422460532,"score_gpt":0.34808014813324156,"score_spread":0.31191215390863625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257021625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97416276,0.000234604,0.0000188149,0.0010217588,0.000054969918,0.00032744184,0.000005999034,0.00007159991,0.024102053],"genre_scores_gemma":[0.9492853,0.00013138814,0.00039506846,0.00013153208,0.0003830981,0.000025577885,0.00006094563,0.000032624466,0.049554456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746776,0.00016068379,0.00029099948,0.0004617495,0.0009422362,0.00067659304],"domain_scores_gemma":[0.99876016,0.00013999765,0.000044312324,0.0003665686,0.0002394425,0.00044951102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007800831,0.0002110604,0.00041383758,0.0006111314,0.00063949707,0.00017491399,0.00013714579,0.00011128164,0.00061663723],"category_scores_gemma":[0.00016814945,0.00016789259,0.00010357479,0.00039686263,0.00047356536,0.00014215849,0.00017762471,0.00039392165,0.0008907542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002625986,0.00061913277,0.9199866,0.00011691576,0.00035534587,0.00021700317,0.00044336388,3.1567296e-7,0.014136237,0.008955047,0.0509123,0.003995127],"study_design_scores_gemma":[0.011019734,0.007999863,0.5943772,0.00046320696,0.00033865386,0.00020225869,0.0014930947,0.000022490563,0.052302383,0.0072540343,0.3236103,0.00091676577],"about_ca_topic_score_codex":0.00015169359,"about_ca_topic_score_gemma":0.000030759493,"teacher_disagreement_score":0.32560942,"about_ca_system_score_codex":0.00010258983,"about_ca_system_score_gemma":0.00012302911,"threshold_uncertainty_score":0.99988717},"labels":[],"label_agreement":null},{"id":"W2260708985","doi":"10.1371/journal.pone.0148231","title":"Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients","year":2016,"lang":"en","type":"review","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary; University Health Network; Ottawa Hospital; University of Ottawa","funders":"ViiV Healthcare; Gilead Sciences; GlaxoSmithKline; AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Intensive care medicine; Viral load; Virology; Immunology","score_opus":0.14429677969752674,"score_gpt":0.34553359029902525,"score_spread":0.2012368106014985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260708985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035762116,0.97094434,0.000029609719,0.00006184088,0.000032126092,0.02509871,0.00018667064,0.000025842355,0.000044641183],"genre_scores_gemma":[0.0009639839,0.9852321,0.0004424464,0.000024586028,0.000016430515,0.012588043,0.00030732693,0.00004498539,0.0003800674],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962006,0.00029371082,0.0016724815,0.0005472648,0.00091859704,0.0003673511],"domain_scores_gemma":[0.99647695,0.00087353913,0.0013521916,0.00074142654,0.00046178268,0.00009410764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027359644,0.0006810954,0.0038364984,0.00018931384,0.00005119171,0.000017433525,0.00028680748,0.00011528067,0.00010386565],"category_scores_gemma":[0.00015767552,0.00025519935,0.00036220482,0.00043790622,0.0001368451,0.0001196444,0.00007588047,0.00012329652,0.000016175734],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067027105,0.010236045,0.0011110026,0.9456111,0.005721787,0.000016297097,0.0005408561,6.484489e-8,6.542223e-7,0.000038492224,0.000036519148,0.036016878],"study_design_scores_gemma":[0.004425597,0.0029860798,0.00045319923,0.97959566,0.009214551,0.0000011700215,0.0000821212,0.0000017356326,0.000025648791,0.0000048467605,0.002914372,0.00029499762],"about_ca_topic_score_codex":0.0000024805722,"about_ca_topic_score_gemma":0.0000029505607,"teacher_disagreement_score":0.03572188,"about_ca_system_score_codex":0.00036188317,"about_ca_system_score_gemma":0.00043751686,"threshold_uncertainty_score":0.99999005},"labels":[],"label_agreement":null},{"id":"W2265497608","doi":"10.1002/2211-5463.12025","title":"A targeted <scp>DNA</scp> substrate mechanism for the inhibition of <scp>HIV</scp>‐1 integrase by inhibitors with antiretroviral activity","year":2015,"lang":"en","type":"article","venue":"FEBS Open Bio","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Saint Joseph University; Agence Universitaire de la Francophonie; Merck","keywords":"Integrase; Raltegravir; DNA; Chemistry; Long terminal repeat; Binding site; Biochemistry; Molecular biology; Biology; Virology; Human immunodeficiency virus (HIV); Viral load","score_opus":0.025032493099124167,"score_gpt":0.2648463247449232,"score_spread":0.23981383164579903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265497608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190736,0.00014137238,0.0013486278,0.00099445,0.00017841297,0.0026321015,0.00022793778,0.00007112803,0.0024986265],"genre_scores_gemma":[0.9813067,0.000032414573,0.0020496063,0.00017161256,0.0000950095,0.0002949117,0.00051182206,0.000056889425,0.015481058],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811316,0.00008554725,0.0003690004,0.00047831365,0.00048192858,0.000472027],"domain_scores_gemma":[0.9983639,0.0002817874,0.0003147967,0.00041194903,0.00034420707,0.00028333307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058781885,0.00037751714,0.00054881704,0.00013268406,0.00017684346,0.000119191915,0.00025137624,0.00016640949,0.000008618889],"category_scores_gemma":[0.000387362,0.00022922755,0.00012535763,0.00046191315,0.00014925035,0.00039490403,0.0001449482,0.00023377866,0.000062959625],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013091771,0.0038050823,0.09244572,0.00037533548,0.0024570746,0.00018771125,0.010154636,0.000006122924,0.26309478,0.0043052775,0.616965,0.0048940848],"study_design_scores_gemma":[0.0077600246,0.0016254102,0.0027328506,0.00026714042,0.0004226076,0.000024737614,0.0037891658,0.00023550972,0.9721333,0.00048475727,0.010424071,0.00010046187],"about_ca_topic_score_codex":0.00029348172,"about_ca_topic_score_gemma":0.00016662895,"teacher_disagreement_score":0.7090385,"about_ca_system_score_codex":0.00017328569,"about_ca_system_score_gemma":0.00044494602,"threshold_uncertainty_score":0.93476284},"labels":[],"label_agreement":null},{"id":"W2267471943","doi":"10.18433/j3x61s","title":"Prodrugs of Antiinfective Agents: A Review","year":2016,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Indian Council of Medical Research","keywords":"Prodrug; Biopharmaceutical; Pharmacology; Drug; Medicine; Pharmacokinetics; Biology; Biotechnology","score_opus":0.18391192073445223,"score_gpt":0.5182740319425718,"score_spread":0.3343621112081196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267471943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000274583,0.991363,0.000012716147,0.003931059,0.0005032462,0.0012778976,0.000021712183,0.000015016182,0.002847895],"genre_scores_gemma":[0.000075541575,0.9974792,0.0004834651,0.0005017373,0.0004009351,0.00002537069,0.000003517569,0.000028025554,0.001002217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99531597,0.00039894693,0.0019777701,0.00040463218,0.0013934681,0.0005092183],"domain_scores_gemma":[0.99662656,0.0004737058,0.0016907563,0.00017816998,0.0004623941,0.00056839635],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025480145,0.000507316,0.0029614712,0.00050477765,0.00010733897,0.000025070918,0.00056581787,0.00007766417,0.0020633647],"category_scores_gemma":[0.00039550496,0.00025117194,0.0013042105,0.0011636034,0.0006062182,0.00033040755,0.00013538377,0.000591771,0.00016422225],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044071214,0.0004933109,0.00020635044,0.039851036,0.000849707,0.00024947166,0.000041277388,2.4050388e-8,0.000015029815,0.000045658082,0.009961781,0.9482423],"study_design_scores_gemma":[0.0014603098,0.00015250719,0.00000406526,0.11565808,0.0050379382,0.0010940374,0.000006803099,0.0000035626965,0.00028546577,0.00001328186,0.8760621,0.00022185448],"about_ca_topic_score_codex":0.0000012098858,"about_ca_topic_score_gemma":1.01781964e-7,"teacher_disagreement_score":0.9480204,"about_ca_system_score_codex":0.00027375337,"about_ca_system_score_gemma":0.0022178954,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W2270189214","doi":"10.1016/s1473-3099(16)00013-x","title":"Early HIV treatment to forestall drug resistance","year":2016,"lang":"en","type":"letter","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Emtricitabine; Lamivudine; Drug resistance; Medicine; Tenofovir; Epidemiology; Drug; Pharmacology; Virology; Internal medicine; Human immunodeficiency virus (HIV); Biology; Virus; Genetics","score_opus":0.015232422947351998,"score_gpt":0.25745467388653404,"score_spread":0.24222225093918204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270189214","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015393674,0.001110698,0.00003882801,0.9522088,0.0003983165,0.0018214468,0.0007063084,0.0006311912,0.02769074],"genre_scores_gemma":[0.012136783,0.00067152525,0.00011045835,0.34619898,0.012264041,0.0012922204,0.00071848265,0.00016477509,0.62644273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976175,0.00012855414,0.00032879686,0.00061047194,0.00049826724,0.0008164457],"domain_scores_gemma":[0.9980198,0.00031612042,0.00015523587,0.0011672961,0.00010475525,0.00023676868],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000081045466,0.0006136745,0.0009845201,0.00018790842,0.00024257801,0.00008822831,0.00025662125,0.00018874249,0.00031696627],"category_scores_gemma":[0.00006316548,0.00031716996,0.00035974156,0.00020865492,0.000114123846,0.00006127947,0.00008070821,0.0003557666,0.0021637843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002522575,0.00013969326,0.03523397,0.00014391038,0.00073910673,0.0008565996,0.00035178853,4.681992e-7,0.0000026436007,0.000070614464,0.96065897,0.0015499817],"study_design_scores_gemma":[0.002732109,0.00012077513,0.008997149,0.0005883066,0.00090855773,0.000024987336,0.000007373654,3.8764148e-7,0.000033036493,0.00087774836,0.9853161,0.00039344636],"about_ca_topic_score_codex":0.000040636096,"about_ca_topic_score_gemma":0.00013770354,"teacher_disagreement_score":0.60600984,"about_ca_system_score_codex":0.0007766775,"about_ca_system_score_gemma":0.00029211384,"threshold_uncertainty_score":0.99992806},"labels":[],"label_agreement":null},{"id":"W2270630361","doi":"10.1097/qad.0000000000000809","title":"CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States","year":2015,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, University of North Carolina at Chapel Hill; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; Medical Center, University of Rochester; University of North Carolina at Chapel Hill; Saint Christopher's Hospital for Children; School of Medicine, New York University; International Maternal Pediatric Adolescent AIDS Clinical Trials Network; University of Washington; Johns Hopkins University; U.S. President’s Emergency Plan for AIDS Relief; Children's National Hospital; National Center for Advancing Translational Sciences; Seattle Children's Research Institute; University of Florida Health; School of Medicine, Duke University; University of Miami; York University; University of Rochester; State University of New York; U.S. Public Health Service; University of Illinois at Urbana-Champaign; Tulane University; St. Jude Children's Research Hospital; Florida Department of Health; Texas Children's Hospital; University of Southern California; University of Colorado Denver; Leonard M. Miller School of Medicine; University of California, San Diego; Yale University; United States Agency for International Development","keywords":"Cart; Medicine; Viral load; Regimen; Confidence interval; Antiretroviral therapy; Internal medicine; Cohort; Cohort study; Observational study; Human immunodeficiency virus (HIV); Pediatrics; Immunology","score_opus":0.019841712524036503,"score_gpt":0.2657754040302201,"score_spread":0.2459336915061836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270630361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99822116,0.0004104218,0.000012874312,0.00060074026,0.000032428718,0.00054438354,0.00002592208,0.000026182184,0.00012590236],"genre_scores_gemma":[0.99893624,0.0002869545,0.0002176541,0.00015484018,0.000008573879,0.000029315597,0.00022580456,0.000016732625,0.00012389067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850804,0.0001910101,0.0004175592,0.00022601866,0.0004125075,0.00024484834],"domain_scores_gemma":[0.99936116,0.00008629052,0.00013151704,0.0002261304,0.00014895144,0.00004594507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046634808,0.00024815396,0.0004999589,0.00038460593,0.000022528457,0.000029577193,0.00012165856,0.00011442109,0.000015860473],"category_scores_gemma":[0.00004158744,0.00014715303,0.00006676594,0.0005695025,0.00018400198,0.00022264915,0.000032933258,0.00018843793,0.000002250656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009100208,0.0006010952,0.97895014,0.000028218194,0.000095030024,0.000044519216,0.016627435,0.000005900266,0.0008834079,0.0003101298,0.000025421245,0.0015186958],"study_design_scores_gemma":[0.010363561,0.004390031,0.96892667,0.000052143656,0.000035653196,0.000004541406,0.01357426,0.00012691414,0.0018865998,0.0004118756,0.00006496957,0.00016281065],"about_ca_topic_score_codex":0.0006553256,"about_ca_topic_score_gemma":0.000070165326,"teacher_disagreement_score":0.010023486,"about_ca_system_score_codex":0.00007119423,"about_ca_system_score_gemma":0.00016409015,"threshold_uncertainty_score":0.6000726},"labels":[],"label_agreement":null},{"id":"W2272014925","doi":"10.1182/blood.v122.21.3970.3970","title":"ODE-Adefovir As Potential Therapeutic Agent In AML","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Adefovir; Pharmacology; Biology; Chemistry; Virology; Hepatitis B virus; Virus","score_opus":0.010523186428210776,"score_gpt":0.2388148631267285,"score_spread":0.22829167669851774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272014925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98374605,0.0007377851,0.00001681755,0.0037857231,0.000087868626,0.0005311412,9.329959e-7,0.000055917466,0.011037778],"genre_scores_gemma":[0.9760351,0.00008195565,0.00050407014,0.00050621864,0.000073419564,0.00009515471,0.000021225895,0.000018095421,0.02266477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914485,0.000023978122,0.00018175085,0.00019636945,0.00020288888,0.00025014614],"domain_scores_gemma":[0.9996403,0.0000128109905,0.000029011526,0.00018389616,0.000027581555,0.00010639501],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000057538877,0.00013269253,0.00018591569,0.00010250964,0.00003309596,0.000019840516,0.000057144298,0.00006280239,0.0012979279],"category_scores_gemma":[0.000008990741,0.00009987559,0.00006464692,0.00012495801,0.000023250313,0.000055631255,0.000027046173,0.00010210962,0.0029207354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027501845,0.01662313,0.74146676,0.00023985811,0.002541313,0.0035825754,0.007174418,0.000011855469,0.06159344,0.0016794549,0.013149227,0.15166292],"study_design_scores_gemma":[0.029611506,0.0006739826,0.8727848,0.00024625816,0.0010194379,0.00052797876,0.00094955455,0.00021333554,0.056584187,0.0026763105,0.033956904,0.00075576245],"about_ca_topic_score_codex":0.0000931652,"about_ca_topic_score_gemma":0.0000126417435,"teacher_disagreement_score":0.15090716,"about_ca_system_score_codex":0.000038638977,"about_ca_system_score_gemma":0.0000770705,"threshold_uncertainty_score":0.999615},"labels":[],"label_agreement":null},{"id":"W2276636569","doi":"10.1021/acs.jmedchem.5b01357","title":"A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing","year":2016,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; University of British Columbia; AIDS Vancouver","funders":"Canadian Institutes of Health Research","keywords":"Chemistry; Reverse transcriptase; Cytotoxicity; Stereochemistry; EC50; Integrase; Integrase inhibitor; Lead compound; HIV-1 protease; Human immunodeficiency virus (HIV); Protease; In vitro; Viral replication; Structure–activity relationship; Enzyme; Virology; Biochemistry; Virus; RNA; DNA; Viral load; Biology; Antiretroviral therapy; Gene","score_opus":0.01737620930105004,"score_gpt":0.2618886162776841,"score_spread":0.24451240697663407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276636569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9322723,0.0001405878,0.057222612,0.009419491,0.00010528094,0.00030217358,0.000021812173,0.000010468715,0.00050524675],"genre_scores_gemma":[0.9938977,0.000030606865,0.004523827,0.000050397055,0.0005001953,0.000024364534,0.000012051826,0.000019487148,0.0009414017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99729276,0.000037905163,0.0012755259,0.00026277755,0.000946226,0.00018483415],"domain_scores_gemma":[0.9972202,0.00023907084,0.0014223501,0.00047612767,0.00047605418,0.00016618324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001075789,0.000196242,0.000523948,0.00013041109,0.00006381046,0.000010314995,0.00030104647,0.00008245181,0.000026537602],"category_scores_gemma":[0.00055529556,0.000108770604,0.00021395247,0.00020797881,0.00015044403,0.00007692865,0.000044813285,0.00019296598,0.0000026161538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010279875,0.0009169714,0.009099199,0.00037231785,0.0004917678,0.0000214933,0.0010598762,0.00058266707,0.9812458,0.00001022057,0.0021932006,0.0029784979],"study_design_scores_gemma":[0.0036366067,0.00010196897,0.0069091762,0.002289471,0.0005965662,0.00041721913,0.00052584807,0.0016148807,0.98330796,0.000016070879,0.00044841494,0.00013580604],"about_ca_topic_score_codex":0.000006987685,"about_ca_topic_score_gemma":3.1343978e-7,"teacher_disagreement_score":0.061625343,"about_ca_system_score_codex":0.00023830729,"about_ca_system_score_gemma":0.0002307126,"threshold_uncertainty_score":0.44355366},"labels":[],"label_agreement":null},{"id":"W2277933729","doi":"10.1155/2003/309724","title":"Nelfinavir and Non‐Nucleoside Reverse Transcriptase Inhibitor‐Based Salvage Regimes in Heavily Hiv Pretreated Patients","year":2003,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta Hospital; Alberta Hospital Edmonton; Royal Victoria Hospital","funders":"Pfizer","keywords":"Nelfinavir; Efavirenz; Reverse-transcriptase inhibitor; Medicine; Salvage therapy; Viral load; Lamivudine; Reverse transcriptase; Protease inhibitor (pharmacology); Nucleoside Reverse Transcriptase Inhibitor; Internal medicine; Nucleoside; Virology; Human immunodeficiency virus (HIV); Pharmacology; Antiretroviral therapy; Biology; Chemotherapy; Virus; RNA","score_opus":0.0036499196825463026,"score_gpt":0.20110120588283614,"score_spread":0.19745128620028984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277933729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454725,0.0018585372,0.000015941845,0.0027443836,0.00023033329,0.0002354108,0.00006941742,0.0000070077976,0.0002917205],"genre_scores_gemma":[0.9974981,0.0002019178,0.00007191912,0.0018545778,0.000038866372,0.000005175876,0.000057600217,0.000015195722,0.00025662468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885243,0.000116069496,0.00039740815,0.00019399784,0.00007742598,0.00036264252],"domain_scores_gemma":[0.9978236,0.000067715744,0.000101356396,0.00008621567,0.00009962433,0.001821485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017014441,0.00018341516,0.00043026317,0.00046227293,0.000086324784,0.000014530846,0.000040114417,0.00017192209,0.00020112342],"category_scores_gemma":[0.0006007051,0.00014311628,0.00008586185,0.00019846631,0.0002651782,0.00005592099,0.0000049605064,0.0002524189,0.000004361596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012041406,0.00025769364,0.9820568,0.00006493174,0.00009456998,0.0015040338,0.00022540025,5.866415e-7,0.00030161595,0.000030660736,0.013398186,0.0019451282],"study_design_scores_gemma":[0.04127443,0.0025807165,0.74262214,0.0022858959,0.0009119075,0.0032690777,0.00042299606,0.000022984004,0.0012033529,0.00016724614,0.2045366,0.0007026774],"about_ca_topic_score_codex":0.00061617995,"about_ca_topic_score_gemma":0.0019187217,"teacher_disagreement_score":0.23943466,"about_ca_system_score_codex":0.00020043801,"about_ca_system_score_gemma":0.0020014471,"threshold_uncertainty_score":0.58361125},"labels":[],"label_agreement":null},{"id":"W2278758730","doi":"10.1139/cjm-2015-0725","title":"Might dolutegravir be part of a functional cure for HIV?","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase; Human immunodeficiency virus (HIV); Drug resistance; Integrase inhibitor; Antiretroviral therapy; Virology; ANTIRETROVIRAL AGENTS; Medicine; Pharmacology; Biology; Genetics; Viral load","score_opus":0.04546272478766144,"score_gpt":0.2845139872656365,"score_spread":0.23905126247797504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278758730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024367871,0.9928023,0.00006968184,0.0038714302,0.0010093782,0.00048654733,0.0014885956,0.000002613485,0.00024504866],"genre_scores_gemma":[0.000010675927,0.96453625,0.00076625607,0.00018123585,0.00076364644,0.00002507525,0.0008470683,0.000044212167,0.03282559],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983936,0.00008319943,0.0008966787,0.00019799128,0.000048058955,0.0003804732],"domain_scores_gemma":[0.99813825,0.00018641267,0.0007119263,0.00017464459,0.00031979854,0.00046895433],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027220152,0.00030445564,0.0017869204,0.00060876325,0.000060544313,0.000005270618,0.00016380246,0.0004075885,0.0010176799],"category_scores_gemma":[0.000084509025,0.00018031412,0.0007866629,0.000116119605,0.00017033679,0.000024430192,0.000009153293,0.00026811167,0.000060483555],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053413227,0.0000418944,0.0001319821,0.0023794405,0.0019774104,0.00023276973,0.00006823375,3.496819e-8,0.00005406685,0.00024173321,0.81484383,0.17997517],"study_design_scores_gemma":[0.0011758575,0.00017170401,0.000004796442,0.008634872,0.0011929785,0.00376411,0.000010879562,1.4842595e-8,0.000021722355,0.000025182806,0.9848441,0.00015378724],"about_ca_topic_score_codex":0.000025051198,"about_ca_topic_score_gemma":0.0009941338,"teacher_disagreement_score":0.17982137,"about_ca_system_score_codex":0.0004242727,"about_ca_system_score_gemma":0.008013776,"threshold_uncertainty_score":0.9998955},"labels":[],"label_agreement":null},{"id":"W2282613813","doi":"10.1155/2003/891968","title":"Response to a Protease‐Inhibitor (Ritonavir)‐Containing Combination Antiretroviral Regimen in HIV‐Infected Children","year":2003,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children; Pediatric Oncology Group","funders":"","keywords":"Ritonavir; Viral load; Regimen; Medicine; Protease inhibitor (pharmacology); Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.004149560163304406,"score_gpt":0.2256887046540605,"score_spread":0.2215391444907561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2282613813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935147,0.0007260177,0.000032484895,0.004920525,0.00020072045,0.0004347028,0.000028228897,0.000011109685,0.0001314919],"genre_scores_gemma":[0.99854267,0.000025011808,0.000088586006,0.0009109476,0.00007330729,0.0000130576445,0.00003584594,0.000014754295,0.00029581544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986338,0.00029757686,0.0004071147,0.00019186547,0.00009708801,0.00037257248],"domain_scores_gemma":[0.99814194,0.00010902684,0.000113354836,0.00009061734,0.00012752383,0.0014175315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047768548,0.00016450646,0.0004045397,0.00060730183,0.00009820525,0.000019531146,0.000055984583,0.00015881327,0.00018600243],"category_scores_gemma":[0.0018326202,0.00013521969,0.00008631775,0.0002583868,0.00013407064,0.00005391079,0.000010983816,0.000273426,0.000012639936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054018124,0.00019180497,0.99101293,0.000013950441,0.00011170405,0.00096713955,0.00029642734,6.9976085e-7,0.0013724095,0.00017715145,0.0028146934,0.002500936],"study_design_scores_gemma":[0.015057099,0.00414113,0.9411173,0.0008922462,0.00021181903,0.008164687,0.0002241999,0.0000052374135,0.00070054276,0.00015386718,0.028971206,0.00036066285],"about_ca_topic_score_codex":0.0005137256,"about_ca_topic_score_gemma":0.0012192946,"teacher_disagreement_score":0.0498956,"about_ca_system_score_codex":0.00039778603,"about_ca_system_score_gemma":0.0027874582,"threshold_uncertainty_score":0.55140984},"labels":[],"label_agreement":null},{"id":"W2283091835","doi":"10.4103/0300-1652.171613","title":"Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays","year":2015,"lang":"en","type":"article","venue":"Nigerian Medical Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Genotyping; Drug resistance; Virology; Genotype; Human immunodeficiency virus (HIV); Viral load; Antiretroviral drug; Biology; HIV drug resistance; Lentivirus; Medicine; Gene; Antiretroviral therapy; Genetics; Viral disease","score_opus":0.01203924903877936,"score_gpt":0.24754353642651838,"score_spread":0.23550428738773901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283091835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840304,0.0030696166,0.005694861,0.0058217226,0.00027063396,0.00018420382,0.000051111416,0.000023838047,0.0008535973],"genre_scores_gemma":[0.9877642,0.00022265819,0.010297299,0.00043909444,0.00023663139,0.0000040909536,0.00011206859,0.000026072528,0.0008979128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716544,0.00018666865,0.00073926465,0.0002572069,0.0013263035,0.00032513074],"domain_scores_gemma":[0.9982898,0.00015137986,0.00035706983,0.00019437782,0.00013560175,0.0008717343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010931869,0.00021317595,0.0006421909,0.00013698239,0.00007418243,0.000021541677,0.00017232679,0.00015973084,0.00029071711],"category_scores_gemma":[0.00041553273,0.00016488288,0.000107331034,0.00017538352,0.00032084383,0.00011063628,0.000040394174,0.00043996266,0.000008866542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040065018,0.0020217104,0.66269475,0.0005291076,0.0013514371,0.0030036964,0.007094967,0.0000030248855,0.08634527,0.00052715465,0.19347687,0.038945526],"study_design_scores_gemma":[0.20905805,0.007907966,0.3449061,0.034586523,0.0045864624,0.0024359352,0.017662,0.0051340694,0.16573955,0.011120306,0.19077659,0.0060864757],"about_ca_topic_score_codex":0.00006335109,"about_ca_topic_score_gemma":0.00005884376,"teacher_disagreement_score":0.31778863,"about_ca_system_score_codex":0.00016811896,"about_ca_system_score_gemma":0.00059753354,"threshold_uncertainty_score":0.6723729},"labels":[],"label_agreement":null},{"id":"W22837822","doi":"","title":"Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness.","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Emtricitabine; Delphi method; Human immunodeficiency virus (HIV); Cytidine; Medicine; Lamivudine; Compact space; Family medicine; Viral load; Antiretroviral therapy; Mathematics; Virology; Biology; Statistics; Virus","score_opus":0.0670320308015545,"score_gpt":0.2652468707427912,"score_spread":0.19821483994123668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W22837822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98685884,0.0003109774,0.000031227497,0.0069113676,0.00004541436,0.001022214,0.0000116895235,0.0001084007,0.0046998737],"genre_scores_gemma":[0.99388033,0.00012876581,0.00069222576,0.00015630989,0.0001482616,0.00033353886,0.000072820396,0.00001801653,0.004569738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988937,0.00007787413,0.00019748628,0.00028724674,0.00020867388,0.00033506125],"domain_scores_gemma":[0.9992922,0.00025518378,0.00007799741,0.00018112094,0.000036292815,0.00015720395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026457393,0.00020252772,0.00043357714,0.00016862087,0.000091152746,0.00003487625,0.000053991254,0.00005926808,0.000006023198],"category_scores_gemma":[0.00008232104,0.00013251884,0.000049884107,0.00014104517,0.00009566405,0.000026262944,0.000022603974,0.00010868786,0.000009211835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048301797,0.00028183148,0.80830765,0.000064364154,0.0006683255,0.000047178542,0.0017576044,0.0000011500772,0.000024005574,0.00025444734,0.008588159,0.17952229],"study_design_scores_gemma":[0.0037103018,0.00012875705,0.9823407,0.000070813556,0.0001140643,0.000018094632,0.00015835185,0.00008903909,0.0010026632,0.000088824265,0.012068779,0.00020962009],"about_ca_topic_score_codex":0.000026417716,"about_ca_topic_score_gemma":0.000011042479,"teacher_disagreement_score":0.17931266,"about_ca_system_score_codex":0.00004531951,"about_ca_system_score_gemma":0.00003308783,"threshold_uncertainty_score":0.54039615},"labels":[],"label_agreement":null},{"id":"W2289938826","doi":"10.1128/aac.01490-15","title":"HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument","year":2015,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Sanger sequencing; Concordance; Drug resistance; HIV drug resistance; Biology; Pyrosequencing; Population; Multiplex; Deep sequencing; Massive parallel sequencing; Genetics; DNA sequencing; Medicine; Computational biology; Virology; Viral load; Human immunodeficiency virus (HIV); Gene; Genome","score_opus":0.03870477749486575,"score_gpt":0.24243695121568412,"score_spread":0.20373217372081837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2289938826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9198801,0.000045307017,0.000014732425,0.07660848,0.000088833,0.00042333727,0.000014948077,0.000058605106,0.0028656535],"genre_scores_gemma":[0.93002576,0.00018798308,0.0026879974,0.01706451,0.000093124916,0.00001597878,0.00006255308,0.0000399792,0.049822107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886405,0.00003517218,0.00024407319,0.00032721844,0.00023552678,0.00029393728],"domain_scores_gemma":[0.9993714,0.00008164362,0.000097293196,0.00022572919,0.00007061895,0.00015332994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001954535,0.00024156076,0.00025728383,0.00004146792,0.00019252443,0.000058286496,0.000097128446,0.000055282373,0.000069410366],"category_scores_gemma":[0.000043059295,0.00015436044,0.000048994403,0.00014646437,0.000081596016,0.000051469415,0.000027984905,0.00013748748,0.000056550907],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031255887,0.00025143655,0.042891104,0.000040139996,0.00019496863,0.00004517869,0.002435953,0.0000014988351,0.008654171,0.000111567446,0.9424775,0.0025839137],"study_design_scores_gemma":[0.015152481,0.00013771777,0.010690227,0.0011030374,0.00014476798,0.0000457515,0.00094625703,0.00019830707,0.17999475,0.00036983588,0.7904007,0.0008161724],"about_ca_topic_score_codex":0.000052730855,"about_ca_topic_score_gemma":0.000012724288,"teacher_disagreement_score":0.17134057,"about_ca_system_score_codex":0.00017154266,"about_ca_system_score_gemma":0.00010785479,"threshold_uncertainty_score":0.6294636},"labels":[],"label_agreement":null},{"id":"W2312257867","doi":"10.1097/qad.0b013e328349a9c2","title":"The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool","year":2011,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"U.S. Public Health Service","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); Medicine; Sida; Lentivirus; Intensive care medicine; Medical physics; Viral disease; Virology; Computer science; Viral load","score_opus":0.05695610322726095,"score_gpt":0.30483459382387534,"score_spread":0.2478784905966144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312257867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971663,0.00005398097,0.000052772833,0.0005750154,0.000096850614,0.0011479444,0.000030251882,0.00007498005,0.0008019221],"genre_scores_gemma":[0.96161306,0.000031452382,0.03059018,0.00024772465,0.00006688292,0.00033937255,0.000099642304,0.000028373153,0.006983297],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979941,0.00020901398,0.00067284703,0.00037211296,0.00041913937,0.00033273236],"domain_scores_gemma":[0.99870205,0.00010845599,0.000101728576,0.00062890537,0.00011578086,0.0003431025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069940696,0.0002677183,0.00049141806,0.00013727693,0.00011276245,0.000008174164,0.00020313812,0.000093207505,0.00021460414],"category_scores_gemma":[0.000058246587,0.0001457609,0.00009277382,0.0002007915,0.000058009155,0.000061242106,0.000053625492,0.000052987918,0.00009158542],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08178712,0.016497225,0.094045445,0.00006862345,0.0025502772,0.0007095754,0.13092932,0.0000069354405,0.044699665,0.0006893669,0.0023496056,0.62566686],"study_design_scores_gemma":[0.008758585,0.037475005,0.3175105,0.00025952983,0.00017996092,0.000118879514,0.00928486,0.00004480847,0.3978284,0.000017314886,0.22797553,0.00054665166],"about_ca_topic_score_codex":0.000026915523,"about_ca_topic_score_gemma":0.00002664921,"teacher_disagreement_score":0.62512016,"about_ca_system_score_codex":0.00022885016,"about_ca_system_score_gemma":0.00045539136,"threshold_uncertainty_score":0.5943957},"labels":[],"label_agreement":null},{"id":"W2312642584","doi":"10.1097/01.qai.0000185314.56556.c3","title":"Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials","year":2005,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; University of British Columbia","funders":"","keywords":"Enfuvirtide; Regimen; Medicine; Human immunodeficiency virus (HIV); Clinical trial; Internal medicine; Sida; Surgery; Virology; Viral disease; Immunology; Gp41","score_opus":0.05574507091467743,"score_gpt":0.36926656977827593,"score_spread":0.3135214988635985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312642584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511,0.0017590002,0.000012367275,0.0012691846,0.0003934022,0.00096825336,0.000011175735,0.000018024868,0.00045862308],"genre_scores_gemma":[0.9953629,0.0017106762,0.0019084015,0.00003667053,0.000058005233,0.000020713434,0.000035480683,0.000032883654,0.0008343188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941067,0.0010589984,0.003216409,0.00037015212,0.00072859635,0.00051913527],"domain_scores_gemma":[0.9952491,0.0027027845,0.0012696437,0.00044556285,0.00017785399,0.00015507116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004135109,0.0003965807,0.0019784584,0.000760931,0.00010128536,0.000056533154,0.00030743235,0.00018868642,0.00012296696],"category_scores_gemma":[0.00192612,0.00024183403,0.0005391621,0.0009862746,0.00027005942,0.00043757842,0.00006024388,0.00021884876,0.000028093431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040443484,0.02541178,0.854764,0.0001263571,0.002318283,0.0010878148,0.020951446,0.0003668611,0.0035889905,0.00017001327,0.0020598127,0.04871119],"study_design_scores_gemma":[0.09874077,0.0050159646,0.88895303,0.000569008,0.0006988543,0.00028523465,0.003375123,0.0002699432,0.00086489104,0.000019067611,0.0008679583,0.0003401734],"about_ca_topic_score_codex":0.00006720207,"about_ca_topic_score_gemma":0.000025902047,"teacher_disagreement_score":0.058297284,"about_ca_system_score_codex":0.00042712744,"about_ca_system_score_gemma":0.0004956611,"threshold_uncertainty_score":0.98617053},"labels":[],"label_agreement":null},{"id":"W2312930817","doi":"10.1097/00007691-200206000-00001","title":"Critical Issues in Therapeutic Drug Monitoring of Antiretroviral Drugs","year":2002,"lang":"en","type":"review","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Therapeutic drug monitoring; Medicine; Pharmacokinetics; Drug; Antiretroviral therapy; Antiretroviral drug; Pharmacology; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Intensive care medicine; Human immunodeficiency virus (HIV); ANTIRETROVIRAL AGENTS; Viral load; Virology","score_opus":0.06114185799801884,"score_gpt":0.3766669653323431,"score_spread":0.31552510733432426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312930817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030332885,0.99147564,0.000008011761,0.0003268371,0.0021008174,0.0013277372,0.000013373027,0.00021405648,0.0015002526],"genre_scores_gemma":[0.08013145,0.9002656,0.0008206313,0.000010383076,0.0015124526,0.00023726234,0.000017216536,0.00026298582,0.016742067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994297,0.000453683,0.0018374148,0.0010343798,0.0011747377,0.0012027433],"domain_scores_gemma":[0.99718237,0.00084268197,0.000434632,0.0010549224,0.00017866355,0.00030672786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000777777,0.0012744628,0.0039592865,0.0010538943,0.00016738322,0.000099694305,0.0005865928,0.00044060862,0.00015231154],"category_scores_gemma":[0.00006109351,0.0010499895,0.00092480937,0.00112042,0.00025535835,0.00027087587,0.00017113933,0.0012869796,0.0003076746],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004662208,0.0007208096,0.0323494,0.01183725,0.0010697704,0.00021340672,0.0041617337,6.219814e-7,0.000018246474,0.0002182762,0.000051638406,0.9493122],"study_design_scores_gemma":[0.0053824107,0.00043494173,0.0050423536,0.1578356,0.010631857,0.00023832999,0.005937658,0.00004252907,0.0023829082,0.0005384158,0.807719,0.0038140288],"about_ca_topic_score_codex":0.0000923826,"about_ca_topic_score_gemma":9.665519e-7,"teacher_disagreement_score":0.94549817,"about_ca_system_score_codex":0.0009956086,"about_ca_system_score_gemma":0.0003776896,"threshold_uncertainty_score":0.99942774},"labels":[],"label_agreement":null},{"id":"W2312954548","doi":"10.1097/00002030-200111230-00017","title":"Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Resistance mutation; Reverse transcriptase; Drug resistance; Immunology; Viral load; Medicine; Internal medicine; Virology; Lentivirus; Biology; Viral disease; Human immunodeficiency virus (HIV); Polymerase chain reaction","score_opus":0.009292628340977672,"score_gpt":0.2305666770690848,"score_spread":0.22127404872810713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312954548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976758,0.00012939046,0.0000095033365,0.0001409802,0.000030236408,0.00040600894,0.000029882885,0.00002318313,0.0015550291],"genre_scores_gemma":[0.9975483,0.000094551564,0.0018250744,0.00006814871,0.000025314517,0.000010669501,0.00007468347,0.000022027529,0.0003312206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835527,0.00012493526,0.00050214713,0.0002840921,0.00041317957,0.00032038626],"domain_scores_gemma":[0.9992283,0.0001386537,0.00022972246,0.00019642401,0.000121992125,0.000084896004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026956774,0.00021913383,0.00053194456,0.00022540728,0.000044530003,0.000006864017,0.000090321635,0.00010380388,0.00007798642],"category_scores_gemma":[0.00006409167,0.00016653037,0.00010081826,0.00038820773,0.00009796808,0.000106920175,0.000045338442,0.00015946521,0.000012618366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023381761,0.0010269319,0.9446598,0.000035852474,0.000075737844,0.00009141886,0.0011543919,0.0000014999935,0.043558024,0.00003628191,0.000044897206,0.006976952],"study_design_scores_gemma":[0.007828772,0.0012734141,0.86226976,0.00025838387,0.00006112311,0.0000047931712,0.0006908874,0.000023332559,0.12697843,0.000032487063,0.0003957862,0.00018280622],"about_ca_topic_score_codex":0.00012790931,"about_ca_topic_score_gemma":0.000012297582,"teacher_disagreement_score":0.0834204,"about_ca_system_score_codex":0.00015233194,"about_ca_system_score_gemma":0.00008515697,"threshold_uncertainty_score":0.67909116},"labels":[],"label_agreement":null},{"id":"W2313539652","doi":"10.1139/cjc-2013-0052","title":"Facile protection-free one-pot synthesis of 7-deaza-2′-deoxyguanosine-5′-triphosphate — A versatile molecular biology probe","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Deoxyguanosine; Chemistry; Pyrophosphate; Combinatorial chemistry; Hydrolysis; Yield (engineering); DNA; Biochemistry; Enzyme","score_opus":0.00959303217767397,"score_gpt":0.20827195239676716,"score_spread":0.1986789202190932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313539652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98362416,0.0010360585,0.0003739217,0.007934785,0.00011424603,0.0005303942,0.000054664048,0.00001396984,0.0063177706],"genre_scores_gemma":[0.9943908,0.000021331824,0.0024589442,0.000070095106,0.00007228756,0.00005020128,0.00001081915,0.000021457121,0.0029041034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988673,0.000020961636,0.00046436276,0.0001538463,0.00017945601,0.00031410033],"domain_scores_gemma":[0.9983075,0.000035038534,0.00028800115,0.0002867316,0.00046496742,0.0006177128],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012747219,0.00017307982,0.000423356,0.0001316307,0.00005632189,0.000018564511,0.00020524795,0.00015591046,0.0019379657],"category_scores_gemma":[0.000573187,0.00015177015,0.00014249716,0.00021705205,0.00012411931,0.00007437499,0.000015955538,0.00022715962,0.000032944332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013433727,0.00025200372,0.016984824,0.0007142277,0.0014473498,0.0005316499,0.0008411204,0.000010486943,0.94723785,0.000050314644,0.017775504,0.014020361],"study_design_scores_gemma":[0.0013084443,0.00008743233,0.001506094,0.00040145003,0.00015934398,0.00023379645,0.00018471883,0.000011135084,0.98861027,0.000532024,0.0068052583,0.00016001669],"about_ca_topic_score_codex":0.0012879099,"about_ca_topic_score_gemma":0.00014506807,"teacher_disagreement_score":0.041372463,"about_ca_system_score_codex":0.00027803797,"about_ca_system_score_gemma":0.0019179389,"threshold_uncertainty_score":0.9989744},"labels":[],"label_agreement":null},{"id":"W2313954337","doi":"10.1177/095632020401500401","title":"Potential of 4′-C-Substituted Nucleosides for the Treatment of HIV-1","year":2004,"lang":"en","type":"review","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ottawa Hospital Research Institute","keywords":"Human immunodeficiency virus (HIV); Stereochemistry; Chemistry; Pharmacology; Virology; Medicine","score_opus":0.023442323400439172,"score_gpt":0.310387022912384,"score_spread":0.28694469951194485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313954337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016607275,0.9952023,0.00009836148,0.00031140287,0.00008192599,0.001840037,0.00022712916,0.000042128057,0.00053601066],"genre_scores_gemma":[0.0017464277,0.9883187,0.0010989764,0.00001105115,0.00026038886,0.00019304827,0.0006759107,0.00008844494,0.0076070908],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982346,0.0000136655,0.0007581054,0.0004217102,0.0002669616,0.00030490587],"domain_scores_gemma":[0.9985873,0.00012999083,0.0005358531,0.00057488325,0.00010893046,0.00006300906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007463942,0.00058920175,0.0020528208,0.000054520497,0.00007034819,0.000011348755,0.00020797666,0.00031071034,0.00014490043],"category_scores_gemma":[0.000011548273,0.00034403324,0.001395127,0.00022925224,0.00023437511,0.00003061628,0.000013502564,0.00010914491,0.000012607822],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033633356,0.0022846528,0.000060938353,0.028528653,0.0052756253,0.000038902643,0.00034287688,8.371325e-7,0.0037547962,0.000021375372,0.0007048412,0.9586502],"study_design_scores_gemma":[0.004330694,0.00017522789,0.000013461739,0.007046894,0.0035453842,0.000046688416,0.00003932571,0.0000051540715,0.105955705,0.00002151717,0.8785018,0.00031820583],"about_ca_topic_score_codex":0.000010395629,"about_ca_topic_score_gemma":5.3005186e-7,"teacher_disagreement_score":0.95833194,"about_ca_system_score_codex":0.00023988474,"about_ca_system_score_gemma":0.0006051309,"threshold_uncertainty_score":0.9999012},"labels":[],"label_agreement":null},{"id":"W2314401326","doi":"10.5414/cpp44180","title":"Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product","year":2006,"lang":"en","type":"article","venue":"International Journal of Clinical Pharmacology and Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Efavirenz; Bioequivalence; Reverse-transcriptase inhibitor; Pharmacokinetics; Capsule; Bioavailability; Cmax; Pharmacology; Crossover study; Medicine; Chemistry; Human immunodeficiency virus (HIV); Viral load; Virology; Biology; Antiretroviral therapy; Placebo","score_opus":0.06567932079286021,"score_gpt":0.4078633520262846,"score_spread":0.3421840312334244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314401326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98527634,0.0009769098,0.000045603192,0.0125232395,0.00083447574,0.00024009927,0.000012931875,0.0000017207684,0.00008868452],"genre_scores_gemma":[0.9979945,0.00037200897,0.00035192576,0.0007274066,0.0003302609,0.0000023032242,0.0000030170047,0.0000033088177,0.00021531445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855363,0.00020636481,0.00087946927,0.00008502272,0.0002165849,0.00005894795],"domain_scores_gemma":[0.99855316,0.00027892506,0.00058543426,0.000059046735,0.0004965737,0.000026844613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086501514,0.00007887291,0.00036126887,0.000060442882,0.000029360135,0.0000038509634,0.000094369105,0.000048700418,0.00002514739],"category_scores_gemma":[0.000042477877,0.000039095423,0.00012273752,0.00010773755,0.00054883835,0.000054847827,0.000024355259,0.00021477502,3.4713128e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023259416,0.0050959247,0.7821904,0.00013517641,0.0076708873,0.000044430068,0.0046927077,0.00006400267,0.14208975,0.005720209,0.007815746,0.021221368],"study_design_scores_gemma":[0.048041437,0.0007980742,0.6434838,0.00018156703,0.0025139756,0.00026949722,0.00033393578,0.0013936346,0.23062658,0.0052609188,0.06689501,0.00020155351],"about_ca_topic_score_codex":0.0000063802117,"about_ca_topic_score_gemma":0.0000024716128,"teacher_disagreement_score":0.13870656,"about_ca_system_score_codex":0.000017750559,"about_ca_system_score_gemma":0.00014357906,"threshold_uncertainty_score":0.20222178},"labels":[],"label_agreement":null},{"id":"W2314718629","doi":"10.1097/qai.0000000000000932","title":"Critical Review","year":2016,"lang":"en","type":"review","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine","score_opus":0.053180212360789916,"score_gpt":0.36342004590844473,"score_spread":0.31023983354765483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314718629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000071224335,0.99411446,0.000056815297,0.0021853978,0.0012562101,0.0007893295,0.000026365695,0.00006588994,0.0014984254],"genre_scores_gemma":[0.000018449928,0.98560816,0.0010941196,0.000090262954,0.00019538362,0.000043298507,0.00003079946,0.00013623721,0.012783295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939806,0.00032978065,0.0033024068,0.00045723104,0.001191321,0.00073868677],"domain_scores_gemma":[0.9957878,0.00096271525,0.0014447377,0.0007957195,0.0006476976,0.0003613435],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019006373,0.0008065993,0.0058615557,0.0011039195,0.0001445428,0.00005359489,0.00064849714,0.0003610923,0.00086280296],"category_scores_gemma":[0.0025417744,0.00044379247,0.0026419957,0.0011690463,0.00029373623,0.00032159177,0.00015601271,0.0003340075,0.001979477],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019755564,0.00039993197,0.000009519312,0.067918874,0.0008893411,0.0024491192,0.000041290965,5.8484457e-9,0.0000029411262,0.00023855998,0.016710136,0.9113205],"study_design_scores_gemma":[0.0005304958,0.00036528608,0.000016468626,0.29077318,0.0043511023,0.015863638,0.00001459805,8.7750394e-8,0.000003006534,0.0000596961,0.68768966,0.0003327648],"about_ca_topic_score_codex":6.3087305e-7,"about_ca_topic_score_gemma":4.269191e-8,"teacher_disagreement_score":0.91098773,"about_ca_system_score_codex":0.00044772524,"about_ca_system_score_gemma":0.0015904366,"threshold_uncertainty_score":0.9998014},"labels":[],"label_agreement":null},{"id":"W2314841159","doi":"10.1097/00002030-200203290-00015","title":"To stop or not to stop: That is the question, but what is the answer?","year":2002,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Intensive care medicine; Medicine; Regimen; Adverse effect; Population; Ritonavir; Context (archaeology); Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Internal medicine; Viral load","score_opus":0.034579521503664605,"score_gpt":0.29713746717948836,"score_spread":0.26255794567582375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314841159","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0072333342,0.00083822664,0.00010436751,0.98739004,0.0010308198,0.0016953157,0.00006922461,0.00010114509,0.0015375502],"genre_scores_gemma":[0.0019850382,0.0004824341,0.00073975325,0.5931611,0.0015465734,0.00019899748,0.00008883955,0.000063940766,0.4017333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972387,0.00014458413,0.00036213073,0.00068231556,0.0009933134,0.00057898235],"domain_scores_gemma":[0.9979155,0.0003353728,0.00010535847,0.0013034025,0.00016255454,0.00017783235],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035303738,0.00056327815,0.00060368265,0.00022221351,0.0002831114,0.00023093402,0.000506401,0.00042407116,0.0028219211],"category_scores_gemma":[0.000075857635,0.00026381388,0.00024336175,0.00045297877,0.00008405495,0.00014680534,0.00015495492,0.0009177798,0.004456845],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007773976,0.00004834146,0.0011444866,0.000045739383,0.00043359178,0.00037069616,0.0076742847,2.753325e-7,0.000008625436,0.000022242551,0.9647391,0.02543488],"study_design_scores_gemma":[0.0005761086,0.0002994944,0.0015065805,0.0005641481,0.00054793287,0.00007356413,0.0009609151,0.000002985878,0.0012187967,0.00003099787,0.99386126,0.00035722187],"about_ca_topic_score_codex":0.00013006465,"about_ca_topic_score_gemma":0.00001544038,"teacher_disagreement_score":0.40019575,"about_ca_system_score_codex":0.00028066363,"about_ca_system_score_gemma":0.0001529794,"threshold_uncertainty_score":0.9999814},"labels":[],"label_agreement":null},{"id":"W2314944728","doi":"10.1097/00002030-200203290-00019","title":"Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors","year":2002,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Saquinavir; Indinavir; Amprenavir; Ritonavir; Pharmacology; Nelfinavir; Lopinavir; Protease inhibitor (pharmacology); Efavirenz; Nevirapine; Protease; Medicine; Virology; Biology; Viral load; HIV-1 protease; Virus; Biochemistry; Enzyme","score_opus":0.013772910068925464,"score_gpt":0.23705699939392336,"score_spread":0.22328408932499788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314944728","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52003086,0.0064760996,0.000010560429,0.45734283,0.00075929484,0.004761383,0.00036426066,0.00049344875,0.009761271],"genre_scores_gemma":[0.365808,0.0004634097,0.00540031,0.15388711,0.007864367,0.00096343446,0.007337077,0.000472662,0.45780364],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971756,0.00013883511,0.0007627665,0.0005827227,0.00085483515,0.00048525477],"domain_scores_gemma":[0.998435,0.00015288178,0.00031747745,0.00070490583,0.00020690524,0.0001827996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016791731,0.00060869777,0.001083132,0.0004662312,0.00007598478,0.000018831723,0.00018520934,0.0006238488,0.00081371434],"category_scores_gemma":[0.00012606576,0.00048661605,0.0003829989,0.00040395398,0.00014902373,0.000091137044,0.00010324808,0.0010835838,0.00034050224],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008077933,0.00046959554,0.053018425,0.0005740186,0.0006371131,0.002397994,0.00025371517,2.0047527e-7,0.00012000032,0.000004490353,0.93871,0.0037336843],"study_design_scores_gemma":[0.0043015573,0.00061294064,0.0019788488,0.0018870737,0.0014595651,0.00021328949,0.00007213084,0.000006684077,0.009198051,0.000041448624,0.97952247,0.00070592295],"about_ca_topic_score_codex":0.00024044888,"about_ca_topic_score_gemma":0.0000034991187,"teacher_disagreement_score":0.44804236,"about_ca_system_score_codex":0.00017403522,"about_ca_system_score_gemma":0.00021448577,"threshold_uncertainty_score":0.99975854},"labels":[],"label_agreement":null},{"id":"W2315476807","doi":"10.1093/jac/dkw071","title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","year":2016,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Genome Canada; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Dolutegravir; Integrase inhibitor; Integrase; Elvitegravir; Virology; Drug resistance; Medicine; Ritonavir; Biology; Genetics; Virus; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.012105083557039247,"score_gpt":0.3010445109096439,"score_spread":0.28893942735260464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315476807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669127,0.000043831446,0.01677087,0.015184371,0.0002745494,0.00070168346,0.00000785896,0.000020305559,0.00008384641],"genre_scores_gemma":[0.85717946,0.00003092,0.1381762,0.0017107617,0.00012868625,0.00001635098,0.0000037562252,0.000062451894,0.002691404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99734986,0.00004203397,0.0013478441,0.0003546472,0.00046097036,0.00044461671],"domain_scores_gemma":[0.9986567,0.00007916747,0.00035999992,0.00022136462,0.00029915877,0.00038358997],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007311646,0.00037592056,0.0008626496,0.0010599061,0.000071733266,0.00004922483,0.00023193173,0.00011695975,0.000054123102],"category_scores_gemma":[0.00012578322,0.00024861543,0.00030454338,0.00085254776,0.000031291478,0.0002172066,0.00003074625,0.00019297561,0.000069163514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043538264,0.0005527684,0.026896246,0.000045956604,0.00041357835,0.00022965916,0.016033152,0.000013756715,0.90215796,0.000010694387,0.0071817795,0.04211062],"study_design_scores_gemma":[0.008447491,0.00029268677,0.005083,0.0040147314,0.00004350114,0.000053336626,0.00043976455,0.0000014447646,0.9563906,0.000021214722,0.024856238,0.00035596493],"about_ca_topic_score_codex":0.00001030079,"about_ca_topic_score_gemma":0.00019585162,"teacher_disagreement_score":0.12140533,"about_ca_system_score_codex":0.0008605178,"about_ca_system_score_gemma":0.0005307919,"threshold_uncertainty_score":0.9999966},"labels":[],"label_agreement":null},{"id":"W2316945952","doi":"10.1055/s-0031-1296371","title":"A Single-dose, Randomized, Open-label, Two-period Crossover Bioequivalence Study Comparing a Fixed-Dose Pediatric Combination of Lamivudine and Stavudine Tablet for Oral Suspension with Individual Liquid Formulations in Healthy Adult Male Volunteers","year":2011,"lang":"en","type":"article","venue":"Arzneimittelforschung","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vertex Pharmaceuticals (Canada); Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Stavudine; Lamivudine; Bioequivalence; Fixed-dose combination; Pharmacology; Pharmacokinetics; Crossover study; Medicine; Zidovudine; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Virology; Sida; Virus; Viral disease","score_opus":0.07768172737483126,"score_gpt":0.3217633594496312,"score_spread":0.24408163207479994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316945952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923049,0.00020029064,0.00036222476,0.00035069097,0.00008469848,0.006210363,0.000030877985,0.000045021152,0.00041091742],"genre_scores_gemma":[0.9857935,0.00006866868,0.012931938,0.000090872636,0.000030373556,0.0004509093,0.0001893735,0.000048520127,0.00039586762],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99744415,0.00012991823,0.0009129736,0.00055316475,0.00043971348,0.0005200588],"domain_scores_gemma":[0.99847,0.00026107562,0.0003821751,0.0003138708,0.00039532877,0.0001775209],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010248121,0.00037169454,0.0011636023,0.00050955894,0.0002386818,0.000066607456,0.00019797968,0.000086183296,0.000044583194],"category_scores_gemma":[0.00024211295,0.00029542958,0.000060809234,0.0006960768,0.00015635643,0.00059698813,0.00024142639,0.00019767089,0.000004386599],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20416665,0.007922335,0.7697343,0.00035660792,0.0004894339,0.000087370296,0.014309581,0.000024526724,0.00032607972,0.0017901526,0.00017567449,0.0006172865],"study_design_scores_gemma":[0.8577792,0.011965537,0.115852684,0.00046476466,0.0017147979,0.00014333928,0.0032511465,0.0065218243,0.0013494729,0.00017774933,0.000041304134,0.00073815277],"about_ca_topic_score_codex":0.00061691005,"about_ca_topic_score_gemma":0.0016243455,"teacher_disagreement_score":0.6538816,"about_ca_system_score_codex":0.00014031139,"about_ca_system_score_gemma":0.0002179877,"threshold_uncertainty_score":0.9999498},"labels":[],"label_agreement":null},{"id":"W2317747011","doi":"10.1097/ftd.0b013e31821c2772","title":"Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected Patients, With and Without HCV Coinfection, Receiving Boosted or Unboosted Regimens","year":2011,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Atazanavir; Medicine; Ritonavir; Coinfection; Internal medicine; Regimen; Gastroenterology; Therapeutic drug monitoring; Interquartile range; Lopinavir; Dosing; Hepatitis C virus; Population; Enfuvirtide; Cirrhosis; Pharmacology; Viral load; Abacavir; Pharmacokinetics; Immunology; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy","score_opus":0.026180406911470163,"score_gpt":0.26062398575960527,"score_spread":0.2344435788481351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317747011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736446,0.0004461561,0.00008036389,0.000092664144,0.00021183779,0.0009546747,0.000004479418,0.00012941823,0.0007159692],"genre_scores_gemma":[0.9968103,0.0002303819,0.0018366566,0.000009011474,0.000066884604,0.00006288108,0.000009332389,0.000061348415,0.00091319386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802655,0.00019577082,0.0005165059,0.00050837087,0.00033339876,0.000419402],"domain_scores_gemma":[0.9988144,0.00020021682,0.00021090668,0.00040238147,0.00020591647,0.00016619323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048770048,0.0003855933,0.00061661354,0.00027023026,0.00014051999,0.000026079344,0.000078634155,0.00011319797,0.000034099976],"category_scores_gemma":[0.00004489309,0.00027922555,0.00003983089,0.0004978405,0.00018968432,0.00023320928,0.00006469571,0.00028494297,0.0000033942613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011670258,0.00044290491,0.97422886,0.00014454898,0.00036923584,0.000009112123,0.006734447,0.0000010611626,0.0008171535,0.000025592037,0.0000012582169,0.016058806],"study_design_scores_gemma":[0.005428285,0.0002730235,0.98186857,0.000841524,0.0003600152,0.00001714258,0.0007263703,0.000036651676,0.009993636,0.00006611233,0.00009290532,0.0002957518],"about_ca_topic_score_codex":0.00018415393,"about_ca_topic_score_gemma":0.000023341909,"teacher_disagreement_score":0.015763056,"about_ca_system_score_codex":0.00020761219,"about_ca_system_score_gemma":0.000118281416,"threshold_uncertainty_score":0.99996597},"labels":[],"label_agreement":null},{"id":"W2317784542","doi":"10.1097/00002030-200103300-00009","title":"HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Resistance mutation; Protease; Reverse transcriptase; Virology; Genotyping; Population; Biology; Cohort; Protease inhibitor (pharmacology); Lentivirus; Medicine; Viral load; Genotype; Cohort study; Immunology; Internal medicine; Virus; Viral disease; Antiretroviral therapy; Genetics; Polymerase chain reaction; Enzyme; Gene","score_opus":0.015342372331342603,"score_gpt":0.2630079625741517,"score_spread":0.2476655902428091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317784542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749464,0.00028663914,0.00009515028,0.0010014523,0.000025276382,0.0008547467,0.00010521643,0.000034004388,0.00010289839],"genre_scores_gemma":[0.9951543,0.00078799226,0.0020441783,0.0006040087,0.000034034587,0.000078907826,0.00025369774,0.000016405837,0.0010264582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989748,0.000067789806,0.00025160375,0.0002989962,0.00018907935,0.00021772334],"domain_scores_gemma":[0.9995881,0.00003537635,0.0000703642,0.0001535072,0.000022282009,0.00013037038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001860953,0.00016964565,0.0003545548,0.00015272204,0.000053857108,0.00002036672,0.000032551543,0.000038958893,0.000057131972],"category_scores_gemma":[0.000034218603,0.00013631934,0.000033843462,0.00030350892,0.000057126115,0.00012555844,0.0000145387485,0.0001175785,0.000013653374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018343578,0.00026152917,0.9863639,0.000007685363,0.00012578744,0.0001569096,0.002301655,8.342207e-8,0.0001866731,0.000010893264,0.00016038844,0.010241045],"study_design_scores_gemma":[0.004538674,0.00026273303,0.99055386,0.000026407855,0.000105594845,0.000008999311,0.00017807353,0.000033080512,0.00008763003,0.000025860441,0.004038368,0.00014071132],"about_ca_topic_score_codex":0.00051762257,"about_ca_topic_score_gemma":0.0000065805552,"teacher_disagreement_score":0.010100334,"about_ca_system_score_codex":0.000044009816,"about_ca_system_score_gemma":0.000040474202,"threshold_uncertainty_score":0.5558942},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2317972666","doi":"10.1080/15284336.2015.1111555","title":"Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles","year":2016,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Women's College Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Viremia; Medicine; Regimen; Virology; Drug resistance; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Viral load; Internal medicine; Immunology; Reverse transcriptase; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Polymerase chain reaction; Genetics","score_opus":0.10623582874814227,"score_gpt":0.3866071786211991,"score_spread":0.2803713498730568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317972666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9130075,0.00037345546,0.0002798377,0.07457075,0.00044761103,0.0075740716,0.0002639823,0.00011954463,0.0033632738],"genre_scores_gemma":[0.86867136,0.00033927173,0.004372048,0.0010647977,0.0009281181,0.00062801316,0.00006454225,0.000054762513,0.12387709],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997332,0.000512367,0.0011963518,0.00043342882,0.00023430685,0.00029154913],"domain_scores_gemma":[0.99047476,0.00837449,0.00047507725,0.00036536963,0.00011687029,0.00019340852],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054709325,0.00020442084,0.0010285773,0.000047999438,0.00015930686,0.000028703806,0.0001224578,0.00011846317,0.00016581276],"category_scores_gemma":[0.014084167,0.00008463117,0.00031115994,0.000091512695,0.00024219672,0.000055835946,0.00007093575,0.00007797454,0.00028833095],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053078897,0.0014029352,0.3499442,0.00023998981,0.0017928962,0.000028818253,0.0014109513,1.5354163e-7,0.00050106633,0.0033993928,0.44116187,0.14703882],"study_design_scores_gemma":[0.108923525,0.0018994393,0.08407442,0.0026082247,0.0009636803,0.0000034218344,0.00009179208,0.000042508997,0.002588084,0.0022585215,0.79583895,0.0007074484],"about_ca_topic_score_codex":0.0000010795172,"about_ca_topic_score_gemma":0.000003324011,"teacher_disagreement_score":0.35467705,"about_ca_system_score_codex":0.00007283253,"about_ca_system_score_gemma":0.00008771731,"threshold_uncertainty_score":0.9942206},"labels":[],"label_agreement":null},{"id":"W2318022415","doi":"10.1056/nejm200103293441307","title":"Interactions among Drugs for HIV and Opportunistic Infections","year":2001,"lang":"en","type":"review","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Drug; Human immunodeficiency virus (HIV); Intensive care medicine; Opportunistic infection; Antiretroviral therapy; Antiretroviral drug; Immunology; Viral disease; Pharmacology; Viral load","score_opus":0.058342856166098835,"score_gpt":0.36375059531024334,"score_spread":0.3054077391441445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318022415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052801974,0.98717123,0.0019141319,0.0058925264,0.0009977493,0.0007480355,0.00001615335,0.00002004082,0.0031873565],"genre_scores_gemma":[0.000084938845,0.95749027,0.0006375901,0.000066910005,0.0045463433,0.00002175131,0.00016276831,0.000042261192,0.036947154],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982003,0.000070568414,0.0010347965,0.00018770568,0.00029344528,0.00021321484],"domain_scores_gemma":[0.9975234,0.0007835051,0.00074393116,0.00016210183,0.00021128992,0.00057574105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005666979,0.00034544332,0.0019416441,0.0006778351,0.00010022772,0.000015051084,0.00007523666,0.00012347246,0.00036505645],"category_scores_gemma":[0.00047548275,0.00020214205,0.00029490696,0.00026179367,0.00011224558,0.00008501568,0.000020287656,0.0005564839,0.000008360322],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005933908,0.00010776252,0.00028443438,0.0018995529,0.0008560532,0.0002645419,0.00039375533,1.554559e-7,1.7818259e-7,0.00007137679,0.05742826,0.9386346],"study_design_scores_gemma":[0.016251361,0.00054271927,0.000027939579,0.022811053,0.006984677,0.007219239,0.00010560679,0.000007458538,1.2649157e-7,0.000084523075,0.9458236,0.00014167716],"about_ca_topic_score_codex":0.000013372832,"about_ca_topic_score_gemma":0.000020675383,"teacher_disagreement_score":0.9384929,"about_ca_system_score_codex":0.00016722159,"about_ca_system_score_gemma":0.0006855703,"threshold_uncertainty_score":0.8243113},"labels":[],"label_agreement":null},{"id":"W2318124317","doi":"10.1097/coh.0b013e328356db89","title":"Resistance to HIV integrase inhibitors","year":2012,"lang":"en","type":"review","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research; amfAR, The Foundation for AIDS Research","keywords":"Elvitegravir; Integrase; Raltegravir; Integrase inhibitor; Biology; Genetics; Mutation; Drug resistance; Computational biology; Virology; Gene; Virus; Antiretroviral therapy; Viral load","score_opus":0.08433393700583193,"score_gpt":0.3806411832473745,"score_spread":0.2963072462415426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318124317","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015638057,0.99469715,0.00003845003,0.0003612496,0.0028876178,0.0010899489,0.0000763985,0.000045975736,0.0007875818],"genre_scores_gemma":[0.000020708665,0.98817116,0.00072824076,0.000011044412,0.0009563938,0.0003270595,0.00091815006,0.00004644027,0.00882082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979881,0.00009354403,0.00071229547,0.0005190241,0.00027361806,0.00041338516],"domain_scores_gemma":[0.99900264,0.000092886155,0.00014625091,0.00032704006,0.00003970967,0.00039148485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026983823,0.00050764624,0.0013629313,0.0005760048,0.00005166963,0.000029607712,0.00010900013,0.00018520969,0.00008776454],"category_scores_gemma":[0.000057988826,0.00036349538,0.00023645247,0.000565446,0.00005042459,0.00007524017,0.000115785,0.00046555503,0.00047106913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022155622,0.00025916827,0.0026240184,0.020099724,0.00007967648,0.00000481146,0.0002944583,1.1280987e-8,4.0875356e-8,0.0007163998,0.060161155,0.9157384],"study_design_scores_gemma":[0.00059701287,0.000029889441,0.000060165887,0.058599908,0.00030530666,0.0000125305305,0.00003532255,2.632137e-7,9.0193595e-7,0.000017195865,0.9400097,0.00033176856],"about_ca_topic_score_codex":8.569926e-7,"about_ca_topic_score_gemma":0.0000012648173,"teacher_disagreement_score":0.9154066,"about_ca_system_score_codex":0.00024629472,"about_ca_system_score_gemma":0.00021239478,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W2318685045","doi":"10.1097/00002030-200108170-00019","title":"Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Toronto General Hospital; University of British Columbia; Memorial University of Newfoundland; University Health Network","funders":"","keywords":"Efavirenz; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Virology; Salvage therapy; Viral load; Medicine; Retrospective cohort study; Antiretroviral therapy; Human immunodeficiency virus (HIV); Internal medicine; Oncology; Biology; RNA; Chemotherapy","score_opus":0.0161043363835187,"score_gpt":0.2681944168319753,"score_spread":0.2520900804484566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318685045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989001,0.00025974875,0.00014235348,0.0068752426,0.00022934024,0.00077712984,0.000031615768,0.00020460566,0.0024789872],"genre_scores_gemma":[0.9601221,0.0001317388,0.0060869423,0.0023383254,0.00030405904,0.00007115218,0.00008207088,0.00007275383,0.030790823],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793637,0.00008143039,0.00043655207,0.0005136177,0.00042603162,0.000605975],"domain_scores_gemma":[0.99889624,0.000078385616,0.00006995934,0.00046337966,0.00007776172,0.0004142464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035935338,0.0003960711,0.00053928245,0.0004858399,0.00019266378,0.000053633183,0.00014916339,0.00014405425,0.0004045931],"category_scores_gemma":[0.00007625025,0.0003239486,0.0002492887,0.0007204468,0.000066356864,0.00023232467,0.00003617307,0.00026007398,0.0005676743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006649615,0.00059052143,0.7463025,0.000039657916,0.0004584492,0.003025595,0.0073296814,0.0000017038793,0.10802337,0.00008774736,0.08075329,0.04673786],"study_design_scores_gemma":[0.023507446,0.008846049,0.16878377,0.00092825165,0.00049649866,0.00036153005,0.005572937,0.000058910777,0.10112347,0.000056178837,0.6887613,0.0015036631],"about_ca_topic_score_codex":0.00008412574,"about_ca_topic_score_gemma":0.000013895725,"teacher_disagreement_score":0.608008,"about_ca_system_score_codex":0.00018401594,"about_ca_system_score_gemma":0.00019297347,"threshold_uncertainty_score":0.99992126},"labels":[],"label_agreement":null},{"id":"W2318797576","doi":"10.1155/2007/902682","title":"Patient Care and Support Measures Overcome Reluctance to Initiate New Regimen Containing Enfuvirtide","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Enfuvirtide; Regimen; Medicine; Human immunodeficiency virus (HIV); Pharmacology; Internal medicine; Virology; Immunology; Antigen; Gp41","score_opus":0.006941846692562888,"score_gpt":0.23895289717914753,"score_spread":0.23201105048658463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318797576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98939353,0.007142206,0.00020651163,0.0018687646,0.00031174347,0.00018265661,0.00002745155,0.000009766423,0.00085736887],"genre_scores_gemma":[0.99619645,0.00027771425,0.00013949868,0.0030055656,0.00016992145,0.0000017706889,0.00001942822,0.000012332674,0.00017734258],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897194,0.00003462869,0.000373287,0.00016183134,0.000094936164,0.00036338207],"domain_scores_gemma":[0.9967868,0.00010180066,0.000108753135,0.00007491773,0.00015517753,0.0027725927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016987619,0.00014552307,0.0003628185,0.0002706019,0.0001036731,0.00001528744,0.00004227148,0.000112475456,0.00018275231],"category_scores_gemma":[0.0005745022,0.000113163405,0.00006582271,0.000095969684,0.00013742161,0.00003935576,0.00001814159,0.00019322301,0.0000057559273],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003836646,0.000048700673,0.8229669,0.00005893682,0.000334994,0.004798518,0.0041425573,5.9571187e-7,0.0006220454,0.0002016084,0.010307089,0.15613438],"study_design_scores_gemma":[0.011068958,0.008281171,0.30033702,0.0014724929,0.0007788404,0.021911891,0.0034467222,7.6752247e-7,0.0009767296,0.0004951824,0.65056944,0.00066082104],"about_ca_topic_score_codex":0.0011562912,"about_ca_topic_score_gemma":0.008118099,"teacher_disagreement_score":0.6402623,"about_ca_system_score_codex":0.00025083567,"about_ca_system_score_gemma":0.002158145,"threshold_uncertainty_score":0.46146697},"labels":[],"label_agreement":null},{"id":"W2319033825","doi":"10.7448/ias.17.2.19192","title":"O131: The HIV treatment response prediction system: using the experience of treating tens of thousands of patients to guide optimal drug selection","year":2014,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Selection (genetic algorithm); Human immunodeficiency virus (HIV); Drug; Drug response; Intensive care medicine; Pharmacology; Medical physics; Virology; Machine learning","score_opus":0.012227996100706599,"score_gpt":0.27786218881718233,"score_spread":0.26563419271647576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319033825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957866,0.000025753568,0.0018762758,0.001566666,0.0002967167,0.00025139304,0.00002319253,0.0000050401527,0.00016837902],"genre_scores_gemma":[0.9910145,0.000015955082,0.0066967527,0.000049701866,0.00015182946,0.00000818059,0.0000028024933,0.000010095252,0.0020501853],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819434,0.00016458491,0.00071009557,0.00009713765,0.00073274685,0.00010108464],"domain_scores_gemma":[0.9979864,0.00029408117,0.00082751585,0.00015778137,0.00069429644,0.00003995197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009658007,0.00011906148,0.0002660011,0.00006151974,0.00013106469,0.000011447562,0.00023710661,0.000036192472,0.000012600077],"category_scores_gemma":[0.00024888996,0.00005238109,0.0003822563,0.0002046611,0.00008121577,0.000082942875,0.000059876846,0.00009921141,4.786986e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029310335,0.0009619001,0.839079,0.00006620525,0.0021698838,0.0000014745043,0.07796158,0.010443858,0.05891207,0.00013073056,0.005295266,0.0020469509],"study_design_scores_gemma":[0.011908209,0.0035295223,0.40541458,0.0031170894,0.0019321969,0.0003785683,0.057684258,0.081427895,0.4204237,0.000036417096,0.013827691,0.00031989286],"about_ca_topic_score_codex":0.000057277488,"about_ca_topic_score_gemma":0.0000028333086,"teacher_disagreement_score":0.43366447,"about_ca_system_score_codex":0.0008154781,"about_ca_system_score_gemma":0.00017631572,"threshold_uncertainty_score":0.21360388},"labels":[],"label_agreement":null},{"id":"W2319205124","doi":"10.3109/00365548.2011.598870","title":"Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort","year":2011,"lang":"en","type":"article","venue":"Scandinavian Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Gilead Sciences; GlaxoSmithKline","keywords":"Medicine; Prospective cohort study; Antiretroviral therapy; Cohort; Cohort study; Sida; Human immunodeficiency virus (HIV); Pediatrics; Viral disease; Internal medicine; Family medicine; Viral load","score_opus":0.00998145479583348,"score_gpt":0.23911168391990162,"score_spread":0.22913022912406814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319205124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357957,0.00045242347,0.000011350179,0.00005069142,0.00033441727,0.0005884611,0.00013986097,0.000039808037,0.0048034056],"genre_scores_gemma":[0.99848115,0.00021387788,0.00020087276,0.000032865566,0.00013619915,0.000041478128,0.000107173015,0.000024803992,0.00076155615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981669,0.00007983687,0.0007286504,0.00032072852,0.00037916633,0.00032468265],"domain_scores_gemma":[0.99866796,0.0000624561,0.0004174904,0.00022787065,0.0002554674,0.00036876914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008488869,0.0002975108,0.0006257894,0.0004130557,0.00009989835,0.000029457753,0.000096580945,0.00007718164,0.00015911157],"category_scores_gemma":[0.00019308271,0.00021365705,0.00024673063,0.00033514097,0.00012283497,0.00031712957,0.00002074429,0.00015647023,0.000031944826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015286651,0.002953661,0.98456967,0.0000070982355,0.0004688356,0.0008330637,0.005472741,6.4230454e-7,0.000020665462,0.000012473,0.0002348274,0.0038976322],"study_design_scores_gemma":[0.016104963,0.0037466171,0.9773675,0.0003391623,0.00045510536,0.000039453585,0.00036881753,0.0000034397774,0.0008968768,0.00036991638,0.000104647195,0.00020345232],"about_ca_topic_score_codex":0.0009884351,"about_ca_topic_score_gemma":0.00014409126,"teacher_disagreement_score":0.014576297,"about_ca_system_score_codex":0.0008700754,"about_ca_system_score_gemma":0.00030002207,"threshold_uncertainty_score":0.8712682},"labels":[],"label_agreement":null},{"id":"W2319514196","doi":"10.1016/s2352-3018(16)00046-1","title":"Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study","year":2016,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of British Columbia; University of British Columbia; BC Centre for Disease Control; Ministry of Health; Simon Fraser University; Vancouver Coastal Health; AIDS Vancouver","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Genotyping; Human immunodeficiency virus (HIV); Transmission (telecommunications); Medicine; Virology; Computational biology; Genetics; Biology; Genotype; Computer science; Telecommunications","score_opus":0.039492395299084986,"score_gpt":0.33349713584131885,"score_spread":0.29400474054223386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319514196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948331,0.000061025483,0.00019967234,0.0037478262,0.000051223742,0.00066212734,0.000059306152,0.00009412834,0.00029158514],"genre_scores_gemma":[0.9922454,0.00009588876,0.0038384588,0.000018494427,0.0004164925,0.000033394794,0.00007290253,0.000030294577,0.0032486764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986855,0.00013137043,0.0003475743,0.00027503402,0.00027961808,0.0002809093],"domain_scores_gemma":[0.9991239,0.00010486967,0.00012414386,0.0004720914,0.000057039895,0.00011795461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034403513,0.00018610897,0.0004128133,0.000051707397,0.00015413994,0.000017439146,0.00012399771,0.000041265554,0.00043978612],"category_scores_gemma":[0.0000095531,0.00009929493,0.000055354205,0.00012288016,0.000039340295,0.00011183886,0.000032209307,0.00007610278,0.00013754796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007630648,0.0005623158,0.88120466,0.000024845396,0.00035676255,0.00077903905,0.024185026,0.0000040304994,0.05285788,0.000013352568,0.0021166927,0.037132323],"study_design_scores_gemma":[0.026031818,0.00063168746,0.89605707,0.0005242221,0.0010463188,0.0002452126,0.0151295345,0.000420438,0.05497493,0.00013953078,0.004292518,0.00050671125],"about_ca_topic_score_codex":0.00028437213,"about_ca_topic_score_gemma":0.000018909443,"teacher_disagreement_score":0.036625613,"about_ca_system_score_codex":0.00009010676,"about_ca_system_score_gemma":0.000071347895,"threshold_uncertainty_score":0.48153496},"labels":[],"label_agreement":null},{"id":"W2320698474","doi":"10.1097/00002030-200307250-00024","title":"A manic episode associated with efavirenz therapy for HIV infection","year":2003,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Emergency department; Medicine; Ritonavir; Efavirenz; Pediatrics; Psychiatry; Mood; Internal medicine; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.04568585671896281,"score_gpt":0.32868071777579355,"score_spread":0.28299486105683075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320698474","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013434136,0.99453586,0.00019236868,0.00007189035,0.00014276881,0.0025178795,0.000029418074,0.00011395422,0.0022615094],"genre_scores_gemma":[0.000032263386,0.93964016,0.0007199326,0.00008354564,0.00008329961,0.00097478396,0.0012238363,0.00009370483,0.05714844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866486,0.00009626573,0.0003593962,0.0003701105,0.00020606186,0.00030330213],"domain_scores_gemma":[0.99917096,0.00015705316,0.00022827931,0.0002680922,0.00008205575,0.0000935876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023746706,0.00042656256,0.0013908651,0.00020167914,0.00008808699,0.000020325204,0.00005289975,0.00028117848,0.00012162401],"category_scores_gemma":[0.000049656563,0.0002645146,0.0004038967,0.0003948952,0.000026431624,0.00004054691,0.000009252333,0.00020387306,0.00014748095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036423433,0.0004195906,0.0033137568,0.0019020227,0.002673415,0.000029410172,0.000045162367,4.1427235e-8,1.0974797e-7,0.0001413857,0.008354489,0.9830842],"study_design_scores_gemma":[0.0024718917,0.0005447562,0.0001367482,0.0063557727,0.002152949,0.000045889912,0.0000021066783,9.085827e-7,0.0000040374553,0.000024055124,0.987983,0.00027789336],"about_ca_topic_score_codex":0.000007018483,"about_ca_topic_score_gemma":0.000011169288,"teacher_disagreement_score":0.9828063,"about_ca_system_score_codex":0.00038601644,"about_ca_system_score_gemma":0.00035553685,"threshold_uncertainty_score":0.9999807},"labels":[],"label_agreement":null},{"id":"W2321454061","doi":"10.1503/cmaj.151224","title":"CD4 measurement in a 54-year-old man with sustained HIV-1 viral suppression","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada); University of Toronto","funders":"","keywords":"Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Immunology; Pediatrics; Virology; Internal medicine","score_opus":0.007121493119807546,"score_gpt":0.21473752997797946,"score_spread":0.2076160368581719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321454061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62805027,0.00011115495,0.00022538002,0.3639746,0.00037719586,0.00047095888,0.000020498384,0.000037744194,0.0067321653],"genre_scores_gemma":[0.97915506,0.00005864482,0.0002932387,0.0024985392,0.00047368134,0.000017477567,0.00001244294,0.000022105041,0.017468823],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672407,0.00012618073,0.00038048095,0.00018504768,0.0020022884,0.0005819349],"domain_scores_gemma":[0.9977866,0.00005994017,0.0001342155,0.00010666693,0.00038602948,0.0015265421],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014023748,0.00015319222,0.0002700904,0.000311358,0.00012662992,0.0000349744,0.00010204404,0.00022056972,0.003002895],"category_scores_gemma":[0.00087354385,0.000088947265,0.000064077794,0.00019450823,0.000030570478,0.000114461625,0.000011859923,0.00041486102,0.00021934061],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014312891,0.000112670394,0.8036682,0.000012286431,0.00019747586,0.002547382,0.00055882236,2.4857144e-7,0.00009523218,0.00018743925,0.17878535,0.013691761],"study_design_scores_gemma":[0.024242634,0.000342981,0.47994325,0.0021212804,0.00014904929,0.0006652568,0.0012730672,0.000045011715,0.0004896794,0.00023865404,0.49001357,0.0004755816],"about_ca_topic_score_codex":0.00042719222,"about_ca_topic_score_gemma":0.021169813,"teacher_disagreement_score":0.36147606,"about_ca_system_score_codex":0.0046470836,"about_ca_system_score_gemma":0.0038406109,"threshold_uncertainty_score":0.9991739},"labels":[],"label_agreement":null},{"id":"W2322121101","doi":"10.1093/infdis/jiw125","title":"Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women","year":2016,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; Centers for Disease Control and Prevention; National Institutes of Health; University of Washington; Bill and Melinda Gates Foundation","keywords":"Emtricitabine; Tubulopathy; Medicine; Pre-exposure prophylaxis; Placebo; Glycosuria; Internal medicine; Odds ratio; Renal function; Urology; Gastroenterology; Endocrinology; Kidney disease; Human immunodeficiency virus (HIV); Pathology; Virology; Men who have sex with men; Viral load; Antiretroviral therapy; Diabetes mellitus","score_opus":0.0030024697974750194,"score_gpt":0.1887776744625792,"score_spread":0.1857752046651042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322121101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854755,0.00047139556,0.00007039479,0.00018215862,0.00003284916,0.0004795435,0.00002106469,0.000018828927,0.00017618678],"genre_scores_gemma":[0.9985864,0.00040060683,0.000012383304,0.000011145809,0.00004855427,0.000026004735,0.0000025433749,0.000019094485,0.000893227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986687,0.0002209225,0.00040949776,0.000115324685,0.0003637514,0.00022184424],"domain_scores_gemma":[0.9987259,0.00021389588,0.000519781,0.00013987052,0.00025568742,0.00014484892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005129444,0.00017597606,0.00041107868,0.0002198617,0.00007498344,0.000011613518,0.00005914262,0.000053282667,0.000041019055],"category_scores_gemma":[0.000390491,0.00007539254,0.0000641222,0.00031027512,0.00012369482,0.00017902783,0.000026103427,0.00014686544,0.0000025454476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024076155,0.001106519,0.9849507,0.00007011515,0.0008117571,0.000059361148,0.0014700695,0.000017702974,0.0017301628,0.0000029345888,0.00010478725,0.0072682747],"study_design_scores_gemma":[0.010946464,0.008007099,0.97589874,0.0006876452,0.0007018955,0.00012755494,0.0004412188,0.000022875136,0.002588563,0.00041568655,0.000017283863,0.00014496341],"about_ca_topic_score_codex":0.000014378949,"about_ca_topic_score_gemma":0.000018005348,"teacher_disagreement_score":0.00905195,"about_ca_system_score_codex":0.00035460075,"about_ca_system_score_gemma":0.00027308922,"threshold_uncertainty_score":0.30744186},"labels":[],"label_agreement":null},{"id":"W2322229803","doi":"10.1021/ol5021114","title":"A Highly Concise and Convergent Synthesis of HCV Polymerase Inhibitor Deleobuvir (BI 207127): Application of a One-Pot Borylation–Suzuki Coupling Reaction","year":2014,"lang":"en","type":"article","venue":"Organic Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Borylation; Chemistry; Suzuki reaction; Combinatorial chemistry; Coupling (piping); Convergent synthesis; Polymerase; Stereochemistry; Organic chemistry; Palladium; Catalysis; Enzyme; Aryl","score_opus":0.006861424673065895,"score_gpt":0.2095225324310113,"score_spread":0.2026611077579454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322229803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910654,0.000087284905,0.0021022041,0.006183096,0.00006332685,0.00039258867,0.0000068068516,0.00003924014,0.000060048053],"genre_scores_gemma":[0.99872535,0.000054173077,0.00062168756,0.0003248759,0.00008676975,0.00004186344,0.00004133291,0.000026272579,0.00007764243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894184,0.000013557116,0.00039051924,0.00024780075,0.00025747324,0.00014878187],"domain_scores_gemma":[0.99919784,0.00014458483,0.00024562722,0.00023736224,0.00007506175,0.000099508485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019390986,0.00014943979,0.0003362046,0.00013408776,0.000050698713,0.000005919788,0.000043106986,0.00007056631,0.000043886354],"category_scores_gemma":[0.00008685498,0.00013928954,0.0000509551,0.00017935857,0.00007492366,0.00007621007,0.000021206812,0.00007399317,0.000025211551],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013488634,0.00015168994,0.01655238,0.0001358684,0.00014732577,0.0000024328401,0.00034847792,0.000002130682,0.9769278,0.00009561815,0.0004884081,0.0050129844],"study_design_scores_gemma":[0.0016452662,0.00006388782,0.011347309,0.00015276967,0.00035251104,0.000007736697,0.00008623248,0.0010547388,0.98420554,0.000008719475,0.0009282273,0.00014705284],"about_ca_topic_score_codex":0.00006356999,"about_ca_topic_score_gemma":0.0000106407415,"teacher_disagreement_score":0.0076599782,"about_ca_system_score_codex":0.0001226531,"about_ca_system_score_gemma":0.00006320332,"threshold_uncertainty_score":0.5680062},"labels":[],"label_agreement":null},{"id":"W2322747971","doi":"10.1021/ol503612h","title":"Selective Lewis Acid Catalyzed Assembly of Phosphonomethyl Ethers: Three-Step Synthesis of Tenofovir","year":2015,"lang":"en","type":"article","venue":"Organic Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Bill and Melinda Gates Foundation","keywords":"Chemistry; Tenofovir; Yield (engineering); Catalysis; Lewis acids and bases; Human immunodeficiency virus (HIV); Combinatorial chemistry; Ether; Organic chemistry; Virology","score_opus":0.016456641630164824,"score_gpt":0.23602014818917588,"score_spread":0.21956350655901105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322747971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900561,0.00027619695,0.0010302563,0.0072299624,0.000100324265,0.0003776645,0.000013631748,0.000050141138,0.0008657027],"genre_scores_gemma":[0.9959083,0.000014689969,0.0034059326,0.0003064385,0.000044503435,0.00002739103,0.000021399474,0.000046365258,0.00022498335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862957,0.000049795777,0.00037588962,0.00028805435,0.00038137953,0.0002753114],"domain_scores_gemma":[0.99891865,0.00013832911,0.0002667189,0.00036755673,0.0001463237,0.00016242113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031486744,0.00022228106,0.0005883011,0.0001742592,0.000028982317,0.0000067370656,0.00014608212,0.00009454154,0.0001229805],"category_scores_gemma":[0.00033697605,0.00017840469,0.00012232823,0.000510875,0.000107887194,0.00009321223,0.000053046624,0.00012986697,0.00012395559],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000306733,0.00036856896,0.03632253,0.00010338565,0.0011734714,0.000047899186,0.0033955474,0.0000015829651,0.94220865,0.000015899604,0.009426234,0.0066294814],"study_design_scores_gemma":[0.0019063465,0.00009070258,0.0067253015,0.00010786854,0.0003632882,0.000017405977,0.00057634944,0.000018867866,0.9895491,0.000011662683,0.0004587283,0.00017436234],"about_ca_topic_score_codex":0.00017304659,"about_ca_topic_score_gemma":0.0000607051,"teacher_disagreement_score":0.047340453,"about_ca_system_score_codex":0.00032178845,"about_ca_system_score_gemma":0.00031897324,"threshold_uncertainty_score":0.7275132},"labels":[],"label_agreement":null},{"id":"W2323536702","doi":"10.5414/cnp65013","title":"Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals","year":2006,"lang":"en","type":"article","venue":"Clinical Nephrology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Indinavir; Crystalluria; Medicine; Urine; Asymptomatic; Internal medicine; Gastroenterology; Human immunodeficiency virus (HIV); Sida; Virology; Viral disease","score_opus":0.01940111284835111,"score_gpt":0.3036991303884954,"score_spread":0.2842980175401443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323536702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961073,0.000063512634,0.000010841146,0.0064265197,0.0001087136,0.0010232424,0.000058154616,0.00023965363,0.0024586415],"genre_scores_gemma":[0.9848008,0.00004421146,0.00048105276,0.0021907084,0.0002100923,0.00011305964,0.0016006926,0.000070387876,0.010489002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959401,0.00044328245,0.0014057629,0.00088283484,0.00038557162,0.00094246474],"domain_scores_gemma":[0.99782777,0.0007765287,0.00043836603,0.0004955097,0.000160007,0.00030181938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081591035,0.00049690186,0.00137856,0.000443283,0.000103301514,0.000026564658,0.00019698974,0.0008190837,0.00083431817],"category_scores_gemma":[0.0004468678,0.00038839146,0.00020409074,0.00103356,0.00043137057,0.000106783205,0.00012179175,0.000858429,0.00039933983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085361185,0.003820116,0.9735506,0.000016975448,0.000610313,0.0012890178,0.00019853732,0.0000037643322,0.00071991736,0.000061182334,0.018143011,0.000732913],"study_design_scores_gemma":[0.017173855,0.0011463537,0.97010994,0.00019724741,0.00039631914,0.00009324719,0.000024361409,0.00004537755,0.0010732337,0.00029986468,0.009041688,0.00039849413],"about_ca_topic_score_codex":0.00007606049,"about_ca_topic_score_gemma":0.0002487891,"teacher_disagreement_score":0.016320242,"about_ca_system_score_codex":0.000264937,"about_ca_system_score_gemma":0.0003477449,"threshold_uncertainty_score":0.99985677},"labels":[],"label_agreement":null},{"id":"W2323588417","doi":"10.1177/095632020001100602","title":"Selection of Resistance-Conferring Mutations in HIV-1 by the Nucleoside Reverse Transcriptase Inhibitors (+/-)dOTC and (+/-)dOTFC","year":2000,"lang":"en","type":"article","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BioPhage Pharma (Canada); Jewish General Hospital","funders":"Medical Research Council Canada","keywords":"Reverse transcriptase; Resistance mutation; Biology; Mutation; Nucleoside; Virology; Nucleotidyltransferase; Virus; Genotype; Molecular biology; Genetics; RNA; Gene","score_opus":0.00566320649577984,"score_gpt":0.22530737920162283,"score_spread":0.219644172705843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323588417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845117,0.00028134105,0.000006429107,0.0043424554,0.0000120769955,0.00025317864,0.000021544514,0.00003671171,0.010534614],"genre_scores_gemma":[0.9616027,0.0004875019,0.0003630551,0.00021514362,0.000047088666,0.000022491935,0.00007392043,0.000025378027,0.037162714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990043,0.000020808911,0.0003106772,0.00027218007,0.0001772018,0.00021480306],"domain_scores_gemma":[0.9996625,0.000031307794,0.00006513846,0.0001563147,0.00003131715,0.000053400243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114114424,0.00019191808,0.00026450126,0.00003335175,0.000083470084,0.000015627693,0.00005854246,0.00008998822,0.00047176096],"category_scores_gemma":[0.000009201144,0.00015354042,0.00007780571,0.0002676373,0.00013582889,0.000096337295,0.0000043392283,0.00017299362,0.000009642879],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006345795,0.00045213467,0.041894108,0.00021003866,0.00016819974,0.000026734493,0.0029813782,0.0000012331935,0.91263676,0.000009114616,0.026843008,0.014142697],"study_design_scores_gemma":[0.0033497352,0.000023678755,0.0049731936,0.00022062578,0.000061017752,0.000020549052,0.00045205324,0.000050392457,0.95283544,0.000048017624,0.037786003,0.00017927351],"about_ca_topic_score_codex":0.000039626568,"about_ca_topic_score_gemma":0.000019744128,"teacher_disagreement_score":0.040198687,"about_ca_system_score_codex":0.00006957245,"about_ca_system_score_gemma":0.00006191138,"threshold_uncertainty_score":0.6261197},"labels":[],"label_agreement":null},{"id":"W2323613275","doi":"10.1136/sextrans-2011-050102.31","title":"S8.1 Lessons learnt from global HIV drug resistance initiative: implications for MDR-GC","year":2011,"lang":"en","type":"article","venue":"Sexually Transmitted Infections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"HIV drug resistance; Medicine; Human immunodeficiency virus (HIV); Drug resistance; Resistance (ecology); Drug; Accreditation; Virology; Pharmacology; Antiretroviral therapy; Medical education; Viral load; Biology","score_opus":0.04379978904220315,"score_gpt":0.3072426242186427,"score_spread":0.2634428351764395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323613275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35933176,0.0013617257,0.30384874,0.1291756,0.001101274,0.005772603,0.004785827,0.0020683524,0.1925541],"genre_scores_gemma":[0.9504361,0.00014325786,0.022866754,0.00071562163,0.00016759924,0.0010690892,0.0012798544,0.00006157883,0.023260143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984102,0.000065009226,0.00043058372,0.0005198452,0.0001607437,0.0004135865],"domain_scores_gemma":[0.9987612,0.00019744798,0.00010119746,0.00043647745,0.00026294298,0.00024078389],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011927482,0.00029964733,0.00036569423,0.00013390607,0.00048297294,0.000028208844,0.00012500156,0.00013130043,0.00037557524],"category_scores_gemma":[0.00006670762,0.00028064643,0.00019006168,0.0005862989,0.00012816125,0.00017764124,0.000016915421,0.00021218065,0.00017551836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012898146,0.011215281,0.56092864,0.00034163165,0.0055989604,0.00006262252,0.029406521,0.000014118227,0.003142469,0.13521677,0.23060748,0.022175709],"study_design_scores_gemma":[0.0069287433,0.0002020309,0.69051164,0.00020490513,0.0013532898,0.000031586387,0.001105831,0.000035864534,0.0021421982,0.027902931,0.26882544,0.0007554992],"about_ca_topic_score_codex":0.000094012314,"about_ca_topic_score_gemma":0.0019786225,"teacher_disagreement_score":0.5911043,"about_ca_system_score_codex":0.00023808793,"about_ca_system_score_gemma":0.00040556223,"threshold_uncertainty_score":0.9999646},"labels":[],"label_agreement":null},{"id":"W2323931901","doi":"10.1097/00002030-200208160-00008","title":"Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients","year":2002,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; AIDS Vancouver; University of Toronto; HIV Legal Network; University Health Network","funders":"Institut National Du Cancer","keywords":"Viral load; Medicine; Human immunodeficiency virus (HIV); Sida; Internal medicine; Virology; Viral disease; Lentivirus; Immunology","score_opus":0.0093776825413945,"score_gpt":0.20146785937175085,"score_spread":0.19209017683035634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323931901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217147,0.000027649543,0.000002666796,0.00073268,0.0000443442,0.0005126504,0.000033125478,0.00012046692,0.0063549397],"genre_scores_gemma":[0.9814507,0.000008737953,0.00018410505,0.00018413871,0.000020257907,0.00006023283,0.00026924442,0.000026096734,0.017796533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827754,0.00011451279,0.0003008715,0.00040490614,0.00045565705,0.0004465316],"domain_scores_gemma":[0.9992041,0.00014468093,0.00014564047,0.00019488204,0.00014461076,0.00016609226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010698907,0.0002917493,0.00049787556,0.00014196559,0.00011543986,0.00001997422,0.00007214613,0.00024555347,0.00069404684],"category_scores_gemma":[0.0002505716,0.00020687621,0.00007650395,0.00038612648,0.00018992931,0.00009675931,0.00006632918,0.00030106664,0.00034466683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027753325,0.00091983395,0.98752,0.000007039183,0.00025327477,0.00046817632,0.00097098324,0.000001891084,0.00003656155,0.000018244453,0.009274217,0.00025226932],"study_design_scores_gemma":[0.010735214,0.0010639329,0.984916,0.00018749962,0.00014495311,0.000012023745,0.0001669074,0.00022725243,0.00042688462,0.000015678095,0.0018325443,0.00027111347],"about_ca_topic_score_codex":0.000025274558,"about_ca_topic_score_gemma":0.00038042545,"teacher_disagreement_score":0.011441594,"about_ca_system_score_codex":0.000807703,"about_ca_system_score_gemma":0.00004757786,"threshold_uncertainty_score":0.84361666},"labels":[],"label_agreement":null},{"id":"W2324646331","doi":"10.1097/00002030-200212060-00003","title":"The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses","year":2002,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Resistance mutation; Reverse transcriptase; Biology; Virology; Viral replication; Mutagenesis; Primer (cosmetics); Mutation; Mutant; Virus; Genetics; Molecular biology; Gene; RNA; Chemistry","score_opus":0.032611638490643614,"score_gpt":0.2788804971687878,"score_spread":0.24626885867814421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324646331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834259,0.0010074321,0.000028500172,0.014237034,0.0000784621,0.0004378383,0.000008327301,0.000026500054,0.0007500068],"genre_scores_gemma":[0.9915281,0.0003771548,0.00024286109,0.00024316079,0.000023791132,0.00004125679,0.00012126371,0.000009665312,0.00741275],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918026,0.00008739502,0.00027437785,0.00016369288,0.00019005721,0.00010421719],"domain_scores_gemma":[0.99938756,0.00008253193,0.00009569337,0.00031795556,0.00008949995,0.000026773105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003102526,0.000084159015,0.00011358348,0.00005522235,0.0001005906,0.000012787725,0.000066659886,0.000043046377,0.00004845619],"category_scores_gemma":[0.00018608698,0.000048716272,0.000032310712,0.0004033952,0.000068151516,0.00010346864,0.000005313308,0.00007915476,0.000062494255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083739386,0.0010001995,0.08333743,0.000058950915,0.00034110618,0.000039108694,0.017148742,0.00003260625,0.20676272,0.0008666804,0.56368655,0.12588853],"study_design_scores_gemma":[0.0062970757,0.00095371116,0.044334106,0.00035309143,0.00058487564,0.000046924833,0.00433517,0.0020818573,0.5197052,0.0004195776,0.4204659,0.00042255648],"about_ca_topic_score_codex":0.000058603313,"about_ca_topic_score_gemma":0.000014496854,"teacher_disagreement_score":0.31294245,"about_ca_system_score_codex":0.00006484142,"about_ca_system_score_gemma":0.000029593768,"threshold_uncertainty_score":0.1986592},"labels":[],"label_agreement":null},{"id":"W2324813392","doi":"10.1136/sextrans-2011-050209","title":"Transmission of HIV-1 drug resistance in Benin could jeopardise future treatment options","year":2011,"lang":"en","type":"article","venue":"Sexually Transmitted Infections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de Santé Publique du Québec; Centre hospitalier universitaire de Québec; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research; Pfizer","keywords":"Medicine; Seroconversion; Transmission (telecommunications); Health care; Serology; Human immunodeficiency virus (HIV); Pediatrics; Internal medicine; Family medicine; Immunology; Antibody","score_opus":0.016028786024377184,"score_gpt":0.25565781497585033,"score_spread":0.23962902895147314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324813392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9222406,0.0037866496,0.00530039,0.010779547,0.000449437,0.002462922,0.0001713829,0.00043563917,0.05437343],"genre_scores_gemma":[0.9428789,0.0018271537,0.011814705,0.00005736128,0.000088457055,0.00029340605,0.0002229067,0.000054144275,0.042762976],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984066,0.00008618186,0.00055461866,0.00038284302,0.00024074843,0.00032903062],"domain_scores_gemma":[0.99921554,0.000055669247,0.00008292516,0.00034024895,0.00010002038,0.00020558182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011169533,0.00031106855,0.0004812962,0.0004335178,0.00014422307,0.000007584461,0.00007415634,0.00014923248,0.0008911714],"category_scores_gemma":[0.0000062521344,0.00025556167,0.00020428421,0.0007407984,0.0000928419,0.00013278273,0.000005679821,0.00022448912,0.00006275254],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003718181,0.060444232,0.545804,0.0015056547,0.0045353468,0.0010370259,0.25454134,0.00014413758,0.013773897,0.018348617,0.0286458,0.06750173],"study_design_scores_gemma":[0.030407114,0.0015600682,0.46349782,0.0013469657,0.0026219354,0.00014625293,0.0051265713,0.00033795973,0.026074676,0.001807274,0.46539503,0.0016783468],"about_ca_topic_score_codex":0.00007224324,"about_ca_topic_score_gemma":0.0011270213,"teacher_disagreement_score":0.43674922,"about_ca_system_score_codex":0.00019939891,"about_ca_system_score_gemma":0.00018249382,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W2325043508","doi":"10.1136/sextrans-2011-050108.461","title":"P3-S3.12 Transmitted HIV drug resistance mutations in Ontario, Canada, 2002–2009","year":2011,"lang":"en","type":"article","venue":"Sexually Transmitted Infections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; Sunnybrook Health Science Centre; Health Sciences Centre; Canadian AIDS Treatment Information Exchange; Ontario HIV Treatment Network","funders":"","keywords":"Medicine; Viral load; HIV drug resistance; Cohort; Drug resistance; Men who have sex with men; Human immunodeficiency virus (HIV); Internal medicine; Cohort study; Virology; Antiretroviral therapy","score_opus":0.01408913025175746,"score_gpt":0.21891704734527517,"score_spread":0.20482791709351772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325043508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8278215,0.0003685071,0.004296348,0.010867092,0.0006526432,0.0020109345,0.00014645318,0.00045744824,0.15337907],"genre_scores_gemma":[0.7551974,0.00003586797,0.004494693,0.00067768764,0.000043214623,0.00029255036,0.0003737471,0.00006681334,0.23881799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759847,0.00009766181,0.00070354325,0.0005459376,0.00042399156,0.0006304244],"domain_scores_gemma":[0.99889857,0.00011737603,0.000089152054,0.00040696972,0.00015927834,0.0003286763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017394818,0.00040783442,0.0004897924,0.0004667951,0.00030109592,0.0000213913,0.00013068768,0.00014579004,0.003873827],"category_scores_gemma":[0.00002634028,0.00039979763,0.0001301109,0.00084465626,0.00011067565,0.00021125373,0.000008025955,0.00063865626,0.00011490234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095014356,0.007321806,0.7008744,0.0002946972,0.0018914301,0.001697532,0.068594426,0.00009642169,0.00057765224,0.0028928572,0.21247184,0.0023368266],"study_design_scores_gemma":[0.0073849596,0.00015065317,0.6851872,0.0003068242,0.00064523704,0.00010510933,0.001355784,0.00005107197,0.0013548146,0.00086182525,0.30171257,0.0008839545],"about_ca_topic_score_codex":0.7115605,"about_ca_topic_score_gemma":0.99872303,"teacher_disagreement_score":0.28716254,"about_ca_system_score_codex":0.00091185136,"about_ca_system_score_gemma":0.0031377925,"threshold_uncertainty_score":0.9998454},"labels":[],"label_agreement":null},{"id":"W2325266202","doi":"10.1097/00002030-200301240-00020","title":"No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection","year":2003,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reverse transcriptase; Virology; Protease; Drug resistance; Human immunodeficiency virus (HIV); Virus; Biology; Resistance (ecology); Lentivirus; HIV drug resistance; Medicine; Antiretroviral therapy; Gene; Viral disease; Viral load; Genetics; Polymerase chain reaction; Enzyme","score_opus":0.009360686530349613,"score_gpt":0.2293506382343865,"score_spread":0.2199899517040369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325266202","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6296012,0.0045798062,0.00006365429,0.3174681,0.00038176271,0.009177323,0.0004947608,0.00018844423,0.038044974],"genre_scores_gemma":[0.049390893,0.0022824937,0.034169283,0.40930825,0.0007750659,0.0060814726,0.010137913,0.0004062858,0.48744833],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972178,0.00039286716,0.0007513315,0.000751279,0.00038667256,0.00050006557],"domain_scores_gemma":[0.99898607,0.00014396841,0.00014910733,0.00043620382,0.00008003473,0.00020460055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005005008,0.00047157373,0.00076021394,0.0011084096,0.000056569876,0.000028770228,0.000072688104,0.0004941263,0.00013286984],"category_scores_gemma":[0.00054180477,0.00047682572,0.00009922528,0.00094693905,0.000118182084,0.00021724809,0.000019687672,0.0012923126,0.0000646533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014627507,0.0008427809,0.31674135,0.0021286139,0.000087500586,0.017683009,0.00082292606,0.0000012204274,0.0001068611,0.000041347233,0.65971565,0.00036600188],"study_design_scores_gemma":[0.010747883,0.00008974003,0.07487873,0.0036292463,0.00023247718,0.00004943024,0.000042456188,0.000005944687,0.00007073337,0.00032961136,0.90925753,0.0006662088],"about_ca_topic_score_codex":0.0007681772,"about_ca_topic_score_gemma":0.0022762055,"teacher_disagreement_score":0.58021027,"about_ca_system_score_codex":0.0010333381,"about_ca_system_score_gemma":0.0008168998,"threshold_uncertainty_score":0.9997683},"labels":[],"label_agreement":null},{"id":"W2325966141","doi":"10.2174/187152609787847668","title":"Sequencing of Therapy to Avoid Resistance and the Need for New Antiretroviral Drugs in the Treatment of HIV Disease","year":2009,"lang":"en","type":"review","venue":"Infectious Disorders - Drug Targets","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Stavudine; Context (archaeology); Abacavir; Ritonavir; Drug resistance; Medicine; Antiretroviral therapy; Intensive care medicine; Emtricitabine; Human immunodeficiency virus (HIV); Zidovudine; Lamivudine; Virology; Pharmacology; Biology; Virus; Viral load; Genetics; Viral disease","score_opus":0.017892150564667284,"score_gpt":0.2944946303050831,"score_spread":0.2766024797404158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325966141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032979695,0.9859212,0.00005332937,0.0030858607,0.00008963059,0.0067562563,0.000060736238,0.000032702283,0.00070231286],"genre_scores_gemma":[0.009800869,0.9854281,0.00021601109,0.00017439766,0.00008778014,0.00060706824,0.0001377181,0.00005156324,0.0034965202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782753,0.00026028085,0.0007835303,0.00044400568,0.00031782832,0.00036684735],"domain_scores_gemma":[0.99824744,0.0006400602,0.00039238404,0.0005209948,0.000057025984,0.00014210859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003979833,0.00055370806,0.0018303423,0.0003288726,0.00013008794,0.000023888972,0.00017972932,0.00010356192,0.000009919362],"category_scores_gemma":[0.00009818939,0.00028094806,0.0006539989,0.00054308365,0.00015781938,0.000049982267,0.000017257094,0.00014774223,0.0000039912316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00127822,0.0013582684,0.0033731263,0.0040607085,0.0009861214,0.00001534497,0.021709386,0.000006471064,8.346002e-7,0.00053035375,0.0056882245,0.96099293],"study_design_scores_gemma":[0.013400464,0.0007098272,0.000456723,0.0047999993,0.0016312333,0.0000060887924,0.0006116145,0.000010559428,0.000016546148,0.0015534757,0.97635376,0.00044971934],"about_ca_topic_score_codex":0.00028719666,"about_ca_topic_score_gemma":0.00042230124,"teacher_disagreement_score":0.9706655,"about_ca_system_score_codex":0.00032363425,"about_ca_system_score_gemma":0.0007027205,"threshold_uncertainty_score":0.9999643},"labels":[],"label_agreement":null},{"id":"W2326074019","doi":"10.1177/095632020401500302","title":"Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development","year":2004,"lang":"en","type":"review","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Dosing; Protease inhibitor (pharmacology); Virology; Reverse-transcriptase inhibitor; Pharmacology; Human immunodeficiency virus (HIV); ANTIRETROVIRAL AGENTS; Medicine; Biology; Antiretroviral therapy; Viral load; Genetics; RNA","score_opus":0.12437243587991338,"score_gpt":0.4137304869345004,"score_spread":0.289358051054587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326074019","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026121128,0.97086644,0.000016231475,0.00015223051,0.000058977268,0.0007116177,0.0000144464375,0.000023905368,0.002035026],"genre_scores_gemma":[0.014193591,0.9801219,0.0009555179,0.000014323164,0.00008467088,0.000019382607,0.00011882745,0.00005022742,0.004441522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971625,0.000054188455,0.001388201,0.0007052781,0.0003797999,0.00031001907],"domain_scores_gemma":[0.998704,0.00008832267,0.0005743402,0.00040415843,0.00007774323,0.00015142163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003318973,0.0005532899,0.0024457402,0.000096074815,0.000025732612,0.000008180528,0.00017168545,0.00040458303,0.00044780772],"category_scores_gemma":[0.000041233092,0.00044247508,0.00048713063,0.00031583876,0.0002602431,0.00004489733,0.00007486134,0.0005040848,0.0000099065055],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096567324,0.0013995303,0.008774019,0.017778244,0.00083985744,0.000016702783,0.0012481065,1.0611467e-8,0.000028670043,0.0000068243367,0.0007839156,0.9690276],"study_design_scores_gemma":[0.0063497806,0.00008217363,0.007276914,0.03880522,0.0007334417,0.000029011238,0.0002980382,0.0000021090339,0.009437346,0.00007762277,0.9361725,0.00073583843],"about_ca_topic_score_codex":0.000015013848,"about_ca_topic_score_gemma":0.000003124263,"teacher_disagreement_score":0.9682917,"about_ca_system_score_codex":0.0002723178,"about_ca_system_score_gemma":0.0020751585,"threshold_uncertainty_score":0.9998027},"labels":[],"label_agreement":null},{"id":"W2326526667","doi":"10.1097/qad.0b013e32835c1213","title":"Learning from drug changes in antiretroviral therapy","year":2013,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cart; Medicine; Reverse-transcriptase inhibitor; Drug; Antiretroviral therapy; Viral load; Protease inhibitor (pharmacology); Viral replication; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Nucleoside analogue; Drug holiday; Pharmacology; Human immunodeficiency virus (HIV); Virology; Intensive care medicine; Virus; Nucleoside; Biology","score_opus":0.018611695612955635,"score_gpt":0.2436833562068711,"score_spread":0.22507166059391545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326526667","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5004203,0.001441692,0.0000017784414,0.49388164,0.000346524,0.00053670123,0.000008392391,0.000114544695,0.0032484632],"genre_scores_gemma":[0.12308752,0.0021058568,0.0013528392,0.3887229,0.0047978307,0.0002413765,0.0033649167,0.00016974691,0.476157],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985133,0.00009730616,0.0002187104,0.00042161616,0.0003508013,0.00039831095],"domain_scores_gemma":[0.9994303,0.00011292011,0.00009366471,0.00027695348,0.00003435116,0.000051840936],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009212082,0.00034809246,0.000602313,0.00031216096,0.00004412023,0.000035798985,0.00011888337,0.00039917152,0.0015876436],"category_scores_gemma":[0.000020516052,0.00026457084,0.000106575586,0.00017168837,0.000041498937,0.000052559055,0.000042148105,0.0013534954,0.0010119798],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002616791,0.0000433663,0.22482978,0.00002850806,0.00021436281,0.0007680907,0.001045603,1.1500022e-7,0.00012842602,7.975821e-7,0.7472481,0.025666704],"study_design_scores_gemma":[0.0019078489,0.00025861157,0.0126632545,0.00030615987,0.000067273024,0.0000056863396,0.000102771686,0.000012107147,0.0010173722,0.00003962749,0.98330957,0.00030969965],"about_ca_topic_score_codex":0.00055091636,"about_ca_topic_score_gemma":0.000020389616,"teacher_disagreement_score":0.47290856,"about_ca_system_score_codex":0.0001292585,"about_ca_system_score_gemma":0.00007794207,"threshold_uncertainty_score":0.9999806},"labels":[],"label_agreement":null},{"id":"W2327539131","doi":"10.1155/2008/479752","title":"Solid Organ Transplantation and HIV: A Changing Paradigm","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Contraindication; Medicine; Transplantation; Population; Organ transplantation; Intensive care medicine; Epidemiology; Pediatrics; Internal medicine; Pathology; Environmental health; Alternative medicine","score_opus":0.005590847186272775,"score_gpt":0.22832236406823112,"score_spread":0.22273151688195833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327539131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922946,0.0026225715,0.00018326983,0.0045313207,0.0001492672,0.000083670624,0.000026687103,0.0000071872846,0.00010143239],"genre_scores_gemma":[0.9968279,0.0018924158,0.000033965283,0.0008254416,0.0001408217,0.0000019738432,0.00003528785,0.000007898855,0.0002342679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99936,0.00003006494,0.0002056897,0.00009839912,0.000046042078,0.00025979226],"domain_scores_gemma":[0.9987354,0.000043705335,0.00006150211,0.00003715194,0.000043851116,0.0010783598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079692145,0.00009764448,0.00025665568,0.00027879668,0.00017124137,0.0000064304695,0.000025632839,0.000088226356,0.00020402938],"category_scores_gemma":[0.000076430224,0.000073203344,0.000048460955,0.00008710845,0.00022901267,0.000034393244,0.0000045740326,0.00012600428,0.000005009101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011074892,0.00010640464,0.9754916,0.00012444706,0.0003815754,0.00857343,0.0033308624,6.33773e-7,0.00085985527,0.00028474812,0.0043156734,0.006420019],"study_design_scores_gemma":[0.022388473,0.001951181,0.47707623,0.0015455683,0.0017654592,0.39358756,0.0010798685,0.00005517673,0.0013502599,0.00062491914,0.0977962,0.00077911833],"about_ca_topic_score_codex":0.00012990243,"about_ca_topic_score_gemma":0.00082732434,"teacher_disagreement_score":0.49841538,"about_ca_system_score_codex":0.000063780506,"about_ca_system_score_gemma":0.0010476037,"threshold_uncertainty_score":0.29851457},"labels":[],"label_agreement":null},{"id":"W2327700251","doi":"10.1097/01.qai.0000186361.42834.61","title":"Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms","year":2005,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug resistance; HIV drug resistance; Algorithm; Drug; Medicine; Resistance (ecology); Virology; Computer science; Biology; Antiretroviral therapy; Pharmacology; Viral load; Microbiology","score_opus":0.0062060013517595035,"score_gpt":0.2282096602859493,"score_spread":0.2220036589341898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327700251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8844632,0.10719503,0.00019420171,0.0062482837,0.00009836538,0.00038758552,0.000021161062,0.000019735873,0.001372447],"genre_scores_gemma":[0.9611597,0.004664701,0.008893705,0.000019388912,0.000028996581,0.000008023437,0.0000023326738,0.000024950665,0.02519819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719906,0.0001545735,0.0013645234,0.00021284289,0.0007692116,0.00029981005],"domain_scores_gemma":[0.9978739,0.0003857766,0.00088582624,0.00038852906,0.00037744912,0.0000885018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014566253,0.00023638265,0.0008781834,0.00032466004,0.00011138656,0.000014844835,0.00034451764,0.00006682628,0.000051760155],"category_scores_gemma":[0.00022125863,0.00014776771,0.00029962035,0.00060315273,0.0006257936,0.00024728398,0.00003973686,0.0001264122,0.0000072266776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053451467,0.01469649,0.25048593,0.020492444,0.011379332,0.0017044526,0.2461448,0.00033302867,0.19293758,0.027617445,0.026255572,0.15450144],"study_design_scores_gemma":[0.06733345,0.001302485,0.48672315,0.016319387,0.0061748326,0.003318188,0.019027868,0.0010440488,0.35225388,0.008236537,0.036407523,0.0018586305],"about_ca_topic_score_codex":0.000003591131,"about_ca_topic_score_gemma":0.00000382621,"teacher_disagreement_score":0.23623723,"about_ca_system_score_codex":0.0000687698,"about_ca_system_score_gemma":0.00019798022,"threshold_uncertainty_score":0.60257924},"labels":[],"label_agreement":null},{"id":"W2328400276","doi":"10.1097/00002030-200211080-00001","title":"Notes from the XIV International AIDS Conference in Barcelona, Spain","year":2002,"lang":"en","type":"editorial","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enfuvirtide; Viral load; Medicine; Regimen; Human immunodeficiency virus (HIV); Internal medicine; Virology; Surgery; Immunology; Gp41","score_opus":0.018795497157991035,"score_gpt":0.270932491454754,"score_spread":0.25213699429676295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328400276","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011037707,0.0012889116,0.00022309592,0.016453728,0.951446,0.000902854,0.00063170167,0.00013928387,0.017876696],"genre_scores_gemma":[0.07997113,0.0013923475,0.004216829,0.00038053142,0.78670436,0.0001767733,0.0058308146,0.00009646744,0.12123073],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775505,0.00009946467,0.00041574825,0.0004864204,0.00095144456,0.0002918503],"domain_scores_gemma":[0.99737436,0.0018173988,0.000117654236,0.00041691665,0.00017679515,0.00009686308],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003349387,0.00035669564,0.00052023167,0.00016706812,0.00005645495,0.00006787081,0.0003952995,0.0004737429,0.003441249],"category_scores_gemma":[0.0011618257,0.00024047508,0.00014209028,0.00017746667,0.00009584654,0.00006569774,0.00013676044,0.000805948,0.00090163125],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000777736,0.000177712,0.028580846,0.000014627276,0.00037376466,0.00017602288,0.0009145418,4.5200903e-7,0.000018144632,0.00015972726,0.95849484,0.011011567],"study_design_scores_gemma":[0.0022228973,0.00007451079,0.0024513283,0.00049419404,0.00015493977,0.0000018941862,0.00010326785,0.000060743125,0.00008585254,0.00025910343,0.993845,0.0002463027],"about_ca_topic_score_codex":0.000406672,"about_ca_topic_score_gemma":0.00026786534,"teacher_disagreement_score":0.16474165,"about_ca_system_score_codex":0.00027976776,"about_ca_system_score_gemma":0.0003612461,"threshold_uncertainty_score":0.99987626},"labels":[],"label_agreement":null},{"id":"W2328463947","doi":"10.1136/sextrans-2011-050109.143","title":"O4-S1.05 RNA helicases, p72 and p68 and HDAC1 interact with HIV-1 integrase and affect viral replication","year":2011,"lang":"en","type":"article","venue":"Sexually Transmitted Infections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Integrase; Virology; Viral replication; Integrase inhibitor; Biology; Reverse transcriptase; Virus; RNA; Genetics; Viral load; Gene; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.01620351155072859,"score_gpt":0.25998343137613195,"score_spread":0.24377991982540337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328463947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077564,0.00028411084,0.0029837473,0.0013827533,0.000054263324,0.0007116503,0.000027396947,0.00017977647,0.0036006733],"genre_scores_gemma":[0.9946687,0.00046108293,0.0023974378,0.0002378297,0.000042034862,0.00013463061,0.00016356315,0.000034537406,0.0018601485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988448,0.0000557433,0.00024596183,0.00050114957,0.00012400467,0.00022832547],"domain_scores_gemma":[0.99921095,0.00010446328,0.000063045874,0.00031241876,0.00007751342,0.00023161146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012955241,0.00026769016,0.00029310407,0.00026756493,0.00019870131,0.0000400656,0.00003233648,0.000095587944,0.00012041983],"category_scores_gemma":[0.000042397045,0.00019943697,0.00003460862,0.00025360403,0.00017635766,0.00022645012,0.000018826968,0.0002516698,0.00002570937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017945856,0.003584915,0.72928447,0.0006329347,0.0026150336,0.0004332235,0.024025809,0.0000010959174,0.015801456,0.0027740344,0.005377481,0.21367495],"study_design_scores_gemma":[0.02052873,0.0094817225,0.8680441,0.001309944,0.0035919505,0.005661116,0.002936288,0.0006978554,0.029910628,0.0008577231,0.055172388,0.0018075685],"about_ca_topic_score_codex":0.00021104903,"about_ca_topic_score_gemma":0.0003870726,"teacher_disagreement_score":0.21186738,"about_ca_system_score_codex":0.00004633335,"about_ca_system_score_gemma":0.000071301736,"threshold_uncertainty_score":0.81328034},"labels":[],"label_agreement":null},{"id":"W2328918516","doi":"10.1097/ftd.0b013e3182834057","title":"Negligible Effect of Tenofovir on Atazanavir Trough Concentrations and Genotypic Inhibitory Quotients in the Presence and Absence of Ritonavir","year":2013,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Clinique Paro Excellence; McGill University Health Centre; Université de Montréal","funders":"McGill University Health Centre","keywords":"Atazanavir; Ritonavir; Medicine; Odds ratio; Confidence interval; Therapeutic drug monitoring; Internal medicine; Pharmacology; Tolerability; Therapeutic effect; Drug; Adverse effect; Gastroenterology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.013962422783873673,"score_gpt":0.27494571641829246,"score_spread":0.2609832936344188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328918516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645126,0.0018029653,0.000004146429,0.00035236985,0.00011452635,0.0007780138,0.0000020216796,0.000012398253,0.00048230568],"genre_scores_gemma":[0.9989082,0.00033784457,0.00014434144,0.000020638297,0.00005646391,0.00007467969,0.0000022022787,0.000010840642,0.00044474585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989887,0.00011508077,0.00025377286,0.00018899949,0.0002640449,0.00018939153],"domain_scores_gemma":[0.9992028,0.0004146801,0.000082528626,0.00021215371,0.00003684973,0.000050998926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022668377,0.00015004048,0.00026444098,0.00007897951,0.00006376782,0.000015516656,0.00008353103,0.00004014553,0.000006807804],"category_scores_gemma":[0.00002031708,0.000094792995,0.000029989887,0.00016043027,0.00014223815,0.00011554934,0.000028945184,0.00013449525,0.000006688964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013018219,0.00019372349,0.93388045,0.00018163423,0.000094488365,0.0000071897407,0.008077073,0.000012916851,0.026972592,0.00012106612,0.00002860481,0.030300077],"study_design_scores_gemma":[0.0025120247,0.0003800447,0.86891747,0.00069969695,0.000098209974,0.0000097154425,0.0013641078,0.000141151,0.12541263,0.00014637846,0.00017874202,0.0001398291],"about_ca_topic_score_codex":0.00016564346,"about_ca_topic_score_gemma":0.0000033940896,"teacher_disagreement_score":0.09844003,"about_ca_system_score_codex":0.000034309192,"about_ca_system_score_gemma":0.00003260662,"threshold_uncertainty_score":0.3865546},"labels":[],"label_agreement":null},{"id":"W2329003397","doi":"10.1177/095632020701800205","title":"Kinetics of Inhibition of HIV Type 1 Reverse Transcriptase-Bearing NRTI-associated Mutations by Apricitabine Triphosphate","year":2007,"lang":"en","type":"article","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Resistance mutation; Biology; Primer (cosmetics); Nucleotidyltransferase; Reverse-transcriptase inhibitor; Mutation; Molecular biology; Virology; Nucleoside Reverse Transcriptase Inhibitor; Wild type; Nucleoside; Mutant; Chemistry; RNA; Genetics; Gene","score_opus":0.009658679323601324,"score_gpt":0.24775137503491812,"score_spread":0.2380926957113168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329003397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947629,0.00032043,0.0002954567,0.00064667186,0.000031545456,0.00021019408,0.00005171107,0.000045276665,0.0036357904],"genre_scores_gemma":[0.99011135,0.00021119101,0.00085467537,0.00009938492,0.000028140914,0.0000031348636,0.00064316235,0.000030324854,0.00801866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987999,0.000009166695,0.00047333597,0.00020912374,0.00026710416,0.00024135542],"domain_scores_gemma":[0.99933875,0.00003635857,0.00021097183,0.00017002046,0.00017610277,0.000067771325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014834084,0.00018953977,0.00037389933,0.00004677801,0.000028152675,0.0000044917897,0.000051547737,0.00013249218,0.00019271331],"category_scores_gemma":[0.000040007984,0.0001819934,0.00012365323,0.00043529604,0.00009901169,0.00005600535,0.0000073488804,0.00011895418,0.0000064665696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033074603,0.00081842736,0.013391376,0.00013035063,0.00020184192,0.000016069216,0.0004648134,6.735954e-7,0.97937137,0.0000035684604,0.0038711631,0.0013995755],"study_design_scores_gemma":[0.004215291,0.00009446395,0.0039505814,0.00017604147,0.000118998236,0.000003942698,0.00016897995,0.000018273453,0.988768,0.000021143935,0.0023175324,0.00014674505],"about_ca_topic_score_codex":0.00001651575,"about_ca_topic_score_gemma":0.0000013138681,"teacher_disagreement_score":0.009440795,"about_ca_system_score_codex":0.00009001033,"about_ca_system_score_gemma":0.00003870852,"threshold_uncertainty_score":0.74214756},"labels":[],"label_agreement":null},{"id":"W2329100397","doi":"10.1097/qai.0b013e31827a0d71","title":"Pharmacokinetics of Maraviroc, Raltegravir, Darunavir, and Etravirine in the Semen of HIV-Infected Men","year":2013,"lang":"en","type":"letter","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Maple Leaf Medical Clinic; St. Michael's Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Raltegravir; Maraviroc; Etravirine; Darunavir; Medicine; Concomitant; Regimen; Atazanavir; Dosing; Pharmacology; Viral load; Internal medicine; Sexual transmission; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.016762904554740513,"score_gpt":0.26808421360291274,"score_spread":0.25132130904817224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329100397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8722973,0.013421695,0.000029423372,0.11034437,0.00044679898,0.0014354148,0.000087915316,0.000027961736,0.001909112],"genre_scores_gemma":[0.96000737,0.011249835,0.002754386,0.007853057,0.00047369816,0.000060237344,0.00042321812,0.0002334912,0.016944721],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99498755,0.0003559783,0.0023525187,0.0003505265,0.0013665603,0.0005868877],"domain_scores_gemma":[0.99652725,0.0005399385,0.0017855983,0.00060888956,0.00045055163,0.00008779292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013572355,0.000610901,0.0019838864,0.0014178619,0.00006927637,0.000040478546,0.0006757659,0.00043646092,0.00022500806],"category_scores_gemma":[0.0001939212,0.00038431265,0.00044315928,0.0010731728,0.0004301319,0.00021100992,0.0001426821,0.0008925972,0.000025125271],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008471209,0.0030377037,0.057173517,0.004633208,0.0037878524,0.00697107,0.009639779,0.000026357482,0.052781176,0.00008007309,0.8452935,0.015728602],"study_design_scores_gemma":[0.041031823,0.009248919,0.6610268,0.011546197,0.010616419,0.01864034,0.005201062,0.00039588005,0.026873617,0.0011158439,0.21130516,0.0029979555],"about_ca_topic_score_codex":0.000059480655,"about_ca_topic_score_gemma":6.825071e-7,"teacher_disagreement_score":0.6339884,"about_ca_system_score_codex":0.00012771852,"about_ca_system_score_gemma":0.000324385,"threshold_uncertainty_score":0.9998609},"labels":[],"label_agreement":null},{"id":"W2329651258","doi":"10.1097/qad.0000000000001065","title":"Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?","year":2016,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Consorzio Interuniversitario Biotecnologie","keywords":"Medicine; Kidney disease; Regimen; Poisson regression; Internal medicine; Renal function; Incidence (geometry); Quartile; Retrospective cohort study; Cohort; Surgery; Confidence interval; Population","score_opus":0.008083724288270509,"score_gpt":0.2604505722796364,"score_spread":0.2523668479913659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329651258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97940433,0.000917786,0.0017764014,0.014754708,0.00047845623,0.0015295369,0.0007162794,0.00015554944,0.00026695468],"genre_scores_gemma":[0.9683137,0.001996433,0.00050506764,0.00021628091,0.0005914286,0.00017116862,0.00012720434,0.00004577233,0.028032938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857426,0.000069126065,0.00025594063,0.00037357246,0.00026251018,0.00046460508],"domain_scores_gemma":[0.9985148,0.0002667554,0.00014516797,0.00057706836,0.00006005416,0.00043617003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034594946,0.0002775128,0.00030827662,0.000081546896,0.0002841855,0.000033660883,0.0001487019,0.00006735206,0.00047121634],"category_scores_gemma":[0.00042711562,0.00009301731,0.00032750846,0.00014864092,0.00012158365,0.00019238939,0.000061203085,0.00011194582,0.00022585725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007892215,0.00021714397,0.9133063,0.0000551503,0.000729825,0.000028951305,0.00022620308,0.0000013246862,0.00012395601,0.00014250813,0.031338602,0.053040802],"study_design_scores_gemma":[0.021407291,0.003646309,0.6226785,0.0007530981,0.0031522692,0.000010417329,0.000089937865,0.00048031294,0.0025427395,0.0038573523,0.34065244,0.0007293128],"about_ca_topic_score_codex":0.00011244134,"about_ca_topic_score_gemma":0.000023500792,"teacher_disagreement_score":0.30931383,"about_ca_system_score_codex":0.000344239,"about_ca_system_score_gemma":0.00027049874,"threshold_uncertainty_score":0.51594883},"labels":[],"label_agreement":null},{"id":"W2330399120","doi":"10.1097/00002030-200301030-00001","title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","year":2003,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Biology; Virology; Efavirenz; Reverse transcriptase; Nevirapine; Genotype; Mutation; Genetics; Gene; Virus; Polymerase chain reaction; Viral load","score_opus":0.0200485203743622,"score_gpt":0.2915979826713447,"score_spread":0.27154946229698246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330399120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179965,0.000082042796,0.0004891169,0.0017996408,0.0002268253,0.0010137294,0.000031193766,0.00006877422,0.004489042],"genre_scores_gemma":[0.9725967,0.00000855714,0.01143111,0.0026923404,0.000042569365,0.00016315853,0.000041657444,0.000040777046,0.012983103],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828136,0.00006362648,0.00046721322,0.00045026565,0.00032847354,0.00040907844],"domain_scores_gemma":[0.9991727,0.000054725828,0.000050763865,0.00029309053,0.00007921547,0.00034953153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002094106,0.00026626937,0.00037824176,0.00035477628,0.000095518815,0.000043469267,0.00007972454,0.00010145151,0.00018692065],"category_scores_gemma":[0.00019644438,0.0002523466,0.00010080888,0.00065866753,0.000047953847,0.00015986188,0.000012616613,0.00014147391,0.0006214547],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033101444,0.0017558886,0.53220534,0.0003441168,0.00040044365,0.0029149451,0.038189664,0.00020225754,0.31402722,0.0021402803,0.098453455,0.006056221],"study_design_scores_gemma":[0.013584323,0.0007157596,0.08903131,0.00094194093,0.00021682295,0.000028758554,0.0027350192,0.000014475918,0.6183511,0.00014649777,0.27335402,0.0008799422],"about_ca_topic_score_codex":0.000056697598,"about_ca_topic_score_gemma":0.00018226521,"teacher_disagreement_score":0.44317406,"about_ca_system_score_codex":0.00028768365,"about_ca_system_score_gemma":0.00018703112,"threshold_uncertainty_score":0.99999285},"labels":[],"label_agreement":null},{"id":"W2330651972","doi":"10.1021/jm501010f","title":"Modular Assembly of Purine-like Bisphosphonates as Inhibitors of HIV-1 Reverse Transcriptase","year":2014,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Chemistry; Reverse transcriptase; Synthon; Stereochemistry; Purine; DNA polymerase; Pyrophosphate; Nucleic acid; DNA; Nucleotide; Enzyme; Polymerase; Pyrimidine; Combinatorial chemistry; RNA; Biochemistry","score_opus":0.006245897837822531,"score_gpt":0.23371340020301615,"score_spread":0.2274675023651936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330651972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914169,0.0017828075,0.00009734506,0.0026547238,0.00022477668,0.00009702958,0.000007445752,0.000008848315,0.0037101766],"genre_scores_gemma":[0.99031824,0.00024213918,0.0014499282,0.00009051003,0.00026006406,0.0000019408908,0.000015912985,0.000021483496,0.0075998097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977198,0.000028160519,0.0009581673,0.00015487318,0.00092353055,0.00021545235],"domain_scores_gemma":[0.99832475,0.00008421559,0.00064801925,0.00022777547,0.00039351787,0.00032171118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006633569,0.0002162096,0.0007617958,0.000110604036,0.000025391199,0.0000034977809,0.00015871081,0.00013673463,0.0003498719],"category_scores_gemma":[0.00031598585,0.00015848292,0.00029257796,0.00019890329,0.00014655312,0.00007589314,0.000019958423,0.0003449211,0.000007670915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012011782,0.00082263927,0.011149585,0.0013048648,0.00063148467,0.00061207754,0.0011177165,0.000013651844,0.951214,0.00001688072,0.029184358,0.0027315307],"study_design_scores_gemma":[0.00538627,0.00045773326,0.0012937732,0.0016402951,0.0006578437,0.0008878956,0.00083508383,0.00004685152,0.9527036,0.00007051148,0.035883732,0.00013639666],"about_ca_topic_score_codex":0.000012563676,"about_ca_topic_score_gemma":3.564796e-7,"teacher_disagreement_score":0.0098558115,"about_ca_system_score_codex":0.000088450935,"about_ca_system_score_gemma":0.00032320485,"threshold_uncertainty_score":0.64627457},"labels":[],"label_agreement":null},{"id":"W2331233939","doi":"10.1155/2006/384135","title":"Organ Transplantation in HIV Infected Individuals: The Time Has Come ‐ Should there Be Criteria?","year":2006,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Ontario HIV Treatment Network","keywords":"Medicine; Liver transplantation; Human immunodeficiency virus (HIV); Antiretroviral therapy; Transplantation; Organ transplantation; Infectious disease (medical specialty); Hepatitis C virus; Hepatitis C; Immunology; Disease; Kidney transplantation; Liver disease; Virology; Hepatitis; Intensive care medicine; Virus; Viral load; Internal medicine","score_opus":0.009373102326454394,"score_gpt":0.2378072128052814,"score_spread":0.228434110478827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331233939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722829,0.0017101448,0.00002936637,0.025224159,0.00014461036,0.00017445345,0.00010665608,0.000010006523,0.00031768926],"genre_scores_gemma":[0.9976532,0.00017098428,0.000017945662,0.0014958857,0.00015839774,0.0000047458616,0.00019535903,0.000011960697,0.00029151846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900776,0.0001294808,0.00036722358,0.000118233984,0.000082176746,0.00029510973],"domain_scores_gemma":[0.9991219,0.00014472383,0.00009750857,0.00007055811,0.00007794546,0.00048737144],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022302664,0.00013995016,0.00031826657,0.00026097993,0.00013846936,0.00003162725,0.00007479677,0.0001532505,0.0011232434],"category_scores_gemma":[0.00013511197,0.00008673466,0.00007359165,0.00016744321,0.00031819046,0.000044515116,0.000007707758,0.00025342827,0.000012876248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004925185,0.00014588214,0.97558,0.000040977717,0.00014060676,0.0011885132,0.00047416246,0.0000014730641,0.00091976405,0.00012855655,0.020110352,0.001220473],"study_design_scores_gemma":[0.007135964,0.00040745875,0.877479,0.0004437473,0.0005242171,0.007911388,0.00014150814,0.0000119326605,0.000259019,0.00040562765,0.105041325,0.00023880447],"about_ca_topic_score_codex":0.0014101334,"about_ca_topic_score_gemma":0.015601081,"teacher_disagreement_score":0.09810098,"about_ca_system_score_codex":0.00012890776,"about_ca_system_score_gemma":0.001330416,"threshold_uncertainty_score":0.9997899},"labels":[],"label_agreement":null},{"id":"W2331891559","doi":"10.3851/imp1912","title":"Telbivudine Exerts no Antiviral Activity against HIV-1 <i>In Vitro</i> and in Humans","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Telbivudine; Virology; In vivo; In vitro; Drug resistance; Antiviral drug; Human immunodeficiency virus (HIV); Biology; Drug; Genotype; Virus; Medicine; Hepatitis B virus; Pharmacology; Lamivudine; Microbiology; Genetics; Gene","score_opus":0.027933703811589442,"score_gpt":0.26063006942563127,"score_spread":0.23269636561404183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331891559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97158086,0.00027809793,0.000008262184,0.00048219526,0.00008878627,0.0005189908,0.000008193065,0.000056012304,0.026978584],"genre_scores_gemma":[0.9918296,0.0017274058,0.00065427134,0.00030456856,0.00006384056,0.00003688066,0.000032186686,0.00003431247,0.00531695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863845,0.000076283715,0.00025672078,0.00042305858,0.00018317104,0.0004223356],"domain_scores_gemma":[0.9995683,0.000035156223,0.00006569282,0.00023955152,0.000027742033,0.000063554195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022357801,0.00029038725,0.00049758214,0.00024900312,0.0000561453,0.000015987469,0.00007836098,0.000107878324,0.000045906392],"category_scores_gemma":[0.00001087,0.00023289843,0.00007993929,0.00027127122,0.00010639254,0.00024797246,0.000038116672,0.00022292932,0.0001271365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003002777,0.0015859685,0.73230904,0.000029441226,0.00008941864,0.0006331104,0.002477317,3.9550798e-8,0.18602782,0.000032776064,0.00065112335,0.07316116],"study_design_scores_gemma":[0.009333874,0.00026733853,0.6373514,0.0001801244,0.000018695577,0.0000064393676,0.00009925807,0.00006137206,0.34555504,0.000099171906,0.0065793237,0.0004479511],"about_ca_topic_score_codex":0.00006169758,"about_ca_topic_score_gemma":0.00006330009,"teacher_disagreement_score":0.15952721,"about_ca_system_score_codex":0.0000621589,"about_ca_system_score_gemma":0.000052218184,"threshold_uncertainty_score":0.94973224},"labels":[],"label_agreement":null},{"id":"W2332917663","doi":"10.1097/qai.0b013e31820eefbe","title":"A Randomized Crossover Study to Determine Relative Bioequivalence of Tenofovir, Emtricitabine, and Efavirenz (Atripla) Fixed-Dose Combination Tablet Compared With a Compounded Oral Liquid Formulation Derived From the Tablet","year":2011,"lang":"en","type":"letter","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; Chulalongkorn University; University of Alabama at Birmingham","keywords":"Bioequivalence; Efavirenz; Emtricitabine; Tenofovir; Fixed-dose combination; Crossover study; Medicine; Pharmacology; Pharmacokinetics; Randomized controlled trial; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Virology; Antiretroviral therapy","score_opus":0.03289672565851643,"score_gpt":0.2726282544102697,"score_spread":0.2397315287517533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332917663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751254,0.00263488,0.0009490406,0.016827919,0.00038427557,0.0038167662,0.000105619336,0.000048970942,0.00010718245],"genre_scores_gemma":[0.9920192,0.00019136131,0.0032299554,0.0021749462,0.00010382739,0.000096406286,0.00028290966,0.00010584783,0.001795587],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939136,0.0008059537,0.0024750596,0.0006108776,0.0015494252,0.0006450726],"domain_scores_gemma":[0.99325323,0.0020016774,0.0027370597,0.00070824387,0.0011462468,0.00015353721],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020148589,0.0008365752,0.0034066266,0.0010727037,0.0003643487,0.00013885832,0.00059854705,0.00032227603,0.00007686223],"category_scores_gemma":[0.0007758595,0.000493578,0.00046597887,0.0013033815,0.00054172846,0.0007003201,0.0002380054,0.00065234356,0.000015347903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7197813,0.01304419,0.060482904,0.0015118222,0.02292965,0.007894417,0.09523304,0.0001629105,0.018380908,0.00011838242,0.058622044,0.00183846],"study_design_scores_gemma":[0.7777752,0.026718926,0.14962392,0.007086908,0.018366218,0.0031395182,0.005536449,0.0011194127,0.0051046032,0.00086423324,0.0020367394,0.0026278468],"about_ca_topic_score_codex":0.00034249888,"about_ca_topic_score_gemma":0.000014842702,"teacher_disagreement_score":0.089696586,"about_ca_system_score_codex":0.00034395867,"about_ca_system_score_gemma":0.0006478611,"threshold_uncertainty_score":0.99975157},"labels":[],"label_agreement":null},{"id":"W2333403787","doi":"10.1097/md.0000000000001743","title":"Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?","year":2015,"lang":"en","type":"article","venue":"Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Geomechanica (Canada)","funders":"","keywords":"Raltegravir; Medicine; Regimen; Concomitant; Cmax; Pharmacokinetics; Dosing; Therapeutic drug monitoring; Adverse effect; Internal medicine; Pharmacology; Clinical endpoint; Human immunodeficiency virus (HIV); Viral load; Clinical trial; Antiretroviral therapy; Virology","score_opus":0.030334439284975784,"score_gpt":0.2998596330085212,"score_spread":0.26952519372354544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333403787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88892514,0.0018509588,0.000010184044,0.065003276,0.00036918724,0.0008563809,0.0000067237584,0.00008180629,0.042896368],"genre_scores_gemma":[0.95276093,0.00023567858,0.00026365274,0.0010227603,0.0005489873,0.00007407224,0.000117744006,0.000021916767,0.04495427],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983643,0.000100212645,0.0003316905,0.00030406754,0.0005242611,0.00037544433],"domain_scores_gemma":[0.99915975,0.00009124003,0.000067874906,0.00040659055,0.000058650956,0.00021588341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046124635,0.00026663466,0.0004930077,0.00019124869,0.0000597766,0.000012409012,0.00013401514,0.0000751858,0.00010847615],"category_scores_gemma":[0.000119887176,0.00009821883,0.00006763479,0.0002406852,0.00017052084,0.0000716013,0.000020509671,0.00015969969,0.00015940702],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045563688,0.00078994856,0.8910886,0.000025562684,0.00016718083,0.0015397021,0.033184282,9.472253e-7,0.00047356306,0.00022541192,0.02417887,0.047870293],"study_design_scores_gemma":[0.035410225,0.0060890196,0.19717114,0.0005867509,0.0007067767,0.00020185094,0.04256313,0.00020593683,0.00322315,0.0019395101,0.71139425,0.0005082784],"about_ca_topic_score_codex":0.0007555407,"about_ca_topic_score_gemma":0.00041901358,"teacher_disagreement_score":0.69391745,"about_ca_system_score_codex":0.00028530284,"about_ca_system_score_gemma":0.00017930065,"threshold_uncertainty_score":0.40052477},"labels":[],"label_agreement":null},{"id":"W2335490466","doi":"10.1097/00042560-200111010-00008","title":"Evaluation of Two Commercial Kits for the Detection of Genotypic Drug Resistance on a Panel of HIV Type 1 Subtypes A Through J","year":2001,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Genotyping; Genotype; Drug resistance; Virology; Biology; HIV drug resistance; Viral load; Human immunodeficiency virus (HIV); Genetics; Lentivirus; Viral disease; Antiretroviral therapy; Gene","score_opus":0.06529887181630281,"score_gpt":0.3253485504068372,"score_spread":0.2600496785905344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335490466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98687637,0.009900429,0.00095738244,0.0009119243,0.00039647945,0.0005860069,0.000007945117,0.000008856208,0.00035461923],"genre_scores_gemma":[0.997124,0.0007260917,0.001073836,0.0000128411175,0.00003929152,0.000012902972,0.0000062262366,0.0000214851,0.0009832954],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974433,0.00017324969,0.0010018505,0.00014063192,0.0010383525,0.0002026105],"domain_scores_gemma":[0.9967241,0.00045829342,0.0010135215,0.00029989926,0.0014725025,0.0000316581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024319766,0.00016829204,0.0006153562,0.0002849829,0.000108370834,0.0000065949403,0.000201302,0.0000578919,0.00003943808],"category_scores_gemma":[0.00070256635,0.000109351204,0.00026232158,0.0007394334,0.00015023809,0.00013540914,0.000022768014,0.00007665428,0.0000053474487],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031972528,0.00922621,0.057726216,0.0020828904,0.007333521,0.00012805103,0.050628148,0.0029903376,0.6059801,0.0036262616,0.0034807927,0.22482492],"study_design_scores_gemma":[0.026235897,0.0049021477,0.56914395,0.0032842576,0.0080293985,0.00070546736,0.0051623234,0.0021200175,0.37097538,0.0063662617,0.0024786256,0.0005962374],"about_ca_topic_score_codex":0.00002187089,"about_ca_topic_score_gemma":0.000022148013,"teacher_disagreement_score":0.51141775,"about_ca_system_score_codex":0.0001433188,"about_ca_system_score_gemma":0.00035210277,"threshold_uncertainty_score":0.44592127},"labels":[],"label_agreement":null},{"id":"W2335501781","doi":"10.1097/00002030-200112070-00025","title":"A compromise strategy for patients with multiple drug failure","year":2001,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Regimen; Intensive care medicine; Drug; Drug resistance; Medicine; Clinical equipoise; Modalities; Clinical trial; Internal medicine; Biology; Pharmacology","score_opus":0.012952082767174411,"score_gpt":0.23525962065519143,"score_spread":0.22230753788801702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335501781","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20125009,0.00026356286,0.00041524912,0.77692825,0.0006028532,0.011464162,0.0008301179,0.000515949,0.007729753],"genre_scores_gemma":[0.121339604,0.000042475043,0.04160642,0.24397257,0.0043515065,0.0018874385,0.036209654,0.00049317104,0.55009717],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998375,0.000024811232,0.00026987263,0.0004772426,0.0004001467,0.00045292606],"domain_scores_gemma":[0.9990993,0.00012538556,0.00012440351,0.00037206896,0.00017581943,0.00010302356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004831572,0.00042905376,0.0006036941,0.00016078168,0.00008827949,0.00003294493,0.00011345565,0.00032239093,0.00020487963],"category_scores_gemma":[0.000019773868,0.0002925573,0.0001535725,0.00014094752,0.00005086832,0.000057494282,0.0000252136,0.00053042354,0.00012572536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019213647,0.0002594354,0.11930758,0.00021900881,0.00048794702,0.00024839962,0.000108571425,5.243526e-7,0.0000010397175,0.000003341127,0.87739277,0.001779261],"study_design_scores_gemma":[0.009634845,0.0005943189,0.0026671481,0.00028869777,0.0005019249,0.000011474661,0.00005145762,0.00002171731,0.000037837075,0.000025137875,0.9857994,0.00036604056],"about_ca_topic_score_codex":0.000030268222,"about_ca_topic_score_gemma":0.000022986016,"teacher_disagreement_score":0.5423674,"about_ca_system_score_codex":0.0001927156,"about_ca_system_score_gemma":0.00015564801,"threshold_uncertainty_score":0.9999527},"labels":[],"label_agreement":null},{"id":"W2339098831","doi":"10.1016/j.bmcl.2016.04.053","title":"Novel nucleoside-based antimalarial compounds","year":2016,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Chemistry; Nucleoside; Antimalarial Agent; Plasmodium falciparum; Malaria; Combinatorial chemistry; Stereochemistry","score_opus":0.012835334703087684,"score_gpt":0.22763125964047032,"score_spread":0.21479592493738264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339098831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85252833,0.00008777701,0.002951872,0.14181454,0.0002950264,0.0002675558,0.000023981975,0.00022398456,0.0018069391],"genre_scores_gemma":[0.99072385,0.000011635812,0.002214849,0.0036326319,0.00088007114,0.000015621601,0.00007757254,0.000053454543,0.0023903043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802274,0.000013316227,0.00038599817,0.0004914005,0.00060147344,0.0004850539],"domain_scores_gemma":[0.9989244,0.00010719207,0.00011974228,0.00042599544,0.00007033397,0.00035238822],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018384437,0.00034028522,0.00043227134,0.0000624185,0.0001007867,0.00001722651,0.00018112562,0.00014274691,0.0014504723],"category_scores_gemma":[0.00012466924,0.00021945155,0.00014181546,0.00021395323,0.00026534888,0.00005798096,0.000044232445,0.00017923175,0.0002435886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023958541,0.00023827387,0.010416596,0.00009044179,0.00016055699,0.00026334677,0.000053176336,5.1446396e-8,0.9618529,0.0000064415767,0.025892952,0.0007856521],"study_design_scores_gemma":[0.011016578,0.000052592353,0.010370398,0.00059640256,0.00031529786,0.00042522905,0.00004380895,0.000013274927,0.9501976,0.0000038206995,0.026586838,0.00037817867],"about_ca_topic_score_codex":0.000010343373,"about_ca_topic_score_gemma":7.947194e-7,"teacher_disagreement_score":0.13819554,"about_ca_system_score_codex":0.0003354716,"about_ca_system_score_gemma":0.00028621356,"threshold_uncertainty_score":0.99946237},"labels":[],"label_agreement":null},{"id":"W2339878931","doi":"10.1093/jac/dkw046","title":"Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site","year":2016,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Université du Québec à Montréal; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Human immunodeficiency virus (HIV); Transporter; Antiretroviral drug; Drug; Biology; Enzyme; Virology; Pharmacology; Antiretroviral therapy; Biochemistry; Viral load; Gene","score_opus":0.004009480062091573,"score_gpt":0.2357029998685708,"score_spread":0.23169351980647923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339878931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812514,0.00044696106,0.0012658798,0.016576106,0.00011330834,0.0002936046,0.000019711895,0.000015337311,0.000017644708],"genre_scores_gemma":[0.9950542,0.0005069341,0.002139333,0.0010010833,0.00022010239,0.0000014723655,0.000014766804,0.000026611184,0.0010354873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987148,0.000037899797,0.0005406162,0.00019621615,0.00022572036,0.00028472408],"domain_scores_gemma":[0.9993752,0.000022693957,0.00019001005,0.00011013416,0.00012336417,0.00017859052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026115027,0.00021704855,0.00059194607,0.00033856303,0.000057689715,0.000024615294,0.000073271825,0.00007624038,0.00009788604],"category_scores_gemma":[0.000017616094,0.00014112447,0.00013363574,0.00018212378,0.00007072892,0.00017740586,0.000009312906,0.00012966136,0.00001355052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000765944,0.00027250577,0.08181034,0.000018832076,0.0001608245,0.0005744519,0.00064501615,0.0000020394389,0.9034869,0.000033619013,0.008404965,0.003824539],"study_design_scores_gemma":[0.0140693225,0.0003547226,0.11448266,0.00051950663,0.0001899456,0.0006535259,0.000023226228,0.0000028160455,0.85221773,0.000017399765,0.017227639,0.00024147512],"about_ca_topic_score_codex":0.000008610555,"about_ca_topic_score_gemma":0.0000062775243,"teacher_disagreement_score":0.051269166,"about_ca_system_score_codex":0.00008371801,"about_ca_system_score_gemma":0.000081841776,"threshold_uncertainty_score":0.5754889},"labels":[],"label_agreement":null},{"id":"W2340099473","doi":"10.1177/135965350701200315","title":"Five-Year Follow up of Once-Daily Therapy with Emtricitabine, Didanosine and Efavirenz (Montana ANRS 091 Trial)","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Emtricitabine; Efavirenz; Didanosine; Tolerability; Medicine; Regimen; Internal medicine; Adverse effect; Lipodystrophy; Gastroenterology; Immunology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.018782236023382425,"score_gpt":0.27160611842065696,"score_spread":0.25282388239727455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340099473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187696,0.0019210575,0.00007749742,0.0008631575,0.00018540885,0.0011244735,0.000008274528,0.000067215406,0.003875951],"genre_scores_gemma":[0.9796045,0.0034484018,0.001218691,0.0002064803,0.00015856358,0.000022536746,0.00003655333,0.00004924836,0.015255068],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983472,0.000052095602,0.00040692821,0.00037861484,0.00042179253,0.00039333067],"domain_scores_gemma":[0.9991697,0.0001228236,0.00016969616,0.00031181096,0.00011023218,0.000115717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003645845,0.0003328834,0.0006385164,0.00022100535,0.00009824172,0.000021558053,0.00009992677,0.000112506066,0.000059797534],"category_scores_gemma":[0.000014218518,0.00021434583,0.00013447514,0.00049709494,0.00015648169,0.00014541844,0.000016766015,0.00014777733,0.000015322468],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19929855,0.0022314894,0.47696862,0.000042125466,0.0016816993,0.0003884494,0.0060159713,3.1602815e-7,0.020382227,0.00051331124,0.0035539102,0.28892332],"study_design_scores_gemma":[0.42047173,0.012698491,0.36508644,0.00034871406,0.0002106896,0.000048432823,0.0011874426,0.000022324255,0.16152097,0.00021391983,0.0372576,0.00093325495],"about_ca_topic_score_codex":0.00008014316,"about_ca_topic_score_gemma":0.000058467293,"teacher_disagreement_score":0.28799006,"about_ca_system_score_codex":0.000057177418,"about_ca_system_score_gemma":0.00014093937,"threshold_uncertainty_score":0.8740769},"labels":[],"label_agreement":null},{"id":"W2340849517","doi":"10.1128/jvi.02131-15","title":"Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239","year":2015,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Simian immunodeficiency virus; Elvitegravir; Integrase; Raltegravir; Biology; Virology; Integrase inhibitor; Virus; Peripheral blood mononuclear cell; Recombinant DNA; Mutation; Molecular biology; Genetics; Viral load; Human immunodeficiency virus (HIV); In vitro; Gene; Antiretroviral therapy","score_opus":0.01239872390658087,"score_gpt":0.24355645215411975,"score_spread":0.23115772824753889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340849517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958617,0.0002488495,0.000063220716,0.0032795204,0.00018982102,0.00018485101,0.000008971525,0.0000030058843,0.00016004902],"genre_scores_gemma":[0.9989409,0.00012871252,0.00009941548,0.00004205617,0.000029923542,0.0000026501175,0.0000050161643,0.000009357464,0.0007419684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988306,0.000104707215,0.000631851,0.00007477826,0.00024030029,0.000117740834],"domain_scores_gemma":[0.99939746,0.0000436772,0.00024241909,0.00010941775,0.0001592001,0.000047828427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045289675,0.00009137241,0.00035157602,0.00020540292,0.000015152135,0.0000021253995,0.00009651715,0.00006517734,0.0000141765195],"category_scores_gemma":[0.000090329115,0.000054079883,0.00009091625,0.0002472884,0.00013508699,0.000069005015,0.000011194109,0.0001827779,0.0000019479344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019971123,0.00068216946,0.058477752,0.00008418656,0.00012555753,0.000072026545,0.009263141,0.000017298651,0.92798907,0.00014900726,0.00029783117,0.00084484357],"study_design_scores_gemma":[0.00820716,0.0005554982,0.21910438,0.0007017872,0.0002520639,0.00007739455,0.0015419287,0.000040983756,0.7667374,0.00035118198,0.0022898193,0.0001403999],"about_ca_topic_score_codex":0.000010664642,"about_ca_topic_score_gemma":0.00009947138,"teacher_disagreement_score":0.16125166,"about_ca_system_score_codex":0.000058871785,"about_ca_system_score_gemma":0.0002451867,"threshold_uncertainty_score":0.22053136},"labels":[],"label_agreement":null},{"id":"W2341868726","doi":"10.1093/jac/dkw109","title":"Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity","year":2016,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; University of British Columbia","keywords":"Dolutegravir; Raltegravir; Integrase; Integrase inhibitor; Mutant; Virology; Biology; Drug resistance; DNA; Mutation; Resistance mutation; Recombinant DNA; Genetics; Reverse transcriptase; Molecular biology; Virus; Gene; Viral load; Antiretroviral therapy; Polymerase chain reaction","score_opus":0.010032740565375082,"score_gpt":0.24137299641477694,"score_spread":0.23134025584940185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341868726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954976,0.00031315724,0.00024048361,0.009485042,0.000084651445,0.00020140382,0.000027876456,0.000022280794,0.00007534076],"genre_scores_gemma":[0.99434996,0.0022809487,0.0017721818,0.00029140504,0.0001413963,0.0000019921301,0.000013426179,0.000027202306,0.0011214678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871147,0.0000794739,0.00046533463,0.00022090052,0.0002356343,0.0002871613],"domain_scores_gemma":[0.9989882,0.00019404647,0.00034768225,0.00014257366,0.00011673113,0.00021076035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032267804,0.0002498752,0.00053574576,0.00046036154,0.00007208382,0.00003117977,0.0000908655,0.00012018813,0.00011414696],"category_scores_gemma":[0.0001872045,0.00015581882,0.00013523008,0.00030815214,0.00016467852,0.00030872977,0.000016254116,0.00018937561,0.000013877458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041124467,0.00093080086,0.08503879,0.00004253973,0.00025368136,0.00051143614,0.00024031523,1.3510044e-7,0.89844316,0.000042645053,0.006322751,0.004061315],"study_design_scores_gemma":[0.01897738,0.00021343246,0.08675655,0.0032755015,0.00016391245,0.0008721672,0.000085794556,0.0000044601347,0.883835,0.000067077424,0.0053593013,0.00038943035],"about_ca_topic_score_codex":0.00003408952,"about_ca_topic_score_gemma":0.00007217412,"teacher_disagreement_score":0.014864932,"about_ca_system_score_codex":0.0002993407,"about_ca_system_score_gemma":0.00032698596,"threshold_uncertainty_score":0.6354107},"labels":[],"label_agreement":null},{"id":"W2343174409","doi":"10.1186/s12977-016-0265-x","title":"Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses","year":2016,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Integrase; Virology; Dolutegravir; Viral replication; Reverse transcriptase; Mutant; Biology; Mutation; Resistance mutation; Plasmid; Integrase inhibitor; Virus; Viral load; DNA; Human immunodeficiency virus (HIV); Genetics; Polymerase chain reaction; Gene; Antiretroviral therapy","score_opus":0.01733287712530532,"score_gpt":0.28370891531307013,"score_spread":0.2663760381877648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343174409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931348,0.00007634229,0.00011918254,0.0038400504,0.00004981505,0.00041021133,0.00003215266,0.000043235184,0.0022941998],"genre_scores_gemma":[0.9947895,0.000020761476,0.00048158722,0.00018220356,0.00003243951,0.000092944436,0.000022683533,0.000016563736,0.0043613473],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986054,0.0001922436,0.00037950565,0.0003896711,0.00018832377,0.0002448933],"domain_scores_gemma":[0.998771,0.0004394173,0.00014865467,0.00052596646,0.000047031288,0.000067943816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037959518,0.00015412932,0.0003752951,0.00022804803,0.00004086105,0.0000026707844,0.000075592885,0.00012393584,0.00007712601],"category_scores_gemma":[0.00055746787,0.00010123203,0.00007529721,0.00018348945,0.00016515818,0.00005057825,0.00001836997,0.00010423397,0.00016609649],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004863187,0.00053696806,0.44690967,0.0001375472,0.00014166265,0.00008452834,0.00041222837,0.000002344793,0.5327384,0.0057077287,0.0018845655,0.0065811733],"study_design_scores_gemma":[0.0070777237,0.0023765797,0.55583143,0.00035203435,0.0001612472,0.0000137424295,0.000018770852,0.000012653119,0.42231122,0.00093022635,0.010674693,0.00023970101],"about_ca_topic_score_codex":0.00001982082,"about_ca_topic_score_gemma":0.00013616902,"teacher_disagreement_score":0.110427186,"about_ca_system_score_codex":0.00025265498,"about_ca_system_score_gemma":0.000065470915,"threshold_uncertainty_score":0.41281223},"labels":[],"label_agreement":null},{"id":"W2343783954","doi":"10.1111/tmi.12717","title":"Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda","year":2016,"lang":"en","type":"article","venue":"Tropical Medicine & International Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of British Columbia","funders":"World Health Organization; Henry M. Jackson Foundation; Rwanda Biomedical Centre; U.S. Department of Defense","keywords":"Medicine; HIV drug resistance; Internal medicine; Odds ratio; Viral load; Drug resistance; Genotyping; Retrospective cohort study; Regimen; Confidence interval; Cohort; Logistic regression; Antiretroviral therapy; Cohort study; Human immunodeficiency virus (HIV); Virology; Genotype","score_opus":0.019468325004346414,"score_gpt":0.3079457535451554,"score_spread":0.288477428540809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343783954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7895668,0.00030538838,0.00003233961,0.2093159,0.00009318981,0.00030535087,0.000010267765,0.000011229037,0.00035949927],"genre_scores_gemma":[0.994186,0.0005891214,0.00029319437,0.0020742738,0.00013382638,0.000060253504,0.000006750944,0.000008569843,0.002648002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987197,0.000059755734,0.00041522528,0.0002257205,0.00039077597,0.00018881052],"domain_scores_gemma":[0.9992718,0.00033141265,0.00010652927,0.0001395445,0.000049531194,0.000101153026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014888731,0.00013206522,0.00031235174,0.00011379777,0.00005418262,0.000003491942,0.00009251547,0.00004297181,0.0001972495],"category_scores_gemma":[0.00013492069,0.00005737144,0.000038268452,0.00007794911,0.00028333798,0.000041035855,0.000021586895,0.000130132,0.000009218723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020736498,0.00022388536,0.96649384,0.00002855128,0.00003345985,0.00006171877,0.0011041267,1.0602902e-7,0.000019500907,0.0013357878,0.002406143,0.026219208],"study_design_scores_gemma":[0.0043720733,0.0006401247,0.9749278,0.0006980299,0.000008147366,0.000013726609,0.00008055348,0.000024244784,0.00005861721,0.00040291325,0.018719686,0.000054081156],"about_ca_topic_score_codex":0.00005042518,"about_ca_topic_score_gemma":0.0018506721,"teacher_disagreement_score":0.20724162,"about_ca_system_score_codex":0.00013577504,"about_ca_system_score_gemma":0.0000743893,"threshold_uncertainty_score":0.23395394},"labels":[],"label_agreement":null},{"id":"W2344218605","doi":"10.1016/j.jval.2015.03.1435","title":"HIV treatment strategies In europe (EU): Adoption of Single Tablet Regimen (STR)","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tolerability; Medicine; Dosing; Regimen; Family medicine; Quarter (Canadian coin); Human immunodeficiency virus (HIV); Demography; Pediatrics; Geography; Internal medicine; Adverse effect","score_opus":0.08063424318367501,"score_gpt":0.3113629764906792,"score_spread":0.23072873330700416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344218605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790529,0.0014919288,0.000037473874,0.008460105,0.000117572985,0.0008386963,0.000010462042,0.000045119818,0.009945761],"genre_scores_gemma":[0.98989147,0.0005516559,0.0043534706,0.00010067943,0.00005161804,0.00003491242,0.00011980556,0.00002215151,0.0048742252],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860466,0.00015633318,0.00048448896,0.00022584363,0.00023088975,0.0002977766],"domain_scores_gemma":[0.99936867,0.00004602501,0.00013245353,0.00021264306,0.00007210232,0.0001680922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043196385,0.00015069426,0.00039643928,0.00024027302,0.000018563793,0.000009712123,0.000043983066,0.000050826613,0.000014798031],"category_scores_gemma":[0.00004734744,0.000121017205,0.00002616191,0.0004878619,0.0000311193,0.00009241803,0.000016448492,0.00007865954,0.000056332257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002799456,0.016388286,0.809911,0.002009907,0.00035615484,0.001303715,0.068208106,0.021909093,0.0021574437,0.020638136,0.01961546,0.034703214],"study_design_scores_gemma":[0.09587489,0.026116043,0.2567785,0.010913721,0.00033402446,0.00039181908,0.04359376,0.014167422,0.015018746,0.0049497043,0.52964866,0.0022126692],"about_ca_topic_score_codex":0.0019196171,"about_ca_topic_score_gemma":0.00014121104,"teacher_disagreement_score":0.55313253,"about_ca_system_score_codex":0.00090228225,"about_ca_system_score_gemma":0.0013389443,"threshold_uncertainty_score":0.49349383},"labels":[],"label_agreement":null},{"id":"W2345747541","doi":"10.1021/acsmedchemlett.6b00135","title":"Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group","year":2016,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada)","funders":"","keywords":"Morpholine; HIV-1 protease; Protease; Protease inhibitor (pharmacology); Enzyme; Potency; Human immunodeficiency virus (HIV); Chemistry; Pharmacology; Bioavailability; Stereochemistry; Biochemistry; Medicine; Virology; In vitro; Organic chemistry; Viral load; Antiretroviral therapy","score_opus":0.016283096070707596,"score_gpt":0.24977472087759037,"score_spread":0.23349162480688276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345747541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834969,0.00005398667,0.0011741406,0.014424128,0.00009700141,0.00037721358,0.000049420658,0.00006725143,0.0002599776],"genre_scores_gemma":[0.9942017,0.00001603874,0.001339318,0.0006918983,0.00056340056,0.0000762871,0.00022552823,0.000043783388,0.0028420289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792224,0.000020451702,0.000530153,0.00047617764,0.00059347536,0.00045748756],"domain_scores_gemma":[0.99888545,0.000109033506,0.00024930298,0.0003915268,0.000069307316,0.00029539503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029861685,0.00033061,0.0005255332,0.00008746234,0.000071373965,0.00001612108,0.0001519205,0.00009832205,0.00009640451],"category_scores_gemma":[0.00015729535,0.00021559112,0.000104292645,0.0001775656,0.00024196191,0.00028152854,0.000059463087,0.00020260179,0.000023349188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007028916,0.00031716021,0.020081297,0.00023104707,0.00018655919,0.00048215277,0.00048717082,4.3885044e-7,0.97504425,0.000009091238,0.0017044345,0.0007534931],"study_design_scores_gemma":[0.008858153,0.00016819956,0.0016269778,0.0018043848,0.0002830526,0.000277477,0.00061940815,0.000015626103,0.98469675,0.000005516718,0.0013174369,0.00032704783],"about_ca_topic_score_codex":0.000018311557,"about_ca_topic_score_gemma":0.0000012577315,"teacher_disagreement_score":0.018454319,"about_ca_system_score_codex":0.00021694864,"about_ca_system_score_gemma":0.00013625463,"threshold_uncertainty_score":0.87915504},"labels":[],"label_agreement":null},{"id":"W2356970211","doi":"10.1155/2006/682640","title":"General Management Strategies for Efavirenz Therapy and Associated Adverse Events","year":2006,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Université de Montréal","funders":"","keywords":"Efavirenz; Adverse effect; Medicine; Depression (economics); Intensive care medicine; Central nervous system; Pharmacotherapy; Psychiatry; Pediatrics; Human immunodeficiency virus (HIV); Antiretroviral therapy; Internal medicine; Immunology; Viral load","score_opus":0.006142512749049373,"score_gpt":0.2301040168810178,"score_spread":0.22396150413196844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356970211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465185,0.0028795248,0.00008216962,0.0016003099,0.00021232697,0.00023174201,0.00005359416,0.0000074006944,0.00028110645],"genre_scores_gemma":[0.9973928,0.00069534365,0.00011789095,0.0006134788,0.0001482896,0.000010352809,0.00008263921,0.000009936573,0.000929289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993136,0.000034260476,0.00024235365,0.00011594005,0.000051102914,0.00024274438],"domain_scores_gemma":[0.9991925,0.0000470708,0.00009295091,0.000042359712,0.000077454286,0.0005476905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010792176,0.00011841814,0.00026362846,0.00016336964,0.00010692424,0.000008739325,0.000034672645,0.00009785722,0.00010267405],"category_scores_gemma":[0.000042292937,0.00008626954,0.00008380806,0.000054616332,0.00012889312,0.000037012782,0.0000069986363,0.00008073204,0.000001209571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024659073,0.0004163823,0.9417621,0.00012204935,0.0013970665,0.001101158,0.00017628435,0.000005084086,0.00042317962,0.00289621,0.026917921,0.02453597],"study_design_scores_gemma":[0.020808516,0.0013660813,0.84451,0.00045972256,0.0007598359,0.0021745015,0.00040538702,0.000027593289,0.000062541054,0.0046625864,0.12439729,0.00036589775],"about_ca_topic_score_codex":0.00063956785,"about_ca_topic_score_gemma":0.004276038,"teacher_disagreement_score":0.09747937,"about_ca_system_score_codex":0.0001117229,"about_ca_system_score_gemma":0.00082780846,"threshold_uncertainty_score":0.35179695},"labels":[],"label_agreement":null},{"id":"W2375301095","doi":"","title":"Studies on Blood Pharmacokinetics and Bioavailability of Ceftiofur in Ducks","year":2010,"lang":"en","type":"article","venue":"Shenyang Nongye Daxue xuebao","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Pharmacokinetics; Bioavailability; Ceftiofur; Cmax; Chemistry; Pharmacology; Absorption (acoustics); Oral administration; High-performance liquid chromatography; Chromatography; Medicine; Cephalosporin; Antibiotics; Biochemistry","score_opus":0.020807436669529725,"score_gpt":0.3188032595928476,"score_spread":0.2979958229233179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2375301095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940414,0.0004550392,7.876041e-7,0.0014765109,0.0002944088,0.00041026945,0.000019509009,0.00003632366,0.003265743],"genre_scores_gemma":[0.9935599,0.00019762624,0.001769915,0.00010904871,0.000087813474,0.000028875422,0.000021958178,0.000019395387,0.0042054784],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987859,0.000033672914,0.000375303,0.00033928486,0.00022877222,0.00023703896],"domain_scores_gemma":[0.9992325,0.00015446925,0.00008477461,0.00031306103,0.00010449326,0.00011071638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034925595,0.00020458247,0.0004208403,0.00020099535,0.00004361554,0.000009160523,0.00006953107,0.00008776408,0.000111992194],"category_scores_gemma":[0.00023153276,0.00016034392,0.000056471014,0.00024508926,0.00018223085,0.000053679676,0.00006538543,0.00029374682,0.00003666896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030875587,0.0019323949,0.90531343,0.00048123358,0.000592072,0.00021307985,0.0045962874,0.0000028580705,0.07842414,0.00057307887,0.0023509266,0.005211762],"study_design_scores_gemma":[0.016179409,0.0010181231,0.37996998,0.0006370074,0.0010818803,0.00011455111,0.0019055172,0.00012622795,0.57816166,0.0007929549,0.01922372,0.00078896503],"about_ca_topic_score_codex":0.00001587221,"about_ca_topic_score_gemma":0.00014211601,"teacher_disagreement_score":0.5253434,"about_ca_system_score_codex":0.00003353509,"about_ca_system_score_gemma":0.00007735384,"threshold_uncertainty_score":0.65386355},"labels":[],"label_agreement":null},{"id":"W2387445105","doi":"","title":"Influence of bcr/abl fusion protein on cell repair function after DNA damage","year":2008,"lang":"en","type":"article","venue":"Di-Si Junyi Daxue xuebao","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services","funders":"","keywords":"Comet assay; DNA damage; Transfection; Cell culture; Molecular biology; breakpoint cluster region; Chemistry; DNA repair; ABL; Cell growth; DNA; Cell biology; Biology; Signal transduction; Biochemistry; Genetics; Gene; Tyrosine kinase","score_opus":0.008319613728488178,"score_gpt":0.2130905436516968,"score_spread":0.2047709299232086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2387445105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889726,0.00013325438,0.000022407554,0.00040956674,0.000090255395,0.0009461272,0.000012089446,0.00017656099,0.0092371525],"genre_scores_gemma":[0.94495887,0.00004353943,0.00078592263,0.00026815356,0.00009077223,0.00016928685,0.00008222788,0.00003851699,0.05356271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819696,0.00006262706,0.0004355336,0.00046169996,0.00050189457,0.00034130414],"domain_scores_gemma":[0.9989015,0.000038910286,0.00014814163,0.00059460016,0.00014327135,0.00017361906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017572063,0.00029112687,0.00039401976,0.00023663144,0.00012832377,0.000008897561,0.0000916742,0.00014741022,0.00023287241],"category_scores_gemma":[0.00006365408,0.00023709412,0.00017198798,0.0003628548,0.00010812051,0.00018849602,0.000069355,0.00021885856,0.0005817473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00865739,0.0069906013,0.5873296,0.001731736,0.0006724258,0.0031090851,0.00845695,0.0003499066,0.34377936,0.0005804664,0.033164475,0.0051779877],"study_design_scores_gemma":[0.005276078,0.0013097278,0.68837494,0.00090706674,0.00025764122,0.0000616618,0.000156704,0.00018623254,0.22940408,0.00008280905,0.07339653,0.00058655685],"about_ca_topic_score_codex":0.00005118116,"about_ca_topic_score_gemma":0.000018021625,"teacher_disagreement_score":0.114375286,"about_ca_system_score_codex":0.00012919612,"about_ca_system_score_gemma":0.00015424195,"threshold_uncertainty_score":0.96684176},"labels":[],"label_agreement":null},{"id":"W2397692736","doi":"10.3851/imp3010","title":"Efficacy and Safety of a Switch to Rilpivirine-Based Regimens in Treatment-Experienced HIV-1-Infected Patients: A Cohort Study","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rilpivirine; Medicine; Human immunodeficiency virus (HIV); Cohort; Internal medicine; Cohort study; Antiretroviral therapy; Viral load; Oncology; Virology","score_opus":0.024745624430365838,"score_gpt":0.3018561189093522,"score_spread":0.2771104944789864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397692736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956043,0.0000565915,0.000016367325,0.0004843037,0.00004245557,0.0031034292,0.000007470746,0.00004763154,0.00063744554],"genre_scores_gemma":[0.9979781,0.000045319153,0.00033597054,0.00008988233,0.000016835542,0.00017405713,0.000059356145,0.000023723263,0.0012767783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986194,0.000102148275,0.00035229215,0.00037544215,0.00029442782,0.0002563098],"domain_scores_gemma":[0.9992993,0.00006683644,0.000079963094,0.0002953752,0.000110656794,0.00014787725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018216294,0.00025351456,0.00055052934,0.00022500572,0.000037503956,0.000010774739,0.000056556728,0.00004957878,0.000019080539],"category_scores_gemma":[0.000046499765,0.0001797715,0.000050677867,0.00046659223,0.000050415056,0.00007050291,0.000021566479,0.00005748886,0.000026282434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040241103,0.005200139,0.9756896,0.0000035285009,0.00018408145,0.00004027319,0.0062924908,0.000001846021,0.00061558286,0.000005168895,0.00013047818,0.007812737],"study_design_scores_gemma":[0.03933084,0.0045531085,0.94829303,0.000060168295,0.00004654374,0.0000010183209,0.0004791149,0.000022922588,0.00554642,0.0000025224597,0.0014916039,0.00017272387],"about_ca_topic_score_codex":0.00011642964,"about_ca_topic_score_gemma":0.000055698314,"teacher_disagreement_score":0.035306733,"about_ca_system_score_codex":0.00016539678,"about_ca_system_score_gemma":0.00014177512,"threshold_uncertainty_score":0.7330869},"labels":[],"label_agreement":null},{"id":"W2398926585","doi":"10.1177/135965350100600108","title":"Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Antiretroviral drug; Drug resistance; Human immunodeficiency virus (HIV); Medicine; Drug-naïve; Internal medicine; Drug; Antiretroviral therapy; HIV drug resistance; Didanosine; Viral load; Efavirenz; Pharmacology; Virology; Biology; Genetics","score_opus":0.011982501845383724,"score_gpt":0.26320116213799166,"score_spread":0.2512186602926079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398926585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906464,0.000272747,0.000005318613,0.0026751517,0.00010924679,0.0009787729,0.000010759469,0.000047179143,0.0052544246],"genre_scores_gemma":[0.9627319,0.0008326002,0.0008290984,0.0003920041,0.00005728498,0.00008097497,0.00009388032,0.000031717,0.03495056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832106,0.000076540826,0.00037187446,0.00042107922,0.00032368978,0.00048577954],"domain_scores_gemma":[0.99952596,0.000030075358,0.000067718414,0.0002395022,0.000053091568,0.000083641804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001877571,0.00025505843,0.00039785993,0.00036212624,0.000050839095,0.000020771553,0.00011635904,0.0000631376,0.00007085739],"category_scores_gemma":[0.000020963203,0.0002120843,0.00008261819,0.0007644518,0.000041070147,0.00015797825,0.000031845422,0.00015835912,0.00036701912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009698813,0.00080077955,0.97882915,0.000013449693,0.000027739978,0.00013337214,0.0027598876,2.2240476e-7,0.00031601137,0.00012127649,0.0049715242,0.011056714],"study_design_scores_gemma":[0.0067054154,0.00018437128,0.9548524,0.00030258455,0.0000073891824,0.0000011007472,0.00032937716,0.000007850063,0.00629017,0.000120554185,0.030898094,0.00030069883],"about_ca_topic_score_codex":0.000053769036,"about_ca_topic_score_gemma":0.00018760879,"teacher_disagreement_score":0.029696139,"about_ca_system_score_codex":0.00015316001,"about_ca_system_score_gemma":0.00006459336,"threshold_uncertainty_score":0.86485463},"labels":[],"label_agreement":null},{"id":"W2399282214","doi":"10.1503/cmaj.151412","title":"Single-tablet antiretroviral treatment (once daily)","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Golder Associates (Canada); University Health Network","funders":"","keywords":"Abacavir; Emtricitabine; Lamivudine; Nucleoside Reverse Transcriptase Inhibitor; Regimen; Medicine; Tenofovir; Reverse-transcriptase inhibitor; Antiretroviral treatment; Human immunodeficiency virus (HIV); Stavudine; Reverse transcriptase; Virology; Antiretroviral therapy; Pharmacology; Internal medicine; Viral load; Virus; Chemistry","score_opus":0.011117487990543625,"score_gpt":0.23250045729884128,"score_spread":0.22138296930829765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399282214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70209956,0.0005633444,0.00023028693,0.2698893,0.0012831171,0.0003203907,0.0000535238,0.000076029064,0.025484432],"genre_scores_gemma":[0.9003763,0.00055460515,0.0005520362,0.004452378,0.001841961,0.000012717886,0.0000209059,0.000031030842,0.09215802],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.997654,0.00008738084,0.00038411157,0.00018864115,0.0010734423,0.00061239937],"domain_scores_gemma":[0.99734575,0.00013658594,0.00015232628,0.000117173375,0.00021284085,0.002035343],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005245841,0.00017028315,0.00030572852,0.000212797,0.0002240407,0.000054491287,0.00009526508,0.00025215012,0.0046667713],"category_scores_gemma":[0.0007582341,0.00010243583,0.00013673195,0.0001481512,0.00003853882,0.00013783875,0.000008597229,0.00022418481,0.0007879137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028956065,0.0001681391,0.45821995,0.000004275343,0.0004192327,0.0034581074,0.00027667618,6.298702e-8,0.0003121251,0.00009835472,0.10903936,0.42797476],"study_design_scores_gemma":[0.004683969,0.00036399375,0.021665098,0.00020576437,0.00009831915,0.00061521115,0.00013132425,0.000011812816,0.0006716828,0.0000551582,0.9713251,0.00017257064],"about_ca_topic_score_codex":0.0005046498,"about_ca_topic_score_gemma":0.0062253606,"teacher_disagreement_score":0.86228573,"about_ca_system_score_codex":0.0051628216,"about_ca_system_score_gemma":0.003439157,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W2400820382","doi":"","title":"High prevalence of genotypic zidovudine resistance among HIV-infected Canadian children.","year":2001,"lang":"en","type":"letter","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Zidovudine; Genotype; Human immunodeficiency virus (HIV); Environmental health; Resistance (ecology); Virology; Drug resistance; Pediatrics; Viral disease; Genetics; Biology","score_opus":0.00895679150738827,"score_gpt":0.1866809355963444,"score_spread":0.17772414408895615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400820382","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14027758,0.003067268,0.000016490856,0.83054394,0.00080183113,0.0073360247,0.0010290429,0.00029115367,0.016636664],"genre_scores_gemma":[0.16394997,0.0010881798,0.0006143257,0.05800132,0.003039711,0.002849972,0.004271573,0.00020220553,0.76598275],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99702156,0.00007562528,0.0005828696,0.00066988025,0.00058037357,0.001069693],"domain_scores_gemma":[0.9982703,0.00006975729,0.00030612331,0.00075206446,0.0001862457,0.00041552153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001887119,0.00051208504,0.0008284943,0.00062378595,0.00009502869,0.000021951517,0.00027623642,0.00063722586,0.00052612065],"category_scores_gemma":[0.00012970612,0.00045512762,0.0001921329,0.00051706156,0.00016431115,0.00007051618,0.000041514068,0.0008968864,0.00009660859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024193421,0.00004195185,0.27570656,0.00044110892,0.00046118983,0.0006662589,0.00003413075,3.3451002e-7,4.751036e-7,0.0000073590127,0.7212203,0.0013960872],"study_design_scores_gemma":[0.0009768636,0.0000076974975,0.6957878,0.00020470806,0.0005206102,0.000026099371,7.822435e-7,2.6923948e-7,0.000079924925,0.00002562105,0.3020861,0.00028356127],"about_ca_topic_score_codex":0.006545337,"about_ca_topic_score_gemma":0.016809393,"teacher_disagreement_score":0.77254266,"about_ca_system_score_codex":0.0007674195,"about_ca_system_score_gemma":0.0004434198,"threshold_uncertainty_score":0.9997901},"labels":[],"label_agreement":null},{"id":"W2400934244","doi":"10.1177/135965350400900215","title":"Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Amprenavir; Univariate analysis; Medicine; Regimen; Lentivirus; Multivariate analysis; Virology; Internal medicine; Protease; Biology; Molecular biology; Gastroenterology; Human immunodeficiency virus (HIV); HIV-1 protease; Viral disease","score_opus":0.04791851658269943,"score_gpt":0.33075501861853995,"score_spread":0.28283650203584054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400934244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95845985,0.00005131414,0.000035006837,0.039949365,0.000017978491,0.00061417976,0.0000047870403,0.00001974304,0.0008477805],"genre_scores_gemma":[0.9973125,0.00015266036,0.00007166921,0.0015338127,0.00003052009,0.000058061745,0.000009566825,0.000010023554,0.00082120823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901474,0.00023872312,0.00018206626,0.00016666758,0.00020234198,0.00019548854],"domain_scores_gemma":[0.9993373,0.00023677619,0.000043062348,0.00032742452,0.000021962025,0.00003344629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004013871,0.0001433798,0.00019260295,0.00010764548,0.00007647647,0.000011248738,0.00014017985,0.000057223617,0.00002822848],"category_scores_gemma":[0.0000625163,0.000059060814,0.0001481566,0.0003888305,0.00007573752,0.000036630674,0.000013750309,0.00016198424,0.00014807242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07087354,0.010254696,0.64637434,0.000011825187,0.00080368633,0.0009881043,0.045912653,0.00021966085,0.15648176,0.0071474398,0.01711805,0.043814242],"study_design_scores_gemma":[0.0028410708,0.0022251606,0.98382574,0.00007847755,0.000011692619,0.000018828112,0.00020017165,0.0000037061382,0.0054974006,0.0005235034,0.0046789744,0.00009524446],"about_ca_topic_score_codex":0.000043986274,"about_ca_topic_score_gemma":0.000011013967,"teacher_disagreement_score":0.33745143,"about_ca_system_score_codex":0.00008374703,"about_ca_system_score_gemma":0.0000865167,"threshold_uncertainty_score":0.240843},"labels":[],"label_agreement":null},{"id":"W2404779005","doi":"10.1007/978-1-59745-170-3_29","title":"Isolation of Drug-Resistant Mutant HIV Variants Using Tissue Culture Drug Selection","year":2009,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Drug; Drug resistance; Selection (genetic algorithm); Mutant; Human immunodeficiency virus (HIV); Isolation (microbiology); Virus; Biology; Computational biology; Virology; Pharmacology; Bioinformatics; Genetics; Gene; Computer science","score_opus":0.016673012328269354,"score_gpt":0.3783515313429898,"score_spread":0.3616785190147205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404779005","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16327594,0.00060034194,0.83368176,0.0008893412,0.00011046638,0.0004164806,0.0000045325964,0.000033649772,0.0009874749],"genre_scores_gemma":[0.16878255,0.000029640014,0.82983965,0.00013509642,0.000030348789,0.0000069242924,0.000044951194,0.0000121463045,0.001118681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983285,0.00061452313,0.00039593386,0.0003187108,0.00009716135,0.0002451701],"domain_scores_gemma":[0.9995007,0.00004773262,0.00013527901,0.00017443151,0.00008510595,0.000056772962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006774534,0.00017911938,0.0004177968,0.0002390102,0.000042665386,0.000004982247,0.0000637489,0.0001511869,0.00004789907],"category_scores_gemma":[0.0001503514,0.0001455413,0.00006706833,0.00045227207,0.000042452917,0.000027628923,0.0000205307,0.00016205342,0.0000041250364],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017164959,0.00015973805,0.002942594,0.00001879547,0.00006337337,0.00005234681,0.0007971052,0.000037607468,0.9873808,0.0010743041,0.00005360438,0.0072480976],"study_design_scores_gemma":[0.0015630068,0.00018793227,0.0029340843,0.00010239762,0.00014553266,0.00006439513,0.00013434491,0.002715258,0.9858259,0.0039542043,0.002180443,0.0001924938],"about_ca_topic_score_codex":0.000029092053,"about_ca_topic_score_gemma":0.000009111522,"teacher_disagreement_score":0.0070556034,"about_ca_system_score_codex":0.00014142336,"about_ca_system_score_gemma":0.00008846968,"threshold_uncertainty_score":0.5935002},"labels":[],"label_agreement":null},{"id":"W2406140628","doi":"","title":"After Toronto, 46th ICAAC offers back to basics.","year":2006,"lang":"en","type":"other","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Antiretroviral therapy; Presentation (obstetrics); Pipeline (software); Variety (cybernetics); Public relations; Medicine; History; Political science; Family medicine; Computer science; Viral load","score_opus":0.0098690550595074,"score_gpt":0.21325520741885087,"score_spread":0.2033861523593435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406140628","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015323926,0.0018012637,0.000026477694,0.0023659684,0.00047277522,0.002441253,0.000056773322,0.00018266484,0.9924996],"genre_scores_gemma":[0.0016686256,0.000093379516,0.0014493538,0.0009115684,0.0007546212,0.0032486862,0.00022176903,0.00040769184,0.9912443],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983434,0.00002132799,0.0002337822,0.00047240252,0.00035617003,0.0005729296],"domain_scores_gemma":[0.99905646,0.000014615745,0.000071923714,0.00044906454,0.00002526084,0.00038264986],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008753205,0.0003873058,0.00053457846,0.00015065708,0.000016392747,0.000028436747,0.00010498469,0.000253201,0.0060900687],"category_scores_gemma":[0.000015981204,0.00030988894,0.0001477302,0.00010809212,0.000032319003,0.000035756577,0.000055720757,0.000109242406,0.0018382343],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007926911,0.00015668877,0.0060335863,0.00008993841,0.0003033974,0.00011139981,0.000058804562,3.31406e-8,2.1851552e-7,0.000018207389,0.95407957,0.03906891],"study_design_scores_gemma":[0.0010474698,0.000013055868,0.08166888,0.00010324811,0.00019068304,0.0000055866535,0.000012077027,1.5545483e-7,0.000028212753,0.0000038766284,0.9166397,0.00028704552],"about_ca_topic_score_codex":0.00039706475,"about_ca_topic_score_gemma":0.0037146255,"teacher_disagreement_score":0.0756353,"about_ca_system_score_codex":0.00047727587,"about_ca_system_score_gemma":0.000070846705,"threshold_uncertainty_score":0.9999353},"labels":[],"label_agreement":null},{"id":"W2406362442","doi":"10.3851/imp2908","title":"Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Nevirapine; Tolerability; Medicine; Internal medicine; Adverse effect; Population; Pharmacology; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy; Environmental health","score_opus":0.0043824124745371,"score_gpt":0.22208401534603697,"score_spread":0.21770160287149987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406362442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984434,0.00019999278,0.000012076315,0.0002731518,0.0000292094,0.00092149695,0.0000069470652,0.00002283611,0.00009088031],"genre_scores_gemma":[0.99901557,0.000045447774,0.00021490155,0.00032969596,0.0000144073465,0.00015149187,0.00005073102,0.000018797726,0.00015897072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985003,0.00031767978,0.00026962772,0.00040407848,0.00023743387,0.00027087014],"domain_scores_gemma":[0.99933773,0.00028188562,0.000063501844,0.00018307981,0.00006257177,0.00007122146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006155334,0.00014001862,0.0004220926,0.00005135835,0.00008207229,0.000052475916,0.000046572884,0.000047514717,0.000032087544],"category_scores_gemma":[0.00015039252,0.00015888746,0.000023187975,0.00028439722,0.00005454889,0.00008840012,0.000010259811,0.00012167089,4.2207776e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058387057,0.0002220012,0.9621829,0.000050998624,0.000021194379,0.00013521298,0.00010202438,0.000003949589,0.0005408295,9.3780636e-7,0.000008736239,0.036147356],"study_design_scores_gemma":[0.0047447057,0.00017839532,0.993443,0.00048446772,0.000007727143,0.000011218625,0.00008279838,0.00042047835,0.00030320036,0.000009740302,0.000127335,0.00018692783],"about_ca_topic_score_codex":0.7839292,"about_ca_topic_score_gemma":0.9308117,"teacher_disagreement_score":0.14688247,"about_ca_system_score_codex":0.0002311788,"about_ca_system_score_gemma":0.0002922048,"threshold_uncertainty_score":0.64792424},"labels":[],"label_agreement":null},{"id":"W2408781497","doi":"","title":"Are resistance puzzlers caught in a data quagmire? XIV International HIV Drug Resistance Workshop. June 7-11, 2005, Quebec, Canada.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Resistance (ecology); Human immunodeficiency virus (HIV); Political science; Library science; Medicine; Family medicine; Biology; Computer science","score_opus":0.02288472843463924,"score_gpt":0.23997218026025618,"score_spread":0.21708745182561695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408781497","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003082251,0.002067334,0.000017624,0.991776,0.00048795613,0.00084736274,0.00014238466,0.00006749552,0.0015115866],"genre_scores_gemma":[0.006961333,0.00019829505,0.0011676551,0.001061015,0.0003265226,0.0006590606,0.0006135914,0.00003812782,0.9889744],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724996,0.000061049395,0.00054206094,0.0006885665,0.0007275476,0.0007308072],"domain_scores_gemma":[0.9983388,0.00012808116,0.00023944923,0.0008736165,0.00008965946,0.00033035318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047303052,0.0002898236,0.0004125705,0.00020714132,0.000083804356,0.000054860793,0.000546814,0.00008081017,0.00019834308],"category_scores_gemma":[0.00036942677,0.00027089365,0.00004606174,0.00039120213,0.00006877931,0.00031805795,0.00015515079,0.00024235477,0.000037700513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002645738,0.00017629204,0.0009916549,0.000037353853,0.00012547185,0.00043299666,0.00021393789,0.000007420946,0.0000012346105,0.00009576832,0.9975318,0.00012150494],"study_design_scores_gemma":[0.0020487392,5.011877e-9,0.009462223,0.00019549632,0.000048628663,0.0000044152894,0.00032760913,0.000040084942,0.00008000245,0.000012833682,0.98751825,0.0002617359],"about_ca_topic_score_codex":0.0011735494,"about_ca_topic_score_gemma":0.99994123,"teacher_disagreement_score":0.9987677,"about_ca_system_score_codex":0.0017555476,"about_ca_system_score_gemma":0.0006701176,"threshold_uncertainty_score":0.9999743},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":true,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2408964196","doi":"10.1021/acsmedchemlett.6b00194","title":"Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs","year":2016,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Potency; Integrase; Pharmacophore; Pharmacology; Pharmacokinetics; Chemistry; Chemical space; Integrase inhibitor; Raltegravir; Human immunodeficiency virus (HIV); Computational biology; Stereochemistry; Virology; Biochemistry; Drug discovery; Biology; In vitro; Antiretroviral therapy; Viral load","score_opus":0.0187867308546198,"score_gpt":0.24792975860624847,"score_spread":0.22914302775162868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408964196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8983844,0.00040952465,0.00051152,0.09975232,0.00006499179,0.0003465638,0.000006613987,0.00007310961,0.0004509788],"genre_scores_gemma":[0.992219,0.000052034306,0.0009838637,0.0031223542,0.00035113166,0.0001269512,0.000025149715,0.000030037545,0.0030895197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988251,0.000009432234,0.00023606254,0.00032400017,0.00028040816,0.00032502232],"domain_scores_gemma":[0.99940413,0.000097939475,0.00006842358,0.0001660304,0.00006304997,0.0002004443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014485074,0.00022310305,0.00027642158,0.000032311335,0.0000821973,0.000009626636,0.000072405375,0.00005566751,0.00009090433],"category_scores_gemma":[0.000100035766,0.00013022395,0.00005924322,0.00006967187,0.00017070146,0.000047293986,0.000020821837,0.00007727433,0.0000099635745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027324737,0.00005068829,0.004086891,0.0004022803,0.00011314626,0.000113145885,0.0001919247,5.996972e-7,0.97434723,0.0000012206535,0.010985346,0.00943428],"study_design_scores_gemma":[0.0060886713,0.000060092963,0.00037853088,0.0007730153,0.00031205278,0.000113356866,0.00010151735,0.00005592989,0.97516227,0.0000070893375,0.01674321,0.00020427721],"about_ca_topic_score_codex":0.000004726246,"about_ca_topic_score_gemma":2.1366505e-7,"teacher_disagreement_score":0.09662997,"about_ca_system_score_codex":0.000093202405,"about_ca_system_score_gemma":0.00009708672,"threshold_uncertainty_score":0.53103787},"labels":[],"label_agreement":null},{"id":"W2409673291","doi":"10.1177/135965350901400408","title":"Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Abbott Laboratories","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Medicine; Tolerability; Regimen; Pharmacokinetics; Gastroenterology; Internal medicine; Area under the curve; Interquartile range; Pharmacology; Viral load; Human immunodeficiency virus (HIV); Adverse effect; Antiretroviral therapy; Immunology","score_opus":0.0372966081615957,"score_gpt":0.30808345389957575,"score_spread":0.27078684573798006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409673291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625397,0.00086237665,0.0000047438884,0.0006986964,0.000080696824,0.0007514984,0.000021049034,0.00004745693,0.0012795114],"genre_scores_gemma":[0.9917006,0.006358009,0.00054836593,0.000047821577,0.00006819276,0.000031991414,0.000094060284,0.000021766527,0.0011292049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878854,0.000074208365,0.00034108947,0.00033139295,0.00020054073,0.00026425198],"domain_scores_gemma":[0.9994835,0.000081551974,0.00008271143,0.00023001363,0.000046507867,0.00007569428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000075585966,0.00026234883,0.00051111844,0.00012047645,0.00005987614,0.000005777208,0.000057588484,0.00008017221,0.00004711788],"category_scores_gemma":[0.000009582619,0.00020096602,0.0000990882,0.00026496203,0.00018114057,0.00006997981,0.000020393052,0.000110615394,0.000020059173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023374709,0.0014605512,0.93336064,0.000010613522,0.0002724715,0.00008683425,0.0014072075,8.8649784e-7,0.004830212,0.000021434706,0.00010934102,0.056102347],"study_design_scores_gemma":[0.021853477,0.0014234215,0.91801494,0.000051953357,0.000059581456,0.000029642842,0.000035479585,0.000046003624,0.05474895,0.000014552407,0.0035131501,0.00020885716],"about_ca_topic_score_codex":0.00016725858,"about_ca_topic_score_gemma":0.000027793296,"teacher_disagreement_score":0.05589349,"about_ca_system_score_codex":0.00012256793,"about_ca_system_score_gemma":0.00011611208,"threshold_uncertainty_score":0.81951565},"labels":[],"label_agreement":null},{"id":"W2409826994","doi":"10.1093/ajhp/58.7.591","title":"HIV pharmacy specialty residency program in Canada","year":2001,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"","keywords":"Pharmacy; Specialty; Pharmacist; Medicine; Human immunodeficiency virus (HIV); Library science; Family medicine; Computer science","score_opus":0.02684858083831775,"score_gpt":0.34511293129917375,"score_spread":0.318264350460856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409826994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86100554,0.0030819906,0.00005939155,0.13085964,0.0007646367,0.001192931,0.000011062007,0.000057136236,0.0029676652],"genre_scores_gemma":[0.9929914,0.00183385,0.002426968,0.0012136594,0.0005541095,0.000036082474,0.00000929841,0.00004184747,0.00089280686],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99595195,0.00040961654,0.0017601339,0.00026796342,0.000868212,0.0007421436],"domain_scores_gemma":[0.99743134,0.000120596815,0.0012491259,0.00021216548,0.00023446803,0.00075227756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009058473,0.0002982286,0.0011784479,0.00039409494,0.00012153495,0.000021016409,0.00021919335,0.000011443026,0.00021719448],"category_scores_gemma":[0.00003836791,0.00024108068,0.00015014438,0.00092616054,0.000069112255,0.00017589015,0.000029340608,0.0004861347,0.000040800962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00056973513,0.00033402536,0.6465512,0.00016604732,0.00016411545,0.0035888604,0.0005148969,0.000008210078,0.000019889987,0.000013695859,0.021034935,0.3270344],"study_design_scores_gemma":[0.014840637,0.00066955615,0.112092786,0.0016245409,0.0001798807,0.0062308954,0.005360485,0.0003744374,0.0004334325,0.0000074636873,0.85775083,0.00043507892],"about_ca_topic_score_codex":0.47269058,"about_ca_topic_score_gemma":0.18125652,"teacher_disagreement_score":0.8367159,"about_ca_system_score_codex":0.004058829,"about_ca_system_score_gemma":0.014238867,"threshold_uncertainty_score":0.99976444},"labels":[],"label_agreement":null},{"id":"W2410435067","doi":"10.1016/s1016-8478(23)17030-0","title":"Analysis of the DNA Substrate Structure and Number of the Processing Sites on the Activities of HIV-1 Integrase In Vitro","year":2001,"lang":"en","type":"article","venue":"Molecules and Cells","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum; Institut National de la Recherche Scientifique","funders":"","keywords":"Integrase; DNA; Nucleotide; Enzyme; In vitro; Biochemistry; Deoxyribozyme; Chemistry; Cleavage (geology); Base pair; Active site; Molecule; Stereochemistry; Biology; Biophysics; Gene","score_opus":0.0071703210488981645,"score_gpt":0.22703972021611976,"score_spread":0.2198693991672216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410435067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99841523,0.00015788415,0.0000036842932,0.0006411931,0.000006124167,0.00012017354,0.00002181075,0.000001448094,0.0006324208],"genre_scores_gemma":[0.9990984,0.00006284711,0.00004950152,0.000053219654,0.000003286556,0.0000021287185,0.000004906024,0.000004235191,0.00072146795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99953806,0.000037162306,0.0001383117,0.000089869834,0.00012349841,0.00007306802],"domain_scores_gemma":[0.9996903,0.00005003886,0.000097154916,0.00012647426,0.000021206564,0.000014819471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005444644,0.00008329276,0.00020034243,0.00004440832,0.00003407672,0.0000066087823,0.00004835659,0.000028451708,0.000034838613],"category_scores_gemma":[0.00000766714,0.00003385654,0.000060323484,0.00031179408,0.00012771666,0.000014958027,0.000024710771,0.000069264235,1.1057091e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022560038,0.00016755791,0.45669717,0.000119659664,0.000553756,0.000007705227,0.00536351,0.00003254859,0.53274703,0.00013816963,0.000061383354,0.0038859043],"study_design_scores_gemma":[0.00033417012,0.000012476941,0.12406932,0.000102380094,0.0004579878,0.0000030689316,0.0016908593,0.00037280115,0.8727915,0.00008994962,0.00003482775,0.000040609135],"about_ca_topic_score_codex":0.000027899074,"about_ca_topic_score_gemma":0.00006461548,"teacher_disagreement_score":0.34004453,"about_ca_system_score_codex":0.00000831074,"about_ca_system_score_gemma":0.000025752546,"threshold_uncertainty_score":0.13806297},"labels":[],"label_agreement":null},{"id":"W2411980887","doi":"10.1021/acs.jmedchem.5b01180","title":"Pronounced Inhibition Shift from HIV Reverse Transcriptase to Herpetic DNA Polymerases by Increasing the Flexibility of α-Carboxy Nucleoside Phosphonates","year":2015,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; KU Leuven; Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Science Foundation Ireland","keywords":"Chemistry; Reverse transcriptase; DNA polymerase; Nucleoside; DNA; Flexibility (engineering); Nucleotidyltransferase; Human immunodeficiency virus (HIV); Polymerase; Virology; RNA; Biochemistry; Biology; Gene","score_opus":0.017440914586444922,"score_gpt":0.25592145227961927,"score_spread":0.23848053769317434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411980887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833741,0.0020313128,0.0000604099,0.013575582,0.00010678498,0.00020173255,0.00005016766,0.000013504567,0.0005863713],"genre_scores_gemma":[0.99771583,0.000038639002,0.0009511741,0.00047034613,0.00026063147,0.0000058483724,0.000058580143,0.000018009003,0.00048093116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979344,0.00007182071,0.0007357273,0.0001968396,0.0008481005,0.00021311773],"domain_scores_gemma":[0.9985081,0.00016509244,0.00036293035,0.00023955123,0.0002457645,0.00047856246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008691325,0.00021397801,0.0005214555,0.0000428324,0.00005001464,0.000012732436,0.00013116795,0.0000934774,0.00022773034],"category_scores_gemma":[0.0006235451,0.00013552811,0.00014962314,0.00018242285,0.0001545113,0.00009764841,0.000024194485,0.00033371395,0.00000690103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00532064,0.0009857595,0.028601348,0.0002468322,0.00047121517,0.00038045537,0.0069909417,0.0000059029753,0.92281973,0.0000021535918,0.032144953,0.002030066],"study_design_scores_gemma":[0.005274089,0.00027374306,0.0038048138,0.0015430595,0.000636827,0.00030859152,0.0045669316,0.000017921746,0.97961396,0.0001581819,0.0036407518,0.00016110051],"about_ca_topic_score_codex":0.00017154182,"about_ca_topic_score_gemma":0.0000039643633,"teacher_disagreement_score":0.056794256,"about_ca_system_score_codex":0.00029135114,"about_ca_system_score_gemma":0.0005503902,"threshold_uncertainty_score":0.55266756},"labels":[],"label_agreement":null},{"id":"W2412571829","doi":"10.1177/135965350400900407","title":"Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Amprenavir; Lopinavir; Ritonavir; Lopinavir/ritonavir; Medicine; Virology; Reverse-transcriptase inhibitor; Viral load; Internal medicine; Gastroenterology; Biology; Virus; Antiretroviral therapy; Protease; HIV-1 protease; Enzyme","score_opus":0.01476171776978681,"score_gpt":0.25943529803548254,"score_spread":0.24467358026569574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412571829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543625,0.00049889006,0.00001821086,0.002214723,0.000042427615,0.0012200604,0.000013625165,0.000092912094,0.0004629056],"genre_scores_gemma":[0.99397117,0.0032317294,0.0010681025,0.0006378827,0.000051409894,0.00010004506,0.00015021939,0.000048367856,0.00074109435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804276,0.00011528541,0.00038927607,0.00057683076,0.0003346114,0.0005412212],"domain_scores_gemma":[0.99940956,0.00006853237,0.0000912677,0.00027363756,0.00004788094,0.00010910243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014715592,0.00044313943,0.00061965914,0.0002574588,0.00007876626,0.000038324673,0.000115509276,0.00022045289,0.000114040195],"category_scores_gemma":[0.00001357183,0.00026504122,0.00006928642,0.00061589293,0.00017452831,0.00023765041,0.00003248768,0.000388827,0.0000583067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004609797,0.0023412216,0.96725166,0.000013556615,0.00010612819,0.000577042,0.0012533673,0.0000023993225,0.002334945,0.00009344692,0.00013824848,0.021278184],"study_design_scores_gemma":[0.037387293,0.0023644827,0.94878596,0.00029757406,0.000013794348,0.000025272326,0.000104801205,0.00000772242,0.004791543,0.0002437503,0.005554404,0.00042339033],"about_ca_topic_score_codex":0.00015125384,"about_ca_topic_score_gemma":0.0005362298,"teacher_disagreement_score":0.032777496,"about_ca_system_score_codex":0.00015034659,"about_ca_system_score_gemma":0.00014364462,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W2414552970","doi":"","title":"Challenges of the unmet needs in the treatment-experienced patient.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Intensive care medicine; Dosing; Antiretroviral therapy; Drug resistance; Human immunodeficiency virus (HIV); ANTIRETROVIRAL AGENTS; Drug; HIV drug resistance; Drug development; Pharmacology; Viral load; Immunology; Adverse effect","score_opus":0.035614010342446704,"score_gpt":0.24021641673893315,"score_spread":0.20460240639648644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414552970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9420656,0.001437657,4.6376024e-7,0.005456026,0.00010874585,0.0012168873,0.0000014508091,0.000011096224,0.04970208],"genre_scores_gemma":[0.99445736,0.0004627153,0.000044937693,0.00013752277,0.000012784944,0.0017890637,0.0000020447408,0.0000074376917,0.0030861131],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916065,0.00010022244,0.00017270088,0.000119129574,0.00021582333,0.00023146925],"domain_scores_gemma":[0.99951774,0.000066734014,0.00005131767,0.00030215725,0.00001816424,0.00004391425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015646665,0.00011130864,0.00016918521,0.00007849993,0.000040888102,0.0000052790724,0.000082712395,0.00003577781,0.00002114737],"category_scores_gemma":[0.00006559913,0.000049280792,0.00007644167,0.00032228918,0.000057023535,0.000028165969,0.0000087177505,0.000049411607,0.000005237473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016094962,0.0040012286,0.22182226,0.00004603532,0.00037311483,0.000058943388,0.15212758,0.0000030323936,0.00006374075,0.015449035,0.0012314323,0.60466266],"study_design_scores_gemma":[0.0041189776,0.00018459014,0.7706181,0.000032316493,0.00013522267,0.00003696665,0.025645573,0.0000022299282,0.023632549,0.00030179505,0.17512219,0.00016948527],"about_ca_topic_score_codex":0.000008023393,"about_ca_topic_score_gemma":0.000044806075,"teacher_disagreement_score":0.60449314,"about_ca_system_score_codex":0.00008912312,"about_ca_system_score_gemma":0.000036503134,"threshold_uncertainty_score":0.20096125},"labels":[],"label_agreement":null},{"id":"W2415009490","doi":"10.1177/135965350501000801","title":"TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals <i>in Vitro</i>","year":2005,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pharmacology; Drug; Protease inhibitor (pharmacology); CCR5 receptor antagonist; In vitro; Medicine; Human immunodeficiency virus (HIV); Chemistry; Internal medicine; Antiretroviral therapy; Virology; Viral load; Inflammation; Chemokine receptor; Biochemistry","score_opus":0.030810820858888907,"score_gpt":0.2673798028364486,"score_spread":0.23656898197755966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415009490","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10591438,0.0020907284,0.000146117,0.86593413,0.00071174384,0.0026475703,0.00023089713,0.00038411687,0.021940317],"genre_scores_gemma":[0.15070838,0.0014344377,0.007045964,0.43093717,0.005887589,0.0003775571,0.0013282673,0.0005217868,0.40175885],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679846,0.00010567541,0.0006401012,0.0008946872,0.0006758728,0.0008852182],"domain_scores_gemma":[0.99870485,0.00013278701,0.0003178984,0.0006528814,0.00010336058,0.00008820571],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019868721,0.00088091666,0.0012418799,0.00061603385,0.00018563902,0.00016093941,0.00024201308,0.0003610063,0.00031876558],"category_scores_gemma":[0.000009238672,0.00063478365,0.00033631478,0.00055441196,0.00021212905,0.0003767439,0.000038858107,0.0018090656,0.00044578803],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001407986,0.0014756446,0.010007663,0.00009317315,0.0010514212,0.0010897461,0.001172533,7.163567e-7,0.03397018,0.000009365153,0.93452245,0.015199119],"study_design_scores_gemma":[0.0067760814,0.00018588097,0.00034475786,0.0006726192,0.00011371232,0.000095842785,0.000069773494,0.000013339101,0.042435642,0.0000099598965,0.948589,0.0006933679],"about_ca_topic_score_codex":0.00029798286,"about_ca_topic_score_gemma":0.00011005674,"teacher_disagreement_score":0.43499696,"about_ca_system_score_codex":0.0003186268,"about_ca_system_score_gemma":0.00037011542,"threshold_uncertainty_score":0.99961036},"labels":[],"label_agreement":null},{"id":"W2415049193","doi":"10.1177/135965350400900414","title":"Predictive Value of HIV-1 Protease Genotype and Virtual Phenotype on the Virological Response to Lopinavir/Ritonavir-Containing Salvage Regimens","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University Health Network; McGill University; University of Toronto; Montreal General Hospital","funders":"","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Internal medicine; Virology; Viral load; Regimen; Odds ratio; Population; Univariate analysis; Genotype; Salvage therapy; Biology; Medicine; Oncology; Immunology; Multivariate analysis; Human immunodeficiency virus (HIV); Genetics; Antiretroviral therapy; Chemotherapy","score_opus":0.021165686277663992,"score_gpt":0.2760755676495867,"score_spread":0.2549098813719227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415049193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850572,0.00019594344,0.0002592134,0.0122366985,0.00005073451,0.0013878137,0.00002155543,0.00006004455,0.0007308003],"genre_scores_gemma":[0.9960331,0.00011263099,0.00081635185,0.0015126353,0.00008364849,0.00008874658,0.000015108229,0.000029274395,0.0013085353],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985087,0.00022917932,0.0002583066,0.00037843356,0.0003258966,0.00029951724],"domain_scores_gemma":[0.99917585,0.00025103719,0.00008698899,0.0003167394,0.000058593407,0.00011082367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052298285,0.0002571314,0.00036269796,0.00010534463,0.00015130555,0.000016652686,0.00011300435,0.00010439064,0.000031206466],"category_scores_gemma":[0.00013436911,0.00015371591,0.00008552917,0.0002248174,0.00018305871,0.00006688826,0.000050738152,0.00022934364,0.00009141113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2424036,0.0040920135,0.08000262,0.000045567613,0.0017338942,0.0011663518,0.03350299,0.00016939845,0.54591835,0.045108724,0.0015359956,0.044320483],"study_design_scores_gemma":[0.018134004,0.029717185,0.73755103,0.0007196058,0.00018069767,0.00005115192,0.0017772467,0.00008492078,0.19648692,0.0027370816,0.0117821,0.00077805464],"about_ca_topic_score_codex":0.00001807171,"about_ca_topic_score_gemma":0.0000013451967,"teacher_disagreement_score":0.6575484,"about_ca_system_score_codex":0.00009371269,"about_ca_system_score_gemma":0.00015300565,"threshold_uncertainty_score":0.6268353},"labels":[],"label_agreement":null},{"id":"W2416661311","doi":"10.1177/135965350501000119","title":"Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Tolerability; Clinical trial; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Drug development; Clinical study design; Medicine; Pharmacodynamics; Pharmacology; Reverse-transcriptase inhibitor; Intensive care medicine; Biology; Drug; Human immunodeficiency virus (HIV); Bioinformatics; Pharmacokinetics; Virology; Antiretroviral therapy; Viral load; Adverse effect; Genetics; RNA","score_opus":0.12900661530849614,"score_gpt":0.3734704503012295,"score_spread":0.24446383499273336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416661311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416032,0.004147348,0.006196114,0.043276303,0.0005670795,0.003380524,0.000014953478,0.000099524645,0.0007149688],"genre_scores_gemma":[0.9464714,0.0088125905,0.034548,0.0005993014,0.0008716859,0.00019870044,0.000052986044,0.00004612374,0.008399236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998909,0.00002745253,0.00047759057,0.00023441242,0.00014433985,0.00020719423],"domain_scores_gemma":[0.9993978,0.0001820896,0.00011109501,0.0001763642,0.00006819396,0.000064457294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050742354,0.00016714302,0.00031373487,0.00006118303,0.000120288925,0.000007496494,0.00005938091,0.000091344584,0.000022140694],"category_scores_gemma":[0.00003238699,0.0001051139,0.0002666517,0.00007329424,0.00005002764,0.00008945834,0.000007021413,0.000079999045,0.000019524225],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011471285,0.00055496814,0.010095448,0.00003994677,0.00043611965,9.034492e-7,0.0032055448,6.7785226e-7,0.001505574,0.00021284002,0.02604888,0.95675194],"study_design_scores_gemma":[0.0073872115,0.00035814606,0.028248895,0.0000877754,0.000096768556,0.000002197534,0.00017730726,0.000050449784,0.057992157,0.00008818261,0.90537256,0.00013833951],"about_ca_topic_score_codex":0.0000056401054,"about_ca_topic_score_gemma":0.00005957838,"teacher_disagreement_score":0.9566136,"about_ca_system_score_codex":0.000038845938,"about_ca_system_score_gemma":0.00020800183,"threshold_uncertainty_score":0.42864203},"labels":[],"label_agreement":null},{"id":"W2417038233","doi":"10.1097/qai.0000000000000868","title":"Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis","year":2015,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health","keywords":"Tenofovir; Emtricitabine; Pre-exposure prophylaxis; Renal function; Medicine; Human immunodeficiency virus (HIV); Urology; Virology; Internal medicine; Antiretroviral therapy; Viral load; Men who have sex with men","score_opus":0.01194101974134517,"score_gpt":0.24411819060982134,"score_spread":0.23217717086847617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417038233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99342483,0.004860962,0.00023195286,0.00043842406,0.0001929852,0.00055470003,0.000010625666,0.00003391835,0.00025162645],"genre_scores_gemma":[0.99540997,0.00024145172,0.0013328814,0.000011455529,0.00003611405,0.000018523408,0.000023406199,0.00003398926,0.0028922365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964843,0.00024055321,0.0015870424,0.00035853803,0.00082327245,0.00050633075],"domain_scores_gemma":[0.9978324,0.00014260058,0.0008478371,0.000384313,0.000531501,0.00026135586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026383966,0.00034132053,0.0011562409,0.0009092068,0.00007935722,0.000038545557,0.00020490438,0.00015557636,0.00003761269],"category_scores_gemma":[0.0009954094,0.0002502457,0.00018950173,0.001421637,0.00021241308,0.0005711051,0.00016527087,0.00021487354,0.000010022797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047674435,0.0019604138,0.9352026,0.000491692,0.00063871953,0.00058659416,0.015711192,0.000099923906,0.029249256,0.000030585703,0.00032010945,0.010941453],"study_design_scores_gemma":[0.011876334,0.0062662764,0.97036755,0.00078859064,0.00035429254,0.00077944587,0.0051042377,0.00023743202,0.003124337,0.0005169232,0.00021349831,0.00037105204],"about_ca_topic_score_codex":0.000032629538,"about_ca_topic_score_gemma":0.000003731703,"teacher_disagreement_score":0.035164963,"about_ca_system_score_codex":0.00051940937,"about_ca_system_score_gemma":0.0004883163,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W2417794644","doi":"10.1155/2001/645147","title":"Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz","year":2001,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Alberta Hip and Knee Clinic; University of Calgary","funders":"Pfizer Canada; Department of Medicine, University of Toronto; McGill University; F. Hoffmann-La Roche; Agouron Pharmaceuticals; DuPont; Abbott Laboratories; GlaxoSmithKline; Merck; University of Toronto; Pfizer; University of Alberta; Bristol-Myers Squibb","keywords":"Efavirenz; Medicine; Discontinuation; Adverse effect; Intensive care medicine; Rash; Antiretroviral therapy; Human immunodeficiency virus (HIV); Psychiatry; Viral load; Family medicine; Internal medicine","score_opus":0.00961502112865052,"score_gpt":0.24614777072937052,"score_spread":0.23653274960072002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417794644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90573883,0.0010271904,0.00001419927,0.08990075,0.00044972214,0.000279122,0.00005701101,0.0000066341563,0.0025265228],"genre_scores_gemma":[0.99320585,0.000784697,0.000035815705,0.004383729,0.000054403285,0.000010937484,0.00004018485,0.000011086955,0.0014732778],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990835,0.00006143559,0.00034767663,0.00012698732,0.00007138121,0.00030902028],"domain_scores_gemma":[0.9978332,0.000079532445,0.000085277636,0.0001228544,0.00009504368,0.0017841205],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001633795,0.00012542571,0.00026119838,0.0003462978,0.0001592061,0.000009926698,0.00009773387,0.00009903861,0.0016129325],"category_scores_gemma":[0.00009799579,0.00008034844,0.000090321424,0.00021442419,0.00012590279,0.000019067562,0.00001193037,0.00017477963,0.000026631413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023075317,0.00058240234,0.5191121,0.00009021642,0.0041345027,0.006229041,0.0027651812,0.000009038591,0.00029652333,0.007819069,0.23534566,0.22338551],"study_design_scores_gemma":[0.0035722153,0.0010912243,0.08725082,0.0013864809,0.0005004975,0.004653172,0.0011388821,0.0000073227297,0.00007269349,0.00038949327,0.89965844,0.00027873975],"about_ca_topic_score_codex":0.019449532,"about_ca_topic_score_gemma":0.09452462,"teacher_disagreement_score":0.6643128,"about_ca_system_score_codex":0.0003684663,"about_ca_system_score_gemma":0.0012844594,"threshold_uncertainty_score":0.9992997},"labels":[],"label_agreement":null},{"id":"W2418527354","doi":"10.1177/135965350100600105","title":"Predictors of Virological Response in HIV-Infected Patients to Salvage Antiretroviral Therapy that Includes Nelfinavir","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of Toronto; University Health Network","funders":"","keywords":"Nelfinavir; Salvage therapy; Medicine; Reverse transcriptase; Internal medicine; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Viral load; Virology; Indinavir; Zidovudine; Sida; Population; Lentivirus; Cohort; Human immunodeficiency virus (HIV); Gastroenterology; Biology; Viral disease; Antiretroviral therapy; Chemotherapy; RNA","score_opus":0.025609689694692822,"score_gpt":0.28316745155591944,"score_spread":0.2575577618612266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418527354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638504,0.00018885841,0.000027274722,0.0014215924,0.00012196355,0.0010189692,0.000018001643,0.00010289424,0.00071538554],"genre_scores_gemma":[0.99597585,0.0012564752,0.00028687515,0.00072445004,0.00005464763,0.00004638434,0.00007849164,0.000039329087,0.00153752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978646,0.00030507616,0.0004307188,0.0004249835,0.00046363266,0.0005109571],"domain_scores_gemma":[0.99913895,0.00016959068,0.000117062555,0.00034032733,0.00007206805,0.00016200414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044878357,0.00034011248,0.0006016015,0.00040938167,0.00007149591,0.00001739886,0.00016969464,0.0001700015,0.0001166111],"category_scores_gemma":[0.000111740774,0.00024071145,0.00016213059,0.0007095106,0.0001150148,0.00016016954,0.00005913458,0.0002002511,0.00007712145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019199602,0.0016963445,0.9419588,0.000004194957,0.000115330084,0.00013825983,0.0013138268,0.0000010254337,0.022774307,0.000010769771,0.00066765654,0.012119913],"study_design_scores_gemma":[0.008443745,0.0040445602,0.9476951,0.00007296753,0.000011536115,0.000004509722,0.00005471119,0.0000114701525,0.030943656,0.000026340502,0.008467173,0.00022427567],"about_ca_topic_score_codex":0.00003025903,"about_ca_topic_score_gemma":0.000006416192,"teacher_disagreement_score":0.011895636,"about_ca_system_score_codex":0.00011015873,"about_ca_system_score_gemma":0.000107176646,"threshold_uncertainty_score":0.9815928},"labels":[],"label_agreement":null},{"id":"W2418594260","doi":"10.20411/pai.v1i1.104","title":"Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review","year":2016,"lang":"en","type":"review","venue":"Pathogens and Immunity","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Integrase; Human immunodeficiency virus (HIV); Integrase inhibitor; Virology; Biology; Computational biology; Antiretroviral therapy; Viral load","score_opus":0.0764939837752569,"score_gpt":0.3775715423004838,"score_spread":0.3010775585252269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418594260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004374869,0.9966584,0.0000062811996,0.0001621895,0.000057345627,0.002172464,0.00033063494,0.000023041472,0.00015216286],"genre_scores_gemma":[0.000013138978,0.9959036,0.0011654315,0.00003846052,0.00006127791,0.000328008,0.00034206267,0.00004028126,0.0021077201],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984685,0.00014973943,0.00075286475,0.00030024516,0.00011658284,0.0002120662],"domain_scores_gemma":[0.99851257,0.00043105838,0.00040237163,0.0003334211,0.00022865778,0.0000919131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061678316,0.0004345279,0.002632591,0.0001464639,0.0001638418,0.000010475221,0.00007689356,0.00012133975,0.00002706919],"category_scores_gemma":[0.0003842298,0.00024132551,0.00033066317,0.000113879716,0.00018611341,0.000042344065,0.00016057765,0.00016402257,0.000010782367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024527366,0.00016502418,0.000043964774,0.2036783,0.0013810198,0.000011384915,0.00038252267,5.876407e-11,0.000054768163,0.00006700205,0.0028395483,0.791352],"study_design_scores_gemma":[0.0009677386,0.00015146715,0.00001261492,0.18671311,0.004588881,0.000067125584,0.00013846702,1.0086802e-7,0.000032430755,0.00003757871,0.8070498,0.00024066868],"about_ca_topic_score_codex":0.0000036709814,"about_ca_topic_score_gemma":0.0000034174518,"teacher_disagreement_score":0.80421025,"about_ca_system_score_codex":0.00007483414,"about_ca_system_score_gemma":0.00013341215,"threshold_uncertainty_score":0.9840969},"labels":[],"label_agreement":null},{"id":"W2423411180","doi":"10.1177/135965350400900308","title":"The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Nelfinavir; Amprenavir; Saquinavir; Lopinavir; Indinavir; Ritonavir; Protease; Biology; Drug resistance; Virology; Protease inhibitor (pharmacology); Resistance mutation; Atazanavir; Lentivirus; Darunavir; Genetics; HIV-1 protease; Virus; Viral load; Gene; Viral disease; Reverse transcriptase; Antiretroviral therapy; Enzyme","score_opus":0.011686820211874805,"score_gpt":0.25909179243735847,"score_spread":0.24740497222548366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2423411180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715006,0.00020560996,0.0000012491045,0.0007216158,0.00002481236,0.0015325391,0.000010047385,0.000017958522,0.0003361193],"genre_scores_gemma":[0.99643016,0.001557271,0.00020586903,0.00004102969,0.000024102957,0.0001519189,0.000016850234,0.000015970161,0.0015568389],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990019,0.0000625327,0.00030525163,0.0001990243,0.00024770852,0.00018359043],"domain_scores_gemma":[0.9994626,0.000052091058,0.00016613811,0.00017316797,0.00011871433,0.000027294502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000956189,0.00017471626,0.00026018292,0.00010075104,0.000072452036,0.0000064758115,0.000060646762,0.000052543946,0.0000046235496],"category_scores_gemma":[0.000021301255,0.00009886174,0.00007675182,0.000304748,0.000100346486,0.00008378307,0.0000051054053,0.000072078554,0.000008950216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006314498,0.0031045033,0.934372,0.000022650607,0.00019148478,0.000009906734,0.0023966385,0.000021148287,0.02752015,0.0003979062,0.00009798012,0.025551135],"study_design_scores_gemma":[0.00888419,0.0018952846,0.4709013,0.00026261722,0.000007375754,3.3019384e-7,0.000060532144,0.000001244845,0.5164027,0.00024361008,0.0012484734,0.00009230097],"about_ca_topic_score_codex":0.000042201784,"about_ca_topic_score_gemma":0.000035260815,"teacher_disagreement_score":0.48888257,"about_ca_system_score_codex":0.00014738747,"about_ca_system_score_gemma":0.00015303734,"threshold_uncertainty_score":0.40314648},"labels":[],"label_agreement":null},{"id":"W2461594029","doi":"10.3851/imp3059","title":"A Case of a Probable drug Interaction between Lurasidone and Atazanavir-Based Antiretroviral Therapy","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Atazanavir; Lurasidone; CYP3A4; Pharmacology; Ritonavir; Drug; Paliperidone; Protease inhibitor (pharmacology); Drug interaction; Therapeutic drug monitoring; Antipsychotic drug; Medicine; Antipsychotic; Cytochrome P450; Antiretroviral therapy; Internal medicine; Metabolism; Human immunodeficiency virus (HIV); Virology; Viral load","score_opus":0.062016771864384465,"score_gpt":0.3203811694096541,"score_spread":0.25836439754526963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461594029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657065,0.00074407354,0.00006291509,0.0010436713,0.000074665535,0.00063329603,0.000011490012,0.00006419853,0.0007950705],"genre_scores_gemma":[0.9962901,0.00029662868,0.0011851683,0.00012624382,0.00009326985,0.00002545616,0.00007066182,0.000029891246,0.0018826014],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888015,0.00008800222,0.00029527035,0.0002812784,0.00021822804,0.00023707033],"domain_scores_gemma":[0.9993446,0.000061459636,0.00013417641,0.00023098094,0.00010684662,0.0001219388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002809822,0.00022747106,0.0004416862,0.0001638333,0.00006460023,0.000024589015,0.000052682015,0.00006809094,0.00001735049],"category_scores_gemma":[0.000014098247,0.00016676707,0.000092444054,0.00025009422,0.00010433443,0.0002116628,0.000016885491,0.00013501482,0.000018993229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015426282,0.0005950161,0.862732,0.000034741133,0.0003431038,0.0007703435,0.0023451732,6.560053e-7,0.004302899,0.000045513098,0.0016423769,0.12564553],"study_design_scores_gemma":[0.087009646,0.011553828,0.11211132,0.00090781495,0.00046579778,0.0017644905,0.004946313,0.00087233435,0.73284125,0.0008496458,0.044791818,0.001885741],"about_ca_topic_score_codex":0.0001947547,"about_ca_topic_score_gemma":0.000025947702,"teacher_disagreement_score":0.7506207,"about_ca_system_score_codex":0.000052563417,"about_ca_system_score_gemma":0.00014051847,"threshold_uncertainty_score":0.6800564},"labels":[],"label_agreement":null},{"id":"W2463348369","doi":"10.1016/j.virusres.2016.07.006","title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","year":2016,"lang":"en","type":"review","venue":"Virus Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research; Fonds de recherche du Québec; Genome Canada","keywords":"Dolutegravir; Biology; Drug resistance; Human immunodeficiency virus (HIV); Drug; Virology; Computational biology; Pharmacology; Genetics; Antiretroviral therapy; Viral load","score_opus":0.08690769165193687,"score_gpt":0.45414295016934075,"score_spread":0.3672352585174039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463348369","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009163928,0.9783841,0.000009886598,0.0054000258,0.00020952341,0.005868327,0.000128452,0.000028907922,0.0090544345],"genre_scores_gemma":[0.000047156926,0.6997347,0.0019780262,0.000051395804,0.00008142312,0.0007454829,0.000034897555,0.00006226253,0.29726467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99431753,0.00081597315,0.0015910199,0.00094866555,0.0014858202,0.0008409858],"domain_scores_gemma":[0.99676466,0.00086455105,0.00014654071,0.00150993,0.00023770428,0.00047662656],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038269062,0.00041017326,0.0017180191,0.0012038874,0.00012262845,0.00003025505,0.00081578584,0.00027339687,0.00048409458],"category_scores_gemma":[0.00031216262,0.00022067201,0.00037934165,0.0020936045,0.00013186687,0.000023932182,0.0006409908,0.0008978994,0.0059042363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023560209,0.00024469808,0.00030410817,0.0032666894,0.00055669114,0.00043911167,0.00025149892,3.9288938e-7,0.0000010190339,0.001120722,0.06898404,0.9245954],"study_design_scores_gemma":[0.0008701045,0.00007419572,0.0015345314,0.022277972,0.00019084585,0.00000394868,0.000034951954,2.3233355e-7,0.0000067854958,0.00022707121,0.974562,0.00021734252],"about_ca_topic_score_codex":0.00006910277,"about_ca_topic_score_gemma":0.0006525735,"teacher_disagreement_score":0.9243781,"about_ca_system_score_codex":0.00061915634,"about_ca_system_score_gemma":0.0005203437,"threshold_uncertainty_score":0.99486977},"labels":[],"label_agreement":null},{"id":"W2463778710","doi":"10.1093/jac/dkw217","title":"An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype","year":2016,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Genotype; Genotyping; Receiver operating characteristic; Statistics; Human immunodeficiency virus (HIV); Set (abstract data type); Medicine; Biology; Computer science; Immunology; Mathematics; Genetics","score_opus":0.029340148136490236,"score_gpt":0.296032181093388,"score_spread":0.2666920329568978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463778710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9270504,0.000065618406,0.048219472,0.023704674,0.000043046537,0.00085154094,0.000022463291,0.000010371678,0.000032389824],"genre_scores_gemma":[0.9640946,0.00004077965,0.034565903,0.0007195115,0.00007773548,0.000007864649,0.000008091269,0.000017936978,0.00046762777],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859256,0.00007319273,0.000455631,0.00018995753,0.0005215104,0.00016714382],"domain_scores_gemma":[0.9990384,0.000040320432,0.00022497009,0.00015942322,0.00032404953,0.0002128118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005154432,0.00021009213,0.00042157967,0.00007575969,0.00009749577,0.00003312671,0.00010147087,0.000041740514,0.000019636751],"category_scores_gemma":[0.0000060292946,0.00007594077,0.000045868688,0.00014023446,0.000059928127,0.00010535232,0.000017376771,0.000042483964,0.000006502393],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029955965,0.0020774542,0.3595631,0.00017008091,0.006886442,0.000091807204,0.040188167,0.018220216,0.0047527775,0.00030994177,0.02902791,0.5087561],"study_design_scores_gemma":[0.20831999,0.01476574,0.5709338,0.00773289,0.007227014,0.009640164,0.008286657,0.04883127,0.05552025,0.0004295338,0.06583482,0.00247784],"about_ca_topic_score_codex":0.000016458383,"about_ca_topic_score_gemma":0.000115391216,"teacher_disagreement_score":0.5062783,"about_ca_system_score_codex":0.0004380207,"about_ca_system_score_gemma":0.0010410707,"threshold_uncertainty_score":0.30967748},"labels":[],"label_agreement":null},{"id":"W2464927114","doi":"10.1016/j.meegid.2016.06.047","title":"Differences among HIV-1 subtypes in drug resistance against integrase inhibitors","year":2016,"lang":"en","type":"review","venue":"Infection Genetics and Evolution","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Elvitegravir; Raltegravir; Integrase; Dolutegravir; Integrase inhibitor; Drug resistance; Biology; Human immunodeficiency virus (HIV); Virology; Genetics; Medicine; Pharmacology; Antiretroviral therapy; Viral load","score_opus":0.014966157755268224,"score_gpt":0.26686800250007503,"score_spread":0.2519018447448068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464927114","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024687054,0.9725354,0.00010280641,0.00010056159,0.00035792432,0.00063412474,0.000015359512,0.000048952694,0.0015178208],"genre_scores_gemma":[0.02426978,0.96397763,0.000089661895,0.000005066035,0.00017286483,0.0000745342,0.000100986974,0.000027281803,0.011282173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986113,0.00009866232,0.0004968843,0.00038804283,0.00017943006,0.00022573721],"domain_scores_gemma":[0.9993785,0.00006200501,0.00020623922,0.00017894858,0.00006291249,0.000111417765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017103604,0.00032704146,0.0007285726,0.0004446542,0.00008769904,0.00002895801,0.000036219077,0.00023052761,0.00002087901],"category_scores_gemma":[0.000041790227,0.0002191742,0.00014962125,0.0002449704,0.00010064592,0.000052287254,0.00003691418,0.00021613047,0.00006930803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022649241,0.00018724203,0.37345672,0.004823316,0.00024050937,0.000030304482,0.00022849967,3.0659953e-7,0.0000021028009,0.00012244353,0.004605061,0.61628085],"study_design_scores_gemma":[0.0005882492,0.00002632027,0.03953818,0.02199057,0.00036900816,0.000010619878,0.000015594023,0.000009543161,0.000008260914,0.00010940705,0.93699926,0.0003349763],"about_ca_topic_score_codex":0.00003900366,"about_ca_topic_score_gemma":0.0009904894,"teacher_disagreement_score":0.9323942,"about_ca_system_score_codex":0.00045904052,"about_ca_system_score_gemma":0.00018836682,"threshold_uncertainty_score":0.8937664},"labels":[],"label_agreement":null},{"id":"W2466799643","doi":"10.1021/acs.oprd.6b00163","title":"A Robust Kilo-Scale Synthesis of Doravirine","year":2016,"lang":"en","type":"article","venue":"Organic Process Research & Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Cyanation; Nitrile; Yield (engineering); Reverse-transcriptase inhibitor; Chemistry; Combinatorial chemistry; Human immunodeficiency virus (HIV); Stereochemistry; Reverse transcriptase; Virology; Organic chemistry; Medicine; Physics; Biochemistry; RNA","score_opus":0.05038471161418943,"score_gpt":0.3315111484182423,"score_spread":0.28112643680405286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466799643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633852,0.0003754617,0.0013906022,0.015631411,0.00008850683,0.0014640836,0.000016997812,0.00019263403,0.017455086],"genre_scores_gemma":[0.95868224,0.00039065626,0.008588516,0.00003282765,0.000057453904,0.00033460723,0.000013692071,0.00006213789,0.031837877],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963113,0.00009408098,0.00059956464,0.00058264885,0.001600726,0.00081164815],"domain_scores_gemma":[0.9978856,0.0003083028,0.000102988146,0.00045258718,0.00085363997,0.00039690637],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012675859,0.00027254032,0.0005221233,0.0005076781,0.00020658637,0.000022943086,0.00034167932,0.00012276125,0.0028245829],"category_scores_gemma":[0.0007346417,0.00016664507,0.00006569609,0.0010387051,0.00023556403,0.00014412045,0.00023579231,0.00021714445,0.0011402159],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015822756,0.004309443,0.19315237,0.0023965163,0.0016192052,0.00046391095,0.008506352,9.0652264e-7,0.33413517,0.00035163198,0.020542683,0.43293953],"study_design_scores_gemma":[0.001775657,0.0001078777,0.027786063,0.0011616786,0.00004462263,0.000049986415,0.00044704007,0.0000028936997,0.95282286,0.00025924417,0.015265353,0.00027673593],"about_ca_topic_score_codex":0.0000065060076,"about_ca_topic_score_gemma":0.000036800582,"teacher_disagreement_score":0.6186877,"about_ca_system_score_codex":0.00064923655,"about_ca_system_score_gemma":0.00235526,"threshold_uncertainty_score":0.9996375},"labels":[],"label_agreement":null},{"id":"W2468218924","doi":"10.1097/qad.0000000000001191","title":"The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir","year":2016,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Virology; Human immunodeficiency virus (HIV); Drug resistance; Resistance mutation; Nucleoside; Lentivirus; Mutation; Biology; Medicine; Genetics; Reverse transcriptase; Viral disease; Antiretroviral therapy; RNA; Gene; Viral load","score_opus":0.010096273761068378,"score_gpt":0.25674143215941986,"score_spread":0.2466451583983515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468218924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9270733,0.0042482316,0.000566259,0.050697148,0.00015723704,0.001060064,0.00007693477,0.000048088954,0.016072731],"genre_scores_gemma":[0.92276835,0.000919773,0.002255531,0.00008051773,0.000023184844,0.00012658564,0.000013278479,0.00001387627,0.073798895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887854,0.0000884022,0.0003664064,0.00021421054,0.00024011356,0.0002123107],"domain_scores_gemma":[0.99892676,0.00045973717,0.00011190616,0.00035447848,0.00008653648,0.00006060127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032827916,0.00012821915,0.00017314359,0.00006695027,0.00023226789,0.000012701547,0.00012303673,0.000036461373,0.000032873646],"category_scores_gemma":[0.00022381128,0.00006137154,0.00005418938,0.00034168985,0.00026756068,0.00008037683,0.00003353183,0.00008801693,0.000029133216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014918784,0.001865935,0.4984471,0.0004943667,0.0015209517,0.00030452674,0.0383225,0.000033056225,0.035163518,0.16682887,0.12612487,0.12940244],"study_design_scores_gemma":[0.006680042,0.00019271123,0.72658384,0.002637373,0.0004853216,0.000015324347,0.010512811,0.0000523699,0.017044898,0.024649315,0.21047173,0.00067424984],"about_ca_topic_score_codex":0.0000126759205,"about_ca_topic_score_gemma":0.0009730702,"teacher_disagreement_score":0.22813678,"about_ca_system_score_codex":0.000058970734,"about_ca_system_score_gemma":0.00012418971,"threshold_uncertainty_score":0.25026587},"labels":[],"label_agreement":null},{"id":"W2469493284","doi":"10.1089/aid.2014.5546.abstract","title":"Longitudinal Analysis of SIVmac239 Mutations around the 12 Protease Cleavage Sites and their Correlations with Viral Load Reduction and CD4 counts","year":2014,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Human immunodeficiency virus (HIV); Clinical microbiology; Virology; Medicine; Biology; Microbiology","score_opus":0.056469578183708534,"score_gpt":0.33940200132246673,"score_spread":0.2829324231387582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469493284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968027,0.00027960984,0.00007743056,0.00023313495,0.000005676016,0.00031244813,0.000015677639,0.000012114882,0.0022612098],"genre_scores_gemma":[0.99563706,0.00007808881,0.0001602918,0.000008969862,0.00004207572,0.000030638654,0.000048742568,0.0000076177807,0.003986543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991842,0.0000754264,0.00012515576,0.00018694306,0.00027060203,0.00015765759],"domain_scores_gemma":[0.9993974,0.00016152277,0.000041289364,0.00015183733,0.00015530437,0.0000926485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038545468,0.00008917435,0.00018108478,0.00028388208,0.00039687715,0.00005963188,0.000032458825,0.000032001888,0.00005146318],"category_scores_gemma":[0.00008378845,0.00005094615,0.0000246288,0.0003101906,0.00058347493,0.00008997793,0.000031327556,0.00014745281,0.0000051450256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014090582,0.0001160945,0.99082345,0.00003922002,0.000689342,0.000004018905,0.0013049789,0.0000014569043,0.0009052097,0.0033338233,0.0006769911,0.0019645297],"study_design_scores_gemma":[0.0010974507,0.0014427725,0.99028075,0.00006921469,0.00063789793,0.000022285263,0.0016816736,0.00020314525,0.0012405167,0.0014259621,0.0017806847,0.0001176452],"about_ca_topic_score_codex":0.00012018282,"about_ca_topic_score_gemma":0.00020125702,"teacher_disagreement_score":0.0019078612,"about_ca_system_score_codex":0.000036816335,"about_ca_system_score_gemma":0.00006430253,"threshold_uncertainty_score":0.30524984},"labels":[],"label_agreement":null},{"id":"W2471505848","doi":"10.1177/135965350400900602","title":"Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Tolerability; Lamivudine; Regimen; Didanosine; Internal medicine; Efavirenz; Nelfinavir; Medicine; Stavudine; Zidovudine; Gastroenterology; Adverse effect; Viral load; Pharmacology; Immunology; Human immunodeficiency virus (HIV); Viral disease; Antiretroviral therapy; Virus","score_opus":0.019668753747712413,"score_gpt":0.2831689572905201,"score_spread":0.2635002035428077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471505848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961611,0.00009383811,0.0000720841,0.001839303,0.00010158508,0.0014882786,0.000016387783,0.000020918213,0.00020650159],"genre_scores_gemma":[0.9961252,0.00019522704,0.00022252956,0.000034867804,0.000035452977,0.00001801012,0.000017684244,0.000013821561,0.0033371898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902374,0.000062425665,0.00033710367,0.00022115411,0.00021831013,0.00013728828],"domain_scores_gemma":[0.9993898,0.000074902775,0.00016571382,0.00025242177,0.00009051494,0.000026621601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029252478,0.00014194107,0.00034499879,0.000051875602,0.000112790185,0.00000536519,0.000057587506,0.000036016838,0.000009384781],"category_scores_gemma":[0.000025651678,0.00008909982,0.0001239572,0.00015575999,0.00010967137,0.00006954732,0.000035867855,0.00006328054,0.000002817835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012469983,0.0018989336,0.980308,0.00002980341,0.00022110541,0.0000015390208,0.0029558968,0.000006866209,0.0060711186,0.0001336161,0.00012750752,0.0069986186],"study_design_scores_gemma":[0.011415788,0.00104567,0.8816968,0.000060680726,0.00007080192,0.0000030629,0.00013154211,0.00001718051,0.1041053,0.0001523675,0.001205447,0.00009531218],"about_ca_topic_score_codex":0.00015069365,"about_ca_topic_score_gemma":0.000064996544,"teacher_disagreement_score":0.098611146,"about_ca_system_score_codex":0.00008969613,"about_ca_system_score_gemma":0.000058323127,"threshold_uncertainty_score":0.36333853},"labels":[],"label_agreement":null},{"id":"W2472086923","doi":"","title":"Exploring antiretroviral interactions: still pioneer days. 6th International Workshop on Clinical Pharmacology of HIV Therapy, April 28-30, 2005, Québec.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); Medicine; Pharmacology; Psychology; Family medicine; Viral load","score_opus":0.14126359552993095,"score_gpt":0.3491307448499423,"score_spread":0.20786714932001132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472086923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456675,0.00043741218,0.00014349681,0.04226008,0.0032112976,0.0009741612,0.000015049657,0.00012696032,0.0071640187],"genre_scores_gemma":[0.95433384,0.0018095613,0.00046813322,0.0010125117,0.0016092663,0.00090218865,0.00005196604,0.000029346156,0.03978318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833506,0.00006949477,0.00058893533,0.000328385,0.00031866573,0.00035947407],"domain_scores_gemma":[0.99907315,0.00028437554,0.00016577732,0.0001916047,0.0000912209,0.00019386137],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037591477,0.00019522439,0.00035790904,0.00025623693,0.000040841525,0.000014349094,0.00014583574,0.00006465106,0.0011865335],"category_scores_gemma":[0.00014520867,0.00015735162,0.00016790585,0.00012144451,0.00008407889,0.00024599594,0.000056447396,0.000308817,0.00024527902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016894925,0.002607053,0.120940365,0.000011711753,0.0013664672,0.000053201464,0.0008982746,0.00007432602,0.00014332961,0.000056408855,0.13248457,0.7396748],"study_design_scores_gemma":[0.0058743246,0.00007423305,0.16830437,0.000055336863,0.00011628515,0.00001549707,0.00016477666,0.0002782899,0.0032313364,0.0000038095795,0.8216897,0.0001920337],"about_ca_topic_score_codex":0.000030004736,"about_ca_topic_score_gemma":0.00006372184,"teacher_disagreement_score":0.73948276,"about_ca_system_score_codex":0.0003183493,"about_ca_system_score_gemma":0.000115487106,"threshold_uncertainty_score":0.99972653},"labels":[],"label_agreement":null},{"id":"W2472178212","doi":"","title":"Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Nevirapine; Reverse-transcriptase inhibitor; Viral load; Virology; Lentivirus; Proportional hazards model; Internal medicine; Medicine; Efavirenz; Biology; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease","score_opus":0.049605881862354796,"score_gpt":0.28484857773868677,"score_spread":0.23524269587633198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472178212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953854,0.00008803532,0.0000055744936,0.00033414928,0.00009695424,0.0016245743,0.000004000069,0.00005613919,0.002405167],"genre_scores_gemma":[0.99777246,0.000031294676,0.0002764892,0.00050274725,0.000021641028,0.0011003059,0.000024250556,0.00002066401,0.00025014553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749565,0.0002598875,0.0007082885,0.00050875015,0.00035377117,0.00067364017],"domain_scores_gemma":[0.9990596,0.00023447242,0.0001105144,0.0002922265,0.00006706598,0.0002361165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009799409,0.00026483295,0.0005264773,0.00024600906,0.000060289272,0.000033036227,0.00011032559,0.00015125264,0.000072851566],"category_scores_gemma":[0.0020646404,0.00021027889,0.00008753885,0.0004004498,0.00007916635,0.0002001437,0.00004254652,0.00029491575,0.000018362432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010255508,0.001088425,0.9634122,0.000012203539,0.00002689397,0.00007244361,0.0005710972,0.000021031288,0.00001891438,0.00004975378,0.000010386882,0.033691082],"study_design_scores_gemma":[0.007916909,0.00011367004,0.99051315,0.0000309378,0.000016097329,0.0000036303004,0.000088562774,0.000019929701,0.0007051972,0.0001535773,0.00023253774,0.00020580352],"about_ca_topic_score_codex":0.00010572406,"about_ca_topic_score_gemma":0.0003453858,"teacher_disagreement_score":0.03348528,"about_ca_system_score_codex":0.00042321184,"about_ca_system_score_gemma":0.000100175974,"threshold_uncertainty_score":0.8574924},"labels":[],"label_agreement":null},{"id":"W2472927957","doi":"10.1093/jac/dkw265","title":"Virological efficacy of PI monotherapy for HIV-1 in clinical practice","year":2016,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"British Infection Society; Wellcome Trust","keywords":"Discontinuation; Medicine; Internal medicine; Observational study; Clinical trial; Incidence (geometry); Viral load; Protease inhibitor (pharmacology); Drug resistance; Combination therapy; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Biology","score_opus":0.02638770790598407,"score_gpt":0.3484199496250195,"score_spread":0.32203224171903544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472927957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93113536,0.00013382905,0.0033740439,0.06450908,0.0001943671,0.00041976123,0.0000070530905,0.000009366524,0.00021711645],"genre_scores_gemma":[0.90884906,0.00409657,0.07953908,0.004730441,0.00066921406,0.000004145766,0.0000041543935,0.000052487743,0.0020548229],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981249,0.000086192136,0.0011802313,0.00018043695,0.00020307436,0.0002251869],"domain_scores_gemma":[0.9978885,0.0008875665,0.0006902901,0.00015994498,0.0002655752,0.00010808839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010412874,0.0001689019,0.0007281316,0.00017532865,0.000021331967,0.000008075316,0.000133743,0.00016702415,0.00011230668],"category_scores_gemma":[0.00042901168,0.00009486579,0.00041075793,0.00013205333,0.00011538991,0.0001387101,0.000010049054,0.00017446268,0.000011873983],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06590598,0.01178867,0.11397956,0.00008483373,0.0018007121,0.00032363884,0.0012126028,0.0000053644294,0.52149886,0.00019987614,0.095784895,0.18741499],"study_design_scores_gemma":[0.12614158,0.004141639,0.09455089,0.0010663117,0.00032978828,0.0009152407,0.000094061346,0.000017630018,0.27811387,0.00018041358,0.49400857,0.0004400026],"about_ca_topic_score_codex":0.000001099527,"about_ca_topic_score_gemma":7.488399e-7,"teacher_disagreement_score":0.39822367,"about_ca_system_score_codex":0.00008216961,"about_ca_system_score_gemma":0.00022841802,"threshold_uncertainty_score":0.3868515},"labels":[],"label_agreement":null},{"id":"W2473682917","doi":"10.1177/135965350701200703","title":"Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Reverse transcriptase; Genotyping; Virology; Transmission (telecommunications); Protease; Biology; Integrase; Index case; Genotype; Viral load; Human immunodeficiency virus (HIV); Gp41; Drug resistance; Genetics; Polymerase chain reaction; Enzyme; Antibody; Epitope; Gene","score_opus":0.017663606525148735,"score_gpt":0.2910289731068751,"score_spread":0.27336536658172633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473682917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961291,0.0002829366,0.0007497557,0.0009729588,0.000048419453,0.0004097543,0.000039706993,0.00005199112,0.0013153878],"genre_scores_gemma":[0.9946792,0.00010013736,0.002724123,0.00027558368,0.000073298695,0.00000616124,0.00022643761,0.000023941213,0.0018911186],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988669,0.000043082397,0.00025999505,0.0002534602,0.00032970455,0.00024683206],"domain_scores_gemma":[0.9994612,0.00005499255,0.000055509594,0.00021362885,0.00006446348,0.00015026092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019584951,0.00017831361,0.0003091496,0.00017073844,0.000051119816,0.000010083868,0.00009012087,0.000069204434,0.00016195477],"category_scores_gemma":[0.0000049933396,0.00013084798,0.0000908603,0.00027685528,0.000039076476,0.00008711506,0.000012652154,0.000088592424,0.000048246347],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045409645,0.0015849405,0.28834054,0.000021363414,0.00058821833,0.00024850352,0.04062096,6.355738e-7,0.41117597,0.00011217836,0.0035275666,0.24923816],"study_design_scores_gemma":[0.0048425505,0.00049993827,0.48128968,0.00014099063,0.00007128866,0.0000017645968,0.0005978289,0.000005367533,0.47290802,0.00006815964,0.039361473,0.0002129076],"about_ca_topic_score_codex":0.00014909197,"about_ca_topic_score_gemma":0.00005772895,"teacher_disagreement_score":0.24902526,"about_ca_system_score_codex":0.000033547432,"about_ca_system_score_gemma":0.000070498056,"threshold_uncertainty_score":0.5335826},"labels":[],"label_agreement":null},{"id":"W2474869173","doi":"10.1097/qad.0000000000000866","title":"The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir","year":2015,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase; Integrase inhibitor; Virology; Biology; Drug resistance; Genetics; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.017290245653993775,"score_gpt":0.26631337939022737,"score_spread":0.24902313373623358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474869173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9294764,0.0036560055,0.0006461155,0.021517122,0.00015602204,0.0010665047,0.00003334023,0.00005872968,0.043389775],"genre_scores_gemma":[0.9595051,0.00019737342,0.004014736,0.00025891888,0.000033087166,0.00009172775,0.000044660497,0.000021031397,0.03583336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984733,0.00011877769,0.00037692336,0.0002618952,0.00049915636,0.00026998375],"domain_scores_gemma":[0.9988384,0.0001615857,0.00017290658,0.00050061924,0.00022329892,0.0001031555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063282484,0.00019888922,0.00028238597,0.00009937001,0.00014290719,0.000020864045,0.00021453669,0.000050121685,0.000026704456],"category_scores_gemma":[0.000111107096,0.00009703254,0.000057781213,0.00080749515,0.0002279164,0.00010397269,0.00003235918,0.00020802642,0.000045588138],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005522048,0.0008526655,0.31075847,0.00026924023,0.0006933889,0.00045210004,0.04063534,0.0000790591,0.0008547781,0.016802149,0.60509163,0.01798913],"study_design_scores_gemma":[0.029675439,0.0019288362,0.16579328,0.0052086907,0.001031036,0.000042459505,0.15821394,0.00085240806,0.05214629,0.015291636,0.5677006,0.0021153444],"about_ca_topic_score_codex":0.00006823962,"about_ca_topic_score_gemma":0.0017794237,"teacher_disagreement_score":0.14496519,"about_ca_system_score_codex":0.00010368845,"about_ca_system_score_gemma":0.00029825745,"threshold_uncertainty_score":0.39568722},"labels":[],"label_agreement":null},{"id":"W2478522716","doi":"10.1093/ofid/ofw141","title":"A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans","year":2016,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Gilead Sciences","keywords":"Rilpivirine; Emtricitabine; Medicine; Nevirapine; Tenofovir; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Pharmacology; Viral load","score_opus":0.017449163620749667,"score_gpt":0.27761020771915523,"score_spread":0.26016104409840557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2478522716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98355705,0.0006669358,0.001072045,0.0032985704,0.00018035766,0.00489383,0.00036635963,0.00034089157,0.005623979],"genre_scores_gemma":[0.9934442,0.00016325916,0.00017364479,0.0015611222,0.000060449507,0.0013997002,0.0004755863,0.00009930903,0.0026227513],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99574816,0.0005008905,0.0010502895,0.0010868025,0.0005660269,0.0010478549],"domain_scores_gemma":[0.9975935,0.0006140556,0.00031915342,0.0008478372,0.00020094769,0.0004244879],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004750842,0.000757544,0.0017763422,0.00056963455,0.00043594424,0.0003232383,0.00054756796,0.00019665109,0.0017395084],"category_scores_gemma":[0.0005645575,0.00046470598,0.00046912435,0.0010190915,0.0002748981,0.000543686,0.0003394733,0.00021091002,0.00029519002],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06756595,0.0081274165,0.7396594,0.00003165583,0.00059715996,0.0002440596,0.00026838662,0.000034305805,0.17149484,0.00027156278,0.0017751778,0.009930039],"study_design_scores_gemma":[0.63881433,0.0050398847,0.31508195,0.0007784969,0.00065884134,0.000015622578,0.000073080555,0.00020795873,0.029247455,0.002963844,0.005371736,0.0017468109],"about_ca_topic_score_codex":0.0016813327,"about_ca_topic_score_gemma":0.0005157919,"teacher_disagreement_score":0.57124835,"about_ca_system_score_codex":0.0005100872,"about_ca_system_score_gemma":0.00047392127,"threshold_uncertainty_score":0.9997805},"labels":[],"label_agreement":null},{"id":"W2485174595","doi":"10.1093/acprof:oso/9780199225859.003.0015","title":"The OPTIMA Cohort","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cohort; Environmental science; Mathematics; Statistics","score_opus":0.015833989652394468,"score_gpt":0.23415749999499902,"score_spread":0.21832351034260455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485174595","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028759596,0.0014473347,0.000009920134,0.0038587612,0.00013938743,0.00053737784,0.0000031955663,0.000088354405,0.9938869],"genre_scores_gemma":[0.000101525846,0.0079208035,0.0011201875,0.00024994393,0.00015851486,0.000022998765,0.00010970484,0.000045112803,0.9902712],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903077,0.0000028442707,0.0002232547,0.00023332123,0.00033347047,0.00017631307],"domain_scores_gemma":[0.9993468,0.000059797738,0.000056960984,0.00036536186,0.00006457675,0.00010651955],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006358169,0.00025195067,0.00032034185,0.00005203533,0.00016239719,0.000012448294,0.00007401387,0.00016292561,0.0025216967],"category_scores_gemma":[0.0000069439507,0.0001312856,0.0001605353,0.000011549906,0.00010314574,0.000012468834,0.00004041725,0.0001995744,0.004977397],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004792904,0.000024844807,0.0011572602,0.000011234784,0.001023835,0.00053362246,0.000051104875,7.402825e-8,7.654196e-7,0.024984324,0.9618282,0.010336814],"study_design_scores_gemma":[0.00042347165,0.00003249298,0.00045067235,0.000064588174,0.00020602347,0.00016560005,0.000003738959,0.000003313646,0.000028645414,0.00026322404,0.9982119,0.0001463378],"about_ca_topic_score_codex":0.0000033428269,"about_ca_topic_score_gemma":0.000006633369,"teacher_disagreement_score":0.0363837,"about_ca_system_score_codex":0.00011251125,"about_ca_system_score_gemma":0.00020303708,"threshold_uncertainty_score":0.99839014},"labels":[],"label_agreement":null},{"id":"W2489655347","doi":"10.4102/sajhivmed.v17i1.458","title":"Associations between plasma tenofovir concentration and renal function markers in HIV-infected women","year":2016,"lang":"en","type":"article","venue":"Southern African Journal of HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Science North","funders":"North-West University","keywords":"Renal function; Albuminuria; Medicine; Creatinine; Tenofovir; Urology; Internal medicine; Urine; Endocrinology; Gastroenterology; Human immunodeficiency virus (HIV); Immunology","score_opus":0.01087097120876367,"score_gpt":0.2272077716481071,"score_spread":0.21633680043934342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489655347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98018354,0.00011342551,0.000628284,0.01744714,0.00008839371,0.00020070511,0.00005349715,0.000019383491,0.0012656426],"genre_scores_gemma":[0.99473774,0.00005503316,0.00021121751,0.000067728484,0.0003818348,0.0000050882836,0.00003284672,0.000018167317,0.0044903634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835193,0.00011882936,0.00065608305,0.00015371053,0.00043895678,0.0002804654],"domain_scores_gemma":[0.99872154,0.00027731308,0.0004582576,0.00009661299,0.00017036241,0.000275939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008020491,0.00016400742,0.00052380725,0.00022890528,0.00005940304,0.000007651787,0.000053442505,0.00007362158,0.00032245708],"category_scores_gemma":[0.00038033302,0.000091927104,0.000049000384,0.00028523963,0.00013701306,0.0001038529,0.000012808565,0.00017984406,0.000037999784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007887439,0.00009558656,0.96592504,0.000010589341,0.00047803743,0.00008624159,0.009543103,6.486425e-7,0.0057312166,0.000027691578,0.0034216954,0.013891415],"study_design_scores_gemma":[0.023873786,0.0015944726,0.9538183,0.0010812331,0.00061414496,0.000096777876,0.009589113,0.000021494146,0.0002904911,0.00040772915,0.008373743,0.00023871982],"about_ca_topic_score_codex":0.000006057602,"about_ca_topic_score_gemma":0.000008575344,"teacher_disagreement_score":0.023085041,"about_ca_system_score_codex":0.00048901705,"about_ca_system_score_gemma":0.00019096342,"threshold_uncertainty_score":0.37486786},"labels":[],"label_agreement":null},{"id":"W2503158616","doi":"10.1017/cbo9780511543586.004","title":"General principles of pharmacotherapy for the patient with HIV infection","year":2005,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Medicine; Antiretroviral therapy; Regimen; Pharmacotherapy; Human immunodeficiency virus (HIV); Virology; Combination therapy; Pharmacology; Viral load; Biology; Internal medicine; RNA; Genetics","score_opus":0.02495834755418474,"score_gpt":0.22517905360120746,"score_spread":0.20022070604702272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503158616","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053743953,0.0003562605,0.0009010536,0.00015359305,0.0000932734,0.0018578325,0.00018332318,0.00006565548,0.9910146],"genre_scores_gemma":[0.0014250325,0.0005958562,0.00072440406,0.00006506572,0.00013982542,0.000007217544,0.00009583055,0.000039260914,0.99690753],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992082,0.000010964283,0.00016025685,0.0002516407,0.0002126342,0.00015627062],"domain_scores_gemma":[0.99923265,0.000051092306,0.00021045587,0.00025558443,0.00017053318,0.00007969974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042743693,0.00025763348,0.00032110512,0.00011332721,0.00012160219,0.000007415647,0.00008612053,0.00011787741,0.0000108175445],"category_scores_gemma":[0.0000015900424,0.00018125091,0.0001772501,0.000006802669,0.00012627203,0.000029275836,0.000047126912,0.0001531253,0.0000027804222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006852652,0.0003384669,0.0006974336,0.000712128,0.007606024,0.00039388856,0.0011081145,0.0001754237,0.00067829265,0.82119375,0.09313409,0.06710974],"study_design_scores_gemma":[0.0026810605,0.00018039842,0.000080778416,0.00018527314,0.0009328011,0.00002677805,0.000011666724,0.0001707676,0.0059986864,4.261247e-7,0.98954535,0.00018603134],"about_ca_topic_score_codex":0.000028260587,"about_ca_topic_score_gemma":0.0000045826982,"teacher_disagreement_score":0.89641124,"about_ca_system_score_codex":0.00019521867,"about_ca_system_score_gemma":0.00015457455,"threshold_uncertainty_score":0.73911977},"labels":[],"label_agreement":null},{"id":"W2503404095","doi":"10.7448/ias.19.1.20978","title":"Long‐term effectiveness of initiating non‐nucleoside reverse transcriptase inhibitor‐ versus ritonavir‐boosted protease inhibitor‐based antiretroviral therapy: implications for first‐line therapy choice in resource‐limited settings","year":2016,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Medicine; Regimen; Reverse-transcriptase inhibitor; Cart; Protease inhibitor (pharmacology); Nucleoside Reverse Transcriptase Inhibitor; Viral load; Ritonavir; Antiretroviral therapy; Internal medicine; Reverse transcriptase; Virology; Human immunodeficiency virus (HIV); Polymerase chain reaction","score_opus":0.03239843662087626,"score_gpt":0.30800392590609615,"score_spread":0.2756054892852199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503404095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810578,0.00015185597,0.00056868786,0.016486512,0.00037859616,0.0011659346,0.00012956269,0.000016189852,0.000044846824],"genre_scores_gemma":[0.99646115,0.00010329708,0.002069918,0.00067863887,0.00034575583,0.000082183135,0.000035952417,0.000038684317,0.00018443385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981233,0.00011615234,0.0007858398,0.00023569867,0.0005126245,0.00022640961],"domain_scores_gemma":[0.9973453,0.0010538584,0.00069358235,0.00023034486,0.0005764613,0.000100442405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010054237,0.00024330533,0.00042484276,0.00019116321,0.00013759296,0.000025477555,0.00032070305,0.00012619374,0.000024216402],"category_scores_gemma":[0.00042487067,0.0001447322,0.0007225772,0.0003291435,0.0001254663,0.00024384596,0.00004043273,0.0002698968,0.0000010777866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009302262,0.0013685845,0.67557245,0.00017965508,0.0011705097,0.000013272686,0.0008103792,0.00003119478,0.2959361,0.00004067786,0.0019304034,0.013644514],"study_design_scores_gemma":[0.060950957,0.0024018944,0.6499664,0.004460445,0.00023004539,0.00004216868,0.00014813629,0.00015817695,0.27490604,0.00014415062,0.0062546805,0.00033688644],"about_ca_topic_score_codex":0.000014471674,"about_ca_topic_score_gemma":0.0000050301355,"teacher_disagreement_score":0.051648695,"about_ca_system_score_codex":0.00051746925,"about_ca_system_score_gemma":0.00027782287,"threshold_uncertainty_score":0.5902008},"labels":[],"label_agreement":null},{"id":"W2509168921","doi":"10.1016/j.cmi.2016.08.012","title":"A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure","year":2016,"lang":"en","type":"article","venue":"Clinical Microbiology and Infection","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institutes of Health; ViiV Healthcare; Instituto de Salud Carlos III; Janssen Biotech; Canadian Institutes of Health Research; Ministry of Health, British Columbia; Genome Canada; Gilead Sciences; Merck; AbbVie; Genome British Columbia; Bristol-Myers Squibb","keywords":"Viremia; Human immunodeficiency virus (HIV); Drug; Medicine; Antiretroviral drug; Viral load; Plasma levels; Internal medicine; Antiretroviral therapy; Oncology; Virology; Pharmacology","score_opus":0.03514670568740851,"score_gpt":0.2662219785652692,"score_spread":0.23107527287786067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2509168921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944701,0.00007215348,0.00031238355,0.0039165188,0.00039672237,0.00042651405,0.000014511384,0.00010496806,0.0002861184],"genre_scores_gemma":[0.99722534,0.00022465334,0.00023555032,0.00020348905,0.00019222005,0.000027693577,0.0000615587,0.0000113789465,0.0018180999],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99857104,0.00018255528,0.0005075637,0.0004193467,0.00005762529,0.00026188197],"domain_scores_gemma":[0.9993128,0.00015327259,0.00015099019,0.00014467968,0.000114615985,0.00012360982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004878634,0.00018612435,0.00034446185,0.000054614775,0.0001416651,0.000009970704,0.00003145941,0.00031475618,0.0001448687],"category_scores_gemma":[0.0003489281,0.00011634062,0.000100875324,0.00007306102,0.00025877004,0.00009979413,0.000040437542,0.0001822709,0.00020957651],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005502442,0.0005219945,0.40106103,0.000041556406,0.00022483707,0.000011368507,0.00006803954,3.9812863e-7,0.5863928,0.00002559378,0.0038669682,0.00723514],"study_design_scores_gemma":[0.019445663,0.0010693728,0.60517246,0.0007559336,0.0004373835,0.00037110609,0.00002509142,0.0000356908,0.33857837,0.00015169207,0.033486713,0.00047051546],"about_ca_topic_score_codex":0.0000023364541,"about_ca_topic_score_gemma":0.000041097803,"teacher_disagreement_score":0.24781446,"about_ca_system_score_codex":0.00017225154,"about_ca_system_score_gemma":0.00007730978,"threshold_uncertainty_score":0.4744233},"labels":[],"label_agreement":null},{"id":"W2510140996","doi":"10.1016/s2352-3018(16)30091-1","title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Medicine; Efavirenz; Dolutegravir; Adverse effect; Meta-analysis; Odds ratio; Raltegravir; Viral load; Internal medicine; Indinavir; MEDLINE; Confidence interval; Antiretroviral therapy; Human immunodeficiency virus (HIV); Family medicine","score_opus":0.15608744855203652,"score_gpt":0.3874352813437313,"score_spread":0.23134783279169477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510140996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011348817,0.98980826,0.00019616314,0.0019082235,0.000022490236,0.007731807,0.00022060167,0.000014301031,0.000086824664],"genre_scores_gemma":[0.00017936368,0.994772,0.00015440705,0.000056615314,0.00014864701,0.0010965312,0.00012676221,0.000020033802,0.0034456109],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99795437,0.00037643846,0.000989884,0.00028717122,0.00018534681,0.00020680756],"domain_scores_gemma":[0.9959772,0.0022005911,0.00094364973,0.0007362133,0.000095346004,0.00004696193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076118094,0.00044514213,0.010356236,0.00007744649,0.00013529258,0.000010865276,0.00012152223,0.00007401517,0.00006682214],"category_scores_gemma":[0.00003584305,0.00014153197,0.0014653713,0.0004441051,0.00015523999,0.000021043958,0.000026068783,0.00007523625,0.0000063003613],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027811914,0.0003968117,0.00035590515,0.4063077,0.56814706,0.000002814297,0.00071291084,0.000003760742,2.8842646e-8,0.0002255706,0.0027326562,0.020836642],"study_design_scores_gemma":[0.0018835152,0.00042987836,0.000060356753,0.036264803,0.6344219,0.000015520322,0.0000058326045,0.000014920555,7.2907454e-7,0.000010712361,0.32675493,0.00013693336],"about_ca_topic_score_codex":0.00000558434,"about_ca_topic_score_gemma":0.00001351893,"teacher_disagreement_score":0.3700429,"about_ca_system_score_codex":0.000060813243,"about_ca_system_score_gemma":0.000057377987,"threshold_uncertainty_score":0.7079316},"labels":[],"label_agreement":null},{"id":"W2513754479","doi":"10.4212/cjhp.v69i4.1582","title":"Possible Atazanavir-Induced Cholelithiasis in a Pregnant Woman: A Case Report","year":2016,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Atazanavir; Medicine; Obstetrics; Gynecology; Family medicine","score_opus":0.026420134502836676,"score_gpt":0.2963489285316534,"score_spread":0.2699287940288167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513754479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496912,0.00079416734,0.0000036496301,0.0474551,0.0003877496,0.00034514148,0.000010770115,0.000007388403,0.0013048841],"genre_scores_gemma":[0.99403596,0.000058135145,0.00013040529,0.00029507754,0.0001813239,0.000011827242,0.000002121983,0.000024111034,0.0052610575],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9985173,0.000057791072,0.0005614049,0.0001651745,0.00027015942,0.0004282209],"domain_scores_gemma":[0.99845296,0.000052659507,0.00025800985,0.00026430754,0.00018507078,0.0007869812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005671399,0.00018131823,0.00031102452,0.00031964708,0.00015972511,0.000041774434,0.00016955596,0.00003681888,0.00026229478],"category_scores_gemma":[0.0001781159,0.00009197429,0.00014712437,0.000276325,0.00008628725,0.00023793885,0.00001750915,0.00027342423,0.0000549503],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013563003,0.00020571702,0.17228244,0.000021575932,0.0004019131,0.78018445,0.003900687,6.9005813e-7,0.00046684453,0.000050791023,0.0097779315,0.03257135],"study_design_scores_gemma":[0.035319068,0.0020167527,0.1260734,0.004841735,0.0012512461,0.70052105,0.0023411391,0.000040699488,0.029024463,0.0008424889,0.096452676,0.0012752886],"about_ca_topic_score_codex":0.0092148315,"about_ca_topic_score_gemma":0.023012556,"teacher_disagreement_score":0.08667475,"about_ca_system_score_codex":0.00063205644,"about_ca_system_score_gemma":0.0024341797,"threshold_uncertainty_score":0.9973829},"labels":[],"label_agreement":null},{"id":"W2515728039","doi":"10.7448/ias.19.1.20995","title":"Effects of a switch from tenofovir‐ to abacavir‐based antiretroviral therapy, with or without atazanavir, on renal function","year":2016,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; St. Paul's Hospital; University of British Columbia Hospital","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Atazanavir; Abacavir; Medicine; Renal function; Creatinine; Interquartile range; Emtricitabine; Urology; Lamivudine; Ritonavir; Internal medicine; Viral load; Regimen; Gastroenterology; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.01206587446503589,"score_gpt":0.256766816179387,"score_spread":0.2447009417143511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515728039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882924,0.0000486719,0.0031202398,0.0076337857,0.0003978403,0.00027975373,0.000016827567,0.000010622545,0.00019984116],"genre_scores_gemma":[0.9868568,0.000046214598,0.005560362,0.001379156,0.00033407265,0.000008775907,0.000003500421,0.000020757023,0.0057903174],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983645,0.000042536798,0.0003572351,0.00015664005,0.0009438383,0.00013523998],"domain_scores_gemma":[0.99880975,0.0002575916,0.0003819013,0.00015918454,0.00029468784,0.00009685386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002359503,0.00016899893,0.00031777655,0.00007793395,0.00005598082,0.000017409531,0.0002471485,0.000061188104,0.000096794516],"category_scores_gemma":[0.00008442367,0.000065076885,0.00034639394,0.00016369809,0.00005950737,0.00011859979,0.000037686947,0.00017141996,0.000014061053],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025048878,0.0018694861,0.4847643,0.000044114484,0.005438456,0.000081635604,0.0012210533,0.0000382694,0.4096651,0.00010446874,0.016465113,0.05525912],"study_design_scores_gemma":[0.037367225,0.014373103,0.4370878,0.005019789,0.0009782407,0.00012718423,0.00033371104,0.00021934028,0.4803883,0.00029467777,0.023376105,0.0004345055],"about_ca_topic_score_codex":0.000025427416,"about_ca_topic_score_gemma":0.000006143928,"teacher_disagreement_score":0.070723206,"about_ca_system_score_codex":0.0002936757,"about_ca_system_score_gemma":0.0002731101,"threshold_uncertainty_score":0.26537582},"labels":[],"label_agreement":null},{"id":"W2519560458","doi":"10.1016/j.molbiopara.2016.08.007","title":"An insertion in the methyltransferase domain of P. falciparum trimethylguanosine synthase harbors a classical nuclear localization signal","year":2016,"lang":"en","type":"article","venue":"Molecular and Biochemical Parasitology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Indian Institute of Technology Bombay; Industrial Research and Consultancy Centre; University Grants Commission","keywords":"NLS; Biology; Nuclear localization sequence; Importin; Nuclear transport; Plasmodium falciparum; Green fluorescent protein; Cell biology; Genetics; Gene; Cell nucleus","score_opus":0.008815792714292092,"score_gpt":0.2844794068647306,"score_spread":0.2756636141504385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519560458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98125577,0.00024194302,0.0102991145,0.007823507,0.000015675576,0.0002652415,0.000006008907,0.00001647325,0.000076248325],"genre_scores_gemma":[0.9985644,0.000032291955,0.0008274526,0.00048146577,0.00001762442,0.000018328363,0.000036301313,0.000011896396,0.000010231746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886245,0.00021983343,0.00027655892,0.00027413003,0.00016731548,0.00019971715],"domain_scores_gemma":[0.9995632,0.00008919488,0.000037470527,0.00017422835,0.000033675584,0.00010222746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018829845,0.00014432996,0.0002917988,0.000107217355,0.000031099557,0.0000058278306,0.00007619235,0.00017360083,0.000038549777],"category_scores_gemma":[0.0000479857,0.00007881998,0.00006590878,0.00019878156,0.000235673,0.000033294797,0.000012138476,0.00009535694,0.0000055066876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076169026,0.0006472893,0.018429354,0.000023304392,0.000055081953,0.00014004954,0.00025584202,5.7681524e-7,0.97619885,0.0010461935,0.00017821249,0.0022635795],"study_design_scores_gemma":[0.0037398925,0.0005487227,0.01396737,0.00007814501,0.00014042186,0.000093801515,0.000085308864,0.00016821949,0.979727,0.00061823823,0.0006758363,0.00015703464],"about_ca_topic_score_codex":0.000016511161,"about_ca_topic_score_gemma":0.000003965859,"teacher_disagreement_score":0.017308619,"about_ca_system_score_codex":0.000028783243,"about_ca_system_score_gemma":0.000041720705,"threshold_uncertainty_score":0.32141855},"labels":[],"label_agreement":null},{"id":"W2519719564","doi":"10.1016/s2352-3018(16)30119-9","title":"Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey","year":2016,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"Consejo Nacional de Ciencia y Tecnología; Public Health Agency of Canada","keywords":"HIV drug resistance; Medicine; Drug resistance; Christian ministry; Logistic regression; Viral load; Antiretroviral therapy; Internal medicine; Drug; Human immunodeficiency virus (HIV); Family medicine; Virology; Pharmacology; Biology","score_opus":0.03023313826595585,"score_gpt":0.3250900929173727,"score_spread":0.2948569546514168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519719564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778832,0.0012033342,0.000019969746,0.018094622,0.000027083965,0.001032432,0.0002115424,0.000018720528,0.0015090754],"genre_scores_gemma":[0.9889512,0.00084523286,0.000038134276,0.000074323536,0.00004527216,0.00010714333,0.00004707761,0.000017382325,0.009874212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981666,0.00079113164,0.00021597033,0.00026763277,0.00032706937,0.00023156701],"domain_scores_gemma":[0.9963964,0.002968024,0.00011934564,0.0003587494,0.00011127394,0.0000461989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017625211,0.00020465869,0.00047441677,0.00007212436,0.00007543082,0.000011177943,0.00013751646,0.00003514844,0.000049715345],"category_scores_gemma":[0.00033991307,0.00007717016,0.00006467423,0.0002339396,0.00010454249,0.000066919165,0.000039687555,0.00009852061,0.000023640165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007999224,0.0002716008,0.97867334,0.00004130129,0.00039021188,0.000021346417,0.0014407961,0.0000066314883,0.00037304504,0.0011157672,0.009478035,0.00018868002],"study_design_scores_gemma":[0.0057988935,0.0001749103,0.98083866,0.0006868753,0.000025304334,0.0000027333972,0.000027494038,0.000039226616,0.0112349745,0.0007161054,0.0003564125,0.000098431],"about_ca_topic_score_codex":0.000043301483,"about_ca_topic_score_gemma":0.0003075679,"teacher_disagreement_score":0.018020298,"about_ca_system_score_codex":0.00018729272,"about_ca_system_score_gemma":0.00008503678,"threshold_uncertainty_score":0.31469077},"labels":[],"label_agreement":null},{"id":"W2529825828","doi":"10.1111/hiv.12435","title":"An assessment of the relationship between the World Health Organization <scp>HIV</scp> drug resistance early warning indicators and <scp>HIV</scp> drug resistance acquisition","year":2016,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research; Ministry of Health, British Columbia; National Institutes of Health; International AIDS Society; Michael Smith Health Research BC; World Health Organization","keywords":"Medicine; HIV drug resistance; Odds ratio; Emtricitabine; Confidence interval; Logistic regression; Drug resistance; Lamivudine; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Viral load; Microbiology","score_opus":0.013899104203674163,"score_gpt":0.29451642142528334,"score_spread":0.28061731722160915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529825828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.893113,0.0014072816,0.0025721372,0.096016616,0.00020213006,0.0013406874,0.000055159013,0.00016289111,0.005130065],"genre_scores_gemma":[0.8959162,0.00017473596,0.0016776075,0.0006409012,0.00038224313,0.000047386726,0.0002742669,0.00006909546,0.10081751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614716,0.0005984826,0.00096187735,0.00062214094,0.0011390977,0.00053122215],"domain_scores_gemma":[0.994446,0.00317152,0.0009024099,0.00086642726,0.00023773035,0.0003759144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018663912,0.000396973,0.00069172855,0.00045855637,0.0007630255,0.000033618842,0.0003360253,0.00010348452,0.00003416375],"category_scores_gemma":[0.0015043494,0.00020823533,0.000068518006,0.0018178414,0.00050272973,0.00026868787,0.00009130912,0.0004441119,0.00003065793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000105750005,0.000083314066,0.89924634,0.0001574565,0.000098549186,0.0000070472993,0.0076248427,7.5829695e-7,0.00020552037,0.003491728,0.08880423,0.00026966934],"study_design_scores_gemma":[0.0029528418,0.000053216667,0.958326,0.0024439227,0.00026834404,0.000004440949,0.0014366765,0.000005667598,0.00090543216,0.0005486374,0.032986768,0.000068088484],"about_ca_topic_score_codex":0.000014428996,"about_ca_topic_score_gemma":0.00022866261,"teacher_disagreement_score":0.09568745,"about_ca_system_score_codex":0.00037428192,"about_ca_system_score_gemma":0.00046272101,"threshold_uncertainty_score":0.84915906},"labels":[],"label_agreement":null},{"id":"W2531730587","doi":"10.1182/blood.v118.21.3606.3606","title":"A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Jewish General Hospital","funders":"","keywords":"Cytarabine; Medicine; EIF4E; Ribavirin; Myeloid leukemia; Oncology; Cancer; Cancer research; Leukemia; Myeloid; Internal medicine; Temozolomide; Chemotherapy; Immunology; Translation (biology); Biology; Gene; Messenger RNA","score_opus":0.012918365873787937,"score_gpt":0.2423963824091339,"score_spread":0.22947801653534594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531730587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806887,0.00017010246,0.0000057981965,0.0001259437,0.00002170268,0.001081681,0.000009284172,0.00003350132,0.0004830944],"genre_scores_gemma":[0.99791545,0.00013972164,0.00087509304,0.00003178545,0.000013738313,0.00009234649,0.0000410949,0.000023124336,0.00086763885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987964,0.000049514183,0.00033899033,0.00035385948,0.00024208047,0.00021914615],"domain_scores_gemma":[0.9994145,0.000034146815,0.000119505225,0.00023438761,0.000068151996,0.00012933215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015688407,0.00023346973,0.00046426518,0.00023078495,0.00004788246,0.000011285103,0.00005451621,0.00006639522,0.000023284587],"category_scores_gemma":[0.000015078368,0.00017585733,0.000021121743,0.0002485697,0.00008555887,0.00012723805,0.000046220808,0.00013466305,0.0000057128404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022226241,0.035384245,0.9277629,0.00020242993,0.0013028097,0.0014495562,0.015691532,8.058075e-7,0.009790127,0.00021108628,0.000100390134,0.0058814534],"study_design_scores_gemma":[0.12066719,0.006857686,0.820099,0.00029847492,0.0012197752,0.00015401021,0.00092453614,0.000036830465,0.049294487,0.00012990033,0.000028944394,0.00028919865],"about_ca_topic_score_codex":0.00032762453,"about_ca_topic_score_gemma":0.00029173083,"teacher_disagreement_score":0.11844456,"about_ca_system_score_codex":0.000060195795,"about_ca_system_score_gemma":0.000107235785,"threshold_uncertainty_score":0.7171254},"labels":[],"label_agreement":null},{"id":"W2540468541","doi":"10.26843/investigacao.v15i6.1553","title":"COMPLEXO DE OURO, UM POTENCIAL CANDIDATO PARA TRATAMENTO DA FASE AGUDA DA DOENÇA DE CHAGAS","year":2016,"lang":"pt","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Molecular biology; Physics; Biology","score_opus":0.039879913038536226,"score_gpt":0.2991337136117553,"score_spread":0.25925380057321906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2540468541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9224825,0.00093808194,0.010541605,0.045265734,0.0009386136,0.0018944402,0.00049227907,0.0003544004,0.017092343],"genre_scores_gemma":[0.7819428,0.0002720571,0.0020051054,0.0015913836,0.00064906804,0.00010134309,0.00017665313,0.00007784749,0.21318373],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957769,0.00021661681,0.0007771237,0.00084498804,0.0007191489,0.0016652533],"domain_scores_gemma":[0.9974739,0.00020229288,0.00019975819,0.0007524248,0.0001221506,0.0012494613],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005613797,0.0007351389,0.0008608722,0.00026289816,0.0003369759,0.0001321193,0.00036758845,0.00028359445,0.0074682697],"category_scores_gemma":[0.00012134891,0.00047527047,0.00026780996,0.00032315793,0.00021151702,0.00021970276,0.0001663361,0.00027004338,0.0029874828],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021092705,0.003840749,0.44304854,0.00038899,0.0030653449,0.0077589424,0.016541721,0.0000025371196,0.025727222,0.0074178395,0.41244018,0.07765867],"study_design_scores_gemma":[0.070429824,0.0030221315,0.23487681,0.0037563376,0.0049744556,0.001581353,0.013914694,0.0013833292,0.1030133,0.0013528432,0.5563931,0.0053018373],"about_ca_topic_score_codex":0.0017472557,"about_ca_topic_score_gemma":0.0021728906,"teacher_disagreement_score":0.20817174,"about_ca_system_score_codex":0.0013504252,"about_ca_system_score_gemma":0.0015670564,"threshold_uncertainty_score":0.9997699},"labels":[],"label_agreement":null},{"id":"W2547674430","doi":"10.3851/imp3105","title":"Reporting on the Prevalence of Antiretroviral Drug Resistance in a Regional HIV Population over 20 Years: A Word of Caution","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Hip and Knee Clinic","funders":"","keywords":"Medicine; Population; Drug resistance; Prevalence; HIV drug resistance; Internal medicine; Human immunodeficiency virus (HIV); Epidemiology; Viral load; Immunology; Antiretroviral therapy; Environmental health; Biology","score_opus":0.02995695752612521,"score_gpt":0.29092920642927816,"score_spread":0.26097224890315296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547674430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965644,0.0002689892,0.000007689126,0.002498522,0.00002799322,0.0002777519,0.0000056233184,0.0000118774815,0.0003371899],"genre_scores_gemma":[0.9857686,0.00044339555,0.00022652876,0.000049978622,0.000028485136,0.000010554735,0.0000071323343,0.0000093211665,0.013455989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988418,0.000067606365,0.0005170227,0.00017247887,0.00027686986,0.0001241712],"domain_scores_gemma":[0.9991328,0.00009244878,0.0005211903,0.00020528064,0.000034729313,0.000013555372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043623414,0.000092341594,0.00021029972,0.000088606095,0.000020733165,0.0000027873366,0.00005268562,0.000034208162,0.000038537015],"category_scores_gemma":[0.000085449756,0.000050426963,0.000076116674,0.00018597212,0.00006338319,0.00008367684,0.000008930218,0.0000555423,0.00000480701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072207424,0.00015921492,0.96686566,0.000042041138,0.000039117684,0.00001848124,0.00079755555,9.5809554e-8,0.017457591,0.0010860661,0.0010685724,0.011743516],"study_design_scores_gemma":[0.0012727424,0.00005841039,0.9827285,0.0008720962,0.000010616595,0.000001231663,0.000022091013,0.0000050206454,0.013638058,0.0005054082,0.0008226528,0.000063167565],"about_ca_topic_score_codex":0.00003122291,"about_ca_topic_score_gemma":0.00003008074,"teacher_disagreement_score":0.01586283,"about_ca_system_score_codex":0.000053628333,"about_ca_system_score_gemma":0.000043640986,"threshold_uncertainty_score":0.20563519},"labels":[],"label_agreement":null},{"id":"W254883539","doi":"10.1097/fpc.0000000000000145","title":"PharmGKB summary","year":2015,"lang":"en","type":"review","venue":"Pharmacogenetics and Genomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences","keywords":"Biology; Computational biology","score_opus":0.09559619220075762,"score_gpt":0.3947711068157638,"score_spread":0.29917491461500617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W254883539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004727375,0.9950211,0.000007044071,0.000118755124,0.00029057855,0.0009833459,0.00013276529,0.000038368384,0.0033607504],"genre_scores_gemma":[0.0000017478432,0.9789803,0.001539219,0.00013590537,0.00044887775,0.000071003,0.0005678298,0.00009679679,0.018158317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998509,0.0000456967,0.00048010916,0.00043714212,0.00020325331,0.00032480602],"domain_scores_gemma":[0.9990168,0.000037420774,0.00015536248,0.000241908,0.00007808599,0.00047039546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020388185,0.00048647047,0.0013796266,0.00017427473,0.00006564139,0.000035262758,0.00011551584,0.00017274749,0.00008096051],"category_scores_gemma":[0.000005980989,0.00038499545,0.0002512089,0.00014455427,0.00005834636,0.000016703743,0.0001553825,0.00026075728,0.0002228984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014926754,0.00009693172,0.0000253953,0.0042528734,0.00074730895,0.00012677773,0.000083256156,1.7129126e-7,0.000003919834,0.000009391283,0.020404251,0.9742348],"study_design_scores_gemma":[0.0010151635,0.000035308218,8.572461e-7,0.0010398516,0.004703138,0.00025058512,0.0000074180693,0.000023655883,0.000022674332,0.000024135297,0.99251777,0.00035942692],"about_ca_topic_score_codex":0.0000012083534,"about_ca_topic_score_gemma":5.220301e-7,"teacher_disagreement_score":0.97387534,"about_ca_system_score_codex":0.0002012112,"about_ca_system_score_gemma":0.0007653546,"threshold_uncertainty_score":0.99986017},"labels":[],"label_agreement":null},{"id":"W2550942625","doi":"10.1128/aac.01364-16","title":"Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study","year":2016,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Merck","keywords":"Drug; Drug-drug interaction; Atorvastatin; Drug interaction; Pharmacology; Medicine","score_opus":0.014246322668180352,"score_gpt":0.28186934573173844,"score_spread":0.26762302306355806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550942625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986438,0.0000051251914,0.00001739496,0.01221589,0.00008637967,0.00045345858,0.000022324186,0.000029112884,0.0007323117],"genre_scores_gemma":[0.97663206,0.00028829311,0.0004218804,0.0008234241,0.00005492963,0.000007056306,0.000019073508,0.000020765987,0.02173252],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9990784,0.000030320334,0.00033001427,0.00026715896,0.00013447485,0.00015960884],"domain_scores_gemma":[0.9995339,0.00003280184,0.00012756498,0.00017405297,0.000060996943,0.00007070619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012983788,0.00016244229,0.00028088308,0.000087614746,0.000047036043,0.000012476567,0.00004804,0.000026640684,0.00017637527],"category_scores_gemma":[0.000009165252,0.00009810159,0.00006208078,0.000096054864,0.00004816211,0.00007578763,0.000024534953,0.00004481554,0.00003194207],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004194566,0.004522567,0.36329928,0.00009548959,0.0009234058,0.00009656721,0.014620389,2.2944626e-7,0.08191795,0.000012857873,0.4040185,0.12629822],"study_design_scores_gemma":[0.05632102,0.00064875145,0.46854308,0.00080968335,0.00027392746,0.00006726212,0.002237804,0.000014340011,0.21229517,0.00003166889,0.25815973,0.000597568],"about_ca_topic_score_codex":0.000082710554,"about_ca_topic_score_gemma":0.00003241012,"teacher_disagreement_score":0.14585875,"about_ca_system_score_codex":0.000034403154,"about_ca_system_score_gemma":0.000031570864,"threshold_uncertainty_score":0.40004668},"labels":[],"label_agreement":null},{"id":"W2557368926","doi":"10.1097/qad.0000000000001275","title":"Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin","year":2016,"lang":"en","type":"letter","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Ritonavir; Cobicistat; Darunavir; Pharmacology; CYP2C9; Atazanavir; Warfarin; Medicine; Chemistry; Internal medicine; Viral load; Virology; Cytochrome P450; Atrial fibrillation; Metabolism; Human immunodeficiency virus (HIV)","score_opus":0.010176478948452874,"score_gpt":0.26018968806890563,"score_spread":0.2500132091204528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557368926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7005411,0.00009560653,0.000076859134,0.29383463,0.0007673102,0.0012413244,0.0003708124,0.0000609161,0.0030114637],"genre_scores_gemma":[0.6572271,0.000076222044,0.0029431104,0.31973448,0.00181792,0.0011640129,0.0036986344,0.00015219027,0.013186306],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967172,0.00016281367,0.0008304575,0.00086668966,0.0008449594,0.0005778391],"domain_scores_gemma":[0.9987507,0.00027542788,0.00015155929,0.0005892435,0.00005988571,0.00017317342],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021174236,0.00058244454,0.00077024935,0.00096574746,0.000035826288,0.00005789879,0.00027134304,0.00044697843,0.0009381719],"category_scores_gemma":[0.00010959867,0.00044890255,0.0001733133,0.00027224698,0.000028559636,0.00017849896,0.0002278428,0.0011002396,0.00092235167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009096989,0.0014254292,0.36059275,0.00016466153,0.0011104237,0.03504617,0.008481745,0.0000096083295,0.0017542148,0.00009296372,0.40511304,0.177112],"study_design_scores_gemma":[0.0068537854,0.00040662938,0.032303464,0.002880308,0.00012213287,0.000021106725,0.00006462446,0.000030133506,0.0009219666,0.00030031192,0.9553227,0.00077285705],"about_ca_topic_score_codex":0.0024700558,"about_ca_topic_score_gemma":0.0007057878,"teacher_disagreement_score":0.55020964,"about_ca_system_score_codex":0.0011587611,"about_ca_system_score_gemma":0.00022424781,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W2557504094","doi":"10.1182/blood.v118.21.1856.1856","title":"Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Multiple myeloma; Internal medicine; Pharmacokinetics; Lenalidomide; Neutropenia; Lymphoma; Pharmacology; Oncology; Toxicity; Leukemia","score_opus":0.05237532207231623,"score_gpt":0.3222238660342339,"score_spread":0.2698485439619177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557504094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623877,0.0001230229,0.000011738614,0.0003199665,0.000112074085,0.0018057605,0.0002117548,0.00007127683,0.0011056531],"genre_scores_gemma":[0.9952533,0.00006174394,0.002431714,0.00003876835,0.00017427764,0.00007435581,0.00013348654,0.000041215335,0.0017911067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748003,0.00013540818,0.0008763582,0.00079867843,0.0002992123,0.00041029515],"domain_scores_gemma":[0.9986683,0.0004128854,0.00017160033,0.00043582177,0.000050561383,0.0002608335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006646551,0.00034117012,0.000703378,0.00021350932,0.0001094711,0.00001809033,0.00013092572,0.00015844827,0.00013839967],"category_scores_gemma":[0.00024291515,0.00030459792,0.0000891653,0.00022416553,0.00010021103,0.0001422339,0.0002003787,0.00039776077,0.000047076643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016627666,0.11177454,0.8397437,0.000052349507,0.00072608946,0.0015900853,0.009737737,0.0000013244211,0.011557944,0.0000013412439,0.00074775226,0.007439467],"study_design_scores_gemma":[0.20185678,0.0046879547,0.75499016,0.00035986758,0.00086828443,0.000022391925,0.00058550085,0.0007986265,0.034523856,0.000015398009,0.00079185504,0.00049936085],"about_ca_topic_score_codex":0.0009529138,"about_ca_topic_score_gemma":0.0019552796,"teacher_disagreement_score":0.18522911,"about_ca_system_score_codex":0.00007386961,"about_ca_system_score_gemma":0.00010254909,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W2558158598","doi":"10.1182/blood.v116.21.2995.2995","title":"Inhibiting Translation as a Novel Strategy to Target Multiple Myeloma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Biology; Apoptosis; Flow cytometry; Molecular biology; Viability assay; Cell culture; Cytotoxicity; Bortezomib; Annexin A5; Peripheral blood mononuclear cell; Cell biology; Annexin; Biochemistry; Multiple myeloma; Immunology; In vitro","score_opus":0.01909367073031665,"score_gpt":0.26287415636694345,"score_spread":0.2437804856366268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558158598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293746,0.00003545349,0.0003176804,0.0014026088,0.00006584138,0.00042822416,0.000009186659,0.00008794595,0.014715582],"genre_scores_gemma":[0.95498186,0.0000013223593,0.041625265,0.0001400458,0.0001515554,0.00003900635,0.000068250054,0.000019788627,0.0029729092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992218,0.0000058705,0.00017851143,0.00020752361,0.00017914732,0.00020717081],"domain_scores_gemma":[0.9995933,0.000038875016,0.00003001093,0.0001269578,0.000047377267,0.00016345171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009353895,0.00012484909,0.00015360961,0.000087700726,0.000066003646,0.000019088486,0.000036740796,0.00007309246,0.0001920453],"category_scores_gemma":[0.00006383339,0.00010717751,0.00005026487,0.00014864697,0.000012972611,0.0000567115,0.00001103754,0.00014187518,0.0002910269],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101850346,0.0017506527,0.057619754,0.00004858781,0.00019056183,0.0002080879,0.0024708116,0.000006163597,0.90853715,0.000490234,0.00023830363,0.028337825],"study_design_scores_gemma":[0.019056652,0.00053646025,0.059186213,0.00016345436,0.00033811713,0.0005145862,0.0004743366,0.00044230593,0.88884395,0.00022017119,0.02972066,0.0005031152],"about_ca_topic_score_codex":0.000020267471,"about_ca_topic_score_gemma":0.00009993524,"teacher_disagreement_score":0.041307583,"about_ca_system_score_codex":0.000009365457,"about_ca_system_score_gemma":0.00009994143,"threshold_uncertainty_score":0.4370572},"labels":[],"label_agreement":null},{"id":"W2561842738","doi":"10.1097/md.0000000000005578","title":"Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B","year":2016,"lang":"en","type":"review","venue":"Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fourth Military Medical University","keywords":"Adefovir; Medicine; Renal function; Internal medicine; Creatinine; Gastroenterology; Odds ratio; Nephrotoxicity; Liver function; Confidence interval; Urology; Kidney; Hepatitis B virus; Immunology; Lamivudine","score_opus":0.09311392789172075,"score_gpt":0.3814342030687134,"score_spread":0.28832027517699266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561842738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075518514,0.98981804,0.00039372675,0.0036328947,0.00019470452,0.0046806196,0.00009932011,0.00010095923,0.0003245765],"genre_scores_gemma":[0.0015766469,0.978248,0.00015332238,0.00010691226,0.0023557462,0.0010586849,0.0013079823,0.000106304564,0.0150864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758685,0.000112033784,0.00084510096,0.0006269954,0.0003835752,0.00044547746],"domain_scores_gemma":[0.9974532,0.0012817988,0.00035720738,0.00050574035,0.00008117177,0.0003208473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045627754,0.00063107384,0.002443496,0.00037344953,0.00017297201,0.000012809657,0.00014424513,0.0004030105,0.0003587156],"category_scores_gemma":[0.00026677287,0.0003440453,0.000293401,0.00027125247,0.00027006192,0.00006757364,0.000048488007,0.0003277172,0.00011571645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022832759,0.000045060802,0.1557143,0.00878405,0.00046751963,0.000038161605,0.00009134917,6.5189193e-10,4.5486192e-7,0.00007538429,0.0044837585,0.83027714],"study_design_scores_gemma":[0.004185716,0.0006523314,0.084391095,0.031481463,0.0016816499,0.00006864271,0.0000014163147,1.994365e-7,0.0000030196022,0.00008038608,0.8771342,0.00031986999],"about_ca_topic_score_codex":0.000014161316,"about_ca_topic_score_gemma":0.000026486614,"teacher_disagreement_score":0.87265044,"about_ca_system_score_codex":0.00052664423,"about_ca_system_score_gemma":0.0005268144,"threshold_uncertainty_score":0.9999012},"labels":[],"label_agreement":null},{"id":"W2563652492","doi":"10.1007/978-981-10-2113-8_7","title":"Pharmacodynamic Interactions Between Antiretrovirals and Other Agents","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacodynamics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Pharmacology; Medicine; Computer science; Pharmacokinetics; Virology; Viral load","score_opus":0.043198359578637296,"score_gpt":0.3254674979496093,"score_spread":0.282269138370972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563652492","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020752759,0.00015672545,0.00007965596,0.0017933028,0.00016565049,0.00043946522,0.00012172339,0.000102653175,0.99506557],"genre_scores_gemma":[0.027953843,0.0002495227,0.00029884503,0.00041736153,0.00029170787,0.000009958489,0.00007767239,0.00007214097,0.970629],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900377,0.000006902242,0.00027929983,0.00033211673,0.00019565369,0.00018223896],"domain_scores_gemma":[0.99944556,0.00005670935,0.000104150786,0.00019353906,0.00003585952,0.00016416622],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000051661016,0.00031579027,0.00045055256,0.00022915176,0.00005687095,0.000015466647,0.000048638944,0.00013028517,0.00909197],"category_scores_gemma":[0.0000042033475,0.00020484667,0.00011968372,0.000013717991,0.00006538915,0.00005549592,0.00005652572,0.00017370847,0.0018287089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003028694,0.0002874171,0.19324023,0.00053257437,0.013334732,0.00074937416,0.0007617166,2.9029652e-8,0.0012175983,0.068339854,0.26693916,0.45429444],"study_design_scores_gemma":[0.0014671537,0.000050790244,0.0010514674,0.000522436,0.0006903534,0.00003170557,0.000005106565,0.0000038773355,0.00017405821,0.00075445324,0.99497926,0.00026932114],"about_ca_topic_score_codex":0.0000044399885,"about_ca_topic_score_gemma":0.000006235282,"teacher_disagreement_score":0.7280401,"about_ca_system_score_codex":0.00012599102,"about_ca_system_score_gemma":0.000054712094,"threshold_uncertainty_score":0.99894845},"labels":[],"label_agreement":null},{"id":"W2566553184","doi":"10.1007/978-981-10-2113-8","title":"Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs","year":2016,"lang":"en","type":"book","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacodynamics; Pharmacokinetics; Pharmacology; Drug; Antiretroviral drug; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Viral load","score_opus":0.007747513478450137,"score_gpt":0.26125354617517266,"score_spread":0.2535060326967225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566553184","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017449817,0.00041576475,0.000034895576,0.002780779,0.00033315006,0.000995172,0.00010894396,0.0003237535,0.9775577],"genre_scores_gemma":[0.055610675,0.00045352717,0.0001634113,0.00033851486,0.00020144368,0.000049472088,0.0006057691,0.000101182675,0.942476],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983111,0.000037860493,0.00034550167,0.000520986,0.00041219906,0.00037234876],"domain_scores_gemma":[0.99904615,0.00015785515,0.00020339488,0.00020414541,0.00013258471,0.000255872],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010489066,0.00052508333,0.0006574762,0.00034153755,0.00010971385,0.00002761043,0.000081809994,0.00009219308,0.0021885096],"category_scores_gemma":[0.000012751934,0.00032184157,0.00012252404,0.00009646648,0.00015129916,0.000120732024,0.000067216315,0.00042206966,0.00034203942],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082487945,0.0008039338,0.012350349,0.00038001273,0.008473823,0.00082810805,0.0014811539,3.095758e-7,0.0009734833,0.00061462726,0.8426783,0.13059102],"study_design_scores_gemma":[0.020692322,0.00037570222,0.0016923369,0.0046289754,0.005964803,0.000282739,0.00011535313,0.00037576025,0.0011971553,0.00026997304,0.9628538,0.0015510726],"about_ca_topic_score_codex":0.000008321319,"about_ca_topic_score_gemma":0.000026428504,"teacher_disagreement_score":0.12903994,"about_ca_system_score_codex":0.0006516453,"about_ca_system_score_gemma":0.00050374033,"threshold_uncertainty_score":0.99992335},"labels":[],"label_agreement":null},{"id":"W2570376902","doi":"10.1097/fpc.0000000000000263","title":"Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202","year":2017,"lang":"en","type":"article","venue":"Pharmacogenetics and Genomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Public Health Agency of Canada","keywords":"Efavirenz; Internal medicine; Genome-wide association study; Clinical trial; Medicine; Pharmacogenetics; Oncology; Biology; Single-nucleotide polymorphism; Viral load; Human immunodeficiency virus (HIV); Immunology; Genetics; Antiretroviral therapy; Genotype; Gene","score_opus":0.10536133911839711,"score_gpt":0.4594565667727651,"score_spread":0.35409522765436796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570376902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945162,0.000015057771,0.000037064805,0.00011240527,0.00019097365,0.05427417,0.000024904175,0.000008002988,0.00017541254],"genre_scores_gemma":[0.9909818,0.00011260919,0.0016464508,0.00009985669,0.00011420276,0.0066168928,0.000021677255,0.000022462282,0.00038402266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973674,0.0006051552,0.0012474611,0.0003079193,0.00025550532,0.0002165857],"domain_scores_gemma":[0.9982462,0.00040440445,0.00078681123,0.00025568277,0.00014397592,0.00016290553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004146714,0.00018566476,0.00116633,0.00012740202,0.0001074453,0.00004366703,0.00011464372,0.000076383854,0.000015880492],"category_scores_gemma":[0.0014023213,0.00014865519,0.00013840527,0.000058729904,0.00004328142,0.000041056246,0.00014137058,0.00013772749,0.00000909214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02680063,0.0021435958,0.9491744,0.00003820294,0.0005329308,0.000010468412,0.0013493251,0.0000048848497,0.00039658268,0.000007750563,0.00013746253,0.019403743],"study_design_scores_gemma":[0.46530476,0.00165378,0.5284538,0.00004833535,0.00077946455,2.7538695e-7,0.00009613487,0.00044432687,0.0011883122,0.00007639263,0.0017295465,0.0002248223],"about_ca_topic_score_codex":0.000046245266,"about_ca_topic_score_gemma":0.000025323734,"teacher_disagreement_score":0.43850413,"about_ca_system_score_codex":0.000103020575,"about_ca_system_score_gemma":0.00007096764,"threshold_uncertainty_score":0.6061983},"labels":[],"label_agreement":null},{"id":"W2578570244","doi":"10.1097/qai.0000000000001291","title":"Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission","year":2017,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Michael's Hospital; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Children's Hospital of Eastern Ontario; University of Toronto; SickKids Foundation; University of Ottawa; Hospital for Sick Children","funders":"","keywords":"Medicine; Nevirapine; Pharmacokinetics; Regimen; Gestational age; Adverse effect; Prospective cohort study; Birth weight; Gastroenterology; Internal medicine; Trough Concentration; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Pregnancy; Immunology","score_opus":0.0231973610959064,"score_gpt":0.3102915825984183,"score_spread":0.2870942215025119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578570244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901996,0.005552839,0.0014385524,0.0020957773,0.00017819801,0.00044755888,0.000003592428,0.000010016972,0.00007383256],"genre_scores_gemma":[0.99025923,0.006084903,0.0030587655,0.000008654602,0.000017413047,0.000005855421,0.00001295013,0.000020134768,0.00053210836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983921,0.00006336037,0.00084612274,0.00015577322,0.00032523915,0.00021740944],"domain_scores_gemma":[0.9990292,0.00013511164,0.00040258476,0.000176105,0.00018957761,0.00006741784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008656737,0.00016346652,0.0005589766,0.00036229694,0.00016754952,0.00003455029,0.0001640336,0.00007898248,0.000021583333],"category_scores_gemma":[0.0002274671,0.0001237714,0.00018055829,0.00015604409,0.0001364994,0.00035144077,0.000027280681,0.00008038403,0.0000010605967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048752115,0.002288843,0.19537936,0.0005378501,0.00038098067,0.000104735795,0.002543296,0.000022617594,0.2308894,0.00034096345,0.00015973915,0.562477],"study_design_scores_gemma":[0.021036765,0.0036638265,0.9088458,0.0016176092,0.00024529075,0.00027319492,0.00028899507,0.0021718207,0.060384564,0.00068632705,0.0005762682,0.00020955247],"about_ca_topic_score_codex":0.000004043204,"about_ca_topic_score_gemma":2.6441373e-7,"teacher_disagreement_score":0.7134664,"about_ca_system_score_codex":0.00006258987,"about_ca_system_score_gemma":0.00009210437,"threshold_uncertainty_score":0.50472516},"labels":[],"label_agreement":null},{"id":"W2587896987","doi":"10.3851/imp3139","title":"Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Children's Hospital of Eastern Ontario; Université de Montréal; University Health Network; University of Toronto; Toronto General Hospital; McGill University Health Centre","funders":"Merck Canada; McGill University Health Centre; Gilead Sciences","keywords":"Raltegravir; Dosing; Medicine; Therapeutic drug monitoring; Drug; Gestational age; Pediatrics; Pregnancy; Drug resistance; Human immunodeficiency virus (HIV); Viral load; Pharmacology; Antiretroviral therapy; Immunology; Biology","score_opus":0.023197962399288497,"score_gpt":0.3033020600364695,"score_spread":0.28010409763718097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587896987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911307,0.0005737891,0.0040318193,0.0029047215,0.000040478466,0.00116552,0.0000025842014,0.000046905934,0.00010349086],"genre_scores_gemma":[0.9900278,0.00022145148,0.006275947,0.00005162096,0.000047890764,0.000113812996,0.000005005943,0.00003875351,0.0032177267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879044,0.000065154774,0.00029560985,0.0003013916,0.00023879702,0.00030861158],"domain_scores_gemma":[0.9995214,0.000107193744,0.000049757902,0.0001809477,0.00006582486,0.00007492087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021726388,0.00021334118,0.0003535734,0.00015188621,0.00005764663,0.000015840094,0.000075350436,0.000068057794,0.00001634205],"category_scores_gemma":[0.000013610527,0.00011990664,0.00010796353,0.00021193932,0.000035963003,0.00016436611,0.000012899348,0.00005293923,0.0000039503657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004099432,0.00061758043,0.11798043,0.00012921747,0.00026048077,0.000031929045,0.0068858084,0.000001277412,0.5730477,0.00010247954,0.00007902531,0.29676464],"study_design_scores_gemma":[0.010884851,0.0011911042,0.3523631,0.007333737,0.00009602733,0.00002108047,0.00037708465,0.000101566344,0.62430197,0.0002854542,0.0026540775,0.00038992884],"about_ca_topic_score_codex":0.000006313677,"about_ca_topic_score_gemma":0.000004618402,"teacher_disagreement_score":0.2963747,"about_ca_system_score_codex":0.00008784996,"about_ca_system_score_gemma":0.00007886111,"threshold_uncertainty_score":0.4889651},"labels":[],"label_agreement":null},{"id":"W2588103380","doi":"10.1093/ofid/ofw172.14","title":"Is Routine Therapeutic Drug Monitoring of Antiretroviral Agents Warranted in Human Immunodeficiency Virus-Infected Children?","year":2016,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Drug; Intensive care medicine; Virology; Antiretroviral drug; Antiretroviral therapy; Immunology; Viral load; Pharmacology","score_opus":0.015297181510779401,"score_gpt":0.30027274546808014,"score_spread":0.2849755639573007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588103380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953189,0.00042645537,0.000016932345,0.00043557765,0.00014155416,0.0010597331,0.000076510936,0.00010024868,0.0024240986],"genre_scores_gemma":[0.99689484,0.00014126983,0.000016865524,0.000093692914,0.000029303374,0.00008290565,0.000061248604,0.000044226235,0.0026356492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982265,0.00007742554,0.0004995965,0.00041060892,0.0003123834,0.0004734852],"domain_scores_gemma":[0.999119,0.00004838168,0.00018702996,0.0004250442,0.00009060441,0.00012997845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012120743,0.0003017651,0.00052946905,0.00029606358,0.00020205376,0.0000511098,0.00024494514,0.0000629611,0.0004924405],"category_scores_gemma":[0.00004421052,0.00020558437,0.00017707441,0.00047542847,0.000100580764,0.00031825108,0.00020019061,0.000097301185,0.000074610245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001461103,0.0015913706,0.98373985,0.000023622139,0.0002834598,0.000018993665,0.0003291956,6.0934946e-7,0.0065039545,0.000104353705,0.00028953946,0.0069689364],"study_design_scores_gemma":[0.006957404,0.00038929482,0.9736289,0.00045151607,0.00020106026,0.000012528102,0.00009530986,0.000006980219,0.017703466,0.00023595063,0.00006521643,0.0002523955],"about_ca_topic_score_codex":0.00081814564,"about_ca_topic_score_gemma":0.000047015998,"teacher_disagreement_score":0.011199511,"about_ca_system_score_codex":0.00023502774,"about_ca_system_score_gemma":0.00012416164,"threshold_uncertainty_score":0.83834875},"labels":[],"label_agreement":null},{"id":"W2591014544","doi":"10.1016/j.bmcl.2017.02.039","title":"Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV","year":2017,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Shionogi","keywords":"Raltegravir; Aminal; Integrase; Chemistry; Pharmacology; Integrase inhibitor; Pharmacokinetics; Human immunodeficiency virus (HIV); Virology; Stereochemistry; Medicine; Biochemistry; Antiretroviral therapy; Viral load","score_opus":0.014728017510283953,"score_gpt":0.24677313280944854,"score_spread":0.23204511529916458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591014544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782163,0.0006174254,0.006351358,0.014125599,0.0000776756,0.000489211,0.000052249256,0.000010177451,0.000060006925],"genre_scores_gemma":[0.99765337,0.00063282676,0.00062355096,0.000054803077,0.00021930934,0.000030298917,0.00008493554,0.000018754317,0.000682161],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905187,0.00000790865,0.0003113484,0.00022465283,0.00023604745,0.00016816633],"domain_scores_gemma":[0.9992948,0.00010359522,0.00012435902,0.00034207784,0.00005138975,0.000083770516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010850373,0.00020309427,0.00036966123,0.00002798095,0.0001380695,0.000018256073,0.00010261806,0.00006619947,0.000048622795],"category_scores_gemma":[0.00005138757,0.00011938688,0.00011283457,0.000042664127,0.00040381178,0.00007259292,0.000010777496,0.000060517774,4.0059908e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009624157,0.00051880616,0.010754738,0.00049514085,0.00076353666,0.00004276299,0.0016465263,0.000013858175,0.9797012,0.000008644827,0.0008799872,0.0042123743],"study_design_scores_gemma":[0.00644708,0.00023475429,0.0038042339,0.00030474455,0.0011634687,0.000053581014,0.00077171257,0.00025031785,0.98615336,0.0000021739709,0.0006825616,0.00013200466],"about_ca_topic_score_codex":0.000024089151,"about_ca_topic_score_gemma":0.0000028852003,"teacher_disagreement_score":0.019437062,"about_ca_system_score_codex":0.00008276922,"about_ca_system_score_gemma":0.000087075015,"threshold_uncertainty_score":0.48684555},"labels":[],"label_agreement":null},{"id":"W2591672881","doi":"10.1097/md.0000000000006282","title":"High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic","year":2017,"lang":"en","type":"article","venue":"Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université du Québec à Montréal","funders":"","keywords":"Medicine; Viral load; Regimen; Genotyping; Drug resistance; Internal medicine; Antiretroviral therapy; Genotype; Virology; Human immunodeficiency virus (HIV); Biology","score_opus":0.0136101558089547,"score_gpt":0.26130197323098586,"score_spread":0.24769181742203117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591672881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97211576,0.00021205613,0.000047039877,0.026608981,0.000028625907,0.00076124293,0.000064702566,0.000014046788,0.00014756751],"genre_scores_gemma":[0.9970995,0.00002166777,0.0020325014,0.0001950606,0.00007725477,0.000047873724,0.00012200522,0.000016931215,0.00038720033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985049,0.000089140914,0.00044245616,0.00032866898,0.00031815463,0.0003166999],"domain_scores_gemma":[0.9989926,0.00010856052,0.0002111408,0.00048789175,0.00009322069,0.00010656815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029359624,0.00019574958,0.00062918285,0.00029916063,0.0000701679,0.000012566145,0.00017668547,0.00007905865,0.00007072877],"category_scores_gemma":[0.00032047747,0.00012023379,0.000034961424,0.00036632462,0.00023291432,0.00008045491,0.000066644745,0.00021563272,0.0000013966421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096862996,0.00016352166,0.98712975,0.00007434354,0.000097655124,0.00015896064,0.00798763,0.0000052245696,0.00042501403,0.00012551372,0.00029142495,0.0025723183],"study_design_scores_gemma":[0.0060221236,0.0007664081,0.9898354,0.0005779234,0.00014323913,0.000021690377,0.0018540903,0.000005774595,0.00042946488,0.000028721428,0.00020237682,0.0001128333],"about_ca_topic_score_codex":0.0003277099,"about_ca_topic_score_gemma":0.0026266277,"teacher_disagreement_score":0.026413921,"about_ca_system_score_codex":0.000089614216,"about_ca_system_score_gemma":0.00007698688,"threshold_uncertainty_score":0.49029917},"labels":[],"label_agreement":null},{"id":"W2592154010","doi":"10.1177/2054358117695792","title":"First Canadian Case Report of Kidney Transplantation From an HIV-Positive Donor to an HIV-Positive Recipient","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Kidney Health and Disease","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Saint-Luc; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Kidney transplantation; Transplantation; Nephrology; Internal medicine; Kidney disease; Intensive care medicine; Immunology","score_opus":0.0159831278741543,"score_gpt":0.2912145981539073,"score_spread":0.27523147027975303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592154010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6362536,0.00038219176,0.0001182986,0.35131848,0.0004443832,0.0008258367,0.00989807,0.0000072651515,0.00075185],"genre_scores_gemma":[0.9529499,0.00013996568,0.001596181,0.041764285,0.00033845342,0.000015457787,0.0024184731,0.00003499167,0.0007422982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811375,0.000093389375,0.000666212,0.00033871402,0.00024218371,0.00054573145],"domain_scores_gemma":[0.8987887,0.000029593737,0.00042345576,0.0003941147,0.0003221138,0.10004201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033165203,0.00023986226,0.00048419126,0.00050977943,0.00091879413,0.00009507507,0.00013950477,0.00007742595,0.0001383036],"category_scores_gemma":[0.003655626,0.00021924151,0.00009807125,0.00009051783,0.000114457485,0.0003773441,0.000006452427,0.00018466137,0.000008982615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018400323,0.0002609216,0.4152249,0.00032672298,0.00028932665,0.31309816,0.01943976,0.000007744106,0.000007938641,0.00010921219,0.24593675,0.0034585106],"study_design_scores_gemma":[0.019732688,0.0040161135,0.7058031,0.009073783,0.0024667466,0.044384085,0.00585639,0.00038227573,0.00035816745,0.00047857407,0.2058657,0.0015823785],"about_ca_topic_score_codex":0.43884206,"about_ca_topic_score_gemma":0.56271553,"teacher_disagreement_score":0.3166963,"about_ca_system_score_codex":0.00078613404,"about_ca_system_score_gemma":0.09440111,"threshold_uncertainty_score":0.9107328},"labels":[],"label_agreement":null},{"id":"W2592367943","doi":"10.2147/hiv.s108756","title":"Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks","year":2017,"lang":"en","type":"article","venue":"HIV/AIDS - Research and Palliative Care","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Ritonavir; Atazanavir; Abacavir; Medicine; Adverse effect; Lamivudine; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Gastroenterology; Virology; Antiretroviral therapy; Virus","score_opus":0.0964436235399211,"score_gpt":0.39035964002528317,"score_spread":0.2939160164853621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592367943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887632,0.001098078,0.0005164592,0.0014977,0.000021903552,0.0032458906,0.0012621712,0.00007946172,0.00351514],"genre_scores_gemma":[0.927952,0.00034626827,0.0046907472,0.000037423542,0.000061246225,0.0005422099,0.0013191984,0.000100543744,0.06495035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639904,0.00028282506,0.00039753315,0.0008899069,0.0010849952,0.00094571174],"domain_scores_gemma":[0.9955872,0.0008228489,0.00026266402,0.00089502253,0.0018680396,0.00056418503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000685519,0.0005367581,0.0009986894,0.00039618582,0.00092274125,0.00014306823,0.00030742178,0.00021513719,0.000079893165],"category_scores_gemma":[0.0006055622,0.00032462217,0.000103171646,0.00045142486,0.0010025756,0.000250699,0.00014936773,0.0004906808,0.000025774394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09645427,0.00054026226,0.8763504,0.0007922299,0.0014299521,0.00054491014,0.006533024,0.0000010878351,0.004741941,0.00022309167,0.010130033,0.0022588046],"study_design_scores_gemma":[0.11365578,0.042041812,0.624142,0.005291669,0.0014574154,0.0001326227,0.027496992,0.000575078,0.1311492,0.00012742417,0.051659305,0.002270724],"about_ca_topic_score_codex":0.0001575821,"about_ca_topic_score_gemma":0.00042149844,"teacher_disagreement_score":0.2522084,"about_ca_system_score_codex":0.00038498902,"about_ca_system_score_gemma":0.0010971556,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W2593231312","doi":"10.1016/s2352-3018(17)30032-2","title":"Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","year":2017,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care","funders":"","keywords":"Emtricitabine; Rilpivirine; Tenofovir alafenamide; Efavirenz; Medicine; Regimen; Tolerability; Placebo; Internal medicine; Pharmacology; Virology; Adverse effect; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.020916609253126443,"score_gpt":0.3013084049091931,"score_spread":0.28039179565606664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593231312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888252,0.00013446782,0.00026066348,0.0036530558,0.00006370989,0.0060467157,0.00006740937,0.00012361453,0.0008251817],"genre_scores_gemma":[0.99627495,0.00013745687,0.00093602913,0.00015736505,0.00023080205,0.00047067244,0.00015609835,0.000068681715,0.001567926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972467,0.00011260308,0.0006061618,0.00083268806,0.00049150956,0.0007103797],"domain_scores_gemma":[0.99786174,0.0002168103,0.00036433467,0.0010566763,0.00016245023,0.0003379706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005765366,0.00064025656,0.0013642627,0.00027374123,0.00064583204,0.0002986216,0.00028201638,0.000107826236,0.000024363533],"category_scores_gemma":[0.000100093865,0.00036185404,0.00005670457,0.0003948908,0.00014229602,0.0004938516,0.00025956938,0.00050355354,0.00003491577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19741526,0.0016790958,0.78823924,0.000103874205,0.0006113592,0.00049987395,0.00790041,0.000056050358,0.000762351,0.0000049983887,0.00012831212,0.0025991558],"study_design_scores_gemma":[0.39996758,0.0010050389,0.5942431,0.00049705454,0.0005776369,0.000042063337,0.00042040253,0.0021726121,0.00048005578,0.000018154687,0.00014683603,0.00042943726],"about_ca_topic_score_codex":0.0017487059,"about_ca_topic_score_gemma":0.0041087773,"teacher_disagreement_score":0.2025523,"about_ca_system_score_codex":0.00016976526,"about_ca_system_score_gemma":0.00024121767,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W2593423583","doi":"10.1016/s2352-3018(17)30031-0","title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","year":2017,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care","funders":"Gilead Sciences","keywords":"Rilpivirine; Emtricitabine; Tenofovir alafenamide; Medicine; Regimen; Placebo; Cobicistat; Internal medicine; Tolerability; Clinical endpoint; Pharmacology; Randomized controlled trial; Human immunodeficiency virus (HIV); Virology; Adverse effect; Viral load; Antiretroviral therapy","score_opus":0.023017805838606284,"score_gpt":0.3063705951627395,"score_spread":0.2833527893241332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593423583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98806596,0.000056679273,0.00030768974,0.004248276,0.00006866809,0.0059944605,0.00005402908,0.0001245569,0.0010796832],"genre_scores_gemma":[0.99628145,0.00007411539,0.00092646613,0.00016685773,0.00025506894,0.00048798954,0.00016940571,0.00006130722,0.0015773268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751884,0.00009994963,0.0005344872,0.000707769,0.00048066693,0.0006582642],"domain_scores_gemma":[0.9979421,0.00015905061,0.00032975376,0.0011365942,0.00015140383,0.0002810908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052910706,0.00054887444,0.0012013736,0.00020165165,0.00056945265,0.00023610039,0.00030744998,0.00008946337,0.000041019943],"category_scores_gemma":[0.000077935445,0.0003015608,0.000060785078,0.00030726206,0.00010536635,0.00041436567,0.00021124534,0.00046604802,0.00007186406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24693373,0.0019246121,0.739083,0.00007549929,0.0006340816,0.000544236,0.0081538465,0.0000921846,0.0007086361,0.000004677805,0.00014874773,0.0016967442],"study_design_scores_gemma":[0.4623238,0.00093827746,0.5317536,0.0005389266,0.00051063986,0.000029504949,0.00045812488,0.002084271,0.00072105526,0.000014953218,0.00023163283,0.00039521552],"about_ca_topic_score_codex":0.0018720451,"about_ca_topic_score_gemma":0.0067467317,"teacher_disagreement_score":0.2153901,"about_ca_system_score_codex":0.00016413369,"about_ca_system_score_gemma":0.00019424313,"threshold_uncertainty_score":0.9999437},"labels":[],"label_agreement":null},{"id":"W2594780159","doi":"","title":"Etravirine(Intelence) for HIV infection.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Western University; University of Toronto","funders":"","keywords":"Etravirine; Human immunodeficiency virus (HIV); Virology; Medicine; Antiretroviral therapy; Viral load","score_opus":0.03761676306691787,"score_gpt":0.2441633626910776,"score_spread":0.20654659962415972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594780159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94447535,0.0002617931,0.0016260803,0.012489877,0.00044953468,0.0029995998,0.000011503298,0.00028493197,0.037401304],"genre_scores_gemma":[0.8295542,0.00014058474,0.0010796692,0.0002162367,0.00021793514,0.0025115188,0.000038607053,0.000015186334,0.16622603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993122,0.000006535039,0.00013723315,0.00016170689,0.00012319698,0.0002590798],"domain_scores_gemma":[0.99963087,0.000037506525,0.000025583671,0.00012013175,0.000055543598,0.00013035306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008748277,0.000095960495,0.00015161192,0.00008772844,0.00008769664,0.0000052154123,0.000027059714,0.00004200182,0.00006622252],"category_scores_gemma":[0.00008768204,0.000076094504,0.000081601385,0.000115177776,0.000036549336,0.00004952965,0.000011436759,0.000056093082,0.00010751087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021384076,0.000526431,0.66712415,0.000079115074,0.00028743542,0.000092547445,0.00044073444,0.0000018327174,0.000022015434,0.00043469784,0.20034583,0.13043138],"study_design_scores_gemma":[0.001538859,0.000016308346,0.6470944,0.000006651611,0.00004712195,0.00009942999,0.0000071941845,0.000013392131,0.0019310609,0.000053611464,0.34910977,0.00008218767],"about_ca_topic_score_codex":0.0000064056553,"about_ca_topic_score_gemma":0.0000058059645,"teacher_disagreement_score":0.14876394,"about_ca_system_score_codex":0.00008406169,"about_ca_system_score_gemma":0.00004158238,"threshold_uncertainty_score":0.3103044},"labels":[],"label_agreement":null},{"id":"W2598099381","doi":"10.1039/c7md00052a","title":"Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity","year":2017,"lang":"en","type":"article","venue":"MedChemComm","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Structural Genomics Consortium; Toronto Public Health","funders":"Novartis Pharma; Ministero dello Sviluppo Economico; Wellcome Trust; Agence Nationale de la Recherche; Wellcome; Imperial College London; Cancer Research UK; Ontario Ministry of Economic Development and Innovation; Alliance Française contre les Maladies Parasitaires; European Federation of Pharmaceutical Industries and Associations; Fundação de Amparo à Pesquisa do Estado de São Paulo; Genome Canada; European Commission; Pfizer","keywords":"Lysine; Methyltransferase; Histone; Biology; Quinazoline; Computational biology; Chemistry; Biochemistry; Methylation; Gene; Stereochemistry; Amino acid","score_opus":0.05188663878967256,"score_gpt":0.31464778519907816,"score_spread":0.2627611464094056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598099381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742425,0.00005963734,0.0029805286,0.008312236,0.00009186468,0.000709992,0.00008159498,0.000035198256,0.0003047209],"genre_scores_gemma":[0.9945054,0.000041311378,0.0040420257,0.000020393709,0.000041223055,0.00003877292,0.00017133722,0.000021375095,0.0011181589],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907595,0.00006259094,0.00016447454,0.00028097775,0.00024107854,0.00017493889],"domain_scores_gemma":[0.99899495,0.00016601494,0.00020677826,0.00042215642,0.00010310442,0.00010698474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003148654,0.00019735111,0.00042113135,0.00011181217,0.0004327656,0.000029669678,0.000057732184,0.00015889121,0.00003541492],"category_scores_gemma":[0.00021196288,0.00016772619,0.00009087799,0.000058576254,0.00014196303,0.00033574746,0.000029871822,0.00020938023,0.0000019287195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012185158,0.0007706734,0.21617836,0.00071426475,0.0005224068,0.00002361742,0.0019840205,0.0000041583953,0.7411087,0.00066664256,0.0012424379,0.0355662],"study_design_scores_gemma":[0.0028430605,0.000055752254,0.29562443,0.000092117334,0.00028592703,0.000013604362,0.00003057293,0.0002854522,0.6993965,0.0006733406,0.00056684966,0.00013243462],"about_ca_topic_score_codex":0.00005184692,"about_ca_topic_score_gemma":0.00016017929,"teacher_disagreement_score":0.07944606,"about_ca_system_score_codex":0.00011848432,"about_ca_system_score_gemma":0.000078329555,"threshold_uncertainty_score":0.68396753},"labels":[],"label_agreement":null},{"id":"W2599305164","doi":"10.1128/jvi.00079-17","title":"Correction for Baig et al., Determinants of Efficient Degradation of APOBEC3 Restriction Factors by HIV-1 Vif","year":2017,"lang":"en","type":"erratum","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Biology; Human immunodeficiency virus (HIV); Genetics; Virology","score_opus":0.021186248814600704,"score_gpt":0.31603070141803485,"score_spread":0.29484445260343417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599305164","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94257766,0.0016819019,0.0035733923,0.0035669087,0.045135874,0.0011339708,0.00025936012,0.00001731289,0.002053592],"genre_scores_gemma":[0.42521605,0.012498068,0.0029870903,0.000568499,0.0014747514,0.000061539795,0.0031661089,0.00023061887,0.5537973],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981388,0.000099488614,0.00097858,0.00019693267,0.00038852732,0.00019766751],"domain_scores_gemma":[0.99611497,0.00020617431,0.0029554656,0.00023282679,0.00041126614,0.000079304344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004803541,0.00024509805,0.001012287,0.0005688822,0.00007595801,0.000007835759,0.00014093734,0.00041848244,0.000022872764],"category_scores_gemma":[0.0005232634,0.00018456393,0.000313961,0.00007948026,0.00008633567,0.00006827144,0.0000259233,0.0004927111,0.0000023519242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083853194,0.0004954923,0.01125265,0.000121493395,0.00030639148,0.00001802938,0.00018342223,0.000014666644,0.0025778415,0.0000026156972,0.9816702,0.002518678],"study_design_scores_gemma":[0.006158215,0.004714695,0.05666647,0.0013771938,0.0018886416,0.00037194596,0.00020952141,0.001714807,0.017306557,0.000026547135,0.90924364,0.0003217677],"about_ca_topic_score_codex":0.000035763136,"about_ca_topic_score_gemma":0.000029386703,"teacher_disagreement_score":0.5517437,"about_ca_system_score_codex":0.00019578448,"about_ca_system_score_gemma":0.0005665518,"threshold_uncertainty_score":0.7526299},"labels":[],"label_agreement":null},{"id":"W2600324759","doi":"10.1097/qad.0000000000001476","title":"Individualized antiretroviral therapeutic approaches","year":2017,"lang":"en","type":"editorial","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Intensive care medicine; Virology; Viral load","score_opus":0.045683321960452654,"score_gpt":0.30606435938681403,"score_spread":0.2603810374263614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600324759","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016137329,0.0024784652,0.000029217947,0.0005749907,0.92931,0.000929291,0.0001615784,0.00023149817,0.06467122],"genre_scores_gemma":[0.014111784,0.00037508877,0.0020447255,0.00005008742,0.7098836,0.00012597347,0.003429843,0.00012541475,0.2698535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976344,0.00006536324,0.00033040406,0.00055369653,0.0009907754,0.00042537082],"domain_scores_gemma":[0.9984414,0.00019583073,0.0002541712,0.00086723815,0.000089770205,0.00015159273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003514473,0.00047904698,0.0009238912,0.00022020478,0.00021681505,0.00012266506,0.00033964566,0.000859203,0.00017965098],"category_scores_gemma":[0.00026879692,0.00035955047,0.0002894377,0.00008572758,0.00014769651,0.000091515874,0.000120630495,0.00069994514,0.00047597467],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012818651,0.00019507276,0.010511196,0.00015429004,0.0011949397,0.0001192542,0.00035014417,1.5198951e-8,0.000007112545,0.0000949135,0.948905,0.038339857],"study_design_scores_gemma":[0.0034793275,0.00042368006,0.0006503043,0.00023599993,0.001065295,0.0000059329927,0.000039786974,0.0000029273306,0.00014228426,0.00013267824,0.9934664,0.00035538655],"about_ca_topic_score_codex":0.000023003618,"about_ca_topic_score_gemma":0.0000023561277,"teacher_disagreement_score":0.21942641,"about_ca_system_score_codex":0.00015133139,"about_ca_system_score_gemma":0.00080561795,"threshold_uncertainty_score":0.9998856},"labels":[],"label_agreement":null},{"id":"W2600456904","doi":"","title":"La mégère apprivoisée : élaborer des stratégies pour la gestion de la résistance aux médicaments dans la grippe et l'infection par le virus de l'immunodéficience humaine","year":2012,"lang":"fr","type":"dissertation","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Center for AIDS Research, University of Washington; National Institutes of Health; Robert Koch Institut; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Deutsche Forschungsgemeinschaft; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Tulane University","keywords":"Gynecology; Human immunodeficiency virus (HIV); Humanities; Medicine; Philosophy; Virology","score_opus":0.012428434023237801,"score_gpt":0.29938506219304417,"score_spread":0.2869566281698064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600456904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91006917,0.0030851008,0.0120933065,0.0009429954,0.000363496,0.0006888652,0.000057445493,0.00027507948,0.07242455],"genre_scores_gemma":[0.93849874,0.0050768144,0.009293117,0.000082631195,0.0001570141,0.00031792055,0.0010450282,0.00012052815,0.04540818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951492,0.001663822,0.0007581434,0.0007321726,0.000654418,0.0010422323],"domain_scores_gemma":[0.9974304,0.0010740216,0.00040713843,0.00044719092,0.00026480202,0.00037645947],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002445779,0.0008628906,0.0007199579,0.00031010274,0.00073120254,0.00025603635,0.00027287178,0.0010903289,0.0003006069],"category_scores_gemma":[0.00049896725,0.00079195475,0.00025416206,0.0005491175,0.0008014147,0.0005295073,0.00006669304,0.0010697686,0.00019018163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061684643,0.005728625,0.6411603,0.0015586417,0.00125854,0.00045349606,0.04563041,0.0003808241,0.1564705,0.115643404,0.0019959246,0.029102448],"study_design_scores_gemma":[0.0026075074,0.000118790704,0.92895573,0.0022279613,0.00089000765,0.00028189202,0.009389968,0.0003975426,0.03562248,0.0015059061,0.017211597,0.00079061143],"about_ca_topic_score_codex":0.0049576494,"about_ca_topic_score_gemma":0.0050049014,"teacher_disagreement_score":0.2877954,"about_ca_system_score_codex":0.0012697052,"about_ca_system_score_gemma":0.0025866749,"threshold_uncertainty_score":0.9994531},"labels":[],"label_agreement":null},{"id":"W2604690888","doi":"10.1097/qad.0000000000001494","title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","year":2017,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; AIDS Vancouver","funders":"","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase inhibitor; Medicine; Hazard ratio; Drug resistance; Proportional hazards model; Virology; Integrase; Poisson regression; Internal medicine; Confidence interval; Viral load; Population; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Genetics; Environmental health","score_opus":0.013648140938471552,"score_gpt":0.2577449524362835,"score_spread":0.24409681149781193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604690888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735596,0.00022843838,0.0006645186,0.010070137,0.00013845084,0.0004570325,0.0000123538985,0.00007418319,0.014795252],"genre_scores_gemma":[0.9186722,0.000032831907,0.002925033,0.00014998288,0.00007419614,0.000044127122,0.000036527395,0.000027008397,0.078038104],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989224,0.00002180035,0.00019041674,0.00029920597,0.00031166186,0.0002545001],"domain_scores_gemma":[0.99905473,0.000022148433,0.000040797473,0.00061819085,0.0000783178,0.00018581763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013972633,0.00020671832,0.00027626197,0.00007263522,0.0002714176,0.000041328483,0.00011425501,0.000048262853,0.00023836677],"category_scores_gemma":[0.000021973692,0.00013818643,0.00008712944,0.00006706043,0.00012581052,0.000092103604,0.000010206734,0.00013862038,0.00006722304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009882267,0.0031907237,0.781097,0.0007994901,0.0027401212,0.0038427121,0.0066633,0.000008778536,0.011914827,0.005990471,0.15775281,0.016117528],"study_design_scores_gemma":[0.040734015,0.001166179,0.09827295,0.002874736,0.0019225361,0.000033177177,0.001078597,0.000056760207,0.40435624,0.00032971238,0.44773763,0.0014374609],"about_ca_topic_score_codex":0.000028169274,"about_ca_topic_score_gemma":0.00023710397,"teacher_disagreement_score":0.682824,"about_ca_system_score_codex":0.0000715988,"about_ca_system_score_gemma":0.00017276796,"threshold_uncertainty_score":0.5635079},"labels":[],"label_agreement":null},{"id":"W2604758836","doi":"10.1158/1557-3125.dnarepair16-pr09","title":"Abstract PR09: APOBEC3A sensitizes leukemia cells to inhibitors of the replication checkpoint","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Leukemia; Cancer research; DNA damage; Myeloid leukemia; Mutagenesis; DNA; Genetics; Mutation; Gene","score_opus":0.05334662400103262,"score_gpt":0.39441150993028057,"score_spread":0.34106488592924794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604758836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722657,0.0001620934,0.000014789195,0.019298892,0.000102699916,0.00097251596,0.000008587908,0.000014890962,0.007159809],"genre_scores_gemma":[0.98999286,0.00006344728,0.0003230528,0.00010901877,0.000081310194,0.00014948742,0.0000054400657,0.000024865461,0.0092505235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998176,0.00005930427,0.00023140004,0.00037138327,0.00084087276,0.00032105547],"domain_scores_gemma":[0.99784696,0.000029399274,0.00009937369,0.0015202244,0.00035004818,0.0001539688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077834865,0.000115297335,0.00019446459,0.000113745686,0.00029656445,0.000050067563,0.00027838597,0.000069347356,0.00007608954],"category_scores_gemma":[0.00028869588,0.000078997444,0.00011103774,0.00018076685,0.00016849765,0.000039660405,0.00024457442,0.00026749057,0.0000925515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011700941,0.00006537333,0.004242189,0.000101959646,0.0000934038,0.00006775967,0.00053901545,0.000025192263,0.97470546,0.000073375544,0.009210418,0.01075885],"study_design_scores_gemma":[0.00055745954,0.000035810503,0.051364478,0.00027613042,0.000022105134,0.0000032832545,0.00006267458,0.00002217642,0.93648165,0.00005712792,0.011043597,0.000073501564],"about_ca_topic_score_codex":0.0010679244,"about_ca_topic_score_gemma":0.00011340862,"teacher_disagreement_score":0.04712229,"about_ca_system_score_codex":0.0005598214,"about_ca_system_score_gemma":0.0007833703,"threshold_uncertainty_score":0.32214224},"labels":[],"label_agreement":null},{"id":"W2604771433","doi":"10.1016/j.bcp.2017.04.001","title":"Guanine α-carboxy nucleoside phosphonate (G-α-CNP) shows a different inhibitory kinetic profile against the DNA polymerases of human immunodeficiency virus (HIV) and herpes viruses","year":2017,"lang":"en","type":"article","venue":"Biochemical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"DNA polymerase; Polymerase; Nucleotide; Guanine; Nucleoside; Enzyme; DNA; Reverse transcriptase; Biochemistry; Biology; Nucleoside triphosphate; Phosphonate; Chemistry; Molecular biology; Stereochemistry; RNA","score_opus":0.019826384616680216,"score_gpt":0.30113485665583234,"score_spread":0.2813084720391521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604771433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99007696,0.005906751,0.0000012224481,0.0016630905,0.00025651706,0.00063230464,0.000048780727,0.000055216286,0.0013591456],"genre_scores_gemma":[0.9969648,0.00042165225,0.00006697451,0.00073416904,0.00016904791,0.00012085908,0.000039092607,0.00003480775,0.0014485971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841833,0.00006125794,0.0004471099,0.00042576215,0.00024778667,0.0003997261],"domain_scores_gemma":[0.9989963,0.00010822942,0.0002632534,0.0004097154,0.0000681525,0.00015430737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108233566,0.0003297947,0.00051916816,0.00007840426,0.0003802546,0.000030615058,0.0003073822,0.00013649378,0.00044045775],"category_scores_gemma":[0.00005855807,0.000214366,0.00012456048,0.00006101626,0.0008465642,0.000057774836,0.00032561846,0.00020639213,0.000025803543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031101072,0.0008371767,0.0036373362,0.00007195719,0.00024210618,0.000046512785,0.00030551973,1.00073756e-7,0.97162026,0.000043214888,0.021366429,0.00151837],"study_design_scores_gemma":[0.0033362138,0.00016538784,0.016502142,0.000084973166,0.0003337921,0.000015660264,0.000074163996,0.000057544836,0.97608656,0.000021447699,0.0031079615,0.00021415879],"about_ca_topic_score_codex":0.00007606749,"about_ca_topic_score_gemma":0.000004336823,"teacher_disagreement_score":0.018258467,"about_ca_system_score_codex":0.00007111301,"about_ca_system_score_gemma":0.00007282535,"threshold_uncertainty_score":0.87415916},"labels":[],"label_agreement":null},{"id":"W2605993465","doi":"10.1186/s12879-017-2379-8","title":"Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients","year":2017,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; University of Ottawa; McGill University Health Centre; University of British Columbia; Maple Leaf Medical Clinic; Women's College Hospital; St. Paul's Hospital; Ottawa Hospital; University Health Network; University of Toronto; Regina Qu'Appelle Health Region; St. Michael's Hospital","funders":"National Institute on Drug Abuse; Lady Davis Institute for Medical Research; National Institutes of Health; Canadian Institutes of Health Research; Ministry of Health, British Columbia; Memorial University of Newfoundland; University of Waterloo; University of Toronto; Simon Fraser University; University of Ottawa; McGill University; Institute for Clinical Evaluative Sciences; Public Health Agency of Canada; Ontario HIV Treatment Network; McMaster University; Ottawa Hospital Research Institute; Université de Montréal; Cancer Care Ontario; Stryker; Public Health Agency","keywords":"Darunavir; Ritonavir; Atazanavir; Antiretroviral therapy; Medicine; Medical microbiology; Virology; Internal medicine; Human immunodeficiency virus (HIV); Pharmacology; Viral load","score_opus":0.030112662576001863,"score_gpt":0.3426403028199819,"score_spread":0.31252764024398005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605993465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995842,0.00076385395,0.00018280836,0.000092381684,0.000350869,0.0015328834,0.00043704206,0.00012669565,0.00067146536],"genre_scores_gemma":[0.9975505,0.0000676449,0.0006923084,0.0000936709,0.00016278759,0.0001640548,0.00063077465,0.00006123443,0.0005770351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979868,0.00006248643,0.00052522897,0.0005449625,0.0004427996,0.00043770933],"domain_scores_gemma":[0.99811786,0.00019086554,0.00045562207,0.0007040504,0.0002493497,0.00028224118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011510154,0.00041151454,0.0008279862,0.00019103126,0.0006810474,0.00012055082,0.00019378986,0.00013982465,0.00003788257],"category_scores_gemma":[0.0002866408,0.00034932053,0.00032573068,0.000095822455,0.00037602108,0.000309202,0.000087856686,0.00013145998,0.000012993899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010660159,0.0025973623,0.9705944,0.00031015434,0.00019407565,0.000007908234,0.00011409985,0.0000027223352,0.00024623037,0.00010633072,0.0008259986,0.023934668],"study_design_scores_gemma":[0.014406103,0.002930231,0.9767412,0.00020869779,0.000387283,0.0000028491777,0.000044595712,0.0006509638,0.002779202,0.00009963078,0.0013823941,0.00036683603],"about_ca_topic_score_codex":0.00017811194,"about_ca_topic_score_gemma":0.00004962026,"teacher_disagreement_score":0.023567833,"about_ca_system_score_codex":0.00010608659,"about_ca_system_score_gemma":0.00029905088,"threshold_uncertainty_score":0.9998959},"labels":[],"label_agreement":null},{"id":"W2606334551","doi":"10.1002/cpdd.358","title":"Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Merck","keywords":"Raltegravir; Pharmacokinetics; Bioavailability; Pharmacology; Medicine; Biopharmaceutics; Dosing; Biopharmaceutics Classification System; In vivo; Human immunodeficiency virus (HIV); Chemistry; Virology; Antiretroviral therapy; In vitro; Biological activity; Biology; Viral load; Biochemistry; Pharmacognosy; Biotechnology","score_opus":0.08495309511939617,"score_gpt":0.41743036901476527,"score_spread":0.3324772738953691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606334551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934002,0.00021244693,0.000024420357,0.0027838196,0.00067404966,0.0007805535,0.000009397805,0.000022009886,0.0020931126],"genre_scores_gemma":[0.9805075,0.00046773892,0.015905349,0.00026948447,0.00010052406,0.00003786967,0.000030811345,0.000021877098,0.0026588384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974546,0.00010949152,0.0014580223,0.00039585252,0.00025219168,0.00032988773],"domain_scores_gemma":[0.99802506,0.00065942266,0.0005999003,0.00030627678,0.0001779999,0.00023135287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008348278,0.00024644358,0.00080526574,0.00020300336,0.00014740303,0.000009388248,0.00024515323,0.00014719187,0.00013793848],"category_scores_gemma":[0.00036558445,0.00021240056,0.00011599375,0.000105667576,0.00059046404,0.00010113404,0.00025857438,0.0003261893,0.000018289722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001021389,0.0033553478,0.9116704,0.00022243618,0.00066647213,0.00012499538,0.0023154086,0.000011181669,0.01380762,0.000070685775,0.00622914,0.060504958],"study_design_scores_gemma":[0.019761747,0.00016482455,0.84492475,0.0002302719,0.00033272261,0.000013132438,0.000116813455,0.0006442402,0.1053385,0.00012996764,0.028055895,0.0002871191],"about_ca_topic_score_codex":0.000015476278,"about_ca_topic_score_gemma":0.00004154088,"teacher_disagreement_score":0.091530874,"about_ca_system_score_codex":0.000103357765,"about_ca_system_score_gemma":0.00040810238,"threshold_uncertainty_score":0.86614436},"labels":[],"label_agreement":null},{"id":"W2610818384","doi":"10.1093/jac/dkx118","title":"HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters","year":2017,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"Center for AIDS Research, University of Washington; National Institute of Allergy and Infectious Diseases; Fonds de recherche du Québec; Vlaamse regering; Canadian Institutes of Health Research; Genome Canada; Fonds Wetenschappelijk Onderzoek; McGill University; National Institutes of Health; Case Western Reserve University; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Dolutegravir; Elvitegravir; Biology; Virology; Phylogenetic tree; Integrase; Genetics; Viral evolution; Cluster (spacecraft); Integrase inhibitor; Viral load; Human immunodeficiency virus (HIV); Genome; Gene; Antiretroviral therapy","score_opus":0.013703276979517637,"score_gpt":0.24774878468637168,"score_spread":0.23404550770685403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610818384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99146736,0.00015310208,0.00058650674,0.006682699,0.00027900975,0.00050501485,0.0000816985,0.000023476965,0.00022113639],"genre_scores_gemma":[0.97836363,0.00013647576,0.017890291,0.0022752124,0.00037309216,0.0000027764522,0.0001295859,0.00007187646,0.0007570681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981341,0.000057373127,0.0006873984,0.0003880233,0.0002518134,0.0004813411],"domain_scores_gemma":[0.9984906,0.000029967692,0.00060655316,0.00036270608,0.00020088379,0.00030930186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016157898,0.00046323836,0.00086463196,0.0003052936,0.00022309956,0.0002651594,0.00039833348,0.00019050155,0.000103271406],"category_scores_gemma":[0.00001720666,0.00033921152,0.0002107968,0.00015840707,0.000084742634,0.00022513233,0.00006358349,0.0005133507,0.000017689934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004563662,0.002021777,0.19719583,0.000048584407,0.00091475574,0.00060865056,0.012559834,0.00023658194,0.75831604,5.1939793e-7,0.019913035,0.003620717],"study_design_scores_gemma":[0.059017695,0.0013694902,0.073738545,0.005163195,0.00068349525,0.00017041057,0.0037574077,0.0014021137,0.84158033,0.000025772377,0.011602189,0.0014893459],"about_ca_topic_score_codex":0.00019686989,"about_ca_topic_score_gemma":0.0006042214,"teacher_disagreement_score":0.123457275,"about_ca_system_score_codex":0.00027908722,"about_ca_system_score_gemma":0.00033342297,"threshold_uncertainty_score":0.999906},"labels":[],"label_agreement":null},{"id":"W2611751186","doi":"10.1093/cid/cix428","title":"Patterns of Transmitted Drug Resistance and Virological Response to First-line Antiretroviral Treatment Among Human Immunodeficiency Virus–Infected People Who Use Illicit Drugs in a Canadian Setting","year":2017,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; AIDS Vancouver; University of British Columbia","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Medicine; Odds ratio; Drug resistance; Confidence interval; Reverse-transcriptase inhibitor; Virology; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Immunology; Antiretroviral therapy; Biology","score_opus":0.020388952332641878,"score_gpt":0.31965941494590255,"score_spread":0.2992704626132607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611751186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641067,0.00016248565,0.000009441827,0.0019080287,0.00007959794,0.0009975772,0.00023932366,0.0000795738,0.00011328689],"genre_scores_gemma":[0.997278,0.00036434882,0.000024356246,0.00018931608,0.000046890884,0.00010919335,0.00008261729,0.0000340769,0.0018712134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973101,0.00031686795,0.00090348034,0.00064684125,0.00023345725,0.00058925664],"domain_scores_gemma":[0.9972824,0.0008965613,0.00027257093,0.0006856568,0.00010843395,0.0007543874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005344704,0.00035600908,0.0009645474,0.00033616755,0.00059410307,0.00011168516,0.00015519318,0.00016501265,0.000060020924],"category_scores_gemma":[0.0017279523,0.0002899323,0.00026294292,0.00017649512,0.00023765393,0.00019125515,0.000071974086,0.00021760067,0.0000105216595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089916226,0.0013898343,0.9941889,0.00005965712,0.00013446086,0.00022302104,0.0016494443,0.0000043422297,0.00008681247,0.000020085576,0.000071788236,0.0012724627],"study_design_scores_gemma":[0.005216525,0.0009873599,0.99185413,0.00041806823,0.00025798942,0.0000023089074,0.000073485855,0.000074628595,0.000109875444,0.00003492509,0.0006941243,0.00027660278],"about_ca_topic_score_codex":0.086839825,"about_ca_topic_score_gemma":0.5111224,"teacher_disagreement_score":0.42428255,"about_ca_system_score_codex":0.00036768217,"about_ca_system_score_gemma":0.00032643718,"threshold_uncertainty_score":0.9999553},"labels":[],"label_agreement":null},{"id":"W2614550113","doi":"10.3109/9781420087369-7","title":"Antiretroviral therapy","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Antiretroviral therapy; Medicine; Human immunodeficiency virus (HIV); Virology; Viral load","score_opus":0.023586910572972984,"score_gpt":0.2547733457608349,"score_spread":0.2311864351878619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614550113","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001206679,0.00074692717,0.000023368084,0.0025732152,0.00014709079,0.00034955956,0.000009927318,0.00012810853,0.9959011],"genre_scores_gemma":[0.0019065964,0.0017541153,0.0005010212,0.000482808,0.00030602055,0.0000074977365,0.000057741698,0.00006281835,0.9949214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908906,0.0000027338133,0.00019580759,0.0002769664,0.0002579047,0.00017752474],"domain_scores_gemma":[0.9994719,0.000021754584,0.00005930291,0.00028917842,0.000049110575,0.00010877685],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000041280444,0.0002923448,0.00039971594,0.0001281858,0.0000328241,0.000008681422,0.00005423515,0.0002137091,0.012621174],"category_scores_gemma":[0.000002621584,0.00015804422,0.00018625136,0.000009090836,0.000052405565,0.000025119698,0.000023140026,0.000116652074,0.005052314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029216756,0.000104557585,0.003620054,0.000044591226,0.0014571758,0.0006733652,0.00011672747,1.5622671e-9,0.00018041462,0.3642841,0.18627454,0.4429523],"study_design_scores_gemma":[0.0017410344,0.00021215706,0.00013589162,0.00021772372,0.00006752114,0.000028279193,0.0000017300915,1.8978656e-7,0.00042259268,0.0026713668,0.9942792,0.00022231854],"about_ca_topic_score_codex":9.688778e-7,"about_ca_topic_score_gemma":0.0000011502586,"teacher_disagreement_score":0.8080047,"about_ca_system_score_codex":0.00009006015,"about_ca_system_score_gemma":0.00013267563,"threshold_uncertainty_score":0.99572235},"labels":[],"label_agreement":null},{"id":"W2616475084","doi":"10.1371/journal.pone.0174777","title":"Development and validation of reversed-phase HPLC gradient method for the estimation of efavirenz in plasma","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"Sun Pharma","keywords":"Efavirenz; Chromatography; Detection limit; High-performance liquid chromatography; Reverse-transcriptase inhibitor; Chemistry; Pharmacokinetics; Calibration curve; Tenofovir; Coefficient of variation; Standard curve; Elution; Reproducibility; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology; Pharmacology; Medicine","score_opus":0.08677250243587724,"score_gpt":0.34005902792712106,"score_spread":0.2532865254912438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616475084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531025,0.000037861522,0.0024761185,0.0010937187,0.00001499832,0.0008104584,0.0000071209074,0.0000061855626,0.00024329202],"genre_scores_gemma":[0.67519915,0.000029140992,0.32354343,0.000007960226,0.0000087638755,0.00009795637,0.000036778103,0.0000067335977,0.001070081],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993279,0.000016498889,0.00026626175,0.00011733716,0.00018485135,0.00008716489],"domain_scores_gemma":[0.99937177,0.00013938073,0.00019538919,0.00019820279,0.00006368405,0.000031597494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039646993,0.00007646664,0.00023628176,0.00007551148,0.000086123044,0.000007792129,0.000052960368,0.000032369077,0.000009339558],"category_scores_gemma":[0.00023930131,0.000053585667,0.000022397378,0.000038172217,0.00003606786,0.000059502527,0.000025613657,0.000035873756,0.000001916062],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003656302,0.019474056,0.10886405,0.0044796597,0.0043204213,0.000030739193,0.03730796,0.0001267468,0.10231146,0.005065896,0.0007577777,0.7136049],"study_design_scores_gemma":[0.0063403267,0.00015779216,0.024023747,0.0006506275,0.00044834346,0.0000019185306,0.00016454887,0.019400688,0.9482586,0.00015582403,0.0003122539,0.000085367545],"about_ca_topic_score_codex":0.00001536679,"about_ca_topic_score_gemma":0.000014993584,"teacher_disagreement_score":0.8459471,"about_ca_system_score_codex":0.000046997968,"about_ca_system_score_gemma":0.00006411014,"threshold_uncertainty_score":0.21851602},"labels":[],"label_agreement":null},{"id":"W2616754233","doi":"10.2147/ott.s136484","title":"The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia","year":2017,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation; Children's Hospital Foundation","keywords":"Nelfinavir; Protease inhibitor (pharmacology); Refractory (planetary science); Medicine; Leukemia; Human immunodeficiency virus (HIV); Protease; Pharmacology; Virology; Immunology; Chemistry; Antiretroviral therapy; Biology; Enzyme; Viral load","score_opus":0.034973207282945014,"score_gpt":0.2994211456358922,"score_spread":0.2644479383529472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616754233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91438574,0.063703604,0.0006944466,0.010448989,0.00039532743,0.0064047207,0.000062311454,0.000059299833,0.0038455408],"genre_scores_gemma":[0.91698235,0.056558613,0.0017966239,0.00022679666,0.00069726387,0.0011519183,0.000041947602,0.00005587761,0.022488587],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989073,0.000024454303,0.0002546014,0.00028376287,0.00022449461,0.00030533905],"domain_scores_gemma":[0.9986869,0.00021179466,0.00023917983,0.0006429216,0.00008617733,0.00013302894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002658395,0.0002556656,0.00032691102,0.00003909122,0.0010532427,0.0000832365,0.00017016771,0.000082300205,0.000013481004],"category_scores_gemma":[0.000034372628,0.00011007369,0.00017649333,0.000045935216,0.00018198918,0.0000693576,0.000019389798,0.000085923435,0.000006089205],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008075578,0.0076845847,0.15051624,0.00017998776,0.002975182,0.000030279929,0.009894547,0.000006702002,0.0046721105,0.0030737845,0.005210854,0.80768013],"study_design_scores_gemma":[0.018909464,0.0030085766,0.04486304,0.000030292284,0.0004861358,0.000027388387,0.00047575662,0.00073754543,0.0040143495,0.00050029677,0.9266229,0.0003242439],"about_ca_topic_score_codex":0.000065214896,"about_ca_topic_score_gemma":0.0000040577784,"teacher_disagreement_score":0.92141205,"about_ca_system_score_codex":0.00013408407,"about_ca_system_score_gemma":0.0003877843,"threshold_uncertainty_score":0.8100798},"labels":[],"label_agreement":null},{"id":"W2622470207","doi":"10.1186/s12977-017-0360-7","title":"HIV drug resistance against strand transfer integrase inhibitors","year":2017,"lang":"en","type":"review","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase; Integrase inhibitor; Drug resistance; Medicine; Biology; Virology; Pharmacology; Genetics; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.049074487715270516,"score_gpt":0.3381716428923646,"score_spread":0.2890971551770941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622470207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015593728,0.9807202,0.000024607823,0.0017496949,0.00045332752,0.0012343492,0.000094544965,0.000105052284,0.015462261],"genre_scores_gemma":[0.00014010671,0.8437377,0.00021320015,0.00010199171,0.00034674283,0.00014378176,0.00079428643,0.000097009986,0.15442517],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971358,0.00021642706,0.00088387995,0.00083323504,0.0003192129,0.0006114064],"domain_scores_gemma":[0.9982211,0.00017055603,0.00023237844,0.0010118742,0.00005990687,0.00030417717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034244478,0.0007661781,0.0031371298,0.0004082514,0.00020535593,0.000038515485,0.00033612302,0.00069322356,0.00017816736],"category_scores_gemma":[0.00011116751,0.0005460069,0.00087879895,0.00015211145,0.00029919288,0.00006706406,0.000051393512,0.0009839085,0.00068896974],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001912438,0.00028772376,0.0002283709,0.012717279,0.0016597395,0.002086794,0.0002799442,3.106695e-8,0.0000019876454,0.0002505668,0.05979593,0.9225004],"study_design_scores_gemma":[0.0014722847,0.000042032763,0.0000102347,0.0077301036,0.0022700771,0.000060263275,0.000011616794,3.30055e-7,0.000007365664,0.000015802703,0.987976,0.00040389306],"about_ca_topic_score_codex":0.0000032099374,"about_ca_topic_score_gemma":0.000089502944,"teacher_disagreement_score":0.92818004,"about_ca_system_score_codex":0.00032936674,"about_ca_system_score_gemma":0.0007476774,"threshold_uncertainty_score":0.9996991},"labels":[],"label_agreement":null},{"id":"W2624972996","doi":"10.1093/infdis/jix293","title":"High Time to Start Human Immunodeficiency Virus Type 1–Infected Patients on Integrase Inhibitors in Sub-Saharan Africa","year":2017,"lang":"en","type":"letter","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Virology; Integrase; Integrase inhibitor; Human immunodeficiency virus (HIV); Lentivirus; Medicine; Virus; Viral disease; Biology; Immunology; Antiretroviral therapy; Viral load","score_opus":0.010277010233055793,"score_gpt":0.2426741067535,"score_spread":0.2323970965204442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624972996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686591,0.0010579493,0.0000011345297,0.026587386,0.00079766073,0.00095000607,0.0001223174,0.000058172547,0.0017662626],"genre_scores_gemma":[0.96713,0.0006108513,0.000010465765,0.021903524,0.0018603329,0.000033964418,0.00049236114,0.00015646924,0.007802008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973944,0.00026646876,0.00080195116,0.00025351363,0.0008206433,0.00046306296],"domain_scores_gemma":[0.99769133,0.00022923903,0.0007819342,0.0006028399,0.000496019,0.00019864339],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029427928,0.0005107888,0.0008846228,0.00089641457,0.0003196013,0.00008392688,0.00035494703,0.0002484335,0.00044127528],"category_scores_gemma":[0.00052150665,0.000311141,0.00030288432,0.0003369387,0.00011306027,0.00012441233,0.000088380395,0.001355164,0.0009438677],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007120049,0.0016223711,0.014412587,0.00006232525,0.0005020459,0.0009128208,0.00028911125,0.0000135826685,0.00040141857,5.974583e-7,0.97979647,0.0012746893],"study_design_scores_gemma":[0.016059907,0.011597652,0.20183057,0.007209241,0.0048640906,0.0002812117,0.00003090255,0.000004852654,0.0024201584,0.00037557443,0.7536359,0.0016899357],"about_ca_topic_score_codex":0.000121221434,"about_ca_topic_score_gemma":0.00002222346,"teacher_disagreement_score":0.22616054,"about_ca_system_score_codex":0.00074110756,"about_ca_system_score_gemma":0.00039242193,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W2626729825","doi":"10.1093/jac/dkx195","title":"Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice","year":2017,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research; Universitätsspital Zürich; Universität Zürich; McGill University","keywords":"Dolutegravir; Raltegravir; Integrase inhibitor; Virology; Viral load; Pharmacology; Viral replication; Integrase; Biology; Medicine; Virus; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.016219545688388112,"score_gpt":0.296255890938481,"score_spread":0.28003634525009286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626729825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740741,0.000062928746,0.00026299065,0.023962937,0.0001638675,0.00065347203,0.000009370492,0.000022394597,0.00078789616],"genre_scores_gemma":[0.94626284,0.0006308337,0.027196154,0.0039521176,0.00044324397,0.000010703484,0.00000912389,0.00013602359,0.021358963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99807274,0.00005416955,0.00070845283,0.0003235761,0.0003809365,0.00046011395],"domain_scores_gemma":[0.9983383,0.000047751637,0.000621249,0.00051770353,0.00022892663,0.00024606712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003791369,0.0004059902,0.0009619368,0.00036891256,0.00020911187,0.00024173062,0.00049045787,0.0001552019,0.00038447723],"category_scores_gemma":[0.000032286207,0.00024883472,0.00021387829,0.0001805218,0.00011764752,0.0004212102,0.000027156799,0.000402366,0.000051460567],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04319842,0.0018915576,0.053036842,0.000112397734,0.0013473294,0.0021804736,0.0066006402,0.000021428272,0.81943357,0.000030642055,0.057629917,0.014516785],"study_design_scores_gemma":[0.07582537,0.0020366893,0.08522555,0.0025781495,0.0002714138,0.0018658375,0.0006103013,0.00002678176,0.7033794,0.000052212017,0.12702854,0.0010997426],"about_ca_topic_score_codex":0.00005839781,"about_ca_topic_score_gemma":0.00015579857,"teacher_disagreement_score":0.11605415,"about_ca_system_score_codex":0.00022654138,"about_ca_system_score_gemma":0.00036417285,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W2637190300","doi":"10.1007/978-3-319-46718-4_37","title":"HIV-1 Resistance to Integrase Inhibitors","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Integrase; Reverse transcriptase; Virology; Integrase inhibitor; Nevirapine; Human immunodeficiency virus (HIV); Drug resistance; Protease; Nucleoside Reverse Transcriptase Inhibitor; Medicine; Pharmacology; Drug; Antiretroviral therapy; Biology; Viral load; Enzyme; Microbiology; Genetics; Polymerase chain reaction","score_opus":0.018893833266302108,"score_gpt":0.2631449488154765,"score_spread":0.2442511155491744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2637190300","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044443885,0.00032527334,0.000047672238,0.011837896,0.00026989117,0.00064806914,0.000033162094,0.00011705375,0.9866765],"genre_scores_gemma":[0.0009650597,0.00012429601,0.003978386,0.00051380845,0.000361916,0.000029511055,0.00020237772,0.00007559932,0.993749],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985956,0.0000036086421,0.000317076,0.00047784197,0.00036642601,0.00023946541],"domain_scores_gemma":[0.9986042,0.000028208286,0.00012414144,0.0007890723,0.000115798786,0.00033861643],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009021406,0.0004113794,0.0005708308,0.00023359706,0.00011649147,0.000037616523,0.00014513887,0.00025022632,0.002470519],"category_scores_gemma":[0.000051702653,0.00030181726,0.00019307753,0.000011099033,0.000064588974,0.000038433544,0.000090783935,0.00027310333,0.007872536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001678133,0.000042229523,0.00029988127,0.00008397798,0.00037503717,0.0008211293,0.00022244707,1.8335053e-8,0.000014113633,0.036609307,0.95488924,0.0064748246],"study_design_scores_gemma":[0.00068075064,0.00004033013,0.000059329843,0.0013429063,0.00022411816,0.000011512277,0.000014068305,1.9135476e-7,0.0005448622,0.0012418146,0.9955251,0.00031499227],"about_ca_topic_score_codex":0.000005097226,"about_ca_topic_score_gemma":0.00021121437,"teacher_disagreement_score":0.040635902,"about_ca_system_score_codex":0.0002516487,"about_ca_system_score_gemma":0.00022502558,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W2654786797","doi":"10.1097/qad.0000000000001575","title":"Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection","year":2017,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; AIDS Vancouver; Simon Fraser University","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; Medical Research Council; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Wellcome Trust","keywords":"Human immunodeficiency virus (HIV); Medicine; Pre-exposure prophylaxis; Virology; Immunology; Immune system; Lentivirus; Viral load; Viral disease; Men who have sex with men","score_opus":0.01565204553304255,"score_gpt":0.2872757739418092,"score_spread":0.27162372840876664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2654786797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95931345,0.000030963558,0.036769174,0.0004449163,0.00028887446,0.0029271892,0.00007122962,0.00004693073,0.000107297325],"genre_scores_gemma":[0.9619853,0.0000025462539,0.029191326,0.000020916043,0.000145143,0.00043572774,0.00028661435,0.000031221065,0.007901223],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892086,0.000023104354,0.0003403287,0.00028291327,0.00019476727,0.00023802447],"domain_scores_gemma":[0.99904275,0.0000248064,0.00024142845,0.00044141835,0.00015890722,0.00009069755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016224569,0.00017942069,0.000376868,0.0001603559,0.00026591937,0.00003539674,0.00011604754,0.000110240326,0.00002666875],"category_scores_gemma":[0.000111518806,0.00015484534,0.0003064336,0.000056419205,0.000059426286,0.00013541323,0.000041166702,0.000060115482,0.000016509985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00489139,0.0016908369,0.64189154,0.00081568776,0.00066117186,0.0000118900725,0.00037427168,0.00013943402,0.2240532,0.00035360933,0.0017972804,0.12331966],"study_design_scores_gemma":[0.02486591,0.037462264,0.4317259,0.00066251727,0.0009950509,0.000010690724,0.000029627583,0.004646484,0.4960623,0.000408164,0.0025875065,0.00054360036],"about_ca_topic_score_codex":0.000048839134,"about_ca_topic_score_gemma":0.000005101886,"teacher_disagreement_score":0.27200907,"about_ca_system_score_codex":0.000077376884,"about_ca_system_score_gemma":0.00010399817,"threshold_uncertainty_score":0.631441},"labels":[],"label_agreement":null},{"id":"W2657999412","doi":"10.1071/sh16190","title":"Analysis of transmitted HIV drug resistance from 2005 to 2015 in Victoria, Australia: a comparison of the old and the new","year":2017,"lang":"en","type":"article","venue":"Sexual Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada)","funders":"","keywords":"Genital warts; Thrush; Medicine; Gonorrhea; Drug resistance; Human immunodeficiency virus (HIV); Human papilloma virus; Drug; Resistance (ecology); Virology; Syphilis; Internal medicine; Cancer; Pharmacology; Cervical cancer; Biology; Microbiology","score_opus":0.03730813676293031,"score_gpt":0.36875542457322885,"score_spread":0.33144728781029853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2657999412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91066146,0.0007322778,0.000036673016,0.08780396,0.000082816965,0.00051044655,0.00005272205,0.000004963466,0.00011465666],"genre_scores_gemma":[0.95561206,0.000036485668,0.000658199,0.00017855085,0.000040667852,0.000007208804,0.000024102774,0.0000058776573,0.043436866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987841,0.00010254851,0.00046469216,0.00018994835,0.00026570953,0.00019295326],"domain_scores_gemma":[0.998923,0.00011348846,0.0002658218,0.0005208467,0.000031476287,0.00014535006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039281754,0.000107323394,0.0006501314,0.0000960103,0.00010527154,0.000009561265,0.00016420803,0.000036530364,0.000038663347],"category_scores_gemma":[0.000043945915,0.00005915853,0.00005101188,0.0002515323,0.00010208679,0.000027842872,0.00002972801,0.00012304103,0.00000362405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010031811,0.0002392835,0.88815886,0.00008927495,0.00070154114,0.000002035225,0.036461882,0.00001248313,0.000053720738,0.00028473188,0.07196432,0.0010286691],"study_design_scores_gemma":[0.0044862977,0.00003459814,0.97827065,0.00017778898,0.00049845676,1.5321436e-7,0.0013798989,0.0001309211,0.00032959154,0.00010588019,0.014511057,0.00007471628],"about_ca_topic_score_codex":0.009082996,"about_ca_topic_score_gemma":0.09788442,"teacher_disagreement_score":0.09011177,"about_ca_system_score_codex":0.000082650746,"about_ca_system_score_gemma":0.00023118396,"threshold_uncertainty_score":0.9975156},"labels":[],"label_agreement":null},{"id":"W2669291943","doi":"10.1097/qai.0000000000001487","title":"Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?","year":2017,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism","keywords":"Abacavir; Medicine; Zidovudine; Human immunodeficiency virus (HIV); Virology; Family medicine; Antiretroviral therapy; Viral disease; Viral load","score_opus":0.040101126692650535,"score_gpt":0.2979542009404163,"score_spread":0.25785307424776577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2669291943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98226166,0.0046666483,0.0006228596,0.009584621,0.0004470583,0.0010087987,0.000040033545,0.00003988734,0.0013284092],"genre_scores_gemma":[0.9899478,0.0014126732,0.0027936164,0.000038981212,0.00009859301,0.0000718782,0.00004486068,0.00006859909,0.005522981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666595,0.000044143293,0.0013880499,0.0004399859,0.00084103685,0.0006208364],"domain_scores_gemma":[0.9967307,0.00023555354,0.0015390087,0.0007696907,0.00052464945,0.0002004139],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011887063,0.00041051517,0.0011371116,0.0006605764,0.0004015699,0.00011724611,0.0005357076,0.00013672857,0.000028513741],"category_scores_gemma":[0.0009513574,0.0002851338,0.0003691557,0.0003412872,0.00026335803,0.0006110937,0.000099582394,0.00020558527,0.00001928071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0579853,0.025575042,0.4122819,0.0045956695,0.011365715,0.2072561,0.07694452,0.0012965179,0.015795983,0.0010722401,0.04945599,0.13637502],"study_design_scores_gemma":[0.08732918,0.013808274,0.74657357,0.014878859,0.0023810628,0.046748497,0.0036785048,0.0022438478,0.029519584,0.0012154463,0.04914608,0.002477078],"about_ca_topic_score_codex":0.000048618036,"about_ca_topic_score_gemma":0.000043600518,"teacher_disagreement_score":0.33429167,"about_ca_system_score_codex":0.00025352227,"about_ca_system_score_gemma":0.0003501997,"threshold_uncertainty_score":0.99996006},"labels":[],"label_agreement":null},{"id":"W2704285213","doi":"10.1177/1060028017717018","title":"Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences","year":2017,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Toronto General Hospital","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of General Medical Sciences","keywords":"Cobicistat; Ritonavir; Medicine; Atazanavir; Pharmacology; Darunavir; Elvitegravir; Virology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.3547082306218688,"score_gpt":0.5143660171639742,"score_spread":0.15965778654210544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2704285213","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005586357,0.9939853,0.0000014693009,0.0011361782,0.0012115708,0.0016789793,0.00035018334,0.00009130089,0.0009864141],"genre_scores_gemma":[0.00021779546,0.9869422,0.00012274105,0.00041735283,0.0007343167,0.0002720939,0.0002927012,0.00014269348,0.010858117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624056,0.00015767117,0.0013820918,0.00075913244,0.00073984946,0.0007206792],"domain_scores_gemma":[0.99703735,0.00027335438,0.0013692478,0.0007096257,0.00019258565,0.0004178536],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038838087,0.0009965983,0.0034212987,0.00040687004,0.0001833211,0.00005386986,0.0006219179,0.00026941244,0.0015073968],"category_scores_gemma":[0.000031399835,0.0007288824,0.0012927791,0.00018705934,0.00029206832,0.0001778275,0.000064841544,0.00051025004,0.00015256568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008980163,0.0006975812,0.000056179437,0.008097947,0.00668114,0.00043341823,0.00018383535,9.5404815e-8,0.00070271955,0.000048760798,0.027123291,0.955077],"study_design_scores_gemma":[0.0043310695,0.00033041253,0.000008029317,0.0061452943,0.002526048,0.000023452032,0.000014155692,0.0000072227726,0.009021236,0.000040657236,0.97692806,0.0006243591],"about_ca_topic_score_codex":0.000028137023,"about_ca_topic_score_gemma":0.000002415815,"teacher_disagreement_score":0.95445263,"about_ca_system_score_codex":0.00009654215,"about_ca_system_score_gemma":0.0008444463,"threshold_uncertainty_score":0.99951625},"labels":[],"label_agreement":null},{"id":"W2714685582","doi":"10.1016/j.cmi.2017.06.014","title":"Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996–2016","year":2017,"lang":"en","type":"article","venue":"Clinical Microbiology and Infection","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Human immunodeficiency virus (HIV); Cohort; Drug resistance; Medicine; HIV drug resistance; Cohort study; Resistance (ecology); Drug; Virology; Internal medicine; Antiretroviral therapy; Biology; Psychiatry; Viral load; Microbiology","score_opus":0.021702309047899833,"score_gpt":0.3235793564215709,"score_spread":0.30187704737367105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2714685582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98860466,0.00024075988,0.00000693004,0.0038874384,0.0002582327,0.00012465,0.000025917841,0.0000094587585,0.0068419245],"genre_scores_gemma":[0.9779422,0.0003715019,0.00011594185,0.000097149525,0.000058587193,0.000008746513,0.00009719978,0.000005055008,0.021303598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912906,0.000065816195,0.000350013,0.00024400938,0.000015101059,0.0001960244],"domain_scores_gemma":[0.9994334,0.00007152588,0.0001389858,0.00021380826,0.000035756737,0.00010653939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005195627,0.00009404361,0.00033348295,0.00014773541,0.00015394336,0.0000066049533,0.000040051265,0.00017431082,0.000113701004],"category_scores_gemma":[0.00017627222,0.000074747266,0.00006943071,0.000051850133,0.00022996905,0.000050910854,0.000027065502,0.00018365624,0.00003085148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012493698,0.00014786501,0.9883238,0.000015412388,0.000075866265,0.000019950361,0.00004540385,1.5736305e-8,0.00013566761,0.00017201557,0.009667378,0.0012716574],"study_design_scores_gemma":[0.0019051883,0.000043790213,0.9119334,0.00010002639,0.000053987013,0.000017138942,0.000003062958,0.0000019243812,0.00014468438,0.000050241935,0.08568116,0.00006535147],"about_ca_topic_score_codex":0.0027497537,"about_ca_topic_score_gemma":0.30002755,"teacher_disagreement_score":0.29727778,"about_ca_system_score_codex":0.000056298075,"about_ca_system_score_gemma":0.0001256522,"threshold_uncertainty_score":0.71274513},"labels":[],"label_agreement":null},{"id":"W2725704509","doi":"10.1186/s12977-017-0361-6","title":"Tribute to Mark Wainberg","year":2017,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Alberta; McGill University; Western University","funders":"Lady Davis Institute for Medical Research; Jewish General Hospital","keywords":"Tribute; Medicine; Computational biology; Computer graphics (images); Computer science; Art history; Biology; History","score_opus":0.018000944317869912,"score_gpt":0.3067909784079255,"score_spread":0.2887900340900556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725704509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82683766,0.00007238293,0.00015406487,0.14254276,0.00033496317,0.00034825748,0.0000079622,0.00006725743,0.029634692],"genre_scores_gemma":[0.7883107,0.000026642067,0.0015963364,0.001129288,0.00015451106,0.000027854234,0.00001790044,0.000014098211,0.2087227],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916273,0.000021415311,0.00014256669,0.00024678904,0.00012018081,0.00030631633],"domain_scores_gemma":[0.9990807,0.000040915376,0.000058746642,0.0005939698,0.00003334908,0.00019232047],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013848329,0.000120831464,0.00028334488,0.000084642015,0.0002004957,0.000019252968,0.00014242048,0.00010277804,0.00043857077],"category_scores_gemma":[0.0002788719,0.000096127886,0.000067805406,0.000035550544,0.00006161116,0.00003793707,0.00010009932,0.00010607224,0.0015514622],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006969493,0.000215913,0.73001134,0.00002526549,0.00030469464,0.0008944947,0.0002801537,6.582875e-7,0.0034236042,0.00100768,0.23881897,0.024320269],"study_design_scores_gemma":[0.0018131036,0.00032398445,0.3558057,0.000014344175,0.00007771225,0.000056573645,0.00001035172,0.000013989637,0.0016186554,0.00018606852,0.6399695,0.00011000372],"about_ca_topic_score_codex":0.000018604098,"about_ca_topic_score_gemma":0.000034136032,"teacher_disagreement_score":0.40115052,"about_ca_system_score_codex":0.00007644434,"about_ca_system_score_gemma":0.000059692728,"threshold_uncertainty_score":0.999226},"labels":[],"label_agreement":null},{"id":"W2727134113","doi":"10.3917/reco.555.0973","title":"Accès aux multithérapies antirétrovirales du Sida","year":2004,"lang":"fr","type":"article","venue":"Revue économique","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Center for Interuniversity Research and Analysis on Organizations; Université du Québec à Montréal","funders":"","keywords":"Humanities; Political science; Human immunodeficiency virus (HIV); Gynecology; Philosophy; Medicine; Family medicine","score_opus":0.028615838666463687,"score_gpt":0.25153465932607594,"score_spread":0.22291882065961224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727134113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8337721,0.034421064,0.00063904934,0.113871194,0.0027432127,0.0011467417,0.00006395658,0.00020724513,0.0131354],"genre_scores_gemma":[0.7982935,0.015400985,0.012923379,0.00085293775,0.002964524,0.00010685812,0.00010651601,0.0001009396,0.16925038],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980355,0.00006438425,0.00057719916,0.0005606601,0.000066462526,0.0006957964],"domain_scores_gemma":[0.99875945,0.00015658882,0.00016740942,0.00047141028,0.000095777126,0.0003493671],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022907498,0.00046176306,0.0007093437,0.00019463304,0.00017786706,0.000081612416,0.00020112848,0.00031662724,0.00064261525],"category_scores_gemma":[0.00016273918,0.00046616056,0.00027323596,0.00018856996,0.0002490929,0.00034506584,0.00011076641,0.00030175832,0.0045256787],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048803023,0.0041870056,0.41878223,0.003317423,0.003569222,0.008024494,0.012178786,0.002086063,0.0028816306,0.28314355,0.029569618,0.23177193],"study_design_scores_gemma":[0.010281415,0.00044786718,0.02993776,0.004039335,0.00071951083,0.0008714226,0.00077533635,0.00065728725,0.014605852,0.0050575454,0.9314514,0.001155316],"about_ca_topic_score_codex":0.0005588209,"about_ca_topic_score_gemma":0.000619626,"teacher_disagreement_score":0.90188175,"about_ca_system_score_codex":0.0009908819,"about_ca_system_score_gemma":0.00093205046,"threshold_uncertainty_score":0.999779},"labels":[],"label_agreement":null},{"id":"W2735129180","doi":"10.1016/s2214-109x(17)30247-4","title":"Use of the GeneXpert tuberculosis system for HIV viral load testing in India","year":2017,"lang":"en","type":"letter","venue":"The Lancet Global Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"GeneXpert MTB/RIF; Tuberculosis; Medicine; Viral load; Virology; Private sector; Tuberculosis diagnosis; Human immunodeficiency virus (HIV); Public health; Economic growth; Mycobacterium tuberculosis; Pathology","score_opus":0.06913766374648572,"score_gpt":0.3369758627010361,"score_spread":0.26783819895455035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735129180","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027512977,0.0012117226,0.0000110978135,0.9638049,0.00074087706,0.002906355,0.00090990844,0.00007477603,0.0028274118],"genre_scores_gemma":[0.16511059,0.00043975792,0.008349637,0.80093294,0.011515147,0.0008449366,0.0008098731,0.00016006766,0.011837038],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977586,0.00018656504,0.00052873074,0.00034336816,0.0004954332,0.0006872643],"domain_scores_gemma":[0.9980031,0.00023821746,0.0005282245,0.0010493343,0.000113502734,0.00006762404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000594688,0.00031515764,0.0010687902,0.000038104467,0.00025121102,0.000037822923,0.0004614852,0.00027736474,0.0000026652358],"category_scores_gemma":[0.00020792853,0.00016417702,0.000169048,0.00015722292,0.0000962262,0.000044165816,0.00012268302,0.000548334,0.000019558234],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010883641,0.000040472547,0.0701246,0.001457418,0.00017335296,0.000063098196,0.0003397385,0.0000017571962,0.0000022389222,0.000090998044,0.9246826,0.0029148583],"study_design_scores_gemma":[0.004467712,0.00020522697,0.17788939,0.0072169187,0.00031829684,0.0002570572,0.00010050677,0.0002741526,0.00007267788,0.00013842483,0.8086566,0.00040304207],"about_ca_topic_score_codex":0.0013063229,"about_ca_topic_score_gemma":0.00013408778,"teacher_disagreement_score":0.16287191,"about_ca_system_score_codex":0.002129919,"about_ca_system_score_gemma":0.0014273241,"threshold_uncertainty_score":0.66949445},"labels":[],"label_agreement":null},{"id":"W2735576184","doi":"10.1016/s2352-3018(17)30095-4","title":"Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study","year":2017,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare","keywords":"Dolutegravir; Emtricitabine; Medicine; Abacavir; Atazanavir; Ritonavir; Lamivudine; Raltegravir; Regimen; Population; Viral load; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","score_opus":0.053532587897694564,"score_gpt":0.33669633711391955,"score_spread":0.283163749216225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735576184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855597,0.00020276349,0.000013592494,0.00331071,0.00014955281,0.0053311656,0.00052692986,0.000089587316,0.0018197522],"genre_scores_gemma":[0.9925884,0.00055056124,0.0002035475,0.00005293024,0.00014433876,0.0007384228,0.0015040026,0.000051351348,0.004166464],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973928,0.00026164413,0.000617069,0.00075593055,0.00039426525,0.000578342],"domain_scores_gemma":[0.99786735,0.0003310134,0.000469135,0.0009856595,0.00012718196,0.00021963552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010597588,0.00050492137,0.0012433925,0.00017813849,0.0006296882,0.00041219676,0.00035572416,0.0001296394,0.00002413084],"category_scores_gemma":[0.0003006466,0.00032855425,0.000027404916,0.00032211788,0.00021228974,0.0005718832,0.00041753257,0.0004336513,0.000051802752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62760985,0.013366431,0.27479765,0.0002327165,0.0027747154,0.0014233806,0.025637306,0.00001333432,0.002051086,0.00007449898,0.0036823314,0.048336707],"study_design_scores_gemma":[0.602994,0.0029058568,0.3899771,0.00040521054,0.000567694,0.00002455209,0.0004823719,0.0013882598,0.00013439552,0.0000946593,0.0006072894,0.0004185741],"about_ca_topic_score_codex":0.0028804413,"about_ca_topic_score_gemma":0.0022276,"teacher_disagreement_score":0.11517945,"about_ca_system_score_codex":0.0004389703,"about_ca_system_score_gemma":0.00022288706,"threshold_uncertainty_score":0.9999167},"labels":[],"label_agreement":null},{"id":"W2738541296","doi":"10.1016/s0140-6736(17)31917-7","title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":504,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Ottawa Hospital","funders":"Bristol-Myers Squibb","keywords":"Rilpivirine; Abacavir; Medicine; Lamivudine; Tolerability; Emtricitabine; Dosing; Internal medicine; Pharmacology; Adverse effect; Viral load; Virology; Human immunodeficiency virus (HIV)","score_opus":0.043063743959305054,"score_gpt":0.33840094762995726,"score_spread":0.2953372036706522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738541296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117965,0.000057956328,0.00009517209,0.0037014484,0.000104638355,0.002289188,0.000030378593,0.00002289655,0.0025186592],"genre_scores_gemma":[0.99755585,0.0002451992,0.0007652918,0.00005473284,0.00036591492,0.00012091363,0.000070296956,0.000018903007,0.0008029106],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998695,0.000099249475,0.0004058035,0.0003075472,0.00021470794,0.00027767854],"domain_scores_gemma":[0.99863154,0.00013284631,0.000352013,0.0007276412,0.000069503854,0.00008647907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010696308,0.0002120583,0.0008416797,0.00007240786,0.00022321437,0.00009989959,0.00021192453,0.000072727475,0.00001305178],"category_scores_gemma":[0.0003236546,0.00012606633,0.000035597383,0.00010968173,0.00015174,0.00021573035,0.00012941686,0.00026819386,0.00000860176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88319343,0.0022668696,0.07377625,0.0002752734,0.00041561032,0.00032745916,0.0026410217,0.0000038379208,0.00046429975,0.000024609237,0.001020272,0.03559105],"study_design_scores_gemma":[0.9172025,0.001373475,0.07660567,0.00095199456,0.000208047,0.000038412887,0.00008210133,0.00034148933,0.0014592331,0.000025236592,0.0015282814,0.0001836023],"about_ca_topic_score_codex":0.0011723291,"about_ca_topic_score_gemma":0.0012976784,"teacher_disagreement_score":0.03540745,"about_ca_system_score_codex":0.00005726747,"about_ca_system_score_gemma":0.00011372506,"threshold_uncertainty_score":0.51408356},"labels":[],"label_agreement":null},{"id":"W2739715939","doi":"10.1371/journal.pone.0181357","title":"Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Teva Pharmaceutical Industries; Gilead Sciences; GlaxoSmithKline","keywords":"Dolutegravir; Raltegravir; Etravirine; Elvitegravir; Virology; Ritonavir; Abacavir; Emtricitabine; Efavirenz; Lamivudine; Atazanavir; Stavudine; Darunavir; Nevirapine; Nelfinavir; Didanosine; Medicine; Viral load; Human immunodeficiency virus (HIV); Virus; Hepatitis B virus","score_opus":0.022605114864099378,"score_gpt":0.2613956555886105,"score_spread":0.2387905407245111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739715939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98353606,0.00050432316,0.0013374799,0.006062528,0.000059078448,0.003231732,0.00021852154,0.00009824674,0.0049520386],"genre_scores_gemma":[0.97208726,0.000008872806,0.020758266,0.000040879277,0.000044948258,0.0004277309,0.0000917775,0.00001897388,0.006521268],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919176,0.00002141984,0.00024211871,0.00019654569,0.00022187701,0.00012625448],"domain_scores_gemma":[0.99886394,0.000104364655,0.00022910665,0.00039039785,0.00035413966,0.000058052934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011549605,0.000117092175,0.00034827695,0.00006734414,0.00014597866,0.000025525373,0.00009630309,0.000039265404,0.000016552072],"category_scores_gemma":[0.00027622085,0.000097790406,0.000038684768,0.00005898954,0.00004538038,0.000070472335,0.000015990852,0.00003715633,0.000043893342],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022975596,0.043832004,0.62377447,0.011276244,0.0087302495,0.0003329132,0.036080938,0.000006765315,0.22789432,0.0017851412,0.019183775,0.0041275965],"study_design_scores_gemma":[0.021992467,0.0011339913,0.04664915,0.008197539,0.0017705701,0.0000013446908,0.0032387685,0.004529182,0.90995795,0.00007805187,0.0019138963,0.0005370772],"about_ca_topic_score_codex":0.0000037427778,"about_ca_topic_score_gemma":0.000038010876,"teacher_disagreement_score":0.68206364,"about_ca_system_score_codex":0.0001400566,"about_ca_system_score_gemma":0.00015905526,"threshold_uncertainty_score":0.3987777},"labels":[],"label_agreement":null},{"id":"W2741014493","doi":"10.1002/cjce.22955","title":"Design and scale‐up of an alkylated Minisci reaction to produce ethionamide with 4‐cyanopyridine as raw materials","year":2017,"lang":"en","type":"article","venue":"The Canadian Journal of Chemical Engineering","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Natural Science Foundation of Beijing Municipality; National Natural Science Foundation of China","keywords":"Alkylation; Catalysis; Chemistry; Raw material; Yield (engineering); Methanol; Recrystallization (geology); Nuclear chemistry; Organic chemistry; Materials science; Metallurgy","score_opus":0.013156047532008261,"score_gpt":0.23381940383057434,"score_spread":0.2206633562985661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741014493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951482,0.000036339,0.00008140217,0.00441107,0.00010717196,0.0001751135,0.0000014155646,0.000005328856,0.00003399648],"genre_scores_gemma":[0.99647963,0.0000030740146,0.0031014641,0.000036149784,0.00009333064,0.00000294235,0.0000030913116,0.000016993125,0.00026334068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993768,0.00001205653,0.00020696966,0.00009110011,0.00015159183,0.00016150452],"domain_scores_gemma":[0.9991083,0.000029585668,0.00012065625,0.00019486102,0.00011683283,0.0004297413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003599765,0.00010587064,0.0002373921,0.00010052647,0.0000756936,0.000037390153,0.000114115974,0.00005095296,0.00001363902],"category_scores_gemma":[0.00022092075,0.00006735576,0.00001849644,0.000050610077,0.00005605097,0.00009959906,0.000009259802,0.00012929422,0.0000019854388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002181574,0.000011076718,0.000197529,0.000026687747,0.00009850992,0.00009346342,0.0008692782,0.00024084165,0.9976386,0.00001187768,0.00011748638,0.00047653506],"study_design_scores_gemma":[0.00068104075,0.00013081769,0.002449878,0.0003674162,0.00009514627,0.0007438847,0.000018820709,0.00011191924,0.99514544,0.000015927764,0.00015879242,0.00008089043],"about_ca_topic_score_codex":0.00039713338,"about_ca_topic_score_gemma":0.00013415873,"teacher_disagreement_score":0.0043749204,"about_ca_system_score_codex":0.00009552224,"about_ca_system_score_gemma":0.00033554246,"threshold_uncertainty_score":0.2746688},"labels":[],"label_agreement":null},{"id":"W2742200330","doi":"10.1016/s2352-3018(17)30109-1","title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; University of British Columbia","funders":"World Health Organization","keywords":"Medicine; Lopinavir; Ritonavir; Regimen; Meta-analysis; Adverse effect; Internal medicine; Randomized controlled trial; Reverse-transcriptase inhibitor; Systematic review; Raltegravir; Viral load; MEDLINE; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.24034386631433577,"score_gpt":0.4170376145085893,"score_spread":0.1766937481942535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742200330","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025089716,0.9904166,0.00003574229,0.00041019672,0.00001722306,0.008196253,0.00062445895,0.000014160115,0.00026029244],"genre_scores_gemma":[0.00018819331,0.9863417,0.0010772124,0.000056503344,0.000105662686,0.0007762228,0.00053316925,0.000028613596,0.010892679],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99732786,0.00045605868,0.0013219411,0.00040906,0.00021006659,0.00027500946],"domain_scores_gemma":[0.99595916,0.0009967613,0.0017210043,0.0011354588,0.00010761855,0.00007996767],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00095581164,0.0005883179,0.019624347,0.000125657,0.00012827922,0.000019702422,0.00022216707,0.000105936975,0.00008698332],"category_scores_gemma":[0.00005105398,0.0002528461,0.0018529891,0.00027770275,0.00018051238,0.000033618482,0.000044029894,0.000087004955,0.000006050436],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023878798,0.00029023306,0.00006432587,0.54439384,0.44150513,0.000006347601,0.0006110911,7.7206204e-7,1.2986531e-7,0.000217078,0.0017013097,0.01097095],"study_design_scores_gemma":[0.0026841138,0.00066436897,0.000024033381,0.043273814,0.7689858,0.000022211809,0.000019122546,0.000010292152,0.0000021585383,0.000014105348,0.18407792,0.00022203462],"about_ca_topic_score_codex":0.000002879456,"about_ca_topic_score_gemma":0.000008739306,"teacher_disagreement_score":0.50112003,"about_ca_system_score_codex":0.000057441768,"about_ca_system_score_gemma":0.0001216634,"threshold_uncertainty_score":0.9999924},"labels":[],"label_agreement":null},{"id":"W2742218033","doi":"10.6000/1929-6029.2017.06.03.2","title":"A Smooth Test of Goodness-of-Fit for the Baseline Hazard Function for Time-to-First Occurrence in Recurrent Events: An Application to HIV Retention Data","year":2017,"lang":"en","type":"article","venue":"International Journal of Statistics in Medical Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Censoring (clinical trials); Goodness of fit; Statistics; Proportional hazards model; Mathematics; Hazard; Event (particle physics); Hazard ratio; Confidence interval","score_opus":0.15420581731420308,"score_gpt":0.48190537986138143,"score_spread":0.32769956254717836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742218033","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02532482,0.00011494788,0.92847806,0.040246937,0.0005787008,0.0020093687,0.0031751718,0.000003533193,0.00006848288],"genre_scores_gemma":[0.9505626,0.00043912066,0.04645826,0.000103241895,0.00050226017,0.00022358871,0.0011215017,0.000019442636,0.00057000766],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99697167,0.00007465895,0.0007622764,0.00020747303,0.0018040229,0.00017992008],"domain_scores_gemma":[0.9944939,0.0027368523,0.00032160108,0.000374084,0.0018805033,0.00019306099],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006638505,0.000081986575,0.00024226999,0.00041482828,0.0000772261,0.000025728043,0.0009923516,0.000056603032,0.00012260456],"category_scores_gemma":[0.02728782,0.000058393678,0.000035865633,0.00014338532,0.00010702822,0.00012689894,0.00019922397,0.00028093247,0.000011315736],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067682466,0.002891796,0.06546097,0.0002864732,0.00022324696,0.00004631025,0.00054820534,0.00009477166,0.00048822118,0.0016550305,0.04872422,0.8728125],"study_design_scores_gemma":[0.01953024,0.00570926,0.36950848,0.0080729695,0.00027452724,0.000057051107,0.0007802086,0.4059396,0.0008758604,0.011855756,0.17701668,0.00037937736],"about_ca_topic_score_codex":0.000034673158,"about_ca_topic_score_gemma":0.0003440703,"teacher_disagreement_score":0.9252378,"about_ca_system_score_codex":0.00021898627,"about_ca_system_score_gemma":0.00056912255,"threshold_uncertainty_score":0.9809058},"labels":[],"label_agreement":null},{"id":"W2742453534","doi":"10.1007/s12250-017-4002-y","title":"Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou, China","year":2017,"lang":"en","type":"article","venue":"Virologica Sinica","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Science Foundation of Jiangsu Province; Government of Jiangsu Province","keywords":"Drug resistance; Nevirapine; Efavirenz; Drug; Virology; HIV-1 protease; Resistance mutation; Mutation; Population; Reverse transcriptase; HIV drug resistance; Biology; Gene mutation; Medicine; Protease; Pharmacology; Virus; Viral load; Genetics; Polymerase chain reaction; Gene; Antiretroviral therapy; Enzyme","score_opus":0.013612985358714627,"score_gpt":0.26223530904889536,"score_spread":0.24862232369018072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742453534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846883,0.00020941206,0.000005545098,0.011858942,0.000046314755,0.00067905814,0.000025940575,0.000042264895,0.0024442119],"genre_scores_gemma":[0.9886884,0.00015362192,0.0007738145,0.000030050349,0.000027078382,0.000028561173,0.00010545757,0.000013194728,0.010179808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988187,0.000087183085,0.00042479025,0.00028429698,0.00022548021,0.00015955068],"domain_scores_gemma":[0.9984941,0.00012696577,0.0006311687,0.0006014616,0.00009240212,0.000053892116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024090808,0.00017331779,0.0004056608,0.00006444198,0.00029744295,0.000015237053,0.00014746579,0.0000923357,0.000044574404],"category_scores_gemma":[0.00043042307,0.00010302722,0.00008797896,0.00011720139,0.00025812758,0.000084317784,0.000090229616,0.000112909736,0.000005876895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007409432,0.00044230866,0.9917822,0.0001558002,0.00016115101,0.000021714834,0.000878987,0.0000067679057,0.0018981657,0.000466004,0.0023903542,0.001055596],"study_design_scores_gemma":[0.0019513164,0.000081873775,0.98565155,0.00021467441,0.00017989795,0.0000056904883,0.000022791652,0.00008442618,0.010292995,0.0005588626,0.0008578444,0.00009806804],"about_ca_topic_score_codex":0.00008732023,"about_ca_topic_score_gemma":0.00021500108,"teacher_disagreement_score":0.011828891,"about_ca_system_score_codex":0.00003703355,"about_ca_system_score_gemma":0.000036588026,"threshold_uncertainty_score":0.42013282},"labels":[],"label_agreement":null},{"id":"W2745634744","doi":"10.1093/jac/dkx280","title":"M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA","year":2017,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Virology; Chemistry; Human immunodeficiency virus (HIV); Biology; Biochemistry; Polymerase chain reaction; Gene","score_opus":0.02519497383542487,"score_gpt":0.2923863513285688,"score_spread":0.267191377493144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745634744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982219,0.0001206145,0.00025498305,0.015997859,0.00024870082,0.00047926157,0.00004274844,0.0000098029195,0.0006270533],"genre_scores_gemma":[0.99651396,0.001156384,0.0010965022,0.00022318229,0.00012762193,0.0000033245904,0.0000055438004,0.00002040327,0.0008530495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865663,0.00006703031,0.00050204457,0.00021646701,0.00027281654,0.0002850305],"domain_scores_gemma":[0.99873984,0.0000682382,0.00052965456,0.00039955243,0.00014935879,0.00011337394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006117502,0.00025111498,0.00063282653,0.00022724547,0.00037934378,0.000088641245,0.00025060232,0.000120845165,0.000051805197],"category_scores_gemma":[0.000044380027,0.00016926919,0.00028273082,0.00016444818,0.0005509014,0.00040346928,0.00002253696,0.00040642527,0.000006571549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047193565,0.0013841194,0.051058225,0.00013082485,0.00043398576,0.0003259594,0.0019925302,0.000011867604,0.9298513,0.00043498102,0.0075438037,0.0021130652],"study_design_scores_gemma":[0.021281319,0.0002556234,0.10259668,0.0007522732,0.0003965246,0.00045093324,0.0001678409,0.000030253517,0.86533505,0.00003628702,0.008382924,0.00031431683],"about_ca_topic_score_codex":0.000098079225,"about_ca_topic_score_gemma":0.00008158826,"teacher_disagreement_score":0.064516254,"about_ca_system_score_codex":0.00010846827,"about_ca_system_score_gemma":0.0003798583,"threshold_uncertainty_score":0.6902597},"labels":[],"label_agreement":null},{"id":"W2749244437","doi":"10.1016/j.ijid.2008.01.013","title":"Book review","year":2008,"lang":"en","type":"article","venue":"International Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Alternative medicine; Section (typography); Clinical trial; Family medicine; Intensive care medicine; Health care; Viral load; Pathology; Political science; Computer science","score_opus":0.009309966863391585,"score_gpt":0.28588984558743546,"score_spread":0.2765798787240439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749244437","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.122239776,0.8171049,0.00037195504,0.041591067,0.0021261326,0.0004629565,0.000029679684,0.0001093021,0.015964266],"genre_scores_gemma":[0.5822184,0.33969724,0.00024228854,0.045409817,0.0013580149,0.00001751643,0.000048707585,0.000032117518,0.030975847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990401,0.000018788158,0.00032724038,0.000067681896,0.0004676654,0.000078471145],"domain_scores_gemma":[0.999005,0.0000401194,0.00019445755,0.00006552969,0.0005511069,0.00014377378],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004721262,0.00008764211,0.0002198243,0.00015408895,0.000036268513,0.000007752565,0.000083791616,0.000017496972,0.0018063543],"category_scores_gemma":[0.00017629868,0.000063760155,0.00022064758,0.00006657424,0.000038206614,0.00014610223,0.000017934124,0.000081917424,0.00010599462],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084552106,0.00056610384,0.18214269,0.000059751106,0.00065833505,0.0021857847,0.00004991245,0.0000021517712,0.000017815566,0.000025328593,0.81184775,0.0023598487],"study_design_scores_gemma":[0.0024554036,0.00016974687,0.063897684,0.0018528854,0.00034408606,0.010276159,0.0000067187016,0.0000034712853,0.00023735281,0.00006535132,0.9205867,0.00010440811],"about_ca_topic_score_codex":0.0000014019547,"about_ca_topic_score_gemma":2.6405675e-7,"teacher_disagreement_score":0.4774076,"about_ca_system_score_codex":0.0001487578,"about_ca_system_score_gemma":0.0002611206,"threshold_uncertainty_score":0.9991061},"labels":[],"label_agreement":null},{"id":"W2749665406","doi":"10.1128/jvi.00912-17","title":"HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity","year":2017,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Government of Canada; ViiV Healthcare","keywords":"Integrase; Acetylation; Biology; Histone; Dolutegravir; Viral replication; Integrase inhibitor; Histone acetyltransferase; Histone deacetylase; Lysine; Molecular biology; Biochemistry; Virology; Virus; DNA; Gene; Amino acid","score_opus":0.011715574505855017,"score_gpt":0.2981513438205108,"score_spread":0.28643576931465575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749665406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417767,0.00047905458,0.0016276743,0.05457558,0.00023946552,0.0001874131,0.000020432712,0.000011319702,0.0010823902],"genre_scores_gemma":[0.97408915,0.00014046952,0.0019187942,0.0007123454,0.00015017619,0.0000053973,0.0000040291643,0.000020005353,0.022959627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988863,0.00007291885,0.0003022539,0.00019411242,0.0002676568,0.0002767878],"domain_scores_gemma":[0.9988578,0.000049246144,0.0002813161,0.0004070265,0.00011472223,0.00028991277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028548276,0.00018523054,0.0005680548,0.00013777765,0.00019894954,0.000021652939,0.00021446482,0.00013445351,0.0002337206],"category_scores_gemma":[0.00011300334,0.00013926001,0.00016518732,0.000055862907,0.000106540065,0.00012300895,0.000029911256,0.00032564855,0.00011245406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023324403,0.00073984015,0.012831053,0.000035525478,0.00038788767,0.0011067034,0.0006023208,4.4323582e-7,0.7868331,0.000023049211,0.19338933,0.0017183197],"study_design_scores_gemma":[0.008635985,0.0010973983,0.15030487,0.0001679733,0.0005618865,0.00023315307,0.000028345888,0.0000092052205,0.5576525,0.00009972892,0.28090018,0.0003087772],"about_ca_topic_score_codex":0.000009096437,"about_ca_topic_score_gemma":0.00002411859,"teacher_disagreement_score":0.2291806,"about_ca_system_score_codex":0.00018242442,"about_ca_system_score_gemma":0.00012856911,"threshold_uncertainty_score":0.5678858},"labels":[],"label_agreement":null},{"id":"W2754128718","doi":"10.1097/qad.0000000000001617","title":"Dolutegravir and metformin","year":2017,"lang":"pl","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Kingston Process Metallurgy (Canada); St. Michael's Hospital","funders":"Gilead Sciences","keywords":"Metformin; Dolutegravir; Medicine; Lactic acidosis; Pharmacokinetics; Hypoglycemia; Pharmacology; Internal medicine; Endocrinology; Gastroenterology; Insulin; Immunology; Viral load","score_opus":0.0243779193749067,"score_gpt":0.3067908372004372,"score_spread":0.2824129178255305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754128718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8780484,0.009078659,0.000067080815,0.007936301,0.0011764647,0.00067558174,0.000036452595,0.00006808765,0.10291298],"genre_scores_gemma":[0.7512701,0.0015656119,0.0029865103,0.00012724155,0.000270639,0.000017781884,0.000023157443,0.000025201758,0.24371372],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869984,0.000027026723,0.00025224473,0.0003606564,0.00025865788,0.00040156193],"domain_scores_gemma":[0.99870104,0.00006399788,0.00014396766,0.0007634951,0.000048858154,0.00027862456],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032191895,0.00027462406,0.00043793517,0.000101368794,0.00058982085,0.00016682054,0.00019404732,0.00014501052,0.00046242887],"category_scores_gemma":[0.00016250696,0.00021186381,0.00009089353,0.000048458365,0.00022681037,0.00022259245,0.00018806793,0.0001822646,0.0010517478],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119454155,0.00028162196,0.5759366,0.00015292777,0.0008793278,0.00070164935,0.0022268258,3.192343e-8,0.0003296525,0.0063643097,0.015883053,0.39712453],"study_design_scores_gemma":[0.009027947,0.0007507086,0.3815603,0.00082689995,0.0017486531,0.00019153362,0.00087687036,0.00009296635,0.0077888803,0.0018415791,0.59452015,0.00077352446],"about_ca_topic_score_codex":0.00013446929,"about_ca_topic_score_gemma":0.000020393625,"teacher_disagreement_score":0.5786371,"about_ca_system_score_codex":0.00006983372,"about_ca_system_score_gemma":0.00013244347,"threshold_uncertainty_score":0.99972606},"labels":[],"label_agreement":null},{"id":"W2754237340","doi":"10.1038/s41598-017-12052-9","title":"GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro","year":2017,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Basic Energy Sciences; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; Office of Science; Bristol-Myers Squibb; U.S. Department of Energy","keywords":"Darunavir; Amprenavir; Moiety; Chemistry; Lopinavir; Raltegravir; HIV-1 protease; Stereochemistry; Protease; Isostere; Atazanavir; Human immunodeficiency virus (HIV); Virology; Biology; Biochemistry; Enzyme; Viral load; Antiretroviral therapy","score_opus":0.015995785369658254,"score_gpt":0.26071469480924114,"score_spread":0.24471890943958288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754237340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807465,0.0001226072,0.00008165164,0.0038482256,0.0028304572,0.0027246645,0.000059348866,0.00021503099,0.009371481],"genre_scores_gemma":[0.93176657,0.000014365382,0.0012002642,0.00006878609,0.00017589387,0.00024091838,0.00037967865,0.0000799227,0.06607363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99391556,0.00025290667,0.0011633817,0.0019970608,0.0012984651,0.0013726028],"domain_scores_gemma":[0.99554193,0.00008057917,0.0010691164,0.0023873358,0.00033011948,0.00059093564],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0036757018,0.0006901434,0.0010893422,0.0007750701,0.0014459617,0.00081525143,0.00039920156,0.0002574733,0.00008597607],"category_scores_gemma":[0.0009388185,0.00060719607,0.00030903638,0.0006532496,0.0005218491,0.0010900309,0.00034720136,0.00069735805,0.0002235762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023938136,0.0020862136,0.06543785,0.00041500185,0.0002911207,0.052809775,0.0027489993,0.000015805617,0.85512054,0.00008616244,0.013635934,0.0049587605],"study_design_scores_gemma":[0.005717994,0.00012575761,0.021125203,0.0015603516,0.00019455903,0.0004970524,0.00036389602,0.0011889798,0.94175446,0.00046243562,0.025847923,0.0011613778],"about_ca_topic_score_codex":0.00015987827,"about_ca_topic_score_gemma":0.00017540388,"teacher_disagreement_score":0.08663391,"about_ca_system_score_codex":0.00082788,"about_ca_system_score_gemma":0.0016464391,"threshold_uncertainty_score":0.999854},"labels":[],"label_agreement":null},{"id":"W2756243586","doi":"10.1177/2325957417718624","title":"Chest Deformity and Disability due to Tenofovir-Induced Hypophosphatemic Osteomalacia: Case Report and Call for Improved Global Access to Laboratory Testing","year":2017,"lang":"en","type":"article","venue":"Journal of the International Association of Providers of AIDS Care (JIAPAC)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital; Western University; University of British Columbia","funders":"","keywords":"Osteomalacia; Hypophosphatemia; Medicine; Urinalysis; Tenofovir; Internal medicine; Tubulopathy; Gastroenterology; Osteoporosis; Human immunodeficiency virus (HIV); Kidney disease; Surgery; Immunology; Urinary system","score_opus":0.0220366554555176,"score_gpt":0.3136972146153725,"score_spread":0.2916605591598549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756243586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977035,0.00004123839,0.000048108963,0.02148368,0.00040498265,0.0007034324,0.000145271,0.0000056505883,0.00013267445],"genre_scores_gemma":[0.9932353,0.0000025067222,0.0061745998,0.0001867852,0.0001249792,0.000015175592,0.000005023946,0.0000101346095,0.00024548336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984658,0.00003374498,0.0007035636,0.00018995919,0.00046102097,0.00014595217],"domain_scores_gemma":[0.9953737,0.00024921756,0.001763074,0.00021916676,0.0022399598,0.00015483785],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009372576,0.00014459238,0.00041695617,0.00006413272,0.00017413127,0.00010021621,0.00026710695,0.000092109236,0.0000018533756],"category_scores_gemma":[0.009832187,0.00010399713,0.0001279575,0.00010011996,0.000054272405,0.00042581605,0.00022045906,0.00012384118,2.067848e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004092023,0.00011586294,0.9808578,0.00013157944,0.00045445966,0.00022242067,0.000770107,0.000003835258,0.0047592716,0.000016398517,0.0008158151,0.011443271],"study_design_scores_gemma":[0.0037712029,0.0007130863,0.9545741,0.00042664428,0.00044772806,0.0025925215,0.0012270872,0.000060179886,0.035219975,0.0003137737,0.0004644082,0.00018930921],"about_ca_topic_score_codex":0.00032185388,"about_ca_topic_score_gemma":0.0005285647,"teacher_disagreement_score":0.030460704,"about_ca_system_score_codex":0.0012349987,"about_ca_system_score_gemma":0.00043283985,"threshold_uncertainty_score":0.9985084},"labels":[],"label_agreement":null},{"id":"W2756332356","doi":"10.1128/aac.01695-17","title":"Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1","year":2017,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Integrase; Virology; Integrase inhibitor; Biology; Simian immunodeficiency virus; Pharmacology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.012991836632203067,"score_gpt":0.26715275149974466,"score_spread":0.2541609148675416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756332356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934433,0.00006958854,0.000012927806,0.005129574,0.00006692592,0.00034478033,0.00006667689,0.000021962042,0.00084427075],"genre_scores_gemma":[0.993238,0.0023883064,0.0006168161,0.0007399796,0.00006684919,0.000004119154,0.000030955664,0.000029656689,0.002885338],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99899143,0.00002306047,0.00022178753,0.00037986398,0.00013492549,0.00024892544],"domain_scores_gemma":[0.9993089,0.000020800186,0.00018277246,0.00030076195,0.000051062587,0.00013570357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109921064,0.0002862317,0.00048759006,0.00009287561,0.0003140054,0.000100480254,0.000078745004,0.00011898205,0.000016911285],"category_scores_gemma":[0.000016066166,0.00021411131,0.00007273387,0.000046949972,0.00039757745,0.00015540037,0.00007783887,0.00014149648,0.000003149832],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013834811,0.0007724177,0.40510404,0.00027972343,0.00058303936,0.0001552801,0.0016637276,3.9130754e-8,0.44012368,0.000074821255,0.008523772,0.14133596],"study_design_scores_gemma":[0.010163686,0.0002649214,0.66157895,0.0006357786,0.00020589356,0.000039495695,0.00016930637,0.00006005683,0.30287898,0.00005553967,0.02346254,0.00048484103],"about_ca_topic_score_codex":0.00010735705,"about_ca_topic_score_gemma":0.00003407714,"teacher_disagreement_score":0.2564749,"about_ca_system_score_codex":0.000023496272,"about_ca_system_score_gemma":0.00005117611,"threshold_uncertainty_score":0.87312055},"labels":[],"label_agreement":null},{"id":"W2756659961","doi":"10.1093/ofid/ofx163.1078","title":"Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender","year":2017,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"ViiV Healthcare; Kaiser Permanente; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Regimen; Subgroup analysis; Internal medicine; Clinical endpoint; Human immunodeficiency virus (HIV); Randomized controlled trial; Confidence interval; Virology","score_opus":0.022834116490273035,"score_gpt":0.3095120588597432,"score_spread":0.28667794236947014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756659961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9445677,0.0010063839,0.000025063944,0.001767167,0.000061354214,0.0006155852,0.0003078375,0.000034037617,0.05161491],"genre_scores_gemma":[0.9779163,0.00050184823,0.00008614834,0.00012755406,0.000011039103,0.000038710667,0.00027936857,0.000014509856,0.021024508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903905,0.000028909011,0.000235298,0.00033231094,0.00015873754,0.00020569228],"domain_scores_gemma":[0.9990236,0.00006460012,0.00019223668,0.0004422409,0.000050765375,0.00022652955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011189217,0.00016663013,0.0004957272,0.00014972156,0.00037775576,0.0001992325,0.00011885445,0.000048435613,0.0000929534],"category_scores_gemma":[0.00016014097,0.00013367002,0.00008979432,0.00014273085,0.00015582681,0.00024184602,0.00026893354,0.000051736897,0.000009460521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033230305,0.0005297619,0.954801,0.000040051662,0.0021879748,0.000058977974,0.00023338718,7.857666e-7,0.00004965026,0.0001737074,0.033813667,0.007778681],"study_design_scores_gemma":[0.0049358467,0.00016192748,0.97672063,0.000046450245,0.0040611494,0.0000104452565,0.00015740468,0.00007790522,0.00019029806,0.0003498175,0.013084446,0.00020365036],"about_ca_topic_score_codex":0.00031281798,"about_ca_topic_score_gemma":0.00047561704,"teacher_disagreement_score":0.03334865,"about_ca_system_score_codex":0.000033846223,"about_ca_system_score_gemma":0.000051195304,"threshold_uncertainty_score":0.5450905},"labels":[],"label_agreement":null},{"id":"W2760299280","doi":"10.1371/journal.pone.0184848","title":"Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Island Health; Simon Fraser University; AIDS Vancouver; University of British Columbia","funders":"Genome British Columbia; Michael Smith Health Research BC; Providence Health Care; Canadian Institutes of Health Research; Genome Canada; Gilead Sciences","keywords":"Drug resistance; Medicine; HIV drug resistance; Internal medicine; Logistic regression; Viral load; Odds ratio; Hazard ratio; Proportional hazards model; Demography; Confidence interval; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Genetics","score_opus":0.02663337119798946,"score_gpt":0.22985740962552298,"score_spread":0.2032240384275335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760299280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872382,0.0010783556,6.5071544e-7,0.007969305,0.00002645931,0.0005252892,0.00003643998,0.000024171179,0.0031011044],"genre_scores_gemma":[0.872995,0.00013085178,0.0034382741,0.000109346925,0.000022245968,0.000051185634,0.000013485682,0.000020307321,0.12321927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861485,0.000027659886,0.0003294263,0.00033517505,0.00040831402,0.00028457041],"domain_scores_gemma":[0.9989514,0.00017097683,0.0001884839,0.00036094687,0.00016551794,0.00016271482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019944887,0.00011398379,0.00045121083,0.000056635752,0.0002929654,0.0001744626,0.00021618076,0.000040098417,0.000026753505],"category_scores_gemma":[0.00053137343,0.00016705785,0.000023276123,0.00019347106,0.000109998145,0.0001440392,0.00011062396,0.00015767688,0.0000021619771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000355514,0.00030241976,0.9723986,0.00036498267,0.00012403923,0.00020392501,0.0003780776,1.1076068e-7,0.0001477748,0.000003722212,0.025825834,0.00021498019],"study_design_scores_gemma":[0.0014646627,0.0000064285837,0.9919605,0.004597154,0.0001323762,0.0000021485578,0.00014489023,0.000017298624,0.00071805227,0.000183746,0.0005771724,0.00019553142],"about_ca_topic_score_codex":0.26035136,"about_ca_topic_score_gemma":0.9950577,"teacher_disagreement_score":0.73470634,"about_ca_system_score_codex":0.00014723004,"about_ca_system_score_gemma":0.00038075098,"threshold_uncertainty_score":0.744574},"labels":[],"label_agreement":null},{"id":"W2760663538","doi":"10.1093/jac/dkx332","title":"Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors","year":2017,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Industrial Macromolecular Crystallography Association Collaborative Access Team","keywords":"Reverse transcriptase; Binding site; Nucleotidyltransferase; Resistance mutation; Primer (cosmetics); Mutant; Biology; Chemistry; Mutation; Enzyme; Potency; Virology; Primer binding site; In vitro; Molecular biology; Biochemistry; RNA","score_opus":0.017901067241605194,"score_gpt":0.2742311818239794,"score_spread":0.2563301145823742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760663538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97181636,0.000048145677,0.0018193448,0.025128627,0.0006997641,0.00018392187,0.000031159605,0.0000083116065,0.00026434998],"genre_scores_gemma":[0.9883041,0.0002428284,0.00462701,0.0004439983,0.0003946774,8.3741736e-7,0.000014429397,0.000023894985,0.005948261],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882346,0.0000107831265,0.00064980425,0.00011895316,0.00027141254,0.00012558303],"domain_scores_gemma":[0.998495,0.000011379962,0.00086736755,0.00024081676,0.00029768696,0.00008777888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031223302,0.00013423974,0.00035334166,0.00017708795,0.0001298446,0.000037186957,0.00014535073,0.00007830082,0.00012425947],"category_scores_gemma":[0.000042896252,0.00010672497,0.00027734382,0.000063359126,0.00011596734,0.00023845701,0.00000829735,0.00014546976,0.00001267778],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000908883,0.000930524,0.010321883,0.000052042527,0.00032074153,0.000027536424,0.0004876381,0.000004777239,0.92321056,0.000025287172,0.062269256,0.0014408447],"study_design_scores_gemma":[0.011944131,0.00014512095,0.016635526,0.00036396587,0.00020779425,0.00039648495,0.0000826069,0.000035190827,0.93182945,0.000014979716,0.038197327,0.00014739338],"about_ca_topic_score_codex":0.0000041006356,"about_ca_topic_score_gemma":8.874747e-7,"teacher_disagreement_score":0.024684628,"about_ca_system_score_codex":0.000069634894,"about_ca_system_score_gemma":0.00019516668,"threshold_uncertainty_score":0.43521178},"labels":[],"label_agreement":null},{"id":"W2762494287","doi":"10.1007/s00705-017-3572-1","title":"Prevalence of HIV-1 pre-treatment drug resistance in a southern province of Iran, 2016-2017","year":2017,"lang":"en","type":"article","venue":"Archives of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Hormozgan University of Medical Sciences","keywords":"Reverse transcriptase; Drug resistance; Virology; Biology; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Population; HIV drug resistance; Mutation; Protease; Protease inhibitor (pharmacology); Human immunodeficiency virus (HIV); Genetics; Polymerase chain reaction; Viral load; Medicine; Gene; Antiretroviral therapy; Enzyme; Environmental health","score_opus":0.013588743986156882,"score_gpt":0.27047422051518666,"score_spread":0.25688547652902977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762494287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98513746,0.0012538298,0.00004795691,0.0015572811,0.000029895013,0.0005888726,0.0000878733,0.000009055869,0.011287788],"genre_scores_gemma":[0.9256811,0.00046407228,0.005222242,0.000009274729,0.000014388681,0.00003421327,0.000009770631,0.000011987539,0.068552956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988489,0.0000771391,0.00043481623,0.00028198434,0.000137001,0.00022012317],"domain_scores_gemma":[0.99849963,0.00018598759,0.00048648898,0.0007506894,0.000019523146,0.000057686633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010800509,0.00016245227,0.0005230588,0.00013590384,0.00004857174,0.0000022454262,0.000277265,0.000046408906,0.000031413896],"category_scores_gemma":[0.00007776304,0.00012358466,0.00010768266,0.00002388972,0.0006458823,0.000041612537,0.00009269323,0.00006954104,0.000013564953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003624263,0.0015983736,0.9407106,0.001216616,0.00031646574,0.000099364006,0.021827204,0.000005745794,0.02435248,0.00064221787,0.00038438805,0.0052222554],"study_design_scores_gemma":[0.0056058746,0.0005304504,0.96444863,0.0009196767,0.000202885,0.000007915394,0.00020774317,0.000059486094,0.025094345,0.0014466852,0.0013250572,0.00015123472],"about_ca_topic_score_codex":0.00014208155,"about_ca_topic_score_gemma":0.0009546812,"teacher_disagreement_score":0.059456352,"about_ca_system_score_codex":0.00002085489,"about_ca_system_score_gemma":0.00019581585,"threshold_uncertainty_score":0.5039636},"labels":[],"label_agreement":null},{"id":"W2765201621","doi":"","title":"Accurate prediction of response to HIV therapy without a genotype: a potential tool for therapy optimization in resource-limited settings","year":2013,"lang":"en","type":"article","venue":"Queensland's institutional digital repository (The University of Queensland)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Antiretroviral therapy; Medicine; Genotype; Human immunodeficiency virus (HIV); Viral load; Internal medicine; Computer science; Oncology; Biology; Virology; Genetics","score_opus":0.010197875906445572,"score_gpt":0.20966219956424173,"score_spread":0.19946432365779615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765201621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98106146,0.00007800081,0.012791229,0.0025925976,0.00007203493,0.0017270645,0.00012781334,0.000051646653,0.0014981318],"genre_scores_gemma":[0.9912178,0.000038853148,0.0027334483,0.000107012675,0.00005751639,0.00001392227,0.0002533717,0.000014984001,0.005563093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869204,0.0000913214,0.00035789842,0.0002939645,0.00035838087,0.00020639008],"domain_scores_gemma":[0.9989652,0.00014727026,0.00019137138,0.0002386231,0.00036438773,0.00009311528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020597132,0.0001939555,0.00031610654,0.00025801396,0.00022994353,0.000036223042,0.00014482887,0.000120005636,0.00003244407],"category_scores_gemma":[0.00009383963,0.00015089303,0.00015595448,0.00026596608,0.00021608802,0.00033299238,0.00004139535,0.000109947454,0.00001430527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10951829,0.0030996997,0.7006964,0.00027556642,0.0021099835,0.00031351866,0.012940143,0.093024,0.030579126,0.0005840105,0.033108454,0.0137508055],"study_design_scores_gemma":[0.020056829,0.0014734229,0.8796277,0.00068998925,0.0001531635,0.00020123352,0.0013270763,0.01717346,0.0046507753,0.00012365972,0.07399357,0.00052913924],"about_ca_topic_score_codex":0.00006335319,"about_ca_topic_score_gemma":0.0000032024493,"teacher_disagreement_score":0.17893128,"about_ca_system_score_codex":0.0001692443,"about_ca_system_score_gemma":0.00034206145,"threshold_uncertainty_score":0.6153239},"labels":[],"label_agreement":null},{"id":"W2765383827","doi":"10.1186/s12981-017-0185-4","title":"HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study","year":2017,"lang":"en","type":"article","venue":"AIDS Research and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital; University of British Columbia Hospital","funders":"National Institute on Drug Abuse; Gilead Sciences","keywords":"Darunavir; Cobicistat; Medicine; Elvitegravir; Ritonavir; Regimen; Raltegravir; Emtricitabine; Viral load; Internal medicine; Pharmacology; Pharmacokinetics; Tenofovir alafenamide; Renal function; Adverse effect; Maraviroc; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.148074484666812,"score_gpt":0.45502848805176266,"score_spread":0.30695400338495066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765383827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856706,0.001250997,0.000058394926,0.0056052725,0.000071517556,0.003951341,0.000040097166,0.00007286262,0.0032788636],"genre_scores_gemma":[0.9352797,0.002896404,0.00038724244,0.000105299645,0.00016810816,0.00097186246,0.00008800747,0.00005472696,0.060048614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969653,0.00020817512,0.00037045422,0.00078770786,0.0008583523,0.0008100023],"domain_scores_gemma":[0.9976739,0.00017405827,0.0000926438,0.0011087346,0.00031477906,0.0006358746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008104418,0.00038530325,0.00054672954,0.00048740872,0.0011408487,0.00036294007,0.00034036362,0.00007533641,0.0001755628],"category_scores_gemma":[0.00008337836,0.00026214257,0.000093464936,0.00036049087,0.00022328904,0.0001999225,0.00013369584,0.0002709881,0.0003665761],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007596641,0.006845542,0.2987993,0.000049695813,0.0015256865,0.0007239805,0.008834175,0.000002680783,0.02588223,0.00043965093,0.0044691623,0.64483124],"study_design_scores_gemma":[0.06668348,0.032592636,0.6292791,0.00021769264,0.00032923007,0.00007824734,0.004521466,0.00044634056,0.029118448,0.0019027106,0.23357502,0.0012556337],"about_ca_topic_score_codex":0.00032182006,"about_ca_topic_score_gemma":0.000039721457,"teacher_disagreement_score":0.6435756,"about_ca_system_score_codex":0.0004699547,"about_ca_system_score_gemma":0.00037799304,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W2767681128","doi":"10.1097/qai.0000000000001575","title":"Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis","year":2017,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health","keywords":"Pre-exposure prophylaxis; Renal function; Medicine; Tenofovir; Creatinine; Human immunodeficiency virus (HIV); Kidney; Prospective cohort study; Internal medicine; Urology; Immunology","score_opus":0.02418578017365398,"score_gpt":0.2869737303720918,"score_spread":0.2627879501984378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767681128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950851,0.0020729878,0.0003087554,0.00044874867,0.001117322,0.0004740006,0.000014095977,0.00004321334,0.00043575902],"genre_scores_gemma":[0.9920081,0.00014174645,0.0047422526,0.0000071579575,0.00009177194,0.000012154672,0.000021707685,0.000059458263,0.0029156548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963219,0.00013743946,0.0017231624,0.00039482524,0.0008670515,0.0005556008],"domain_scores_gemma":[0.996266,0.000054382683,0.0020509276,0.00085429737,0.0005352349,0.00023913191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001330627,0.0004014435,0.0011280049,0.0009169436,0.00044493968,0.000117565105,0.00040335223,0.00021059594,0.0000551529],"category_scores_gemma":[0.0013389006,0.00031622837,0.0003893335,0.0006512118,0.00028463837,0.0009829893,0.00012495789,0.00029965272,0.0000111952695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038582052,0.00076499715,0.90216273,0.00025093846,0.00032581465,0.002478699,0.0017812421,0.000038057588,0.08842029,0.000019934658,0.00009356138,0.0032778988],"study_design_scores_gemma":[0.0044338806,0.0017398738,0.9786894,0.0018740982,0.000489025,0.003956429,0.0008244962,0.0001274477,0.0073181177,0.00010884559,0.00009941408,0.00033898323],"about_ca_topic_score_codex":0.00024667525,"about_ca_topic_score_gemma":0.0000048155034,"teacher_disagreement_score":0.08110217,"about_ca_system_score_codex":0.00036519233,"about_ca_system_score_gemma":0.00089909305,"threshold_uncertainty_score":0.99992895},"labels":[],"label_agreement":null},{"id":"W2767788676","doi":"10.1097/qad.0000000000001689","title":"Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort","year":2017,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"European Commission","keywords":"Seroconversion; Multinational corporation; Cohort; Human immunodeficiency virus (HIV); Medicine; Virology; Drug resistance; HIV drug resistance; Antiretroviral drug; Cohort study; Internal medicine; Antiretroviral therapy; Biology; Viral load; Business; Microbiology","score_opus":0.010809571690343215,"score_gpt":0.2685975401087677,"score_spread":0.2577879684184245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767788676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97709024,0.00008121035,0.000027681517,0.0062496946,0.000045838704,0.00016272091,0.000009766434,0.000017840168,0.016314993],"genre_scores_gemma":[0.8725667,0.000013647675,0.0048044445,0.00002913444,0.000016653392,0.000017139117,0.000091350295,0.00000766527,0.12245325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992509,0.00001837044,0.0002051738,0.00016962813,0.00023367314,0.00012226416],"domain_scores_gemma":[0.9995405,0.000026090289,0.00009064707,0.00023767988,0.00005246199,0.00005260545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016988254,0.00009512119,0.0002210797,0.0001657289,0.000074461306,0.0000075333746,0.000088414,0.00004091618,0.00016310273],"category_scores_gemma":[0.000028946197,0.00008029941,0.00006104629,0.000100427664,0.00006279963,0.00009634306,0.000016763826,0.000069506576,0.000021735388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017908738,0.00018938299,0.99128145,0.000033093187,0.000051029565,0.000048231344,0.00075799366,1.5918383e-7,0.0001918862,0.0002506208,0.004281768,0.0027353088],"study_design_scores_gemma":[0.0042326692,0.000019387027,0.97260606,0.0001634172,0.00004981753,0.0000018783429,0.00006316854,0.000064688844,0.0041952603,0.00008564033,0.018431684,0.00008633151],"about_ca_topic_score_codex":0.000037271126,"about_ca_topic_score_gemma":0.000119832584,"teacher_disagreement_score":0.10613826,"about_ca_system_score_codex":0.00006360026,"about_ca_system_score_gemma":0.000063534906,"threshold_uncertainty_score":0.3274515},"labels":[],"label_agreement":null},{"id":"W2767855113","doi":"10.1111/hiv.12562","title":"Antiretroviral pill count and clinical outcomes in treatment‐naïve patients with <scp>HIV</scp> infection","year":2017,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; National Institute of Allergy and Infectious Diseases; Medical Research Council; Ministerio de Ciencia e Innovación; Michael Smith Health Research BC; Agence Nationale de Recherches sur le Sida et les Hépatites Virales; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Institut National de la Santé et de la Recherche Médicale; Office of Research and Development; Styrelsen för Internationellt Utvecklingssamarbete; GlaxoSmithKline; Bristol-Myers Squibb; Stichting HIV Monitoring; European Commission; Pfizer; Canadian Institutes of Health Research; National Science Foundation","keywords":"Medicine; Pill; Human immunodeficiency virus (HIV); Antiretroviral treatment; Antiretroviral therapy; Internal medicine; Viral load; Virology; Pharmacology","score_opus":0.023231523268152483,"score_gpt":0.31631041539328514,"score_spread":0.29307889212513266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767855113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99058014,0.00009420916,0.000019439758,0.0025350936,0.0002889092,0.0007246463,0.000016836993,0.000053615444,0.005687131],"genre_scores_gemma":[0.9809816,0.0005170813,0.00026301655,0.00024012393,0.00020138895,0.000035067555,0.00023173948,0.00003050296,0.01749952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982782,0.000048397633,0.0004901204,0.00044384546,0.0003999583,0.00033947642],"domain_scores_gemma":[0.99866694,0.00023012646,0.00024890475,0.0005046007,0.000093752154,0.0002556535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000256638,0.00032158327,0.0008239267,0.00019856321,0.00020282091,0.000026361817,0.000072938936,0.00012239417,0.00003389633],"category_scores_gemma":[0.00054440816,0.00018299386,0.000069546826,0.00008483647,0.00036589333,0.00016619942,0.00004499805,0.00018579546,0.00008074998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114045484,0.00082018314,0.9884634,0.000026325355,0.00027498516,0.00014897733,0.0005738575,1.01885746e-7,0.0000029442726,0.000031767875,0.0036649972,0.005878429],"study_design_scores_gemma":[0.023536095,0.002531695,0.95776075,0.00029805492,0.00038277052,0.000012241018,0.000100836194,0.00003306769,0.000021515758,0.000016408205,0.015226482,0.00008007744],"about_ca_topic_score_codex":0.0003047386,"about_ca_topic_score_gemma":0.00037695144,"teacher_disagreement_score":0.03070263,"about_ca_system_score_codex":0.00019307405,"about_ca_system_score_gemma":0.000093356415,"threshold_uncertainty_score":0.7462273},"labels":[],"label_agreement":null},{"id":"W2768299619","doi":"10.1016/s2352-3018(17)30190-x","title":"Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study","year":2017,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Research Foundation; Centers for Disease Control and Prevention; Danmarks Grundforskningsfond; British HIV Association; ViiV Healthcare; World Health Organization; United States Agency for International Development; Gilead Sciences; Bill and Melinda Gates Foundation","keywords":"Medicine; Drug resistance; Public health; Drug; Environmental health; Pharmacology; Intensive care medicine; Virology; Nursing; Microbiology","score_opus":0.15626217656039787,"score_gpt":0.37594046088286254,"score_spread":0.21967828432246467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768299619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646917,0.0019262674,0.00032681387,0.02588739,0.000029284269,0.0038091838,0.000039751518,0.000015916916,0.0032737209],"genre_scores_gemma":[0.9970008,0.00092027354,0.0005115804,0.000023557554,0.000042593714,0.00052765606,0.000011931977,0.000011276655,0.00095032464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800265,0.0007101238,0.00035524913,0.00023171434,0.00034155496,0.00035873562],"domain_scores_gemma":[0.9981961,0.00042215874,0.0002515671,0.0010116524,0.000065924105,0.00005255137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029039283,0.00014949414,0.0005583161,0.00014725213,0.000173199,0.00002665025,0.00044968183,0.000026406837,0.0000029923467],"category_scores_gemma":[0.00019109825,0.00008327267,0.000053699598,0.00031621713,0.00013661533,0.0001034804,0.000075168675,0.00017199336,0.0000048527727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024346737,0.010653805,0.7931467,0.0011546419,0.00070122123,0.0001303991,0.16674913,0.0020164016,0.00029864692,0.014561833,0.0038381636,0.0043143504],"study_design_scores_gemma":[0.010053941,0.00020214367,0.9781205,0.0013734099,0.00008620012,0.0000044411377,0.0026093617,0.0014796233,0.00055815076,0.002038651,0.0032917254,0.0001818577],"about_ca_topic_score_codex":0.0006180592,"about_ca_topic_score_gemma":0.0018432635,"teacher_disagreement_score":0.18497376,"about_ca_system_score_codex":0.00024176008,"about_ca_system_score_gemma":0.00031222796,"threshold_uncertainty_score":0.3395761},"labels":[],"label_agreement":null},{"id":"W2771770118","doi":"10.1073/pnas.1715874115","title":"Resource limitation prevents the emergence of drug resistance by intensifying within-host competition","year":2017,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Competition (biology); Host (biology); Resistance (ecology); Resource (disambiguation); Drug; Drug resistance; Business; Biology; Ecology; Pharmacology; Computer science; Microbiology","score_opus":0.04377416190133497,"score_gpt":0.31637463138876953,"score_spread":0.27260046948743455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771770118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534249,0.00020099456,0.0000015747513,0.034321196,0.000020125393,0.00029101854,0.000009281047,0.0000064534274,0.011724506],"genre_scores_gemma":[0.99225503,0.0000486835,0.0014792538,0.00013463708,0.000024608855,0.000009701136,6.9193476e-7,0.000003171282,0.006044197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983817,0.0000074087793,0.00032657982,0.00016645207,0.001025084,0.00009279269],"domain_scores_gemma":[0.99868095,0.00008708361,0.00084623776,0.000019094772,0.00034253814,0.000024078523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012400725,0.00007575608,0.00014233582,0.000065647095,0.00045624076,0.000018436907,0.0005283952,0.00003417881,0.000007899796],"category_scores_gemma":[0.0008709601,0.000042196683,0.00005441402,0.00021689126,0.0008395,0.00028067193,0.000096911324,0.000109427616,0.0000012106938],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030360266,0.00041398738,0.17265263,0.00071318966,0.0002175647,5.379411e-8,0.01109937,0.000021635307,0.6025999,0.12653345,0.084807135,0.0006374644],"study_design_scores_gemma":[0.00073389313,0.000041657353,0.23840411,0.001621245,0.00009247117,0.0000058413048,0.0031962588,0.0005171496,0.7363411,0.016113332,0.0028020667,0.00013084584],"about_ca_topic_score_codex":0.0000035121673,"about_ca_topic_score_gemma":3.3474316e-7,"teacher_disagreement_score":0.13374121,"about_ca_system_score_codex":0.000023788325,"about_ca_system_score_gemma":0.00003459092,"threshold_uncertainty_score":0.3509081},"labels":[],"label_agreement":null},{"id":"W2773116112","doi":"10.1186/s40249-017-0377-0","title":"Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries","year":2017,"lang":"en","type":"article","venue":"Infectious Diseases of Poverty","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Fogarty International Center; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Johnson Cancer Research Center, Kansas State University; Center for AIDS Research, University of Washington; National Institutes of Health; Case Western Reserve University","keywords":"Zidovudine; Lamivudine; Stavudine; Virology; Medicine; Cart; Drug resistance; Regimen; Sanger sequencing; Internal medicine; Pharmacology; Biology; Human immunodeficiency virus (HIV); Virus; Viral disease; Mutation; Genetics","score_opus":0.008660601079149895,"score_gpt":0.27938144507087775,"score_spread":0.27072084399172786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773116112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99697435,0.000073842704,0.000025862439,0.0012100657,0.00007792257,0.00071220484,0.00030090133,0.000027906959,0.00059692113],"genre_scores_gemma":[0.9980783,0.000057256195,0.00004395062,0.00013912247,0.000025459465,0.000045267676,0.00001098142,0.000015951793,0.0015837384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999026,0.000026428834,0.0002690581,0.00026072658,0.0002194293,0.00019836363],"domain_scores_gemma":[0.99900025,0.0001326413,0.0001506395,0.00038082953,0.00011380528,0.00022181304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005682693,0.00023346591,0.00057313364,0.0002552689,0.00010133137,0.000021001888,0.000043752167,0.00004615669,0.000013888731],"category_scores_gemma":[0.00026201096,0.00015554146,0.00013153696,0.00009370629,0.00006015178,0.00008797959,0.00003928879,0.000038613394,0.00002465578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014488614,0.0006494377,0.99587196,0.00014448455,0.00030498524,0.00006672298,0.0004121836,0.000029394614,0.00029170568,0.000022521554,0.00008993737,0.000667775],"study_design_scores_gemma":[0.0030727996,0.0010044102,0.9786079,0.0007012929,0.00015751332,0.000004574424,0.000044062996,0.000010587021,0.016111491,0.000036195815,0.000112281756,0.0001368929],"about_ca_topic_score_codex":0.00037483973,"about_ca_topic_score_gemma":0.0013897627,"teacher_disagreement_score":0.017264092,"about_ca_system_score_codex":0.0005567413,"about_ca_system_score_gemma":0.00009373214,"threshold_uncertainty_score":0.63427967},"labels":[],"label_agreement":null},{"id":"W2780240470","doi":"10.1093/cid/cix1108","title":"Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Wellcome; Medical Research Council; National Institute for Health and Care Research; Wellcome Trust","keywords":"Reverse transcriptase; Protease; Antiretroviral therapy; Human immunodeficiency virus (HIV); Protease inhibitor (pharmacology); Lentivirus; Viral disease","score_opus":0.08633466016572307,"score_gpt":0.3796961659347159,"score_spread":0.29336150576899284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780240470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9118317,0.07983513,0.00004674668,0.00015221987,0.000099459074,0.0077064326,0.0002705264,0.000037182625,0.000020632626],"genre_scores_gemma":[0.9867649,0.0114643015,0.000010858397,0.00005711593,0.000026010077,0.0014176553,0.00008884776,0.00002683548,0.00014345067],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970757,0.00067040365,0.0013157864,0.00046901652,0.00024008277,0.00022902536],"domain_scores_gemma":[0.99690795,0.0009858026,0.00080532936,0.00088211946,0.0002829857,0.00013583137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012136953,0.0003604246,0.002924855,0.00028486003,0.0002822039,0.00003703871,0.00011112797,0.00011472655,0.000063675114],"category_scores_gemma":[0.00079837034,0.00020738806,0.0017855286,0.0004655441,0.0003594389,0.00012911725,0.000018850355,0.00011285023,0.0000029777368],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040927827,0.03497582,0.6229303,0.18846653,0.14099523,0.00008505456,0.0003395478,0.000036103283,0.006863727,0.00007633545,0.00030514252,0.0008334578],"study_design_scores_gemma":[0.016646892,0.012859643,0.35075715,0.004961215,0.6018877,0.0000038147314,0.000017903238,0.00016580436,0.01190647,0.00010574181,0.00016573413,0.0005219182],"about_ca_topic_score_codex":0.00020936562,"about_ca_topic_score_gemma":0.000110639136,"teacher_disagreement_score":0.46089247,"about_ca_system_score_codex":0.00011175468,"about_ca_system_score_gemma":0.00016845953,"threshold_uncertainty_score":0.84570396},"labels":[],"label_agreement":null},{"id":"W2786980145","doi":"","title":"Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin, in adults treated with the regimen approved in Australia, Canada, New Zealand, and Switzerland","year":2016,"lang":"en","type":"article","venue":"Queensland's institutional digital repository (The University of Queensland)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ombitasvir; Dasabuvir; Paritaprevir; Medicine; Ritonavir; Ribavirin; Regimen; Virology; Internal medicine; Human immunodeficiency virus (HIV); Hepatitis C virus; Virus; Viral load","score_opus":0.008319216307772269,"score_gpt":0.19809255923004432,"score_spread":0.18977334292227205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786980145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959173,0.00014029654,0.000029524961,0.0019223706,0.0000113381775,0.0006725537,0.000048870435,0.000010720513,0.0012469969],"genre_scores_gemma":[0.98025256,0.000107174055,0.000125396,0.000016781152,0.00001710221,0.0000018424778,0.000029459407,0.000009061999,0.019440608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988215,0.0000522796,0.00025567872,0.00034559643,0.00031288736,0.00021208667],"domain_scores_gemma":[0.99918133,0.00022295945,0.00015175162,0.00021213948,0.000078067824,0.00015374673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009387583,0.0002372782,0.00043934342,0.00009764762,0.00015764816,0.000023716088,0.000099952624,0.00008050303,0.000005334914],"category_scores_gemma":[0.000024649627,0.00011183045,0.000024943296,0.00017571147,0.0008512013,0.0002462644,0.00006052274,0.00014428778,7.1826975e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013004792,0.00013960103,0.9820362,0.000071660186,0.00022138905,0.0003946731,0.0010923649,0.000008071826,0.00007918569,0.00014541215,0.00077919895,0.0020275065],"study_design_scores_gemma":[0.01650251,0.00051781884,0.9702082,0.0015861425,0.00014659196,0.00047330212,0.00049397105,0.000019820965,0.00017656107,0.00002120992,0.009635522,0.00021832908],"about_ca_topic_score_codex":0.08272235,"about_ca_topic_score_gemma":0.18719476,"teacher_disagreement_score":0.10447242,"about_ca_system_score_codex":0.00014293769,"about_ca_system_score_gemma":0.00072448375,"threshold_uncertainty_score":0.92338586},"labels":[],"label_agreement":null},{"id":"W2789683631","doi":"10.1128/jcm.01673-17","title":"Performance of the Xpert HIV-1 Viral Load Assay: a Systematic Review and Meta-analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"GeneXpert MTB/RIF; Viral load; Medicine; Human immunodeficiency virus (HIV); Point of care; Confidence interval; Point-of-care testing; External quality assessment; Tuberculosis; Virology; Internal medicine; Immunology; Mycobacterium tuberculosis; Pathology","score_opus":0.12132623883971479,"score_gpt":0.4189369186077176,"score_spread":0.2976106797680028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789683631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000073426156,0.99676126,0.0000038532376,0.0017335734,0.000167643,0.0011200166,0.000045407116,0.0000031408388,0.00009167923],"genre_scores_gemma":[0.000054921282,0.99048394,0.00052925316,0.0007454674,0.000118061784,0.000022704104,0.000019524623,0.000019130715,0.008007001],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99211574,0.001828562,0.0053813374,0.000296514,0.00016635479,0.00021149917],"domain_scores_gemma":[0.9920367,0.001289247,0.0054013217,0.0006048476,0.00053349696,0.00013439103],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00588682,0.0004122538,0.017422127,0.00018863591,0.000042241994,0.0000070577294,0.0004018237,0.00043334407,0.00027462977],"category_scores_gemma":[0.0017630638,0.0001583457,0.0076256325,0.00041316796,0.00035055165,0.000034352877,0.00014665686,0.0007191436,0.00006966546],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037518847,0.0002712211,0.00028087065,0.567273,0.42037806,0.000022553446,0.000024181472,2.3209376e-8,7.5092794e-7,0.0000032456085,0.0101648355,0.0015437537],"study_design_scores_gemma":[0.00029837346,0.00023789432,0.000008757934,0.040996168,0.6911947,0.0010485954,0.0000017291031,5.120973e-7,8.245989e-7,9.537312e-7,0.26611084,0.00010065184],"about_ca_topic_score_codex":6.1579954e-7,"about_ca_topic_score_gemma":0.0000017981278,"teacher_disagreement_score":0.5262768,"about_ca_system_score_codex":0.00008736032,"about_ca_system_score_gemma":0.0008376579,"threshold_uncertainty_score":0.99716526},"labels":[],"label_agreement":null},{"id":"W2789779680","doi":"10.1097/coh.0b013e3282fbaaba","title":"Inhibitory quotient in HIV pharmacology","year":2008,"lang":"en","type":"article","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Therapeutic drug monitoring; Quotient; Pharmacology; Darunavir; Drug; Integrase inhibitor; Medicine; Inhibitory postsynaptic potential; Raltegravir; Cutoff; Drug resistance; Biology; Human immunodeficiency virus (HIV); Virology; Mathematics; Antiretroviral therapy; Internal medicine; Viral load; Genetics; Physics","score_opus":0.04770511680994157,"score_gpt":0.33190567738166743,"score_spread":0.2842005605717259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789779680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862214,0.0069933175,0.000037904156,0.0019160307,0.0032448866,0.0004748389,0.000009647268,0.00004139526,0.0010606218],"genre_scores_gemma":[0.98984694,0.006367837,0.00040599887,0.000070169284,0.00050257513,0.000108647066,0.00016921759,0.00001655441,0.002512065],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893606,0.00005040618,0.00031599915,0.00028232907,0.00015735706,0.00025782912],"domain_scores_gemma":[0.9996832,0.000039510734,0.000041403106,0.000090776644,0.000022304124,0.00012280424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011175961,0.00016069201,0.00027444633,0.00032648366,0.000051531828,0.000004284584,0.000041448948,0.00006019253,0.00012667158],"category_scores_gemma":[0.000012327024,0.00013725263,0.00004286303,0.00023634318,0.00008920068,0.000067556066,0.000050797615,0.00022080733,0.00008975808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011229927,0.0008370618,0.9259999,0.0001847565,0.000021098136,0.000038460777,0.0018797667,0.0000045438806,0.00012942287,0.0003340295,0.06250117,0.007957523],"study_design_scores_gemma":[0.016428057,0.0002968013,0.33300668,0.0011813488,0.00003880646,0.00013300011,0.00043800825,0.00045600173,0.0015061087,0.000119754724,0.6459175,0.0004779908],"about_ca_topic_score_codex":0.0000032897349,"about_ca_topic_score_gemma":7.6126634e-7,"teacher_disagreement_score":0.5929932,"about_ca_system_score_codex":0.000113411865,"about_ca_system_score_gemma":0.000106865984,"threshold_uncertainty_score":0.55969995},"labels":[],"label_agreement":null},{"id":"W2789833340","doi":"10.1177/2325957417752260","title":"Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review","year":2018,"lang":"en","type":"review","venue":"Journal of the International Association of Providers of AIDS Care (JIAPAC)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Elvitegravir; Darunavir; Cobicistat; Emtricitabine; Medicine; Tenofovir; Antiretroviral therapy; Ritonavir; Human immunodeficiency virus (HIV); Pharmacology; Internal medicine; Virology; Viral load","score_opus":0.014861679482592708,"score_gpt":0.2933917816542058,"score_spread":0.2785301021716131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789833340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063512556,0.92909,0.000014340093,0.0018957248,0.00065489154,0.0036821072,0.00025494865,0.000015647429,0.00087978266],"genre_scores_gemma":[0.04544809,0.95064497,0.0006290366,0.0001161099,0.000105722596,0.000082873994,0.00019756304,0.000051929677,0.002723715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958495,0.00028694986,0.0016572311,0.0003721346,0.001594639,0.00023954472],"domain_scores_gemma":[0.9915611,0.00028607465,0.0052316138,0.0002727002,0.0025617995,0.00008669777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000589369,0.00049818755,0.002171676,0.00059107115,0.000081186015,0.00004911538,0.0004061254,0.00021443599,0.000020710506],"category_scores_gemma":[0.0008362292,0.00028417466,0.00063906726,0.00072155485,0.00016440445,0.0004724773,0.000077552046,0.00038582901,0.0000018924919],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027111117,0.0035185122,0.46012574,0.011170992,0.00960452,0.00007503736,0.014883861,0.000004099848,0.00005177095,0.00032141033,0.0047952556,0.49273768],"study_design_scores_gemma":[0.07734823,0.04060057,0.0838197,0.33722275,0.013861655,0.0002914564,0.008017911,0.000049579674,0.0014037439,0.0008135574,0.43364516,0.0029256816],"about_ca_topic_score_codex":0.000069599126,"about_ca_topic_score_gemma":0.000033909055,"teacher_disagreement_score":0.48981202,"about_ca_system_score_codex":0.0075346334,"about_ca_system_score_gemma":0.001580651,"threshold_uncertainty_score":0.999961},"labels":[],"label_agreement":null},{"id":"W2790132647","doi":"10.1016/j.bmc.2018.02.017","title":"Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively “Freeze” the pre-translocated complex during the polymerization catalytic cycle","year":2018,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Reverse transcriptase; Pharmacophore; Chemistry; Pyrophosphate; Primer (cosmetics); DNA; Catalytic cycle; Human immunodeficiency virus (HIV); Enzyme; Polymerization; DNA polymerase; RNA; DNA synthesis; Biochemistry; Combinatorial chemistry; Molecular biology; Virology; Biology; Gene; Organic chemistry","score_opus":0.024352444283347135,"score_gpt":0.2809224619830885,"score_spread":0.25657001769974136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790132647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837298,0.0006297394,0.00031311123,0.01283114,0.00025998542,0.0013729132,0.00010166494,0.00014274403,0.00061895105],"genre_scores_gemma":[0.992109,0.00006615808,0.00008204383,0.0005279298,0.000831191,0.00010480704,0.00046433622,0.0000547936,0.005759716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981369,0.000034625853,0.00038566798,0.00044614033,0.0005317647,0.00046494923],"domain_scores_gemma":[0.9990643,0.00005592909,0.00015127384,0.00037740832,0.00015229212,0.00019879041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023765379,0.0003360085,0.00030993277,0.000039179344,0.00053189235,0.00002451037,0.00026651888,0.00011196036,0.00058255735],"category_scores_gemma":[0.00006590325,0.00020125751,0.0001235709,0.00044200936,0.00041679808,0.00008090164,0.000032631397,0.00022195767,0.00003516343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006670533,0.00018737663,0.0043764105,0.00030811582,0.00038173667,0.000021916068,0.0028387778,1.9142992e-7,0.97609264,0.0000014560541,0.014365818,0.00075848674],"study_design_scores_gemma":[0.0047921287,0.00008809885,0.010449471,0.00022801803,0.00070622796,0.00014784696,0.0010513336,0.00017548617,0.9725797,0.000007454396,0.009554061,0.00022018302],"about_ca_topic_score_codex":0.00004681426,"about_ca_topic_score_gemma":0.0000071245045,"teacher_disagreement_score":0.01230321,"about_ca_system_score_codex":0.00028430825,"about_ca_system_score_gemma":0.00028297905,"threshold_uncertainty_score":0.8207043},"labels":[],"label_agreement":null},{"id":"W2790757720","doi":"10.3390/v10020060","title":"High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia","year":2018,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Simon Fraser University","funders":"Canadian Institutes of Health Research; Simon Fraser University; Michael Smith Health Research BC","keywords":"Genotyping; Cart; Drug resistance; Medicine; HIV drug resistance; Dried blood spot; Regimen; Etravirine; Virology; Drug; Internal medicine; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Pharmacology; Genotype; Biology; Genetics","score_opus":0.0240682997695202,"score_gpt":0.27634553642590226,"score_spread":0.2522772366563821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790757720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974566,0.00044988774,0.000019348565,0.0010988332,0.00008310936,0.00045070215,0.00007767357,0.00006702868,0.00029678099],"genre_scores_gemma":[0.9937409,0.000150464,0.0014735425,0.00023746608,0.00012990093,0.00001861158,0.000036828995,0.000036286452,0.0041759843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984923,0.000077653756,0.0004936227,0.0003365266,0.00028122822,0.00031869407],"domain_scores_gemma":[0.99933505,0.000103588245,0.00011918024,0.0002989166,0.00008173985,0.000061495135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002583926,0.00023661116,0.0004763515,0.00031898625,0.000056949808,0.0000132898585,0.00009252254,0.00010843752,0.00022408874],"category_scores_gemma":[0.00009160317,0.00018953225,0.00006362896,0.00052254513,0.00014169278,0.000098016026,0.000038395603,0.00019539532,0.00014086836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006204723,0.0004485169,0.98232603,0.000037704605,0.000100690755,0.000049246348,0.007273506,0.0000045319935,0.007016455,0.00020938995,0.00040655417,0.0015068725],"study_design_scores_gemma":[0.010736056,0.0003108027,0.8838571,0.00088600797,0.00004390089,0.000004804206,0.00027735802,0.000037477304,0.10118935,0.00024463117,0.0020180906,0.00039443598],"about_ca_topic_score_codex":0.0007167919,"about_ca_topic_score_gemma":0.005382032,"teacher_disagreement_score":0.098468974,"about_ca_system_score_codex":0.00010152305,"about_ca_system_score_gemma":0.00012334292,"threshold_uncertainty_score":0.7728901},"labels":[],"label_agreement":null},{"id":"W2791029557","doi":"10.1097/qai.0000000000001649","title":"Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada","year":2018,"lang":"en","type":"letter","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; University of Manitoba","funders":"British Columbia Centre for Disease Control; Public Health Agency; Public Health Agency of Canada","keywords":"Raltegravir; Dolutegravir; Integrase inhibitor; Elvitegravir; Integrase; Medicine; Drug resistance; ANTIRETROVIRAL AGENTS; Virology; Human immunodeficiency virus (HIV); Pharmacology; Antiretroviral therapy; Biology; Viral load; Genetics","score_opus":0.0099447566250841,"score_gpt":0.2173568242446781,"score_spread":0.207412067619594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791029557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.788882,0.032267075,0.000015851934,0.17164208,0.0026333253,0.0009967991,0.00017790878,0.000041543382,0.0033433884],"genre_scores_gemma":[0.7437916,0.011458473,0.0068442496,0.037189227,0.0017434068,0.00007961598,0.0005620441,0.00049422437,0.1978372],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99371517,0.00025456282,0.0028029664,0.0005186849,0.0019140377,0.00079460384],"domain_scores_gemma":[0.9958777,0.00044030356,0.0021012914,0.0007695772,0.0006601333,0.00015101828],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011676879,0.0006820421,0.0020654441,0.00141901,0.00009095131,0.000028823968,0.00080280064,0.0003470934,0.00011240837],"category_scores_gemma":[0.00045253572,0.0005339919,0.00050274655,0.0011463976,0.0003537893,0.00027649937,0.00014910105,0.000934251,0.00003473214],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028469192,0.0002632415,0.024663705,0.0036706373,0.0004514005,0.00966937,0.0009706094,0.0000042277466,0.00045557978,0.0000021708388,0.95819,0.0013743377],"study_design_scores_gemma":[0.020538433,0.001749201,0.18218572,0.09517253,0.004668574,0.00498897,0.004205247,0.000048758033,0.017274966,0.00031138698,0.66418475,0.0046714568],"about_ca_topic_score_codex":0.008085767,"about_ca_topic_score_gemma":0.006768405,"teacher_disagreement_score":0.29400527,"about_ca_system_score_codex":0.0028830303,"about_ca_system_score_gemma":0.007478318,"threshold_uncertainty_score":0.99971116},"labels":[],"label_agreement":null},{"id":"W2791485162","doi":"10.1097/qad.0000000000001781","title":"Adverse drug reactions to integrase strand transfer inhibitors","year":2018,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research; World Health Organization","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Cobicistat; Medicine; Discontinuation; Hazard ratio; Integrase inhibitor; Tolerability; Population; Adverse effect; Internal medicine; Virology; Confidence interval; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.011793220021736108,"score_gpt":0.2665681439924157,"score_spread":0.2547749239706796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791485162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782734,0.000019124489,0.00042778676,0.0035442826,0.0002969356,0.0003477747,0.000008291056,0.000092972106,0.01698942],"genre_scores_gemma":[0.9458739,0.000011308304,0.0021258665,0.00037688343,0.00025505622,0.000030987732,0.00002513912,0.000017381788,0.05128343],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992223,0.000016663062,0.00018648247,0.00020641672,0.00017191957,0.00019622213],"domain_scores_gemma":[0.9994691,0.000025781948,0.0000088937795,0.00019213873,0.0000748473,0.00022924006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000106103056,0.00013161429,0.00016436353,0.00015448092,0.000088589324,0.000007496126,0.000040097242,0.000042883516,0.0007970638],"category_scores_gemma":[0.00002805229,0.00010017223,0.00008181708,0.0002763872,0.000056352983,0.00007114324,0.000010217594,0.000098136574,0.001289513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023700718,0.0033452387,0.26573527,0.00022869499,0.0023752232,0.00076466723,0.06470126,0.0000044930994,0.06662748,0.005037386,0.4352245,0.1535857],"study_design_scores_gemma":[0.0044302987,0.0007602348,0.014530438,0.00032323808,0.0004417118,0.000052080697,0.002423834,0.0000117335385,0.17766681,0.00012291456,0.7988749,0.00036177604],"about_ca_topic_score_codex":0.00006532392,"about_ca_topic_score_gemma":0.000060129136,"teacher_disagreement_score":0.3636504,"about_ca_system_score_codex":0.00007671689,"about_ca_system_score_gemma":0.00007735344,"threshold_uncertainty_score":0.9994881},"labels":[],"label_agreement":null},{"id":"W2791665254","doi":"10.1016/j.antiviral.2018.02.010","title":"Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series","year":2018,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Darunavir; Therapeutic drug monitoring; Medicine; Pharmacodynamics; Pharmacokinetics; Internal medicine; Viral load; Salvage therapy; Human immunodeficiency virus (HIV); Enfuvirtide; Drug; Antiretroviral therapy; Oncology; Pharmacology; Virology; Immunology; Chemotherapy","score_opus":0.06808064592542144,"score_gpt":0.3891810107672819,"score_spread":0.32110036484186044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791665254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935404,0.00013360825,0.0000063852967,0.00096559885,0.00013252183,0.0010148395,0.000007517885,0.00010006997,0.004099045],"genre_scores_gemma":[0.9860247,0.00008452437,0.0005855417,0.000024177785,0.00015183337,0.00021685597,0.000053063446,0.000049040696,0.012810292],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970847,0.00037912428,0.00034910426,0.00058244204,0.0007167443,0.00088790443],"domain_scores_gemma":[0.99869204,0.00028565899,0.000057325862,0.00047767293,0.00035730674,0.00012998994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005763835,0.0002970229,0.0003931362,0.00058175967,0.0004271507,0.00008598258,0.00012319564,0.00010108571,0.000053594413],"category_scores_gemma":[0.00022217799,0.00023031868,0.00008726179,0.0011436696,0.00037938848,0.00031677735,0.000082976985,0.0003114828,0.00030875643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082822563,0.0011353041,0.950466,0.00003600632,0.00010034806,0.0033382026,0.008163933,1.2876514e-7,0.008321616,0.00002605301,0.0003322879,0.02725191],"study_design_scores_gemma":[0.016854698,0.003993743,0.42561787,0.0012218489,0.00010541937,0.00020652701,0.006745971,0.00039363932,0.53901464,0.000098440956,0.004946755,0.0008004269],"about_ca_topic_score_codex":0.00035365537,"about_ca_topic_score_gemma":0.00035047188,"teacher_disagreement_score":0.53069305,"about_ca_system_score_codex":0.00069233455,"about_ca_system_score_gemma":0.00037644274,"threshold_uncertainty_score":0.9392123},"labels":[],"label_agreement":null},{"id":"W2791842602","doi":"10.1093/jcag/gwy008.181","title":"A180 IMPROVED RENAL LABORATORY PARAMETERS IN CHB PATIENTS TREATED WITH TAF COMPARED WITH TDF","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada); Toronto General Hospital","funders":"","keywords":"Medicine; Internal medicine; Kidney disease; Renal function; Tenofovir alafenamide; Urology; Creatinine; Diabetes mellitus; Tenofovir; Gastroenterology; Stage (stratigraphy); Placebo; Endocrinology; Viral load; Human immunodeficiency virus (HIV); Immunology; Pathology; Antiretroviral therapy","score_opus":0.005308937125228466,"score_gpt":0.20058525012876738,"score_spread":0.19527631300353893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791842602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373406,0.0000029639182,0.0000064522187,0.005816325,0.000087954,0.00021129758,0.000028107917,0.0000026991077,0.00011016263],"genre_scores_gemma":[0.9979826,0.0000022770441,0.00072356226,0.00068403396,0.000039053157,0.0000036394586,0.000012140567,0.0000118059015,0.00054087286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878466,0.00016453139,0.00038831346,0.00009874817,0.00026705075,0.0002966733],"domain_scores_gemma":[0.99817604,0.000029277448,0.0008043879,0.0001181573,0.00067123317,0.00020092078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030566734,0.00012049146,0.0003879381,0.00029307205,0.000058826143,0.0000094430225,0.00010742349,0.00007228945,0.000021488602],"category_scores_gemma":[0.0000893389,0.00007260914,0.000055881035,0.00021880287,0.00009166736,0.00006161555,0.000008705587,0.00019836871,0.0000025211275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017248662,0.00012477917,0.99466866,0.0000045287056,0.00043373008,0.000022279082,0.00029061153,0.000014017822,0.00008163413,0.0000017032813,0.0025968056,0.000036364105],"study_design_scores_gemma":[0.009558762,0.0027606615,0.98581564,0.0001269927,0.00018470775,0.000024588848,0.000059204755,0.00004427316,0.0004106885,0.0000037491488,0.0009621196,0.000048608068],"about_ca_topic_score_codex":0.0017029268,"about_ca_topic_score_gemma":0.3971235,"teacher_disagreement_score":0.39542055,"about_ca_system_score_codex":0.0015398794,"about_ca_system_score_gemma":0.00059962104,"threshold_uncertainty_score":0.6138774},"labels":[],"label_agreement":null},{"id":"W2792985786","doi":"10.1177/2040206618762985","title":"Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa","year":2018,"lang":"en","type":"article","venue":"Antiviral chemistry & chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Bill and Melinda Gates Foundation","keywords":"Rilpivirine; Efavirenz; Virology; Reverse transcriptase; Reverse-transcriptase inhibitor; Nevirapine; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Medicine; Resistance mutation; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Biology; Polymerase chain reaction; Genetics","score_opus":0.013935754908560982,"score_gpt":0.262476883679566,"score_spread":0.24854112877100504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792985786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98827875,0.0005244559,0.00009023833,0.0029085083,0.000091229274,0.0005448681,0.000086323205,0.00017235064,0.0073032584],"genre_scores_gemma":[0.9612986,0.00017479277,0.0016638899,0.0004829533,0.0007282827,0.000061083985,0.00020351104,0.0000953081,0.0352916],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972514,0.000025069041,0.00057153916,0.00091435644,0.0004969566,0.00074069225],"domain_scores_gemma":[0.99867785,0.00005699161,0.00017517006,0.0007085579,0.00015022226,0.00023123452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016954869,0.000576036,0.0007075792,0.000104732055,0.00016251246,0.00009796006,0.00031808927,0.00024328667,0.0010779359],"category_scores_gemma":[0.00005001261,0.00049580756,0.00020787361,0.0005853139,0.00035102956,0.00017242516,0.000061135725,0.00029660936,0.00032013128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020894352,0.0006354918,0.85161006,0.00006166298,0.0002744092,0.00016273248,0.0053969766,0.0000012130326,0.13316476,0.000005762189,0.0045170397,0.0020804678],"study_design_scores_gemma":[0.0074742474,0.00022713136,0.16578346,0.00029865024,0.000029807561,0.000002402586,0.00013245735,0.00003958792,0.7689457,0.00011009535,0.05633606,0.00062043394],"about_ca_topic_score_codex":0.00010116218,"about_ca_topic_score_gemma":0.00014911305,"teacher_disagreement_score":0.6858266,"about_ca_system_score_codex":0.00021879563,"about_ca_system_score_gemma":0.00013007248,"threshold_uncertainty_score":0.9998352},"labels":[],"label_agreement":null},{"id":"W2793118728","doi":"10.1177/1060028018758432","title":"Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review","year":2018,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Dolutegravir; Rilpivirine; Medicine; Observational study; Randomized controlled trial; Tolerability; Regimen; Lamivudine; Internal medicine; Intensive care medicine; Oncology; Antiretroviral therapy; Viral load; Adverse effect; Human immunodeficiency virus (HIV); Virology; Virus","score_opus":0.11562210985620895,"score_gpt":0.44478281922673707,"score_spread":0.3291607093705281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793118728","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023740156,0.9910146,0.0000015416263,0.0016258449,0.00019082338,0.0051905345,0.00016590342,0.00007078021,0.0015025685],"genre_scores_gemma":[0.000009391883,0.98380667,0.0001431763,0.002547717,0.0002251963,0.00087512867,0.0008520905,0.00014210444,0.011398525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622154,0.00037834755,0.001472336,0.0007573143,0.0005083183,0.00066214113],"domain_scores_gemma":[0.99780935,0.00014939412,0.000785188,0.000613686,0.00038424256,0.00025815147],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041295978,0.0009980869,0.003620931,0.00049725914,0.000050065846,0.000014699219,0.00022406981,0.00024022264,0.0016288838],"category_scores_gemma":[0.00003935185,0.00062918273,0.0012018031,0.00088633137,0.0001293389,0.00009934828,0.000026331922,0.00027678552,0.00060765457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030306584,0.0029140376,0.00028247034,0.009390314,0.0020698374,0.00012918004,0.00023048707,1.5150157e-8,0.0000069921934,0.000021349293,0.08566556,0.8989867],"study_design_scores_gemma":[0.0057170587,0.00096754363,0.0000424054,0.05842288,0.0005794642,0.000031675943,0.000003326762,5.1758786e-7,0.00038930704,0.000019955805,0.93335944,0.00046640917],"about_ca_topic_score_codex":0.00004542875,"about_ca_topic_score_gemma":0.0000059427343,"teacher_disagreement_score":0.8985203,"about_ca_system_score_codex":0.00025489353,"about_ca_system_score_gemma":0.0008342584,"threshold_uncertainty_score":0.99961597},"labels":[],"label_agreement":null},{"id":"W2794150437","doi":"10.1089/aid.2017.0184","title":"Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance","year":2018,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Dolutegravir; Raltegravir; Integrase inhibitor; Medicine; Virology; Lamivudine; Darunavir; Reverse-transcriptase inhibitor; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Emtricitabine; Internal medicine; Pharmacology; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy; Biology; Microbiology; Hepatitis B virus","score_opus":0.04577232815104935,"score_gpt":0.3268700893455081,"score_spread":0.28109776119445873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794150437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530286,0.00025821113,0.000017179937,0.0010363205,0.000025366237,0.001254009,0.00017046687,0.000052777945,0.001882813],"genre_scores_gemma":[0.9948587,0.00010196534,0.00085772626,0.00019153579,0.00008532593,0.0001373227,0.00026111092,0.00005205349,0.0034543008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970728,0.0003049669,0.00042071703,0.0006134184,0.00091966474,0.0006684165],"domain_scores_gemma":[0.998044,0.00018371416,0.000043183416,0.000648025,0.0006783362,0.00040269777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055224507,0.00033631566,0.00050275703,0.0007655222,0.00059240806,0.000093744464,0.00019928065,0.00015411824,0.00013080744],"category_scores_gemma":[0.00008632529,0.00025710906,0.000076747,0.00079576654,0.0013281957,0.00031851878,0.00003914958,0.0007727405,0.000026502772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0107136965,0.0022665197,0.9630131,0.00022550169,0.00030584141,0.0002473854,0.0041313176,9.547582e-8,0.0015052359,0.0012105579,0.014849061,0.0015316746],"study_design_scores_gemma":[0.020184986,0.006492618,0.8949688,0.0035959312,0.00022487367,0.000004607404,0.0051439013,0.0000014954807,0.036318365,0.0004951733,0.031821754,0.0007474794],"about_ca_topic_score_codex":0.00021676821,"about_ca_topic_score_gemma":0.0049179397,"teacher_disagreement_score":0.068044305,"about_ca_system_score_codex":0.00036264962,"about_ca_system_score_gemma":0.0002400394,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W2794472562","doi":"10.1093/infdis/jiy175","title":"The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors","year":2018,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Integrase; Virology; Integrase inhibitor; Virus; Drug resistance; Medicine; Biology; Viral load; Human immunodeficiency virus (HIV); Genetics; Antiretroviral therapy","score_opus":0.01025034288864627,"score_gpt":0.2460232821861529,"score_spread":0.23577293929750665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794472562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526465,0.0007136901,0.0010517782,0.0016382744,0.00028128372,0.00055271975,0.00004397137,0.000056791203,0.00039684615],"genre_scores_gemma":[0.99725246,0.00066680816,0.000026364874,0.0002510835,0.0002866038,0.000018391507,0.000007780197,0.000035487305,0.0014550422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980196,0.00021024856,0.0005536738,0.00017905347,0.0006733677,0.0003640855],"domain_scores_gemma":[0.9980303,0.0003010096,0.00022335284,0.0002866225,0.0008318695,0.0003268235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005951517,0.00031401473,0.00040303072,0.00017097732,0.0007277193,0.000106909756,0.00017902018,0.00007193868,0.000051037714],"category_scores_gemma":[0.00030961906,0.00014945267,0.00019914661,0.0004655598,0.00045419246,0.00017884921,0.000014494741,0.00035184433,0.000024244451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18922609,0.012655953,0.5439388,0.00052357896,0.03261808,0.0029644344,0.042785496,0.0004273554,0.106222324,0.0022868847,0.039339855,0.02701116],"study_design_scores_gemma":[0.07081039,0.009322094,0.571497,0.013194328,0.011171722,0.0013438232,0.008072552,0.00006649636,0.29288864,0.0030470707,0.016046133,0.0025396873],"about_ca_topic_score_codex":0.000086132146,"about_ca_topic_score_gemma":0.0036686114,"teacher_disagreement_score":0.18666634,"about_ca_system_score_codex":0.0008324648,"about_ca_system_score_gemma":0.0007625475,"threshold_uncertainty_score":0.6094503},"labels":[],"label_agreement":null},{"id":"W2795103913","doi":"10.1093/infdis/jiy176","title":"HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy","year":2018,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Integrase; Virology; Integrase inhibitor; Drug resistance; Medicine; Viral load; Human immunodeficiency virus (HIV); Biology; Genetics; Antiretroviral therapy","score_opus":0.003089663807920755,"score_gpt":0.21285747552346618,"score_spread":0.20976781171554543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795103913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950766,0.00012251876,0.00069502916,0.0030945207,0.00006349144,0.00031712317,0.0000148723575,0.000017635466,0.0005982048],"genre_scores_gemma":[0.9975022,0.00005827424,0.00043722268,0.0006185856,0.000091930975,0.0000069165435,0.0000054885336,0.000016894446,0.0012624961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991091,0.00006787892,0.00026116776,0.000099204066,0.00025972232,0.00020296461],"domain_scores_gemma":[0.9991854,0.000056261906,0.0001823456,0.00018050011,0.00025968457,0.00013582756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014082062,0.00015075786,0.0002665418,0.0001562194,0.0000863573,0.000014408556,0.000106035666,0.00003088106,0.000043840188],"category_scores_gemma":[0.00006733481,0.0000733628,0.00006002055,0.0002999461,0.00010013882,0.00007826319,0.000015638727,0.00013309228,0.00003236729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035996102,0.00054789777,0.9894051,0.000010790043,0.00013966003,0.000036293317,0.00038927398,0.000018498533,0.000008161645,0.00011245682,0.0051564313,0.0005758265],"study_design_scores_gemma":[0.0057481662,0.0013634777,0.9895307,0.00030540308,0.00016729598,0.000030459161,0.00020722326,0.000021780346,0.000047973113,0.00035405258,0.002097973,0.00012551885],"about_ca_topic_score_codex":0.000007373833,"about_ca_topic_score_gemma":0.0006010619,"teacher_disagreement_score":0.0030584584,"about_ca_system_score_codex":0.0004068238,"about_ca_system_score_gemma":0.00010989772,"threshold_uncertainty_score":0.2991648},"labels":[],"label_agreement":null},{"id":"W2800224917","doi":"10.1002/jcph.1103","title":"Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects","year":2018,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Merck","keywords":"Rifabutin; Pharmacokinetics; Pharmacology; Drug interaction; Rifamycin; Reverse-transcriptase inhibitor; Antibacterial agent; Medicine; Chemistry; Antibiotics; Sida; Human immunodeficiency virus (HIV); Immunology; Clarithromycin","score_opus":0.08523358754433018,"score_gpt":0.4618648557188534,"score_spread":0.3766312681745232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800224917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877817,0.00059990125,0.000012721201,0.009978258,0.0009893824,0.0002524257,0.000003016299,0.000003972046,0.00037864418],"genre_scores_gemma":[0.9961401,0.0011131595,0.0007941331,0.0007821584,0.0008028118,0.000001610157,0.0000013018,0.000010425258,0.00035429682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970424,0.00060163275,0.0017983097,0.00010213123,0.0002441887,0.00021131733],"domain_scores_gemma":[0.99650866,0.00181169,0.0010272551,0.00013938974,0.00036020056,0.00015278735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029629834,0.00011372694,0.0008472302,0.00014494041,0.000027582208,9.347451e-7,0.0001918396,0.000106265354,0.00028837513],"category_scores_gemma":[0.00069627096,0.00006630701,0.00016425783,0.00022844752,0.00044101718,0.00004008689,0.0000550061,0.00047294673,0.000014464821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07492271,0.0059624887,0.7902489,0.00020130588,0.0011599804,0.00025034972,0.0027405631,0.000021266183,0.0721905,0.000029817851,0.03412393,0.01814824],"study_design_scores_gemma":[0.05789005,0.017434515,0.65841144,0.00040655799,0.0011613029,0.0003965091,0.00065087207,0.00014474629,0.24461667,0.00033383406,0.01835188,0.0002016126],"about_ca_topic_score_codex":0.000018337409,"about_ca_topic_score_gemma":0.00003064215,"teacher_disagreement_score":0.17242618,"about_ca_system_score_codex":0.00003494096,"about_ca_system_score_gemma":0.00047579836,"threshold_uncertainty_score":0.31575054},"labels":[],"label_agreement":null},{"id":"W2801905566","doi":"","title":"Kinase Inhibitors and Nucleoside Analogues as Novel Therapies to Inhibit HIV-1 or ZEBOV Replication","year":2017,"lang":"en","type":"dissertation","venue":"TSpace (University of Toronto)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Blood Services","keywords":"Virology; Nucleoside analogue; Nucleoside; Replication (statistics); Human immunodeficiency virus (HIV); Medicine; Biology; Genetics","score_opus":0.018919905171536557,"score_gpt":0.2828792314134613,"score_spread":0.2639593262419247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801905566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9191682,0.001020716,0.000025946452,0.005492298,0.00014631945,0.0008962457,0.000047126694,0.00008229431,0.07312088],"genre_scores_gemma":[0.6132986,0.0010042067,0.0028810278,0.000044487617,0.00006180869,0.0000027084711,0.000839999,0.00003136714,0.38183582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988486,0.000017961658,0.00013710349,0.0005159822,0.00028722765,0.0001930975],"domain_scores_gemma":[0.9986486,0.000032718708,0.00030990885,0.00061601814,0.0001862554,0.00020653046],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011894686,0.0002727491,0.0005049283,0.00012539106,0.00028834847,0.000025872821,0.00016232398,0.00023098687,0.0022257576],"category_scores_gemma":[0.000076337295,0.0002689912,0.000113129645,0.00005103147,0.00007218707,0.00026275028,0.000050676426,0.000113193,0.00007448204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010252621,0.0013541447,0.01265033,0.0014514211,0.0025574858,0.00046930037,0.31798974,0.0000010981036,0.044881996,0.00087806076,0.043980855,0.56353295],"study_design_scores_gemma":[0.005190182,0.0008306335,0.7919989,0.0020731885,0.0012509801,0.00002888281,0.11072933,0.000022285209,0.007428158,0.000026323361,0.0795733,0.0008477906],"about_ca_topic_score_codex":0.025218729,"about_ca_topic_score_gemma":0.083519064,"teacher_disagreement_score":0.7793486,"about_ca_system_score_codex":0.0003068618,"about_ca_system_score_gemma":0.00022417979,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W2802802304","doi":"10.1089/aid.2017.0135","title":"Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana","year":2018,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fogarty International Center; Alliance for Accelerating Excellence in Science in Africa; National Institutes of Health; African Academy of Sciences; New Partnership for Africa's Development; Wellcome Trust","keywords":"Rilpivirine; Etravirine; Nevirapine; Efavirenz; Virology; Medicine; Drug resistance; Reverse-transcriptase inhibitor; Resistance mutation; Internal medicine; Reverse transcriptase; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Polymerase chain reaction; Gene; Genetics","score_opus":0.05731739124099637,"score_gpt":0.36473970989870563,"score_spread":0.30742231865770925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802802304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981132,0.0004567984,0.000010366618,0.00021235233,0.000018346534,0.0007743127,0.000028083217,0.000026125064,0.00036040312],"genre_scores_gemma":[0.99577135,0.00051264075,0.00056659605,0.00003973519,0.000028611319,0.00004472181,0.000088718654,0.000023163617,0.0029244698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793196,0.00021135963,0.00046483925,0.0004191946,0.00053872867,0.00043392976],"domain_scores_gemma":[0.9987749,0.00033636525,0.000099102894,0.00025043776,0.00041180057,0.00012738409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070951076,0.00019169944,0.00036493494,0.0010401868,0.00018879831,0.00003987781,0.0001014209,0.00008772591,0.00013659599],"category_scores_gemma":[0.0005381252,0.00015373506,0.000028691285,0.0009753139,0.0007018149,0.00021740256,0.000058450194,0.0002913933,0.000007969168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014044256,0.00090693485,0.9909211,0.00031736618,0.000031043917,0.000027806262,0.00041664595,1.8813884e-7,0.0021823375,0.0005347713,0.00015878941,0.003098621],"study_design_scores_gemma":[0.008087039,0.0058568204,0.97839946,0.0004916077,0.000014253855,7.0033906e-7,0.00006913129,0.000027774455,0.0063792397,0.00027122514,0.00026447084,0.00013830181],"about_ca_topic_score_codex":0.00021807484,"about_ca_topic_score_gemma":0.0010891779,"teacher_disagreement_score":0.012521634,"about_ca_system_score_codex":0.000129812,"about_ca_system_score_gemma":0.0001838654,"threshold_uncertainty_score":0.6269134},"labels":[],"label_agreement":null},{"id":"W2803180787","doi":"10.1111/hiv.12607","title":"Prospective plasma efavirenz concentration assessment in Chinese HIV‐infected adults enrolled in a large multicentre study","year":2018,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Fogarty International Center; U.S. Food and Drug Administration; Chinese Academy of Medical Sciences","keywords":"Efavirenz; Medicine; Interquartile range; Prospective cohort study; Dosing; Internal medicine; Gastroenterology; Confidence interval; Pharmacokinetics; Therapeutic drug monitoring; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Virology","score_opus":0.006614475736459234,"score_gpt":0.3014390435329665,"score_spread":0.2948245677965073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803180787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985676,0.000075552976,0.000042772775,0.003522721,0.00024767517,0.004008279,0.000009696286,0.00009719056,0.0063201347],"genre_scores_gemma":[0.9950596,0.000032627962,0.00038593193,0.00016033364,0.00033936146,0.00025589863,0.00026115504,0.000031855026,0.0034732232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733996,0.00017206691,0.00073788187,0.00060372346,0.0006151267,0.0005312206],"domain_scores_gemma":[0.99894214,0.00015493386,0.00015994615,0.00033060656,0.00020440835,0.0002079512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052672665,0.00038120348,0.00081851083,0.00034161174,0.00008085063,0.0000106351,0.00009203161,0.00010594576,0.00076817453],"category_scores_gemma":[0.0003724201,0.00025984904,0.000048815255,0.0009258438,0.000109599234,0.00012260009,0.000051944768,0.0003693845,0.00018501599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00188196,0.004048906,0.96016926,0.000045493987,0.00013473393,0.00053401705,0.03131581,0.0000012607994,0.00028841945,0.000041379717,0.00091725413,0.00062148756],"study_design_scores_gemma":[0.08562987,0.0011744166,0.8997968,0.0007195794,0.00011548042,0.000015297204,0.005537245,0.0062857694,0.00013216386,0.00001439128,0.0003732997,0.00020571203],"about_ca_topic_score_codex":0.00012256378,"about_ca_topic_score_gemma":0.003478787,"teacher_disagreement_score":0.083747916,"about_ca_system_score_codex":0.0006136698,"about_ca_system_score_gemma":0.00024904837,"threshold_uncertainty_score":0.9999854},"labels":[],"label_agreement":null},{"id":"W2803591712","doi":"10.1016/j.jpba.2018.05.019","title":"Probing DNA damage induced by common antiviral agents using multiple analytical techniques","year":2018,"lang":"en","type":"article","venue":"Journal of Pharmaceutical and Biomedical Analysis","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Chemistry; Hyperchromicity; Ledipasvir; DNA; DNA damage; Sofosbuvir; Daclatasvir; Guanine; Biochemistry; Ribavirin; Nucleotide; Genotype","score_opus":0.05732490418096418,"score_gpt":0.38527762082028705,"score_spread":0.32795271663932285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803591712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283594,0.00009721386,0.0024368346,0.0041546463,0.00006388834,0.00013859905,0.000010195711,0.000024208262,0.00023847006],"genre_scores_gemma":[0.9953455,0.00008135618,0.0034243006,0.00051733264,0.0003451006,0.0000014530748,0.000026491283,0.000012680839,0.00024579142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977848,0.00011263411,0.00077541545,0.00024756358,0.0007223349,0.00035723677],"domain_scores_gemma":[0.99869484,0.00011002668,0.000223744,0.0001159768,0.00019525152,0.00066015136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006698484,0.00022222019,0.00078797544,0.0006228571,0.00014290152,0.00004502483,0.00012204875,0.00015842354,0.00028099393],"category_scores_gemma":[0.00011578174,0.00014087082,0.0003427337,0.0012647889,0.0004563987,0.0001363485,0.00010161155,0.00040043844,0.000008445539],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015816457,0.0044895397,0.32489604,0.00018594753,0.014102657,0.0012577154,0.00072721805,1.7203182e-7,0.4572635,0.000047422243,0.009300955,0.1861472],"study_design_scores_gemma":[0.017000174,0.0037989947,0.0421478,0.0010327671,0.05013106,0.0008403174,0.0007334972,0.35231766,0.41574958,0.00027058792,0.11443505,0.0015425184],"about_ca_topic_score_codex":0.000011874737,"about_ca_topic_score_gemma":0.0000035680164,"teacher_disagreement_score":0.35231748,"about_ca_system_score_codex":0.00010718039,"about_ca_system_score_gemma":0.00009125912,"threshold_uncertainty_score":0.57445455},"labels":[],"label_agreement":null},{"id":"W2804779891","doi":"10.1136/bmjgh-2017-000651","title":"Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment","year":2018,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; U.S. Food and Drug Administration; U.S. President’s Emergency Plan for AIDS Relief","keywords":"Formulary; Food and drug administration; Medicine; Human immunodeficiency virus (HIV); Administration (probate law); Virology; Environmental health; Pharmacology; Political science; Law","score_opus":0.02771934738262266,"score_gpt":0.4076645423030717,"score_spread":0.37994519492044904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804779891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849078,0.000058394424,0.000023589133,0.008429856,0.000109688524,0.0014146201,0.00029745608,0.000018897192,0.004739711],"genre_scores_gemma":[0.9987154,0.00002464592,0.00035374056,0.00026429785,0.00010109905,0.000018846464,0.000049431932,0.0000056189115,0.00046693924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862576,0.00007610565,0.00043956866,0.0002531518,0.0003642438,0.00024115786],"domain_scores_gemma":[0.9990615,0.000016642942,0.00028748089,0.00032083163,0.00010513833,0.00020838933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018458403,0.00018079155,0.00034201497,0.000031815587,0.00009663121,0.000018868372,0.00008786728,0.000046909965,0.000011768844],"category_scores_gemma":[0.000035028454,0.00011025843,0.000107490756,0.00034632147,0.00009022674,0.00007044489,0.00003419936,0.000031141528,0.00000851173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018238424,0.0008605235,0.9435563,0.00009394864,0.00019522235,0.000004434381,0.00074319204,0.0000042258616,0.000015083372,0.0018886895,0.014783963,0.036030546],"study_design_scores_gemma":[0.0023352404,0.010586375,0.98443705,0.00025085144,0.00006461067,0.000036518108,0.00009380893,0.000043660973,0.0014075028,0.00016124368,0.0004861032,0.00009702001],"about_ca_topic_score_codex":0.0009271598,"about_ca_topic_score_gemma":0.001232314,"teacher_disagreement_score":0.040880732,"about_ca_system_score_codex":0.0011940857,"about_ca_system_score_gemma":0.0015749164,"threshold_uncertainty_score":0.4496208},"labels":[],"label_agreement":null},{"id":"W2804985360","doi":"10.1093/cid/ciy400","title":"Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011–2015","year":2018,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"National Institute on Drug Abuse; National Institute of Mental Health","keywords":"Medicine; Hazard ratio; Proportional hazards model; Confidence interval; Cohort; Internal medicine; Relative risk; Antiretroviral therapy; Cohort study; Viral load; Human immunodeficiency virus (HIV); Immunology","score_opus":0.036362783886480524,"score_gpt":0.3722739506453897,"score_spread":0.3359111667589092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804985360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722624,0.00023881509,0.0000068282,0.0005451933,0.00012902566,0.0011871939,0.000009933217,0.00007515738,0.00058161584],"genre_scores_gemma":[0.9982052,0.00045382816,0.000031583306,0.00011403432,0.00019250136,0.00009727417,0.000034766214,0.000016806349,0.0008540189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983344,0.00019343854,0.00059483293,0.0004453556,0.000222859,0.00020911639],"domain_scores_gemma":[0.99904716,0.00024493565,0.00014146045,0.00026328868,0.00009031117,0.00021286526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023882344,0.00022237086,0.0006654583,0.0001473125,0.0000893355,0.000016520285,0.000050830862,0.00011787552,0.00026701455],"category_scores_gemma":[0.00021841971,0.00014842606,0.00013028095,0.00014809455,0.00032180728,0.0000656865,0.00004288248,0.00011529624,0.00005809348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002940087,0.010364625,0.9811562,0.000007633534,0.00038301575,0.00006288787,0.00030836047,6.1515664e-7,0.000010964788,0.000016276572,0.00077049027,0.0066249585],"study_design_scores_gemma":[0.008480913,0.010568425,0.97954047,0.000022295202,0.00025288275,0.0000058898454,0.00011508179,0.00009274877,0.000033395267,0.00011507443,0.00064053276,0.00013231875],"about_ca_topic_score_codex":0.00010928807,"about_ca_topic_score_gemma":0.00026307037,"teacher_disagreement_score":0.008186905,"about_ca_system_score_codex":0.0000771694,"about_ca_system_score_gemma":0.00010934906,"threshold_uncertainty_score":0.6052639},"labels":[],"label_agreement":null},{"id":"W2805014735","doi":"10.18433/jpps29394","title":"Evaluation of Ion-pair Formation of Adefovir to Improve Permeation across Artificial and Biological Membranes","year":2018,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Shahid Beheshti University of Medical Sciences","keywords":"Permeation; Membrane; Chemistry; Adefovir; Biophysics; Biology; Biochemistry; Virology","score_opus":0.31155983145232735,"score_gpt":0.5227060744286097,"score_spread":0.21114624297628237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805014735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14679882,0.85013056,0.00010327307,0.0007933667,0.000650658,0.0013114118,0.0000461163,0.000010551072,0.00015526751],"genre_scores_gemma":[0.14280637,0.8556772,0.00078793813,0.000054371754,0.0005962265,0.00002580492,0.000015319109,0.0000115687235,0.000025236892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589455,0.00044088406,0.0014861061,0.00027370485,0.0016108442,0.00029390713],"domain_scores_gemma":[0.9972608,0.00033256112,0.001023543,0.00008906017,0.001002402,0.00029163598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006520243,0.00027112802,0.0011397327,0.00034720555,0.00013533277,0.00003588264,0.00021945304,0.00010338965,0.0001931285],"category_scores_gemma":[0.0007042274,0.00015880812,0.00033446512,0.0006579191,0.0004908844,0.00034388053,0.00008577108,0.00025558966,0.000014209349],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017441822,0.00028515028,0.0001890654,0.002169581,0.00016785109,0.0000053294652,0.0007263676,0.000003237909,0.0024144952,0.00002015596,0.00014615184,0.9936982],"study_design_scores_gemma":[0.0038841,0.0011461694,0.00016674647,0.0067215855,0.0071842596,0.0005297155,0.0005899725,0.005233548,0.05227233,0.00020942264,0.9216168,0.00044536838],"about_ca_topic_score_codex":0.0000032036298,"about_ca_topic_score_gemma":0.0000017154766,"teacher_disagreement_score":0.9932528,"about_ca_system_score_codex":0.00019620435,"about_ca_system_score_gemma":0.0007624402,"threshold_uncertainty_score":0.6476007},"labels":[],"label_agreement":null},{"id":"W2806355504","doi":"10.1093/jac/dky179","title":"2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings","year":2018,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Maraviroc; Genotype; Receiver operating characteristic; Genotyping; Statistics; Oncology; Medicine; Human immunodeficiency virus (HIV); Computer science; Internal medicine; Biology; Virology; Mathematics; Genetics","score_opus":0.017789104945958097,"score_gpt":0.2725003607535703,"score_spread":0.2547112558076122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806355504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8274374,0.0000113685455,0.15058452,0.019695362,0.0001005123,0.0020436693,0.000040790033,0.000024228553,0.00006216442],"genre_scores_gemma":[0.73744756,0.000007463077,0.25721356,0.0015903427,0.00025492738,0.000035166344,0.00002183053,0.000052038416,0.0033771244],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795526,0.00004353833,0.00086231367,0.00030741823,0.00049074757,0.00034069267],"domain_scores_gemma":[0.9981637,0.00010903383,0.00053265586,0.00033427626,0.0006216795,0.00023863715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004870577,0.00036131422,0.0008130468,0.00013658678,0.00023908252,0.00004577024,0.00026685288,0.000060169234,0.000036703084],"category_scores_gemma":[0.000013225339,0.00014576815,0.00014802914,0.00031416788,0.000113338356,0.00010609159,0.00002895815,0.000101883226,0.00002683865],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21365863,0.008259921,0.16357583,0.0018650641,0.02639016,0.00011267153,0.23908527,0.022812331,0.038249217,0.00016272398,0.24123186,0.044596322],"study_design_scores_gemma":[0.12547219,0.022754226,0.059039567,0.010651184,0.0035517411,0.0021779402,0.0059376825,0.008090771,0.6007479,0.00011010788,0.1587552,0.0027114744],"about_ca_topic_score_codex":0.000014093242,"about_ca_topic_score_gemma":0.00013668367,"teacher_disagreement_score":0.5624987,"about_ca_system_score_codex":0.00052369846,"about_ca_system_score_gemma":0.0018082765,"threshold_uncertainty_score":0.59442526},"labels":[],"label_agreement":null},{"id":"W2807747793","doi":"10.1097/qad.0000000000001903","title":"Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout","year":2018,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Integrase; Integrase inhibitor; Virology; Drug resistance; Medicine; Drug; Human immunodeficiency virus (HIV); Pharmacology; HIV drug resistance; Biology; Genetics; Viral load; Antiretroviral therapy","score_opus":0.0060547395603646175,"score_gpt":0.25289102509330064,"score_spread":0.24683628553293602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807747793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884421,0.00014102667,0.0005686843,0.0026976345,0.00014674952,0.0004017245,0.00002842449,0.000062304134,0.0075113103],"genre_scores_gemma":[0.90534717,0.000004899447,0.015531639,0.00010848872,0.000054926997,0.000043991586,0.00012144438,0.000024847634,0.07876259],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889445,0.000030386236,0.0002576304,0.00026648105,0.00031799573,0.00023302443],"domain_scores_gemma":[0.99932253,0.000060416045,0.00006160466,0.00027561627,0.00011244539,0.00016737761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014279904,0.0001665803,0.0002758923,0.00014379817,0.0001218303,0.000013459074,0.00007572281,0.00004361152,0.000093975774],"category_scores_gemma":[0.000067363464,0.0001129528,0.000074259144,0.0004339779,0.00007575554,0.00010769993,0.000028852735,0.00009073214,0.00012809456],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010357932,0.0007194518,0.2656774,0.00012583504,0.000656918,0.00015167794,0.0128413625,0.000002634126,0.08673204,0.00037411362,0.6286724,0.0030103794],"study_design_scores_gemma":[0.0055769435,0.00081519154,0.0065989075,0.0023867066,0.0006273378,0.000012197851,0.0041954713,0.000019950516,0.8755441,0.00020161898,0.10353171,0.00048988906],"about_ca_topic_score_codex":0.00004449775,"about_ca_topic_score_gemma":0.00007364717,"teacher_disagreement_score":0.78881204,"about_ca_system_score_codex":0.000089153604,"about_ca_system_score_gemma":0.000106508436,"threshold_uncertainty_score":0.46060815},"labels":[],"label_agreement":null},{"id":"W2807973130","doi":"10.1016/s2352-3018(18)30099-7","title":"What did we learn from the bictegravir switch studies?","year":2018,"lang":"en","type":"letter","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Tenofovir alafenamide; Emtricitabine; Dolutegravir; Medicine; Abacavir; Internal medicine; Virology; Oncology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.07294376727259798,"score_gpt":0.3181492163741765,"score_spread":0.2452054491015785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807973130","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003774363,0.014958159,0.0000046681107,0.97540605,0.0017192597,0.000727899,0.000078217876,0.00014057431,0.0031907808],"genre_scores_gemma":[0.00041031901,0.023448152,0.00027142803,0.61678725,0.03161634,0.00016711079,0.0010030151,0.00010254339,0.3261938],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771535,0.00020506902,0.00033311022,0.0005107286,0.00062565773,0.0006100773],"domain_scores_gemma":[0.9974304,0.0007582703,0.00019999524,0.0014445828,0.00011639151,0.0000503894],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036980616,0.0005047187,0.001061669,0.000051017796,0.0003043209,0.0001413632,0.0006283781,0.0003331345,0.00061942736],"category_scores_gemma":[0.00007648109,0.00021173836,0.00021789086,0.00016674145,0.00032286014,0.000088578716,0.00022797266,0.0016180484,0.005559635],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007647896,0.000026071786,0.0013531154,0.000055114622,0.0015776027,0.0002944104,0.0045695305,5.2544074e-8,0.000008607495,0.0000132004125,0.9894133,0.0026125058],"study_design_scores_gemma":[0.0013030265,0.000047316393,0.0008396585,0.001067473,0.0007451093,0.000023171018,0.001016323,0.000003454633,0.00007876971,0.0011456723,0.993476,0.000254052],"about_ca_topic_score_codex":0.000029428758,"about_ca_topic_score_gemma":0.000049520688,"teacher_disagreement_score":0.3586188,"about_ca_system_score_codex":0.00015850406,"about_ca_system_score_gemma":0.00011714427,"threshold_uncertainty_score":0.99521464},"labels":[],"label_agreement":null},{"id":"W2810063204","doi":"10.1016/j.jval.2018.04.044","title":"Dolutegravir and Rilpivirine to Treat Virologically Suppressed Adults Living with HIV-1: A Canadian Cost-Utility Analysis","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Rilpivirine; Dolutegravir; Human immunodeficiency virus (HIV); Medicine; Virology; Antiretroviral therapy; Viral load","score_opus":0.021294070653612593,"score_gpt":0.2763232802801294,"score_spread":0.2550292096265168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810063204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98445576,0.00013719643,0.0001601493,0.012624642,0.000023668445,0.0010163959,0.00004938915,0.00004185502,0.001490967],"genre_scores_gemma":[0.992999,0.000070564434,0.0042003957,0.0011942842,0.000055426877,0.00006950984,0.000054322998,0.0000148672625,0.0013416167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815893,0.00016648586,0.00035161444,0.00051173323,0.00021872834,0.0005924879],"domain_scores_gemma":[0.99844766,0.00016065386,0.000062486004,0.0003344541,0.00007952661,0.0009152171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053636194,0.00021159978,0.00054432405,0.00056392973,0.00015410235,0.00002067755,0.000073261835,0.00007689483,0.00023332941],"category_scores_gemma":[0.00012730861,0.0001495555,0.000045647237,0.0009753375,0.00008926345,0.000044263,0.000032294593,0.00014474877,0.000052577954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003817823,0.0002030243,0.98830134,0.00009869412,0.00014867415,0.00009078065,0.0038060374,0.0000444176,0.000007531212,0.000038491627,0.0007809437,0.0060982774],"study_design_scores_gemma":[0.0015597275,0.0008186417,0.9890153,0.00031542906,0.00015671116,0.000019798585,0.00022548491,0.0038978157,0.00003129592,0.0000139092135,0.0037857913,0.00016008507],"about_ca_topic_score_codex":0.19296707,"about_ca_topic_score_gemma":0.35564777,"teacher_disagreement_score":0.16268069,"about_ca_system_score_codex":0.00042852745,"about_ca_system_score_gemma":0.000613377,"threshold_uncertainty_score":0.812407},"labels":[],"label_agreement":null},{"id":"W2823804928","doi":"","title":"Comparación de tres métodos genotípicos para la detección de resistencia del VIH-1 a los antirretrovirales","year":2002,"lang":"es","type":"article","venue":"Revista española de quimioterapia. Suplemento","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Genotyping; Human immunodeficiency virus (HIV); Medicine; Molecular biology; Biology; Virology; Genetics; Genotype; Gene","score_opus":0.030809351161640706,"score_gpt":0.3087243280288967,"score_spread":0.277914976867256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2823804928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9435915,0.038875613,0.003241737,0.008457664,0.00017440451,0.0027142214,0.00044153674,0.00042859738,0.0020747655],"genre_scores_gemma":[0.9545864,0.011346114,0.0150414305,0.0015201368,0.00071420445,0.00032831763,0.0002665545,0.00025744157,0.015939398],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909303,0.0015838428,0.0019421797,0.001484386,0.0012306176,0.0028286723],"domain_scores_gemma":[0.9953732,0.0008081004,0.0006931344,0.0015443166,0.0002454244,0.0013358606],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0019929165,0.0014910834,0.001986962,0.0007761722,0.0006922822,0.00096718105,0.00089677866,0.0006174279,0.0032422633],"category_scores_gemma":[0.00037112244,0.0014479109,0.00089205045,0.00087522983,0.00038684762,0.0004144217,0.00030473113,0.0009523677,0.0010228894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012283131,0.002977112,0.83535445,0.003571328,0.0033981563,0.0038407475,0.0072124405,0.00003010031,0.022400372,0.005859677,0.079842456,0.03428485],"study_design_scores_gemma":[0.011637407,0.001189079,0.2060111,0.0047387006,0.003805728,0.0008295344,0.001057593,0.010918469,0.014350641,0.00013609753,0.7427374,0.0025882404],"about_ca_topic_score_codex":0.00032699737,"about_ca_topic_score_gemma":0.00016016439,"teacher_disagreement_score":0.66289496,"about_ca_system_score_codex":0.0022434825,"about_ca_system_score_gemma":0.0007117941,"threshold_uncertainty_score":0.9997838},"labels":[],"label_agreement":null},{"id":"W2861721336","doi":"10.1089/apc.2018.0020","title":"Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005–2013","year":2018,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Mental Health","keywords":"Medicine; Proportional hazards model; Demography; Drug resistance; Hazard ratio; HIV drug resistance; Viral load; Human immunodeficiency virus (HIV); Cohort; Internal medicine; Antiretroviral therapy; Immunology; Confidence interval","score_opus":0.005351895105905635,"score_gpt":0.22299943029997077,"score_spread":0.21764753519406513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2861721336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952165,0.0017692703,0.000001171493,0.00006651265,0.000042380696,0.0005587011,0.000030271756,0.00001902866,0.002296194],"genre_scores_gemma":[0.9935053,0.0006789394,0.0013295906,0.000022792328,0.000027079175,0.000099177785,0.000021177433,0.000016361899,0.0042995526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985244,0.000080785976,0.00041281173,0.00029683905,0.00029882605,0.00038629762],"domain_scores_gemma":[0.99939555,0.000058802296,0.00009951973,0.00023019707,0.00009007169,0.00012584426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015754117,0.00020793157,0.0003702316,0.00023771991,0.000064724714,0.000011178825,0.00006001963,0.000057505848,0.0000635348],"category_scores_gemma":[0.000035373876,0.00017167932,0.00003909947,0.0002063076,0.00009574424,0.0001164719,0.00007090815,0.00009147677,0.00000870622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017409843,0.00025462237,0.9242649,0.000642181,0.00008042186,0.00007953155,0.04781582,8.780922e-7,0.0010603417,0.000021321808,0.00020504798,0.023833955],"study_design_scores_gemma":[0.018010257,0.011361565,0.84528524,0.006503025,0.00022610601,0.000034687215,0.026411664,0.000057227546,0.089939944,0.00010660384,0.0011881371,0.0008755306],"about_ca_topic_score_codex":0.00026336606,"about_ca_topic_score_gemma":0.00037691108,"teacher_disagreement_score":0.08887961,"about_ca_system_score_codex":0.0005324711,"about_ca_system_score_gemma":0.00009144078,"threshold_uncertainty_score":0.70008796},"labels":[],"label_agreement":null},{"id":"W2871288639","doi":"10.4081/jphia.2018.767","title":"Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso","year":2018,"lang":"en","type":"article","venue":"Journal of Public Health in Africa","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"H2020 European Research Council; African Population and Health Research Center; International Development Research Centre","keywords":"HIV drug resistance; Genotyping; Medicine; Drug resistance; Antiretroviral therapy; Antiretroviral drug; Human immunodeficiency virus (HIV); Viral load; Antiretroviral treatment; Resistance mutation; Pediatrics; Virology; Biology; Genotype; Genetics; Polymerase chain reaction; Gene","score_opus":0.04648279660661439,"score_gpt":0.31970286418953675,"score_spread":0.2732200675829224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2871288639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867328,0.0045659184,0.000008108608,0.006536252,0.00010343718,0.00031910124,0.000006273546,0.0000064511974,0.0017217001],"genre_scores_gemma":[0.9966116,0.0010490629,0.0010293423,0.000082684775,0.000040195424,0.000005674819,0.0000030868655,0.000017556627,0.0011608016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976659,0.00026748728,0.0010946465,0.00020202449,0.00025536824,0.0005145871],"domain_scores_gemma":[0.99885625,0.000091495924,0.0005331873,0.00020028344,0.00013578194,0.00018297641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021819908,0.00019295907,0.0007189164,0.0009686087,0.00006707107,0.00002210589,0.00012709861,0.00006951378,0.000032969947],"category_scores_gemma":[0.00019389365,0.00013694188,0.000056073794,0.0008842544,0.00011788746,0.00018602509,0.000029748919,0.00024705034,0.000002447776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006675655,0.0027439892,0.8125459,0.00023075072,0.00012723717,0.00026166372,0.13933815,0.0000013948977,0.001974376,0.0001986595,0.0013937542,0.04051658],"study_design_scores_gemma":[0.011741984,0.0033190914,0.9327003,0.0020192515,0.000019802637,0.000075894444,0.007187793,0.0000957858,0.00059736293,0.00049413816,0.04141736,0.0003312332],"about_ca_topic_score_codex":0.00043428162,"about_ca_topic_score_gemma":0.0021542825,"teacher_disagreement_score":0.13215035,"about_ca_system_score_codex":0.0010179034,"about_ca_system_score_gemma":0.001012109,"threshold_uncertainty_score":0.55843276},"labels":[],"label_agreement":null},{"id":"W2884117835","doi":"10.1093/cid/ciy589","title":"Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Instituto de Salud Carlos III; ViiV Healthcare; Gilead Sciences; European and Developing Countries Clinical Trials Partnership; Wellcome Trust; Styrelsen för Internationellt Utvecklingssamarbete; Irish Aid; Pfizer; Medical Research Council; Abbott Laboratories","keywords":"Protease inhibitor (pharmacology); Medicine; Observational study; Randomized controlled trial; Protease; Virology; Human immunodeficiency virus (HIV); Internal medicine; Sida; Immunology; Viral disease; Antiretroviral therapy; Viral load; Biology; Enzyme","score_opus":0.031965192712516424,"score_gpt":0.35037593252776494,"score_spread":0.31841073981524853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884117835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931213,0.00039374616,0.00003870086,0.00014706966,0.0003246022,0.005774328,0.000056216766,0.00008620439,0.000057784197],"genre_scores_gemma":[0.99800175,0.00007475894,0.000046756722,0.00018115554,0.00036181443,0.0007675614,0.00026426243,0.000034369714,0.00026754508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99527234,0.0011484098,0.0021064123,0.0006001591,0.0005633651,0.00030933073],"domain_scores_gemma":[0.9967976,0.0008421533,0.0008361259,0.0005438327,0.0007940058,0.00018624224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017854254,0.00035053358,0.0012634553,0.00050828484,0.00023151372,0.0000556941,0.0001590458,0.00020671295,0.00027920396],"category_scores_gemma":[0.003023257,0.00024029183,0.0004204061,0.0017971734,0.00069530954,0.00028685317,0.000040470266,0.00034596375,0.00001999862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.240822,0.0055473214,0.7522115,0.00005450564,0.00043613446,0.000008580439,0.000506362,0.000048882768,0.00010454844,0.00017125208,0.000014635893,0.0000742593],"study_design_scores_gemma":[0.4153368,0.0026685994,0.5784964,0.00036058328,0.0004196629,2.689954e-7,0.000049829945,0.0007275476,0.0005002653,0.0010974642,0.000056638975,0.0002859489],"about_ca_topic_score_codex":0.00032781146,"about_ca_topic_score_gemma":0.0014995013,"teacher_disagreement_score":0.1745148,"about_ca_system_score_codex":0.0003578543,"about_ca_system_score_gemma":0.0010075658,"threshold_uncertainty_score":0.97988164},"labels":[],"label_agreement":null},{"id":"W2884916801","doi":"10.1093/infdis/jiy428","title":"Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors","year":2018,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Elvitegravir; Raltegravir; Integrase; Integrase inhibitor; Virology; Biology; Drug resistance; Genetics; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.03496878937147072,"score_gpt":0.3475834808612713,"score_spread":0.31261469148980053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884916801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802554,0.00020242362,0.0006097868,0.00044275293,0.00008707575,0.00018557758,0.000006584061,0.000009538081,0.00043070057],"genre_scores_gemma":[0.99864393,0.000025132971,0.00040155393,0.00006135092,0.00013367878,0.000001956675,0.0000017073919,0.000007870741,0.00072280364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930936,0.00004129208,0.0003383,0.00006108875,0.00015548248,0.00009448952],"domain_scores_gemma":[0.99909717,0.00025047828,0.00019883923,0.00007508014,0.00023806405,0.00014039122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016321683,0.000083859806,0.00017929735,0.00018563366,0.00007634664,0.000016936196,0.00003533854,0.000020835547,0.000042586576],"category_scores_gemma":[0.0007694822,0.00005465825,0.00004546477,0.00021581574,0.000100590245,0.00010294525,0.000016070187,0.000066390254,0.0000031085983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006043349,0.00018709786,0.9900566,0.000033704586,0.000100149045,0.000015186674,0.0037330568,0.00016584228,0.001972897,0.000036866808,0.001231351,0.0018629107],"study_design_scores_gemma":[0.008815819,0.000730876,0.95282966,0.0013930278,0.0006236425,0.00011420729,0.0019792097,0.0002516578,0.029835328,0.0014159532,0.0017949627,0.00021567161],"about_ca_topic_score_codex":0.00009397983,"about_ca_topic_score_gemma":0.00042478292,"teacher_disagreement_score":0.037226956,"about_ca_system_score_codex":0.00008714141,"about_ca_system_score_gemma":0.00018637258,"threshold_uncertainty_score":0.22288986},"labels":[],"label_agreement":null},{"id":"W2885066505","doi":"10.1089/aid.2015.0039","title":"High Prevalence of HIV Low Abundance Drug-Resistant Variants in a Treatment-Naive Population in North Rift Kenya","year":2015,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Drug resistance; Population; Pyrosequencing; Medicine; Amplicon; Virology; Biology; Internal medicine; Polymerase chain reaction; Genetics; Environmental health","score_opus":0.06040174943836,"score_gpt":0.3468720946724733,"score_spread":0.2864703452341133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885066505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979535,0.0006625922,0.000002027914,0.00016816931,0.000021999384,0.000689857,0.000048668877,0.000018848243,0.0004343495],"genre_scores_gemma":[0.9903438,0.00039280282,0.00045693276,0.000010926712,0.000044988057,0.000078398654,0.00008072716,0.000019919014,0.008571501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997786,0.00019892515,0.00043118905,0.00042092786,0.0006588936,0.0005040752],"domain_scores_gemma":[0.99902457,0.00014546957,0.000079971986,0.00031245753,0.00018572908,0.00025180273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060988264,0.00019239295,0.00044359564,0.0007253696,0.000093500836,0.000032261945,0.000114040224,0.00006609003,0.00006339724],"category_scores_gemma":[0.00019352457,0.0001529321,0.000038955623,0.0006274409,0.00019985125,0.00019929941,0.00006795639,0.00020972593,0.000027006996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008131192,0.0008239924,0.9932138,0.00023085611,0.00005184114,0.00020473507,0.002051024,0.0000035656133,0.0002557899,0.0011917427,0.00031143212,0.0008481458],"study_design_scores_gemma":[0.004684213,0.0014492422,0.991104,0.00038911463,0.00002253518,0.0000031219784,0.00034265945,0.000009335388,0.0008959634,0.0007888892,0.00018600206,0.00012493967],"about_ca_topic_score_codex":0.0037621015,"about_ca_topic_score_gemma":0.0077493456,"teacher_disagreement_score":0.008137151,"about_ca_system_score_codex":0.0005081279,"about_ca_system_score_gemma":0.00026091572,"threshold_uncertainty_score":0.623639},"labels":[],"label_agreement":null},{"id":"W2886948215","doi":"10.4212/cjhp.v50i1.2006","title":"Lamivudine and Zidovudine: A Novel Combination","year":2018,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Zidovudine; Lamivudine; Virology; Medicine; Human immunodeficiency virus (HIV); Viral disease; Virus","score_opus":0.018815390646587313,"score_gpt":0.280817196075159,"score_spread":0.26200180542857165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886948215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93873006,0.00052472926,0.00003055097,0.05707991,0.00046985483,0.00017907929,0.0000053037634,0.0000053658546,0.0029751456],"genre_scores_gemma":[0.99606067,0.000043719032,0.00032469485,0.00051592704,0.00036793936,0.0000016534999,0.0000034193554,0.000011776536,0.0026701784],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937546,0.0000127210105,0.00019892098,0.0000708175,0.00015740076,0.000184664],"domain_scores_gemma":[0.9991205,0.000024175695,0.00010880976,0.00007709285,0.00027928408,0.0003901749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023136471,0.000097137134,0.00015233409,0.00014302856,0.00020430303,0.000039174894,0.00008494859,0.00001725277,0.00018962371],"category_scores_gemma":[0.00006396714,0.00006132844,0.000047235393,0.0001412307,0.0001883495,0.00011528478,0.000010160723,0.00014856616,0.000033315904],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042460844,0.00093891163,0.6483593,0.00009585718,0.00222782,0.0016574191,0.018896334,0.0000019926567,0.00416043,0.0080750855,0.2752996,0.03986261],"study_design_scores_gemma":[0.02923779,0.0033962263,0.3621579,0.0004093816,0.0012307232,0.0030629677,0.0008484626,0.00061861257,0.017547917,0.0023090262,0.57852083,0.000660123],"about_ca_topic_score_codex":0.0007789226,"about_ca_topic_score_gemma":0.002143123,"teacher_disagreement_score":0.30322126,"about_ca_system_score_codex":0.00013986052,"about_ca_system_score_gemma":0.0006125513,"threshold_uncertainty_score":0.25009015},"labels":[],"label_agreement":null},{"id":"W2886954576","doi":"10.1101/393207","title":"<i>sierra-local</i> : A lightweight standalone application for secure HIV-1 drug resistance prediction","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Government of Canada; Ontario Genomics; Ontario Genomics Institute; Genome Canada","keywords":"Concordance; Confidentiality; Human immunodeficiency virus (HIV); Resistance (ecology); Interpretation (philosophy); Computer science; Drug resistance; Data mining; Data science; Computer security; Medicine; Bioinformatics; Family medicine; Biology","score_opus":0.007722440253410795,"score_gpt":0.2176390478896852,"score_spread":0.2099166076362744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886954576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5485122,0.011673335,0.36789945,0.029002182,0.00519926,0.024368921,0.007998878,0.004703151,0.0006426192],"genre_scores_gemma":[0.9538312,0.0005924526,0.035959233,0.00034499203,0.0018976448,0.004134593,0.000044244298,0.00032792773,0.0028676924],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962148,0.00007384302,0.0008346707,0.0015070694,0.0006795903,0.00069001043],"domain_scores_gemma":[0.9962894,0.0000744623,0.0005448186,0.0015440555,0.0011012302,0.00044606786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065382075,0.000772089,0.0009110984,0.0003324671,0.00032532908,0.00010471623,0.00033537735,0.0006407845,0.000051875337],"category_scores_gemma":[0.00009816064,0.00074534246,0.0002770293,0.000526264,0.00020045316,0.00014171169,0.0002080723,0.00056907325,0.00017699559],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039213435,0.0034443636,0.032072853,0.011031436,0.004278185,0.0002485514,0.0006239934,0.000028785911,0.30337057,0.004667527,0.6362742,0.000038206646],"study_design_scores_gemma":[0.003786931,0.00007456885,0.008439607,0.0018961478,0.0010636491,6.5423684e-8,0.000010226166,0.0007073192,0.30672884,0.000027393751,0.676257,0.0010082524],"about_ca_topic_score_codex":0.00000510235,"about_ca_topic_score_gemma":0.00001378756,"teacher_disagreement_score":0.40531904,"about_ca_system_score_codex":0.00106414,"about_ca_system_score_gemma":0.0011765871,"threshold_uncertainty_score":0.99949974},"labels":[],"label_agreement":null},{"id":"W2887170399","doi":"10.1186/s12977-018-0440-3","title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","year":2018,"lang":"en","type":"article","venue":"Retrovirology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; BC Children's Hospital; Jewish General Hospital","funders":"Université de Montréal; McGill University; Genome Canada; Gilead Sciences","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase inhibitor; Virology; Biology; Integrase; Drug resistance; Microbiology; Medicine; Viral load; Virus; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.01119201152111467,"score_gpt":0.2854821367145856,"score_spread":0.27429012519347096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887170399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336785,0.0009191979,0.00011495123,0.0023011663,0.00014505538,0.0008590649,0.000015619544,0.000108535874,0.0021685325],"genre_scores_gemma":[0.98612195,0.00040593403,0.009776194,0.0005008306,0.00016616918,0.000104071325,0.000062702915,0.0000617071,0.0028004122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707144,0.00028917743,0.00072292285,0.00092449033,0.00025435202,0.0007376077],"domain_scores_gemma":[0.99864006,0.0002404644,0.00023619964,0.0004241537,0.00019913063,0.00026001036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037411266,0.00044988026,0.00088979094,0.00040509138,0.00019229089,0.000027303311,0.000119447526,0.00035786504,0.00006443407],"category_scores_gemma":[0.00018191294,0.0003241942,0.000097312775,0.0006619878,0.00079877203,0.00013149067,0.00007786871,0.0006385666,0.00006463449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039015296,0.00049684366,0.9678158,0.00005767694,0.00034307028,0.00040145445,0.0021679439,2.963439e-7,0.013069058,0.0005549847,0.0010715021,0.010119838],"study_design_scores_gemma":[0.010666875,0.0061285365,0.94173497,0.00045003774,0.00036461983,0.00031028374,0.0011908475,0.00016061595,0.010791348,0.001203193,0.026098477,0.00090020965],"about_ca_topic_score_codex":0.00010710448,"about_ca_topic_score_gemma":0.0015049254,"teacher_disagreement_score":0.026080847,"about_ca_system_score_codex":0.00012573498,"about_ca_system_score_gemma":0.0002594305,"threshold_uncertainty_score":0.999921},"labels":[],"label_agreement":null},{"id":"W2887284835","doi":"10.1093/infdis/jiy475","title":"Reply to Darcis and Berkhout","year":2018,"lang":"en","type":"letter","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Vereniging Trustfonds Erasmus Universiteit Rotterdam","keywords":"Medicine","score_opus":0.009454221505235758,"score_gpt":0.2578795168211752,"score_spread":0.24842529531593946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887284835","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07234545,0.0028256925,0.000044079512,0.9204645,0.00063469604,0.0004649241,0.000040473,0.000045796703,0.0031343652],"genre_scores_gemma":[0.021963332,0.0015148793,0.00015250624,0.94707257,0.009440065,0.000012641016,0.00004188566,0.00008044642,0.019721689],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863493,0.000107265885,0.00041117187,0.00013915604,0.00047866697,0.0002287861],"domain_scores_gemma":[0.99858457,0.00023242831,0.00033008636,0.00029874328,0.0003376394,0.00021656392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023806856,0.0002508228,0.00050532934,0.0002876647,0.00013571828,0.000041258736,0.00012042228,0.00011192864,0.00030550876],"category_scores_gemma":[0.00028663225,0.00013734953,0.00018342065,0.00014710738,0.00011279403,0.000055396406,0.00006730258,0.00054480525,0.000104937586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016779742,0.000082737664,0.018213972,0.00019425435,0.0006315265,0.00063865696,0.00041103415,2.1442402e-7,0.0000046676805,8.463037e-7,0.9785407,0.0011135527],"study_design_scores_gemma":[0.0011799568,0.0007235899,0.0080802115,0.0011998758,0.0020287847,0.0022811717,0.000041702722,5.786192e-7,0.00006095448,0.0002098843,0.9840239,0.00016937147],"about_ca_topic_score_codex":0.000022181677,"about_ca_topic_score_gemma":0.0000026760572,"teacher_disagreement_score":0.050382115,"about_ca_system_score_codex":0.00016018905,"about_ca_system_score_gemma":0.0002932929,"threshold_uncertainty_score":0.56009513},"labels":[],"label_agreement":null},{"id":"W2887935769","doi":"10.1093/infdis/jiy479","title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institutes of Health; Harvard University Center for AIDS Research; Harvard University; Fred Hutchinson Cancer Research Center; Janssen Pharmaceuticals; Gilead Sciences; Styrelsen för Internationellt Utvecklingssamarbete; Center for AIDS Research, University of Washington; AIDS Healthcare Foundation; GlaxoSmithKline; Canadian Institutes of Health Research; University of Washington; amfAR, The Foundation for AIDS Research","keywords":"Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Antiretroviral drug; Intensive care medicine; Immunology; Viral load","score_opus":0.01985700599769024,"score_gpt":0.3328229900501709,"score_spread":0.31296598405248066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887935769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899055,0.0057933214,0.00010514967,0.0025722748,0.0007468004,0.0007479875,0.00003103241,0.000020490641,0.00007748799],"genre_scores_gemma":[0.9968406,0.0017246691,0.000011119904,0.00023561816,0.00061357743,0.000029140008,0.000005146008,0.000016786687,0.00052335544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743694,0.00060199056,0.0010247602,0.00014185945,0.00059474417,0.00019967885],"domain_scores_gemma":[0.99640644,0.00154987,0.0008030812,0.00035612233,0.0007186338,0.00016584362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011128663,0.00020488696,0.0006949292,0.00009776819,0.00026570816,0.000026570662,0.00015187358,0.000045224762,0.000058795686],"category_scores_gemma":[0.0009006968,0.0000910707,0.00029739426,0.00012728079,0.00056002685,0.00009424503,0.000045625326,0.00016481137,0.00003795808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062752487,0.0019964473,0.9737079,0.0000093901945,0.0075672055,0.00008922997,0.002547701,0.0000015267059,0.00005629536,0.0000062992103,0.0042130337,0.003529696],"study_design_scores_gemma":[0.023297496,0.0049346965,0.95910424,0.00020672363,0.006140506,0.000049349495,0.0049774568,0.000028157585,0.00017931384,0.00040395925,0.00055225607,0.0001258221],"about_ca_topic_score_codex":0.00003839501,"about_ca_topic_score_gemma":0.00011321742,"teacher_disagreement_score":0.017022246,"about_ca_system_score_codex":0.00013821493,"about_ca_system_score_gemma":0.00024198576,"threshold_uncertainty_score":0.37137556},"labels":[],"label_agreement":null},{"id":"W2888611404","doi":"10.1093/infdis/jiy437","title":"Reply to Achieng and Riedel","year":2018,"lang":"en","type":"letter","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine","score_opus":0.009885462935028927,"score_gpt":0.2556932798470162,"score_spread":0.24580781691198725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888611404","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1549161,0.0018598707,0.00006415414,0.8396792,0.0005537569,0.00044000664,0.000027058026,0.0000443062,0.0024155478],"genre_scores_gemma":[0.06676791,0.00093465316,0.00016873264,0.90543604,0.0091448035,0.000013330731,0.000032869797,0.00008312255,0.01741856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987482,0.00010735373,0.0003817829,0.00013254797,0.00040738695,0.0002227252],"domain_scores_gemma":[0.9987279,0.00022361256,0.00031457364,0.00026799177,0.00026230238,0.00020358691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022951144,0.00024170348,0.0004691965,0.00020541194,0.00015439134,0.000039456718,0.00011245137,0.00010973181,0.00013273933],"category_scores_gemma":[0.00024747377,0.00013162004,0.00016391206,0.0001545434,0.000104621635,0.000058367084,0.000061422616,0.0005828018,0.00007970794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017753485,0.00008853329,0.014006825,0.00008124451,0.00058716163,0.00053474575,0.00043220533,6.894602e-7,0.0000074530376,0.0000014102889,0.9830189,0.0010633308],"study_design_scores_gemma":[0.0013730195,0.00079670345,0.010635638,0.00054989173,0.0022376277,0.0024348947,0.000058466678,0.0000013372268,0.000058828653,0.00020345725,0.98146635,0.00018376298],"about_ca_topic_score_codex":0.000014434637,"about_ca_topic_score_gemma":0.0000027688234,"teacher_disagreement_score":0.088148184,"about_ca_system_score_codex":0.00013336136,"about_ca_system_score_gemma":0.0002397377,"threshold_uncertainty_score":0.53673095},"labels":[],"label_agreement":null},{"id":"W2889088682","doi":"10.18433/jpps30068","title":"Identification of Mechanism and Pathway of the Interaction between the African Traditional Medicine, Sutherlandia Frutescens, and the Antiretroviral Protease Inhibitor, Atazanavir, in Human Subjects Using Population Pharmacokinetic (PK) Analysis","year":2018,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Atazanavir; Pharmacology; Pharmacokinetics; Population; CYP3A4; Protease inhibitor (pharmacology); Chemistry; Drug; Bioavailability; Biology; Traditional medicine; Biochemistry; Medicine; Metabolism; Immunology; Human immunodeficiency virus (HIV); Cytochrome P450; Antiretroviral therapy; Viral load","score_opus":0.0760124840899286,"score_gpt":0.3816866436056007,"score_spread":0.30567415951567206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889088682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951513,0.00035414286,0.00013266165,0.0036915636,0.00015517615,0.00045519604,0.000010331856,0.0000031319516,0.00004649329],"genre_scores_gemma":[0.99943596,0.000104158455,0.00006877765,0.000080932914,0.0002818877,0.0000043458376,0.00000346456,0.000005295668,0.000015202288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768835,0.00044503517,0.00080526917,0.0001721941,0.0007255132,0.00016362073],"domain_scores_gemma":[0.9986574,0.00031047867,0.0006857481,0.000088134555,0.00015714181,0.00010110327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026942727,0.00013401119,0.00036567703,0.0003176863,0.00027801393,0.000028943607,0.00018686977,0.000024129517,0.00005531651],"category_scores_gemma":[0.00013652124,0.000060705148,0.00011510529,0.0010678631,0.0012405529,0.00024486982,0.000045635847,0.00025539836,2.1814607e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064418284,0.00023335301,0.760078,0.00007618869,0.00050270907,0.0000076419565,0.002777524,0.000023386063,0.22429793,0.0010030982,0.000029381132,0.0103265755],"study_design_scores_gemma":[0.013190022,0.00053506094,0.472746,0.00045689955,0.0056411,0.00015325326,0.001723379,0.049474496,0.45280287,0.0027815949,0.00025987398,0.00023546598],"about_ca_topic_score_codex":0.00017836667,"about_ca_topic_score_gemma":0.00001208423,"teacher_disagreement_score":0.28733203,"about_ca_system_score_codex":0.00006548063,"about_ca_system_score_gemma":0.00008561253,"threshold_uncertainty_score":0.45708686},"labels":[],"label_agreement":null},{"id":"W2889920960","doi":"10.1080/15257770.2018.1500697","title":"Synthesis of cyclobutane nucleoside analogues 3: Preparation of carbocyclic derivatives of oxetanocin","year":2018,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Cyclobutane; Chemistry; Stereoselectivity; Stereochemistry; Trifluoromethanesulfonate; Cyclobutanes; Nucleobase; Methylene; Ring (chemistry); Alkylation; Thymine; Hydroxymethyl; Cyclobutene; Structural isomer; Medicinal chemistry; Organic chemistry; Catalysis; DNA","score_opus":0.013633939353856768,"score_gpt":0.2802160647017298,"score_spread":0.266582125347873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889920960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838367,0.00030826303,0.00009418851,0.0006289513,0.00015534426,0.0008198148,0.00008273633,0.00015110063,0.013922894],"genre_scores_gemma":[0.98067915,0.00024386903,0.01815076,0.000093438604,0.00013967758,0.000032848282,0.000034727433,0.0001198805,0.0005056222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959852,0.00017707252,0.0017262236,0.000689875,0.00084613485,0.0005754947],"domain_scores_gemma":[0.99647236,0.00043451486,0.0010563462,0.0010113994,0.00076445675,0.0002609515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004856466,0.0005708223,0.0016457081,0.00061094726,0.00015175297,0.00002079615,0.00040441102,0.00027066426,0.00068194565],"category_scores_gemma":[0.00067469926,0.00050514616,0.0004917704,0.0009425822,0.0014734317,0.00036564024,0.00018582206,0.00019508158,0.00008384144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026031039,0.001962666,0.23951422,0.0011065818,0.0022458148,0.000053790056,0.009270498,0.000017683164,0.7198083,0.003496278,0.00263721,0.01728388],"study_design_scores_gemma":[0.0016568042,0.0012544743,0.1847772,0.0010967935,0.00092760596,0.000052594914,0.0016688078,0.0004950339,0.8051114,0.0006424843,0.0018691624,0.00044763673],"about_ca_topic_score_codex":0.00017684746,"about_ca_topic_score_gemma":0.00007936731,"teacher_disagreement_score":0.08530313,"about_ca_system_score_codex":0.00015041816,"about_ca_system_score_gemma":0.00021012708,"threshold_uncertainty_score":0.99974},"labels":[],"label_agreement":null},{"id":"W2893011762","doi":"10.1128/mbio.01450-18","title":"Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”","year":2018,"lang":"en","type":"erratum","venue":"mBio","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Virology; Human immunodeficiency virus (HIV); Chemistry; Medicine; Antiretroviral therapy; Viral load","score_opus":0.02318856997971345,"score_gpt":0.3023209842039498,"score_spread":0.27913241422423635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893011762","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008550933,0.037770975,0.00508969,0.44257236,0.08429188,0.029784378,0.0055890977,0.003042779,0.38330793],"genre_scores_gemma":[0.0028073424,0.00075885124,0.0029885927,0.0029283005,0.0008877869,0.0013175231,0.024265578,0.00012768446,0.9639183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701065,0.00016804536,0.0006625022,0.00080427993,0.0007181028,0.00063641695],"domain_scores_gemma":[0.9976208,0.00017302888,0.0005744492,0.00065534667,0.0007554259,0.00022094633],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006289405,0.0006825427,0.0008407505,0.00024890818,0.0005366159,0.00016172581,0.00031151724,0.0006043623,0.00017575787],"category_scores_gemma":[0.0009788309,0.00044458496,0.0004126013,0.00044299624,0.00035268933,0.00013470929,0.00006588675,0.00076901034,0.00023160718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041984243,0.00044138124,0.00041302355,0.000100772195,0.0007135329,0.000058635953,0.0005365043,3.88182e-8,0.000030838197,0.0013723094,0.99550974,0.00040337455],"study_design_scores_gemma":[0.0022869708,0.000193722,0.0023716025,0.0024367906,0.00089823426,0.000018230245,0.00024459924,0.00003463416,0.0003864754,0.0007171943,0.98993474,0.00047678727],"about_ca_topic_score_codex":0.000029453515,"about_ca_topic_score_gemma":0.0012044761,"teacher_disagreement_score":0.5806104,"about_ca_system_score_codex":0.0007781804,"about_ca_system_score_gemma":0.0017836767,"threshold_uncertainty_score":0.99980056},"labels":[],"label_agreement":null},{"id":"W2894152930","doi":"10.1128/jvi.01156-18","title":"Correction for Anstett et al., “HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity”","year":2018,"lang":"en","type":"erratum","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"ViiV Healthcare","keywords":"Dolutegravir; Biology; Acetyltransferase; Acetylation; Human immunodeficiency virus (HIV); Histone acetyltransferase; Virology; Histone; Genetics; Antiretroviral therapy; DNA; Viral load","score_opus":0.01018281782159404,"score_gpt":0.29643088637207726,"score_spread":0.28624806855048324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894152930","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18270865,0.015633661,0.07325984,0.57079244,0.13268183,0.0058964896,0.0013935366,0.00022485197,0.017408712],"genre_scores_gemma":[0.008643227,0.0018446398,0.0034760782,0.015239461,0.0018199481,0.00008147985,0.0005441175,0.00016847804,0.96818256],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976606,0.00020638498,0.0006872419,0.0004796892,0.00047723175,0.0004888561],"domain_scores_gemma":[0.9980617,0.00019837516,0.000589337,0.00035754955,0.00043696724,0.000356048],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005794413,0.00051049585,0.0013874248,0.0005506116,0.00012935868,0.000022396138,0.00020315552,0.0006486275,0.00024017524],"category_scores_gemma":[0.00020478832,0.00041457842,0.00045888964,0.0002526495,0.00011931761,0.00010735465,0.00002435769,0.0012212837,0.00007815179],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003477037,0.0006139745,0.00005460617,0.00011347979,0.0007278427,0.00021296692,0.00050824013,3.7679192e-7,0.052659217,0.0000026255643,0.9410205,0.0006091642],"study_design_scores_gemma":[0.0036300728,0.0021835277,0.00052512076,0.0005333574,0.0008274872,0.00019477283,0.000021136191,0.000020929427,0.022959178,0.000018480672,0.96877575,0.00031018184],"about_ca_topic_score_codex":0.000009858704,"about_ca_topic_score_gemma":0.000119221186,"teacher_disagreement_score":0.95077384,"about_ca_system_score_codex":0.00063228543,"about_ca_system_score_gemma":0.0006832164,"threshold_uncertainty_score":0.9998306},"labels":[],"label_agreement":null},{"id":"W2895507830","doi":"10.1021/acs.jmedchem.8b01258","title":"Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides","year":2018,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; University of New Brunswick","funders":"Akademie Věd České Republiky; Technologická Agentura České Republiky; Grantová Agentura České Republiky; Ministerstvo Školství, Mládeže a Tělovýchovy; Gilead Sciences","keywords":"Chemistry; Stereochemistry; Combinatorial chemistry; Cytotoxic T cell; Biochemistry; In vitro","score_opus":0.009994041818971858,"score_gpt":0.2532842068645368,"score_spread":0.24329016504556494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895507830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570304,0.0014320163,0.000014641845,0.0017630239,0.00003244957,0.00008289493,0.0000030358951,0.0000072044327,0.000961701],"genre_scores_gemma":[0.9960581,0.00063513237,0.0025639844,0.000048693368,0.00033380184,0.0000016607585,0.00000121549,0.000013461766,0.00034397037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892884,0.000017623663,0.00042549332,0.00015061663,0.00031682942,0.00016059737],"domain_scores_gemma":[0.9991234,0.00014081843,0.00028435607,0.00009460146,0.00015828895,0.00019855073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042539614,0.00015757773,0.0004937425,0.00007737262,0.000053556014,0.00000968964,0.000046326382,0.00008457062,0.000048248665],"category_scores_gemma":[0.0003331379,0.0001102957,0.000043660333,0.00007854077,0.00039940423,0.00006970247,0.000042815325,0.00019077514,6.7774073e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081537984,0.0001509651,0.12753983,0.0007871714,0.00032498725,0.00042724496,0.0006432828,2.2584283e-8,0.8602831,0.0000064281307,0.0003176646,0.00870398],"study_design_scores_gemma":[0.0026010906,0.00039646676,0.028220912,0.0010596699,0.0004673352,0.0026205203,0.000679244,0.000046310437,0.96340066,0.00006213295,0.0003382392,0.00010742816],"about_ca_topic_score_codex":0.0000022919576,"about_ca_topic_score_gemma":6.486537e-7,"teacher_disagreement_score":0.1031176,"about_ca_system_score_codex":0.000026944239,"about_ca_system_score_gemma":0.00010218648,"threshold_uncertainty_score":0.44977283},"labels":[],"label_agreement":null},{"id":"W2896446932","doi":"10.1186/s13104-018-3804-9","title":"Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea","year":2018,"lang":"en","type":"article","venue":"BMC Research Notes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"European and Developing Countries Clinical Trials Partnership","keywords":"Medicine; Drug resistance; Transmission (telecommunications); Outbreak; Genotyping; Context (archaeology); Population; Virology; Human immunodeficiency virus (HIV); Internal medicine; Environmental health; Genotype; Biology; Microbiology","score_opus":0.03617357923756749,"score_gpt":0.3405427516852344,"score_spread":0.3043691724476669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896446932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898416,0.0029936398,0.000009795424,0.00484591,0.000017104707,0.0010431897,0.00003396666,0.000005864447,0.0012089728],"genre_scores_gemma":[0.9981097,0.00035408407,0.00053715473,0.000033846776,0.000024723156,0.000052391413,0.000024693982,0.0000123719165,0.0008510179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971518,0.0010708371,0.00047383824,0.00026019072,0.00063323573,0.0004100986],"domain_scores_gemma":[0.9972624,0.0020363461,0.000064694825,0.00034619574,0.00024217373,0.000048152608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025020977,0.0001392456,0.00047711423,0.00028140668,0.00005446989,0.000017063143,0.000226507,0.000058069498,0.000022747423],"category_scores_gemma":[0.0011020992,0.00007759468,0.000059202514,0.00079594535,0.00087471603,0.000049800372,0.000047959347,0.0002750478,0.00000607412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047373846,0.00014715226,0.95992005,0.000245352,0.000021911053,0.00003136603,0.03237972,3.7866113e-7,0.00043211025,0.0006693621,0.00051272963,0.00090247235],"study_design_scores_gemma":[0.019049723,0.00012260515,0.9594899,0.00058903656,0.000011007696,0.0000031368638,0.010188501,0.00017316877,0.00839882,0.00017593322,0.0016822807,0.000115883464],"about_ca_topic_score_codex":0.0012237006,"about_ca_topic_score_gemma":0.046338428,"teacher_disagreement_score":0.045114726,"about_ca_system_score_codex":0.000087979184,"about_ca_system_score_gemma":0.00028601903,"threshold_uncertainty_score":0.97106344},"labels":[],"label_agreement":null},{"id":"W2897956631","doi":"10.1002/jia2.25193","title":"Bioinformatic data processing pipelines in support of next‐generation sequencing‐based <scp>HIV</scp> drug resistance testing: the Winnipeg Consensus","year":2018,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Genome British Columbia; Genome Canada","keywords":"HIV drug resistance; Medicine; Human immunodeficiency virus (HIV); Data mining; Metagenomics; Computational biology; Computer science; Data science; Viral load; Virology; Antiretroviral therapy; Biology; Genetics","score_opus":0.11470657110557879,"score_gpt":0.3105198346677334,"score_spread":0.19581326356215462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897956631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9575813,0.00029218197,0.0012373229,0.037280604,0.00064853963,0.00032538432,0.00004279536,0.000016584354,0.002575332],"genre_scores_gemma":[0.9311454,0.00001913574,0.05915747,0.0017468494,0.00061409903,0.000003287073,0.000039556486,0.000014375624,0.0072598015],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981437,0.00004615309,0.00079531345,0.000121434554,0.00075008284,0.0001433249],"domain_scores_gemma":[0.9975877,0.00032763043,0.0008406109,0.0002827807,0.00091529253,0.000046010275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013211677,0.00013127194,0.00022983791,0.00007319048,0.00012858048,0.000059746224,0.0005651414,0.000043614484,0.0000147321825],"category_scores_gemma":[0.0012301045,0.000070765294,0.00014309782,0.00033908902,0.00020804371,0.00024562282,0.00011449016,0.00023027188,0.0000051749425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013569444,0.0003913548,0.091383845,0.00029260988,0.00072281295,0.00003845459,0.0133067025,0.0003052118,0.046010733,0.00012667122,0.844008,0.0032778746],"study_design_scores_gemma":[0.017666789,0.0005940451,0.036456253,0.0063428343,0.0015760188,0.001488441,0.021015381,0.4780594,0.2052245,0.0020902338,0.22893576,0.00055034243],"about_ca_topic_score_codex":0.0000098068185,"about_ca_topic_score_gemma":0.00004900069,"teacher_disagreement_score":0.61507225,"about_ca_system_score_codex":0.00028709043,"about_ca_system_score_gemma":0.0012691285,"threshold_uncertainty_score":0.2885725},"labels":[],"label_agreement":null},{"id":"W2898149304","doi":"10.3851/imp3274","title":"Optimizing Concentrations of Concomitant Antiretrovirals by Reducing Etravirine Doses: Two Case Reports of Complex Drug-drug Interactions","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Etravirine; Darunavir; Elvitegravir; Dolutegravir; Raltegravir; Drug; Pharmacology; Medicine; Concomitant; Drug interaction; Enfuvirtide; Maraviroc; Human immunodeficiency virus (HIV); Internal medicine; Antiretroviral therapy; Virology; Viral load; Immunology","score_opus":0.03408805450868194,"score_gpt":0.33665609141918984,"score_spread":0.3025680369105079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898149304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991723,0.0004199715,0.00019043364,0.00080467446,0.00024580673,0.0005576819,0.00004975475,0.000053293676,0.005955366],"genre_scores_gemma":[0.99058247,0.0003073583,0.0047602034,0.000105282175,0.000114695846,0.000014548371,0.00012437813,0.000029741856,0.0039613307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825984,0.00009230128,0.00080311875,0.00033154618,0.00024088784,0.00027229212],"domain_scores_gemma":[0.99868333,0.00012796544,0.00046294954,0.00038934767,0.00025236895,0.0000840458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027768785,0.00023378484,0.0005782189,0.00014730239,0.00016666629,0.000018676454,0.000057972153,0.000029589984,0.00023854872],"category_scores_gemma":[0.000033779816,0.00019286886,0.00016277503,0.00033017446,0.00035041297,0.00021230178,0.000028686723,0.00013901251,0.000010083353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049502205,0.0013517778,0.087508544,0.00006022387,0.0008620147,0.0022555199,0.011210001,0.0000036960766,0.8564908,0.0003475309,0.027755992,0.011658854],"study_design_scores_gemma":[0.0043468294,0.00040023177,0.0022923518,0.000390792,0.00015833894,0.001711155,0.0020374462,0.0003676952,0.9742439,0.000049147806,0.013693359,0.00030877048],"about_ca_topic_score_codex":0.0006187514,"about_ca_topic_score_gemma":0.00008928719,"teacher_disagreement_score":0.117753066,"about_ca_system_score_codex":0.00006474317,"about_ca_system_score_gemma":0.00012913765,"threshold_uncertainty_score":0.78649634},"labels":[],"label_agreement":null},{"id":"W2899304056","doi":"10.1159/000491705","title":"Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Myeloid leukemia; In vivo; Cytotoxic T cell; In vitro; Pharmacology; Leukemia; Adefovir; Cytotoxicity; Chemistry; Medicine; Cancer research; Biology; Immunology; Biochemistry","score_opus":0.008264345592563787,"score_gpt":0.23678963432553182,"score_spread":0.22852528873296804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899304056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968188,0.00031609673,0.00005170661,0.0015307367,0.000033083386,0.00081591454,0.0000032243693,0.000032680022,0.0003978054],"genre_scores_gemma":[0.9968076,0.00041065883,0.0009303404,0.00039455685,0.000051725438,0.00008990064,0.000005836162,0.00003924999,0.001270136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998671,0.000052896805,0.00021079909,0.00048305927,0.0001969533,0.000385292],"domain_scores_gemma":[0.9994553,0.00010714638,0.00006237831,0.00021332529,0.00002163768,0.0001402461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017455341,0.00030349364,0.0005264043,0.00031057242,0.0000492381,0.000030182617,0.00005427993,0.00013969323,0.00001886197],"category_scores_gemma":[0.000021625743,0.00023201616,0.000026170628,0.00037180388,0.00023340699,0.00010589567,0.000026518064,0.00023117555,0.0000073082215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044994117,0.0004139569,0.06432424,0.00016326281,0.00014491988,0.0007296933,0.0032412226,0.0000011729063,0.901162,0.0000056397616,0.00015386924,0.025160607],"study_design_scores_gemma":[0.011987539,0.0003442108,0.23817584,0.0004104628,0.000031504125,0.000055224995,0.000048731534,0.0003460527,0.7479646,0.000048132057,0.00034117818,0.0002465315],"about_ca_topic_score_codex":0.00013048649,"about_ca_topic_score_gemma":0.00046134074,"teacher_disagreement_score":0.1738516,"about_ca_system_score_codex":0.00045372717,"about_ca_system_score_gemma":0.00018845785,"threshold_uncertainty_score":0.94613445},"labels":[],"label_agreement":null},{"id":"W2899936086","doi":"10.1016/j.medmal.2018.10.005","title":"Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France","year":2018,"lang":"en","type":"article","venue":"Médecine et Maladies Infectieuses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Regimen; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Protease inhibitor (pharmacology); Medicine; Internal medicine; Antiretroviral therapy; Cohort; Human immunodeficiency virus (HIV); Viral load; Virology","score_opus":0.029516457905519655,"score_gpt":0.31462055845746295,"score_spread":0.2851041005519433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899936086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627009,0.0006542717,0.000006632973,0.023350907,0.0003363328,0.0008942943,0.000024266785,0.00014738608,0.011884995],"genre_scores_gemma":[0.9468607,0.0012676568,0.0001638041,0.0020237565,0.00051931274,0.00023106762,0.00006274601,0.00006237423,0.04880861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980556,0.00009311135,0.0003718224,0.0005058371,0.00043320638,0.0005404561],"domain_scores_gemma":[0.9986303,0.00031113828,0.00013149036,0.0006330358,0.00017279865,0.000121259785],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030132005,0.00042045157,0.000578157,0.0003023097,0.00017581771,0.000065908236,0.00018419515,0.00014791852,0.0024553621],"category_scores_gemma":[0.0004338065,0.00027729044,0.00010601391,0.0007298681,0.00022071492,0.00018254603,0.00017115846,0.0002487354,0.00038744244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019738001,0.0007427709,0.96781904,0.000057608406,0.00038666753,0.000072542665,0.0020970735,0.0000051199827,0.0001193291,0.000144079,0.026445616,0.001912797],"study_design_scores_gemma":[0.0043763868,0.0012152644,0.80504066,0.00027394554,0.00018375994,0.00003376536,0.00009659815,0.000022048525,0.0012495936,0.000085760716,0.18717252,0.00024970365],"about_ca_topic_score_codex":0.00042964763,"about_ca_topic_score_gemma":0.0062415604,"teacher_disagreement_score":0.16277836,"about_ca_system_score_codex":0.00014516656,"about_ca_system_score_gemma":0.00010508701,"threshold_uncertainty_score":0.99996793},"labels":[],"label_agreement":null},{"id":"W2900808794","doi":"10.9734/jammr/2018/45018","title":"Human Immunodeficiency Virus Infection, Treatments, and Therapy: Effect of the CCR5 Mutation","year":2018,"lang":"en","type":"article","venue":"Journal of Advances in Medicine and Medical Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Medicine; Mutation; Biology; Genetics; Gene","score_opus":0.03673638433248768,"score_gpt":0.45593459554587074,"score_spread":0.4191982112133831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900808794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96998376,0.024013385,0.000021591319,0.0038536345,0.00014260979,0.0002758538,3.1465797e-7,0.000002605474,0.0017062186],"genre_scores_gemma":[0.9481273,0.0509889,0.000053610387,0.00008114617,0.00023846368,0.00000792475,9.69577e-7,0.00000701428,0.000494614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99762136,0.00030366192,0.00046352792,0.00012500734,0.0012864366,0.00020002315],"domain_scores_gemma":[0.99871826,0.0005542877,0.00014762228,0.00011661122,0.0002978389,0.00016535887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003321705,0.00010349982,0.00039728152,0.00034462803,0.00014526924,0.0000049198047,0.00008582144,0.00007163886,0.00014957697],"category_scores_gemma":[0.0019365466,0.00004604919,0.000041036987,0.00046083258,0.0011328054,0.000117412776,0.000043278276,0.00042750777,0.0000011821263],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000961923,0.00046255073,0.3354014,0.00021003163,0.00016708577,0.00020161689,0.0034996003,3.660716e-7,0.005322069,0.00015171587,0.001113463,0.6525082],"study_design_scores_gemma":[0.05415306,0.045496915,0.69682884,0.010496954,0.00040478515,0.0023584557,0.0022213755,0.00013175368,0.049147185,0.0041234023,0.13433251,0.00030479618],"about_ca_topic_score_codex":0.000090152236,"about_ca_topic_score_gemma":0.000054891923,"teacher_disagreement_score":0.6522034,"about_ca_system_score_codex":0.00007058856,"about_ca_system_score_gemma":0.00018497343,"threshold_uncertainty_score":0.41738686},"labels":[],"label_agreement":null},{"id":"W2900832196","doi":"10.1111/hiv.12692","title":"Prevalence and determinants of resistance mutations in <scp>HIV</scp>‐1‐infected patients exposed to integrase inhibitors in a large Italian cohort","year":2018,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Janssen Biotech; ViiV Healthcare; Hologic; Meso Scale Diagnostics; Gilead Sciences; Siemens Healthineers; Bristol-Myers Squibb","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase; Medicine; Integrase inhibitor; Discontinuation; Interquartile range; Cohort; Internal medicine; Human immunodeficiency virus (HIV); Drug resistance; Genotype; Logistic regression; Virology; Viral load; Antiretroviral therapy; Genetics; Biology","score_opus":0.009610114967328678,"score_gpt":0.26587265733506776,"score_spread":0.2562625423677391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900832196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962753,0.00017650823,0.000026411899,0.000631972,0.00010391464,0.0010974363,0.000037184906,0.000024945415,0.0016263111],"genre_scores_gemma":[0.9933005,0.00005679632,0.000529216,0.00014646063,0.00005902498,0.000092566086,0.00009333326,0.000020085872,0.0057020467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822927,0.00006614152,0.00062269013,0.00037643462,0.00037011117,0.00033534935],"domain_scores_gemma":[0.99900126,0.0002071123,0.00013189517,0.00025064222,0.00019062757,0.00021847618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035664605,0.00021239422,0.0004872027,0.00052005285,0.000043847886,0.0000040877344,0.00007418064,0.0000772644,0.000045683842],"category_scores_gemma":[0.0016348513,0.00016551827,0.000024908702,0.0007416868,0.00019287967,0.0000838037,0.00004642276,0.0001285261,0.000036171175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083252475,0.00040353514,0.98388934,0.00018992188,0.000022608245,0.00009251443,0.009364739,6.472232e-8,0.0004924824,0.000010597339,0.0049770717,0.0004738922],"study_design_scores_gemma":[0.006477066,0.0003966751,0.9822969,0.003189175,0.00008957388,0.000004767597,0.0010814492,0.00004629948,0.004790153,0.000020406242,0.001533306,0.00007426002],"about_ca_topic_score_codex":0.000026546422,"about_ca_topic_score_gemma":0.0014482357,"teacher_disagreement_score":0.00828329,"about_ca_system_score_codex":0.00012905907,"about_ca_system_score_gemma":0.000091709495,"threshold_uncertainty_score":0.67496395},"labels":[],"label_agreement":null},{"id":"W2901310338","doi":"10.1097/qco.0000000000000509","title":"Optimizing antiretroviral regimens in chronic kidney disease","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Renal function; Kidney disease; Atazanavir; Cobicistat; Nephrotoxicity; Creatinine; Internal medicine; Kidney; Urology; Tenofovir alafenamide; Ritonavir; Gastroenterology; Immunology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.05394096107540336,"score_gpt":0.37488287943211346,"score_spread":0.3209419183567101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901310338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006979211,0.992358,0.000012534455,0.00006433798,0.0045296755,0.002174407,0.0002569587,0.00020132959,0.00033291805],"genre_scores_gemma":[0.00025057184,0.9930095,0.00002250872,0.000016579297,0.0015693017,0.00093060755,0.0035885386,0.000107856424,0.0005045052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99655765,0.0002417616,0.0010537503,0.0009962536,0.00043230716,0.0007182679],"domain_scores_gemma":[0.9979068,0.0001239443,0.0003648072,0.0006583313,0.000071036506,0.00087506656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015340278,0.000823451,0.0018978055,0.0013041444,0.00010901217,0.00006957602,0.00019352547,0.0002071728,0.00028918168],"category_scores_gemma":[0.00034060146,0.00069871393,0.00072733936,0.00105419,0.00016892407,0.00016855859,0.00017674541,0.0005605251,0.0005207157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012901562,0.0038477785,0.14277577,0.16251214,0.00054328726,0.0001955086,0.00023639677,0.000007835537,4.147142e-8,0.00032666753,0.08046172,0.60896385],"study_design_scores_gemma":[0.0024119732,0.00017888726,0.0011615641,0.105646044,0.0007771379,0.000019161589,0.000005535151,0.00003659424,7.669673e-8,0.00003970084,0.88911706,0.0006062819],"about_ca_topic_score_codex":0.000012476135,"about_ca_topic_score_gemma":0.000004499442,"teacher_disagreement_score":0.8086553,"about_ca_system_score_codex":0.0028639606,"about_ca_system_score_gemma":0.0042610276,"threshold_uncertainty_score":0.9995464},"labels":[],"label_agreement":null},{"id":"W2902172836","doi":"10.1021/acs.jmedchem.8b00843","title":"The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic","year":2018,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Institute of Allergy and Infectious Diseases; Government of Shandong Province; Science and Engineering Research Board; National Institutes of Health; Uppsala Universitet; National Natural Science Foundation of China; Department of Science and Technology, Ministry of Science and Technology, India; National Institute of Mental Health; European Molecular Biology Laboratory; Shandong University; Villum Fonden","keywords":"Efavirenz; Etravirine; Nevirapine; Rilpivirine; Reverse transcriptase; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Virology; Human immunodeficiency virus (HIV); Chemistry; Pharmacology; Medicine; Antiretroviral therapy; Viral load; RNA","score_opus":0.014573884992419066,"score_gpt":0.28610526849495627,"score_spread":0.2715313835025372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902172836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97412974,0.0008998155,0.00010446324,0.02008462,0.0006016589,0.00015182614,0.000020069945,0.000008960207,0.003998849],"genre_scores_gemma":[0.98308724,0.00043064303,0.002046358,0.00068728736,0.0025154888,0.0000030849358,0.000010876454,0.000027974485,0.011191055],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975888,0.000035288886,0.0010901067,0.0001748586,0.0008314296,0.00027949954],"domain_scores_gemma":[0.99797183,0.00020070327,0.0005413717,0.00029758379,0.00045576686,0.0005327708],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008965518,0.00020901728,0.0005684622,0.0000686643,0.000114422175,0.000013800286,0.0002489398,0.00012474714,0.0009777081],"category_scores_gemma":[0.00050132314,0.00012626883,0.00025547022,0.00021993328,0.00024461505,0.000070361464,0.000033732707,0.000491603,0.00009644675],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030232265,0.0005211196,0.021173993,0.00016207842,0.0009904788,0.0010546953,0.0043422887,5.77119e-7,0.3262272,0.000001499463,0.6338523,0.008650517],"study_design_scores_gemma":[0.008861384,0.0010681425,0.009551446,0.0031825406,0.0012401575,0.00082861143,0.0056785056,0.000016257203,0.7166634,0.00009923813,0.25254261,0.0002676571],"about_ca_topic_score_codex":0.000016086155,"about_ca_topic_score_gemma":0.0000053147946,"teacher_disagreement_score":0.39043626,"about_ca_system_score_codex":0.00014652197,"about_ca_system_score_gemma":0.00048854254,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W2907044052","doi":"10.1093/cid/ciy1132","title":"Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia","keywords":"Dolutegravir; Medicine; Abacavir; Lamivudine; Regimen; Adverse effect; Clinical endpoint; Internal medicine; Cumulative incidence; Viral load; Combination therapy; Randomized controlled trial; Resistance mutation; Gastroenterology; Virology; Human immunodeficiency virus (HIV); Transplantation; Virus; Hepatitis B virus; Antiretroviral therapy","score_opus":0.03736842829765436,"score_gpt":0.37005227666941354,"score_spread":0.3326838483717592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907044052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98717445,0.00082477235,0.0042766505,0.00058027863,0.000980845,0.004909296,0.00005689435,0.00028340935,0.0009133815],"genre_scores_gemma":[0.9944697,0.0017171009,0.00015308558,0.00020614617,0.0013039804,0.0013585527,0.00008261717,0.00007389599,0.00063494645],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99601847,0.0007395007,0.0014155183,0.00078026095,0.00045670872,0.000589553],"domain_scores_gemma":[0.9927812,0.0049986113,0.0007002511,0.0008212948,0.00045384016,0.00024481016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014445585,0.00056309334,0.001904539,0.00016421352,0.0007131747,0.00009002225,0.00026003402,0.00030114365,0.00046282582],"category_scores_gemma":[0.0009813758,0.00032264422,0.0011739765,0.00051241444,0.0015560536,0.00016737287,0.000077933924,0.00040976534,0.00003796567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7394938,0.011593244,0.2275088,0.00016172718,0.0047286125,0.000012892869,0.00090292696,0.00002896273,0.0013110017,0.0014326128,0.0006481871,0.012177219],"study_design_scores_gemma":[0.7535055,0.018517746,0.22055697,0.00023113386,0.0022617895,0.000008580342,0.00004059438,0.0004213121,0.00044432934,0.00073643035,0.002688554,0.00058700825],"about_ca_topic_score_codex":0.00030101603,"about_ca_topic_score_gemma":0.0009051225,"teacher_disagreement_score":0.014011729,"about_ca_system_score_codex":0.00021481125,"about_ca_system_score_gemma":0.00060973974,"threshold_uncertainty_score":0.9999226},"labels":[],"label_agreement":null},{"id":"W2909866007","doi":"10.3851/imp3287","title":"Impact of three Decades of Antiretroviral Therapy in a Longitudinal Population Cohort Study","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pill; Regimen; Population; Efavirenz; Viral load; Cohort study; Mortality rate; Internal medicine; Cohort; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Pharmacology; Environmental health","score_opus":0.03908051172415777,"score_gpt":0.3525158055405722,"score_spread":0.31343529381641444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909866007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825305,0.00020292206,0.000013888953,0.00003841035,0.000048807753,0.0010845069,0.0000047908075,0.000021344702,0.00033230457],"genre_scores_gemma":[0.9992294,0.00020127362,0.00020178157,0.000007894491,0.00006606448,0.000017974986,0.000023521843,0.000020877374,0.0002312497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987407,0.000063688436,0.00040469875,0.0002532174,0.00032000896,0.00021772587],"domain_scores_gemma":[0.99940175,0.000032254735,0.00016110016,0.00026427183,0.000107103166,0.000033506712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030443363,0.00019778078,0.0005432957,0.00026657066,0.00003586416,0.000006972537,0.00008533959,0.0000643156,0.00009859763],"category_scores_gemma":[0.000011986309,0.0001328511,0.0001632864,0.00045676916,0.00010793819,0.00012571512,0.000015177629,0.00008275339,0.000009186603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015645298,0.0017862964,0.96026576,0.000004927366,0.00051396375,0.000015649459,0.0007782237,2.5464834e-7,0.0056318706,0.00002002989,0.000032216936,0.029386252],"study_design_scores_gemma":[0.005040024,0.0067112944,0.9802989,0.000052691135,0.00002616827,0.0000029959217,0.000053158856,0.000033499462,0.007581927,0.00007873783,0.00000743781,0.00011316628],"about_ca_topic_score_codex":0.0012462437,"about_ca_topic_score_gemma":0.00022041646,"teacher_disagreement_score":0.029273087,"about_ca_system_score_codex":0.00006361253,"about_ca_system_score_gemma":0.00007093923,"threshold_uncertainty_score":0.541751},"labels":[],"label_agreement":null},{"id":"W2912043628","doi":"10.1093/ofid/ofz060","title":"Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; AIDS Vancouver; University of British Columbia","funders":"Genome Canada","keywords":"Dolutegravir; Elvitegravir; Integrase; Raltegravir; Medicine; Virology; Integrase inhibitor; Drug resistance; Adverse effect; Reverse transcriptase; Human immunodeficiency virus (HIV); Pharmacology; Genetics; Antiretroviral therapy; Biology; Polymerase chain reaction; Viral load; Gene","score_opus":0.006501649035744697,"score_gpt":0.23990855958682245,"score_spread":0.23340691055107776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912043628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993871,0.0021018996,0.000009046326,0.000093521034,0.000032301108,0.001005248,0.0007728402,0.000015385369,0.002098808],"genre_scores_gemma":[0.989909,0.00019888912,0.00001662621,0.000029757019,0.000008653267,0.00006048481,0.00012536808,0.0000156555,0.009635549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847823,0.00005193925,0.00043775697,0.00042953048,0.00029446604,0.0003080927],"domain_scores_gemma":[0.9993411,0.000061512554,0.0000743539,0.00027100643,0.000089975874,0.00016207142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012314359,0.00015590545,0.00060451665,0.00012708287,0.00014051895,0.0001509901,0.00014449433,0.000051728894,0.00067788106],"category_scores_gemma":[0.000026027057,0.00019471471,0.00010983365,0.0005531903,0.000088600245,0.0002235097,0.00006492735,0.00011170248,0.000003720711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058504767,0.0003991829,0.996553,0.00025622195,0.00050560053,0.000063173444,0.0000749606,0.0000016035082,0.000075812655,0.000011412037,0.0013607208,0.0006398284],"study_design_scores_gemma":[0.0027866273,0.0001772285,0.9944809,0.0005348843,0.001254904,0.0000046048444,0.00014249627,0.0000028073864,0.00012699339,0.0000828968,0.00019904447,0.00020662311],"about_ca_topic_score_codex":0.7147719,"about_ca_topic_score_gemma":0.98555243,"teacher_disagreement_score":0.27078053,"about_ca_system_score_codex":0.00020647958,"about_ca_system_score_gemma":0.00060766604,"threshold_uncertainty_score":0.7940235},"labels":[],"label_agreement":null},{"id":"W2912368193","doi":"10.1093/bioinformatics/btz531","title":"Simultaneous prediction of multiple outcomes using revised stacking algorithms","year":2019,"lang":"en","type":"article","venue":"Bioinformatics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of Saskatchewan","funders":"Canada Research Chairs","keywords":"Stacking; Computer science; Algorithm; Chemistry","score_opus":0.025746495298406714,"score_gpt":0.2706057821646921,"score_spread":0.24485928686628539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912368193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917599,0.00005692434,0.004607461,0.0001089572,0.00026982705,0.00089710054,0.00005643507,0.0000919173,0.0021515065],"genre_scores_gemma":[0.8902178,0.000029081897,0.10661938,0.00007155621,0.000027667409,0.0000033673111,0.00010883262,0.00001608492,0.0029062484],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989687,0.000007786289,0.00048215353,0.00007794729,0.00029294632,0.0001704378],"domain_scores_gemma":[0.99930626,0.00012094708,0.00017950381,0.0002212632,0.00010408412,0.00006792728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011588185,0.00013210361,0.00031945034,0.000116508556,0.00003612674,0.000011352553,0.00004619819,0.00006675638,0.00006421005],"category_scores_gemma":[0.00012696434,0.00009842079,0.00008380387,0.00013325893,0.00002072515,0.0001328977,0.000030918254,0.000067877074,0.00010434089],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009373678,0.00024747927,0.9685046,0.0011279946,0.000415097,0.00001946594,0.0045205387,0.00086473156,0.0011794332,0.000034633165,0.00032668182,0.022665594],"study_design_scores_gemma":[0.0041418695,0.00016095708,0.012690758,0.0004671339,0.0001964561,0.00003540092,0.0011874994,0.97231805,0.0034196223,0.000006278141,0.005206561,0.00016942188],"about_ca_topic_score_codex":0.0000059010267,"about_ca_topic_score_gemma":6.144507e-7,"teacher_disagreement_score":0.9714533,"about_ca_system_score_codex":0.000102637765,"about_ca_system_score_gemma":0.0000844203,"threshold_uncertainty_score":0.40134832},"labels":[],"label_agreement":null},{"id":"W2913067630","doi":"10.1093/cid/ciz136","title":"Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses","year":2019,"lang":"en","type":"letter","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health","keywords":"Integrase; Medicine; Mechanism (biology); Integrase inhibitor; Virology; Genetics; Computational biology; Human immunodeficiency virus (HIV); Biology; Viral load; Antiretroviral therapy","score_opus":0.02315738672305654,"score_gpt":0.3227349820827932,"score_spread":0.29957759535973666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913067630","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68130714,0.0012951269,0.000032474767,0.29676452,0.0042746225,0.0032851219,0.00025535122,0.00081754394,0.011968111],"genre_scores_gemma":[0.3151812,0.0014907229,0.00006391514,0.6195752,0.004443155,0.00034903976,0.00239392,0.00020080595,0.05630206],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958557,0.00042338474,0.0013896542,0.0010911134,0.0006316202,0.000608565],"domain_scores_gemma":[0.9974043,0.00095004064,0.0004441759,0.0007546437,0.00018022259,0.0002666662],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031431118,0.00067114993,0.0014100686,0.00052295177,0.000095791205,0.000076426775,0.00017212289,0.0012282429,0.00022223301],"category_scores_gemma":[0.0019616429,0.0005667033,0.00076436234,0.00045285578,0.00018176188,0.00016111591,0.00012029535,0.0023291802,0.0014516889],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002611706,0.0009573134,0.22749826,0.0003961053,0.00041668143,0.0028596236,0.00004850614,8.028233e-7,0.0000042508086,0.00004640539,0.7666638,0.00084709155],"study_design_scores_gemma":[0.008456397,0.00081489974,0.04079961,0.0037876545,0.001246176,0.000021821501,0.00004765874,0.000022105753,0.0000911055,0.003343738,0.9401441,0.0012247267],"about_ca_topic_score_codex":0.00005477814,"about_ca_topic_score_gemma":0.00018370687,"teacher_disagreement_score":0.36612594,"about_ca_system_score_codex":0.0008557007,"about_ca_system_score_gemma":0.0010409842,"threshold_uncertainty_score":0.99997246},"labels":[],"label_agreement":null},{"id":"W2913484557","doi":"10.1186/s12981-019-0218-2","title":"First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda","year":2019,"lang":"en","type":"article","venue":"AIDS Research and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Allergy and Infectious Diseases; Center for AIDS Research, University of Washington; National Institutes of Health; Case Western Reserve University; Government of Canada; Ontario Genomics Institute; Canadian Institutes of Health Research; Genome Canada; Ontario Genomics","keywords":"Medicine; Population; Regimen; Odds ratio; Odds; Human immunodeficiency virus (HIV); Logistic regression; Demography; Internal medicine; Virology; Environmental health","score_opus":0.08104054131575734,"score_gpt":0.3965010510338658,"score_spread":0.31546050971810846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913484557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997738,0.0009364695,0.000005511276,0.0005887026,0.000016550986,0.00054540933,0.000021249894,0.0000057350435,0.0001423691],"genre_scores_gemma":[0.9917895,0.0033989814,0.00035638225,0.0000075732373,0.000010877735,0.000067850895,0.00012285028,0.000008757257,0.0042371857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989191,0.000054853783,0.00025837985,0.00027675307,0.00025059085,0.00024027794],"domain_scores_gemma":[0.9993918,0.00023616238,0.000031111074,0.00016154555,0.00009601841,0.0000833831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003909194,0.0001108265,0.00034872137,0.0009984446,0.00006875395,0.000026557951,0.000037353013,0.00006543576,0.0001735319],"category_scores_gemma":[0.000039200015,0.0000787454,0.000055127297,0.00096220884,0.00008543143,0.0000760776,0.00002149487,0.000106383915,0.000008060906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007963318,0.00068595784,0.99212885,0.000017372508,0.00039607036,0.000014063046,0.00078757416,0.00004591429,0.00025967704,0.000080630496,0.000010417531,0.004777114],"study_design_scores_gemma":[0.0069001326,0.0009440247,0.9885682,0.000038428396,0.000017679788,0.0000020776354,0.00012649271,0.0018916599,0.0005133505,0.00034842824,0.0005836532,0.00006587027],"about_ca_topic_score_codex":0.0015607043,"about_ca_topic_score_gemma":0.0041298294,"teacher_disagreement_score":0.006103801,"about_ca_system_score_codex":0.00010167127,"about_ca_system_score_gemma":0.000063764994,"threshold_uncertainty_score":0.32111442},"labels":[],"label_agreement":null},{"id":"W2913510970","doi":"10.22374/1710-6222.26.1.1","title":"CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTION IN A LARGE ANTIRETROVIRAL TREATMENT CENTRE IN LAGOS, NIGERIA","year":2019,"lang":"en","type":"article","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lamivudine; Stavudine; Zidovudine; Drug; Didanosine; Internal medicine; Reverse-transcriptase inhibitor; Concomitant; Drug interaction; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Immunology; Viral disease; Virus","score_opus":0.0329322989361517,"score_gpt":0.40107623994443664,"score_spread":0.36814394100828496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913510970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991335,0.00024252578,0.0000064417286,0.0066769947,0.001235639,0.00040596357,0.0000037554578,0.0000070638407,0.00008665562],"genre_scores_gemma":[0.99454325,0.0024919359,0.00025310973,0.0010834066,0.00026129355,0.000002535299,0.000022733819,0.000015184197,0.0013265171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974414,0.00036065775,0.0015664333,0.00022043783,0.00017120672,0.00023987245],"domain_scores_gemma":[0.99872017,0.0004194016,0.000556078,0.00008714666,0.000083330095,0.00013386468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001048232,0.0001662391,0.00068529294,0.00023549708,0.000023947374,0.000013928395,0.000057763547,0.00012301849,0.00023475087],"category_scores_gemma":[0.000027191143,0.000121265264,0.00019331623,0.00012377443,0.00003129687,0.00011008141,0.000021757569,0.00042216879,0.000022348955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021816702,0.002189714,0.9777109,0.000015745165,0.0002704895,0.00014186412,0.0006550632,0.000018554047,0.00052761566,0.00002148341,0.00015693544,0.016109943],"study_design_scores_gemma":[0.023879413,0.0016052629,0.954069,0.00013733881,0.00035251633,0.000027570055,0.0010271802,0.0027177052,0.00021056643,0.00018461145,0.015598634,0.0001902003],"about_ca_topic_score_codex":0.000031021827,"about_ca_topic_score_gemma":0.00013019274,"teacher_disagreement_score":0.02364192,"about_ca_system_score_codex":0.00022286737,"about_ca_system_score_gemma":0.00011286734,"threshold_uncertainty_score":0.49450538},"labels":[],"label_agreement":null},{"id":"W2914093604","doi":"10.1177/1060028019830788","title":"Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV","year":2019,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Dolutegravir; Elvitegravir; Cobicistat; Medicine; Obstetrics; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.05241973805525467,"score_gpt":0.3673745688517171,"score_spread":0.3149548307964624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914093604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014954024,0.98159444,0.000002092446,0.00074338366,0.000088325025,0.0022436713,0.00012589165,0.000013241986,0.00023490944],"genre_scores_gemma":[0.001582543,0.99546933,0.00013533322,0.00022572081,0.000052555984,0.00011727482,0.000027408685,0.000072520976,0.0023173403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978101,0.00019233458,0.00083418796,0.00042851473,0.0003619235,0.00037288747],"domain_scores_gemma":[0.9986891,0.00016932875,0.00054149184,0.000331266,0.00010267175,0.0001661209],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041023555,0.00055135647,0.0019129677,0.00033984895,0.000032809385,0.000011226097,0.00017770579,0.0001527549,0.000076658565],"category_scores_gemma":[0.000010327325,0.0002840805,0.00019447651,0.00051326066,0.00021301309,0.000064708336,0.00006494987,0.00043326127,0.0000031290085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008099798,0.000510824,0.0016494967,0.012237303,0.0016259258,0.000029700823,0.0016434292,5.54354e-7,0.00060804293,0.000030571748,0.0014628519,0.97939134],"study_design_scores_gemma":[0.004938496,0.0003339384,0.00021674269,0.029837096,0.00087473163,0.00005431924,0.000112764305,0.0000069372854,0.0057129143,0.000020908337,0.95752805,0.000363091],"about_ca_topic_score_codex":0.000014741481,"about_ca_topic_score_gemma":0.000003747111,"teacher_disagreement_score":0.9790282,"about_ca_system_score_codex":0.000060806593,"about_ca_system_score_gemma":0.00036759494,"threshold_uncertainty_score":0.99996114},"labels":[],"label_agreement":null},{"id":"W2914442791","doi":"10.1093/ofid/ofy273","title":"Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; Gilead Sciences","keywords":"Tenofovir; Medicine; Cohort; Correlation; Drug; Cohort study; Internal medicine; Pharmacology; Human immunodeficiency virus (HIV); Virology; Mathematics","score_opus":0.009908696184235772,"score_gpt":0.26866326791694345,"score_spread":0.25875457173270766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914442791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846474,0.0002568476,0.000011676843,0.0039121583,0.00006884181,0.004174744,0.000021963744,0.000024575573,0.0068818256],"genre_scores_gemma":[0.9975957,0.000029682718,0.000011430762,0.00030016608,0.000026726291,0.00022874646,0.00006086541,0.000014724833,0.001731934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988474,0.00018378279,0.00023446034,0.0002895797,0.00024418326,0.0002005747],"domain_scores_gemma":[0.99919146,0.00034531075,0.00008370068,0.00026416383,0.000031970987,0.00008337877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055779825,0.00017282797,0.00031739278,0.0000941182,0.00025158498,0.00016116431,0.00010495285,0.000033772278,0.000050040486],"category_scores_gemma":[0.00006957436,0.000089714136,0.000044942182,0.00021967059,0.000118355005,0.00019918184,0.00017088625,0.00011027849,0.000044152723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020806385,0.0003275881,0.9940026,0.000010675536,0.0003268617,0.000018473176,0.0013532917,0.0000036989566,0.0000016633684,0.00020606944,0.0011354176,0.002405625],"study_design_scores_gemma":[0.009705047,0.00017115202,0.9851858,0.000051997322,0.0004736307,0.00002468108,0.0023917807,0.000036014542,0.000005873217,0.000949127,0.0008839863,0.00012092684],"about_ca_topic_score_codex":0.00054238026,"about_ca_topic_score_gemma":0.0003496973,"teacher_disagreement_score":0.012948357,"about_ca_system_score_codex":0.000060760074,"about_ca_system_score_gemma":0.00008109424,"threshold_uncertainty_score":0.36584362},"labels":[],"label_agreement":null},{"id":"W2914992431","doi":"10.21105/joss.01186","title":"sierra-local: A lightweight standalone application for drug resistance prediction","year":2019,"lang":"en","type":"article","venue":"The Journal of Open Source Software","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Government of Canada; Ontario Genomics; Ontario Genomics Institute; Genome Canada","keywords":"Resistance (ecology); Computer science; Environmental science; Ecology; Biology","score_opus":0.0105056349353525,"score_gpt":0.268980868568465,"score_spread":0.2584752336331125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914992431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5099735,0.0030133626,0.4489622,0.02846392,0.00046755633,0.006152596,0.00006629836,0.00012555698,0.0027749797],"genre_scores_gemma":[0.78689694,0.00020381932,0.017834919,0.00043564188,0.00029436225,0.0000752247,0.000055448698,0.000072065064,0.1941316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876815,0.000060754744,0.00044982356,0.00013825989,0.00039647732,0.00018650567],"domain_scores_gemma":[0.9986029,0.00022006096,0.00040793707,0.0003212638,0.00033401453,0.000113808244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009999572,0.00014336949,0.0003592354,0.00007871971,0.00016294727,0.000044244436,0.00035281276,0.00005193608,0.00009222219],"category_scores_gemma":[0.000067665795,0.000084836625,0.000111783746,0.00018221537,0.000045173434,0.00021523354,0.00007083433,0.00018508288,0.00005451451],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027370155,0.0019450579,0.12888753,0.0011001375,0.0029679253,0.00005334455,0.03766662,0.00070820627,0.005052948,0.0008127663,0.68733937,0.10609593],"study_design_scores_gemma":[0.0071290163,0.0002999575,0.005163831,0.0006809789,0.0005977778,0.00015293492,0.0017815287,0.00016705421,0.005773646,0.0010364489,0.9770269,0.00018994618],"about_ca_topic_score_codex":0.0000055869623,"about_ca_topic_score_gemma":0.000014502226,"teacher_disagreement_score":0.43112728,"about_ca_system_score_codex":0.00020535948,"about_ca_system_score_gemma":0.0002168993,"threshold_uncertainty_score":0.3459537},"labels":[],"label_agreement":null},{"id":"W2917802638","doi":"10.1016/s0168-8278(08)60847-8","title":"845 PRECLINICAL PHARMACOKINETIC AND ADME CHARACTERIZATION OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV NS5B POLYMERASE INHIBITOR","year":2008,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"ADME; Chemistry; Pharmacokinetics; NS5B; Pharmacology; Virology; Medicine; Hepatitis C virus; Virus; Hepacivirus","score_opus":0.02686971266776195,"score_gpt":0.29784110220081633,"score_spread":0.2709713895330544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917802638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488455,0.00036284997,0.00026831252,0.0037986394,0.00034459637,0.0001728746,0.000007470543,0.000007595507,0.00015313904],"genre_scores_gemma":[0.9964668,0.00046396468,0.0018508417,0.00032548406,0.0002352906,0.0000037542711,0.000012996219,0.000017590297,0.00062325335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986135,0.00004736445,0.000807608,0.00014741071,0.00019614113,0.0001879916],"domain_scores_gemma":[0.99892616,0.000109399174,0.0004909026,0.00010312952,0.00016361673,0.0002068038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015813262,0.0001458892,0.0006228937,0.00021720066,0.000053897827,0.0000042096585,0.00006069433,0.00011655008,0.00011812283],"category_scores_gemma":[0.000102053935,0.00011606352,0.00011681119,0.00012642375,0.00018125126,0.00009935085,0.000029215918,0.00021556792,0.000010393359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087347627,0.0007553679,0.7375833,0.00007238947,0.00029031455,0.0006665485,0.00088333996,3.282966e-7,0.25353894,0.00001194383,0.0006959198,0.004628168],"study_design_scores_gemma":[0.016139228,0.001481776,0.7342671,0.00035929255,0.0007342179,0.011585899,0.00004545759,0.00044899984,0.22738159,0.000025551686,0.007258856,0.00027202172],"about_ca_topic_score_codex":0.000004825398,"about_ca_topic_score_gemma":0.0000018191635,"teacher_disagreement_score":0.026157346,"about_ca_system_score_codex":0.000030254052,"about_ca_system_score_gemma":0.00034253977,"threshold_uncertainty_score":0.4732933},"labels":[],"label_agreement":null},{"id":"W2918180482","doi":"10.1111/hiv.12716","title":"Two‐drug <i>vs</i>. three‐drug combinations for <scp>HIV</scp>‐1: Do we have enough data to make the switch?","year":2019,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Cilag; ViiV Healthcare; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Drug; Regimen; Adverse effect; Viral load; Pharmacology; Drug resistance; Pill; Combination therapy; HIV drug resistance; Human immunodeficiency virus (HIV); Intensive care medicine; Antiretroviral therapy; Immunology; Internal medicine","score_opus":0.11122952422885235,"score_gpt":0.3698249872706382,"score_spread":0.2585954630417858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918180482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069093267,0.9141398,0.0005594407,0.06401866,0.001323336,0.009413911,0.0011311907,0.00017934952,0.009227381],"genre_scores_gemma":[0.000018980916,0.781199,0.0014621724,0.001428429,0.0015041643,0.0010916317,0.0103168115,0.00022053978,0.20275831],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942505,0.00020002662,0.0016077635,0.00159866,0.0013137828,0.0010292785],"domain_scores_gemma":[0.991345,0.0032165812,0.00068488106,0.0038000639,0.00035218117,0.0006013164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017796064,0.0012636321,0.0039135558,0.00061155995,0.00040349257,0.00007049936,0.0017545571,0.0002621562,0.00020251446],"category_scores_gemma":[0.0011913308,0.00070564426,0.00049775065,0.00087718054,0.00025528637,0.00012542443,0.0007501763,0.00093538,0.0019643356],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021949107,0.0003571083,0.00010085704,0.007536588,0.0010321528,0.00008033938,0.0018129891,5.083888e-7,4.777243e-7,0.0014662737,0.7785745,0.20901626],"study_design_scores_gemma":[0.006739711,0.00016097254,0.000021282955,0.027749574,0.007775715,0.00017293693,0.00072211673,0.0000589589,0.0000025306367,0.00019670236,0.95608175,0.00031775472],"about_ca_topic_score_codex":0.000050647337,"about_ca_topic_score_gemma":0.00025332064,"teacher_disagreement_score":0.2086985,"about_ca_system_score_codex":0.00037159637,"about_ca_system_score_gemma":0.0010908514,"threshold_uncertainty_score":0.9995395},"labels":[],"label_agreement":null},{"id":"W2919382782","doi":"10.1016/s2352-3018(19)30035-9","title":"Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection","year":2019,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute of Allergy and Infectious Diseases; Fogarty International Center; National Institutes of Health","keywords":"Bedaquiline; Efavirenz; Medicine; Tuberculosis; Nevirapine; Drug resistance; Extensively drug-resistant tuberculosis; Antiretroviral therapy; Pharmacology; Viral load; Human immunodeficiency virus (HIV); Internal medicine; Virology; Mycobacterium tuberculosis; Pathology","score_opus":0.015502712836171433,"score_gpt":0.27576214317048175,"score_spread":0.2602594303343103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919382782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914766,0.00044184696,0.000016387106,0.0049775327,0.00007332643,0.0004757772,0.00003006337,0.000055948367,0.004781431],"genre_scores_gemma":[0.98581,0.0006421047,0.00035227364,0.000079845326,0.0001808793,0.00001775368,0.00009106337,0.000018286693,0.012807785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910223,0.00004633791,0.00022126106,0.00021317485,0.00018764452,0.00022936262],"domain_scores_gemma":[0.9994158,0.00007659865,0.000085084794,0.0003354701,0.000028360977,0.000058680438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016376487,0.00017561355,0.00049398653,0.00007151784,0.00007152782,0.000014086697,0.00004505618,0.000038629463,0.00010194126],"category_scores_gemma":[0.0000098263945,0.0001009987,0.00008606235,0.0001106813,0.000039514554,0.000053218042,0.000020839892,0.00007132493,0.00019382779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000587841,0.00029706556,0.9724391,0.00012295878,0.00036231632,0.000016501956,0.002190246,0.000003592822,0.015246547,0.00026387113,0.003101439,0.0053685284],"study_design_scores_gemma":[0.018741671,0.0015824036,0.85141414,0.0005205825,0.0011347838,0.00009044168,0.0006884138,0.0016644484,0.06434966,0.00019633421,0.059101276,0.00051583716],"about_ca_topic_score_codex":0.000089575056,"about_ca_topic_score_gemma":0.000023453278,"teacher_disagreement_score":0.121024944,"about_ca_system_score_codex":0.00011100529,"about_ca_system_score_gemma":0.00003894345,"threshold_uncertainty_score":0.41186073},"labels":[],"label_agreement":null},{"id":"W2920650314","doi":"10.1002/jcph.1399","title":"A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid‐Reducing Agents","year":2019,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Pharmacokinetics; Antacid; Pharmacology; Drug interaction; Zidovudine; Chemistry; Reverse-transcriptase inhibitor; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Sida; Virology","score_opus":0.11937628668729905,"score_gpt":0.47735217306619193,"score_spread":0.3579758863788929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920650314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97930634,0.000102775775,0.000043990887,0.016607543,0.0014848064,0.00144287,0.0000021928745,0.000014944898,0.0009945158],"genre_scores_gemma":[0.98575515,0.00011906671,0.001096537,0.004699134,0.0007851387,0.000009310413,0.0000019395534,0.00003174555,0.0075019863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966514,0.00079558836,0.0013730492,0.00022558784,0.0006222018,0.00033214802],"domain_scores_gemma":[0.99761754,0.00064981513,0.0006482598,0.0002541333,0.0003852153,0.000445058],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034487937,0.00023500374,0.0009435494,0.00014806559,0.00006353309,0.000013053831,0.00034129331,0.0000529356,0.0019130406],"category_scores_gemma":[0.00012419016,0.00012333221,0.00016472295,0.00019515959,0.00008980602,0.000067503046,0.00014551857,0.0006854407,0.00042178694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0788387,0.019249646,0.5820746,0.00012742447,0.013235267,0.0040575825,0.017886272,0.0008887177,0.026078163,0.0000040705895,0.23041978,0.027139813],"study_design_scores_gemma":[0.22504227,0.080815256,0.41560543,0.0007417686,0.028157583,0.004333768,0.006732433,0.0014134255,0.043567285,0.00012406398,0.19216995,0.0012967937],"about_ca_topic_score_codex":0.000003130219,"about_ca_topic_score_gemma":0.000002857097,"teacher_disagreement_score":0.16646914,"about_ca_system_score_codex":0.00007384362,"about_ca_system_score_gemma":0.000418294,"threshold_uncertainty_score":0.99899936},"labels":[],"label_agreement":null},{"id":"W2920874835","doi":"10.1182/blood-2018-99-114345","title":"5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cytidine deaminase; Cytarabine; HEK 293 cells; Nucleoside; Cytidine; Wild type; Cell culture; IC50; Molecular biology; Chemistry; Pharmacology; Cancer research; Biology; Biochemistry; Mutant; Enzyme; Myeloid leukemia; Genetics; Gene","score_opus":0.00583787542143912,"score_gpt":0.23433161636638566,"score_spread":0.22849374094494654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920874835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272823,0.0006242815,0.00011005561,0.0013886648,0.0001276762,0.000677546,0.000007529936,0.00007245814,0.0042635375],"genre_scores_gemma":[0.98277,0.000055260913,0.0029635886,0.0003248086,0.00020204896,0.0000626109,0.000020911591,0.000026715024,0.013574044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883217,0.000023809002,0.00019325025,0.00037078775,0.0002486428,0.00033135634],"domain_scores_gemma":[0.9992954,0.000036403104,0.000041546788,0.000291792,0.00006482524,0.00027000345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097130884,0.00019843178,0.0003068267,0.000107255626,0.00011474129,0.000019696625,0.00006639518,0.00005994169,0.000028383702],"category_scores_gemma":[0.00006479373,0.00016178052,0.00004858126,0.00019841807,0.00006196432,0.00005015138,0.000054396358,0.00007595339,0.0003144694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006068678,0.0031035074,0.756122,0.0010359769,0.0013244117,0.001446343,0.0028514504,2.6009587e-7,0.20314267,0.0008641402,0.021016886,0.00848547],"study_design_scores_gemma":[0.011655338,0.0006153219,0.8045029,0.0009506658,0.0006697605,0.00014040762,0.000041108327,0.000008793852,0.16759391,0.00018390283,0.013228221,0.0004096631],"about_ca_topic_score_codex":0.0000047165527,"about_ca_topic_score_gemma":0.000014363078,"teacher_disagreement_score":0.04838089,"about_ca_system_score_codex":0.00006197267,"about_ca_system_score_gemma":0.00005820507,"threshold_uncertainty_score":0.65972185},"labels":[],"label_agreement":null},{"id":"W2921556780","doi":"10.1097/qai.0000000000001989","title":"Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response","year":2019,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"National Cancer Institute; National Institutes of Health; Università degli Studi di Brescia; University of Cape Town; Leidos; Frederick National Laboratory for Cancer Research; Johns Hopkins University; U.S. Department of Defense","keywords":"Human immunodeficiency virus (HIV); Medicine; Virology; Viral load; Antiretroviral therapy; Immunology","score_opus":0.01687808872057265,"score_gpt":0.25895398641258843,"score_spread":0.2420758976920158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921556780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330187,0.00036923325,0.00027829528,0.004416264,0.0001236511,0.0012961499,0.00007927157,0.00006385167,0.00007144049],"genre_scores_gemma":[0.9906333,0.00007653924,0.005069867,0.000121334284,0.000029022074,0.00009354626,0.000026098749,0.000049302824,0.0039009831],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965893,0.0003924387,0.0012771098,0.00042178194,0.0007251801,0.00059418497],"domain_scores_gemma":[0.9960769,0.002314194,0.0006430921,0.00045338288,0.0002938704,0.00021859893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017796557,0.00043936315,0.0013171466,0.0007172542,0.0001663983,0.000037176404,0.00024823216,0.00018523574,0.00027552262],"category_scores_gemma":[0.0011663308,0.00025732958,0.0005179072,0.0005587478,0.00015839818,0.00016773895,0.00008877692,0.00013231928,0.00010049367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22093654,0.0061855707,0.25455987,0.00021051812,0.0019302459,0.0010966385,0.005145795,0.00035326404,0.50651443,0.00020171383,0.0011609629,0.0017044409],"study_design_scores_gemma":[0.018425837,0.04422362,0.9128497,0.0010037237,0.0011381512,0.0029393448,0.0008684172,0.000484585,0.016177865,0.00014895726,0.0012050655,0.00053472485],"about_ca_topic_score_codex":0.0000016679518,"about_ca_topic_score_gemma":2.4859278e-7,"teacher_disagreement_score":0.65828985,"about_ca_system_score_codex":0.00038515776,"about_ca_system_score_gemma":0.00033993166,"threshold_uncertainty_score":0.9999879},"labels":[],"label_agreement":null},{"id":"W2935830518","doi":"10.5543/tkda.2019.63479","title":"Complex drugs interactions in a HIV-seropositive heart transplant recipient","year":2019,"lang":"en","type":"article","venue":"Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Life expectancy; Heart transplantation; Antiretroviral therapy; Intensive care medicine; Drug; Immunology; Antiretroviral drug; Transplantation; Viral load; Virology; Internal medicine; Pharmacology; Population","score_opus":0.014750126471962324,"score_gpt":0.2639148456264093,"score_spread":0.249164719154447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935830518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640735,0.0003922128,0.0004920005,0.010699549,0.00047047684,0.0014209361,0.00015470345,0.000049622435,0.022247035],"genre_scores_gemma":[0.9905661,0.00037609477,0.0042973775,0.00047998075,0.000100118465,0.000040879837,0.0001237451,0.00003299177,0.003982742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976621,0.00032519124,0.0006670473,0.00048491865,0.0003671183,0.0004935953],"domain_scores_gemma":[0.99824196,0.0006700044,0.00025286226,0.000641896,0.000078967314,0.00011432318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027230752,0.0003411385,0.0013051839,0.0001396813,0.00008631158,0.0000066337284,0.000338352,0.000118024866,0.00007083953],"category_scores_gemma":[0.000025025276,0.00024989693,0.0014392013,0.0002717032,0.0006276886,0.0000720221,0.00019293363,0.0005118017,0.00004787339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019528912,0.0005823514,0.8400898,0.00070455996,0.0045336843,0.000031678952,0.047733143,0.0013587095,0.056376044,0.0005671801,0.04388356,0.0021864097],"study_design_scores_gemma":[0.0069530965,0.00033293536,0.93554777,0.0011795212,0.00064295554,0.00053418934,0.0052150907,0.001288433,0.0109584145,0.0008991405,0.035944358,0.00050410413],"about_ca_topic_score_codex":0.00004895848,"about_ca_topic_score_gemma":0.00000855088,"teacher_disagreement_score":0.09545797,"about_ca_system_score_codex":0.00012051062,"about_ca_system_score_gemma":0.00019672934,"threshold_uncertainty_score":0.99999535},"labels":[],"label_agreement":null},{"id":"W2937154946","doi":"10.1002/cpdd.685","title":"Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacology; Metformin; Pharmacokinetic interaction; Drug interaction; Internal medicine","score_opus":0.05189335607255027,"score_gpt":0.4140086072678435,"score_spread":0.3621152511952932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937154946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362457,0.00019985902,0.000007638319,0.0022008717,0.0008941489,0.0020781874,0.0000017920021,0.000009835223,0.000983079],"genre_scores_gemma":[0.9965234,0.00007607023,0.0020579484,0.00040568897,0.00003180045,0.00012551581,0.000024635083,0.000016187803,0.0007387958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966494,0.0004601579,0.0014391771,0.00034670392,0.0008269285,0.00027762336],"domain_scores_gemma":[0.9987847,0.00033414084,0.00034450987,0.00019432079,0.0002500863,0.00009223277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047177053,0.0001955391,0.0006377818,0.00021302274,0.000026147982,0.000002371933,0.00016473232,0.00010259737,0.00022959638],"category_scores_gemma":[0.00012974528,0.00013364837,0.00010789035,0.00053578714,0.00012192167,0.00006321867,0.00007780494,0.00035570585,0.000021361351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019195561,0.0021144536,0.97594035,0.00016106271,0.0005636507,0.000030849234,0.0020914467,0.0005386182,0.0020670062,0.000014740667,0.000898258,0.013660026],"study_design_scores_gemma":[0.04587925,0.0006240318,0.8637072,0.0005832394,0.0010881444,0.000016174841,0.00077362085,0.0042751147,0.0772495,0.00005166176,0.0054067615,0.00034533624],"about_ca_topic_score_codex":0.000018412764,"about_ca_topic_score_gemma":0.00019586225,"teacher_disagreement_score":0.11223316,"about_ca_system_score_codex":0.00041426555,"about_ca_system_score_gemma":0.0022898302,"threshold_uncertainty_score":0.5450022},"labels":[],"label_agreement":null},{"id":"W2937367049","doi":"10.1002/cpt.1477","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz‐Containing Antiretroviral Therapy","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"European and Developing Countries Clinical Trials Partnership; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Human Genome Research Institute; National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research; National Institutes of Health; Partnership for Advanced Computing in Europe AISBL","keywords":"Efavirenz; CYP2B6; Discontinuation; Medicine; Reverse-transcriptase inhibitor; Pharmacogenetics; Adverse effect; Guideline; Pharmacology; Internal medicine; Oncology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Genotype; Cytochrome P450; Biology; CYP1A2; Viral load; Pathology; Genetics","score_opus":0.10445328640151225,"score_gpt":0.4935270597406963,"score_spread":0.389073773339184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937367049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976752,0.0021293894,0.00056311674,0.014682435,0.002775147,0.0026929993,0.000050443952,0.00012616455,0.00022833058],"genre_scores_gemma":[0.8464287,0.012153264,0.01078644,0.12642013,0.0015497933,0.00013889941,0.00031384954,0.00010566923,0.0021032956],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589133,0.00038172322,0.0020858417,0.0007773907,0.0002500097,0.000613689],"domain_scores_gemma":[0.99734825,0.0012348251,0.00047506456,0.00029411406,0.00030882438,0.0003389318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018248471,0.00040832374,0.001003545,0.000105442516,0.00015134367,0.000029118379,0.00018379005,0.00033778904,0.00061938894],"category_scores_gemma":[0.000020514317,0.0003421197,0.00040845343,0.00015021548,0.00037816996,0.000088974964,0.000096658,0.00053290377,0.000096447344],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033248963,0.00095318793,0.7980566,0.000035795187,0.002562932,0.00002533565,0.00017075801,0.000001869904,0.008698415,0.0000254808,0.030536702,0.15560801],"study_design_scores_gemma":[0.0554689,0.006739206,0.05325948,0.000031875887,0.0031980497,0.00003973983,0.00036012506,0.0024540515,0.010055827,0.00012443373,0.86765397,0.000614336],"about_ca_topic_score_codex":0.0000028702427,"about_ca_topic_score_gemma":0.000002259975,"teacher_disagreement_score":0.83711725,"about_ca_system_score_codex":0.00006186255,"about_ca_system_score_gemma":0.0003961722,"threshold_uncertainty_score":0.9999031},"labels":[],"label_agreement":null},{"id":"W2938037645","doi":"10.1017/cts.2017.137","title":"2432","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical and Translational Science","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Population; Regimen; Human immunodeficiency virus (HIV); Family medicine; Internal medicine; Environmental health","score_opus":0.10634671825896752,"score_gpt":0.46019171126216835,"score_spread":0.3538449930032008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938037645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95334184,0.00013779143,0.00025578204,0.035552923,0.00026898037,0.000047420133,9.900697e-7,0.000002300541,0.010391965],"genre_scores_gemma":[0.99149346,0.00011893933,0.0068999985,0.000113802475,0.00019938758,1.8927875e-7,2.1317275e-7,0.0000013978405,0.0011726351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990049,0.000008538134,0.00039814872,0.00008580502,0.0004136942,0.000088923596],"domain_scores_gemma":[0.9992196,0.00010111098,0.00020839137,0.000080371785,0.00016962958,0.00022090455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013930823,0.000040860006,0.00018123582,0.000045565084,0.00026138793,0.0000470298,0.00011284245,0.000024742592,0.00005224411],"category_scores_gemma":[0.00036956876,0.00002438113,0.00008325614,0.000039664883,0.00064597,0.00027904965,0.000011564738,0.00011672993,0.0000071562563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011951705,0.00011797298,0.9327007,0.00000406874,0.000027759319,0.000044449214,0.000064981614,5.8792625e-7,0.00008313199,0.0021779337,0.0001388202,0.06452008],"study_design_scores_gemma":[0.0015518114,0.0000843455,0.9845395,0.00004447799,0.000036730922,0.000099974655,0.000006045455,0.00009226172,0.000108370026,0.0029919972,0.010415066,0.000029417111],"about_ca_topic_score_codex":7.920651e-7,"about_ca_topic_score_gemma":0.000001698773,"teacher_disagreement_score":0.06449067,"about_ca_system_score_codex":0.0000029341227,"about_ca_system_score_gemma":0.00041917164,"threshold_uncertainty_score":0.23801033},"labels":[],"label_agreement":null},{"id":"W2940002115","doi":"","title":"Genotypic resistance testing of antiretrovirals in HIV","year":2004,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Genotype; Medicine; Genetics; Biology; Gene","score_opus":0.021563778536809367,"score_gpt":0.259297637537598,"score_spread":0.23773385900078864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940002115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9333079,0.00021387484,0.0001289085,0.0016514102,0.000015792262,0.00016951025,0.0000011033636,0.000034338573,0.06447715],"genre_scores_gemma":[0.9123633,0.000009408229,0.052491583,0.0000639773,0.000012402098,0.0000047381113,0.000005230092,0.00000697582,0.0350424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941015,0.000006368305,0.00020499926,0.00012197681,0.00012178728,0.00013471137],"domain_scores_gemma":[0.9997447,0.000029449662,0.000036845264,0.00011806539,0.000034086217,0.000036818354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008190273,0.000071359,0.00017909803,0.00009518766,0.000014924563,0.0000024487265,0.000030610052,0.00002788253,0.00005533757],"category_scores_gemma":[0.000078185185,0.000054942127,0.000023465655,0.00028202625,0.000023537435,0.000031840766,0.000012277866,0.000046129666,0.000059584483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008912447,0.00030714826,0.98105055,0.00011624718,0.000038913044,0.0001821108,0.00067459396,0.000011370164,0.010240464,0.0045145447,0.00070927554,0.002065645],"study_design_scores_gemma":[0.009055876,0.00016176398,0.8397467,0.0010645458,0.00006918252,0.000019140698,0.00035460375,0.000021962544,0.14278333,0.0023941428,0.0040593366,0.00026943258],"about_ca_topic_score_codex":0.00002743161,"about_ca_topic_score_gemma":0.000082165716,"teacher_disagreement_score":0.14130387,"about_ca_system_score_codex":0.00008559411,"about_ca_system_score_gemma":0.00010990739,"threshold_uncertainty_score":0.2240475},"labels":[],"label_agreement":null},{"id":"W2941145247","doi":"10.18203/2319-2003.ijbcp20191565","title":"Antiretroviral-induced adverse drug reactions in HIV-infected patients in Mali: a resource-limited setting experience","year":2019,"lang":"en","type":"article","venue":"International Journal of Basic & Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of Biomedical Imaging and Bioengineering; Fogarty International Center; National Institutes of Health; Northwestern University","keywords":"Medicine; Nevirapine; Stavudine; Incidence (geometry); Population; Adverse drug reaction; Zidovudine; Internal medicine; Pediatrics; Prospective cohort study; Human immunodeficiency virus (HIV); Antiretroviral therapy; Pharmacovigilance; Cohort; Drug reaction; Adverse effect; Drug; Viral load; Immunology; Viral disease; Pharmacology; Environmental health","score_opus":0.02547409655305624,"score_gpt":0.3777266174933883,"score_spread":0.3522525209403321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941145247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999953,0.000019346351,0.000005134465,0.0060614455,0.0024181171,0.00033783613,0.0000057497596,0.000014421846,0.001138387],"genre_scores_gemma":[0.99624324,0.00008981285,0.0003816382,0.0013718551,0.00037623622,0.000008300069,0.000028621713,0.00001688392,0.0014834208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709207,0.0003206573,0.0015679689,0.00027258368,0.00048461312,0.0002621218],"domain_scores_gemma":[0.9979768,0.0007433331,0.0006447153,0.000103211125,0.00036847786,0.00016347339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007855091,0.00016673343,0.0004892132,0.0006398382,0.000019551788,0.000009822174,0.0002487552,0.0001194657,0.0007323238],"category_scores_gemma":[0.00057181716,0.00014505885,0.00020673442,0.00029375486,0.00006326007,0.00022918842,0.00008894419,0.0007938708,0.00015511598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015869685,0.0017342026,0.98414904,0.000009930149,0.0002232099,0.00072714844,0.0008053578,0.000030184354,0.0023949023,0.000010368479,0.0041295933,0.004199086],"study_design_scores_gemma":[0.01882344,0.00040354286,0.9605272,0.0003319554,0.00006894886,0.00008320156,0.00039347608,0.00047801688,0.0013292393,0.000016782338,0.017398298,0.00014592879],"about_ca_topic_score_codex":0.000023057326,"about_ca_topic_score_gemma":0.000014277517,"teacher_disagreement_score":0.023621876,"about_ca_system_score_codex":0.00042136118,"about_ca_system_score_gemma":0.00028035385,"threshold_uncertainty_score":0.80184317},"labels":[],"label_agreement":null},{"id":"W2941177974","doi":"10.1186/s12879-019-3934-2","title":"Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study","year":2019,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; University of British Columbia","funders":"U.S. President’s Emergency Plan for AIDS Relief; Global Fund to Fight AIDS, Tuberculosis and Malaria","keywords":"Medical microbiology; Parasitology; Tropical medicine; Human immunodeficiency virus (HIV); Medicine; Family medicine; Internal medicine; Virology; Pathology","score_opus":0.00923309396751245,"score_gpt":0.2609813142653696,"score_spread":0.25174822029785715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941177974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956831,0.00003516287,0.0000019472707,0.00005485848,0.000054723583,0.0015063245,0.00005306883,0.000040762854,0.0025701025],"genre_scores_gemma":[0.99791604,0.0000059370636,0.000024489242,0.000074846736,0.000027686005,0.00021289068,0.00044004217,0.000011420529,0.0012866202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987707,0.000120929384,0.0002460207,0.00038500316,0.00031957007,0.00015775108],"domain_scores_gemma":[0.99947125,0.00011124185,0.00006784557,0.00011084612,0.00015368387,0.00008516183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006312408,0.00016182427,0.00025578827,0.000253547,0.000041563686,0.000018111532,0.000025429137,0.00006185711,0.00022459922],"category_scores_gemma":[0.00021857869,0.00012864728,0.000054736247,0.00019481182,0.000037562182,0.00010861824,0.00003674744,0.0001317139,0.000090121895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004743205,0.0021073848,0.9951226,0.00006482136,0.00004575965,0.000039717448,0.0013069124,0.000041641462,0.000003303285,0.000033334403,0.0006204163,0.00013980549],"study_design_scores_gemma":[0.010805823,0.0010061678,0.98603594,0.00011466699,0.000046479818,0.0000022117397,0.0016454945,0.00008140772,0.000015685866,0.00008316063,0.000045645156,0.00011730863],"about_ca_topic_score_codex":0.000025051793,"about_ca_topic_score_gemma":0.0021022502,"teacher_disagreement_score":0.010331502,"about_ca_system_score_codex":0.00024215742,"about_ca_system_score_gemma":0.00008110042,"threshold_uncertainty_score":0.5246084},"labels":[],"label_agreement":null},{"id":"W2942205195","doi":"10.1101/621755","title":"Systematic determination of in vitro phenotypic resistance to HIV-1 integrase strand transfer inhibitors from clinical samples","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of British Columbia; AIDS Vancouver","funders":"Canadian Institutes of Health Research; Genome British Columbia; Genome Canada","keywords":"Integrase; Dolutegravir; Biology; Virology; Amplicon; Reverse transcriptase; Molecular biology; Phenotype; Integrase inhibitor; Mutagenesis; Human immunodeficiency virus (HIV); Genetics; RNA; Mutation; Polymerase chain reaction; Gene; Viral load; Antiretroviral therapy","score_opus":0.01930602408296743,"score_gpt":0.2584569889597728,"score_spread":0.23915096487680537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942205195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845744,0.00096008595,0.0057928027,0.00041761476,0.00074660283,0.003002358,0.0005126513,0.00010087877,0.000009561624],"genre_scores_gemma":[0.97959566,0.0001159159,0.019579487,0.000078541874,0.00017453342,0.00029183103,0.0000064036617,0.000092023605,0.000065575354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99607086,0.00029754709,0.0017424702,0.0009657122,0.0005404974,0.00038291386],"domain_scores_gemma":[0.99758905,0.0003707761,0.0003227265,0.0010778037,0.00034967315,0.00028997223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009619664,0.00055288617,0.0017593116,0.0005093298,0.000036083246,0.00005105169,0.00028306633,0.000525789,0.000030059382],"category_scores_gemma":[0.00053826795,0.0004989391,0.00029096735,0.0004342606,0.00007922565,0.000085475156,0.000106598556,0.0006236064,0.00008978608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040822797,0.002934216,0.23598367,0.06336243,0.0021158995,0.0005227838,0.0007971538,0.00002250714,0.68916637,0.00027427007,0.0007094664,0.00002895576],"study_design_scores_gemma":[0.0070547136,0.00014548282,0.24660073,0.059088472,0.0018557915,2.5262974e-8,0.00006843708,0.00030259904,0.6830849,0.000008263134,0.000454753,0.0013358352],"about_ca_topic_score_codex":0.000040229846,"about_ca_topic_score_gemma":0.000037749516,"teacher_disagreement_score":0.013786684,"about_ca_system_score_codex":0.0004383149,"about_ca_system_score_gemma":0.000709261,"threshold_uncertainty_score":0.9997462},"labels":[],"label_agreement":null},{"id":"W2943292855","doi":"10.1097/qad.0000000000002191","title":"Probable hepatotoxicity with dolutegravir","year":2019,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; McGill University Health Centre; University Health Network","funders":"","keywords":"Dolutegravir; Lamivudine; Ritonavir; Abacavir; Medicine; Lopinavir; Emtricitabine; Gastroenterology; Atazanavir; Liver function; Pharmacology; Virology; Raltegravir; Liver function tests; Internal medicine; Viral load; Hepatitis B virus; Human immunodeficiency virus (HIV)","score_opus":0.05880997389086793,"score_gpt":0.33006679401229977,"score_spread":0.2712568201214318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943292855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035407767,0.97785807,0.000020771935,0.000050861396,0.00010568793,0.0021329923,0.000016239752,0.00010014632,0.01967985],"genre_scores_gemma":[0.000008015938,0.8405988,0.003473643,0.00004518277,0.00009404425,0.0002360414,0.00033649858,0.00006933286,0.1551384],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984215,0.000052519117,0.00035655466,0.00047800347,0.00033702175,0.0003544296],"domain_scores_gemma":[0.9990003,0.00005685756,0.0001588359,0.0005747534,0.000055334178,0.00015388362],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014208179,0.000484453,0.0019737072,0.00018562586,0.000050218383,0.000023837905,0.00012867169,0.00024575056,0.00021361471],"category_scores_gemma":[0.000013504681,0.0002696804,0.00033629767,0.0004143149,0.000042442694,0.000050666695,0.000053650412,0.000335936,0.0024622334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002550809,0.00027709006,0.002538261,0.022479162,0.0013670824,0.0002542425,0.000053602223,4.023306e-8,1.4119503e-7,0.00044962618,0.00682184,0.9657334],"study_design_scores_gemma":[0.00066135114,0.0002738206,0.000011976166,0.015648667,0.0027053826,0.0002093838,0.0000057521174,4.5436585e-7,0.0000047696344,0.00001173895,0.98016304,0.00030367976],"about_ca_topic_score_codex":0.000009561586,"about_ca_topic_score_gemma":0.000003730002,"teacher_disagreement_score":0.97334117,"about_ca_system_score_codex":0.0002543988,"about_ca_system_score_gemma":0.00088184717,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W2943299573","doi":"10.1177/0956462418815292","title":"Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen","year":2019,"lang":"en","type":"article","venue":"International Journal of STD & AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Maple Leaf Medical Clinic; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Regimen; Interquartile range; Reverse-transcriptase inhibitor; Internal medicine; Proportional hazards model; Viral load; Zidovudine; Integrase inhibitor; Protease inhibitor (pharmacology); Gastroenterology; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease","score_opus":0.012208928948882009,"score_gpt":0.29287311267060445,"score_spread":0.2806641837217224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943299573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949978,0.00013216905,0.00025129714,0.0009176749,0.0005861679,0.00021849522,0.000025950656,0.000007912925,0.0028625436],"genre_scores_gemma":[0.99538994,0.00014235258,0.0033839613,0.000096155294,0.00014217972,0.000004546521,0.000024892153,0.000012046268,0.00080392644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975887,0.00006982088,0.00095448265,0.00017313527,0.0010603218,0.0001535396],"domain_scores_gemma":[0.998052,0.00010913025,0.0008202016,0.00018746525,0.00075115706,0.00008006505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005922202,0.00016682853,0.0005149279,0.00036705035,0.000017825445,0.000016004024,0.0002268052,0.000086246706,0.0005184568],"category_scores_gemma":[0.00009779933,0.00012522469,0.00030287594,0.00013958223,0.00008833765,0.00028281868,0.00007963015,0.00022320148,0.000015784733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007797584,0.0006749356,0.9905835,0.00007365255,0.00065455463,0.00012305539,0.00029346845,0.000027692111,0.004760863,0.00038519246,0.00021204559,0.0014312827],"study_design_scores_gemma":[0.0035216145,0.003018388,0.98503125,0.0003560468,0.00017105862,0.00009981676,0.0001760324,0.00023848814,0.006418711,0.0001701385,0.00068592315,0.00011255749],"about_ca_topic_score_codex":0.000016405045,"about_ca_topic_score_gemma":0.0000024134706,"teacher_disagreement_score":0.0055522746,"about_ca_system_score_codex":0.0003233549,"about_ca_system_score_gemma":0.00021984275,"threshold_uncertainty_score":0.56767386},"labels":[],"label_agreement":null},{"id":"W2945178990","doi":"10.1002/cpdd.699","title":"Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Methadone; Medicine; Pharmacokinetics; Dosing; Confidence interval; Pharmacology; Drug interaction; Methadone maintenance; Internal medicine","score_opus":0.08319404251493585,"score_gpt":0.4393486597931239,"score_spread":0.35615461727818803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945178990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905162,0.00025226397,0.000005754759,0.0046998025,0.0013456219,0.0015163373,0.0000016439747,0.00001824165,0.0016441214],"genre_scores_gemma":[0.995533,0.0001240485,0.000989522,0.0005188368,0.00012621906,0.00009883747,0.000021680962,0.000015620337,0.0025722503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716824,0.0006419787,0.0009980581,0.0003843158,0.0005766529,0.00023074256],"domain_scores_gemma":[0.9986989,0.00051974284,0.0002551711,0.00017258494,0.00023810554,0.000115505005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004072781,0.000187819,0.00052415003,0.00016246049,0.000040577117,0.0000044679923,0.0001284657,0.00010065401,0.0008959521],"category_scores_gemma":[0.00014462996,0.00013085055,0.0000849133,0.00028859108,0.00013446166,0.000065885084,0.00018270576,0.0004300428,0.00011624076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021716073,0.00063680304,0.87279624,0.00007939297,0.0006831055,0.000006890685,0.0009968053,0.000029474608,0.0023316909,0.000004633795,0.004140302,0.11807752],"study_design_scores_gemma":[0.011627135,0.000057751015,0.9298526,0.00015347051,0.0010077315,0.000010196969,0.00011494047,0.0009091439,0.03136013,0.00007599189,0.0246593,0.00017159978],"about_ca_topic_score_codex":0.0000068138393,"about_ca_topic_score_gemma":0.000012408784,"teacher_disagreement_score":0.117905915,"about_ca_system_score_codex":0.00027310874,"about_ca_system_score_gemma":0.0005417687,"threshold_uncertainty_score":0.9810047},"labels":[],"label_agreement":null},{"id":"W2949479811","doi":"10.1002/chin.200209223","title":"ChemInform Abstract: Novel 5‐Vinyl Pyrimidine Nucleosides with Potent anti‐Hepatitis B Virus Activity.","year":2002,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chemistry; Pyrimidine; Combinatorial chemistry; Hepatitis B virus; Stereochemistry; Virus; Virology","score_opus":0.02080769381643747,"score_gpt":0.22899156707116355,"score_spread":0.2081838732547261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949479811","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32748622,0.00011316475,0.0000012594128,0.0015597215,0.00007020606,0.00047104392,0.000030249043,0.00020148534,0.67006665],"genre_scores_gemma":[0.85137683,0.0005146953,0.00028881864,0.0002767502,0.0001317294,0.00006025737,0.00010014835,0.000049124308,0.14720166],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981634,3.3986705e-8,0.00038451483,0.0003347392,0.00055318186,0.000564137],"domain_scores_gemma":[0.9988352,0.00004474379,0.00019354711,0.00045370567,0.00013126511,0.00034155132],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008490019,0.00042860626,0.00051857956,0.00014681116,0.00014366476,0.000057611767,0.0001440686,0.00016981554,0.0034735028],"category_scores_gemma":[0.000043634373,0.00031972709,0.00014552324,0.0002878081,0.00012605831,0.0004309265,0.00007050625,0.0002680759,0.0006428877],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029834415,0.0018281937,0.008398286,0.00047532696,0.0007681576,0.00036815522,0.0030923688,7.283526e-7,0.029992351,0.00009159599,0.101607025,0.8530795],"study_design_scores_gemma":[0.003933203,0.00018522606,0.04796601,0.0003326493,0.00023425787,0.00036113066,0.0001614807,0.00010622533,0.8348614,0.000004699126,0.111257516,0.0005962084],"about_ca_topic_score_codex":0.00012926893,"about_ca_topic_score_gemma":0.000057840978,"teacher_disagreement_score":0.8524833,"about_ca_system_score_codex":0.00032697193,"about_ca_system_score_gemma":0.00008595268,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W2949972510","doi":"10.1002/chin.201015199","title":"ChemInform Abstract: A Stereoselective Approach to Nucleosides and 4′‐Thioanalogues from Acyclic Precursors.","year":2010,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Chemistry; Stereoselectivity; Combinatorial chemistry; Stereochemistry; Organic chemistry; Catalysis","score_opus":0.013409842496915606,"score_gpt":0.24489555544878502,"score_spread":0.23148571295186943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949972510","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31350568,0.00005578888,3.4646953e-7,0.00049506355,0.00005725495,0.00045643246,0.000020214033,0.00007559675,0.6853336],"genre_scores_gemma":[0.92775357,0.000027201799,0.0018682354,0.00038160683,0.00017355777,0.00013129473,0.00032230423,0.00003118719,0.06931104],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987126,5.823097e-8,0.0003198071,0.00034128956,0.00025962718,0.00036662383],"domain_scores_gemma":[0.9990289,0.00007290947,0.000092678056,0.0003253122,0.000086350556,0.000393836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010284617,0.0002938251,0.00038026017,0.00012102023,0.000092022536,0.00006323358,0.0001263983,0.0001883999,0.00058465614],"category_scores_gemma":[0.00010078865,0.00023466245,0.000079758436,0.00018612682,0.00008980293,0.00022994775,0.000093836476,0.00034204326,0.00036876072],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046095104,0.00069993077,0.016147796,0.00025635315,0.0007665223,0.000023140003,0.03141074,2.7331021e-8,0.013904982,0.00031666315,0.119319044,0.81669384],"study_design_scores_gemma":[0.0036355066,0.0001234167,0.22391677,0.00018689652,0.00034128118,0.00012943857,0.002743755,0.000018972249,0.5583444,0.00036852062,0.2093219,0.0008691047],"about_ca_topic_score_codex":0.00006191872,"about_ca_topic_score_gemma":0.00003926912,"teacher_disagreement_score":0.81582475,"about_ca_system_score_codex":0.00008206019,"about_ca_system_score_gemma":0.00010193934,"threshold_uncertainty_score":0.9569257},"labels":[],"label_agreement":null},{"id":"W2950411696","doi":"10.1139/v00-105","title":"Syntheses of 4-[1-(2-deoxy-β-<scp>D</scp>-ribofuranosyl)]-derivatives of 2-substituted-5-fluoroaniline: \"cytosine replacement\" analogs of deoxycytidine for evaluation as anticancer and antihuman immunodeficiency virus (anti-HIV) agents","year":2000,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry; Deoxycytidine; Stereochemistry; Cytosine; Aniline; Ring (chemistry); Human immunodeficiency virus (HIV); Deoxycytidine kinase; DNA; Biochemistry; Virology; Cancer; Organic chemistry","score_opus":0.01965339565049134,"score_gpt":0.27803279913124496,"score_spread":0.2583794034807536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950411696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924513,0.0037607118,0.00003146421,0.00023719839,0.00005449295,0.00036309598,0.0001467832,0.0000042846054,0.0029506627],"genre_scores_gemma":[0.997309,0.0006747198,0.0007717821,0.000023924587,0.000057738645,0.000008446033,0.00006044794,0.000023678844,0.0010702435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979799,0.000034747223,0.0009819058,0.00022811025,0.00047043792,0.0003049154],"domain_scores_gemma":[0.9977505,0.00022247073,0.0006867553,0.000264778,0.00076812395,0.00030733604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055151235,0.00023668658,0.00074235693,0.00021059506,0.000089521876,0.000013619601,0.00015176024,0.00011679763,0.0010045348],"category_scores_gemma":[0.001140103,0.00021085302,0.00017171206,0.0002690519,0.00034588034,0.00014065516,0.000011346637,0.00013726638,0.000001474081],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054467726,0.0006747026,0.0980608,0.0016373048,0.0017197994,0.00012936292,0.0042059477,0.00016881409,0.88278365,0.00006919679,0.0031155373,0.006890191],"study_design_scores_gemma":[0.004161414,0.0002608806,0.029389808,0.0013724618,0.0006748285,0.00022626482,0.00077175745,0.0001475154,0.960861,0.00013047236,0.0018830255,0.000120537385],"about_ca_topic_score_codex":0.0003142714,"about_ca_topic_score_gemma":0.00009000535,"teacher_disagreement_score":0.07807737,"about_ca_system_score_codex":0.00017958332,"about_ca_system_score_gemma":0.0019072772,"threshold_uncertainty_score":0.9999087},"labels":[],"label_agreement":null},{"id":"W2950696463","doi":"10.1002/chin.200051205","title":"ChemInform Abstract: Synthesis and Antiviral Activities of N‐9‐Oxypurine 1,3‐Dioxolane and 1,3‐Oxathiolane Nucleosides.","year":2000,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Dioxolane; Chemistry; Combinatorial chemistry; Service (business); Stereochemistry; World Wide Web; Library science; Medicinal chemistry; Business; Computer science; Marketing","score_opus":0.008479063168518384,"score_gpt":0.22207833029306048,"score_spread":0.2135992671245421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950696463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5755897,0.00023883583,8.437748e-9,0.00027135847,0.000011651947,0.00015686594,0.00001566396,0.000039689538,0.42367622],"genre_scores_gemma":[0.91223645,0.0011513121,0.00012092913,0.000055981596,0.00004948035,0.000023535491,0.000041314674,0.000020021247,0.08630098],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989229,8.803172e-8,0.000356544,0.00020599151,0.00022994736,0.00028451535],"domain_scores_gemma":[0.99938583,0.00011216444,0.000102038844,0.00021744585,0.000030859126,0.00015164846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001223126,0.0002549844,0.0004853183,0.00009579519,0.00006226817,0.000023652845,0.00005911713,0.00012539767,0.0018849564],"category_scores_gemma":[0.000044152657,0.00020692215,0.000064714004,0.00009991725,0.00018516123,0.00025034655,0.00004325897,0.00013178047,0.00003436826],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027967297,0.00012948747,0.004121662,0.00054355577,0.00019278524,0.000041472376,0.0019771182,9.967022e-9,0.0031033552,0.000044556524,0.0045435512,0.9850228],"study_design_scores_gemma":[0.0019722066,0.00010585535,0.04467084,0.00042622924,0.00022278156,0.0002572535,0.00062833074,0.000010446,0.90868884,0.00003368564,0.042621177,0.0003623309],"about_ca_topic_score_codex":0.00002117007,"about_ca_topic_score_gemma":0.0000048814927,"teacher_disagreement_score":0.98466045,"about_ca_system_score_codex":0.000048246235,"about_ca_system_score_gemma":0.00006297169,"threshold_uncertainty_score":0.99902743},"labels":[],"label_agreement":null},{"id":"W2951046821","doi":"10.1002/chin.200239187","title":"Synthesis and Evaluation of Keto‐Glutamine Analogues as Inhibitors of Hepatitis A Virus 3C Proteinase.","year":2002,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Glutamine; Hepatitis virus; Virology; Biochemistry; Hepatitis C virus; Stereochemistry; Virus; Amino acid","score_opus":0.024373973134427334,"score_gpt":0.2592621715532628,"score_spread":0.2348881984188355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951046821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92346823,0.0006030576,2.7039746e-7,0.0002489395,0.000017119037,0.00048558388,0.0000129651535,0.000015138487,0.07514871],"genre_scores_gemma":[0.99337965,0.00041795525,0.00017935084,0.000014066473,0.000026580317,0.00010105832,0.00003424374,0.000008681632,0.005838423],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990504,0.0000014955793,0.00030619508,0.00011442371,0.00041500383,0.000112508],"domain_scores_gemma":[0.999409,0.00005193393,0.00014081973,0.00014919609,0.00018084314,0.00006817047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022634899,0.000114270835,0.00026904556,0.00011446055,0.000022407607,0.000003738738,0.000030344954,0.00006258671,0.00062317523],"category_scores_gemma":[0.0003117472,0.00009186645,0.00005154774,0.00015602562,0.00007583251,0.000077768615,0.000022462978,0.000039491395,0.000024869254],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000893687,0.00042600828,0.030695822,0.0005430277,0.0003288535,0.000014513371,0.004132067,2.9107002e-7,0.014486884,0.00004098478,0.0060196947,0.94322246],"study_design_scores_gemma":[0.0010720511,0.000118669595,0.010274355,0.00032739664,0.00031132877,0.000017433724,0.00016080527,0.00030730275,0.9857654,0.000034297092,0.001518544,0.00009241625],"about_ca_topic_score_codex":0.00011626698,"about_ca_topic_score_gemma":0.000037222086,"teacher_disagreement_score":0.9712785,"about_ca_system_score_codex":0.000084435946,"about_ca_system_score_gemma":0.00005339367,"threshold_uncertainty_score":0.6823332},"labels":[],"label_agreement":null},{"id":"W2951913422","doi":"10.1002/chin.200137195","title":"ChemInform Abstract: Design and Synthesis of a Conformationally Restricted trans Peptide Isostere Based on the Bioactive Conformations of Saquinavir and Nelfinavir.","year":2001,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sciencetech (Canada)","funders":"","keywords":"Chemistry; Nelfinavir; Isostere; Saquinavir; Combinatorial chemistry; Stereochemistry; Human immunodeficiency virus (HIV); Virology","score_opus":0.022424135158117184,"score_gpt":0.24228211163660934,"score_spread":0.21985797647849215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951913422","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12261013,0.000066155015,0.00006580838,0.0024737627,0.000016444015,0.0013843558,0.00008130695,0.0000442834,0.87325776],"genre_scores_gemma":[0.9949911,0.00020770461,0.00055241486,0.00018448508,0.0000073867327,0.00006205891,0.00007577671,0.0000106107145,0.00390841],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989542,3.8418227e-7,0.0005022966,0.00009917461,0.0002583494,0.00018560469],"domain_scores_gemma":[0.99865663,0.00059672294,0.00026106968,0.00020063603,0.00015638974,0.00012854188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020119373,0.00019084572,0.00030529787,0.00014858332,0.00007816047,0.00001323265,0.00007648243,0.000097335775,0.00027394356],"category_scores_gemma":[0.00021543332,0.0001279573,0.00006604331,0.00021527837,0.00020264563,0.00022441843,0.000016638573,0.000113114635,0.0000064451306],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004145367,0.00092396373,0.0020211982,0.0015190289,0.000938157,0.000030084107,0.026872335,0.000007463986,0.0033409137,0.0019220616,0.012635479,0.94564396],"study_design_scores_gemma":[0.00760305,0.0006990447,0.06470864,0.0018098123,0.00070223265,0.00018081216,0.008429805,0.002870697,0.8976746,0.0001685636,0.014539283,0.00061340735],"about_ca_topic_score_codex":0.000015869282,"about_ca_topic_score_gemma":0.0000018808711,"teacher_disagreement_score":0.94503057,"about_ca_system_score_codex":0.0000556787,"about_ca_system_score_gemma":0.00023916307,"threshold_uncertainty_score":0.5217948},"labels":[],"label_agreement":null},{"id":"W2951983324","doi":"10.1038/s41598-019-45328-3","title":"A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Rush University","keywords":"Sanger sequencing; HIV drug resistance; Genotyping; Drug resistance; Human immunodeficiency virus (HIV); Computational biology; Viral load; DNA sequencing; Medicine; Biology; Virology; Antiretroviral therapy; Microbiology; Genetics; Genotype; DNA; Gene","score_opus":0.009423573163279873,"score_gpt":0.23933001755834363,"score_spread":0.22990644439506375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951983324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850637,0.00073158793,0.00033746095,0.0014766741,0.0020216352,0.0013043114,0.00000442917,0.000083180785,0.008977058],"genre_scores_gemma":[0.64242095,0.000010278532,0.003450732,0.000030900304,0.00003487284,0.000049390448,0.00010397891,0.000015654774,0.35388324],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811137,0.00000928107,0.00040714248,0.00076708174,0.0003537347,0.00035139365],"domain_scores_gemma":[0.9988363,0.000066229426,0.00019939723,0.00058915763,0.00016237312,0.00014655199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008954755,0.00016709602,0.00031951716,0.00012540956,0.00022326516,0.00010765528,0.00004986964,0.000047680503,0.000094624615],"category_scores_gemma":[0.00010090691,0.00013675255,0.000081171886,0.00024264869,0.000097439326,0.0001271083,0.000038413644,0.00006557814,0.00006642649],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012608182,0.00062124006,0.25586537,0.0024058386,0.00064337987,0.001287631,0.01283058,0.000019506035,0.2926962,0.0010105723,0.41921562,0.012143246],"study_design_scores_gemma":[0.002689131,0.000028456727,0.009606746,0.000478989,0.00006732838,0.00020378882,0.00035181333,0.00019547991,0.1294171,0.0040921303,0.8523134,0.00055561156],"about_ca_topic_score_codex":0.0000016526816,"about_ca_topic_score_gemma":0.00006654501,"teacher_disagreement_score":0.4330978,"about_ca_system_score_codex":0.00009058846,"about_ca_system_score_gemma":0.00020449907,"threshold_uncertainty_score":0.5576607},"labels":[],"label_agreement":null},{"id":"W2952544614","doi":"10.1021/jm990336n","title":"2‘,6‘-Dimethylphenoxyacetyl:  A New Achiral High Affinity P<sub>3</sub>-P<sub>2</sub>Ligand for Peptidomimetic-Based HIV Protease Inhibitors","year":2000,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Chemistry; Peptidomimetic; Stereochemistry; Protease; Ligand (biochemistry); Protease inhibitor (pharmacology); HIV-1 protease; Chemical synthesis; Potency; Structure–activity relationship; Bioavailability; In vitro; Human immunodeficiency virus (HIV); Enzyme; Receptor; Biochemistry; Pharmacology; Virology; Antiretroviral therapy; Peptide","score_opus":0.00974252970065202,"score_gpt":0.23642444972708332,"score_spread":0.2266819200264313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952544614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98642904,0.0008384509,0.00035665152,0.010615203,0.00024216037,0.0008837108,0.000029691626,0.000069255024,0.00053584797],"genre_scores_gemma":[0.9892522,0.0001809398,0.004740066,0.00058168115,0.0030247532,0.000057523535,0.00010837789,0.000099535864,0.0019548913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958911,0.00006814637,0.0013883193,0.00051028206,0.0013813546,0.00076081714],"domain_scores_gemma":[0.9967696,0.00031306667,0.0007385758,0.00043359777,0.00040818207,0.0013369459],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010267494,0.0006500345,0.0012570543,0.00020279463,0.00021124077,0.000049128066,0.00029545833,0.00037704763,0.00027075567],"category_scores_gemma":[0.0005978127,0.0005106919,0.0006193264,0.0003980962,0.00022190464,0.00017298461,0.00003682601,0.001054848,0.00006924254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005607021,0.0010748776,0.0021199975,0.000667856,0.000630456,0.00080524926,0.00044605497,0.000044816064,0.9041211,0.0000022939087,0.051151685,0.03332861],"study_design_scores_gemma":[0.019792827,0.00074946403,0.0009271529,0.0014784168,0.0012670999,0.0007600779,0.00023523753,0.00007922984,0.96805173,0.00015586842,0.0060521,0.0004508136],"about_ca_topic_score_codex":0.0000069795924,"about_ca_topic_score_gemma":0.0000022941297,"teacher_disagreement_score":0.06393063,"about_ca_system_score_codex":0.000513775,"about_ca_system_score_gemma":0.0021531421,"threshold_uncertainty_score":0.99973446},"labels":[],"label_agreement":null},{"id":"W2952851976","doi":"10.1002/chin.200829215","title":"ChemInform Abstract: Docking Ligands into Flexible and Solvated Macromolecules. Part 2. Development and Application of FITTED 1.5 to the Virtual Screening of Potential HCV Polymerase Inhibitors.","year":2008,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Chemistry; Docking (animal); Macromolecule; Combinatorial chemistry; Polymerase; Computational biology; Nanotechnology; Stereochemistry; Computational chemistry; Biochemistry; Enzyme","score_opus":0.010585982108847005,"score_gpt":0.23436203381375545,"score_spread":0.22377605170490844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952851976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590165,0.00026756318,0.000039195744,0.000562558,0.000032114272,0.0005238943,0.000006489733,0.000044783865,0.012621763],"genre_scores_gemma":[0.99518645,0.00006228527,0.00058241654,0.00009981425,0.000053691874,0.000055029534,0.00016177281,0.000016278298,0.0037822686],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986841,1.17481086e-7,0.0005663802,0.00019951214,0.00032387426,0.00022599525],"domain_scores_gemma":[0.9992865,0.000028840257,0.0002058536,0.00019445525,0.00011609563,0.00016825803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016042136,0.00020616634,0.00031203317,0.00012496,0.0001629945,0.000012222825,0.00007868557,0.00009724489,0.000027570064],"category_scores_gemma":[0.000034665365,0.00015420745,0.00004508599,0.00025853136,0.00013358383,0.00010799502,0.00012286064,0.000107927466,0.0000057435805],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034118447,0.00013665603,0.0031461702,0.00023960833,0.00024027954,0.000020766709,0.014595158,0.0000023214952,0.044566296,0.000035165398,0.0032377325,0.93343866],"study_design_scores_gemma":[0.0013754757,0.00005758453,0.0050948905,0.00019686259,0.000054388966,0.000060795628,0.0008264694,0.00005173207,0.9803211,0.000002646324,0.011795373,0.00016268699],"about_ca_topic_score_codex":0.000036836387,"about_ca_topic_score_gemma":0.000005766933,"teacher_disagreement_score":0.9357548,"about_ca_system_score_codex":0.00005396355,"about_ca_system_score_gemma":0.0001504636,"threshold_uncertainty_score":0.62883973},"labels":[],"label_agreement":null},{"id":"W2953023130","doi":"10.1002/chin.200114228","title":"ChemInform Abstract: Synthesis of N‐1‐Oxypyrimidine 1,3‐Dioxolane and 1,3‐Oxathiolane Nucleosides.","year":2001,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Chemistry; Dioxolane; Combinatorial chemistry; Stereochemistry; Organic chemistry","score_opus":0.0140252107245593,"score_gpt":0.2388341739796191,"score_spread":0.22480896325505978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953023130","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21660791,0.0003357161,1.0404987e-7,0.0009342725,0.00004249145,0.00028159554,0.000011825348,0.00008512947,0.78170097],"genre_scores_gemma":[0.9152196,0.0009051147,0.00021471173,0.00012488053,0.00008876603,0.000038810394,0.00008163459,0.000028363174,0.083298124],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985861,5.4566325e-8,0.00051893713,0.0002234863,0.00031946038,0.00035196551],"domain_scores_gemma":[0.9990037,0.00012213502,0.00018145658,0.0003349014,0.00010248855,0.00025531155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018294613,0.0002760887,0.0005313199,0.00013988194,0.000058259255,0.000017335058,0.000101762256,0.00016144528,0.0018401118],"category_scores_gemma":[0.00017475788,0.0002219994,0.00010856199,0.00020176567,0.0001145165,0.00017169761,0.00006714995,0.00014899843,0.000114224866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041703976,0.00032924596,0.009251901,0.0007052572,0.00037565094,0.00017656862,0.0014383629,4.8889103e-8,0.0071853567,0.00017589118,0.035525624,0.944419],"study_design_scores_gemma":[0.0023048494,0.00010046952,0.03249736,0.00050909753,0.00032601412,0.0006587897,0.0007132904,0.00001404398,0.802062,0.00005287965,0.16033024,0.0004310062],"about_ca_topic_score_codex":0.000020217936,"about_ca_topic_score_gemma":0.000004773427,"teacher_disagreement_score":0.943988,"about_ca_system_score_codex":0.000101633785,"about_ca_system_score_gemma":0.00009996015,"threshold_uncertainty_score":0.9990723},"labels":[],"label_agreement":null},{"id":"W2953075685","doi":"10.1002/chin.200639210","title":"Lysine Sulfonamides as Novel HIV‐Protease Inhibitors: Nε‐Acyl Aromatic α‐Amino Acids.","year":2006,"lang":"en","type":"article","venue":"ChemInform","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Chemistry; Protease; Lysine; Human immunodeficiency virus (HIV); Combinatorial chemistry; Amino acid; Stereochemistry; Biochemistry; Enzyme; Virology","score_opus":0.009107588328691494,"score_gpt":0.2296623801134912,"score_spread":0.2205547917847997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953075685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51745033,0.00035316954,0.000015417227,0.0027500947,0.00012567002,0.00082310283,0.000018018614,0.00026501922,0.47819918],"genre_scores_gemma":[0.7160392,0.000020801865,0.0013600355,0.00027603644,0.000392336,0.00012792465,0.00070925767,0.000040631105,0.2810338],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825025,5.0575557e-7,0.0005414107,0.00029304053,0.00046651097,0.00044831514],"domain_scores_gemma":[0.99910915,0.00004940037,0.00015242117,0.00039830286,0.00007598754,0.00021475196],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012667784,0.00034921555,0.00042927117,0.0001631648,0.000101483885,0.000045910292,0.00011264069,0.0001388212,0.0003644288],"category_scores_gemma":[0.000117893236,0.00027895175,0.00016722754,0.00030898702,0.00009879812,0.00021946615,0.00006820227,0.00015763426,0.001321387],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009465964,0.006233391,0.06718906,0.002272284,0.0014086833,0.0012075867,0.0055662403,0.000008917816,0.08939292,0.0024858485,0.5996543,0.22363418],"study_design_scores_gemma":[0.007747082,0.0001381109,0.011807486,0.0006592844,0.0003752488,0.00035083038,0.00053348544,0.00012593601,0.7623709,0.00061362545,0.21454713,0.0007308916],"about_ca_topic_score_codex":0.000041806074,"about_ca_topic_score_gemma":0.0000055828664,"teacher_disagreement_score":0.672978,"about_ca_system_score_codex":0.00029102853,"about_ca_system_score_gemma":0.00023534975,"threshold_uncertainty_score":0.99996626},"labels":[],"label_agreement":null},{"id":"W2953881185","doi":"10.1177/2325958219849101","title":"Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection","year":2019,"lang":"en","type":"article","venue":"Journal of the International Association of Providers of AIDS Care (JIAPAC)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Multiple drug resistance; Stage (stratigraphy); Antiretroviral drug; Drug; Medicine; Drug resistance; Virology; Antiretroviral therapy; Biology; Pharmacology; Viral load; Microbiology","score_opus":0.004780555769997002,"score_gpt":0.2440557374097326,"score_spread":0.2392751816397356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953881185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981593,0.000028647755,0.000018504938,0.00056921644,0.00021155985,0.00040170323,0.0002944687,0.000003149252,0.00031346356],"genre_scores_gemma":[0.99794304,0.000020448024,0.00040894782,0.000012906776,0.000025345205,0.0000024978533,0.000040676627,0.000015666537,0.001530452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970804,0.00013282183,0.00075580884,0.00013863726,0.0017631412,0.00012918912],"domain_scores_gemma":[0.9929901,0.00024958726,0.0040611713,0.00023441059,0.0024232212,0.000041562533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046485584,0.00018461412,0.00075309473,0.0005780357,0.000030029118,0.000007954594,0.00025313435,0.00006509987,0.000040144037],"category_scores_gemma":[0.00038186955,0.000094556985,0.0006069499,0.00064500305,0.00007865455,0.00017840324,0.000052693304,0.00018152977,3.0436186e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026474732,0.0005394157,0.97921056,0.000118325865,0.006704626,6.3311654e-7,0.0022009506,0.00478794,0.0028771935,0.000042604323,0.00008410108,0.00078619685],"study_design_scores_gemma":[0.004717025,0.0025477207,0.95749664,0.00065704767,0.0013674165,4.923225e-7,0.001435673,0.00015231072,0.03147624,0.0000074545856,0.00005037659,0.000091582755],"about_ca_topic_score_codex":0.00027845567,"about_ca_topic_score_gemma":0.00030448684,"teacher_disagreement_score":0.028599048,"about_ca_system_score_codex":0.0008842188,"about_ca_system_score_gemma":0.0003521096,"threshold_uncertainty_score":0.3855922},"labels":[],"label_agreement":null},{"id":"W295445146","doi":"","title":"Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility.","year":2009,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reverse transcriptase; RNase H; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Biology; Mutation; Virology; Genetics; Resistance mutation; Viral replication; Zidovudine; Point mutation; Reverse-transcriptase inhibitor; HIV drug resistance; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Viral load; RNA; Gene; Viral disease","score_opus":0.009932904532637154,"score_gpt":0.226023484566744,"score_spread":0.21609058003410686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W295445146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218625,0.00010164339,0.000013405098,0.005330502,0.000032277385,0.0012973913,0.000008172273,0.00000997929,0.0010203988],"genre_scores_gemma":[0.99861896,0.000027558957,0.000100718586,0.00019730965,0.000012342345,0.00017260786,0.000023887995,0.0000035387743,0.0008430807],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993569,0.00007722489,0.00018293335,0.00012186036,0.00014101756,0.00012003158],"domain_scores_gemma":[0.999585,0.00017638491,0.000046494162,0.00012017233,0.000023044551,0.00004894571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000290772,0.00007689692,0.00017021291,0.000113586626,0.0000243688,0.0000029492403,0.00002806965,0.00002573779,0.0000051487928],"category_scores_gemma":[0.00012398798,0.000051250343,0.000043877226,0.00018079384,0.000050689006,0.000035723035,0.0000021572098,0.00006562564,0.0000015564739],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076483604,0.024225969,0.31623808,0.003219891,0.0009574216,0.0012772512,0.11354807,0.00006277305,0.028760672,0.015777748,0.03327919,0.45500457],"study_design_scores_gemma":[0.0048602954,0.000110037356,0.96743286,0.00006680706,0.00017259711,0.000009476499,0.00075169664,0.000010540835,0.025343988,0.0005138733,0.0006630981,0.000064760476],"about_ca_topic_score_codex":0.00001892219,"about_ca_topic_score_gemma":0.0000446706,"teacher_disagreement_score":0.65119475,"about_ca_system_score_codex":0.000039351566,"about_ca_system_score_gemma":0.000017497523,"threshold_uncertainty_score":0.20899284},"labels":[],"label_agreement":null},{"id":"W2954620310","doi":"10.1093/jac/dkz256","title":"A systematic review of the genetic mechanisms of dolutegravir resistance","year":2019,"lang":"en","type":"review","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Dolutegravir; Medicine; Integrase inhibitor; Regimen; Virology; Drug resistance; Pharmacology; Virus; Internal medicine; Viral load; Antiretroviral therapy; Genetics; Biology","score_opus":0.01759548024620889,"score_gpt":0.29222341668792684,"score_spread":0.27462793644171796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954620310","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019416613,0.9963464,0.00011298194,0.00072314247,0.00027587736,0.0023318892,0.000024647517,0.0000040120617,0.00016163754],"genre_scores_gemma":[0.000008846813,0.9887293,0.0045792423,0.00047714871,0.00006574533,0.0000071952613,0.0000060935795,0.00006425519,0.0060621914],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99617434,0.000244561,0.002632011,0.00018715576,0.00056697975,0.00019496503],"domain_scores_gemma":[0.9940914,0.00012253213,0.0046777837,0.0006502774,0.00039010425,0.00006789707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006948043,0.00042050664,0.005469776,0.00020877569,0.000026516194,0.000008736426,0.0005048131,0.00020081332,0.00007181208],"category_scores_gemma":[0.00009290241,0.00021067186,0.0021391106,0.0004695094,0.000069772366,0.000032808748,0.000033582233,0.0003559268,0.000012886584],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004194657,0.00019312053,0.0000014167014,0.9880964,0.0019123328,0.00002065122,0.00007435744,3.575507e-8,0.00025237814,0.000029778781,0.0065902723,0.0027872752],"study_design_scores_gemma":[0.00090994,0.00008055907,0.0000017797263,0.9076706,0.007099033,0.00059534155,0.000007233422,8.211005e-8,0.0012986821,0.000019989946,0.082161896,0.00015485537],"about_ca_topic_score_codex":9.3023857e-7,"about_ca_topic_score_gemma":7.572278e-7,"teacher_disagreement_score":0.08042583,"about_ca_system_score_codex":0.00017521897,"about_ca_system_score_gemma":0.0011460921,"threshold_uncertainty_score":0.8590949},"labels":[],"label_agreement":null},{"id":"W2955154","doi":"10.1051/medsci/20042010882","title":"Résistance du VIH aux antirétroviraux","year":2004,"lang":"fr","type":"review","venue":"médecine/sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug resistance; ANTIRETROVIRAL AGENTS; Antiretroviral therapy; Medicine; Intensive care medicine; Lentivirus; Drug; HIV drug resistance; Sida; Antiretroviral treatment; Virology; Viral load; Biology; Pharmacology; Viral disease; Genetics","score_opus":0.055969071974404476,"score_gpt":0.34899279626711116,"score_spread":0.2930237242927067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069724617,0.9337755,0.00026320713,0.007919188,0.003211835,0.0015113946,0.000069712856,0.0001528407,0.052399077],"genre_scores_gemma":[0.0025914917,0.9254206,0.006094717,0.00041495616,0.0016658365,0.00014839841,0.00011462034,0.000085933585,0.06346347],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99305844,0.00025758016,0.0015522292,0.0017970166,0.0016504496,0.001684263],"domain_scores_gemma":[0.99729955,0.00060797436,0.0006706882,0.0006925177,0.00018789835,0.0005413624],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.001597229,0.0013123712,0.002808338,0.0006746797,0.0013310012,0.0002603351,0.0011538179,0.00046969941,0.0027612005],"category_scores_gemma":[0.0004630249,0.00093921303,0.00084008137,0.0026758988,0.00221574,0.00036409416,0.00026852815,0.0006100457,0.008749858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007337958,0.0040649944,0.05240287,0.03344181,0.0018156399,0.0030393659,0.0013360494,0.000083686675,0.000035610286,0.14255832,0.038722303,0.722426],"study_design_scores_gemma":[0.0022460206,0.0005739841,0.0012040446,0.038256753,0.0015569231,0.00036652916,0.00024460148,0.00004238574,0.000046112746,0.0011652824,0.9533085,0.0009888555],"about_ca_topic_score_codex":0.00013377891,"about_ca_topic_score_gemma":0.000056686935,"teacher_disagreement_score":0.9145862,"about_ca_system_score_codex":0.0011375791,"about_ca_system_score_gemma":0.006489684,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W2955217622","doi":"10.1016/j.antiviral.2019.104543","title":"Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1","year":2019,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Vancouver Infectious Diseases Centre; Canada Research Chairs; McGill University; Maple Leaf Medical Clinic","funders":"Janssen Pharmaceuticals; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Arthur Foundation; Johnson and Johnson; Gilead Sciences; Merck; Yale University","keywords":"Darunavir; Emtricitabine; Tenofovir alafenamide; Medicine; Internal medicine; Adverse effect; Cobicistat; Gastroenterology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.03428119433678359,"score_gpt":0.3278131052699593,"score_spread":0.29353191093317577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955217622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746078,0.00032147884,0.0001028256,0.009004117,0.00012303477,0.014133737,0.00018161756,0.000048706515,0.0014766589],"genre_scores_gemma":[0.9912064,0.00015592988,0.0008027208,0.00015892151,0.0001239466,0.0007403575,0.000108065986,0.0000782579,0.006625365],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99092317,0.0024418202,0.0017861694,0.0014630387,0.002111089,0.0012747007],"domain_scores_gemma":[0.9926049,0.004470679,0.0006093415,0.0014635789,0.0005187762,0.0003327348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046829423,0.00072723534,0.0020512203,0.0006683177,0.00041693545,0.000120945864,0.00069180893,0.00021072266,0.0000374516],"category_scores_gemma":[0.0039996747,0.00037768984,0.00028381214,0.002272336,0.000531924,0.0003575413,0.00071353203,0.0007495413,0.000051208055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8734399,0.0034662336,0.0034142577,0.00009829073,0.0005308661,0.00015020114,0.025442882,0.00021945912,0.08052601,0.000027641125,0.00044527173,0.012239003],"study_design_scores_gemma":[0.913333,0.013431582,0.007004165,0.0036452983,0.00044805591,0.000011141267,0.0041122623,0.004363256,0.05199674,0.00005205001,0.00085058034,0.00075187086],"about_ca_topic_score_codex":0.0024975666,"about_ca_topic_score_gemma":0.00029665508,"teacher_disagreement_score":0.039893106,"about_ca_system_score_codex":0.00079496694,"about_ca_system_score_gemma":0.001211618,"threshold_uncertainty_score":0.9998675},"labels":[],"label_agreement":null},{"id":"W2966490059","doi":"10.1186/s40249-019-0573-1","title":"The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030","year":2019,"lang":"en","type":"letter","venue":"Infectious Diseases of Poverty","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Allergy and Infectious Diseases; Academisch Medisch Centrum; Universiteit van Amsterdam","keywords":"Efavirenz; Nevirapine; Medicine; Developing country; Public health; Tolerability; Regimen; Drug resistance; Lamivudine; Environmental health; Adverse effect; Human immunodeficiency virus (HIV); Viral load; Virology; Antiretroviral therapy; Pharmacology; Economic growth; Internal medicine; Hepatitis B virus; Biology; Virus","score_opus":0.007090802984421769,"score_gpt":0.24964637331843517,"score_spread":0.2425555703340134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966490059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7469818,0.006604164,0.0002185987,0.23481968,0.000817443,0.0062614214,0.0039917096,0.00010532922,0.00019983028],"genre_scores_gemma":[0.90088207,0.0021421418,0.00011056588,0.09020789,0.00046752224,0.00047622714,0.0022331583,0.00012660668,0.003353834],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759865,0.00010341015,0.0007208921,0.0004908381,0.0006319122,0.00045431644],"domain_scores_gemma":[0.9981083,0.00050650863,0.0004175078,0.0005574094,0.00024827707,0.00016196752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001866028,0.00048846425,0.0010285394,0.0003507623,0.00013084241,0.00004378846,0.0001943383,0.00028266362,0.000038882932],"category_scores_gemma":[0.0001536438,0.0003278302,0.00032293025,0.00027449534,0.00022928003,0.0000972458,0.00007516073,0.00032073792,0.000010725498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015400519,0.00050118164,0.5497517,0.0010895449,0.001141814,0.000024351335,0.0003153028,0.00001178416,0.00016028303,0.000053509444,0.44177777,0.0036326726],"study_design_scores_gemma":[0.022621188,0.009246289,0.34074345,0.0025124843,0.0017432238,0.000039055878,0.00021573644,0.00033836902,0.0011228952,0.0005645729,0.6192915,0.001561211],"about_ca_topic_score_codex":0.0003184392,"about_ca_topic_score_gemma":0.000021434736,"teacher_disagreement_score":0.20900826,"about_ca_system_score_codex":0.00034806837,"about_ca_system_score_gemma":0.0003724995,"threshold_uncertainty_score":0.9999174},"labels":[],"label_agreement":null},{"id":"W2969769660","doi":"10.1111/hiv.12790","title":"Lack of effectiveness of adherence counselling in reversing virological failure among patients on long‐term antiretroviral therapy in rural Uganda","year":2019,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"Medical Research Council; Canadian Institutes of Health Research; Fogarty International Center; National Institutes of Health; Michael Smith Health Research BC","keywords":"Medicine; Interquartile range; Viral load; Asymptomatic; Antiretroviral therapy; Internal medicine; Christian ministry; Human immunodeficiency virus (HIV); Immunology","score_opus":0.018921666879449694,"score_gpt":0.28037279094415957,"score_spread":0.2614511240647099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969769660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983675,0.00019895793,0.000018859379,0.000120516226,0.000107496446,0.0008236384,0.0000032085088,0.000010818944,0.00034902556],"genre_scores_gemma":[0.9992917,0.00023917107,0.000055368917,0.00004378798,0.00002239704,0.000010044691,0.00009477723,0.000012560096,0.00023017534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858695,0.00013556163,0.000425441,0.00023374488,0.00039452154,0.00022376841],"domain_scores_gemma":[0.9992836,0.0002493771,0.00015076813,0.00018674402,0.00006898769,0.00006053527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004539426,0.00018554804,0.0007094414,0.0002471211,0.000014385876,0.0000016595635,0.0000796873,0.00010867708,0.00013152623],"category_scores_gemma":[0.000041568794,0.00012367238,0.000052035393,0.0003192186,0.00015604317,0.00006167931,0.000011123635,0.00021062691,0.000014336989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020400542,0.00046131987,0.989011,0.00029656652,0.000037263675,0.000049501545,0.0010970944,0.000010804662,0.0042362907,0.000016495404,0.000030941457,0.0027126814],"study_design_scores_gemma":[0.014799792,0.003037488,0.9717822,0.005338589,0.000023236777,0.000001906934,0.00013563217,0.00005975202,0.0046895496,0.000018605255,0.000015610958,0.00009765756],"about_ca_topic_score_codex":0.00007326314,"about_ca_topic_score_gemma":0.00002605687,"teacher_disagreement_score":0.017228808,"about_ca_system_score_codex":0.0000963678,"about_ca_system_score_gemma":0.000032227537,"threshold_uncertainty_score":0.5043213},"labels":[],"label_agreement":null},{"id":"W2974333472","doi":"10.3390/v11090877","title":"Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia","year":2019,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver; Simon Fraser University","funders":"Canadian Institutes of Health Research; Vetenskapsrådet","keywords":"Drug resistance; Cart; Medicine; Virology; Population; Transmission (telecommunications); Viral load; Genotyping; HIV drug resistance; Reverse transcriptase; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Immunology; Human immunodeficiency virus (HIV); Biology; Antiretroviral therapy; Environmental health; Genotype; Polymerase chain reaction; Microbiology","score_opus":0.007621139785305507,"score_gpt":0.24477301966805917,"score_spread":0.23715187988275366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974333472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958506,0.0017202614,0.0000018083088,0.00033057036,0.00004260654,0.000864014,0.000026918635,0.000052061376,0.0011111243],"genre_scores_gemma":[0.9478201,0.0009054627,0.0003896353,0.00004035583,0.000013630027,0.000037679205,0.000030173032,0.000017771441,0.050745178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989984,0.000047760215,0.00027920166,0.00030217893,0.00017758193,0.00019486228],"domain_scores_gemma":[0.99939704,0.0001320477,0.00010350924,0.00026009444,0.000034238124,0.00007307761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008829111,0.00019011728,0.00033992404,0.00013340259,0.00002763078,0.00000974998,0.000054599306,0.00007001723,0.00014624142],"category_scores_gemma":[0.000036927486,0.00014258764,0.00004248984,0.00016658647,0.000081393,0.00010914818,0.00003570675,0.00009339876,0.00010126174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021332267,0.00027250373,0.996216,0.00013579255,0.000119433505,0.000012670846,0.0016191172,0.0000030286346,0.0005031365,0.00009089853,0.00066415966,0.00014996213],"study_design_scores_gemma":[0.0024819826,0.00005985906,0.9826299,0.00073351397,0.00010825991,0.0000041523317,0.00003203018,0.000020667281,0.013136278,0.000029844672,0.0006325999,0.00013091732],"about_ca_topic_score_codex":0.00007631758,"about_ca_topic_score_gemma":0.00019177538,"teacher_disagreement_score":0.049634054,"about_ca_system_score_codex":0.00009202212,"about_ca_system_score_gemma":0.00007570934,"threshold_uncertainty_score":0.5814555},"labels":[],"label_agreement":null},{"id":"W2975489513","doi":"10.3390/pathogens8040161","title":"Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study","year":2019,"lang":"en","type":"article","venue":"Pathogens","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver; Simon Fraser University","funders":"Canadian Institutes of Health Research; Vetenskapsrådet; Michael Smith Health Research BC","keywords":"Viral load; Medicine; Cart; Hazard ratio; Internal medicine; Regimen; Proportional hazards model; Confidence interval; Prospective cohort study; Cohort; Cohort study; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.01469587147760042,"score_gpt":0.276973209264546,"score_spread":0.26227733778694556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975489513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953455,0.00015281294,0.0000027005249,0.000031944735,0.000047838064,0.004167352,0.000052185103,0.000062011495,0.00013769919],"genre_scores_gemma":[0.998665,0.0001475656,0.00023861224,0.000017114442,0.000016218151,0.00020403761,0.00012860297,0.000034272813,0.00054862886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825644,0.00028369334,0.00041912764,0.0005228979,0.00020209601,0.00031576902],"domain_scores_gemma":[0.99925977,0.00019323423,0.00012136652,0.00026772896,0.000075272415,0.00008263349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039463953,0.0003283414,0.0006714856,0.00026126966,0.00006503289,0.000017605476,0.00005517247,0.00013263119,0.000041126128],"category_scores_gemma":[0.00008994905,0.00023352273,0.0000920833,0.00025459428,0.00009322725,0.00009241232,0.000050600185,0.00019435343,0.000021021237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015139502,0.0033880249,0.9798488,0.000008938871,0.0006164413,0.00016833308,0.006619659,0.000001221817,0.0070688818,0.0000014640984,0.000001607686,0.00076265255],"study_design_scores_gemma":[0.013181237,0.003297613,0.9798257,0.00008484476,0.00014999809,0.000031411568,0.00061944727,0.00018627726,0.002423525,0.000001978272,9.273903e-7,0.000197089],"about_ca_topic_score_codex":0.000039735307,"about_ca_topic_score_gemma":0.00005479803,"teacher_disagreement_score":0.011667286,"about_ca_system_score_codex":0.00017041418,"about_ca_system_score_gemma":0.000076649965,"threshold_uncertainty_score":0.9522781},"labels":[],"label_agreement":null},{"id":"W2975541626","doi":"10.1093/cid/ciz926","title":"Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid","year":2019,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; University at Buffalo; University of California, San Diego; National Institutes of Health; Gilead Sciences","keywords":"Elvitegravir; Cobicistat; Tenofovir alafenamide; Emtricitabine; Medicine; Cerebrospinal fluid; Pharmacokinetics; Regimen; Pharmacology; Dosing; Internal medicine; Gastroenterology; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy","score_opus":0.01915818136845207,"score_gpt":0.34782622511064887,"score_spread":0.3286680437421968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975541626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593866,0.00016310859,0.000057283753,0.0016776639,0.00022451868,0.00096813106,0.000014002084,0.00009597742,0.00086067937],"genre_scores_gemma":[0.99779844,0.00012484328,0.00013170532,0.0011698874,0.000094309245,0.000053921016,0.00002321595,0.000031331136,0.00057236163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981074,0.00017280153,0.0005213585,0.00058033713,0.0002268154,0.00039132155],"domain_scores_gemma":[0.9987855,0.00047226838,0.000092650705,0.00028049218,0.0000439022,0.00032521778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033294558,0.00026943424,0.00064155826,0.0003011306,0.00004462827,0.00003473585,0.00006565038,0.000116199284,0.00005438008],"category_scores_gemma":[0.0003519839,0.00023089837,0.00014160243,0.00040568842,0.000068397865,0.00011663984,0.000078689874,0.0003513632,0.00013606582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055002776,0.0019820607,0.97936577,0.00009901055,0.000057451616,0.00015688068,0.000053569052,0.00003817952,0.0017159581,0.000027817974,0.00028478532,0.01566852],"study_design_scores_gemma":[0.008017473,0.0006839317,0.9871339,0.00037293707,0.0001215129,0.0000039956826,0.000024900228,0.0015756201,0.0006205858,0.00012588408,0.0010498019,0.00026946145],"about_ca_topic_score_codex":0.00006760859,"about_ca_topic_score_gemma":0.00011704998,"teacher_disagreement_score":0.01539906,"about_ca_system_score_codex":0.00016968691,"about_ca_system_score_gemma":0.000258457,"threshold_uncertainty_score":0.9415762},"labels":[],"label_agreement":null},{"id":"W2976335759","doi":"10.1021/acs.oprd.9b00382","title":"Practical Synthesis of Ethyl 3-Fluoro-1-pyrrole-2-carboxylate: A Key Fragment of a Potent Drug Candidate against Hepatitis B Virus","year":2019,"lang":"en","type":"article","venue":"Organic Process Research & Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre in Green Chemistry and Catalysis","funders":"Institut National des Sciences Appliquées Rouen; Institut Universitaire de France; Centre National de la Recherche Scientifique; Agence Nationale de la Recherche","keywords":"Yield (engineering); Combinatorial chemistry; Pyrrole; Carboxylate; Chemistry; Fragment (logic); Hepatitis B virus; Drug; Drug candidate; Drug discovery; Stereochemistry; Virus; Organic chemistry; Virology; In vitro; Biochemistry; Materials science; Pharmacology; Medicine; Computer science","score_opus":0.02141220921952703,"score_gpt":0.33015991739282025,"score_spread":0.3087477081732932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976335759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863124,0.00049604825,0.000120588484,0.005526005,0.00011139723,0.0019639481,0.000029612516,0.000064752574,0.0053752526],"genre_scores_gemma":[0.98504305,0.0018878496,0.0064743436,0.000093609706,0.000034798057,0.00036112193,0.00007417186,0.00009013363,0.0059409095],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.992706,0.00032804988,0.0013790346,0.0008977228,0.0036319739,0.001057216],"domain_scores_gemma":[0.9961132,0.0006131415,0.00039250264,0.0008118157,0.0015296026,0.0005397595],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028097043,0.00046207375,0.0011323101,0.00078087527,0.00018587876,0.000050594437,0.00048001288,0.00021070908,0.0011161806],"category_scores_gemma":[0.0013547112,0.00037125478,0.00014683053,0.0014346702,0.00022139066,0.00023779628,0.00046565675,0.0006998479,0.0007062088],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044275825,0.011241651,0.5051696,0.008372535,0.006484619,0.0014550693,0.042013574,0.000028146376,0.27490202,0.0007514588,0.015447882,0.12970589],"study_design_scores_gemma":[0.0022875487,0.00021995987,0.02680841,0.0012877354,0.00010933919,0.00003778824,0.0012521736,0.00013344335,0.96160936,0.00014504646,0.005675049,0.0004341127],"about_ca_topic_score_codex":0.00021227577,"about_ca_topic_score_gemma":0.00019245417,"teacher_disagreement_score":0.6867074,"about_ca_system_score_codex":0.0009794666,"about_ca_system_score_gemma":0.005953046,"threshold_uncertainty_score":0.99987394},"labels":[],"label_agreement":null},{"id":"W2976858486","doi":"10.1021/acschembio.9b00237","title":"Selection of 2'-Deoxy-2'-Fluoroarabino Nucleic Acid (FANA) Aptamers that Bind HIV-1 Integrase with Picomolar Affinity","year":2019,"lang":"en","type":"article","venue":"ACS Chemical Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Medical Research Council Canada; Division of Intramural Research, National Institute of Allergy and Infectious Diseases","keywords":"Integrase; Aptamer; Nucleic acid; Human immunodeficiency virus (HIV); Selection (genetic algorithm); Computational biology; Virology; Chemistry; Biology; Biochemistry; Molecular biology; Computer science","score_opus":0.01028534210916121,"score_gpt":0.23376642165001063,"score_spread":0.22348107954084942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976858486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958238,0.000064936525,0.000027730965,0.00135845,0.00007059767,0.00036515988,0.00001319515,0.00006592339,0.0022102257],"genre_scores_gemma":[0.9962466,0.000047249305,0.0018767883,0.0001971736,0.000040624625,0.000022149605,0.00028052885,0.00002273612,0.0012661883],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886996,0.000044925335,0.00023353532,0.00038768494,0.00013839142,0.00032553013],"domain_scores_gemma":[0.99932253,0.00008639301,0.000121069104,0.00025297515,0.00008203727,0.0001349927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010898649,0.00023282508,0.00050361414,0.00010914767,0.000028304077,0.0000050041403,0.000113384165,0.0002456265,0.0006109432],"category_scores_gemma":[0.000051651863,0.00015680204,0.000087246444,0.00023317219,0.0001897961,0.000052018782,0.00005558561,0.00028981903,0.00047790117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005457445,0.00028423368,0.3778403,0.00004365456,0.00031137842,0.000008778331,0.00016125782,9.241155e-8,0.61708057,0.00019918346,0.00078693824,0.0027378346],"study_design_scores_gemma":[0.0030570026,0.00047504978,0.0052050436,0.00007269983,0.00017331203,0.00007123308,0.00017448232,0.000021810165,0.9859239,0.00008322858,0.0045319735,0.00021029232],"about_ca_topic_score_codex":0.00001622792,"about_ca_topic_score_gemma":0.000004462286,"teacher_disagreement_score":0.37263528,"about_ca_system_score_codex":0.000117628384,"about_ca_system_score_gemma":0.000100389065,"threshold_uncertainty_score":0.66893995},"labels":[],"label_agreement":null},{"id":"W2980344219","doi":"10.1097/qai.0000000000002135","title":"Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals","year":2019,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; Alberta Hip and Knee Clinic; University of Calgary","funders":"Janssen Pharmaceuticals; Bill and Melinda Gates Foundation; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Medical Research Council; Gilead Sciences","keywords":"Medicine; Confidence interval; Viral load; Hazard ratio; Internal medicine; Regimen; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.011754962486262337,"score_gpt":0.25450985321851327,"score_spread":0.24275489073225093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980344219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596083,0.002637453,0.00006950518,0.00015573476,0.00015240646,0.0005956413,0.000018093204,0.000014878799,0.00039544463],"genre_scores_gemma":[0.9969531,0.00013273062,0.0024160563,0.0000061425503,0.000008973195,0.0000067645465,0.000024256788,0.000029793224,0.0004221335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730635,0.00031003848,0.0012251296,0.00020660156,0.0006635042,0.00028839594],"domain_scores_gemma":[0.9976535,0.00068731693,0.0009184542,0.00021957431,0.00047051744,0.00005067248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018567543,0.0002347773,0.001055775,0.00089560903,0.000042998923,0.000011801242,0.00020508381,0.000092365466,0.000021386453],"category_scores_gemma":[0.0002735102,0.00018101983,0.00024023771,0.0013881811,0.00012597199,0.00035044382,0.00002420932,0.00013480414,0.000007560061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010332728,0.00081451726,0.90515643,0.0007256435,0.0003201065,0.00011429669,0.0066174655,0.000025364756,0.08213584,0.00015720245,0.000012164547,0.0028876807],"study_design_scores_gemma":[0.006178457,0.0016395978,0.8956316,0.00411798,0.000109758264,0.00012531765,0.00090563623,0.000025583613,0.090863794,0.00025473445,0.000004626622,0.00014287594],"about_ca_topic_score_codex":0.00001425816,"about_ca_topic_score_gemma":9.91733e-7,"teacher_disagreement_score":0.009524809,"about_ca_system_score_codex":0.00014279493,"about_ca_system_score_gemma":0.00030892674,"threshold_uncertainty_score":0.7381774},"labels":[],"label_agreement":null},{"id":"W2980416038","doi":"10.1089/aid.2017.0205","title":"Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda","year":2018,"lang":"en","type":"article","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Allergy and Infectious Diseases; Center for AIDS Research, University of Washington; National Institutes of Health; Case Western Reserve University; Government of Canada; Ontario Genomics Institute; Canadian Institutes of Health Research; Johnson Cancer Research Center, Kansas State University; Genome Canada; Ontario Genomics","keywords":"Dolutegravir; Raltegravir; Elvitegravir; Drug resistance; Regimen; Medicine; Virology; Etravirine; Integrase inhibitor; Cart; Resistance mutation; Ritonavir; Reverse-transcriptase inhibitor; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Reverse transcriptase; Biology; Genetics; Polymerase chain reaction; Gene","score_opus":0.09642557988437224,"score_gpt":0.37370460826677504,"score_spread":0.2772790283824028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980416038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709034,0.0002289023,0.000008015824,0.0007426753,0.00001503091,0.00035098713,0.00002522879,0.000009681715,0.0015291242],"genre_scores_gemma":[0.96323246,0.00013435048,0.001100295,0.000026785494,0.000036589605,0.000023912533,0.000020042671,0.000011297788,0.03541424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849963,0.000115152194,0.00032470864,0.00021941603,0.00052679837,0.0003142919],"domain_scores_gemma":[0.9987335,0.00041313653,0.00006980932,0.00033802207,0.0003458,0.00009970575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006251907,0.00010068008,0.0002441967,0.00035247474,0.00020315433,0.000028196477,0.00011281934,0.000038044644,0.00016930785],"category_scores_gemma":[0.00027255178,0.00006552708,0.000039264974,0.00049338356,0.0010115004,0.00012665968,0.00007291159,0.0001977907,0.000017688373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028810443,0.00025971886,0.96859896,0.00010991122,0.00006683758,0.00004747677,0.0037353123,1.2781113e-7,0.0030076583,0.005612761,0.017809952,0.00046317506],"study_design_scores_gemma":[0.0017428308,0.000636861,0.9267165,0.0005416408,0.000032680953,0.000007050112,0.0015984689,0.0000028405198,0.027888088,0.0031887537,0.037502557,0.00014169418],"about_ca_topic_score_codex":0.00034891765,"about_ca_topic_score_gemma":0.0027127045,"teacher_disagreement_score":0.04188243,"about_ca_system_score_codex":0.000049878094,"about_ca_system_score_gemma":0.00019490115,"threshold_uncertainty_score":0.37269154},"labels":[],"label_agreement":null},{"id":"W2981250909","doi":"10.1093/jac/dkz417","title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","year":2019,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; National Institute of Allergy and Infectious Diseases; Agence Nationale de Recherches sur le Sida et les Hépatites Virales; World Health Organization","keywords":"Virology; Drug resistance; Integrase; HIV drug resistance; Human immunodeficiency virus (HIV); Mutation; Drug; Integrase inhibitor; Medicine; Biology; Microbiology; Genetics; Pharmacology; Viral load; Gene; Antiretroviral therapy","score_opus":0.006664571610054501,"score_gpt":0.23633862532695474,"score_spread":0.22967405371690025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981250909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95560455,0.0007760319,0.006604413,0.03544673,0.00028469262,0.00091399514,0.00009831311,0.000013715095,0.00025757265],"genre_scores_gemma":[0.9763081,0.0007140403,0.005821421,0.00048126775,0.00014909648,0.000005671337,0.000022752594,0.000039440467,0.016458204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986044,0.000039047656,0.00069785793,0.00016890782,0.00027350738,0.00021625367],"domain_scores_gemma":[0.99883944,0.00027738864,0.00022223676,0.00019709274,0.0003854648,0.00007836949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039291487,0.0002100186,0.00057008496,0.00012256004,0.00007916864,0.000022377697,0.00016562047,0.0000694173,0.00011141688],"category_scores_gemma":[0.000022084996,0.00013357462,0.0003912153,0.00024409335,0.0001162891,0.00010782898,0.0000025225959,0.00020669619,0.000005243264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025482114,0.0019335692,0.014327453,0.0014123067,0.00325622,0.00006841104,0.012344796,0.00009373124,0.76881254,0.00032308075,0.16895881,0.0029869913],"study_design_scores_gemma":[0.031016737,0.00018778584,0.006085001,0.0015509743,0.00039865312,0.00007249966,0.00057464495,0.000042701595,0.78315717,0.00011434941,0.17639743,0.00040207658],"about_ca_topic_score_codex":0.0000020406098,"about_ca_topic_score_gemma":0.000099568955,"teacher_disagreement_score":0.03496546,"about_ca_system_score_codex":0.00006960653,"about_ca_system_score_gemma":0.00027766626,"threshold_uncertainty_score":0.5447015},"labels":[],"label_agreement":null},{"id":"W2981520117","doi":"10.1093/ofid/ofz360.2183","title":"2505. Incidence of Transmitted Drug Resistance and Its Clinical Implications Between 1999 and 2018 in a Regional HIV Population","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Hip and Knee Clinic; Alberta Bible College","funders":"","keywords":"Medicine; Tolerability; Cohort; Incidence (geometry); HIV drug resistance; Internal medicine; Population; Antiretroviral therapy; Clinical trial; Drug resistance; Viral load; Adverse effect; Human immunodeficiency virus (HIV); Immunology; Environmental health","score_opus":0.020715070381665864,"score_gpt":0.3249915475451721,"score_spread":0.30427647716350625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981520117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99013287,0.0009036211,0.000010341103,0.006865319,0.00002180921,0.0010214248,0.00005276075,0.000021018652,0.0009708265],"genre_scores_gemma":[0.9963256,0.0003388913,0.0001491337,0.00015106252,0.000015717102,0.000064752356,0.00019836932,0.000011877405,0.0027445918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998998,0.000058028203,0.00037823946,0.0002948636,0.00012302499,0.00014784538],"domain_scores_gemma":[0.9993261,0.00019369619,0.000119194025,0.00017348188,0.000051676998,0.00013583091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014419579,0.00011652628,0.0003449857,0.000101685764,0.0000700836,0.000023578019,0.0000686873,0.000050485076,0.000033032582],"category_scores_gemma":[0.000060180526,0.00010259245,0.000045650915,0.00018613496,0.0000506366,0.00022349536,0.00006594122,0.00007523346,0.00001612741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011820826,0.00020133068,0.99439263,0.000066050736,0.000056833713,0.0000023247485,0.00008780895,3.9879262e-7,0.000011137115,0.0012495543,0.0024019638,0.0014117777],"study_design_scores_gemma":[0.0025016572,0.000053686534,0.9926017,0.00024282692,0.00011335982,0.0000054882253,0.000036230744,0.000020413203,0.000018188017,0.0024783355,0.0018224433,0.00010567464],"about_ca_topic_score_codex":0.00014636095,"about_ca_topic_score_gemma":0.00064884225,"teacher_disagreement_score":0.0067142565,"about_ca_system_score_codex":0.00005043463,"about_ca_system_score_gemma":0.00009974669,"threshold_uncertainty_score":0.41835988},"labels":[],"label_agreement":null},{"id":"W2981758607","doi":"10.1093/ofid/ofz359.145","title":"2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Clinique Paro Excellence; Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Regimen; Efavirenz; Rilpivirine; Maintenance therapy; Randomized controlled trial; Phases of clinical research; Internal medicine; Clinical trial; Human immunodeficiency virus (HIV); Chemotherapy; Antiretroviral therapy; Viral load","score_opus":0.010852257676632253,"score_gpt":0.28696907807981964,"score_spread":0.2761168204031874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981758607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843728,0.00070152,0.000004124676,0.003099602,0.0001086119,0.0018704474,0.00015029762,0.00005684933,0.0096357325],"genre_scores_gemma":[0.98368615,0.00079145055,0.0000390501,0.00032750418,0.000018695033,0.000037521615,0.00015933192,0.00002925948,0.014911025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843705,0.000086520835,0.00040007714,0.00050993013,0.00021949418,0.00034690817],"domain_scores_gemma":[0.99884206,0.00019111171,0.00016560931,0.00043560236,0.000102325095,0.00026330445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002286671,0.00027182908,0.00057564577,0.000080994236,0.00014898839,0.00010019475,0.00012230984,0.000048342983,0.00021559473],"category_scores_gemma":[0.00010900759,0.00020125961,0.00009323116,0.00015677845,0.00018590825,0.00029492239,0.00025956155,0.000106502586,0.00007965462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032803447,0.0010825503,0.977236,0.00009332824,0.00027541045,0.00004806171,0.00030510078,0.0000023629948,0.00005783961,0.0002594965,0.0016055354,0.015753988],"study_design_scores_gemma":[0.019613529,0.0005628544,0.9741788,0.00027925262,0.00016260706,0.000070685404,0.0001102932,0.000013667076,0.00042874092,0.0004183187,0.0039041946,0.0002570804],"about_ca_topic_score_codex":0.00053322676,"about_ca_topic_score_gemma":0.00046843354,"teacher_disagreement_score":0.016333183,"about_ca_system_score_codex":0.000095612566,"about_ca_system_score_gemma":0.00018017655,"threshold_uncertainty_score":0.82071286},"labels":[],"label_agreement":null},{"id":"W2981761967","doi":"10.1093/ofid/ofz360.2188","title":"2510. Systematic Literature Review of Multiclass Resistance in Heavily Treatment Experienced Persons with HIV","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cochrane Library; Human immunodeficiency virus (HIV); MEDLINE; Resistance (ecology); Systematic review; Family medicine; Antiretroviral therapy; Inclusion (mineral); Data extraction; Meta-analysis; Viral load; Internal medicine; Psychology; Political science","score_opus":0.006925458676778449,"score_gpt":0.2693958987176888,"score_spread":0.26247044004091036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981761967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72245395,0.19142567,0.000015458894,0.0059090657,0.00018227045,0.019029653,0.0002193297,0.00015862672,0.060606003],"genre_scores_gemma":[0.96376264,0.005132043,0.00029650374,0.0003451792,0.000008203581,0.001288877,0.0001389201,0.000030074847,0.028997567],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9986169,0.00009161825,0.0003951995,0.00035709547,0.00026352098,0.00027571214],"domain_scores_gemma":[0.9990027,0.00007973746,0.00017740285,0.0004810407,0.000103866594,0.00015524184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008373878,0.0002659235,0.0008928517,0.00012273237,0.00006216638,0.00005430933,0.0001257021,0.000043755328,0.0001777106],"category_scores_gemma":[0.000061862396,0.00016418246,0.00012865501,0.00047368673,0.000043252152,0.00022308409,0.000049160033,0.0000616686,0.000074446354],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057679147,0.0022976415,0.8815243,0.107288435,0.00046750638,0.00032853364,0.0033623646,0.0000027125848,0.000051026098,0.0006492856,0.0033226158,0.00012875663],"study_design_scores_gemma":[0.020456152,0.0019832985,0.05493998,0.90883666,0.0015494613,0.00019313196,0.004302459,0.000060622147,0.0008053348,0.00005841944,0.0059122336,0.0009022557],"about_ca_topic_score_codex":0.000024416704,"about_ca_topic_score_gemma":0.00020668325,"teacher_disagreement_score":0.82658434,"about_ca_system_score_codex":0.0003538385,"about_ca_system_score_gemma":0.00023790156,"threshold_uncertainty_score":0.6695167},"labels":[],"label_agreement":null},{"id":"W2981809579","doi":"10.1093/ofid/ofz359.043","title":"884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dosing; Medicine; Rilpivirine; Tolerability; Clinical endpoint; Regimen; Adverse effect; Internal medicine; Clinical trial; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology","score_opus":0.02739097346984783,"score_gpt":0.3417454218479364,"score_spread":0.31435444837808857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981809579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847458,0.0016532846,0.000014913217,0.0014144329,0.00013912185,0.0024481802,0.000027391998,0.00002790149,0.009528954],"genre_scores_gemma":[0.9955025,0.00071026606,0.00011352653,0.000817932,0.000016398053,0.00033935157,0.000027112357,0.00002060651,0.0024523442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986274,0.00007777233,0.00034195455,0.00035991077,0.00023984812,0.0003530967],"domain_scores_gemma":[0.99914646,0.00016162208,0.00014583381,0.0003387877,0.00011877378,0.00008853381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014188376,0.00024649446,0.0005177263,0.00008073743,0.00015155788,0.000060265476,0.0001610389,0.00003610937,0.00009819307],"category_scores_gemma":[0.00012410626,0.00014993538,0.00007331009,0.00038385266,0.00007749575,0.0002781657,0.00020082286,0.00011332495,0.00006181653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094626955,0.0018831821,0.93779206,0.00011499215,0.00035792,0.000076780016,0.0064627305,0.000018753295,0.0002509405,0.00041926626,0.0071097133,0.044567417],"study_design_scores_gemma":[0.10311195,0.042881254,0.62209266,0.007471746,0.0011382445,0.00043925032,0.08467033,0.00020617238,0.026688557,0.010324576,0.097720705,0.0032545603],"about_ca_topic_score_codex":0.0007404026,"about_ca_topic_score_gemma":0.0007048152,"teacher_disagreement_score":0.31569937,"about_ca_system_score_codex":0.00010908202,"about_ca_system_score_gemma":0.00012361213,"threshold_uncertainty_score":0.6114187},"labels":[],"label_agreement":null},{"id":"W2985537913","doi":"10.1016/j.ejmech.2019.111866","title":"Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants","year":2019,"lang":"en","type":"article","venue":"European Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Chinese Academy of Medical Sciences; National Natural Science Foundation of China","keywords":"Chemistry; Pyrimidine; Acetamide; Ligand (biochemistry); Stereochemistry; In vivo; IC50; Protease; In vitro; Enzyme inhibitor; Cytotoxicity; HIV-1 protease; Enzyme; Nucleic acid; Biological activity; Human immunodeficiency virus (HIV); Structure–activity relationship; Potency; Protease inhibitor (pharmacology); Biochemistry; Virology; Biology; Receptor; Organic chemistry","score_opus":0.018861210007039508,"score_gpt":0.26887755298939164,"score_spread":0.25001634298235215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985537913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917637,0.0003580956,0.00017863716,0.0026303495,0.00005884628,0.0004909799,0.000013880285,0.000012104384,0.00449339],"genre_scores_gemma":[0.99698544,0.00006280709,0.0012890062,0.00012312965,0.00026775236,0.0000037698037,0.00002227284,0.000027011265,0.0012187868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776137,0.0001124303,0.00056360505,0.0003118312,0.0010234015,0.00022738586],"domain_scores_gemma":[0.9983003,0.000081168,0.0005099367,0.0002301368,0.00046211111,0.0004163127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018653377,0.00026408542,0.00051552005,0.00009343254,0.00004924865,0.000011442765,0.00012498337,0.000049867966,0.000109462955],"category_scores_gemma":[0.0005244946,0.00016776883,0.00008163606,0.00016860728,0.00010526715,0.00008445286,0.00007144624,0.00032973758,0.000021699983],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009154325,0.0010596816,0.012310124,0.00037981034,0.0003182718,0.0010496653,0.0007761367,0.00006448895,0.95980346,8.3481484e-7,0.001116631,0.013966568],"study_design_scores_gemma":[0.0083969105,0.00399857,0.07530306,0.0046643666,0.0006507168,0.0010803669,0.0008484785,0.00020368595,0.9035865,0.0000028253155,0.0009673445,0.00029719336],"about_ca_topic_score_codex":0.0000013094356,"about_ca_topic_score_gemma":8.349383e-8,"teacher_disagreement_score":0.06299294,"about_ca_system_score_codex":0.00015207146,"about_ca_system_score_gemma":0.00041347233,"threshold_uncertainty_score":0.6841414},"labels":[],"label_agreement":null},{"id":"W2990226592","doi":"10.1016/j.ejmech.2019.111900","title":"Rational design and Structure−Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase","year":2019,"lang":"en","type":"article","venue":"European Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Natural Science Foundation of China","keywords":"Chemistry; Coumarin; Reverse transcriptase; Rational design; Potency; Protease; IC50; Docking (animal); Enzyme; Human immunodeficiency virus (HIV); HIV-1 protease; Stereochemistry; Structure–activity relationship; Pharmacology; In vitro; Enzyme inhibitor; Combinatorial chemistry; Biochemistry; Virology; RNA; Organic chemistry; Nanotechnology","score_opus":0.016189080099612688,"score_gpt":0.2397227649883351,"score_spread":0.22353368488872244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990226592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950211,0.00012499138,0.0011722187,0.0017336464,0.00004183759,0.00042529646,0.000016348191,0.000006561921,0.0014579961],"genre_scores_gemma":[0.9967322,0.000020412579,0.0017586278,0.00008714942,0.00011958268,0.0000023740156,0.0000152043285,0.000017877454,0.0012465814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986526,0.0002892518,0.00033673018,0.00018927072,0.00041306252,0.00011913226],"domain_scores_gemma":[0.9989093,0.00033749756,0.00030671144,0.000120253695,0.00011681961,0.00020941015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071141013,0.00018398397,0.00033950832,0.00006924341,0.000053646887,0.000008888493,0.000052584895,0.000037263842,0.00014890918],"category_scores_gemma":[0.00036932554,0.0001335375,0.000054786353,0.00007136711,0.00013154808,0.00007671853,0.000012317388,0.0004098396,0.0000074548616],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021562932,0.0010528149,0.24871133,0.0013370952,0.0009314038,0.0020580504,0.005166103,0.0003075196,0.70081735,0.000118316435,0.0053409254,0.0125961825],"study_design_scores_gemma":[0.017757833,0.0029883925,0.47324106,0.0030922312,0.0005597158,0.0010018994,0.00056084024,0.00023061114,0.4987239,0.000109569264,0.0014016755,0.0003322753],"about_ca_topic_score_codex":3.8733774e-7,"about_ca_topic_score_gemma":4.4800792e-8,"teacher_disagreement_score":0.22452973,"about_ca_system_score_codex":0.00006633308,"about_ca_system_score_gemma":0.00014196389,"threshold_uncertainty_score":0.5445501},"labels":[],"label_agreement":null},{"id":"W2991197165","doi":"10.71781/28614","title":"Caractérisation des mécanismes moléculaires et virologiques contribuant à la persistance du VIH-1 chez les individus sous thérapie antirétrovirale","year":2019,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University; Canadian Foundation for AIDS Research; Delaney AIDS Research Enterprise; Styrelsen för Internationellt Utvecklingssamarbete; amfAR, The Foundation for AIDS Research","keywords":"Human immunodeficiency virus (HIV); Medicine; Virology","score_opus":0.006276174313790982,"score_gpt":0.1919225805805086,"score_spread":0.1856464062667176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991197165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9165527,0.060382348,0.00040926374,0.0010781523,0.0009129855,0.0009433773,0.00020925853,0.00018828732,0.019323586],"genre_scores_gemma":[0.9270274,0.008673962,0.0009360357,0.00011131083,0.00020552834,0.000060390044,0.0021139223,0.000062999294,0.060808435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962184,0.00056636956,0.00062545226,0.0009133353,0.0009297981,0.000746691],"domain_scores_gemma":[0.9975223,0.0005503964,0.00066579954,0.00042124558,0.00046340766,0.00037685508],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00057598087,0.00082080544,0.0009144664,0.00045932402,0.0050141923,0.00012259296,0.00036646964,0.00090035243,0.00009613685],"category_scores_gemma":[0.00023802306,0.00084391044,0.0005447283,0.00032532928,0.00080334337,0.0005506743,0.00014165704,0.00070397276,0.00013649689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002518325,0.0013268045,0.75949734,0.0007853289,0.0037760043,0.008226114,0.1648111,0.0013767971,0.018688846,0.02825079,0.00097641815,0.009766116],"study_design_scores_gemma":[0.0062163123,0.0005189116,0.8250135,0.0023467226,0.0031176354,0.001285574,0.098860145,0.0021314255,0.024656784,0.00029351472,0.034189694,0.0013697707],"about_ca_topic_score_codex":0.015202894,"about_ca_topic_score_gemma":0.006545525,"teacher_disagreement_score":0.06595096,"about_ca_system_score_codex":0.007820719,"about_ca_system_score_gemma":0.0034576608,"threshold_uncertainty_score":0.99940115},"labels":[],"label_agreement":null},{"id":"W2991386570","doi":"","title":"Biochemical evidence of HIV-1 subtype B and C different patterns of resistance to integrase inhibitors","year":2010,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Integrase; Integrase inhibitor; Human immunodeficiency virus (HIV); Virology; Lentivirus; Drug resistance; Biology; Genetics; Medicine; Viral disease; Antiretroviral therapy; Viral load","score_opus":0.01264810899267628,"score_gpt":0.2677510112963209,"score_spread":0.25510290230364463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991386570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804,0.0002122647,0.000060967377,0.0012865152,0.000073324234,0.00016120965,0.000009204137,0.0000104825185,0.00014598429],"genre_scores_gemma":[0.99558645,0.00004518162,0.0016881089,0.000037862254,0.000034390774,0.000010227178,0.000008731394,0.00000812319,0.0025808928],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993468,0.000010615856,0.00021013156,0.00016087297,0.00016583472,0.00010577795],"domain_scores_gemma":[0.99947476,0.0000862539,0.00005210621,0.00020269131,0.00006646657,0.00011771841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079077414,0.00009929161,0.00023163734,0.00008122074,0.000011421137,0.0000029341643,0.000049847746,0.00005035962,0.00005675469],"category_scores_gemma":[0.00018351951,0.00006948893,0.00003964308,0.00009823447,0.00005102669,0.000025703137,0.000045667544,0.000100751924,0.000008485853],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016876556,0.00011861662,0.7367495,0.00014367775,0.000040056413,0.00000783979,0.00046647826,7.1905286e-9,0.25950122,0.00021647541,0.0014787511,0.0011086107],"study_design_scores_gemma":[0.00055456616,0.00016955053,0.1846568,0.0008278225,0.00007830133,0.0000036277513,0.0001098442,0.0000013122901,0.8128165,0.00003137874,0.00067136326,0.00007892065],"about_ca_topic_score_codex":0.000014783531,"about_ca_topic_score_gemma":0.00003448081,"teacher_disagreement_score":0.5533153,"about_ca_system_score_codex":0.000016628013,"about_ca_system_score_gemma":0.000033116175,"threshold_uncertainty_score":0.28336763},"labels":[],"label_agreement":null},{"id":"W2991424058","doi":"10.18553/jmcp.2019.19174","title":"Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus","year":2019,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Medicaid; Pharmacy; Regimen; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Health care; Internal medicine; Pediatrics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Family medicine","score_opus":0.012712894579016629,"score_gpt":0.29402682291888543,"score_spread":0.2813139283398688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991424058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916389,0.006012396,0.0000032725056,0.00038941667,0.00028564103,0.0007862899,0.000018236315,0.000009933432,0.0008558871],"genre_scores_gemma":[0.9953238,0.0039334423,0.000077568635,0.00025290024,0.00020574656,0.00000396113,0.00011930395,0.000031883166,0.000051402618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692875,0.00016795663,0.0009367321,0.0002691582,0.0013672371,0.00033016634],"domain_scores_gemma":[0.9983288,0.000058359557,0.00082669477,0.00019065778,0.0003498002,0.00024566962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048548327,0.00025946795,0.0007404148,0.00048357784,0.000106152176,0.00002965154,0.00018163335,0.000071555834,0.00031370283],"category_scores_gemma":[0.00004393018,0.00019603838,0.0001177908,0.00026669956,0.00007906978,0.0003123676,0.000055807668,0.00050875003,0.0000026448079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011403806,0.00040984846,0.88543695,0.00028620492,0.0001764337,0.0001408244,0.007913336,0.000006981504,0.00015203001,0.000012843046,0.00011722135,0.104206964],"study_design_scores_gemma":[0.022804525,0.0014786031,0.9717452,0.0016506613,0.00008414826,0.000025802558,0.0007973521,0.000005370886,0.0010499309,0.0000017412145,0.00018036301,0.00017633173],"about_ca_topic_score_codex":0.00022831741,"about_ca_topic_score_gemma":0.0002185286,"teacher_disagreement_score":0.10403063,"about_ca_system_score_codex":0.00086320966,"about_ca_system_score_gemma":0.00051339,"threshold_uncertainty_score":0.7994213},"labels":[],"label_agreement":null},{"id":"W2991632468","doi":"10.33380/2305-2066-2019-8-4-53-60","title":"Chemical and Toxicological Analysis of Antiretroviral Drugs","year":2019,"lang":"en","type":"article","venue":"Drug development & registration","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Efavirenz; Nevirapine; Atazanavir; Ritonavir; Darunavir; Abacavir; Zidovudine; Medicine; Pharmacology; Lamivudine; Lopinavir; Urine; Human immunodeficiency virus (HIV); Virology; Internal medicine; Viral load; Antiretroviral therapy; Viral disease; Virus","score_opus":0.009202233969733001,"score_gpt":0.24868486596939834,"score_spread":0.23948263199966535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991632468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228483,0.00007079627,0.00006337654,0.00080939045,0.000045551096,0.00036463476,0.0000027738204,0.000044434546,0.0063142236],"genre_scores_gemma":[0.9794514,0.00002618212,0.0069054128,0.000084189254,0.00001656749,0.000018503142,0.00036065708,0.0000090352,0.013128046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985752,0.00002504623,0.00045390107,0.00035234055,0.00039433644,0.0001991538],"domain_scores_gemma":[0.9994219,0.00004226603,0.0001567922,0.00019410923,0.000079115234,0.00010582414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026300154,0.00017771014,0.00047717313,0.00026819584,0.000041313608,0.00001985897,0.00005854446,0.000093502975,0.00020848485],"category_scores_gemma":[0.000027978944,0.00014374695,0.00009841547,0.00054095656,0.000067093446,0.00008882717,0.00003952821,0.00009542337,0.000043737622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003176126,0.00061608804,0.9285381,0.00017269226,0.0016884255,0.000027472297,0.0044394326,0.000006334668,0.040719636,0.0019664553,0.0014555968,0.020052172],"study_design_scores_gemma":[0.004574085,0.00020621745,0.78623474,0.0001787414,0.002075029,0.000025696123,0.0014952782,0.0015308207,0.18498671,0.00006929317,0.017908001,0.00071538816],"about_ca_topic_score_codex":0.0000061766045,"about_ca_topic_score_gemma":0.0000068780473,"teacher_disagreement_score":0.14426708,"about_ca_system_score_codex":0.00011851273,"about_ca_system_score_gemma":0.00019114687,"threshold_uncertainty_score":0.586183},"labels":[],"label_agreement":null},{"id":"W2996597631","doi":"10.1111/hiv.12835","title":"Response to Noe, Oldenbuettel and Jaeger","year":2019,"lang":"en","type":"letter","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Tenofovir alafenamide; Medicine; Emtricitabine; Weight gain; Dolutegravir; Weight change; Internal medicine; Weight loss; Clinical trial; Oncology; Human immunodeficiency virus (HIV); Body weight; Antiretroviral therapy; Family medicine; Obesity; Viral load","score_opus":0.016190606272450683,"score_gpt":0.26791978997591953,"score_spread":0.25172918370346886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996597631","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009576997,0.0008330449,0.000041890453,0.9777433,0.00066618953,0.0012420014,0.00003000247,0.000113293456,0.009753231],"genre_scores_gemma":[0.00040607073,0.00011117715,0.0005771615,0.56156236,0.002462127,0.00005902968,0.00046867158,0.000079604666,0.4342738],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712074,0.00013005684,0.00050939096,0.0007791153,0.00087943306,0.0005812603],"domain_scores_gemma":[0.9980936,0.00058659515,0.00012457489,0.00079068146,0.00012781368,0.00027674224],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00053804775,0.0005840591,0.0011920683,0.00069921074,0.00006593559,0.000014999463,0.00015046787,0.0005766137,0.0015309702],"category_scores_gemma":[0.00031639508,0.00040203638,0.0000970564,0.0002983039,0.0001520057,0.000038489237,0.00008020746,0.0010746378,0.0032396195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079390616,0.000033235505,0.0022967588,0.00027824542,0.00025014518,0.0036139067,0.0012031948,5.5841635e-8,0.00042552708,0.0000039941997,0.99031895,0.0007820612],"study_design_scores_gemma":[0.0044577564,0.00043605093,0.0048312983,0.0017894747,0.000528393,0.00037507736,0.00006790588,0.00000397539,0.00008590229,0.000010820468,0.98704165,0.00037170196],"about_ca_topic_score_codex":0.0000156434,"about_ca_topic_score_gemma":0.0000021737746,"teacher_disagreement_score":0.42452058,"about_ca_system_score_codex":0.00019552156,"about_ca_system_score_gemma":0.00026847352,"threshold_uncertainty_score":0.9998432},"labels":[],"label_agreement":null},{"id":"W3000260590","doi":"10.1097/qai.0000000000002261","title":"Darunavir Pharmacokinetics With an Increased Dose During Pregnancy","year":2020,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institutes of Health; York University; International Maternal Pediatric Adolescent AIDS Clinical Trials Network; University of California, San Diego; Texas Children's Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development; University of Miami","keywords":"Darunavir; Ritonavir; Pharmacokinetics; Medicine; Postpartum period; Pregnancy; Area under the curve; Internal medicine; Urology; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Virology","score_opus":0.022535909023323506,"score_gpt":0.2704133886239485,"score_spread":0.24787747960062498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000260590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924127,0.0043786704,0.00010796489,0.0018863501,0.00014897725,0.00036805688,0.0000078053245,0.0001048748,0.00058459514],"genre_scores_gemma":[0.99386466,0.00060373015,0.004460365,0.00008606399,0.00008865367,0.000009496105,0.000019218054,0.000070181486,0.00079765334],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974023,0.000095539974,0.000909551,0.00031477513,0.0008103044,0.00046754346],"domain_scores_gemma":[0.99836326,0.00006291034,0.0005040391,0.0003120394,0.00029593724,0.00046184502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022569404,0.00035363028,0.00079020223,0.00035488766,0.00017130189,0.000058716436,0.00033005176,0.00008028233,0.00016848276],"category_scores_gemma":[0.00013289001,0.0002469879,0.00021384054,0.00092241814,0.00013342776,0.00049505406,0.00007143383,0.00018709779,0.000065651926],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015975298,0.008531541,0.24549472,0.0029173144,0.004868988,0.05658184,0.0268807,0.0004684994,0.59767187,0.00027796972,0.0013213289,0.039009947],"study_design_scores_gemma":[0.05379012,0.017618375,0.7088746,0.006162094,0.0039415043,0.027573787,0.0058618877,0.0012168261,0.17106254,0.00010137317,0.0018867365,0.0019101595],"about_ca_topic_score_codex":0.000006162052,"about_ca_topic_score_gemma":3.3489098e-7,"teacher_disagreement_score":0.4633799,"about_ca_system_score_codex":0.00010972158,"about_ca_system_score_gemma":0.0003346961,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W3000709627","doi":"10.1093/cid/ciz1243","title":"Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study","year":2020,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"ViiV Healthcare","keywords":"Tenofovir alafenamide; Medicine; Dolutegravir; Regimen; Lamivudine; Adverse effect; Internal medicine; Population; Viral load; Pharmacology; Human immunodeficiency virus (HIV); Immunology; Virus; Hepatitis B virus","score_opus":0.021628873131507142,"score_gpt":0.3442438337001976,"score_spread":0.3226149605686905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000709627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926733,0.00043616164,0.000491711,0.0007449918,0.00008106622,0.005343012,0.000054407006,0.000110644374,0.000064711894],"genre_scores_gemma":[0.99853873,0.00018514038,0.0004859137,0.00023994641,0.00006396227,0.00024457907,0.000045464683,0.000046456757,0.00014978524],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633217,0.000532145,0.0015925306,0.00079023786,0.00033074146,0.00042216718],"domain_scores_gemma":[0.9948297,0.0034145864,0.0006841899,0.00043411762,0.00027606063,0.00036135607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013204892,0.00043108518,0.0020917826,0.00019290611,0.00015541306,0.00002704317,0.0001754944,0.00009452152,0.000031070496],"category_scores_gemma":[0.005092445,0.0002708957,0.00025915893,0.0005313528,0.00026662336,0.00012865537,0.00017512061,0.00030791672,0.00000329177],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34405255,0.012687191,0.63050914,0.0005452851,0.00058819534,0.00015235206,0.0050483556,0.00010155552,0.0015102257,0.00003787719,0.0002733703,0.0044939048],"study_design_scores_gemma":[0.553932,0.01325871,0.41909242,0.0058530397,0.002163607,0.000008396897,0.0014112861,0.0028398535,0.0005507184,0.000051385505,0.00014887724,0.00068967673],"about_ca_topic_score_codex":0.00018195513,"about_ca_topic_score_gemma":0.00027414472,"teacher_disagreement_score":0.21141672,"about_ca_system_score_codex":0.00008632955,"about_ca_system_score_gemma":0.00026404992,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W3004204832","doi":"10.1038/s41598-020-58544-z","title":"Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia; University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; Genome Canada; Canadian Institutes of Health Research; Brown University; Genome British Columbia; Center for AIDS Research, University of Washington","keywords":"HIV drug resistance; Medicine; Quality assurance; Computational biology; Human immunodeficiency virus (HIV); Data mining; Computer science; Biology; External quality assessment; Virology; Antiretroviral therapy; Viral load; Pathology","score_opus":0.12291907320372035,"score_gpt":0.30750757281439284,"score_spread":0.18458849961067247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004204832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397063,0.00024927608,0.002272607,0.0018865617,0.0004628175,0.000428843,0.0000029794069,0.000053954995,0.0006723191],"genre_scores_gemma":[0.9465248,0.000002003123,0.035601743,0.000029310258,0.00011205358,0.000026870626,0.0003301379,0.000010022448,0.01736309],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99817234,0.000015574797,0.0007091096,0.0005135455,0.00040477922,0.0001846628],"domain_scores_gemma":[0.9986642,0.0000451302,0.00041701295,0.00032252842,0.00043768136,0.00011342464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060284196,0.00012151082,0.0003894777,0.00017474203,0.00024044701,0.00006711016,0.000049212373,0.00002841561,0.000026607691],"category_scores_gemma":[0.0003753324,0.00010183288,0.00012148895,0.0013231116,0.000070596834,0.00013783289,0.000022514225,0.000052158135,0.000007080172],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006623568,0.00011842602,0.68850416,0.00047597976,0.0003850945,0.00008304082,0.0070886374,0.0024653035,0.21403015,0.0000091372885,0.08254657,0.0042272536],"study_design_scores_gemma":[0.0006632866,0.000038905193,0.0029554034,0.00020342898,0.0015584481,0.000019314879,0.0009704621,0.57769066,0.3879211,0.000039444807,0.027642867,0.00029669685],"about_ca_topic_score_codex":0.0000036478966,"about_ca_topic_score_gemma":0.000044692162,"teacher_disagreement_score":0.6855488,"about_ca_system_score_codex":0.00008162677,"about_ca_system_score_gemma":0.00026514076,"threshold_uncertainty_score":0.4152624},"labels":[],"label_agreement":null},{"id":"W3005888737","doi":"10.1016/j.jgar.2020.01.018","title":"Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice","year":2020,"lang":"en","type":"letter","venue":"Journal of Global Antimicrobial Resistance","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lamivudine; Dolutegravir; Medicine; Virology; Dual (grammatical number); Viral load; Virus; Antiretroviral therapy; Art","score_opus":0.015050348046967948,"score_gpt":0.24746329313048535,"score_spread":0.2324129450835174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005888737","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09367789,0.0025480827,0.0000458113,0.8974587,0.0005900038,0.0012289602,0.0008088643,0.000075564974,0.0035661503],"genre_scores_gemma":[0.17993094,0.0066175796,0.014859101,0.7115274,0.0076404014,0.000049306185,0.00092846557,0.00048550108,0.07796128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99461144,0.00021208782,0.0018086853,0.0008647793,0.0014905793,0.00101244],"domain_scores_gemma":[0.99678206,0.00013656903,0.001556786,0.00051660975,0.0007092934,0.00029867768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027485777,0.0010962537,0.002451069,0.00030381177,0.00018168008,0.00018272831,0.0006056725,0.0006391354,0.0002251601],"category_scores_gemma":[0.00008501267,0.0007956441,0.0006381308,0.00084516,0.00029221596,0.0002531837,0.000088306115,0.0022473277,0.00007706021],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01396729,0.00033686392,0.0011830503,0.00065547327,0.0012320165,0.035834752,0.00033037222,0.000003669463,0.011342658,0.000025846231,0.93501526,0.0000727524],"study_design_scores_gemma":[0.02070215,0.0010293265,0.004324058,0.0052417275,0.0007409833,0.0011105972,0.00007090828,0.000004614719,0.0062567294,0.000112062524,0.95931286,0.0010939868],"about_ca_topic_score_codex":0.000057907702,"about_ca_topic_score_gemma":0.00049214147,"teacher_disagreement_score":0.18593125,"about_ca_system_score_codex":0.0017913834,"about_ca_system_score_gemma":0.0020706474,"threshold_uncertainty_score":0.99944943},"labels":[],"label_agreement":null},{"id":"W3007329046","doi":"10.1002/jia2.25420","title":"Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate – emtricitabine for HIV pre‐exposure prophylaxis","year":2020,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Canadian HIV Trials Network, Canadian Institutes of Health Research; Agence Nationale de Recherches sur le Sida et les Hépatites Virales; Agence Nationale de la Recherche; Sidaction; Styrelsen för Internationellt Utvecklingssamarbete; Gilead Sciences; CHIST-ERA; Bill and Melinda Gates Foundation","keywords":"Medicine; Emtricitabine; Pre-exposure prophylaxis; Renal function; Tenofovir; Placebo; Urology; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Men who have sex with men; Immunology","score_opus":0.011323524023408943,"score_gpt":0.23317750726169226,"score_spread":0.22185398323828331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007329046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95067036,0.000058450347,0.0014693289,0.046175122,0.00012416458,0.0006382867,0.000021328402,0.000016820122,0.00082612364],"genre_scores_gemma":[0.9821857,0.00002349494,0.002316922,0.00141685,0.00046189374,0.000037316426,0.000017224242,0.00002385262,0.013516717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859416,0.000037588397,0.00038547395,0.00018322322,0.0006243794,0.00017515638],"domain_scores_gemma":[0.99904513,0.00008286308,0.00041389884,0.00008639972,0.00023812051,0.00013360802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049858703,0.00016632846,0.0002748301,0.00006550212,0.000103626226,0.00004412633,0.0001770539,0.000062950465,0.0000353977],"category_scores_gemma":[0.0001841119,0.00009279464,0.00017915224,0.00020161463,0.000038865193,0.00016677176,0.00005862036,0.00029965982,0.0000019643594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023356685,0.0003901072,0.9420587,0.00017371163,0.0015645791,0.000024070514,0.009656862,0.0006198613,0.007941033,0.000040158746,0.031593405,0.0036018328],"study_design_scores_gemma":[0.045176372,0.017306508,0.76997924,0.004340831,0.0017597226,0.00014249844,0.01795785,0.06220062,0.057677176,0.0011412969,0.021163318,0.0011545516],"about_ca_topic_score_codex":0.000005873088,"about_ca_topic_score_gemma":0.000009799499,"teacher_disagreement_score":0.17207946,"about_ca_system_score_codex":0.0004446661,"about_ca_system_score_gemma":0.00020336811,"threshold_uncertainty_score":0.37840554},"labels":[],"label_agreement":null},{"id":"W3008140779","doi":"10.33380/2305-2066-2020-9-1-99-108","title":"Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method","year":2020,"lang":"en","type":"article","venue":"Drug development & registration","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Atazanavir; Ritonavir; Pharmacokinetics; Chromatography; Human plasma; Protein precipitation; Therapeutic drug monitoring; Chemistry; Pharmacology; Human immunodeficiency virus (HIV); Medicine; Antiretroviral therapy; Viral load; Virology","score_opus":0.025053923488284408,"score_gpt":0.2949525593858599,"score_spread":0.2698986358975755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008140779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939315,0.000112990805,0.0020191679,0.0020879593,0.000026608468,0.00069410336,0.0000046832124,0.00005047744,0.0010725164],"genre_scores_gemma":[0.8525229,0.000044555138,0.14458291,0.00008972931,0.000025178668,0.000093782386,0.0008431543,0.000024388728,0.0017733861],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800164,0.0000720702,0.00078653096,0.0004894737,0.0004306177,0.00021966256],"domain_scores_gemma":[0.99930733,0.00004937598,0.0002704466,0.000118655546,0.000082916435,0.00017128358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005072601,0.00026874698,0.00039032067,0.00017529713,0.0001387458,0.00004235903,0.00006364912,0.000106268984,0.00001993275],"category_scores_gemma":[0.00005274869,0.0002625684,0.000025499307,0.0002659009,0.000055514185,0.00025017277,0.000053730117,0.00013574988,0.000006582391],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056866044,0.0010772136,0.17952691,0.0016841821,0.0003178796,0.000117328724,0.07369046,0.000016188449,0.26729667,0.0016110723,0.0035941987,0.47049922],"study_design_scores_gemma":[0.0035191183,0.00007629236,0.054749645,0.00032571433,0.000081370104,0.000029313866,0.0010065471,0.0011462553,0.8995891,0.000059418857,0.038923245,0.00049396616],"about_ca_topic_score_codex":0.000024449184,"about_ca_topic_score_gemma":0.00007637305,"teacher_disagreement_score":0.63229245,"about_ca_system_score_codex":0.00017067375,"about_ca_system_score_gemma":0.00024811018,"threshold_uncertainty_score":0.99998266},"labels":[],"label_agreement":null},{"id":"W3008969995","doi":"10.1128/aac.02101-19","title":"Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa","year":2020,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"Canadian Institutes of Health Research; U.S. President’s Emergency Plan for AIDS Relief; Bill and Melinda Gates Foundation; United States Agency for International Development","keywords":"Etravirine; Genotype; Phenotype; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Genetics; Medicine; Viral load; Gene","score_opus":0.028403331496568627,"score_gpt":0.2479251438544464,"score_spread":0.21952181235787777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008969995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784172,0.00032064703,0.001242424,0.018460121,0.000051938714,0.00096619315,0.00041796095,0.000077029246,0.000046459936],"genre_scores_gemma":[0.9907444,0.0006092077,0.00365649,0.0034528323,0.0003315255,0.00002164153,0.00075411657,0.00006825085,0.00036153043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984788,0.000025928715,0.0003656115,0.0005835645,0.00016411045,0.00038202162],"domain_scores_gemma":[0.99938565,0.00006879264,0.00011645129,0.00018067437,0.00005258832,0.00019586066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000066827946,0.00036493604,0.000593734,0.00008721135,0.00012533905,0.000055400393,0.00011104767,0.00013481591,0.00013615082],"category_scores_gemma":[0.000021072832,0.00029389048,0.00008926039,0.00024720895,0.000118613716,0.000081567,0.00003131409,0.00016101977,0.000012098927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004187391,0.00041853456,0.9605718,0.00015974454,0.00043813433,0.00002555066,0.0076359296,0.000008071393,0.0060742977,0.000015009435,0.0064902348,0.013975284],"study_design_scores_gemma":[0.03768517,0.0017317664,0.83516055,0.0003205779,0.00027081583,0.0000015111771,0.00015966747,0.0017623027,0.015591572,0.0001155295,0.10630442,0.00089611555],"about_ca_topic_score_codex":0.000059427628,"about_ca_topic_score_gemma":0.000023490364,"teacher_disagreement_score":0.12541127,"about_ca_system_score_codex":0.00003121212,"about_ca_system_score_gemma":0.00007772484,"threshold_uncertainty_score":0.9999513},"labels":[],"label_agreement":null},{"id":"W3009494891","doi":"10.1056/nejmoa1904398","title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Medicine; Confidence interval; Liter; Clinical endpoint; Internal medicine; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Integrase inhibitor; Pharmacotherapy; Viral load; Randomized controlled trial; Antiretroviral therapy; Virology","score_opus":0.026036512102548176,"score_gpt":0.2850169726029176,"score_spread":0.2589804605003694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009494891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.778251,0.0036963588,0.016918315,0.1988108,0.0004451473,0.00053391844,0.000011434271,0.000020047099,0.0013129718],"genre_scores_gemma":[0.9891814,0.00055113505,0.0058704014,0.00046989648,0.0017834718,0.0000012758344,0.000013839543,0.000016725286,0.0021118335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889433,0.000026672804,0.0005112416,0.00011959295,0.0002923535,0.0001558293],"domain_scores_gemma":[0.99883395,0.00022045188,0.00032989355,0.000075665455,0.00017944122,0.00036058348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038272142,0.0001369937,0.0005784279,0.00009160642,0.00003237251,0.0000034276388,0.000059360143,0.000042469528,0.00009199258],"category_scores_gemma":[0.00066541857,0.00007822465,0.000062976396,0.00010997091,0.00006716722,0.000062364285,0.00001869429,0.00018397701,0.0000012805133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01186546,0.00024598348,0.22309129,0.0010449584,0.00081009435,0.0011426344,0.014196498,0.000024239811,0.039037745,0.00021733441,0.14913146,0.5591923],"study_design_scores_gemma":[0.33270365,0.008752234,0.06128334,0.007047366,0.0018920853,0.0032486764,0.0025572649,0.0009886075,0.030386426,0.000628491,0.55007565,0.00043622046],"about_ca_topic_score_codex":0.000008153505,"about_ca_topic_score_gemma":0.000004141058,"teacher_disagreement_score":0.5587561,"about_ca_system_score_codex":0.000023432107,"about_ca_system_score_gemma":0.000117984375,"threshold_uncertainty_score":0.31899086},"labels":[],"label_agreement":null},{"id":"W3009684042","doi":"10.1097/00126334-200008150-00006","title":"Predicting HIV RNA Virologic Outcome at 52-Weeks Follow-Up in Antiretroviral Clinical Trials","year":2000,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network","funders":"","keywords":"Medicine; Internal medicine; Viral load; Clinical trial; Antiretroviral therapy; Sida; Gastroenterology; Human immunodeficiency virus (HIV); Viral disease; Immunology","score_opus":0.08186959230116878,"score_gpt":0.37003028793339987,"score_spread":0.2881606956322311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009684042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99094146,0.0036560155,0.00002516161,0.0017532115,0.001363206,0.0005598621,0.000013500461,0.000089039895,0.0015985486],"genre_scores_gemma":[0.9707836,0.0012487916,0.0010465371,0.00013097031,0.00017934234,0.00001275566,0.000023259696,0.00005933075,0.026515435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912495,0.0010070102,0.005357156,0.00050133193,0.0010402487,0.00084473396],"domain_scores_gemma":[0.99618673,0.0013733902,0.0014477214,0.0005229601,0.00016721364,0.00030196173],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0111180255,0.00049595477,0.0028794578,0.0008998445,0.00022933006,0.00006248782,0.00047818426,0.00036457478,0.0011793482],"category_scores_gemma":[0.0036089807,0.00034739703,0.0013772631,0.0009935349,0.00025937156,0.00041806424,0.00012365592,0.0004576218,0.0005265973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002556376,0.0009712463,0.96675104,0.00006307644,0.0004437709,0.0020277805,0.0006954202,0.0000413089,0.0021171528,0.0000115698485,0.0009960718,0.023325186],"study_design_scores_gemma":[0.026821075,0.004434915,0.95784026,0.000729315,0.0011637434,0.0036463924,0.0008432336,0.0006275038,0.00138503,0.00015310224,0.0017065927,0.00064882106],"about_ca_topic_score_codex":0.000015220979,"about_ca_topic_score_gemma":0.0000036664355,"teacher_disagreement_score":0.024916885,"about_ca_system_score_codex":0.0004049246,"about_ca_system_score_gemma":0.00030091318,"threshold_uncertainty_score":0.9998978},"labels":[],"label_agreement":null},{"id":"W3009734312","doi":"10.1186/s12941-020-0345-6","title":"Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week","year":2020,"lang":"en","type":"article","venue":"Annals of Clinical Microbiology and Antimicrobials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"European and Developing Countries Clinical Trials Partnership","keywords":"Rifabutin; Lopinavir; Lopinavir/ritonavir; Ritonavir; Pharmacokinetics; Medicine; Pharmacology; Human immunodeficiency virus (HIV); Medical microbiology; Tuberculosis; Virology; Internal medicine; Antiretroviral therapy; Viral load; Clarithromycin; Pathology","score_opus":0.06711339682590832,"score_gpt":0.36594399408093325,"score_spread":0.2988305972550249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009734312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862366,0.00025411352,0.0000072539947,0.01202907,0.00009003472,0.0006010463,0.0004570009,0.000026863154,0.00029803196],"genre_scores_gemma":[0.9919941,0.0036689488,0.0012040014,0.002396876,0.00008696224,0.0000068550125,0.00036452117,0.000027367609,0.00025038508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969834,0.0003180439,0.0016232487,0.00058741734,0.00007070601,0.00041719532],"domain_scores_gemma":[0.99793327,0.00088120095,0.0004917659,0.00017340259,0.00029888607,0.00022145489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054525014,0.00034056554,0.0015067495,0.00013177966,0.00006172836,0.000009854971,0.00013254292,0.00036182496,0.0002587821],"category_scores_gemma":[0.0008494048,0.00025812376,0.00018785043,0.0002271801,0.00063982845,0.00007345377,0.0001471979,0.00036257243,0.00003674522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003702671,0.0019746923,0.8108442,0.0004585929,0.0006774723,0.000033760898,0.00076621375,0.0000015628922,0.15393196,0.000019996718,0.019283324,0.008305562],"study_design_scores_gemma":[0.023806192,0.003748582,0.60191125,0.0018723304,0.000652307,0.00007642697,0.00020385493,0.0001154505,0.33925864,0.00004900239,0.02738053,0.000925446],"about_ca_topic_score_codex":0.000017878338,"about_ca_topic_score_gemma":0.000029137129,"teacher_disagreement_score":0.20893295,"about_ca_system_score_codex":0.000006850322,"about_ca_system_score_gemma":0.00013098777,"threshold_uncertainty_score":0.9999871},"labels":[],"label_agreement":null},{"id":"W3009824331","doi":"10.7573/dic.2019-11-4","title":"Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection","year":2020,"lang":"en","type":"review","venue":"Drugs in Context","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina; McGill University; Jewish General Hospital","funders":"","keywords":"Reverse-transcriptase inhibitor; Lamivudine; Medicine; Regimen; Nucleoside Reverse Transcriptase Inhibitor; Virology; Drug resistance; Nucleoside; Clinical trial; Pharmacology; Human immunodeficiency virus (HIV); Virus; Sida; Internal medicine; Antiretroviral therapy; Viral disease; Biology; Viral load; Genetics","score_opus":0.07832152487031797,"score_gpt":0.3881401415408423,"score_spread":0.30981861667052435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009824331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005501093,0.98541164,0.00029080868,0.00355684,0.00062279514,0.007986691,0.00063835474,0.000053616182,0.00088912994],"genre_scores_gemma":[0.00072156946,0.9951049,0.00071246945,0.00035362772,0.00017973194,0.00077625806,0.00032421463,0.000034965924,0.0017922467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782145,0.0000712416,0.0013170859,0.0003502725,0.00022326733,0.00021666933],"domain_scores_gemma":[0.9982854,0.00079081015,0.000387049,0.00030562788,0.00008591769,0.00014516161],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035597524,0.0004256477,0.0015675459,0.00024978377,0.00008192233,0.000028972656,0.00007516965,0.00021977557,0.000017246834],"category_scores_gemma":[0.00013968967,0.00026432643,0.0005092448,0.00035339946,0.00016049972,0.000120778255,0.00001552969,0.00027038294,0.00005319678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007812123,0.00080136856,0.00012964681,0.0056788437,0.000538793,0.000008634245,0.0017032305,1.5035516e-7,8.6378736e-7,0.00020356351,0.008395529,0.9817582],"study_design_scores_gemma":[0.007478927,0.00044920342,0.00005775946,0.006380989,0.001793842,0.0000056501403,0.00017274983,0.000052006882,0.000022564724,0.0000041510416,0.98337936,0.00020276471],"about_ca_topic_score_codex":0.000020131,"about_ca_topic_score_gemma":0.000040968418,"teacher_disagreement_score":0.9815554,"about_ca_system_score_codex":0.0002524884,"about_ca_system_score_gemma":0.0003232387,"threshold_uncertainty_score":0.99998087},"labels":[],"label_agreement":null},{"id":"W3011812216","doi":"10.1139/cjc-2020-0049","title":"Diastereoselective and regioselective synthesis of adenosine thionucleoside analogues using an acyclic approach","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Chemistry; Nucleobase; Regioselectivity; Stereochemistry; Purine; Purine metabolism; Combinatorial chemistry; Organic chemistry; DNA; Enzyme; Catalysis; Biochemistry","score_opus":0.03176174026551299,"score_gpt":0.23854035810382612,"score_spread":0.20677861783831314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011812216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581844,0.0007850881,0.00016449367,0.0013536372,0.000012311813,0.000082540224,0.000012491656,0.000004746261,0.0017662545],"genre_scores_gemma":[0.99735695,0.000033653756,0.002229158,0.00011654062,0.00014515764,0.00000136499,0.0000066617595,0.000017986973,0.00009251375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992009,0.000027107382,0.0002863185,0.000154184,0.00014082217,0.00019067421],"domain_scores_gemma":[0.9985914,0.00005434552,0.00021673967,0.000087705106,0.00020578266,0.0008440167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089923014,0.00013898559,0.0003944795,0.00008630506,0.000061479455,0.000016959428,0.00008472219,0.00008128339,0.000033133965],"category_scores_gemma":[0.0002988792,0.00012088623,0.00007168979,0.00022210997,0.000106479565,0.00010951408,0.000007898427,0.00019825583,5.1155337e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014713688,0.0008388039,0.36477727,0.001904184,0.0053679706,0.0031312231,0.05665569,0.00013338332,0.5353458,0.000053718177,0.006191428,0.024129178],"study_design_scores_gemma":[0.0025845221,0.0003808712,0.024809502,0.00077749323,0.0011130243,0.0022243904,0.008875358,0.001069171,0.956607,0.00009346283,0.0009870484,0.00047815792],"about_ca_topic_score_codex":0.00021220687,"about_ca_topic_score_gemma":0.0001014882,"teacher_disagreement_score":0.42126122,"about_ca_system_score_codex":0.00015904328,"about_ca_system_score_gemma":0.0010916659,"threshold_uncertainty_score":0.49295974},"labels":[],"label_agreement":null},{"id":"W3022616229","doi":"","title":"Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Organ transplantation; Transplantation; Kidney transplantation; Medicine; Virology; Liver transplantation; Intensive care medicine; Immunology; Internal medicine","score_opus":0.022252066587619114,"score_gpt":0.24669528045970446,"score_spread":0.22444321387208535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022616229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754536,0.000113622766,0.00008300521,0.0012340111,0.000018546885,0.0005481711,0.000008632982,0.00003828297,0.00041036433],"genre_scores_gemma":[0.9977122,0.00005663648,0.0006949016,0.00019869313,0.000016024042,0.00031221702,0.00011841615,0.0000114572185,0.00087946124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909467,0.000035058085,0.0001510623,0.00026386918,0.00019870275,0.00025664765],"domain_scores_gemma":[0.9995053,0.000035012516,0.00004217805,0.00018174358,0.00003512727,0.00020067948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030135797,0.00012696952,0.00020957987,0.00035859246,0.00009336673,0.000030797815,0.000052269406,0.000054330296,0.00008996943],"category_scores_gemma":[0.000033282977,0.0000927653,0.000036089194,0.0005299647,0.00007128918,0.0001930756,0.000004906967,0.0001428408,0.000004028841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029876668,0.0004901191,0.9807222,0.00007732904,0.00024547058,0.00017853506,0.003753792,0.000004649397,0.0056520896,0.00006205,0.000049162976,0.008465822],"study_design_scores_gemma":[0.0017696655,0.00004897545,0.99217504,0.000040940813,0.000848723,0.000013766868,0.00011834489,0.00017523955,0.0045265355,0.00000310807,0.0001543828,0.00012530023],"about_ca_topic_score_codex":0.00024985737,"about_ca_topic_score_gemma":0.002372021,"teacher_disagreement_score":0.011452803,"about_ca_system_score_codex":0.00004358366,"about_ca_system_score_gemma":0.000088312074,"threshold_uncertainty_score":0.37828594},"labels":[],"label_agreement":null},{"id":"W3024254134","doi":"10.1007/s11904-004-0017-8","title":"Management of HIV-infected patients with multidrug-resistant virus","year":2004,"lang":"en","type":"review","venue":"Current HIV/AIDS Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Providence Health Care; AIDS Vancouver","funders":"","keywords":"Virology; Multiple drug resistance; Human immunodeficiency virus (HIV); Medicine; Virus; Biology; Drug resistance; Microbiology","score_opus":0.020970593966350877,"score_gpt":0.3012844125039963,"score_spread":0.2803138185376454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024254134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008722993,0.989634,0.0001417891,0.000016701646,0.0007982525,0.0054408615,0.00025128273,0.00022817054,0.0026166574],"genre_scores_gemma":[0.00035441693,0.9753957,0.0039037368,0.0000031059421,0.00009933038,0.0005310501,0.0075518214,0.00021507317,0.011945763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938694,0.00010694825,0.002435344,0.0013626367,0.001474348,0.0007513239],"domain_scores_gemma":[0.99557614,0.00006071741,0.0020181162,0.0015247044,0.00037115547,0.0004491903],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00028665687,0.0012966014,0.0035233456,0.0007494889,0.00012666378,0.000037241734,0.00021204751,0.0002864487,0.0002504503],"category_scores_gemma":[0.000043132855,0.0008784089,0.00093586266,0.0010254985,0.00016878729,0.00011706777,0.00023635686,0.0005579034,0.00022347404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015869747,0.004687699,0.007666021,0.08262208,0.004097977,0.0053324993,0.00020998699,0.0000018696122,2.8854305e-7,0.00016269594,0.0032873228,0.89177287],"study_design_scores_gemma":[0.0027232005,0.00023118143,0.0012389255,0.09979794,0.008248238,0.00016510037,0.000022430371,7.071348e-7,0.000013226828,0.000014883903,0.8867144,0.0008297716],"about_ca_topic_score_codex":0.0000058945216,"about_ca_topic_score_gemma":0.00000265149,"teacher_disagreement_score":0.8909431,"about_ca_system_score_codex":0.0009974132,"about_ca_system_score_gemma":0.0008882051,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W3025428915","doi":"10.3390/v12050556","title":"External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations","year":2020,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; Public Health Agency; Public Health Agency of Canada","keywords":"External quality assessment; HIV drug resistance; Medical physics; Medicine; Human immunodeficiency virus (HIV); Protocol (science); Consistency (knowledge bases); Genotyping; Computer science; Family medicine; Pathology; Viral load; Antiretroviral therapy; Biology; Alternative medicine","score_opus":0.39606192633614445,"score_gpt":0.40962483388002513,"score_spread":0.013562907543880676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025428915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47325015,0.000907652,0.3186167,0.18663917,0.00052779604,0.009409346,0.00041687267,0.0020917857,0.008140538],"genre_scores_gemma":[0.6175948,0.0000023398113,0.37756094,0.003294702,0.00024582472,0.00038464065,0.00012081559,0.00001818081,0.0007777479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864036,0.00008172064,0.0004071782,0.00035625932,0.00029109637,0.00022337325],"domain_scores_gemma":[0.99882096,0.0004877722,0.000108327076,0.00016864453,0.00021704148,0.0001972567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022214508,0.00017573456,0.00027549555,0.00003942337,0.00021327342,0.00011160694,0.000043572734,0.000048801307,0.000100595804],"category_scores_gemma":[0.001082113,0.00014803796,0.00007128619,0.00013433388,0.00008100799,0.00010136241,0.000015441228,0.00011048273,0.00003094987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012332659,0.00360104,0.16797955,0.0014786992,0.00064413546,0.00055594294,0.0024013643,0.00073824066,0.48486552,0.06876807,0.2540167,0.013717476],"study_design_scores_gemma":[0.0253457,0.0016073999,0.035381608,0.0012053202,0.0017966911,0.00004375472,0.001104634,0.19678418,0.434759,0.006155264,0.29326802,0.002548421],"about_ca_topic_score_codex":0.00001392891,"about_ca_topic_score_gemma":0.000106346204,"teacher_disagreement_score":0.19604595,"about_ca_system_score_codex":0.00019768196,"about_ca_system_score_gemma":0.00092915905,"threshold_uncertainty_score":0.60368127},"labels":[],"label_agreement":null},{"id":"W3025465733","doi":"10.3390/v12050550","title":"External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges","year":2020,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Sanger sequencing; Genotyping; HIV drug resistance; External quality assessment; Standardization; Medicine; Computational biology; DNA sequencing; Human immunodeficiency virus (HIV); Medical physics; Computer science; Biology; Viral load; Virology; Antiretroviral therapy; Genetics; Pathology; DNA; Genotype","score_opus":0.44731434345483484,"score_gpt":0.3821493620733981,"score_spread":0.06516498138143673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025465733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8699291,0.006899605,0.017691774,0.10000057,0.00017991045,0.0023551784,0.000082185434,0.00040008526,0.0024616274],"genre_scores_gemma":[0.87312365,0.00039664807,0.12108237,0.0032612141,0.0003028167,0.00021043187,0.000071103874,0.000035801855,0.0015159461],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987971,0.00008174839,0.00031033973,0.00036329747,0.00026048324,0.00018701257],"domain_scores_gemma":[0.9992741,0.00016979028,0.00012510132,0.0001549936,0.000116961484,0.00015908136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031601868,0.00017481079,0.00025890578,0.000044872664,0.00012572031,0.00004394081,0.00005371859,0.00004307803,0.000019206394],"category_scores_gemma":[0.00021207346,0.00014960908,0.000039487484,0.000086392676,0.000037584843,0.00014524581,0.000022836644,0.00007315191,0.0000066882353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012498635,0.0007497129,0.11235137,0.0030057305,0.0004688133,0.00015637385,0.0051849033,0.000048929505,0.827583,0.008171664,0.018615548,0.022414107],"study_design_scores_gemma":[0.019556848,0.0008432956,0.04944525,0.0020983156,0.0007355216,0.000011779983,0.002007968,0.016370393,0.6708322,0.0014987248,0.2349454,0.0016542926],"about_ca_topic_score_codex":0.000013774929,"about_ca_topic_score_gemma":0.00009599856,"teacher_disagreement_score":0.21632984,"about_ca_system_score_codex":0.00017261667,"about_ca_system_score_gemma":0.00033390897,"threshold_uncertainty_score":0.6100881},"labels":[],"label_agreement":null},{"id":"W3028663891","doi":"10.1007/s40262-020-00898-8","title":"Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review","year":2020,"lang":"en","type":"review","venue":"Clinical Pharmacokinetics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Dolutegravir; Raltegravir; Pharmacology; Elvitegravir; Pharmacokinetics; Pharmacodynamics; Integrase; Integrase inhibitor; Medicine; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.15606513772846373,"score_gpt":0.4919753380905803,"score_spread":0.3359102003621166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028663891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005355756,0.98975724,0.00020199931,0.0013850156,0.0011366123,0.0050013354,0.00117719,0.00018137218,0.0006236731],"genre_scores_gemma":[0.00037818894,0.9888216,0.0017793734,0.0017517925,0.0014430402,0.00010553145,0.0047427244,0.00021199984,0.0007657459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9878874,0.0018385018,0.0069873785,0.0017387051,0.0008414094,0.0007066131],"domain_scores_gemma":[0.99438936,0.0012654418,0.001084471,0.00076248194,0.0005381815,0.0019600873],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018827022,0.0015828119,0.009600187,0.00027759623,0.00009162834,0.000044119734,0.00062368327,0.0007993762,0.001002945],"category_scores_gemma":[0.00021880797,0.0012166321,0.0020409895,0.0009940413,0.0011366142,0.0001534539,0.0002497736,0.0033952896,0.00018550524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006022214,0.0037276328,0.00032105684,0.037678257,0.0059406953,0.0006143641,0.00014529051,8.4763946e-7,0.000011192462,0.000022842285,0.099843495,0.8510921],"study_design_scores_gemma":[0.008189309,0.0008934268,0.000020171052,0.023670906,0.03810016,0.00013142875,0.00002594925,0.0007732112,0.00005618956,0.000007799655,0.9271698,0.00096167583],"about_ca_topic_score_codex":0.0000014742307,"about_ca_topic_score_gemma":0.0000014957577,"teacher_disagreement_score":0.85013044,"about_ca_system_score_codex":0.000113235925,"about_ca_system_score_gemma":0.0011035198,"threshold_uncertainty_score":0.9999103},"labels":[],"label_agreement":null},{"id":"W3031418164","doi":"10.1200/jco.2020.38.15_suppl.8510","title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Vancouver General Hospital; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"Karyopharm Therapeutics","keywords":"Tolerability; Medicine; Daratumumab; Internal medicine; Dexamethasone; Refractory (planetary science); Phases of clinical research; Oncology; Gastroenterology; Adverse effect; Pharmacology; Lenalidomide; Clinical trial","score_opus":0.06782082982133822,"score_gpt":0.3764753852132049,"score_spread":0.3086545553918667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031418164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98448855,0.00029604018,0.000060480812,0.013846996,0.00023431763,0.0002379006,0.0000023049643,0.000009431006,0.0008239951],"genre_scores_gemma":[0.982396,0.00024494206,0.0145089375,0.0021763719,0.00033117947,0.0000026002947,0.0000074300706,0.000018536393,0.00031397157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997397,0.00025827723,0.0015744086,0.00022135573,0.00034619594,0.00020274479],"domain_scores_gemma":[0.99677163,0.0014814149,0.0008482138,0.000104376435,0.00026657566,0.00052777457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009919688,0.00015738524,0.0012559308,0.000103799066,0.000029704705,0.0000065984873,0.000083213636,0.00026293838,0.00007223588],"category_scores_gemma":[0.0031837828,0.00009905764,0.00013023985,0.00017868706,0.000137432,0.00012451268,0.000047126003,0.00094427215,0.000023268514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009372086,0.0019047273,0.90397793,0.000020185455,0.00026267656,0.00071824726,0.00036329444,0.000002686672,0.000010814449,0.0000062577315,0.0029506302,0.08041046],"study_design_scores_gemma":[0.036340527,0.011893774,0.872935,0.00010372781,0.00019982178,0.00003568817,0.00010388262,0.00009456977,0.00002089234,0.000015078874,0.07815348,0.000103585415],"about_ca_topic_score_codex":0.0000029915846,"about_ca_topic_score_gemma":0.000032834505,"teacher_disagreement_score":0.08030687,"about_ca_system_score_codex":0.000105500316,"about_ca_system_score_gemma":0.0007316628,"threshold_uncertainty_score":0.41024452},"labels":[],"label_agreement":null},{"id":"W3032582312","doi":"10.3390/v12060586","title":"Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium","year":2020,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University of British Columbia; University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; Consejo Nacional de Ciencia y Tecnología; Public Health Agency; Public Health Agency of Canada","keywords":"HIV drug resistance; Sanger sequencing; Drug resistance; Human immunodeficiency virus (HIV); Medicine; DNA sequencing; Computational biology; Virology; Antiretroviral therapy; Biology; Viral load; Genetics","score_opus":0.09013228476923313,"score_gpt":0.2968887581965474,"score_spread":0.2067564734273143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032582312","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38667694,0.0041517415,0.00006235799,0.58067113,0.0003405032,0.0026946876,0.00061435037,0.00060346466,0.02418482],"genre_scores_gemma":[0.4273771,0.00017802122,0.013890343,0.050849855,0.0011883617,0.00051979884,0.00010808159,0.00018244529,0.50570595],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889684,0.000035494395,0.00026905362,0.00032493475,0.0001938159,0.0002798843],"domain_scores_gemma":[0.99872786,0.00057353324,0.00016751386,0.00025802915,0.00012504937,0.00014801968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121351026,0.0002034678,0.00030064635,0.000035902278,0.00019148439,0.000034856817,0.000115037634,0.000046861733,0.00014017033],"category_scores_gemma":[0.00028584042,0.00013162996,0.00006771709,0.00022867763,0.00009596328,0.00003836722,0.000038302725,0.00012232705,0.0002292684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039758455,0.00009503368,0.019868268,0.0003170188,0.00018309377,0.00011926798,0.002140794,8.445863e-7,0.011237982,0.00033888972,0.965137,0.00016423936],"study_design_scores_gemma":[0.0015184325,0.000031678504,0.0011929362,0.00019723644,0.000140427,0.000012811005,0.0006876055,0.000036042875,0.023626268,0.00011239026,0.972276,0.00016822701],"about_ca_topic_score_codex":0.0000031427603,"about_ca_topic_score_gemma":0.000077170975,"teacher_disagreement_score":0.5298213,"about_ca_system_score_codex":0.00004667979,"about_ca_system_score_gemma":0.0001248674,"threshold_uncertainty_score":0.53677136},"labels":[],"label_agreement":null},{"id":"W3033664814","doi":"10.3390/v12060617","title":"Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations","year":2020,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; Consejo Nacional de Ciencia y Tecnología; Public Health Agency; Public Health Agency of Canada","keywords":"Genotyping; HIV drug resistance; Sanger sequencing; Massive parallel sequencing; Computer science; Medicine; DNA sequencing; Human immunodeficiency virus (HIV); Viral load; Biology; Virology; Antiretroviral therapy; Genetics; Genotype","score_opus":0.35404961579799255,"score_gpt":0.44495023673967804,"score_spread":0.0909006209416855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033664814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000099372395,0.9950184,0.00009572146,0.0017847095,0.00016773773,0.0022594281,0.00035778308,0.00010888516,0.000107927546],"genre_scores_gemma":[0.000032893848,0.9653371,0.030739896,0.00073626766,0.000609104,0.00053434155,0.00077550235,0.000059082508,0.0011757965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814045,0.00014201779,0.0008965043,0.00048645478,0.00015609156,0.00017848123],"domain_scores_gemma":[0.99833876,0.00077401876,0.00035730182,0.00019214943,0.0001902209,0.0001475512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003211095,0.00030632736,0.0010229854,0.00010769406,0.0002479395,0.00012622058,0.000037395108,0.00011467377,0.000046726233],"category_scores_gemma":[0.00067527074,0.0002525697,0.00012885954,0.00023194231,0.000063911204,0.0001528411,0.00002683634,0.0001565628,0.000043646876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033873563,0.0001424329,0.0014094379,0.014514269,0.0012896289,0.00014052221,0.0008740362,1.8515875e-7,0.00017616594,0.0025305192,0.4858,0.49308893],"study_design_scores_gemma":[0.0007508077,0.000029088633,0.0000051973884,0.0020641899,0.0014282867,0.000009521464,0.00009763104,0.000014008835,0.000107343476,0.000051532228,0.99522346,0.00021891792],"about_ca_topic_score_codex":0.0000047758153,"about_ca_topic_score_gemma":0.00015130633,"teacher_disagreement_score":0.5094235,"about_ca_system_score_codex":0.00015357665,"about_ca_system_score_gemma":0.0017571694,"threshold_uncertainty_score":0.99999267},"labels":[],"label_agreement":null},{"id":"W3034026100","doi":"10.1097/qad.0000000000002603","title":"First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines","year":2020,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; Centre for Global Health Research","funders":"Medical Research Council; University Hospitals Coventry and Warwickshire NHS Trust; Barts Health NHS Trust; Public Health England; North Bristol NHS Trust; King's College London; Imperial College London; Imperial College Healthcare NHS Trust; Middlesex University; St. George's, University of London; University Hospitals of Leicester NHS Trust; University College London; Chelsea and Westminster Hospital NHS Foundation Trust; King's College Hospital NHS Foundation Trust; University of Sussex; Wellcome Trust","keywords":"Hazard ratio; Discontinuation; Regimen; Internal medicine; Medicine; Interquartile range; Reverse-transcriptase inhibitor; Proportional hazards model; Confidence interval; Integrase inhibitor; Protease inhibitor (pharmacology); Cohort study; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.040045557169506106,"score_gpt":0.30637007342771705,"score_spread":0.26632451625821096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034026100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8402732,0.00022863712,0.00009742086,0.15852721,0.00025119208,0.00041088046,0.0000043083073,0.00006042538,0.00014669796],"genre_scores_gemma":[0.9925611,0.0001111477,0.0018662558,0.00036842874,0.00034977874,0.000053360567,0.0000731297,0.000020462952,0.0045963377],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892986,0.000025841577,0.0004575604,0.00022316228,0.00020518796,0.00015838009],"domain_scores_gemma":[0.9995342,0.000085242624,0.00006623307,0.00020018434,0.00004214234,0.000072034236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016442026,0.00017165544,0.00036990634,0.00010947891,0.000043003132,0.0000068273866,0.000058265796,0.00004467016,0.000048503276],"category_scores_gemma":[0.00041096593,0.00009245923,0.00018389589,0.00042468187,0.000028705623,0.000041462717,0.0000320284,0.00007462976,0.00008803353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007994932,0.0001989412,0.963524,0.000022351149,0.00043350144,0.000070081885,0.002582434,0.000089767615,0.00031527117,0.000093916315,0.01789,0.014699774],"study_design_scores_gemma":[0.047448102,0.0064182244,0.35251448,0.0011954018,0.004378478,0.000044787164,0.018116198,0.005591022,0.14748725,0.0010751013,0.41397932,0.0017516279],"about_ca_topic_score_codex":0.00010659968,"about_ca_topic_score_gemma":0.00007268484,"teacher_disagreement_score":0.61100954,"about_ca_system_score_codex":0.00011501524,"about_ca_system_score_gemma":0.00005880585,"threshold_uncertainty_score":0.3770378},"labels":[],"label_agreement":null},{"id":"W3034274180","doi":"10.3390/v12060645","title":"Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework","year":2020,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Human immunodeficiency virus (HIV); Quality (philosophy); Computer science; Data mining; Medicine; Data science; Viral load; Virology; Antiretroviral therapy","score_opus":0.2480234086914881,"score_gpt":0.41991271198827534,"score_spread":0.17188930329678725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034274180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050768434,0.9933124,0.0021815447,0.0004156129,0.00042718556,0.001666125,0.0017789032,0.0000668848,0.00010053908],"genre_scores_gemma":[0.0012186255,0.99027836,0.0027207762,0.0006768361,0.00040829304,0.0001621319,0.004358512,0.000036095687,0.00014038313],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99564815,0.0008477461,0.0024254615,0.0004006747,0.0004929388,0.00018500556],"domain_scores_gemma":[0.99651587,0.0010247601,0.001163668,0.0009944981,0.00017178296,0.00012943335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018139627,0.0003404602,0.0022246416,0.00021183013,0.000039466868,0.000056587196,0.00029314324,0.00035731622,0.000017148812],"category_scores_gemma":[0.00211669,0.00026658192,0.0001620537,0.0005502256,0.00006971335,0.00043084388,0.000055235327,0.0005024451,0.00017729374],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014635937,0.0015743122,0.018825477,0.25150922,0.0042003435,0.00042556232,0.0020839754,0.00006402602,0.000027493481,0.0074804355,0.15267265,0.5596729],"study_design_scores_gemma":[0.0010335972,0.000015693138,0.00002914156,0.015076225,0.00053818134,7.573213e-7,0.000056221506,0.00028087353,0.0000065356967,0.0000022561085,0.9827452,0.0002153756],"about_ca_topic_score_codex":0.000039908617,"about_ca_topic_score_gemma":0.000090891095,"teacher_disagreement_score":0.83007246,"about_ca_system_score_codex":0.0003642659,"about_ca_system_score_gemma":0.0031175255,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W3035229792","doi":"10.3390/v12060627","title":"Development and Application of Performance Assessment Criteria for Next-Generation Sequencing-Based HIV Drug Resistance Assays","year":2020,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Sanger sequencing; Quality assurance; Medicine; Standardization; External quality assessment; Clinical microbiology; Drug resistance; Human immunodeficiency virus (HIV); Medical physics; Computational biology; Computer science; Data mining; DNA sequencing; Viral load; Virology; Biology; Antiretroviral therapy; Microbiology; Pathology; DNA","score_opus":0.10222095833284281,"score_gpt":0.3205096652558905,"score_spread":0.21828870692304767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035229792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9216313,0.0002984338,0.06946652,0.0067292615,0.000048548976,0.001164164,0.000024655801,0.00008437259,0.00055274856],"genre_scores_gemma":[0.84135747,0.000022999295,0.15696724,0.00073734915,0.00006616086,0.00024051074,0.00016166024,0.000015300302,0.00043132197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991357,0.000017827995,0.0002923969,0.0002428874,0.0001862617,0.00012494712],"domain_scores_gemma":[0.9995618,0.000038301358,0.00010646588,0.00011384288,0.0000940281,0.000085548694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001696197,0.0001296867,0.00020920836,0.000051195868,0.00010092419,0.000020244799,0.000041902924,0.00003388474,0.000016149583],"category_scores_gemma":[0.000024166937,0.00011270821,0.000025142068,0.00010890718,0.000028794633,0.00011408013,0.000014777105,0.000042096126,0.000008063428],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069026416,0.00031743778,0.04498241,0.0019833578,0.00023236383,0.0000071493114,0.0045785587,0.000083415434,0.90666,0.0019536726,0.015324611,0.023186736],"study_design_scores_gemma":[0.001999107,0.0000555742,0.0034525031,0.00013100289,0.00009287223,9.3315225e-7,0.0001820263,0.034814596,0.7525563,0.00000965853,0.20650837,0.00019705747],"about_ca_topic_score_codex":0.0000018599649,"about_ca_topic_score_gemma":0.00002282319,"teacher_disagreement_score":0.19118376,"about_ca_system_score_codex":0.00013098303,"about_ca_system_score_gemma":0.00034664772,"threshold_uncertainty_score":0.45961073},"labels":[],"label_agreement":null},{"id":"W3036720956","doi":"10.3390/v12060666","title":"Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing","year":2020,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Bottleneck; Computer science; External quality assessment; Raw data; Human immunodeficiency virus (HIV); Software; Data mining; Computational biology; Medicine; Biology; Embedded system; Operating system","score_opus":0.3024744946804234,"score_gpt":0.3832677222496408,"score_spread":0.08079322756921736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036720956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95735943,0.00021253042,0.03098161,0.0089833345,0.000112039146,0.0014943222,0.000034342997,0.0003350166,0.00048739454],"genre_scores_gemma":[0.81437945,0.0000033861402,0.18133456,0.0019251875,0.0003878984,0.0002541906,0.00018856396,0.000034147455,0.0014926159],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982569,0.00007484114,0.0005571022,0.00041239927,0.00036691877,0.00033182566],"domain_scores_gemma":[0.99899644,0.00019878361,0.00027059426,0.00017905918,0.0001651732,0.00018994106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046604508,0.00020903924,0.00032329344,0.000043165794,0.00019092832,0.00010098525,0.00007783041,0.00004727346,0.00005229251],"category_scores_gemma":[0.00037866685,0.00017860545,0.00009347781,0.0001971531,0.00003555549,0.00016911767,0.000024017983,0.00011284608,0.0000234778],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003663243,0.00041941705,0.5301355,0.00090100634,0.00018084924,0.00014949031,0.0025849403,0.000079765385,0.42817497,0.00036189827,0.004622884,0.03202296],"study_design_scores_gemma":[0.015215768,0.0005160446,0.035001643,0.0017892565,0.0007772819,0.000008418698,0.0027310762,0.06688604,0.8046481,0.00037288605,0.0704471,0.0016063894],"about_ca_topic_score_codex":0.000035579797,"about_ca_topic_score_gemma":0.000062343905,"teacher_disagreement_score":0.49513385,"about_ca_system_score_codex":0.00024341124,"about_ca_system_score_gemma":0.00063468824,"threshold_uncertainty_score":0.72833186},"labels":[],"label_agreement":null},{"id":"W3037443794","doi":"10.3390/v12070694","title":"Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping","year":2020,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; AIDS Vancouver; University of British Columbia","funders":"National Institute on Minority Health and Health Disparities; National Institute of Allergy and Infectious Diseases; Public Health Agency of Canada; University of North Carolina at Chapel Hill; Public Health England; Brown University","keywords":"Sanger sequencing; Genotyping; Concordance; DNA sequencing; Biology; HIV drug resistance; Genetics; Drug resistance; Computational biology; Human immunodeficiency virus (HIV); Virology; Genotype; Viral load; DNA; Gene; Antiretroviral therapy","score_opus":0.19111461461812412,"score_gpt":0.3494872228951715,"score_spread":0.15837260827704736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037443794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609123,0.0018372327,0.025560101,0.010059838,0.000123675,0.0011777548,0.00011108836,0.000132629,0.00008536876],"genre_scores_gemma":[0.841484,0.0000070919837,0.15473318,0.0028521956,0.00016088602,0.0000836317,0.00008485273,0.000027625923,0.0005665367],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912304,0.000028660403,0.0002984844,0.00023399621,0.0001612341,0.00015461203],"domain_scores_gemma":[0.99943715,0.00006745835,0.000094392744,0.0001345622,0.0001347704,0.0001316459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009568243,0.00012929292,0.00029266218,0.00007515145,0.00008107322,0.000016362086,0.000054898406,0.00003635131,0.000027883749],"category_scores_gemma":[0.00015849737,0.00011826763,0.000048137634,0.00022762993,0.000019656944,0.000077774646,0.00001292292,0.000051814106,0.000048609716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031475897,0.00012045733,0.011893081,0.00023900467,0.000070352406,0.0000060264724,0.004240455,0.00022960536,0.9400287,0.00004124056,0.042174753,0.0006415396],"study_design_scores_gemma":[0.0018453721,0.000057574387,0.0005940177,0.00017220678,0.0001018989,9.9139484e-8,0.00055964856,0.009328308,0.9063582,0.0000012138964,0.080816954,0.00016453587],"about_ca_topic_score_codex":0.000006086305,"about_ca_topic_score_gemma":0.00010632577,"teacher_disagreement_score":0.12917309,"about_ca_system_score_codex":0.00013127005,"about_ca_system_score_gemma":0.00025289183,"threshold_uncertainty_score":0.4822814},"labels":[],"label_agreement":null},{"id":"W3039765753","doi":"10.1158/1557-3265.ovca19-a74","title":"Abstract A74: The HIV protease inhibitor nelfinavir, alone or in combination with the proteasome inhibitor bortezomib, is cytotoxic to high-grade serous ovarian cancer cells regardless of platinum sensitivity","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Bortezomib; Unfolded protein response; Nelfinavir; Proteasome inhibitor; Proteasome; Cancer research; Medicine; Pharmacology; Ovarian cancer; Cancer; Multiple myeloma; Immunology; Endoplasmic reticulum; Biology; Internal medicine; Cell biology","score_opus":0.11290561721237395,"score_gpt":0.40891170304770197,"score_spread":0.296006085835328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039765753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77822375,0.00008445623,0.00001916813,0.21578355,0.000088479675,0.005571898,0.0001384244,0.000030387504,0.000059889797],"genre_scores_gemma":[0.99271446,0.00012534036,0.00030541405,0.001956505,0.00061542704,0.0019236372,0.000025566136,0.000057845617,0.0022758134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99533033,0.0007891108,0.0008855315,0.00076613884,0.0015294957,0.0006993662],"domain_scores_gemma":[0.9968697,0.0012243586,0.00024857486,0.0005803892,0.000488683,0.0005883309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033490676,0.00030447284,0.00076275744,0.0001362128,0.00023521422,0.00006393499,0.00027510035,0.00020431564,0.00026731074],"category_scores_gemma":[0.0008307781,0.00015589368,0.00012173312,0.0012277402,0.0004827843,0.000119745266,0.00023045085,0.0015165239,0.00009813624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08446542,0.011536178,0.37291515,0.0031234976,0.0019484486,0.004385301,0.029192932,0.0003576236,0.115820415,0.00023468815,0.3266762,0.049344145],"study_design_scores_gemma":[0.036406666,0.00472562,0.52642334,0.0035347918,0.0003273242,0.000025278852,0.0029330442,0.0010566545,0.39549926,0.00009827002,0.027968785,0.0010009313],"about_ca_topic_score_codex":0.0020429553,"about_ca_topic_score_gemma":0.0021577282,"teacher_disagreement_score":0.29870743,"about_ca_system_score_codex":0.00046417094,"about_ca_system_score_gemma":0.0024736272,"threshold_uncertainty_score":0.6588626},"labels":[],"label_agreement":null},{"id":"W3041960630","doi":"10.24875/aidsrev.20000012","title":"Impact of Pre-antiretroviral Therapy CD4 Counts on Drug Resistance and Treatment Failure: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"Aids Reviews","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Université du Québec en Abitibi-Témiscamingue","funders":"","keywords":"Antiretroviral therapy; Antiretroviral drug; Medicine; Drug resistance; Intensive care medicine; Drug; Human immunodeficiency virus (HIV); Pharmacotherapy; Internal medicine; Pharmacology; Viral load; Virology; Biology","score_opus":0.04283416977615065,"score_gpt":0.35908228395259495,"score_spread":0.3162481141764443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041960630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000029021576,0.98903847,0.0000011772037,0.00015990259,0.000042291616,0.009351885,0.00005338337,0.00003001824,0.0013200017],"genre_scores_gemma":[0.0000025972727,0.9686555,0.00042471066,0.00010758072,0.00005709819,0.0010487265,0.00018743191,0.00006359868,0.029452747],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969004,0.00050685933,0.0015128347,0.00050999975,0.0003336489,0.00023624972],"domain_scores_gemma":[0.99790585,0.00012991359,0.0009630743,0.000771732,0.000050880168,0.00017853572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004587723,0.0007515513,0.007407416,0.00012882831,0.000037570677,0.000018006353,0.0001545291,0.00011530222,0.0002021446],"category_scores_gemma":[0.00018647447,0.00036912225,0.0015193247,0.00046916876,0.000045755412,0.00003638809,0.000025219013,0.0001861734,0.0006388126],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014819454,0.00011405757,0.000016014204,0.5904863,0.0010860227,0.000033607525,0.00006363593,4.082365e-10,5.0275993e-8,0.000028889452,0.029691393,0.37846524],"study_design_scores_gemma":[0.00026498613,0.00035606392,0.0000016651186,0.41963908,0.003531062,0.000022088161,7.419578e-7,5.6259534e-8,1.9941919e-7,0.0000011882114,0.5760343,0.00014859498],"about_ca_topic_score_codex":0.000004025828,"about_ca_topic_score_gemma":0.0000025209458,"teacher_disagreement_score":0.5463429,"about_ca_system_score_codex":0.00045941307,"about_ca_system_score_gemma":0.0003921369,"threshold_uncertainty_score":0.9998761},"labels":[],"label_agreement":null},{"id":"W3043410578","doi":"10.1016/j.jve.2020.100004","title":"A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection","year":2020,"lang":"en","type":"article","venue":"Journal of Virus Eradication","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"U.S. Army Medical Research Acquisition Activity; National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; ViiV Healthcare; National Institute of Allergy and Infectious Diseases; National Health and Medical Research Council; Delaney AIDS Research Enterprise; National Institute of Neurological Disorders and Stroke; Medical Research Council; Gilead Sciences","keywords":"Vorinostat; Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Randomized controlled trial; Antiretroviral treatment; Virology; Internal medicine; Viral load; Biology","score_opus":0.03227883092817708,"score_gpt":0.30460086464364705,"score_spread":0.27232203371547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043410578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570185,0.00017721225,0.0013906079,0.0017381225,0.00009577121,0.00078291824,0.000004234246,0.000016547914,0.00009274112],"genre_scores_gemma":[0.99571544,0.0016763047,0.0020100274,0.00007642551,0.00032538586,0.000047582555,0.000020529142,0.000016597261,0.00011169081],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986518,0.00013151324,0.0006781475,0.00012298406,0.00030782106,0.00010775415],"domain_scores_gemma":[0.998836,0.000055385077,0.0007727466,0.00008657204,0.00014543062,0.00010389349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022099026,0.00015438328,0.0005977169,0.00019994398,0.000041239677,0.000017176977,0.00003187183,0.000049719027,0.000055124805],"category_scores_gemma":[0.00005449262,0.00009488881,0.00022612471,0.00017989021,0.00004617864,0.00022861456,0.0000065897393,0.0001200463,0.0000075737294],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94738024,0.00057148765,0.02738309,0.000033148637,0.0013938326,0.000072737836,0.004621396,0.000009113232,0.008751918,0.00000831212,0.000020624295,0.009754079],"study_design_scores_gemma":[0.9294635,0.005642641,0.015478152,0.00022797208,0.000847669,0.00013033689,0.00005301,0.00027114354,0.047530692,0.000011149721,0.00023267562,0.0001110439],"about_ca_topic_score_codex":0.000011369166,"about_ca_topic_score_gemma":0.000002055809,"teacher_disagreement_score":0.038778774,"about_ca_system_score_codex":0.00017001024,"about_ca_system_score_gemma":0.00013906784,"threshold_uncertainty_score":0.38694534},"labels":[],"label_agreement":null},{"id":"W3044115816","doi":"10.1016/s2055-6640(20)31114-6","title":"The R263K resistance substitution decreases levels of integrated HIV DNA over time","year":2016,"lang":"en","type":"article","venue":"Journal of Virus Eradication","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Substitution (logic); Human immunodeficiency virus (HIV); DNA; Virology; Chemistry; Computer science; Biology; Genetics; Programming language","score_opus":0.014263890959971734,"score_gpt":0.2630799556451251,"score_spread":0.24881606468515335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044115816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859362,0.0014455733,0.0026377765,0.008694081,0.00010655586,0.00018551793,0.000024752,0.000013852872,0.00095567544],"genre_scores_gemma":[0.9870405,0.0007156796,0.0014124205,0.000050119026,0.00009454474,0.0000037947198,0.000007470158,0.000008969139,0.010666495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896246,0.00006010223,0.00046599243,0.000078691955,0.00032842264,0.00010432648],"domain_scores_gemma":[0.99881154,0.0001685091,0.0004935363,0.0001560534,0.0002837118,0.000086648026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039540976,0.00008939741,0.00019158114,0.00011061265,0.00007906605,0.000010141617,0.00008622306,0.000044680033,0.00027526912],"category_scores_gemma":[0.00033385112,0.00004182974,0.00008605631,0.0001586335,0.000102246995,0.0001494526,0.000006538388,0.000068442336,0.000059274207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030799226,0.00078897976,0.033755813,0.000047109712,0.00087759795,0.00006566558,0.0005652419,0.0000014966192,0.83964974,0.005955206,0.07178242,0.043430805],"study_design_scores_gemma":[0.0054330514,0.00021728645,0.3414432,0.001519748,0.00044547624,0.00014229822,0.000058332324,0.000042217845,0.459261,0.0017256178,0.18952829,0.00018349079],"about_ca_topic_score_codex":0.0000023576724,"about_ca_topic_score_gemma":0.000008474934,"teacher_disagreement_score":0.38038874,"about_ca_system_score_codex":0.00025226135,"about_ca_system_score_gemma":0.00034367747,"threshold_uncertainty_score":0.3014004},"labels":[],"label_agreement":null},{"id":"W3048405736","doi":"10.1093/cid/ciaa1037","title":"Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada","year":2020,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of British Columbia","funders":"National Institute on Minority Health and Health Disparities; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute on Aging; National Eye Institute; National Institute on Drug Abuse; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; National Institutes of Health; Agency for Healthcare Research and Quality; National Center for Advancing Translational Sciences; Health Resources and Services Administration","keywords":"Dolutegravir; Medicine; Hazard ratio; Integrase inhibitor; Regimen; Internal medicine; Efavirenz; Raltegravir; Cohort; Confidence interval; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.025915749772032808,"score_gpt":0.34153715106180793,"score_spread":0.3156214012897751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048405736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815696,0.00026151678,0.000021645219,0.000202435,0.000066534,0.0011199259,0.0001226878,0.000033933495,0.000014329717],"genre_scores_gemma":[0.99895406,0.0005310424,0.0000051371203,0.00013991675,0.00002737187,0.00006217763,0.00025873387,0.000016565473,0.0000049858736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976533,0.00068822113,0.00086750067,0.00032950364,0.00030407772,0.00015738739],"domain_scores_gemma":[0.997079,0.0021466517,0.0001492211,0.00017439248,0.00031464896,0.00013605178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006798166,0.00019513942,0.0007686724,0.00009530299,0.00007567001,0.000010875695,0.00006175371,0.00007221131,0.0000029996534],"category_scores_gemma":[0.0007970284,0.000118521486,0.000100275676,0.00065790035,0.00077956106,0.00005934397,0.000016241216,0.00021323629,3.4793933e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001742966,0.001207029,0.9945292,0.0006259684,0.0006628105,0.0001086871,0.0007181836,0.00007198684,0.000033265427,0.00002079146,0.00016722393,0.00011188574],"study_design_scores_gemma":[0.0086201085,0.0038395866,0.98179287,0.0010567231,0.0009096873,9.377969e-7,0.0029503757,0.00028054556,0.00038513544,0.000015135803,0.0000131978795,0.00013568944],"about_ca_topic_score_codex":0.025179882,"about_ca_topic_score_gemma":0.084681705,"teacher_disagreement_score":0.059501823,"about_ca_system_score_codex":0.000059390448,"about_ca_system_score_gemma":0.00054863543,"threshold_uncertainty_score":0.98131156},"labels":[],"label_agreement":null},{"id":"W3049033558","doi":"10.1093/cid/ciaa1169","title":"Safety and Efficacy of Rifampin or Isoniazid Among People With <i>Mycobacterium tuberculosis</i> Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials","year":2020,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; University of Alberta; BC Centre for Disease Control; University of British Columbia; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Isoniazid; Tuberculosis; Internal medicine; Randomized controlled trial; Mycobacterium tuberculosis; Incidence (geometry); Adverse effect; Rifampicin; Post-hoc analysis; Pathology","score_opus":0.03212588069392193,"score_gpt":0.3589393835203391,"score_spread":0.3268135028264172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049033558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962723,0.0007782375,0.00031770935,0.0005716793,0.000032838707,0.0016278411,0.00024300133,0.00008660116,0.00006975891],"genre_scores_gemma":[0.9963716,0.0027163436,0.000061825354,0.0004503879,0.00005013257,0.000085477666,0.00016024912,0.000028572547,0.000075410615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648654,0.0009527018,0.0016448481,0.00045169547,0.00025332012,0.00021088612],"domain_scores_gemma":[0.9935245,0.0046747657,0.0010015354,0.00023671931,0.00022401861,0.00033846026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012271163,0.00028143785,0.0031510664,0.00026059357,0.00019122945,0.000035106965,0.000038159258,0.00009086936,0.00033141533],"category_scores_gemma":[0.003298273,0.00015481243,0.00042895498,0.0009293437,0.0005582108,0.00012896064,0.000046484096,0.0001477291,0.0000016643091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05117026,0.0020400125,0.9374513,0.00038485142,0.0069405823,0.000006997043,0.0009814847,0.000031686865,0.00006405448,0.00003010113,0.00005340038,0.0008452654],"study_design_scores_gemma":[0.07506997,0.0041682003,0.9073577,0.00059171993,0.012233593,0.0000074821005,0.00015679689,0.00014635945,0.000027865037,0.0000036957545,0.00004531827,0.00019131685],"about_ca_topic_score_codex":0.00066369714,"about_ca_topic_score_gemma":0.0020284061,"teacher_disagreement_score":0.030093627,"about_ca_system_score_codex":0.00004713858,"about_ca_system_score_gemma":0.00034585418,"threshold_uncertainty_score":0.63130677},"labels":[],"label_agreement":null},{"id":"W3082576563","doi":"10.1097/qai.0000000000002466","title":"Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials","year":2020,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Torii Pharmaceutical; ViiV Healthcare; Gilead Sciences; GlaxoSmithKline","keywords":"Rilpivirine; Medicine; Fluid-attenuated inversion recovery; Atlas (anatomy); Clinical trial; Antiretroviral therapy; Human immunodeficiency virus (HIV); Internal medicine; Medical physics; Virology; Radiology; Viral load; Magnetic resonance imaging","score_opus":0.048869903210912426,"score_gpt":0.32198488777266826,"score_spread":0.2731149845617558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082576563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804086,0.009783404,0.004430018,0.004248283,0.00020195598,0.0006999085,0.00005967302,0.00003920346,0.00012894007],"genre_scores_gemma":[0.99235815,0.0015639061,0.0040102364,0.0000980554,0.000070084854,0.000019999685,0.000056217323,0.000046987392,0.0017763603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99632734,0.00019791616,0.0020758351,0.0003557937,0.0005688889,0.00047419738],"domain_scores_gemma":[0.9966962,0.00072358997,0.0015848838,0.00027632064,0.0004831018,0.00023590808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023154374,0.00037150423,0.0026212789,0.00091450167,0.00016036819,0.000054285756,0.00024573275,0.000109343346,0.00012939263],"category_scores_gemma":[0.0017997812,0.00025554706,0.00095092354,0.0020374053,0.00014902123,0.00030994083,0.000058266407,0.00013477003,0.000009375939],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03312217,0.0094516575,0.08068505,0.0017075759,0.06991189,0.0022632908,0.026824227,0.00093079585,0.552162,0.00042938103,0.010461176,0.21205077],"study_design_scores_gemma":[0.2484103,0.040456027,0.16398919,0.0044279112,0.09072145,0.003653119,0.027457075,0.026940282,0.3681145,0.00092435477,0.02083141,0.0040743863],"about_ca_topic_score_codex":0.000017457745,"about_ca_topic_score_gemma":0.0000020715954,"teacher_disagreement_score":0.21528813,"about_ca_system_score_codex":0.00009906197,"about_ca_system_score_gemma":0.00029843833,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W3082751997","doi":"10.1093/jac/dkaa355","title":"Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda","year":2020,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Center for AIDS Research, University of Washington; Western University; Ontario Genomics Institute; University of Otago","keywords":"Raltegravir; Dolutegravir; Integrase inhibitor; Integrase; Virology; Drug resistance; Human immunodeficiency virus (HIV); Medicine; Biology; Lentivirus; Antiretroviral therapy; Genetics; Viral load; Viral disease","score_opus":0.0313928375420259,"score_gpt":0.28549761329644285,"score_spread":0.2541047757544169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082751997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884375,0.000025614987,0.001980353,0.008678741,0.00010045237,0.0005118972,0.00021886076,0.000010806263,0.00003578354],"genre_scores_gemma":[0.9890233,0.000101623635,0.009901019,0.0004924782,0.00009746665,0.0000027918738,0.00013110763,0.000039908875,0.00021027675],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981547,0.000052455816,0.0009847081,0.00024917984,0.00032447878,0.00023447438],"domain_scores_gemma":[0.99916226,0.00008484799,0.00021804366,0.00011615896,0.00025069198,0.00016797495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019797843,0.0002405025,0.00066488475,0.00035043567,0.00003364042,0.000025095449,0.00012844359,0.00011874167,0.000038546936],"category_scores_gemma":[0.00007474098,0.00020413919,0.00014669633,0.00062450056,0.000044907585,0.00017948069,0.0000067595383,0.0003144809,0.0000075813728],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018098282,0.0016712947,0.23408072,0.00031931174,0.0005391948,0.00028042294,0.03389604,0.00085161283,0.7011092,0.0000430289,0.00656122,0.0025496825],"study_design_scores_gemma":[0.039091907,0.00041160107,0.51669496,0.0029387383,0.00014826136,0.0000023605048,0.0012432461,0.00009322354,0.43771437,0.00012328336,0.0010447049,0.00049336685],"about_ca_topic_score_codex":0.000064046,"about_ca_topic_score_gemma":0.0011133928,"teacher_disagreement_score":0.28261423,"about_ca_system_score_codex":0.00018859516,"about_ca_system_score_gemma":0.00028379346,"threshold_uncertainty_score":0.8324554},"labels":[],"label_agreement":null},{"id":"W3083718901","doi":"10.1093/ofid/ofaa404","title":"Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto; McGill University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Université de Montréal; Canadian Institutes of Health Research; Islamic Development Bank; ViiV Healthcare","keywords":"Dolutegravir; Virology; Medicine; Ritonavir; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Protease; Virus; Antiretroviral therapy; Viral load; Biology; Enzyme; Polymerase chain reaction","score_opus":0.019881573948538896,"score_gpt":0.3007526553480875,"score_spread":0.2808710813995486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083718901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98452705,0.000056884623,0.00015998649,0.00064482813,0.000024813226,0.01180502,0.0021908784,0.000081837214,0.0005086918],"genre_scores_gemma":[0.99219966,0.000014869306,0.0012208648,0.00014851696,0.00002038145,0.002009451,0.0036961702,0.00007663662,0.0006134619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666935,0.00011772889,0.0008412006,0.0011480054,0.00068674074,0.0005369637],"domain_scores_gemma":[0.99754274,0.000079157995,0.00055544096,0.00093868875,0.0003236359,0.0005603293],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018418902,0.000548439,0.0013588205,0.0005712666,0.00042067276,0.00012482508,0.0003180164,0.00005477311,0.000035665897],"category_scores_gemma":[0.0000846738,0.0003738171,0.00014321509,0.0024745124,0.0001373039,0.0004455473,0.00019714514,0.00012562863,0.00000862823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014115844,0.003374905,0.9751498,0.00008765603,0.0022002691,0.000039275114,0.0014157179,0.0003156009,0.00018047514,0.000016202106,0.0022236372,0.00088059],"study_design_scores_gemma":[0.012295587,0.0043752748,0.97125673,0.0005314952,0.0069913287,5.2740495e-7,0.00052351353,0.00015613817,0.0016143688,0.0000039698393,0.0017389278,0.0005121351],"about_ca_topic_score_codex":0.011560072,"about_ca_topic_score_gemma":0.1592139,"teacher_disagreement_score":0.14765383,"about_ca_system_score_codex":0.0009164709,"about_ca_system_score_gemma":0.00033180232,"threshold_uncertainty_score":0.9998714},"labels":[],"label_agreement":null},{"id":"W3093018885","doi":"10.1016/j.eclinm.2020.100573","title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis","year":2020,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; McMaster University; Impact; University of British Columbia","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; World Health Organization","keywords":"Dolutegravir; Efavirenz; Medicine; Emtricitabine; Tolerability; Adverse effect; Internal medicine; Population; Odds ratio; Discontinuation; Viral load; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Environmental health","score_opus":0.09930021354409332,"score_gpt":0.35940918563815855,"score_spread":0.26010897209406525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093018885","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20655441,0.7396285,0.00063336926,0.04539841,0.00004376221,0.0073051043,0.00025788,0.000077391946,0.000101165664],"genre_scores_gemma":[0.9345977,0.059575547,0.0027861474,0.0013592471,0.00015524139,0.00024043681,0.00035337885,0.000022753931,0.0009095515],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970431,0.00028119027,0.0014920163,0.00066710234,0.00025567535,0.00026093365],"domain_scores_gemma":[0.9965136,0.0020865144,0.00048705318,0.00039279007,0.0001592269,0.000360825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094969897,0.0004522383,0.005783092,0.00008541149,0.00013180664,0.00002165668,0.00007171816,0.00013066195,0.00006181623],"category_scores_gemma":[0.00046717215,0.00024517943,0.00064383534,0.0006778351,0.00041542333,0.000077190496,0.000055614746,0.00018671772,0.0000015114944],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003922052,0.0017047409,0.49155,0.12055229,0.35953814,0.00012812144,0.016880188,0.000029082365,0.000014646806,0.00038353103,0.0036379395,0.0016592772],"study_design_scores_gemma":[0.01809411,0.006644696,0.14253767,0.014868706,0.81126046,0.000045152043,0.00045074738,0.0031687678,0.000024974395,0.00015771712,0.002116898,0.0006301047],"about_ca_topic_score_codex":0.00000730333,"about_ca_topic_score_gemma":0.000031753832,"teacher_disagreement_score":0.72804326,"about_ca_system_score_codex":0.000029304509,"about_ca_system_score_gemma":0.000041462805,"threshold_uncertainty_score":0.99981266},"labels":[],"label_agreement":null},{"id":"W3093948793","doi":"10.24875/aidsrev.20000005","title":"Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa","year":2021,"lang":"en","type":"review","venue":"Aids Reviews","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"National Cancer Institute; National Institutes of Health","keywords":"Drug; Dolutegravir; Medicine; Polypharmacy; Pharmacology; DrugBank; Cancer; Concomitant; Drug interaction; ANTIRETROVIRAL AGENTS; Drug repositioning; Population; Human immunodeficiency virus (HIV); Pharmacokinetics; Antiretroviral therapy; Internal medicine; Family medicine; Viral load; Environmental health","score_opus":0.03691685907530889,"score_gpt":0.32996660215403484,"score_spread":0.29304974307872594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093948793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015292804,0.9955417,0.0000010295399,0.00018463639,0.000121871904,0.0028032318,0.00004597896,0.000014369267,0.001134274],"genre_scores_gemma":[0.0000130372455,0.9812977,0.0004915775,0.000045668643,0.000050781215,0.0013869966,0.00051579595,0.00005399133,0.016144492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975014,0.00033064303,0.001025216,0.00059225765,0.00022570335,0.00032479875],"domain_scores_gemma":[0.99897456,0.00011087176,0.00031154233,0.0004037014,0.000057589354,0.00014172863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003220758,0.0005265742,0.0030965023,0.00044595645,0.000036166373,0.00002545363,0.00009759923,0.000059106198,0.00032638837],"category_scores_gemma":[0.000068864545,0.0003296487,0.00025753188,0.00097561546,0.000036542566,0.000107130814,0.00007469445,0.0005142877,0.00018980182],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009118967,0.000298265,0.0141806565,0.008089737,0.00015313928,0.0000610801,0.00025370868,3.013305e-8,1.614349e-8,0.0000030408196,0.022586754,0.9543645],"study_design_scores_gemma":[0.0010250191,0.000018204862,0.0007860367,0.0969548,0.0008755724,0.00000826354,0.0000088045235,3.055571e-7,2.5725484e-7,8.225282e-7,0.9000464,0.00027553216],"about_ca_topic_score_codex":0.00004566815,"about_ca_topic_score_gemma":0.0007253856,"teacher_disagreement_score":0.9540889,"about_ca_system_score_codex":0.0004794455,"about_ca_system_score_gemma":0.00034683553,"threshold_uncertainty_score":0.99991554},"labels":[],"label_agreement":null},{"id":"W3098710190","doi":"10.1097/md.0000000000023335","title":"Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV","year":2020,"lang":"en","type":"article","venue":"Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Dolutegravir; Medicine; Hazard ratio; Internal medicine; Viral load; Regimen; Viremia; Cohort; Oncology; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV); Confidence interval","score_opus":0.01426186590033621,"score_gpt":0.26779295709366174,"score_spread":0.2535310911933255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3098710190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96939796,0.00043564197,0.00049498666,0.027691152,0.00001984928,0.0008929131,0.0000062407344,0.000098747085,0.00096252654],"genre_scores_gemma":[0.9947557,0.00003936849,0.002087693,0.0008443564,0.00008669485,0.00007176206,0.00002034992,0.00003935059,0.0020547356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799114,0.00006933995,0.00043195105,0.00055774156,0.00054223667,0.00040758494],"domain_scores_gemma":[0.9987512,0.00026707846,0.0001716482,0.0003232942,0.000058441983,0.0004282885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026903488,0.00040950274,0.001060985,0.00017790176,0.00009379612,0.0000114313525,0.00012235572,0.00008386153,0.00012602948],"category_scores_gemma":[0.00037113638,0.00020251298,0.000098383025,0.0005753622,0.00013049567,0.00006989168,0.00005599465,0.00024870472,0.000018980289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011913361,0.00012755852,0.988812,0.00013757456,0.00042125717,0.00039656952,0.0056369756,0.000024318522,0.00066418556,0.000016048427,0.0023423769,0.00022975303],"study_design_scores_gemma":[0.004324612,0.0048670038,0.987549,0.0012394887,0.00052588806,0.000029776227,0.00062814256,0.000051058123,0.0000934066,0.000007173644,0.0004512149,0.00023325125],"about_ca_topic_score_codex":0.000108399094,"about_ca_topic_score_gemma":0.00040118635,"teacher_disagreement_score":0.026846794,"about_ca_system_score_codex":0.0001081213,"about_ca_system_score_gemma":0.000075442105,"threshold_uncertainty_score":0.82582396},"labels":[],"label_agreement":null},{"id":"W3099871382","doi":"10.3390/cancers12113437","title":"The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir","year":2020,"lang":"en","type":"review","venue":"Cancers","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canada Foundation for Innovation; McGill University; Rivkin Center for Ovarian Cancer","keywords":"Nelfinavir; Medicine; Cancer; Pharmacology; Protease inhibitor (pharmacology); Proteasome inhibitor; Cancer cell; Cancer research; Immunology; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Multiple myeloma; Antiretroviral therapy","score_opus":0.049816808239698696,"score_gpt":0.30313077490049406,"score_spread":0.25331396666079536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099871382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000107427026,0.99246013,4.194117e-7,0.0034434418,0.00041518602,0.0028748868,0.000059177113,0.00002973535,0.0006096143],"genre_scores_gemma":[0.00011441195,0.9717496,0.000018732635,0.00012016318,0.00034579658,0.0013318517,0.000016090384,0.000049504008,0.026253838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985507,0.000085750624,0.00045018992,0.00029861357,0.00034354225,0.00027116717],"domain_scores_gemma":[0.99899733,0.000029238694,0.00032333835,0.00042942123,0.00007530942,0.0001453853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107910986,0.0003388551,0.0010624777,0.00003524586,0.000170966,0.000020478945,0.0002697524,0.00011250332,0.00004311108],"category_scores_gemma":[0.00011591614,0.00013482841,0.0004473506,0.0003550956,0.00024000579,0.00002720779,0.000105776366,0.00033734462,0.000070661394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005041648,0.00002553511,0.00012628421,0.015689995,0.000968734,0.00002014673,0.00051098916,0.0000012283202,0.000017483353,0.000028896213,0.049021084,0.9335392],"study_design_scores_gemma":[0.00035827703,0.000019818568,0.000003868833,0.020303924,0.0010272865,0.0000069149123,0.00006888519,0.0000035635637,0.00050258444,0.0000010225134,0.9775554,0.00014847312],"about_ca_topic_score_codex":0.00003074533,"about_ca_topic_score_gemma":0.000007852107,"teacher_disagreement_score":0.93339074,"about_ca_system_score_codex":0.0014365854,"about_ca_system_score_gemma":0.00779767,"threshold_uncertainty_score":0.9978272},"labels":[],"label_agreement":null},{"id":"W3100521696","doi":"10.1093/infdis/jiaa683","title":"Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"World Health Organization; ZonMw; Bill and Melinda Gates Foundation","keywords":"Efavirenz; Emtricitabine; Reverse-transcriptase inhibitor; Regimen; Lamivudine; Medicine; Drug resistance; Virology; Nucleoside Reverse Transcriptase Inhibitor; Population; Internal medicine; HIV drug resistance; Reverse transcriptase; Virus; Antiretroviral therapy; Viral load; Biology; Environmental health; Polymerase chain reaction; Microbiology; Hepatitis B virus","score_opus":0.05376882230958936,"score_gpt":0.37890942357199553,"score_spread":0.3251406012624062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100521696","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008494456,0.98879176,0.000005687322,0.00010715313,0.00002963162,0.0023436905,0.00014166893,0.000017633387,0.00006829558],"genre_scores_gemma":[0.0901397,0.90940416,0.0000401853,0.000099795834,0.00003303666,0.00007514454,0.00003363624,0.000044898956,0.00012944388],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99314773,0.002135953,0.0035753504,0.00031016476,0.00055391586,0.0002768634],"domain_scores_gemma":[0.99465674,0.00089850154,0.0034778847,0.0005061917,0.00022934105,0.00023136284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002033582,0.0006431085,0.010462795,0.0006706588,0.00015048528,0.0000389021,0.00023441955,0.00010058292,0.00009727298],"category_scores_gemma":[0.0005913801,0.00031497903,0.005811796,0.0015908651,0.00011799153,0.00016039131,0.0000493575,0.0005774676,0.0000030738852],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042595598,0.0026425864,0.01799211,0.50736475,0.46470854,0.0006944265,0.0035498326,0.0000038817775,0.0000033982888,0.000015062667,0.0003830467,0.0022164409],"study_design_scores_gemma":[0.001598707,0.0010412205,0.00064859726,0.06196476,0.93376935,0.00016916497,0.00014451878,0.0000013618975,9.3719166e-7,0.000011672413,0.00035982183,0.00028986324],"about_ca_topic_score_codex":0.00013993093,"about_ca_topic_score_gemma":0.00011470693,"teacher_disagreement_score":0.46906084,"about_ca_system_score_codex":0.00045781286,"about_ca_system_score_gemma":0.000786306,"threshold_uncertainty_score":0.9999302},"labels":[],"label_agreement":null},{"id":"W3101001050","doi":"10.1139/gen-2020-0112","title":"Determination of reverse transcriptase inhibitor resistance mutations in HIV-1 infected children in Côte d’Ivoire","year":2020,"lang":"en","type":"article","venue":"Genome","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Reverse transcriptase; Virology; Resistance mutation; Biology; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Genotype; Human immunodeficiency virus (HIV); Viral load; Polymerase chain reaction; Antiretroviral therapy; Genetics; Gene","score_opus":0.01113358082493671,"score_gpt":0.23089439950293988,"score_spread":0.21976081867800318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101001050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922225,0.00020650591,0.00012859571,0.0059458725,0.000020153011,0.00053705054,0.000063926585,0.000025885693,0.0008495035],"genre_scores_gemma":[0.994268,0.000029256344,0.0034030052,0.0001837899,0.000030768188,0.000032287706,0.00037082,0.000012197832,0.0016699039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921817,0.000035486966,0.0003044253,0.00018046818,0.00012911022,0.00013233979],"domain_scores_gemma":[0.9997255,0.000017378545,0.000054928336,0.000096170115,0.000034015437,0.000071979965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006887917,0.00009877758,0.00021205263,0.00022801929,0.000018651257,0.0000037463667,0.000038912323,0.000047448004,0.000072155235],"category_scores_gemma":[0.000056742843,0.0000976726,0.0000401137,0.0006147628,0.000028014116,0.000069264686,0.000009561684,0.000096431744,0.000039210794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009631886,0.0012869602,0.80948657,0.00059660536,0.00013295919,0.0008018154,0.053950883,0.00006486362,0.12671535,0.00035690283,0.0011970853,0.0044468297],"study_design_scores_gemma":[0.005504727,0.00009403743,0.98379725,0.00021367597,0.00007640076,0.0000066083676,0.0002666351,0.000091198315,0.0044947024,0.00007608894,0.0051924633,0.00018621588],"about_ca_topic_score_codex":0.000011611087,"about_ca_topic_score_gemma":0.00012777053,"teacher_disagreement_score":0.17431068,"about_ca_system_score_codex":0.000099808865,"about_ca_system_score_gemma":0.00009895337,"threshold_uncertainty_score":0.3982973},"labels":[],"label_agreement":null},{"id":"W3101667531","doi":"10.1093/jac/dkaa471","title":"Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir","year":2020,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"National Institutes of Health; McGill University Health Centre; Francis Crick Institute; McGill University; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Dolutegravir; Integrase; Virology; Integrase inhibitor; Genetics; Integrases; DNA; Biology; Mutation; Medicine; Human immunodeficiency virus (HIV); Gene; Antiretroviral therapy","score_opus":0.021334945498389442,"score_gpt":0.27315537646986093,"score_spread":0.2518204309714715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101667531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944241,0.00004023285,0.00007472351,0.004811901,0.000020033087,0.00054028933,0.00002960609,0.0000073252913,0.00005180067],"genre_scores_gemma":[0.9964182,0.000060979433,0.0031921198,0.00018051133,0.000035256377,0.000004116203,0.00006416744,0.00001977209,0.000024881418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853617,0.00008774113,0.00070609414,0.00012138202,0.00041489955,0.0001336952],"domain_scores_gemma":[0.9985134,0.00004646151,0.0008582301,0.00011028737,0.00040706852,0.00006456467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027379056,0.0001530058,0.00052017753,0.00023378679,0.000027246657,0.000010363065,0.00019835206,0.00006369419,0.00004294853],"category_scores_gemma":[0.000034981735,0.000093067545,0.00010617153,0.0006966334,0.00017015616,0.00017267282,0.0000098322125,0.00019035736,7.040928e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017742224,0.012235713,0.14284818,0.0010361352,0.00337732,0.00065886683,0.08754798,0.00022299925,0.7143206,0.00023789625,0.0041672597,0.015604814],"study_design_scores_gemma":[0.016561843,0.004753343,0.04586262,0.00094847823,0.00046777588,0.00012765492,0.0047547775,0.0002083186,0.9260585,0.00004584778,0.000034787558,0.00017606192],"about_ca_topic_score_codex":0.00003245429,"about_ca_topic_score_gemma":0.00001703486,"teacher_disagreement_score":0.21173789,"about_ca_system_score_codex":0.000030834082,"about_ca_system_score_gemma":0.0003607917,"threshold_uncertainty_score":0.37951845},"labels":[],"label_agreement":null},{"id":"W3112648094","doi":"10.21203/rs.2.24292/v1","title":"Alarming rate of transmitted drug resistance mutations and genetic diversity in newly HIV-1-infected patients in Benin","year":2020,"lang":"en","type":"preprint","venue":"Research Square (Research Square)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Genetic diversity; Drug resistance; Transmission (telecommunications); Human immunodeficiency virus (HIV); Phylogenetic tree; Mutation; HIV drug resistance; Drug; Virology; Phylogenetic diversity; Biology; Medicine; Genetics; Antiretroviral therapy; Viral load; Gene; Pharmacology; Environmental health; Population","score_opus":0.06322329469720443,"score_gpt":0.36469253195696577,"score_spread":0.3014692372597613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112648094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814457,0.001136264,0.0000951732,0.0107234735,0.00005500951,0.005422297,0.00031184376,0.00006738233,0.00074282417],"genre_scores_gemma":[0.9918001,0.0018251578,0.0020341557,0.000020362402,0.00006066653,0.00044831476,0.0011133649,0.00008516264,0.0026126923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98921645,0.003381789,0.0011093243,0.0015555787,0.003106198,0.0016306859],"domain_scores_gemma":[0.99400884,0.0022109144,0.00016397769,0.00082557433,0.002024261,0.0007664049],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0038631994,0.00053936214,0.0011950242,0.0035434715,0.0004922572,0.0001138586,0.00063737994,0.00042847043,0.0001701538],"category_scores_gemma":[0.0023750458,0.0005398136,0.00020823807,0.0035675908,0.0007459118,0.00017143802,0.0023879304,0.0039774263,0.0000700819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017863915,0.0017906707,0.95957404,0.004987425,0.00024372962,0.0017593125,0.022040334,0.00009318818,0.0004315643,0.000120133234,0.0044863727,0.0026868244],"study_design_scores_gemma":[0.009050794,0.00031051948,0.9766142,0.004898854,0.000060295653,0.0000024188937,0.001959662,0.0014235704,0.0013005898,0.00296884,0.000931906,0.00047839378],"about_ca_topic_score_codex":0.0029715782,"about_ca_topic_score_gemma":0.0064801835,"teacher_disagreement_score":0.02008067,"about_ca_system_score_codex":0.0013709257,"about_ca_system_score_gemma":0.001971223,"threshold_uncertainty_score":0.9997053},"labels":[],"label_agreement":null},{"id":"W3113296383","doi":"10.3390/v12121456","title":"Application of a Sanger-Based External Quality Assurance Strategy for the Transition of HIV-1 Drug Resistance Assays to Next Generation Sequencing","year":2020,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases; National Institute of Allergy and Infectious Diseases","keywords":"Quality assurance; Sanger sequencing; External quality assessment; HIV drug resistance; Medicine; Human immunodeficiency virus (HIV); Medical physics; Data mining; DNA sequencing; Computational biology; Computer science; Virology; Viral load; Biology; Pathology; Genetics; Antiretroviral therapy","score_opus":0.2091575424745035,"score_gpt":0.38911670450741853,"score_spread":0.17995916203291504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113296383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017748502,0.8542634,0.14118941,0.0008630301,0.00005121946,0.0029323052,0.0004341245,0.00003140291,0.000057597103],"genre_scores_gemma":[0.009386651,0.96359247,0.022547767,0.0003977705,0.00048172288,0.0021059508,0.0007298032,0.0000821458,0.0006757452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982978,0.00014849786,0.00077778136,0.0003248964,0.00031935328,0.00013168233],"domain_scores_gemma":[0.99852663,0.0004389495,0.00050570164,0.00031317896,0.00015300383,0.00006252683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004315375,0.00024502934,0.0009753245,0.00009129501,0.00006398508,0.000016763377,0.00012150249,0.00009275838,0.000013707484],"category_scores_gemma":[0.00008238201,0.000167152,0.000278408,0.00029665252,0.00003597459,0.00006436422,0.0000073183455,0.000103263155,0.000012199935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040048925,0.00024077937,0.0000367288,0.036834445,0.0005781369,0.000007059491,0.0010887757,0.0002447924,0.012733326,0.00074584264,0.004849054,0.9422406],"study_design_scores_gemma":[0.0010100561,0.000074802505,0.00004386664,0.009969573,0.001849825,0.0000028502604,0.000109081884,0.0009065064,0.010690838,0.000034840803,0.97498286,0.00032488993],"about_ca_topic_score_codex":0.000047544294,"about_ca_topic_score_gemma":0.00018007802,"teacher_disagreement_score":0.97013384,"about_ca_system_score_codex":0.00020928279,"about_ca_system_score_gemma":0.00066911854,"threshold_uncertainty_score":0.6816261},"labels":[],"label_agreement":null},{"id":"W3114535215","doi":"10.4102/sajhivmed.v21i1.1125","title":"The influence of haemodialysis on CD4+ T-cell counts in people living with human immunodeficiency virus with end-stage kidney disease","year":2020,"lang":"en","type":"article","venue":"Southern African Journal of HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health; Saskatchewan Health Authority","funders":"","keywords":"Medicine; Dialysis; Kidney disease; Hemodialysis; Internal medicine; Transplantation; End stage renal disease; Kidney transplantation; Cohort; Immunology; Human immunodeficiency virus (HIV); Lymphocyte","score_opus":0.009622509744777288,"score_gpt":0.2282837158590944,"score_spread":0.2186612061143171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114535215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997843,0.0003967191,0.000052156625,0.0063186763,0.00001794559,0.00017023172,0.000027253998,0.000008980248,0.003029615],"genre_scores_gemma":[0.997136,0.00006152906,0.000073255826,0.00030779888,0.00006426542,0.0000039023694,0.0000061537876,0.00002207279,0.0023249963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984591,0.00006593765,0.00044214647,0.00014584698,0.0006874748,0.00019951489],"domain_scores_gemma":[0.998787,0.00013805067,0.0004040623,0.00019869114,0.00014612738,0.00032609774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003548559,0.00017126508,0.0004427613,0.00014987463,0.00008565821,0.000008075061,0.00017731189,0.000020783722,0.000287684],"category_scores_gemma":[0.00020453511,0.00008186596,0.000059250233,0.00045135457,0.0002139207,0.00003849241,0.000019100607,0.0002468381,0.000028103515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034917113,0.00090142334,0.8966249,0.00025624273,0.0005623574,0.0011503025,0.08676321,0.0007083834,0.0063499846,0.00014188234,0.0020490843,0.0010004829],"study_design_scores_gemma":[0.044642393,0.016710695,0.7214514,0.01590678,0.004815488,0.00024089612,0.15491009,0.0005900389,0.0019564813,0.00012461333,0.037063774,0.0015873645],"about_ca_topic_score_codex":0.00003350512,"about_ca_topic_score_gemma":0.000022243923,"teacher_disagreement_score":0.17517355,"about_ca_system_score_codex":0.0000764473,"about_ca_system_score_gemma":0.00041219723,"threshold_uncertainty_score":0.3338397},"labels":[],"label_agreement":null},{"id":"W3114693725","doi":"10.1002/jia2.25656","title":"Prevalence of pretreatment HIV drug resistance in key populations: a systematic review and meta‐analysis","year":2020,"lang":"en","type":"review","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Impact","funders":"Ministerie van Buitenlandse Zaken; World Health Organization","keywords":"Medicine; HIV drug resistance; Population; Meta-analysis; Drug resistance; Odds ratio; Genotyping; Demography; Antiretroviral therapy; Human immunodeficiency virus (HIV); Genotype; Environmental health; Viral load; Internal medicine; Virology; Biology; Genetics","score_opus":0.05219156618538204,"score_gpt":0.3432135401597869,"score_spread":0.2910219739744049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114693725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006190919,0.9910875,0.000031860178,0.007363162,0.000060119903,0.0012738192,0.000085645675,0.0000039132833,0.000087791916],"genre_scores_gemma":[0.00006539436,0.9709155,0.0075817266,0.00020106406,0.00002904422,0.00008961083,0.000015120229,0.000016298054,0.021086259],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99678224,0.00025740176,0.0018011264,0.0002153558,0.0008396336,0.00010423367],"domain_scores_gemma":[0.9968456,0.0002485372,0.0022570624,0.00027888935,0.00029204434,0.00007784023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087557785,0.00030186548,0.0039856094,0.00016156332,0.00003446878,0.000019749074,0.0004189121,0.00007424469,0.00009939902],"category_scores_gemma":[0.0002976478,0.00015132256,0.0039884397,0.00069253304,0.00004898579,0.000092100694,0.00011546012,0.00032647373,0.000003363182],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010597742,0.00020856799,0.0005353704,0.7371117,0.25703153,0.00002584425,0.00066451763,0.0000017378878,7.117491e-8,0.00021435859,0.0040548923,0.00014085305],"study_design_scores_gemma":[0.00032686003,0.000015858275,0.00005334807,0.15451987,0.818408,0.000089709174,0.000037198803,0.000008986222,8.5960795e-7,0.00008824187,0.026328258,0.00012278068],"about_ca_topic_score_codex":0.000002610782,"about_ca_topic_score_gemma":0.000011435302,"teacher_disagreement_score":0.5825918,"about_ca_system_score_codex":0.000553632,"about_ca_system_score_gemma":0.00032137448,"threshold_uncertainty_score":0.61707544},"labels":[],"label_agreement":null},{"id":"W3117465415","doi":"10.1016/s2352-3018(20)30268-x","title":"Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study","year":2020,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Cancer Institute; National Institute of Mental Health; Office of the Director; Ministério da Saúde","keywords":"Dolutegravir; Medicine; Efavirenz; Miscarriage; Obstetrics; Pregnancy; Propensity score matching; Retrospective cohort study; Cohort; Cohort study; Gynecology; Pediatrics; Antiretroviral therapy; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Virology","score_opus":0.029556217772091272,"score_gpt":0.3068919010422285,"score_spread":0.27733568327013725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117465415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98284054,0.000117026924,7.060023e-7,0.012616791,0.00002247177,0.0010650388,0.000012134747,0.00003491954,0.0032903934],"genre_scores_gemma":[0.996667,0.00012568379,0.00005211828,0.0013585839,0.00005103083,0.00012636563,0.000008912746,0.000012699691,0.001597564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989537,0.000072073046,0.0001730078,0.00025596182,0.00032389525,0.0002213328],"domain_scores_gemma":[0.9996928,0.000061389976,0.00003988473,0.0001342228,0.000021972462,0.000049736547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025476838,0.00014095203,0.00044913666,0.0000738658,0.000037370566,0.000015698086,0.00008310239,0.000029239569,0.000035959994],"category_scores_gemma":[0.000068131245,0.00008311425,0.000023397857,0.0002449754,0.000036584952,0.00004601195,0.000029973575,0.00020666057,0.000030025298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034920298,0.0004078366,0.9854657,0.000006492038,0.000118400894,0.00005863529,0.011643484,9.786531e-7,0.000020428966,0.000259437,0.00045838451,0.0012109944],"study_design_scores_gemma":[0.006931582,0.0006143379,0.991131,0.00007386158,0.0000075375856,9.592716e-7,0.0005958643,0.00003747774,0.000023605748,0.0003300896,0.00016827206,0.00008542343],"about_ca_topic_score_codex":0.000016697086,"about_ca_topic_score_gemma":0.000029149975,"teacher_disagreement_score":0.013826523,"about_ca_system_score_codex":0.00020882681,"about_ca_system_score_gemma":0.000053406267,"threshold_uncertainty_score":0.33893007},"labels":[],"label_agreement":null},{"id":"W3118513334","doi":"10.1093/ofid/ofaa439.1194","title":"1008. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab in Expanded Access Protocol (TMB-311)","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Viremia; Internal medicine; Regimen; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.031953073956163654,"score_gpt":0.38383679394943215,"score_spread":0.3518837199932685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118513334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9162121,0.00001846571,0.000018932815,0.011323451,0.000049465776,0.06965575,0.00014307268,0.00020886782,0.0023699328],"genre_scores_gemma":[0.92856157,0.000005178095,0.000014837526,0.0050197467,0.000050691677,0.0651068,0.00013155062,0.000050846375,0.0010588019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974837,0.00028054373,0.00043029507,0.00076888374,0.0004102974,0.00062629895],"domain_scores_gemma":[0.9977256,0.00013879717,0.00012436528,0.0005201575,0.00006957466,0.0014215212],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016383298,0.00047648328,0.0006410333,0.0002473787,0.0002142374,0.00033104068,0.00045232,0.0000863886,0.0014858148],"category_scores_gemma":[0.0005145267,0.00035265245,0.0002422407,0.0006562013,0.000058790898,0.0004777783,0.00061683665,0.00019167023,0.0004969642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050258823,0.002452136,0.9335401,0.00011728853,0.00015228649,0.0013823793,0.00019193819,0.000062955995,0.000034950524,0.00001546829,0.007637156,0.004154524],"study_design_scores_gemma":[0.009475206,0.0018118316,0.98537153,0.00024470408,0.00012978731,0.00001718058,0.000028302567,0.000052728035,0.00023859461,0.00016023172,0.002056728,0.000413151],"about_ca_topic_score_codex":0.00008913725,"about_ca_topic_score_gemma":0.000110723275,"teacher_disagreement_score":0.05183146,"about_ca_system_score_codex":0.0006080669,"about_ca_system_score_gemma":0.0007100416,"threshold_uncertainty_score":0.99989253},"labels":[],"label_agreement":null},{"id":"W3119363120","doi":"10.1093/ofid/ofaa439.832","title":"638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Tolerability; Regimen; Rilpivirine; Adverse effect; Abacavir; Population; Internal medicine; Viral load; Dosing; Pharmacology; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.023789557961036822,"score_gpt":0.2957637981779105,"score_spread":0.27197424021687366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119363120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703004,0.00050100475,0.0003097532,0.019384742,0.00010041839,0.0029030242,0.00024538254,0.00011104159,0.006144263],"genre_scores_gemma":[0.9965256,0.0006714997,0.00014551368,0.0007389552,0.00006164676,0.00013810422,0.0001717973,0.000031773532,0.001515147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985556,0.00005582402,0.00042385017,0.0005075194,0.0001584736,0.00029874494],"domain_scores_gemma":[0.9987925,0.00033344736,0.00019331231,0.00022934325,0.00013387334,0.00031746604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016870789,0.0002516385,0.00050964515,0.000056074587,0.0002866709,0.0001047211,0.00007644577,0.00006818023,0.00006712003],"category_scores_gemma":[0.00051367376,0.00020286166,0.00010086239,0.00019894572,0.00014657566,0.0003027891,0.00016741875,0.00010099332,0.000012742924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066067083,0.00097448565,0.9484454,0.00026178875,0.00041687555,0.000033589393,0.00065037183,0.000010955729,0.00006720931,0.00030372138,0.005999849,0.036229093],"study_design_scores_gemma":[0.030228576,0.0027247774,0.92726856,0.00033978725,0.00034848723,0.000091221234,0.0003813472,0.00014163512,0.001352211,0.000495773,0.036190182,0.00043746288],"about_ca_topic_score_codex":0.00024140027,"about_ca_topic_score_gemma":0.00013883229,"teacher_disagreement_score":0.035791628,"about_ca_system_score_codex":0.0000812522,"about_ca_system_score_gemma":0.0001794664,"threshold_uncertainty_score":0.82724583},"labels":[],"label_agreement":null},{"id":"W3119490951","doi":"10.1093/ofid/ofaa439.1171","title":"985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"","keywords":"Medicine; Renal function; Tenofovir alafenamide; Internal medicine; Diabetes mellitus; Creatinine; Comorbidity; Adverse effect; Urology; Endocrinology; Immunology","score_opus":0.02644458426099416,"score_gpt":0.3359318767647508,"score_spread":0.3094872925037566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119490951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790917,0.0000695912,0.0000030490119,0.01067394,0.00004999992,0.0010265426,0.0000671202,0.000018359086,0.008999705],"genre_scores_gemma":[0.9977085,0.000050868006,0.000004991549,0.0015377098,0.000050084014,0.00008313884,0.00007476948,0.0000112590915,0.00047865417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896944,0.00008428468,0.0002339932,0.00017644333,0.0003608556,0.00017498384],"domain_scores_gemma":[0.99936354,0.00022921244,0.00006259534,0.0001461967,0.000013380967,0.00018506021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106808046,0.00015297411,0.00040549017,0.000055210425,0.000068996975,0.00006254543,0.00013875349,0.00004200678,0.00042714152],"category_scores_gemma":[0.00033689008,0.00007921579,0.00014414352,0.00012653212,0.000104397135,0.00010693677,0.00011685005,0.00011350132,0.000017203638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005852436,0.0011917321,0.97199553,0.000024765426,0.00030644782,0.00040561118,0.0007996357,0.0000031452641,0.000003018218,0.00083067367,0.017228914,0.0013580886],"study_design_scores_gemma":[0.064063735,0.0035998372,0.9279955,0.00017770843,0.00026663093,0.000026553424,0.0005826231,0.00004154185,0.0000397133,0.000747033,0.0022478334,0.00021125893],"about_ca_topic_score_codex":0.00030137427,"about_ca_topic_score_gemma":0.00015456077,"teacher_disagreement_score":0.0582113,"about_ca_system_score_codex":0.00005074834,"about_ca_system_score_gemma":0.00024565565,"threshold_uncertainty_score":0.46769002},"labels":[],"label_agreement":null},{"id":"W3120580289","doi":"10.1093/ofid/ofaa439.1215","title":"1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dosing; Medicine; Rilpivirine; Regimen; Clinical endpoint; Antiretroviral therapy; Internal medicine; Clinical trial; Human immunodeficiency virus (HIV); Viral load; Virology","score_opus":0.04923846734264716,"score_gpt":0.3537956273583668,"score_spread":0.30455716001571964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120580289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911999,0.0018618582,0.0003913238,0.001049822,0.000050362025,0.0042568995,0.00007536669,0.00005215763,0.001062283],"genre_scores_gemma":[0.9932666,0.0033453584,0.00039614894,0.00020825252,0.00001440028,0.0016082952,0.000108763976,0.000031553154,0.001020639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867785,0.000030798485,0.00037588386,0.0004445747,0.00013530963,0.00033556536],"domain_scores_gemma":[0.99925363,0.00006629541,0.00018412535,0.00020872174,0.000108327156,0.00017892035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048084417,0.00030610163,0.0006043275,0.0000967563,0.00015714008,0.0000537596,0.00009174784,0.000028583134,0.000047871752],"category_scores_gemma":[0.00002050244,0.00020817423,0.00008517957,0.00027417933,0.000100341356,0.00021379007,0.00014567054,0.000056063924,0.000003959257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00436022,0.0033820693,0.8053791,0.00047286044,0.0021491114,0.0002493515,0.0029267105,0.00003708362,0.00006335576,0.0002246131,0.00042794668,0.18032755],"study_design_scores_gemma":[0.29959273,0.12097234,0.49796146,0.013185596,0.0050836676,0.00026467536,0.036237445,0.0009187616,0.0131992465,0.0008378503,0.008534465,0.0032117313],"about_ca_topic_score_codex":0.00016150832,"about_ca_topic_score_gemma":0.0007747426,"teacher_disagreement_score":0.30741763,"about_ca_system_score_codex":0.00029252787,"about_ca_system_score_gemma":0.00010954152,"threshold_uncertainty_score":0.84890985},"labels":[],"label_agreement":null},{"id":"W3120912770","doi":"10.1093/ofid/ofaa439.1221","title":"1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); University Health Network","funders":"","keywords":"Rilpivirine; Medicine; Abacavir; Dolutegravir; Randomized controlled trial; Human immunodeficiency virus (HIV); Internal medicine; Lamivudine; Antiretroviral therapy; Viral load; Family medicine","score_opus":0.0276448731580631,"score_gpt":0.29478786491525344,"score_spread":0.26714299175719036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120912770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88158137,0.00021012637,0.000033312837,0.02903257,0.00035379158,0.0027488214,0.00013549345,0.00048833806,0.08541618],"genre_scores_gemma":[0.98011374,0.00013364328,0.00008536153,0.006947671,0.000071315415,0.00023533421,0.00040935038,0.00007864429,0.011924918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738747,0.0000821629,0.00066442543,0.0007728315,0.00048941886,0.00060371],"domain_scores_gemma":[0.99817646,0.00017151676,0.0003645307,0.0005375214,0.00015997303,0.0005899895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000104425206,0.00048501993,0.0007115469,0.000115125564,0.00037637717,0.00018150125,0.00022139543,0.0000871771,0.00041108957],"category_scores_gemma":[0.0007926214,0.0003504525,0.00027954174,0.00041869987,0.00007624406,0.0002934288,0.00022176305,0.00023646184,0.0006529847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003650028,0.0024442472,0.90075934,0.0000401284,0.0010887281,0.0015667133,0.0007935893,0.000028447963,0.00004405589,0.00022637179,0.031121707,0.05823664],"study_design_scores_gemma":[0.040885266,0.007943776,0.7083536,0.0007735456,0.00077731715,0.00021662473,0.0017224526,0.00013458697,0.0046483497,0.000904765,0.23197846,0.0016612881],"about_ca_topic_score_codex":0.00042866138,"about_ca_topic_score_gemma":0.00013275557,"teacher_disagreement_score":0.20085675,"about_ca_system_score_codex":0.00021749678,"about_ca_system_score_gemma":0.00033525805,"threshold_uncertainty_score":0.99989474},"labels":[],"label_agreement":null},{"id":"W3120915669","doi":"10.1093/ofid/ofaa439.426","title":"116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Rilpivirine; Medicine; Adverse effect; Tolerability; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Antiretroviral therapy; Virology","score_opus":0.01793653676494958,"score_gpt":0.2866787662986212,"score_spread":0.26874222953367166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120915669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862131,0.0002638362,0.00008416457,0.0023535965,0.00008284089,0.0024748344,0.00089441944,0.000085636515,0.0075476076],"genre_scores_gemma":[0.99868906,0.00010299938,0.000057609464,0.00021706466,0.000072084935,0.00008628147,0.00032841376,0.00005710116,0.0003893846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971264,0.00064070633,0.00061555573,0.0007600252,0.0003989964,0.0004582874],"domain_scores_gemma":[0.9972748,0.0015172668,0.00041162327,0.0004296714,0.00010139852,0.00026522804],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042523592,0.00045738954,0.0008975092,0.000106082196,0.00032448678,0.00020471618,0.0002513211,0.00011231048,0.000030039893],"category_scores_gemma":[0.000924886,0.00035111886,0.00015322593,0.00048628202,0.00016855399,0.00059739396,0.00062798895,0.00042051956,0.000014118709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008265,0.0015928703,0.96886384,0.000053675554,0.0006915945,0.00090647314,0.005548935,0.000014956656,0.0001066218,0.000009010175,0.00018050062,0.013766512],"study_design_scores_gemma":[0.0149434805,0.0007818367,0.9756941,0.00048229977,0.00053779915,0.000023790988,0.0056020864,0.00024655642,0.0010080019,0.000018304336,0.00028978873,0.00037192993],"about_ca_topic_score_codex":0.0058243717,"about_ca_topic_score_gemma":0.0066438657,"teacher_disagreement_score":0.013394582,"about_ca_system_score_codex":0.00025479004,"about_ca_system_score_gemma":0.0004619272,"threshold_uncertainty_score":0.9998941},"labels":[],"label_agreement":null},{"id":"W3124223906","doi":"","title":"Early Initiation of Highly Active Antiretroviral Therapies for Aids: Dynamic choice with Endogenous and Exogenous Learning","year":2008,"lang":"fr","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"Centre National de la Recherche Scientifique","keywords":"Human immunodeficiency virus (HIV); Antiretroviral therapy; Antiretroviral treatment; Humanities; Political science; Welfare economics; Gynecology; Medicine; Viral load; Virology; Economics; Philosophy","score_opus":0.03196990746241386,"score_gpt":0.2925969784724802,"score_spread":0.2606270710100663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124223906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860902,0.0018060524,0.000022970924,0.00025400848,0.00016801187,0.002531488,0.00011816904,0.000032634867,0.008976462],"genre_scores_gemma":[0.9339026,0.054479722,0.0029991895,0.000014041648,0.00017227558,0.00047447046,0.00029871942,0.00011545682,0.007543477],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99642223,0.0003767681,0.00078084326,0.0009911192,0.00037571564,0.0010533462],"domain_scores_gemma":[0.9968373,0.0016690416,0.00044017663,0.00048632646,0.0003311048,0.00023601342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000911161,0.0005293979,0.0011072303,0.0007342241,0.00038911033,0.000061803876,0.00025555046,0.0004441673,0.000026488364],"category_scores_gemma":[0.00038821262,0.00050154957,0.00017293119,0.00020571625,0.00076910126,0.0002028568,0.0002552335,0.0012732341,0.0000075212447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028803356,0.00088279316,0.29946455,0.0010345703,0.0024488105,0.0002495515,0.02634942,0.0016430293,0.0036191097,0.00036251202,0.0000030088352,0.6610623],"study_design_scores_gemma":[0.040597588,0.028219428,0.8177188,0.007472825,0.0011287361,0.0009329787,0.035054497,0.01680828,0.016123014,0.0008784149,0.031256065,0.0038093897],"about_ca_topic_score_codex":0.00034605805,"about_ca_topic_score_gemma":0.0002816013,"teacher_disagreement_score":0.6572529,"about_ca_system_score_codex":0.0017693298,"about_ca_system_score_gemma":0.0013249051,"threshold_uncertainty_score":0.99974364},"labels":[],"label_agreement":null},{"id":"W3126309097","doi":"10.1371/journal.pone.0246171","title":"Higher plasma drug levels in elderly people living with HIV treated with darunavir","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Gilead Sciences; Cilag; GlaxoSmithKline; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Darunavir; Efavirenz; Medicine; Concomitant; Atazanavir; Internal medicine; Drug; Pharmacokinetics; Human immunodeficiency virus (HIV); Antiretroviral therapy; Pharmacology; Viral load; Immunology","score_opus":0.02578711878309317,"score_gpt":0.22127084350642853,"score_spread":0.19548372472333536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126309097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868296,0.00012985263,0.0000053378253,0.003432585,0.0000082681745,0.00034275374,0.000009834342,0.000104009094,0.009137785],"genre_scores_gemma":[0.85653794,0.000027648386,0.005423046,0.000080999984,0.000039704686,0.00008080991,0.000074016614,0.00004370668,0.13769214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857503,0.00004631359,0.000209706,0.00038765336,0.0004452173,0.00033609188],"domain_scores_gemma":[0.9992705,0.0001133698,0.00005474229,0.00029599512,0.00012176762,0.00014362746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007157272,0.00023517279,0.00048383884,0.00011940485,0.00006115605,0.000029633222,0.000054732292,0.000057412202,0.0008628491],"category_scores_gemma":[0.00002423536,0.00016641842,0.000029948069,0.00052980345,0.000030486304,0.00010512514,0.00003229374,0.00018900917,0.00017285458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019050002,0.003965844,0.9867838,0.00017291434,0.00096568704,0.0011780761,0.0029848116,0.00000280668,0.002633627,0.000040675313,0.0004901648,0.00059111137],"study_design_scores_gemma":[0.008514337,0.000441869,0.9202186,0.004260207,0.0008760196,0.000071018774,0.00081863324,0.00012238168,0.06361588,0.000009253783,0.00057466625,0.000477166],"about_ca_topic_score_codex":0.000050461487,"about_ca_topic_score_gemma":0.0009879143,"teacher_disagreement_score":0.13029166,"about_ca_system_score_codex":0.000149278,"about_ca_system_score_gemma":0.0002549635,"threshold_uncertainty_score":0.94475925},"labels":[],"label_agreement":null},{"id":"W3127470435","doi":"10.1097/ftd.0000000000000876","title":"Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication","year":2021,"lang":"en","type":"article","venue":"Therapeutic Drug Monitoring","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; AIDS Vancouver","funders":"","keywords":"Efavirenz; Emtricitabine; Medicine; Dosing; Human immunodeficiency virus (HIV); Pharmacology; Internal medicine; Viral load; Antiretroviral therapy; Virology","score_opus":0.03912168531065941,"score_gpt":0.3072488445579075,"score_spread":0.2681271592472481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127470435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887461,0.00475344,0.0012151487,0.0034088825,0.00033657724,0.00045598397,0.00000989151,0.00014136147,0.00093260244],"genre_scores_gemma":[0.9765372,0.00017975071,0.01522577,0.0002835121,0.00030206534,0.00017900659,0.00006498244,0.0000544703,0.007173201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984251,0.0001008456,0.00039327587,0.0003681284,0.00037727127,0.00033537866],"domain_scores_gemma":[0.9987839,0.00017545391,0.00005114011,0.0007029691,0.00010341326,0.0001831129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022031352,0.00026100388,0.00036227942,0.00013165282,0.000225768,0.00009181964,0.0001436663,0.000060192095,0.00018451297],"category_scores_gemma":[0.000016665725,0.00023942858,0.000114854134,0.00037789726,0.000016697577,0.00018995289,0.00012208582,0.00020710407,0.00015228635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003784005,0.00059031334,0.61347085,0.00007203443,0.001458267,0.00016634095,0.03742014,0.00009821258,0.05778473,0.00007942539,0.00028838502,0.28819293],"study_design_scores_gemma":[0.0028180152,0.00002266317,0.8034706,0.0010668798,0.00075977674,0.000027275002,0.0022909734,0.00047898784,0.17313878,0.00085831503,0.014380513,0.0006871857],"about_ca_topic_score_codex":0.00006431424,"about_ca_topic_score_gemma":0.00006307634,"teacher_disagreement_score":0.28750575,"about_ca_system_score_codex":0.00024115776,"about_ca_system_score_gemma":0.0001257802,"threshold_uncertainty_score":0.97636145},"labels":[],"label_agreement":null},{"id":"W3133487357","doi":"10.1097/qad.0000000000002854","title":"Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; AIDS Vancouver; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institute of Mental Health; National Institutes of Health","keywords":"Integrase; Dolutegravir; Virology; Genotyping; Integrase inhibitor; Medicine; Drug resistance; Raltegravir; Genotype; Human immunodeficiency virus (HIV); Biology; Viral load; Antiretroviral therapy; Genetics; Gene","score_opus":0.010815645807876556,"score_gpt":0.25959731662934704,"score_spread":0.24878167082147049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133487357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949744,0.001571136,0.000007913524,0.0015664295,0.000050243605,0.00042142358,0.000030381601,0.000033439002,0.0013446716],"genre_scores_gemma":[0.9869406,0.0008447416,0.001286168,0.00016705442,0.000037644517,0.00009803378,0.000117380616,0.000022640386,0.010485743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988459,0.00007621679,0.00026007483,0.00036845027,0.0001952311,0.00025415287],"domain_scores_gemma":[0.9994622,0.00008659827,0.0000558653,0.00024221955,0.00005732962,0.00009578182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001104412,0.0002318589,0.00038345536,0.0002489967,0.000060388036,0.00003367202,0.0000335676,0.00008662459,0.00008673628],"category_scores_gemma":[0.00003116349,0.00016478256,0.000044732464,0.00067373697,0.00006907517,0.000117718555,0.00003070704,0.00016325287,0.000017952767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003046663,0.0008114855,0.989197,0.00002289535,0.00018198184,0.00039170583,0.0035772845,9.290371e-7,0.00031791884,0.00004596085,0.0004282073,0.0047199773],"study_design_scores_gemma":[0.013010678,0.001760252,0.937742,0.0007383963,0.00013394174,0.00006760916,0.0011989964,0.000010804639,0.030319804,0.00012330846,0.0145502975,0.00034389851],"about_ca_topic_score_codex":0.00019731592,"about_ca_topic_score_gemma":0.0016683525,"teacher_disagreement_score":0.051454972,"about_ca_system_score_codex":0.00029769013,"about_ca_system_score_gemma":0.0003130674,"threshold_uncertainty_score":0.67196375},"labels":[],"label_agreement":null},{"id":"W3134513179","doi":"10.1080/14656566.2021.1902504","title":"Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults","year":2021,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Tenofovir alafenamide; Emtricitabine; Medicine; Pre-exposure prophylaxis; Human immunodeficiency virus (HIV); Cobicistat; Tenofovir; Microbicides for sexually transmitted diseases; Prodrug; Pharmacology; Men who have sex with men; Elvitegravir; Pill; Internal medicine; Virology; Viral load; Antiretroviral therapy; Population; Environmental health; Syphilis","score_opus":0.08268813015531437,"score_gpt":0.44715164221954157,"score_spread":0.3644635120642272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134513179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022619963,0.9697819,0.000040923445,0.0017657671,0.0010056412,0.0044317357,0.000089651956,0.000047144928,0.00021732031],"genre_scores_gemma":[0.00088223023,0.99484426,0.00037153598,0.00022702901,0.00026999283,0.0008672415,0.00040428803,0.000093627765,0.0020397697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952195,0.001688099,0.0013202546,0.0006248491,0.0008177891,0.00032946275],"domain_scores_gemma":[0.9968421,0.0008911057,0.0012431061,0.000646203,0.0002754905,0.000102026024],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016149135,0.00056766625,0.0015210706,0.0004437878,0.00020271109,0.000019369003,0.00026824724,0.00018857463,0.00025819172],"category_scores_gemma":[0.00023783665,0.00031190776,0.00049375603,0.0011801857,0.0000758941,0.00006627959,0.00007940993,0.0003717936,0.000048821723],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089337,0.00096548896,0.0006666583,0.000884581,0.0010753719,0.0000049745813,0.005949724,0.00006959942,0.00052240596,0.000026409576,0.0053552096,0.9835862],"study_design_scores_gemma":[0.011389671,0.001567533,0.001501813,0.019620089,0.0005063672,0.000037945036,0.00031764427,0.0011365828,0.0055671777,0.00001785137,0.9576674,0.00066989276],"about_ca_topic_score_codex":0.00015054032,"about_ca_topic_score_gemma":0.000012659774,"teacher_disagreement_score":0.9829163,"about_ca_system_score_codex":0.0006910781,"about_ca_system_score_gemma":0.00067147793,"threshold_uncertainty_score":0.9999333},"labels":[],"label_agreement":null},{"id":"W3134682517","doi":"10.1128/aac.02406-20","title":"Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes","year":2021,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Elvitegravir; Dolutegravir; Integrase; Raltegravir; Mutant; Chemistry; Virology; Integrase inhibitor; DNA; Stereochemistry; Pharmacology; Biology; Human immunodeficiency virus (HIV); Viral load; Biochemistry; Antiretroviral therapy; Gene","score_opus":0.012325884329344589,"score_gpt":0.25600571350537527,"score_spread":0.24367982917603068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134682517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912705,0.00006973057,0.00013924901,0.0077593857,0.00006622733,0.00013933469,0.000080726764,0.000024290854,0.00045059697],"genre_scores_gemma":[0.9874462,0.0010560795,0.0015143425,0.002134038,0.00007517485,0.000002679901,0.0008777259,0.000021439924,0.0068723555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928415,0.00002081918,0.00021776132,0.00021829142,0.00011736244,0.00014164408],"domain_scores_gemma":[0.9996287,0.000024855495,0.000081649356,0.00013056763,0.000072595125,0.00006161666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003620283,0.0001433988,0.00030763893,0.00004133726,0.000058630543,0.000021527218,0.000037413156,0.000067456764,0.00056509813],"category_scores_gemma":[0.000007564799,0.00011555298,0.00009142544,0.00011838815,0.000049934373,0.000043335072,0.000019791918,0.000062761224,0.000020308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017442822,0.0008541979,0.81134176,0.00006027621,0.00085585145,0.000082776656,0.0021382137,1.9021647e-7,0.114918575,0.00008723039,0.052430965,0.017055506],"study_design_scores_gemma":[0.00424619,0.000039193248,0.6326278,0.000260722,0.00016808743,0.000015528649,0.0002226591,0.00002586356,0.33419034,0.00011462742,0.027899513,0.00018952247],"about_ca_topic_score_codex":0.00004754616,"about_ca_topic_score_gemma":0.000035024,"teacher_disagreement_score":0.21927175,"about_ca_system_score_codex":0.000032177843,"about_ca_system_score_gemma":0.000052942243,"threshold_uncertainty_score":0.6187428},"labels":[],"label_agreement":null},{"id":"W3137211483","doi":"10.1016/j.ijid.2021.03.018","title":"Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings","year":2021,"lang":"en","type":"article","venue":"International Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Resistance mutation; Dolutegravir; Medicine; Emtricitabine; Antiretroviral therapy; ANTIRETROVIRAL AGENTS; Human immunodeficiency virus (HIV); Viral load; Tenofovir; Drug resistance; Lamivudine; Virology; Internal medicine; Virus; Biology; Genetics","score_opus":0.005521465338640821,"score_gpt":0.2714505992303197,"score_spread":0.2659291338916789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137211483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985862,0.00066610944,0.0000051420434,0.00045898114,0.00010323989,0.000116903,0.000014688588,0.0000070942924,0.000041652424],"genre_scores_gemma":[0.9993335,0.00026768818,0.000092669434,0.00014934893,0.00004359403,0.00000659263,0.000013853205,0.000010945351,0.00008180361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894494,0.00008194813,0.00032158487,0.00014378819,0.00037492043,0.00013279551],"domain_scores_gemma":[0.9992,0.00014079465,0.00015811334,0.00005955958,0.00030962838,0.00013191454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012206428,0.00013648375,0.00024936,0.0003907713,0.00002553292,0.000056524685,0.000049389022,0.00003267958,0.000042930988],"category_scores_gemma":[0.000236489,0.00009332482,0.00006523212,0.00017349437,0.00006009571,0.00022563194,0.00002745082,0.00012750298,0.0000010187676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063618333,0.000730491,0.9879846,0.000013707844,0.00019948963,0.0012576965,0.0011893747,0.000010548778,0.00010596338,0.0000049389755,0.000008830606,0.0021325187],"study_design_scores_gemma":[0.009320089,0.00070044224,0.9877756,0.0009598248,0.000021381315,0.0003115714,0.0002682043,0.000018678713,0.0004315396,0.00007224569,0.000025040534,0.00009538446],"about_ca_topic_score_codex":0.000020174128,"about_ca_topic_score_gemma":0.000017367125,"teacher_disagreement_score":0.002958255,"about_ca_system_score_codex":0.00026443624,"about_ca_system_score_gemma":0.00030038838,"threshold_uncertainty_score":0.38056758},"labels":[],"label_agreement":null},{"id":"W3137565606","doi":"10.1097/qad.0000000000002883","title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Rilpivirine; Human immunodeficiency virus (HIV); Medicine; Post-hoc analysis; Internal medicine; Reverse-transcriptase inhibitor; Virology; Viral load; Antiretroviral therapy","score_opus":0.03831060326286144,"score_gpt":0.2636071792219853,"score_spread":0.22529657595912383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137565606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633396,0.00011243242,0.0012894325,0.0010964422,0.000053207248,0.00016753215,0.000012407515,0.000046629935,0.0008879612],"genre_scores_gemma":[0.976226,0.000039034232,0.015870422,0.00007025004,0.000041343148,0.000049767095,0.00006859404,0.000014223089,0.0076203835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892145,0.000037937712,0.0002622804,0.0003323356,0.00021452938,0.00023143717],"domain_scores_gemma":[0.99931115,0.00010996046,0.000059289316,0.00026204047,0.000089964386,0.00016757501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015510329,0.00016674059,0.0004925707,0.00025712824,0.00006884482,0.0000149107245,0.00004486501,0.000054438802,0.00025088846],"category_scores_gemma":[0.00020135174,0.00013146737,0.000118161355,0.0010231874,0.000027239828,0.00011068095,0.00009312888,0.00010971111,0.000024187502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003771302,0.00013519225,0.989841,0.000029365465,0.0015965463,0.00015138628,0.0010505932,0.00007314199,0.0044038906,0.000029054649,0.00018417291,0.0024679448],"study_design_scores_gemma":[0.0018341417,0.0002063707,0.9531968,0.00011911168,0.0024199854,0.00002176005,0.0014812422,0.00020158233,0.035880264,0.000012725653,0.0043919403,0.00023407312],"about_ca_topic_score_codex":0.00006152117,"about_ca_topic_score_gemma":0.000039865376,"teacher_disagreement_score":0.036644198,"about_ca_system_score_codex":0.000054899578,"about_ca_system_score_gemma":0.00006779212,"threshold_uncertainty_score":0.5361084},"labels":[],"label_agreement":null},{"id":"W3148955583","doi":"10.4021/jem34w","title":"Influence of Efavirenz and Nevirapine on the Pharmacodynamics and Pharmacokinetics of Gliclazide in Rabbits","year":2011,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gliclazide; Medicine; Pharmacokinetics; Efavirenz; Pharmacology; Pharmacodynamics; Nevirapine; Reverse-transcriptase inhibitor; Diabetes mellitus; Human immunodeficiency virus (HIV); Endocrinology; Virology; Viral load; Antiretroviral therapy","score_opus":0.02321115172852707,"score_gpt":0.2811576343942844,"score_spread":0.2579464826657573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148955583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98928297,0.0091160145,0.0000043463397,0.0010618645,0.00005933671,0.00012496651,0.0000033858228,0.0000019903634,0.00034513278],"genre_scores_gemma":[0.98058075,0.01849708,0.0005409654,0.00021677918,0.000027811395,0.0000022100394,3.9988868e-7,0.0000058765213,0.00012813698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918205,0.00006687901,0.00041165968,0.00008976914,0.00010632691,0.00014334498],"domain_scores_gemma":[0.99939317,0.000114627976,0.00025695362,0.000072360985,0.00009356014,0.00006932843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018987822,0.00011409101,0.00041445694,0.00021032362,0.000022049973,0.0000017122237,0.000055919838,0.00003699105,0.000016001339],"category_scores_gemma":[0.000070034344,0.000068527246,0.000034112523,0.000098658704,0.00023322996,0.00006246958,0.00004037822,0.00023264848,3.3542435e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042988444,0.0017667613,0.59826136,0.00044817373,0.0022650813,0.00109208,0.012077526,0.00005131133,0.24382219,0.028875383,0.00050919765,0.10653208],"study_design_scores_gemma":[0.008122751,0.00034017576,0.8463578,0.00019063549,0.000659939,0.0009022016,0.00020583476,0.000053797805,0.13552819,0.0007742055,0.006756132,0.000108317094],"about_ca_topic_score_codex":0.000010442416,"about_ca_topic_score_gemma":0.000002915103,"teacher_disagreement_score":0.24809644,"about_ca_system_score_codex":0.000005471523,"about_ca_system_score_gemma":0.000038906557,"threshold_uncertainty_score":0.279446},"labels":[],"label_agreement":null},{"id":"W3152367169","doi":"10.1371/journal.pone.0246766","title":"The impact of routine HIV drug resistance testing in Ontario: A controlled interrupted time series study","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sinai Health System; St. Michael's Hospital; Population Health Research Institute; Ontario HIV Treatment Network; McMaster University; Impact; Women's College Hospital; University Health Network; Hamilton Health Sciences; University of Toronto; Public Health Ontario; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"Department of Family and Community Medicine, University of Toronto; University of Toronto; Ontario Ministry of Health and Long-Term Care; Ontario HIV Treatment Network; Institute for Clinical Evaluative Sciences","keywords":"Interrupted Time Series Analysis; Interrupted time series; Medicine; Emergency department; Population; Public health; Human immunodeficiency virus (HIV); Drug resistance; Demography; Resistance (ecology); Emergency medicine; Family medicine; Gerontology; Pediatrics; Psychological intervention; Environmental health; Psychiatry; Nursing","score_opus":0.033838269928000056,"score_gpt":0.25658672699547697,"score_spread":0.22274845706747692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152367169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040526,0.0002339157,5.194281e-7,0.0020217127,0.000007668421,0.0008722981,0.0000034877708,0.000031131745,0.006424032],"genre_scores_gemma":[0.7746292,0.000005179209,0.0012023044,0.0000089998775,0.0000118870275,0.00006849171,0.000018385119,0.0000121887715,0.22404338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987394,0.00010564174,0.0004386624,0.00019779136,0.00030217218,0.00021633881],"domain_scores_gemma":[0.99895954,0.000337085,0.00012452561,0.0002798676,0.00023944477,0.000059526763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033006654,0.00015520802,0.000668707,0.000060884722,0.00006950126,0.000021066162,0.00006846767,0.000023836119,0.00020795701],"category_scores_gemma":[0.00070751715,0.0000947803,0.000082729726,0.00029102067,0.00003669856,0.000051049272,0.000054863052,0.00017329726,0.000033037642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003161866,0.008342,0.97102964,0.000031120297,0.0022659132,0.000314294,0.008031102,0.0000014365322,0.0061345794,0.0000073103556,0.0006303047,0.000050423783],"study_design_scores_gemma":[0.03544631,0.00055832096,0.94696254,0.0018957217,0.0009216086,0.000011912593,0.0028751947,0.00035713168,0.010541731,0.00008731376,0.00007272876,0.00026948383],"about_ca_topic_score_codex":0.0014748819,"about_ca_topic_score_gemma":0.07560983,"teacher_disagreement_score":0.21761936,"about_ca_system_score_codex":0.00035035907,"about_ca_system_score_gemma":0.00050477125,"threshold_uncertainty_score":0.9412579},"labels":[],"label_agreement":null},{"id":"W3155004931","doi":"10.1177/0956462421999931","title":"Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate– to tenofovir alafenamide–containing ART among individuals with HIV in Canada: A retrospective study","year":2021,"lang":"en","type":"article","venue":"International Journal of STD & AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Maple Leaf Medical Clinic; Women's College Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Tenofovir alafenamide; Medicine; Tenofovir; Human immunodeficiency virus (HIV); Retrospective cohort study; Cobicistat; Internal medicine; Virology; Antiretroviral therapy; Pharmacology; Viral load","score_opus":0.0065697654749128,"score_gpt":0.23779778853498015,"score_spread":0.23122802306006734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155004931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512017,0.00056783215,0.0000427195,0.0036082312,0.00013807509,0.0002900329,0.000038016296,0.0000052599007,0.00018966793],"genre_scores_gemma":[0.99697846,0.00009176739,0.00186315,0.0003728873,0.0001817166,0.000046635665,0.00002260698,0.000022746239,0.00042001056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767685,0.00010489835,0.0005991165,0.000325418,0.0010331691,0.0002605303],"domain_scores_gemma":[0.9989856,0.00009727956,0.00029482486,0.00011312943,0.00031939594,0.00018976117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047843778,0.00023788202,0.0006237264,0.00068647857,0.000034172,0.000088166336,0.00016227539,0.000043807842,0.00011640445],"category_scores_gemma":[0.00012677937,0.00017661089,0.000042944772,0.0003706074,0.00002543442,0.00030385747,0.0001300861,0.0004209048,0.0000033552947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006982871,0.00031783286,0.97865784,0.000004011143,0.0011463404,0.0066477126,0.008403644,0.000023485856,0.00025883477,0.000015780226,0.00004677537,0.003779479],"study_design_scores_gemma":[0.0046974625,0.00040475014,0.98440486,0.000754457,0.00015751406,0.00015404807,0.00801958,0.000019764018,0.00075269234,0.00008290216,0.000376307,0.00017563772],"about_ca_topic_score_codex":0.043596283,"about_ca_topic_score_gemma":0.7652805,"teacher_disagreement_score":0.7216842,"about_ca_system_score_codex":0.00087145186,"about_ca_system_score_gemma":0.0011911156,"threshold_uncertainty_score":0.9627725},"labels":[],"label_agreement":null},{"id":"W3156341605","doi":"10.1093/jac/dkab126","title":"Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir","year":2021,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Rilpivirine; Lamivudine; Drug resistance; Resistance mutation; Reverse-transcriptase inhibitor; Virology; Pharmacology; Medicine; Human immunodeficiency virus (HIV); Biology; Sida; Genetics; Virus; Reverse transcriptase; Viral load; Polymerase chain reaction; Antiretroviral therapy; Viral disease; Gene","score_opus":0.006373698283029102,"score_gpt":0.24472358784036552,"score_spread":0.2383498895573364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156341605","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95272803,0.0028823612,0.0006354314,0.040853243,0.00022563114,0.0005078849,0.000032396863,0.000027084203,0.0021079218],"genre_scores_gemma":[0.32939285,0.005906664,0.16525882,0.002650859,0.00082276994,0.000009498504,0.00006805636,0.00008524116,0.49580523],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999088,0.000024142348,0.00036895985,0.00017409949,0.00014208109,0.00020275377],"domain_scores_gemma":[0.9991276,0.00003129321,0.00021897691,0.000105040745,0.00041307733,0.00010399038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001590032,0.00016647422,0.00040649567,0.00007985689,0.00013923403,0.00004597008,0.000052646305,0.00007551049,0.000052499305],"category_scores_gemma":[0.000018014192,0.00012795033,0.00016925894,0.00019641715,0.000040067276,0.00010531828,0.000008721128,0.00020274994,0.0000028822226],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006760549,0.00042231064,0.0021418766,0.0001949449,0.00023707892,0.00008473926,0.0011562888,0.0000011464931,0.47825783,0.000022459946,0.51634485,0.00046040642],"study_design_scores_gemma":[0.0056371065,0.000086945896,0.0006253374,0.00026814092,0.00014301001,0.00051508396,0.00015829134,0.000002662463,0.69695014,0.00010145896,0.29536766,0.00014419794],"about_ca_topic_score_codex":0.0000012052865,"about_ca_topic_score_gemma":0.000008310262,"teacher_disagreement_score":0.6233352,"about_ca_system_score_codex":0.00007246297,"about_ca_system_score_gemma":0.00030222954,"threshold_uncertainty_score":0.5217663},"labels":[],"label_agreement":null},{"id":"W3158347976","doi":"10.1182/blood.v130.suppl_1.4253.4253","title":"Predictive Factors of Overall Survival and the Completion of Four Cycles of Azacitidine: An MDS-CAN Study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada; Centre hospitalier de l'Université Laval; McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; Juravinski Hospital; Queen Elizabeth II Health Sciences Centre; University of Alberta; Saskatchewan Cancer Agency; CancerCare Manitoba; Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University; Vancouver General Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Azacitidine; Medicine; Oncology; Internal medicine; Biology; DNA methylation; Genetics","score_opus":0.03766719118776251,"score_gpt":0.28532502152743017,"score_spread":0.24765783033966765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158347976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809515,0.000034191828,0.0000071891786,0.00018293542,0.000032154374,0.00050479214,0.000049667804,0.0000070698197,0.0010868172],"genre_scores_gemma":[0.99966043,0.000025089977,0.00010181247,0.0000020073053,0.000022068336,0.00000778541,0.000018116547,0.0000073221263,0.000155371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992848,0.0000639267,0.0002150114,0.00011835178,0.00023890445,0.000078976016],"domain_scores_gemma":[0.99926746,0.00008091252,0.0002241318,0.00029296384,0.00009283653,0.00004169484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021165343,0.000093925104,0.0003692591,0.000042050408,0.00007301815,0.0000060433026,0.00008490566,0.000025996773,0.000011860032],"category_scores_gemma":[0.0000779904,0.000055571643,0.000047070138,0.000021918351,0.000200765,0.000046112178,0.000048186423,0.000043812393,2.1985572e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029087614,0.0014974801,0.9915792,0.00004203127,0.0005535837,0.0000047106796,0.0044251443,4.163498e-7,0.0010882857,0.00035596054,0.000009292406,0.00015302206],"study_design_scores_gemma":[0.011568193,0.00059984723,0.9750452,0.000056663397,0.00050112547,0.0000024630804,0.0020031957,0.00002068857,0.01002552,0.00012580818,0.0000072698604,0.000044024353],"about_ca_topic_score_codex":0.00030727233,"about_ca_topic_score_gemma":0.0001366939,"teacher_disagreement_score":0.016533995,"about_ca_system_score_codex":0.000006461609,"about_ca_system_score_gemma":0.00003370606,"threshold_uncertainty_score":0.2266146},"labels":[],"label_agreement":null},{"id":"W3159995876","doi":"10.1007/s40121-021-00449-z","title":"Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV","year":2021,"lang":"en","type":"article","venue":"Infectious Diseases and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Emtricitabine; Medicine; Tenofovir alafenamide; Internal medicine; Adverse effect; Randomized controlled trial; Pharmacology; Abacavir; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.013020102288195433,"score_gpt":0.24456767852141206,"score_spread":0.23154757623321662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159995876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885914,0.010566598,0.000077959216,0.00016505753,0.0000073119445,0.000283445,0.000057229652,0.000028814267,0.0002222246],"genre_scores_gemma":[0.99419016,0.0048345877,0.000083991654,0.00004413776,0.0000070960673,0.00001742686,0.000063308435,0.00001594061,0.0007433741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908185,0.000057283658,0.00028311825,0.00026382625,0.00017048029,0.00014345525],"domain_scores_gemma":[0.99909914,0.0002867113,0.0001361473,0.0001825366,0.00014928154,0.00014616533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000802865,0.000193568,0.0009467162,0.0002430389,0.00008558452,0.000020303236,0.000019217516,0.000044662393,0.00013676415],"category_scores_gemma":[0.000029484785,0.00012097873,0.0002138494,0.0007192045,0.00010483338,0.000067371955,0.000026524654,0.000052871626,2.7162338e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020279142,0.0005350261,0.92953944,0.000058960795,0.0670727,0.000020038811,0.0007852156,0.00003378329,0.0001736937,0.00006409552,0.000006780016,0.0015074891],"study_design_scores_gemma":[0.0028909126,0.00021289263,0.93549925,0.000032575463,0.060593106,0.000017248274,0.0001235329,0.00022578513,0.0001936116,0.00003441473,0.000054582077,0.00012211113],"about_ca_topic_score_codex":0.00012409654,"about_ca_topic_score_gemma":0.00010276878,"teacher_disagreement_score":0.006479591,"about_ca_system_score_codex":0.00001627466,"about_ca_system_score_gemma":0.00011148379,"threshold_uncertainty_score":0.49333695},"labels":[],"label_agreement":null},{"id":"W3160215751","doi":"10.31083/ph.2021.0197","title":"Effect of itraconazole on the pharmacokinetics of faldaprevir in healthy subjects","year":2021,"lang":"en","type":"article","venue":"˜Die œPharmazie","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Pharmacology; Itraconazole; Medicine; Dosing; Antifungal","score_opus":0.01805841095068999,"score_gpt":0.3214406057928947,"score_spread":0.3033821948422047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160215751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985074,0.0027093953,0.0000034220434,0.004773714,0.00018826705,0.00064295426,0.000018218496,0.000021373511,0.006568664],"genre_scores_gemma":[0.9960013,0.0013489884,0.00009195439,0.00073504774,0.00006617927,0.000048291462,0.00003707022,0.000022007069,0.0016491866],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985161,0.00023468239,0.00041066678,0.00023261918,0.00033672276,0.00026921066],"domain_scores_gemma":[0.9988216,0.00059264206,0.00012275588,0.0002792918,0.000082679886,0.00010100869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004943949,0.00019544837,0.00048500267,0.00011334122,0.000033270964,0.0000043318605,0.00010139719,0.00005271402,0.00044513922],"category_scores_gemma":[0.00010618325,0.00012772395,0.00013267512,0.00032324358,0.00006408352,0.000028483832,0.00005257179,0.00023298715,0.00006307422],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017511621,0.008306823,0.44250652,0.0081595,0.0027292685,0.0032824813,0.007934866,0.00018195687,0.24883825,0.0014104211,0.05587749,0.2032608],"study_design_scores_gemma":[0.008220207,0.0007656547,0.009076288,0.0003862595,0.00025813095,0.000020495809,0.00008368927,0.00018426322,0.9642881,0.000023010012,0.016555047,0.0001388236],"about_ca_topic_score_codex":0.000014956546,"about_ca_topic_score_gemma":0.000014076646,"teacher_disagreement_score":0.71544987,"about_ca_system_score_codex":0.000075188436,"about_ca_system_score_gemma":0.00018991774,"threshold_uncertainty_score":0.52084315},"labels":[],"label_agreement":null},{"id":"W3161017411","doi":"10.1097/qad.0000000000002936","title":"Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Wellcome Trust; McMaster University","keywords":"Dolutegravir; Lamivudine; Efavirenz; Emtricitabine; Medicine; Regimen; Viral load; Reverse-transcriptase inhibitor; Virology; Integrase inhibitor; Internal medicine; Abacavir; Gastroenterology; Virus; Antiretroviral therapy; Hepatitis B virus","score_opus":0.015822460923092228,"score_gpt":0.26596752068631346,"score_spread":0.2501450597632212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161017411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930921,0.0024652916,0.000052581305,0.002443991,0.000069141955,0.0005525745,0.000022453383,0.00006946552,0.0012323818],"genre_scores_gemma":[0.987761,0.00091792515,0.0037032438,0.0005890748,0.00009896516,0.00003669208,0.0002535688,0.000041065345,0.0065984665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979842,0.000095276424,0.00058404985,0.00058809837,0.00032415517,0.00042425617],"domain_scores_gemma":[0.99884117,0.00027869045,0.00015257053,0.0004460087,0.00012972955,0.0001518458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033241426,0.00034879646,0.00075797515,0.00030019923,0.00008982847,0.000019727957,0.00010752456,0.00018316039,0.00040059473],"category_scores_gemma":[0.00021321281,0.0002686746,0.0001468795,0.0006528814,0.00014284115,0.000094171395,0.00007219854,0.00027769437,0.000033586846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005408525,0.0035278748,0.8685986,0.0005075498,0.0005924556,0.002007885,0.0016723901,0.00006474987,0.026077472,0.00044148223,0.0004936584,0.090607375],"study_design_scores_gemma":[0.12291881,0.021025697,0.55606306,0.0031617067,0.0005916924,0.00035000365,0.0013153686,0.0034243998,0.26733112,0.001066608,0.020959394,0.0017921621],"about_ca_topic_score_codex":0.00009880804,"about_ca_topic_score_gemma":0.0000853916,"teacher_disagreement_score":0.31253552,"about_ca_system_score_codex":0.00008544353,"about_ca_system_score_gemma":0.00025320714,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W3168701893","doi":"10.1007/s41669-021-00275-6","title":"Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto; University Health Network","funders":"Addis Ababa University","keywords":"Dolutegravir; Efavirenz; Human immunodeficiency virus (HIV); Medicine; Virology; Tenofovir; Second line; Pediatrics; Antiretroviral therapy; First line; Internal medicine; Viral load","score_opus":0.05826420296885351,"score_gpt":0.3741730334568439,"score_spread":0.31590883048799034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168701893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069786,0.00008077891,0.000013621799,0.0029689453,0.00017722101,0.0016365445,0.00030098922,0.00001752813,0.0041065295],"genre_scores_gemma":[0.99145615,0.00048194765,0.0018048694,0.0005633025,0.000021685344,0.00038733607,0.0022730073,0.000031811433,0.0029798604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976381,0.00016324944,0.000903931,0.00071714475,0.00017121324,0.0004063641],"domain_scores_gemma":[0.99849296,0.0003171538,0.00024756836,0.00054824457,0.00016557622,0.00022851664],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003485109,0.00035841443,0.0011690585,0.0005526785,0.000057082096,0.000043155316,0.00026385064,0.00012241075,0.0012023271],"category_scores_gemma":[0.000104667226,0.0003414692,0.0002815435,0.00090083486,0.00005999339,0.00017537996,0.00017283358,0.0002068237,0.00010582778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005740146,0.0050875973,0.97160625,0.000058348134,0.0030409489,0.00020804127,0.0016835402,0.0013303248,0.000055499702,0.00018554492,0.0006046874,0.010399065],"study_design_scores_gemma":[0.24222754,0.0018580985,0.55764884,0.00048372295,0.01079532,0.000005603702,0.0015511534,0.07815851,0.06347983,0.00019889827,0.04188877,0.0017037335],"about_ca_topic_score_codex":0.002455124,"about_ca_topic_score_gemma":0.011495701,"teacher_disagreement_score":0.41395745,"about_ca_system_score_codex":0.0012811711,"about_ca_system_score_gemma":0.000807315,"threshold_uncertainty_score":0.99990374},"labels":[],"label_agreement":null},{"id":"W3172905499","doi":"10.1089/aid.2021.0027","title":"Short Communication: Prevalence of Transmitted Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors in European and North American Countries Over 20 Years: An Updated Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"AIDS Research and Human Retroviruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Integrase inhibitor; Integrase; Virology; Resistance (ecology); Drug resistance; Reverse transcriptase; Medicine; Human immunodeficiency virus (HIV); Reverse-transcriptase inhibitor; Environmental health; Biology; Antiretroviral therapy; Sida; Viral disease; Polymerase chain reaction; Genetics; Viral load","score_opus":0.1340555047307003,"score_gpt":0.40528900597180734,"score_spread":0.271233501241107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172905499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13147147,0.866175,0.0000025075692,0.00011454692,0.000006218426,0.001289219,0.00060890464,0.000025201798,0.00030692216],"genre_scores_gemma":[0.12960945,0.86434776,0.00078627805,0.0000644966,0.000023714088,0.00011226455,0.0009107204,0.000060302747,0.0040850327],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956089,0.0012792888,0.0009678471,0.0008068775,0.0008541145,0.00048293246],"domain_scores_gemma":[0.9978094,0.00021166545,0.0001579872,0.0010774307,0.00031549446,0.00042802116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015198876,0.00042156724,0.0029191228,0.0012292375,0.00018852256,0.000113318754,0.00035468923,0.00008562502,0.00024422226],"category_scores_gemma":[0.0000613462,0.00034184937,0.00049769913,0.0027116088,0.0007934804,0.00018884146,0.00013773158,0.0006439043,0.000007399315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010626543,0.003188349,0.57979,0.03449045,0.1974197,0.0030371812,0.014003544,0.0000011324066,0.000045113196,0.0006987545,0.02967432,0.13658883],"study_design_scores_gemma":[0.00077194197,0.00089498993,0.14525607,0.0022855613,0.077241324,0.000007873317,0.0004111998,2.5717137e-7,0.000028645674,0.0000058867404,0.77250314,0.00059310463],"about_ca_topic_score_codex":0.00036332966,"about_ca_topic_score_gemma":0.005984573,"teacher_disagreement_score":0.74282885,"about_ca_system_score_codex":0.0001329678,"about_ca_system_score_gemma":0.00025712204,"threshold_uncertainty_score":0.9999034},"labels":[],"label_agreement":null},{"id":"W3175868284","doi":"10.1016/s2352-3018(21)00071-0","title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"National Institute of Allergy and Infectious Diseases; AbbVie; Gilead Sciences; Merck; Eli Lilly and Company","keywords":"Emtricitabine; Medicine; Tenofovir alafenamide; Placebo; Pre-exposure prophylaxis; Tenofovir; Human immunodeficiency virus (HIV); Randomized controlled trial; Pharmacology; Internal medicine; Antiretroviral therapy; Men who have sex with men; Virology; Viral load; Alternative medicine","score_opus":0.027452324851493348,"score_gpt":0.2935112847525631,"score_spread":0.26605895990106976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175868284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737174,0.0044764197,0.00033511495,0.0105660325,0.00016104161,0.009242033,0.00088727026,0.00008439539,0.0005302785],"genre_scores_gemma":[0.9708597,0.0019013932,0.0014022937,0.00015602306,0.0009508037,0.000753938,0.0015192884,0.00007951459,0.02237703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99651116,0.00027041574,0.0012813509,0.0008807371,0.0004392207,0.0006171262],"domain_scores_gemma":[0.99626094,0.0019629807,0.00053868536,0.0007283096,0.0002300312,0.00027902774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001246824,0.00057737593,0.002260278,0.00018886421,0.000293594,0.0001065022,0.00018517299,0.00020625195,0.00003083144],"category_scores_gemma":[0.0007758492,0.00035178775,0.00022684537,0.00037686058,0.0002709423,0.00015871951,0.00017916349,0.0003489207,0.000008708332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9794808,0.0015025702,0.0044372464,0.00028979225,0.0014953028,0.00015858116,0.0025682221,0.000008970331,0.0016780023,0.000035921934,0.0009884328,0.0073561603],"study_design_scores_gemma":[0.9812178,0.0021954298,0.010463867,0.0003584867,0.0017109929,0.00006798285,0.00012934963,0.00045019525,0.0019001053,0.00009830496,0.0010121764,0.00039530586],"about_ca_topic_score_codex":0.000018563514,"about_ca_topic_score_gemma":0.000029891024,"teacher_disagreement_score":0.02184675,"about_ca_system_score_codex":0.00009792421,"about_ca_system_score_gemma":0.00053718005,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W3179570450","doi":"10.1097/qad.0000000000003025","title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.","year":2022,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Rilpivirine; Tolerability; Regimen; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Adverse effect; Atlas (anatomy); Viral load; Virology","score_opus":0.06818869719114717,"score_gpt":0.3697766567304088,"score_spread":0.30158795953926165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179570450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958717,0.00011531084,0.000262248,0.0006035206,0.000075784956,0.002233541,0.000105136874,0.00006179108,0.0006709491],"genre_scores_gemma":[0.9726376,0.00000581212,0.008507164,0.000032384767,0.00006264786,0.0005630478,0.00041871658,0.000042301133,0.017730314],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99818105,0.00011701916,0.00045544628,0.00045427927,0.00050475064,0.00028745623],"domain_scores_gemma":[0.9988858,0.00024798908,0.00022769276,0.00039271338,0.0001463116,0.00009946393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006525152,0.00024237362,0.00050144625,0.00018382317,0.00030249418,0.000010353818,0.000068078334,0.00002352012,0.00010097094],"category_scores_gemma":[0.00013771627,0.0001715479,0.00010456347,0.0003685813,0.00003023425,0.00006149077,0.00006258735,0.00010686128,0.000008436925],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045989595,0.042882983,0.3565994,0.00019650001,0.0037795103,0.0015581608,0.031238087,0.00044648667,0.016273191,0.000043486838,0.0027383275,0.49825427],"study_design_scores_gemma":[0.4712417,0.33549783,0.045462303,0.0006289362,0.008297066,0.000500936,0.059115756,0.010611832,0.042746373,0.000085052576,0.024269523,0.0015426804],"about_ca_topic_score_codex":0.00012263507,"about_ca_topic_score_gemma":0.000024859466,"teacher_disagreement_score":0.4967116,"about_ca_system_score_codex":0.0002799391,"about_ca_system_score_gemma":0.00022796055,"threshold_uncertainty_score":0.699552},"labels":[],"label_agreement":null},{"id":"W3183049553","doi":"10.3390/microorganisms9071509","title":"Predicted Cellular Interactors of the Endogenous Retrovirus-K Integrase Enzyme","year":2021,"lang":"en","type":"article","venue":"Microorganisms","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Winnipeg","funders":"Natural Sciences and Engineering Research Council of Canada; University of Winnipeg; ALS Association","keywords":"Interactome; Biology; Integrase; Retrovirus; Helicase; Computational biology; Carcinogenesis; Cell biology; Genetics; DNA; Virus; Cancer; Gene; RNA","score_opus":0.014604665153700106,"score_gpt":0.21208774994742524,"score_spread":0.19748308479372514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183049553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947822,0.0005808714,0.00013984233,0.001304751,0.00035787508,0.00027972274,0.000046280995,0.00005626208,0.0024521842],"genre_scores_gemma":[0.98020583,0.000034458826,0.0010678006,0.00029048228,0.000060284918,0.0000070224287,0.00011959674,0.000034145305,0.018180361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887776,0.00006508834,0.00032773794,0.00025615943,0.00024307564,0.00023014568],"domain_scores_gemma":[0.9991151,0.000044838187,0.00009921036,0.0004819357,0.00016022497,0.000098711076],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007916817,0.00018523663,0.00030479796,0.000060410577,0.00007673802,0.0000149790285,0.00014062799,0.000088700166,0.0012784499],"category_scores_gemma":[0.000119194476,0.000120994366,0.00016465099,0.0003727931,0.00008138312,0.000034848916,0.00013030354,0.00021316798,0.00009493814],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038375092,0.00033899405,0.026842436,0.000041537754,0.00026581582,0.0003166827,0.0020317272,1.5663404e-7,0.9662455,0.000045041445,0.0033434862,0.0004902611],"study_design_scores_gemma":[0.0010646549,0.000058330166,0.0034097815,0.00012386272,0.00022209233,0.00024645255,0.0005133086,0.0000029915452,0.9802968,0.000034192897,0.013924701,0.00010282302],"about_ca_topic_score_codex":0.000021624788,"about_ca_topic_score_gemma":0.00001914833,"teacher_disagreement_score":0.023432655,"about_ca_system_score_codex":0.00013996623,"about_ca_system_score_gemma":0.0003452532,"threshold_uncertainty_score":0.9996345},"labels":[],"label_agreement":null},{"id":"W3183949559","doi":"10.21203/rs.3.rs-22911/v1","title":"Moderate rate of resistance mutations transmitted to antiretrovirals and genetic diversity in newly HIV-1 patients diagnosed in Benin.","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Genetic diversity; Transmission (telecommunications); Drug resistance; Human immunodeficiency virus (HIV); Mutation; Phylogenetic tree; Mutation rate; Intravenous drug; Transmission rate; HIV drug resistance; Virology; Resistance (ecology); Drug; Medicine; Biology; Genetics; Antiretroviral therapy; Environmental health; Gene; Viral load; Pharmacology; Population; Viral disease","score_opus":0.05321874925608462,"score_gpt":0.34298029650962963,"score_spread":0.289761547253545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183949559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910451,0.00034256425,0.00009086175,0.005473458,0.000022689894,0.0024347997,0.000289518,0.000018830395,0.00028216428],"genre_scores_gemma":[0.995991,0.00047208884,0.0017215217,0.00004374383,0.00001512052,0.00016130475,0.00043098547,0.000024222743,0.0011400124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974543,0.0004199082,0.00044558916,0.00062788604,0.000632963,0.00041939356],"domain_scores_gemma":[0.99876887,0.00028159708,0.00006704261,0.00029135583,0.00032485757,0.0002662748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037768457,0.00022414772,0.00059110846,0.0008039384,0.0001067505,0.000030360554,0.00016851854,0.00015858749,0.0000304373],"category_scores_gemma":[0.0004046362,0.00021952538,0.00006877787,0.00081892073,0.000096385666,0.000049124923,0.00059356843,0.0006366724,0.000020568485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010833328,0.0004975218,0.9819453,0.0013840359,0.000082205785,0.0007645099,0.011620786,0.00024842293,0.00014534386,0.000025969599,0.0010573134,0.0011452802],"study_design_scores_gemma":[0.0044602565,0.00019432874,0.99096465,0.0017564871,0.00003202336,2.452479e-7,0.0004284769,0.0005961121,0.0005959753,0.0006771448,0.00011611457,0.0001781548],"about_ca_topic_score_codex":0.00046920963,"about_ca_topic_score_gemma":0.0012497641,"teacher_disagreement_score":0.01119231,"about_ca_system_score_codex":0.00031040283,"about_ca_system_score_gemma":0.00036390012,"threshold_uncertainty_score":0.8951985},"labels":[],"label_agreement":null},{"id":"W3188150096","doi":"10.60692/hb41n-f3v45","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy","year":2019,"lang":"en","type":"article","venue":"PMC","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Efavirenz; CYP2B6; Reverse-transcriptase inhibitor; Discontinuation; Medicine; Pharmacogenetics; Guideline; Pharmacology; Adverse effect; Internal medicine; Antiretroviral therapy; Virology; Genotype; Human immunodeficiency virus (HIV); Biology; Cytochrome P450; CYP1A2; Genetics; Viral load; Pathology","score_opus":0.050297562462441846,"score_gpt":0.4199689223152229,"score_spread":0.3696713598527811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188150096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528974,0.00075764913,0.00039800623,0.0016766818,0.0002854509,0.001053591,0.000019647925,0.00004300166,0.00047623593],"genre_scores_gemma":[0.9812808,0.0007885273,0.013779383,0.0010461957,0.00023097731,0.000045480785,0.00020668967,0.000025470032,0.0025964433],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987753,0.000033684966,0.00054273295,0.00027370322,0.00014558656,0.00022898095],"domain_scores_gemma":[0.9994337,0.0001106047,0.00011568843,0.00013558293,0.00009570551,0.000108703076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004122181,0.00014565946,0.00029752144,0.00005661066,0.000054356933,0.000018330367,0.0000408933,0.000055296725,0.0002994465],"category_scores_gemma":[0.000023702702,0.00011740698,0.00008865341,0.000058119993,0.000034050994,0.000049606424,0.00002362938,0.000073565694,0.000046081568],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000362653,0.00008419817,0.8413235,0.000019199122,0.00018277312,0.0000057300135,0.00022905204,2.8876227e-7,0.0027480135,0.00005434042,0.0037814775,0.15120877],"study_design_scores_gemma":[0.05252331,0.0044623693,0.367535,0.000105887404,0.00060162635,0.000044098826,0.001578479,0.0014547211,0.04109622,0.00017752447,0.5297851,0.00063569855],"about_ca_topic_score_codex":0.000009220118,"about_ca_topic_score_gemma":0.0000034669597,"teacher_disagreement_score":0.5260036,"about_ca_system_score_codex":0.000029913079,"about_ca_system_score_gemma":0.000109256216,"threshold_uncertainty_score":0.47877178},"labels":[],"label_agreement":null},{"id":"W3188832799","doi":"10.1016/j.idnow.2021.06.283","title":"Évaluation des profils génotypiques associés à la sensibilité du VIH-1 à l’ibalizumab","year":2021,"lang":"fr","type":"article","venue":"Infectious Diseases Now","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Virology","score_opus":0.01563008267912477,"score_gpt":0.2836366562658511,"score_spread":0.26800657358672636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188832799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9080211,0.03877275,0.0005756772,0.006480555,0.0025325865,0.0011067889,0.00023226962,0.00055425183,0.04172402],"genre_scores_gemma":[0.9149788,0.005114872,0.0010635513,0.00043605434,0.0013089348,0.00018825974,0.0006471703,0.00009703065,0.076165326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963883,0.00096867396,0.000565684,0.0007259489,0.00060587487,0.00074551196],"domain_scores_gemma":[0.99718755,0.0007790897,0.00017103071,0.000513823,0.0008207755,0.0005277093],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004752142,0.00050335267,0.0006299177,0.00016058981,0.0003702189,0.00018644669,0.00007491169,0.00031463016,0.0022675467],"category_scores_gemma":[0.0017699973,0.0005025541,0.00042092404,0.00061024487,0.00035266808,0.00029734898,0.000113326685,0.00027732435,0.0015279496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011484572,0.0036802227,0.7698288,0.0008258143,0.0014407812,0.0024169008,0.002611265,0.000051445673,0.00024689687,0.001588593,0.019554542,0.1976399],"study_design_scores_gemma":[0.010286347,0.0005821659,0.8306514,0.0029439963,0.005980987,0.0015529171,0.0009898365,0.0019182726,0.013868036,0.019419398,0.11039044,0.0014161889],"about_ca_topic_score_codex":0.00011078896,"about_ca_topic_score_gemma":0.00050823804,"teacher_disagreement_score":0.1962237,"about_ca_system_score_codex":0.0013840891,"about_ca_system_score_gemma":0.0018913569,"threshold_uncertainty_score":0.9997426},"labels":[],"label_agreement":null},{"id":"W3189773485","doi":"10.7554/elife.68174","title":"Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy","year":2021,"lang":"en","type":"article","venue":"eLife","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"FP7 Health; Medical Research Council; Universiteit van Amsterdam; European Commission; ZonMw; National Institute for Health and Care Research; Amsterdam University Medical Centers","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Nevirapine; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); RNA; Virology; Nucleoside; Viral load; Regimen; Biology; Medicine; Virus; Antiretroviral therapy; Internal medicine; Genetics","score_opus":0.020835458328725073,"score_gpt":0.24672832052784932,"score_spread":0.22589286219912424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189773485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892426,0.00023090662,0.00012083242,0.007479057,0.00018949596,0.0020266785,0.00020691367,0.0001940511,0.00030947008],"genre_scores_gemma":[0.9876028,0.000032193515,0.0007222295,0.006042689,0.000073155745,0.00016510436,0.00085347064,0.000100145895,0.0044082184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99692506,0.00020916876,0.00056191225,0.00072566717,0.0010042555,0.0005739415],"domain_scores_gemma":[0.9981223,0.00009299438,0.00024085488,0.00041464303,0.0006649861,0.00046424367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004073449,0.00054972613,0.0007935724,0.00031012742,0.00028593373,0.00011370196,0.00010434207,0.00022813416,0.00025531254],"category_scores_gemma":[0.00011040067,0.00046018435,0.00019156995,0.0009959355,0.000101372454,0.0001690007,0.000019128802,0.000319648,0.000052832514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008207971,0.017823622,0.33315295,0.00018247678,0.001666969,0.0026818598,0.0069348025,0.00005567981,0.5177325,0.000012376121,0.108783506,0.0027652718],"study_design_scores_gemma":[0.052435327,0.0021333345,0.066258475,0.00091726036,0.00020155706,0.0000047855856,0.00028786933,0.0012185053,0.87002677,0.0000051356997,0.005714946,0.00079603534],"about_ca_topic_score_codex":0.000042827756,"about_ca_topic_score_gemma":0.000025053845,"teacher_disagreement_score":0.35229427,"about_ca_system_score_codex":0.00041363193,"about_ca_system_score_gemma":0.0009102583,"threshold_uncertainty_score":0.999785},"labels":[],"label_agreement":null},{"id":"W3193532577","doi":"10.1093/jac/dkab276","title":"High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations","year":2021,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; University of Otago; Gilead Sciences","keywords":"Raltegravir; Virology; Dolutegravir; Biology; Integrase inhibitor; Drug resistance; Microbiology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.008385848879589616,"score_gpt":0.23122782316325394,"score_spread":0.2228419742836643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193532577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914911,0.00030808288,0.0003513089,0.0073583922,0.00006589655,0.0002904184,0.000043341195,0.000013030413,0.00007846527],"genre_scores_gemma":[0.9296814,0.0005454534,0.06445039,0.00065275055,0.00005593383,0.0000034335105,0.000056509794,0.000040066894,0.004514068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986733,0.000053871747,0.00049803185,0.00027822965,0.00024126052,0.00025527095],"domain_scores_gemma":[0.99889433,0.00009571134,0.00023818614,0.00015205833,0.00043708016,0.000182653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015259233,0.00023919308,0.0005336701,0.0002622444,0.00009708997,0.000058270696,0.000058923808,0.00008564537,0.000014742569],"category_scores_gemma":[0.00009747077,0.00018433874,0.000057890862,0.0005259221,0.00007234815,0.00014299409,0.000016027509,0.00025019827,0.0000030525061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062674517,0.0012279664,0.8301883,0.00025115832,0.0004551933,0.0008328968,0.0042267065,0.000027627233,0.14738292,0.00010631039,0.0059547997,0.0030787257],"study_design_scores_gemma":[0.023535594,0.00027070584,0.81392515,0.0021405492,0.00014732365,0.00016349986,0.00030895104,0.000008230817,0.14572212,0.0000799505,0.013240157,0.00045776906],"about_ca_topic_score_codex":0.000016326407,"about_ca_topic_score_gemma":0.001004973,"teacher_disagreement_score":0.06409908,"about_ca_system_score_codex":0.00013440294,"about_ca_system_score_gemma":0.00029336612,"threshold_uncertainty_score":0.75171155},"labels":[],"label_agreement":null},{"id":"W3196652163","doi":"10.1016/j.bmc.2021.116369","title":"Synthesis and evaluation of squaramide and thiosquaramide inhibitors of the DNA repair enzyme SNM1A","year":2021,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Chemistry; Squaric acid; Nuclease; Thymidine; Enzyme; Nucleoside; Biochemistry; Moiety; Squaramide; Nucleoside triphosphate; DNA; Stereochemistry; Nucleotide","score_opus":0.015663566701032833,"score_gpt":0.2534867176606992,"score_spread":0.23782315095966636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196652163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087703,0.004604567,0.0000015293067,0.0023090262,0.0000623391,0.00019638872,0.0000064839146,0.000024333702,0.0019182944],"genre_scores_gemma":[0.9983626,0.00020737744,0.00017561916,0.00005563041,0.00009127064,0.000013084948,0.000011250094,0.00001496423,0.0010682116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984108,0.00006547879,0.00039148857,0.00028330175,0.0007021716,0.00014671311],"domain_scores_gemma":[0.9989524,0.00016383157,0.00017094544,0.0003380029,0.00026671734,0.000108120745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063040334,0.00016266743,0.00036424148,0.000026134,0.000051036768,0.0000038395815,0.00005508825,0.00012384706,0.00029237306],"category_scores_gemma":[0.0010736326,0.00011167894,0.000084182335,0.00021682587,0.00024209512,0.000022696711,0.00007482226,0.00012923575,0.0000014960577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007563493,0.00023019548,0.04821694,0.000982098,0.00034639338,0.000033418102,0.0010664368,3.027715e-7,0.94258434,0.00002374944,0.0015024354,0.0049380506],"study_design_scores_gemma":[0.0011606981,0.000025014588,0.033464782,0.0007323359,0.0009941327,0.00019648724,0.001269117,0.00010294867,0.9614546,0.000055480516,0.0004528627,0.00009156954],"about_ca_topic_score_codex":0.000015227482,"about_ca_topic_score_gemma":0.000005715449,"teacher_disagreement_score":0.018870221,"about_ca_system_score_codex":0.00010756975,"about_ca_system_score_gemma":0.00054013304,"threshold_uncertainty_score":0.45541352},"labels":[],"label_agreement":null},{"id":"W3196702731","doi":"10.1097/coh.0000000000000705","title":"An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors","year":2021,"lang":"en","type":"review","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University Health Centre; University Health Network","funders":"","keywords":"Reverse transcriptase; Integrase; Integrase inhibitor; Adverse effect; Virology; Human immunodeficiency virus (HIV); Medicine; Reverse-transcriptase inhibitor; Pharmacology; Chemistry; Antiretroviral therapy; Viral load; Polymerase chain reaction; Biochemistry; Gene","score_opus":0.03336055516265139,"score_gpt":0.32512920127025124,"score_spread":0.29176864610759984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196702731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010472175,0.98394126,0.00001820692,0.00015141844,0.0035664912,0.0016293791,0.00011520912,0.000055881355,0.0000500096],"genre_scores_gemma":[0.00095750997,0.9940476,0.0004518762,0.000053910055,0.00083850714,0.00019397227,0.0031625847,0.00007762238,0.00021641652],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741304,0.0003326017,0.0006938419,0.00093276275,0.00030453654,0.00032319297],"domain_scores_gemma":[0.9989243,0.00007288349,0.00021376686,0.00036674502,0.000052686246,0.00036960398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021998762,0.00070250727,0.0013713784,0.00075020717,0.00010819449,0.000059768634,0.000070775124,0.00021401166,0.00005326665],"category_scores_gemma":[0.000029375475,0.0005013982,0.00020702265,0.00067570014,0.00008694743,0.00019914506,0.000033532728,0.0006740872,0.000022403858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105583706,0.0010620196,0.0028696102,0.02412924,0.00022538683,0.00014344556,0.0004395161,9.27876e-7,0.000010343102,0.0003048359,0.020910183,0.9497989],"study_design_scores_gemma":[0.0031465595,0.0007469307,0.00013849253,0.034802824,0.00084379624,0.000109297376,0.00008562456,0.000019048375,0.000026660573,0.0000032476448,0.9595122,0.00056535413],"about_ca_topic_score_codex":0.0000035456442,"about_ca_topic_score_gemma":0.000006355114,"teacher_disagreement_score":0.94923353,"about_ca_system_score_codex":0.00011941817,"about_ca_system_score_gemma":0.00029742887,"threshold_uncertainty_score":0.99974376},"labels":[],"label_agreement":null},{"id":"W3196726451","doi":"10.1097/coh.0000000000000701","title":"The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy","year":2021,"lang":"en","type":"review","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Polypharmacy; Medicine; Integrase inhibitor; Adverse effect; Intensive care medicine; Dosing; Pharmacy; Pharmacology; Drug; Health care; Efavirenz; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Family medicine","score_opus":0.1160170922071356,"score_gpt":0.40318970362960005,"score_spread":0.2871726114224644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196726451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014558157,0.9953282,0.0000077438335,0.00014360255,0.0020243118,0.0006309221,0.000023028326,0.000012363593,0.0003739996],"genre_scores_gemma":[0.0048045963,0.993331,0.000041386444,0.0000022351637,0.0001215709,0.00012479872,0.0003455709,0.00001639217,0.0012124104],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862194,0.00017516971,0.0006586665,0.0002906278,0.00011948899,0.00013412171],"domain_scores_gemma":[0.99927247,0.00023981385,0.00021708553,0.00017458848,0.000038267404,0.000057792513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024385603,0.000237517,0.00078851526,0.0003143865,0.00007318201,0.000018481867,0.000046688667,0.000060566108,0.000014991016],"category_scores_gemma":[0.000044214466,0.00015544059,0.00016701053,0.00037478152,0.000098873265,0.00010819817,0.000053109667,0.00044395291,0.0000032945193],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003826289,0.00027970827,0.016958464,0.003417814,0.00012583405,0.0000038447806,0.00061119645,4.717824e-8,5.2705457e-7,0.00056041154,0.002366093,0.9756378],"study_design_scores_gemma":[0.0010363669,0.000059267208,0.00078932755,0.026918845,0.000051479863,0.000037620805,0.00079331413,0.000010408832,0.0000014315989,0.000016872735,0.97015923,0.00012584096],"about_ca_topic_score_codex":0.000032706088,"about_ca_topic_score_gemma":0.000009564431,"teacher_disagreement_score":0.97551197,"about_ca_system_score_codex":0.0001277352,"about_ca_system_score_gemma":0.0002609785,"threshold_uncertainty_score":0.63386834},"labels":[],"label_agreement":null},{"id":"W3196876339","doi":"10.1177/135965350801302s03","title":"The World Health Organization's global strategy for prevention and assessment of HIV drug resistance","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Developing country; Public health; Resource (disambiguation); Human immunodeficiency virus (HIV); Environmental health; Antiretroviral therapy; Economic growth; Viral load; Family medicine; Nursing; Surgery; Computer science","score_opus":0.029745058370603223,"score_gpt":0.3470594945262849,"score_spread":0.31731443615568167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196876339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95275086,0.003670816,0.002189381,0.034392413,0.0000994224,0.001683837,0.000025698384,0.000058753398,0.0051288344],"genre_scores_gemma":[0.9209571,0.0037483086,0.0048523513,0.00010507461,0.000033322827,0.000018871397,0.00005926292,0.000010550251,0.07021517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934185,0.00004444494,0.00019654255,0.00013709794,0.00014132568,0.00013874639],"domain_scores_gemma":[0.999604,0.00005238261,0.00011011751,0.00011498794,0.00008562979,0.00003287174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015232034,0.000091379865,0.00017686312,0.000023626117,0.00024070666,0.000010922878,0.000039189315,0.000015475625,0.000009461793],"category_scores_gemma":[0.0000068606696,0.000058938425,0.000035722842,0.00023912397,0.000066059205,0.00005430143,0.0000077228,0.000036847385,0.0000013794842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057988946,0.0008649944,0.79898924,0.000120269135,0.0004955463,0.000011953247,0.0009194648,0.0000015983132,0.00044798784,0.039888002,0.092989124,0.06469192],"study_design_scores_gemma":[0.007506915,0.00032724073,0.82363075,0.00020225217,0.000038077607,0.000012324417,0.00028535168,0.00006557441,0.006024171,0.0028357815,0.15885244,0.00021914976],"about_ca_topic_score_codex":0.000003853634,"about_ca_topic_score_gemma":0.00016142939,"teacher_disagreement_score":0.06586331,"about_ca_system_score_codex":0.000063530635,"about_ca_system_score_gemma":0.00025859062,"threshold_uncertainty_score":0.24034393},"labels":[],"label_agreement":null},{"id":"W3197105112","doi":"10.22541/au.162995857.74770313/v1","title":"Efficacy, effectiveness, and safety of integrase inhibitors in the treatment of HIV/AIDS in patients with tuberculosis: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dolutegravir; Raltegravir; Efavirenz; Integrase inhibitor; Tuberculosis; Internal medicine; Emtricitabine; Meta-analysis; Clinical trial; Observational study; Coinfection; Virology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Pathology","score_opus":0.02435665989541336,"score_gpt":0.3016166321714728,"score_spread":0.2772599722760594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197105112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089970604,0.9899431,0.000002678086,0.000069729176,0.000005164416,0.008962918,0.00006690298,0.000007731748,0.00004206267],"genre_scores_gemma":[0.0012829064,0.9964582,0.00016161766,0.000014044963,0.0000022497445,0.0014126597,0.00037545848,0.000029214949,0.00026369767],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959767,0.0013467919,0.0015750941,0.0005038095,0.0004167674,0.0001808229],"domain_scores_gemma":[0.9974459,0.001259462,0.0005165064,0.00059762906,0.00011156359,0.00006898692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010122436,0.000598674,0.011983352,0.00068228354,0.000019476456,0.00001025628,0.00008166996,0.00012764076,0.000031018324],"category_scores_gemma":[0.00013319778,0.00023233623,0.0012321819,0.002227548,0.00007894316,0.000034843935,0.000034948393,0.00012584249,0.0000024272842],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050234317,0.0019914869,0.0061047277,0.77220225,0.21228054,0.00004672948,0.000458023,2.6927927e-7,5.557393e-9,0.0000347985,0.000012242448,0.006818713],"study_design_scores_gemma":[0.0020834203,0.00042803268,0.0012976099,0.15926181,0.8359812,0.000007653025,0.00012465345,4.440624e-7,0.0000012576835,6.0534853e-7,0.0006276379,0.00018567068],"about_ca_topic_score_codex":0.00006255697,"about_ca_topic_score_gemma":0.00011900334,"teacher_disagreement_score":0.6237007,"about_ca_system_score_codex":0.00020703794,"about_ca_system_score_gemma":0.00014288319,"threshold_uncertainty_score":0.9474396},"labels":[],"label_agreement":null},{"id":"W3197919879","doi":"10.1097/coh.0000000000000703","title":"Renal adverse drug reactions","year":2021,"lang":"en","type":"review","venue":"Current Opinion in HIV and AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Tenofovir alafenamide; Adverse effect; Renal function; Kidney disease; Internal medicine; Nephrotoxicity; Intensive care medicine; Human immunodeficiency virus (HIV); Kidney; Antiretroviral therapy; Immunology; Viral load","score_opus":0.08407169046312456,"score_gpt":0.3891782671093819,"score_spread":0.30510657664625734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197919879","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000064548676,0.99591243,0.000014797242,0.0001854245,0.0022823424,0.0005859317,0.000050003637,0.0000384303,0.00092417886],"genre_scores_gemma":[0.0000018974313,0.98556936,0.00040183845,0.0000041605567,0.00052209664,0.00019380332,0.002246423,0.00002980011,0.011030642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983171,0.0001086234,0.00062468677,0.00048242213,0.00021860581,0.00024853507],"domain_scores_gemma":[0.9992508,0.00010239901,0.00015197997,0.0002751515,0.00004246337,0.00017715906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017626536,0.0003671244,0.0012393345,0.000389404,0.00007287752,0.00001913268,0.00006343915,0.00013395592,0.00022345172],"category_scores_gemma":[0.000048891103,0.00028148838,0.0003265756,0.00045430395,0.000049343522,0.00006285925,0.000083948486,0.0004992988,0.0001444358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000514244,0.0003031374,0.0006329376,0.015321818,0.00015195356,0.000019733716,0.00014905693,9.040881e-8,4.0291685e-8,0.0008022603,0.035725065,0.94688874],"study_design_scores_gemma":[0.0007198662,0.000017127943,0.000039704944,0.06297055,0.00033602622,0.0000867019,0.000056477955,0.0000023525308,2.7748436e-7,0.000011745447,0.9355264,0.00023280986],"about_ca_topic_score_codex":0.000002475157,"about_ca_topic_score_gemma":5.427024e-7,"teacher_disagreement_score":0.9466559,"about_ca_system_score_codex":0.00016608834,"about_ca_system_score_gemma":0.00042375334,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W3201398398","doi":"","title":"A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.","year":2021,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Elvitegravir; Raltegravir; Dolutegravir; Emtricitabine; Cobicistat; Renal function; Urology; Tenofovir alafenamide; Medicine; Creatinine; Ritonavir; Pharmacology; Internal medicine; Gastroenterology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology","score_opus":0.05459871068159821,"score_gpt":0.3156500497431734,"score_spread":0.2610513390615752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201398398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932094,0.00006785951,0.000045627887,0.0004106769,0.000071687726,0.005418644,0.00010983304,0.00003196739,0.0006343027],"genre_scores_gemma":[0.99196756,0.0000121842995,0.00039115894,0.000068483205,0.000028073457,0.0015526277,0.00047807294,0.000052976815,0.005448854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996882,0.00027888297,0.00091354747,0.0005832879,0.00079355086,0.0005487374],"domain_scores_gemma":[0.9980088,0.00026030306,0.000571855,0.0005381993,0.0004204177,0.00020044069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076062995,0.00045139508,0.00090642244,0.00039178546,0.00014903223,0.00007458713,0.00025184956,0.00009645338,0.0000596218],"category_scores_gemma":[0.00046765475,0.00022142848,0.0001025828,0.0021006786,0.00017981925,0.0003126102,0.00013538485,0.0003754124,0.0000063556668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027151462,0.051724583,0.78592306,0.00014718459,0.0011814208,0.00027475617,0.0028373133,0.000018169161,0.0008277504,0.00020273955,0.0006487467,0.12906279],"study_design_scores_gemma":[0.07880511,0.015083379,0.90112025,0.0003112494,0.0005000046,0.000018871873,0.0013482731,0.0004077311,0.0018414006,0.000199268,0.000037818885,0.00032663456],"about_ca_topic_score_codex":0.00045363232,"about_ca_topic_score_gemma":0.0007518299,"teacher_disagreement_score":0.12873615,"about_ca_system_score_codex":0.0006067039,"about_ca_system_score_gemma":0.00079204346,"threshold_uncertainty_score":0.9029591},"labels":[],"label_agreement":null},{"id":"W3202083716","doi":"10.1016/j.cbi.2021.109688","title":"1,2,3-Triazole derivatives: synthesis, docking, cytotoxicity analysis and in vivo antimalarial activity","year":2021,"lang":"en","type":"article","venue":"Chemico-Biological Interactions","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universidade Federal de Juiz de Fora; Fundação de Amparo à Pesquisa do Estado de Minas Gerais; Centre for Blood Research, University of British Columbia; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Plasmodium berghei; In silico; In vivo; Antimalarial Agent; Plasmodium falciparum; Docking (animal); Pharmacology; Cytotoxicity; Chloroquine; Hemolysis; Chemistry; In vitro; Biochemistry; Biology; Malaria; Medicine; Immunology","score_opus":0.03359017070248488,"score_gpt":0.3138602364129706,"score_spread":0.28027006571048574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202083716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353707,0.00006282274,0.00031964423,0.0016308954,0.000063270614,0.00016108583,0.000032386914,0.000056316523,0.004136536],"genre_scores_gemma":[0.99691606,0.00018680113,0.0012872813,0.000110166635,0.000077509416,0.00007332321,0.000058958813,0.000007498335,0.0012824184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988483,0.0000842602,0.00026611262,0.00045610528,0.00010194083,0.00024327253],"domain_scores_gemma":[0.9989751,0.0005412325,0.00008507702,0.00019878238,0.00007705003,0.00012274152],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011261222,0.00019347612,0.0005278462,0.00017907057,0.00009757428,0.00003395049,0.000051996532,0.00014203988,0.001467442],"category_scores_gemma":[0.0007045043,0.00014917787,0.00019089473,0.0006836243,0.000098138786,0.00011330962,0.000099185534,0.00032015212,0.000016967453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023503485,0.0008142698,0.28492424,0.000013511589,0.00081673195,0.00012932438,0.00016280384,0.0000035138055,0.71192604,0.00004014948,0.0002783858,0.0006559493],"study_design_scores_gemma":[0.0005981163,0.000018383498,0.15206383,0.000050378152,0.00033592133,0.000055445875,0.00021412315,0.0002691258,0.8442369,0.0000414468,0.001961712,0.00015459218],"about_ca_topic_score_codex":0.000025594158,"about_ca_topic_score_gemma":0.00007809223,"teacher_disagreement_score":0.13286042,"about_ca_system_score_codex":0.00016452359,"about_ca_system_score_gemma":0.00006304654,"threshold_uncertainty_score":0.9994454},"labels":[],"label_agreement":null},{"id":"W3207677309","doi":"10.1097/qad.0000000000003085","title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Rilpivirine; Dosing; Medicine; Dolutegravir; Adverse effect; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Clinical endpoint; Clinical trial; Virology; Antiretroviral therapy","score_opus":0.018537715999332904,"score_gpt":0.2898791553787556,"score_spread":0.2713414393794227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207677309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959964,0.0009869786,0.00042707653,0.0016261949,0.00010870481,0.00032859354,0.000021363361,0.000022519422,0.00048214846],"genre_scores_gemma":[0.97061104,0.000054348282,0.022180002,0.00027698293,0.00007841133,0.00005511846,0.000065795524,0.000025641315,0.00665268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991597,0.000022531356,0.000202884,0.00024920036,0.00016275278,0.0002029249],"domain_scores_gemma":[0.9994905,0.00006892219,0.00003968129,0.00019884823,0.00008579907,0.00011622293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012478487,0.00012995259,0.00029856295,0.000072624774,0.00004153706,0.000020160127,0.0000351473,0.000054353073,0.00012527227],"category_scores_gemma":[0.000053973723,0.00010731871,0.00006918802,0.00016911775,0.000022992415,0.00006541115,0.00004677148,0.0000676817,0.0000115710745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014227337,0.0003469399,0.6592725,0.00012740068,0.00029986678,0.00042887096,0.0041410006,0.0000046397236,0.018187352,0.00003672689,0.0032180373,0.31251395],"study_design_scores_gemma":[0.009989643,0.0007454636,0.72568583,0.0007018372,0.0002490375,0.000056076922,0.0009681078,0.00007467057,0.15622719,0.00010909662,0.10477551,0.00041754858],"about_ca_topic_score_codex":0.000018580533,"about_ca_topic_score_gemma":0.000013567121,"teacher_disagreement_score":0.31209642,"about_ca_system_score_codex":0.00003133728,"about_ca_system_score_gemma":0.000078825164,"threshold_uncertainty_score":0.437633},"labels":[],"label_agreement":null},{"id":"W3208432497","doi":"10.1021/acsmedchemlett.1c00428","title":"2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing","year":2021,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; AIDS Vancouver; Université de Sherbrooke; Simon Fraser University; University of British Columbia","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Michael Smith Health Research BC","keywords":"Human immunodeficiency virus (HIV); Messenger RNA; Chemistry; Computer science; Combinatorial chemistry; Virology; Medicine; Biochemistry","score_opus":0.020942398719257183,"score_gpt":0.2777294264691316,"score_spread":0.25678702774987444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208432497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812613,0.0017849607,0.00040339213,0.015220521,0.00006335517,0.00021667559,0.00003463433,0.00008867184,0.0009264686],"genre_scores_gemma":[0.9945357,0.00010531677,0.0018467656,0.0014705806,0.00024429252,0.000025891622,0.00078532856,0.00004895049,0.0009371651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972492,0.000051399093,0.0005654238,0.0005781742,0.0009909774,0.0005648587],"domain_scores_gemma":[0.998444,0.00014625666,0.00029730963,0.0005103742,0.0002114272,0.000390602],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003130356,0.00045263136,0.00085190166,0.00013274449,0.00009840833,0.000030247138,0.00019063668,0.00015722046,0.00036729578],"category_scores_gemma":[0.00017482339,0.00036117143,0.00027050095,0.000577981,0.00024750945,0.00009678293,0.00005704053,0.00039640197,0.000019650925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018170637,0.00038445008,0.14112875,0.0013014275,0.0005004722,0.0023032834,0.0008146436,0.000054633612,0.8443035,5.374392e-7,0.0069772666,0.0020493348],"study_design_scores_gemma":[0.0039739828,0.000042476895,0.02596638,0.0016161929,0.00068276655,0.0002979048,0.0009291293,0.00019352521,0.96481496,0.000005208942,0.0011253122,0.00035215658],"about_ca_topic_score_codex":0.000018874383,"about_ca_topic_score_gemma":0.0000013634095,"teacher_disagreement_score":0.120511465,"about_ca_system_score_codex":0.00034380853,"about_ca_system_score_gemma":0.0008704896,"threshold_uncertainty_score":0.999884},"labels":[],"label_agreement":null},{"id":"W3209378758","doi":"10.1002/pds.5379","title":"Do contemporary antiretrovirals increase the risk of end‐stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design","year":2021,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; McGill University; University of Calgary; McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Institute on Aging; National Eye Institute; National Institute on Drug Abuse; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Institute on Minority Health and Health Disparities; National Center for Research Resources; National Institute of General Medical Sciences; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; National Institutes of Health","keywords":"Atazanavir; Medicine; Darunavir; Efavirenz; Emtricitabine; Coinfection; Hazard ratio; Lamivudine; Internal medicine; Hepatitis C; Liver disease; Cohort; Abacavir; Hepatitis B; Raltegravir; Antiretroviral therapy; Virology; Viral load; Human immunodeficiency virus (HIV); Confidence interval; Chronic hepatitis","score_opus":0.07004946016774118,"score_gpt":0.3664767678041334,"score_spread":0.29642730763639225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209378758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040735,0.0037064368,0.000062774714,0.00420267,0.00003414382,0.0011214057,0.00029113697,0.000011335705,0.00016272445],"genre_scores_gemma":[0.9864715,0.010921972,0.00029263666,0.0017018423,0.00005281621,0.000088341934,0.00032193027,0.000012015246,0.00013697166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99112475,0.007356133,0.0005353235,0.00041614007,0.00029845108,0.0002692234],"domain_scores_gemma":[0.9890628,0.010057321,0.00026943558,0.00026071226,0.00020777965,0.00014199385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005704382,0.00018968538,0.00051009574,0.00010079099,0.00029751725,0.000015302145,0.00009732221,0.00003663614,0.000057257694],"category_scores_gemma":[0.0015274106,0.000104494124,0.00004952368,0.00047304682,0.00050446467,0.000090987494,0.00006219621,0.00040623115,0.000003854736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035993068,0.00044485324,0.98197687,0.000016515081,0.0002785088,0.00008297694,0.0022124315,0.000027767299,0.00012737377,0.00006743708,0.0029848537,0.008181105],"study_design_scores_gemma":[0.0026363092,0.0003177667,0.9929939,0.000047118003,0.00009597169,5.918132e-7,0.001018461,0.00045487712,0.00081439933,0.00021981982,0.0012997251,0.00010109577],"about_ca_topic_score_codex":0.0011208964,"about_ca_topic_score_gemma":0.000117985175,"teacher_disagreement_score":0.011016994,"about_ca_system_score_codex":0.000045752255,"about_ca_system_score_gemma":0.0002552857,"threshold_uncertainty_score":0.42611465},"labels":[],"label_agreement":null},{"id":"W3216594878","doi":"10.7326/m21-3037","title":"Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity","year":2021,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases; Fogarty International Center; National Heart, Lung, and Blood Institute; U.S. National Library of Medicine; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; National Institutes of Health; amfAR, The Foundation for AIDS Research","keywords":"Dolutegravir; Human immunodeficiency virus (HIV); Pregnancy; Population; MEDLINE; Reproductive health; Young adult","score_opus":0.044978935227145515,"score_gpt":0.3325274828947344,"score_spread":0.28754854766758886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216594878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964334,0.0045421305,0.000017282582,0.0046080304,0.00008410279,0.00025960975,0.000027488513,0.000009617283,0.00080842915],"genre_scores_gemma":[0.9973927,0.0006460585,0.0003059877,0.00037660796,0.00015851881,0.000027485903,0.000021106653,0.000016860864,0.0010546577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998299,0.00007839931,0.0006638403,0.00035876376,0.00034543243,0.00025456847],"domain_scores_gemma":[0.9990116,0.00020371856,0.00019791644,0.00021842074,0.00027659175,0.00009175427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004304641,0.00022149917,0.0008057937,0.0002463724,0.000018126244,0.000008761815,0.00006304971,0.00006557446,0.00009481156],"category_scores_gemma":[0.00038523303,0.00015431306,0.000052400817,0.00023614809,0.00048783657,0.00011225836,0.00006309343,0.00022585246,0.000001416819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024499656,0.00020191618,0.98378694,0.0011664436,0.00026662234,0.003240983,0.008021171,0.0000015246812,0.00029421595,0.00016916024,0.000050387738,0.0003506503],"study_design_scores_gemma":[0.0041351006,0.00054429355,0.9083737,0.029119957,0.00008193435,0.00020151808,0.0022335616,0.00001039426,0.05484655,0.00014299009,0.00015260497,0.00015738765],"about_ca_topic_score_codex":0.00071141304,"about_ca_topic_score_gemma":0.0017238517,"teacher_disagreement_score":0.07541326,"about_ca_system_score_codex":0.000039202343,"about_ca_system_score_gemma":0.00011878558,"threshold_uncertainty_score":0.62927043},"labels":[],"label_agreement":null},{"id":"W32280133","doi":"10.1155/2000/640718","title":"Pharmacokinetic Interaction between Zidovudine and Trimethoprim/sulphamethoxazole in HIV‐1 Infected Children","year":2000,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Pharmacokinetics; Zidovudine; Medicine; Trimethoprim; Pharmacology; Metabolite; Oral administration; Drug; Human immunodeficiency virus (HIV); Antibiotics; Internal medicine; Chemistry; Virology; Viral disease","score_opus":0.005829457037355148,"score_gpt":0.2602789270920584,"score_spread":0.25444947005470325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W32280133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383616,0.0025848462,0.000026996231,0.0029555995,0.000117125084,0.0001817124,0.00003796771,0.000009638632,0.00024994594],"genre_scores_gemma":[0.997749,0.0010017717,0.0001016193,0.0005678431,0.00022653349,0.0000034665293,0.00007015156,0.000012219446,0.00026739427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894154,0.00013307302,0.0004131484,0.00016919935,0.000060574697,0.0002824346],"domain_scores_gemma":[0.99849486,0.00014925185,0.00009064914,0.00006112627,0.000059505535,0.001144633],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020841067,0.00015782051,0.00045332423,0.00044662968,0.000065002496,0.00001466346,0.0000464942,0.00014053378,0.001703776],"category_scores_gemma":[0.00023509396,0.00012400674,0.00007242287,0.00018749316,0.0001982473,0.00006029583,0.000010467848,0.00035001093,0.000010195274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061452476,0.000076503326,0.85629356,0.000018297174,0.00019940137,0.0002540657,0.00012349029,9.921359e-7,0.00029220976,0.0000042946085,0.001463428,0.14121233],"study_design_scores_gemma":[0.0070700385,0.00037191474,0.9599423,0.00026281562,0.0003989855,0.004822827,0.000026277161,0.000013771285,0.0002168854,0.00006983013,0.026639821,0.00016453206],"about_ca_topic_score_codex":0.00082899415,"about_ca_topic_score_gemma":0.00068957586,"teacher_disagreement_score":0.1410478,"about_ca_system_score_codex":0.00014467158,"about_ca_system_score_gemma":0.0007453904,"threshold_uncertainty_score":0.9992088},"labels":[],"label_agreement":null},{"id":"W338559656","doi":"10.1177/135965350801300116","title":"Characterization of drug Resistance in Antiretroviral-Treated Patients Infected with HIV-1 CRF02_AG and AGK Subtypes in Mali and Burkina Faso","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"U.S. Public Health Service","keywords":"Efavirenz; Nevirapine; Stavudine; Virology; Lamivudine; Drug resistance; Zidovudine; Genotype; Reverse transcriptase; Population; Internal medicine; Medicine; Didanosine; Cohort; Biology; Viral load; Viral disease; Human immunodeficiency virus (HIV); Antiretroviral therapy; Polymerase chain reaction; Virus; Genetics; Gene","score_opus":0.0077590531039058944,"score_gpt":0.2155871698676818,"score_spread":0.2078281167637759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W338559656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988309,0.00019491753,0.000002887346,0.0002168014,0.000011137527,0.00044500333,0.00000934466,0.000020671103,0.00026832765],"genre_scores_gemma":[0.99539965,0.00224045,0.00015594786,0.00003722453,0.0000076679835,0.000013292809,0.00016709385,0.000017135155,0.001961554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991906,0.000054123862,0.00022457959,0.00022688763,0.00014044603,0.00016332694],"domain_scores_gemma":[0.99969965,0.00002308133,0.000092971495,0.000104186685,0.00004976485,0.000030362316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058814057,0.00016129816,0.00032031102,0.00020820882,0.00003671427,0.000007014133,0.000025930096,0.00004941417,0.0000064343362],"category_scores_gemma":[0.000007677076,0.00011946656,0.000015876607,0.00037331725,0.00010817473,0.00015279565,0.000011070158,0.00007357276,0.0000021015214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012034137,0.00031608742,0.97798365,0.000030549814,0.000031111842,0.00007206891,0.0017511236,2.6417904e-8,0.017401429,0.000012304984,0.000017998094,0.001180209],"study_design_scores_gemma":[0.005687553,0.00018752819,0.9669538,0.00022153942,0.000008878043,0.000002837119,0.000019915888,0.0000071877994,0.026555665,0.0000075222624,0.00022642642,0.000121103665],"about_ca_topic_score_codex":0.000055759785,"about_ca_topic_score_gemma":0.00013047984,"teacher_disagreement_score":0.011029835,"about_ca_system_score_codex":0.000029637256,"about_ca_system_score_gemma":0.000034661683,"threshold_uncertainty_score":0.48717052},"labels":[],"label_agreement":null},{"id":"W401659393","doi":"","title":"Determinants of HIV drug resistance testing in British Columbia","year":2009,"lang":"en","type":"dissertation","venue":"Summit (Simon Fraser University)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Resistance (ecology); Drug resistance; HIV drug resistance; Drug; Medicine; Virology; Pharmacology; Biology; Antiretroviral therapy; Genetics; Viral load; Ecology","score_opus":0.009428574809201931,"score_gpt":0.21880329746640526,"score_spread":0.20937472265720333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W401659393","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97172153,0.0002784787,5.40639e-7,0.000049597627,0.00009595125,0.0004379624,0.000042935942,0.000051603027,0.027321417],"genre_scores_gemma":[0.40944174,0.00013814165,0.00082952186,0.000014057976,0.00002081868,0.0000013317791,0.00057922944,0.000026603419,0.58894855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985357,0.000046871522,0.0003490309,0.0004551855,0.00030942846,0.0003037719],"domain_scores_gemma":[0.99907476,0.00007368305,0.00027106187,0.0002523832,0.00020477743,0.00012333819],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000090872,0.00020676848,0.00062885875,0.00037278092,0.000101081314,0.000036306257,0.00018931896,0.00022846,0.0001029624],"category_scores_gemma":[0.00008044139,0.00035741783,0.00012193239,0.00093731715,0.000040472332,0.000120891884,0.000021834563,0.0002802065,0.000020810041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014767477,0.00025004573,0.95420575,0.0003416623,0.000046875797,0.0035554273,0.00006864779,4.7542324e-7,0.0000033991616,0.0000019787335,0.03466847,0.006709586],"study_design_scores_gemma":[0.006529704,0.000079051046,0.8541048,0.009619824,0.00067192386,1.2238293e-7,0.026126046,0.000025176121,0.0013839701,0.000099224875,0.10048215,0.00087801216],"about_ca_topic_score_codex":0.0028227381,"about_ca_topic_score_gemma":0.97406906,"teacher_disagreement_score":0.9712463,"about_ca_system_score_codex":0.0003094658,"about_ca_system_score_gemma":0.00040292804,"threshold_uncertainty_score":0.99988776},"labels":[],"label_agreement":null},{"id":"W4200083317","doi":"10.1097/qad.0000000000003069","title":"Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Institute on Aging; National Eye Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities; National Center for Research Resources; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); Lentivirus; Sida; Integrase inhibitor; Integrase; Viral disease; Immunopathology; Viral load","score_opus":0.016224129390643854,"score_gpt":0.25777551069758237,"score_spread":0.2415513813069385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200083317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978171,0.0002007404,0.000313225,0.00066433963,0.00010415804,0.00024750893,0.0000056081158,0.00009494297,0.0005523793],"genre_scores_gemma":[0.98608726,0.000022617673,0.0091483565,0.0006630742,0.000058472135,0.000018852837,0.00010862314,0.000028850056,0.0038638944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887085,0.000053424777,0.00020493008,0.0003251444,0.0002729743,0.00027269713],"domain_scores_gemma":[0.99938536,0.000056152174,0.00006114394,0.00028221164,0.00009695055,0.00011818767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008348037,0.00023363343,0.00037154925,0.00011351835,0.00008489543,0.000025940628,0.000051173316,0.00008438276,0.00020815969],"category_scores_gemma":[0.00003880283,0.00014375699,0.0001164693,0.00030544572,0.00009596813,0.000084008694,0.000022449303,0.0001587805,0.00004066705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032570568,0.00035812362,0.99196804,0.000019282159,0.00021628746,0.0008914718,0.00025496056,0.000005823686,0.00118497,0.00002485875,0.00019410148,0.0045563676],"study_design_scores_gemma":[0.021488328,0.0021453998,0.86475736,0.000657852,0.00038273004,0.000081644015,0.0012575253,0.0011364787,0.105694875,0.000029295028,0.001752079,0.0006164468],"about_ca_topic_score_codex":0.000044504726,"about_ca_topic_score_gemma":0.000015467956,"teacher_disagreement_score":0.1272107,"about_ca_system_score_codex":0.00009246205,"about_ca_system_score_gemma":0.00022502817,"threshold_uncertainty_score":0.58622396},"labels":[],"label_agreement":null},{"id":"W4200312451","doi":"10.1089/apc.2021.0118","title":"Uptake Success and Cost Savings from Switching to a Two-Drug Antiretroviral Regimen","year":2021,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Medicine; Lamivudine; Regimen; Tolerability; Drug; Viral load; Internal medicine; Intensive care medicine; Human immunodeficiency virus (HIV); Pharmacology; Virology; Adverse effect; Chronic hepatitis; Virus","score_opus":0.00899946119897782,"score_gpt":0.25673992251779754,"score_spread":0.24774046131881972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200312451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452186,0.002032371,0.000044667857,0.00018635594,0.00015551929,0.0003544518,0.000041444382,0.000043608263,0.0026197364],"genre_scores_gemma":[0.9933175,0.0001306632,0.0041832407,0.00050055975,0.00007351324,0.000031568292,0.00023341729,0.000022080916,0.0015074528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987611,0.000035000678,0.00024095665,0.00043833128,0.00026656198,0.00025803168],"domain_scores_gemma":[0.99928945,0.000058799713,0.000048395064,0.00022380028,0.00012523182,0.0002543331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005214087,0.00020738998,0.00034534538,0.00009530821,0.00015170367,0.000073967654,0.00004132325,0.00004832588,0.000052497828],"category_scores_gemma":[0.000041077576,0.00017489708,0.00005607309,0.0001951578,0.000023090257,0.00010890379,0.00013670915,0.00012224079,0.000015527223],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007648739,0.000057022316,0.40744922,0.000037714974,0.00011238727,0.00027198787,0.014573718,3.9732308e-7,0.0009988,0.00006484871,0.0007923547,0.5755651],"study_design_scores_gemma":[0.051554907,0.0776495,0.40039635,0.00691912,0.0036593063,0.0005358465,0.1462425,0.00045057025,0.12973663,0.00091330725,0.1766288,0.0053131715],"about_ca_topic_score_codex":0.00037893959,"about_ca_topic_score_gemma":0.0001846519,"teacher_disagreement_score":0.5702519,"about_ca_system_score_codex":0.00008139544,"about_ca_system_score_gemma":0.00009254053,"threshold_uncertainty_score":0.7132096},"labels":[],"label_agreement":null},{"id":"W4200447938","doi":"10.1093/ofid/ofab466.1072","title":"877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes","year":2021,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Rilpivirine; Medicine; Population; Internal medicine; Regimen; Human immunodeficiency virus (HIV); Viral load; Virology; Antiretroviral therapy; Environmental health","score_opus":0.011397384306848361,"score_gpt":0.3088464482955847,"score_spread":0.2974490639887364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200447938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444026,0.00039924728,0.00010831729,0.001644329,0.00004905364,0.00068873947,0.00004202034,0.00009678422,0.0025312426],"genre_scores_gemma":[0.99579775,0.00041172322,0.00026126805,0.0007539743,0.000019215608,0.00009974864,0.00014476375,0.00003142423,0.0024801253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985518,0.000057765687,0.00025034888,0.0005460497,0.00020809445,0.0003859615],"domain_scores_gemma":[0.99895847,0.00015656163,0.00013243532,0.00030598536,0.00007293984,0.00037362755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004656474,0.00031167184,0.0005912363,0.000076569326,0.0004024337,0.00018530834,0.00008691855,0.000028753053,0.00010740273],"category_scores_gemma":[0.00013697801,0.00021969512,0.000058821865,0.00036096404,0.00029169337,0.00024607294,0.00029453178,0.00011996723,0.000014022689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004760726,0.00097569847,0.9457659,0.000024176543,0.00025562974,0.00066799007,0.00035220294,0.000003858985,0.000015612351,0.000039119914,0.00010359549,0.051320117],"study_design_scores_gemma":[0.007402969,0.00070494565,0.986381,0.000059199352,0.000324232,0.00028136777,0.00095728796,0.000023536519,0.0001716226,0.00001368684,0.0033709416,0.00030921906],"about_ca_topic_score_codex":0.00026958328,"about_ca_topic_score_gemma":0.0018967806,"teacher_disagreement_score":0.051010896,"about_ca_system_score_codex":0.00007401149,"about_ca_system_score_gemma":0.00017462557,"threshold_uncertainty_score":0.8958907},"labels":[],"label_agreement":null},{"id":"W4200502653","doi":"10.1097/qad.0000000000003025","title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Rilpivirine; Tolerability; Regimen; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Phases of clinical research; Adverse effect; Clinical trial; Virology","score_opus":0.07318126596459043,"score_gpt":0.3788883562795782,"score_spread":0.3057070903149878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200502653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959415,0.00021119973,0.0006575873,0.00080968224,0.00006601458,0.001427079,0.000047108,0.00004850007,0.0007912935],"genre_scores_gemma":[0.95723176,0.000019739504,0.023452993,0.000030455474,0.00008428245,0.00017502149,0.00036443345,0.000036517875,0.018604772],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99829394,0.00008370868,0.00047366103,0.0004858658,0.00038326267,0.0002795451],"domain_scores_gemma":[0.99864125,0.00025838864,0.00017844615,0.00043654337,0.00036521672,0.00012017389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040736687,0.00025246892,0.00055633945,0.00010865618,0.00012322547,0.000015446907,0.00004072528,0.00004330198,0.00004414143],"category_scores_gemma":[0.00027167978,0.00016999393,0.00011216919,0.0003183641,0.000030427113,0.000064067266,0.00003259208,0.00007213139,0.000015466649],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018505184,0.035687916,0.2744079,0.00029601203,0.0040020915,0.003156509,0.018220028,0.00008997996,0.033926185,0.000041016687,0.0011050918,0.6105621],"study_design_scores_gemma":[0.38176566,0.12464643,0.0692547,0.0022082443,0.008765377,0.0005219596,0.030784851,0.0048783273,0.3660966,0.000072953844,0.009673723,0.0013311853],"about_ca_topic_score_codex":0.0000638267,"about_ca_topic_score_gemma":0.00006220486,"teacher_disagreement_score":0.6092309,"about_ca_system_score_codex":0.00017584478,"about_ca_system_score_gemma":0.0003461302,"threshold_uncertainty_score":0.69321513},"labels":[],"label_agreement":null},{"id":"W4200619631","doi":"10.1093/ofid/ofab466.1095","title":"900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study)","year":2021,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Regimen; Internal medicine; Human immunodeficiency virus (HIV); Population; Intention-to-treat analysis; Dolutegravir; Gastroenterology; Viral load; Randomized controlled trial; Antiretroviral therapy; Immunology","score_opus":0.013681325840387924,"score_gpt":0.310759673922971,"score_spread":0.29707834808258304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200619631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98021865,0.00008595556,0.0008382096,0.009679249,0.00023445317,0.0038038944,0.000027785176,0.00014706275,0.0049647335],"genre_scores_gemma":[0.99154055,0.00001065951,0.0008614121,0.0040829815,0.000042228196,0.0009705136,0.00016798096,0.00006586244,0.0022578214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971808,0.00020332997,0.00059773045,0.000868786,0.0004595049,0.00068984675],"domain_scores_gemma":[0.9984587,0.00019492969,0.00017097326,0.0005964471,0.00018751895,0.00039144632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003315885,0.000436539,0.0007789787,0.0003151337,0.00035559371,0.00032680784,0.0002557198,0.00011398828,0.00035983778],"category_scores_gemma":[0.0004648292,0.00039303265,0.00015656282,0.00086347066,0.000020981819,0.00042675532,0.0006154216,0.00025685204,0.00019570919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084531825,0.004556269,0.96772164,0.000056465633,0.0002132837,0.0010462734,0.006315264,0.000182788,0.0017555937,0.00010796713,0.0066289823,0.010570138],"study_design_scores_gemma":[0.041913882,0.005418243,0.8866725,0.0035695035,0.0009739333,0.000088382585,0.022111317,0.0015017004,0.018024096,0.001597393,0.016261237,0.0018677926],"about_ca_topic_score_codex":0.00050467387,"about_ca_topic_score_gemma":0.0008308595,"teacher_disagreement_score":0.08104914,"about_ca_system_score_codex":0.0005641023,"about_ca_system_score_gemma":0.00034533069,"threshold_uncertainty_score":0.9998522},"labels":[],"label_agreement":null},{"id":"W4205239019","doi":"10.1097/01.idc.0000090390.89010.9c","title":"Enfurvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America","year":2002,"lang":"en","type":"article","venue":"Infectious Diseases in Clinical Practice","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Regimen; Viral load; Internal medicine; Human immunodeficiency virus (HIV); Drug resistance; Antiretroviral therapy; Randomized controlled trial; Gastroenterology; Immunology","score_opus":0.03132352717077874,"score_gpt":0.35199784088312114,"score_spread":0.3206743137123424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205239019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926138,0.00048136865,0.00013110833,0.0026615597,0.00032406257,0.001192359,0.000052543048,0.0001427262,0.002400474],"genre_scores_gemma":[0.994924,0.0015449378,0.00092382793,0.0010150182,0.00033319715,0.0002196752,0.00011861948,0.000041615764,0.00087912387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719214,0.00041785178,0.0010420451,0.00066818815,0.00030723872,0.00037256134],"domain_scores_gemma":[0.9962278,0.0025291706,0.00035214378,0.00035397263,0.00015014847,0.00038678528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005011373,0.00028235995,0.00055702694,0.00030284765,0.00014345904,0.000059943523,0.000056099536,0.00014108342,0.00011693977],"category_scores_gemma":[0.0061539514,0.0002553986,0.00015808287,0.0005683374,0.00015375105,0.00055967557,0.00007258093,0.00045408506,0.00012637817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012855999,0.005278883,0.9619553,0.00008906547,0.000084293155,0.00017252572,0.00076033495,0.000032699063,0.0000047041176,0.00003230385,0.0021979127,0.028106367],"study_design_scores_gemma":[0.009822979,0.00097084115,0.93757504,0.00015121105,0.000504152,0.000033659166,0.0003488844,0.0018540794,0.0000063373304,0.00013047196,0.048226297,0.0003760475],"about_ca_topic_score_codex":0.00017621944,"about_ca_topic_score_gemma":0.0011845257,"teacher_disagreement_score":0.046028383,"about_ca_system_score_codex":0.00022305136,"about_ca_system_score_gemma":0.000111787755,"threshold_uncertainty_score":0.9999898},"labels":[],"label_agreement":null},{"id":"W4206403922","doi":"10.1093/jac/dkab498","title":"Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study","year":2021,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; AIDS Vancouver; Simon Fraser University","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase; Virology; Biology; Integrase inhibitor; Virus; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.020298847117569484,"score_gpt":0.3152648389863508,"score_spread":0.29496599186878136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206403922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936203,0.000060510232,0.0016701688,0.0038459073,0.00009346768,0.00050406967,0.000051136332,0.000008111975,0.00014637967],"genre_scores_gemma":[0.99307376,0.000098076525,0.005979973,0.00025266898,0.00003501483,0.000003016673,0.000027081654,0.000030594314,0.00049983326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789155,0.0001159552,0.0012686894,0.000197373,0.0003551584,0.00017125532],"domain_scores_gemma":[0.9983232,0.00013046822,0.00029515254,0.00023632575,0.0008340029,0.00018086191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034688483,0.0002236729,0.0007514117,0.00029151712,0.00004432088,0.000017806751,0.00012316131,0.00007971183,0.000107837775],"category_scores_gemma":[0.00017054914,0.00016930778,0.00054277625,0.00055890356,0.0000740325,0.000074280324,0.000008767948,0.00028675055,0.0000032333999],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010992378,0.031885643,0.07136645,0.0001418845,0.0050533023,0.00089032925,0.0107880775,0.00027656285,0.85908574,0.00013497908,0.0059884014,0.0033962636],"study_design_scores_gemma":[0.0487063,0.005832959,0.059577923,0.00236988,0.0010962663,0.00012055051,0.0016830734,0.000014698529,0.8796319,0.0001383682,0.00042502198,0.00040310103],"about_ca_topic_score_codex":0.00000956464,"about_ca_topic_score_gemma":0.000049177772,"teacher_disagreement_score":0.037713923,"about_ca_system_score_codex":0.0001466612,"about_ca_system_score_gemma":0.0007452344,"threshold_uncertainty_score":0.69041705},"labels":[],"label_agreement":null},{"id":"W4206602596","doi":"10.1038/s41598-021-03958-6","title":"DNA binding by the antimalarial compound artemisinin","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Natural Sciences and Engineering Research Council of Canada; Fonds Wetenschappelijk Onderzoek; Vlaamse regering; York University","keywords":"Artemisinin; Malaria; Plasmodium falciparum; Computational biology; DNA; Computer science; Virology; Biology; Genetics; Immunology","score_opus":0.015932096399232248,"score_gpt":0.2541505134831981,"score_spread":0.23821841708396588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206602596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786608,0.0001383881,0.0000131062525,0.0045799883,0.006397545,0.0004945178,0.000008867889,0.0000745128,0.009632236],"genre_scores_gemma":[0.83160824,0.0000011002251,0.00016912066,0.00007395801,0.00006478509,0.00005091283,0.0003755921,0.000013426417,0.16764286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99790895,0.000059166254,0.00036801898,0.0005150067,0.0008631038,0.00028576766],"domain_scores_gemma":[0.9990492,0.00003871476,0.00017808794,0.0005866267,0.000046067198,0.00010134606],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015728308,0.00012339411,0.00018629213,0.000112880705,0.0013230552,0.00015470324,0.00009850812,0.000022508286,0.0012133279],"category_scores_gemma":[0.000050668183,0.00008388949,0.00009416054,0.0005320199,0.00016354768,0.000058456535,0.00014739833,0.00017176665,0.00007489698],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003141046,0.00027446877,0.023703594,0.000008701418,0.00009341626,0.002140447,0.0010317547,0.0000041838994,0.04591285,0.000056498106,0.9257771,0.0009655853],"study_design_scores_gemma":[0.00058709073,0.00003844734,0.00073253183,0.000016463957,0.00008353554,0.0026928184,0.00059137994,0.00006244615,0.020608524,0.00035165492,0.97409546,0.00013962289],"about_ca_topic_score_codex":0.000006476579,"about_ca_topic_score_gemma":0.000001808311,"teacher_disagreement_score":0.15801063,"about_ca_system_score_codex":0.00015358158,"about_ca_system_score_gemma":0.00025986004,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W4207018194","doi":"10.1093/cid/ciac036","title":"Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"ViiV Healthcare","keywords":"Tenofovir alafenamide; Dolutegravir; Medicine; Discontinuation; Regimen; Internal medicine; Adverse effect; Lamivudine; Population; Tolerability; Viral load; Emtricitabine; Immunology; Human immunodeficiency virus (HIV); Virus; Hepatitis B virus; Antiretroviral therapy","score_opus":0.03473619077966352,"score_gpt":0.35916907759688704,"score_spread":0.32443288681722354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207018194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935142,0.0004201745,0.00032561045,0.000646454,0.00032584142,0.0042848308,0.0003297744,0.000060190647,0.000092961855],"genre_scores_gemma":[0.99850947,0.00019226891,0.00038038506,0.00012849817,0.0000904567,0.0003719147,0.00019148641,0.000028618848,0.00010691537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965853,0.0007516487,0.0014176305,0.00058575184,0.00033552834,0.00032412438],"domain_scores_gemma":[0.9869646,0.011596998,0.00070647075,0.00045486132,0.00015525067,0.000121830824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016582054,0.00029584212,0.0014135161,0.000096874865,0.00029044648,0.000019706265,0.00017602436,0.00007137088,0.00003842174],"category_scores_gemma":[0.007375756,0.00016527553,0.0002677386,0.00040562492,0.00028396776,0.00008433207,0.00019192103,0.00032556584,9.863088e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9754558,0.005404665,0.01375304,0.00005549352,0.00031006694,0.00003395057,0.0019479514,0.000105465944,0.00049845385,0.000052802872,0.00019964043,0.002182672],"study_design_scores_gemma":[0.9544334,0.00943408,0.031804025,0.0013124209,0.00088136544,0.0000020484183,0.0005881205,0.00071399735,0.00015253879,0.000106764506,0.00032126432,0.00024997597],"about_ca_topic_score_codex":0.00057760515,"about_ca_topic_score_gemma":0.00035287195,"teacher_disagreement_score":0.021022398,"about_ca_system_score_codex":0.00012765468,"about_ca_system_score_gemma":0.00029719635,"threshold_uncertainty_score":0.88300014},"labels":[],"label_agreement":null},{"id":"W4210254172","doi":"10.3390/v14020273","title":"High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort","year":2022,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; Public Health Agency of Canada; University of Manitoba","funders":"Canadian Institutes of Health Research; Max Rady College of Medicine, University of Manitoba; University of Manitoba; Manitoba Medical Service Foundation","keywords":"Human leukocyte antigen; Drug resistance; Integrase; Allele; Medicine; Cohort; Immunology; Population; Antiretroviral therapy; Human immunodeficiency virus (HIV); Gene; Biology; Virology; Viral load; Genetics; Internal medicine; Antigen","score_opus":0.02779437296411999,"score_gpt":0.2585526450482999,"score_spread":0.2307582720841799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210254172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942616,0.00044734345,0.000004230932,0.0038059042,0.000053413303,0.0007501791,0.00012680954,0.000030293899,0.0005201758],"genre_scores_gemma":[0.9683841,0.0003864744,0.00018053426,0.0001987121,0.00002800273,0.00029936366,0.00015307218,0.00001482456,0.030354949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987358,0.0001596154,0.00023786529,0.00021821864,0.0004844837,0.00016405483],"domain_scores_gemma":[0.99934113,0.00025825098,0.00016690063,0.00015218969,0.00004607774,0.000035447327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033899763,0.00013647485,0.00024393525,0.00011939252,0.00012975957,0.00001266097,0.000052058247,0.000036495443,0.00004764091],"category_scores_gemma":[0.000054697815,0.00008660754,0.000024453877,0.00041689223,0.00001795657,0.000068293164,0.000025017865,0.0001205378,0.000008189347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063392264,0.0005417099,0.981796,0.000019010622,0.00029814884,0.00005816034,0.002686592,0.000026892396,0.00047142748,0.00016426129,0.013127696,0.00017615357],"study_design_scores_gemma":[0.0033301741,0.0001673131,0.9394634,0.000076760414,0.00025824347,0.0000052523455,0.0010491904,0.000030536474,0.0048234765,0.00003141763,0.05062882,0.00013543919],"about_ca_topic_score_codex":0.0001667916,"about_ca_topic_score_gemma":0.00055544515,"teacher_disagreement_score":0.04233265,"about_ca_system_score_codex":0.0005923415,"about_ca_system_score_gemma":0.00013483196,"threshold_uncertainty_score":0.3531753},"labels":[],"label_agreement":null},{"id":"W4210301895","doi":"10.1093/cid/ciac086","title":"Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort","year":2022,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; University of Kentucky; Gilead Sciences; ViiV Healthcare; Eli Lilly and Company","keywords":"Dolutegravir; Medicine; Tenofovir alafenamide; Human immunodeficiency virus (HIV); Antiretroviral therapy; Guideline; Virology; Cohort; Family medicine; Viral load; Internal medicine","score_opus":0.06325531741392115,"score_gpt":0.3910461156022266,"score_spread":0.3277907981883054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210301895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398905,0.0016501442,0.000039316,0.00018454163,0.0004030434,0.0031258531,0.0004970137,0.000058168684,0.00005289703],"genre_scores_gemma":[0.9938127,0.0009899093,0.0000046224823,0.00009051403,0.00011359317,0.0015631615,0.0031353666,0.000031968983,0.000258198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602634,0.0013227401,0.0009865223,0.00049294654,0.00062705827,0.0005443774],"domain_scores_gemma":[0.9952795,0.003561466,0.00024585656,0.00055967335,0.0002295652,0.00012393607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021440086,0.00026315617,0.0006972117,0.0001671314,0.0008121355,0.00006698594,0.00029931293,0.000057833466,0.00010320287],"category_scores_gemma":[0.000351991,0.00013565739,0.00030672314,0.0012516505,0.00046393633,0.000051139563,0.00012520963,0.00057030574,0.00000678837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066193455,0.0041952245,0.9886642,0.000031443025,0.00051197986,0.000024804478,0.0011060813,0.00039449078,0.0000015506199,0.000058539026,0.0036308942,0.00071884063],"study_design_scores_gemma":[0.0054127197,0.0064463504,0.9753068,0.00026452268,0.00066483376,0.0000022422985,0.0044820975,0.0007705356,0.0000028206061,0.000104166196,0.0063824793,0.00016043491],"about_ca_topic_score_codex":0.0053757983,"about_ca_topic_score_gemma":0.00077203626,"teacher_disagreement_score":0.01335742,"about_ca_system_score_codex":0.0005407143,"about_ca_system_score_gemma":0.00041717433,"threshold_uncertainty_score":0.8126635},"labels":[],"label_agreement":null},{"id":"W4210416276","doi":"10.2196/26891","title":"An Android-Based Mobile App (ARVPredictor) for the Detection of HIV Drug-Resistance Mutations and Treatment at the Point of Care: Development Study","year":2022,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"mHealth; Android (operating system); Point of care; Internet privacy; License; World Wide Web; Health care; Computer science; Medicine; Nursing; Operating system","score_opus":0.025744942351780188,"score_gpt":0.35733223140826925,"score_spread":0.33158728905648904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210416276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217856,0.0007175698,0.00031983032,0.00082252343,0.00003310475,0.00563648,0.00012370957,0.000018421735,0.00014979346],"genre_scores_gemma":[0.9867608,0.00002059164,0.00019068376,0.0000072301114,0.000011536932,0.009900492,0.0001398722,0.000014780624,0.0029539885],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9981449,0.0002968913,0.0003481246,0.00020354416,0.0007624648,0.0002440764],"domain_scores_gemma":[0.99849945,0.0006644041,0.00011829101,0.00031722186,0.00032839342,0.00007223261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009126002,0.00013399338,0.00023628034,0.00019671682,0.0011279027,0.000014227656,0.00012601937,0.000018575356,0.00005439366],"category_scores_gemma":[0.000020449224,0.00007348858,0.000064844935,0.0004055247,0.00021092908,0.00007111056,0.00009937688,0.0001381606,0.0000029018775],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008062228,0.0090652015,0.040289238,0.0007673121,0.0017201317,0.000020557844,0.8598732,0.0006600103,0.00604601,0.00012574178,0.0032354482,0.07013492],"study_design_scores_gemma":[0.022318128,0.009859444,0.13622233,0.00013462988,0.00035406134,0.000015065974,0.48881346,0.0036674726,0.24086604,0.00007376966,0.09730495,0.000370666],"about_ca_topic_score_codex":0.000023246717,"about_ca_topic_score_gemma":0.0006118952,"teacher_disagreement_score":0.37105975,"about_ca_system_score_codex":0.0008719576,"about_ca_system_score_gemma":0.00037414982,"threshold_uncertainty_score":0.867503},"labels":[],"label_agreement":null},{"id":"W4210486996","doi":"10.1080/14656566.2022.2029409","title":"An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV","year":2022,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Dolutegravir; Medicine; Abacavir; Lamivudine; Emtricitabine; Tolerability; Pharmacology; Fixed-dose combination; Integrase inhibitor; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy; Adverse effect; Hepatitis B virus; Virus","score_opus":0.26138356818045766,"score_gpt":0.51806958953392,"score_spread":0.25668602135346236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210486996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004832964,0.98905283,0.00012238773,0.0009929147,0.0013583638,0.007858644,0.00031008566,0.000043004846,0.00021342137],"genre_scores_gemma":[0.000032670792,0.9887853,0.00060989306,0.00021211068,0.00054653495,0.005876545,0.0019308218,0.0001240269,0.0018820632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968239,0.0004205342,0.000895851,0.00059144787,0.00097390177,0.0002943783],"domain_scores_gemma":[0.9979877,0.0004482534,0.00050610374,0.00073369365,0.00016613943,0.00015810825],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007674562,0.0005970106,0.0016459095,0.00040001993,0.00015400602,0.000012024151,0.00029115065,0.000118595206,0.0017587614],"category_scores_gemma":[0.00001668348,0.0003455075,0.0007799998,0.00041798886,0.00004965177,0.00004904707,0.000014462664,0.0001285339,0.000025404708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006792976,0.0016672873,0.0000033980032,0.00044590383,0.0016799171,0.0000012358034,0.0030399049,0.000011487133,0.00011037722,0.00007362877,0.006666015,0.9856216],"study_design_scores_gemma":[0.006861893,0.0020121448,0.0000035032983,0.0011527592,0.00068055035,0.000007924894,0.00021009574,0.0003156048,0.0016522165,0.000007681909,0.9868141,0.0002815388],"about_ca_topic_score_codex":0.000016881588,"about_ca_topic_score_gemma":9.0408554e-7,"teacher_disagreement_score":0.98534,"about_ca_system_score_codex":0.000569546,"about_ca_system_score_gemma":0.0006593283,"threshold_uncertainty_score":0.9998997},"labels":[],"label_agreement":null},{"id":"W4210592442","doi":"10.1021/acs.jmedchem.1c01913","title":"Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase","year":2022,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Chemistry; Moiety; Linker; Farnesyl pyrophosphate; Stereochemistry; Pyrophosphate; Biochemistry; In vivo; ATP synthase; Enzyme","score_opus":0.0206177107558329,"score_gpt":0.27392990759084096,"score_spread":0.25331219683500805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210592442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681634,0.0010767767,0.000003087388,0.0014484586,0.0001684239,0.00019944174,0.000016554031,0.000004646534,0.0002662708],"genre_scores_gemma":[0.99952424,0.000026695077,0.00016933841,0.000036281075,0.000103943064,0.000008861217,0.0000071543363,0.000011456288,0.00011204053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972705,0.00010206362,0.0006698734,0.00013427484,0.0016891271,0.00013414804],"domain_scores_gemma":[0.99825174,0.0001375804,0.0008242354,0.00019651253,0.00046286144,0.00012709778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012939915,0.00015769931,0.0004584903,0.000098168806,0.0001664688,0.00000433349,0.00015997523,0.000052537103,0.0007644107],"category_scores_gemma":[0.0003999171,0.00010149829,0.00016956143,0.00024930062,0.00021416477,0.000049242597,0.000061682214,0.0003312076,1.6664796e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001075416,0.00051567337,0.03865145,0.000654578,0.0006353924,0.00019528519,0.0013281786,0.00047846884,0.9496758,0.000009403361,0.0011591685,0.0056211865],"study_design_scores_gemma":[0.00547856,0.0001424402,0.017861502,0.0007062503,0.0020061089,0.00031966477,0.0015856016,0.00031791866,0.9712495,0.000058267575,0.00016487669,0.0001092974],"about_ca_topic_score_codex":0.0000136067065,"about_ca_topic_score_gemma":7.280288e-7,"teacher_disagreement_score":0.021573713,"about_ca_system_score_codex":0.00024177947,"about_ca_system_score_gemma":0.0006395116,"threshold_uncertainty_score":0.8369761},"labels":[],"label_agreement":null},{"id":"W4210921298","doi":"10.1093/ofid/ofac067","title":"Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study","year":2022,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Clinique Paro Excellence","funders":"Janssen Research and Development; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Bristol-Myers Squibb; Shionogi; Abbott Laboratories","keywords":"Rilpivirine; Medicine; Drug; Pharmacology; Pharmacotherapy; Intensive care medicine; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.008686091588122195,"score_gpt":0.2831361867598051,"score_spread":0.27445009517168295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210921298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610496,0.00077039533,0.0000016622868,0.0004843326,0.00005145443,0.0018674552,0.000104572486,0.000021831038,0.00059332384],"genre_scores_gemma":[0.99739134,0.0002823937,0.000016431903,0.00010673141,0.000006497995,0.00018054727,0.00004059493,0.000020649515,0.0019547872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880296,0.00012308972,0.00030670085,0.00032255848,0.00024995476,0.00019474045],"domain_scores_gemma":[0.99930406,0.00008952363,0.000119915356,0.00029974335,0.00005562163,0.00013116862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020380205,0.00016784272,0.00047379447,0.000087826884,0.00012549797,0.000024716775,0.00010367967,0.000017294005,0.00040845855],"category_scores_gemma":[0.00004717542,0.00013910109,0.00007173956,0.00018363932,0.00015035385,0.00009869834,0.0004382458,0.00009121795,0.0000032973662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028535181,0.0035086803,0.9699091,0.00004106976,0.0003029261,0.00011460528,0.0007367647,0.0000023671603,0.000017961462,0.000045076147,0.00019427351,0.022273716],"study_design_scores_gemma":[0.008533145,0.0011092348,0.9885506,0.00004163218,0.00016996091,0.000041355666,0.0004534469,0.0000023760185,0.00006951068,0.00016991151,0.0007260681,0.00013272752],"about_ca_topic_score_codex":0.00052894367,"about_ca_topic_score_gemma":0.0003575576,"teacher_disagreement_score":0.022140987,"about_ca_system_score_codex":0.00007699708,"about_ca_system_score_gemma":0.00012460267,"threshold_uncertainty_score":0.5672378},"labels":[],"label_agreement":null},{"id":"W4211077933","doi":"10.1016/j.bjid.2021.101719","title":"TROCA PARA A COMBINAÇÃO DE DOSE FIXA DE DOLUTEGRAVIR/LAMIVUDINA É NÃO INFERIOR A UM REGIME BASEADO EM TENOFOVIR ALAFENAMIDA NA MANUTENÇÃO DA SUPRESSÃO VIROLÓGICA POR 144 SEMANAS (ESTUDO TANGO)","year":2022,"lang":"pt","type":"article","venue":"The Brazilian Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Dolutegravir; Physics; Medicine; Human immunodeficiency virus (HIV); Tenofovir; Gynecology; Antiretroviral therapy; Viral load; Virology","score_opus":0.01317014428473982,"score_gpt":0.26324836460889106,"score_spread":0.2500782203241512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211077933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97538996,0.011334627,0.00035328662,0.008711343,0.0009802049,0.0018305529,0.00047162385,0.00020709631,0.0007213101],"genre_scores_gemma":[0.97870374,0.0013346877,0.00013916018,0.0018487957,0.0006422137,0.00029848897,0.00012488973,0.00021775944,0.016690295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9916989,0.0019738413,0.0018674167,0.00081862696,0.0018103878,0.0018308315],"domain_scores_gemma":[0.994003,0.0008914312,0.001733279,0.0012849555,0.00042542614,0.0016619015],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018106669,0.0012346774,0.0018879127,0.00090966467,0.0021579938,0.00038877272,0.0012614494,0.00023315586,0.0023836729],"category_scores_gemma":[0.00064649637,0.0009384677,0.001416053,0.001252602,0.00050989777,0.0004955056,0.0006507319,0.0019017995,0.00019706303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010879344,0.016206788,0.78840184,0.0010186575,0.01154803,0.024820438,0.025284028,0.0013146732,0.0014675088,0.00060050405,0.099087335,0.019370839],"study_design_scores_gemma":[0.044266872,0.011559137,0.8325481,0.0028727034,0.017722948,0.019847164,0.028001351,0.0023634469,0.00056638115,0.0034495268,0.03381071,0.002991676],"about_ca_topic_score_codex":0.00019345907,"about_ca_topic_score_gemma":0.00011993392,"teacher_disagreement_score":0.06527663,"about_ca_system_score_codex":0.0026981793,"about_ca_system_score_gemma":0.0031312227,"threshold_uncertainty_score":0.99930656},"labels":[],"label_agreement":null},{"id":"W4213206827","doi":"10.1093/cid/ciac136","title":"Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Center for AIDS Research, University of North Carolina at Chapel Hill; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Harvard University Center for AIDS Research","keywords":"Vorinostat; Medicine; Tamoxifen; Oncology; Internal medicine; Viremia; Clinical trial; Zidovudine; Immunology; Pharmacology; Human immunodeficiency virus (HIV); Breast cancer; Cancer; Histone; Biology; Viral disease; Histone deacetylase","score_opus":0.13499400826791808,"score_gpt":0.470558162529907,"score_spread":0.33556415426198893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213206827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952285,0.00025992058,0.0000022289796,0.00013620277,0.0011756887,0.0024477758,0.0001264288,0.000114919385,0.00050833536],"genre_scores_gemma":[0.9974956,0.0004051411,0.000004337844,0.00046050086,0.0005519481,0.0006258312,0.000105675455,0.000052684,0.00029831007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99044275,0.004635636,0.0027856687,0.00075881823,0.00081196247,0.00056518085],"domain_scores_gemma":[0.992406,0.0053598736,0.00092320103,0.00089626864,0.00006985518,0.0003447634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00648709,0.00043314364,0.0018486825,0.00032920088,0.00042811438,0.00004233796,0.00033158026,0.00019247184,0.0008282375],"category_scores_gemma":[0.004023346,0.00025523454,0.001597505,0.0005794406,0.00026555735,0.00008711342,0.00020788235,0.001031037,0.00003861211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063127615,0.028803317,0.8475173,0.000014787261,0.00065229484,0.000088805326,0.0003916162,0.000028736593,0.0009368812,0.00010865546,0.0014006952,0.056929268],"study_design_scores_gemma":[0.093391664,0.062193893,0.84244055,0.00010687872,0.00019653357,0.0000018168778,0.00016451665,0.000021434795,0.00017109363,0.0004896879,0.00053851807,0.000283429],"about_ca_topic_score_codex":0.00008379893,"about_ca_topic_score_gemma":0.000004255561,"teacher_disagreement_score":0.056645837,"about_ca_system_score_codex":0.00046506996,"about_ca_system_score_gemma":0.0005326486,"threshold_uncertainty_score":0.99999},"labels":[],"label_agreement":null},{"id":"W4214555329","doi":"10.1177/20503121221081335","title":"Treatment failure and its associated factors among children receiving highly active antiretroviral therapy in Ethiopia: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"SAGE Open Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Odds ratio; Confidence interval; Meta-analysis; Funnel plot; Publication bias; Cochrane Library; MEDLINE; Internal medicine; Pediatrics","score_opus":0.08337900479977235,"score_gpt":0.3580261511705964,"score_spread":0.27464714637082405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214555329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009840888,0.98232335,3.591382e-7,0.0013875117,0.000028527034,0.014784712,0.00019900518,0.000037850703,0.00025458905],"genre_scores_gemma":[0.0016316625,0.98214936,0.000027168064,0.00019539439,0.000021606185,0.0022235913,0.002224321,0.0000867545,0.011440159],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994412,0.0016054015,0.0016779203,0.0011233442,0.0007155171,0.00046578233],"domain_scores_gemma":[0.99688137,0.00083442405,0.001266566,0.000659374,0.000062262894,0.00029599757],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014775363,0.0011564423,0.016538957,0.0008759644,0.0002195645,0.00006617331,0.00037065023,0.00031116232,0.0019933297],"category_scores_gemma":[0.0006338619,0.000598098,0.001068716,0.0021250402,0.0001003918,0.00020090134,0.0002730503,0.00072056096,0.0000065664035],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003319855,0.0006071637,0.0054967217,0.23276807,0.73000604,0.0007973752,0.0037119784,5.450861e-8,2.0489881e-7,0.000010942765,0.00021395774,0.026354263],"study_design_scores_gemma":[0.002626622,0.00092028326,0.0016342558,0.064461626,0.9212827,0.00007992508,0.00032673895,0.0000011264623,5.8720525e-7,0.0000019516979,0.008110645,0.000553512],"about_ca_topic_score_codex":0.00062295835,"about_ca_topic_score_gemma":0.00049756956,"teacher_disagreement_score":0.19127665,"about_ca_system_score_codex":0.00084746,"about_ca_system_score_gemma":0.00027786323,"threshold_uncertainty_score":0.999647},"labels":[],"label_agreement":null},{"id":"W4214767832","doi":"10.1111/j.1464-2662.2006.00374.x","title":"Oral Abstracts","year":2006,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Citation; Information retrieval; Library science; Computer science","score_opus":0.014790517297552435,"score_gpt":0.26602817644491317,"score_spread":0.25123765914736074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214767832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48494822,0.0010762414,0.0001954137,0.08295497,0.00038523806,0.0005059465,0.0000046132623,0.00028303417,0.4296463],"genre_scores_gemma":[0.81702524,0.000027367283,0.0015733677,0.0006568334,0.0005816062,0.000014117901,0.00022060538,0.000018837898,0.17988203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891317,0.000010947325,0.00029999446,0.00019961478,0.00032733614,0.0002489435],"domain_scores_gemma":[0.9995128,0.000037953385,0.00005481558,0.00020100833,0.000053673073,0.00013975054],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015514814,0.00015438153,0.00030589825,0.00012107727,0.000051107185,0.0000040451228,0.00004409577,0.000055118973,0.001319579],"category_scores_gemma":[0.000043025215,0.00010149795,0.000043310683,0.00016875185,0.00009251501,0.000036216425,0.000013034683,0.000107213775,0.000980859],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012259533,0.00037663212,0.07761969,0.00006262445,0.0000936552,0.0010258124,0.000333235,0.0000041735825,0.002405484,0.001489454,0.9097612,0.006705437],"study_design_scores_gemma":[0.0062674303,0.0001487644,0.26223063,0.00024649195,0.00021725068,0.0001878123,0.00013348866,0.000036736903,0.002411377,0.0004666142,0.7274919,0.00016148145],"about_ca_topic_score_codex":0.00008569615,"about_ca_topic_score_gemma":0.000027734803,"teacher_disagreement_score":0.332077,"about_ca_system_score_codex":0.00006534917,"about_ca_system_score_gemma":0.00005842282,"threshold_uncertainty_score":0.999797},"labels":[],"label_agreement":null},{"id":"W4214873802","doi":"10.3390/v14030516","title":"Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis","year":2022,"lang":"en","type":"review","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Combination therapy; Gastroenterology; Tolerability; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Clinical trial; Population; Adverse effect; Immunology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.0421553591607571,"score_gpt":0.3333476280797398,"score_spread":0.2911922689189827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214873802","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86843103,0.12741317,0.0000027110548,0.0000026119396,0.00004103835,0.0032602227,0.0003934071,0.000037112717,0.0004187287],"genre_scores_gemma":[0.32199037,0.6718019,0.00082055235,0.000055402234,0.000028714707,0.00091667054,0.0039807637,0.00017668802,0.00022889799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722415,0.00017290922,0.0010945867,0.0005764234,0.00065877143,0.00027317228],"domain_scores_gemma":[0.9984659,0.00014072361,0.00071240665,0.0004911266,0.000101568585,0.00008826689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023576796,0.00047182007,0.002378467,0.00083527394,0.00010290782,0.000015057254,0.00012273855,0.00010126796,0.00008652805],"category_scores_gemma":[0.000032813787,0.00032407028,0.0001235247,0.0011059727,0.00014161305,0.00012971353,0.00016257958,0.00029242967,0.0000036761792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021752711,0.0026415722,0.8766307,0.006299179,0.00020387632,0.0000025822426,0.00027710077,0.0000012152825,0.000004560593,0.000008860425,0.00006291502,0.113649905],"study_design_scores_gemma":[0.0023814898,0.0017676306,0.9046869,0.005904125,0.00071590306,7.0806186e-7,0.000021898702,1.5655552e-7,0.000051039468,0.0000012938898,0.084106565,0.00036225017],"about_ca_topic_score_codex":0.0018005153,"about_ca_topic_score_gemma":0.00070544274,"teacher_disagreement_score":0.54644066,"about_ca_system_score_codex":0.0004185923,"about_ca_system_score_gemma":0.0002398791,"threshold_uncertainty_score":0.99992114},"labels":[],"label_agreement":null},{"id":"W4220775300","doi":"10.1186/s12882-022-02721-x","title":"Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"BMC Nephrology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fudan University; Shanghai Municipal Health Commission","keywords":"Medicine; Meta-analysis; Incidence (geometry); Renal function; Internal medicine; Confidence interval; Systematic review; MEDLINE; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Viral load","score_opus":0.049337383069756054,"score_gpt":0.2996989176242124,"score_spread":0.25036153455445637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220775300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009552991,0.9947682,0.00017601025,0.00026298268,0.000015913976,0.0045913076,0.00005159624,0.000037506845,0.000086935936],"genre_scores_gemma":[0.000018820396,0.98795694,0.0006330337,0.00085920125,0.000010889817,0.0037038212,0.00065382227,0.000039960487,0.0061235256],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966941,0.0008861468,0.001201465,0.00058694225,0.0003784281,0.00025292108],"domain_scores_gemma":[0.9973323,0.00045366105,0.0011582718,0.000774884,0.00008260502,0.00019828435],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008041288,0.0005129361,0.011248936,0.0005819256,0.00007211147,0.00000818265,0.00014843191,0.00016105598,0.0023383545],"category_scores_gemma":[0.0002374045,0.00028873768,0.0016616416,0.0015278832,0.00008981014,0.000051168026,0.00012250716,0.00024698753,0.000030425394],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024638652,0.00008064851,0.0005030203,0.78051966,0.21695592,0.000034756325,0.000068583046,2.7591014e-7,1.610975e-8,0.000017213664,0.0016499731,0.00014528267],"study_design_scores_gemma":[0.00026574408,0.0001846152,0.000079506615,0.009326108,0.89978254,0.00025539543,0.000018017427,0.000005001747,3.1913878e-8,0.0000021792043,0.08988762,0.00019326947],"about_ca_topic_score_codex":0.000042496828,"about_ca_topic_score_gemma":0.00023396408,"teacher_disagreement_score":0.77119356,"about_ca_system_score_codex":0.00011782608,"about_ca_system_score_gemma":0.0006172895,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W4220789486","doi":"10.1111/hiv.13288","title":"Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV","year":2022,"lang":"en","type":"review","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Regimen; Population; Acknowledgement; Intensive care medicine; Clinical trial; Surgery; Internal medicine; Environmental health","score_opus":0.08007605925303118,"score_gpt":0.3128087548945643,"score_spread":0.2327326956415331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220789486","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064431675,0.92087597,0.0000018035167,0.004906665,0.00037290997,0.0067408085,0.00011166701,0.00009034635,0.002468149],"genre_scores_gemma":[0.011289784,0.9769829,0.00030058814,0.00022503511,0.00033445138,0.0024891028,0.0008453634,0.00015215405,0.007380623],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945819,0.00079154695,0.0017465453,0.0010668573,0.0010481676,0.00076500035],"domain_scores_gemma":[0.9947231,0.0032126924,0.0008517532,0.0009187722,0.000037462996,0.00025626505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007890783,0.0011879582,0.0031520345,0.0010588943,0.00031895214,0.000055195,0.00028747355,0.00025715347,0.00036268614],"category_scores_gemma":[0.0004250026,0.00053563685,0.00027147928,0.0015824791,0.0004639422,0.00014478556,0.00022431593,0.00074823,0.000014062011],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004628535,0.0023103452,0.11349882,0.0019139976,0.0019972664,0.0016191064,0.09247562,0.000034782868,0.00000842408,0.00010714967,0.008176856,0.7773948],"study_design_scores_gemma":[0.008049105,0.002133117,0.0017046119,0.056977205,0.0020728621,0.00034759997,0.012923232,0.000024345356,0.000034554174,0.0000015471237,0.9151653,0.00056654005],"about_ca_topic_score_codex":0.00034588316,"about_ca_topic_score_gemma":0.000115246556,"teacher_disagreement_score":0.90698844,"about_ca_system_score_codex":0.0015714475,"about_ca_system_score_gemma":0.00072810304,"threshold_uncertainty_score":0.99970955},"labels":[],"label_agreement":null},{"id":"W4221000028","doi":"10.1111/hiv.13298","title":"Antiretroviral drug switches to zidovudine‐based regimens and loss to follow‐up during the first COVID‐19 lockdown in Bali, Indonesia","year":2022,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada","keywords":"Medicine; Zidovudine; Efavirenz; Pill; Lamivudine; Viral load; Population; Indonesian; Antiretroviral therapy; Pediatrics; Human immunodeficiency virus (HIV); Family medicine; Internal medicine; Virology; Environmental health; Pharmacology; Virus; Viral disease","score_opus":0.014956023932885483,"score_gpt":0.26034167540434944,"score_spread":0.24538565147146396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221000028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80088615,0.0003707629,0.000051748073,0.19687381,0.00022009063,0.001074628,0.00001496013,0.00007475799,0.00043310906],"genre_scores_gemma":[0.971391,0.00002653407,0.00015832296,0.009050414,0.0001971438,0.00033793645,0.00007034097,0.000041096275,0.018727178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763554,0.00007664252,0.00046605975,0.0005676559,0.0007359903,0.00051812566],"domain_scores_gemma":[0.9986255,0.00019637511,0.0000882579,0.00048714233,0.000041685154,0.0005610509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069590734,0.00033128477,0.0006028048,0.0005309149,0.000485791,0.000014769589,0.00021036972,0.000043268727,0.00047365844],"category_scores_gemma":[0.00023456421,0.00022373506,0.00006437019,0.0010523527,0.0001201303,0.000043817454,0.00024436731,0.0003237432,0.000051575968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010342033,0.00017021364,0.9198082,0.00018488707,0.000093600815,0.0011127506,0.012829213,0.00009490849,0.0007492078,0.000059878937,0.063522525,0.0003404111],"study_design_scores_gemma":[0.03244384,0.0013433945,0.63081396,0.00073143037,0.00034908147,0.0004554391,0.008263614,0.0002538851,0.0015361415,0.00004690739,0.32303038,0.000731918],"about_ca_topic_score_codex":0.00028699794,"about_ca_topic_score_gemma":0.00031354715,"teacher_disagreement_score":0.28899422,"about_ca_system_score_codex":0.0005886505,"about_ca_system_score_gemma":0.0002353152,"threshold_uncertainty_score":0.9123651},"labels":[],"label_agreement":null},{"id":"W4221048768","doi":"10.2174/0929867329666220314121446","title":"Ninety Years of Pentamidine: The Development and Applications ofPentamidine and its Analogs","year":2022,"lang":"en","type":"review","venue":"Current Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pentamidine; Drug development; Pharmacology; Drug; Medicine; Chemistry; Pneumonia; Internal medicine","score_opus":0.06374505282914454,"score_gpt":0.34871175680691785,"score_spread":0.2849667039777733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221048768","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012599468,0.9965717,0.0000060689167,0.000103538405,0.00008225185,0.0010760244,0.000039956165,0.000025401421,0.00083512184],"genre_scores_gemma":[0.00042508275,0.99541324,0.000057918336,0.0000120217155,0.00021528512,0.00068081904,0.0011406055,0.000034647586,0.0020203616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979768,0.00003855086,0.0007230761,0.00048242253,0.00053119013,0.00024798219],"domain_scores_gemma":[0.9988397,0.00021323335,0.00036821558,0.0003103627,0.000044872766,0.00022361946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034152594,0.00038904126,0.0011551518,0.00008697504,0.00014027387,0.000009472437,0.00019723293,0.00010907765,0.00047101104],"category_scores_gemma":[0.000063930864,0.0002690088,0.00014242873,0.0003398076,0.00015320326,0.0000212142,0.00027322202,0.0005808005,0.000010054173],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010759948,0.00017712632,0.00016522915,0.023118032,0.0003606729,0.000022405928,0.00024212574,1.2878661e-8,0.000008049826,0.000030085428,0.0010851998,0.9747803],"study_design_scores_gemma":[0.0005853539,0.000020976639,0.00014136065,0.004042729,0.0017123764,0.00028150118,0.00022286877,0.000002768582,0.00007012829,0.0000036029844,0.9927027,0.00021363383],"about_ca_topic_score_codex":9.1834795e-7,"about_ca_topic_score_gemma":4.823368e-7,"teacher_disagreement_score":0.9916175,"about_ca_system_score_codex":0.00019583944,"about_ca_system_score_gemma":0.00059773,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W4229056645","doi":"10.1021/acs.jnatprod.1c01225","title":"Ansellone J, a Potent <i>in Vitro</i> and <i>ex Vivo</i> HIV-1 Latency Reversal Agent Isolated from a <i>Phorbas</i> sp. Marine Sponge","year":2022,"lang":"en","type":"review","venue":"Journal of Natural Products","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; Wellcome; Philadelphia Foundation; Canadian Institutes of Health Research; New Partnership for Africa's Development; Simon Fraser University; Government of the United Kingdom; Natural Sciences and Engineering Research Council of Canada; African Academy of Sciences; Government of Canada; Wistar Institute; Wellcome Trust","keywords":"Ex vivo; Sponge; Latency (audio); In vitro; In vivo; Context (archaeology); Chemistry; Stereochemistry; Human immunodeficiency virus (HIV); Activator (genetics); Biology; Biochemistry; Virology; Genetics; Botany","score_opus":0.0223496899438943,"score_gpt":0.2643598604073769,"score_spread":0.2420101704634826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229056645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036597615,0.98924196,8.812134e-7,0.0037006135,0.0014362899,0.001484053,0.00012387925,0.00003412143,0.0003184417],"genre_scores_gemma":[0.0005684745,0.98171335,0.002423702,0.00032970446,0.00078593974,0.000021178681,0.0006351574,0.00011337546,0.013409112],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995325,0.00035292003,0.0018943748,0.00082509883,0.000997089,0.00060550694],"domain_scores_gemma":[0.99732876,0.00020572491,0.0013841813,0.00051936985,0.00023041907,0.0003315243],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008521391,0.0008754163,0.003364396,0.0007639806,0.000110015935,0.00005954027,0.0003443281,0.00028445272,0.0003240047],"category_scores_gemma":[0.00026680971,0.000613654,0.0006322169,0.0011312586,0.000076351855,0.00024187587,0.00034060457,0.002402839,0.000051364437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034054623,0.0017228487,0.00020181539,0.008878935,0.0034247388,0.023632454,0.0007521023,7.4313283e-7,0.0013754443,0.00000448613,0.0580212,0.8985798],"study_design_scores_gemma":[0.0032466396,0.00030775616,0.00007393226,0.005120988,0.0031750067,0.0043482957,0.00004144096,0.00000913687,0.00023563243,0.000023854738,0.9828529,0.0005644456],"about_ca_topic_score_codex":0.00004773621,"about_ca_topic_score_gemma":0.000007115274,"teacher_disagreement_score":0.9248317,"about_ca_system_score_codex":0.00087491906,"about_ca_system_score_gemma":0.000921682,"threshold_uncertainty_score":0.9998987},"labels":[],"label_agreement":null},{"id":"W4229593096","doi":"10.1038/sj.ki.5001795","title":"Indinavir crystalluria","year":2006,"lang":"en","type":"review","venue":"Kidney International","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Indinavir; Crystalluria; Urine; Monoclinic crystal system; Chemistry; Crystallography; Crystal structure; Biology; Human immunodeficiency virus (HIV); Biochemistry; Sida; Virology","score_opus":0.036364033248256517,"score_gpt":0.3579942399423958,"score_spread":0.32163020669413933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229593096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010503763,0.8694575,0.000035722238,0.0019386226,0.001005461,0.00057260966,0.0002887279,0.000093437324,0.12660687],"genre_scores_gemma":[0.0000025025815,0.76118,0.0013047782,0.00017906477,0.0006458976,0.000119242475,0.0077574397,0.000044503973,0.22876659],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984088,0.000027786686,0.0005190002,0.00036084987,0.00047545056,0.00020811956],"domain_scores_gemma":[0.99920225,0.00004186896,0.00020980502,0.00022458835,0.000082046274,0.0002394625],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009106129,0.00035780834,0.0008787142,0.0003782088,0.000040490362,0.000043316722,0.00021375155,0.0002271636,0.0021979036],"category_scores_gemma":[0.00009839299,0.00026987444,0.0004710128,0.00015294908,0.000035538145,0.00005391914,0.000081542305,0.00027591726,0.0017257219],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008025183,0.00028350635,0.00013899563,0.002458279,0.0013985219,0.00033709995,0.000029731651,2.9786884e-8,2.3226436e-7,0.0008033787,0.5858247,0.40871745],"study_design_scores_gemma":[0.00061413884,0.000014634435,0.000020489122,0.007376397,0.00080543186,0.00025459763,0.0000018574746,0.0000026235343,8.9888414e-7,0.000044222306,0.9906459,0.00021881943],"about_ca_topic_score_codex":0.000008377614,"about_ca_topic_score_gemma":0.0000013951707,"teacher_disagreement_score":0.40849864,"about_ca_system_score_codex":0.0004979077,"about_ca_system_score_gemma":0.0008680159,"threshold_uncertainty_score":0.9999753},"labels":[],"label_agreement":null},{"id":"W4229950133","doi":"10.1201/9781420005875-52","title":"Contributors","year":2018,"lang":"en","type":"book-chapter","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.01612867126711514,"score_gpt":0.2479330947931632,"score_spread":0.23180442352604805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229950133","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005544898,0.00025826565,0.000028594524,0.0017441276,0.00018739894,0.0003611375,0.000014491476,0.00012414495,0.9972264],"genre_scores_gemma":[0.0003424265,0.00011791572,0.0007907013,0.00041731316,0.00038732623,0.0000070438014,0.00026856022,0.000044204775,0.9976245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999151,0.0000019356394,0.00020398191,0.00024684204,0.00023028812,0.00016598469],"domain_scores_gemma":[0.9994092,0.000022754424,0.000059321734,0.0002518316,0.00011472228,0.00014217406],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000053114934,0.00024986806,0.00041081203,0.00010702009,0.000035166006,0.000009048363,0.0000421086,0.00023598531,0.041289452],"category_scores_gemma":[0.0000101580135,0.00017391476,0.00014350029,0.000010245857,0.00006496235,0.000014117264,0.00003277846,0.00012344086,0.01335512],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007112709,0.0000429072,0.0003157535,0.000040459377,0.0009022135,0.0003527741,0.00011844589,2.3746607e-9,0.000005180719,0.07731906,0.9167432,0.004088847],"study_design_scores_gemma":[0.00093640527,0.000083189916,0.000041000025,0.0001713232,0.00028462044,0.000035170917,0.0000051109146,9.210978e-7,0.0001937749,0.002636455,0.99543434,0.00017771259],"about_ca_topic_score_codex":0.0000014720732,"about_ca_topic_score_gemma":0.000007655628,"teacher_disagreement_score":0.078691095,"about_ca_system_score_codex":0.00012637119,"about_ca_system_score_gemma":0.00014228516,"threshold_uncertainty_score":0.9874131},"labels":[],"label_agreement":null},{"id":"W4233840672","doi":"10.1038/nrd1091","title":"Enfuvirtide","year":2003,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"","keywords":"Enfuvirtide; Medicine; Human immunodeficiency virus (HIV); Virology; Pharmacology; Immunology; Gp41; Antibody","score_opus":0.0317649771547431,"score_gpt":0.3658934153795231,"score_spread":0.33412843822478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233840672","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.8932585e-7,0.9716418,0.000008947274,0.00026263032,0.00089941884,0.004099078,0.00006351786,0.00008588077,0.022938143],"genre_scores_gemma":[2.293335e-7,0.7903463,0.0008465117,0.00056693336,0.000412294,0.0005197011,0.00094760227,0.00014014842,0.20622027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954641,0.0005021947,0.0016283304,0.0011078878,0.00062607863,0.0006714338],"domain_scores_gemma":[0.9973142,0.00019998685,0.0007703234,0.0013258043,0.00006672811,0.0003229288],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008080325,0.0013108284,0.006174339,0.00041671292,0.000118363656,0.0001185916,0.00035273613,0.0010562468,0.00037177448],"category_scores_gemma":[0.0002888756,0.00079054415,0.0028971946,0.0009681629,0.00007609335,0.0002711505,0.00011383677,0.0024903838,0.003244986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000061200726,0.00020667084,0.000013398905,0.03840865,0.00054116664,0.0002116909,0.000025565598,6.9261366e-9,5.7358204e-8,0.0005621749,0.18617505,0.7738494],"study_design_scores_gemma":[0.0004139559,0.000015403604,0.0000011835614,0.059913754,0.005148188,0.0003559936,0.0000059714785,5.876322e-8,0.0000017150952,0.000027541084,0.9334557,0.00066055567],"about_ca_topic_score_codex":0.0000015200134,"about_ca_topic_score_gemma":0.0000050830163,"teacher_disagreement_score":0.7731889,"about_ca_system_score_codex":0.000644193,"about_ca_system_score_gemma":0.0011155147,"threshold_uncertainty_score":0.9999643},"labels":[],"label_agreement":null},{"id":"W4234935877","doi":"10.1016/s0021-9258(19)61477-8","title":"Differential Influence of Nucleoside Analog-resistance Mutations K65R and L74V on the Overall Mutation Rate and Error Specificity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reverse transcriptase; Biology; Wild type; Virology; Mutant; Mutation; Nucleoside; Virus; Molecular biology; Point mutation; Nucleoside analogue; RNA; Genetics; Gene","score_opus":0.02601147464876453,"score_gpt":0.2672526110299081,"score_spread":0.24124113638114358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234935877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874985,0.00027168787,0.000003898197,0.0004390315,0.0000095244295,0.00007857601,0.00002156942,0.0000033650342,0.00042249332],"genre_scores_gemma":[0.9989911,0.00034152085,0.00012291028,0.00004211414,0.000017440343,0.0000010346425,0.00001237669,0.0000032891048,0.00046826724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923736,0.000039540595,0.00039440268,0.00010713534,0.0001335419,0.00008803319],"domain_scores_gemma":[0.9994465,0.0000887143,0.00022071056,0.00008511429,0.00010520428,0.00005376264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013877316,0.00010195468,0.00025557683,0.00002277272,0.00006520015,0.000007665754,0.000059125934,0.000068173,0.0004221099],"category_scores_gemma":[0.00008598315,0.000057098634,0.000063571686,0.000081668695,0.0002159461,0.000039005983,0.0000072425114,0.00015786002,9.397513e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079913257,0.0002999045,0.005227882,0.00005319573,0.000076498,0.000047256268,0.00031888124,0.000014721979,0.9927577,0.000052718813,0.00008335333,0.00026877812],"study_design_scores_gemma":[0.0021909466,0.00053170347,0.46360838,0.00032897494,0.00019079668,0.00008018311,0.00032633397,0.000023875127,0.53156024,0.00068555126,0.0003370923,0.00013591902],"about_ca_topic_score_codex":0.0000059342483,"about_ca_topic_score_gemma":0.0000012321645,"teacher_disagreement_score":0.46119744,"about_ca_system_score_codex":0.000024355773,"about_ca_system_score_gemma":0.00003037474,"threshold_uncertainty_score":0.46218073},"labels":[],"label_agreement":null},{"id":"W4235282310","doi":"10.21203/rs.3.rs-44964/v1","title":"Guidelines are Needed for Studies of Pre-Treatment HIV Drug Resistance: A Methodological Study","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; McMaster University","funders":"World Health Organization","keywords":"Human immunodeficiency virus (HIV); Drug; Drug resistance; Resistance (ecology); Medicine; HIV drug resistance; Intensive care medicine; Psychology; Pharmacology; Virology; Antiretroviral therapy; Biology; Viral load; Microbiology","score_opus":0.5668967837558321,"score_gpt":0.5772472296599783,"score_spread":0.010350445904146244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235282310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68993115,0.034980882,0.00077051244,0.23607977,0.0004976909,0.035347782,0.0009389794,0.00044628038,0.0010069569],"genre_scores_gemma":[0.5053485,0.0102237975,0.17333326,0.00026199216,0.0017051409,0.020138897,0.0013554423,0.0002801478,0.2873528],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9936971,0.0013504263,0.0012098483,0.0012994767,0.0017156493,0.00072749495],"domain_scores_gemma":[0.9918354,0.002844669,0.0003635605,0.0010286485,0.0035770999,0.00035061195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003630643,0.00061204954,0.0022836495,0.00050102023,0.00027318473,0.00004873013,0.00037489834,0.00025823998,0.00006101956],"category_scores_gemma":[0.007806841,0.0004001357,0.0005730675,0.0005424228,0.00026626824,0.000034085588,0.0010966302,0.0006828419,0.000028994602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016523926,0.009532435,0.06356274,0.019464798,0.015889775,0.0015188227,0.060169216,0.00007519513,0.00040566575,0.0003903956,0.80801785,0.0044492073],"study_design_scores_gemma":[0.045732956,0.009584641,0.05007995,0.026792256,0.0061670556,0.000023260109,0.5271778,0.00073823135,0.024514975,0.020594701,0.28572252,0.0028716351],"about_ca_topic_score_codex":0.000073990945,"about_ca_topic_score_gemma":0.00037521851,"teacher_disagreement_score":0.5222953,"about_ca_system_score_codex":0.0009417467,"about_ca_system_score_gemma":0.0009906809,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W4235677641","doi":"10.1522/030631083","title":"Note sur les degouts pileux","year":2013,"lang":"fr","type":"book","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Philosophy; Humanities","score_opus":0.028151976531391926,"score_gpt":0.25530533462806704,"score_spread":0.2271533580966751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235677641","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015745576,0.007087921,0.00065492565,0.009871331,0.0022278295,0.0016231304,0.000043925542,0.00024389436,0.9766725],"genre_scores_gemma":[0.0046501015,0.0023203152,0.0064830836,0.0005199883,0.0016864554,0.00012673381,0.00086631684,0.00014545002,0.98320156],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967105,0.000084335166,0.000788336,0.00078147405,0.0006799337,0.00095541414],"domain_scores_gemma":[0.99772155,0.00045023748,0.00021146015,0.00067559426,0.00034224268,0.00059893855],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022541234,0.0009275812,0.0011675981,0.00028996952,0.00020714483,0.000065652,0.00025369998,0.0008536077,0.04452409],"category_scores_gemma":[0.000130653,0.00070737646,0.00038703028,0.00012704148,0.0002886034,0.00013569198,0.00017357805,0.00064694433,0.06841245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049345723,0.00054014806,0.012642429,0.00084378966,0.0013030187,0.00081276865,0.0006700337,0.000001257713,0.0000660408,0.025845455,0.7534377,0.20378803],"study_design_scores_gemma":[0.0024699334,0.00015534018,0.0039187763,0.001976858,0.00097421574,0.00007753558,0.000077548175,0.00014895787,0.00047441473,0.00037688928,0.98860526,0.0007442585],"about_ca_topic_score_codex":0.00044215244,"about_ca_topic_score_gemma":0.00048261564,"teacher_disagreement_score":0.23516758,"about_ca_system_score_codex":0.0011827445,"about_ca_system_score_gemma":0.0017776722,"threshold_uncertainty_score":0.9995377},"labels":[],"label_agreement":null},{"id":"W4236102739","doi":"10.21203/rs.3.rs-22911/v3","title":"Moderate rate of transmitted resistance mutations to antiretrovirals and genetic diversity in newly HIV-1 patients diagnosed in Benin.","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Genetic diversity; Transmission (telecommunications); Drug resistance; Human immunodeficiency virus (HIV); Mutation; Phylogenetic tree; Virology; Transmission rate; Mutation rate; HIV drug resistance; Drug; Resistance (ecology); Intravenous drug; Biology; Medicine; Genetics; Antiretroviral therapy; Environmental health; Gene; Viral load; Pharmacology; Population; Viral disease","score_opus":0.05321874925608462,"score_gpt":0.34298029650962963,"score_spread":0.289761547253545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236102739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911576,0.00034307275,0.00009160488,0.0053688623,0.000022745104,0.0024516901,0.0002869437,0.00001883815,0.0002586525],"genre_scores_gemma":[0.9959305,0.0004719671,0.0019047717,0.000044360022,0.0000151363,0.00016169065,0.00042598665,0.00002425214,0.0010213343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745154,0.0004205184,0.00044582962,0.00062832044,0.00063410756,0.00041967758],"domain_scores_gemma":[0.99876666,0.00028262247,0.00006707627,0.00029178505,0.0003253007,0.0002665282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037860053,0.00022421566,0.0005915417,0.00080401526,0.00010705655,0.000030395973,0.00016891591,0.00015866099,0.000030872132],"category_scores_gemma":[0.00040875707,0.00021954585,0.00006880521,0.0008179215,0.00009667791,0.000049156846,0.0005943591,0.00063714926,0.000020551655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010628718,0.00048837194,0.98285264,0.001358088,0.00008064852,0.0007497818,0.010856863,0.00024419324,0.00014300983,0.00002705123,0.0009837335,0.0011527403],"study_design_scores_gemma":[0.0044274195,0.00019281491,0.9910324,0.0017420298,0.000031748066,2.4331436e-7,0.00036392757,0.00059191085,0.00059222744,0.0007449168,0.00010362599,0.00017669],"about_ca_topic_score_codex":0.00047876986,"about_ca_topic_score_gemma":0.0012789317,"teacher_disagreement_score":0.010492936,"about_ca_system_score_codex":0.00031061235,"about_ca_system_score_gemma":0.00036786977,"threshold_uncertainty_score":0.89528203},"labels":[],"label_agreement":null},{"id":"W4237874417","doi":"10.1155/2009/658125","title":"Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV‐Infected Adults","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital; University of Ottawa; St. Paul's Hospital","funders":"","keywords":"Etravirine; Human immunodeficiency virus (HIV); Virology; Medicine; Antiretroviral therapy; Viral load","score_opus":0.026276810648828103,"score_gpt":0.2727545993392275,"score_spread":0.2464777886903994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237874417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803188,0.0037982177,0.000018957277,0.014985528,0.00015980445,0.00041986664,0.00027895218,0.0000020323293,0.00001782852],"genre_scores_gemma":[0.9970733,0.0017274207,0.00012869453,0.00073413673,0.00011379008,0.000012480166,0.00005210079,0.000008658971,0.00014939645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989511,0.00007024557,0.0005276576,0.00010543966,0.00007031695,0.0002752822],"domain_scores_gemma":[0.9981195,0.00052336673,0.00015918376,0.000116181815,0.00042529692,0.000656493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001441239,0.00013877208,0.0004156793,0.0002797154,0.00010969012,0.0000046167825,0.00007478678,0.000107743304,0.000099139594],"category_scores_gemma":[0.00088205945,0.00007047929,0.00015500873,0.00014650308,0.00042827503,0.00001511902,0.0000034165912,0.00009740247,7.638194e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042252245,0.0004169947,0.95209885,0.000057067005,0.0006684437,0.0013701603,0.0016585467,0.000040563486,0.00013639034,0.000077477634,0.031669244,0.011383747],"study_design_scores_gemma":[0.019292781,0.0051073395,0.5526505,0.00067507965,0.001196242,0.01644336,0.0011803947,0.00023793618,0.0003488089,0.00003128167,0.40252775,0.00030850017],"about_ca_topic_score_codex":0.10421651,"about_ca_topic_score_gemma":0.44797942,"teacher_disagreement_score":0.3994483,"about_ca_system_score_codex":0.00020405547,"about_ca_system_score_gemma":0.0040317047,"threshold_uncertainty_score":0.9017486},"labels":[],"label_agreement":null},{"id":"W4238609583","doi":"10.1139/y00-110","title":"Uptake properties of lamivudine (3TC) by a continuous renal epithelial cell line","year":2001,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council","keywords":"Organic cation transport proteins; Cytidine; Chemistry; Nucleoside; Kidney; Tetraethylammonium; Renal physiology; Biophysics; Biochemistry; Pharmacology; Biology; Transporter; Endocrinology; Renal function; Potassium","score_opus":0.015395429990508983,"score_gpt":0.24539400233101508,"score_spread":0.22999857234050608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238609583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918605,0.003603294,0.0000067166984,0.0036185137,0.00032675208,0.00014219017,0.000024056564,0.0000035284456,0.00041442222],"genre_scores_gemma":[0.9935249,0.0006769992,0.00011189251,0.00069115654,0.00029899788,0.000004222747,0.000012511724,0.000010740472,0.0046685888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990787,0.00007841817,0.00037755183,0.00012238276,0.000058214166,0.0002847233],"domain_scores_gemma":[0.9991483,0.00003321464,0.0002019123,0.00005532918,0.00017082141,0.00039040265],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014918894,0.00013833902,0.0004834235,0.00017936408,0.000074084885,0.0000026557111,0.000077615805,0.00010894827,0.0011959149],"category_scores_gemma":[0.000015893025,0.000100874604,0.00007577946,0.00009288166,0.0002744534,0.000042036867,0.000009764237,0.00023848748,0.000009428323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000665609,0.00012666416,0.0029784157,0.000060413637,0.000290282,0.0003612979,0.0005563237,0.0000047866183,0.97541726,0.00001015908,0.018431023,0.001097766],"study_design_scores_gemma":[0.005836059,0.0011840614,0.0027116446,0.0000696257,0.0004117738,0.0007721887,0.00013048702,0.00003383128,0.85899305,0.00009889811,0.12961735,0.00014100481],"about_ca_topic_score_codex":0.0001891247,"about_ca_topic_score_gemma":0.00027240458,"teacher_disagreement_score":0.11642419,"about_ca_system_score_codex":0.0000446062,"about_ca_system_score_gemma":0.0006709626,"threshold_uncertainty_score":0.9997171},"labels":[],"label_agreement":null},{"id":"W4238793251","doi":"10.1155/2001/319279","title":"Nevirapine Use to Reduce Mother‐To‐Child Transmission of HIV in Canada","year":2001,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nevirapine; Rash; Virology; Reverse transcriptase; Reverse-transcriptase inhibitor; Medicine; Transmission (telecommunications); Nucleoside Reverse Transcriptase Inhibitor; Drug resistance; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Internal medicine; Viral load; Genetics; Polymerase chain reaction","score_opus":0.005597103395257899,"score_gpt":0.21762313277859646,"score_spread":0.21202602938333856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238793251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97763824,0.0012447615,0.00009889678,0.020504553,0.00015589499,0.00018074359,0.000041633575,0.0000023788052,0.0001329144],"genre_scores_gemma":[0.99629587,0.00034006714,0.00008941887,0.0028893566,0.00006970638,0.0000026769076,0.000013733882,0.0000102002,0.00028897965],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990816,0.0000478038,0.00038453095,0.00012749655,0.00007901025,0.00027956188],"domain_scores_gemma":[0.99766845,0.000056731737,0.00006641772,0.00007557487,0.00008661323,0.0020462116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009221524,0.00011852308,0.0003836406,0.00034463182,0.00004114861,0.0000049957125,0.00006377432,0.00006971034,0.0005158862],"category_scores_gemma":[0.00025153832,0.000089017405,0.000056845885,0.00022695446,0.000059591574,0.000027552665,0.0000075719518,0.00015676701,0.0000029867635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027175146,0.00012647209,0.9283359,0.0000496884,0.0001442866,0.00233628,0.00034957103,0.000022022581,0.0013591321,0.000022685726,0.020855512,0.046126686],"study_design_scores_gemma":[0.0052219974,0.0007369871,0.45706627,0.001585445,0.00016421128,0.006081542,0.00023078668,0.000011672305,0.0005631537,0.000023268225,0.52806515,0.00024950068],"about_ca_topic_score_codex":0.4242613,"about_ca_topic_score_gemma":0.8551763,"teacher_disagreement_score":0.50720966,"about_ca_system_score_codex":0.00041258734,"about_ca_system_score_gemma":0.0051263836,"threshold_uncertainty_score":0.90939844},"labels":[],"label_agreement":null},{"id":"W4238989107","doi":"10.1016/b978-0-12-801238-3.96593-0","title":"Dideoxyinosine☆","year":2016,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Didanosine; Nucleoside; Reverse transcriptase; Nucleoside analogue; Chemistry; Metabolite; Virology; Pharmacology; Biology; Human immunodeficiency virus (HIV); Biochemistry; Zidovudine; RNA; Viral disease","score_opus":0.015208760380564745,"score_gpt":0.24495503725783138,"score_spread":0.22974627687726665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238989107","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022922579,0.0012547907,0.0000023924908,0.0017208862,0.0003028971,0.00075057475,0.00003110639,0.00014455762,0.99576986],"genre_scores_gemma":[0.00028139265,0.00023031124,0.0005203573,0.00053972786,0.00061057706,0.00005169681,0.00006017957,0.00013673247,0.997569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983053,0.000008940955,0.0004280262,0.0004958699,0.00042662557,0.00033519848],"domain_scores_gemma":[0.99882466,0.000049744005,0.00016077473,0.0006005103,0.000107907814,0.0002564134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000097817894,0.00052216183,0.0007479783,0.00020754442,0.00007728925,0.000017817742,0.00011657429,0.00034399424,0.0019770637],"category_scores_gemma":[0.000012676598,0.000344907,0.00033903882,0.000007805326,0.0001220862,0.000022463408,0.000089433626,0.00028418953,0.0051102876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045453762,0.000016824506,0.00008998223,0.000088858025,0.0004721764,0.00041193786,0.00010020548,1.4252122e-9,0.000026695854,0.009616901,0.004737124,0.98439384],"study_design_scores_gemma":[0.001141437,0.000060573468,0.000057218775,0.0015573645,0.00045794548,0.000092270115,0.0000016663887,1.3711188e-7,0.00016885778,0.005103897,0.99097735,0.0003812663],"about_ca_topic_score_codex":4.4715044e-8,"about_ca_topic_score_gemma":0.0000028156371,"teacher_disagreement_score":0.98624027,"about_ca_system_score_codex":0.00021896073,"about_ca_system_score_gemma":0.0002687406,"threshold_uncertainty_score":0.9999003},"labels":[],"label_agreement":null},{"id":"W4239486570","doi":"10.1007/3-540-29623-9_2200","title":"Reverse Transcriptase, Human Immunodeficiency Virus Type‐1","year":2005,"lang":"en","type":"book-chapter","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Virology; Human immunodeficiency virus (HIV); Medicine; Biology; Genetics; RNA; Gene","score_opus":0.02931255038490996,"score_gpt":0.26934364818059503,"score_spread":0.24003109779568507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239486570","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023968834,0.0024724985,0.000013115535,0.0010823443,0.00022831946,0.0005461068,0.00003444878,0.0001808893,0.9952026],"genre_scores_gemma":[0.002202239,0.00091204396,0.0010609473,0.00064708904,0.00018905329,0.000009818881,0.0005933296,0.00009104473,0.9942944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998362,0.0000064253027,0.00045825262,0.00045591383,0.00041452763,0.0003028881],"domain_scores_gemma":[0.99912107,0.000012069154,0.00009552826,0.0005152931,0.000106121006,0.00014992543],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009534054,0.0004725689,0.00060765597,0.00024647146,0.00012834746,0.000017474496,0.000120495286,0.00033356712,0.026748937],"category_scores_gemma":[0.0000047849016,0.00037521147,0.00027760072,0.00004480188,0.00008728848,0.000052017574,0.000028678534,0.00036473403,0.0051728436],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003906473,0.00092496845,0.00019513724,0.00031572336,0.0020314993,0.0016681552,0.001172144,6.7582516e-7,0.0065079564,0.28481907,0.6657557,0.036218368],"study_design_scores_gemma":[0.0012761218,0.00015054984,0.0000644557,0.00024234437,0.0005637385,0.00006179595,0.000018590139,0.0000014149562,0.0005524128,0.0005410117,0.99613225,0.00039529693],"about_ca_topic_score_codex":0.000034104592,"about_ca_topic_score_gemma":0.00004591456,"teacher_disagreement_score":0.3303766,"about_ca_system_score_codex":0.00023956377,"about_ca_system_score_gemma":0.00019320798,"threshold_uncertainty_score":0.99987},"labels":[],"label_agreement":null},{"id":"W4240519671","doi":"10.1128/aac.02534-13","title":"Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Integrase; Integrase inhibitor; Drug resistance; Virology; Human immunodeficiency virus (HIV); Drug; Lentivirus; Medicine; Biology; Genetics; Pharmacology; Antiretroviral therapy; Viral disease; Viral load","score_opus":0.00547975468341358,"score_gpt":0.2256827680605884,"score_spread":0.22020301337717482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240519671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935819,0.00011280517,0.000014539552,0.005288615,0.000020706157,0.00031429218,0.000026119786,0.000008032533,0.0006329726],"genre_scores_gemma":[0.99388725,0.00040609066,0.00090679683,0.00050526496,0.000010820649,0.000009990771,0.00005712377,0.000009114082,0.004207579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992032,0.000022346465,0.00031576952,0.00019062082,0.000117877426,0.00015019519],"domain_scores_gemma":[0.9995349,0.000020832784,0.00010511653,0.00022433886,0.00006511197,0.00004968527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000063879816,0.00013400437,0.0003685503,0.00016363601,0.000040122926,0.000008504108,0.0000970903,0.00006020948,0.00019875393],"category_scores_gemma":[0.000008713159,0.00008532195,0.00016515277,0.00064886204,0.00017484235,0.000037846352,0.000023618859,0.00008922869,0.0000053208882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017936561,0.0011486624,0.7785718,0.00006708303,0.0017308715,0.0000042840775,0.0028731532,0.0000031245822,0.18121314,0.00048425532,0.031988032,0.0017362573],"study_design_scores_gemma":[0.0033056445,0.000013432597,0.69903994,0.00032294763,0.00079263083,0.0000029393273,0.00037514832,0.00022849427,0.27835816,0.00020850862,0.01714006,0.00021211397],"about_ca_topic_score_codex":0.0002135236,"about_ca_topic_score_gemma":0.00012730727,"teacher_disagreement_score":0.09714502,"about_ca_system_score_codex":0.00003413393,"about_ca_system_score_gemma":0.00004890077,"threshold_uncertainty_score":0.34793282},"labels":[],"label_agreement":null},{"id":"W4243068281","doi":"10.2165/00151234-201106200-00034","title":"Azacitidine reimbursed in Quebec, Canada","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Azacitidine; Public health; Medicine; Chemistry; Nursing","score_opus":0.02704849171701705,"score_gpt":0.29306961876654736,"score_spread":0.2660211270495303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243068281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94283366,0.00015294964,0.000010475068,0.020560453,0.0006459464,0.0005791237,0.000016747781,0.00006143874,0.035139225],"genre_scores_gemma":[0.90909785,0.00017593919,0.0011643098,0.01409007,0.00008755502,0.000076411845,0.000073059935,0.000048816935,0.07518597],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986348,0.000025821637,0.0005031966,0.00033059804,0.00010344766,0.0004021039],"domain_scores_gemma":[0.9992974,0.000055605597,0.00010223196,0.0002617076,0.000024527311,0.00025856696],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000098075536,0.00026503386,0.0005255563,0.00015908634,0.00003828848,0.000013024638,0.00013351247,0.000048815804,0.0019478683],"category_scores_gemma":[0.000015799742,0.00023543625,0.00010430676,0.00009531094,0.000022847484,0.00013105985,0.000046621597,0.00017694077,0.00020224508],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018070765,0.0002401505,0.9023219,0.000029049734,0.00029777942,0.00038963664,0.000848487,0.0000038450703,0.00015925926,0.0002874459,0.088763535,0.006478207],"study_design_scores_gemma":[0.013331603,0.0000364139,0.42050797,0.000050968803,0.00028642145,0.00003081972,0.00059936644,0.0002700882,0.014688153,0.00019334187,0.54921967,0.0007851849],"about_ca_topic_score_codex":0.7944252,"about_ca_topic_score_gemma":0.9681824,"teacher_disagreement_score":0.4818139,"about_ca_system_score_codex":0.0008786842,"about_ca_system_score_gemma":0.0008792556,"threshold_uncertainty_score":0.9989645},"labels":[],"label_agreement":null},{"id":"W4243412737","doi":"10.3410/f.1116100.572081","title":"Faculty Opinions recommendation of A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.","year":2008,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Lopinavir; Ritonavir; Efavirenz; Combination therapy; Lopinavir/ritonavir; Medicine; Emtricitabine; Pharmacology; Internal medicine; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load","score_opus":0.06389892056024891,"score_gpt":0.3868856224196,"score_spread":0.3229867018593511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243412737","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011462312,0.0068950974,0.00004106366,0.12730724,0.00126756,0.0040462613,0.8601502,0.00007920944,0.00009870839],"genre_scores_gemma":[0.00033760708,0.00837664,0.00068066,0.0014423047,0.00016372053,0.0006554687,0.98542273,0.0000830822,0.002837795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916485,0.00079997635,0.0031010879,0.0010792615,0.0028035783,0.00056762644],"domain_scores_gemma":[0.9884149,0.0003774294,0.0032414761,0.0017496346,0.0058318162,0.00038477103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011263846,0.0010990573,0.002427005,0.00072499755,0.00039989658,0.00009314669,0.0013460746,0.0011686231,0.00033266403],"category_scores_gemma":[0.0013175767,0.0007741736,0.0011485984,0.002796212,0.0006446411,0.0005016683,0.0001956152,0.0013078562,0.00004403859],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006133858,0.007441656,0.00019381984,0.002640765,0.0009257465,0.0000010427656,0.0006593586,1.2247878e-7,0.000038467366,0.00018539859,0.97268933,0.014610907],"study_design_scores_gemma":[0.012657251,0.0017744341,0.00299585,0.008112239,0.00030026026,0.000025460371,0.000085303494,0.000021635144,0.0007781407,0.000019367753,0.9726149,0.00061515346],"about_ca_topic_score_codex":0.00013943254,"about_ca_topic_score_gemma":0.0000074302425,"teacher_disagreement_score":0.12586492,"about_ca_system_score_codex":0.00044827748,"about_ca_system_score_gemma":0.0009882385,"threshold_uncertainty_score":0.99947095},"labels":[],"label_agreement":null},{"id":"W4243447794","doi":"10.3410/f.1345975.817075","title":"Faculty Opinions recommendation of Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.","year":2009,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Reverse transcriptase; Human immunodeficiency virus (HIV); Antagonism; Virology; Tenofovir; Biology; Genetics; RNA; Gene; Receptor","score_opus":0.01611345377861771,"score_gpt":0.319065347263653,"score_spread":0.30295189348503526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243447794","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007353259,0.0027369163,0.00004336568,0.23197359,0.00025330193,0.002232097,0.76272845,0.000010240754,0.000014692297],"genre_scores_gemma":[0.0002449124,0.00072057516,0.0010340076,0.0016600708,0.00010075421,0.00021256659,0.99472666,0.000019079636,0.0012813668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965762,0.00031522888,0.001440224,0.00046817661,0.0009584553,0.00024170936],"domain_scores_gemma":[0.9955675,0.0002180318,0.0011622105,0.0009050965,0.0020168116,0.00013032295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008830529,0.00039496468,0.00078049,0.0002910061,0.00026791258,0.000047436617,0.0005966867,0.00037129063,0.00008809067],"category_scores_gemma":[0.002594677,0.00019688421,0.0004181164,0.0015865503,0.00031012567,0.00022013648,0.00010729591,0.0004659123,0.0000020518971],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010144855,0.00020736913,0.00006955092,0.00270145,0.0001371628,2.2223296e-7,0.00053252233,1.7025668e-7,0.000024184494,0.00023036514,0.9906323,0.0053632655],"study_design_scores_gemma":[0.0014890174,0.00008112629,0.0108264955,0.007763469,0.00045739254,0.000022768394,0.00019864179,0.000027199661,0.0002524812,0.00007723442,0.97862667,0.00017750116],"about_ca_topic_score_codex":0.000038127087,"about_ca_topic_score_gemma":0.000017885788,"teacher_disagreement_score":0.23199822,"about_ca_system_score_codex":0.00012285534,"about_ca_system_score_gemma":0.00047595878,"threshold_uncertainty_score":0.8028705},"labels":[],"label_agreement":null},{"id":"W4243472008","doi":"10.1016/j.vascn.2017.09.003","title":"Cytoplasmic Distribution of HIV-1 Tat Sensitizes Jurkat T Cells to Sulphamethoxazole-hydroxylamine Induced Toxicity","year":2017,"lang":"en","type":"article","venue":"Journal of Pharmacological and Toxicological Methods","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Jurkat cells; Hydroxylamine; Toxicity; Human immunodeficiency virus (HIV); Chemistry; Virology; Pharmacology; Medicine; Biochemistry; Immunology; T cell; Organic chemistry","score_opus":0.06173652721216818,"score_gpt":0.4144234767855426,"score_spread":0.35268694957337443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243472008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98242706,0.0001457258,0.007979299,0.008059155,0.00044518383,0.00046649406,0.0000308524,0.000022833587,0.00042341358],"genre_scores_gemma":[0.88606197,0.000252357,0.11227098,0.00053729664,0.00023931736,0.000010524946,0.0000057100006,0.000009853925,0.00061199086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99732864,0.00066906074,0.0009140222,0.0003368078,0.00034547024,0.0004060167],"domain_scores_gemma":[0.997078,0.0009923426,0.00076211756,0.00019978941,0.000311775,0.0006559736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002382493,0.0003158038,0.0011958911,0.00012513285,0.00027260833,0.000051640443,0.00026592912,0.00029444735,0.00027188638],"category_scores_gemma":[0.001520813,0.00018748206,0.00030220434,0.00015899139,0.00028682634,0.000147359,0.0002859257,0.0005856538,0.000012537437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016336681,0.0011658071,0.0036083758,0.000039016268,0.00036565165,0.0005152437,0.000108149776,0.000012819659,0.9424933,0.00013257796,0.0013377132,0.048587665],"study_design_scores_gemma":[0.003919272,0.0025617154,0.073844954,0.00008152334,0.0006835774,0.00036957758,0.00007110264,0.00024261448,0.91264045,0.00065941556,0.004697828,0.00022796687],"about_ca_topic_score_codex":0.0000013427415,"about_ca_topic_score_gemma":5.1584357e-7,"teacher_disagreement_score":0.104291685,"about_ca_system_score_codex":0.0001435863,"about_ca_system_score_gemma":0.00008302582,"threshold_uncertainty_score":0.76452965},"labels":[],"label_agreement":null},{"id":"W4244949237","doi":"10.21203/rs.3.rs-22911/v2","title":"Moderate rate of transmitted resistance mutations to antiretrovirals and genetic diversity in newly HIV-1 patients diagnosed in Benin.","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Genetic diversity; Transmission (telecommunications); Drug resistance; Human immunodeficiency virus (HIV); Mutation; Phylogenetic tree; HIV drug resistance; Mutation rate; Transmission rate; Virology; Intravenous drug; Resistance (ecology); Drug; Medicine; Biology; Genetics; Antiretroviral therapy; Environmental health; Viral load; Gene; Pharmacology; Population; Viral disease","score_opus":0.05321874925608462,"score_gpt":0.34298029650962963,"score_spread":0.289761547253545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244949237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911576,0.00034307275,0.00009160488,0.0053688623,0.000022745104,0.0024516901,0.0002869437,0.00001883815,0.0002586525],"genre_scores_gemma":[0.9959305,0.0004719671,0.0019047717,0.000044360022,0.0000151363,0.00016169065,0.00042598665,0.00002425214,0.0010213343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745154,0.0004205184,0.00044582962,0.00062832044,0.00063410756,0.00041967758],"domain_scores_gemma":[0.99876666,0.00028262247,0.00006707627,0.00029178505,0.0003253007,0.0002665282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037860053,0.00022421566,0.0005915417,0.00080401526,0.00010705655,0.000030395973,0.00016891591,0.00015866099,0.000030872132],"category_scores_gemma":[0.00040875707,0.00021954585,0.00006880521,0.0008179215,0.00009667791,0.000049156846,0.0005943591,0.00063714926,0.000020551655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010628718,0.00048837194,0.98285264,0.001358088,0.00008064852,0.0007497818,0.010856863,0.00024419324,0.00014300983,0.00002705123,0.0009837335,0.0011527403],"study_design_scores_gemma":[0.0044274195,0.00019281491,0.9910324,0.0017420298,0.000031748066,2.4331436e-7,0.00036392757,0.00059191085,0.00059222744,0.0007449168,0.00010362599,0.00017669],"about_ca_topic_score_codex":0.00047876986,"about_ca_topic_score_gemma":0.0012789317,"teacher_disagreement_score":0.010492936,"about_ca_system_score_codex":0.00031061235,"about_ca_system_score_gemma":0.00036786977,"threshold_uncertainty_score":0.89528203},"labels":[],"label_agreement":null},{"id":"W4245595183","doi":"10.1097/00002030-900000000-96977","title":"Relevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat","year":2019,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cilag; Universitair Medisch Centrum Groningen; Rijksuniversiteit Groningen","keywords":"Cobicistat; Ritonavir; Pharmacokinetics; Pharmacology; Drug; Medicine; Lidocaine; Anesthesia; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.006417499004120289,"score_gpt":0.265721731616781,"score_spread":0.25930423261266067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245595183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871245,0.00096595887,0.000008971542,0.0074422103,0.00015781746,0.00050775515,0.000007650248,0.00001281577,0.003772335],"genre_scores_gemma":[0.95591384,0.00042434802,0.00022567183,0.00022580072,0.00005633337,0.00002207877,0.0000073365186,0.000010690718,0.043113887],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932,0.00005845208,0.00018864003,0.00015944496,0.00015185458,0.00012160831],"domain_scores_gemma":[0.9992014,0.00043452496,0.000075248725,0.00020117404,0.00003990538,0.000047746307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001701617,0.000111622445,0.00024075448,0.000036688718,0.00007018963,0.000009586213,0.000067517634,0.0000128507045,0.00008288674],"category_scores_gemma":[0.000036465135,0.00005719643,0.00005026752,0.00013970517,0.00020442836,0.000054794302,0.00006937891,0.0001491057,0.000026255391],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007091632,0.00020871942,0.85310405,0.00034379875,0.001048105,0.000015220714,0.012561914,0.0000035074002,0.008001244,0.0012601239,0.01529892,0.107445225],"study_design_scores_gemma":[0.03695427,0.0003208654,0.30963132,0.0017796556,0.0028605517,0.00016745276,0.0036174124,0.00085670897,0.17898683,0.0013944107,0.46269843,0.0007321018],"about_ca_topic_score_codex":0.00007104979,"about_ca_topic_score_gemma":0.000011718579,"teacher_disagreement_score":0.54347277,"about_ca_system_score_codex":0.00003196174,"about_ca_system_score_gemma":0.0000355932,"threshold_uncertainty_score":0.23324028},"labels":[],"label_agreement":null},{"id":"W4246572655","doi":"10.1163/2210-7975_hrd-0124-0036","title":"no396-canada-deplores-chinas-sentencing-of-liu-xiaobo-dec-25-2009-1pp","year":2016,"lang":"en","type":"dataset","venue":"Human Rights Documents online","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.016993095249077755,"score_gpt":0.2992270908588778,"score_spread":0.2822339956098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246572655","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025894698,0.0005081138,0.0000039172205,0.0012722955,0.0011427712,0.0014669456,0.9689031,0.00012499442,0.0006831439],"genre_scores_gemma":[0.0017670203,0.00027353433,0.00045618814,0.0003601671,0.0010355222,0.00006555979,0.93276256,0.000117908094,0.063161545],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99398035,0.00012715987,0.001687858,0.0012472017,0.0019043967,0.0010530449],"domain_scores_gemma":[0.9960882,0.00012636697,0.0009269385,0.0018475294,0.0003620675,0.0006488658],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024441228,0.0012588039,0.0019103365,0.00071817846,0.000477911,0.000059207967,0.00078913535,0.000482639,0.0052495026],"category_scores_gemma":[0.000050225055,0.00080365245,0.00040850736,0.0003027061,0.00025751797,0.00021868329,0.00032728966,0.00064876676,0.0004131219],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021100268,0.0016881238,0.0006109261,0.00040560146,0.0014455655,0.0016548802,0.00004141125,1.9375294e-7,0.00003918851,0.00009450056,0.9934778,0.0003307859],"study_design_scores_gemma":[0.0056029605,0.000387001,0.0006221126,0.0019832938,0.001138656,0.00012809053,0.000020757905,0.0000013010641,0.00039345413,0.0006161489,0.98824453,0.00086167775],"about_ca_topic_score_codex":0.07795681,"about_ca_topic_score_gemma":0.49894243,"teacher_disagreement_score":0.42098564,"about_ca_system_score_codex":0.0010772122,"about_ca_system_score_gemma":0.0012595656,"threshold_uncertainty_score":0.99944144},"labels":[],"label_agreement":null},{"id":"W4247168396","doi":"10.1007/978-3-0348-7869-2_7","title":"Salvage therapy","year":2004,"lang":"en","type":"book-chapter","venue":"Birkhäuser Basel eBooks","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Viral load; Antiretroviral therapy; Medicine; Human immunodeficiency virus (HIV); Salvage therapy; Immunology; Internal medicine; Intensive care medicine; Chemotherapy","score_opus":0.030555345201234894,"score_gpt":0.24982347675856398,"score_spread":0.21926813155732908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247168396","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049237,0.0012474633,0.000026701357,0.0010477836,0.00026913718,0.0012549025,0.000050155122,0.00038879804,0.9952227],"genre_scores_gemma":[0.0052216854,0.000450242,0.0014019841,0.0016092423,0.00045252926,0.000074882875,0.00025200672,0.0002647939,0.99027264],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977761,0.000013493383,0.00049810973,0.0006764393,0.0005988306,0.0004370643],"domain_scores_gemma":[0.99853814,0.00004980794,0.00018070065,0.0007895711,0.00012071752,0.00032108277],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013909368,0.0007496676,0.0008262784,0.00034911526,0.00012188561,0.00003734875,0.00016622599,0.0005162499,0.0033692427],"category_scores_gemma":[0.000008223027,0.0005972973,0.00044240605,0.000018774901,0.00013997564,0.000029548028,0.000064871674,0.0004952332,0.0025648193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020538657,0.0009021127,0.0013079136,0.00087907776,0.0076269,0.01084008,0.0042093745,0.0000015072561,0.0012652555,0.55979365,0.14534256,0.26577768],"study_design_scores_gemma":[0.004347792,0.00020367815,0.00018760715,0.000828255,0.00032565295,0.00008250852,0.000010576428,0.0000010961586,0.0021936472,0.010327575,0.980816,0.0006756019],"about_ca_topic_score_codex":0.000014498326,"about_ca_topic_score_gemma":0.000015426654,"teacher_disagreement_score":0.8354735,"about_ca_system_score_codex":0.00035678764,"about_ca_system_score_gemma":0.00081349415,"threshold_uncertainty_score":0.99964786},"labels":[],"label_agreement":null},{"id":"W4247833276","doi":"10.1107/s0108270105034591","title":"Stavudine","year":2005,"lang":"en","type":"article","venue":"Acta Crystallographica Section C Crystal Structure Communications","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Stavudine; Hydrogen bond; Differential scanning calorimetry; Molecule; Crystallography; Chemistry; Crystal structure; Stereochemistry; Human immunodeficiency virus (HIV); Physics; Organic chemistry; Biology; Thermodynamics","score_opus":0.01674132566587677,"score_gpt":0.27199426559392587,"score_spread":0.2552529399280491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247833276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8672099,0.0013585485,0.0010103526,0.10394881,0.00033350353,0.001607815,0.00016844258,0.0010205441,0.023342084],"genre_scores_gemma":[0.9768166,0.000622941,0.01816542,0.00047506636,0.00026523476,0.00006335254,0.0007010568,0.000046934907,0.0028433756],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983421,0.00009287895,0.00047201625,0.00037481287,0.00035322036,0.00036497472],"domain_scores_gemma":[0.99758065,0.00010946249,0.00016010522,0.0016534476,0.00023621928,0.00026009415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012525267,0.00031269685,0.00034660054,0.0004587498,0.00061764295,0.00006748131,0.00041910162,0.00021653251,0.0009241678],"category_scores_gemma":[0.000061396735,0.0002763352,0.00022607212,0.0010198108,0.00029318078,0.00027135175,0.00024168634,0.0005578905,0.000004360354],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003310118,0.0014667101,0.03822314,0.00009379048,0.0013939718,0.00001419128,0.0022524192,0.000041449133,0.89752924,0.0024212615,0.044416644,0.011816194],"study_design_scores_gemma":[0.0013421992,0.000088506196,0.020145128,0.00003857961,0.00019456458,0.0002631708,0.0002684155,0.00025413613,0.00036412437,0.0004780437,0.97627753,0.00028559376],"about_ca_topic_score_codex":0.000021602984,"about_ca_topic_score_gemma":0.0007575313,"teacher_disagreement_score":0.9318609,"about_ca_system_score_codex":0.0002336117,"about_ca_system_score_gemma":0.00013159879,"threshold_uncertainty_score":0.99998915},"labels":[],"label_agreement":null},{"id":"W4249106987","doi":"10.3410/f.4071956.3844054","title":"Faculty Opinions recommendation of International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.","year":2010,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Zidovudine; Tenofovir; Reverse transcriptase; Virology; Human immunodeficiency virus (HIV); Mutation; Nucleoside Reverse Transcriptase Inhibitor; Cohort; Reverse-transcriptase inhibitor; Medicine; Biology; Sida; Genetics; Internal medicine; Antiretroviral therapy; Viral disease; Viral load; Gene; RNA","score_opus":0.020006690374560595,"score_gpt":0.33817689561310366,"score_spread":0.31817020523854306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249106987","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007670863,0.00029015157,0.0000056543336,0.13710885,0.00028988987,0.0015166298,0.85997826,0.0000034505551,0.000040021117],"genre_scores_gemma":[0.00892339,0.0004985155,0.00021559747,0.0005725717,0.000035603323,0.00012604852,0.9891905,0.000008597102,0.0004291452],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623257,0.0005596863,0.0014104135,0.00034118642,0.0012997435,0.00015638658],"domain_scores_gemma":[0.99588406,0.0002626701,0.0014580841,0.00091103144,0.0014345184,0.000049645794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016952388,0.0002818221,0.0009072592,0.0005593149,0.0000734346,0.000021438236,0.0009397067,0.00031062216,0.00009477082],"category_scores_gemma":[0.0029033804,0.00012952251,0.00049913704,0.0030145934,0.0005882649,0.0002075689,0.00020300777,0.0007176771,5.2436036e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041841817,0.0007263331,0.008463259,0.0023785227,0.0007482981,3.13743e-7,0.0012960652,5.019212e-7,0.00004765098,0.00013678893,0.9851888,0.0009716152],"study_design_scores_gemma":[0.00085439446,0.000048756032,0.21050468,0.005039144,0.000986514,0.0000103691145,0.00023609328,0.000044149263,0.00019771987,0.000011258418,0.7819649,0.00010203012],"about_ca_topic_score_codex":0.00020843478,"about_ca_topic_score_gemma":0.00013858984,"teacher_disagreement_score":0.20322393,"about_ca_system_score_codex":0.0000688695,"about_ca_system_score_gemma":0.00035178338,"threshold_uncertainty_score":0.52817744},"labels":[],"label_agreement":null},{"id":"W4249221115","doi":"10.1515/iupac.84.1203","title":"Terminal Deoxynucleotidyl Transferase (TDT)","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Medicine; Immune system; Philosophy; Linguistics","score_opus":0.013037319365475482,"score_gpt":0.3829772418246846,"score_spread":0.36993992245920915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249221115","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011280068,0.0006040989,0.00007299123,0.0050787446,0.00048239948,0.0007983611,0.9914887,0.00012876185,0.00021791967],"genre_scores_gemma":[0.00009745481,0.0013707017,0.0002640764,0.0005280041,0.0010153648,0.000048635597,0.9834883,0.000084549334,0.013102905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625075,0.00007008431,0.000723983,0.0007784385,0.0014850795,0.00069167867],"domain_scores_gemma":[0.9978814,0.00009086983,0.00015508739,0.00095481606,0.00039264816,0.0005251474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037392764,0.00078262616,0.0012270077,0.00042193144,0.00014978141,0.0000474504,0.0002755359,0.00048092083,0.010044563],"category_scores_gemma":[0.00018026367,0.0005289057,0.0004061458,0.000222096,0.00018823048,0.00008836242,0.00007957737,0.00058613205,0.000042420757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080617133,0.00091920234,0.00010225574,0.00035966322,0.00059402105,0.0031312408,0.000041227308,4.4165315e-8,0.000019503665,0.0000045084385,0.9826733,0.0113488715],"study_design_scores_gemma":[0.0054730778,0.0004308611,0.00014909952,0.0013877904,0.0011062105,0.00035101286,0.000026980993,0.000001375137,0.0001382746,0.00002949681,0.99033076,0.00057508604],"about_ca_topic_score_codex":0.000030196277,"about_ca_topic_score_gemma":0.0003088747,"teacher_disagreement_score":0.012884986,"about_ca_system_score_codex":0.000810925,"about_ca_system_score_gemma":0.0019260229,"threshold_uncertainty_score":0.9997162},"labels":[],"label_agreement":null},{"id":"W4250102434","doi":"10.1086/340988","title":"Reply","year":2002,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine","score_opus":0.05078051523301693,"score_gpt":0.350039241495014,"score_spread":0.29925872626199707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250102434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90049624,0.0017728732,0.000052062558,0.010652558,0.0007387063,0.0005579089,0.0000158281,0.0007683535,0.084945485],"genre_scores_gemma":[0.9562923,0.000552107,0.000049596394,0.004382908,0.00040919316,0.000037922597,0.000025161195,0.000019691488,0.038231157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891067,0.000052842162,0.00039011973,0.00029341158,0.00015537061,0.00019761107],"domain_scores_gemma":[0.9989385,0.00025156268,0.00006398444,0.0003076946,0.00006159044,0.00037666783],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008615267,0.00013031007,0.00031965363,0.00005743846,0.00008294616,0.000018347568,0.000039767034,0.000060793005,0.00257479],"category_scores_gemma":[0.00065107195,0.00010057987,0.00027004312,0.0001516529,0.00011179431,0.000049877504,0.000030656192,0.00013009492,0.0027301097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014647751,0.0016758272,0.81822413,0.000016579337,0.00015386542,0.00014181432,0.000022959508,2.9485696e-7,9.4493686e-7,0.00010023494,0.160079,0.019569727],"study_design_scores_gemma":[0.003506299,0.0004122778,0.658115,0.000068878515,0.00047854107,0.000029859677,0.000015858746,0.0001566451,0.000019562458,0.00049758225,0.33649763,0.00020182083],"about_ca_topic_score_codex":0.0000027767258,"about_ca_topic_score_gemma":0.0000018763078,"teacher_disagreement_score":0.17641863,"about_ca_system_score_codex":0.00004506363,"about_ca_system_score_gemma":0.000036847934,"threshold_uncertainty_score":0.998337},"labels":[],"label_agreement":null},{"id":"W4250670446","doi":"10.1097/00126334-200309011-00001","title":"Introduction","year":2003,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Providence Health Care","funders":"","keywords":"Nevirapine; Medicine; Human immunodeficiency virus (HIV); Family medicine; Pharmacology; Antiretroviral therapy; Viral load","score_opus":0.013142886690831817,"score_gpt":0.25378636921349407,"score_spread":0.24064348252266224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250670446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98368746,0.005277543,0.00045918414,0.0053059426,0.0015970601,0.00020807903,0.000001198642,0.000058445676,0.0034050632],"genre_scores_gemma":[0.9733534,0.00047412884,0.00509684,0.000037523,0.00016264303,0.0000044528056,0.000005922166,0.00003337178,0.02083173],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980237,0.00008911979,0.00081516965,0.000191984,0.00054326776,0.00033678114],"domain_scores_gemma":[0.99883044,0.00006653814,0.00038770933,0.0002916153,0.00029468164,0.00012901709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009719573,0.0002024873,0.00055667793,0.0005737112,0.00012471597,0.000032101918,0.00012759876,0.0000804211,0.00048731093],"category_scores_gemma":[0.00059894973,0.00014882583,0.0002836124,0.0007691092,0.0000928118,0.00026900545,0.000018707793,0.00010574046,0.00031778507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002874862,0.013600965,0.21369877,0.0012840941,0.0065494305,0.009986336,0.016069632,0.00040393433,0.3138561,0.034937665,0.28360954,0.10312867],"study_design_scores_gemma":[0.022475813,0.0069352337,0.2283828,0.0012149485,0.0028026698,0.08683812,0.009368455,0.00009647647,0.19602455,0.0040674396,0.4399517,0.001841793],"about_ca_topic_score_codex":0.0000014296103,"about_ca_topic_score_gemma":1.5554663e-7,"teacher_disagreement_score":0.15634216,"about_ca_system_score_codex":0.00016385799,"about_ca_system_score_gemma":0.00027019563,"threshold_uncertainty_score":0.60689414},"labels":[],"label_agreement":null},{"id":"W4251879600","doi":"10.1128/aac.02916-14","title":"Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase","year":2014,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Integrase; Integrase inhibitor; Drug resistance; Virology; Drug; Antiretroviral drug; Human immunodeficiency virus (HIV); HIV drug resistance; Lentivirus; Pharmacology; Medicine; Biology; Genetics; Viral disease; Antiretroviral therapy; Viral load","score_opus":0.005205748087593694,"score_gpt":0.22871349922133824,"score_spread":0.22350775113374455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251879600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949392,0.00007481005,0.00005238071,0.0038486926,0.000023684497,0.00018555926,0.000025584897,0.000008176993,0.00084190624],"genre_scores_gemma":[0.99542224,0.00029351702,0.00090416806,0.00052104954,0.000014703091,0.0000040931577,0.000058166253,0.000009073155,0.0027729585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920887,0.000031740492,0.00030303487,0.00019576523,0.00011972674,0.00014085532],"domain_scores_gemma":[0.99953437,0.000027786373,0.00010863458,0.0002359112,0.000047897123,0.000045406097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011387369,0.0001308729,0.0003862521,0.00016088168,0.000042210217,0.0000059556655,0.00009664347,0.000059223916,0.00006021861],"category_scores_gemma":[0.000014270167,0.000085070016,0.00016695558,0.00060946355,0.0001714598,0.000022996826,0.000021980968,0.000087099645,0.0000019853676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039608928,0.0012178514,0.83834076,0.00008753384,0.0017046065,0.0000037909756,0.002963264,0.000006614263,0.13546701,0.0015533881,0.01583495,0.002424159],"study_design_scores_gemma":[0.0050637294,0.000022858085,0.5539836,0.0004592639,0.001258505,0.0000035550283,0.0002461355,0.00050903636,0.37585235,0.00027421067,0.062052377,0.00027436696],"about_ca_topic_score_codex":0.00007194483,"about_ca_topic_score_gemma":0.00015227697,"teacher_disagreement_score":0.28435713,"about_ca_system_score_codex":0.000029743318,"about_ca_system_score_gemma":0.000040769704,"threshold_uncertainty_score":0.34690547},"labels":[],"label_agreement":null},{"id":"W4253522419","doi":"10.1007/s100590000007","title":"Characterization of Mutant HIV-1 Integrase Carrying Amino Acid Changes in the Catalytic Domain","year":2000,"lang":"en","type":"article","venue":"Molecules and Cells","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum; Université de Montréal","funders":"","keywords":"Mutant; Mutagenesis; Integrase; Enzyme; Amino acid; Chemistry; Isoleucine; Biochemistry; Biology; Leucine; Gene","score_opus":0.006894816889893893,"score_gpt":0.21013597642047038,"score_spread":0.20324115953057648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253522419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963725,0.00012393047,0.000037815567,0.0017679556,0.000013579525,0.00023413086,0.000015644093,0.0000068762133,0.0014275728],"genre_scores_gemma":[0.99719,0.00034314647,0.0001454014,0.00022066015,0.000017739978,0.000018307523,0.00012663643,0.000007668155,0.001930423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950165,0.000025522993,0.0001257832,0.00012152755,0.00010739249,0.00011815375],"domain_scores_gemma":[0.9998053,0.000011553646,0.000030307336,0.00010913595,0.000010912982,0.000032812182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000821779,0.00009268916,0.00014669322,0.000056657307,0.00002787196,0.0000101526475,0.00003811201,0.00003109511,0.0001175168],"category_scores_gemma":[0.0000019026228,0.000057691264,0.00002312277,0.00009721819,0.000033668515,0.000018901428,0.000008608354,0.000052679094,0.00002215108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008015053,0.00018821501,0.0027252373,0.000086030595,0.000045060722,0.00021794128,0.0103205135,5.2995927e-7,0.9523221,0.00008356836,0.000059777325,0.033870872],"study_design_scores_gemma":[0.001459121,0.000114700735,0.015245726,0.00019905175,0.00010153246,0.00004882811,0.001676971,0.0001127973,0.97186667,0.000043191318,0.008991805,0.00013962795],"about_ca_topic_score_codex":0.000016990627,"about_ca_topic_score_gemma":0.000028809438,"teacher_disagreement_score":0.033731245,"about_ca_system_score_codex":0.000017855367,"about_ca_system_score_gemma":0.000017242792,"threshold_uncertainty_score":0.23525815},"labels":[],"label_agreement":null},{"id":"W4281676013","doi":"10.1016/s2352-3018(22)00046-7","title":"Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study","year":2022,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; Medical Research Council; Center for AIDS Research, University of Washington; European Regional Development Fund; Stichting HIV Monitoring; Agence Nationale de Recherches sur le Sida et les Hépatites Virales; Ministerie van Volksgezondheid, Welzijn en Sport; Instituto de Salud Carlos III; ViiV Healthcare; Institut National de la Santé et de la Recherche Médicale; Deutsches Zentrum für Infektionsforschung; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Styrelsen för Internationellt Utvecklingssamarbete; Gilead Sciences; Wellcome Trust; National Institute for Health and Care Research; U.S. Department of Veterans Affairs; Office of Research and Development; National Science Foundation","keywords":"Medicine; Human immunodeficiency virus (HIV); Cohort; Antiretroviral therapy; Cohort study; Drug; Demography; Pediatrics; Virology; Viral load; Internal medicine; Pharmacology","score_opus":0.031943929646097394,"score_gpt":0.2848515534860085,"score_spread":0.2529076238399111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281676013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996301,0.000039779956,0.0000042695,0.0013235072,0.00001042105,0.0009814444,0.00012280139,0.000026074475,0.001190712],"genre_scores_gemma":[0.9984626,0.000041598072,0.00012357868,0.00013365634,0.000026948312,0.00013847924,0.00022051853,0.000018016362,0.0008345756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869317,0.00020094561,0.0002357201,0.00024895964,0.00039521282,0.00022599947],"domain_scores_gemma":[0.999417,0.00005482264,0.00014172282,0.00029749091,0.000048661423,0.000040277937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029497553,0.00013988663,0.00047859622,0.00007557946,0.00007296538,0.000007881616,0.00009769884,0.00001032132,0.0000150448805],"category_scores_gemma":[0.000023324921,0.00008785749,0.000013815268,0.0005462099,0.00007810595,0.00005211874,0.00008938204,0.0002540271,0.0000028388124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007482367,0.0007862416,0.97901535,0.000013579187,0.0005263393,0.00032901124,0.017862886,0.00011817275,0.0000034644704,0.000014296928,0.00045437348,0.00012802669],"study_design_scores_gemma":[0.0061089485,0.00040508594,0.99084,0.00004106412,0.00027195003,0.0000095910445,0.0016920732,0.00041851835,0.000004653945,0.000007272214,0.00009555382,0.0001052567],"about_ca_topic_score_codex":0.0003782304,"about_ca_topic_score_gemma":0.0037853331,"teacher_disagreement_score":0.016170813,"about_ca_system_score_codex":0.000102419974,"about_ca_system_score_gemma":0.00011818946,"threshold_uncertainty_score":0.35827243},"labels":[],"label_agreement":null},{"id":"W4281791708","doi":"10.1016/s2352-3018(22)00103-5","title":"Can integrase inhibitors reduce mortality?","year":2022,"lang":"en","type":"letter","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Dolutegravir; Raltegravir; Medicine; Integrase inhibitor; Integrase; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Viral load","score_opus":0.044449010200333365,"score_gpt":0.2965098776661206,"score_spread":0.2520608674657872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281791708","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010938657,0.00034271742,0.0000010237549,0.9647049,0.00070782035,0.0006081277,0.00021736258,0.00016650915,0.02231294],"genre_scores_gemma":[0.0056116795,0.00023780788,0.00017470782,0.6432936,0.012601606,0.00035199372,0.0042591183,0.00011179482,0.33335766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979688,0.00014914358,0.00031788193,0.00042020617,0.0006269929,0.00051697047],"domain_scores_gemma":[0.9986502,0.00010309823,0.00015005544,0.0009876263,0.000036778878,0.000072230054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030078078,0.00037612033,0.00076345477,0.000121438185,0.00018254197,0.000032056396,0.00034903493,0.00021432557,0.0019531895],"category_scores_gemma":[0.000050981227,0.0002291356,0.00020524277,0.00024148282,0.00011111977,0.0000227505,0.00016003157,0.0022104774,0.00031611972],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045974084,0.00004114923,0.002476055,0.000102845,0.00057535595,0.0018719871,0.0008197733,3.5591808e-7,0.00001175661,0.000046055327,0.9935535,0.00045519948],"study_design_scores_gemma":[0.0009418649,0.000041236053,0.00041864984,0.00014962397,0.00055428396,0.00010290043,0.0001478865,0.000003557761,0.00022149159,0.00024627405,0.9969235,0.00024869895],"about_ca_topic_score_codex":0.0001163889,"about_ca_topic_score_gemma":0.000033094875,"teacher_disagreement_score":0.32141122,"about_ca_system_score_codex":0.0003545079,"about_ca_system_score_gemma":0.00029844136,"threshold_uncertainty_score":0.9989592},"labels":[],"label_agreement":null},{"id":"W4282827346","doi":"10.1097/qai.0000000000003038","title":"Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine","year":2022,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fogarty International Center","keywords":"Dolutegravir; Lopinavir; Ritonavir; Medicine; Efavirenz; Regimen; Viral load; Internal medicine; Confidence interval; Odds ratio; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.04329300339581226,"score_gpt":0.33855091696261,"score_spread":0.29525791356679776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282827346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350184,0.0034632133,0.000038639908,0.0015122087,0.000508906,0.00050778774,0.000018002933,0.000028110315,0.00042126418],"genre_scores_gemma":[0.9935711,0.0010575427,0.001347617,0.00008690747,0.00003357815,0.000022939264,0.000025499641,0.000039315222,0.0038154887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569964,0.0003086027,0.0020284846,0.00032749138,0.0011801419,0.00045562926],"domain_scores_gemma":[0.99759614,0.00049773155,0.0010740801,0.00040654384,0.00028060112,0.00014488661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018888513,0.0003703344,0.0019616147,0.0009639092,0.00022041796,0.000020811196,0.00042485486,0.00008362759,0.00028144178],"category_scores_gemma":[0.00014849244,0.00024251034,0.0005482517,0.0014632925,0.0003573718,0.00022907641,0.00013110417,0.0003801761,0.0000218251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004055793,0.003375834,0.9793488,0.000050464834,0.0008563113,0.0009572842,0.004810712,0.00017374735,0.00067673496,0.000096793156,0.0004812819,0.0051162355],"study_design_scores_gemma":[0.020972632,0.020323008,0.94666713,0.00035080663,0.00028705606,0.0023748893,0.005555505,0.0001061434,0.0014709391,0.0001707264,0.0013225657,0.00039861718],"about_ca_topic_score_codex":0.000071534225,"about_ca_topic_score_gemma":0.0000107840115,"teacher_disagreement_score":0.032681696,"about_ca_system_score_codex":0.00020539296,"about_ca_system_score_gemma":0.00057631946,"threshold_uncertainty_score":0.9889285},"labels":[],"label_agreement":null},{"id":"W4282961898","doi":"10.1158/1538-7445.am2022-1839","title":"Abstract 1839: Nelfinavir induced-cytotoxicity towards high-grade serous ovarian cancer cells involves induction of the unfolded protein response, modulation of protein synthesis, DNA damage, lysosomal impairment, and potentiation of toxicity caused by proteasome inhibition","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Unfolded protein response; Nelfinavir; Cancer research; Pharmacology; Medicine; Biology; Chemistry; Endoplasmic reticulum; Immunology; Cell biology","score_opus":0.04260717220798169,"score_gpt":0.31636442164737705,"score_spread":0.27375724943939533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282961898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99011344,0.00013016119,0.0000084017465,0.0037566477,0.00005692124,0.005533332,0.00036112394,0.000024828394,0.000015135695],"genre_scores_gemma":[0.99596316,0.000034707056,0.0001081045,0.000012940813,0.000045411325,0.003213301,0.000054419674,0.00003554719,0.00053239346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99613667,0.0008994838,0.00064032635,0.0004498871,0.0014807918,0.0003928448],"domain_scores_gemma":[0.99842054,0.00007831393,0.00051601167,0.00040845998,0.0004342598,0.00014242771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019061908,0.00022572333,0.0004470145,0.00041970226,0.0003357896,0.000020897727,0.00016172245,0.00015303293,0.0001895897],"category_scores_gemma":[0.0002530188,0.00018482047,0.00009218951,0.0011157854,0.00022551273,0.00024212332,0.00021554207,0.0005420356,5.8384325e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023317095,0.0008893178,0.003855219,0.0006192262,0.00016688355,0.0000063256853,0.0011604113,0.00007866632,0.9883567,0.000035468045,0.00015285253,0.0023472323],"study_design_scores_gemma":[0.001523748,0.00032509267,0.26265642,0.0004697846,0.000043505013,0.000001667882,0.00037309856,0.00006559593,0.7342553,0.00015477244,0.000019995674,0.000110994275],"about_ca_topic_score_codex":0.004461157,"about_ca_topic_score_gemma":0.00019095834,"teacher_disagreement_score":0.25880122,"about_ca_system_score_codex":0.0011453411,"about_ca_system_score_gemma":0.0016009927,"threshold_uncertainty_score":0.753676},"labels":[],"label_agreement":null},{"id":"W4283079234","doi":"10.3390/pathogens11060693","title":"Probe Capture Enrichment Methods for HIV and HCV Genome Sequencing and Drug Resistance Genotyping","year":2022,"lang":"en","type":"review","venue":"Pathogens","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Sanger sequencing; Genotyping; Biology; Massive parallel sequencing; DNA sequencing; Genome; Computational biology; Whole genome sequencing; Virology; Deep sequencing; Genetics; DNA; Gene; Genotype","score_opus":0.055711466254488466,"score_gpt":0.3533919128151366,"score_spread":0.2976804465606481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283079234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000059462996,0.9915348,0.0034532922,0.00034894634,0.000117482756,0.0031405906,0.0001933366,0.00006690202,0.0011386524],"genre_scores_gemma":[8.273472e-7,0.7611469,0.2099277,0.00006945487,0.00009903776,0.001139469,0.0005693441,0.000080405,0.02696684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976673,0.00026587467,0.0005868104,0.0008235989,0.00021034824,0.0004460537],"domain_scores_gemma":[0.99865526,0.0004130317,0.00029084482,0.0003720446,0.00004769218,0.00022112987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010320616,0.000545575,0.0016621569,0.0002367211,0.0003291031,0.000039794395,0.00010248535,0.00015755871,0.00008356905],"category_scores_gemma":[0.00012110995,0.00043057906,0.00026689228,0.00025223847,0.00004987586,0.00003678172,0.00017516853,0.0003400864,0.00000527611],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033721022,0.000056456818,0.00003050719,0.03258777,0.0008406235,0.00019746085,0.0040685837,1.8471779e-7,0.00008132965,0.00038564682,0.00068950467,0.9610282],"study_design_scores_gemma":[0.00053560734,0.000018903726,0.000005977128,0.0022032673,0.0025103104,0.00013101687,0.00024587853,0.0000066194434,0.0000038348826,0.00009036113,0.9938431,0.000405169],"about_ca_topic_score_codex":0.000002430973,"about_ca_topic_score_gemma":0.000007773589,"teacher_disagreement_score":0.9931536,"about_ca_system_score_codex":0.00074819446,"about_ca_system_score_gemma":0.0005241285,"threshold_uncertainty_score":0.9998146},"labels":[],"label_agreement":null},{"id":"W4283397709","doi":"10.2196/33429","title":"Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study","year":2022,"lang":"en","type":"article","venue":"JMIR Public Health and Surveillance","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Observational study; Medicine; Regimen; Retrospective cohort study; Human immunodeficiency virus (HIV); Cohort study; Antiretroviral drug; Cohort; Drug; Antiretroviral therapy; Antiretroviral treatment; Internal medicine; Virology; Intensive care medicine; Pharmacology; Viral load","score_opus":0.013162515113973941,"score_gpt":0.280219830946766,"score_spread":0.2670573158327921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283397709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448884,0.00011179945,0.0000032045812,0.0017784414,0.00006355865,0.0031843646,0.000035748206,0.00004011596,0.00029394488],"genre_scores_gemma":[0.9976205,0.000026973834,0.000038223807,0.00008950025,0.00002408622,0.0007628175,0.0003457581,0.000018338316,0.0010737558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764395,0.0005476041,0.00042525443,0.00042101933,0.0006028453,0.00035932407],"domain_scores_gemma":[0.9990995,0.00012647589,0.00022466293,0.0002293449,0.000094617986,0.00022540722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013099157,0.0002165127,0.0006716421,0.00023096405,0.00027377286,0.000018928713,0.00004464193,0.000023234481,0.00002724058],"category_scores_gemma":[0.00005847123,0.00015727828,0.00004351394,0.0005067242,0.00002905026,0.00010001067,0.000049315342,0.00017267592,0.0000013731358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013380529,0.0014809257,0.991228,0.000089458554,0.0001505385,0.000017720635,0.0018535777,0.000002031075,6.143406e-7,0.00001866681,0.00027635184,0.003544048],"study_design_scores_gemma":[0.00918792,0.009579346,0.97876227,0.000015820508,0.000005043304,0.0000027182987,0.00018601347,0.000035189423,0.0000012236327,0.0000015808279,0.0021026204,0.00012025309],"about_ca_topic_score_codex":0.00043937875,"about_ca_topic_score_gemma":0.00027123126,"teacher_disagreement_score":0.012465742,"about_ca_system_score_codex":0.0012073687,"about_ca_system_score_gemma":0.00060137425,"threshold_uncertainty_score":0.6413622},"labels":[],"label_agreement":null},{"id":"W4283587189","doi":"10.3390/pathogens11070724","title":"Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials","year":2022,"lang":"en","type":"article","venue":"Pathogens","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Point-of-care testing; HIV drug resistance; Human immunodeficiency virus (HIV); Medicine; Drug resistance; Antiretroviral therapy; Turnaround time; Regimen; Intensive care medicine; Viral load; Virology; Computer science; Immunology; Surgery; Biology; Microbiology","score_opus":0.013689059816817064,"score_gpt":0.27912124006945105,"score_spread":0.265432180252634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283587189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324856,0.05459241,0.000296506,0.0060937423,0.00062476797,0.0017448614,0.0005183525,0.00011665766,0.003527133],"genre_scores_gemma":[0.9456876,0.00046409812,0.022542518,0.000031121475,0.000102242055,0.00030243458,0.00010638762,0.000026824408,0.030736767],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99919367,0.000026099115,0.00018616942,0.00022315857,0.00020140503,0.00016947695],"domain_scores_gemma":[0.9995358,0.000083748964,0.00007769515,0.00015653802,0.00007624239,0.000069969035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001238787,0.00010867129,0.0002298122,0.00007088919,0.00017808963,0.000005782059,0.0000493633,0.000015514284,0.000039405848],"category_scores_gemma":[0.000052895502,0.000097956596,0.00006866859,0.000109852175,0.00002670545,0.00003948896,0.000055074008,0.000052804586,0.0000027956132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022903413,0.0010129984,0.8184311,0.0036895298,0.0006427824,0.00058135705,0.02736762,0.000033106884,0.0638063,0.0017391981,0.025928486,0.054477174],"study_design_scores_gemma":[0.005764741,0.00025008424,0.029321661,0.000323904,0.0005758166,0.000053794138,0.013459974,0.000017728386,0.06124343,0.0009788843,0.88752735,0.00048266497],"about_ca_topic_score_codex":5.257466e-7,"about_ca_topic_score_gemma":0.000005012126,"teacher_disagreement_score":0.86159885,"about_ca_system_score_codex":0.00006398853,"about_ca_system_score_gemma":0.000056251487,"threshold_uncertainty_score":0.3994554},"labels":[],"label_agreement":null},{"id":"W4283726433","doi":"10.3390/pathogens11070739","title":"Overview of the Analytes Applied in Genotypic HIV Drug Resistance Testing","year":2022,"lang":"en","type":"review","venue":"Pathogens","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Public Health Agency; Public Health Agency of Canada","keywords":"Human immunodeficiency virus (HIV); Analyte; HIV drug resistance; Genotype; Drug; Drug resistance; Population; Relevance (law); Computational biology; Medicine; Biology; Pharmacology; Virology; Chromatography; Antiretroviral therapy; Chemistry; Genetics; Environmental health; Viral load","score_opus":0.1093614608389237,"score_gpt":0.3255115602728225,"score_spread":0.21615009943389882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283726433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000066119595,0.9873512,8.9647295e-7,0.0001460103,0.000068006506,0.0011472378,0.00008219621,0.000025826335,0.011112525],"genre_scores_gemma":[0.000042911903,0.97844285,0.0015942369,0.000034897825,0.000046457448,0.00031352503,0.0001596907,0.000053152948,0.019312276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980589,0.00015964094,0.0007159078,0.00040655705,0.0003873641,0.0002716073],"domain_scores_gemma":[0.9985135,0.00037211043,0.00041575535,0.0006120842,0.000028043003,0.00005849023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043424763,0.00034098353,0.0015127806,0.00020314437,0.00009281074,0.0000066302023,0.00025181775,0.00007977904,0.0003018304],"category_scores_gemma":[0.0001618177,0.00021648039,0.0003801453,0.0013634525,0.000042463536,0.0000108487175,0.00018746675,0.00035771678,0.000038111437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002629583,0.00045742214,0.0040540337,0.054148544,0.00071834115,0.00028400705,0.0012549883,0.0000015945981,0.000016010632,0.00085906236,0.004448725,0.93373096],"study_design_scores_gemma":[0.00029659065,0.0000030885387,0.000499919,0.008105332,0.0012027947,0.000014219147,0.000049420916,0.0000013382844,0.0000044344115,0.000039082293,0.9895973,0.00018644854],"about_ca_topic_score_codex":0.0000034915263,"about_ca_topic_score_gemma":0.00006133891,"teacher_disagreement_score":0.9851486,"about_ca_system_score_codex":0.00031363912,"about_ca_system_score_gemma":0.00054544717,"threshold_uncertainty_score":0.8827814},"labels":[],"label_agreement":null},{"id":"W4283761097","doi":"10.3390/molecules27134212","title":"The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2","year":2022,"lang":"en","type":"article","venue":"Molecules","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Gilead Sciences","keywords":"Emtricitabine; Virology; Reverse transcriptase; Tenofovir alafenamide; Prodrug; Nucleoside; Pharmacology; Nucleoside Reverse Transcriptase Inhibitor; Medicine; Biology; Virus; RNA; Viral load; Biochemistry; Antiretroviral therapy; Gene","score_opus":0.013443300753829985,"score_gpt":0.24987677221689664,"score_spread":0.23643347146306665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283761097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766433,0.0011868919,0.000019735691,0.010359899,0.00007543679,0.0003979532,0.000024518642,0.00007452594,0.011217724],"genre_scores_gemma":[0.9931676,0.00016507077,0.00038780828,0.0016536147,0.000032951353,0.00010205913,0.000042282838,0.000033471923,0.004415189],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882287,0.00008071971,0.00020164662,0.0002915078,0.00031631617,0.00028696636],"domain_scores_gemma":[0.99944454,0.000093842595,0.00009738776,0.0002463852,0.000052000425,0.00006586458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014340715,0.00018596626,0.00024339533,0.00011892136,0.0006558593,0.000038489794,0.0001073809,0.000028477574,0.000019462324],"category_scores_gemma":[0.00006991314,0.00012896679,0.000073233015,0.000299735,0.00010461889,0.000042440613,0.0002019044,0.00021332067,0.00003858476],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024368856,0.0029508846,0.23585707,0.00024009986,0.0037835243,0.008614676,0.013900147,0.00008365101,0.23056887,0.008543368,0.35320956,0.13981126],"study_design_scores_gemma":[0.00912887,0.0009099663,0.33650342,0.00016150721,0.00064252655,0.00033959385,0.014670727,0.0013690686,0.09069586,0.00201822,0.54243886,0.0011214175],"about_ca_topic_score_codex":0.000029796605,"about_ca_topic_score_gemma":0.000047705405,"teacher_disagreement_score":0.18922926,"about_ca_system_score_codex":0.00022575742,"about_ca_system_score_gemma":0.000091944465,"threshold_uncertainty_score":0.5259113},"labels":[],"label_agreement":null},{"id":"W4285491645","doi":"10.1097/qad.0000000000003234","title":"Estimating the minimum antiretroviral adherence required for plasma HIV-1 RNA viral load suppression among people living with HIV who use unregulated drugs","year":2022,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; British Columbia Centre on Substance Use","funders":"National Institute on Drug Abuse","keywords":"Regimen; Viral load; Medicine; Confidence interval; Internal medicine; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Prospective cohort study; Cohort; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.013246643791208285,"score_gpt":0.24645137917694535,"score_spread":0.23320473538573705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285491645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99696213,0.000034381155,0.00055161974,0.00063455163,0.00021585624,0.0009806385,0.000046115067,0.0001396988,0.00043502418],"genre_scores_gemma":[0.95149994,0.000002105852,0.010284769,0.00008036287,0.000089227295,0.0003295242,0.00017476495,0.000055915516,0.037483398],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997915,0.00012358504,0.00036859093,0.00046188876,0.0006378164,0.00049306493],"domain_scores_gemma":[0.99864197,0.00050291483,0.00019989889,0.00042683037,0.00010337496,0.00012499288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040454316,0.00029596308,0.00041541999,0.000107511754,0.00072224817,0.000086323096,0.00021408589,0.000061374485,0.0002031892],"category_scores_gemma":[0.00018128408,0.00019531902,0.00012386187,0.00040013465,0.00010604497,0.0003278687,0.00023201152,0.00025112985,0.000021252374],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009930137,0.00037569716,0.9447561,0.00014617416,0.00039256903,0.00008112048,0.021874856,0.0006985866,0.0029005134,0.00009683779,0.018951744,0.0087327985],"study_design_scores_gemma":[0.022286681,0.0071177487,0.3791534,0.003307856,0.0017569965,0.00022370488,0.013825754,0.553733,0.013816719,0.00012468996,0.0028428773,0.0018105491],"about_ca_topic_score_codex":0.000097372395,"about_ca_topic_score_gemma":0.000012051227,"teacher_disagreement_score":0.56560266,"about_ca_system_score_codex":0.00026189414,"about_ca_system_score_gemma":0.00025742786,"threshold_uncertainty_score":0.7964878},"labels":[],"label_agreement":null},{"id":"W4286685640","doi":"10.1101/2022.07.22.501121","title":"An assessment of Nano-RECall: Interpretation of Oxford Nanopore sequence data for HIV-1 drug resistance testing","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; National Health Laboratory Service; National Institutes of Health; Universiteit Stellenbosch; South African Medical Research Council","keywords":"Sanger sequencing; Nanopore sequencing; Amplicon; Minion; Computational biology; Biology; Consensus sequence; Genotyping; HIV drug resistance; Genetics; Drug resistance; DNA sequencing; Human immunodeficiency virus (HIV); Polymerase chain reaction; Gene; Genotype; Virology; Peptide sequence; Viral load","score_opus":0.03889034857000116,"score_gpt":0.3176655268984511,"score_spread":0.27877517832844995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286685640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707017,0.0015805286,0.013444893,0.0018612845,0.001028618,0.0045703356,0.006260707,0.0004186872,0.00013323456],"genre_scores_gemma":[0.7787807,0.00011527085,0.22029209,0.000044663124,0.000072387294,0.0003890685,0.0000603644,0.00009664156,0.00014882574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99660456,0.00014962068,0.0010391793,0.0011582965,0.0006611277,0.00038722288],"domain_scores_gemma":[0.9952221,0.00023729482,0.0011096242,0.0024215428,0.0008155154,0.00019393013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011414684,0.00047984178,0.0009461329,0.00031352803,0.00013811479,0.000043549233,0.0008831879,0.00018984568,0.00007879796],"category_scores_gemma":[0.00048054676,0.00049160724,0.00012783967,0.00052724,0.00013143555,0.00022124093,0.0006711651,0.00042902294,0.0000013539186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004951694,0.0019666122,0.14502166,0.009320414,0.0014655639,0.00012628296,0.00027515038,0.00024477197,0.8355758,0.0010260264,0.0044242125,0.00005829963],"study_design_scores_gemma":[0.0132250395,0.0010695886,0.17414017,0.02055234,0.005770776,3.421759e-7,0.00030399012,0.16623627,0.512629,0.000037713115,0.10089164,0.005143175],"about_ca_topic_score_codex":0.000016818363,"about_ca_topic_score_gemma":0.000009578631,"teacher_disagreement_score":0.32294688,"about_ca_system_score_codex":0.00052321545,"about_ca_system_score_gemma":0.0015818188,"threshold_uncertainty_score":0.99975353},"labels":[],"label_agreement":null},{"id":"W4292003352","doi":"","title":"Abstracts of the XIV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. 7-11 June 2005, Quebec City, Canada.","year":2005,"lang":"en","type":"other","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Environmental health; Gerontology; Family medicine","score_opus":0.025284161225743392,"score_gpt":0.26411205359675427,"score_spread":0.23882789237101087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292003352","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034929034,0.00220918,0.000007867449,0.6697468,0.0012730199,0.0025691907,0.0002694608,0.00009151437,0.32034007],"genre_scores_gemma":[0.0055403113,0.0005712883,0.0004476303,0.0003079731,0.00046647582,0.00035006963,0.0001261412,0.00009320233,0.9920969],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832094,0.000040687657,0.0005777103,0.0003701675,0.00039820417,0.0002923224],"domain_scores_gemma":[0.9986687,0.00015618835,0.00044349348,0.0004693409,0.00006337801,0.0001989366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033291185,0.00022926404,0.0004016601,0.00010810907,0.00004393847,0.000018776724,0.00025725484,0.0001563125,0.00040266025],"category_scores_gemma":[0.00021727702,0.0001621245,0.00009524461,0.00011209612,0.00015190274,0.000026056807,0.000111897985,0.0002336618,0.000007992133],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026293206,0.00014261756,0.02339594,0.00004022209,0.0003279427,0.0000071570526,0.00002139906,3.4309684e-7,1.0993683e-7,0.00031556492,0.97215563,0.003566782],"study_design_scores_gemma":[0.0005760482,7.4221674e-8,0.3159278,0.00013470309,0.00010731488,0.0000034146217,0.000009188353,5.8555713e-7,0.0000102172535,0.0000071222444,0.6831285,0.00009505641],"about_ca_topic_score_codex":0.008388694,"about_ca_topic_score_gemma":0.9927392,"teacher_disagreement_score":0.9843505,"about_ca_system_score_codex":0.00035159962,"about_ca_system_score_gemma":0.00087732956,"threshold_uncertainty_score":0.99821454},"labels":[],"label_agreement":null},{"id":"W4292242368","doi":"10.1097/qad.0000000000003308","title":"Can simplified antiretroviral drug combination therapies resist resistance?","year":2022,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; Vancouver Infectious Diseases Centre","funders":"","keywords":"Medicine; Regimen; Drug holiday; Viral load; Drug resistance; Clinical trial; Drug; Internal medicine; Antiretroviral therapy; HIV drug resistance; Human immunodeficiency virus (HIV); Intensive care medicine; Immunology; Pharmacology; Biology","score_opus":0.010685783199991925,"score_gpt":0.24369222867448562,"score_spread":0.2330064454744937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292242368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968843,0.000519993,0.0000076725,0.0145326825,0.00019368554,0.0003255985,0.00002442845,0.00011760921,0.01543532],"genre_scores_gemma":[0.8342541,0.000021561626,0.00049606775,0.00040383264,0.00003452884,0.00007560443,0.00018177327,0.000018516466,0.16451402],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989384,0.000079203724,0.00018325081,0.00021868388,0.00037771542,0.00020279337],"domain_scores_gemma":[0.9995581,0.000046465357,0.00005741376,0.00023351451,0.000041172225,0.00006335729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021565544,0.00012492864,0.0002025759,0.00013463447,0.00035454388,0.000018427101,0.00008464107,0.000020142365,0.00043164502],"category_scores_gemma":[0.000020251737,0.000111452544,0.00007059038,0.00030556213,0.00004314633,0.00004153105,0.000058926566,0.00013988747,0.000027071663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009802375,0.001161553,0.7262095,0.00011349058,0.0006432958,0.00038984048,0.011863848,0.0000025963204,0.0032450326,0.041998755,0.20051101,0.012880802],"study_design_scores_gemma":[0.014623015,0.0014715852,0.32581538,0.00011443612,0.0004657247,0.000047431986,0.011842365,0.000047552086,0.011103891,0.011873671,0.6216774,0.00091755646],"about_ca_topic_score_codex":0.00004644328,"about_ca_topic_score_gemma":0.00003801411,"teacher_disagreement_score":0.42116636,"about_ca_system_score_codex":0.00023983786,"about_ca_system_score_gemma":0.000110263456,"threshold_uncertainty_score":0.47262102},"labels":[],"label_agreement":null},{"id":"W4293070037","doi":"10.5863/1551-6776-27.6.551","title":"Is Routine Therapeutic Drug Monitoring of Anti-Retroviral Agents Warranted in Children Living with HIV?","year":2022,"lang":"en","type":"article","venue":"The Journal of Pediatric Pharmacology and Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; BC Children's Hospital; University of Toronto","funders":"","keywords":"Medicine; Raltegravir; Dolutegravir; Ritonavir; Therapeutic drug monitoring; Interquartile range; Trough level; Viral load; Therapeutic index; Internal medicine; Integrase inhibitor; Reverse-transcriptase inhibitor; Adverse effect; Antiretroviral therapy; Pharmacology; Drug; Pharmacokinetics; Human immunodeficiency virus (HIV); Virology; Transplantation","score_opus":0.018774270813809838,"score_gpt":0.29506999497245195,"score_spread":0.2762957241586421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293070037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247134,0.00507075,0.000025803562,0.0019371597,0.00021246423,0.00024434092,0.0000061027713,0.0000074823306,0.000024558723],"genre_scores_gemma":[0.99406135,0.0047465255,0.00010807055,0.00046099498,0.00030106984,0.000004767633,0.0000014921006,0.000019257406,0.00029648998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860567,0.00029166442,0.00043294852,0.00010424003,0.00033059766,0.00023490471],"domain_scores_gemma":[0.99917376,0.0002097826,0.0003924651,0.00009017541,0.00007249192,0.0000613218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007988294,0.0001637572,0.00037197393,0.00028411436,0.00016447197,0.000004639867,0.00017212454,0.000034458575,0.00013689093],"category_scores_gemma":[0.0000033911858,0.00010154118,0.000066068904,0.00041155986,0.000072448085,0.000063391766,0.00007296516,0.0005611173,0.000001160509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005461017,0.00046342902,0.9901499,0.00001890764,0.00095611834,0.00003190662,0.0055079036,0.0000774857,0.001330611,0.00000230553,0.00017144503,0.0007438523],"study_design_scores_gemma":[0.0059200632,0.00061867747,0.986063,0.000022127164,0.0027822207,0.0005311609,0.0012831612,0.00021004361,0.002281208,0.000028134296,0.00012998721,0.00013019057],"about_ca_topic_score_codex":0.000005729729,"about_ca_topic_score_gemma":2.9790638e-7,"teacher_disagreement_score":0.0053739618,"about_ca_system_score_codex":0.00007988858,"about_ca_system_score_gemma":0.00014942326,"threshold_uncertainty_score":0.41407293},"labels":[],"label_agreement":null},{"id":"W4293206958","doi":"10.3390/pathogens11090966","title":"Current Research on HIV Drug Resistance—A Topical Collection with “Pathogens”","year":2022,"lang":"en","type":"editorial","venue":"Pathogens","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug resistance; Medicine; Current (fluid); Virology; Drug; Intensive care medicine; Biology; Pharmacology; Microbiology; Engineering","score_opus":0.032559048438271454,"score_gpt":0.3395776513736809,"score_spread":0.30701860293540945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293206958","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005598111,0.004796859,0.000048849528,0.007904918,0.92792726,0.0042691017,0.0016121746,0.00046533,0.04737743],"genre_scores_gemma":[0.00046230317,0.0018656398,0.0011772211,0.00003238358,0.43557224,0.0013561423,0.0048464853,0.00019179856,0.5544958],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99351317,0.0005146006,0.0004907521,0.0011952764,0.0034720746,0.00081411045],"domain_scores_gemma":[0.9971438,0.0008978268,0.0001588947,0.00084509095,0.00060895603,0.00034541346],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011185632,0.00053656363,0.000810501,0.00074349507,0.00076205767,0.00006480584,0.0002537924,0.00036209243,0.0010561193],"category_scores_gemma":[0.0005073189,0.00042396,0.00023115217,0.0010984289,0.00013414065,0.00003557475,0.00017845663,0.0025294228,0.00033946725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017291822,0.000744983,0.0006936554,0.0002828005,0.0002131348,0.001049691,0.0008099343,0.0000012814052,0.00003475315,0.00016704253,0.99332654,0.00094701425],"study_design_scores_gemma":[0.0024095406,0.00031047533,0.00019584848,0.00060897606,0.00029608753,0.000011707778,0.00027385578,0.000004818769,0.00013829506,0.000046789646,0.9952957,0.00040789752],"about_ca_topic_score_codex":0.000008319556,"about_ca_topic_score_gemma":0.00023781341,"teacher_disagreement_score":0.50711834,"about_ca_system_score_codex":0.0020165571,"about_ca_system_score_gemma":0.0020751609,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W4293221161","doi":"10.3390/pharmaceutics14091761","title":"A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model","year":2022,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; AIDS Vancouver; Toronto General Hospital; University of British Columbia; University Health Network","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Emtricitabine; Pharmacology; Pharmacokinetics; Medicine; Dosing; Human immunodeficiency virus (HIV); Viral load; Virology; Antiretroviral therapy","score_opus":0.05144345860322575,"score_gpt":0.34247419170621807,"score_spread":0.2910307331029923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293221161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962434,0.0011240974,0.00021648231,0.000323684,0.000050587874,0.0014815344,0.000030857474,0.000045273704,0.00048405313],"genre_scores_gemma":[0.99338317,0.0005572721,0.0022365898,0.00010431216,0.000009343402,0.00025431937,0.000038819468,0.000030617484,0.0033855285],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987394,0.00009085461,0.00034260144,0.00026171695,0.00035186546,0.00021354589],"domain_scores_gemma":[0.9995711,0.000029120745,0.00009097458,0.00015916565,0.000045088993,0.00010457024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014412582,0.00017502312,0.0002869917,0.000280346,0.00008633421,0.000007195304,0.00007689567,0.000023127108,0.00011496317],"category_scores_gemma":[0.000009695676,0.00016400406,0.000032729713,0.00041931725,0.000028155708,0.000052683936,0.00012109305,0.00025527854,0.0000014829848],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014178552,0.01571629,0.24199517,0.00036636513,0.00062799914,0.00048326148,0.03722211,0.66115993,0.015645556,0.00007981126,0.00032910658,0.024956565],"study_design_scores_gemma":[0.020319542,0.00043144258,0.001469875,0.00006648189,0.0005435468,0.000036015357,0.0024075022,0.96903706,0.0047271783,0.000044859324,0.000640575,0.00027592067],"about_ca_topic_score_codex":0.00002745456,"about_ca_topic_score_gemma":0.0000089907235,"teacher_disagreement_score":0.30787715,"about_ca_system_score_codex":0.00012589224,"about_ca_system_score_gemma":0.0001003315,"threshold_uncertainty_score":0.66878915},"labels":[],"label_agreement":null},{"id":"W4293507321","doi":"10.1111/hiv.13376","title":"Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic <scp>NRTI</scp> resistance","year":2022,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Tenofovir alafenamide; Emtricitabine; Medicine; Viral load; Virology; Dolutegravir; Resistance mutation; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Reverse transcriptase; Biology; Polymerase chain reaction; Genetics","score_opus":0.005847662508757921,"score_gpt":0.2025820058327435,"score_spread":0.19673434332398557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293507321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675807,0.0015574824,0.000080838174,0.008697726,0.00024399676,0.0012731884,0.000037878806,0.00014373029,0.02038446],"genre_scores_gemma":[0.8640023,0.000052877098,0.0012309285,0.0010279819,0.00014568004,0.0002649723,0.00080849486,0.00007528016,0.13239153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969181,0.00011285897,0.0005748725,0.0005814309,0.0011868753,0.0006258546],"domain_scores_gemma":[0.99867314,0.00020750263,0.00018336362,0.0005248757,0.00013191727,0.000279175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040069822,0.00037306448,0.0006882816,0.00061691,0.00022746918,0.000007997315,0.00020300309,0.0000622086,0.00045225487],"category_scores_gemma":[0.00023558772,0.00026237135,0.00005956143,0.0013690264,0.00014654092,0.000085006985,0.000108178865,0.00047731,0.00010925808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006331111,0.0010340539,0.9094362,0.00011094171,0.00020740068,0.0008171742,0.004837683,0.000021849048,0.00012463564,0.00039514335,0.081032254,0.0013495219],"study_design_scores_gemma":[0.017099263,0.0007519031,0.79109216,0.00027772773,0.00023079582,0.00002079489,0.0013096065,0.000029510462,0.00007973512,0.00017581462,0.1887831,0.00014960687],"about_ca_topic_score_codex":0.00003028727,"about_ca_topic_score_gemma":0.000076694574,"teacher_disagreement_score":0.118344076,"about_ca_system_score_codex":0.000709706,"about_ca_system_score_gemma":0.00036672282,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W4294146852","doi":"10.21203/rs.3.rs-2012078/v1","title":"Genotypic Correlates of Resistance to the HIV-1 Strand Transfer Integrase Inhibitor Cabotegravir","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Dolutegravir; Integrase; Elvitegravir; Raltegravir; Rilpivirine; Virology; Drug resistance; Integrase inhibitor; Pharmacology; Human immunodeficiency virus (HIV); Genotype; Medicine; Biology; Chemistry; Antiretroviral therapy; Genetics; Viral load; Gene","score_opus":0.041450086810694134,"score_gpt":0.35686316358243175,"score_spread":0.31541307677173763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294146852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950885,0.0076095415,0.00040255405,0.025273269,0.00045290007,0.0063872915,0.001723621,0.00010166933,0.007164156],"genre_scores_gemma":[0.9232643,0.0007650253,0.00048595582,0.00004564666,0.00019266827,0.000909251,0.00091744296,0.00007133498,0.07334834],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956329,0.0005190401,0.0005676544,0.0007239332,0.0019020801,0.0006544029],"domain_scores_gemma":[0.99753237,0.00046126728,0.000049526036,0.0010838127,0.00053630606,0.00033671386],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016385746,0.0003663697,0.0006577855,0.0005647427,0.00034246716,0.00005660328,0.0005146735,0.00023715566,0.0017065206],"category_scores_gemma":[0.00029845943,0.00023976943,0.00030613074,0.00082676427,0.00021302326,0.000030475436,0.0005063513,0.0024494042,0.00023483508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023034468,0.0066420394,0.2177272,0.020235116,0.006608664,0.0042184815,0.12420595,0.0015351776,0.0048436252,0.007578746,0.548766,0.03460454],"study_design_scores_gemma":[0.009333873,0.0017982491,0.11116116,0.011971283,0.001046577,0.000039099454,0.02855583,0.00019515166,0.018015012,0.002193915,0.8140257,0.0016641413],"about_ca_topic_score_codex":0.00012454744,"about_ca_topic_score_gemma":0.0005885874,"teacher_disagreement_score":0.2652597,"about_ca_system_score_codex":0.00061091606,"about_ca_system_score_gemma":0.0012878386,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W4294626474","doi":"10.1111/jcpt.13750","title":"Antiretroviral <scp>drug–drug</scp> interactions: A comparison of online drug interaction databases","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Pharmacy and Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Drug interaction; Database; Pharmacology; Identification (biology); Drug-drug interaction; Human immunodeficiency virus (HIV); Drug class; Family medicine; Computer science","score_opus":0.17657137484151653,"score_gpt":0.49399404442563927,"score_spread":0.31742266958412274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294626474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914095,0.0028240373,0.00008127507,0.0037337479,0.0014014483,0.00018269864,0.00005841902,0.000015007167,0.00029389077],"genre_scores_gemma":[0.99088734,0.0029791414,0.0015151122,0.0011510047,0.00049060315,0.0000035326839,0.000065881824,0.000021497546,0.0028858848],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695337,0.00037485693,0.0017938617,0.00018394945,0.0005118401,0.00018211897],"domain_scores_gemma":[0.9964529,0.0016856632,0.0013017545,0.00015859898,0.00021766295,0.00018339182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010483363,0.00018617284,0.00080848567,0.00023183276,0.00015131608,0.00001744164,0.0001408221,0.000016372314,0.00017016672],"category_scores_gemma":[0.00017860845,0.00014487306,0.0003330789,0.00021516759,0.00011019863,0.00027282353,0.00011949486,0.0011921142,0.0000047960693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022841296,0.009091634,0.83171856,0.00011856382,0.0022715786,0.00014729366,0.0030701566,0.000053297717,0.0011412215,0.000071185335,0.02569675,0.12433561],"study_design_scores_gemma":[0.009183223,0.0006561829,0.013943134,0.00024275687,0.0015501784,0.00039311984,0.0073432713,0.0039296662,0.005371205,0.000109663124,0.95717233,0.000105250176],"about_ca_topic_score_codex":0.000016166823,"about_ca_topic_score_gemma":0.000011464719,"teacher_disagreement_score":0.9314756,"about_ca_system_score_codex":0.00006398968,"about_ca_system_score_gemma":0.00025099964,"threshold_uncertainty_score":0.5907752},"labels":[],"label_agreement":null},{"id":"W4294919176","doi":"10.1093/cid/ciac731","title":"Effect of Adopting the New Race-Free 2021 Chronic Kidney Disease Epidemiology Collaboration Estimated Glomerular Filtration Rate Creatinine Equation on Racial Differences in Kidney Disease Progression Among People With Human Immunodeficiency Virus: An Observational Study","year":2022,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University Health Centre","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Institute on Aging; Gilead Sciences; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Intercept Pharmaceuticals; Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; University of California, San Francisco; Government of Alberta; Agency for Healthcare Research and Quality; National Institutes of Health; National Human Genome Research Institute; Health Resources and Services Administration; Centers for Disease Control and Prevention; National Institute on Deafness and Other Communication Disorders; National Institute on Drug Abuse; AstraZeneca","keywords":"Renal function; Kidney disease; Hazard ratio; Medicine; Creatinine; Confidence interval; Internal medicine; Epidemiology; Endocrinology; Urology","score_opus":0.08053940275710339,"score_gpt":0.4092007721827359,"score_spread":0.3286613694256325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294919176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360985,0.00041479777,0.00014089457,0.0018641356,0.00020858258,0.0034258142,0.00021612935,0.000097778284,0.000022024793],"genre_scores_gemma":[0.9941253,0.000054549222,0.000035675566,0.00022902581,0.00021788762,0.0013251015,0.0038332152,0.00003273703,0.00014648888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936814,0.0034593914,0.0012179926,0.0007056291,0.0005984002,0.00033721176],"domain_scores_gemma":[0.995301,0.0022558027,0.0008107551,0.00066095736,0.00019963767,0.00077185675],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020661578,0.00036691487,0.0008288602,0.00020523349,0.00074594334,0.00005022118,0.00021457291,0.00006762845,0.000423508],"category_scores_gemma":[0.012904101,0.00024163001,0.00016562255,0.000994925,0.00022985789,0.0003012653,0.00013304026,0.00035994832,0.000005514473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041335453,0.005870083,0.98294747,0.00013444568,0.00017152468,0.000041790852,0.00047835705,0.0029583469,0.0000480906,0.00012260993,0.00048230405,0.0026114075],"study_design_scores_gemma":[0.009163282,0.008404452,0.9654407,0.0004566,0.0009238994,5.8467924e-7,0.00015620749,0.014972427,0.000022309976,0.00018765581,0.000036936573,0.00023493696],"about_ca_topic_score_codex":0.0001429132,"about_ca_topic_score_gemma":0.0002529045,"teacher_disagreement_score":0.017506788,"about_ca_system_score_codex":0.00035085608,"about_ca_system_score_gemma":0.0022043886,"threshold_uncertainty_score":0.9954106},"labels":[],"label_agreement":null},{"id":"W4296777393","doi":"10.1093/infdis/jiac386","title":"Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse Models","year":2022,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Women's Health Research Institute; University Health Network; Toronto General Hospital; University of Toronto; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; Canadian Institutes of Health Research; Centre for Blood Research, University of British Columbia; National Institutes of Health; University of British Columbia","keywords":"Dolutegravir; Biology; Raltegravir; Embryonic stem cell; Virology; Virus; Genetics; Viral load","score_opus":0.010648112145538747,"score_gpt":0.2317314919775182,"score_spread":0.22108337983197945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296777393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972827,0.001954785,0.0000695084,0.000083294326,0.0001037587,0.00040411382,0.000006832615,0.000019245026,0.00007579871],"genre_scores_gemma":[0.99915344,0.000132824,0.000005085745,0.000040559273,0.000057313962,0.000025950128,0.000031756415,0.000017928229,0.0005351727],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99881774,0.00026151852,0.00036863834,0.00012929943,0.00028373604,0.00013904265],"domain_scores_gemma":[0.99937177,0.00006966488,0.00029420338,0.0001210014,0.00005982144,0.000083558065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029921602,0.000160936,0.00025547837,0.00034077495,0.00045041525,0.00004201796,0.000050940394,0.000034719487,0.000033294273],"category_scores_gemma":[0.000009805553,0.00011541205,0.000059899616,0.0001812343,0.000041162537,0.00023430456,0.00006190005,0.00023975526,5.148123e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003276401,0.0024065755,0.104877844,0.00026319464,0.0002489116,0.000058059384,0.009072936,0.0025816767,0.8736237,0.0003238597,0.0005109537,0.0057046437],"study_design_scores_gemma":[0.030824203,0.0072660013,0.63331014,0.0006734609,0.0032140624,0.0008955736,0.005650769,0.014721053,0.2970461,0.0050621824,0.00008888857,0.0012475641],"about_ca_topic_score_codex":0.000028356213,"about_ca_topic_score_gemma":0.000084990046,"teacher_disagreement_score":0.5765776,"about_ca_system_score_codex":0.0003127232,"about_ca_system_score_gemma":0.00007545111,"threshold_uncertainty_score":0.4706367},"labels":[],"label_agreement":null},{"id":"W4297021294","doi":"10.1097/qai.0000000000003103","title":"Limited Impact of First-Line Drug Resistance Mutations on Virologic Response Among Patients Receiving Second-Line Antiretroviral Therapy in Rural Uganda","year":2022,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"Medical Research Council","keywords":"Medicine; Viral load; Internal medicine; Drug resistance; Antiretroviral therapy; Protease inhibitor (pharmacology); Drug holiday; Expanded access; Resistance mutation; Human immunodeficiency virus (HIV); Immunology; Reverse transcriptase; Polymerase chain reaction","score_opus":0.014398900473255044,"score_gpt":0.26806738519672557,"score_spread":0.25366848472347053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297021294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965851,0.0016602881,0.000006090933,0.00077076425,0.0003074428,0.00048656823,0.000052165087,0.000032521573,0.00009906722],"genre_scores_gemma":[0.9958382,0.000331201,0.00023732657,0.000032053857,0.00001660051,0.000025537649,0.000072472125,0.00004559372,0.0034009616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635774,0.0005182203,0.0014989967,0.00026453892,0.0008864398,0.00047408877],"domain_scores_gemma":[0.9974739,0.000689938,0.0010655893,0.00037032124,0.00028584123,0.00011443836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018669158,0.00034231244,0.0009448613,0.0015267171,0.00030841408,0.000027028824,0.00033978757,0.00007465736,0.0003663881],"category_scores_gemma":[0.00072217913,0.00025755662,0.00049884507,0.0017284245,0.00017338275,0.00029862652,0.00008873647,0.0003266285,0.000007103482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016614152,0.0032624176,0.9621493,0.00005526627,0.00042119613,0.00060314307,0.0052083014,0.0014680707,0.006672671,0.0000064532796,0.0005943127,0.002944698],"study_design_scores_gemma":[0.008805856,0.00830644,0.9788746,0.00037805975,0.00007640048,0.00012684689,0.0009850295,0.00020242439,0.0018539715,0.00007496184,0.0000772519,0.00023815915],"about_ca_topic_score_codex":0.00003167288,"about_ca_topic_score_gemma":0.000018615394,"teacher_disagreement_score":0.01672528,"about_ca_system_score_codex":0.0006871089,"about_ca_system_score_gemma":0.00031313146,"threshold_uncertainty_score":0.99998766},"labels":[],"label_agreement":null},{"id":"W4297876224","doi":"10.1093/femsre/fuac040","title":"New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?","year":2022,"lang":"en","type":"review","venue":"FEMS Microbiology Reviews","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Western University","keywords":"Cart; Drug resistance; Biology; Human immunodeficiency virus (HIV); Drug; HIV drug resistance; Antiretroviral therapy; Virology; Viral load; Pharmacology; Genetics","score_opus":0.02928404632685996,"score_gpt":0.30075471000954107,"score_spread":0.27147066368268113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297876224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030177129,0.99132645,0.0000048931224,0.0018662745,0.0006804871,0.0036518883,0.00025181024,0.00010670051,0.0020813243],"genre_scores_gemma":[7.5241246e-7,0.781695,0.0011105443,0.00028732303,0.0003785572,0.0002973088,0.0031181818,0.00011345198,0.21299887],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954009,0.00063134724,0.0017164879,0.0013886144,0.000106439824,0.00075620867],"domain_scores_gemma":[0.99749076,0.00024174829,0.0009622797,0.0009504224,0.000028113238,0.0003266556],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006760069,0.0012434496,0.0052706418,0.00047094948,0.00026743565,0.00003618812,0.0003573987,0.00052005413,0.0013132703],"category_scores_gemma":[0.00013042717,0.0008541351,0.0010829348,0.0006100551,0.00018155292,0.000057137466,0.00031404805,0.0012623412,0.0022131419],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004211871,0.0000931157,0.00009546786,0.005975274,0.00034250275,0.00011073017,0.0002407178,4.2372292e-9,0.00001221015,0.00003285734,0.5250322,0.4680228],"study_design_scores_gemma":[0.0010580698,0.00012079062,0.0000022814784,0.016738232,0.0018181682,0.000458608,0.00002488996,5.1374567e-8,0.000008545869,0.000009797698,0.9790693,0.0006912708],"about_ca_topic_score_codex":0.000006415173,"about_ca_topic_score_gemma":0.000013857652,"teacher_disagreement_score":0.46733153,"about_ca_system_score_codex":0.0005257513,"about_ca_system_score_gemma":0.00060848054,"threshold_uncertainty_score":0.99959964},"labels":[],"label_agreement":null},{"id":"W4298148582","doi":"10.1016/j.antiviral.2022.105427","title":"Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir","year":2022,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Dolutegravir; Integrase; Elvitegravir; Raltegravir; Virology; Integrase inhibitor; Rilpivirine; Drug resistance; Pharmacology; Human immunodeficiency virus (HIV); Genotype; Medicine; Drug; Biology; Viral load; Genetics; Antiretroviral therapy; Gene","score_opus":0.040519588999534624,"score_gpt":0.33569647352513765,"score_spread":0.29517688452560303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298148582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811396,0.00067704276,0.00008642937,0.011814906,0.00008508682,0.0009056745,0.00011143398,0.00002041261,0.0051594116],"genre_scores_gemma":[0.9212635,0.000075353375,0.00013342407,0.0000670895,0.000052768064,0.00013187513,0.00006162866,0.00002078007,0.07819356],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977189,0.00028229313,0.0002575765,0.00029129733,0.0010297904,0.00042018783],"domain_scores_gemma":[0.9991478,0.00025212538,0.00001532193,0.0003379077,0.00016458238,0.00008226563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011871231,0.00013032353,0.0002450685,0.00025334998,0.0003967509,0.000019361885,0.00022463223,0.00003787018,0.00023309691],"category_scores_gemma":[0.00011670818,0.000083961364,0.00009744498,0.00093431957,0.00015692902,0.00004357217,0.000113433845,0.00064809615,0.00023376626],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017199669,0.0037857045,0.2389496,0.0005921974,0.0014356152,0.0019465518,0.047759034,0.000030004405,0.1651841,0.012618491,0.44925532,0.061243728],"study_design_scores_gemma":[0.010337545,0.0028068672,0.11640526,0.00070746994,0.0003321308,0.000049829912,0.022141099,0.00018121758,0.3116108,0.001145279,0.53345996,0.00082256424],"about_ca_topic_score_codex":0.00005818055,"about_ca_topic_score_gemma":0.00022422771,"teacher_disagreement_score":0.1464267,"about_ca_system_score_codex":0.00014503102,"about_ca_system_score_gemma":0.000317997,"threshold_uncertainty_score":0.34238452},"labels":[],"label_agreement":null},{"id":"W4298363631","doi":"10.1177/135965350300800506","title":"Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Nevirapine; Viral load; Reverse-transcriptase inhibitor; Internal medicine; Proportional hazards model; Virology; Medicine; Lentivirus; Efavirenz; Gastroenterology; Immunology; Biology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.049314907136050544,"score_gpt":0.32553297407748044,"score_spread":0.2762180669414299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298363631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684554,0.000211547,0.0000114766335,0.0002623303,0.00009798336,0.0009819875,0.000004728951,0.00006486838,0.001519533],"genre_scores_gemma":[0.9979499,0.00042926313,0.0004470863,0.00083487283,0.00002980744,0.000083289706,0.0000308728,0.00003207322,0.00016285172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728775,0.00039937563,0.00074892776,0.0005955566,0.00037818777,0.0005902101],"domain_scores_gemma":[0.9991023,0.00022320966,0.0001346534,0.0003484404,0.00007620469,0.00011522625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007680555,0.00037194142,0.0006817456,0.00025561152,0.00009298673,0.000042723506,0.00014221169,0.00018811206,0.0001351683],"category_scores_gemma":[0.00035964465,0.0002823728,0.000141921,0.00047432678,0.0001215765,0.00030475494,0.000027658189,0.00036140962,0.000041648265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026580228,0.0016854523,0.96751213,0.000006453966,0.00004240226,0.00008806316,0.0011941942,0.000008441087,0.0016643065,0.00010703238,0.000009823236,0.025023675],"study_design_scores_gemma":[0.012708159,0.000926765,0.97636884,0.000082143655,0.000007406017,0.0000029506377,0.00012961794,0.00003445191,0.008782144,0.00029108912,0.00036610418,0.0003003369],"about_ca_topic_score_codex":0.00014667903,"about_ca_topic_score_gemma":0.00015954643,"teacher_disagreement_score":0.024723338,"about_ca_system_score_codex":0.00020895935,"about_ca_system_score_gemma":0.00013282998,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W4298816057","doi":"","title":"Basic principles and clinical implications. Abstracts from the XIV International HIV Drug Resistance Workshop. June 7-11, 2005. Québec City, Québec, Canada.","year":2005,"lang":"en","type":"other","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"HIV drug resistance; Human immunodeficiency virus (HIV); Drug resistance; Medicine; Drug; Family medicine; Library science; Virology; Gerontology; Antiretroviral therapy; Pharmacology; Biology; Viral load; Computer science; Genetics","score_opus":0.026986158088933062,"score_gpt":0.26011550738834804,"score_spread":0.23312934929941498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298816057","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000893549,0.0067052958,0.0000074417508,0.8904026,0.00062469096,0.001364609,0.0002852121,0.00011635418,0.09960024],"genre_scores_gemma":[0.0016897222,0.001680164,0.0005183588,0.0014877045,0.0013984886,0.00075265317,0.00045762042,0.00015872178,0.9918566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783695,0.0000558846,0.0006497055,0.0005938962,0.00044973093,0.00041381046],"domain_scores_gemma":[0.99799544,0.0006055367,0.00039662392,0.000602658,0.000059904833,0.00033986242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035882043,0.00034857946,0.00048373325,0.00009198206,0.00010254436,0.000055312004,0.00034999847,0.0001921304,0.0014225988],"category_scores_gemma":[0.00034992347,0.0002478839,0.00010486058,0.000089570196,0.00016863328,0.00003833177,0.00012621909,0.0003565845,0.000056766356],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044615976,0.0001354151,0.027698109,0.000012070773,0.00058871385,0.00002359585,0.000048545775,2.8355845e-7,4.8056442e-8,0.00005700081,0.9666605,0.004731103],"study_design_scores_gemma":[0.0008306273,9.674893e-8,0.23116305,0.00010906316,0.00019510565,0.000004243154,0.000021645083,0.0000013081986,0.0000021627025,0.000006806623,0.7674879,0.00017803321],"about_ca_topic_score_codex":0.2748302,"about_ca_topic_score_gemma":0.9998535,"teacher_disagreement_score":0.8922563,"about_ca_system_score_codex":0.00077419647,"about_ca_system_score_gemma":0.002522866,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W4299806083","doi":"","title":"Factors associated with virologic failure in HIV patients on antiretroviral therapy.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Retrospective cohort study; Odds ratio; Confidence interval; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","score_opus":0.030310071816879506,"score_gpt":0.20923275081810266,"score_spread":0.17892267900122316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299806083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614096,0.000020755198,2.886248e-7,0.001340626,0.000060626422,0.0009965454,0.000024964267,0.00006268464,0.0013525477],"genre_scores_gemma":[0.9915303,0.000003278328,0.0000066903895,0.0003216646,0.000010163357,0.0010627715,0.00038352085,0.000019128609,0.0066624563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988035,0.0000836057,0.00014515808,0.00023510994,0.00038502173,0.00034763294],"domain_scores_gemma":[0.9996587,0.000049743874,0.00006949438,0.00012489047,0.000018665327,0.00007849372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013606025,0.00015896004,0.000235296,0.00016957682,0.00009603157,0.000009218254,0.00006968129,0.000039858616,0.00012318998],"category_scores_gemma":[0.000050034814,0.00010215355,0.00004596338,0.00033254558,0.000022810254,0.000037840728,0.00003365304,0.00021320442,0.00000620551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002505357,0.0009729877,0.98999465,0.0000017297021,0.00010963184,0.000036579946,0.00039136884,0.000005937644,0.0000020023826,0.000012923825,0.0016098403,0.0066118278],"study_design_scores_gemma":[0.0051249643,0.0003671149,0.9904783,0.0000053680965,0.000018550725,3.4804086e-7,0.00014063012,0.0000046320392,0.0001147031,0.000010224305,0.0036219815,0.00011322191],"about_ca_topic_score_codex":0.000005856798,"about_ca_topic_score_gemma":0.000027244072,"teacher_disagreement_score":0.006498606,"about_ca_system_score_codex":0.00037086953,"about_ca_system_score_gemma":0.000033759345,"threshold_uncertainty_score":0.41657007},"labels":[],"label_agreement":null},{"id":"W4300079042","doi":"","title":"Dolutegravir &ndash; a review of the pharmacology, efficacy, and safety in the treatment of HIV","year":2015,"lang":"en","type":"review","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dolutegravir; Pharmacology; Human immunodeficiency virus (HIV); Medicine; Virology; Antiretroviral therapy","score_opus":0.33210277039363767,"score_gpt":0.5999163211335549,"score_spread":0.2678135507399172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300079042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009419417,0.9899077,0.0000010781989,0.0008191887,0.00028884402,0.0052633756,0.00019363072,0.000008081065,0.0025761565],"genre_scores_gemma":[0.00020988236,0.99742645,0.00008031189,0.00019457725,0.00011961955,0.00026478744,0.00007875033,0.000054969987,0.001570665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99473536,0.0013077147,0.0022188094,0.00049165153,0.00088885677,0.00035758445],"domain_scores_gemma":[0.9955658,0.00086993445,0.0022487198,0.00080775825,0.0002970861,0.00021070577],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025475956,0.00069636805,0.0047565876,0.0006006464,0.000107568885,0.00007675786,0.0018449542,0.00020599416,0.0019659],"category_scores_gemma":[0.00017208743,0.00032391885,0.00077746,0.001503131,0.0003322915,0.00023314127,0.00044842027,0.00049732486,0.000010387017],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023947422,0.0023587295,0.008284997,0.035244074,0.002344726,0.000112272486,0.00058788655,4.5442198e-7,0.000022580987,0.000020544358,0.07088474,0.8798995],"study_design_scores_gemma":[0.0023109345,0.000048319518,0.008392063,0.08925408,0.005293297,0.00011077445,0.000030335534,4.994654e-7,0.00007178449,0.000050006376,0.8941853,0.000252578],"about_ca_topic_score_codex":0.00009639868,"about_ca_topic_score_gemma":0.000017558608,"teacher_disagreement_score":0.87964696,"about_ca_system_score_codex":0.00041709078,"about_ca_system_score_gemma":0.0011997849,"threshold_uncertainty_score":0.99992126},"labels":[],"label_agreement":null},{"id":"W4300502505","doi":"10.17615/gxe7-9176","title":"Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Partenariat Canadien Contre Le Cancer; Center for AIDS Research, University of North Carolina at Chapel Hill; Georgia Clinical and Translational Science Alliance; Johns Hopkins University","keywords":"Emtricitabine; Tenofovir; Dosing; Pharmacokinetics; Pharmacology; Medicine; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load","score_opus":0.03525841487794304,"score_gpt":0.2684770273885745,"score_spread":0.23321861251063145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300502505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98912776,0.0014343314,0.000048093,0.00587209,0.00017352002,0.0016418645,0.000017345692,0.00011183644,0.0015731697],"genre_scores_gemma":[0.98900783,0.00001824718,0.0084222,0.0014725477,0.00010737645,0.00018923572,0.0000698797,0.00004395889,0.0006687253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976362,0.000120061915,0.0007157023,0.00055007264,0.00046793767,0.0005100365],"domain_scores_gemma":[0.9989882,0.00016493411,0.000112884896,0.00027007476,0.00008706439,0.00037682682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017430249,0.00034414628,0.000692897,0.00037126595,0.00007640381,0.00007685442,0.00019862787,0.00007337743,0.0006490447],"category_scores_gemma":[0.00022793833,0.00029400107,0.00008246968,0.0015758981,0.00006216693,0.000539756,0.00015671534,0.00026645183,0.000027326743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046346523,0.0016298555,0.91528404,0.00048267446,0.00028715,0.00067310664,0.06419721,0.00006752944,0.004629765,0.00018283624,0.0028400042,0.005091163],"study_design_scores_gemma":[0.04793863,0.009612681,0.890681,0.0019592931,0.0010676878,0.000020500598,0.022781169,0.001600151,0.017764611,0.00063695485,0.0039982907,0.0019390094],"about_ca_topic_score_codex":0.00032752805,"about_ca_topic_score_gemma":0.00011511064,"teacher_disagreement_score":0.043303978,"about_ca_system_score_codex":0.00012798174,"about_ca_system_score_gemma":0.00041067932,"threshold_uncertainty_score":0.9999512},"labels":[],"label_agreement":null},{"id":"W4300799264","doi":"10.17615/1yjd-7183","title":"Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy–Experienced Patients with HIV Infection in North America","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Agency for Healthcare Research and Quality; Gilead Sciences; GlaxoSmithKline; Kaiser Permanente; Johns Hopkins University; Pfizer; Bristol-Myers Squibb","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); Medicine; Antiretroviral treatment; Intensive care medicine; Demography; Internal medicine; Immunology; Viral load; Sociology","score_opus":0.01641269562363461,"score_gpt":0.23106307669341633,"score_spread":0.2146503810697817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300799264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817234,0.000069166534,0.000010541089,0.0009774483,0.000020232432,0.0004313146,0.000014730416,0.00007179917,0.00023241508],"genre_scores_gemma":[0.99781555,0.000045627377,0.0010277992,0.00013951697,0.000023977447,0.00009502621,0.0004976847,0.000019573457,0.0003352726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988938,0.00004679798,0.00024885885,0.00036457204,0.0002073801,0.00023858694],"domain_scores_gemma":[0.99960625,0.000020057527,0.00007352701,0.00013753488,0.000018047853,0.00014456573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000016807362,0.00025268385,0.00036923643,0.00019553478,0.000055517874,0.00004953516,0.000035798425,0.000051851224,0.00007089746],"category_scores_gemma":[0.00001137144,0.00016811404,0.000042798612,0.0006833658,0.0001721805,0.00048918824,0.00002687446,0.00010385441,0.0000043954165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035566048,0.00045767584,0.97344697,0.000012242125,0.00008065116,0.000088195025,0.017049525,0.000012039744,0.0000092972805,0.000054045173,0.00006348113,0.008370223],"study_design_scores_gemma":[0.0057235956,0.0008430669,0.9911231,0.000027434296,0.000024836885,6.7574035e-7,0.0005034924,0.0001892013,0.0006062795,0.000011449464,0.0007742118,0.00017265532],"about_ca_topic_score_codex":0.0005222903,"about_ca_topic_score_gemma":0.0019887756,"teacher_disagreement_score":0.017676137,"about_ca_system_score_codex":0.00010576255,"about_ca_system_score_gemma":0.000073475094,"threshold_uncertainty_score":0.6855492},"labels":[],"label_agreement":null},{"id":"W4301182908","doi":"10.4212/cjhp.3234","title":"Trends in Use of Combination Antiretroviral Therapy and Treatment Response from 2000 to 2016 in the Canadian Observational Cohort (CANOC): A Longitudinal Cohort Study","year":2022,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University of Regina; Memorial University of Newfoundland; McGill University Health Centre; Montreal Clinical Research Institute; Ottawa Hospital; Maple Leaf Medical Clinic; University of Toronto; University of Ottawa; AIDS Vancouver; University of British Columbia","funders":"","keywords":"Observational study; Antiretroviral therapy; Cohort; Medicine; Cohort study; Marginal structural model; Human immunodeficiency virus (HIV); Family medicine; Internal medicine; Viral load","score_opus":0.06727088026883069,"score_gpt":0.3108916949771661,"score_spread":0.24362081470833544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301182908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750642,0.00034845437,1.3264504e-7,0.023177011,0.00017345499,0.0010179292,0.00014435651,0.0000018595068,0.00007258457],"genre_scores_gemma":[0.9983103,0.00004066784,0.000035301327,0.0004397479,0.00004496199,0.000077994795,0.000060206286,0.0000149138705,0.00097587577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817944,0.00042119276,0.00045413407,0.00017839139,0.00047862812,0.00028821445],"domain_scores_gemma":[0.99901146,0.00017971008,0.00015467285,0.00018326197,0.00010941564,0.00036146698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011751108,0.00017440965,0.00033842982,0.00086878677,0.00030240143,0.00006225088,0.00019573218,0.00001931309,0.0003274236],"category_scores_gemma":[0.000053577747,0.0001115862,0.00007447668,0.000653838,0.00007284991,0.00016071949,0.0000141489145,0.00026165502,0.0000019667382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009936907,0.00046400932,0.979732,5.9442226e-7,0.00030833692,0.0010263895,0.010403905,0.000035205754,0.0000139331405,0.00002062264,0.0029656189,0.004035743],"study_design_scores_gemma":[0.0049494505,0.0021866926,0.9847501,0.000019805577,0.00011287196,0.000042809326,0.00078914466,0.00004546425,0.000024773304,0.000025942058,0.00694608,0.00010690183],"about_ca_topic_score_codex":0.721653,"about_ca_topic_score_gemma":0.83281755,"teacher_disagreement_score":0.111164555,"about_ca_system_score_codex":0.0025621033,"about_ca_system_score_gemma":0.003924992,"threshold_uncertainty_score":0.6962767},"labels":[],"label_agreement":null},{"id":"W4301872251","doi":"10.17615/rrcd-m118","title":"Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Enfuvirtide; Virology; Human immunodeficiency virus (HIV); Medicine; Drug; Pharmacology; Immunology","score_opus":0.01607704533283419,"score_gpt":0.22146920021804423,"score_spread":0.20539215488521004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301872251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894778,0.00021016251,0.00047004686,0.008460223,0.000056812274,0.00057170924,0.00004233554,0.0001381016,0.0005727832],"genre_scores_gemma":[0.9819779,0.000035519777,0.013422716,0.00089957466,0.00023435993,0.0000803275,0.00056067685,0.00003463346,0.0027543227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907523,0.000029764497,0.00024975638,0.00030217026,0.00014212423,0.00020093279],"domain_scores_gemma":[0.999552,0.00005644109,0.00006485664,0.00011536915,0.000025561063,0.00018574584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003325089,0.00017143405,0.00027574526,0.00011321045,0.00010435033,0.00006281692,0.000034355886,0.00004515108,0.000046606867],"category_scores_gemma":[0.00007536698,0.00013838736,0.00004354647,0.0002934172,0.00007677027,0.0003586277,0.000054093256,0.00009490656,0.00003058731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012652859,0.00020379321,0.95733184,0.00019004685,0.00006044782,0.000043911215,0.022191886,0.00000716657,0.0006396842,0.0022305099,0.011723292,0.0041121515],"study_design_scores_gemma":[0.012760771,0.0013139982,0.7071281,0.00028508442,0.00030404888,0.000008565799,0.0045881094,0.0020747313,0.016935445,0.0022441295,0.25146505,0.0008919633],"about_ca_topic_score_codex":0.000020826921,"about_ca_topic_score_gemma":0.00010562397,"teacher_disagreement_score":0.25020373,"about_ca_system_score_codex":0.000030002542,"about_ca_system_score_gemma":0.00012365142,"threshold_uncertainty_score":0.5643273},"labels":[],"label_agreement":null},{"id":"W4301882122","doi":"","title":"Profile of etravirine for the treatment of HIV infection","year":2010,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Etravirine; Human immunodeficiency virus (HIV); Virology; Medicine; Antiretroviral therapy; Viral load","score_opus":0.18554357633765647,"score_gpt":0.5371367110016888,"score_spread":0.3515931346640323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301882122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910678,0.002851933,0.00020355408,0.000679682,0.00046197133,0.0018096468,0.00008435533,0.000017822586,0.0028231791],"genre_scores_gemma":[0.9849361,0.0071713114,0.0010530655,0.000030338726,0.00017394152,0.00021625882,0.000043061238,0.000036505415,0.0063394043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983763,0.00004894558,0.00071467523,0.00023494645,0.00040333756,0.00022177592],"domain_scores_gemma":[0.9980363,0.0003779907,0.0006535335,0.00042069357,0.00037867203,0.00013279382],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051074947,0.00023834466,0.0007320204,0.00041645986,0.00012735507,0.00007675487,0.00041680402,0.000090851354,0.005462399],"category_scores_gemma":[0.00013576988,0.00014428637,0.0002815234,0.00046001383,0.0001348889,0.0003599867,0.00009298712,0.00015603189,0.000009199249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005877542,0.0019291231,0.80810755,0.00016356003,0.0009445163,0.000008427024,0.00045448449,0.000009520127,0.109488435,0.00010132334,0.013630586,0.064574696],"study_design_scores_gemma":[0.0022383428,0.00009415939,0.646896,0.00016328746,0.00044838813,0.00001331441,0.000036397247,0.00006207209,0.3098066,0.00030663912,0.039809283,0.00012550177],"about_ca_topic_score_codex":0.00029845146,"about_ca_topic_score_gemma":0.000112994516,"teacher_disagreement_score":0.20031816,"about_ca_system_score_codex":0.000077506724,"about_ca_system_score_gemma":0.00019806268,"threshold_uncertainty_score":0.99544674},"labels":[],"label_agreement":null},{"id":"W4304990344","doi":"10.1038/s41598-022-22163-7","title":"Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute on Drug Abuse; Centers for Disease Control and Prevention; National Institutes of Health; National Institute of Mental Health; Nazarbayev University","keywords":"Nevirapine; Darunavir; Zidovudine; Human immunodeficiency virus (HIV); Emtricitabine; Virology; Medicine; Antiretroviral treatment; Antiretroviral therapy; Viral load; Viral disease","score_opus":0.009802107331163198,"score_gpt":0.24732804650364262,"score_spread":0.23752593917247944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304990344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99067026,0.00019146674,0.000013195596,0.0009657513,0.0013348899,0.0006060121,0.0000056884496,0.00009716235,0.0061155544],"genre_scores_gemma":[0.89394504,0.0000045207603,0.00031270803,0.00002464694,0.00001762039,0.00014844452,0.0004517228,0.000016614258,0.10507869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997889,0.00007335607,0.00046534842,0.00058848446,0.00067483744,0.00030900323],"domain_scores_gemma":[0.9990562,0.000029571544,0.00018381244,0.0005438274,0.000084552405,0.00010204446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080459495,0.00013802726,0.00023918849,0.00042682566,0.00051999715,0.00008129366,0.000067256165,0.000027987115,0.00080751494],"category_scores_gemma":[0.00008148177,0.00012576849,0.000084261475,0.0016256943,0.00012465294,0.00012669887,0.00006127842,0.00017641658,0.000021108235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003989463,0.00037430951,0.96867853,0.000011175986,0.000028114287,0.0019420643,0.0031911775,0.00002937413,0.0017037845,0.000049680493,0.023512252,0.00043963265],"study_design_scores_gemma":[0.0016330332,0.000088666304,0.8835051,0.000053141208,0.000033446297,0.00020775029,0.0010133664,0.00012480859,0.0036841214,0.0014093278,0.10796095,0.00028626612],"about_ca_topic_score_codex":0.000040082392,"about_ca_topic_score_gemma":0.0004881152,"teacher_disagreement_score":0.098963134,"about_ca_system_score_codex":0.00028731837,"about_ca_system_score_gemma":0.00039540994,"threshold_uncertainty_score":0.88417226},"labels":[],"label_agreement":null},{"id":"W4308263533","doi":"10.1016/j.jgar.2022.11.001","title":"HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report","year":2022,"lang":"en","type":"article","venue":"Journal of Global Antimicrobial Resistance","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Dolutegravir; Human immunodeficiency virus (HIV); Virology; Medicine; Antiretroviral therapy; Viral load","score_opus":0.013205399814427718,"score_gpt":0.2702702983435353,"score_spread":0.2570648985291076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308263533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717464,0.0037813406,0.00013442703,0.011010128,0.000874923,0.00077450485,0.00030229613,0.00006545511,0.01131056],"genre_scores_gemma":[0.90674675,0.0002859541,0.011480571,0.0005004062,0.00025771235,0.000032635977,0.00007881209,0.00003764096,0.08057955],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965106,0.00018587279,0.0014208391,0.0004921049,0.000814104,0.0005764649],"domain_scores_gemma":[0.99753636,0.00008148935,0.0011316541,0.0004907708,0.00039717084,0.00036255905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054769934,0.00046198186,0.0009940704,0.00014584951,0.0005877609,0.00007937324,0.0002544113,0.000085268846,0.00020337415],"category_scores_gemma":[0.00016762113,0.00036947487,0.0005333786,0.0007511426,0.00014978672,0.00018985379,0.00009261169,0.0003642801,0.00003266029],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048609953,0.0014929859,0.006883613,0.00017549084,0.0010811979,0.69515544,0.00079852383,0.000069820446,0.00413726,0.0002065344,0.28361154,0.0015265944],"study_design_scores_gemma":[0.020534813,0.0016667821,0.006093696,0.0018270877,0.0019755862,0.4013528,0.0030023193,0.000028980834,0.006421037,0.0008391366,0.5548057,0.0014520588],"about_ca_topic_score_codex":0.000036597994,"about_ca_topic_score_gemma":0.0006904935,"teacher_disagreement_score":0.29380265,"about_ca_system_score_codex":0.0025060861,"about_ca_system_score_gemma":0.0014864489,"threshold_uncertainty_score":0.9998757},"labels":[],"label_agreement":null},{"id":"W4309326210","doi":"10.1097/qad.0000000000003370","title":"Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient","year":2022,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Emtricitabine; Lamivudine; Brain biopsy; Gastroenterology; Internal medicine; Ritonavir; Viral load; Anesthesia; Immunology; Biopsy; Hepatitis B virus","score_opus":0.01588714091195001,"score_gpt":0.2541923871255736,"score_spread":0.23830524621362362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309326210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914004,0.00037717068,0.000012938401,0.0018073982,0.0003835104,0.0010172566,0.000023844575,0.00014313831,0.004834293],"genre_scores_gemma":[0.9885845,0.00005742386,0.0014912857,0.0009582461,0.00009217689,0.00087243784,0.00022218519,0.00006672654,0.0076549775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972662,0.00016600016,0.0006366156,0.00062754675,0.0006852869,0.00061839994],"domain_scores_gemma":[0.99888223,0.00015056194,0.0001294261,0.0005333076,0.000061143815,0.00024332131],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033624095,0.00038532712,0.0006535796,0.00046083514,0.00023225578,0.000026848087,0.00019138788,0.000095141,0.001171435],"category_scores_gemma":[0.00012841016,0.0003320279,0.00018327167,0.0011071827,0.000044138127,0.00013233945,0.0003080541,0.0005151437,0.00023433536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011741911,0.0025463577,0.80985034,0.00007533719,0.00037813126,0.0038538112,0.0040021352,0.000097675096,0.008799087,0.0007461811,0.009861007,0.15861572],"study_design_scores_gemma":[0.06726362,0.021346115,0.48783776,0.00052411493,0.0010480216,0.00081967545,0.011631775,0.0013862931,0.027118154,0.0014529977,0.37598428,0.003587179],"about_ca_topic_score_codex":0.00034017354,"about_ca_topic_score_gemma":0.00003814258,"teacher_disagreement_score":0.36612326,"about_ca_system_score_codex":0.00070761825,"about_ca_system_score_gemma":0.00034159882,"threshold_uncertainty_score":0.99991316},"labels":[],"label_agreement":null},{"id":"W4309993098","doi":"","title":"Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir","year":2013,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rilpivirine; Emtricitabine; Tenofovir; Human immunodeficiency virus (HIV); Medicine; Virology; Antiretroviral therapy; Viral load","score_opus":0.11639033731204021,"score_gpt":0.4718401250625817,"score_spread":0.3554497877505415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309993098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560064,0.0023125466,0.000046090227,0.000066819164,0.000066126406,0.0011876593,0.000014674861,0.000008971365,0.0006964664],"genre_scores_gemma":[0.9976132,0.0019119798,0.0002550208,0.000019401368,0.000011551415,0.000046313246,0.00001565441,0.000016971067,0.000109888046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806076,0.00029727153,0.00077937124,0.0002961483,0.00039700174,0.00016945694],"domain_scores_gemma":[0.998082,0.00045268875,0.00062117825,0.00021184138,0.0005069359,0.00012537255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081145245,0.00020672573,0.00086345454,0.00042595272,0.000055705885,0.00008613427,0.00018316462,0.000087044566,0.00083697017],"category_scores_gemma":[0.00024136664,0.0001493499,0.00005390149,0.00065060204,0.00023215967,0.00092774176,0.00018936578,0.00019003091,0.0000015536251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064316904,0.0020910022,0.9612547,0.00027440573,0.00023772479,0.0000033276965,0.00012798657,7.4660426e-7,0.001083274,0.000008715019,0.000540822,0.03373414],"study_design_scores_gemma":[0.005645837,0.00020054453,0.9899525,0.0007904606,0.00009649323,0.0000027342858,0.000020323825,0.000030000563,0.0024625577,0.0005281366,0.00013291606,0.00013751813],"about_ca_topic_score_codex":0.00060233014,"about_ca_topic_score_gemma":0.000043279702,"teacher_disagreement_score":0.03359662,"about_ca_system_score_codex":0.000055035074,"about_ca_system_score_gemma":0.0001309825,"threshold_uncertainty_score":0.9164236},"labels":[],"label_agreement":null},{"id":"W4311110137","doi":"","title":"Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks","year":2017,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Abacavir; Atazanavir; Ritonavir; Lamivudine; Virology; Human immunodeficiency virus (HIV); Medicine; Pharmacology; Antiretroviral therapy; Viral load; Virus","score_opus":0.20657935108747505,"score_gpt":0.5178299181230693,"score_spread":0.3112505670355943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311110137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99034435,0.0021471037,0.00041243338,0.00086962717,0.000109191555,0.0026366538,0.0003834025,0.00007756606,0.003019678],"genre_scores_gemma":[0.9775694,0.0013554187,0.0017505902,0.00013796451,0.00007914743,0.00025153012,0.00021388943,0.00016871122,0.018473346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961401,0.00023498137,0.0010436858,0.00080757786,0.0010701446,0.0007034957],"domain_scores_gemma":[0.995054,0.000540547,0.0017340955,0.0012776152,0.00085196027,0.00054176786],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012115679,0.0007438768,0.001999375,0.0007655718,0.00063462625,0.00060608954,0.0015467422,0.00021411775,0.0017513307],"category_scores_gemma":[0.00046360467,0.0004698764,0.0002262046,0.00064620393,0.00046267945,0.0015990367,0.0003942202,0.00040861664,0.000015802425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058510795,0.0011135037,0.8515388,0.00027315997,0.0023763992,0.00046170564,0.00042551846,0.000011805362,0.053432584,0.000010310999,0.027964616,0.0038808472],"study_design_scores_gemma":[0.021146337,0.0004916932,0.82885677,0.0019727563,0.0014365886,0.00022528366,0.00018703178,0.00011868128,0.13276915,0.00005913109,0.011893443,0.00084312895],"about_ca_topic_score_codex":0.0005724349,"about_ca_topic_score_gemma":0.00024241919,"teacher_disagreement_score":0.07933656,"about_ca_system_score_codex":0.0003210558,"about_ca_system_score_gemma":0.0010255397,"threshold_uncertainty_score":0.9997753},"labels":[],"label_agreement":null},{"id":"W4311732615","doi":"10.1093/ofid/ofac492.1083","title":"1252. A Real-World Observational Study on HIV-Infected Patients who Switched from Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada","year":2022,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Infectious Diseases Centre; GlaxoSmithKline (Canada); University of British Columbia","funders":"","keywords":"Medicine; Dolutegravir; Lamivudine; Discontinuation; Nevirapine; Observational study; Internal medicine; Adverse effect; Virology; Human immunodeficiency virus (HIV); Viral load; Hepatitis B virus; Virus; Antiretroviral therapy","score_opus":0.019714621929952752,"score_gpt":0.26071297896710977,"score_spread":0.24099835703715702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311732615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829645,0.000031708547,0.0000010783083,0.0023073426,0.00042584632,0.0046571638,0.0027669051,0.00009566588,0.0014178478],"genre_scores_gemma":[0.9820659,0.000011303535,0.000038470826,0.0031808747,0.000055762044,0.0015595182,0.004036407,0.00007533038,0.008976429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679106,0.00022429707,0.00071393314,0.00081220677,0.00090671366,0.0005517728],"domain_scores_gemma":[0.99861115,0.00012583044,0.00017168614,0.00045376612,0.00015337439,0.00048418267],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014653828,0.00033622235,0.0007550777,0.000235043,0.00060225517,0.0002746311,0.0002803173,0.000039109556,0.0020237654],"category_scores_gemma":[0.00016514634,0.00045905338,0.00013560987,0.0013316391,0.00002760169,0.00026378012,0.00032612763,0.0003031501,0.000027504515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035044397,0.0052847276,0.80547416,0.000012400174,0.00025496972,0.0005920079,0.0003438602,0.000035861347,0.000013724472,0.0000073086385,0.18630634,0.001324204],"study_design_scores_gemma":[0.012002217,0.000928392,0.96378815,0.00020990828,0.00026173936,0.0000043414548,0.0008920054,0.000018889259,0.000013332758,0.00007892819,0.021351052,0.0004510409],"about_ca_topic_score_codex":0.9319249,"about_ca_topic_score_gemma":0.99144053,"teacher_disagreement_score":0.16495529,"about_ca_system_score_codex":0.0020960139,"about_ca_system_score_gemma":0.001285244,"threshold_uncertainty_score":0.99978614},"labels":[],"label_agreement":null},{"id":"W4311746946","doi":"10.1093/ofid/ofac492.109","title":"1586. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race","year":2022,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Regeneron Pharmaceuticals; Gilead Sciences; Moderna; Pfizer; Eli Lilly and Company","keywords":"Rilpivirine; Medicine; Regimen; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Antiretroviral therapy; Virology","score_opus":0.013550688263491803,"score_gpt":0.3114046751923415,"score_spread":0.2978539869288497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311746946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98913103,0.0012074965,0.00016025506,0.0025827743,0.000090197624,0.0015239496,0.00014277195,0.00012189396,0.005039644],"genre_scores_gemma":[0.9904437,0.00020658174,0.00017447029,0.00071335287,0.000015241258,0.00034720876,0.00021352919,0.000044284607,0.007841619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984,0.00007428408,0.00026991015,0.0005398552,0.00031852844,0.0003974594],"domain_scores_gemma":[0.9991195,0.00017055802,0.000105450876,0.00029733006,0.00003786971,0.00026929693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009003598,0.0003233863,0.00050193304,0.000062716404,0.0010155146,0.00016557176,0.00012870536,0.000030382844,0.00040103772],"category_scores_gemma":[0.00006557371,0.0002463006,0.000052670217,0.00025518754,0.0001565708,0.00043667317,0.00044229795,0.00017353045,0.000009532637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012320597,0.0022915243,0.9758486,0.00003928326,0.00034029534,0.00023562823,0.0019781953,0.000008107423,0.00006097973,0.00019771424,0.0036649767,0.014102594],"study_design_scores_gemma":[0.10426803,0.007507345,0.57245,0.00041190838,0.0020920974,0.0014456713,0.019469962,0.0001547143,0.0018950163,0.000304455,0.287552,0.0024488177],"about_ca_topic_score_codex":0.0003692523,"about_ca_topic_score_gemma":0.000103547485,"teacher_disagreement_score":0.40339866,"about_ca_system_score_codex":0.00015425244,"about_ca_system_score_gemma":0.00017391217,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W4312067470","doi":"10.1186/s12879-022-07894-2","title":"Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India","year":2022,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; Fogarty International Center; National Heart, Lung, and Blood Institute; amfAR, The Foundation for AIDS Research; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Antiretroviral therapy; Viral load; Tropical medicine; Medical microbiology; Internal medicine; Logistic regression; Human immunodeficiency virus (HIV); Cross-sectional study; Pediatrics; Immunology; Pathology","score_opus":0.007615959536449221,"score_gpt":0.22425950000349534,"score_spread":0.21664354046704612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312067470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997403,0.00029739863,0.00004395247,0.0001465358,0.000082061524,0.0006684875,0.00003275608,0.00023783518,0.0010879359],"genre_scores_gemma":[0.99632204,0.000038222974,0.00014030417,0.00021700044,0.000100580066,0.00045082954,0.00013670548,0.000041906533,0.0025524085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832505,0.00019598998,0.0002751362,0.00043735837,0.000359033,0.0004074075],"domain_scores_gemma":[0.9991972,0.00023804729,0.00011210121,0.00024315833,0.000034914214,0.00017456617],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001646248,0.00027525198,0.00042351295,0.00030391087,0.0003092118,0.000043954526,0.00009295883,0.00005997562,0.0027825262],"category_scores_gemma":[0.00010410349,0.00021218426,0.00012873832,0.00061812275,0.0000668504,0.00014944759,0.00011366432,0.00031680134,0.000027047447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023296181,0.0011999574,0.99571794,0.00005008475,0.00010129781,0.00016778731,0.0008456555,0.00014754609,0.000042979078,0.000023707815,0.0008085691,0.0006614903],"study_design_scores_gemma":[0.0034829485,0.0010770474,0.99370897,0.000071423085,0.00007275443,0.0000812789,0.0005784842,0.00014755473,0.00003286716,0.000026128848,0.0004621045,0.0002584564],"about_ca_topic_score_codex":0.000052506835,"about_ca_topic_score_gemma":0.001108862,"teacher_disagreement_score":0.0032499868,"about_ca_system_score_codex":0.00026509856,"about_ca_system_score_gemma":0.00026373993,"threshold_uncertainty_score":0.99812907},"labels":[],"label_agreement":null},{"id":"W4313491992","doi":"10.1111/tmi.13851","title":"<scp>Nano‐RECall</scp> provides an integrated pipeline for <scp>HIV</scp>‐1 drug resistance testing from Oxford Nanopore sequence data","year":2023,"lang":"en","type":"article","venue":"Tropical Medicine & International Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"South African Medical Research Council; Medical Research Council; National Health Laboratory Service; National Cancer Institute; National Institutes of Health; Universiteit Stellenbosch","keywords":"Sanger sequencing; Nanopore sequencing; Amplicon; Minion; Drug resistance; Biology; HIV drug resistance; Computational biology; Mutation; DNA sequencing; Genetics; Polymerase chain reaction; Virology; Human immunodeficiency virus (HIV); Gene; Viral load","score_opus":0.11222916845867426,"score_gpt":0.3769453898817297,"score_spread":0.26471622142305545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313491992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70706826,0.0031504203,0.02411312,0.24298996,0.0033488949,0.0056065614,0.0035849763,0.002207966,0.007929833],"genre_scores_gemma":[0.46805155,0.0023840081,0.16898392,0.01321949,0.006321533,0.00078632,0.05894774,0.00033956894,0.28096586],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995518,0.0001479886,0.0012211017,0.0011461677,0.0011543265,0.0008124065],"domain_scores_gemma":[0.9945096,0.0028777097,0.00043610195,0.0008296692,0.00063012535,0.0007168232],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006765294,0.00046988888,0.000850783,0.00035273322,0.00027267248,0.000046182708,0.00084865687,0.00013648253,0.000068361456],"category_scores_gemma":[0.008633635,0.00034943546,0.00008165605,0.00077793025,0.000266254,0.00031499975,0.00021873618,0.0004826881,0.0001015549],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017593899,0.0007250644,0.1030347,0.00052566285,0.00037203217,0.00029204125,0.0039671254,0.000008953406,0.0009032372,0.001979572,0.84496534,0.04305032],"study_design_scores_gemma":[0.0064546005,0.00055191206,0.033874277,0.0027888492,0.00016805038,0.000043752272,0.002250245,0.04439912,0.0003106533,0.001630025,0.90739006,0.0001384729],"about_ca_topic_score_codex":0.00038807033,"about_ca_topic_score_gemma":0.0010666362,"teacher_disagreement_score":0.27303603,"about_ca_system_score_codex":0.00055648154,"about_ca_system_score_gemma":0.0007884247,"threshold_uncertainty_score":0.99989575},"labels":[],"label_agreement":null},{"id":"W431499791","doi":"10.1097/qai.0000000000000698","title":"HIV-1 Group O Resistance Against Integrase Inhibitors","year":2015,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase; Virology; Integrase inhibitor; Biology; Human immunodeficiency virus (HIV); Genetics; Viral load; Antiretroviral therapy","score_opus":0.022286778035681087,"score_gpt":0.26184283803023456,"score_spread":0.23955605999455348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W431499791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97368884,0.012973163,0.0003362544,0.0037415826,0.0015551344,0.0003182466,0.0000093842045,0.00010663,0.0072707618],"genre_scores_gemma":[0.9739757,0.00046745536,0.005693827,0.00009588478,0.00013601923,0.000009579674,0.000032115422,0.00005861604,0.019530796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967301,0.00011742253,0.0013065466,0.0002851015,0.0010440386,0.0005168208],"domain_scores_gemma":[0.9978566,0.00014329702,0.00063351466,0.0004274632,0.0005275493,0.00041153582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014695816,0.00035537567,0.00087141455,0.00080248964,0.00013143984,0.00006349106,0.00033120686,0.000110572226,0.00003912476],"category_scores_gemma":[0.00081851083,0.00025772103,0.00041875587,0.0010546746,0.00020136332,0.00044478607,0.0000865134,0.00020966692,0.0003111261],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007415473,0.010027756,0.2236106,0.0011621496,0.0044908877,0.030342428,0.028954113,0.0001591504,0.04623311,0.0034825795,0.5820763,0.062045418],"study_design_scores_gemma":[0.10066514,0.014161634,0.1802666,0.022573384,0.0059885345,0.022008358,0.075577416,0.00056275947,0.06419474,0.0065157446,0.5008003,0.006685362],"about_ca_topic_score_codex":0.000005086228,"about_ca_topic_score_gemma":0.0000029628127,"teacher_disagreement_score":0.09324966,"about_ca_system_score_codex":0.00044406633,"about_ca_system_score_gemma":0.0005101702,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W4316506412","doi":"10.1093/cid/ciad023","title":"Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; University of Cape Town; National Research Foundation; National Institute of Allergy and Infectious Diseases; McMaster University; Wellcome Trust; Wellcome","keywords":"Dolutegravir; Medicine; Emtricitabine; Efavirenz; Lamivudine; Placebo; Dosing; Randomized controlled trial; Adverse effect; Internal medicine; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","score_opus":0.08331070069054886,"score_gpt":0.4208768176560899,"score_spread":0.33756611696554106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316506412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98730844,0.0002536325,0.0000099514145,0.000587591,0.00088229094,0.00923343,0.00013526679,0.00017164266,0.0014177494],"genre_scores_gemma":[0.99379164,0.00052835006,0.00003049387,0.0002777391,0.00064106274,0.0019043951,0.00090062356,0.00004000883,0.0018856894],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99555093,0.0008468787,0.002159854,0.00055053766,0.0004351213,0.00045666308],"domain_scores_gemma":[0.99553365,0.0031990781,0.0004603781,0.0003585927,0.00012873719,0.00031958305],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015461317,0.00040613062,0.0029085919,0.0005585768,0.000090962756,0.000031858766,0.00013070762,0.00018812186,0.0016679512],"category_scores_gemma":[0.0005721325,0.000286606,0.0012371588,0.00074367976,0.00035118248,0.00011120022,0.000084199244,0.00037030282,0.0001277249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8853119,0.004786935,0.104187354,0.000046719528,0.0014774962,0.0001849373,0.0002038442,0.00000960491,0.000015758947,0.00009075474,0.002120728,0.0015639446],"study_design_scores_gemma":[0.98667943,0.0026248423,0.008222583,0.00009530536,0.0006736655,0.0000029041369,0.00010371673,0.00031446872,0.00014844302,0.00040455043,0.0004698305,0.00026026825],"about_ca_topic_score_codex":0.0000833081,"about_ca_topic_score_gemma":0.00022255362,"teacher_disagreement_score":0.1013675,"about_ca_system_score_codex":0.000092170274,"about_ca_system_score_gemma":0.0006684142,"threshold_uncertainty_score":0.99995863},"labels":[],"label_agreement":null},{"id":"W4317506066","doi":"10.3390/metabo13020151","title":"Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity","year":2023,"lang":"en","type":"article","venue":"Metabolites","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; University of British Columbia; Natural Sciences and Engineering Research Council of Canada; Karolinska Institutet; Michael Smith Health Research BC; Science for Life Laboratory; Canada Foundation for Innovation","keywords":"Dihydrofolate reductase; Chemistry; Cancer cell; In silico; Proguanil; Cancer; Metabolite; Pharmacology; Biochemistry; Enzyme; Biology; Gene; Chloroquine; Genetics; Immunology; Malaria","score_opus":0.024975745949914672,"score_gpt":0.3147182043274793,"score_spread":0.2897424583775646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317506066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99011123,0.003176801,0.000012621981,0.0054716873,0.00019673059,0.00042219582,0.00010887095,0.0001054791,0.0003944109],"genre_scores_gemma":[0.97823673,0.0047921734,0.0011065595,0.0005054066,0.00015454461,0.00021314414,0.000055313063,0.00003145383,0.014904646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986869,0.000047875124,0.00020337377,0.00039316562,0.0002407897,0.0004278908],"domain_scores_gemma":[0.9994739,0.000058390287,0.000045070065,0.00018138641,0.000053631073,0.00018759145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020198437,0.00021906015,0.00050829817,0.0003750178,0.00006240337,0.000026394893,0.00006592828,0.00006768424,0.0002212058],"category_scores_gemma":[0.000038929098,0.00017273864,0.00006186744,0.0008179374,0.000036903097,0.000098358105,0.00007865922,0.00012102918,0.00017955249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009264833,0.00023674162,0.73814905,0.000095774056,0.00025397798,0.00010180874,0.0015806843,0.000071769064,0.23358795,0.00007964979,0.006652806,0.01909713],"study_design_scores_gemma":[0.0010272238,0.000025769628,0.707325,0.00007660851,0.00009976886,0.0000015919949,0.00012161676,0.00015734955,0.23971789,0.00007334813,0.051176965,0.00019687823],"about_ca_topic_score_codex":0.000748487,"about_ca_topic_score_gemma":0.00030868835,"teacher_disagreement_score":0.04452416,"about_ca_system_score_codex":0.0000753162,"about_ca_system_score_gemma":0.00011097453,"threshold_uncertainty_score":0.70440775},"labels":[],"label_agreement":null},{"id":"W4317568027","doi":"10.1093/cid/ciad020","title":"Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study","year":2023,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"Janssen Research and Development; Gilead Sciences; Insmed; ViiV Healthcare; National Institutes of Health; Pfizer","keywords":"Rilpivirine; Medicine; Tolerability; Human immunodeficiency virus (HIV); Dosing; Regimen; Internal medicine; Viral load; Adverse effect; Virology; Antiretroviral therapy","score_opus":0.06474784941476527,"score_gpt":0.4037233714721519,"score_spread":0.3389755220573867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317568027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933968,0.00042499258,0.000016330874,0.00019218169,0.00042132082,0.003986249,0.00014550514,0.00041503814,0.0010015905],"genre_scores_gemma":[0.9965525,0.0009280244,0.00003555156,0.000095385214,0.00020808222,0.00039340064,0.0007268005,0.00006309297,0.0009971412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995571,0.0007091278,0.0015882783,0.0011504892,0.0004474739,0.00053359964],"domain_scores_gemma":[0.9960342,0.0021553917,0.0004602021,0.00067603006,0.00024811397,0.00042608444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013656917,0.0005354868,0.001788578,0.00033229156,0.00045925417,0.0002036699,0.00017587346,0.00018451476,0.00009653126],"category_scores_gemma":[0.0025664463,0.00040358186,0.0001681059,0.0012581584,0.0003956702,0.00037278494,0.00034797093,0.0005853006,0.0001479834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09621435,0.023140224,0.86810666,0.00006621508,0.0008532597,0.0013016508,0.0011022151,0.000019833238,0.000025455109,0.0000071410177,0.0003665301,0.008796485],"study_design_scores_gemma":[0.4177651,0.0040524127,0.57537377,0.0005508928,0.00084882905,0.000009211981,0.0002823853,0.00041526376,0.000017209772,0.00008921683,0.000180042,0.0004156503],"about_ca_topic_score_codex":0.0066724503,"about_ca_topic_score_gemma":0.005936269,"teacher_disagreement_score":0.3215508,"about_ca_system_score_codex":0.00018265036,"about_ca_system_score_gemma":0.00042334417,"threshold_uncertainty_score":0.9999422},"labels":[],"label_agreement":null},{"id":"W4318261511","doi":"10.1097/qai.0000000000003157","title":"Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks","year":2023,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"National Research Foundation; Wellcome Trust; ViiV Healthcare; McMaster University; Gilead Sciences","keywords":"Dolutegravir; Lamivudine; Emtricitabine; Medicine; Viremia; Viral load; Reverse-transcriptase inhibitor; Regimen; Virology; Integrase inhibitor; Internal medicine; Nucleoside Reverse Transcriptase Inhibitor; Adverse effect; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virus; Hepatitis B virus","score_opus":0.02064008435789448,"score_gpt":0.28178993106008016,"score_spread":0.26114984670218566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318261511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396896,0.0025050072,0.000035541154,0.0021881398,0.00040747647,0.00052329595,0.000019149405,0.0001086554,0.00024375317],"genre_scores_gemma":[0.9834415,0.0008251918,0.002315631,0.00006355808,0.000052977302,0.00002832557,0.000019909505,0.000065859735,0.013187097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966943,0.000093745286,0.0012006686,0.00042675858,0.00079603365,0.00078847905],"domain_scores_gemma":[0.9985835,0.00026312436,0.00035668843,0.0003500656,0.00019338272,0.00025325094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009987564,0.00049919996,0.0013876341,0.0013841824,0.00019503127,0.00008517328,0.00020588315,0.00013129081,0.000044485583],"category_scores_gemma":[0.00019212636,0.00031742518,0.0002706693,0.0013557894,0.00015387323,0.00037941334,0.00008352763,0.00016758387,0.00007944666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002157498,0.0013249496,0.90927935,0.00021647122,0.001138453,0.0069831377,0.012269952,0.00008909141,0.016926458,0.000081123915,0.000383675,0.04914984],"study_design_scores_gemma":[0.013158634,0.014059557,0.9544003,0.00096736045,0.0005404918,0.0021397055,0.005635161,0.000108218715,0.0064216848,0.0001719939,0.0016876344,0.00070925424],"about_ca_topic_score_codex":0.00009843492,"about_ca_topic_score_gemma":0.00007261029,"teacher_disagreement_score":0.048440587,"about_ca_system_score_codex":0.00054354017,"about_ca_system_score_gemma":0.0004949579,"threshold_uncertainty_score":0.99992776},"labels":[],"label_agreement":null},{"id":"W4318261891","doi":"10.1097/txd.0000000000001441","title":"Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review","year":2023,"lang":"en","type":"review","venue":"Transplantation Direct","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Université de Montréal; McGill University Health Centre","funders":"Université de Montréal","keywords":"Medicine; Psychological intervention; MEDLINE; Human immunodeficiency virus (HIV); Intensive care medicine; Health care; Population; Family medicine; Nursing; Environmental health","score_opus":0.08044763700753992,"score_gpt":0.3983329547409286,"score_spread":0.3178853177333887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318261891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002693259,0.9935125,0.0007014162,0.00025456684,0.000101017264,0.003546943,0.000082542865,0.00030949424,0.0014646024],"genre_scores_gemma":[0.00007383911,0.99277776,0.00037594858,0.00010130756,0.00005566665,0.0009513948,0.0015831059,0.00014572195,0.0039352276],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99708486,0.0003033414,0.0011982155,0.0005885467,0.00038663438,0.00043840232],"domain_scores_gemma":[0.9984232,0.0008333512,0.0003287542,0.00022968776,0.00005496576,0.0001300439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004948662,0.00055968977,0.0020450996,0.00064329256,0.000125409,0.000040941977,0.00013029906,0.00013348515,0.00047404433],"category_scores_gemma":[0.000020491314,0.00044345832,0.00052730966,0.0014011615,0.000030299101,0.00015846633,0.000007786081,0.00033315664,0.0003506854],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042133754,0.00020905466,0.0005301672,0.9462751,0.0009577944,0.0005536106,0.0019278121,0.0000061277046,8.622475e-7,0.000009939531,0.000082643855,0.04940475],"study_design_scores_gemma":[0.001519433,0.000058516438,0.00018944113,0.98508686,0.009473838,0.0005520022,0.000042682575,0.000006295937,0.0000106468615,0.0000011734892,0.002604342,0.00045478158],"about_ca_topic_score_codex":0.000013663539,"about_ca_topic_score_gemma":0.0016675072,"teacher_disagreement_score":0.048949968,"about_ca_system_score_codex":0.000241789,"about_ca_system_score_gemma":0.0009329292,"threshold_uncertainty_score":0.9998017},"labels":[],"label_agreement":null},{"id":"W4318754808","doi":"10.1093/cid/ciad056","title":"CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study","year":2023,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec en Abitibi-Témiscamingue; McGill University Health Centre; Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Hazard ratio; Reverse-transcriptase inhibitor; Regimen; Internal medicine; Confidence interval; CD4-CD8 Ratio; Cohort; Integrase inhibitor; Cohort study; Viral load; Antiretroviral therapy; Gastroenterology; CD8; Virology; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.05239955803707738,"score_gpt":0.37744250254723827,"score_spread":0.3250429445101609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998916,0.00015969193,0.0000024319597,0.005453886,0.0006158483,0.0028861747,0.00013483649,0.0001434896,0.0006144886],"genre_scores_gemma":[0.9946625,0.00013205405,0.0000014576382,0.00095039426,0.00020258385,0.00024852212,0.000078883684,0.000030209785,0.0036933515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644405,0.0008278771,0.0012110372,0.0005787069,0.0005639752,0.00037434258],"domain_scores_gemma":[0.9960059,0.0022841939,0.00036543977,0.001115025,0.00012432302,0.000105149484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014622915,0.00029008233,0.0006842493,0.00010537724,0.0005434301,0.00007103444,0.0004479305,0.000083333005,0.00002475099],"category_scores_gemma":[0.0019377057,0.00013459082,0.00040067287,0.0010109845,0.00029002136,0.00010404193,0.00031160214,0.00047907725,0.00012443127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053965877,0.001823497,0.9866807,0.000003945257,0.0004275039,0.000023740064,0.0026222127,0.000045703346,0.00008504328,0.00003509018,0.0054211156,0.0022918293],"study_design_scores_gemma":[0.004054666,0.00036733414,0.9898641,0.00008372815,0.00027149188,4.987798e-7,0.004099855,0.00004673043,0.00013021106,0.00010611142,0.0008201013,0.00015518353],"about_ca_topic_score_codex":0.0066271224,"about_ca_topic_score_gemma":0.008567054,"teacher_disagreement_score":0.004673391,"about_ca_system_score_codex":0.00020089284,"about_ca_system_score_gemma":0.00028664566,"threshold_uncertainty_score":0.99998784},"labels":[],"label_agreement":null},{"id":"W4319982031","doi":"10.3390/v15020490","title":"HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay—Results of a Nationally Representative Survey, 2018–2019","year":2023,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Dolutegravir; Darunavir; HIV drug resistance; Medicine; Efavirenz; Ritonavir; Drug resistance; Nevirapine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Internal medicine; Viral load; Microbiology; Biology","score_opus":0.05953505043780295,"score_gpt":0.33955636187568816,"score_spread":0.2800213114378852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319982031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529845,0.00024527925,0.000002758963,0.00089822075,0.00007443853,0.0005410489,0.00025636933,0.00007065202,0.002612772],"genre_scores_gemma":[0.9888684,0.00054009934,0.0016687555,0.0001892356,0.000044984372,0.00005988273,0.0004888034,0.000030957624,0.008108879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977638,0.00029060635,0.0007860308,0.00040047558,0.00044862038,0.0003104317],"domain_scores_gemma":[0.9978161,0.0014907301,0.00027145375,0.00022750311,0.00014186148,0.00005233734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010687237,0.00019462981,0.00041870656,0.0005652211,0.000052736108,0.000015017029,0.00011069389,0.0000629787,0.000038882532],"category_scores_gemma":[0.0019159089,0.0001565927,0.00005120284,0.0014809568,0.000065584245,0.00022256467,0.000056818473,0.00017167979,0.00006723582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061845058,0.00030585923,0.9635424,0.00009670753,0.000091254864,0.00039319092,0.014062604,0.000012070145,0.0006786464,0.000090794514,0.0136357965,0.00090616173],"study_design_scores_gemma":[0.011070528,0.00012480051,0.9782486,0.0014789258,0.00000830958,0.000002142261,0.0016568813,0.00017746154,0.0064646467,0.00009375909,0.00045782689,0.00021613477],"about_ca_topic_score_codex":0.00088195445,"about_ca_topic_score_gemma":0.005539482,"teacher_disagreement_score":0.014706175,"about_ca_system_score_codex":0.000115237955,"about_ca_system_score_gemma":0.00031756333,"threshold_uncertainty_score":0.6385665},"labels":[],"label_agreement":null},{"id":"W4321211317","doi":"10.1039/d2ob02223k","title":"A mechanistic study of thiol addition to <i>N</i>-acryloylpiperidine","year":2023,"lang":"en","type":"article","venue":"Organic & Biomolecular Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Chemistry; Thiol; Nucleophile; Reaction rate constant; Ionic strength; Leaving group; Kinetic isotope effect; Computational chemistry; Combinatorial chemistry; Enthalpy; Reactivity (psychology); Hammett equation; Aqueous solution; Physical chemistry; Organic chemistry; Thermodynamics; Kinetics","score_opus":0.010047711371574002,"score_gpt":0.25734505360134163,"score_spread":0.24729734222976762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321211317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352515,0.000038587445,0.0029741058,0.00095626304,0.000061250044,0.00069564837,0.000030086248,0.00024360351,0.0014752905],"genre_scores_gemma":[0.99424183,0.000011979474,0.00027730252,0.000089998925,0.00005349549,0.000076601216,0.00026727244,0.00004316638,0.0049383556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873513,0.000015331085,0.00027209613,0.00035682684,0.0003688606,0.00025178416],"domain_scores_gemma":[0.9992415,0.000017048567,0.00006219708,0.0004083174,0.000090402296,0.00018058388],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011209689,0.00019534024,0.00030197794,0.00007983394,0.00005697639,0.000010348119,0.000107948894,0.00007836368,0.0011212905],"category_scores_gemma":[0.000109015746,0.00017852188,0.000071960196,0.00093951926,0.000017941684,0.000017044995,0.000103540726,0.000081541104,0.00043532054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005900988,0.00058838946,0.0002513523,0.00012783111,0.0001828163,0.0004747373,0.00060627086,1.1675015e-7,0.99411863,0.000003812993,0.0031869416,0.00040009257],"study_design_scores_gemma":[0.0016824846,0.00022038897,0.00046943466,0.000095363524,0.00019079834,0.000055460467,0.0011840161,0.000026879407,0.9942146,0.000021946822,0.001666624,0.00017197996],"about_ca_topic_score_codex":0.00000483987,"about_ca_topic_score_gemma":0.0000019312358,"teacher_disagreement_score":0.0034630653,"about_ca_system_score_codex":0.000090681424,"about_ca_system_score_gemma":0.00011115392,"threshold_uncertainty_score":0.9997918},"labels":[],"label_agreement":null},{"id":"W4321770339","doi":"10.1371/journal.pone.0280339","title":"Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NSW Ministry of Health; Department of Health, Government of Western Australia; Department of Health and Aged Care, Australian Government; McGill University; Australian Government; Department of Health, State Government of Victoria; University of New South Wales; Burnet Institute","keywords":"Tenofovir; Pre-exposure prophylaxis; Medicine; Observational study; Antiretroviral therapy; Cohort study; Human immunodeficiency virus (HIV); Cohort; Internal medicine; Virology; Viral load; Men who have sex with men","score_opus":0.07439878502868591,"score_gpt":0.27497095102820407,"score_spread":0.20057216599951816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321770339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941743,0.000052274176,0.0000063950984,0.00064019917,0.000013362282,0.004740202,0.000069782036,0.00022425185,0.00007923501],"genre_scores_gemma":[0.97939754,0.00004486421,0.0010253065,0.00006769237,0.00008361467,0.0013005368,0.0012360318,0.000048326456,0.016796071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981636,0.00006816622,0.00028767524,0.00044855726,0.0006967654,0.0003352333],"domain_scores_gemma":[0.9992294,0.00006987261,0.00011188619,0.0002335259,0.00021356299,0.00014175742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044499963,0.000244406,0.00046224796,0.00012443367,0.0001926881,0.0000459107,0.00006832306,0.00007167548,0.000026518048],"category_scores_gemma":[0.000058892227,0.00016713521,0.00004096228,0.00036639918,0.000051411225,0.00015196575,0.000030217789,0.000120933735,0.000013177866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011964259,0.01121622,0.9811893,0.000055379707,0.0025008128,0.00004976007,0.0014139558,0.0000021900541,0.0015458444,0.00001618216,0.00026612123,0.0005477842],"study_design_scores_gemma":[0.0075689238,0.014685818,0.9749102,0.00016726083,0.0003732601,0.0000016741403,0.00025199947,0.0008354241,0.00093351013,0.000041867625,0.000021129974,0.00020895511],"about_ca_topic_score_codex":0.000008043028,"about_ca_topic_score_gemma":0.000024791403,"teacher_disagreement_score":0.016716836,"about_ca_system_score_codex":0.00011881126,"about_ca_system_score_gemma":0.0001600605,"threshold_uncertainty_score":0.6815576},"labels":[],"label_agreement":null},{"id":"W4322775162","doi":"10.1158/1538-7445.sabcs22-p4-07-03","title":"Abstract P4-07-03: The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Tamoxifen; Medicine; Breast cancer; Interquartile range; Internal medicine; Oncology; Prospective cohort study; Cohort; Cancer; Logistic regression; Gynecology","score_opus":0.0684520206467842,"score_gpt":0.3978296457534012,"score_spread":0.329377625106617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473643,0.00009586146,0.0000014001076,0.001603254,0.00002679056,0.0013416937,0.00030138082,0.000024317169,0.0018688577],"genre_scores_gemma":[0.9836078,0.00012514814,0.000011629571,0.000008818989,0.00010402251,0.0025839733,0.000015891152,0.00003651399,0.01350618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979846,0.000043030348,0.00021399379,0.00033371503,0.00064187235,0.00078280026],"domain_scores_gemma":[0.99890727,0.00025107377,0.00006503266,0.00033116108,0.00025522843,0.00019025199],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007943865,0.00017150644,0.00031422122,0.0003187939,0.000114965704,0.000026712418,0.00021038935,0.000063631196,0.0009847727],"category_scores_gemma":[0.000045163088,0.00009081419,0.00006614217,0.0010594634,0.00021611413,0.00006474609,0.000056465924,0.00035273813,0.0001538218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007257535,0.0004163472,0.8874958,0.0004047333,0.0007484618,0.000153186,0.05658219,0.0009733449,0.0045344373,0.000016207026,0.0288514,0.012566315],"study_design_scores_gemma":[0.002785763,0.00043347463,0.99148095,0.0007188073,0.000015332958,0.0000014136169,0.0023494982,0.00019952604,0.0015547855,0.000054843436,0.0002820528,0.00012353079],"about_ca_topic_score_codex":0.001256149,"about_ca_topic_score_gemma":0.00036603678,"teacher_disagreement_score":0.10398513,"about_ca_system_score_codex":0.0010196022,"about_ca_system_score_gemma":0.0012903087,"threshold_uncertainty_score":0.9999285},"labels":[],"label_agreement":null},{"id":"W4327675561","doi":"10.1093/aje/kwad057","title":"Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine","year":2023,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Minority Health and Health Disparities; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Eye Institute; National Institute on Aging; National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Government of Alberta; Agency for Healthcare Research and Quality; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Health Resources and Services Administration; National Institute on Deafness and Other Communication Disorders; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; Centers for Disease Control and Prevention","keywords":"Efavirenz; Regimen; Medicine; Internal medicine; Confidence interval; Cohort; Reverse-transcriptase inhibitor; Pediatrics; Viral load; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.1727406204627607,"score_gpt":0.4871029224319855,"score_spread":0.31436230196922477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327675561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96906173,0.0003868336,0.014499089,0.01459137,0.0007218592,0.0005783896,0.000007959651,0.00003697613,0.000115783914],"genre_scores_gemma":[0.83539826,0.0011028316,0.15745078,0.0027030394,0.00077446783,0.00004958209,0.000039666702,0.000067889494,0.0024134754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996504,0.00042563165,0.0019987847,0.00035250097,0.00017706209,0.0005419895],"domain_scores_gemma":[0.99343884,0.0046551535,0.0010562097,0.00031397247,0.00017302202,0.00036281382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00428656,0.00026349418,0.0020853712,0.0005048302,0.00015080789,0.0000035227233,0.00016051615,0.000078951234,0.000036119247],"category_scores_gemma":[0.004495935,0.00015542997,0.0005113569,0.00041957086,0.00032335994,0.000049849583,0.000053939617,0.00018687859,0.000027507354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021817402,0.00084861455,0.5796273,0.000023344319,0.002200584,0.0002500651,0.0026288726,0.00070326816,0.011991857,0.0004192319,0.0056868657,0.3934383],"study_design_scores_gemma":[0.043738462,0.12409802,0.6566782,0.0018158432,0.0054038423,0.001368225,0.009216936,0.0064907577,0.0021362563,0.006596144,0.14071715,0.0017401691],"about_ca_topic_score_codex":0.00018989529,"about_ca_topic_score_gemma":0.000010900698,"teacher_disagreement_score":0.39169812,"about_ca_system_score_codex":0.0003320955,"about_ca_system_score_gemma":0.00019351204,"threshold_uncertainty_score":0.633825},"labels":[],"label_agreement":null},{"id":"W4362635829","doi":"10.1055/a-2069-4552","title":"Stereoselective Total Synthesis of Stereoisomers of Entecavir","year":2023,"lang":"en","type":"article","venue":"Synthesis","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Chemistry; Entecavir; Stereoselectivity; Total synthesis; Stereochemistry; Organic chemistry; Catalysis","score_opus":0.014419579845495262,"score_gpt":0.25930407102110226,"score_spread":0.24488449117560698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362635829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989434,0.000074530704,0.000014985053,0.0008561284,0.00006892311,0.00032755843,0.00005640545,0.00008833611,0.0090791425],"genre_scores_gemma":[0.9932833,0.00008565973,0.0006928949,0.000010091228,0.000023718549,0.00010704805,0.0000075086828,0.000024664863,0.0057651196],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872464,0.00006148892,0.00037220513,0.00024047124,0.00034454674,0.00025663513],"domain_scores_gemma":[0.99867654,0.00071451627,0.00014170929,0.0002844142,0.000093453345,0.000089365865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021974684,0.00017395578,0.0005544012,0.00040221558,0.00003456418,0.0000036967692,0.00008462538,0.00007474051,0.0003162056],"category_scores_gemma":[0.0004260458,0.00014155208,0.00020004618,0.00061502255,0.000094793184,0.000051529125,0.000049772545,0.000061899824,0.00018720502],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017439036,0.0020824121,0.28011227,0.0018150234,0.006075012,0.00028472484,0.007339879,0.000012431393,0.085145116,0.00055945135,0.008578708,0.60625106],"study_design_scores_gemma":[0.00057402166,0.00012063485,0.10249234,0.0006029201,0.00057276076,0.000018326453,0.0018139986,0.00005914178,0.8925295,0.00005955237,0.00096147676,0.00019535041],"about_ca_topic_score_codex":0.000028425915,"about_ca_topic_score_gemma":0.0000055766636,"teacher_disagreement_score":0.8073844,"about_ca_system_score_codex":0.00007220788,"about_ca_system_score_gemma":0.000105116815,"threshold_uncertainty_score":0.57723266},"labels":[],"label_agreement":null},{"id":"W4362636282","doi":"10.1101/2023.04.05.23288183","title":"HIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"Medical Research Council; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Dolutegravir; Human immunodeficiency virus (HIV); HIV drug resistance; Drug resistance; Cohort; Medicine; Virology; Drug; Antiretroviral therapy; Pharmacology; Viral load; Internal medicine; Biology; Genetics","score_opus":0.030449998433720663,"score_gpt":0.32256856986813953,"score_spread":0.2921185714344189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362636282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98279846,0.0014424579,0.000034971028,0.011561412,0.00027951712,0.0013277656,0.00033185215,0.000108545966,0.0021150177],"genre_scores_gemma":[0.8214217,0.0014920157,0.0027394479,0.00011454017,0.00005079505,0.00083111087,0.0022681016,0.00006987512,0.17101243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972153,0.00019976885,0.0007684411,0.0007965341,0.00071603444,0.00030393983],"domain_scores_gemma":[0.9977961,0.00053964567,0.0003765847,0.0007867026,0.00039836226,0.000102575475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007942085,0.00043130506,0.0018734935,0.001467455,0.000052123567,0.000013759279,0.00017673404,0.00015302977,0.000054913475],"category_scores_gemma":[0.00039503173,0.00034864296,0.00031473147,0.0030712686,0.00011953312,0.000018891198,0.00014471092,0.0004110937,0.00019941007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004114271,0.00042064808,0.95497644,0.0004593395,0.011752646,0.000257561,0.005182065,0.0009103677,0.000022082313,0.00012356244,0.025467398,0.000016459788],"study_design_scores_gemma":[0.0018359799,0.000035786154,0.9811618,0.0017602065,0.0069762613,1.432297e-7,0.0012152807,0.00040129316,0.0012083489,0.00022705823,0.0047629643,0.00041493383],"about_ca_topic_score_codex":0.000026474781,"about_ca_topic_score_gemma":0.009440804,"teacher_disagreement_score":0.1688974,"about_ca_system_score_codex":0.00050766545,"about_ca_system_score_gemma":0.0005728923,"threshold_uncertainty_score":0.9998966},"labels":[],"label_agreement":null},{"id":"W4366243067","doi":"10.1128/aac.01386-22","title":"The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration","year":2023,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Dolutegravir; Integrase; Integrase inhibitor; Virology; Human immunodeficiency virus (HIV); Medicine; Viral load; Antiretroviral therapy","score_opus":0.021781009272300023,"score_gpt":0.26509320661474994,"score_spread":0.2433121973424499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366243067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808099,0.000007962007,0.00008899778,0.018222751,0.0000264475,0.000629109,0.00006561858,0.00008043898,0.00006873745],"genre_scores_gemma":[0.99532443,0.0004701827,0.0003478034,0.00019759942,0.000012653451,0.00005642863,0.0008732364,0.000022978005,0.0026946794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920964,0.00004575303,0.00020993,0.00024150952,0.00013047017,0.00016271994],"domain_scores_gemma":[0.99940854,0.00012611956,0.00014858972,0.00013625585,0.00012355673,0.00005693168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001367155,0.00017973593,0.00024336933,0.000105356004,0.00025201618,0.000038729635,0.00003908498,0.00005754231,0.000008752074],"category_scores_gemma":[0.00003101386,0.000102235485,0.00004488912,0.00036200622,0.00020461257,0.0000536333,0.000007914338,0.00006888361,0.0000079084875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075665032,0.009143245,0.27454007,0.00035552392,0.010987089,0.00018173577,0.07808229,0.00009903189,0.1740159,0.0033525617,0.25069958,0.1909765],"study_design_scores_gemma":[0.044602722,0.0043467646,0.5354828,0.0016955853,0.0011450594,0.000039871582,0.009045797,0.007113174,0.38492674,0.0007143823,0.009916174,0.00097093097],"about_ca_topic_score_codex":0.00006842361,"about_ca_topic_score_gemma":0.00022057527,"teacher_disagreement_score":0.26094273,"about_ca_system_score_codex":0.00011821941,"about_ca_system_score_gemma":0.00008458743,"threshold_uncertainty_score":0.4169042},"labels":[],"label_agreement":null},{"id":"W4376874487","doi":"10.1016/j.mmifmc.2023.03.359","title":"Variations du poids et des paramètres métaboliques sous CAB+RPV injectable ou B/F/TAF oral","year":2023,"lang":"fr","type":"article","venue":"Médecine et Maladies Infectieuses Formation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Gynecology; Medicine","score_opus":0.029170427291989848,"score_gpt":0.3208989582454755,"score_spread":0.2917285309534856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376874487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8986044,0.006471051,0.013430161,0.03548441,0.004581464,0.0021639317,0.00030535855,0.0018493967,0.037109856],"genre_scores_gemma":[0.9084198,0.024041928,0.0039607007,0.00090934127,0.0007394999,0.00037655988,0.0018882044,0.0001338724,0.0595301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964089,0.00045937762,0.0010102018,0.00046103905,0.0005715986,0.0010888982],"domain_scores_gemma":[0.9976468,0.0006878006,0.0003497296,0.00049411005,0.00052842393,0.0002931373],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013245826,0.00066362036,0.000777803,0.00095364667,0.000612159,0.0003088703,0.00019057286,0.00031054034,0.0010495726],"category_scores_gemma":[0.0013194814,0.00061599363,0.00024490673,0.0015889986,0.00025617212,0.0025410985,0.0002655008,0.000457894,0.00317352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028002242,0.0017105542,0.6728114,0.0016302369,0.0013274093,0.00018304866,0.040084112,0.0041974992,0.00015916652,0.058854382,0.18701097,0.031751238],"study_design_scores_gemma":[0.008308962,0.0010942649,0.6334274,0.0022706613,0.001204309,0.00048110556,0.003630723,0.0127123725,0.002228364,0.013048503,0.3203181,0.0012752869],"about_ca_topic_score_codex":0.0010255759,"about_ca_topic_score_gemma":0.002739626,"teacher_disagreement_score":0.13330713,"about_ca_system_score_codex":0.0007083767,"about_ca_system_score_gemma":0.00046035295,"threshold_uncertainty_score":0.9998636},"labels":[],"label_agreement":null},{"id":"W4376880039","doi":"10.1016/j.mmifmc.2023.03.190","title":"Efficacité durable du switch d'un régime 3-4DR à base de TAF vers un régime 2DR DTG/3TC dans l'étude TANGO jusqu'à S196","year":2023,"lang":"fr","type":"article","venue":"Médecine et Maladies Infectieuses Formation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Virology","score_opus":0.012023901814167882,"score_gpt":0.25015244047045704,"score_spread":0.23812853865628916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376880039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482574,0.0017305329,0.0039436803,0.024329383,0.003136416,0.0017601466,0.00013823311,0.0010913678,0.015612856],"genre_scores_gemma":[0.9459554,0.009082004,0.0020762938,0.0010433006,0.000987399,0.0003683028,0.0014266184,0.0002110674,0.03884961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99467725,0.00043018948,0.0014146513,0.0007632295,0.0009468048,0.0017679079],"domain_scores_gemma":[0.99667877,0.0008609002,0.00053398125,0.0009306851,0.0003695945,0.00062609394],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017328351,0.0010313129,0.0010917065,0.0009882561,0.00073827844,0.00022982042,0.0003805749,0.00048952986,0.0025139437],"category_scores_gemma":[0.0010713518,0.0009855586,0.00044294668,0.0020128198,0.0002478828,0.0016818909,0.00034877958,0.00073169405,0.0072758943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012696006,0.0041864305,0.6799216,0.0034616292,0.00397,0.0018348393,0.05284341,0.0068896925,0.006913475,0.010691714,0.1962253,0.03179231],"study_design_scores_gemma":[0.029853722,0.0021447698,0.5861718,0.0040929266,0.003506806,0.0016325584,0.0068073324,0.023827747,0.061418105,0.0018496912,0.2758305,0.0028640167],"about_ca_topic_score_codex":0.0004163512,"about_ca_topic_score_gemma":0.00083505205,"teacher_disagreement_score":0.093749784,"about_ca_system_score_codex":0.0017529768,"about_ca_system_score_gemma":0.0004695181,"threshold_uncertainty_score":0.9992595},"labels":[],"label_agreement":null},{"id":"W4378194650","doi":"10.1007/978-3-031-26078-0_12","title":"New Antiretroviral Agents for HIV Infection","year":2023,"lang":"en","type":"book-chapter","venue":"Emerging infectious diseases of the 21st century","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Medicine; Computer science; Viral load","score_opus":0.014634938150639886,"score_gpt":0.25877427552585847,"score_spread":0.2441393373752186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378194650","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02279121,0.010270495,0.0005884292,0.0071642157,0.03163352,0.014911113,0.0026347334,0.0037377176,0.90626854],"genre_scores_gemma":[0.03470445,0.0031286776,0.00006982268,0.00014534913,0.0009273572,0.00006140047,0.00072802015,0.00021465973,0.96002024],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981969,0.000019372554,0.00049102417,0.00045027255,0.0004876896,0.00035475843],"domain_scores_gemma":[0.9985933,0.00007830773,0.00041389663,0.000545703,0.00013629853,0.00023254492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007806296,0.00047851715,0.0006318154,0.00034109596,0.00022941973,0.000024644498,0.00014335132,0.00022423192,0.00040510777],"category_scores_gemma":[0.00011495586,0.00036985506,0.00097149477,0.0001331275,0.00007535207,0.000069366724,0.0001643135,0.0002500079,0.00020795084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005826793,0.0007314163,0.41664672,0.0027969126,0.0064023375,0.000063040156,0.00058733235,0.0001167777,0.000042934014,0.049957052,0.43913662,0.08293618],"study_design_scores_gemma":[0.005544956,0.00040958636,0.039484892,0.0025203682,0.005105706,0.000031896947,0.000036705453,0.000057207784,0.00013215235,0.0055768746,0.94022316,0.0008764924],"about_ca_topic_score_codex":0.00005504986,"about_ca_topic_score_gemma":0.000021266404,"teacher_disagreement_score":0.50108653,"about_ca_system_score_codex":0.0003160069,"about_ca_system_score_gemma":0.00036828485,"threshold_uncertainty_score":0.99987537},"labels":[],"label_agreement":null},{"id":"W4378619580","doi":"10.3390/medicina59061041","title":"Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection","year":2023,"lang":"en","type":"review","venue":"Medicina","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Human immunodeficiency virus (HIV); Drug resistance; Rilpivirine; Multiple drug resistance; Virology; Pharmacology; Antiretroviral therapy; Viral load; Biology; Microbiology","score_opus":0.06026421496698506,"score_gpt":0.30445887004383637,"score_spread":0.2441946550768513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378619580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007957795,0.9692139,0.000009623776,0.008546517,0.0007630709,0.012969738,0.00011602998,0.00009291514,0.00033038977],"genre_scores_gemma":[0.0037476264,0.97883487,0.000088197216,0.00003309007,0.00014196057,0.0018171632,0.00028304648,0.00009957939,0.014954461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968907,0.0001562829,0.0014039123,0.00055193243,0.0005706892,0.00042643343],"domain_scores_gemma":[0.9968111,0.0016104965,0.0007336596,0.00063703157,0.000112523645,0.000095192234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081235624,0.00065828045,0.0017830976,0.0003363061,0.00031306813,0.000014338554,0.00019800168,0.00023869552,0.000023391838],"category_scores_gemma":[0.00017921033,0.00024802372,0.0003680914,0.00067454664,0.00029441266,0.000029822753,0.000055908637,0.00030075878,0.000060231494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015764724,0.008802777,0.010944502,0.06664894,0.017355334,0.00045098332,0.07387572,0.000012031291,0.000025329995,0.0033349278,0.0465183,0.7704547],"study_design_scores_gemma":[0.00409709,0.00049630797,0.0027940797,0.019682178,0.0024979883,0.000017705697,0.00038310484,0.000044397402,0.00027545542,0.000018006256,0.96943396,0.0002597246],"about_ca_topic_score_codex":0.00008846078,"about_ca_topic_score_gemma":0.00066563353,"teacher_disagreement_score":0.92291564,"about_ca_system_score_codex":0.0006770271,"about_ca_system_score_gemma":0.00047290546,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W4379052361","doi":"10.5114/hivar.2023.127727","title":"Drug-selective pressure effect on HIV integrase mutations in antiretroviral naïve and experienced patients","year":2023,"lang":"en","type":"article","venue":"HIV & AIDS Review","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pasteur Institute of Iran","keywords":"Integrase; Medicine; Human immunodeficiency virus (HIV); Virology; Antiretroviral drug; Integrase inhibitor; Antiretroviral therapy; Drug; Internal medicine; Pharmacology; Viral load","score_opus":0.009518727408848347,"score_gpt":0.2897774196362867,"score_spread":0.2802586922274384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379052361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830286,0.011089902,0.000005069886,0.00084984425,0.000086167434,0.002170813,0.000028561904,0.00012015345,0.0026209194],"genre_scores_gemma":[0.98122466,0.0062829303,0.00020582948,0.0002812994,0.000023760882,0.00057417934,0.0004343737,0.0000272119,0.010945732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858457,0.00017263017,0.0003182487,0.00037954134,0.00027661753,0.00026841322],"domain_scores_gemma":[0.9993724,0.00017087394,0.00007268283,0.00020376893,0.00006178803,0.000118448115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025415627,0.00023767512,0.0005607124,0.00022821937,0.000075700766,0.000014122995,0.00006257423,0.000044632503,0.000081856815],"category_scores_gemma":[0.0003770218,0.00016764499,0.00009575201,0.0008862651,0.000055558936,0.000091361624,0.000040094124,0.0001826203,0.00044229583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024834814,0.0005761149,0.80442935,0.0038799585,0.00031860115,0.0002320376,0.0045907428,0.0000017086414,0.00008586206,0.00026220412,0.042064086,0.14331096],"study_design_scores_gemma":[0.032317936,0.008534445,0.68451804,0.084782474,0.0043622493,0.00006831178,0.0023990457,0.0005425337,0.012451446,0.00035105244,0.16706088,0.0026115861],"about_ca_topic_score_codex":0.00000529854,"about_ca_topic_score_gemma":0.000003960886,"teacher_disagreement_score":0.14069937,"about_ca_system_score_codex":0.000079953425,"about_ca_system_score_gemma":0.000057343736,"threshold_uncertainty_score":0.6836364},"labels":[],"label_agreement":null},{"id":"W4380149697","doi":"10.1016/j.jval.2023.03.994","title":"EPH112 Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Canadian Healthcare Perspective","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tenofovir alafenamide; Emtricitabine; Medicine; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Viral load","score_opus":0.03494687805753612,"score_gpt":0.3124821156191319,"score_spread":0.2775352375615958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98356736,0.0009734322,0.0000056912154,0.012504846,0.00006813679,0.0012882047,0.0008316129,0.000046573412,0.00071413175],"genre_scores_gemma":[0.9967447,0.0011000445,0.0007413563,0.000080325335,0.00006134142,0.00007021354,0.00074111583,0.00004001111,0.00042091572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998013,0.00018154831,0.00065905566,0.000390415,0.00020981119,0.00054613943],"domain_scores_gemma":[0.9985858,0.00021144576,0.0002948734,0.00033074507,0.00011217627,0.00046492522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029161875,0.0002694999,0.000777561,0.0010775966,0.00007101729,0.0000063085554,0.00007087642,0.00009506608,0.00009553377],"category_scores_gemma":[0.000041723535,0.00020125911,0.00014061923,0.00071052683,0.000055107204,0.00007696143,0.000012246509,0.00012983728,0.000066154316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00075587654,0.00036979155,0.9579498,0.00022285577,0.0007108601,0.0001712436,0.02673642,0.0042262916,0.00005058322,0.0015134946,0.00075273257,0.0065400456],"study_design_scores_gemma":[0.007105086,0.003646818,0.9758749,0.0007947078,0.0001024465,0.000021083155,0.0046873954,0.005961577,0.00036834506,0.0008831506,0.00028106503,0.00027340226],"about_ca_topic_score_codex":0.8120945,"about_ca_topic_score_gemma":0.17693618,"teacher_disagreement_score":0.63515836,"about_ca_system_score_codex":0.01182348,"about_ca_system_score_gemma":0.013263806,"threshold_uncertainty_score":0.9923301},"labels":[],"label_agreement":null},{"id":"W4380290416","doi":"10.1093/jac/dkad184","title":"Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under <i>in vitro</i> selective drug pressure","year":2023,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Rilpivirine; Lamivudine; Efavirenz; Reverse-transcriptase inhibitor; Virology; Drug resistance; Cross-resistance; Biology; Chemistry; Sida; Human immunodeficiency virus (HIV); Virus; Microbiology; Viral load; Viral disease; Antiretroviral therapy","score_opus":0.013744869195041323,"score_gpt":0.2890343163888135,"score_spread":0.2752894471937722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380290416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611843,0.000081092476,0.00017015013,0.037960276,0.00008690747,0.00036890316,0.00002381577,0.000033893873,0.000090626665],"genre_scores_gemma":[0.97848135,0.00023276595,0.0074745486,0.004279695,0.00014315332,0.0000073064884,0.000008273966,0.000046171088,0.009326727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988269,0.000052460975,0.0004153767,0.00020906865,0.00022050204,0.00027568068],"domain_scores_gemma":[0.9993026,0.00012064127,0.00011756239,0.00010994322,0.0001528072,0.00019640953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030447458,0.00018306237,0.00042074316,0.0006438294,0.000081695376,0.00004863445,0.00008410235,0.000053889005,0.000034026234],"category_scores_gemma":[0.00006383237,0.00015533308,0.00008859679,0.00077718624,0.000032411106,0.00012177216,0.000035269368,0.00018943906,0.00005215709],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048641292,0.0002789254,0.022495981,0.00004186092,0.00044600133,0.00023985241,0.006889325,0.00028278504,0.9093922,0.000005848934,0.052049,0.00301412],"study_design_scores_gemma":[0.005269222,0.00021440526,0.09105713,0.00036741688,0.00013170336,0.00029548636,0.00043758392,0.000026198935,0.86514294,0.000042994652,0.03676082,0.00025408945],"about_ca_topic_score_codex":0.00002455003,"about_ca_topic_score_gemma":0.000025706033,"teacher_disagreement_score":0.06856115,"about_ca_system_score_codex":0.000103681894,"about_ca_system_score_gemma":0.0001683533,"threshold_uncertainty_score":0.63342994},"labels":[],"label_agreement":null},{"id":"W4380485347","doi":"10.2196/46767","title":"Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"JMIR Public Health and Surveillance","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Science and Technology Major Project; Beijing Municipal Health Commission","keywords":"Meta-analysis; Human immunodeficiency virus (HIV); Medicine; Systematic review; Risk analysis (engineering); MEDLINE; Intensive care medicine; Biology; Virology; Internal medicine","score_opus":0.15594456643292137,"score_gpt":0.41166679604708545,"score_spread":0.2557222296141641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380485347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000038221797,0.9870032,0.00008891295,0.0042359536,0.000020978432,0.00826207,0.0002578097,0.00005093018,0.000076307435],"genre_scores_gemma":[0.000023638804,0.98842126,0.00020356245,0.00047450062,0.00001968704,0.0011835769,0.0009757138,0.000048883256,0.008649164],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960567,0.000581656,0.0018726143,0.0006554854,0.00030517264,0.00052838074],"domain_scores_gemma":[0.9962649,0.0013057631,0.0011760695,0.00047960287,0.00015634233,0.00061734446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034003363,0.00049095816,0.010771343,0.00044070516,0.00017547152,0.000051736064,0.00009625619,0.00015197632,0.000033626835],"category_scores_gemma":[0.0010294096,0.00031001106,0.00080542814,0.0012049102,0.000054184147,0.00006524663,0.00008875876,0.00018710652,0.0000067765627],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008218811,0.000055902823,0.00037906808,0.9350102,0.047227826,0.000005869203,0.00012894049,1.635212e-8,5.082973e-10,0.000021115964,0.00094452436,0.01621831],"study_design_scores_gemma":[0.0016619858,0.00020380152,0.00036504905,0.039175335,0.15198806,0.00011075089,0.00009219964,0.00002522018,6.4813013e-9,0.0000021232197,0.8057439,0.000631624],"about_ca_topic_score_codex":0.000015864245,"about_ca_topic_score_gemma":0.000039859697,"teacher_disagreement_score":0.89583486,"about_ca_system_score_codex":0.00011547898,"about_ca_system_score_gemma":0.00073341455,"threshold_uncertainty_score":0.9999352},"labels":[],"label_agreement":null},{"id":"W4380680885","doi":"10.1111/hiv.13520","title":"Treatment‐emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series","year":2023,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; AIDS Vancouver; Vancouver Infectious Diseases Centre; University of British Columbia; St. Michael's Hospital","funders":"Canada Research Chairs","keywords":"Emtricitabine; Medicine; Tenofovir alafenamide; Virology; Drug resistance; Abacavir; Viral quasispecies; Resistance mutation; Reverse transcriptase; Internal medicine; Viral load; Oncology; Human immunodeficiency virus (HIV); Genetics; Virus; Antiretroviral therapy; Biology; Polymerase chain reaction; Gene","score_opus":0.018529698080600114,"score_gpt":0.2531929371088467,"score_spread":0.2346632390282466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380680885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720286,0.0031448773,0.000012301339,0.02177226,0.00013640178,0.0009569281,0.00006136267,0.00033816785,0.0015490593],"genre_scores_gemma":[0.78858864,0.008026121,0.0009477501,0.00018623132,0.00022733939,0.00016447005,0.00032969026,0.00008059506,0.20144919],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979303,0.000059411697,0.0004353537,0.0005841605,0.0004424034,0.00054836896],"domain_scores_gemma":[0.9989621,0.000059639955,0.000098525474,0.00042911668,0.00008408034,0.00036651976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014753763,0.00048181837,0.0007139986,0.00046160797,0.0003133921,0.000014913374,0.000059595306,0.00008544373,0.00019100445],"category_scores_gemma":[0.00004100553,0.00028588256,0.0000831824,0.0010668599,0.00029751324,0.00016288337,0.000017525317,0.00014878369,0.000051440853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016351838,0.0014173536,0.53134346,0.0011471704,0.002835806,0.29940784,0.029811649,0.0000048185534,0.04089153,0.0007603138,0.058353946,0.017674293],"study_design_scores_gemma":[0.1941178,0.018898128,0.21987341,0.004254681,0.0043934225,0.05876301,0.038555812,0.00025875005,0.022463428,0.00034006574,0.4347887,0.0032928144],"about_ca_topic_score_codex":0.0001309133,"about_ca_topic_score_gemma":0.00017978014,"teacher_disagreement_score":0.37643474,"about_ca_system_score_codex":0.0002011751,"about_ca_system_score_gemma":0.00017365755,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W4381470336","doi":"10.1093/cid/ciad370","title":"Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure","year":2023,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Medicine; Internal medicine; Dosing; Regimen; Population; Body mass index; Post-hoc analysis; Quartile; Proportional hazards model; Viral load; Pharmacology; Human immunodeficiency virus (HIV); Confidence interval; Immunology; Antiretroviral therapy","score_opus":0.06304437516076282,"score_gpt":0.349674355742804,"score_spread":0.28662998058204114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381470336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99670583,0.000030516681,0.0007589959,0.0001707696,0.00013309503,0.0018077753,0.00017359907,0.00015877916,0.000060631523],"genre_scores_gemma":[0.99872965,0.00003978055,0.00009182207,0.000046561836,0.000028862505,0.00018396259,0.0007206138,0.00002379148,0.0001349373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760437,0.00029829546,0.0010853078,0.000489221,0.00024948665,0.00027330342],"domain_scores_gemma":[0.99691373,0.0016433046,0.000565545,0.00017740295,0.00042206942,0.00027794228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000328705,0.00026047748,0.0008325674,0.0000917075,0.00016210986,0.000018596493,0.00003621691,0.00016068839,0.000018520232],"category_scores_gemma":[0.0014106577,0.00018671398,0.0002425637,0.00042498516,0.0001839452,0.00014351873,0.00003532071,0.00012464837,0.0000014957072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006922376,0.0043713367,0.9857262,0.00005419299,0.0006553635,0.0000032630794,0.0005221087,0.00013374111,0.00002579851,0.00005002142,0.00027506094,0.0074907057],"study_design_scores_gemma":[0.008770155,0.0052669398,0.9733771,0.0001697422,0.00079342374,7.9562983e-7,0.00037347552,0.009390494,0.0010477013,0.00053333264,0.00007304419,0.00020376209],"about_ca_topic_score_codex":0.00008910531,"about_ca_topic_score_gemma":0.0002824025,"teacher_disagreement_score":0.012349036,"about_ca_system_score_codex":0.00013038446,"about_ca_system_score_gemma":0.00023358232,"threshold_uncertainty_score":0.76139754},"labels":[],"label_agreement":null},{"id":"W4381838846","doi":"10.1371/journal.pone.0285787","title":"High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Gilead Sciences","keywords":"Medicine; Renal function; Tenofovir alafenamide; Internal medicine; Regimen; Dolutegravir; Emtricitabine; Kidney disease; Ritonavir; Creatinine; Lopinavir; Viral load; Immunology; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.07955401607254327,"score_gpt":0.3224839405957895,"score_spread":0.24292992452324624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381838846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577653,0.00003121793,0.000022360096,0.001979702,0.000051822037,0.0019843422,0.00002821967,0.00008154929,0.000044253782],"genre_scores_gemma":[0.9900776,0.00033999467,0.0026506304,0.00013019009,0.0002394782,0.00027133888,0.0002180804,0.000049753427,0.006022944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982647,0.000060989027,0.0005406003,0.0003618473,0.00043151106,0.00034039185],"domain_scores_gemma":[0.9987803,0.0005590784,0.00016235275,0.00024258124,0.000060689545,0.00019500816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005660373,0.00019941661,0.00069614535,0.00022494954,0.000070035254,0.0000127268,0.00007827923,0.000098248696,0.00012893051],"category_scores_gemma":[0.0003842413,0.00014973983,0.0001296054,0.00037143927,0.000051863255,0.000055731525,0.0000546713,0.0001476034,0.000039095612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014940847,0.004808479,0.9745528,0.00013718814,0.0007097582,0.00006557119,0.0012818513,0.000010148644,0.000107269036,0.0000055189084,0.0026829247,0.00069761125],"study_design_scores_gemma":[0.078775816,0.006082227,0.908013,0.0023289213,0.00019830451,6.8899897e-7,0.000113235285,0.0013824868,0.0028095087,0.000005001114,0.00009293316,0.00019788677],"about_ca_topic_score_codex":0.00004076398,"about_ca_topic_score_gemma":0.00011301889,"teacher_disagreement_score":0.06653985,"about_ca_system_score_codex":0.00008568304,"about_ca_system_score_gemma":0.00011172883,"threshold_uncertainty_score":0.61062133},"labels":[],"label_agreement":null},{"id":"W4383384414","doi":"10.1016/s0016-5085(23)03879-9","title":"257 OPERATIONAL CHALLENGES FOR IMPLEMENTING THE “TORONTO PROTOCOL“, GLECAPREVIR/PIBRENTASVIR+EZETIMIBE, FOR SOLID ORGAN TRANSPLANTATION FROM HCV NAT+ DONORS TO HCV-UNINFECTED RECIPIENTS","year":2023,"lang":"en","type":"article","venue":"Gastroenterology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nat; Ezetimibe; Medicine; Protocol (science); Virology; Internal medicine; Mathematics; Pathology; Statistics","score_opus":0.03741876832583512,"score_gpt":0.3398792702702781,"score_spread":0.30246050194444296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383384414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8746123,0.000037436515,0.0074278456,0.029491618,0.0006322705,0.08636475,0.0007899054,0.00029078271,0.00035312204],"genre_scores_gemma":[0.5964302,0.00026899786,0.01825295,0.003171886,0.001079407,0.36621723,0.010663466,0.0001806608,0.0037352233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997963,0.00010142167,0.00049661973,0.0005008314,0.00021411099,0.00072401896],"domain_scores_gemma":[0.99917704,0.00016245054,0.000120682955,0.00024271794,0.00015609433,0.00014099413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039535182,0.00026740876,0.00037403396,0.00011225162,0.00031637785,0.0000317153,0.0001677117,0.00008465339,0.0002472739],"category_scores_gemma":[0.00005503407,0.00019952902,0.00013762315,0.000099076315,0.00003398878,0.00012083418,0.00006894409,0.000077207966,0.000044588953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025839744,0.0022627623,0.70844245,0.0012484114,0.005051919,0.000075859985,0.03492616,0.00020827132,0.018005382,0.0010810487,0.12455742,0.07830057],"study_design_scores_gemma":[0.050418366,0.0075149164,0.63213205,0.00058953883,0.0012904594,0.00007177398,0.0024199863,0.002342984,0.009422276,0.0005313112,0.2925557,0.0007106408],"about_ca_topic_score_codex":0.000060830243,"about_ca_topic_score_gemma":0.003741086,"teacher_disagreement_score":0.27985248,"about_ca_system_score_codex":0.0001711402,"about_ca_system_score_gemma":0.00006506623,"threshold_uncertainty_score":0.81365573},"labels":[],"label_agreement":null},{"id":"W4385213879","doi":"10.1016/j.lana.2023.100553","title":"Living kidney donors with HIV: experience and outcomes from a case series by the HOPE in Action Consortium","year":2023,"lang":"en","type":"article","venue":"The Lancet Regional Health - Americas","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health, Pakistan; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; University of California, San Francisco; Perelman School of Medicine, University of Pennsylvania; Medical Center, University of Pittsburgh; University of Illinois at Urbana-Champaign; Health Resources and Services Administration; Ochsner Health; Rush University; University of Arkansas for Medical Sciences; Drexel University; University of Cincinnati; University of Pittsburgh; Johns Hopkins University; University of California, Los Angeles; Massachusetts General Hospital; University of Minnesota; University of Miami; York University; Northwestern University; Cleveland Clinic; Emory University; Weill Cornell Medical College; University of Pennsylvania; Virginia Commonwealth University; University of California, San Diego; Yale University; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Nephrectomy; Renal function; Donation; Internal medicine; Kidney disease; Kidney","score_opus":0.07738851611054275,"score_gpt":0.3618751743346472,"score_spread":0.28448665822410446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385213879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80285424,0.00024278511,0.000016054262,0.19630796,0.00004124029,0.0003278062,0.000023225826,0.000066218716,0.000120472665],"genre_scores_gemma":[0.97791255,0.0027484628,0.00049514096,0.011847871,0.00011399993,0.00021475751,0.00007165022,0.000020027568,0.006575568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890596,0.00012316773,0.00019781516,0.00023296587,0.0002135002,0.00032661165],"domain_scores_gemma":[0.99908197,0.00038189316,0.0001148859,0.00024812322,0.0000193064,0.0001538062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024005488,0.00014831104,0.00036367238,0.000049539387,0.00025683542,0.000020935002,0.00007135427,0.00002419291,0.000030826555],"category_scores_gemma":[0.000052450003,0.00007172371,0.000023587663,0.00035425677,0.00030440732,0.00008127751,0.000044268832,0.00017866385,0.000027955017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005013266,0.00008865385,0.8502794,0.00006482683,0.00010920551,0.0006558371,0.032649495,0.00000432027,0.000023658207,0.00012997552,0.108211465,0.007281864],"study_design_scores_gemma":[0.003283397,0.00038181667,0.74504876,0.000717348,0.00007161556,0.0046156677,0.041741602,0.00037332432,0.000051875515,0.00011422757,0.2032179,0.0003824861],"about_ca_topic_score_codex":0.0022984622,"about_ca_topic_score_gemma":0.0005079061,"teacher_disagreement_score":0.18446009,"about_ca_system_score_codex":0.00009596218,"about_ca_system_score_gemma":0.00021580048,"threshold_uncertainty_score":0.34746027},"labels":[],"label_agreement":null},{"id":"W4385330352","doi":"10.2217/pgs-2023-0058","title":"Single-Nucleotide Polymorphisms in ABC Drug Transporters Alter Expression and Circulating Tenofovir in Healthy South African Women Exposed to Pre-Exposure Prophylaxis","year":2023,"lang":"en","type":"article","venue":"Pharmacogenomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Inyuvesi Yakwazulu-Natali; South African Medical Research Council","keywords":"Single-nucleotide polymorphism; Tenofovir; SNP; Genotype; Biology; Gene; Pharmacology; Drug; Gene expression; Pre-exposure prophylaxis; Medicine; Genetics; Virology; Human immunodeficiency virus (HIV); Men who have sex with men","score_opus":0.022755794483241224,"score_gpt":0.2640044930331719,"score_spread":0.2412486985499307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385330352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631566,0.000141079,0.000016443104,0.0018088954,0.00013513367,0.001310728,0.000031114425,0.000113607406,0.00012736503],"genre_scores_gemma":[0.9975246,0.000060071372,0.0008545813,0.00061835564,0.000096125004,0.00021653052,0.000059780952,0.00007097348,0.00049897644],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977927,0.000074535994,0.0005873792,0.0005749457,0.00026101238,0.0007093929],"domain_scores_gemma":[0.9991899,0.000059705024,0.000102598824,0.0002050302,0.000023507266,0.00041923823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043390063,0.00029824345,0.00045985292,0.00063566543,0.00009200945,0.000026076908,0.00010537195,0.000062767154,0.000042471587],"category_scores_gemma":[0.000013919062,0.00027648488,0.000056617835,0.000700434,0.00004093058,0.000103754304,0.00006191888,0.00024085947,0.000038309645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020355466,0.0004176672,0.2922983,0.00018462159,0.00007140784,0.00057264516,0.16257851,0.00022841433,0.52287453,0.0000013095998,0.00011536888,0.018621702],"study_design_scores_gemma":[0.058420546,0.0031221271,0.568609,0.0018465428,0.00029030535,0.000119716315,0.039550144,0.0040795086,0.312534,0.00020184921,0.007908682,0.003317578],"about_ca_topic_score_codex":0.000039093848,"about_ca_topic_score_gemma":0.000034214736,"teacher_disagreement_score":0.2763107,"about_ca_system_score_codex":0.00055615156,"about_ca_system_score_gemma":0.0001315258,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W4385360042","doi":"10.51731/cjht.2023.700","title":"Fostemsavir (Rukobia)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Human immunodeficiency virus (HIV); Regimen; Family medicine; Drug; Intensive care medicine; Pharmacology; Political science; Surgery; Health care; Law","score_opus":0.0469626711215796,"score_gpt":0.3081190507480522,"score_spread":0.2611563796264726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385360042","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4561149,0.033024773,0.000043209653,0.5067837,0.00084416545,0.00054335495,0.000017909297,0.0005975061,0.0020304841],"genre_scores_gemma":[0.99356025,0.00075444195,0.0006162224,0.0003573871,0.000013878055,0.00000654826,0.0000074805425,0.000015310769,0.0046685054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988591,0.000020704856,0.00042101045,0.00009801703,0.00015460838,0.00044652805],"domain_scores_gemma":[0.99935454,0.000035908564,0.00018786592,0.00017692886,0.00010436249,0.0001404062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047489267,0.00010128329,0.00034422657,0.0010446273,0.0001726211,0.000015233244,0.00014293274,0.00009940442,0.000026859796],"category_scores_gemma":[0.00028175904,0.00007951401,0.000073232775,0.00066315674,0.000099112054,0.000054347576,0.000014889199,0.0002639413,0.00015232293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015051493,0.000021217802,0.051308803,0.00013373351,0.00012790415,0.0020856084,0.0008208399,0.000002753343,0.00003353431,0.00072007946,0.1876164,0.7571141],"study_design_scores_gemma":[0.0010643548,0.00036953395,0.04053336,0.0005095186,0.000028233608,0.00081116514,0.006620086,0.00000951841,0.000645234,0.001954967,0.94731915,0.00013489158],"about_ca_topic_score_codex":0.0005074319,"about_ca_topic_score_gemma":0.0013525975,"teacher_disagreement_score":0.75970274,"about_ca_system_score_codex":0.0004097019,"about_ca_system_score_gemma":0.0032273885,"threshold_uncertainty_score":0.57252485},"labels":[],"label_agreement":null},{"id":"W4385567107","doi":"10.1016/s2352-3018(23)00141-8","title":"Metabolic implications and safety of dolutegravir use in pregnancy","year":2023,"lang":"en","type":"review","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Toronto General Hospital; University Health Network","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institutes of Health","keywords":"Dolutegravir; Medicine; Pregnancy; MEDLINE; Obstetrics; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genetics","score_opus":0.13531982175592852,"score_gpt":0.3691383769915026,"score_spread":0.23381855523557407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385567107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050706603,0.9960194,0.000004588671,0.0011841948,0.00003117151,0.0012133083,0.00019132398,0.000039365492,0.0012659306],"genre_scores_gemma":[0.0000127610565,0.9822431,0.00040825916,0.000021277987,0.000078775476,0.00027841594,0.00025588862,0.000032567394,0.016668957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989339,0.00009002043,0.00043646147,0.00022221684,0.000107744745,0.00020964372],"domain_scores_gemma":[0.99892616,0.0002791012,0.00016419149,0.0005622273,0.0000223789,0.000045938792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019507157,0.00021305382,0.0016148875,0.00014463172,0.00003730486,0.000009766991,0.00014210216,0.000092386166,0.000017020504],"category_scores_gemma":[0.00006334063,0.000115057344,0.00013907415,0.0004690571,0.000059772556,0.00003030649,0.00007920291,0.00021802344,0.00011001133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026783713,0.00010535553,0.0057851844,0.008813847,0.0007644159,0.000024898252,0.0004571097,1.08685676e-7,5.2317785e-7,0.0088835545,0.0047277343,0.97041047],"study_design_scores_gemma":[0.0006623864,0.000006498141,0.014451922,0.017661076,0.0010025688,0.000025845946,0.00001094603,5.8795627e-7,6.111059e-7,0.00019393045,0.9658756,0.00010798966],"about_ca_topic_score_codex":0.00002344478,"about_ca_topic_score_gemma":0.000078618876,"teacher_disagreement_score":0.9703025,"about_ca_system_score_codex":0.000038134564,"about_ca_system_score_gemma":0.00016541762,"threshold_uncertainty_score":0.46919024},"labels":[],"label_agreement":null},{"id":"W4385644651","doi":"10.1007/s40121-023-00848-4","title":"Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens","year":2023,"lang":"en","type":"article","venue":"Infectious Diseases and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"ViiV Healthcare","keywords":"Dolutegravir; Medicine; Emtricitabine; Tenofovir alafenamide; Cobicistat; Regimen; Lamivudine; Rilpivirine; Elvitegravir; Tolerability; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Adverse effect; Virology; Antiretroviral therapy","score_opus":0.030172931464950398,"score_gpt":0.2926663668731265,"score_spread":0.26249343540817616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620841,0.0019321209,0.000031001837,0.028291646,0.00025211254,0.00318005,0.00043623592,0.00094947754,0.0028432284],"genre_scores_gemma":[0.95373046,0.0038882464,0.00006609513,0.0008826532,0.00021364399,0.00052058557,0.0007973112,0.00011131074,0.039789703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976992,0.00015728136,0.0003979187,0.00058508577,0.00045914605,0.00070137664],"domain_scores_gemma":[0.99803704,0.00060094637,0.00026165412,0.00047041848,0.00027730325,0.0003526327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003797488,0.0004570365,0.000779014,0.00025715376,0.0007686971,0.0001419127,0.000115907256,0.00006550033,0.000055987155],"category_scores_gemma":[0.00006808133,0.0002646132,0.00016290613,0.0008726158,0.00018008352,0.000105722334,0.00005070849,0.00020931048,0.000016165686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009256603,0.0010312455,0.79459625,0.00020543416,0.0024612355,0.00028138034,0.0022868896,0.000033867193,0.000043288423,0.0017205984,0.17665596,0.011427229],"study_design_scores_gemma":[0.0654539,0.0050807544,0.49324024,0.0029081213,0.0020282946,0.00016084468,0.0027842121,0.001102742,0.0008375215,0.0031361796,0.4211307,0.0021364796],"about_ca_topic_score_codex":0.0005748692,"about_ca_topic_score_gemma":0.004086614,"teacher_disagreement_score":0.30135602,"about_ca_system_score_codex":0.0005897203,"about_ca_system_score_gemma":0.0003385025,"threshold_uncertainty_score":0.9999806},"labels":[],"label_agreement":null},{"id":"W4385651241","doi":"10.1016/s2352-3018(23)00136-4","title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","year":2023,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare","keywords":"Emtricitabine; Rilpivirine; Medicine; Tenofovir alafenamide; Dolutegravir; Internal medicine; Population; Tolerability; Adverse effect; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy","score_opus":0.03948339338740951,"score_gpt":0.32625762674939673,"score_spread":0.2867742333619872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385651241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744965,0.000088396686,0.0001961823,0.0054487786,0.00011939387,0.0055617345,0.00016042362,0.000116681505,0.00085877144],"genre_scores_gemma":[0.99657845,0.00025278452,0.0017060747,0.00008463312,0.00017373718,0.00019499804,0.00022861663,0.000043240638,0.0007374454],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965833,0.00034401825,0.0010687102,0.0008320435,0.00044393048,0.00072803575],"domain_scores_gemma":[0.9965469,0.0019897947,0.00036946216,0.00071036094,0.00010730526,0.00027615772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024682286,0.0004953065,0.0018543501,0.00022462883,0.00024173762,0.00011510185,0.0003799618,0.0001470187,0.000010009959],"category_scores_gemma":[0.0015303157,0.00030363025,0.00006856694,0.0007248638,0.0001608803,0.00020450918,0.00047033487,0.0005562578,0.000010284646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9552899,0.00091784983,0.01622205,0.00013703387,0.00024262037,0.00037530967,0.0072783465,0.00008950594,0.0021472091,0.000010541955,0.0002067763,0.01708287],"study_design_scores_gemma":[0.8321474,0.0027183157,0.15875283,0.0008066925,0.00027743168,0.00002007834,0.00050624576,0.0033725135,0.000547858,0.000019143077,0.00043913783,0.00039233055],"about_ca_topic_score_codex":0.00037228645,"about_ca_topic_score_gemma":0.0010182699,"teacher_disagreement_score":0.14253078,"about_ca_system_score_codex":0.0001756868,"about_ca_system_score_gemma":0.00025417036,"threshold_uncertainty_score":0.9999416},"labels":[],"label_agreement":null},{"id":"W4386112777","doi":"10.17615/z01j-zj18","title":"Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy","year":2023,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Dental and Craniofacial Research; National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institute on Deafness and Other Communication Disorders; National Institute on Drug Abuse; National Institute of Nursing Research; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Institute on Aging; Center for AIDS Research, University of Washington; Centers for Disease Control and Prevention; University of Washington; Johns Hopkins University; ViiV Healthcare; National Institutes of Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Kaiser Permanente; Emory University; Case Western Reserve University; University of North Carolina at Chapel Hill; Agency for Healthcare Research and Quality; Government of Alberta; Canadian Institutes of Health Research; Vanderbilt University; National Human Genome Research Institute; Health Resources and Services Administration","keywords":"Antiretroviral therapy; Integrase; Integrase inhibitor; Human immunodeficiency virus (HIV); Virology; Medicine; Viral load","score_opus":0.022581490798530945,"score_gpt":0.2446314809333982,"score_spread":0.22204999013486726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386112777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592924,0.00011161256,0.00013274298,0.002145774,0.0001293326,0.00043494717,0.000012200345,0.0005406131,0.0005635555],"genre_scores_gemma":[0.9829119,0.000009528113,0.008556555,0.0005252411,0.00008209999,0.0000359193,0.00025866923,0.000045838646,0.007574241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987528,0.00004062105,0.00022723917,0.00031988166,0.00030581385,0.0003536654],"domain_scores_gemma":[0.99938375,0.000117986725,0.00007643022,0.00026066226,0.00003697478,0.00012419088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077370525,0.0002831641,0.0003870314,0.00028015167,0.00015571188,0.00008248471,0.000087436136,0.00009756808,0.00013586164],"category_scores_gemma":[0.000043581196,0.00016534027,0.00009950815,0.000549365,0.00024798795,0.00033115954,0.00004081419,0.00015537729,0.00010396059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000764707,0.00015269054,0.9929128,0.00003497763,0.00018761262,0.00040048486,0.0009713494,0.000014586456,0.0001388603,0.00085230614,0.0023465147,0.0012230992],"study_design_scores_gemma":[0.019323083,0.0017995001,0.9248249,0.00079938944,0.00025666057,0.000018673283,0.0029105556,0.0040601003,0.039950687,0.0014184833,0.003748048,0.00088992657],"about_ca_topic_score_codex":0.000034233817,"about_ca_topic_score_gemma":0.000010589937,"teacher_disagreement_score":0.06808792,"about_ca_system_score_codex":0.000042707343,"about_ca_system_score_gemma":0.00023722064,"threshold_uncertainty_score":0.6742381},"labels":[],"label_agreement":null},{"id":"W4386112828","doi":"10.17615/4syf-p824","title":"Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada","year":2023,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Integrase; Human immunodeficiency virus (HIV); Integrase inhibitor; Virology; Cohort; Antiretroviral therapy; Medicine; Lentivirus; Viral disease; Viral load; Internal medicine","score_opus":0.01868141166854968,"score_gpt":0.2889621287623069,"score_spread":0.27028071709375723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386112828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987055,0.00016725846,0.000008792311,0.00020336741,0.000042852622,0.00074987375,0.00006493406,0.000031338965,0.000026049916],"genre_scores_gemma":[0.9992118,0.000102735125,0.00006626454,0.000018927467,0.000007124949,0.000046739333,0.00045998738,0.000013423247,0.00007298959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876106,0.00024133094,0.00038533309,0.0001851804,0.00028442385,0.00014266804],"domain_scores_gemma":[0.998802,0.00082703563,0.000063119274,0.00014326767,0.00013409009,0.000030465199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053739507,0.00014396179,0.00041720367,0.00020854309,0.00007824258,0.000015895643,0.00005330934,0.000045280933,0.0000016074896],"category_scores_gemma":[0.00009917633,0.00008296615,0.000026552394,0.0009904975,0.000535125,0.0001272608,0.00001348165,0.00010646038,2.0352705e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015300058,0.00018246402,0.9877607,0.0005618253,0.00041871396,0.000107922104,0.007826235,0.00004479529,0.00026850495,0.0009272199,0.00032954972,0.00004203171],"study_design_scores_gemma":[0.0069767563,0.001540554,0.93139344,0.0020320758,0.00032814243,0.0000014743129,0.03526438,0.00025102458,0.0217847,0.00023520905,0.000030279058,0.00016195577],"about_ca_topic_score_codex":0.046077523,"about_ca_topic_score_gemma":0.1198837,"teacher_disagreement_score":0.07380618,"about_ca_system_score_codex":0.00003500755,"about_ca_system_score_gemma":0.00046888765,"threshold_uncertainty_score":0.96027476},"labels":[],"label_agreement":null},{"id":"W4386152617","doi":"10.1111/bcp.15893","title":"Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults","year":2023,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Darunavir; Etravirine; Tolerability; Pharmacokinetics; Ritonavir; Pharmacology; Chemistry; Dosing; Area under the curve; Geometric mean; Medicine; Internal medicine; Adverse effect; Viral load; Mathematics; Human immunodeficiency virus (HIV)","score_opus":0.047053930772478464,"score_gpt":0.40507006901566733,"score_spread":0.3580161382431889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386152617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875521,0.0005354643,0.0000035506096,0.01064482,0.0006798334,0.0004983348,0.000020234755,0.000010468932,0.000055175708],"genre_scores_gemma":[0.9937437,0.004060267,0.00051637745,0.0009893118,0.00036044564,0.000009493637,0.00000795089,0.000013905491,0.00029852358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757594,0.00033286068,0.0013910831,0.00021894893,0.00027450535,0.00020668919],"domain_scores_gemma":[0.9983529,0.00064252113,0.0005095548,0.0000767069,0.00019906442,0.00021924496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011144492,0.00012763056,0.0007028259,0.00009305869,0.000054303404,0.000012563841,0.00008822619,0.000113632326,0.000061725164],"category_scores_gemma":[0.00025346415,0.00008730982,0.00008252596,0.00030195413,0.00033538995,0.000085770465,0.00007526454,0.0006175595,0.0000016171691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10320645,0.00346308,0.58509296,0.00089163106,0.0005980262,0.0046939133,0.00071547437,0.00001678463,0.001974405,0.000008029193,0.01692647,0.28241277],"study_design_scores_gemma":[0.030191924,0.0041216686,0.9530141,0.0008441273,0.0003022562,0.002884384,0.0001816839,0.00034410166,0.0012453711,0.000038635782,0.0066998084,0.0001319475],"about_ca_topic_score_codex":0.00001731442,"about_ca_topic_score_gemma":0.00010130885,"teacher_disagreement_score":0.3679211,"about_ca_system_score_codex":0.000034737182,"about_ca_system_score_gemma":0.00036640672,"threshold_uncertainty_score":0.3560391},"labels":[],"label_agreement":null},{"id":"W4386953567","doi":"10.1371/journal.pmed.1004293","title":"Recommendations on data sharing in HIV drug resistance research","year":2023,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention; ViiV Healthcare; Medical Research Council; Gilead Sciences","keywords":"Drug resistance; Medicine; HIV drug resistance; Drug; Antiretroviral drug; Transmission (telecommunications); Human immunodeficiency virus (HIV); Intensive care medicine; Virology; Biology; Viral load; Pharmacology; Antiretroviral therapy; Genetics","score_opus":0.365614082148529,"score_gpt":0.44886905615815975,"score_spread":0.08325497400963078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386953567","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13245405,0.0004186276,0.000010199935,0.78849006,0.00023712871,0.0010102981,0.00003788936,0.00029694822,0.07704478],"genre_scores_gemma":[0.30183196,0.001835504,0.002263873,0.0009241998,0.00068546267,0.00022603154,0.004662485,0.0000797355,0.68749076],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997797,0.00008216007,0.00036142068,0.0005940498,0.00073925056,0.00042612298],"domain_scores_gemma":[0.9980417,0.0005532795,0.00003836806,0.0011152436,0.00008964513,0.00016174497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019273238,0.00013527971,0.0003061475,0.00079787354,0.00013680068,0.000010060837,0.00038553713,0.000042674204,0.0006158086],"category_scores_gemma":[0.0012891428,0.00010196023,0.000015396166,0.0016094971,0.00009556265,0.000086681095,0.00028934647,0.0004293554,0.0014312777],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001478945,0.00029241774,0.02096818,0.000120057455,0.00008004021,0.00040289722,0.0027569542,5.770298e-7,0.00031881727,0.0010818632,0.9722465,0.0015837555],"study_design_scores_gemma":[0.009764239,0.00013291318,0.032457143,0.00996798,0.00015106211,0.000010468013,0.0049780053,0.0026998732,0.0015601617,0.0026496495,0.9352514,0.0003770624],"about_ca_topic_score_codex":0.000020319436,"about_ca_topic_score_gemma":0.00040339996,"teacher_disagreement_score":0.7875659,"about_ca_system_score_codex":0.00020327525,"about_ca_system_score_gemma":0.00010078433,"threshold_uncertainty_score":0.9993462},"labels":[],"label_agreement":null},{"id":"W4387246264","doi":"10.1101/2023.09.30.23296350","title":"HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, &amp; Surveillance Pipeline","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Human immunodeficiency virus (HIV); HIV drug resistance; Identification (biology); Pipeline (software); Virology; Drug resistance; Drug; Medicine; Computational biology; Computer science; Pharmacology; Biology; Viral load; Antiretroviral therapy; Microbiology","score_opus":0.04308615488723088,"score_gpt":0.3154210557713319,"score_spread":0.272334900884101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387246264","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5603431,0.010113437,0.054828133,0.3291018,0.009735397,0.013288957,0.0015301111,0.003563749,0.017495345],"genre_scores_gemma":[0.23801848,0.0010411713,0.0067380453,0.00016258685,0.0006514015,0.0009954037,0.008020738,0.00016292113,0.74420923],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946719,0.00042935365,0.001330763,0.0014503639,0.0015892047,0.0005284504],"domain_scores_gemma":[0.99558187,0.00028103183,0.00062017096,0.0019891292,0.0012480811,0.00027971392],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034717,0.00061343337,0.00092098344,0.00044147027,0.00022014188,0.00011826318,0.000481538,0.00027576232,0.0007398684],"category_scores_gemma":[0.0013821275,0.0005549713,0.00027599235,0.00062934076,0.00012938482,0.00007424313,0.00036367233,0.0006185611,0.0051743425],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017896769,0.00044564944,0.2379872,0.0008738008,0.0006998577,0.00021005956,0.0035146985,0.00024414426,0.00029827727,0.00033293827,0.7547449,0.00046953105],"study_design_scores_gemma":[0.0049287463,0.000008036263,0.44313195,0.0021866017,0.0012465637,0.00003826036,0.00029066956,0.0035298464,0.0010378701,0.0068924935,0.535149,0.0015599744],"about_ca_topic_score_codex":0.0000167477,"about_ca_topic_score_gemma":0.0007272816,"teacher_disagreement_score":0.7267139,"about_ca_system_score_codex":0.00051501056,"about_ca_system_score_gemma":0.0010293432,"threshold_uncertainty_score":0.9996902},"labels":[],"label_agreement":null},{"id":"W4387412211","doi":"10.2196/50894","title":"Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study","year":2023,"lang":"en","type":"article","venue":"JMIR Public Health and Surveillance","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"State Key Laboratory of Infectious Disease Prevention and Control; Chinese Center for Disease Control and Prevention; National Natural Science Foundation of China","keywords":"Observational study; Human immunodeficiency virus (HIV); Drug resistance; Transmission (telecommunications); Drug; China; Medicine; Virology; Environmental health; Biology; Pharmacology; Internal medicine; Genetics; Computer science; Geography; Telecommunications","score_opus":0.021049200751891185,"score_gpt":0.29670266880763957,"score_spread":0.27565346805574836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387412211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91288686,0.0020169315,0.000027658629,0.081781425,0.0000322167,0.0028728747,0.000019357616,0.000040501192,0.00032217323],"genre_scores_gemma":[0.9927396,0.00080812257,0.00026712212,0.00062872045,0.00002781947,0.0006591261,0.00033017303,0.000017798287,0.0045215134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975208,0.0006502701,0.0004922418,0.00042968386,0.00037527952,0.00053170347],"domain_scores_gemma":[0.99906456,0.00030912724,0.000108156455,0.00018545889,0.000039094622,0.00029358032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002047466,0.00021019566,0.00047841712,0.00017059968,0.00017373009,0.000049077495,0.000068848116,0.00005162733,0.000012931354],"category_scores_gemma":[0.000081076636,0.00014076779,0.000035730518,0.0008173086,0.00009142174,0.00010311685,0.000050538943,0.00021990549,0.000004309908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003085247,0.00035133463,0.9793477,0.00008407762,0.000058304835,0.0000795607,0.013492992,0.000009059124,4.6324706e-7,0.00019121966,0.0038963389,0.0021804338],"study_design_scores_gemma":[0.00952393,0.000045786215,0.982438,0.00013306933,0.000002374062,0.0000018056959,0.00091031403,0.0009508653,5.599609e-7,0.00006926504,0.0058081415,0.00011587426],"about_ca_topic_score_codex":0.00007059384,"about_ca_topic_score_gemma":0.0009782301,"teacher_disagreement_score":0.08115271,"about_ca_system_score_codex":0.00015725681,"about_ca_system_score_gemma":0.0002846548,"threshold_uncertainty_score":0.5740344},"labels":[],"label_agreement":null},{"id":"W4387476411","doi":"10.1111/hiv.13546","title":"Daily ritonavir‐boosted darunavir for viral suppression in pregnancy (<scp>DRV‐P</scp>)","year":2023,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"B.C. Women's Hospital & Health Centre; Women's Health Research Institute; University of British Columbia; Children's & Women's Health Centre of British Columbia","funders":"","keywords":"Darunavir; Medicine; Ritonavir; Pregnancy; Discontinuation; Viral load; Dosing; Adverse effect; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.02808124465369344,"score_gpt":0.3071274317591992,"score_spread":0.27904618710550577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387476411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94308287,0.003144398,0.00025304907,0.026292518,0.0014157495,0.0039436584,0.00010195717,0.000789001,0.020976808],"genre_scores_gemma":[0.73373574,0.0008246259,0.0016142082,0.0007350883,0.0008706767,0.00095797586,0.003908909,0.0001504455,0.2572023],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749225,0.00005943434,0.0006173198,0.00056937244,0.0005755523,0.00068608404],"domain_scores_gemma":[0.9985504,0.00048022487,0.00011841303,0.00045063795,0.00009778478,0.00030250347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039207545,0.0003578365,0.00070909876,0.00054389145,0.0001225743,0.000010181542,0.00016338675,0.0001863457,0.000110963774],"category_scores_gemma":[0.00061765494,0.0002566662,0.000108801796,0.0007708321,0.00012970934,0.00011974266,0.0000880215,0.00027293793,0.0004398346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038853832,0.000772505,0.18340963,0.0009238964,0.0002822797,0.0018821942,0.010548621,0.000009024225,0.023147374,0.0004912406,0.7508043,0.027340388],"study_design_scores_gemma":[0.053284332,0.0016783829,0.34796748,0.013577549,0.00067524455,0.00014191456,0.0039376933,0.002313081,0.016309591,0.0015659949,0.5580915,0.00045720974],"about_ca_topic_score_codex":0.000026982796,"about_ca_topic_score_gemma":0.000023448545,"teacher_disagreement_score":0.2362255,"about_ca_system_score_codex":0.00014498206,"about_ca_system_score_gemma":0.00014947199,"threshold_uncertainty_score":0.99998856},"labels":[],"label_agreement":null},{"id":"W4387485265","doi":"10.1016/s2352-3018(23)00228-x","title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","year":2023,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institute on Drug Abuse; Fogarty International Center; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; Medical Research Council; Agence Nationale de Recherches sur le Sida et les Hépatites Virales; Ministerie van Volksgezondheid, Welzijn en Sport; Deutsches Zentrum für Infektionsforschung; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Styrelsen för Internationellt Utvecklingssamarbete; Gilead Sciences; Centre Hospitalier Universitaire de Bordeaux; National Institute of Diabetes and Digestive and Kidney Diseases; ViiV Healthcare; National Science Foundation","keywords":"Dolutegravir; Medicine; Cohort; Drug resistance; HIV drug resistance; Integrase inhibitor; Cohort study; Virology; Internal medicine; Antiretroviral therapy; Viral load; Human immunodeficiency virus (HIV); Genetics; Biology","score_opus":0.017772571501365637,"score_gpt":0.2825013528993654,"score_spread":0.26472878139799977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387485265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9467315,0.0002780751,0.000023414526,0.044499762,0.00005477335,0.00069977524,0.000115183015,0.00017873039,0.007418764],"genre_scores_gemma":[0.9219504,0.0003084958,0.00049180706,0.00080228335,0.000113007954,0.00016805423,0.00063328113,0.000024603376,0.07550805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984363,0.00016773006,0.00024544622,0.00034672214,0.00040838923,0.0003954683],"domain_scores_gemma":[0.99900246,0.00022986063,0.00008769281,0.0005530534,0.00006268725,0.000064249594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057515514,0.00021379646,0.0006894768,0.0003571328,0.00012298084,0.00003045758,0.00017465392,0.000047017376,0.00008864722],"category_scores_gemma":[0.000048062207,0.00013211017,0.00012681146,0.0038817874,0.00006761074,0.00003697238,0.000021917873,0.0002025253,0.00060087396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011190312,0.00015451391,0.8904291,0.000018144738,0.0006646786,0.000116511925,0.0032126652,0.0000877438,0.000086123764,0.00045862573,0.103489,0.00016386941],"study_design_scores_gemma":[0.004981351,0.000057976868,0.9533075,0.00011084189,0.0003482521,4.8527187e-7,0.00057438243,0.00095949665,0.000756259,0.00016062072,0.038512304,0.00023054317],"about_ca_topic_score_codex":0.000029297831,"about_ca_topic_score_gemma":0.0011491331,"teacher_disagreement_score":0.068089284,"about_ca_system_score_codex":0.0001694478,"about_ca_system_score_gemma":0.00018209229,"threshold_uncertainty_score":0.77232194},"labels":[],"label_agreement":null},{"id":"W4387737106","doi":"10.1371/journal.pgph.0001948","title":"Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countries","year":2023,"lang":"en","type":"review","venue":"PLOS Global Public Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Drug resistance; Pandemic; Medicine; HIV drug resistance; Resistance (ecology); Human immunodeficiency virus (HIV); Population; Drug; Antiretroviral therapy; Environmental health; Intensive care medicine; Virology; Coronavirus disease 2019 (COVID-19); Pharmacology; Viral load; Biology; Disease; Internal medicine; Infectious disease (medical specialty)","score_opus":0.07828523086157965,"score_gpt":0.3669105854477348,"score_spread":0.2886253545861551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387737106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010248118,0.9752784,0.0000059608,0.0202818,0.00009714861,0.0025422329,0.00045007575,0.0001827166,0.00013686741],"genre_scores_gemma":[0.0001677358,0.9949509,0.0039133057,0.000029523264,0.00008350424,0.0003576455,0.00019507745,0.00003085524,0.00027148973],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975747,0.000092969654,0.0008911062,0.0005517584,0.0003359915,0.00055350456],"domain_scores_gemma":[0.99844134,0.0004685694,0.00047946713,0.0002496028,0.00014279856,0.00021819916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007994337,0.00041380792,0.0019360229,0.00034934038,0.00012233212,0.00006927641,0.000109261775,0.00019200395,0.0000016257367],"category_scores_gemma":[0.0003920867,0.00030471047,0.00006271025,0.00084491086,0.00012861464,0.00008995517,0.00016435473,0.00029886258,0.0000014316395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038945203,0.0003485104,0.05876621,0.47522402,0.00048346966,0.00003373148,0.00041001601,1.3652637e-8,1.3131622e-8,0.004516825,0.003149712,0.45702854],"study_design_scores_gemma":[0.00213727,0.00009561483,0.0028721632,0.09443384,0.00030542037,0.000032588152,0.0010626741,0.000034427263,1.0918164e-7,0.0003843369,0.8982761,0.0003654995],"about_ca_topic_score_codex":0.000008997913,"about_ca_topic_score_gemma":0.00015446846,"teacher_disagreement_score":0.89512634,"about_ca_system_score_codex":0.00048949197,"about_ca_system_score_gemma":0.0019687032,"threshold_uncertainty_score":0.9999405},"labels":[],"label_agreement":null},{"id":"W4387943827","doi":"10.1016/j.mmifmc.2022.03.280","title":"Tolérance de cabotégravir + rilpivirine pendant les phases d'instauration orale et de traitement à longue durée d'action : une analyse combinée de 3 études de Phase 3","year":2022,"lang":"fr","type":"article","venue":"Médecine et Maladies Infectieuses Formation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Humanities; Physics; Mathematics; Philosophy","score_opus":0.03489658540963537,"score_gpt":0.35038479153783714,"score_spread":0.3154882061282018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387943827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94052154,0.0021465258,0.04046738,0.012452343,0.000682371,0.0011964769,0.00022222156,0.00024025103,0.0020709164],"genre_scores_gemma":[0.9838887,0.0038985482,0.004005439,0.00087372184,0.0002843183,0.0005643674,0.0015605945,0.00007688492,0.0048474334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995896,0.0009112079,0.0010531129,0.0004567203,0.00063505344,0.0010479137],"domain_scores_gemma":[0.99808264,0.00033399242,0.0005978266,0.0004140938,0.00023080946,0.00034062605],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019586934,0.0006109447,0.00069111213,0.00065686693,0.0008373782,0.00017825194,0.0002021366,0.00015799502,0.0016289321],"category_scores_gemma":[0.0003454697,0.00064291817,0.00027003008,0.0009688135,0.00015129193,0.001492576,0.00015883018,0.00067766686,0.000039072736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036081085,0.022259675,0.5884833,0.0034311872,0.0029377888,0.0010055543,0.08115283,0.084149405,0.04001998,0.01929197,0.03475594,0.11890431],"study_design_scores_gemma":[0.06320272,0.007985623,0.42159504,0.0029286847,0.0051604155,0.0049035256,0.042886227,0.12651241,0.09479546,0.0033375358,0.22389089,0.002801492],"about_ca_topic_score_codex":0.002517965,"about_ca_topic_score_gemma":0.01125712,"teacher_disagreement_score":0.18913494,"about_ca_system_score_codex":0.0048824865,"about_ca_system_score_gemma":0.0012725829,"threshold_uncertainty_score":0.9996022},"labels":[],"label_agreement":null},{"id":"W4387943866","doi":"10.1016/j.mmifmc.2022.03.279","title":"Cabotégravir + rilpivirine à longue durée d'action tous les 2 mois : résultats d'ATLAS 2M à 152 semaines","year":2022,"lang":"fr","type":"article","venue":"Médecine et Maladies Infectieuses Formation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"","keywords":"Medicine; Rilpivirine; Gynecology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Viral load","score_opus":0.026341599629727902,"score_gpt":0.29468104599985445,"score_spread":0.2683394463701265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387943866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93840635,0.009309308,0.004293383,0.02321059,0.007614615,0.002221558,0.00032008265,0.0005896867,0.014034399],"genre_scores_gemma":[0.8982057,0.0054343026,0.0010019087,0.00053522707,0.0011584929,0.00057392445,0.0019888226,0.00013389873,0.09096774],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954531,0.00055374054,0.0012717291,0.0006479574,0.0010147941,0.0010586808],"domain_scores_gemma":[0.9975359,0.00048695007,0.0006330143,0.00065183424,0.0003787015,0.00031361775],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009909852,0.00083558,0.0009087687,0.00089953584,0.0012339478,0.00015674338,0.00025047915,0.00023195783,0.005054116],"category_scores_gemma":[0.0005001775,0.00082723564,0.00034458423,0.0012084347,0.00020646857,0.001558313,0.00048466987,0.00092843466,0.0008903403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001758242,0.0067106546,0.43360704,0.0045220153,0.0028514531,0.0010058325,0.03598942,0.023507353,0.0018536196,0.010093877,0.30427694,0.17382357],"study_design_scores_gemma":[0.010896402,0.0018462202,0.18547508,0.00096868246,0.001333105,0.002194076,0.008526133,0.00515463,0.0044748946,0.0011272407,0.7765917,0.0014118038],"about_ca_topic_score_codex":0.0011358084,"about_ca_topic_score_gemma":0.0029688452,"teacher_disagreement_score":0.4723148,"about_ca_system_score_codex":0.0019981258,"about_ca_system_score_gemma":0.00035145498,"threshold_uncertainty_score":0.9998876},"labels":[],"label_agreement":null},{"id":"W4388011566","doi":"10.1016/j.ijantimicag.2023.107018","title":"Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort","year":2023,"lang":"en","type":"article","venue":"International Journal of Antimicrobial Agents","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"Merck Sharp and Dohme; ViiV Healthcare; Janssen Pharmaceuticals; Gilead Sciences","keywords":"Medicine; Confounding; Cohort; Proportional hazards model; Internal medicine; Cohort study; Toxicity; Subgroup analysis; Survival analysis; Logistic regression; Prospective cohort study; Confidence interval","score_opus":0.0319933260248944,"score_gpt":0.29225480289594946,"score_spread":0.26026147687105505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388011566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863693,0.0000065526942,0.00033015246,0.0120795015,0.0004403476,0.00023738328,0.0004950038,0.000011670989,0.000030071775],"genre_scores_gemma":[0.9940971,0.00024328793,0.00036163337,0.0008158337,0.00015960292,0.0000015747615,0.0024867686,0.00001599579,0.0018182122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864805,0.000025988267,0.0005447654,0.00017692744,0.0004833833,0.00012090378],"domain_scores_gemma":[0.99884284,0.000094783136,0.0003750784,0.00018139437,0.00043097683,0.00007491118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018684914,0.00013012669,0.000278492,0.0001427461,0.000053829957,0.000038789512,0.00030134906,0.000035844703,0.000053334807],"category_scores_gemma":[0.00020608115,0.000083188,0.000058737256,0.00012442177,0.00003101519,0.00018965953,0.00024353917,0.00008723273,0.00005425286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029496354,0.000328536,0.957042,0.000010002949,0.00079879025,0.0000674799,0.00077346613,0.00002708709,0.012621013,0.0000018418916,0.023963675,0.004071147],"study_design_scores_gemma":[0.0025584945,0.000051207622,0.9874777,0.0003324798,0.00018610146,0.000011687235,0.000026104883,0.0005938391,0.003763225,0.0000134259235,0.0049006096,0.00008510778],"about_ca_topic_score_codex":0.00001966562,"about_ca_topic_score_gemma":0.000015432015,"teacher_disagreement_score":0.030435719,"about_ca_system_score_codex":0.000058456888,"about_ca_system_score_gemma":0.00004762267,"threshold_uncertainty_score":0.33923084},"labels":[],"label_agreement":null},{"id":"W4388015553","doi":"10.52226/revista.v22i85.264","title":"¿Es posible que se genere resistencia al dolutegravir cuando se utiliza este agente en el tratamiento de primera línea?","year":2023,"lang":"es","type":"article","venue":"Actualizaciones en Sida e Infectología","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Humanities; Human immunodeficiency virus (HIV); Dolutegravir; Medicine; Philosophy; Antiretroviral therapy; Viral load; Virology","score_opus":0.03144998101611874,"score_gpt":0.3478878969322933,"score_spread":0.31643791591617454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388015553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981706,0.00339672,0.00017436415,0.0076069534,0.0010718305,0.0017612881,0.00031608334,0.0009818882,0.0029848465],"genre_scores_gemma":[0.95486706,0.009058802,0.00083631393,0.0014869017,0.0005491372,0.00038065301,0.0021219973,0.0002486711,0.030450476],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99302137,0.001143127,0.001363929,0.0014797389,0.0010171597,0.0019746935],"domain_scores_gemma":[0.9958326,0.001352881,0.00044604167,0.001298776,0.00026356961,0.000806113],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012973013,0.0013144432,0.0016180765,0.0010972988,0.00062434457,0.0002330799,0.0006279782,0.00091995194,0.0007096713],"category_scores_gemma":[0.00085628044,0.0011339717,0.00065458694,0.0016823142,0.00029090076,0.00046065194,0.0004989117,0.000805094,0.002901468],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022901862,0.003258992,0.69589883,0.0021504622,0.0068497974,0.009069112,0.068199255,0.00018005556,0.044449177,0.0130060045,0.1334632,0.021184938],"study_design_scores_gemma":[0.012126834,0.0013128505,0.2231117,0.0022212148,0.0031692695,0.0010215116,0.005408911,0.0013990279,0.056432877,0.00057568593,0.69042844,0.0027916927],"about_ca_topic_score_codex":0.00079463195,"about_ca_topic_score_gemma":0.00056792895,"teacher_disagreement_score":0.55696523,"about_ca_system_score_codex":0.00073740986,"about_ca_system_score_gemma":0.0011351185,"threshold_uncertainty_score":0.9999607},"labels":[],"label_agreement":null},{"id":"W4388572392","doi":"10.1097/cm9.0000000000002881","title":"Drug resistance mutations among people living with HIV with treatment failure in Henan Province, China","year":2023,"lang":"en","type":"letter","venue":"Chinese Medical Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Drug resistance; Phylogenetic tree; Medicine; Viral load; HIV drug resistance; Subtyping; Human immunodeficiency virus (HIV); Virology; Gene; Genetics; Biology; Antiretroviral therapy","score_opus":0.0046299918619895335,"score_gpt":0.23005472017640602,"score_spread":0.22542472831441648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388572392","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28116035,0.00019207365,0.00016733717,0.7156345,0.00021050133,0.00095219124,0.00002225341,0.00015182418,0.0015089781],"genre_scores_gemma":[0.20977692,0.00097133016,0.0077108587,0.041957054,0.0117883915,0.0010131708,0.0024274522,0.0008209213,0.72353387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531025,0.00020968514,0.0007848186,0.00067440566,0.0021744259,0.00084641617],"domain_scores_gemma":[0.9979426,0.00045225737,0.00040151665,0.00043208516,0.00013580344,0.0006356895],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00046520383,0.0008184406,0.0012860404,0.00074240606,0.00032808856,0.00013404666,0.00030870194,0.000465489,0.00052631326],"category_scores_gemma":[0.00032097354,0.00041327768,0.00021859801,0.0009939685,0.00025902482,0.00018528351,0.00006288335,0.0032058696,0.00009457805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013860648,0.00036729735,0.4897394,0.000311199,0.00066943973,0.040979847,0.0044181147,0.000007704071,3.8207682e-7,0.0000019340948,0.462822,0.0005440919],"study_design_scores_gemma":[0.01451731,0.0005956055,0.7541548,0.022834897,0.0011784305,0.0062241205,0.0008744832,0.00021526782,0.000004450407,0.00016472311,0.19779047,0.0014454108],"about_ca_topic_score_codex":0.000079625526,"about_ca_topic_score_gemma":0.025802173,"teacher_disagreement_score":0.7220249,"about_ca_system_score_codex":0.000933027,"about_ca_system_score_gemma":0.0028933084,"threshold_uncertainty_score":0.9998319},"labels":[],"label_agreement":null},{"id":"W4388841520","doi":"10.5539/jmbr.v12n1p10","title":"Molecular Evaluation of HIV-1 HAART Efficacy, Comparison of TDF+3TC+EFV and AZT+3TC+NVP Regimens","year":2023,"lang":"en","type":"article","venue":"Journal of Molecular Biology Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Department of Defense","keywords":"Efavirenz; Viral load; Lamivudine; Zidovudine; Medicine; Human immunodeficiency virus (HIV); Context (archaeology); Virology; Antiretroviral treatment; Internal medicine; Regimen; Antiretroviral therapy; Pharmacology; Biology; Viral disease; Virus","score_opus":0.13985343514383147,"score_gpt":0.4952006654136935,"score_spread":0.35534723026986204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388841520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914139,0.002558518,0.00023825494,0.004400824,0.00006225309,0.00036821802,0.000005462507,0.0000073421716,0.0009452649],"genre_scores_gemma":[0.99816364,0.00024699763,0.0011141932,0.00002121038,0.000036159166,0.0000095901905,0.000043269385,0.000018783403,0.00034616244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99686027,0.00080252404,0.0006674093,0.00021160406,0.0011204539,0.0003377198],"domain_scores_gemma":[0.9976791,0.00027570486,0.00029688756,0.0002735331,0.0013070225,0.0001677206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00446414,0.00013185457,0.00056132313,0.0008069733,0.00006014978,0.000008024736,0.00016092723,0.00017198731,0.000063133564],"category_scores_gemma":[0.0009953289,0.000104413375,0.00015486524,0.00063493196,0.00033620364,0.000029538689,0.00012851802,0.0004190844,0.000027217135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008312871,0.0007163321,0.0700397,0.00014517801,0.0012724185,0.0004250449,0.0012388506,0.00018874225,0.9046427,0.00090262986,0.007961962,0.011635175],"study_design_scores_gemma":[0.011113002,0.0031829625,0.049172364,0.00062923256,0.0007685529,0.000285531,0.0012705246,0.0030085053,0.92545074,0.0016915489,0.0031999508,0.00022707488],"about_ca_topic_score_codex":0.0000063543403,"about_ca_topic_score_gemma":0.000002110007,"teacher_disagreement_score":0.020867331,"about_ca_system_score_codex":0.00008038696,"about_ca_system_score_gemma":0.0005301347,"threshold_uncertainty_score":0.42578536},"labels":[],"label_agreement":null},{"id":"W4389030754","doi":"10.1093/ofid/ofad500.1422","title":"1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF","year":2023,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Emtricitabine; Tolerability; Tenofovir alafenamide; Clinical endpoint; Population; Regimen; Rilpivirine; Internal medicine; Randomized controlled trial; Adverse effect; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Family medicine; Environmental health","score_opus":0.013265741334404446,"score_gpt":0.29275946981448636,"score_spread":0.2794937284800819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389030754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558365,0.00009307709,0.00003381787,0.004011466,0.0004585492,0.005635397,0.00045110076,0.00042320424,0.0330569],"genre_scores_gemma":[0.98400277,0.00040965236,0.00010196384,0.00026633748,0.000102134385,0.0007431901,0.0011541046,0.00006595259,0.0131538985],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99724245,0.00036277898,0.00082420406,0.00048168632,0.00051531085,0.0005735493],"domain_scores_gemma":[0.99779725,0.00068991695,0.00042431278,0.0005617792,0.00014767832,0.0003790483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063162606,0.0003879757,0.0015827504,0.0003544405,0.0002438959,0.00012444145,0.00026734744,0.00006931147,0.000114058035],"category_scores_gemma":[0.0011350856,0.00029056726,0.0004760658,0.0010160039,0.00033390077,0.00022711993,0.00031024902,0.00016637739,0.00026004546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6175753,0.0024200398,0.2951751,0.00008339916,0.0017287482,0.00027103018,0.000619934,0.000029562943,0.000009302626,0.0001798095,0.06460046,0.017307298],"study_design_scores_gemma":[0.9060618,0.0018549054,0.05139562,0.00016322138,0.0015956264,0.000020289985,0.0005401583,0.00015902752,0.00019942268,0.00030231412,0.037190937,0.0005166764],"about_ca_topic_score_codex":0.0020370272,"about_ca_topic_score_gemma":0.0026528854,"teacher_disagreement_score":0.28848648,"about_ca_system_score_codex":0.00015333264,"about_ca_system_score_gemma":0.0005974211,"threshold_uncertainty_score":0.99995464},"labels":[],"label_agreement":null},{"id":"W4389655166","doi":"10.1093/jac/dkad375","title":"Temporal trends and transmission dynamics of pre-treatment HIV-1 drug resistance within and between risk groups in Kenya, 1986–2020","year":2023,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Manitoba","funders":"Alliance for Accelerating Excellence in Science in Africa; New Partnership for Africa's Development; Svenska Sällskapet för Medicinsk Forskning; Government of the United Kingdom; African Academy of Sciences; Manitoba Health Research Council; Wellcome Trust; Wellcome; Vetenskapsrådet; International AIDS Vaccine Initiative","keywords":"HIV drug resistance; Transmission (telecommunications); Drug resistance; Human immunodeficiency virus (HIV); Phylogenetic tree; Demography; Antiretroviral therapy; Virology; Medicine; Viral load; Biology; Genetics; Gene","score_opus":0.007008336600449204,"score_gpt":0.25103075094389865,"score_spread":0.24402241434344946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389655166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822053,0.00032843294,0.00010972977,0.017002596,0.00004650452,0.00017422215,0.00003890749,0.000016935543,0.00007740376],"genre_scores_gemma":[0.9774952,0.005775113,0.0073165214,0.000052005686,0.00009404073,0.0000014535234,0.0000659595,0.000035367786,0.009164367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986363,0.0000617793,0.0006882511,0.0002076797,0.00020992776,0.00019604946],"domain_scores_gemma":[0.99918413,0.00006912853,0.00043425258,0.000117637566,0.000055386194,0.00013943869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038965588,0.00022362002,0.000677202,0.0003850396,0.000056968936,0.000017491293,0.00006500541,0.000094491705,0.000016852242],"category_scores_gemma":[0.000008814565,0.00016239104,0.00012196078,0.00045170498,0.000090651236,0.00009994756,0.000012262142,0.00019333135,0.0000010714932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041632443,0.000609085,0.9175597,0.0002493003,0.0007289367,0.00036520636,0.012924347,0.000018043755,0.0114906905,0.00001383851,0.010393912,0.04148369],"study_design_scores_gemma":[0.037640538,0.0010138253,0.8537468,0.0027018217,0.0007002905,0.00029344618,0.0006957928,0.00086209585,0.08648717,0.0003578657,0.014849769,0.0006506401],"about_ca_topic_score_codex":0.000026675643,"about_ca_topic_score_gemma":0.0001400836,"teacher_disagreement_score":0.07499648,"about_ca_system_score_codex":0.00014960139,"about_ca_system_score_gemma":0.00010726472,"threshold_uncertainty_score":0.6622114},"labels":[],"label_agreement":null},{"id":"W4390097833","doi":"10.1093/infdis/jiad580","title":"Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials","year":2023,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Research and Development; ViiV Healthcare","keywords":"Rilpivirine; Pharmacokinetics; Pharmacology; Medicine; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.02278962211361726,"score_gpt":0.34174625024741667,"score_spread":0.31895662813379944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390097833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943269,0.0023739054,0.00037112067,0.0016663476,0.00026062617,0.00055045966,0.00003829711,0.00006381279,0.00034853801],"genre_scores_gemma":[0.99271214,0.005569881,0.0000083734185,0.00011381203,0.00026466782,0.0000074533423,0.000039950985,0.000032597727,0.0012511192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791414,0.0003733166,0.0008771789,0.0001402233,0.00039193596,0.0003032124],"domain_scores_gemma":[0.99795854,0.001020725,0.00049312256,0.00014925278,0.00010624391,0.0002721436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013793414,0.00024214003,0.0007651038,0.00037361044,0.00014295445,0.00003797139,0.000100237805,0.00005659501,0.00010632365],"category_scores_gemma":[0.00068558246,0.00014987835,0.00015832442,0.00051039347,0.000092677736,0.00011104743,0.000050978942,0.00033307693,0.000020302718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024082929,0.0046159085,0.80612946,0.00043367557,0.0037064743,0.0036739607,0.003235101,0.0026306184,0.016735598,0.000023285882,0.04140588,0.09332713],"study_design_scores_gemma":[0.25443608,0.003815924,0.6781272,0.0017074221,0.010190976,0.0024770754,0.0033329953,0.005397315,0.013475098,0.00095998467,0.02455202,0.0015278967],"about_ca_topic_score_codex":0.000050789,"about_ca_topic_score_gemma":0.000015035028,"teacher_disagreement_score":0.23035315,"about_ca_system_score_codex":0.00022357925,"about_ca_system_score_gemma":0.00027326634,"threshold_uncertainty_score":0.6111862},"labels":[],"label_agreement":null},{"id":"W4390271738","doi":"10.1111/hiv.13593","title":"Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with <scp>HIV</scp>: Real‐world insights from <scp>BICSTaR</scp> cohorts","year":2023,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"Merck Canada; Moderna; Novavax; Gilead Sciences; Pfizer; Mylan; ViiV Healthcare; Eli Lilly and Company","keywords":"Emtricitabine; Medicine; Tenofovir alafenamide; Internal medicine; Regimen; Tolerability; Population; Adverse effect; Clinical endpoint; Human immunodeficiency virus (HIV); Viral load; Clinical trial; Immunology; Antiretroviral therapy","score_opus":0.007947414303070334,"score_gpt":0.23507398326186732,"score_spread":0.227126568958797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390271738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97851574,0.0012937384,0.0001588982,0.0012729357,0.00023807627,0.0018927655,0.000091605674,0.0002585332,0.016277686],"genre_scores_gemma":[0.97461617,0.0019745694,0.00056026364,0.00016499964,0.0002687135,0.00022070813,0.0017701221,0.00012579882,0.020298675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587804,0.0002667963,0.0009938158,0.0009804494,0.0010816706,0.00079925475],"domain_scores_gemma":[0.994721,0.0034590985,0.00034472157,0.00070465147,0.00023861925,0.00053189415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074197503,0.0007075075,0.001951658,0.0014289902,0.0001597527,0.000017071658,0.0002055528,0.00020966132,0.000038766888],"category_scores_gemma":[0.00073586236,0.00048012158,0.00010783441,0.0031937826,0.0003836619,0.00018240744,0.000148188,0.00048954884,0.000110374356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034448382,0.0004176914,0.9711265,0.00048196912,0.00065230473,0.0012703208,0.009748664,0.000051829684,0.0030565578,0.00044920502,0.011501216,0.00089924654],"study_design_scores_gemma":[0.014514081,0.00056718674,0.96205515,0.002630182,0.0006662887,0.00003282633,0.002862658,0.00038843136,0.002531019,0.00049025484,0.01312643,0.00013547993],"about_ca_topic_score_codex":0.001714898,"about_ca_topic_score_gemma":0.0043784697,"teacher_disagreement_score":0.014169597,"about_ca_system_score_codex":0.00039974807,"about_ca_system_score_gemma":0.00047068813,"threshold_uncertainty_score":0.99976504},"labels":[],"label_agreement":null},{"id":"W4391732864","doi":"","title":"Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide","year":2020,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Darunavir; Tenofovir alafenamide; Emtricitabine; Cobicistat; Human immunodeficiency virus (HIV); Medicine; Virology; Antiretroviral therapy; Viral load","score_opus":0.16908233559454064,"score_gpt":0.45633552726642074,"score_spread":0.2872531916718801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391732864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946505,0.0025844306,0.00005232168,0.00048420858,0.00011555428,0.0011913958,0.00024112374,0.00002781732,0.0006526596],"genre_scores_gemma":[0.9914563,0.0067586293,0.0005508778,0.00014089691,0.000051935134,0.00005894831,0.00009055495,0.000052154483,0.00083972997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972023,0.00016290035,0.0010999843,0.0005765897,0.0005566284,0.0004016012],"domain_scores_gemma":[0.99791145,0.0004981904,0.0006654051,0.0002618765,0.00020230985,0.00046074874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000272381,0.000440792,0.0011974262,0.00054486934,0.00010702756,0.00021462147,0.0004225936,0.00010300917,0.0008366534],"category_scores_gemma":[0.0005216739,0.0003204216,0.00009056253,0.00074326573,0.0001276069,0.00085432315,0.0004243284,0.00022261232,0.0000033084327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011695798,0.0010243542,0.96642274,0.00029824744,0.00035070415,0.00017897673,0.0018735115,0.000010870318,0.005233561,0.0000014705329,0.0015799017,0.021856107],"study_design_scores_gemma":[0.006676519,0.00026980802,0.9814522,0.0011961047,0.00024093303,0.000015520172,0.00027211665,0.00019138346,0.008148099,0.000028113398,0.0012059462,0.00030324573],"about_ca_topic_score_codex":0.000598282,"about_ca_topic_score_gemma":0.00024723323,"teacher_disagreement_score":0.02155286,"about_ca_system_score_codex":0.0002680194,"about_ca_system_score_gemma":0.00030455348,"threshold_uncertainty_score":0.9999248},"labels":[],"label_agreement":null},{"id":"W4391965063","doi":"10.1177/13596535241233128","title":"Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada","year":2024,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Emtricitabine; Efavirenz; Medicine; Lamivudine; Abacavir; Context (archaeology); Incidence (geometry); Darunavir; Atazanavir; Adverse effect; Internal medicine; Pre-exposure prophylaxis; Human immunodeficiency virus (HIV); Virology; Viral load; Hepatitis B virus; Men who have sex with men; Syphilis; Antiretroviral therapy","score_opus":0.009831239983374972,"score_gpt":0.24051907442377488,"score_spread":0.2306878344403999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391965063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971724,0.0008662685,0.00002478648,0.0004761654,0.00017304953,0.0009777413,0.00012668228,0.00004874543,0.00013417148],"genre_scores_gemma":[0.9850335,0.0013090677,0.0002708045,0.00003428661,0.000038675098,0.00012552628,0.00026377803,0.000018210467,0.012906114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988087,0.000054883556,0.0003343976,0.00033538896,0.00023982683,0.00022684052],"domain_scores_gemma":[0.99956805,0.000036410194,0.00005163328,0.00017536656,0.00005965732,0.00010890569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011524599,0.00013389242,0.0002959817,0.00012359279,0.00009749191,0.00004127625,0.000048404905,0.000059076327,0.000042263026],"category_scores_gemma":[0.000016800932,0.00015073986,0.00005944249,0.00061062275,0.00008610814,0.00013926606,0.000014718272,0.00009677546,0.000005983302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004095981,0.00032203886,0.96198374,0.00003798519,0.00020307563,0.00015873331,0.0005741191,0.0000030893702,0.0010679612,0.000009259859,0.0014792917,0.034119733],"study_design_scores_gemma":[0.0017306058,0.00044983203,0.9826251,0.00029870693,0.000060850864,0.000017645545,0.00016837448,0.00012396366,0.0013296746,0.0000072629487,0.013040357,0.00014759469],"about_ca_topic_score_codex":0.4972363,"about_ca_topic_score_gemma":0.79141486,"teacher_disagreement_score":0.29417858,"about_ca_system_score_codex":0.00038646223,"about_ca_system_score_gemma":0.0005746347,"threshold_uncertainty_score":0.6146993},"labels":[],"label_agreement":null},{"id":"W4392168727","doi":"10.3390/pharmaceutics16030323","title":"Synthesis and Preliminary Evaluation of an ASGPr-Targeted Polycationic β-Cyclodextrin Carrier for Nucleosides and Nucleotides","year":2024,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Workers Compensation Board of Alberta","funders":"Alberta Cancer Board","keywords":"Nucleotide; Chemistry; Nucleoside; Prodrug; Asialoglycoprotein receptor; Biochemistry; Stereochemistry; In vitro; Hepatocyte","score_opus":0.059867096310631356,"score_gpt":0.3760885410809896,"score_spread":0.31622144477035824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392168727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98684585,0.010224904,0.000047531834,0.0015380325,0.00009889077,0.0008671777,0.000058737733,0.000062631996,0.0002562262],"genre_scores_gemma":[0.995813,0.0006706899,0.0027167737,0.000053804997,0.000057323865,0.0001298595,0.000043023654,0.000028258357,0.00048727266],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991128,0.00005642326,0.00021129566,0.00023404369,0.00024315518,0.0001422803],"domain_scores_gemma":[0.99935955,0.00023472952,0.000040138366,0.00011405717,0.00013060748,0.00012093815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054913474,0.00012862647,0.00018311417,0.00013618628,0.0000726081,0.000030076726,0.000029813762,0.000047969857,0.00007911808],"category_scores_gemma":[0.00013736422,0.00011127965,0.00003733182,0.00011453179,0.000067066285,0.00013441594,0.00002232017,0.000062444815,0.0000029245484],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000962675,0.00052612263,0.023816098,0.0021636283,0.0013707832,0.00002710774,0.0067614825,0.00004546144,0.044492256,0.00091722846,0.0014456792,0.91747147],"study_design_scores_gemma":[0.0040334496,0.0003925242,0.03925695,0.00063902617,0.0072973855,0.00011819562,0.0011433117,0.44131327,0.484461,0.0015244884,0.019404922,0.00041547167],"about_ca_topic_score_codex":0.0000054498532,"about_ca_topic_score_gemma":0.0000035523371,"teacher_disagreement_score":0.917056,"about_ca_system_score_codex":0.00006647052,"about_ca_system_score_gemma":0.00015322315,"threshold_uncertainty_score":0.45378527},"labels":[],"label_agreement":null},{"id":"W4392344369","doi":"10.1097/qai.0000000000003395","title":"Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196","year":2024,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"ViiV Healthcare; Gilead Sciences","keywords":"Dolutegravir; Regimen; Tenofovir alafenamide; Medicine; Lamivudine; Drug; Virology; Oncology; Pharmacology; Human immunodeficiency virus (HIV); Internal medicine; Virus; Viral load; Antiretroviral therapy; Hepatitis B virus","score_opus":0.02704949612599699,"score_gpt":0.297265296963276,"score_spread":0.27021580083727903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392344369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585643,0.011653924,0.00024447945,0.02658489,0.00066457066,0.0017057044,0.000019475694,0.000076803124,0.00048586994],"genre_scores_gemma":[0.9916759,0.0003904718,0.0025517414,0.0002439251,0.00012844548,0.00006949296,0.00001788858,0.0000850102,0.0048371255],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9945502,0.0005652908,0.001998598,0.0005669332,0.0016195781,0.0006993534],"domain_scores_gemma":[0.9958639,0.0020703238,0.00061616645,0.0010923401,0.00022981383,0.00012745647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003910623,0.00055359496,0.0013520038,0.0008244242,0.00030762822,0.00019452376,0.0011441289,0.000088672394,0.00011070858],"category_scores_gemma":[0.00072023354,0.00026474698,0.00050211506,0.0029571226,0.00013829529,0.00046878995,0.00017379415,0.0004818427,0.000110463894],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014457414,0.03332369,0.06435666,0.0016495652,0.010408061,0.0337575,0.65609616,0.0031670218,0.04965143,0.0015961872,0.095950946,0.03558536],"study_design_scores_gemma":[0.0426185,0.012732256,0.61894965,0.020302106,0.007546038,0.00550787,0.24139956,0.0030042133,0.013301374,0.0027613943,0.029135026,0.002742],"about_ca_topic_score_codex":0.00078813,"about_ca_topic_score_gemma":0.00011202597,"teacher_disagreement_score":0.554593,"about_ca_system_score_codex":0.0003436289,"about_ca_system_score_gemma":0.0008838982,"threshold_uncertainty_score":0.99998045},"labels":[],"label_agreement":null},{"id":"W4392785398","doi":"10.1093/cid/ciae143","title":"Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies","year":2024,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"David Geffen School of Medicine, University of California, Los Angeles; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; Medical Research Council; University of California, San Francisco; University of Illinois at Urbana-Champaign; Substance Abuse and Mental Health Services Administration; National Institutes of Health; Universidad Nacional Mayor de San Marcos; International AIDS Society; Universidade de São Paulo; Chinese University of Hong Kong; National Institute for Health and Care Research; Instituut voor Tropische Geneeskunde; European and Developing Countries Clinical Trials Partnership; Centers for Disease Control and Prevention; Auckland District Health Board; Rhode Island Department of Health; Wellcome Trust; London School of Hygiene and Tropical Medicine; Imperial College London; Johns Hopkins University; University of Washington; Gilead Sciences; University of Toronto; Yale University; George Washington University; Sanofi; China Medical University; Bristol-Myers Squibb; California Institute for Regenerative Medicine; Pfizer; ViiV Healthcare; Bill and Melinda Gates Foundation; University of Pennsylvania; United States Agency for International Development; Magee-Womens Research Institute; Georgetown University; Doris Duke Charitable Foundation","keywords":"Emtricitabine; Medicine; Incidence (geometry); Discontinuation; Pre-exposure prophylaxis; Internal medicine; Adverse effect; Tenofovir; Drug resistance; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Men who have sex with men; Virology","score_opus":0.032224844066065406,"score_gpt":0.37347923850204845,"score_spread":0.34125439443598304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392785398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95011467,0.04645576,0.00011295247,0.00037894546,0.00033298164,0.0012523832,0.00063319976,0.0002721621,0.0004469286],"genre_scores_gemma":[0.99336094,0.0012602323,0.00025927342,0.00012576517,0.00017651463,0.0004033582,0.00051243237,0.00003553882,0.0038659298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642515,0.00024463306,0.001299039,0.0010846762,0.00042827774,0.00051820884],"domain_scores_gemma":[0.997653,0.001045848,0.00033155232,0.00045822942,0.0002715686,0.00023979596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065931276,0.00045360718,0.0012349889,0.00041663702,0.0003246486,0.00019774406,0.00018348655,0.0001781073,0.00007539983],"category_scores_gemma":[0.0015399131,0.00035354806,0.00042026467,0.0022678666,0.00036219024,0.00026128284,0.00020980122,0.00032015616,0.00005928867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022271623,0.0011095497,0.9878717,0.00031563922,0.003772652,0.00011653572,0.0008614827,0.000018148517,0.000022541999,0.000255293,0.002437066,0.0029966694],"study_design_scores_gemma":[0.0027958923,0.0005912193,0.98418385,0.0007633039,0.0054344786,0.0000016641235,0.0002982792,0.00014203409,0.000011609326,0.004485058,0.0008690471,0.00042354834],"about_ca_topic_score_codex":0.00007585495,"about_ca_topic_score_gemma":0.0010396463,"teacher_disagreement_score":0.045195527,"about_ca_system_score_codex":0.0003361437,"about_ca_system_score_gemma":0.00046950168,"threshold_uncertainty_score":0.99989164},"labels":[],"label_agreement":null},{"id":"W4392922439","doi":"10.1503/cmaj.231498","title":"Long-acting injectable antiretroviral therapy for HIV-1 infection in adults","year":2024,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"Gilead Sciences","keywords":"Rilpivirine; Regimen; Dolutegravir; Integrase inhibitor; Human immunodeficiency virus (HIV); Integrase; Medicine; Antiretroviral therapy; Reverse-transcriptase inhibitor; Raltegravir; Virology; Antiretroviral drug; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Pharmacology; Internal medicine; Viral load; Biology; Polymerase chain reaction","score_opus":0.008376657008611984,"score_gpt":0.2599429300656579,"score_spread":0.2515662730570459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392922439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95749784,0.0007795794,0.00034070993,0.03686482,0.0012740457,0.000391777,0.000014637543,0.00005046001,0.0027861265],"genre_scores_gemma":[0.9904874,0.00061688374,0.0001917079,0.0013900473,0.0013505486,0.000029368559,0.00005838612,0.000023667797,0.0058519836],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850285,0.000051338615,0.0003317608,0.00015787997,0.0005498821,0.00040629544],"domain_scores_gemma":[0.99900687,0.00013673947,0.00006623676,0.000045216508,0.00013447141,0.00061046134],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010107184,0.00011019512,0.00020198197,0.00039483805,0.00013908514,0.00009505475,0.000042425996,0.00023207694,0.00094350195],"category_scores_gemma":[0.00065085746,0.000092414506,0.0001072656,0.00034793353,0.000011275644,0.0001580827,0.000004064344,0.00056187046,0.00010558491],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050150946,0.00004378637,0.80369824,0.000042589556,0.00014962131,0.00057138497,0.00078133214,0.0000012880739,0.0000047192852,0.0000613895,0.04900485,0.14559062],"study_design_scores_gemma":[0.008621005,0.0004928225,0.3527219,0.0020432207,0.00007164901,0.0007109391,0.0004106421,0.003864742,0.00017133336,0.00020342603,0.6303331,0.0003552113],"about_ca_topic_score_codex":0.0015989292,"about_ca_topic_score_gemma":0.01914507,"teacher_disagreement_score":0.5813283,"about_ca_system_score_codex":0.0019367122,"about_ca_system_score_gemma":0.0028685492,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W4393038504","doi":"10.1186/s12981-024-00604-9","title":"Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies","year":2024,"lang":"en","type":"article","venue":"AIDS Research and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare","keywords":"Dolutegravir; Medicine; Lamivudine; Regimen; Adverse effect; Population; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy; Virus; Environmental health","score_opus":0.051694521813472616,"score_gpt":0.34841352520425783,"score_spread":0.2967190033907852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393038504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721641,0.014792818,0.000019383295,0.011959847,0.000017515225,0.000858488,0.000057227295,0.000025550506,0.0001050549],"genre_scores_gemma":[0.98007506,0.017764073,0.00093909225,0.00009771497,0.000051387844,0.00005506712,0.0000412455,0.000017933577,0.00095839554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837184,0.00022613342,0.00026683984,0.0004215817,0.00039703416,0.0003165882],"domain_scores_gemma":[0.9976259,0.0019214636,0.000024496601,0.00022040239,0.000074002615,0.0001337628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012043782,0.0001693793,0.00040899758,0.00019283537,0.00012062241,0.00006913165,0.00008795307,0.000058909005,0.00002003033],"category_scores_gemma":[0.00025060057,0.00008498321,0.000022933413,0.00047251928,0.00018680136,0.00006623413,0.00011211872,0.00034480242,0.0000063431944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0872711,0.0018244219,0.34952727,0.00029951468,0.005540024,0.0013046097,0.13385202,0.0000057845177,0.11703891,0.0012430986,0.010781559,0.29131168],"study_design_scores_gemma":[0.0134255765,0.0029115742,0.969819,0.0007773584,0.000051519637,0.00001551828,0.0027605977,0.000035805635,0.0014378164,0.0010920194,0.0075091203,0.00016411043],"about_ca_topic_score_codex":0.00030903987,"about_ca_topic_score_gemma":0.0004927653,"teacher_disagreement_score":0.6202917,"about_ca_system_score_codex":0.000032145894,"about_ca_system_score_gemma":0.00007203319,"threshold_uncertainty_score":0.34655145},"labels":[],"label_agreement":null},{"id":"W4393066965","doi":"10.1099/acmi.0.000815.v1","title":"HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, &amp; Surveillance Pipeline","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Foundation for the National Institutes of Health","keywords":"Human immunodeficiency virus (HIV); HIV drug resistance; Identification (biology); Pipeline (software); Drug; Drug resistance; Virology; Medicine; Computer science; Pharmacology; Biology; Viral load; Microbiology; Antiretroviral therapy","score_opus":0.02436993542160956,"score_gpt":0.3083733515808489,"score_spread":0.28400341615923935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393066965","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045500495,0.036612734,0.06744697,0.51309973,0.008988408,0.015600173,0.0015694207,0.0036335357,0.30754852],"genre_scores_gemma":[0.11527099,0.00068995316,0.014930641,0.00023542129,0.0005211992,0.0006664738,0.00705188,0.00010211085,0.86053133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99505913,0.00025149665,0.0013117982,0.0015125421,0.001422771,0.00044225506],"domain_scores_gemma":[0.9962741,0.00016427586,0.000362339,0.001686373,0.0012575838,0.0002553089],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002214034,0.0006426026,0.00085235696,0.0004233919,0.00014908588,0.00021109257,0.00034085734,0.00028183998,0.0027996618],"category_scores_gemma":[0.00044937665,0.00052818755,0.00029788632,0.00049061613,0.00010434585,0.000057044235,0.0005282591,0.0007279822,0.0068790414],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010502589,0.0003170314,0.0034848,0.0010090802,0.00065824215,0.000093873045,0.0022338612,0.00008233247,0.00009323418,0.0021314153,0.98900175,0.00078935066],"study_design_scores_gemma":[0.0039954633,0.000007223669,0.011980817,0.002949497,0.0022043462,0.00007441575,0.00044563445,0.007220346,0.0010828321,0.031829163,0.9365304,0.0016798491],"about_ca_topic_score_codex":0.00002088535,"about_ca_topic_score_gemma":0.00082270947,"teacher_disagreement_score":0.5529828,"about_ca_system_score_codex":0.00074859685,"about_ca_system_score_gemma":0.0016231199,"threshold_uncertainty_score":0.999717},"labels":[],"label_agreement":null},{"id":"W4393177493","doi":"10.1016/s2352-3018(23)00300-4","title":"Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study","year":2024,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Mental Health; ViiV Healthcare; International Maternal Pediatric Adolescent AIDS Clinical Trials Network; Gilead Sciences","keywords":"Rilpivirine; Medicine; Pharmacokinetics; Pharmacology; Human immunodeficiency virus (HIV); Dolutegravir; Phases of clinical research; Oncology; Internal medicine; Virology; Antiretroviral therapy; Viral load; Clinical trial","score_opus":0.08758692114915416,"score_gpt":0.38746151361632614,"score_spread":0.29987459246717196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461174,0.0005643973,0.00027275633,0.000691285,0.0000766644,0.002669033,0.000043462915,0.000072358576,0.0009982851],"genre_scores_gemma":[0.9955396,0.0003010683,0.0017390337,0.00008926756,0.00007627327,0.000078028475,0.000046989382,0.00004517535,0.0020845751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975092,0.00021546795,0.00062385824,0.000641325,0.0003505196,0.00065962254],"domain_scores_gemma":[0.99890596,0.0002669041,0.0002286311,0.00035838463,0.00006893481,0.00017116466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008366248,0.00046025112,0.001210891,0.0001926034,0.00022698876,0.00018998879,0.00028818575,0.00007818914,0.000083493076],"category_scores_gemma":[0.0000741807,0.00026452474,0.000028531806,0.0006221466,0.00014845186,0.00034876648,0.00035355476,0.00059461687,0.0000125753395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050857652,0.00802296,0.8703266,0.0015264215,0.0016397382,0.004201263,0.03111827,0.00023107918,0.016312333,0.00001541684,0.0009885146,0.014759778],"study_design_scores_gemma":[0.31200212,0.008128818,0.5318333,0.011608916,0.0034761515,0.0011274181,0.019310562,0.08356378,0.023225445,0.000032421016,0.003245437,0.002445627],"about_ca_topic_score_codex":0.0001751845,"about_ca_topic_score_gemma":0.00053531484,"teacher_disagreement_score":0.33849326,"about_ca_system_score_codex":0.00011719771,"about_ca_system_score_gemma":0.00016402597,"threshold_uncertainty_score":0.9999807},"labels":[],"label_agreement":null},{"id":"W4393977836","doi":"10.3389/fnmol.2024.1376681","title":"Perinatal exposure to atazanavir-based antiretroviral regimens in a mouse model leads to differential long-term motor and cognitive deficits dependent on the NRTI backbone","year":2024,"lang":"en","type":"article","venue":"Frontiers in Molecular Neuroscience","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Occupational Cancer Research Centre; Toronto Centre for Phenogenomics; University Health Network; University of Toronto; Toronto General Hospital; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Atazanavir; Neuroscience; Cognition; Medicine; Term (time); Human immunodeficiency virus (HIV); Physical medicine and rehabilitation; Antiretroviral therapy; Psychology; Virology; Viral load","score_opus":0.013452506111062922,"score_gpt":0.25619402364737287,"score_spread":0.24274151753630996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393977836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585463,0.00020103615,0.038330883,0.0014244972,0.00028499472,0.0010664494,0.000064783875,0.000040766336,0.000040290255],"genre_scores_gemma":[0.99513125,0.000015258228,0.0013656797,0.0012744493,0.000011254621,0.00012673778,0.000014198101,0.000033582637,0.0020275847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790686,0.000080044185,0.000234639,0.00078345893,0.0005467107,0.00044827326],"domain_scores_gemma":[0.9994431,0.0000337738,0.000024445404,0.00026686763,0.000024068646,0.00020775346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015303458,0.00027159962,0.00027863286,0.00046797574,0.00008299627,0.00011313154,0.00018747583,0.00006299758,0.000004345911],"category_scores_gemma":[0.00013536956,0.00020610285,0.00005539856,0.0005218817,0.00013236824,0.000080655154,0.00012629331,0.0002840392,0.00001156459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013979784,0.00079315464,0.35400397,0.00019368333,0.000039276663,0.0070054,0.0019769676,0.0017970722,0.6255693,0.00025878538,0.0005861048,0.006378311],"study_design_scores_gemma":[0.008613028,0.0068887845,0.36439323,0.0024548233,0.0003098425,0.00013816623,0.00057136256,0.16232148,0.4523267,0.00005198609,0.00011097506,0.0018196441],"about_ca_topic_score_codex":0.000007615585,"about_ca_topic_score_gemma":0.000013675879,"teacher_disagreement_score":0.17324263,"about_ca_system_score_codex":0.00014803704,"about_ca_system_score_gemma":0.00013753367,"threshold_uncertainty_score":0.84046304},"labels":[],"label_agreement":null},{"id":"W4394572632","doi":"10.3390/molecules29071647","title":"Synthesis of 4′-Thionucleoside Analogues Bearing a C2′ Stereogenic All-Carbon Quaternary Center","year":2024,"lang":"en","type":"article","venue":"Molecules","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Glycomics Network; Canadian Institutes of Health Research; Alliance de recherche numérique du Canada","keywords":"Stereocenter; Chemistry; Stereochemistry; SN2 reaction; Intramolecular force; Nucleobase; Steric effects; Aldol reaction; Glycosidic bond; Enantioselective synthesis; Organic chemistry; DNA; Catalysis","score_opus":0.018953483111771738,"score_gpt":0.2658023037244121,"score_spread":0.24684882061264035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394572632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981464,0.001912583,0.00006082178,0.0020545041,0.000112744274,0.00017957774,0.0000118317785,0.00011762388,0.005735693],"genre_scores_gemma":[0.99485964,0.00021521754,0.0015007351,0.00009170261,0.000046711386,0.000028631177,0.00003455124,0.00003378295,0.003189013],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990441,0.00003189512,0.00024725043,0.0002535628,0.00022189737,0.00020128523],"domain_scores_gemma":[0.9996067,0.000061139246,0.00003230905,0.0001968952,0.00002370697,0.00007922943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085849286,0.00015751338,0.00025183606,0.00019574129,0.000019477646,0.00002278432,0.000068117624,0.000055361103,0.000062217696],"category_scores_gemma":[0.00002213896,0.00012275632,0.00013953558,0.00011317222,0.00003660405,0.00003699414,0.00005880616,0.00008455238,0.00008242916],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094732764,0.0023808114,0.47654095,0.0038790866,0.013320891,0.011006185,0.013243309,0.000019834364,0.30329356,0.0027325163,0.009419378,0.16321616],"study_design_scores_gemma":[0.0023119594,0.00039759543,0.06190012,0.0054342807,0.0018740648,0.00045335764,0.0008271707,0.006588593,0.88722795,0.0006652681,0.03142591,0.0008937037],"about_ca_topic_score_codex":0.000059501726,"about_ca_topic_score_gemma":0.000017340275,"teacher_disagreement_score":0.5839344,"about_ca_system_score_codex":0.000058946353,"about_ca_system_score_gemma":0.00004635526,"threshold_uncertainty_score":0.50058573},"labels":[],"label_agreement":null},{"id":"W4394687636","doi":"10.1016/j.jviromet.2024.114939","title":"A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens","year":2024,"lang":"en","type":"article","venue":"Journal of Virological Methods","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Dried blood spot; Genotyping; Reverse transcriptase; HIV drug resistance; Virology; Viral load; Drug resistance; Protease; Biology; Human immunodeficiency virus (HIV); HIV-1 protease; Nested polymerase chain reaction; Polymerase chain reaction; Antiretroviral therapy; Microbiology; Gene; Genotype; Genetics; Enzyme","score_opus":0.03409945540066772,"score_gpt":0.36761079704004074,"score_spread":0.333511341639373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394687636","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87944645,0.0039428463,0.09231124,0.022302276,0.00057023874,0.0005468865,0.000029158644,0.00011802644,0.0007328711],"genre_scores_gemma":[0.3292861,0.0002485191,0.6636519,0.00022739463,0.00034159748,0.000022694838,0.000022243104,0.000038599417,0.0061609657],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977009,0.0006949585,0.0007620272,0.00028698085,0.00029777148,0.00025735254],"domain_scores_gemma":[0.9966956,0.002657061,0.0002220253,0.00014864976,0.00012785717,0.000148846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031010835,0.00019473844,0.0006583782,0.0002187289,0.000041715746,0.000046604688,0.00011156726,0.00013564363,0.00022726425],"category_scores_gemma":[0.0011953685,0.00012902405,0.00022674046,0.00034232633,0.000053781685,0.00009383741,0.00002385835,0.00038575774,0.000018311806],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033617496,0.0093495175,0.097057186,0.0010698892,0.009699188,0.04370102,0.012673032,0.0003170904,0.5836882,0.006770328,0.07873377,0.12332327],"study_design_scores_gemma":[0.034149673,0.0017841593,0.26882312,0.0021152585,0.0027946134,0.000909555,0.0007218697,0.003923627,0.17812137,0.06537824,0.439879,0.0013995282],"about_ca_topic_score_codex":0.0000016137782,"about_ca_topic_score_gemma":0.00001674981,"teacher_disagreement_score":0.5713407,"about_ca_system_score_codex":0.00013028954,"about_ca_system_score_gemma":0.00011891878,"threshold_uncertainty_score":0.5261448},"labels":[],"label_agreement":null},{"id":"W4394739816","doi":"10.19191/ep24.1.a702.012","title":"CEDRIC-HIV: la checklist per gli studi sulla resistenza ai farmaci anti-HIV.","year":2024,"lang":"it","type":"letter","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University","funders":"","keywords":"Human immunodeficiency virus (HIV); Checklist; Humanities; Medicine; Virology; Philosophy; Psychology","score_opus":0.02115739146638018,"score_gpt":0.25780210895922334,"score_spread":0.23664471749284316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394739816","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006556524,0.011188052,0.000032995868,0.80815387,0.0052244603,0.006187114,0.00080222666,0.000720616,0.16113417],"genre_scores_gemma":[0.03153473,0.0017970625,0.00029879058,0.07538617,0.0075461064,0.006226555,0.0020678663,0.0004970087,0.8746457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903769,0.0005514359,0.0017147927,0.0024518152,0.0020472093,0.0028578574],"domain_scores_gemma":[0.9962934,0.00054834463,0.0004363372,0.0015093583,0.00035578976,0.00085673685],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0014186584,0.0019869409,0.0025484804,0.0010808806,0.00042687356,0.0006039163,0.00082352373,0.0015920876,0.0013761888],"category_scores_gemma":[0.0002952585,0.001625541,0.0010935303,0.0010653134,0.00049873965,0.00021069826,0.00066171633,0.0040433216,0.00978909],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018213593,0.00056301174,0.017680999,0.002199182,0.0052839494,0.011115954,0.0013286179,0.000001119423,0.000016288674,0.00016949794,0.95415413,0.0073051252],"study_design_scores_gemma":[0.0041961186,0.000028299912,0.07288128,0.00065682264,0.0045771077,0.0002897608,0.00023986096,0.000010590691,0.00020332694,0.000052593747,0.9154251,0.0014390893],"about_ca_topic_score_codex":0.000032380514,"about_ca_topic_score_gemma":0.000012826297,"teacher_disagreement_score":0.7327677,"about_ca_system_score_codex":0.0013101472,"about_ca_system_score_gemma":0.00063432404,"threshold_uncertainty_score":0.99970406},"labels":[],"label_agreement":null},{"id":"W4394857132","doi":"10.1093/ofid/ofae182","title":"Renal Transplantation in HIV-positive and HIV-negative People With Advanced Stages of Kidney Disease: Equity in Transplantation","year":2024,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Lawson Health Research Institute; University of Toronto; University Health Network; Western University","funders":"Health Canada; Western University; Ontario Ministry of Health and Long-Term Care; London Health Sciences Centre","keywords":"Medicine; Transplantation; Kidney transplantation; Interquartile range; Hazard ratio; Dialysis; Internal medicine; Population; Kidney disease; Incidence (geometry); End stage renal disease; Confidence interval; Hemodialysis; Environmental health","score_opus":0.007311946066978944,"score_gpt":0.2903425116393388,"score_spread":0.28303056557235984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394857132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884718,0.00055464904,0.0005247974,0.0023641533,0.000041096322,0.001787172,0.0015113545,0.000059204765,0.004685769],"genre_scores_gemma":[0.99649715,0.000977907,0.0002010463,0.00010173021,0.0000075888315,0.00027378835,0.0013185272,0.00002134698,0.0006009228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891394,0.00006487953,0.00025303048,0.00034033298,0.00020998248,0.00021785696],"domain_scores_gemma":[0.9994183,0.00014117477,0.000051788444,0.00009353398,0.000042476484,0.00025269468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000077945595,0.00019002262,0.00031399727,0.00026027006,0.000057535923,0.00006129832,0.000053173902,0.00003423976,0.000078684134],"category_scores_gemma":[0.00003919052,0.00015184867,0.000042677657,0.00040713605,0.00006389063,0.0005039549,0.00002687764,0.00009352876,0.000006956169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034429007,0.00060623855,0.9836478,0.001111653,0.00015094677,0.00065657776,0.004224751,0.00013208066,0.00016821026,0.0010331592,0.0002580519,0.0045676227],"study_design_scores_gemma":[0.008384163,0.000388703,0.9823028,0.0037954699,0.00057128957,0.00004673426,0.0006221677,0.00028899187,0.0021967646,0.001041263,0.00009862367,0.0002630753],"about_ca_topic_score_codex":0.00017065383,"about_ca_topic_score_gemma":0.0017208579,"teacher_disagreement_score":0.008025339,"about_ca_system_score_codex":0.0001561659,"about_ca_system_score_gemma":0.0004962832,"threshold_uncertainty_score":0.61922085},"labels":[],"label_agreement":null},{"id":"W4394963648","doi":"10.1097/md.0000000000037785","title":"Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study","year":2024,"lang":"en","type":"article","venue":"Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Clair College; Maple Leaf Medical Clinic; Gilead Sciences (Canada); University of Regina","funders":"Gilead Sciences; Eli Lilly and Company","keywords":"Medicine; Emtricitabine; Observational study; Tenofovir alafenamide; Human immunodeficiency virus (HIV); Tenofovir; Cohort study; Virology; Family medicine; Internal medicine; Antiretroviral therapy; Viral load","score_opus":0.011869882905769295,"score_gpt":0.246988971598005,"score_spread":0.23511908869223572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394963648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762749,0.0010989427,0.00002042478,0.020119183,0.00011481233,0.001614761,0.000060881197,0.0000128112915,0.00068326923],"genre_scores_gemma":[0.9987493,0.00005009203,0.00007112532,0.000115928146,0.00007485954,0.00007092064,0.00010889029,0.000018718276,0.0007401599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853307,0.00014303064,0.00035824123,0.00026452192,0.00051762536,0.00018351653],"domain_scores_gemma":[0.9986953,0.00073012797,0.0000643422,0.00030071693,0.000109225584,0.00010028999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007676588,0.0001805633,0.0004842709,0.00017244482,0.000085916654,0.0000061440055,0.00011730041,0.000047102665,0.000067398825],"category_scores_gemma":[0.00015429889,0.00007826232,0.00003485471,0.0009355326,0.00020384681,0.000040356274,0.000035367862,0.00019965206,0.0000022203399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024932215,0.00010350664,0.9922546,0.000081706676,0.00040307836,0.000060511502,0.0052100327,0.000013190195,0.00011571626,0.0002240012,0.0004083133,0.00087597856],"study_design_scores_gemma":[0.0031771413,0.0002493093,0.99183196,0.0010452585,0.00044593564,0.00000867105,0.0012130743,0.0001998863,0.00012611627,0.000106724874,0.0015207052,0.00007522027],"about_ca_topic_score_codex":0.103356704,"about_ca_topic_score_gemma":0.40293357,"teacher_disagreement_score":0.29957685,"about_ca_system_score_codex":0.0003049919,"about_ca_system_score_gemma":0.0009985748,"threshold_uncertainty_score":0.9026141},"labels":[],"label_agreement":null},{"id":"W4395465591","doi":"10.1097/qai.0000000000003434","title":"Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data","year":2024,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"ViiV Healthcare; Gilead Sciences; University of Warwick; GlaxoSmithKline","keywords":"Emtricitabine; Dolutegravir; Tenofovir alafenamide; Virology; Medicine; Tenofovir; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy","score_opus":0.04077285838012889,"score_gpt":0.3002681926624679,"score_spread":0.259495334282339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395465591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645802,0.029896917,0.0028401045,0.0013092222,0.000103410945,0.0006003287,0.0003762605,0.000074382355,0.0002191779],"genre_scores_gemma":[0.974675,0.006466276,0.011118504,0.000028901852,0.000037517246,0.000037558824,0.00042233622,0.000106106716,0.0071078073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932005,0.00024587815,0.0030023004,0.0009737538,0.0017334622,0.00084409746],"domain_scores_gemma":[0.9942922,0.00083296176,0.0021679252,0.0015013681,0.00091257866,0.00029298165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002083816,0.0007142862,0.0029440033,0.0021889713,0.00021351854,0.00015041263,0.00071960414,0.00016550516,0.00009922708],"category_scores_gemma":[0.0006540379,0.00042615682,0.0004603433,0.0089877425,0.00059856055,0.0010182265,0.00017811937,0.00029598098,0.0000063993966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010001456,0.0023176062,0.8865668,0.0020444905,0.039852854,0.029680908,0.010133734,0.0012596251,0.0072077946,0.00022472937,0.00091694447,0.00979304],"study_design_scores_gemma":[0.011591722,0.0041546277,0.9185352,0.006521363,0.029966852,0.0054000583,0.0042784014,0.013261543,0.0037650492,0.00013993538,0.0008735299,0.0015117433],"about_ca_topic_score_codex":0.0001914783,"about_ca_topic_score_gemma":0.00024076371,"teacher_disagreement_score":0.031968355,"about_ca_system_score_codex":0.00036750612,"about_ca_system_score_gemma":0.0022857438,"threshold_uncertainty_score":0.99981904},"labels":[],"label_agreement":null},{"id":"W4396533360","doi":"10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4884","title":"Latent Class Analysis of Structural Factors Reveals Subgroups With Differential Adherence to Bedaquiline and Antiretroviral Therapy Among People Living With HIV and Drug Resistant Tuberculosis","year":2024,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; York University","funders":"","keywords":"Tuberculosis; Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Pharmacotherapy; Drug; Virology; Internal medicine; Viral load; Pharmacology; Pathology","score_opus":0.00931017310358362,"score_gpt":0.24203048833834356,"score_spread":0.23272031523475994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396533360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998398,0.0003782193,0.00011366616,0.00041997744,0.000025738684,0.00047144908,0.000041255124,0.00007083819,0.000080856604],"genre_scores_gemma":[0.9946061,0.00012503716,0.0008327559,0.000018820761,0.000019117333,0.000018959247,0.00008359222,0.000028496339,0.004267151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841565,0.000048317692,0.00033411506,0.00052275334,0.00039754467,0.00028163524],"domain_scores_gemma":[0.9992481,0.00015804722,0.00006590567,0.00022518789,0.00008033203,0.00022242541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010717693,0.00032210074,0.00072148873,0.00044934382,0.000086470165,0.00008837705,0.00005700696,0.000053114403,0.00022280634],"category_scores_gemma":[0.000012348115,0.00017017333,0.00009298242,0.0009229314,0.00010659072,0.00013746126,0.00005657436,0.000121826226,0.0000010503181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037383617,0.000055124234,0.9875465,0.00012842251,0.0028771162,0.000028029373,0.005454695,0.000004590436,0.002724543,0.00007383492,0.00007590203,0.00065741374],"study_design_scores_gemma":[0.0008155412,0.0008405706,0.991719,0.00041702605,0.0018209595,0.000006038037,0.0010665854,0.0014797845,0.0015911487,0.000003950988,0.000005906648,0.00023349687],"about_ca_topic_score_codex":0.0006273487,"about_ca_topic_score_gemma":0.0029285883,"teacher_disagreement_score":0.00438811,"about_ca_system_score_codex":0.00006221141,"about_ca_system_score_gemma":0.0000501528,"threshold_uncertainty_score":0.69394666},"labels":[],"label_agreement":null},{"id":"W4396749398","doi":"10.1016/s2352-3018(24)00031-6","title":"Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial","year":2024,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Pharmacology; Internal medicine; Pediatrics; Viral load; Virology","score_opus":0.042275877114148076,"score_gpt":0.3296904653911674,"score_spread":0.2874145882770193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396749398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788348,0.0001661045,0.00011984943,0.010751599,0.00014329757,0.005173897,0.00029293224,0.00011559605,0.004401887],"genre_scores_gemma":[0.9911767,0.00023592125,0.0017413314,0.0006939234,0.00037877637,0.00043612448,0.00026229283,0.00006079516,0.0050141313],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969347,0.00023624676,0.0007402951,0.00082040357,0.0006294121,0.00063895225],"domain_scores_gemma":[0.99818057,0.0004437867,0.00019140619,0.0008964603,0.00009703451,0.00019076529],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010940153,0.00052134594,0.0014147667,0.00019955356,0.00011256175,0.00012644427,0.0005983404,0.00012956906,0.00008474791],"category_scores_gemma":[0.000111559406,0.00026531244,0.00008392182,0.0007884495,0.00017159196,0.00019514258,0.00013484486,0.0005915037,0.000143954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9619176,0.0038832047,0.0020013792,0.00011608712,0.00044801238,0.0010911428,0.004551953,0.000021176496,0.008749152,0.00006892453,0.008408532,0.008742852],"study_design_scores_gemma":[0.955589,0.01990105,0.005126117,0.0018223089,0.0002562876,0.000046170742,0.00021900542,0.0009200062,0.0065068183,0.00004327589,0.009043717,0.00052625657],"about_ca_topic_score_codex":0.0001458602,"about_ca_topic_score_gemma":0.00013486414,"teacher_disagreement_score":0.016017845,"about_ca_system_score_codex":0.00011500271,"about_ca_system_score_gemma":0.0003661552,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W4399075566","doi":"10.1016/j.mmifmc.2024.04.386","title":"Le switch vers dolutégravir/lamivudine (DTG/3TC) est non inférieur à la poursuite des traitements à base de ténofovir alafénamide (TAF) à la semaine 196 : analyses en sous-groupes de l'étude TANGO","year":2024,"lang":"fr","type":"article","venue":"Médecine et Maladies Infectieuses Formation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lamivudine; Medicine; Humanities; Art; Virology; Virus","score_opus":0.017899127235537583,"score_gpt":0.3246817929655481,"score_spread":0.3067826657300105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399075566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.925691,0.008278207,0.034597363,0.008161744,0.0009097215,0.0012240252,0.00016961592,0.0005890837,0.02037923],"genre_scores_gemma":[0.9738048,0.0104691675,0.0042406674,0.00041570983,0.00061814435,0.00022021185,0.00065922923,0.00017835535,0.009393723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99515414,0.00078579714,0.0012360532,0.0006993227,0.000725878,0.0013987934],"domain_scores_gemma":[0.99668115,0.0016753732,0.00031987,0.0005495008,0.00026196308,0.00051211717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002476015,0.0009840567,0.0009856825,0.0012086291,0.00044925918,0.00053808204,0.00031061264,0.00046730065,0.00045405797],"category_scores_gemma":[0.0010096696,0.00092857337,0.00046591705,0.0013125435,0.00041623603,0.0022847091,0.000266364,0.0007556696,0.00041336167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012531099,0.0067502945,0.6154815,0.013499619,0.010645615,0.0038391473,0.123512074,0.015539396,0.042798296,0.02146292,0.043406684,0.101811334],"study_design_scores_gemma":[0.017912544,0.0017982037,0.5942661,0.0136865685,0.0060722306,0.0027763434,0.009798155,0.045920536,0.034288812,0.004007651,0.2667767,0.002696127],"about_ca_topic_score_codex":0.001639707,"about_ca_topic_score_gemma":0.0038720672,"teacher_disagreement_score":0.22337002,"about_ca_system_score_codex":0.0016685418,"about_ca_system_score_gemma":0.0013169687,"threshold_uncertainty_score":0.9993165},"labels":[],"label_agreement":null},{"id":"W4399096628","doi":"10.3389/fimmu.2024.1394644","title":"Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare","keywords":"Medicine; Adverse effect; Internal medicine; Young adult; Human immunodeficiency virus (HIV); Immunology","score_opus":0.01351517270485693,"score_gpt":0.32065883056778577,"score_spread":0.30714365786292885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399096628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893877,0.0070351306,0.00011993451,0.00031692343,0.00064692675,0.0024061135,0.000021749425,0.000017054434,0.000048504793],"genre_scores_gemma":[0.9970215,0.0008782203,0.0005281388,0.000013611375,0.000017682993,0.00037648497,0.00005435287,0.000020916292,0.001089124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851054,0.0001407173,0.0005497596,0.00036517746,0.00009427409,0.0003395418],"domain_scores_gemma":[0.99946123,0.00015125358,0.0000572292,0.00027652943,0.00001912631,0.00003462835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036875933,0.0002065933,0.00060460187,0.0006232273,0.000030844407,0.000017880735,0.0001158503,0.00009684476,0.000016486561],"category_scores_gemma":[0.00006178325,0.0001419757,0.000107939326,0.00050577056,0.000072668525,0.000102497375,0.000040597377,0.00014177065,0.0000030814235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014272923,0.0019520501,0.56487113,0.000062747524,0.00084298145,0.0006167478,0.12363236,0.000007137035,0.0012911479,0.0000083723635,0.00034500397,0.29209742],"study_design_scores_gemma":[0.019627672,0.00577195,0.9614086,0.00064702047,0.00007716977,0.00004829448,0.010976266,0.00007488757,0.00068935537,0.000030430829,0.00045980597,0.0001885347],"about_ca_topic_score_codex":0.00049568195,"about_ca_topic_score_gemma":0.00048435008,"teacher_disagreement_score":0.3965375,"about_ca_system_score_codex":0.0006644323,"about_ca_system_score_gemma":0.00016794831,"threshold_uncertainty_score":0.5789601},"labels":[],"label_agreement":null},{"id":"W4399730738","doi":"10.1093/ofid/ofae343","title":"HIV Subtypes and Drug-resistance-associated Mutations in US Blood Donors, 2015–2020","year":2024,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Food and Drug Administration; Office of the Assistant Secretary for Health; Hamilton Health Sciences Foundation; National Institutes of Health; OPEC Fund for International Development","keywords":"Reverse transcriptase; Virology; Genotype; Population; Medicine; Drug resistance; Human immunodeficiency virus (HIV); Polymerase chain reaction; Nucleoside Reverse Transcriptase Inhibitor; Nested polymerase chain reaction; Biology; Genetics; Viral load; Gene; Antiretroviral therapy","score_opus":0.005457130036993526,"score_gpt":0.26183788924085327,"score_spread":0.2563807592038597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399730738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620009,0.005652779,0.0000057208713,0.010900508,0.00018679127,0.0010387248,0.00017227161,0.0002311451,0.019811155],"genre_scores_gemma":[0.9548056,0.0005504835,0.000060388727,0.00019619123,0.0000263441,0.00021667524,0.00047505138,0.000031877604,0.043637376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890035,0.00004832843,0.00024104108,0.0003632269,0.0001565654,0.0002905014],"domain_scores_gemma":[0.9994472,0.00012423562,0.00004217311,0.00015282973,0.00004566525,0.00018786956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008959887,0.00019457967,0.00029684245,0.00017158319,0.00015890527,0.00023819468,0.00007663817,0.000051042247,0.00027021725],"category_scores_gemma":[0.00009629163,0.00016721786,0.000072899646,0.0004599945,0.000059744834,0.00025750403,0.00010387902,0.00010963393,0.00015170699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052027965,0.00068699877,0.93408895,0.000081987826,0.00039931567,0.00045920484,0.00033885203,0.0000030707108,0.000013348796,0.000906526,0.062395565,0.0005741284],"study_design_scores_gemma":[0.009483194,0.00016748937,0.90279394,0.0015590319,0.0022061602,0.00009222346,0.000646811,0.00018149152,0.00033400452,0.0073884013,0.07436841,0.0007788275],"about_ca_topic_score_codex":0.0002622696,"about_ca_topic_score_gemma":0.005438439,"teacher_disagreement_score":0.03129502,"about_ca_system_score_codex":0.00015167489,"about_ca_system_score_gemma":0.0002831545,"threshold_uncertainty_score":0.6818946},"labels":[],"label_agreement":null},{"id":"W4399891293","doi":"10.1099/acmi.0.000815.v2","title":"HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, &amp; Surveillance Pipeline","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"European and Developing Countries Clinical Trials Partnership; Foundation for the National Institutes of Health","keywords":"Human immunodeficiency virus (HIV); HIV drug resistance; Identification (biology); Pipeline (software); Drug; Drug resistance; Virology; Medicine; Computer science; Pharmacology; Biology; Viral load; Genetics; Antiretroviral therapy","score_opus":0.02436993542160956,"score_gpt":0.3083733515808489,"score_spread":0.28400341615923935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399891293","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045500495,0.036612734,0.06744697,0.51309973,0.008988408,0.015600173,0.0015694207,0.0036335357,0.30754852],"genre_scores_gemma":[0.11527099,0.00068995316,0.014930641,0.00023542129,0.0005211992,0.0006664738,0.00705188,0.00010211085,0.86053133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99505913,0.00025149665,0.0013117982,0.0015125421,0.001422771,0.00044225506],"domain_scores_gemma":[0.9962741,0.00016427586,0.000362339,0.001686373,0.0012575838,0.0002553089],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002214034,0.0006426026,0.00085235696,0.0004233919,0.00014908588,0.00021109257,0.00034085734,0.00028183998,0.0027996618],"category_scores_gemma":[0.00044937665,0.00052818755,0.00029788632,0.00049061613,0.00010434585,0.000057044235,0.0005282591,0.0007279822,0.0068790414],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010502589,0.0003170314,0.0034848,0.0010090802,0.00065824215,0.000093873045,0.0022338612,0.00008233247,0.00009323418,0.0021314153,0.98900175,0.00078935066],"study_design_scores_gemma":[0.0039954633,0.000007223669,0.011980817,0.002949497,0.0022043462,0.00007441575,0.00044563445,0.007220346,0.0010828321,0.031829163,0.9365304,0.0016798491],"about_ca_topic_score_codex":0.00002088535,"about_ca_topic_score_gemma":0.00082270947,"teacher_disagreement_score":0.5529828,"about_ca_system_score_codex":0.00074859685,"about_ca_system_score_gemma":0.0016231199,"threshold_uncertainty_score":0.999717},"labels":[],"label_agreement":null},{"id":"W4399977905","doi":"10.1186/s12879-024-09469-9","title":"Multi-state Markov model for time to treatment changes for HIV/AIDS patients: a retrospective cohort national datasets, Ethiopia","year":2024,"lang":"en","type":"article","venue":"BMC Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Regimen; Medicine; Retrospective cohort study; Population; Cohort; Demography; Pediatrics; Internal medicine; Environmental health","score_opus":0.01936213828497368,"score_gpt":0.2976257005268645,"score_spread":0.2782635622418908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399977905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49217713,0.0021166955,0.17452595,0.00572736,0.0017259395,0.04795987,0.26941186,0.0035369156,0.0028182734],"genre_scores_gemma":[0.5820309,0.00022948798,0.07320811,0.0016626592,0.0009942214,0.029335693,0.08102611,0.00039872035,0.23111409],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983218,0.0000275555,0.00025993958,0.00065353105,0.00035987375,0.00037730727],"domain_scores_gemma":[0.9988541,0.0002460797,0.00005326872,0.00022356329,0.00033845927,0.00028454704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012956564,0.00034814037,0.00041757137,0.00031520313,0.00019331342,0.00008009629,0.000060057897,0.000071240516,0.0001302705],"category_scores_gemma":[0.00032409444,0.00027934223,0.0002345184,0.00022307411,0.00003670903,0.00011920639,0.000041483334,0.00005283148,0.00028003196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016905743,0.0053075557,0.7357607,0.00092124246,0.0029514513,0.000022328328,0.0014356234,0.0005238976,0.00009406383,0.0005114055,0.23895523,0.011825963],"study_design_scores_gemma":[0.03561817,0.0059831482,0.3103855,0.0010050685,0.0057204934,0.000028269313,0.00008422722,0.47718242,0.0006791974,0.002151593,0.15911679,0.0020451231],"about_ca_topic_score_codex":0.000008386161,"about_ca_topic_score_gemma":0.00012077635,"teacher_disagreement_score":0.47665852,"about_ca_system_score_codex":0.0013969926,"about_ca_system_score_gemma":0.00054502557,"threshold_uncertainty_score":0.99996585},"labels":[],"label_agreement":null},{"id":"W4400517861","doi":"10.1093/jac/dkae197","title":"Breakthrough HIV viraemia on bictegravir/emtricitabine/tenofovir alafenamide in the third trimester of pregnancy","year":2024,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Emtricitabine; Tenofovir alafenamide; Human immunodeficiency virus (HIV); Virology; Medicine; Pregnancy; Didanosine; Obstetrics; Gynecology; Sida; Biology; Antiretroviral therapy; Viral disease; Viral load","score_opus":0.011965067941220193,"score_gpt":0.27351598583653225,"score_spread":0.26155091789531204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400517861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94997454,0.0018442624,0.00016778192,0.04189477,0.00039797157,0.00057819247,0.00001515395,0.000028626411,0.0050986805],"genre_scores_gemma":[0.9830297,0.002255945,0.0022443344,0.0025799603,0.00033984368,0.0000045011043,0.000013329719,0.00005970151,0.009472646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982402,0.00008070163,0.00079979916,0.00020379308,0.00040577588,0.00026976608],"domain_scores_gemma":[0.9991718,0.00017465102,0.00024260752,0.00024244761,0.000106783955,0.00006172368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041985817,0.00026579056,0.0005923949,0.0004384556,0.000036612888,0.000049533806,0.00022888285,0.00012879274,0.00007058121],"category_scores_gemma":[0.000024805937,0.0001484389,0.00038132124,0.0005982198,0.000080135134,0.00016259681,0.000013223346,0.0004787406,0.000037237514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006690538,0.006649534,0.035312425,0.0013037325,0.0028554061,0.0056963866,0.034051422,0.0000612275,0.43660128,0.0011719322,0.39732838,0.07227773],"study_design_scores_gemma":[0.03259015,0.0032410948,0.047931895,0.022445973,0.0009921828,0.005037728,0.000898427,0.00014843777,0.69725376,0.0010639064,0.1873238,0.0010726618],"about_ca_topic_score_codex":0.000007847407,"about_ca_topic_score_gemma":0.000002591006,"teacher_disagreement_score":0.26065245,"about_ca_system_score_codex":0.00017950199,"about_ca_system_score_gemma":0.00055892655,"threshold_uncertainty_score":0.6053163},"labels":[],"label_agreement":null},{"id":"W4400659888","doi":"10.1002/phar.2921","title":"Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary","year":2024,"lang":"en","type":"article","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Rilpivirine; Human immunodeficiency virus (HIV); Family medicine; Pharmacy; Alternative medicine; Novelty; Antiretroviral therapy; Intensive care medicine; Viral load; Psychology","score_opus":0.06779717410569928,"score_gpt":0.43549418265694395,"score_spread":0.36769700855124465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400659888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816543,0.008000823,0.00010116548,0.008101313,0.00014986141,0.0012162331,0.00073955784,0.0000105018,0.000026231612],"genre_scores_gemma":[0.8362046,0.16161658,0.00039204906,0.0012501036,0.00027648246,0.000027582268,0.000047211463,0.000031128293,0.00015430167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509543,0.002327342,0.0017472723,0.0002892952,0.00025624756,0.0002843896],"domain_scores_gemma":[0.9941406,0.0036787721,0.0016524832,0.00011048365,0.00017426962,0.00024337402],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.003272991,0.00031388705,0.0011128758,0.00018138491,0.00024888734,0.00001042115,0.00020657454,0.00004590353,0.000045370023],"category_scores_gemma":[0.000023043698,0.00018314477,0.00034028367,0.00037907794,0.0030639393,0.00018278167,0.00003076625,0.0005094183,5.988452e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005258266,0.002341782,0.6270495,0.0002663242,0.008170918,0.000028182267,0.01892762,0.000014267485,0.027170397,0.00007078808,0.14577618,0.16492574],"study_design_scores_gemma":[0.28354803,0.040601242,0.30680656,0.0028651655,0.037233245,0.0022007232,0.029259218,0.031195793,0.077383436,0.0021686426,0.1842078,0.002530119],"about_ca_topic_score_codex":0.0004496381,"about_ca_topic_score_gemma":0.00006735577,"teacher_disagreement_score":0.32024294,"about_ca_system_score_codex":0.00006252237,"about_ca_system_score_gemma":0.00030590282,"threshold_uncertainty_score":0.99964917},"labels":[],"label_agreement":null},{"id":"W4400664295","doi":"10.1503/cmaj.231498-f","title":"Antirétroviral injectable à action prolongée pour l’infection à VIH-1 chez l’adulte","year":2024,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Medicine","score_opus":0.010574469905574773,"score_gpt":0.2660389843337974,"score_spread":0.25546451442822266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400664295","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2986741,0.021365358,0.0009775632,0.60802054,0.041256197,0.0008567438,0.00012865663,0.0002531999,0.028467614],"genre_scores_gemma":[0.6150078,0.008365451,0.00034193718,0.0042952336,0.02399728,0.000039280312,0.00014526765,0.00011024871,0.3476975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954406,0.00041734462,0.0007395535,0.00038695088,0.0017353222,0.0012802177],"domain_scores_gemma":[0.99633336,0.00021254223,0.00020768447,0.00012438181,0.00042379808,0.0026982457],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0030150372,0.00034063603,0.00044338443,0.0006665531,0.00050660974,0.0004306687,0.00012479804,0.0010088617,0.01912448],"category_scores_gemma":[0.0013636713,0.0003213952,0.00029655875,0.00079937436,0.00007214669,0.0005603507,0.000020110874,0.0023053358,0.0062395623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000026559963,0.000156506,0.12325851,0.00022035351,0.0012371583,0.0041975286,0.0013231686,0.000008007277,0.00007533665,0.00076864223,0.6295436,0.23918465],"study_design_scores_gemma":[0.0017005198,0.00015976916,0.025664447,0.001647799,0.0005039208,0.0027652187,0.0004089876,0.004368451,0.00023620043,0.00025222567,0.9619683,0.00032418178],"about_ca_topic_score_codex":0.0066751163,"about_ca_topic_score_gemma":0.033683173,"teacher_disagreement_score":0.6037253,"about_ca_system_score_codex":0.00908283,"about_ca_system_score_gemma":0.014384087,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W4400733587","doi":"10.1099/acmi.0.000815.v3","title":"HIV-DRIVES: HIV drug resistance identification, variant evaluation, and surveillance pipeline","year":2024,"lang":"en","type":"article","venue":"Access Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"European and Developing Countries Clinical Trials Partnership; Fogarty International Center; Foundation for the National Institutes of Health","keywords":"Human immunodeficiency virus (HIV); Pipeline (software); Identification (biology); Drug; HIV drug resistance; Drug resistance; Virology; Medicine; Computer science; Biology; Pharmacology; Genetics; Viral load; Antiretroviral therapy; Programming language","score_opus":0.015238156221431622,"score_gpt":0.3081279297745085,"score_spread":0.2928897735530769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400733587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72172564,0.048517164,0.01034375,0.20615208,0.0021388282,0.0031459113,0.0004603215,0.00069033285,0.006825993],"genre_scores_gemma":[0.85894984,0.00058189756,0.00092099386,0.00031504373,0.00015195312,0.000104339095,0.0015276431,0.00002761774,0.13742065],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855584,0.0001373765,0.00041313938,0.0005620158,0.00009211683,0.00023951156],"domain_scores_gemma":[0.99913687,0.00015789356,0.000078739795,0.000306559,0.00024834104,0.00007158272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065857713,0.00018724248,0.0002884962,0.00017167024,0.00010433204,0.0000969233,0.00014864476,0.000083470164,0.00041986015],"category_scores_gemma":[0.000120160985,0.00014897936,0.000046322202,0.00030416317,0.00012933809,0.00014892763,0.00008342562,0.00012118501,0.0003492663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014172676,0.00016536217,0.06302051,0.00035747967,0.00040285304,0.00016938093,0.0016213887,0.000004394706,0.033152908,0.0017452776,0.895696,0.003522712],"study_design_scores_gemma":[0.0026618764,0.000013878811,0.036137044,0.00034965857,0.0003272788,0.00041230433,0.000155483,0.0009056362,0.012051194,0.0014918128,0.94500786,0.0004859648],"about_ca_topic_score_codex":0.000005090815,"about_ca_topic_score_gemma":0.00011502476,"teacher_disagreement_score":0.20583704,"about_ca_system_score_codex":0.000109807675,"about_ca_system_score_gemma":0.0002256391,"threshold_uncertainty_score":0.6075202},"labels":[],"label_agreement":null},{"id":"W4400745688","doi":"10.1002/cpt.3370","title":"Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dolutegravir; Bridging (networking); Human immunodeficiency virus (HIV); Population; Medicine; Antiretroviral therapy; Virology; Environmental health; Viral load; Computer science","score_opus":0.041195131179588805,"score_gpt":0.3980079425941253,"score_spread":0.3568128114145365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400745688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201214,0.001311361,0.00005331555,0.004774646,0.0009917691,0.00070341397,0.0000851713,0.000063047395,0.000005152262],"genre_scores_gemma":[0.99473166,0.0019042668,0.0006710864,0.002125051,0.00008989807,0.000024469606,0.00013465527,0.000039749055,0.00027915504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945443,0.0016306973,0.0027001114,0.0005334534,0.00027146906,0.0003199389],"domain_scores_gemma":[0.99543756,0.003467644,0.00045535126,0.0002593495,0.00017427752,0.0002058205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031557356,0.0002935478,0.0011214602,0.0003337493,0.000034966637,0.000012428336,0.00010513486,0.00036910313,0.00007016991],"category_scores_gemma":[0.00040461763,0.00023791313,0.00021780175,0.00043780723,0.0003949971,0.000082369625,0.00008900673,0.00079001754,0.000012595704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046680983,0.0018864119,0.7282882,0.0001323205,0.0009639945,0.00056279293,0.0010575138,0.000001619529,0.041490708,0.00001012332,0.002325509,0.17659985],"study_design_scores_gemma":[0.005490093,0.0020906946,0.9706289,0.0004057498,0.0009698602,0.000045388224,0.00013597163,0.0009370862,0.0061378498,0.00003778532,0.012876683,0.00024393694],"about_ca_topic_score_codex":0.000009934127,"about_ca_topic_score_gemma":0.0000025686627,"teacher_disagreement_score":0.24234071,"about_ca_system_score_codex":0.00011133326,"about_ca_system_score_gemma":0.0005566204,"threshold_uncertainty_score":0.97018164},"labels":[],"label_agreement":null},{"id":"W4400895497","doi":"10.1101/2024.07.20.24310740","title":"Predicting emergent Dolutegravir resistance in South Africa: A modelling study","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Dolutegravir; Resistance (ecology); Virology; Medicine; Biology; Human immunodeficiency virus (HIV); Ecology; Antiretroviral therapy","score_opus":0.04766799789007835,"score_gpt":0.2848253388621216,"score_spread":0.23715734097204322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400895497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824148,0.0061000446,0.00026488482,0.00091680133,0.0007804741,0.001955465,0.000031553118,0.00026011764,0.007275883],"genre_scores_gemma":[0.9593816,0.00010055505,0.003368657,0.000012264542,0.00023108927,0.00055547204,0.000046413483,0.00008933948,0.03621464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967615,0.00011107249,0.0008243914,0.0010909376,0.0007050752,0.0005070324],"domain_scores_gemma":[0.99880457,0.000049602302,0.00015600058,0.00071857823,0.00008240722,0.00018885531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007893622,0.00051351293,0.00080425345,0.00051464187,0.00007320282,0.000054261563,0.00021813628,0.00021852122,0.00005830933],"category_scores_gemma":[0.0000605638,0.00042063376,0.00021525731,0.00048729993,0.000031480828,0.000022436188,0.000654075,0.0012692264,0.00016815632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027800738,0.0013418024,0.8506528,0.001278804,0.0010793204,0.0027415284,0.13970488,0.0018608149,0.000023594932,0.00014051475,0.00070756394,0.00019035023],"study_design_scores_gemma":[0.03966079,0.0017402641,0.36696437,0.06731848,0.018824209,0.00007772564,0.10502625,0.2619301,0.0014691219,0.06025144,0.064756565,0.011980671],"about_ca_topic_score_codex":0.000035413836,"about_ca_topic_score_gemma":0.00032432607,"teacher_disagreement_score":0.48368844,"about_ca_system_score_codex":0.00037253444,"about_ca_system_score_gemma":0.0003509188,"threshold_uncertainty_score":0.9998245},"labels":[],"label_agreement":null},{"id":"W4401162253","doi":"10.3390/v16081230","title":"Phylogenetic Network Analyses Reveal the Influence of Transmission Clustering on the Spread of HIV Drug Resistance in Quebec from 2002 to 2022","year":2024,"lang":"en","type":"article","venue":"Viruses","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada); McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Resistance mutation; Viremia; Transmission (telecommunications); Drug resistance; Darunavir; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Integrase; Reverse transcriptase; Biology; Integrase inhibitor; Men who have sex with men; Internal medicine; Medicine; Genetics; RNA; Gene","score_opus":0.02891737647592999,"score_gpt":0.3010664767379857,"score_spread":0.2721491002620557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401162253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874542,0.006568888,0.000071361115,0.0048706806,0.000041897427,0.00034042582,0.000022470313,0.000016548249,0.00061356847],"genre_scores_gemma":[0.9817269,0.00031344587,0.0008428027,0.0004248921,0.000056741144,0.000034693217,0.0000042510833,0.000014667523,0.016581597],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99902326,0.00009089234,0.00030076274,0.00019648099,0.0002427655,0.0001458285],"domain_scores_gemma":[0.99918455,0.00042954358,0.000047202695,0.00027618062,0.000022898468,0.00003961584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018926612,0.00012320103,0.00022931753,0.00008264235,0.000041351894,0.000012387015,0.00013204565,0.000028190661,0.00015705342],"category_scores_gemma":[0.0000371418,0.0000631485,0.00005962466,0.00049852463,0.00005360005,0.000030560295,0.000032281565,0.000106401436,0.000029867238],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038407426,0.0008022108,0.10082438,0.0011457587,0.0016334208,0.0003778999,0.047100347,0.043015588,0.51999617,0.00087908725,0.2356839,0.0447005],"study_design_scores_gemma":[0.0015830977,0.00014850571,0.4699768,0.014385522,0.0006091817,0.0000024243923,0.0011210744,0.0009404078,0.26020765,0.00067888293,0.24985544,0.0004909869],"about_ca_topic_score_codex":0.0021653185,"about_ca_topic_score_gemma":0.010076655,"teacher_disagreement_score":0.36915246,"about_ca_system_score_codex":0.000049056798,"about_ca_system_score_gemma":0.00008077693,"threshold_uncertainty_score":0.562301},"labels":[],"label_agreement":null},{"id":"W4401558776","doi":"10.1016/j.ijantimicag.2024.107301","title":"Dual therapy based on co-formulated darunavir/ritonavir plus lamivudine for initial therapy of HIV infection: The ANDES randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"International Journal of Antimicrobial Agents","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministerio de Defensa, Argentina; Fundación Hesperia; International Society of Addiction Medicine","keywords":"Darunavir; Ritonavir; Lamivudine; Medicine; Randomized controlled trial; Human immunodeficiency virus (HIV); Dual (grammatical number); Antiretroviral therapy; Internal medicine; Virology; Viral load; Virus","score_opus":0.03450164870358155,"score_gpt":0.35953769552440407,"score_spread":0.32503604682082254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401558776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811173,0.0002132624,0.0010682887,0.009988983,0.003561143,0.0031545344,0.00008344958,0.000029415802,0.00078364066],"genre_scores_gemma":[0.9956115,0.0008224202,0.00022469845,0.0008228026,0.001344317,0.00005755684,0.00014813416,0.000028038889,0.00094057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977941,0.00017854392,0.0010582653,0.00016291543,0.0006480945,0.0001581157],"domain_scores_gemma":[0.9979557,0.00083019247,0.00047469971,0.00009844033,0.0005836159,0.000057398054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010982314,0.00023674456,0.0009815674,0.0004026124,0.00007654418,0.00009708681,0.00015981523,0.00009375235,0.00035706995],"category_scores_gemma":[0.00016785598,0.00012427557,0.0009919134,0.00012501387,0.00012211075,0.0001320382,0.000013643379,0.00022464301,0.0000110209085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97549856,0.0009677682,0.00016201835,0.000015936022,0.00427129,0.00017866887,0.00037054298,0.00023230772,0.00430274,0.00010807471,0.01049098,0.0034011041],"study_design_scores_gemma":[0.9570197,0.0008448058,0.00018791216,0.0004346263,0.00025099673,0.00012844606,0.0000102019385,0.0037932666,0.025908273,0.00006353847,0.011235981,0.00012224539],"about_ca_topic_score_codex":0.000008641882,"about_ca_topic_score_gemma":0.0000010565664,"teacher_disagreement_score":0.021605533,"about_ca_system_score_codex":0.0001497405,"about_ca_system_score_gemma":0.00052759453,"threshold_uncertainty_score":0.50678104},"labels":[],"label_agreement":null},{"id":"W4402234511","doi":"10.1080/17460913.2024.2391190","title":"Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year","year":2024,"lang":"en","type":"article","venue":"Future Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Emtricitabine; Tenofovir alafenamide; Human immunodeficiency virus (HIV); Tenofovir; Medicine; Virology; Antiretroviral therapy; Viral load","score_opus":0.003928970883316443,"score_gpt":0.23030194591872463,"score_spread":0.22637297503540818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402234511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117655,0.0007507788,0.000050647104,0.0058175297,0.00024409509,0.0015695605,0.00020727143,0.00005200583,0.0001315392],"genre_scores_gemma":[0.9698533,0.000013156274,0.0022696336,0.0001712383,0.00017925339,0.00011784487,0.00032443143,0.000037815484,0.027033342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916387,0.000054400327,0.00020558487,0.00030195335,0.00004986757,0.0002243279],"domain_scores_gemma":[0.99951124,0.00013548345,0.000041823827,0.00020982693,0.00004574102,0.000055870172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013973494,0.00018954341,0.00037334586,0.00015335609,0.000073815136,0.000011488844,0.000080126636,0.0000774641,0.000022997969],"category_scores_gemma":[0.000024766883,0.000098207536,0.000061892606,0.00035883609,0.000042318316,0.00001800597,0.00006626385,0.000119562785,0.00001058569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002935235,0.00088506006,0.54739904,0.00072103785,0.0020216475,0.00018468071,0.08911331,0.0000037758737,0.27698785,0.0005856336,0.07461987,0.0045428644],"study_design_scores_gemma":[0.057829153,0.017844073,0.38204482,0.0029172718,0.005273036,0.001104971,0.16471048,0.00022229318,0.09411207,0.00015895735,0.27149764,0.0022852332],"about_ca_topic_score_codex":0.00003566134,"about_ca_topic_score_gemma":0.00036740728,"teacher_disagreement_score":0.19687778,"about_ca_system_score_codex":0.000063824096,"about_ca_system_score_gemma":0.00016331983,"threshold_uncertainty_score":0.4004787},"labels":[],"label_agreement":null},{"id":"W4402574548","doi":"10.1136/sextrans-2024-056198","title":"Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Sexually Transmitted Infections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; MEDLINE; Cochrane Library; Viral load; Systematic review; Meta-analysis; Intensive care medicine; Drug resistance; Regimen; Human immunodeficiency virus (HIV); Immunology; Internal medicine; Biology; Psychiatry","score_opus":0.06415432582186492,"score_gpt":0.3429482116032494,"score_spread":0.2787938857813845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402574548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000055719997,0.9923077,0.0003583151,0.0009908723,0.000063565465,0.0052231033,0.00020196932,0.00020689917,0.0006419516],"genre_scores_gemma":[0.00006679841,0.97833824,0.00018508904,0.00038727463,0.000026078536,0.0022016065,0.0005988453,0.00011128542,0.018084805],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960426,0.00046283487,0.0017484975,0.00091154524,0.00039694938,0.00043754393],"domain_scores_gemma":[0.998512,0.00022711637,0.000291035,0.0007118369,0.00007844813,0.0001795238],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006995418,0.0009670137,0.009435806,0.0020474908,0.000120578436,0.000099796096,0.0001535244,0.0003058044,0.00032931217],"category_scores_gemma":[0.000043213277,0.00059752766,0.002932934,0.0040940153,0.000070862065,0.00012156434,0.000036455745,0.0008411269,0.00025260373],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002327315,0.00025504877,0.000018818982,0.73017746,0.2631805,0.00015574135,0.00017530633,4.5457736e-7,9.760268e-8,0.00003716278,0.00030842182,0.005688676],"study_design_scores_gemma":[0.00033466166,0.000075886324,0.000005266009,0.067245156,0.90150964,0.00016269987,0.000022429282,0.000015072708,1.7076302e-7,0.000025621772,0.03012029,0.00048311614],"about_ca_topic_score_codex":0.00003475409,"about_ca_topic_score_gemma":0.00010405377,"teacher_disagreement_score":0.6629323,"about_ca_system_score_codex":0.00026218686,"about_ca_system_score_gemma":0.00037251617,"threshold_uncertainty_score":0.9996476},"labels":[],"label_agreement":null},{"id":"W4403343117","doi":"10.1111/bcp.16289","title":"2024 updates to the Québec antiretroviral therapeutic drug monitoring guidelines: Key changes over 10 years","year":2024,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Key (lock); Drug; Therapeutic drug monitoring; Medicine; Human immunodeficiency virus (HIV); Pharmacology; Computer science; Family medicine; Computer security","score_opus":0.07170331695501822,"score_gpt":0.44060071588062283,"score_spread":0.3688973989256046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403343117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88571376,0.036798645,0.000024022778,0.0669057,0.009800022,0.00036802108,0.000013436588,0.000046433266,0.00032993814],"genre_scores_gemma":[0.92204946,0.0126403,0.0010652572,0.006459827,0.011313155,0.000028542603,0.000004759005,0.000054456224,0.046384245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977973,0.00020263076,0.0010810188,0.00024634693,0.0003703196,0.00030235774],"domain_scores_gemma":[0.99858236,0.0006184822,0.00017475983,0.000098620425,0.00025202005,0.00027377863],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015554134,0.00015734762,0.0005716148,0.00013771188,0.00007351897,0.000085319916,0.00023645001,0.000097118005,0.0021583086],"category_scores_gemma":[0.00030608286,0.00011671527,0.00031973823,0.0002450883,0.00010445727,0.000094556664,0.000084396364,0.0007226183,0.00033606263],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024780625,0.00016450648,0.0200918,0.000026898522,0.0008272251,0.003382803,0.0002034612,0.000006382817,0.00023842619,0.000003489936,0.59112465,0.38368252],"study_design_scores_gemma":[0.0019754767,0.00061087415,0.03776396,0.00053258624,0.00074231095,0.0013296132,0.0001272311,0.0001186772,0.0004402811,0.000039128467,0.9561792,0.00014067252],"about_ca_topic_score_codex":0.00020319471,"about_ca_topic_score_gemma":0.00022081599,"teacher_disagreement_score":0.38354185,"about_ca_system_score_codex":0.00009752905,"about_ca_system_score_gemma":0.0006281318,"threshold_uncertainty_score":0.99875385},"labels":[],"label_agreement":null},{"id":"W4403710570","doi":"10.17615/cf2t-6846","title":"Pharmacokinetic Modeling to Guide Preclinical Development of an Islatravir-Eluting Reservoir-Style Biodegradable Implant for Long-Acting HIV PrEP","year":2024,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of North Carolina at Chapel Hill; National Institutes of Health; Partenariat Canadien Contre Le Cancer; U.S. President’s Emergency Plan for AIDS Relief; Center for AIDS Research, University of Washington; United States Agency for International Development","keywords":"Human immunodeficiency virus (HIV); Pharmacokinetics; Implant; Medicine; Pharmacology; Surgery; Virology","score_opus":0.0651676740537915,"score_gpt":0.35045225858898393,"score_spread":0.28528458453519245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403710570","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89630085,0.002965083,0.08515642,0.0059849843,0.00080115965,0.0025173586,0.00010929729,0.0007455871,0.00541927],"genre_scores_gemma":[0.31739512,0.0000123006685,0.65960586,0.00022379404,0.00030214342,0.00019826063,0.00044547723,0.000095080315,0.021721933],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997592,0.00003926704,0.00093075976,0.000584995,0.0003491834,0.0005038102],"domain_scores_gemma":[0.99894726,0.00031927382,0.000082504404,0.0002950977,0.00009445135,0.00026139262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005575293,0.00029414857,0.00047840268,0.00024321584,0.0002079586,0.00014205893,0.00018462981,0.00010565926,0.00011481941],"category_scores_gemma":[0.00019621597,0.00023499077,0.0001261337,0.0003235386,0.000041087114,0.00046735807,0.00015966748,0.00017378877,0.000041732077],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00916861,0.0037677325,0.035067625,0.0126676,0.007526832,0.0011969132,0.14023738,0.009677826,0.038584042,0.013476728,0.13041322,0.5982155],"study_design_scores_gemma":[0.0045890803,0.000659851,0.0003922656,0.0034859574,0.0008132919,0.00012920384,0.0028308916,0.38706496,0.36659643,0.0026862514,0.22961308,0.0011387515],"about_ca_topic_score_codex":0.000015307078,"about_ca_topic_score_gemma":0.000021146061,"teacher_disagreement_score":0.5970768,"about_ca_system_score_codex":0.00010017968,"about_ca_system_score_gemma":0.00085879065,"threshold_uncertainty_score":0.9582645},"labels":[],"label_agreement":null},{"id":"W4404174570","doi":"10.4049/jimmunol.212.supp.0907.5108","title":"Is AIDS an Actinopathy? HIV Inhibition of ARP2/3 is Reminiscent of Primary Immunodeficiencies in Normal Progressors but Absent in A Subset of HIV Controllers.","year":2024,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Foods","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Immunology; Biology; Medicine","score_opus":0.01595027447173965,"score_gpt":0.26106669197601184,"score_spread":0.24511641750427218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404174570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880591,0.0082817,0.000011771941,0.0028299985,0.00012407804,0.00030928545,0.000023622697,0.0000058222663,0.00035459417],"genre_scores_gemma":[0.99749684,0.0017015041,0.00029423332,0.000052692012,0.000019265477,0.000005682224,0.0000129661,0.000014474529,0.00040232076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978633,0.00020454694,0.0012075084,0.00012301118,0.00035179444,0.0002498382],"domain_scores_gemma":[0.9987759,0.0001728826,0.0005924568,0.00023859333,0.00018922464,0.000030947842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001187811,0.00017281821,0.0007913748,0.00063058455,0.000022467546,0.0000051699053,0.00016471642,0.00011327436,0.0000846162],"category_scores_gemma":[0.000056197197,0.000110127614,0.00015701346,0.00039208203,0.00030664058,0.00014408966,0.00006645395,0.00040089252,0.0000051735205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014266489,0.0037984487,0.11532603,0.00074767164,0.0014865872,0.00062035205,0.08989131,0.000053257223,0.7585828,0.0002734391,0.0007217943,0.01423183],"study_design_scores_gemma":[0.014213557,0.004216209,0.25524384,0.0037046056,0.0005858823,0.0015463111,0.021054437,0.00024293564,0.6981136,0.00020869356,0.0006094309,0.0002604786],"about_ca_topic_score_codex":0.000041487652,"about_ca_topic_score_gemma":0.000008338156,"teacher_disagreement_score":0.1399178,"about_ca_system_score_codex":0.00021453685,"about_ca_system_score_gemma":0.0004447427,"threshold_uncertainty_score":0.44908735},"labels":[],"label_agreement":null},{"id":"W4404185126","doi":"10.1093/infdis/jiae551","title":"Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption","year":2024,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"NHLBI Division of Intramural Research; National Institute of Allergy and Infectious Diseases; Instituto Nacional do Câncer, Ministério da Saúde; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; Gilead Sciences","keywords":"Human immunodeficiency virus (HIV); Drug holiday; Virology; Dynamics (music); Medicine; Immunology; Intensive care medicine; Psychology","score_opus":0.008130029747551906,"score_gpt":0.27511799530823605,"score_spread":0.26698796556068416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404185126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901304,0.0072059976,0.00042541453,0.00073368783,0.00032770453,0.0004582485,0.00008150246,0.000086257576,0.00055075955],"genre_scores_gemma":[0.99692285,0.0006560937,0.0000092742475,0.00007074078,0.0001962474,0.00003639293,0.000028292452,0.000032081276,0.0020480137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985726,0.00011735964,0.0005293427,0.00015778125,0.0003658829,0.00025704235],"domain_scores_gemma":[0.999184,0.00011548181,0.0001661793,0.0002366349,0.00013067768,0.00016698794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017326088,0.00028445187,0.00042274667,0.00033093043,0.00016010358,0.00009748283,0.00008624511,0.00005131204,0.0001843633],"category_scores_gemma":[0.000022416754,0.00015070042,0.0004448505,0.00020304511,0.00010057951,0.00018862604,0.000021062671,0.0001638379,0.000082883904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006388949,0.009559093,0.91114193,0.00028817877,0.015205148,0.004485067,0.0075037093,0.0003871859,0.003190413,0.0006559686,0.0011448184,0.04004956],"study_design_scores_gemma":[0.016604492,0.01647556,0.92949724,0.0017300013,0.023151923,0.0032933592,0.0007437552,0.0043537146,0.0007775973,0.001415985,0.001319931,0.00063646166],"about_ca_topic_score_codex":0.00011330874,"about_ca_topic_score_gemma":0.00005047083,"teacher_disagreement_score":0.039413102,"about_ca_system_score_codex":0.0014973177,"about_ca_system_score_gemma":0.00024528368,"threshold_uncertainty_score":0.6145385},"labels":[],"label_agreement":null},{"id":"W4404371830","doi":"10.1097/tp.0000000000005271","title":"Clinical and Histopathological Findings in HIV-positive to HIV-positive Kidney Transplant Recipients","year":2024,"lang":"en","type":"article","venue":"Transplantation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Sept Iles","funders":"","keywords":"Medicine; Biopsy; Cohort; Internal medicine; Gastroenterology; Kidney transplantation; Nephropathy; Transplantation; Chronic allograft nephropathy; Pathology","score_opus":0.01799826205923877,"score_gpt":0.30791109328934185,"score_spread":0.2899128312301031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404371830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858915,0.00013015005,0.0031486168,0.007354959,0.00024310022,0.0006808724,0.0003568402,0.00009963938,0.0020943142],"genre_scores_gemma":[0.9906197,0.0006911824,0.0033484674,0.0006607584,0.0000620764,0.000059863036,0.0011583421,0.000020814929,0.003378805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998508,0.00009529863,0.0004222762,0.0005027437,0.00022046111,0.0002512155],"domain_scores_gemma":[0.9994154,0.00017535442,0.000017704057,0.000082311235,0.00002800333,0.00028121096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032604003,0.00020192066,0.00032518306,0.00025916757,0.000054789874,0.000028548866,0.000043325468,0.00014160183,0.00006573157],"category_scores_gemma":[0.000020614747,0.00016435298,0.00008094778,0.0002473739,0.000071510236,0.00011410067,0.0000061300966,0.00024998735,0.00024944765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003862589,0.00061503134,0.9322144,0.0003854062,0.00018569123,0.009118153,0.036344882,0.0000033649892,0.0036556814,0.0017124652,0.002525015,0.009377339],"study_design_scores_gemma":[0.0036827456,0.00038182005,0.9868047,0.002471995,0.00043312288,0.00049427437,0.00009129434,0.000169033,0.0037831918,0.00009732631,0.001318743,0.00027173306],"about_ca_topic_score_codex":0.000009972396,"about_ca_topic_score_gemma":0.000017877031,"teacher_disagreement_score":0.054590337,"about_ca_system_score_codex":0.000117761134,"about_ca_system_score_gemma":0.00009324096,"threshold_uncertainty_score":0.67021203},"labels":[],"label_agreement":null},{"id":"W4404471199","doi":"10.1093/jac/dkae408","title":"Pretreatment and acquired HIV drug resistance in Belize—results of nationally representative surveys, 2021–22","year":2024,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; World Health Organization; Global Fund to Fight AIDS, Tuberculosis and Malaria","keywords":"Dolutegravir; Medicine; Nevirapine; HIV drug resistance; Efavirenz; Drug resistance; Integrase inhibitor; Integrase; Cross-sectional study; Young adult; Viral load; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Biology","score_opus":0.009204698843173027,"score_gpt":0.27597195282587345,"score_spread":0.2667672539827004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404471199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605423,0.003077547,0.00015319865,0.034039386,0.00019830275,0.0003944143,0.00007003592,0.0000122073225,0.0015125975],"genre_scores_gemma":[0.9481196,0.0045603854,0.011929125,0.00018509495,0.0001542737,0.000003332044,0.000054121396,0.000035208475,0.034958895],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984551,0.00012122308,0.0007220961,0.00022652006,0.00031430754,0.00016076147],"domain_scores_gemma":[0.9991317,0.00019894358,0.00026210415,0.00012213165,0.00020725664,0.00007790412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081226556,0.00017884115,0.00047389898,0.00032708482,0.000028692924,0.000031291576,0.000074075346,0.00005940011,0.00009296694],"category_scores_gemma":[0.000056167344,0.00013550068,0.00013715531,0.00033614654,0.0000875084,0.00015207942,0.000016749045,0.000121259385,0.0000051415386],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014146699,0.003487922,0.066362806,0.0008681687,0.0046409573,0.003074984,0.03799665,0.000033334665,0.21083613,0.00036349444,0.6448595,0.01332935],"study_design_scores_gemma":[0.048582394,0.0004940567,0.14440602,0.007003056,0.0004494513,0.00060126296,0.00072865875,0.00012092051,0.7181955,0.00071197614,0.07798626,0.00072046596],"about_ca_topic_score_codex":0.000013938872,"about_ca_topic_score_gemma":0.00006797668,"teacher_disagreement_score":0.56687325,"about_ca_system_score_codex":0.00018373589,"about_ca_system_score_gemma":0.00033768095,"threshold_uncertainty_score":0.55255574},"labels":[],"label_agreement":null},{"id":"W4404764993","doi":"10.1039/d4sc05679e","title":"A flexible and scalable synthesis of 4′-thionucleosides","year":2024,"lang":"en","type":"article","venue":"Chemical Science","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Canadian Glycomics Network; Natural Sciences and Engineering Research Council of Canada; Québec Consortium for Drug Discovery","keywords":"Scalability; Pyrimidine; Purine; Computer science; Combinatorial chemistry; De novo synthesis; Process (computing); Chemistry; Computer architecture; Stereochemistry; Programming language; Biochemistry; Enzyme; Operating system","score_opus":0.011300327703051562,"score_gpt":0.27314835122652836,"score_spread":0.2618480235234768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404764993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97977763,0.00056989427,0.000028578579,0.0024951294,0.000036321904,0.00007754239,0.0000013764978,0.00006232259,0.01695122],"genre_scores_gemma":[0.99362,0.00004320615,0.0036802322,0.000030812775,0.00001566573,0.000008105178,4.9837723e-7,0.0000037369375,0.002597777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933815,0.0000020566458,0.00009216274,0.00020169691,0.00020942575,0.00015649004],"domain_scores_gemma":[0.99967086,0.00008108358,0.000008888845,0.00008711347,0.000029183906,0.00012288529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018466635,0.00005428135,0.000109317356,0.000069235415,0.00003506126,0.000024831912,0.00005665088,0.000022372991,0.000085975546],"category_scores_gemma":[0.00017385739,0.00003668756,0.000022278164,0.0004531947,0.00040193583,0.000083595805,0.000053109732,0.000041543033,0.00004061764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000132776295,0.000060926122,0.00431882,0.00017777365,0.000017281918,0.000019050356,0.00025811527,6.894641e-8,0.9586991,0.0020458659,0.001475711,0.032914013],"study_design_scores_gemma":[0.00007400817,0.000010079366,0.0010211465,0.00026587414,0.000028880424,0.00002584556,0.00003209477,0.0002942414,0.9953673,0.00037557358,0.0024609335,0.000044037508],"about_ca_topic_score_codex":0.0000038764097,"about_ca_topic_score_gemma":1.2717945e-7,"teacher_disagreement_score":0.03666819,"about_ca_system_score_codex":0.00004695022,"about_ca_system_score_gemma":0.00014154062,"threshold_uncertainty_score":0.14960752},"labels":[],"label_agreement":null},{"id":"W4404880524","doi":"10.1093/ofid/ofae705","title":"Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report","year":2024,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Dolutegravir; Medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.017650042683233308,"score_gpt":0.314621246516989,"score_spread":0.29697120383375564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404880524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97501194,0.0027236668,0.00009763669,0.00073645107,0.00034027876,0.0009817268,0.000076435404,0.00020001821,0.019831868],"genre_scores_gemma":[0.9840461,0.00024048505,0.000057126126,0.00012951935,0.000042921,0.0001877483,0.00016084757,0.000041347063,0.0150938975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848187,0.00003183382,0.00040204506,0.0005551736,0.00019093875,0.0003381387],"domain_scores_gemma":[0.9992961,0.000049630737,0.0000709635,0.00035904243,0.00006738989,0.00015685536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017023043,0.00026145534,0.00034802489,0.00027366367,0.00030440383,0.00029087075,0.000072173534,0.00007920849,0.00021273571],"category_scores_gemma":[0.00006326685,0.00022232605,0.00008743234,0.000543341,0.00007250089,0.00037037343,0.00017780306,0.0001932846,0.000047740712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014895709,0.0014843158,0.911956,0.00036449826,0.0002768096,0.073452,0.0004956168,0.0000040582468,0.00078541733,0.0030644624,0.004327144,0.003640705],"study_design_scores_gemma":[0.009575427,0.0010393185,0.73697877,0.0036494683,0.0013294811,0.11531949,0.00085352856,0.0001603915,0.0011601769,0.0037585844,0.12438044,0.0017949224],"about_ca_topic_score_codex":0.0033881688,"about_ca_topic_score_gemma":0.00846122,"teacher_disagreement_score":0.17497724,"about_ca_system_score_codex":0.00028079434,"about_ca_system_score_gemma":0.0002527051,"threshold_uncertainty_score":0.90661937},"labels":[],"label_agreement":null},{"id":"W4405526095","doi":"10.2139/ssrn.5061255","title":"Sex Differences in Discontinuations Due to Side Effects of Second-Generation Integrase Strand Transfer Inhibitors: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"SSRN Electronic Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Women's Health Research Institute; University of British Columbia","funders":"","keywords":"Integrase; Meta-analysis; Computational biology; Pharmacology; Chemistry; Biology; Medicine; Genetics; Internal medicine; DNA","score_opus":0.03363756704114695,"score_gpt":0.31199062564881674,"score_spread":0.2783530586076698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405526095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024355011,0.9952069,0.000511634,0.0005638021,0.0000341168,0.0033717025,0.000031287982,0.000010884257,0.000026114829],"genre_scores_gemma":[0.00803474,0.9841121,0.00003793571,0.000038879694,0.000051109193,0.0006122424,0.000101618,0.000034767007,0.006976644],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963364,0.00056703493,0.0016061453,0.00040560358,0.00036944723,0.00071535475],"domain_scores_gemma":[0.9990622,0.00021921431,0.0002539514,0.00024363006,0.000074101554,0.00014695177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017470154,0.00053271756,0.007303975,0.0010161083,0.000051859086,0.000062562765,0.00011910379,0.00013891717,0.000039559145],"category_scores_gemma":[0.00013186922,0.00028262616,0.0018049638,0.0011237699,0.000025457068,0.00008374434,0.00001837169,0.0012316338,0.000011751517],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000042144147,0.00016506309,0.000004672468,0.6859778,0.3035662,0.00008916797,0.00056954176,1.2791158e-7,0.000003972455,0.0006932985,0.000046985373,0.008878959],"study_design_scores_gemma":[0.00029447055,0.00017743047,0.0000017600461,0.06136096,0.9367634,0.0004314225,0.00013085123,0.000002430839,0.0000101748365,0.00022930984,0.00035075378,0.0002470553],"about_ca_topic_score_codex":0.00001507654,"about_ca_topic_score_gemma":0.003681737,"teacher_disagreement_score":0.6331972,"about_ca_system_score_codex":0.00057385844,"about_ca_system_score_gemma":0.0016333568,"threshold_uncertainty_score":0.99996257},"labels":[],"label_agreement":null},{"id":"W4405673510","doi":"10.14715/cmb/2024.70.11.1","title":"HIV-2 drug resistance genotyping and viral load among HIV-2 infected adults inBurkina Faso, West Africa","year":2024,"lang":"en","type":"article","venue":"Cellular and Molecular Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas University","funders":"","keywords":"Genotyping; Human immunodeficiency virus (HIV); Virology; Viral load; Drug resistance; HIV drug resistance; Antiretroviral drug; Medicine; Resistance (ecology); Lentivirus; Antiretroviral therapy; Biology; Viral disease; Genotype; Microbiology; Genetics; Ecology","score_opus":0.0046296138651285325,"score_gpt":0.21795693665587745,"score_spread":0.21332732279074892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405673510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952929,0.035935912,0.0033451135,0.0021447213,0.0001492516,0.0004431077,0.000016720543,0.00014769568,0.004888479],"genre_scores_gemma":[0.9849683,0.00058161194,0.0011212743,0.00009361475,0.000062187304,0.000037993173,0.00025208303,0.000033047843,0.012849881],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864954,0.00007899626,0.0002415409,0.00055835117,0.000109812136,0.0003617814],"domain_scores_gemma":[0.99947774,0.000044695757,0.00003910642,0.00021398939,0.000056582296,0.00016789137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014666926,0.00026492644,0.0003353033,0.00015502032,0.000100203484,0.00004110493,0.000056743385,0.00016137047,0.00004242576],"category_scores_gemma":[0.00004314502,0.00021781438,0.000076682045,0.0001852121,0.00021728847,0.0000426311,0.00009865201,0.00020245336,0.00005643611],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012227384,0.0005084552,0.08259732,0.002129196,0.0024569114,0.009729193,0.015835386,0.0000020054958,0.8325581,0.015596817,0.02060471,0.016759194],"study_design_scores_gemma":[0.008677071,0.00036116008,0.012249136,0.0022642328,0.0014084523,0.00025157502,0.00057402207,0.0012870207,0.21155459,0.0027800738,0.75685287,0.0017398148],"about_ca_topic_score_codex":0.000016769867,"about_ca_topic_score_gemma":0.0000317815,"teacher_disagreement_score":0.73624814,"about_ca_system_score_codex":0.00006916084,"about_ca_system_score_gemma":0.00011020174,"threshold_uncertainty_score":0.88822126},"labels":[],"label_agreement":null},{"id":"W4406235685","doi":"10.1016/s2211-9698(18)78442-2","title":"10.1016/s2211-9698(18)78442-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Virology","score_opus":0.007888782769095609,"score_gpt":0.19808447403067356,"score_spread":0.19019569126157795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406235685","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017386457,0.00010848154,4.928283e-7,0.0023183457,0.000001769829,0.0003603217,0.000007888728,0.00016811503,0.99529594],"genre_scores_gemma":[0.00024006017,0.0000012816114,0.00064141606,0.000099810284,0.0001415463,0.000042216892,0.0000727924,0.000032348154,0.9987285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895465,0.000019894798,0.00020067322,0.0002637104,0.00024851665,0.000312523],"domain_scores_gemma":[0.9993474,0.000028755861,0.000020830828,0.00029695735,0.00004174028,0.00026430967],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000091965936,0.00018613558,0.00026584638,0.00010401015,0.000070172064,0.000019015315,0.000087256325,0.000065778804,0.99858284],"category_scores_gemma":[0.00002051279,0.00015386596,0.0000821359,0.00022376135,0.000025324665,0.000051509818,0.000025443915,0.00009543892,0.9975496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013934288,0.00014375352,0.0000038615813,0.000007849194,0.0000777544,0.00006472932,0.00004536698,0.0000017963101,0.000025510928,4.8997305e-7,0.620108,0.37938157],"study_design_scores_gemma":[0.0011093654,0.000154947,0.00019954206,0.000052712636,0.00009385802,0.000036971487,0.000002278493,0.00003792298,0.0003765589,0.000003238873,0.99776334,0.00016929163],"about_ca_topic_score_codex":0.000008139539,"about_ca_topic_score_gemma":1.7379757e-7,"teacher_disagreement_score":0.37921226,"about_ca_system_score_codex":0.0000905354,"about_ca_system_score_gemma":0.000076667406,"threshold_uncertainty_score":0.6274472},"labels":[],"label_agreement":null},{"id":"W4406418553","doi":"10.1016/j.yped.2012.10.006","title":"10.1016/j.yped.2012.10.006","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Nevirapine; Lopinavir/ritonavir; Lopinavir; Ritonavir; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load","score_opus":0.006316334489283993,"score_gpt":0.19419700360737427,"score_spread":0.1878806691180903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406418553","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013915788,0.00014345077,4.0519637e-7,0.0023116774,0.0000015861801,0.00033162368,0.000008318124,0.0001546165,0.9956567],"genre_scores_gemma":[0.00013910605,9.4876526e-7,0.00048233834,0.000075466756,0.00015708066,0.00003786764,0.00009263311,0.000030883235,0.9989837],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989974,0.00001967436,0.00018969424,0.00024655205,0.00023898037,0.0003076884],"domain_scores_gemma":[0.99935913,0.000031191477,0.000021070104,0.0002867731,0.000045109315,0.00025672512],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000089482164,0.0001795729,0.0002537647,0.00009791887,0.00006521611,0.000017997321,0.000082586324,0.00006431489,0.99893206],"category_scores_gemma":[0.0000197855,0.00014699518,0.00007521997,0.00019371841,0.00002434312,0.00006760432,0.000024705609,0.00008183936,0.99837196],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014926292,0.00013613151,0.0000021427281,0.0000071135064,0.000066893226,0.000044546883,0.000035485886,0.0000012549789,0.000019361858,4.4102777e-7,0.63396066,0.36557668],"study_design_scores_gemma":[0.0010313923,0.00016587757,0.00015705726,0.000046440513,0.00009033234,0.000027996897,0.0000015426474,0.00002414757,0.00027145274,0.0000030440567,0.9980179,0.00016281389],"about_ca_topic_score_codex":0.000006430763,"about_ca_topic_score_gemma":2.391453e-7,"teacher_disagreement_score":0.36541387,"about_ca_system_score_codex":0.00007812244,"about_ca_system_score_gemma":0.0000713742,"threshold_uncertainty_score":0.59942895},"labels":[],"label_agreement":null},{"id":"W4406430904","doi":"10.1016/s0024-7804(97)83189-2","title":"10.1016/s0024-7804(97)83189-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.006955131510018508,"score_gpt":0.18925532365976183,"score_spread":0.18230019214974333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406430904","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001159447,0.00011795725,4.7738456e-7,0.002892408,0.0000014717723,0.00036167653,0.0000073228007,0.00016727489,0.99529195],"genre_scores_gemma":[0.00019311601,0.0000010212127,0.0006098822,0.00010363825,0.00013895023,0.000042643416,0.000068475696,0.000032152195,0.9988101],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989604,0.000019657724,0.00019912516,0.00026380055,0.00024778448,0.000309279],"domain_scores_gemma":[0.99935216,0.000030053245,0.000020295995,0.000293518,0.00004145055,0.00026254522],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000090841575,0.00018578651,0.00026362235,0.00010364299,0.0000687091,0.000019257486,0.00008616546,0.00006548132,0.9981673],"category_scores_gemma":[0.000020354048,0.00015310584,0.00008096677,0.00022243087,0.00002542857,0.00005066342,0.00002534922,0.000096180906,0.9987062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015822434,0.00015794333,0.0000056150925,0.00000905058,0.00008441173,0.00006724341,0.000054154178,0.0000015964112,0.00001948128,0.000001101182,0.44102472,0.5584164],"study_design_scores_gemma":[0.0010842846,0.00015719868,0.00015695878,0.000054566273,0.00009179786,0.00003493706,0.0000021230749,0.0000407351,0.00029356178,0.0000049416067,0.9979102,0.00016870043],"about_ca_topic_score_codex":0.000008496055,"about_ca_topic_score_gemma":2.044403e-7,"teacher_disagreement_score":0.55824775,"about_ca_system_score_codex":0.000087105094,"about_ca_system_score_gemma":0.000068637324,"threshold_uncertainty_score":0.6243475},"labels":[],"label_agreement":null},{"id":"W4406494073","doi":"10.51731/cjht.25.1059","title":"Cabotegravir (Apretude)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.014424990178748594,"score_gpt":0.2988635952017083,"score_spread":0.2844386050229597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406494073","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20646936,0.1415937,0.0006308665,0.6409851,0.00089063303,0.00064163166,0.000012962125,0.00023786297,0.008537941],"genre_scores_gemma":[0.99079067,0.0005850425,0.002165094,0.0009012906,0.000005364976,0.0000046792584,0.000002668547,0.0000071534732,0.005538044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990076,0.00002060174,0.00042868167,0.000096804004,0.00010597487,0.0003403478],"domain_scores_gemma":[0.99940574,0.000028320424,0.00015333557,0.00018728833,0.00013383082,0.000091472066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003156457,0.00010741707,0.00036466427,0.0008959611,0.00016625866,0.000016927226,0.00016216295,0.00011177871,0.000027572672],"category_scores_gemma":[0.00026915345,0.000080703205,0.00007258737,0.0004226427,0.00012062889,0.000043804954,0.000011957131,0.0003220562,0.00001305977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024627945,0.000041407544,0.09011804,0.00015977837,0.00022700394,0.00065632054,0.000400623,0.0000015818231,0.000028273864,0.0058127013,0.076386824,0.8261428],"study_design_scores_gemma":[0.0011917017,0.00021526677,0.043697078,0.00089024124,0.000055148925,0.00028140694,0.003221146,0.0000038524963,0.0009823893,0.004621477,0.9447322,0.00010810421],"about_ca_topic_score_codex":0.0010513249,"about_ca_topic_score_gemma":0.0024166312,"teacher_disagreement_score":0.8683454,"about_ca_system_score_codex":0.0006223694,"about_ca_system_score_gemma":0.0061755353,"threshold_uncertainty_score":0.99945855},"labels":[],"label_agreement":null},{"id":"W4406496071","doi":"10.1016/s0029-7437(05)70068-9","title":"10.1016/s0029-7437(05)70068-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Nevirapine; Advisory committee; Business; Medicine; Political science; Virology; Public administration; Human immunodeficiency virus (HIV)","score_opus":0.0069132902303341865,"score_gpt":0.1967427849888838,"score_spread":0.18982949475854963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406496071","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017490161,0.000078744546,5.9448956e-7,0.003159304,3.8001807e-7,0.00035566947,0.00000810043,0.0001940701,0.99445415],"genre_scores_gemma":[0.00019930852,9.078424e-7,0.000718518,0.00010885929,0.00013604495,0.000038493523,0.00007593447,0.000031892487,0.99869007],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897236,0.000019634534,0.00019713103,0.00026111645,0.00023923285,0.00031055533],"domain_scores_gemma":[0.9993565,0.00003065056,0.00002082975,0.00028885817,0.000040363324,0.00026280736],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000091182665,0.00018359761,0.00026397483,0.00010332179,0.00006921041,0.000018135548,0.00008587895,0.00006423393,0.99799085],"category_scores_gemma":[0.000020087124,0.00015186986,0.000080204525,0.00021956395,0.000024603549,0.000051677973,0.000024777759,0.000092821334,0.9977343],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013990383,0.00015226581,0.0000028299362,0.000007954297,0.00007616608,0.000061916726,0.00005317347,0.0000019927688,0.000022887476,7.1007537e-7,0.7965899,0.20289026],"study_design_scores_gemma":[0.0010782016,0.00017021823,0.00017201438,0.00005288074,0.00008946495,0.000047873433,0.0000021984642,0.000038641036,0.00033386672,0.0000043713153,0.99784356,0.00016672869],"about_ca_topic_score_codex":0.000008149394,"about_ca_topic_score_gemma":2.1727871e-7,"teacher_disagreement_score":0.20272353,"about_ca_system_score_codex":0.00009095116,"about_ca_system_score_gemma":0.00006949298,"threshold_uncertainty_score":0.61930734},"labels":[],"label_agreement":null},{"id":"W4406500294","doi":"10.1016/s0029-7437(07)70226-4","title":"10.1016/s0029-7437(07)70226-4","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Virology; Medicine; Computational biology; Biology","score_opus":0.007055214713851327,"score_gpt":0.197449807948076,"score_spread":0.1903945932342247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406500294","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015036123,0.00011460661,5.639773e-7,0.0025208015,3.4751656e-7,0.0003728488,0.000007946714,0.0001903196,0.99528897],"genre_scores_gemma":[0.00015899728,0.0000012467515,0.00071640144,0.00009629841,0.00013326219,0.000045485718,0.00007385043,0.000031938613,0.9987425],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989572,0.000020213392,0.00020334544,0.000262726,0.00024782153,0.00030869414],"domain_scores_gemma":[0.99934703,0.00002983004,0.00002134023,0.0002979802,0.00004110339,0.00026274144],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009459669,0.00018535086,0.00027053888,0.00009559725,0.00007069983,0.000018219229,0.0000879241,0.00006261657,0.9987589],"category_scores_gemma":[0.000021013004,0.00015281308,0.00008243031,0.00020242245,0.00002474148,0.00005079173,0.000025348258,0.00009565578,0.9987811],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014108574,0.0001573609,0.0000038163303,0.000009336465,0.000078926256,0.00005335325,0.000053578256,0.0000018134168,0.000020120924,6.7485865e-7,0.801815,0.19766496],"study_design_scores_gemma":[0.0010443033,0.00015814956,0.00018136474,0.00005553716,0.00009170989,0.000040301267,0.0000021035755,0.000036232632,0.00028660885,0.0000037467846,0.99793166,0.00016826311],"about_ca_topic_score_codex":0.000008617994,"about_ca_topic_score_gemma":2.0978867e-7,"teacher_disagreement_score":0.1974967,"about_ca_system_score_codex":0.000089498135,"about_ca_system_score_gemma":0.00007038813,"threshold_uncertainty_score":0.6231537},"labels":[],"label_agreement":null},{"id":"W4406671258","doi":"10.1016/b978-0-08-051980-7.50009-3","title":"10.1016/b978-0-08-051980-7.50009-3","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Materials science","score_opus":0.00929561518535669,"score_gpt":0.19053615445049732,"score_spread":0.18124053926514064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406671258","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017983771,0.0005182258,3.49311e-7,0.0013635521,0.0000058781898,0.000907958,0.00008258048,0.00026683806,0.9968528],"genre_scores_gemma":[0.0000010982425,0.0000047444546,0.00034470405,0.00011601124,0.00045289044,0.00004904002,0.0007355663,0.00017818203,0.99811774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978271,0.000013233059,0.00048607768,0.0006455627,0.00056374393,0.00046427117],"domain_scores_gemma":[0.9985876,0.000055293902,0.00011236068,0.00067488843,0.000102737366,0.0004670995],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011155128,0.00066475157,0.00089214055,0.00040094514,0.00009565824,0.00003469121,0.00019393957,0.00041260722,0.998205],"category_scores_gemma":[0.000016454374,0.00058667583,0.00030238426,0.00006830031,0.00006702037,0.00004743053,0.000090347414,0.00039451118,0.9987111],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024386549,0.00007840039,1.02610024e-7,0.000037599708,0.0004445065,0.00034198863,0.000033012693,6.14314e-7,0.0000024782264,0.000053487336,0.5010369,0.49772707],"study_design_scores_gemma":[0.0011187864,0.00025398293,0.0000038315047,0.0005072699,0.0005428635,0.0000916026,5.060699e-7,0.000004344857,0.000033768534,0.000113660506,0.9967702,0.0005591662],"about_ca_topic_score_codex":0.000004784583,"about_ca_topic_score_gemma":3.488069e-7,"teacher_disagreement_score":0.49716792,"about_ca_system_score_codex":0.00027143073,"about_ca_system_score_gemma":0.00025607817,"threshold_uncertainty_score":0.99965847},"labels":[],"label_agreement":null},{"id":"W4406944849","doi":"10.1093/ofid/ofae631.774","title":"P-576. Real-world Experience with the Two-Drug Regimen Dolutegravir/Lamivudine for the Treatment of HIV-1 among Vulnerable People Living with HIV in Canada: Preliminary Results from a Chart Review Study","year":2025,"lang":"en","type":"review","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Infectious Diseases Centre; GlaxoSmithKline (Canada)","funders":"","keywords":"Dolutegravir; Medicine; Human immunodeficiency virus (HIV); Lamivudine; Regimen; Virology; Rilpivirine; Family medicine; Pediatrics; Antiretroviral therapy; Internal medicine; Viral load; Virus","score_opus":0.01798693368333191,"score_gpt":0.3066840443462142,"score_spread":0.2886971106628823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406944849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035776515,0.96453935,0.0000056554454,0.0019587218,0.0001074404,0.025513683,0.0011810603,0.000048283517,0.0030681689],"genre_scores_gemma":[0.020674592,0.9247528,0.000041729898,0.000107829444,0.000057975445,0.019363657,0.0010574083,0.000083582054,0.033860438],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963688,0.00045924788,0.001051916,0.0009982598,0.0005272847,0.00059447234],"domain_scores_gemma":[0.9941979,0.0031313095,0.0008548601,0.0014674513,0.00015993959,0.00018856014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003862215,0.00086926034,0.0029426948,0.00019090866,0.0005627612,0.0000969975,0.00061756733,0.000045906796,0.000069621405],"category_scores_gemma":[0.00016068753,0.00038986004,0.00031177464,0.0011883499,0.00011301764,0.000177484,0.00024481915,0.00025237014,0.000005030019],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030604599,0.009112662,0.6732318,0.01900926,0.0082473485,0.0005761928,0.007897463,0.00007203617,2.0207976e-8,0.000060410897,0.101506494,0.17722587],"study_design_scores_gemma":[0.016532635,0.0036122773,0.06987818,0.2619569,0.02973199,0.000052598505,0.010779371,0.00004610405,0.0000022688566,0.000009653091,0.6059095,0.0014884776],"about_ca_topic_score_codex":0.589811,"about_ca_topic_score_gemma":0.93282115,"teacher_disagreement_score":0.6033536,"about_ca_system_score_codex":0.0017815055,"about_ca_system_score_gemma":0.00525903,"threshold_uncertainty_score":0.99985534},"labels":[],"label_agreement":null},{"id":"W4407050204","doi":"10.17615/ckzp-gs13","title":"Corrigendum to: Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada","year":2025,"lang":"en","type":"erratum","venue":"UNC Libraries","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Integrase; Virology; Human immunodeficiency virus (HIV); Integrase inhibitor; Antiretroviral therapy; Cohort; Medicine; Internal medicine; Viral load","score_opus":0.018452403782290867,"score_gpt":0.2886119761034629,"score_spread":0.27015957232117205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407050204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994557,0.0009603167,0.000022058712,0.00024854415,0.0015392733,0.0019676387,0.00042547687,0.000027153708,0.00025251947],"genre_scores_gemma":[0.98486197,0.0004487047,0.00015117423,0.000094863135,0.000059330374,0.00017942337,0.0045469734,0.000042628748,0.0096149575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997673,0.00042759196,0.00075992226,0.00040291427,0.00050595455,0.00023065945],"domain_scores_gemma":[0.99844784,0.0006619295,0.0001625581,0.0003082716,0.00035906717,0.000060310067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000579261,0.00037040396,0.001104729,0.00046096524,0.00011457151,0.00003499483,0.00013630571,0.00019829127,0.0000033069641],"category_scores_gemma":[0.0002122902,0.00022377526,0.0000620044,0.0011618369,0.00065656845,0.000115978415,0.00003315147,0.00042920298,1.3619827e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00639292,0.00079489953,0.80911523,0.0056569027,0.0027701182,0.00034593602,0.013446637,0.000026909824,0.000049603896,0.001386329,0.15993154,0.000082959166],"study_design_scores_gemma":[0.02654774,0.011266969,0.7861473,0.057460595,0.0052415226,0.000007920347,0.087185055,0.00030003043,0.016518088,0.0004859372,0.007241096,0.0015977438],"about_ca_topic_score_codex":0.10665919,"about_ca_topic_score_gemma":0.3330002,"teacher_disagreement_score":0.22634104,"about_ca_system_score_codex":0.00012269623,"about_ca_system_score_gemma":0.0028190287,"threshold_uncertainty_score":0.91252905},"labels":[],"label_agreement":null},{"id":"W4408936365","doi":"10.1016/s2214-109x(24)00553-9","title":"Predicted dolutegravir resistance in people living with HIV in South Africa during 2020–35: a modelling study","year":2025,"lang":"en","type":"article","venue":"The Lancet Global Health","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases; National Institute of Allergy and Infectious Diseases; Medical Research Council; Università degli Studi di Roma Tor Vergata; Deutschen Konsortium für Translationale Krebsforschung; Bundesministerium für Bildung und Forschung; Universität Zürich; Astellas Pharma; NordForsk; Bundesministerium für Gesundheit; ViiV Healthcare; Ministerie van Volksgezondheid, Welzijn en Sport; HORIZON EUROPE Framework Programme; Gilead Sciences; University of Bristol; Istituto Superiore di Sanità; Styrelsen för Internationellt Utvecklingssamarbete; National Institute on Alcohol Abuse and Alcoholism; British HIV Association; Rigshospitalet; Bill and Melinda Gates Foundation; Deutsches Zentrum für Infektionsforschung; National Institutes of Health; Shionogi; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Ministero della Salute; Pfizer; National Science Foundation","keywords":"Dolutegravir; Human immunodeficiency virus (HIV); Virology; Medicine; Resistance (ecology); Environmental health; Antiretroviral therapy; Biology; Viral load","score_opus":0.017384667370350094,"score_gpt":0.28965645064978546,"score_spread":0.27227178327943535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408936365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790545,0.00136675,0.00037620318,0.011419743,0.00004818428,0.0013695153,0.000035903184,0.00010182151,0.0062273983],"genre_scores_gemma":[0.992779,0.00015908705,0.0014937005,0.00022674268,0.00006220893,0.000109715686,0.000010445903,0.000010049517,0.0051490627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981399,0.00017884956,0.00039288518,0.00037103888,0.00030221947,0.00061509095],"domain_scores_gemma":[0.99930483,0.00007484351,0.000092854236,0.00039902068,0.000034945482,0.0000935067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005922999,0.00020052893,0.000608796,0.00009575139,0.00014479295,0.000021206293,0.00016401317,0.000041271025,0.0000064740493],"category_scores_gemma":[0.00003223747,0.00013134183,0.000028696726,0.0013567902,0.00002742466,0.000046833517,0.000071506445,0.00027635947,0.000007597919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010151237,0.00052549364,0.96116763,0.0002478395,0.00007929726,0.00007868015,0.034528665,0.0009999321,4.4335724e-7,0.00033242328,0.0009234067,0.00010103418],"study_design_scores_gemma":[0.0055333665,0.00010028431,0.9829837,0.0024310295,0.000040674156,0.0000044875387,0.006085031,0.0020748074,0.0000010863372,0.0002458619,0.00037028117,0.00012939921],"about_ca_topic_score_codex":0.00028315338,"about_ca_topic_score_gemma":0.010742657,"teacher_disagreement_score":0.028443635,"about_ca_system_score_codex":0.0010033181,"about_ca_system_score_gemma":0.000632697,"threshold_uncertainty_score":0.5994655},"labels":[],"label_agreement":null},{"id":"W4409130125","doi":"10.1097/qad.0000000000004133","title":"Bictegravir/emtricitabine/tenofovir alafenamide after virologic failure to cabotegravir/rilpivirine","year":2025,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Rilpivirine; Emtricitabine; Tenofovir alafenamide; Tenofovir; Medicine; Human immunodeficiency virus (HIV); Virology; Internal medicine; Antiretroviral therapy; Viral load","score_opus":0.004473660625199603,"score_gpt":0.2542331580118725,"score_spread":0.2497594973866729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409130125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9448458,0.0007950415,0.0017897419,0.031449042,0.0003562233,0.0012061216,0.000030752035,0.00032576057,0.019201506],"genre_scores_gemma":[0.8118951,0.000042348576,0.013028253,0.004243039,0.000108919,0.00028853206,0.0000792152,0.000034243007,0.17028038],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794394,0.000059855476,0.00043333456,0.000606683,0.0003510673,0.0006051056],"domain_scores_gemma":[0.9988273,0.000098113785,0.00004871855,0.00061625213,0.00012386384,0.000285761],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021599304,0.0004147106,0.0005915721,0.0006436195,0.00011397002,0.000043447806,0.00018814315,0.00019269655,0.0005591603],"category_scores_gemma":[0.0001342876,0.0003048164,0.00020174759,0.0012879078,0.00007246097,0.00009835649,0.00016539523,0.00028774235,0.0014009887],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012496042,0.0010141237,0.8535024,0.0001691555,0.0010232775,0.001350357,0.00094809226,0.000015413269,0.009675133,0.0047674538,0.063792445,0.062492553],"study_design_scores_gemma":[0.0043284493,0.0007087691,0.47147503,0.00029299964,0.0006800717,0.000056021647,0.00025369268,0.00003529766,0.006675345,0.0018909588,0.5130014,0.00060198375],"about_ca_topic_score_codex":0.00005358018,"about_ca_topic_score_gemma":0.000058823964,"teacher_disagreement_score":0.44920892,"about_ca_system_score_codex":0.0002934118,"about_ca_system_score_gemma":0.0003297856,"threshold_uncertainty_score":0.9999404},"labels":[],"label_agreement":null},{"id":"W4409358012","doi":"10.1093/cid/ciaf191","title":"Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With HIV on Dolutegravir in Europe and Thailand","year":2025,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Imperial College Healthcare NHS Trust; University College London; Imperial College London; ViiV Healthcare; St George's University Hospitals NHS Foundation Trust; Clinical Trials Fund, Canadian Institutes of Health Research; University Hospital Southampton NHS Foundation Trust; McMaster University; Medical Research Council Canada; Alder Hey Children's NHS Foundation Trust; Gilead Sciences","keywords":"Medicine; Discontinuation; Dolutegravir; Viral load; Cumulative incidence; Adverse effect; Internal medicine; Incidence (geometry); Human immunodeficiency virus (HIV); Cohort; Antiretroviral therapy; Immunology","score_opus":0.007076144534294257,"score_gpt":0.2921953868292679,"score_spread":0.2851192422949736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409358012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731326,0.00038655262,0.0000055329283,0.0012510378,0.000048978356,0.0005977005,0.000030387528,0.00004629672,0.00032027002],"genre_scores_gemma":[0.99787354,0.0006397082,0.000022251274,0.00060052564,0.000027901171,0.000022321527,0.0000461906,0.000014539624,0.0007530293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986747,0.00013482074,0.00040371084,0.00045223706,0.0001221387,0.00021240214],"domain_scores_gemma":[0.999363,0.00018355635,0.000057392706,0.00016783315,0.000030227327,0.00019800515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013067755,0.00022757928,0.0005258262,0.00018931182,0.00007004999,0.000036582413,0.00003650141,0.00009115231,0.0000066109446],"category_scores_gemma":[0.00027153364,0.0001476724,0.00003868149,0.00018927625,0.00017858174,0.00007831305,0.00009157311,0.00025630093,0.000005103499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006288843,0.0012395955,0.9940921,0.00005367352,0.000100667596,0.00006953103,0.000032551045,0.000001061637,0.0000015687342,0.000083586994,0.00061628746,0.0030805073],"study_design_scores_gemma":[0.011641342,0.00033209875,0.9863932,0.0008159263,0.00014979571,0.0000088169945,0.000014722511,0.000015387976,0.000005930557,0.00015907772,0.00031421415,0.00014945427],"about_ca_topic_score_codex":0.000028607825,"about_ca_topic_score_gemma":0.00015464134,"teacher_disagreement_score":0.011012458,"about_ca_system_score_codex":0.000032478667,"about_ca_system_score_gemma":0.00008736844,"threshold_uncertainty_score":0.60219055},"labels":[],"label_agreement":null},{"id":"W4409511411","doi":"10.2139/ssrn.5209620","title":"Assessing in silico Tools for Accurate Pathogenicity Prediction in CHD Nucleosome Remodelers","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Concordia University","funders":"","keywords":"In silico; Pathogenicity; Computational biology; Nucleosome; Computer science; Biology; Genetics; DNA; Histone; Microbiology; Gene","score_opus":0.0375328379167827,"score_gpt":0.32741582850256234,"score_spread":0.28988299058577965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409511411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812244,0.0026637428,0.008290275,0.003744492,0.00056332897,0.0018478913,0.00005328177,0.000072354116,0.001540212],"genre_scores_gemma":[0.9852493,0.005285522,0.0015508578,0.00010674153,0.0003180015,0.00018085049,0.00028774308,0.00004622134,0.006974794],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99589366,0.00014594494,0.0009456451,0.00058820785,0.00036548622,0.0020610522],"domain_scores_gemma":[0.9989342,0.00015364433,0.00034979233,0.0003033317,0.00014656669,0.00011242696],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002311915,0.00041816203,0.0007789324,0.00076141814,0.00012892816,0.00020180596,0.00023068942,0.00044693574,0.000016468015],"category_scores_gemma":[0.00030022382,0.00038526466,0.00031684057,0.00034386106,0.000029369072,0.00042863036,0.0001432079,0.004143804,0.0000059355866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0048612026,0.004333385,0.25583935,0.0021982372,0.0049368306,0.000532705,0.0055203936,0.01414015,0.0039184885,0.019828541,0.0012717831,0.682619],"study_design_scores_gemma":[0.06500366,0.0019535066,0.21699652,0.020538533,0.003468419,0.0022571837,0.01723761,0.11107085,0.0025086708,0.54528874,0.00949986,0.004176449],"about_ca_topic_score_codex":0.000049274688,"about_ca_topic_score_gemma":0.0011751519,"teacher_disagreement_score":0.6784425,"about_ca_system_score_codex":0.0065827346,"about_ca_system_score_gemma":0.010803162,"threshold_uncertainty_score":0.9998599},"labels":[],"label_agreement":null},{"id":"W4409839046","doi":"10.1101/2025.04.23.650336","title":"Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidine","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; University of Miami; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Leukemia and Lymphoma Society","keywords":"Epigenomics; Azacitidine; Computational biology; Oncology; Biology; Medicine; DNA methylation; Genetics; Gene","score_opus":0.012192651235979207,"score_gpt":0.24941946057419004,"score_spread":0.23722680933821083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409839046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283373,0.0018365538,0.00048600984,0.0017968204,0.00034340893,0.001819915,0.00060166256,0.0002562645,0.000025634825],"genre_scores_gemma":[0.9905626,0.0007071517,0.007764234,0.00022862165,0.000114615235,0.0002579052,0.000002728629,0.000057405512,0.0003047253],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969594,0.0003132494,0.0007854329,0.001096385,0.00035354783,0.00049196807],"domain_scores_gemma":[0.9974488,0.00031331193,0.0003163856,0.0009678609,0.00053152593,0.00042210976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011744625,0.0006283233,0.0010915285,0.0007252453,0.0001058659,0.00006454251,0.00034236145,0.0006742523,0.000060041508],"category_scores_gemma":[0.0007141295,0.0005427332,0.00017946091,0.0005514715,0.00019033154,0.000047273596,0.00058905565,0.00061846786,0.000019460915],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019784982,0.00032403905,0.050574142,0.0007579546,0.0007351195,0.00025545066,0.00005155218,0.000022316526,0.94406176,0.0003288923,0.0009027287,0.000007565239],"study_design_scores_gemma":[0.0011361795,0.00029949722,0.49889925,0.0014747622,0.0004271865,4.4615014e-8,0.0000076339875,0.0000323824,0.49190196,0.000006694461,0.0052719847,0.00054240326],"about_ca_topic_score_codex":0.000030971623,"about_ca_topic_score_gemma":0.0000024478686,"teacher_disagreement_score":0.45215976,"about_ca_system_score_codex":0.00032082424,"about_ca_system_score_gemma":0.0014236601,"threshold_uncertainty_score":0.9997024},"labels":[],"label_agreement":null},{"id":"W4409956934","doi":"10.1002/cpdd.1538","title":"A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Medicine; Tolerability; Dosing; Pharmacokinetics; Adverse effect; Pharmacology; Regimen; Internal medicine","score_opus":0.0388030569631078,"score_gpt":0.4428926940845356,"score_spread":0.40408963712142776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409956934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990444,0.00029698203,0.00033984543,0.0024755246,0.0006102137,0.0055321166,0.0000038464295,0.00003973336,0.00025774245],"genre_scores_gemma":[0.9938616,0.00026754383,0.004206635,0.0003719013,0.00006357885,0.00040610728,0.00008682676,0.000017046974,0.0007187451],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939614,0.0012756968,0.0032714016,0.0007354619,0.00034959635,0.00040647268],"domain_scores_gemma":[0.9968377,0.0020345207,0.0005054463,0.00018874799,0.00027762138,0.00015598575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0064850943,0.00034346135,0.0017213337,0.00032392147,0.0001022831,0.000011735475,0.00012884875,0.00014277853,0.00011614512],"category_scores_gemma":[0.0010398405,0.00029354467,0.00010871119,0.0005218897,0.00022183332,0.00011280863,0.00015434778,0.00054096576,0.0000060446137],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13356392,0.0069603543,0.7943307,0.00027007962,0.0007218755,0.00007381995,0.009340967,0.00018428535,0.0001366565,0.000019470062,0.00021995862,0.05417787],"study_design_scores_gemma":[0.68772066,0.0002249863,0.29170957,0.000687558,0.00062555633,0.0000035437204,0.00086892245,0.014794653,0.0027338522,0.00012962747,0.00020023582,0.0003008282],"about_ca_topic_score_codex":0.00007481312,"about_ca_topic_score_gemma":0.00020532556,"teacher_disagreement_score":0.5541567,"about_ca_system_score_codex":0.00041902342,"about_ca_system_score_gemma":0.0009219371,"threshold_uncertainty_score":0.99995166},"labels":[],"label_agreement":null},{"id":"W4410269180","doi":"10.1164/ajrccm.2025.211.abstracts.a1035","title":"Bedaquiline Adherence Predicts Retention-in-Care in Patients With Drug-Resistant Tuberculosis and HIV","year":2025,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; York University","funders":"","keywords":"Medicine; Bedaquiline; Tuberculosis; Human immunodeficiency virus (HIV); Drug resistant tuberculosis; Drug resistance; Drug; Medication adherence; Antiretroviral drug; Intensive care medicine; Mycobacterium tuberculosis; Antiretroviral therapy; Viral load; Virology; Internal medicine; Pharmacology; Microbiology; Pathology","score_opus":0.007172763908372606,"score_gpt":0.2693070734704969,"score_spread":0.2621343095621243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410269180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873335,0.0077718897,0.000019743591,0.003914772,0.000063113424,0.00022005655,0.0000088901825,0.000006720126,0.0006613363],"genre_scores_gemma":[0.9985481,0.0001053182,0.00038546612,0.000798753,0.00005166715,0.000008911929,0.00001015806,0.000010098993,0.00008153977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984516,0.00011898078,0.0005540419,0.00024272043,0.00040380924,0.00022884874],"domain_scores_gemma":[0.9988315,0.00022106052,0.000098128294,0.00013208867,0.00046919612,0.00024800425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024096017,0.00018721638,0.0006311212,0.00041117085,0.00005110357,0.000009583831,0.000058853348,0.00003948092,0.000024009045],"category_scores_gemma":[0.00035770584,0.0001219595,0.00003713783,0.0004696838,0.00070663635,0.000090800626,0.00002937997,0.00030416233,5.5806447e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019458485,0.00013678169,0.96185035,0.0003427781,0.00005721438,0.00030856568,0.0023557146,3.73061e-7,0.000039872462,0.00012061675,0.00025335667,0.032588515],"study_design_scores_gemma":[0.010014006,0.0067966445,0.9476435,0.004560336,0.00041236577,0.000015247393,0.028373407,0.0000035205062,0.0001034913,0.00004124839,0.0018818647,0.00015436606],"about_ca_topic_score_codex":0.000015150746,"about_ca_topic_score_gemma":0.000055120912,"teacher_disagreement_score":0.03243415,"about_ca_system_score_codex":0.00013332728,"about_ca_system_score_gemma":0.00020472168,"threshold_uncertainty_score":0.4973364},"labels":[],"label_agreement":null},{"id":"W4410345224","doi":"10.1097/qai.0000000000003694","title":"Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples","year":2025,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; AIDS Vancouver; University of British Columbia","funders":"","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Integrase; Gp41; Integrase inhibitor; Human immunodeficiency virus (HIV); Genetics; Virology; Pharmacology; Medicine; Biology; Antiretroviral therapy; Viral load","score_opus":0.03426196351191732,"score_gpt":0.32216391934843525,"score_spread":0.2879019558365179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410345224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379355,0.0022796874,0.00010928336,0.0028208324,0.00044679086,0.00026576134,0.000006112221,0.000021507278,0.00025646828],"genre_scores_gemma":[0.993189,0.000483881,0.0040670186,0.000034537974,0.000017561802,0.000011994041,0.000018864142,0.000016616723,0.0021605773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967755,0.00019693712,0.0021975217,0.00020152408,0.00038025161,0.00024823367],"domain_scores_gemma":[0.99813324,0.00073959795,0.0005626162,0.00023384752,0.00025886943,0.000071822265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020382514,0.00017057912,0.00077787106,0.0017273674,0.000045690056,0.000015906859,0.00017863572,0.00012180169,0.000012904727],"category_scores_gemma":[0.0021073562,0.00013792275,0.00022262978,0.002259539,0.00025311531,0.00021515736,0.000044645534,0.00018851823,0.000015502112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005619048,0.0007060467,0.9800253,0.00033288452,0.00022920957,0.00050205673,0.0037717966,0.000043271375,0.006636937,0.0011262567,0.0014848018,0.0045795245],"study_design_scores_gemma":[0.004239413,0.0002980142,0.97885984,0.0034125545,0.000153243,0.000056967976,0.003383826,0.000059340815,0.006284325,0.0029279573,0.00018570409,0.00013880475],"about_ca_topic_score_codex":0.000030970543,"about_ca_topic_score_gemma":0.00007874836,"teacher_disagreement_score":0.0044407197,"about_ca_system_score_codex":0.00020664238,"about_ca_system_score_gemma":0.0006918755,"threshold_uncertainty_score":0.56243265},"labels":[],"label_agreement":null},{"id":"W4410517499","doi":"10.1016/j.eclinm.2025.103246","title":"Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"EClinicalMedicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"B.C. Women's Hospital & Health Centre; St. Paul's Hospital; Simon Fraser University; Women's Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Meta-analysis; Integrase; Pharmacology; Traditional medicine; Virology; Human immunodeficiency virus (HIV); Internal medicine","score_opus":0.07914096702613073,"score_gpt":0.3779392754212757,"score_spread":0.298798308395145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410517499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008561989,0.9891911,0.00032607088,0.002207729,0.00006453184,0.007885207,0.000089737085,0.000019456205,0.00013050629],"genre_scores_gemma":[0.0016019767,0.98481196,0.00024324984,0.0005321247,0.00006583143,0.0019701656,0.0005543764,0.000023209384,0.0101971],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9946715,0.000794372,0.0031958588,0.0006874478,0.00042219055,0.0002285929],"domain_scores_gemma":[0.9955732,0.003101511,0.0003596122,0.00060899626,0.00011080087,0.0002458589],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.001486381,0.0006070647,0.015642446,0.0009462326,0.00003522576,0.000015317826,0.00014217179,0.00024487625,0.0001903941],"category_scores_gemma":[0.0021153323,0.0003233671,0.0017117261,0.0016253511,0.00008679116,0.00004580026,0.0000405959,0.000406807,0.00000961753],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005659347,0.00030687192,0.00003374923,0.89825994,0.09479023,0.00009733344,0.00025461736,4.1724945e-8,7.7350353e-7,0.00002229615,0.00036882842,0.0058596805],"study_design_scores_gemma":[0.00076655607,0.00017920238,0.000043511922,0.19640662,0.80117327,0.000012637084,0.000026163034,0.0000024748208,0.0000063670177,0.000006481214,0.001164992,0.00021174565],"about_ca_topic_score_codex":0.000018738989,"about_ca_topic_score_gemma":0.0005268669,"teacher_disagreement_score":0.706383,"about_ca_system_score_codex":0.000070929374,"about_ca_system_score_gemma":0.00033165212,"threshold_uncertainty_score":0.99992186},"labels":[],"label_agreement":null},{"id":"W4410716596","doi":"10.1080/07391102.2025.2507814","title":"A new strategy based on drug-linker-nanocarrier interactions to design new HIV-1 non-nucleoside reverse transcriptase inhibitors","year":2025,"lang":"en","type":"article","venue":"Journal of Biomolecular Structure and Dynamics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Linker; Nanocarriers; Human immunodeficiency virus (HIV); Drug; Chemistry; Virology; Pharmacology; Medicine; Antiretroviral therapy; Computer science; Biochemistry; Viral load; RNA","score_opus":0.006331688921812462,"score_gpt":0.2562699660311819,"score_spread":0.24993827710936944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410716596","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14986698,0.0003891139,0.81669205,0.030304717,0.001015226,0.00081573415,0.00006005045,0.00003019647,0.0008259142],"genre_scores_gemma":[0.90159327,0.000037752277,0.08627441,0.002769106,0.00018415756,0.000001962614,0.000049739898,0.000034239354,0.009055359],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987724,0.000047839814,0.00046311133,0.00022388232,0.0002802995,0.00021250852],"domain_scores_gemma":[0.9990257,0.000042526804,0.00014435378,0.00019979237,0.00011798263,0.00046963242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010364538,0.00025951027,0.00039540665,0.000549933,0.00008571087,0.00006176775,0.00009114206,0.00010235414,0.000065609005],"category_scores_gemma":[0.000040416613,0.00020024183,0.00019255442,0.0004509373,0.000025036932,0.00008702044,0.000015469961,0.0003140379,0.0000042996703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009271543,0.00076878944,0.010809097,0.00040756696,0.0031875297,0.0061500273,0.0040241177,0.008596363,0.20990749,0.0014992654,0.50257564,0.2428026],"study_design_scores_gemma":[0.08624278,0.009246533,0.031105742,0.013891953,0.013202542,0.0040971357,0.005999344,0.13355476,0.45568287,0.012463574,0.2301255,0.0043872627],"about_ca_topic_score_codex":0.000035601686,"about_ca_topic_score_gemma":0.00005066322,"teacher_disagreement_score":0.75172627,"about_ca_system_score_codex":0.00021537737,"about_ca_system_score_gemma":0.0009870768,"threshold_uncertainty_score":0.81656253},"labels":[],"label_agreement":null},{"id":"W4410796275","doi":"10.1016/j.jcv.2025.105807","title":"Clinical and sociodemographic correlates of emergent or evolving HIV drug resistance in low viral load specimens in British Columbia, Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"Canadian Institutes of Health Research","keywords":"HIV drug resistance; Viral load; Human immunodeficiency virus (HIV); Drug resistance; Resistance (ecology); Medicine; Virology; Demography; Gerontology; Antiretroviral therapy; Biology; Sociology; Genetics; Ecology","score_opus":0.01484598745115701,"score_gpt":0.3178696106527493,"score_spread":0.3030236232015923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410796275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873304,0.0028042605,0.000009080589,0.008552219,0.0007544281,0.0001988269,0.0000061424507,0.0000034199252,0.00034121747],"genre_scores_gemma":[0.98194325,0.0037892568,0.0011419503,0.0006930037,0.00010756618,0.0000032502128,0.0000025976774,0.00001002763,0.012309101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99551296,0.0004221293,0.0031775953,0.00028066372,0.00031743533,0.00028921655],"domain_scores_gemma":[0.997082,0.0017105639,0.00066982576,0.00015207977,0.00019710875,0.00018844967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025363413,0.00012026839,0.0013982587,0.00012898308,0.000037087673,0.000013396139,0.00013393746,0.0002485685,0.00022377538],"category_scores_gemma":[0.0021603033,0.0001293272,0.0002273211,0.00028787757,0.00037113228,0.000058040037,0.00006954143,0.00096235663,0.0000012977536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010473889,0.00074800465,0.96138024,0.000069978174,0.00026034415,0.0016634255,0.00007549034,0.0000020507853,0.0000044454864,0.000012994314,0.032957856,0.0017777844],"study_design_scores_gemma":[0.008512573,0.00020248136,0.98335713,0.00087817817,0.00014208413,0.000043018234,0.00013618308,0.00008516734,0.0000021993678,0.000646865,0.0059002917,0.000093821924],"about_ca_topic_score_codex":0.018716162,"about_ca_topic_score_gemma":0.9578813,"teacher_disagreement_score":0.93916506,"about_ca_system_score_codex":0.0001449777,"about_ca_system_score_gemma":0.0025623012,"threshold_uncertainty_score":0.9878183},"labels":[],"label_agreement":null},{"id":"W4411085041","doi":"10.1097/qad.0000000000004251","title":"Virological success despite archived INSTI drug resistance mutations on INSTI-based antiretroviral regimens","year":2025,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Antiretroviral therapy; Integrase; Regimen; Human immunodeficiency virus (HIV); Drug resistance; Viral load; Drug; Prospective cohort study; Mutation; Internal medicine; Virology; Oncology; Pharmacology; Biology; Genetics; Gene","score_opus":0.011668332086053822,"score_gpt":0.27981652661621315,"score_spread":0.2681481945301593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411085041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95179623,0.00011996901,0.0009815091,0.007961485,0.00015229722,0.0004223202,0.000014435214,0.00015522898,0.038396496],"genre_scores_gemma":[0.9309667,0.000014413636,0.006958088,0.0015298813,0.000033465338,0.00007113193,0.00015808796,0.000013555947,0.060254715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986882,0.00008625053,0.00027506432,0.00037830524,0.00025035313,0.00032181776],"domain_scores_gemma":[0.999209,0.00023651039,0.000059585967,0.00033002437,0.000053284966,0.00011161389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015558972,0.00020932981,0.0003155766,0.00030457356,0.00022541349,0.000026396594,0.00012114043,0.00006978816,0.000060061462],"category_scores_gemma":[0.00015393773,0.00016420509,0.000107960055,0.00038496513,0.00016901504,0.00005693781,0.00003911315,0.0002215296,0.000109046094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022218178,0.0016584756,0.93308866,0.00019519369,0.0004626309,0.0008189496,0.0009871855,0.00008296812,0.0026553161,0.02724539,0.016839903,0.013743483],"study_design_scores_gemma":[0.016472235,0.0012441061,0.8385126,0.0013782002,0.0007271988,0.000008411602,0.00023479057,0.000646483,0.035507236,0.0035980965,0.10087964,0.0007909944],"about_ca_topic_score_codex":0.000013891094,"about_ca_topic_score_gemma":0.000049246235,"teacher_disagreement_score":0.09457608,"about_ca_system_score_codex":0.00013020719,"about_ca_system_score_gemma":0.00026125056,"threshold_uncertainty_score":0.66960895},"labels":[],"label_agreement":null},{"id":"W4411242999","doi":"10.1007/s12686-025-01389-3","title":"Micro-tube reusability protocol for DNA shearing: an economical and eco-friendly option for DNA library preparations","year":2025,"lang":"en","type":"article","venue":"Conservation Genetics Resources","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canada Foundation for Innovation","keywords":"Reusability; Environmentally friendly; DNA; Protocol (science); Shearing (physics); Tube (container); Nanotechnology; Biochemical engineering; Biology; Materials science; Computer science; Engineering; Composite material; Ecology; Genetics; Operating system; Medicine","score_opus":0.032451339206708854,"score_gpt":0.33327144133924685,"score_spread":0.300820102132538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411242999","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9273412,0.00004020591,0.0019371818,0.008293667,0.000036090347,0.061423834,0.000047364843,0.00008667043,0.00079378905],"genre_scores_gemma":[0.11246368,0.00004037231,0.34288177,0.002470375,0.00045022674,0.49429467,0.0016660115,0.000114337,0.04561853],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989193,0.000040443323,0.00040566555,0.0003937793,0.00006633447,0.00017449429],"domain_scores_gemma":[0.99921507,0.00019562231,0.000090869486,0.00028797096,0.000107416694,0.00010303637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017133921,0.00015462375,0.00021777152,0.0001199931,0.00022180931,0.000108358334,0.00007900468,0.000117235715,0.000033339853],"category_scores_gemma":[0.00009438733,0.00014612939,0.00006360671,0.00010233578,0.000094547286,0.00014395727,0.000050713978,0.00005036694,0.000002912323],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041949414,0.0014822992,0.8793171,0.0018364367,0.0004763478,0.0000017347938,0.0035011275,0.00012223983,0.016557394,0.0052208374,0.06409123,0.023198288],"study_design_scores_gemma":[0.0038539302,0.00039743786,0.114194185,0.00008938481,0.00010446385,0.00000307127,0.00017627137,0.009175734,0.03727185,0.0019164623,0.832644,0.00017324345],"about_ca_topic_score_codex":0.0000017749484,"about_ca_topic_score_gemma":0.00001871632,"teacher_disagreement_score":0.8148775,"about_ca_system_score_codex":0.000057434798,"about_ca_system_score_gemma":0.00024342445,"threshold_uncertainty_score":0.59589833},"labels":[],"label_agreement":null},{"id":"W4411371017","doi":"10.1016/j.ijregi.2025.100685","title":"Real-world effectiveness, safety, and health-related quality of life in people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide—12-month results of the BICSTaR French cohort","year":2025,"lang":"en","type":"article","venue":"IJID Regions","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centers for Disease Control and Prevention; Académie canadienne du génie; Gilead Sciences","keywords":"Emtricitabine; Tenofovir alafenamide; Tenofovir; Human immunodeficiency virus (HIV); Medicine; Quality of life (healthcare); Gerontology; Virology; Antiretroviral therapy; Viral load; Nursing","score_opus":0.017033517147357333,"score_gpt":0.28069347827475677,"score_spread":0.2636599611273994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411371017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723805,0.0006599718,0.00012768178,0.015130285,0.00010475096,0.001701602,0.000049405495,0.000058716578,0.009787081],"genre_scores_gemma":[0.9880682,0.0008631787,0.00051574386,0.000056469347,0.000011228701,0.00005153617,0.00005946186,0.000022674007,0.010351457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717456,0.00053239067,0.0011451051,0.00044527868,0.0003648343,0.0003378223],"domain_scores_gemma":[0.9973665,0.00124258,0.0005103775,0.000596427,0.00014891467,0.00013523623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018593686,0.0002620204,0.0010414643,0.00048342248,0.0001791797,0.000009025831,0.00014237518,0.000105495026,0.0000064278383],"category_scores_gemma":[0.0006713797,0.00016971161,0.000113661845,0.0019344925,0.00021088886,0.000070234324,0.00012607189,0.0003061568,0.0000012508465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004798859,0.00037972126,0.99332845,0.00047083615,0.00034292517,0.000005274626,0.0021510234,0.00006172501,0.00009706998,0.0014383261,0.0008618212,0.00038294154],"study_design_scores_gemma":[0.004144025,0.00010877867,0.9906669,0.0038712232,0.00013456297,0.0000044078606,0.00030370735,0.000087198,0.0001047272,0.00020896146,0.00022323595,0.00014224443],"about_ca_topic_score_codex":0.019395499,"about_ca_topic_score_gemma":0.04919514,"teacher_disagreement_score":0.029799642,"about_ca_system_score_codex":0.00045391865,"about_ca_system_score_gemma":0.0014392878,"threshold_uncertainty_score":0.98713446},"labels":[],"label_agreement":null},{"id":"W4411658433","doi":"10.51847/yipcuwj","title":"10.51847/yIpCuwj","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Efavirenz; Lamivudine; Dosage form; Chromatography; Chemistry; Pharmacology; Medicine; Human immunodeficiency virus (HIV); Virology; Virus; Antiretroviral therapy; Viral load","score_opus":0.00655495715530934,"score_gpt":0.19930451817972433,"score_spread":0.19274956102441498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411658433","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062042573,0.000055248027,2.6471722e-7,0.002860318,0.000001814959,0.0002525429,0.0000038077148,0.00012139359,0.99050033],"genre_scores_gemma":[0.00063787546,9.0128987e-7,0.0005467499,0.00014312434,0.000084919775,0.000025530338,0.000044033197,0.000019283589,0.9984976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930733,0.0000111992995,0.00012920632,0.00017476935,0.00016678101,0.00021068491],"domain_scores_gemma":[0.999557,0.000017409602,0.000011162753,0.00020197817,0.000025951193,0.0001865027],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000058344758,0.00011810161,0.00017552618,0.00006631717,0.000045549787,0.00001119813,0.00005287236,0.000039916176,0.9936503],"category_scores_gemma":[0.000011720931,0.0000961996,0.000051053867,0.00015592687,0.0000149207035,0.00003165882,0.00001432496,0.000052177464,0.99221677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014012834,0.00013157247,0.000009533998,0.0000063335074,0.00006364035,0.0000668853,0.000052400705,0.0000016993695,0.00004405139,0.0000010547822,0.13895683,0.86052585],"study_design_scores_gemma":[0.00076625304,0.00010930964,0.00034023612,0.000032812084,0.000054884902,0.000026320948,0.0000011586345,0.000023776562,0.0001587274,0.0000010743975,0.9983794,0.0001060523],"about_ca_topic_score_codex":0.000004429217,"about_ca_topic_score_gemma":8.455524e-8,"teacher_disagreement_score":0.8604198,"about_ca_system_score_codex":0.00005629752,"about_ca_system_score_gemma":0.000047964215,"threshold_uncertainty_score":0.39229056},"labels":[],"label_agreement":null},{"id":"W4411686992","doi":"10.1093/jac/dkaf184","title":"Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tula Foundation","funders":"ViiV Healthcare; Gilead Sciences","keywords":"Rilpivirine; Discontinuation; Medicine; Human immunodeficiency virus (HIV); Cohort; Internal medicine; Intensive care medicine; Pharmacology; Antiretroviral therapy; Virology; Viral load","score_opus":0.011734513081147516,"score_gpt":0.2704345326795208,"score_spread":0.25870001959837324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411686992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995976,0.00015971286,0.0006600219,0.0024637652,0.00005771044,0.00055220036,0.000057342553,0.0000053508934,0.00006795223],"genre_scores_gemma":[0.99766374,0.0013442049,0.00066450326,0.00007097746,0.00004673915,0.0000037351792,0.00009044549,0.000013300986,0.000102350896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988276,0.00012261864,0.0005429815,0.0002072235,0.0001683972,0.00013122463],"domain_scores_gemma":[0.9987149,0.00040278936,0.00044025612,0.00028030257,0.000113661365,0.000048043312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043240152,0.00018279867,0.000716183,0.00011065146,0.000035675876,0.000014887563,0.00015790222,0.00007156147,0.00002440902],"category_scores_gemma":[0.000061434715,0.000097593154,0.00006970734,0.00020913202,0.0001061569,0.00011992781,0.000036235393,0.00012774991,2.2800971e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040287226,0.000679584,0.92120206,0.000048573478,0.0011350246,0.000026829082,0.0008112204,0.000029894616,0.070064515,0.0000046511486,0.000236189,0.0017327161],"study_design_scores_gemma":[0.008594814,0.00048072106,0.90445197,0.00067927653,0.00033695213,0.000018957926,0.000112291746,0.0000745977,0.08508667,0.0000043457126,0.00008937602,0.000070030364],"about_ca_topic_score_codex":0.00038231653,"about_ca_topic_score_gemma":0.00029289722,"teacher_disagreement_score":0.016750108,"about_ca_system_score_codex":0.00009695929,"about_ca_system_score_gemma":0.00032222742,"threshold_uncertainty_score":0.39797333},"labels":[],"label_agreement":null},{"id":"W4412024091","doi":"10.1101/2025.06.30.662352","title":"<i>N</i> -Alkyl Sulfamates as a New Class of nsP2 Cysteine Protease Inhibitors with Broad Spectrum Antialphaviral Activity","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Ontario Genomics; National Institutes of Health; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Genome Canada; McGill University; North Carolina Biotechnology Center; Bayer; Pfizer; Bristol-Myers Squibb","keywords":"Broad spectrum; Cysteine protease; Alkyl; Cysteine; Protease; Spectrum (functional analysis); Class (philosophy); Chemistry; Biochemistry; Enzyme; Physics; Combinatorial chemistry; Organic chemistry; Computer science","score_opus":0.00865248576534208,"score_gpt":0.22636534187023286,"score_spread":0.21771285610489077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412024091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903705,0.0008455543,0.0002734353,0.0038190251,0.0005674244,0.0032449784,0.00024428975,0.00046458706,0.00017019137],"genre_scores_gemma":[0.993233,0.00017685787,0.004421732,0.00016342168,0.00046225605,0.00027113716,0.000002871747,0.00012822665,0.0011404947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99622476,0.00012635242,0.0007743315,0.0013036466,0.00082220446,0.00074870116],"domain_scores_gemma":[0.9966712,0.00006315005,0.00069979724,0.0014686403,0.00039430204,0.0007029295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000363428,0.0009949673,0.0015196853,0.0006029544,0.00013491717,0.000100912985,0.00036070932,0.0005953886,0.00007191018],"category_scores_gemma":[0.00019499123,0.0008564984,0.00030431972,0.0009490731,0.00020664763,0.00017720161,0.00046837976,0.00092908205,0.00007426048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003725381,0.0031964625,0.16348259,0.00594748,0.0037109682,0.0017902232,0.00013061803,0.000036341462,0.8100783,0.0007764529,0.0070603755,0.000064767875],"study_design_scores_gemma":[0.004426708,0.00048152148,0.025469849,0.004095355,0.0010564866,2.7167965e-7,0.0000059048516,0.000060488335,0.95470285,0.0000035357862,0.008812933,0.00088407705],"about_ca_topic_score_codex":0.00059921324,"about_ca_topic_score_gemma":0.000020548636,"teacher_disagreement_score":0.14462453,"about_ca_system_score_codex":0.0005215658,"about_ca_system_score_gemma":0.006013074,"threshold_uncertainty_score":0.9996219},"labels":[],"label_agreement":null},{"id":"W4412048113","doi":"10.1136/bmjopen-2024-094384","title":"Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada","year":2025,"lang":"en","type":"article","venue":"BMJ Open","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Raltegravir; Medicine; Pharmacokinetics; Pharmacology; Tolerability; Dosing; Oral administration; Human immunodeficiency virus (HIV); Adverse effect; Virology; Antiretroviral therapy; Viral load","score_opus":0.07481423031424839,"score_gpt":0.4500005682025587,"score_spread":0.3751863378883103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412048113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6223006,7.7221233e-7,0.000011882043,0.00033488497,0.000011625177,0.37659177,0.00010334928,0.0000023421587,0.0006427097],"genre_scores_gemma":[0.66007835,2.3147143e-7,0.00074897736,0.000057080393,0.0000020826392,0.3377198,0.00003761876,0.000011076605,0.0013447629],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982817,0.00012472988,0.0006532025,0.00035077397,0.00033627232,0.00025331226],"domain_scores_gemma":[0.9991892,0.00009039028,0.00027056114,0.00020034042,0.00018558538,0.000063950036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005397475,0.00021860519,0.0007018976,0.00016211957,0.000034658966,0.000025386871,0.0002941687,0.00001926852,0.000013837301],"category_scores_gemma":[0.00004404338,0.00016357019,0.000018542793,0.00046108948,0.00004055992,0.0001269445,0.00016772553,0.00012524577,4.236051e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067439675,0.0039001347,0.91285163,0.0007154282,0.00037001408,0.000121162935,0.009365133,0.0013938164,0.00065881596,0.000047982117,0.0014278523,0.0017083561],"study_design_scores_gemma":[0.61349374,0.0032632253,0.3502299,0.0031108737,0.00024890236,0.000002215446,0.0070339027,0.0059528584,0.015843796,0.000022366303,0.00041604388,0.00038221633],"about_ca_topic_score_codex":0.29545826,"about_ca_topic_score_gemma":0.65545005,"teacher_disagreement_score":0.5626218,"about_ca_system_score_codex":0.0007945104,"about_ca_system_score_gemma":0.004450274,"threshold_uncertainty_score":0.7894595},"labels":[],"label_agreement":null},{"id":"W4412146868","doi":"10.1002/jia2.26470","title":"Persistent sex disparities in access to dolutegravir‐based antiretroviral therapy in Latin America and the Caribbean: results from a retrospective observational study using data from 2017 to 2022","year":2025,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; U.S. National Library of Medicine; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Drug Abuse; Fogarty International Center; National Institute of Mental Health; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Vanderbilt University Medical Center; Vanderbilt University","keywords":"Dolutegravir; Medicine; Latin Americans; Observational study; Antiretroviral therapy; Retrospective cohort study; Family medicine; Human immunodeficiency virus (HIV); Internal medicine; Viral load","score_opus":0.12615311769085685,"score_gpt":0.3716301668033199,"score_spread":0.24547704911246304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412146868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95670384,0.00015108082,0.00012919633,0.041593436,0.00034135242,0.0005300417,0.00047022433,0.000003347873,0.00007746983],"genre_scores_gemma":[0.99180317,0.00006333424,0.004188301,0.0027711282,0.00014425041,0.00001187965,0.00008554111,0.000007493255,0.00092488836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982368,0.00013449044,0.0005420064,0.00026915685,0.0006906964,0.00012684538],"domain_scores_gemma":[0.9987772,0.00043560588,0.00024662065,0.00030906405,0.00018394578,0.00004757826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006710858,0.0001466395,0.00036877088,0.00011764499,0.0001071533,0.0001336604,0.00074614654,0.000039093888,0.000018934332],"category_scores_gemma":[0.00040887552,0.00008261835,0.0001753558,0.0004038742,0.0000762975,0.00021018986,0.0004571707,0.00034573855,7.1190163e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016571698,0.0003757723,0.9820208,0.000001826335,0.0008304015,0.000012898613,0.005245535,0.00037562923,0.00026362573,0.000019080704,0.008764102,0.00043317775],"study_design_scores_gemma":[0.008514313,0.0001512598,0.9765976,0.00023048566,0.000093321665,0.0000016849323,0.004163596,0.009053154,0.00008405419,0.00028804567,0.0007426047,0.00007989228],"about_ca_topic_score_codex":0.004804741,"about_ca_topic_score_gemma":0.00069034775,"teacher_disagreement_score":0.03882231,"about_ca_system_score_codex":0.0007023544,"about_ca_system_score_gemma":0.00032113394,"threshold_uncertainty_score":0.7263363},"labels":[],"label_agreement":null},{"id":"W4412427036","doi":"10.1093/infdis/jiaf362","title":"Fetal Defects in Mice Treated With Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir, and Cabotegravir","year":2025,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Toronto General Hospital; University Health Network","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Ontario HIV Treatment Network","keywords":"Dolutegravir; Raltegravir; Emtricitabine; Biology; Medicine; Internal medicine; Virology; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.007115393526495005,"score_gpt":0.26262549842359806,"score_spread":0.2555101048971031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412427036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275464,0.005412769,0.00027452133,0.00033353898,0.00007739518,0.00055210927,0.000027073487,0.000026278361,0.0005416811],"genre_scores_gemma":[0.9986671,0.00073932955,0.00006281055,0.000060244653,0.000042284297,0.000010795161,0.000017197246,0.000023564058,0.00037667103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981427,0.0002318182,0.0007952986,0.00018551837,0.0003666885,0.0002779774],"domain_scores_gemma":[0.998793,0.00035436059,0.00021655302,0.00019258112,0.00024228808,0.0002012342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030228213,0.00034866366,0.00089273124,0.00064116204,0.000112417474,0.000031355215,0.00011858637,0.00010110509,0.000020407231],"category_scores_gemma":[0.00008087516,0.00018691103,0.0001993373,0.0007998523,0.00029860451,0.00014648432,0.000018860112,0.0004572514,0.000001778277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003994212,0.0018940797,0.97975534,0.00021783373,0.0008844559,0.00014048182,0.0012318684,0.00007223205,0.004659367,0.00013849756,0.0004106458,0.0066010007],"study_design_scores_gemma":[0.0342021,0.0041040294,0.8808337,0.0052119526,0.008250997,0.0006990329,0.006155139,0.00016878857,0.05814479,0.0009201463,0.0006793777,0.00062997214],"about_ca_topic_score_codex":0.00037806612,"about_ca_topic_score_gemma":0.000717553,"teacher_disagreement_score":0.09892165,"about_ca_system_score_codex":0.00015645094,"about_ca_system_score_gemma":0.00043379664,"threshold_uncertainty_score":0.7622011},"labels":[],"label_agreement":null},{"id":"W4412467682","doi":"10.1093/ofid/ofaf356","title":"Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Adverse effect; Regimen; Interquartile range; Randomized controlled trial; Internal medicine; African american; Clinical trial; Race (biology); Post-hoc analysis; Demography","score_opus":0.0420978437707997,"score_gpt":0.40809201455333516,"score_spread":0.3659941707825355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412467682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98664457,0.0014743797,0.00032119596,0.0042591854,0.0001483609,0.0025128813,0.0011003858,0.00006758707,0.0034714867],"genre_scores_gemma":[0.9932467,0.0005164753,0.000120993995,0.00042177323,0.000039920895,0.000071287795,0.0011531361,0.000019989819,0.004409757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977102,0.0002919069,0.0010375342,0.0005469681,0.00017815974,0.00023520754],"domain_scores_gemma":[0.99684983,0.0020122465,0.00033414928,0.0004387418,0.00007455554,0.0002904936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008679356,0.00025861696,0.0010840241,0.00010955027,0.00017218525,0.00009142867,0.00011312008,0.00011709412,0.00010480092],"category_scores_gemma":[0.0015040569,0.00019860725,0.00014643933,0.00017809785,0.00020349748,0.0001131322,0.00020968923,0.00012591683,0.000008988878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011389124,0.003004219,0.8906732,0.000060756596,0.0009655182,0.00006167325,0.000042656287,9.101261e-7,0.00008209528,0.00007151339,0.0244082,0.069240116],"study_design_scores_gemma":[0.17875135,0.0014044456,0.80108553,0.0009927598,0.003014892,0.0000072262765,0.00005261459,0.00013770533,0.0020654807,0.0005637264,0.011527894,0.00039640663],"about_ca_topic_score_codex":0.000112728914,"about_ca_topic_score_gemma":0.00012598647,"teacher_disagreement_score":0.16736223,"about_ca_system_score_codex":0.000053269014,"about_ca_system_score_gemma":0.0003257641,"threshold_uncertainty_score":0.8098968},"labels":[],"label_agreement":null},{"id":"W4412782083","doi":"10.1111/hiv.70086","title":"The association between <scp>HIV</scp> drug resistance testing, viral suppression and mortality in Ontario: a retrospective cohort study","year":2025,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sinai Health System; University Health Network; Programs for Assessment of Technology in Health Research Institute; Toronto Public Health; St. Michael's Hospital; Population Health Research Institute; McMaster University; Impact; Women's College Hospital; Hamilton Health Sciences; University of Toronto; Public Health Ontario; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"Canada Research Chairs; Ministry of Long-Term Care; Ontario HIV Treatment Network; Department of Family and Community Medicine, University of Toronto; University of Toronto; Ministry of Health, Ontario","keywords":"Medicine; Viral load; Retrospective cohort study; Cohort; Odds ratio; Logistic regression; Drug resistance; Internal medicine; Cohort study; Regimen; HIV drug resistance; Odds; Immunology; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.013118421047896291,"score_gpt":0.27581386937361574,"score_spread":0.26269544832571945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412782083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581296,0.00030856248,0.000011336724,0.004080471,0.00017431061,0.0013931416,0.000005945951,0.00005554926,0.035841096],"genre_scores_gemma":[0.7799375,0.0000298913,0.000105685525,0.00008662311,0.00008048301,0.00008259948,0.00006461596,0.000010305827,0.21960227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786925,0.00015835276,0.0005082944,0.0004481646,0.00068571174,0.00033023217],"domain_scores_gemma":[0.9982196,0.00097637234,0.00019914917,0.00033512607,0.0001656992,0.00010402706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016555361,0.00022531797,0.0006142508,0.00014337551,0.00024036187,0.000021763848,0.00008999451,0.00008016327,0.000014166096],"category_scores_gemma":[0.0019504449,0.0001417645,0.00003224755,0.00042811732,0.000100378165,0.00006429048,0.00007658486,0.0004480264,0.000010054516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029996036,0.00016324906,0.95039725,0.000021731707,0.00034249024,0.000050891147,0.0039665466,9.0441524e-8,0.00003107712,0.000087872555,0.044826347,0.00008248448],"study_design_scores_gemma":[0.0042354204,0.00008228157,0.9805799,0.00054383435,0.00057164347,8.476249e-7,0.0012136853,0.000009560689,0.0000766992,0.00047704112,0.012156815,0.00005223453],"about_ca_topic_score_codex":0.004778259,"about_ca_topic_score_gemma":0.08407709,"teacher_disagreement_score":0.18376118,"about_ca_system_score_codex":0.0013808482,"about_ca_system_score_gemma":0.000244153,"threshold_uncertainty_score":0.93263614},"labels":[],"label_agreement":null},{"id":"W4412938215","doi":"10.1016/s2352-3018(25)00131-6","title":"Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process","year":2025,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; St. Michael's Hospital","funders":"Center for AIDS Research, University of Washington; National Institutes of Health; Indian Council of Medical Research; Moderna; Cilag; Novocure; Amgen; ViiV Healthcare; Biogen; Gilead Sciences; Sanofi; Bristol-Myers Squibb; AstraZeneca; Pfizer; Queen Mary University of London; Emory University","keywords":"Rilpivirine; Medicine; Discontinuation; Tenofovir; Human immunodeficiency virus (HIV); Family medicine; Internal medicine; Antiretroviral therapy; Viral load","score_opus":0.0858507870796823,"score_gpt":0.35256378575541253,"score_spread":0.26671299867573023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412938215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898299,0.00018091447,0.0002037885,0.0086650755,0.00002616587,0.0007688471,0.00007484585,0.000019823316,0.00023062361],"genre_scores_gemma":[0.99859506,0.00017162983,0.00055229204,0.0001388553,0.00005014173,0.00009606837,0.00016790794,0.000006777933,0.00022127149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993007,0.00010706193,0.00017601797,0.00018769149,0.000105488165,0.00012303643],"domain_scores_gemma":[0.9990226,0.0006307675,0.00008147769,0.00013182401,0.00010663953,0.000026696676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007019128,0.00010481923,0.00024740366,0.000049054044,0.00019364744,0.00008090878,0.000078182995,0.000032878255,0.0000073626643],"category_scores_gemma":[0.00032201209,0.00005672535,0.000014146367,0.00011827786,0.00010390255,0.00010989562,0.00004188056,0.00010608301,1.7772408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006443496,0.00022782345,0.9892732,0.00002766235,0.00021189643,0.0000031468392,0.0037442828,0.0000050230096,0.00022556598,0.00054382725,0.00030606435,0.0047871904],"study_design_scores_gemma":[0.0039808806,0.00016839687,0.9894938,0.000069986505,0.00008141969,0.000012885161,0.003911687,0.00077413814,0.00018464257,0.000992355,0.0002541839,0.000075645585],"about_ca_topic_score_codex":0.00006701206,"about_ca_topic_score_gemma":0.00089487527,"teacher_disagreement_score":0.00876514,"about_ca_system_score_codex":0.000012489046,"about_ca_system_score_gemma":0.00004103627,"threshold_uncertainty_score":0.23131926},"labels":[],"label_agreement":null},{"id":"W4413108968","doi":"10.1111/apt.70327","title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment","year":2025,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Toronto Liver Centre; University of Toronto","funders":"Gilead Sciences","keywords":"Tenofovir alafenamide; Tenofovir; Medicine; Hepatitis B; Internal medicine; Emtricitabine; Chronic hepatitis; Virology; Human immunodeficiency virus (HIV); Pharmacology; Lamivudine; Viral load; Virus; Antiretroviral therapy","score_opus":0.011533508807962407,"score_gpt":0.294771667927084,"score_spread":0.2832381591191216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413108968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931426,0.0035255386,0.000010530043,0.0015104394,0.00017299563,0.0013197403,0.00011228908,0.000015925527,0.00018994536],"genre_scores_gemma":[0.99414575,0.004248222,0.0002857252,0.00049242895,0.000011928026,0.00005121156,0.00019414588,0.000025331003,0.00054525124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823624,0.0001754349,0.0007000305,0.00037107067,0.00018895089,0.00032824877],"domain_scores_gemma":[0.9993021,0.000136603,0.00023004126,0.00019420333,0.00004527607,0.000091797905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017073572,0.00029845198,0.00077506626,0.00023575418,0.00005833952,0.0000035648573,0.000096595024,0.00012518697,0.000048472295],"category_scores_gemma":[0.0000010307282,0.00026834733,0.000120780045,0.00029687068,0.00026431362,0.00007657846,0.000097198215,0.00014003864,0.0000013458675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020326462,0.002500337,0.7994163,0.00016509106,0.011883024,0.00003805003,0.0027277514,0.000010212126,0.14071456,0.00001514727,0.00014032338,0.040356558],"study_design_scores_gemma":[0.05474421,0.003846077,0.77172625,0.00048658563,0.01306167,0.000005564977,0.00040322245,0.0004235072,0.15193294,0.00005524739,0.0028849058,0.0004298054],"about_ca_topic_score_codex":0.00041627808,"about_ca_topic_score_gemma":0.00017971307,"teacher_disagreement_score":0.05271156,"about_ca_system_score_codex":0.00052620686,"about_ca_system_score_gemma":0.0002758815,"threshold_uncertainty_score":0.9999769},"labels":[],"label_agreement":null},{"id":"W4413109677","doi":"10.1093/jac/dkaf281","title":"A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study","year":2025,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"","keywords":"Rilpivirine; Discontinuation; Regimen; Medicine; Internal medicine; Prospective cohort study; Dolutegravir; Proportional hazards model; Adverse effect; Viral load; Surgery; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology","score_opus":0.006782796883800142,"score_gpt":0.2782817854096676,"score_spread":0.27149898852586746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413109677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955828,0.00009592816,0.000025501386,0.0010494966,0.00006918119,0.002990199,0.0000028139063,0.00000916334,0.00017489349],"genre_scores_gemma":[0.9994517,0.00022515342,0.00006892197,0.0000733451,0.00003178328,0.000011643187,0.0000014144188,0.000019588093,0.000116465315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834055,0.00024795014,0.00065311807,0.0003056883,0.00025620958,0.0001964965],"domain_scores_gemma":[0.99880606,0.00033282247,0.00033728936,0.00022232861,0.00023212614,0.00006938606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013112087,0.00025235853,0.0008500937,0.00019416855,0.00011537658,0.000031150772,0.0000917292,0.00005951814,0.0000059909235],"category_scores_gemma":[0.00015192524,0.00015767587,0.00008903258,0.0003687195,0.000105747764,0.00009737466,0.00004438531,0.00034215514,4.7844367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073939404,0.0049019554,0.9758282,0.00010470102,0.001357795,0.00012119668,0.0059501855,0.000021144475,0.0030382131,0.0000023007094,0.000015461253,0.0012649543],"study_design_scores_gemma":[0.015622464,0.0009178904,0.97269493,0.00042434945,0.00026578893,0.00003585538,0.0028311613,0.000010125303,0.007071564,0.000007837428,0.0000072797893,0.00011077779],"about_ca_topic_score_codex":0.0003560143,"about_ca_topic_score_gemma":0.0018385864,"teacher_disagreement_score":0.008228525,"about_ca_system_score_codex":0.00026781528,"about_ca_system_score_gemma":0.00023826295,"threshold_uncertainty_score":0.6429835},"labels":[],"label_agreement":null},{"id":"W4413185250","doi":"10.1093/narmme/ugaf029","title":"Mechanism and spectrum of inhibition of viral polymerases by 2′-deoxy-2′-β-fluoro-4′-azidocytidine or azvudine","year":2025,"lang":"en","type":"article","venue":"NAR Molecular Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Virology; Polymerase; RNA polymerase; Biology; Coronavirus; Reverse transcriptase; RNA-dependent RNA polymerase; Virus; RNA; Viral replication; Enzyme; Medicine; Gene; Coronavirus disease 2019 (COVID-19); Biochemistry","score_opus":0.0064180976867987,"score_gpt":0.25962139787698113,"score_spread":0.25320330019018245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413185250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96213645,0.008469525,0.003293834,0.02176319,0.0001427487,0.0007307632,0.00003126664,0.000058653855,0.0033735891],"genre_scores_gemma":[0.99151975,0.0006799636,0.0010155009,0.00070479856,0.000046211102,0.000020866115,0.00016713177,0.000023904659,0.0058218814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998385,0.000048131224,0.0005724328,0.000323343,0.00043019874,0.00024089498],"domain_scores_gemma":[0.9992513,0.0000725986,0.00016527285,0.00028350693,0.000096668875,0.00013064854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020666438,0.000256869,0.00073108013,0.000370493,0.00004297324,0.0000027390136,0.00005905383,0.00011469247,0.00031215936],"category_scores_gemma":[0.0001683837,0.00018113795,0.000075547396,0.0004799943,0.00021771966,0.000042359457,0.000062364605,0.00013203596,0.0000034795826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007812263,0.00039488985,0.0012341195,0.00043917942,0.00045666526,0.00031228483,0.0003081249,2.5714527e-7,0.974971,0.010450765,0.0076060086,0.0030455065],"study_design_scores_gemma":[0.007492579,0.0011051565,0.0006146957,0.0012098409,0.0005740679,0.00006597413,0.00021864614,0.00004991109,0.98404837,0.0019455634,0.0025334575,0.00014174274],"about_ca_topic_score_codex":0.00009456017,"about_ca_topic_score_gemma":0.0000066951493,"teacher_disagreement_score":0.029383313,"about_ca_system_score_codex":0.00006744222,"about_ca_system_score_gemma":0.00014958822,"threshold_uncertainty_score":0.73865914},"labels":[],"label_agreement":null},{"id":"W4413324424","doi":"10.1101/2025.08.15.25333258","title":"The dolutegravir failure cohort: a multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Dolutegravir; Darunavir; Medicine; Cohort; Virology; Human immunodeficiency virus (HIV); Internal medicine; Antiretroviral therapy; Viral load","score_opus":0.04358908550069654,"score_gpt":0.35133559392906044,"score_spread":0.30774650842836393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413324424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7378203,0.00007702997,0.00005791245,0.0014407277,0.0004684861,0.25908685,0.00008377183,0.00009360734,0.00087129395],"genre_scores_gemma":[0.6519277,0.000084244515,0.000953523,0.000060760292,0.00025838998,0.34444806,0.00015025689,0.000114705996,0.002002382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895259,0.0016843427,0.003080187,0.0023390672,0.0021318102,0.0012386675],"domain_scores_gemma":[0.99253416,0.0026376157,0.0011774125,0.002730085,0.00050811947,0.00041257756],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.006658678,0.001513419,0.0038106497,0.0007499517,0.00033666822,0.00018847451,0.001315501,0.00071584346,0.00002769647],"category_scores_gemma":[0.0009806309,0.00078631466,0.0005673799,0.00218989,0.0004212544,0.00009333509,0.0005732041,0.0033914223,0.00003339875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44914678,0.0049882564,0.5397848,0.00018750512,0.002015706,0.0003939514,0.0012725162,0.000056939472,0.000020064756,0.000016914153,0.0010425481,0.0010740235],"study_design_scores_gemma":[0.4301201,0.0042095706,0.55016065,0.0022540377,0.0014537498,0.000009889964,0.0005321918,0.00009751425,0.0001338786,0.000014505609,0.010278356,0.0007355857],"about_ca_topic_score_codex":0.0010208463,"about_ca_topic_score_gemma":0.04675085,"teacher_disagreement_score":0.08589264,"about_ca_system_score_codex":0.0008427891,"about_ca_system_score_gemma":0.0028280928,"threshold_uncertainty_score":0.99976146},"labels":[],"label_agreement":null},{"id":"W4413500380","doi":"10.1177/09564624251371800","title":"Real-world persistence of bictegravir versus dolutegravir single-tablet regimens: A retrospective cohort study in a large urban Canadian HIV clinic","year":2025,"lang":"en","type":"article","venue":"International Journal of STD & AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada); Maple Leaf Medical Clinic; Women's College Hospital; University of Toronto","funders":"Gilead Sciences","keywords":"Discontinuation; Medicine; Adverse effect; Dolutegravir; Internal medicine; Retrospective cohort study; Emtricitabine; Tenofovir alafenamide; Viral load; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","score_opus":0.02504963118491734,"score_gpt":0.3167568690692242,"score_spread":0.29170723788430686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413500380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95535564,0.00019916237,0.000017629452,0.0022235,0.0010257208,0.0004781496,0.000058723457,0.00001031817,0.040631134],"genre_scores_gemma":[0.9735347,0.00011425902,0.0009527162,0.00011079976,0.0001282514,0.000013198132,0.000027567261,0.000014690887,0.025103806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763566,0.000096819094,0.000901598,0.00026319426,0.0008165407,0.00028618245],"domain_scores_gemma":[0.9981323,0.00016269101,0.00039808138,0.00020898509,0.0009168234,0.00018110745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009137206,0.00020225917,0.00062515127,0.0016414727,0.000050031693,0.000033439894,0.00033297908,0.000069384834,0.00027377324],"category_scores_gemma":[0.0003023445,0.00017181771,0.00021717575,0.00067106803,0.00006982852,0.00013674039,0.00005476127,0.00040664518,0.000017227416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014008707,0.0012166369,0.9877372,0.000008726363,0.001915853,0.00079773314,0.0012511166,0.0000018367867,0.0000808882,0.0007381565,0.004414655,0.00043632815],"study_design_scores_gemma":[0.010040148,0.0010508538,0.97770756,0.00071059464,0.00041099882,0.000029307554,0.0027502466,0.000020014168,0.00018245766,0.00015276158,0.006806276,0.00013880154],"about_ca_topic_score_codex":0.0070530577,"about_ca_topic_score_gemma":0.050102297,"teacher_disagreement_score":0.04304924,"about_ca_system_score_codex":0.0026110276,"about_ca_system_score_gemma":0.0012205045,"threshold_uncertainty_score":0.99955904},"labels":[],"label_agreement":null},{"id":"W4413940363","doi":"10.1002/bcp.70209","title":"Therapeutic drug monitoring of dolutegravir in children and adolescents living with HIV: A retrospective study","year":2025,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval; Centre Hospitalier Universitaire Sainte-Justine; Children's Hospital of Eastern Ontario; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Dolutegravir; Medicine; Drug; Retrospective cohort study; Human immunodeficiency virus (HIV); Pediatrics; Therapeutic drug monitoring; Pharmacology; Antiretroviral therapy; Internal medicine; Virology; Viral load","score_opus":0.017252828810309876,"score_gpt":0.37220630591843484,"score_spread":0.35495347710812497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413940363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680316,0.0018404655,0.000015536456,0.00045387333,0.0003388489,0.00045438285,0.0000018665601,0.000006267726,0.000085615444],"genre_scores_gemma":[0.99759865,0.0013101677,0.00035564855,0.0001264979,0.00022053326,0.000005986196,3.991281e-7,0.000010426891,0.00037171287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998154,0.0003127974,0.00094928365,0.00019734752,0.00021114093,0.00017545374],"domain_scores_gemma":[0.999091,0.00021935014,0.00034702712,0.00005831544,0.00017484323,0.00010945718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010506402,0.0001153094,0.000775003,0.00017807823,0.000038403272,0.000011643774,0.000097664895,0.000062113824,0.000020078847],"category_scores_gemma":[0.00012582126,0.00009977993,0.000092685754,0.00022089864,0.00010006329,0.00007049052,0.0000528286,0.0006616898,8.2092697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006853063,0.002873228,0.9783268,0.000024735406,0.0009985251,0.00046512505,0.0002531997,0.000001904221,0.000052602434,0.0000012873917,0.000443354,0.01587394],"study_design_scores_gemma":[0.012328518,0.0005388112,0.9838909,0.0016594667,0.000569538,0.00040750517,0.00038746934,0.0000053014796,0.000097913275,0.000028369179,0.000017136827,0.00006905848],"about_ca_topic_score_codex":0.000030229081,"about_ca_topic_score_gemma":0.000020400274,"teacher_disagreement_score":0.015804881,"about_ca_system_score_codex":0.000071420814,"about_ca_system_score_gemma":0.00023498427,"threshold_uncertainty_score":0.40689075},"labels":[],"label_agreement":null},{"id":"W4414129354","doi":"10.1097/qai.0000000000003763","title":"HIV Drug Resistance Among Key Populations in Nigeria: Insights From the 2020 Integrated Biological and Behavioral Surveillance Survey","year":2025,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada; Manitoba Health","funders":"Canada Research Chairs; Global Fund to Fight AIDS, Tuberculosis and Malaria","keywords":"Key (lock); Human immunodeficiency virus (HIV); Drug resistance; Efavirenz; Resistance (ecology); Public health surveillance; Drug","score_opus":0.02960381627684115,"score_gpt":0.29131580987240147,"score_spread":0.2617119935955603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414129354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848892,0.011528603,0.0000788904,0.0026253588,0.00041425243,0.00028419634,0.000034813613,0.000022666452,0.00012198184],"genre_scores_gemma":[0.99448663,0.0007366447,0.0008147854,0.000029521187,0.000017904298,0.000009721807,0.00013243582,0.000014350707,0.0037580356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759126,0.00048845186,0.001041609,0.00028374963,0.0003140612,0.0002808923],"domain_scores_gemma":[0.9984467,0.0005809167,0.00034796895,0.00029688154,0.00024967798,0.000077837394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009798758,0.00025478224,0.000746061,0.00032077255,0.00019934317,0.00006806196,0.0002669314,0.000119915996,0.000040791445],"category_scores_gemma":[0.0006198345,0.00014993735,0.00013724294,0.0013818145,0.000284672,0.00018323012,0.000086117136,0.00022021227,0.000010889946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002781736,0.00029291966,0.9945934,0.00000844693,0.000086790715,0.00022690551,0.0013330017,0.000004462835,0.0005894184,0.000050330265,0.0022102986,0.00032586418],"study_design_scores_gemma":[0.0016028271,0.00006530768,0.9954686,0.00042655063,0.0000524476,0.000038317383,0.0012246274,0.000027215994,0.00015712754,0.00035510655,0.00043800697,0.00014386272],"about_ca_topic_score_codex":0.00021253541,"about_ca_topic_score_gemma":0.0020008453,"teacher_disagreement_score":0.010791958,"about_ca_system_score_codex":0.00015728311,"about_ca_system_score_gemma":0.00022342584,"threshold_uncertainty_score":0.6114268},"labels":[],"label_agreement":null},{"id":"W4414439845","doi":"10.1093/jac/dkaf345","title":"Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Antimicrobial Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"Ministero della Salute; ViiV Healthcare; Gilead Sciences","keywords":"Antiretroviral therapy; Cohort; Cohort study; Human immunodeficiency virus (HIV); Foundation (evidence); Randomized controlled trial; Sida; MEDLINE","score_opus":0.01915368196622881,"score_gpt":0.28718541864323444,"score_spread":0.26803173667700564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414439845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98906606,0.00025468392,0.0012936813,0.008287462,0.00015097157,0.00060236885,0.00005147369,0.000011636627,0.0002816403],"genre_scores_gemma":[0.99341214,0.0038971836,0.0013009312,0.0004786535,0.00013233721,0.0000030155584,0.00022311826,0.000028376833,0.00052427023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985384,0.00014279273,0.00056392926,0.00026647758,0.00028861102,0.00019980114],"domain_scores_gemma":[0.9985435,0.00036451127,0.0003811218,0.00045836566,0.00019630272,0.000056213317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080188387,0.00023999455,0.0007108962,0.00020216264,0.00007725003,0.00003421948,0.00035461664,0.000096231895,0.00006880085],"category_scores_gemma":[0.000054576034,0.00014033426,0.00012729599,0.0004591702,0.00014467534,0.00019660754,0.00003648794,0.000283719,0.0000036579825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077530057,0.000859533,0.9427413,0.000090788846,0.001492977,0.000047535028,0.00051306735,0.000018840665,0.0379579,0.000038535047,0.006012431,0.0024741075],"study_design_scores_gemma":[0.023251943,0.0007458537,0.90988284,0.0023055293,0.00030612067,0.000050423852,0.00017605357,0.0002807557,0.057998914,0.000041029354,0.004732049,0.00022847307],"about_ca_topic_score_codex":0.0003106174,"about_ca_topic_score_gemma":0.00011519387,"teacher_disagreement_score":0.032858428,"about_ca_system_score_codex":0.00014553913,"about_ca_system_score_gemma":0.0005499823,"threshold_uncertainty_score":0.57226646},"labels":[],"label_agreement":null},{"id":"W4414548305","doi":"10.1097/qad.0000000000004261","title":"Off target effects of HIV integrase strand transfer inhibitors in cell and animal models: a scoping review","year":2025,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"B.C. Women's Hospital & Health Centre; Women's Health Research Institute; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Integrase; Adverse effect; Lentivirus; Human immunodeficiency virus (HIV); In vivo; Cell; In vitro; Integrase inhibitor; Clinical trial","score_opus":0.008712050014593175,"score_gpt":0.26080972001344555,"score_spread":0.25209766999885236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414548305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.884621,0.108857,0.0006048342,0.00088984834,0.000047311078,0.0014344422,0.000003966662,0.000022229193,0.0035193565],"genre_scores_gemma":[0.98478174,0.0124857705,0.001423737,0.00020027932,0.00000936112,0.000051734063,0.00001595993,0.00000950089,0.0010219376],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9992197,0.000042416938,0.00029387124,0.0001894955,0.00011194279,0.00014252923],"domain_scores_gemma":[0.99970424,0.00008763872,0.000016997948,0.00010798727,0.000026454647,0.000056684818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015908289,0.00013565531,0.0004380507,0.00015451784,0.000016679924,0.000004284748,0.000031291023,0.00005037236,0.000020137184],"category_scores_gemma":[0.000028419492,0.00010459929,0.000059488248,0.0002638801,0.000035569043,0.00006544088,0.000015169389,0.00010296299,0.0000025868121],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002075189,0.0047825645,0.42832455,0.35633722,0.0013673987,0.001260291,0.010709944,0.000031642434,0.041812316,0.004567086,0.012430784,0.13630101],"study_design_scores_gemma":[0.023749404,0.0014153697,0.005936457,0.50375456,0.0016647439,0.000017109498,0.00041637904,0.0010079094,0.45937547,0.0008797395,0.0011092658,0.00067359797],"about_ca_topic_score_codex":0.000010960749,"about_ca_topic_score_gemma":0.000008113947,"teacher_disagreement_score":0.42238808,"about_ca_system_score_codex":0.00003218594,"about_ca_system_score_gemma":0.00013942627,"threshold_uncertainty_score":0.42654353},"labels":[],"label_agreement":null},{"id":"W4414572355","doi":"10.1016/j.ebiom.2025.105929","title":"Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial","year":2025,"lang":"en","type":"article","venue":"EBioMedicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"NIHR Clinical Research Network North West London; Radboud Universitair Medisch Centrum; ViiV Healthcare","keywords":"Pharmacokinetics; Clinical trial; MEDLINE; Randomized controlled trial","score_opus":0.015384626429121008,"score_gpt":0.314817308919119,"score_spread":0.299432682489998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414572355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812625,0.00038115363,0.00010225367,0.004922423,0.00015655241,0.012076571,0.000015288499,0.000038421596,0.0010448542],"genre_scores_gemma":[0.9959131,0.00025374355,0.00050426816,0.00042835122,0.00014357643,0.0005772315,0.00021761544,0.000026287642,0.0019358172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732447,0.00027344708,0.00087077665,0.0005919671,0.0004607123,0.00047865583],"domain_scores_gemma":[0.99849015,0.0006685452,0.00016402022,0.0004446464,0.00007930392,0.00015333887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012499721,0.00042009912,0.00094502437,0.000584584,0.00021289212,0.00006727619,0.0003069819,0.00008691897,0.00006787864],"category_scores_gemma":[0.00022646193,0.00025375752,0.000042311345,0.001619162,0.00014731754,0.0001955897,0.00020256221,0.00041811733,0.000009802319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062388387,0.0058988943,0.91522306,0.00006730157,0.00050954695,0.00020439981,0.0061239246,0.000005325955,0.00038461105,0.00002414428,0.00091676065,0.008253643],"study_design_scores_gemma":[0.42736942,0.000629056,0.5686459,0.0006846836,0.0005292771,0.000025617339,0.00078527065,0.00077707355,0.00003164148,0.000007671773,0.0003466591,0.00016776248],"about_ca_topic_score_codex":0.0006963424,"about_ca_topic_score_gemma":0.001101592,"teacher_disagreement_score":0.36498103,"about_ca_system_score_codex":0.0002314377,"about_ca_system_score_gemma":0.00029994771,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W4414756473","doi":"10.1097/qad.0000000000004367","title":"Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial","year":2025,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Randomized controlled trial; MEDLINE; Randomization; Quality of life (healthcare); Research design","score_opus":0.018264223773620317,"score_gpt":0.2971820952701223,"score_spread":0.278917871496502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414756473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401575,0.00028700446,0.000070162874,0.0007699666,0.00006822115,0.0018124636,0.000026801816,0.00003409649,0.0029155165],"genre_scores_gemma":[0.99259496,0.00018180517,0.0021427192,0.00004099232,0.000033582128,0.0002037635,0.00006498992,0.000012500594,0.004724664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99828094,0.00016772871,0.0006874511,0.00039124957,0.00018721957,0.00028543337],"domain_scores_gemma":[0.9981775,0.00127361,0.000117964286,0.00029146535,0.000035373294,0.00010405703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040423145,0.0002326579,0.0010686407,0.00019411334,0.00004988256,0.000014857515,0.000053499032,0.000076525714,0.000038671104],"category_scores_gemma":[0.0004330225,0.00014834451,0.00008795145,0.00034951218,0.00016799734,0.00006501484,0.00003514046,0.00008208793,0.000006837721],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9409767,0.0011162311,0.03888433,0.000015851316,0.0006885575,0.00005833068,0.009235594,0.0000062971626,0.00038337798,0.00013740669,0.00004417391,0.00845315],"study_design_scores_gemma":[0.9555953,0.00089130923,0.038457494,0.0007954409,0.00056362886,0.0000017940147,0.0006318835,0.00010768806,0.0024449779,0.000036760706,0.0003330988,0.00014062837],"about_ca_topic_score_codex":0.0004011991,"about_ca_topic_score_gemma":0.00007980257,"teacher_disagreement_score":0.014618597,"about_ca_system_score_codex":0.000105326435,"about_ca_system_score_gemma":0.00023117737,"threshold_uncertainty_score":0.60493135},"labels":[],"label_agreement":null},{"id":"W4414978049","doi":"10.1016/j.ijid.2025.108104","title":"Experience of treatment with long-acting injectable cabotegravir/rilpivirine (LA iCAB/RPV) in viremic young patients with perinatally acquired HIV with adherence challenges: A five-case series","year":2025,"lang":"en","type":"article","venue":"International Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Standard of care; Series (stratigraphy); Cohort; Sida","score_opus":0.0080030744033161,"score_gpt":0.26486442516772923,"score_spread":0.25686135076441313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414978049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712366,0.0005932854,0.00019868366,0.0002189796,0.00009369906,0.0003255714,0.000026458041,0.000022930371,0.0013967307],"genre_scores_gemma":[0.9980746,0.00042440774,0.00037814476,0.000019864081,0.000034755525,0.0000660432,0.00002291728,0.000019891346,0.00095941086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998585,0.00005555481,0.00045116106,0.00024390017,0.00047251914,0.00019187594],"domain_scores_gemma":[0.99850696,0.00011674521,0.00039232842,0.00015218132,0.0007113821,0.000120392346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006356758,0.00027113594,0.0004459569,0.00042752706,0.000061677376,0.000046213896,0.00012704585,0.00004225805,0.000048660506],"category_scores_gemma":[0.000070405105,0.00016878117,0.0000793299,0.00025727585,0.00016569624,0.0004691221,0.000037943908,0.000103084196,0.0000013783064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004649999,0.0018536093,0.974008,0.00008011526,0.0011357894,0.0055634836,0.00391504,0.00017211374,0.000051303952,0.00007315672,0.000008569662,0.008488781],"study_design_scores_gemma":[0.036367334,0.011747433,0.91391736,0.007630129,0.0009606638,0.014858468,0.010656602,0.00010362745,0.0025380566,0.000080192345,0.0005333925,0.0006067306],"about_ca_topic_score_codex":0.00018474642,"about_ca_topic_score_gemma":0.0008806388,"teacher_disagreement_score":0.06009067,"about_ca_system_score_codex":0.00062350277,"about_ca_system_score_gemma":0.00068606844,"threshold_uncertainty_score":0.6882697},"labels":[],"label_agreement":null},{"id":"W4415207184","doi":"10.1021/acs.jmedchem.5c01802","title":"<i> <b>N</b> </i> -Alkyl Sulfamates as a New Class of nsP2 Cysteine Protease Inhibitors with Broad-Spectrum Antialphaviral Activity","year":2025,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"Center for Scientific Review; National Institute of Allergy and Infectious Diseases; University of North Carolina at Chapel Hill; National Institutes of Health; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; North Carolina Biotechnology Center","keywords":"Alphavirus; Glutathione; Cysteine protease; Cysteine; Enzyme; Protease; Potency; Cysteine Proteinase Inhibitors","score_opus":0.005431410953027385,"score_gpt":0.2517073578672546,"score_spread":0.24627594691422725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415207184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97420007,0.0011204769,0.00015607136,0.018085385,0.00013659077,0.0002818526,0.0000037888628,0.000021757483,0.0059940303],"genre_scores_gemma":[0.98017216,0.0001087712,0.00059445517,0.00018572458,0.0005014689,0.0000049547293,0.0000075143084,0.000020549638,0.018404404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795896,0.000028165161,0.00067067775,0.00021883858,0.0008289979,0.00029439063],"domain_scores_gemma":[0.9983841,0.000075648546,0.0006110191,0.00024182959,0.00022804468,0.00045935478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034470067,0.00028844402,0.0008110274,0.00015037255,0.000054825923,0.0000138761825,0.00015663503,0.0001470677,0.00015024416],"category_scores_gemma":[0.00024894046,0.00019080516,0.00019096084,0.0003997987,0.00016521757,0.00011962596,0.00004335125,0.0005542093,0.0000049951755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011167942,0.0017663277,0.0606177,0.0021426023,0.0015917156,0.0035297158,0.0007047291,0.0000073811607,0.8677006,0.000035377197,0.038812447,0.0119235115],"study_design_scores_gemma":[0.009369913,0.0009385717,0.0017742257,0.0035598637,0.00081989705,0.0016131416,0.0004014625,0.000012187652,0.9712889,0.000096134725,0.009958154,0.00016755315],"about_ca_topic_score_codex":0.0000559408,"about_ca_topic_score_gemma":0.0000038650583,"teacher_disagreement_score":0.10358834,"about_ca_system_score_codex":0.00022004443,"about_ca_system_score_gemma":0.0024397962,"threshold_uncertainty_score":0.7780809},"labels":[],"label_agreement":null},{"id":"W4415315812","doi":"10.1016/j.jiac.2025.102834","title":"Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study","year":2025,"lang":"en","type":"article","venue":"Journal of Infection and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Tenofovir alafenamide; Adverse effect; Regimen; Randomized controlled trial; Phases of clinical research","score_opus":0.014842593459145377,"score_gpt":0.33487991543443796,"score_spread":0.32003732197529255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415315812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947053,0.0000849893,0.0018499466,0.0020931968,0.000115793744,0.00090628595,5.0223423e-7,0.000011276848,0.00023270494],"genre_scores_gemma":[0.9984024,0.00016309622,0.0007832132,0.00026526014,0.000034485893,0.000018217836,0.0000017810764,0.000015229286,0.0003163115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984351,0.00022979679,0.000702732,0.0001604756,0.0002857537,0.00018619017],"domain_scores_gemma":[0.9990455,0.00031703166,0.00032047203,0.00013736062,0.00011298647,0.00006664731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015655067,0.00021562501,0.00093292334,0.0006269367,0.00006263496,0.00004274094,0.000064255895,0.00005131935,0.0000102126405],"category_scores_gemma":[0.0001522684,0.000117194315,0.00012432205,0.00048962375,0.000030915373,0.00018328268,0.000009784605,0.0003222479,3.453804e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072607845,0.0024831446,0.8557138,0.000026081112,0.0006376699,0.00011250533,0.010247322,0.000047164296,0.0008418012,0.000012810693,0.000015904738,0.057253987],"study_design_scores_gemma":[0.44433057,0.002639418,0.54504234,0.00041680314,0.00036134993,0.000048286987,0.004656963,0.0003635328,0.0017225067,0.000038600207,0.0002073823,0.00017223862],"about_ca_topic_score_codex":0.00034350253,"about_ca_topic_score_gemma":0.0015611536,"teacher_disagreement_score":0.37172273,"about_ca_system_score_codex":0.00013915438,"about_ca_system_score_gemma":0.00010897212,"threshold_uncertainty_score":0.47790456},"labels":[],"label_agreement":null},{"id":"W4415936435","doi":"10.1021/acsmedchemlett.5c00510","title":"<i>S</i> -Adenosylhomocysteine Analogs Selectively Suppress Pan-Coronavirus Replication by Inhibition of nsp14 Methyltransferase","year":2025,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; University of Toronto","funders":"National Institute of General Medical Sciences; Michigan Technology Tri-Corridor; Takeda Canada; Genentech; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; Structural Genomics Consortium; Division of Cancer Prevention, National Cancer Institute; Merck KGaA; Genome Canada; National Institute of Allergy and Infectious Diseases; Bayer; Chicago Biomedical Consortium; Bristol-Myers Squibb; Office of Science; Boehringer Ingelheim; U.S. Department of Energy; Pfizer; Janssen Research and Development; Michigan Economic Development Corporation; National Science Foundation","keywords":"Methyltransferase; Docking (animal); Cytotoxicity; Enzyme; Viral replication; Plasma protein binding; Transferase; Coronavirus disease 2019 (COVID-19); Coronavirus","score_opus":0.009360647879220184,"score_gpt":0.2719855091314359,"score_spread":0.2626248612522157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415936435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97387946,0.0007776681,0.00096824736,0.021452026,0.000052322644,0.00039739057,0.00004642464,0.000078012665,0.002348447],"genre_scores_gemma":[0.993794,0.00010332234,0.0002944294,0.0020645573,0.00008062569,0.00009111519,0.0008600922,0.000020907464,0.0026909136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817055,0.00004010686,0.0005120522,0.0005406991,0.00044352392,0.00029307112],"domain_scores_gemma":[0.9990041,0.00011825091,0.0001325229,0.0004751754,0.0001428349,0.00012707947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026202603,0.00027133428,0.00048289905,0.00008926608,0.000075138494,0.00001024265,0.00011588937,0.00013733807,0.00008768727],"category_scores_gemma":[0.00010336162,0.00024306214,0.00010247852,0.0004612418,0.00017670901,0.00007568514,0.000026652166,0.00028270693,0.0000073443075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003249256,0.00025329043,0.0043516667,0.00048730223,0.00030467974,0.000087312794,0.0002990934,8.526425e-7,0.9629288,0.000012725983,0.028783485,0.0021659068],"study_design_scores_gemma":[0.0031063803,0.000047675836,0.0018818562,0.00044243093,0.00048706675,0.000061850486,0.0001612195,0.000007372637,0.98757535,0.000026059439,0.006034472,0.00016825923],"about_ca_topic_score_codex":0.00007397682,"about_ca_topic_score_gemma":0.0000019040473,"teacher_disagreement_score":0.024646599,"about_ca_system_score_codex":0.0002399807,"about_ca_system_score_gemma":0.00013879193,"threshold_uncertainty_score":0.99117863},"labels":[],"label_agreement":null},{"id":"W4416305956","doi":"10.1137/24m1720196","title":"Incorporating Drug Adherence Stochasticity Into Pharmacokinetics and Pharmacodynamics to Understand the HIV Transmission Dynamics Through a MultiScale System","year":2025,"lang":"en","type":"article","venue":"SIAM Journal on Applied Mathematics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Fundamental Research Funds for the Central Universities; China Scholarship Council; Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China","keywords":"Multiscale modeling; Pharmacodynamics; Human immunodeficiency virus (HIV); Pharmacokinetics; Transmission (telecommunications); Drug; Antiretroviral therapy","score_opus":0.01347993096135063,"score_gpt":0.29140081754140307,"score_spread":0.27792088658005243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416305956","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08545392,0.00016016403,0.8977277,0.0059263273,0.00017717661,0.0014927981,0.000013921902,0.00009090031,0.008957083],"genre_scores_gemma":[0.83676666,0.00012500977,0.16047224,0.00050705584,0.00006783666,0.00004089561,0.000013595938,0.000042107888,0.0019646236],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982652,0.00003609132,0.0006514952,0.00026891346,0.00048205422,0.00029623404],"domain_scores_gemma":[0.9988971,0.00029552574,0.0002562161,0.00021453998,0.00010440784,0.0002322084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004734262,0.00033508628,0.00048063273,0.00014445673,0.0004906852,0.00010628933,0.00018546106,0.00007624135,0.000015130825],"category_scores_gemma":[0.000027369491,0.00021450943,0.00008235627,0.00037369094,0.00010027829,0.000052882253,0.00007960891,0.000550241,0.000026397765],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003687579,0.0053228866,0.000773107,0.013578883,0.003728407,0.0008105764,0.1330845,0.013031903,0.024917366,0.5959401,0.02106812,0.18405657],"study_design_scores_gemma":[0.012460961,0.00029338515,0.00008793422,0.0060730968,0.0018863231,0.00055514334,0.056957975,0.8872647,0.00869021,0.022540823,0.0023092786,0.0008801361],"about_ca_topic_score_codex":0.000002021277,"about_ca_topic_score_gemma":0.0000064960536,"teacher_disagreement_score":0.8742328,"about_ca_system_score_codex":0.0005794156,"about_ca_system_score_gemma":0.00017683055,"threshold_uncertainty_score":0.87474406},"labels":[],"label_agreement":null},{"id":"W4416566942","doi":"10.1007/s40121-025-01252-w","title":"Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies","year":2025,"lang":"en","type":"article","venue":"Infectious Diseases and Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Pooled analysis; Cohort; Quality of life (healthcare); Cohort study; Human immunodeficiency virus (HIV); Meta-analysis","score_opus":0.022493580057333477,"score_gpt":0.3110487440105296,"score_spread":0.28855516395319614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416566942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934407,0.0041582515,0.0002737826,0.0013325496,0.000028384724,0.0006114846,0.000056461628,0.000036352714,0.000062073625],"genre_scores_gemma":[0.9953832,0.003659514,0.00015711946,0.0002570622,0.000019846682,0.00015830297,0.00009872601,0.000008336346,0.000257894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901116,0.00006853836,0.000321293,0.00030201717,0.00017056972,0.00012641143],"domain_scores_gemma":[0.99927956,0.00027243939,0.00009093122,0.00014468015,0.000102122736,0.000110267545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085810054,0.00019175236,0.00064336584,0.00037545656,0.000092529874,0.000021299084,0.000016698983,0.000035589735,0.000018386096],"category_scores_gemma":[0.000050880208,0.0001284074,0.00008161325,0.0007753011,0.000028892004,0.00006792305,0.00001241066,0.000040566112,7.6962715e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007018801,0.0004155489,0.9742054,0.000023966817,0.008362348,0.0000041793382,0.0008826204,0.000085768566,0.00020534827,0.00014351086,0.000018070075,0.014951371],"study_design_scores_gemma":[0.004428098,0.000196811,0.9929814,0.000050966137,0.001213627,4.865727e-7,0.0003387378,0.00010029499,0.000040056653,0.00048186898,0.000051142502,0.00011652341],"about_ca_topic_score_codex":0.0031438242,"about_ca_topic_score_gemma":0.004923936,"teacher_disagreement_score":0.018776,"about_ca_system_score_codex":0.00020400384,"about_ca_system_score_gemma":0.00020953518,"threshold_uncertainty_score":0.52363014},"labels":[],"label_agreement":null},{"id":"W4417400390","doi":"10.1080/14787210.2025.2605685","title":"Point-of-care tests for HIV drug resistance monitoring: an update of the literature and future viewpoints","year":2025,"lang":"en","type":"review","venue":"Expert Review of Anti-infective Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Public Health Agency; Public Health Agency of Canada","keywords":"Viewpoints; Human immunodeficiency virus (HIV); Key (lock); HIV drug resistance; Drug resistance; Antiretroviral drug; Scalability; Antiretroviral therapy","score_opus":0.01625058593990644,"score_gpt":0.36364789241588114,"score_spread":0.3473973064759747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417400390","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009252247,0.9925576,0.000006250099,0.0013674246,0.0004366078,0.005084446,0.00018221873,0.000022253436,0.00025072054],"genre_scores_gemma":[0.00001896906,0.99562204,0.0018600111,0.00016749988,0.00038330277,0.0004176936,0.00026000815,0.000060225364,0.0012102614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734634,0.0004097543,0.0010744177,0.0005815224,0.00034017183,0.00024777892],"domain_scores_gemma":[0.9969583,0.00028058785,0.000990919,0.0009482467,0.00073238375,0.00008956206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043877962,0.0006801052,0.003770398,0.0001988842,0.00009272765,0.000013619731,0.0003223871,0.00023013941,0.00002479736],"category_scores_gemma":[0.00011130364,0.00036550942,0.0011101126,0.00079185213,0.00014608796,0.00011144121,0.00007382602,0.00030779504,0.0000013370243],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008315643,0.00032014312,0.00028924365,0.29881066,0.000962379,0.000005432752,0.00256631,2.543392e-9,0.000018493583,0.00028174554,0.0061059473,0.69055647],"study_design_scores_gemma":[0.00071881025,0.00007206813,0.00013155102,0.31382617,0.0005017219,0.000008372497,0.000059952803,1.661309e-8,0.00067499204,0.000031800126,0.68377924,0.00019527007],"about_ca_topic_score_codex":0.0000012316352,"about_ca_topic_score_gemma":0.0000017189902,"teacher_disagreement_score":0.6903612,"about_ca_system_score_codex":0.00011140779,"about_ca_system_score_gemma":0.0005034137,"threshold_uncertainty_score":0.99987966},"labels":[],"label_agreement":null},{"id":"W45130134","doi":"10.1155/2008/370535","title":"Acute Renal Failure in Four HIV‐Infected Patients: Potential Association with Tenofovir and Nonsteroidal Anti‐Inflammatory Drugs","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Creatinine; Ritonavir; Dialysis; Viral load; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.001902014571963346,"score_gpt":0.17422311932310616,"score_spread":0.17232110475114282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W45130134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964024,0.00030896184,0.000026575695,0.0028327776,0.000126507,0.00017681583,0.00005692357,0.00000910507,0.00005994831],"genre_scores_gemma":[0.9988488,0.00026320666,0.00005323124,0.00043372132,0.00012173915,0.0000037016187,0.000064108346,0.000012995649,0.00019847792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891585,0.000085996566,0.00035270152,0.0001693631,0.00013397913,0.00034211783],"domain_scores_gemma":[0.9985031,0.000060273367,0.00019574334,0.00005936011,0.00020664738,0.0009748658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012144616,0.0001691611,0.0004129338,0.0003623078,0.00014495084,0.000014632169,0.00004349947,0.00020271279,0.00011815707],"category_scores_gemma":[0.00017003009,0.00012064045,0.000065908556,0.00012630688,0.00023642319,0.00008558793,0.000014525369,0.0003112659,0.000004484827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001153209,0.000092676564,0.99110764,0.000018938168,0.00036375318,0.0024853272,0.0002736493,0.0000010002309,0.0003541806,0.0000046650607,0.0038647966,0.001318068],"study_design_scores_gemma":[0.010453952,0.0005662998,0.9728431,0.00025273554,0.0003624772,0.0069117798,0.00006549947,0.000008271535,0.000053200998,0.000010648313,0.00829322,0.0001788285],"about_ca_topic_score_codex":0.00019330741,"about_ca_topic_score_gemma":0.003037288,"teacher_disagreement_score":0.018264538,"about_ca_system_score_codex":0.00028425982,"about_ca_system_score_gemma":0.0016920118,"threshold_uncertainty_score":0.4919575},"labels":[],"label_agreement":null},{"id":"W581037100","doi":"10.1155/2015/731043","title":"A Case Series of Third‐Trimester Raltegravir Initiation: Impact on Maternal HIV‐1 Viral Load and Obstetrical Outcomes","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; B.C. Women's Hospital & Health Centre; Women's Health Research Institute; University of British Columbia","funders":"Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Raltegravir; Medicine; Viral load; Human immunodeficiency virus (HIV); Series (stratigraphy); Second trimester; Pregnancy; Antiretroviral therapy; Obstetrics; Virology; Fetus; Biology","score_opus":0.011951480247048861,"score_gpt":0.261401302175118,"score_spread":0.2494498219280691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W581037100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422747,0.002498339,0.0000061464807,0.002581595,0.00026769444,0.00010888552,0.000095838644,0.0000056068843,0.00020842903],"genre_scores_gemma":[0.99880505,0.000099456236,0.000037156744,0.000596133,0.000101939695,0.0000019492027,0.000015843842,0.0000087527405,0.00033373613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991004,0.00007665384,0.00036570293,0.00011771728,0.00011060771,0.0002289273],"domain_scores_gemma":[0.9978328,0.00011971707,0.00014091737,0.000072533236,0.0001985422,0.0016355431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013215852,0.00016061492,0.00047678596,0.00026412768,0.000056432462,0.000017581582,0.000039533585,0.00013106293,0.00012491748],"category_scores_gemma":[0.00057929,0.00009740415,0.00011486408,0.00008215128,0.00028296185,0.00006868481,0.000014698966,0.00018971252,0.0000057809916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027577876,0.00010936771,0.97700834,0.00003588087,0.0003160938,0.01309714,0.00046982634,6.938542e-7,0.00003063314,0.000086971195,0.0057740603,0.0027952397],"study_design_scores_gemma":[0.023453703,0.006823782,0.48750204,0.0006808116,0.0011327455,0.45624962,0.0010023746,0.00001339423,0.00043057968,0.00072364166,0.02146224,0.00052507495],"about_ca_topic_score_codex":0.00080425973,"about_ca_topic_score_gemma":0.0006195365,"teacher_disagreement_score":0.48950627,"about_ca_system_score_codex":0.0002483329,"about_ca_system_score_gemma":0.002749926,"threshold_uncertainty_score":0.48782504},"labels":[],"label_agreement":null},{"id":"W632797437","doi":"10.71781/27479","title":"The Role of Second Generation Antiretroviral Drugs in HIV-1 Subtype B and non-B Variants Harboring Natural Polymorphisms and Drug Resistance Mutations","year":2012,"lang":"en","type":"dissertation","venue":"Open MIND","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Styrelsen för Internationellt Utvecklingssamarbete; Université de Montréal; Harvard University; Pfizer","keywords":"Rilpivirine; Etravirine; Virology; Drug resistance; Reverse transcriptase; Biology; Protease; Resistance mutation; Mutation; Virus; Reverse-transcriptase inhibitor; Gene; Genetics; Viral load; Polymerase chain reaction; Antiretroviral therapy; Enzyme","score_opus":0.009468075643566505,"score_gpt":0.2619745238141546,"score_spread":0.2525064481705881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W632797437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847677,0.0045051235,3.3486435e-7,0.00018776239,0.00019644474,0.00061934063,0.000028780169,0.0000010490437,0.0096935],"genre_scores_gemma":[0.8671913,0.00009315471,0.0013652028,0.0000036703052,0.00005834793,0.000033106353,0.0010176281,0.000018847331,0.13021874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989918,0.00003773199,0.00032879878,0.00027526641,0.0001745839,0.00019181773],"domain_scores_gemma":[0.99943393,0.00006339229,0.00020949532,0.00016447851,0.000062976076,0.00006571334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002615424,0.00019106663,0.0003087561,0.00012242059,0.00016254504,0.000092131355,0.00009344456,0.00009551802,0.00011549549],"category_scores_gemma":[0.000026941643,0.00014656059,0.000026944213,0.00013405904,0.000043654785,0.00021899468,0.000033627177,0.00018096215,0.000015697447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025717386,0.00063198333,0.40580714,0.00040777738,0.0010263989,0.000087590146,0.12564233,8.267134e-7,0.18342488,0.0007810885,0.0017049053,0.27791336],"study_design_scores_gemma":[0.003694774,0.000051610015,0.90327644,0.00077571766,0.000442151,0.000010640361,0.0071328096,0.00025336767,0.0758383,0.00008419399,0.00794224,0.0004977568],"about_ca_topic_score_codex":0.00006784431,"about_ca_topic_score_gemma":0.004447538,"teacher_disagreement_score":0.4974693,"about_ca_system_score_codex":0.000057341036,"about_ca_system_score_gemma":0.00020034764,"threshold_uncertainty_score":0.5976568},"labels":[],"label_agreement":null},{"id":"W658842411","doi":"10.1371/journal.pone.0128310","title":"Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Fonds de Recherche du Québec - Santé; Styrelsen för Internationellt Utvecklingssamarbete; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Integrase; Integrase inhibitor; Allosteric regulation; Binding site; DNA; Reverse transcriptase; Chemistry; Biology; Biochemistry; Virology; Enzyme; Human immunodeficiency virus (HIV); RNA; Gene","score_opus":0.09411689921232547,"score_gpt":0.27011296492752745,"score_spread":0.175996065715202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W658842411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980913,0.00008646892,0.0000053585663,0.0011752348,0.00001650979,0.00053216936,0.000017660768,0.000012101434,0.00006323728],"genre_scores_gemma":[0.9960295,0.000008715861,0.0021155868,0.000011524077,0.00004159235,0.000018523735,0.00004407425,0.000008168851,0.0017223308],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934894,0.00002661455,0.0001972031,0.000095353724,0.00025186833,0.00007999657],"domain_scores_gemma":[0.9995487,0.000019426476,0.00012944474,0.00009900448,0.00015796346,0.00004550902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000944091,0.00008549041,0.0002663909,0.000055673987,0.00003972968,0.0000049206883,0.00003133388,0.00002445181,0.000004895371],"category_scores_gemma":[0.00010774724,0.00005171726,0.000022379501,0.000109251,0.000090460555,0.00006112372,0.00005862926,0.000058547892,0.0000019372715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001905396,0.00028903462,0.20916358,0.00039776557,0.000923217,0.0000057925336,0.006067021,6.914488e-8,0.7823135,0.000056451765,0.000041002033,0.0005520315],"study_design_scores_gemma":[0.0026179987,0.00017251022,0.038229696,0.002718553,0.00043529164,0.000006572117,0.0019573865,0.00020166564,0.95349056,0.000040992232,0.000029043971,0.00009973349],"about_ca_topic_score_codex":0.0000024640303,"about_ca_topic_score_gemma":0.0000025548613,"teacher_disagreement_score":0.17117706,"about_ca_system_score_codex":0.000036656882,"about_ca_system_score_gemma":0.0000386508,"threshold_uncertainty_score":0.21089686},"labels":[],"label_agreement":null},{"id":"W6886019952","doi":"10.14288/1.0223147","title":"Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients","year":2016,"lang":"en","type":"article","venue":"Open Collections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Efavirenz; Pharmacokinetics; Cmin; Saquinavir; Adverse effect; Confidence interval; Population; Regimen; Cmax","score_opus":0.012631675620624344,"score_gpt":0.2725592885414722,"score_spread":0.2599276129208479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6886019952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93192,0.000060702343,0.00017297057,0.0011580558,0.00022795847,0.0024186675,0.00024311649,0.00006070202,0.06373783],"genre_scores_gemma":[0.790185,0.00022012947,0.001088383,0.000036370988,0.000028342285,0.00006314712,0.00007553247,0.000026543337,0.2082766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860036,0.000086526816,0.00047522006,0.00034267496,0.0002243325,0.00027087305],"domain_scores_gemma":[0.99919754,0.00016629389,0.0001335731,0.00021562265,0.00014530854,0.0001416413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001288806,0.00020864417,0.00043367693,0.00017826958,0.0003797529,0.000063127234,0.00012009092,0.00008766733,0.00048785633],"category_scores_gemma":[0.00014764092,0.00015375478,0.000059622325,0.0009553522,0.00011567038,0.00016809156,0.00016041534,0.00012979699,0.000031460928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025294072,0.0036097788,0.84811854,0.0000683385,0.00042886095,0.000053760767,0.0009350006,0.000011863752,0.008959762,0.000032735843,0.09213372,0.04311821],"study_design_scores_gemma":[0.0457539,0.0010318188,0.87179524,0.0008096885,0.00034843382,0.00002463472,0.00010992925,0.00025355376,0.01253784,0.000057446367,0.06677837,0.0004991444],"about_ca_topic_score_codex":0.0004416332,"about_ca_topic_score_gemma":0.0001534955,"teacher_disagreement_score":0.14453876,"about_ca_system_score_codex":0.0002473173,"about_ca_system_score_gemma":0.00022745455,"threshold_uncertainty_score":0.6269938},"labels":[],"label_agreement":null},{"id":"W6886099532","doi":"10.14288/1.0362101","title":"Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients","year":2017,"lang":"en","type":"article","venue":"Open Collections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Discontinuation; Regimen; Hazard ratio; Retrospective cohort study; Cohort; Cohort study; Proportional hazards model; Relative risk","score_opus":0.047509438848144014,"score_gpt":0.36914832141615384,"score_spread":0.3216388825680098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6886099532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490544,0.00022080555,0.00023827908,0.0011086654,0.00062350713,0.0048786364,0.00060201227,0.000066468354,0.04320721],"genre_scores_gemma":[0.91940385,0.000047487432,0.004950027,0.00008255794,0.00007034681,0.00029004263,0.00032446164,0.000042805186,0.07478845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983209,0.00004813434,0.00048680033,0.00048323604,0.00031634822,0.00034457998],"domain_scores_gemma":[0.9984418,0.00011836211,0.00035540975,0.00064901635,0.00026361717,0.0001717965],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0002037344,0.00028831718,0.0007261352,0.00012866453,0.0033026421,0.0006282947,0.00037675185,0.00013503457,0.00011576741],"category_scores_gemma":[0.0001293022,0.00025269992,0.00016434123,0.00025375967,0.00024923406,0.00039428668,0.00017524873,0.0001700126,0.0000057795423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00137864,0.0023136525,0.9215317,0.00006749378,0.00032099654,0.0000065941936,0.00027364498,0.0000017012649,0.00071116193,0.000066948785,0.050087675,0.023239808],"study_design_scores_gemma":[0.04710492,0.011192618,0.79057574,0.00058208435,0.00068039267,0.000013323298,0.000580626,0.0033321062,0.031667236,0.00034135435,0.11287758,0.0010520192],"about_ca_topic_score_codex":0.0020171572,"about_ca_topic_score_gemma":0.0002822517,"teacher_disagreement_score":0.13095595,"about_ca_system_score_codex":0.000120001765,"about_ca_system_score_gemma":0.0003448505,"threshold_uncertainty_score":0.99999255},"labels":[],"label_agreement":null},{"id":"W6889116447","doi":"10.25384/sage.21754071","title":"Supplemental material - Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy","year":2022,"lang":"en","type":"article","venue":"Sage Journals Data","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Raltegravir; Therapeutic drug monitoring; Plasma concentration; Pregnancy; Drug; Therapeutic index; Trough level; Trough (economics)","score_opus":0.06321103607943912,"score_gpt":0.34702700411094783,"score_spread":0.2838159680315087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6889116447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99230003,0.0043574525,0.000008265312,0.001649204,0.0000608064,0.00047115757,0.0011308738,0.000011183842,0.00001104652],"genre_scores_gemma":[0.99788946,0.0012020122,0.00019418109,0.00000435979,0.00008520774,0.000022577387,0.00031288702,0.000011393721,0.00027794068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853474,0.00053147593,0.00033643038,0.00018185876,0.00024545073,0.00017001996],"domain_scores_gemma":[0.9989601,0.0004944548,0.00019133354,0.00027778075,0.000012319193,0.00006403839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008445859,0.00012326721,0.0002479557,0.00005042052,0.00039976634,0.00005029041,0.00013426092,0.000023266895,0.00042118772],"category_scores_gemma":[0.00007709619,0.00007613673,0.000039546303,0.000101142905,0.0000805834,0.00022302149,0.00023181249,0.00020725155,7.6262324e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002920422,0.00004882589,0.986886,0.000018985622,0.00023973716,0.000041748404,0.0019995684,0.0000033285698,0.005282136,0.0000040338937,0.000050390347,0.0025048032],"study_design_scores_gemma":[0.006595458,0.00012980714,0.9891749,0.00025145547,0.00021636633,0.00017566801,0.0008214943,0.00005237863,0.0023038175,0.00018177813,0.000023816612,0.0000730365],"about_ca_topic_score_codex":0.00003718682,"about_ca_topic_score_gemma":0.0000018293574,"teacher_disagreement_score":0.00558943,"about_ca_system_score_codex":0.00010391761,"about_ca_system_score_gemma":0.00008766958,"threshold_uncertainty_score":0.461171},"labels":[],"label_agreement":null},{"id":"W6901763257","doi":"10.60692/exm98-2f486","title":"Multi-state Markov Model for time to treatment changes for HIV/AIDS patients: A retrospective cohort national datasets, Ethiopia","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Retrospective cohort study; Regimen; Cohort; Markov model; Pharmacotherapy; Drug","score_opus":0.03906336135393023,"score_gpt":0.266770189443002,"score_spread":0.22770682808907178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901763257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60576963,0.000006195422,0.19637208,0.0042381957,0.00085570413,0.03631108,0.15181157,0.0021748366,0.002460742],"genre_scores_gemma":[0.7974574,0.0000013537845,0.047425743,0.0007356258,0.00017391908,0.011350632,0.05298186,0.000086791915,0.08978665],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99825376,0.00002154706,0.0005377662,0.00030432647,0.0004975974,0.00038501885],"domain_scores_gemma":[0.99869233,0.00002629732,0.00020026903,0.00026906602,0.00062895636,0.00018305669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043081402,0.00029862966,0.00045006274,0.0005442029,0.00020353899,0.00007500852,0.000088547626,0.00010051783,0.000019015262],"category_scores_gemma":[0.000071994036,0.00022980705,0.00012177084,0.00031422792,0.000015775231,0.00028604467,0.000047941005,0.000043014705,0.00202779],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034021835,0.00018884106,0.6609127,0.002172627,0.002850771,0.000008745749,0.21228454,0.0013589072,0.000014738565,0.00020806768,0.11129017,0.0053076926],"study_design_scores_gemma":[0.03162507,0.0013666184,0.16213505,0.0007489028,0.00066257134,0.000015646869,0.0036046654,0.7715762,0.0007902767,0.000008048524,0.026439507,0.0010274246],"about_ca_topic_score_codex":0.0000017915145,"about_ca_topic_score_gemma":0.0000011813472,"teacher_disagreement_score":0.7702173,"about_ca_system_score_codex":0.0011666843,"about_ca_system_score_gemma":0.00014057076,"threshold_uncertainty_score":0.99874926},"labels":[],"label_agreement":null},{"id":"W6901958736","doi":"10.6084/m9.figshare.13558680.v1","title":"Additional file 5 of HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple drug resistance; Human immunodeficiency virus (HIV); Sensitivity (control systems); MEDLINE; Drug resistance","score_opus":0.03531599220748224,"score_gpt":0.267156527685438,"score_spread":0.23184053547795577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901958736","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000716458,0.017763838,1.1129378e-7,0.00052986335,9.240691e-7,0.00039807198,0.9807077,0.00001549766,0.0005768198],"genre_scores_gemma":[0.00043181962,0.00018935151,0.0006417426,0.0002472323,0.0000063340094,0.0021481726,0.9748893,0.000008435337,0.021437641],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9991919,0.00006834593,0.00028971606,0.0001963676,0.00017731592,0.00007635533],"domain_scores_gemma":[0.9989558,0.00047699382,0.00012949455,0.00017585536,0.00019199049,0.00006986575],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000035596655,0.00011686332,0.0009675241,0.00008368226,0.000039468818,0.0000115676385,0.000015229972,0.00003490648,0.9726822],"category_scores_gemma":[0.0020542934,0.000081144484,0.00029872425,0.00034273465,0.0000052821633,0.000046851077,0.000035811256,0.00004856134,0.00024955807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017568588,0.000042144824,0.0000052546807,0.08129481,0.029204387,0.000026662578,0.000030186857,8.173481e-8,9.922171e-7,8.0342727e-7,0.88938975,0.0000031875009],"study_design_scores_gemma":[0.00048701544,0.00003930205,0.005084994,0.08433959,0.7230581,0.00016130965,0.000077914454,0.00012416372,0.00015932697,0.000007651049,0.1861619,0.0002987377],"about_ca_topic_score_codex":0.0000017672143,"about_ca_topic_score_gemma":0.000026448106,"teacher_disagreement_score":0.9724326,"about_ca_system_score_codex":0.00002338953,"about_ca_system_score_gemma":0.000059310092,"threshold_uncertainty_score":0.3308976},"labels":[],"label_agreement":null},{"id":"W6902152265","doi":"10.6084/m9.figshare.14451075.v1","title":"Additional file 2 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug; MEDLINE; Confidentiality; Drug trial","score_opus":0.275671499480915,"score_gpt":0.42569026588947256,"score_spread":0.15001876640855755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902152265","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005541569,0.0010336228,7.55418e-7,0.0016306957,0.000016098857,0.00087396224,0.9953999,0.000030396326,0.00046044678],"genre_scores_gemma":[0.00035431105,0.000013448282,0.042662278,0.00009164954,0.00010034398,0.004738607,0.8249845,0.000015931986,0.12703896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998725,0.000092549075,0.00047026292,0.00029072128,0.0002683945,0.00015309686],"domain_scores_gemma":[0.9945918,0.0036083607,0.0002524757,0.00023296961,0.0012544981,0.000059895057],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006415761,0.0001813928,0.0006557248,0.000060510523,0.000060543527,0.0000047460853,0.000058226582,0.000047963644,0.8596706],"category_scores_gemma":[0.0129019385,0.00012560762,0.00019881122,0.00018714505,0.000014623907,0.000028507116,0.000069122056,0.00003978163,0.00008306712],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021121324,0.0008642511,0.00006097474,0.00036961448,0.0008367151,0.00007954138,0.0008308302,0.0000013175334,0.000009893947,0.0000015703641,0.99625796,0.00047610595],"study_design_scores_gemma":[0.002151921,0.00018596281,0.003985343,0.0052639507,0.00020527189,0.000008024148,0.009116127,0.000011026731,0.003422654,0.0000589623,0.9754549,0.0001358339],"about_ca_topic_score_codex":6.839731e-7,"about_ca_topic_score_gemma":0.000072731236,"teacher_disagreement_score":0.85958755,"about_ca_system_score_codex":0.00009068602,"about_ca_system_score_gemma":0.00029366376,"threshold_uncertainty_score":0.9954128},"labels":[],"label_agreement":null},{"id":"W6902155166","doi":"10.6084/m9.figshare.14451072.v1","title":"Additional file 1 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug; MEDLINE; Public health; Data collection","score_opus":0.28350094117784813,"score_gpt":0.42645560018801537,"score_spread":0.14295465901016724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902155166","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055779185,0.0010163628,7.7222205e-7,0.001638697,0.000015995034,0.00087517273,0.99541515,0.000030390036,0.0004496436],"genre_scores_gemma":[0.0003604787,0.000013095195,0.043629445,0.0000916753,0.000098862845,0.0048356764,0.8242578,0.000015960457,0.126697],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987248,0.00009258154,0.00047004502,0.00029094683,0.00026846398,0.00015315524],"domain_scores_gemma":[0.9945353,0.0036617897,0.0002521175,0.00023343935,0.0012574202,0.000059905717],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000064521955,0.00018145247,0.00065555883,0.00006055153,0.00006053894,0.000004735453,0.000058260124,0.000047963356,0.8620277],"category_scores_gemma":[0.013062904,0.00012565011,0.00019885099,0.00018729565,0.000014624116,0.000028486924,0.00006913211,0.000039791106,0.00008399387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021252432,0.00086501084,0.000063075626,0.00036638047,0.00083716016,0.00007739259,0.0008305558,0.0000013117256,0.000010266831,0.0000015431167,0.9962718,0.00046297748],"study_design_scores_gemma":[0.0021570234,0.0001876894,0.004090987,0.0053821956,0.00020799277,0.000008081505,0.009299991,0.0000112085345,0.0034773625,0.000059033835,0.974981,0.0001374172],"about_ca_topic_score_codex":6.769153e-7,"about_ca_topic_score_gemma":0.00007228864,"teacher_disagreement_score":0.8619437,"about_ca_system_score_codex":0.00009065916,"about_ca_system_score_gemma":0.00029502143,"threshold_uncertainty_score":0.99525046},"labels":[],"label_agreement":null},{"id":"W6902198993","doi":"10.6084/m9.figshare.25459577.v1","title":"Additional file 1 of Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"SALSA; Pooled analysis; Baseline (sea); Table (database); Real world data","score_opus":0.024311130525910846,"score_gpt":0.2571515200393557,"score_spread":0.23284038951344485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902198993","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.102987744,0.00059344136,3.355274e-7,0.0014856734,0.000007278273,0.0004041454,0.894326,0.000024511251,0.00017090606],"genre_scores_gemma":[0.37279886,0.000037026708,0.001719416,0.000108661035,0.00006069281,0.00032924901,0.6236938,0.000018577386,0.0012336879],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99910295,0.000044178636,0.000263293,0.00026508965,0.00019635561,0.00012814601],"domain_scores_gemma":[0.9962135,0.0034784416,0.000064520034,0.00013683298,0.000052397227,0.000054339696],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006151662,0.00013890094,0.00033290684,0.00006928805,0.000035796533,0.0000149994785,0.00005917769,0.000048948474,0.2219516],"category_scores_gemma":[0.0019502067,0.00007921711,0.000029486024,0.0002072452,0.000018005378,0.000043662963,0.00010023183,0.00013848302,0.00008453905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076464907,0.00008912582,0.0002458162,0.000098423305,0.00026552827,0.00007894357,0.0033730844,0.0000028466675,0.00020369102,0.0000019024366,0.9938574,0.0010185821],"study_design_scores_gemma":[0.0031007337,0.00026496328,0.8250173,0.0120898355,0.000097852295,0.000013778407,0.0006706322,0.000054016524,0.00013755543,0.000029877927,0.15838075,0.00014271968],"about_ca_topic_score_codex":0.000016331576,"about_ca_topic_score_gemma":0.00028676473,"teacher_disagreement_score":0.83547664,"about_ca_system_score_codex":0.0000266447,"about_ca_system_score_gemma":0.000070719,"threshold_uncertainty_score":0.77875966},"labels":[],"label_agreement":null},{"id":"W6902215890","doi":"10.6084/m9.figshare.14451078","title":"Additional file 3 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Checklist; Human immunodeficiency virus (HIV); Drug; MEDLINE; Drug trial","score_opus":0.27923903771450065,"score_gpt":0.4258390995963325,"score_spread":0.14660006188183183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902215890","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005623515,0.0010223791,7.771928e-7,0.0016314893,0.00001616289,0.0008756009,0.99540824,0.000030364967,0.00045265042],"genre_scores_gemma":[0.0003652966,0.000013315565,0.04319616,0.000091769914,0.0001002362,0.004750775,0.8222363,0.000015988713,0.12923016],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872476,0.00009248851,0.00047026333,0.0002908144,0.00026852102,0.00015314294],"domain_scores_gemma":[0.9945578,0.0036280707,0.00025215765,0.00023307277,0.0012689775,0.000059900085],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006449144,0.00018142581,0.0006556287,0.000060530434,0.000060533504,0.000004745607,0.000058221874,0.000047959096,0.85890543],"category_scores_gemma":[0.01305929,0.00012561669,0.00019883775,0.00018722314,0.000014625201,0.000028509801,0.000069079964,0.00003978262,0.00008495266],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021370126,0.000863954,0.000063119274,0.00037263517,0.0008358299,0.00007831016,0.0008299986,0.000001311209,0.000010286184,0.000001531934,0.99625957,0.0004697502],"study_design_scores_gemma":[0.0021753577,0.00018631782,0.0040414985,0.0053388816,0.00020483522,0.000007955918,0.009200069,0.000011161446,0.0035351536,0.0000588672,0.97510326,0.00013662812],"about_ca_topic_score_codex":6.8493677e-7,"about_ca_topic_score_gemma":0.00007280138,"teacher_disagreement_score":0.8588205,"about_ca_system_score_codex":0.00009103457,"about_ca_system_score_gemma":0.00029519165,"threshold_uncertainty_score":0.99525416},"labels":[],"label_agreement":null},{"id":"W6910884751","doi":"10.5167/uzh-8143","title":"Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?","year":2008,"lang":"en","type":"article","venue":"Zurich Open Repository and Archive (University of Zurich)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Abacavir; Nevirapine; Efavirenz; Lamivudine; Nelfinavir; Zidovudine; Cohort; Hazard ratio; Odds ratio; Cohort study","score_opus":0.03271802060275515,"score_gpt":0.31658760271415654,"score_spread":0.2838695821114014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6910884751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956844,0.000047085818,0.0001010327,0.00076820265,0.00018180945,0.0012214533,0.000016600483,0.000023681803,0.0019557439],"genre_scores_gemma":[0.9857807,0.000694356,0.012257537,0.00019902384,0.000059714872,0.0000028790057,0.00005556732,0.000018607263,0.0009316229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665195,0.0011940968,0.00075907883,0.00069983624,0.0003339614,0.00036107228],"domain_scores_gemma":[0.99827844,0.0007994666,0.00027058178,0.00030059833,0.00008827977,0.0002626192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011989697,0.00026598573,0.00083250273,0.0003027013,0.0002863895,0.000016671218,0.00036141506,0.00017929646,0.000018048719],"category_scores_gemma":[0.0001625444,0.00021217515,0.00018386634,0.00036295506,0.00024915743,0.0005962856,0.00031746287,0.00052979216,0.0000115119565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002959785,0.0021367525,0.9791513,0.000029235413,0.00017528821,0.0016382331,0.0039832047,0.0000016714891,0.0002324838,0.000009562933,0.00035111292,0.009331356],"study_design_scores_gemma":[0.006507943,0.002543124,0.9881036,0.00019705255,0.00007675954,0.000041757252,0.0009469416,0.000046863184,0.000069811584,0.00003914452,0.0011680108,0.00025897913],"about_ca_topic_score_codex":0.00019447441,"about_ca_topic_score_gemma":0.0001365348,"teacher_disagreement_score":0.012156504,"about_ca_system_score_codex":0.00005746477,"about_ca_system_score_gemma":0.00017068221,"threshold_uncertainty_score":0.86522514},"labels":[],"label_agreement":null},{"id":"W6920419010","doi":"10.60692/rnae0-z5w17","title":"The frequencies of naturally occurring protease inhibitor resistance mutations in HIV proviral sequences of drug naïve sex workers in Nairobi, Kenya and their correlation with host immune response driven positively selected mutations in HIV-1","year":2014,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Manitoba","funders":"","keywords":"Drug resistance; Human immunodeficiency virus (HIV); Drug; Antiretroviral drug; Protease inhibitor (pharmacology); Immune system; Mutation; Protease; Antiretroviral therapy","score_opus":0.006960687919471002,"score_gpt":0.19368018612363586,"score_spread":0.18671949820416486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920419010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735093,0.000024839135,0.0005255273,0.00028340804,0.000024952216,0.001472523,0.00006771379,0.00003330024,0.00021679669],"genre_scores_gemma":[0.9981516,2.9816349e-7,0.0010984092,0.000007653194,0.000005801042,0.00022120314,0.00009138293,0.000008707145,0.0004149414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982987,0.00027816038,0.0008490753,0.00014541813,0.0002380902,0.00019056899],"domain_scores_gemma":[0.99892527,0.00013236945,0.00047829415,0.00015626923,0.00026599344,0.000041827396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066752185,0.0001823283,0.00031834675,0.00052189204,0.00010835757,0.000041940693,0.000073719544,0.00007025556,7.2376116e-7],"category_scores_gemma":[0.00012516533,0.00011716147,0.00002928977,0.0007281877,0.00013695672,0.000502833,0.000020153515,0.00016549716,0.0000049736864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001269914,0.000010927057,0.7914875,0.0002730953,0.00003335508,0.000005326658,0.20592584,0.0006211541,0.00027636823,0.00004859771,0.000003260472,0.000044670895],"study_design_scores_gemma":[0.0034368094,0.0000814855,0.88473386,0.003146426,0.000025530975,0.000018808252,0.09888234,0.004370769,0.005143929,0.0000022224394,0.0000067416827,0.00015109767],"about_ca_topic_score_codex":0.00006629993,"about_ca_topic_score_gemma":0.00009960664,"teacher_disagreement_score":0.10704349,"about_ca_system_score_codex":0.00033420388,"about_ca_system_score_gemma":0.00032011498,"threshold_uncertainty_score":0.4777706},"labels":[],"label_agreement":null},{"id":"W6920442312","doi":"10.6084/m9.figshare.13558680","title":"Additional file 5 of HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple drug resistance; Human immunodeficiency virus (HIV); Sensitivity (control systems); MEDLINE; Drug resistance","score_opus":0.03531599220748224,"score_gpt":0.267156527685438,"score_spread":0.23184053547795577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920442312","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000716458,0.017763838,1.1129378e-7,0.00052986335,9.240691e-7,0.00039807198,0.9807077,0.00001549766,0.0005768198],"genre_scores_gemma":[0.00043181962,0.00018935151,0.0006417426,0.0002472323,0.0000063340094,0.0021481726,0.9748893,0.000008435337,0.021437641],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9991919,0.00006834593,0.00028971606,0.0001963676,0.00017731592,0.00007635533],"domain_scores_gemma":[0.9989558,0.00047699382,0.00012949455,0.00017585536,0.00019199049,0.00006986575],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000035596655,0.00011686332,0.0009675241,0.00008368226,0.000039468818,0.0000115676385,0.000015229972,0.00003490648,0.9726822],"category_scores_gemma":[0.0020542934,0.000081144484,0.00029872425,0.00034273465,0.0000052821633,0.000046851077,0.000035811256,0.00004856134,0.00024955807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017568588,0.000042144824,0.0000052546807,0.08129481,0.029204387,0.000026662578,0.000030186857,8.173481e-8,9.922171e-7,8.0342727e-7,0.88938975,0.0000031875009],"study_design_scores_gemma":[0.00048701544,0.00003930205,0.005084994,0.08433959,0.7230581,0.00016130965,0.000077914454,0.00012416372,0.00015932697,0.000007651049,0.1861619,0.0002987377],"about_ca_topic_score_codex":0.0000017672143,"about_ca_topic_score_gemma":0.000026448106,"teacher_disagreement_score":0.9724326,"about_ca_system_score_codex":0.00002338953,"about_ca_system_score_gemma":0.000059310092,"threshold_uncertainty_score":0.3308976},"labels":[],"label_agreement":null},{"id":"W6920504993","doi":"10.6084/m9.figshare.14451075","title":"Additional file 2 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug; MEDLINE; Confidentiality; Drug trial","score_opus":0.275671499480915,"score_gpt":0.42569026588947256,"score_spread":0.15001876640855755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920504993","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005541569,0.0010336228,7.55418e-7,0.0016306957,0.000016098857,0.00087396224,0.9953999,0.000030396326,0.00046044678],"genre_scores_gemma":[0.00035431105,0.000013448282,0.042662278,0.00009164954,0.00010034398,0.004738607,0.8249845,0.000015931986,0.12703896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998725,0.000092549075,0.00047026292,0.00029072128,0.0002683945,0.00015309686],"domain_scores_gemma":[0.9945918,0.0036083607,0.0002524757,0.00023296961,0.0012544981,0.000059895057],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006415761,0.0001813928,0.0006557248,0.000060510523,0.000060543527,0.0000047460853,0.000058226582,0.000047963644,0.8596706],"category_scores_gemma":[0.0129019385,0.00012560762,0.00019881122,0.00018714505,0.000014623907,0.000028507116,0.000069122056,0.00003978163,0.00008306712],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021121324,0.0008642511,0.00006097474,0.00036961448,0.0008367151,0.00007954138,0.0008308302,0.0000013175334,0.000009893947,0.0000015703641,0.99625796,0.00047610595],"study_design_scores_gemma":[0.002151921,0.00018596281,0.003985343,0.0052639507,0.00020527189,0.000008024148,0.009116127,0.000011026731,0.003422654,0.0000589623,0.9754549,0.0001358339],"about_ca_topic_score_codex":6.839731e-7,"about_ca_topic_score_gemma":0.000072731236,"teacher_disagreement_score":0.85958755,"about_ca_system_score_codex":0.00009068602,"about_ca_system_score_gemma":0.00029366376,"threshold_uncertainty_score":0.9954128},"labels":[],"label_agreement":null},{"id":"W6920972720","doi":"10.6084/m9.figshare.25459684","title":"Additional file 2 of Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"SALSA; Pooled analysis; Clinical trial; Baseline (sea); Physical activity; Renal transplant; Adverse effect","score_opus":0.0235665023628804,"score_gpt":0.25667510707875224,"score_spread":0.23310860471587183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920972720","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10262618,0.00060370273,3.2944237e-7,0.001481676,0.000007334356,0.00040435107,0.8946769,0.000024559373,0.00017495968],"genre_scores_gemma":[0.3695405,0.00003805664,0.0016885854,0.000108976994,0.0000617167,0.00032421152,0.6269783,0.000018605844,0.0012410613],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991031,0.000044164495,0.00026340436,0.0002649021,0.00019630924,0.00012810143],"domain_scores_gemma":[0.9962599,0.003432242,0.00006460649,0.00013658761,0.00005228824,0.00005433322],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000061199586,0.00013885925,0.00033298373,0.00006924524,0.00003579901,0.000015030205,0.0000591466,0.000048948743,0.21886648],"category_scores_gemma":[0.0019280236,0.000079192665,0.000029480641,0.00020709315,0.000018005143,0.0000436912,0.00010021852,0.00013845293,0.00008368754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007617239,0.000089215755,0.00023876764,0.000099395766,0.00026588043,0.00008108784,0.0033802146,0.0000028633463,0.00019728801,0.0000019365677,0.99383485,0.0010467863],"study_design_scores_gemma":[0.0031272736,0.00026556093,0.81960684,0.0119749075,0.000097722295,0.000013836214,0.0006655641,0.00005378822,0.0001370345,0.000030165522,0.1638846,0.00014273562],"about_ca_topic_score_codex":0.000016486874,"about_ca_topic_score_gemma":0.00028836596,"teacher_disagreement_score":0.8299503,"about_ca_system_score_codex":0.000026651906,"about_ca_system_score_gemma":0.00007042192,"threshold_uncertainty_score":0.7818476},"labels":[],"label_agreement":null},{"id":"W6928981349","doi":"10.3897/zookeys.75.767.maps9-12","title":"Maps 9-12 from: Brunke A, Marshall S (2011) Contributions to the faunistics and bionomics of Staphylinidae (Coleoptera) in northeastern North America: discoveries made through study of the University of Guelph Insect Collection, Ontario, Canada. ZooKeys 75: 29-68. https://doi.org/10.3897/zookeys.75.767","year":2011,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bionomics; Melanism; Distribution (mathematics); Zoogeography; Aquatic insect; Entomophthorales; Entomology","score_opus":0.023797860494516217,"score_gpt":0.20998967179206598,"score_spread":0.18619181129754978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6928981349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68772674,0.00017970848,0.00045983592,0.001148422,0.00022419334,0.0038496524,0.00244129,0.000103278726,0.30386686],"genre_scores_gemma":[0.6767661,0.00025337233,0.000113881215,0.00003904924,0.00004816079,2.1867069e-7,0.0012466185,0.00048285263,0.32104975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983385,0.00029851485,0.00038854565,0.00036481422,0.00037101586,0.00023858692],"domain_scores_gemma":[0.9985581,0.000043276086,0.00038088937,0.00055128336,0.0003567194,0.00010974768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015906554,0.00024041995,0.0004833444,0.00019433432,0.0005178065,0.000034132194,0.0005218722,0.00008310001,0.032934662],"category_scores_gemma":[0.000105462714,0.00019061092,0.000058737038,0.0004004261,0.00030196056,0.000056273322,0.00073871197,0.0003116908,0.0006654281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013970921,0.0020088921,0.26718158,0.00023750911,0.0015718668,0.00005074574,0.038607303,0.000047971964,0.00004266819,0.00022448914,0.6872799,0.0013500088],"study_design_scores_gemma":[0.0014909457,0.00035931516,0.28579658,0.00012440966,0.00017951646,0.0000012986421,0.0026211739,0.000012883192,0.000028216744,0.000007924857,0.70922637,0.00015132796],"about_ca_topic_score_codex":0.69269156,"about_ca_topic_score_gemma":0.61264163,"teacher_disagreement_score":0.08004994,"about_ca_system_score_codex":0.0005052065,"about_ca_system_score_gemma":0.00018985837,"threshold_uncertainty_score":0.9679494},"labels":[],"label_agreement":null},{"id":"W6929456239","doi":"10.48610/6aea03b","title":"Knowledge Translation and Impact Questionnaire: Summary of questions","year":2022,"lang":"en","type":"dataset","venue":"The University of Queensland","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Likert scale; Knowledge translation; Scale (ratio); Translation (biology); Work (physics)","score_opus":0.024041495646623223,"score_gpt":0.26799103559123316,"score_spread":0.24394953994460994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929456239","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008901195,0.006376271,0.00003211746,0.0016128093,0.00008791792,0.0006080066,0.9816045,0.000025020097,0.0007521173],"genre_scores_gemma":[0.013103016,0.005497197,0.00017047524,0.000011094744,0.000036760703,8.7194894e-7,0.97541434,0.000012478923,0.005753792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993868,0.00011065733,0.00012529352,0.00013724249,0.0001499196,0.00009008809],"domain_scores_gemma":[0.9994175,0.00010925876,0.0001247324,0.00023337548,0.00005798108,0.000057158817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017309694,0.00013385252,0.00031457382,0.00016926393,0.00014839492,0.00000234238,0.00009648017,0.00008786696,0.0014940756],"category_scores_gemma":[0.000015691223,0.00010381723,0.00010399874,0.00014657645,0.00018393704,0.000034403874,0.000056446795,0.00018548666,0.0000058264513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025328394,0.00017740343,0.0024328195,0.00023978563,0.00033455723,0.000026577469,0.0010903339,0.0000034394868,0.0000062589224,0.0000111056215,0.993967,0.0014574365],"study_design_scores_gemma":[0.0015373318,0.00020997661,0.017012617,0.000375375,0.0011469335,0.000032813892,0.00028928492,0.000023819537,0.000007995415,0.000037000267,0.9792022,0.00012464325],"about_ca_topic_score_codex":0.0011047311,"about_ca_topic_score_gemma":0.00066271535,"teacher_disagreement_score":0.01476479,"about_ca_system_score_codex":0.00008867892,"about_ca_system_score_gemma":0.000249369,"threshold_uncertainty_score":0.9994187},"labels":[],"label_agreement":null},{"id":"W6929518472","doi":"10.5061/dryad.6f774","title":"Data from: Phylogenetic relatedness, phenotypic similarity, and plant-soil feedbacks","year":2016,"lang":"en","type":"dataset","venue":"Data Archiving and Networked Services (DANS)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Trait; Phylogenetic tree; Biodiversity; Plant species; Plant ecology; Similarity (geometry); Plant evolution; Plant community","score_opus":0.03215056037261502,"score_gpt":0.2704214792511941,"score_spread":0.23827091887857907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929518472","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013467461,0.005962843,0.000034767418,0.0006200612,0.00040268566,0.00050315383,0.97869986,0.00009531442,0.00021383136],"genre_scores_gemma":[0.0012222626,0.021152686,0.00061487564,0.00040990507,0.0009522537,0.000019320023,0.9746653,0.00007500231,0.0008884336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995898,0.00021360266,0.00065976154,0.0019991938,0.0004976011,0.00073183386],"domain_scores_gemma":[0.9940988,0.0005734841,0.00032946642,0.0045023416,0.000030595522,0.00046535308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004958318,0.000831887,0.0010771782,0.00019276243,0.00039571262,0.00018312641,0.0021783565,0.00040873667,0.00017228162],"category_scores_gemma":[0.00002959109,0.00060242217,0.00004515064,0.00018241002,0.00024660563,0.0003100263,0.0053303656,0.0007155981,0.0001483989],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034404485,0.0001872955,0.010560003,0.00096042076,0.0011606247,0.00032134194,0.00031553852,0.0000015823214,0.000027722679,0.0000015661099,0.9794672,0.006652661],"study_design_scores_gemma":[0.0023162672,0.00006995761,0.012876029,0.003987604,0.0021453162,0.00012311817,0.00011549048,0.005072151,0.0000045628417,0.00017032822,0.9723326,0.0007865778],"about_ca_topic_score_codex":0.0013044418,"about_ca_topic_score_gemma":0.009643021,"teacher_disagreement_score":0.015189844,"about_ca_system_score_codex":0.00004123755,"about_ca_system_score_gemma":0.00017675576,"threshold_uncertainty_score":0.9996427},"labels":[],"label_agreement":null},{"id":"W6929547087","doi":"10.5061/dryad.67n79r2","title":"Data from: Landscape, colonization and life history: their effects on genetic diversity in four sympatric species inhabiting a dendritic system","year":2019,"lang":"en","type":"dataset","venue":"DRYAD","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Colonization; Sympatric speciation; Genetic diversity; Metapopulation; Gene flow; Colonisation; Genetic structure; Biological dispersal","score_opus":0.045719640977400666,"score_gpt":0.23620226242222903,"score_spread":0.19048262144482836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929547087","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16132504,0.0039678374,0.000007687909,0.0001800706,0.00077705557,0.0012289028,0.832208,0.000052300034,0.00025312864],"genre_scores_gemma":[0.09170691,0.00050706865,0.00007889209,0.00014383724,0.00030084382,0.000020782014,0.90633273,0.000022800685,0.0008861426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984995,0.00012703311,0.00025658912,0.00056800066,0.0003140857,0.00023479329],"domain_scores_gemma":[0.99859846,0.00037432127,0.00016217816,0.00069904584,0.00003741473,0.00012859404],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015164872,0.00030788057,0.0006318186,0.00036570846,0.00008804337,0.000023665258,0.00024838676,0.00022300462,0.000077311655],"category_scores_gemma":[0.0001932172,0.00026173776,0.000036534162,0.00016377597,0.000025552663,0.000059025962,0.0005708635,0.00025817193,0.00031396153],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006544027,0.00007415558,0.110562295,0.001233773,0.00016023585,0.0005437754,0.00018166877,0.0000011306307,0.0000018230286,0.000001724679,0.88706344,0.00011051155],"study_design_scores_gemma":[0.005564344,0.00024286108,0.19999829,0.00372749,0.0011627356,0.00003705242,0.00029912384,0.0006764768,0.000011339103,0.0000023961798,0.7877076,0.0005702632],"about_ca_topic_score_codex":0.00016043652,"about_ca_topic_score_gemma":0.00029606343,"teacher_disagreement_score":0.09935583,"about_ca_system_score_codex":0.0006398865,"about_ca_system_score_gemma":0.00022152743,"threshold_uncertainty_score":0.9999835},"labels":[],"label_agreement":null},{"id":"W6929883078","doi":"10.5255/ukda-sn-8514-1","title":"Quarterly Labour Force Survey Household Dataset, April - June, 2019","year":2020,"lang":"en","type":"dataset","venue":"UK Data Archive","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Unemployment; Work (physics); Sample (material); Survey data collection; Northern ireland; Data collection; Work force; Data source","score_opus":0.04859788392198446,"score_gpt":0.2917794080818453,"score_spread":0.24318152415986086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929883078","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002953136,0.0002553783,0.00012286357,0.001271997,0.00060826354,0.0010555529,0.99648553,0.0000898533,0.0000810505],"genre_scores_gemma":[0.000009167196,0.0010056873,0.0017950895,0.0013175395,0.00055327045,0.000044929362,0.98551804,0.00008550062,0.009670776],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99583226,0.00029539812,0.0007382163,0.0016335383,0.00078686024,0.00071371894],"domain_scores_gemma":[0.9938586,0.0005047712,0.00033861143,0.00464391,0.000042903892,0.0006112231],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051777414,0.000799638,0.0011906129,0.00031719366,0.00016733356,0.00012465662,0.0019018775,0.00024838815,0.0006015473],"category_scores_gemma":[0.00028295847,0.00067885255,0.000110493405,0.00034142032,0.00015757937,0.00022294118,0.0012152932,0.0009920872,0.0064768805],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038453686,0.00028253967,0.0004042162,0.00031672936,0.00091203296,0.0010363834,0.000105886844,2.020547e-7,0.000007383853,0.000014522088,0.996027,0.00050855876],"study_design_scores_gemma":[0.0020527479,0.00023676794,0.0040797675,0.0002454603,0.00069825584,0.00007614979,0.000039034345,0.000015575344,0.0000059245626,0.000041866704,0.9918787,0.00062977825],"about_ca_topic_score_codex":0.0026924198,"about_ca_topic_score_gemma":0.006554732,"teacher_disagreement_score":0.01096747,"about_ca_system_score_codex":0.00007910685,"about_ca_system_score_gemma":0.0007805055,"threshold_uncertainty_score":0.99956626},"labels":[],"label_agreement":null},{"id":"W6930466949","doi":"10.5281/zenodo.13973843","title":"Linked collectors and determiners for: Canadian National Collection of Insects.","year":2024,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Data collection; Attribution; Natural (archaeology); Biodiversity","score_opus":0.03194582849760584,"score_gpt":0.26558708265265124,"score_spread":0.23364125415504539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930466949","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010348218,0.000165451,0.000009863943,0.0012724239,0.00019504667,0.0013559645,0.9847593,0.00015232526,0.011054853],"genre_scores_gemma":[0.0037301984,0.00027976467,0.00013503776,0.000094710864,0.00013072,4.300659e-7,0.9884322,0.00057829043,0.006618638],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867,0.00007197205,0.000275767,0.0003651934,0.0003631352,0.0002539535],"domain_scores_gemma":[0.998745,0.00003767409,0.00009139285,0.00019038915,0.0006757909,0.00025973597],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034341426,0.00018351714,0.00026049413,0.0009891856,0.0008374221,0.00018137132,0.00020242362,0.00015793246,0.00239415],"category_scores_gemma":[0.0006044632,0.00018156321,0.000064201675,0.0006383017,0.00010560519,0.0000528182,0.00019139233,0.00023215191,0.0014723834],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088732726,0.00006152573,0.0000037342907,0.0004465341,0.0002193,0.000023486962,0.00024340728,9.1428336e-7,0.000072362825,0.000041022315,0.9970861,0.0017128557],"study_design_scores_gemma":[0.0008492937,0.0002775895,0.00013935337,0.00015574427,0.0001464579,0.00013667268,0.000057036348,0.000087509565,0.00006293038,0.000040484785,0.9978977,0.00014923893],"about_ca_topic_score_codex":0.0009037866,"about_ca_topic_score_gemma":0.0004925686,"teacher_disagreement_score":0.0044362145,"about_ca_system_score_codex":0.0007074892,"about_ca_system_score_gemma":0.00013268266,"threshold_uncertainty_score":0.99930507},"labels":[],"label_agreement":null},{"id":"W6930547592","doi":"10.5281/zenodo.12687613","title":"Environmental and food web determinants of Lake Trout mercury concentrations in Ontario Lakes","year":2025,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of the Environment, Conservation and Parks; Lakehead University","funders":"","keywords":"Trout; Food web; Boreal; Biomagnification; Mercury (programming language); Habitat; Forage fish; Dissolved organic carbon; Piscivore","score_opus":0.018347162672863872,"score_gpt":0.2274364055146153,"score_spread":0.20908924284175143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930547592","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.067350805,0.00045146004,0.000025691872,0.0003642271,0.00008440173,0.0013268528,0.00153074,0.00026412238,0.9286017],"genre_scores_gemma":[0.41535327,0.0005167238,0.00023775637,0.00004244061,0.00003787175,1.6282344e-7,0.0027615258,0.0015490982,0.57950115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99899554,0.000079234655,0.00023421655,0.00029125036,0.00020825976,0.00019147768],"domain_scores_gemma":[0.99955434,0.000010766873,0.00009707262,0.00021712837,0.000030188596,0.00009052587],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011048846,0.000158826,0.00027759842,0.0003165398,0.00018314042,0.000052785686,0.00015648089,0.00010102981,0.02981149],"category_scores_gemma":[0.000045725934,0.0001557221,0.00003749217,0.00011362334,0.00013347706,0.00003902047,0.00024688168,0.00018943095,0.0008357135],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002683806,0.0018278387,0.042274445,0.0007949048,0.0008987019,0.00020045624,0.005665766,0.0000011197523,0.0021865005,0.0015619033,0.87661964,0.06770036],"study_design_scores_gemma":[0.001340704,0.00018622687,0.012102346,0.0002715518,0.00006595543,0.000030490637,0.00013290894,0.0000119783035,0.00011573977,0.000008537084,0.98561513,0.00011843766],"about_ca_topic_score_codex":0.00010504831,"about_ca_topic_score_gemma":0.0039727543,"teacher_disagreement_score":0.34910056,"about_ca_system_score_codex":0.00017217308,"about_ca_system_score_gemma":0.000030217681,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W6930875358","doi":"10.5281/zenodo.165537","title":"FIGURE 21 in Guide to the Parasites of Fishes of Canada Part V: Nematoda","year":2016,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Taxonomy (biology); Sparganosis; Morphology (biology); Holotype","score_opus":0.01588620496923735,"score_gpt":0.25283072070000395,"score_spread":0.2369445157307666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930875358","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007159726,0.00023674441,0.000042208794,0.0064174575,0.00007322995,0.0007983491,0.0004457036,0.00009738323,0.99117297],"genre_scores_gemma":[0.005886177,0.00019436865,0.00018193883,0.00014555,0.000120133576,1.4888568e-7,0.00078506325,0.0019593618,0.99072725],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987188,0.000116409865,0.0002998148,0.0002325318,0.00040048917,0.00023194599],"domain_scores_gemma":[0.99910086,0.000033625176,0.00014737133,0.00041467277,0.00018917274,0.0001142819],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002625703,0.00014709364,0.00029172288,0.00021931384,0.00014373843,0.000026097852,0.00039912693,0.00006323448,0.060465697],"category_scores_gemma":[0.00045051298,0.00009776141,0.000038709964,0.00029755526,0.00006559863,0.000019531932,0.00027889857,0.00010887757,0.0016478049],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036833353,0.0000621002,0.00012827806,0.00014152497,0.000101344776,0.000024624223,0.00029853432,0.0000012329141,0.00010054168,0.00018480704,0.99314046,0.0057797013],"study_design_scores_gemma":[0.00041491483,0.00005593937,0.00061699364,0.00066124136,0.00002426941,0.0000136560075,0.00013233385,0.0000018395656,0.0004666188,0.000004444537,0.9975155,0.00009227178],"about_ca_topic_score_codex":0.0046747024,"about_ca_topic_score_gemma":0.0029834984,"teacher_disagreement_score":0.058817893,"about_ca_system_score_codex":0.00015233175,"about_ca_system_score_gemma":0.000049191032,"threshold_uncertainty_score":0.99912953},"labels":[],"label_agreement":null},{"id":"W6930982545","doi":"10.5281/zenodo.15151450","title":"Table 2. Available Sclerocoelus Marshall, 1995 in A revision of the genus Sclerocoelus Marshall (Diptera: Sphaeroceridae)","year":2025,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Table (database); Barcode; Sequence (biology); Bin","score_opus":0.02680956487841907,"score_gpt":0.2500344718227005,"score_spread":0.22322490694428143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930982545","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028144838,0.0028496657,0.000058986046,0.0033725824,0.0005887867,0.005896285,0.91539806,0.0005184116,0.06850273],"genre_scores_gemma":[0.002366317,0.003406721,0.00030556606,0.00038123212,0.0001680548,5.779901e-7,0.95575875,0.0008009443,0.036811847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963993,0.00040205248,0.000807518,0.0008475952,0.00089171896,0.00065181724],"domain_scores_gemma":[0.99735534,0.000052147177,0.00036583835,0.0013932275,0.00061472296,0.00021873976],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00085063494,0.0004514273,0.00071897754,0.0006219707,0.00094199425,0.0002964332,0.0014784585,0.00028943366,0.023282725],"category_scores_gemma":[0.0007337064,0.00037321803,0.00016907616,0.0015997228,0.00019591076,0.00017589456,0.002718857,0.0008196644,0.003959307],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024156233,0.000495352,0.000025278185,0.0010745672,0.00017435463,0.00008307002,0.00015535104,0.0000054362686,0.00012735116,0.00003251129,0.9755352,0.02204996],"study_design_scores_gemma":[0.0020775436,0.000169799,0.00034995942,0.0020148116,0.0001694618,0.000089208275,0.00006670419,0.000034560984,0.00019729567,0.0000072834137,0.99453795,0.00028540712],"about_ca_topic_score_codex":0.0001408007,"about_ca_topic_score_gemma":0.000010213183,"teacher_disagreement_score":0.04036067,"about_ca_system_score_codex":0.00056546775,"about_ca_system_score_gemma":0.000089467474,"threshold_uncertainty_score":0.99987197},"labels":[],"label_agreement":null},{"id":"W6931247127","doi":"10.5281/zenodo.3792525","title":"Oreiscelio cultrarius Talamas &amp; Johnson &amp; van Noort &amp; Masner &amp; Polaszek 2009, sp. n.","year":2009,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agriculture and Agri-Food Canada","funders":"","keywords":"Sculpture; Seta; Dorsum; Apex (geometry); Pedicel","score_opus":0.038316495692692486,"score_gpt":0.2722459459214909,"score_spread":0.23392945022879838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931247127","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25751075,0.0009432662,0.008304361,0.017447995,0.00042326024,0.0028464359,0.0004997599,0.0037514614,0.7082727],"genre_scores_gemma":[0.41328278,0.0014286877,0.01750508,0.0019142862,0.0010567647,6.7420655e-7,0.029627752,0.0036233056,0.53156066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624044,0.00027777054,0.0006314605,0.0009094333,0.0009965835,0.00094429025],"domain_scores_gemma":[0.9972234,0.000033597673,0.00019662704,0.0011315095,0.0007325315,0.0006823488],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007204964,0.00048074836,0.0005042076,0.00063824287,0.0016743648,0.0006026658,0.0007042186,0.00019730124,0.0396216],"category_scores_gemma":[0.00066764833,0.0004433784,0.00019909602,0.0011626504,0.00020062603,0.0003131349,0.00043573696,0.0006141874,0.09697804],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038651025,0.0010384908,0.00038729198,0.000083366576,0.0002444419,0.00008020049,0.002468643,0.000021432223,0.013012509,0.0009244373,0.9429722,0.038380478],"study_design_scores_gemma":[0.0019652918,0.00018069158,0.005156214,0.000110867164,0.000120332916,0.0005425288,0.000074154406,0.000008463406,0.0004957548,0.00023447747,0.99065274,0.00045845547],"about_ca_topic_score_codex":0.000031393196,"about_ca_topic_score_gemma":0.000011316778,"teacher_disagreement_score":0.17671205,"about_ca_system_score_codex":0.00044456503,"about_ca_system_score_gemma":0.0000293314,"threshold_uncertainty_score":0.9998018},"labels":[],"label_agreement":null},{"id":"W6931411217","doi":"10.5281/zenodo.6108877","title":"Two links in the research data life cycle: collaboration between a university and long-term repository","year":2022,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Commission","keywords":"Trustworthiness; Research data; Information system; Information repository; The Internet; Audit; SWORD; Data curation; Digital preservation","score_opus":0.060434769683019036,"score_gpt":0.3033162431707371,"score_spread":0.24288147348771805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931411217","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010986531,0.000804981,0.000050889645,0.0073722606,0.00008649861,0.002377654,0.001021012,0.0005471165,0.97675306],"genre_scores_gemma":[0.14173998,0.0018994982,0.00042387669,0.00024135246,0.0010768784,3.0813518e-7,0.05521146,0.0059170467,0.7934896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698484,0.0012143733,0.00019384513,0.00059445394,0.00071959203,0.00029288107],"domain_scores_gemma":[0.9985002,0.000072004266,0.00010434482,0.0009591145,0.0002016543,0.00016268184],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001513414,0.00015884123,0.00022811616,0.0006529988,0.001400135,0.00032715374,0.0010477075,0.00014240961,0.009347982],"category_scores_gemma":[0.00035220277,0.00014287034,0.000021311958,0.0011058545,0.0002078936,0.00011136238,0.0021648342,0.0009100362,0.0008151305],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095910334,0.00018633157,0.0015605553,0.0001401201,0.00016543016,0.00041041203,0.0016721719,5.744618e-7,0.000019775218,0.0002890565,0.98506385,0.010395821],"study_design_scores_gemma":[0.0012717322,0.00012751008,0.008456757,0.00010449022,0.00007301082,0.00006498455,0.0013036043,0.000021926362,0.0000031317672,0.000006380226,0.9884356,0.00013085155],"about_ca_topic_score_codex":0.00007426535,"about_ca_topic_score_gemma":0.000016407033,"teacher_disagreement_score":0.18326347,"about_ca_system_score_codex":0.00033215346,"about_ca_system_score_gemma":0.00005018101,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W6931716264","doi":"10.5683/sp2/e6upgt","title":"Waterton Visitor Centre -- Waterton -- Laser Scanning -- Metadata -- 2018","year":2018,"lang":"en","type":"dataset","venue":"Borealis","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Metadata; Visitor pattern; Laser scanning; 3d scanning","score_opus":0.015688205331153945,"score_gpt":0.26560594949954014,"score_spread":0.2499177441683862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931716264","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000274162,0.00022036719,0.00000490004,0.003040693,0.00068543636,0.00078722264,0.99411315,0.00014755836,0.0007265379],"genre_scores_gemma":[0.000019542762,0.00046853666,0.00069798273,0.0005860602,0.0017386583,0.000060085666,0.95616645,0.00009673623,0.04016595],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99636465,0.00010769018,0.0007089472,0.0010323222,0.00087895285,0.0009074115],"domain_scores_gemma":[0.99718165,0.000055389108,0.00026794698,0.001767945,0.00021072029,0.00051633216],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029452407,0.0008674119,0.0011383913,0.0004056934,0.00022922833,0.00019906972,0.00050207734,0.0005725237,0.001243911],"category_scores_gemma":[0.00007746677,0.00060949026,0.0003075456,0.00020800276,0.00015536851,0.00029970272,0.00035339658,0.00041203987,0.00081819494],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022851375,0.00031995933,0.00028339782,0.00030319078,0.0010208116,0.00086471305,0.00017940286,1.06942636e-7,0.000020962381,0.0000020348914,0.9963745,0.00040241584],"study_design_scores_gemma":[0.0017587605,0.00013794993,0.00027742557,0.0007375547,0.001671526,0.00008311333,0.00004987048,0.0000055112455,0.0041407906,0.000011882443,0.99049073,0.0006349025],"about_ca_topic_score_codex":0.010332425,"about_ca_topic_score_gemma":0.004487553,"teacher_disagreement_score":0.039439414,"about_ca_system_score_codex":0.00035900038,"about_ca_system_score_gemma":0.00028910796,"threshold_uncertainty_score":0.99995977},"labels":[],"label_agreement":null},{"id":"W6931839009","doi":"10.5281/zenodo.8212217","title":"FIGURE 2. 50 in Studies in Hygrocybe s.l. (Hygrocyboideae, Hygrophoraceae) in Brazil: New species of Humidicutis and Neohygrocybe","year":2023,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ontario Museum","funders":"","keywords":"Identification (biology); Line (geometry); Sequence (biology)","score_opus":0.05713003591854387,"score_gpt":0.3048795352262231,"score_spread":0.2477494993076792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931839009","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029844802,0.01000237,0.000025742396,0.004166436,0.00028115383,0.0029551352,0.00023301448,0.0013879226,0.95110345],"genre_scores_gemma":[0.033609387,0.01721001,0.0004404526,0.00008856878,0.00022173277,5.2510075e-7,0.0009255488,0.0070723924,0.94043136],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997631,0.00020442432,0.00059526006,0.00063784944,0.0004615485,0.00046990646],"domain_scores_gemma":[0.9990477,0.00006617843,0.00020170833,0.00039139632,0.00012014199,0.00017285335],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00048076943,0.00035417013,0.00078389345,0.0017658203,0.00015344926,0.00008273899,0.00035092302,0.00021895046,0.0072633782],"category_scores_gemma":[0.00066791696,0.00034236675,0.00006093958,0.0013652811,0.00025322582,0.00009081321,0.000736787,0.00047228206,0.0021404775],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019794426,0.00027436443,0.0012565394,0.0007049655,0.000205553,0.00051379454,0.0048861015,0.0000056961926,0.00028808689,0.0005402124,0.97054464,0.020582104],"study_design_scores_gemma":[0.0026272193,0.00017036695,0.008177413,0.0019010182,0.00003791345,0.000042051637,0.0017703908,0.000011355595,0.00013435852,0.000078281344,0.9847641,0.00028555898],"about_ca_topic_score_codex":0.0003709291,"about_ca_topic_score_gemma":0.0002298112,"teacher_disagreement_score":0.020296546,"about_ca_system_score_codex":0.00044310698,"about_ca_system_score_gemma":0.000026548036,"threshold_uncertainty_score":0.99990284},"labels":[],"label_agreement":null},{"id":"W6939069829","doi":"10.60692/v1n26-eb696","title":"Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy‐years","year":2014,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; University of British Columbia","funders":"","keywords":"Viremia; Efavirenz; Viral load; Percentile; Lopinavir; Cumulative incidence; Antiretroviral therapy","score_opus":0.04250480904279052,"score_gpt":0.24260134608306932,"score_spread":0.2000965370402788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939069829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520093,0.000006774923,0.0021665879,0.000049199574,0.0000932392,0.00039706018,0.0000048219804,0.00006100293,0.0020203835],"genre_scores_gemma":[0.9992759,1.743224e-7,0.00044692386,0.000049402963,0.000033713306,0.000009037923,0.000018941038,0.000007407692,0.00015845889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905187,0.000045866567,0.00044828112,0.00008718222,0.00022437534,0.00014240216],"domain_scores_gemma":[0.9993967,0.000018862898,0.0002171486,0.0002289349,0.00007369113,0.00006467112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027565588,0.00012493345,0.000283923,0.0001274733,0.00009382639,0.000043712767,0.000058254656,0.00005458315,0.0000045026],"category_scores_gemma":[0.000015536065,0.000081022044,0.00004511019,0.00013866262,0.000045915112,0.00016465157,0.000043671556,0.00006503744,0.0000879073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013392183,0.000004283117,0.9539534,0.000438817,0.00011280043,0.0000021051692,0.043986674,0.00005271263,0.00001283606,0.00017204008,0.00004164769,0.0010888068],"study_design_scores_gemma":[0.0058539407,0.00006610582,0.964913,0.0012286697,0.00023563288,0.00014060571,0.005610697,0.019147694,0.0015872695,5.930662e-7,0.0010205718,0.0001951914],"about_ca_topic_score_codex":0.0000090977055,"about_ca_topic_score_gemma":1.3826023e-7,"teacher_disagreement_score":0.038375977,"about_ca_system_score_codex":0.000079152596,"about_ca_system_score_gemma":0.000029921845,"threshold_uncertainty_score":0.3303983},"labels":[],"label_agreement":null},{"id":"W6939207931","doi":"10.60692/3kc3y-0qr02","title":"Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy‐years","year":2014,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; University of British Columbia","funders":"","keywords":"Viremia; Efavirenz; Viral load; Percentile; Lopinavir; Cumulative incidence; Antiretroviral therapy","score_opus":0.04250480904279052,"score_gpt":0.24260134608306932,"score_spread":0.2000965370402788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939207931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520093,0.000006774923,0.0021665879,0.000049199574,0.0000932392,0.00039706018,0.0000048219804,0.00006100293,0.0020203835],"genre_scores_gemma":[0.9992759,1.743224e-7,0.00044692386,0.000049402963,0.000033713306,0.000009037923,0.000018941038,0.000007407692,0.00015845889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905187,0.000045866567,0.00044828112,0.00008718222,0.00022437534,0.00014240216],"domain_scores_gemma":[0.9993967,0.000018862898,0.0002171486,0.0002289349,0.00007369113,0.00006467112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027565588,0.00012493345,0.000283923,0.0001274733,0.00009382639,0.000043712767,0.000058254656,0.00005458315,0.0000045026],"category_scores_gemma":[0.000015536065,0.000081022044,0.00004511019,0.00013866262,0.000045915112,0.00016465157,0.000043671556,0.00006503744,0.0000879073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013392183,0.000004283117,0.9539534,0.000438817,0.00011280043,0.0000021051692,0.043986674,0.00005271263,0.00001283606,0.00017204008,0.00004164769,0.0010888068],"study_design_scores_gemma":[0.0058539407,0.00006610582,0.964913,0.0012286697,0.00023563288,0.00014060571,0.005610697,0.019147694,0.0015872695,5.930662e-7,0.0010205718,0.0001951914],"about_ca_topic_score_codex":0.0000090977055,"about_ca_topic_score_gemma":1.3826023e-7,"teacher_disagreement_score":0.038375977,"about_ca_system_score_codex":0.000079152596,"about_ca_system_score_gemma":0.000029921845,"threshold_uncertainty_score":0.3303983},"labels":[],"label_agreement":null},{"id":"W6939464700","doi":"10.6084/m9.figshare.25459577","title":"Additional file 1 of Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"SALSA; Pooled analysis; Baseline (sea); Table (database); Real world data","score_opus":0.024311130525910846,"score_gpt":0.2571515200393557,"score_spread":0.23284038951344485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939464700","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.102987744,0.00059344136,3.355274e-7,0.0014856734,0.000007278273,0.0004041454,0.894326,0.000024511251,0.00017090606],"genre_scores_gemma":[0.37279886,0.000037026708,0.001719416,0.000108661035,0.00006069281,0.00032924901,0.6236938,0.000018577386,0.0012336879],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99910295,0.000044178636,0.000263293,0.00026508965,0.00019635561,0.00012814601],"domain_scores_gemma":[0.9962135,0.0034784416,0.000064520034,0.00013683298,0.000052397227,0.000054339696],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006151662,0.00013890094,0.00033290684,0.00006928805,0.000035796533,0.0000149994785,0.00005917769,0.000048948474,0.2219516],"category_scores_gemma":[0.0019502067,0.00007921711,0.000029486024,0.0002072452,0.000018005378,0.000043662963,0.00010023183,0.00013848302,0.00008453905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076464907,0.00008912582,0.0002458162,0.000098423305,0.00026552827,0.00007894357,0.0033730844,0.0000028466675,0.00020369102,0.0000019024366,0.9938574,0.0010185821],"study_design_scores_gemma":[0.0031007337,0.00026496328,0.8250173,0.0120898355,0.000097852295,0.000013778407,0.0006706322,0.000054016524,0.00013755543,0.000029877927,0.15838075,0.00014271968],"about_ca_topic_score_codex":0.000016331576,"about_ca_topic_score_gemma":0.00028676473,"teacher_disagreement_score":0.83547664,"about_ca_system_score_codex":0.0000266447,"about_ca_system_score_gemma":0.000070719,"threshold_uncertainty_score":0.77875966},"labels":[],"label_agreement":null},{"id":"W6939674045","doi":"10.6084/m9.figshare.26555456","title":"Additional file 1 of Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); Expanded access; Sida; Population; MEDLINE","score_opus":0.01390159298420645,"score_gpt":0.252961105305159,"score_spread":0.23905951232095252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939674045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96745723,0.000051448555,0.0000033996325,0.00037310278,0.000021991023,0.00047437777,0.019334294,0.0000066695034,0.012277485],"genre_scores_gemma":[0.923504,0.000009816853,0.011464634,0.000033583536,0.00006945289,0.000219309,0.015882831,0.000022844457,0.04879354],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9989826,0.00004114144,0.00024333835,0.00032557594,0.00020065143,0.00020665504],"domain_scores_gemma":[0.99903536,0.0006719465,0.000059976508,0.00013324208,0.000028944216,0.00007054215],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013697702,0.00015941494,0.0003196869,0.00015271449,0.000040529812,0.00006793788,0.0001201083,0.00009026874,0.84763867],"category_scores_gemma":[0.000100747624,0.00010832865,0.000052335465,0.00036468555,0.000060018232,0.00021829775,0.000078572855,0.00021257525,0.00037092302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001669449,0.00046791593,0.22255707,0.000046778197,0.00025534703,0.0004618562,0.003064399,0.000002829389,0.00020660121,0.0000053240346,0.73166394,0.04110101],"study_design_scores_gemma":[0.0011137777,0.00064610696,0.81172013,0.0021093905,0.000029788362,0.000061052095,0.0006579357,0.00024668674,0.0005112437,0.000008027902,0.18267938,0.00021644357],"about_ca_topic_score_codex":0.00001017171,"about_ca_topic_score_gemma":0.000497552,"teacher_disagreement_score":0.84726775,"about_ca_system_score_codex":0.000055620963,"about_ca_system_score_gemma":0.0002442221,"threshold_uncertainty_score":0.47675887},"labels":[],"label_agreement":null},{"id":"W6939791517","doi":"10.6084/m9.figshare.28750931","title":"Additional file 1 of Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV","year":2025,"lang":"en","type":"article","venue":"Open MIND","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Human immunodeficiency virus (HIV); Tenofovir alafenamide; Population; MEDLINE","score_opus":0.03088780700346242,"score_gpt":0.3047366075760538,"score_spread":0.27384880057259137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939791517","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058928993,0.0008526317,0.000640583,0.016115949,0.00023058028,0.010191918,0.8044639,0.000045068828,0.10853036],"genre_scores_gemma":[0.0052688387,0.000030259838,0.112721115,0.0002490219,0.00012282244,0.0025949075,0.12422421,0.000049375274,0.75473946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865234,0.000030009534,0.00028844088,0.0004375975,0.00024072884,0.0003509017],"domain_scores_gemma":[0.99823606,0.00094138284,0.00018750498,0.00032079313,0.00019631804,0.00011793306],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012662173,0.0002747335,0.00063116394,0.00030085316,0.00013083442,0.000050732935,0.0002289126,0.00009073003,0.30118227],"category_scores_gemma":[0.00023580354,0.0001793625,0.00009002185,0.00049453054,0.00008923614,0.00012248574,0.00010598741,0.00010863651,0.00016127444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002236594,0.00042877282,0.0027286003,0.00007304213,0.0010976392,0.00016669155,0.0005084402,7.00721e-7,0.00012560993,0.00011538877,0.8862936,0.10622491],"study_design_scores_gemma":[0.0051602246,0.00047437657,0.022804199,0.0015074735,0.00064827944,0.000056562018,0.0004297085,0.000030363552,0.0037122641,0.000030797924,0.96487284,0.0002728991],"about_ca_topic_score_codex":0.000009225549,"about_ca_topic_score_gemma":0.0005291897,"teacher_disagreement_score":0.68023974,"about_ca_system_score_codex":0.00009726171,"about_ca_system_score_gemma":0.0011917647,"threshold_uncertainty_score":0.731419},"labels":[],"label_agreement":null},{"id":"W6954661152","doi":"10.57745/xqf82u","title":"MBS_DATA_33_ANALYSE_PROSPECTIVE.tab","year":2024,"lang":"fr","type":"dataset","venue":"Recherche Data Gouv France","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Identification (biology); Context (archaeology); Point (geometry)","score_opus":0.20218822284925086,"score_gpt":0.42123465250663367,"score_spread":0.2190464296573828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6954661152","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002817681,0.104269385,0.00047841592,0.0079455655,0.003886291,0.0012688374,0.87992823,0.00022415166,0.0019709358],"genre_scores_gemma":[0.000009161494,0.051232602,0.013652191,0.00057343434,0.0040136254,0.00016063289,0.7955055,0.00017348566,0.13467933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911796,0.0009967856,0.001419472,0.003526805,0.0012481062,0.0016292228],"domain_scores_gemma":[0.98931986,0.0015023446,0.00040299713,0.007767228,0.00026426988,0.0007432829],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.004595995,0.0015824839,0.0020668786,0.0005400842,0.00028317957,0.00039888363,0.003559587,0.002194869,0.0057193222],"category_scores_gemma":[0.0029599722,0.0014044287,0.0003510482,0.0023519099,0.000497686,0.00087749836,0.0030724325,0.0055602817,0.23169778],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010641265,0.0009898933,0.00084634626,0.0028788166,0.003814943,0.002065759,0.0002930799,0.0000012912652,0.000050077568,0.00015416497,0.95666444,0.032134756],"study_design_scores_gemma":[0.0015193003,0.0001091077,0.00024808059,0.00498368,0.0051938975,0.00021276707,0.00024807503,0.0010910593,0.0002648166,0.0006570261,0.9841916,0.0012805703],"about_ca_topic_score_codex":0.00066450716,"about_ca_topic_score_gemma":0.0006811175,"teacher_disagreement_score":0.22597846,"about_ca_system_score_codex":0.002280202,"about_ca_system_score_gemma":0.0021199132,"threshold_uncertainty_score":0.9996923},"labels":[],"label_agreement":null},{"id":"W6957516977","doi":"10.60692/69x7e-wwz70","title":"Multi-state Markov Model for time to treatment changes for HIV/AIDS patients: A retrospective cohort national datasets, Ethiopia","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Retrospective cohort study; Regimen; Cohort; Markov model; Pharmacotherapy; Drug","score_opus":0.03906336135393023,"score_gpt":0.266770189443002,"score_spread":0.22770682808907178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957516977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60576963,0.000006195422,0.19637208,0.0042381957,0.00085570413,0.03631108,0.15181157,0.0021748366,0.002460742],"genre_scores_gemma":[0.7974574,0.0000013537845,0.047425743,0.0007356258,0.00017391908,0.011350632,0.05298186,0.000086791915,0.08978665],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99825376,0.00002154706,0.0005377662,0.00030432647,0.0004975974,0.00038501885],"domain_scores_gemma":[0.99869233,0.00002629732,0.00020026903,0.00026906602,0.00062895636,0.00018305669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043081402,0.00029862966,0.00045006274,0.0005442029,0.00020353899,0.00007500852,0.000088547626,0.00010051783,0.000019015262],"category_scores_gemma":[0.000071994036,0.00022980705,0.00012177084,0.00031422792,0.000015775231,0.00028604467,0.000047941005,0.000043014705,0.00202779],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034021835,0.00018884106,0.6609127,0.002172627,0.002850771,0.000008745749,0.21228454,0.0013589072,0.000014738565,0.00020806768,0.11129017,0.0053076926],"study_design_scores_gemma":[0.03162507,0.0013666184,0.16213505,0.0007489028,0.00066257134,0.000015646869,0.0036046654,0.7715762,0.0007902767,0.000008048524,0.026439507,0.0010274246],"about_ca_topic_score_codex":0.0000017915145,"about_ca_topic_score_gemma":0.0000011813472,"teacher_disagreement_score":0.7702173,"about_ca_system_score_codex":0.0011666843,"about_ca_system_score_gemma":0.00014057076,"threshold_uncertainty_score":0.99874926},"labels":[],"label_agreement":null},{"id":"W6957904359","doi":"10.60692/x6640-1fq15","title":"Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen","year":2011,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); McGill University; University of British Columbia","funders":"","keywords":"Tolerability; Adverse effect; Regimen; Randomized controlled trial; Viral load; Maintenance therapy; Incidence (geometry); Protease inhibitor (pharmacology)","score_opus":0.05293399418870327,"score_gpt":0.24665504590300408,"score_spread":0.19372105171430082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957904359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916204,0.0000017554119,0.00047762587,0.0001394056,0.00006906546,0.003450573,0.000013179882,0.000046479294,0.0041814856],"genre_scores_gemma":[0.99941415,3.5404602e-7,0.00014373712,0.000113127346,0.00000814863,0.00017571312,0.00002407974,0.000009244923,0.00011144636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805164,0.00032299876,0.0009553255,0.00016385027,0.00032471796,0.00018145668],"domain_scores_gemma":[0.9988502,0.00012950778,0.00041723915,0.00038128125,0.0001628853,0.00005887932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013129738,0.0002038483,0.0006189283,0.00018934633,0.000090288035,0.00003739062,0.00008531636,0.000038972834,0.000018655835],"category_scores_gemma":[0.00009758748,0.00010809469,0.00007401392,0.00017749897,0.00006966787,0.00019462586,0.00002572409,0.00009715941,0.000035641246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03914103,0.00021663451,0.87097555,0.00012466792,0.00012953879,0.000002513512,0.08876284,0.0000062103372,4.6587465e-7,0.000068158355,0.000020235162,0.0005521493],"study_design_scores_gemma":[0.19887382,0.00037060538,0.790362,0.00054272177,0.00005327367,0.0000014632901,0.008998313,0.0004013093,0.0002616031,0.0000016580043,0.000012148406,0.00012109243],"about_ca_topic_score_codex":0.000021495218,"about_ca_topic_score_gemma":5.891424e-7,"teacher_disagreement_score":0.15973279,"about_ca_system_score_codex":0.0001393811,"about_ca_system_score_gemma":0.000060830283,"threshold_uncertainty_score":0.44079736},"labels":[],"label_agreement":null},{"id":"W6957914655","doi":"10.60692/5w6c0-23n31","title":"Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study","year":2024,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Adverse effect; Clinical trial; Discontinuation; Young adult; Absolute neutrophil count; Clinical endpoint","score_opus":0.029133230384686036,"score_gpt":0.3047852142516716,"score_spread":0.2756519838669856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957914655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606544,0.000042681335,0.0002364738,0.000051371444,0.00015529712,0.003180165,0.000099132696,0.00003807335,0.00013136154],"genre_scores_gemma":[0.9990443,0.000002485003,0.00005231449,0.000011382064,0.000021100816,0.00040077954,0.00007122437,0.000010345128,0.00038606251],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99859524,0.000060809034,0.00078113563,0.00016946706,0.00018892119,0.0002044395],"domain_scores_gemma":[0.99951816,0.000036571448,0.000106940475,0.00023133376,0.000046367888,0.000060627113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045600373,0.00018255791,0.00038753924,0.00046567182,0.0000414904,0.000083423285,0.00006482594,0.00005147958,0.000007605118],"category_scores_gemma":[0.000014093263,0.0001081883,0.00010310445,0.00038213833,0.000012935649,0.00036285227,0.00002161606,0.000051098912,0.000029839139],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002347563,0.00005168053,0.36712772,0.00033417644,0.00016079658,0.000042845062,0.61511296,0.000010550788,0.000007938824,0.0000025781144,0.000011146647,0.014790066],"study_design_scores_gemma":[0.013612235,0.0019475218,0.92840034,0.0020780005,0.000079345766,0.0000619585,0.05284848,0.00043291395,0.00032611156,1.4766918e-7,0.00005170745,0.00016125412],"about_ca_topic_score_codex":0.00008446439,"about_ca_topic_score_gemma":0.000013934551,"teacher_disagreement_score":0.56226444,"about_ca_system_score_codex":0.0004681253,"about_ca_system_score_gemma":0.00009278449,"threshold_uncertainty_score":0.44117907},"labels":[],"label_agreement":null},{"id":"W6958110617","doi":"10.60692/9e4rh-4ya35","title":"Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies","year":2024,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Regimen; Adverse effect; Incidence (geometry); Population; Human immunodeficiency virus (HIV); Clinical trial","score_opus":0.024664085236699357,"score_gpt":0.23658842646251366,"score_spread":0.2119243412258143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958110617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964706,0.000109831584,0.0004897474,0.0015837845,0.0000621886,0.000835286,0.00019427211,0.00007790234,0.00017641422],"genre_scores_gemma":[0.99879056,0.000007934045,0.0007256993,0.00008744211,0.000030262214,0.000049745715,0.000089949885,0.000008790307,0.00020964157],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99875826,0.00006874638,0.00058534107,0.00018872171,0.00023991853,0.00015902083],"domain_scores_gemma":[0.9994289,0.00013640538,0.00011203109,0.00019970193,0.00005569566,0.000067237364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004583898,0.00017698365,0.00040984445,0.00016728199,0.00006227605,0.00007508621,0.000058155714,0.000060244947,0.0000038564854],"category_scores_gemma":[0.00006794113,0.000091285816,0.000026596837,0.00024889762,0.000030114867,0.0001831507,0.00007296295,0.00011654151,0.00005145182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049581067,0.000018876546,0.30346033,0.00068723434,0.0008595785,0.000069810645,0.6876333,0.000046204193,0.00010766716,0.00007260337,0.00062323955,0.0014630941],"study_design_scores_gemma":[0.006557441,0.00014671947,0.967418,0.0020450044,0.00019177068,0.00003185973,0.02255812,0.00030497706,0.00014669813,0.0000017975335,0.0004626483,0.00013496654],"about_ca_topic_score_codex":0.000034587476,"about_ca_topic_score_gemma":0.000020162088,"teacher_disagreement_score":0.6650751,"about_ca_system_score_codex":0.00006936183,"about_ca_system_score_gemma":0.00003313959,"threshold_uncertainty_score":0.37225276},"labels":[],"label_agreement":null},{"id":"W6958175418","doi":"10.6084/m9.figshare.14451078.v1","title":"Additional file 3 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Checklist; Human immunodeficiency virus (HIV); Drug; MEDLINE; Drug trial","score_opus":0.27923903771450065,"score_gpt":0.4258390995963325,"score_spread":0.14660006188183183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958175418","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005623515,0.0010223791,7.771928e-7,0.0016314893,0.00001616289,0.0008756009,0.99540824,0.000030364967,0.00045265042],"genre_scores_gemma":[0.0003652966,0.000013315565,0.04319616,0.000091769914,0.0001002362,0.004750775,0.8222363,0.000015988713,0.12923016],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872476,0.00009248851,0.00047026333,0.0002908144,0.00026852102,0.00015314294],"domain_scores_gemma":[0.9945578,0.0036280707,0.00025215765,0.00023307277,0.0012689775,0.000059900085],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006449144,0.00018142581,0.0006556287,0.000060530434,0.000060533504,0.000004745607,0.000058221874,0.000047959096,0.85890543],"category_scores_gemma":[0.01305929,0.00012561669,0.00019883775,0.00018722314,0.000014625201,0.000028509801,0.000069079964,0.00003978262,0.00008495266],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021370126,0.000863954,0.000063119274,0.00037263517,0.0008358299,0.00007831016,0.0008299986,0.000001311209,0.000010286184,0.000001531934,0.99625957,0.0004697502],"study_design_scores_gemma":[0.0021753577,0.00018631782,0.0040414985,0.0053388816,0.00020483522,0.000007955918,0.009200069,0.000011161446,0.0035351536,0.0000588672,0.97510326,0.00013662812],"about_ca_topic_score_codex":6.8493677e-7,"about_ca_topic_score_gemma":0.00007280138,"teacher_disagreement_score":0.8588205,"about_ca_system_score_codex":0.00009103457,"about_ca_system_score_gemma":0.00029519165,"threshold_uncertainty_score":0.99525416},"labels":[],"label_agreement":null},{"id":"W6958284561","doi":"10.6084/m9.figshare.22608299","title":"Additional file 1 of Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Drug resistance; Table (database); In vitro; Clinical trial","score_opus":0.012622849196066977,"score_gpt":0.2268736240624264,"score_spread":0.2142507748663594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958284561","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013013773,0.00011608219,0.0000011074922,0.0004557386,0.0000047309813,0.0006491465,0.99674124,0.00003378079,0.0006968105],"genre_scores_gemma":[0.016547294,0.000007870684,0.0009633125,0.0000063189627,0.00003721894,0.0016215746,0.9411676,0.000019685102,0.03962911],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930316,0.000012038623,0.00018866082,0.00014277743,0.00021529067,0.00013809504],"domain_scores_gemma":[0.9987694,0.00072164385,0.00012515897,0.00016699842,0.00017536432,0.000041459833],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000011403266,0.0001231697,0.00025683857,0.000081849714,0.000049335074,0.0000024930093,0.000055766206,0.00003233878,0.7758735],"category_scores_gemma":[0.00010320656,0.000073932046,0.00014552589,0.00030194668,0.000022218885,0.00002238449,0.000006720518,0.000028807659,0.000113273774],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035267067,0.00030255597,0.000033881275,0.00017190396,0.00035016413,0.000011389548,0.00063084584,0.000006218607,0.00009668452,0.0000026589835,0.99708986,0.00095116685],"study_design_scores_gemma":[0.0025802983,0.00028120476,0.012720764,0.0020460528,0.00019175916,0.0000048669244,0.0004078877,0.00032455017,0.0062053446,0.000011472217,0.97513026,0.00009553271],"about_ca_topic_score_codex":0.0000028424863,"about_ca_topic_score_gemma":0.00004177567,"teacher_disagreement_score":0.77576023,"about_ca_system_score_codex":0.000033092983,"about_ca_system_score_gemma":0.0001694571,"threshold_uncertainty_score":0.30148613},"labels":[],"label_agreement":null},{"id":"W6958461947","doi":"10.6084/m9.figshare.1015636","title":"HA-Pseudotyped Retroviral Vectors for Screening and Evaluation of Anti-Flu Inhibitors","year":2014,"lang":"en","type":"article","venue":"UCL Discovery (University College London)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Virus; Human immunodeficiency virus (HIV); Pandemic; Vector (molecular biology); Disease control","score_opus":0.016108815979129415,"score_gpt":0.23629936991371125,"score_spread":0.22019055393458184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958461947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948825,0.00006332575,0.0016869269,0.0008643824,0.00012202471,0.00078505266,0.00011657468,0.000032114756,0.0014470717],"genre_scores_gemma":[0.98419327,0.000015972784,0.0025034295,0.000033085977,0.000056485584,0.0000025133288,0.00011359021,0.000015706923,0.013065972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885565,0.00008676488,0.00015416155,0.0002936463,0.00040673572,0.00020303391],"domain_scores_gemma":[0.99928814,0.000118076765,0.00011907772,0.00018703697,0.00018880922,0.0000988396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044323062,0.00015848542,0.00034400544,0.0002727336,0.00018920246,0.000012445268,0.00006750043,0.00007455349,0.00003462487],"category_scores_gemma":[0.000106150226,0.00015911448,0.00012441388,0.00030400834,0.00009217397,0.00043354812,0.00006647218,0.000075395816,0.000005946019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006407043,0.0013654182,0.8703435,0.0009148242,0.0021284402,0.0001438597,0.0036257957,0.00025089408,0.016449545,0.035733495,0.03561502,0.027022159],"study_design_scores_gemma":[0.061175454,0.0020800473,0.80613685,0.0009554176,0.005241402,0.00007223315,0.008429939,0.062299766,0.018763628,0.00071674,0.032783125,0.0013454199],"about_ca_topic_score_codex":0.000046235542,"about_ca_topic_score_gemma":0.000053469004,"teacher_disagreement_score":0.06420668,"about_ca_system_score_codex":0.00014645736,"about_ca_system_score_gemma":0.0001692513,"threshold_uncertainty_score":0.64885},"labels":[],"label_agreement":null},{"id":"W6958510341","doi":"10.6084/m9.figshare.14451081","title":"Additional file 4 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug; MEDLINE; Data collection; Confidentiality","score_opus":0.28093922938872706,"score_gpt":0.4263757788701445,"score_spread":0.14543654948141743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958510341","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055976067,0.0010265415,7.8252987e-7,0.0016287827,0.000016015878,0.00087660394,0.99540955,0.00003041534,0.00045153179],"genre_scores_gemma":[0.00037654844,0.00001337058,0.04342127,0.000092253926,0.00009959603,0.0047707763,0.8256088,0.00001605062,0.12560135],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987246,0.00009247587,0.00047043944,0.00029084494,0.0002685034,0.00015316115],"domain_scores_gemma":[0.99457526,0.0036351478,0.00025218778,0.00023318826,0.0012442955,0.000059899925],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006454561,0.00018143903,0.0006557905,0.000060559887,0.000060565013,0.000004748248,0.00005826668,0.000047963338,0.85675234],"category_scores_gemma":[0.012870851,0.00012564164,0.00019885384,0.00018719812,0.00001462795,0.000028514161,0.00006910751,0.000039781327,0.00008313964],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021621044,0.00086514576,0.00006332074,0.000369898,0.00083655765,0.000078662044,0.00083158223,0.0000012931895,0.0000101300075,0.0000015917097,0.9962558,0.00046976854],"study_design_scores_gemma":[0.0021933015,0.00019199876,0.004112172,0.005418725,0.00020901488,0.000008142338,0.009343901,0.000011341256,0.0035024108,0.000060232232,0.9748104,0.00013835866],"about_ca_topic_score_codex":6.785777e-7,"about_ca_topic_score_gemma":0.00007311377,"teacher_disagreement_score":0.8566692,"about_ca_system_score_codex":0.000090668254,"about_ca_system_score_gemma":0.00029403495,"threshold_uncertainty_score":0.9954442},"labels":[],"label_agreement":null},{"id":"W6961362747","doi":"10.14288/1.0221618","title":"Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort","year":2015,"lang":"en","type":"article","venue":"Open Collections","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Propensity score matching; Logistic regression; Odds; Odds ratio; Antiretroviral therapy; Cohort; Multivariate analysis; Hospital readmission","score_opus":0.041267807893312206,"score_gpt":0.3223225641008708,"score_spread":0.2810547562075586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6961362747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7992896,0.00020004912,0.00003308214,0.0025313487,0.00020849255,0.0017600337,0.000020799838,0.000043699234,0.19591291],"genre_scores_gemma":[0.7545894,0.00005990457,0.0023909512,0.000026344695,0.000027360242,0.00009072372,0.000031940675,0.000011683542,0.2427717],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99929595,0.000031295072,0.00018943835,0.00018889742,0.00017648614,0.0001179228],"domain_scores_gemma":[0.9994267,0.000030346573,0.00007782903,0.00014991072,0.00013785769,0.00017735988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095984724,0.00010964265,0.00035607014,0.000059892092,0.00032014935,0.00009449345,0.00006618998,0.000054223758,0.00014618576],"category_scores_gemma":[0.000038148268,0.00008476068,0.000035038745,0.00044128168,0.00005384939,0.00011078022,0.00006284575,0.00008290693,0.000007678981],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011907575,0.0018746281,0.36328378,0.000011741916,0.0006844039,0.000022457278,0.0054088156,9.690706e-7,0.00031424462,0.00006767363,0.6206242,0.006516343],"study_design_scores_gemma":[0.045077093,0.015281864,0.41085207,0.0005245417,0.0010516669,0.00019840195,0.026542882,0.00089890725,0.09661936,0.0013635731,0.40026867,0.0013209694],"about_ca_topic_score_codex":0.0010274284,"about_ca_topic_score_gemma":0.000061349594,"teacher_disagreement_score":0.22035551,"about_ca_system_score_codex":0.00010389691,"about_ca_system_score_gemma":0.00035262274,"threshold_uncertainty_score":0.34564403},"labels":[],"label_agreement":null},{"id":"W6962586364","doi":"10.17605/osf.io/r5n8w","title":"Integrase Inhibitor Toxicity in Cell and Animal Models: A Scoping Review Protocol","year":2022,"lang":"en","type":"article","venue":"OSF Preprints (OSF Preprints)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Integrase; Protocol (science); Cell; Integrase inhibitor; Toxicity; Animal model; Human immunodeficiency virus (HIV); Cell culture","score_opus":0.02373200728968913,"score_gpt":0.3016174300219974,"score_spread":0.2778854227323083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6962586364","genre_codex":"other","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2926838,0.00007269997,0.00026802754,0.0038056953,0.000117251475,0.24145241,0.00002431546,0.00028066302,0.46129513],"genre_scores_gemma":[0.32747698,0.0007486931,0.005871841,0.0015438129,0.000091641305,0.45206505,0.00006938682,0.0001304288,0.21200214],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641746,0.00047505915,0.0007210853,0.0015051066,0.0004849581,0.00039630188],"domain_scores_gemma":[0.9980561,0.00014740769,0.00019547786,0.0012934515,0.00006710879,0.00024046036],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0030552777,0.00031022512,0.00061858405,0.00020464118,0.00018599741,0.00003461447,0.0002841485,0.00007883102,0.12999839],"category_scores_gemma":[0.00046573355,0.00030733988,0.00012951637,0.00035783474,0.00007492214,0.000193645,0.0015056123,0.0005938068,0.031936068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011830531,0.028472189,0.4794112,0.1152983,0.0014171534,0.0050162007,0.030404072,0.0016904076,0.044323407,0.0028198734,0.1592048,0.120111875],"study_design_scores_gemma":[0.08694875,0.00027398096,0.034814786,0.19189636,0.0026599679,0.0032115737,0.0063358224,0.030642567,0.29034638,0.011945472,0.3315204,0.009403921],"about_ca_topic_score_codex":0.00006029454,"about_ca_topic_score_gemma":0.000046197878,"teacher_disagreement_score":0.4445964,"about_ca_system_score_codex":0.000514207,"about_ca_system_score_gemma":0.00046938894,"threshold_uncertainty_score":0.9999379},"labels":[],"label_agreement":null},{"id":"W6969363756","doi":"10.5683/sp3/ynlnh9","title":"UNI-CEN Boundaries (CBF-Harmonized Shorelines) - Census Tract (CT) - 2006 - File Geodatabase format (WGS84 / EPSG:4326)","year":2022,"lang":"en","type":"dataset","venue":"Borealis","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Shapefile; North American Datum of 1927; File format; Documentation; Census; Geocoding; Data file; Boundary (topology)","score_opus":0.022495151586751392,"score_gpt":0.276798040742978,"score_spread":0.25430288915622656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6969363756","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009345656,0.0015864125,0.000003778525,0.0024936937,0.0005832911,0.0014921476,0.9920165,0.00026664196,0.0014641039],"genre_scores_gemma":[0.000008728549,0.0021872807,0.0007068561,0.00092268793,0.00049329427,0.0007280898,0.98598766,0.00014377636,0.008821649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99515116,0.00017680011,0.0011823152,0.001028739,0.0013552526,0.0011057602],"domain_scores_gemma":[0.99650717,0.00029019848,0.00051396154,0.0018952775,0.00019851062,0.0005948973],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047273346,0.0011139034,0.0015438457,0.00059881335,0.00092156377,0.00030387705,0.0006344074,0.00029449727,0.075274825],"category_scores_gemma":[0.00039086217,0.0009460519,0.0004945444,0.0005277686,0.00033233044,0.00026982854,0.00049794023,0.0011562937,0.00025983548],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043425345,0.0010723484,0.000102368096,0.000406243,0.0006637165,0.0051020924,0.00015923158,0.0000011346826,0.0000012092702,0.000024104545,0.99048805,0.0015452171],"study_design_scores_gemma":[0.004061131,0.00015813028,0.00031776098,0.00022740936,0.0014147847,0.0007069204,0.0002679456,0.000018371067,0.00003900667,0.000026750891,0.99185485,0.00090692355],"about_ca_topic_score_codex":0.03053668,"about_ca_topic_score_gemma":0.0055611935,"teacher_disagreement_score":0.07501499,"about_ca_system_score_codex":0.0007448937,"about_ca_system_score_gemma":0.0016382236,"threshold_uncertainty_score":0.999299},"labels":[],"label_agreement":null},{"id":"W6976629351","doi":"10.60692/z29sf-1w718","title":"Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration","year":2005,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Reverse transcriptase; Drug resistance; Antiretroviral therapy; Protease; Antiretroviral treatment; Genotype; Protease inhibitor (pharmacology); Human immunodeficiency virus (HIV)","score_opus":0.019536457448283893,"score_gpt":0.24897689631973996,"score_spread":0.22944043887145607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976629351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975915,0.000019850588,0.00008378174,0.00015964804,0.000024758043,0.00076922425,0.00065987074,0.000027034792,0.00066431804],"genre_scores_gemma":[0.99925274,0.0000026365828,0.0004166913,0.000026928761,0.000019804094,0.000014385764,0.000095315096,0.0000041760113,0.000167314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910617,0.000032587115,0.00046414067,0.000096258176,0.00019803554,0.00010282156],"domain_scores_gemma":[0.9993581,0.000003135476,0.00024646314,0.00014961956,0.00016229616,0.0000803462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016423654,0.00013057026,0.0002480234,0.00010295014,0.000034418255,0.000019683073,0.00002276752,0.00006423743,0.0000045626316],"category_scores_gemma":[0.000013347783,0.00008902017,0.000044205703,0.000194245,0.000032538766,0.000272402,0.0000057301504,0.000033168686,0.000022642434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005969358,0.000029120887,0.9435785,0.00037704312,0.00018139773,0.0000045448446,0.046354163,0.000016791424,0.00009344914,0.000083630395,0.00041290908,0.0028990859],"study_design_scores_gemma":[0.020029526,0.0017400568,0.96783316,0.0005367882,0.00012231492,0.00006074816,0.0034694076,0.0010396851,0.004510705,5.6314116e-7,0.000452394,0.00020467979],"about_ca_topic_score_codex":0.000020460542,"about_ca_topic_score_gemma":3.613523e-7,"teacher_disagreement_score":0.042884756,"about_ca_system_score_codex":0.00013471823,"about_ca_system_score_gemma":0.0001181935,"threshold_uncertainty_score":0.3630137},"labels":[],"label_agreement":null},{"id":"W6976657143","doi":"10.60692/zytvh-er472","title":"Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen","year":2011,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); McGill University; University of British Columbia","funders":"","keywords":"Tolerability; Adverse effect; Regimen; Randomized controlled trial; Viral load; Maintenance therapy; Incidence (geometry); Protease inhibitor (pharmacology)","score_opus":0.05293399418870327,"score_gpt":0.24665504590300408,"score_spread":0.19372105171430082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976657143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916204,0.0000017554119,0.00047762587,0.0001394056,0.00006906546,0.003450573,0.000013179882,0.000046479294,0.0041814856],"genre_scores_gemma":[0.99941415,3.5404602e-7,0.00014373712,0.000113127346,0.00000814863,0.00017571312,0.00002407974,0.000009244923,0.00011144636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805164,0.00032299876,0.0009553255,0.00016385027,0.00032471796,0.00018145668],"domain_scores_gemma":[0.9988502,0.00012950778,0.00041723915,0.00038128125,0.0001628853,0.00005887932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013129738,0.0002038483,0.0006189283,0.00018934633,0.000090288035,0.00003739062,0.00008531636,0.000038972834,0.000018655835],"category_scores_gemma":[0.00009758748,0.00010809469,0.00007401392,0.00017749897,0.00006966787,0.00019462586,0.00002572409,0.00009715941,0.000035641246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03914103,0.00021663451,0.87097555,0.00012466792,0.00012953879,0.000002513512,0.08876284,0.0000062103372,4.6587465e-7,0.000068158355,0.000020235162,0.0005521493],"study_design_scores_gemma":[0.19887382,0.00037060538,0.790362,0.00054272177,0.00005327367,0.0000014632901,0.008998313,0.0004013093,0.0002616031,0.0000016580043,0.000012148406,0.00012109243],"about_ca_topic_score_codex":0.000021495218,"about_ca_topic_score_gemma":5.891424e-7,"teacher_disagreement_score":0.15973279,"about_ca_system_score_codex":0.0001393811,"about_ca_system_score_gemma":0.000060830283,"threshold_uncertainty_score":0.44079736},"labels":[],"label_agreement":null},{"id":"W6976670566","doi":"10.60692/83t1f-19666","title":"Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration","year":2005,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Reverse transcriptase; Drug resistance; Antiretroviral therapy; Protease; Antiretroviral treatment; Genotype; Protease inhibitor (pharmacology); Human immunodeficiency virus (HIV)","score_opus":0.019536457448283893,"score_gpt":0.24897689631973996,"score_spread":0.22944043887145607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976670566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975915,0.000019850588,0.00008378174,0.00015964804,0.000024758043,0.00076922425,0.00065987074,0.000027034792,0.00066431804],"genre_scores_gemma":[0.99925274,0.0000026365828,0.0004166913,0.000026928761,0.000019804094,0.000014385764,0.000095315096,0.0000041760113,0.000167314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910617,0.000032587115,0.00046414067,0.000096258176,0.00019803554,0.00010282156],"domain_scores_gemma":[0.9993581,0.000003135476,0.00024646314,0.00014961956,0.00016229616,0.0000803462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016423654,0.00013057026,0.0002480234,0.00010295014,0.000034418255,0.000019683073,0.00002276752,0.00006423743,0.0000045626316],"category_scores_gemma":[0.000013347783,0.00008902017,0.000044205703,0.000194245,0.000032538766,0.000272402,0.0000057301504,0.000033168686,0.000022642434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005969358,0.000029120887,0.9435785,0.00037704312,0.00018139773,0.0000045448446,0.046354163,0.000016791424,0.00009344914,0.000083630395,0.00041290908,0.0028990859],"study_design_scores_gemma":[0.020029526,0.0017400568,0.96783316,0.0005367882,0.00012231492,0.00006074816,0.0034694076,0.0010396851,0.004510705,5.6314116e-7,0.000452394,0.00020467979],"about_ca_topic_score_codex":0.000020460542,"about_ca_topic_score_gemma":3.613523e-7,"teacher_disagreement_score":0.042884756,"about_ca_system_score_codex":0.00013471823,"about_ca_system_score_gemma":0.0001181935,"threshold_uncertainty_score":0.3630137},"labels":[],"label_agreement":null},{"id":"W6976770268","doi":"10.6084/m9.figshare.14451072","title":"Additional file 1 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug; MEDLINE; Public health; Data collection","score_opus":0.28350094117784813,"score_gpt":0.42645560018801537,"score_spread":0.14295465901016724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976770268","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055779185,0.0010163628,7.7222205e-7,0.001638697,0.000015995034,0.00087517273,0.99541515,0.000030390036,0.0004496436],"genre_scores_gemma":[0.0003604787,0.000013095195,0.043629445,0.0000916753,0.000098862845,0.0048356764,0.8242578,0.000015960457,0.126697],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987248,0.00009258154,0.00047004502,0.00029094683,0.00026846398,0.00015315524],"domain_scores_gemma":[0.9945353,0.0036617897,0.0002521175,0.00023343935,0.0012574202,0.000059905717],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000064521955,0.00018145247,0.00065555883,0.00006055153,0.00006053894,0.000004735453,0.000058260124,0.000047963356,0.8620277],"category_scores_gemma":[0.013062904,0.00012565011,0.00019885099,0.00018729565,0.000014624116,0.000028486924,0.00006913211,0.000039791106,0.00008399387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021252432,0.00086501084,0.000063075626,0.00036638047,0.00083716016,0.00007739259,0.0008305558,0.0000013117256,0.000010266831,0.0000015431167,0.9962718,0.00046297748],"study_design_scores_gemma":[0.0021570234,0.0001876894,0.004090987,0.0053821956,0.00020799277,0.000008081505,0.009299991,0.0000112085345,0.0034773625,0.000059033835,0.974981,0.0001374172],"about_ca_topic_score_codex":6.769153e-7,"about_ca_topic_score_gemma":0.00007228864,"teacher_disagreement_score":0.8619437,"about_ca_system_score_codex":0.00009065916,"about_ca_system_score_gemma":0.00029502143,"threshold_uncertainty_score":0.99525046},"labels":[],"label_agreement":null},{"id":"W6976863690","doi":"10.60692/tcf7q-mkf36","title":"Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies","year":2024,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Regimen; Adverse effect; Incidence (geometry); Population; Human immunodeficiency virus (HIV); Clinical trial","score_opus":0.024664085236699357,"score_gpt":0.23658842646251366,"score_spread":0.2119243412258143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976863690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964706,0.000109831584,0.0004897474,0.0015837845,0.0000621886,0.000835286,0.00019427211,0.00007790234,0.00017641422],"genre_scores_gemma":[0.99879056,0.000007934045,0.0007256993,0.00008744211,0.000030262214,0.000049745715,0.000089949885,0.000008790307,0.00020964157],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99875826,0.00006874638,0.00058534107,0.00018872171,0.00023991853,0.00015902083],"domain_scores_gemma":[0.9994289,0.00013640538,0.00011203109,0.00019970193,0.00005569566,0.000067237364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004583898,0.00017698365,0.00040984445,0.00016728199,0.00006227605,0.00007508621,0.000058155714,0.000060244947,0.0000038564854],"category_scores_gemma":[0.00006794113,0.000091285816,0.000026596837,0.00024889762,0.000030114867,0.0001831507,0.00007296295,0.00011654151,0.00005145182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049581067,0.000018876546,0.30346033,0.00068723434,0.0008595785,0.000069810645,0.6876333,0.000046204193,0.00010766716,0.00007260337,0.00062323955,0.0014630941],"study_design_scores_gemma":[0.006557441,0.00014671947,0.967418,0.0020450044,0.00019177068,0.00003185973,0.02255812,0.00030497706,0.00014669813,0.0000017975335,0.0004626483,0.00013496654],"about_ca_topic_score_codex":0.000034587476,"about_ca_topic_score_gemma":0.000020162088,"teacher_disagreement_score":0.6650751,"about_ca_system_score_codex":0.00006936183,"about_ca_system_score_gemma":0.00003313959,"threshold_uncertainty_score":0.37225276},"labels":[],"label_agreement":null},{"id":"W6976983753","doi":"10.60692/fc0fm-hhj43","title":"Five‐year follow up of genotypic resistance patterns in HIV‐1 subtype C infected patients in Botswana after failure of thymidine analogue‐based regimens","year":2009,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Didanosine; Stavudine; Genotype; Reverse transcriptase; Reverse-transcriptase inhibitor; Resistance mutation; Nucleotidyltransferase; Regimen","score_opus":0.011415380085882689,"score_gpt":0.20134080804770144,"score_spread":0.18992542796181874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976983753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981047,0.0000060832044,0.00028895595,0.00015062068,0.000055861932,0.00066787656,0.00013900582,0.00003417388,0.0005527045],"genre_scores_gemma":[0.9986219,4.3238936e-7,0.0004360089,0.000058541136,0.0000090208005,0.000035306755,0.0003355633,0.000008453308,0.0004947998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982995,0.00006053831,0.0009139951,0.00014820104,0.00035093492,0.00022684856],"domain_scores_gemma":[0.9990049,0.000008947194,0.0003749383,0.00031289822,0.00023151861,0.0000668179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018056665,0.00019596014,0.0004726091,0.000686893,0.00001770575,0.000011856333,0.00007403028,0.00011795879,0.000025396923],"category_scores_gemma":[0.00002353499,0.000158928,0.00008065498,0.000519887,0.00001719062,0.00023387278,0.00001580723,0.00009390237,0.000057817193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092665275,0.000029280076,0.9788669,0.00053578743,0.000036032656,0.000011033521,0.019394599,0.000019339728,0.0000032602788,0.000021364967,0.00010575615,0.000050006478],"study_design_scores_gemma":[0.008292905,0.00011167305,0.98734504,0.0013981429,0.000041375926,0.0000010134515,0.0014892505,0.0001504753,0.00097342924,9.256702e-7,0.00006177755,0.00013401218],"about_ca_topic_score_codex":0.000018889486,"about_ca_topic_score_gemma":0.00004971421,"teacher_disagreement_score":0.017905347,"about_ca_system_score_codex":0.0002189553,"about_ca_system_score_gemma":0.000085989566,"threshold_uncertainty_score":0.6480896},"labels":[],"label_agreement":null},{"id":"W6977206496","doi":"10.6084/m9.figshare.14451081.v1","title":"Additional file 4 of Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ontario HIV Treatment Network; Population Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug; MEDLINE; Data collection; Confidentiality","score_opus":0.28093922938872706,"score_gpt":0.4263757788701445,"score_spread":0.14543654948141743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977206496","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055976067,0.0010265415,7.8252987e-7,0.0016287827,0.000016015878,0.00087660394,0.99540955,0.00003041534,0.00045153179],"genre_scores_gemma":[0.00037654844,0.00001337058,0.04342127,0.000092253926,0.00009959603,0.0047707763,0.8256088,0.00001605062,0.12560135],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987246,0.00009247587,0.00047043944,0.00029084494,0.0002685034,0.00015316115],"domain_scores_gemma":[0.99457526,0.0036351478,0.00025218778,0.00023318826,0.0012442955,0.000059899925],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006454561,0.00018143903,0.0006557905,0.000060559887,0.000060565013,0.000004748248,0.00005826668,0.000047963338,0.85675234],"category_scores_gemma":[0.012870851,0.00012564164,0.00019885384,0.00018719812,0.00001462795,0.000028514161,0.00006910751,0.000039781327,0.00008313964],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021621044,0.00086514576,0.00006332074,0.000369898,0.00083655765,0.000078662044,0.00083158223,0.0000012931895,0.0000101300075,0.0000015917097,0.9962558,0.00046976854],"study_design_scores_gemma":[0.0021933015,0.00019199876,0.004112172,0.005418725,0.00020901488,0.000008142338,0.009343901,0.000011341256,0.0035024108,0.000060232232,0.9748104,0.00013835866],"about_ca_topic_score_codex":6.785777e-7,"about_ca_topic_score_gemma":0.00007311377,"teacher_disagreement_score":0.8566692,"about_ca_system_score_codex":0.000090668254,"about_ca_system_score_gemma":0.00029403495,"threshold_uncertainty_score":0.9954442},"labels":[],"label_agreement":null},{"id":"W6989341610","doi":"","title":"Antiretroviral Therapy [International Conference on AIDS (16th: 2006: Toronto, Canada)]","year":2006,"lang":"en","type":"article","venue":"The Journal of the Abraham Lincoln Association","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); MEDLINE; Disease; Pharmacotherapy","score_opus":0.010781059140091675,"score_gpt":0.24922655123002585,"score_spread":0.23844549208993418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6989341610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9240897,0.00039910473,0.000027743708,0.0389941,0.0018380029,0.0003361638,0.000025273263,0.000015275056,0.03427459],"genre_scores_gemma":[0.9506692,0.00028957558,0.00013349687,0.0007611272,0.0007861084,0.0000022634945,0.000009306718,0.000012497095,0.047336373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807465,0.00016472916,0.0004189409,0.000077530494,0.0010768303,0.00018728957],"domain_scores_gemma":[0.9984965,0.00015476692,0.0007669088,0.00016701607,0.00036769637,0.00004715022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007947659,0.00013659486,0.00023078015,0.00003576394,0.00017662988,0.000034793396,0.00027978825,0.000067793786,0.00024964707],"category_scores_gemma":[0.000117980046,0.00007055366,0.00013390246,0.00010024354,0.000020323503,0.00012270804,0.000021381235,0.00023830886,0.000010257194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010728212,0.00073728035,0.66431135,0.00000708602,0.0011742207,0.000031897118,0.00085849775,0.00019657184,0.005551355,0.0020463497,0.31414065,0.009871932],"study_design_scores_gemma":[0.007313291,0.00094706233,0.89497113,0.00024851365,0.00038995844,0.000094063704,0.00072108,0.00044711013,0.010229658,0.001247256,0.08310578,0.0002850768],"about_ca_topic_score_codex":0.027582852,"about_ca_topic_score_gemma":0.068060346,"teacher_disagreement_score":0.23103486,"about_ca_system_score_codex":0.0026296896,"about_ca_system_score_gemma":0.0007583399,"threshold_uncertainty_score":0.97889256},"labels":[],"label_agreement":null},{"id":"W6999199093","doi":"","title":"Characterization of tight-binding nonnucleoside inhibitors of HIV-1 reverse transcriptase","year":2002,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reverse transcriptase; Nucleotidyltransferase; Enzyme; Reverse-transcriptase inhibitor; Enzyme inhibitor; Binding site; Allosteric regulation","score_opus":0.01463856102003193,"score_gpt":0.22798963574807493,"score_spread":0.213351074728043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6999199093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714376,0.000110381014,1.7065626e-7,0.000062161555,0.000819203,0.001156324,0.0020936334,0.00011410023,0.024206474],"genre_scores_gemma":[0.90639496,0.00052062643,0.0007633437,0.00005907692,0.00005517837,0.0000848021,0.010256246,0.0002040714,0.081661694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959727,0.0001557128,0.0015641383,0.0008004835,0.0009917525,0.00051522104],"domain_scores_gemma":[0.9974147,0.000073097646,0.0010895217,0.0006125017,0.00048083096,0.00032935065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040100107,0.00075602584,0.0013598026,0.00091735105,0.0003120709,0.000016899106,0.00024688727,0.00072800415,0.00082651444],"category_scores_gemma":[0.00020270837,0.000749102,0.00056837616,0.00076054846,0.00006841811,0.00047191393,0.00003415825,0.0007701216,0.00028147068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005993641,0.0009253275,0.00069431367,0.0017831485,0.00072346866,0.00017805543,0.00014656785,6.718485e-7,0.97106755,0.0018250566,0.000058960108,0.021997511],"study_design_scores_gemma":[0.0031662376,0.0002266063,0.0031906865,0.0032389953,0.0013509659,0.00003157562,0.00036461625,0.000008569186,0.947565,0.00011073026,0.040030126,0.0007158457],"about_ca_topic_score_codex":0.000042409396,"about_ca_topic_score_gemma":0.00005260631,"teacher_disagreement_score":0.065042585,"about_ca_system_score_codex":0.00049531175,"about_ca_system_score_gemma":0.00008785851,"threshold_uncertainty_score":0.999496},"labels":[],"label_agreement":null},{"id":"W7000937567","doi":"","title":"The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia","year":2017,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protease; Apoptosis; Autophagy; Leukemia; Drug resistance; Drug; Chemotherapy; Refractory (planetary science); Clinical trial","score_opus":0.23792191082418537,"score_gpt":0.5201715764226235,"score_spread":0.2822496655984381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000937567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.901825,0.07422479,0.0011984752,0.0037417961,0.00090647116,0.009783109,0.00018579615,0.000060788938,0.008073792],"genre_scores_gemma":[0.9450133,0.038452554,0.000898069,0.00014901202,0.00067812565,0.0012077889,0.000034610515,0.00009409692,0.013472464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971399,0.000116300485,0.00091897725,0.00048624902,0.0008102433,0.00052838237],"domain_scores_gemma":[0.99562323,0.00077112485,0.0015020925,0.001373301,0.000396143,0.000334106],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0012194582,0.00047180505,0.0009075953,0.0003088875,0.0014378992,0.0008264163,0.0019712623,0.00014059289,0.00039922603],"category_scores_gemma":[0.00046291447,0.0002432917,0.00047087512,0.00030840604,0.00030959086,0.0007369118,0.00031460085,0.0002818252,0.000015680385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045010415,0.006238005,0.771322,0.0004302766,0.0034313507,0.0000659168,0.0020655664,0.000057345824,0.014763398,0.00032262687,0.03573634,0.16106611],"study_design_scores_gemma":[0.013412461,0.0003869718,0.7542228,0.00038819163,0.003141804,0.00007018486,0.0006156032,0.0005974001,0.03162847,0.001360361,0.19336899,0.0008067841],"about_ca_topic_score_codex":0.0003282446,"about_ca_topic_score_gemma":0.000013156627,"teacher_disagreement_score":0.16025932,"about_ca_system_score_codex":0.0005071476,"about_ca_system_score_gemma":0.0012106276,"threshold_uncertainty_score":0.9998621},"labels":[],"label_agreement":null},{"id":"W7002350656","doi":"","title":"Modified nucleotides and nucleic acids for the discovery of antiretroviral agents targeting HIV-1 reverse transcriptase","year":2010,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reverse transcriptase; RNase H; Nucleic acid; RNA; Polymerase; RNase P; DNA; Nucleotide; Cytidine; Oligonucleotide","score_opus":0.01787248523127887,"score_gpt":0.25316997586621726,"score_spread":0.23529749063493838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002350656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98900187,0.0005011286,0.0000012447352,0.00012591758,0.000990315,0.0019640292,0.0022874621,0.00009773509,0.005030268],"genre_scores_gemma":[0.95341814,0.0005642922,0.001966335,0.00016389143,0.000070322625,0.00019032006,0.0029392838,0.0001994566,0.040487986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99673647,0.000112524685,0.00097519124,0.00087707245,0.0006690432,0.00062971085],"domain_scores_gemma":[0.9980185,0.00029115428,0.00054565404,0.00061026507,0.00028218474,0.00025224884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000731516,0.00076305744,0.0010445333,0.00031761616,0.00093275856,0.000080086924,0.00033987733,0.0006132047,0.00009020788],"category_scores_gemma":[0.0005869553,0.00058115146,0.0005610588,0.00029806446,0.00014647523,0.0006055288,0.00006069316,0.0011076203,0.00003157166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009842917,0.00262184,0.0065917233,0.008195483,0.006070207,0.0004751504,0.00075491803,0.00002129337,0.7313088,0.04386508,0.0011870576,0.1890655],"study_design_scores_gemma":[0.03159577,0.0021671737,0.03802734,0.0057007847,0.014032353,0.00014986633,0.008675902,0.0007594768,0.6140066,0.006967503,0.27295262,0.0049646106],"about_ca_topic_score_codex":0.00009837772,"about_ca_topic_score_gemma":0.00011096137,"teacher_disagreement_score":0.27176556,"about_ca_system_score_codex":0.00020512621,"about_ca_system_score_gemma":0.000093860166,"threshold_uncertainty_score":0.999664},"labels":[],"label_agreement":null},{"id":"W7005590333","doi":"","title":"Redirecting lentiviral integration : a study of human immunodeficiency virus integrase","year":2006,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Provirus; Integrase; Human immunodeficiency virus (HIV); Virus; Lentivirus; Viral replication; Viral entry","score_opus":0.01968242031754315,"score_gpt":0.2815883534520917,"score_spread":0.2619059331345486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7005590333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90990067,0.00034641352,1.5056114e-7,0.000007405838,0.0006956602,0.001846399,0.00019146258,0.0002519395,0.08675987],"genre_scores_gemma":[0.9334604,0.000045278302,0.0002802168,0.000016514767,0.000042739375,0.00027209913,0.0034188882,0.00018063103,0.062283225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99488693,0.00033827775,0.001734317,0.0011661825,0.0012293495,0.00064493174],"domain_scores_gemma":[0.9971478,0.00012566293,0.0010524179,0.00083041197,0.0006682028,0.00017551353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008924904,0.00097174896,0.0013938464,0.0010609071,0.0010336607,0.000060123377,0.00036415752,0.0005779785,0.00015864195],"category_scores_gemma":[0.00041779215,0.00088318635,0.00048365266,0.0009592917,0.000057215108,0.0004315608,0.0000938317,0.0015462794,0.00010654255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017817495,0.01753929,0.0033314156,0.0009788119,0.0025573638,0.00077409926,0.0010266538,0.000006325997,0.6556232,0.007834549,0.00007570045,0.30847085],"study_design_scores_gemma":[0.012825637,0.003926908,0.025614483,0.0047789225,0.0050443653,0.00008254368,0.024522992,0.000033578453,0.913498,0.0031027382,0.00391196,0.002657907],"about_ca_topic_score_codex":0.0030459708,"about_ca_topic_score_gemma":0.0090622995,"teacher_disagreement_score":0.30581293,"about_ca_system_score_codex":0.0010912784,"about_ca_system_score_gemma":0.00011388263,"threshold_uncertainty_score":0.9993619},"labels":[],"label_agreement":null},{"id":"W7010300110","doi":"","title":"Hospitalization due to adverse drug reactions and drug interactions before and after HAART","year":2000,"lang":"en","type":"article","venue":"PubMed Central","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug reaction; Drug; Adverse effect; Retrospective cohort study; Antiretroviral therapy; Population; Causality (physics); Human immunodeficiency virus (HIV)","score_opus":0.004384893419166689,"score_gpt":0.21142230678380744,"score_spread":0.20703741336464074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7010300110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859576,0.00006444053,0.0000228725,0.010381422,0.00022425957,0.00065506244,0.000015851834,0.00006557886,0.0026128953],"genre_scores_gemma":[0.9250684,0.00008411477,0.0005906954,0.00030596933,0.00015228499,0.00029013545,0.00007098943,0.000016429172,0.073421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989677,0.000018142275,0.00017247014,0.00024118811,0.00012516367,0.00047532163],"domain_scores_gemma":[0.9993167,0.0000149992575,0.000022805796,0.00012364605,0.00002361604,0.0004982543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007913999,0.00013722976,0.00015293181,0.00009937359,0.00009860913,0.000026933923,0.000021266267,0.000022547189,0.00046261132],"category_scores_gemma":[0.000024553641,0.000118557204,0.000037169113,0.00013912558,0.000036368634,0.00020879564,0.000017554645,0.00008738597,0.000062129446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025505424,0.00033573958,0.8779143,0.0000427714,0.00018349463,0.00020082742,0.00995569,0.0000073071033,0.000012262294,0.00013531206,0.01111883,0.09983841],"study_design_scores_gemma":[0.00075646304,0.000011871065,0.8662864,0.000050514172,0.00010159771,0.00010475368,0.00028772597,0.00003635601,0.00013139531,0.000035171604,0.13209257,0.00010521462],"about_ca_topic_score_codex":0.000047911093,"about_ca_topic_score_gemma":0.0006423151,"teacher_disagreement_score":0.120973736,"about_ca_system_score_codex":0.00016730548,"about_ca_system_score_gemma":0.00003770166,"threshold_uncertainty_score":0.50652695},"labels":[],"label_agreement":null},{"id":"W7027044478","doi":"","title":"Cellular and virological mechanisms of HIV-1 dolutegravir-specific resistance","year":2017,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Faculty of Medicine, McGill University; McGill University","keywords":"Immune system; Virus; Cell; Mutation; Resistance (ecology)","score_opus":0.018481345112091516,"score_gpt":0.24283390412196365,"score_spread":0.22435255900987214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027044478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8211982,0.0026224246,0.0000021235344,0.0001547108,0.00073441357,0.001350234,0.00096709287,0.00017939543,0.17279138],"genre_scores_gemma":[0.7539037,0.0013940508,0.0039656833,0.00006256593,0.00004363615,0.00012468756,0.0022203715,0.00014784677,0.23813747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99604064,0.00017639899,0.0009481789,0.0012470696,0.0009428717,0.00064484705],"domain_scores_gemma":[0.9971613,0.00014550598,0.00080861495,0.0011291256,0.00032143248,0.00043401367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006584818,0.0008619009,0.0014499235,0.00037461764,0.00092570117,0.000059051825,0.000440666,0.0010086142,0.0004009984],"category_scores_gemma":[0.00026224498,0.0007537055,0.00038330036,0.00020264917,0.00015165661,0.00025595864,0.0000933873,0.001116936,0.00026089355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004115533,0.0018688092,0.00028375068,0.0021922,0.0017139448,0.002478043,0.00006881555,6.718888e-7,0.4629115,0.44117635,0.00038378942,0.082806624],"study_design_scores_gemma":[0.0055195573,0.00042476732,0.0070707332,0.0022122983,0.0012308137,0.00006847903,0.0004083571,0.0000030107487,0.5439026,0.060379196,0.37721458,0.0015656681],"about_ca_topic_score_codex":0.00001747824,"about_ca_topic_score_gemma":0.00017751145,"teacher_disagreement_score":0.38079715,"about_ca_system_score_codex":0.00036073156,"about_ca_system_score_gemma":0.00007753426,"threshold_uncertainty_score":0.9994914},"labels":[],"label_agreement":null},{"id":"W7027309921","doi":"","title":"Cohorte de patients vivant avec le VIH et ayant de la résistance prouvée ou présumée : analyse des changements de traitement pour une trithérapie contenant deux inhibiteurs nucléosidiques de la transcriptase inverse (INTI) avec du dolutégravir ou du ténofovir/abacavir avec un troisième agent","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Université de Montréal; Canadian Institutes of Health Research; Islamic Development Bank; ViiV Healthcare; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Human immunodeficiency virus (HIV); Diphenylacetylene; HIV diagnosis","score_opus":0.008345900926829072,"score_gpt":0.2098888876066681,"score_spread":0.20154298667983903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027309921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97745436,0.0063426797,0.0049211574,0.004485627,0.0005106091,0.0023936068,0.0004134346,0.00024059016,0.0032379604],"genre_scores_gemma":[0.9683906,0.007032325,0.010041622,0.0007771751,0.00024393549,0.00038616508,0.002299932,0.00016451911,0.010663769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928103,0.0015801421,0.0013226835,0.0013957579,0.0013240809,0.0015670259],"domain_scores_gemma":[0.9960675,0.0003139339,0.00095912407,0.00051061594,0.00059430226,0.0015544703],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013318461,0.0013723283,0.0013521585,0.00073270814,0.0036010987,0.00019990098,0.00061685394,0.00081042526,0.000044318604],"category_scores_gemma":[0.00028643222,0.0014395227,0.00091355405,0.0008751359,0.00083094835,0.0005941851,0.00017040796,0.0009846264,0.0000382163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00865925,0.008953664,0.4189599,0.0015217843,0.0071334643,0.03920361,0.41455624,0.0010722111,0.07956862,0.008744637,0.0035063832,0.008120239],"study_design_scores_gemma":[0.031443868,0.0010996675,0.7412525,0.0050158915,0.008394789,0.0018450526,0.07466369,0.013632339,0.07842199,0.0009730002,0.040535413,0.0027218447],"about_ca_topic_score_codex":0.01854927,"about_ca_topic_score_gemma":0.018731767,"teacher_disagreement_score":0.33989254,"about_ca_system_score_codex":0.01663288,"about_ca_system_score_gemma":0.00714152,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W7029038915","doi":"","title":"How the horrible tragedy of the Humboldt Broncos bus crash affects communities in Canada","year":2018,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crash; Tragedy (event); Executive director; Affect (linguistics)","score_opus":0.006897732478792449,"score_gpt":0.17558654676450347,"score_spread":0.16868881428571103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7029038915","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021250262,0.00033163794,5.8205135e-8,0.0020770153,0.00023208915,0.0008767226,0.00006431714,0.00002794294,0.9942652],"genre_scores_gemma":[0.036571905,0.00019678031,0.00011290033,0.00023249445,0.00006988534,0.000027765413,0.00009465046,0.00006610198,0.96262753],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856836,0.00013803958,0.0003948651,0.000100174766,0.0005345488,0.00026399153],"domain_scores_gemma":[0.99866253,0.00015756144,0.00045501883,0.0005642273,0.000095173695,0.0000654598],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000206671,0.00029204553,0.0004923515,0.00006416729,0.000081601764,0.000024372657,0.0003594851,0.00017265114,0.056177247],"category_scores_gemma":[0.00006392513,0.00017825529,0.00011896737,0.000017420198,0.00018335589,2.0210194e-7,0.00009596705,0.00027807968,0.00030673263],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004155145,0.000044334316,0.00040849764,0.0004805572,0.00013117488,0.000014054206,0.0005879275,0.000012802445,2.6397683e-7,0.0000073528386,0.99755406,0.0007173936],"study_design_scores_gemma":[0.00092218514,0.00007312294,0.00034705116,0.0008428905,0.00010709145,0.000049032256,0.0018468997,0.000007658296,0.00007201626,0.0000018021854,0.9955646,0.00016569626],"about_ca_topic_score_codex":0.59987307,"about_ca_topic_score_gemma":0.9366536,"teacher_disagreement_score":0.33678055,"about_ca_system_score_codex":0.00023507311,"about_ca_system_score_gemma":0.00046347317,"threshold_uncertainty_score":0.9446855},"labels":[],"label_agreement":null},{"id":"W7033327307","doi":"","title":"Philosophical apprenticeships contemporary continental philosophy in Canada","year":2009,"lang":"en","type":"other","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Apprenticeship; Field (mathematics); Action (physics); Continental philosophy","score_opus":0.024480811507114675,"score_gpt":0.2390541206190396,"score_spread":0.21457330911192493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7033327307","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006606749,0.0017129801,0.0000019829454,0.022387417,0.00022690905,0.0008703345,0.000033750905,0.00013270586,0.9739733],"genre_scores_gemma":[0.26500598,0.00008133122,0.00034362826,0.0012942513,0.0004574713,0.000030944917,0.0006015597,0.0002219463,0.7319629],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982176,0.000039815775,0.00042878272,0.0004868281,0.00049847376,0.00032850137],"domain_scores_gemma":[0.99922925,0.000029010313,0.00014131259,0.00033062795,0.000018706807,0.0002510873],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060848066,0.00044893313,0.00084633764,0.00032916377,0.000017740595,0.000010335593,0.00012809625,0.00024087571,0.004244589],"category_scores_gemma":[0.000013925843,0.00035936869,0.00009722209,0.00018413462,0.000043734133,0.000024158253,0.00003854658,0.0003722344,0.00022044023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009767994,0.00034268203,0.038296584,0.00013760594,0.00025246435,0.0013955662,0.000026189362,4.5408772e-8,0.000001931696,0.00090621854,0.9578822,0.00066079636],"study_design_scores_gemma":[0.008208675,0.00009702649,0.006590807,0.0018436908,0.00016196772,0.00007420636,0.00010832472,0.0000143526295,0.000044264907,0.00069080887,0.98133796,0.00082790316],"about_ca_topic_score_codex":0.3461616,"about_ca_topic_score_gemma":0.70653623,"teacher_disagreement_score":0.36037466,"about_ca_system_score_codex":0.0005044171,"about_ca_system_score_gemma":0.00214693,"threshold_uncertainty_score":0.99988586},"labels":[],"label_agreement":null},{"id":"W7083881826","doi":"","title":"Red Sox become 1st team in majors to clinch playoff spot","year":2018,"lang":"en","type":"other","venue":"Internet Archive (Internet Archive)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"League; Work (physics); Look-ahead","score_opus":0.013926969042156907,"score_gpt":0.26800075874878404,"score_spread":0.25407378970662714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7083881826","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010451431,0.00015420347,0.0010358263,0.0012959022,0.001182607,0.002711193,0.00046478026,0.00045649326,0.9822476],"genre_scores_gemma":[0.0142140705,0.00014545865,0.012149645,0.0007343419,0.001189748,0.0003340855,0.0019554724,0.0009451395,0.96833205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99441427,0.000292044,0.0013160775,0.0018564793,0.00079020706,0.0013308924],"domain_scores_gemma":[0.9971647,0.000300137,0.000443659,0.0011690508,0.000053249318,0.0008692038],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00034121593,0.0013487807,0.0018296249,0.0026352059,0.000033390214,0.000095645744,0.0010679874,0.00037274853,0.025446808],"category_scores_gemma":[0.0001588436,0.0011834401,0.00058413495,0.00033574676,0.0004360786,0.0000658219,0.0010805326,0.0010240393,0.022399537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014042333,0.00074266683,0.01989657,0.0002746155,0.0010892755,0.0013307041,0.0048716073,8.3116015e-7,0.00014601342,0.0004069679,0.96900606,0.0008304373],"study_design_scores_gemma":[0.003793363,0.0009320745,0.0053491667,0.0053971326,0.00023601018,0.00023551176,0.00012705367,0.00028274287,0.00050637993,0.00056897156,0.9814732,0.0010983797],"about_ca_topic_score_codex":0.0058117304,"about_ca_topic_score_gemma":0.046202753,"teacher_disagreement_score":0.04039102,"about_ca_system_score_codex":0.00032783733,"about_ca_system_score_gemma":0.00028373412,"threshold_uncertainty_score":0.9999263},"labels":[],"label_agreement":null},{"id":"W7084113733","doi":"10.64628/aam.wsqfkcrtt","title":"Global collaborations are changing conditions for women in STEM","year":2019,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Government (linguistics); Work (physics); Context (archaeology); Perspective (graphical)","score_opus":0.01619922381242284,"score_gpt":0.27917833109756685,"score_spread":0.262979107285144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084113733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662024,0.000022434144,0.00011527606,0.004353714,0.00009184245,0.0010215938,0.00009721845,0.0000522973,0.028043253],"genre_scores_gemma":[0.8245461,0.00000240801,0.0004995714,0.00021208028,0.00001919251,0.00028487758,0.00008630318,0.000005026398,0.17434447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944127,0.000006357323,0.00011305772,0.00012100228,0.00007584327,0.00024245697],"domain_scores_gemma":[0.99972385,0.000026845102,0.000024289026,0.000092757684,0.00006035812,0.000071901704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008043333,0.00006706854,0.00015100857,0.00010121824,0.000040718704,0.000010836127,0.000020854304,0.000030747316,0.0003706027],"category_scores_gemma":[0.00000859088,0.000055485943,0.000023022109,0.0004259397,0.000007058532,0.000049322487,0.000010552153,0.000017606002,0.00019478949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006556719,0.0002854027,0.96606976,0.00008798872,0.00012577564,0.000017478185,0.0021132422,0.000022341297,0.00010442386,0.016748779,0.013924607,0.0004346445],"study_design_scores_gemma":[0.027656121,0.00058751705,0.63312864,0.0005931438,0.0001571104,0.000045378485,0.118370436,0.0034008152,0.0016719546,0.0033086145,0.2102544,0.0008258468],"about_ca_topic_score_codex":0.0000020094674,"about_ca_topic_score_gemma":0.00011040555,"teacher_disagreement_score":0.3329411,"about_ca_system_score_codex":0.00041176024,"about_ca_system_score_gemma":0.00013403765,"threshold_uncertainty_score":0.40578398},"labels":[],"label_agreement":null},{"id":"W7084138828","doi":"10.64628/aap.95mfpedqk","title":"Un lien direct est établi entre l’insomnie chronique et les problèmes de mémoire chez les personnes âgées","year":2019,"lang":"fr","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"","keywords":"Identity (music); Context (archaeology); Subject (documents); Set (abstract data type)","score_opus":0.008668447202898038,"score_gpt":0.2398016967711297,"score_spread":0.23113324956823167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084138828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65946925,0.032359816,0.0001093074,0.05706423,0.00075576914,0.0016732365,0.000055982353,0.00039468412,0.24811774],"genre_scores_gemma":[0.55387217,0.0045926915,0.006215946,0.0002293695,0.00048609174,0.00009443568,0.00011912237,0.000076569915,0.43431363],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996843,0.0003151456,0.00049492286,0.0007736116,0.00045243013,0.0011209123],"domain_scores_gemma":[0.9984775,0.0003849248,0.00016000764,0.00045163924,0.00013473845,0.00039117926],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005945065,0.0006986979,0.00083332043,0.00022652156,0.00030490343,0.00012621465,0.00024602597,0.00047553846,0.018289441],"category_scores_gemma":[0.000120134064,0.00054835516,0.00028344078,0.00034726935,0.0002835847,0.00029801947,0.00014644925,0.0004632358,0.0028567128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020713212,0.0031517232,0.769936,0.001987867,0.0020875211,0.00043013293,0.03835858,0.000100353594,0.0022025525,0.02502537,0.041167628,0.11534512],"study_design_scores_gemma":[0.010299548,0.00084030005,0.08617235,0.0049989,0.0014610585,0.0003272537,0.028243737,0.0028059478,0.072307914,0.00027040075,0.7903163,0.0019563253],"about_ca_topic_score_codex":0.0015333418,"about_ca_topic_score_gemma":0.0009974652,"teacher_disagreement_score":0.7491486,"about_ca_system_score_codex":0.00073543313,"about_ca_system_score_gemma":0.00092122355,"threshold_uncertainty_score":0.9996968},"labels":[],"label_agreement":null},{"id":"W7095789431","doi":"","title":"CLINICAL REVIEW 3TC: A Canadian Scientific Success Story","year":2015,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Human life; Immune system; MEDLINE; Quality (philosophy)","score_opus":0.0938252160679774,"score_gpt":0.380957355523342,"score_spread":0.2871321394553646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095789431","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2398997,0.049877,0.000045865716,0.17203519,0.0038547793,0.0025682896,0.000019117411,0.00030660804,0.53139347],"genre_scores_gemma":[0.25057802,0.0016575558,0.0028684433,0.0072539584,0.00021893824,0.000045135235,0.00017069619,0.000024422296,0.73718286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988673,0.00006704708,0.0002579961,0.00027265295,0.00027837686,0.00025667515],"domain_scores_gemma":[0.9983807,0.000031156673,0.000033155273,0.00032213636,0.00018378746,0.0010490355],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013865962,0.0001020844,0.00028932793,0.00012148974,0.00009192541,0.000023756445,0.00008647,0.000050899274,0.00091923936],"category_scores_gemma":[0.0002444457,0.00007139632,0.000081894774,0.0002566533,0.00010004892,0.000059268656,0.00002160324,0.00013061336,0.0024968046],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066104544,0.00007677012,0.14805023,0.00009977298,0.000047500907,0.00013674809,0.00009082095,2.011454e-8,4.5185746e-7,0.0001616429,0.8381674,0.013161978],"study_design_scores_gemma":[0.0008010523,0.000037098827,0.010994985,0.00047388827,0.00010172208,0.00002357665,0.000045962017,0.000008981102,0.000012037667,0.00001699861,0.98739207,0.00009163446],"about_ca_topic_score_codex":0.0036321052,"about_ca_topic_score_gemma":0.060869098,"teacher_disagreement_score":0.20578937,"about_ca_system_score_codex":0.00024068974,"about_ca_system_score_gemma":0.0024816103,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W7095966796","doi":"","title":"PHARMACY PRACTICE Antiretroviral Therapeutic Drug Monitoring in Canada: Current Status and Recommendations for Clinical Practice","year":2014,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Therapeutic drug monitoring; Clinical Practice; Drug; Pharmacy practice; Pharmacy; Human immunodeficiency virus (HIV); Clinical pharmacy; Pharmacotherapy","score_opus":0.08131726029069818,"score_gpt":0.43884333938098363,"score_spread":0.35752607909028544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095966796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6852556,0.00881833,0.00199232,0.28383416,0.004652673,0.003406868,0.000031065654,0.0001495658,0.01185944],"genre_scores_gemma":[0.9681185,0.00576447,0.022947777,0.0012032407,0.00026684016,0.000080574246,0.00004438305,0.000021359068,0.0015528452],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859554,0.00017506404,0.00044508735,0.00027351597,0.00020485731,0.00030590987],"domain_scores_gemma":[0.9971209,0.0022669667,0.00013880237,0.00013798437,0.00014507251,0.000190262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079031376,0.00014054678,0.00025225923,0.000068055255,0.00008478418,0.000025861627,0.000039449424,0.000019065094,0.000026772772],"category_scores_gemma":[0.001030418,0.00011404007,0.000034761204,0.0001202157,0.000019230656,0.00031086357,0.000029634153,0.0002407688,0.0000073957663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027476644,0.0003593002,0.6000154,0.000031518775,0.000120940975,0.000006695207,0.00032339196,2.7957338e-7,0.0000044638837,0.00036406922,0.008361142,0.390138],"study_design_scores_gemma":[0.0050633345,0.00009212563,0.048565574,0.00006610632,0.0002896619,0.000013743239,0.001835795,0.0005833844,0.00015677628,0.000025091558,0.9431653,0.00014311237],"about_ca_topic_score_codex":0.10937628,"about_ca_topic_score_gemma":0.042615023,"teacher_disagreement_score":0.93480414,"about_ca_system_score_codex":0.00039006554,"about_ca_system_score_gemma":0.001143548,"threshold_uncertainty_score":0.97485477},"labels":[],"label_agreement":null},{"id":"W7097273403","doi":"","title":"Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease","year":2003,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Antiretroviral therapy; Population; Drug; Sida; Human immunodeficiency virus (HIV); Antiretroviral drug; Disease; Retrospective cohort study","score_opus":0.020843689019606648,"score_gpt":0.2769018275647595,"score_spread":0.25605813854515286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097273403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966966,0.000078608704,0.000107752545,0.0007497654,0.000032307536,0.0007886157,0.0000074255026,0.000050254483,0.0014887046],"genre_scores_gemma":[0.9923434,0.000050748447,0.003970585,0.00011223658,0.000007966061,0.000076967444,0.00020797225,0.000013808947,0.0032162897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990497,0.000043394866,0.00028121573,0.00021788574,0.00019067475,0.0002171173],"domain_scores_gemma":[0.99964374,0.00004180494,0.000041839034,0.00013929418,0.000021725205,0.000111590045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007597159,0.00014351559,0.0002276581,0.00014823033,0.00003353526,0.000012126282,0.000026622783,0.000032986027,0.00017352801],"category_scores_gemma":[0.0000578397,0.000098341734,0.00003065781,0.0003019992,0.000026053658,0.00013529943,0.0000037269363,0.000074162854,0.000011522813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004172851,0.00032632332,0.9957277,0.000010211121,0.000024093353,0.000058729867,0.00020557536,0.0000669876,0.00006434102,0.0016522228,0.000030815117,0.0014157168],"study_design_scores_gemma":[0.008171415,0.0001285672,0.98981625,0.0000652223,0.000019168603,0.0000030649678,0.00012696603,0.0004670833,0.00039592484,0.000067123445,0.0006185324,0.00012067313],"about_ca_topic_score_codex":0.000079986334,"about_ca_topic_score_gemma":0.0004126113,"teacher_disagreement_score":0.0077541303,"about_ca_system_score_codex":0.00013753178,"about_ca_system_score_gemma":0.00012493791,"threshold_uncertainty_score":0.40102595},"labels":[],"label_agreement":null},{"id":"W7097616207","doi":"","title":"2013. Can J Infect Dis Med Microbiol 2014;25(3):159-162.","year":2016,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liver transplantation; Transplantation; Liver disease; Hepatitis C; Hepatitis C virus; Coinfection; Disease; Hepatitis","score_opus":0.007589048704051542,"score_gpt":0.23312561225060932,"score_spread":0.22553656354655777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097616207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68656343,0.0007202739,0.0008216156,0.16761228,0.00078408833,0.001907467,0.00010201195,0.0006981544,0.14079069],"genre_scores_gemma":[0.55792594,0.00027184235,0.0010656386,0.00051785563,0.00010833855,0.000033637487,0.000058355745,0.00002680827,0.43999156],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887455,0.000028933939,0.00025629112,0.00030780907,0.00016360535,0.00036883692],"domain_scores_gemma":[0.99922377,0.00008642672,0.000050722105,0.00033762693,0.00007120746,0.0002302328],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012435252,0.00022497027,0.00030641034,0.00012089545,0.00005818096,0.000013518712,0.000077778815,0.00008607899,0.005147876],"category_scores_gemma":[0.0000400104,0.00011359149,0.00011291029,0.00010751667,0.000064197164,0.00006499362,0.00005438192,0.00006181779,0.004999175],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059408267,0.0002778366,0.14714424,0.000028674194,0.00037344784,0.00007865367,0.00031617476,3.1424754e-8,0.032898396,0.00030912607,0.80122125,0.017292745],"study_design_scores_gemma":[0.0072779097,0.00020651011,0.04567852,0.0002759486,0.00026140927,0.000097878365,0.00009419383,0.0000035533621,0.08239015,0.00012167091,0.86309487,0.00049738307],"about_ca_topic_score_codex":0.00022722255,"about_ca_topic_score_gemma":0.00050959334,"teacher_disagreement_score":0.29920086,"about_ca_system_score_codex":0.00016063043,"about_ca_system_score_gemma":0.00015602169,"threshold_uncertainty_score":0.9957755},"labels":[],"label_agreement":null},{"id":"W7097817515","doi":"","title":"(See the article by Henrich et al, on pages 93–98.) There now are 12 dozen US Food and Drug Administration–, Health Canada–,","year":2016,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dozen; Human immunodeficiency virus (HIV); Food and drug administration; Selection (genetic algorithm); Drug; Clinical trial; Randomized controlled trial","score_opus":0.013724224977886302,"score_gpt":0.2537111813802399,"score_spread":0.2399869564023536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097817515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50135064,0.00052143214,0.000015141418,0.49194497,0.0000440048,0.00034345838,0.00003198831,0.00003491275,0.0057134507],"genre_scores_gemma":[0.9268608,0.00046908765,0.000118664684,0.01743803,0.000023530685,0.000033403096,0.00001857419,0.000015976568,0.055021904],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988978,0.00007156733,0.00020282905,0.00025023016,0.00030793235,0.00026967892],"domain_scores_gemma":[0.9992593,0.00017505437,0.000075065545,0.0002519704,0.000035379886,0.00020321603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019926066,0.00016451758,0.00020282544,0.000022015198,0.00015991299,0.000028460701,0.000059859267,0.000024779632,0.00033818197],"category_scores_gemma":[0.00002909115,0.00007471052,0.000024024834,0.000066458946,0.00004031567,0.000053626416,0.00002238089,0.000079983656,0.00006071668],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059835103,0.00014882845,0.06350868,0.000011872502,0.000104535306,0.000018000923,0.0002625578,8.204775e-8,0.00011163592,0.00034694237,0.9315871,0.003839901],"study_design_scores_gemma":[0.0034745685,0.0007145699,0.17519294,0.0002005715,0.000054009543,0.000035497927,0.0016812165,0.000009666178,0.012145549,0.00012750394,0.8060899,0.0002740196],"about_ca_topic_score_codex":0.0067903227,"about_ca_topic_score_gemma":0.576721,"teacher_disagreement_score":0.5699307,"about_ca_system_score_codex":0.00015291775,"about_ca_system_score_gemma":0.00063225545,"threshold_uncertainty_score":0.9998236},"labels":[],"label_agreement":null},{"id":"W7097859531","doi":"","title":"CASE REPORT Cerebral microsporidiosis u B","year":2000,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lopinavir; Ritonavir; Paresis; Lopinavir/ritonavir; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Stavudine","score_opus":0.013356647718399244,"score_gpt":0.25561524490137294,"score_spread":0.24225859718297368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097859531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79624796,0.000045081408,0.000012985894,0.003023291,0.00004506806,0.00016490203,0.0000016661637,0.000106944826,0.20035207],"genre_scores_gemma":[0.527323,0.000006606286,0.0041006394,0.00026948182,0.000054442702,0.000009123556,0.000032136228,0.000009284419,0.46819526],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9992992,0.0000057321563,0.00019897729,0.00020202839,0.00011814542,0.0001758626],"domain_scores_gemma":[0.99958235,0.000009401125,0.000019261544,0.00023101857,0.00002694878,0.00013102186],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006904318,0.00010591821,0.00017087735,0.0000389069,0.000062619816,0.000010573687,0.000019853964,0.00004151142,0.015537933],"category_scores_gemma":[0.0000073521496,0.00007630274,0.000071783266,0.00010955706,0.000020697069,0.000041856012,0.000007886216,0.000053021857,0.0012806478],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096342716,0.00035824784,0.109289154,0.000020534779,0.0002177528,0.77642816,0.0006313793,4.2993295e-7,0.00009132241,0.000105766434,0.086372964,0.02638795],"study_design_scores_gemma":[0.002320168,0.00006869773,0.006571102,0.000028725002,0.00019205798,0.64644057,0.00018955373,0.000025757125,0.013018064,0.00005180528,0.33085886,0.00023464137],"about_ca_topic_score_codex":0.00006590566,"about_ca_topic_score_gemma":0.000019183142,"teacher_disagreement_score":0.26892495,"about_ca_system_score_codex":0.000050993873,"about_ca_system_score_gemma":0.00006509649,"threshold_uncertainty_score":0.999497},"labels":[],"label_agreement":null},{"id":"W7098077360","doi":"","title":"Open Access Towards targeted screening for acute HIV infections in British Columbia","year":2013,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Seroconversion; Human immunodeficiency virus (HIV); Drug resistance; HIV diagnosis; Hiv test; Sida; Men who have sex with men; Nucleic acid test","score_opus":0.03826643379626332,"score_gpt":0.35145656381594664,"score_spread":0.3131901300196833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7098077360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460448,0.000047354068,0.004683199,0.008925404,0.00013854996,0.0049904385,0.00004891901,0.00016967056,0.034951642],"genre_scores_gemma":[0.58621836,0.000049456587,0.035134558,0.0007918322,0.000060178965,0.0019855725,0.0004609897,0.000034748584,0.37526432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910945,0.000014305631,0.00023677242,0.00025665422,0.00011383246,0.00026897815],"domain_scores_gemma":[0.99953645,0.000032574193,0.00003748532,0.0001429761,0.00012047821,0.00013001525],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000105332554,0.00008656516,0.00027708604,0.00007375761,0.00012753352,0.0010597256,0.0002248787,0.000061974024,0.005216589],"category_scores_gemma":[0.000051627696,0.000110486595,0.000058282516,0.00029847023,0.000020716761,0.0007101136,0.00028350885,0.000079187426,0.00010133132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012533769,0.00030759416,0.6244262,0.000015989706,0.00028690448,0.00003177725,0.00008993517,0.0000012212386,0.000059646663,0.000013062509,0.3328577,0.041897476],"study_design_scores_gemma":[0.0075777243,0.00012804203,0.94360995,0.00017929802,0.00017812029,0.00008057077,0.00021015777,0.00080916233,0.00042298573,0.0003939455,0.046134844,0.00027518152],"about_ca_topic_score_codex":0.048032172,"about_ca_topic_score_gemma":0.09079167,"teacher_disagreement_score":0.35982648,"about_ca_system_score_codex":0.000085655214,"about_ca_system_score_gemma":0.00015868846,"threshold_uncertainty_score":0.9999773},"labels":[],"label_agreement":null},{"id":"W7098872609","doi":"","title":"By Duanjie Chen The cheerful opening message in Finance Minister Jim Flaherty’s October 30","year":2007,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Income tax; Statutory law; Government (linguistics); Tax reform; Capital (architecture); Corporate tax; Neutrality; Tax rate","score_opus":0.011945120372628093,"score_gpt":0.2701825789901095,"score_spread":0.25823745861748143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7098872609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69019705,0.0010461169,0.00029134046,0.02430054,0.00012538733,0.00071445457,0.0000028686184,0.00006361293,0.2832586],"genre_scores_gemma":[0.6384238,0.000040227547,0.0013788554,0.0022148266,0.00003866062,0.000023924591,0.0000215212,0.000018802732,0.3578394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987275,0.000021804526,0.00032410864,0.00027710022,0.00025454612,0.00039496034],"domain_scores_gemma":[0.9994575,0.00009743983,0.000051144205,0.00028705498,0.000031445987,0.00007543845],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005150343,0.00019335376,0.00026213762,0.000061719664,0.0000694429,0.000024430467,0.00012377287,0.00008143186,0.0015719786],"category_scores_gemma":[0.00003202501,0.00011196939,0.000059915885,0.0002186203,0.00005762821,0.000096202784,0.00006354415,0.00017973909,0.0005837106],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048272868,0.0010735625,0.3276248,0.00008061036,0.0003764199,0.00123983,0.009062523,0.0000018923271,0.005212963,0.001130634,0.597755,0.055958994],"study_design_scores_gemma":[0.004120877,0.00007382536,0.08303594,0.00014147157,0.000078597586,0.000040962972,0.0009007462,0.00007912806,0.036457933,0.000037199334,0.874715,0.00031835638],"about_ca_topic_score_codex":0.000047476457,"about_ca_topic_score_gemma":0.00014357896,"teacher_disagreement_score":0.27695993,"about_ca_system_score_codex":0.00010653507,"about_ca_system_score_gemma":0.00006616693,"threshold_uncertainty_score":0.9993407},"labels":[],"label_agreement":null},{"id":"W7100110129","doi":"","title":"Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates","year":2010,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Darunavir; Genotype; Phenotype; Multivariate analysis; Drug resistance; Cohort","score_opus":0.023827326720562935,"score_gpt":0.32218937635579203,"score_spread":0.2983620496352291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100110129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599105,0.0005176984,0.0010680767,0.00022692796,0.00016163004,0.0005412698,0.000052710446,0.00008405471,0.0013565656],"genre_scores_gemma":[0.97746855,0.00023487765,0.017951969,0.000121534234,0.0001397107,0.000015856178,0.00010078278,0.000041057123,0.0039256355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686974,0.0001407522,0.001204587,0.00090185826,0.0004796205,0.00040344175],"domain_scores_gemma":[0.99801165,0.00031030274,0.00040215123,0.0006583198,0.00021594642,0.00040162078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012003721,0.00036845668,0.0011700495,0.00035951808,0.00022538929,0.00005736375,0.00014641568,0.0002881073,0.00023254208],"category_scores_gemma":[0.00020282801,0.00030634252,0.0001611348,0.0005041429,0.00028217552,0.0002877657,0.0001251516,0.0005236946,0.0000032684625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077745214,0.0003105823,0.9880551,0.000080664315,0.002263279,0.000029158942,0.0008148096,0.0000035972569,0.0041363225,0.0008386835,0.000024288485,0.0026660387],"study_design_scores_gemma":[0.0022232707,0.000119216646,0.9892519,0.0001266966,0.0035720135,0.00000858934,0.00054863305,0.0026469263,0.0007262923,0.00012633907,0.00033135028,0.0003187309],"about_ca_topic_score_codex":0.00018652694,"about_ca_topic_score_gemma":0.009728657,"teacher_disagreement_score":0.01852249,"about_ca_system_score_codex":0.000048706323,"about_ca_system_score_gemma":0.00016838766,"threshold_uncertainty_score":0.99993885},"labels":[],"label_agreement":null},{"id":"W7100299766","doi":"","title":"with a Decrease in the Monitored Viral Load","year":2016,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Viral load; Drug resistance; Logistic regression; Reverse transcriptase; HIV drug resistance; Drug; Protease inhibitor (pharmacology); Protease","score_opus":0.009993094396588865,"score_gpt":0.2438682754990436,"score_spread":0.23387518110245475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100299766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532377,0.00004026703,0.0000988675,0.017065715,0.000014154733,0.00026620584,7.2881585e-7,0.000029517934,0.029246807],"genre_scores_gemma":[0.95965016,0.000010654798,0.0011161022,0.00038240873,0.000030880547,0.000039726478,0.0000019233764,0.0000053638587,0.0387628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994929,0.000016721324,0.00007464312,0.00010052258,0.00018937771,0.00012583262],"domain_scores_gemma":[0.99970853,0.00004613817,0.000011164195,0.0001450259,0.00002196944,0.00006718497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008706584,0.00007163112,0.000086847045,0.000031369957,0.000018589768,0.0000058010637,0.00003953474,0.000018334247,0.00019930738],"category_scores_gemma":[0.000027390051,0.000022738406,0.000018655233,0.00007778633,0.000028229815,0.00003433054,0.000007428652,0.000027741062,0.00020308768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008018637,0.00062107237,0.95268536,0.0000086913,0.00011278443,0.00085983606,0.0018082252,4.402055e-8,0.0010850248,0.001084331,0.012419073,0.028513674],"study_design_scores_gemma":[0.027876941,0.0007924884,0.85229874,0.0005465001,0.0002233507,0.00031730768,0.001609936,0.000018234501,0.021910995,0.0006816209,0.09329627,0.00042759095],"about_ca_topic_score_codex":0.000048858197,"about_ca_topic_score_gemma":0.000080264224,"teacher_disagreement_score":0.10038661,"about_ca_system_score_codex":0.000070930444,"about_ca_system_score_gemma":0.0001487791,"threshold_uncertainty_score":0.2610349},"labels":[],"label_agreement":null},{"id":"W7104290267","doi":"10.71781/796","title":"Cohorte de patients vivant avec le VIH et ayant de la résistance prouvée ou présumée : analyse des changements de traitement pour une trithérapie contenant deux inhibiteurs nucléosidiques de la transcriptase inverse (INTI) avec du dolutégravir ou du ténofovir/abacavir avec un troisième agent","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Diphenylacetylene; HIV diagnosis","score_opus":0.008345900926829072,"score_gpt":0.2098888876066681,"score_spread":0.20154298667983903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104290267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97745436,0.0063426797,0.0049211574,0.004485627,0.0005106091,0.0023936068,0.0004134346,0.00024059016,0.0032379604],"genre_scores_gemma":[0.9683906,0.007032325,0.010041622,0.0007771751,0.00024393549,0.00038616508,0.002299932,0.00016451911,0.010663769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928103,0.0015801421,0.0013226835,0.0013957579,0.0013240809,0.0015670259],"domain_scores_gemma":[0.9960675,0.0003139339,0.00095912407,0.00051061594,0.00059430226,0.0015544703],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013318461,0.0013723283,0.0013521585,0.00073270814,0.0036010987,0.00019990098,0.00061685394,0.00081042526,0.000044318604],"category_scores_gemma":[0.00028643222,0.0014395227,0.00091355405,0.0008751359,0.00083094835,0.0005941851,0.00017040796,0.0009846264,0.0000382163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00865925,0.008953664,0.4189599,0.0015217843,0.0071334643,0.03920361,0.41455624,0.0010722111,0.07956862,0.008744637,0.0035063832,0.008120239],"study_design_scores_gemma":[0.031443868,0.0010996675,0.7412525,0.0050158915,0.008394789,0.0018450526,0.07466369,0.013632339,0.07842199,0.0009730002,0.040535413,0.0027218447],"about_ca_topic_score_codex":0.01854927,"about_ca_topic_score_gemma":0.018731767,"teacher_disagreement_score":0.33989254,"about_ca_system_score_codex":0.01663288,"about_ca_system_score_gemma":0.00714152,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W7104448779","doi":"10.71781/11998","title":"Synthesis of 1,2-methano-tetrahydrofuran derivatives and 1´,2´-methano-2´,3´-dideoxynucleosides as potential antivirals","year":2018,"lang":"en","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cyclopropanation; Antibacterial agent","score_opus":0.004950234498581002,"score_gpt":0.1971947715801106,"score_spread":0.19224453708152958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104448779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95360297,0.0083979145,0.000023608958,0.00031409526,0.00038158032,0.00051096146,0.000055671466,0.00008751828,0.036625657],"genre_scores_gemma":[0.9035883,0.0012412065,0.002362183,0.000029605748,0.00012169934,0.000029735225,0.00034338376,0.0000477845,0.092236094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762046,0.00011860541,0.00051061163,0.00065868173,0.00072001165,0.0003715977],"domain_scores_gemma":[0.998374,0.00016049389,0.00048132183,0.00035328168,0.00034317106,0.00028777044],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00019133686,0.00051681715,0.0008457807,0.00058661494,0.0018937818,0.000030625353,0.00018806057,0.00045955594,0.00012439239],"category_scores_gemma":[0.0001791016,0.0005083818,0.00034249207,0.00031132757,0.00040395802,0.00024394468,0.00009977743,0.0002632344,0.000052814274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013500634,0.0023836265,0.09539329,0.003297615,0.012125648,0.012999599,0.09782827,0.00003084833,0.6874858,0.00655796,0.0036703795,0.064726286],"study_design_scores_gemma":[0.0023005884,0.0003520057,0.1250878,0.0017292316,0.0026442232,0.0011956311,0.026033053,0.000097522396,0.82963604,0.00041655567,0.009675297,0.0008320465],"about_ca_topic_score_codex":0.0027947393,"about_ca_topic_score_gemma":0.0006025452,"teacher_disagreement_score":0.14215021,"about_ca_system_score_codex":0.0010781207,"about_ca_system_score_gemma":0.0012508306,"threshold_uncertainty_score":0.9997368},"labels":[],"label_agreement":null},{"id":"W7111420055","doi":"10.6084/m9.figshare.29615211.v1","title":"Additional file 1 of Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide","year":2025,"lang":"","type":"article","venue":"Open MIND","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Cohort; Cohort study; Opera; Retrospective cohort study","score_opus":0.022762616071150845,"score_gpt":0.2961815329729818,"score_spread":0.27341891690183096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111420055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8265504,0.0003343528,0.0000072215807,0.008513109,0.00010767282,0.004343393,0.14679909,0.0000039157285,0.013340819],"genre_scores_gemma":[0.61614096,0.0004919877,0.009067599,0.0008193256,0.00008216904,0.008210758,0.08606828,0.000045594636,0.2790733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976872,0.0002226155,0.0007334229,0.000654297,0.0003105267,0.00039189914],"domain_scores_gemma":[0.9977584,0.0013756143,0.00022756154,0.00045706946,0.00009059652,0.00009077594],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028919955,0.00045871205,0.00079104246,0.00043236325,0.00018446516,0.00015935738,0.00027528452,0.00015113088,0.37976295],"category_scores_gemma":[0.00016113227,0.00025751023,0.00011081067,0.0005436042,0.00025756127,0.00029497273,0.00019256595,0.00023209874,0.0003048212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026046175,0.0048491806,0.76493007,0.000091229864,0.0029236092,0.00071943575,0.008646739,0.0000039054153,0.00018413825,0.000040524006,0.07767958,0.137327],"study_design_scores_gemma":[0.0027836382,0.00044595325,0.7622988,0.0013590574,0.0005402574,0.000028423408,0.0010549091,0.0000607382,0.00006489918,0.000013849896,0.23114596,0.00020347587],"about_ca_topic_score_codex":0.000078994715,"about_ca_topic_score_gemma":0.0004700948,"teacher_disagreement_score":0.37945813,"about_ca_system_score_codex":0.00036873968,"about_ca_system_score_gemma":0.00070541905,"threshold_uncertainty_score":0.9999877},"labels":[],"label_agreement":null},{"id":"W7116905565","doi":"10.5281/zenodo.17993277","title":"Supplementary Data for A tale of two mechanisms: Clarification of the pathway for MDB4 catalyzed glycosidic bond cleavage using MD and QM/MM calculations","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge","funders":"","keywords":"Glycosidic bond; Bond cleavage; Cleavage (geology); Catalysis; Component (thermodynamics)","score_opus":0.05462929379254761,"score_gpt":0.3039554465892207,"score_spread":0.24932615279667308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116905565","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2077133,0.004735591,0.5965432,0.017392494,0.0014329507,0.03513456,0.12590984,0.00047006735,0.010668034],"genre_scores_gemma":[0.94017315,0.00040314466,0.01606896,0.00012824242,0.000114576185,0.0000017089176,0.039931387,0.0009691916,0.0022096436],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974443,0.00025815808,0.00081924855,0.0006659953,0.0004078814,0.00040447296],"domain_scores_gemma":[0.99736613,0.00014108834,0.0004178641,0.0012040732,0.000738441,0.00013242445],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013499305,0.00025269846,0.00040995356,0.00035523964,0.0019502143,0.00016558976,0.00091563305,0.000105202045,0.0009466128],"category_scores_gemma":[0.0007339062,0.00022853148,0.00011490671,0.0007963363,0.00030584185,0.00023516412,0.0015917879,0.00018389811,0.000023544046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023208775,0.0029696939,0.00029150496,0.0047847712,0.002899462,0.000009486724,0.008401161,0.00008606637,0.44032276,0.114480875,0.33828264,0.08515068],"study_design_scores_gemma":[0.012385701,0.00050838,0.0005854451,0.0009811852,0.0018115666,0.000046682275,0.0036146094,0.017370641,0.17135052,0.0023880762,0.788507,0.00045018818],"about_ca_topic_score_codex":0.000086493,"about_ca_topic_score_gemma":0.000010370558,"teacher_disagreement_score":0.73245984,"about_ca_system_score_codex":0.0002543869,"about_ca_system_score_gemma":0.000088771994,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W7116910779","doi":"10.7326/annals-25-01939","title":"Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1","year":2025,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hillsborough Hospital","funders":"","keywords":"Tenofovir alafenamide; Adverse effect; Human immunodeficiency virus (HIV); Oral administration; Clinical trial","score_opus":0.036857470742707184,"score_gpt":0.3283943603110338,"score_spread":0.29153688956832663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116910779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9130183,0.0030345875,0.00024121841,0.05300463,0.00030838244,0.0006049938,0.000029630548,0.000060311206,0.029697975],"genre_scores_gemma":[0.94959813,0.0005540454,0.0011330193,0.0016611372,0.00010275886,0.000034479614,0.00006400077,0.000033381886,0.04681907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771786,0.00007183921,0.0006915781,0.0004940244,0.0005191645,0.0005055239],"domain_scores_gemma":[0.9988161,0.00021067838,0.00018268058,0.00032778582,0.00022320343,0.00023959458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041540217,0.00041960357,0.0010276189,0.0008387233,0.00005889034,0.000014038403,0.00020372898,0.0001320398,0.00012637046],"category_scores_gemma":[0.00023646142,0.0002734827,0.000098868004,0.00074132736,0.0004728054,0.00015497558,0.000083581224,0.00043695958,0.00001993225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031425312,0.0015175719,0.7239748,0.0008136227,0.0028598348,0.0030592112,0.012211103,0.000024540464,0.003745953,0.0028700896,0.157839,0.05965896],"study_design_scores_gemma":[0.10576703,0.012971223,0.73633116,0.017648676,0.0020244818,0.0004536337,0.015358843,0.001535245,0.00921108,0.0009042303,0.09634414,0.0014502635],"about_ca_topic_score_codex":0.0012471004,"about_ca_topic_score_gemma":0.00059487886,"teacher_disagreement_score":0.074341714,"about_ca_system_score_codex":0.0001521064,"about_ca_system_score_gemma":0.0005217842,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W7116940674","doi":"10.5281/zenodo.17993276","title":"Supplementary Data for A tale of two mechanisms: Clarification of the pathway for MDB4 catalyzed glycosidic bond cleavage using MD and QM/MM calculations","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge","funders":"","keywords":"Glycosidic bond; Bond cleavage; Cleavage (geology); Catalysis; Component (thermodynamics)","score_opus":0.05462929379254761,"score_gpt":0.3039554465892207,"score_spread":0.24932615279667308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116940674","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2077133,0.004735591,0.5965432,0.017392494,0.0014329507,0.03513456,0.12590984,0.00047006735,0.010668034],"genre_scores_gemma":[0.94017315,0.00040314466,0.01606896,0.00012824242,0.000114576185,0.0000017089176,0.039931387,0.0009691916,0.0022096436],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974443,0.00025815808,0.00081924855,0.0006659953,0.0004078814,0.00040447296],"domain_scores_gemma":[0.99736613,0.00014108834,0.0004178641,0.0012040732,0.000738441,0.00013242445],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013499305,0.00025269846,0.00040995356,0.00035523964,0.0019502143,0.00016558976,0.00091563305,0.000105202045,0.0009466128],"category_scores_gemma":[0.0007339062,0.00022853148,0.00011490671,0.0007963363,0.00030584185,0.00023516412,0.0015917879,0.00018389811,0.000023544046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023208775,0.0029696939,0.00029150496,0.0047847712,0.002899462,0.000009486724,0.008401161,0.00008606637,0.44032276,0.114480875,0.33828264,0.08515068],"study_design_scores_gemma":[0.012385701,0.00050838,0.0005854451,0.0009811852,0.0018115666,0.000046682275,0.0036146094,0.017370641,0.17135052,0.0023880762,0.788507,0.00045018818],"about_ca_topic_score_codex":0.000086493,"about_ca_topic_score_gemma":0.000010370558,"teacher_disagreement_score":0.73245984,"about_ca_system_score_codex":0.0002543869,"about_ca_system_score_gemma":0.000088771994,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W7130704328","doi":"10.6084/m9.figshare.29615211","title":"Additional file 1 of Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Cohort; Cohort study; Opera; Retrospective cohort study","score_opus":0.01822040008461056,"score_gpt":0.2602279549025844,"score_spread":0.2420075548179738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7130704328","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019120645,0.00047373594,3.3504375e-7,0.0025491696,0.000035720415,0.0016920447,0.97398496,0.000027555161,0.0021158368],"genre_scores_gemma":[0.089409575,0.00008430677,0.00029389863,0.00070699904,0.00005516331,0.010933955,0.8629203,0.000024831912,0.03557101],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978732,0.00016457196,0.00062924,0.0005650744,0.0003502704,0.00041767035],"domain_scores_gemma":[0.9971508,0.0019816274,0.00022040891,0.00041831227,0.00013761137,0.00009127445],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000075604905,0.00049063674,0.00067796826,0.0004891132,0.00016402398,0.000071679875,0.00016632577,0.00018375038,0.8924466],"category_scores_gemma":[0.00069478684,0.00028185442,0.00015545599,0.000586525,0.00006523631,0.0001943346,0.000109203735,0.0002731331,0.00070331694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041755612,0.0012010132,0.09328244,0.00029055582,0.0009254406,0.0003244865,0.0014693784,0.0000018635532,0.000013163955,0.000010326997,0.8960496,0.0060141534],"study_design_scores_gemma":[0.0014690463,0.00027419243,0.7042071,0.007249488,0.00022253678,0.00002493962,0.00028301,0.00007090401,0.000016749735,0.000008393765,0.28598815,0.00018548049],"about_ca_topic_score_codex":0.000017369464,"about_ca_topic_score_gemma":0.0001284513,"teacher_disagreement_score":0.89174324,"about_ca_system_score_codex":0.00038619118,"about_ca_system_score_gemma":0.0005653976,"threshold_uncertainty_score":0.99996334},"labels":[],"label_agreement":null},{"id":"W7161937518","doi":"10.82308/33935","title":"Characterization of HIV-1 Integrase Strand Transfer Inhibitor (INSTI)-enzyme interactions towards long- term strategies to suppress viremia, mitigate antiretroviral resistance and prevent transmission at a population-level","year":2020,"lang":"en","type":"dissertation","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mutation; Human immunodeficiency virus (HIV); Virus; Integrase; Cowpox virus","score_opus":0.015859694964274987,"score_gpt":0.2767993187516365,"score_spread":0.2609396237873615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161937518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234116,0.00014286245,0.0023427864,0.0012090821,0.00026998785,0.0017508707,0.00051803543,0.00009222943,0.0013329636],"genre_scores_gemma":[0.9108048,0.0002688037,0.0010186924,0.000045873858,0.000090195346,0.000121353325,0.020221554,0.00007183017,0.06735687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974988,0.00006756154,0.0009262552,0.0006920882,0.00052871293,0.00028658542],"domain_scores_gemma":[0.9990327,0.00003188829,0.00016223181,0.00023182888,0.00018433655,0.00035703764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007535272,0.00057054136,0.00085496664,0.00035041643,0.00015042182,0.000082645216,0.0001049532,0.0002719981,0.0003988249],"category_scores_gemma":[0.00001839167,0.0004799773,0.0002146776,0.00029162783,0.000041324987,0.00039283762,0.000017517219,0.00032122785,0.000012931385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007831169,0.0009534654,0.013954711,0.0056951763,0.0010448593,0.00016835683,0.02373712,0.000003503643,0.92852634,0.00020675568,0.0007305199,0.01714805],"study_design_scores_gemma":[0.003450904,0.00042790914,0.4339006,0.0055315136,0.0012501846,0.000017518652,0.0013558674,0.00008532938,0.5516477,0.00001838922,0.001545212,0.0007688492],"about_ca_topic_score_codex":0.00007551896,"about_ca_topic_score_gemma":0.0016953218,"teacher_disagreement_score":0.4199459,"about_ca_system_score_codex":0.00023431497,"about_ca_system_score_gemma":0.00029668334,"threshold_uncertainty_score":0.9997652},"labels":[],"label_agreement":null},{"id":"W7161961226","doi":"10.82308/34829","title":"Looking at HIV-1 transmission in Quebec through a phylogenetic lens","year":2020,"lang":"en","type":"dissertation","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dolutegravir; Integrase; Transmission (telecommunications); Tropism; Phylogenetic tree; Integrase inhibitor; Genotyping; Reverse transcriptase","score_opus":0.015983426190218582,"score_gpt":0.26961660679450494,"score_spread":0.25363318060428636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161961226","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5884939,0.005178778,0.00033410243,0.010692256,0.00039196163,0.0023609232,0.000012757064,0.00027344798,0.39226186],"genre_scores_gemma":[0.13593617,0.0009386367,0.0047803954,0.00039803324,0.000095776486,0.00009455513,0.0051131872,0.00008409269,0.85255915],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984966,0.00002731625,0.00039759875,0.00048057194,0.0003258432,0.00027208313],"domain_scores_gemma":[0.9995877,0.00003037459,0.0000798018,0.00016774751,0.000034626588,0.00009975984],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000035085497,0.0003507074,0.00055080996,0.0001305594,0.00005739607,0.000013976144,0.0000689349,0.00027028375,0.0014352887],"category_scores_gemma":[0.000010777308,0.00027593586,0.00015497535,0.00022002823,0.000013242274,0.0000488705,0.000012428596,0.0002360339,0.0005438681],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008806505,0.003736104,0.13230366,0.011124995,0.0035607826,0.00665461,0.3129386,0.00003169918,0.11404182,0.002289298,0.11800669,0.28650525],"study_design_scores_gemma":[0.008921828,0.00023477644,0.045282077,0.003928605,0.0011937753,0.000034491717,0.004703852,0.00019471112,0.10046142,0.00014830724,0.8336604,0.001235735],"about_ca_topic_score_codex":0.000796221,"about_ca_topic_score_gemma":0.015758066,"teacher_disagreement_score":0.7156537,"about_ca_system_score_codex":0.00036762108,"about_ca_system_score_gemma":0.00033073217,"threshold_uncertainty_score":0.9999693},"labels":[],"label_agreement":null},{"id":"W7161971040","doi":"10.82308/43897","title":"Computer-aided design and synthesis of papain-like protease and 3-chymotrypsin-like protease inhibitors involved in the replication of SARS-CoV-2","year":2023,"lang":"en","type":"dissertation","venue":"","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protease; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); DNA replication","score_opus":0.039688620734102543,"score_gpt":0.29553751882736645,"score_spread":0.2558488980932639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161971040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919053,0.00023649674,0.00018244701,0.0007277054,0.00011806786,0.006539202,0.000009576425,0.000068924186,0.00021232589],"genre_scores_gemma":[0.9758441,0.00032527954,0.01581352,0.0001796904,0.00006987883,0.0022675057,0.00074470683,0.00010133882,0.004654021],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756306,0.00028045935,0.0008249575,0.0006527914,0.00045543635,0.00022330579],"domain_scores_gemma":[0.9981775,0.00047478112,0.00047067186,0.00062090054,0.00018538932,0.000070718306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010495646,0.00038235346,0.00075238524,0.00045501374,0.00006605229,0.000024562907,0.000120793426,0.00026248852,0.000004673233],"category_scores_gemma":[0.00031528302,0.0002631996,0.00009416758,0.0004781635,0.00009720466,0.00007222072,0.000034661793,0.00021511059,0.0000054530797],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01453479,0.01242804,0.1462779,0.040489607,0.004691901,0.00090136024,0.0889436,0.000021024589,0.28328303,0.0011348643,0.07642811,0.33086577],"study_design_scores_gemma":[0.007953675,0.0011521595,0.12277246,0.00957838,0.0017517303,0.00004199102,0.010104685,0.002931591,0.84062606,0.0008539224,0.0010449045,0.0011884632],"about_ca_topic_score_codex":0.0003438621,"about_ca_topic_score_gemma":0.00017318137,"teacher_disagreement_score":0.557343,"about_ca_system_score_codex":0.00006622753,"about_ca_system_score_gemma":0.00029929788,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W97603576","doi":"10.1177/135965350300800605","title":"Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance","year":2003,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Drug resistance; Biology; Resistance mutation; Nucleoside; Mutation; Nucleoside analogue; Antiretroviral therapy; Virology; Genetics; Medicine; Human immunodeficiency virus (HIV); Viral load; RNA; Gene","score_opus":0.0705908247958759,"score_gpt":0.38020921021209636,"score_spread":0.30961838541622044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W97603576","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003454843,0.994714,0.0000030204094,0.00041187645,0.0002583937,0.0019770674,0.00011867221,0.00005126027,0.002120231],"genre_scores_gemma":[0.000061175735,0.9904192,0.0012925728,0.0008793937,0.00016368068,0.000051268264,0.0002785927,0.00010494465,0.006749171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580455,0.0006476695,0.001914578,0.00078662863,0.0004276401,0.00041890796],"domain_scores_gemma":[0.9981135,0.00017176993,0.00073061173,0.0006819218,0.00011153809,0.00019062347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011086633,0.00072569103,0.0043067494,0.00023115448,0.000079917,0.000019061396,0.00017342504,0.0003613764,0.00010547741],"category_scores_gemma":[0.00010677299,0.0005187788,0.0013366241,0.00062878424,0.0003385361,0.00012993903,0.000027827331,0.0005767419,0.00006572696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013980441,0.0005606346,0.0016245951,0.071773306,0.0010521383,0.0003943036,0.000059285598,2.95875e-10,0.0000047283424,0.00016811852,0.05687718,0.8673459],"study_design_scores_gemma":[0.0014645099,0.0003198488,0.00007487939,0.14623053,0.0012960528,0.000034371547,0.000008927119,6.935671e-8,0.000015243991,0.000014242862,0.8501623,0.00037898403],"about_ca_topic_score_codex":0.000011239419,"about_ca_topic_score_gemma":0.0000049922655,"teacher_disagreement_score":0.8669669,"about_ca_system_score_codex":0.000069542526,"about_ca_system_score_gemma":0.00045013818,"threshold_uncertainty_score":0.99972636},"labels":[],"label_agreement":null}]}